PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Feng, Q; Li, S; Ma, HM; Yang, WT; Zheng, PS				Feng, Qian; Li, Shan; Ma, Hong-Mei; Yang, Wen-Ting; Zheng, Peng-Sheng			LGR6 activates the Wnt/beta-catenin signaling pathway and forms a beta-catenin/TCF7L2/LGR6 feedback loop in LGR6(high) cervical cancer stem cells	ONCOGENE			English	Article							COMPARATIVE MODELING ANALYSIS; 78 LOW-INCOME; TUMOR-FORMATION; PROLIFERATION; ELIMINATION; REGULATOR; GENERATE; IMPACT	The leucine-rich repeat-containing G-protein-coupled receptor 6 (LGR6) is considered to be a stem cell marker in many normal tissues and promotes tissue development, regeneration, and repair. LGR6 is also related to the initiation and progression of some malignant tumors. However, the role of LGR6 in cervical cancer has not been reported. Here, immunohistochemistry and western blotting showed that LGR6 was significantly upregulated in cervical cancer, compared with the normal cervix. By analyzing The Cancer Genome Atlas database, LGR6 was found to be correlated with a poor prognosis of cervical cancer. Then, a small population of LGR6(high) cells isolated by using the fluorescence-activated cell sorting exhibited enhanced properties of cancer stem cells including self-renewal, differentiation, and tumorigenicity. Moreover, RNA sequencing revealed that LGR6 was correlated with the Wnt signaling pathway and TOP/FOP, reverse transcription-PCR, and western blotting further proved that LGR6 could activate the Wnt/beta-catenin signaling pathway. Interestingly, LGR6 upregulated the expression of TCF7L2 by activating the Wnt/beta-catenin pathway. Then, TCF7L2 combining with beta-catenin in the nucleus enhanced LGR6 transcription by binding the promoter of LGR6, which further activated the Wnt signaling to form a positive feedback loop. Thus, our study demonstrated that LGR6 activated a novel beta-catenin/TCF7L2/LGR6-positive feedback loop in LGR6(high) cervical cancer stem cells (CSCs), which provided a new therapeutic strategy for targeting cervical CSCs to improve the prognosis of cervical cancer patients.	[Feng, Qian; Li, Shan; Ma, Hong-Mei; Yang, Wen-Ting; Zheng, Peng-Sheng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Reprod Med, Xian 710061, Shaanxi, Peoples R China; [Zheng, Peng-Sheng] Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Sect Canc Stem Cell Res, Xian 710061, Shaanxi, Peoples R China	Xi'an Jiaotong University; Ministry of Education, China	Zheng, PS (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Reprod Med, Xian 710061, Shaanxi, Peoples R China.; Zheng, PS (corresponding author), Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Sect Canc Stem Cell Res, Xian 710061, Shaanxi, Peoples R China.	zpsheng@mail.xjtu.edu.cn			Fundamental Research Funds for the Central Universities [xzy012020064]; National Natural Science Foundation of China [81472728, 81672910]	Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by a grant Dr. Wen-Ting Yang from the Fundamental Research Funds for the Central Universities (xzy012020064) and Prof. Peng-Sheng Zheng from the National Natural Science Foundation of China (Nos. 81472728 and 81672910).	Blaas L, 2016, NAT CELL BIOL, V18, P1346, DOI 10.1038/ncb3434; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brisson M, 2020, LANCET, V395, P575, DOI 10.1016/S0140-6736(20)30068-4; Canfell K, 2020, LANCET, V395, P591, DOI 10.1016/S0140-6736(20)30157-4; Cao HZ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.393; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Chen Q, 2014, ONCOTARGET, V5, P9092, DOI 10.18632/oncotarget.2377; Chiang N, 2019, J CLIN INVEST, V129, P5294, DOI 10.1172/JCI129448; Clara JA, 2020, NAT REV CLIN ONCOL, V17, P204, DOI 10.1038/s41571-019-0293-2; Cohen PA, 2019, LANCET, V393, P169, DOI 10.1016/S0140-6736(18)32470-X; Cui L, 2013, J CLIN INVEST, V123, P1647, DOI 10.1172/JCI65048; da Costa SCS, 2019, J CLIN ONCOL, V37, P3124, DOI 10.1200/JCO.19.00674; Day BW, 2019, ACTA NEUROPATHOL, V138, P1033, DOI 10.1007/s00401-019-02069-x; de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113; Di Stefano B, 2018, NAT METHODS, V15, P732, DOI 10.1038/s41592-018-0104-1; Farias LMB, 2004, CANCER RES, V64, P6996, DOI 10.1158/0008-5472.CAN-04-1204; Grove EA, 2011, GENE DEV, V25, P1759, DOI 10.1101/gad.17594311; Guinot A, 2016, CANCER RES, V76, P4012, DOI 10.1158/0008-5472.CAN-15-3302; Hockel M, 2019, LANCET ONCOL, V20, P1316, DOI 10.1016/S1470-2045(19)30389-4; Lee JH, 2017, CELL, V170, P1149, DOI 10.1016/j.cell.2017.07.028; Lehoczky JA, 2015, P NATL ACAD SCI USA, V112, P13249, DOI 10.1073/pnas.1518874112; Lewis A, 2014, CELL REP, V8, P983, DOI 10.1016/j.celrep.2014.07.020; Li L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0782-8; Liu D., 2020, STEM CELLS; Liu SY, 2013, ONCOTARGET, V4, P2462, DOI 10.18632/oncotarget.1578; Liu XF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087092; Lv YP, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0179-2; Lytle NK, 2018, NAT REV CANCER, V18, P669, DOI 10.1038/s41568-018-0056-x; Mazzoni SM, 2014, CANCER LETT, V355, P1, DOI 10.1016/j.canlet.2014.09.018; Mir R, 2016, ONCOGENE, V35, P1679, DOI 10.1038/onc.2015.232; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Powell AE, 2012, CELL, V149, P146, DOI 10.1016/j.cell.2012.02.042; Ravindranath A, 2008, CURR MOL MED, V8, P38; Ren WW, 2014, P NATL ACAD SCI USA, V111, P16401, DOI 10.1073/pnas.1409064111; Rodin D, 2019, LANCET ONCOL, V20, P915, DOI 10.1016/S1470-2045(19)30308-0; Ruan XH, 2019, MOL THER-ONCOLYTICS, V14, P94, DOI 10.1016/j.omto.2019.04.002; Ruiz EJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4175; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Song KH, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2016.87; Su PH, 2019, CANCER LETT, V450, P53, DOI 10.1016/j.canlet.2019.01.033; Sun Q, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01749-7; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334; Valkenburg Kenneth C, 2011, Cancers (Basel), V3, P2050, DOI 10.3390/cancers3022050; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Viny AD, 2019, CELL STEM CELL, V25, P682, DOI 10.1016/j.stem.2019.08.003; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1109-z; Wang YD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.272; Yi F, 2011, NAT CELL BIOL, V13, P762, DOI 10.1038/ncb2283; Yong X, 2016, CANCER LETT, V374, P292, DOI 10.1016/j.canlet.2016.02.032	52	3	3	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6103	6114		10.1038/s41388-021-02002-1	http://dx.doi.org/10.1038/s41388-021-02002-1		SEP 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34489551	Green Published, hybrid			2022-12-28	WOS:000692963000003
J	Sun, J; Gaidosh, G; Xu, Y; Mookhtiar, A; Man, N; Cingaram, PR; Blumenthal, E; Shiekhattar, R; Goka, ET; Nimer, SD; Lippman, ME				Sun, Jun; Gaidosh, Gabriel; Xu, Ye; Mookhtiar, Adnan; Man, Na; Cingaram, Pradeep Reddy; Blumenthal, Ezra; Shiekhattar, Ramin; Goka, Erik T.; Nimer, Stephen D.; Lippman, Marc E.			RAC1 plays an essential role in estrogen receptor alpha function in breast cancer cells	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; ENDOCRINE THERAPY; GENE-EXPRESSION; GTPASE; DEGRADATION; COACTIVATOR; LOCALIZATION; MUTATIONS; MECHANISM; EHT-1864	The activity of Rho family GTPase protein, RAC1, which plays important normal physiological functions, is dysregulated in multiple cancers. RAC1 is expressed in both estrogen receptor alpha (ER)-positive and ER-negative breast cancer (BC) cells. However, ER-positive BC is more sensitive to RAC1 inhibition. We have determined that reducing RAC1 activity, using siRNA or EHT 1864 (a small molecule Rac inhibitor), leads to rapid ER protein degradation. RAC1 interacts with ER within the ER complex and RAC1 localizes to chromatin binding sites for ER upon estrogen treatment. RAC1 activity is important for RNA Pol II function at both promoters and enhancers of ER target genes and ER-regulated gene transcription is blocked by EHT 1864, in a dose-dependent manner. Having identified that RAC1 is an essential ER cofactor for ER protein stability and ER transcriptional activity, we report that RAC1 inhibition could be an effective therapeutic approach for ER-positive BC.	[Sun, Jun; Xu, Ye; Nimer, Stephen D.; Lippman, Marc E.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Sun, Jun; Xu, Ye; Mookhtiar, Adnan; Man, Na; Shiekhattar, Ramin; Nimer, Stephen D.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Gaidosh, Gabriel; Cingaram, Pradeep Reddy; Blumenthal, Ezra; Shiekhattar, Ramin] Univ Miami, Dept Human Genet, Miami, FL USA; [Goka, Erik T.] Geneyus LLC, Miami, FL USA; [Nimer, Stephen D.] Univ Miami, Dept Biochem & Mol Biol, Miami, FL 33101 USA; [Lippman, Marc E.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA	University of Miami; University of Miami; University of Miami; University of Miami; Georgetown University	Nimer, SD; Lippman, ME (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.; Nimer, SD (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.; Nimer, SD (corresponding author), Univ Miami, Dept Biochem & Mol Biol, Miami, FL 33101 USA.; Lippman, ME (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.	snimer@med.miami.edu; mlippman@med.miami.edu	Cingaram, Pradeep Reddy/AAG-7322-2019	Cingaram, Pradeep Reddy/0000-0002-9643-9725; Blumenthal, Ezra/0000-0001-7607-088X	National Cancer Institute (NCI) [5R01CA166835, 1P30CA240139]	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by a generous gift from the Lampert family (MEL), National Cancer Institute (NCI) grants 5R01CA166835 (SDN), and 1P30CA240139 (the Sylvester Comprehensive Cancer Center). We thank the Oncogenomics Shared Resource of the Sylvester Comprehensive Cancer Center for providing expertize and guidance on next generation sequencing services. Xue Xiao and Justin Sun provided assistance in figure generation.	Akbar H, 2006, METHOD ENZYMOL, V406, P554, DOI 10.1016/S0076-6879(06)06043-5; AlFakeeh A, 2018, CURR ONCOL, V25, pS18, DOI 10.3747/co.25.3752; Bates M, 2007, SCIENCE, V317, P1749, DOI 10.1126/science.1146598; Beckedorff F, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107917; BRUNNER N, 1993, CANCER RES, V53, P3229; Buongiorno P, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-73; Chu I, 2007, J CLIN INVEST, V117, P2205, DOI 10.1172/JCI21739; Daly B, 2017, JAMA ONCOL, V3, P928, DOI 10.1001/jamaoncol.2016.6380; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Goka ET, 2015, ONCOGENE, V34, P5395, DOI 10.1038/onc.2014.468; Goka ET, 2019, MOL CANCER THER, V18, P957, DOI 10.1158/1535-7163.MCT-18-0955; Hajdo-Milasinovic A, 2007, J CELL SCI, V120, P555, DOI 10.1242/jcs.03364; Hampsch RA, 2017, ONCOTARGET, V8, P21806, DOI 10.18632/oncotarget.15586; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Hein AL, 2016, ONCOGENE, V35, P6319, DOI 10.1038/onc.2016.163; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Jamieson C, 2015, J CELL SCI, V128, P3933, DOI 10.1242/jcs.167742; Johnson AB, 2012, MOL CELL ENDOCRINOL, V348, P430, DOI 10.1016/j.mce.2011.04.021; Kazanietz MG, 2017, CANCER RES, V77, P5445, DOI 10.1158/0008-5472.CAN-17-1456; Korkmaz G, 2016, NAT BIOTECHNOL, V34, P192, DOI 10.1038/nbt.3450; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Kurdi AT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13048; Kwapisz D, 2017, BREAST CANCER RES TR, V166, P41, DOI 10.1007/s10549-017-4385-3; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lanning CC, 2004, J BIOL CHEM, V279, P44197, DOI 10.1074/jbc.M404977200; Levet F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10007-4; Liang J, 2013, ANNU REV PHYSIOL, V75, P225, DOI 10.1146/annurev-physiol-030212-183708; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; LIPPMAN ME, 1975, NATURE, V256, P592, DOI 10.1038/256592a0; Liu F, 2020, NUCLEIC ACIDS RES, V48, P2956, DOI 10.1093/nar/gkaa065; Lupien M, 2009, MOL CELL BIOL, V29, P3413, DOI 10.1128/MCB.00020-09; Maldonado MD, 2018, CANCER RES, V78, P3101, DOI 10.1158/0008-5472.CAN-18-0619; Nagase M, 2013, NAT REV NEPHROL, V9, P86, DOI 10.1038/nrneph.2012.282; Narumiya S, 2018, FEBS LETT, V592, P1763, DOI 10.1002/1873-3468.13087; Navarro-Lerida I, 2015, DEV CELL, V32, P318, DOI 10.1016/j.devcel.2014.12.019; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nonclercq D, 2004, MOL CELL ENDOCRINOL, V227, P53, DOI 10.1016/j.mce.2004.07.003; Oesterreich S, 2001, CANCER RES, V61, P5771; Onesto C, 2008, METHOD ENZYMOL, V439, P111, DOI 10.1016/S0076-6879(07)00409-0; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Paulsen MT, 2013, P NATL ACAD SCI USA, V110, P2240, DOI 10.1073/pnas.1219192110; Payapilly A, 2018, CURR OPIN CELL BIOL, V54, P50, DOI 10.1016/j.ceb.2018.04.009; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Reinbolt RE, 2015, SEMIN ONCOL NURS, V31, P146, DOI 10.1016/j.soncn.2015.02.002; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rosenblatt AE, 2011, ENDOCR-RELAT CANCER, V18, P207, DOI 10.1677/ERC-10-0049; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284; Shutes A, 2007, J BIOL CHEM, V282, P35666, DOI 10.1074/jbc.M703571200; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; Szostakowska M, 2019, BREAST CANCER RES TR, V173, P489, DOI 10.1007/s10549-018-5023-4; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Walker MP, 2011, ONCOGENE, V30, P1984, DOI 10.1038/onc.2010.583; Yang CF, 2006, MOL CELL BIOL, V26, P831, DOI 10.1128/MCB.26.3.831-842.2006; Yi P, 2017, MOL CELL, V67, P733, DOI 10.1016/j.molcel.2017.07.026; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	61	1	1	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5950	5962		10.1038/s41388-021-01985-1	http://dx.doi.org/10.1038/s41388-021-01985-1		AUG 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34373577	hybrid, Green Published			2022-12-28	WOS:000683273100001
J	Chen, TL; Zhang, FB; Liu, J; Huang, ZL; Zheng, YF; Deng, SK; Liu, Y; Wang, JH; Sun, XL				Chen, Taoliang; Zhang, Fabing; Liu, Jie; Huang, Zhilin; Zheng, Yaofeng; Deng, Shaokang; Liu, Yang; Wang, Jihui; Sun, Xinlin			Dual role of WNT5A in promoting endothelial differentiation of glioma stem cells and angiogenesis of glioma derived endothelial cells	ONCOGENE			English	Article							MALIGNANT GLIOMAS; GLIOBLASTOMA; PROLIFERATION; CANCER; OVEREXPRESSION; ACTIVATION; EXPRESSION; PROGNOSIS; THERAPY; PATHWAY	Glioma is a devastating cancer with a rich vascular network. No anti-angiogenic treatment is available for prolonging the overall survival of glioma patients. Recent studies have demonstrated that the endothelial differentiation of glioma stem cells (GSCs) into glioma-derived endothelial cells (GDECs) may be a novel target for anti-angiogenic therapy in glioma; however, the underlying mechanisms of this process remain unknown. Here, we report that wingless-related integration site (WNT) family member 5A (WNT5A) plays significant roles in GSC endothelial differentiation and GDECs angiogenesis. WNT5A is preferentially secreted by GDECs, and inhibition of WNT5A suppresses angiogenesis and tumorigenesis in GDECs. Silencing of WNT5A in GDECs also disrupts the impact of GDECs on stimulating GSC endothelial differentiation. Frizzled-4 is a receptor that mediates the effect of WNT5A on GSC endothelial differentiation and angiogenesis of GDECs via GSK3 beta/beta-catenin/epithelial-mesenchymal transition signalling. The shWNT5A@cRGD-DDD liposomes, targeting WNT5A, exert anti-angiogenic effects in vivo. In this study, we identified that WNT5A has a dual functional role in modulating the endothelial differentiation of GSCs and angiogenesis of GDECs, indicating that WNT5A is a potential target for anti-angiogenesis-based therapeutics in glioma.	[Chen, Taoliang; Zhang, Fabing; Liu, Jie; Huang, Zhilin; Zheng, Yaofeng; Deng, Shaokang; Liu, Yang; Wang, Jihui; Sun, Xinlin] Southern Med Univ, Zhujiang Hosp, Natl Key Clin Specialty,Dept Neurosurg, Engn Technol Res Ctr,Educ Minist China,Guangdong, Guangzhou, Peoples R China	Southern Medical University - China	Liu, Y; Wang, JH; Sun, XL (corresponding author), Southern Med Univ, Zhujiang Hosp, Natl Key Clin Specialty,Dept Neurosurg, Engn Technol Res Ctr,Educ Minist China,Guangdong, Guangzhou, Peoples R China.	lynanchang@hotmail.com; 346wangjihui@163.com; zjsunxinlin@163.com		Liu, Yang/0000-0001-9658-0000	Natural Science Foundation of China [81772652, 81802481]; Natural Science Foundation of Guangdong Province [2018A030310423]; China Postdoctoral Science Foundation [2020M672737]; President Foundation of ZhuJiang Hospital, Southern Medical University [jzjj2018rc04, yjjj2019qn14]; Guangzhou Science and Technology Planning Project [202102020015]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); President Foundation of ZhuJiang Hospital, Southern Medical University; Guangzhou Science and Technology Planning Project	Xinlin Sun received funding from the Natural Science Foundation of China (No. 81772652). Jihui Wang received funding from the Natural Science Foundation of China (No. 81802481), Natural Science Foundation of Guangdong Province (No. 2018A030310423), China Postdoctoral Science Foundation funded project (No. 2020M672737) and President Foundation of ZhuJiang Hospital, Southern Medical University (No. jzjj2018rc04). Taoliang Chen received funding from the President Foundation of ZhuJiang Hospital, Southern Medical University (No. yjjj2019qn14) and Guangzhou Science and Technology Planning Project (No. 202102020015)	Abdulkhalek S, 2014, CLIN TRANSL MED, V3, DOI 10.1186/s40169-014-0028-z; Akhtar N, 2018, DEV CELL, V47, P135, DOI 10.1016/j.devcel.2018.10.007; Carlson JC, 2021, NEURO-ONCOLOGY, V23, P932, DOI 10.1093/neuonc/noaa297; Chen TL, 2019, ONCOGENE, V38, P1183, DOI 10.1038/s41388-018-0515-6; Chen YL, 2020, CLIN NEUROL NEUROSUR, V198, DOI 10.1016/j.clineuro.2020.106239; Cheng CW, 2008, BIOCHEM BIOPH RES CO, V365, P285, DOI 10.1016/j.bbrc.2007.10.166; Deshors P, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2055-6; Ekstrom EJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-88; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Frenquelli M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.615190; Habu M, 2014, J BIOCHEM, V156, P29, DOI 10.1093/jb/mvu015; Han S, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7681926; Han Y, 2020, J DENT RES, V99, P804, DOI 10.1177/0022034520912190; Hardee ME, 2012, AM J PATHOL, V181, P1126, DOI 10.1016/j.ajpath.2012.06.030; Hu BL, 2016, CELL, V167, P1281, DOI 10.1016/j.cell.2016.10.039; Jiang X, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02978-w; Junge HJ, 2009, CELL, V139, P299, DOI 10.1016/j.cell.2009.07.048; Kamino M, 2011, CANCER SCI, V102, P540, DOI 10.1111/j.1349-7006.2010.01815.x; Kemper K, 2010, CANCER RES, V70, P719, DOI 10.1158/0008-5472.CAN-09-1820; Li XK, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.532581; Li ZT, 2020, MOL THER-NUCL ACIDS, V19, P827, DOI 10.1016/j.omtn.2019.09.034; Liu J, 2020, ACS APPL MATER INTER, V12, P52354, DOI 10.1021/acsami.0c14288; Liu ZY, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3578-9; Ma L, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4855; Masckauchan TNH, 2006, MOL BIOL CELL, V17, P5163, DOI 10.1091/mbc.E06-04-0320; Mei X, 2017, NEURO-ONCOLOGY, V19, P1109, DOI 10.1093/neuonc/nox016; Mooi J, 2021, CLIN CANCER RES, V27, P2159, DOI 10.1158/1078-0432.CCR-20-2714; Ostrom Quinn T, 2019, Neuro Oncol, V21, pv1, DOI 10.1093/neuonc/noz150; Piao Y, 2013, CLIN CANCER RES, V19, P4392, DOI 10.1158/1078-0432.CCR-12-1557; Plate KH, 2012, ACTA NEUROPATHOL, V124, P763, DOI 10.1007/s00401-012-1066-5; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Shi YN, 2017, CLIN CHIM ACTA, V471, P263, DOI 10.1016/j.cca.2017.06.017; Sun L, 2020, GENE, V747, DOI 10.1016/j.gene.2020.144657; Sun Z, 2020, MOL THER-NUCL ACIDS, V22, P1092, DOI 10.1016/j.omtn.2020.10.021; Suva ML, 2020, CANCER CELL, V37, P630, DOI 10.1016/j.ccell.2020.04.001; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wei YC, 2019, AGING-US, V11, P8951, DOI 10.18632/aging.102359; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wu HB, 2017, AUTOPHAGY, V13, P1528, DOI 10.1080/15548627.2017.1336277; Yang DH, 2009, CIRC RES, V104, P372, DOI 10.1161/CIRCRESAHA.108.185405; Yang XH, 2020, MOL MED REP, V22, P2981, DOI 10.3892/mmr.2020.11377; Yang Y, 2018, MOL CARCINOGEN, V57, P842, DOI 10.1002/mc.22805; Yin JL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16789-2; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; Yu JM, 2007, CANCER LETT, V257, P172, DOI 10.1016/j.canlet.2007.07.011; Yu L, 2012, ONCOL REP, V27, P416, DOI 10.3892/or.2011.1481; Yu XL, 2021, EXP BIOL MED, V246, P20, DOI 10.1177/1535370220955139; Zeng Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.610661; Zhang L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01589-8; Zhang XJ, 2018, TRENDS BIOCHEM SCI, V43, P1033, DOI 10.1016/j.tibs.2018.09.002; Zhang YK, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20182161; Zhang YH, 2017, ONCOL REP, V38, P1156, DOI 10.3892/or.2017.5728	52	3	3	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5081	5094		10.1038/s41388-021-01922-2	http://dx.doi.org/10.1038/s41388-021-01922-2		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34188250				2022-12-28	WOS:000668080200002
J	Huo, FC; Zhu, ZM; Zhu, WT; Du, QY; Liang, J; Mou, J				Huo, Fu-Chun; Zhu, Zhi-Man; Zhu, Wen-Tao; Du, Qiu-Ying; Liang, Jia; Mou, Jie			METTL3-mediated m(6)A methylation of SPHK2 promotes gastric cancer progression by targeting KLF2	ONCOGENE			English	Article								N6-methyladenosine (m(6)A) RNA methylation is profoundly involved in epigenetic regulation, especially for carcinogenesis and tumor progression. Mounting evidence suggests that methyltransferase METTL3 regulates malignant behaviors of gastric cancer (GC). However, the clinical significance and biological implication of SPHK2 and its related m(6)A modification in GC remain unclear. In this study, quantitative real-time PCR (qRT-PCR), western blot and immunohistochemistry were utilized to detect the expression profiles and prognostic significance of SPHK2 in GC. Here, we showed that increased SPHK2 was signified a poor prognosis of GC patients. Phosphorylation and ubiquitination assays were used to investigate the possible mechanisms of SPHK2-mediated KLF2 expression. SPHK2 can promote the phosphorylation of KLF2, which triggers the ubiquitination and degradation of KLF2 protein in GC. Methylated RNA immunoprecipitation (MeRIP) was performed to uncover the m(6)A modification of SPHK2 mRNA. METTL3 promotes translation of SPHK2 mRNA via an m(6)A-YTHDF1-dependent manner. Functionally, SPHK2 facilitates GC cell proliferation, migration and invasion by inhibiting KLF2 expression. SPHK2/KLF2 regulates the cell proliferation, migration, and invasion induced by METTL3 in GC. Overall, our findings reveal that METTL3-mediated m(6)A modification of SPHK2 contributes to GC progression, which extends the understanding of the importance m(6)A methylation in GC and represents a potential target for GC therapy.	[Huo, Fu-Chun; Zhu, Wen-Tao; Du, Qiu-Ying; Liang, Jia; Mou, Jie] Xuzhou Med Univ, Dept Pathol, Xuzhou, Jiangsu, Peoples R China; [Zhu, Zhi-Man] Jiangsu Coll Nursing, Dept Basic Med, Huaian, Peoples R China; [Mou, Jie] Xuzhou Med Univ, Jiangsu Key Lab New Drug & Clin Pharm, Xuzhou, Jiangsu, Peoples R China; [Mou, Jie] Xuzhou Med Univ, Sch Pharm, Xuzhou, Jiangsu, Peoples R China	Xuzhou Medical University; Xuzhou Medical University; Xuzhou Medical University	Mou, J (corresponding author), Xuzhou Med Univ, Dept Pathol, Xuzhou, Jiangsu, Peoples R China.; Mou, J (corresponding author), Xuzhou Med Univ, Jiangsu Key Lab New Drug & Clin Pharm, Xuzhou, Jiangsu, Peoples R China.; Mou, J (corresponding author), Xuzhou Med Univ, Sch Pharm, Xuzhou, Jiangsu, Peoples R China.	mou.jie@xzhmu.edu.cn						Alarcon CR, 2015, NATURE, V519, P482, DOI 10.1038/nature14281; Bialkowska AB, 2017, DEVELOPMENT, V144, P737, DOI 10.1242/dev.145441; Bornschein J, 2014, FRONT BIOSCI-LANDMRK, V19, P312, DOI 10.2741/4210; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Britten CD, 2017, CLIN CANCER RES, V23, P4642, DOI 10.1158/1078-0432.CCR-16-2363; Chen Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1671-5; Chu JH, 2014, BIOMED PHARMACOTHER, V68, P1089, DOI 10.1016/j.biopha.2014.10.001; Costamagna G, 2012, ANN ITAL CHIR, V83, P183; Dong JL, 2018, BIOMED PHARMACOTHER, V105, P922, DOI 10.1016/j.biopha.2018.06.052; Hasanifard L, 2019, J CELL PHYSIOL, V234, P8162, DOI 10.1002/jcp.27612; He HB, 2019, BIOCHEM BIOPH RES CO, V517, P581, DOI 10.1016/j.bbrc.2019.07.058; Huo FC, 2019, CELL DEATH DIFFER, V26, P994, DOI 10.1038/s41418-018-0178-4; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Kao SH, 2017, ONCOGENE, V36, P5916, DOI 10.1038/onc.2017.302; Li XB, 2018, CANCER GENE THER, V25, P58, DOI 10.1038/s41417-017-0007-9; Lian YF, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0333-9; Liang JY, 2018, J CONTROL RELEASE, V286, P348, DOI 10.1016/j.jconrel.2018.07.039; Lin S, 2019, OPEN MED-WARSAW, V14, P25, DOI 10.1515/med-2019-0005; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Liu H, 2016, LIFE SCI, V151, P23, DOI 10.1016/j.lfs.2016.02.098; Liu W, 2016, TUMOR BIOL, V37, P6331, DOI 10.1007/s13277-015-4480-1; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003; Marfe G, 2015, MINI-REV MED CHEM, V15, P300, DOI 10.2174/1389557515666150227105415; Matsubara J, 2011, ONCOLOGY-BASEL, V81, P291, DOI 10.1159/000334462; Pham DH, 2014, ONCOGENE, V33, P5559, DOI 10.1038/onc.2013.502; Qiu WW, 2016, ONCOTARGET, V7, P39907, DOI 10.18632/oncotarget.9530; Rane MJ, 2019, EBIOMEDICINE, V40, P743, DOI 10.1016/j.ebiom.2019.01.021; Shi WN, 2017, ONCOTARGET, V8, P39605, DOI 10.18632/oncotarget.17174; Shimada H, 2014, GASTRIC CANCER, V17, P26, DOI 10.1007/s10120-013-0259-5; Sun E, 2016, TUMOR BIOL, V37, P473, DOI 10.1007/s13277-015-3818-z; Wang BS, 2018, AM J MENS HEALTH, V13, DOI 10.1177/1557988318816907; Wang L, 2019, EUR REV MED PHARMACO, V23, P201, DOI [10.26355/eurrev_201908_18648, 10.26355/eurrev_201908_1864d]; Wang Q, 2020, GUT, V69, P1193, DOI 10.1136/gutjnl-2019-319639; Wang QQ, 2019, AM J TRANSL RES, V11, P4895; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wei J, 2016, WORLD J GASTROENTERO, V22, P7478, DOI 10.3748/wjg.v22.i33.7478; Xiao GQ, 2018, ONCOL RES, V26, P1183, DOI 10.3727/096504018X15151495109394; Xie P, 2011, BIOCHEM BIOPH RES CO, V407, P254, DOI 10.1016/j.bbrc.2011.03.016; Xue KC, 2017, EUR REV MED PHARMACO, V21, P3794; Xun C, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0205-y; Yang DD, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00115; Yuan XH, 2020, EUR REV MED PHARMACO, V24, P673, DOI 10.26355/eurrev_202001_20044; Yue B, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1065-4; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033	45	27	27	3	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2968	2981		10.1038/s41388-021-01753-1	http://dx.doi.org/10.1038/s41388-021-01753-1		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33758320				2022-12-28	WOS:000631804500001
J	Ke, XY; Chen, Y; Tham, VYY; Lin, RYT; Dakle, P; Nacro, K; Puhaindran, ME; Houghton, P; Pang, A; Lee, VK; Ding, LW; Gery, S; Hill, J; Chen, LL; Xu, L; Koeffler, HP				Ke, Xin-Yu; Chen, Ye; Tham, Valarie Yu-Yan; Lin, Ruby Yu-Tong; Dakle, Pushkar; Nacro, Kassoum; Puhaindran, Mark Edward; Houghton, Peter; Pang, Angela; Lee, Victor Kwanmin; Ding, Ling-Wen; Gery, Sigal; Hill, Jeffrey; Chen, Leilei; Xu, Liang; Koeffler, H. Phillip			MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma	ONCOGENE			English	Article								Soft tissue sarcoma (STS) is a heterogeneous disease that arises from connective tissues. Clinical outcome of patients with advanced tumors especially de-differentiated liposarcoma and uterine leiomyosarcoma remains unsatisfactory, despite intensive treatment regimens including maximal surgical resection, radiation, and chemotherapy. MAP kinase-interacting serine/threonine-protein kinase 1 and 2 (MNK1/2) have been shown to contribute to oncogenic translation via phosphorylation of eukaryotic translation initiation factor 4E (eIF4E). However, little is known about the role of MNK1/2 and their downstream targets in STS. In this study, we show that depletion of either MNK1 or MNK2 suppresses cell viability, anchorage-independent growth, and tumorigenicity of STS cells. We also identify a compelling antiproliferative efficacy of a novel, selective MNK inhibitor ETC-168. Cellular responsiveness of STS cells to ETC-168 correlates positively with that of phosphorylated ribosomal protein S6 (RPS6). Mirroring MNK1/2 silencing, ETC-168 treatment strongly blocks eIF4E phosphorylation and represses expression of sarcoma-driving onco-proteins including E2F1, FOXM1, and WEE1. Moreover, combination of ETC-168 and MCL1 inhibitor S63845 exerts a synergistic antiproliferative activity against STS cells. In summary, our study reveals crucial roles of MNK1/2 and their downstream targets in STS tumorigenesis. Our data encourage further clinical translation of MNK inhibitors for STS treatment.	[Ke, Xin-Yu; Chen, Ye; Tham, Valarie Yu-Yan; Lin, Ruby Yu-Tong; Dakle, Pushkar; Chen, Leilei; Xu, Liang; Koeffler, H. Phillip] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Ke, Xin-Yu; Chen, Leilei] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore, Singapore; [Nacro, Kassoum] Agcy Sci Technol & Res, Expt Drug Dev Ctr, Singapore, Singapore; [Puhaindran, Mark Edward; Pang, Angela; Koeffler, H. Phillip] Natl Univ, Natl Univ Hosp, Canc Inst, Singapore, Singapore; [Puhaindran, Mark Edward] Natl Univ Singapore Hosp, Div Musculoskeletal Oncol, Univ Orthopaed Hand & Reconstruct Microsurg Clust, Singapore, Singapore; [Puhaindran, Mark Edward] Natl Univ Singapore Hosp, Dept Hand & Reconstruct Microsurg, Singapore, Singapore; [Houghton, Peter] UT Hlth San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX USA; [Lee, Victor Kwanmin] Natl Univ Singapore Hosp, Dept Pathol, Singapore, Singapore; [Ding, Ling-Wen] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pathol, Singapore, Singapore; [Gery, Sigal; Koeffler, H. Phillip] Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; [Hill, Jeffrey] Univ Sussex, Sch Life Sci, Sussex Drug Discovery Ctr, Brighton, E Sussex, England	National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Experimental Drug Development Centre (EDDC); National University of Singapore; National University of Singapore; National University of Singapore; University of Texas System; University of Texas Health San Antonio; National University of Singapore; National University of Singapore; Cedars Sinai Medical Center; University of Sussex	Chen, Y; Xu, L (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.	zjuchenye@gmail.com; xuliang.zju@gmail.com	Xu, Liang/I-9877-2014; Ding, Ling-Wen/H-6916-2019	Xu, Liang/0000-0002-2700-4840; Ding, Ling-Wen/0000-0003-0022-1551; Lin, Ruby/0000-0003-3229-4659; Lee, Victor Kwan Min/0000-0001-7803-0005	Biomedical Sciences Institutes; Joint Council Office (JCO), Agency for Science, Technology and Research, Singapore [11 03 FG 07 05]; National Institutes of Health [R01-CA200992-04]; Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award [NMRC/STaR/0021/2014]; Singapore Ministry of Education [MOE2017-T21-033]; RNA Biology Center at the Cancer Science Institute of Singapore of NUS as part of Singapore Ministry of Education's AcRF [MOE2014-T3-1-006]; NMRC Centre Grant Programme [NMRC/CG/012/2013, CGAug16M005, NMRC/CG/M005/2017_NCIS]; National Research Foundation Singapore; Singapore Ministry of Education under its Research Centres of Excellence initiatives; NUS Center for Cancer Research (N2CR), Cancer Programme under Translational Research Programmes; Yong Loo Lin School of Medicine, NUS [NUHSRO/2020/122/MSC/07/Cancer]; NCIS Centre Grant; NCIS Yong Siew Yoon Research grant; NMRC Open Fund Young Individual Research Grants [MOH-OFYIRG19Nov-0016, MOH-OFYIRG18May-0001]; Walk Foundation	Biomedical Sciences Institutes; Joint Council Office (JCO), Agency for Science, Technology and Research, Singapore; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award(Ministry of Health-SingaporeNational Medical Research Council, Singapore); Singapore Ministry of Education(Ministry of Education, Singapore); RNA Biology Center at the Cancer Science Institute of Singapore of NUS as part of Singapore Ministry of Education's AcRF; NMRC Centre Grant Programme(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under its Research Centres of Excellence initiatives(Ministry of Education, Singapore); NUS Center for Cancer Research (N2CR), Cancer Programme under Translational Research Programmes; Yong Loo Lin School of Medicine, NUS; NCIS Centre Grant; NCIS Yong Siew Yoon Research grant; NMRC Open Fund Young Individual Research Grants; Walk Foundation	We thank Drs Pierre Aman, Christopher DM Fletcher, Florence Pedeutour, Eugenio Erba, Jun Nishio, Peter Moller, Dominique Broccoli, Raphael Pollock, Peter Houghton, Stefan Frohling, Karen Sisley, Abdulazeez Salawu, Matthew Ho, Omid Khorram, Rebecca Lock, and Alex Matter for generous sharing of cell lines and reagents. We also thank kind helps from Dr Motomi Osato, Dr Yangyang Song, Mr. Haoqing Shen, and Dr Jian Han in experiments and discussion. The discovery of ETC-168 (also known as AUM168 in AUM Biosciences) was financially supported by Biomedical Sciences Institutes and Joint Council Office (JCO Project 11 03 FG 07 05), Agency for Science, Technology and Research, Singapore. This work is funded by the National Institutes of Health (R01-CA200992-04 to HPK), Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award to HPK. (NMRC/STaR/0021/2014), the Singapore Ministry of Education Academic Research Fund Tier 2 (MOE2017-T21-033), the RNA Biology Center at the Cancer Science Institute of Singapore of NUS as part of funding under the Singapore Ministry of Education's AcRF Tier 3 grants (MOE2014-T3-1-006), the NMRC Centre Grant Programme awarded to National University Cancer Institute of Singapore (NMRC/CG/012/2013, CGAug16M005 and NMRC/CG/M005/2017_NCIS) and the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiatives. It is additionally supported by NUS Center for Cancer Research (N2CR), Cancer Programme under Translational Research Programmes, Yong Loo Lin School of Medicine, NUS (NUHSRO/2020/122/MSC/07/Cancer), a Seed Funding Program within the NCIS Centre Grant, a NCIS Yong Siew Yoon Research grant through donations from the Yong Loo Lin Trust, and philanthropic donations from the Wendy Walk Foundation, Ms. Tricia West and Ms. Linda Abrams. YC and LX are supported by the NMRC Open Fund Young Individual Research Grants (MOH-OFYIRG19Nov-0016 and MOH-OFYIRG18May-0001).	AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Bhat M, 2015, NAT REV DRUG DISCOV, V14, P261, DOI 10.1038/nrd4505; Brown MC, 2017, CELL REP, V18, P1444, DOI 10.1016/j.celrep.2017.01.023; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09257-z; Coindre JM, 2001, CANCER-AM CANCER SOC, V91, P1914, DOI 10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; Diab S, 2014, CHEM BIOL, V21, P441, DOI 10.1016/j.chembiol.2014.01.011; Dreas A, 2017, CURR MED CHEM, V24, P3025, DOI 10.2174/0929867324666170203123427; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Fletcher CDM, 2013, WHO CLASSIFICATION T; George S, 2018, J CLIN ONCOL, V36, P144, DOI 10.1200/JCO.2017.75.9845; Grzmil M, 2014, J CLIN INVEST, V124, P742, DOI 10.1172/JCI70198; Grzmil M, 2011, CANCER RES, V71, P2392, DOI 10.1158/0008-5472.CAN-10-3112; Guo QY, 2019, CANCER RES, V79, P1646, DOI 10.1158/0008-5472.CAN-18-1602; Guo ZH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10397-9; Hay N, 2010, P NATL ACAD SCI USA, V107, P13975, DOI 10.1073/pnas.1008908107; Hazawa M, 2020, ONCOGENE, V39, P2212, DOI 10.1038/s41388-019-1137-3; Hazawa M, 2018, EMBO REP, V19, P73, DOI 10.15252/embr.201744523; Hernando E, 2007, NAT MED, V13, P748, DOI 10.1038/nm1560; Hou S, 2017, CLIN TRANSL ONCOL, V19, P1107, DOI 10.1007/s12094-017-1646-x; Hu SI, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002466; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Lazar AJ, 2017, CELL, V171, P950, DOI 10.1016/j.cell.2017.10.014; Lim S, 2013, P NATL ACAD SCI USA, V110, pE2298, DOI 10.1073/pnas.1301838110; Lock R, 2016, J CLIN INVEST, V126, P2181, DOI 10.1172/JCI85183; Lopez G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188859; Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892; Matheson CJ, 2016, TRENDS PHARMACOL SCI, V37, P872, DOI 10.1016/j.tips.2016.06.006; Nishio J, 2003, INT J ONCOL, V22, P535; Pang A, 2016, JAMA ONCOL, V2, P941, DOI 10.1001/jamaoncol.2016.0241; Persson F, 2008, CANCER LETT, V260, P37, DOI 10.1016/j.canlet.2007.10.032; Salawu A, 2016, BRIT J CANCER, V115, P1058, DOI 10.1038/bjc.2016.259; Santag S, 2017, CANCER LETT, V390, P21, DOI 10.1016/j.canlet.2016.12.029; Sekiyama N, 2015, P NATL ACAD SCI USA, V112, pE4036, DOI 10.1073/pnas.1512118112; Sharma B, 2012, J BIOL CHEM, V287, P42352, DOI 10.1074/jbc.M112.400721; Snyder EL, 2009, J PATHOL, V218, P292, DOI 10.1002/path.2564; Thelin-Jarnum S, 1999, INT J CANCER, V83, P30, DOI 10.1002/(SICI)1097-0215(19990924)83:1<30::AID-IJC6>3.0.CO;2-4; Uboldi S, 2012, INT J CANCER, V131, P59, DOI 10.1002/ijc.26340; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; Vitale G, 2012, BIOTECHNOL ADV, V30, P169, DOI 10.1016/j.biotechadv.2011.08.001; Wabitsch M, 2000, INT J CANCER, V88, P889, DOI 10.1002/1097-0215(20001215)88:6<889::AID-IJC8>3.0.CO;2-N; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Webster KR, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.1554.1554; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wilson C, 2014, CANCER RES, V74, P5878, DOI 10.1158/0008-5472.CAN-14-1009; Xu L, 2018, P NATL ACAD SCI USA, V115, pE5086, DOI 10.1073/pnas.1712363115; Xu YC, 2019, NAT MED, V25, P301, DOI 10.1038/s41591-018-0321-2; Yang H, 2018, J MED CHEM, V61, P4348, DOI 10.1021/acs.jmedchem.7b01714; Yang W, 2020, ONCOGENE, V39, P3650, DOI 10.1038/s41388-020-1240-5; Yao S, 2018, SEMIN CANCER BIOL, V50, P77, DOI 10.1016/j.semcancer.2017.11.018; Zhan Y, 2017, J CLIN INVEST, V127, P4179, DOI 10.1172/JCI91258	56	6	6	6	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1851	1867		10.1038/s41388-021-01661-4	http://dx.doi.org/10.1038/s41388-021-01661-4		FEB 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564073	Green Published, hybrid			2022-12-28	WOS:000616489100006
J	Yoshida, K; Yokoi, A; Sugiyama, M; Oda, S; Kitami, K; Tamauchi, S; Ikeda, Y; Yoshikawa, N; Nishino, K; Niimi, K; Suzuki, S; Kikkawa, F; Yokoi, T; Kajiyama, H				Yoshida, Kosuke; Yokoi, Akira; Sugiyama, Mai; Oda, Shingo; Kitami, Kazuhisa; Tamauchi, Satoshi; Ikeda, Yoshiki; Yoshikawa, Nobuhisa; Nishino, Kimihiro; Niimi, Kaoru; Suzuki, Shiro; Kikkawa, Fumitaka; Yokoi, Tsuyoshi; Kajiyama, Hiroaki			Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance	ONCOGENE			English	Article							CANCER CELLS; IDENTIFICATION; MIR-509-3P; SENSITIVITY; MICRORNAS; APOPTOSIS; GENES	Ovarian clear cell carcinoma (OCCC) is a histological subtype of epithelial ovarian cancer and exhibits dismal prognosis due to chemoresistance. Moreover, only few effective therapeutic options exist for patients with recurrent OCCC, and an understanding of its molecular characteristics is essential for the development of novel therapeutic approaches. In the present study, we investigated unique MicroRNAs (miRNA) profiles in recurrent/metastatic OCCC and the role of miRNAs in cisplatin resistance. Comprehensive miRNA sequencing revealed that expression of several miRNAs, including miR-508-3p, miR-509-3p, miR-509-3-5p, and miR-514a-3p was remarkably less in recurrent cancer tissues when compared with that in paired primary cancer tissues. These miRNAs are located in the chrXq27.3 region on the genome. Moreover, its expression was negative in omental metastases in two patients with advanced OCCC. In vitro analyses revealed that overexpression of miR-509-3p and miR-509-3-5p reversed cisplatin resistance and yes-associated protein 1 (YAP1) was partially responsible for the resistance. Immunohistochemistry revealed that YAP1 expression was inversely correlated with the chrXq27.3 miRNA cluster expression. In conclusion, these findings suggest that alteration of the chrXq27.3 miRNA cluster could play a critical role in chemoresistance and miRNAs in the cluster and their target genes can be potential therapeutic targets.	[Yoshida, Kosuke; Yokoi, Akira; Kitami, Kazuhisa; Tamauchi, Satoshi; Ikeda, Yoshiki; Yoshikawa, Nobuhisa; Nishino, Kimihiro; Niimi, Kaoru; Suzuki, Shiro; Kikkawa, Fumitaka; Kajiyama, Hiroaki] Nagoya Univ, Dept Obstet & Gynecol, Grad Sch Med, Nagoya, Aichi, Japan; [Yoshida, Kosuke; Yokoi, Akira] Nagoya Univ, Inst Adv Res, Nagoya, Aichi, Japan; [Yoshida, Kosuke; Oda, Shingo; Yokoi, Tsuyoshi] Nagoya Univ, Div Clin Pharmacol, Dept Drug Safety Sci, Grad Sch Med, Nagoya, Aichi, Japan; [Sugiyama, Mai] Nagoya Univ, Dept Obstet & Gynecol Collaborat Res, Bell Res Ctr, Grad Sch Med, Nagoya, Aichi, Japan	Nagoya University; Nagoya University; Nagoya University; Nagoya University	Yokoi, A (corresponding author), Nagoya Univ, Dept Obstet & Gynecol, Grad Sch Med, Nagoya, Aichi, Japan.; Yokoi, A (corresponding author), Nagoya Univ, Inst Adv Res, Nagoya, Aichi, Japan.	ayokoi@med.nagoya-u.ac.jp	YOSHIKAWA, NOBUHISA/AAE-5967-2021; YOSHIDA, Kosuke/AAM-6507-2020	YOSHIDA, Kosuke/0000-0003-1484-4872; Ikeda, Yoshiki/0000-0002-9456-0468; Yoshikawa, Nobuhisa/0000-0001-8662-9421	Japan Society for the Promotion of Science [16K15704, 16H02616, 17H04338, 19H03797, 20K22806]; Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED) [20ck0106630h0001]; Aichi Cancer Research Foundation; Program for Promoting the Enhancement of Research Universities at Nagoya University	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED); Aichi Cancer Research Foundation(Aichi Cancer Research Foundation); Program for Promoting the Enhancement of Research Universities at Nagoya University	We express our highest appreciation to all members of the Department of Drug Safety Sciences, Division of Clinical Pharmacology, and Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine. Moreover, we received technical support from the Division for Medical Research Engineering, Nagoya University Graduate School of Medicine. Furthermore, we thank Enago (https://www.enago.jp/) for English editing of this manuscript. This study was supported by a Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research: Grant Numbers 16K15704, 16H02616, 17H04338, 19H03797, and 20K22806, and Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED): Grant Number 20ck0106630h0001. Aichi Cancer Research Foundation supported as well. Moreover, research reported in this publication was supported by the Program for Promoting the Enhancement of Research Universities as young researcher units for the advancement of new and undeveloped fields at Nagoya University.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Anglesio MS, 2011, GYNECOL ONCOL, V121, P407, DOI 10.1016/j.ygyno.2011.01.005; Bagnoli M, 2011, ONCOTARGET, V2, P1265, DOI 10.18632/oncotarget.401; Boone JD, 2015, GYNECOL ONCOL, V138, P486, DOI 10.1016/j.ygyno.2015.05.022; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chan CK, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160275; Chen W, 2017, PHARMACOGENOMICS, V18, P1671, DOI 10.2217/pgs-2017-0115; Chen W, 2016, PHARMACOGENOMICS, V17, P187, DOI 10.2217/pgs.15.166; Chorn G, 2012, RNA, V18, P1796, DOI 10.1261/rna.031278.111; Damia G, 2019, CANCERS, V11, DOI 10.3390/cancers11010119; Das MK, 2016, CANCER GENOM PROTEOM, V13, P63; Elgaaen BV, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-80; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Ghafouri-Fard S, 2020, EXP MOL PATHOL, V113, DOI 10.1016/j.yexmp.2020.104381; Ghosh S, 2019, BIOORG CHEM, V88, DOI 10.1016/j.bioorg.2019.102925; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kabekkodu SP, 2020, WIRES RNA, V11, DOI 10.1002/wrna.1563; Li J, 2016, ONCOGENE, V35, P5501, DOI 10.1038/onc.2016.90; Matsui M, 2016, MOL THER, V24, P946, DOI 10.1038/mt.2016.39; Mendes ND, 2009, NUCLEIC ACIDS RES, V37, P2419, DOI 10.1093/nar/gkp145; Mihanfar A, 2019, J CELL PHYSIOL, V234, P3180, DOI 10.1002/jcp.26060; Nam EJ, 2016, ONCOTARGET, V7, P70524, DOI 10.18632/oncotarget.12045; Niu LL, 2019, GENE, V686, P63, DOI 10.1016/j.gene.2018.11.011; Ozata DM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.464; Pan YH, 2016, ONCOTARGET, V7, P25930, DOI 10.18632/oncotarget.8412; Ramaiah M, 2019, EMBO REP, V20, DOI 10.15252/embr.201846566; Reggiani F, 2020, BBA-REV CANCER, V1873, DOI 10.1016/j.bbcan.2020.188341; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Song J, 2018, ONCOL LETT, V16, P3949, DOI 10.3892/ol.2018.9141; Streicher KL, 2012, ONCOGENE, V31, P1558, DOI 10.1038/onc.2011.345; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang J, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-199; Wang XH, 2016, BIOCHEM BIOPH RES CO, V478, P676, DOI 10.1016/j.bbrc.2016.08.006; Wei X, 2019, ONCOL REP, V42, P2768, DOI 10.3892/or.2019.7370; Xia Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109575; Yan TT, 2018, CANCER RES, V78, P1751, DOI 10.1158/0008-5472.CAN-17-2101; Yoshida K, 2019, CARCINOGENESIS, V40, P1435, DOI 10.1093/carcin/bgz135; Yoshida K, 2018, ONCOL LETT, V16, P515, DOI 10.3892/ol.2018.8610; Zanconato F, 2019, NAT REV CANCER, V19, P454, DOI 10.1038/s41568-019-0168-y; Zhai QN, 2012, BIOCHEM BIOPH RES CO, V419, P621, DOI 10.1016/j.bbrc.2012.02.060; Zhao LJ, 2019, ONCOGENE, V38, P2305, DOI 10.1038/s41388-018-0577-5; Zhou YF, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00139	44	8	8	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1255	1268		10.1038/s41388-020-01595-3	http://dx.doi.org/10.1038/s41388-020-01595-3		JAN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420363	hybrid, Green Published			2022-12-28	WOS:000607346000011
J	Nimmakayala, RK; Leon, F; Rachagani, S; Rauth, S; Nallasamy, P; Marimuthu, S; Shailendra, GK; Chhonker, YS; Chugh, S; Chirravuri, R; Gupta, R; Mallya, K; Prajapati, DR; Lele, SM; Caffrey, TC; Grem, JL; Grandgenett, PM; Hollingsworth, MA; Murry, DJ; Batra, SK; Ponnusamy, MP				Nimmakayala, Rama Krishna; Leon, Frank; Rachagani, Satyanarayana; Rauth, Sanchita; Nallasamy, Palanisamy; Marimuthu, Saravanakumar; Shailendra, Gautam K.; Chhonker, Yashpal S.; Chugh, Seema; Chirravuri, Ramakanth; Gupta, Rohitesh; Mallya, Kavita; Prajapati, Dipakkumar R.; Lele, Subodh M.; C. Caffrey, Thomas; L. Grem, Jean; Grandgenett, Paul M.; Hollingsworth, Michael A.; Murry, Daryl J.; Batra, Surinder K.; Ponnusamy, Moorthy P.			Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							OXIDATIVE-PHOSPHORYLATION; MITOCHONDRIAL BIOGENESIS; TUMOR-GROWTH; IDENTIFICATION; GLIOBLASTOMA; GEMCITABINE; PLASTICITY; RESISTANCE; BIOMARKER	Pancreatic ductal adenocarcinoma (PDAC) metastasizes to distant organs, which is the primary cause of mortality; however, specific features mediating organ-specific metastasis remain unexplored. Emerging evidence demonstrates that cancer stem cells (CSCs) and cellular metabolism play a pivotal role in metastasis. Here we investigated the role of distinct subtypes of pancreatic CSCs and their metabolomic signatures in organ-specific metastatic colonization. We found that PDAC consists of ALDH+/CD133+ and drug-resistant (MDR1+) subtypes of CSCs with specific metabolic and stemness signatures. Human PDAC tissues with gemcitabine treatment, autochthonous mouse tumors from Kras(G12D); Pdx1-Cre (KC) and Kras(G12D); Trp53(R172H); Pdx-1 Cre (KPC) mice, and KPC- Liver/Lung metastatic cells were used to evaluate the CSC, EMT (epithelial-to-mesenchymal transition), and metabolic profiles. A strong association was observed between distinct CSC subtypes and organ-specific colonization. The liver metastasis showed drug-resistant CSC- and EMT-like phenotype with aerobic glycolysis and fatty acid beta-oxidation-mediated oxidative (glyco-oxidative) metabolism. On the contrary, lung metastasis displayed ALDH+/CD133+ and MET-like phenotype with oxidative metabolism. These results were obtained by evaluating FACS-based side population (SP), autofluorescence (AF+) and Alde-red assays for CSCs, and Seahorse-based oxygen consumption rate (OCR), extracellular acidification rate (ECAR), and fatty acid beta-oxidation (FAO)-mediated OCR assays for metabolic features along with specific gene signatures. Further, we developed in vitro human liver and lung PDAC metastasis models by using a combination of liver or lung decellularized scaffolds, a co-culture, and a sphere culture methods. PDAC cells grown in the liver-mimicking model showed the enrichment of MDR1+ and CPT1A+ populations, whereas the PDAC cells grown in the lung-mimicking environment showed the enrichment of ALDH+/CD133+ populations. In addition, we observed significantly elevated expression of ALDH1 in lung metastasis and MDR1/LDH-A expression in liver metastasis compared to human primary PDAC tumors. Our studies elucidate that distinct CSCs adapt unique metabolic signatures for organotropic metastasis, which will pave the way for the development of targeted therapy for PDAC metastasis.	[Nimmakayala, Rama Krishna; Leon, Frank; Rachagani, Satyanarayana; Rauth, Sanchita; Nallasamy, Palanisamy; Marimuthu, Saravanakumar; Shailendra, Gautam K.; Chugh, Seema; Chirravuri, Ramakanth; Gupta, Rohitesh; Mallya, Kavita; Batra, Surinder K.; Ponnusamy, Moorthy P.] Univ Nebraska, Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Chhonker, Yashpal S.; Murry, Daryl J.] Univ Nebraska, Med Ctr, Coll Pharm, Dept Pharm Practice & Sci, 986145 Nebraska Med Ctr, Omaha, NE 68198 USA; [Prajapati, Dipakkumar R.; Lele, Subodh M.] Univ Nebraska, Coll Med, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [C. Caffrey, Thomas; L. Grem, Jean; Grandgenett, Paul M.; Hollingsworth, Michael A.; Batra, Surinder K.; Ponnusamy, Moorthy P.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK; Ponnusamy, MP (corresponding author), Univ Nebraska, Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Batra, SK; Ponnusamy, MP (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu; mpalanim@unmc.edu	Gautam, Shailendra/GLQ-9528-2022; Nimmakayala, Rama Krishna/CAG-5670-2022; Prajapati, Dipakkumar R/AAH-7578-2021; Nallasamy, Palanisamy/AAH-7727-2021; Marimuthu, Saravanakumar/AAJ-2878-2021; Gautam, Shailendra/ABD-2991-2021	Nimmakayala, Rama Krishna/0000-0003-4637-4828; Prajapati, Dipakkumar R/0000-0001-8954-890X; Nallasamy, Palanisamy/0000-0001-8962-2487; Marimuthu, Saravanakumar/0000-0003-3640-5408; Gautam, Shailendra/0000-0002-8959-1331; gupta, rohitesh/0000-0001-8515-5869	National Institutes of Health [P01 CA217798, R01 CA210637, R01 CA183459, R01 CA195586, R01 CA201444, R01 CA228524, U01 CA200466, R01 CA247471, R50CA211462, P50CA12729, U01 CA210240]; Nebraska Department of Health and Human Services [LB595]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nebraska Department of Health and Human Services	We thank Craig Semerad, Victoria B. Smith, and Samantha Wall of the Flow Cytometry Research Facility, University of Nebraska Medical Center, for assisting with flow cytometry. We thank Janice A. Taylor and James R. Talaska of the Advanced Microscopy Core Facility at the University of Nebraska Medical Center for assisting with confocal microscopy. Further, we thank Dr. Kelly Stauch, Seahorse Core director at the University of Nebraska Medical Center, for assisting with Seahorse experiments. We were supported primarily by the following grants from the National Institutes of Health P01 CA217798, R01 CA210637, R01 CA183459, R01 CA195586, R01 CA201444, R01 CA228524, U01 CA200466, R01 CA228524, R01 CA247471, R50CA211462, P50CA12729 and U01 CA210240, and the Nebraska Department of Health and Human Services LB595.	Akada M, 2005, CLIN CANCER RES, V11, P3094, DOI 10.1158/1078-0432.CCR-04-1785; Bhagwandin VJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148807; Celia-Terrassa T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08509-2; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Ciavardelli D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.285; De Luca A, 2015, ONCOTARGET, V6, P14777, DOI 10.18632/oncotarget.4401; Doege H, 2006, GASTROENTEROLOGY, V130, P1245, DOI 10.1053/j.gastro.2006.02.006; Gao WC, 2013, GASTROENTEROLOGY, V145, P636, DOI 10.1053/j.gastro.2013.05.049; Grillet F, 2017, GUT, V66, P1802, DOI 10.1136/gutjnl-2016-311447; Han SH, 2019, AUTOPHAGY, V15, P2076, DOI 10.1080/15548627.2019.1596492; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Duong HQ, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6030052; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hu J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.72; Huang P, 2008, WORLD J GASTROENTERO, V14, P3903, DOI 10.3748/wjg.14.3903; Jiao L, 2018, AUTOPHAGY, V14, P671, DOI 10.1080/15548627.2017.1381804; Kim MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020636; Klonisch T, 2008, TRENDS MOL MED, V14, P450, DOI 10.1016/j.molmed.2008.08.003; Lamb R, 2015, ONCOTARGET, V6, P30453, DOI 10.18632/oncotarget.5852; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li CW, 2009, METHODS MOL BIOL, V568, P161, DOI 10.1007/978-1-59745-280-9_10; Liao JQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084941; Lin YH, 2018, HEPATOLOGY, V67, P188, DOI 10.1002/hep.29462; Liou GY, 2019, INT J BIOCHEM CELL B, V106, P1, DOI 10.1016/j.biocel.2018.10.013; Luo M, 2018, CELL METAB, V28, P69, DOI 10.1016/j.cmet.2018.06.006; Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563; Mashimo T, 2014, CELL, V159, P1603, DOI 10.1016/j.cell.2014.11.025; Menendez Javier A, 2014, Oncoscience, V1, P803; Menendez JA, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00262; Miranda-Lorenzo I, 2014, NAT METHODS, V11, P1161, DOI [10.1038/NMETH.3112, 10.1038/nmeth.3112]; Niess H, 2015, TARGET ONCOL, V10, P215, DOI 10.1007/s11523-014-0323-z; Nimmakayala RK, 2019, BBA-REV CANCER, V1871, P50, DOI 10.1016/j.bbcan.2018.10.006; Nimmakayala RK, 2018, GASTROENTEROLOGY, V155, P892, DOI 10.1053/j.gastro.2018.05.041; Pasto A, 2014, ONCOTARGET, V5, P4305, DOI 10.18632/oncotarget.2010; Poruk KE, 2017, CLIN CANCER RES, V23, P2681, DOI 10.1158/1078-0432.CCR-16-1467; Ramamoorthy P, 2019, CANCER RES, V79, P1681, DOI 10.1158/0008-5472.CAN-18-2602; Rasheed ZA, 2010, JNCI-J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535; Rawla P, 2019, WORLD J ONCOL, V10, P10, DOI 10.14740/wjon1166; Richard V, 2013, J BIOMED RES INT, V2013, P8; Rubin MA, 2014, CANCER DISCOV, V4, P1262, DOI 10.1158/2159-8290.CD-14-1075; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; Schild T, 2018, CANCER CELL, V33, P347, DOI 10.1016/j.ccell.2018.02.001; Shukla SK, 2017, CANCER CELL, V32, P71, DOI 10.1016/j.ccell.2017.06.004; Wang TY, 2018, CELL METAB, V27, P136, DOI 10.1016/j.cmet.2017.11.001; Wang YN, 2018, ONCOGENE, V37, P6025, DOI 10.1038/s41388-018-0384-z; Zhou YF, 2011, J BIOL CHEM, V286, P32843, DOI 10.1074/jbc.M111.260935	48	32	32	5	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					215	231		10.1038/s41388-020-01518-2	http://dx.doi.org/10.1038/s41388-020-01518-2		OCT 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33110235				2022-12-28	WOS:000582768100004
J	Gamaev, L; Mizrahi, L; Friehmann, T; Rosenberg, N; Pappo, O; Olam, D; Zeira, E; Halpern, KB; Caruso, S; Zucman-Rossi, J; Axelrod, JH; Galun, E; Goldenberg, DS				Gamaev, Lika; Mizrahi, Lina; Friehmann, Tomer; Rosenberg, Nofar; Pappo, Orit; Olam, Devorah; Zeira, Evelyne; Bahar Halpern, Keren; Caruso, Stefano; Zucman-Rossi, Jessica; Axelrod, Jonathan H.; Galun, Eithan; Goldenberg, Daniel S.			The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma	ONCOGENE			English	Article							NONCODING RNA H19; LIVER CARCINOGENESIS; MOLECULAR-MECHANISMS; MURINE; GENE; EXPRESSION; POLYPLOIDIZATION; CLASSIFICATION; PROLIFERATION; CONTRIBUTES	The oncofetal long noncoding RNA (lncRNA) H19 is postnatally repressed in most tissues, and re-expressed in many cancers, including hepatocellular carcinoma (HCC). The role of H19 in carcinogenesis is a subject of controversy. We aimed to examine the role of H19 in chronic inflammation-mediated hepatocarcinogenesis using the Mdr2/Abcb4 knockout (Mdr2-KO) mouse, a well-established HCC model. For this goal, we have generated Mdr2-KO/H19-KO double knockout (dKO) mice and followed spontaneous tumor development in the dKO and control Mdr2-KO mice. Cellular localization of H19 and effects of H19 loss in the liver were determined in young and old Mdr2-KO mice. Tumor incidence and tumor load were both significantly decreased in the liver of dKO versus Mdr2-KO females. The expression levels of H19 and Igf2 were variable in nontumor liver tissues of Mdr2-KO females and were significantly downregulated in most matched tumors. In nontumor liver tissue of aged Mdr2-KO females, H19 was expressed mainly in hepatocytes, and hepatocyte proliferation was increased compared to dKO females. At an early age, dKO females displayed lower levels of liver injury and B-cell infiltration, with higher percentage of binuclear hepatocytes. In human samples, H19 expression was higher in females, positively correlated with cirrhosis (in nontumor liver samples) and negatively correlated with CTNNB1 (beta-catenin) mutations and patients' survival (in tumors). Our data demonstrate that the lncRNA H19 is pro-oncogenic during the development of chronic inflammation-mediated HCC in the Mdr2-KO mouse model, mainly by increasing liver injury and decreasing hepatocyte polyploidy in young mice.	[Gamaev, Lika; Mizrahi, Lina; Friehmann, Tomer; Rosenberg, Nofar; Olam, Devorah; Zeira, Evelyne; Axelrod, Jonathan H.; Galun, Eithan; Goldenberg, Daniel S.] Hadassah Hebrew Univ, Med Ctr, Goldyne Savad Inst Gene & Cell Therapy, Jerusalem, Israel; [Pappo, Orit] Hadassah Hebrew Univ, Med Ctr, Dept Pathol, Jerusalem, Israel; [Bahar Halpern, Keren] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel; [Caruso, Stefano; Zucman-Rossi, Jessica] Univ Paris, Sorbonne Univ, INSERM, Ctr Rech Cordeliers,Funct Genom Solid Tumors Lab, F-75006 Paris, France; [Zucman-Rossi, Jessica] Hop Europeen Georges Pompidou, AP HP, F-75015 Paris, France	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Weizmann Institute of Science; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Goldenberg, DS (corresponding author), Hadassah Hebrew Univ, Med Ctr, Goldyne Savad Inst Gene & Cell Therapy, Jerusalem, Israel.	goldenberg@hadassah.org.il	zucman-rossi, Jessica/B-5098-2009; j, zucman-rossi/AAV-3594-2021; Caruso, Stefano/AAA-9564-2020; Galun, Eithan/AAD-9117-2022	zucman-rossi, Jessica/0000-0002-5687-0334; j, zucman-rossi/0000-0002-5687-0334; Caruso, Stefano/0000-0002-6319-3642; Galun, Eithan/0000-0002-6243-6702; Goldenberg, Daniel/0000-0002-1618-4145	Robert H. Benson Living Trust; Selma Kron Foundation; Kamea Scientific Foundation of the Israeli Government; ISF [923/14, 486/2017]; Labex OncoImunology; CARPEM; INSERM; Ligue Nationale contre le Cancer (Equipe Labellisee); Labex OncoImmunology (investissement d'avenir); grant IREB; Coup d'Elan de la Fondation Bettencourt-Schueller; SIRIC CARPEM; Raymond Rosen Award from the Fondation pour le Recherche Medicale; Prix Rene and Andree Duquesne-Comite de Paris Ligue Contre le Cancer; Fondation Merieux; ERC [786575-RxmiRcanceR]; Deutsche Forschungsgemeinschaft (DFG) [SFB841]; NIH [CA197081-02]; MOST; ISF collaboration with Canada [2473/2017]; ICORE-ISF [41/2011]; DKFZ-MOST	Robert H. Benson Living Trust; Selma Kron Foundation; Kamea Scientific Foundation of the Israeli Government; ISF(Israel Science Foundation); Labex OncoImunology; CARPEM; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue Nationale contre le Cancer (Equipe Labellisee)(Ligue nationale contre le cancer); Labex OncoImmunology (investissement d'avenir)(French National Research Agency (ANR)); grant IREB; Coup d'Elan de la Fondation Bettencourt-Schueller; SIRIC CARPEM; Raymond Rosen Award from the Fondation pour le Recherche Medicale; Prix Rene and Andree Duquesne-Comite de Paris Ligue Contre le Cancer; Fondation Merieux; ERC(European Research Council (ERC)European Commission); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MOST; ISF collaboration with Canada; ICORE-ISF; DKFZ-MOST	Robert H. Benson Living Trust and Selma Kron Foundation to student fellowships. DSG is supported by the Kamea Scientific Foundation of the Israeli Government. JHA was supported by ISF 923/14. SC was supported by a funding from Labex OncoImunology and CARPEM. The JZR group was supported by INSERM, Ligue Nationale contre le Cancer (Equipe Labellisee), Labex OncoImmunology (investissement d'avenir), grant IREB, Coup d'Elan de la Fondation Bettencourt-Schueller, the SIRIC CARPEM, Raymond Rosen Award from the Fondation pour le Recherche Medicale, Prix Rene and Andree Duquesne-Comite de Paris Ligue Contre le Cancer and Fondation Merieux. The work of EG was supported by the: ERC advance-GA No. 786575-RxmiRcanceR, Deutsche Forschungsgemeinschaft (DFG) SFB841 project C3, NIH CA197081-02, MOST, ISF collaboration with Canada (2473/2017), personal ISF (486/2017), ICORE-ISF (41/2011), and by DKFZ-MOST.	Adriaenssens E, 1999, ONCOGENE, V18, P4460, DOI 10.1038/sj.onc.1202819; Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Chen X, 2015, CANCER SCI, V106, P972, DOI 10.1111/cas.12700; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; Ella E, 2014, ONCOTARGET, V5, P10318, DOI 10.18632/oncotarget.2515; Faggioli F, 2018, HEPATOLOGY, V67, P1970, DOI 10.1002/hep.29636; Goyal N, 2019, J MOL MED, V97, P115, DOI 10.1007/s00109-018-1718-6; Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200; Hao PP, 2015, J HEPATOL, V62, P1278, DOI 10.1016/j.jhep.2014.12.033; Hoppstadter J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01446; Jiang YC, 2018, HEPATOL COMMUN, V2, P1356, DOI 10.1002/hep4.1252; Jones SA, 2016, ANN RHEUM DIS, V75, P739, DOI 10.1136/annrheumdis-2015-207744; Katzenellenbogen M, 2006, CANCER RES, V66, P4001, DOI 10.1158/0008-5472.CAN-05-2937; Katzenellenbogen M, 2007, MOL CANCER RES, V5, P1159, DOI 10.1158/1541-7786.MCR-07-0172; Lecerf C, 2019, CELL MOL LIFE SCI, V76, P4673, DOI 10.1007/s00018-019-03240-z; Lee JW, 2019, NATURE, V567, P249, DOI 10.1038/s41586-019-1004-y; Li XJY, 2018, HEPATOLOGY, V68, P599, DOI 10.1002/hep.29838; Li XJY, 2017, HEPATOLOGY, V66, P869, DOI 10.1002/hep.29145; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Martinez-Quetglas I, 2016, GASTROENTEROLOGY, V151, P1192, DOI 10.1053/j.gastro.2016.09.001; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; MAUAD TH, 1994, AM J PATHOL, V145, P1237; Nemeth J, 2009, HEPATOLOGY, V50, P1251, DOI 10.1002/hep.23099; Pope C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187557; Potikha T, 2013, HEPATOLOGY, V58, P192, DOI 10.1002/hep.26335; Raveh E, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0458-2; Ricci E, 2019, J LEUKOCYTE BIOL, V105, P187, DOI 10.1002/JLB.3AB0718-255R; Robert O, 2016, J HEPATOL, V64, P916, DOI 10.1016/j.jhep.2015.11.023; Schultheiss CS, 2017, CELL STRESS, V1, P37, DOI 10.15698/cst2017.10.105; Shoshani O, 2012, CANCER RES, V72, P6403, DOI 10.1158/0008-5472.CAN-12-1155; Stoyanov E, 2015, ONCOTARGET, V6, P11047, DOI 10.18632/oncotarget.3567; Uehara T, 2013, TOXICOL SCI, V132, P53, DOI 10.1093/toxsci/kfs342; Wilkinson PD, 2019, HEPATOLOGY, V69, P1242, DOI 10.1002/hep.30286; Xu GQ, 2015, ONCOTARGET, V6, P33636, DOI 10.18632/oncotarget.5602; Yamamoto Y, 2004, J HEPATOL, V40, P808, DOI 10.1016/j.jhep.2004.01.022; Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x; Yang JB, 2018, ONCOGENE, V37, P1192, DOI 10.1038/s41388-017-0048-4; Yang NM, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0756-7; Yang XW, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-909; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yoshimizu T, 2008, P NATL ACAD SCI USA, V105, P12417, DOI 10.1073/pnas.0801540105; Zhang JQ, 2019, HEPATOLOGY, V69, P1549, DOI 10.1002/hep.30153; Zhang L, 2013, CARCINOGENESIS, V34, P577, DOI 10.1093/carcin/bgs381; Zhang SY, 2018, DEV CELL, V44, P447, DOI 10.1016/j.devcel.2018.01.010; Zhang YX, 2016, SCI REP-UK, V6, DOI 10.1038/srep20559; Zhao RZ, 2020, NATURE, V577, P416, DOI 10.1038/s41586-019-1873-0; Zhu PP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8122	47	14	14	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					127	139		10.1038/s41388-020-01513-7	http://dx.doi.org/10.1038/s41388-020-01513-7		OCT 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33093654	Green Published			2022-12-28	WOS:000581554300001
J	Leonard, MK; Puts, GS; Pamidimukkala, N; Adhikary, G; Xu, YL; Kwok, E; Jin, YX; Snyder, D; Matsangos, N; Novak, M; Mahurkar, A; Shetty, AC; Slominski, RM; De Fabo, EC; Noonan, FP; Day, CP; Rigi, M; Slominski, AT; Webb, MG; Craig, DW; Merlino, G; Eckert, RL; Carpten, JD; Manojlovic, Z; Kaetzel, DM				Leonard, M. Kathryn; Puts, Gemma S.; Pamidimukkala, Nidhi; Adhikary, Gautam; Xu, Yili; Kwok, Eric; Jin, Yuxin; Snyder, Devin; Matsangos, Nicolette; Novak, Marian; Mahurkar, Anup; Shetty, Amol C.; Slominski, Radomir M.; De Fabo, Edward C.; Noonan, Frances P.; Day, Chi-Ping; Rigi, Mohammed; Slominski, Andrzej T.; Webb, Michelle G.; Craig, David W.; Merlino, Glenn; Eckert, Richard L.; Carpten, John D.; Manojlovic, Zarko; Kaetzel, David M.			Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients	ONCOGENE			English	Article							NM23/NUCLEOSIDE DIPHOSPHATE-KINASE; SUPPRESSOR FUNCTION; PROSTATE-CANCER; CTLA-4 BLOCKADE; UVEAL MELANOMA; CELL MOTILITY; MUTATIONS; NM23-H1; ABERRATIONS; REPAIR	Hepatocyte growth factor-overexpressing mice that harbor a deletion of the Ink4a/p16 locus (HP mice) form melanomas with low metastatic potential in response to UV irradiation. Here we report that these tumors become highly metastatic following hemizygous deletion of the Nme1 and Nme2 metastasis suppressor genes (HPN mice). Whole-genome sequencing of melanomas from HPN mice revealed a striking increase in lung metastatic activity that is associated with missense mutations in eight signature genes (Arhgap35, Atp8b4, Brca1, Ift172, Kif21b, Nckap5, Pcdha2, and Zfp869). RNA-seq analysis of transcriptomes from HP and HPN primary melanomas identified a 32-gene signature (HPN lung metastasis signature) for which decreased expression is strongly associated with lung metastatic potential. Analysis of transcriptome data from The Cancer Genome Atlas revealed expression profiles of these genes that predict improved survival of patients with cutaneous or uveal melanoma. Silencing of three representative HPN lung metastasis signature genes (ARRDC3, NYNRIN, RND3) in human melanoma cells resulted in increased invasive activity, consistent with roles for these genes as mediators of the metastasis suppressor function of NME1 and NME2. In conclusion, our studies have identified a family of genes that mediate suppression of melanoma lung metastasis, and which may serve as prognostic markers and/or therapeutic targets for clinical management of metastatic melanoma.	[Leonard, M. Kathryn; Puts, Gemma S.; Pamidimukkala, Nidhi; Adhikary, Gautam; Snyder, Devin; Matsangos, Nicolette; Novak, Marian; Eckert, Richard L.; Kaetzel, David M.] Univ Maryland Baltimore, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Leonard, M. Kathryn; Puts, Gemma S.; Pamidimukkala, Nidhi; Adhikary, Gautam; Snyder, Devin; Eckert, Richard L.; Kaetzel, David M.] Univ Maryland Baltimore, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Sch Med, Baltimore, MD 21201 USA; [Xu, Yili; Kwok, Eric; Jin, Yuxin; Webb, Michelle G.; Craig, David W.; Carpten, John D.; Manojlovic, Zarko] Univ Southern Calif, Keck Sch Med, Dept Translat Genom, Los Angeles, CA 90007 USA; [Mahurkar, Anup; Shetty, Amol C.] Univ Maryland Baltimore, Sch Med, Inst Genome Sci, Baltimore, MD USA; [Slominski, Radomir M.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA; [De Fabo, Edward C.; Noonan, Frances P.] George Washington Univ, Med Ctr, Washington, DC 20037 USA; [Day, Chi-Ping; Merlino, Glenn] NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA; [Rigi, Mohammed; Slominski, Andrzej T.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Kaetzel, David M.] VA Maryland Hlth Care Syst, Res & Dev Serv, Baltimore, MD 21201 USA; [Leonard, M. Kathryn] Amer Assoc Canc Res, Philadelphia, PA USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Southern California; University System of Maryland; University of Maryland Baltimore; University of Alabama System; University of Alabama Birmingham; George Washington University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alabama System; University of Alabama Birmingham	Kaetzel, DM (corresponding author), Univ Maryland Baltimore, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.; Kaetzel, DM (corresponding author), Univ Maryland Baltimore, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Sch Med, Baltimore, MD 21201 USA.; Kaetzel, DM (corresponding author), VA Maryland Hlth Care Syst, Res & Dev Serv, Baltimore, MD 21201 USA.	DKaetzel@som.umaryland.edu	Craig, David Wesley/K-6961-2019	Craig, David Wesley/0000-0003-2040-1955; Xu, Yili/0000-0001-8508-4706; Matsangos, Nicolette/0000-0002-3542-2612; LEONARD, M. Kathryn/0000-0002-8432-6803; Snyder, Devin/0000-0001-8528-7538	National Institutes of Health/National Cancer Institute [R01 CA83237, R01 CA159871, R01 CA159871-S1, R01 CA211909, P30 CA134274, T32 CA154274]; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01 AR071189]; National Institutes of Health/National Institute of General Medical Sciences [R25 GM055036]; Maryland Stem Cell Research Foundation [MSCRFI-1638]; Veterans Administration (VA Merit Grant) [1I01BX004293]; Baltimore Research and Education Foundation, VA Maryland Health Care System	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institutes of Health/National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Maryland Stem Cell Research Foundation; Veterans Administration (VA Merit Grant)(US Department of Veterans Affairs); Baltimore Research and Education Foundation, VA Maryland Health Care System	The authors gratefully acknowledge the expert technical assistance of A. Greenawalt and B. Hazzard, and to I. Violich for providing guidance in development of the mouse computational pipeline. This work was supported by the National Institutes of Health/National Cancer Institute through research grants R01 CA83237, R01 CA159871 and R01 CA159871-S1 (DMK), R01 CA211909 (RLE), center core grant P30 CA134274 and training grant T32 CA154274, by research grant R01 AR071189 (ATS) from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, and by education grant R25 GM055036 from the National Institutes of Health/National Institute of General Medical Sciences. The study was also supported by funding from the Maryland Stem Cell Research Foundation (MSCRFI-1638, DMK), the Veterans Administration (VA Merit Grant 1I01BX004293, ATS), and the Baltimore Research and Education Foundation, VA Maryland Health Care System.	Aaron KA, 2020, OTOL NEUROTOL, V41, P522, DOI 10.1097/MAO.0000000000002580; Abkevich V, 2012, BRIT J CANCER, V107, P1776, DOI 10.1038/bjc.2012.451; Ahn A, 2017, MOL CANCER THER, V16, P1002, DOI 10.1158/1535-7163.MCT-16-0535; Arakaki AKS, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071886; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Bektic J, 2005, PROSTATE, V64, P332, DOI 10.1002/pros.20243; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Boissan M, 2005, JNCI-J NATL CANCER I, V97, P836, DOI 10.1093/jnci/dji143; Boissan M, 2012, B CANCER, V99, P431, DOI 10.1684/bdc.2012.1550; Chen DC, 2019, ONCOGENE, V38, P6429, DOI 10.1038/s41388-019-0891-6; Chen LH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028222; Diskin SJ, 2006, GENOME RES, V16, P1149, DOI 10.1101/gr.5076506; Draheim KM, 2010, ONCOGENE, V29, P5032, DOI 10.1038/onc.2010.250; Ekizoglu S, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4381-y; Fei F, 2017, ONCOTARGET, V8, P73219, DOI 10.18632/oncotarget.18016; Fisher ML, 2017, ONCOTARGET, V8, P110257, DOI 10.18632/oncotarget.22628; Garibyan L, 2010, CURR ONCOL REP, V12, P319, DOI 10.1007/s11912-010-0119-y; Hamidi H, 2018, NAT REV CANCER, V18, P532, DOI 10.1038/s41568-018-0038-z; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; Heraud C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040351; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Horak CE, 2007, CANCER RES, V67, P11751, DOI 10.1158/0008-5472.CAN-07-3175; Horak CE, 2007, CANCER RES, V67, P7238, DOI 10.1158/0008-5472.CAN-07-0962; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Johansson P, 2016, ONCOTARGET, V7, P4624, DOI 10.18632/oncotarget.6614; Kaetzel DM, 2015, N-S ARCH PHARMACOL, V388, P199, DOI 10.1007/s00210-014-1010-4; Kandasamy S, 2020, MOL CANCER RES, V18, P343, DOI 10.1158/1541-7786.MCR-19-0914; Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72; Klein RM, 2009, CANCER RES, V69, P2224, DOI 10.1158/0008-5472.CAN-08-3201; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Leonard MK, 2019, EXP CELL RES, V374, P85, DOI 10.1016/j.yexcr.2018.11.010; Leonard MK, 2018, LAB INVEST, V98, P327, DOI 10.1038/labinvest.2017.108; LEONE A, 1993, ONCOGENE, V8, P2325; Liang WS, 2017, GENOME RES, V27, P524, DOI 10.1101/gr.213348.116; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Mahamdallie S, 2019, LANCET CHILD ADOLESC, V3, P322, DOI 10.1016/S2352-4642(19)30018-5; Manojlovic Z, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007087; Marino N, 2012, CANCER METAST REV, V31, P593, DOI 10.1007/s10555-012-9374-8; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656; Molina-Ortiz I, 2009, J BIOL CHEM, V284, P15147, DOI 10.1074/jbc.M807834200; Morrison GJ, 2020, INT J CANCER, V146, P2845, DOI 10.1002/ijc.32915; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; Pamidimukkala N, 2021, BRIT J CANCER, V124, P161, DOI 10.1038/s41416-020-01096-w; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Paysan L, 2016, MOL CANCER RES, V14, P1033, DOI 10.1158/1541-7786.MCR-16-0164; Perez-Guijarro E, 2020, NAT MED, V26, P781, DOI 10.1038/s41591-020-0818-3; Popova T, 2012, CANCER RES, V72, P5454, DOI 10.1158/0008-5472.CAN-12-1470; Postel EH, 2009, DEV DYNAM, V238, P775, DOI 10.1002/dvdy.21887; Recio JA, 2002, CANCER RES, V62, P6724; Roberts A, 2013, NAT METHODS, V10, P71, DOI [10.1038/NMETH.2251, 10.1038/nmeth.2251]; Roberts A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-r22; Rubenstein NM, 2005, EXP CELL RES, V305, P74, DOI 10.1016/j.yexcr.2004.12.010; Shain AH, 2015, NAT GENET, V47, P1194, DOI 10.1038/ng.3382; Sheng Y, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4592-2; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith SC, 2009, NAT REV CANCER, V9, P253, DOI 10.1038/nrc2594; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Snyder D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58996-3; Soung YH, 2014, SCI REP-UK, V4, DOI 10.1038/srep03846; Spivak G, 2016, ARCH TOXICOL, V90, P2583, DOI 10.1007/s00204-016-1820-x; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Tamura K, 2009, CANCER RES, V69, P8133, DOI 10.1158/0008-5472.CAN-09-0775; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Xiao JT, 2018, AM J CANCER RES, V8, P132; Xue RY, 2019, DNA REPAIR, V77, P27, DOI 10.1016/j.dnarep.2019.03.003; Yang MM, 2009, MUTAT RES-FUND MOL M, V660, P74, DOI 10.1016/j.mrfmmm.2008.09.015; Yang ZY, 2020, J CELL MOL MED, V24, P4510, DOI 10.1111/jcmm.15109; Zhang KM, 2016, J INVEST DERMATOL, V136, P464, DOI 10.1016/j.jid.2015.11.006; Zhang QB, 2011, INT J CANCER, V128, P40, DOI 10.1002/ijc.25307; Zheng Y, 2017, CURR MOL MED, V17, P221, DOI 10.2174/1566524017666170807144711	76	1	1	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6329	6342		10.1038/s41388-021-01998-w	http://dx.doi.org/10.1038/s41388-021-01998-w		AUG 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34433909	Green Accepted			2022-12-28	WOS:000688395700002
J	Zhang, EB; Zhang, XP; Wang, K; Zhang, FK; Chen, TW; Ma, N; Ni, QZ; Wang, YK; Zheng, QW; Cao, HJ; Xia, J; Zhu, B; Xu, S; Ding, XF; Wang, X; Li, ZG; Cheng, SQ; Xie, D; Li, JJ				Zhang, Er-Bin; Zhang, Xiuping; Wang, Kang; Zhang, Fengkun; Chen, Tian-Wei; Ma, Ning; Ni, Qian-Zhi; Wang, Yi-Kang; Zheng, Qian-Wen; Cao, Hui-Jun; Xia, Ji; Zhu, Bing; Xu, Sheng; Ding, Xufen; Wang, Xiang; Li, Zhigang; Cheng, Shuqun; Xie, Dong; Li, Jing-Jing			Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis	ONCOGENE			English	Article							CELL-GROWTH; SORAFENIB; PATHWAY; PHOSPHORYLATION; SIROLIMUS; RAPAMYCIN; KINASE; CANCER; RAPTOR	The prognosis of hepatocellular carcinoma (HCC) remains unsatisfactory due to limited effective treatment options. In this work, we investigated the therapeutic efficacy of Terbinafine for HCC and the underlying mechanism. The influence of Terbinafine on cell growth, 3D spheroid formation, clonogenic survival, and protein synthesis was investigated in human HCC cell lines. Co-immunoprecipitation, immunofluorescence, and other techniques were employed to explore how Terbinafine exerts its anticancer effect. Subcutaneous tumorigenicity assay, orthotopic and patient-derived xenograft (PDX) HCC models were used to evaluate the anticancer effect of Terbinafine monotherapy and the combinatorial treatment with Terbinafine and sorafenib against HCC. The anticancer activity of Terbinafine was Squalene epoxidase (SQLE)-independent. Instead, Terbinafine robustly suppressed the proliferation of HCC cells by inhibiting mTORC1 signaling via activation of AMPK. Terbinafine alone or in combination with sorafenib delayed tumor progression and markedly prolonged the survival of tumor-bearing mice. The synergy between Terbinafine and sorafenib was due to concomitant inhibition of mTORC1 and induction of severe persistent DNA double-strand breaks (DSBs), which led to the delayed proliferation and accelerated cell death. Terbinafine showed promising anticancer efficacy in preclinical models of HCC and may serve as a potential therapeutic strategy for HCC.	[Zhang, Er-Bin; Zhang, Fengkun; Chen, Tian-Wei; Ma, Ning; Ni, Qian-Zhi; Wang, Yi-Kang; Zheng, Qian-Wen; Cao, Hui-Jun; Xia, Ji; Zhu, Bing; Xu, Sheng; Ding, Xufen; Xie, Dong; Li, Jing-Jing] Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Nutr Metab & Food Safety, Shanghai 200031, Peoples R China; [Zhang, Xiuping; Wang, Kang; Cheng, Shuqun] Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 4, Shanghai 2000438, Peoples R China; [Zhang, Xiuping] Chinese People Liberat Army PLA, Fac Hepatopancreato Biliary Surg, Gen Hosp, Beijing 100853, Peoples R China; [Zhang, Xiuping] Inst Hepatobiliary Surg Chinese PLA, Beijing 100853, Peoples R China; [Zheng, Qian-Wen; Xie, Dong] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China; [Wang, Xiang] Huzhou Univ, Affiliated Hosp 1, Peoples Hosp Huzhou 1, Huzhou 313000, Zhejiang, Peoples R China; [Li, Zhigang] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Sect Esophageal Surg, Shanghai 200030, Peoples R China; [Xie, Dong] China Natl Ctr Food Safety Risk Assessment, NHC Key Lab Food Safety Risk Assessment, Beijing 100022, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; University of Chinese Academy of Sciences, CAS; Naval Medical University; ShanghaiTech University; Huzhou University; Shanghai Jiao Tong University	Xie, D; Li, JJ (corresponding author), Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Nutr Metab & Food Safety, Shanghai 200031, Peoples R China.; Cheng, SQ (corresponding author), Naval Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 4, Shanghai 2000438, Peoples R China.; Xie, D (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China.; Xie, D (corresponding author), China Natl Ctr Food Safety Risk Assessment, NHC Key Lab Food Safety Risk Assessment, Beijing 100022, Peoples R China.	chengshuqun@aliyun.com; dxie@sibs.ac.cn; tide7@163.com	cheng, sq/GPT-4112-2022; Cao, Huijun/HDM-1523-2022; Li, Jing/GYU-5036-2022	, Ning/0000-0003-1825-8854	National Key R&D Program of China [2018YFC1603002, 2018YFC1604404]; National Natural Science Foundation of China [81730083, 82030084, 31771538, 81972757]; Youth Innovation Promotion Association of Chinese Academy of Sciences fund [2017324]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Innovation Promotion Association of Chinese Academy of Sciences fund	This work was supported by the National Key R&D Program of China (2018YFC1603002 and 2018YFC1604404), National Natural Science Foundation of China (81730083 and 82030084) to Dong Xie; and National Natural Science Foundation of China (31771538 and 81972757), Youth Innovation Promotion Association of Chinese Academy of Sciences fund (2017324) to Jing-Jing Li.	Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Decaens T, 2012, DIGEST LIVER DIS, V44, P610, DOI 10.1016/j.dld.2012.02.005; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Ferrin G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041266; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Guan DX, 2015, HEPATOLOGY, V62, P1791, DOI 10.1002/hep.28117; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Humphreys, 2004, J DRUG EVALUATION, V2, P133, DOI DOI 10.3109/14791130500070064; Iavarone M, 2011, HEPATOLOGY, V54, P2055, DOI 10.1002/hep.24644; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2014, CLIN CANCER RES, V20, P2072, DOI 10.1158/1078-0432.CCR-13-0547; Matter MS, 2014, J HEPATOL, V60, P855, DOI 10.1016/j.jhep.2013.11.031; Menon S, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002739; Piguet AC, 2011, MOL CANCER THER, V10, P1007, DOI 10.1158/1535-7163.MCT-10-0666; Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886; Prieto J, 2015, NAT REV GASTRO HEPAT, V12, P681, DOI 10.1038/nrgastro.2015.173; Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168; Revankar SG, 2008, FUTURE MICROBIOL, V3, P9, DOI 10.2217/17460913.3.1.9; Rizell M, 2008, INT J CLIN ONCOL, V13, P66, DOI 10.1007/s10147-007-0733-3; Sahin F, 2004, CLIN CANCER RES, V10, P8421, DOI 10.1158/1078-0432.CCR-04-0941; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Schoniger-Hekele M, 2010, ALIMENT PHARM THER, V32, P763, DOI 10.1111/j.1365-2036.2010.04404.x; Semela D, 2007, J HEPATOL, V46, P840, DOI 10.1016/j.jhep.2006.11.021; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Thomas HE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003923; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; Villanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006	42	4	5	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5302	5313		10.1038/s41388-021-01934-y	http://dx.doi.org/10.1038/s41388-021-01934-y		JUL 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34247189				2022-12-28	WOS:000671644900003
J	Zhao, SL; Guan, BJ; Mi, YS; Shi, DB; Wei, P; Gu, YZ; Cai, SJ; Xu, Y; Li, XX; Yan, DW; Huang, MZ; Li, DW				Zhao, Senlin; Guan, Bingjie; Mi, Yushuai; Shi, Debing; Wei, Ping; Gu, Yanzi; Cai, Sanjun; Xu, Ye; Li, Xinxiang; Yan, Dongwang; Huang, Mingzhu; Li, Dawei			LncRNA MIR17HG promotes colorectal cancer liver metastasis by mediating a glycolysis-associated positive feedback circuit	ONCOGENE			English	Article								Glycolysis plays a crucial role in reprogramming the metastatic tumor microenvironment. A series of lncRNAs have been identified to function as oncogenic molecules by regulating glycolysis. However, the roles of glycolysis-related lncRNAs in regulating colorectal cancer liver metastasis (CRLM) remain poorly understood. In the present study, the expression of the glycolysis-related lncRNA MIR17HG gradually increased from adjacent normal to CRC to the paired liver metastatic tissues, and high MIR17HG expression predicted poor survival, especially in patients with liver metastasis. Functionally, MIR17HG promoted glycolysis in CRC cells and enhanced their invasion and liver metastasis in vitro and in vivo. Mechanistically, MIR17HG functioned as a ceRNA to regulate HK1 expression by sponging miR-138-5p, resulting in glycolysis in CRC cells and leading to their invasion and liver metastasis. More interestingly, lactate accumulated via glycolysis activated the p38/Elk-1 signaling pathway to promote the transcriptional expression of MIR17HG in CRC cells, forming a positive feedback loop, which eventually resulted in persistent glycolysis and the invasion and liver metastasis of CRC cells. In conclusion, the present study indicates that the lactate-responsive lncRNA MIR17HG, acting as a ceRNA, promotes CRLM through a glycolysis-mediated positive feedback circuit and might be a novel biomarker and therapeutic target for CRLM.	[Zhao, Senlin; Shi, Debing; Cai, Sanjun; Xu, Ye; Li, Xinxiang; Li, Dawei] Fudan Univ, Shanghai Canc Ctr, Dept Colorectal Surg, Shanghai, Peoples R China; [Zhao, Senlin; Shi, Debing; Wei, Ping; Cai, Sanjun; Xu, Ye; Li, Xinxiang; Huang, Mingzhu; Li, Dawei] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Guan, Bingjie; Yan, Dongwang] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Gen Surg, Shanghai, Peoples R China; [Mi, Yushuai] Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Gastrointestinal Surg, Jinan, Peoples R China; [Wei, Ping] Fudan Univ, Canc Inst, Shanghai Canc Ctr, Shanghai, Peoples R China; [Wei, Ping] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai, Peoples R China; [Gu, Yanzi] Fudan Univ, Shanghai Canc Ctr, Dept Biobank, Shanghai, Peoples R China; [Huang, Mingzhu] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China	Fudan University; Fudan University; Shanghai Jiao Tong University; Shandong University; Fudan University; Fudan University; Fudan University; Fudan University	Li, DW (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Colorectal Surg, Shanghai, Peoples R China.; Huang, MZ; Li, DW (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.; Yan, DW (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Gen Surg, Shanghai, Peoples R China.; Huang, MZ (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China.	yandw70@163.com; mingzhuhuang0718@163.com; li_dawei@fudan.edu.cn	xu, ye/GQO-8972-2022		National Nature Science Foundation of China [81772583, 81871931, 81802420, 81972293, 82003088]; Shanghai Sailing Program [19YF1409600]; Nature Science Foundation of Shandong Province [ZR2019PH008]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Sailing Program; Nature Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province)	This research was supported by grants from the National Nature Science Foundation of China (81772583, 81871931, 81802420, 81972293, 82003088), Shanghai Sailing Program (19YF1409600), the Nature Science Foundation of Shandong Province (ZR2019PH008).	Alspach E, 2014, CANCER DISCOV, V4, P716, DOI 10.1158/2159-8290.CD-13-0743; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen C, 2019, ONCOGENE, V38, P4527, DOI 10.1038/s41388-019-0735-4; Chen F, 2019, NAT CELL BIOL, V21, P498, DOI 10.1038/s41556-019-0299-0; Chen JA, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0947-9; Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0; Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633; Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x; Graziano F, 2017, PHARMACOGENOMICS J, V17, P258, DOI 10.1038/tpj.2016.13; He D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13911-x; Hu QS, 2019, NAT IMMUNOL, V20, P835, DOI 10.1038/s41590-019-0400-7; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Ippolito L, 2019, TRENDS BIOCHEM SCI, V44, P153, DOI 10.1016/j.tibs.2018.10.011; Jiao Lin, 2018, Autophagy, V14, P671, DOI 10.1080/15548627.2017.1381804; Koutsioumpa M, 2019, GUT, V68, P1271, DOI 10.1136/gutjnl-2017-315690; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Lee DC, 2015, CELL, V161, P595, DOI 10.1016/j.cell.2015.03.011; Lee HJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10374-y; Lee YS, 2018, CELL HOST MICROBE, V24, P833, DOI 10.1016/j.chom.2018.11.002; Li Q, 2019, HEPATOLOGY, V70, P1298, DOI 10.1002/hep.30671; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Liu QH, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-020-01021-x; Miranda-Goncalves V, 2013, NEURO-ONCOLOGY, V15, P172, DOI 10.1093/neuonc/nos298; Olivero CE, 2020, MOL CELL, V77, P761, DOI 10.1016/j.molcel.2019.12.014; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Puccini A, 2018, NAT REV CLIN ONCOL, V15, P77, DOI 10.1038/nrclinonc.2017.185; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Rapino F, 2018, NATURE, V558, P605, DOI 10.1038/s41586-018-0243-7; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Wei S, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-020-1112-3; Wiel C, 2019, CELL, V178, P330, DOI 10.1016/j.cell.2019.06.005; Xiao GA, 2019, EUR UROL, V76, P315, DOI 10.1016/j.eururo.2018.11.012; Xie LYJ, 2019, CELL CYCLE, V18, P2110, DOI 10.1080/15384101.2019.1641388; Xu J, 2019, CANCER RES, V79, P4882, DOI 10.1158/0008-5472.CAN-18-3880; Zhao X, 2020, AUTOPHAGY, V16, P70, DOI 10.1080/15548627.2019.1598750; Zhuang M, 2019, EBIOMEDICINE, V41, P286, DOI 10.1016/j.ebiom.2018.12.049; Zhuo W, 2019, GASTROENTEROLOGY, V156, P676, DOI 10.1053/j.gastro.2018.10.054	40	16	16	5	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4709	4724		10.1038/s41388-021-01859-6	http://dx.doi.org/10.1038/s41388-021-01859-6		JUN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34145399	Green Published, hybrid			2022-12-28	WOS:000663295300004
J	Alonso-Maranon, J; Villanueva, A; Piulats, JM; Martinez-Iniesta, M; Sole, L; Martin-Liberal, J; Segura, S; Pujol, RM; Iglesias, M; Bigas, A; Gallardo, F; Espinosa, L				Alonso-Maranon, Josune; Villanueva, Alberto; Piulats, Josep Maria; Martinez-Iniesta, Maria; Sole, Laura; Martin-Liberal, Juan; Segura, Sonia; Pujol, Ramon M.; Iglesias, Mar; Bigas, Anna; Gallardo, Fernando; Espinosa, Lluis			Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair	ONCOGENE			English	Article								Invasive malignant melanoma (MM) is an aggressive tumor with no curative therapy in advanced stages. Chemotherapy has not demonstrated its efficacy in MM and current treatment for tumors carrying the most frequent BRAFV600E mutation consists of BRAF inhibitors alone or in combination with MAPK pathway inhibitors. We previously found that BRAF inhibition prevents activation of the DNA-damage repair (DDR) pathway in colorectal cancer thus potentiating the effect of chemotherapy. We now show that different chemotherapy agents inflict DNA damage in MM cells, which is efficiently repaired, associated with activation of the ATM-dependent DDR machinery. Pharmacologic inhibition of BRAF impairs ATM and DDR activation in these cells, leading to sustained DNA damage. Combination treatments involving DNA-damaging agents and BRAF inhibitors increase tumor cell death in vitro and in vivo, and impede MM regrowth after treatment cessation. We propose to reconsider the use of chemotherapy in combination with BRAF inhibitors for MM treatment.	[Alonso-Maranon, Josune; Sole, Laura; Bigas, Anna; Espinosa, Lluis] CIBERONC, Stem Cells & Canc Res Lab IMIM, Barcelona, Spain; [Alonso-Maranon, Josune; Sole, Laura; Pujol, Ramon M.; Bigas, Anna; Gallardo, Fernando; Espinosa, Lluis] Hosp del Mar Med Res Inst IMIM, Canc Res Program, Barcelona, Spain; [Villanueva, Alberto; Martinez-Iniesta, Maria] IDIBELL, Grp Chemoresistance & Predict Factors, Subprogram Canc Therapeut Resistance ProCURE, ICO,Oncobell Program, Barcelona, Spain; [Piulats, Josep Maria; Martin-Liberal, Juan] CIBERONC, Med Oncol Dept, Catalan Inst Canc ICO, IDIBELL OncoBell, Barcelona, Spain; [Segura, Sonia; Pujol, Ramon M.; Gallardo, Fernando] Inst Hosp del Mar Investigac Med IMIM, Dept Dermatol, Barcelona, Spain; [Segura, Sonia; Pujol, Ramon M.; Gallardo, Fernando] Univ Autonoma Barcelona, Barcelona, Spain; [Iglesias, Mar] Univ Autonoma Barcelona, Inst Mar Investigac Med, Dept Pathol, CIBERONC, Barcelona, Spain; [Bigas, Anna] Inst Josep Carreras Leucemia IJC, Barcelona, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Catalan Institute of Oncology; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Autonomous University of Barcelona; Autonomous University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC	Bigas, A; Espinosa, L (corresponding author), CIBERONC, Stem Cells & Canc Res Lab IMIM, Barcelona, Spain.; Bigas, A; Gallardo, F; Espinosa, L (corresponding author), Hosp del Mar Med Res Inst IMIM, Canc Res Program, Barcelona, Spain.; Villanueva, A (corresponding author), IDIBELL, Grp Chemoresistance & Predict Factors, Subprogram Canc Therapeut Resistance ProCURE, ICO,Oncobell Program, Barcelona, Spain.; Gallardo, F (corresponding author), Inst Hosp del Mar Investigac Med IMIM, Dept Dermatol, Barcelona, Spain.; Gallardo, F (corresponding author), Univ Autonoma Barcelona, Barcelona, Spain.; Bigas, A (corresponding author), Inst Josep Carreras Leucemia IJC, Barcelona, Spain.	avillanueva@iconcologia.net; abigas@imim.es; fgallardo@parcdesalutmar.cat; lespinosa@imim.es	Piulats, Josep M/F-2862-2019	Piulats, Josep M/0000-0002-3606-1724; Sole Font, Laura/0000-0002-3195-0565; Alonso, Josune/0000-0001-6783-5166; Martinez-Iniesta, Maria/0000-0001-6252-6671; Bigas, Anna/0000-0003-4801-6899	Instituto de Salud Carlos III FEDER [PI19/00013, PI19/01320, PI19/01210]; Generalitat de Catalunya [2017SGR135]; Pla Director d'Oncologia de Catalunya (XBTC); Fundacion hna; Javier Lamas Miralles grant	Instituto de Salud Carlos III FEDER(Instituto de Salud Carlos IIIEuropean Commission); Generalitat de Catalunya(Generalitat de Catalunya); Pla Director d'Oncologia de Catalunya (XBTC); Fundacion hna; Javier Lamas Miralles grant	We want to thank the Bigas' and Espinosa's lab members for constructive discussions and suggestions and technical support. This work was funded by grants from Instituto de Salud Carlos III FEDER PI19/00013 to LE, PI19/01320 to AV and PI19/01210 to JM-L, Generalitat de Catalunya 2017SGR135 and the "Xarxa de Bancs de tumors sponsored by Pla Director d'Oncologia de Catalunya (XBTC) and Fundacion hna to AV research team in the development of orthoxenografts/PDOX. JA-M is a recipient of Javier Lamas Miralles grant.	Buecher B, 2010, FAM CANCER, V9, P663, DOI 10.1007/s10689-010-9379-9; Colombino M, 2012, J CLIN ONCOL, V30, P2522, DOI 10.1200/JCO.2011.41.2452; Colomer C, 2019, MOL CELL, V75, P669, DOI 10.1016/j.molcel.2019.05.036; Colomer C, 2018, BRIT J CANCER, V118, P839, DOI 10.1038/bjc.2017.459; Fernandez-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Gallardo F, 2015, ONCOTARGET, V6, P9284, DOI 10.18632/oncotarget.3252; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Luke JJ, 2013, CLIN DERMATOL, V31, P290, DOI 10.1016/j.clindermatol.2012.08.016; Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656; Margalef P, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005886; Margalef P, 2012, CELL REP, V2, P840, DOI 10.1016/j.celrep.2012.08.028; Monahan KB, 2010, ONCOGENE, V29, P5809, DOI 10.1038/onc.2010.314; Nogueira C, 2010, ONCOGENE, V29, P6222, DOI 10.1038/onc.2010.349; Planchard D, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.107; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Robb R, 2019, CLIN CANCER RES, V25, P4749, DOI 10.1158/1078-0432.CCR-18-3625; Schreck KC, 2018, ONCOLOGY-NY, V32, P555; Toll A, 2015, ARCH DERMATOL RES, V307, P721, DOI 10.1007/s00403-015-1579-6; Wilson MA, 2016, CANCER TREAT RES, V167, P209, DOI 10.1007/978-3-319-22539-5_8; Zaman A, 2019, CANCERS, V11, DOI 10.3390/cancers11081197; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982	23	1	1	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					5042	5048		10.1038/s41388-021-01879-2	http://dx.doi.org/10.1038/s41388-021-01879-2		JUN 2021	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34140639				2022-12-28	WOS:000662838900006
J	Liao, YN; Liu, Y; Shao, ZL; Xia, XH; Deng, YF; Cai, JY; Yao, LY; He, JC; Yu, CF; Hu, TM; Sun, WS; Liu, F; Tang, DL; Liu, JB; Huang, HBA				Liao, Yuning; Liu, Yuan; Shao, Zhenlong; Xia, Xiaohong; Deng, Yuanfei; Cai, Jianyu; Yao, Leyi; He, Jinchan; Yu, Cuifu; Hu, Tumei; Sun, Wenshuang; Liu, Fang; Tang, Daolin; Liu, Jinbao; Huang, Hongbiao			A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance	ONCOGENE			English	Article							SIX1; PROLIFERATION; HOMEOPROTEIN; INHIBITOR; APOPTOSIS; AR-V7	Prostate cancer (PC) is the second most common cancer with limited treatment option in males. Although the reactivation of embryonic signals in adult cells is one of the characteristics of cancer, the underlying protein degradation mechanism remains elusive. Here, we show that the molecular chaperone GRP75 is a key player in PC cells by maintaining the protein stability of SIX1, a transcription factor for embryonic development. Mechanistically, GRP75 provides a platform to recruit the deubiquitinating enzyme USP1 to inhibit K48-linked polyubiquitination of SIX1. Structurally, the C-terminus of GRP75 (433-679 aa) contains a peptide binding domain, which is required for the formation of GRP75-USP1-SIX1 protein complex. Functionally, pharmacological or genetic inhibition of the GRP75-USP1-SIX1 protein complex suppresses tumor growth and overcomes the castration resistance of PC cells in vitro and in xenograft mouse models. Clinically, the protein expression of SIX1 in PC tumor tissues is positively correlated with the expression of GRP75 and USP1. These new findings not only enhance our understanding of the protein degradation mechanism, but also may provide a potential way to enhance the anti-cancer activity of androgen suppression therapy.	[Liao, Yuning; Liu, Yuan; Shao, Zhenlong; Xia, Xiaohong; Liu, Jinbao; Huang, Hongbiao] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Guangdong, Peoples R China; [Liao, Yuning; Liu, Yuan; Shao, Zhenlong; Xia, Xiaohong; Cai, Jianyu; Yao, Leyi; He, Jinchan; Yu, Cuifu; Hu, Tumei; Sun, Wenshuang; Liu, Jinbao; Huang, Hongbiao] Guangzhou Med Univ, Sch Basic Med Sci, Guangzhou Municipal & Guangdong Prov Key Lab Prot, Guangzhou, Guangdong, Peoples R China; [Deng, Yuanfei; Liu, Fang] First Peoples Hosp Foshan, Dept Pathol, Foshan, Guangdong, Peoples R China; [Tang, Daolin] Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Dallas, TX USA	Guangzhou Medical University; Guangzhou Medical University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Liu, JB; Huang, HBA (corresponding author), Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Guangdong, Peoples R China.; Liu, JB; Huang, HBA (corresponding author), Guangzhou Med Univ, Sch Basic Med Sci, Guangzhou Municipal & Guangdong Prov Key Lab Prot, Guangzhou, Guangdong, Peoples R China.	jliu@gzhmu.edu.cn; hhb800616@126.com	Tang, Daolin/B-2905-2010; Tang, Daolin/ABD-5062-2021	Tang, Daolin/0000-0002-1903-6180; Liao, Yuning/0000-0003-0343-1933; shao, zhenlong/0000-0001-8039-8706	National Natural Science Foundation of China [82072810, 82002481, 81972399]; Science and Technology Program of Guangzhou [202002030107]; projects from Foundation for Higher Education of Guangdong [2019KQNCX113]; Special fund of Foshan Summit plan [2019D001]; Foshan Science technology and Medical foundation [1920001000958]; Guangzhou key medical discipline construction project fund	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangzhou; projects from Foundation for Higher Education of Guangdong; Special fund of Foshan Summit plan; Foshan Science technology and Medical foundation; Guangzhou key medical discipline construction project fund	This work was supported by National Natural Science Foundation of China (82072810, 82002481, 81972399), the Science and Technology Program of Guangzhou (202002030107), projects from Foundation for Higher Education of Guangdong (2019KQNCX113), Special fund of Foshan Summit plan (2019D001), Grant from Foshan Science technology and Medical foundation (1920001000958) and Guangzhou key medical discipline construction project fund.	Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burress H, 2019, J BIOL CHEM, V294, P12122, DOI 10.1074/jbc.RA119.008568; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; Chen Z, 2018, P NATL ACAD SCI USA, V115, P6810, DOI 10.1073/pnas.1718811115; Christensen KL, 2007, ONCOGENE, V26, P3406, DOI 10.1038/sj.onc.1210122; Culig Z, 2014, CANCER METAST REV, V33, P413, DOI 10.1007/s10555-013-9474-0; Fizazi K, 2020, LANCET ONCOL; Fushimi C, 2018, ANN ONCOL, V29, P979, DOI 10.1093/annonc/mdx771; He L, 2018, CELL RES, V28, P934, DOI 10.1038/s41422-018-0079-6; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Li L, 2018, CANCER CELL, V33, P368, DOI 10.1016/j.ccell.2018.01.010; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Li ZM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059203; Liang Q, 2014, NAT CHEM BIOL, V10, P298, DOI [10.1038/nchembio.1455, 10.1038/NCHEMBIO.1455]; Liao YN, 2020, THERANOSTICS, V10, P3366, DOI 10.7150/thno.41849; Liao YN, 2019, CELL DISCOV, V5, DOI 10.1038/s41421-019-0092-z; Liao YN, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1165-4; Liao YN, 2018, ONCOGENE, V37, P1896, DOI 10.1038/s41388-017-0069-z; Liao YN, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.477; Lim KS, 2018, MOL CELL, V72, P925, DOI 10.1016/j.molcel.2018.10.045; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Ng KT, 2006, BRIT J CANCER, V95, P1050, DOI 10.1038/sj.bjc.6603399; Ryu SW, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000606; Saad F, 2020, EUR UROL; Starenki D, 2015, ONCOGENE, V34, P4624, DOI 10.1038/onc.2014.392; Tian SR, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01508-0; Tucci M, 2019, CANCER TREAT REV, V74, P35, DOI 10.1016/j.ctrv.2019.01.002; Wen SM, 2020, ONCOGENE, V39, P6556, DOI 10.1038/s41388-020-01456-z; Wu KM, 2013, CANCER RES, V73, P4488, DOI 10.1158/0008-5472.CAN-12-4078; Wu PK, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay1478; Wu PK, 2020, ONCOGENE, V39, P4257, DOI 10.1038/s41388-020-1285-5; Wu PK, 2013, MOL CELL BIOL, V33, P4051, DOI 10.1128/MCB.00021-13; Xia XH, 2019, CANCER LETT, V465, P118, DOI 10.1016/j.canlet.2019.09.003; Yi X, 2008, MOL CELL PROTEOMICS, V7, P315, DOI 10.1074/mcp.M700116-MCP200; Zeng J, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0215-z; Zhu ZL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1054-7	38	8	8	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4291	4306		10.1038/s41388-021-01851-0	http://dx.doi.org/10.1038/s41388-021-01851-0		JUN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34079090				2022-12-28	WOS:000657217400007
J	Qiao, YN; Jin, T; Guan, SD; Cheng, SJ; Wen, SY; Zeng, H; Zhao, MJ; Yang, LP; Wan, XY; Qiu, YX; Li, Q; Liu, MR; Hou, YX				Qiao, Yina; Jin, Ting; Guan, Shengdong; Cheng, Shaojie; Wen, Siyang; Zeng, Huan; Zhao, Maojia; Yang, Liping; Wan, Xueying; Qiu, Yuxiang; Li, Qiao; Liu, Manran; Hou, Yixuan			Long non-coding RNA Lnc-408 promotes invasion and metastasis of breast cancer cell by regulating LIMK1	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LNCRNA HOTAIR; MIGRATION; MOTILITY; GROWTH; DIFFERENTIATION; PROGRESSION; STATISTICS; ACTIVATION; APOPTOSIS	Invasion and metastasis are the leading causes of death in patients with breast cancer (BC), and epithelial-mesenchymal transformation (EMT) plays an essential role in this process. Here, we found that Lnc-408, a novel long noncoding RNA (lncRNA), is significantly upregulated in BC cells undergoing EMT and in BC tumor with lymphatic metastases compared with those without lymphatic metastases. Lnc-408 can enhance BC invasion and metastasis by regulating the expression of LIMK1. Mechanistically, Lnc-408 serves as a sponge for miR-654-5p to relieve the suppression of miR-654-5p on its target LIMK1. Knockdown or knockout of Lnc-408 in invasive BC cells clearly decreased LIMK1 levels, and ectopic Lnc-408 in MCF-7 cells increased LIMK1 expression to promote cell invasion. Lnc-408-mediated enhancement of LIMK1 plays a key role in cytoskeletal stability and promotes invadopodium formation in BC cells via p-cofilin/F-actin. In addition, the increased LIMK1 also facilitates the expression of MMP2, ITGB1, and COL1A1 by phosphorylating CREB. In conclusion, our findings reveal that Lnc-408 promotes BC invasion and metastasis via the Lnc-408/miR-654-5p/LIMK1 axis, highlighting a novel promising target for the diagnosis and treatment of BC.	[Qiao, Yina; Jin, Ting; Guan, Shengdong; Cheng, Shaojie; Wen, Siyang; Zeng, Huan; Zhao, Maojia; Yang, Liping; Wan, Xueying; Qiu, Yuxiang; Li, Qiao; Liu, Manran] Chongqing Med Univ, Chinese Minist Educ, Key Lab Lab Med Diagnost, Chongqing, Peoples R China; [Hou, Yixuan] Chongqing Med Univ, Expt Teaching & Lab Management Ctr, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University	Hou, YX (corresponding author), Chongqing Med Univ, Expt Teaching & Lab Management Ctr, Chongqing, Peoples R China.	yixuan_hou@cqmu.edu.cn		Qiao, Yina/0000-0001-5351-0870	National Natural Science Foundation of China (NSFC) [81874199, 31671481, 81773078, 81560430]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported in part by the National Natural Science Foundation of China (NSFC 81773078, NSFC 81560430) for YH. And also supported by the National Natural Science Foundation of China (NSFC 81874199, and NSFC 31671481) for ML.	Aggelou H, 2018, VIRCHOWS ARCH, V472, P727, DOI 10.1007/s00428-018-2298-0; Arun G, 2016, GENE DEV, V30, P34, DOI 10.1101/gad.270959.115; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Chen PX, 2014, ONCOL REP, V32, P2070, DOI 10.3892/or.2014.3461; Chi YJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091015; Collette J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112319; Dong LF, 2019, J CELL BIOCHEM, V120, P4851, DOI 10.1002/jcb.27435; Fan CN, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1640-2; Grayson M, 2012, NATURE, V485, pS49, DOI 10.1038/485S49a; Hu P, 2014, CELL SIGNAL, V26, P83, DOI 10.1016/j.cellsig.2013.10.001; Huang FD, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4914707; Huang QY, 2019, CANCERS, V11, DOI 10.3390/cancers11111802; Huang Y, 2018, J CELL MOL MED, V22, P5768, DOI 10.1111/jcmm.13866; Jang I, 2012, KOREAN J PHYSIOL PHA, V16, P159, DOI 10.4196/kjpp.2012.16.3.159; Kang CG, 2015, BIOORG MED CHEM LETT, V25, P1956, DOI 10.1016/j.bmcl.2015.03.024; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Li CH, 2013, INT J BIOCHEM CELL B, V45, P1895, DOI 10.1016/j.biocel.2013.05.030; Li DF, 2018, MOL CELL BIOCHEM, V444, P169, DOI 10.1007/s11010-017-3241-4; Li M, 2017, MOL ONCOL, V11, P1698, DOI 10.1002/1878-0261.12133; Li Z, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21933; Li ZW, 2017, ONCOTARGET, V8, P67329, DOI 10.18632/oncotarget.18622; Liang YR, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01206-5; Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106; Lu H, 2018, INT J ONCOL, V53, P2695, DOI 10.3892/ijo.2018.4592; Lu RZ, 2018, CANCER BIOMARK, V22, P249, DOI 10.3233/CBM-170874; Majem B, 2019, ONCOGENE, V38, P6035, DOI 10.1038/s41388-019-0860-0; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Mitra A, 2015, ONCOTARGET, V6, P10697, DOI 10.18632/oncotarget.4037; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Perkel JM, 2013, BIOTECHNIQUES, V54, P119, DOI 10.2144/000113997; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Tan YY, 2016, AM J CANCER RES, V6, P522; Tapia T, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-6; Todorovski Z, 2015, MOL CELL BIOL, V35, P1316, DOI 10.1128/MCB.01263-14; Wang LY, 2013, MOL ONCOL, V7, P1116, DOI 10.1016/j.molonc.2013.08.007; Wu YA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00407; Xu XZ, 2020, EUR REV MED PHARMACO, V24, P3517, DOI 10.26355/eurrev_202004_20811; Yang EJ, 2004, J BIOL CHEM, V279, P8903, DOI 10.1074/jbc.M311913200; Yang JJ, 2016, INT J BIOCHEM CELL B, V71, P62, DOI 10.1016/j.biocel.2015.12.004; Yin JL, 2020, FASEB J, V34, P4557, DOI 10.1096/fj.201901384RR; Yu TH, 2014, J STEROID BIOCHEM, V143, P392, DOI 10.1016/j.jsbmb.2014.05.003; Yu Y, 2017, BIOMED PHARMACOTHER, V90, P555, DOI 10.1016/j.biopha.2017.03.054; Zhao WY, 2018, CANCER MED-US, V7, P842, DOI 10.1002/cam4.1353; Zhou ML, 2016, STEM CELLS, V34, P55, DOI 10.1002/stem.2219	46	6	7	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4198	4213		10.1038/s41388-021-01845-y	http://dx.doi.org/10.1038/s41388-021-01845-y		JUN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34079084	Green Published, hybrid			2022-12-28	WOS:000657217400002
J	Thomson, CS; Pundavela, J; Perrino, MR; Coover, RA; Choi, K; Chaney, KE; Rizvi, TA; Largaespada, DA; Ratner, N				Thomson, Craig S.; Pundavela, Jay; Perrino, Melissa R.; Coover, Robert A.; Choi, Kwangmin; Chaney, Katherine E.; Rizvi, Tilat A.; Largaespada, David A.; Ratner, Nancy			WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth	ONCOGENE			English	Article							BETA-CATENIN; SCHWANN-CELLS; STEM-CELLS; MECHANISMS; PROMOTES; TRANSFORMATION; PROGRESSION; ACTIVATION; INVASION; MITOGENS	Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft-tissue sarcomas that cause significant mortality in adults with neurofibromatosis type 1. We compared gene expression of growth factors in normal human nerves to MPNST and normal human Schwann cells to MPNST cell lines. We identified WNT5A as the most significantly upregulated ligand-coding gene and verified its protein expression in MPNST cell lines and tumors. In many contexts WNT5A acts as an oncogene. However, inhibiting WNT5A expression using shRNA did not alter MPNST cell proliferation, invasion, migration, or survival in vitro. Rather, shWNT5A-treated MPNST cells upregulated mRNAs associated with the remodeling of extracellular matrix and with immune cell communication. In addition, these cells secreted increased amounts of the proinflammatory cytokines CXCL1, CCL2, IL6, CXCL8, and ICAM1. Versus controls, shWNT5A-expressing MPNST cells formed larger tumors in vivo. Grafted tumors contained elevated macrophage/stromal cells, larger and more numerous blood vessels, and increased levels of Mmp9, Cxcl13, Lipocalin-1, and Ccl12. In some MPNST settings, these effects were mimicked by targeting the WNT5A receptor ROR2. These data suggest that the non-canonical Wnt ligand WNT5A inhibits MPNST tumor formation by modulating the MPNST microenvironment, so that blocking WNT5A accelerates tumor growth in vivo.	[Thomson, Craig S.] Univ Cincinnati, Coll Med, Dept Pharmacol & Syst Physiol, Cincinnati, OH 45220 USA; [Thomson, Craig S.; Pundavela, Jay; Perrino, Melissa R.; Coover, Robert A.; Choi, Kwangmin; Chaney, Katherine E.; Rizvi, Tilat A.; Ratner, Nancy] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Perrino, Melissa R.; Ratner, Nancy] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45220 USA; [Largaespada, David A.] Univ Minnesota, Coll Biol Sci, Dept Genet Cell Biol & Dev, Minneapolis, MN USA; [Coover, Robert A.] High Point Univ, Fred Wilson Sch Pharm, Dept Basic Pharmaceut Sci, High Point, NC USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Minnesota System; University of Minnesota Twin Cities	Ratner, N (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.; Ratner, N (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45220 USA.	Nancy.ratner@cchmc.org		Pundavela, Jay/0000-0003-2861-4736; RATNER, NANCY/0000-0001-5030-9354; Perrino, Melissa/0000-0002-0598-7102	National Institute of Health (NIH) [5R01NS086219]	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank the CCHMC research pathology core for tissue processing and embedding and the viral vector core for lentivirus preparation. This research was supported by the National Institute of Health (NIH) 5R01NS086219, to DAL and NR.	Ahsan S, 2016, ONCOTARGET, V7, P57171, DOI 10.18632/oncotarget.11036; Asem MS, 2016, CANCERS, V8, DOI 10.3390/cancers8090079; Banerjee J, 2020, GENES-BASEL, V11, DOI 10.3390/genes11020226; Berger H, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00031; Bi LQ, 2014, INT J CLIN EXP PATHO, V7, P987; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Brohl AS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15183-1; Brosseau JP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07452-y; Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906; Cho H, 2016, WOUND REPAIR REGEN, V24, P829, DOI 10.1111/wrr.12453; Choi K, 2017, SCI REP-UK, V7, DOI 10.1038/srep43315; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; DeLeon-Pennell KY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94207; Dong S, 2015, CLIN LAB, V61, P537, DOI 10.7754/Clin.Lab.2014.141127; Ekstrom EJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-88; Evans DG, 2010, AM J MED GENET A, V152A, P327, DOI 10.1002/ajmg.a.33139; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Green J, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a009175; Grigoryan T, 2013, P NATL ACAD SCI USA, V110, P18174, DOI 10.1073/pnas.1310490110; Handolias D, 2008, FUTURE ONCOL, V4, P211, DOI 10.2217/14796694.4.2.211; Huang L, 2016, EXP THER MED, V12, P3851, DOI 10.3892/etm.2016.3885; Huang TC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181034; Jang J, 2017, SCI REP-UK, V7, DOI 10.1038/srep41612; Jiang HJ, 2013, NEUROCHEM RES, V38, P346, DOI 10.1007/s11064-012-0925-8; Katoh M, 2017, INT J ONCOL, V51, P1357, DOI 10.3892/ijo.2017.4129; Katoh M, 2017, INT J MOL MED, V40, P587, DOI 10.3892/ijmm.2017.3071; Katoh M, 2009, INT J MOL MED, V23, P763, DOI 10.3892/ijmm_00000190; Khan AQ, 2019, SEMIN CANCER BIOL, V54, P1, DOI 10.1016/j.semcancer.2018.03.001; Kim J, 2010, J IMMUNOL, V185, P1274, DOI 10.4049/jimmunol.1000181; Kobayashi C, 2006, CANCER GENET CYTOGEN, V165, P98, DOI 10.1016/j.cancergencyto.2005.07.006; Largaespada D, 2013, CANCER CELL, V23, P269, DOI 10.1016/j.ccr.2013.03.001; Li H, 2016, LAB INVEST, V96, P1105, DOI 10.1038/labinvest.2016.88; Li ZQ, 2018, INT J MED SCI, V15, P1415, DOI 10.7150/ijms.26741; Liu AR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090229; Long HT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1693-z; Lopez-Bergami P, 2020, CANCER METAST REV, V39, P933, DOI 10.1007/s10555-020-09878-7; Luo C, 2020, J CLIN INVEST, V130, P853, DOI 10.1172/JCI130038; Luscan A, 2014, CLIN CANCER RES, V20, P358, DOI 10.1158/1078-0432.CCR-13-0780; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mahller YY, 2008, CANCER RES, V68, P1170, DOI 10.1158/0008-5472.CAN-07-2734; Mahller YY, 2006, PEDIATR BLOOD CANCER, V46, P745, DOI 10.1002/pbc.20565; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; Miettinen MM, 2017, HUM PATHOL, V67, P1, DOI 10.1016/j.humpath.2017.05.010; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; O'Neil NJ, 2017, NAT REV GENET, V18, P613, DOI 10.1038/nrg.2017.47; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Prada CE, 2013, ACTA NEUROPATHOL, V125, P159, DOI 10.1007/s00401-012-1056-7; Prasad CP, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0421-0; Rauner M, 2012, J BONE MINER RES, V27, P575, DOI 10.1002/jbmr.1488; Rebalka IA, 2018, AM J PHYSIOL-CELL PH, V315, pC714, DOI 10.1152/ajpcell.00195.2017; Reilly KM, 2013, CANCER DISCOV, V3, P610, DOI 10.1158/2159-8290.CD-13-0192; RIDLEY AJ, 1989, J CELL BIOL, V109, P3419, DOI 10.1083/jcb.109.6.3419; Roman-Gomez J, 2007, EUR J CANCER, V43, P2736, DOI 10.1016/j.ejca.2007.10.004; Sapi Z, 2016, GENE CHROMOSOME CANC, V55, P786, DOI 10.1002/gcc.22379; Shurell E, 2016, ONCOTARGET, V7, P64300, DOI 10.18632/oncotarget.11734; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Sohier P, 2017, GENE CHROMOSOME CANC, V56, P421, DOI 10.1002/gcc.22446; Tian F, 2015, INT J MOL SCI, V16, P3178, DOI 10.3390/ijms16023178; de Vasconcelos RAT, 2019, CANCER MED-US, V8, P972, DOI 10.1002/cam4.1977; Tu B, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130811; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Wang TX, 2019, J CANCER RES THER, V15, P904, DOI 10.4103/jcrt.JCRT_886_18; Wang ZG, 2015, ONCOL REP, V34, P391, DOI 10.3892/or.2015.3966; Watson AL, 2013, CANCER DISCOV, V3, P674, DOI 10.1158/2159-8290.CD-13-0081; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Widemann BC, 2009, CURR ONCOL REP, V11, P322, DOI 10.1007/s11912-009-0045-z; Yamagata K, 2012, J BIOL CHEM, V287, P1588, DOI 10.1074/jbc.M111.315127; Yamamoto T, 1999, J BIOCHEM-TOKYO, V126, P799, DOI 10.1093/oxfordjournals.jbchem.a022519; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Zhang C, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0246-z; Zhang CY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10999-3; Zhao LY, 2017, EBIOMEDICINE, V16, P87, DOI 10.1016/j.ebiom.2017.01.021; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	76	4	4	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4229	4241		10.1038/s41388-021-01773-x	http://dx.doi.org/10.1038/s41388-021-01773-x		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34079083	Green Accepted			2022-12-28	WOS:000657217400006
J	Yusenko, MV; Trentmann, A; Casolari, DA; Ghani, LA; Lenz, M; Horn, M; Dorner, W; Klempnauer, S; Mootz, HD; Arteaga, MF; Mikesch, JH; Andrea, RJD; Gonda, TJ; Muller-Tidow, C; Schmidt, TJ; Klempnauer, KH				Yusenko, Maria V.; Trentmann, Amke; Casolari, Debora A.; Abdel Ghani, Luca; Lenz, Mairin; Horn, Melanie; Doerner, Wolfgang; Klempnauer, Stefan; Mootz, Henning D.; Arteaga, Maria Francisca; Mikesch, Jan-Henrik; Andrea, Richard J. D'; Gonda, Thomas J.; Mueller-Tidow, Carsten; Schmidt, Thomas J.; Klempnauer, Karl-Heinz			C/EBP beta is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia	ONCOGENE			English	Article							DEPENDENT GENE-EXPRESSION; TRANSCRIPTION FACTOR MYB; V-MYB; NF-M; SYNERGISTIC ACTIVATION; SESQUITERPENE LACTONES; STEM-CELLS; C-MYB; DIFFERENTIATION; ENHANCER	Transcription factor MYB has recently emerged as a promising drug target for the treatment of acute myeloid leukemia (AML). Here, we have characterized a group of natural sesquiterpene lactones (STLs), previously shown to suppress MYB activity, for their potential to decrease AML cell proliferation. Unlike what was initially thought, these compounds inhibit MYB indirectly via its cooperation partner C/EBP beta. C/EBP beta-inhibitory STLs affect the expression of a large number of MYB-regulated genes, suggesting that the cooperation of MYB and C/EBP beta broadly shapes the transcriptional program of AML cells. We show that expression of GFI1, a direct MYB target gene, is controlled cooperatively by MYB, C/EBP beta, and co-activator p300, and is down-regulated by C/EBP beta-inhibitory STLs, exemplifying that they target the activity of composite MYB-C/EBP beta-p300 transcriptional modules. Ectopic expression of GFI1, a zinc-finger protein that is required for the maintenance of hematopoietic stem and progenitor cells, partially abrogated STL-induced myelomonocytic differentiation, implicating GFI1 as a relevant target of C/EBP beta-inhibitory STLs. Overall, our data identify C/EBP beta as a pro-leukemogenic factor in AML and suggest that targeting of C/EBP beta may have therapeutic potential against AML.	[Yusenko, Maria V.; Trentmann, Amke; Abdel Ghani, Luca; Doerner, Wolfgang; Mootz, Henning D.; Klempnauer, Karl-Heinz] Westfalische Wilhelms Univ, Inst Biochem, Munster, Germany; [Casolari, Debora A.; Andrea, Richard J. D'] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia; [Casolari, Debora A.; Andrea, Richard J. D'] Univ South Australia, Adelaide, SA, Australia; [Lenz, Mairin; Schmidt, Thomas J.] Westfalische Wilhelms Univ, Inst Pharmaceut Biol & Phytochem, Munster, Germany; [Horn, Melanie; Mueller-Tidow, Carsten] Univ Hosp Heidelberg, Dept Med 5, Hematol, Oncol,Rheumatol, Heidelberg, Germany; [Klempnauer, Stefan] Ruhr Univ, Dept Math, Bochum, Germany; [Arteaga, Maria Francisca; Mikesch, Jan-Henrik] Westfalische Wilhelms Univ, Univ Hosp, Dept Med Hematol & Oncol A, Munster, Germany; [Gonda, Thomas J.] Univ South Australia, Canc Res Inst, Adelaide, SA, Australia	University of Munster; Centre for Cancer Biology; SA Pathology; University of South Australia; University of Munster; Ruprecht Karls University Heidelberg; Ruhr University Bochum; University of Munster; University of South Australia	Klempnauer, KH (corresponding author), Westfalische Wilhelms Univ, Inst Biochem, Munster, Germany.	klempna@uni-muenster.de	Arteaga, Maria Francisca/GPS-7709-2022; Schmidt, Thomas J/M-1678-2016	Arteaga, Maria Francisca/0000-0003-3280-5113; Schmidt, Thomas J/0000-0003-2634-9705; Casolari, Debora/0000-0001-5072-0880	Deutsche Krebshilfe; Else Kroner-Fresenius Stiftung; Deutsche Jose Carreras Leukamie-Stiftung e.V	Deutsche Krebshilfe(Deutsche Krebshilfe); Else Kroner-Fresenius Stiftung; Deutsche Jose Carreras Leukamie-Stiftung e.V	We thank Bianca Berkenfeld, Stephanie Wulff, and Fredrick Hohn for expert technical assistance and help and the students Anna-Lena Feldberg and Lucas Forster for help in the initial pilot experiments. This work was supported by grants from the Deutsche Krebshilfe, the Else Kroner-Fresenius Stiftung and the Deutsche Jose Carreras Leukamie-Stiftung e.V. We also thank the Core Facility Genomics at the Medical Faculty of the University of Munster for performing next-generation-sequencing and preliminary data analysis.	Anastasov N, 2010, HAEMATOL-HEMATOL J, V95, P760, DOI 10.3324/haematol.2009.014050; Arteaga MF, 2013, CANCER CELL, V23, P376, DOI 10.1016/j.ccr.2013.02.014; Barth J, 2019, LEUKEMIA, V33, P1411, DOI 10.1038/s41375-018-0375-7; Bujnicki T, 2012, LEUKEMIA, V26, P615, DOI 10.1038/leu.2011.275; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chayka O, 2005, MOL CELL BIOL, V25, P499, DOI 10.1128/MCB.25.1.499-511.2005; Clappier E, 2007, BLOOD, V110, P1251, DOI 10.1182/blood-2006-12-064683; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Galkina A, 2019, MOLECULES, V24, DOI 10.3390/molecules24061068; Hess JL, 2006, BLOOD, V108, P297, DOI 10.1182/blood-2005-12-5014; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; HU YL, 1991, ONCOGENE, V6, P1549; Jakobs A, 2016, LEUKEMIA, V30, P1612, DOI 10.1038/leu.2016.16; Jakobs A, 2016, J BIOL CHEM, V291, P26098, DOI 10.1074/jbc.M116.748129; Jin SH, 2010, J CLIN INVEST, V120, P593, DOI 10.1172/JCI38030; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; Kim MH, 2009, PROSTATE, V69, P1435, DOI 10.1002/pros.20993; Lahortiga I, 2007, NAT GENET, V39, P593, DOI 10.1038/ng2025; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Liu X, 2015, MOL CANCER THER, V14, P1273, DOI 10.1158/1535-7163.MCT-15-0271; Lomenick Brett, 2011, Curr Protoc Chem Biol, V3, P163; Maiques-Diaz A, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2018.1481813; Maiques-Diaz A, 2018, CELL REP, V22, P3641, DOI 10.1016/j.celrep.2018.03.012; Mandelbaum J, 2018, J EXP MED, V215, P2673, DOI 10.1084/jem.20180939; Mansour MR, 2014, SCIENCE, V346, P1373, DOI 10.1126/science.1259037; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; Nerlov C, 2008, CURR OPIN CELL BIOL, V20, P180, DOI 10.1016/j.ceb.2008.02.002; Nerlov C, 2007, TRENDS CELL BIOL, V17, P318, DOI 10.1016/j.tcb.2007.07.004; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Pal R, 2009, BLOOD, V114, P3890, DOI 10.1182/blood-2009-01-201111; Plachetka A, 2008, MOL CELL BIOL, V28, P2102, DOI 10.1128/MCB.01943-07; Rahman S, 2017, BLOOD, V129, P3221, DOI 10.1182/blood-2016-09-742148; Ramaswamy K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02618-6; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; Regalo G, 2006, J PATHOL, V210, P398, DOI 10.1002/path.2063; Roe JS, 2015, MOL CELL, V58, P1028, DOI 10.1016/j.molcel.2015.04.011; Schmidt TJ, 2014, ANTIMICROB AGENTS CH, V58, P325, DOI 10.1128/AAC.01263-13; Schomburg C, 2013, EUR J MED CHEM, V63, P313, DOI 10.1016/j.ejmech.2013.02.018; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Sebastian T, 2006, CELL CYCLE, V5, P953, DOI 10.4161/cc.5.9.2733; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Uttarkar S, 2017, EXP HEMATOL, V47, P31, DOI 10.1016/j.exphem.2016.12.003; Uttarkar S, 2016, MOL CANCER THER, V15, P2905, DOI 10.1158/1535-7163.MCT-16-0185; Uttarkar S, 2016, BLOOD, V127, P1173, DOI 10.1182/blood-2015-09-668632; Uttarkar S, 2015, MOL CANCER THER, V14, P1276, DOI 10.1158/1535-7163.MCT-14-0662; van Bergen MGJM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01027; van der Meer LT, 2010, LEUKEMIA, V24, P1834, DOI 10.1038/leu.2010.195; Walf-Vorderwulbecke V, 2018, LEUKEMIA, V32, P882, DOI 10.1038/leu.2017.317; Yusenko M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31620-1; Zeng H, 2004, EMBO J, V23, P4116, DOI 10.1038/sj.emboj.7600419; Zhao L, 2014, ONCOGENE, V33, P4442, DOI 10.1038/onc.2013.419; Zhao L, 2011, NUCLEIC ACIDS RES, V39, P4664, DOI 10.1093/nar/gkr024; Zuber J, 2011, GENE DEV, V25, P1628, DOI 10.1101/gad.17269211	60	5	5	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4746	4758		10.1038/s41388-021-01800-x	http://dx.doi.org/10.1038/s41388-021-01800-x		MAY 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	33958723	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000648041500001
J	Qin, WR; Xu, GC; Tai, PWL; Wang, CM; Luo, L; Li, CJ; Hu, X; Xue, JX; Lu, Y; Zhou, Q; Wei, Q; Wen, TF; Hu, JK; Xiao, YY; Yang, L; Li, WM; Flotte, TR; Wei, YQ; Gao, GP				Qin, Wanru; Xu, Guangchao; Tai, Phillip W. L.; Wang, Chunmei; Luo, Li; Li, Chengjian; Hu, Xun; Xue, Jianxin; Lu, You; Zhou, Qiao; Wei, Qiang; Wen, Tianfu; Hu, Jiankun; Xiao, Yuanyuan; Yang, Li; Li, Weimin; Flotte, Terence R.; Wei, Yuquan; Gao, Guangping			Large-scale molecular epidemiological analysis of AAV in a cancer patient population	ONCOGENE			English	Article								Recombinant adeno-associated viruses (rAAVs) are well-established vectors for delivering therapeutic genes. However, previous reports have suggested that wild-type AAV is linked to hepatocellular carcinoma, raising concern with the safety of rAAVs. In addition, a recent long-term follow-up study in canines, which received rAAVs for factor VIII gene therapy, demonstrated vector integration into the genome of liver cells, reviving the uncertainty between AAV and cancer. To further explore this relationship, we performed large-scale molecular epidemiology of AAV in resected tumor samples and non-lesion tissues collected from 413 patients, reflecting nine carcinoma types: breast carcinoma, rectal cancer, pancreas carcinoma, brain tumor, hepatoid adenocarcinoma, hepatocellular carcinoma, gastric carcinoma, lung squamous, and adenocarcinoma. We found that over 80% of patients were AAV-positive among all nine types of carcinoma examined. Importantly, the AAV sequences detected in patient-matched tumor and adjacent non-lesion tissues showed no significant difference in incidence, abundance, and variation. In addition, no specific AAV sequences predominated in tumor samples. Our data shows that AAV genomes are equally abundant in tumors and adjacent normal tissues, but lack clonality. The finding critically adds to the epidemiological profile of AAV in humans, and provides insights that may assist rAAV-based clinical studies and gene therapy strategies.	[Qin, Wanru; Xu, Guangchao; Wang, Chunmei; Luo, Li; Xiao, Yuanyuan; Yang, Li; Li, Weimin; Wei, Yuquan] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China; [Xu, Guangchao; Tai, Phillip W. L.; Luo, Li; Flotte, Terence R.; Gao, Guangping] Univ Massachusetts, Sch Med, Horae Gene Therapy Ctr, Worcester, MA 01605 USA; [Xu, Guangchao; Tai, Phillip W. L.; Gao, Guangping] Univ Massachusetts, Sch Med, Microbiol & Physiol Syst, Worcester, MA 01605 USA; [Li, Chengjian] Fornax Biotech, Worcester, MA USA; [Hu, Xun] Sichuan Univ, West China Hosp, Biobank, Chengdu, Peoples R China; [Xue, Jianxin; Lu, You] Sichuan Univ, West China Hosp, Canc Ctr, Dept Thorac Oncol, Chengdu, Peoples R China; [Xue, Jianxin; Lu, You] Sichuan Univ, West China Hosp, Canc Ctr, State Key Lab Biotherapy, Chengdu, Peoples R China; [Zhou, Qiao] Sichuan Univ, West China Hosp, West China Med Sch, Pathol Dept, Chengdu, Peoples R China; [Zhou, Qiao] Sichuan Univ, West China Hosp, West China Med Sch, State Key Lab Biotherapy, Chengdu, Peoples R China; [Wei, Qiang] Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Peoples R China; [Wen, Tianfu] Sichuan Univ, West China Hosp, Dept Liver Surg, Chengdu, Peoples R China; [Hu, Jiankun] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Peoples R China; [Hu, Jiankun] Sichuan Univ, West China Hosp, Lab Gastr Canc, Chengdu, Peoples R China; [Flotte, Terence R.] Univ Massachusetts, Sch Med, Pediat, Worcester, MA 01605 USA	Sichuan University; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; University of Massachusetts System; University of Massachusetts Worcester	Wei, YQ (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China.; Flotte, TR; Gao, GP (corresponding author), Univ Massachusetts, Sch Med, Horae Gene Therapy Ctr, Worcester, MA 01605 USA.; Gao, GP (corresponding author), Univ Massachusetts, Sch Med, Microbiol & Physiol Syst, Worcester, MA 01605 USA.; Flotte, TR (corresponding author), Univ Massachusetts, Sch Med, Pediat, Worcester, MA 01605 USA.	Terry.Flotte@umassmed.edu; yqwei@scu.edu.cn; guangping.gao@umassmed.edu		Tai, Phillip/0000-0001-7409-8344; Xu, Guangchao/0000-0002-3806-2245	University of Massachusetts Medical School; NIH [R01NS076991-01, P01AI100263-01, P01HL131471-02, R01AI121135, UG3HL147367-01, R01HL097088, U19AI149646-01]	University of Massachusetts Medical School; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the University of Massachusetts Medical School (an internal grant) and by the NIH (R01NS076991-01, P01AI100263-01, P01HL131471-02, R01AI121135, UG3HL147367-01, R01HL097088, and U19AI149646-01).	Afgan E, 2018, NUCLEIC ACIDS RES, V46, pW537, DOI 10.1093/nar/gky379; Berns KI, 2020, HUM GENE THER, V31, P518, DOI 10.1089/hum.2020.017; Berns KI, 2015, HUM GENE THER, V26, P779, DOI 10.1089/hum.2015.29014.kib; Boutin S, 2010, HUM GENE THER, V21, P704, DOI 10.1089/hum.2009.182; Buning H, 2015, MOL THER, V23, P1673, DOI 10.1038/mt.2015.182; Calcedo R, 2009, J INFECT DIS, V199, P381, DOI 10.1086/595830; Chandler RJ, 2016, MOL THER, V24, P198, DOI 10.1038/mt.2016.17; Chandler RJ, 2015, J CLIN INVEST, V125, P870, DOI 10.1172/JCI79213; Chen CL, 2005, J VIROL, V79, P14781, DOI 10.1128/JVI.79.23.14781-14792.2005; Donsante A, 2007, SCIENCE, V317, P477, DOI 10.1126/science.1142658; Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Gao GP, 2003, P NATL ACAD SCI USA, V100, P6081, DOI 10.1073/pnas.0937739100; Gil-Farina I, 2016, CURR OPIN VIROL, V21, P35, DOI 10.1016/j.coviro.2016.07.004; Halbert CL, 2006, HUM GENE THER, V17, P440, DOI 10.1089/hum.2006.17.440; Hanlon KS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12449-2; Huser D, 2017, J VIROL, V91, DOI 10.1128/JVI.02137-16; KOTIN RM, 1991, GENOMICS, V10, P831, DOI 10.1016/0888-7543(91)90470-Y; Kramer CJH, 2019, BREAST CANCER RES TR, V173, P55, DOI 10.1007/s10549-018-4987-4; La Bella T, 2020, GUT, V69, P737, DOI 10.1136/gutjnl-2019-318281; Li HJ, 2011, BLOOD, V117, P3311, DOI 10.1182/blood-2010-08-302729; Ling C, 2015, J INTEGR MED-JIM, V13, P341, DOI 10.1016/S2095-4964(15)60200-X; Liu Q, 2014, GENE THER, V21, P732, DOI 10.1038/gt.2014.47; Liu Q, 2013, J MED VIROL, V85, P1550, DOI 10.1002/jmv.23647; Logan GJ, 2017, NAT GENET, V49, P1267, DOI 10.1038/ng.3893; Mesker WE, 2007, CELL ONCOL, V29, P387; Miller DG, 2004, NAT GENET, V36, P767, DOI 10.1038/ng1380; Nakai H, 2003, MOL THER, V7, P101, DOI 10.1016/S1525-0016(02)00023-0; Nault JC, 2016, MOL THER, V24, P659, DOI 10.1038/mt.2016.47; Nault JC, 2015, NAT GENET, V47, P1187, DOI 10.1038/ng.3389; Nguyen GN, 2021, NAT BIOTECHNOL, V39, P47, DOI 10.1038/s41587-020-0741-7; Ogden PJ, 2019, SCIENCE, V366, P1139, DOI 10.1126/science.aaw2900; Pachori AS, 2004, BIOCHEM BIOPH RES CO, V313, P528, DOI 10.1016/j.bbrc.2003.11.140; Rosas LE, 2012, MOL THER, V20, P2098, DOI 10.1038/mt.2012.197; Schnepp BC, 2005, J VIROL, V79, P14793, DOI 10.1128/JVI.79.23.14793-14803.2005; Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573-019-0012-9; Wang PR, 2012, P NATL ACAD SCI USA, V109, P11264, DOI 10.1073/pnas.1117032109; Zhong L, 2013, HUM GENE THER, V24, P520, DOI 10.1089/hum.2012.112	38	5	5	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3060	3071		10.1038/s41388-021-01725-5	http://dx.doi.org/10.1038/s41388-021-01725-5		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33782545	Green Accepted			2022-12-28	WOS:000634614900001
J	Moreno, T; Monterde, B; Gonzalez-Silva, L; Betancor-Fernandez, I; Revilla, C; Agraz-Doblas, A; Freire, J; Isidro, P; Quevedo, L; Blanco, R; Montes-Moreno, S; Cereceda, L; Astudillo, A; Casar, B; Crespo, P; Torres, CM; Scaffidi, P; Gomez-Roman, J; Salido, E; Varela, I				Moreno, Thaidy; Monterde, Beatriz; Gonzalez-Silva, Laura; Betancor-Fernandez, Isabel; Revilla, Carlos; Agraz-Doblas, Antonio; Freire, Javier; Isidro, Pablo; Quevedo, Laura; Blanco, Rosa; Montes-Moreno, Santiago; Cereceda, Laura; Astudillo, Aurora; Casar, Berta; Crespo, Piero; Morales Torres, Cristina; Scaffidi, Paola; Gomez-Roman, Javier; Salido, Eduardo; Varela, Ignacio			ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer	ONCOGENE			English	Article								The survival rate in lung cancer remains stubbornly low and there is an urgent need for the identification of new therapeutic targets. In the last decade, several members of the SWI/SNF chromatin remodeling complexes have been described altered in different tumor types. Nevertheless, the precise mechanisms of their impact on cancer progression, as well as the application of this knowledge to cancer patient management are largely unknown. In this study, we performed targeted sequencing of a cohort of lung cancer patients on genes involved in chromatin structure. In addition, we studied at the protein level the expression of these genes in cancer samples and performed functional experiments to identify the molecular mechanisms linking alterations of chromatin remodeling genes and tumor development. Remarkably, we found that 20% of lung cancer patients show ARID2 protein loss, partially explained by the presence of ARID2 mutations. In addition, we showed that ARID2 deficiency provokes profound chromatin structural changes altering cell transcriptional programs, which bolsters the proliferative and metastatic potential of the cells both in vitro and in vivo. Moreover, we demonstrated that ARID2 deficiency impairs DNA repair, enhancing the sensitivity of the cells to DNA-damaging agents. Our findings support that ARID2 is a bona fide tumor suppressor gene in lung cancer that may be exploited therapeutically.	[Moreno, Thaidy; Monterde, Beatriz; Gonzalez-Silva, Laura; Revilla, Carlos; Agraz-Doblas, Antonio; Quevedo, Laura; Blanco, Rosa; Casar, Berta; Crespo, Piero; Varela, Ignacio] Univ Cantabria, Inst Biomed & Biotecnol Cantabria, CSIC, Santander, Spain; [Betancor-Fernandez, Isabel; Salido, Eduardo] Ctr Invest Biomed Red Enfermedades Raras CIBERER, Dept Patol, Tenerife, Spain; [Freire, Javier; Montes-Moreno, Santiago; Cereceda, Laura; Gomez-Roman, Javier] HUMV IDIVAL, Serv Anat Patol & Biobanco Valdecilla, Santander, Spain; [Isidro, Pablo; Astudillo, Aurora] Hosp Univ Cent Asturias, Biobanco Principado Asturias BBPA, Oviedo, Spain; [Casar, Berta; Crespo, Piero] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Morales Torres, Cristina; Scaffidi, Paola] Francis Crick Inst, Canc Epigenet Lab, London, England	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Hospital Universitario Marques de Valdecilla (HUMV); Central University Hospital Asturias; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Francis Crick Institute	Varela, I (corresponding author), Univ Cantabria, Inst Biomed & Biotecnol Cantabria, CSIC, Santander, Spain.	ignacio.varela@unican.es	Montes-Moreno, Santiago/E-7008-2011; Scaffidi, Paola/GRS-9019-2022; José Javier, Gómez-Román/AAC-8156-2021; Astudillo, Aurora/AAA-5487-2022; Crespo, Piero/M-3273-2014; Varela, Ignacio/G-1699-2016	Montes-Moreno, Santiago/0000-0002-3565-8262; Scaffidi, Paola/0000-0002-3642-4193; José Javier, Gómez-Román/0000-0002-2849-9435; Astudillo, Aurora/0000-0001-8947-8809; Crespo, Piero/0000-0003-2825-7783; Quevedo, Laura/0000-0001-8902-5818; Moreno Rodriguez, Thaidy/0000-0003-3588-3889; CERECEDA, LAURA/0000-0002-0106-1898; Gonzalez-Silva, Laura/0000-0001-8625-1473; Varela, Ignacio/0000-0002-0969-506X	Spanish Ministerio de Economia y Competitividad (MINECO) [SAF2012-31627, SAF2016-76758-R]; Fundacion Ramon Areces grant; European Research Council [ERC2014-StG637904]; Ayudas para la formacion de profesorado universitario (FPU, Ministerio de Educacion y Formacion Profesional, Spain); MINECO/FEDER, UE [SAF-2015-63638R]; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC); Asociacion Espanola Contra el Cancer (AECC) [GCB141423113]; Retos Jovenes Investigadores grant (AEI/FEDER, UE) [SAF-2015-73364-JIN]; Fundacion Francisco Cobos; Francis Crick Institute; Cancer Research UK [FC001152]; UK Medical Research Council [FC001152]; Servicio de Salud del Principado de Asturias; Fundacion Bancaria Cajastur; Wellcome Trust [FC001152]; Instituto de Salud Carlos III; Programa Ramon y Cajal (MINECO, Spain); Ayudas para la contratacion de investigadores predoctorales (MINECO, Spain)	Spanish Ministerio de Economia y Competitividad (MINECO); Fundacion Ramon Areces grant; European Research Council(European Research Council (ERC)European Commission); Ayudas para la formacion de profesorado universitario (FPU, Ministerio de Educacion y Formacion Profesional, Spain)(German Research Foundation (DFG)); MINECO/FEDER, UE; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC); Asociacion Espanola Contra el Cancer (AECC); Retos Jovenes Investigadores grant (AEI/FEDER, UE); Fundacion Francisco Cobos; Francis Crick Institute; Cancer Research UK(Cancer Research UK); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Servicio de Salud del Principado de Asturias; Fundacion Bancaria Cajastur; Wellcome Trust(Wellcome TrustEuropean Commission); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Programa Ramon y Cajal (MINECO, Spain); Ayudas para la contratacion de investigadores predoctorales (MINECO, Spain)	IV is supported by SAF2012-31627 and SAF2016-76758-R grants from the Spanish Ministerio de Economia y Competitividad (MINECO), by a Fundacion Ramon Areces grant and by ERC2014-StG637904 grant from the European Research Council. IV has been awardee of the Programa Ramon y Cajal (MINECO, Spain). TM has been awardee of the Ayudas para la contratacion de investigadores predoctorales (MINECO, Spain). BM is awardee of the Ayudas para la formacion de profesorado universitario (FPU, Ministerio de Educacion y Formacion Profesional, Spain). PC laboratory is supported by grant SAF-2015-63638R (MINECO/FEDER, UE); by Centro de Investigacion Biomedica en Red de Cancer (CIBERONC) and by Asociacion Espanola Contra el Cancer (AECC), grant GCB141423113. BC has been supported by a Retos Jovenes Investigadores grant SAF-2015-73364-JIN (AEI/FEDER, UE) and a grant from Fundacion Francisco Cobos. PS is supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001152) and the UK Medical Research Council (FC001152). HUCA/IUOPA is jointly financed by Servicio de Salud del Principado de Asturias, Instituto de Salud Carlos III, and Fundacion Bancaria Cajastur. This research was funded in part by the Wellcome Trust [FC001152].	Alver BH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14648; Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Fishilevich S, 2017, DATABASE-OXFORD, DOI 10.1093/database/bax028; Flowers S, 2010, CANCER RES, V70, P8282, DOI 10.1158/0008-5472.CAN-10-2205; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Gelsomino F, 2014, CANCERS, V6, P2100, DOI 10.3390/cancers6042100; Giacobbe A, 2016, ONCOGENE, V35, P1602, DOI 10.1038/onc.2015.230; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Kayser G, 2015, BRIT J CANCER, V112, P866, DOI 10.1038/bjc.2015.2; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Lauand C, 2015, BRAZ J MED BIOL RES, V48, P382, DOI 10.1590/1414-431X20144262; Lee HS, 2010, EMBO J, V29, P1434, DOI 10.1038/emboj.2010.27; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lovly CM, 2011, NAT REV CLIN ONCOL, V8, P68, DOI 10.1038/nrclinonc.2010.224; Manceau G, 2013, INT J CANCER, V132, P2217, DOI 10.1002/ijc.27900; Martinez N, 2014, LEUKEMIA, V28, P1334, DOI 10.1038/leu.2013.365; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mularoni L, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0994-0; Nakayama RT, 2017, NAT GENET, V49, P1613, DOI 10.1038/ng.3958; Niimi A, 2012, NUCLEIC ACIDS RES, V40, P7393, DOI 10.1093/nar/gks453; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Ray A, 2009, MOL CELL BIOL, V29, P6206, DOI 10.1128/MCB.00503-09; Reisman DN, 2003, CANCER RES, V63, P560; Robinson JT, 2017, CANCER RES, V77, pE31, DOI 10.1158/0008-5472.CAN-17-0337; Romero OA, 2014, CANCER DISCOV, V4, P292, DOI 10.1158/2159-8290.CD-13-0799; Rugo HS, 2016, NEW ENGL J MED, V375, P23, DOI 10.1056/NEJMoa1513749; Sheffield NC, 2013, GENOME RES, V23, P777, DOI 10.1101/gr.152140.112; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor MD, 2018, CLIN EXP METASTAS, V35, P15, DOI 10.1007/s10585-017-9869-3; Tordella L, 2016, GENE DEV, V30, P2187, DOI 10.1101/gad.286112.116; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394; Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	44	9	9	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2923	2935		10.1038/s41388-021-01748-y	http://dx.doi.org/10.1038/s41388-021-01748-y		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742126	Green Accepted			2022-12-28	WOS:000630655600001
J	Berdiel-Acer, M; Maia, A; Hristova, Z; Borgoni, S; Vetter, M; Burmester, S; Becki, C; Michels, B; Abnaof, K; Binenbaum, I; Bethmann, D; Chatziioannou, A; Hasmann, M; Thomssen, C; Espinet, E; Wiemann, S				Berdiel-Acer, Mireia; Maia, Ana; Hristova, Zhivka; Borgoni, Simone; Vetter, Martina; Burmester, Sara; Becki, Corinna; Michels, Birgitta; Abnaof, Khalid; Binenbaum, Ilona; Bethmann, Daniel; Chatziioannou, Aristotelis; Hasmann, Max; Thomssen, Christoph; Espinet, Elisa; Wiemann, Stefan			Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts	ONCOGENE			English	Article							INTRACELLULAR DOMAIN; ERBB RECEPTORS; GENE ONTOLOGY; EXPRESSION; HER3; SUBTYPES; ANTIBODY; HETEROGENEITY; METASTASIS; DISCOVERY	HER3 is highly expressed in luminal breast cancer subtypes. Its activation by NRG1 promotes activation of AKT and ERK1/2, contributing to tumour progression and therapy resistance. HER3-targeting agents that block this activation, are currently under phase 1/2 clinical studies, and although they have shown favorable tolerability, their activity as a single agent has proven to be limited. Here we show that phosphorylation and activation of HER3 in luminal breast cancer cells occurs in a paracrine manner and is mediated by NRG1 expressed by cancer-associated fibroblasts (CAFs). Moreover, we uncover a HER3-independent NRG1 signaling in CAFs that results in the induction of a strong migratory and pro-fibrotic phenotype, describing a subtype of CAFs with elevated expression of NRG1 and an associated transcriptomic profile that determines their functional properties. Finally, we identified Hyaluronan Synthase 2 (HAS2), a targetable molecule strongly correlated with NRG1, as an attractive player supporting NRG1 signaling in CAFs.	[Berdiel-Acer, Mireia; Maia, Ana; Hristova, Zhivka; Borgoni, Simone; Burmester, Sara; Becki, Corinna; Michels, Birgitta; Abnaof, Khalid; Wiemann, Stefan] German Canc Res Ctr, Div Mol Genome Anal, Heidelberg, Germany; [Maia, Ana; Hristova, Zhivka; Borgoni, Simone] Ruprecht Karls Univ Heidelberg, Fac Biosci, Heidelberg, Germany; [Vetter, Martina; Thomssen, Christoph] Martin Luther Univ Halle Wittenberg, Dept Gynecol, Halle, Germany; [Binenbaum, Ilona] German Canc Res Ctr, Div Med Informat Translat Oncol, Heidelberg, Germany; [Binenbaum, Ilona] Univ Patras, Dept Biol, Patras, Greece; [Binenbaum, Ilona; Chatziioannou, Aristotelis] Natl Hellen Res Fdn, Inst Chem Biol, Athens, Greece; [Bethmann, Daniel] Martin Luther Univ Halle Wittenberg, Inst Pathol, Halle, Germany; [Chatziioannou, Aristotelis] E NIOS Pc, Kallithea Athens, Greece; [Hasmann, Max] Roche Diagnostics, Penzberg, Germany; [Espinet, Elisa] German Canc Res Ctr, Div Stem Cells & Canc, Heidelberg, Germany; [Espinet, Elisa] Heidelberg Inst Stem Cell Technol & Expt Med HI S, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Martin Luther University Halle Wittenberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Patras; National Hellenic Research Foundation; Martin Luther University Halle Wittenberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Berdiel-Acer, M; Wiemann, S (corresponding author), German Canc Res Ctr, Div Mol Genome Anal, Heidelberg, Germany.	mireia.berdiel@gmail.com; s.wiemann@dkfz-heidelberg.de	Wiemann, Stefan/E-4424-2013; Thomssen, Christoph/ABC-3102-2021	Wiemann, Stefan/0000-0003-4683-3174; Maia, Ana/0000-0003-1261-7211; Berdiel-Acer, Mireia/0000-0002-9777-9457; Hristova, Zhivka/0000-0003-2609-3623; Espinet, Elisa/0000-0002-0690-9878; Michels, Birgitta E./0000-0001-9948-4567	Projekt DEAL	Projekt DEAL	Open Access funding enabled and organized by Projekt DEAL.	Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Balko JM, 2012, P NATL ACAD SCI USA, V109, P221, DOI 10.1073/pnas.1115802109; Berdiel-Acer M, 2014, MOL ONCOL, V8, P1290, DOI 10.1016/j.molonc.2014.04.006; Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8; Cejalvo JM, 2017, CANCER RES, V77, P2213, DOI 10.1158/0008-5472.CAN-16-2717; Chua YL, 2009, ONCOGENE, V28, P4041, DOI 10.1038/onc.2009.259; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cortez E, 2014, SEMIN CANCER BIOL, V25, P3, DOI 10.1016/j.semcancer.2013.12.010; Costea DE, 2013, CANCER RES, V73, P3888, DOI 10.1158/0008-5472.CAN-12-4150; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Fujiwara S, 2014, BREAST CANCER-TOKYO, V21, P472, DOI 10.1007/s12282-012-0415-5; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jacob W, 2018, CANCER TREAT REV, V68, P111, DOI 10.1016/j.ctrv.2018.06.011; Karachaliou N, 2017, BIODRUGS, V31, P63, DOI 10.1007/s40259-016-0205-2; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Kim J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-383; Kim YH, 2019, CANCER SCI, V110, P2226, DOI 10.1111/cas.14070; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kolb A, 2007, INT J CANCER, V120, P514, DOI 10.1002/ijc.22360; Koutsandreas Theodoros, 2016, International Journal of Monitoring and Surveillance Technologies Research, V4, P30, DOI 10.4018/IJMSTR.2016040103; Kudo D, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030600; Ledonne A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010275; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Lisanti MP, 2014, CELL CYCLE, V13, P580, DOI 10.4161/cc.27379; Liu HY, 2017, DEV CELL, V41, P392, DOI 10.1016/j.devcel.2017.04.024; Liu XL, 2019, BIOL PROCED ONLINE, V21, DOI 10.1186/s12575-019-0093-1; Loeb JA, 1998, MOL CELL NEUROSCI, V11, P77, DOI 10.1006/mcne.1998.0676; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; Mei L, 2008, NAT REV NEUROSCI, V9, P437, DOI 10.1038/nrn2392; Mei L, 2014, NEURON, V83, P27, DOI 10.1016/j.neuron.2014.06.007; Meulendijks D, 2017, CLIN CANCER RES, V23, P5406, DOI 10.1158/1078-0432.CCR-17-0812; Meulendijks D, 2016, CLIN CANCER RES, V22, P877, DOI 10.1158/1078-0432.CCR-15-1683; Mirschberger C, 2013, CANCER RES, V73, P5183, DOI 10.1158/0008-5472.CAN-13-0099; Mishra R, 2018, ONCOL REV, V12, P45, DOI 10.4081/oncol.2018.355; Montero JC, 2008, CLIN CANCER RES, V14, P3237, DOI 10.1158/1078-0432.CCR-07-5133; Morrison MM, 2013, J CLIN INVEST, V123, P4329, DOI 10.1172/JCI66764; Morsing M, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0769-2; Ocana A, 2016, ONCOTARGET, V7, P45042, DOI 10.18632/oncotarget.8648; Ogier C, 2018, CANCER LETT, V432, P227, DOI 10.1016/j.canlet.2018.06.023; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Orimo A, 2007, CANCER BIOL THER, V6, P618, DOI 10.4161/cbt.6.4.4255; Parra LM, 2015, MOL CELL BIOL, V35, P3381, DOI 10.1128/MCB.00500-15; Patel AK, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0087-x; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; Qian GQ, 2015, CANCER-AM CANCER SOC, V121, P3600, DOI 10.1002/cncr.29549; Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002; Saadi A, 2010, P NATL ACAD SCI USA, V107, P2177, DOI 10.1073/pnas.0909797107; Sadlonova A, 2009, CANCER MICROENVIRON, V2, P9, DOI 10.1007/s12307-008-0017-0; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Sahin O, 2007, P NATL ACAD SCI USA, V104, P6579, DOI 10.1073/pnas.0606827104; Schneeweiss A, 2018, INVEST NEW DRUG, V36, P848, DOI 10.1007/s10637-018-0562-4; Shee K, 2018, J EXP MED, V215, P895, DOI 10.1084/jem.20171818; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Sonntag J, 2014, EXPERT REV PROTEOMIC, V11, P757, DOI 10.1586/14789450.2014.971113; Sorlie T, 2004, EUR J CANCER, V40, P2667, DOI 10.1016/j.ejca.2004.08.021; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Vargas AC, 2012, BREAST CANCER RES TR, V135, P153, DOI 10.1007/s10549-012-2123-4; Walker RA, 2001, BREAST CANCER RES, V3, P143, DOI 10.1186/bcr287; Weinstein IB, 1997, CLIN CANCER RES, V3, P2696; Wernig G, 2017, P NATL ACAD SCI USA, V114, P4757, DOI 10.1073/pnas.1621375114; Willem M, 2016, BRAIN RES BULL, V126, P178, DOI 10.1016/j.brainresbull.2016.07.003; Wilson TR, 2011, CANCER CELL, V20, P158, DOI 10.1016/j.ccr.2011.07.011; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoshida E, 2018, ANTICANCER RES, V38, P5799, DOI 10.21873/anticanres.12919; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yun S, 2018, GASTRIC CANCER, V21, P225, DOI 10.1007/s10120-017-0732-7; Zhang K, 2012, ONCOGENE, V31, P4609, DOI 10.1038/onc.2011.606; Zhang ZW, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0458-0	76	7	7	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2651	2666		10.1038/s41388-021-01719-3	http://dx.doi.org/10.1038/s41388-021-01719-3		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33692466	hybrid, Green Submitted, Green Published			2022-12-28	WOS:000627285600003
J	Meng, CJ; Zhan, J; Chen, DL; Shao, GZ; Zhang, HQ; Gu, W; Luo, JY				Meng, Chunjie; Zhan, Jun; Chen, Delin; Shao, Genze; Zhang, Hongquan; Gu, Wei; Luo, Jianyuan			The deubiquitinase USP11 regulates cell proliferation and ferroptotic cell death via stabilization of NRF2 USP11 deubiquitinates and stabilizes NRF2	ONCOGENE			English	Article								The transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) plays a key role in cancer progression and is tightly regulated by the proteasome pathway. E3 ligases that mediate NRF2 ubiquitination have been widely reported, but the mechanism of NRF2 deubiquitination remains largely unclear. Here, we identified ubiquitin-specific-processing protease 11 (USP11) in NRF2 complexes and confirmed an interaction between these two proteins. We further found that USP11 deubiquitinates NRF2; this modification stabilizes NRF2. Functionally, USP11 depletion contributes to the suppression of cell proliferation and induction of ferroptotic cell death due to ROS-mediated stress, which can be largely abrogated by overexpression of NRF2. Finally, immunohistochemical staining of USP11 and NRF2 was performed using a lung tissue microarray, which revealed that USP11 is highly expressed in patients with NSCLC and positively correlated with NRF2 expression. Together, USP11 stabilizes NRF2 and is thus an important player in cell proliferation and ferroptosis.	[Meng, Chunjie; Luo, Jianyuan] Peking Univ, Beijing Key Lab Prot Posttranslat Modificat & Cel, Dept Biochem & Biophys, Dept Med Genet,Ctr Med Genet,Hlth Sci Ctr, Beijing, Peoples R China; [Zhan, Jun; Zhang, Hongquan] Peking Univ, Dept Human Anat Histol & Embryol, Key Lab Carcinogenesis & Translat Res, Minist Educ,Hlth Sci Ctr, Beijing, Peoples R China; [Zhan, Jun; Zhang, Hongquan] Peking Univ, State Key Lab Nat & Biomimet Drugs, Hlth Sci Ctr, Beijing, Peoples R China; [Chen, Delin; Gu, Wei] Columbia Univ, Dept Pathol & Cell Biol, Inst Canc Genet, New York, NY USA; [Shao, Genze] Peking Univ, Sch Basic Med Sci, Dept Cell Biol, Hlth Sci Ctr, Beijing, Peoples R China	Peking University; Peking University; Peking University; Columbia University; Peking University	Luo, JY (corresponding author), Peking Univ, Beijing Key Lab Prot Posttranslat Modificat & Cel, Dept Biochem & Biophys, Dept Med Genet,Ctr Med Genet,Hlth Sci Ctr, Beijing, Peoples R China.	luojianyuan@bjmu.edu.cn		Shao, Genze/0000-0002-4374-3969; Gu, Wei/0000-0002-1480-2368	National Natural Science Foundation of China [81874147, 81671389, 81621063, 81773199]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from National Natural Science Foundation of China (81874147, 81671389, 81621063, 81773199). We thank core facility at Peking University Health Science Center for experiment help. We thank members in Wei Gu's Lab (Columbia University Medical school) for helps to finish the project.	Bai XP, 2016, DRUG METAB REV, V48, P541, DOI 10.1080/03602532.2016.1197239; Chen DL, 2017, MOL CELL, V68, P224, DOI 10.1016/j.molcel.2017.09.009; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; DeNicola GM, 2015, NAT GENET, V47, P1475, DOI 10.1038/ng.3421; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dodson M, 2019, REDOX BIOL, V23, DOI 10.1016/j.redox.2019.101107; Fan Z, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.65; Gorrini C, 2013, J EXP MED, V210, P1529, DOI 10.1084/jem.20121337; Hammad A, 2019, CANCER LETT, V467, P40, DOI 10.1016/j.canlet.2019.09.016; Hanpude P, 2015, IUBMB LIFE, V67, P544, DOI 10.1002/iub.1402; Harris IS, 2019, CELL METAB, V29, P1166, DOI 10.1016/j.cmet.2019.01.020; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Hussain S, 2009, CELL CYCLE, V8, P1688, DOI 10.4161/cc.8.11.8739; Jayakumar S, 2015, MUTAT RES-FUND MOL M, V779, P33, DOI 10.1016/j.mrfmmm.2015.06.007; Jeong Y, 2017, CANCER DISCOV, V7, P86, DOI 10.1158/2159-8290.CD-16-0127; Jiang T, 2015, FREE RADICAL BIO MED, V88, P199, DOI 10.1016/j.freeradbiomed.2015.06.014; Kapadia B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03028-y; Kobayashi EH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11624; Lee EW, 2015, CELL DEATH DIFFER, V22, P1463, DOI 10.1038/cdd.2014.234; Lewerenz J, 2013, ANTIOXID REDOX SIGN, V18, P522, DOI 10.1089/ars.2011.4391; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lignitto L, 2019, CELL, V178, P316, DOI 10.1016/j.cell.2019.06.003; Lister A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-37; Liu BY, 2019, ONCOGENE, V38, P2501, DOI 10.1038/s41388-018-0605-5; Liu PF, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101702; Liu T, 2019, CANCER RES, V79, P1913, DOI 10.1158/0008-5472.CAN-18-3037; Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Niture SK, 2012, J BIOL CHEM, V287, P9873, DOI 10.1074/jbc.M111.312694; Orthwein A, 2015, NATURE, V528, P422, DOI 10.1038/nature16142; Ou Y, 2016, P NATL ACAD SCI USA, V113, pE6806, DOI 10.1073/pnas.1607152113; Park MK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08481-x; Roh JL, 2017, REDOX BIOL, V11, P254, DOI 10.1016/j.redox.2016.12.010; Schoenfeld AR, 2004, MOL CELL BIOL, V24, P7444, DOI 10.1128/MCB.24.17.7444-7455.2004; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251; Tao S, 2014, CANCER RES, V74, P7430, DOI 10.1158/0008-5472.CAN-14-1439; Ting X, 2019, NUCLEIC ACIDS RES, V47, P9721, DOI 10.1093/nar/gkz726; Villeneuve NF, 2013, MOL CELL, V51, P68, DOI 10.1016/j.molcel.2013.04.022; Wang D, 2018, J MOL CELL BIOL, V10, P60, DOI 10.1093/jmcb/mjx034; Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wiel C, 2019, CELL, V178, P330, DOI 10.1016/j.cell.2019.06.005; Wu HC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4214; Xia XJ, 2019, CURR GENE THER, V19, P117, DOI 10.2174/1566523219666190628152137; Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Yu M, 2016, J BIOL CHEM, V291, P959, DOI 10.1074/jbc.M114.624478; Zhan J, 2019, THERANOSTICS, V9, P2084, DOI 10.7150/thno.29463; Zhang YL, 2019, CELL CYCLE, V18, P773, DOI 10.1080/15384101.2019.1597506	52	18	18	1	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1706	1720		10.1038/s41388-021-01660-5	http://dx.doi.org/10.1038/s41388-021-01660-5		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33531626				2022-12-28	WOS:000613991700002
J	Ochiiwa, H; Ailiken, G; Yokoyama, M; Yamagata, K; Nagano, H; Yoshimura, C; Muraoka, H; Ishida, K; Haruma, T; Nakayama, A; Hashimoto, N; Murata, K; Nishimura, M; Kawashima, Y; Ohara, O; Ohkubo, S; Tanaka, T				Ochiiwa, Hiroaki; Ailiken, Guzhanuer; Yokoyama, Masataka; Yamagata, Kazuyuki; Nagano, Hidekazu; Yoshimura, Chihoko; Muraoka, Hiromi; Ishida, Keiji; Haruma, Tomonori; Nakayama, Akitoshi; Hashimoto, Naoko; Murata, Kazutaka; Nishimura, Motoi; Kawashima, Yusuke; Ohara, Osamu; Ohkubo, Shuichi; Tanaka, Tomoaki			TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia	ONCOGENE			English	Article							PEVONEDISTAT TAK-924/MLN4924; PHASE-I; CULLIN; NEDD8; FLIP; MLN4924; PROTEIN; CHEMORESISTANCE; TRANSCRIPTION; EXPRESSION	TAS4464, a potent, selective small molecule NEDD8-activating enzyme (NAE) inhibitor, leads to inactivation of cullin-RING E3 ubiquitin ligases (CRLs) and consequent accumulations of its substrate proteins. Here, we investigated the antitumor properties and action mechanism of TAS4464 in acute myeloid leukemia (AML). TAS4464 induced apoptotic cell death in various AML cell lines. TAS4464 treatments resulted in the activation of both the caspase-9-mediated intrinsic apoptotic pathway and caspase-8-mediated extrinsic apoptotic pathway in AML cells; combined treatment with inhibitors of these caspases markedly diminished TAS4464-induced apoptosis. In each apoptotic pathway, TAS4464 induced the mRNA transcription of the intrinsic proapoptotic factor NOXA and decreased that of the extrinsic antiapoptotic factor c-FLIP. RNA-sequencing analysis showed that the signaling pathway of the CRL substrate c-Myc was enriched after TAS4464 treatment. Chromatin immunoprecipitation (ChIP) assay revealed that TAS4464-induced c-Myc bound to the PMAIP1 (encoding NOXA) and CFLAR (encoding c-FLIP) promoter regions, and siRNA-mediated c-Myc knockdown neutralized both TAS4464-mediated NOXA induction and c-FLIP downregulation. TAS4464 activated both caspase-8 and caspase-9 along with an increase in NOXA and a decrease in c-FLIP, resulting in complete tumor remission in a human AML xenograft model. These findings suggest that NAE inhibition leads to anti-AML activity via a novel c-Myc-dependent apoptosis induction mechanism.	[Ochiiwa, Hiroaki; Yoshimura, Chihoko; Muraoka, Hiromi; Ishida, Keiji; Haruma, Tomonori; Ohkubo, Shuichi] Taiho Pharmaceut Co Ltd, Discovery & Preclin Res Div, 3 Okubo, Tsukuba, Ibaraki 3002611, Japan; [Ailiken, Guzhanuer; Yokoyama, Masataka; Yamagata, Kazuyuki; Nagano, Hidekazu; Nakayama, Akitoshi; Hashimoto, Naoko; Murata, Kazutaka; Tanaka, Tomoaki] Chiba Univ, Grad Sch Med, Dept Mol Diag, Chiba 2608670, Japan; [Nishimura, Motoi] Chiba Univ Hosp, Div Lab Med Clin Genet & Prote, Chiba 2608670, Japan; [Kawashima, Yusuke; Ohara, Osamu] Kazusa DNA Res Inst, Dept Appl Genom, Kisarazu, Chiba 2920818, Japan	Taiho Pharmaceutical; Chiba University; Chiba University; Kazusa DNA Research Institute	Ohkubo, S (corresponding author), Taiho Pharmaceut Co Ltd, Discovery & Preclin Res Div, 3 Okubo, Tsukuba, Ibaraki 3002611, Japan.; Tanaka, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Diag, Chiba 2608670, Japan.	s-ohkubo@taiho.co.jp; tomoaki@restaff.chiba-u.jp	Ohara, Osamu/G-5448-2015	Ohara, Osamu/0000-0002-3328-9571; YAMAGATA, Kazuyuki/0000-0002-5804-6090	Taiho Pharmaceutical Co., Ltd., Japan; Fostering Joint International Research [19KK0407]; Naito Foundation; Novartis Foundation (Japan); Cell Science Research Foundation; Princess Takamatsu Cancer Research Fund; Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care; Hamaguchi biochemistry Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Yamaguchi endocrine Foundation; Donated Fund of Next Generation Hormone Academy for Human Health Longevity; Takeda Science Foundation;  [19H03708];  [20K08397];  [20K07561];  [18K08464];  [19K07635];  [18K07439]	Taiho Pharmaceutical Co., Ltd., Japan; Fostering Joint International Research; Naito Foundation(Naito Memorial Foundation); Novartis Foundation (Japan)(Novartis); Cell Science Research Foundation(Cell Science Research Foundation, Japan); Princess Takamatsu Cancer Research Fund; Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care; Hamaguchi biochemistry Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Yamaguchi endocrine Foundation; Donated Fund of Next Generation Hormone Academy for Human Health Longevity; Takeda Science Foundation(Takeda Science Foundation (TSF)); ; ; ; ; ; 	This study was funded by Taiho Pharmaceutical Co., Ltd., Japan, and was supported by Grants-in-Aid for Scientific Research-KAKENHI-, Scientific Research [(B) #19H03708, (C) #20K08397, (C) #20K07561, (C) #18K08464, (C) #19K07635, (C) #18K07439], and Fostering Joint International Research [(A) #19KK0407]. This work was partly supported by the Takeda Science Foundation, the Naito Foundation, the Novartis Foundation (Japan), the Cell Science Research Foundation, the Princess Takamatsu Cancer Research Fund, the Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care, the Hamaguchi biochemistry Foundation, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Yamaguchi endocrine Foundation and the Donated Fund of Next Generation Hormone Academy for Human Health & Longevity.	Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bhatia S, 2016, INVEST NEW DRUG, V34, P439, DOI 10.1007/s10637-016-0348-5; Bogenberger J, 2017, ONCOTARGET, V8, P107206, DOI 10.18632/oncotarget.22284; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Conti S, 2016, CELL SIGNAL, V28, P1262, DOI 10.1016/j.cellsig.2016.06.003; DiNardo CD, 2019, BLOOD, V133, P7, DOI 10.1182/blood-2018-08-868752; Enchev RI, 2015, NAT REV MOL CELL BIO, V16, P30, DOI 10.1038/nrm3919; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kawashima Y, 2019, J PROTEOME RES, V18, P301, DOI 10.1021/acs.jproteome.8b00609; Kiechle FL, 2002, CLIN CHIM ACTA, V326, P27, DOI 10.1016/S0009-8981(02)00297-8; Knorr KLB, 2015, CELL DEATH DIFFER, V22, P2133, DOI 10.1038/cdd.2015.74; Konopleva M, 2002, BRIT J HAEMATOL, V118, P521, DOI 10.1046/j.1365-2141.2002.03637.x; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kumar C Chandra, 2011, Genes Cancer, V2, P95, DOI 10.1177/1947601911408076; Li LH, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju083; Li XX, 2019, ONCOTARGETS THER, V12, P3295, DOI 10.2147/OTT.S194549; Lockhart AC, 2019, INVEST NEW DRUG, V37, P87, DOI 10.1007/s10637-018-0610-0; McLornan D, 2013, BRIT J HAEMATOL, V160, P188, DOI 10.1111/bjh.12108; Mehta SV, 2013, NEOPLASMA, V60, P666, DOI 10.4149/neo_2013_085; Muraoka H, 2019, CANCER SCI, V110, P3802, DOI 10.1111/cas.14209; Pan Yongfu, 2012, Int J Biochem Mol Biol, V3, P273; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Phesse TJ, 2014, CELL DEATH DIFFER, V21, P956, DOI 10.1038/cdd.2014.15; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Ricci MS, 2004, MOL CELL BIOL, V24, P8541, DOI 10.1128/MCB.24.19.8541-8555.2004; Sarantopoulos J, 2016, CLIN CANCER RES, V22, P847, DOI 10.1158/1078-0432.CCR-15-1338; Shah JJ, 2016, CLIN CANCER RES, V22, P34, DOI 10.1158/1078-0432.CCR-15-1237; Soucy Teresa A, 2010, Genes Cancer, V1, P708, DOI 10.1177/1947601910382898; Soucy TA, 2009, CLIN CANCER RES, V15, P3912, DOI 10.1158/1078-0432.CCR-09-0343; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; Sweet K, 2014, CURR HEMATOL MALIG R, V9, P109, DOI 10.1007/s11899-014-0199-0; Swords RT, 2015, BRIT J HAEMATOL, V169, P534, DOI 10.1111/bjh.13323; Tanaka T, 2020, DRYAD DIGITAL REPOSI, DOI [10.5061/dryad.hqbzkh1f6, DOI 10.5061/DRYAD.HQBZKH1F6]; Wirth M, 2014, NUCLEIC ACIDS RES, V42, P10433, DOI 10.1093/nar/gku763; Xie P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.195; Xie P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4733; Yoshimura C, 2019, MOL CANCER THER, V18, P1205, DOI 10.1158/1535-7163.MCT-18-0644; Zhao LQ, 2011, MOL CANCER THER, V10, P2415, DOI 10.1158/1535-7163.MCT-11-0401; Zhou LS, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0979-1	43	11	11	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1217	1230		10.1038/s41388-020-01586-4	http://dx.doi.org/10.1038/s41388-020-01586-4		JAN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420360	Green Published, hybrid			2022-12-28	WOS:000607346000017
J	Qasim, SL; Sierra, L; Shuck, R; Kurenbekova, L; Patel, TD; Rajapakshe, K; Wulff, J; Nakahata, K; Kim, HR; Landesman, Y; Unger, TJ; Coarfa, C; Yustein, JT				Qasim, Shawki L.; Sierra, Laura; Shuck, Ryan; Kurenbekova, Lyazat; Patel, Tajhal D.; Rajapakshe, Kimal; Wulff, Jade; Nakahata, Kengo; Kim, Ha Ram; Landesman, Yosef; Unger, T. J.; Coarfa, Cristian; Yustein, Jason T.			p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma	ONCOGENE			English	Article							BETA-CATENIN; CELL-LINES; PAK4; TRANSLOCATION; TUMORS; CYTOTOXICITY; CONSISTENCY; CHROMOSOME; ACTIVATION; GROWTH	Ewing sarcoma (ES) is the second most common bone tumor in children and young adults. Unfortunately, there have been minimal recent advancements in improving patient outcomes, especially in metastatic and recurrent diseases. In this study, we investigated the biological role of p21-activated kinases (PAKs) in ES, and the ability to therapeutically target them in high-risk disease. Via informatics analysis, we established the inverse association of PAK1 and PAK4 expression with clinical stage and outcome in ES patients. Through expression knockdown and small-molecule inhibition of PAKs, utilizing FRAX-597, KPT-9274, and PF-3758309 in multiple ES cell lines and patient-derived xenograft models, we further explored the role of PAKs in ES tumor growth and metastatic capabilities. In vitro studies in several ES cell lines indicated that diminishing PAK1 and PAK4 expression reduces tumor cell viability, migratory, and invasive properties. In vivo studies using PAK4 inhibitors, KPT-9274 and PF-3758309 demonstrated significant inhibition of primary and metastatic tumor formation, while transcriptomic analysis of PAK4-inhibitor-treated tumors identified concomitant suppression of Notch, beta-catenin, and hypoxia-mediated signatures. In addition, the analysis showed enrichment of anti-tumor immune regulatory mechanisms, including interferon (IFN)-gamma and IFN-alpha responses. Altogether, our molecular and pre-clinical studies are the first to establish a critical role for PAKs in ES development and progression, and consequently as viable therapeutic targets for the treatment of high-risk ES in the near future.	[Qasim, Shawki L.; Sierra, Laura; Shuck, Ryan; Kurenbekova, Lyazat; Patel, Tajhal D.; Wulff, Jade; Nakahata, Kengo; Kim, Ha Ram; Yustein, Jason T.] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; [Qasim, Shawki L.; Sierra, Laura; Shuck, Ryan; Kurenbekova, Lyazat; Patel, Tajhal D.; Wulff, Jade; Nakahata, Kengo; Kim, Ha Ram; Yustein, Jason T.] Baylor Coll Med, Texas Childrens Hematol Ctr, Houston, TX 77030 USA; [Qasim, Shawki L.; Sierra, Laura; Shuck, Ryan; Kurenbekova, Lyazat; Patel, Tajhal D.; Wulff, Jade; Nakahata, Kengo; Kim, Ha Ram; Yustein, Jason T.] Baylor Coll Med, Faris D Virani Ewing Sarcoma Ctr, Houston, TX 77030 USA; [Rajapakshe, Kimal; Coarfa, Cristian; Yustein, Jason T.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Rajapakshe, Kimal; Coarfa, Cristian; Yustein, Jason T.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA; [Landesman, Yosef; Unger, T. J.] Karyopharm Therapeut Inc, Newton, MA 02459 USA; [Yustein, Jason T.] Baylor Coll Med, Canc & Cell Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Yustein, JT (corresponding author), Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Texas Childrens Hematol Ctr, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Faris D Virani Ewing Sarcoma Ctr, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Canc & Cell Biol Program, Houston, TX 77030 USA.	yustein@bcm.edu			Cancer Prevention and Research Institute of Texas (CPRIT) post-doctoral training grant [RP160283]; Faris D. Virani Ewing sarcoma Center; Cytometry and Cell Sorting Core at Baylor College of Medicine; CPRIT Core Facility Support Award [CPRIT-RP180672]; NIH [CA125123, RR024574]	Cancer Prevention and Research Institute of Texas (CPRIT) post-doctoral training grant; Faris D. Virani Ewing sarcoma Center; Cytometry and Cell Sorting Core at Baylor College of Medicine; CPRIT Core Facility Support Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by Cancer Prevention and Research Institute of Texas (CPRIT) post-doctoral training grant RP160283 (S.Q.) and The Faris D. Virani Ewing sarcoma Center. This project was supported by the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the CPRIT Core Facility Support Award (CPRIT-RP180672) and the NIH (CA125123 and RR024574).	Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Aboukameel A, 2017, MOL CANCER THER, V16, P76, DOI 10.1158/1535-7163.MCT-16-0205; Abu Aboud O, 2016, MOL CANCER THER, V15, P2119, DOI 10.1158/1535-7163.MCT-16-0197; [Anonymous], 2018, CELLTITER GLO LUMINE; Arias-Romero LE, 2010, ONCOGENE, V29, P5839, DOI 10.1038/onc.2010.318; Batra S, 2004, CANCER RES, V64, P5415, DOI 10.1158/0008-5472.CAN-04-0377; BLOOM ET, 1972, CANCER RES, V32, P960; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; CHOU TC, 1994, JNCI-J NATL CANCER I, V86, P1517, DOI 10.1093/jnci/86.20.1517; Co LLC S-A, 96992 CELL COUNT KIT; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Hawkins AG, 2018, MOL CELL PROTEOMICS, V17, P901, DOI 10.1074/mcp.RA118.000596; He H, 2013, P21 ACTIVATED KINASE; Heske CM, 2017, CLIN CANCER RES, V23, P7301, DOI 10.1158/1078-0432.CCR-17-1121; Jin-Xing Y, 2018, EXPRESSION PAK4 BREA; JOUNG M, 2012, EPJ WEB C, V32; Li Y, 2012, BBA-MOL CELL RES, V1823, P465, DOI 10.1016/j.bbamcr.2011.11.013; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; Lu W, 2013, ONCOL REP, V29, P1547, DOI 10.3892/or.2013.2237; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mileshkin LR, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.e13607; Mutz CN, 2017, ONCOTARGET, V8, P24679, DOI 10.18632/oncotarget.14976; Naing A, 2017, ANN ONCOL, P28; Pedersen EA, 2016, CANCER RES, V76, P5040, DOI 10.1158/0008-5472.CAN-15-3422; Pietsch T, 2018, MHH ES 1 NEW EWING S; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Radu M, PAK SIGNALING DEV PR; Rane C, 2017, SCI REP-UK, V7, DOI 10.1038/srep42555; Rane CK, 2019, SEMIN CANCER BIOL, V54, P40, DOI 10.1016/j.semcancer.2018.01.006; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; Ries LAG, 1975, NIH PUB; Ryu BJ, 2014, MOL CELL BIOCHEM, V389, P69, DOI 10.1007/s11010-013-1928-8; Salamon J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095822; Satterfield L, 2017, INT J CANCER, V141, P2062, DOI 10.1002/ijc.30909; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Siu MK, 2018, P21 ACTIVATED KINASE; Stiller CA, 2006, EUR J CANCER, V42, P2006, DOI 10.1016/j.ejca.2006.06.002; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Technologies L, 2018, LIP RNAIMAX REAG PRO; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; Volchenboum SL, 2015, J PATHOL CLIN RES, V1, P83, DOI 10.1002/cjp2.9; WHANGPENG J, 1986, CANCER GENET CYTOGEN, V21, P185, DOI 10.1016/0165-4608(86)90001-4; Yeo D, 2018, ROLE P21 ACTIVATED K; Yeo D, 2018, FRAX597 PAK1 INHIBIT; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	47	6	6	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1176	1190		10.1038/s41388-020-01600-9	http://dx.doi.org/10.1038/s41388-020-01600-9		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33414491				2022-12-28	WOS:000605931900001
J	Gu, GW; Tian, L; Herzog, SK; Rechoum, Y; Gelsomino, L; Gao, M; Du, LL; Kim, JA; Dustin, D; Lo, HC; Beyer, AR; Edwards, DG; Gonzalez, T; Tsimelzon, A; Huang, HJ; Fernandez, NM; Grimm, SL; Hilsenbeck, SG; Liu, D; Xu, J; Alaniz, A; Li, SQ; Mills, GB; Janku, F; Kittler, R; Zhang, XHF; Coarfa, C; Foulds, CE; Symmans, WF; Ando, S; Fuqua, SAW				Gu, Guowei; Tian, Lin; Herzog, Sarah K.; Rechoum, Yassine; Gelsomino, Luca; Gao, Meng; Du, Lili; Kim, Jin-Ah; Dustin, Derek; Lo, Hin Ching; Beyer, Amanda R.; Edwards, David G.; Gonzalez, Thomas; Tsimelzon, Anna; Huang, Helen J.; Fernandez, Natalie M.; Grimm, Sandra L.; Hilsenbeck, Susan G.; Liu, Dan; Xu, Jun; Alaniz, Alyssa; Li, Shunqiang; Mills, Gordon B.; Janku, Filip; Kittler, Ralf; Zhang, Xiang H. -F.; Coarfa, Cristian; Foulds, Charles E.; Symmans, W. Fraser; Ando, Sebastiano; Fuqua, Suzanne A. W.			Hormonal modulation of ESR1 mutant metastasis	ONCOGENE			English	Article							BREAST-CANCER; ANDROGEN RECEPTOR; ER-ALPHA; TAMOXIFEN RESISTANCE; ESTROGEN-RECEPTORS; MUTATIONS; INHIBITOR; BIOMARKERS; THERAPY; SNAIL	Estrogen receptor alpha gene (ESR1) mutations occur frequently in ER-positive metastatic breast cancer, and confer clinical resistance to aromatase inhibitors. Expression of the ESR1 Y537S mutation induced an epithelial-mesenchymal transition (EMT) with cells exhibiting enhanced migration and invasion potential in vitro. When small subpopulations of Y537S ESR1 mutant cells were injected along with WT parental cells, tumor growth was enhanced with mutant cells becoming the predominant population in distant metastases. Y537S mutant primary xenograft tumors were resistant to the antiestrogen tamoxifen (Tam) as well as to estradiol (E-2) withdrawal. Y537S ESR1 mutant primary tumors metastasized efficiently in the absence of E-2; however, Tam treatment significantly inhibited metastasis to distant sites. We identified a nine-gene expression signature, which predicted clinical outcomes of ER-positive breast cancer patients, as well as breast cancer metastasis to the lung. Androgen receptor (AR) protein levels were increased in mutant models, and the AR agonist dihydrotestosterone significantly inhibited estrogen-regulated gene expression, EMT, and distant metastasis in vivo, suggesting that AR may play a role in distant metastatic progression of ESR1 mutant tumors.	[Gu, Guowei; Herzog, Sarah K.; Rechoum, Yassine; Kim, Jin-Ah; Dustin, Derek; Lo, Hin Ching; Beyer, Amanda R.; Edwards, David G.; Gonzalez, Thomas; Tsimelzon, Anna; Hilsenbeck, Susan G.; Alaniz, Alyssa; Zhang, Xiang H. -F.; Fuqua, Suzanne A. W.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Gu, Guowei; Zhang, Xiang H. -F.; Foulds, Charles E.; Fuqua, Suzanne A. W.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Gu, Guowei; Gelsomino, Luca; Ando, Sebastiano] Univ Calabria, Dept Pharm Hlth & Nutr Sci, Arcavacata Di Rende, Italy; [Tian, Lin] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA; [Herzog, Sarah K.] Baylor Coll Med, Integrat Mol & Biomed Sci Program, Houston, TX 77030 USA; [Gao, Meng] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Du, Lili; Symmans, W. Fraser] Univ Texas MD Anderson Canc Ctr, Dept Pathol & Translat Mol Pathol, Houston, TX 77030 USA; [Dustin, Derek] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA; [Huang, Helen J.; Janku, Filip] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA; [Fernandez, Natalie M.; Liu, Dan; Xu, Jun] Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Grimm, Sandra L.; Hilsenbeck, Susan G.; Zhang, Xiang H. -F.; Coarfa, Cristian; Foulds, Charles E.; Fuqua, Suzanne A. W.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Li, Shunqiang] Washington Univ, Sch Med, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA; [Mills, Gordon B.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Kittler, Ralf] UT Southwestern Med Ctr, Eugene McDermott Ctr Human Growth & Dev, Dallas, TX USA; [Kittler, Ralf] UT Southwestern Med Ctr, Dept Pharmacol, Dallas, TX USA; [Foulds, Charles E.] Baylor Coll Med, Ctr Precis Environm Hlth, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of Calabria; Memorial Sloan Kettering Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Washington University (WUSTL); Oregon Health & Science University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Baylor College of Medicine	Fuqua, SAW (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.; Fuqua, SAW (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Fuqua, SAW (corresponding author), Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.	sfuqua@bcm.edu	Kittler, Ralf/I-4662-2013; Kittler, Ralf/AAD-4258-2020	Kittler, Ralf/0000-0002-0098-6792; Kittler, Ralf/0000-0002-0098-6792; Herzog, Sarah/0000-0003-3782-7389; Zhang, Xiang/0000-0002-5674-8670; Gonzalez, Thomas/0000-0003-4497-3106; Tian, Lin/0000-0003-3661-4453	Breast Cancer Research Foundation [BCRF 19-055, BCRF-19-110]; NIH [R01 CA207270, R01CA072038]; Cancer Prevention Institute of Texas CPRIT MIRA; Adrienne Helis Malvin Medical Research Foundation Cancer Program M-2017; Dan L Duncan Cancer Center Cell-based assay screening core [P30 CA125123-05]; Translational Breast Cancer Research Training Program [T32-CA203690-02]; Predoctoral Institutional Research Training Grant (T32) Training Grant [5T32GM008231-30]; Cancer Prevention Institute of Texas (CPRIT) [T32 2389301302, RP170005]; NIEHS [P30 ES030285, P42 ES027725]; Susan G. Komen Breast Cancer Foundation [U01 CA217842, SAC110052]	Breast Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Institute of Texas CPRIT MIRA; Adrienne Helis Malvin Medical Research Foundation Cancer Program M-2017; Dan L Duncan Cancer Center Cell-based assay screening core; Translational Breast Cancer Research Training Program; Predoctoral Institutional Research Training Grant (T32) Training Grant; Cancer Prevention Institute of Texas (CPRIT); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Susan G. Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation)	Breast Cancer Research Foundation BCRF 19-055, NIH R01 CA207270, NIH R01CA072038, Cancer Prevention Institute of Texas CPRIT MIRA (Kelly Hunt, PI) to SAWF; Adrienne Helis Malvin Medical Research Foundation Cancer Program M-2017 to CEF; P30 CA125123-05 Dan L Duncan Cancer Center Cell-based assay screening core; Translational Breast Cancer Research Training Program T32-CA203690-02; Predoctoral Institutional Research Training Grant (T32) Training Grant 5T32GM008231-30; T32 2389301302, Cancer Prevention Institute of Texas (CPRIT) RP170005; NIEHS grants P30 ES030285, P42 ES027725; U01 CA217842, Susan G. Komen Breast Cancer Foundation SAC110052, Breast Cancer Research Foundation BCRF-19-110.	Barone I, 2011, JNCI-J NATL CANCER I, V103, P538, DOI 10.1093/jnci/djr058; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Chandarlapaty S, 2016, JAMA ONCOL, V2, P1310, DOI 10.1001/jamaoncol.2016.1279; Chiang KC, 2019, CANCER MANAG RES, V11, P1893, DOI 10.2147/CMAR.S196485; Ciupek A, 2015, BREAST CANCER RES TR, V154, P225, DOI 10.1007/s10549-015-3609-7; Cochrane DR, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3599; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; De Amicis F, 2010, BREAST CANCER RES TR, V121, P1, DOI 10.1007/s10549-009-0436-8; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; Fuqua SAW, 2001, J MAMMARY GLAND BIOL, V6, P407, DOI 10.1023/A:1014782813943; Fuqua SAW, 2014, BREAST CANCER RES TR, V144, P11, DOI 10.1007/s10549-014-2847-4; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI [10.1126/scitranslmed.aab0021, 10.1126/scitranslmed.aac7551]; Gates LA, 2018, ONCOGENE, V37, P4581, DOI 10.1038/s41388-018-0284-2; Gelsomino L, 2016, BREAST CANCER RES TR, V157, P253, DOI 10.1007/s10549-016-3829-5; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Harris LN, 2016, J CLIN ONCOL, V34, P1134, DOI 10.1200/JCO.2015.65.2289; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; Hickey TE, 2012, MOL ENDOCRINOL, V26, P1252, DOI 10.1210/me.2012-1107; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Howlader N., 2016, SEER CANC STAT REV 1; Jeselsohn R, 2018, CANCER CELL, V33, P173, DOI 10.1016/j.ccell.2018.01.004; Jiang J, 2011, ONCOGENE, V30, P4498, DOI 10.1038/onc.2011.154; Jin LT, 2018, CANCER BIOL THER, V19, P858, DOI 10.1080/15384047.2018.1456599; Kim JA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12991; Klein CA, 2013, NATURE, V501, P365, DOI 10.1038/nature12628; Kollipara RK, 2015, GENOM DATA, V3, P80, DOI 10.1016/j.gdata.2014.11.015; Krop I, 2018, P 2017 SAN ANT BREAS; Lambert Jr, 2001, METH MOL B, V176, P273; Li C, 2014, ONCOTARGET, V5, P8429, DOI 10.18632/oncotarget.2316; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Li YQ, 2015, INT J ONCOL, V46, P1461, DOI 10.3892/ijo.2015.2878; Lima JF, 2016, J CLIN MED, V5, DOI 10.3390/jcm5070065; Martin M, 2017, NAT COMMUN, V8, DOI [10.1038/ncomms15127, 10.1038/s41467-017-01864-y]; Mihaly Z, 2013, BREAST CANCER RES TR, V140, P219, DOI 10.1007/s10549-013-2622-y; Narayanan R, 2018, MOL CELL ENDOCRINOL, V465, P134, DOI 10.1016/j.mce.2017.06.013; O'Leary B, 2018, CANCER DISCOV, V8, P1390, DOI 10.1158/2159-8290.CD-18-0264; Park SH, 2008, MOL ENDOCRINOL, V22, P2085, DOI 10.1210/me.2007-0512; Pidugu VK, 2019, ONCOGENE, V38, P3232, DOI 10.1038/s41388-018-0662-9; Ponnusamy S, 2019, ISCIENCE, V21, P341, DOI 10.1016/j.isci.2019.10.038; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rangel N, 2018, ENDOCR-RELAT CANCER, V25, P163, DOI 10.1530/ERC-17-0417; Razavi P, 2018, CANCER CELL, V34, P427, DOI 10.1016/j.ccell.2018.08.008; Rechoum Y, 2014, BREAST CANCER RES TR, V147, P473, DOI 10.1007/s10549-014-3082-8; Selever J, 2011, CLIN CANCER RES, V17, P6510, DOI 10.1158/1078-0432.CCR-11-1403; Sinn BV, 2019, NPJ BREAST CANCER, V5, DOI 10.1038/s41523-019-0111-0; Takeshita T, 2015, TRANSL RES, V166, P540, DOI 10.1016/j.trsl.2015.09.003; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Zhang QX, 1997, CANCER RES, V57, P1244	49	9	9	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					997	1011		10.1038/s41388-020-01563-x	http://dx.doi.org/10.1038/s41388-020-01563-x		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33323970	Green Accepted			2022-12-28	WOS:000599126500001
J	Guha, P; Gardell, J; Rabinowitz, B; Lopes, M; DaSilva, NA; Rowley, D; Katz, SC				Guha, Prajna; Gardell, Jillian; Rabinowitz, Benjamin; Lopes, Mikayla; DaSilva, Nicholas A.; Rowley, David; Katz, Steven C.			Monocytic and granulocytic myeloid-derived suppressor cell plasticity and differentiation are organ-specific	ONCOGENE			English	Article							LIVER METASTASES; CANCER; ANERGY; MICE	Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that proliferate in the setting of cancer and have potent immunosuppressive functions hindering anti-tumor immunity. Here we establish that the immunologic landscape and tumor microenvironments (TME) vary between different organs which discretely shape MDSC repertoires. We found that pSTAT3 signaling exerts a dominant effect on MDSC programming in liver metastasis (LM). In contrast, in lung metastasis (LuM), MDSC programming is driven mainly by pSTAT5. Adoptive transfer of LM-MDSC into LuM resulted in a shift from pSTAT3 signaling to pSTAT5, in association with an overall shift toward lung MDSC programming. A shift from more immunosuppressive M-MDSC to G-MDSC, along with enhanced differentiation of MDSCs into pro-inflammatory M1 macrophages in LuM, indicated that MDSC plasticity and differentiation patterns are environmentally dependent. Using mass spectroscopy, we confirmed that LM-MDSCs showed enhanced expression of key proliferation pathway markers. This confirmed that liver-specific MDSC programing was comprehensive but reversible, implying that therapeutic targeting of LM-MDSC could prime the TME in a favorable manner. Our data suggest that MDSC programming in response to malignancy is highly dependent on organ-specific conditions and is modifiable.	[Guha, Prajna; Gardell, Jillian; Rabinowitz, Benjamin; Lopes, Mikayla; Katz, Steven C.] Roger Williams Med Ctr, Immunooncol Inst, Providence, RI 02908 USA; [Guha, Prajna; Gardell, Jillian; Rabinowitz, Benjamin; Lopes, Mikayla; Katz, Steven C.] Roger Williams Med Ctr, Dept Med, Immunotherapy Serv, Providence, RI 02908 USA; [Guha, Prajna; Katz, Steven C.] Boston Univ, Dept Surg, Sch Med, Boston, MA 02215 USA; [Guha, Prajna; DaSilva, Nicholas A.; Rowley, David; Katz, Steven C.] Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA	Roger Williams Medical Center; Roger Williams Medical Center; Boston University; University of Rhode Island	Katz, SC (corresponding author), Roger Williams Med Ctr, Immunooncol Inst, Providence, RI 02908 USA.; Katz, SC (corresponding author), Roger Williams Med Ctr, Dept Med, Immunotherapy Serv, Providence, RI 02908 USA.; Katz, SC (corresponding author), Boston Univ, Dept Surg, Sch Med, Boston, MA 02215 USA.; Katz, SC (corresponding author), Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.	skatz@chartercare.org	Lopes, Mikayla C/GRO-2554-2022	Rowley, David/0000-0001-7808-1312				Amici SA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01593; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Burga RA, 2015, CANCER IMMUNOL IMMUN, V64, P817, DOI 10.1007/s00262-015-1692-6; Centuori SM, 2012, J LEUKOCYTE BIOL, V92, P987, DOI 10.1189/jlb.0911465; Chan T, 2011, INT IMMUNOPHARMACOL, V11, P879, DOI 10.1016/j.intimp.2010.12.024; Cheng HY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00421; Chiu DKC, 2016, HEPATOLOGY, V64, P797, DOI 10.1002/hep.28655; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Guha P, 2017, CANCER GENE THER, V24, P114, DOI 10.1038/cgt.2016.54; Guha P, 2019, ONCOGENE, V38, P533, DOI 10.1038/s41388-018-0449-z; Hardy LL, 2008, J IMMUNOL, V180, P5956, DOI 10.4049/jimmunol.180.9.5956; Hawila E, 2017, CELL REP, V21, P2212, DOI 10.1016/j.celrep.2017.10.104; Horst AK, 2016, CELL MOL IMMUNOL, V13, P277, DOI 10.1038/cmi.2015.112; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Jablonski KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145342; Jones RP, 2017, LIVER CANCER, V6, P66, DOI 10.1159/000449348; Katz SC, 2016, CANCER GENE THER, V23, P142, DOI 10.1038/cgt.2016.14; Kolahian S, 2016, EUR RESPIR J, V47, P967, DOI 10.1183/13993003.01572-2015; Li HQ, 2009, J IMMUNOL, V182, P240, DOI 10.4049/jimmunol.182.1.240; Lin A, 2010, IMMUNOL LETT, V127, P77, DOI 10.1016/j.imlet.2009.09.003; Nefedova Y, 2005, CANCER RES, V65, P9525, DOI 10.1158/0008-5472.CAN-05-0529; Oliver AJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00070; Perez-Soler R, 2004, CLIN CANCER RES, V10, p4238S, DOI 10.1158/1078-0432.CCR-040017; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Qin SG, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00307; Rodriguez PC, 2008, IMMUNOL REV, V222, P180, DOI 10.1111/j.1600-065X.2008.00608.x; Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977; Thorn M, 2016, CANCER GENE THER, V23, P188, DOI 10.1038/cgt.2016.19; Thorn M, 2014, J LEUKOCYTE BIOL, V96, P883, DOI 10.1189/jlb.3A0114-012RR; Umemura N, 2008, J LEUKOCYTE BIOL, V83, P1136, DOI 10.1189/jlb.0907611; Waight JD, 2013, J CLIN INVEST, V123, P4464, DOI 10.1172/JCI68189; Zheng PP, 2018, DRUG DISCOV TODAY, V23, P1175, DOI 10.1016/j.drudis.2018.02.012	33	8	8	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					693	704		10.1038/s41388-020-01559-7	http://dx.doi.org/10.1038/s41388-020-01559-7		NOV 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33230244				2022-12-28	WOS:000591948700001
J	Chen, J; Xuan, ZF; Song, WF; Han, WL; Chen, H; Du, YH; Xie, HY; Zhao, YC; Zheng, SS; Song, PH				Chen, Jun; Xuan, Zefeng; Song, Wenfeng; Han, Weili; Chen, Hao; Du, Yehui; Xie, Haiyang; Zhao, Yongchao; Zheng, Shusen; Song, Penghong			EAG1 enhances hepatocellular carcinoma proliferation by modulating SKP2 and metastasis through pseudopod formation	ONCOGENE			English	Article							UBIQUITIN; ASTEMIZOLE; PATHWAY; INVOLVEMENT; PROGRESSION; EXPRESSION; CHANNELS	Ether-a-go-go-1 (EAG1), one of the potassium channels, is involved in various physiological processes and plays an important role in the tumorigenesis of many kinds of cancer. EAG1 is highly expressed in hepatocarcinoma cells and is closely related to clinical prognosis, but the molecular mechanism remains elusive. In this study, we verified that EAG1 promotes the proliferation of hepatocellular carcinoma (HCC) both in vitro and in vivo. It promotes cell cycle progression by inhibiting the ubiquitination of SKP2. In addition, EAG1 promotes the migration and invasion of HCC by promoting cell pseudopod formation. Furthermore, in a high-pressure plasmid-injected mouse liver orthotopic carcinoma model, astemizole, an EAG family blocker, can significantly inhibit the formation of liver cancer. Meanwhile, liver-specific EAG1 knockout mice show resistance to hepatocarcinogenesis. This research demonstrated that EAG1 plays an important role in the progression of HCC, and could be a potential therapeutic target for HCC.	[Chen, Jun; Xuan, Zefeng; Song, Wenfeng; Chen, Hao; Xie, Haiyang; Zheng, Shusen; Song, Penghong] Zhejiang Univ, Sch Med, Div Hepatobiliary & Pancreat Surg, Dept Surg,Affiliated Hosp 1, Hangzhou, Peoples R China; [Chen, Jun; Xuan, Zefeng; Song, Wenfeng; Chen, Hao; Xie, Haiyang; Zhao, Yongchao; Zheng, Shusen; Song, Penghong] NHC Key Lab Combined Multiorgan Transplantat, Hangzhou, Peoples R China; [Chen, Jun; Xuan, Zefeng; Song, Wenfeng; Chen, Hao; Xie, Haiyang; Zheng, Shusen; Song, Penghong] Chinese Acad Med Sci, Key Lab Diag & Treatment Organ Transplantat, Res Unit Collaborat Diag & Treatment Hepatobiliar, 2019RU019, Hangzhou, Peoples R China; [Chen, Jun; Xuan, Zefeng; Song, Wenfeng; Chen, Hao; Xie, Haiyang; Zheng, Shusen; Song, Penghong] Res Ctr Diag & Treatment Hepatobiliary Dis, Key Lab Organ Transplantat, Hangzhou 310003, Zhejiang, Peoples R China; [Chen, Jun; Han, Weili; Chen, Hao] Zhejiang Univ, Sch Med, Dept Lung Transplantat, Affiliated Hosp 1, Hangzhou, Peoples R China; [Xuan, Zefeng] Zhejiang Univ, Sch Med, Div Breast Surg, Dept Surg,Affiliated Hosp 1, Hangzhou, Peoples R China; [Du, Yehui] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Thyroid Dis Diag & Treatment Ctr, Hangzhou, Peoples R China; [Zhao, Yongchao] Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou 310029, Peoples R China	Zhejiang University; Chinese Academy of Medical Sciences - Peking Union Medical College; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University	Zheng, SS; Song, PH (corresponding author), Zhejiang Univ, Sch Med, Div Hepatobiliary & Pancreat Surg, Dept Surg,Affiliated Hosp 1, Hangzhou, Peoples R China.; Zheng, SS; Song, PH (corresponding author), NHC Key Lab Combined Multiorgan Transplantat, Hangzhou, Peoples R China.; Zheng, SS; Song, PH (corresponding author), Chinese Acad Med Sci, Key Lab Diag & Treatment Organ Transplantat, Res Unit Collaborat Diag & Treatment Hepatobiliar, 2019RU019, Hangzhou, Peoples R China.; Zheng, SS; Song, PH (corresponding author), Res Ctr Diag & Treatment Hepatobiliary Dis, Key Lab Organ Transplantat, Hangzhou 310003, Zhejiang, Peoples R China.	shusenzheng@zju.edu.cn; songpenghong@zju.edu.cn			National Natural Science Foundation of China [81272675, 81870434]; Key Research and Development Plan of Zhejiang Province [2020C04003]; National ST Major Project [2017ZX10203205]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development Plan of Zhejiang Province; National ST Major Project	This work was supported by the National Natural Science Foundation of China (81272675 and 81870434) to PS, the Key Research and Development Plan of Zhejiang Province (2020C04003) to PS, the National S&T Major Project (2017ZX10203205) to SZ.	Bertuccio P, 2017, J HEPATOL, V67, P302, DOI 10.1016/j.jhep.2017.03.011; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006; Chen TP, 2007, GYNECOL ONCOL, V104, P516, DOI 10.1016/j.ygyno.2006.09.015; Chen X, 2014, AM J PATHOL, V184, P912, DOI 10.1016/j.ajpath.2013.12.002; Chavez-Lopez MD, 2015, TUMOR BIOL, V36, P6149, DOI 10.1007/s13277-015-3299-0; Chavez-Lopez MD, 2014, INT J GYNECOL CANCER, V24, P824, DOI 10.1097/IGC.0000000000000151; Diaz L, 2009, CANCER RES, V69, P3300, DOI 10.1158/0008-5472.CAN-08-2036; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Garcia-Quiroz J, 2011, ANTI-CANCER AGENT ME, V11, P307, DOI 10.2174/187152011795347513; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Guo XC, 2017, GENE DEV, V31, P247, DOI 10.1101/gad.294348.116; Haitin Y, 2013, NATURE, V501, P444, DOI 10.1038/nature12487; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Liu GX, 2015, INT J CLIN EXP PATHO, V8, P15093; Liu YT, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0462-3; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Pardo LA, 2014, NAT REV CANCER, V14, P39, DOI 10.1038/nrc3635; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; SHETERLINE P, 1995, PROTEIN PROFILE, V2, P1; Signoretti S, 2016, J CLIN INVEST, V126, P4387, DOI 10.1172/JCI90690; Stotz M, 2015, ANTICANCER RES, V35, P5737; Uddin S, 2016, SEMIN CANCER BIOL, V36, P18, DOI 10.1016/j.semcancer.2015.09.008; Vaiana SM, 2001, J BIOL PHYS, V27, P133, DOI 10.1023/A:1013146530021; Wang XZ, 2017, J MEMBRANE BIOL, V250, P123, DOI 10.1007/s00232-016-9944-8; Wei Z, 2013, CELL SIGNAL, V25, P931, DOI 10.1016/j.cellsig.2013.01.011; Wickenden AD, 2002, PHARMACOL THERAPEUT, V94, P157, DOI 10.1016/S0163-7258(02)00201-2; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Yoshida Y, 2012, ONCOGENE, V31, P4128, DOI 10.1038/onc.2011.570; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	34	5	5	3	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					163	176		10.1038/s41388-020-01522-6	http://dx.doi.org/10.1038/s41388-020-01522-6		OCT 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33097858				2022-12-28	WOS:000582109600001
J	Yang, G; Huang, L; Jia, HT; Aikemu, B; Zhang, S; Shao, YF; Hong, HJ; Yesseyeva, G; Wang, CX; Li, SC; Sun, J; Zheng, MH; Ma, JJ				Yang, Guang; Huang, Ling; Jia, Hongtao; Aikemu, Batuer; Zhang, Sen; Shao, Yanfei; Hong, Hiju; Yesseyeva, Galiya; Wang, Chenxing; Li, Shuchun; Sun, Jing; Zheng, Minhua; Ma, Junjun			NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; METASTASIS SUPPRESSOR NDRG1; MONOCLONAL-ANTIBODY; 1ST-LINE TREATMENT; ENDOCYTOSIS; CHEMOTHERAPY; MECHANISMS; STATISTICS; RESISTANCE; MIGRATION	N-myc downstream-regulated gene 1 (NDRG1) is a key regulator that interacts with many classic tumor signaling pathways, including some molecules downstream of the epidermal growth factor receptor (EGFR). However, whether NDRG1 is involved in the mechanism of resistance to cetuximab (CTX), the first monoclonal antibody targeting the EGFR has not been reported. Here, we found that NDRG1 enhanced the sensitivity of CTX in colorectal cancer (CRC) cell lines. Afterwards, we determined the underlying mechanism of this phenomenon. We demonstrated that NDRG1 inhibited the expression of EGFR; blocked EGFR phosphorylation and reduced the EGFR distribution in the cell membrane, cytoplasm and nucleus. And then, NDRG1 suppressed the EGFR downstream signaling: RAS/RAF/ERK and PI3k/AKT/mTOR pathways. Moreover, we discovered that NDRG1 attenuated the endocytosis and degradation of EGFR induced by caveolin-1 (Cav1). Additionally, our findings were further observed in an animal model and human tissues. Our results represent a potentially significant discovery that explains the mechanisms of NDRG1 in CTX resistance. NDRG1 could be a promising biomarker to predict optimum responses to CTX, and a key target to enhance CTX activity in the treatment of metastatic CRC (mCRC).	[Yang, Guang; Huang, Ling; Jia, Hongtao; Aikemu, Batuer; Zhang, Sen; Shao, Yanfei; Hong, Hiju; Yesseyeva, Galiya; Wang, Chenxing; Li, Shuchun; Sun, Jing; Zheng, Minhua; Ma, Junjun] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Gen Surg, Shanghai, Peoples R China; [Yang, Guang; Huang, Ling; Jia, Hongtao; Aikemu, Batuer; Zhang, Sen; Shao, Yanfei; Hong, Hiju; Yesseyeva, Galiya; Wang, Chenxing; Li, Shuchun; Sun, Jing; Zheng, Minhua; Ma, Junjun] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai Minimally Invas Surg Ctr, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Sun, J; Zheng, MH; Ma, JJ (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Gen Surg, Shanghai, Peoples R China.; Sun, J; Zheng, MH; Ma, JJ (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai Minimally Invas Surg Ctr, Shanghai, Peoples R China.	sj11788@rjh.com.cn; zmhtiger@yeah.net; marsnew1997@163.com	zhang, sen/GXH-3513-2022	huang, ling/0000-0001-5584-0419	National Nature Science Foundation of China (NSFC) [81871984, 81572818]	National Nature Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work is supported by National Nature Science Foundation of China (NSFC) (Grant No. 81871984, 81572818).	Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Brand TM, 2011, CANCER BIOL THER, V11, P777, DOI 10.4161/cbt.11.9.15050; Brankatschk B, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002351; Caldieri G, 2018, PROG MOL SUBCELL BIO, V57, P235, DOI 10.1007/978-3-319-96704-2_9; Cercek A, 2010, CURR ONCOL REP, V12, P153, DOI 10.1007/s11912-010-0096-1; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Dixon KM, 2013, BRIT J CANCER, V108, P409, DOI 10.1038/bjc.2012.582; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4; Koo CL, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-25; Kovacevic Z, 2006, CARCINOGENESIS, V27, P2355, DOI 10.1093/carcin/bgl146; Kovacevic Z, 2013, ANTIOXID REDOX SIGN, V18, P874, DOI 10.1089/ars.2011.4273; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Liao HJ, 2009, CANCER RES, V69, P6179, DOI 10.1158/0008-5472.CAN-09-0049; Melotte V, 2010, FASEB J, V24, P4153, DOI 10.1096/fj.09-151464; Menezes SV, 2019, J BIOL CHEM, V294, P4045, DOI 10.1074/jbc.RA118.006279; Mi L, 2017, ONCOGENE, V36, P4323, DOI 10.1038/onc.2017.74; Morandell S, 2008, PROTEOMICS, V8, P4383, DOI 10.1002/pmic.200800204; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Nishimura Noriyuki, 2008, V440, P89, DOI 10.1007/978-1-59745-178-9_7; Pinilla-Macua I, 2015, METHOD CELL BIOL, V130, P347, DOI 10.1016/bs.mcb.2015.05.008; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Sousa LP, 2012, P NATL ACAD SCI USA, V109, P4419, DOI 10.1073/pnas.1200164109; Sun J, 2013, CARCINOGENESIS, V34, P1943, DOI 10.1093/carcin/bgt163; Sun J, 2013, MOL PHARMACOL, V83, P454, DOI 10.1124/mol.112.083097; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Teis D, 2006, J CELL BIOL, V175, P861, DOI 10.1083/jcb.200607025; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Venook AP, 2005, CLIN COLORECTAL CANC, V5, P292, DOI 10.3816/CCC.2005.n.043; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wasan H, 2014, LANCET ONCOL, V15, P631, DOI 10.1016/S1470-2045(14)70106-8; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Yang G, 2021, ONCOL REP, V45, DOI 10.3892/or.2021.7983; Yu CR, 2019, THER ADV GASTROENTER, V12, DOI 10.1177/1756284819858507	41	9	9	3	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					5993	6006		10.1038/s41388-021-01962-8	http://dx.doi.org/10.1038/s41388-021-01962-8		AUG 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34385595	Green Published, hybrid			2022-12-28	WOS:000684526700001
J	Rugolo, F; Bazan, NG; Calandria, J; Jun, BK; Raschella, G; Melino, G; Agostini, M				Rugolo, Francesco; Bazan, Nicolas G.; Calandria, Jorgelina; Jun, Bokkyoo; Raschella, Giuseppe; Melino, Gerry; Agostini, Massimiliano			The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome	ONCOGENE			English	Article							FATTY-ACID SYNTHESIS; LIPID-METABOLISM; RETINOIC ACID; INHIBITION; CELLS	Cancer cells exhibit dysregulation of critical genes including those involved in lipid biosynthesis, with subsequent defects in metabolism. Here, we show that ELOngation of Very Long chain fatty acids protein 4 (ELOVL4), a rate-limiting enzyme in the biosynthesis of very-long polyunsaturated fatty acids (n-3, >= 28 C), is expressed and transcriptionally repressed by the oncogene MYCN in neuroblastoma cells. In keeping, ELOVL4 positively regulates neuronal differentiation and lipids droplets accumulation in neuroblastoma cells. At the molecular level we found that MYCN binds to the promoter of ELOVL4 in close proximity to the histone deacetylases HDAC1, HDAC2, and the transcription factor Sp1 that can cooperate in the repression of ELOVL4 expression. Accordingly, in vitro differentiation results in an increase of fatty acid with 34 carbons with 6 double bonds (FA34:6); and when MYCN is silenced, FA34:6 metabolite is increased compared with the scrambled. In addition, analysis of large neuroblastoma datasets revealed that ELOVL4 expression is highly expressed in localized clinical stages 1 and 2, and low in high-risk stages 3 and 4. More importantly, high expression of ELOVL4 stratifies a subsets of neuroblastoma patients with good prognosis. Indeed, ELOVL4 expression is a marker of better overall clinical survival also in MYCN not amplified patients and in those with neuroblastoma-associated mutations. In summary, our findings indicate that MYCN, by repressing the expression of ELOVL4 and lipid metabolism, contributes to the progression of neuroblastoma.	[Rugolo, Francesco; Melino, Gerry; Agostini, Massimiliano] Univ Roma Tor Vergata, Dept Expt Med, TOR, Rome, Italy; [Bazan, Nicolas G.; Calandria, Jorgelina; Jun, Bokkyoo] Louisiana State Univ Hlth New Orleans, Sch Med, Neurosci Ctr Excellence, New Orleans, LA USA; [Raschella, Giuseppe] Italian Natl Agcy New Technol, Lab Hlth & Environm, Energy & Sustainable Econ Dev ENEA, Rome, Italy	University of Rome Tor Vergata; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Italian National Agency New Technical Energy & Sustainable Economics Development	Melino, G; Agostini, M (corresponding author), Univ Roma Tor Vergata, Dept Expt Med, TOR, Rome, Italy.	melino@uniroma2.it; m.agostini@med.uniroma2.it	; Agostini, Massimiliano/G-9579-2014	Rugolo, Francesco/0000-0002-3174-100X; MELINO, GERRY/0000-0001-9428-5972; Bazan, Nicolas/0000-0002-9243-5444; Agostini, Massimiliano/0000-0003-3124-2072	Associazione Italiana per la Ricerca contro il Cancro (AIRC) [20473]; Ministry of Health and MAECI Italy-China Science and Technology Cooperation [PGR00961]; Regione Lazio through LazioInnova Progetto Gruppo di Ricerca [85-2017-14986]	Associazione Italiana per la Ricerca contro il Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministry of Health and MAECI Italy-China Science and Technology Cooperation; Regione Lazio through LazioInnova Progetto Gruppo di Ricerca	This research was funded by Associazione Italiana per la Ricerca contro il Cancro (AIRC) to GM (IG#20473; 2018-2022), Ministry of Health and MAECI Italy-China Science and Technology Cooperation (#PGR00961) to GM. Work has been also supported by Regione Lazio through LazioInnova Progetto Gruppo di Ricerca n 85-2017-14986.	Agbaga MP, 2008, P NATL ACAD SCI USA, V105, P12843, DOI 10.1073/pnas.0802607105; Agostini M, 2016, CELL DEATH DIFFER, V23, P1502, DOI 10.1038/cdd.2016.36; Amelio I, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-00373-0; Amelio I, 2020, BIOL DIRECT, V15, DOI 10.1186/s13062-020-00274-3; Bazan NG, 2018, MOL ASPECTS MED, V64, P18, DOI 10.1016/j.mam.2018.09.003; Bellomaria A, 2012, CELL CYCLE, V11, P3638, DOI 10.4161/cc.21918; Bhattacharjee S, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700735; Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035; Carroll PA, 2015, CANCER CELL, V27, P271, DOI 10.1016/j.ccell.2014.11.024; Chen JCY, 2020, BIOL DIRECT, V15, DOI 10.1186/s13062-020-00287-y; Chierici M, 2020, BIOL DIRECT, V15, DOI 10.1186/s13062-020-0259-4; Ciocci M, 2016, ONCOTARGET, V7, P84338, DOI 10.18632/oncotarget.12609; DeBose-Boyd RA, 2018, TRENDS BIOCHEM SCI, V43, P358, DOI 10.1016/j.tibs.2018.01.005; Depuydt P, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.240; Dickerman BA, 2019, NAT MED, V25, P1601, DOI 10.1038/s41591-019-0597-x; Han YT, 2019, BIOL DIRECT, V14, DOI 10.1186/s13062-019-0244-y; Han YT, 2019, BIOL DIRECT, V14, DOI 10.1186/s13062-018-0229-2; Harris ZN, 2019, BIOL DIRECT, V14, DOI 10.1186/s13062-019-0242-0; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Iraci N, 2011, CANCER RES, V71, P404, DOI 10.1158/0008-5472.CAN-10-2627; Jun B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05433-7; Lamastra FR, 2014, RSC ADV, V4, P61809, DOI 10.1039/c4ra12519c; Lin YC, 2008, CANCER RES, V68, P2375, DOI 10.1158/0008-5472.CAN-07-5807; Liu L, 2020, BIOL DIRECT, V15, DOI 10.1186/s13062-020-00264-5; Lutz W, 1996, ONCOGENE, V13, P803; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; McGregor GH, 2020, CANCER RES, V80, P175, DOI 10.1158/0008-5472.CAN-19-0644; Mihaylov I, 2019, BIOL DIRECT, V14, DOI 10.1186/s13062-019-0249-6; Mizutani Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067317; Nicolai S, 2020, MOL ONCOL, V14, P294, DOI 10.1002/1878-0261.12605; Nohturfft A, 2009, ANNU REV CELL DEV BI, V25, P539, DOI 10.1146/annurev.cellbio.24.110707.175344; Pallucca R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090764; Petroni A, 1996, J LIPID MEDIAT CELL, V14, P39, DOI 10.1016/0929-7855(96)00506-8; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; Pieraccioli M, 2018, P NATL ACAD SCI USA, V115, P7356, DOI 10.1073/pnas.1801435115; Riscal R, 2019, MOL CELL, V76, P220, DOI 10.1016/j.molcel.2019.09.008; Rohrig F, 2016, NAT REV CANCER, V16, P732, DOI 10.1038/nrc.2016.89; ROSS RA, 1983, J NATL CANCER I, V71, P741; Snaebjornsson MT, 2020, CELL METAB, V31, P62, DOI 10.1016/j.cmet.2019.11.010; Snaebjornsson MT, 2019, NATURE, V566, P333, DOI 10.1038/d41586-019-00352-1; Sulciner ML, 2018, CANCER METAST REV, V37, P557, DOI 10.1007/s10555-018-9754-9; Sumsion GR, 2020, BIOL DIRECT, V15, DOI 10.1186/s13062-019-0257-6; Teo W, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2016897118; Thiam AR, 2017, J CELL SCI, V130, P315, DOI 10.1242/jcs.192021; THIELE CJ, 1991, CANCER METAST REV, V10, P311, DOI 10.1007/BF00554793; Ruiz-Perez MV, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102128; Yao L, 2015, CANCER RES, V75, P1388, DOI 10.1158/0008-5472.CAN-14-2561; Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817; Zirath H, 2013, P NATL ACAD SCI USA, V110, P10258, DOI 10.1073/pnas.1222404110	50	8	8	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5741	5751		10.1038/s41388-021-01959-3	http://dx.doi.org/10.1038/s41388-021-01959-3		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34333551				2022-12-28	WOS:000679771600001
J	Alfei, F; Ho, PC; Lo, WL				Alfei, Francesca; Ho, Ping-Chih; Lo, Wan-Lin			DCision-making in tumors governs T cell anti-tumor immunity	ONCOGENE			English	Review							PLASMACYTOID DENDRITIC CELLS; ENDOTHELIAL GROWTH-FACTOR; MELANOMA PROGRESSION; INHIBITORY RECEPTORS; DOWN-REGULATION; IFN-GAMMA; TGF-BETA; ANTIGEN; CANCER; CTLA-4	The exploitation of T cell-based immunotherapies and immune checkpoint blockade for cancer treatment has dramatically shifted oncological treatment paradigms and broadened the horizons of cancer immunology. Dendritic cells have emerged as the critical tailors of T cell immune responses, which initiate and coordinate anti-tumor immunity. Importantly, genetic alterations in cancer cells, cytokines and chemokines produced by cancer and stromal cells, and the process of tumor microenvironmental regulation can compromise dendritic cell-T cell cross-talk, thereby disrupting anti-tumor T cell responses. This review summarizes how T cell activation is controlled by dendritic cells and how the tumor microenvironment alters dendritic cell properties in the context of the anti-tumor immune cycle. Furthermore, we will highlight therapeutic options for tailoring dendritic cell-mediated decision-making in T cells for cancer treatment.	[Alfei, Francesca; Ho, Ping-Chih] Univ Lausanne, Dept Oncol, Lausanne, Switzerland; [Ho, Ping-Chih] Univ Lausanne, Ludwig Inst Canc Res, Lausanne, Switzerland; [Lo, Wan-Lin] Univ Calif San Francisco, Dept Med, Div Rheumatol, Rosalind Russell & Ephraim P Engleman Arthrit Res, San Francisco, CA 94143 USA; [Lo, Wan-Lin] Univ Utah, Dept Pathol, Div Microbiol & Immunol, Salt Lake City, UT 84112 USA	University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne; University of California System; University of California San Francisco; Utah System of Higher Education; University of Utah	Ho, PC (corresponding author), Univ Lausanne, Dept Oncol, Lausanne, Switzerland.; Ho, PC (corresponding author), Univ Lausanne, Ludwig Inst Canc Res, Lausanne, Switzerland.; Lo, WL (corresponding author), Univ Calif San Francisco, Dept Med, Div Rheumatol, Rosalind Russell & Ephraim P Engleman Arthrit Res, San Francisco, CA 94143 USA.; Lo, WL (corresponding author), Univ Utah, Dept Pathol, Div Microbiol & Immunol, Salt Lake City, UT 84112 USA.	ping-chih.ho@unil.ch; wan-lin.lo@path.utah.edu		Lo, Wan-Lin/0000-0002-9074-6847; Ho, Ping-Chih/0000-0003-3078-3774	Swiss Government Excellence Fellowship; EMBO Postdoctoral Fellowship; European Research Council [802773-MitoGuide]; SNSF [31003A_182470]; Cancer Research Institute (CLIP investigator award); Cancer Research Institute (Lloyd J. Old STAR award); NIH NIAID Career Transition Award [K22AI143960]; Ludwig Cancer Research	Swiss Government Excellence Fellowship; EMBO Postdoctoral Fellowship(European Molecular Biology Organization (EMBO)); European Research Council(European Research Council (ERC)European Commission); SNSF(Swiss National Science Foundation (SNSF)); Cancer Research Institute (CLIP investigator award); Cancer Research Institute (Lloyd J. Old STAR award); NIH NIAID Career Transition Award; Ludwig Cancer Research	We thank Matt Gubin (MD Anderson Cancer Center) and Haopeng Wang (ShanghaiTech University) for providing helpful feedback on the paper. FA is supported by a Swiss Government Excellence Fellowship and EMBO Postdoctoral Fellowship. P-CH is funded by Ludwig Cancer Research, the European Research Council Starting Grant (802773-MitoGuide), SNSF project grants (31003A_182470), and the Cancer Research Institute (CLIP investigator award and Lloyd J. Old STAR award). W-LL is supported by NIH NIAID Career Transition Award K22AI143960.	Abelin JG, 2019, IMMUNITY, V51, P766, DOI 10.1016/j.immuni.2019.08.012; Alspach E, 2019, NATURE, V574, P696, DOI 10.1038/s41586-019-1671-8; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Arslan F, 2007, BRIT J CANCER, V96, P1560, DOI 10.1038/sj.bjc.6603766; Aspord C, 2013, CANCER IMMUNOL RES, V1, P402, DOI 10.1158/2326-6066.CIR-13-0114-T; Belladonna ML, 2008, J IMMUNOL, V181, P5194, DOI 10.4049/jimmunol.181.8.5194; Berdiaki A, 2008, BBA-GEN SUBJECTS, V1780, P194, DOI 10.1016/j.bbagen.2007.10.005; Binnewies M, 2019, CELL, V177, P556, DOI 10.1016/j.cell.2019.02.005; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Borst J, 2018, NAT REV IMMUNOL, V18, P635, DOI 10.1038/s41577-018-0044-0; Brewitz A, 2017, IMMUNITY, V46, P205, DOI 10.1016/j.immuni.2017.01.003; Briukhovetska D, 2021, NAT REV CANCER, V21, P481, DOI 10.1038/s41568-021-00363-z; Brown RD, 2001, BLOOD, V98, P2992, DOI 10.1182/blood.V98.10.2992; Burbage M, 2020, NATURE, V584, P523, DOI 10.1038/d41586-020-02339-9; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Cancel JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00009; Cao W, 2014, J IMMUNOL, V192, P2920, DOI 10.4049/jimmunol.1302801; Caronni N, 2018, CANCER RES, V78, P1685, DOI 10.1158/0008-5472.CAN-17-1307; Chakraborty AK, 2014, NAT IMMUNOL, V15, P798, DOI 10.1038/ni.2940; Chen J, 2019, NATURE, V567, P530, DOI 10.1038/s41586-019-0985-x; Cheng WC, 2019, NAT IMMUNOL, V20, P206, DOI 10.1038/s41590-018-0290-0; Chomarat P, 2000, NAT IMMUNOL, V1, P510, DOI 10.1038/82763; Conrad C, 2012, CANCER RES, V72, P5240, DOI 10.1158/0008-5472.CAN-12-2271; Corthay A, 2009, CANCER RES, V69, P5901, DOI 10.1158/0008-5472.CAN-08-4816; Courtney AH, 2018, TRENDS BIOCHEM SCI, V43, P108, DOI 10.1016/j.tibs.2017.11.008; Cubillos-Ruiz JR, 2015, CELL, V161, P1527, DOI 10.1016/j.cell.2015.05.025; DALAL BI, 1993, AM J PATHOL, V143, P381; Diao J, 2011, J IMMUNOL, V186, P5058, DOI 10.4049/jimmunol.1004125; Dong R, 2020, EMBO J, V39, DOI 10.15252/embj.2020104730; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Fernandes RA, 2020, NATURE, V586, P779, DOI 10.1038/s41586-020-2851-2; Ferris ST, 2020, NATURE, V584, P624, DOI 10.1038/s41586-020-2611-3; FISCHER JR, 1994, EUR J CANCER, V30A, P2125, DOI 10.1016/0959-8049(94)00364-B; Flavell RA, 2010, NAT REV IMMUNOL, V10, P554, DOI 10.1038/nri2808; Fong L, 2001, P NATL ACAD SCI USA, V98, P8809, DOI 10.1073/pnas.141226398; Fourcade J, 2012, CANCER RES, V72, P887, DOI 10.1158/0008-5472.CAN-11-2637; Fu CM, 2020, P NATL ACAD SCI USA, V117, P23730, DOI 10.1073/pnas.2002345117; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Gao JJ, 2017, NAT MED, V23, P551, DOI 10.1038/nm.4308; Gaud G, 2018, NAT REV IMMUNOL, V18, P485, DOI 10.1038/s41577-018-0020-8; Gee MH, 2018, CELL, V172, P549, DOI 10.1016/j.cell.2017.11.043; Giuffrida L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23331-5; Gottfried E, 2006, BLOOD, V107, P2013, DOI 10.1182/blood-2005-05-1795; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Gubin MM, 2018, CELL, V175, P1443, DOI 10.1016/j.cell.2018.11.003; Gubin MM, 2015, J CLIN INVEST, V125, P3413, DOI 10.1172/JCI80008; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Gudipati V, 2020, NAT IMMUNOL, V21, P848, DOI 10.1038/s41590-020-0719-0; Hack K, 2012, CLIN EXP DERMATOL, V37, P557, DOI 10.1111/j.1365-2230.2012.04362.x; Herber DL, 2010, NAT MED, V16, P880, DOI 10.1038/nm.2172; Huang CY, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100862; Imai K, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-3; Itakura E, 2011, MODERN PATHOL, V24, P801, DOI 10.1038/modpathol.2011.5; June CH, 2014, HUM GENE THER, V25, P779, DOI 10.1089/hum.2014.2533; Kel JM, 2010, J IMMUNOL, V185, P3248, DOI 10.4049/jimmunol.1000981; Khuu CH, 2007, MOL IMMUNOL, V44, P1598, DOI 10.1016/j.molimm.2006.08.006; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Le Bon A, 2003, NAT IMMUNOL, V4, P1009, DOI 10.1038/ni978; Li WT, 2020, IMMUNITY, V53, P456, DOI 10.1016/j.immuni.2020.07.011; Lindner SE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz3223; Linsley PS, 1996, IMMUNITY, V4, P535, DOI 10.1016/S1074-7613(00)80480-X; Liu XD, 2019, NATURE, V567, P525, DOI 10.1038/s41586-019-0979-8; Lorenzi S, 2011, J IMMUNOL, V186, P5142, DOI 10.4049/jimmunol.1004163; Malissen B, 2020, CELL RES, V30, P948, DOI 10.1038/s41422-020-00420-6; Marzo AL, 2000, J IMMUNOL, V165, P6047, DOI 10.4049/jimmunol.165.11.6047; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; Montoya M, 2002, BLOOD, V99, P3263, DOI 10.1182/blood.V99.9.3263; Munoz-Erazo L, 2020, CELL MOL IMMUNOL, V17, P570, DOI 10.1038/s41423-020-0457-0; Nikitovic D, 2006, IUBMB LIFE, V58, P47, DOI 10.1080/15216540500531713; Nurieva R, 2006, EMBO J, V25, P2623, DOI 10.1038/sj.emboj.7601146; Oyama T, 1998, J IMMUNOL, V160, P1224; Qureshi OS, 2012, J BIOL CHEM, V287, P9429, DOI 10.1074/jbc.M111.304329; Qureshi OS, 2011, SCIENCE, V332, P600, DOI 10.1126/science.1202947; Ricciardelli C, 2002, CLIN CANCER RES, V8, P1054; Robert F, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.2511; Roth TL, 2020, CELL, V181, P728, DOI 10.1016/j.cell.2020.03.039; Rumpret M, 2020, NAT REV IMMUNOL, V20, P771, DOI 10.1038/s41577-020-0352-z; Salio M, 2003, EUR J IMMUNOL, V33, P1052, DOI 10.1002/eji.200323676; Salter AI, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat6753; Scheper W, 2019, NAT MED, V25, P89, DOI 10.1038/s41591-018-0266-5; Schietinger A, 2016, IMMUNITY, V45, P389, DOI 10.1016/j.immuni.2016.07.011; Scott AC, 2019, NATURE, V571, P270, DOI 10.1038/s41586-019-1324-y; Shang WJ, 2018, P NATL ACAD SCI USA, V115, pE4051, DOI 10.1073/pnas.1801340115; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma P, 2020, NAT REV IMMUNOL, V20, P75, DOI 10.1038/s41577-020-0275-8; Shifrut E, 2018, CELL, V175, P1958, DOI 10.1016/j.cell.2018.10.024; Sitkovsky MV, 2014, CANCER IMMUNOL RES, V2, P598, DOI 10.1158/2326-6066.CIR-14-0075; Sockolosky JT, 2018, SCIENCE, V359, P1037, DOI 10.1126/science.aar3246; Sockolosky JT, 2016, P NATL ACAD SCI USA, V113, pE2646, DOI 10.1073/pnas.1604268113; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Sugiura D, 2019, SCIENCE, V364, P558, DOI 10.1126/science.aav7062; Sun ZC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11782-w; Tang M, 2015, CELL REP, V13, P2851, DOI 10.1016/j.celrep.2015.11.053; Tel J, 2013, CANCER RES, V73, P1063, DOI 10.1158/0008-5472.CAN-12-2583; Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771; Terra M, 2018, CANCER RES, V78, P3014, DOI 10.1158/0008-5472.CAN-17-2719; Theocharis AD, 2010, FEBS J, V277, P3904, DOI 10.1111/j.1742-4658.2010.07800.x; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Trendel N, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.aay9363; Valk E, 2008, TRENDS IMMUNOL, V29, P272, DOI 10.1016/j.it.2008.02.011; vanderMerwe PA, 1997, J EXP MED, V185, P393, DOI 10.1084/jem.185.3.393; Veglia F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02186-9; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Vigano S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00925; von Rahden BHA, 2006, MOL CARCINOGEN, V45, P786, DOI 10.1002/mc.20259; Waickman AT, 2012, CANCER IMMUNOL IMMUN, V61, P917, DOI 10.1007/s00262-011-1155-7; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Weber EW, 2021, SCIENCE, V372, P49, DOI 10.1126/science.aba1786; Wehbi VL, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00222; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Werfel TA, 2018, SEMIN IMMUNOPATHOL, V40, P545, DOI 10.1007/s00281-018-0698-5; Wu L, 2020, CELL MOL IMMUNOL, V17, P600, DOI 10.1038/s41423-020-0470-3; Wu W, 2020, CELL, V182, P855, DOI 10.1016/j.cell.2020.07.018; Xu MM, 2017, IMMUNITY, V47, P363, DOI 10.1016/j.immuni.2017.07.016; Xu XZ, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201905085; Yang YM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag1209; Yarchoan M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126908; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; Zhao YL, 2019, IMMUNITY, V51, P1059, DOI 10.1016/j.immuni.2019.11.003	120	4	4	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5253	5261		10.1038/s41388-021-01946-8	http://dx.doi.org/10.1038/s41388-021-01946-8		JUL 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34290401	Green Published, hybrid			2022-12-28	WOS:000677857200001
J	Wu, YH; Huang, YF; Chang, TH; Chen, CC; Wu, PY; Huang, SC; Chou, CY				Wu, Yi-Hui; Huang, Yu-Fang; Chang, Tzu-Hao; Chen, Chien-Chin; Wu, Pei-Ying; Huang, Soon-Cen; Chou, Cheng-Yang			COL11A1 activates cancer-associated fibroblasts by modulating TGF-beta 3 through the NF-kappa B/IGFBP2 axis in ovarian cancer cells	ONCOGENE			English	Article							NF-KAPPA-B; TGF-BETA; BREAST-CANCER; CARCINOMA; GROWTH; EXPRESSION; IL-6; CHEMORESISTANCE; SIGNATURE; SURVIVAL	Ovarian cancer has a unique tumor microenvironment (TME) that enables cancer-associated fibroblasts (CAFs) to interact with cellular and matrix constituents and influence tumor development and migration into the peritoneal cavity. Collagen type XI alpha 1 (COL11A1) is overexpressed in CAFs; therefore this study examines its role during CAF activation in epithelial ovarian cancer (EOC). Coculturing human ovarian fibroblasts (HOFs) with high COL11A1-expressing EOC cells or exposure to the conditioned medium of these cells prompted the expression of COL11A1 and CAF phenotypes. Conversely, coculturing HOFs with low COL11A1-expressing EOC cells or COL11A1-knockdown abrogated COL11A1 overexpression and secretion, in addition to CAF activation. Increased p-SP1 expression attributed to COL11A1-mediated extracellular signal-regulated kinase activation (ERK) induced p65 translocation into the nucleus and augmented its binding to the insulin-like growth factor binding protein 2 (IGFBP2) promoter, ultimately inducing TGF-beta 3 activation. The CAF-cancer cell crosstalk triggered interleukin-6 release, which in turn promoted EOC cell proliferation and invasiveness. These in vitro results were confirmed by in vivo findings in a mouse model, showing that COL11A1 overexpression in EOC cells promoted tumor formation and CAF activation, which was inhibited by TGF-beta 3 antibody. Human tumors with high TGF-beta 3 levels showed elevated expression of COL11A1 and IGFBP2, which was associated with poor survival. Our findings suggest the possibility that anti-TGF-beta 3 treatment strategy may be effective in targeting CAFs in COL11A1-positive ovarian tumors.	[Wu, Yi-Hui] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Huang, Yu-Fang; Wu, Pei-Ying; Chou, Cheng-Yang] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Obstet & Gynecol, Tainan, Taiwan; [Chang, Tzu-Hao] Taipei Med Univ, Grad Inst Biomed Informat, Taipei, Taiwan; [Chen, Chien-Chin] Chia Yi Christian Hosp, Dept Pathol, Ditmanson Med Fdn, Chiayi, Taiwan; [Chen, Chien-Chin] Chia Nan Univ Pharm & Sci, Dept Cosmet Sci, Tainan, Taiwan; [Huang, Soon-Cen] Chi Mei Med Ctr, Dept Obstet & Gynecol, Tainan, Taiwan	Chi Mei Hospital; National Cheng Kung University; National Cheng Kung University Hospital; Taipei Medical University; Chia Nan University of Pharmacy & Science; Chi Mei Hospital	Chou, CY (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Obstet & Gynecol, Tainan, Taiwan.; Huang, SC (corresponding author), Chi Mei Med Ctr, Dept Obstet & Gynecol, Tainan, Taiwan.	hsc.gyn@gmail.com; chougyn@mail.ncku.edu.tw	Chen, Chien-Chin/A-9977-2016; Wu, Pei Ying/AGR-9702-2022	Chen, Chien-Chin/0000-0001-9599-0884; Wu, Yi-Hui/0000-0002-8657-6371; Huang, Soon-Cen/0000-0001-8085-576X	National Science Council (MOST) [108-2314-B-384-011-MY3, 108-2314-B-006-061-MY2]; Chi Mei Medical Center, Liouying Campus [CLFHR10822, CLFHR10911, CMLMOST10901, CLFHR10921]	National Science Council (MOST); Chi Mei Medical Center, Liouying Campus	This work was supported by grants from the National Science Council (MOST: No. 108-2314-B-384-011-MY3 and 108-2314-B-006-061-MY2). The study was also supported by grants from the Chi Mei Medical Center, Liouying Campus (CLFHR10822, CLFHR10911, CMLMOST10901, and CLFHR10921).	Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Barcellos-Hoff MH, 2005, BREAST CANCER RES, V7, P33, DOI 10.1186/bcr972; Bartlett JM, 1997, EUR J CANCER, V33, P2397, DOI 10.1016/S0959-8049(97)00304-3; Bierie B, 2008, CANCER RES, V68, P1809, DOI 10.1158/0008-5472.CAN-07-5597; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Bran G, 2011, IN VIVO, V25, P579; Browning L, 2018, CANCER MANAG RES, V10, P6685, DOI 10.2147/CMAR.S179189; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cazals V, 1999, BBA-MOL CELL RES, V1448, P349, DOI 10.1016/S0167-4889(98)00095-0; Chen MF, 2012, CLIN SCI, V122, P459, DOI 10.1042/CS20110434; Cheon DJ, 2014, CLIN CANCER RES, V20, P711, DOI 10.1158/1078-0432.CCR-13-1256; Cirri P, 2011, AM J CANCER RES, V1, P482; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; D'Arcangelo E, 2020, BRIT J CANCER, V122, P931, DOI 10.1038/s41416-019-0705-1; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Erkan M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-88; Fischer H, 2001, CARCINOGENESIS, V22, P875, DOI 10.1093/carcin/22.6.875; Garcia-Pravia C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078327; Hawsawi NM, 2008, CANCER RES, V68, P2717, DOI 10.1158/0008-5472.CAN-08-0192; Hong SH, 2000, FASEB J, V14, P1499, DOI 10.1096/fj.99-0802com; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695534; Mienaltowski MJ, 2014, ADV EXP MED BIOL, V802, P5, DOI 10.1007/978-94-007-7893-1_2; Nallanthighal S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2442-z; Navab R, 2011, P NATL ACAD SCI USA, V108, P7160, DOI 10.1073/pnas.1014506108; Papageorgis P, 2015, J ONCOL, V2015, DOI 10.1155/2015/587193; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Rada M, 2018, ONCOGENE, V37, P4809, DOI 10.1038/s41388-018-0297-x; Ren B, 2006, BBA-REV CANCER, V1765, P178, DOI 10.1016/j.bbcan.2005.11.002; RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Stover DG, 2007, J CELL BIOCHEM, V101, P851, DOI 10.1002/jcb.21149; Tao LL, 2017, ONCOL LETT, V14, P2611, DOI 10.3892/ol.2017.6497; Verona EV, 2007, CANCER RES, V67, P5737, DOI 10.1158/0008-5472.CAN-07-0444; von Strandmann EP, 2017, TRENDS CANCER, V3, P137, DOI 10.1016/j.trecan.2016.12.005; Worzfeld T, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00024; Wu YH, 2014, ONCOGENE, V33, P3432, DOI 10.1038/onc.2013.307; Wu YH, 2017, INT J CANCER, V141, P2305, DOI 10.1002/ijc.30932; Wu YH, 2015, ONCOTARGET, V6, P23748, DOI 10.18632/oncotarget.4250; Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613; Yeung TL, 2013, CANCER RES, V73, P5016, DOI 10.1158/0008-5472.CAN-13-0023; Yu Y, 2014, BRIT J CANCER, V110, P724, DOI 10.1038/bjc.2013.768; Zigrino P, 2005, BIOCHIMIE, V87, P321, DOI 10.1016/j.biochi.2004.10.025	43	19	19	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4503	4519		10.1038/s41388-021-01865-8	http://dx.doi.org/10.1038/s41388-021-01865-8		JUN 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34117361				2022-12-28	WOS:000660409400001
J	Lodillinsky, C; Fuhrmann, L; Irondelle, M; Pylypenko, O; Li, XY; Bonsang-Kitzis, H; Reyal, F; Vacher, S; Calmel, C; De Wever, O; Bieche, I; Lacombe, ML; Eijan, AM; Houdusse, A; Vincent-Salomon, A; Weiss, SJ; Chavrier, P; Boissan, M				Lodillinsky, Catalina; Fuhrmann, Laetitia; Irondelle, Marie; Pylypenko, Olena; Li, Xiao-Yan; Bonsang-Kitzis, Helene; Reyal, Fabien; Vacher, Sophie; Calmel, Claire; De Wever, Olivier; Bieche, Ivan; Lacombe, Marie-Lise; Eijan, Ana Maria; Houdusse, Anne; Vincent-Salomon, Anne; Weiss, Stephen J.; Chavrier, Philippe; Boissan, Mathieu			Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance	ONCOGENE			English	Article							CARCINOMA IN-SITU; TUMOR-CELLS; DYNAMIN; TRAFFICKING; MICROINVASION; PROGRESSION; TRANSITION; MIGRATION	Membrane Type 1 Matrix Metalloprotease (MT1-MMP) contributes to the invasive progression of breast cancers by degrading extracellular matrix tissues. Nucleoside diphosphate kinase, NME1/NM23-H1, has been identified as a metastasis suppressor; however, its contribution to local invasion in breast cancer is not known. Here, we report that NME1 is up-regulated in ductal carcinoma in situ (DCIS) as compared to normal breast epithelial tissues. NME1 levels drop in microinvasive and invasive components of breast tumor cells relative to synchronous DCIS foci. We find a strong anti-correlation between NME1 and plasma membrane MT1-MMP levels in the invasive components of breast tumors, particularly in aggressive histological grade III and triple-negative breast cancers. Knockout of NME1 accelerates the invasive transition of breast tumors in the intraductal xenograft model. At the mechanistic level, we find that MT1-MMP, NME1 and dynamin-2, a GTPase known to require GTP production by NME1 for its membrane fission activity in the endocytic pathway, interact in clathrin-coated vesicles at the plasma membrane. Loss of NME1 function increases MT1-MMP surface levels by inhibiting endocytic clearance. As a consequence, the ECM degradation and invasive potentials of breast cancer cells are enhanced. This study identifies the down-modulation of NME1 as a potent driver of the in situ-to invasive transition during breast cancer progression.	[Lodillinsky, Catalina; Eijan, Ana Maria] Univ Buenos Aires, Inst Oncol Angel H Roffo, Res Area, Buenos Aires, DF, Argentina; [Lodillinsky, Catalina; Eijan, Ana Maria] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina; [Fuhrmann, Laetitia; Vincent-Salomon, Anne] PSL Res Univ, Inst Curie, Diagnost & Theranost Med Div, Paris, France; [Irondelle, Marie; Pylypenko, Olena; Houdusse, Anne; Chavrier, Philippe] PSL Res Univ, Inst Curie, UMR144, CNRS, Paris, France; [Li, Xiao-Yan; Weiss, Stephen J.] Univ Michigan, Life Sci Inst, Dept Internal Med, Div Med Genet, Ann Arbor, MI 48109 USA; [Bonsang-Kitzis, Helene; Reyal, Fabien] Inst Curie, Dept Surg, Paris, France; [Bonsang-Kitzis, Helene; Reyal, Fabien] Inst Curie, Translat Res Dept, RT2Lab Team, Immun & Canc,INSERM,U932, Paris, France; [Vacher, Sophie; Bieche, Ivan] Inst Curie, Pharmacogen Unit, Paris, France; [Calmel, Claire; Lacombe, Marie-Lise; Boissan, Mathieu] Univ Sorbonne, CRSA, St Antoine Res Ctr, INSERM,UMR S 938, Paris, France; [De Wever, Olivier] Univ Ghent, Canc Res Inst Ghent CRIG, Dept Human Struct & Repair, Lab Expt Canc Res, Ghent, Belgium; [Boissan, Mathieu] Tenon Hosp, AP HP, Lab Biochem & Hormonol, Paris, France; [Bonsang-Kitzis, Helene] Hop Prive Peupliers, RAMSAY Gen Sante, Gynecol & Breast Surg & Cancerol Ctr, Paris, France	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; University of Michigan System; University of Michigan; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Boissan, M (corresponding author), Univ Sorbonne, CRSA, St Antoine Res Ctr, INSERM,UMR S 938, Paris, France.; Boissan, M (corresponding author), Tenon Hosp, AP HP, Lab Biochem & Hormonol, Paris, France.	mathieu.boissan@inserm.fr	de wever, olivier/J-3094-2013; EIJAN, ANA MARIA/AAC-8849-2022; CHAVRIER, Philippe/B-4707-2010	de wever, olivier/0000-0002-5453-760X; CALMEL, Claire/0000-0001-7215-7910; Pylypenko, Olena/0000-0001-7073-5238; CHAVRIER, Philippe/0000-0002-7351-733X	NIH/NCI [R01 CA071699]; Breast Cancer Research Foundation; Margolies Family Discovery Fund for Cancer Research; University of Michigan Rogel Cancer Center Support Grant [P30 CA046592]; Fondation ARC pour la Recherche sur le Cancer [PGA1 RF20170205408]; Fondation Ruban Rose (Prix Avenir 2018); Groupement des Entreprises Francaises contre le Cancer (GEFLUC); Canceropole-Ile de France [2015-1-EMERG-25-INSERM 6-1]; PLAN CANCER [C19048DS];  [ANR-10-INBS-04]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation; Margolies Family Discovery Fund for Cancer Research; University of Michigan Rogel Cancer Center Support Grant; Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Fondation Ruban Rose (Prix Avenir 2018); Groupement des Entreprises Francaises contre le Cancer (GEFLUC); Canceropole-Ile de France(Region Ile-de-France); PLAN CANCER; 	The authors acknowledge the Breast Cancer Study Group and the Incentive and Cooperative Research Program "Breast cancer: Cell Invasion and Motility" and patients of Institut Curie for the breast tumor samples, Drs. C. Tomasetto, P. De camilli, P. S. Steeg and E. Smythe for kindly providing reagents, cell lines and samples for this study, the Nikon Imaging Centre @ Institut Curie-CNRS and Cell and Tissue Imaging Facility of Institut Curie, member of the France Bio Imaging national research infrastructure (ANR-10-INBS-04) for help with image acquisition, F. Guillonneau from the Proteomic Facility 3P5, Paris-Descartes University for MALDI-MS analysis, Sandra Antoine from Institut Curie for help with the collagenolysis assay, and C. Kikuti from Institut Curie for help with SEC-MALS analysis. This work was supported by grants from the NIH/NCI to S.J.W and X.Y.L. (R01 CA071699) as well as the Breast Cancer Research Foundation and the Margolies Family Discovery Fund for Cancer Research to S.J.W and X.Y.L. Additional support was provided by the University of Michigan Rogel Cancer Center Support Grant (P30 CA046592). Funding for this work was provided by Fondation ARC pour la Recherche sur le Cancer (PGA1 RF20170205408) and Fondation Ruban Rose (Prix Avenir 2018) to PC, the Groupement des Entreprises Francaises contre le Cancer (GEFLUC), Canceropole-Ile de France (no 2015-1-EMERG-25-INSERM 6-1) and PLAN CANCER (Project C19048DS) to MB.	Baldassarre M, 2003, MOL BIOL CELL, V14, P1074, DOI 10.1091/mbc.E02-05-0308; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Boissan M, 2005, JNCI-J NATL CANCER I, V97, P836, DOI 10.1093/jnci/dji143; Boissan M, 2018, LAB INVEST, V98, P164, DOI 10.1038/labinvest.2017.137; Boissan M, 2014, SCIENCE, V344, P1510, DOI 10.1126/science.1253768; Boissan M, 2010, CANCER RES, V70, P7710, DOI 10.1158/0008-5472.CAN-10-1887; Casasent AK, 2017, J PATHOL, V241, P208, DOI 10.1002/path.4840; Castro-Castro A, 2016, ANNU REV CELL DEV BI, V32, P555, DOI 10.1146/annurev-cellbio-111315-125227; Cowell CF, 2013, MOL ONCOL, V7, P859, DOI 10.1016/j.molonc.2013.07.005; Dammai V, 2003, GENE DEV, V17, P2812, DOI 10.1101/gad.1096903; de Mascarel I, 2002, CANCER, V94, P2134, DOI 10.1002/cncr.10451; Eppinga RD, 2012, ONCOGENE, V31, P1228, DOI 10.1038/onc.2011.329; Feinberg TY, 2018, DEV CELL, V47, P145, DOI 10.1016/j.devcel.2018.08.025; Gifford V, 2019, BIOCHEM SOC T, V47, P811, DOI 10.1042/BST20180363; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Khan I, 2019, CANCER RES, V79, P4689, DOI 10.1158/0008-5472.CAN-19-0492; Kushner MH, 2020, EMBO REP, V21, DOI 10.15252/embr.201948741; Lee S, 2012, CANCER RES, V72, P4574, DOI 10.1158/0008-5472.CAN-12-0636; Li XY, 2008, MOL BIOL CELL, V19, P3221, DOI 10.1091/mbc.E08-01-0016; Lodillinsky C, 2016, ONCOGENE, V35, P344, DOI 10.1038/onc.2015.87; Marino N, 2012, CANCER METAST REV, V31, P593, DOI 10.1007/s10555-012-9374-8; Meister M, 2014, FEBS J, V281, P2956, DOI 10.1111/febs.12834; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Monteiro P, 2013, J CELL BIOL, V203, P1063, DOI 10.1083/jcb.201306162; Nicoziani P, 2000, MOL BIOL CELL, V11, P481, DOI 10.1091/mbc.11.2.481; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Ouatas T, 2003, J BIOENERG BIOMEMBR, V35, P73, DOI 10.1023/A:1023497924277; Perentes JY, 2011, CANCER RES, V71, P4527, DOI 10.1158/0008-5472.CAN-10-4376; Planchon D, 2018, J CELL SCI, V131, DOI 10.1242/jcs.218925; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Razidlo GL, 2013, DEV CELL, V24, P573, DOI 10.1016/j.devcel.2013.02.010; Rosse C, 2014, P NATL ACAD SCI USA, V111, pE1872, DOI 10.1073/pnas.1400749111; Rowe RG, 2008, TRENDS CELL BIOL, V18, P560, DOI 10.1016/j.tcb.2008.08.007; Sopik V, 2018, BREAST CANCER RES TR, V167, P787, DOI 10.1007/s10549-017-4572-2; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Szabova L, 2008, ONCOGENE, V27, P3274, DOI 10.1038/sj.onc.1210982; Tan CY, 2018, LAB INVEST, V98, P219, DOI 10.1038/labinvest.2017.105; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; van Seijen M, 2019, BRIT J CANCER, V121, P285, DOI 10.1038/s41416-019-0478-6; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Zala Diana, 2017, F1000Res, V6, P724, DOI 10.12688/f1000research.11561.2	42	8	8	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					4019	4032		10.1038/s41388-021-01826-1	http://dx.doi.org/10.1038/s41388-021-01826-1		MAY 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	34012098	Green Published, hybrid			2022-12-28	WOS:000652080600001
J	Lager, TW; Conner, C; Keating, CR; Warshaw, JN; Panopoulos, AD				Lager, Tyson W.; Conner, Clay; Keating, Claudia R.; Warshaw, Jane N.; Panopoulos, Athanasia D.			Cell surface GRP78 and Dermcidin cooperate to regulate breast cancer cell migration through Wnt signaling	ONCOGENE			English	Article							STEM-CELLS; COLOCALIZATION; GENE	The heat shock protein GRP78 typically resides in the endoplasmic reticulum in normal tissues, but it has been shown to be expressed on the cell surface of several cancer cells, and some stem cells, where it can act as a signaling molecule by not-yet-fully defined mechanisms. Although cell surface GRP78 (sGRP78) has emerged as an attractive chemotherapeutic target, understanding how sGRP78 is functioning in cancer has been complicated by the fact that sGRP78 can function in a cell-context dependent manner, with a diverse array of reported binding partners, to regulate a variety of cellular responses. We had previously shown that sGRP78 was important in regulating pluripotent stem cell (PSC) functions, and hypothesized that embryonic-like mechanisms of GRP78 were critical to regulating aggressive breast cancer cell functions. Here, using proteomics we identify Dermcidin (DCD) as a novel sGRP78 binding partner common to both PSCs and breast cancer cells. We show that GRP78 and DCD cooperate to regulate stem cell and cancer cell migration that is dependent on the cell surface functions of these proteins. Finally, we identify Wnt/beta-catenin signaling, a critical pathway in stem cell and cancer cell biology, as an important downstream intermediate in regulating this migration phenotype.	[Lager, Tyson W.; Conner, Clay; Keating, Claudia R.; Warshaw, Jane N.; Panopoulos, Athanasia D.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; [Lager, Tyson W.; Conner, Clay; Panopoulos, Athanasia D.] Univ Notre Dame, Ctr Stem Cells & Regenerat Med, Notre Dame, IN 46556 USA; [Panopoulos, Athanasia D.] Univ Notre Dame, Harper Canc Res Inst, Notre Dame, IN 46556 USA; [Keating, Claudia R.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA; [Warshaw, Jane N.] Univ Texas Southwestern Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [Warshaw, Jane N.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA	University of Notre Dame; University of Notre Dame; University of Notre Dame; Loyola University Chicago; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Panopoulos, AD (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.; Panopoulos, AD (corresponding author), Univ Notre Dame, Ctr Stem Cells & Regenerat Med, Notre Dame, IN 46556 USA.; Panopoulos, AD (corresponding author), Univ Notre Dame, Harper Canc Res Inst, Notre Dame, IN 46556 USA.	apanopou@nd.edu	Keating, Charles/HGE-0760-2022	Lager, Tyson/0000-0002-4815-9761	American Cancer Society Research Scholar Grant [RSG-20-022-01-CDD]; Indiana Clinical and Translational Sciences Institute [UL1TR001108]; National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award [TL1TR001107]; Hiller Family Research Fellowship; Gallagher Family; Walther Cancer Foundation Advancing Basic Cancer grant	American Cancer Society Research Scholar Grant(American Cancer Society); Indiana Clinical and Translational Sciences Institute; National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award; Hiller Family Research Fellowship; Gallagher Family; Walther Cancer Foundation Advancing Basic Cancer grant	This work was supported in part by an American Cancer Society Research Scholar Grant (RSG-20-022-01-CDD), a Walther Cancer Foundation Advancing Basic Cancer grant, and by grant UL1TR001108 from the Indiana Clinical and Translational Sciences Institute (to ADP). CC was supported in part by grant TL1TR001107 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. CRK was supported in part through a Hiller Family Research Fellowship. We thank the members of the D'Souza-Schorey laboratory for kindly providing valuable advice for the TOPFlash assays; Drs. Michelle Joyce, Matthew Champion, and Bill Boggess of the Notre Dame Mass Spectrometry and Proteomics Facility for proteomics; and Dr. Sara Cole of the Optical Microscopy Core, Notre Dame Integrated Imaging Facility (NDIIF), for her microscopy assistance and expertise. We thank Drs. Jonathan Kelber and Peter Gray for valuable discussions, and three anonymous reviewers for their helpful comments. We are grateful to the Gallagher Family for their generous support of stem cell research at the University of Notre Dame.	Bancovik J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1022-6; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Conner C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60269-y; Davidson DJ, 2005, CANCER RES, V65, P4663, DOI 10.1158/0008-5472.CAN-04-3426; Dunn KW, 2011, AM J PHYSIOL-CELL PH, V300, pC723, DOI 10.1152/ajpcell.00462.2010; Holm F, 2015, P NATL ACAD SCI USA, V112, P15444, DOI 10.1073/pnas.1506943112; Kelber JA, 2009, ONCOGENE, V28, P2324, DOI 10.1038/onc.2009.97; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Liu GH, 2011, NATURE, V472, P221, DOI 10.1038/nature09879; Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Matsuda Y, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2317; Miharada K, 2011, CELL STEM CELL, V9, P330, DOI 10.1016/j.stem.2011.07.016; Mizuno H, 2010, P NATL ACAD SCI USA, V107, P22745, DOI 10.1073/pnas.1017001108; Panopoulos AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019743; Porter D, 2003, P NATL ACAD SCI USA, V100, P10931, DOI 10.1073/pnas.1932980100; Schittek B, 2012, J INNATE IMMUN, V4, P349, DOI 10.1159/000336844; Spike BT, 2014, STEM CELL REP, V2, P427, DOI 10.1016/j.stemcr.2014.02.010; Stewart GD, 2008, CURR OPIN CLIN NUTR, V11, P208, DOI 10.1097/MCO.0b013e3282fb7b8d; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Tsai YL, 2018, P NATL ACAD SCI USA, V115, pE4245, DOI 10.1073/pnas.1714866115; Tsai YL, 2015, J BIOL CHEM, V290, P8049, DOI 10.1074/jbc.M114.618736; Tseng CC, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201900377; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304	27	5	5	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					4050	4059		10.1038/s41388-021-01821-6	http://dx.doi.org/10.1038/s41388-021-01821-6		MAY 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	33981001	Green Accepted			2022-12-28	WOS:000650166200001
J	Venugopalan, A; Lynberg, M; Cultraro, CM; Nguyen, KDP; Zhang, X; Waris, M; Dayal, N; Abebe, A; Maity, TK; Guha, U				Venugopalan, Abhilash; Lynberg, Matthew; Cultraro, Constance M.; Nguyen, Khoa Dang P.; Zhang, Xu; Waris, Maryam; Dayal, Noelle; Abebe, Asebot; Maity, Tapan K.; Guha, Udayan			SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma	ONCOGENE			English	Article								Mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain constitutively activate EGFR resulting in lung tumorigenesis. Activated EGFR modulates downstream signaling by altering phosphorylation-driven interactions that promote growth and survival. Secretory carrier membrane proteins (SCAMPs) are a family of transmembrane proteins that regulate recycling of receptor proteins, including EGFR. The potential role of SCAMPs in mutant EGFR function and tumorigenesis has not been elucidated. Using quantitative mass-spectrometry-based phosphoproteomics, we identified SCAMP3 as a target of mutant EGFRs in lung adenocarcinoma and sought to further investigate the role of SCAMP3 in the regulation of lung tumorigenesis. Here we show that activated EGFR, either directly or indirectly phosphorylates SCAMP3 at Y86 and this phosphorylation increases the interaction of SCAMP3 with both wild-type and mutant EGFRs. SCAMP3 knockdown increases lung adenocarcinoma cell survival and increases xenograft tumor growth in vivo, demonstrating a tumor suppressor role of SCAMP3 in lung tumorigenesis. The tumor suppressor function is a result of SCAMP3 promoting EGFR degradation and attenuating MAP kinase signaling pathways. SCAMP3 knockdown also increases multinucleated cells in culture, suggesting that SCAMP3 is required for efficient cytokinesis. The enhanced growth, increased colony formation, reduced EGFR degradation and multinucleation phenotype of SCAMP3-depleted cells were reversed by re-expression of wild-type SCAMP3, but not SCAMP3 Y86F, suggesting that Y86 phosphorylation is critical for SCAMP3 function. Taken together, the results of this study demonstrate that SCAMP3 functions as a novel tumor suppressor in lung cancer by modulating EGFR signaling and cytokinesis that is partly Y86 phosphorylation-dependent.	[Venugopalan, Abhilash; Lynberg, Matthew; Cultraro, Constance M.; Nguyen, Khoa Dang P.; Zhang, Xu; Waris, Maryam; Dayal, Noelle; Abebe, Asebot; Maity, Tapan K.; Guha, Udayan] NCI, Thorac & GI Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Guha, Udayan] Bristol Myers Squibb, Lawrenceville, NJ 08648 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Bristol-Myers Squibb	Venugopalan, A; Guha, U (corresponding author), NCI, Thorac & GI Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.; Guha, U (corresponding author), Bristol Myers Squibb, Lawrenceville, NJ 08648 USA.	abhilash.venugopalan@nih.gov; udayan.guha@nih.gov		Guha, Udayan/0000-0003-1087-9218; Nguyen, Khoa Dang/0000-0003-0888-304X	NIH Intramural Research Program, Center of Cancer Research, National Cancer Institute	NIH Intramural Research Program, Center of Cancer Research, National Cancer Institute	We thank Gaga Geneti for the assistance with the mice handling and treatments. This research was supported by the NIH Intramural Research Program, Center of Cancer Research, National Cancer Institute.	Aoh QL, 2009, MOL BIOL CELL, V20, P1816, DOI 10.1091/mbc.E08-09-0894; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Awasthi S, 2018, DATA BRIEF, V19, P424, DOI 10.1016/j.dib.2018.04.086; Awasthi S, 2018, J PROTEOMICS, V189, P48, DOI 10.1016/j.jprot.2018.04.005; Beaumatin F, 2019, MOL CELL, V76, P163, DOI 10.1016/j.molcel.2019.07.021; Brose MS, 2002, CANCER RES, V62, P6997; Castle A, 2005, J CELL SCI, V118, P3769, DOI 10.1242/jcs.02503; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; Diaz-Carballo D, 2018, CANCER RES, V78, P2318, DOI 10.1158/0008-5472.CAN-17-1861; Falguieres T, 2012, TRAFFIC, V13, P131, DOI 10.1111/j.1600-0854.2011.01291.x; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao S, 2020, BIORXIV, DOI [10.1101/2020.07.04.187617, DOI 10.1101/2020.07.04.187617]; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Ghosh D, 2016, STEM CELLS, V34, P2276, DOI 10.1002/stem.2411; Glubb DM, 2017, ONCOTARGET, V8, P64670, DOI 10.18632/oncotarget.18501; Kulyte A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50210-3; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maity TK, 2015, CANCER DISCOV, V5, P534, DOI 10.1158/2159-8290.CD-14-0750; Mittal K, 2017, BRIT J CANCER, V116, P1186, DOI 10.1038/bjc.2017.78; Murray D., 2018, CANCERS, V10, p118.; Padron D, 2007, CANCER RES, V67, P7695, DOI 10.1158/0008-5472.CAN-07-0484; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Parekh A, 2018, ONCOGENE, V37, P4546, DOI 10.1038/s41388-018-0272-6; Pinilla-Macua I, 2017, ELIFE, V6, DOI 10.7554/eLife.31993; Pinilla-Macua I, 2016, P NATL ACAD SCI USA, V113, P2122, DOI 10.1073/pnas.1520301113; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Schiel JA, 2012, NAT CELL BIOL, V14, P1068, DOI 10.1038/ncb2577; Singleton DR, 1997, J CELL SCI, V110, P2099; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Stewart EL, 2015, TRANSL LUNG CANCER R, V4, P67, DOI 10.3978/j.issn.2218-6751.2014.11.06; Suarez-Arroyo IJ, 2016, AM J CANCER RES, V6, P1720; Tabara K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041017; Thomas P, 2016, BIOCHEM BIOPH RES CO, V478, P1028, DOI 10.1016/j.bbrc.2016.08.012; Tomas A, 2014, TRENDS CELL BIOL, V24, P26, DOI 10.1016/j.tcb.2013.11.002; Venugopalan A, 2016, ONCOTARGET, V7, P54137, DOI 10.18632/oncotarget.11021; Walsh AM, 2014, INTEGR BIOL-UK, V6, P312, DOI 10.1039/c3ib40176f; Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015; Wu TT, 1998, MOL BIOL CELL, V9, P1661, DOI 10.1091/mbc.9.7.1661; Zhang XY, 2017, ONCOTARGET, V8, P109247, DOI 10.18632/oncotarget.22665; Zhang X, 2017, MOL CELL PROTEOMICS, V16, P891, DOI 10.1074/mcp.M117.067439; Zhang X, 2015, PROTEOMICS, V15, P340, DOI 10.1002/pmic.201400315	45	4	4	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3331	3346		10.1038/s41388-021-01764-y	http://dx.doi.org/10.1038/s41388-021-01764-y		APR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33850265	Green Accepted			2022-12-28	WOS:000639730800001
J	Wang, ZL; Shi, YP; Ying, CT; Jiang, Y; Hu, JF				Wang, Zhenlin; Shi, Yuping; Ying, Chenting; Jiang, Yang; Hu, Jiangfeng			Hypoxia-induced PLOD1 overexpression contributes to the malignant phenotype of glioblastoma via NF-kappa B signaling	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; CELL; EXPRESSION; PROGRESSION; LANDSCAPE; DIFFERENTIATION; ANGIOGENESIS; METASTASIS; PROGNOSIS; SUBTYPES	Procollagen lysyl hydroxylase 1 (PLOD1) is highly expressed in malignant tumors such as esophageal squamous cell carcinoma, gastric cancer, and colorectal cancer. Bioinformatics analysis revealed that PLOD1 is associated with the progression of GBM, particularly the most malignant mesenchymal subtype (MES). Moreover, in the TCGA and CGGA datasets, the mean survival time of patients with high PLOD1 expression was significantly shorter than that of patients with low expression. The clinical samples confirmed this result. Therefore, we aimed to investigate the effect of PLOD1 on the development of mesenchymal GBM in vitro and in vivo and its possible mechanisms. Molecular experiments were conducted on the patient-derived glioma stem cells and found that PLOD1 expressed higher in tumor tissues and cancer cell lines of patients with GBM, especially in the MES. PLOD1 also enhanced tumor viability, proliferation, migration, and promoted MES transition while inhibited apoptosis. Tumor xenograft results also indicated that PLOD1 overexpression significantly promotes malignant behavior of tumors. Mechanistically, bioinformatics analysis further revealed that PLOD1 expression was closely associated with the NF-kappa B signaling pathway. Besides, we also found that hypoxic environments also enhanced the tumor-promoting effects of PLOD1. In conclusion, overexpression of PLOD1 may be an important factor in the enhanced invasiveness and MES transition of GBM. Thus, PLOD1 is a potential treatment target for mesenchymal GBM or even all GBM.	[Wang, Zhenlin] Shanghai Jiao Tong Univ, Sch Med, Dept Neurosurg, Shanghai Gen Hosp, 100 Haining Rd, Shanghai, Peoples R China; [Shi, Yuping] Shanghai Jiao Tong Univ, Shanghai TongRen Hosp, Dept Nephrol, Sch Med, 1111 Xianxia Rd, Shanghai, Peoples R China; [Ying, Chenting] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthoped, Sch Med, 100 Haining Rd, Shanghai, Peoples R China; [Jiang, Yang] Tongji Univ, Shanghai Peoples Hosp 10, Dept Neurosurg, Sch Med, Shanghai 200072, Peoples R China; [Hu, Jiangfeng] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gastroenterol, Sch Med, 100 Haining Rd, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tongji University; Shanghai Jiao Tong University	Jiang, Y (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Dept Neurosurg, Sch Med, Shanghai 200072, Peoples R China.; Hu, JF (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gastroenterol, Sch Med, 100 Haining Rd, Shanghai, Peoples R China.	windjy0523@qq.com; doctorhjf@foxmail.com			National Natural Science Foundation of China [81900544]; Shanghai Sailing Program [19YF1439000]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Sailing Program	We thank Zhitao Jing at the Department of Neurosurgery, The First Affiliated Hospital of China Medical University for molecular experimental technical support. This work was sponsored by grants from the National Natural Science Foundation of China (Grant 81900544) and Shanghai Sailing Program (Grant 19YF1439000).	Auffinger Brenda, 2012, F1000 Med Rep, V4, P18; Behnan J, 2019, BRAIN, V142, P847, DOI 10.1093/brain/awz044; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Bush NAO, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0585-6; Cai X., 2018, ONCOTARGET, V9, P9540, DOI [10.18632/oncotarget.23476, DOI 10.18632/ONCOTARGET.23476]; Cheng P, 2016, CANCER RES, V76, P7219, DOI 10.1158/0008-5472.CAN-15-2860; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Du HZ, 2017, BIOMED PHARMACOTHER, V90, P670, DOI 10.1016/j.biopha.2017.04.023; Engler JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043339; Friedmann-Morvinski D, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501292; Gilkes DM, 2013, MOL CANCER RES, V11, P456, DOI 10.1158/1541-7786.MCR-12-0629; Giunta C, 2005, MOL GENET METAB, V86, P269, DOI 10.1016/j.ymgme.2005.04.014; Han S, 2014, BRIT J CANCER, V110, P2560, DOI 10.1038/bjc.2014.162; Hofbauer KH, 2003, EUR J BIOCHEM, V270, P4515, DOI 10.1046/j.1432-1033.2003.03846.x; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huse JT, 2011, GLIA, V59, P1190, DOI 10.1002/glia.21165; Ji XJ, 2014, INT J CANCER, V135, P574, DOI 10.1002/ijc.28699; Jiang Y, 2019, J PATHOL, V249, P26, DOI 10.1002/path.5278; Jiang Y, 2019, CANCER RES, V79, P2593, DOI 10.1158/0008-5472.CAN-18-3297; Jiang Y, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0210-1; Kundu S, 2016, MOL CANCER RES, V14, P1243, DOI 10.1158/1541-7786.MCR-16-0223; Li B, 2012, CLIN CANCER RES, V18, P5595, DOI 10.1158/1078-0432.CCR-12-1427; Li LW, 2017, AM J TRANSL RES, V9, P3741; Li W, 2012, NEURO-ONCOLOGY, V14, P958, DOI 10.1093/neuonc/nos116; Liu P, 2018, MED SCI MONITOR, V24, P2098, DOI 10.12659/MSM.906945; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mao P, 2013, P NATL ACAD SCI USA, V110, P8644, DOI 10.1073/pnas.1221478110; Moreno M, 2017, CELL REP, V21, P2183, DOI 10.1016/j.celrep.2017.10.083; Moresco EMY, 2011, CURR BIOL, V21, pR488, DOI 10.1016/j.cub.2011.05.039; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Oudin MJ, 2016, CANCER DISCOV, V6, P516, DOI 10.1158/2159-8290.CD-15-1183; Peinado H, 2008, CANCER RES, V68, P4541, DOI 10.1158/0008-5472.CAN-07-6345; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Qi YF, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00066; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198-009-1066-z; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Song YF, 2020, NEURO-ONCOLOGY, V22, P46, DOI 10.1093/neuonc/noz136; Srivastava C, 2018, INT J CANCER, V142, P805, DOI 10.1002/ijc.31092; Sun L, 2016, BIOMED PHARMACOTHER, V81, P145, DOI 10.1016/j.biopha.2016.03.053; Trong PD, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102903; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Venteicher AS, 2017, SCIENCE, V355, DOI 10.1126/science.aai8478; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wade A, 2013, FEBS J, V280, P2399, DOI 10.1111/febs.12109; Waghmare I, 2014, STEM CELL TRANSL MED, V3, P1262, DOI 10.5966/sctm.2014-0086; Wang DZ, 2018, GENET TEST MOL BIOMA, V22, P366, DOI 10.1089/gtmb.2018.0009; Wang HX, 2015, NEOPLASIA, V17, P239, DOI 10.1016/j.neo.2015.02.002; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xue H, 2016, AUTOPHAGY, V12, P1129, DOI 10.1080/15548627.2016.1178446; Yamada Y, 2019, MOL ONCOL, V13, P1898, DOI 10.1002/1878-0261.12532; Yamini B, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7090125; Zhang YS, 2018, BIOMED PHARMACOTHER, V104, P566, DOI 10.1016/j.biopha.2018.05.079; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	58	18	18	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1458	1475		10.1038/s41388-020-01635-y	http://dx.doi.org/10.1038/s41388-020-01635-y		JAN 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33420370	hybrid, Green Published			2022-12-28	WOS:000607346000006
J	Xu, YY; Guo, J; Liu, J; Xie, Y; Li, X; Jiang, HM; Wang, JJ; Peng, ZY; Wang, JY; Wang, S; Wan, C; Chen, LT; Zhong, YP; Liu, BZ; Liu, ZQ				Xu, Yinyin; Guo, Jing; Liu, Jing; Xie, Ying; Li, Xin; Jiang, Hongmei; Wang, Jingjing; Peng, Ziyi; Wang, Jingya; Wang, Sheng; Wan, Chao; Chen, Lanting; Zhong, Yuping; Liu, Beizhong; Liu, Zhiqiang			Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma	ONCOGENE			English	Article							BONE-DISEASE; DICKKOPF-1 DKK1; IN-VIVO; GROWTH; SUPPRESSION; ANTIBODY; GENE	Myeloma cells produce excessive levels of dickkopf-1 (DKK1), which mediates the inhibition of Wnt signaling in osteoblasts, leading to multiple myeloma (MM) bone disease. Nevertheless, the precise mechanisms underlying DKK1 overexpression in myeloma remain incompletely understood. Herein, we provide evidence that hypoxia promotes DKK1 expression in myeloma cells. Under hypoxic conditions, p38 kinase phosphorylated cAMP-responsive element-binding protein (CREB) and drove its nuclear import to activate DKK1 transcription. In addition, high levels of DKK1 were associated with the presence of focal bone lesions in patients with t(4;14) MM, overexpressing the histone methyltransferase MMSET, which was identified as a downstream target gene of hypoxia-inducible factor (HIF)-1 alpha. Furthermore, we found that CREB could recruit MMSET, leading to the stabilization of HIF-1 alpha protein and the increased dimethylation of histone H3 at lysine 36 on the DKK1 promoter. Knockdown of CREB in myeloma cells alleviated the suppression of osteoblastogenesis by myeloma-secreted DKK1 in vitro. Combined treatment with a CREB inhibitor and the hypoxia-activated prodrug TH-302 (evofosfamide) significantly reduced MM-induced bone destruction in vivo. Taken together, our findings reveal that hypoxia and a cytogenetic abnormality regulate DKK1 expression in myeloma cells, and provide an additional rationale for the development of therapeutic strategies that interrupt DKK1 to cure MM.	[Xu, Yinyin; Liu, Beizhong] Chongqing Med Univ, Clin Lab, Yongchuan Hosp, Chongqing, Peoples R China; [Xu, Yinyin; Wan, Chao; Liu, Beizhong] Chongqing Med Univ, Dept Lab Med, Key Lab Lab Med Diagnost, Minist Educ, Chongqing, Peoples R China; [Guo, Jing; Liu, Jing; Xie, Ying; Li, Xin; Jiang, Hongmei; Wang, Jingjing; Peng, Ziyi; Wang, Jingya; Wang, Sheng; Liu, Zhiqiang] Tianjin Med Univ, Prov & Minist Cosponsored Collaborat Innovat Ctr, Tianjin Key Lab Cellular Homeostasis & Human Dis, Dept Physiol & Pathophysiol,Sch Basic Med Sci, Tianjin, Peoples R China; [Chen, Lanting] Chongqing Med Univ, Dept Hematol, Yongchuan Hosp, Chongqing, Peoples R China; [Zhong, Yuping] Qingdao Municipal Hosp, Dept Hematol, Qingdao, Shandong, Peoples R China; [Liu, Zhiqiang] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Tianjin Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China	Chongqing Medical University; Chongqing Medical University; Tianjin Medical University; Chongqing Medical University; Qingdao Municipal Hospital; Tianjin Medical University	Liu, BZ (corresponding author), Chongqing Med Univ, Clin Lab, Yongchuan Hosp, Chongqing, Peoples R China.; Liu, BZ (corresponding author), Chongqing Med Univ, Dept Lab Med, Key Lab Lab Med Diagnost, Minist Educ, Chongqing, Peoples R China.; Liu, ZQ (corresponding author), Tianjin Med Univ, Prov & Minist Cosponsored Collaborat Innovat Ctr, Tianjin Key Lab Cellular Homeostasis & Human Dis, Dept Physiol & Pathophysiol,Sch Basic Med Sci, Tianjin, Peoples R China.; Liu, ZQ (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Tianjin Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.	liubeizhong@cqmu.edu.cn; zhiqiangliu@tmu.edu.cn	WANG, JINGYI/GSJ-1241-2022; wang, jing/GRS-7509-2022; Liu, Zhiqiang/E-6950-2014; Wang, Jin/GYA-2019-2022; wang, jing/GVT-8700-2022	Liu, Zhiqiang/0000-0002-0677-8097; Liu, Jing/0000-0002-2112-2416	National Natural Science Foundation of China [81670201, 81870161, 82070221, 81900215, 81772280]; Natural Science Foundation of Tianjin [16JCYBJC42600]; Natural Science Foundation of Beijing [7162067]; Talent Project of Tianjin Medical University [11601501/2016KJ0317]; College Student Innovation Program of Tianjin Medical University [201810062011]; Development Program of Yongchuan Hospital of Chongqing Medical University [YJJC201706]; Innovation Project of Postgraduate Program of Yongchuan Hospital of Chongqing Medical University [YJSCX201901]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin); Natural Science Foundation of Beijing(Beijing Natural Science Foundation); Talent Project of Tianjin Medical University; College Student Innovation Program of Tianjin Medical University; Development Program of Yongchuan Hospital of Chongqing Medical University; Innovation Project of Postgraduate Program of Yongchuan Hospital of Chongqing Medical University	This work was supported by the National Natural Science Foundation of China (81670201, 81870161, 82070221, ZL; 81900215, Jingya W; 81772280, BL), the Natural Science Foundation of Tianjin (16JCYBJC42600, ZL), the Natural Science Foundation of Beijing (7162067, ZP), the Talent Project of Tianjin Medical University (11601501/2016KJ0317, ZL), the College Student Innovation Program of Tianjin Medical University (201810062011, XL), the Development Program of Yongchuan Hospital of Chongqing Medical University (YJJC201706, Yinyin X), and the Innovation Project of Postgraduate Program of Yongchuan Hospital of Chongqing Medical University (YJSCX201901, Yinyin X).	Abe Masahiro, 2019, Clin Calcium, V29, P349, DOI 10.20837/4201903349; Adamik J, 2019, JBMR, V3; Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Bhaskar Archana, 2016, Int J Adv Res (Indore), V4, P706; Borsi E, 2015, TRANSL RES, V165, P641, DOI 10.1016/j.trsl.2014.12.001; Charan Jaykaran, 2013, Indian J Psychol Med, V35, P121, DOI 10.4103/0253-7176.116232; Colla S, 2007, BLOOD, V109, P4470, DOI 10.1182/blood-2006-11-056747; Craig JC, 2001, J BIOL CHEM, V276, P11719, DOI 10.1074/jbc.M010263200; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Eda Homare, 2016, Cancer Treat Res, V169, P251; Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood-2008-11-191577; Garces JJ, 2020, LEUKEMIA, V34, P589, DOI 10.1038/s41375-019-0588-4; Guo KT, 2014, J CANCER RES CLIN, V140, P1261, DOI 10.1007/s00432-014-1642-2; He J, 2012, CANCER RES, V72, P6393, DOI 10.1158/0008-5472.CAN-12-2664; Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104; Intini G, 2015, BONE, V75, P151, DOI 10.1016/j.bone.2015.01.008; Liu H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8949; Liu ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085571; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; Muz B, 2019, HAEMATOLOGICA, V104, DOI 10.3324/haematol.2018.194688; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Pozzi S, 2013, BONE, V53, P487, DOI 10.1016/j.bone.2013.01.012; Qian JF, 2007, BLOOD, V110, P1587, DOI 10.1182/blood-2007-03-082529; Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood-2008-01-132134; Rajkumar SV, 2020, AM J HEMATOL, V95, P548, DOI 10.1002/ajh.25791; Richardson PG, 2010, BLOOD, V116, P679, DOI 10.1182/blood-2010-02-268862; Schoenhals M, 2017, CELL CYCLE, V16, P1104, DOI 10.1080/15384101.2017.1317408; Silvestris F, 2004, BRIT J HAEMATOL, V126, P475, DOI 10.1111/j.1365-2141.2004.05084.x; Storti P, 2013, LEUKEMIA, V27, P1697, DOI 10.1038/leu.2013.24; Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-017-0037-4; Tosi P, 2008, EUR J HAEMATOL, V80, P31, DOI 10.1111/j.1600-0609.2007.00974.x; van Andel H, 2019, LEUKEMIA, V33, P1063, DOI 10.1038/s41375-019-0404-1; Wang H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040955; Wu C, 2018, CANCER MED-US, V7, P3899, DOI 10.1002/cam4.1596; Xie Y, 2020, ONCOGENE, V39, P922, DOI 10.1038/s41388-019-1037-6; Xie ZG, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/636514; Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood-2006-09-047712; Yang P, 2012, MOL CELL BIOL, V32, P3121, DOI 10.1128/MCB.00204-12; Zhou FL, 2013, BLOOD REV, V27, P261, DOI 10.1016/j.blre.2013.08.002; Zhu HL, 2016, SCI REP-UK, V6, DOI 10.1038/srep26859	40	10	11	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1231	1241		10.1038/s41388-020-01590-8	http://dx.doi.org/10.1038/s41388-020-01590-8		JAN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420361	hybrid, Green Published			2022-12-28	WOS:000607346000018
J	Poorebrahim, M; Melief, J; de Coana, YP; Wickstrom, SL; Cid-Arregui, A; Kiessling, R				Poorebrahim, Mansour; Melief, Jeroen; Pico de Coana, Yago; Wickstrom, Stina L.; Cid-Arregui, Angel; Kiessling, Rolf			Counteracting CAR T cell dysfunction	ONCOGENE			English	Review							ARYL-HYDROCARBON RECEPTOR; INHIBITORY RECEPTORS; 4-1BB COSTIMULATION; ANTITUMOR EFFICACY; EFFECTOR FUNCTIONS; TUMOR STROMA; LIFE-SPAN; EXHAUSTION; SENESCENCE; PD-1	In spite of high rates of complete remission following chimeric antigen receptor (CAR) T cell therapy, the efficacy of this approach is limited by generation of dysfunctional CAR T cells in vivo, conceivably induced by immunosuppressive tumor microenvironment (TME) and excessive antigen exposure. Exhaustion and senescence are two critical dysfunctional states that impose a pivotal hurdle for successful CAR T cell therapies. Recently, modified CAR T cells with an "exhaustion-resistant" phenotype have shown superior antitumor functions and prolonged lifespan. In addition, several studies have indicated the feasibility of senescence delay in CAR T cells. Here, we review the latest reports regarding blockade of CAR T cell exhaustion and senescence with a particular focus on the exhaustion-inducing pathways. Subsequently, we describe what potential these latest insights offer for boosting the potency of adoptive cell transfer (ACT) therapies involving CAR T cells. Furthermore, we discuss how induction of costimulation, cytokine exposure, and TME modulation can impact on CAR T cell efficacy and persistence, while potential safety issues associated with reinvigorated CAR T cells will also be addressed.	[Poorebrahim, Mansour; Melief, Jeroen; Pico de Coana, Yago; Wickstrom, Stina L.; Kiessling, Rolf] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Poorebrahim, Mansour; Cid-Arregui, Angel] German Canc Res Ctr, Targeted Tumor Vaccines Grp, Clin Cooperat Unit Appl Tumor Immun, Heidelberg, Germany	Karolinska Institutet; Helmholtz Association; German Cancer Research Center (DKFZ)	Poorebrahim, M; Kiessling, R (corresponding author), Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.; Poorebrahim, M (corresponding author), German Canc Res Ctr, Targeted Tumor Vaccines Grp, Clin Cooperat Unit Appl Tumor Immun, Heidelberg, Germany.	mansour.poorebrahim@dkfz-heidelberg.de; rolf.kiessling@ki.se	Wickström, Stina L/AAJ-2194-2020; Cid-Arregui, Angel/ABC-5812-2021; Poorebrahim, Mansour/AAP-4133-2021; Pico de Coana, Yago/E-2102-2018	Cid-Arregui, Angel/0000-0003-1433-2922; Pico de Coana, Yago/0000-0002-5362-8761; Wickstrom, Stina/0000-0003-0349-4918; Kiessling, Rolf/0000-0003-0663-5763	Swedish Cancer Society [CAN2016/315]	Swedish Cancer Society(Swedish Cancer Society)	MP was supported by a postdoctoral fellowship from Rolf Kiessling's project grant from the Swedish Cancer Society (CAN2016/315). He is now an Alexander von Humboldt fellow. ACA gratefully acknowledges Prof. Harald zur Hausen for his continuous scientific support and encouragement.	Abu Eid R, 2017, CANCER RES, V77, P4135, DOI 10.1158/0008-5472.CAN-16-1925; Akbar AN, 2011, NAT REV IMMUNOL, V11, P289, DOI 10.1038/nri2959; Alizadeh D, 2019, CANCER IMMUNOL RES, V7, P759, DOI 10.1158/2326-6066.CIR-18-0466; Allard B, 2017, IMMUNOL REV, V276, P121, DOI 10.1111/imr.12528; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Bae J, 2014, J IMMUNOL, V193, P3101, DOI 10.4049/jimmunol.1401025; Bai Y, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.40; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Batra SA, 2020, CANCER IMMUNOL RES, V8, P309, DOI 10.1158/2326-6066.CIR-19-0293; Beavis PA, 2017, J CLIN INVEST, V127, P929, DOI 10.1172/JCI89455; Beltra JC, 2020, IMMUNITY, V52, P825, DOI 10.1016/j.immuni.2020.04.014; Bengsch B, 2016, IMMUNITY, V45, P358, DOI 10.1016/j.immuni.2016.07.008; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; Blagosklonny MV, 2012, AGING-US, V4, P159, DOI 10.18632/aging.100443; Bonifant CL, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.11; Bowers JS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01221; Boyerinas B, 2017, BLOOD, V130; Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103; Cassetta L, 2018, IMMUNOLOGY, V155, P285, DOI 10.1111/imm.12976; Cham CM, 2008, EUR J IMMUNOL, V38, P2438, DOI 10.1002/eji.200838289; Chen J, 2019, NATURE, V567, P530, DOI 10.1038/s41586-019-0985-x; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cherkassky L, 2016, J CLIN INVEST, V126, P3130, DOI 10.1172/JCI83092; Chmielewski M, 2017, CELL REP, V21, P3205, DOI 10.1016/j.celrep.2017.11.063; Chong EA, 2017, BLOOD, V129, P1039, DOI 10.1182/blood-2016-09-738245; Cui J, 2020, CANCERS, V12, DOI 10.3390/cancers12010139; Davis T, 2007, BIOORG MED CHEM LETT, V17, P6832, DOI 10.1016/j.bmcl.2007.10.036; Garrod KR, 2012, CELL REP, V2, P1438, DOI 10.1016/j.celrep.2012.10.015; Gomes-Silva D, 2017, CELL REP, V21, P17, DOI 10.1016/j.celrep.2017.09.015; Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005; Guedan S, 2020, J CLIN INVESTIG; Guedan S, 2018, JCI INSIGHT, V11; Guedan S, 2014, BLOOD, V124, P1070, DOI 10.1182/blood-2013-10-535245; Hartley J, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1064; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Hoogi S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0721-y; Hu BL, 2017, CELL REP, V20, P3025, DOI 10.1016/j.celrep.2017.09.002; Huang BZ, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2019.1684127; Hui EF, 2017, SCIENCE, V355, P1428, DOI 10.1126/science.aaf1292; Jia B, 2019, CANCER RES, V79, P1635, DOI 10.1158/0008-5472.CAN-18-3107; John LB, 2013, CLIN CANCER RES, V19, P5636, DOI 10.1158/1078-0432.CCR-13-0458; Katz SC, 2016, CANCER GENE THER, V23, P142, DOI 10.1038/cgt.2016.14; Kerkar SP, 2013, MOL THER, V21, P1369, DOI 10.1038/mt.2013.58; Kerkar SP, 2011, J CLIN INVEST, V121, P4746, DOI 10.1172/JCI58814; Khan O, 2019, NATURE, V571, P211, DOI 10.1038/s41586-019-1325-x; Kim EH, 2012, J IMMUNOL, V188, P4305, DOI 10.4049/jimmunol.1103568; Klebanoff CA, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95103; Kloss CC, 2018, MOL THER, V26, P1855, DOI 10.1016/j.ymthe.2018.05.003; Kong KF, 2011, NAT IMMUNOL, V12, P1105, DOI 10.1038/ni.2120; LaFleur MW, 2019, NAT IMMUNOL, V20, P1335, DOI 10.1038/s41590-019-0480-4; Leclerc M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11280-z; Leone RD, 2020, NAT REV CANCER, V20, P516, DOI 10.1038/s41568-020-0273-y; Leontieva OV, 2010, AGING-US, V2, P924, DOI 10.18632/aging.100265; Li GB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121322; Li JJ, 2018, FRONT NEUROL, V9, P1, DOI 10.3389/fneur.2018.00623; Ligtenberg MA, 2018, MOL THER, V26, P1482, DOI 10.1016/j.ymthe.2018.04.015; Ligtenberg MA, 2016, J IMMUNOL, V196, P759, DOI 10.4049/jimmunol.1401710; Lim AR, 2020, ELIFE, V9, DOI 10.7554/eLife.55185; Liu X, 2020, J CLIN INVEST, V130, P1073, DOI 10.1172/JCI133679; Liu XD, 2019, NATURE, V567, P525, DOI 10.1038/s41586-019-0979-8; Loffek S, 2018, J ONCOL, V2018, DOI 10.1155/2018/9732939; Long AH, 2016, CANCER IMMUNOL RES, V4, P869, DOI 10.1158/2326-6066.CIR-15-0230; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Luiten RM, 2003, BLOOD, V101, P4512, DOI 10.1182/blood-2002-07-2018; Lynn RC, 2019, NATURE, V576, P293, DOI 10.1038/s41586-019-1805-z; Man K, 2017, IMMUNITY, V47, P1129, DOI 10.1016/j.immuni.2017.11.021; Marro BS, 2019, CELL REP, V29, P3293, DOI 10.1016/j.celrep.2019.10.119; Martinez M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00128; Masoumi E, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01546-6; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; McKinney EF, 2018, NAT IMMUNOL, V19, P213, DOI 10.1038/s41590-018-0045-y; Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670; Moon E, 2017, AACR, V77, P13; Newick K, 2016, CANCER IMMUNOL RES, V4, P541, DOI 10.1158/2326-6066.CIR-15-0263; Ninomiya S, 2015, BLOOD, V125, P3905, DOI 10.1182/blood-2015-01-621474; Odorizzi PM, 2015, J EXP MED, V212, P1125, DOI 10.1084/jem.20142237; Parihar R, 2019, CANCER IMMUNOL RES, V7, P363, DOI 10.1158/2326-6066.CIR-18-0572; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Pegram HJ, 2012, BLOOD, V119, P4133, DOI 10.1182/blood-2011-12-400044; Petersen C, 2019, NEURO-ONCOLOGY, V21, P95, DOI 10.1093/neuonc/noz036.134; Philipson BI, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay8248; Poorebrahim M, 2020, PHARMACOL THERAPEUT, V214, DOI 10.1016/j.pharmthera.2020.107603; Poorebrahim M, 2019, CRIT REV CL LAB SCI, V56, P393, DOI 10.1080/10408363.2019.1633512; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Rafiq S, 2018, NAT BIOTECHNOL, V36, P847, DOI 10.1038/nbt.4195; Rao RR, 2012, IMMUNITY, V36, P374, DOI 10.1016/j.immuni.2012.01.015; Ravishankar B, 2015, P NATL ACAD SCI USA, V112, P10774, DOI 10.1073/pnas.1504276112; Ren JT, 2017, ONCOTARGET, V8, P17002, DOI 10.18632/oncotarget.15218; Rota G, 2018, CELL REP, V23, P39, DOI 10.1016/j.celrep.2018.03.026; Roth A, 2003, BLOOD, V102, P849, DOI 10.1182/blood-2002-07-2015; Rupp LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00462-8; Sacchetti B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081903; Scharping NE, 2016, IMMUNITY, V45, P374, DOI [10.1016/j.immuni.2016.07.009, 10.1016/j.immuni.2016.08.009]; Schorer M, 2020, NAT COMMUN, V11, P1; Seo H, 2019, P NATL ACAD SCI USA, V116, P12410, DOI 10.1073/pnas.1905675116; Shah NN, 2019, NAT REV CLIN ONCOL, V16, P372, DOI 10.1038/s41571-019-0184-6; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3; Singh H, 2011, CANCER RES, V71, P3516, DOI 10.1158/0008-5472.CAN-10-3843; Song YZ, 2018, AGING CELL, V17, DOI 10.1111/acel.12716; Staron MM, 2014, IMMUNITY, V41, P802, DOI 10.1016/j.immuni.2014.10.013; Suarez ER, 2016, ONCOTARGET, V7, P34341, DOI 10.18632/oncotarget.9114; Sun C, 2020, CANCER CELL, V37, P216, DOI 10.1016/j.ccell.2019.12.014; Tang N, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133977; Tanoue K, 2017, CANCER RES, V77, P2040, DOI 10.1158/0008-5472.CAN-16-1577; van der Stegen SJC, 2015, NAT REV DRUG DISCOV, V14, P499, DOI 10.1038/nrd4597; Wang J, 2019, CELL, V176, P334, DOI 10.1016/j.cell.2018.11.010; Wang LCS, 2014, CANCER IMMUNOL RES, V2, P154, DOI 10.1158/2326-6066.CIR-13-0027; Wang XC, 2019, J HEPATOL, V71, P731, DOI 10.1016/j.jhep.2019.05.015; Warrington KJ, 2003, BLOOD, V101, P3543, DOI 10.1182/blood-2002-08-2574; Wei P, 2014, LAB INVEST, V94, P528, DOI 10.1038/labinvest.2014.8; Wentink MWJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00446; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wiede F, 2020, EMBO J, V39, DOI 10.15252/embj.2019103637; Wilkinson B, 2002, NAT IMMUNOL, V3, P272, DOI 10.1038/ni767; Xie YJ, 2019, P NATL ACAD SCI USA, V116, P7624, DOI 10.1073/pnas.1817147116; Xu Y, 2014, BLOOD, V123, P3750, DOI 10.1182/blood-2014-01-552174; Yazdanifar M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091070; Ye BX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0814-0; Yin YB, 2018, MOL THER-ONCOLYTICS, V11, P20, DOI 10.1016/j.omto.2018.08.002; Yokosuka T, 2012, J EXP MED, V209, P1201, DOI 10.1084/jem.20112741; Yoo HJ, 2019, INT J MOL SCI, V18, P2469; Young A, 2016, CANCER CELL, V30, P391, DOI 10.1016/j.ccell.2016.06.025; Yu SN, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1057-4; Zeng Sulin, 2018, Cancer Transl Med, V4, P70, DOI 10.4103/ctm.ctm_22_18; Zhang P, 2018, IMMUNOTHERAPY-UK, V10, P935, DOI 10.2217/imt-2018-0012; Zhao YJ, 2020, CELL MOL IMMUNOL, V17, P27, DOI 10.1038/s41423-019-0344-8; Zheng WT, 2018, LEUKEMIA, V32, P1157, DOI 10.1038/s41375-017-0008-6; Zhou JX, 2019, PROTEIN CELL, V10, P764, DOI 10.1007/s13238-019-0643-y; Zou F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11893-4	135	38	38	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					421	435		10.1038/s41388-020-01501-x	http://dx.doi.org/10.1038/s41388-020-01501-x		NOV 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33168929	Green Published, hybrid			2022-12-28	WOS:000587997700002
J	Jin, Y; Zhou, Y; Deng, WF; Wang, YC; Lee, RJ; Liu, YN; Elias, N; Hu, YC; Luo, MH; Liu, RM; Guan, BW; Geng, J; Xu, J; Ma, JF; Zhou, JP; Liu, N; Blute, ML; Colvin, RB; Wu, CL; Miao, Y				Jin, Yu; Zhou, Yi; Deng, Wenfeng; Wang, Yuchen; Lee, Richard J.; Liu, Yanna; Elias, Nahel; Hu, Yangcheng; Luo, Min-Hua; Liu, Rumin; Guan, Bowen; Geng, Jian; Xu, Jian; Ma, Junfeng; Zhou, Jiapeng; Liu, Na; Blute, Michael L.; Colvin, Robert B.; Wu, Chin-Lee; Miao, Yun			Genome-wide profiling of BK polyomavirus integration in bladder cancer of kidney transplant recipients reveals mechanisms of the integration at the nucleotide level	ONCOGENE			English	Article							INFECTION; VIRUS; MICROHOMOLOGY; REPLICATION; BLOOD	Chronic BK polyomavirus (BKPyV) infection is recognized as a potential oncogenic factor of urothelial carcinoma (UC) in renal transplant recipients. Recent studies have reported a positive correlation among BKPyV integration, persistent overexpression of viral large T antigen (TAg), and malignancy, yet little is known about the specific integration mechanisms and the impacts of viral integration. Here, we performed whole-genome sequencing (WGS) and viral capture-based sequencing on high-grade immunohistochemically TAg-positive UCs in two renal transplant recipients. A total of 181 integration sites, including the three found by WGS, were identified by viral capture-based sequencing, indicating its enhanced sensitivity and ability in identifying low-read integration sites in subpopulations of the tumor cells. The microhomologies between human and BKPyV genomes were significantly enriched in the flanking regions of 84.5% the integration sites, with a median length of 7 bp. Notably, 75 human genes formed fusion sequences due to viral insertional integration. Among them, the expression of 15 genes were statistically associated with UC based on GEO2R expression analysis. Our results indicated a multisite and multifragment linear integration pattern and a potential microhomology or nonhomologous end joining integration mechanism at the single-nucleotide level. We put forward a potential selection mechanism driven by immunity and centered on viral integration in the carcinogenesis of BKPyV.	[Jin, Yu; Zhou, Yi; Deng, Wenfeng; Wang, Yuchen; Liu, Yanna; Hu, Yangcheng; Liu, Rumin; Guan, Bowen; Geng, Jian; Xu, Jian; Miao, Yun] Southern Med Univ, Nanfang Hosp, Div Transplantat, Guangzhou, Peoples R China; [Lee, Richard J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA; [Elias, Nahel] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA; [Luo, Min-Hua] Wuhan Inst Virol, State Key Lab Virol, CAS Ctr Excellence Brain Sci & Intelligence Techn, Wuhan, Peoples R China; [Ma, Junfeng; Zhou, Jiapeng; Liu, Na] Mygenostics Co, Beijing, Peoples R China; [Blute, Michael L.; Wu, Chin-Lee] Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA 02115 USA; [Colvin, Robert B.; Wu, Chin-Lee] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA	Southern Medical University - China; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Chinese Academy of Sciences; Wuhan Institute of Virology, CAS; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Miao, Y (corresponding author), Southern Med Univ, Nanfang Hosp, Div Transplantat, Guangzhou, Peoples R China.; Wu, CL (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA 02115 USA.; Wu, CL (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA.	cwu2@mgh.harvard.edu; miaoyunecho@126.com		Elias, Nahel/0000-0001-6466-7347	National Natural Science Foundation of China [81500573]; Science Foundation of Guangdong Province [2020A1515010674]; Science and Technology Planning Project of Guangzhou [201803010109]; President Funding of Nanfang Hospital [2018B009, 2018C003]; College Students' Innovative Entrepreneurial Training Plan Program [201812121148, X202012121239, 202012121046]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Planning Project of Guangzhou; President Funding of Nanfang Hospital; College Students' Innovative Entrepreneurial Training Plan Program	This work was funded by the National Natural Science Foundation of China (81500573), the Science Foundation of Guangdong Province (2020A1515010674), the Science and Technology Planning Project of Guangzhou (201803010109), the President Funding of Nanfang Hospital (2018B009, 2018C003) and College Students' Innovative Entrepreneurial Training Plan Program (201812121148, X202012121239, 202012121046).	Awan AA, 2018, AM J NEPHROL, V48, P472, DOI 10.1159/000495081; Billups K, 2015, PROG TRANSPLANT, V25, P182, DOI 10.7182/pit2015826; Cangemi M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00160; Chang HHY, 2017, NAT REV MOL CELL BIO, V18, P495, DOI 10.1038/nrm.2017.48; Egli A, 2009, J INFECT DIS, V199, P837, DOI 10.1086/597126; Elfadawy N, 2018, INFECT DIS CLIN N AM, V32, P599, DOI 10.1016/j.idc.2018.04.009; Fu FX, 2018, CLIN SCI, V132, P1753, DOI 10.1042/CS20180443; Groves IJ, 2018, J PATHOL, V245, P9, DOI 10.1002/path.5058; Gupta G, 2018, AM J TRANSPLANT, V18, P245, DOI 10.1111/ajt.14530; Hesbacher S, 2016, ONCOTARGET, V7, P32956, DOI 10.18632/oncotarget.8793; Houben R, 2015, INT J CANCER, V136, pE290, DOI 10.1002/ijc.29200; Hu Z, 2015, NAT GENET, V47, P158, DOI 10.1038/ng.3178; Kean JM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000363; Kenan DJ, 2017, AM J TRANSPLANT, V17, P1674, DOI 10.1111/ajt.14191; Kenan DJ, 2015, J PATHOL, V237, P379, DOI 10.1002/path.4584; Lee YJ, 2014, BIOL BLOOD MARROW TR, V20, P1204, DOI 10.1016/j.bbmt.2014.04.017; Li WY, 2013, GENOMICS, V102, P338, DOI 10.1016/j.ygeno.2013.07.002; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; McCabe M, 2006, ONCOGENE, V25, P2727, DOI 10.1038/sj.onc.1209266; Michel Ortega Rosa M, 2016, J Immunother Cancer, V4, P63; Morrical SW, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016444; Muller DC, 2018, J PATHOL, V244, P265, DOI 10.1002/path.5012; Nickeleit V, 2018, J PATHOL, V246, P7, DOI 10.1002/path.5127; O'Neill JP, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13669; Ottaviani D, 2014, TRENDS GENET, V30, P85, DOI 10.1016/j.tig.2014.01.001; Papadimitriou JC, 2016, AM J TRANSPLANT, V16, P398, DOI 10.1111/ajt.13550; Pinto M, 2014, J INFECTION, V68, pS2, DOI 10.1016/j.jinf.2013.09.009; Roberts ISD, 2008, BRIT J CANCER, V99, P1383, DOI 10.1038/sj.bjc.6604711; Rosales BM, 2020, INT J CANCER, V146, P2703, DOI 10.1002/ijc.32585; Saribas AS, 2016, J CELL PHYSIOL, V231, P2115, DOI 10.1002/jcp.25329; Sirohi D, 2018, MODERN PATHOL, V31, P1429, DOI 10.1038/s41379-018-0065-z; Starrett GJ, 2019, CURR OPIN VIROL, V39, P8, DOI 10.1016/j.coviro.2019.06.009; Trofe-Clark J, 2016, SEMIN NEPHROL, V36, P372, DOI 10.1016/j.semnephrol.2016.05.014; Wang YC, 2020, ONCOGENE, V39, P5734, DOI 10.1038/s41388-020-01398-6; Yi K, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0112-3; Zhang F, 2009, NAT GENET, V41, P849, DOI 10.1038/ng.399; Zhou XS, 2015, MOL MED REP, V11, P910, DOI 10.3892/mmr.2014.2861	37	3	4	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					46	54		10.1038/s41388-020-01502-w	http://dx.doi.org/10.1038/s41388-020-01502-w		OCT 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33051598				2022-12-28	WOS:000577556100003
J	Feng, HR; Jin, ZJ; Liang, JY; Zhao, QW; Zhan, L; Yang, ZY; Yan, JQ; Kuang, J; Cheng, X; Qiu, WH				Feng, Haoran; Jin, Zhijian; Liang, Juyong; Zhao, Qiwu; Zhan, Ling; Yang, Zheyu; Yan, Jiqi; Kuang, Jie; Cheng, Xi; Qiu, Weihua			FOXK2 transcriptionally activating VEGFA induces apatinib resistance in anaplastic thyroid cancer through VEGFA/VEGFR1 pathway	ONCOGENE			English	Article							COLORECTAL-CANCER; HEPATOCELLULAR-CARCINOMA; TYROSINE KINASE; INHIBITOR; CELLS; SUPPRESSES; EXPRESSION; PROGNOSIS; GROWTH	Anaplastic thyroid carcinoma (ATC) is a rare and extremely aggressive type of thyroid cancer, and the potential mechanisms involved in ATC progression remains unclarified. In this study, we found that forkhead box K2 (FOXK2) was upregulated in ATC tissues, and the expression of FOXK2 was associated with tumor size. Evidenced by RNA-seq and Chromatin immunoprecipitation (ChIP)-seq assays, FOXK2 positively regulated VEGF and VEGFR signaling network, among which only VEGFA could be noticed in both RNA-seq and ChIP-seq results. ChIP, dual-luciferase reporter system and functional experiments further confirmed that FOXK2 promoted angiogenesis by inducing the transcription of VEGFA. On VEGFR2 blockage by specific targeting agent, such as Apatinib, FOXK2 could rapidly trigger therapeutic resistance. Mechanical analyses revealed that VEGFA transcriptionally induced by FOXK2 could bind to VEGFR1 as a compensation for VEGFR2 blockage, which promoted angiogenesis by activating ERK, PI3K/AKT and P38/MAPK signaling in human umbilical vein endothelial cells (HUVECs). Synergic effect on anti-angiogenesis could be observed when VEGFR1 suppressor AF321 was included in VEGFR2 inhibition system, which clarified the pivot role of FOXK2 in VEGFR2 targeting therapy resistance. More importantly, the binding of VEGFA to VEGFR1 could further promoter FOXK2-mediated VEGFA transcription, which consequently constituted a positive feedback loop. Therefore, the novel loop VEGFA/VEGFR1/FOXK2 functioned importantly in resistance to VEGFR2 targeting therapy in FOXK2(+) ATCs. Altogether, FOXK2 plays critical roles in ATC angiogenesis and VEGFR2 blockage resistance by inducing VEGFA transcription. FOXK2 represents a potentially new therapeutic strategy and biomarker for anti-angiogenic therapy against ATC.	[Feng, Haoran; Jin, Zhijian; Liang, Juyong; Zhao, Qiwu; Zhan, Ling; Yang, Zheyu; Yan, Jiqi; Kuang, Jie; Cheng, Xi; Qiu, Weihua] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Feng, Haoran] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai Inst Digest Surg, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Kuang, J; Cheng, X; Qiu, WH (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gen Surg, Shanghai, Peoples R China.	kuangjie823@msn.com; drchengxi@126.com; qwh11072@rjh.com.cn			National Natural Science Foundation of China [82072948, 82003169, 82002475]; Shanghai Sailing Program [20YF1427700]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Sailing Program	The study was supported by the National Natural Science Foundation of China, 82072948 (WQ); National Natural Science Foundation of China, 82003169 (HF); National Natural Science Foundation of China, 82002475 (XC) and Shanghai Sailing Program, 20YF1427700 (XC).	Abbey CA, 2014, MATRIX BIOL, V38, P36, DOI 10.1016/j.matbio.2014.06.006; Bayless KJ, 2009, NAT PROTOC, V4, P1888, DOI 10.1038/nprot.2009.221; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; de Moraes GN, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.26; de Moraes GN, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0038-6; de Moraes GN, 2019, CANCERS, V11, DOI 10.3390/cancers11030393; Du F, 2019, THERANOSTICS, V9, P3879, DOI 10.7150/thno.31716; El Atat O, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020171; Fang ZJ, 2018, CANCER LETT, V415, P58, DOI 10.1016/j.canlet.2017.11.040; Feng HR, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1054-3; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Guo Y, 2016, BIOTECHNOL LETT, V38, P893, DOI 10.1007/s10529-016-2046-y; Hu XC, 2014, INT J CANCER, V135, P1961, DOI 10.1002/ijc.28829; Jin ZJ, 2017, CELL PHYSIOL BIOCHEM, V44, P1471, DOI 10.1159/000485583; Kebebew E, 2005, CANCER-AM CANCER SOC, V103, P1330, DOI 10.1002/cncr.20936; Lin MF, 2017, INT J BIOCHEM CELL B, V88, P155, DOI 10.1016/j.biocel.2017.05.019; Liu MT, 2019, THORAC CANCER, V10, P1868, DOI 10.1111/1759-7714.13162; Liu Y, 2019, CANCER LETT, V458, P1, DOI 10.1016/j.canlet.2019.05.030; Mesange P, 2014, ONCOTARGET, V5, P4709, DOI 10.18632/oncotarget.1671; Molinaro E, 2017, NAT REV ENDOCRINOL, V13, P644, DOI 10.1038/nrendo.2017.76; National Institute of Statistics, 2018, CA-CANCER J CLIN; Nowak-Sliwinska P, 2018, ANGIOGENESIS, V21, P425, DOI 10.1007/s10456-018-9613-x; Qian Y, 2017, BIOCHEM BIOPH RES CO, V483, P475, DOI 10.1016/j.bbrc.2016.12.119; Rajabi S, 2019, ENDOCR J, V66, P277, DOI 10.1507/endocrj.EJ18-0537; Ramos-Vara JA, 2005, VET PATHOL, V42, P405, DOI 10.1354/vp.42-4-405; Roviello G, 2016, CANCER LETT, V372, P187, DOI 10.1016/j.canlet.2016.01.014; Scott LJ, 2018, DRUGS, V78, P747, DOI 10.1007/s40265-018-0903-9; Shan L, 2016, CANCER CELL, V30, P708, DOI 10.1016/j.ccell.2016.09.010; Shi ZY, 2016, ANN SURG ONCOL, V23, P211, DOI 10.1245/s10434-015-4515-2; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Smallridge RC, 2010, CLIN ONCOL-UK, V22, P486, DOI 10.1016/j.clon.2010.03.013; Sun TT, 2016, JPN J CLIN ONCOL, V46, P209, DOI 10.1093/jjco/hyv185; Taylor SC, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/361590; Tian S, 2011, CANCER SCI, V102, P1374, DOI 10.1111/j.1349-7006.2011.01939.x; Wang DN, 2019, J DIABETES COMPLICAT, V33, P374, DOI 10.1016/j.jdiacomp.2019.02.001; Wang SY, 2018, CANCER LETT, V439, P78, DOI 10.1016/j.canlet.2018.09.026; Wu L, 2017, IRAN J BASIC MED SCI, V20, P990, DOI 10.22038/IJBMS.2017.9263; Xu ZQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1010-2; Xue JM, 2018, ONCOTARGETS THER, V11, P6119, DOI 10.2147/OTT.S172717; Zadeh MAH, 2015, MOL ONCOL, V9, P167, DOI 10.1016/j.molonc.2014.07.017; Zhang F, 2018, INT J CANCER, V142, P2543, DOI 10.1002/ijc.31278; Zhang X, 2018, J CLIN ENDOCR METAB, V103, P3640, DOI 10.1210/jc.2018-00381	42	3	3	5	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6115	6129		10.1038/s41388-021-01830-5	http://dx.doi.org/10.1038/s41388-021-01830-5		SEP 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34489549				2022-12-28	WOS:000692963000002
J	Magrin, L; Fanale, D; Brando, C; Fiorino, A; Corsini, LR; Sciacchitano, R; Filorizzo, C; Dimino, A; Russo, A; Bazan, V				Magrin, Luigi; Fanale, Daniele; Brando, Chiara; Fiorino, Alessia; Corsini, Lidia Rita; Sciacchitano, Roberta; Filorizzo, Clarissa; Dimino, Alessandra; Russo, Antonio; Bazan, Viviana			POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes	ONCOGENE			English	Review							PROOFREADING DOMAIN MUTATIONS; FAMILIAL COLORECTAL-CANCER; LYNCH-SYNDROME; GERMLINE MUTATIONS; MISMATCH-REPAIR; DNA-POLYMERASE; ADENOMATOUS POLYPOSIS; PATHOGENIC VARIANTS; PD-1 BLOCKADE; GUIDELINES	POLE, POLD1, and NTHL1 are involved in DNA replication and have recently been recognized as hereditary cancer-predisposing genes, because their alterations are associated with colorectal cancer and other tumors. POLE/POLD1-associated syndrome shows an autosomal dominant inheritance, whereas NTHL1-associated syndrome follows an autosomal recessive pattern. Although the prevalence of germline monoallelic POLE/POLD1 and biallelic NTHL1 pathogenic variants is low, they determine different phenotypes with a broad tumor spectrum overlapping that of other hereditary conditions like Lynch Syndrome or Familial Adenomatous Polyposis. Endometrial and breast cancers, and probably ovarian and brain tumors are also associated with POLE/POLD1 alterations, while breast cancer and other unusual tumors are correlated with NTHL1 pathogenic variants. POLE-mutated colorectal and endometrial cancers are associated with better prognosis and may show favorable responses to immunotherapy. Since POLE/POLD1-mutated tumors show a high tumor mutational burden producing an increase in neoantigens, the identification of POLE/POLD1 alterations could help select patients suitable for immunotherapy treatment. In this review, we will investigate the role of POLE, POLD1, and NTHL1 genetic variants in cancer predisposition, discussing the potential future therapeutic applications and assessing the utility of performing a routine genetic testing for these genes, in order to implement prevention and surveillance strategies in mutation carriers.	[Magrin, Luigi; Fanale, Daniele; Brando, Chiara; Fiorino, Alessia; Corsini, Lidia Rita; Sciacchitano, Roberta; Filorizzo, Clarissa; Dimino, Alessandra; Russo, Antonio] Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, I-90127 Palermo, Italy; [Bazan, Viviana] Univ Palermo, Dept Biomed Neurosci & Adv Diag, I-90127 Palermo, Italy	University of Palermo; University of Palermo	Russo, A (corresponding author), Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, I-90127 Palermo, Italy.	antonio.russo@usa.net						ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Aoude LG, 2015, FAM CANCER, V14, P621, DOI 10.1007/s10689-015-9826-8; Belhadj S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45281-1; Bellido F, 2016, GENET MED, V18, P325, DOI 10.1038/gim.2015.75; Bourdais R, 2017, CRIT REV ONCOL HEMAT, V113, P242, DOI 10.1016/j.critrevonc.2017.03.027; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Briggs S, 2013, J PATHOL, V230, P148, DOI 10.1002/path.4185; Campbell BB, 2017, CELL, V171, P1042, DOI 10.1016/j.cell.2017.09.048; Chubb D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11883; Church DN, 2013, HUM MOL GENET, V22, P2820, DOI 10.1093/hmg/ddt131; Colas C, 2012, ADV CANCER RES, V113, P121, DOI 10.1016/B978-0-12-394280-7.00004-X; Das L, 2020, DNA REPAIR, V93, DOI 10.1016/j.dnarep.2020.102920; Dhooge M, 2020, EUR J MED GENET, V63, DOI 10.1016/j.ejmg.2020.104080; Djursby M, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.566266; Domingo E, 2016, LANCET GASTROENTEROL, V1, P207, DOI 10.1016/S2468-1253(16)30014-0; Drost J, 2017, SCIENCE, V358, P234, DOI 10.1126/science.aao3130; Elsayed FA, 2020, GASTROENTEROLOGY, V159, DOI 10.1053/j.gastro.2020.08.042; Esteban-Jurado C, 2017, ONCOTARGET, V8, P26732, DOI 10.18632/oncotarget.15810; Fabrizio DA, 2018, J GASTROINTEST ONCOL, V9, P610, DOI 10.21037/jgo.2018.05.06; Fanale D, 2020, CANCERS, V12, DOI 10.3390/cancers12092415; Fancello L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0647-4; Fang H, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008572; Forgo E, 2020, HISTOPATHOLOGY, V76, P366, DOI 10.1111/his.13984; Gao SC, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108833; Gelsomino F, 2016, CANCER TREAT REV, V51, P19, DOI 10.1016/j.ctrv.2016.10.005; Gong J, 2017, J NATL COMPR CANC NE, V15, P142, DOI 10.6004/jnccn.2017.0016; Grolleman JE, 2019, CANCER CELL, V35, P256, DOI 10.1016/j.ccell.2018.12.011; Groves A, 2019, FAM CANCER, V18, P179, DOI 10.1007/s10689-018-0107-1; Hamzaoui N, 2020, GENET MED, V22, P1533, DOI 10.1038/s41436-020-0828-z; Hansen MF, 2015, FAM CANCER, V14, P437, DOI 10.1007/s10689-015-9803-2; Haradhvala NJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04002-4; He JJ, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-7553; He Y, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019281; Hegde M, 2014, GENET MED, V16, P101, DOI 10.1038/gim.2013.166; Hocke S, 2016, ONCOTARGET, V7, P7080, DOI 10.18632/oncotarget.6857; Howitt BE, 2015, JAMA ONCOL, V1, P1319, DOI 10.1001/jamaoncol.2015.2151; Hu HG, 2021, CANCER MED-US, V10, P135, DOI 10.1002/cam4.3579; Imboden S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214318; Jansen AML, 2016, EUR J HUM GENET, V24, P1089, DOI 10.1038/ejhg.2015.252; Job A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76033-1; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Leon-Castillo A, 2020, J PATHOL, V250, P323, DOI 10.1002/path.5372; Lewis KM, 2014, CURR PROB CANCER, V38, P216, DOI 10.1016/j.currproblcancer.2014.10.002; Li, 2019, ABSTRACT 5137 COMPRE, P5137; Li N, 2021, NPJ BREAST CANCER, V7, DOI 10.1038/s41523-021-00255-3; Limpose KL, 2018, NUCLEIC ACIDS RES, V46, P4515, DOI 10.1093/nar/gky162; Lindor NM, 2005, JAMA-J AM MED ASSOC, V293, P1979, DOI 10.1001/jama.293.16.1979; Liu J, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1280; Mao R, 2021, GENET MED, V23, P1807, DOI 10.1038/s41436-021-01207-9; McConechy MK, 2016, CLIN CANCER RES, V22, P2865, DOI 10.1158/1078-0432.CCR-15-2233; Mehnert JM, 2016, J CLIN INVEST, V126, P2334, DOI 10.1172/JCI84940; Mertz TM, 2017, ONCOGENE, V36, P4427, DOI 10.1038/onc.2017.22; Mur P, 2020, GENET MED, V22, P2089, DOI 10.1038/s41436-020-0922-2; Nieuwenhuis MH, 2012, GUT, V61, P734, DOI 10.1136/gut.2010.229104; Nijman SMB, 2011, FEBS LETT, V585, P1, DOI 10.1016/j.febslet.2010.11.024; Palles C, 2022, FAM CANCER, V21, P197, DOI 10.1007/s10689-021-00256-y; Palles C, 2013, NAT GENET, V45, P136, DOI 10.1038/ng.2503; Pilati C, 2017, J PATHOL, V242, P10, DOI 10.1002/path.4880; Pursell ZF, 2007, SCIENCE, V317, P127, DOI 10.1126/science.1144067; Rayner E, 2016, NAT REV CANCER, V16, P71, DOI 10.1038/nrc.2015.12; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rivera B, 2015, NEW ENGL J MED, V373, P1985, DOI 10.1056/NEJMc1506878; Rosner G, 2018, DIS COLON RECTUM, V61, P1073, DOI 10.1097/DCR.0000000000001150; Rousseau B, 2021, NEW ENGL J MED, V384, P1168, DOI 10.1056/NEJMc2031965; Schubert SA, 2020, MUTAGENESIS, V35, P221, DOI 10.1093/mutage/gez027; Short E, 2015, J MED GENET, V52, P791, DOI 10.1136/jmedgenet-2015-103298; Silberman R, 2019, JCO PRECIS ONCOL, V3, P1, DOI 10.1200/PO.18.00214; Siraj AK, 2020, ENDOCR CONNECT, V9, P923, DOI 10.1530/EC-20-0258; Siraj AK, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1368; Siraj AK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1058-9; Spier I, 2015, INT J CANCER, V137, P320, DOI 10.1002/ijc.29396; Stjepanovic N, 2019, ANN ONCOL, V30, P1558, DOI 10.1093/annonc/mdz233; Strickler JH, 2021, CLIN CANCER RES, V27, P1236, DOI 10.1158/1078-0432.CCR-20-3054; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Urso EDL, 2021, DIGEST LIVER DIS, V53, P409, DOI 10.1016/j.dld.2020.11.018; Valle L, 2014, HUM MOL GENET, V23, P3506, DOI 10.1093/hmg/ddu058; Vande Perre P, 2019, FAM CANCER, V18, P173, DOI 10.1007/s10689-018-0102-6; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Wang F, 2019, JAMA ONCOL, V5, P1504, DOI 10.1001/jamaoncol.2019.2963; Weren RDA, 2018, J PATHOL, V244, P135, DOI 10.1002/path.5002; Weren RDA, 2015, NAT GENET, V47, P668, DOI 10.1038/ng.3287; Wong A, 2016, GYNECOL ONCOL, V141, P113, DOI 10.1016/j.ygyno.2015.12.031; Yao JQ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46064-4; Zhao PF, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0738-1	85	14	15	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5893	5901		10.1038/s41388-021-01984-2	http://dx.doi.org/10.1038/s41388-021-01984-2		AUG 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34363023				2022-12-28	WOS:000682519100003
J	Garcia-Dominguez, DJ; Hajji, N; Sanchez-Molina, S; Figuerola-Bou, E; de Pablos, RM; Espinosa-Oliva, AM; Andres-Leon, E; Terron-Camero, LC; Flores-Campos, R; Pascual-Pasto, G; Robles, MJ; Carcaboso, AM; Mora, J; de Alava, E; Hontecillas-Prieto, L; Machado, I; Llombart-Bosch, A; Magagnoli, G; Scotlandi, K				Garcia-Dominguez, Daniel J.; Hajji, Nabil; Sanchez-Molina, Sara; Figuerola-Bou, Elisabet; de Pablos, Rocio M.; Espinosa-Oliva, Ana M.; Andres-Leon, Eduardo; Terron-Camero, Laura Carmen; Flores-Campos, Rocio; Pascual-Pasto, Guillem; Robles, Maria Jose; Carcaboso, Angel M.; Mora, Jaume; de Alava, Enrique; Hontecillas-Prieto, Lourdes; Machado, Isidro; Llombart-Bosch, Antonio; Magagnoli, Giovanna; Scotlandi, Katia			Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma	ONCOGENE			English	Article							HISTONE DEACETYLASE 6; EWS-FLI1; SP1; OVEREXPRESSION; PROLIFERATION; TRANSCRIPTION; COMBINATION; MECHANISMS; REPRESSION; BORTEZOMIB	Ewing sarcoma (EWS) is an aggressive bone and soft tissue tumor of children and young adults in which the principal driver is a fusion gene, EWSR1-FLI1. Although the essential role of EWSR1-FLI1 protein in the regulation of oncogenesis, survival, and tumor progression processes has been described in-depth, little is known about the regulation of chimeric fusion-gene expression. Here, we demonstrate that the active nuclear HDAC6 in EWS modulates the acetylation status of specificity protein 1 (SP1), consequently regulating the SP1/P300 activator complex binding to EWSR1 and EWSR1-FLI1 promoters. Selective inhibition of HDAC6 impairs binding of the activator complex SP1/P300, thereby inducing EWSR1-FLI1 downregulation and significantly reducing its oncogenic functions. In addition, sensitivity of EWS cell lines to HDAC6 inhibition is higher than other tumor or non-tumor cell lines. High expression of HDAC6 in primary EWS tumor samples from patients correlates with a poor prognosis in two independent series accounting 279 patients. Notably, a combination treatment of a selective HDAC6 and doxorubicin (a DNA damage agent used as a standard therapy of EWS patients) dramatically inhibits tumor growth in two EWS murine xenograft models. These results could lead to suitable and promising therapeutic alternatives for patients with EWS.	[Garcia-Dominguez, Daniel J.; de Pablos, Rocio M.; Espinosa-Oliva, Ana M.; Flores-Campos, Rocio; Robles, Maria Jose; de Alava, Enrique; Hontecillas-Prieto, Lourdes] Univ Seville, CIBERONC, Inst Biomed Seville IBiS, Hosp Univ Virgen Rocio,CSIC, Seville, Spain; [Hajji, Nabil] Imperial Coll London, Div Brain Sci, London, England; [Sanchez-Molina, Sara; Figuerola-Bou, Elisabet; Mora, Jaume] Hosp St Joan Deu, Dev Tumour Biol Lab, Barcelona, Spain; [de Pablos, Rocio M.; Espinosa-Oliva, Ana M.] Univ Seville, Fac Pharm, Dept Biochem & Mol Biol, Seville, Spain; [Andres-Leon, Eduardo; Terron-Camero, Laura Carmen] Consejo Super Invest Cient IPBLN CSIC, Bioinformat Unit, Inst Parasitol & Biomed Lopez Neyra, Granada, Spain; [Pascual-Pasto, Guillem; Carcaboso, Angel M.] Hosp St Joan de Deu, Pediat Hematol & Oncol, Inst Recerca St Joan de Deu, Barcelona, Spain; [Robles, Maria Jose; de Alava, Enrique] Univ Seville, CIBERONC, Pathol Unit, Hosp Univ Virgen Rocio,CSIC, Seville, Spain; [Machado, Isidro] Inst Valenciano Oncol, Pathol Dept, Valencia, Spain; [Llombart-Bosch, Antonio] Univ Valencia, Pathol Dept, Valencia, Spain; [Magagnoli, Giovanna] IRCCS Ist Ortoped Rizzoli, Dept Pathol, Bologna, Italy; [Scotlandi, Katia] IRRCS Ist Ortoped Rizzoli, Expt Oncol Lab, Bologna, Italy; [de Alava, Enrique] Univ Seville, Sch Med, Dept Normal & Pathol Cytol & Histol, Seville, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; Imperial College London; University of Barcelona; University of Sevilla; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; Virgen del Rocio University Hospital; Instituto Valenciano De Oncologia; University of Valencia; University of Sevilla	Garcia-Dominguez, DJ; de Alava, E; Hontecillas-Prieto, L (corresponding author), Univ Seville, CIBERONC, Inst Biomed Seville IBiS, Hosp Univ Virgen Rocio,CSIC, Seville, Spain.; Hajji, N (corresponding author), Imperial Coll London, Div Brain Sci, London, England.; de Alava, E (corresponding author), Univ Seville, CIBERONC, Pathol Unit, Hosp Univ Virgen Rocio,CSIC, Seville, Spain.; de Alava, E (corresponding author), Univ Seville, Sch Med, Dept Normal & Pathol Cytol & Histol, Seville, Spain.	dgarcia-ibis@us.es; n.hajji@imperial.ac.uk; enrique.alava.sspa@juntadeandalucia.es; lhontecillas-ibis@us.es	Garcia, Daniel Jose/B-5366-2016; Scotlandi, Katia/J-9009-2016; Andrés-León., Eduardo/K-8944-2014; de Alava, Enrique/GOH-0368-2022; Sanchez-Molina, Sara/B-2148-2017; magagnoli, giovanna/D-1723-2019	Garcia, Daniel Jose/0000-0001-8150-2747; Scotlandi, Katia/0000-0001-6114-9499; Andrés-León., Eduardo/0000-0002-0621-9914; de Alava, Enrique/0000-0001-8400-046X; Sanchez-Molina, Sara/0000-0002-1430-131X; Hajji, Nabil/0000-0002-0695-920X; Pascual-Pasto, Guillem/0000-0001-8537-261X; magagnoli, giovanna/0000-0002-6430-1318; Flores-Campos, Rocio/0000-0002-2563-4136; Carcaboso, Angel/0000-0002-8485-426X; Figuerola-Bou, Elisabet/0000-0002-6839-9586	Asociacion Espanola Contra el Cancer (AECC); Ministry of Science of Spain-FEDER (CIBERONC) [PI1700464, PI2000003, RD06/0020/0059]; CIBERONC [CB16/12/00361]; Consejeria de Salud, Junta de Andalucia [PI-0197-2016, PI-0013-2018, ECAI F2-0012-2018]	Asociacion Espanola Contra el Cancer (AECC); Ministry of Science of Spain-FEDER (CIBERONC); CIBERONC; Consejeria de Salud, Junta de Andalucia(Junta de Andalucia)	Research in the E.D.A. lab is supported by Asociacion Espanola Contra el Cancer (AECC), the Ministry of Science of Spain-FEDER (CIBERONC, PI1700464, PI2000003, RD06/0020/0059)S. D.G.D. and L.H.P. are supported by CIBERONC (CB16/12/00361). D.G.D., M.J.R. and L.H.P. are PhD researchers funded by the Consejeria de Salud, Junta de Andalucia (PI-0197-2016, ECAI F2-0012-2018 and PI-0013-2018, respectively).	Abdul-Salam VB, 2020, NOVEL NUCLEAR ROLE H, DOI [DOI 10.1101/2020.11.02.356121V1, 10.1101/2020.11.02.356121v1]; Amengual JE, 2015, CLIN CANCER RES, V21, P4663, DOI 10.1158/1078-0432.CCR-14-3068; Azahri NSM, 2012, J CELL BIOCHEM, V113, P2597, DOI 10.1002/jcb.24135; Ban J, 2011, ONCOGENE, V30, P2173, DOI 10.1038/onc.2010.581; Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148; Cao JL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0788-2; de Nigris F, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115605; Formisano L, 2015, J NEUROSCI, V35, P7332, DOI 10.1523/JNEUROSCI.2174-14.2015; Furumai R, 2002, CANCER RES, V62, P4916; Garcia-Dominguez DJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234243; Garcia-Dominguez Daniel Jose, 2018, Oncotarget, V9, P31397, DOI 10.18632/oncotarget.25829; Giorgi C, 2015, ONCOTARGET, V6, P28895, DOI 10.18632/oncotarget.5000; Grunewald TGP, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0003-x; Herrero-Martin D, 2009, BRIT J CANCER, V101, P80, DOI 10.1038/sj.bjc.6605104; Hontecillas-Prieto L, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.578011; Huang PY, 2017, ONCOTARGET, V8, P2694, DOI 10.18632/oncotarget.13738; Hung JJ, 2006, MOL CELL BIOL, V26, P1770, DOI 10.1128/MCB.26.5.1770-1785.2006; Kanno K, 2012, ONCOL REP, V28, P867, DOI 10.3892/or.2012.1898; Keskin T, 2020, CELL REP, V30, P4567, DOI 10.1016/j.celrep.2019.12.053; Lee DH, 2018, INT J ONCOL, V53, P844, DOI 10.3892/ijo.2018.4405; Lee YS, 2008, CANCER RES, V68, P7561, DOI 10.1158/0008-5472.CAN-08-0188; Liu YJ, 2012, J BIOL CHEM, V287, P29168, DOI 10.1074/jbc.M112.371120; Llombart-Bosch A, 2009, VIRCHOWS ARCH, V455, P397, DOI 10.1007/s00428-009-0842-7; Machado I, 2018, VIRCHOWS ARCH, V472, P815, DOI 10.1007/s00428-018-2316-2; Mackintosh C, 2012, ONCOGENE, V31, P1287, DOI 10.1038/onc.2011.317; Martinez-Lage M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18875-x; Moller E, 2009, ONCOL REP, V21, P641, DOI 10.3892/or_00000267; Montoya C, 2020, ONCOL REP, V43, P1199, DOI 10.3892/or.2020.7489; Nacev BA, 2020, NAT REV CANCER, V20, P608, DOI 10.1038/s41568-020-0288-4; Negmeldin AT, 2017, ACS MED CHEM LETT, V8, P281, DOI 10.1021/acsmedchemlett.6b00124; Pattenden SG, 2016, P NATL ACAD SCI USA, V113, P3018, DOI 10.1073/pnas.1521827113; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Ray A, 2018, LEUKEMIA, V32, P843, DOI 10.1038/leu.2017.322; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Sakimura R, 2005, INT J CANCER, V116, P784, DOI 10.1002/ijc.21069; Sanchez-Molina S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba3058; Sankar S, 2013, ONCOGENE, V32, P5089, DOI 10.1038/onc.2012.525; Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood-2011-10-387365; Scotlandi K, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040968; Seidel C, 2015, EPIGENOMICS-UK, V7, P103, DOI [10.2217/EPI.14.69, 10.2217/epi.14.69]; Sun YJ, 2018, CURR TOP MED CHEM, V18, P2420, DOI 10.2174/1568026619666181210152115; Tang F, 2017, CANCER TREAT REV, V59, P33, DOI 10.1016/j.ctrv.2017.06.006; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Waby JS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-275; Wang XX, 2018, EUR J MED CHEM, V143, P1406, DOI 10.1016/j.ejmech.2017.10.040; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Wang ZH, 2016, CANCER LETT, V379, P134, DOI 10.1016/j.canlet.2016.06.001; Yang CJ, 2015, ONCOTARGET, V6, P30263, DOI 10.18632/oncotarget.4749; Yee AJ, 2016, LANCET ONCOL, V17, P1569, DOI 10.1016/S1470-2045(16)30375-8; Zhang Y, 2008, MOL CELL BIOL, V28, P1688, DOI 10.1128/MCB.01154-06	50	6	6	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5843	5853		10.1038/s41388-021-01974-4	http://dx.doi.org/10.1038/s41388-021-01974-4		AUG 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34345016	Green Published, hybrid			2022-12-28	WOS:000681523500004
J	Su, JC; Wu, GD; Ye, Y; Zhang, JL; Zeng, LX; Huang, XD; Zheng, YF; Bai, RH; Zhuang, LS; Li, M; Pan, L; Deng, JG; Li, R; Deng, S; Zhang, SP; Zuo, ZX; Liu, ZX; Lin, JZ; Lin, DX; Zheng, J				Su, Jiachun; Wu, Guandi; Ye, Ying; Zhang, Jialiang; Zeng, Lingxing; Huang, Xudong; Zheng, Yanfen; Bai, Ruihong; Zhuang, Lisha; Li, Mei; Pan, Ling; Deng, Junge; Li, Rui; Deng, Shuang; Zhang, Shaoping; Zuo, Zhixiang; Liu, Zexian; Lin, Junzhong; Lin, Dongxin; Zheng, Jian			NSUN2-mediated RNA 5-methylcytosine promotes esophageal squamous cell carcinoma progression via LIN28B-dependent GRB2 mRNA stabilization	ONCOGENE			English	Article							POOR-PROGNOSIS; GENE-EXPRESSION; MISU NSUN2; METHYLTRANSFERASE; METHYLATION; PROLIFERATION; BINDING; TRANSFORMATION; METASTASIS; INHIBITION	5-Methylcytosine (m(5)C) is a posttranscriptional RNA modification participating in many critical bioprocesses, but its functions in human cancer remain unclear. Here, by detecting the transcriptome-wide m(5)C profiling in esophageal squamous cell carcinoma (ESCC), we showed increased m(5)C methylation in ESCC tumors due to the overexpressed m(5)C methyltransferase NSUN2. Aberrant expression of NSUN2 was positively regulated by E2F Transcription Factor 1 (E2F1). High NSUN2 levels predicted poor survival of ESCC patients. Moreover, silencing NSUN2 suppressed ESCC tumorigenesis and progression in Nsun2 knockout mouse models. Mechanistically, NSUN2 induced m(5)C modification of growth factor receptor-bound protein 2 (GRB2) and stabilized its mRNA, which was mediated by a novel m(5)C mediator, protein lin-28 homolog B (LIN28B). Elevated GRB2 levels increased the activation of PI3K/AKT and ERK/MAPK signalling. These results demonstrate that NSUN2 enhances the initiation and progression of ESCC via m(5)C-LIN28B dependent stabilization of GRB2 transcript, providing a promising epitranscriptomic-targeted therapeutic strategy for ESCC.	[Su, Jiachun; Wu, Guandi; Ye, Ying; Zhang, Jialiang; Zeng, Lingxing; Huang, Xudong; Zheng, Yanfen; Bai, Ruihong; Li, Mei; Pan, Ling; Deng, Junge; Li, Rui; Deng, Shuang; Zhang, Shaoping; Zuo, Zhixiang; Liu, Zexian; Lin, Junzhong; Lin, Dongxin; Zheng, Jian] Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Su, Jiachun; Wu, Guandi; Ye, Ying; Zhang, Jialiang; Zeng, Lingxing; Huang, Xudong; Zheng, Yanfen; Bai, Ruihong; Li, Mei; Pan, Ling; Deng, Junge; Li, Rui; Deng, Shuang; Zhang, Shaoping; Zuo, Zhixiang; Liu, Zexian; Lin, Junzhong; Lin, Dongxin; Zheng, Jian] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China; [Zhuang, Lisha] Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou, Peoples R China; [Lin, Junzhong] Sun Yat Sen Univ Canc Ctr, Dept Surg, Guangzhou, Peoples R China; [Lin, Dongxin] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr,Dept Etiol & Carcinogenesis, Beijing, Peoples R China; [Lin, Dongxin; Zheng, Jian] Nanjing Med Univ, Collaborat Innovat Ctr Canc Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Nanjing Medical University	Lin, JZ; Lin, DX; Zheng, J (corresponding author), Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China.; Lin, JZ; Lin, DX; Zheng, J (corresponding author), Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China.; Lin, JZ (corresponding author), Sun Yat Sen Univ Canc Ctr, Dept Surg, Guangzhou, Peoples R China.; Lin, DX (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr,Dept Etiol & Carcinogenesis, Beijing, Peoples R China.; Lin, DX; Zheng, J (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Peoples R China.	linjzh@sysucc.org.cn; lindx@sysucc.org.cn; zhengjian@sysucc.org.cn	Zhang, Jialiang/HDN-0467-2022; Zuo, Zhixiang/M-4441-2016	Zuo, Zhixiang/0000-0002-2492-2689; Su, Jiachun/0000-0002-8445-4901; Zeng, Lingxing/0000-0002-0846-8762; Zheng, Jian/0000-0001-9831-7038	Program for Guangdong Introducing Innovative and Entrepreneurial Teams [2017ZT07S096]; Natural Science Foundation of China [U1601229]; National Young Top-notch Talent Support Program; Sun Yat-sen University Intramural Funds	Program for Guangdong Introducing Innovative and Entrepreneurial Teams; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Young Top-notch Talent Support Program; Sun Yat-sen University Intramural Funds	We thank Dr. Bin Shen (Department of Histology and Embryology, Nanjing Medical University, Nanjing, China) for his generous donation of Nsun2 +/- C57BL/6J mice. This study was supported by the Program for Guangdong Introducing Innovative and Entrepreneurial Teams (2017ZT07S096 to DL), Natural Science Foundation of China (U1601229 to DL), National Young Top-notch Talent Support Program (to JZ) and Sun Yat-sen University Intramural Funds (to DL and to JZ).	Amort T, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-016-1139-1; Blanco S, 2016, NATURE, V534, P335, DOI 10.1038/nature18282; Blanco S, 2014, EMBO J, V33, P2020, DOI 10.15252/embj.201489282; Bourgeois G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133321; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Budkina KS, 2020, BIOCHEMISTRY-MOSCOW+, V85, P1, DOI 10.1134/S0006297920140011; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Chen X, 2019, NAT CELL BIOL, V21, P978, DOI 10.1038/s41556-019-0361-y; CHENG J, 2018, NAT COMMUN, V9; David R, 2017, PLANT CELL, V29, P445, DOI 10.1105/tpc.16.00751; Delaunay S, 2019, NAT CELL BIOL, V21, P552, DOI 10.1038/s41556-019-0319-0; Flores JV, 2017, STEM CELL REP, V8, P112, DOI 10.1016/j.stemcr.2016.11.014; Frye M, 2006, CURR BIOL, V16, P971, DOI 10.1016/j.cub.2006.04.027; Frye M, 2010, CANCER LETT, V289, P71, DOI 10.1016/j.canlet.2009.08.004; Giubellino A, 2007, CANCER RES, V67, P6012, DOI 10.1158/0008-5472.CAN-07-0022; Hamano R, 2012, BRIT J CANCER, V106, P1415, DOI 10.1038/bjc.2012.90; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Hussain S, 2013, CELL REP, V4, P255, DOI 10.1016/j.celrep.2013.06.029; Ijaz M, 2017, PROTEIN PEPTIDE LETT, V24, P1084, DOI 10.2174/0929866525666171123213148; Keskin T, 2020, CELL REP, V30, P4567, DOI 10.1016/j.celrep.2019.12.053; Khan MA, 2012, AM J HUM GENET, V90, P856, DOI 10.1016/j.ajhg.2012.03.023; Khoddami V, 2013, NAT BIOTECHNOL, V31, P458, DOI 10.1038/nbt.2566; Khosronezhad N, 2015, J ASSIST REPROD GEN, V32, P807, DOI 10.1007/s10815-015-0443-0; Li B, 2016, CLIN CANCER RES, V22, P1243, DOI 10.1158/1078-0432.CCR-15-1196; Li LY, 2015, J PROTEOMICS, V117, P145, DOI 10.1016/j.jprot.2015.01.016; Li LY, 2014, INT J CLIN EXP PATHO, V7, P3132; Lu LG, 2018, CANCER INVEST, V36, P246, DOI 10.1080/07357907.2018.1466896; Luo YH, 2016, CIRC RES, V118, P944, DOI 10.1161/CIRCRESAHA.115.307674; Madison BB, 2013, GENE DEV, V27, P2233, DOI 10.1101/gad.224659.113; Motorin Y, 2010, NUCLEIC ACIDS RES, V38, P1415, DOI 10.1093/nar/gkp1117; Nan P, 2020, CARCINOGENESIS, V41, P1263, DOI 10.1093/carcin/bgz200; Nicolau-Neto Pedro, 2018, Oncotarget, V9, P16634, DOI 10.18632/oncotarget.24621; Ohanian M, 2018, LANCET HAEMATOL, V5, pE136, DOI 10.1016/S2352-3026(18)30021-8; Piovesan D, 2016, NUCLEIC ACIDS RES, V44, pW367, DOI 10.1093/nar/gkw315; Roundtree IA, 2017, CELL, V169, P1187, DOI 10.1016/j.cell.2017.05.045; Sajini AA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10020-7; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Schumann U, 2020, BMC BIOL, V18, DOI 10.1186/s12915-020-00769-5; Selmi T, 2021, NUCLEIC ACIDS RES, V49, DOI 10.1093/nar/gkaa1193; Shi QZ, 2018, CELL PHYSIOL BIOCHEM, V46, P2187, DOI 10.1159/000489548; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smyth EC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.48; Song MQ, 2018, MOL CANCER THER, V17, P1540, DOI 10.1158/1535-7163.MCT-17-0823; Squires JE, 2012, NUCLEIC ACIDS RES, V40, P5023, DOI 10.1093/nar/gks144; Trixl L, 2019, WIRES RNA, V10, DOI 10.1002/wrna.1510; Van Haute L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12039; Veschi V, 2017, CANCER CELL, V31, P50, DOI 10.1016/j.ccell.2016.12.002; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang WG, 2016, WIRES RNA, V7, P838, DOI 10.1002/wrna.1380; Wang XC, 2018, BIOMED PHARMACOTHER, V104, P383, DOI 10.1016/j.biopha.2018.05.064; Wang Y, 2014, NAT CELL BIOL, V16, P191, DOI 10.1038/ncb2902; Yang JC, 2017, FUTURE ONCOL, V13, P1981, DOI 10.2217/fon-2017-0084; Yang X, 2017, CELL RES, V27, P606, DOI 10.1038/cr.2017.55; Yang Y, 2019, MOL CELL, V75, P1188, DOI 10.1016/j.molcel.2019.06.033; Zhang JP, 2019, BLOOD, V134, P171, DOI 10.1182/blood.2019001043	57	11	11	6	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5814	5828		10.1038/s41388-021-01978-0	http://dx.doi.org/10.1038/s41388-021-01978-0		AUG 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34345012	Green Published, hybrid			2022-12-28	WOS:000681523500001
J	Li, DD; She, JJ; Hu, XH; Zhang, MX; Sun, RN; Qin, SS				Li, Dandan; She, Jiajun; Hu, Xinhui; Zhang, Meixin; Sun, Ruonan; Qin, Shanshan			The ELF3-regulated lncRNA UBE2CP3 is over-stabilized by RNA-RNA interactions and drives gastric cancer metastasis via miR-138-5p/ITGA2 axis	ONCOGENE			English	Article							CROSSTALK; CELLS	LncRNAs play essential roles in tumorigenesis and tumor progression. Pseudogene UBE2CP3 is an antisense intronic lncRNA. However, the biological function of UBE2CP3 in gastric cancer (GC) remains unknown. In this study, we revealed that lncRNA UBE2CP3 was aberrantly upregulated in multiple independent gastric cancer cohorts, and its overexpression was clinically associated with poor prognosis in GC. UBE2CP3 was mainly located in cytoplasm and promoted migratory and invasive capacities of GC cells in vitro and in vivo. Mechanismly, a novel dysregulated ceRNA network UB2CP3/miR-138-5p/ITGA2 was identified in GC by transcriptome sequencing. Furthermore, rescue assay further confirmed that UBE2CP3 mainly promoted GC progression through miR-138-5p/ITGA2 axis. More importantly, our data proved that UBE2CP3/IGFBP7 could form an RNA duplex, thereby directly interacting with the ILF3 protein. In turn, this RNA-RNA interaction between IGFBP7 mRNA and UBE2CP3 mediated by ILF3 protein plays an essential role in protecting the mRNA stability of UBE2CP3. In addition, transcription factor ELF3 was identified to be a direct repressor of lncRNA UBE2CP3 in GC. Taken together, overexpression of UBE2CP3 promotes tumor progression via cascade amplification of ITGA2 upregulation in GC. Our finding has revealed that the dysregulation of UBE2CP3 is probably due to the downregulation of ELF3 and/or the overexpression of IGFBP7 mRNA in GC. Our findings reveal, for the first time, that UBE2CP3 plays crucial a role in GC progression by modulating miR-138-5p/ITGA2 axis, suggesting that UBE2CP3 may serve as a potential therapeutic target in GC.	[Li, Dandan; Qin, Shanshan] Hubei Univ Med, Sch Basic Med Sci, Hubei Key Lab Embryon Stem Cell Res, Shiyan, Hubei, Peoples R China; [Li, Dandan; She, Jiajun; Hu, Xinhui; Zhang, Meixin; Sun, Ruonan; Qin, Shanshan] Hubei Univ Med, Acad Biomed Res, Lab Tumor Biol, Shiyan, Hubei, Peoples R China	Hubei University of Medicine; Hubei University of Medicine	Qin, SS (corresponding author), Hubei Univ Med, Sch Basic Med Sci, Hubei Key Lab Embryon Stem Cell Res, Shiyan, Hubei, Peoples R China.; Qin, SS (corresponding author), Hubei Univ Med, Acad Biomed Res, Lab Tumor Biol, Shiyan, Hubei, Peoples R China.	qinss77@163.com	Qin, Shanshan/HGU-6157-2022	Qin, Shanshan/0000-0002-8527-5278; Li, Dandan/0000-0002-6224-8867	National Natural Science Foundation of China [81802375]; Hubei University of Medicine [2016QDJZR07, 2017QDJZR05]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hubei University of Medicine	This study was supported by grants from the National Natural Science Foundation of China (grant no. 81802375); the Faculty Development Grants from Hubei University of Medicine (grant nos. 2016QDJZR07 and 2017QDJZR05).	Bala P, 2021, ONCOGENE, V40, P863, DOI 10.1038/s41388-020-01537-z; Canel M, 2013, J CELL SCI, V126, P393, DOI 10.1242/jcs.100115; Chan JJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051310; Chuang YC, 2018, BIOL PROCED ONLINE, V10, DOI 10.1186/s12575-018-0073-x; Dong JQ, 2017, CLIN CANCER RES, V23, P3461, DOI 10.1158/1078-0432.CCR-16-2180; Gaballa R, 2020, CANCERS, V12, DOI 10.3390/cancers12082300; Hayashi H, 2015, ONCOGENE, V34, P199, DOI 10.1038/onc.2013.547; He D, 2021, ONCOGENE, V40, P355, DOI 10.1038/s41388-020-01528-0; Huang L, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.203; Karreth FA, 2013, CANCER DISCOV, V3, P1113, DOI 10.1158/2159-8290.CD-13-0202; Li DD, 2020, MOL THER-NUCL ACIDS, V19, P109, DOI 10.1016/j.omtn.2019.11.003; Li DD, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00220; Liu Q, 2016, MOL THER, V24, P1726, DOI 10.1038/mt.2016.151; Liu XS, 2016, TUMOR BIOL, V37, P7951, DOI 10.1007/s13277-015-4696-0; Lou WY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00085; Lv Y, 2021, ONCOGENE, V40, P3826, DOI 10.1038/s41388-021-01812-7; Ma HW, 2017, ONCOTARGET, V8, P52211, DOI 10.18632/oncotarget.11075; Pandolfi P, 2012, EUR J CANCER, V48, pS16, DOI 10.1016/S0959-8049(12)70773-6; Pang L, 2017, ONCOL REP, V38, P1295, DOI 10.3892/or.2017.5745; Ren DY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1496-1; Salemi Z, 2021, J CELL PHYSIOL, V236, P4954, DOI 10.1002/jcp.30202; Shi XF, 2013, CANCER LETT, V339, P159, DOI 10.1016/j.canlet.2013.06.013; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Wang JJ, 2021, FEBS OPEN BIO, V11, P1814, DOI 10.1002/2211-5463.13125; Wang Q, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00308; Wang X., 2021, CLIN TRANSL MED, V11; Wu LF, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.325; Xu YC, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0684-8; Yan LT, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.255; Yang Y, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.155; Yeh M, 2019, AM J CANCER RES, V9, P1118; Zhang W, 2020, CANCER MANAG RES, V12, P8137, DOI 10.2147/CMAR.S253777; Zhao SL, 2021, ONCOGENE, V40, P4709, DOI 10.1038/s41388-021-01859-6; Zheng J, 2019, ONCOGENE, V38, P7073, DOI 10.1038/s41388-019-0934-z	34	18	18	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5403	5415		10.1038/s41388-021-01948-6	http://dx.doi.org/10.1038/s41388-021-01948-6		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34274947	Green Published, hybrid			2022-12-28	WOS:000673748200002
J	Pietrobono, S; Gaudio, E; Gagliardi, S; Zitani, M; Carrassa, L; Migliorini, F; Petricci, E; Manetti, F; Makukhin, N; Bond, AG; Paradise, BD; Ciulli, A; Fernandez-Zapico, ME; Bertoni, F; Stecca, B				Pietrobono, Silvia; Gaudio, Eugenio; Gagliardi, Sinforosa; Zitani, Mariapaola; Carrassa, Laura; Migliorini, Francesca; Petricci, Elena; Manetti, Fabrizio; Makukhin, Nikolai; Bond, Adam G.; Paradise, Brooke D.; Ciulli, Alessio; Fernandez-Zapico, Martin E.; Bertoni, Francesco; Stecca, Barbara			Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma	ONCOGENE			English	Article							SELF-RENEWAL; DNA-DAMAGE; STEM-CELL; BET; CANCER; PROTEIN; GROWTH; TUMORIGENICITY; PROLIFERATION; SUPPRESSES	Despite the development of new targeted and immune therapies, the prognosis of metastatic melanoma remains bleak. Therefore, it is critical to better understand the mechanisms controlling advanced melanoma to develop more effective treatment regimens. Hedgehog/GLI (HH/GLI) signaling inhibitors targeting the central pathway transducer Smoothened (SMO) have shown to be clinical efficacious in skin cancer; however, several mechanisms of non-canonical HH/GLI pathway activation limit their efficacy. Here, we identify a novel SOX2-BRD4 transcriptional complex driving the expression of GLI1, the final effector of the HH/GLI pathway, providing a novel mechanism of non-canonical SMO-independent activation of HH/GLI signaling in melanoma. Consistently, we find a positive correlation between the expression of GLI1 and SOX2 in human melanoma samples and cell lines. Further, we show that combined targeting of canonical HH/GLI pathway with the SMO inhibitor MRT-92 and of the SOX2-BRD4 complex using a potent Proteolysis Targeted Chimeras (PROTACs)-derived BRD4 degrader (MZ1), yields a synergistic anti-proliferative effect in melanoma cells independently of their BRAF, NRAS, and NF1 mutational status, with complete abrogation of GLI1 expression. Combination of MRT-92 and MZ1 strongly potentiates the antitumor effect of either drug as single agents in an orthotopic melanoma model. Together, our data provide evidence of a novel mechanism of non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex, and describe the efficacy of a new combinatorial treatment for a subset of melanomas with an active SOX2-BRD4-GLI1 axis.	[Pietrobono, Silvia; Gagliardi, Sinforosa; Zitani, Mariapaola; Carrassa, Laura; Stecca, Barbara] Inst Canc Res & Prevent ISPRO, Core Res Lab, Florence, Italy; [Gaudio, Eugenio; Bertoni, Francesco] USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland; [Migliorini, Francesca; Petricci, Elena; Manetti, Fabrizio] Univ Siena, Dept Biotechnol Chem & Pharm, Siena, Italy; [Makukhin, Nikolai; Bond, Adam G.; Ciulli, Alessio] Univ Dundee, Sch Life Sci, Div Biol Chem & Drug Discovery, James Black Ctr, Dundee, Scotland; [Paradise, Brooke D.; Fernandez-Zapico, Martin E.] Mayo Clin, Schulze Ctr Novel Therapeut, Dept Oncol, Div Oncol Res, Rochester, MN USA; [Bertoni, Francesco] Oncol Inst Southern Switzerland, Bellinzona, Switzerland	Institute of Oncology Research (IOR); Universita della Svizzera Italiana; University of Siena; University of Dundee; Mayo Clinic; Institute of Oncology Research (IOR)	Pietrobono, S; Stecca, B (corresponding author), Inst Canc Res & Prevent ISPRO, Core Res Lab, Florence, Italy.	silvia.pietrobono@ittumori.it; b.stecca@ispro.toscana.it	Manetti, Fabrizio/Q-9412-2019; Petricci, Elena/AAB-9275-2022; Pietrobono, Silvia S/K-3932-2016; Bertoni, Francesco/G-6922-2014	Manetti, Fabrizio/0000-0002-9598-2339; Pietrobono, Silvia S/0000-0002-5544-7286; Stecca, Barbara/0000-0003-1197-1622; Bond, Adam/0000-0002-1271-1032; Makukhin, Nikolai/0000-0003-2465-0748; Migliorini, Francesca/0000-0003-2149-978X; Bertoni, Francesco/0000-0001-5637-8983; Carrassa, Laura/0000-0003-2707-4301	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG-14184, IG-23091]; Institute for Cancer Research, Prevention and Clinical Network (ISPRO); AIRC fellowship [21168]; UK Biotechnology and Biological Sciences Research Council (BBSRC) [BB/J001201/2]; European Research Council (ERC) [ERC-2012-StG-311460]; Medical Research Scotland PhD studentship [1170-2017]	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Institute for Cancer Research, Prevention and Clinical Network (ISPRO); AIRC fellowship(Fondazione AIRC per la ricerca sul cancro); UK Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); European Research Council (ERC)(European Research Council (ERC)European Commission); Medical Research Scotland PhD studentship	We thank Fritz Aberger (University of Salzburg, Austria) for SOX2 promoter/enhancer reporter plasmids. The BS lab was partially supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) (IG-14184 and IG-23091) and by institutional funding from the Institute for Cancer Research, Prevention and Clinical Network (ISPRO). SP was supported by AIRC fellowship (n. 21168). The AC lab was funded by awards from the UK Biotechnology and Biological Sciences Research Council (BBSRC, grant BB/J001201/2) and the European Research Council (ERC, Starting Grant ERC-2012-StG-311460 DrugE3CRLs). AGB was supported by a Medical Research Scotland PhD studentship (1170-2017).	Andrieu Guillaume, 2016, Drug Discov Today Technol, V19, P45, DOI 10.1016/j.ddtec.2016.06.004; Andrieu GP, 2019, CANCER LETT, V465, P45, DOI 10.1016/j.canlet.2019.08.013; Bora-Singhal N, 2015, NEOPLASIA, V17, P538, DOI 10.1016/j.neo.2015.07.001; Cao JY, 2019, NATURE, V566, P496, DOI 10.1038/s41586-019-0969-x; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cochrane CR, 2015, CANCERS, V7, P1554, DOI 10.3390/cancers7030851; Noblejas-Lopez MD, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1387-5; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Echevarria-Vargas IM, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708446; Erkes DA, 2019, PIGM CELL MELANOMA R, V32, P687, DOI 10.1111/pcmr.12788; Fang XF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-11; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Floyd SR, 2013, NATURE, V498, P246, DOI 10.1038/nature12147; Gadd MS, 2017, NAT CHEM BIOL, V13, P514, DOI [10.1038/nchembio.2329, 10.1038/NCHEMBIO.2329]; Gallagher SJ, 2014, J INVEST DERMATOL, V134, P2795, DOI 10.1038/jid.2014.243; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hogg SJ, 2017, CELL REP, V18, P2162, DOI 10.1016/j.celrep.2017.02.011; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huang YS, 2016, CLIN CANCER RES, V22, P4259, DOI 10.1158/1078-0432.CCR-15-2068; Jalili A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069064; Jenkins RW, 2021, J INVEST DERMATOL, V141, P23, DOI 10.1016/j.jid.2020.03.943; Jia YF, 2019, ONCOGENE, V38, P1764, DOI 10.1038/s41388-018-0553-0; Kamath A, 2019, BIORXIV326470, DOI [10.1038/s41388-021-01783-9, DOI 10.1038/S41388-021-01783-9]; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Kumar K, 2015, SCI REP-UK, V5, DOI 10.1038/srep09489; Long J, 2014, J BIOL CHEM, V289, P35494, DOI 10.1074/jbc.M114.595348; Lu LL, 2020, CELL DEATH DIFFER, V27, P255, DOI 10.1038/s41418-019-0353-2; Mazumdar T, 2011, CANCER RES, V71, P5904, DOI 10.1158/0008-5472.CAN-10-4173; O'Reilly KE, 2013, PHARMACEUTICALS, V6, P1429, DOI 10.3390/ph6111429; Paoluzzi L, 2016, CANCER MED-US, V5, P1183, DOI 10.1002/cam4.667; Pietrobono S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19575-2; Pietrobono S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00556; Pietrobono S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0142-0; Riverso M, 2017, ONCOGENE, V36, P3322, DOI 10.1038/onc.2016.481; Santini R, 2014, ONCOGENE, V33, P4697, DOI 10.1038/onc.2014.71; Santini R, 2012, STEM CELLS, V30, P1808, DOI 10.1002/stem.1160; Segura MF, 2013, CANCER RES, V73, P6264, DOI 10.1158/0008-5472.CAN-13-0122-T; Sekulic A, 2016, CELL, V164, P831, DOI 10.1016/j.cell.2016.02.021; Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016; Song H, 2019, EUR J PHARMACOL, V852, P189, DOI 10.1016/j.ejphar.2019.03.018; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Swift LH, 2014, INT J MOL SCI, V15, P3403, DOI 10.3390/ijms15033403; Tang YJ, 2014, NAT MED, V20, P732, DOI 10.1038/nm.3613; Ullman-Cullere MH, 1999, LAB ANIM SCI, V49, P319; Vardabasso C, 2015, MOL CELL, V59, P75, DOI 10.1016/j.molcel.2015.05.009; Venkataraman S, 2014, ONCOTARGET, V5, P2355; Wu FJ, 2017, CELL CHEM BIOL, V24, P252, DOI 10.1016/j.chembiol.2017.02.010; Wuebben EL, 2017, ONCOTARGET, V8, P44917, DOI 10.18632/oncotarget.16570; Zengerle M, 2015, ACS CHEM BIOL, V10, P1770, DOI 10.1021/acschembio.5b00216; Zhu HR, 2016, CELL REP, V16, P2829, DOI 10.1016/j.celrep.2016.08.032	51	10	10	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3799	3814		10.1038/s41388-021-01783-9	http://dx.doi.org/10.1038/s41388-021-01783-9		MAY 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33958721	Green Published, hybrid			2022-12-28	WOS:000648041500007
J	Bajpai, D; Mehdizadeh, S; Uchiyama, A; Inoue, Y; Sawaya, A; Overmiller, A; Brooks, SR; Hasneen, K; Kellett, M; Palazzo, E; Motegi, S; Yuspa, SH; Cataisson, C; Morasso, MI				Bajpai, Deepti; Mehdizadeh, Spencer; Uchiyama, Akihiko; Inoue, Yuta; Sawaya, Andrew; Overmiller, Andrew; Brooks, Stephen R.; Hasneen, Kowser; Kellett, Meghan; Palazzo, Elisabetta; Motegi, Sei-ichiro; Yuspa, Stuart H.; Cataisson, Christophe; Morasso, Maria, I			Loss of DLX3 tumor suppressive function promotes progression of SCC through EGFR-ERBB2 pathway	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; HOMEOBOX GENE-EXPRESSION; TREATED MOUSE EPIDERMIS; SKIN TUMORS; HOX GENES; LUNG-CANCER; KERATIN; DIFFERENTIATION; CARCINOGENESIS; INFLAMMATION	Cutaneous squamous cell carcinoma (cSCC) ranks second in the frequency of all skin cancers. The balance between keratinocyte proliferation and differentiation is disrupted in the pathological development of cSCC. DLX3 is a homeobox transcription factor which plays pivotal roles in embryonic development and epidermal homeostasis. To investigate the impact of DLX3 expression on cSCC prognosis, we carried out clinicopathologic analysis of DLX3 expression which showed statistical correlation between tumors of higher pathologic grade and levels of DLX3 protein expression. Further, Kaplan-Meier survival curve analysis demonstrated that low DLX3 expression correlated with poor patient survival. To model the function of Dlx3 in skin tumorigenesis, a two-stage dimethylbenzanthracene (DMBA)/12-O-tetradecanoylphorbol 13-acetate (TPA) study was performed on mice genetically depleted of Dlx3 in skin epithelium (Dlx3cKO). Dlx3cKO mice developed significantly more tumors, with more rapid tumorigenesis compared to control mice. In Dlx3cKO mice treated only with DMBA, tumors developed after similar to 16 weeks suggesting that loss of Dlx3 has a tumor promoting effect. Whole transcriptome analysis of tumor and skin tissue from our mouse model revealed spontaneous activation of the EGFR-ERBB2 pathway in the absence of Dlx3. Together, our findings from human and mouse model system support a tumor suppressive function for DLX3 in skin and underscore the efficacy of therapeutic approaches that target EGFR-ERBB2 pathway.	[Bajpai, Deepti; Mehdizadeh, Spencer; Sawaya, Andrew; Overmiller, Andrew; Hasneen, Kowser; Kellett, Meghan; Palazzo, Elisabetta; Morasso, Maria, I] NIAMSD, Lab Skin Biol, NIH, Bethesda, MD 20892 USA; [Uchiyama, Akihiko; Inoue, Yuta; Motegi, Sei-ichiro] Gunma Univ, Dept Dermatol, Grad Sch Med, Maebashi, Gumma, Japan; [Brooks, Stephen R.] NIAMSD, Biodata Min & Discovery Sect, NIH, Bethesda, MD 20892 USA; [Yuspa, Stuart H.; Cataisson, Christophe] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Gunma University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Morasso, MI (corresponding author), NIAMSD, Lab Skin Biol, NIH, Bethesda, MD 20892 USA.	morassom@mail.nih.gov	BAJPAI, DEEPTI/AGZ-6770-2022; PALAZZO, ELISABETTA/J-5287-2016	BAJPAI, DEEPTI/0000-0001-5701-8218; PALAZZO, ELISABETTA/0000-0002-0812-5524	Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH [ZIA-AR041124]	Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH (ZIA-AR041124 to MIM). We thank Gutierrez-Cruz and S. Dell'Orso of the NIAMS Genome Analysis Core Facility and members of the NIAMS Light Imaging Core Facility. This work used the computational resources of the NIH High-Performance Computing Biowulf Cluster. We also thank all members of our laboratories for their continuous support. BioRender was used to create experimental design schematic.	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Bhattacharya S, 2018, J INVEST DERMATOL, V138, P1052, DOI 10.1016/j.jid.2017.11.033; Cataisson C, 2009, CANCER RES, V69, P319, DOI 10.1158/0008-5472.CAN-08-2490; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; Dahlhoff M, 2017, J INVEST DERMATOL, V137, P921, DOI 10.1016/j.jid.2016.11.023; Dahlhoff M, 2015, MOL ONCOL, V9, P1825, DOI 10.1016/j.molonc.2015.06.007; Dahlhoff M, 2011, EXP DERMATOL, V20, P290, DOI 10.1111/j.1600-0625.2010.01192.x; Darwiche N, 2007, ONCOGENE, V26, P6885, DOI 10.1038/sj.onc.1210491; El-Abaseri TB, 2005, CANCER RES, V65, P3958, DOI 10.1158/0008-5472.CAN-04-2204; Gilbert PM, 2010, J CLIN INVEST, V120, P1535, DOI 10.1172/JCI39534; GIMENEZCONTI I, 1990, CARCINOGENESIS, V11, P1995, DOI 10.1093/carcin/11.11.1995; Herbst RS, 2002, CANCER-AM CANCER SOC, V94, P1593, DOI 10.1002/cncr.10372; Hwang J, 2008, DEVELOPMENT, V135, P3149, DOI 10.1242/dev.022202; Hwang J, 2011, P NATL ACAD SCI USA, V108, P11566, DOI 10.1073/pnas.1019658108; Karia PS, 2013, J AM ACAD DERMATOL, V68, P957, DOI 10.1016/j.jaad.2012.11.037; Kiguchi K, 1998, MOL CARCINOGEN, V22, P73, DOI 10.1002/(SICI)1098-2744(199806)22:2<73::AID-MC2>3.0.CO;2-L; Kiguchi K, 2010, CANCER PREV RES, V3, P940, DOI 10.1158/1940-6207.CAPR-10-0010; Lallas A, 2015, BRIT J DERMATOL, V172, P1308, DOI 10.1111/bjd.13510; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo ZF, 2019, CANCERS, V11, DOI 10.3390/cancers11030323; Morasso Maria I., 2005, Birth Defects Research, V75, P163, DOI 10.1002/bdrc.20047; Mueller MM, 2006, EUR J CANCER, V42, P735, DOI 10.1016/j.ejca.2006.01.014; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; Nyati MK, 2006, NAT REV CANCER, V6, P876, DOI 10.1038/nrc1953; Palazzo E, 2016, ONCOGENE, V35, P3114, DOI 10.1038/onc.2015.380; Palazzo E, 2017, CELL DEATH DIFFER, V24, P717, DOI 10.1038/cdd.2017.5; Plowright L, 2009, BRIT J CANCER, V100, P470, DOI 10.1038/sj.bjc.6604857; Que SKT, 2018, J AM ACAD DERMATOL, V78, P237, DOI 10.1016/j.jaad.2017.08.059; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Samuel S, 2005, EUR J CANCER, V41, P2428, DOI 10.1016/j.ejca.2005.08.014; Schneider MR, 2016, ONCOGENE, V35, P2949, DOI 10.1038/onc.2015.372; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Subramanian J, 2019, ONCOLOGIST, V24, pE1303, DOI 10.1634/theoncologist.2018-0845; Sun YQ, 2018, CANCER CELL, V34, P643, DOI 10.1016/j.ccell.2018.08.018; TOFTGARD R, 1985, CANCER RES, V45, P5845; Wheeler DL, 2013, J SKIN CANCER, V2013, DOI 10.1155/2013/971495; Wilker E, 2005, MOL CARCINOGEN, V44, P137, DOI 10.1002/mc.20132; Witsch E, 2010, PHYSIOLOGY, V25, P85, DOI 10.1152/physiol.00045.2009; Xian WJ, 1997, ONCOGENE, V14, P1435, DOI 10.1038/sj.onc.1200980	44	1	1	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3680	3694		10.1038/s41388-021-01802-9	http://dx.doi.org/10.1038/s41388-021-01802-9		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33947961	Green Accepted			2022-12-28	WOS:000647084500001
J	Papoutsoglou, P; Rodrigues, DM; Moren, A; Bergman, A; Ponten, F; Coulouarn, C; Caja, L; Heldin, CH; Moustakas, A				Papoutsoglou, Panagiotis; Rodrigues-Junior, Dorival Mendes; Moren, Anita; Bergman, Andrew; Ponten, Fredrik; Coulouarn, Cedric; Caja, Laia; Heldin, Carl-Henrik; Moustakas, Aristidis			The noncoding MIR100HG RNA enhances the autocrine function of transforming growth factor beta signaling	ONCOGENE			English	Article								Activation of the transforming growth factor beta (TGF beta) pathway modulates the expression of genes involved in cell growth arrest, motility, and embryogenesis. An expression screen for long noncoding RNAs indicated that TGF beta induced mir-100-let-7a-2-mir-125b-1 cluster host gene (MIR100HG) expression in diverse cancer types, thus confirming an earlier demonstration of TGF beta-mediated transcriptional induction of MIR100HG in pancreatic adenocarcinoma. MIR100HG depletion attenuated TGF beta signaling, expression of TGF beta-target genes, and TGF beta-mediated cell cycle arrest. Moreover, MIR100HG silencing inhibited both normal and cancer cell motility and enhanced the cytotoxicity of cytostatic drugs. MIR100HG overexpression had an inverse impact on TGF beta signaling responses. Screening for downstream effectors of MIR100HG identified the ligand TGF beta 1. MIR100HG and TGFB1 mRNA formed ribonucleoprotein complexes with the RNA-binding protein HuR, promoting TGF beta 1 cytokine secretion. In addition, TGF beta regulated let-7a-2-3p, miR-125b-5p, and miR-125b-1-3p expression, all encoded by MIR100HG intron-3. Certain intron-3 miRNAs may be involved in TGF beta/SMAD-mediated responses (let-7a-2-3p) and others (miR-100, miR-125b) in resistance to cytotoxic drugs mediated by MIR100HG. In support of a model whereby TGF beta induces MIR100HG, which then enhances TGF beta 1 secretion, analysis of human carcinomas showed that MIR100HG expression correlated with expression of TGFB1 and its downstream extracellular target TGFBI. Thus, MIR100HG controls the magnitude of TGF beta signaling via TGF beta 1 autoinduction and secretion in carcinomas.	[Papoutsoglou, Panagiotis; Rodrigues-Junior, Dorival Mendes; Moren, Anita; Bergman, Andrew; Caja, Laia; Heldin, Carl-Henrik; Moustakas, Aristidis] Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, Sci Life Lab, Box 582, Uppsala, Sweden; [Papoutsoglou, Panagiotis; Coulouarn, Cedric] Univ Rennes, Ctr Lutte Canc Eugene Marquis, InInserm, UMR S 1242,COSS Chem Oncogenesis Stress Signaling, Rennes, France; [Ponten, Fredrik] Uppsala Univ, Rudbeck Lab, Dept Immunol Genet & Pathol, Box 256, Uppsala, Sweden	Uppsala University; UNICANCER; Centre Eugene Marquis; Universite de Rennes; Uppsala University	Moustakas, A (corresponding author), Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, Sci Life Lab, Box 582, Uppsala, Sweden.	aris.moustakas@imbim.uu.se	Papoutsoglou, Panagiotis/AAF-8898-2019; Rodrigues, Dorival Mendes/E-1808-2011; Coulouarn, Cedric/E-5472-2011	Papoutsoglou, Panagiotis/0000-0003-2115-3500; Rodrigues, Dorival Mendes/0000-0002-8861-9240; Coulouarn, Cedric/0000-0002-5692-9586; Ponten, Fredrik/0000-0003-0703-3940; Caja Puigsubira, Laia/0000-0002-8786-8763	Cancerfonden [CAN2012/438, CAN2015/438, CAN2018/469]; Vetenskapsradet [K2013-66X-14936-10-5, 2017-01588-3, 2018-02757-3, 2015-02757, 2020-01291]; Barncancerfonden [PR2018-0091]; European Research Council [787472]; Bodossaki Foundation; Alexander Onassis Foundation, Greece; Inserm; Universite de Rennes-1; ITMO Cancer AVIESAN Plan Cancer [C18007NS]; Ludwig Cancer Research,	Cancerfonden(Swedish Cancer Society); Vetenskapsradet(Swedish Research Council); Barncancerfonden; European Research Council(European Research Council (ERC)European Commission); Bodossaki Foundation; Alexander Onassis Foundation, Greece; Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite de Rennes-1; ITMO Cancer AVIESAN Plan Cancer; Ludwig Cancer Research,	This work was supported by Ludwig Cancer Research, Cancerfonden [CAN2012/438, CAN2015/438, CAN2018/469] to ArM, Vetenskapsradet [K2013-66X-14936-10-5, 2017-01588-3, 2018-02757-3] to ArM, [2015-02757, 2020-01291] to CHH, Barncancerfonden [PR2018-0091] to ArM, European Research Council [787472] to CHH, Bodossaki Foundation and Alexander Onassis Foundation, Greece to PP, Inserm, Universite de Rennes-1, and ITMO Cancer AVIESAN Plan Cancer [C18007NS] to CC.	Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67; Bai DN, 2012, CELL SIGNAL, V24, P1426, DOI 10.1016/j.cellsig.2012.03.003; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen DH, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004177; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; Davis BN, 2010, MOL CELL, V39, P373, DOI 10.1016/j.molcel.2010.07.011; Dews M, 2010, CANCER RES, V70, P8233, DOI 10.1158/0008-5472.CAN-10-2412; Emmrich S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-171; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gordian Edna, 2019, Oncotarget, V10, P810, DOI 10.18632/oncotarget.26574; Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Bueno MJ, 2011, BBA-MOL BASIS DIS, V1812, P592, DOI 10.1016/j.bbadis.2011.02.002; Li WH, 2019, ONCOL LETT, V18, P6483, DOI 10.3892/ol.2019.11060; Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Maupin KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013002; Merdrignac A, 2018, HEPATOL COMMUN, V2, P254, DOI 10.1002/hep4.1142; Montes M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7967; Nabors LB, 2001, CANCER RES, V61, P2154; Ottaviani S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03962-x; Pabis M, 2019, NUCLEIC ACIDS RES, V47, P1011, DOI 10.1093/nar/gky1138; Papoutsoglou P, 2020, CANCER SCI, V111, P2672, DOI 10.1111/cas.14509; Papoutsoglou P, 2019, CELL REP, V28, P3182, DOI 10.1016/j.celrep.2019.08.028; Pelechano V, 2013, NAT REV GENET, V14, P880, DOI 10.1038/nrg3594; Spangberg K, 2000, VIROLOGY, V274, P378, DOI 10.1006/viro.2000.0461; Su XC, 2019, BIOMED PHARMACOTHER, V109, P788, DOI 10.1016/j.biopha.2018.10.029; Sun QY, 2018, NUCLEIC ACIDS RES, V46, P10405, DOI 10.1093/nar/gky696; Tordonato C, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00072; Vlachos IS, 2017, METHODS MOL BIOL, V1517, P25, DOI 10.1007/978-1-4939-6563-2_2; Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002; Wang SW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0869-2	35	4	4	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3748	3765		10.1038/s41388-021-01803-8	http://dx.doi.org/10.1038/s41388-021-01803-8		MAY 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33941855	Green Published, hybrid			2022-12-28	WOS:000646512300002
J	Song, D; Lan, JQ; Chen, YQ; Liu, AY; Wu, Q; Zhao, CC; Feng, YD; Wang, J; Luo, XL; Cao, ZX; Cao, XN; Hu, JB; Wang, GH				Song, Da; Lan, Jingqin; Chen, Yaqi; Liu, Anyi; Wu, Qi; Zhao, Chongchong; Feng, Yongdong; Wang, Jing; Luo, Xuelai; Cao, Zhixin; Cao, Xiaonian; Hu, Junbo; Wang, Guihua			NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein	ONCOGENE			English	Article								Tumor angiogenesis plays vital roles in tumorigenesis and development; regulatory mechanism of angiogenesis is still not been fully elucidated. NSD2, a histone methyltransferase catalyzing di-methylation of histone H3 at lysine 36, has been proved a critical molecule in proliferation, metastasis, and tumorigenesis. But its role in tumor angiogenesis remains unknown. Here we demonstrated that NSD2 promoted tumor angiogenesis in vitro and in vivo. Furthermore, we confirmed that the angiogenic function of NSD2 was mediated by STAT3. Momentously, we found that NSD2 promoted the methylation and activation of STAT3. In addition, mass spectrometry and site-directed mutagenesis assays revealed that NSD2 methylated STAT3 at lysine 163 (K163). Meanwhile, K to R mutant at K163 of STAT3 attenuated the activation and angiogenic function of STAT3. Taken together, we conclude that methylation of STAT3 catalyzed by NSD2 promotes the activation of STAT3 pathway and enhances the ability of tumor angiogenesis. Our findings investigate a NSD2-dependent methylation-phosphorylation regulation pattern of STAT3 and reveal that NSD2/STAT3/VEGFA axis might be a potential target for tumor therapy.	[Song, Da; Lan, Jingqin; Chen, Yaqi; Liu, Anyi; Wu, Qi; Feng, Yongdong; Luo, Xuelai; Cao, Zhixin; Cao, Xiaonian; Hu, Junbo; Wang, Guihua] Huazhong Univ Sci & Technol, Tongji Hosp, GI Canc Res Inst, Wuhan, Peoples R China; [Lan, Jingqin] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Thyroid & Breast Surg, Wuhan, Peoples R China; [Zhao, Chongchong] Tsinghua Univ, Technol Ctr Prot Sci, Prot Facil, Beijing, Peoples R China; [Wang, Jing] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan, Peoples R China; [Cao, Xiaonian] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Thorac Surg, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Tsinghua University; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Hu, JB; Wang, GH (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, GI Canc Res Inst, Wuhan, Peoples R China.	jbhu@tjh.tjmu.edu.cn; ghwang@tjh.tjmu.edu.cn	Wang, Guihua/AAX-3130-2021		NSFC [81773113, 81922053, 81702264, 81974432, 81874186]	NSFC(National Natural Science Foundation of China (NSFC))	We are grateful to the members in Guihua Wang's lab and Junbo Hu's lab for the critical inputs and suggestions. This work is supported by NSFC (No. 81773113 GW, No. 81922053 GW, No.81702264 XC, No. 81974432 GW, and No. 81874186 JH).	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Aytes A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07511-4; Bharadwaj U, 2020, PHARMACOL REV, V72, P486, DOI 10.1124/pr.119.018440; Biggar KK, 2015, NAT REV MOL CELL BIO, V16, P5, DOI 10.1038/nrm3915; Canavese M, 2017, INT J CANCER, V140, P2183, DOI 10.1002/ijc.30567; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Cheong CM, 2020, CANCER LETT, V475, P99, DOI 10.1016/j.canlet.2020.01.040; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dasgupta M, 2015, P NATL ACAD SCI USA, V112, P3985, DOI 10.1073/pnas.1503152112; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; Foltz SM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16434-y; Guo JP, 2019, NAT CELL BIOL, V21, P226, DOI 10.1038/s41556-018-0261-6; Haibe Y, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00221; Hamamoto R, 2015, NAT REV CANCER, V15, P110, DOI 10.1038/nrc3884; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1347-1; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Hou ZL, 2020, CANCER LETT, V487, P63, DOI 10.1016/j.canlet.2020.05.029; Hudlebusch HR, 2011, CLIN CANCER RES, V17, P2919, DOI 10.1158/1078-0432.CCR-10-1302; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042; Lhoumaud P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12811-4; Luo J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09784-9; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nimura K, 2009, NATURE, V460, P287, DOI 10.1038/nature08086; Park JW, 2018, ONCOGENE, V37, P6212, DOI 10.1038/s41388-018-0393-y; Saltz LB, 2016, LANCET ONCOL, V17, P1469, DOI 10.1016/S1470-2045(16)30213-3; Smeets D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06567-6; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Stratman AN, 2011, BLOOD, V117, P3709, DOI 10.1182/blood-2010-11-316752; Stratman AN, 2010, BLOOD, V116, P4720, DOI 10.1182/blood-2010-05-286872; Stubbs MC, 2019, CLIN CANCER RES, V25, P300, DOI 10.1158/1078-0432.CCR-18-0098; Swaroop A, 2019, ONCOGENE, V38, P671, DOI 10.1038/s41388-018-0474-y; Wang GH, 2019, NAT CELL BIOL, V21, P214, DOI 10.1038/s41556-018-0266-1; Wang JJ, 2019, ACTA PHARMACOL SIN, V40, P1067, DOI 10.1038/s41401-018-0199-z; Wang XW, 2012, NUCLEIC ACIDS RES, V40, pD1144, DOI 10.1093/nar/gkr1013; Xie ZG, 2019, LEUKEMIA, V33, P739, DOI 10.1038/s41375-018-0300-0; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang JF, 2019, CANCER DISCOV, V9, P1306, DOI 10.1158/2159-8290.CD-18-0083; Zhang X, 2015, CELL MOL LIFE SCI, V72, P4257, DOI 10.1007/s00018-015-2001-4	45	4	4	4	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2952	2967		10.1038/s41388-021-01747-z	http://dx.doi.org/10.1038/s41388-021-01747-z		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742125				2022-12-28	WOS:000630655600003
J	Wang, M; Zhao, XX; Qiu, R; Gong, Z; Huang, F; Yu, WJ; Shen, B; Sha, X; Dong, HB; Huang, JY; Wang, L; Zhu, W; Xu, WR				Wang, Mei; Zhao, Xinxin; Qiu, Rong; Gong, Zheng; Huang, Feng; Yu, Wanjun; Shen, Bo; Sha, Xin; Dong, Haibo; Huang, Jiaying; Wang, Lin; Zhu, Wei; Xu, Wenrong			Lymph node metastasis-derived gastric cancer cells educate bone marrow-derived mesenchymal stem cells via YAP signaling activation by exosomal Wnt5a	ONCOGENE			English	Article							BLOOD-VESSELS; IN-VIVO; INVASION; EXIT	Lymph node metastasis (LNM), a common metastatic gastric-cancer (GC) route, is closely related to poor prognosis in GC patients. Bone marrow-derived mesenchymal stem cells (BM-MSCs) preferentially engraft at metastatic lesions. Whether BM-MSCs are specifically reprogrammed by LNM-derived GC cells (LNM-GCs) and incorporated into metastatic LN microenvironment to prompt GC malignant progression remains unknown. Herein, we found that LNM-GCs specifically educated BM-MSCs via secretory exosomes. Exosomal Wnt5a was identified as key protein mediating LNM-GCs education of BM-MSCs, which was verified by analysis of serum exosomes collected from GC patients with LNM. Wnt5a-enriched exosomes induced YAP dephosphorylation in BM-MSCs, whereas Wnt5a-deficient exosomes exerted the opposite effect. Inhibition of YAP signaling by verteporfin blocked LNM-GC exosome- and serum exosome-mediated reprogramming in BM-MSCs. Analysis of MSC-like cells obtained from metastatic LN tissues of GC patients (GLN-MSCs) confirmed that BM-MSCs incorporated into metastatic LN microenvironment, and that YAP activation participated in maintaining their tumor-promoting phenotype and function. Collectively, our results show that LNM-GCs specifically educated BM-MSCs via exosomal Wnt5a-elicited activation of YAP signaling. This study provides new insights into the mechanisms of LNM in GC and BM-MSC reprogramming, and will provide potential therapeutic targets and detection indicators for GC patients with LNM.	[Wang, Mei; Zhao, Xinxin; Qiu, Rong; Gong, Zheng; Huang, Feng; Yu, Wanjun; Huang, Jiaying; Wang, Lin; Zhu, Wei; Xu, Wenrong] Jiangsu Univ, Sch Med, Key Lab Med Sci & Lab Med Jiangsu Prov, Zhenjiang, Jiangsu, Peoples R China; [Shen, Bo] Nanjing Med Univ, Affiliated Canc Hosp, Dept Oncol, Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China; [Shen, Bo] Nanjing Med Univ, Jiangsu Inst Canc Res, Affiliated Canc Hosp, Nanjing, Jiangsu, Peoples R China; [Sha, Xin] Jiangsu Univ, Affiliated Hosp Jiangsu Univ, Dept Surg, Zhenjiang, Jiangsu, Peoples R China; [Dong, Haibo] Jiangsu Univ, Dept Hematol, Nanjing Drum Tower Hosp, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China	Jiangsu University; Nanjing Medical University; Nanjing Medical University; Jiangsu University; Jiangsu University; Nanjing University	Wang, M (corresponding author), Jiangsu Univ, Sch Med, Key Lab Med Sci & Lab Med Jiangsu Prov, Zhenjiang, Jiangsu, Peoples R China.	wangmei8417@163.com			National Natural Science Foundation of China [81772641, 81902510, 81302119, 81972313, 81972822]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China [grant numbers 81772641, 81902510, 81302119, 81972313, and 81972822].	Astudillo P, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00110; Baglio SR, 2017, CLIN CANCER RES, V23, P3721, DOI 10.1158/1078-0432.CCR-16-2726; Barcellos-de-Souza P, 2013, BBA-REV CANCER, V1836, P321, DOI 10.1016/j.bbcan.2013.10.004; Blache U, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201900304; Blogowski W, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1099798; Brown M, 2018, SCIENCE, V359, P1408, DOI 10.1126/science.aal3662; Canesin G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184418; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Deng JY, 2014, WORLD J GASTROENTERO, V20, P3967, DOI 10.3748/wjg.v20.i14.3967; Flanagan DJ, 2019, CANCER RES, V79, P970, DOI 10.1158/0008-5472.CAN-18-2095; Gangoda L, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201600370; Gonzalez ME, 2017, CELL REP, V18, P1215, DOI 10.1016/j.celrep.2016.12.079; Gross JC, 2012, NAT CELL BIOL, V14, P1036, DOI 10.1038/ncb2574; Hanaki H, 2012, MOL CANCER THER, V11, P298, DOI 10.1158/1535-7163.MCT-11-0682; Ji H, 2013, PROTEOMICS, V13, P1672, DOI 10.1002/pmic.201200562; Kasashima H, 2016, AM J PATHOL, V186, P3028, DOI 10.1016/j.ajpath.2016.07.024; Lazar I, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12380; Li XX, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0269-y; Lin LY, 2016, ONCOGENE, V35, P6038, DOI 10.1038/onc.2016.131; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Luo C, 2020, J CLIN INVEST, V130, P853, DOI 10.1172/JCI130038; Meade Kayla J, 2019, Oncotarget, V10, P3027, DOI 10.18632/oncotarget.26903; Nam S, 2017, CELL PHYSIOL BIOCHEM, V41, P33, DOI 10.1159/000455934; Pan ZJ, 2017, INT J ONCOL, V51, P1055, DOI 10.3892/ijo.2017.4101; Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013; Pellino A, 2019, WORLD J GASTROENTERO, V25, P5773, DOI 10.3748/wjg.v25.i38.5773; Pereira ER, 2018, SCIENCE, V359, P1403, DOI 10.1126/science.aal3622; Ridge SM, 2018, INT J CANCER, V142, P2056, DOI 10.1002/ijc.31226; Ridge SM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0597-8; Safholm A, 2008, CLIN CANCER RES, V14, P6556, DOI 10.1158/1078-0432.CCR-08-0711; Shen YM, 2019, STEM CELLS DEV, V28, P464, DOI 10.1089/scd.2018.0125; Shi YF, 2017, NAT REV DRUG DISCOV, V16, P35, DOI 10.1038/nrd.2016.193; Sleeman JP, 2015, J MOL MED, V93, P1173, DOI 10.1007/s00109-015-1351-6; Tao SC, 2017, THERANOSTICS, V7, P180, DOI 10.7150/thno.17133; Wang M, 2014, BRIT J CANCER, V110, P1199, DOI 10.1038/bjc.2014.14; Xie CY, 2017, STEM CELL TRANSL MED, V6, P1120, DOI 10.1002/sctm.16-0204; Yamamoto H, 2009, GASTROENTEROLOGY, V137, P242, DOI 10.1053/j.gastro.2009.02.003; Zheng YG, 2019, DEV CELL, V50, P264, DOI 10.1016/j.devcel.2019.06.003; Zhu HY, 2016, INT J BIOL SCI, V12, P389, DOI 10.7150/ijbs.13688; Zhu T, 2018, ONCOL LETT, V15, P3409, DOI 10.3892/ol.2018.7813	40	15	15	8	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2296	2308		10.1038/s41388-021-01722-8	http://dx.doi.org/10.1038/s41388-021-01722-8		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33654199	hybrid, Green Published			2022-12-28	WOS:000624398900004
J	Schafer, A; Haenig, B; Erupathil, J; Strickner, P; Sabato, D; Welford, RWD; Klaeyle, L; Simon, E; Krepler, C; Brafford, P; Xiao, M; Herlyn, M; Gstaiger, M; Lehembre, F; Renz, I				Schaefer, Alexander; Haenig, Benedicte; Erupathil, Julie; Strickner, Panja; Sabato, Daniela; Welford, Richard W. D.; Klaeyle, Lheanna; Simon, Elise; Krepler, Clemens; Brafford, Patricia; Xiao, Min; Herlyn, Meenhard; Gstaiger, Matthias; Lehembre, Francois; Renz, Imke			Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma	ONCOGENE			English	Article							METASTATIC MELANOMA; CONFERS RESISTANCE; CELLS; EXPRESSION; APOPTOSIS; ANTAGONIST; SURVIVAL; BEHAVIOR; THERAPY; GROWTH	The clinical benefit of MAPK pathway inhibition in melanoma patients carrying BRAF mutations is temporal. After the initial response to treatment, the majority of tumors will develop resistance and patients will relapse. Here we demonstrate that the endothelin-endothelin receptor B (ETBR) signaling pathway confers resistance to MAPK pathway inhibitors in BRAF mutated melanoma. MAPK blockade, in addition to being anti-proliferative, induces a phenotypic change which is characterized by increased expression of melanocyte-specific genes including ETBR. In the presence of MAPK inhibitors, activation of ETBR by endothelin enables the sustained proliferation of melanoma cells. In mouse models of melanoma, including patient-derived xenograft models, concurrent inhibition of the MAPK pathway and ETBR signaling resulted in a more effective anti-tumor response compared to MAPK pathway inhibition alone. The combination treatment significantly reduced tumor growth and prolonged survival compared to therapies with MAPK pathway inhibitors alone. The phosphoproteomic analysis revealed that ETBR signaling did not induce resistance towards MAPK pathway inhibitors by restoring MAPK activity, but instead via multiple alternative signaling pathways downstream of the small G proteins GNAq/11. Together these data indicate that a combination of MAPK pathway inhibitors with ETBR antagonists could have a synergistically beneficial effect in melanoma patients with hyperactivated MAPK signaling pathways.	[Schaefer, Alexander; Gstaiger, Matthias] Swiss Fed Inst Technol, Inst Mol Syst Biol, Dept Biol, Otto Stern Weg 3, CH-8093 Zurich, Switzerland; [Haenig, Benedicte; Erupathil, Julie; Strickner, Panja; Sabato, Daniela; Welford, Richard W. D.; Klaeyle, Lheanna; Simon, Elise; Lehembre, Francois; Renz, Imke] Idorsia Pharmaceut Ltd, Drug Discovery Biol, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland; [Krepler, Clemens; Brafford, Patricia; Xiao, Min; Herlyn, Meenhard] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program & Melanoma Res, 3601 Spruce St, Philadelphia, PA 19104 USA; [Schaefer, Alexander] Swiss BioQuant AG, CH-4153 Reinach, Switzerland; [Simon, Elise] Novartis Inst BioMed Res, CH-4002 Basel, Switzerland; [Krepler, Clemens] Merck, N Wales, PA 19454 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Idorsia Pharmaceuticals Ltd; The Wistar Institute; Novartis	Renz, I (corresponding author), Idorsia Pharmaceut Ltd, Drug Discovery Biol, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland.	imke.renz@idorsia.com			Idorsia Pharmaceuticals Ltd.	Idorsia Pharmaceuticals Ltd.	The study was funded by Idorsia Pharmaceuticals Ltd.	Asundi J, 2014, MOL CANCER THER, V13, P1599, DOI 10.1158/1535-7163.MCT-13-0446; Asundi J, 2011, CLIN CANCER RES, V17, P965, DOI 10.1158/1078-0432.CCR-10-2340; Bagnato A, 2004, CANCER RES, V64, P1436, DOI 10.1158/0008-5472.CAN-03-2344; Barton M, 2008, CAN J PHYSIOL PHARM, V86, P485, DOI 10.1139/Y08-059; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Borrull A, 2016, MABS-AUSTIN, V8, P1371, DOI 10.1080/19420862.2016.1208865; Chiriboga L, 2016, MELANOMA RES, V26, P236, DOI 10.1097/CMR.0000000000000235; Christensen C, 2005, ONCOGENE, V24, P6292, DOI 10.1038/sj.onc.1208758; Demunter A, 2001, VIRCHOWS ARCH, V438, P485, DOI 10.1007/s004280000362; Faiao-Flores F, 2019, CLIN CANCER RES, V25, P5686, DOI 10.1158/1078-0432.CCR-18-3382; Haq R, 2013, P NATL ACAD SCI USA, V110, P4321, DOI 10.1073/pnas.1205575110; Hoek KS, 2008, PIGM CELL MELANOMA R, V21, P665, DOI 10.1111/j.1755-148X.2008.00505.x; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Jankov RP, 2006, PEDIATR RES, V60, P245, DOI 10.1203/01.pdr.0000233056.37254.0b; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Johnson DB, 2015, EUR J CANCER, V51, P2792, DOI 10.1016/j.ejca.2015.08.022; Kakadia S, 2018, ONCOTARGETS THER, V11, P7095, DOI 10.2147/OTT.S182721; Kefford R, 2007, INVEST NEW DRUG, V25, P247, DOI 10.1007/s10637-006-9014-7; Kefford RF, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-69; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Lahav R, 2004, CANCER RES, V64, P8945, DOI 10.1158/0008-5472.CAN-04-1510; Lahav R, 1999, P NATL ACAD SCI USA, V96, P11496, DOI 10.1073/pnas.96.20.11496; Lin NX, 2007, J HUAZHONG U SCI-MED, V27, P611, DOI 10.1007/s11596-007-0535-x; Luebker SA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00268; Maffei R, 2017, ONCOTARGET, V8, P90013, DOI 10.18632/oncotarget.21341; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Nelson JB, 2005, NEOPLASIA, V7, P631, DOI 10.1593/neo.04787; Paulitschke V, 2019, EMBO J, V38, DOI 10.15252/embj.201695874; Rosano L, 2004, J CARDIOVASC PHARM, V44, pS136, DOI 10.1097/01.fjc.0000166247.35992.dd; Rosano L, 2013, NAT REV CANCER, V13, P637, DOI 10.1038/nrc3546; Sandhu S, 2020, INVEST NEW DRUG, V38, P844, DOI 10.1007/s10637-019-00832-1; Sato-Jin K, 2008, FASEB J, V22, P1155, DOI 10.1096/fj.07-9080com; Schafer A, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20198828; Schorlemmer A, 2008, TRENDS CARDIOVAS MED, V18, P233, DOI 10.1016/j.tcm.2008.11.005; Shoushtari AN, 2014, MELANOMA RES, V24, P525, DOI 10.1097/CMR.0000000000000121; Smith MP, 2017, EMBO MOL MED, V9, P1011, DOI 10.15252/emmm.201607156; Smith MP, 2016, CANCER CELL, V29, P270, DOI 10.1016/j.ccell.2016.02.003; Spinella F, 2007, CANCER RES, V67, P1725, DOI 10.1158/0008-5472.CAN-06-2606; Tang L, 2008, J CUTAN MED SURG, V12, P64, DOI 10.2310/7750.2008.06164; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Wu-Wong JR, 2002, CLIN SCI, V103, p107S, DOI 10.1042/CS103S107S; Xing F, 2012, ONCOGENE, V31, P446, DOI 10.1038/onc.2011.250; YOHN JJ, 1994, BIOCHEM BIOPH RES CO, V201, P449, DOI 10.1006/bbrc.1994.1722	44	5	5	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1659	1673		10.1038/s41388-020-01628-x	http://dx.doi.org/10.1038/s41388-020-01628-x		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33500549				2022-12-28	WOS:000611934200001
J	Zhang, X; Liu, Y; Dai, L; Shi, G; Deng, J; Luo, Q; Xie, Q; Cheng, L; Li, CL; Lin, Y; Wang, QN; Fan, P; Zhang, HT; Su, XL; Zhang, S; Yang, Y; Hu, X; Gong, QY; Yu, DC; Zheng, L; Deng, HX				Zhang, Xin; Liu, Yi; Dai, Lei; Shi, Gang; Deng, Jie; Luo, Qiang; Xie, Qian; Cheng, Lin; Li, Chunlei; Lin, Yi; Wang, Qingnan; Fan, Ping; Zhang, Hantao; Su, Xiaolan; Zhang, Shuang; Yang, Yang; Hu, Xun; Gong, Qiyong; Yu, Dechao; Zheng, Lei; Deng, Hongxin			BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells	ONCOGENE			English	Article							STEM-CELLS; EXTRACELLULAR VESICLES; CANCER; INFLAMMATION; METASTASIS; ACTIVATION; AP-1	The basic leucine zipper ATF-like transcription factor 2 (BATF2) has been implicated in inflammatory responses and anti-tumour effects. Little, however, is known regarding its extracellular role in maintaining a non-supportive cancer microenvironment. Here, we show that BATF2 inhibits glioma growth and myeloid-derived suppressor cells (MDSCs) recruitment. Interestingly, extracellular vesicles (EVs) from BATF2-overexpressing glioma cell lines (BATF2-EVs) inhibited MDSCs chemotaxis in vitro. Moreover, BATF2 inhibited intracellular SDF-1 alpha and contributes to decreased SDF-1 alpha in EVs. In addition, BATF2 downregulation-induced MDSCs recruitment were reversed by blocking SDF-1 alpha/CXCR4 signalling upon AMD3100 treatment. Specifically, detection of EVs in 24 pairs of gliomas and healthy donors at different stages revealed that the abundance of BATF2-positive EVs in plasma (BATF2(+) plEVs) can distinguish stage III-IV glioma from stage I-II glioma and healthy donors. Taken together, our study identified novel regulatory functions of BATF2 in regulating MDSCs recruitment, providing a prognostic value in terms of the number of BATF2(+) plEVs in glioma stage.	[Zhang, Xin; Liu, Yi; Dai, Lei; Shi, Gang; Deng, Jie; Cheng, Lin; Li, Chunlei; Lin, Yi; Wang, Qingnan; Zhang, Hantao; Su, Xiaolan; Yang, Yang; Yu, Dechao; Deng, Hongxin] Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Xin; Liu, Yi; Dai, Lei; Shi, Gang; Deng, Jie; Cheng, Lin; Li, Chunlei; Lin, Yi; Wang, Qingnan; Zhang, Hantao; Su, Xiaolan; Yang, Yang; Yu, Dechao; Deng, Hongxin] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Xin; Zheng, Lei] Southern Med Univ, Nanfang Hosp, Lab Med Ctr, Guangzhou 510515, Guangdong, Peoples R China; [Luo, Qiang; Gong, Qiyong] Sichuan Univ, West China Hosp, Huaxi MR Res Ctr, Dept Radiol, Chengdu 610041, Sichuan, Peoples R China; [Xie, Qian] Sichuan Univ, Gen Practice Dept, West China Hosp, Chengdu 610041, Sichuan, Peoples R China; [Fan, Ping; Hu, Xun] Sichuan Univ, West China Hosp, Huaxi Biobank, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Shuang] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China	Sichuan University; Southern Medical University - China; Sichuan University; Sichuan University; Sichuan University; Sichuan University	Deng, HX (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.; Deng, HX (corresponding author), Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.; Zheng, L (corresponding author), Southern Med Univ, Nanfang Hosp, Lab Med Ctr, Guangzhou 510515, Guangdong, Peoples R China.	nfyyzhenglei@smu.edu.cn; denghongx@scu.edu.cn	Gong, Qiyong/W-3052-2019	Gong, Qiyong/0000-0002-5912-4871; Liu, Yi/0000-0003-3108-7981; Deng, Hongxin/0000-0001-5094-1376	National Natural Science Foundation of China [81772939, 81902147]; National Key R&D Program of China [2017YFA0105702]; 1.3.5 project for disciplines of excellence in West China Hospital, Sichuan University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; 1.3.5 project for disciplines of excellence in West China Hospital, Sichuan University	Our study was supported by the National Natural Science Foundation of China Program grant (no. 81772939), National Natural Science Foundation of China Program grant (no. 81902147), the National Key R&D Program of China grant (no. 2017YFA0105702) and 1.3.5 project for disciplines of excellence in West China Hospital, Sichuan University.	Alexander BM, 2018, CLIN CANCER RES, V24, P737, DOI 10.1158/1078-0432.CCR-17-0764; Andrade AF, 2017, INVEST NEW DRUG, V35, P26, DOI 10.1007/s10637-016-0401-4; Boussiotis VA, 2018, ONCOGENE, V37, P1121, DOI 10.1038/s41388-017-0024-z; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Dai L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11996; Dash R, 2010, ONCOGENE, V29, P4412, DOI 10.1038/onc.2010.194; Dash R, 2014, CANCER RES, V74, P563, DOI 10.1158/0008-5472.CAN-13-1062; Devignes CS, 2018, P NATL ACAD SCI USA, V115, pE992, DOI 10.1073/pnas.1718009115; Dorayappan KDP, 2018, ONCOGENE, V37, P3806, DOI 10.1038/s41388-018-0189-0; Dubinski D, 2016, NEURO-ONCOLOGY, V18, P807, DOI 10.1093/neuonc/nov280; Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636; Genschmer KR, 2019, CELL, V176, P113, DOI 10.1016/j.cell.2018.12.002; Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139; Hu BL, 2016, CELL, V167, P1281, DOI 10.1016/j.cell.2016.10.039; Hu Y, 2019, J CLIN INVEST, V129, P3072, DOI 10.1172/JCI124979; Huang Q, 2011, TUMOR BIOL, V32, P1191, DOI 10.1007/s13277-011-0222-1; Huse JT, 2014, CLIN CANCER RES, V20, P5601, DOI 10.1158/1078-0432.CCR-14-0831; Janssens R, 2018, CELL MOL IMMUNOL, V15, P299, DOI 10.1038/cmi.2017.107; Jin X, 2012, BRAIN, V135, P1055, DOI 10.1093/brain/aws028; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kabe Y, 2018, CLIN CHEM, V64, P1463, DOI 10.1373/clinchem.2018.291963; Kalinichenko SV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039505; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Keklikoglou I, 2019, NAT CELL BIOL, V21, P190, DOI 10.1038/s41556-018-0256-3; Khalife J, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129348; Kucharzewska P, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20304; Lee SY, 2016, GENES DIS, V3, P198, DOI 10.1016/j.gendis.2016.04.007; Li WH, 2014, APMIS, V122, P1080, DOI 10.1111/apm.12261; Liao YX, 2013, INT J MOL MED, V32, P1239, DOI 10.3892/ijmm.2013.1521; Liu ZB, 2015, CLIN CANCER RES, V21, P1752, DOI 10.1158/1078-0432.CCR-14-1564; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Morad G, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1627164; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Ricklefs F, 2016, CANCER RES, V76, P2876, DOI 10.1158/0008-5472.CAN-15-3432; Santiago-Dieppa DR, 2014, EXPERT REV MOL DIAGN, V14, P819, DOI 10.1586/14737159.2014.943193; Schmid RS, 2016, NEURO-ONCOLOGY, V18, P962, DOI 10.1093/neuonc/nov321; Shao HL, 2018, CHEM REV, V118, P1917, DOI 10.1021/acs.chemrev.7b00534; Shao HL, 2012, NAT MED, V18, P1835, DOI 10.1038/nm.2994; Solito S, 2011, BLOOD, V118, P2254, DOI 10.1182/blood-2010-12-325753; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Tan JN, 2017, J IMMUNOL, V198, P2269, DOI 10.4049/jimmunol.1600610; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Tian Y, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1697028; Wang XX, 2018, CELL STEM CELL, V22, P514, DOI 10.1016/j.stem.2018.03.011; Weller M, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.17	50	7	7	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1516	1530		10.1038/s41388-020-01627-y	http://dx.doi.org/10.1038/s41388-020-01627-y		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452462	hybrid, Green Published			2022-12-28	WOS:000607998600012
J	Roggero, CM; Jin, LJ; Cao, SB; Sonavane, R; Kopplin, NG; Ta, HQ; Ekoue, DN; Witwer, M; Ma, SH; Liu, H; Ma, TF; Gioeli, D; Raj, GV; Dong, Y				Roggero, Carlos M.; Jin, Lianjin; Cao, Subing; Sonavane, Rajni; Kopplin, Noa G.; Ta, Huy Q.; Ekoue, Dede N.; Witwer, Michael; Ma, Shihong; Liu, Hong; Ma, Tianfang; Gioeli, Daniel; Raj, Ganesh V.; Dong, Yan			A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells	ONCOGENE			English	Article							SPLICE VARIANTS; RESISTANCE; ENZALUTAMIDE; ABIRATERONE; AR-V7; AR; BINDING; GROWTH; INHIBITION; EXPRESSION	Expression of the androgen receptor splice variant 7 (AR-V7) is frequently detected in castrate resistant prostate cancer and associated with resistance to AR-targeted therapies. While we have previously noted that homodimerization is required for the transcriptional activity of AR-V7 and that AR-V7 can also form heterodimers with the full-length AR (AR-FL), there are still many gaps of knowledge in AR-V7 stepwise activation. In the present study, we show that neither AR-V7 homodimerization nor AR-V7/AR-FL heterodimerization requires cofactors or DNA binding. AR-V7 can enter the nucleus as a monomer and drive a transcriptional program and DNA-damage repair as a homodimer. While forming a heterodimer with AR-FL to induce nuclear localization of unliganded AR-FL, AR-V7 does not need to interact with AR-FL to drive gene transcription or DNA-damage repair in prostate cancer cells that co-express AR-V7 and AR-FL. These data indicate that AR-V7 can function independently of its interaction with AR-FL in the true castrate state or "absence of ligand", providing support for the utility of targeting AR-V7 in improving outcomes of patients with castrate resistant prostate cancer.	[Roggero, Carlos M.; Sonavane, Rajni; Kopplin, Noa G.; Ekoue, Dede N.; Witwer, Michael; Ma, Shihong; Raj, Ganesh V.] UT SouthWestern Med Ctr Dallas, Dept Urol, Dallas, TX USA; [Jin, Lianjin; Cao, Subing; Ma, Tianfang; Dong, Yan] Tulane Univ, Sch Med, Tulane Canc Ctr, Dept Struct & Cellular Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA; [Ta, Huy Q.; Gioeli, Daniel] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA USA; [Liu, Hong] Tulane Univ, Sch Med, Dept Biochem & Mol Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA; [Raj, Ganesh V.] UT Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA	Tulane University; University of Virginia; Tulane University	Raj, GV (corresponding author), UT SouthWestern Med Ctr Dallas, Dept Urol, Dallas, TX USA.; Dong, Y (corresponding author), Tulane Univ, Sch Med, Tulane Canc Ctr, Dept Struct & Cellular Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA.; Raj, GV (corresponding author), UT Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.	ganesh.raj@utsouthwestern.edu; ydong@tulane.edu		Ma, Tianfang/0000-0003-4161-882X	Department of Defense [W81XWH-19-1-0363, W81XWH-17-10674, W81XWH-15-1-0439, W81XWH-16-1-0317]; Prostate Cancer Foundation Challenge Award; Mimi and John Cole Foundation; Charles Y. Pak grant; National Institutes of Health [R01CA188609, R01 CA178338]	Department of Defense(United States Department of Defense); Prostate Cancer Foundation Challenge Award; Mimi and John Cole Foundation; Charles Y. Pak grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was funded by grants from the Department of Defense (W81XWH-19-1-0363, W81XWH-17-10674), Prostate Cancer Foundation Challenge Award, Mimi and John Cole Foundation and Charles Y. Pak grant to GVR, from the National Institutes of Health (R01CA188609) and the Department of Defense (W81XWH-15-1-0439 and W81XWH-16-1-0317) to YD, and from the National Institutes of Health (R01 CA178338) to DG. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.	Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Bai SS, 2019, ONCOGENE, V38, P4977, DOI 10.1038/s41388-019-0768-8; Cai CM, 2011, ENDOCR-RELAT CANCER, V18, pR175, DOI 10.1530/ERC-10-0339; Cai L, 2018, MOL CELL, V72, P341, DOI 10.1016/j.molcel.2018.08.029; Cao B, 2014, ONCOTARGET, V5, P1646, DOI 10.18632/oncotarget.1802; Cao SB, 2019, ONCOGENE, V38, P7060, DOI 10.1038/s41388-019-0947-7; Cao SB, 2016, ENDOCR-RELAT CANCER, V23, pT199, DOI 10.1530/ERC-16-0298; Cato L, 2019, CANCER CELL, V35, P401, DOI 10.1016/j.ccell.2019.01.008; Chan SC, 2015, NUCLEIC ACIDS RES, V43, P5880, DOI 10.1093/nar/gkv262; Chan SC, 2012, J BIOL CHEM, V287, P19736, DOI 10.1074/jbc.M112.352930; Chen Z, 2018, P NATL ACAD SCI USA, V115, P6810, DOI 10.1073/pnas.1718811115; Davis ID, 2019, NEW ENGL J MED, V381, P121, DOI 10.1056/NEJMoa1903835; de Bono J, 2017, NEW ENGL J MED, V377, P1694; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dong Y, 2004, CANCER RES, V64, P19, DOI 10.1158/0008-5472.CAN-03-2789; Dong Y, 2005, MOL CANCER THER, V4, P1047, DOI 10.1158/1535-7163.MCT-05-0124; Dubbink HJ, 2004, MOL ENDOCRINOL, V18, P2132, DOI 10.1210/me.2003-0375; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; He YD, 2018, NUCLEIC ACIDS RES, V46, P1895, DOI 10.1093/nar/gkx1306; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536; Kohli M, 2017, CLIN CANCER RES, V23, P4704, DOI 10.1158/1078-0432.CCR-17-0017; Kounatidou E, 2019, NUCLEIC ACIDS RES, V47, P5634, DOI 10.1093/nar/gkz286; Krause WC, 2014, INT J BIOCHEM CELL B, V54, P49, DOI 10.1016/j.biocel.2014.06.013; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Loriot Y, 2017, CANCER-AM CANCER SOC, V123, P253, DOI 10.1002/cncr.30336; Lu J, 2015, J UROLOGY, V193, P690, DOI 10.1016/j.juro.2014.08.043; Magani F, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20188202; Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728; Nadiminty N, 2013, MOL CANCER THER, V12, P1629, DOI 10.1158/1535-7163.MCT-13-0027; Nyquist MD, 2013, P NATL ACAD SCI USA, V110, P17492, DOI 10.1073/pnas.1308587110; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sartor O, 2018, NEW ENGL J MED, V378, P645, DOI 10.1056/NEJMra1701695; Scher HI, 2016, JAMA ONCOL, V2, P1441, DOI 10.1001/jamaoncol.2016.1828; Shaffer PL, 2004, P NATL ACAD SCI USA, V101, P4758, DOI 10.1073/pnas.0401123101; Shafi AA, 2015, ONCOTARGET, V6, P31997, DOI 10.18632/oncotarget.5585; Sharp A, 2019, EUR UROL, V76, P676, DOI 10.1016/j.eururo.2019.04.006; Sharp A, 2019, J CLIN INVEST, V129, P192, DOI 10.1172/JCI122819; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Ta HQ, 2020, ELIFE, V9, DOI 10.7554/eLife.51378; Todenhofer T, 2017, J UROLOGY, V197, P135, DOI 10.1016/j.juro.2016.06.094; Uo T, 2017, ONCOGENE, V36, P1440, DOI 10.1038/onc.2016.313; van Royen ME, 2012, J CELL SCI, V125, P1970, DOI 10.1242/jcs.096792; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Welti J, 2016, EUR UROL, V70, P599, DOI 10.1016/j.eururo.2016.03.049; Xu D, 2015, CANCER RES, V75, P3663, DOI 10.1158/0008-5472.CAN-15-0381; Yin Y, 2017, CANCER RES, V77, P4745, DOI 10.1158/0008-5472.CAN-17-0164; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhan Y, 2017, MOL CANCER RES, V15, P59, DOI 10.1158/1541-7786.MCR-16-0236	54	13	13	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1106	1117		10.1038/s41388-020-01585-5	http://dx.doi.org/10.1038/s41388-020-01585-5		DEC 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323969	Green Accepted			2022-12-28	WOS:000599126500002
J	Haldrup, J; Strand, SH; Cieza-Borrella, C; Jakobsson, ME; Riedel, M; Norgaard, M; Hedensted, S; Dagnaes-Hansen, F; Ulhoi, BP; Eeles, R; Borre, M; Olsen, JV; Thomsen, M; Kote-Jarai, Z; Sorensen, KD				Haldrup, Jakob; Strand, Siri H.; Cieza-Borrella, Clara; Jakobsson, Magnus E.; Riedel, Maria; Norgaard, Maibritt; Hedensted, Stine; Dagnaes-Hansen, Frederik; Ulhoi, Benedicte Parm; Eeles, Rosalind; Borre, Michael; Olsen, Jesper, V; Thomsen, Martin; Kote-Jarai, Zsofia; Sorensen, Karina D.			FRMD6 has tumor suppressor functions in prostate cancer	ONCOGENE			English	Article							EXPRESSION ANALYSIS; GENE; YAP/TAZ; TOPHAT; WILLIN	Available tools for prostate cancer (PC) prognosis are suboptimal but may be improved by better knowledge about genes driving tumor aggressiveness. Here, we identified FRMD6 (FERM domain-containing protein 6) as an aberrantly hypermethylated and significantly downregulated gene in PC. Low FRMD6 expression was associated with postoperative biochemical recurrence in two large PC patient cohorts. In overexpression and CRISPR/Cas9 knockout experiments in PC cell lines, FRMD6 inhibited viability, proliferation, cell cycle progression, colony formation, 3D spheroid growth, and tumor xenograft growth in mice. Transcriptomic, proteomic, and phospho-proteomic profiling revealed enrichment of Hippo/YAP and c-MYC signaling upon FRMD6 knockout. Connectivity Map analysis and drug repurposing experiments identified pyroxamide as a new potential therapy for FRMD6 deficient PC cells. Finally, we established orthotropic Frmd6 and Pten, or Pten only (control) knockout in the ROSA26 mouse prostate. After 12 weeks, Frmd6/Pten double knockouts presented high-grade prostatic intraepithelial neoplasia (HG-PIN) and hyperproliferation, while Pten single-knockouts developed only regular PIN lesions and displayed lower proliferation. In conclusion, FRMD6 was identified as a novel tumor suppressor gene and prognostic biomarker candidate in PC.	[Haldrup, Jakob; Strand, Siri H.; Norgaard, Maibritt; Hedensted, Stine; Sorensen, Karina D.] Aarhus Univ Hosp, Dept Mol Med, Aarhus, Denmark; [Haldrup, Jakob; Strand, Siri H.; Riedel, Maria; Norgaard, Maibritt; Hedensted, Stine; Sorensen, Karina D.] Aarhus Univ, Dept Clin Med, Aarhus, Denmark; [Cieza-Borrella, Clara; Eeles, Rosalind; Kote-Jarai, Zsofia] Inst Canc Res, Div Genet & Epidemiol, Oncogenet, London, England; [Jakobsson, Magnus E.; Olsen, Jesper, V] Univ Copenhagen, Novo Nordisk Fdn, Ctr Prot Res, Copenhagen, Denmark; [Jakobsson, Magnus E.] Lund Univ, Dept Immunotechnol, S-22100 Lund, Sweden; [Dagnaes-Hansen, Frederik; Thomsen, Martin] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Ulhoi, Benedicte Parm] Aarhus Univ Hosp, Inst Pathol, Aarhus, Denmark; [Eeles, Rosalind] Inst Canc Res, London, England; [Eeles, Rosalind] Royal Marsden NHS Fdn Trust, London, England; [Borre, Michael] Aarhus Univ Hosp, Dept Urol, Aarhus, Denmark	Aarhus University; Aarhus University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Novo Nordisk Foundation; University of Copenhagen; Lund University; Aarhus University; Aarhus University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Aarhus University	Sorensen, KD (corresponding author), Aarhus Univ Hosp, Dept Mol Med, Aarhus, Denmark.; Sorensen, KD (corresponding author), Aarhus Univ, Dept Clin Med, Aarhus, Denmark.	kdso@clin.au.dk	Olsen, Jesper/ABH-4638-2020; Thomsen, Martin/AAU-5014-2021	Olsen, Jesper/0000-0002-4747-4938; Thomsen, Martin/0000-0002-5055-7531; Cieza-Borrella, Clara/0000-0003-2739-1040; Riedel, Maria/0000-0002-6545-0243; Borre, Michael/0000-0002-1519-9185; Strand, Siri/0000-0001-6596-9945; Sorensen, Karina Dalsgaard/0000-0002-4902-5490; Eeles, Rosalind/0000-0002-3698-6241	Royal Marsden NHS Foundation Trust; de Laszlo Foundation; Danish Cancer Society; Velux Foundation (KDS); Novo Nordisk Foundation [NNF16OC0023048, NNF16OC0022946, NNF14CC0001]; Independent Research Fund Denmark, The Harboe Foundation; Lundbeck Foundation [R231-2016-2682]; National Institute of Health Research; Aarhus University; NIHR	Royal Marsden NHS Foundation Trust(Royal Society of New ZealandMarsden Fund (NZ)); de Laszlo Foundation; Danish Cancer Society(Danish Cancer Society); Velux Foundation (KDS); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Independent Research Fund Denmark, The Harboe Foundation; Lundbeck Foundation(Lundbeckfonden); National Institute of Health Research(National Institute for Health Research (NIHR)); Aarhus University; NIHR(National Institute for Health Research (NIHR))	Prof. Raymond C. Bergan (Department of Medicine, Northwestern University, Chicago, USA) generously provided the PC-3M cell line. The DU145-MN1 cell line was kindly provided by Dr Volker Jung (Institute of Urology and Pediatric Urology, University of Saarland, Hamburg/Saar, Germany). We thank Dr SOren Vang, Dr Morten Muhlig, and Dr Michael Knudsen for bioinformatics support. The Danish Cancer Biobank (DCB) is acknowledged for biological material. Ros Eeles and Zsofia Kote-Karai are supported by NIHR support to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust. Clara Cieza-Borella was supported by a donation from the Burstons and by research donations from the de Laszlo Foundation. This work was supported by The Danish Cancer Society (KDS), The Velux Foundation (KDS), The Novo Nordisk Foundation [NNF16OC0023048 (KDS); NNF16OC0022946 (MEJ); NNF14CC0001 (JVO)], The Independent Research Fund Denmark, The Harboe Foundation (JHJ), The Lundbeck Foundation [R231-2016-2682 (MEJ)], National Institute of Health Research (RE), The Biomedical Research Centre at the Institute of Cancer Research and Royal Marsden NHS Foundation Trust (RE), Richard and Debbi Burston, Nick Phillips and Bradshaw Foundation (CCB), and Aarhus University (JHJ/SHS).	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Angus L, 2012, ONCOGENE, V31, P238, DOI 10.1038/onc.2011.224; [Anonymous], 2013, P NATL ACAD SCI USA, V110, P17160; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bocci F, 2019, INTEGR BIOL-UK, V11, P251, DOI 10.1093/intbio/zyz021; Brawer Michael K, 2005, Rev Urol, V7 Suppl 3, pS11; Dart DA, 2017, ONCOGENESIS, V6, DOI 10.1038/s41389-017-0007-5; Feber A, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r30; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guan CJ, 2019, BIOCHEM BIOPH RES CO, V515, P112, DOI 10.1016/j.bbrc.2019.05.025; Gunn-Moore FJ, 2005, FEBS LETT, V579, P5089, DOI 10.1016/j.febslet.2005.07.097; Gunn-Moore FJ, 2016, GENES-BASEL, V7, DOI 10.3390/genes7070037; Haldrup C, 2018, MOL ONCOL, V12, P545, DOI 10.1002/1878-0261.12183; Haldrup C, 2016, MOL ONCOL, V10, P825, DOI 10.1016/j.molonc.2016.02.001; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hedegaard J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098187; Hieronymus H, 2014, P NATL ACAD SCI USA, V111, P11139, DOI 10.1073/pnas.1411446111; Ishiuchi T, 2012, GENES CELLS, V17, P387, DOI 10.1111/j.1365-2443.2012.01593.x; Ishiuchi T, 2011, NAT CELL BIOL, V13, P860, DOI 10.1038/ncb2274; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Jolly MK, 2019, PHARMACOL THERAPEUT, V194, P161, DOI 10.1016/j.pharmthera.2018.09.007; Jolly MK, 2016, ONCOTARGET, V7, P27067, DOI 10.18632/oncotarget.8166; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Long Q, 2014, CANCER RES, V74, P3228, DOI 10.1158/0008-5472.CAN-13-2699; Morris TJ, 2014, BIOINFORMATICS, V30, P428, DOI 10.1093/bioinformatics/btt684; Moya IM, 2019, NAT REV MOL CELL BIO, V20, P211, DOI 10.1038/s41580-018-0086-y; Nebbioso A, 2017, CLIN CANCER RES, V23, P2542, DOI 10.1158/1078-0432.CCR-15-2388; Nishimoto M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47301-6; Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014; Poole CJ, 2017, GENES-BASEL, V8, DOI 10.3390/genes8050142; Riedel M, 2018, JOVE-J VIS EXP, DOI 10.3791/57525; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Schmidt L, 2018, BRIT J CANCER, V119, P1527, DOI 10.1038/s41416-018-0321-5; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Stauffer S, 2016, FEBS J, V283, P1800, DOI 10.1111/febs.13718; Steineck G, 2002, NEW ENGL J MED, V347, P790, DOI 10.1056/NEJMoa021483; Strand SH, 2017, ONCOTARGET, V8, P5774, DOI 10.18632/oncotarget.14391; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Visser-Grieve S, 2012, ONCOGENE, V31, P1189, DOI 10.1038/onc.2011.318; Wang JZ, 2018, BIOCHEM BIOPH RES CO, V506, P590, DOI 10.1016/j.bbrc.2018.10.088; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Xu Y, 2016, ONCOTARGET, V7, P70080, DOI 10.18632/oncotarget.12148; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhou PJ, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0609-y; Zhu YT, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv129; Zhu YT, 2014, NAT METHODS, V11, P599, DOI 10.1038/nmeth.2956	52	14	14	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					763	776		10.1038/s41388-020-01548-w	http://dx.doi.org/10.1038/s41388-020-01548-w		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33249427				2022-12-28	WOS:000594680900001
J	Kim, JY; Kim, HJ; Jung, CW; Choi, BI; Lee, DH; Park, MJ				Kim, Jeong-Yub; Kim, Hee-Jin; Jung, Chan-Woong; Choi, Byung-Il; Lee, Dae-Hee; Park, Myung-Jin			PARK7 maintains the stemness of glioblastoma stem cells by stabilizing epidermal growth factor receptor variant III	ONCOGENE			English	Article							PARKINSONS-DISEASE; CANCER-CELLS; DJ-1; IDENTIFICATION; EXPRESSION; TARGET; GLIOMA; EGFR; SOX2; ONCOGENE	PARK7 is involved in many key cellular processes, including cell proliferation, transcriptional regulation, cellular differentiation, oxidative stress protection, and mitochondrial function maintenance. Deregulation of PARK7 has been implicated in the pathogenesis of various human diseases, including cancer. Here, we aimed to clarify the effect of PARK7 on stemness and radioresistance of glioblastoma stem cells (GSCs). Serum differentiation and magnetic cell sorting of GSCs revealed that PARK7 was preferentially expressed in GSCs rather than differentiated GSCs. Immunohistochemical staining showed enhanced expression of PARK7 in glioma tissues compared to that in normal brain tissues. shRNA-mediated knockdown of PARK7 inhibited the self-renewal activity of GSCs in vitro, as evidenced by the results of neurosphere formation, limiting dilution, and soft-agar clonogenic assays. In addition, PARK7 knockdown suppressed GSC invasion and enhanced GSC sensitivity to ionizing radiation (IR). PARK7 knockdown suppressed expression of GSC signatures including nestin, epidermal growth factor receptor variant III (EGFRvIII), SOX2, NOTCH1, and OCT4. Contrarily, overexpression of PARK7 in CD133(-) non-GSCs increased self-renewal activities, migration, and IR resistance, and rescued the reduction of GSC factors under shPARK7-transfected and serum-differentiation conditions. Intriguingly, PARK7 acted as a co-chaperone of HSP90 by binding to it, protecting EGFRvIII from proteasomal degradation. Knockdown of PARK7 increased the production of reactive oxygen species, inducing partial apoptosis and enhancing IR sensitivity in GSCs. Finally, PARK7 knockdown increased mouse survival and IR sensitivity in vivo. Based on these data, we propose that PARK7 plays a pivotal role in the maintenance of stemness and therapeutic resistance in GSCs.	[Kim, Jeong-Yub; Kim, Hee-Jin; Jung, Chan-Woong; Park, Myung-Jin] Korea Inst Radiol & Med Sci, Div Radiat Canc Sci, Radiat Therapeut Dev Team, Seoul, South Korea; [Kim, Hee-Jin] Korea Univ, Sch Biomed Sci, Seoul, South Korea; [Jung, Chan-Woong] Korea Univ, Dept Life Sci, Seoul, South Korea; [Choi, Byung-Il] Korea Univ, Coll Med, Guro Hosp, Div Gastroenterol,Dept Internal Med, 148 Gurodong Ro, Seoul, South Korea; [Lee, Dae-Hee] Gangneung Wonju Natl Univ, Dept Marine Food Sci & Technol, Gangwon, South Korea	Korea Institute of Radiological & Medical Sciences; Korea University; Korea University; Korea University; Korea University Medicine (KU Medicine); Kangnung Wonju National University	Park, MJ (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Canc Sci, Radiat Therapeut Dev Team, Seoul, South Korea.; Lee, DH (corresponding author), Gangneung Wonju Natl Univ, Dept Marine Food Sci & Technol, Gangwon, South Korea.	neogene@gwnu.ac.kr; mjpark@kirams.re.kr	Kim, Heejin/HII-8568-2022		Korea Institute of Radiological and Medical Sciences (KIRAMS) - Ministry of Science and ICT (MSIT), Republic of Korea [50531-2019]; Nuclear Research and Development Program of the National Research Foundation of Korea (NRF) - MSIT, Republic of Korea [NRF-2017M2A2A7A02019889]; NRF - MSIT, Republic of Korea [NRF-2019R1A2C2089249]	Korea Institute of Radiological and Medical Sciences (KIRAMS) - Ministry of Science and ICT (MSIT), Republic of Korea(Ministry of Science & ICT (MSIT), Republic of KoreaMinistry of Science, ICT & Future Planning, Republic of Korea); Nuclear Research and Development Program of the National Research Foundation of Korea (NRF) - MSIT, Republic of Korea(National Research Foundation of KoreaMinistry of Science & ICT (MSIT), Republic of Korea); NRF - MSIT, Republic of Korea(National Research Foundation of KoreaMinistry of Science & ICT (MSIT), Republic of Korea)	This study was supported by a grant of the Korea Institute of Radiological and Medical Sciences (KIRAMS), funded by Ministry of Science and ICT (MSIT), Republic of Korea. (No. 50531-2019), Nuclear Research and Development Program of the National Research Foundation of Korea (NRF) funded by MSIT, Republic of Korea (No. NRF-2017M2A2A7A02019889), and NRF grant funded by MSIT, Republic of Korea (No. NRF-2019R1A2C2089249).	Ahsan A, 2012, NEOPLASIA, V14, P670, DOI 10.1593/neo.12986; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bowman RL, 2017, NEURO-ONCOLOGY, V19, P139, DOI 10.1093/neuonc/now247; Bradley E, 2012, STEM CELLS, V30, P1624, DOI 10.1002/stem.1143; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Cao J, 2017, ADV EXP MED BIOL, V1037, P203, DOI 10.1007/978-981-10-6583-5_13; Cao J, 2015, BIOCHEM PHARMACOL, V93, P241, DOI 10.1016/j.bcp.2014.11.012; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chen Y, 2012, J CANCER RES CLIN, V138, P1463, DOI 10.1007/s00432-012-1205-3; Clements CM, 2006, P NATL ACAD SCI USA, V103, P15091, DOI 10.1073/pnas.0607260103; Echeverria PC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026044; Emlet DR, 2014, CANCER RES, V74, P1238, DOI 10.1158/0008-5472.CAN-13-1407; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Gao X, 2011, DRUG TODAY, V47, P215, DOI 10.1358/dot.2011.47.3.1519657; Giaime E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040501; Girotto S, 2014, J BIOL CHEM, V289, P10887, DOI 10.1074/jbc.M113.535112; Hammoud MA, 1996, J NEURO-ONCOL, V27, P65, DOI 10.1007/BF00146086; Im JY, 2012, HUM MOL GENET, V21, P3013, DOI 10.1093/hmg/dds131; Jahani-Asl A, 2016, NAT NEUROSCI, V19, P798, DOI 10.1038/nn.4295; Junn E, 2009, J NEUROSCI RES, V87, P123, DOI 10.1002/jnr.21831; Kawate T, 2017, ADV EXP MED BIOL, V1037, P45, DOI 10.1007/978-981-10-6583-5_4; Kim J, 2015, STEM CELLS DEV, V24, P284, DOI 10.1089/scd.2014.0210; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Kim Y, 2012, MOL CELL PROTEOMICS, V11, P1870, DOI 10.1074/mcp.M112.017889; Knobbe CB, 2011, J PROTEOME RES, V10, P4388, DOI 10.1021/pr200225c; Kudryavtsev VA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173640; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lavictoire SJ, 2003, J BIOL CHEM, V278, P5292, DOI 10.1074/jbc.M209494200; Le Naour F, 2001, CLIN CANCER RES, V7, P3328; Lee DH, 2018, AUTOPHAGY, V14, P1870, DOI 10.1080/15548627.2018.1491212; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Oh SE, 2017, ADV EXP MED BIOL, V1037, P97, DOI 10.1007/978-981-10-6583-5_8; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Osuka S, 2017, J CLIN INVEST, V127, P415, DOI 10.1172/JCI89587; Parsanejad M, 2014, J NEUROSCI, V34, P8043, DOI 10.1523/JNEUROSCI.1244-13.2014; Raninga PV, 2017, ADV EXP MED BIOL, V1037, P67, DOI 10.1007/978-981-10-6583-5_6; Raninga Prahlad V, 2014, Oncoscience, V1, P95; Ren HG, 2011, J BIOL CHEM, V286, P35308, DOI 10.1074/jbc.M110.207134; Rybak AP, 2013, CELL SIGNAL, V25, P2734, DOI 10.1016/j.cellsig.2013.08.041; Schmitz M, 2007, BRIT J CANCER, V96, P1293, DOI 10.1038/sj.bjc.6603696; Shendelman S, 2004, PLOS BIOL, V2, P1764, DOI 10.1371/journal.pbio.0020362; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Takahashi-Niki K, 2017, ADV EXP MED BIOL, V1037, P89, DOI 10.1007/978-981-10-6583-5_7; Takahashi-Niki K, 2015, J BIOL CHEM, V290, P17838, DOI 10.1074/jbc.M115.666271; Thorne AH, 2016, NEURO-ONCOLOGY, V18, P914, DOI 10.1093/neuonc/nov319; Tillman JE, 2007, CANCER RES, V67, P4630, DOI 10.1158/0008-5472.CAN-06-4556; Vasseur S, 2009, P NATL ACAD SCI USA, V106, P1111, DOI 10.1073/pnas.0812745106; Wang B, 2016, TRANSL NEURODEGENER, V5, DOI 10.1186/s40035-016-0065-1; Xu K, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705504; Yin J, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002152; Zhang S, 2016, ONCOTARGET, V7, P65758, DOI 10.18632/oncotarget.11613; Zhong HQ, 2015, REDOX BIOL, V4, P193, DOI 10.1016/j.redox.2014.12.011; Zhou L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023936; Zou ZZ, 2017, APOPTOSIS, V22, P1321, DOI 10.1007/s10495-017-1424-9	59	9	10	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					508	521		10.1038/s41388-020-01543-1	http://dx.doi.org/10.1038/s41388-020-01543-1		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33188296				2022-12-28	WOS:000589573800003
J	Wang, YA; Sfakianos, J; Tewari, AK; Cordon-cardo, C; Kyprianou, N				Wang, Yuanshuo Alice; Sfakianos, John; Tewari, Ashutosh K.; Cordon-cardo, Carlos; Kyprianou, Natasha			Molecular tracing of prostate cancer lethality	ONCOGENE			English	Review							EXPRESSION SIGNATURE; PRECISION MEDICINE; TUMOR-SUPPRESSOR; CROSS-RESISTANCE; DNA METHYLATION; LARGE ONCOSOMES; POOR-PROGNOSIS; GENOME-WIDE; CABAZITAXEL; DOCETAXEL	Prostate cancer is diagnosed mostly in men over the age of 50 years, and has favorable 5-year survival rates due to early cancer detection and availability of curative surgical management. However, progression to metastasis and emergence of therapeutic resistance are responsible for the majority of prostate cancer mortalities. Recent advancement in sequencing technologies and computational capabilities have improved the ability to organize and analyze large data, thus enabling the identification of novel biomarkers for survival, metastatic progression and patient prognosis. Large-scale sequencing studies have also uncovered genetic and epigenetic signatures associated with prostate cancer molecular subtypes, supporting the development of personalized targeted-therapies. However, the current state of mainstream prostate cancer management does not take full advantage of the personalized diagnostic and treatment modalities available. This review focuses on interrogating biomarkers of prostate cancer progression, including gene signatures that correspond to the acquisition of tumor lethality and those of predictive and prognostic value in progression to advanced disease, and suggest how we can use our knowledge of biomarkers and molecular subtypes to improve patient treatment and survival outcomes.	[Wang, Yuanshuo Alice; Sfakianos, John; Tewari, Ashutosh K.; Kyprianou, Natasha] Icahn Sch Med Mt Sinai, Dept Urol, New York, NY 10029 USA; [Sfakianos, John; Tewari, Ashutosh K.; Cordon-cardo, Carlos; Kyprianou, Natasha] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Cordon-cardo, Carlos; Kyprianou, Natasha] Icahn Sch Med Mt Sinai, Dept Pathol & Lab Med, New York, NY 10029 USA; [Kyprianou, Natasha] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Kyprianou, N (corresponding author), Icahn Sch Med Mt Sinai, Dept Urol, New York, NY 10029 USA.; Kyprianou, N (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.; Kyprianou, N (corresponding author), Icahn Sch Med Mt Sinai, Dept Pathol & Lab Med, New York, NY 10029 USA.; Kyprianou, N (corresponding author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA.	natasha.kyprianou@mountsinai.org			NIH/NCI [R01 CA232574]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	NIH/NCI R01 CA232574.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Agell L, 2012, AM J PATHOL, V181, P1585, DOI 10.1016/j.ajpath.2012.08.005; Akamatsu S, 2015, CELL REP, V12, P922, DOI 10.1016/j.celrep.2015.07.012; Al Nakouzi N, 2015, EUR UROL, V68, P228, DOI 10.1016/j.eururo.2014.04.015; Almassi N, 2018, JAMA ONCOL, V4, P554, DOI 10.1001/jamaoncol.2017.3159; Bauman DR, 2006, MOL ENDOCRINOL, V20, P444, DOI 10.1210/me.2005-0287; Beltran H, 2019, CLIN CANCER RES, V25, P43, DOI 10.1158/1078-0432.CCR-18-1912; Beltran H, 2017, CLIN CANCER RES, V23, P6802, DOI 10.1158/1078-0432.CCR-17-1034; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2013, EUR UROL, V63, P920, DOI 10.1016/j.eururo.2012.08.053; Berney DM, 2009, BRIT J CANCER, V100, P888, DOI 10.1038/sj.bjc.6604951; Bilir B, 2016, CANCER RES, V76, P1112, DOI 10.1158/0008-5472.CAN-15-1868; Borno ST, 2012, CANCER DISCOV, V2, P1024, DOI 10.1158/2159-8290.CD-12-0041; Bougen NM, 2013, CANCER LETT, V332, P19, DOI 10.1016/j.canlet.2012.12.012; Boutros PC, 2015, NAT GENET, V47, P736, DOI 10.1038/ng.3315; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Broustas CG, 2012, J BIOL CHEM, V287, P41324, DOI 10.1074/jbc.M112.402784; Bu HJ, 2011, PROSTATE, V71, P575, DOI 10.1002/pros.21273; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Cajigas-Du Ross Christina K, 2018, Oncotarget, V9, P30363, DOI 10.18632/oncotarget.25744; Canovas V, 2017, ONCOTARGET, V8, P59165, DOI 10.18632/oncotarget.19467; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chang KH, 2013, CELL, V154, P1074, DOI 10.1016/j.cell.2013.07.029; Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028552; Chen X, 2016, CLIN CANCER RES, V22, P4505, DOI 10.1158/1078-0432.CCR-15-2956; Chien MH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1247-3; Ciardiello C, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1317-6; Clarke NW, 2009, ASIAN J ANDROL, V11, P57, DOI 10.1038/aja.2008.29; Conteduca V, 2019, EUR J CANCER, V116, P158, DOI 10.1016/j.ejca.2019.05.007; Copeland BT, 2013, MOL CANCER RES, V11, P95, DOI 10.1158/1541-7786.MCR-12-0468; Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Dey P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128239; Di Vizio D, 2012, AM J PATHOL, V181, P1573, DOI 10.1016/j.ajpath.2012.07.030; Di Vizio D, 2009, CANCER RES, V69, P5601, DOI 10.1158/0008-5472.CAN-08-3860; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855; Figiel S, 2017, HUM PATHOL, V61, P26, DOI 10.1016/j.humpath.2016.10.013; Fisher G, 2013, BRIT J CANCER, V108, P271, DOI 10.1038/bjc.2012.598; Formosa A, 2013, ONCOGENE, V32, P127, DOI 10.1038/onc.2012.14; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; Fraser JA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55665-y; Fraser M, 2015, UROL ONCOL-SEMIN ORI, V33, P85, DOI 10.1016/j.urolonc.2013.10.020; Gajula RP, 2013, MOL CANCER RES, V11, P1387, DOI 10.1158/1541-7786.MCR-13-0218-T; Galletti G, 2017, CANCER TREAT REV, V57, P16, DOI 10.1016/j.ctrv.2017.04.008; Giri VN, 2020, J CLIN ONCOL; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Gorges TM, 2016, CLIN CHEM, V62, P1504, DOI 10.1373/clinchem.2016.260299; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guan B, 2017, ONCOTARGET, V8, P8162, DOI 10.18632/oncotarget.14131; Han RB, 2020, AM J TRANSL RES, V12, P1428; Harris KS, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/8629234; Hearn JWD, 2016, LANCET ONCOL, V17, P1435, DOI 10.1016/S1470-2045(16)30227-3; Helpap B, 2009, HISTOL HISTOPATHOL, V24, P661, DOI 10.14670/HH-24.661; Howlader N., 2021, SEER CANC STAT REV, P1975; Hudson BD, 2013, BRIEF FUNCT GENOMICS, V12, P397, DOI 10.1093/bfgp/elt021; Kalin M, 2011, EUR UROL, V60, P1235, DOI 10.1016/j.eururo.2011.06.038; Kamoun A, 2018, ANN ONCOL, V29, P1814, DOI 10.1093/annonc/mdy224; Kanwal R, 2018, CANCER LETT, V430, P25, DOI 10.1016/j.canlet.2018.05.014; Karanikolas BDW, 2010, PROSTATE, V70, P675, DOI 10.1002/pros.21112; Ketola K, 2017, CLIN CANCER RES, V23, P6923, DOI 10.1158/1078-0432.CCR-17-0901; Kim W, 2014, CLIN CANCER RES, V20, P6269, DOI 10.1158/1078-0432.CCR-14-1595; Ku SY, 2019, NAT REV UROL, V16, P645, DOI 10.1038/s41585-019-0237-8; Kwon OJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5416; Labrecque MP, 2016, ONCOTARGET, V7, P24284, DOI 10.18632/oncotarget.8301; Lambros MB, 2018, CLIN CANCER RES, V24, P5635, DOI 10.1158/1078-0432.CCR-18-0862; Larkin SET, 2012, BRIT J CANCER, V106, P157, DOI 10.1038/bjc.2011.490; Lassi K, 2010, CURR OPIN ONCOL, V22, P263, DOI 10.1097/CCO.0b013e3283380939; Lee JW, 2013, J BIOL CHEM, V288, P30054, DOI 10.1074/jbc.M113.481283; Lee YC, 2013, MOL CANCER RES, V11, P405, DOI 10.1158/1541-7786.MCR-12-0551; Leon-Mateos L, 2017, ONCOTARGET, V8, P54708, DOI 10.18632/oncotarget.18025; Li MF, 2018, J CANCER RES THER, V14, P864, DOI 10.4103/jcrt.JCRT_734_17; Lin ZY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0615-x; Lindberg J, 2013, EUR UROL, V63, P347, DOI 10.1016/j.eururo.2012.03.050; Liu CF, 2019, MOL CANCER THER, V18, P1875, DOI 10.1158/1535-7163.MCT-18-1322; Liu CF, 2017, MOL CANCER THER, V16, P35, DOI 10.1158/1535-7163.MCT-16-0186; Liu CF, 2016, ONCOTARGET, V7, P32210, DOI 10.18632/oncotarget.8493; Liu CF, 2015, CANCER RES, V75, P1413, DOI 10.1158/0008-5472.CAN-14-3080; Lombard AP, 2017, MOL CANCER THER, V16, P2257, DOI 10.1158/1535-7163.MCT-17-0179; Long Q, 2014, CANCER RES, V74, P3228, DOI 10.1158/0008-5472.CAN-13-2699; Lotan TL, 2011, MODERN PATHOL, V24, P820, DOI 10.1038/modpathol.2011.7; Luo Y, 2015, ONCOTARGET, V6, P22564, DOI 10.18632/oncotarget.4197; Magadoux L, 2014, INT J ONCOL, V45, P919, DOI 10.3892/ijo.2014.2517; Majid S, 2013, CLIN CANCER RES, V19, P73, DOI 10.1158/1078-0432.CCR-12-2952; Majid S, 2012, CANCER RES, V72, P6435, DOI 10.1158/0008-5472.CAN-12-2181; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Marin-Aguilera M, 2019, INT J CANCER, V145, P1970, DOI 10.1002/ijc.32238; Martin SK, 2016, CANCER RES, V76, P912, DOI 10.1158/0008-5472.CAN-15-2078; Merrill RM, 2000, UROLOGY, V55, P730, DOI 10.1016/S0090-4295(99)00564-6; Minciacchi VR, 2017, CANCER RES, V77, P2306, DOI 10.1158/0008-5472.CAN-16-2942; Minciacchi VR, 2015, ONCOTARGET, V6, P11327, DOI 10.18632/oncotarget.3598; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Modena A, 2016, TARGET ONCOL, V11, P569, DOI 10.1007/s11523-016-0450-9; Mosquera JM, 2013, NEOPLASIA, V15, P1, DOI 10.1593/neo.121550; Mostaghel EA, 2019, CLIN CANCER RES, V25, P426, DOI 10.1158/1078-0432.CCR-18-1431; Mout L, 2018, EBIOMEDICINE, V27, P182, DOI 10.1016/j.ebiom.2017.12.024; Munkley J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05489-5; Murphy AB, 2020, UROLOGY, V142, P166, DOI 10.1016/j.urology.2020.01.052; Nilsson EM, 2015, ONCOTARGET, V6, P35710, DOI 10.18632/oncotarget.5958; Nolan KD, 2015, J BIOL CHEM, V290, P8271, DOI 10.1074/jbc.M115.637496; Nordstrom T, 2017, BMC UROL, V17, DOI 10.1186/s12894-017-0281-8; O'Reilly E, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00134; Oh JJ, 2015, KOREAN J UROL, V56, P109, DOI 10.4111/kju.2015.56.2.109; Ok S, 2012, IMMUNOPHARM IMMUNOT, V34, P768, DOI 10.3109/08923973.2012.654494; Oliveira KCS, 2020, MOL CANCER RES, V18, P517, DOI 10.1158/1541-7786.MCR-19-0768; Olson A, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008451; Oon SF, 2011, NAT REV UROL, V8, P131, DOI 10.1038/nrurol.2011.11; Osorio LA, 2016, MOL MED REP, V13, P778, DOI 10.3892/mmr.2015.4585; Pal SK, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2017.12.006; Penney KL, 2011, J CLIN ONCOL, V29, P2391, DOI 10.1200/JCO.2010.32.6421; Pettersson A, 2013, JNCI-J NATL CANCER I, V105, P1881, DOI 10.1093/jnci/djt332; Pezaro CJ, 2014, EUR UROL, V66, P459, DOI 10.1016/j.eururo.2013.11.044; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Rajasekhar VK, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1159; Ramachandran K, 2016, ANTICANCER RES, V36, P161; Ramalho-Carvalho J, 2017, CANCER LETT, V385, P150, DOI 10.1016/j.canlet.2016.10.028; Ramalinga M, 2015, ONCOTARGET, V6, P34446, DOI 10.18632/oncotarget.5920; Reyes Edwin E, 2015, J Transl Sci, V1; Reyes EE, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0313-z; Ross RW, 2012, LANCET ONCOL, V13, P1105, DOI 10.1016/S1470-2045(12)70263-2; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Salinas CA, 2014, NAT REV UROL, V11, P317, DOI 10.1038/nrurol.2014.91; Santoni M, 2016, EUR UROL, V69, P186, DOI 10.1016/j.eururo.2015.05.041; Sekino Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163936; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Skvortsova K, 2019, CANCER CELL, V35, P297, DOI 10.1016/j.ccell.2019.01.004; Spratt DE, 2019, CLIN CANCER RES, V25, P6721, DOI 10.1158/1078-0432.CCR-19-1587; Stephenson AJ, 2005, CANCER-AM CANCER SOC, V104, P290, DOI 10.1002/cncr.21157; Sun YF, 2011, J CANCER RES CLIN, V137, P1151, DOI 10.1007/s00432-011-0988-y; Tan HL, 2014, CLIN CANCER RES, V20, P890, DOI 10.1158/1078-0432.CCR-13-1982; Tan SH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041255; Tomlins SA, 2015, EUR UROL, V68, P555, DOI 10.1016/j.eururo.2015.04.033; Tzelepi V, 2011, J CLIN ONCOL, V29, P2574, DOI 10.1200/JCO.2010.33.2999; van Soest RJ, 2015, EUR J CANCER, V51, P2562, DOI 10.1016/j.ejca.2015.07.037; van Soest RJ, 2015, EUR UROL, V67, P981, DOI 10.1016/j.eururo.2014.11.033; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Wang L, 2018, ANN ONCOL, V29, P352, DOI 10.1093/annonc/mdx689; Wang X, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007609; Wang ZG, 2016, SCI REP-UK, V6, DOI 10.1038/srep25602; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Williams LV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083991; Wu YM, 2018, CELL, V173, P1770, DOI 10.1016/j.cell.2018.04.034; Xu S, 2016, ONCOL REP, V36, P10, DOI 10.3892/or.2016.4791; Yang L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00872-8; Yang YJ, 2019, BJU INT, V124, P258, DOI 10.1111/bju.14642; Yepuru M, 2013, CLIN CANCER RES, V19, P5613, DOI 10.1158/1078-0432.CCR-13-1151; Yi CY, 2018, INT J BIOCHEM CELL B, V102, P138, DOI 10.1016/j.biocel.2018.07.009; You SY, 2016, CANCER RES, V76, P4948, DOI 10.1158/0008-5472.CAN-16-0902; Zhang K, 2017, ONCOGENE, V36, P5681, DOI 10.1038/onc.2017.177; Zhang T, 2020, CLIN GENITOURIN CANC, V18, P1, DOI 10.1016/j.clgc.2019.09.015; Zhao JG, 2020, MOL CANCER THER, V19, P1708, DOI 10.1158/1535-7163.MCT-20-0015; Zhao LY, 2014, CANCER EPIDEM BIOMAR, V23, P1047, DOI 10.1158/1055-9965.EPI-13-0696; Zheng JF, 2016, BIOCHEM BIOPH RES CO, V480, P508, DOI 10.1016/j.bbrc.2016.08.120	155	3	3	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2020	39	50					7225	7238		10.1038/s41388-020-01496-5	http://dx.doi.org/10.1038/s41388-020-01496-5		OCT 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PD4HE	33046797	Green Accepted			2022-12-28	WOS:000578784100004
J	Xu, GQ; Yang, ZJ; Ding, YZ; Liu, Y; Zhang, L; Wang, BS; Tang, M; Jing, TT; Jiao, K; Xu, XL; Chen, ZH; Xiang, L; Xu, C; Fu, YJ; Zhao, XJ; Jin, WL; Liu, YZ				Xu, Guiqin; Yang, Zhaojuan; Ding, Yizong; Liu, Yun; Zhang, Li; Wang, Boshi; Tang, Ming; Jing, Tiantian; Jiao, Kun; Xu, Xiaoli; Chen, Zehong; Xiang, Lvzhu; Xu, Chen; Fu, Yujie; Zhao, Xiaojing; Jin, Weilin; Liu, Yongzhong			The deubiquitinase USP16 functions as an oncogenic factor in K-RAS-driven lung tumorigenesis	ONCOGENE			English	Article							P38-ALPHA MAP KINASE; P38 MAPK; OXIDATIVE STRESS; GENE-EXPRESSION; ACTIVATION; STEM; STAT3; PHOSPHORYLATION; STABILIZATION; PROGRESSION	K-RAS mutation and molecular alterations of its surrogates function essentially in lung tumorigenesis and malignant progression. However, it remains elusive how tumor-promoting and deleterious events downstream of K-RAS signaling are coordinated in lung tumorigenesis. Here, we show that USP16, a deubiquitinase involved in various biological processes, functions as a promoter for the development of K-RAS-driven lung tumor. Usp16 deletion significantly attenuates K-ras(G12D)-mutation-induced lung tumorigenesis in mice. USP16 upregulation upon RAS activation averts reactive oxygen species (ROS)-induced p38 activation that would otherwise detrimentally influence the survival and proliferation of tumor cells. In addition, USP16 interacts with and deubiquitinates JAK1, and thereby promoting lung tumor growth by augmenting JAK1 signaling. Therefore, our results reveal that USP16 functions critically in the K-RAS-driven lung tumorigenesis through modulating the strength of p38 and JAK1 signaling.	[Xu, Guiqin; Yang, Zhaojuan; Liu, Yun; Zhang, Li; Wang, Boshi; Tang, Ming; Jing, Tiantian; Chen, Zehong; Xiang, Lvzhu; Xu, Chen; Liu, Yongzhong] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai, Peoples R China; [Ding, Yizong; Fu, Yujie; Zhao, Xiaojing] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Thorac Surg, Shanghai, Peoples R China; [Jiao, Kun; Xu, Xiaoli] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China; [Jin, Weilin] Lanzhou Univ, Clin Med Coll 1, Hosp 1, Inst Canc Neurosci,Med Frontier Innovat Res Ctr, Lanzhou, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Lanzhou University	Liu, YZ (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai, Peoples R China.	liuyzg@shsci.org	Jin, Wei-Lin/A-8355-2013	Jin, Wei-Lin/0000-0001-8011-2405; Liu, Yongzhong/0000-0002-1477-116X	National Natural Science Foundation of China [81802746, 81572694, 81972579]; Natural Science Foundation of Shanghai [20ZR1454100]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai)	This work was supported by the National Natural Science Foundation of China (81802746, 81572694, and 81972579), and the Natural Science Foundation of Shanghai (20ZR1454100).	Adachi Y, 2008, ONCOGENE, V27, P4921, DOI 10.1038/onc.2008.133; Adorno M, 2013, NATURE, V501, P380, DOI 10.1038/nature12530; Ali SA, 2016, CANCER CELL, V29, P367, DOI 10.1016/j.ccell.2016.02.012; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Brooks GD, 2016, CANCER RES, V76, P866, DOI 10.1158/0008-5472.CAN-15-2388; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Cai SY, 1999, P NATL ACAD SCI USA, V96, P2828, DOI 10.1073/pnas.96.6.2828; Chen X, 2019, CANCER LETT, V456, P49, DOI 10.1016/j.canlet.2019.04.020; Chuang CH, 2017, NAT MED, V23, P291, DOI 10.1038/nm.4285; D'Amico S, 2018, GENE DEV, V32, P1175, DOI 10.1101/gad.311852.118; Deng KY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0126-x; Deng L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0107-0; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Fasbender A, 1998, J CLIN INVEST, V102, P184, DOI 10.1172/JCI2732; Grabner B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7285; Gu Y, 2016, P NATL ACAD SCI USA, V113, pE51, DOI 10.1073/pnas.1517041113; Gwinn DM, 2018, CANCER CELL, V33, P91, DOI 10.1016/j.ccell.2017.12.003; Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001; Hill KS, 2014, ONCOGENE, V33, P2134, DOI 10.1038/onc.2013.147; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Joo HY, 2007, NATURE, V449, P1068, DOI 10.1038/nature06256; Kennedy NJ, 2007, CANCER CELL, V11, P101, DOI 10.1016/j.ccr.2007.01.009; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Lim JKM, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2192-y; Liu CM, 2020, AGING-US, V12, P8680, DOI 10.18632/aging.103191; Liu D, 2017, ONCOL LETT, V14, P3959, DOI 10.3892/ol.2017.6690; Lu L, 2018, ONCOGENE, V37, P5292, DOI 10.1038/s41388-018-0340-y; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; Metz HE, 2016, P NATL ACAD SCI USA, V113, P8795, DOI 10.1073/pnas.1601989113; Miotto B, 2018, NUCLEIC ACIDS RES, V46, P4392, DOI 10.1093/nar/gky149; Nicke B, 2005, MOL CELL, V20, P673, DOI 10.1016/j.molcel.2005.10.038; Obana M, 2012, AM J PHYSIOL-HEART C, V303, pH569, DOI 10.1152/ajpheart.00060.2012; Pan J, 2015, ONCOGENE, V34, P3957, DOI 10.1038/onc.2014.327; Qi XM, 2004, J BIOL CHEM, V279, P22138, DOI 10.1074/jbc.M313964200; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Song LX, 2011, MOL CANCER THER, V10, P481, DOI 10.1158/1535-7163.MCT-10-0502; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Taverna JA, 2020, CANCER RES, V80, P1551, DOI 10.1158/0008-5472.CAN-19-3183; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Xu Jianming, 2005, Curr Protoc Mol Biol, VChapter 28, DOI 10.1002/0471142727.mb2801s70; Xu Y, 2013, CELL CYCLE, V12, P3219, DOI 10.4161/cc.26278; Yan MX, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1479-2; Yang W, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4818; Zhang JG, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920917558; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874; Zhang Y, 2019, J CLIN INVEST, V129, P2856, DOI 10.1172/JCI123801; Zhou J, 2015, ONCOGENE, V34, P3804, DOI 10.1038/onc.2014.318; Zhu ZH, 2014, CANCER DISCOV, V4, P452, DOI 10.1158/2159-8290.CD-13-0646; Zhuo XL, 2015, J CELL BIOL, V210, P727, DOI 10.1083/jcb.201502044	50	2	2	7	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5482	5494		10.1038/s41388-021-01964-6	http://dx.doi.org/10.1038/s41388-021-01964-6		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34294846				2022-12-28	WOS:000678017100001
J	Shapira, S; Boustanai, I; Kazanov, D; Ben Shimon, M; Fokra, A; Arber, N				Shapira, Shiran; Boustanai, Ilana; Kazanov, Dina; Ben Shimon, Marina; Fokra, Ahmad; Arber, Nadir			Innovative dual system approach for selective eradication of cancer cells using viral-based delivery of natural bacterial toxin-antitoxin system	ONCOGENE			English	Article							MUTANT P53; GENE-THERAPY; MUTATIONS; DNA	The inactivation of p53, a tumor suppressor, and the activation of the RAS oncogene are the most frequent genetic alterations in cancer. We have shown that a unique E. coli MazF-MazE toxin-antitoxin (TA) system can be used for selective and effective eradication of RAS-mutated cancer cells. This out of the box strategy holds great promise for effective cancer treatment and management. We provide proof of concept for a novel platform to selectively eradicate cancer cells using an adenoviral delivery system based on the adjusted natural bacterial system. We generated adenoviral vectors carrying the mazF toxin (pAdEasy-Py4-SV40mP-mCherry-MazF) and the antitoxin mazE (pAdEasy-RGC-SV40mP-MazE-IRES-GFP) under the regulation of RAS and p53, resp. The control vector carries the toxin without the RAS-responsive element (pAdEasy-Delta Py4-SV40mP-mCherry-MazF). In vitro, the mazF-mazE TA system (Py4-SV40mP-mCherry-MazF+RGC-SV40mP-MazE-IRES-GFP) induced massive, dose-dependent cell death, at 69% compared to 19% for the control vector, in a co-infected HCT116 cell line. In vivo, the system caused significant tumor growth inhibition of HCT116 (KRAS(mut)/p53(mut)) tumors at 73 and 65% compared to PBS and Delta PY4 control groups, resp. In addition, we demonstrate 65% tumor growth inhibition in HCT116 (KRAS(mut)/p53(wt)) cells, compared to the other two control groups, indicating a contribution of the antitoxin in blocking system leakage in WT RAS cells. These data provide evidence of the feasibility of using mutations in the p53 and RAS pathway to efficiently kill cancer cells. The platform, through its combination of the antitoxin (mazE) with the toxin (mazF), provides effective protection of normal cells from basal low activity or leakage of mazF.	[Shapira, Shiran; Boustanai, Ilana; Kazanov, Dina; Ben Shimon, Marina; Fokra, Ahmad; Arber, Nadir] Tel Aviv Sourasky Med Ctr, Integrated Canc Prevent Ctr, Tel Aviv, Israel; [Shapira, Shiran; Boustanai, Ilana; Kazanov, Dina; Ben Shimon, Marina; Fokra, Ahmad; Arber, Nadir] Tel Aviv Sourasky Med Ctr, Hlth Promot Ctr, Tel Aviv, Israel; [Shapira, Shiran; Boustanai, Ilana; Fokra, Ahmad; Arber, Nadir] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Arber, N (corresponding author), Tel Aviv Sourasky Med Ctr, Integrated Canc Prevent Ctr, Tel Aviv, Israel.; Arber, N (corresponding author), Tel Aviv Sourasky Med Ctr, Hlth Promot Ctr, Tel Aviv, Israel.; Arber, N (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	nadira@tlvmc.gov.il						Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bykov VJN, 2018, NAT REV CANCER, V18, P89, DOI 10.1038/nrc.2017.109; Crystal RG, 2014, HUM GENE THER, V25, P3, DOI 10.1089/hum.2013.2527; Davis TB, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27584-x; Do PM, 2012, GENE DEV, V26, P830, DOI 10.1101/gad.181685.111; Duffy MJ, 2017, EUR J CANCER, V83, P258, DOI 10.1016/j.ejca.2017.06.023; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Dvory-Sobol H, 2005, BIOMED PHARMACOTHER, V59, pS370, DOI 10.1016/S0753-3322(05)80081-2; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jeng HH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2173; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kodaz H, 2017, EURASIAN J MED ONCOL, V1, P1, DOI 10.14744/ejmo.2017.22931; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Ledford H, 2015, NATURE, V528, P317, DOI 10.1038/528317a; Lee CS, 2017, GENES DIS, V4, P43, DOI 10.1016/j.gendis.2017.04.001; Lisiansky V, 2012, CANCER GENE THER, V19, P862, DOI 10.1038/cgt.2012.73; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Naumov I, 2012, EXP CELL RES, V318, P160, DOI 10.1016/j.yexcr.2011.09.015; Papke B, 2017, SCIENCE, V355, P1158, DOI 10.1126/science.aam7622; Sagiv E, 2006, GASTROENTEROLOGY, V131, P630, DOI 10.1053/j.gastro.2006.04.028; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shapira S, 2017, ONCOTARGET, V8, P38581, DOI 10.18632/oncotarget.16934; Shima F, 2013, P NATL ACAD SCI USA, V110, P8182, DOI 10.1073/pnas.1217730110; Soussi T, 2015, CELL DEATH DIFFER, V22, P1239, DOI 10.1038/cdd.2015.53; Stites EC, 2018, CPT-PHARMACOMET SYST, V7, P342, DOI 10.1002/psp4.12291; Tomasini P, 2016, ONCOLOGIST, V21, P1450, DOI 10.1634/theoncologist.2015-0084; Witsch E, 2010, PHYSIOLOGY, V25, P85, DOI 10.1152/physiol.00045.2009; Yue XT, 2017, J MOL BIOL, V429, P1595, DOI 10.1016/j.jmb.2017.03.030; Zenonos K, 2013, WORLD J GASTRO ONCOL, V5, P97, DOI 10.4251/wjgo.v5.i5.97; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7	32	1	1	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					4967	4979		10.1038/s41388-021-01792-8	http://dx.doi.org/10.1038/s41388-021-01792-8		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34172933	Green Published, hybrid			2022-12-28	WOS:000667360400001
J	Liang, SK; Hsu, CC; Song, HL; Huang, YC; Kuo, CW; Yao, X; Li, CC; Yang, HC; Hung, YL; Chao, SY; Wu, SC; Tsai, FR; Chen, JK; Liao, WN; Cheng, SC; Tsou, TC; Wang, IC				Liang, Sheng-Kai; Hsu, Chia-Chan; Song, Hsiang-Lin; Huang, Yu-Chi; Kuo, Chun-Wei; Yao, Xiang; Li, Chien-Cheng; Yang, Hui-Chen; Hung, Yu-Ling; Chao, Sheng-Yang; Wu, Shun-Chi; Tsai, Feng-Ren; Chen, Jen-Kun; Liao, Wei-Neng; Cheng, Shin-Chin; Tsou, Tsui-Chun; Wang, I-Ching			FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis	ONCOGENE			English	Article							M1 TRANSCRIPTION FACTOR; PROGRESSION; EXPRESSION; BORTEZOMIB; INITIATION; INDUCTION; LANDSCAPE; SURVIVAL; TARGET; GENES	Small cell lung cancer (SCLC) continues to cause poor clinical outcomes due to limited advances in sustained treatments for rapid cancer cell proliferation and progression. The transcriptional factor Forkhead Box M1 (FOXM1) regulates cell proliferation, tumor initiation, and progression in multiple cancer types. However, its biological function and clinical significance in SCLC remain unestablished. Analysis of the Cancer Cell Line Encyclopedia and SCLC datasets in the present study disclosed significant upregulation of FOXM1 mRNA in SCLC cell lines and tissues. Gene set enrichment analysis (GSEA) revealed that FOXM1 is positively correlated with pathways regulating cell proliferation and DNA damage repair, as evident from sensitization of FOXM1-depleted SCLC cells to chemotherapy. Furthermore, Foxm1 knockout inhibited SCLC formation in the Rb1(fl/fl)Trp53(fl/fl)Myc(LSL/LSL) (RPM) mouse model associated with increased levels of neuroendocrine markers, Ascl1 and Cgrp, and decrease in Yap1. Consistently, FOXM1 depletion in NCI-H1688 SCLC cells reduced migration and enhanced apoptosis and sensitivity to cisplatin and etoposide. SCLC with high FOXM1 expression (N = 30, 57.7%) was significantly correlated with advanced clinical stage, extrathoracic metastases, and decrease in overall survival (OS), compared with the low-FOXM1 group (7.90 vs. 12.46 months). Moreover, the high-FOXM1 group showed shorter progression-free survival after standard chemotherapy, compared with the low-FOXM1 group (3.90 vs. 8.69 months). Our collective findings support the utility of FOXM1 as a prognostic biomarker and potential molecular target for SCLC.	[Liang, Sheng-Kai; Yang, Hui-Chen] Natl Taiwan Univ Hosp, Dept Internal Med, Hsinchu Branch, Hsinchu 300, Taiwan; [Liang, Sheng-Kai; Hsu, Chia-Chan; Huang, Yu-Chi; Yao, Xiang; Li, Chien-Cheng; Hung, Yu-Ling; Chao, Sheng-Yang; Wang, I-Ching] Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu 300, Taiwan; [Song, Hsiang-Lin; Kuo, Chun-Wei] Natl Taiwan Univ Hosp, Dept Pathol, Hsinchu Branch, Hsinchu, Taiwan; [Huang, Yu-Chi; Hung, Yu-Ling; Wang, I-Ching] Natl Tsing Hua Univ, Train Res Ctr, Hsinchu 300, Taiwan; [Wu, Shun-Chi; Tsai, Feng-Ren] Natl Tsing Hua Univ, Dept Engn & Syst Sci, Hsinchu 300, Taiwan; [Chen, Jen-Kun; Liao, Wei-Neng] Natl Hlth Res Inst, Inst Biomed Engn & Nanomed, Miaoli 350, Taiwan; [Cheng, Shin-Chin] Xiamen Univ, Sch Life Sci, Xiamen 361102, Fujian, Peoples R China; [Tsou, Tsui-Chun] Natl Hlth Res Inst, Natl Inst Environm Hlth Sci, Miaoli 350, Taiwan; [Wang, I-Ching] Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan	National Taiwan University; National Taiwan University Hospital; National Tsing Hua University; National Taiwan University; National Taiwan University Hospital; National Tsing Hua University; National Tsing Hua University; National Health Research Institutes - Taiwan; Xiamen University; National Health Research Institutes - Taiwan; National Tsing Hua University	Wang, IC (corresponding author), Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu 300, Taiwan.; Wang, IC (corresponding author), Natl Tsing Hua Univ, Train Res Ctr, Hsinchu 300, Taiwan.; Wang, IC (corresponding author), Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan.	icwang@life.nthu.edu.tw	; CHENG, SHIH-CHIN/H-4567-2015	SONG, HSIANG-LIN/0000-0002-8720-6436; Wang, I-Ching/0000-0003-4398-2975; CHENG, SHIH-CHIN/0000-0003-1251-8774; LIANG, SHENG-KAI/0000-0003-3486-2293; Liao, WEI NENG/0000-0002-1857-741X	NHRI Laboratory Animal Center [LA-109-PP-01]; National Taiwan University Hospital Hsinchu Branch research grant [NTUH-HC 108-s267]; Ministry of Science and Technology of Taiwan grant [MOST105-2628-B-007-003-MY3, MOST109-2314-B-007-005-MY3]; National Tsing Hua University [108Q2502E1, 109Q2714E1, 110Q2501E1]; Brain Research Center under the Higher Education Sprout Project; Ministry of Education in Taiwan; Ministry of Science and Technology in Taiwan	NHRI Laboratory Animal Center; National Taiwan University Hospital Hsinchu Branch research grant; Ministry of Science and Technology of Taiwan grant; National Tsing Hua University; Brain Research Center under the Higher Education Sprout Project; Ministry of Education in Taiwan(Ministry of Education, Taiwan); Ministry of Science and Technology in Taiwan(Ministry of Science and Technology, Taiwan)	We thank all study participants and staff at NTUH-HC for their contribution to this project, Feng-Yuan Tsai (NHRI), and NHRI Laboratory Animal Center (LA-109-PP-01), and I-BEN Service (TSSI-BN-31) for technical assistance, Stephen Elledge (Harvard Medical School) for kindly providing the pInducer10-mir-RUP-PheS plasmid, Pradip Raychaudhuri (UIC) and Vladimir Kalinichenko (CCHMC) for kindly providing the Foxm1fl/ fl mice. This work was supported by the National Taiwan University Hospital Hsinchu Branch research grant NTUH-HC 108-s267 (S-K L), the Ministry of Science and Technology of Taiwan grant MOST105-2628-B-007-003-MY3 and MOST109-2314-B-007-005-MY3 (I-C W), National Tsing Hua University grant 108Q2502E1, 109Q2714E1, 110Q2501E1 (I-C W), and by the Brain Research Center under the Higher Education Sprout Project, co-funded by the Ministry of Education and the Ministry of Science and Technology in Taiwan.	Alexandrov LB, 2016, SCIENCE, V354, P618, DOI 10.1126/science.aag0299; Barsotti AM, 2009, ONCOGENE, V28, P4295, DOI 10.1038/onc.2009.282; BHAT UG, 2009, PLOS ONE, V4; Borromeo MD, 2016, CELL REP, V16, P1259, DOI 10.1016/j.celrep.2016.06.081; Byers LA, 2012, CANCER DISCOV, V2, P798, DOI 10.1158/2159-8290.CD-12-0112; Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545; Dammert MA., 2019, NAT COMMUN, V10; Davies AM, 2007, CLIN CANCER RES, V13, p4647S, DOI 10.1158/1078-0432.CCR-07-0334; de Moraes GN, 2015, CELL SIGNAL, V27, P2496, DOI 10.1016/j.cellsig.2015.09.013; Fang PP, 2018, MOL CANCER RES, V16, P961, DOI 10.1158/1541-7786.MCR-17-0607; Gardner EE, 2017, CANCER CELL, V31, P286, DOI 10.1016/j.ccell.2017.01.006; Gartel AL, 2010, EXPERT OPIN INV DRUG, V19, P235, DOI 10.1517/13543780903563364; Gemenetzidis E, 2010, CANCER RES, V70, P9515, DOI 10.1158/0008-5472.CAN-10-2173; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Ireland AS, 2020, CANCER CELL, V38, P60, DOI 10.1016/j.ccell.2020.05.001; Jackman DM, 2005, LANCET, V366, P1385, DOI 10.1016/S0140-6736(05)67569-1; Jiang LY, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005895; Kalemkerian GP, 2013, J NATL COMPR CANC NE, V11, P78, DOI 10.6004/jnccn.2013.0011; Karachaliou N, 2013, TRANSL LUNG CANCER R, V2, P172, DOI 10.3978/j.issn.2218-6751.2013.01.01; KARIM S, 2012, ONCOL REV, V6; Keenan AB, 2019, NUCLEIC ACIDS RES, V47, pW212, DOI 10.1093/nar/gkz446; Kim SH, 2015, STEM CELL REP, V4, P226, DOI 10.1016/j.stemcr.2014.12.006; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Krupczak-Hollis K, 2004, DEV BIOL, V276, P74, DOI 10.1016/j.ydbio.2004.08.022; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; McColl K, 2017, ONCOTARGET, V8, P73745, DOI 10.18632/oncotarget.20572; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Mok T, 2020, ANN ONCOL, V31, P1056, DOI 10.1016/j.annonc.2020.04.478; Mollaoglu G, 2017, CANCER CELL, V31, P270, DOI 10.1016/j.ccell.2016.12.005; Nicholson AG, 2016, J THORAC ONCOL, V11, P300, DOI 10.1016/j.jtho.2015.10.008; Okada K, 2013, ANN SURG ONCOL, V20, P1035, DOI 10.1245/s10434-012-2680-0; Pal S, 2018, CANCER RES, V78, P4007, DOI 10.1158/0008-5472.CAN-17-3691; PAN C, 2016, BMC CANCER, V16; Pandit B, 2009, CELL CYCLE, V8, P3425, DOI 10.4161/cc.8.20.9628; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Rotinen M, 2018, NAT MED, V24, P1887, DOI 10.1038/s41591-018-0241-1; Sato T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01911; Semenova EA, 2015, GENE DEV, V29, P1447, DOI 10.1101/gad.263145.115; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stec DE, 1999, J BIOL CHEM, V274, P21285, DOI 10.1074/jbc.274.30.21285; Taromi S, 2017, ONCOTARGET, V8, P97061, DOI 10.18632/oncotarget.21221; Ustiyan V, 2012, DEV BIOL, V370, P198, DOI 10.1016/j.ydbio.2012.07.028; vanDiest PJ, 1997, J CLIN PATHOL, V50, P801, DOI 10.1136/jcp.50.10.801; Varemo L, 2013, NUCLEIC ACIDS RES, V41, P4378, DOI 10.1093/nar/gkt111; Wang IC, 2008, ONCOGENE, V27, P4137, DOI 10.1038/onc.2008.60; Wang IC, 2014, ONCOGENE, V33, P5391, DOI 10.1038/onc.2013.475; Wang IC, 2008, J BIOL CHEM, V283, P20770, DOI 10.1074/jbc.M709892200; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang ZB, 2011, CANCER RES, V71, P4292, DOI 10.1158/0008-5472.CAN-10-4087; Wierstra I, 2006, FEBS J, V273, P4645, DOI 10.1111/j.1742-4658.2006.05468.x	57	7	7	1	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4847	4858		10.1038/s41388-021-01895-2	http://dx.doi.org/10.1038/s41388-021-01895-2		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34155349				2022-12-28	WOS:000664006700004
J	Walter, W; Haferlach, C; Nadarajah, N; Schmidts, I; Kuhn, C; Kern, W; Haferlach, T				Walter, Wencke; Haferlach, Claudia; Nadarajah, Niroshan; Schmidts, Ines; Kuhn, Constanze; Kern, Wolfgang; Haferlach, Torsten			How artificial intelligence might disrupt diagnostics in hematology in the near future	ONCOGENE			English	Review							FLOW-CYTOMETRY DATA; LYMPHOID-CELLS; CLASSIFICATION; BLOOD	Artificial intelligence (AI) is about to make itself indispensable in the health care sector. Examples of successful applications or promising approaches range from the application of pattern recognition software to pre-process and analyze digital medical images, to deep learning algorithms for subtype or disease classification, and digital twin technology and in silico clinical trials. Moreover, machine-learning techniques are used to identify patterns and anomalies in electronic health records and to perform ad-hoc evaluations of gathered data from wearable health tracking devices for deep longitudinal phenotyping. In the last years, substantial progress has been made in automated image classification, reaching even superhuman level in some instances. Despite the increasing awareness of the importance of the genetic context, the diagnosis in hematology is still mainly based on the evaluation of the phenotype. Either by the analysis of microscopic images of cells in cytomorphology or by the analysis of cell populations in bidimensional plots obtained by flow cytometry. Here, AI algorithms not only spot details that might escape the human eye, but might also identify entirely new ways of interpreting these images. With the introduction of high-throughput next-generation sequencing in molecular genetics, the amount of available information is increasing exponentially, priming the field for the application of machine learning approaches. The goal of all the approaches is to allow personalized and informed interventions, to enhance treatment success, to improve the timeliness and accuracy of diagnoses, and to minimize technically induced misclassifications. The potential of AI-based applications is virtually endless but where do we stand in hematology and how far can we go?	[Walter, Wencke; Haferlach, Claudia; Nadarajah, Niroshan; Schmidts, Ines; Kuhn, Constanze; Kern, Wolfgang; Haferlach, Torsten] MLL Munich Leukemia Lab, Munich, Germany	MLL Munich Leukemia Laboratory	Haferlach, T (corresponding author), MLL Munich Leukemia Lab, Munich, Germany.	torsten.haferlach@mll.com	Walter, Wencke/ABA-6205-2021	Walter, Wencke/0000-0002-5083-9838				Ai C, 2018, J GENET GENOMICS, V45, P489, DOI 10.1016/j.jgg.2018.08.002; Albaradei Somayah, 2020, Gene X, V5, P100035, DOI 10.1016/j.gene.2020.100035; Alferez S, 2016, INT J LAB HEMATOL, V38, P209, DOI 10.1111/ijlh.12473; Alferez S, 2014, INT J LAB HEMATOL, V36, P472, DOI 10.1111/ijlh.12175; Alferez S, 2015, AM J CLIN PATHOL, V143, P168, DOI 10.1309/AJCP78IFSTOGZZJN; Alomari YM, 2014, COMPUT MATH METHOD M, V2014, DOI 10.1155/2014/979302; Amann J, 2020, BMC MED INFORM DECIS, V20, DOI 10.1186/s12911-020-01332-6; Angeletti Cesar, 2018, J Pathol Inform, V9, P16, DOI 10.4103/jpi.jpi_76_17; Biehl M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059401; Bigorra L, 2019, BRIT J HAEMATOL, V184, P1035, DOI 10.1111/bjh.15230; Bigorra L, 2017, J CLIN LAB ANAL, V31, DOI 10.1002/jcla.22024; Bjornsson B, 2019, GENOME MED, V12, DOI 10.1186/s13073-019-0701-3; Boldu L, 2019, J CLIN PATHOL, V72, P755, DOI 10.1136/jclinpath-2019-205949; Castillo D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212127; Cutillo CM, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0254-2; Delshadpour S, 2003, P ANN INT IEEE EMBS, V25, P2249, DOI 10.1109/IEMBS.2003.1280243; Dias R, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0689-8; Dimitriou N, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00264; Duetz C, 2020, CURR OPIN ONCOL, V32, P162, DOI 10.1097/CCO.0000000000000607; Dundar M, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-314; El Achi H, 2020, CANCERS, V12, DOI 10.3390/cancers12040797; Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056; Fjelland R, 2020, HUM SOC SCI COMMUN, V7, DOI 10.1057/s41599-020-0494-4; Fu XY, 2020, ACTA CYTOL, V64, P588, DOI 10.1159/000509524; Gagula-Palalic S, 2014, 2014 IEEE-EMBS INTERNATIONAL CONFERENCE ON BIOMEDICAL AND HEALTH INFORMATICS (BHI), P626, DOI 10.1109/BHI.2014.6864442; Grisan E, 2007, P ANN INT IEEE EMBS, P5513, DOI 10.1109/IEMBS.2007.4353594; Haferlach C, 2020, BLOOD, V136, DOI 10.1182/blood-2020-137463; Hilton CB, 2019, BLOOD, V134, DOI 10.1182/blood-2019-126967; Hoffman GE, 2019, NUCLEIC ACIDS RES, V47, P10597, DOI 10.1093/nar/gkz808; Holzinger A, 2019, WIRES DATA MIN KNOWL, V9, DOI 10.1002/widm.1312; Jaganathan K, 2019, CELL, V176, P535, DOI 10.1016/j.cell.2018.12.015; Jobin A, 2019, NAT MACH INTELL, V1, P389, DOI 10.1038/s42256-019-0088-2; Kimura K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49942-z; Ko BS, 2018, EBIOMEDICINE, V37, P91, DOI 10.1016/j.ebiom.2018.10.042; Lai CM, 2020, HUM MUTAT, V41, P1079, DOI 10.1002/humu.24011; Lakoumentas J, 2009, J BIOMED INFORM, V42, P251, DOI 10.1016/j.jbi.2008.11.003; Licandro R, 2018, P 7 INT C PATT REC A; Madhavan S, 2021, NAT CANCER, V2, P9, DOI 10.1038/s43018-020-00163-8; Mallick PK, 2020, PERS UBIQUIT COMPUT, DOI 10.1007/s00779-020-01467-3; Manninen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072932; Meggendorfer M, 2019, BLOOD, V134, DOI 10.1182/blood-2019-126449; Menden K, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba2619; Moshavash Z, 2018, J DIGIT IMAGING, V31, P702, DOI 10.1007/s10278-018-0074-y; Muller ML, 2020, BLOOD, V136, DOI 10.1182/blood-2020-140927; Nazha Aziz, 2019, JCO Precis Oncol, V3, DOI 10.1200/po.19.00119; Neoh SC, 2015, SCI REP-UK, V5, DOI 10.1038/srep14938; Nicora G, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01030; Oskouei B. C., 2010, Proceedings 2010 International Conference on Digital Image Computing: Techniques and Applications (DICTA 2010), P605, DOI 10.1109/DICTA.2010.107; Pansombut T, 2019, COMPUT INTEL NEUROSC, V2019, DOI 10.1155/2019/7519603; Parida L, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1007332; Patel-Murray NL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57691-7; Patkar N, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0244-2; Pohlkamp C, 2020, BLOOD, V136, DOI 10.1182/blood-2020-140215; Poplin R, 2018, NAT BIOTECHNOL, V36, P983, DOI 10.1038/nbt.4235; Pouyan MB, 2016, BMC MED GENOMICS, V9, DOI 10.1186/s12920-016-0201-x; Qin YL, 2019, IEEE T MED IMAGING, V38, P2569, DOI 10.1109/TMI.2019.2905841; Qiu YC, 2016, PROC SPIE, V9709, DOI 10.1117/12.2217418; Quang D, 2015, BIOINFORMATICS, V31, P761, DOI 10.1093/bioinformatics/btu703; Radakovich N, 2020, BLOOD, V136, DOI 10.1182/blood-2020-139412; Roshtkhari MJ, 2008, INT CONF SIGN PROCES, P849, DOI 10.1109/ICOSP.2008.4697261; Saez-Rodriguez J, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20199042; Sakellaropoulos T, 2019, CELL REP, V29, P3367, DOI 10.1016/j.celrep.2019.11.017; Samek W., 2017, ITU J ICT DISCOVERIE; Shafique S, 2018, TECHNOL CANCER RES T, V17, DOI 10.1177/1533033818802789; Shaikh AF, 2020, LEUKEMIA LYMPHOMA, V61, P3154, DOI 10.1080/10428194.2020.1798951; Sharma M, 2017, IEEE COMPUT SOC CONF, P786, DOI 10.1109/CVPRW.2017.109; Shouval R, 2021, BRIT J HAEMATOL, V192, P239, DOI 10.1111/bjh.16915; Sirinukunwattana K, 2020, BLOOD ADV, V4, P3284, DOI 10.1182/bloodadvances.2020002230; Swati, 2017, IEEE INT CONF COMP V, P72, DOI 10.1109/ICCVW.2017.17; Swerdlow SH, 2008, WHO CLASSIFICATION T; Topol EJ, 2019, NAT MED, V25, P44, DOI 10.1038/s41591-018-0300-7; Wagner S, 2019, BLOOD ADV, V3, P1330, DOI 10.1182/bloodadvances.2018030726; Wu JT, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.22779; Wu YY, 2020, JMIR MED INF, V8, DOI 10.2196/15963; Yurkovich JT, 2020, NAT REV CLIN ONCOL, V17, P183, DOI 10.1038/s41571-019-0273-6; Zare H, 2012, AM J CLIN PATHOL, V137, P75, DOI 10.1309/AJCPMMLQ67YOMGEW; Zhao M, 2020, CYTOM PART A, V97, P1073, DOI 10.1002/cyto.a.24159; Zou J, 2019, NAT GENET, V51, P12, DOI 10.1038/s41588-018-0295-5	78	9	9	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4271	4280		10.1038/s41388-021-01861-y	http://dx.doi.org/10.1038/s41388-021-01861-y		JUN 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34103684	hybrid, Green Published			2022-12-28	WOS:000659032900005
J	Wang, XY; Dong, JN; Li, XJ; Cheng, ZN; Zhu, QB				Wang, Xueying; Dong, Jiani; Li, Xiaojing; Cheng, Zeneng; Zhu, Qubo			CPSF4 regulates circRNA formation and microRNA mediated gene silencing in hepatocellular carcinoma	ONCOGENE			English	Article							CIRCULAR RNAS; POLYADENYLATION; IDENTIFICATION; CLEAVAGE; GROWTH	CircRNAs play essential roles in various physiological processes and involves in many diseases, in particular cancer. Global downregulation of circRNA expression has been observed in hepatocellular carcinoma (HCC) in many studies. Previous studies revealed that the pre-mRNA 3 ' end processing complex participates in circRNA cyclization and plays an important role in HCC tumorigenesis. Therefore, we explored the role of CPSF4, for 3 ' end formation and cleavage, in circRNA formation. Clinical research has shown that CPSF4 expression is upregulated in HCC and that high expression of CPSF4 is associated with poor prognosis in HCC patients. Mechanistic studies have demonstrated that CPSF4 reduces the levels of circRNAs, which possess a polyadenylation signal sequence and this decrease in circRNAs reduces the accumulation of miRNA and disrupts the miRNA-mediated gene silencing in HCC. Experiments in cell culture and xenograft mouse models showed that CPSF4 promotes the proliferation of HCC cells and enhances tumorigenicity. Moreover, CPSF4 antagonizes the tumor suppressor effect of its downstream circRNA in HCC. In summary, CPSF4 acts as an oncogene in HCC through circRNA inhibition and disruption of miRNA-mediated gene silencing.	[Wang, Xueying; Dong, Jiani; Cheng, Zeneng; Zhu, Qubo] Cent South Univ, Xiangya Sch Pharmaceut Sci, Changsha 2, Peoples R China; [Li, Xiaojing] Shanghai Gen Hosp, Shanghai, Peoples R China		Zhu, QB (corresponding author), Cent South Univ, Xiangya Sch Pharmaceut Sci, Changsha 2, Peoples R China.	qubozhu@csu.edu.cn	Zhu, Qubo/ACT-7180-2022		National Natural Science Foundation of China [C0709-31201056]; Hunan Provincial Natural Science Foundation of China [2018JJ2493]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Natural Science Foundation of China(Natural Science Foundation of Hunan Province)	This work was supported by the National Natural Science Foundation of China (C0709-31201056) and the Hunan Provincial Natural Science Foundation of China (2018JJ2493).	Bachmayr-Heyda A, 2015, SCI REP-UK, V5, DOI 10.1038/srep08057; Bezzi M, 2017, CELL RES, V27, P1401, DOI 10.1038/cr.2017.136; Chan SL, 2014, GENE DEV, V28, P2370, DOI 10.1101/gad.250993.114; Chang CC, 2016, BIOSENS BIOELECTRON, V78, P200, DOI 10.1016/j.bios.2015.11.051; Chen Q, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.152872; Clerici M, 2017, ELIFE, V6, DOI 10.7554/eLife.33111; Ding JY, 2019, BIOL CHEM, V400, P247, DOI 10.1515/hsz-2018-0232; Ebermann Constanze, 2020, F1000Res, V9, DOI 10.12688/f1000research.25060.1; Enuka Y, 2016, NUCLEIC ACIDS RES, V44, P1370, DOI 10.1093/nar/gkv1367; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Fu LY, 2017, ONCOTARGET, V8, P58405, DOI 10.18632/oncotarget.16881; Greene J, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00038; Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Li XJ, 2020, ONCOGENE, V39, P891, DOI 10.1038/s41388-019-1030-0; Liang DM, 2017, MOL CELL, V68, P940, DOI 10.1016/j.molcel.2017.10.034; Lin XM, 2018, MED SCI MONIT BASIC, V24, P70, DOI 10.12659/MSMBR.909737; Liu SY, 2019, BMC CANCER, V19, P1; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Meng XW, 2017, BIOINFORMATICS, V33, P3314, DOI 10.1093/bioinformatics/btx446; Misra A, 2016, RNA BIOL, V13, P259, DOI 10.1080/15476286.2015.1112490; Misra A, 2015, MOL CELL, V58, P819, DOI 10.1016/j.molcel.2015.03.016; Noble CG, 2007, NUCLEIC ACIDS RES, V35, P87, DOI 10.1093/nar/gkl1010; Qiu LP, 2019, LIFE SCI, V231, DOI 10.1016/j.lfs.2019.116660; Qu SB, 2017, RNA BIOL, V14, P992, DOI 10.1080/15476286.2016.1220473; Qu SB, 2015, CANCER LETT, V365, P141, DOI 10.1016/j.canlet.2015.06.003; Song CL, 2019, J CELL PHYSIOL, V234, P2460, DOI 10.1002/jcp.26764; Sun M, 2017, CANCER LETT, V410, P158, DOI 10.1016/j.canlet.2017.09.026; Tan S, 2018, ONCOGENE, V37, P4887, DOI 10.1038/s41388-018-0280-6; Trifonov A, 2016, J PHYS CHEM C, V120, P15743, DOI 10.1021/acs.jpcc.5b11308; Wang ZL, 2013, GLAND SURG, V2, P25, DOI 10.3978/j.issn.2227-684X.2013.02.07; Wilusz JE, 2013, SCIENCE, V340, P440, DOI 10.1126/science.1238522; Wu BW, 2020, J CANCER, V11, P5727, DOI 10.7150/jca.46554; Wu JR, 2019, BIOCHEM CELL BIOL, V97, P722, DOI 10.1139/bcb-2019-0008; Xu S, 2018, PEERJ, V6, DOI 10.7717/peerj.5503; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Yang Q, 2019, BBA-MOL CELL RES, V1866, P1533, DOI 10.1016/j.bbamcr.2019.07.001; Yi CH, 2016, CANCER LETT, V381, P1, DOI 10.1016/j.canlet.2016.07.016; Yoshio TD, 1997, MOL CELL BIOL, V17, P3907, DOI 10.1128/MCB.17.7.3907; Yu J, 2018, J HEPATOL, V68, P1214, DOI 10.1016/j.jhep.2018.01.012; Zhang H, 2015, CANCER LETT, V367, P49, DOI 10.1016/j.canlet.2015.07.010; Zhang XW, 2018, ONCOTARGETS THER, V11, P2853, DOI 10.2147/OTT.S158008; Zhong YX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0827-8	44	6	6	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4338	4351		10.1038/s41388-021-01867-6	http://dx.doi.org/10.1038/s41388-021-01867-6		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34103682				2022-12-28	WOS:000659032900002
J	Richart, L; Bidard, FC; Margueron, R				Richart, Laia; Bidard, Francois-Clement; Margueron, Raphael			Enhancer rewiring in tumors: an opportunity for therapeutic intervention	ONCOGENE			English	Review							BET BROMODOMAIN INHIBITORS; SUPER-ENHANCER; GENE-EXPRESSION; TRANSCRIPTIONAL ADDICTION; SELECTIVE-INHIBITION; OVERCOME RESISTANCE; TARGETED THERAPY; BLADDER-CANCER; CELL IDENTITY; WHOLE-GENOME	Enhancers are cis-regulatory sequences that fine-tune expression of their target genes in a spatiotemporal manner. They are recognized by sequence-specific transcription factors, which in turn recruit transcriptional coactivators that facilitate transcription by promoting assembly and activation of the basal transcriptional machinery. Their functional importance is underscored by the fact that they are often the target of genetic and nongenetic events in human disease that disrupt their sequence, interactome, activation potential, and/or chromatin environment. Dysregulation of transcription and addiction to transcriptional effectors that interact with and modulate enhancer activity are common features of cancer cells and are amenable to therapeutic intervention. Here, we discuss the current knowledge on enhancer biology, the broad spectrum of mechanisms that lead to their malfunction in tumor cells, and recent progress in developing drugs that efficaciously target their dependencies.	[Richart, Laia; Margueron, Raphael] Paris Sci & Lettres Res Univ, Inst Curie, Paris, France; [Richart, Laia; Margueron, Raphael] CNRS, UMR3215, INSERM, U934/, Paris, France; [Bidard, Francois-Clement] Inst Curie, Dept Med Oncol, Paris, France; [Bidard, Francois-Clement] SIRIC2 Inst Curie, Circulating Tumor Biomarkers Lab, Paris, France; [Bidard, Francois-Clement] Univ Paris Saclay, UVSQ, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Saclay	Margueron, R (corresponding author), Paris Sci & Lettres Res Univ, Inst Curie, Paris, France.; Margueron, R (corresponding author), CNRS, UMR3215, INSERM, U934/, Paris, France.	raphael.margueron@curie.fr	Margueron, Raphael/B-9996-2015	Margueron, Raphael/0000-0002-9093-7977	Fondation pour la Recherche Medicale [Equipe FRM EQU202003010312]; Pfizer	Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Pfizer(Pfizer)	Work in the lab of RM is supported by the Fondation pour la Recherche Medicale (Equipe FRM EQU202003010312). LR work was partly supported by a research grant from Pfizer. We thank Daniel Holoch and Ming-Kang Lee for their critical review of the manuscript.	Abramson JS, 2015, BLOOD, V126; Affer M, 2014, LEUKEMIA, V28, P1725, DOI 10.1038/leu.2014.70; Akhtar MS, 2009, MOL CELL, V34, P387, DOI 10.1016/j.molcel.2009.04.016; Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277; Albrecht BK, 2016, J MED CHEM, V59, P1330, DOI 10.1021/acs.jmedchem.5b01882; Alekseyenko AA, 2015, GENE DEV, V29, P1507, DOI 10.1101/gad.267583.115; Ali S, 2009, CANCER RES, V69, P6208, DOI 10.1158/0008-5472.CAN-09-0301; Ambrosini G, 2019, CANCER RES, V79, P2415, DOI 10.1158/0008-5472.CAN-18-3177; Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Andricovich J, 2018, CANCER CELL, V33, P512, DOI 10.1016/j.ccell.2018.02.003; Arfaoui A, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809930; Bagratuni T, 2020, EUR J CANCER, V126, P125, DOI 10.1016/j.ejca.2019.11.017; Bahr C, 2018, NATURE, V553, P515, DOI 10.1038/nature25193; Balbas-Martinez C, 2013, NAT GENET, V45, P1464, DOI 10.1038/ng.2799; Bandopadhayay P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10307-9; Beauchamp EM, 2019, BLOOD, V133, P1171, DOI 10.1182/blood-2018-08-870089; Belakavadi M, 2008, MOL CELL BIOL, V28, P3932, DOI 10.1128/MCB.02191-07; Benabdallah NS, 2019, MOL CELL, V76, P473, DOI 10.1016/j.molcel.2019.07.038; Benabdallah NS, 2015, COLD SH Q B, V80, P45, DOI 10.1101/sqb.2015.80.027268; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Bihani T, 2015, ONCOTARGET, V6, P2407, DOI 10.18632/oncotarget.2964; Boedicker C, 2020, ONCOGENE, V39, P3837, DOI 10.1038/s41388-020-1229-0; Boija A, 2018, CELL, V175, P1842, DOI 10.1016/j.cell.2018.10.042; Bolin S, 2018, ONCOGENE, V37, P2850, DOI 10.1038/s41388-018-0135-1; Bose DA, 2017, CELL, V168, P135, DOI 10.1016/j.cell.2016.12.020; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Calebiro D, 2016, J CLIN INVEST, V126, P3383, DOI 10.1172/JCI84894; Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038; Calvo-Vidal, 2017, NAT COMMUN, V8; Camero S, 2020, CANCER LETT, V479, P71, DOI 10.1016/j.canlet.2020.03.011; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Casa V, 2020, GENOME RES, V30, P515, DOI 10.1101/gr.253211.119; Catarino RR, 2018, GENE DEV, V32, P202, DOI 10.1101/gad.310367.117; Chaidos A, 2014, BLOOD, V123, P697, DOI 10.1182/blood-2013-01-478420; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Chen H, 2018, CELL, V173, P386, DOI 10.1016/j.cell.2018.03.027; Chen JW, 2021, CLIN CANCER RES, V27, P1438, DOI 10.1158/1078-0432.CCR-20-3044; Chipumuro E, 2014, CELL, V159, P1126, DOI 10.1016/j.cell.2014.10.024; Cho WK, 2018, SCIENCE, V361, P412, DOI 10.1126/science.aar4199; Christensen CL, 2014, CANCER CELL, V26, P909, DOI 10.1016/j.ccell.2014.10.019; Chua V, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809081; Clarke PA, 2016, ELIFE, V5, DOI 10.7554/eLife.20722; Cromm PM, 2017, CELL CHEM BIOL, V24, P1181, DOI 10.1016/j.chembiol.2017.05.024; Dai XP, 2017, NAT MED, V23, DOI 10.1038/nm.4378; Dale T, 2015, NAT CHEM BIOL, V11, P973, DOI 10.1038/nchembio.1952; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dave K, 2017, ELIFE, V6, DOI 10.7554/eLife.23382; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; De Koninck M, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026476; De Santa F, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000384; Debruyne DN, 2019, NATURE, V572, P676, DOI 10.1038/s41586-019-1472-0; Noblejas-Lopez MD, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1387-5; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Deng WL, 2014, CELL, V158, P849, DOI 10.1016/j.cell.2014.05.050; Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082; Donner AJ, 2010, NAT STRUCT MOL BIOL, V17, P194, DOI 10.1038/nsmb.1752; Drier Y, 2016, NAT GENET, V48, P265, DOI 10.1038/ng.3502; Edmondson SD, 2019, BIOORG MED CHEM LETT, V29, P1555, DOI 10.1016/j.bmcl.2019.04.030; El Khattabi L, 2019, CELL, V178, P1145, DOI 10.1016/j.cell.2019.07.011; Esnault C, 2008, MOL CELL, V31, P337, DOI 10.1016/j.molcel.2008.06.021; Fagan RJ, 2019, CANCER LETT, V458, P56, DOI 10.1016/j.canlet.2019.05.024; Faivre EJ, 2020, NATURE, V578, P306, DOI 10.1038/s41586-020-1930-8; Fant CB, 2019, TRANSCR-AUSTIN, V10, P76, DOI 10.1080/21541264.2018.1556915; Fehling SC, 2020, CANCER LETT, V468, P48, DOI 10.1016/j.canlet.2019.10.011; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Fiskus W, 2021, LEUKEMIA, V35, P2621, DOI 10.1038/s41375-021-01181-w; Flavahan WA, 2019, NATURE, V575, P229, DOI 10.1038/s41586-019-1668-3; Flavahan WA, 2016, NATURE, V529, P110, DOI 10.1038/nature16490; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; Frankel N, 2010, NATURE, V466, P490, DOI 10.1038/nature09158; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; Fulco CP, 2019, NAT GENET, V51, P1664, DOI 10.1038/s41588-019-0538-0; Galbraith MD, 2019, TRANSCR-AUSTIN, V10, P118, DOI 10.1080/21541264.2018.1539615; Gilan O, 2020, SCIENCE, V368, P387, DOI 10.1126/science.aaz8455; Gollavilli PN, 2018, CANCER RES, V78, P4760, DOI 10.1158/0008-5472.CAN-18-0484; Groschel S, 2014, CELL, V157, P369, DOI 10.1016/j.cell.2014.02.019; Grubert F, 2015, CELL, V162, P1051, DOI 10.1016/j.cell.2015.07.048; Gu WT, 2013, CELL CYCLE, V12, P987, DOI 10.4161/cc.24003; Guerra SL, 2020, CANCER CELL, V37, P705, DOI 10.1016/j.ccell.2020.03.004; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Haller F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08069-x; Hamilton WB, 2019, NATURE, V575, P355, DOI 10.1038/s41586-019-1732-z; Han XY, 2020, NAT STRUCT MOL BIOL, V27, P333, DOI 10.1038/s41594-020-0394-8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harms PW., 2014, HUM PATHOL, V1, P21, DOI DOI 10.1016/J.EHPC.2014.07.002; Hnisz D, 2018, ANNU REV CANC BIOL, V2, P21, DOI 10.1146/annurev-cancerbio-030617-050134; Hnisz D, 2017, CELL, V169, P13, DOI 10.1016/j.cell.2017.02.007; Hnisz D, 2015, MOL CELL, V58, P362, DOI 10.1016/j.molcel.2015.02.014; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Iniguez AB, 2018, CANCER CELL, V34, P922, DOI 10.1016/j.ccell.2018.11.005; Iniguez AB, 2018, CANCER CELL, V33, P202, DOI 10.1016/j.ccell.2017.12.009; Jiang YY, 2017, GUT, V66, P1358, DOI 10.1136/gutjnl-2016-311818; Jin X, 2018, MOL CELL, V71, P592, DOI 10.1016/j.molcel.2018.06.036; Kagey MH, 2010, NATURE, V467, P430, DOI 10.1038/nature09380; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Katainen R, 2015, NAT GENET, V47, P818, DOI 10.1038/ng.3335; Kelso TWR, 2014, MOL CELL BIOL, V34, P3675, DOI 10.1128/MCB.00595-14; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Klein IA, 2020, SCIENCE, V368, P1386, DOI 10.1126/science.aaz4427; Knoechel B, 2014, NAT GENET, V46, P364, DOI 10.1038/ng.2913; Kojic A, 2018, NAT STRUCT MOL BIOL, V25, P496, DOI 10.1038/s41594-018-0070-4; Kurimchak AM, 2016, CELL REP, V16, P1273, DOI 10.1016/j.celrep.2016.06.091; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lam FC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04315-4; Lambert JP, 2019, MOL CELL, V73, P621, DOI 10.1016/j.molcel.2018.11.006; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Latif AL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20378-8; Leal AS, 2017, CANCER LETT, V394, P76, DOI 10.1016/j.canlet.2017.02.021; Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292; Li B, 2017, CANCER RES, V77, P3834, DOI 10.1158/0008-5472.CAN-16-2546; Li WP, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0761-2; Li WB, 2013, NATURE, V498, P516, DOI 10.1038/nature12210; Liao SD, 2018, GENE DEV, V32, P1188, DOI 10.1101/gad.315648.118; Liddicoat BJ, 2020, MOL CELL, V78, P991, DOI 10.1016/j.molcel.2020.05.026; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Lu HS, 2015, ELIFE, V4, DOI 10.7554/eLife.06535; Lu J, 2015, CHEM BIOL, V22, P755, DOI 10.1016/j.chembiol.2015.05.009; Lucking U, 2017, CHEMMEDCHEM, V12, P1776, DOI 10.1002/cmdc.201700447; Madsen JGS, 2020, NAT GENET, V52, P1227, DOI 10.1038/s41588-020-0709-z; Mahe M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708163; Matkar S, 2015, CANCER CELL, V28, P472, DOI 10.1016/j.ccell.2015.09.005; Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; McDermott MSJ, 2017, ONCOTARGET, V8, P12558, DOI 10.18632/oncotarget.14894; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Mir M, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.182766; Moreno V, 2020, ANN ONCOL, V31, P780, DOI 10.1016/j.annonc.2020.03.294; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Morrison-Smiths CD, 2020, MOL CANCER THER, V19, P1406, DOI 10.1158/1535-7163.MCT-20-0087; Muller M, 2016, STEM CELL RES, V16, P349, DOI 10.1016/j.scr.2016.02.005; Nabet B, 2015, CELL REP, V12, P1300, DOI 10.1016/j.celrep.2015.06.078; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Nora EP, 2012, NATURE, V485, P381, DOI 10.1038/nature11049; Northcott PA, 2017, NATURE, V547, P311, DOI 10.1038/nature22973; Nott A, 2019, SCIENCE, V366, P1134, DOI 10.1126/science.aay0793; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Olson CM, 2018, NAT CHEM BIOL, V14, P163, DOI [10.1038/nchembio.2538, 10.1038/NCHEMBIO.2538]; Ortega-Molina A, 2015, NAT MED, V21, P1199, DOI 10.1038/nm.3943; Ozer HG, 2018, CANCER DISCOV, V8, P458, DOI 10.1158/2159-8290.CD-17-0902; Pandey PK, 2005, MOL CELL BIOL, V25, P10695, DOI 10.1128/MCB.25.24.10695-10710.2005; Patel H, 2018, MOL CANCER THER, V17, P1156, DOI 10.1158/1535-7163.MCT-16-0847; Pelish HE, 2015, NATURE, V526, P273, DOI 10.1038/nature14904; Phillips-Cremins JE, 2013, CELL, V153, P1281, DOI 10.1016/j.cell.2013.04.053; Piha-Paul SA, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkz093; Piunti A, 2017, NAT MED, V23, P493, DOI 10.1038/nm.4296; Piya S, 2019, J CLIN INVEST, V129, P1878, DOI 10.1172/JCI120654; Puente XS, 2015, NATURE, V526, P519, DOI 10.1038/nature14666; Pulikkan JA, 2018, CELL, V174, P172, DOI 10.1016/j.cell.2018.05.048; Quereda V, 2019, CANCER CELL, V36, P545, DOI 10.1016/j.ccell.2019.09.004; Raina K, 2016, P NATL ACAD SCI USA, V113, P7124, DOI 10.1073/pnas.1521738113; Rao SSP, 2017, CELL, V171, P305, DOI 10.1016/j.cell.2017.09.026; Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021; Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898; Rickels R, 2018, TRENDS CELL BIOL, V28, P608, DOI 10.1016/j.tcb.2018.04.003; Risom T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05729-w; Rusan M, 2018, CANCER DISCOV, V8, P59, DOI 10.1158/2159-8290.CD-17-0461; Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958; Saenz DT, 2020, BLOOD, V135, P1255, DOI 10.1182/blood.2019002922; Sanborn AL, 2015, P NATL ACAD SCI USA, V112, pE6456, DOI 10.1073/pnas.1518552112; Schilbach S, 2017, NATURE, V551, P204, DOI 10.1038/nature24282; Segura MF, 2013, CANCER RES, V73, P6264, DOI 10.1158/0008-5472.CAN-13-0122-T; Sharko AC, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010144; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Sin-Chan P, 2019, CANCER CELL, V36, P51, DOI 10.1016/j.ccell.2019.06.002; Siu KT, 2017, LEUKEMIA, V31, P1760, DOI 10.1038/leu.2016.355; Spitz F, 2016, SEMIN CELL DEV BIOL, V57, P57, DOI 10.1016/j.semcdb.2016.06.017; Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335; Stevens JL, 2002, SCIENCE, V296, P755, DOI 10.1126/science.1068943; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Stubbs MC, 2019, CLIN CANCER RES, V25, P300, DOI 10.1158/1078-0432.CCR-18-0098; Sun B, 2018, LEUKEMIA, V32, P343, DOI 10.1038/leu.2017.207; Sur I, 2016, NAT REV CANCER, V16, P483, DOI 10.1038/nrc.2016.62; Sze CC, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026427; Takahashi H, 2011, CELL, V146, P92, DOI 10.1016/j.cell.2011.06.005; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Tothova Z, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.142149; van Arensbergen J, 2014, TRENDS CELL BIOL, V24, P695, DOI 10.1016/j.tcb.2014.07.004; Vazquez R, 2017, ONCOTARGET, V8, P7598, DOI 10.18632/oncotarget.13814; Walsh L, 2019, CLIN CANCER RES, V25, P7139, DOI 10.1158/1078-0432.CCR-19-0713; Wang YB, 2015, CELL, V163, P174, DOI 10.1016/j.cell.2015.08.063; Waring MJ, 2016, NAT CHEM BIOL, V12, P1097, DOI [10.1038/NCHEMBIO.2210, 10.1038/nchembio.2210]; Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023; Welter Danielle, 2014, Nucleic Acids Res, V42, pD1001, DOI 10.1093/nar/gkt1229; Welti J, 2018, CLIN CANCER RES, V24, P3149, DOI 10.1158/1078-0432.CCR-17-3571; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Wu WY, 2020, MOL CELL, V78, P1114, DOI 10.1016/j.molcel.2020.04.034; Yan LM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19770-1; Yang L, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1645; Yang X, 2012, P NATL ACAD SCI USA, V109, pE2813, DOI 10.1073/pnas.1204311109; Yokoyama Y, 2016, CANCER RES, V76, P6320, DOI 10.1158/0008-5472.CAN-16-0854; Zawistowski JS, 2017, CANCER DISCOV, V7, P302, DOI 10.1158/2159-8290.CD-16-0653; Zengerle M, 2015, ACS CHEM BIOL, V10, P1770, DOI 10.1021/acschembio.5b00216; Zhang GT, 2013, J MED CHEM, V56, P9251, DOI 10.1021/jm401334s; Zhang HH, 2018, CELL, V175, P1244, DOI 10.1016/j.cell.2018.09.051; Zhang JJ, 2020, CLIN CANCER RES, V26, P2681, DOI 10.1158/1078-0432.CCR-19-1418; Zhang TH, 2016, NAT CHEM BIOL, V12, P876, DOI 10.1038/nchembio.2166; Zhang W, 2020, CANCER LETT, V469, P510, DOI 10.1016/j.canlet.2019.11.027; Zhang XH, 2018, LEUKEMIA, V32, P2224, DOI 10.1038/s41375-018-0044-x; Zhang XY, 2016, NAT GENET, V48, P176, DOI 10.1038/ng.3470; Zhou S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14318-9; Zimmerman MW, 2018, CANCER DISCOV, V8, P320, DOI 10.1158/2159-8290.CD-17-0993	206	4	4	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3475	3491		10.1038/s41388-021-01793-7	http://dx.doi.org/10.1038/s41388-021-01793-7		MAY 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33934105				2022-12-28	WOS:000645962300001
J	Eniafe, J; Jiang, S				Eniafe, Joseph; Jiang, Shuai			The functional roles of TCA cycle metabolites in cancer	ONCOGENE			English	Review							ONCOMETABOLITE 2-HYDROXYGLUTARATE; REDUCTIVE CARBOXYLATION; GLUTAMINE-METABOLISM; FUMARATE HYDRATASE; SUPPORTS GROWTH; DEFICIENT CELLS; IDH MUTATIONS; SDH MUTATIONS; CITRATE; HISTONE	The tricarboxylic acid cycle (TCA cycle) has been known for decades as a hub for generating cellular energy and precursors for biosynthetic pathways. Several cancers harbor mutations that affect the integrity of this cycle, mostly at the levels of isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), and fumarate hydratase (FH). This results in dysregulation in the production of TCA cycle metabolites and is probably implicated in cancer initiation. By modulating cellular activities, including metabolism and signaling, TCA cycle intermediates are able to impact the processes of cancer development and progression. In this review, we discuss the functional roles of the TCA cycle intermediates in suppressing or promoting the progression of cancers. A further understanding of TCA metabolites' roles and molecular mechanisms in oncogenesis would prompt developing novel metabolite-based cancer therapy in the future.	[Eniafe, Joseph; Jiang, Shuai] Louisiana State Univ, Dept Microbiol & Immunol, Hlth Sci Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Jiang, S (corresponding author), Louisiana State Univ, Dept Microbiol & Immunol, Hlth Sci Ctr, Shreveport, LA 71130 USA.	sjiang@lsuhsc.edu		Jiang, Shuai/0000-0002-0572-4660; Eniafe, Joseph/0000-0003-4616-4273	Louisiana State University (LSU) Feist-Weiller Cancer Center (FWCC) Legacy Funds [149741373A]; Intramural Research Council [110251225A]; Micro Seed Funds	Louisiana State University (LSU) Feist-Weiller Cancer Center (FWCC) Legacy Funds; Intramural Research Council; Micro Seed Funds	The authors apologize to the researchers whose work was not cited because of space limitation. The authors are supported by Louisiana State University (LSU) Feist-Weiller Cancer Center (FWCC) Legacy Funds (149741373A), Intramural Research Council Support (110251225A), and the Micro Seed Funds. Figures are created with BioRender.com. We thank Patrick Simon for his contributions during the editing stage of the paper.	Abla H, 2020, SEMIN CELL DEV BIOL, V98, P26, DOI 10.1016/j.semcdb.2019.05.031; Alderson NL, 2006, ARCH BIOCHEM BIOPHYS, V450, P1, DOI 10.1016/j.abb.2006.03.005; Bardella C, 2011, BBA-BIOENERGETICS, V1807, P1432, DOI 10.1016/j.bbabio.2011.07.003; Bennett Saidu Nathaniel Edward, 2018, Oncotarget, V9, P9088, DOI 10.18632/oncotarget.24144; Bottcher M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1445454; Bouillez A, 2016, CANCER RES, V76, P1538, DOI 10.1158/0008-5472.CAN-15-1804; Brahimi-Horn MC, 2011, CURR OPIN GENET DEV, V21, P67, DOI 10.1016/j.gde.2010.10.006; Bunse L, 2018, NAT MED, V24, P1192, DOI 10.1038/s41591-018-0095-6; Caiazza C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112613; Chatterjee N, 2017, ENVIRON MOL MUTAGEN, V58, P235, DOI 10.1002/em.22087; Chen JY, 2016, SCI REP-UK, V6, DOI 10.1038/srep32428; Chen LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115708; Chen QY, 2018, CELL METAB, V27, P1007, DOI 10.1016/j.cmet.2018.03.002; Chesney J, 2006, CURR OPIN CLIN NUTR, V9, P535, DOI 10.1097/01.mco.0000241661.15514.fb; Chinopoulos C, 2018, ASN NEURO, V10, DOI 10.1177/1759091418818261; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Dang L, 2016, ANN ONCOL, V27, P599, DOI 10.1093/annonc/mdw013; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Duran RV, 2012, MOL CELL, V47, P349, DOI 10.1016/j.molcel.2012.05.043; Eckel-Passow JE, 2015, NEW ENGL J MED, V372, P2499, DOI 10.1056/NEJMoa1407279; El Sayed SM, 2012, J BIOENERG BIOMEMBR, V44, P513, DOI 10.1007/s10863-012-9455-y; Fan J, 2013, J BIOL CHEM, V288, P31363, DOI 10.1074/jbc.M113.502740; Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019; Fernandez HR, 2018, CELL DEATH DIFFER, V25, P1239, DOI 10.1038/s41418-018-0101-z; Filipp FV, 2012, PIGM CELL MELANOMA R, V25, P375, DOI 10.1111/j.1755-148X.2012.00989.x; Gaglio D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.56; Gameiro PA, 2013, CELL METAB, V17, P372, DOI 10.1016/j.cmet.2013.02.002; Gao CC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154576; Han GC, 2016, IN VITRO CELL DEV-AN, V52, P1034, DOI 10.1007/s11626-016-0069-2; Han YB, 2017, J BIOL CHEM, V292, P4789, DOI 10.1074/jbc.M116.763821; Hanai J, 2012, J CELL PHYSIOL, V227, P1709, DOI 10.1002/jcp.22895; Hanse EA, 2017, ONCOGENE, V36, P3915, DOI 10.1038/onc.2017.36; Hui S, 2017, NATURE, V551, P115, DOI 10.1038/nature24057; Icard P, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0676-y; Icard P, 2012, BBA-REV CANCER, V1825, P111, DOI 10.1016/j.bbcan.2011.10.007; Intlekofer AM, 2017, NAT CHEM BIOL, V13, P494, DOI [10.1038/NCHEMBIO.2307, 10.1038/nchembio.2307]; Jeong SM, 2016, SCI REP-UK, V6, DOI 10.1038/srep30767; Jiang YH, 2015, NAT CELL BIOL, V17, P1158, DOI 10.1038/ncb3209; Johnson TI, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0912-3; Kaluzki I, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111329; Kiwerska K, 2019, J APPL GENET, V60, P329, DOI 10.1007/s13353-019-00516-9; Kuang Y, 2018, CANCER MED-US, V7, P1416, DOI 10.1002/cam4.1410; Kuiper C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00359; Laukka T, 2016, J BIOL CHEM, V291, P4256, DOI 10.1074/jbc.M115.688762; Letouze E, 2013, CANCER CELL, V23, P739, DOI 10.1016/j.ccr.2013.04.018; Li L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12235; Lim JKM., 2019, CELL DEATH DIS, V10, P1; Lin CC, 2012, SCI REP-UK, V2, DOI 10.1038/srep00785; Lincet H, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-72; Liu H, 2019, AM J TRANSL RES, V11, P4713; Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Marino G, 2014, MOL CELL, V53, P710, DOI 10.1016/j.molcel.2014.01.016; Martinez S, 2015, J BIOL CHEM, V290, P20702, DOI 10.1074/jbc.R115.648691; McBrayer SK, 2018, CELL, V175, P101, DOI 10.1016/j.cell.2018.08.038; McGuirk S, 2020, TRENDS CANCER, V6, P49, DOI 10.1016/j.trecan.2019.11.009; MELENDEZRODRIGU.AA, 2019, CELL REP, V26, DOI DOI 10.1016/J.CELREP.2019.01.106; Morris JP, 2019, NATURE, V573, P595, DOI 10.1038/s41586-019-1577-5; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; O'Flaherty L, 2010, HUM MOL GENET, V19, P3844, DOI 10.1093/hmg/ddq305; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; Peng MX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1475-7; Philippe I, 2016, DRUG RESIST UPDATE, V29, P47, DOI 10.1016/j.drup.2016.09.003; Raffel S, 2017, NATURE, V551, P384, DOI 10.1038/nature24294; Ren JG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04626-4; Rzeski W, 2012, SCAND J GASTROENTERO, V47, P565, DOI 10.3109/00365521.2012.660539; Saidu NEB, 2017, MOL CANCER THER, V16, P529, DOI 10.1158/1535-7163.MCT-16-0405; Schmidt C, 2020, SEMIN CELL DEV BIOL, V98, P15, DOI 10.1016/j.semcdb.2019.05.002; Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Shafer Danielle, 2020, Neurooncol Adv, V2, pvdz052, DOI 10.1093/noajnl/vdz052; Smestad J, 2018, ISCIENCE, V2, P63, DOI 10.1016/j.isci.2018.03.012; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Sulkowski PL, 2018, NAT GENET, V50, P1086, DOI 10.1038/s41588-018-0170-4; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Sullivan LB, 2013, MOL CELL, V51, P236, DOI 10.1016/j.molcel.2013.05.003; Tardito S, 2015, NAT CELL BIOL, V17, P1556, DOI 10.1038/ncb3272; Tennant DA, 2009, ONCOGENE, V28, P4009, DOI 10.1038/onc.2009.250; Tennant DA, 2009, CARCINOGENESIS, V30, P1269, DOI 10.1093/carcin/bgp070; Trefely S, 2020, MOL METAB, V38, DOI 10.1016/j.molmet.2020.01.005; Tseng PL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21361-6; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Valesky EM, 2016, EXP DERMATOL, V25, P200, DOI 10.1111/exd.12907; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Wang TA, 2016, ONCOL REP, V35, P1287, DOI 10.3892/or.2015.4511; Wang YG, 2017, NATURE, V552, P273, DOI 10.1038/nature25003; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Williams NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00141; Wu JY, 2020, MOL CELL, V77, P213, DOI 10.1016/j.molcel.2019.10.023; Xia Y, 2018, ONCOL LETT, V15, P6622, DOI 10.3892/ol.2018.8111; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xie X, 2015, BRIT J PHARMACOL, V172, P3929, DOI 10.1111/bph.13184; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yang ZK, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-017-0664-4; Ye D, 2013, CANCER CELL, V23, P274, DOI 10.1016/j.ccr.2013.03.005; Yi CH, 2011, CELL, V146, P607, DOI 10.1016/j.cell.2011.06.050; Yogev O, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000328; Zaslona Z, 2020, MOL CELL, V78, P814, DOI 10.1016/j.molcel.2020.04.002; Zhang BX, 2017, J CANCER, V8, P2088, DOI 10.7150/jca.19373; Zhang ZH, 2011, NAT CHEM BIOL, V7, P58, DOI 10.1038/NCHEMBIO.495; Zhao YQ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55718-2; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011	108	29	29	8	39	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3351	3363		10.1038/s41388-020-01639-8	http://dx.doi.org/10.1038/s41388-020-01639-8		APR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33864000				2022-12-28	WOS:000640748600002
J	Solan, JL; Hingorani, SR; Lampe, PD				Solan, Joell L.; Hingorani, Sunil R.; Lampe, Paul D.			Cx43 phosphorylation sites regulate pancreatic cancer metastasis	ONCOGENE			English	Article								Pancreatic ductal adenocarcinoma (PDA) is aggressive, highly metastatic and characterized by a robust desmoplasia. Connexin proteins that form gap junctions have been implicated in tumor suppression for over 30 years. Cx43, the most widely expressed connexin, regulates cell behaviors, including migration and proliferation. Thus, we hypothesized that Cx43 could regulate PDA progression. Phosphorylation of Cx43 by Casein Kinase 1 (CK1) regulates gap junction assembly. We interbred the well-established Kras(LSL-G12D/+;p48Cre/+) (KC) mouse model of PDA with homozygous "knock-in" mutant Cx43 mice bearing amino acid substitution at CK1 sites (Cx43(CK1A)) and found profound and surprising effects on cancer progression. Crossing the Cx43(CK1A) mouse onto the KC background (termed KC;Cx(CK1A)) led to significant extension of lifespan, from a median of 370 to 486 days (p = 0.03) and a decreased incidence of metastasis (p = 0.045). However, when we examined early stages of disease, we found more rapid onset of tissue remodeling in the KC;Cx(CK1A) mouse followed by divergence to a cystic phenotype. During tumorigenesis, gap junctions are increasingly present in stromal cells of the KC mice but are absent from the KC;Cx43(CK1A) mice. Tail vein metastasis assays with cells derived from KC or KC;Cx(CK1A) tumors showed that KC;Cx(CK1A) cells could efficiently colonize the lung and downregulate Cx43 expression, arguing that inhibition of metastasis was not occurring at the distal site. Instead, stromal gap junctions, their associated signaling events or other unknown Cx43-dependent events facilitate metastatic capacity in the primary tumor.	[Solan, Joell L.; Hingorani, Sunil R.; Lampe, Paul D.] Publ Hlth Sci Div, Translat Res Program, Seattle, WA 98109 USA; [Solan, Joell L.; Lampe, Paul D.] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA; [Hingorani, Sunil R.] Fred Hutchinson Canc Res Ctr, Clin Div, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Lampe, PD (corresponding author), Publ Hlth Sci Div, Translat Res Program, Seattle, WA 98109 USA.; Lampe, PD (corresponding author), Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA.	plampe@fredhutch.org		Lampe, Paul/0000-0002-1399-2761; Hingorani, Sunil/0000-0002-3869-8729	National Institutes of Health [R21CA149554, GM55632]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	H & E pathology analysis was performed by Sue Knoblaugh, DVM, Diplomate ACVP. Yutaka Yasui, PhD performed power calculations and aided in the experimental design of the mouse experiments. This work was supported by grants R21CA149554 and GM55632 from the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Aasen T, 2016, NAT REV CANCER, V16, P775, DOI 10.1038/nrc.2016.105; Angst E, 2006, BRIT J CANCER, V95, P307, DOI 10.1038/sj.bjc.6603256; Barrett R, 2020, CURR OPIN IMMUNOL, V64, P80, DOI 10.1016/j.coi.2020.03.004; Best SA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12164-y; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Cen G, 2017, ONCOL REP, V37, P1189, DOI 10.3892/or.2017.5355; Chen XM, 2019, NAT REV DRUG DISCOV, V18, P99, DOI 10.1038/s41573-018-0004-1; Chu GC, 2007, J CELL BIOCHEM, V101, P887, DOI 10.1002/jcb.21209; Cigliola V, 2015, PANCREAS, V44, P1234, DOI 10.1097/MPA.0000000000000378; Cooper CD, 2002, J BIOL CHEM, V277, P44962, DOI 10.1074/jbc.M209427200; Daley D, 2017, J EXP MED, V214, P1711, DOI 10.1084/jem.20161707; Dvorak HF, 2015, CANCER IMMUNOL RES, V3, P1, DOI 10.1158/2326-6066.CIR-14-0209; Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215; Garcia-Rodriguez L, 2011, MOL CANCER THER, V10, P505, DOI 10.1158/1535-7163.MCT-10-0693; Gomez D, 2012, CARDIOVASC RES, V95, P156, DOI 10.1093/cvr/cvs115; Grek CL, 2015, WOUND REPAIR REGEN, V23, P203, DOI 10.1111/wrr.12275; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Helms E, 2020, CANCER DISCOV, V10, P648, DOI 10.1158/2159-8290.CD-19-1353; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Huang Guo-Ying, 2011, J Cardiovasc Dis Res, V2, P206, DOI 10.4103/0975-3583.89804; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; King TJ, 2005, BBA-BIOMEMBRANES, V1719, P24, DOI 10.1016/j.bbamem.2005.07.010; King TJ, 2004, CARCINOGENESIS, V25, P669, DOI 10.1093/carcin/bgh071; King TJ, 2005, ONCOGENE, V24, P1718, DOI 10.1038/sj.onc.1208355; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Kyo N, 2008, ONCOL REP, V19, P627; Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922; Lampe PD, 2006, J CELL SCI, V119, P3435, DOI 10.1242/jcs.03089; Lastwika KJ, 2019, J CELL SCI, V132, DOI 10.1242/jcs.234633; Lo A, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92232; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; Maitra A, 2005, ADV ANAT PATHOL, V12, P81, DOI 10.1097/01.pap.0000155055.14238.25; Mann KM, 2016, PHARMACOL THERAPEUT, V168, P29, DOI 10.1016/j.pharmthera.2016.09.003; Masamune A, 2013, PANCREAS, V42, P308, DOI 10.1097/MPA.0b013e31825c51d6; Mazur PK, 2010, P NATL ACAD SCI USA, V107, P13438, DOI 10.1073/pnas.1002423107; Mugisho OO, 2018, BBA-GEN SUBJECTS, V1862, P385, DOI 10.1016/j.bbagen.2017.11.015; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Remo BF, 2011, CIRC RES, V108, P1459, DOI 10.1161/CIRCRESAHA.111.244046; Richards TS, 2004, J CELL BIOL, V167, P555, DOI 10.1083/jcb.200404142; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Salameh A, 2013, BBA-BIOMEMBRANES, V1828, P147, DOI 10.1016/j.bbamem.2011.12.030; Schofield HK, 2018, CELL MOL GASTROENTER, V5, P169, DOI 10.1016/j.jcmgh.2017.10.008; Sin WC, 2016, ONCOGENE, V35, P1504, DOI 10.1038/onc.2015.210; Solan JL, 2019, J BIOL CHEM, V294, P11762, DOI 10.1074/jbc.RA119.009162; Solan JL, 2016, SEMIN CELL DEV BIOL, V50, P40, DOI 10.1016/j.semcdb.2015.12.010; Solan JL, 2014, FEBS LETT, V588, P1423, DOI 10.1016/j.febslet.2014.01.049; Solan JL, 2012, J MEMBRANE BIOL, V245, P255, DOI 10.1007/s00232-012-9446-2; Solan JL, 2009, BIOCHEM J, V419, P261, DOI 10.1042/BJ20082319; Song MB, 2009, EXP BIOL MED, V234, P1192, DOI 10.3181/0902-RM-80; TROSKO JE, 1990, PATHOBIOLOGY, V58, P265, DOI 10.1159/000163596; Vickman Renee E, 2020, Oncotarget, V11, P3621, DOI 10.18632/oncotarget.27736; Whittle MC, 2019, GASTROENTEROLOGY, V156, P2085, DOI 10.1053/j.gastro.2018.12.044; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yang WD, 2019, ISCIENCE, V19, P450, DOI 10.1016/j.isci.2019.07.033; Yen TNF, 2002, SURGERY, V131, P129, DOI 10.1067/msy.2002.119192; Zhang XH, 2015, LEUKEMIA LYMPHOMA, V56, P211, DOI 10.3109/10428194.2014.913289; Zhang ZQ, 2016, CELL PHYSIOL BIOCHEM, V39, P423, DOI 10.1159/000445636	59	2	3	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1909	1920		10.1038/s41388-021-01668-x	http://dx.doi.org/10.1038/s41388-021-01668-x		FEB 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33603164	Green Accepted			2022-12-28	WOS:000619433100006
J	Lin, CC; Blessing, AM; Pulliam, TL; Shi, Y; Wilkenfeld, SR; Han, JJ; Murray, MM; Pham, AH; Duong, K; Brun, SN; Shaw, RJ; Ittmann, MM; Frigo, DE				Lin, Chenchu; Blessing, Alicia M.; Pulliam, Thomas L.; Shi, Yan; Wilkenfeld, Sandi R.; Han, Jenny J.; Murray, Mollianne M.; Pham, Alexander H.; Duong, Kevin; Brun, Sonja N.; Shaw, Reuben J.; Ittmann, Michael M.; Frigo, Daniel E.			Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling	ONCOGENE			English	Article							PROTEIN-KINASE KINASE; ANDROGEN RECEPTOR; CELL-GROWTH; TARGETING AUTOPHAGY; SURVIVAL MECHANISM; ULK1; AMPK; PHOSPHORYLATION; DEPRIVATION; AXIS	Previous work has suggested androgen receptor (AR) signaling mediates prostate cancer progression in part through the modulation of autophagy. However, clinical trials testing autophagy inhibition using chloroquine derivatives in men with castration-resistant prostate cancer (CRPC) have yet to yield promising results, potentially due to the side effects of this class of compounds. We hypothesized that identification of the upstream activators of autophagy in prostate cancer could highlight alternative, context-dependent targets for blocking this important cellular process during disease progression. Here, we used molecular, genetic, and pharmacological approaches to elucidate an AR-mediated autophagy cascade involving Ca2+/calmodulin-dependent protein kinase kinase 2 (CAMKK2; a kinase with a restricted expression profile), 5'-AMP-activated protein kinase (AMPK), and Unc-51 like autophagy activating kinase 1 (ULK1), but independent of canonical mechanistic target of rapamycin (mTOR) activity. Increased CAMKK2-AMPK-ULK1 signaling correlated with disease progression in genetic mouse models and patient tumor samples. Importantly, CAMKK2 disruption impaired tumor growth and prolonged survival in multiple CRPC preclinical mouse models. Similarly, an inhibitor of AMPK-ULK1 blocked autophagy, cell growth, and colony formation in prostate cancer cells. Collectively, our findings converge to demonstrate that AR can co-opt the CAMKK2-AMPK-ULK1 signaling cascade to promote prostate cancer by increasing autophagy. Thus, this pathway may represent an alternative autophagic target in CRPC.	[Lin, Chenchu; Pulliam, Thomas L.; Wilkenfeld, Sandi R.; Han, Jenny J.; Murray, Mollianne M.; Frigo, Daniel E.] Univ Texas MD Anderson Canc Ctr, Dept Canc Syst Imaging, Houston, TX 77030 USA; [Lin, Chenchu; Wilkenfeld, Sandi R.; Duong, Kevin] Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA; [Blessing, Alicia M.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Blessing, Alicia M.; Pulliam, Thomas L.; Shi, Yan; Pham, Alexander H.; Frigo, Daniel E.] Univ Houston, Ctr Nucl Receptors & Cell Signaling, Houston, TX 77004 USA; [Blessing, Alicia M.; Pulliam, Thomas L.; Frigo, Daniel E.] Univ Houston, Dept Biol & Biochem, Houston, TX 77004 USA; [Brun, Sonja N.; Shaw, Reuben J.] Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA; [Ittmann, Michael M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX USA; [Ittmann, Michael M.] Dan L Duncan Canc Ctr, Houston, TX USA; [Ittmann, Michael M.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Frigo, Daniel E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Frigo, Daniel E.] Houston Methodist Res Inst, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Houston System; University of Houston; University of Houston System; University of Houston; Salk Institute; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; The Methodist Hospital System; The Methodist Hospital - Houston	Frigo, DE (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Syst Imaging, Houston, TX 77030 USA.; Frigo, DE (corresponding author), Univ Houston, Ctr Nucl Receptors & Cell Signaling, Houston, TX 77004 USA.; Frigo, DE (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77004 USA.; Frigo, DE (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.; Frigo, DE (corresponding author), Houston Methodist Res Inst, Houston, TX 77030 USA.	frigo@mdanderson.org		Wilkenfeld, Sandi/0000-0002-4973-8941; Shi, Yan/0000-0003-4580-7556	National Institutes of Health [NIH R01CA184208]; American Cancer Society [RSG-16-084-01-TBE]; Antje Wuelfrath Gee and Harry Gee, Jr. Family Legacy Scholarship; Robert Hazelwood Graduate Fellowship for Cancer Research; CFP foundation; CCSG; NIH [P30CA016672]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Antje Wuelfrath Gee and Harry Gee, Jr. Family Legacy Scholarship; Robert Hazelwood Graduate Fellowship for Cancer Research; CFP foundation; CCSG; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Drs. Mondira Kundu, Christopher Counter and Nancy Weigel for plasmids and reagents, Kenneth Dunner, Jr. in the High Resolution Electron Microscopy Core Facility at MDACC for help with TEM, and Dr. Jeff Spencer for help with sgRNA design. This work was supported by grants from the National Institutes of Health (NIH R01CA184208 to DEF), American Cancer Society (RSG-16-084-01-TBE to DEF), an Institutional Research Grant (to DEF) and generous philanthropic contributions to The University of Texas MD Anderson Moon Shots Program (to DEF). This work was also supported by an Antje Wuelfrath Gee and Harry Gee, Jr. Family Legacy Scholarship, Robert Hazelwood Graduate Fellowship for Cancer Research (to CL) and MD Anderson Odyssey fellow supported by the CFP foundation (to AMB). Electron microscopy was performed by the CCSG-funded MDACC High Resolution Electron Microscopy Facility while histology was performed with the CCSG-funded MDACC Research Histology Core Laboratory, NIH grant P30CA016672.	Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11; Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Asquith CRM, 2018, MOLECULES, V23, DOI 10.3390/molecules23051221; Bach M, 2011, BIOCHEM J, V440, P283, DOI 10.1042/BJ20101894; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bennett HL, 2013, BJU INT, V111, P672, DOI 10.1111/j.1464-410X.2012.11409.x; Berglund L, 2008, MOL CELL PROTEOMICS, V7, P2019, DOI 10.1074/mcp.R800013-MCP200; Blessing AM, 2017, AUTOPHAGY, V13, P506, DOI 10.1080/15548627.2016.1268300; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chaturvedi AP, 2019, ADV EXP MED BIOL, V1210, P333, DOI 10.1007/978-3-030-32656-2_15; Chhipa RR, 2011, CELL SIGNAL, V23, P1466, DOI 10.1016/j.cellsig.2011.04.008; Comincini Sergio, 2018, J CANC METASTASIS TR, V4; Dadwal UC, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00335; Daskalaki I, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00104; Dite TA, 2018, J BIOL CHEM, V293, P8874, DOI 10.1074/jbc.RA118.003547; Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031; Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Frigo DE, 2011, CANCER RES, V71, P528, DOI 10.1158/0008-5472.CAN-10-2581; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940; Haeussler M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1012-2; Hardie DG, 2011, EMBO J, V30, P634, DOI 10.1038/emboj.2011.12; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Kaini RR, 2012, BIOCHEM BIOPH RES CO, V425, P150, DOI 10.1016/j.bbrc.2012.07.054; Karacosta LG, 2012, J BIOL CHEM, V287, P24832, DOI 10.1074/jbc.M112.370783; Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363; Khan AS, 2017, NAT REV UROL, V14, P164, DOI 10.1038/nrurol.2016.272; Kim J, 2011, CELL CYCLE, V10, P1337, DOI 10.4161/cc.10.9.15291; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kranzbuhler B, 2019, PROSTATE, V79, P206, DOI 10.1002/pros.23725; Kukimoto-Niino M, 2011, J BIOL CHEM, V286, P22570, DOI 10.1074/jbc.M111.251710; Laker RC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00520-9; Lamoureux F, 2013, CLIN CANCER RES, V19, P833, DOI 10.1158/1078-0432.CCR-12-3114; Lee JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015394; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049; Liu B, 2015, UROLOGY, V85, P1424, DOI 10.1016/j.urology.2015.03.006; Loffler AS, 2011, AUTOPHAGY, V7, P696, DOI 10.4161/auto.7.7.15451; Marcelo KL, 2016, TRENDS ENDOCRIN MET, V27, P706, DOI 10.1016/j.tem.2016.06.001; Martin KR, 2018, ISCIENCE, V8, P74, DOI 10.1016/j.isci.2018.09.012; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mathew R, 2011, COLD SH Q B, V76, P389, DOI 10.1101/sqb.2012.76.011015; Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mortezavi A, 2019, WORLD J UROL, V37, P351, DOI 10.1007/s00345-018-2385-5; Munkley J, 2014, ONCOTARGET, V5, P131, DOI 10.18632/oncotarget.1405; Nguyen HG, 2014, ONCOGENE, V33, P4521, DOI 10.1038/onc.2014.25; Niture Suryakant, 2018, Oncotarget, V9, P26884, DOI 10.18632/oncotarget.25529; O'Byrne SN, 2020, MOLECULES, V25, DOI 10.3390/molecules25020325; Penfold L, 2018, CANCER RES, V78, P6747, DOI 10.1158/0008-5472.CAN-18-0585; Petherick KJ, 2015, J BIOL CHEM, V290, P28726, DOI [10.1074/jbc.C114.627778, 10.1074/jbc.A114.627778]; Price DJ, 2018, BIOORG MED CHEM LETT, V28, P1958, DOI 10.1016/j.bmcl.2018.03.034; Profeta GS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52795-1; Racioppi L, 2012, J BIOL CHEM, V287, P31658, DOI 10.1074/jbc.R112.356485; Santanam U, 2016, GENE DEV, V30, P399, DOI 10.1101/gad.274134.115; Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010; Shat JJ, 2020, J CELL PHYSIOL, V235, P2129, DOI 10.1002/jcp.29117; Shi Y, 2013, MOL ENDOCRINOL, V27, P280, DOI 10.1210/me.2012-1260; Solitro AR, 2016, FUTURE MED CHEM, V8, P73, DOI 10.4155/fmc.15.166; Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063; Tan Q, 2016, NEOPLASIA, V18, P347, DOI 10.1016/j.neo.2016.04.003; Tarver T, 2012, J CONS HLTH INTERNET, V16, P366, DOI 10.1080/15398285.2012.701177; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tennakoon JB, 2014, ONCOGENE, V33, P5251, DOI 10.1038/onc.2013.463; Tian WL, 2015, FEBS LETT, V589, P1847, DOI 10.1016/j.febslet.2015.05.020; Verbaanderd C, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.781; Wang L, 2016, EBIOMEDICINE, V7, P50, DOI 10.1016/j.ebiom.2016.03.022; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; White MA, 2018, ENDOCR-RELAT CANCER, V25, P453, DOI 10.1530/ERC-17-0051; Yang Y, 2020, CELL DEATH DIFFER, V27, P858, DOI 10.1038/s41418-019-0480-9; Zachari M, 2017, ESSAYS BIOCHEM, V61, P585, DOI 10.1042/EBC20170021; Zhang HY, 2017, J CLIN PATHOL, V70, P383, DOI 10.1136/jclinpath-2016-203926; Zhang Yun, 2019, Sichuan Da Xue Xue Bao Yi Xue Ban, V50, P323; Zhao F, 2016, ONCOTARGET, V7, P5366, DOI 10.18632/oncotarget.6783	81	13	13	5	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1690	1705		10.1038/s41388-021-01658-z	http://dx.doi.org/10.1038/s41388-021-01658-z		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33531625	Green Accepted, Green Submitted			2022-12-28	WOS:000613991700003
J	Wood, GE; Hockings, H; Hilton, DM; Kermorgant, S				Wood, Georgina E.; Hockings, Helen; Hilton, Danielle M.; Kermorgant, Stephanie			The role of MET in chemotherapy resistance	ONCOGENE			English	Review							HEPATOCYTE GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; TARGETING C-MET; LUNG-CANCER; BREAST-CANCER; SOMATIC MUTATIONS; SCATTER-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CISPLATIN RESISTANCE	Chemotherapy remains the mainstay of treatment in the majority of solid and haematological malignancies. Resistance to cytotoxic chemotherapy is a major clinical problem and substantial research is ongoing into potential methods of overcoming this resistance. One major target, the receptor tyrosine kinase MET, has generated increasing interest with multiple clinical trials in progress. Overexpression of MET is frequently observed in a range of different cancers and is associated with poor prognosis. Studies have shown that MET promotes resistance to targeted therapies, including those targeting EGFR, BRAF and MEK. More recently, several reports suggest that MET also contributes to cytotoxic chemotherapy resistance. Here we review the preclinical evidence of MET's role in chemotherapy resistance, the mechanisms by which this resistance is mediated and the translational relevance of MET inhibitor therapy for patients with chemotherapy resistant disease.	[Wood, Georgina E.; Hockings, Helen; Hilton, Danielle M.; Kermorgant, Stephanie] Queen Mary Univ London, Barts Canc Inst, John Vane Sci Ctr, Charterhouse Sq, London EC1M 6BQ, England	University of London; Queen Mary University London	Wood, GE; Kermorgant, S (corresponding author), Queen Mary Univ London, Barts Canc Inst, John Vane Sci Ctr, Charterhouse Sq, London EC1M 6BQ, England.	georgina.wood3@nhs.net; s.kermorgant@qmul.ac.uk	Kermorgant, Stephanie/AAB-4931-2020	Kermorgant, Stephanie/0000-0001-5921-479X; Wood, Georgina/0000-0003-2610-3545	MRC [G0501003] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abraham J, 2015, LEUKEMIA LYMPHOMA, V56, P26, DOI 10.3109/10428194.2014.907890; Avan A, 2013, CURR PHARM DESIGN, V19, P940, DOI 10.2174/138161213804547312; Barrow-McGee R, 2014, INT J BIOCHEM CELL B, V49, P69, DOI 10.1016/j.biocel.2014.01.009; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Beviglia L, 1999, INT J CANCER, V83, P640, DOI 10.1002/(SICI)1097-0215(19991126)83:5<640::AID-IJC13>3.0.CO;2-D; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Bowers DC, 2000, CANCER RES, V60, P4277; Brandes F, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1064-9; Caenepeel S, 2017, ONCOTARGET, V8, P17795, DOI 10.18632/oncotarget.14855; Canadas I, 2014, CLIN CANCER RES, V20, P938, DOI 10.1158/1078-0432.CCR-13-1330; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Catenacci DVT, 2017, LANCET ONCOL, V18, P1467, DOI 10.1016/S1470-2045(17)30566-1; Cattley Russell C, 2004, Toxicol Pathol, V32 Suppl 1, P116, DOI 10.1080/01926230490426507; Chen JT, 2008, AM J RESP CELL MOL, V38, P559, DOI 10.1165/rcmb.2007-0001OC; Chen QY, 2016, ONCOTARGET, V7, P24510, DOI 10.18632/oncotarget.8229; Choi SW, 2010, SMALL, V6, P1492, DOI 10.1002/smll.201000544; Choueiri TK, 2016, LANCET ONCOL, V17, P917, DOI 10.1016/S1470-2045(16)30107-3; Chu SH, 2010, ONCOL REP, V24, P189, DOI 10.3892/or_00000845; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Copin MC, 2016, LUNG CANCER, V101, P59, DOI 10.1016/j.lungcan.2016.09.009; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Cosse JP, 2008, ANTI-CANCER AGENT ME, V8, P790, DOI 10.2174/187152008785914798; Delitto D, 2014, WORLD J GASTROENTERO, V20, P8458, DOI 10.3748/wjg.v20.i26.8458; delPeso L, 1997, SCIENCE, V278, P687; Desbats MA, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00281; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Duval K, 2017, PHYSIOLOGY, V32, P266, DOI 10.1152/physiol.00036.2016; Elliott BE, 2002, CAN J PHYSIOL PHARM, V80, P91, DOI 10.1139/y02-010; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Finisguerra V, 2015, NATURE, V522, P349, DOI 10.1038/nature14407; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Glodde N, 2017, IMMUNITY, V47, P789, DOI 10.1016/j.immuni.2017.09.012; Hage C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.158; Hara T, 2019, ANN SURG ONCOL, V26, P899, DOI 10.1245/s10434-018-07126-5; Hervieu A, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00086; Huang MG, 2016, J CLIN INVEST, V126, P1801, DOI 10.1172/JCI84876; Huang XX, 2017, AM J TRANSL RES, V9, P1667; Hughes Veronica S, 2019, Oncotarget, V10, P184, DOI 10.18632/oncotarget.26546; Hughes VS, 2018, TRENDS CANCER, V4, P94, DOI 10.1016/j.trecan.2017.11.009; Hung TH, 2015, CANCER GENE THER, V22, P262, DOI 10.1038/cgt.2015.15; Iveson T, 2014, LANCET ONCOL, V15, P1007, DOI 10.1016/S1470-2045(14)70023-3; Jia LZ, 2018, MED SCI MONITOR, V24, P8239, DOI 10.12659/MSM.913514; Jiang WG, 2001, CLIN CANCER RES, V7, P2555; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Jung KA, 2015, MOL PHARMACOL, V87, P465, DOI 10.1124/mol.114.096065; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Kermorgant S, 2008, J CELL BIOL, V182, P855, DOI 10.1083/jcb.200806076; Ko B, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.09; Koch JP, 2020, ONCOGENE, V39, P2845, DOI 10.1038/s41388-020-1193-8; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Lasagna N, 2006, CANCER RES, V66, P2673, DOI 10.1158/0008-5472.CAN-05-2290; Lee CT, 2008, DIS COLON RECTUM, V51, P1268, DOI 10.1007/s10350-008-9297-1; Li CW, 2011, GASTROENTEROLOGY, V141, P2218, DOI 10.1053/j.gastro.2011.08.009; Li EZ, 2016, TUMOR BIOL, V37, P7843, DOI 10.1007/s13277-015-4318-x; Li M, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0420-2; Litman T, 2000, J CELL SCI, V113, P2011; Lu W, 2019, DEV CELL, V49, P361, DOI 10.1016/j.devcel.2019.04.010; Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495; Marchion DC, 2013, ONCOL REP, V29, P2011, DOI 10.3892/or.2013.2329; Martin LP, 2014, GYNECOL ONCOL, V132, P526, DOI 10.1016/j.ygyno.2013.12.018; Matsumoto K, 1993, EXS, V65, P225; Medova Michaela, 2010, Genes Cancer, V1, P1053, DOI 10.1177/1947601910388030; Menard L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4907; Meng QH, 2000, BIOCHEM BIOPH RES CO, V274, P772, DOI 10.1006/bbrc.2000.3199; Moschetta M, 2013, CLIN CANCER RES, V19, P4371, DOI 10.1158/1078-0432.CCR-13-0039; Neklason DW, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-424; Nunes T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124036; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Organ Shawna Leslie, 2011, Ther Adv Med Oncol, V3, pS7, DOI 10.1177/1758834011422556; Ozasa H, 2014, CANCER SCI, V105, P1032, DOI 10.1111/cas.12447; Park WS, 1999, CANCER RES, V59, P307; Petterson SA, 2015, J NEURO-ONCOL, V122, P517, DOI 10.1007/s11060-015-1723-3; Pothula SP, 2017, ONCOTARGET, V8, P76722, DOI 10.18632/oncotarget.20822; Que WZ, 2011, MOL MED REP, V4, P343, DOI 10.3892/mmr.2011.426; Rajadurai CV, 2012, J CELL SCI, V125, P2940, DOI 10.1242/jcs.100834; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Rucki AA, 2017, MOL CANCER THER, V16, P2399, DOI 10.1158/1535-7163.MCT-16-0452; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Siegfried JM, 1998, ANN THORAC SURG, V66, P1915, DOI 10.1016/S0003-4975(98)01165-5; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; Stacy AE, 2013, MOL PHARMACOL, V84, P655, DOI 10.1124/mol.113.088609; Sun S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166058; Tang MKS, 2010, NEOPLASIA, V12, P128, DOI 10.1593/neo.91438; Tang XL, 2017, J PHARMACOL SCI, V135, P1, DOI 10.1016/j.jphs.2017.06.006; Tovar EA, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.03.64; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Vaidyanathan A, 2016, BRIT J CANCER, V115, P431, DOI 10.1038/bjc.2016.203; van Leenders GJLH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026753; Wang J, 2017, CLIN EXP PHARMACOL P, V44, P79, DOI 10.1111/1440-1681.12672; Wang J, 2016, GENES DIS, V3, P3, DOI 10.1016/j.gendis.2016.01.002; Wang KL, 2012, ARCH BIOCHEM BIOPHYS, V526, P38, DOI 10.1016/j.abb.2012.07.003; Watermann I, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0362-5; Wei DY, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160470; Wolf J, 2019, J CLIN ONCOL, V37; Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9; Yashiro M, 2013, BRIT J CANCER, V109, P2619, DOI 10.1038/bjc.2013.638; Yu ZR, 2012, INT J BIOCHEM CELL B, V44, P2144, DOI 10.1016/j.biocel.2012.08.022; Zhang QM, 2020, INT J NANOMED, V15, P2323, DOI 10.2147/IJN.S231214; Zhou H, 2011, J BIOL CHEM, V286, P25687, DOI 10.1074/jbc.M110.212944; Zhou JB, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00343	105	27	27	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					1927	1941		10.1038/s41388-020-01577-5	http://dx.doi.org/10.1038/s41388-020-01577-5		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33526881	Green Published, hybrid			2022-12-28	WOS:000613601600001
J	Zhu, PP; He, F; Hou, YX; Tu, G; Li, Q; Jin, T; Zeng, H; Qin, YL; Wan, XY; Qiao, YN; Qiu, YX; Teng, Y; Liu, MR				Zhu, Pengpeng; He, Fang; Hou, Yixuan; Tu, Gang; Li, Qiao; Jin, Ting; Zeng, Huan; Qin, Yilu; Wan, Xueying; Qiao, Yina; Qiu, Yuxiang; Teng, Yong; Liu, Manran			A novel hypoxic long noncoding RNA KB-1980E6.3 maintains breast cancer stem cell stemness via interacting with IGF2BP1 to facilitate c-Myc mRNA stability	ONCOGENE			English	Article							LNCRNA THOR INCREASES; TUMOR HYPOXIA; PROLIFERATION; METASTASIS; HIF-1-ALPHA; EXPRESSION; BINDING; RECOGNITION; INVASION; FEEDBACK	The hostile hypoxic microenvironment takes primary responsibility for the rapid expansion of breast cancer tumors. However, the underlying mechanism is not fully understood. Here, using RNA sequencing (RNA-seq) analysis, we identified a hypoxia-induced long noncoding RNA (lncRNA) KB-1980E6.3, which is aberrantly upregulated in clinical breast cancer tissues and closely correlated with poor prognosis of breast cancer patients. The enhanced lncRNA KB-1980E6.3 facilitates breast cancer stem cells (BCSCs) self-renewal and tumorigenesis under hypoxic microenvironment both in vitro and in vivo. Mechanistically, lncRNA KB-1980E6.3 recruited insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) to form a lncRNA KB-1980E6.3/IGF2BP1/c-Myc signaling axis that retained the stability of c-Myc mRNA through increasing binding of IGF2BP1 with m6A-modified c-Myc coding region instability determinant (CRD) mRNA. In conclusion, we confirm that lncRNA KB-1980E6.3 maintains the stemness of BCSCs through lncRNA KB-1980E6.3/IGF2BP1/c-Myc axis and suggest that disrupting this axis might provide a new therapeutic target for refractory hypoxic tumors.	[Zhu, Pengpeng; Li, Qiao; Jin, Ting; Zeng, Huan; Qin, Yilu; Wan, Xueying; Qiao, Yina; Qiu, Yuxiang; Liu, Manran] Chongqing Med Univ, Key Lab Lab Med Diagnost, Chinese Minist Educ, Chongqing 400016, Peoples R China; [He, Fang] Chongqing Med Univ, Affiliated Hosp 1, Dept Pharm, Chongqing 400016, Peoples R China; [Hou, Yixuan] Chongqing Med Univ, Expt Teaching Ctr Basic Med Sci, Chongqing 400016, Peoples R China; [Tu, Gang] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing 400016, Peoples R China; [Teng, Yong] Dent Coll Georgia, Dept Oral Biol & Dx Sci, Augusta, GA 30907 USA; [Teng, Yong] Augusta Univ, Georgia Canc Ctr, Augusta, GA 30907 USA	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University; Chongqing Medical University; University System of Georgia; Augusta University	Liu, MR (corresponding author), Chongqing Med Univ, Key Lab Lab Med Diagnost, Chinese Minist Educ, Chongqing 400016, Peoples R China.	manranliu@cqmu.edu.cn	Teng, Yong/AAK-4160-2020	Teng, Yong/0000-0002-1856-7289	National Natural Science Foundation of China (NSFC) [81874199, 31671481, 81472476]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported in part by National Natural Science Foundation of China (NSFC 81874199, NSFC 31671481, and NSFC 81472476). We would like to thank Reid Loveless for his help in English language editing.	Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Bhandari V, 2019, NAT GENET, V51, P308, DOI 10.1038/s41588-018-0318-2; Bueno MJ, 2011, BLOOD, V117, P6255, DOI 10.1182/blood-2010-10-315432; Chen X, 2018, CLIN CANCER RES, V24, P2002, DOI 10.1158/1078-0432.CCR-17-2376; Chen Y, 2018, J CLIN INVEST, V128, P1937, DOI 10.1172/JCI95089; Cho SW, 2018, CELL, V173, P1398, DOI 10.1016/j.cell.2018.03.068; Choudhry H, 2016, MOL ASPECTS MED, V47-48, P35, DOI 10.1016/j.mam.2016.01.003; De Los Angeles A, 2015, NATURE, V525, P469, DOI 10.1038/nature15515; Deng SJ, 2018, ONCOGENE, V37, P5811, DOI 10.1038/s41388-018-0382-1; Han DL, 2019, NATURE, V566, P270, DOI 10.1038/s41586-019-0916-x; Hua Q, 2020, THERANOSTICS, V10, P4762, DOI 10.7150/thno.43839; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Huang JG, 2016, NUCLEIC ACIDS RES, V44, P3059, DOI 10.1093/nar/gkv1353; Huang XW, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0628-y; Huttelmaier S, 2005, NATURE, V438, P512, DOI 10.1038/nature04115; Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9; Jung HM, 2013, MOL BIOL CELL, V24, P1638, DOI 10.1091/mbc.E12-12-0891; Kalimutho M, 2019, TRENDS PHARMACOL SCI, V40, P198, DOI 10.1016/j.tips.2019.01.005; Kang CL, 2019, THERANOSTICS, V9, P4421, DOI 10.7150/thno.32854; Kapinova A, 2018, BIOMED PHARMACOTHER, V99, P51, DOI 10.1016/j.biopha.2017.12.104; Kuo TC, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00654-x; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Lan J, 2018, P NATL ACAD SCI USA, V115, pE9640, DOI 10.1073/pnas.1809695115; Lee H, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0226-3; Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776; Li HZ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0738-0; Lin F, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-58; Liu DL, 2016, TUMOR BIOL, V37, P5039, DOI 10.1007/s13277-015-4355-5; Liu L, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00420; Liu ML, 2019, THERANOSTICS, V9, P4795, DOI 10.7150/thno.30988; Liu N, 2015, NATURE, V518, P560, DOI 10.1038/nature14234; Liu YB, 2017, BIOMED PHARMACOTHER, V91, P731, DOI 10.1016/j.biopha.2017.05.007; Luo LY, 2018, ONCOGENE, V37, P6166, DOI 10.1038/s41388-018-0396-8; Luo ML, 2020, JNCI-J NATL CANCER I, V112, P356, DOI 10.1093/jnci/djz134; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; Muller S, 2019, NUCLEIC ACIDS RES, V47, P375, DOI 10.1093/nar/gky1012; Niu YL, 2020, CANCER RES, V80, P964, DOI 10.1158/0008-5472.CAN-19-1532; Peng WX, 2020, MOL THER, V28, P9, DOI 10.1016/j.ymthe.2019.09.024; Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4; Prensner JR, 2014, NEOPLASIA, V16, P900, DOI 10.1016/j.neo.2014.09.001; Shang YM, 2018, BIOMED PHARMACOTHER, V106, P1243, DOI 10.1016/j.biopha.2018.07.052; Shih JW, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0358-4; Shih JW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15874; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song H, 2018, BIOMED PHARMACOTHER, V108, P338, DOI 10.1016/j.biopha.2018.09.057; Tong J, 2020, HAEMATOLOGICA, V105, P1630, DOI 10.3324/haematol.2019.218289; Wang C, 2019, ONCOGENE, V38, P1611, DOI 10.1038/s41388-018-0548-x; Wang YF, 2014, NEOPLASIA, V16, P1094, DOI 10.1016/j.neo.2014.10.008; Wang YR, 2020, J EXP MED, V217, DOI 10.1084/jem.20190950; Weidensdorfer D, 2009, RNA, V15, P104, DOI 10.1261/rna.1175909; Wen X, 2018, THERANOSTICS, V8, P5676, DOI 10.7150/thno.28538; Wu HJ, 2019, FEBS OPEN BIO, V9, P781, DOI 10.1002/2211-5463.12620; Wu JY, 2019, J HEPATOL, V70, P918, DOI 10.1016/j.jhep.2018.12.015; Xiao ZD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00902-z; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yang F, 2014, FEBS J, V281, P802, DOI 10.1111/febs.12625; Yang HJ, 2019, BIOCHIMIE, V165, P9, DOI 10.1016/j.biochi.2019.06.012; Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0954-x; Yang XC, 2018, BIOCHEM BIOPH RES CO, V498, P207, DOI 10.1016/j.bbrc.2018.02.211; Yang ZC, 2018, EXP CELL RES, V368, P194, DOI 10.1016/j.yexcr.2018.04.030; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-00321-0, 10.1038/s41467-017-01968-5]; Zhang XZ, 2020, CANCERS, V12, DOI 10.3390/cancers12051245; Zheng ZQ, 2019, CANCER RES, V79, P4612, DOI 10.1158/0008-5472.CAN-19-0799; Zhou ML, 2016, STEM CELLS, V34, P55, DOI 10.1002/stem.2219; Zou ZG, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0758-8	68	66	67	6	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1609	1627		10.1038/s41388-020-01638-9	http://dx.doi.org/10.1038/s41388-020-01638-9		JAN 2021	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33469161	hybrid, Green Published			2022-12-28	WOS:000608959500001
J	Kuo, TC; Wu, MH; Yang, SH; Chen, ST; Hsu, TW; Jhuang, JY; Liao, YY; Tien, YW; Huang, MC				Kuo, Ting-Chun; Wu, Ming-Hsun; Yang, Shih-Hung; Chen, Syue-Ting; Hsu, Tzu-Wen; Jhuang, Jie-Yang; Liao, Ying-Yu; Tien, Yu-Wen; Huang, Min-Chuan			C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin alpha(v)	ONCOGENE			English	Article							CANCER-CELLS; GLYCOSYLATION; ADHESION; FAK	Pancreatic adenocarcinoma (PDAC) is a leading cause of cancer-related death. Altered glycosylation contributes to tumor progression and chemoresistance in many cancers. C1GALT1 is the key enzyme controlling the elongation of GalNAc-type O-glycosylation. Here we showed that C1GALT1 was overexpressed in 85% (107/126) of PDAC tumors compared with adjacent non-tumor tissues. High expression of C1GALT1 was associated with poor disease-free and overall survival (n = 99). C1GALT1 knockdown using siRNA suppressed cell viability, migration, and invasion as well as increased gemcitabine sensitivity in PDAC cells. In contrast, C1GALT1 overexpression enhanced cell migration and invasion. In subcutaneous and pancreatic orthotopic injection models, C1GALT1 knockdown decreased tumor growth and metastasis of PDAC cells in NOD/SCID mice. Mechanistically, C1GALT1 knockdown dramatically suppressed cell-extracellular matrix (ECM) adhesion, which was associated with decreased phosphorylation of FAK at Y397/Y925 and changes in O-glycans on integrins including the beta(1), alpha(v), and alpha(5) subunits. Using functional blocking antibodies, we identified integrin alpha(v) as a critical factor in C1GALT1-mediated invasiveness of PDAC cells. In conclusion, this study not only reveals that C1GALT1 could be a potential therapeutic target for PDAC but also provides novel insights into the role of O-glycosylation in the alpha subunits of integrins.	[Kuo, Ting-Chun; Chen, Syue-Ting; Hsu, Tzu-Wen; Liao, Ying-Yu; Huang, Min-Chuan] Natl Taiwan Univ, Grad Inst Anat & Cell Biol, Coll Med, Taipei, Taiwan; [Kuo, Ting-Chun; Wu, Ming-Hsun; Tien, Yu-Wen] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Kuo, Ting-Chun] Natl Taiwan Univ Hosp, Dept Traumatol, Taipei, Taiwan; [Yang, Shih-Hung] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan; [Jhuang, Jie-Yang] Mackay Mem Hosp, Dept Pathol, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Mackay Memorial Hospital	Huang, MC (corresponding author), Natl Taiwan Univ, Grad Inst Anat & Cell Biol, Coll Med, Taipei, Taiwan.; Tien, YW (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan.	ywtien5106@ntu.edu.tw; mchuang@ntu.edu.tw	wu, larry/AAV-5282-2021	wu, larry/0000-0002-8811-9203; KUO, TING-CHUN/0000-0003-1960-1423; TIEN, YU-WEN/0000-0002-9126-2705; HUANG, MIN-CHUAN/0000-0002-0704-3447	National Taiwan University Hospital [105-N3200, 106-N3608, 107-N3965, 109-O02]; Ministry of Science and Technology, Taiwan [107-2314-B-002-233-MY3, 108-2320-B-002 -064 -MY3, 106-2321-B-002-034]	National Taiwan University Hospital(National Taiwan University); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by National Taiwan University Hospital (105-N3200, 106-N3608, 107-N3965, and 109-O02 to Dr TCK) and Ministry of Science and Technology, Taiwan (107-2314-B-002-233-MY3 to Dr TCK, 108-2320-B-002 -064 -MY3 to Dr MCH, and 106-2321-B-002-034 to Dr YWT). In addition, we are grateful to Dr WH Lee (Genomics Research Center, Academia Sinica, Taiwan) for providing human PDAC and HPaSteC cell lines. We thank Dr Kelvin K. Tsai (National Health Research Institutes, Taiwan) for providing human HPDE cells. And we thank Dr CL Hsu and Dr YT Huang (Department of Medical Research, National Taiwan University Hospital, Taiwan) as well as Ms Chun-Chi Chen (Graduate Institute of Anatomy and Cell Biology, National Taiwan University, Taiwan) for their technical support during the study.	Adorno-Cruz V, 2019, GENES DIS, V6, P16, DOI 10.1016/j.gendis.2018.12.003; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Chen CH, 2016, GYNECOL ONCOL, V140, P131, DOI 10.1016/j.ygyno.2015.11.025; Chen ST, 2018, ONCOGENE, V37, P6041, DOI 10.1038/s41388-018-0403-0; Chia J, 2016, BBA-GEN SUBJECTS, V1860, P1623, DOI 10.1016/j.bbagen.2016.03.008; Chou CH, 2017, INT J GYNECOL CANCER, V27, P863, DOI 10.1097/IGC.0000000000000965; Chou CH, 2015, ONCOTARGET, V6, P6123, DOI 10.18632/oncotarget.3045; Chugh S, 2018, GASTROENTEROLOGY, V155, P1608, DOI 10.1053/j.gastro.2018.08.007; El-Brolosy MA, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006780; Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Guan JL, 2010, IUBMB LIFE, V62, P268, DOI 10.1002/iub.303; Hakamada K, 2019, ANN GASTROENT SURG, V3, P120, DOI 10.1002/ags3.12244; Hamidi H, 2018, NAT REV CANCER, V18, P532, DOI 10.1038/s41568-018-0038-z; Hatley RJD, 2018, ANGEW CHEM INT EDIT, V57, P3298, DOI 10.1002/anie.201707948; Hung JS, 2014, ONCOTARGET, V5, P2096, DOI 10.18632/oncotarget.1815; Kang R, 2011, AUTOPHAGY, V7, P442, DOI 10.4161/auto.7.4.14681; Klein AP, 2004, CANCER RES, V64, P2634, DOI 10.1158/0008-5472.CAN-03-3823; Lee PC, 2020, ONCOGENE, V39, P2724, DOI 10.1038/s41388-020-1178-7; Lin MC, 2018, ONCOGENE, V37, P5780, DOI 10.1038/s41388-018-0375-0; Liu C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092743; Magalhaes A, 2017, CANCER CELL, V31, P733, DOI 10.1016/j.ccell.2017.05.012; Mitra SK, 2006, ONCOGENE, V25, P5969, DOI 10.1038/sj.onc.1209588; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Saitoh M, 2018, J BIOCHEM, V164, P257, DOI 10.1093/jb/mvy047; Tsai CH, 2016, CANCER RES, V76, P5756, DOI 10.1158/0008-5472.CAN-16-0641; Weis SM, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006478; Wu YM, 2013, CANCER RES, V73, P5580, DOI 10.1158/0008-5472.CAN-13-0869; Zhang CY, 2018, J CANCER, V9, P2666, DOI 10.7150/jca.25252	29	12	12	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1242	1254		10.1038/s41388-020-01594-4	http://dx.doi.org/10.1038/s41388-020-01594-4		JAN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420364	Green Published, hybrid			2022-12-28	WOS:000607346000012
J	Pantano, F; Croset, M; Driouch, K; Bednarz-Knoll, N; Iuliani, M; Ribelli, G; Bonnelye, E; Wikman, H; Geraci, S; Bonin, F; Simonetti, S; Vincenzi, B; Hong, SS; Sousa, S; Pantel, K; Tonini, G; Santini, D; Clezardin, P				Pantano, Francesco; Croset, Martine; Driouch, Keltouma; Bednarz-Knoll, Natalia; Iuliani, Michele; Ribelli, Giulia; Bonnelye, Edith; Wikman, Harriet; Geraci, Sandra; Bonin, Florian; Simonetti, Sonia; Vincenzi, Bruno; Hong, Saw See; Sousa, Sofia; Pantel, Klaus; Tonini, Giuseppe; Santini, Daniele; Clezardin, Philippe			Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions	ONCOGENE			English	Article							CELL-MIGRATION; OSTEOBLAST DIFFERENTIATION; TUMOR-CELLS; EXPRESSION; LUNG; VOLOCIXIMAB; SURVIVAL; GROWTH; COLONIZATION; INHIBITION	Bone metastasis remains a major cause of mortality and morbidity in breast cancer. Therefore, there is an urgent need to better select high-risk patients in order to adapt patient's treatment and prevent bone recurrence. Here, we found that integrin alpha5 (ITGA5) was highly expressed in bone metastases, compared to lung, liver, or brain metastases. High ITGA5 expression in primary tumors correlated with the presence of disseminated tumor cells in bone marrow aspirates from early stage breast cancer patients (n = 268; p = 0.039). ITGA5 was also predictive of poor bone metastasis-free survival in two separate clinical data sets (n = 855, HR = 1.36, p = 0.018 and n = 427, HR = 1.62, p = 0.024). This prognostic value remained significant in multivariate analysis (p = 0.028). Experimentally, ITGA5 silencing impaired tumor cell adhesion to fibronectin, migration, and survival. ITGA5 silencing also reduced tumor cell colonization of the bone marrow and formation of osteolytic lesions in vivo. Conversely, ITGA5 overexpression promoted bone metastasis. Pharmacological inhibition of ITGA5 with humanized monoclonal antibody M200 (volociximab) recapitulated inhibitory effects of ITGA5 silencing on tumor cell functions in vitro and tumor cell colonization of the bone marrow in vivo. M200 also markedly reduced tumor outgrowth in experimental models of bone metastasis or tumorigenesis, and blunted cancer-associated bone destruction. ITGA5 was not only expressed by tumor cells but also osteoclasts. In this respect, M200 decreased human osteoclast-mediated bone resorption in vitro. Overall, this study identifies ITGA5 as a mediator of breast-to-bone metastasis and raises the possibility that volociximab/M200 could be repurposed for the treatment of ITGA5-positive breast cancer patients with bone metastases.	[Pantano, Francesco; Croset, Martine; Bonnelye, Edith; Geraci, Sandra; Sousa, Sofia; Clezardin, Philippe] INSERM, UMR S1033, LYOS, Lyon, France; [Pantano, Francesco; Croset, Martine; Bonnelye, Edith; Geraci, Sandra; Hong, Saw See; Sousa, Sofia; Clezardin, Philippe] Univ Lyon, Villeurbanne, France; [Pantano, Francesco; Iuliani, Michele; Ribelli, Giulia; Simonetti, Sonia; Vincenzi, Bruno; Tonini, Giuseppe; Santini, Daniele] Campus Biomed Univ Rome, Dept Med Oncol, Rome, Italy; [Driouch, Keltouma; Bonin, Florian] Inst Curie, Serv Genet, Unite Pharmacogen, Paris, France; [Bednarz-Knoll, Natalia; Wikman, Harriet; Pantel, Klaus] Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, Hamburg, Germany; [Bednarz-Knoll, Natalia] Med Univ Gdansk, Lab Translat Oncol, Gdansk, Poland; [Hong, Saw See] INRA, UMR 754, Lyon, France; [Clezardin, Philippe] Univ Sheffield, Oncol & Metab Dept, Sheffield, S Yorkshire, England	Institut National de la Sante et de la Recherche Medicale (Inserm); University Campus Bio-Medico - Rome Italy; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Hamburg; University Medical Center Hamburg-Eppendorf; Fahrenheit Universities; Medical University Gdansk; INRAE; University of Sheffield	Clezardin, P (corresponding author), INSERM, UMR S1033, LYOS, Lyon, France.; Clezardin, P (corresponding author), Univ Lyon, Villeurbanne, France.; Clezardin, P (corresponding author), Univ Sheffield, Oncol & Metab Dept, Sheffield, S Yorkshire, England.	philippe.clezardin@inserm.fr	Bonnelye, Edith/AAT-9134-2021; Pantano, Francesco/D-8459-2012; Clezardin, Philippe/M-8071-2014	Pantano, Francesco/0000-0002-2894-9686; Clezardin, Philippe/0000-0003-0149-4463; Wikman, Harriet/0000-0001-6862-0888; Bednarz-Knoll, Natalia/0000-0001-9506-942X	"Ligue contre le cancer" cd69, 2016; Breast Cancer Research Foundation (BCRF, USA) [BCRF-16-096]; Deutsche Forschungsgemeinschaft, SPP microBONE; INSERM, University Claude Bernard Lyon 1; "Project LIA/LEA 2016" of the University of Lyon, within the program "Investissements d'Avenir" [ASC17018CSA, ANR-11-IDEX-0007]; LabEX DEVweCAN of the University of Lyon, within the program "Investissements d'Avenir" [ANR-11-IDEX-0007, ANR-10-LABX-61]; Inca [Transla09-112]	"Ligue contre le cancer" cd69, 2016; Breast Cancer Research Foundation (BCRF, USA); Deutsche Forschungsgemeinschaft, SPP microBONE(German Research Foundation (DFG)); INSERM, University Claude Bernard Lyon 1; "Project LIA/LEA 2016" of the University of Lyon, within the program "Investissements d'Avenir"(French National Research Agency (ANR)); LabEX DEVweCAN of the University of Lyon, within the program "Investissements d'Avenir"(French National Research Agency (ANR)); Inca(Institut National du Cancer (INCA) France)	MC acknowledges the support of "Ligue contre le cancer" cd69, 2016. KD acknowledges the support of Inca (Grant No. Transla09-112). FB is supported by the Breast Cancer Research Foundation (BCRF, USA) (BCRF-16-096, 2016-2017). KP is supported by the Deutsche Forschungsgemeinschaft, SPP microBONE. PC is supported by INSERM, University Claude Bernard Lyon 1, the "Project LIA/LEA 2016" (Grant No.: ASC17018CSA), and the LabEX DEVweCAN (ANR-10-LABX-61) of the University of Lyon, within the program "Investissements d'Avenir" (ANR-11-IDEX-0007) operated by the French National Research Agency (ANR).	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Almokadem S, 2012, EXPERT OPIN BIOL TH, V12, P251, DOI 10.1517/14712598.2012.646985; Anderson JA, 2007, BRIT J CANCER, V96, P1394, DOI 10.1038/sj.bjc.6603720; Bartkowiak K, 2015, CANCER RES, V75, P5367, DOI 10.1158/0008-5472.CAN-14-3728; Bednarz-Knoll N, 2015, ONCOTARGET, V6, P26789, DOI 10.18632/oncotarget.4628; Bell-McGuinn KM, 2011, GYNECOL ONCOL, V121, P273, DOI 10.1016/j.ygyno.2010.12.362; Besse B, 2013, ANN ONCOL, V24, P90, DOI 10.1093/annonc/mds281; Bieche I, 2001, CANCER RES, V61, P1652; Bonnelye E, 2001, J CELL BIOL, V153, P971, DOI 10.1083/jcb.153.5.971; Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801; Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918; Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-00216-3; Croset M, 2018, CANCER RES, V78, P5259, DOI 10.1158/0008-5472.CAN-17-3058; Croset M, 2014, J BONE MINER RES, V29, P1886, DOI 10.1002/jbmr.2215; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Duffy MJ, 2008, CLIN CHEM, V54, P1770, DOI 10.1373/clinchem.2008.110056; Fan LC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162933; Fehm T, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1869; FIDLER IJ, 1973, EUR J CANCER, V9, P223, DOI 10.1016/S0014-2964(73)80022-2; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Hamidi H, 2018, NAT REV CANCER, V18, P532, DOI 10.1038/s41568-018-0038-z; Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106; Harrell JC, 2012, BREAST CANCER RES TR, V132, P523, DOI 10.1007/s10549-011-1619-7; Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785; HUGHES DE, 1993, J BONE MINER RES, V8, P527; Imanishi Y, 2007, CANCER RES, V67, P4254, DOI 10.1158/0008-5472.CAN-06-4100; Iuliani M, 2015, ONCOTARGET, V6, P12520, DOI 10.18632/oncotarget.3724; Jami MS, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-194; Ju JLA, 2017, MOL CANCER RES, V15, P723, DOI 10.1158/1541-7786.MCR-16-0338; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Khalili P, 2006, MOL CANCER THER, V5, P2271, DOI 10.1158/1535-7163.MCT-06-0100; Korah R, 2004, CANCER RES, V64, P4514, DOI 10.1158/0008-5472.CAN-03-3853; Landemaine T, 2008, CANCER RES, V68, P6092, DOI 10.1158/0008-5472.CAN-08-0436; Lehtinen L, 2012, J PATHOL, V226, P674, DOI 10.1002/path.3956; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Oudin MJ, 2016, CANCER DISCOV, V6, P516, DOI 10.1158/2159-8290.CD-15-1183; Pantel K, 1994, J Hematother, V3, P165, DOI 10.1089/scd.1.1994.3.165; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027; Pignatelli J, 2012, J CELL BIOL, V197, P421, DOI 10.1083/jcb.201108143; Qin L, 2011, CANCER RES, V71, P1742, DOI 10.1158/0008-5472.CAN-10-3453; Reynaud C, 2017, CANCER RES, V77, P268, DOI 10.1158/0008-5472.CAN-15-2621; Ricart AD, 2008, CLIN CANCER RES, V14, P7924, DOI 10.1158/1078-0432.CCR-08-0378; Schnitt SJ, 2010, MODERN PATHOL, V23, pS60, DOI 10.1038/modpathol.2010.33; Simon KO, 1997, J BIOL CHEM, V272, P29380, DOI 10.1074/jbc.272.46.29380; Sin S, 2011, J NATL CANCER I, V103, P1323, DOI 10.1093/jnci/djr290; Truong HH, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004751; VanderVeldeZimmermann D, 1997, EXP CELL RES, V230, P111, DOI 10.1006/excr.1996.3405; Wiedswang G, 2003, CYTOTHERAPY, V5, P40, DOI 10.1080/14653240310000065; Wu ZG, 2018, BIOCHEM BIOPH RES CO, V498, P495, DOI 10.1016/j.bbrc.2018.03.007; Yao HR, 2016, BREAST CANCER RES TR, V157, P489, DOI 10.1007/s10549-016-3844-6; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhang ZZ, 2015, AM J CANCER RES, V5, P772; Zhao YS, 2007, CANCER RES, V67, P5821, DOI 10.1158/0008-5472.CAN-06-4499; Zuo T, 2018, TRANSL ONCOL, V11, P346, DOI 10.1016/j.tranon.2018.01.021	55	25	25	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1284	1299		10.1038/s41388-020-01603-6	http://dx.doi.org/10.1038/s41388-020-01603-6		JAN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420367	hybrid, Green Published, Green Submitted, Green Accepted			2022-12-28	WOS:000607346000004
J	Vareslija, D; Ward, E; Purcell, SP; Cosgrove, NS; Cocchiglia, S; O'Halloran, PJ; Charmsaz, S; Bane, FT; Brett, FM; Farrell, M; Cryan, J; Beausang, A; Hudson, L; Turnbul, AK; Dixon, JM; Hill, ADK; Priedigkeit, N; Oesterreich, S; Lee, AV; Sims, AH; Redmond, AM; Carroll, JS; Young, LS				Vareslija, Damir; Ward, Elspeth; Purcell, Siobhan P.; Cosgrove, Nicola S.; Cocchiglia, Sinead; O'Halloran, Philip J.; Charmsaz, Sara; Bane, Fiona T.; Brett, Francesca M.; Farrell, Michael; Cryan, Jane; Beausang, Alan; Hudson, Lance; Turnbul, Arran K.; Dixon, J. Michael; Hill, Arnold D. K.; Priedigkeit, Nolan; Oesterreich, Steffi; Lee, Adrian V.; Sims, Andrew H.; Redmond, Aisling M.; Carroll, Jason S.; Young, Leonie S.			Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype	ONCOGENE			English	Article							STEROID-RECEPTOR; PROTEIN COMPLEX; ALPHA; COACTIVATORS; RESISTANCE; EXPRESSION; TRANSCRIPTION; MECHANISMS; MUTATIONS; THERAPY	Steroid regulated cancer cells use nuclear receptors and associated regulatory proteins to orchestrate transcriptional networks to drive disease progression. In primary breast cancer, the coactivator AIB1 promotes estrogen receptor (ER) transcriptional activity to enhance cell proliferation. The function of the coactivator in ER+ metastasis however is not established. Here we describe AIB1 as a survival factor, regulator of pro-metastatic transcriptional pathways and a promising actionable target. Genomic alterations and functional expression of AIB1 associated with reduced disease-free survival in patients and enhanced metastatic capacity in novel CDX and PDX ex-vivo models of ER+ metastatic disease. Comparative analysis of the AIB1 interactome with complementary RNAseq characterized AIB1 as a transcriptional repressor. Specifically, we report that AIB1 interacts with MTA2 to form a repressive complex, inhibiting CDH1 (encoding E-cadherin) to promote EMT and drive progression. We further report that pharmacological and genetic inhibition of AIB1 demonstrates significant anti-proliferative activity in patient-derived models establishing AIB1 as a viable strategy to target endocrine resistant metastasis. This work defines a novel role for AIB1 in the regulation of EMT through transcriptional repression in advanced cancer cells with a considerable implication for prognosis and therapeutic interventions.	[Vareslija, Damir; Ward, Elspeth; Purcell, Siobhan P.; Cosgrove, Nicola S.; Cocchiglia, Sinead; Charmsaz, Sara; Bane, Fiona T.; Hudson, Lance; Hill, Arnold D. K.; Young, Leonie S.] Royal Coll Surgeons Ireland, Dept Surg, Endocrine Oncol Res Grp, Dublin, Ireland; [O'Halloran, Philip J.] Beaumont Hosp, Dept Neurosurg, Natl Neurosurg Ctr, Dublin, Ireland; [Brett, Francesca M.; Farrell, Michael; Cryan, Jane; Beausang, Alan] Beaumont Hosp, Dept Neuropathol, Natl Neurosurg Ctr, Dublin, Ireland; [Turnbul, Arran K.; Dixon, J. Michael] Breast Canc Now Res Labs, Edinburgh EH4 2XU, Midlothian, Scotland; [Priedigkeit, Nolan; Oesterreich, Steffi; Lee, Adrian V.] Univ Pittsburgh, Univ Pittsburgh Canc Inst, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Oesterreich, Steffi; Lee, Adrian V.] Univ Pittsburgh, Univ Pittsburgh Canc Inst, Magee Womens Res Inst, Dept Womens Canc Res Ctr, Pittsburgh, PA USA; [Lee, Adrian V.] Univ Pittsburgh, Dept Human Genet, Univ Pittsburgh Canc Inst, Pittsburgh, PA USA; [Sims, Andrew H.] Univ Edinburgh, MRC Inst Genet & Mol Med, Western Gen Hosp, Appl Bioinformat Canc Grp,Canc Res UK Ctr, Edinburgh, Midlothian, Scotland; [Redmond, Aisling M.; Carroll, Jason S.] Univ Cambridge, Canc Res UK Cambridge Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England	Royal College of Surgeons - Ireland; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Edinburgh; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Vareslija, D; Young, LS (corresponding author), Royal Coll Surgeons Ireland, Dept Surg, Endocrine Oncol Res Grp, Dublin, Ireland.	damirvareslija@rcsi.ie; lyoung@rcsi.ie		Ward, Elspeth/0000-0002-7530-2279; O'Halloran, Philip J/0000-0001-9175-8682; Carroll, Jason/0000-0003-3643-0080; Vareslija, Damir/0000-0003-1000-0357; Brett, Francesca/0000-0002-7453-4027; Cosgrove, Nicola/0000-0002-8296-115X	Breast Cancer Ireland [GR 14-0883]; Irish Cancer Society Collaborative Cancer Research Centre grant [CCRC13GAL]; Breast Cancer NOW grant [2018JulPR1094, 2019AugSF1310]; Irish Cancer Society Research Fellowship [STB19VAR]; Walk the Walk	Breast Cancer Ireland; Irish Cancer Society Collaborative Cancer Research Centre grant; Breast Cancer NOW grant; Irish Cancer Society Research Fellowship; Walk the Walk	We would like to acknowledge Robert Bagnall for his technical assistance in performing protein characterization experiments in this manuscript. We would like to acknowledge Aisling Hegarty for her tissue bank and database curation. We are thankful to the patients who generously provided tumor tissue for our studies and to the surgical, pathology and tissue bank colleagues for their substantial assistance and support. We kindly acknowledge the funding support from Breast Cancer Ireland (GR 14-0883)(LY),the Irish Cancer Society Collaborative Cancer Research Centre grant, (CCRC13GAL)(LY) and Breast Cancer NOW grant, 2018JulPR1094 (LY, DV). This work is supported by Irish Cancer Society Research Fellowship STB19VAR (DV). This work is supported by funding from Breast Cancer Now Grant, 2019AugSF1310 with the generous support of Walk the Walk (DV).	Alkner S, 2017, BREAST CANCER RES TR, V166, P481, DOI 10.1007/s10549-017-4416-0; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Arnedos M, 2014, ANN ONCOL, V25, P605, DOI 10.1093/annonc/mdt575; Browne AL, 2018, ONCOGENE, V37, P2008, DOI 10.1038/s41388-017-0042-x; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Covington KR, 2013, BREAST CANCER RES TR, V141, P375, DOI 10.1007/s10549-013-2709-5; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Foulds CE, 2013, MOL CELL, V51, P185, DOI 10.1016/j.molcel.2013.06.007; Fu JJ, 2012, INT J BIOL SCI, V8, P522, DOI 10.7150/ijbs.4164; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Gao ZG, 2005, J BIOL CHEM, V280, P21091, DOI 10.1074/jbc.M500754200; Garee JP, 2014, MOL ENDOCRINOL, V28, P846, DOI 10.1210/me.2013-1379; Gates LA, 2018, ONCOGENE, V37, P4581, DOI 10.1038/s41388-018-0284-2; Giltnane JM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7993; Groner AC, 2017, J CLIN INVEST, V127, P1126, DOI 10.1172/JCI88885; Guo S, 2014, INT J CLIN ONCOL, V19, P319, DOI 10.1007/s10147-013-0549-2; Hanker AB, 2020, CANCER CELL, V37, P496, DOI 10.1016/j.ccell.2020.03.009; Jansen MPHM, 2013, CANCER RES, V73, P6632, DOI 10.1158/0008-5472.CAN-13-0704; Jeselsohn R, 2018, CANCER CELL, V33, P173, DOI 10.1016/j.ccell.2018.01.004; Jeselsohn R, 2014, CLIN CANCER RES, V20, P1757, DOI 10.1158/1078-0432.CCR-13-2332; Karmakar S, 2010, MOL ENDOCRINOL, V24, P1187, DOI 10.1210/me.2009-0480; Lefebvre C, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002201; Ma CX, 2015, NAT REV CANCER, V15, P261, DOI 10.1038/nrc3920; McBryan J, 2015, CLIN CANCER RES, V21, P5371, DOI 10.1158/1078-0432.CCR-14-2155; Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Naeem H, 2007, MOL CELL BIOL, V27, P120, DOI 10.1128/MCB.00815-06; Nguyen VTM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10044; O'Hara J, 2012, CLIN CANCER RES, V18, P3305, DOI 10.1158/1078-0432.CCR-11-3300; Oesterreich S, 2003, CANCER RES, V63, P5203; Padmanaban V, 2019, NATURE, V573, P439, DOI 10.1038/s41586-019-1526-3; Priedigkeit N, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95703; Priedigkeit N, 2017, JAMA ONCOL, V3, P666, DOI 10.1001/jamaoncol.2016.5630; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; Rohira AD, 2017, CANCER RES, V77, P4293, DOI 10.1158/0008-5472.CAN-16-2982; Shafi AA, 2018, EUR UROL ONCOL, V1, P325, DOI 10.1016/j.euo.2018.04.019; Siegel MB, 2018, J CLIN INVEST, V128, P1371, DOI 10.1172/JCI96153; Torres-Arzayus MI, 2010, CANCER RES, V70, P4102, DOI 10.1158/0008-5472.CAN-09-4080; Uhlenhaut NH, 2013, MOL CELL, V49, P158, DOI 10.1016/j.molcel.2012.10.013; Vareslija D, 2019, JNCI-J NATL CANCER I, V111, P388, DOI 10.1093/jnci/djy110; Vareslija D, 2017, METHODS MOL BIOL, V1501, P327, DOI 10.1007/978-1-4939-6475-8_17; Vareslija D, 2016, CLIN CANCER RES, V22, P2765, DOI 10.1158/1078-0432.CCR-15-1583; Walsh CA, 2014, CANCER RES, V74, P2533, DOI 10.1158/0008-5472.CAN-13-2133; Wang L, 2016, HORM CANCER-US, V7, P229, DOI 10.1007/s12672-016-0261-6; Wang L, 2015, CANCER CELL, V28, P240, DOI 10.1016/j.ccell.2015.07.005; Ward E, 2018, CLIN CANCER RES, V24, P3692, DOI 10.1158/1078-0432.CCR-17-2615; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Yan J, 2008, CANCER RES, V68, P5460, DOI 10.1158/0008-5472.CAN-08-0955; Yi P, 2017, MOL CELL, V67, P733, DOI 10.1016/j.molcel.2017.07.026; Zwart W, 2016, CLIN CANCER RES, V22, P479, DOI 10.1158/1078-0432.CCR-14-3277	50	5	6	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1318	1331		10.1038/s41388-020-01606-3	http://dx.doi.org/10.1038/s41388-020-01606-3		JAN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420368	Green Published, hybrid			2022-12-28	WOS:000607346000008
J	Kong, DG; Zhou, HB; Neelakantan, D; Hughes, CJ; Hsu, JY; Srinivasan, RR; Lewis, MT; Ford, HL				Kong, Deguang; Zhou, Hengbo; Neelakantan, Deepika; Hughes, Connor J.; Hsu, Jessica Y.; Srinivasan, Ramakrishnan Rajaram; Lewis, Michael T.; Ford, Heide L.			VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; INTRATUMOR HETEROGENEITY; HEDGEHOG PATHWAY; STEM-CELLS; LYMPHANGIOGENESIS; AXIS; RECEPTOR; CONTRIBUTES; INHIBITION; EXPRESSION	It is well established that a subset of cells within primary breast cancers can undergo an epithelial-to-mesenchymal transition (EMT), although the role of EMT in metastasis remains controversial. We previously demonstrated that breast cancer cells that had undergone an oncogenic EMT could increase metastasis of neighboring cancer cells via non-canonical paracrine-mediated activation of GLI activity that is dependent on SIX1 expression in the EMT cancer cells. However, the mechanism by which these SIX1-expressing EMT cells activate GLI signaling remained unclear. In this study, we demonstrate a novel mechanism for activation of GLI-mediated signaling in epithelial breast tumor cells via EMT cell-induced production and secretion of VEGF-C. We show that VEGF-C, secreted by breast cancer cells that have undergone an EMT, promotes paracrine-mediated increases in proliferation, migration, and invasion of epithelial breast cancer cells, via non-canonical activation of GLI-signaling. We further show that the aggressive phenotypes, including metastasis, imparted by EMT cells on adjacent epithelial cancer cells can be disrupted by either inhibiting VEGF-C in EMT cells or by knocking down NRP2, a receptor which interacts with VEGF-C, in neighboring epithelial cancer cells. Interrogation of TCGA and GEO public datasets supports the relevance of this pathway in human breast cancer, demonstrating that VEGF-C strongly correlates with activation of Hedgehog signaling and EMT in the human disease. Our study suggests that the VEGF-C/NRP2/GLI axis is a novel and conserved paracrine means by which EMT cells enhance metastasis, and provides potential targets for therapeutic intervention in this heterogeneous disease.	[Kong, Deguang; Zhou, Hengbo; Neelakantan, Deepika; Hughes, Connor J.; Hsu, Jessica Y.; Ford, Heide L.] Univ Colorado, Dept Pharmacol, Anschutz Med Campus, Aurora, CO 80045 USA; [Kong, Deguang] Wuhan Univ, Zhongnan Hosp, Dept Gen Surg, Wuhan, Hubei, Peoples R China; [Zhou, Hengbo; Ford, Heide L.] Univ Colorado, Program Canc Biol, Anschutz Med Campus, Aurora, CO 80045 USA; [Neelakantan, Deepika; Ford, Heide L.] Univ Colorado, Program Mol Biol, Anschutz Med Campus, Aurora, CO 80045 USA; [Hughes, Connor J.; Hsu, Jessica Y.; Ford, Heide L.] Univ Colorado, Program Pharmacol, Anschutz Med Campus, Aurora, CO 80045 USA; [Hughes, Connor J.; Ford, Heide L.] Univ Colorado, Med Scientist Training Program, Anschutz Med Campus, Aurora, CO 80045 USA; [Srinivasan, Ramakrishnan Rajaram; Lewis, Michael T.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Wuhan University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Baylor College of Medicine	Ford, HL (corresponding author), Univ Colorado, Dept Pharmacol, Anschutz Med Campus, Aurora, CO 80045 USA.; Ford, HL (corresponding author), Univ Colorado, Program Canc Biol, Anschutz Med Campus, Aurora, CO 80045 USA.; Ford, HL (corresponding author), Univ Colorado, Program Mol Biol, Anschutz Med Campus, Aurora, CO 80045 USA.; Ford, HL (corresponding author), Univ Colorado, Program Pharmacol, Anschutz Med Campus, Aurora, CO 80045 USA.; Ford, HL (corresponding author), Univ Colorado, Med Scientist Training Program, Anschutz Med Campus, Aurora, CO 80045 USA.	Heide.Ford@cuanschutz.edu		Hughes, Connor/0000-0001-6295-8167; Zhou, Hengbo/0000-0002-9948-7909; Ford, Heide/0000-0002-2860-9841	Animal Imaging SR of the University of Colorado Cancer Center [P30CA046934]; Dan L. Duncan Comprehensive Cancer Center (BCM) [P30CA125123]; Cancer Prevention and Research Initiative of Texas (CPRIT) (BCM) [RP170691];  [R01CA224867];  [F99CA234940]	Animal Imaging SR of the University of Colorado Cancer Center; Dan L. Duncan Comprehensive Cancer Center (BCM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Initiative of Texas (CPRIT) (BCM); ; 	This work was supported by R01CA224867 to HLF and MTL, and F99CA234940 to HZ. We would like to thank the Functional Genomics Shared Resource (SR), the Cell Technologies SR, and the Animal Imaging SR of the University of Colorado Cancer Center (P30CA046934) for help with these studies. We would also like to acknowledge support from The Dan L. Duncan Comprehensive Cancer Center (BCM, P30CA125123) and the Cancer Prevention and Research Initiative of Texas (CPRIT) (BCM, RP170691).	Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Aparicio S, 2013, NEW ENGL J MED, V368, P842, DOI 10.1056/NEJMra1204892; Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021; Blevins MA, 2015, EXPERT OPIN THER TAR, V19, P213, DOI 10.1517/14728222.2014.978860; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Calbo J, 2011, CANCER CELL, V19, P244, DOI 10.1016/j.ccr.2010.12.021; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Chen JC, 2013, INT J MOL SCI, V14, P88, DOI 10.3390/ijms14010088; Dias S, 2002, BLOOD, V99, P2179, DOI 10.1182/blood.V99.6.2179; Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Jimeno A, 2013, CLIN CANCER RES, V19, P2766, DOI 10.1158/1078-0432.CCR-12-3654; Joukov V, 1996, EMBO J, V15, P290; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kampen KR, 2018, CANCER RES, V78, P5940, DOI 10.1158/0008-5472.CAN-18-0250; Kong DG, 2016, ONCOTARGET, V7, P50755, DOI 10.18632/oncotarget.9394; Lin JM, 2005, CANCER RES, V65, P6901, DOI 10.1158/0008-5472.CAN-05-0408; Lin L, 2019, CANCERS, V11, DOI 10.3390/cancers11081156; Lindstrom LS, 2018, JNCI-J NATL CANCER I, V110, P726, DOI 10.1093/jnci/djx270; Liu D, 2014, CANCER RES, V74, P5597, DOI 10.1158/0008-5472.CAN-13-3598; Liu Q, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0339-1; Lund AW, 2012, CELL REP, V1, P191, DOI 10.1016/j.celrep.2012.01.005; Ma F, 2020, INT J CANCER, V146, P1359, DOI 10.1002/ijc.32536; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Micalizzi DS, 2010, CANCER RES, V70, P10371, DOI 10.1158/0008-5472.CAN-10-1354; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Neelakantan D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15773; Pietrobono S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00556; Pinskey JM, 2017, J BIOL CHEM, V292, P15192, DOI 10.1074/jbc.M117.783845; Po A, 2017, ONCOGENE, V36, P4641, DOI 10.1038/onc.2017.91; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Su JL, 2007, BRIT J CANCER, V96, P541, DOI 10.1038/sj.bjc.6603487; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Towers CG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10077; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Wang CA, 2015, EXP BIOL MED, V240, P718, DOI 10.1177/1535370215583802; Wang CA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0462-2; Wang CA, 2012, J CLIN INVEST, V122, P1895, DOI 10.1172/JCI59858; Wang JW, 2018, CANCER LETT, V418, P176, DOI 10.1016/j.canlet.2018.01.040; Wei T, 2017, R PACKAGE CORRPLOT V; Xu YL, 2010, J CELL BIOL, V188, P115, DOI 10.1083/jcb.200903137; Yang F, 2017, CARCINOGENESIS, V38, P900, DOI 10.1093/carcin/bgx071; Yang F, 2016, INT J BIOL SCI, V12, P1568, DOI 10.7150/ijbs.16874; Yeh YW, 2017, ONCOTARGET, V8, P5603, DOI 10.18632/oncotarget.13629; Zhang DP, 2010, CANCER RES, V70, P2495, DOI 10.1158/0008-5472.CAN-09-3488; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	54	24	27	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					964	979		10.1038/s41388-020-01539-x	http://dx.doi.org/10.1038/s41388-020-01539-x		DEC 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33299122	Green Accepted			2022-12-28	WOS:000599028900001
J	Girondel, C; Levesque, K; Langlois, MJ; Pasquin, S; Saba-El-Leil, MK; Rivard, N; Friesel, R; Servant, MJ; Gauchat, JF; Lesage, S; Meloche, S				Girondel, Charlotte; Levesque, Kim; Langlois, Marie-Josee; Pasquin, Sarah; Saba-El-Leil, Marc K.; Rivard, Nathalie; Friesel, Robert; Servant, Marc J.; Gauchat, Jean-Francois; Lesage, Sylvie; Meloche, Sylvain			Loss of interleukin-17 receptor D promotes chronic inflammation-associated tumorigenesis	ONCOGENE			English	Article							SIMILAR EXPRESSION; COLORECTAL-CANCER; DOWN-REGULATION; IL-17 RECEPTOR; SEF; CELLS; CARCINOGENESIS; INHIBITOR; CYTOKINES; INTERACTS	Interleukin-17 receptor D (IL-17RD), also known as similar expression to Fgf genes (SEF), is proposed to act as a signaling hub that negatively regulates mitogenic signaling pathways, like the ERK1/2 MAP kinase pathway, and innate immune signaling. The expression of IL-17RD is downregulated in certain solid tumors, which has led to the hypothesis that it may exert tumor suppressor functions. However, the role of IL-17RD in tumor biology remains to be studied in vivo. Here, we show that genetic disruption of Il17rd leads to the increased formation of spontaneous tumors in multiple tissues of aging mice. Loss of IL-17RD also promotes tumor development in a model of colitis-associated colorectal cancer, associated with an exacerbated inflammatory response. Colon tumors from IL-17RD-deficient mice are characterized by a strong enrichment in inflammation-related gene signatures, elevated expression of pro-inflammatory tumorigenic cytokines, such as IL-17A and IL-6, and increased STAT3 tyrosine phosphorylation. We further show that RNAi depletion of IL-17RD enhances Toll-like receptor and IL-17A signaling in colon adenocarcinoma cells. No change in the proliferation of normal or tumor intestinal epithelial cells was observed upon genetic inactivation of IL-17RD. Our findings establish IL-17RD as a tumor suppressor in mice and suggest that the protein exerts its function mainly by limiting the extent and duration of inflammation.	[Girondel, Charlotte; Levesque, Kim; Saba-El-Leil, Marc K.; Meloche, Sylvain] Inst Res Immunol & Canc, Montreal, PQ, Canada; [Girondel, Charlotte; Pasquin, Sarah; Gauchat, Jean-Francois; Meloche, Sylvain] Univ Montreal, Dept Pharmacol & Physiol, Fac Med, Montreal, PQ, Canada; [Langlois, Marie-Josee; Rivard, Nathalie] Univ Sherbrooke, Dept Immunol & Cell Biol, Fac Med & Hlth Sci, Sherbrooke, PQ, Canada; [Friesel, Robert] Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME USA; [Servant, Marc J.] Univ Montreal, Fac Pharm, Montreal, PQ, Canada; [Lesage, Sylvie] Maisonneuve Rosemont Hosp, Dept Immunol Oncol, Montreal, PQ, Canada; [Lesage, Sylvie] Univ Montreal, Fac Med, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada; [Meloche, Sylvain] Univ Montreal, Mol Biol Program, Fac Med, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; University of Sherbrooke; Maine Medical Center; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Meloche, S (corresponding author), Inst Res Immunol & Canc, Montreal, PQ, Canada.; Meloche, S (corresponding author), Univ Montreal, Dept Pharmacol & Physiol, Fac Med, Montreal, PQ, Canada.; Meloche, S (corresponding author), Univ Montreal, Mol Biol Program, Fac Med, Montreal, PQ, Canada.	sylvain.meloche@umontreal.ca		Servant, Marc/0000-0003-2014-4127; Lesage, Sylvie/0000-0002-0968-2795	Fonds de recherche Sante Quebec; Cancer Research Society	Fonds de recherche Sante Quebec; Cancer Research Society	We thank C. Kuo and G.R. van den Brink for reagents, J. Hinsinger for histology, L. Gaboury for pathology assistance, P. Melancon for qPCR analysis, J. Huber for RNA-seq, and P. Gendron for help with bioinformatic analyses. CG is recipient of a studentship from the Fonds de recherche Sante Quebec. SM held the Canada Research Chair in Cellular Signaling. Work in the Meloche laboratory was supported by a grant from the Cancer Research Society.	Beringer A, 2016, TRENDS MOL MED, V22, P230, DOI 10.1016/j.molmed.2016.01.001; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; Darby S, 2006, ONCOGENE, V25, P4122, DOI 10.1038/sj.onc.1209428; Darby S, 2009, BRIT J CANCER, V101, P1891, DOI 10.1038/sj.bjc.6605379; Duhamel S, 2012, CANCER RES, V72, P626, DOI 10.1158/0008-5472.CAN-11-2126; Fichtner-Feigl S, 2015, TRENDS IMMUNOL, V36, P451, DOI 10.1016/j.it.2015.06.007; Fuchs Y, 2012, DEV CELL, V23, P611, DOI 10.1016/j.devcel.2012.07.013; Furman D, 2019, NAT MED, V25, P1822, DOI 10.1038/s41591-019-0675-0; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Gonneaud A, 2016, SCI REP-UK, V6, DOI 10.1038/srep38195; He Q, 2016, J CELL BIOCHEM, V117, P2346, DOI 10.1002/jcb.25532; He Q, 2014, J BONE MINER RES, V29, P1217, DOI 10.1002/jbmr.2114; Hurtado CG, 2018, GASTROENTEROLOGY, V155, P1706, DOI 10.1053/j.gastro.2018.08.056; Kovalenko D, 2003, J BIOL CHEM, V278, P14087, DOI 10.1074/jbc.C200606200; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Mellett M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7669; Mellett M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2127; Monin L, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028522; Murphy T, 2010, J PATHOL, V220, P452, DOI 10.1002/path.2657; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Parang B, 2016, METHODS MOL BIOL, V1422, P297, DOI 10.1007/978-1-4939-3603-8_26; Pekow J, 2017, CLIN CANCER RES, V23, P5281, DOI 10.1158/1078-0432.CCR-17-0171; Peng DH, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaq1238; Razi S, 2019, CYTOKINE, V116, P7, DOI 10.1016/j.cyto.2018.12.021; Ren YM, 2008, CELL SIGNAL, V20, P518, DOI 10.1016/j.cellsig.2007.11.010; Ren YM, 2006, BIOCHEM BIOPH RES CO, V347, P988, DOI 10.1016/j.bbrc.2006.06.193; Ron D, 2008, INT J BIOCHEM CELL B, V40, P2040, DOI 10.1016/j.biocel.2008.03.013; Rong ZL, 2009, CELL RES, V19, P208, DOI 10.1038/cr.2008.320; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Soulez M, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00527-18; Stidham RW, 2018, CLIN COLON RECT SURG, V31, P168, DOI 10.1055/s-0037-1602237; Su Y, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau9657; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Wang KP, 2014, IMMUNITY, V41, P1052, DOI 10.1016/j.immuni.2014.11.009; West NR, 2015, NAT REV IMMUNOL, V15, P615, DOI 10.1038/nri3896; Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015; Zisman-Rozen S, 2007, ONCOGENE, V26, P6093, DOI 10.1038/sj.onc.1210424	43	15	15	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					452	464		10.1038/s41388-020-01540-4	http://dx.doi.org/10.1038/s41388-020-01540-4		NOV 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33177649				2022-12-28	WOS:000588591500001
J	Angel, I; Kerman, OP; Rousso-Noori, L; Friedmann-Morvinski, D				Angel, Inbar; Pilo Kerman, Ori; Rousso-Noori, Liat; Friedmann-Morvinski, Dinorah			Tenascin C promotes cancer cell plasticity in mesenchymal glioblastoma	ONCOGENE			English	Article							NF-KAPPA-B; STEM-CELLS; GLIOMA; ACTIVATION; DIFFERENTIATION; TRANSFORMATION; ANGIOGENESIS; INHIBITION; PROGNOSIS; RAS	Interconversion of transformed non-stem cells to cancer stem cells, termed cancer cell plasticity, contributes to intra-tumor heterogeneity and its molecular mechanisms are currently unknown. Here, we have identified Tenascin C (TNC) to be upregulated and secreted in mesenchymal glioblastoma (MES GBM) subtype with high NF-kappa B signaling activity. Silencing TNC decreases proliferation, migration and suppresses self-renewal of glioma stem cells. Loss of TNC in MES GBM compromises de-differentiation of transformed astrocytes and blocks the ability of glioma stem cells to differentiate into tumor derived endothelial cells (TDEC). Inhibition of NF-kappa B activity or TNC knockdown in tumor cells decreased their tumorigenic potential in vivo. Our results uncover a link between NF-kappa B activation in MES GBM and high levels of TNC in GBM extracellular matrix. We suggest that TNC plays an important role in the autocrine regulation of glioma cell plasticity and hence can be a potential molecular target for MES GBM.	[Angel, Inbar; Pilo Kerman, Ori; Rousso-Noori, Liat; Friedmann-Morvinski, Dinorah] Tel Aviv Univ, Sch Neurobiol Biochem & Biophys, George S Wise Fac Life Sci, Tel Aviv, Israel; [Friedmann-Morvinski, Dinorah] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel	Tel Aviv University; Tel Aviv University	Friedmann-Morvinski, D (corresponding author), Tel Aviv Univ, Sch Neurobiol Biochem & Biophys, George S Wise Fac Life Sci, Tel Aviv, Israel.; Friedmann-Morvinski, D (corresponding author), Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel.	dino@tauex.tau.ac.il		Friedmann-Morvinski, Dinorah/0000-0002-6394-9876; Rousso Noori, Liat/0000-0001-7582-3165	Israel Science Foundation [1310/15]; Israel Cancer Research Fund (Research Career Development Award); EU-FP7 Marie Curie Actions (Career Integration Grant)	Israel Science Foundation(Israel Science Foundation); Israel Cancer Research Fund (Research Career Development Award); EU-FP7 Marie Curie Actions (Career Integration Grant)	We thank Yifeng Xia and Eugene Ke for assistance in bioinformatic analysis, and Prof. Michal Baniyash for critically reading the manuscript. This research was supported by grants to DF-M from the Israel Science Foundation (Grant no. 1310/15), the Israel Cancer Research Fund (Research Career Development Award), and the EU-FP7 Marie Curie Actions (Career Integration Grant).	Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bottero V, 2006, CELL DEATH DIFFER, V13, P785, DOI 10.1038/sj.cdd.4401888; Bowman RL, 2017, NEURO-ONCOLOGY, V19, P139, DOI 10.1093/neuonc/now247; Brosicke N, 2015, CELL ADHES MIGR, V9, P131, DOI 10.1080/19336918.2014.1000071; Cabrera MC, 2015, WORLD J STEM CELLS, V7, P27, DOI 10.4252/wjsc.v7.i1.27; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chiquet-Ehrismann R, 2014, MATRIX BIOL, V37, P112, DOI 10.1016/j.matbio.2014.01.007; Dufraine J, 2008, ONCOGENE, V27, P5132, DOI 10.1038/onc.2008.227; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Friedmann-Morvinski D, 2016, ONCOGENE, V35, P608, DOI 10.1038/onc.2015.119; Friedmann-Morvinski D, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501292; Friedmann-Morvinski Dinorah, 2014, Critical Reviews in Oncogenesis, V19, P327; Friedmann-Morvinski D, 2014, EMBO REP, V15, P244, DOI 10.1002/embr.201338254; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Garcion E, 2004, DEVELOPMENT, V131, P3423, DOI 10.1242/dev.01202; Gridley T, 2007, DEVELOPMENT, V134, P2709, DOI 10.1242/dev.004184; Hovinga KE, 2010, STEM CELLS, V28, P1019, DOI 10.1002/stem.429; Huse JT, 2011, GLIA, V59, P1190, DOI 10.1002/glia.21165; Ischenko I, 2013, P NATL ACAD SCI USA, V110, P3937, DOI 10.1073/pnas.1219592110; Langlois B, 2014, ONCOTARGET, V5, P10529, DOI 10.18632/oncotarget.2470; Lowy CM, 2015, CELL ADHES MIGR, V9, P112, DOI 10.1080/19336918.2015.1008331; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martiny-Baron G, 2010, ANGIOGENESIS, V13, P259, DOI 10.1007/s10456-010-9183-z; Marumoto T, 2009, NAT MED, V15, P110, DOI 10.1038/nm.1863; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; Midwood KS, 2016, J CELL SCI, V129, P4321, DOI 10.1242/jcs.190546; Midwood KS, 2011, CELL MOL LIFE SCI, V68, P3175, DOI 10.1007/s00018-011-0783-6; Miroshnikova YA, 2016, NAT CELL BIOL, V18, P1336, DOI 10.1038/ncb3429; Nie S, 2015, J PROTEOME RES, V14, P814, DOI 10.1021/pr5008653; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Poltavets V, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00431; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Rupp T, 2016, CELL REP, V17, P2607, DOI 10.1016/j.celrep.2016.11.012; Saito N, 2014, STEM CELLS, V32, P301, DOI 10.1002/stem.1528; Sarkar S, 2017, CANCER RES, V77, P3231, DOI 10.1158/0008-5472.CAN-16-2171; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Soda Y, 2011, P NATL ACAD SCI USA, V108, P4274, DOI 10.1073/pnas.1016030108; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Xia SL, 2016, NEURO-ONCOLOGY, V18, P507, DOI 10.1093/neuonc/nov171; Yamini B, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7090125; Yoshida T, 2015, CELL ADHES MIGR, V9, P96, DOI 10.1080/19336918.2015.1008332; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	51	17	18	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2020	39	46					6990	7004		10.1038/s41388-020-01506-6	http://dx.doi.org/10.1038/s41388-020-01506-6		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OQ9FF	33077835				2022-12-28	WOS:000579741400001
J	Chen, L; Jin, XH; Luo, J; Duan, JL; Cai, MY; Chen, JW; Feng, ZH; Guo, AM; Wang, FW; Xie, D				Chen, Li; Jin, Xiao-Han; Luo, Jie; Duan, Jin-Ling; Cai, Mu-Yan; Chen, Jie-Wei; Feng, Zi-Hao; Guo, Austin Meng; Wang, Feng-Wei; Xie, Dan			ITLN1 inhibits tumor neovascularization and myeloid derived suppressor cells accumulation in colorectal carcinoma	ONCOGENE			English	Article							ANGIOGENIC SWITCH; PROGENITOR CELLS; HUMAN INTELECTIN; PROMOTES; METASTASIS; VASCULOGENESIS; IDENTIFICATION; RECRUITMENT; EXPRESSION; GROWTH	Low levels of ITLN1 have been correlated with obesity-related colorectal carcinogenesis, however, the specific functions and underlying mechanisms remain unclear. Thus, we sought to explore the inhibitory role of ITLN1 in the tumor-permissive microenvironment that exists during the first occurrence and subsequent development of colorectal carcinoma (CRC). Results indicated that ITLN1 was frequently lost in CRC tissues and ITLN1 to be an independent prognostic predictor of CRC. Orthotopic and subcutaneous tumor xenograft approaches were then used to further confirm the protective role of ITLN1 during tumor progression. Increased ITLN1 expression in CRC cells significantly inhibited local pre-existing vessels sprouting, EPC recruitment and the infiltration of immunosuppressive myeloid-derived suppressor cells (MDSCs) into tumor tissues without affecting the behavior of CRC cells in vitro. Comparatively, ITLN1-derived MDSCs had a lower suppressive effect on T cell proliferation, NOS2 expression, and ROS production. In addition, ITLN1 overexpression markedly suppressed bone marrow (BM)-derived hematopoietic progenitor cells (HPC) differentiation into MDSCs as well as NOS2 activity on MDSCs. Using H-2b+YFP + chimerism through bone marrow transplantation, increased ITLN1 in HCT116 significantly reduced the BM-derived EPCs and MDSCs in vivo mobilization. Mechanistically, results indicated ITLN1 inhibited tumor-derived IL-17D and CXCL2 (MIP2) through the KEAP1/Nrf2/ROS/IL-17D and p65 NF-kappa B/CXCL2 signaling cascades dependent on PI3K/AKT/GSK3ss. This effect was reversed by the PI3K selective inhibitor LY294002. Collectively, ITLN1 synergistically suppressed IL-17D and CXCL2-mediated tumor vascularization, bone marrow derived EPC recruitment, as well as MDSCs generation and trafficking. Thus, ITLN1 potentially serves as a critical prognostic and therapeutic target for CRC.	[Chen, Li; Jin, Xiao-Han; Luo, Jie; Duan, Jin-Ling; Wang, Feng-Wei; Xie, Dan] Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Chen, Li; Jin, Xiao-Han; Luo, Jie; Duan, Jin-Ling; Wang, Feng-Wei; Xie, Dan] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China; [Chen, Li] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Guangzhou Inst Pediat, Guangzhou, Guangdong, Peoples R China; [Cai, Mu-Yan; Chen, Jie-Wei; Xie, Dan] Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou, Peoples R China; [Feng, Zi-Hao] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Peoples R China; [Guo, Austin Meng] New York Med Coll, Dept Pharmacol, New York, NY USA	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University; Sun Yat Sen University; Sun Yat Sen University; New York Medical College	Xie, D (corresponding author), Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China.; Xie, D (corresponding author), Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China.; Xie, D (corresponding author), Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou, Peoples R China.	xiedan@sysucc.org.cn		jie, luo/0000-0002-0791-1419	National Key R&D Program of China [2017YFC1309000, 2016YFC1302305]; National Natural Science Foundation of China [81430055, 81572359, 81602063, 81730072, 81772595, 8197227]; National Natural Science Foundation for Youth [81502259]; Natural Science Foundation of Guangdong [S1014030001589]; 61th China Postdoctoral Science foundation [2017M612816]; Guangzhou Science and Technology Plan Projects [201803040019, 201904020044]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation for Youth; Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); 61th China Postdoctoral Science foundation(China Postdoctoral Science Foundation); Guangzhou Science and Technology Plan Projects	This work was supported by grants from the National Key R&D Program of China (No. 2017YFC1309000 and No. 2016YFC1302305); the National Natural Science Foundation of China (No.81430055, 81572359, 81602063, 81730072, 81772595, 8197227); the National Natural Science Foundation for Youth (No.81502259); the Natural Science Foundation of Guangdong (No. S1014030001589); the 61th China Postdoctoral Science foundation (2017M612816) and the Guangzhou Science and Technology Plan Projects (No. 201803040019, 201904020044).	Achyut BR, 2015, CANCER LETT, V369, P416, DOI 10.1016/j.canlet.2015.09.004; Aleksandrova K, 2016, CANCER RES, V76, P3862, DOI 10.1158/0008-5472.CAN-15-3464; Alissa EM, 2016, J CLIN TRANSL ENDOCR, V3, P7, DOI 10.1016/j.jcte.2015.12.001; Au-Yeung CL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17383-2; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Cai MY, 2011, GUT, V60, P967, DOI 10.1136/gut.2010.231993; Caiado F, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-4; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388; Chung AS, 2013, NAT MED, V19, P1114, DOI 10.1038/nm.3291; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gao DC, 2008, SCIENCE, V319, P195, DOI 10.1126/science.1150224; Gonzalez-Donquiles C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177549; Hanrahan V, 2003, J PATHOL, V200, P183, DOI 10.1002/path.1339; Hempen PM, 2003, CANCER RES, V63, P994; Huang YJ, 2018, BIOCHEM CELL BIOL, V96, P475, DOI 10.1139/bcb-2017-0291; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113; Kaplan RN, 2007, TRENDS MOL MED, V13, P72, DOI 10.1016/j.molmed.2006.12.003; Katoh H, 2013, CANCER CELL, V24, P631, DOI 10.1016/j.ccr.2013.10.009; Kim HJ, 2012, J PROTEOMICS, V75, P2983, DOI 10.1016/j.jprot.2011.12.002; Kim TH, 2011, CANCER RES, V71, P2260, DOI 10.1158/0008-5472.CAN-10-3007; Komiya T, 1998, BIOCHEM BIOPH RES CO, V251, P759, DOI 10.1006/bbrc.1998.9513; Lee JK, 2001, GLYCOBIOLOGY, V11, P65, DOI 10.1093/glycob/11.1.65; Li CQ, 2009, P NATL ACAD SCI USA, V106, P14547, DOI 10.1073/pnas.0907539106; Li D, 2015, ONCOTARGET, V6, P16168, DOI 10.18632/oncotarget.3753; Li D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0320-6; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Maeda K, 2016, J CANCER, V7, P207, DOI 10.7150/jca.13732; Mancinelli R, 2018, BIOMETALS, V31, P369, DOI 10.1007/s10534-018-0094-6; Mody K, 2018, CANCER J, V24, P165, DOI 10.1097/PPO.0000000000000328; Moldogazieva NT, 2018, CANCER RES, V78, P6040, DOI 10.1158/0008-5472.CAN-18-0980; Morandi F, 2014, J IMMUNOL, V192, P2634, DOI 10.4049/jimmunol.1302656; Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Patan S, 2004, CANC TREAT, V117, P3; Paul J, 2017, CANCER CELL, V31, P64, DOI 10.1016/j.ccell.2016.12.003; Saddawi-Konefka R, 2016, CELL REP, V16, P2348, DOI 10.1016/j.celrep.2016.07.075; Schmidt A, 2007, CIRC RES, V101, P125, DOI 10.1161/CIRCRESAHA.107.148932; Shin K, 2008, BIOL PHARM BULL, V31, P1605, DOI 10.1248/bpb.31.1605; Starnes T, 2002, J IMMUNOL, V169, P642, DOI 10.4049/jimmunol.169.2.642; Suzuki YA, 2005, CELL MOL LIFE SCI, V62, P2560, DOI 10.1007/s00018-005-5371-1; Taki M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03966-7; Tanigawa N, 1996, CANCER RES, V56, P2671; Tanigawa N, 1997, CANCER RES, V57, P1043; Tepper OM, 2005, BLOOD, V105, P1068, DOI 10.1182/blood-2004-03-1051; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Tsuji S, 2001, J BIOL CHEM, V276, P23456, DOI 10.1074/jbc.M103162200; Wali A, 2005, LUNG CANCER, V48, P19, DOI 10.1016/j.lungcan.2004.10.011; Wang DZ, 2017, CANCER RES, V77, P3655, DOI 10.1158/0008-5472.CAN-16-3199; Washimi K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039889; Xie D, 2003, INT J CANCER, V107, P896, DOI 10.1002/ijc.11514; Xu HW, 2017, CARCINOGENESIS, V38, P281, DOI 10.1093/carcin/bgw121; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yang RZ, 2006, AM J PHYSIOL-ENDOC M, V290, pE1253, DOI 10.1152/ajpendo.00572.2004; Zhang C, 2014, CARCINOGENESIS, V35, P2771, DOI 10.1093/carcin/bgu192; Zhang H, 2017, ONCOGENE, V36, P2095, DOI 10.1038/onc.2016.367; Zhang YY, 2013, EUR J PHARMACOL, V698, P137, DOI 10.1016/j.ejphar.2012.11.016	63	4	4	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5925	5937		10.1038/s41388-021-01965-5	http://dx.doi.org/10.1038/s41388-021-01965-5		AUG 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34363021				2022-12-28	WOS:000682519100004
J	Park, SH; Fong, KW; Mong, E; Martin, MC; Schiltz, GE; Yu, JD				Park, Su H.; Fong, Ka-Wing; Mong, Ezinne; Martin, M. Cynthia; Schiltz, Gary E.; Yu, Jindan			Going beyond Polycomb: EZH2 functions in prostate cancer	ONCOGENE			English	Review							HISTONE METHYLTRANSFERASE ACTIVITY; GROUP PROTEIN EZH2; ZESTE HOMOLOG 2; GENE-EXPRESSION; PRC2 RECRUITMENT; SUPPRESSES METHYLATION; CONTEMPORARY INCIDENCE; REPRESSIVE COMPLEX-2; NUCLEOSOME-BINDING; LYSINE METHYLATION	The Polycomb group (PcG) protein Enhancer of Zeste Homolog 2 (EZH2) is one of the three core subunits of the Polycomb Repressive Complex 2 (PRC2). It harbors histone methyltransferase activity (MTase) that specifically catalyze histone 3 lysine 27 (H3K27) methylation on target gene promoters. As such, PRC2 are epigenetic silencers that play important roles in cellular identity and embryonic stem cell maintenance. In the past two decades, mounting evidence supports EZH2 mutations and/or over-expression in a wide array of hematological cancers and solid tumors, including prostate cancer. Further, EZH2 is among the most upregulated genes in neuroendocrine prostate cancers, which become abundant due to the clinical use of high-affinity androgen receptor pathway inhibitors. While numerous studies have reported epigenetic functions of EZH2 that inhibit tumor suppressor genes and promote tumorigenesis, discordance between EZH2 and H3K27 methylation has been reported. Further, enzymatic EZH2 inhibitors have shown limited efficacy in prostate cancer, warranting a more comprehensive understanding of EZH2 functions. Here we first review how canonical functions of EZH2 as a histone MTase are regulated and describe the various mechanisms of PRC2 recruitment to the chromatin. We further outline non-histone substrates of EZH2 and discuss post-translational modifications to EZH2 itself that may affect substrate preference. Lastly, we summarize non-canonical functions of EZH2, beyond its MTase activity and/or PRC2, as a transcriptional cofactor and discuss prospects of its therapeutic targeting in prostate cancer.	[Park, Su H.; Fong, Ka-Wing; Mong, Ezinne; Yu, Jindan] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Fong, Ka-Wing] Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY USA; [Martin, M. Cynthia; Schiltz, Gary E.] Northwestern Univ, Dept Chem, Evanston, IL 60201 USA; [Schiltz, Gary E.] Northwestern Univ, Feinberg Sch Med, Dept Pharmacol, Chicago, IL 60611 USA; [Schiltz, Gary E.; Yu, Jindan] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Yu, Jindan] Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; University of Kentucky; Northwestern University; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine	Yu, JD (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA.; Yu, JD (corresponding author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.; Yu, JD (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA.	jindan-yu@northwestern.edu			NIH/NCI [R01CA227918, T32CA09560, prostate SPORE P50CA180995]; Department of Defense [W81XWH-17-1-0405, W81XWH-17-1-0578]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense)	This work was supported in part by the NIH/NCI R01CA227918 (to JY), training grant T32CA09560 (to SP), prostate SPORE P50CA180995 (to JY), and Department of Defense grants W81XWH-17-1-0405 and W81XWH-17-1-0578 (to JY).	Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Alanee S, 2015, ANTICANCER RES, V35, P4145; Aranda S, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500737; Ardehali MB, 2017, MOL CELL, V68, P872, DOI 10.1016/j.molcel.2017.10.025; Atchison L, 2003, EMBO J, V22, P1347, DOI 10.1093/emboj/cdg124; Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Beltran M, 2016, GENOME RES, V26, P896, DOI 10.1101/gr.197632.115; Beringer M, 2016, MOL CELL, V64, P645, DOI 10.1016/j.molcel.2016.10.018; Bhatnagar S, 2014, NATURE, V516, P116, DOI 10.1038/nature13955; Biggar KK, 2015, NAT REV MOL CELL BIO, V16, P5, DOI 10.1038/nrm3915; Blackledge NP, 2020, MOL CELL, V77, P857, DOI 10.1016/j.molcel.2019.12.001; Blackledge NP, 2014, CELL, V157, P1445, DOI 10.1016/j.cell.2014.05.004; Boulay G, 2012, J BIOL CHEM, V287, P10509, DOI 10.1074/jbc.M111.320234; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Brien GL, 2012, NAT STRUCT MOL BIOL, V19, P1273, DOI 10.1038/nsmb.2449; Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cao R, 2008, MOL CELL BIOL, V28, P1862, DOI 10.1128/MCB.01589-07; Caruso Lisa B, 2018, Oncotarget, V9, P10585, DOI 10.18632/oncotarget.24291; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chen BL, 2013, CELL CYCLE, V12, P112, DOI 10.4161/cc.23030; Chen SA, 2010, NAT CELL BIOL, V12, P1108, DOI 10.1038/ncb2116; Chen SM, 2018, MOL CELL, V69, P840, DOI 10.1016/j.molcel.2018.01.039; Chen XR, 2016, J PINEAL RES, V61, P208, DOI 10.1111/jpi.12341; Choi J, 2017, NAT STRUCT MOL BIOL, V24, P1039, DOI 10.1038/nsmb.3488; Ciavatta DJ, 2010, J CLIN INVEST, V120, P3209, DOI 10.1172/JCI40034; Clarke SG, 2013, TRENDS BIOCHEM SCI, V38, P243, DOI 10.1016/j.tibs.2013.02.004; Clermont PL, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0074-4; Conway E, 2018, MOL CELL, V70, P408, DOI 10.1016/j.molcel.2018.03.005; Cooper S, 2014, CELL REP, V7, P1456, DOI 10.1016/j.celrep.2014.04.012; Cromm PM, 2017, CELL CHEM BIOL, V24, P1181, DOI 10.1016/j.chembiol.2017.05.024; Cyrta J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19328-1; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Fan WQ, 2010, EMBO J, V29, P4223, DOI 10.1038/emboj.2010.268; Ferrari KJ, 2014, MOL CELL, V53, P49, DOI 10.1016/j.molcel.2013.10.030; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002; Grijzenhout A, 2016, DEVELOPMENT, V143, P2716, DOI 10.1242/dev.123935; Gunawan M, 2015, NAT IMMUNOL, V16, P505, DOI 10.1038/ni.3125; Hamamoto R, 2015, NAT REV CANCER, V15, P110, DOI 10.1038/nrc3884; Hauri S, 2016, CELL REP, V17, P583, DOI 10.1016/j.celrep.2016.08.096; He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111; Hojfeldt JW, 2018, NAT STRUCT MOL BIOL, V25, P225, DOI 10.1038/s41594-018-0036-6; Holoch D, 2017, TRENDS BIOCHEM SCI, V42, P531, DOI 10.1016/j.tibs.2017.04.003; Hwang-Verslues WW, 2013, P NATL ACAD SCI USA, V110, P12331, DOI 10.1073/pnas.1222684110; Jain P, 2016, BIOESSAYS, V38, P446, DOI 10.1002/bies.201500162; Jermann P, 2014, P NATL ACAD SCI USA, V111, pE3415, DOI 10.1073/pnas.1400672111; Jiao LY, 2020, P NATL ACAD SCI USA, V117, P16992, DOI 10.1073/pnas.1914866117; Jiao LY, 2015, SCIENCE, V350, DOI 10.1126/science.aac4383; Justin N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11316; Kalb R, 2014, NAT STRUCT MOL BIOL, V21, P569, DOI 10.1038/nsmb.2833; Kaneko S, 2010, GENE DEV, V24, P2615, DOI 10.1101/gad.1983810; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim J, 2018, CELL REP, V25, P2808, DOI 10.1016/j.celrep.2018.11.035; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kim KH, 2015, NAT MED, V21, P1491, DOI 10.1038/nm.3968; Kim T, 2004, MOL CELL BIOL, V24, P10151, DOI 10.1128/MCB.24.23.10151-10160.2004; Kleb B, 2016, EPIGENETICS-US, V11, P184, DOI 10.1080/15592294.2016.1146851; Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110; Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171; Kovalovsky D, 2008, NAT IMMUNOL, V9, P1055, DOI 10.1038/ni.1641; Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Kung PP, 2018, J MED CHEM, V61, P650, DOI 10.1021/acs.jmedchem.7b01375; Kuntz KW, 2016, J MED CHEM, V59, P1556, DOI 10.1021/acs.jmedchem.5b01501; Kurmasheva RT, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26218; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Laugesen A, 2019, MOL CELL, V74, P8, DOI 10.1016/j.molcel.2019.03.011; Lee CH, 2019, GENE DEV, V33, P1428, DOI 10.1101/gad.328773.119; Lee CH, 2018, MOL CELL, V70, P435, DOI 10.1016/j.molcel.2018.03.019; Lee CH, 2018, MOL CELL, V70, P422, DOI 10.1016/j.molcel.2018.03.020; Lee JM, 2012, MOL CELL, V48, P572, DOI 10.1016/j.molcel.2012.09.004; Lee JK, 2016, CANCER CELL, V29, P536, DOI 10.1016/j.ccell.2016.03.001; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Li G, 2010, GENE DEV, V24, P368, DOI 10.1101/gad.1886410; Li HJ, 2017, NATURE, V549, P287, DOI 10.1038/nature23881; Li J, 2017, ONCOGENE, V36, P2991, DOI 10.1038/onc.2016.453; Li T, 2008, MOL CELL BIOL, V28, P6473, DOI 10.1128/MCB.00204-08; Liefke R, 2016, MOL CELL, V64, P659, DOI 10.1016/j.molcel.2016.10.019; Liefke R, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.8; Long YC, 2020, NAT GENET, V52, P931, DOI 10.1038/s41588-020-0662-x; Lu HQ, 2016, AM J CANCER RES, V6, P2737; Luo J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09784-9; Lynch MD, 2012, EMBO J, V31, P317, DOI 10.1038/emboj.2011.399; Ma AQ, 2020, NAT CHEM BIOL, V16, P214, DOI 10.1038/s41589-019-0421-4; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398; Martin KA, 2015, MOL CELL BIOL, V35, P3934, DOI 10.1128/MCB.00635-15; Martin MC, 2020, J MED CHEM, V63, P15344, DOI 10.1021/acs.jmedchem.0c01344; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Mendenhall EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001244; Michaelis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019705; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Morishima S, 2019, BLOOD, V134, DOI 10.1182/blood-2019-125507; Moussa HF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09628-6; Mukhopadhyay NK, 2014, ONCOGENE, V33, P3235, DOI 10.1038/onc.2013.294; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Musselman CA, 2012, NAT STRUCT MOL BIOL, V19, P1266, DOI 10.1038/nsmb.2435; Nalawansha DA, 2020, CELL CHEM BIOL, V27, P998, DOI 10.1016/j.chembiol.2020.07.020; Nekrasov M, 2005, EMBO REP, V6, P348, DOI 10.1038/sj.embor.7400376; Neri F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r91; Oksuz O, 2018, MOL CELL, V70, P1149, DOI 10.1016/j.molcel.2018.05.023; Paik WK, 2007, TRENDS BIOCHEM SCI, V32, P146, DOI 10.1016/j.tibs.2007.01.006; Palacios D, 2010, CELL STEM CELL, V7, P455, DOI 10.1016/j.stem.2010.08.013; Parimi V, 2014, AM J CLIN EXP UROL, V2, P273; Park SH, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe2261; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Perino M, 2018, NAT GENET, V50, P1002, DOI 10.1038/s41588-018-0134-8; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Pettersson Mariell, 2019, Drug Discov Today Technol, V31, P15, DOI 10.1016/j.ddtec.2019.01.002; Puca L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04495-z; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Riising EM, 2014, MOL CELL, V55, P347, DOI 10.1016/j.molcel.2014.06.005; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Riquelme E, 2016, CANCER RES, V76, P675, DOI 10.1158/0008-5472.CAN-15-1141; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rondinelli B, 2017, NAT CELL BIOL, V19, P1371, DOI 10.1038/ncb3626; Sanulli S, 2015, MOL CELL, V57, P769, DOI 10.1016/j.molcel.2014.12.020; Sarma K, 2008, MOL CELL BIOL, V28, P2718, DOI 10.1128/MCB.02017-07; Schmitges FW, 2011, MOL CELL, V42, P330, DOI 10.1016/j.molcel.2011.03.025; Sherry MM, 2009, STEM CELLS, V27, P2383, DOI 10.1002/stem.185; Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Son J, 2013, GENE DEV, V27, P2663, DOI 10.1101/gad.225888.113; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622; Takaya T, 2008, J BIOL CHEM, V283, P9828, DOI 10.1074/jbc.M707391200; Tamburri S, 2020, MOL CELL, V77, P840, DOI 10.1016/j.molcel.2019.11.021; Tan HL, 2014, CLIN CANCER RES, V20, P890, DOI 10.1158/1078-0432.CCR-13-1982; Tanay A, 2007, P NATL ACAD SCI USA, V104, P5521, DOI 10.1073/pnas.0609746104; Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706; Taplin ME, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-CT094; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Vasanthakumar A, 2017, EMBO REP, V18, P619, DOI 10.15252/embr.201643237; Vaswani RG, 2016, J MED CHEM, V59, P9928, DOI 10.1021/acs.jmedchem.6b01315; Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009; Wang DJ, 2015, ONCOTARGET, V6, P41045, DOI 10.18632/oncotarget.5728; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang L, 2013, EMBO J, V32, P1584, DOI 10.1038/emboj.2013.95; Wang W, 2008, AM J SURG PATHOL, V32, P65, DOI 10.1097/PAS.0b013e318058a96b; Wang XY, 2019, GENE DEV, V33, P1416, DOI 10.1101/gad.328849.119; Wang XY, 2017, NAT STRUCT MOL BIOL, V24, P1028, DOI 10.1038/nsmb.3487; Wang ZX, 2002, BIOCHEM J, V368, P947, DOI 10.1042/BJ20020557; Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139; Wienken M, 2016, MOL CELL, V61, P68, DOI 10.1016/j.molcel.2015.12.008; Wilson BG, 2010, CANCER CELL, V18, P316, DOI 10.1016/j.ccr.2010.09.006; Wu H, 2011, NATURE, V473, P389, DOI 10.1038/nature09934; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yamaguchi H, 2018, ONCOGENE, V37, P208, DOI 10.1038/onc.2017.311; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Zaffuto E, 2017, CLIN GENITOURIN CANC, V15, pE793, DOI 10.1016/j.clgc.2017.04.006; Zee BM, 2012, MOL CELL BIOL, V32, P2503, DOI 10.1128/MCB.06673-11; Zhang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06177-2; Zhang Z, 2011, STEM CELLS, V29, P229, DOI 10.1002/stem.578	162	13	14	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5788	5798		10.1038/s41388-021-01982-4	http://dx.doi.org/10.1038/s41388-021-01982-4		AUG 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34349243	Green Accepted			2022-12-28	WOS:000681147100001
J	Mecozzi, N; Vera, O; Karreth, FA				Mecozzi, Nicol; Vera, Olga; Karreth, Florian A.			Squaring the circle: circRNAs in melanoma	ONCOGENE			English	Review							CIRCULAR RNAS; CELL-PROLIFERATION; MALIGNANT-MELANOMA; CANCER; PROGRESSION; TRANSLATION; BIOGENESIS; REVEALS; MIR-135B-5P; EXPRESSION	Non-coding RNAs are emerging as critical molecules in the genesis, progression, and therapy resistance of cutaneous melanoma. This includes circular RNAs (circRNAs), a class of non-coding RNAs with distinct characteristics that forms through non-canonical back-splicing. In this review, we summarize the features and functions of circRNAs and introduce the current knowledge of the roles of circRNAs in melanoma. We also highlight the various mechanisms of action of the well-studied circRNA CDR1as and describe how it acts as a melanoma tumor suppressor. We further discuss the utility of circRNAs as biomarkers, therapeutic targets, and therapeutic agents in melanoma and outline challenges that must be overcome to comprehensively characterize circRNA functions.	[Mecozzi, Nicol; Vera, Olga; Karreth, Florian A.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Karreth, FA (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA.	florian.karreth@moffitt.org			NCI/NIH [R01 CA259046]; Harry J. Lloyd Charitable Foundation	NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Harry J. Lloyd Charitable Foundation	This work was supported by grants from the NCI/NIH (R01 CA259046) and the Harry J. Lloyd Charitable Foundation to FAK.	Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Barrett SP, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007114; Begum S, 2018, ONCOGENE, V37, P4055, DOI 10.1038/s41388-018-0230-3; Bian DH, 2018, BIOMED PHARMACOTHER, V108, P165, DOI 10.1016/j.biopha.2018.08.152; CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; Chen H, 2019, ONCOTARGETS THER, V12, P3869, DOI 10.2147/OTT.S207938; Chen J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02799-x; Chen LL, 2020, NAT REV MOL CELL BIO, V21, P475, DOI 10.1038/s41580-020-0243-y; Chen LL, 2015, RNA BIOL, V12, P381, DOI 10.1080/15476286.2015.1020271; Chen YC, 2010, J INVEST DERMATOL, V130, P2790, DOI 10.1038/jid.2010.222; Chen ZB, 2020, LIFE SCI, V243, DOI 10.1016/j.lfs.2020.117323; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; Conn VM, 2017, NAT PLANTS, V3, DOI 10.1038/nplants.2017.53; Du WW, 2017, CELL DEATH DIFFER, V24, P357, DOI 10.1038/cdd.2016.133; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Errichelli L, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14741; Fang L, 2019, CANCER LETT, V459, P216, DOI 10.1016/j.canlet.2019.05.036; Fattore L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061930; Giles KM, 2016, ONCOTARGET, V7, P31663, DOI 10.18632/oncotarget.9421; Giles KM, 2013, BIOCHEM BIOPH RES CO, V430, P706, DOI 10.1016/j.bbrc.2012.11.086; Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z; Hanniford D, 2020, CANCER CELL, V37, P55, DOI 10.1016/j.ccell.2019.12.007; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hansen TB, 2011, EMBO J, V30, P4414, DOI 10.1038/emboj.2011.359; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Holdt LM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12429; Horsham JL, 2015, J CLIN MED, V4, P1668, DOI 10.3390/jcm4091668; Hu Y, 2019, MELANOMA RES, V29, P119, DOI 10.1097/CMR.0000000000000524; Hung HX, 2020, NUCLEIC ACIDS RES, V48, P10368, DOI 10.1093/nar/gkaa704; Ivanov A, 2015, CELL REP, V10, P170, DOI 10.1016/j.celrep.2014.12.019; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jin C, 2020, CELL BIOCHEM BIOPHYS, V78, P77, DOI 10.1007/s12013-019-00895-0; Karreth FA, 2020, P SINGAP NATL ACAD S, V14, P145, DOI [10.1142/S2591722620400104, DOI 10.1142/S2591722620400104]; Karreth FA, 2021, GENETIC TOOLS STABLE, DOI [10.1101/2021.05.27.446018, DOI 10.1101/2021.05.27.446018]; Karreth FA, 2013, CANCER DISCOV, V3, P1113, DOI 10.1158/2159-8290.CD-13-0202; Kleaveland B, 2018, CELL, V174, P350, DOI 10.1016/j.cell.2018.05.022; Kramer MC, 2015, GENE DEV, V29, P2168, DOI 10.1101/gad.270421.115; Kristensen LS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18355-2; Lasda E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148407; Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017; Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161; Li P, 2018, CELL PHYSIOL BIOCHEM, V46, P1606, DOI 10.1159/000489208; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liang DM, 2017, MOL CELL, V68, P940, DOI 10.1016/j.molcel.2017.10.034; Liang WC, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1685-4; Lin QL, 2021, J DERMATOL TREAT, V32, P231, DOI 10.1080/09546634.2019.1654069; Lou JC, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01253-y; Lu JJ, 2020, MOL CELL BIOCHEM, V475, P227, DOI 10.1007/s11010-020-03875-8; Lu RJ, 2020, INT J CLIN EXP PATHO, V13, P1791; Luan WK, 2018, BIOCHEM BIOPH RES CO, V502, P22, DOI 10.1016/j.bbrc.2018.05.114; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Nemlich Y, 2013, J CLIN INVEST, V123, P2703, DOI 10.1172/JCI62980; Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021; Piwecka M, 2017, SCIENCE, V357, DOI 10.1126/science.aam8526; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Qian P, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2444-x; Rambow F, 2019, GENE DEV, V33, P1295, DOI 10.1101/gad.329771.119; Ren JW, 2015, INT J CLIN EXP PATHO, V8, P6356; Rybak-Wolf A, 2015, MOL CELL, V58, P870, DOI 10.1016/j.molcel.2015.03.027; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Salzman J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003777; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Sarkar D, 2015, EPIGENETICS-US, V10, P103, DOI 10.1080/15592294.2014.1003746; Shain AH, 2018, CANCER CELL, V34, P45, DOI 10.1016/j.ccell.2018.06.005; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Szabo L, 2015, GENOME BIOL, V16, DOI [10.1186/s13059-015-0690-5, 10.1186/s13059-016-1123-9]; Tang WT, 2017, ONCOTARGETS THER, V10, P2045, DOI 10.2147/OTT.S131597; Tian S, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-01832-9; Turner N, 2018, CLIN EXP METASTAS, V35, P379, DOI 10.1007/s10585-018-9893-y; Ulitsky I, 2012, CELL, V151, P684, DOI 10.1016/j.cell.2012.10.002; Vendramin R, 2018, NAT STRUCT MOL BIOL, V25, P1035, DOI 10.1038/s41594-018-0143-4; Veno MT, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0801-3; Vera O, 2021, CANCERS, V13, DOI 10.3390/cancers13061408; Vergara IA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21576-8; Wang Q, 2018, ONCOL REP, V39, P1813, DOI 10.3892/or.2018.6263; Wang Y, 2015, RNA, V21, P172, DOI 10.1261/rna.048272.114; Wei CY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01191-9; Westholm JO, 2014, CELL REP, V9, P1966, DOI 10.1016/j.celrep.2014.10.062; Xiao MS, 2020, TRENDS CELL BIOL, V30, P226, DOI 10.1016/j.tcb.2019.12.004; Xu LL, 2017, J CANCER RES CLIN, V143, P17, DOI 10.1007/s00432-016-2256-7; Yang Q, 2017, CELL DEATH DIFFER, V24, P1609, DOI 10.1038/cdd.2017.86; Yang Yibing, 2018, J Natl Cancer Inst, V110, DOI 10.1093/jnci/djx166; Yang Y, 2017, CELL RES, V27, P626, DOI 10.1038/cr.2017.31; Yang ZG, 2017, MOL THER, V25, P2062, DOI 10.1016/j.ymthe.2017.05.022; Yin D, 2021, HUM EXP TOXICOL, V40, P310, DOI 10.1177/0960327120950014; Yoshimoto R, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101345; You XT, 2015, NAT NEUROSCI, V18, P603, DOI 10.1038/nn.3975; Zhang ML, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06862-2; Zhang ML, 2018, ONCOGENE, V37, P1805, DOI 10.1038/s41388-017-0019-9; Zhang XH, 2020, EUR REV MED PHARMACO, V24, P1309, DOI 10.26355/eurrev_202002_20188; Zhang Y, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02263-9; Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017; Zheng X, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1010-6; Zhong Q, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0959-y; Zou Y, 2019, EUR REV MED PHARMACO, V23, P10918, DOI 10.26355/eurrev_201912_19795	99	3	3	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5559	5566		10.1038/s41388-021-01977-1	http://dx.doi.org/10.1038/s41388-021-01977-1		JUL 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34331015	Green Accepted			2022-12-28	WOS:000679620500006
J	Li, YY; Fei, H; Lin, QW; Liang, F; You, YA; Li, M; Wu, MY; Qu, Y; Li, PF; Yuan, Y; Chen, T; Jiang, H				Li, Yiying; Fei, He; Lin, Qiwang; Liang, Fan; You, Yanan; Li, Ming; Wu, Mengyao; Qu, Ying; Li, Pengfei; Yuan, Yan; Chen, Tong; Jiang, Hua			ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; EXPRESSION; PROMOTES; HETEROGENEITY; INVASION	Peritoneal metastasis is a common issue in the progression of high-grade serous ovarian cancers (HGSOCs), yet the underlying mechanism remains unconfirmed. We demonstrated that ZEB2, the transcription factor of epithelial-mesenchymal transition (EMT), was upregulated in ascites cells from HGSOC patients and in CD133(+) cancer stem-like cells (CSLCs) from epithelial ovarian cancer (EOC) cell lines. SiRNA-mediated knockdown of ZEB2 in EOC cells decreased the percentage of CSLCs and reduced the colony forming potential, cell invasion capacity and expression of pluripotent genes Oct4 and Nanog. Inhibition of ZEB2 also induced cellular apoptosis and impacted the tumorigenicity of ovarian CSLCs. The mesenchymal markers N-cadherin and vimentin were downregulated, while the epithelial marker E-cadherin was upregulated after ZEB2 knockdown. MiR-200a, a molecule that downregulates ZEB2, had the opposite effect of ZEB2 expression in EOC-CSLCs. A retrospective study of 98 HGSOC patients on the relationship of ascites volume, pelvic and abdominal metastasis, International Federation of Gynecology and Obstetrics (FIGO) stage and the malignant involvement of abdominal organs and lymph nodes was performed. Patients with high expression of ZEB2 in tumour tissues had a higher metastasis rate and a poorer prognosis than those with low expression. The parameters of ZEB2 expression and ascites volume were strongly linked with the prognostic outcome of HGSOC patients and had higher hazard ratios. These findings illustrated that ZEB2 facilitates the invasive metastasis of EOC-CSLCs and can predict peritoneal metastasis and a poor prognosis in HGSOC patients.	[Li, Yiying; Fei, He; Lin, Qiwang; Liang, Fan; You, Yanan; Li, Ming; Jiang, Hua] Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol, Shanghai 200011, Peoples R China; [Li, Yiying] Nanchang Univ, Affiliated Hosp 1, Dept Gynecol, Nanchang 330006, Jiangxi, Peoples R China; [Fei, He] Fudan Univ, Shanghai Peoples Hosp 5, Dept Gynecol, Shanghai 200240, Peoples R China; [Wu, Mengyao; Qu, Ying; Li, Pengfei; Yuan, Yan; Chen, Tong] Fudan Univ, Huashan Hosp, Dept Hematol, Shanghai 200040, Peoples R China; [Jiang, Hua] Shanghai Key Lab Female Reprod Endocrine Related, Shanghai 200011, Peoples R China	Fudan University; Nanchang University; Fudan University; Fudan University	Jiang, H (corresponding author), Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol, Shanghai 200011, Peoples R China.; Chen, T (corresponding author), Fudan Univ, Huashan Hosp, Dept Hematol, Shanghai 200040, Peoples R China.; Jiang, H (corresponding author), Shanghai Key Lab Female Reprod Endocrine Related, Shanghai 200011, Peoples R China.	chentong@fudan.edu.cn; jianghua@fudan.edu.cn	Liang, Fan/HGA-0248-2022		National Natural Science Foundation of China [81870081]; Program for Outstanding Medical Academic Leader of Shanghai [2019LJ05]; Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research [2019CXJQ01]; Clinical Research Plan of Shanghai Hospital Development Center [SHDC2020CR1048B]; High-level Professional Physician Training Program of Minhang District [2020MZYS17]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Outstanding Medical Academic Leader of Shanghai; Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research; Clinical Research Plan of Shanghai Hospital Development Center; High-level Professional Physician Training Program of Minhang District	This study was supported by grants from the National Natural Science Foundation of China (81870081), the Program for Outstanding Medical Academic Leader of Shanghai (2019LJ05) and the Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research (2019CXJQ01) to TC, the Clinical Research Plan of Shanghai Hospital Development Center (SHDC2020CR1048B) to HJ and High-level Professional Physician Training Program of Minhang District (2020MZYS17) to HF.	Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284; Alberto-Aguilar DR, 2019, CANCER MICROENVIRON, V12, P181, DOI 10.1007/s12307-019-00227-z; Aslan B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8351; Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374; Choi PW, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061207; den Ouden Judith E, 2020, Oncotarget, V11, P4570, DOI 10.18632/oncotarget.27827; Gu SW, 2019, INT J CLIN EXP PATHO, V12, P2009; Han Q, 2019, INT J MOL MED, V44, P2245, DOI 10.3892/ijmm.2019.4361; Hooda J, 2019, CANCER RES, V79, P760, DOI 10.1158/0008-5472.CAN-18-2297; Hu YT, 2019, CANCER LETT, V457, P142, DOI 10.1016/j.canlet.2019.04.034; Ignacio RMC, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e29; Jiang H, 2012, MOL MED, V18, P1197, DOI 10.2119/molmed.2012.00075; Jolly MK, 2019, PHARMACOL THERAPEUT, V194, P161, DOI 10.1016/j.pharmthera.2018.09.007; Kim S, 2016, CANCER SCI, V107, P1173, DOI 10.1111/cas.12987; Kim S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31097-y; Kotrbova A, 2020, THERANOSTICS, V10, P537, DOI 10.7150/thno.37423; Liu CM, 2015, TUMOR BIOL, V36, P7213, DOI 10.1007/s13277-015-3437-8; Liu C, 2018, FUTURE ONCOL, V14, P2875, DOI 10.2217/fon-2018-0155; Loret N, 2019, CANCERS, V11, DOI 10.3390/cancers11060838; Lourenco AR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14556-x; Lytle NK, 2018, NAT REV CANCER, V18, P669, DOI 10.1038/s41568-018-0056-x; Matte I, 2012, AM J CANCER RES, V2, P566; Mo LH, 2015, MOL CANCER THER, V14, P747, DOI 10.1158/1535-7163.MCT-14-0579; Moussa RA, 2019, WORLD J ONCOL, V10, P199, DOI 10.14740/wjon1234; Pakula M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010137; Saini U, 2017, ONCOGENE, V36, P168, DOI 10.1038/onc.2016.197; Scott CL, 2018, IMMUNITY, V49, P312, DOI 10.1016/j.immuni.2018.07.004; Shepherd TG, 2006, NAT PROTOC, V1, P2643, DOI 10.1038/nprot.2006.328; Shi J, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6321-x; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Song N, 2016, CELL PHYSIOL BIOCHEM, V38, P351, DOI 10.1159/000438635; Song Q, 2019, ONCOTARGETS THER, V12, P7387, DOI 10.2147/OTT.S218161; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Tripathi S, 2020, ANNU REV BIOPHYS, V49, P1, DOI 10.1146/annurev-biophys-121219-081557; Webb TJ, 2012, CANCER RES, V72, P3744, DOI 10.1158/0008-5472.CAN-11-2695; Wu QG, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay9819; Yamanoi K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50794-w; Yan Z, 2017, INT J GYNECOL CANCER, V27, P1343, DOI 10.1097/IGC.0000000000001037; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9; Yeung KT, 2017, MOL ONCOL, V11, P28, DOI 10.1002/1878-0261.12017; YU DH, 1993, CANCER RES, V53, P891; Zhang YY, 2020, AM J REPROD IMMUNOL, V84, DOI 10.1111/aji.13251; Zhao YX, 2018, CELL CYCLE, V17, P250, DOI 10.1080/15384101.2017.1417708; Zheng TT, 2019, ONCOTARGETS THER, V12, P6145, DOI 10.2147/OTT.S209784	45	5	5	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5131	5141		10.1038/s41388-021-01913-3	http://dx.doi.org/10.1038/s41388-021-01913-3		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34211089	hybrid, Green Published			2022-12-28	WOS:000668832500002
J	Ottina, E; Panova, V; Doglio, L; Kazachenka, A; Cornish, G; Kirkpatrick, J; Attig, J; Young, GR; Litchfield, K; Lesluyes, T; Van Loo, P; Swanton, C; MacRae, J; Tuting, T; Kassiotis, G				Ottina, Eleonora; Panova, Veera; Doglio, Laura; Kazachenka, Anastasiya; Cornish, Georgina; Kirkpatrick, Joanna; Attig, Jan; Young, George R.; Litchfield, Kevin; Lesluyes, Tom; Van Loo, Peter; Swanton, Charles; MacRae, James; Tuting, Thomas; Kassiotis, George			E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion	ONCOGENE			English	Article							CANCER; CELLS; CHECKPOINTS; PROMOTES; THERAPY; INNATE; IMPACT; GENES	The ubiquitin-proteasome system maintains protein homoeostasis, underpins the cell cycle, and is dysregulated in cancer. However, the role of individual E3 ubiquitin ligases, which mediate the final step in ubiquitin-mediated proteolysis, remains incompletely understood. Identified through screening for cancer-specific endogenous retroviral transcripts, we show that the little-studied E3 ubiquitin ligase HECTD2 exerts dominant control of tumour progression in melanoma. HECTD2 cell autonomously drives the proliferation of human and murine melanoma cells by accelerating the cell cycle. HECTD2 additionally regulates cancer cell production of immune mediators, initiating multiple immune suppressive pathways, which include the cyclooxygenase 2 (COX2) pathway. Accordingly, higher HECTD2 expression is associated with weaker anti-tumour immunity and unfavourable outcome of PD-1 blockade in human melanoma and counteracts immunity against a model tumour antigen in murine melanoma. This central, multifaceted role of HECTD2 in cancer cell-autonomous proliferation and in immune evasion may provide a single target for a multipronged therapy of melanoma.	[Ottina, Eleonora; Panova, Veera; Doglio, Laura; Kazachenka, Anastasiya; Cornish, Georgina; Attig, Jan; Kassiotis, George] Francis Crick Inst, Retroviral Immunol Lab, London, England; [Kirkpatrick, Joanna; MacRae, James] Francis Crick Inst, Prote STP, London, England; [Young, George R.] Francis Crick Inst, Retrovirus Host Interact Lab, London, England; [Litchfield, Kevin; Swanton, Charles] Francis Crick Inst, Canc Evolut & Genome Instabil Lab, London, England; [Lesluyes, Tom; Van Loo, Peter] Francis Crick Inst, Canc Genom Lab, London, England; [Tuting, Thomas] Univ Magdeburg, Dept Dermatol, Lab Expt Dermatol, Magdeburg, Germany; [Kassiotis, George] Imperial Coll London, Dept Infect Dis, Fac Med, London, England	Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Otto von Guericke University; Imperial College London	Kassiotis, G (corresponding author), Francis Crick Inst, Retroviral Immunol Lab, London, England.; Kassiotis, G (corresponding author), Imperial Coll London, Dept Infect Dis, Fac Med, London, England.	george.kassiotis@crick.ac.uk	Lesluyes, Tom/GSD-4621-2022; Lesluyes, Tom/AAB-6229-2019; Young, George/C-6733-2009	Lesluyes, Tom/0000-0003-2251-5884; Lesluyes, Tom/0000-0003-2251-5884; Young, George/0000-0002-1203-588X; Litchfield, Kevin/0000-0002-3725-0914; MacRae, James/0000-0002-1464-8583; Swanton, Charles/0000-0002-4299-3018; Ottina, Eleonora/0000-0002-9630-496X; Attig, Jan/0000-0002-2159-2880; Panova, Veera/0000-0001-8433-6430	Francis Crick Institute [FC001099, FC001169, FC001202]; Cancer Research UK (CRUK); UK Medical Research Council (MRC); Wellcome Trust; Wellcome Trust [FC001099, FC001169, FC001202, 102898/B/13/Z]; CRUK [C55533/A22158]	Francis Crick Institute; Cancer Research UK (CRUK)(Cancer Research UK); UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Wellcome Trust(Wellcome TrustEuropean Commission); CRUK(Cancer Research UK)	We are grateful for assistance from the Advanced Light Microscopy, Biological Research Facility, Cell Services, Flow Cytometry and Scientific Computing facilities at the Francis Crick Institute. The results shown here are in whole or part based upon data generated by the TCGA Research Network (http://cancergenome.nih.gov).This work benefited from data assembled by the CCLE consortium. This work was supported by the Francis Crick Institute (FC001099, FC001169, FC001202), which receives its core funding from Cancer Research UK (CRUK), the UK Medical Research Council (MRC), and the Wellcome Trust; and by the Wellcome Trust (102898/B/13/Z to GK) and CRUK (C55533/A22158 to GK). This research was funded in whole, or in part, by the Wellcome Trust (102898/B/13/Z; FC001099, FC001169, FC001202). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Attig J, 2019, GENOME RES, V29, P1578, DOI 10.1101/gr.248922.119; Bald T, 2014, NATURE, V507, P109, DOI 10.1038/nature13111; Barclay AN, 2014, ANNU REV IMMUNOL, V32, P25, DOI 10.1146/annurev-immunol-032713-120142; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bedognetti D, 2016, CURR OPIN IMMUNOL, V39, P150, DOI 10.1016/j.coi.2016.02.001; Coon TA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3881; Danelli L, 2021, CELL MOL IMMUNOL, V18, P1809, DOI 10.1038/s41423-020-0415-x; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Garofalo M, 2012, CURR MOL MED, V12, P27, DOI 10.2174/156652412798376170; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Hinshaw DC, 2019, CANCER RES, V79, P4557, DOI 10.1158/0008-5472.CAN-18-3962; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Ishak CA, 2020, ANNU REV CANC BIOL, V4, P159, DOI 10.1146/annurev-cancerbio-030419-033525; Kassiotis G, 2016, NAT REV IMMUNOL, V16, P207, DOI 10.1038/nri.2016.27; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Lau AN, 2020, ANNU REV CANC BIOL, V4, P17, DOI 10.1146/annurev-cancerbio-030419-033333; Lloyd SE, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-90; Lloyd SE, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000383; MacKie RM, 2009, ANN ONCOL, V20, P1, DOI 10.1093/annonc/mdp252; Ottina E, 2018, CANCER IMMUNOL RES, V6, P1292, DOI 10.1158/2326-6066.CIR-18-0038; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pelechano V, 2013, NAT REV GENET, V14, P880, DOI 10.1038/nrg3594; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rossi M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09754-1; Schumacher TN, 2019, ANNU REV IMMUNOL, V37, P173, DOI 10.1146/annurev-immunol-042617-053402; Sperka T, 2012, NAT REV MOL CELL BIO, V13, P579, DOI 10.1038/nrm3420; Spranger S, 2018, NAT REV CANCER, V18, P139, DOI 10.1038/nrc.2017.117; Sun T, 2014, ONCOGENE, V33, P2790, DOI 10.1038/onc.2013.230; Suo C, 2018, BIOL DIRECT, V13, DOI 10.1186/s13062-018-0218-5; Takimoto CH, 2019, ANN ONCOL, V30, P486, DOI 10.1093/annonc/mdz006; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Wang YY, 2020, J CELL SCI, V133, DOI 10.1242/jcs.228072; Wellenstein MD, 2018, IMMUNITY, V48, P399, DOI 10.1016/j.immuni.2018.03.004; Wu S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05467-z; Zapparoli E, 2020, NUCLEIC ACIDS RES, V48, P9053, DOI 10.1093/nar/gkaa628; Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015	42	2	2	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5567	5578		10.1038/s41388-021-01885-4	http://dx.doi.org/10.1038/s41388-021-01885-4		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34145398	hybrid, Green Published			2022-12-28	WOS:000663295300001
J	Malkomes, P; Lunger, I; Oppermann, E; Abou-El-Ardat, K; Oellerich, T; Gunther, S; Canbulat, C; Bothur, S; Schnutgen, F; Yu, WJ; Wingert, S; Haetscher, N; Catapano, C; Dietz, MS; Heilemann, M; Kvasnicka, HM; Holzer, K; Serve, H; Bechstein, WO; Rieger, MA				Malkomes, Patrizia; Lunger, Ilaria; Oppermann, Elsie; Abou-El-Ardat, Khalil; Oellerich, Thomas; Guenther, Stefan; Canbulat, Can; Bothur, Sabrina; Schnuetgen, Frank; Yu, Weijia; Wingert, Susanne; Haetscher, Nadine; Catapano, Claudia; Dietz, Marina S.; Heilemann, Mike; Kvasnicka, Hans-Michael; Holzer, Katharina; Serve, Hubert; Bechstein, Wolf Otto; Rieger, Michael A.			Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53	ONCOGENE			English	Article							TISSUE TRANSGLUTAMINASE; TP53 MUTATION; STEM-CELLS; INHIBITION; EXPRESSION; SURVIVAL; TG2; ADJUVANT; INVASION; DISEASE	Despite a high clinical need for the treatment of colorectal carcinoma (CRC) as the second leading cause of cancer-related deaths, targeted therapies are still limited. The multifunctional enzyme Transglutaminase 2 (TGM2), which harbors transamidation and GTPase activity, has been implicated in the development and progression of different types of human cancers. However, the mechanism and role of TGM2 in colorectal cancer are poorly understood. Here, we present TGM2 as a promising drug target. In primary patient material of CRC patients, we detected an increased expression and enzymatic activity of TGM2 in colon cancer tissue in comparison to matched normal colon mucosa cells. The genetic ablation of TGM2 in CRC cell lines using shRNAs or CRISPR/Cas9 inhibited cell expansion and tumorsphere formation. In vivo, tumor initiation and growth were reduced upon genetic knockdown of TGM2 in xenotransplantations. TGM2 ablation led to the induction of Caspase-3-driven apoptosis in CRC cells. Functional rescue experiments with TGM2 variants revealed that the transamidation activity is critical for the pro-survival function of TGM2. Transcriptomic and protein-protein interaction analyses applying various methods including super-resolution and time-lapse microscopy showed that TGM2 directly binds to the tumor suppressor p53, leading to its inactivation and escape of apoptosis induction. We demonstrate here that TGM2 is an essential survival factor in CRC, highlighting the therapeutic potential of TGM2 inhibitors in CRC patients with high TGM2 expression. The inactivation of p53 by TGM2 binding indicates a general anti-apoptotic function, which may be relevant in cancers beyond CRC.	[Malkomes, Patrizia; Oppermann, Elsie; Canbulat, Can; Holzer, Katharina; Bechstein, Wolf Otto] Goethe Univ Hosp Frankfurt, Dept Gen Visceral & Transplant Surg, Frankfurt, Germany; [Lunger, Ilaria; Abou-El-Ardat, Khalil; Oellerich, Thomas; Bothur, Sabrina; Schnuetgen, Frank; Yu, Weijia; Wingert, Susanne; Haetscher, Nadine; Serve, Hubert; Rieger, Michael A.] Goethe Univ Hosp Frankfurt, Dept Med, Hematol Oncol, Frankfurt, Germany; [Abou-El-Ardat, Khalil; Oellerich, Thomas; Schnuetgen, Frank; Serve, Hubert; Rieger, Michael A.] German Canc Consortium & German Canc Res Ctr DKFZ, Heidelberg, Germany; [Oellerich, Thomas; Schnuetgen, Frank; Serve, Hubert; Rieger, Michael A.] Frankfurt Canc Inst, Frankfurt, Germany; [Guenther, Stefan] Max Planck Inst Heart & Lung Res, Dept Cardiac Dev & Remodelling 1, Bad Nauheim, Germany; [Catapano, Claudia; Dietz, Marina S.; Heilemann, Mike] Goethe Univ Frankfurt, Inst Phys & Theoret Chem, Single Mol Biophys, Frankfurt, Germany; [Kvasnicka, Hans-Michael] Goethe Univ Frankfurt, Senckenberg Inst Pathol, Frankfurt, Germany; [Rieger, Michael A.] Cardio Pulm Inst, Frankfurt, Germany; [Holzer, Katharina] Philipps Univ Marburg, Dept Visceral Thorac & Vasc Surg, Marburg, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Max Planck Society; Goethe University Frankfurt; Goethe University Frankfurt; Philipps University Marburg	Rieger, MA (corresponding author), Goethe Univ Hosp Frankfurt, Dept Med, Hematol Oncol, Frankfurt, Germany.; Rieger, MA (corresponding author), German Canc Consortium & German Canc Res Ctr DKFZ, Heidelberg, Germany.; Rieger, MA (corresponding author), Frankfurt Canc Inst, Frankfurt, Germany.; Rieger, MA (corresponding author), Cardio Pulm Inst, Frankfurt, Germany.	m.rieger@em.uni-frankfurt.de	Malkomes, Patrizia/AAV-3314-2021; Schnütgen, Frank/ABD-8637-2020; Kvasnicka, Hans Michael/E-7993-2011	Schnütgen, Frank/0000-0002-2426-6685; Kvasnicka, Hans Michael/0000-0002-3081-1395; Heilemann, Mike/0000-0002-9821-3578; Yu, Weijia/0000-0001-8471-3048	Else Kroner Fresenius-Stiftung; Deutsche Krebshilfe; LOEWE Centers Cell and Gene Therapy Frankfurt (Hessen State Ministry for Higher Education, Research and the Arts) [III L 4-518/17.004 [2014]]; Frankfurt Cancer Institute (Hessen State Ministry for Higher Education, Research and the Arts) [III L 5 - 519/03/03.001 - [0015]]; Projekt DEAL	Else Kroner Fresenius-Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); LOEWE Centers Cell and Gene Therapy Frankfurt (Hessen State Ministry for Higher Education, Research and the Arts); Frankfurt Cancer Institute (Hessen State Ministry for Higher Education, Research and the Arts); Projekt DEAL	The study was supported in part by the Else Kroner Fresenius-Stiftung, the Deutsche Krebshilfe (both to P.M.) and by the LOEWE Centers Cell and Gene Therapy Frankfurt (Hessen State Ministry for Higher Education, Research and the Arts, III L 4-518/17.004 [2014]) and Frankfurt Cancer Institute (Hessen State Ministry for Higher Education, Research and the Arts, III L 5 - 519/03/03.001 - [0015]). Open Access funding enabled and organized by Projekt DEAL.	Advani S, 2019, J SURG ONCOL, V119, P642, DOI 10.1002/jso.25441; Ahvazi B, 2002, EMBO J, V21, P2055, DOI 10.1093/emboj/21.9.2055; Antonyak MA, 2006, P NATL ACAD SCI USA, V103, P18609, DOI 10.1073/pnas.0604844103; Ashour AA, 2014, J CELL MOL MED, V18, P2235, DOI 10.1111/jcmm.12361; Ayinde O, 2017, ONCOTARGET, V8, P20025, DOI 10.18632/oncotarget.15370; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Barrier A, 2006, J CLIN ONCOL, V24, P4685, DOI 10.1200/JCO.2005.05.0229; Begg GE, 2006, P NATL ACAD SCI USA, V103, P19683, DOI 10.1073/pnas.0609283103; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cellura D, 2015, MOL CANCER RES, V13, P1095, DOI 10.1158/1541-7786.MCR-14-0466; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Chhabra A, 2009, ANTICANCER RES, V29, P1909; Condello S, 2018, CANCER RES, V78, P2990, DOI 10.1158/0008-5472.CAN-17-2319; Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126; Dietz P., 2020, METHODS, VS1046-2023, P30024; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fisher ML, 2016, CANCER RES, V76, P7265, DOI 10.1158/0008-5472.CAN-16-2032; FOLK JE, 1966, J BIOL CHEM, V241, P3238; Goh AM, 2011, J PATHOL, V223, P116, DOI 10.1002/path.2784; Nguyen HT, 2018, ONCOL LETT, V16, P9, DOI 10.3892/ol.2018.8679; Harwardt MLIE, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082803; Hilsenbeck O, 2016, NAT BIOTECHNOL, V34, P703, DOI 10.1038/nbt.3626; Hwang JY, 2008, CANCER RES, V68, P5849, DOI 10.1158/0008-5472.CAN-07-6130; Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175; Fernandez-Acenero M, 2016, VIRCHOWS ARCH, V469, P611, DOI 10.1007/s00428-016-2020-z; Kang JH, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.14; Klock C, 2012, SEMIN IMMUNOPATHOL, V34, P513, DOI 10.1007/s00281-012-0305-0; Kosa K, 1997, BIOCHEM BIOPH RES CO, V232, P737, DOI 10.1006/bbrc.1997.6363; Kotsakis P, 2011, AMINO ACIDS, V41, P909, DOI 10.1007/s00726-010-0790-1; Ku BM, 2013, FASEB J, V27, P3487, DOI 10.1096/fj.12-224220; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1202, P1, DOI 10.1016/0167-4838(93)90055-V; LORAND L, 1992, P NATL ACAD SCI USA, V89, P11161, DOI 10.1073/pnas.89.23.11161; Malkomes P, 2016, ANN SURG ONCOL, V23, P2849, DOI 10.1245/s10434-016-5218-z; Mangala LS, 2007, ONCOGENE, V26, P2459, DOI 10.1038/sj.onc.1210035; Mehta Kapil, 2011, Cancers (Basel), V3, P897, DOI 10.3390/cancers3010897; MICANOVIC R, 1994, J BIOL CHEM, V269, P9190; Mishra S, 2006, BIOCHEM BIOPH RES CO, V339, P726, DOI 10.1016/j.bbrc.2005.11.071; Miyoshi N, 2010, ANN SURG ONCOL, V17, P967, DOI 10.1245/s10434-009-0865-y; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Naldini L, 1998, CURR OPIN BIOTECH, V9, P457, DOI 10.1016/S0958-1669(98)80029-3; O'Connor ES, 2011, J CLIN ONCOL, V29, P3381, DOI 10.1200/JCO.2010.34.3426; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; Oono M, 2014, J NEUROCHEM, V128, P403, DOI 10.1111/jnc.12441; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; Pinkas DM, 2007, PLOS BIOL, V5, P2788, DOI 10.1371/journal.pbio.0050327; Rieger MA, 2009, SCIENCE, V325, P217, DOI 10.1126/science.1171461; SARKAR NK, 1957, BIOCHIM BIOPHYS ACTA, V25, P451, DOI 10.1016/0006-3002(57)90512-7; Sauer M, 2017, CHEM REV, V117, P7478, DOI 10.1021/acs.chemrev.6b00667; Shah MA, 2016, J CLIN ONCOL, V34, P843, DOI 10.1200/JCO.2015.63.0558; Shao MH, 2009, CANCER RES, V69, P9192, DOI 10.1158/0008-5472.CAN-09-1257; Soussi T, 2005, HUM MUTAT, V25, P6, DOI 10.1002/humu.20114; Tatsukawa H, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-4; Telci D, 2006, FRONT BIOSCI-LANDMRK, V11, P867, DOI 10.2741/1843; Thalheimer FB, 2014, STEM CELL REP, V3, DOI 10.1016/j.stemcr.2014.05.010; Varga J, 2017, NAT CELL BIOL, V19, P1133, DOI 10.1038/ncb3611; Verma A, 2008, CLIN CANCER RES, V14, P1997, DOI 10.1158/1078-0432.CCR-07-1533; Verma A, 2008, CLIN CANCER RES, V14, P2476, DOI 10.1158/1078-0432.CCR-07-4529; Yeo SY, 2016, ELIFE, V5, DOI 10.7554/eLife.07101; Yin J, 2017, CANCER RES, V77, P4973, DOI 10.1158/0008-5472.CAN-17-0388; Zhang H, 2016, CANCER RES, V76, P6410, DOI 10.1158/0008-5472.CAN-16-0595	60	2	2	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4352	4367		10.1038/s41388-021-01847-w	http://dx.doi.org/10.1038/s41388-021-01847-w		JUN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34103685	Green Published, hybrid			2022-12-28	WOS:000659032900003
J	Nathansen, J; Lukiyanchuk, V; Hein, L; Stolte, MI; Borgmann, K; Lock, S; Kurth, I; Baumann, M; Krause, M; Linge, A; Dubrovska, A				Nathansen, Jacqueline; Lukiyanchuk, Vasyl; Hein, Linda; Stolte, Maya-Isabel; Borgmann, Kerstin; Lock, Steffen; Kurth, Ina; Baumann, Michael; Krause, Mechthild; Linge, Annett; Dubrovska, Anna			Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L	ONCOGENE			English	Article							GOOD PROGNOSIS SUBGROUPS; POSTOPERATIVE RADIOCHEMOTHERAPY; HUMAN-PAPILLOMAVIRUS; MARKER EXPRESSION; DNA-DAMAGE; CANCER; CHK1; HPV; MULTICENTER; HNSCC	Head and neck squamous cell carcinoma (HNSCC) is often being diagnosed at an advanced stage, conferring a poor prognosis. The probability of local tumor control after radiotherapy depends on the eradication of cancer stem cells (CSCs) with activated DNA repair. This study provides evidence that the CSC-related transcription factor Oct4 contributes to HNSCC radioresistance by regulating DNA damage response and the CSC phenotype. Knockdown of Oct4 A isoform reduced self-renewal capacity in HNSCC and led to partial tumor cell radiosensitization caused by transcriptional downregulation of the cell cycle checkpoint kinases CHK1 and WEE1 and homologous recombination (HR) repair genes PSMC3IP and RAD54L. Besides, PARP inhibition with Olaparib selectively radiosensitized Oct4 A knockout, but not wild-type HNSCC cells. This finding links Oct4 A to the HR-mediated DNA repair mechanisms. In turn, knockdown of PSMC3IP and RAD54L reduced the HNSCC self-renewal capacity and clonogenic cell survival after irradiation, suggesting the interplay between DNA repair and the CSC phenotype. Similar to the effect of Oct4 knockdown, overexpression of Oct4 also resulted in significant HNSCC radiosensitization and increased DNA damage, suggesting that Oct4-dependent regulation of DNA repair depends on its fine-tuned expression. In line with this observation, HNSCC patients with high and low nuclear Oct4 expression at the invasive tumor front exhibited better loco-regional tumor control after postoperative radio(chemo)therapy compared to the intermediate expression subgroup. Thus, we found that the Oct4-driven transcriptional program plays a critical role in regulating HNSCC radioresistance, and a combination of radiotherapy with PARP inhibitors may induce synthetic lethality in Oct4-deregulated tumors.	[Nathansen, Jacqueline; Lukiyanchuk, Vasyl; Hein, Linda; Lock, Steffen; Kurth, Ina; Baumann, Michael; Krause, Mechthild; Linge, Annett; Dubrovska, Anna] Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, OncoRay Natl Ctr Radiat Res Oncol, Fac Med, Dresden, Germany; [Nathansen, Jacqueline; Lukiyanchuk, Vasyl; Hein, Linda; Lock, Steffen; Kurth, Ina; Baumann, Michael; Krause, Mechthild; Linge, Annett; Dubrovska, Anna] Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, Univ Hosp Carl Gustav Carus, Dresden, Germany; [Nathansen, Jacqueline; Lukiyanchuk, Vasyl; Krause, Mechthild; Dubrovska, Anna] Helmholtz Zentrum Dresden Rossendorf, Inst Radiooncol OncoRay, Dresden, Germany; [Stolte, Maya-Isabel; Borgmann, Kerstin] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Lab Radiobiol & Expt Radiooncol, Hamburg, Germany; [Lock, Steffen; Krause, Mechthild; Linge, Annett; Dubrovska, Anna] German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany; [Lock, Steffen; Kurth, Ina; Baumann, Michael; Krause, Mechthild; Linge, Annett; Dubrovska, Anna] German Canc Res Ctr, Heidelberg, Germany; [Lock, Steffen; Baumann, Michael; Krause, Mechthild; Linge, Annett] Tech Univ Dresden, Dept Radiotherapy & Radiat Oncol, Fac Med, Dresden, Germany; [Lock, Steffen; Baumann, Michael; Krause, Mechthild; Linge, Annett] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany; [Krause, Mechthild; Linge, Annett] Natl Ctr Tumor Dis NCT, Partner Site Dresden, Dresden, Germany; [Krause, Mechthild; Linge, Annett] Tech Univ Dresden, Fac Med, Dresden, Germany; [Krause, Mechthild; Linge, Annett] Helmholtz Zentrum Dresden Rossendorf HZDR, Dresden, Germany	Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Technische Universitat Dresden; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); University of Hamburg; University Medical Center Hamburg-Eppendorf; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Technische Universitat Dresden; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Technische Universitat Dresden; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR)	Linge, A; Dubrovska, A (corresponding author), Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, OncoRay Natl Ctr Radiat Res Oncol, Fac Med, Dresden, Germany.; Linge, A; Dubrovska, A (corresponding author), Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, Univ Hosp Carl Gustav Carus, Dresden, Germany.; Dubrovska, A (corresponding author), Helmholtz Zentrum Dresden Rossendorf, Inst Radiooncol OncoRay, Dresden, Germany.; Linge, A; Dubrovska, A (corresponding author), German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany.; Linge, A; Dubrovska, A (corresponding author), German Canc Res Ctr, Heidelberg, Germany.; Linge, A (corresponding author), Tech Univ Dresden, Dept Radiotherapy & Radiat Oncol, Fac Med, Dresden, Germany.; Linge, A (corresponding author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany.; Linge, A (corresponding author), Natl Ctr Tumor Dis NCT, Partner Site Dresden, Dresden, Germany.; Linge, A (corresponding author), Tech Univ Dresden, Fac Med, Dresden, Germany.; Linge, A (corresponding author), Helmholtz Zentrum Dresden Rossendorf HZDR, Dresden, Germany.	Annett.Linge@uniklinikum-dresden.de; a.dubrovska@hzdr.de		Kurth, Ina/0000-0001-9261-5165; Linge, Annett/0000-0001-9636-1721; Baumann, Michael/0000-0002-9340-974X	Deutsche Forschungsgemeinschaft (DFG) [SPP 2084, 401326337, 416001651]; Wilhelm Sander-Stiftung [2017.106.1]; BMBF [02NUK032, 02NUK035B, 03Z1NN11]; DFG [BO1868-5]; Hubertus Wald Stiftung; Hamburger Krebsgesellschaft e.V.	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Wilhelm Sander-Stiftung; BMBF(Federal Ministry of Education & Research (BMBF)); DFG(German Research Foundation (DFG)); Hubertus Wald Stiftung; Hamburger Krebsgesellschaft e.V.	We greatly appreciate Liane Stolz-Kieslich for her help with immunochistochemical staining, the members of the Group of Biomarkers for Individualized Radiotherapy for their critical reading of the manuscript and the team of The Core Facilities of the Technology Platform at BIOTEC TU Dresden for their constant technical support. Work in AD lab was partially supported by grants from Deutsche Forschungsgemeinschaft (DFG) (SPP 2084: mu BONE, 401326337 and 416001651), from Wilhelm Sander-Stiftung (2017.106.1) and BMBF (03Z1NN11). Work in KB lab was partially supported by DFG (BO1868-5) and BMBF (Grant 02NUK032 and 02NUK035B), Hubertus Wald Stiftung, and Hamburger Krebsgesellschaft e.V.	Akagi K, 2014, GENOME RES, V24, P185, DOI 10.1101/gr.164806.113; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartucci M, 2012, CELL DEATH DIFFER, V19, P768, DOI 10.1038/cdd.2011.170; Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419; Bertrand G, 2014, STEM CELL REV REP, V10, P114, DOI 10.1007/s12015-013-9467-y; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Butof R, 2013, RADIOTHER ONCOL, V108, P388, DOI 10.1016/j.radonc.2013.06.002; Carpen T, 2020, CANCER IMMUNOL IMMUN, V69, P1615, DOI 10.1007/s00262-020-02570-3; Chen YC, 2009, BIOCHEM BIOPH RES CO, V385, P307, DOI 10.1016/j.bbrc.2009.05.048; Chow LQM, 2020, NEW ENGL J MED, V382, P60, DOI 10.1056/NEJMra1715715; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Digomann D, 2019, CLIN CANCER RES, V25, P3152, DOI 10.1158/1078-0432.CCR-18-2951; Fong YW, 2013, MOL CELL, V52, P291, DOI 10.1016/j.molcel.2013.10.018; Gao Y, 2012, STEM CELLS, V30, P665, DOI 10.1002/stem.1034; Geissler C, 2012, IN VIVO, V26, P593; Hammachi F, 2012, CELL REPORTS, V1, P99, DOI 10.1016/j.celrep.2011.12.002; Hashibe M, 2009, CANCER EPIDEM BIOMAR, V18, P541, DOI 10.1158/1055-9965.EPI-08-0347; Heyer WD, 2006, NUCLEIC ACIDS RES, V34, P4115, DOI 10.1093/nar/gkl481; Jung JW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028068; Kagohara LT, 2020, BRIT J CANCER, V123, P101, DOI 10.1038/s41416-020-0851-5; Kim JY, 2018, INT J ONCOL, V53, P47, DOI 10.3892/ijo.2018.4391; Kim Ran-Ju, 2011, Lab Anim Res, V27, P147, DOI 10.5625/lar.2011.27.2.147; Kimple RJ, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.01.37; Kimple RJ, 2013, CANCER RES, V73, P4791, DOI 10.1158/0008-5472.CAN-13-0587; Koo BS, 2015, ONCOGENE, V34, P2317, DOI 10.1038/onc.2014.174; Krajewska M, 2013, ONCOGENE, V32, P3001, DOI 10.1038/onc.2012.296; Krause M, 2017, ADV DRUG DELIVER REV, V109, P63, DOI 10.1016/j.addr.2016.02.002; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Kurth I, 2015, ONCOTARGET, V6, P34494, DOI 10.18632/oncotarget.5417; Lee J, 2006, J BIOL CHEM, V281, P33554, DOI 10.1074/jbc.M603937200; Leemans CR, 2018, NAT REV CANCER, V18, P269, DOI 10.1038/nrc.2018.11; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Linge A, 2016, RADIOTHER ONCOL, V121, P364, DOI 10.1016/j.radonc.2016.11.008; Linge A, 2016, CLIN CANCER RES, V22, P2639, DOI 10.1158/1078-0432.CCR-15-1990; Liu C, 2020, ORAL ONCOL, V100, DOI 10.1016/j.oraloncology.2019.104469; Lohaus F, 2014, RADIOTHER ONCOL, V113, P317, DOI 10.1016/j.radonc.2014.11.011; Manic G, 2018, GUT, V67, P903, DOI 10.1136/gutjnl-2016-312623; Meng L, 2018, ONCOL LETT, V16, P522, DOI 10.3892/ol.2018.8607; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; O'Sullivan B, 2013, J CLIN ONCOL, V31, P543, DOI 10.1200/JCO.2012.44.0164; Peitzsch C, 2019, CANCERS, V11, DOI 10.3390/cancers11050616; Pezza RJ, 2014, NUCLEIC ACIDS RES, V42, P2346, DOI 10.1093/nar/gkt1234; Pitroda SP, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008291; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Rachmadi Lisnawati, 2019, Oman Med J, V34, P224, DOI 10.5001/omj.2019.43; Razzouk S, 2014, CLIN GENET, V86, P412, DOI 10.1111/cge.12487; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Ruan ZY, 2019, CANCER MANAG RES, V11, P389, DOI 10.2147/CMAR.S180418; Schulz A, 2019, CANCERS, V11, DOI 10.3390/cancers11060862; Shao MH, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3424956; Shi GL, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt39; Smith HL, 2020, EXPERT REV MOL MED, V22, DOI 10.1017/erm.2020.3; Song B, 2018, BIOCHEM BIOPH RES CO, V503, P1980, DOI 10.1016/j.bbrc.2018.07.145; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321; Trosko JE, 2019, CANCERS, V11, DOI 10.3390/cancers11010087; Vaddi PK, 2019, CANCERS, V11, DOI 10.3390/cancers11091331; Venkatesha VA, 2012, NEOPLASIA, V14, P519, DOI 10.1593/neo.12538; Ventela S, 2015, ONCOTARGET, V6, P144, DOI 10.18632/oncotarget.2670; Vitale I, 2017, MOL CELL, V66, P306, DOI 10.1016/j.molcel.2017.04.006; Wang X, 2009, STEM CELLS, V27, P1265, DOI 10.1002/stem.58; Wurster S, 2016, ONCOTARGET, V7, P9732, DOI 10.18632/oncotarget.6947; Yaromina A, 2007, RADIOTHER ONCOL, V83, P304, DOI 10.1016/j.radonc.2007.04.020; Zhang Y, 2019, J BONE MINER RES, V34, P2287, DOI 10.1002/jbmr.3857; Zhou YW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0606-x	67	10	10	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4214	4228		10.1038/s41388-021-01842-1	http://dx.doi.org/10.1038/s41388-021-01842-1		JUN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34079088	Green Published, hybrid			2022-12-28	WOS:000657217400009
J	Zhang, XL; Hu, LP; Yang, Q; Qin, WT; Wang, X; Xu, CJ; Tian, GA; Yang, XM; Yao, LL; Zhu, L; Nie, HZ; Li, Q; Xu, Q; Zhang, ZG; Zhang, YL; Li, J; Wang, YH; Jiang, SH				Zhang, Xue-Li; Hu, Li-Peng; Yang, Qin; Qin, Wei-Ting; Wang, Xu; Xu, Chun-Jie; Tian, Guang-Ang; Yang, Xiao-Mei; Yao, Lin-Li; Zhu, Lei; Nie, Hui-Zhen; Li, Qing; Xu, Qing; Zhang, Zhi-Gang; Zhang, Yan-Li; Li, Jun; Wang, Ya-Hui; Jiang, Shu-Heng			CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-beta receptors in colorectal cancer	ONCOGENE			English	Article							TRIPLE-HELIX REPEAT; TUMOR-ASSOCIATED MACROPHAGES; CELL; EXPRESSION; PROGRESSION; STATISTICS; MIGRATION; INVASION; GENES	Metastasis is a major cause of cancer-related deaths. Tumor-intrinsic properties can determine whether tumor metastasis occurs or not. Here, by comparing the gene expression patterns in primary colorectal cancer (CRC) patients with or without metastasis, we found that Collagen Triple Helix Repeat Containing 1 (CTHRC1) in primary CRC served as a metastasis-associated gene. Animal experiments verified that CTHRC1 secreted by CRC cells promoted hepatic metastasis, which was closely correlated with macrophage infiltration. Depletion of macrophages by liposomal clodronate largely abolished the promoting effect of CTHRC1 on CRC liver metastasis. Furthermore, we demonstrated that CTHRC1 modulated macrophage polarization to M2 phenotypes through TGF-beta signaling. A mechanistic study revealed that CTHRC1 bound directly to TGF-beta receptor II and TGF-beta receptor III, stabilized the TGF-beta receptor complex, and activated TGF-beta signaling. The combination treatment of CTHRC1 monoclonal antibody and anti-PD-1 blocking antibody effectively suppressed CRC hepatic metastasis. Taken together, our data demonstrated that CTHRC1 is an intrinsic marker of CRC metastasis and further revealed that CTHRC1 promoted CRC liver metastasis by reshaping infiltrated macrophages through TGF-beta signaling, suggesting that CTHRC1 could be a potential biomarker for the early prediction of and a therapeutic target of CRC hepatic metastasis.	[Zhang, Xue-Li; Hu, Li-Peng; Yang, Qin; Wang, Xu; Tian, Guang-Ang; Yang, Xiao-Mei; Yao, Lin-Li; Zhu, Lei; Nie, Hui-Zhen; Li, Qing; Zhang, Zhi-Gang; Zhang, Yan-Li; Li, Jun; Wang, Ya-Hui; Jiang, Shu-Heng] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Ren Ji Hosp,Shanghai Canc Inst, Shanghai, Peoples R China; [Qin, Wei-Ting] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Radiat Oncol, Shanghai, Peoples R China; [Xu, Chun-Jie; Xu, Qing] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Gastrointestinal Surg, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhang, YL; Li, J; Wang, YH; Jiang, SH (corresponding author), Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Ren Ji Hosp,Shanghai Canc Inst, Shanghai, Peoples R China.	ylzhang@shsci.org; junli@shsci.org; yhwang@shsci.org; shjiang@shsci.org		Zhang, Yan-Li/0000-0002-8942-5325; Zhang, Xueli/0000-0001-8306-0639; Wang, Xu/0000-0002-3768-777X	National Natural Science Foundation of China [81802890, 81902370, 81871923, 31801212, 81872242]; Natural Science Foundation of Shanghai [18ZR1436900]; Shanghai Municipal Health Commission [202040092, 202040104, 201740105]; Program of Shanghai Academic/Technology Research Leader [19XD1403400]; Shanghai International Science and Technology Cooperation Fund [18410721000]; Excellent Academic Leader of Shanghai Municipal Health Bureau [2018BR32]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20191809]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Shanghai Municipal Health Commission; Program of Shanghai Academic/Technology Research Leader; Shanghai International Science and Technology Cooperation Fund; Excellent Academic Leader of Shanghai Municipal Health Bureau; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support	This study was supported by the National Natural Science Foundation of China (No. 81802890 to X-LZ; No. 81902370 to S-HJ; No. 81871923 to JL; No. 31801212 to L-LY, No. 81872242 to Y-LZ), the Natural Science Foundation of Shanghai (No. 18ZR1436900 to X-LZ), the Shanghai Municipal Health Commission (No. 202040092 to X-LZ; No. 202040104, to Y-LZ; No. 201740105 to H-ZN), Program of Shanghai Academic/Technology Research Leader (No. 19XD1403400, to Z-GZ), Shanghai International Science and Technology Cooperation Fund (No. 18410721000, to Z-GZ), Excellent Academic Leader of Shanghai Municipal Health Bureau (No. 2018BR32, to Z-GZ), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20191809, to JL). We thank Dr Dong-Xue Li, Dr Shan Huang, Dr Li-li Zhu, Dr Shan Zhang, Yue Sun, and Kai-Xia Zhou for assistance with our experiments.	Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Chang GJ, 2007, J NATL CANCER I, V99, P433, DOI 10.1093/jnci/djk092; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Chen XF, 2018, INT J CANCER, V143, P2561, DOI 10.1002/ijc.31730; Chen YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070324; Chevrier S, 2017, CELL, V169, P736, DOI 10.1016/j.cell.2017.04.016; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Dehnel N, 2017, CURR OPIN PHARMACOL, V35, P12, DOI 10.1016/j.coph.2017.04.007; Dhupkar P, 2018, CANCER MED-US, V7, P2654, DOI 10.1002/cam4.1518; Gao B, 2016, INT J ONCOL, V49, P1108, DOI 10.3892/ijo.2016.3591; Gao Y, 2019, DEV CELL, V49, P375, DOI 10.1016/j.devcel.2019.04.012; Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396; Jiang N, 2016, J CANCER, V7, P2213, DOI 10.7150/jca.16539; Jin YR, 2017, BONE, V97, P153, DOI 10.1016/j.bone.2017.01.022; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Ki DH, 2007, INT J CANCER, V121, P2005, DOI 10.1002/ijc.22975; Kim HC, 2014, ONCOTARGET, V5, P519, DOI 10.18632/oncotarget.1714; Kim J, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6058147; Kim SK, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0319-y; Kimura H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003174; Leclere L, 2020, GENOME BIOL EVOL, V12, P3957, DOI 10.1093/gbe/evaa020; Li J, 2019, EBIOMEDICINE, V40, P43, DOI 10.1016/j.ebiom.2019.01.009; Li LY, 2019, CLIN EXP METASTAS, V36, P351, DOI 10.1007/s10585-019-09971-4; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Lind H, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000433; Lu D, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/1919082; Lu M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169439; Manfredi S, 2006, ANN SURG, V244, P254, DOI 10.1097/01.sla.0000217629.94941.cf; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Muller S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1362-4; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ni SJ, 2018, CANCER MED-US, V7, P5643, DOI 10.1002/cam4.1807; Obenauf AC, 2015, TRENDS CANCER, V1, P76, DOI 10.1016/j.trecan.2015.07.009; Park EH, 2013, CARCINOGENESIS, V34, P694, DOI 10.1093/carcin/bgs378; Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6; Perilli L, 2014, GENOM DATA, V2, P184, DOI 10.1016/j.gdata.2014.06.017; Pyagay P, 2005, CIRC RES, V96, P261, DOI 10.1161/01.RES.0000154262.07264.12; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Qian ZY, 2017, ONCOTARGET, V8, P25500, DOI 10.18632/oncotarget.16064; Qin S, 2019, BIOMED PHARMACOTHER, V113, DOI 10.1016/j.biopha.2019.01.055; Rivera LB, 2013, CANCER CELL, V24, P687, DOI 10.1016/j.ccr.2013.11.014; Santoni M, 2018, BBA-REV CANCER, V1869, P78, DOI 10.1016/j.bbcan.2017.10.007; Segnan N, 2017, CANCER-AM CANCER SOC, V123, P4767, DOI 10.1002/cncr.31032; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stange DE, 2010, GUT, V59, P1236, DOI 10.1136/gut.2009.195701; Takeshita S, 2013, J CLIN INVEST, V123, P3914, DOI 10.1172/JCI69493; Tang L, 2006, CLIN CANCER RES, V12, P3716, DOI 10.1158/1078-0432.CCR-06-0030; Vitale I, 2019, CELL METAB, V30, P36, DOI 10.1016/j.cmet.2019.06.001; Wang P, 2012, CANCER SCI, V103, P1327, DOI 10.1111/j.1349-7006.2012.02292.x; Xu CJ, 2017, BIOMED PHARMACOTHER, V91, P1167, DOI 10.1016/j.biopha.2017.05.056; Yamasaki M, 2007, INT J ONCOL, V30, P129; Yan L, 2015, AM J CANCER RES, V5, P1447; Yang XM, 2015, INT J CLIN EXP PATHO, V8, P12793; Zumsteg A, 2009, CURR OPIN ONCOL, V21, P60, DOI 10.1097/CCO.0b013e32831bed7e	56	14	15	7	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					3959	3973		10.1038/s41388-021-01827-0	http://dx.doi.org/10.1038/s41388-021-01827-0		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	33986509				2022-12-28	WOS:000650146400002
J	Li, M; Shi, MK; Hu, CY; Chen, BJ; Li, SF				Li, Ming; Shi, Minke; Hu, Chaoyue; Chen, Baojun; Li, Shufeng			MALAT1 modulated FOXP3 ubiquitination then affected GINS1 transcription and drived NSCLC proliferation	ONCOGENE			English	Article							LONG NONCODING RNA; DNA-REPLICATION; SUPPRESSIVE ACTIVITY; EXPRESSION; PROMOTES; PSF1; INHIBITION; CDC45; ASSOCIATION; METASTASIS	An increasing number of studies have shown that long-noncoding RNAs (lncRNAs) are involved in the post-translational modifications (PTMs) of protein in a variety of tumors. However, little is known about the exact regulation mechanism of lncRNAs in regulating PTMs in non-small-cell lung carcinoma (NSCLC) proliferation. Metastasis-associated lung adenocarcinoma transcript1 (MALAT1) and GINS complex subunit 1(GINS1) both were upregulated and promoted proliferation progression in NSCLC. In this study, the clinicopathologic significance of MALAT1 and GINS1 in NSCLC was investigated, a positive correlation in their expression was found. The silencing of MALAT1 decreased GINS1 expression and inhibited NSCLC proliferation in vitro and in vivo. The upregulation of GINS1 reversed NSCLC proliferation inhibited by MALAT1 knockdown. FOXP3 (forkhead box protein 3) was identified as the critical transcription factor for GINS1 transcription. In addition, MALAT1 could stabilize FOXP3 by binding to zinc finger (ZF) domain and leucine zipper (LZ) domain of FOXP3. Interestingly, these two domains were also interaction domains for FOXP3 binding with E3 ligase STUB1 (STIP1 homology and U-box containing protein 1). In this way, MALAT1 masked the protein-interacting domain, and inhibited FOXP3 ubiquitination by STUB1. Together, our results identified a novel regulatory axis of MALAT1-FOXP3-GINS1, and demonstrated that MALAT1 played an important modulatory role in PTM of FOXP3 which affects GINS1 transcription and drives proliferation character in NSCLC.	[Li, Ming; Li, Shufeng] Southeast Univ, Key Lab Dev Genes & Human Dis, Minist Educ, Dept Biochem & Mol Biol,Med Sch, Nanjing, Peoples R China; [Shi, Minke; Hu, Chaoyue; Chen, Baojun] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Thorac & Cardiovasc Surg, Nanjing, Peoples R China	Southeast University - China; Nanjing University	Li, SF (corresponding author), Southeast Univ, Key Lab Dev Genes & Human Dis, Minist Educ, Dept Biochem & Mol Biol,Med Sch, Nanjing, Peoples R China.	shufengli@seu.edu.cn		hu, chaoyue/0000-0002-3284-5636; Li, Shufeng/0000-0003-4857-4532; Li, Ming/0000-0001-9637-1030				Amodio N, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0606-4; Brown JA, 2016, P NATL ACAD SCI USA, V113, P14013, DOI 10.1073/pnas.1614759113; Chen L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0196-9; Chen RB, 2017, NUCLEIC ACIDS RES, V45, P9947, DOI 10.1093/nar/gkx600; Chen ZJ, 2013, IMMUNITY, V39, P272, DOI 10.1016/j.immuni.2013.08.006; Colamatteo A, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03136; Cottineau J, 2017, J CLIN INVEST, V127, P1991, DOI 10.1172/JCI90727; Cunha LL, 2012, CLINICS, V67, P483, DOI 10.6061/clinics/2012(05)13; Gambus A, 2006, NAT CELL BIOL, V8, P358, DOI 10.1038/ncb1382; Ilves I, 2010, MOL CELL, V37, P247, DOI 10.1016/j.molcel.2009.12.030; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Jia H, 2019, BBA-REV CANCER, V1871, P170, DOI 10.1016/j.bbcan.2018.12.004; Jiang RQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15129; Jin D, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0830-6; Kwon HS, 2012, J IMMUNOL, V188, P2712, DOI 10.4049/jimmunol.1100903; Li M, 2015, FEBS LETT, V589, P1018, DOI 10.1016/j.febslet.2015.03.004; Li SF, 2018, CANCER SCI, V109, P1346, DOI 10.1111/cas.13587; Li SF, 2015, J CANCER RES CLIN, V141, P1909, DOI 10.1007/s00432-015-1951-0; Li ZY, 2015, CELL MOL IMMUNOL, V12, P558, DOI 10.1038/cmi.2015.10; Lian YF, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20181178; Liu NA, 2017, NUCLEIC ACIDS RES, V45, P6051, DOI 10.1093/nar/gkx141; Liu YJ, 2013, NAT MED, V19, P1173, DOI 10.1038/nm.3286; Loo CS, 2020, IMMUNITY, V53, P143, DOI 10.1016/j.immuni.2020.06.011; Ma HL, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6985031; Ma XD, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122997; Malakar P, 2019, CANCER RES, V79, P2480, DOI 10.1158/0008-5472.CAN-18-1432; Masai H, 2010, ANNU REV BIOCHEM, V79, P89, DOI 10.1146/annurev.biochem.052308.103205; Nakahara I, 2010, GENES CELLS, V15, P1015, DOI 10.1111/j.1365-2443.2010.01442.x; Song XM, 2012, CELL REPORTS, V1, P665, DOI 10.1016/j.celrep.2012.04.012; Srinivasan SV, 2013, CELL REP, V3, P1629, DOI 10.1016/j.celrep.2013.04.002; Stamato MA, 2017, ONCOTARGET, V8, P106527, DOI 10.18632/oncotarget.22507; Szylberg L, 2016, ANTICANCER RES, V36, P3789; Tahara H, 2015, PROSTATE CANCER P D, V18, P56, DOI 10.1038/pcan.2014.46; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; Tang L, 2019, CLIN TRANSL ONCOL, V21, P1624, DOI 10.1007/s12094-019-02090-2; Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011; Ueno M, 2005, MOL CELL BIOL, V25, P10528, DOI 10.1128/MCB.25.23.10528-10532.2005; van Loosdregt J, 2010, BLOOD, V115, P965, DOI 10.1182/blood-2009-02-207118; Wang W, 2016, ONCOTARGET, V7, P25668, DOI 10.18632/oncotarget.8257; Wang XC, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0144-8; Yang SC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0700-1; Yu T, 2017, CANCER RES, V77, P5782, DOI 10.1158/0008-5472.CAN-17-0671; Yu WW, 2019, ONCOGENE, V38, P1225, DOI 10.1038/s41388-018-0463-1; Zhang A, 2015, CELL REP, V13, P209, DOI 10.1016/j.celrep.2015.08.069; Zhang JY, 2015, TUMOR BIOL, V36, P2163, DOI 10.1007/s13277-014-2826-8; Zhang XJ, 2017, RNA BIOL, V14, P1705, DOI 10.1080/15476286.2017.1358347	46	8	8	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3870	3884		10.1038/s41388-021-01816-3	http://dx.doi.org/10.1038/s41388-021-01816-3		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33972684				2022-12-28	WOS:000648930100001
J	Kang, X; Li, WL; Liu, WX; Liang, H; Deng, JY; Wong, CC; Zhao, SN; Kang, W; To, KF; Chiu, PWY; Wang, GY; Yu, J; Ng, EKW				Kang, Xi; Li, Weilin; Liu, Weixin; Liang, Han; Deng, Jingyu; Wong, Chi Chun; Zhao, Sinan; Kang, Wei; To, Ka Fai; Chiu, Philip Wai Yan; Wang, Guiying; Yu, Jun; Ng, Enders Kwok Wai			LIMK1 promotes peritoneal metastasis of gastric cancer and is a therapeutic target	ONCOGENE			English	Article							ACTIVATION; KINASES	Peritoneal metastasis is a common form of metastasis among advanced gastric cancer patients. In this study, we reported the identification of LIM domain kinase 1 (LIMK1) as a promoter of gastric cancer peritoneal metastasis, and its potential to be a therapeutic target of dabrafenib (DAB). Using transcriptomic sequencing of paired gastric cancer peritoneal metastasis, primary tumors, and normal gastric tissues, we first unveiled that LIMK1 is selectively up-regulated in metastatic tumors. Increased LIMK1 in gastric cancer peritoneal metastasis was validated by immunohistochemistry analysis of an independent patient cohort. In vitro functional studies demonstrated that LIMK1 knockout or knockdown significantly inhibited cell migration and invasion of gastric cancer cells. LIMK1 knockout also abrogated peritoneal and liver metastases of gastric cancer cells in nude mice in vivo. Dabrafenib, a small molecule targeting LIMK1, was found to decrease cell migration and invasion of gastric cancer cells in vitro and abolish peritoneal and liver metastasis formation in vivo. Mechanistically, either LIMK1 knockout or Dabrafenib inhibited LIMK1 expression and phosphorylation of its downstream target cofilin. Taken together, our results demonstrated that LIMK1 functions as a metastasis promoter in gastric cancer by inhibiting LIMK1-p-cofilin and that Dabrafenib has the potential to serve as a novel treatment for gastric cancer peritoneal metastasis.	[Kang, Xi; Li, Weilin; Liu, Weixin; Wong, Chi Chun; Zhao, Sinan; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Peoples R China; [Kang, Xi; Li, Weilin; Liu, Weixin; Wong, Chi Chun; Zhao, Sinan; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China; [Kang, Xi; Wang, Guiying] Hebei Med Univ, Dept Surg, Hosp 4, Shijiazhuang, Hebei, Peoples R China; [Li, Weilin; Chiu, Philip Wai Yan; Ng, Enders Kwok Wai] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China; [Liang, Han; Deng, Jingyu] Tianjin Med Univ Canc Hosp, Dept Gastroenterol, City Key Lab Tianjin Canc Ctr, Tianjin, Peoples R China; [Liang, Han; Deng, Jingyu] Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Zhao, Sinan] Hebei Med Univ, Dept Endocrinol, Hosp 2, Shijiazhuang, Hebei, Peoples R China; [Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Hebei Medical University; Chinese University of Hong Kong; Tianjin Medical University; Hebei Medical University; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China.; Wang, GY (corresponding author), Hebei Med Univ, Dept Surg, Hosp 4, Shijiazhuang, Hebei, Peoples R China.; Ng, EKW (corresponding author), Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China.	wangguiyingtgzy@163.com; junyu@cuhk.edu.hk; endersng@surgery.cuhk.edu.hk	KANG, Wei/C-5451-2016; Chiu, Philip/ABB-1454-2020; Li, Weilin/ABG-9032-2021	KANG, Wei/0000-0002-4651-677X; Chiu, Philip/0000-0001-9292-112X; Wong, Chi Chun/0000-0003-1362-3541	National Natural Science Foundation of China (NSFC) [81772501, 81972576]; RGC-CRF Hong Kong [C7065-18G]; CUHK; Shenzhen Virtual University Park Support Scheme;  [MOST-2016YFC1303200]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); RGC-CRF Hong Kong; CUHK(Chinese University of Hong Kong); Shenzhen Virtual University Park Support Scheme; 	This project was supported by research funds from MOST-2016YFC1303200; National Natural Science Foundation of China (NSFC) (81772501, 81972576); RGC-CRF Hong Kong (C7065-18G); Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.	[Anonymous], 2015, JINHUA WANG NG DABRA; Bell R, 2017, CURR MOL MED, V17, P200, DOI 10.2174/1566524017666170807144946; Bernard O, 2007, INT J BIOCHEM CELL B, V39, P1071, DOI 10.1016/j.biocel.2006.11.011; Cejalvo JM, 2017, CANCER RES, V77, P2213, DOI 10.1158/0008-5472.CAN-16-2717; CHAN DYS, 2017, J GASTROINTEST SURG; Chen PX, 2014, ONCOL REP, V32, P2070, DOI 10.3892/or.2014.3461; COOLEN M, 2009, CURR OPIN NEUROBIOL; Dal Bo M, 2016, LEUKEMIA, V30, P2011, DOI 10.1038/leu.2016.88; Davidson B, 2014, HUM PATHOL, V45, P691, DOI 10.1016/j.humpath.2013.11.003; DEDRICK RL, 1978, CANCER TREAT REP, V62, P1; FIFE CM, 2014, BRIT J PHARMACOL; Fu JJ, 2018, PHYTOMEDICINE, V49, P23, DOI 10.1016/j.phymed.2018.06.009; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; GlaxoSmithKline, 2013, TAFINLAR DABRAFENIB; Gu Y, 2018, TRANSL ONCOL, V11, P1012, DOI 10.1016/j.tranon.2018.06.003; Henderson BW, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw9318; HOHMANN D, 2019, CELLS-BASEL; HSIEH SHK, 2006, J NEUROSCI; Ishizone S, 2006, CHEMOTHERAPY, V52, P301, DOI 10.1159/000096002; Kobayashi D, 2017, GASTRIC CANCER, V20, pS111, DOI 10.1007/s10120-016-0662-9; LEE SY, 2017, PHARM RES; LIM MK, 2007, EXP CELL RES; LING H, 2020, INT J ONCOL; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MASHIACHFARKASH E, 2012, ONCOTARGET; McConnell BV, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-75; MENG Y, 2002, NEURON; PAGET S, 1989, CANCER METAST REV, V8, P98; Pierce A, 2008, EUR J CANCER, V44, P151, DOI 10.1016/j.ejca.2007.10.017; Pirini F, 2017, ONCOTARGET, V8, P38501, DOI 10.18632/oncotarget.16258; PUSZKIEL A, 2019, CLIN PHARMACOKINET; Rak, 2014, ONCOSCIENCE, DOI 10.18632/oncoscience.7; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rawla P, 2019, GASTROENTEROL REV, V14, P26, DOI 10.5114/pg.2018.80001; SCHRATT GM, 2006, NATURE; SESHADRI RA, 2016, WORLD J GASTROENTERO; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; SU J, 2017, SCI REP-UK, V7; Sugarbaker Paul H, 2003, Semin Surg Oncol, V21, P233, DOI 10.1002/ssu.10042; SUN F, 2017, ONCOL LETT; Tang YY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0825-x; Thomassen I, 2014, INT J CANCER, V134, P622, DOI 10.1002/ijc.28373; TURSUN B, 2005, GENE DEV; Wang Z, 2019, WORLD J SURG ONCOL, V17, DOI 10.1186/s12957-019-1761-y; YU Q, 2018, BRIT J PHARMACOL; Zhou Y, 2013, ONCOL REP, V29, P394, DOI 10.3892/or.2012.2115	46	13	13	7	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3422	3433		10.1038/s41388-021-01656-1	http://dx.doi.org/10.1038/s41388-021-01656-1		APR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33883692	hybrid, Green Published			2022-12-28	WOS:000642072200001
J	Liu, JY; Huang, Z; Chen, HN; Qin, SY; Chen, Y; Jiang, JW; Zhang, Z; Luo, MC; Ye, Q; Xie, N; Zhou, ZG; Wei, YQ; Xie, K; Huang, CH				Liu, Jiayang; Huang, Zhao; Chen, Hai-Ning; Qin, Siyuan; Chen, Yan; Jiang, Jingwen; Zhang, Zhe; Luo, Maochao; Ye, Qin; Xie, Na; Zhou, Zong-Guang; Wei, Yuquan; Xie, Ke; Huang, Canhua			ZNF37A promotes tumor metastasis through transcriptional control of THSD4/TGF-beta axis in colorectal cancer	ONCOGENE			English	Article							DIFFERENTIATION	Poorly differentiated colorectal cancer (CRC) is characterized by aggressive invasion and stromal fibroblast activation, which results in rapid progression and poor therapeutic consequences. However, the regulatory mechanism involved remains unclear. Here, we showed that ZNF37A, a member of KRAB-ZFP family, was upregulated in poorly differentiated CRCs and associated with tumor metastasis. ZNF37A enhanced the metastatic potential of multiple CRC cell lines and promoted distant metastasis in an orthotopic CRC model. Further investigation attributed the ZNF37A-exacerbated metastasis to increased extracellular TGF-beta and the consequent activation of cancer-associated fibroblasts (CAFs) in tumor microenvironment (TME). Mechanistically, ZNF37A formed a complex with KAP1 and bound to the promoter of THSD4, a TME modulator, to suppress its transcription, which is required for ZNF37A-mediated TGF-beta activation and CRC metastasis. Collectively, our study indicates that ZNF37A promotes TGF-beta signaling in CRC cells and activates CAFs by transcriptionally repressing THSD4 to drive CRC metastasis, implicating ZNF37A as a potential biomarker for CRC differentiation and progression.	[Liu, Jiayang; Huang, Zhao; Qin, Siyuan; Chen, Yan; Jiang, Jingwen; Zhang, Zhe; Luo, Maochao; Wei, Yuquan; Huang, Canhua] West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China; [Liu, Jiayang; Huang, Zhao; Qin, Siyuan; Chen, Yan; Jiang, Jingwen; Zhang, Zhe; Luo, Maochao; Wei, Yuquan; Huang, Canhua] West China Hosp, Ctr Canc, Chengdu, Peoples R China; [Liu, Jiayang; Huang, Zhao; Qin, Siyuan; Chen, Yan; Jiang, Jingwen; Zhang, Zhe; Luo, Maochao; Wei, Yuquan; Huang, Canhua] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu, Peoples R China; [Liu, Jiayang; Huang, Zhao; Qin, Siyuan; Chen, Yan; Jiang, Jingwen; Zhang, Zhe; Luo, Maochao; Wei, Yuquan; Huang, Canhua] Collaborat Innovat Ctr Biotherapy, Chengdu, Peoples R China; [Chen, Hai-Ning; Zhou, Zong-Guang] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Gastrointestinal Surg, Chengdu, Peoples R China; [Chen, Hai-Ning; Zhou, Zong-Guang] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China; [Ye, Qin; Xie, Ke] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Dept Oncol, Chengdu, Sichuan, Peoples R China; [Ye, Qin; Xie, Ke] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu, Sichuan, Peoples R China; [Xie, Na] Sichuan Univ, West China Hosp, West China Sch Basic Med Sci & Forens Med, Chengdu, Peoples R China; [Xie, Na] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China; [Xie, Na] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China; [Xie, Na] Collaborat Innovat Ctr Biotherapy, Chengdu, Peoples R China; [Huang, Canhua] Chengdu Univ Tradit Chinese Med, Sch Basic Med Sci, Chengdu, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China; Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China; Sichuan University; Sichuan University; Sichuan University; Chengdu University of Traditional Chinese Medicine	Huang, CH (corresponding author), West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China.; Huang, CH (corresponding author), West China Hosp, Ctr Canc, Chengdu, Peoples R China.; Huang, CH (corresponding author), Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu, Peoples R China.; Huang, CH (corresponding author), Collaborat Innovat Ctr Biotherapy, Chengdu, Peoples R China.; Xie, K (corresponding author), Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Dept Oncol, Chengdu, Sichuan, Peoples R China.; Xie, K (corresponding author), Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu, Sichuan, Peoples R China.; Huang, CH (corresponding author), Chengdu Univ Tradit Chinese Med, Sch Basic Med Sci, Chengdu, Sichuan, Peoples R China.	mei97@sina.com; hcanhua@hotmail.com	Jiang, Jing wen/AAP-5996-2021; Chen, Hai-Ning/AAR-8059-2021	Chen, Hai-Ning/0000-0003-0104-8498; Huang, Zhao/0000-0001-9994-2070; , Zongguang/0000-0002-7616-1199	Guangdong Basic and Applied Basic Research Foundation [2019B030302012]; National Key RAMP;D Program of China [2020YFA0509400, 2020YFC2002700]; Chinese NSFC [81821002, 81672867, 81790251, 81702378]; China Postdoctoral Science Foundation [2019T120845, 2018M643496]	Guangdong Basic and Applied Basic Research Foundation; National Key RAMP;D Program of China; Chinese NSFC(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by grants from Guangdong Basic and Applied Basic Research Foundation (2019B030302012), National Key R&D Program of China (2020YFA0509400, 2020YFC2002700), the Chinese NSFC (nos 81821002, 81672867, 81790251, 81702378) and China Postdoctoral Science Foundation (2019T120845, 2018M643496).	Adamski V, 2020, ONCOGENE, V39, P4421, DOI 10.1038/s41388-020-1302-8; Aiello NM, 2019, J EXP MED, V216, P1016, DOI 10.1084/jem.20181827; Alexandre C., 2015, NAT GENET, V47; Alonso-Alconada L, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-223; Andre T, 2015, J CLIN ONCOL, V33, P4176, DOI 10.1200/JCO.2015.63.4238; Arendt D, 2016, NAT REV GENET, V17, P744, DOI 10.1038/nrg.2016.127; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Berg KCG, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0691-y; Chakravarthy A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06654-8; Cohen H, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0464-0; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; Derwinger K, 2010, ACTA ONCOL, V49, P57, DOI 10.3109/02841860903334411; Ecco G, 2017, DEVELOPMENT, V144, P2719, DOI 10.1242/dev.132605; Fleming M, 2012, J GASTROINTEST ONCOL, V3, P153, DOI 10.3978/j.issn.2078-6891.2012.030; Gauthier M, 2013, HUM MOL GENET, V22, P5188, DOI 10.1093/hmg/ddt373; Gremel G, 2015, J GASTROENTEROL, V50, P46, DOI 10.1007/s00535-014-0958-7; Guo Z, 2017, NUCLEIC ACIDS RES, V46, P1266; Iwafuchi-Doi M, 2014, GENE DEV, V28, P2679, DOI 10.1101/gad.253443.114; Jung B, 2017, GASTROENTEROLOGY, V152, P36, DOI 10.1053/j.gastro.2016.10.015; Kobayashi H, 2019, NAT REV GASTRO HEPAT, V16, P282, DOI 10.1038/s41575-019-0115-0; Koliaraki V, 2017, GASTROENTEROLOGY, V152, P964, DOI 10.1053/j.gastro.2016.11.049; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Li HP, 2017, NAT GENET, V49, P708, DOI 10.1038/ng.3818; Liu R, 2013, CANCER RES, V73, P5926, DOI 10.1158/0008-5472.CAN-12-4718; McCarthy N, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3272; Nathan RW., 2015, NAT REV IMMUNOL, V15; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171; Robertson IB, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021907; Saito M, 2011, J BIOL CHEM, V286, P38602, DOI 10.1074/jbc.M111.243451; Schmitges FW, 2016, GENOME RES, V26, P1742, DOI 10.1101/gr.209643.116; Tada Y, 2015, ONCOGENE, V34, P752, DOI 10.1038/onc.2013.599; Takahashi K, 2016, NAT REV MOL CELL BIO, V17, P183, DOI 10.1038/nrm.2016.8; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Tauriello DVF, 2016, TRENDS CANCER, V2, P495, DOI 10.1016/j.trecan.2016.08.001; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Tsutsui K, 2010, J BIOL CHEM, V285, P4870, DOI 10.1074/jbc.M109.076919; Valkenburg KC, 2018, NAT REV CLIN ONCOL, V15, P366, DOI 10.1038/s41571-018-0007-1; Wu D, 2016, HEPATOLOGY, V64, P1148, DOI 10.1002/hep.28708; Yau C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2753; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	45	6	6	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3394	3407		10.1038/s41388-021-01713-9	http://dx.doi.org/10.1038/s41388-021-01713-9		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33875786				2022-12-28	WOS:000641218600005
J	Puhr, M; Eigentler, A; Handle, F; Hackl, H; Ploner, C; Heidegger, I; Schaefer, G; Brandt, MP; Hoefer, J; Van der Pluijm, G; Klocker, H				Puhr, Martin; Eigentler, Andrea; Handle, Florian; Hackl, Hubert; Ploner, Christian; Heidegger, Isabel; Schaefer, Georg; Brandt, Maximilian P.; Hoefer, Julia; Van der Pluijm, Gabri; Klocker, Helmut			Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer	ONCOGENE			English	Article								Despite increasing options for treatment of castration-resistant prostate cancer, development of drug resistance is inevitable. The glucocorticoid receptor (GR) is a prime suspect for acquired therapy resistance, as prostate cancer (PCa) cells are able to increase GR signaling during anti-androgen therapy and thereby circumvent androgen receptor (AR)-blockade and cell death. As standard AR-directed therapies fail to block the GR and GR inhibitors might result in intolerable side effects, the identification of GR signature genes, which are better suited for a targeted approach, is of clinical importance. Therefore, the specific epithelial and stromal GR signature was determined in cancer-associated fibroblasts as well as in abiraterone and enzalutamide-resistant cells after glucocorticoid (GC) treatment. Microarray and ChIP analysis identified MAO-A as a directly up-regulated mutual epithelial and stromal GR target, which is induced after GC treatment and during PCa progression. Elevated MAO-A levels were confirmed in in vitro cell models, in primary tissue cultures after GC treatment, and in patients after neoadjuvant chemotherapy with GCs. MAO-A expression correlates with GR/AR activity as well as with a reduced progression-free survival. Pharmacological MAO-A inhibition combined with 2(nd) generation AR signaling inhibitors or chemotherapeutics results in impaired growth of androgen-dependent, androgen-independent, and long-term anti-androgen-treated cells. In summary, these findings demonstrate that targeting MAO-A represents an innovative therapeutic strategy to synergistically block GR and AR dependent PCa cell growth and thereby overcome therapy resistance.	[Puhr, Martin; Eigentler, Andrea; Handle, Florian; Heidegger, Isabel; Hoefer, Julia; Klocker, Helmut] Med Univ Innsbruck, Dept Urol, Innsbruck, Austria; [Hackl, Hubert] Med Univ Innsbruck, Bioctr, Inst Bioinformat, Innsbruck, Austria; [Ploner, Christian] Med Univ Innsbruck, Dept Plast Reconstruct & Aesthet Surg Innsbruck, Innsbruck, Austria; [Schaefer, Georg] Med Univ Innsbruck, Dept Pathol, Innsbruck, Austria; [Brandt, Maximilian P.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Urol, Mainz, Germany; [Van der Pluijm, Gabri] Leiden Univ, Med Ctr, Dept Urol, Leiden, Netherlands	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Johannes Gutenberg University of Mainz; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Puhr, M (corresponding author), Med Univ Innsbruck, Dept Urol, Innsbruck, Austria.	martin.puhr@i-med.ac.at	Hackl, Hubert/B-3168-2018	Hackl, Hubert/0000-0003-4055-3841; van der Pluijm, Gabri/0000-0002-1351-1884; Handle, Florian/0000-0002-7558-5635; Ploner, Christian/0000-0002-0313-2960	Anniversary Fund of the Oesterreichische Nationalbank (OeNB) [18280]	Anniversary Fund of the Oesterreichische Nationalbank (OeNB)	This study was supported by the Anniversary Fund of the Oesterreichische Nationalbank (OeNB), grant number 18280 to MP.	Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Courcot E, 2012, DRUG METAB DISPOS, V40, P1953, DOI 10.1124/dmd.112.046896; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Finberg JPM, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00340; Fizazi K, 2019, NEW ENGL J MED, V380, P1235, DOI 10.1056/NEJMoa1815671; Gaur S, 2019, PROSTATE, V79, P667, DOI 10.1002/pros.23774; Geney R, 2002, CLIN CHEM LAB MED, V40, P918, DOI 10.1515/CCLM.2002.161; Gordon RR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104271; Grupp K, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-145; Handle F, 2018, MOL CANCER THER, V17, P2722, DOI 10.1158/1535-7163.MCT-18-0508; Heidenreich A, 2014, EUR J CANCER, V50, P1090, DOI 10.1016/j.ejca.2014.01.006; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hunter P, 2010, EMBO REP, V11, P667, DOI 10.1038/embor.2010.122; Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536; Kalsbeek AMF, 2016, AGING-US, V8, P2702, DOI 10.18632/aging.101044; Kluetz PG, 2013, CLIN CANCER RES, V19, P6650, DOI 10.1158/1078-0432.CCR-13-2134; Kroon J, 2016, ENDOCR-RELAT CANCER, V23, P35, DOI 10.1530/ERC-15-0343; Lempiainen JK, 2017, MOL CELL PROTEOMICS, V16, P1462, DOI 10.1074/mcp.M117.067488; Leon-Mateos L, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072066; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Liao CP, 2018, ONCOGENE, V37, P5175, DOI 10.1038/s41388-018-0325-x; Luo F., 2020, NAT MED, P1, DOI [DOI 10.1038/S41591-020-0897-1, 10.1038/s41591-020-0897-1]; Luo JH, 2002, MOL CARCINOGEN, V33, P25, DOI 10.1002/mc.10018; Meyer JH, 2006, ARCH GEN PSYCHIAT, V63, P1209, DOI 10.1001/archpsyc.63.11.1209; Ndibe C, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-014-0320-6; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Puhr M, 2018, CLIN CANCER RES, V24, P927, DOI 10.1158/1078-0432.CCR-17-0989; Puhr M, 2012, AM J PATHOL, V181, P2188, DOI 10.1016/j.ajpath.2012.08.011; Schopf B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15237-5; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Small EJ, 2015, CLIN CANCER RES, V21, P3862, DOI 10.1158/1078-0432.CCR-15-0079; Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Vanaja DK, 2003, CANCER RES, V63, P3877; Wang KL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15396-5; Welsh JB, 2001, CANCER RES, V61, P5974; Wu JB, 2017, CANCER CELL, V31, P368, DOI 10.1016/j.ccell.2017.02.003; Wu JB, 2014, J CLIN INVEST, V124, P2891, DOI 10.1172/JCI70982; Yin LJ, 2018, STEM CELLS, V36, P1249, DOI 10.1002/stem.2831	42	7	7	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3087	3100		10.1038/s41388-021-01754-0	http://dx.doi.org/10.1038/s41388-021-01754-0		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33795839	Green Published, hybrid			2022-12-28	WOS:000635873300001
J	Zhao, LN; Bjorklund, M; Caldez, MJ; Zheng, J; Kaldis, P				Zhao, Li Na; Bjorklund, Mikael; Caldez, Matias J.; Zheng, Jie; Kaldis, Philipp			Therapeutic targeting of the mitochondrial one-carbon pathway: perspectives, pitfalls, and potential	ONCOGENE			English	Review							SERINE; METHOTREXATE; METABOLISM; GLYCINE; FOLATE; PROLIFERATION; MECHANISMS; EXPRESSION; INHIBITOR	Most of the drugs currently prescribed for cancer treatment are riddled with substantial side effects. In order to develop more effective and specific strategies to treat cancer, it is of importance to understand the biology of drug targets, particularly the newly emerging ones. A comprehensive evaluation of these targets will benefit drug development with increased likelihood for success in clinical trials. The folate-mediated one-carbon (1C) metabolism pathway has drawn renewed attention as it is often hyperactivated in cancer and inhibition of this pathway displays promise in developing anticancer treatment with fewer side effects. Here, we systematically review individual enzymes in the 1C pathway and their compartmentalization to mitochondria and cytosol. Based on these insight, we conclude that (1) except the known 1C targets (DHFR, GART, and TYMS), MTHFD2 emerges as good drug target, especially for treating hematopoietic cancers such as CLL, AML, and T-cell lymphoma; (2) SHMT2 and MTHFD1L are potential drug targets; and (3) MTHFD2L and ALDH1L2 should not be considered as drug targets. We highlight MTHFD2 as an excellent therapeutic target and SHMT2 as a complementary target based on structural/biochemical considerations and up-to-date inhibitor development, which underscores the perspectives of their therapeutic potential.	[Zhao, Li Na; Kaldis, Philipp] Lund Univ, Dept Clin Sci, Malmo, Sweden; [Bjorklund, Mikael] Zhejiang Univ Univ Edinburgh ZJU UoE Inst, Haining, Zhejiang, Peoples R China; [Bjorklund, Mikael] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Bjorklund, Mikael] Univ Edinburgh, Coll Med & Vet Med, Dept Biomed Sci, Edinburgh, Midlothian, Scotland; [Caldez, Matias J.] Osaka Univ, World Premier Int Res Ctr Initiat WPI, Immunol Frontier Res Ctr IFReC, Lab Host Def, Osaka, Japan; [Zheng, Jie] Shanghai Tech Univ, Sch Informat Sci & Technol, Shanghai, Peoples R China	Lund University; Zhejiang University; University of Edinburgh; Osaka University; ShanghaiTech University	Zhao, LN; Kaldis, P (corresponding author), Lund Univ, Dept Clin Sci, Malmo, Sweden.	lina.zhao@med.lu.se; philipp.kaldis@med.lu.se	Zhao, Lina/GVR-7716-2022; Kaldis, Philipp/G-2714-2010	Kaldis, Philipp/0000-0002-7247-7591; ZHAO, LINA/0000-0001-6552-0929	A*STAR International Fellowship (AIF) from Singapore; IngaBritt och Arne Lundbergs Forskningsstiftelse [LU2020-0013]; Faculty of Medicine, Lund University; Swedish Foundation for Strategic Research [IRC15-0067]; Swedish Research Council, Strategic Research Area EXODIAB [2009-1039]	A*STAR International Fellowship (AIF) from Singapore; IngaBritt och Arne Lundbergs Forskningsstiftelse; Faculty of Medicine, Lund University; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Research Council, Strategic Research Area EXODIAB(Swedish Research Council)	LNZ was supported by an A*STAR International Fellowship (AIF) from Singapore. This work is supported by the IngaBritt och Arne Lundbergs Forskningsstiftelse LU2020-0013; PK is supported by the Faculty of Medicine, Lund University; the Swedish Foundation for Strategic Research Dnr IRC15-0067, and Swedish Research Council, Strategic Research Area EXODIAB, Dnr 2009-1039. LNZ would like to thank Prof. Chew Lock Yue (NTU) and Prof. Ulf Ryde (LU) for comments on the manuscript.	Agapakis CM, 2012, NAT CHEM BIOL, V8, P527, DOI [10.1038/NCHEMBIO.975, 10.1038/nchembio.975]; Agarwal PK, 2002, P NATL ACAD SCI USA, V99, P2794, DOI 10.1073/pnas.052005999; Agarwal S, 2019, TRANSL ONCOL, V12, P1461, DOI 10.1016/j.tranon.2019.07.011; Alberts B., 2014, MOL BIOL CELL; Albrecht K, 2010, CLIN EXP RHEUMATOL, V28, pS95; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Anderson DD, 2012, J BIOL CHEM, V287, P4790, DOI 10.1074/jbc.M111.302174; Anderson DD, 2011, P NATL ACAD SCI USA, V108, P15163, DOI 10.1073/pnas.1103623108; Anderson DD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005839; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; ASAI A, 2018, CELL PHYSIOL BIOCHEM, V4; Balut C, 2008, KIDNEY INT, V73, P226, DOI 10.1038/sj.ki.5002632; Bertino JR, 1996, STEM CELLS, V14, P5, DOI 10.1002/stem.140005; Bolusani S, 2011, J BIOL CHEM, V286, P5166, DOI 10.1074/jbc.M110.196840; Boron WF, 2004, ADV PHYSIOL EDUC, V28, P160, DOI 10.1152/advan.00045.2004; Brodsky G, 1997, HUM MOL GENET, V6, P2043, DOI 10.1093/hmg/6.12.2043; Bronder JL, 2002, CANCER RES, V62, P5236; Burda P, 2015, J INHERIT METAB DIS, V38, P863, DOI 10.1007/s10545-015-9810-3; Burdelski C, 2015, ONCOTARGET, V6, P8377, DOI 10.18632/oncotarget.3107; CALVERT AH, 1986, J CLIN ONCOL, V4, P1245, DOI 10.1200/JCO.1986.4.8.1245; Cario H, 2011, AM J HUM GENET, V88, P226, DOI 10.1016/j.ajhg.2011.01.007; Carver JR, 2013, SEMIN ONCOL, V40, P229, DOI 10.1053/j.seminoncol.2013.01.005; Chan ESL, 2010, NAT REV RHEUMATOL, V6, P175, DOI 10.1038/nrrheum.2010.5; Chattopadhyay S, 2007, MOL CANCER THER, V6, P404, DOI 10.1158/1535-7163.MCT-06-0343; Chen D, 2017, J BIOL CHEM, V292, P13449, DOI 10.1074/jbc.M117.787267; Choi YK, 2018, BIOMOL THER, V26, P19, DOI 10.4062/biomolther.2017.178; Chu E, 2003, CANCER CHEMOTH PHARM, V52, pS80, DOI 10.1007/s00280-003-0625-9; CYBULSKI RL, 1976, BIOCHEMISTRY-US, V15, P3183, DOI 10.1021/bi00660a004; Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36; Deis SM, 2016, BIOCHEMISTRY-US, V55, P4574, DOI 10.1021/acs.biochem.6b00412; Di Pietro E, 2002, MOL CELL BIOL, V22, P4158, DOI 10.1128/MCB.22.12.4158-4166.2002; DUCH DS, 1993, CANCER RES, V53, P810; Ducker GS, 2016, CELL METAB, V23, P1140, DOI 10.1016/j.cmet.2016.04.016; Eich ML, 2019, TRANSL ONCOL, V12, P1416, DOI 10.1016/j.tranon.2019.07.012; Estrada A, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a028324; Fadaka A., 2017, J ONCOLOGICAL SCI, V3, P45, DOI [10.1016/j.jons.2017.06.002, DOI 10.1016/J.JONS.2017.06.002]; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; Florio R, 2011, BBA-PROTEINS PROTEOM, V1814, P1489, DOI 10.1016/j.bbapap.2010.10.010; Fox JT, 2008, VITAM HORM, V79, P1, DOI 10.1016/S0083-6729(08)00401-9; Frantz MC, 2010, ENVIRON MOL MUTAGEN, V51, P462, DOI 10.1002/em.20554; FU C, 2017, CANCER RES, V8; Giardina G, 2015, FEBS J, V282, P1225, DOI 10.1111/febs.13211; Gu YL, 2017, ONCOL RES, V25, P1069, DOI 10.3727/096504016X14829256525028; Guiducci G, 2019, NUCLEIC ACIDS RES, V47, P4240, DOI 10.1093/nar/gkz129; Gustafsson R, 2017, CANCER RES, V77, P937, DOI 10.1158/0008-5472.CAN-16-1476; Hu Y., 2018, FASEB J, V32, P49, DOI [10.1096/fj.201701480R, DOI 10.1096/FJ.201701480R]; Huang X, 2010, BIOCHEMISTRY-US, V49, P2475, DOI 10.1021/bi901457e; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Ju H.Q., 2018, JNCI-J NATL CANCER I; KAWAI J, 2019, J MED CHEM; Kawai J, 2019, ACS MED CHEM LETT, V10, P893, DOI 10.1021/acsmedchemlett.9b00069; KIT S, 1955, CANCER RES, V15, P715; KOSEKI J, 2018, ONCOL RES, V8; KOTOULA V, 2012, AM J HUM GENET, V12; Koufaris C, 2018, CANCER METAB, V6, DOI 10.1186/s40170-018-0185-4; Kremer JM, 2004, ARTHRITIS RHEUM-US, V50, P1370, DOI 10.1002/art.20278; Kreuzaler P, 2020, MOL METAB, V33, P83, DOI 10.1016/j.molmet.2019.08.021; Krupenko NI, 2010, J BIOL CHEM, V285, P23054, DOI 10.1074/jbc.M110.128843; Kujovich JL, 2016, OBSTET GYN CLIN N AM, V43, P247, DOI 10.1016/j.ogc.2016.01.009; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Lee D, 2017, J CLIN INVEST, V127, P1856, DOI 10.1172/JCI90253; Lee GY, 2014, CANCER RES, V74, P3114, DOI 10.1158/0008-5472.CAN-13-2683; Lin H, 2018, CELL PHYSIOL BIOCHEM, V51, P991, DOI 10.1159/000495402; Lin JG, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1214-z; Liu Y, 2019, EUR REV MED PHARMACO, V23, P9379, DOI 10.26355/eurrev_201911_19431; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Lovelace LL, 2009, PROTEIN SCI, V18, P1628, DOI 10.1002/pro.171; LUCAS S, 2018, NATURE, V1; Marani M, 2016, ONCOTARGET, V7, P4570, DOI 10.18632/oncotarget.6726; McGuirk S, 2020, TRENDS CANCER, V6, P49, DOI 10.1016/j.trecan.2019.11.009; Medwig-Kinney TN, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.185850; MEJIA NR, 1988, BIOCHEM BIOPH RES CO, V155, P1, DOI 10.1016/S0006-291X(88)81040-4; MEJIA NR, 1985, J BIOL CHEM, V260, P4616; Minton DR, 2018, MOL CELL, V69, P610, DOI 10.1016/j.molcel.2018.01.024; Momb J, 2013, P NATL ACAD SCI USA, V110, P549, DOI 10.1073/pnas.1211199110; Morscher RJ, 2018, NATURE, V554, P128, DOI 10.1038/nature25460; Nagura E, 1988, Gan To Kagaku Ryoho, V15, P2882; New Antifolates in Clinical Development, CANC NETWORK; Nilsson R, 2019, GENE, V716, DOI 10.1016/j.gene.2019.144032; NILSSON R, 2014, ONCOL LETT, V5; Ning SL, 2018, GASTROENT RES PRACT, V2018, DOI 10.1155/2018/4369253; Nishimura T, 2019, ONCOGENE, V38, P2464, DOI 10.1038/s41388-018-0589-1; Noguchi K, 2018, ONCOL LETT, V16, P1827, DOI 10.3892/ol.2018.8795; NONAKA H, 2019, ONCOTARGET, V10; Organista-Nava J, 2018, ONCOL LETT, V15, P8405, DOI 10.3892/ol.2018.8429; Patel H, 2003, J BIOL CHEM, V278, P19436, DOI 10.1074/jbc.M301718200; Patel Samir N, 2005, Expert Rev Anti Infect Ther, V3, P849, DOI 10.1586/14787210.3.6.849; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; PERI KG, 1993, BIOCHIM BIOPHYS ACTA, V1171, P281, DOI 10.1016/0167-4781(93)90066-M; Peters EJ, 2009, PHARMACOGENET GENOM, V19, P399, DOI 10.1097/FPC.0b013e328329fdec; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; Pikman Y, 2016, J EXP MED, V213, P1285, DOI 10.1084/jem.20151574; Prasannan P, 2003, J BIOL CHEM, V278, P43178, DOI 10.1074/jbc.M304319200; Purcell W Thomas, 2003, Curr Oncol Rep, V5, P114, DOI 10.1007/s11912-003-0098-3; Rabinowitz, 2017, CELL METAB, V25, P27, DOI 10.1016/j.cmet.2016.08.009; Raimondi MV, 2019, MOLECULES, V24, DOI 10.3390/molecules24061140; Rajagopalan PTR, 2002, P NATL ACAD SCI USA, V99, P13481, DOI 10.1073/pnas.172501499; RIOSORLANDI EM, 1988, J BIOL CHEM, V263, P4662; Robert F, 2004, J CLIN ONCOL, V22, p213S; Sarret C, 2019, NPJ GENOM MED, V4, DOI 10.1038/s41525-019-0092-9; Schober AF, 2019, CELL REP, V27, P3359, DOI 10.1016/j.celrep.2019.05.030; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; Sdelci S, 2019, NAT GENET, V51, P990, DOI 10.1038/s41588-019-0413-z; SHEPPARD NG, 2015, CANCER METAB, V5; Shih C, 1997, CANCER RES, V57, P1116; Shin M, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0173-0; Shin M, 2014, J BIOL CHEM, V289, P15507, DOI 10.1074/jbc.M114.555573; Shiratori R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55296-3; Shirmanova MV, 2015, BBA-GEN SUBJECTS, V1850, P1905, DOI 10.1016/j.bbagen.2015.05.001; Sneader W, 2005, DRUG DISCOVERY: A HISTORY, P1, DOI 10.1002/0470015535; SNELL K, 1989, CANCER LETT, V44, P217, DOI 10.1016/0304-3835(89)90064-5; Srinivasan B, 2015, FEBS J, V282, P1922, DOI 10.1111/febs.13244; STOVER P, 1991, J BIOL CHEM, V266, P1543; Stover PJ, 1997, J BIOL CHEM, V272, P1842, DOI 10.1074/jbc.272.3.1842; TANI H, 2018, CANCER RES, V8; Tedeschi PM, 2015, MOL CANCER RES, V13, P1361, DOI 10.1158/1541-7786.MCR-15-0117; Toriello HV, 2005, GENET MED, V7, P283, DOI 10.1097/00125817-200504000-00009; Toyama BH, 2013, NAT REV MOL CELL BIO, V14, P55, DOI 10.1038/nrm3496; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; VAZQUEZ A, 2011, GENOME BIOL, V6; Vazquez A, 2013, CANCER RES, V73, P478, DOI 10.1158/0008-5472.CAN-12-3709; Wang H, 2020, BIOL RES, V53, DOI 10.1186/s40659-020-00314-2; Wang JJ, 2015, ONCOL LETT, V9, P940, DOI 10.3892/ol.2014.2773; Wang WY, 2018, EUR J MED CHEM, V158, P502, DOI 10.1016/j.ejmech.2018.09.027; Wang Y, 2006, CURR CANCER THER REV, V2, P271, DOI 10.2174/157339406777934717; Webber S, 1996, CANCER CHEMOTH PHARM, V37, P509, DOI 10.1007/s002800050422; Welin M, 2010, NUCLEIC ACIDS RES, V38, P7308, DOI 10.1093/nar/gkq595; White KA, 2017, J CELL SCI, V130, P663, DOI 10.1242/jcs.195297; Wojtuszkiewicz A, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0158-9; Woo CC, 2016, ONCOTARGET, V7, P53005, DOI 10.18632/oncotarget.10415; Wrobel A, 2020, J ANTIBIOT, V73, P5, DOI 10.1038/s41429-019-0240-6; Wu M, 2017, ONCOTARGETS THER, V10, P3781, DOI 10.2147/OTT.S130409; Xu TY, 2019, AM J CANCER RES, V9, P250; Yan Y, 2019, CLIN EXP PHARMACOL P, V46, P928, DOI 10.1111/1440-1681.13125; Yang X, 2018, CANCER RES, V78, P372, DOI 10.1158/0008-5472.CAN-17-1912; Yeh ETH, 2004, CIRCULATION, V109, P3122, DOI 10.1161/01.CIR.0000133187.74800.B9; Yu C, 2020, J CELL MOL MED, V24, P1568, DOI 10.1111/jcmm.14844; Yuthavong Y, 2012, P NATL ACAD SCI USA, V109, P16823, DOI 10.1073/pnas.1204556109; ZACHARIAE H, 1990, BRIT J DERMATOL, V122, P127, DOI 10.1111/j.1365-2133.1990.tb02890.x; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	140	11	11	6	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2339	2354		10.1038/s41388-021-01695-8	http://dx.doi.org/10.1038/s41388-021-01695-8		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33664451				2022-12-28	WOS:000625833000002
J	Fan, QH; Gong, TT; Zheng, CN; Ng, JMY; Chen, JQ; Myers, C; Hensley, H; Curran, T; Yang, ZJ				Fan, Qianhai; Gong, Tingting; Zheng, Chaonan; Ng, Jessica M. Y.; Chen, Jianquan; Myers, Cynthia; Hensley, Harvey; Curran, Tom; Yang, Zeng-jie			Statins repress hedgehog signaling in medulloblastoma with no bone toxicities	ONCOGENE			English	Article							SERUM CONCENTRATIONS; GROWTH-PLATE; CHOLESTEROL; REDUCTASE; PATHWAY; INHIBITORS; CHILDREN; CELLS; DIFFERENTIATION; CHONDROCYTES	The Hedgehog (Hh) pathway plays an indispensable role in bone development and genetic activation of the pathway results in medulloblastoma (MB), the most common malignant brain tumor in children. Inhibitors of Hh pathway (such as vismodegib and sonedigib), which are used to treat MB, cause irreversible defects in bone growth in young children. Cholesterol is required for the activation of the Hh pathway, and statins, inhibitors of cholesterol biosynthesis, suppress MB growth by repressing Hh signaling in tumor cells. Here, we investigate the role of cholesterol biosynthesis in the proliferation and Hh signaling in chondrocytes, and examine the bone development in mice after statin treatment. Statins significantly inhibited MB growth in young mice, but caused no defects in bone development. Conditional deletion of NADP steroid dehydrogenase-like (NSDHL), an enzyme necessary for cholesterol biosynthesis, suppressed cholesterol synthesis in chondrocytes, and disrupted the growth plate in mouse femur and tibia, indicating the important function of intracellular cholesterol in bone development. Hh pathway activation and the proliferation of chondrocytes were inhibited by statin treatment in vitro; however, statins did not impair bone growth in vivo due to insufficient penetration into the bone. Our studies reveal a critical role of cholesterol in bone development, and support the utilization of statins for treatment of MB as well as other Hh pathway-associated malignancies.	[Fan, Qianhai; Zheng, Chaonan] Soochow Univ, Coll Pharmaceut Sci, Pediat Canc Ctr, Suzhou 215007, Jiangsu, Peoples R China; [Fan, Qianhai; Yang, Zeng-jie] Temple Univ Hlth Syst, Fox Chase Canc Ctr, Canc Biol Program, Philadelphia, PA 19140 USA; [Gong, Tingting; Chen, Jianquan] Soochow Univ, Med Coll, Orthoped Inst, Suzhou 215007, Jiangsu, Peoples R China; [Ng, Jessica M. Y.; Curran, Tom] Childrens Mercy Kansas City, Childrens Res Inst, Kansas City, MO USA; [Myers, Cynthia] Temple Univ Hlth Syst, Fox Chase Canc Ctr, Organ Synth Facil, Philadelphia, PA USA; [Hensley, Harvey] Temple Univ Hlth Syst, Fox Chase Canc Ctr, Small Anim Imaging Facil, Philadelphia, PA USA	Soochow University - China; Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Soochow University - China; Children's Mercy Hospital; Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Yang, ZJ (corresponding author), Temple Univ Hlth Syst, Fox Chase Canc Ctr, Canc Biol Program, Philadelphia, PA 19140 USA.	zengjie.yang@fccc.edu	Curran, Thomas/AAE-7631-2019	Curran, Thomas/0000-0003-1444-7551	American Cancer Society [RSG1605301NEC]; American Brain Tumor Association [DG1900025]; PA CURE Health Research Fund [CURE 4100068716]; National Natural Science Foundation of China [81803616]; Natural Science Foundation of Jiangsu Higher Education Institutions [18KJB350010]	American Cancer Society(American Cancer Society); American Brain Tumor Association; PA CURE Health Research Fund; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Higher Education Institutions	We would like to thank Drs. Andrey Efimov, Kathy Cai, Dusica Cvetkovic, and James Oesterling for technical assistance; and Drs. Maike Sander, Joan Font-Burgada, and Sergei Grivenniko for providing transgenic mice. This research was supported by American Cancer Society (RSG1605301NEC to Z.-j.Y.), American Brain Tumor Association (DG1900025 to Z.-j.Y.), PA CURE Health Research Fund (CURE 4100068716 to Z.-j.Y.), National Natural Science Foundation of China (81803616 to C.Z.), and the Natural Science Foundation of Jiangsu Higher Education Institutions (18KJB350010 to C.Z.).	Atwood SX, 2015, CANCER CELL, V27, P342, DOI 10.1016/j.ccell.2015.02.002; Bosnakovski D, 2006, BIOTECHNOL BIOENG, V93, P1152, DOI 10.1002/bit.20828; Byrne EFX, 2016, NATURE, V535, P517, DOI 10.1038/nature18934; Cavalli FMG, 2017, CANCER CELL, V31, P737, DOI 10.1016/j.ccell.2017.05.005; Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140-6736(00)02400-4; Cunningham D, 2015, HUM MOL GENET, V24, P2808, DOI 10.1093/hmg/ddv042; Curran T, 2018, OPEN BIOL, V8, DOI 10.1098/rsob.180098; DUGGAN DE, 1990, DRUG METAB REV, V22, P333, DOI 10.3109/03602539009041088; Gajjar A, 2013, CLIN CANCER RES, V19, P6305, DOI 10.1158/1078-0432.CCR-13-1425; Gofflot F, 2003, HUM MOL GENET, V12, P1187, DOI 10.1093/hmg/ddg129; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gordon RE, 2018, CLIN CANCER RES, V24, P1375, DOI 10.1158/1078-0432.CCR-17-2923; Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95; Haraguchi R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235840; He LY, 2018, METHODS MOL BIOL, V1711, P351, DOI 10.1007/978-1-4939-7493-1_17; Hedger G, 2019, STRUCTURE, V27, P549, DOI 10.1016/j.str.2018.11.003; Hovestadt V, 2020, NAT REV CANCER, V20, P42, DOI 10.1038/s41568-019-0223-8; Huang PX, 2016, CELL, V166, P1176, DOI 10.1016/j.cell.2016.08.003; Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216; Ianevski A, 2020, BIOINFORMATICS, V36, P2645, DOI 10.1093/bioinformatics/btaa102; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Kalliokoski A, 2009, BRIT J PHARMACOL, V158, P693, DOI 10.1111/j.1476-5381.2009.00430.x; Kan C, 2018, BONE, V109, P71, DOI 10.1016/j.bone.2017.06.014; Kantola T, 1998, CLIN PHARMACOL THER, V63, P397, DOI 10.1016/S0009-9236(98)90034-0; Kellick KA, 2014, J CLIN LIPIDOL, V8, pS30, DOI 10.1016/j.jacl.2014.02.010; Kieran MW, 2017, NEURO-ONCOLOGY, V19, P1542, DOI 10.1093/neuonc/nox109; Kimura H, 2008, CANCER CELL, V13, P249, DOI 10.1016/j.ccr.2008.01.027; Konig A, 2000, AM J MED GENET, V90, P339; Kopp JL, 2011, DEVELOPMENT, V138, P653, DOI 10.1242/dev.056499; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Kusters DM, 2014, JAMA-J AM MED ASSOC, V312, P1055, DOI 10.1001/jama.2014.8892; LAUGHLIN RC, 1962, JAMA-J AM MED ASSOC, V181, P339, DOI 10.1001/jama.1962.03050300059020a; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Lee Y, 2007, ONCOGENE, V26, P6442, DOI 10.1038/sj.onc.1210467; Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5; Lilja JJ, 1998, CLIN PHARMACOL THER, V64, P477, DOI 10.1016/S0009-9236(98)90130-8; Liu XY, 1999, NAT GENET, V22, P182, DOI 10.1038/9700; Long FX, 2001, DEVELOPMENT, V128, P5099; Luchetti G, 2016, ELIFE, V5, DOI 10.7554/eLife.20304; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002-220682; Maeda Y, 2007, P NATL ACAD SCI USA, V104, P6382, DOI 10.1073/pnas.0608449104; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Myers BR, 2017, P NATL ACAD SCI USA, V114, pE11141, DOI 10.1073/pnas.1717891115; Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Ohba S, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4020020; Robinson GW, 2017, ONCOTARGET, V8, P69295, DOI 10.18632/oncotarget.20619; Rocha VZ, 2018, J CLIN LIPIDOL, V12, P12, DOI 10.1016/j.jacl.2017.11.007; Roth M, 2012, BRIT J PHARMACOL, V165, P1260, DOI 10.1111/j.1476-5381.2011.01724.x; ROUX C, 1980, J NUTR, V110, P2310, DOI 10.1093/jn/110.11.2310; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x; Schwalbe EC, 2017, LANCET ONCOL, V18, P958, DOI 10.1016/S1470-2045(17)30243-7; Sharpe HJ, 2015, CANCER CELL, V27, P327, DOI 10.1016/j.ccell.2015.02.001; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Suzuki A, 2020, BONE RES, V8, DOI 10.1038/s41413-019-0078-3; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Tsushima H, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.162396; Wang PS, 2000, JAMA-J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211; Wu SF, 2004, J BIOL CHEM, V279, P4642, DOI 10.1074/jbc.M305518200; Xu RS, 2018, BONE RES, V6, DOI 10.1038/s41413-018-0034-7; Yadav B, 2015, COMPUT STRUCT BIOTEC, V13, P504, DOI 10.1016/j.csbj.2015.09.001; Yang J, 2015, INT J ORAL SCI, V7, P73, DOI 10.1038/ijos.2015.14; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003	65	5	5	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2258	2272		10.1038/s41388-021-01701-z	http://dx.doi.org/10.1038/s41388-021-01701-z		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33649536				2022-12-28	WOS:000623739900007
J	Koschut, D; Ray, D; Li, ZH; Giarin, E; Groet, J; Alic, I; Kham, SKY; Chng, WJ; Ariffin, H; Weinstock, DM; Yeoh, AEJ; Basso, G; Nizetic, D				Koschut, David; Ray, Debleena; Li, Zhenhua; Giarin, Emanuela; Groet, Jurgen; Alic, Ivan; Kham, Shirley Kow-Yin; Chng, Wee Joo; Ariffin, Hany; Weinstock, David M.; Yeoh, Allen Eng-Juh; Basso, Giuseppe; Nizetic, Dean			RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia	ONCOGENE			English	Article								Leukemias are routinely sub-typed for risk/outcome prediction and therapy choice using acquired mutations and chromosomal rearrangements. Down syndrome acute lymphoblastic leukemia (DS-ALL) is characterized by high frequency of CRLF2-rearrangements, JAK2-mutations, or RAS-pathway mutations. Intriguingly, JAK2 and RAS-mutations are mutually exclusive in leukemic sub-clones, causing dichotomy in therapeutic target choices. We prove in a cell model that elevated CRLF2 in combination with constitutionally active JAK2 is sufficient to activate wtRAS. On primary clinical DSALL samples, we show that wtRAS-activation is an obligatory consequence of mutated/hyperphosphorylated JAK2. We further prove that CRLF2-ligand TSLP boosts the direct binding of active PTPN11 to wtRAS, providing the molecular mechanism for the wtRAS activation. Pre-inhibition of RAS or PTPN11, but not of PI3K or JAK-signaling, prevented TSLP-induced RAS-GTP boost. Cytotoxicity assays on primary clinical DS-ALL samples demonstrated that, regardless of mutation status, high-risk leukemic cells could only be killed using RAS-inhibitor or PTPN11-inhibitor, but not PI3K/JAK-inhibitors, suggesting a unified treatment target for up to 80% of DS-ALL. Importantly, protein activities-based principal-component-analysis multivariate clusters analyzed for independent outcome prediction using Cox proportional-hazards model showed that protein-activity (but not mutation-status) was independently predictive of outcome, demanding a paradigm-shift in patient-stratification strategy for precision therapy in high-risk ALL.	[Koschut, David; Ray, Debleena; Alic, Ivan; Nizetic, Dean] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore; [Li, Zhenhua; Kham, Shirley Kow-Yin] Natl Univ Singapore, Dept Paediat, Yong Loo Lin Sch Med, Singapore, Singapore; [Giarin, Emanuela; Basso, Giuseppe] Univ Padua, Dept Womens & Childrens Hlth SDB, Hematol Oncol Lab, Padua, Italy; [Groet, Jurgen; Nizetic, Dean] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England; [Alic, Ivan] Univ Zagreb, Fac Vet Med, Dept Anat Histol & Embryol, Zagreb, Croatia; [Chng, Wee Joo; Yeoh, Allen Eng-Juh] Natl Univ Canc Inst, Singapore, Singapore; [Ariffin, Hany] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia; [Weinstock, David M.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Basso, Giuseppe] Italian Inst Genom Med, Turin, Italy	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore; University of Padua; University of London; Queen Mary University London; University of Zagreb; National University of Singapore; Universiti Malaya; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Italian Institute for Genomic Medicine (IIGM)	Nizetic, D (corresponding author), Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.	d.nizetic@qmul.ac.uk	ARIFFIN, HANY/B-8590-2010	ARIFFIN, HANY/0000-0002-4607-8837; Nizetic, Dean/0000-0001-5486-5761; Koschut, David/0000-0003-2204-5165; Ray, Debleena/0000-0002-8232-4062; Alic, Ivan/0000-0002-8125-8198; Li, Zhenhua/0000-0002-3623-6571	Singapore Ministry of Education Academic Research Funds Tier 2 grants [2015-T2-2-119, 2015-T2-1-023]; AIRC [IG 19186]; Fondazione Cariparo [17/07]	Singapore Ministry of Education Academic Research Funds Tier 2 grants; AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Cariparo(Fondazione Cariparo)	Singapore Ministry of Education Academic Research Funds Tier 2 grants (2015-T2-2-119 and 2015-T2-1-023) to DN; AIRC IG 19186 and Fondazione Cariparo 17/07 to GB.	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bercovich D, 2008, LANCET, V372, P1484, DOI 10.1016/S0140-6736(08)61341-0; Berger R, 1997, CANCER GENET CYTOGEN, V94, P8, DOI 10.1016/S0165-4608(96)00351-2; Bhojwani D, 2013, LANCET ONCOL, V14, pE205, DOI 10.1016/S1470-2045(12)70580-6; Buitenkamp TD, 2014, BLOOD, V123, P70, DOI 10.1182/blood-2013-06-509463; Bunda S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9859; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; De Vita S, 2007, BRIT J HAEMATOL, V137, P337, DOI 10.1111/j.1365-2141.2007.06574.x; Den Boer ML, 2009, LANCET ONCOL, V10, P125, DOI 10.1016/S1470-2045(08)70339-5; Groet J, 2003, LANCET, V361, P1617, DOI 10.1016/S0140-6736(03)13266-7; Harrison CJ, 2013, HEMATOL-AM SOC HEMAT, P118, DOI 10.1182/asheducation-2013.1.118; Hasle H, 2016, GENET MED, V18, P1151, DOI 10.1038/gim.2016.23; Hobbs GA, 2016, J CELL SCI, V129, P1287, DOI 10.1242/jcs.182873; Holmfeldt L, 2013, NAT GENET, V45, P242, DOI 10.1038/ng.2532; Hunger SP, 2015, BLOOD, V125, P3977, DOI 10.1182/blood-2015-02-580043; Inaba H, 2013, LANCET, V381, P1943, DOI 10.1016/S0140-6736(12)62187-4; Knight T, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00160; Laurent AP, 2020, CLIN CANCER RES, V26, P3307, DOI 10.1158/1078-0432.CCR-19-3519; Lee P, 2016, LEUKEMIA, V30, P1816, DOI 10.1038/leu.2016.164; McMahon LP, 2005, MOL ENDOCRINOL, V19, P175, DOI 10.1210/me.2004-0305; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Mohi MG, 1998, MOL BIOL CELL, V9, P3299, DOI 10.1091/mbc.9.12.3299; Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253; Nguyen K, 2008, LEUKEMIA, V22, P2142, DOI 10.1038/leu.2008.251; Nikolaev SI, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5654; Nikolaev SI, 2013, BLOOD, V122, P554, DOI 10.1182/blood-2013-03-491936; Nizetic D, 2012, NAT REV CANCER, V12, P721, DOI 10.1038/nrc3355; Norton A, 2007, BLOOD, V110, P1077, DOI 10.1182/blood-2007-03-080374; Paulsson K, 2008, GENE CHROMOSOME CANC, V47, P26, DOI 10.1002/gcc.20502; Potter N, 2019, LEUKEMIA, V33, P893, DOI 10.1038/s41375-018-0297-4; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Pui CH, 2015, J CLIN ONCOL, V33, P2938, DOI 10.1200/JCO.2014.59.1636; Roberts KG, 2018, BEST PRACT RES CL HA, V31, P351, DOI 10.1016/j.beha.2018.09.003; Roberts KG, 2017, BLOOD ADV, V1, P1657, DOI 10.1182/bloodadvances.2017011296; Roberts KG, 2015, NAT REV CLIN ONCOL, V12, P344, DOI 10.1038/nrclinonc.2015.38; Roberts KG, 2012, CANCER CELL, V22, P153, DOI 10.1016/j.ccr.2012.06.005; Russell LJ, 2009, BLOOD, V114, P2688, DOI 10.1182/blood-2009-03-208397; Ryan SL, 2016, LEUKEMIA, V30, P1824, DOI 10.1038/leu.2016.80; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Schwartzman O, 2017, P NATL ACAD SCI USA, V114, pE4030, DOI 10.1073/pnas.1702489114; Tasian SK, 2017, BLOOD, V130, P2064, DOI 10.1182/blood-2017-06-743252; Tasian SK, 2017, BLOOD, V129, P177, DOI 10.1182/blood-2016-05-707653; Tasian SK, 2012, BLOOD, V120, P833, DOI 10.1182/blood-2011-12-389932; Thompson BJ, 2015, J EXP MED, V212, P723, DOI 10.1084/jem.20150002; Vyas P, 2006, EARLY HUM DEV, V82, P767, DOI 10.1016/j.earlhumdev.2006.09.016; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Yamamoto T, 2006, LEUKEMIA RES, V30, P1085, DOI 10.1016/j.leukres.2006.02.004; Yeoh AEJ, 2018, J CLIN ONCOL, V36, P2726, DOI 10.1200/JCO.2018.78.3050; Yeoh AEJ, 2012, J CLIN ONCOL, V30, P2384, DOI 10.1200/JCO.2011.40.5936; Yoda A, 2010, P NATL ACAD SCI USA, V107, P252, DOI 10.1073/pnas.0911726107	50	3	3	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					746	762		10.1038/s41388-020-01567-7	http://dx.doi.org/10.1038/s41388-020-01567-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RA8FZ	33247204	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000631656200001
J	Lu, YW; Li, XD; Liu, HL; Xue, J; Zeng, Z; Dong, XR; Zhang, T; Wu, G; Yang, KY; Xu, SB				Lu, Yanwei; Li, Xudong; Liu, Hongli; Xue, Jun; Zeng, Zhen; Dong, Xiaorong; Zhang, Tao; Wu, Gang; Yang, Kunyu; Xu, Shuangbing			beta-Trcp and CK1 delta-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma	ONCOGENE			English	Article							ZIPPER TUMOR-SUPPRESSOR; UBIQUITIN LIGASE; MEDIATED DEGRADATION; RADIORESISTANCE; PROLIFERATION; PROTEINS; CATENIN; FAMILY; EXPORT	Distant metastasis is the leading cause of treatment failure in patients with hepatocellular carcinoma (HCC). However, the underlying mechanisms have not been fully elucidated. Here, we report that Leucine zipper tumor suppressor 2 (LZTS2) is downregulated and correlated with poor prognosis in HCC. Furthermore, we provide evidence that LZTS2 associates with p85 to inhibit the activation of PI3K/AKT signaling and impairs HCC tumorigenesis and metastasis in vitro and in vivo. Moreover, we identify LZTS2 as a bona fide substrate of the E3 ligase beta-Trcp and protein kinase CK1 delta, which are responsible for the ubiquitination and degradation of LZTS2. Importantly, we show that the beta-Trcp and CK1 delta-mediated degradation of LZTS2 promotes HCC progression and metastasis by activating PI3K/AKT signaling. Collectively, our study not only illustrates the roles of LZTS2 in regulating HCC tumorigenesis and metastasis but also reveals a novel posttranslational modification of LZTS2 by beta-Trcp and CK1 delta, indicating that the beta-Trcp/CK1 delta/LZTS2/PI3K axis may be a novel oncogenic driver involved in HCC progression and metastasis.	[Lu, Yanwei; Li, Xudong; Liu, Hongli; Xue, Jun; Zeng, Zhen; Dong, Xiaorong; Zhang, Tao; Wu, Gang; Yang, Kunyu; Xu, Shuangbing] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan 430022, Peoples R China	Huazhong University of Science & Technology	Wu, G; Yang, KY; Xu, SB (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan 430022, Peoples R China.	xhzlwg@163.com; yangky71@aliyun.com; xsb723@hust.edu.cn		Xu, Shuangbing/0000-0002-9166-7788	Hubei Provincial Natural Science Fund for Distinguished Young Scholars [2019CFA063]; National Natural Science Foundation of China [81874041]; Wuhan Science and Technology Bureau [2019020701011437]	Hubei Provincial Natural Science Fund for Distinguished Young Scholars; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Wuhan Science and Technology Bureau	This work was supported by the Hubei Provincial Natural Science Fund for Distinguished Young Scholars (2019CFA063 to SX), the National Natural Science Foundation of China (81874041 to SX), and the grants from the Wuhan Science and Technology Bureau (2019020701011437 to SX).	Asrani SK, 2019, J HEPATOL, V70, P151, DOI 10.1016/j.jhep.2018.09.014; Buetow L, 2016, NAT REV MOL CELL BIO, V17, P626, DOI 10.1038/nrm.2016.91; Cabeza-Arvelaiz Y, 2001, ONCOGENE, V20, P6707, DOI 10.1038/sj.onc.1204866; Cui QZ, 2013, J HISTOCHEM CYTOCHEM, V61, P659, DOI 10.1369/0022155413495875; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Huang LY., 2018, NAT COMMUN, V9; Huang YM, 2018, THERANOSTICS, V8, P1286, DOI 10.7150/thno.22552; Johnson DT, 2013, J BIOL CHEM, V288, P3727, DOI 10.1074/jbc.M112.417568; Kim JM, 2011, MOL CELL BIOCHEM, V346, P125, DOI 10.1007/s11010-010-0599-y; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Li YY, 2011, J BIOL CHEM, V286, P45116, DOI 10.1074/jbc.M111.267328; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Lu YW, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.434; Ma J, 2018, CELL DEATH DIFFER, V25, P1473, DOI 10.1038/s41418-017-0055-6; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Peng Y, 2011, J BIOL CHEM, V286, P40331, DOI 10.1074/jbc.M111.302059; Rosenberg LH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac8773; Senft D, 2018, NAT REV CANCER, V18, P69, DOI 10.1038/nrc.2017.105; Shaik S, 2012, J EXP MED, V209, P1289, DOI 10.1084/jem.20112446; Shen ZS, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1349-y; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Thyssen G, 2006, MOL CELL BIOL, V26, P8857, DOI 10.1128/MCB.01031-06; Wang ZF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7833; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Wen W, 2012, HEPATOLOGY, V55, P1787, DOI 10.1002/hep.25596; Xie J, 2018, THERANOSTICS, V8, P650, DOI 10.7150/thno.21963; Xu SB, 2018, CANCER LETT, V420, P38, DOI 10.1016/j.canlet.2018.01.067; Xu SB, 2014, MOL CELL PROTEOMICS, V13, P2986, DOI 10.1074/mcp.M113.036699; Yau R, 2016, NAT CELL BIOL, V18, P579, DOI 10.1038/ncb3358; Zhang DM, 2014, J MOL NEUROSCI, V53, P637, DOI 10.1007/s12031-014-0230-x; Zheng NN, 2016, BBA-REV CANCER, V1866, P12, DOI 10.1016/j.bbcan.2016.05.001; Zheng NN, 2016, INT J BIOCHEM CELL B, V73, P99, DOI 10.1016/j.biocel.2016.02.005	37	6	6	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1269	1283		10.1038/s41388-020-01596-2	http://dx.doi.org/10.1038/s41388-020-01596-2		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420362	Green Published, hybrid			2022-12-28	WOS:000607346000010
J	Yin, LJ; Li, JJ; Wang, J; Pu, TJ; Wei, J; Li, QL; Wu, BJ				Yin, Lijuan; Li, Jingjing; Wang, Jing; Pu, Tianjie; Wei, Jing; Li, Qinlong; Wu, Boyang Jason			MAOA promotes prostate cancer cell perineural invasion through SEMA3C/PlexinA2/NRP1-cMET signaling	ONCOGENE			English	Article							MONOAMINE-OXIDASE; RECEPTOR; METASTASIS; EXPRESSION; GROWTH; NEUROGENESIS; ACTIVATION; MECHANISMS; REGULATOR; SURVIVAL	Perineural invasion (PNI), a pathologic feature defined as cancer cell invasion in, around, and through nerves, is an indicator of poor prognosis and survival in prostate cancer (PC). Despite widespread recognition of the clinical significance of PNI, the molecular mechanisms are largely unknown. Here, we report that monoamine oxidase A (MAOA) is a clinically and functionally important mediator of PNI in PC. MAOA promotes PNI of PC cells in vitro and tumor innervation in an orthotopic xenograft model. Mechanistically, MAOA activates SEMA3C in a Twist1-dependent transcriptional manner, which in turn stimulates cMET to facilitate PNI via autocrine or paracrine interaction with coactivated PlexinA2 and NRP1. Furthermore, MAOA inhibitor treatment effectively reduces PNI of PC cells in vitro and tumor-infiltrating nerve fiber density along with suppressed xenograft tumor growth and progression in mice. Collectively, these findings characterize the contribution of MAOA to the pathogenesis of PNI and provide a rationale for using MAOA inhibitors as a targeted treatment for PNI in PC.	[Yin, Lijuan; Li, Qinlong] Cedars Sinai Med Ctr, Dept Med, Samuel Oschin Comprehens Canc Inst, Urooncol Res Program, Los Angeles, CA 90048 USA; [Li, Jingjing; Wang, Jing; Pu, Tianjie; Wei, Jing; Wu, Boyang Jason] Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Spokane, WA 99202 USA; [Yin, Lijuan] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu 610041, Sichuan, Peoples R China; [Li, Jingjing] Shanghai Jiao Tong Univ, Sch Pharm, Lab Regener, Shanghai 200240, Peoples R China	Cedars Sinai Medical Center; Washington State University; Sichuan University; Shanghai Jiao Tong University	Wu, BJ (corresponding author), Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Spokane, WA 99202 USA.	boyang.wu@wsu.edu	Pu, Tianjie/AFD-8574-2022; Pu, Tianjie/AAE-9454-2022	Li, Jingjing/0000-0002-0661-5642	DOD Prostate Cancer Research Program [W81XWH-15-1-0493, W81XWH-19-1-0279]; NIH/NCI [R37CA233658]; WSU startup fund	DOD Prostate Cancer Research Program; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); WSU startup fund	We thank Gina Chu (Cedars-Sinai Medical Center) for technical help, Leland W.K. Chung (Cedars-Sinai Medical Center) for comprehensive support of this study, and Gary Mawyer for editorial assistance. This work was supported by DOD Prostate Cancer Research Program grants W81XWH-15-1-0493 and W81XWH-19-1-0279, NIH/NCI grant R37CA233658, and the WSU startup fund to BJW.	Ayala GE, 2008, CLIN CANCER RES, V14, P7593, DOI 10.1158/1078-0432.CCR-08-1164; Bakst RL, 2016, J NEUROL SURG PART B, V77, P96, DOI 10.1055/s-0036-1571835; Binmadi NO, 2012, AM J PATHOL, V180, P1232, DOI 10.1016/j.ajpath.2011.12.009; Bortolato M, 2008, ADV DRUG DELIVER REV, V60, P1527, DOI 10.1016/j.addr.2008.06.002; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Chauvet S, 2007, NEURON, V56, P807, DOI 10.1016/j.neuron.2007.10.019; Chen WR, 2007, J PERIPHER NERV SYST, V12, P121, DOI 10.1111/j.1529-8027.2007.00131.x; Chilton JK, 2006, DEV BIOL, V292, P13, DOI 10.1016/j.ydbio.2005.12.048; Ciftci S, 2015, PROSTATE, V75, P1783, DOI 10.1002/pros.23067; DeLancey JO, 2013, UROLOGY, V81, P354, DOI 10.1016/j.urology.2012.09.034; Deng XY, 2014, CANCER TREAT REV, V40, P730, DOI 10.1016/j.ctrv.2014.04.003; Ding Y, 2013, CLIN CANCER RES, V19, P6101, DOI 10.1158/1078-0432.CCR-12-3669; Eide T, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-4; Flamand V, 2010, J CANCER RES CLIN, V136, P1761, DOI 10.1007/s00432-010-0835-6; Gaur S, 2019, PROSTATE, V79, P667, DOI 10.1002/pros.23774; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; He SB, 2014, P NATL ACAD SCI USA, V111, pE2008, DOI 10.1073/pnas.1402944111; Herman JG, 2007, INT J ONCOL, V30, P1231; Huyett P, 2017, JOVE-J VIS EXP, DOI 10.3791/55043; Jobling P, 2015, CANCER RES, V75, P1777, DOI 10.1158/0008-5472.CAN-14-3180; Khatiwada P, 2020, PEERJ, V8, DOI 10.7717/peerj.8921; Knudsen BS, 2002, UROLOGY, V60, P1113, DOI 10.1016/S0090-4295(02)01954-4; KO KR, 2018, SCI REP UK, V8; Kraus RD, 2019, ADV RADIAT ONCOL, V4, P96, DOI 10.1016/j.adro.2018.09.006; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Li JJ, 2020, ONCOGENE, V39, P3305, DOI 10.1038/s41388-020-1217-4; Liebig C, 2009, CANCER-AM CANCER SOC, V115, P3379, DOI 10.1002/cncr.24396; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Maru N, 2001, HUM PATHOL, V32, P828, DOI 10.1053/hupa.2001.26456; Parra LM, 2010, NAT NEUROSCI, V13, P29, DOI 10.1038/nn.2457; Peacock JW, 2018, EMBO MOL MED, V10, P219, DOI 10.15252/emmm.201707689; Pundavela J, 2014, AM J PATHOL, V184, P3156, DOI 10.1016/j.ajpath.2014.08.009; Saloman JL, 2016, TRENDS NEUROSCI, V39, P880, DOI 10.1016/j.tins.2016.10.002; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Swiercz JM, 2004, J CELL BIOL, V165, P869, DOI 10.1083/jcb.200312094; Tam KJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11914-6; Tam KJ, 2017, ONCOTARGET, V8, P9617, DOI 10.18632/oncotarget.14168; True L, 2006, P NATL ACAD SCI USA, V103, P10991, DOI 10.1073/pnas.0603678103; VILLERS A, 1989, J UROLOGY, V142, P763, DOI 10.1016/S0022-5347(17)38881-X; Westerink RHS, 2008, ACTA PHYSIOL, V192, P273, DOI 10.1111/j.1748-1716.2007.01805.x; Wong VV, 1997, J BIOL CHEM, V272, P5187, DOI 10.1074/jbc.272.8.5187; Wu JB, 2017, CANCER CELL, V31, P368, DOI 10.1016/j.ccell.2017.02.003; Wu JB, 2014, J CLIN INVEST, V124, P2891, DOI 10.1172/JCI70982; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhang DX, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10798	47	15	15	6	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1362	1374		10.1038/s41388-020-01615-2	http://dx.doi.org/10.1038/s41388-020-01615-2		JAN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420365	Green Accepted			2022-12-28	WOS:000607346000001
J	Kaushik, G; Seshacharyulu, P; Rauth, S; Nallasamy, P; Rachagani, S; Nimmakayala, RK; Vengoji, R; Mallya, K; Chirravuri-Venkata, R; Singh, AB; Foster, JM; Ly, QP; Smith, LM; Lele, SM; Malafa, MP; Jain, M; Ponnusamy, MP; Batra, SK				Kaushik, Garima; Seshacharyulu, Parthasarathy; Rauth, Sanchita; Nallasamy, Palanisamy; Rachagani, Satyanarayana; Nimmakayala, Rama Krishna; Vengoji, Raghupathy; Mallya, Kavita; Chirravuri-Venkata, Ramakanth; Singh, Amar B.; Foster, Jason M.; Ly, Quan P.; Smith, Lynette M.; Lele, Subodh M.; Malafa, Mokenge P.; Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.			Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis	ONCOGENE			English	Article							ERBB FAMILY BLOCKER; DRUG-RESISTANCE; POOR-PROGNOSIS; TUMOR-GROWTH; CELLS; AFATINIB; EGFR; DIFFERENTIATION; OVEREXPRESSION; ADENOCARCINOMA	Pancreatic cancer (PC) is difficult to defeat due to mechanism (s) driving metastasis and drug resistance. Cancer stemness is a major challenging phenomenon associated with PC metastasis and limiting therapy efficacy. In this study, we evaluated the pre-clinical and clinical significance of eradicating pancreatic cancer stem cells (PCSC) and its components using a pan-EGFR inhibitor afatinib in combination with gemcitabine. Afatinib in combination with gemcitabine significantly reduced Kras(G12D/+); Pdx-1 Cre (KC) (P < 0.01) and Kras(G12D/+); p53(R172H/+); Pdx-1 Cre (KPC) (P < 0.05) derived mouse tumoroids and KPC-derived murine syngeneic cell line growth compared to gemcitabine/afatinib alone treatment. The drug combination also reduced PC xenograft tumor burden (P < 0.05) and the incidence of metastasis by affecting key stemness markers, as confirmed by co-localization studies. Moreover, the drug combination significantly decreases the growth of various PC patient-derived organoids (P < 0.001). We found that SOX9 is significantly overexpressed in high-grade PC tumors (P < 0.05) and in chemotherapy-treated patients compared to chemo-naive patients (P < 0.05). These results were further validated using publicly available datasets. Moreover, afatinib alone or in combination with gemcitabine decreased stemness and tumorspheres by reducing phosphorylation of EGFR family proteins, ERK, FAK, and CSC markers. Mechanistically, afatinib treatment decreased CSC markers by downregulating SOX9 via FOXA2. Indeed, EGFR and FOXA2 depletion reduced SOX9 expression in PCSCs. Taken together, pan-EGFR inhibition by afatinib impedes PCSCs growth and metastasis via the EGFR/ERK/FOXA2/SOX9 axis. This novel mechanism of pan-EGFR inhibitor and its ability to eradicate CSC may serve as a tailor-made approach to enhance chemotherapeutic benefits in other cancer types.	[Kaushik, Garima; Seshacharyulu, Parthasarathy; Rauth, Sanchita; Nallasamy, Palanisamy; Rachagani, Satyanarayana; Nimmakayala, Rama Krishna; Vengoji, Raghupathy; Mallya, Kavita; Chirravuri-Venkata, Ramakanth; Singh, Amar B.; Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Foster, Jason M.; Ly, Quan P.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Div Surg Oncol, Omaha, NE USA; [Smith, Lynette M.] UNMC, Dept Biostat, Omaha, NE USA; [Lele, Subodh M.; Batra, Surinder K.] UNMC, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Malafa, Mokenge P.] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL USA; [Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; H Lee Moffitt Cancer Center & Research Institute; University of Nebraska System; University of Nebraska Medical Center	Ponnusamy, MP; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Batra, SK (corresponding author), UNMC, Dept Pathol & Microbiol, Omaha, NE 68198 USA.; Ponnusamy, MP; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.	mpalanim@unmc.edu; sbatra@unmc.edu	Nallasamy, Palanisamy/AAH-7727-2021; Nimmakayala, Rama Krishna/CAG-5670-2022; Kaushik, Garima/AAO-7279-2021; Seshacharyulu, Parthasarathy/AGL-7648-2022	Nallasamy, Palanisamy/0000-0001-8962-2487; Nimmakayala, Rama Krishna/0000-0003-4637-4828; Kaushik, Garima/0000-0002-7631-4028; Seshacharyulu, Parthasarathy/0000-0002-2348-3901	National Institutes of Health [P01 CA217798, R01 CA183459, R01 CA195586, R01 CA206444, R01 CA210637, R01 CA228524, R01 CA247471, U01 CA200466, U01 CA210240]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research paper is supported, in parts, by grants from the National Institutes of Health (This work was supported, in parts, by the National Institutes of Health (P01 CA217798, R01 CA183459, R01 CA195586, R01 CA206444, R01 CA210637, R01 CA228524, R01 CA247471, U01 CA200466, and U01 CA210240).	Abhold EL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032459; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Chen K, 2014, ONCOL REP, V32, P755, DOI 10.3892/or.2014.3245; Clark PA, 2012, NEOPLASIA, V14, P420, DOI 10.1596/neo.12432; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Dalerba P, 2007, CELL STEM CELL, V1, P241, DOI 10.1016/j.stem.2007.08.012; Ding Q, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-15; Engle JA, 2014, AM J HEALTH-SYST PH, V71, P1933, DOI 10.2146/ajhp130654; Fitzgerald Timothy L., 2015, Advances in Biological Regulation, V59, P65, DOI 10.1016/j.jbior.2015.06.003; Fitzgerald Timothy L., 2014, Advances in Biological Regulation, V56, P45, DOI 10.1016/j.jbior.2014.05.001; Furuya T, 2017, J THORAC DIS, V9, pE890, DOI 10.21037/jtd.2017.09.123; Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53; Han Haiyong, 2013, Cancer Cell, V23, P424, DOI 10.1016/j.ccr.2013.03.008; Hennig R, 2005, CANCER RES, V65, P6011, DOI 10.1158/0008-5472.CAN-04-4090; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Herreros-Villanueva M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.23; Hirsh V, 2015, BIODRUGS, V29, P167, DOI 10.1007/s40259-015-0130-9; Ioannou N, 2011, BRIT J CANCER, V105, P1554, DOI 10.1038/bjc.2011.396; Jiang H, 2015, MOL CANCER RES, V13, P1554, DOI 10.1158/1541-7786.MCR-15-0240; Karmakar S, 2017, ONCOTARGET, V8, P14806, DOI 10.18632/oncotarget.14775; Kelley RK, 2008, BIOL-TARGETS THER, V2, P83; Lavon N, 2006, STEM CELLS, V24, P1923, DOI 10.1634/stemcells.2005-0397; Li YW, 2013, CANCER LETT, V338, P94, DOI 10.1016/j.canlet.2012.03.018; Ling SZ, 2011, CANCER RES, V71, P3812, DOI 10.1158/0008-5472.CAN-10-3072; Lynn FC, 2007, P NATL ACAD SCI USA, V104, P10500, DOI 10.1073/pnas.0704054104; Macha MA, 2017, ONCOTARGET, V8, P20961, DOI 10.18632/oncotarget.15468; Majhi PD, 2013, J THORAC ONCOL, V8, P398, DOI 10.1097/JTO.0b013e3182829e06; Modjtahedi H, 2014, N-S ARCH PHARMACOL, V387, P505, DOI 10.1007/s00210-014-0967-3; Mukhopadhyay P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054455; Nimmakayala RK, 2018, GASTROENTEROLOGY, V155, P892, DOI 10.1053/j.gastro.2018.05.041; Nomura A, 2015, ONCOTARGET, V6, P8313, DOI 10.18632/oncotarget.3228; PASSARO A, 2019, ANN ONCOL         S2, V30, pii48, DOI DOI 10.1093/annonc/mdz063.013; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Roy S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013674; Sarkar FH, 2009, MINERVA CHIR, V64, P489; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Seshacharyulu P, 2015, ONCOTARGET, V6, P5164, DOI 10.18632/oncotarget.3286; Seymour Philip A, 2014, Rev Diabet Stud, V11, P51, DOI 10.1900/RDS.2014.11.51; Shroff S, 2014, HUM PATHOL, V45, P456, DOI 10.1016/j.humpath.2013.10.008; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Steelman LS, 2016, CURR PHARM DESIGN, V22, P2358, DOI 10.2174/1381612822666160304151011; Tanase CP, 2014, WORLD J GASTROENTERO, V20, P10790, DOI 10.3748/wjg.v20.i31.10790; Tebbutt N, 2013, NAT REV CANCER, V13, P663, DOI 10.1038/nrc3559; Torres MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080580; Ueda S, 2004, PANCREAS, V29, pE1, DOI 10.1097/00006676-200407000-00061; Van den Broeck A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-354; Vaz AP, 2014, BRIT J CANCER, V111, P486, DOI 10.1038/bjc.2014.152; Vengoji R, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1264-2; Yang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097578; Zhou G, 2012, APPL BIOCHEM BIOTECH, V167, P2257, DOI 10.1007/s12010-012-9752-2; Zhou XC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096718	53	24	24	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					848	862		10.1038/s41388-020-01564-w	http://dx.doi.org/10.1038/s41388-020-01564-w		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33288882	Green Accepted			2022-12-28	WOS:000599015000002
J	Jia, YF; Ding, XM; Zhou, LH; Zhang, L; Yang, XC				Jia, Yuefeng; Ding, Xuemei; Zhou, Lihua; Zhang, Li; Yang, Xuecheng			Mesenchymal stem cells-derived exosomal microRNA-139-5p restrains tumorigenesis in bladder cancer by targeting PRC1	ONCOGENE			English	Article							IN-VITRO; GROWTH; MIR-139-5P; CYCLE	microRNAs (miRNAs) can be delivered to tumor cells where they exert their function via mesenchymal stem cells (MSCs)-derived exosomes. This study investigated exosomal transfer of miR-139-5p to bladder cancer cells and their role in the regulation of tumorigenesis. The dysregulation of polycomb repressor complex 1 (PRC1) in bladder cancer was characterized by RNA quantification, and its functional significance in bladder cancer cells was identified by loss-of-function experiments. We predicted the miR-139-5p that could play a role in regulating PRC1, which was further verified using dual-luciferase reporter gene assay. Next, we altered the expression of miR-139-5p and PRC1 in bladder cancer cells to identify their functions in cancer progression. Bladder cancer cells were co-cultured with exosomes isolated from human umbilical cord mesenchymal stem cells (hUCMSCs) over-expressing miR-139-5p. The intercellular transfer of miR-139-5p along with in vitro and in vivo functions was determined using gain- and loss-of-function approaches. Our results revealed that PRC1 levels were increased in bladder cancer tissues and cells, and silencing PRC1 appeared to impede the cell proliferation, migration, and invasion potentials. In addition, miR-139-5p was observed to be down-regulated in bladder cancer, which targeted PRC1 and reduced its expression, hereby resulting in ameliorated tumorigenic characteristics of bladder cancer cells in vitro. Furthermore, we noted that miR-139-5p from hUCMSCs-derived exosomes could be transferred into bladder cancer cells to down-regulate the PRC1 expression. Moreover, hUCMSCs-derived exosomal miR-139-5p conferred a suppressive role on bladder cancer development in vitro and in vivo. These data together supported the tumor-inhibiting role of MSCs-derived exosomal miR-139-5p in bladder cancer, highlighting a promising therapeutic strategy.	[Jia, Yuefeng; Yang, Xuecheng] Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao 266003, Peoples R China; [Ding, Xuemei; Zhang, Li] Qingdao Univ, Affiliated Hosp, Dept Surg, Qingdao 266003, Peoples R China; [Zhou, Lihua] Qingdao Univ, Affiliated Hosp, Dept Pharm, Qingdao 266003, Peoples R China	Qingdao University; Qingdao University; Qingdao University	Yang, XC (corresponding author), Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao 266003, Peoples R China.	m18661805062@163.com						Alzahrani FA, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/8058979; Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Chen Y, 2018, AM J PHYSIOL-CELL PH, V315, pC225, DOI 10.1152/ajpcell.00283.2017; Cosenza S, 2018, THERANOSTICS, V8, P1399, DOI 10.7150/thno.21072; Dai SP, 2015, BIOCHEM BIOPH RES CO, V467, P204, DOI 10.1016/j.bbrc.2015.10.006; De Faveri LE, 2015, TRANSL ONCOL, V8, P387, DOI 10.1016/j.tranon.2015.08.002; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; Di Meo A, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0644-5; He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945; Jiang C, 2018, J CELL BIOCHEM, V119, P6429, DOI 10.1002/jcb.26610; Kamat AM, 2016, LANCET, V388, P2796, DOI 10.1016/S0140-6736(16)30512-8; Keller S, 2009, CANCER LETT, V278, P73, DOI 10.1016/j.canlet.2008.12.028; Kluth LA, 2015, EUR UROL, V68, P238, DOI 10.1016/j.eururo.2015.01.032; Li JB, 2014, CHEM SOC REV, V43, P506, DOI 10.1039/c3cs60312a; Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359; Liang W, 2013, MOL CELL BIOCHEM, V382, P283, DOI 10.1007/s11010-013-1745-0; Liu PF, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0021-9; Luo HB, 2015, J HUAZHONG U SCI-MED, V35, P730, DOI 10.1007/s11596-015-1498-y; Luo HB, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317718414; Milane L, 2015, J CONTROL RELEASE, V219, P278, DOI 10.1016/j.jconrel.2015.06.029; Pakravan K, 2017, CELL ONCOL, V40, P457, DOI 10.1007/s13402-017-0335-7; Sanli O, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.22; Shang S, 2019, CANCER MED-US, V8, P7728, DOI 10.1002/cam4.2633; Sun Q, 2018, ONCOL LETT, V16, P793, DOI 10.3892/ol.2018.8773; Tang H, 2019, DIGEST LIVER DIS, V51, P1314, DOI 10.1016/j.dld.2019.02.012; Wang B, 2018, INT J NANOMED, V13, P5257, DOI 10.2147/IJN.S167880; Wang K, 2017, J CELL MOL MED, V21, P3730, DOI 10.1111/jcmm.13282; Xu W, 2015, INT J CLIN EXP PATHO, V8, P3864; Xu XD, 2014, ASIAN PAC J CANCER P, V15, P3471, DOI 10.7314/APJCP.2014.15.8.3471; Yonemori M, 2016, CANCER SCI, V107, P1233, DOI 10.1111/cas.13002; Yoshino H, 2013, NAT REV UROL, V10, P396, DOI 10.1038/nrurol.2013.113; Zhan P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0682-z; Zhang B, 2017, J CELL MOL MED, V21, P1329, DOI 10.1111/jcmm.13063; Zhang LJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-124; Zhu S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02863-3	35	38	39	2	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					246	261		10.1038/s41388-020-01486-7	http://dx.doi.org/10.1038/s41388-020-01486-7		OCT 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33122828				2022-12-28	WOS:000582827800005
J	Zhai, SY; Xu, ZW; Xie, JJ; Zhang, J; Wang, XJ; Peng, CH; Li, HW; Chen, H; Shen, BY; Deng, XX				Zhai, Shuyu; Xu, Zhiwei; Xie, Junjie; Zhang, Jun; Wang, Xinjing; Peng, Chenghong; Li, Hongwei; Chen, Hao; Shen, Baiyong; Deng, Xiaxing			Epigenetic silencing of LncRNA LINC00261 promotes c-myc-mediated aerobic glycolysis by regulating miR-222-3p/HIPK2/ERK axis and sequestering IGF2BP1	ONCOGENE			English	Article							LONG NONCODING RNAS; SIGNALING PATHWAY; PANCREATIC-CANCER; METHYLATION; HIPK2	Long noncoding RNAs have been identified as key regulators in the progression of various cancers. LINC00261 has been reported as a tumor suppressor in multiple cancers. However, its function and underlying mechanisms in pancreatic cancer remain largely unclear. Quantitative real-time PCR was performed to detect RNA expression. In situ hybridization was used to discover the subcellular location. The direct binding of LINC00261 to miR-222-3p was verified using a dual-luciferase reporter assay and RNA immunoprecipitation. LINC00261-binding proteins were detected using an RNA pulldown assay. LINC00261 was downregulated in pancreatic cancer tissues and cell lines. Its reduced expression was correlated with advanced pathological stage and poor prognosis. Forced expression of LINC00261 suppressed pancreatic cancer glycolysis and proliferation and induced cell cycle arrest and apoptosis. Mechanistically, downregulation of LINC00261 was caused by hypermethylation of the CpG island in the promoter region and EZH2-mediated histone H3 lysine 27 trimethylation. Moreover, LINC00261 exerted its biological function by binding to miR-222-3p to activate the HIPK2/ERK/c-myc pathway. In addition, LINC00261 could also reduce c-myc expression by sequestering IGF2BP1. Our study suggests that LINC00261 functions as a tumor suppressor in pancreatic cancer and identifies novel epigenetic and posttranscriptional regulatory mechanisms of LINC00261, which contribute to the targeted therapy of pancreatic cancer.	[Zhai, Shuyu; Xu, Zhiwei; Xie, Junjie; Zhang, Jun; Wang, Xinjing; Peng, Chenghong; Li, Hongwei; Chen, Hao; Shen, Baiyong; Deng, Xiaxing] Shanghai Jiao Tong Univ, Ruijin Hosp, Res Inst Pancreat Dis, Dept Gen Surg,Pancreat Dis Ctr,Sch Med, Shanghai, Peoples R China; [Zhai, Shuyu; Xu, Zhiwei; Xie, Junjie; Zhang, Jun; Wang, Xinjing; Peng, Chenghong; Li, Hongwei; Chen, Hao; Shen, Baiyong; Deng, Xiaxing] Shanghai Jiao Tong Univ, Sch Med, Res Inst Pancreat Dis, Shanghai, Peoples R China; [Zhai, Shuyu; Xu, Zhiwei; Xie, Junjie; Zhang, Jun; Wang, Xinjing; Peng, Chenghong; Li, Hongwei; Chen, Hao; Shen, Baiyong; Deng, Xiaxing] Shanghai Jiao Tong Univ, Inst Translat Med, State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Chen, H; Shen, BY; Deng, XX (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Res Inst Pancreat Dis, Dept Gen Surg,Pancreat Dis Ctr,Sch Med, Shanghai, Peoples R China.; Chen, H; Shen, BY; Deng, XX (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Res Inst Pancreat Dis, Shanghai, Peoples R China.; Chen, H; Shen, BY; Deng, XX (corresponding author), Shanghai Jiao Tong Univ, Inst Translat Med, State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China.	haochendr@126.com; shenby@shsmu.edu.cn; dxx10716@rjh.com.cn		Peng, Chenghong/0000-0002-5573-7873				Amin V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7370; Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006; Chen TX, 2020, ONCOL REP, V43, P930, DOI 10.3892/or.2020.7480; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Chiorean EG, 2015, DRUG DES DEV THER, V9, P3529, DOI 10.2147/DDDT.S60328; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Gits CMM, 2013, BRIT J CANCER, V109, P1625, DOI 10.1038/bjc.2013.483; Guo CX, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01332-6; Guo JP, 2018, ONCOTARGETS THER, V11, P8643, DOI 10.2147/OTT.S175745; He J, 2019, CANCER LETT, V450, P98, DOI 10.1016/j.canlet.2019.02.033; Hofmann TG, 2013, BIOESSAYS, V35, P55, DOI 10.1002/bies.201200060; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Huang XW, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0628-y; Ihle MA, 2015, MOL ONCOL, V9, P1421, DOI 10.1016/j.molonc.2015.03.013; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Klutstein M, 2016, CANCER RES, V76, P3446, DOI 10.1158/0008-5472.CAN-15-3278; Luo H, 2015, BRAIN, V138, P3654, DOI 10.1093/brain/awv287; Muller S, 2018, NUCLEIC ACIDS RES, V46, P6285, DOI 10.1093/nar/gky229; MULLER S, 2015, MOL CANCER, V14; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Qin Y, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12603; Rashid F, 2016, GENOM PROTEOM BIOINF, V14, P73, DOI 10.1016/j.gpb.2016.03.005; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Saul VV, 2013, J MOL MED, V91, P1051, DOI 10.1007/s00109-013-1042-0; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008; Shi HL, 2019, MOL CELL, V74, P640, DOI 10.1016/j.molcel.2019.04.025; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sun SS, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819892256; Wang X, 2020, ARCH BIOCHEM BIOPHYS, V689, DOI 10.1016/j.abb.2020.108469; Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001; Yan DS, 2019, J CELL PHYSIOL, V234, P22648, DOI 10.1002/jcp.28831; Yang HJ, 2019, BIOCHIMIE, V165, P9, DOI 10.1016/j.biochi.2019.06.012; Yu YC, 2017, J CELL MOL MED, V21, P955, DOI 10.1111/jcmm.13035; Zeng LP, 2016, J CELL MOL MED, V20, P559, DOI 10.1111/jcmm.12760; Zhang BG, 2018, AM J TRANSL RES, V10, P2648; Zhu S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15403-9	37	38	39	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					277	291		10.1038/s41388-020-01525-3	http://dx.doi.org/10.1038/s41388-020-01525-3		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33122827	Green Published, hybrid			2022-12-28	WOS:000582827800004
J	Zhang, MX; Zhang, LZ; Fu, LM; Yao, HH; Tan, L; Feng, ZH; Li, JY; Lu, J; Pan, YH; Shu, GN; Li, PJ; Tang, YM; Liao, ZY; Wei, JH; Chen, W; Guo, JP; Luo, JH; Chen, ZH				Zhang, Ming-xiao; Zhang, Li-zhen; Fu, Liang-min; Yao, Hao-hua; Tan, Lei; Feng, Zi-hao; Li, Jia-ying; Lu, Jun; Pan, Yi-hui; Shu, Guan-nan; Li, Peng-ju; Tang, Yi-ming; Liao, Zhuang-yao; Wei, Jin-huan; Chen, Wei; Guo, Jian-ping; Luo, Jun-hang; Chen, Zhen-hua			Positive feedback regulation of lncRNA PVT1 and HIF2 alpha contributes to clear cell renal cell carcinoma tumorigenesis and metastasis	ONCOGENE			English	Article							LONG NONCODING RNAS; PROMOTES PROLIFERATION; CANCER; HSP90; BINDING; DOMAIN; ALPHA; ANTAGONIST; GROWTH; HIF-2	Long noncoding RNAs (lncRNAs) have been reported to exert important roles in tumors, including clear cell renal cell carcinoma (ccRCC). PVT1 is an important oncogenic lncRNA which has critical effects on onset and development of various cancers, however, the underlying mechanism of PVT1 functioning in ccRCC remains largely unknown. VHL deficiency-induced HIF2 alpha accumulation is one of the major factors for ccRCC. Here, we identified the potential molecular mechanism of PVT1 in promoting ccRCC development by stabilizing HIF2 alpha. PVT1 was significantly upregulated in ccRCC tissues and high PVT1 expression was associated with poor prognosis of ccRCC patients. Both gain-of-function and loss-of function experiments revealed that PVT1 enhanced ccRCC cells proliferation, migration, and invasion and induced tumor angiogenesis in vitro and in vivo. Mechanistically, PVT1 interacted with HIF2 alpha protein and enhanced its stability by protecting it from ubiquitination-dependent degradation, thereby exerting its biological significance. Meanwhile, HIF2 alpha bound to the enhancer of PVT1 to transactivate its expression. Furthermore, HIF2 alpha specific inhibitor could repress PVT1 expression and its oncogenic functions. Therefore, our study demonstrates that the PVT1/ HIF2 alpha positive feedback loop involves in tumorigenesis and progression of ccRCC, which may be exploited for anticancer therapy.	[Zhang, Ming-xiao; Zhang, Li-zhen; Fu, Liang-min; Yao, Hao-hua; Tan, Lei; Feng, Zi-hao; Li, Jia-ying; Lu, Jun; Pan, Yi-hui; Shu, Guan-nan; Li, Peng-ju; Tang, Yi-ming; Liao, Zhuang-yao; Wei, Jin-huan; Chen, Wei; Luo, Jun-hang; Chen, Zhen-hua] Sun Yat Sen Univ, Dept Urol, Affiliated Hosp 1, Guangzhou, Peoples R China; [Tan, Lei] Southern Med Univ, Nanfang Hosp, Dept Urol, Guangzhou, Peoples R China; [Guo, Jian-ping; Luo, Jun-hang] Sun Yat Sen Univ, Affiliated Hosp 1, Inst Precis Med, Guangzhou, Peoples R China; [Luo, Jun-hang] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Peoples R China	Sun Yat Sen University; Southern Medical University - China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Luo, JH; Chen, ZH (corresponding author), Sun Yat Sen Univ, Dept Urol, Affiliated Hosp 1, Guangzhou, Peoples R China.; Guo, JP; Luo, JH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Inst Precis Med, Guangzhou, Peoples R China.; Luo, JH (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Peoples R China.	guojp6@mail.sysu.edu.cn; luojunh@mail.sysu.edu.cn; chenzhh75@mail.sysu.edu.cn		Zhang, Li-Zhen/0000-0002-3106-6825	National Natural Science Foundation of China [81902576, 81725016, 81872094, 82002684]; Natural Science Foundation of Guangdong Province, China [2017B020227004, 2017A030313538, 2018A030310327]; Medical Scientific Research Foundation of Guangdong Province, China [A2018051]; Guangdong Basic and Applied Basic Research Foundation [2020A1515111077]; China Postdoctoral Science Foundation [236464]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); Medical Scientific Research Foundation of Guangdong Province, China; Guangdong Basic and Applied Basic Research Foundation; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (No.81902576, No.81725016, No. 81872094 and No. 82002684), the Natural Science Foundation of Guangdong Province, China (2017B020227004, 2017A030313538, 2018A030310327), the Medical Scientific Research Foundation of Guangdong Province, China (A2018051), Guangdong Basic and Applied Basic Research Foundation (2020A1515111077), and China Postdoctoral Science Foundation Funded Project (No. 236464).	Baba M, 2003, ONCOGENE, V22, P2728, DOI 10.1038/sj.onc.1206373; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Clark PE, 2009, KIDNEY INT, V76, P939, DOI 10.1038/ki.2009.296; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Courtney KD, 2018, J CLIN ONCOL, V36, P867, DOI 10.1200/JCO.2017.74.2627; Ehrlich ES, 2009, P NATL ACAD SCI USA, V106, P20330, DOI 10.1073/pnas.0810571106; Escudier B, 2007, DRUGS, V67, P1257, DOI 10.2165/00003495-200767090-00002; Frank I, 2003, J UROLOGY, V170, P2225, DOI 10.1097/01.ju.0000095541.10333.a7; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Grampp S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13183; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Katschinski DM, 2004, CELL PHYSIOL BIOCHEM, V14, P351, DOI 10.1159/000080345; Li MY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00787; Li WC, 2018, ONCOL LETT, V15, P7855, DOI 10.3892/ol.2018.8315; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Ljungberg B, 2019, EUR UROL, V75, P799, DOI 10.1016/j.eururo.2019.02.011; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Oudard S, 2007, ANN ONCOL, V18, P25, DOI 10.1093/annonc/mdm411; Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ren Y, 2019, ONCOTARGETS THER, V12, P2563, DOI 10.2147/OTT.S190239; Shen C, 2011, CANCER DISCOV, V1, P222, DOI 10.1158/2159-8290.CD-11-0098; Sun M, 2015, ENDOCR REV, V36, P25, DOI 10.1210/er.2014-1034; Takeda N, 2004, CIRC RES, V95, P146, DOI 10.1161/01.RES.0000134920.10128.b4; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Turajlic S, 2018, CELL, V173, P581, DOI 10.1016/j.cell.2018.03.057; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wallace EM, 2016, CANCER RES, V76, P5491, DOI 10.1158/0008-5472.CAN-16-0473; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; Wang H, 2020, J CANCER, V11, P2737, DOI 10.7150/jca.36822; Wang Y, 2020, CELL DEATH DIFFER, V27, P695, DOI 10.1038/s41418-019-0381-y; Wu QJ, 2017, ONCOTARGET, V8, P101865, DOI 10.18632/oncotarget.21706; Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078-0432.CCR-16-0742; Xu Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1064-5; Yang T, 2017, ONCOTARGET, V8, P85353, DOI 10.18632/oncotarget.19743; Yu XG, 2018, J BUON, V23, P48; Zhao J, 2018, ONCOGENE, V37, P4094, DOI 10.1038/s41388-018-0250-z; Zhao L, 2018, J CELL PHYSIOL, V233, P4044, DOI 10.1002/jcp.26072	41	8	8	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5639	5650		10.1038/s41388-021-01971-7	http://dx.doi.org/10.1038/s41388-021-01971-7		JUL 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34321604	Green Published, hybrid			2022-12-28	WOS:000678443300001
J	O'Connor, MJ; Thakar, T; Nicolae, CM; Moldovan, GL				O'Connor, Michael J.; Thakar, Tanay; Nicolae, Claudia M.; Moldovan, George-Lucian			PARP14 regulates cyclin D1 expression to promote cell-cycle progression	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; FAMILY; CANCER; GENE; P21; P53; PROLIFERATION; INHIBITION; DYNAMICS; PARP-14	Cyclin D1 is an essential regulator of the G1-S cell-cycle transition and is overexpressed in many cancers. Expression of cyclin D1 is under tight cellular regulation that is controlled by many signaling pathways. Here we report that PARP14, a member of the poly(ADP-ribose) polymerase (PARP) family, is a regulator of cyclin D1 expression. Depletion of PARP14 leads to decreased cyclin D1 protein levels. In cells with a functional retinoblastoma (RB) protein pathway, this results in G1 cell-cycle arrest and reduced proliferation. Mechanistically, we found that PARP14 controls cyclin D1 mRNA levels. Using luciferase assays, we show that PARP14 specifically regulates cyclin D1 3 ' UTR mRNA stability. Finally, we also provide evidence that G1 arrest in PARP14-depleted cells is dependent on an intact p53-p21 pathway. Our work uncovers a new role for PARP14 in promoting cell-cycle progression through both cyclin D1 and the p53 pathway.	[O'Connor, Michael J.; Thakar, Tanay; Nicolae, Claudia M.; Moldovan, George-Lucian] Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Moldovan, GL (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.	glm29@psu.edu	Thakar, Tanay/AGX-3854-2022	Nicolae, Claudia/0000-0003-4933-5496; Thakar, Tanay/0000-0001-5261-458X	NIH [R01ES026184]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We would like to thank Drs James Broach, Gregory Yochum, Lisa Shantz, Hein Te Riele, Titia de Lange, Nicholas Dyson, Hong-Gang Wang, Raymond Hohl, Myriam Gorospe, Khandan Keyomarsi, and Peter Sicinski for materials and advice, as well as the Penn State College of Medicine Flow Cytometry core for their assistance with flow cytometry experiments. This work was supported by NIH R01ES026184 (to G-LM).	Augustin A, 2003, J CELL SCI, V116, P1551, DOI 10.1242/jcs.00341; Barbarulo A, 2013, ONCOGENE, V32, P4231, DOI 10.1038/onc.2012.448; Benedict B, 2018, ELIFE, V7, DOI 10.7554/eLife.37868; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carbone M, 2008, ONCOGENE, V27, P6083, DOI 10.1038/onc.2008.221; Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010; Cho SH, 2009, BLOOD, V113, P2416, DOI 10.1182/blood-2008-03-144121; DeFilippis RA, 2003, J VIROL, V77, P1551, DOI 10.1128/JVI.77.2.1551-1563.2003; Dyson NJ, 2016, GENE DEV, V30, P1492, DOI 10.1101/gad.282145.116; Ertel A, 2010, CELL CYCLE, V9, P4153, DOI 10.4161/cc.9.20.13454; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Goenka S, 2006, P NATL ACAD SCI USA, V103, P4210, DOI 10.1073/pnas.0506981103; Goetz MP, 2017, J CLIN ONCOL, V35, P3638, DOI 10.1200/JCO.2017.75.6155; Guiley KZ, 2019, SCIENCE, V366, P1330, DOI 10.1126/science.aaw2106; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474; Hydbring P, 2017, CANCER CELL, V31, P576, DOI 10.1016/j.ccell.2017.03.004; Iansante V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8882; Im SA, 2019, NEW ENGL J MED, V381, P307, DOI 10.1056/NEJMoa1903765; Iqbal MB, 2014, BLOOD, V124, P3646, DOI 10.1182/blood-2014-07-588046; Kettner NM, 2019, CLIN CANCER RES, V25, P3996, DOI 10.1158/1078-0432.CCR-18-3274; Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee MS, 2016, ONCOTARGET, V7, P39595, DOI 10.18632/oncotarget.9153; Mayr C, 2017, ANNU REV GENET, V51, P171, DOI 10.1146/annurev-genet-120116-024704; Milek M, 2017, GENOME RES, V27, P1344, DOI 10.1101/gr.218438.116; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Narasimha AM, 2014, ELIFE, V3, DOI 10.7554/eLife.02872; Nicolae CM, 2018, ONCOGENE, V37, P3647, DOI 10.1038/s41388-018-0219-y; Nicolae CM, 2015, NUCLEIC ACIDS RES, V43, P3143, DOI 10.1093/nar/gkv147; Nicolae CM, 2014, J BIOL CHEM, V289, P13627, DOI 10.1074/jbc.M114.556340; Nicolay BN, 2015, GENE DEV, V29, P1875, DOI 10.1101/gad.264127.115; Riley JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083127; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Stengel KR, 2009, J BIOL CHEM, V284, P19265, DOI 10.1074/jbc.M808740200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Velez-Cruz R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081776; Viatour P, 2011, DIS MODEL MECH, V4, P581, DOI 10.1242/dmm.008060; Vyas S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5426; Vyas S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3240; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Yang Z, 2017, MOL CANCER RES, V15, P1579, DOI 10.1158/1541-7786.MCR-17-0084; Yao N, 2019, MOL CARCINOGEN, V58, P1291, DOI 10.1002/mc.23011; Zhang JF, 2016, MOL CELL, V62, P929, DOI 10.1016/j.molcel.2016.04.023	47	8	8	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4872	4883		10.1038/s41388-021-01881-8	http://dx.doi.org/10.1038/s41388-021-01881-8		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34158578	Green Accepted			2022-12-28	WOS:000664429900001
J	Pan, TH; Lin, SC; Lee, YC; Yu, GY; Song, JH; Pan, J; Titus, M; Satcher, RL; Panaretakis, T; Logothetis, C; Yu-Lee, L; Lin, SH				Pan, Tianhong; Lin, Song-Chang; Lee, Yu-Chen; Yu, Guoyu; Song, Jian H.; Pan, Jing; Titus, Mark; Satcher, Robert L.; Panaretakis, Theocharis; Logothetis, Christopher; Yu-Lee, Li-Yuan; Lin, Sue-Hwa			Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone	ONCOGENE			English	Article							ANDROGEN DEPRIVATION THERAPY; ADIPOCYTES; CELLS; GROWTH; RESISTANCE; LNCAP; MODEL; MICROENVIRONMENT; LOCALIZATION; METASTASIS	A fraction of patients undergoing androgen deprivation therapy (ADT) for advanced prostate cancer (PCa) will develop recurrent castrate-resistant PCa (CRPC) in bone. Strategies to prevent CRPC relapse in bone are lacking. Here we show that the cholesterol-lowering drugs statins decrease castration-induced bone marrow adiposity in the tumor microenvironment and reduce PCa progression in bone. Using primary bone marrow stromal cells (BMSC) and M2-10B4 cells, we showed that ADT increases bone marrow adiposity by enhancing BMSC-to-adipocyte transition in vitro. Knockdown of androgen receptor abrogated BMSC-to-adipocyte transition, suggesting an androgen receptor-dependent event. RNAseq analysis showed that androgens reduce the secretion of adipocyte hormones/cytokines including leptin during BMSC-to-adipocyte transition. Treatment of PCa C4-2b, C4-2B4, and PC3 cells with leptin led to an increase in cell cycle progression and nuclear Stat3. RNAseq analysis also showed that androgens inhibit cholesterol biosynthesis pathway, raising the possibility that inhibiting cholesterol biosynthesis may decrease BMSC-to-adipocyte transition. Indeed, statins decreased BMSC-to-adipocyte transition in vitro and castration-induced bone marrow adiposity in vivo. Statin pre-treatment reduced 22RV1 PCa progression in bone after ADT. Our findings with statin may provide one of the mechanisms to the clinical correlations that statin use in patients undergoing ADT seems to delay progression to "lethal" PCa.	[Pan, Tianhong; Satcher, Robert L.] Univ Texas MD Anderson Canc Ctr, Dept Orthoped Oncol, Houston, TX 77030 USA; [Lin, Song-Chang; Lee, Yu-Chen; Yu, Guoyu; Pan, Jing; Lin, Sue-Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Song, Jian H.; Titus, Mark; Panaretakis, Theocharis; Logothetis, Christopher; Lin, Sue-Hwa] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Yu-Lee, Li-Yuan] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.; Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.	slin@mdanderson.org			NIH [CA174798, P50 CA140388, P30 CA016672]; Cancer Prevention and Research Institute of Texas [CPRIT RP150179, RP190252]; Prostate Cancer Foundation; University of Texas MD Anderson Moonshot Program	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; Prostate Cancer Foundation; University of Texas MD Anderson Moonshot Program	This work was supported by grants from the NIH (CA174798, P50 CA140388, P30 CA016672), Cancer Prevention and Research Institute of Texas (CPRIT RP150179, RP190252), the Prostate Cancer Foundation, and funds from The University of Texas MD Anderson Moonshot Program.	Abu EO, 1997, J CLIN ENDOCR METAB, V82, P3493, DOI 10.1210/jc.82.10.3493; Alfaqih MA, 2017, NAT REV UROL, V14, P107, DOI 10.1038/nrurol.2016.199; Azemawah V, 2019, CARDIOVASC DRUG THER, V33, P625, DOI 10.1007/s10557-019-06904-x; Caers J, 2007, LEUKEMIA, V21, P1580, DOI 10.1038/sj.leu.2404658; Calvi LM, 2015, BLOOD, V126, P2443, DOI 10.1182/blood-2015-07-533588; Crnalic S, 2010, ENDOCR-RELAT CANCER, V17, P885, DOI 10.1677/ERC-10-0059; Diedrich J, 2015, HORM MOL BIOL CLIN I, V21, P17, DOI 10.1515/hmbci-2014-0045; Diedrich JD, 2016, ONCOTARGET, V7, P64854, DOI 10.18632/oncotarget.11712; Gimble JM, 1996, BONE, V19, P421, DOI 10.1016/S8756-3282(96)00258-X; Gordon Jacob A, 2018, Oncotarget, V9, P19861, DOI 10.18632/oncotarget.24888; Goto T, 2011, BIOCHEM J, V438, P111, DOI 10.1042/BJ20101939; Hardaway AL, 2015, CLIN EXP METASTAS, V32, P353, DOI 10.1007/s10585-015-9714-5; Hardaway AL, 2014, CANCER METAST REV, V33, P527, DOI 10.1007/s10555-013-9484-y; Harshman LC, 2015, JAMA ONCOL, V1, P495, DOI 10.1001/jamaoncol.2015.0829; Herroon MK, 2013, ONCOTARGET, V4, P2108, DOI 10.18632/oncotarget.1482; Jiao SP, 2019, CELL, V179, P1177, DOI 10.1016/j.cell.2019.10.029; Laurent V, 2019, MOL CANCER RES, V17, P821, DOI 10.1158/1541-7786.MCR-18-0748; Laurent V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10230; Lee YC, 2015, CANCER RES, V75, P4949, DOI 10.1158/0008-5472.CAN-15-1215; Lee YC, 2013, MOL CANCER RES, V11, P405, DOI 10.1158/1541-7786.MCR-12-0551; Lin DS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.510; Liu ZQ, 2015, ONCOTARGET, V6, P34329, DOI 10.18632/oncotarget.6020; Logothetis CJ, 2013, CANCER DISCOV, V3, P849, DOI 10.1158/2159-8290.CD-12-0460; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Lucas-Herald AK, 2017, CLIN SCI, V131, P1405, DOI 10.1042/CS20170090; Mantalaris A, 2001, J PATHOL, V193, P361, DOI 10.1002/1096-9896(0000)9999:9999<::AID-PATH803>3.0.CO;2-W; Morris EV, 2018, J CELL PHYSIOL, V233, P9159, DOI 10.1002/jcp.26884; Ottewell PD, 2014, ENDOCR-RELAT CANCER, V21, P769, DOI 10.1530/ERC-14-0199; Platz EA, 2006, JNCI-J NATL CANCER I, V98, P1819, DOI 10.1093/jnci/djj499; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Sato K, 2004, J HUM GENET, V49, P29, DOI 10.1007/s10038-003-0103-6; Sato S, 2008, CANCER SCI, V99, P316, DOI 10.1111/j.1349-7006.2007.00690.x; Saxena NK, 2007, J BIOL CHEM, V282, P13316, DOI 10.1074/jbc.M609798200; Sharifi N, 2010, ENDOCR-RELAT CANCER, V17, pR305, DOI 10.1677/ERC-10-0187; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; SUTHERLAND HJ, 1991, BLOOD, V78, P666, DOI 10.1182/blood.V78.3.666.bloodjournal783666; Tang KD, 2016, ONCOTARGET, V7, P4939, DOI 10.18632/oncotarget.6643; TAVASSOLI M, 1974, ARCH PATHOL, V98, P189; TAVASSOLI M, 1976, ACTA ANAT, V94, P65; Tencerova M, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00127; THALMANN GN, 1994, CANCER RES, V54, P2577; Thalmann GN, 2000, PROSTATE, V44, P91; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z; Xu LJ, 2018, PROSTATE, V78, P353, DOI 10.1002/pros.23479; Yu-Lee LY, 2018, CANCER RES, V78, P2911, DOI 10.1158/0008-5472.CAN-17-1051; Zhang YX, 2018, P NATL ACAD SCI USA, V115, pE6039, DOI 10.1073/pnas.1806366115	49	5	5	4	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4592	4603		10.1038/s41388-021-01874-7	http://dx.doi.org/10.1038/s41388-021-01874-7		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34127814	Green Accepted			2022-12-28	WOS:000661408100002
J	Wu, QY; Zhang, Y; An, HY; Sun, W; Wang, RZ; Liu, M; Zhang, KT				Wu, Quanyou; Zhang, Yuan; An, Haiyin; Sun, Wei; Wang, Ruozheng; Liu, Meng; Zhang, Kaitai			The landscape and biological relevance of aberrant alternative splicing events in esophageal squamous cell carcinoma	ONCOGENE			English	Article							GENE; TRANSCRIPTOME; ACCURATE; ISOFORMS; RATIO	Aberrant alternative splicing events (AASEs) are key biological processes for tumorigenesis and the rationale for designing splice-switching oligonucleotides (SSOs). However, the landscape of AASEs in esophageal squamous cell carcinoma (ESCC) remains unclear, which undermines the development of SSOs for ESCC. Here, we profiled AASEs based on 125 pairs of RNA-seq libraries. We identified 14,710 AASEs in ESCC, most of which (92.67%) affected coding genes. The first exon of transcripts was frequently changed in ESCC. We constructed a regulatory network where 74 RNA-binding proteins regulated 2142 AASEs. This network was enriched in apoptotic pathways and various adhesion/junction-related processes. Somatic mutations in ESCC regulating ASEs were mainly through trans-regulatory mode and were enriched in intron regions. Isoform switches of apoptotic genes and binding genes both tended to induce "noncoding transcripts" and "domain loss," disrupting the apoptotic and Hippo signaling pathways. All ESCC samples were grouped into three clusters with different AASEs patterns and the second cluster was identified as "cold tumor," with a low abundance of immune cells, activated immune pathways, and immunomodulators. Our work comprehensively profiled the landscape of AASEs in ESCC, revealed novel AASEs related to tumorigenesis and immune microenvironment, and suggested promising directions for designing SSOs for ESCC.	[Wu, Quanyou; Zhang, Kaitai] Chinese Acad Med Sci, State Key Lab Mol Oncol, Dept Etiol & Carcinogenesis, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China; [Wu, Quanyou; Zhang, Kaitai] Peking Union Med Coll, Beijing 100021, Peoples R China; [Zhang, Yuan; Sun, Wei; Wang, Ruozheng; Liu, Meng] Xinjiang Med Univ, Key Lab Oncol Xinjiang Uyghur Autonomous Reg, Affiliated Tumor Hosp, Urumqi, Xinjiang, Peoples R China; [An, Haiyin] Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Dept Med Oncol, Beijing 101149, Peoples R China; [Wang, Ruozheng; Liu, Meng] Chinese Acad Med Sci, Key Lab Canc Immunotherapy & Radiotherapy, Urumqi 830011, Xinjiang, Peoples R China; [Wang, Ruozheng; Liu, Meng] Xinjiang Med Univ, State Key Lab Pathogenesis Prevent & Treatment Hi, Urumqi 830011, Xinjiang, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Xinjiang Medical University; Capital Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Xinjiang Medical University	Zhang, KT (corresponding author), Chinese Acad Med Sci, State Key Lab Mol Oncol, Dept Etiol & Carcinogenesis, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.; Zhang, KT (corresponding author), Peking Union Med Coll, Beijing 100021, Peoples R China.; Liu, M (corresponding author), Xinjiang Med Univ, Key Lab Oncol Xinjiang Uyghur Autonomous Reg, Affiliated Tumor Hosp, Urumqi, Xinjiang, Peoples R China.; Liu, M (corresponding author), Chinese Acad Med Sci, Key Lab Canc Immunotherapy & Radiotherapy, Urumqi 830011, Xinjiang, Peoples R China.; Liu, M (corresponding author), Xinjiang Med Univ, State Key Lab Pathogenesis Prevent & Treatment Hi, Urumqi 830011, Xinjiang, Peoples R China.	liuxiaomeng198154@163.com; zhangkt@cicams.ac.cn		Wu, Quanyou/0000-0002-3180-8606	Research Fund of Key Laboratory of Xinjiang oncology [2017D04006]	Research Fund of Key Laboratory of Xinjiang oncology	This research was supported by the Research Fund of Key Laboratory of Xinjiang oncology (Grant no. 2017D04006). Funders only provided funding and had no role in the study design, data collection, data analysis, interpretation, and writing of the report. The authors thank Dr Wen Zhang (Department of Immunology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China) for providing technical assistance.	Aigner P, 2019, BLOOD ADV, V3, P1989, DOI 10.1182/bloodadvances.2018026385; Akgul C, 2004, CELL MOL LIFE SCI, V61, P2189, DOI 10.1007/s00018-004-4001-7; Alipanahi B, 2015, NAT BIOTECHNOL, V33, P831, DOI 10.1038/nbt.3300; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Armenteros JJA, 2019, NAT BIOTECHNOL, V37, P420, DOI 10.1038/s41587-019-0036-z; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BECHT E, 2016, GENOME BIOL, V17; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonnal SC, 2020, NAT REV CLIN ONCOL, V17, P457, DOI 10.1038/s41571-020-0350-x; Brandt AC, 2020, P NATL ACAD SCI USA, V117, P3627, DOI 10.1073/pnas.1914153117; Chabot B, 2016, J CELL BIOL, V212, P13, DOI 10.1083/jcb.201510032; Crooke ST, 2018, CELL METAB, V27, P714, DOI 10.1016/j.cmet.2018.03.004; Desterro J, 2020, NAT REV DRUG DISCOV, V19, P112, DOI 10.1038/s41573-019-0042-3; FINOTELLO F, 2019, GENOME MED, V11; Frankiw L, 2019, NAT REV IMMUNOL, V19, P675, DOI 10.1038/s41577-019-0195-7; Garrido-Martin D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20578-2; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Halloy F, 2020, NUCLEIC ACIDS RES, V48, P4658, DOI 10.1093/nar/gkaa229; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Kang YJ, 2017, NUCLEIC ACIDS RES, V45, pW12, DOI 10.1093/nar/gkx428; Khorkova O, 2017, NAT BIOTECHNOL, V35, P249, DOI 10.1038/nbt.3784; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Klausen MS, 2019, PROTEINS, V87, P520, DOI 10.1002/prot.25674; Lagergren J, 2017, LANCET, V390, P2383, DOI 10.1016/S0140-6736(17)31462-9; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Li L, 2020, BRIT J CANCER, V123, P1024, DOI 10.1038/s41416-020-0951-2; Li SL, 2019, HEPATOLOGY, V69, P359, DOI 10.1002/hep.30158; Liu M, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102831; Liu YE, 2019, PATHOL RES PRACT, V215, P272, DOI 10.1016/j.prp.2018.10.036; Lucena-Araujo AR, 2015, BLOOD, V126, P2302, DOI 10.1182/blood-2015-01-623330; Mao SS, 2019, CARCINOGENESIS, V40, P121, DOI 10.1093/carcin/bgy123; Marti, 2019, TAPPAS COMPREHENSIVE, DOI 10.1101/690743; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Michaels WE, 2020, NUCLEIC ACIDS RES, V48, P7454, DOI 10.1093/nar/gkaa490; Mogilevsky M, 2018, NUCLEIC ACIDS RES, V46, P11396, DOI 10.1093/nar/gky921; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122; Peterson RE, 2005, DEV DYNAM, V233, P811, DOI 10.1002/dvdy.20412; Racle J, 2017, ELIFE, V6, DOI 10.7554/eLife.26476; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Ryan M, 2016, NUCLEIC ACIDS RES, V44, pD1018, DOI 10.1093/nar/gkv1288; Ryan MC, 2012, BIOINFORMATICS, V28, P2385, DOI 10.1093/bioinformatics/bts452; Shabalin AA, 2012, BIOINFORMATICS, V28, P1353, DOI 10.1093/bioinformatics/bts163; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Soliman MA, 2008, AGING CELL, V7, P783, DOI 10.1111/j.1474-9726.2008.00427.x; Sturm G, 2019, BIOINFORMATICS, V35, pI436, DOI 10.1093/bioinformatics/btz363; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Trincado JL, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1417-1; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Vanharanta S, 2014, ELIFE, V3, DOI 10.7554/eLife.02734; Vitting-Seerup K, 2019, BIOINFORMATICS, V35, P4469, DOI 10.1093/bioinformatics/btz247; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang LY, 2020, NUCLEIC ACIDS RES, V48, P5065, DOI 10.1093/nar/gkaa194; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Xie ZC, 2019, AM J TRANSL RES, V11, P4010; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118	60	5	5	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4184	4197		10.1038/s41388-021-01849-8	http://dx.doi.org/10.1038/s41388-021-01849-8		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34079089				2022-12-28	WOS:000657217400005
J	Xu, QP; Zhang, JW; Telfer, BA; Zhang, H; Ali, N; Chen, FH; Risa, B; Pearson, AJ; Zhang, W; Finegan, KG; Ucar, A; Giurisato, E; Tournier, C				Xu, Qiuping; Zhang, Jingwei; Telfer, Brian A.; Zhang, Hao; Ali, Nisha; Chen, Fuhui; Risa, Blanca; Pearson, Adam J.; Zhang, Wei; Finegan, Katherine G.; Ucar, Ahmet; Giurisato, Emanuele; Tournier, Cathy			The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion	ONCOGENE			English	Article							FAK; ACTIVATION; TRANSITION; MIGRATION; PATHWAYS; ROLES; SRC	There is overwhelming clinical evidence that the extracellular-regulated protein kinase 5 (ERK5) is significantly dysregulated in human breast cancer. However, there is no definite understanding of the requirement of ERK5 in tumor growth and metastasis due to very limited characterization of the pathway in disease models. In this study, we report that a high level of ERK5 is a predictive marker of metastatic breast cancer. Mechanistically, our in vitro data revealed that ERK5 was critical for maintaining the invasive capability of triple-negative breast cancer (TNBC) cells through focal adhesion protein kinase (FAK) activation. Specifically, we found that phosphorylation of FAK at Tyr397 was controlled by a kinase-independent function of ERK5. Accordingly, silencing ERK5 in mammary tumor grafts impaired FAK phosphorylation at Tyr397 and suppressed TNBC cell metastasis to the lung without preventing tumor growth. Collectively, these results establish a functional relationship between ERK5 and FAK signaling in promoting malignancy. Thus, targeting the oncogenic ERK5-FAK axis represents a promising therapeutic strategy for breast cancer exhibiting aggressive clinical behavior.	[Xu, Qiuping; Zhang, Jingwei; Chen, Fuhui; Risa, Blanca; Pearson, Adam J.; Zhang, Wei; Ucar, Ahmet; Giurisato, Emanuele; Tournier, Cathy] Univ Manchester, Div Canc Sci, Sch Med Sci, Fac Biol Med & Hlth, Manchester, Lancs, England; [Telfer, Brian A.; Finegan, Katherine G.] Univ Manchester, Div Pharm & Optometry, Sch Hlth Sci, Fac Biol Med & Hlth, Manchester, Lancs, England; [Zhang, Hao] Sun Yat Sen Univ, Sch Life Sci, State Key Lab Biocontrol, Guangzhou, Peoples R China; [Ali, Nisha] Manchester Univ NHS FT, Wythenshawe Hosp, Manchester, Lancs, England; [Giurisato, Emanuele] Univ Siena, Dept Biotechnol Chem & Pharm, Siena, Italy	University of Manchester; University of Manchester; Sun Yat Sen University; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Siena	Tournier, C (corresponding author), Univ Manchester, Div Canc Sci, Sch Med Sci, Fac Biol Med & Hlth, Manchester, Lancs, England.	cathy.tournier@manchester.ac.uk	GIURISATO, EMANUELE/AAO-2352-2020; GIURISATO, EMANUELE/I-4904-2017	GIURISATO, EMANUELE/0000-0003-0598-6449; GIURISATO, EMANUELE/0000-0003-0598-6449; Tournier, Cathy/0000-0002-4618-2570; Zhang, Wei/0000-0002-3826-7128; Telfer, Brian/0000-0003-1857-5120; Pearson, Adam/0000-0002-6719-9750; Finegan, Katie/0000-0003-2885-0122; Ucar, Ahmet/0000-0002-6551-3486	Worldwide Cancer Research; Medical Research Council	Worldwide Cancer Research; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by a grant from Worldwide Cancer Research to CT and a Confidence in Concept scheme award from the Medical Research Council to KGF. We thank Peter March and Roger Meadow (Bioimaging), Mike Jackson (Flow Cytometry), George Taylor (Mass Spectrometry), Duncan Forster (Wolfson Molecular Imaging Center), and Peter Walker (Histology) from core research facilities (University of Manchester) for very helpful advice, and the staff at the University of Manchester Biological Safety Unit for looking after the mice. We would also like to thank Andrew Gilmore and Stuart Cain from the University of Manchester for providing essential reagents for the execution of the work.	Al-Ejeh F, 2014, ONCOTARGET, V5, P3145, DOI 10.18632/oncotarget.1865; Ali M, 2019, BIOCHEM BIOPH RES CO, V513, P179, DOI 10.1016/j.bbrc.2019.03.145; Antoon JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069291; Barros JC, 2005, J CELL SCI, V118, P1663, DOI 10.1242/jcs.02308; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Brami-Cherrier K, 2014, EMBO J, V33, P356, DOI 10.1002/embj.201386399; Montero JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005565; Castro NE, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2622; Chen RQ, 2012, CANCER RES, V72, P1579, DOI 10.1158/0008-5472.CAN-11-2055; Cronan MR, 2012, ONCOGENE, V31, P3889, DOI 10.1038/onc.2011.544; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Goel RK, 2015, BBA-REV CANCER, V1856, P39, DOI 10.1016/j.bbcan.2015.05.001; Javaid S, 2015, MOL CANCER RES, V13, P934, DOI 10.1158/1541-7786.MCR-14-0604; Ortiz-Ruiz MJ, 2014, ONCOTARGET, V5, P11308, DOI 10.18632/oncotarget.2324; Jiang WW, 2020, PROTEIN CELL, V11, P825, DOI 10.1007/s13238-020-00701-1; Jiang XH, 2007, CELL SIGNAL, V19, P1000, DOI 10.1016/j.cellsig.2006.11.004; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Liu F, 2017, ONCOL REP, V37, P83, DOI 10.3892/or.2016.5256; Locatelli A, 2011, J BIOL CHEM, V286, P21062, DOI 10.1074/jbc.M110.211409; Madak-Erdogan Z, 2014, MOL CANCER RES, V12, P714, DOI 10.1158/1541-7786.MCR-13-0588; Miranda Mariska, 2015, Oncoscience, V2, P99; Narod SA, 2015, J Cancer Policy, V5, P8, DOI 10.1016/j.jcpo.2015.03.002; Nithianandarajah-Jones GN, 2012, CELL SIGNAL, V24, P2187, DOI 10.1016/j.cellsig.2012.07.007; Pavan S, 2018, ONCOGENE, V37, P4197, DOI 10.1038/s41388-018-0270-8; Pearson AJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030929; Perez-Madrigal D, 2012, CELL SIGNAL, V24, P2360, DOI 10.1016/j.cellsig.2012.08.001; Sawhney RS, 2009, J CELL PHYSIOL, V219, P152, DOI 10.1002/jcp.21662; Schramp M, 2008, J CELL BIOL, V181, P1195, DOI 10.1083/jcb.200801078; Sledge GW, 2014, J CLIN ONCOL, V32, P1979, DOI 10.1200/JCO.2014.55.4139; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Tanjoni I, 2010, CANCER BIOL THER, V9, P764, DOI 10.4161/cbt.9.10.11434; Hoang VT, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01164; Villa-Moruzzi E, 2007, BIOCHEM J, V408, P7, DOI 10.1042/BJ20070058; Vuong D, 2014, VIRCHOWS ARCH, V465, P1, DOI 10.1007/s00428-014-1593-7; Wang JH, 2018, ACS CHEM BIOL, V13, P2438, DOI 10.1021/acschembio.7b00638; Williams CAC, 2016, CELL REP, V16, P1820, DOI 10.1016/j.celrep.2016.07.033; Wu JC, 2015, SCI REP-UK, V5, DOI 10.1038/srep18476; Zhou CH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2210; Zouq NK, 2009, J CELL SCI, V122, P357, DOI 10.1242/jcs.030478; Zuo YF, 2015, J CELL BIOCHEM, V116, P124, DOI 10.1002/jcb.24950	41	7	7	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					3929	3941		10.1038/s41388-021-01798-2	http://dx.doi.org/10.1038/s41388-021-01798-2		MAY 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	33981002	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000650166200002
J	Battaglin, F; Chan, P; Pan, YZ; Soni, S; Qu, M; Spiller, ER; Castanon, S; Torres, ETR; Mumenthaler, SM; Kay, SA; Lenz, HJ				Battaglin, Francesca; Chan, Priscilla; Pan, Yuanzhong; Soni, Shivani; Qu, Meng; Spiller, Erin R.; Castanon, Sofi; Torres, Evanthia T. Roussos; Mumenthaler, Shannon M.; Kay, Steve A.; Lenz, Heinz-Josef			Clocking cancer: the circadian clock as a target in cancer therapy	ONCOGENE			English	Review								Disruption of the cellular pathway modulating endogenous 24-h rhythms, referred to as "the circadian clock", has been recently proven to be associated with cancer risk, development, and progression. This pathway operates through a complex network of transcription-translation feedback loops generated by a set of interplaying proteins. The expression of core circadian clock genes is frequently dysregulated in human tumors; however, the specific effects and underlying mechanisms seem to vary depending on the cancer types and are not fully understood. In addition, specific oncogenes may differentially induce the dysregulation of the circadian clock in tumors. Pharmacological modulation of clock components has been shown to result in specific lethality in certain types of cancer cells, and thus holds great promise as a novel anti-cancer therapeutic approach. Here we present an overview of the rationale and current evidence for targeting the clock in cancer treatment.	[Battaglin, Francesca; Soni, Shivani; Castanon, Sofi; Torres, Evanthia T. Roussos; Mumenthaler, Shannon M.; Lenz, Heinz-Josef] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Div Oncol, Los Angeles, CA 90007 USA; [Chan, Priscilla; Pan, Yuanzhong; Qu, Meng; Kay, Steve A.] Univ Southern Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90007 USA; [Spiller, Erin R.; Mumenthaler, Shannon M.] Univ Southern Calif, Lawrence J Ellison Inst Transformat Med, Los Angeles, CA 90007 USA	University of Southern California; University of Southern California; University of Southern California	Lenz, HJ (corresponding author), Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Div Oncol, Los Angeles, CA 90007 USA.	lenz@med.usc.edu	Kay, Steve A/F-6025-2011; Mumenthaler, Shannon M/AGY-8535-2022; Battaglin, Francesca/C-2746-2017; Spiller, Erin/GWZ-2718-2022; Qu, Meng/Q-9933-2017	Kay, Steve A/0000-0002-0402-2878; Battaglin, Francesca/0000-0002-9869-0163; Qu, Meng/0000-0002-1361-5392; Chan, Priscilla/0000-0003-1338-363X; Pan, Yuanzhong/0000-0002-6642-758X; Spiller, Erin/0000-0003-3958-3904; Roussos Torres, Evanthia/0000-0002-0740-5102	USC/Norris Translational Team Accelerator Project Initiative; National Cancer Institute [P30CA014089, UG1CA180830, R01CA23866201]; National Institute of Neurological Disorders and Stroke [1F31NS120654-01]; Gloria Borges WunderGlo Foundation; Gene Gregg Pancreas Research Fund; Victoria Wilson Research Fund	USC/Norris Translational Team Accelerator Project Initiative; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Gloria Borges WunderGlo Foundation; Gene Gregg Pancreas Research Fund; Victoria Wilson Research Fund	Partly supported by the USC/Norris Translational Team Accelerator Project Initiative, the National Cancer Institute (grant numbers P30CA014089, UG1CA180830, R01CA23866201), the National Institute of Neurological Disorders and Stroke (grant number 1F31NS120654-01), the Gloria Borges WunderGlo Foundation, the Gene Gregg Pancreas Research Fund, and the Victoria Wilson Research Fund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute of the National Institutes of Health.	Altman BJ, 2015, CELL METAB, V22, P1009, DOI 10.1016/j.cmet.2015.09.003; Amir M, 2018, CELL REP, V25, P3733, DOI 10.1016/j.celrep.2018.11.101; Ashrafizadeh M, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050110; Battaglin F, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.3576; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Benna C, 2017, ONCOTARGET, V8, P23978, DOI 10.18632/oncotarget.15074; Bibian M, 2013, BIOORG MED CHEM LETT, V23, P4374, DOI 10.1016/j.bmcl.2013.05.075; Burgermeister E, 2019, EBIOMEDICINE, V45, P139, DOI 10.1016/j.ebiom.2019.07.004; Cadenas C, 2014, CELL CYCLE, V13, P3282, DOI 10.4161/15384101.2014.954454; Cao Q, 2009, CANCER RES, V69, P7619, DOI 10.1158/0008-5472.CAN-08-4199; Cao XM, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021174118; Chen PW, 2020, CANCER DISCOV, V10, P371, DOI 10.1158/2159-8290.CD-19-0400; Chun SK, 2015, BIOCHEM BIOPH RES CO, V467, P441, DOI 10.1016/j.bbrc.2015.09.103; Chun SK, 2014, ACS CHEM BIOL, V9, P703, DOI 10.1021/cb400752k; De Mei C, 2015, ONCOGENE, V34, P2597, DOI 10.1038/onc.2014.203; Dierickx P, 2019, P NATL ACAD SCI USA, V116, P12147, DOI 10.1073/pnas.1904226116; Dong Z, 2019, CANCER DISCOV, V9, P1556, DOI 10.1158/2159-8290.CD-19-0215; Duda P, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051110; Duffy DJ, 2014, MOL CANCER THER, V13, P454, DOI 10.1158/1535-7163.MCT-13-0560-T; Fekry B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06648-6; Flynn-Evans EE, 2013, JNCI-J NATL CANCER I, V105, P1292, DOI 10.1093/jnci/djt169; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Gery S, 2007, ONCOGENE, V26, P7916, DOI 10.1038/sj.onc.1210585; He BK, 2016, CELL METAB, V23, P610, DOI 10.1016/j.cmet.2016.03.007; Hirota T, 2012, SCIENCE, V337, P1094, DOI 10.1126/science.1223710; Hirota T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000559; Hirota T, 2008, P NATL ACAD SCI USA, V105, P20746, DOI 10.1073/pnas.0811410106; Huber AL, 2016, MOL CELL, V64, P774, DOI 10.1016/j.molcel.2016.10.012; Hwang-Verslues WW, 2013, P NATL ACAD SCI USA, V110, P12331, DOI 10.1073/pnas.1222684110; Kettner NM, 2016, CANCER CELL, V30, P909, DOI 10.1016/j.ccell.2016.10.007; Kinouchi K, 2020, NAT REV CANCER, V20, P645, DOI 10.1038/s41568-020-0291-9; Kitabayashi T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46454-8; Kojetin D, 2011, ACS CHEM BIOL, V6, P131, DOI 10.1021/cb1002575; Kondratov RV, 2003, GENE DEV, V17, P1921, DOI 10.1101/gad.1099503; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee JW, 2019, J MED CHEM, V62, P1989, DOI 10.1021/acs.jmedchem.8b01541; Lee JW, 2015, CHEMMEDCHEM, V10, P1489, DOI 10.1002/cmdc.201500260; Lee S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010995; Li WH, 2016, BIOCHEM BIOPH RES CO, V472, P156, DOI 10.1016/j.bbrc.2016.02.087; Li Y, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101551; Lian Haiwei, 2019, Asian Pac J Cancer Prev, V20, P23; Liu N, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00159; Lo WY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070198; Luciano AK, 2018, J BIOL CHEM, V293, P9126, DOI 10.1074/jbc.RA117.000773; Mannic T, 2013, J CLIN ENDOCR METAB, V98, P4446, DOI 10.1210/jc.2013-2568; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; Miller S, 2020, CELL CHEM BIOL, V27, P1192, DOI 10.1016/j.chembiol.2020.05.008; Miller S, 2020, NAT CHEM BIOL, V16, P676, DOI 10.1038/s41589-020-0505-1; Mohawk JA, 2012, ANNU REV NEUROSCI, V35, P445, DOI 10.1146/annurev-neuro-060909-153128; de Assis LVM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00185; Noel R, 2012, BIOORG MED CHEM LETT, V22, P3739, DOI 10.1016/j.bmcl.2012.04.023; OSHIMA T, 2019, SCI TRANSL MED, V5, DOI DOI 10.1126/sciadv.aau9060; Oshima T, 2015, ANGEW CHEM INT EDIT, V54, P7193, DOI 10.1002/anie.201502942; Ozturk N, 2009, P NATL ACAD SCI USA, V106, P2841, DOI 10.1073/pnas.0813028106; Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848; Papagiannakopoulos T, 2016, CELL METAB, V24, P324, DOI 10.1016/j.cmet.2016.07.001; Pariollaud M, 2020, CANCER DISCOV, V10, P1455, DOI 10.1158/2159-8290.CD-20-0413; Puram RV, 2016, CELL, V165, P303, DOI 10.1016/j.cell.2016.03.015; Qu FL, 2016, SCI REP-UK, V6, DOI 10.1038/srep22424; Qu M, 2018, P NATL ACAD SCI USA, V115, pE12305, DOI 10.1073/pnas.1816411115; Ramos CA, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100839; Roenneberg T, 2016, CURR BIOL, V26, pR432, DOI 10.1016/j.cub.2016.04.011; Rosenberg LH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac8773; Sancar A, 2021, SCIENCE, V371, P42, DOI 10.1126/science.abb0738; Sato F, 2016, J CANCER, V7, P153, DOI 10.7150/jca.13748; Schernhammer ES, 2006, EPIDEMIOLOGY, V17, P108, DOI 10.1097/01.ede.0000190539.03500.c1; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; Sha Z, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.565225; Shafi AA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20513-5; Shen WT, 2020, THERANOSTICS, V10, P4466, DOI 10.7150/thno.42478; Shostak A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11807; Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030; Solt LA, 2011, FUTURE MED CHEM, V3, P623, DOI [10.4155/FMC.11.9, 10.4155/fmc.11.9]; Straif K, 2007, LANCET ONCOL, V8, P1065, DOI 10.1016/S1470-2045(07)70373-X; Sulli G, 2019, TRENDS CANCER, V5, P475, DOI 10.1016/j.trecan.2019.07.002; Sulli G, 2018, TRENDS PHARMACOL SCI, V39, P812, DOI 10.1016/j.tips.2018.07.003; Sulli G, 2018, NATURE, V553, P351, DOI 10.1038/nature25170; Takahashi JS, 2017, NAT REV GENET, V18, P164, DOI 10.1038/nrg.2016.150; Tamaru T, 2009, NAT STRUCT MOL BIOL, V16, P446, DOI 10.1038/nsmb.1578; Taniguchi H, 2009, CANCER RES, V69, P8447, DOI 10.1158/0008-5472.CAN-09-0551; Tao LL, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0168-5; Tao NN, 2020, CANCER LETT, V481, P1, DOI 10.1016/j.canlet.2020.03.028; Tong H, 2020, ONCOTARGETS THER, V13, P3931, DOI 10.2147/OTT.S237804; Tsuchiya Y, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000305; van der Watt PJ, 2020, MOL CANCER RES, V18, P1340, DOI 10.1158/1541-7786.MCR-19-1074; Viswanathan AN, 2007, CANCER RES, V67, P10618, DOI 10.1158/0008-5472.CAN-07-2485; Walasa WM, 2018, OCCUP ENVIRON MED, V75, P344, DOI 10.1136/oemed-2017-104657; Wang YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034921; Wang YJ, 2010, ACS CHEM BIOL, V5, P1029, DOI 10.1021/cb100223d; Wegrzyn LR, 2017, AM J EPIDEMIOL, V186, P532, DOI 10.1093/aje/kwx140; Westermaier Y, 2017, J COMPUT AID MOL DES, V31, P755, DOI 10.1007/s10822-017-0040-7; Wu YC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02451; Xiong YP, 2019, ONCOTARGETS THER, V12, P993, DOI 10.2147/OTT.S193024; Yang MY, 2015, ANTICANCER RES, V35, P6615; Ye YQ, 2018, CELL SYST, V6, P314, DOI 10.1016/j.cels.2018.01.013; Yeh CM, 2014, INT J ONCOL, V45, P2101, DOI 10.3892/ijo.2014.2627; Yoshitane H, 2009, MOL CELL BIOL, V29, P3675, DOI 10.1128/MCB.01864-08; Yu H, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0056514, 10.1371/journal.pone.0080815]; Yuan FF, 2020, BIOCHEM BIOPH RES CO, V523, P809, DOI 10.1016/j.bbrc.2019.12.105; Zhang SJ, 2016, ONCOTARGET, V7, P66087, DOI 10.18632/oncotarget.11807; Zhang YM, 2019, ONCOL REP, V41, P3545, DOI 10.3892/or.2019.7088; Zou K, 2017, ACTA PHARMACOL SIN, V38, P157, DOI 10.1038/aps.2016.125	102	19	21	4	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3187	3200		10.1038/s41388-021-01778-6	http://dx.doi.org/10.1038/s41388-021-01778-6		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33846572	Green Accepted			2022-12-28	WOS:000639635100006
J	Liu, Y; Tang, TC; Yang, XS; Qin, P; Wang, PS; Zhang, HP; Bai, M; Wu, R; Li, F				Liu, Yang; Tang, Tianchi; Yang, Xiaosheng; Qin, Peng; Wang, Pusen; Zhang, Huiping; Bai, Min; Wu, Rong; Li, Fan			Tumor-derived exosomal long noncoding RNA LINC01133, regulated by Periostin, contributes to pancreatic ductal adenocarcinoma epithelial-mesenchymal transition through the Wnt/beta-catenin pathway by silencing AXIN2	ONCOGENE			English	Article								Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies and rapidly progressive diseases. Exosomes and long noncoding RNAs (lncRNAs) are emerging as vital mediators in tumor cells and their microenvironment. However, the detailed roles and mechanisms of exosomal lncRNAs in PDAC progression remain unknown. Here, we aimed to clarify the clinical significance and mechanisms of exosomal lncRNA 01133 (LINC01133) in PDAC. We analyzed the expression of LINC01133 in PDAC and found that exosomal LINC01133 expression was high and positively correlated with higher TNM stage and poor overall survival rate of PDAC patients. Further research demonstrated that Periostin could increase exosome secretion and then enhance LINC01133 expression. In addition, Periostin increased p-EGFR, p-Erk, and c-myc expression, and c-myc could bind to the LINC01133 promoter region. These findings suggested that LINC01133 can be regulated by Periostin via EGFR pathway activity. We also observed that LINC01133 promoted the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of pancreatic cancer cells. We subsequently evaluated the effect of LINC01133 on the Wnt/beta-catenin pathway and confirmed that LINC01133 can interact with Enhancer Of Zeste Homolog 2 (EZH2) and then promote H3K27 trimethylation. This can further silence AXIN2 and suppress GSK3 activity, ultimately activating beta-catenin. Collectively, these data indicate that exosomal LINC01133 plays an important role in pancreatic tumor progression, and targeting LINC01133 may provide a potential treatment strategy for PDAC.	[Liu, Yang; Bai, Min; Wu, Rong; Li, Fan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ultrasound, Shanghai, Peoples R China; [Tang, Tianchi] Shanghai Jiao Tong Univ, Sch Med, Affiliated Xinhua Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Yang, Xiaosheng] Shanghai Jiao Tong Univ, Dept Neurosurg, Shanghai Peoples Hosp 9, Sch Med, Shanghai, Peoples R China; [Qin, Peng] Shanghai Jiao Tong Univ, Dept Instrument Sci & Engn, Shanghai, Peoples R China; [Wang, Pusen] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Zhang, Huiping] East China Normal Univ, Shanghai Changning Matern & Infant Hlth Hosp, Matern & Infant Hlth Hosp, Dept Ultrasound, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; East China Normal University	Wu, R; Li, F (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ultrasound, Shanghai, Peoples R China.	wurong7111@163.com; medicineli@163.com		Fan, Li/0000-0003-3550-0243	Shanghai Municipal Commission of Health and Family Planning [20184Y0363]; Medical and Engineering Cross-Foundation of Shanghai Jiaotong University [ZH2018QNA21]; Songjiang District Science and Technology Research Projects of Shanghai [19SJKJGG29]; National Natural Science Foundation of China [81571679, 81771838]; Shanghai Natural Science Foundation [19ZR1441500]	Shanghai Municipal Commission of Health and Family Planning; Medical and Engineering Cross-Foundation of Shanghai Jiaotong University; Songjiang District Science and Technology Research Projects of Shanghai; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai)	Funding were provided by Shanghai Municipal Commission of Health and Family Planning (20184Y0363), the Medical and Engineering Cross-Foundation of Shanghai Jiaotong University (ZH2018QNA21), Songjiang District Science and Technology Research Projects of Shanghai (19SJKJGG29), the National Natural Science Foundation of China (Nos. 81571679 and 81771838) and the Shanghai Natural Science Foundation (19ZR1441500).	Bolha L, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/7243968; Danieau G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153751; Ding J, 2018, ONCOGENE, V37, P5037, DOI 10.1038/s41388-018-0175-6; Dong D, 2018, CANCER SCI, V109, P2841, DOI 10.1111/cas.13712; Erkan M, 2012, NAT REV GASTRO HEPAT, V9, P454, DOI 10.1038/nrgastro.2012.115; Feng Y, 2019, CANCER BIOL THER, V20, P1453, DOI 10.1080/15384047.2019.1647058; Foroughi K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123881; Fu YJ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0815-z; Fukushima N, 2008, MODERN PATHOL, V21, P1044, DOI 10.1038/modpathol.2008.77; Gruszka AM, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111403; Han ML, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1145-5; He P, 2018, GASTROENTEROLOGY, V154, P1494, DOI 10.1053/j.gastro.2017.12.005; Huang YK, 2020, AM J CANCER RES, V10, P131; Jin H, 2017, CLIN TRANSL ONCOL, V19, P921, DOI 10.1007/s12094-017-1625-2; Kong JL, 2016, CANCER LETT, V380, P476, DOI 10.1016/j.canlet.2016.07.015; Kumar MM, 2017, CURR TOP MED CHEM, V17, P1750, DOI 10.2174/1568026617666161116144744; Lan B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184332; Liu Y, 2017, ONCOTARGET, V8, P89552, DOI 10.18632/oncotarget.11533; Lu HZ, 2017, CANCER MED-US, V6, P1181, DOI 10.1002/cam4.1064; Makena MR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174242; Murillo-Garzon V, 2017, NAT REV UROL, V14, P683, DOI 10.1038/nrurol.2017.144; Pirogov SA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070668; Ren B, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0858-1; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Ruivo CF, 2017, CANCER RES, V77, P6480, DOI 10.1158/0008-5472.CAN-17-0994; Saini F, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050424; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Sun QY, 2018, NUCLEIC ACIDS RES, V46, P10405, DOI 10.1093/nar/gky696; Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334; Tandon M, 2019, CANCER RES, V79, P5316, DOI 10.1158/0008-5472.CAN-18-3064; Tang B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1128-6; Thomas D, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0927-5; Viotti M, 2018, J CELL BIOL, V217, P763, DOI 10.1083/jcb.201705031; Wang J, 2020, INT J CANCER, V146, P906, DOI 10.1002/ijc.32277; Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841; Ware MJ, 2016, BIOMATERIALS, V108, P129, DOI 10.1016/j.biomaterials.2016.08.041; Wen ZZ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0590-2; Yang XZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0874-1; Zeng FR, 2020, ONCOGENE, V39, P293, DOI 10.1038/s41388-019-0984-2; Zeng HF, 2018, ONCOL RES, V26, P335, DOI 10.3727/096504017X14907375885605; Zhang J, 2015, TUMOR BIOL, V36, P7465, DOI 10.1007/s13277-015-3460-9; Zhang YF, 2018, CANCER LETT, V431, P190, DOI 10.1016/j.canlet.2018.05.027; Zheng YF, 2019, J CELL BIOCHEM, V120, P4172, DOI 10.1002/jcb.27704; Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613	44	21	21	4	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3164	3179		10.1038/s41388-021-01762-0	http://dx.doi.org/10.1038/s41388-021-01762-0		APR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33824474	Green Published, hybrid			2022-12-28	WOS:000637478800003
J	Martinez-Ordonez, A; Seoane, S; Avila, L; Eiro, N; Macia, M; Arias, E; Pereira, F; Garcia-Caballero, T; Gomez-Lado, N; Aguiar, P; Vizoso, F; Perez-Fernandez, R				Martinez-Ordonez, Anxo; Seoane, Samuel; Avila, Leandro; Eiro, Noemi; Macia, Manuel; Arias, Efigenia; Pereira, Fabio; Garcia-Caballero, Tomas; Gomez-Lado, Noemi; Aguiar, Pablo; Vizoso, Francisco; Perez-Fernandez, Roman			POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation	ONCOGENE			English	Article								Metabolic reprogramming is considered hallmarks of cancer. Aerobic glycolysis in tumors cells has been well-known for almost a century, but specific factors that regulate lactate generation and the effects of lactate in both cancer cells and stroma are not yet well understood. In the present study using breast cancer cell lines, human primary cultures of breast tumors, and immune deficient murine models, we demonstrate that the POU1F1 transcription factor is functionally and clinically related to both metabolic reprogramming in breast cancer cells and fibroblasts activation. Mechanistically, we demonstrate that POU1F1 transcriptionally regulates the lactate dehydrogenase A (LDHA) gene. LDHA catalyzes pyruvate into lactate instead of leading into the tricarboxylic acid cycle. Lactate increases breast cancer cell proliferation, migration, and invasion. In addition, it activates normal-associated fibroblasts (NAFs) into cancer-associated fibroblasts (CAFs). Conversely, LDHA knockdown in breast cancer cells that overexpress POU1F1 decreases tumor volume and [F-18]FDG uptake in tumor xenografts of mice. Clinically, POU1F1 and LDHA expression correlate with relapse- and metastasis-free survival. Our data indicate that POU1F1 induces a metabolic reprogramming through LDHA regulation in human breast tumor cells, modifying the phenotype of both cancer cells and fibroblasts to promote cancer progression.	[Martinez-Ordonez, Anxo; Seoane, Samuel; Avila, Leandro; Perez-Fernandez, Roman] Univ Santiago de Compostela, Dept Physiol, Ctr Res Mol Med & Chron Dis CIMUS, Santiago De Compostela, Spain; [Eiro, Noemi; Vizoso, Francisco] Hosp Fdn Jove, Res Unit, Gijon, Spain; [Macia, Manuel; Arias, Efigenia] Univ Santiago de Compostela, Dept Obstet & Gynecol, Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain; [Pereira, Fabio] Univ Santiago de Compostela, Dept Radiat Oncol, Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain; [Garcia-Caballero, Tomas] Univ Santiago de Compostela, Dept Morphol Sci, Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain; [Gomez-Lado, Noemi; Aguiar, Pablo] Univ Santiago de Compostela, Mol Imaging Grp, Dept Psychiat Radiol Publ Hlth Nursing & Med, Santiago De Compostela, Spain; [Gomez-Lado, Noemi; Aguiar, Pablo] Univ Santiago de Compostela, Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain; [Martinez-Ordonez, Anxo] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA	Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela; Cornell University	Perez-Fernandez, R (corresponding author), Univ Santiago de Compostela, Dept Physiol, Ctr Res Mol Med & Chron Dis CIMUS, Santiago De Compostela, Spain.	roman.perez.fernandez@usc.es	Fernández, Pablo Aguiar/ABD-9169-2022; Gómez-Lado, Noemí/AAR-2538-2021; Seoane Ruzo, Samuel/H-6299-2015; Perez-Fernandez, Roman/L-6342-2014; Eiro, Noemi/C-9510-2018	Gómez-Lado, Noemí/0000-0003-2362-3051; Pires Pereira, Fabio/0000-0002-9991-2805; Avila Concepcion, Leandro/0000-0003-4027-4578; Seoane Ruzo, Samuel/0000-0002-9178-0887; Perez-Fernandez, Roman/0000-0002-5894-0615; Arias, Maria Efigenia/0000-0001-8744-9502; Eiro, Noemi/0000-0001-5840-4807	FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal de Investigacion [PGC2018-100776-B-I00]; Conselleria de Cultura, Educacion e Ordenacion Universitaria [GPC2014/001]; FPU grant (Ministerio de Educacion) [FPU14/00548]; BioBank Complejo Hospitalario Universitario de Santiago (CHUS) [PT17/0015/0002]	FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal de Investigacion; Conselleria de Cultura, Educacion e Ordenacion Universitaria; FPU grant (Ministerio de Educacion)(German Research Foundation (DFG)); BioBank Complejo Hospitalario Universitario de Santiago (CHUS)	This study was supported by FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal de Investigacion-PGC2018-100776-B-I00 and from Conselleria de Cultura, Educacion e Ordenacion Universitaria (GPC2014/001), AM-O was supported by an FPU grant (Ministerio de Educacion-FPU14/00548). We are grateful to Dr. M. Fidalgo and Dr. D. Guallar for helping us to design some experiments, to MJ Otero Fraga for IHC analysis, and the BioBank Complejo Hospitalario Universitario de Santiago (CHUS)(PT17/0015/0002) for their collaboration.	An JY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04366-5; Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; Baek G, 2014, CELL REP, V9, P2233, DOI 10.1016/j.celrep.2014.11.025; Ben-Batalla I, 2010, ENDOCR-RELAT CANCER, V17, P73, DOI 10.1677/ERC-09-0100; Ben-Batalla I, 2010, J CLIN INVEST, V120, P4289, DOI 10.1172/JCI42015; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bhagat TD, 2019, ELIFE, V8, DOI 10.7554/eLife.50663; Brown TP, 2020, ONCOGENE, V39, P3292, DOI 10.1038/s41388-020-1216-5; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Davis RT, 2020, NAT CELL BIOL, V22, P310, DOI 10.1038/s41556-020-0477-0; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Gao ZC, 2016, MED SCI MONITOR, V22, P4121, DOI 10.12659/MSM.896107; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Gil-Puig C, 2005, EUR J ENDOCRINOL, V153, P335, DOI 10.1530/eje.1.01962; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang XJ, 2016, BREAST, V30, P39, DOI 10.1016/j.breast.2016.08.014; Hui S, 2017, NATURE, V551, P115, DOI 10.1038/nature24057; Husain Z, 2013, J IMMUNOL, V191, P1486, DOI 10.4049/jimmunol.1202702; Ko YH, 2016, J BIOL CHEM, V291, P26291, DOI 10.1074/jbc.M116.740209; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lee YJ, 2016, ONCOTARGET, V7, P70898, DOI 10.18632/oncotarget.12286; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Luo HJ, 2015, CANCER LETT, V361, P155, DOI 10.1016/j.canlet.2015.02.018; Martinez-Ordonez A, 2018, ONCOGENE, V37, P1430, DOI 10.1038/s41388-017-0036-8; Martinez-Outschoorn UE, 2014, SEMIN CANCER BIOL, V25, P47, DOI 10.1016/j.semcancer.2014.01.005; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P1271, DOI 10.4161/cc.10.8.15330; McGuirk S, 2020, TRENDS CANCER, V6, P49, DOI 10.1016/j.trecan.2019.11.009; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Roland CL, 2014, CANCER RES, V74, P5301, DOI 10.1158/0008-5472.CAN-14-0319; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Seoane S, 2006, MOL ENDOCRINOL, V20, P735, DOI 10.1210/me.2005-0253; Seoane S, 2019, J PATHOL, V249, P381, DOI 10.1002/path.5324; Seoane S, 2015, ONCOTARGET, V6, P14456, DOI 10.18632/oncotarget.3894; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; Zhu JJ, 2019, NAT REV MOL CELL BIO, V20, P436, DOI 10.1038/s41580-019-0123-5	49	10	11	4	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2725	2740		10.1038/s41388-021-01740-6	http://dx.doi.org/10.1038/s41388-021-01740-6		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33714987	hybrid, Green Published			2022-12-28	WOS:000628485300001
J	Kim, H; Son, S; Ko, Y; Shin, I				Kim, Hyungjoo; Son, Seogho; Ko, Yunhyo; Shin, Incheol			CTGF regulates cell proliferation, migration, and glucose metabolism through activation of FAK signaling in triple-negative breast cancer	ONCOGENE			English	Article								Connective tissue growth factor (CTGF), also known as CCN2, is a member of the CCN protein family of secreted proteins with roles in diverse biological processes. CTGF regulates biological functions such as cell proliferation, migration, adhesion, wound healing, and angiogenesis. In this study, we demonstrate a mechanistic link between CTGF and enhanced aerobic glycolysis in triple-negative breast cancer (TNBC). We found that CTGF is overexpressed in TNBC and high CTGF expression is correlated with a poor prognosis. Also, CTGF was required for in vivo tumorigenesis and in vitro proliferation, migration, invasion, and adhesion of TNBC cells. Our results indicate that extracellular CTGF binds directly to integrin alpha v beta 3, activating the FAK/Src/NF-kappa B p65 signaling axis, which results in transcriptional upregulation of Glut3. Neutralization of CTGF decreased cell proliferation, migration, and invasion through downregulation of Glut3-mediated glycolytic phenotypes. Overall, our work suggests a novel function for CTGF as a modulator of cancer metabolism, indicating that CTGF is a potential therapeutic target in TNBC.	[Kim, Hyungjoo; Son, Seogho; Ko, Yunhyo; Shin, Incheol] Hanyang Univ, Dept Life Sci, Seoul 04763, South Korea; [Shin, Incheol] Hanyang Univ, Inst Nat Sci, Seoul 04763, South Korea	Hanyang University; Hanyang University	Shin, I (corresponding author), Hanyang Univ, Dept Life Sci, Seoul 04763, South Korea.; Shin, I (corresponding author), Hanyang Univ, Inst Nat Sci, Seoul 04763, South Korea.	incheol@hanyang.ac.kr		Kim, Hyungjoo/0000-0003-1627-4797	National Research Foundation of Korea (NRF) [2019R1H1A2079999, 2020R1F1A1048616, 2020R1A6A3A13074546]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea)	Grant source, National Research Foundation of Korea (NRF); Grant numbers (grant recipient), 2019R1H1A2079999 (Incheol Shin), 2020R1F1A1048616 (Incheol Shin), 2020R1A6A3A13074546 (Hyungjoo Kim).	Adekola K, 2012, CURR OPIN ONCOL, V24, P650, DOI 10.1097/CCO.0b013e328356da72; Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Ancey PB, 2018, FEBS J, V285, P2926, DOI 10.1111/febs.14577; Aysola K, 2013, HEREDITARY GENET, V2013; Bennewith KL, 2009, CANCER RES, V69, P775, DOI 10.1158/0008-5472.CAN-08-0987; Bosch A, 2010, CANCER TREAT REV, V36, P206, DOI 10.1016/j.ctrv.2009.12.002; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Braig S, 2011, BRIT J CANCER, V105, P231, DOI 10.1038/bjc.2011.226; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen PS, 2007, J CELL SCI, V120, P2053, DOI 10.1242/jcs.03460; Chen PP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000534; Chien WW, 2011, INT J ONCOL, V38, P1741, DOI 10.3892/ijo.2011.985; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Dornhofer N, 2006, CANCER RES, V66, P5816, DOI 10.1158/0008-5472.CAN-06-0081; Garcia P, 2013, INT J EXP PATHOL, V94, P195, DOI 10.1111/iep.12023; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Hall-Glenn F, 2011, CELL MOL LIFE SCI, V68, P3209, DOI 10.1007/s00018-011-0782-7; Han DF, 2015, ONCOTARGET, V6, P26119, DOI 10.18632/oncotarget.4444; Han TY, 2013, CELL ADHES MIGR, V7, P395, DOI 10.4161/cam.26345; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Kikuchi R, 2007, CANCER RES, V67, P7095, DOI 10.1158/0008-5472.CAN-06-4567; Kim H, 2018, BMB REP, V51, P486, DOI 10.5483/BMBRep.2018.51.10.192; Krzeslak A, 2012, PATHOL ONCOL RES, V18, P721, DOI 10.1007/s12253-012-9500-5; Kuo MH, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121568; Ladwa R, 2011, J CLIN PATHOL, V64, P58, DOI 10.1136/jcp.2010.082768; Leask A, 2006, J CELL SCI, V119, P4803, DOI 10.1242/jcs.03270; Lee HK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054652; Lee HS, 2007, J IMMUNOL, V179, P7001, DOI 10.4049/jimmunol.179.10.7001; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lipson KE, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-S1-S24; Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515; Londhe P, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00104; Mauro C, 2011, NAT CELL BIOL, V13, P1272, DOI 10.1038/ncb2324; Neesse A, 2013, P NATL ACAD SCI USA, V110, P12325, DOI 10.1073/pnas.1300415110; Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029; Shakunaga T, 2000, CANCER, V89, P1466, DOI 10.1002/1097-0142(20001001)89:7<1466::AID-CNCR8>3.0.CO;2-G; Shimo T, 2001, ONCOLOGY-BASEL, V61, P315, DOI 10.1159/000055339; Shimo T, 2006, J BONE MINER RES, V21, P1045, DOI 10.1359/JBMR.060416; Sun XY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00428; Tai YL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/690690; Wang GM, 2013, J INT MED RES, V41, P1214, DOI 10.1177/0300060513476595; Wang MY, 2009, CANCER RES, V69, P3482, DOI 10.1158/0008-5472.CAN-08-2524; Wang XJ, 2019, MOL CELL, V76, P148, DOI 10.1016/j.molcel.2019.07.007; Watanabe M, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.21; Welch MD, 2013, BRIT J HAEMATOL, V162, P537, DOI 10.1111/bjh.12417; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Xie D, 2001, CANCER RES, V61, P8917; Yang F, 2005, CANCER RES, V65, P8887, DOI 10.1158/0008-5472.CAN-05-1702; Yin D, 2010, INT J CANCER, V127, P2257, DOI 10.1002/ijc.25257; Yoshida T, 2010, MOL CANCER THER, V9, P1657, DOI 10.1158/1535-7163.MCT-09-0906; Zha XJ, 2015, CANCER LETT, V359, P97, DOI 10.1016/j.canlet.2015.01.001	53	14	14	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2667	2681		10.1038/s41388-021-01731-7	http://dx.doi.org/10.1038/s41388-021-01731-7		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33692467				2022-12-28	WOS:000627285600002
J	Alasadi, A; Cao, B; Guo, JJ; Tao, HL; Collantes, J; Tan, V; Su, XY; Augeri, D; Jin, SK				Alasadi, Amer; Cao, Bin; Guo, Jingjing; Tao, Hanlin; Collantes, Juan; Tan, Victor; Su, Xiaoyang; Augeri, David; Jin, Shengkan			Mitochondrial uncoupler MB1-47 is efficacious in treating hepatic metastasis of pancreatic cancer in murine tumor transplantation models	ONCOGENE			English	Article							GROWTH	Pancreatic ductal adenocarcinoma (PDA) is aggressive cancer characterized by rapid progression, metastatic recurrence, and highly resistant to treatment. PDA cells exhibit aerobic glycolysis, or the Warburg effect, which reduces the flux of pyruvate into mitochondria. As a result, more glycolytic metabolites are shunted to pathways for the production of building blocks (e.g., ribose) and reducing agents (e.g., NADPH) for biosynthesis that are necessary for cell proliferation. In addition, PDA cells are highly addicted to glutamine for both maintaining biosynthetic pathways and achieving redox balance. Mitochondrial uncoupling facilitates proton influx across the mitochondrial inner membrane without generating ATP, leading to a futile cycle that consumes glucose metabolites and glutamine. We synthesized a new mitochondrial uncoupler MB1-47 and tested its effect on cancer cell metabolism and the anticancer activity in pancreatic cancer cell models and murine tumor transplantation models. MB1-47 uncouples mitochondria in the pancreatic cancer cells, resulting in: (1) the acceleration of pyruvate oxidation and TCA turnover; (2) increases in AMP/ATP and ADP/AMP ratios; and (3) a decrease in the synthesis rate of nucleotides and sugar nucleotides. Moreover, MB1-47 arrests cell cycle at G(0)-G(1) phase, reduces clonogenicity, and inhibits cell growth of murine and human pancreatic cancer cells. In vivo studies showed that MB1-47 inhibits tumor growth in murine tumor transplantation models, and inhibits the hepatic metastasis when tumor cells were transplanted intrasplenically. Our results provide proof of concept for a potentially new strategy of treating PDA, and a novel prototype experimental drug for future studies and development.	[Alasadi, Amer; Guo, Jingjing; Tao, Hanlin; Collantes, Juan; Tan, Victor; Jin, Shengkan] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; [Alasadi, Amer] Rutgers State Univ, Robert Wood Johnson Med Sch, Grad Program Physiol & Integrat Biol, Piscataway, NJ USA; [Cao, Bin; Augeri, David] Rutgers State Univ, Ernest Mario Sch Pharm, Med Chem Dept, Piscataway, NJ USA; [Su, Xiaoyang] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Med, Piscataway, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Jin, SK (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA.	victor.jin@rutgers.edu		Tan, Victor/0000-0001-5869-2773; Collantes, Juan Carlos/0000-0002-0154-5075; Alasadi, Amer/0000-0001-6082-1597	Rutgers Busch Biomedical Award; HCED Iraq Scholarship program, New Jersey Cancer Commission Research (NJCCR) Fellowship; Mito BioPharma, LLC; HCED Iraq Scholarship program; NJCCR; NIH [1R21CA216604, 1R21 AA027050]	Rutgers Busch Biomedical Award; HCED Iraq Scholarship program, New Jersey Cancer Commission Research (NJCCR) Fellowship; Mito BioPharma, LLC; HCED Iraq Scholarship program; NJCCR; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors want to thank Frank Leu for reviewing and editing the paper. The project was partially funded by Rutgers Busch Biomedical Award (2014), HCED Iraq Scholarship program, New Jersey Cancer Commission Research (NJCCR) Fellowship, and Mito BioPharma, LLC. AA is supported by HCED Iraq Scholarship program. HT was supported in part by NJCCR. AA, HT, JG, and SJ are partially supported by NIH (1R21CA216604 and 1R21 AA027050).	Alasadi A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0092-6; BLUM R, 2014, CELL, V5; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Efthimiou E, 2001, PANCREATOLOGY, V1, P571, DOI 10.1159/000055865; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Frayha GJ, 1997, GEN PHARMACOL-VASC S, V28, P273, DOI 10.1016/S0306-3623(96)00149-8; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; GILLEN S, 2010, NAT REV CLIN ONCOL, V7; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harper J A, 2001, Obes Rev, V2, P255, DOI 10.1046/j.1467-789X.2001.00043.x; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Jastroch M, 2010, ESSAYS BIOCHEM, V47, P53, DOI [10.1042/BSE0470053, 10.1042/bse0470053]; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mimeault M, 2005, PANCREAS, V31, P301, DOI 10.1097/01.mpa.0000175893.04660.1b; PARASCANDOLA J, 1974, MOL CELL BIOCHEM, V5, P69, DOI 10.1007/BF01874175; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; SHIMIZU M, 1986, MUTAT RES, V170, P11, DOI 10.1016/0165-1218(86)90077-7; Siegel R., 2015, CA-CANCER J CLIN, V65, P29, DOI [10.3322/caac.21254, DOI 10.3322/CAAC.21254, DOI 10.3322/caac.21208]; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Sun SY, 1997, CANCER RES, V57, P4931; Tao HL, 2014, NAT MED, V20, P1263, DOI 10.1038/nm.3699; TERADA H, 1990, ENVIRON HEALTH PERSP, V87, P213, DOI 10.2307/3431027; Wang W, 2009, ACTA PHYSIOL, V196, P55, DOI 10.1111/j.1748-1716.2009.01980.x; Wang YL, 2018, CELL REP, V24, P47, DOI 10.1016/j.celrep.2018.06.008; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Xu J, 2012, CRIT REV FOOD SCI, V52, P373, DOI 10.1080/10408398.2010.500245; Zhou WD, 2012, J PROTEOME RES, V11, P554, DOI 10.1021/pr2009274	37	4	4	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2285	2295		10.1038/s41388-021-01688-7	http://dx.doi.org/10.1038/s41388-021-01688-7		MAR 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33649533				2022-12-28	WOS:000623739900004
J	Zhao, L; Wu, XH; Zheng, JN; Dong, D				Zhao, Lei; Wu, Xiaohong; Zheng, Junnian; Dong, Dong			DNA methylome profiling of circulating tumor cells in lung cancer at single base-pair resolution	ONCOGENE			English	Article							PROMOTER METHYLATION; METASTASIS; SEQ	DNA methylation plays a pivotal role in regulating cellular processes, and altered DNA methylation pattern is a general hallmark of cancer. However, DNA methylome in circulating tumor cells (CTCs) is still a mystery due to the lack of proper analytical techniques. We introduced an efficient workflow, LCM-mu WGBS, which can efficiently profile the DNA methylation of microdissected CTC samples. LCM-mu WGBS combines the laser capture microdissection (LCM)-based CTC capture method and whole-genome bisulfite sequencing in very small CTC population (mu WGBS) to gain insight into the DNA methylation landscape of CTCs. We herein profiled the DNA methylome of CTCs from lung cancer patients. Deriving from a comprehensive analysis of CTC methylome, a unique "CTC DNA methylation signature" that is distinct from primary lung cancer tissues was identified. Further analysis showed that promoter hypermethylation of epithelial genes is a hallmark of stable epithelial-mesenchymal transition process. Moreover, it has been suggested that CTCs are endowed with a stemness-related feature during dissemination and metastasis. This work constitutes a unique DNA methylation analysis of CTCs at single base-pair resolution, which might facilitate to propose noninvasive CTC DNA methylation biomarkers contributing to clinical diagnosis.	[Zhao, Lei; Zheng, Junnian; Dong, Dong] Xuzhou Med Univ, Canc Inst, Xuzhou, Jiangsu, Peoples R China; [Zhao, Lei; Zheng, Junnian; Dong, Dong] Xuzhou Med Univ, Affiliated Hosp, Ctr Clin Oncol, Xuzhou, Jiangsu, Peoples R China; [Zhao, Lei] East China Normal Univ, Sch Life Sci, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai, Peoples R China; [Wu, Xiaohong] Jiangsu Univ, Affiliated Yixing Hosp, Dept Gen Surg, Yixing 214200, Jiangsu, Peoples R China	Xuzhou Medical University; Xuzhou Medical University; East China Normal University; Jiangsu University	Zheng, JN; Dong, D (corresponding author), Xuzhou Med Univ, Canc Inst, Xuzhou, Jiangsu, Peoples R China.; Zheng, JN; Dong, D (corresponding author), Xuzhou Med Univ, Affiliated Hosp, Ctr Clin Oncol, Xuzhou, Jiangsu, Peoples R China.	jnzheng@xzhmu.edu.cn; ddong@xzhmu.edu.cn	Zhao, Lei/AAN-9084-2021	Zhao, Lei/0000-0001-7298-086X; Zheng, Junnian/0000-0003-0208-6410; , Dong/0000-0002-5642-7068	Xuzhou Medical University [D2019027]; Natural Science Fund for Colleges and Universities in Jiangsu Province [20KJA320007]; Training Project for Youth Teams of Science and Technology Innovation at Xuzhou Medical University [TD202008]	Xuzhou Medical University; Natural Science Fund for Colleges and Universities in Jiangsu Province; Training Project for Youth Teams of Science and Technology Innovation at Xuzhou Medical University	This work was supported by grants from Xuzhou Medical University (grant D2019027), Natural Science Fund for Colleges and Universities in Jiangsu Province (20KJA320007), and the Training Project for Youth Teams of Science and Technology Innovation at Xuzhou Medical University (TD202008).	Allard WJ, 2004, CLIN CANCER RES, V10, P6897, DOI 10.1158/1078-0432.CCR-04-0378; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Boral D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00196-1; Chimonidou M, 2013, MOL CANCER RES, V11, P1248, DOI 10.1158/1541-7786.MCR-13-0096; Chimonidou M, 2013, CLIN CHEM, V59, P270, DOI 10.1373/clinchem.2012.191551; Chimonidou M, 2011, CLIN CHEM, V57, P1169, DOI 10.1373/clinchem.2011.165902; Engelmann D, 2012, CANCER RES, V72, P571, DOI 10.1158/0008-5472.CAN-11-2575; Farlik M, 2015, CELL REP, V10, P1386, DOI 10.1016/j.celrep.2015.02.001; Faugeroux V, 2020, EUR UROL ONCOL, V3, P498, DOI 10.1016/j.euo.2018.12.005; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Hansen KD, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-r83, 10.1186/gb-2012-13-10-R83]; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Herrmann C, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks543; Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Keller L, 2019, NAT REV CANCER, V19, P553, DOI 10.1038/s41568-019-0180-2; Korthauer K, 2019, BIOSTATISTICS, V20, P367, DOI 10.1093/biostatistics/kxy007; Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee CC, 2012, J BIOL CHEM, V287, P2798, DOI 10.1074/jbc.M111.258947; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Liu XQ, 2018, EBIOMEDICINE, V35, P244, DOI 10.1016/j.ebiom.2018.08.005; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Pantel K, 2016, ONCOGENE, V35, P1216, DOI 10.1038/onc.2015.192; Park ES, 2018, LAB CHIP, V18, P1736, DOI 10.1039/c8lc00184g; Pixberg CF, 2017, ONCOGENE, V36, P3223, DOI 10.1038/onc.2016.480; Vidal E, 2017, ONCOGENE, V36, P5648, DOI 10.1038/onc.2017.176; Wu SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123976; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217; Zhang YJ, 2015, INT J CANCER, V136, P1228, DOI 10.1002/ijc.29070; Zheng GT, 2018, NUCLEIC ACIDS RES, V46, pD950, DOI 10.1093/nar/gkx1008; Zheng XQ, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0419-x; Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433	38	10	10	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1884	1895		10.1038/s41388-021-01657-0	http://dx.doi.org/10.1038/s41388-021-01657-0		FEB 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564067	Green Published, hybrid			2022-12-28	WOS:000616489100001
J	You, BS; Sun, Y; Luo, J; Wang, KL; Liu, Q; Fang, RZ; Liu, BM; Chou, FJ; Wang, RH; Meng, JL; Huang, CP; Yeh, SY; Chang, CS; Xu, WH				You, Bosen; Sun, Yin; Luo, Jie; Wang, Keliang; Liu, Qing; Fang, Ruizhe; Liu, Bingmei; Chou, Fuju; Wang, Ronghao; Meng, Jialin; Huang, Chi-Ping; Yeh, Shuyuan; Chang, Chawnshang; Xu, Wanhai			Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR	ONCOGENE			English	Article							MESSENGER-RNA DECAY; LONG NONCODING RNAS; GASTRIC-CANCER; METASTASIS; PATTERNS; UPF1	While the androgen receptor (AR) may influence the progression of clear cell renal cell carcinoma (ccRCC), its role to impact vasculogenic mimicry (VM) to alter the ccRCC progression and metastasis remains obscure. Here, we demonstrated that elevated AR expression was positively correlated with tumor-originated vasculogenesis in ccRCC patients. Consistently, in vitro research revealed AR promoted VM formation in ccRCC cell lines via modulating lncRNA-TANAR/TWIST1 signals. Mechanism dissection showed that AR could increase lncRNA-TANAR (TANAR) expression through binding to the androgen response elements (AREs) located in its promoter region. Moreover, we found that TANAR could impede nonsense-mediated mRNA decay (NMD) of TWIST1 mRNA by direct interaction with TWIST1 5'UTR. A preclinical study using in vivo mouse model with orthotopic xenografts of ccRCC cells further confirmed the in vitro data. Together, these results illustrated that AR-mediated TANAR signals might play a crucial role in ccRCC VM formation and metastasis, and targeting this newly identified AR/TANAR/TWIST1 signaling may help in the development of a novel anti-angiogenesis therapy to better suppress the ccRCC progression.	[You, Bosen; Wang, Keliang; Fang, Ruizhe; Xu, Wanhai] Harbin Med Univ, Affiliated Hosp 4, Dept Urol, Harbin 150001, Peoples R China; [You, Bosen; Liu, Qing] Harbin Med Univ, Affiliated Hosp 2, Dept Urol, Harbin 150001, Peoples R China; [You, Bosen; Sun, Yin; Luo, Jie; Wang, Keliang; Liu, Qing; Fang, Ruizhe; Chou, Fuju; Wang, Ronghao; Meng, Jialin; Yeh, Shuyuan; Chang, Chawnshang] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14646 USA; [You, Bosen; Sun, Yin; Luo, Jie; Wang, Keliang; Liu, Qing; Fang, Ruizhe; Chou, Fuju; Wang, Ronghao; Meng, Jialin; Yeh, Shuyuan; Chang, Chawnshang] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14646 USA; [You, Bosen; Sun, Yin; Luo, Jie; Wang, Keliang; Liu, Qing; Fang, Ruizhe; Chou, Fuju; Wang, Ronghao; Meng, Jialin; Yeh, Shuyuan; Chang, Chawnshang] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14646 USA; [Liu, Bingmei] Heilongjiang Prov Hosp, Dept Pathol & Cutaneous Oncol, Harbin 150001, Peoples R China; [Huang, Chi-Ping; Chang, Chawnshang] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung 404, Taiwan; [Huang, Chi-Ping; Chang, Chawnshang] China Med Univ Hosp, Dept Urol, Taichung 404, Taiwan	Harbin Medical University; Harbin Medical University; University of Rochester; University of Rochester; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Xu, WH (corresponding author), Harbin Med Univ, Affiliated Hosp 4, Dept Urol, Harbin 150001, Peoples R China.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14646 USA.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14646 USA.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14646 USA.; Chang, CS (corresponding author), China Med Univ Hosp, Sex Hormone Res Ctr, Taichung 404, Taiwan.; Chang, CS (corresponding author), China Med Univ Hosp, Dept Urol, Taichung 404, Taiwan.	chang@urmc.rochester.edu; xuwanhai@hrbmu.edu.cn	Wang, Ronghao/AAV-9769-2021; You, Bosen/AHC-2523-2022; Meng, Jialin/L-8480-2019; liu, qingqing/HHD-0360-2022	Meng, Jialin/0000-0002-4622-833X; you, bosen/0000-0002-9037-2136; Chang, Chawnshang/0000-0001-8510-3516	NIH [CA155477]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by NIH grant (CA155477).	Adelaiye-Ogala R, 2018, CANCER RES, V78, P2886, DOI 10.1158/0008-5472.CAN-17-3386; Bai J, 2018, J UROLOGY, V199, pE1200; Bao ZQ, 2018, INT J CLIN EXP PATHO, V11, P3656; Cao LM, 2017, ELIFE, V6, DOI 10.7554/eLife.30433; Cui YF, 2015, ONCOTARGET, V6, P11087, DOI 10.18632/oncotarget.3571; Delgado-Bellido D, 2019, CELL DEATH DIFFER, V26, P348, DOI 10.1038/s41418-018-0125-4; Engreitz JM, 2016, NAT REV MOL CELL BIO, V17, P756, DOI 10.1038/nrm.2016.126; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Flippot R, 2019, NAT REV UROL, V16, P484, DOI 10.1038/s41585-019-0195-1; Franks TM, 2010, CELL, V143, P938, DOI 10.1016/j.cell.2010.11.043; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Gong WC, 2016, ONCOTARGET, V7, P70152, DOI 10.18632/oncotarget.12161; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Guo JQ, 2018, MOL THER-NUCL ACIDS, V10, P170, DOI 10.1016/j.omtn.2017.11.011; Han SH, 2020, MOL ONCOL, V14, P1074, DOI 10.1002/1878-0261.12631; Hendrix MJC, 2016, PHARMACOL THERAPEUT, V159, P83, DOI 10.1016/j.pharmthera.2016.01.006; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; Hu ZY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15943; Huang QB, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00701-6; Imamachi N, 2017, GENOME RES, V27, P407, DOI 10.1101/gr.206060.116; Karam R, 2008, ONCOGENE, V27, P4255, DOI 10.1038/onc.2008.62; Khatiwada P, 2020, PEERJ, V8, DOI 10.7717/peerj.8921; Knoll M, 2015, NAT REV ENDOCRINOL, V11, P151, DOI 10.1038/nrendo.2014.229; Kotecha RR, 2019, NAT REV CLIN ONCOL, V16, P621, DOI 10.1038/s41571-019-0209-1; Li R.-H., 2018, CELL DEATH DIS, V9, P1, DOI DOI 10.1038/s41419-017-0012-9; Lopez D, 2009, ARCH BIOCHEM BIOPHYS, V482, P77, DOI 10.1016/j.abb.2008.11.016; Lucca I, 2015, NAT REV UROL, V12, P585, DOI 10.1038/nrurol.2015.232; Luo J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09784-9; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Melero R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10585; Meng J, 2019, ONCOGENE, V38, P228, DOI 10.1038/s41388-018-0428-4; Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989; Popp MW, 2018, CURR OPIN GENET DEV, V48, P44, DOI 10.1016/j.gde.2017.10.007; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Rasti A, 2018, CLIN EXP MED, V18, P177, DOI 10.1007/s10238-017-0481-2; Serova M, 2016, ONCOTARGET, V7, P38467, DOI 10.18632/oncotarget.9542; Shang ZQ, 2019, NUCLEIC ACIDS RES, V47, P4211, DOI 10.1093/nar/gkz108; Sun T, 2011, HEPATOLOGY, V54, P1690, DOI 10.1002/hep.24543; Tao W, 2018, BIOCHEM BIOPH RES CO, V504, P629, DOI 10.1016/j.bbrc.2018.08.122; Vartanian AA, 2009, CAN J UROL, V16, P4726; Velez DO, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01556-7; Wang CF, 2019, P NATL ACAD SCI USA, V116, P14620, DOI 10.1073/pnas.1903432116; Wang KF, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1330-x; Wang L, 2015, ONCOTARGET, V6, P11492, DOI 10.18632/oncotarget.3416; Xia Y, 2019, INT J CANCER, V144, P2227, DOI 10.1002/ijc.31958; Xiao T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0902-5; Xie XN, 2019, CLIN SCI, V133, P1457, DOI 10.1042/CS20181061; Yang J, 2017, ONCOTARGET, V8, P47801, DOI 10.18632/oncotarget.17999; Yochum ZA, 2019, ONCOGENE, V38, P656, DOI 10.1038/s41388-018-0482-y; Yochum ZA, 2017, MOL CANCER RES, V15, P1764, DOI 10.1158/1541-7786.MCR-17-0298; Zerbino DR, 2018, NUCLEIC ACIDS RES, V46, pD754, DOI 10.1093/nar/gkx1098; Zhai W, 2017, CELL DEATH DIFFER, V24, P1502, DOI 10.1038/cdd.2017.74; Zhang JX, 2017, ONCOTARGETS THER, V10, P2923, DOI 10.2147/OTT.S135477; Zhang YH, 2013, J SURG ONCOL, V108, P414, DOI 10.1002/jso.23402; Zhuang JL, 2017, THERANOSTICS, V7, P3053, DOI 10.7150/thno.19542; Zund D, 2013, NAT STRUCT MOL BIOL, V20, P936, DOI 10.1038/nsmb.2635	59	11	11	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1674	1689		10.1038/s41388-020-01616-1	http://dx.doi.org/10.1038/s41388-020-01616-1		JAN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33510354	hybrid, Green Submitted, Green Published			2022-12-28	WOS:000612563100003
J	Lu, J; Bang, H; Kim, SM; Cho, SJ; Ashktorab, H; Smoot, DT; Zheng, CH; Ryeom, SW; Yoon, SS; Yoon, C; Lee, JH				Lu, Jun; Bang, Heejin; Kim, Su Mi; Cho, Soo-Jeong; Ashktorab, Hassan; Smoot, Duane T.; Zheng, Chao-hui; Ryeom, Sandra W.; Yoon, Sam S.; Yoon, Changhwan; Lee, Jun Ho			Lymphatic metastasis-related TBL1XR1 enhances stemness and metastasis in gastric cancer stem-like cells by activating ERK1/2-SOX2 signaling	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; DRUG-RESISTANCE; DOWN-REGULATION; BREAST-CANCER; PROMOTES LYMPHANGIOGENESIS; CHEMOTHERAPY RESISTANCE; LUNG; EXPRESSION; CHEMORESISTANCE; PATHWAY	The poor prognosis of gastric cancer (GC) results largely from metastasis and chemotherapy resistance. Toward novel therapeutic strategies that target or evade these phenomena, we evaluated the function of the transcriptional regulator transducin (beta)-like 1 X-linked receptor 1 (TBL1XR1) in GC cells, including stem-like cells. In this study, the correlation of expression of TBL1XR1 and clinical features and GC patients' outcomes was evaluated. Knockdown or exogenous expression of TBL1XR1 was combined with in vitro (2D and 3D cultures) and in vivo (mouse lung and lymphatic metastasis models) assays to evaluate the function of TBL1XR1. TBL1XR1's downstream signaling was delineated by phospho-kinase array and knockdown of candidate mediators. Analysis of clinical data showed that TBL1XR1 overexpression was correlated with worse prognosis. Functional assays showed that TBL1XR1 promoted stemness, epithelial-mesenchymal transition (EMT), and lung and lymphatic metastasis in GC cells. TBL1XR1 activated ERK1/2-Sox2 signaling and was dependent on signaling via PI3K/AKT, in GC stem-like cells distinguished by CD44 expression. Moreover, inhibition of these signaling proteins reversed chemoresistance in in vitro and in vivo models. Taken together, our results indicate that TBL1XR1 promotes stemness and metastasis in GC, making it a potential prognostic indicator. The PI3K/AKT-TBL1XR1-ERK1/2-Sox2 axis may represent a target for the treatment of GC.	[Lu, Jun; Yoon, Sam S.; Yoon, Changhwan] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA; [Lu, Jun; Zheng, Chao-hui] Fujian Med Univ, Union Hosp, Dept Gastr Surg, Fuzhou, Fujian, Peoples R China; [Bang, Heejin] Hallym Univ, Coll Med, Kangnam Sacred Heart Hosp, Dept Pathol, Seoul, South Korea; [Kim, Su Mi; Lee, Jun Ho] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul, South Korea; [Kim, Su Mi] CHA Univ, Sch Med, CHA Bundang Med Ctr, Dept Surg, Seongnam, Gyeonggi Do, South Korea; [Cho, Soo-Jeong] Seoul Natl Univ Hosp, Liver Res Inst, Dept Internal Med, Seoul, South Korea; [Ashktorab, Hassan; Smoot, Duane T.] Howard Univ, Dept Med, Washington, DC 20059 USA; [Ryeom, Sandra W.] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA	Memorial Sloan Kettering Cancer Center; Fujian Medical University; Hallym University; Sungkyunkwan University (SKKU); Samsung Medical Center; Pochon Cha University; Seoul National University (SNU); Seoul National University Hospital; Howard University; University of Pennsylvania	Yoon, C (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.; Lee, JH (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul, South Korea.	yoonc1@mskcc.org; gsjunholee@gmail.com	Lu, Jun/AAP-1222-2021; Yoon, Changhwan/AAK-7842-2021; Zheng, Chao-hui/HGE-3348-2022	Yoon, Changhwan/0000-0002-8420-9818; Zheng, Chao-hui/0000-0001-8680-3127; CHO, SOO-JEONG/0000-0001-7144-0589	NIH/NCI [1R01 CA158301-01]; Cancer Center Support Grant [P30 CA008748]; Natural Science Foundation of Fujian Province [2019J01155]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support Grant; Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province)	This research was supported by NIH/NCI through 1R01 CA158301-01 (SSY), Cancer Center Support Grant P30 CA008748 (MSKCC), and Natural Science Foundation of Fujian Province (2019J01155). Authors thank Jessica Moore, MS, senior editor and grant writer at MSK, for help in editing and revising the manuscript.	An YF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2308-4; Banerjee A, 2017, NEURO-ONCOLOGY, V19, P1135, DOI 10.1093/neuonc/now282; Bekaii-Saab T, 2017, CANCER-AM CANCER SOC, V123, P1303, DOI 10.1002/cncr.30538; Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen SP, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-195; Cho SJ, 2018, CLIN CANCER RES, V24, P6556, DOI 10.1158/1078-0432.CCR-17-1679; Cho SJ, 2015, INT J CANCER, V136, P810, DOI 10.1002/ijc.29056; Choi HK, 2011, MOL CELL, V43, P203, DOI 10.1016/j.molcel.2011.05.027; Dawood S, 2014, ONCOLOGY-NY, V28, P1101; Dong H, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1776-x; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Etoh T, 2001, CANCER RES, V61, P2145; Farley J, 2013, LANCET ONCOL, V14, P134, DOI 10.1016/S1470-2045(12)70572-7; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Garcia-Mayea Y, 2020, SEMIN CANCER BIOL, V60, P166, DOI 10.1016/j.semcancer.2019.07.022; Han ME, 2011, CELL MOL LIFE SCI, V68, P3589, DOI 10.1007/s00018-011-0672-z; Hao SN, 2014, TUMOR BIOL, V35, P5675, DOI 10.1007/s13277-014-1751-1; Herrera B, 2009, CANCER RES, V69, P9254, DOI 10.1158/0008-5472.CAN-09-2912; Hu J, 2010, INT J CANCER, V127, P2455, DOI 10.1002/ijc.25253; Huang WF, 2014, INT J MOL SCI, V15, P3432, DOI 10.3390/ijms15033432; Ji RB, 2015, CELL CYCLE, V14, P2473, DOI 10.1080/15384101.2015.1005530; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Khromova N, 2012, ONCOGENE, V31, P1389, DOI 10.1038/onc.2011.330; Khurana SS, 2013, J BIOL CHEM, V288, P16085, DOI 10.1074/jbc.M112.445551; Lee KM, 2017, CELL METAB, V26, P633, DOI 10.1016/j.cmet.2017.09.009; Li XH, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0465-z; Liu LP, 2015, GUT, V64, P26, DOI 10.1136/gutjnl-2013-306388; Liu SQ, 2006, DIGEST LIVER DIS, V38, P310, DOI 10.1016/j.dld.2006.01.012; Lu J, 2019, GASTRIC CANCER, V22, P536, DOI 10.1007/s10120-018-0892-0; Martelli AM, 2011, CURR MED CHEM, V18, P2715; Martins-Neves SR, 2018, PHARMACOL RES, V137, P193, DOI 10.1016/j.phrs.2018.10.011; Mashino K, 2002, CANCER RES, V62, P2937; Masters JRW, 2000, BRIT J CANCER, V82, P1495; Nasarre P, 2013, CANCER RES, V73, P7111, DOI 10.1158/0008-5472.CAN-13-1755; Ono H, 2012, ONCOGENE, V31, P4923, DOI 10.1038/onc.2011.646; Nguyen PH, 2017, CLIN CANCER RES, V23, P1586, DOI 10.1158/1078-0432.CCR-15-2157; Ruan XH, 2019, MOL THER-ONCOLYTICS, V14, P94, DOI 10.1016/j.omto.2019.04.002; Salaroglio IC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102505; Samanta D, 2014, P NATL ACAD SCI USA, V111, pE5429, DOI 10.1073/pnas.1421438111; Sciacovelli M, 2017, FEBS J, V284, P3132, DOI 10.1111/febs.14090; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Skog M, 2011, BRIT J CANCER, V105, P1346, DOI 10.1038/bjc.2011.297; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Till JE, 2017, CANCER RES, V77, P5349, DOI 10.1158/0008-5472.CAN-17-0061; Turk CM, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-17; Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3; Wang J, 2014, BRIT J CANCER, V111, P112, DOI 10.1038/bjc.2014.278; Wang YK, 2010, CARCINOGENESIS, V31, P1376, DOI 10.1093/carcin/bgq120; Wildi S, 2001, GUT, V49, P409, DOI 10.1136/gut.49.3.409; Wu G, 2014, INT J CLIN EXP PATHO, V7, P1449; Xi XH, 2019, EUR J PHARMACOL, V844, P259, DOI 10.1016/j.ejphar.2018.12.013; Xia P, 2015, AM J CANCER RES, V5, P1602; Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0954-x; Yoon C, 2019, MOL CANCER RES, V17, P1945, DOI 10.1158/1541-7786.MCR-19-0077; Yoon C, 2016, CLIN CANCER RES, V22, P971, DOI 10.1158/1078-0432.CCR-15-1356; Yoon C, 2014, CLIN CANCER RES, V20, P3974, DOI 10.1158/1078-0432.CCR-14-0011; Yoon SS, 1999, CANCER RES, V59, P6251; Zaytseva YY, 2012, CANCER RES, V72, P1504, DOI 10.1158/0008-5472.CAN-11-4057; Zhang HZ, 2019, INT J BIOL MACROMOL, V128, P574, DOI 10.1016/j.ijbiomac.2019.01.195; Zhang JX, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0586-y; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhao YY, 2015, MOL MED REP, V12, P7335, DOI 10.3892/mmr.2015.4367; Zhou L, 2018, CANCER SCI, V109, P1044, DOI 10.1111/cas.13538; Zhou Q, 2017, ONCOGENE, V36, P1873, DOI 10.1038/onc.2016.352	65	6	6	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					922	936		10.1038/s41388-020-01571-x	http://dx.doi.org/10.1038/s41388-020-01571-x		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33288885				2022-12-28	WOS:000599011200003
J	Tan, XX; Sivakumar, S; Bednarsch, J; Wiltberger, G; Kather, JN; Niehues, J; de Vos-Geelen, J; Valkenburg-van Iersel, L; Kintsler, S; Roeth, A; Hao, GS; Lang, S; Coolsen, ME; den Dulk, M; Aberle, MR; Koolen, J; Gaisa, NT; Damink, SWMO; Neumann, UP; Heij, LR				Tan, Xiuxiang; Sivakumar, Shivan; Bednarsch, Jan; Wiltberger, Georg; Kather, Jakob Nikolas; Niehues, Jan; de Vos-Geelen, Judith; Valkenburg-van Iersel, Liselot; Kintsler, Svetlana; Roeth, Anjali; Hao, Guangshan; Lang, Sven; Coolsen, Marielle E.; den Dulk, Marcel; Aberle, Merel R.; Koolen, Jarne; Gaisa, Nadine T.; Olde Damink, Steven W. M.; Neumann, Ulf P.; Heij, Lara R.			Nerve fibers in the tumor microenvironment in neurotropic cancer-pancreatic cancer and cholangiocarcinoma	ONCOGENE			English	Review							MUSCARINIC ACETYLCHOLINE-RECEPTOR; PREDICTS POOR-PROGNOSIS; PERINEURAL INVASION; GROWTH-FACTOR; INTRAHEPATIC CHOLANGIOCARCINOMA; CLINICAL-SIGNIFICANCE; STELLATE CELLS; EXPRESSION; NEUROGENESIS; PROGRESSION	Pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) are both deadly cancers and they share many biological features besides their close anatomical location. One of the main histological features is neurotropism, which results in frequent perineural invasion. The underlying mechanism of cancer cells favoring growth by and through the nerve fibers is not fully understood. In this review, we provide knowledge of these cancers with frequent perineural invasion. We discuss nerve fiber crosstalk with the main different components of the tumor microenvironment (TME), the immune cells, and the fibroblasts. Also, we discuss the crosstalk between the nerve fibers and the cancer. We highlight the shared signaling pathways of the mechanisms behind perineural invasion in PDAC and CCA. Hereby we have focussed on signaling neurotransmitters and neuropeptides which may be a target for future therapies. Furthermore, we have summarized retrospective results of the previous literature about nerve fibers in PDAC and CCA patients. We provide our point of view in the potential for nerve fibers to be used as powerful biomarker for prognosis, as a tool to stratify patients for therapy or as a target in a (combination) therapy. Taking the presence of nerves into account can potentially change the field of personalized care in these neurotropic cancers.	[Tan, Xiuxiang; Coolsen, Marielle E.; den Dulk, Marcel; Koolen, Jarne; Olde Damink, Steven W. M.; Neumann, Ulf P.; Heij, Lara R.] Maastricht Univ, Med Ctr, Dept Surg, Maastricht, Netherlands; [Tan, Xiuxiang; Bednarsch, Jan; Wiltberger, Georg; Roeth, Anjali; Lang, Sven; Olde Damink, Steven W. M.; Neumann, Ulf P.; Heij, Lara R.] RWTH Aachen Univ Hosp, Dept Gen Gastrointestinal Hepatobiliary & Transpl, Aachen, Germany; [Tan, Xiuxiang; Roeth, Anjali; Aberle, Merel R.; Olde Damink, Steven W. M.] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Maastricht, Netherlands; [Sivakumar, Shivan] Univ Oxford, Dept Oncol, Oxford, England; [Sivakumar, Shivan] Univ Oxford, Kennedy Inst Rheumatol, Oxford, England; [Kather, Jakob Nikolas; Niehues, Jan] Univ Hosp RWTH Aachen, Dept Med 3, Aachen, Germany; [de Vos-Geelen, Judith; Valkenburg-van Iersel, Liselot] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Div Med Oncol,Dept Internal Med, Maastricht, Netherlands; [Kintsler, Svetlana; Gaisa, Nadine T.; Heij, Lara R.] Univ Hosp RWTH Aachen, Inst Pathol, Aachen, Germany; [Hao, Guangshan] Univ Hosp RWTH Aachen, Translat Neurosurg & Neurobiol, Aachen, Germany	Maastricht University; RWTH Aachen University; RWTH Aachen University Hospital; Maastricht University; Maastricht University Medical Centre (MUMC); University of Oxford; University of Oxford; RWTH Aachen University; RWTH Aachen University Hospital; Maastricht University; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Heij, LR (corresponding author), Maastricht Univ, Med Ctr, Dept Surg, Maastricht, Netherlands.; Heij, LR (corresponding author), RWTH Aachen Univ Hosp, Dept Gen Gastrointestinal Hepatobiliary & Transpl, Aachen, Germany.; Heij, LR (corresponding author), Univ Hosp RWTH Aachen, Inst Pathol, Aachen, Germany.	lheij@ukaachen.de	Tan, Xiuxiang/GRX-8703-2022; Heij, Lara/AAU-2792-2020; Kather, Jakob Nikolas/D-4279-2015; hao, guangshan/HGC-8867-2022	Tan, Xiuxiang/0000-0001-6782-9137; Heij, Lara/0000-0002-0602-3356; Kather, Jakob Nikolas/0000-0002-3730-5348; de Vos-Geelen, Judith/0000-0003-2578-1766; Aberle, Merel/0000-0003-1990-1784; Olde Damink, Steven/0000-0002-5202-9345	China Scholarship Council [201806210074]	China Scholarship Council(China Scholarship Council)	X. Tan was funded by China Scholarship Council (Grantnumber: 201806210074). Open Access funding enabled and organized by Projekt DEAL.	Al-Shalan HAM, 2019, CELL TISSUE RES, V378, P239, DOI 10.1007/s00441-019-03052-4; Albo D, 2011, CANCER-AM CANCER SOC, V117, P4834, DOI 10.1002/cncr.26117; Aloe L, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0395-y; Amit M, 2020, NATURE, V578, P449, DOI 10.1038/s41586-020-1996-3; Amonyingcharoen S, 2015, INT J ONCOL, V46, P2317, DOI 10.3892/ijo.2015.2939; Apte MV, 2013, GASTROENTEROLOGY, V144, P1210, DOI 10.1053/j.gastro.2012.11.037; Ayala GE, 2008, CLIN CANCER RES, V14, P7593, DOI 10.1158/1078-0432.CCR-08-1164; Babic T, 2016, PANCREAPEDIA EXOCRIN, P1, DOI [10.3998/panc.2016.27, DOI 10.3998/PANC.2016.27]; Bai H, 2011, CARCINOGENESIS, V32, P1689, DOI 10.1093/carcin/bgr191; Bapat AA, 2011, NAT REV CANCER, V11, P695, DOI 10.1038/nrc3131; Barbieri A, 2015, INT J ONCOL, V47, P527, DOI 10.3892/ijo.2015.3038; Barron TI, 2011, J CLIN ONCOL, V29, P2635, DOI 10.1200/JCO.2010.33.5422; BATSAKIS JG, 1985, ANN OTO RHINOL LARYN, V94, P426; Bertuccio P, 2019, J HEPATOL, V71, P104, DOI 10.1016/j.jhep.2019.03.013; BOCKMAN DE, 1994, GASTROENTEROLOGY, V107, P219, DOI 10.1016/0016-5085(94)90080-9; Campbell K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10269-y; Ceyhan GO, 2010, ANN SURG, V251, P923, DOI 10.1097/SLA.0b013e3181d974d4; Ceyhan GO, 2009, GASTROENTEROLOGY, V136, P177, DOI 10.1053/j.gastro.2008.09.029; Chatterjee D, 2012, AM J SURG PATHOL, V36, P409, DOI 10.1097/PAS.0b013e31824104c5; Chen SH, 2019, AM J CANCER RES, V9, P1; Chesne J, 2019, MUCOSAL IMMUNOL, V12, P10, DOI 10.1038/s41385-018-0063-y; Cirri P, 2011, AM J CANCER RES, V1, P482; Coulouarn C, 2014, J HEPATOL, V60, P1306, DOI 10.1016/j.jhep.2014.02.003; Dang NN, 2016, BIOMED REP, V4, P515, DOI 10.3892/br.2016.625; Demir IE, 2015, NAT REV GASTRO HEPAT, V12, P649, DOI 10.1038/nrgastro.2015.166; Demir Ihsan Ekin, 2010, Cancers (Basel), V2, P1513, DOI 10.3390/cancers2031513; Eichmann A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008910; Farrow B, 2008, J SURG RES, V149, P319, DOI 10.1016/j.jss.2007.12.757; Feng YJ, 2012, HEPATOB PANCREAT DIS, V11, P418, DOI 10.1016/S1499-3872(12)60201-X; Fisher SB, 2012, HPB, V14, P514, DOI 10.1111/j.1477-2574.2012.00489.x; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Franchitto A, 2013, ANN TRANSL MED, V1, DOI 10.3978/j.issn.2305-5839.2012.10.03; Gasparini G, 2019, CANCERS, V11, DOI 10.3390/cancers11070893; Gigliozzi A, 2004, GASTROENTEROLOGY, V127, P1198, DOI 10.1053/j.gastro.2004.06.023; Godinho-Silva C, 2019, ANNU REV IMMUNOL, V37, P19, DOI 10.1146/annurev-immunol-042718-041812; Gritsenko PG, 2012, J PATHOL, V226, P185, DOI 10.1002/path.3031; Grytli HH, 2014, EUR UROL, V65, P635, DOI 10.1016/j.eururo.2013.01.007; Hondermarck H, 2018, TRENDS CANCER, V4, P93, DOI 10.1016/j.trecan.2017.11.008; Huang D, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000172; Iwasaki T, 2019, CANCER SCI, V110, P1491, DOI 10.1111/cas.13975; Jobling P, 2015, CANCER RES, V75, P1777, DOI 10.1158/0008-5472.CAN-14-3180; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Kamiya A, 2019, NAT NEUROSCI, V22, P1289, DOI 10.1038/s41593-019-0430-3; Kanno N, 2002, HEPATOLOGY, V35, P1329, DOI 10.1053/jhep.2002.33330; Khan SA, 2019, LIVER INT, V39, P19, DOI 10.1111/liv.14095; Kim-Fuchs C, 2014, BRAIN BEHAV IMMUN, V40, P40, DOI 10.1016/j.bbi.2014.02.019; Lenz J, 2011, J GASTROINTEST LIVER, V20, P389; Li WJ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00021; Liang DK, 2016, BBA-REV CANCER, V1865, P111, DOI 10.1016/j.bbcan.2016.01.002; Liebig C, 2009, CANCER-AM CANCER SOC, V115, P3379, DOI 10.1002/cncr.24396; Liu Bin, 2002, Hepatobiliary Pancreat Dis Int, V1, P469; Liu H, 2012, CURR PHARM DESIGN, V18, P2395, DOI 10.2174/13816128112092395; Liu HP, 1998, CELL TISSUE RES, V294, P227, DOI 10.1007/s004410051172; Liu TY, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00060; Ma J, 2008, J GASTROEN HEPATOL, V23, P1852, DOI 10.1111/j.1440-1746.2008.05579.x; Maatta M, 2000, CLIN CANCER RES, V6, P2726; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Maisonneuve P, 2019, PRESSE MED, V48, pE113, DOI 10.1016/j.lpm.2019.02.030; March B, 2020, NAT REV UROL, V17, P119, DOI 10.1038/s41585-019-0274-3; Martinez AK, 2017, AM J PATHOL, V187, P1093, DOI 10.1016/j.ajpath.2017.01.011; Mauffrey P, 2019, NATURE, V569, P672, DOI 10.1038/s41586-019-1219-y; Mavros MN, 2014, JAMA SURG, V149, P565, DOI 10.1001/jamasurg.2013.5137; McClements S, 2019, LIVER CANC MECH MANA, P179; Mignini F, 2014, INT J MOL MED, V33, P1392, DOI 10.3892/ijmm.2014.1709; Mizuno K, 2017, HEPATOL RES, V47, P160, DOI 10.1111/hepr.12760; Molloy Niamh H, 2011, Cancers (Basel), V3, P510, DOI 10.3390/cancers3010510; Momi N, 2013, ONCOGENE, V32, P1384, DOI 10.1038/onc.2012.163; Monje M, 2020, CELL, V181, P219, DOI 10.1016/j.cell.2020.03.034; Nakao A, 1996, PANCREAS, V12, P357, DOI 10.1097/00006676-199605000-00006; O'Donnell J, 2012, NEUROCHEM RES, V37, P2496, DOI 10.1007/s11064-012-0818-x; Preston Marnie, 2011, Front Biosci (Schol Ed), V3, P1165; Pundavela J, 2015, MOL ONCOL, V9, P1626, DOI 10.1016/j.molonc.2015.05.001; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Raju B, 2007, NEUROSCIENCE, V149, P715, DOI 10.1016/j.neuroscience.2007.07.048; Ren K, 2020, CLIN ANAT, V33, P630, DOI 10.1002/ca.23470; Renz BW, 2018, CANCER DISCOV, V8, P1458, DOI 10.1158/2159-8290.CD-18-0046; Renz BW, 2018, CANCER CELL, V33, P75, DOI 10.1016/j.ccell.2017.11.007; Rodriguez-Diaz R, 2014, BEST PRACT RES CL EN, V28, P745, DOI 10.1016/j.beem.2014.05.002; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Roy R, 2009, J CLIN ONCOL, V27, P5287, DOI 10.1200/JCO.2009.23.5556; Saloman JL, 2018, PANCREAS, V47, P856, DOI 10.1097/MPA.0000000000001090; Saloman JL, 2016, P NATL ACAD SCI USA, V113, P3078, DOI 10.1073/pnas.1512603113; Schecterson LC, 2010, DEV NEUROBIOL, V70, P332, DOI 10.1002/dneu.20767; Sha M, 2019, BBA-REV CANCER, V1872, P66, DOI 10.1016/j.bbcan.2019.05.005; Shao JX, 2016, THORAC CANCER, V7, P588, DOI 10.1111/1759-7714.12374; Shen FZ, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-24; Shimada K, 2011, PANCREAS, V40, P464, DOI 10.1097/MPA.0b013e31820b5d37; Shirai K, 2008, WORLD J SURG, V32, P2395, DOI 10.1007/s00268-008-9726-2; Sinha S, 2017, CANCER RES, V77, P1868, DOI 10.1158/0008-5472.CAN-16-0899-T; Soto-Tinoco E, 2016, EXP PHYSIOL, V101, P1463, DOI 10.1113/EP085560; Thome JJC, 2016, NAT MED, V22, P72, DOI 10.1038/nm.4008; Ulrich R, 2005, DEV NEUROSCI-BASEL, V27, P408, DOI 10.1159/000088455; Veiga-Fernandes H, 2017, NAT IMMUNOL, V18, P116, DOI 10.1038/ni.3634; Veiga-Fernandes H, 2016, CELL, V165, P801, DOI 10.1016/j.cell.2016.04.041; Xu LB, 2010, WORLD J SURG, V34, P1039, DOI 10.1007/s00268-010-0417-4; Yamada Y, 2012, RADIOLOGY, V263, P419, DOI 10.1148/radiol.12111024; Yang XQ, 2014, WORLD J GASTROENTERO, V20, P4076, DOI 10.3748/wjg.v20.i14.4076; Yu M, 2012, CANCER CELL, V21, P327, DOI 10.1016/j.ccr.2012.03.002; Yue XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062024; Zahalka AH, 2020, NAT REV CANCER, V20, P143, DOI 10.1038/s41568-019-0237-2; Zahalka AH, 2017, SCIENCE, V358, P321, DOI 10.1126/science.aah5072; Zareba P, 2017, CANCER EPIDEM BIOMAR, V26, P719, DOI 10.1158/1055-9965.EPI-16-0237; Zhang LF, 2016, ONCOTARGETS THER, V9, P6719, DOI 10.2147/OTT.S111382; Zhang LF, 2016, CHINESE J CANCER RES, V28, P180, DOI 10.21147/j.issn.1000-9604.2016.02.05; Zhao CM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009569; Zuo HD, 2012, WORLD J RADIOL, V4, P36, DOI 10.4329/wjr.v4.i2.36	106	31	32	13	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					899	908		10.1038/s41388-020-01578-4	http://dx.doi.org/10.1038/s41388-020-01578-4		DEC 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33288884	hybrid, Green Published			2022-12-28	WOS:000599011200001
J	Fountain, DM; Smith, MJ; O'Leary, C; Pathmanaban, ON; Roncaroli, F; Bobola, N; King, AT; Evans, DG				Fountain, Daniel M.; Smith, Miriam J.; O'Leary, Claire; Pathmanaban, Omar N.; Roncaroli, Federico; Bobola, Nicoletta; King, Andrew T.; Evans, Dafydd Gareth			The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges	ONCOGENE			English	Review							GERMLINE SMARCB1 MUTATION; PROTEIN-KINASE-A; TUMOR-LOCALIZATION; TISSUE ORIGINS; CELL; CLASSIFICATION; HEDGEHOG; COMMON; FATE; BAP1	Meningiomas are the most common primary brain tumor and their incidence and prevalence is increasing. This review summarizes current evidence regarding the embryogenesis of the human meninges in the context of meningioma pathogenesis and anatomical distribution. Though not mutually exclusive, chromosomal instability and pathogenic variants affecting the long arm of chromosome 22 (22q) result in meningiomas in neural-crest cell-derived meninges, while variants affecting Hedgehog signaling, PI3K signaling, TRAF7, KLF4, and POLR2A result in meningiomas in the mesodermal-derived meninges of the midline and paramedian anterior, central, and ventral posterior skull base. Current evidence regarding the common pathways for genetic pathogenesis and the anatomical distribution of meningiomas is presented alongside existing understanding of the embryological origins for the meninges prior to proposing next steps for this work.	[Fountain, Daniel M.; O'Leary, Claire; Pathmanaban, Omar N.; Roncaroli, Federico; King, Andrew T.] Salford Royal NHS Fdn Trust, Geoffrey Jefferson Brain Res Ctr, Manchester, Lancs, England; [Fountain, Daniel M.; O'Leary, Claire; Pathmanaban, Omar N.; Roncaroli, Federico; King, Andrew T.] Univ Manchester, Manchester, Lancs, England; [Smith, Miriam J.; Evans, Dafydd Gareth] Univ Manchester, Manchester Acad Hlth Sci Ctr MAHSC, Manchester Ctr Genom Med, Sch Biol Sci,St Marys Hosp,Div Evolut & Genom Sci, Manchester, Lancs, England; [Bobola, Nicoletta] Univ Manchester, Fac Biol Med & Hlth, Sch Med Sci, Manchester, Lancs, England	Salford Royal NHS Foundation Trust; University of Manchester; University of Manchester; University of Manchester	Fountain, DM (corresponding author), Salford Royal NHS Fdn Trust, Geoffrey Jefferson Brain Res Ctr, Manchester, Lancs, England.; Fountain, DM (corresponding author), Univ Manchester, Manchester, Lancs, England.	Daniel.fountain@nhs.net	Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784; Roncaroli, Federico/0000-0003-3650-5572; King, Andrew/0000-0002-6546-7248; Pathmanaban, Omar/0000-0002-5083-9416; Fountain, Daniel/0000-0001-6227-9930				Aavikko M, 2012, AM J HUM GENET, V91, P520, DOI 10.1016/j.ajhg.2012.07.015; Abdel-Rahman MH, 2011, J MED GENET, V48, P856, DOI 10.1136/jmedgenet-2011-100156; Abedalthagafi M, 2016, NEURO-ONCOLOGY, V18, P649, DOI 10.1093/neuonc/nov316; Akhmametyeva EM, 2006, DEV DYNAM, V235, P2771, DOI 10.1002/dvdy.20883; ALMEFTY O, 1990, J NEUROSURG, V73, P840, DOI 10.3171/jns.1990.73.6.0840; Almefty R, 2014, J NEUROSURG, V120, P40, DOI 10.3171/2013.8.JNS13535; Batarfi M, 2017, BIOL COMMUN, V55, P6273; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Boetto J, 2018, ONCOGENE, V37, P4955, DOI 10.1038/s41388-018-0328-7; BONNAL J, 1980, J NEUROSURG, V53, P587, DOI 10.3171/jns.1980.53.5.0587; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Brastianos PK, 2017, VISMODEGIB FAK INHIB, P2; Brastianos PK, 2019, NEURO-ONCOLOGY, V21, pI18, DOI 10.1093/neuonc/noy136; Brastianos PK, 2013, NAT GENET, V45, P285, DOI 10.1038/ng.2526; Brodbelt AR, 2019, BRIT J NEUROSURG, V33, P641, DOI 10.1080/02688697.2019.1661965; Carbone M, 2013, NAT REV CANCER, V13, P153, DOI 10.1038/nrc3459; Catala M, 1998, EMBRYONIC FETAL DEV; Chen CM, 2011, NEUROSURG REV, V34, P281, DOI 10.1007/s10143-011-0321-x; Christiaans I, 2011, J MED GENET, V48, P93, DOI 10.1136/jmg.2010.082420; Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009; Clarke VE, 2016, NAT GENET, V48, P1253, DOI 10.1038/ng.3651; COULY GF, 1992, DEVELOPMENT, V114, P1; Dasgupta K, 2019, GENESIS, V57, DOI 10.1002/dvg.23288; De Monte F, 2011, AL MEFTYS MENINGIOMA, V2nd; DeSisto J, 2020, DEV CELL, V54, P43, DOI 10.1016/j.devcel.2020.06.009; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; Fang L, IMMUNE CELL INFILTRA, DOI 10.1093/neuonc/not110; Goldbrunner R, 2016, LANCET ONCOL, V17, pE383, DOI 10.1016/S1470-2045(16)30321-7; Gutmann DH, 2002, NEOPLASIA, V4, P279, DOI 10.1038/sj.neo.7900249; Hadfield KD, 2010, J MED GENET, V47, P567, DOI 10.1136/jmg.2009.075721; HALATA Z, 1990, ANAT EMBRYOL, V182, P529; Hindley CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23208; Imlay SP, 1998, DIAGN CYTOPATHOL, V18, P131, DOI 10.1002/(SICI)1097-0339(199802)18:2<131::AID-DC9>3.0.CO;2-I; Jia JH, 2004, NATURE, V432, P1045, DOI 10.1038/nature03179; Jiang XB, 2000, DEVELOPMENT, V127, P1607; Jiang XB, 2002, DEV BIOL, V241, P106, DOI 10.1006/dbio.2001.0487; Kalamarides M, 2011, ONCOGENE, V30, P2333, DOI 10.1038/onc.2010.609; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Ketter R, 2008, NEUROSURGERY, V62, P61, DOI 10.1227/01.NEU.0000311062.72626.D6; Kros J, 2001, J PATHOL, V194, P367, DOI 10.1002/path.909; Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0; Langer LF, 2019, ELIFE, V8, DOI 10.7554/eLife.45672; Laulajainen M, 2008, ONCOGENE, V27, P3233, DOI 10.1038/sj.onc.1210988; Lopes MB., 2009, MENINGIOMAS, P25, DOI [10.1007/978-1-84628-784-8_4, DOI 10.1007/978-1-84628-784-8_4]; Magill S, 2019, NEURO-ONCOLOGY, V21, P268; Magill ST, 2019, J NEUROSURG, V131, P1179, DOI 10.3171/2018.6.JNS18118; Magill ST, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.1.FOCUS17753; Maguire LH, 2015, DEV DYNAM, V244, P311, DOI 10.1002/dvdy.24226; Mawrin C, 2010, J NEURO-ONCOL, V99, P379, DOI 10.1007/s11060-010-0342-2; McBratney-Owen B, 2008, DEV BIOL, V322, P121, DOI 10.1016/j.ydbio.2008.07.016; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Nanda A, 2008, SKULL BASE-INTERD AP, V18, P243, DOI 10.1055/s-2007-1016956; Nassiri F, 2019, NEURO-ONCOLOGY, V21, P901, DOI 10.1093/neuonc/noz061; Nie XG, 2005, ACTA ODONTOL SCAND, V63, P127, DOI 10.1080/00016350510019847; ORAHILLY R, 1986, J NEUROPATH EXP NEUR, V45, P588, DOI 10.1097/00005072-198609000-00008; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Pan A, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00061; Patel AJ, 2019, P NATL ACAD SCI USA, V116, P21715, DOI 10.1073/pnas.1912858116; Petrilli AM, 2016, ONCOGENE, V35, P537, DOI 10.1038/onc.2015.125; Preusser M, 2018, NAT REV NEUROL, V14, P106, DOI 10.1038/nrneurol.2017.168; Proctor DT, 2019, NEURO-ONCOLOGY ADV, P1, DOI 10.1093/noajnl/vdz018; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reuss DE, 2013, ACTA NEUROPATHOL, V125, P351, DOI 10.1007/s00401-013-1093-x; Riemenschneider MJ, 2006, LANCET NEUROL, V5, P1045, DOI 10.1016/S1474-4422(06)70625-1; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Sahm F, 2017, LANCET ONCOL, V18, P682, DOI 10.1016/S1470-2045(17)30155-9; Sahm F, 2013, ACTA NEUROPATHOL, V126, P757, DOI 10.1007/s00401-013-1187-5; Schmitz U, 2001, BRIT J CANCER, V84, P199, DOI 10.1054/bjoc.2000.1583; Sensenig E, 1951, CONTR EMBRYOL, V228, P145; Shankar GM, 2017, NEURO-ONCOLOGY, V19, P535, DOI 10.1093/neuonc/now235; Siegenthaler JA, 2011, CURR OPIN GENET DEV, V21, P249, DOI 10.1016/j.gde.2010.12.005; Siegenthaler JA, 2009, CELL, V139, P597, DOI 10.1016/j.cell.2009.10.004; Smith MJ, 2017, HISTOPATHOLOGY, V70, P814, DOI 10.1111/his.13135; Smith MJ, 2015, CANCER GENET-NY, V208, P107, DOI 10.1016/j.cancergen.2015.02.003; Smith MJ, 2014, J PATHOL, V234, P436, DOI 10.1002/path.4427; Smith MJ, 2013, NAT GENET, V45, P295, DOI 10.1038/ng.2552; Smith MJ, 2012, NEUROGENETICS, V13, P141, DOI 10.1007/s10048-012-0319-8; Smith MJ, 2011, J MED GENET, V48, P261, DOI 10.1136/jmg.2010.085241; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Trainor P, 2000, NAT CELL BIOL, V2, P96, DOI 10.1038/35000051; van den Munckhof P, 2012, NEUROGENETICS, V13, P1, DOI 10.1007/s10048-011-0300-y; Vitte J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00346-5; Wada N, 2005, DEVELOPMENT, V132, P3977, DOI 10.1242/dev.01943; Wellenreuther R, 1995, ANAL NEUROFIBROMATOS; Yamashima T, 1997, J NEUROSCI, V17, P2376; Yamashima T, 2009, MENINGIOMAS, P15, DOI DOI 10.1007/978-1-84628-784-8_3; Yoshida T, 2008, MECH DEVELOP, V125, P797, DOI 10.1016/j.mod.2008.06.007; Youngblood MW, 2020, J NEUROSURG, V133, P1345, DOI 10.3171/2019.8.JNS191266; ZADOR Z, 2020, SCI REP UK, V10; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang N, 2010, MERLIN NF2 TUMOR SUP	92	4	4	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					875	884		10.1038/s41388-020-01568-6	http://dx.doi.org/10.1038/s41388-020-01568-6		DEC 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33262459	Green Published, hybrid			2022-12-28	WOS:000595928700006
J	Tang, L; Xiong, W; Zhang, LS; Wang, D; Wang, Y; Wu, YF; Wei, F; Mo, YZ; Hou, XC; Shi, L; Xiong, F; Zhang, SS; Gong, ZJ; Liao, QJ; Xiang, B; Zhang, WL; Zhou, M; Li, XL; Li, GY; Guo, C; Zeng, ZY				Tang, Le; Xiong, Wei; Zhang, Lishen; Wang, Dan; Wang, Yian; Wu, Yingfen; Wei, Fang; Mo, Yongzhen; Hou, Xiangchan; Shi, Lei; Xiong, Fang; Zhang, Shanshan; Gong, Zhaojian; Liao, Qianjin; Xiang, Bo; Zhang, Wenling; Zhou, Ming; Li, Xiaoling; Li, Guiyuan; Guo, Can; Zeng, Zhaoyang			circSETD3 regulates MAPRE1 through miR-615-5p and miR-1538 sponges to promote migration and invasion in nasopharyngeal carcinoma	ONCOGENE			English	Article							CELL-PROLIFERATION; CIRCULAR RNAS; CANCER; EB1; GROWTH; ACTS; EXPRESSION; BIOMARKER; DYNAMICS; CIRCRNAS	Circular RNAs (circRNAs) play an essential role in tumorigenesis and development. However, they have rarely been investigated in nasopharyngeal carcinoma (NPC). This study aimed to investigate the role of circRNA in the invasion and metastasis of NPC. We screened and verified the high expression of circSETD3 in NPC cell lines using RNA sequencing (RNA-Seq) and verified the results of NPC biopsy samples using real-time quantitative polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH). In vivo and in vitro experiments indicated that circSETD3 could promote NPC cell invasion and migration. We compared the proteomic data of NPC cells before and after the overexpression or knockdown of circSETD3 in combination with bioinformatics prediction and experimental verification. It was found that circSETD3 competitively adsorbs to miR-615-5p and miR-1538 and negates their inhibitory effect on MAPRE1 mRNA, thereby upregulating the expression of MAPRE1. The upregulated MAPRE1 then inhibits the acetylation of alpha-tubulin, promotes the dynamic assembly of microtubules, and enhances the invasion and migration capabilities of NPC cells. The results of this study suggest that circSETD3 is a novel molecular marker and a potential target for NPC diagnosis and treatment.	[Tang, Le; Xiong, Wei; Liao, Qianjin; Xiang, Bo; Zhou, Ming; Li, Xiaoling; Li, Guiyuan; Zeng, Zhaoyang] Cent South Univ, Hunan Canc Hosp, NHC Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China; [Tang, Le; Xiong, Wei; Liao, Qianjin; Xiang, Bo; Zhou, Ming; Li, Xiaoling; Li, Guiyuan; Zeng, Zhaoyang] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China; [Tang, Le; Xiong, Wei; Zhang, Lishen; Wang, Dan; Wang, Yian; Wu, Yingfen; Wei, Fang; Mo, Yongzhen; Hou, Xiangchan; Xiang, Bo; Zhang, Wenling; Zhou, Ming; Li, Xiaoling; Li, Guiyuan; Guo, Can; Zeng, Zhaoyang] Cent South Univ, Chinese Minist Educ, Canc Res Inst, Key Lab Carcinogenesis & Canc Invas, Changsha, Hunan, Peoples R China; [Tang, Le; Xiong, Wei; Xiang, Bo; Zhang, Wenling; Zhou, Ming; Li, Xiaoling; Li, Guiyuan; Zeng, Zhaoyang] Cent South Univ, Xiangya Hosp 3, Dis Genome Res Ctr, Hunan Key Lab Nonresolving Inflammat & Canc, Changsha, Hunan, Peoples R China; [Shi, Lei; Gong, Zhaojian] Cent South Univ, Xiangya Hosp 2, Dept Oral & Maxillofacial Surg, Changsha, Hunan, Peoples R China; [Xiong, Fang; Zhang, Shanshan] Cent South Univ, Xiangya Hosp, Dept Stomatol, Changsha, Hunan, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University	Zeng, ZY (corresponding author), Cent South Univ, Hunan Canc Hosp, NHC Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China.; Zeng, ZY (corresponding author), Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China.; Zeng, ZY (corresponding author), Cent South Univ, Chinese Minist Educ, Canc Res Inst, Key Lab Carcinogenesis & Canc Invas, Changsha, Hunan, Peoples R China.; Zeng, ZY (corresponding author), Cent South Univ, Xiangya Hosp 3, Dis Genome Res Ctr, Hunan Key Lab Nonresolving Inflammat & Canc, Changsha, Hunan, Peoples R China.	zengzhaoyang@csu.edu.cn	li, xiao/GSN-6181-2022; li, xiaofeng/GXF-9442-2022		National Natural Science Foundation of China [81672683, 81702907, 81772901, 81772928, 81803025, 81972776, 82072374]; Natural Science Foundation of Hunan Province [2018JJ3704, 2018JJ3815, 2018SK21210, 2018SK21211, 2019JJ50872, 2019JJ50778, 2020JJ4125]; Fundamental Research Funds for the Central South University [2019zzts712, 2019zzts727]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); Fundamental Research Funds for the Central South University	This work was supported by grants from the National Natural Science Foundation of China (81672683, 81702907, 81772901, 81772928, 81803025, 81972776 and 82072374), the Natural Science Foundation of Hunan Province (2018JJ3704, 2018JJ3815, 2018SK21210, 2018SK21211, 2019JJ50872, 2019JJ50778 and 2020JJ4125), and the Fundamental Research Funds for the Central South University (2019zzts712 and 2019zzts727).	Bai YX, 2019, EBIOMEDICINE, V42, P311, DOI 10.1016/j.ebiom.2019.03.045; Berges R, 2016, MOL CANCER THER, V15, P2740, DOI 10.1158/1535-7163.MCT-16-0252; Bo H, 2019, ONCOL REP, V41, P2431, DOI 10.3892/or.2019.7027; Bo H, 2018, J CANCER, V9, P4677, DOI 10.7150/jca.26461; Chen LJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0943-0; Chen LL, 2016, NAT REV MOL CELL BIO, V17, P205, DOI 10.1038/nrm.2015.32; Chen NF, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1594-y; Cheng HP, 2017, ONCOL RES, V25, P587, DOI 10.3727/096504016X14761811155298; Das M, 2018, RNA BIOL, V15, P214, DOI 10.1080/15476286.2017.1397261; Deng XY, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0428-0; Dong X, 2010, J PATHOL, V220, P361, DOI 10.1002/path.2662; Fan CM, 2019, CANCER SCI, V110, P2180, DOI 10.1111/cas.14034; Fan CM, 2021, CANCER LETT, V496, P41, DOI 10.1016/j.canlet.2020.09.006; Fan CM, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07408-w; Fan CM, 2021, SCI CHINA LIFE SCI, V64, P534, DOI 10.1007/s11427-019-1735-4; Fan CM, 2019, J CANCER, V10, P3926, DOI 10.7150/jca.31345; Fan CM, 2019, CARCINOGENESIS, V40, P380, DOI 10.1093/carcin/bgy143; Fan CM, 2018, J CANCER, V9, P2852, DOI 10.7150/jca.25460; Fukushima N, 2009, J NEUROCHEM, V109, P683, DOI 10.1111/j.1471-4159.2009.06013.x; Gao W, 2015, ONCOGENE, V34, P1629, DOI 10.1038/onc.2014.101; Gao Y, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0571-3; Guarnerio J, 2016, CELL, V165, P289, DOI 10.1016/j.cell.2016.03.020; Han Y, 2020, LIFE SCI, V241, DOI 10.1016/j.lfs.2019.117140; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hauptmann J, 2013, DEV CELL, V25, P553, DOI 10.1016/j.devcel.2013.06.009; He RF, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0614-1; He Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0265-y; Huang GL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131225; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Jaulin F, 2010, J CELL BIOL, V190, P443, DOI 10.1083/jcb.201006044; Jayatilaka H, 2018, FASEB J, V32, P1207, DOI 10.1096/fj.201700444RR; Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890; Jiang XJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01709-5; Jiang XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0928-4; Jin K, 2019, CELL MOL LIFE SCI, V76, P4275, DOI 10.1007/s00018-019-03222-1; Kong Z, 2017, BIOCHEM BIOPH RES CO, V493, P1217, DOI 10.1016/j.bbrc.2017.07.162; Li F, 2015, ONCOTARGET, V6, P6001, DOI 10.18632/oncotarget.3469; Li HB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6017-2; Li N, 2011, P NATL ACAD SCI USA, V108, P12851, DOI 10.1073/pnas.1017372108; Li PC, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12165; Li YW, 2017, EMBO REP, V18, P1646, DOI 10.15252/embr.201643581; Lian Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0918-9; Liu M, 2009, MOL CARCINOGEN, V48, P212, DOI 10.1002/mc.20471; Liu Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1894-5; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Mo YZ, 2019, J CANCER, V10, P3789, DOI 10.7150/jca.31166; Mo YZ, 2019, J CANCER, V10, P2342, DOI 10.7150/jca.30454; Peng M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1055-6; Rodrigues-Ferreira S, 2019, BREAST CANCER RES TR, V173, P573, DOI 10.1007/s10549-018-5026-1; Serre L, 2019, J MOL BIOL, V431, P1993, DOI 10.1016/j.jmb.2019.03.028; Shan B, 2008, J BIOL CHEM, V283, P21065, DOI 10.1074/jbc.M802786200; Sugihara Y, 2012, J PROTEOMICS, V75, P5342, DOI 10.1016/j.jprot.2012.06.013; Taguchi A, 2015, CANCER PREV RES, V8, P1112, DOI 10.1158/1940-6207.CAPR-15-0077; Tang L, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0758-7; Tang T, 2020, MOL ONCOL, V14, P2251, DOI 10.1002/1878-0261.12703; Tang YY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0825-x; Tu CF, 2018, CARCINOGENESIS, V39, P1517, DOI 10.1093/carcin/bgy108; Tufo G, 2014, CELL DEATH DIFFER, V21, P685, DOI 10.1038/cdd.2013.193; van Haren J, 2018, NAT CELL BIOL, V20, P252, DOI 10.1038/s41556-017-0028-5; Wan L, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1579490; Wang D, 2020, FASEB J, V34, P8012, DOI 10.1096/fj.202000039RR; Wang D, 2020, CELL MOL LIFE SCI, V77, P2949, DOI 10.1007/s00018-020-03469-z; Wang JJ, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22379; Wang YH, 2005, ONCOGENE, V24, P6637, DOI 10.1038/sj.onc.1208819; Wang YA, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0913-y; Wang YM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0598-7; Wei F, 2021, CELL MOL LIFE SCI, V78, P173, DOI 10.1007/s00018-020-03581-0; Wei F, 2019, J CANCER, V10, P1145, DOI 10.7150/jca.29049; Wei F, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0409-0; Wei F, 2018, BRIT J CANCER, V118, P233, DOI 10.1038/bjc.2017.385; Wieczorek M, 2015, NAT CELL BIOL, V17, P907, DOI 10.1038/ncb3188; Wu CC, 2019, SCI CHINA LIFE SCI, V62, P640, DOI 10.1007/s11427-018-9461-5; Wu P, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1147-3; Wu YF, 2020, FASEB J, V34, P16205, DOI 10.1096/fj.202001508R; Wu YF, 2019, J CANCER, V10, P2185, DOI 10.7150/jca.30222; Wu YZ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1007-1; Xiao L, 2019, CARCINOGENESIS, V40, P819, DOI 10.1093/carcin/bgz095; Xiong F, 2019, CHINESE MED J-PEKING, V132, P749, DOI 10.1097/CM9.0000000000000132; Xu LL, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1041-2; Yang CD, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0771-7; Yu J, 2018, J HEPATOL, V68, P1214, DOI 10.1016/j.jhep.2018.01.012; Zeng ZY, 2011, SCI CHINA LIFE SCI, V54, P966, DOI 10.1007/s11427-011-4223-5; Zhao J, 2020, CANCER LETT, V477, P131, DOI 10.1016/j.canlet.2020.02.010; Zhong YX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0827-8; Zhou RY, 2018, CANCER LETT, V425, P134, DOI 10.1016/j.canlet.2018.03.035; Zhu KJ, 2020, CANCER LETT, V492, P11, DOI 10.1016/j.canlet.2020.07.028	86	36	37	3	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					307	321		10.1038/s41388-020-01531-5	http://dx.doi.org/10.1038/s41388-020-01531-5		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33122825				2022-12-28	WOS:000582827800002
J	Lundy, J; Gearing, LJ; Gao, H; West, AC; McLeod, L; Deswaerte, V; Yu, L; Porazinski, S; Pajic, M; Hertzog, PJ; Croagh, D; Jenkins, BJ				Lundy, Joanne; Gearing, Linden J.; Gao, Hugh; West, Alison C.; McLeod, Louise; Deswaerte, Virginie; Yu, Liang; Porazinski, Sean; Pajic, Marina; Hertzog, Paul J.; Croagh, Daniel; Jenkins, Brendan J.			TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							TOLL-LIKE RECEPTORS; STELLATE CELLS; DIFFERENTIAL EXPRESSION; CANCER; IMMUNOTHERAPY; INFLAMMATION; GEMCITABINE; CARCINOMA; CARCINOGENESIS; IDENTIFICATION	Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis, and is plagued by a paucity of targeted treatment options and tumour resistance to chemotherapeutics. The causal link between chronic inflammation and PDAC suggests that molecular regulators of the immune system promote disease pathogenesis and/or therapeutic resistance, yet their identity is unclear. Here, we couple endoscopic ultrasound-guided fine-needle aspiration, which captures tumour biopsies from all stages, with whole transcriptome profiling of PDAC patient primary tumours to reveal enrichment of the innate immune Toll-like receptor 2 (TLR2) molecular pathway. Augmented TLR2 expression associated with a 4-gene "TLR2 activation" signature, and was prognostic for survival and predictive for gemcitabine-based chemoresistance. Furthermore, antibody-mediated anti-TLR2 therapy suppressed the growth of human PDAC tumour xenografts, independent of a functional immune system. Our results support TLR2-based therapeutic targeting for precision medicine in PDAC, with further clinical utility that TLR2 activation is prognostic and predictive for chemoresponsiveness.	[Lundy, Joanne; Gearing, Linden J.; West, Alison C.; McLeod, Louise; Deswaerte, Virginie; Yu, Liang; Hertzog, Paul J.; Croagh, Daniel; Jenkins, Brendan J.] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic, Australia; [Lundy, Joanne; Gearing, Linden J.; West, Alison C.; McLeod, Louise; Deswaerte, Virginie; Yu, Liang; Hertzog, Paul J.; Jenkins, Brendan J.] Monash Univ, Dept Mol & Translat Sci, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Gao, Hugh; Croagh, Daniel] Monash Univ, Sch Clin Sci Monash Hlth, Dept Surg, Clayton, Vic, Australia; [Porazinski, Sean; Pajic, Marina] Kinghorn Canc Ctr, Garvan Inst Med Res, Darlinghurst, NSW, Australia; [Porazinski, Sean; Pajic, Marina] Univ New South Wales, St Vincents Clin Sch, Fac Med, Darlinghurst, NSW, Australia	Hudson Institute of Medical Research; Monash University; Monash University; Garvan Institute of Medical Research; University of New South Wales Sydney	Jenkins, BJ (corresponding author), Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic, Australia.; Jenkins, BJ (corresponding author), Monash Univ, Dept Mol & Translat Sci, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia.	Brendan.Jenkins@hudson.org.au	Hertzog, Paul/I-7053-2013; Porazinski, Sean/M-6973-2015	Hertzog, Paul/0000-0002-1373-8472; Porazinski, Sean/0000-0003-3804-1150; McLeod, Louise/0000-0002-7595-6432; Gearing, Linden/0000-0003-3508-3056; Lundy, Joanne/0000-0003-0210-4930	Avner Pancreatic Cancer Foundation; CASS Foundation; Operational Infrastructure Support Program by the Victorian Government of Australia; NHMRC Senior Medical Research Fellowship	Avner Pancreatic Cancer Foundation; CASS Foundation; Operational Infrastructure Support Program by the Victorian Government of Australia; NHMRC Senior Medical Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	We are grateful to Angela Vais (Monash Histology Platform, Melbourne, Australia) for immunohistochemistry and immunofluorescence expertise. We also thank Trevor Wilson and Jodee Gould from the MHTP Medical Genomics Facility (Melbourne, Australia) for providing technical expertise and assistance with the AmpliSeq transcriptomics studies, as well as Minoti Apte (University of New South Wales, Australia) for kindly providing human pancreatic stellate cells. We also thank the Australian Pancreatic Cancer Genome Initiative, supported by an Avner Pancreatic Cancer Foundation Grant, for the provision of biospecimens. This work was supported by research grants awarded by the Avner Pancreatic Cancer Foundation and CASS Foundation, as well as the Operational Infrastructure Support Program by the Victorian Government of Australia. BJJ is supported by an NHMRC Senior Medical Research Fellowship.	Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Amrutkar M, 2017, CANCERS, V9, DOI 10.3390/cancers9110157; Apte MV, 2013, GASTROENTEROLOGY, V144, P1210, DOI 10.1053/j.gastro.2012.11.037; Bachem MG, 1998, GASTROENTEROLOGY, V115, P421, DOI 10.1016/S0016-5085(98)70209-4; Berry W, 2018, CANCERS, V10, DOI 10.3390/cancers10020035; Berry W, 2017, INT J CANCER, V140, P2331, DOI 10.1002/ijc.30648; Biankin AV, 2011, HUM GENET, V130, P79, DOI 10.1007/s00439-011-1010-0; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Carbon S, 2017, NUCLEIC ACIDS RES, V45, pD331, DOI 10.1093/nar/gkw1108; Cebrian MJG, 2016, ANTICANCER RES, V36, P4381, DOI 10.21873/anticanres.10981; Chang JH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005541; Chantrill LA, 2015, CLIN CANCER RES, V21, P2029, DOI 10.1158/1078-0432.CCR-15-0426; Chen XL, 2019, EBIOMEDICINE, V40, P135, DOI 10.1016/j.ebiom.2018.12.016; Chou A, 2018, GUT, V67, P2142, DOI 10.1136/gutjnl-2017-315144; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Flo TH, 2001, J LEUKOCYTE BIOL, V69, P474; Foroutan M, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2435-4; Garcea G, 2011, WORLD J SURG, V35, P868, DOI 10.1007/s00268-011-0984-z; Gay NJ, 2014, NAT REV IMMUNOL, V14, P546, DOI 10.1038/nri3713; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Grimmig T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122060; Grimmig T, 2015, INT J ONCOL, V47, P857, DOI 10.3892/ijo.2015.3069; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Hamzah J, 2009, J IMMUNOL, V183, P1091, DOI 10.4049/jimmunol.0900736; Hao L, 2017, DIGEST LIVER DIS, V49, P1249, DOI 10.1016/j.dld.2017.07.001; Jheng HF, 2015, DIS MODEL MECH, V8, P1311, DOI 10.1242/dmm.019398; Kamisawa T, 2016, LANCET, V388, P73, DOI 10.1016/S0140-6736(16)00141-0; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kennedy CL, 2014, ONCOGENE, V33, P2540, DOI 10.1038/onc.2013.205; Knudsen ES, 2017, CLIN CANCER RES, V23, P4429, DOI 10.1158/1078-0432.CCR-17-0162; Lanki Mira A, 2018, Tumour Biol, V40, p1010428318801188, DOI 10.1177/1010428318801188; Leppanen J, 2017, VIRCHOWS ARCH, V470, P401, DOI 10.1007/s00428-017-2087-1; Li WL, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2270-1; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu RJ, 2015, NUCLEIC ACIDS RES, V43, pE97, DOI 10.1093/nar/gkv412; Liu YD, 2019, INT J CANCER, V144, P3056, DOI 10.1002/ijc.32060; McCarthy DJ, 2009, BIOINFORMATICS, V25, P765, DOI 10.1093/bioinformatics/btp053; Nevala-Plagemann C, 2020, NAT REV CLIN ONCOL, V17, P108, DOI 10.1038/s41571-019-0281-6; Ochi A, 2012, J CLIN INVEST, V122, P4118, DOI 10.1172/JCI63606; Ochi A, 2012, J EXP MED, V209, P1671, DOI 10.1084/jem.20111706; Pearson Todd, 2008, Curr Protoc Immunol, VChapter 15, DOI 10.1002/0471142735.im1521s81; Pramanik KC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123890; Pratesi G, 2005, CANCER RES, V65, P6388, DOI 10.1158/0008-5472.CAN-05-0602; Principe DR, 2020, CANCER RES, V80, P3101, DOI 10.1158/0008-5472.CAN-19-2959; Pu N, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.10.91; Pushalkar S, 2018, CANCER DISCOV, V8, P403, DOI 10.1158/2159-8290.CD-17-1134; R Core Team, 2019, R FDN STAT COMP, DOI DOI 10.1007/978-3-540-74686-7; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rosa R, 2011, CLIN CANCER RES, V17, P6531, DOI 10.1158/1078-0432.CCR-10-3376; Roshani R, 2014, CANCER LETT, V345, P157, DOI 10.1016/j.canlet.2013.07.014; Saad MI, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809976; Schmidt J, 2007, BRIT J CANCER, V97, P598, DOI 10.1038/sj.bjc.6603903; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254; Seya T, 2015, CANCER SCI, V106, P1659, DOI 10.1111/cas.12824; Sperb N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155486; Steele CW, 2016, WORLD J GASTRO ONCOL, V8, P380, DOI 10.4251/wjgo.v8.i4.380; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun QQ, 2018, THERANOSTICS, V8, P5072, DOI 10.7150/thno.26546; Thind K, 2017, THER ADV GASTROENTER, V10, P168, DOI 10.1177/1756283X16667909; Torphy RJ, 2018, ANN GASTROENT SURG, V2, P274, DOI 10.1002/ags3.12176; Tye H, 2013, CANCER SCI, V104, P1139, DOI 10.1111/cas.12205; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Urban-Wojciuk Z, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02388; Vaz J, 2014, WORLD J GASTROENTERO, V20, P5808, DOI 10.3748/wjg.v20.i19.5808; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; West AC, 2017, ONCOGENE, V36, P5134, DOI 10.1038/onc.2017.121; West AC, 2015, CURR PHARM DESIGN, V21, P2968, DOI 10.2174/1381612821666150514104411; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Wolpin BM, 2014, NAT GENET, V46, P994, DOI 10.1038/ng.3052; Wu D, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks461; Xu CM, 2020, J ADV RES, V24, P139, DOI 10.1016/j.jare.2020.03.009; Zambirinis CP, 2015, J EXP MED, V212, P2077, DOI 10.1084/jem.20142162	77	5	5	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					6007	6022		10.1038/s41388-021-01992-2	http://dx.doi.org/10.1038/s41388-021-01992-2		AUG 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34400766				2022-12-28	WOS:000685396300002
J	He, SN; Zimmerman, MW; Layden, HM; Berezovskaya, A; Etchin, J; Martel, MW; Thurston, G; Jing, CB; van Rooijen, E; Kaufman, CK; Rodig, SJ; Zon, LI; Patton, EE; Mansour, MR; Look, AT				He, Shuning; Zimmerman, Mark W.; Layden, Hillary M.; Berezovskaya, Alla; Etchin, Julia; Martel, Megan W.; Thurston, Grace; Jing, Chang-Bin; van Rooijen, Ellen; Kaufman, Charles K.; Rodig, Scott J.; Zon, Leonard I.; Patton, E. Elizabeth; Mansour, Marc R.; Look, A. Thomas			Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss	ONCOGENE			English	Article							MUTATIONS; AUTOPHAGY; NF1; GENES; TUMORIGENESIS; TEMSIROLIMUS; SENSITIVITY; CHLOROQUINE; RESISTANCE; SCREEN	Melanomas driven by loss of the NF1 tumor suppressor have a high risk of treatment failure and effective therapies have not been developed. Here we show that loss-of-function mutations of nf1 and pten result in aggressive melanomas in zebrafish, representing the first animal model of NF1-mutant melanomas harboring PTEN loss. MEK or PI3K inhibitors show little activity when given alone due to cross-talk between the pathways, and high toxicity when given together. The mTOR inhibitors, sirolimus, everolimus, and temsirolimus, were the most active single agents tested, potently induced tumor-suppressive autophagy, but not apoptosis. Because addition of the BCL2 inhibitor venetoclax resulted in compensatory upregulation of MCL1, we established a three-drug combination composed of sirolimus, venetoclax, and the MCL1 inhibitor S63845. This well-tolerated drug combination potently and synergistically induces apoptosis in both zebrafish and human NF1/PTEN-deficient melanoma cells, providing preclinical evidence justifying an early-stage clinical trial in patients with NF1/PTEN-deficient melanoma.	[He, Shuning; Zimmerman, Mark W.; Layden, Hillary M.; Berezovskaya, Alla; Etchin, Julia; Martel, Megan W.; Thurston, Grace; Jing, Chang-Bin; Mansour, Marc R.; Look, A. Thomas] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [van Rooijen, Ellen; Kaufman, Charles K.; Zon, Leonard I.] Howard Hughes Med Inst, Childrens Hosp Boston, Stem Cell Program, Boston, MA 02115 USA; [van Rooijen, Ellen; Kaufman, Charles K.] Howard Hughes Med Inst, Childrens Hosp Boston, Div Hematol Oncol, Boston, MA 02115 USA; [Rodig, Scott J.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Patton, E. Elizabeth] Univ Edinburgh, MRC Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh, Midlothian, Scotland; [Mansour, Marc R.] UCL, UCL Canc Inst, Dept Hematol, London, England	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; University of Edinburgh; University of London; University College London	He, SN; Mansour, MR; Look, AT (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.; Mansour, MR (corresponding author), UCL, UCL Canc Inst, Dept Hematol, London, England.	shuning_he@dfci.harvard.edu; m.mansour@ucl.ac.uk; Thomas_Look@dfci.harvard.edu		Zimmerman, Mark/0000-0003-2489-3889; Layden, Hillary/0000-0001-8583-620X; Mansour, Marc/0000-0001-6835-3791	Melanoma Research Alliance award [509233]	Melanoma Research Alliance award	We would like to thank John Gilbert for critical review of the manuscript and editorial suggestions; Kassandra Bacon and Daniel Debiasi for zebrafish husbandry; Jeoren den Hertog, Alejandro Gutierrez and David M. Langenau for providing zebrafish lines; Yi Zhou and Andrew Hong for stimulating suggestions; Christine L. Unitt, Benjamin Ferland and Dana-Farber/Harvard Cancer Center Research Pathology Core for technical support. This study was funded by Melanoma Research Alliance award #509233.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; Avniel-Polak S, 2016, NEUROENDOCRINOLOGY, V103, P724, DOI 10.1159/000442589; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Chen KG, 2009, JNCI-J NATL CANCER I, V101, P1259, DOI 10.1093/jnci/djp259; Cirenajwis H, 2017, MOL ONCOL, V11, P438, DOI 10.1002/1878-0261.12050; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; Dovey M, 2009, ZEBRAFISH, V6, P397, DOI 10.1089/zeb.2009.0606; Faucherre A, 2008, ONCOGENE, V27, P1079, DOI 10.1038/sj.onc.1210730; Garman B, 2017, CELL REP, V21, P1936, DOI 10.1016/j.celrep.2017.10.052; Gutierrez A, 2011, J EXP MED, V208, P1595, DOI 10.1084/jem.20101691; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; He SN, 2012, J PATHOL, V227, P431, DOI 10.1002/path.4013; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; Kaneko M, 2014, J CANCER RES CLIN, V140, P769, DOI 10.1007/s00432-014-1628-0; Kaufman CK, 2016, ADV EXP MED BIOL, V916, P439, DOI 10.1007/978-3-319-30654-4_19; Kaufman CK, 2016, SCIENCE, V351, DOI 10.1126/science.aad2197; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Kuzu OF, 2015, CANCER GROWTH METAST, P81, DOI 10.4137/CGM.S21214; Lam LT, 2010, MOL CANCER THER, V9, P2943, DOI 10.1158/1535-7163.MCT-10-0427; Leverson JD, 2017, CANCER DISCOV, V7, P1376, DOI 10.1158/2159-8290.CD-17-0797; Li ZD, 2019, LEUKEMIA, V33, P262, DOI 10.1038/s41375-018-0201-2; Lister JA, 2014, J INVEST DERMATOL, V134, P133, DOI 10.1038/jid.2013.293; Macintosh RL, 2013, SEMIN CANCER BIOL, V23, P344, DOI 10.1016/j.semcancer.2013.05.006; Maertens Ophelia, 2014, Advances in Biological Regulation, V55, P1, DOI 10.1016/j.jbior.2014.04.002; Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313; Mar VJ, 2013, CLIN CANCER RES, V19, P4589, DOI 10.1158/1078-0432.CCR-13-0398; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Mohana-Kumaran N, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12242; Mukherjee N, 2015, J INVEST DERMATOL, V135, P2155, DOI 10.1038/jid.2015.145; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Potter DS, 2016, COLD SH Q B, V81, P131, DOI 10.1101/sqb.2016.81.030841; Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119; Sharma K, 2014, INT J MOL SCI, V15, P10034, DOI 10.3390/ijms150610034; Shin J, 2012, DIS MODEL MECH, V5, P881, DOI 10.1242/dmm.009779; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Tang Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10358; Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470; Yang SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026343	45	2	2	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5718	5729		10.1038/s41388-021-01926-y	http://dx.doi.org/10.1038/s41388-021-01926-y		JUL 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34331013	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000679620500002
J	Cheng, R; Xiao, LX; Zhou, WY; Jin, XY; Xu, ZC; Xu, C; Wang, PP; Luo, M; Wang, MY; Ma, KX; Cao, HM; Huang, Y; Lin, XY; Pang, FL; Li, YQ; Jiang, QH				Cheng, Rui; Xiao, Lixing; Zhou, Wenyang; Jin, Xiyun; Xu, Zhaochun; Xu, Chang; Wang, Pingping; Luo, Meng; Wang, Mengyun; Ma, Kexin; Cao, Huimin; Huang, Yan; Lin, Xiaoyu; Pang, Fenglan; Li, Yiqun; Jiang, Qinghua			A pan-cancer analysis of alternative splicing of splicing factors in 6904 patients	ONCOGENE			English	Article							PYRUVATE-KINASE; MUTATIONS; GENOME; TRANSCRIPTOME; APOPTOSIS; FAMILIES; M2	Great progress has been made in the investigation on mutation and expression of splicing factor. However, little is known on the role of alternative splicing of splicing factors across cancers. Here, we reported a pan-cancer analysis of alternative splicing of splicing factors spanning 6904 patients across 16 cancer types, and identified 167 splicing factors with implications regulating cancer-specific splicing patterns through alternative splicing. Furthermore, we found that abnormal splicing events of splicing factors could serve as potential common regulators for alternative splicing in different cancers. In addition, we developed a splicing-derived neoepitopes database (ASPNs), which provided the corresponding putative alternative splicing-derived neoepitopes of 16 cancer types. Our results suggested that alternative splicing of splicing factors involved in the pre-RNA splicing process was common across cancer types and may represent an underestimated hallmark of tumorigenesis.	[Cheng, Rui; Xiao, Lixing; Zhou, Wenyang; Jin, Xiyun; Xu, Zhaochun; Xu, Chang; Wang, Pingping; Luo, Meng; Wang, Mengyun; Ma, Kexin; Cao, Huimin; Huang, Yan; Lin, Xiaoyu; Pang, Fenglan; Li, Yiqun; Jiang, Qinghua] Harbin Inst Technol, Sch Life Sci & Technol, Harbin, Peoples R China; [Jiang, Qinghua] Harbin Inst Technol, Minist Educ, Key Lab Biol Big Data, Harbin, Peoples R China	Harbin Institute of Technology; Harbin Institute of Technology	Jiang, QH (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin, Peoples R China.; Jiang, QH (corresponding author), Harbin Inst Technol, Minist Educ, Key Lab Biol Big Data, Harbin, Peoples R China.	qhjiang@hit.edu.cm		cheng, rui/0000-0002-9398-3514; Xiao, Lixing/0000-0003-0929-0086; Ma, Kexin/0000-0002-9930-0104; Zhou, Wenyang/0000-0002-3676-0584; Jin, Xiyun/0000-0003-2795-6451; Wang, Pingping/0000-0001-8888-8005; LUO, Meng/0000-0003-0622-9060	National Natural Science Foundation of China [61822108, 62032007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (Nos. 61822108 and 62032007 to QJ).	Anande G, 2020, CLIN CANCER RES, V26, P3597, DOI 10.1158/1078-0432.CCR-20-0184; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Bechara EG, 2013, MOL CELL, V52, P720, DOI 10.1016/j.molcel.2013.11.010; Biasini Marco, 2014, Nucleic Acids Res, V42, pW252, DOI 10.1093/nar/gku340; Black KL, 2018, NUCLEIC ACIDS RES, V46, P11357, DOI 10.1093/nar/gky946; Blencowe BJ, 2017, TRENDS BIOCHEM SCI, V42, P407, DOI 10.1016/j.tibs.2017.04.001; Brooks AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087361; Chabot B, 2016, J CELL BIOL, V212, P13, DOI 10.1083/jcb.201510032; Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Cieslak MC, 2020, MAR GENOM, V51, DOI 10.1016/j.margen.2019.100723; Climente-Gonzalez H, 2017, CELL REP, V20, P2215, DOI 10.1016/j.celrep.2017.08.012; Coomer AO, 2019, BBA-GENE REGUL MECH, V1862, DOI 10.1016/j.bbagrm.2019.05.006; Davuluri RV, 2008, TRENDS GENET, V24, P167, DOI 10.1016/j.tig.2008.01.008; Dvinge H, 2019, GENOME RES, V29, P1591, DOI 10.1101/gr.246678.118; Dvinge H, 2016, NAT REV CANCER, V16, P413, DOI 10.1038/nrc.2016.51; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Ferreira JA, 2006, ANN STAT, V34, P1827, DOI 10.1214/009053606000000425; Frankiw L, 2019, NAT REV IMMUNOL, V19, P675, DOI 10.1038/s41577-019-0195-7; Golan-Gerstl R, 2011, CANCER RES, V71, P4464, DOI 10.1158/0008-5472.CAN-10-4410; Gui XR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09902-7; Hagen RM, 2012, BIOCHEM SOC T, V40, P870, DOI 10.1042/BST20120026; Hahn CN, 2015, IMMUNOL REV, V263, P257, DOI 10.1111/imr.12241; Hatcher JM, 2018, CELL CHEM BIOL, V25, P460, DOI 10.1016/j.chembiol.2018.01.013; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Hollenbach JA, 2013, INT J IMMUNOGENET, V40, P46, DOI 10.1111/iji.12026; Howard JM, 2018, GENOME RES, V28, P689, DOI 10.1101/gr.229062.117; Hwang JY, 2020, NUCLEIC ACIDS RES, V48, pW300, DOI 10.1093/nar/gkaa237; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Janson G, 2017, BIOINFORMATICS, V33, P444, DOI 10.1093/bioinformatics/btw638; Jones P, 2014, BIOINFORMATICS, V30, P1236, DOI 10.1093/bioinformatics/btu031; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Kedzierska H, 2017, CANCER LETT, V396, P53, DOI 10.1016/j.canlet.2017.03.013; Kim HJ, 2013, NATURE, V495, P467, DOI 10.1038/nature11922; Kim TK, 2015, KOREAN J ANESTHESIOL, V68, P540, DOI 10.4097/kjae.2015.68.6.540; Kobak D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13056-x; Lin JC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122097; Maguire SL, 2015, J PATHOL, V235, P571, DOI 10.1002/path.4483; Martinez-Montiel N, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020545; Mayr C, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a034728; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Norris AD, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00122; Otasek D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1758-4; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Paschalis A, 2018, NAT REV CLIN ONCOL, V15, P663, DOI 10.1038/s41571-018-0085-0; Pradella D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0579-2; Repana D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-018-1612-0; Riley RS, 2019, NAT REV DRUG DISCOV, V18, P175, DOI 10.1038/s41573-018-0006-z; Ryan M, 2016, NUCLEIC ACIDS RES, V44, pD1018, DOI 10.1093/nar/gkv1288; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Sebestyen E, 2016, GENOME RES, V26, P732, DOI 10.1101/gr.199935.115; Shah K, 2020, ONCOGENE, V39, P6172, DOI 10.1038/s41388-020-01429-2; Smart AC, 2018, NAT BIOTECHNOL, V36, P1056, DOI 10.1038/nbt.4239; van der Maaten L, 2014, J MACH LEARN RES, V15, P3221; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Wagner KD, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010041; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Xie RH, 2019, CANCER LETT, V449, P31, DOI 10.1016/j.canlet.2019.01.041; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40; Zhang YJ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00486-7; Zhang ZB, 2020, AGING-US, V12, P14633, DOI 10.18632/aging.103516; Zhao M, 2013, NUCLEIC ACIDS RES, V41, pD970, DOI 10.1093/nar/gks937; Zhu H, 2014, CANCER LETT, V343, P51, DOI 10.1016/j.canlet.2013.09.014	66	3	4	14	35	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5441	5450		10.1038/s41388-021-01947-7	http://dx.doi.org/10.1038/s41388-021-01947-7		JUL 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34285345				2022-12-28	WOS:000675072300001
J	Zhang, YJ; Shi, G; Zhang, HT; Xiong, Q; Cheng, FY; Wang, HL; Luo, JY; Zhang, Y; Shi, PY; Xu, J; Fu, JM; Chen, N; Cheng, L; Li, YM; Dai, L; Yang, Y; Yu, DC; Zhang, S; Deng, HX				Zhang, Yujing; Shi, Gang; Zhang, Hantao; Xiong, Qi; Cheng, Fuyi; Wang, Huiling; Luo, Jieyan; Zhang, Yong; Shi, Pengyi; Xu, Jia; Fu, Jiamei; Chen, Na; Cheng, Lin; Li, Yiming; Dai, Lei; Yang, Yang; Yu, Dechao; Zhang, Shuang; Deng, Hongxin			Dexamethasone enhances the lung metastasis of breast cancer via a PI3K-SGK1-CTGF pathway	ONCOGENE			English	Article							TISSUE GROWTH-FACTOR; IMMUNE SURVEILLANCE; CELL-PROLIFERATION; SIGNALING PATHWAY; ACTIVATES SGK1; MECHANISMS; GENE; PHARMACOKINETICS; CHEMOTHERAPY; CARBOPLATIN	Dexamethasone (Dex), as a pretreatment agent, is widely used to attenuate the side effects of chemotherapy in breast cancer treatment. However, whether and how Dex affects breast cancer metastasis remain to be furtherly understood. In this study, we established several mouse breast cancer metastatic models to study the effect of Dex in vitro and in vivo. Transwell, Western Blot and RNA interference were applied to study the molecular mechanism of Dex in promoting breast cancer cell migration. Meanwhile, the effect of Dex on lung metastasis of breast cancer in Dex combined with PTX chemotherapy was discussed. Our results confirmed that Dex could promote breast cancer cell metastasis both in vitro and in vivo. Mechanistic studies revealed that this pro-metastatic effect of Dex was mediated by the GR-PI3K-SGK1-CTGF pathway in tumor cells. Ligation of Dex and glucocorticoid receptor (GR) on tumor cells activated the PI3K signaling pathway and upregulated serum glucocorticoid-inducible kinase 1 (SGK1) expression, and then increased the expression of connective tissue growth factor (CTGF) through Nedd4l-Smad2. Moreover, Dex was the leading factor for lung metastasis in a standard regimen for breast cancer treatment with paclitaxel and Dex. Importantly, targeting SGK1 with the inhibitor GSK650394 remarkably reduced lung metastasis in this regimen. Our present data provide new insights into Dex-induced breast cancer metastasis and indicate that SGK1 could be a candidate target for the treatment of breast cancer metastasis.	[Zhang, Yujing; Shi, Gang; Zhang, Hantao; Xiong, Qi; Cheng, Fuyi; Wang, Huiling; Shi, Pengyi; Xu, Jia; Fu, Jiamei; Chen, Na; Cheng, Lin; Li, Yiming; Dai, Lei; Yang, Yang; Yu, Dechao; Zhang, Shuang; Deng, Hongxin] Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu, Peoples R China; [Luo, Jieyan; Zhang, Yong; Zhang, Shuang] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Sichuan, Peoples R China; [Yu, Dechao] Innovent Biol Inc, Suzhou, Jiangsu, Peoples R China; [Deng, Hongxin] Chinese Acad Med Sci, Res Unit Gene & Immunotherapy, Beijing, Peoples R China	Sichuan University; Sichuan University; Chinese Academy of Medical Sciences - Peking Union Medical College	Zhang, S; Deng, HX (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu, Peoples R China.; Zhang, S (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Sichuan, Peoples R China.; Deng, HX (corresponding author), Chinese Acad Med Sci, Res Unit Gene & Immunotherapy, Beijing, Peoples R China.	shuang.zhang@scu.edu.cn; denghongx@scu.edu.cn			National Key R&D Program of China [2017YFA0105702]; National Natural Science Foundation of China [81672577, 81772939, 81902918, 81972607]; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University [ZYGD20003]; CAMS Innovation Fund for Medical Science [2019-I2M-5-075]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University; CAMS Innovation Fund for Medical Science	This study was supported by the National Key R&D Program of China grant (no. 2017YFA0105702) and the National Natural Science Foundation of China Program grant (81672577, 81772939, 81902918, 81972607), 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD20003), and CAMS Innovation Fund for Medical Science (2019-I2M-5-075).	Aguiar DP, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-61; Bill R, 2015, FEBS LETT, V589, P1577, DOI 10.1016/j.febslet.2015.05.002; Blomberg OS, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.036236; Borsig L, 2018, GLYCOBIOLOGY, V28, P648, DOI 10.1093/glycob/cwx105; Cantrell W, 2018, MOLECULES, V23, DOI 10.3390/molecules23071791; Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004; Chang YS, 2017, P NATL ACAD SCI USA, V114, pE7159, DOI 10.1073/pnas.1700455114; Chaudhary LN, 2018, SURG ONCOL CLIN N AM, V27, P141, DOI 10.1016/j.soc.2017.08.004; Chen PS, 2007, J CELL SCI, V120, P2053, DOI 10.1242/jcs.03460; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005; Crean JK, 2004, FASEB J, V18, P1541, DOI 10.1096/fj.04-1546fje; Creed TJ, 2009, J IMMUNOL, V183, P164, DOI 10.4049/jimmunol.0801998; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043; Giles AJ, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0371-5; Gonzalez H, 2018, FEBS J, V285, P654, DOI 10.1111/febs.14325; Gupte R, 2013, P NATL ACAD SCI USA, V110, P14616, DOI 10.1073/pnas.1309898110; Guy R, 2002, CELL IMMUNOL, V216, P82, DOI 10.1016/S0008-8749(02)00505-1; Hamidi Hellyeh, 2018, Nat Rev Cancer, V18, P533, DOI 10.1038/s41568-018-0038-z; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]; Karagiannis GS, 2019, CANCER RES, V79, P4567, DOI 10.1158/0008-5472.CAN-19-1147; Karagiannis GS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0026; Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041; Lauby-Secretan B, 2015, NEW ENGL J MED, V372, P2353, DOI 10.1056/NEJMsr1504363; Liu XY, 2018, FUTURE ONCOL, V14, P665, DOI 10.2217/fon-2017-0588; Liu Y, 2016, J MOL MED, V94, P509, DOI 10.1007/s00109-015-1376-x; Lyons TG, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0682-x; Ma XQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08154-1; Manzoni D, 2016, LEUKEMIA RES, V47, P1, DOI 10.1016/j.leukres.2016.05.003; Marinella MA, 2020, J ONCOL PHARM PRACT, V26, P1482, DOI 10.1177/1078155220931921; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200; Mohme M, 2017, NAT REV CLIN ONCOL, V14, P155, DOI 10.1038/nrclinonc.2016.144; Morrison BL, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-35; Obradovic MMS, 2019, NATURE, V567, P540, DOI 10.1038/s41586-019-1019-4; Padmanaban V, 2019, NATURE, V573, P439, DOI 10.1038/s41586-019-1526-3; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Pi LY, 2015, HEPATOLOGY, V61, P678, DOI 10.1002/hep.27425; Picard M, 2017, IMMUNOL ALLERGY CLIN, V37, P679, DOI 10.1016/j.iac.2017.07.004; Ramazani Y, 2018, MATRIX BIOL, V68-69, P44, DOI 10.1016/j.matbio.2018.03.007; Ratman D, 2013, MOL CELL ENDOCRINOL, V380, P41, DOI 10.1016/j.mce.2012.12.014; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Saitoh M, 2018, J BIOCHEM, V164, P257, DOI 10.1093/jb/mvy047; Schwartz RS, 2017, NEW ENGL J MED, V376, P2486, DOI 10.1056/NEJMcibr1701388; Singh PP, 2014, BRIT J ANAESTH, V113, P68, DOI 10.1093/bja/aet577; Stavreva DA, 2009, NAT CELL BIOL, V11, P1093, DOI 10.1038/ncb1922; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Toska E, 2019, CELL REP, V27, P294, DOI 10.1016/j.celrep.2019.02.111; Wang H, 2004, CANCER CHEMOTH PHARM, V53, P459, DOI 10.1007/s00280-003-0759-9; Wang H, 2004, CLIN CANCER RES, V10, P1633, DOI 10.1158/1078-0432.CCR-0829-3; Wang HX, 2017, BIOPHARM DRUG DISPOS, V38, P449, DOI 10.1002/bdd.2085; Wu W, 2005, J BIOL CHEM, V280, P4117, DOI 10.1074/jbc.M411200200; Xu BE, 2005, P NATL ACAD SCI USA, V102, P10315, DOI 10.1073/pnas.0504422102; Yousefi M, 2018, CELL ONCOL, V41, P123, DOI 10.1007/s13402-018-0376-6; Zheng YC, 2012, MOL CANCER THER, V11, P2621, DOI 10.1158/1535-7163.MCT-12-0621	57	8	8	2	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5367	5378		10.1038/s41388-021-01944-w	http://dx.doi.org/10.1038/s41388-021-01944-w		JUL 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34272474	hybrid, Green Published			2022-12-28	WOS:000673332300002
J	Chen, TL; Liu, HD; Liu, ZL; Li, KS; Qin, RX; Wang, Y; Liu, JL; Li, ZP; Gao, QL; Pan, C; Yang, F; Zhao, W; Zhang, ZL; Xu, YF				Chen, Tianli; Liu, Hongda; Liu, Zengli; Li, Kangshuai; Qin, Ruixi; Wang, Yue; Liu, Jialiang; Li, Zhipeng; Gao, Qinglun; Pan, Chang; Yang, Fan; Zhao, Wei; Zhang, Zongli; Xu, Yunfei			FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis	ONCOGENE			English	Article							FACTOR RECEPTOR 4; GROWTH-FACTOR 19; BILE-ACIDS; CANCER; IDENTIFICATION; MUTATIONS; METABOLISM; RESISTANCE; PROGNOSIS	Treatment options for gallbladder carcinoma (GBC) are limited and GBC prognosis remains poor. There is no well-accepted targeted therapy to date, so effective biomarkers of GBC are urgently needed. Here we investigated the expression and correlations of fibroblast growth factor receptors (FGFR1-4) and 18 fibroblast growth factors (FGFs) in two independent patient cohorts and evaluated their prognostic significance. Consequently, we demonstrated that both FGF19 and FGFR4 were unfavorable prognostic biomarkers, and their co-expression was a more sensitive predictor. By analyzing the correlations between all 18 FGFs and FGFR4, we showed that FGF19 expression was significantly associated with FGFR4 and promoted GBC progression via stimulating FGFR4. With experiments using GBC cells, GPBAR1(-/-) mice models, and human subjects, we demonstrated that elevated bile acids (BAs) could increase the transcription and expression of FGF19 and FGFR4 by activating GPBAR1-cAMP-EGR1 pathway. FGF19 secreted from GBC cells promoted GBC progression by stimulating FGFR4 and downstream ERK in an autocrine manner with bile as a potential carrier. Patients with GBC had significantly higher FGF19 in serum and bile, compared to patients with cholelithiasis. BLU9931 inhibited FGFR4 and attenuated its oncogenic effects in GBC cell line. In conclusion, upregulation of BAs elevated co-expression of FGF19 and FGFR4 by activating GPBAR1-cAMP-EGR1 pathway. Co-expression of FGF19 and FGFR4 was a sensitive and unfavorable prognostic marker. GBC cells secreted FGF19 and facilitated progression by activating FGFR4 with bile as a potential carrier in an autocrine pathway.	[Chen, Tianli; Liu, Zengli; Li, Kangshuai; Wang, Yue; Liu, Jialiang; Li, Zhipeng; Zhao, Wei; Zhang, Zongli; Xu, Yunfei] Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan, Peoples R China; [Liu, Hongda] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing, Peoples R China; [Qin, Ruixi] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan, Peoples R China; [Li, Zhipeng] Shandong Univ, Shandong Prov ENT Hosp, Dept Gen Surg, Jinan, Peoples R China; [Gao, Qinglun] Shandong Prov Third Hosp, Dept Hepatobiliary Surg, Jinan, Peoples R China; [Pan, Chang] Shandong Univ, Qilu Hosp, Dept Emergency, Jinan, Peoples R China; [Yang, Fan] Shandong Univ, Sch Med, Minist Educ, Key Lab Expt Teratol, Jinan, Peoples R China; [Yang, Fan] Shandong Univ, Sch Med, Dept Biochem & Mol Biol, Jinan, Peoples R China	Shandong University; Nanjing Medical University; Shandong University; Shandong University; Shandong University; Shandong University; Shandong University	Zhang, ZL; Xu, YF (corresponding author), Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan, Peoples R China.	zzlzzl1900@163.com; xuyunfei1988@126.com		Liu, Hongda/0000-0002-5977-9130; Chen, Tianli/0000-0003-3706-0712	National Natural Science Foundation of China [82072676]; China Postdoctoral Science Foundation [2020M682190]; Shandong University Multidisciplinary Research and Innovation Team of Young Scholars [2020QNQT002]; Shandong Province Major Research and Design Program [2018GSF118169]; Natural Science Foundation of Shandong Province [ZR2019MH008]; Jinan City Science and Technology Development Program [201805017, 201805013]; Major Project of Shandong University Clinical Study [2020SDUCRCA018]; Project of Clinical New Techniques of Qilu Hospital affiliated to Shandong Universtiy, Clinical Research Innovation Fund Project [CXPJJH11800001-2018240]; Hengrui Hepatobiliary and Pancreatic Foundation [Y-2017-144]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Shandong University Multidisciplinary Research and Innovation Team of Young Scholars; Shandong Province Major Research and Design Program; Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Jinan City Science and Technology Development Program; Major Project of Shandong University Clinical Study; Project of Clinical New Techniques of Qilu Hospital affiliated to Shandong Universtiy, Clinical Research Innovation Fund Project; Hengrui Hepatobiliary and Pancreatic Foundation	Our study was supported by the National Natural Science Foundation of China (Grant No. 82072676), the China Postdoctoral Science Foundation (Grant No. 2020M682190), Shandong University Multidisciplinary Research and Innovation Team of Young Scholars (Grant No. 2020QNQT002), Shandong Province Major Research and Design Program (Grant No. 2018GSF118169), Natural Science Foundation of Shandong Province (ZR2019MH008), Jinan City Science and Technology Development Program (Grant No. 201805017, 201805013), the Major Project of Shandong University Clinical Study (Grant No. 2020SDUCRCA018), the Project of Clinical New Techniques of Qilu Hospital affiliated to Shandong Universtiy, Clinical Research Innovation Fund Project (CXPJJH11800001-2018240) and Hengrui Hepatobiliary and Pancreatic Foundation (Grant No.Y-2017-144).	Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Camilleri M, 2017, GASTROENTEROLOGY, V152, P1656, DOI 10.1053/j.gastro.2016.12.052; Choi M, 2006, NAT MED, V12, P1253, DOI 10.1038/nm1501; Dienstmann R, 2014, ANN ONCOL, V25, P552, DOI 10.1093/annonc/mdt419; Elzi David J, 2016, Genes Cancer, V7, P125, DOI 10.18632/genesandcancer.101; Gao LX, 2019, ONCOGENE, V38, P2394, DOI 10.1038/s41388-018-0591-7; Ge HF, 2014, J BIOL CHEM, V289, P30470, DOI 10.1074/jbc.M114.592022; Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666; Goyal L, 2017, CANCER DISCOV, V7, P252, DOI 10.1158/2159-8290.CD-16-1000; Hagel M, 2015, CANCER DISCOV, V5, P424, DOI 10.1158/2159-8290.CD-14-1029; Heinzle C, 2014, CURR PHARM DESIGN, V20, P2881, DOI 10.2174/13816128113199990594; Henley SJ, 2015, CANCER EPIDEM BIOMAR, V24, P1319, DOI 10.1158/1055-9965.EPI-15-0199; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Javle M, 2016, CANCER-AM CANCER SOC, V122, P3838, DOI 10.1002/cncr.30254; Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288; Keitel V, 2019, HANDB EXP PHARMACOL, V256, P19, DOI 10.1007/164_2019_230; Keitel V, 2013, CURR OPIN GASTROEN, V29, P299, DOI 10.1097/MOG.0b013e32835f3f14; Li F, 2020, ONCOGENE, V39, P3507, DOI 10.1038/s41388-020-1227-2; Li JN, 2019, BBA-MOL BASIS DIS, V1865, P895, DOI 10.1016/j.bbadis.2018.05.011; Li ML, 2014, NAT GENET, V46, P872, DOI 10.1038/ng.3030; Li Tiangang, 2015, Adv Pharmacol, V74, P263, DOI 10.1016/bs.apha.2015.04.003; Mhatre S, 2017, LANCET ONCOL, V18, P535, DOI 10.1016/S1470-2045(17)30167-5; Mitin T, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw324; Nakamura H, 2015, NAT GENET, V47, P1003, DOI 10.1038/ng.3375; PLEVRIS JN, 1995, GUT, V37, P127, DOI 10.1136/gut.37.1.127; Qiu B, 2019, EBIOMEDICINE, V50, P166, DOI 10.1016/j.ebiom.2019.11.021; Reue K, 2014, CURR OPIN LIPIDOL, V25, P140, DOI 10.1097/MOL.0000000000000060; Schaap FG, 2009, HEPATOLOGY, V49, P1228, DOI 10.1002/hep.22771; Song KH, 2009, HEPATOLOGY, V49, P297, DOI 10.1002/hep.22627; Sonne DP, 2016, J CLIN ENDOCR METAB, V101, P3002, DOI 10.1210/jc.2016-1607; Sugiyama N, 2010, CANCER RES, V70, P7851, DOI 10.1158/0008-5472.CAN-10-1223; Sun RQ, 2019, EBIOMEDICINE, V47, P142, DOI 10.1016/j.ebiom.2019.08.062; Taylor JG, 2009, J CLIN INVEST, V119, P3395, DOI 10.1172/JCI39703; Tiong KH, 2016, ONCOTARGET, V7, P57633, DOI 10.18632/oncotarget.9328; Tsilidis KK, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7607; Valle JW, 2021, LANCET, V397, P428, DOI 10.1016/S0140-6736(21)00153-7; Valle JW, 2017, CANCER DISCOV, V7, P943, DOI 10.1158/2159-8290.CD-17-0245; Wiedemann M, 2000, GENOMICS, V69, P275, DOI 10.1006/geno.2000.6332; Wu XL, 2011, EXPERT OPIN THER TAR, V15, P1307, DOI 10.1517/14728222.2011.624514; Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050; Xu YF, 2019, ONCOGENE, V38, P868, DOI 10.1038/s41388-018-0485-8; Xu YF, 2014, BIOCHEM BIOPH RES CO, V446, P54, DOI 10.1016/j.bbrc.2014.02.050; Xu YF, 2017, ONCOTARGET, V8, P4888, DOI 10.18632/oncotarget.13982; Yang F, 2020, NATURE, V587, P499, DOI 10.1038/s41586-020-2569-1; Ye YW, 2011, CANCER-AM CANCER SOC, V117, P5304, DOI 10.1002/cncr.26207; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482; Zhou M, 2014, CANCER RES, V74, P3306, DOI 10.1158/0008-5472.CAN-14-0208; Zweers SJLB, 2012, HEPATOLOGY, V55, P575, DOI 10.1002/hep.24702	48	26	25	4	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4941	4953		10.1038/s41388-021-01850-1	http://dx.doi.org/10.1038/s41388-021-01850-1		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34163030				2022-12-28	WOS:000664853000003
J	Zhou, M; Zhang, XL; Liu, C; Nie, DN; Li, SY; Lai, PL; Jin, YL				Zhou, Min; Zhang, Xiuli; Liu, Chang; Nie, Danian; Li, Shuyi; Lai, Peilong; Jin, Yanli			Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE; PHILADELPHIA-CHROMOSOME; MAINTENANCE; RESISTANCE; IMATINIB; THERAPY; HEAD; AXIS; CML	The application of tyrosine kinase inhibitors (TKIs) in clinic has revolutionized chronic myelogenous leukemia (CML) treatment, but fails to eliminate leukemia stem cells (LSCs), which are considered as roots of drug resistance and disease relapse. Thus, eradication of LSCs may be a promising strategy for curing CML. In this study, we found that protein lysine methyltransferase G9A was overexpressed in CML LSCs. The upregulation of G9A by BCR-ABL was independent on its tyrosine kinase activity. Knockdown of G9A by shRNAs or pharmacological inhibition of G9A by UNC0642 significantly suppressed survival and impaired self-renewal capacity of CML LSCs. Inhibition of G9a eradicated LSCs in CML mice driven by BCR-ABL gene and dramatically prolonged survival of the mice. Ex vivo treatment with G9A inhibitor inhibited long-term engraftment of CML CD34(+) cells in immunodeficient mice. Mechanically, tumor suppressor SOX6 was identified as a direct target of G9A in CML LSCs by RNA-seq analysis. Silencing Sox6 at least partially rescued G9a knockdown-mediated LSCs elimination in vivo. Our findings improve the understanding of LSC regulation network and validate G9A as a therapeutic target in CML LSCs. Targeting G9A may be considered as an additional strategy for the treatment of patients with CML.	[Zhou, Min; Zhang, Xiuli; Liu, Chang; Li, Shuyi; Jin, Yanli] Jinan Univ, Inst Tumor Pharmacol, Coll Pharm, Guangzhou, Peoples R China; [Liu, Chang] Jinan Univ, Integrated Chinese & Western Med Postdoctoral Res, Guangzhou, Peoples R China; [Nie, Danian] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hematol, Guangzhou, Peoples R China; [Lai, Peilong] Guangdong Acad Med Sci, Dept Hematol, Guangdong Gen Hosp, Guangzhou, Peoples R China	Jinan University; Jinan University; Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital	Jin, YL (corresponding author), Jinan Univ, Inst Tumor Pharmacol, Coll Pharm, Guangzhou, Peoples R China.	yanlijin2014@jnu.edu.cn			National Natural Science Funds [81922069, 81974505, 82003778]; Natural Science Funds of Guangdong Province for Distinguished Young Scholars [2016A030306036]; Young Scholar of Science and Technology of Guangdong Province [2016TQ03R926]	National Natural Science Funds(National Natural Science Foundation of China (NSFC)); Natural Science Funds of Guangdong Province for Distinguished Young Scholars; Young Scholar of Science and Technology of Guangdong Province	This study was supported by grants from the National Natural Science Funds (Nos. 81922069 and 81974505 to YJ; No. 82003778 to CL); the Natural Science Funds of Guangdong Province for Distinguished Young Scholars (Grant No. 2016A030306036 to YJ); the Young Scholar of Science and Technology of Guangdong Province (2016TQ03R926 to YJ).	Abraham SA, 2016, NATURE, V534, P341, DOI 10.1038/nature18288; Bhat AV, 2019, CANCER RES, V79, P2232, DOI 10.1158/0008-5472.CAN-18-2676; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Cantu C, 2011, BLOOD, V117, P3669, DOI 10.1182/blood-2010-04-282350; Carter BZ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1180; Casciello F, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00487; Chen YY, 2009, NAT GENET, V41, P783, DOI 10.1038/ng.389; Cortes JE, 2013, NEW ENGL J MED, V369, P1783, DOI 10.1056/NEJMoa1306494; Crews LA, 2013, CANCER LETT, V338, P15, DOI 10.1016/j.canlet.2012.08.006; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Gehrmann U, 2019, P NATL ACAD SCI USA, V116, P25839, DOI 10.1073/pnas.1901639116; Holyoake TL, 2017, BLOOD, V129, P1595, DOI 10.1182/blood-2016-09-696013; Hu L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0322-6; Hua KT, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-189; Jain P, 2015, LANCET HAEMATOL, V2, pE376, DOI 10.1016/S2352-3026(15)00127-1; Jin YL, 2017, CLIN CANCER RES, V23, P2842, DOI 10.1158/1078-0432.CCR-16-1298; Jin YL, 2016, J CLIN INVEST, V126, P3961, DOI 10.1172/JCI85239; Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93; Kalmanti L, 2015, LEUKEMIA, V29, P1123, DOI 10.1038/leu.2015.36; Lehnertz B, 2014, GENE DEV, V28, P317, DOI 10.1101/gad.236794.113; Liang ZX, 2020, SEMIN CANCER BIOL, V67, P83, DOI 10.1016/j.semcancer.2019.07.011; Liu C, 2018, CANCER RES, V78, P1522, DOI 10.1158/0008-5472.CAN-17-1733; Liu CW, 2017, MOL CANCER THER, V16, P1421, DOI 10.1158/1535-7163.MCT-16-0567-T; Liu F, 2013, J MED CHEM, V56, P8931, DOI 10.1021/jm401480r; Liu SL, 2015, ONCOTARGET, V6, P6887, DOI 10.18632/oncotarget.3159; Luo CW, 2017, RADIOTHER ONCOL, V124, P395, DOI 10.1016/j.radonc.2017.03.002; Ma L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009587; O'Hare T, 2012, NAT REV CANCER, V12, P513, DOI 10.1038/nrc3317; Pan MR, 2016, ONCOTARGET, V7, P61136, DOI 10.18632/oncotarget.11256; Pfister SX, 2017, NAT REV DRUG DISCOV, V16, P241, DOI 10.1038/nrd.2016.256; Rowbotham SP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07077-1; Saikia T, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0665-2; Segovia C, 2019, NAT MED, V25, P1073, DOI 10.1038/s41591-019-0499-y; Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tao H, 2014, MOL CELL BIOCHEM, V394, P23, DOI 10.1007/s11010-014-2077-4; Toh TB, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0596-9; Tu WB, 2018, CANCER CELL, V34, P579, DOI 10.1016/j.ccell.2018.09.001; Wang J, 2016, ONCOGENE, V35, P1692, DOI 10.1038/onc.2015.234; Wang LH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0120-6; Wang YF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00350-9; Wei L, 2017, J HEPATOL, V67, P758, DOI 10.1016/j.jhep.2017.05.015; Xie HF, 2016, CANCER DISCOV, V6, P1237, DOI 10.1158/2159-8290.CD-15-1439; Zhang HJ, 2019, STEM CELL TRANSL MED, V8, P768, DOI 10.1002/sctm.18-0247; Zhang HJ, 2012, NAT GENET, V44, P861, DOI 10.1038/ng.2350; Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zhou JF, 2018, CLIN CANCER RES, V24, P145, DOI 10.1158/1078-0432.CCR-17-1533	48	4	5	4	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3564	3577		10.1038/s41388-021-01799-1	http://dx.doi.org/10.1038/s41388-021-01799-1		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33931742				2022-12-28	WOS:000645887000003
J	Blokzijl-Franke, S; Ponsioen, B; Schulte-Merker, S; Herbomel, P; Kissa, K; Choorapoikayil, S; den Hertog, J				Blokzijl-Franke, Sasja; Ponsioen, Bas; Schulte-Merker, Stefan; Herbomel, Philippe; Kissa, Karima; Choorapoikayil, Suma; den Hertog, Jeroen			Phosphatidylinositol-3 kinase signaling controls survival and stemness of hematopoietic stem and progenitor cells	ONCOGENE			English	Article								Hematopoietic stem and progenitor cells (HSPCs) are multipotent cells giving rise to all blood lineages during life. HSPCs emerge from the ventral wall of the dorsal aorta (VDA) during a specific timespan in embryonic development through endothelial hematopoietic transition (EHT). We investigated the ontogeny of HSPCs in mutant zebrafish embryos lacking functional pten, an important tumor suppressor with a central role in cell signaling. Through in vivo live imaging, we discovered that in pten mutant embryos a proportion of the HSPCs died upon emergence from the VDA, an effect rescued by inhibition of phosphatidylinositol-3 kinase (PI3K). Surprisingly, inhibition of PI3K in wild-type embryos also induced HSPC death. Surviving HSPCs colonized the caudal hematopoietic tissue (CHT) normally and committed to all blood lineages. Single-cell RNA sequencing indicated that inhibition of PI3K enhanced survival of multipotent progenitors, whereas the number of HSPCs with more stem-like properties was reduced. At the end of the definitive wave, loss of Pten caused a shift to more restricted progenitors at the expense of HSPCs. We conclude that PI3K signaling tightly controls HSPCs survival and both up- and downregulation of PI3K signaling reduces stemness of HSPCs.	[Blokzijl-Franke, Sasja; Ponsioen, Bas; Schulte-Merker, Stefan; Choorapoikayil, Suma; den Hertog, Jeroen] Hubrecht Inst KNAW, Utrecht, Netherlands; [Blokzijl-Franke, Sasja; Ponsioen, Bas; Schulte-Merker, Stefan; Choorapoikayil, Suma; den Hertog, Jeroen] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Ponsioen, Bas] Univ Utrecht, Univ Med Ctr Utrecht, Ctr Mol Med, Mol Canc Res, Utrecht, Netherlands; [Schulte-Merker, Stefan] WWU Munster, Inst Cardiovasc Organogenesis & Regenerat, Med Fac, Munster, Germany; [Herbomel, Philippe; Kissa, Karima] Inst Pasteur, Dept Dev & Stem Cell Biol, Paris, France; [Herbomel, Philippe; Kissa, Karima] CNRS, UMR 3738, Paris, France; [Kissa, Karima; Choorapoikayil, Suma] Univ Montpellier, CNRS, Lab Pathogen Host Interact, INSERM, Montpellier, France; [den Hertog, Jeroen] Leiden Univ, Inst Biol, Leiden, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Munster; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Leiden University; Leiden University - Excl LUMC	den Hertog, J (corresponding author), Hubrecht Inst KNAW, Utrecht, Netherlands.; den Hertog, J (corresponding author), Univ Med Ctr Utrecht, Utrecht, Netherlands.; den Hertog, J (corresponding author), Leiden Univ, Inst Biol, Leiden, Netherlands.	j.denhertog@hubrecht.eu	Kissa, Karima/N-6801-2018	Kissa, Karima/0000-0002-7683-3661	EU (FP7) grant, ZF-CANCER [HEALTH-F2-2008-201439]	EU (FP7) grant, ZF-CANCER	The authors would like to thank Mark Reijnen and animal caretakers for excellent management of the fish facility. Microscopy was done in the Hubrecht Imaging Centre. The authors would like to thank Stefan van der Elst and Reinier van der Linden for FACS-sorting. The authors would like to thank Jeroen Paardekooper Overman for statistical analysis, Laila Ritsma, Sylvain de Rossi, and Miriam Stumpf for technical support and Bas Castelijns for help with scRNA data analysis. This work was supported in part by an EU (FP7) grant, ZF-CANCER (HEALTH-F2-2008-201439).	Alestrom P, 2020, LAB ANIM-UK, V54, P213, DOI 10.1177/0023677219869037; Athanasiadis EI, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02305-6; Baron CS, 2019, CELL, V179, P527, DOI 10.1016/j.cell.2019.08.006; Baron CS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04893-3; Beis D, 2005, DEVELOPMENT, V132, P4193, DOI 10.1242/dev.01970; Bertrand JY, 2010, NATURE, V464, P108, DOI 10.1038/nature08738; Bertrand JY, 2005, P NATL ACAD SCI USA, V102, P134, DOI 10.1073/pnas.0402270102; Blackburn JS, 2014, CANCER CELL, V25, P366, DOI 10.1016/j.ccr.2014.01.032; Boisset JC, 2010, NATURE, V464, P116, DOI 10.1038/nature08764; Bolli N, 2011, BLOOD, V117, P3996, DOI 10.1182/blood-2010-08-304030; Buenrostro JD, 2018, CELL, V173, P1535, DOI 10.1016/j.cell.2018.03.074; Challen GA, 2009, CYTOM PART A, V75A, P14, DOI 10.1002/cyto.a.20674; Chen MJ, 2009, NATURE, V457, P887, DOI 10.1038/nature07619; Choorapoikayil S, 2014, BLOOD, V123, P184, DOI 10.1182/blood-2013-05-501544; Choorapoikayil S, 2013, DIS MODEL MECH, V6, P1159, DOI 10.1242/dmm.012377; Choorapoikayil S, 2012, DIS MODEL MECH, V5, P241, DOI 10.1242/dmm.008326; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Davidson AJ, 2004, ONCOGENE, V23, P7233, DOI 10.1038/sj.onc.1207943; Dixon Giles, 2012, ISRN Hematol, V2012, P915868, DOI 10.5402/2012/915868; Faucherre A, 2008, ONCOGENE, V27, P1079, DOI 10.1038/sj.onc.1210730; Gering M, 2005, DEV CELL, V8, P389, DOI 10.1016/j.devcel.2005.01.010; Godin I, 2002, NAT REV IMMUNOL, V2, P593, DOI 10.1038/nri857; Grun D, 2014, NAT METHODS, V11, P637, DOI [10.1038/NMETH.2930, 10.1038/nmeth.2930]; Gurskaya NG, 2006, NAT BIOTECHNOL, V24, P461, DOI 10.1038/nbt1191; Hashimshony T, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0938-8; Herman JS, 2018, NAT METHODS, V15, P379, DOI 10.1038/nmeth.4662; Hogan BM, 2009, NAT GENET, V41, P396, DOI 10.1038/ng.321; Kartalaei PS, 2015, J EXP MED, V212, P93, DOI 10.1084/jem.20140767; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kissa K, 2008, BLOOD, V111, P1147, DOI 10.1182/blood-2007-07-099499; Kissa K, 2010, NATURE, V464, P112, DOI 10.1038/nature08761; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Kowalczyk MS, 2015, GENOME RES, V25, P1860, DOI 10.1101/gr.192237.115; Lai SJ, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0038-x; Lin HF, 2005, BLOOD, V106, P3803, DOI 10.1182/blood-2005-01-0179; Lin HT, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2011.0334; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Muraro MJ, 2016, CELL SYST, V3, P385, DOI 10.1016/j.cels.2016.09.002; Murayama E, 2006, IMMUNITY, V25, P963, DOI 10.1016/j.immuni.2006.10.015; Nestorowa S, 2016, BLOOD, V128, pE20, DOI 10.1182/blood-2016-05-716480; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Renaud O, 2011, NAT PROTOC, V6, P1897, DOI 10.1038/nprot.2011.408; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Signer RAJ, 2014, NATURE, V509, P49, DOI 10.1038/nature13035; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stachura DL, 2011, METHOD CELL BIOL, V101, P75, DOI 10.1016/B978-0-12-387036-0.00004-9; Stumpf M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154771; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Svoboda O, 2014, BLOOD, V124, P220, DOI 10.1182/blood-2014-03-564682; Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514; Tian Y, 2017, J EXP MED, V214, P3347, DOI 10.1084/jem.20170488; Urasaki A, 2006, GENETICS, V174, P639, DOI 10.1534/genetics.106.060244; van den Brink SC, 2017, NAT METHODS, V14, P935, DOI 10.1038/nmeth.4437; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Xue YY, 2019, CELL REP, V27, P1567, DOI 10.1016/j.celrep.2019.04.030; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zovein AC, 2008, CELL STEM CELL, V3, P625, DOI 10.1016/j.stem.2008.09.018	61	2	2	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2741	2755		10.1038/s41388-021-01733-5	http://dx.doi.org/10.1038/s41388-021-01733-5		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33714985	Green Submitted, hybrid, Green Published			2022-12-28	WOS:000628485300003
J	Ni, MD; Li, JJ; Zhao, HY; Xu, F; Cheng, JY; Yu, M; Ke, GH; Wu, XH				Ni, Mengdong; Li, Jiajia; Zhao, Haiyun; Xu, Fei; Cheng, Jingyi; Yu, Min; Ke, Guihao; Wu, Xiaohua			BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair	ONCOGENE			English	Article							PHASE-II; BINDING PROTEIN; STEM-CELLS; BROMODOMAIN; CARCINOMA; RADIORESISTANCE; EPIGENETICS; COMBINATION; VORINOSTAT; CHROMATIN	Cisplatin-based chemoradiotherapy is the recommended treatment for local advanced cervical cancer, but radioresistance remains one of the most important and unresolved clinical problems. Investigations have revealed aberrant epigenetic modifications as one of the chief culprits for the development of radioresistance. Here, we attempt to identify a radiosensitizer from an epigenetic drug synergy screen and explore the underlying mechanism. We integrated epigenetic inhibitors and radiotherapy in cervical cancer cell lines to identify potential radiosensitizers. We further verified the sensitization effect of the drug and the function of its target gene both in vitro and in vivo. Finally, we validated the clinical significance of its target gene in clinical cervical cancer specimens. We identified JQ1, a BRD4 inhibitor, as a potent radiosensitizer. Functional assays demonstrated that repressing BRD4 activity led to significant radiosensitization and potentiation of DNA damage in cervical cancer cell lines. By using RNA-seq to determine JQ1-mediated changes in transcription, we identified RAD51AP1 as a major BRD4 target gene involved in radiosensitivity. A dual-luciferase reporter assay and ChIP-qPCR showed that BRD4 binds to the promoter region of RAD51AP1 and promotes its transcription, whereas this activity was attenuated by BRD4 inhibition. The in vivo experiments also suggested a synergy between BRD4 inhibition and radiotherapy. High BRD4 expression was found to be related to a worse prognosis and radiation resistance. BRD4 inhibition sensitizes cervical cancer to radiotherapy by inhibiting RAD51AP1 transcription. The combination of JQ1 with radiotherapy merits further evaluation as a therapeutic strategy for improving local control in cervical cancer.	[Ni, Mengdong; Li, Jiajia; Zhao, Haiyun; Xu, Fei; Cheng, Jingyi; Yu, Min; Ke, Guihao; Wu, Xiaohua] Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China; [Ni, Mengdong; Li, Jiajia; Zhao, Haiyun; Xu, Fei; Cheng, Jingyi; Yu, Min; Ke, Guihao; Wu, Xiaohua] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China	Fudan University; Fudan University	Ke, GH; Wu, XH (corresponding author), Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China.; Ke, GH; Wu, XH (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.	kegh5734@126.com; wu.xh@fudan.edu.cn		Yu, Min/0000-0001-9197-2101	National Natural Science Foundation of China [81672569, 81902660]; Natural Science Foundation of Shanghai [19ZR1410700]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai)	This study was supported by grants from the National Natural Science Foundation of China to XW (No. 81672569), the Natural Science Foundation of Shanghai to GK (No. 19ZR1410700), and the National Natural Science Foundation of China to JL (No. 81902660).	Abramson JS, 2015, BLOOD, V126, P1491, DOI DOI 10.1182/BLOOD.V126.23.1491.1491; Aggarwal R, 2017, J CLIN ONCOL, V35, P1231, DOI 10.1200/JCO.2016.70.5350; Bagratuni T, 2020, EUR J CANCER, V126, P125, DOI 10.1016/j.ejca.2019.11.017; Balbous A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2647-9; Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958; Bates SE, 2020, NEW ENGL J MED, V383, P650, DOI 10.1056/NEJMra1805035; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Bitzer M, 2016, J HEPATOL, V65, P280, DOI 10.1016/j.jhep.2016.02.043; Cao LJ, 2019, INT J GYNECOL CANCER, V29, P1244, DOI 10.1136/ijgc-2019-000556; Chaidos A, 2014, BLOOD, V123, P697, DOI 10.1182/blood-2013-01-478420; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Glasspool RM, 2014, BRIT J CANCER, V110, P1923, DOI 10.1038/bjc.2014.116; Harkenrider MM, 2020, JNCI-J NATL CANCER I, V112, P1081, DOI 10.1093/jnci/djaa041; Hatzi VI, 2015, CANCER LETT, V356, P34, DOI 10.1016/j.canlet.2013.11.018; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Jiang ZF, 2019, LANCET ONCOL, V20, P806, DOI 10.1016/S1470-2045(19)30164-0; Karakashev S, 2017, CELL REP, V21, P3398, DOI 10.1016/j.celrep.2017.11.095; Kovalenko OV, 1997, NUCLEIC ACIDS RES, V25, P4946, DOI 10.1093/nar/25.24.4946; Krause M, 2017, ADV DRUG DELIVER REV, V109, P63, DOI 10.1016/j.addr.2016.02.002; Kwon NH, 2008, J CLIN IMMUNOL, V28, P139, DOI 10.1007/s10875-007-9148-1; Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292; Li N, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0789-1; Li XY, 2018, CELL REP, V22, P796, DOI 10.1016/j.celrep.2017.12.078; Lin LL, 2020, INT J GYNECOL CANCER, V30, P409, DOI 10.1136/ijgc-2020-001227; Marie-Egyptienne DT, 2013, CANCER LETT, V341, P63, DOI 10.1016/j.canlet.2012.11.019; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Modesti M, 2007, MOL CELL, V28, P468, DOI 10.1016/j.molcel.2007.08.025; Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156; Najafova Z, 2017, NUCLEIC ACIDS RES, V45, P127, DOI 10.1093/nar/gkw826; Postel-Vinay S, 2019, EUR J CANCER, V109, P103, DOI 10.1016/j.ejca.2018.12.020; Prabakaran PJ, 2017, CLIN CANCER RES, V23, P6044, DOI 10.1158/1078-0432.CCR-17-0969; Rashmi R, 2018, CANCER RES, V78, P1392, DOI 10.1158/0008-5472.CAN-17-2367; Rataj O, 2019, INT J CANCER, V144, P2330, DOI 10.1002/ijc.31986; Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794; Stanlie A, 2014, MOL CELL, V55, P97, DOI 10.1016/j.molcel.2014.05.018; Stonestrom Aaron J, 2016, Drug Discov Today Technol, V19, P23, DOI 10.1016/j.ddtec.2016.05.004; Sun CY, 2018, CANCER CELL, V33, P401, DOI 10.1016/j.ccell.2018.01.019; Tsai CL, 2018, HEPATOLOGY, V67, P586, DOI 10.1002/hep.29328; Wang J, 2017, CANCER LETT, V391, P141, DOI 10.1016/j.canlet.2017.01.031; Wang ZW, 2014, CELL MOL BIOL LETT, V19, P233, DOI 10.2478/s11658-014-0191-7; Welti J, 2018, CLIN CANCER RES, V24, P3149, DOI 10.1158/1078-0432.CCR-17-3571; Williams KE, 2015, STEM CELLS, V33, P327, DOI 10.1002/stem.1843; Yang L, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1645; Yardley DA, 2013, J CLIN ONCOL, V31, P2128, DOI 10.1200/JCO.2012.43.7251; Zhuang HQ, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0109-5; Zibelman M, 2015, INVEST NEW DRUG, V33, P1040, DOI 10.1007/s10637-015-0261-3	51	9	9	4	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2711	2724		10.1038/s41388-021-01735-3	http://dx.doi.org/10.1038/s41388-021-01735-3		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33712705				2022-12-28	WOS:000628201500002
J	Zhou, JF; Wang, YL; Wu, DL; Wang, SS; Chen, ZQ; Xiang, ST; Chan, FL				Zhou, Jianfu; Wang, Yuliang; Wu, Dinglan; Wang, Shusheng; Chen, Zhiqiang; Xiang, Songtao; Chan, Franky Leung			Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer	ONCOGENE			English	Review							STEROIDOGENIC FACTOR-I; TRANSCRIPTIONAL REGULATION; ERR-ALPHA; INCREASED SURVIVAL; EMERGING ROLES; COUP-TFII; HOMOLOG 1; EXPRESSION; LRH-1; METABOLISM	Castration-resistant prostate cancer (CRPC) almost invariably occurs after androgen-deprivation therapy (ADT) for the advanced metastatic disease. It is generally believed that among multiple mechanisms and signaling pathways, CRPC is significantly driven by the reactivation of androgen receptor (AR) signaling in ADT-treated patients with castrate levels of androgen, partially at least mediated by the androgen biosynthesis within the tumor, also known as intratumoral or intraprostatic androgen biosynthesis. Steroidogenic enzymes, such as CYP11A1, CYP17A1, HSD3B1, AKR1C3 and SRD5A, are essential to catalyze the conversion of the initial substrate cholesterol into potent androgens that confers the CRPC progression. Accumulating evidences indicate that many steroidogenic enzymes are upregulated in the progression setting; however, little is known about the dysregulation of these enzymes in CRPC. Orphan nuclear receptors (ONRs) are members of the nuclear receptor superfamily, of which endogenous physiological ligands are unknown and which are constitutively active independent of any physiological ligands. Studies have validated that besides AR, ONRs could be the potential therapeutic targets for prostate cancer, particularly the lethal CRPC progression. Early studies reveal that ONRs play crucial roles in the transcriptional regulation of steroidogenic enzyme genes. Notably, we and others show that three distinct ONRs, including liver receptor homolog-1 (LRH-1, NR5A2), steroidogenic factor 1 (SF-1, AD4BP, NR5A1) and estrogen-related receptor alpha (ERR alpha, NR3B1), can contribute to the CRPC progression by promotion of the intratumoral androgen synthesis via their direct transcriptional regulation on multiple steroidogenic enzymes. This review presents an overview of the current understanding on the intratumoral androgen biosynthesis in CRPC, with a special focus on the emerging roles of ONRs in this process.	[Zhou, Jianfu; Wang, Shusheng; Chen, Zhiqiang; Xiang, Songtao] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Urol, Guangzhou, Peoples R China; [Zhou, Jianfu] Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Peoples R China; [Zhou, Jianfu; Wang, Yuliang; Chan, Franky Leung] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Peoples R China; [Wu, Dinglan] Southern Med Univ, Shenzhen Hosp, Clin Innovat & Res Ctr, Shenzhen Key Lab Viral Oncol, Shenzhen, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Chinese University of Hong Kong; Southern Medical University - China	Xiang, ST (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Urol, Guangzhou, Peoples R China.; Chan, FL (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Peoples R China.	tonyxst@gzucm.edu.cn; franky-chan@cuhk.edu.hk	Chan, Franky/M-1043-2018	Chan, Franky/0000-0003-0567-2052	National Natural Science Foundation of China [81774067, 81802575, 82072830, 81872283]; Medical Science and Technology Research Fund of Guangdong Province [A2020239]; Specific Research Fund for TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine [YN2016MJ03]; Guangdong-Hong Kong collaborative innovation projects from the Department of Science and Technology of Guangdong Province [2017A050506042]; Guangdong Provincial Hospital of Chinese Medicine [YN2018HK02]; General Research Fund, Research Grants Council of Hong Kong [461009, 2140789, 14100914, 14107116, 14110918]; Health and Medical Research Fund [02130066]; Food and Health Bureau of Hong Kong; Eternal Flame Scholar Programme of Guangzhou University of Chinese Medicine	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Science and Technology Research Fund of Guangdong Province; Specific Research Fund for TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine; Guangdong-Hong Kong collaborative innovation projects from the Department of Science and Technology of Guangdong Province; Guangdong Provincial Hospital of Chinese Medicine; General Research Fund, Research Grants Council of Hong Kong(Hong Kong Research Grants Council); Health and Medical Research Fund; Food and Health Bureau of Hong Kong; Eternal Flame Scholar Programme of Guangzhou University of Chinese Medicine	The work described in this article was partially supported by the National Natural Science Foundation of China (No. 81774067, 81802575, 82072830, 81872283), Medical Science and Technology Research Fund of Guangdong Province (No. A2020239), Specific Research Fund for TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine (No. YN2016MJ03), Guangdong-Hong Kong collaborative innovation projects from the Department of Science and Technology of Guangdong Province (No. 2017A050506042) and Guangdong Provincial Hospital of Chinese Medicine (No. YN2018HK02); and also by grants from the General Research Fund (project numbers: 461009, 2140789, 14100914, 14107116, 14110918), Research Grants Council of Hong Kong; a grant from the Health and Medical Research Fund (project number: 02130066), Food and Health Bureau of Hong Kong (to FLC). JZ was awarded by the Eternal Flame Scholar Programme of Guangzhou University of Chinese Medicine.	Armandari I, 2014, PROSTATE INT, V2, P105, DOI 10.12954/PI.14063; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Baek SH, 2014, ANNU REV PHYSIOL, V76, P177, DOI 10.1146/annurev-physiol-030212-183758; BARRIE SE, 1994, J STEROID BIOCHEM, V50, P267, DOI 10.1016/0960-0760(94)90131-7; Benod C, 2011, P NATL ACAD SCI USA, V108, P16927, DOI 10.1073/pnas.1112047108; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buholzer CF, 2005, MOL ENDOCRINOL, V19, P65, DOI 10.1210/me.2004-0061; Cai CM, 2011, CANCER RES, V71, P6503, DOI 10.1158/0008-5472.CAN-11-0532; Chand AL, 2013, STEROIDS, V78, P700, DOI 10.1016/j.steroids.2013.03.001; Chandrasekar T, 2015, TRANSL ANDROL UROL, V4, P365, DOI 10.3978/j.issn.2223-4683.2015.05.02; Chang KH, 2013, CELL, V154, P1074, DOI 10.1016/j.cell.2013.07.029; Chen B, 2014, CANCER GENE THER, V21, P411, DOI 10.1038/cgt.2014.41; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; Clyne CD, 2004, MOL CELL ENDOCRINOL, V215, P39, DOI 10.1016/j.mce.2003.11.001; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Del Tredici AL, 2008, MOL PHARMACOL, V73, P900, DOI 10.1124/mol.107.040089; Ehrlund A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032080; Eichner LJ, 2011, MITOCHONDRION, V11, P544, DOI 10.1016/j.mito.2011.03.121; Evans RM, 2005, MOL ENDOCRINOL, V19, P1429, DOI 10.1210/me.2005-0046; Evans RM, 2014, CELL, V157, P255, DOI 10.1016/j.cell.2014.03.012; Fayard E, 2004, TRENDS CELL BIOL, V14, P250, DOI 10.1016/j.tcb.2004.03.008; Fontana F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020460; Fujimura T, 2007, INT J CANCER, V120, P2325, DOI 10.1002/ijc.22363; GELLER J, 1984, J UROLOGY, V132, P693, DOI 10.1016/S0022-5347(17)49829-6; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; GRINO PB, 1990, ENDOCRINOLOGY, V126, P1165, DOI 10.1210/endo-126-2-1165; Grist E, 2015, J STEROID BIOCHEM, V145, P157, DOI 10.1016/j.jsbmb.2014.09.006; Hanley NA, 2001, MOL ENDOCRINOL, V15, P57, DOI 10.1210/me.15.1.57; Hofland J, 2010, CANCER RES, V70, P1256, DOI 10.1158/0008-5472.CAN-09-2092; HUM DW, 1993, CLIN CHEM, V39, P333; Jia L, 2018, ONCOGENE, V37, P3340, DOI 10.1038/s41388-018-0198-z; Jimenez P, 2003, ENDOCRINOLOGY, V144, P4285, DOI 10.1210/en.2003-0472; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; Lewis SR, 2014, ENDOCRINOLOGY, V155, P358, DOI 10.1210/en.2013-1583; Lin SQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10287; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Madoux F, 2008, MOL PHARMACOL, V73, P1776, DOI 10.1124/mol.108.045963; Martin LJ, 2008, MOL ENDOCRINOL, V22, P2021, DOI 10.1210/me.2007-0370; Martin LJ, 2009, J MOL ENDOCRINOL, V42, P119, DOI 10.1677/JME-08-0095; Mathieu R, 2013, PROSTATE, V73, P1103, DOI 10.1002/pros.22659; Mei L, 2010, MOL CELL ENDOCRINOL, V319, P39, DOI 10.1016/j.mce.2010.01.014; Meinsohn MC, 2019, PHYSIOL REV, V99, P1249, DOI 10.1152/physrev.00019.2018; Mendoza-Villarroel RE, 2014, BIOL REPROD, V91, DOI 10.1095/biolreprod.113.115790; Miao L, 2010, MOL ENDOCRINOL, V24, P1175, DOI 10.1210/me.2009-0470; Miki Y, 2006, CANCER LETT, V244, P24, DOI 10.1016/j.canlet.2005.11.038; Miller S, 2013, INT J ONCOL, V42, P627, DOI 10.3892/ijo.2012.1758; Milona A, 2019, MOL METAB, V30, P221, DOI 10.1016/j.molmet.2019.09.007; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; MOORE CCD, 1991, J STEROID BIOCHEM, V40, P517, DOI 10.1016/0960-0760(91)90271-6; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Parakh TN, 2006, P NATL ACAD SCI USA, V103, P12435, DOI 10.1073/pnas.0603006103; Parker KL, 2002, RECENT PROG HORM RES, V57, P19, DOI 10.1210/rp.57.1.19; Peng N, 2003, J CLIN ENDOCR METAB, V88, P6020, DOI 10.1210/jc.2003-030880; Penning TM, 2014, ENDOCR-RELAT CANCER, V21, pT67, DOI 10.1530/ERC-14-0109; Qin J, 2013, NATURE, V493, P236, DOI 10.1038/nature11674; Reichert ZR, 2016, CANCER J, V22, P326, DOI 10.1097/PPO.0000000000000214; Saxena D, 2007, ENDOCRINOLOGY, V148, P726, DOI 10.1210/en.2006-0108; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Seely J, 2005, ENDOCRINOLOGY, V146, P3605, DOI 10.1210/en.2004-1619; Sharifi N, 2013, MOL ENDOCRINOL, V27, P708, DOI 10.1210/me.2013-1007; Shi YH, 2007, DRUG DISCOV TODAY, V12, P440, DOI 10.1016/j.drudis.2007.04.006; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sirianni R, 2002, J ENDOCRINOL, V174, pR13, DOI 10.1677/joe.0.174R013; Stuchbery R, 2017, NAT REV UROL, V14, P49, DOI 10.1038/nrurol.2016.221; Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078-0432.CCR-05-0525; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Volle DH, 2007, GENE DEV, V21, P303, DOI 10.1101/gad.409307; Wang JJ, 2016, NAT MED, V22, P488, DOI 10.1038/nm.4070; Wang LM, 2016, ONCOTARGET, V7, P14673, DOI 10.18632/oncotarget.7405; Wang Z, 2018, ENDOCR-RELAT CANCER, V25, P35, DOI 10.1530/ERC-17-0280; Wright AS, 1999, ENDOCRINOLOGY, V140, P4509, DOI 10.1210/en.140.10.4509; Wu C, 2018, ONCOL LETT, V16, P2833, DOI 10.3892/ol.2018.8988; Wu DL, 2016, BBA-REV CANCER, V1866, P23, DOI 10.1016/j.bbcan.2016.06.001; Wu J, 2018, CLIN TRANSL ONCOL, V20, P1302, DOI 10.1007/s12094-018-1862-z; Xiao LJ, 2018, CANCER MANAG RES, V10, P2389, DOI 10.2147/CMAR.S162887; Xiao LJ, 2018, CANCER RES, V78, P2205, DOI 10.1158/0008-5472.CAN-17-2341; Xu ZY, 2020, THERANOSTICS, V10, P4201, DOI 10.7150/thno.35589; Xu ZY, 2018, ONCOGENE, V37, P6259, DOI 10.1038/s41388-018-0409-7; Zhao LJ, 2019, ENDOCR REV, V40, P1207, DOI 10.1210/er.2018-00222; Zhou J, 2005, CANCER RES, V65, P657; Zou C, 2014, J PATHOL, V233, P61, DOI 10.1002/path.4329	82	8	8	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2625	2634		10.1038/s41388-021-01737-1	http://dx.doi.org/10.1038/s41388-021-01737-1		MAR 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33750894	hybrid, Green Published			2022-12-28	WOS:000626816500001
J	Yin, XK; Wang, YL; Wang, F; Feng, WX; Bai, SM; Zhao, WW; Feng, LL; Wei, MB; Qin, CL; Wang, F; Chen, ZL; Yi, HJ; Huang, Y; Xie, PY; Kim, T; Wang, YN; Hou, JW; Li, CW; Liu, QT; Fan, XJ; Hung, MC; Wan, XB				Yin, Xin-Ke; Wang, Yun-Long; Wang, Fei; Feng, Wei-Xing; Bai, Shao-Mei; Zhao, Wan-Wen; Feng, Li-Li; Wei, Ming-Biao; Qin, Cao-Litao; Wang, Fang; Chen, Zhi-Li; Yi, Hong-Jun; Huang, Yan; Xie, Pei-Yi; Kim, Taewan; Wang, Ying-Nai; Hou, Jun-Wei; Li, Chia-Wei; Liu, Quentin; Fan, Xin-Juan; Hung, Mien-Chie; Wan, Xiang-Bo			PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer	ONCOGENE			English	Article							STRAND BREAK REPAIR; RECTAL-CANCER; LUNG-CANCER; PROTEIN; P54(NRB); REGULATOR; METHYLTRANSFERASES; PROGRESSION; MUTATIONS; CETUXIMAB	Arginine methylation is an important posttranslational modification catalyzed by protein arginine methyltransferases (PRMTs). However, the role of PRMTs in colorectal cancer (CRC) progression is not well understood. Here we report that non-POU domain-containing octamer-binding protein (NONO) is overexpressed in CRC tissue and is a potential marker for poor prognosis in CRC patients. NONO silencing resulted in decreased proliferation, migration, and invasion of CRC cells, whereas overexpression had the opposite effect. In a xenograft model, tumors derived from NONO-deficient CRC cells were smaller than those derived from wild-type (WT) cells, and PRMT1 inhibition blocked CRC xenograft progression. A mass spectrometry analysis indicated that NONO is a substrate of PRMT1. R251 of NONO was asymmetrically dimethylated by PRMT1 in vitro and in vivo. Compared to NONO WT cells, NONO R251K mutant-expressing CRC cells showed reduced proliferation, migration, and invasion, and PRMT1 knockdown or pharmacological inhibition abrogated the malignant phenotype associated with NONO asymmetric dimethylation in both KRAS WT and mutant CRC cells. Compared to adjacent normal tissue, PRMT1 was highly expressed in the CRC zone in clinical specimens, which was correlated with poor overall survival in patients with locally advanced CRC. These results demonstrate that PRMT1-mediated methylation of NONO at R251 promotes CRC growth and metastasis, and suggest that PRMT1 inhibition may be an effective therapeutic strategy for CRC treatment regardless of KRAS mutation status.	[Yin, Xin-Ke; Wang, Yun-Long; Zhao, Wan-Wen; Wang, Fang; Fan, Xin-Juan; Wan, Xiang-Bo] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou 510655, Guangdong, Peoples R China; [Wang, Yun-Long; Feng, Wei-Xing; Bai, Shao-Mei; Feng, Li-Li; Wei, Ming-Biao; Qin, Cao-Litao; Wan, Xiang-Bo] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Radiat Oncol, Guangzhou 510655, Guangdong, Peoples R China; [Wang, Fei] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Gastroenterol, Shenzhen 518107, Guangdong, Peoples R China; [Chen, Zhi-Li; Yi, Hong-Jun; Huang, Yan; Fan, Xin-Juan] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Pathol, Guangzhou 510655, Guangdong, Peoples R China; [Xie, Pei-Yi] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Radiol, Guangzhou 510655, Guangdong, Peoples R China; [Kim, Taewan] Shenzhen Univ, Carson Canc Stem Cell Vaccines R&D Ctr, Int Canc Ctr, Base Int Sci & Technol Cooperat,Hlth Sci Ctr, Shenzhen 518055, Peoples R China; [Kim, Taewan] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Wang, Ying-Nai; Hou, Jun-Wei; Li, Chia-Wei; Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Li, Chia-Wei] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Liu, Quentin] Dalian Med Univ, Inst Canc Stem Cell, Dalian 116044, Liaoning, Peoples R China; [Liu, Quentin] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Hung, Mien-Chie] China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan; [Hung, Mien-Chie] China Med Univ, Res Ctr Canc Biol, Taichung 404, Taiwan; [Hung, Mien-Chie] China Med Univ, Res Ctr Mol Med, Taichung 404, Taiwan; [Hung, Mien-Chie] Asia Univ, Dept Biotechnol, Taichung 413, Taiwan; [Wan, Xiang-Bo] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Engn, Guangzhou 510655, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Shenzhen University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Texas System; UTMD Anderson Cancer Center; Academia Sinica - Taiwan; Dalian Medical University; State Key Lab Oncology South China; Sun Yat Sen University; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan; Sun Yat Sen University	Fan, XJ; Wan, XB (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou 510655, Guangdong, Peoples R China.; Wan, XB (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Radiat Oncol, Guangzhou 510655, Guangdong, Peoples R China.; Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.; Hung, MC (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan.; Hung, MC (corresponding author), China Med Univ, Res Ctr Canc Biol, Taichung 404, Taiwan.; Hung, MC (corresponding author), China Med Univ, Res Ctr Mol Med, Taichung 404, Taiwan.; Hung, MC (corresponding author), Asia Univ, Dept Biotechnol, Taichung 413, Taiwan.; Wan, XB (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Engn, Guangzhou 510655, Guangdong, Peoples R China.	fanxjuan@mail.sysu.edu.cn; mhung@cmu.edu.tw; wanxbo@mail.sysu.edu.cn	Hou, Junwei/ADR-3580-2022; Li, Chia-Wei/AAC-8660-2019; Kim, Taewan/M-5867-2013; Hung, Mien-Chie/ABD-5911-2021	Li, Chia-Wei/0000-0002-2531-2866; Kim, Taewan/0000-0002-7202-009X; Hung, Mien-Chie/0000-0003-4317-4740; Wang, Ying-Nai/0000-0002-5275-6729; Wang, Yun-Long/0000-0002-5925-6938	Guangdong Science and Technology Project [2017B090901065, 2019B030316003]; Natural Science Foundation of China [81872188, 81902867, 81903152]; Natural Science Foundation of Guangdong Province [2019A1515010901, 2020A1515010314]; China Postdoctoral Science Foundation [2019M663301]	Guangdong Science and Technology Project; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This study was supported by the Guangdong Science and Technology Project (No. 2017B090901065, No. 2019B030316003), Natural Science Foundation of China (No. 81872188, No. 81902867, No. 81903152), Natural Science Foundation of Guangdong Province (No. 2019A1515010901, No. 2020A1515010314), and China Postdoctoral Science Foundation (No. 2019M663301).	Alfano L, 2016, ONCOGENE, V35, P567, DOI 10.1038/onc.2015.107; Alfano L, 2018, J CELL PHYSIOL, V233, P4338, DOI 10.1002/jcp.26269; Amelio AL, 2007, P NATL ACAD SCI USA, V104, P20314, DOI 10.1073/pnas.0707999105; Ansorena E, 2002, HEPATOLOGY, V35, P274, DOI 10.1053/jhep.2002.30419; Bang YJ, 2010, LANCET, V376, P1302; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Benson A, 2018, J NATL COMPR CANC NE, V16, P874, DOI 10.6004/jnccn.2018.0061; Blanc RS, 2017, MOL CELL, V65, P8, DOI 10.1016/j.molcel.2016.11.003; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen ZR, 2016, J CLIN INVEST, V126, P2267, DOI 10.1172/JCI85250; Deshar R, 2019, NUCLEIC ACIDS RES, V47, P762, DOI 10.1093/nar/gky1166; Dienstmann R, 2015, J CLIN ONCOL, V33, P1787, DOI 10.1200/JCO.2014.60.0213; Eram MS, 2016, ACS CHEM BIOL, V11, P772, DOI 10.1021/acschembio.5b00839; Feng PF, 2020, J CELL MOL MED, V24, P4368, DOI 10.1111/jcmm.15141; Greenblatt SM, 2016, EXP HEMATOL, V44, P435, DOI 10.1016/j.exphem.2016.03.009; Herrmann F, 2005, J BIOL CHEM, V280, P38005, DOI 10.1074/jbc.M502458200; Ho TT, 2016, SCI REP-UK, V6, DOI 10.1038/srep34529; Hsu JM, 2011, NAT CELL BIOL, V13, P174, DOI 10.1038/ncb2158; Hu SB, 2015, GENE DEV, V29, P630, DOI 10.1101/gad.257048.114; Hu ZX, 2020, HEPATOLOGY, V72, P548, DOI 10.1002/hep.31062; Iino K, 2020, CANCER SCI, V111, P148, DOI 10.1111/cas.14240; Jaafar L, 2017, NUCLEIC ACIDS RES, V45, P1848, DOI 10.1093/nar/gkw1209; Lei NZ, 2009, NUCLEIC ACIDS RES, V37, P832, DOI 10.1093/nar/gkn941; Li SY, 2009, NUCLEIC ACIDS RES, V37, P6746, DOI 10.1093/nar/gkp741; Li X, 2019, EXPERT OPIN THER PAT, V29, P97, DOI 10.1080/13543776.2019.1567711; Liao HW, 2015, J CLIN INVEST, V125, P4529, DOI 10.1172/JCI82826; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Luo MK, 2012, ACS CHEM BIOL, V7, P443, DOI 10.1021/cb200519y; Mircsof D, 2015, NAT NEUROSCI, V18, P1731, DOI 10.1038/nn.4169; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Petti E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08863-1; Prasanth KV, 2005, CELL, V123, P249, DOI 10.1016/j.cell.2005.08.033; Proteau A, 2005, J MOL BIOL, V346, P1163, DOI 10.1016/j.jmb.2004.12.034; Qin YY, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaw9960; Sauer R, 2012, J CLIN ONCOL, V30, P1926, DOI 10.1200/JCO.2011.40.1836; Schiffnery S, 2011, CARCINOGENESIS, V32, P1176, DOI 10.1093/carcin/bgr103; Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Snijders AP, 2015, RNA, V21, P347, DOI 10.1261/rna.045138.114; Teyssier C, 2005, GENE DEV, V19, P1466, DOI 10.1101/gad.1295005; Tsofack SP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-145; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Van den Eynde M, 2018, CANCER CELL, V34, P1012, DOI 10.1016/j.ccell.2018.11.003; Wang L, 2014, CANCER CELL, V25, P21, DOI 10.1016/j.ccr.2013.12.007; Yamamoto Ryuji, 2018, Oncotarget, V9, P10510, DOI 10.18632/oncotarget.24063; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Yu T, 2017, CANCER RES, V77, P5782, DOI 10.1158/0008-5472.CAN-17-0671; Zhao X, 2008, GENE DEV, V22, P640, DOI 10.1101/gad.1632608; Zhu Z, 2016, ONCOGENE, V35, P1399, DOI 10.1038/onc.2015.197	49	14	14	4	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1375	1389		10.1038/s41388-020-01617-0	http://dx.doi.org/10.1038/s41388-020-01617-0		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420374	hybrid, Green Published			2022-12-28	WOS:000607346000009
J	Cheng, FJ; Chen, CH; Tsai, WC; Wang, BW; Yu, MC; Hsia, TC; Wei, YL; Hsiao, YC; Hu, DW; Ho, CY; Li, TS; Wu, CY; Chou, WY; Yu, YL; Tang, CH; Chen, CY; Chen, CM; Hsu, JL; Chen, HF; Chen, Y; Tu, CY; Hung, MC; Huang, WC				Cheng, Fang-Ju; Chen, Chia-Hung; Tsai, Wen-Chen; Wang, Bo-Wei; Yu, Meng-Chieh; Hsia, Te-Chun; Wei, Ya-Ling; Hsiao, Yu-Chun; Hu, Dai-Wei; Ho, Chien-Yi; Li, Tzong-Shiun; Wu, Chun-Yi; Chou, Wen-Yu; Yu, Yung-Luen; Tang, Chih-Hsin; Chen, Chih-Yi; Chen, Chuan-Mu; Hsu, Jennifer L.; Chen, Hsiao-Fan; Chen, Yeh; Tu, Chih-Yen; Hung, Mien-Chie; Huang, Wei-Chien			Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC	ONCOGENE			English	Article							CELL LUNG-CANCER; MUTATIONS; ERLOTINIB; PREDICTORS; EXPRESSION; SIGNATURE; GEFITINIB; LKB1; TRANSFORMATION; ACTIVATION	Smoker patients with non-small cell lung cancer (NSCLC) have poorer prognosis and survival than those without smoking history. However, the mechanisms underlying the low response rate of those patients to EGFR tyrosine kinase inhibitors (TKIs) are not well understood. Here we report that exposure to cigarette smoke extract enhances glycolysis and attenuates AMP-activated protein kinase (AMPK)-dependent inhibition of mTOR; this in turn reduces the sensitivity of NSCLC cells with wild-type EGFR (EGFR(WT)) to EGFR TKI by repressing expression of liver kinase B1 (LKB1), a master kinase of the AMPK subfamily, via CpG island methylation. In addition, LKB1 expression is correlated positively with sensitivity to TKI in patients with NSCLC. Moreover, combined treatment of EGFR TKI with AMPK activators synergistically increases EGFR TKI sensitivity. Collectively, the current study suggests that LKB1 may serve as a marker to predict EGFR TKI sensitivity in smokers with NSCLC carrying EGFR(WT) and that the combination of EGFR TKI and AMPK activator may be a potentially effective therapeutic strategy against NSCLC with EGFR(WT).	[Cheng, Fang-Ju; Tang, Chih-Hsin] China Med Univ, Grad Inst Basic Med Sci, Taichung 404, Taiwan; [Cheng, Fang-Ju; Hsu, Jennifer L.; Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Cheng, Fang-Ju; Wang, Bo-Wei; Hu, Dai-Wei; Yu, Yung-Luen; Tang, Chih-Hsin; Hsu, Jennifer L.; Hung, Mien-Chie; Huang, Wei-Chien] China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan; [Chen, Chia-Hung; Hsia, Te-Chun; Tu, Chih-Yen] China Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Taichung 404, Taiwan; [Chen, Chia-Hung; Tang, Chih-Hsin; Tu, Chih-Yen] China Med Univ, Sch Med, Taichung 404, Taiwan; [Chen, Chia-Hung] China Med Univ, Dept Resp Therapy, Taichung 404, Taiwan; [Chen, Chia-Hung] Taiwan Clin Trial Consortium Lung Dis TCoC, Taichung 404, Taiwan; [Tsai, Wen-Chen; Chou, Wen-Yu] China Med Univ, Dept Hlth Serv Adm, Taichung 406, Taiwan; [Yu, Meng-Chieh; Wei, Ya-Ling; Hsiao, Yu-Chun; Yu, Yung-Luen; Chen, Hsiao-Fan; Hung, Mien-Chie; Huang, Wei-Chien] China Med Univ Hosp, Ctr Mol Med, Taichung 404, Taiwan; [Ho, Chien-Yi] China Med Univ, Dept Biomed Imaging & Radiol Sci, Taichung 404, Taiwan; [Ho, Chien-Yi] China Med Univ, Hsinchu Hosp, Phys Examinat Ctr, Div Family Med, Hsinchu 302, Taiwan; [Ho, Chien-Yi] China Med Univ, Hsinchu Hosp, Dept Med Res, Hsinchu 302, Taiwan; [Li, Tzong-Shiun] Show Chwan Mem Hosp, Dept Plast Surg, Changhua 500, Taiwan; [Li, Tzong-Shiun] Show Chwan Mem Hosp, Innovat Res Ctr, Changhua 500, Taiwan; [Wu, Chun-Yi] Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei 112, Taiwan; [Yu, Yung-Luen; Hung, Mien-Chie; Huang, Wei-Chien] China Med Univ, PhD Program Canc Biol & Drug Discovery, Taichung 404, Taiwan; [Yu, Yung-Luen; Chen, Hsiao-Fan; Chen, Yeh; Hung, Mien-Chie] China Med Univ, Inst New Drug Dev, Taichung 404, Taiwan; [Yu, Yung-Luen; Chen, Yeh; Huang, Wei-Chien] China Med Univ, Res Ctr Canc Biol, Drug Dev Ctr, Taichung 404, Taiwan; [Yu, Yung-Luen; Chen, Yeh; Hung, Mien-Chie; Huang, Wei-Chien] Asia Univ, Dept Biotechnol, Taichung 413, Taiwan; [Tang, Chih-Hsin] China Med Univ, Chinese Med Res Ctr, Taichung 404, Taiwan; [Chen, Chih-Yi] Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan; [Chen, Chih-Yi] Chung Shan Med Univ Hosp, Dept Surg, Div Thorac Surg, Taichung 402, Taiwan; [Chen, Chuan-Mu] Natl Chung Hsing Univ, Dept Life Sci, Taichung 402, Taiwan; [Chen, Chuan-Mu] Natl Chung Hsing Univ, PhD Program Translat Med, Taichung 402, Taiwan; [Chen, Chuan-Mu] Natl Chung Hsing Univ, IEGG & Anim Biotechnol Ctr, Taichung 402, Taiwan	China Medical University Taiwan; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Show Chwan Memorial Hospital; Show Chwan Memorial Hospital; National Yang Ming Chiao Tung University; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan; China Medical University Taiwan; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; National Chung Hsing University; National Chung Hsing University; National Chung Hsing University	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.; Hung, MC; Huang, WC (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan.; Tu, CY (corresponding author), China Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Taichung 404, Taiwan.; Tu, CY (corresponding author), China Med Univ, Sch Med, Taichung 404, Taiwan.; Hung, MC; Huang, WC (corresponding author), China Med Univ Hosp, Ctr Mol Med, Taichung 404, Taiwan.; Hung, MC; Huang, WC (corresponding author), China Med Univ, PhD Program Canc Biol & Drug Discovery, Taichung 404, Taiwan.; Hung, MC (corresponding author), China Med Univ, Inst New Drug Dev, Taichung 404, Taiwan.; Huang, WC (corresponding author), China Med Univ, Res Ctr Canc Biol, Drug Dev Ctr, Taichung 404, Taiwan.; Hung, MC; Huang, WC (corresponding author), Asia Univ, Dept Biotechnol, Taichung 413, Taiwan.	chesttu@gmail.com; mhung@cmu.edu.tw; whuang@mail.cmu.edu.tw	Wang, Bo/AAU-1329-2021; Wu, Chun-Yi/AAD-4184-2021; Chen, Chuan-Mu/K-7049-2013; Hung, Mien-Chie/ABD-5911-2021; Tsai, Wen-Chen/O-3095-2015; Huang, Wei-Chien/D-1740-2012	Wang, Bo/0000-0001-8947-8526; Wu, Chun-Yi/0000-0002-8217-1692; Chen, Chuan-Mu/0000-0003-2461-9150; Hung, Mien-Chie/0000-0003-4317-4740; Cheng, Fang-Ju/0000-0001-6104-7185; Tsai, Wen-Chen/0000-0002-9684-0789; Huang, Wei-Chien/0000-0001-6467-8716	Ministry of Science Technology, Taiwan [MOST 108-2314-B-039-056, MOST 108-2314-B-039-053]; Ministry of Education (The International Co-cultivation of Talent), China Medical University [CMU106-ASIA-18, CMU107-TU-06]; China Medical University Hospital [DMR-107-023, DMR-108-021]	Ministry of Science Technology, Taiwan; Ministry of Education (The International Co-cultivation of Talent), China Medical University; China Medical University Hospital	This study was supported in part by grants from the Ministry of Science Technology, Taiwan (MOST 108-2314-B-039-056 and MOST 108-2314-B-039-053), the Ministry of Education (The International Co-cultivation of Talent), China Medical University (CMU106-ASIA-18 and CMU107-TU-06), and China Medical University Hospital (DMR-107-023 and DMR-108-021). Experiments and data analysis were performed in part through the use of the Medical Research Core Facilities, Office of Research & Development at China Medical University, Taichung, Taiwan, R.O.C. We thank Chung Shan Medical University for the Seahorse XF24<SUP>e</SUP> Analysis and the Center for Advanced Molecular Imaging and Translation of Chang Gung Memorial Hospital for the analysis with Micro Positron Emission Tomography (MicroPET) system.	An Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047919; Arrieta O, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2658-6; Barupal DK, 2016, CHEM RES TOXICOL, V29, P1818, DOI 10.1021/acs.chemrestox.6b00187; Carey KD, 2006, CANCER RES, V66, P8163, DOI 10.1158/0008-5472.CAN-06-0453; Cha JH, 2018, MOL CELL, V71, P606, DOI 10.1016/j.molcel.2018.07.030; Clark GM, 2006, CLIN LUNG CANCER, V7, P389, DOI 10.3816/CLC.2006.n.022; Daijo H, 2016, SCI REP-UK, V6, DOI 10.1038/srep34424; Der SD, 2014, J THORAC ONCOL, V9, P59, DOI 10.1097/JTO.0000000000000042; Douillard JY, 2010, J CLIN ONCOL, V28, P744, DOI 10.1200/JCO.2009.24.3030; Filosto S, 2012, MOL CANCER THER, V11, P795, DOI 10.1158/1535-7163.MCT-11-0698; Fueger BJ, 2006, J NUCL MED, V47, P999; Gao B, 2010, J THORAC ONCOL, V5, P1130, DOI 10.1097/JTO.0b013e3181e05016; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Gleeson FC, 2015, J THORAC ONCOL, V10, P531, DOI 10.1097/JTO.0000000000000391; He TY, 2014, ANN SURG ONCOL, V21, pS703, DOI 10.1245/s10434-014-3824-1; Huang YH, 2013, ASIAN PAC J CANCER P, V14, P1985, DOI 10.7314/APJCP.2013.14.3.1985; Jorgensen E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-229; Kim MS, 2010, INT J CANCER, V127, P269, DOI 10.1002/ijc.25057; Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469; Li YY, 2018, J CELL BIOCHEM, V119, P8909, DOI 10.1002/jcb.27144; Midha A, 2015, AM J CANCER RES, V5, P2892; Min HY, 2017, CLIN CANCER RES, V23, P1299, DOI 10.1158/1078-0432.CCR-16-0534; Mitsudomi T, 2014, TRANSL LUNG CANCER R, V3, P205, DOI 10.3978/j.issn.2218-6751.2014.08.04; Morgillo F, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2016-000132; Nakamura Y, 2010, J THORAC ONCOL, V5, P1404, DOI 10.1097/JTO.0b013e3181e59a7b; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shiah SG, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00644-z; Siu LL, 2007, J CLIN ONCOL, V25, P2178, DOI 10.1200/JCO.2006.07.6547; Song M.A., 2017, JNCI-J NATL CANCER I, V109; Sun RJ, 2015, INT J CLIN EXP MED, V8, P14070; Suter M, 2006, J BIOL CHEM, V281, P32207, DOI 10.1074/jbc.M606357200; Tarca AL, 2013, BIOINFORMATICS, V29, P2892, DOI 10.1093/bioinformatics/btt492; Tennis MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032921; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Tu CY, 2018, MOL ONCOL, V12, P705, DOI 10.1002/1878-0261.12193; Vanden Heuvel JP, 2018, ELIFE, V7; Vaz M, 2017, CANCER CELL, V32, P360, DOI 10.1016/j.ccell.2017.08.006; Wu JY, 2011, LUNG CANCER, V72, P205, DOI 10.1016/j.lungcan.2010.08.013; Xie Y, 2011, CLIN CANCER RES, V17, P5705, DOI 10.1158/1078-0432.CCR-11-0196; Zeng J, 2013, BIOMED RES INT, V2013, DOI DOI 10.1155/2013/658126; Zeng Q, 2019, THORAC CANCER, V10, P1717, DOI 10.1111/1759-7714.13141; Zhang HY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25702-3; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60	47	4	4	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1162	1175		10.1038/s41388-020-01597-1	http://dx.doi.org/10.1038/s41388-020-01597-1		DEC 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33335306	Green Published, hybrid			2022-12-28	WOS:000599788200001
J	Beck, M; Baranger, M; Moufok-Sadoun, A; Bersuder, E; Hinkel, I; Mellitzer, G; Martin, E; Marisa, L; Duluc, I; de Reynies, A; Gaiddon, C; Freund, JN; Gross, I				Beck, Marine; Baranger, Mathilde; Moufok-Sadoun, Ahlam; Bersuder, Emilie; Hinkel, Isabelle; Mellitzer, Georg; Martin, Elisabeth; Marisa, Laetitia; Duluc, Isabelle; de Reynies, Aurelien; Gaiddon, Christian; Freund, Jean-Noel; Gross, Isabelle			The atypical cadherin MUCDHL antagonizes colon cancer formation and inhibits oncogenic signaling through multiple mechanisms	ONCOGENE			English	Article							MU-PROTOCADHERIN; EXPRESSION; MOUSE; GENE; PATHWAY; GROWTH; MODEL	Cadherins form a large and pleiotropic superfamily of membranous proteins sharing Ca2+-binding repeats. While the importance of classic cadherins such as E- or N-cadherin for tumorigenesis is acknowledged, there is much less information about other cadherins that are merely considered as tissue-specific adhesion molecules. Here, we focused on the atypical cadherin MUCDHL that stood out for its unusual features and unique function in the gut. Analyses of transcriptomic data sets (n > 250) established that MUCDHL mRNA levels are down-regulated in colorectal tumors. Importantly, the decrease of MUCDHL expression is more pronounced in the worst-prognosis subset of tumors and is associated with decreased survival. Molecular characterization of the tumors indicated a negative correlation with proliferation-related processes (e.g., nucleic acid metabolism, DNA replication). Functional genomic studies showed that the loss of MUCDHL enhanced tumor incidence and burden in intestinal tumor-prone mice. Extensive structure/function analyses revealed that the mode of action of MUCDHL goes beyond membrane sequestration of ss-catenin and targets through its extracellular domain key oncogenic signaling pathways (e.g., EGFR, AKT). Beyond MUCDHL, this study illustrates how the loss of a gene critical for the morphological and functional features of mature cells contributes to tumorigenesis by dysregulating oncogenic pathways.	[Beck, Marine; Baranger, Mathilde; Moufok-Sadoun, Ahlam; Bersuder, Emilie; Hinkel, Isabelle; Mellitzer, Georg; Martin, Elisabeth; Duluc, Isabelle; Gaiddon, Christian; Freund, Jean-Noel; Gross, Isabelle] Univ Strasbourg, INSERM, IRFAC, UMR S1113, F-67200 Strasbourg, France; [Marisa, Laetitia; de Reynies, Aurelien] Ligue Natl Canc, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gross, I (corresponding author), Univ Strasbourg, INSERM, IRFAC, UMR S1113, F-67200 Strasbourg, France.	isabelle.gross@unistra.fr	Georg, Mellitzer/R-4180-2016; Gross, Isabelle/P-9859-2019; Gaiddon, Christian/F-7321-2012; DULUC, Isabelle/AAA-7062-2022; Freund, Jean-Noel/R-4383-2016	Georg, Mellitzer/0000-0003-4467-0789; Gross, Isabelle/0000-0002-2783-8773; Gaiddon, Christian/0000-0003-4315-3851; DULUC, Isabelle/0000-0001-8396-6385; Freund, Jean-Noel/0000-0002-0971-3774	INSERM; Fondation ARC [SFI20101201854]; La Ligue Contre Le Cancer [Haute-Marne 2013, Haut-Rhin 2016]	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Fondation ARC; La Ligue Contre Le Cancer(Ligue nationale contre le cancer)	This work was supported by the financial support of INSERM (2013-2019), Fondation ARC (#SFI20101201854), and La Ligue Contre Le Cancer (Haute-Marne 2013, Haut-Rhin 2016); MBe, MBa, EB, AMS, and IH were fellows of the French government (Ministere de l'Enseignement Superieur et de la Recherche). MBe and MBawere also fellows of Fondation ARC, and EB of the FRM.	Balbinot C, 2018, J EXP MED, V215, P911, DOI 10.1084/jem.20170934; Basu Sayon, 2016, F1000Res, V5, DOI 10.12688/f1000research.7579.1; Blasius FM, 2017, ONCOTARGET, V8, P75076, DOI 10.18632/oncotarget.20507; Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; CHANTRET I, 1994, J CELL SCI, V107, P213; Colnot S, 2004, LAB INVEST, V84, P1619, DOI 10.1038/labinvest.3700180; Crawley SW, 2014, CELL, V157, P433, DOI 10.1016/j.cell.2014.01.067; Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008; Ding X, 2020, IRISH J MED SCI, V189, P439, DOI 10.1007/s11845-019-02092-7; Fichera A, 2007, CANCER RES, V67, P827, DOI 10.1158/0008-5472.CAN-05-3343; Gehart H, 2019, NAT REV GASTRO HEPAT, V16, P19, DOI 10.1038/s41575-018-0081-y; Goldberg M, 2000, J BIOL CHEM, V275, P24622, DOI 10.1074/jbc.M000234200; Goldberg M, 2002, AM J PHYSIOL-RENAL, V283, pF454, DOI 10.1152/ajprenal.00012.2002; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Gul IS, 2017, EXP CELL RES, V358, P3, DOI 10.1016/j.yexcr.2017.03.001; Hinkel I, 2012, GASTROENTEROLOGY, V142, P875, DOI 10.1053/j.gastro.2011.12.037; Hu TH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-236; Hughes LAE, 2017, CURR COLORECT CANC R, V13, P455, DOI 10.1007/s11888-017-0395-0; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee CH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-64; Losi L, 2011, HUM PATHOL, V42, P960, DOI 10.1016/j.humpath.2010.10.009; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Markowitz SD, 2002, CANCER CELL, V1, P233, DOI 10.1016/S1535-6108(02)00053-3; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Mateusz B, 2015, GASTROENT RES PRACT, V2015, DOI 10.1155/2015/317093; Mazzolini R, 2012, P NATL ACAD SCI USA, V109, P1530, DOI 10.1073/pnas.1108411109; McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037; Montorsi L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.163; Moulton DE, 2004, PEDIATR RES, V55, P927, DOI 10.1203/01.PDR.0000125260.46861.32; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Novellasdemunt L, 2015, AM J PHYSIOL-CELL PH, V309, pC511, DOI 10.1152/ajpcell.00117.2015; O'Connell MJ, 2010, J CLIN ONCOL, V28, P3937, DOI 10.1200/JCO.2010.28.9538; Parenti S, 2009, ALIMENT PHARM THER, V31, P108, DOI 10.1111/j.1365-2036.2009.04149.x; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647	40	5	5	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					522	535		10.1038/s41388-020-01546-y	http://dx.doi.org/10.1038/s41388-020-01546-y		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33188295	Green Submitted			2022-12-28	WOS:000589573800002
J	Kajino-Sakamoto, R; Fujishita, T; Taketo, MM; Aoki, M				Kajino-Sakamoto, Rie; Fujishita, Teruaki; Taketo, Makoto Mark; Aoki, Masahiro			Synthetic lethality between MyD88 loss and mutations in Wnt/beta-catenin pathway in intestinal tumor epithelial cells	ONCOGENE			English	Article							TUMORIGENESIS; MICE; APC; ACTIVATION; IMMUNITY	Although the Wnt/beta-catenin pathway plays a central role in the carcinogenesis and maintenance of colorectal cancer (CRC), attempts to target the pathway itself have not been very successful. MyD88, an adaptor protein of the TLR/IL-1 beta signaling, has been implicated in the integrity of the intestines as well as in their tumorigenesis. In this study, we aimed to clarify the mechanisms by which epithelial MyD88 contributes to intestinal tumor formation and to address whether MyD88 can be a therapeutic target of CRC. Conditional knockout of MyD88 in intestinal epithelial cells (IECs) reduced tumor formation in Apc(+/Delta 716) mice, accompanied by decreased proliferation and enhanced apoptosis of tumor epithelial cells. Mechanistically, the MyD88 loss caused inactivation of the JNK-mTORC1, NF-kappa B, and Wnt/beta-catenin pathways in tumor cells. Induction of MyD88 knockout in the intestinal tumor-derived organoids, but not in the normal IEC-derived organoids, induced apoptosis and reduced their growth. Treatment with the MyD88 inhibitor ST2825 also suppressed the growth of the intestinal tumor-derived organoids. Knockdown of MYD88 in human CRC cell lines with mutations in APC or CTNNB1 induced apoptosis and reduced their proliferation as well. These results indicate that MyD88 loss is synthetic lethal with mutational activation of the Wnt/beta-catenin signaling in intestinal tumor epithelial cells. Inhibition of MyD88 signaling can thus be a novel therapeutic strategy for familial adenomatous polyposis (FAP) as well as for colorectal cancer harboring mutations in the Wnt/beta-catenin signaling.	[Kajino-Sakamoto, Rie; Fujishita, Teruaki; Aoki, Masahiro] Aichi Canc Ctr Res Inst, Div Pathophysiol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan; [Taketo, Makoto Mark] Kyoto Univ, Grad Sch Med, Div Expt Therapeut, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan; [Aoki, Masahiro] Nagoya Univ, Dept Canc Physiol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4648550, Japan	Aichi Cancer Center; Kyoto University; Nagoya University	Aoki, M (corresponding author), Aichi Canc Ctr Res Inst, Div Pathophysiol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.; Aoki, M (corresponding author), Nagoya Univ, Dept Canc Physiol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4648550, Japan.	msaoki@aichi-cc.jp	Aoki, Masahiro/A-5149-2016	Aoki, Masahiro/0000-0003-4316-9490; Fujishita, Teruaki/0000-0002-4397-2438	JSPS [JP18K07254, JP26111001]	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by JSPS Grant-in-Aid for Scientific Research (JP18K07254) to RKS and JSPS Grant-in-Aid for Scientific Research on Innovative Areas (JP26111001) to MA.	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Colomer C, 2018, BRIT J CANCER, V118, P839, DOI 10.1038/bjc.2017.459; Dhar R, 2009, BIOCHEMISTRY-US, V48, P1474, DOI 10.1021/bi801840s; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Fujishita T, 2017, ONCOGENE, V36, P6480, DOI 10.1038/onc.2017.242; Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105; Fujishita T, 2015, CANCER SCI, V106, P692, DOI 10.1111/cas.12670; Fujishita T, 2011, GASTROENTEROLOGY, V140, P1556, DOI 10.1053/j.gastro.2011.02.007; Fujishita T, 2009, CELL CYCLE, V8, P3684, DOI 10.4161/cc.8.22.9946; Holtorf A, 2018, ONCOIMMUNOLOGY, V7, P1, DOI [10.1080/2162402X.2018.1477461, DOI 10.1080/2162402X.2018.1477461]; Hou B, 2008, IMMUNITY, V29, P272, DOI 10.1016/j.immuni.2008.05.016; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Lee SH, 2010, NAT MED, V16, P665, DOI 10.1038/nm.2143; Miyoshi H, 2013, NAT PROTOC, V8, P2471, DOI 10.1038/nprot.2013.153; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Novellasdemunt L, 2015, AM J PHYSIOL-CELL PH, V309, pC511, DOI 10.1152/ajpcell.00117.2015; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Rohwer N, 2019, ONCOGENE, V38, P5670, DOI 10.1038/s41388-019-0816-4; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Scheeren FA, 2014, NAT CELL BIOL, V16, P1238, DOI 10.1038/ncb3058; Scholer-Dahirel A, 2011, P NATL ACAD SCI USA, V108, P17135, DOI 10.1073/pnas.1104182108; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; Vadde R, 2017, CRIT REV ONCOL HEMAT, V113, P22, DOI 10.1016/j.critrevonc.2017.02.025; Wang EL, 2010, BRIT J CANCER, V102, P908, DOI 10.1038/sj.bjc.6605558; Weber ANR, 2018, CANCER IMMUNOL IMMUN, V67, P1797, DOI 10.1007/s00262-018-2242-9; Xue X, 2014, AM J PHYSIOL-GASTR L, V307, pG187, DOI 10.1152/ajpgi.00112.2014; Zundel W, 2000, GENE DEV, V14, P391	39	6	6	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					408	420		10.1038/s41388-020-01541-3	http://dx.doi.org/10.1038/s41388-020-01541-3		NOV 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33177648				2022-12-28	WOS:000588591400001
J	Kwon, OJ; Zhang, L; Jia, DY; Xin, L				Kwon, Oh-Joon; Zhang, Li; Jia, Deyong; Xin, Li			Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1(+) prostate luminal cells	ONCOGENE			English	Article							LINEAGE PLASTICITY; CANCER; MOUSE; METASTASIS; MODEL; EXPRESSION; RESISTANCE; PHENOTYPE; CARCINOMA; PATTERNS	Prostate adenocarcinoma undergoes neuroendocrine differentiation to acquire resistance toward antihormonal therapies. The underlying mechanisms have been investigated extensively, among which Sox2 has been shown to play a critical role. However, genetic evidence in mouse models for prostate cancer to support the crucial role of Sox2 is missing. The adult mouse prostate luminal cells contain both castration-resistant Sox2-expressing Sca-1(+) cells and castration-responsive Sca-1(-) cells. We show that both types of the luminal cell are susceptible to oncogenic transformation induced by loss of function of the tumor suppressor Pten. The tumors derived from the Sca-1(+) cells are castration resistant and are more inclined to develop castration-induced neuroendocrine differentiation. Genetic ablation of Sox2 suppresses neuroendocrine differentiation but does not impact the castration-resistant property. This study provides direct genetic evidence that Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation of Pten null prostate adenocarcinoma, corroborates that the lineage status of the prostate cancer cells is a determinant for its propensity to exhibit lineage plasticity, and supports that the intrinsic features of cell-of-origin for prostate cancers can dictate their clinical behaviors.	[Kwon, Oh-Joon; Zhang, Li; Jia, Deyong; Xin, Li] Univ Washington, Dept Urol, Seattle, WA 98109 USA; [Xin, Li] Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Xin, L (corresponding author), Univ Washington, Dept Urol, Seattle, WA 98109 USA.; Xin, L (corresponding author), Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA.	xin18@uw.edu	Jia, Deyong/GQP-9611-2022; Jia, Deyong/GSJ-0327-2022	Jia, Deyong/0000-0003-2034-0363; Kwon, Oh-Joon/0000-0001-9067-0240; Xin, Li/0000-0002-7138-0042	 [R01CA190378]		This work is supported by R01CA190378 (LX).	Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Beltran H, 2019, CLIN CANCER RES, V25, P43, DOI 10.1158/1078-0432.CCR-18-1912; Berger A, 2019, J CLIN INVEST, V129, P3924, DOI 10.1172/JCI127961; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Crowell PD, 2019, CELL REP, V28, P1499, DOI 10.1016/j.celrep.2019.07.007; Davies AH, 2018, NAT REV UROL, V15, P271, DOI 10.1038/nrurol.2018.22; Fine SW, 2012, ADV ANAT PATHOL, V19, P204, DOI 10.1097/PAP.0b013e31825c6b92; Goldstein NS, 2002, AM J CLIN PATHOL, V117, P471, DOI 10.1309/G6PR-Y774-X738-FG2K; Guo WX, 2020, NAT GENET, V52, P908, DOI 10.1038/s41588-020-0642-1; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hsu EC, 2020, P NATL ACAD SCI USA, V117, P2032, DOI 10.1073/pnas.1905384117; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Kregel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053701; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Kwon OJ, 2020, ONCOGENE, V39, P7142, DOI 10.1038/s41388-020-01487-6; Kwon OJ, 2020, STEM CELLS, V38, P1479, DOI 10.1002/stem.3253; Kwon OJ, 2016, STEM CELLS, V34, P191, DOI 10.1002/stem.2217; Labrecque MP, 2019, J CLIN INVEST, V129, P4492, DOI 10.1172/JCI128212; Latil M, 2017, CELL STEM CELL, V20, P191, DOI 10.1016/j.stem.2016.10.018; Lee AR, 2018, EBIOMEDICINE, V35, P167, DOI 10.1016/j.ebiom.2018.08.011; Lee TK, 2010, PATHOLOGY, V42, P319, DOI 10.3109/00313021003767314; Li HY, 2020, LAB INVEST, V100, P570, DOI 10.1038/s41374-019-0343-5; Lin D, 2014, CANCER RES, V74, P1272, DOI 10.1158/0008-5472.CAN-13-2921-T; Liu TT, 2016, CHINESE J CANCER RES, V28, P50, DOI 10.3978/j.issn.1000-9604.2016.02.02; Lovnicki J, 2020, J CLIN INVEST, V130, P5338, DOI 10.1172/JCI135373; Ma XQ, 2005, CANCER RES, V65, P5730, DOI 10.1158/0008-5472.CAN-04-4519; Masumori N, 2001, CANCER RES, V61, P2239; McAuley E, 2019, STEM CELLS, V37, P690, DOI 10.1002/stem.2987; Metz EP, 2019, J CELL PHYSIOL, V234, P19298, DOI 10.1002/jcp.28610; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Quintanal-Villalonga A, 2020, NAT REV CLIN ONCOL, V17, P360, DOI 10.1038/s41571-020-0340-z; Schaefer T, 2020, ONCOGENE, V39, P278, DOI 10.1038/s41388-019-0997-x; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Tsujimura A, 2002, J CELL BIOL, V157, P1257, DOI 10.1083/jcb.200202067; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang ZA, 2013, NAT CELL BIOL, V15, P274, DOI 10.1038/ncb2697; Wei X, 2019, CELL STEM CELL, V24, P753, DOI 10.1016/j.stem.2019.03.010; Won OJ, 2016, J CLIN INVEST, V126, P2626, DOI 10.1172/JCI84637; Xin L, 2019, ADV EXP MED BIOL, V1210, P67, DOI 10.1007/978-3-030-32656-2_4; Yu X, 2014, PROSTATE CANCER P D, V17, P301, DOI 10.1038/pcan.2014.29; Yu X, 2011, ONCOGENE, V30, P1868, DOI 10.1038/onc.2010.560; Zhang DX, 2018, STEM CELL REP, V10, P228, DOI 10.1016/j.stemcr.2017.11.016; Zhang L, 2012, TRANSGENIC RES, V21, P1117, DOI 10.1007/s11248-012-9598-y; Zhou ZX, 2007, CANCER RES, V67, P5683, DOI 10.1158/0008-5472.CAN-07-0768; Zou M, 2017, CANCER DISCOV, V7, P736, DOI 10.1158/2159-8290.CD-16-1174	45	13	13	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					203	214		10.1038/s41388-020-01526-2	http://dx.doi.org/10.1038/s41388-020-01526-2		OCT 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33110232	Green Accepted			2022-12-28	WOS:000582768100003
J	Liu, CD; Zhou, XH; Long, Q; Zeng, HY; Sun, QC; Chen, YT; Wu, DH; Liu, L				Liu, Chengdong; Zhou, Xiaohan; Long, Qian; Zeng, Hanyi; Sun, Qingcan; Chen, Yuting; Wu, Dehua; Liu, Li			Small extracellular vesicles containing miR-30a-3p attenuate the migration and invasion of hepatocellular carcinoma by targeting SNAP23 gene	ONCOGENE			English	Article							THERAPEUTIC STRATEGY; EXOSOMES; CELLS; PROLIFERATION; METASTASIS; SECRETION; RELEASE; STRESS	Cancer cells under hypoxic, endoplasmic reticulum, and reactive oxygen species stress secrete copious amounts of small extracellular vesicles (sEVs) to promote tumor metastasis. The effects of blocking stress-induced sEV release on tumor metastasis remain unknown. We found that miR-30a-3p was selectively sorted into sEVs by hepatocellular carcinoma (HCC) cells under the influence of multiple stressors. miR-30a-3p removal from cancer cells through sEVs promoted HCC cell migration and invasion, whereas exogenous overexpression of miR-30a-3p could inhibit migration, invasion, and sEV release by directly targeting SNAP23. HCC cells efficiently absorbed hepatic stellate cell (HSC) sEVs, providing an advantage in the treatment of HCC using HSC sEVs. Treatment with HSC sEVs rich in miR-30a-3p cargo effectively attenuated HCC migration, invasion, and metastasis. Overall, sEVs containing miR-30a-3p decreased sEV secretion as well as the migration, invasion, and metastasis of HCC by directly targeting SNAP23, thereby providing an effective strategy to attenuate metastasis of HCC.	[Liu, Chengdong; Long, Qian; Zeng, Hanyi; Sun, Qingcan; Liu, Li] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou 510515, Guangdong, Peoples R China; [Zhou, Xiaohan; Chen, Yuting; Wu, Dehua] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China	Liu, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou 510515, Guangdong, Peoples R China.; Wu, DH (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China.	18602062748@163.com; liuli@i.smu.edu.cn		Wu, De-Hua/0000-0003-0560-0016	National Nature Science Foundation of China [81773008, 81672756, 81872399, 81972897]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; Natural Science Foundation of Guangdong Province [2017A030311023]; Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program [2017BT01S131]; Guangzhou Technology Project [201804010044]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program; Guangzhou Technology Project	This work was supported by the National Nature Science Foundation of China [grant numbers 81773008, 81672756, 81872399, 81972897], the Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2015), the Natural Science Foundation of Guangdong Province [grant number 2017A030311023], the Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program: 2017BT01S131 and the Guangzhou Technology Project [grant number 201804010044].	An TX, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27522; Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Gross JC, 2012, NAT CELL BIOL, V14, P1036, DOI 10.1038/ncb2574; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hou J, 2018, J ORAL PATHOL MED, V47, P144, DOI 10.1111/jop.12654; Hu JL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1019-x; Huang TT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0967-5; Im EJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09387-4; Johnsen KB, 2014, BBA-REV CANCER, V1846, P75, DOI 10.1016/j.bbcan.2014.04.005; Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341; Kanlikilicer P, 2016, CANCER RES, V76, P7194, DOI 10.1158/0008-5472.CAN-16-0714; Keklikoglou I, 2019, NAT CELL BIOL, V21, P190, DOI 10.1038/s41556-018-0256-3; Kowal J, 2014, CURR OPIN CELL BIOL, V29, P116, DOI 10.1016/j.ceb.2014.05.004; Li L, 2017, HEPATOLOGY, V65, P501, DOI 10.1002/hep.28735; Liu JT, 2019, HEPATOLOGY, V70, P241, DOI 10.1002/hep.30607; Lucchetti D, 2020, CANCERS, V12, DOI 10.3390/cancers12020260; Meng WR, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0982-6; Merchant ML, 2017, NAT REV NEPHROL, V13, P731, DOI 10.1038/nrneph.2017.148; Nishida-Aoki N, 2017, MOL THER, V25, P181, DOI 10.1016/j.ymthe.2016.10.009; O'Neill CP, 2019, CANCERS, V11, DOI 10.3390/cancers11020136; Pavlyukov MS, 2018, CANCER CELL, V34, P119, DOI 10.1016/j.ccell.2018.05.012; Peng DY, 2018, LEUKEMIA, V32, P1180, DOI 10.1038/s41375-018-0015-2; Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016; Qiao Y, 2018, ONCOGENE, V37, P873, DOI 10.1038/onc.2017.387; Spychalski P, 2019, RADIOTHER ONCOL, V132, P127, DOI 10.1016/j.radonc.2018.12.012; Teng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14448; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Vader P, 2016, ADV DRUG DELIVER REV, V106, P148, DOI 10.1016/j.addr.2016.02.006; Wang F, 2018, HEPATOLOGY, V67, P940, DOI 10.1002/hep.29586; Wang W, 2014, EJSO-EUR J SURG ONC, V40, P1586, DOI 10.1016/j.ejso.2013.11.008; Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841; Wang XH, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0468-y; Wei Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14041; Wu XG, 2019, ANGIOGENESIS, V22, P397, DOI 10.1007/s10456-019-09665-1; Xie Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0984-4; Yang L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0990-6; Zeng ZC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07810-w; Zhan CN, 2020, ORAL DIS, V26, P865, DOI 10.1111/odi.13172; Zhang X, 2019, CANCER MANAG RES, V11, P1653, DOI 10.2147/CMAR.S188248; Zhang XN, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0959-5; Zhang ZC, 2017, CANCER LETT, V397, P33, DOI 10.1016/j.canlet.2017.03.004	44	16	16	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					233	245		10.1038/s41388-020-01521-7	http://dx.doi.org/10.1038/s41388-020-01521-7		OCT 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33110233				2022-12-28	WOS:000582768100001
J	Yan, YC; Huang, PB; Mao, K; He, CC; Xu, QD; Zhang, MY; Liu, HH; Zhou, ZY; Zhou, QM; Zhou, QL; Ou, B; Liu, QH; Lin, JH; Chen, RB; Wang, J; Zhang, JL; Xiao, ZY				Yan, Yongcong; Huang, Pinbo; Mao, Kai; He, Chuanchao; Xu, Qiaodong; Zhang, Mengyu; Liu, Haohan; Zhou, Zhenyu; Zhou, Qiming; Zhou, Qianlei; Ou, Bing; Liu, Qinghua; Lin, Jianhong; Chen, Ruibin; Wang, Jie; Zhang, Jianlong; Xiao, Zhiyu			Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; CANCER; EXPRESSION; GROWTH; ACTIVATION; RESISTANCE; DEGRADATION; SURVIVAL; PATHWAY; MYC	Hepatitis B x protein (HBx) affects cellular protein expression and participates in the tumorigenesis and progression of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Metabolic reprogramming contributed to the HCC development, but its role in HBV-related HCC remains largely unclear. Tyrosine-protein phosphatase nonreceptor type 13 (PTPN13) is a significant regulator in tumor development, however, its specific role in hepatocarcinogenesis remains to be explored. Here, we found that decreased PTPN13 expression was associated with HBV/HBx. Patients with low PTPN13 expression showed a poor prognosis. Functional assays revealed that PTPN13 inhibited proliferation and tumorigenesis in vitro and in vivo. Further mechanistic studies indicated that HBx inhibited PTPN13 expression by upregulating the expression of DNMT3A and interacting with DNMT3A. Furthermore, we found that DNMT3A bound to the PTPN13 promoter (-343 to -313 bp) in an epigenetically controlled manner associated with elevated DNA methylation and then inhibited PTPN13 transcription. In addition, we identified IGF2BP1 as a novel PTPN13-interacting gene and demonstrated that PTPN13 influences c-Myc expression by directly and competitively binding to IGF2BP1 to decrease the intracellular concentration of functional IGF2BP1. Overexpressing PTPN13 promoted c-Myc mRNA degradation independent of the protein tyrosine phosphatase (PTP) activity of PTPN13. Importantly, we discovered that the PTPN13-IGF2BP1-c-Myc axis was important for cancer cell growth through promoting metabolic reprogramming. We verified the significant negative correlations between PTPN13 expression and c-Myc, PSPH, and SLC7A1 expression in clinical HCC tissue samples. In summary, our findings demonstrate that PTPN13 is a novel regulator of HBV-related hepatocarcinogenesis and may play an important role in HCC. PTPN13 may serve as a prognostic marker and therapeutic target in HBV-related HCC patients.	[Yan, Yongcong; Huang, Pinbo; Mao, Kai; He, Chuanchao; Liu, Haohan; Zhou, Zhenyu; Zhou, Qiming; Zhou, Qianlei; Liu, Qinghua; Lin, Jianhong; Chen, Ruibin; Wang, Jie; Zhang, Jianlong; Xiao, Zhiyu] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou 510120, Peoples R China; [Yan, Yongcong; Liu, Haohan; Zhou, Qiming; Zhou, Qianlei; Liu, Qinghua; Lin, Jianhong; Chen, Ruibin] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Peoples R China; [Yan, Yongcong; Liu, Haohan; Zhou, Qiming; Zhou, Qianlei; Liu, Qinghua; Lin, Jianhong; Chen, Ruibin] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, RNA Biomed Inst, Guangzhou 510120, Peoples R China; [Xu, Qiaodong] Shantou Univ, Med Coll, Affiliated Hosp 1, Dept Biliary Pancreat Minimally Invas Surg, Shantou 515041, Peoples R China; [Zhang, Mengyu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol & Hepatol, Guangzhou 510120, Peoples R China; [Ou, Bing] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Ultrasound, Guangzhou 510120, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Shantou University; Sun Yat Sen University; Sun Yat Sen University	Huang, PB; Xiao, ZY (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou 510120, Peoples R China.	huangpb@mail2.sysu.edu.cn; xiaozhiy@mail.sysu.edu.cn		Yan, Yongcong/0000-0002-7269-764X	National Natural Science Foundation of China [81572407, 81602112, 81672405, 81702404]; Key project of Natural Science Foundation of Guangdong Province, China [2016A030311051]; Guangdong Basic and Applied Basic Research Foundation [2015A030313096, 2016A030313184, 2017A030313536, 2019A1515011418, 2019A1515011195]; Natural Science Foundation of Guangzhou, China [201607010225]; China Postdoctoral Science Foundation [2020TQ0384]; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology [[2013]163]; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes [KLB09001]; Guangdong Science and Technology Department [2017B030314026]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key project of Natural Science Foundation of Guangdong Province, China; Guangdong Basic and Applied Basic Research Foundation; Natural Science Foundation of Guangzhou, China; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes; Guangdong Science and Technology Department	This work was supported by the National Natural Science Foundation of China (Nos. 81572407, 81602112, 81672405, 81702404); Key project of Natural Science Foundation of Guangdong Province, China (No. 2016A030311051); Guangdong Basic and Applied Basic Research Foundation (Nos. 2015A030313096, 2016A030313184, 2017A030313536, 2019A1515011418, 2019A1515011195); Natural Science Foundation of Guangzhou, China (No. 201607010225); Project funded by China Postdoctoral Science Foundation (2020TQ0384); Grant [2013]163 from Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology; Grant KLB09001 from the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes. Grant from Guangdong Science and Technology Department (2017B030314026).	Bamberg A, 2018, AM J RESP CRIT CARE, V198, P914, DOI 10.1164/rccm.201707-1497OC; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Bollu LR, 2017, CLIN CANCER RES, V23, P2136, DOI 10.1158/1078-0432.CCR-16-0934; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0747-z; Cilia E, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002794; Costantini JL, 2009, BLOOD, V114, P4703, DOI 10.1182/blood-2009-03-213058; Dang H, 2017, CANCER CELL, V32, P101, DOI 10.1016/j.ccell.2017.06.002; Dou CW, 2019, ONCOGENE, V38, P1239, DOI 10.1038/s41388-018-0505-8; Freiss G, 2011, ANTI-CANCER AGENT ME, V11, P78, DOI 10.2174/187152011794941262; Gao Y, 2017, HEPATOLOGY, V66, P1413, DOI 10.1002/hep.29316; Glondu-Lassis M, 2010, CANCER RES, V70, P5116, DOI 10.1158/0008-5472.CAN-09-4368; Gutschner T, 2014, HEPATOLOGY, V59, P1900, DOI 10.1002/hep.26997; Hagemann N, 2013, ONCOGENE, V32, P4602, DOI 10.1038/onc.2012.485; Hamyeh M, 2020, THERANOSTICS, V10, P1016, DOI 10.7150/thno.38537; Han XJ, 2013, EXP MOL PATHOL, V95, P270, DOI 10.1016/j.yexmp.2013.07.008; He J, 2019, CANCER LETT, V450, P98, DOI 10.1016/j.canlet.2019.02.033; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hosono Y, 2017, CELL, V171, P1559, DOI 10.1016/j.cell.2017.11.040; Huang PB, 2020, ONCOGENE, V39, P3774, DOI 10.1038/s41388-020-1254-z; Huang PB, 2015, CLIN CANCER RES, V21, P4420, DOI 10.1158/1078-0432.CCR-14-2067; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Huang XW, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0628-y; Huang YD, 2018, CANCERS, V10, DOI 10.3390/cancers10030082; Kassel O, 2004, GENE DEV, V18, P2518, DOI 10.1101/gad.322404; Kuchay S, 2013, NAT CELL BIOL, V15, P472, DOI 10.1038/ncb2731; Kulik L, 2019, GASTROENTEROLOGY, V156, P477, DOI 10.1053/j.gastro.2018.08.065; Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021; Li Z, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04006-0; Liao B, 2017, INT J ONCOL, V51, P1449, DOI 10.3892/ijo.2017.4126; Lu M, 2019, CELL METAB, V29, P886, DOI 10.1016/j.cmet.2018.12.019; Lucci MA, 2010, CELL ONCOL, V32, P361, DOI 10.3233/CLO-2010-0520; Post A, 2013, P NATL ACAD SCI USA, V110, P11427, DOI 10.1073/pnas.1306595110; Revillion F, 2009, INT J CANCER, V124, P638, DOI 10.1002/ijc.23989; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Sun LC, 2015, CELL RES, V25, P429, DOI 10.1038/cr.2015.33; Sun W, 2018, HEPATOLOGY, V67, P2302, DOI 10.1002/hep.29750; Turner M, 2018, NAT IMMUNOL, V19, P120, DOI 10.1038/s41590-017-0028-4; Varum S, 2019, CELL STEM CELL, V24, P637, DOI 10.1016/j.stem.2019.03.011; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Wang SH, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv190; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Wang ZC, 2015, HEPATOLOGY, V62, P1201, DOI 10.1002/hep.27911; Wieckowski E, 2007, J CELL BIOCHEM, V100, P16, DOI 10.1002/jcb.20922; Wolf E, 2015, TRENDS CELL BIOL, V25, P241, DOI 10.1016/j.tcb.2014.10.006; Yeh SH, 2006, CLIN CANCER RES, V12, P1097, DOI 10.1158/1078-0432.CCR-05-1383; Ying J, 2006, LEUKEMIA, V20, P1173, DOI 10.1038/sj.leu.2404193; Zhan H, 2016, TUMOR BIOL, V37, P9691, DOI 10.1007/s13277-016-4843-2; Zhuang L, 2017, J CELL MOL MED, V21, P2852, DOI 10.1111/jcmm.13198	51	10	10	4	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					28	45		10.1038/s41388-020-01498-3	http://dx.doi.org/10.1038/s41388-020-01498-3		OCT 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33051595	Green Published, hybrid			2022-12-28	WOS:000577556100001
J	Birladeanu, AM; Rogalska, M; Potiri, M; Papadaki, V; Andreadou, M; Kontoyiannis, DL; Lewis, JD; Erpapazoglou, Z; Kafasla, P				Birladeanu, Andrada-Maria; Rogalska, Malgorzata; Potiri, Myrto; Papadaki, Vasiliki; Andreadou, Margarita; Kontoyiannis, Dimitris L.; Lewis, Joe D.; Erpapazoglou, Zoi; Kafasla, Panagiota			The scaffold protein IQGAP1 links heat-induced stress signals to alternative splicing regulation in gastric cancer cells	ONCOGENE			English	Article							PRE-MESSENGER-RNA; SUMO MODIFICATION; NUCLEAR; HNRNP; SUMOYLATION; IDENTIFICATION; TRANSCRIPTOME; REVEALS; SITES; ASSOCIATION	In response to oncogenic signals, Alternative Splicing (AS) regulators such as SR and hnRNP proteins show altered expression levels, subnuclear distribution and/or post-translational modification status, but the link between signals and these changes remains unknown. Here, we report that a cytosolic scaffold protein, IQGAP1, performs this task in response to heat-induced signals. We show that in gastric cancer cells, a nuclear pool of IQGAP1 acts as a tethering module for a group of spliceosome components, including hnRNPM, a splicing factor critical for the response of the spliceosome to heat-shock. IQGAP1 controls hnRNPM's sumoylation, subnuclear localisation and the relevant response of the AS machinery to heat-induced stress. Genome-wide analyses reveal that IQGAP1 and hnRNPM co-regulate the AS of a cell cycle-related RNA regulon in gastric cancer cells, thus favouring the accelerated proliferation phenotype of gastric cancer cells. Overall, we reveal a missing link between stress signals and AS regulation.	[Birladeanu, Andrada-Maria; Potiri, Myrto; Papadaki, Vasiliki; Andreadou, Margarita; Kontoyiannis, Dimitris L.; Erpapazoglou, Zoi; Kafasla, Panagiota] BSRC Alexander Fleming, Inst Fundamental Biomed Res, 34 Fleming St, Athens 16672, Greece; [Rogalska, Malgorzata] Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, Dr Aiguader 88, Barcelona 08003, Spain; [Rogalska, Malgorzata] Univ Pompeu Fabra UPF, Barcelona 08003, Spain; [Kontoyiannis, Dimitris L.] Aristotle Univ Thessaloniki, Dept Biol, Thessaloniki, Greece; [Lewis, Joe D.] European Mol Biol Lab, D-69117 Heidelberg, Germany	Alexander Fleming Biomedical Sciences Research Center; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Aristotle University of Thessaloniki; European Molecular Biology Laboratory (EMBL)	Kafasla, P (corresponding author), BSRC Alexander Fleming, Inst Fundamental Biomed Res, 34 Fleming St, Athens 16672, Greece.	kafasla@fleming.gr	Kafasla, Panagiota/GRR-3951-2022; Kafasla, Panagiota/B-9187-2009; , Panagiota/AAZ-2732-2021; Rogalska, Malgorzata Ewa/O-5962-2016	Kafasla, Panagiota/0000-0002-9730-0397; Lewis, Joe/0000-0002-9926-1328; Kontoyiannis, Dimitris/0000-0003-4682-9490; Rogalska, Malgorzata Ewa/0000-0002-6331-9815; Potiri, Myrto/0000-0001-9051-5881	European Union (European Regional Development Fund) [NSRF 2014-2020] [MIS 5002135]; Hellenic Foundation for Research & Innovation (HFRI); General Secretariat for Research and Technology (GSRT) [846]; European Research Council [ERC] [ERC AdvG 670146]; European Commission [274837]	European Union (European Regional Development Fund) [NSRF 2014-2020]; Hellenic Foundation for Research & Innovation (HFRI); General Secretariat for Research and Technology (GSRT)(Greek Ministry of Development-GSRT); European Research Council [ERC](European Research Council (ERC)European Commission); European Commission(European CommissionEuropean Commission Joint Research Centre)	InfrafrontierGR/Phenotypos Infrastructure, co-funded by Greece and the European Union (European Regional Development Fund) [NSRF 2014-2020, MIS 5002135]; Hellenic Foundation for Research & Innovation (HFRI) and the General Secretariat for Research and Technology (GSRT) [grant agreement 846 to ZE]; MR was supported by the European Research Council [ERC AdvG 670146]; European Commission Grant FP7PEOPLE-2010-IEF [274837] to PK; Stavros Niarchos Foundation (SNF) donation to BSRC "Al. Fleming".	Alfieri C, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170204; Biamonti G, 2009, TRENDS BIOCHEM SCI, V34, P146, DOI 10.1016/j.tibs.2008.11.004; Cherry S, 2020, GENE DEV, V34, P1005, DOI 10.1101/gad.338962.120; CHOI YD, 1984, P NATL ACAD SCI-BIOL, V81, P7471, DOI 10.1073/pnas.81.23.7471; Cvitkovic I, 2013, NUCLEIC ACIDS RES, V41, pD132, DOI 10.1093/nar/gks999; da Fonseca PCA, 2011, NATURE, V470, P274, DOI 10.1038/nature09625; Damianov A, 2016, CELL, V165, P606, DOI 10.1016/j.cell.2016.03.040; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; El Marabti E, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00080; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; Gattoni R, 1996, NUCLEIC ACIDS RES, V24, P2535, DOI 10.1093/nar/24.13.2535; Gohr A, 2019, BIOINFORMATICS, V35, P130, DOI 10.1093/bioinformatics/bty606; Hendriks IA, 2017, NAT STRUCT MOL BIOL, V24, P325, DOI 10.1038/nsmb.3366; Hendriks IA, 2016, METHODS MOL BIOL, V1475, P171, DOI 10.1007/978-1-4939-6358-4_13; Hendriks IA, 2016, NAT REV MOL CELL BIO, V17, P581, DOI 10.1038/nrm.2016.81; Hendriks IA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8289; Hendriks IA, 2014, NAT STRUCT MOL BIOL, V21, P927, DOI 10.1038/nsmb.2890; Heyd F, 2011, TRENDS BIOCHEM SCI, V36, P397, DOI 10.1016/j.tibs.2011.04.003; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Hu W, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44048-y; Huelga SC, 2012, CELL REP, V1, P167, DOI 10.1016/j.celrep.2012.02.001; Irimia M, 2014, CELL, V159, P1511, DOI 10.1016/j.cell.2014.11.035; Johnson M, 2011, INT J BIOCHEM CELL B, V43, P65, DOI 10.1016/j.biocel.2010.09.014; Johnson MA, 2013, BBA-MOL CELL RES, V1833, P2334, DOI 10.1016/j.bbamcr.2013.06.002; Kafasla P, 2000, BIOCHEM J, V350, P495, DOI 10.1042/0264-6021:3500495; Kafasla P, 2002, BIOCHEM J, V363, P793, DOI 10.1042/0264-6021:3630793; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Kim YS, 2014, BIOORG MED CHEM LETT, V24, P1094, DOI 10.1016/j.bmcl.2014.01.010; Lamm N, 2020, NAT CELL BIOL, V22, P1460, DOI 10.1038/s41556-020-00605-6; Langeberg LK, 2015, NAT REV MOL CELL BIO, V16, P232, DOI 10.1038/nrm3966; Li SH, 2000, MOL CELL BIOL, V20, P697, DOI 10.1128/MCB.20.2.697-701.2000; Lian ATY, 2015, CELL CYCLE, V14, P2058, DOI 10.1080/15384101.2015.1044168; Liang ZW, 2017, CANCER LETT, V411, P90, DOI 10.1016/j.canlet.2017.09.046; Liebelt F, 2019, CELL REP, V26, P236, DOI 10.1016/j.celrep.2018.12.027; Liu JQ, 2019, J CELL BIOCHEM, V120, P15790, DOI 10.1002/jcb.28849; Lleres D, 2010, EMBO REP, V11, P445, DOI 10.1038/embor.2010.64; MAHL P, 1989, J CELL BIOL, V109, P1921, DOI 10.1083/jcb.109.5.1921; Marko M, 2010, EXP CELL RES, V316, P390, DOI 10.1016/j.yexcr.2009.10.021; Matic I, 2010, MOL CELL, V39, P641, DOI 10.1016/j.molcel.2010.07.026; McQuin C, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005970; Meissner M, 2000, J CELL BIOCHEM, V76, P559, DOI 10.1002/(SICI)1097-4644(20000315)76:4<559::AID-JCB4>3.0.CO;2-U; Neumayer G, 2014, CELL MOL LIFE SCI, V71, P3027, DOI 10.1007/s00018-014-1582-7; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; Osman MA, 2013, BBA-REV CANCER, V1836, P166, DOI 10.1016/j.bbcan.2013.04.005; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Passacantilli I, 2017, NUCLEIC ACIDS RES, V45, P12270, DOI 10.1093/nar/gkx831; Penas C, 2012, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00060; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Popp MWL, 2013, ANNU REV GENET, V47, P139, DOI 10.1146/annurev-genet-111212-133424; Pozzi B, 2017, NUCLEIC ACIDS RES, V45, P6729, DOI 10.1093/nar/gkx213; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Rosenbaum JC, 2011, MOL CELL, V41, P93, DOI 10.1016/j.molcel.2010.12.004; Santos A, 2015, NUCLEIC ACIDS RES, V43, pD1140, DOI 10.1093/nar/gku1092; Saraiva-Agostinho N, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gky888; Sayedyahossein S, 2016, J BIOL CHEM, V291, P19261, DOI 10.1074/jbc.M116.732529; Shalgi R, 2014, CELL REP, V7, P1362, DOI 10.1016/j.celrep.2014.04.044; Sharma S, 2011, P NATL ACAD SCI USA, V108, P11381, DOI 10.1073/pnas.1019711108; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; Smith JM, 2015, TRENDS CELL BIOL, V25, P171, DOI 10.1016/j.tcb.2014.12.005; Suganuma T, 2010, CELL, V142, P726, DOI 10.1016/j.cell.2010.07.045; Sveen A, 2016, ONCOGENE, V35, P2413, DOI 10.1038/onc.2015.318; Tammsalu T, 2015, NAT PROTOC, V10, P1374, DOI 10.1038/nprot.2015.095; Van Nostrand EL, 2016, NAT METHODS, V13, P508, DOI [10.1038/NMETH.3810, 10.1038/nmeth.3810]; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Vassileva MT, 2004, MOL CELL BIOL, V24, P3623, DOI 10.1128/MCB.24.9.3623-3632.2004; Vertegaal ACO, 2004, J BIOL CHEM, V279, P33791, DOI 10.1074/jbc.M404201200; Wang ZF, 2008, RNA, V14, P802, DOI 10.1261/rna.876308; White CD, 2009, FEBS LETT, V583, P1817, DOI 10.1016/j.febslet.2009.05.007; Yamano Hiroyuki, 2019, F1000Res, V8, DOI 10.12688/f1000research.18582.1; Zhong XY, 2009, GENE DEV, V23, P482, DOI 10.1101/gad.1752109; Zhou ZA, 2016, CELL DIV, V11, DOI 10.1186/s13008-016-0021-6	72	3	3	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5518	5532		10.1038/s41388-021-01963-7	http://dx.doi.org/10.1038/s41388-021-01963-7		JUL 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34294847	Green Submitted, Green Accepted			2022-12-28	WOS:000678016900001
J	Sahu, B; Pihlajamaa, P; Zhang, KY; Palin, K; Ahonen, S; Cervera, A; Ristimaki, A; Aaltonen, LA; Hautaniemi, S; Taipale, J				Sahu, Biswajyoti; Pihlajamaa, Paivi; Zhang, Kaiyang; Palin, Kimmo; Ahonen, Saija; Cervera, Alejandra; Ristimaki, Ari; Aaltonen, Lauri A.; Hautaniemi, Sampsa; Taipale, Jussi			Human cell transformation by combined lineage conversion and oncogene expression	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; HUMAN FIBROBLASTS; RAS ONCOGENES; CANCER; TUMOR; GENES; MYC; METHYLATION; INDUCTION; TUMORIGENESIS	Cancer is the most complex genetic disease known, with mutations implicated in more than 250 genes. However, it is still elusive which specific mutations found in human patients lead to tumorigenesis. Here we show that a combination of oncogenes that is characteristic of liver cancer (CTNNB1, TERT, MYC) induces senescence in human fibroblasts and primary hepatocytes. However, reprogramming fibroblasts to a liver progenitor fate, induced hepatocytes (iHeps), makes them sensitive to transformation by the same oncogenes. The transformed iHeps are highly proliferative, tumorigenic in nude mice, and bear gene expression signatures of liver cancer. These results show that tumorigenesis is triggered by a combination of three elements: the set of driver mutations, the cellular lineage, and the state of differentiation of the cells along the lineage. Our results provide direct support for the role of cell identity as a key determinant in transformation and establish a paradigm for studying the dynamic role of oncogenic drivers in human tumorigenesis.	[Sahu, Biswajyoti; Pihlajamaa, Paivi; Palin, Kimmo; Ahonen, Saija; Ristimaki, Ari; Aaltonen, Lauri A.; Taipale, Jussi] Univ Helsinki, Fac Med, Res Programs Unit, Appl Tumor Genom Res Program, Helsinki, Finland; [Sahu, Biswajyoti; Ristimaki, Ari] Univ Helsinki, Fac Med, Med, Helsinki, Finland; [Sahu, Biswajyoti; Pihlajamaa, Paivi; Taipale, Jussi] Univ Cambridge, Dept Biochem, Cambridge, England; [Sahu, Biswajyoti; Palin, Kimmo; Aaltonen, Lauri A.] iCAN Digital Precis Canc Med Flagship, Helsinki, Finland; [Zhang, Kaiyang; Cervera, Alejandra; Hautaniemi, Sampsa] Univ Helsinki, Fac Med, Res Programs Unit, Res Program Syst Oncol, Helsinki, Finland; [Palin, Kimmo; Aaltonen, Lauri A.] Univ Helsinki, Dept Med & Clin Genet, Helsinki, Finland; [Cervera, Alejandra] Inst Nacl Med Gen6m, Mexico City, DF, Mexico; [Ristimaki, Ari] Univ Helsinki, HUSLAB, Dept Pathol, Helsinki, Finland; [Ristimaki, Ari] Univ Helsinki, HUS Diagnost Ctr, Helsinki, Finland; [Ristimaki, Ari] Helsinki Univ Hosp, Helsinki, Finland; [Taipale, Jussi] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden	University of Helsinki; University of Helsinki; University of Cambridge; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Karolinska Institutet	Taipale, J (corresponding author), Univ Helsinki, Fac Med, Res Programs Unit, Appl Tumor Genom Res Program, Helsinki, Finland.; Taipale, J (corresponding author), Univ Cambridge, Dept Biochem, Cambridge, England.; Taipale, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden.	ajt208@cam.ac.uk	Pihlajamaa, Paivi/AAD-8065-2020; Aaltonen, Lauri/A-5375-2010; Cervera, Alejandra/ABD-8200-2020; Hautaniemi, Sampsa/CAG-0362-2022; Sahu, Biswajyoti/U-6724-2017; Pihlajamaa, Paivi/AAY-2063-2021; Hautaniemi, Sampsa/A-3122-2009	Pihlajamaa, Paivi/0000-0001-9725-6907; Aaltonen, Lauri/0000-0001-6839-4286; Cervera, Alejandra/0000-0002-6274-1168; Hautaniemi, Sampsa/0000-0002-7749-2694; Sahu, Biswajyoti/0000-0001-6576-5440; Pihlajamaa, Paivi/0000-0001-9725-6907; Hautaniemi, Sampsa/0000-0002-7749-2694; Zhang, Kaiyang/0000-0002-0470-9581; Ahonen, Saija/0000-0003-3313-784X; Palin, Kimmo/0000-0002-4621-6128	Academy of Finland (Finnish Center of Excellence in Tumor Genetics Research) [312042, 250345]; Finnish Cancer Foundation; Cancer Research UK [RG99643]; Academy of Finland [250345, 312041, 335823, 319083, 320149, 288836, 274555, 317807]; Sigrid Juselius Foundation; Jane and Aatos Erkko Foundation; Finska Lakaresallskapet; iCAN Digital Precision Cancer Medicine Flagship [320185]; European Union's Horizon 2020 research and innovation program [667403]; University of Helsinki; Helsinki University Central Hospital Research Funds; Helsinki University Central Hospital; iCAN Digital Precision Cancer Medicine Flagship	Academy of Finland (Finnish Center of Excellence in Tumor Genetics Research); Finnish Cancer Foundation; Cancer Research UK(Cancer Research UK); Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Jane and Aatos Erkko Foundation; Finska Lakaresallskapet; iCAN Digital Precision Cancer Medicine Flagship; European Union's Horizon 2020 research and innovation program; University of Helsinki; Helsinki University Central Hospital Research Funds; Helsinki University Central Hospital; iCAN Digital Precision Cancer Medicine Flagship	JT was supported by grants from Academy of Finland (Finnish Center of Excellence in Tumor Genetics Research 2018-2025, grant number 312042 and 2012-2017; 250345), Finnish Cancer Foundation, and Cancer Research UK (grant number RG99643). BS was supported by the Academy of Finland (post-doctoral fellowship, 274555; research fellowship, 317807), Finnish Cancer Foundation, Sigrid Juselius Foundation, Jane and Aatos Erkko Foundation and iCAN Digital Precision Cancer Medicine Flagship. PP was supported by the post-doctoral fellowship 288836 from Academy of Finland. AR was supported by Finska Lakaresallskapet, Helsinki University Central Hospital Research Funds, and Sigrid Juselius Foundation. LA was supported by Academy of Finland (grant numbers 312041, 335823, 250345, 319083, 320149), iCAN Digital Precision Cancer Medicine Flagship (grant number 320185), Finnish Cancer Foundation, Sigrid Juselius Foundation and Jane and Aatos Erkko Foundation. SH was supported by the European Union's Horizon 2020 research and innovDation program under Grant Agreement No. 667403 for HERCULES. Open access funding provided by University of Helsinki including Helsinki University Central Hospital.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; [Anonymous], 2019, WHO CLASSIFICATION T, V5th; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; Beer S, 2004, PLOS BIOL, V2, P1785, DOI 10.1371/journal.pbio.0020332; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Borggrefe T, 2009, CELL MOL LIFE SCI, V66, P1631, DOI 10.1007/s00018-009-8668-7; Bou-Nader M, 2020, GUT, V69, P355, DOI 10.1136/gutjnl-2018-318021; Broutier L, 2017, NAT MED, V23, P1424, DOI 10.1038/nm.4438; Cai SH, 2017, THER ADV GASTROENTER, V10, P761, DOI 10.1177/1756283X17725998; Cairo S, 2008, CANCER CELL, V14, P471, DOI 10.1016/j.ccr.2008.11.002; Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu, 2017, Cell, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Chaffer CL, 2015, CANCER DISCOV, V5, P22, DOI 10.1158/2159-8290.CD-14-0788; Chen HJ, 2019, J EXP MED, V216, P674, DOI 10.1084/jem.20181155; Corces MR, 2017, NAT METHODS, V14, P959, DOI [10.1038/NMETH.4396, 10.1038/nmeth.4396]; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Diamond L, 1980, Adv Cancer Res, V32, P1, DOI 10.1016/S0065-230X(08)60360-7; Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415; Du YY, 2014, CELL STEM CELL, V14, P394, DOI 10.1016/j.stem.2014.01.008; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Farrell JA, 2018, SCIENCE, V360, P979, DOI 10.1126/science.aar3131; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Haigis KM, 2019, SCIENCE, V363, P1150, DOI 10.1126/science.aaw3472; Hooks KB, 2018, HEPATOLOGY, V68, P89, DOI 10.1002/hep.29672; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Huang PY, 2014, CELL STEM CELL, V14, P370, DOI 10.1016/j.stem.2014.01.003; Icay K, 2016, BIODATA MIN, V9, DOI 10.1186/s13040-016-0099-z; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kalkat M, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060151; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kasper M, 2011, P NATL ACAD SCI USA, V108, P4099, DOI 10.1073/pnas.1014489108; Kelly TK, 2012, GENOME RES, V22, P2497, DOI 10.1101/gr.143008.112; Korotkevich G, 2019, FAST GENE SET ENRICH, DOI 10.1101/060012; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Ladewig J, 2012, NAT METHODS, V9, P575, DOI [10.1038/NMETH.1972, 10.1038/nmeth.1972]; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee I, 2020, NAT METHODS, V17, P1191, DOI 10.1038/s41592-020-01000-7; Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191; Liu ML, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3183; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Marthandan S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154531; Martincorena I, 2018, SCIENCE, V362, P911, DOI 10.1126/science.aau3879; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Moinzadeh P, 2005, BRIT J CANCER, V92, P935, DOI 10.1038/sj.bjc.6602448; Moore PS, 2010, NAT REV CANCER, V10, P878, DOI 10.1038/nrc2961; Morris SA, 2014, CELL, V158, P889, DOI 10.1016/j.cell.2014.07.021; Ning BF, 2010, CANCER RES, V70, P7640, DOI 10.1158/0008-5472.CAN-10-0824; Ovaska K, 2010, GENOME MED, V2, DOI 10.1186/gm186; Palin K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06132-1; Pang ZPP, 2011, NATURE, V476, P220, DOI 10.1038/nature10202; Park JW, 2018, SCIENCE, V362, P91, DOI 10.1126/science.aat5749; Rackham OJL, 2016, NAT GENET, V48, P331, DOI 10.1038/ng.3487; Rahman M, 2015, BIOINFORMATICS, V31, P3666, DOI 10.1093/bioinformatics/btv377; RANGANATHAN S, 2016, SCI REP-UK, V6; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Roadmap Epigenomics Consortium, 2015, Nature, V518, P317, DOI 10.1038/nature14248; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192; Sekiya S, 2011, NATURE, V475, P390, DOI 10.1038/nature10263; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; Shin S, 2016, HEPATOLOGY, V64, P1163, DOI 10.1002/hep.28602; Shipony Z, 2020, NAT METHODS, V17, P319, DOI 10.1038/s41592-019-0730-2; Simpson JT, 2017, NAT METHODS, V14, P407, DOI 10.1038/nmeth.4184; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Soneson Charlotte, 2015, F1000Res, V4, P1521, DOI 10.12688/f1000research.7563.1; STEVENSON M, 1986, MOL CELL BIOL, V6, P3410, DOI 10.1128/MCB.6.10.3410; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun R, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.591507; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Taylor AM, 2018, CANCER CELL, V33, P676, DOI 10.1016/j.ccell.2018.03.007; Timek DT, 2012, AM J CLIN PATHOL, V138, P203, DOI 10.1309/AJCPK1ZC9WNHCCMU; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Villanueva A, 2012, GASTROENTEROLOGY, V143, P1660, DOI 10.1053/j.gastro.2012.09.002; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; YAMAGIWA K, 1977, CA-CANCER J CLIN, V27, P172, DOI 10.3322/canjclin.27.3.174; Zerbino DR, 2018, NUCLEIC ACIDS RES, V46, pD754, DOI 10.1093/nar/gkx1098; Zhu B, 2017, ONCOTARGET, V8, P23289, DOI 10.18632/oncotarget.15576	87	3	3	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5533	5547		10.1038/s41388-021-01940-0	http://dx.doi.org/10.1038/s41388-021-01940-0		JUL 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34302118	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000676064800002
J	Schwalbe, EC; Lalchungnunga, H; Lafta, F; Barrow, TM; Strathdee, G				Schwalbe, Edward C.; Lalchungnunga, H.; Lafta, Fadhel; Barrow, Timothy M.; Strathdee, Gordon			Integration of genome-level data to allow identification of subtype-specific vulnerability genes as novel therapeutic targets	ONCOGENE			English	Article							DNA METHYLATION; OUTCOME PREDICTION; MEDULLOBLASTOMA; CLASSIFICATION; LEUKEMIA; CANCER; IGF2BP1	The identification of cancer-specific vulnerability genes is one of the most promising approaches for developing more effective and less toxic cancer treatments. Cancer genomes exhibit thousands of changes in DNA methylation and gene expression, with the vast majority likely to be passenger changes. We hypothesised that, through integration of genome-wide DNA methylation/expression data, we could exploit this inherent variability to identify cancer subtype-specific vulnerability genes that would represent novel therapeutic targets that could allow cancer-specific cell killing. We developed a bioinformatics pipeline integrating genome-wide DNA methylation/gene expression data to identify candidate subtype-specific vulnerability partner genes for the genetic drivers of individual genetic/molecular subtypes. Using acute lymphoblastic leukaemia as an initial model, 21 candidate subtype-specific vulnerability genes were identified across the five common genetic subtypes, with at least one per subtype. To confirm the approach was applicable across cancer types, we also assessed medulloblastoma, identifying 15 candidate subtype-specific vulnerability genes across three of four established subtypes. Almost all identified genes had not previously been implicated in these diseases. Functional analysis of seven candidate subtype-specific vulnerability genes across the two tumour types confirmed that siRNA-mediated knockdown induced significant inhibition of proliferation/induction of apoptosis, which was specific to the cancer subtype in which the gene was predicted to be specifically lethal. Thus, we present a novel approach that integrates genome-wide DNA methylation/expression data to identify cancer subtype-specific vulnerability genes as novel therapeutic targets. We demonstrate this approach is applicable to multiple cancer types and identifies true functional subtype-specific vulnerability genes with high efficiency.	[Schwalbe, Edward C.; Lalchungnunga, H.; Lafta, Fadhel; Barrow, Timothy M.; Strathdee, Gordon] Newcastle Univ, Biosci Inst, Ctr Canc, Newcastle Upon Tyne, Tyne & Wear, England; [Schwalbe, Edward C.] Northumbria Univ, Dept Appl Sci, Newcastle Upon Tyne, Tyne & Wear, England; [Lafta, Fadhel] Univ Baghdad, Coll Sci, Dept Biol, Baghdad, Iraq; [Barrow, Timothy M.] Univ Sunderland, Fac Hlth Sci & Wellbeing, Sunderland, England	Newcastle University - UK; Northumbria University; University of Baghdad; University of Sunderland	Strathdee, G (corresponding author), Newcastle Univ, Biosci Inst, Ctr Canc, Newcastle Upon Tyne, Tyne & Wear, England.	Gordon.Strathdee@ncl.ac.uk		, Lalchungnunga/0000-0003-2718-6223; Barrow, Timothy/0000-0003-4551-3857; Schwalbe, Ed/0000-0002-1190-9469; Strathdee, Gordon/0000-0001-9681-8429	KidsCan; Bloodwise [14024]	KidsCan; Bloodwise	The authors wish to thank Prof James Allan, Prof Steven Clifford, Dr Daniel Williamson and Dr Lisa Russell for the critical reading of the manuscript. This work was supported by project grants from KidsCan (Grant number N/A) and Bloodwise (Grant number 14024).	Bo XC., 2020, SYNTHETIC LETHAL INT; Capper D, 2018, NATURE, V555, P469, DOI 10.1038/nature26000; Cavalli FMG, 2017, CANCER CELL, V31, P737, DOI 10.1016/j.ccell.2017.05.005; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Flora A, 2009, SCIENCE, V326, P1424, DOI 10.1126/science.1181453; Gabriel AS, 2015, EPIGENETICS-US, V10, P717, DOI 10.1080/15592294.2015.1061174; Gao SS, 2018, FUTURE MED CHEM, V10, P2129, DOI 10.4155/fmc-2018-0227; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Guo J, 2016, NUCLEIC ACIDS RES, V44, pD1011, DOI 10.1093/nar/gkv1108; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harrison CJ, 2011, CLIN LAB MED, V31, P631, DOI 10.1016/j.cll.2011.08.016; Jacinto FV, 2007, MUTAGENESIS, V22, P247, DOI 10.1093/mutage/gem009; Kondo Y, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001559; Kulis M, 2015, NAT GENET, V47, P746, DOI 10.1038/ng.3291; Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]; Li Q, 1998, ONCOGENE, V16, P3197, DOI 10.1038/sj.onc.1201831; Liu C, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007701; Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568; Moorman AV, 2010, LANCET ONCOL, V11, P429, DOI 10.1016/S1470-2045(10)70066-8; Nordlund J, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r105; Northcott PA, 2012, ACTA NEUROPATHOL, V123, P615, DOI 10.1007/s00401-011-0899-7; O'Neil NJ, 2017, NAT REV GENET, V18, P613, DOI 10.1038/nrg.2017.47; Oakes CC, 2016, NAT GENET, V48, P253, DOI 10.1038/ng.3488; Peters TJ, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/1756-8935-8-6; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Ryan CJ, 2014, CANCER CELL, V26, P306, DOI 10.1016/j.ccr.2014.08.008; Schwalbe EC, 2017, LANCET ONCOL, V18, P958, DOI 10.1016/S1470-2045(17)30243-7; Schwalbe EC, 2013, ACTA NEUROPATHOL, V125, P359, DOI 10.1007/s00401-012-1077-2; Sharma T, 2019, ACTA NEUROPATHOL, V138, P309, DOI 10.1007/s00401-019-02020-0; Stoskus M, 2016, LEUKEMIA RES, V47, P16, DOI 10.1016/j.leukres.2016.05.009; Stoskus M, 2016, BLOOD CELL MOL DIS, V57, P30, DOI 10.1016/j.bcmd.2015.11.006; Thompson Jordan M., 2015, Yale Journal of Biology and Medicine, V88, P145; Tirado-Magallanes R, 2017, ONCOTARGET, V8, P5629, DOI 10.18632/oncotarget.13562	34	0	0	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5213	5223		10.1038/s41388-021-01923-1	http://dx.doi.org/10.1038/s41388-021-01923-1		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34230614	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000670148000002
J	Vanoli, F; Meskauskaite, B; Herviou, L; Mallen, W; Sung, YS; Fujisawa, Y; Zhang, L; Simon, S; Huangfu, DW; Jasin, M; Antonescu, CR				Vanoli, Fabio; Meskauskaite, Brigita; Herviou, Laurie; Mallen, William; Sung, Yun-Shao; Fujisawa, Yumi; Zhang, Lei; Simon, Steven; Huangfu, Danwei; Jasin, Maria; Antonescu, Cristina R.			Generation of human embryonic stem cell models to exploit the EWSR1-CREB fusion promiscuity as a common pathway of transformation in human tumors	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; SOFT-TISSUE; CHROMOSOMAL TRANSLOCATIONS; CHIMERIC TRANSCRIPTS; PROTEIN EXPRESSION; MOLECULAR ANALYSIS; EWSR1-ATF1 FUSION; GENE FUSION; SARCOMA; DIFFERENTIATION	Chromosomal translocations constitute driver mutations in solid tumors and leukemias. The mechanisms of how related or even identical gene fusions drive the pathogenesis of various tumor types remain elusive. One remarkable example is the presence of EWSR1 fusions with CREB1 and ATF1, members of the CREB family of transcription factors, in a variety of sarcomas, carcinomas and mesotheliomas. To address this, we have developed in vitro models of oncogenic fusions, in particular, EWSR1-CREB1 and EWSR1-ATF1, in human embryonic stem (hES) cells, which are capable of multipotent differentiation, using CRISPR-Cas9 technology and HDR together with conditional fusion gene expression that allows investigation into the early steps of cellular transformation. We show that expression of EWSR1-CREB1/ATF1 fusion in hES cells recapitulates the core gene signatures, respectively, of angiomatoid fibrous histiocytoma (AFH) and gastrointestinal clear cell sarcoma (GI-CCS), although both fusions lead to cell lethality. Conversely, expression of the fusions in hES cells differentiated to mesenchymal progenitors is compatible with prolonged viability while maintaining the core gene signatures. Moreover, in the context of a mesenchymal lineage, the proliferation of cells expressing the EWSR1-CREB1 fusion is further extended by deletion of the tumor suppressor TP53. We expect the generation of isogenic lines carrying oncogenic fusions in various cell lineages to expand our general understanding of how those single genetic events drive tumorigenesis while providing valuable resources for drug discovery.	[Vanoli, Fabio; Meskauskaite, Brigita; Herviou, Laurie; Mallen, William; Sung, Yun-Shao; Fujisawa, Yumi; Zhang, Lei; Simon, Steven; Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Huangfu, Danwei; Jasin, Maria] Mem Sloan Kettering Canc Ctr, Dev Biol Program, 1275 York Ave, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Antonescu, CR (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.; Jasin, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dev Biol Program, 1275 York Ave, New York, NY 10021 USA.	m-jasin@ski.mskcc.org; antonesc@mskcc.org		Herviou, Laurie/0000-0002-8607-8380; Huangfu, Danwei/0000-0002-1145-6199; Vanoli, Fabio/0000-0002-1260-8078; Jasin, Maria/0000-0002-7976-2379	Cycle for Survival; Kristin Ann Carr Foundation; St Baldrick Foundation; Cancer Center Support Grant [NIH P30 CA008748];  [R35 CA253174];  [P50 CA140146];  [P50 CA217694]	Cycle for Survival; Kristin Ann Carr Foundation; St Baldrick Foundation; Cancer Center Support Grant; ; ; 	We thank Chew-Li Soh and Xian Zhang for technical assistance and reagents; members of the Jasin Laboratory for discussions and suggestions; and Rohit Prakash, Travis White and Pei Xin Lim for critical reading of the manuscript. This work was supported in part by: R35 CA253174 (MJ), P50 CA140146 (CRA), P50 CA217694 (CRA), Cycle for Survival (CRA), Kristin Ann Carr Foundation (CRA), St Baldrick Foundation (CRA). Core facilities at MSK are supported by the Cancer Center Support Grant (NIH P30 CA008748).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Antonescu CR, 2002, J MOL DIAGN, V4, P44, DOI 10.1016/S1525-1578(10)60679-4; Antonescu CR, 2007, GENE CHROMOSOME CANC, V46, P1051, DOI 10.1002/gcc.20491; Antonescu CR, 2006, CLIN CANCER RES, V12, P5356, DOI 10.1158/1078-0432.CCR-05-2811; Antonescu CR, 2013, GENE CHROMOSOME CANC, V52, P775, DOI 10.1002/gcc.22073; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Antonescu CR, 2009, CANCER RES, V69, P7175, DOI 10.1158/0008-5472.CAN-09-2068; Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629; Braunreiter CL, 2006, CELL CYCLE, V5, P2753, DOI 10.4161/cc.5.23.3505; Brunet E, 2018, ADV EXP MED BIOL, V1044, P15, DOI 10.1007/978-981-13-0593-1_2; Desmeules P, 2017, AM J SURG PATHOL, V41, P980, DOI 10.1097/PAS.0000000000000864; Feng WR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00634-0; Filion TM, 2009, J CELL PHYSIOL, V220, P586, DOI 10.1002/jcp.21735; Gartel AL, 2002, MOL CANCER THER, V1, P639; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; Hajdu M, 2010, J PATHOL, V221, P300, DOI 10.1002/path.2715; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Hisaoka M, 2008, AM J SURG PATHOL, V32, P452, DOI 10.1097/PAS.0b013e31814b18fb; Jakubauskas A, 2011, EXP MOL PATHOL, V90, P194, DOI 10.1016/j.yexmp.2010.12.005; Kao Yu-Chien, 2017, Am J Surg Pathol, V41, P482, DOI 10.1097/PAS.0000000000000788; Karamchandani JR, 2012, APPL IMMUNOHISTO M M, V20, P445, DOI 10.1097/PAI.0b013e318244ff4b; Komura S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11745-1; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; Liang Q, 2018, NATURE, V563, P701, DOI 10.1038/s41586-018-0733-7; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Mertens F, 2016, GENE CHROMOSOME CANC, V55, P291, DOI 10.1002/gcc.22335; Panagopoulos I, 2002, INT J CANCER, V99, P560, DOI 10.1002/ijc.10404; Pfeifer A, 2001, P NATL ACAD SCI USA, V98, P11450, DOI 10.1073/pnas.201415498; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Qin H, 2007, J BIOL CHEM, V282, P5842, DOI 10.1074/jbc.M610464200; Rossi S, 2007, CLIN CANCER RES, V13, P7322, DOI 10.1158/1078-0432.CCR-07-1744; Stockman DL, 2012, AM J SURG PATHOL, V36, P857, DOI 10.1097/PAS.0b013e31824644ac; Straessler KM, 2013, CANCER CELL, V23, P215, DOI 10.1016/j.ccr.2012.12.019; Thway K, 2011, AM J SURG PATHOL, V35, P1722, DOI 10.1097/PAS.0b013e318227e4d2; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; Vanoli F, 2017, METHODS, V121, P138, DOI 10.1016/j.ymeth.2017.05.006; Vanoli F, 2017, P NATL ACAD SCI USA, V114, P3696, DOI 10.1073/pnas.1700622114; Vriend LEM, 2016, NUCLEIC ACIDS RES, V44, P5204, DOI 10.1093/nar/gkw179; Wang WL, 2009, MODERN PATHOL, V22, P1201, DOI 10.1038/modpathol.2009.85; Zhang Y, 2014, METHODS, V69, P171, DOI 10.1016/j.ymeth.2014.05.003; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	43	2	2	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5095	5104		10.1038/s41388-021-01843-0	http://dx.doi.org/10.1038/s41388-021-01843-0		JUN 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34193943	Green Accepted			2022-12-28	WOS:000668403200001
J	Bauer, J; Cuvelier, N; Ragab, N; Simon-Keller, K; Nitzki, F; Geyer, N; Botermann, DS; Elmer, DP; Rosenberger, A; Rando, TA; Biressi, S; Fagin, JA; Saur, D; Dullin, C; Schildhaus, HU; Schulz-Schaeffer, W; Aberger, F; Uhmann, A; Hahn, H				Bauer, Julia; Cuvelier, Nicole; Ragab, Nada; Simon-Keller, Katja; Nitzki, Frauke; Geyer, Natalie; Botermann, Dominik S.; Elmer, Dominik P.; Rosenberger, Albert; Rando, Thomas A.; Biressi, Stefano; Fagin, James A.; Saur, Dieter; Dullin, Christian; Schildhaus, Hans-Ulrich; Schulz-Schaeffer, Walter; Aberger, Fritz; Uhmann, Anja; Hahn, Heidi			Context-dependent modulation of aggressiveness of pediatric tumors by individual oncogenic RAS isoforms	ONCOGENE			English	Article							EMBRYONAL RHABDOMYOSARCOMA; K-RAS; SIGNALING PATHWAY; CELL-SURVIVAL; N-RAS; CANCER; HEDGEHOG; ACTIVATION; GENE; EXPRESSION	A prototypic pediatric cancer that frequently shows activation of RAS signaling is embryonal rhabdomyosarcoma (ERMS). ERMS also show aberrant Hedgehog (HH)/GLI signaling activity and can be driven by germline mutations in this pathway. We show, that in ERMS cell lines derived from sporadic tumors i.e. from tumors not caused by an inherited genetic variant, HH/GLI signaling plays a subordinate role, because oncogenic mutations in HRAS, KRAS, or NRAS (collectively named oncRAS) inhibit the main HH target GLI1 via the MEK/ERK-axis, but simultaneously increase proliferation and tumorigenicity. oncRAS also modulate expression of stem cell markers in an isoform- and context-dependent manner. In Hh-driven murine ERMS that are caused by a Patched mutation, oncHRAS and mainly oncKRAS accelerate tumor development, whereas oncNRAS induces a more differentiated phenotype. These features occur when the oncRAS mutations are induced at the ERMS precursor stage, but not when induced in already established tumors. Moreover, in contrast to what is seen in human cell lines, oncRAS mutations do not alter Hh signaling activity and marginally affect expression of stem cell markers. Together, all three oncRAS mutations seem to be advantageous for ERMS cell lines despite inhibition of HH signaling and isoform-specific modulation of stem cell markers. In contrast, oncRAS mutations do not inhibit Hh-signaling in Hh-driven ERMS. In this model, oncRAS mutations seem to be advantageous for specific ERMS populations that occur within a specific time window during ERMS development. In addition, this window may be different for individual oncRAS isoforms, at least in the mouse.	[Bauer, Julia; Cuvelier, Nicole; Ragab, Nada; Nitzki, Frauke; Geyer, Natalie; Botermann, Dominik S.; Uhmann, Anja; Hahn, Heidi] Univ Med Ctr Goettingen, Dept Human Genet, Gottingen, Germany; [Simon-Keller, Katja] Heidelberg Univ, Univ Med Ctr Mannheim, Inst Pathol, Mannheim, Germany; [Elmer, Dominik P.; Aberger, Fritz] Paris Lodron Univ Salzburg, Dept Biosci, Canc Cluster Salzburg, Salzburg, Austria; [Rosenberger, Albert] Univ Med Ctr Goettingen, Dept Genet Epidemiol, Gottingen, Germany; [Rando, Thomas A.; Biressi, Stefano] Stanford Univ, Paul Glenn Ctr Biol Aging, Sch Med, Stanford, CA USA; [Rando, Thomas A.; Biressi, Stefano] Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA USA; [Biressi, Stefano] Vet Affairs Palo Alto Hlth Care Syst, Neurol Serv, Palo Alto, CA USA; [Biressi, Stefano] Univ Trento, Dept Cellular Computat & Integrat Biol CIBIO, Povo, Italy; [Biressi, Stefano] Univ Trento, Dulbecco Telethon Inst, Povo, Italy; [Fagin, James A.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Saur, Dieter] Klin & Poliklin Innere Med II, Klinikum Rechts Isar TUM, Munich, Germany; [Dullin, Christian] Univ Med Ctr Goettingen, Inst Diagnost & Intervent Radiol, Gottingen, Germany; [Schildhaus, Hans-Ulrich] Univ Med Ctr Essen, Inst Pathol, Essen, Germany; [Schulz-Schaeffer, Walter] Saarland Univ, Dept Neuropathol, Med Ctr, Homburg, Germany	University of Gottingen; Ruprecht Karls University Heidelberg; Salzburg University; University of Gottingen; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Trento; Fondazione Telethon; Dulbecco Telethon Institute (DTI); University of Trento; Memorial Sloan Kettering Cancer Center; Technical University of Munich; University of Gottingen; University of Duisburg Essen; Universitatsklinikum des Saarlandes	Hahn, H (corresponding author), Univ Med Ctr Goettingen, Dept Human Genet, Gottingen, Germany.	hhahn@gwdg.de	Saur, Dieter/O-8355-2015	Saur, Dieter/0000-0001-5874-0210; Dullin, Christian/0000-0003-4297-8077; Rosenberger, Albert/0000-0001-7848-1332; Botermann, Dominik Simon/0000-0001-7747-7147; Aberger, Fritz/0000-0003-2009-6305; Bauer, Julia/0000-0001-5390-1855; Biressi, Stefano Augusto Maria/0000-0001-8631-3419	German Research Foundation [HA 2197/9-1, HA 2197/9-2]; Wilhelm Sander foundation [2017.110.1]; Austrian Science Fund (FWF) [P25629, W1213]; Projekt DEAL	German Research Foundation(German Research Foundation (DFG)); Wilhelm Sander foundation; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Projekt DEAL	This work was supported by grants HA 2197/9-1 and HA 2197/9-2 from the German Research Foundation to HH, by grant 2017.110.1 of the Wilhelm Sander foundation to HH. and KSK. and by grants P25629 and W1213 of the Austrian Science Fund (FWF) to FA. Open Access funding enabled and organized by Projekt DEAL.	Aberger F, 2012, VITAM HORM, V88, P25, DOI 10.1016/B978-0-12-394622-5.00002-X; Almazan-Moga A, 2017, BRIT J CANCER, V117, P1314, DOI 10.1038/bjc.2017.305; Ashford AL, 2016, CELL MOL LIFE SCI, V73, P883, DOI 10.1007/s00018-015-2032-x; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Biressi S, 2013, DEV BIOL, V379, P195, DOI 10.1016/j.ydbio.2013.04.021; CHARDIN P, 1985, INT J CANCER, V35, P647, DOI 10.1002/ijc.2910350513; Chen L, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005075; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Chen X, 2009, P NATL ACAD SCI USA, V106, P7979, DOI 10.1073/pnas.0900343106; Dasgupta R, 2016, SEMIN PEDIATR SURG, V25, P276, DOI 10.1053/j.sempedsurg.2016.09.011; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Genadry KC, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00475; Geyer N, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00396; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Hettmer S, 2015, J PEDIAT HEMATOL ONC, V37, P147, DOI 10.1097/MPH.0000000000000115; Ignatius MS, 2012, CANCER CELL, V21, P680, DOI 10.1016/j.ccr.2012.03.043; Jongmans MCJ, 2010, GENE CHROMOSOME CANC, V49, P635, DOI 10.1002/gcc.20773; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kratz CP, 2011, AM J MED GENET C, V157C, P83, DOI 10.1002/ajmg.c.30300; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Lauth M, 2010, NAT STRUCT MOL BIOL, V17, P718, DOI 10.1038/nsmb.1833; Martinez-Cruzado L, 2016, SCI REP-UK, V6, DOI 10.1038/srep27878; Mercer SE, 2006, CANCER RES, V66, P5143, DOI 10.1158/0008-5472.CAN-05-1539; MOON B, 2014, JNCI-J NATL CANCER I, V106; Nakahata K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125454; Nitzki F, 2011, ONCOGENE, V30, P4428, DOI 10.1038/onc.2011.157; Paulson V, 2011, GENE CHROMOSOME CANC, V50, P397, DOI 10.1002/gcc.20864; Pietrobono S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00556; Pressey JG, 2011, PEDIATR BLOOD CANCER, V57, P930, DOI 10.1002/pbc.23174; Ridzewski R, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00130; Robbins KM, 2016, AM J MED GENET A, V170, P3197, DOI 10.1002/ajmg.a.37949; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; Sesillo FB, 2019, CELL REP, V26, P689, DOI 10.1016/j.celrep.2018.12.089; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Sieber OM, 2005, NAT REV CANCER, V5, P649, DOI 10.1038/nrc1674; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Soleimani VD, 2011, CANCER CELL, V19, P157, DOI 10.1016/j.ccr.2011.01.044; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stecca B, 2010, J MOL CELL BIOL, V2, P84, DOI 10.1093/jmcb/mjp052; Tostar Ulrica, 2010, Genes Cancer, V1, P941, DOI 10.1177/1947601910385449; Tsumura H, 2006, ONCOGENE, V25, P7673, DOI 10.1038/sj.onc.1209749; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Wang JY, 2011, BLOOD, V118, P368, DOI 10.1182/blood-2010-12-326058; Yohe ME, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan4470; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; Zhao XS, 2015, CANCER RES, V75, P3623, DOI 10.1158/0008-5472.CAN-14-2999-T; Zibat A, 2010, ONCOGENE, V29, P6323, DOI 10.1038/onc.2010.368; Zibat A, 2009, CARCINOGENESIS, V30, P918, DOI 10.1093/carcin/bgp068	54	2	2	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					4955	4966		10.1038/s41388-021-01904-4	http://dx.doi.org/10.1038/s41388-021-01904-4		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34172934	hybrid, Green Published			2022-12-28	WOS:000667016100003
J	Zhao, ZX; Guo, YY; Liu, YY; Sun, LC; Chen, B; Wang, CY; Chen, TT; Wang, YQ; Li, YW; Dong, Q; Ai, LQ; Wang, R; Gu, YY; Li, X				Zhao, Zhangxiang; Guo, YingYing; Liu, Yaoyao; Sun, Lichun; Chen, Bo; Wang, Chengyu; Chen, Tingting; Wang, Yuquan; Li, Yawei; Dong, Qi; Ai, Liqiang; Wang, Ran; Gu, Yunyan; Li, Xia			Individualized lncRNA differential expression profile reveals heterogeneity of breast cancer	ONCOGENE			English	Article							LONG NONCODING RNAS; SUBTYPES; REPAIR	Long non-coding RNAs (lncRNAs) play key regulatory roles in breast cancer. However, population-level differential expression analysis methods disregard the heterogeneous expression of lncRNAs in individual patients. Therefore, we individualized lncRNA expression profiles for breast invasive carcinoma (BRCA) using the method of LncRNA Individualization (LncRIndiv). After evaluating the robustness of LncRIndiv, we constructed an individualized differentially expressed lncRNA (IDElncRNA) profile for BRCA and investigated the subtype-specific IDElncRNAs. The breast cancer subtype-specific IDElncRNA showed frequent co-occurrence with alterations of protein-coding genes, including mutations, copy number variation and differential methylation. We performed hierarchical clustering to subdivide TNBC and revealed mesenchymal subtype and immune subtype for TNBC. The TNBC immune subtype showed a better prognosis than the TNBC mesenchymal subtype. LncRNA PTOV1-AS1 was the top differentially expressed lncRNA in the mesenchymal subtype. And biological experiments validated that the upregulation of PTOV1-AS1 could downregulate TJP1 (ZO-1) and E-Cadherin, and upregulate Vimentin, which suggests PTOV1-AS1 may promote epithelial-mesenchymal transition and lead to migration and invasion of TNBC cells. The mesenchymal subtype showed a higher fraction of M2 macrophages, whereas the immune subtype was more associated with CD4 + T cells. The immune subtype is characterized by genomic instability and upregulation of immune checkpoint genes, thereby suggesting a potential response to immunosuppressive drugs. Last, drug response analysis revealed lncRNA ENSG00000230082 (PRRT3-AS1) is a potential resistance biomarker for paclitaxel in BRCA treatment. Our analysis highlights that IDElncRNAs can characterize inter-tumor heterogeneity in BRCA and the new TNBC subtypes indicate novel insights into TNBC immunotherapy.	[Zhao, Zhangxiang; Liu, Yaoyao; Chen, Bo; Wang, Chengyu; Chen, Tingting; Wang, Yuquan; Li, Yawei; Dong, Qi; Ai, Liqiang; Gu, Yunyan] Harbin Med Univ, Dept Syst Biol, Coll Bioinformat Sci & Technol, Harbin, Peoples R China; [Guo, YingYing] Harbin Med Univ, Coll Pharm, Minist Educ, China Key Lab Cardiovasc Res,Dept Pharmacol,State, Harbin, Peoples R China; [Guo, YingYing] Harbin Med Univ, Heilongjiang Acad Med Sci, Northern Translat Med Res & Cooperat, Harbin, Peoples R China; [Sun, Lichun] Harbin Med Univ, Dept Breast Med Oncol, Canc Hosp, Harbin, Peoples R China; [Wang, Ran] Harbin Med Univ, Dept Physiol, Harbin, Peoples R China; [Li, Xia] Harbin Med Univ, Dept Bioinformat, Coll Bioinformat Sci & Technol, Harbin, Peoples R China	Harbin Medical University; Harbin Medical University; Harbin Medical University; Harbin Medical University; Harbin Medical University; Harbin Medical University	Gu, YY (corresponding author), Harbin Med Univ, Dept Syst Biol, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.; Li, X (corresponding author), Harbin Med Univ, Dept Bioinformat, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.	guyunyan@ems.hrbmu.edu.cn; lixia@hrbmu.edu.cn	li, xia/HHZ-7468-2022	Gu, Yunyan/0000-0001-5693-4126; Wang, Chengyu/0000-0003-2384-0822; Zhao, Zhangxiang/0000-0001-7467-7223; Chen, Tingting/0000-0002-3918-5132	National Natural Science Foundation of China [61673143, 61873075]; National Key R&D Program of China [2018YFC2000100]; Postdoctoral Scientific Research Developmental Fund [LBH-Q16166]; Fundamental Research Funds for the Heilongjiang Provincial Universities [31041180010]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; Postdoctoral Scientific Research Developmental Fund; Fundamental Research Funds for the Heilongjiang Provincial Universities	This work was supported by the National Natural Science Foundation of China [grant number: 61673143, 61873075], the National Key R&D Program of China [grant number: 2018YFC2000100], the Postdoctoral Scientific Research Developmental Fund [no. LBH-Q16166] and the Fundamental Research Funds for the Heilongjiang Provincial Universities [grant number: 31041180010].	Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Bareche Y, 2018, ANN ONCOL, V29, P895, DOI 10.1093/annonc/mdy024; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Bhan A, 2015, BBA-REV CANCER, V1856, P151, DOI 10.1016/j.bbcan.2015.07.001; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Dai XF, 2017, J CANCER, V8, P3131, DOI 10.7150/jca.18457; Ding JR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9554; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Goldhirsch A, 2013, BREAST, V22, pS3, DOI 10.1016/j.breast.2013.07.001; Huang X, 2018, Zhonghua Yi Xue Za Zhi, V98, P1213, DOI 10.3760/cma.j.issn.0376-2491.2018.16.005; Jiang YZ, 2019, CANCER CELL, V35, P428, DOI 10.1016/j.ccell.2019.02.001; Knijnenburg TA, 2018, CELL REP, V23, P239, DOI 10.1016/j.celrep.2018.03.076; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Li YY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15095-1; Luo J, 2010, PHARMACOGENOMICS J, V10, P278, DOI 10.1038/tpj.2010.57; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; Nath A, 2019, P NATL ACAD SCI USA, V116, P22020, DOI 10.1073/pnas.1909998116; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Peng FD, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0666-z; Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534; Pusztai L, 2015, CLIN CANCER RES, V21, P3575, DOI 10.1158/1078-0432.CCR-14-3121; Rahman M, 2015, BIOINFORMATICS, V31, P3666, DOI 10.1093/bioinformatics/btv377; Rotte A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1259-z; Schmitt AM, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026492; Senkus E, 2015, ANN ONCOL, V26, pV8, DOI 10.1093/annonc/mdv298; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sun BY, 2020, ONCOL LETT, V19, P595, DOI 10.3892/ol.2019.11182; Tang JM, 2018, ONCOGENE, V37, P4723, DOI 10.1038/s41388-018-0310-4; Thapar R, 2018, MOLECULES, V23, DOI 10.3390/molecules23112789; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Wang HW, 2015, BIOINFORMATICS, V31, P62, DOI 10.1093/bioinformatics/btu522; Wu SC, 2010, CELL RES, V20, P1109, DOI 10.1038/cr.2010.114; Xing F, 2018, CANCER RES, V78, P4316, DOI 10.1158/0008-5472.CAN-18-1102; Yan XH, 2015, CANCER CELL, V28, P529, DOI 10.1016/j.ccell.2015.09.006; Youness RA, 2019, NON-CODING RNA RES, V4, P36, DOI 10.1016/j.ncrna.2019.01.003; Zhang TZ, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819843889; Zheng RN, 2018, BIOCHEM BIOPH RES CO, V498, P1002, DOI 10.1016/j.bbrc.2018.03.104	38	8	8	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4604	4614		10.1038/s41388-021-01883-6	http://dx.doi.org/10.1038/s41388-021-01883-6		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34131286	hybrid, Green Published			2022-12-28	WOS:000661812800001
J	Ricordel, C; Chaillot, L; Blondel, A; Archambeau, J; Jouan, F; Mouche, A; Tiercin, M; Burel, A; Lena, H; Desrues, B; Guillaudeux, T; Pedeux, R				Ricordel, Charles; Chaillot, Laura; Blondel, Alice; Archambeau, Jerome; Jouan, Florence; Mouche, Audrey; Tiercin, Marie; Burel, Agnes; Lena, Herve; Desrues, Benoit; Guillaudeux, Thierry; Pedeux, Remy			ING2 tumor suppressive protein translocates into mitochondria and is involved in cellular metabolism homeostasis	ONCOGENE			English	Article							INTERMEMBRANE SPACE; CYTOPLASMIC EXPRESSION; DISULFIDE RELAY; PHD FINGER; NUCLEAR; PROGRESSION; P53; P33(ING1B); TUMORIGENESIS; GENES	ING2 (Inhibitor of Growth 2) is a tumor suppressor gene that has been implicated in critical biological functions (cell-cycle regulation, replicative senescence, DNA repair and DNA replication), most of which are recognized hallmarks of tumorigenesis occurring in the cell nucleus. As its close homolog ING1 has been recently observed in the mitochondrial compartment, we hypothesized that ING2 could also translocate into the mitochondria and be involved in new biological functions. In the present study, we demonstrate that ING2 is imported in the inner mitochondrial fraction in a redox-sensitive manner in human cells and that this mechanism is modulated by 14-3-3 eta protein expression. Remarkably, ING2 is necessary to maintain mitochondrial ultrastructure integrity without interfering with mitochondrial networks or polarization. We observed an interaction between ING2 and mtDNA under basal conditions. This interaction appears to be mediated by TFAM, a critical regulator of mtDNA integrity. The loss of mitochondrial ING2 does not impair mtDNA repair, replication or transcription but leads to a decrease in mitochondrial ROS production, suggesting a detrimental impact on OXPHOS activity. We finally show using multiple models that ING2 is involved in mitochondrial respiration and that its loss confers a protection against mitochondrial respiratory chain inhibition in vitro. Consequently, we propose a new tumor suppressor role for ING2 protein in the mitochondria as a metabolic shift gatekeeper during tumorigenesis.	[Ricordel, Charles; Chaillot, Laura; Blondel, Alice; Archambeau, Jerome; Jouan, Florence; Mouche, Audrey; Lena, Herve; Desrues, Benoit; Guillaudeux, Thierry; Pedeux, Remy] Univ Rennes 1, Chem Oncogenesis Stress & Signaling, INSERM, U1242,CLCC Eugene Marquis, Rennes, France; [Ricordel, Charles; Lena, Herve; Desrues, Benoit] Univ Rennes 1, Dept Pulm Med, CHU Pontchaillou, Rennes, France; [Tiercin, Marie] Hop St Malo, Dept Pulm Med, St Malo, France; [Burel, Agnes; Guillaudeux, Thierry] Univ Rennes 1, UMS 3480, BIOSIT, MRic, Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Eugene Marquis; Universite de Rennes; CHU Rennes; Universite de Rennes; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Rennes	Pedeux, R (corresponding author), Univ Rennes 1, Chem Oncogenesis Stress & Signaling, INSERM, U1242,CLCC Eugene Marquis, Rennes, France.	remy.pedeux@univ-rennes1.fr	PEDEUX, Rémy M/I-2603-2014	PEDEUX, Rémy M/0000-0002-2553-7934	La Ligue Contre le Cancer; Nuovo-Soldati Fundation research grant; INSERM (Institut National de la Sante et de la Recherche Medicale); La Ligue Contre le Cancer (Grand Ouest); Association pour la Recherche sur le Cancer (ARC); Fondation pour la Recherche Medicale (FMR) [DEQ20180339169]; AIS Rennes Metropole; Biosit; Action Incitative Universite de Rennes 1; Region Bretagne; FHU Camin (CHU Rennes) doctoral followship	La Ligue Contre le Cancer(Ligue nationale contre le cancer); Nuovo-Soldati Fundation research grant; INSERM (Institut National de la Sante et de la Recherche Medicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); La Ligue Contre le Cancer (Grand Ouest); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Fondation pour la Recherche Medicale (FMR)(Fondation pour la Recherche Medicale); AIS Rennes Metropole(Region Bretagne); Biosit; Action Incitative Universite de Rennes 1; Region Bretagne(Region Bretagne); FHU Camin (CHU Rennes) doctoral followship	We thank S.Manie for his participation and the technical support. We thank the photonic facility of the Microscopy Rennes Imaging Center (MRic-Photonics) of Biosit, Universite de Rennes 1. We thank Pr JA MacDonald and his team members as well as Pr K Riabowol (University of Calgary, Canada) for providing lentiviral vectors and technical support for the generation of the CrispR clones. AM was a recipient of a doctoral fellowship from La Ligue Contre le Cancer and Region Bretagne. C. Ricordel was a recipient of FHU Camin (CHU Rennes) doctoral followship and Nuovo-Soldati Fundation research grant. RP is supported by INSERM (Institut National de la Sante et de la Recherche Medicale). The work was supported by La Ligue Contre le Cancer (Grand Ouest), Association pour la Recherche sur le Cancer (ARC), Fondation pour la Recherche Medicale (FMR, DEQ20180339169), AIS Rennes Metropole, Biosit and Action Incitative Universite de Rennes 1.	Abdrabou A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010318; Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819; Archambeau J, 2020, CANCERS, V12, DOI 10.3390/cancers12010058; Backes S, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00083; Bose P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.321; Dabir DV, 2013, DEV CELL, V25, P81, DOI 10.1016/j.devcel.2013.03.006; Dantas A, 2019, CANCERS, V11, DOI 10.3390/cancers11111817; Dar S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09206-0; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Edwards R, 2020, BIOL CHEM, V401, P737, DOI 10.1515/hsz-2020-0114; Ferre F, 2006, NUCLEIC ACIDS RES, V34, pW182, DOI 10.1093/nar/gkl189; Furda A, 2014, METHODS MOL BIOL, V1105, P419, DOI 10.1007/978-1-62703-739-6_31; Gabriel K, 2007, J MOL BIOL, V365, P612, DOI 10.1016/j.jmb.2006.10.038; Gong W, 2006, MOL CELL BIOL, V26, P2947, DOI 10.1128/MCB.26.8.2947-2954.2006; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Guerillon C, 2014, CANCER LETT, V345, P1, DOI 10.1016/j.canlet.2013.11.016; Guerillon C, 2013, CELL MOL LIFE SCI, V70, P3753, DOI 10.1007/s00018-013-1270-z; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Hilgendorf KI, 2013, GENE DEV, V27, P1003, DOI 10.1101/gad.211326.112; Kaufman BA, 2007, MOL BIOL CELL, V18, P3225, DOI 10.1091/mbc.E07-05-0404; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Larrieu D, 2010, CELL CYCLE, V9, P3984, DOI 10.4161/cc.9.19.13208; Larrieu D, 2009, EMBO REP, V10, P1168, DOI 10.1038/embor.2009.180; Lee SR, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8060949; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Li XH, 2010, J CANCER RES CLIN, V136, P1573, DOI 10.1007/s00432-010-0815-x; Longen S, 2014, DEV CELL, V28, P30, DOI 10.1016/j.devcel.2013.11.007; Ma Y, 2020, J PHYSIOL BIOCHEM, V76, P373, DOI 10.1007/s13105-020-00743-3; Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6; Mouche A, 2019, CELL DEATH DIFFER, V26, P2344, DOI 10.1038/s41418-019-0305-x; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Nicolle O, 2015, TRAFFIC, V16, P893, DOI 10.1111/tra.12289; Pallotti F, 2007, METHOD CELL BIOL, V80, P3, DOI 10.1016/S0091-679X(06)80001-4; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Pile LA, 2003, J BIOL CHEM, V278, P37840, DOI 10.1074/jbc.M305996200; Puleston Daniel, 2015, Cold Spring Harb Protoc, V2015, DOI 10.1101/pdb.prot086298; Quispe-Tintaya W, 2013, BIOTECHNIQUES, V55, P133, DOI 10.2144/000114077; Rosivatz E, 2011, CELL SIGNAL, V23, P478, DOI 10.1016/j.cellsig.2010.10.025; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Satoh H, 2013, CANCER RES, V73, P4158, DOI 10.1158/0008-5472.CAN-12-4499; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shiao YH, 2000, CANCER RES, V60, P2816; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; Sullivan LB, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-17; Szczepanowska J, 2004, FEBS LETT, V578, P316, DOI 10.1016/j.febslet.2004.11.022; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; Valente AJ, 2017, ACTA HISTOCHEM, V119, P315, DOI 10.1016/j.acthis.2017.03.001; van Donselaar E, 2007, TRAFFIC, V8, P471, DOI 10.1111/j.1600-0854.2007.00552.x; Vogtle FN, 2012, MOL CELL PROTEOMICS, V11, P1840, DOI 10.1074/mcp.M112.021105; Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wang YM, 2007, CLIN CANCER RES, V13, P4111, DOI 10.1158/1078-0432.CCR-07-0408; Wang YE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074513; Weckbecker D, 2012, EMBO J, V31, P4348, DOI 10.1038/emboj.2012.263; Ythier D, 2010, ONCOGENE, V29, P5946, DOI 10.1038/onc.2010.325; Zhang JT, 2008, J CANCER RES CLIN, V134, P421, DOI 10.1007/s00432-007-0305-y; Zhu ZL, 2013, ONCOL LETT, V5, P161, DOI 10.3892/ol.2012.983; Zhuang J, 2013, P NATL ACAD SCI USA, V110, P17356, DOI 10.1073/pnas.1310908110; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011	60	4	4	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4111	4123		10.1038/s41388-021-01832-3	http://dx.doi.org/10.1038/s41388-021-01832-3		MAY 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34017078				2022-12-28	WOS:000652439200004
J	Traphagen, NA; Hosford, SR; Jiang, A; Marotti, JD; Brauer, BL; Demidenko, E; Miller, TW				Traphagen, Nicole A.; Hosford, Sarah R.; Jiang, Amanda; Marotti, Jonathan D.; Brauer, Brooke L.; Demidenko, Eugene; Miller, Todd W.			High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer	ONCOGENE			English	Article							POSTMENOPAUSAL WOMEN; ACQUIRED-RESISTANCE; RANDOMIZED-TRIAL; TAMOXIFEN; DIETHYLSTILBESTROL; ESR1; FULVESTRANT; ESTRADIOL; APOPTOSIS	Estrogen receptor alpha (ER)-positive breast cancer is commonly treated with endocrine therapies, including antiestrogens that bind and inhibit ER activity, and aromatase inhibitors that suppress estrogen biosynthesis to inhibit estrogen-dependent ER activity. Paradoxically, treatment with estrogens such as 17b-estradiol can also be effective against ER+ breast cancer. Despite the known efficacy of estrogen therapy, the lack of a predictive biomarker of response and understanding of the mechanism of action have contributed to its limited clinical use. Herein, we demonstrate that ER overexpression confers resistance to estrogen deprivation through ER activation in human ER+ breast cancer cells and xenografts grown in mice. However, ER overexpression and the associated high levels of ER transcriptional activation converted 17b-estradiol from a growth-promoter to a growth-suppressor, offering a targetable therapeutic vulnerability and a potential means of identifying patients likely to benefit from estrogen therapy. Since ER+ breast cancer cells and tumors ultimately developed resistance to continuous estrogen deprivation or continuous 17b-estradiol treatment, we tested schedules of alternating treatments. Oscillation of ER activity through cycling of 17b-estradiol and estrogen deprivation provided long-term control of patient-derived xenografts, offering a novel endocrine-only strategy to manage ER+ breast cancer.	[Traphagen, Nicole A.; Hosford, Sarah R.; Jiang, Amanda; Brauer, Brooke L.; Miller, Todd W.] Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03755 USA; [Marotti, Jonathan D.] Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, Lebanon, NH USA; [Marotti, Jonathan D.] Geisel Sch Med Dartmouth, Lebanon, NH USA; [Marotti, Jonathan D.; Miller, Todd W.] Norris Cotton Canc Ctr, Comprehens Breast Program, Lebanon, NH 03527 USA; [Demidenko, Eugene] Geisel Sch Med Dartmouth, Dept Biomed Data Sci, Lebanon, NH USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College	Miller, TW (corresponding author), Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03755 USA.; Miller, TW (corresponding author), Norris Cotton Canc Ctr, Comprehens Breast Program, Lebanon, NH 03527 USA.	Todd.W.Miller@dartmouth.edu		Jiang, Amanda/0000-0002-0327-6980; Miller, Todd/0000-0001-8912-2909	Susan G. Komen [CCR1533084]; NIH [R01CA200994, R01CA211869, F31CA243409]; NIH (Dartmouth College Norris Cotton Cancer Center Support Grant) [P30CA023108]	Susan G. Komen(Susan G. Komen Breast Cancer Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH (Dartmouth College Norris Cotton Cancer Center Support Grant)	This work was supported by Susan G. Komen (CCR1533084 to TWM) and NIH (R01CA200994 and R01CA211869 to TWM, F31CA243409 to NAT, Dartmouth College Norris Cotton Cancer Center Support Grant P30CA023108). We thank the following Norris Cotton Cancer Center Shared Resources for their support: Mouse Modeling; Pathology; Biostatistics; Microscopy; Genomics.	Agrawal Amit, 2006, World J Surg Oncol, V4, P44, DOI 10.1186/1477-7819-4-44; [Anonymous], 1960, JAMA-J AM MED ASSOC, V172, P1271; Ariazi EA, 2011, P NATL ACAD SCI USA, V108, P18879, DOI 10.1073/pnas.1115188108; Basudan A, 2019, MOL CANCER RES, V17, P457, DOI 10.1158/1541-7786.MCR-18-0946; BEEX L, 1981, CANCER TREAT REP, V65, P179; BERKENSTAM A, 1989, MOL ENDOCRINOL, V3, P22, DOI 10.1210/mend-3-1-22; CARTER AC, 1977, JAMA-J AM MED ASSOC, V237, P2079, DOI 10.1001/jama.237.19.2079; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chatterjee P, 2019, J CLIN INVEST, V129, P4245, DOI 10.1172/JCI127613; Cuzick J, 2010, LANCET ONCOL, V11, P1135, DOI 10.1016/S1470-2045(10)70257-6; Demidenko E., 2013, MIXED MODELS THEORY, Vxxvii; Demidenko E, 2020, ADV STAT APPL R; DeRose Yoko S, 2013, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1423s60; DeSantis CE, 2019, CA-CANCER J CLIN, V69, P438, DOI 10.3322/caac.21583; Desmedt C, 2016, J CLIN ONCOL, V34, P1872, DOI 10.1200/JCO.2015.64.0334; Ellis MJ, 2009, JAMA-J AM MED ASSOC, V302, P774, DOI 10.1001/jama.2009.1204; Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09; Fan P, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-017-0012-7; Fan P, 2015, MOL CANCER RES, V13, P1367, DOI 10.1158/1541-7786.MCR-14-0494; Fan P, 2013, CANCER RES, V73, P4510, DOI 10.1158/0008-5472.CAN-12-4152; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Haddow A, 1944, Br Med J, V2, P393; Hosford SR, 2019, MOL ONCOL, V13, P1778, DOI 10.1002/1878-0261.12528; Ingle JN, 2006, J CLIN ONCOL, V24, P1052, DOI 10.1200/JCO.2005.04.1053; INGLE JN, 1981, NEW ENGL J MED, V304, P16, DOI 10.1056/NEJM198101013040104; Iwase H, 2013, BRIT J CANCER, V109, P1537, DOI 10.1038/bjc.2013.520; Lee, 2017, CUREUS, V9; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Lonning PE, 2001, BREAST CANCER RES TR, V67, P111, DOI 10.1023/A:1010619225209; Ma R, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw236; MATELSKI H, 1985, AM J CLIN ONCOL-CANC, V8, P128, DOI 10.1097/00000421-198504000-00004; Mathew P, 2008, ANN ONCOL, V19, P395, DOI 10.1093/annonc/mdm568; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Nielsen KV, 2011, BREAST CANCER RES TR, V127, P345, DOI 10.1007/s10549-010-0984-y; Peethambaram PP, 1999, BREAST CANCER RES TR, V54, P117, DOI 10.1023/A:1006185805079; PEREIRA B, 2016, P NATL ACAD SCI USA, V7; Perey L, 2007, ANN ONCOL, V18, P64, DOI 10.1093/annonc/mdl341; Robertson JFR, 2004, BRIT J CANCER, V90, pS7, DOI 10.1038/sj.bjc.6601630; Robertson JFR, 2009, J CLIN ONCOL, V27, P4530, DOI 10.1200/JCO.2008.21.1136; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; SANCHEZ C, 2011, MOL CELL BIOL, V13; SCHWEIZER M, 2015, LANCET ONCOL, V7; Schweizer MT, 2016, PROSTATE, V76, P1218, DOI 10.1002/pros.23209; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Simoes BM, 2015, CELL REP, V12, P1968, DOI 10.1016/j.celrep.2015.08.050; Szmulewitz R, 2009, EUR UROL, V56, P97, DOI 10.1016/j.eururo.2009.02.022; Teply BA, 2018, LANCET ONCOL, V19, P76, DOI 10.1016/S1470-2045(17)30906-3; Yu NY, 2019, JAMA ONCOL, V5, P1304, DOI 10.1001/jamaoncol.2019.1856; Zucchini G, 2015, EUR J CANCER, V51, P2725, DOI 10.1016/j.ejca.2015.08.028	51	3	3	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3408	3421		10.1038/s41388-021-01782-w	http://dx.doi.org/10.1038/s41388-021-01782-w		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33875787	Green Accepted			2022-12-28	WOS:000641218600004
J	Ge, LP; Jin, X; Yang, YS; Liu, XY; Shao, ZM; Di, GH; Jiang, YZ				Ge, Li-Ping; Jin, Xi; Yang, Yun-Song; Liu, Xi-Yu; Shao, Zhi-Ming; Di, Gen-Hong; Jiang, Yi-Zhou			Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MICROTUBULE-ASSOCIATED PROTEINS; DEXAMETHASONE; RICOLINOSTAT; COMBINATION; BORTEZOMIB; REGULATOR; DYNAMICS; STATHMIN	Progression of triple-negative breast cancer (TNBC) constitutes a major unresolved clinical challenge, and effective targeted therapies are lacking. Because microtubule dynamics play pivotal roles in breast cancer metastasis, we performed RNA sequencing on 245 samples from TNBC patients to characterize the landscape of microtubule-associated proteins (MAPs). Here, our transcriptome analyses revealed that low expression of one MAP, tektin4, indicated poor patient outcomes. Tektin4 loss led to a marked increase in TNBC migration, invasion, and metastasis and a decrease in microtubule stability. Mechanistically, we identified a novel microtubule-associated complex containing tektin4 and histone deacetylase 6 (HDAC6). Tektin4 loss increased the interaction between HDAC6 and alpha-tubulin, thus decreasing microtubule stability through HDAC6-mediated tubulin deacetylation. Significantly, we found that tektin4 loss sensitized TNBC cells, xenograft models, and patient-derived organoid models to the HDAC6-selective inhibitor ACY1215. Furthermore, tektin4 expression levels were positively correlated with microtubule stability levels in clinical samples. Together, our findings uncover a metastasis suppressor function of tektin4 and support clinical development of HDAC6 inhibition as a new therapeutic strategy for tektin4-deficient TNBC patients.	[Ge, Li-Ping; Jin, Xi; Yang, Yun-Song; Liu, Xi-Yu; Shao, Zhi-Ming; Di, Gen-Hong; Jiang, Yi-Zhou] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai, Peoples R China; [Ge, Li-Ping; Shao, Zhi-Ming] Fudan Univ, Human Phenome Inst, Shanghai, Peoples R China; [Ge, Li-Ping; Jin, Xi; Yang, Yun-Song; Liu, Xi-Yu; Shao, Zhi-Ming; Di, Gen-Hong; Jiang, Yi-Zhou] Fudan Univ, Canc Inst, Shanghai Canc Ctr, Shanghai, Peoples R China; [Ge, Li-Ping; Jin, Xi; Yang, Yun-Song; Liu, Xi-Yu; Shao, Zhi-Ming; Di, Gen-Hong; Jiang, Yi-Zhou] Key Lab Breast Canc Shanghai, Shanghai, Peoples R China; [Shao, Zhi-Ming; Di, Gen-Hong; Jiang, Yi-Zhou] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Shao, Zhi-Ming; Di, Gen-Hong; Jiang, Yi-Zhou] Fudan Univ, Precis Canc Med Ctr, Shanghai Canc Ctr, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University	Di, GH; Jiang, YZ (corresponding author), Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai, Peoples R China.; Di, GH; Jiang, YZ (corresponding author), Fudan Univ, Canc Inst, Shanghai Canc Ctr, Shanghai, Peoples R China.; Di, GH; Jiang, YZ (corresponding author), Key Lab Breast Canc Shanghai, Shanghai, Peoples R China.; Di, GH; Jiang, YZ (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.; Di, GH; Jiang, YZ (corresponding author), Fudan Univ, Precis Canc Med Ctr, Shanghai Canc Ctr, Shanghai, Peoples R China.	genhongdi@163.com; yizhoujiang@fudan.edu.cn		Di, Genhong/0000-0003-1171-7907	National Natural Science Foundation of China [81874112, 91959207, 81922048, 81902684, 81874113]; Program of Shanghai Academic/Technology Research Leader [20XD1421100]; Fok Ying-Tong Education Foundation for College Young Teachers [171034]; Shanghai Sailing Program [19YF1409000]; Innovation Team of Ministry of Education [IRT1223]; Shanghai Key Laboratory of Breast Cancer [12DZ2260100]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program of Shanghai Academic/Technology Research Leader; Fok Ying-Tong Education Foundation for College Young Teachers; Shanghai Sailing Program; Innovation Team of Ministry of Education; Shanghai Key Laboratory of Breast Cancer	We would like to thank all the patients at Fudan University Shanghai Cancer Center for their support and commitment to tissue collection and banking. This work was supported by grants from the National Natural Science Foundation of China (81874112, 91959207, 81922048, 81902684, 81874113), the Program of Shanghai Academic/Technology Research Leader (20XD1421100), the Fok Ying-Tong Education Foundation for College Young Teachers (171034), the Shanghai Sailing Program (19YF1409000), the Innovation Team of Ministry of Education (IRT1223) and the Shanghai Key Laboratory of Breast Cancer (12DZ2260100).	Alesi GN, 2016, ONCOGENE, V35, P5412, DOI 10.1038/onc.2016.79; Amos LA, 2005, ADV PROTEIN CHEM, V71, P257, DOI 10.1016/S0065-3233(04)71007-4; Bhat KMR, 2007, CLIN CANCER RES, V13, P2849, DOI 10.1158/1078-0432.CCR-06-3040; Bitler BG, 2017, NAT CELL BIOL, V19, P962, DOI 10.1038/ncb3582; Cassimeris L, 2001, INT REV CYTOL, V210, P163; Chen JX, 2016, GUT, V65, P1522, DOI 10.1136/gutjnl-2015-310625; Collignon J, 2016, BREAST CANCER-TARGET, V8, P93, DOI 10.2147/BCTT.S69488; Costa RLB, 2017, J ONCOL PRACT, V13, P301, DOI 10.1200/JOP.2017.023333; Dai JL, 1996, MOL ENDOCRINOL, V10, P1582, DOI 10.1210/me.10.12.1582; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DeSantis CE, 2019, CA-CANCER J CLIN, V69, P438, DOI 10.3322/caac.21583; Dong X, 2010, J PATHOL, V220, P361, DOI 10.1002/path.2662; Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Goodson HV, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022608; Gradilone SA, 2013, CANCER RES, V73, P2259, DOI 10.1158/0008-5472.CAN-12-2938; Gu SC, 2016, J BIOL CHEM, V291, P5396, DOI 10.1074/jbc.M115.713123; Howlader N, 2018, CANCER EPIDEM BIOMAR, V27, P619, DOI 10.1158/1055-9965.EPI-17-0627; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Jacob F, 2020, CELL, V180, P188, DOI 10.1016/j.cell.2019.11.036; Jiang YY, 2016, ONCOGENE, V35, P4846, DOI 10.1038/onc.2016.17; Jiang YZ, 2019, CANCER CELL, V35, P428, DOI 10.1016/j.ccell.2019.02.001; Jiang YZ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4802; Laks DR, 2018, NEURO-ONCOLOGY, V20, P764, DOI 10.1093/neuonc/nox215; Le Large TYS, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919841233; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; LHERNAULT SW, 1985, J CELL BIOL, V100, P457, DOI 10.1083/jcb.100.2.457; Li N, 2011, P NATL ACAD SCI USA, V108, P12851, DOI 10.1073/pnas.1017372108; Li T, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0654-9; Liu JR, 2019, BIOCHEM PHARMACOL, V163, P458, DOI 10.1016/j.bcp.2019.03.023; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; Mak AB, 2012, CELL REP, V2, P951, DOI 10.1016/j.celrep.2012.09.016; Nakaya Y, 2008, NAT CELL BIOL, V10, P765, DOI 10.1038/ncb1739; Rey M, 2011, EUR J CELL BIOL, V90, P128, DOI 10.1016/j.ejcb.2010.09.004; Rodrigues-Ferreira S, 2020, BREAST CANCER RES TR, V179, P267, DOI 10.1007/s10549-019-05463-x; Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood-2011-10-387365; Tala, 2014, THERANOSTICS, V4, P1052, DOI 10.7150/thno.9727; Tran DD, 2011, MOL CANCER RES, V9, P1644, DOI 10.1158/1541-7786.MCR-11-0371; Valenzuela-Fernandez A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003; Vogl DT, 2017, CLIN CANCER RES, V23, P3307, DOI 10.1158/1078-0432.CCR-16-2526; Wang J, 2017, ONCOTARGET, V8, P96215, DOI 10.18632/oncotarget.21894; Yang YF, 2014, P NATL ACAD SCI USA, V111, P2158, DOI 10.1073/pnas.1319341111; Yee AJ, 2016, LANCET ONCOL, V17, P1569, DOI 10.1016/S1470-2045(16)30375-8; Zhang Y, 2006, J BIOL CHEM, V281, P2401, DOI 10.1074/jbc.C500241200; Zhao L, 2019, ONCOGENE, V38, P935, DOI 10.1038/s41388-018-0493-8; Zheng ZC, 2018, ENDOCR PATHOL, V29, P310, DOI 10.1007/s12022-018-9549-0; Zilberman Y, 2009, J CELL SCI, V122, P3531, DOI 10.1242/jcs.046813	47	4	4	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2323	2334		10.1038/s41388-021-01655-2	http://dx.doi.org/10.1038/s41388-021-01655-2		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33654196				2022-12-28	WOS:000624398900003
J	Ma, YJ; Zha, JY; Yang, XK; Li, QJ; Zhang, QF; Yin, A; Beharry, Z; Huang, HW; Huang, JT; Bartlett, M; Ye, KX; Yin, H; Cai, HJ				Ma, Yongjie; Zha, Junyi; Yang, XiangKun; Li, Qianjin; Zhang, Qingfu; Yin, Amelia; Beharry, Zanna; Huang, Hanwen; Huang, Jiaoti; Bartlett, Michael; Ye, Kaixiong; Yin, Hang; Cai, Houjian			Long-chain fatty acyl-CoA synthetase 1 promotes prostate cancer progression by elevation of lipogenesis and fatty acid beta-oxidation	ONCOGENE			English	Article								Fatty acid metabolism is essential for the biogenesis of cellular components and ATP production to sustain proliferation of cancer cells. Long-chain fatty acyl-CoA synthetases (ACSLs), a group of rate-limiting enzymes in fatty acid metabolism, catalyze the bioconversion of exogenous or de novo synthesized fatty acids to their corresponding fatty acyl-CoAs. In this study, systematical analysis of ACSLs levels and the amount of fatty acyl-CoAs illustrated that ACSL1 were significantly associated with the levels of a broad spectrum of fatty acyl-CoAs, and were elevated in human prostate tumors. ACSL1 increased the biosynthesis of fatty acyl-CoAs including C16:0-, C18:0-, C18:1-, and C18:2-CoA, triglycerides and lipid accumulation in cancer cells. Mechanistically, ACSL1 modulated mitochondrial respiration, beta-oxidation, and ATP production through regulation of CPT1 activity. Knockdown of ACSL1 inhibited the cell cycle, and suppressed the proliferation and migration of prostate cancer cells in vitro, and growth of prostate xenograft tumors in vivo. Our study implicates ACSL1 as playing an important role in prostate tumor progression, and provides a therapeutic strategy of targeting fatty acid metabolism for the treatment of prostate cancer.	[Ma, Yongjie; Zha, Junyi; Yang, XiangKun; Li, Qianjin; Bartlett, Michael; Cai, Houjian] Univ Georgia, Coll Pharm, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA; [Zhang, Qingfu; Huang, Jiaoti] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA; [Yin, Amelia; Yin, Hang] Univ Georgia, Ctr Mol Med, Dept Biochem & Mol Biol, Athens, GA 30602 USA; [Beharry, Zanna] Univ Virgin Isl, Dept Chem & Phys Sci, St Thomas, VI USA; [Huang, Hanwen] Univ Georgia, Dept Epidemiol & Biostat, Athens, GA 30602 USA; [Ye, Kaixiong] Univ Georgia, Dept Genet, Athens, GA 30602 USA; [Ye, Kaixiong] Univ Georgia, Inst Bioinformat, Athens, GA 30602 USA	University System of Georgia; University of Georgia; Duke University; University System of Georgia; University of Georgia; University of the Virgin Islands; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Cai, HJ (corresponding author), Univ Georgia, Coll Pharm, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA.	caihj@uga.edu		Zha, Junyi/0000-0003-2125-1362; Bartlett, Michael/0000-0003-0626-3234; Zhang, Qingfu/0000-0002-9891-1296; Beharry, Zanna/0000-0002-3900-8523	NIH [R01CA172495]; DOD [W81XWH-15-1-0507]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense)	This work was supported by NIH (R01CA172495) and DOD (W81XWH-15-1-0507) to HC.	BIEBER LL, 1972, ANAL BIOCHEM, V50, P509, DOI 10.1016/0003-2697(72)90061-9; Butler LM, 2016, ENDOCR-RELAT CANCER, V23, pR219, DOI 10.1530/ERC-15-0556; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Ellis JM, 2011, MOL CELL BIOL, V31, P1252, DOI 10.1128/MCB.01085-10; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gazi E, 2007, J LIPID RES, V48, P1846, DOI 10.1194/jlr.M700131-JLR200; Grevengoed TJ, 2015, J LIPID RES, V56, P1572, DOI 10.1194/jlr.M059717; Grevengoed TJ, 2014, ANNU REV NUTR, V34, P1, DOI 10.1146/annurev-nutr-071813-105541; Iijima H, 1996, EUR J BIOCHEM, V242, P186, DOI 10.1111/j.1432-1033.1996.0186r.x; Kim S, 2017, CANCER RES, V77, P6950, DOI 10.1158/0008-5472.CAN-17-0981; Kim S, 2017, J BIOL CHEM, V292, P18422, DOI [10.1074/jbc.M117.798827, 10.1074/jbc.m117.798827]; Koizume S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091430; Kuemmerle NB, 2011, MOL CANCER THER, V10, P427, DOI 10.1158/1535-7163.MCT-10-0802; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Lee K, 2011, J BIOL CHEM, V286, P25655, DOI 10.1074/jbc.M111.228692; Li LO, 2009, J BIOL CHEM, V284, P27816, DOI 10.1074/jbc.M109.022467; Lloyd MD, 2013, PROG LIPID RES, V52, P220, DOI 10.1016/j.plipres.2013.01.001; Mashima T, 2005, JNCI-J NATL CANCER I, V97, P765, DOI 10.1093/jnci/dji133; Sanchez-Martinez R, 2015, ONCOTARGET, V6, P38719, DOI 10.18632/oncotarget.5340; Schlaepfer IR, 2014, MOL CANCER THER, V13, P2361, DOI 10.1158/1535-7163.MCT-14-0183; Soupene E, 2008, EXP BIOL MED, V233, P507, DOI 10.3181/0710-MR-287; Vargas T, 2015, ONCOTARGET, V6, P7348, DOI 10.18632/oncotarget.3130; Wang YY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.87489; Wu XY, 2015, ONCOTARGET, V6, P44849, DOI 10.18632/oncotarget.6438; Wu XY, 2014, AM J CLIN EXP UROL, V2, P111; Yan S, 2015, WORLD J GASTROENTERO, V21, P3492, DOI 10.3748/wjg.v21.i12.3492; Yang XK, 2017, ANAL CHEM, V89, P813, DOI 10.1021/acs.analchem.6b03623; Yen CLE, 2008, J LIPID RES, V49, P2283, DOI 10.1194/jlr.R800018-JLR200; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019	30	19	19	3	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1806	1820		10.1038/s41388-021-01667-y	http://dx.doi.org/10.1038/s41388-021-01667-y		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564069	Green Accepted			2022-12-28	WOS:000616489100012
J	Yan, QX; Zeng, P; Zhou, XQ; Zhao, XY; Chen, RQ; Qiao, J; Feng, L; Zhu, ZJ; Zhang, GZ; Chen, CR				Yan, Qiuxia; Zeng, Peng; Zhou, Xiuqin; Zhao, Xiaoying; Chen, Runqiang; Qiao, Jing; Feng, Ling; Zhu, Zhenjie; Zhang, Guozhi; Chen, Cairong			RBMX suppresses tumorigenicity and progression of bladder cancer by interacting with the hnRNP A1 protein to regulate PKM alternative splicing	ONCOGENE			English	Article								The prognosis for patients with metastatic bladder cancer (BCa) is poor, and it is not improved by current treatments. RNA-binding motif protein X-linked (RBMX) are involved in the regulation of the malignant progression of various tumors. However, the role of RBMX in BCa tumorigenicity and progression remains unclear. In this study, we found that RBMX was significantly downregulated in BCa tissues, especially in muscle-invasive BCa tissues. RBMX expression was negatively correlated with tumor stage, histological grade and poor patient prognosis. Functional assays demonstrated that RBMX inhibited BCa cell proliferation, colony formation, migration, and invasion in vitro and suppressed tumor growth and metastasis in vivo. Mechanistic investigations revealed that hnRNP A1 was an RBMX-binding protein. RBMX competitively inhibited the combination of the RGG motif in hnRNP A1 and the sequences flanking PKM exon 9, leading to the formation of lower PKM2 and higher PKM1 levels, which attenuated the tumorigenicity and progression of BCa. Moreover, RBMX inhibited aerobic glycolysis through hnRNP A1-dependent PKM alternative splicing and counteracted the PKM2 overexpression-induced aggressive phenotype of the BCa cells. In conclusion, our findings indicate that RBMX suppresses BCa tumorigenicity and progression via an hnRNP A1-mediated PKM alternative splicing mechanism. RBMX may serve as a novel prognostic biomarker for clinical intervention in BCa.	[Yan, Qiuxia; Zhou, Xiuqin; Zhao, Xiaoying; Chen, Runqiang; Qiao, Jing; Feng, Ling; Zhu, Zhenjie; Zhang, Guozhi; Chen, Cairong] Guangzhou Med Univ, Ctr Reprod Med, Qingyuan Peoples Hosp, Affiliated Hosp 6, Qingyuan, Guangdong, Peoples R China; [Zeng, Peng] Guangzhou Med Univ, Dept Urol, Qingyuan Peoples Hosp, Affiliated Hosp 6, Qingyuan, Guangdong, Peoples R China	Guangzhou Medical University; Guangzhou Medical University	Yan, QX; Chen, CR (corresponding author), Guangzhou Med Univ, Ctr Reprod Med, Qingyuan Peoples Hosp, Affiliated Hosp 6, Qingyuan, Guangdong, Peoples R China.	yanqiuxia1982@163.com; cairong1222@163.com		Yan, Qiuxia/0000-0002-7701-5126	National Natural Science Foundation of China [82002671]; Guangdong Basic and Applied Basic Research Foundation [2019A1515010249]; Qingyuan Science and Technology Project [2020KJJH023]; China Postdoctoral Science Foundation [2019M663398]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; Qingyuan Science and Technology Project; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (No. 82002671), Guangdong Basic and Applied Basic Research Foundation (No. 2019A1515010249), The Qingyuan Science and Technology Project (No. 2020KJJH023), and China Postdoctoral Science Foundation (No. 2019M663398). We thank Prof. Guojun Zhao and Prof. Lin Qi for providing scientific advices. We would like to thank Laboratory Animal Center, The Sixth Affiliated Hospital of Guangzhou Medical University for support in all animal experiments. Finally, we thank American Journal Experts for the English language editing.	Adamson B, 2012, NAT CELL BIOL, V14, P318, DOI 10.1038/ncb2426; Babjuk M, 2019, EUR UROL, V76, P639, DOI 10.1016/j.eururo.2019.08.016; Barboro P, 2014, CANCER LETT, V352, P152, DOI 10.1016/j.canlet.2014.06.019; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cambier S, 2016, EUR UROL, V69, P60, DOI 10.1016/j.eururo.2015.06.045; Chen M, 2012, NAT STRUCT MOL BIOL, V19, P346, DOI 10.1038/nsmb.2219; Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513; Chen X, 2017, J CELL MOL MED, V21, P1266, DOI 10.1111/jcmm.12999; Chen ZY, 2019, MOL THER, V27, P326, DOI 10.1016/j.ymthe.2018.12.015; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Cirak S, 2011, LANCET, V378, P595, DOI 10.1016/S0140-6736(11)60756-3; Climente-Gonzalez H, 2017, CELL REP, V20, P2215, DOI 10.1016/j.celrep.2017.08.012; Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Elliott DJ, 2019, INT J BIOCHEM CELL B, V108, P1, DOI 10.1016/j.biocel.2018.12.014; Funt SA, 2017, NAT REV CLIN ONCOL, V14, P221, DOI 10.1038/nrclinonc.2016.188; Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152; Georgilis A, 2018, CANCER CELL, V34, P85, DOI 10.1016/j.ccell.2018.06.007; Ghosh M, 2020, NUCLEIC ACIDS RES, V48, P4492, DOI 10.1093/nar/gkaa134; Gu ZM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0392-4; Han N, 2013, J CANCER RES THER, V9, pS129, DOI 10.4103/0973-1482.122506; Heinrich B, 2009, J BIOL CHEM, V284, P14303, DOI 10.1074/jbc.M901026200; Huang JZ, 2017, MOL CELL, V68, P171, DOI 10.1016/j.molcel.2017.09.015; Israelsen WJ, 2015, SEMIN CELL DEV BIOL, V43, P43, DOI 10.1016/j.semcdb.2015.08.004; Jean-Philippe J, 2013, INT J MOL SCI, V14, P18999, DOI 10.3390/ijms140918999; Kanhoush R, 2010, NUCLEUS-PHILA, V1, P109, DOI 10.4161/nucl.1.1.10857; Kashima T, 2007, HUM MOL GENET, V16, P3149, DOI 10.1093/hmg/ddm276; Ko CC, 2014, J BIOL CHEM, V289, P22078, DOI 10.1074/jbc.M114.553248; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Lee SCW, 2016, NAT MED, V22, P976, DOI 10.1038/nm.4165; Lee SCW, 2016, NAT MED, V22, P672, DOI 10.1038/nm.4097; Lew CR, 2015, NAT REV UROL, V12, P383, DOI 10.1038/nrurol.2015.111; Li XB, 2015, THORAC CANCER, V6, P17, DOI 10.1111/1759-7714.12148; Lu JR, 2015, CANCER LETT, V356, P156, DOI 10.1016/j.canlet.2014.04.001; Munschauer M, 2018, NATURE, V561, P132, DOI 10.1038/s41586-018-0453-z; Ouyang YQ, 2011, INT J CANCER, V128, P2010, DOI 10.1002/ijc.25544; Ploussard G, 2014, EUR UROL, V66, P361, DOI 10.1016/j.eururo.2013.09.050; Qian SX, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0360-4; Rajeshkumar NV, 2015, CANCER RES, V75, P3355, DOI 10.1158/0008-5472.CAN-15-0108; Renieri A, 2014, LUNG CANCER, V85, P168, DOI 10.1016/j.lungcan.2014.05.020; Roy R, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1431; Shen SH, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gkr1291; Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066; Shin KH, 2008, NITRIC OXIDE-BIOL CH, V19, P125, DOI 10.1016/j.niox.2008.04.012; Shin KH, 2008, BIOCHEM BIOPH RES CO, V372, P880, DOI 10.1016/j.bbrc.2008.05.175; Shirai T, 2016, J EXP MED, V213, P337, DOI 10.1084/jem.20150900; Song HJ, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00857-7; Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tamada M, 2012, CLIN CANCER RES, V18, P5554, DOI 10.1158/1078-0432.CCR-12-0859; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Thandapani P, 2013, MOL CELL, V50, P613, DOI 10.1016/j.molcel.2013.05.021; Vishnu P, 2011, ONCOTARGETS THER, V4, P97, DOI 10.2147/OTT.S22875; Wang Y, 2014, CANCER CELL, V26, P374, DOI 10.1016/j.ccr.2014.07.010; Wen ZL, 2020, RNA BIOL, V17, P381, DOI 10.1080/15476286.2019.1708547; Xie RH, 2019, CANCER LETT, V449, P31, DOI 10.1016/j.canlet.2019.01.041; Yang H, 2019, ONCOGENE, V38, P4915, DOI 10.1038/s41388-019-0764-z; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Zhang DL, 2018, FRONT MED-PRC, V12, P280, DOI 10.1007/s11684-017-0580-1; Zhang LF, 2015, EMBO J, V34, P2671, DOI 10.15252/embj.201591803; Zhu LY, 2019, MOL THER, V27, P1621, DOI 10.1016/j.ymthe.2019.05.023	61	18	18	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2635	2650		10.1038/s41388-021-01666-z	http://dx.doi.org/10.1038/s41388-021-01666-z		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33564070	hybrid, Green Published			2022-12-28	WOS:000616489100011
J	Abril, YLN; Fernandez, IR; Hong, JY; Chiang, YL; Kutateladze, DA; Zhao, QJ; Yang, M; Hu, J; Sadhukhan, S; Li, B; He, B; Remick, B; Bai, JJ; Mullmann, J; Wang, FY; Maymi, V; Dhawan, R; Auwerx, J; Southard, T; Cerione, RA; Lin, HN; Weiss, RS				Abril, Yashira L. Negron; Fernandez, Irma R.; Hong, Jun Young; Chiang, Ying-Ling; Kutateladze, Dennis A.; Zhao, Qingjie; Yang, Min; Hu, Jing; Sadhukhan, Sushabhan; Li, Bo; He, Bin; Remick, Brenna; Bai, Jessica Jingyi; Mullmann, James; Wang, Fangyu; Maymi, Viviana; Dhawan, Ravi; Auwerx, Johan; Southard, Teresa; Cerione, Richard A.; Lin, Hening; Weiss, Robert S.			Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer	ONCOGENE			English	Article							PROTEIN; DESUCCINYLATION; ANTIOXIDANT; SUCCINYLATION; MALONYLATION; DEMALONYLASE; PROGRESSION; METABOLISM; EXPRESSION; REGULATORS	SIRT5 is a member of the sirtuin family of NAD(+)-dependent protein lysine deacylases implicated in a variety of physiological processes. SIRT5 removes negatively charged malonyl, succinyl, and glutaryl groups from lysine residues and thereby regulates multiple enzymes involved in cellular metabolism and other biological processes. SIRT5 is overexpressed in human breast cancers and other malignancies, but little is known about the therapeutic potential of SIRT5 inhibition for treating cancer. Here we report that genetic SIRT5 disruption in breast cancer cell lines and mouse models caused increased succinylation of IDH2 and other metabolic enzymes, increased oxidative stress, and impaired transformation and tumorigenesis. We, therefore, developed potent, selective, and cell-permeable small-molecule SIRT5 inhibitors. SIRT5 inhibition suppressed the transformed properties of cultured breast cancer cells and significantly reduced mammary tumor growth in vivo, in both genetically engineered and xenotransplant mouse models. Considering that Sirt5 knockout mice are generally normal, with only mild phenotypes observed, these data establish SIRT5 as a promising target for treating breast cancer. The new SIRT5 inhibitors provide useful probes for future investigations of SIRT5 and an avenue for targeting SIRT5 as a therapeutic strategy.	[Abril, Yashira L. Negron; Fernandez, Irma R.; Remick, Brenna; Mullmann, James; Maymi, Viviana; Dhawan, Ravi; Southard, Teresa; Weiss, Robert S.] Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA; [Fernandez, Irma R.; Hong, Jun Young; Chiang, Ying-Ling; Kutateladze, Dennis A.; Zhao, Qingjie; Yang, Min; Hu, Jing; Sadhukhan, Sushabhan; Li, Bo; He, Bin; Bai, Jessica Jingyi; Cerione, Richard A.; Lin, Hening] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; [Li, Bo; Mullmann, James; Wang, Fangyu; Cerione, Richard A.] Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; [Auwerx, Johan] Ecole Polytech Fed Lausanne EPFL, Inst Bioengn, Lab Integrat Syst Physiol, CH-1015 Lausanne, Switzerland; [Lin, Hening] Cornell Univ, Howard Hughes Med Inst, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; [He, Bin] Guizhou Med Univ, Sch Pharm, Guiyang 550004, Peoples R China	Cornell University; Cornell University; Cornell University; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Cornell University; Howard Hughes Medical Institute; Guizhou Medical University	Weiss, RS (corresponding author), Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA.; Lin, HN (corresponding author), Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA.; Lin, HN (corresponding author), Cornell Univ, Howard Hughes Med Inst, Dept Chem & Chem Biol, Ithaca, NY 14853 USA.	hl379@cornell.edu; rsw26@cornell.edu	Auwerx, Johan/ABE-9307-2021; Chiang, Ying-Ling/N-3259-2014	Kutateladze, Dennis/0000-0002-5706-7092; Hong, Jun Young/0000-0002-5257-6525; Maymi, Viviana/0000-0002-1575-3510; Auwerx, Johan/0000-0002-5065-5393; Dhawan, Ravi/0000-0002-2544-341X; Wang, Fangyu/0000-0002-6388-1461; Chiang, Ying-Ling/0000-0001-5591-6209; Negron Abril, Yashira/0000-0002-5922-9999; Weiss, Robert/0000-0003-3327-1379; Sadhukhan, Sushabhan/0000-0002-3302-5875	NIH [CA163255, CA223534]; NIH/NIGMS [T32GM007273, 5T32GM008500]; Cornell Deans Excellence Fellowship; HHMI Gilliam Fellowship; Ecole Polytechnique Federale de Lausanne (EPFL); Swiss National Science Foundation (SNSF) [31003A_179435]; NSF through MRI award [CHE-1531632]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Cornell Deans Excellence Fellowship; HHMI Gilliam Fellowship; Ecole Polytechnique Federale de Lausanne (EPFL); Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); NSF through MRI award	The authors thank the NCI Physical SciencesOncology Network Bioresource Core Facility (PBCF) for MDAMB-231 cells, and Drs. Ruchika Bhawal and Sheng Zhang from the Cornell Proteomics and Metabolomics Facility for technical assistance. This work was supported in part by NIH R01 grants CA163255 and CA223534. YLNA was supported by NIH/NIGMS grant 5T32GM008500, and IRF was supported by NIH/NIGMS grant T32GM007273, a Cornell Deans Excellence Fellowship, and an HHMI Gilliam Fellowship. JA was supported by grants from the Ecole Polytechnique Federale de Lausanne (EPFL), and the Swiss National Science Foundation (SNSF 31003A_179435). This work utilized the Cornell University NMR facility, which is supported in part by the NSF through MRI award CHE-1531632.	Bheda P, 2016, ANNU REV BIOCHEM, V85, P405, DOI 10.1146/annurev-biochem-060815-014537; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chang L, 2018, MOL MED REP, V17, P342, DOI 10.3892/mmr.2017.7875; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Du JT, 2011, SCIENCE, V334, P806, DOI 10.1126/science.1207861; Farooqi AS, 2019, J MED CHEM, V62, P4131, DOI 10.1021/acs.jmedchem.9b00191; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Greene KS, 2019, P NATL ACAD SCI USA, V116, P26625, DOI 10.1073/pnas.1911954116; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]; He B, 2012, J AM CHEM SOC, V134, P1922, DOI 10.1021/ja2090417; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hirschey MD, 2015, MOL CELL PROTEOMICS, V14, P2308, DOI 10.1074/mcp.R114.046664; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Igci M, 2016, GENE, V586, P123, DOI 10.1016/j.gene.2016.04.023; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jiang L, 2016, NATURE, V532, P255, DOI 10.1038/nature17393; Jiang YH, 2020, MED CHEM, V16, P358, DOI 10.2174/1573406415666190603101937; Jing H, 2016, CANCER CELL, V29, P297, DOI 10.1016/j.ccell.2016.02.007; Kalbas D, 2018, J MED CHEM, V61, P2460, DOI 10.1021/acs.jmedchem.7b01648; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; Liem Minh Phan, 2014, Cancer Biology Medicine, V11, P1, DOI 10.7497/j.issn.2095-3941.2014.01.001; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Lin HN, 2012, ACS CHEM BIOL, V7, P947, DOI 10.1021/cb3001793; Lin ZF, 2013, BIOCHEM BIOPH RES CO, V441, P191, DOI 10.1016/j.bbrc.2013.10.033; Liu JJ, 2016, MOLECULES, V21, DOI 10.3390/molecules21091217; Lu WD, 2014, TUMOR BIOL, V35, P10699, DOI 10.1007/s13277-014-2372-4; Maurer B, 2012, ACS MED CHEM LETT, V3, P1050, DOI 10.1021/ml3002709; Nishida Y, 2015, MOL CELL, V59, P321, DOI 10.1016/j.molcel.2015.05.022; Park J, 2013, MOL CELL, V50, P919, DOI 10.1016/j.molcel.2013.06.001; Peng C, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.012658; Polletta L, 2015, AUTOPHAGY, V11, P253, DOI 10.1080/15548627.2015.1009778; Rajabi N, 2017, ANGEW CHEM INT EDIT, V56, P14836, DOI 10.1002/anie.201709050; Rardin MJ, 2013, CELL METAB, V18, P920, DOI 10.1016/j.cmet.2013.11.013; Sadhukhan S, 2016, P NATL ACAD SCI USA, V113, P4320, DOI 10.1073/pnas.1519858113; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Smith BC, 2007, BIOCHEMISTRY-US, V46, P14478, DOI 10.1021/bi7013294; Spiegelman NA, 2019, CHEMMEDCHEM, V14, P744, DOI 10.1002/cmdc.201800715; Spiegelman NA, 2018, CHEMMEDCHEM, V13, P1890, DOI 10.1002/cmdc.201800391; Tan MJ, 2014, CELL METAB, V19, P605, DOI 10.1016/j.cmet.2014.03.014; Unterlass JE, 2019, EXPERT REV MOL MED, V21, DOI 10.1017/erm.2019.4; Wagner GR, 2017, CELL METAB, V25, P823, DOI 10.1016/j.cmet.2017.03.006; Wagner GR, 2014, MOL CELL, V54, P5, DOI 10.1016/j.molcel.2014.03.027; Wang YQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02951-4; Xu L, 2018, ONCOL REP, V39, P2315, DOI 10.3892/or.2018.6319; Yang X, 2018, CANCER RES, V78, P372, DOI 10.1158/0008-5472.CAN-17-1912; Ye XY, 2017, ONCOTARGET, V8, P6984, DOI 10.18632/oncotarget.14346; Yu JJ, 2013, SCI REP-UK, V3, DOI 10.1038/srep02806; Zhou LS, 2016, EMBO REP, V17, P811, DOI 10.15252/embr.201541643	52	22	24	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1644	1658		10.1038/s41388-020-01637-w	http://dx.doi.org/10.1038/s41388-020-01637-w		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33479498	Green Accepted			2022-12-28	WOS:000609352300002
J	Shi, CX; Yang, EJ; Liu, YF; Mou, PK; Ren, GW; Shim, JS				Shi, Changxiang; Yang, Eun Ju; Liu, Yifan; Mou, Pui Kei; Ren, Guowen; Shim, Joong Sup			Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; TUMOR-SUPPRESSOR; C-MYC; DOSE-ESCALATION; DNA-BINDING; DPC4; EXPRESSION; DOMAIN; GENE	The tumor suppressor SMAD4 is frequently mutated in colorectal cancer (CRC). However, no effective targeted therapies exist for CRC with SMAD4 loss. Here, we employed a synthetic lethality drug screening in isogenic SMAD4(+/+) and SMAD4(-/-) HCT116 CRC cells and found that bromodomain and extra-terminal motif (BET) inhibitors, as selective drugs for the growth of SMAD4(-/-) HCT116 cells. BET inhibition selectively induced G1 cell cycle arrest in SMAD4(-/-) cells and this effect was accompanied by the reprogramming of the MYC-p21 axis. Mechanistically, SMAD4 is a transcription repressor of MYC, and MYC in turn represses p21 transcription. SMAD4(-/-) cells lost MYC repression ability, thereby causing the cells addicted to the MYC oncogenic signaling. BET inhibition significantly reduced MYC level and restored p21 expression in SMAD4(-/-) cells, inducing the selective growth arrest. The ectopic overexpression of MYC or the silencing of p21 could rescue the BET inhibitor-induced growth arrest in SMAD4(-/-) cells, verifying this model. Tumor xenograft mouse experiments further demonstrated the synthetic lethality interaction between BET and SMAD4 in vivo. Taken together, our data suggest that BET could be a potential drug target for the treatment of SMAD4-deficient CRC.	[Shi, Changxiang; Yang, Eun Ju; Liu, Yifan; Mou, Pui Kei; Ren, Guowen; Shim, Joong Sup] Univ Macau, Fac Hlth Sci, Canc Ctr, Ave Univ, Taipa, Macau, Peoples R China	University of Macau	Shim, JS (corresponding author), Univ Macau, Fac Hlth Sci, Canc Ctr, Ave Univ, Taipa, Macau, Peoples R China.	jsshim@um.edu.mo	Shim, Joong Sup/G-8383-2011	Shim, Joong Sup/0000-0003-0167-7307	University of Macau [MYRG2019-00116-FHS, MYRG2017-00176-FHS]	University of Macau	We thank to the members of the FHS Animal Facility, Biological Imaging and Stem Cell Core, and Genomics, Bioinformatics and Single Cell Core at the University of Macau for experimental and technical supports. This study was supported by the Multi-Year Research Grants (MYRG2019-00116-FHS and MYRG2017-00176-FHS) to JSS from the University of Macau.	Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Alazzouzi H, 2005, CLIN CANCER RES, V11, P2606, DOI 10.1158/1078-0432.CCR-04-1458; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Alqahtani A, 2019, FUTUR SCI OA, V5, DOI 10.4155/fsoa-2018-0115; Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Choi PS, 2014, P NATL ACAD SCI USA, V111, pE3316, DOI 10.1073/pnas.1406123111; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dong XC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0181-6; Doroshow DB, 2017, ANN ONCOL, V28, P1776, DOI 10.1093/annonc/mdx157; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008-5472.CAN-12-2706; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Gadir N, 2008, ONCOGENE, V27, P1055, DOI 10.1038/sj.onc.1210721; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garcia-Gutierrez L, 2019, GENES-BASEL, V10, DOI 10.3390/genes10030244; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/expphysiol.2010.053793, 10.1113/jphysiol.2010.192278]; Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292; Li Y, 2014, J INTERN MED, V276, P52, DOI 10.1111/joim.12237; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Macias MJ, 2015, TRENDS BIOCHEM SCI, V40, P296, DOI 10.1016/j.tibs.2015.03.012; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269; Peterfia B, 2017, J CANCER, V8, P162, DOI 10.7150/jca.16037; Picaud S, 2013, CANCER RES, V73, P3336, DOI 10.1158/0008-5472.CAN-12-3292; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stathis A, 2018, CANCER DISCOV, V8, P24, DOI 10.1158/2159-8290.CD-17-0605; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Wang H, 2006, CANCER RES, V66, P9722, DOI 10.1158/0008-5472.CAN-05-4602; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yan P, 2016, CLIN CANCER RES, V22, P3037, DOI 10.1158/1078-0432.CCR-15-0939; Zhang BY, 2018, ONCOGENE, V37, P6341, DOI 10.1038/s41388-018-0408-8	61	8	8	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					937	950		10.1038/s41388-020-01580-w	http://dx.doi.org/10.1038/s41388-020-01580-w		DEC 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33293694				2022-12-28	WOS:000599053400001
J	Noh, K; Bach, DH; Choi, HJ; Kim, MS; Wu, SY; Pradeep, S; Ivan, C; Cho, MS; Bayraktar, E; Rodriguez-Aguayo, C; Dasari, SK; Stur, E; Mangala, LS; Lopez-Berestein, G; Sood, AK				Noh, Kyunghee; Duc-Hiep Bach; Choi, Hyun-Jin; Kim, Mark S.; Wu, Sherry Y.; Pradeep, Sunila; Ivan, Cristina; Cho, Min-Soon; Bayraktar, Emine; Rodriguez-Aguayo, Cristian; Dasari, Santosh K.; Stur, Elaine; Mangala, Lingegowda S.; Lopez-Berestein, Gabriel; Sood, Anil K.			The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis	ONCOGENE			English	Article							OVARIAN-CANCER METASTASIS; PLASMINOGEN-ACTIVATOR; SRC KINASES; KAPPA-B; EXPRESSION; PHOSPHORYLATION; PROTECTS; CELLS; FAK	Paxillin (PXN), a key component of the focal adhesion complex, has been associated with cancer progression, but the underlying mechanisms are poorly understood. The purpose of this study was to elucidate mechanisms by which PXN affects cancer growth and progression, which we addressed using cancer patient data, cell lines, and orthotopic mouse models. We demonstrated a previously unrecognized mechanism whereby nuclear PXN enhances angiogenesis by transcriptionally regulating SRC expression. SRC, in turn, increases PLAT expression through NF-kappa B activation; PLAT promotes angiogenesis via LRP1 in endothelial cells. PXN silencing in ovarian cancer mouse models reduced angiogenesis, tumor growth, and metastasis. These findings provide a new understanding of the role of PXN in regulating tumor angiogenesis and growth.	[Noh, Kyunghee; Duc-Hiep Bach; Choi, Hyun-Jin; Kim, Mark S.; Wu, Sherry Y.; Pradeep, Sunila; Bayraktar, Emine; Dasari, Santosh K.; Stur, Elaine; Mangala, Lingegowda S.; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Noh, Kyunghee] Korea Res Inst Biosci & Biotechnol, 125 Gwahak Ro, Daejeon, South Korea; [Choi, Hyun-Jin] Chung Ang Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea; [Ivan, Cristina; Rodriguez-Aguayo, Cristian; Mangala, Lingegowda S.; Lopez-Berestein, Gabriel; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Houston, TX 77030 USA; [Ivan, Cristina; Rodriguez-Aguayo, Cristian; Lopez-Berestein, Gabriel] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Cho, Min-Soon] Univ Texas MD Anderson Canc Ctr, Dept Benign Hematol, Houston, TX 77030 USA; [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chung Ang University; Chung Ang University Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA.; Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Houston, TX 77030 USA.; Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.	asood@mdanderson.org	dasari, santosh kumar/V-3867-2019; Bach, Duc-Hiep/V-5276-2017; Sood, Anoop Kumar/A-7344-2013	dasari, santosh kumar/0000-0003-3078-3424; Bach, Duc-Hiep/0000-0002-9826-3137; Sood, Anoop Kumar/0000-0001-5702-4108; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723; Bayraktar, Emine/0000-0002-5189-1507; Ivan, Cristina/0000-0002-4848-0168	National Institutes of Health [P30 CA016672, P50 CA217685, P50 CA098258, R35 CA209904]; Frank McGraw Memorial Chair in Cancer Research; Ovarian Cancer Research Fund Alliance (OCRFA); Ovarian Cancer Research Alliance (OCRA) [FP00006137]; KRIBB Research Initiative Program; Blanton-Davis Ovarian Cancer Research Program; American Cancer Society Research Professor Award; Judy's Mission	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Frank McGraw Memorial Chair in Cancer Research; Ovarian Cancer Research Fund Alliance (OCRFA); Ovarian Cancer Research Alliance (OCRA); KRIBB Research Initiative Program; Blanton-Davis Ovarian Cancer Research Program; American Cancer Society Research Professor Award(American Cancer Society); Judy's Mission	Portions of this work were supported by the National Institutes of Health (P30 CA016672, P50 CA217685, P50 CA098258, and R35 CA209904), the Blanton-Davis Ovarian Cancer Research Program, American Cancer Society Research Professor Award, Judy's Mission, and the Frank McGraw Memorial Chair in Cancer Research. SP is supported by the Ovarian Cancer Research Fund Alliance (OCRFA). ES is supported by Ovarian Cancer Research Alliance (OCRA number FP00006137). KHN is supported by the KRIBB Research Initiative Program. We thank Dr. Bryan F. Tutt (Department of Scientific Publications) and Nicholas B. Jennings for kindly reviewing this manuscript.	Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Byers LA, 2009, CLIN CANCER RES, V15, P6852, DOI 10.1158/1078-0432.CCR-09-0767; Chen DL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-277; Deakin Nicholas O, 2012, Genes Cancer, V3, P362, DOI 10.1177/1947601912458582; Diaz VM, 2002, GASTROENTEROLOGY, V122, P806, DOI 10.1053/gast.2002.31885; Dong JM, 2009, BIOCHEM J, V418, P173, DOI 10.1042/BJ20080170; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hou XY, 2007, NEUROSCI LETT, V420, P235, DOI 10.1016/j.neulet.2007.03.048; Hu KB, 2008, J AM SOC NEPHROL, V19, P503, DOI 10.1681/ASN.2007030300; Hu W, 2014, CANCER RES, V74, P3282, DOI 10.1158/0008-5472.CAN-13-2066; Ip CKM, 2014, ONCOTARGET, V5, P9133; Kenny HA, 2014, J CLIN INVEST, V124, P4614, DOI 10.1172/JCI74778; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kratimenos P, 2017, PEDIATR HEMAT ONCOL, V34, P221, DOI 10.1080/08880018.2017.1360969; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Li BZ, 2008, J INT MED RES, V36, P273, DOI 10.1177/147323000803600209; Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515; Mackinnon AC, 2011, J CLIN PATHOL, V64, P16, DOI 10.1136/jcp.2010.075853; Lopez-Colome AM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0418-y; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Noh KH, 2020, METABOLISM, V110, DOI 10.1016/j.metabol.2020.154302; Ohki M, 2010, BLOOD, V115, P4302, DOI 10.1182/blood-2009-08-236851; Panetti TS, 2002, FRONT BIOSCI-LANDMRK, V7, pD143, DOI 10.2741/panetti; Phung CD, 2020, J CONTROL RELEASE, V324, P413, DOI 10.1016/j.jconrel.2020.05.029; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Rupaimoole R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6202; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Sen A, 2012, J CLIN INVEST, V122, P2469, DOI 10.1172/JCI62044; Shi JN, 2010, J ORAL PATHOL MED, V39, P548, DOI 10.1111/j.1600-0714.2009.00859.x; Ulfhammer E, 2006, J THROMB HAEMOST, V4, P1781, DOI 10.1111/j.1538-7836.2006.02035.x; Wu SY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11169; Zhou J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1265-1	34	11	11	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					384	395		10.1038/s41388-020-01517-3	http://dx.doi.org/10.1038/s41388-020-01517-3		NOV 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33149280	Green Accepted			2022-12-28	WOS:000585762500001
J	Tumbrink, HL; Heimsoeth, A; Sos, ML				Tumbrink, Hannah L.; Heimsoeth, Alena; Sos, Martin L.			The next tier of EGFR resistance mutations in lung cancer	ONCOGENE			English	Review							ACQUIRED-RESISTANCE; ONCOGENIC MUTATIONS; G724S MUTATION; L718Q MUTATION; NSCLC PATIENT; OSIMERTINIB; T790M; INHIBITOR; MECHANISM; AZD9291	EGFRmutations account for the majority of druggable targets in lung adenocarcinoma. Over the past decades the optimization of EGFR inhibitors revolutionized the treatment options for patients suffering from this disease. The pace of this development was largely dictated by the inevitable emergence of resistance mutations during drug treatment. As a result, a rapid understanding of the structural and molecular biology of the individual mutations is the key for the development of next-generation inhibitors. Currently, the field faces an unprecedented number of combinations of activating mutations with distinct resistance mutations in parallel to the approval of osimertinib as a first-line drug forEGFR-mutant lung cancer. In this review, we present a survey of the diverse landscape of EGFR resistance mechanisms with a focus on new insights into on-targetEGFRkinase mutations. We discuss array of mutations, their structural effects on the EGFR kinase domain as well as the most promising strategies to overcome the individual resistance profiles found in lung cancer patients.	[Tumbrink, Hannah L.; Heimsoeth, Alena; Sos, Martin L.] Univ Hosp Cologne, Inst Pathol, Mol Pathol, D-50937 Cologne, Germany; [Tumbrink, Hannah L.; Heimsoeth, Alena; Sos, Martin L.] Univ Cologne, Fac Med, Dept Translat Genom, Ctr Integrated Oncol Cologne Bonn, D-50931 Cologne, Germany; [Tumbrink, Hannah L.; Heimsoeth, Alena; Sos, Martin L.] Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany	University of Cologne; University of Cologne; University of Cologne	Sos, ML (corresponding author), Univ Hosp Cologne, Inst Pathol, Mol Pathol, D-50937 Cologne, Germany.; Sos, ML (corresponding author), Univ Cologne, Fac Med, Dept Translat Genom, Ctr Integrated Oncol Cologne Bonn, D-50931 Cologne, Germany.; Sos, ML (corresponding author), Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany.	martin.sos@uni-koeln.de	Sos, Martin L/I-1852-2014		Bundesministerium fur Bildung und Forschung (e:Med initative) [01ZX1901A]; Thyssen Foundation [10.19.2.025MN]; German Research Foundation (DFG) within the collaborative research center 1399; Deutsche Krebshilfe [70112888]	Bundesministerium fur Bildung und Forschung (e:Med initative)(Federal Ministry of Education & Research (BMBF)); Thyssen Foundation; German Research Foundation (DFG) within the collaborative research center 1399(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank all members of the Sos Lab for fruitful comments, especially Johannes Bragelmann and Katia Garbert. This work was supported by the Bundesministerium fur Bildung und Forschung (e:Med initative; 01ZX1901A), a research grant by the Thyssen Foundation (10.19.2.025MN), the German Research Foundation (DFG) within the collaborative research center 1399 and the Deutsche Krebshilfe (70112888).	Arulananda S, 2017, J THORAC ONCOL, V12, P1728, DOI 10.1016/j.jtho.2017.08.006; Banno E, 2016, CANCER SCI, V107, P1134, DOI 10.1111/cas.12980; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bennouna J, 2020, CLIN LUNG CANCER, V21, pE10, DOI 10.1016/j.cllc.2019.09.007; Bersanelli M, 2016, J THORAC ONCOL, V11, pE121, DOI 10.1016/j.jtho.2016.05.019; Brown BP, 2019, CLIN CANCER RES, V25, P3341, DOI 10.1158/1078-0432.CCR-18-3829; Callegari D, 2018, CHEM SCI, V9, P2740, DOI 10.1039/c7sc04761d; Chen Kai, 2017, J Thorac Oncol, V12, pe65, DOI 10.1016/j.jtho.2016.12.024; Chen YF, 2017, EUR J MED CHEM, V139, P674, DOI 10.1016/j.ejmech.2017.08.035; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Engelhardt H, 2019, J MED CHEM, V62, P10272, DOI 10.1021/acs.jmedchem.9b01169; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; Ercan D, 2015, CLIN CANCER RES, V21, P3913, DOI 10.1158/1078-0432.CCR-14-2789; Fairclough SR, 2019, EXP HEMATOL ONCOL, V8, DOI 10.1186/s40164-019-0148-7; Fang WF, 2020, J THORAC ONCOL, V15, pE36, DOI 10.1016/j.jtho.2019.09.198; Fassunke J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07078-0; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Guibert N, 2018, ANN ONCOL, V29, P1049, DOI 10.1093/annonc/mdy005; Ho CC, 2017, J THORAC ONCOL, V12, P567, DOI 10.1016/j.jtho.2016.11.2231; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Jia Y, 2016, NATURE, V534, P129, DOI 10.1038/nature17960; Klempner SJ, 2017, LUNG CANCER-TARGETS, V8, P241, DOI 10.2147/LCTT.S147129; Kobayashi Y, 2017, MOL CANCER THER, V16, P357, DOI 10.1158/1535-7163.MCT-16-0407; Lee J, 2020, CANCER-AM CANCER SOC, V126, P2704, DOI 10.1002/cncr.32809; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Leventakos K, 2016, J THORAC ONCOL, V11, P1798, DOI 10.1016/j.jtho.2016.05.007; Liu B, 2006, PROTEINS, V65, P331, DOI 10.1002/prot.21111; Liu YT, 2018, LUNG CANCER, V118, P1, DOI 10.1016/j.lungcan.2018.01.015; Ma L, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.04.37; Mehlman C, 2019, LUNG CANCER, V137, P149, DOI 10.1016/j.lungcan.2019.09.019; Minari R, 2020, CLIN LUNG CANCER, V21, P30072; Niederst MJ, 2015, CLIN CANCER RES, V21, P3924, DOI 10.1158/1078-0432.CCR-15-0560; Nishino M, 2018, LUNG CANCER, V126, P149, DOI 10.1016/j.lungcan.2018.10.026; Offin M, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.18.00126; Ortiz-Cuaran S, 2016, CLIN CANCER RES, V22, P4837, DOI 10.1158/1078-0432.CCR-15-1915; Ou SHI, 2017, LUNG CANCER, V108, P228, DOI 10.1016/j.lungcan.2017.04.003; Oxnard GR, 2018, JAMA ONCOL, V4, P1527, DOI 10.1001/jamaoncol.2018.2969; Oztan A, 2017, LUNG CANCER, V111, P84, DOI 10.1016/j.lungcan.2017.07.002; Peled Nir, 2017, J Thorac Oncol, V12, pe81, DOI 10.1016/j.jtho.2017.02.023; Piotrowska Z, 2018, CANCER DISCOV, V8, P1529, DOI 10.1158/2159-8290.CD-18-1022; Ramalingam SS, 2018, J CLIN ONCOL, V36, P841, DOI 10.1200/JCO.2017.74.7576; Roper N, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100007; Schoenfeld AJ, 2020, CLIN CANCER RES, V26, P2654, DOI [10.1158/10780432.CCR-19-3563, 10.1158/1078-0432.CCR-19-3563]; Sequist LV, 2015, NEW ENGL J MED, V373, P578, DOI 10.1056/NEJMc1506831; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shan YB, 2013, P NATL ACAD SCI USA, V110, P7270, DOI 10.1073/pnas.1220843110; Shan YB, 2012, CELL, V149, P860, DOI 10.1016/j.cell.2012.02.063; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055; Starrett JH, 2020, CANCER RES, V80, P2017, DOI 10.1158/0008-5472.CAN-19-3819; Sutto L, 2013, P NATL ACAD SCI USA, V110, P10616, DOI 10.1073/pnas.1221953110; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854; To C, 2019, CANCER DISCOV, V9, P926, DOI 10.1158/2159-8290.CD-18-0903; Uchibori K, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14768; Wagener-Ryczek S, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06920-3; Walter AO, 2013, CANCER DISCOV, V3, P1404, DOI 10.1158/2159-8290.CD-13-0314; Wang XF, 2019, J THORAC ONCOL, V14, pE85, DOI 10.1016/j.jtho.2019.01.015; Yang X, 2020, CLIN LUNG CANCER, V21, pE258, DOI 10.1016/j.cllc.2019.12.002; Yang Z, 2018, CLIN CANCER RES, V24, P3097, DOI 10.1158/1078-0432.CCR-17-2310; Zhai X, 2020, BIOCHEMISTRY-US, V59, P1428, DOI 10.1021/acs.biochem.0c00104; Zhang Q, 2018, J THORAC ONCOL, V13, P1415, DOI 10.1016/j.jtho.2018.05.024; Zhang Y, 2019, ONCOTARGETS THER, V12, P51, DOI 10.2147/OTT.S188612; Zhao ZR, 2019, ONCOLOGIST, V24, P1368, DOI 10.1634/theoncologist.2018-0567; Zheng D, 2017, ONCOTARGET, V8, P49671, DOI 10.18632/oncotarget.17913	65	41	43	3	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					1	11		10.1038/s41388-020-01510-w	http://dx.doi.org/10.1038/s41388-020-01510-w		OCT 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33060857				2022-12-28	WOS:000577946300001
J	Tiede, S; Kalathur, RKR; Luond, F; von Allmen, L; Szczerba, BM; Hess, M; Vlajnic, T; Muller, B; Murillo, JC; Aceto, N; Christofori, G				Tiede, Stefanie; Kalathur, Ravi Kiran Reddy; Luond, Fabiana; von Allmen, Luca; Szczerba, Barbara Maria; Hess, Mathias; Vlajnic, Tatjana; Mueller, Benjamin; Canales Murillo, James; Aceto, Nicola; Christofori, Gerhard			Multi-color clonal tracking reveals intra-stage proliferative heterogeneity during mammary tumor progression	ONCOGENE			English	Article							BREAST-CANCER; MUTATIONAL EVOLUTION; MOLECULAR PORTRAITS; MELANOMA-CELLS; KI67; EXPRESSION; SUBPOPULATION; STRATEGIES; DYNAMICS; MODEL	Despite major progress in breast cancer research, the functional contribution of distinct cancer cell clones to malignant tumor progression and metastasis remains largely elusive. We have assessed clonal heterogeneity within individual primary tumors and metastases and also during the distinct stages of malignant tumor progression using clonal tracking of cancer cells in the MMTV-PyMT mouse model of metastatic breast cancer. Comparative gene expression analysis of clonal subpopulations reveals a substantial level of heterogeneity across and also within the various stages of breast carcinogenesis. The intra-stage heterogeneity is primarily manifested by differences in cell proliferation, also found within invasive carcinomas of luminal A-, luminal B-, and HER2-enriched human breast cancer. Surprisingly, in the mouse model of clonal tracing of cancer cells, chemotherapy mainly targets the slow-proliferative clonal populations and fails to efficiently repress the fast-proliferative populations. These insights may have considerable impact on therapy selection and response in breast cancer patients.	[Tiede, Stefanie; Kalathur, Ravi Kiran Reddy; Luond, Fabiana; von Allmen, Luca; Szczerba, Barbara Maria; Hess, Mathias; Mueller, Benjamin; Canales Murillo, James; Aceto, Nicola; Christofori, Gerhard] Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland; [Kalathur, Ravi Kiran Reddy] Swiss Inst Bioinformat, CH-4053 Basel, Switzerland; [Vlajnic, Tatjana] Univ Hosp Basel, Inst Pathol, CH-4031 Basel, Switzerland	University of Basel; Swiss Institute of Bioinformatics; University of Basel	Tiede, S; Christofori, G (corresponding author), Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland.	stefanie.tiede@unibas.ch; Gerhard.christofori@unibas.ch			SystemsX.ch MTD project MetastasiX; Swiss National Science Foundation; Swiss Cancer League; Krebsliga Beider Basel	SystemsX.ch MTD project MetastasiX; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Krebsliga Beider Basel	This work was supported by the SystemsX.ch MTD project MetastasiX, the Swiss National Science Foundation, the Swiss Cancer League, and the Krebsliga Beider Basel.	Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; Cai Y, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3563-3; Casasent AK, 2018, CELL, V172, P205, DOI 10.1016/j.cell.2017.12.007; Chen J, 2017, NAT PROTOC, V12, P566, DOI 10.1038/nprot.2017.003; Chen K, 2015, MOL MED, V21, P792, DOI 10.2119/molmed.2015.00126; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Cserni G, 2014, BREAST, V23, P259, DOI 10.1016/j.breast.2014.02.003; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Denkert C, 2015, BREAST, V24, pS67, DOI 10.1016/j.breast.2015.07.017; Dowsett M, 2011, JNCI-J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; Eirew P, 2015, NATURE, V518, P422, DOI 10.1038/nature13952; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koren S, 2015, NATURE, V525, P114, DOI 10.1038/nature14669; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Livet J, 2007, NATURE, V450, P56, DOI 10.1038/nature06293; Macaulay IC, 2016, NAT PROTOC, V11, P36, DOI 10.1038/nprot.2016.138; Macaulay IC, 2015, NAT METHODS, V12, P519, DOI 10.1038/nmeth.3370; Maddipati R, 2015, CANCER DISCOV, V5, P1086, DOI 10.1158/2159-8290.CD-15-0120; Martinez RJ, 2015, J IMMUNOL METHODS, V424, P28, DOI 10.1016/j.jim.2015.04.018; Nguyen LV, 2015, NATURE, V528, P267, DOI 10.1038/nature15742; Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Perego M, 2018, ONCOGENE, V37, P302, DOI 10.1038/onc.2017.341; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Picelli S, 2013, NAT METHODS, V10, P1096, DOI [10.1038/nmeth.2639, 10.1038/NMETH.2639]; Reeves MQ, 2018, NAT CELL BIOL, V20, DOI 10.1038/s41556-018-0109-0; Rios AC, 2019, CANCER CELL, V35, P618, DOI 10.1016/j.ccell.2019.02.010; Rodriguez-Enriquez S, 2006, TOXICOL APPL PHARM, V215, P208, DOI 10.1016/j.taap.2006.02.005; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Szczerba BM, 2019, NATURE, V566, P553, DOI 10.1038/s41586-019-0915-y; Tabassum DP, 2015, NAT REV CANCER, V15, P473, DOI 10.1038/nrc3971; Tang YNJ, 2019, CELL REP, V28, P2837, DOI 10.1016/j.celrep.2019.08.029; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang Y, 2014, NATURE, V512, P155, DOI 10.1038/nature13600; Wu FH, 2017, ONCOTARGET, V8, P78466, DOI 10.18632/oncotarget.19638; Yao CH, 2019, ELIFE, V8, DOI 10.7554/eLife.41351; Yates LR, 2017, CANCER CELL, V32, P169, DOI 10.1016/j.ccell.2017.07.005; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Yerushalmi R, 2010, LANCET ONCOL, V11, P174, DOI 10.1016/S1470-2045(09)70262-1; Zomer A, 2013, STEM CELLS, V31, P602, DOI 10.1002/stem.1296	48	7	7	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					12	27		10.1038/s41388-020-01508-4	http://dx.doi.org/10.1038/s41388-020-01508-4		OCT 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33046799				2022-12-28	WOS:000578784100003
J	Kanumuri, R; Chelluboyina, AK; Biswal, J; Vignesh, R; Pandian, J; Venu, A; Vaishnavi, B; Leena, DJ; Jeyaraman, J; Ganesan, K; Aradhyam, GK; Venkatraman, G; Rayala, SK				Kanumuri, Rahul; Chelluboyina, Aruna Kumar; Biswal, Jayashree; Vignesh, Ravichandran; Pandian, Jaishree; Venu, Akkanapally; Vaishnavi, B.; Leena, D. J.; Jeyaraman, Jeyakanthan; Ganesan, Kumaresan; Aradhyam, Gopala Krishna; Venkatraman, Ganesh; Rayala, Suresh K.			Small peptide inhibitor from the sequence of RUNX3 disrupts PAK1-RUNX3 interaction and abrogates its phosphorylation-dependent oncogenic function	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; STRUCTURE PREDICTION; PEP-FOLD; PROTEIN; EXPRESSION; CELLS; APOPTOSIS; REVERSES; GROWTH; SERVER	P21 Activated Kinase 1 (PAK1) is an oncogenic serine/threonine kinase known to play a significant role in the regulation of cytoskeleton and cell morphology. Runt-related transcription factor 3 (RUNX3) was initially known for its tumor suppressor function, but recent studies have reported the oncogenic role of RUNX3 in various cancers. Previous findings from our laboratory provided evidence that Threonine 209 phosphorylation of RUNX3 acts as a molecular switch in dictating the tissue-specific dualistic functions of RUNX3 for the first time. Based on these proofs and to explore the translational significance of these findings, we designed a small peptide (RMR) from the protein sequence of RUNX3 flanking the Threonine 209 phosphorylation site. The selection of this specific peptide from multiple possible peptides was based on their binding energies, hydrogen bonding, docking efficiency with the active site of PAK1 and their ability to displace PAK1-RUNX3 interaction in our prediction models. We found that this peptide is stable both in in vitro and in vivo conditions, not toxic to normal cells and inhibits the Threonine 209 phosphorylation in RUNX3 by PAK1. We also tested the efficacy of this peptide to block the RUNX3 Threonine 209 phosphorylation mediated tumorigenic functions in in vitro cell culture models, patient-derived explant (PDE) models and in in vivo tumor xenograft models. These results proved that this peptide has the potential to be developed as an efficient therapeutic molecule for targeting RUNX3 Threonine 209 phosphorylation-dependent tumor phenotypes.	[Kanumuri, Rahul; Chelluboyina, Aruna Kumar; Vignesh, Ravichandran; Aradhyam, Gopala Krishna; Rayala, Suresh K.] Indian Inst Technol Madras IITM, Dept Biotechnol, Chennai, Tamil Nadu, India; [Kanumuri, Rahul; Venu, Akkanapally; Vaishnavi, B.; Venkatraman, Ganesh] Sri Ramachandra Inst Higher Educ & Res Deemed Uni, Dept Human Genet, Sri Ramachandra Fac Biomed Sci & Technol, Chennai, Tamil Nadu, India; [Biswal, Jayashree; Jeyaraman, Jeyakanthan] Alagappa Univ, Dept Bioinformat, Struct Biol & Biocomp Lab, Sci Block, Karaikkudi, Tamil Nadu, India; [Pandian, Jaishree; Ganesan, Kumaresan] Madurai Kamaraj Univ, Unit Excellence Canc Genet, Dept Genet, Ctr Excellence Genom Sci,Sch Biol Sci, Madurai, Tamil Nadu, India; [Leena, D. J.] Sri Ramachandra Inst Higher Educ & Res Deemed Uni, Dept Pathol, Chennai, Tamil Nadu, India; [Chelluboyina, Aruna Kumar] Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Case Comprehens Canc Ctr, Cleveland, OH USA	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Madras; Sri Ramachandra Institute of Higher Education & Research; Alagappa University; Madurai Kamaraj University; Sri Ramachandra Institute of Higher Education & Research; Case Western Reserve University	Rayala, SK (corresponding author), Indian Inst Technol Madras IITM, Dept Biotechnol, Chennai, Tamil Nadu, India.; Venkatraman, G (corresponding author), Sri Ramachandra Inst Higher Educ & Res Deemed Uni, Dept Human Genet, Sri Ramachandra Fac Biomed Sci & Technol, Chennai, Tamil Nadu, India.	ganeshv@sriramachandra.edu.in; rayala@iitm.ac.in	CHELLUBOYINA, ARUNA KUMAR/GZL-7536-2022; Kanumuri, Rahul Sankrityayan/AGF-8012-2022; CHELLUBOYINA, ARUNA KUMAR/GXG-8165-2022	CHELLUBOYINA, ARUNA KUMAR/0000-0001-7201-3810; Kanumuri, Rahul Sankrityayan/0000-0001-6039-461X; CHELLUBOYINA, ARUNA KUMAR/0000-0001-7201-3810; , Ravichandran Vignesh/0000-0001-7024-6717	DAE-BRNS [35/14/41/2014-BRNS/2045]; DBT Government of India [BT/PR14340/NNT/28/860/2015]; DST-INDO TAIWAN [GITA/DST/TWN/P-86/2019]; Board of Research in Nuclear Sciences (BRNS) [35/14/02/2018 BRNS/35009]; DST-Fund for Improvement of S&T Infrastructure in Universities & Higher Educational Institutions (FIST) [SR/FST/LSI-667/2016]; DST-Promotion of University Research and Scientific Excellence (PURSE) [SR/PURSE Phase 2/38 (G)]; UGC OBC National Fellowship [F./2015-16/NFO-2015-17-OBC-PON-29027]	DAE-BRNS(Department of Atomic Energy (DAE)Board of Research in Nuclear Sciences (BRNS)); DBT Government of India(Department of Biotechnology (DBT) India); DST-INDO TAIWAN; Board of Research in Nuclear Sciences (BRNS)(Department of Atomic Energy (DAE)Board of Research in Nuclear Sciences (BRNS)); DST-Fund for Improvement of S&T Infrastructure in Universities & Higher Educational Institutions (FIST); DST-Promotion of University Research and Scientific Excellence (PURSE); UGC OBC National Fellowship	The authors thank Dr. Sanjay kumar and Franklin, Department of Biotechnology, Christian Medical College, Vellore, India for helping in peptide uptake studies using animal imaging. We thank Dr. Vidhyarani Shyamsunder, Balaji Dental College, India for the help in establishing Head & Neck PDE model. We thank Bamdeb Patra, Khwajah Mohinudeen, Dr. Ram Prasad, and Srikanth Swamy Swaroop, Indian Institute of Technology-Madras, India for helping in Flow-cytometry experiments, Mass spectrometry experiment, Serum stability assay and for protein expression study, respectively. We thank Dr. Yogesh and Anand, Centre for Toxicology and Developmental Research (CEFT), Sri Ramachandra Institute of Higher Education and Research, India for animal studies. We thank DAE-BRNS (35/14/41/2014-BRNS/2045), DBT (BT/PR14340/NNT/28/860/2015) Government of India for financial support to SKR and the Department of Biotechnology, Indian Institute of Technology Madras (IITM) for infrastructural facilities. JJ thank the DST-INDO TAIWAN (GITA/DST/TWN/P-86/2019 dated: 04.03.2020), Board of Research in Nuclear Sciences (BRNS) (35/14/02/2018 BRNS/35009), DST-Fund for Improvement of S&T Infrastructure in Universities & Higher Educational Institutions (FIST) (SR/FST/LSI-667/2016) (C), DST-Promotion of University Research and Scientific Excellence (PURSE) (No. SR/PURSE Phase 2/38 (G), 2017 and JB is grateful to the UGC OBC National Fellowship (F./2015-16/NFO-2015-17-OBC-PON-29027).	Aljohani AI, 2020, BREAST CANCER RES TR, V181, P541, DOI 10.1007/s10549-020-05646-x; Alqaeisoom N, 2019, INT J PEPT RES THER, V25, P447, DOI 10.1007/s10989-018-9689-6; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049; Beard H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082849; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bird GH, 2010, P NATL ACAD SCI USA, V107, P14093, DOI 10.1073/pnas.1002713107; Cao LQ, 2019, MOL MED REP, V19, P5097, DOI 10.3892/mmr.2019.10212; Chen FF, 2016, ONCOL REP, V35, P1227, DOI 10.3892/or.2015.4515; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; Coto-Llerena M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00979; Damdinsuren A, 2015, LEUKEMIA RES, V39, P1405, DOI 10.1016/j.leukres.2015.09.009; Solano-Iturri JD, 2020, AGING-US, V12, P10337, DOI 10.18632/aging.103261; Date Y, 2020, MOL CELLS, V43, P176, DOI 10.14348/molcells.2019.0285; DelGiorno KE, 2016, CELL, V25, P289; Deng WM, 2012, ANGIOGENESIS, V15, P71, DOI 10.1007/s10456-011-9244-y; Douchi D, 2015, CANCER LETT, V365, P132, DOI 10.1016/j.canlet.2015.05.023; Eldar-Finkelman H, 2009, CURR PHARM DESIGN, V15, P2463, DOI 10.2174/138161209788682253; Gao L, 2016, ONCOTARGET, V7, P87037, DOI 10.18632/oncotarget.13523; George A, 2010, CANCER BIOMARK, V7, P275, DOI 10.3233/CBM-2010-0191; Goh YM, 2010, J BIOL CHEM, V285, P10122, DOI 10.1074/jbc.M109.071381; He WG, 2007, MOL IMMUNOL, V44, P2850, DOI 10.1016/j.molimm.2007.01.022; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Hu K, 2019, SCI REPORTS, V9, P1, DOI DOI 10.1038/s41598-018-37186-2; Jagadeeshan S, 2016, ANN ONCOL, V27, P1546, DOI 10.1093/annonc/mdw184; Jiang Z, 2010, MOL BIOL REP, V37, P3029, DOI 10.1007/s11033-009-9873-z; Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468; Kim J, 2008, BONE, V23, P1; Kudo Y, 2011, J CELL BIOCHEM, V112, P387, DOI 10.1002/jcb.22967; Kumar A, 2016, ONCOGENE, V35, P4857, DOI 10.1038/onc.2016.18; Kumar Arun, 2019, Small GTPases, V10, P264, DOI 10.1080/21541248.2017.1322667; Lee ACL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102383; Lee CWL, 2011, GYNECOL ONCOL, V122, P410, DOI 10.1016/j.ygyno.2011.04.044; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Lim KJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066084; Manandhar S, 2018, BMB REP, V51, P174, DOI 10.5483/BMBRep.2018.51.4.033; Mendes O, 2005, CLIN EXP METASTAS, V22, P237, DOI 10.1007/s10585-005-8115-6; Mevel R, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.148296; Moreira IS, 2007, J COMPUT CHEM, V28, P644, DOI 10.1002/jcc.20566; Otvos L, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00062; Pan JY, 2020, CANCER MED-US, V9, P3829, DOI 10.1002/cam4.2898; Powley IR, 2020, BRIT J CANCER, V122, P735, DOI 10.1038/s41416-019-0672-6; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Raines RT, 2015, METHODS MOL BIOL, V1278, P323, DOI 10.1007/978-1-4939-2425-7_19; Raj GV, 2017, ELIFE, V6, DOI 10.7554/eLife.26857; Saboia TM, 2015, ARCH ORAL BIOL, V60, P223, DOI 10.1016/j.archoralbio.2014.10.002; Salto-Tellez M, 2006, ONCOGENE, V25, P7646, DOI 10.1038/sj.onc.1209739; Sauter W, 2008, CANCER EPIDEM BIOMAR, V17, P1127, DOI 10.1158/1055-9965.EPI-07-2840; Selvarajan V, 2017, LEUKEMIA, V31, P2219, DOI 10.1038/leu.2017.40; Shen YM, 2014, J CHEM THEORY COMPUT, V10, P4745, DOI 10.1021/ct500592m; Soria G, 2008, CANCER LETT, V267, P271, DOI 10.1016/j.canlet.2008.03.018; Sung HJ, 2011, J PROTEOME RES, V10, P1383, DOI 10.1021/pr101154j; Takehara M, 2020, CANCER SCI, V111, P2883, DOI 10.1111/cas.14527; Tanaka S, 2012, INT J CANCER, V131, P2537, DOI 10.1002/ijc.27575; Thangaretnam KP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07482-4; Thevenet P, 2012, NUCLEIC ACIDS RES, V40, pW288, DOI 10.1093/nar/gks419; Tsunematsu T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005892; van Wijnen AJ, 2008, BONE, V23, P1; van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014; Voon DCC, 2012, STEM CELLS, V30, P2088, DOI 10.1002/stem.1183; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Zagani R, 2015, ONCOTARGET, V6, P28282, DOI 10.18632/oncotarget.5061; Zhang XL, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0029084, 10.1371/journal.pone.0031868]; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40	66	1	1	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5327	5341		10.1038/s41388-021-01927-x	http://dx.doi.org/10.1038/s41388-021-01927-x		JUL 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34253860				2022-12-28	WOS:000672308900001
J	Fares, B; Berger, L; Bangiev-Girsh, E; Kakun, RR; Ghannam-Shahbari, D; Tabach, Y; Zohar, Y; Gottlieb, E; Perets, R				Fares, Basem; Berger, Liron; Bangiev-Girsh, Einav; Kakun, Reli Rachel; Ghannam-Shahbari, Dima; Tabach, Yuval; Zohar, Yaniv; Gottlieb, Eyal; Perets, Ruth			PAX8 plays an essential antiapoptotic role in uterine serous papillary cancer	ONCOGENE			English	Article							ENDOMETRIAL CANCER; INTRAEPITHELIAL CARCINOMA; HISTONE MODIFICATIONS; OVARIAN-CANCER; P53; EXPRESSION; PATHOGENESIS; INHIBITION; BINDING; PHOSPHORYLATION	Endometrial carcinoma (EC) is the fourth-most common cancer in women in the United States, and generally carries a favorable prognosis. However, about 10% of EC patients have a rare and aggressive form, uterine serous papillary carcinoma (USPC), which carries a much higher mortality rate. The developmental transcription factor PAX8 is expressed in nearly 100% of USPCs. We show that PAX8 plays a critical antiapoptotic role in USPC and this role is established via transcriptional activation of two aberrant signaling pathways. First, PAX8 positively regulates mutated p53, and missense p53 mutations have an oncogenic gain of function effect. Second, PAX8 directly transcriptionally regulates p21, in a p53-independent manner, and p21 acquires a growth promoting role that is mediated via cytoplasmic localization of the protein. We propose that mutated p53 and cytoplasmic p21 can independently mediate the pro-proliferative role of PAX8 in USPC. In addition, we performed a genome-wide transcriptome analysis to detect pathways that are regulated by PAX8, and propose that metabolism and HIF-1alpha -related pathways are potential candidates for mediating the role of PAX8 in USPC. Taken together our findings demonstrate for the first time that PAX8 is an essential lineage marker in USPC, and suggest its mechanism of action.	[Fares, Basem; Bangiev-Girsh, Einav; Kakun, Reli Rachel; Ghannam-Shahbari, Dima; Gottlieb, Eyal; Perets, Ruth] Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Haifa, Israel; [Fares, Basem; Berger, Liron; Bangiev-Girsh, Einav; Kakun, Reli Rachel; Ghannam-Shahbari, Dima; Perets, Ruth] Clin Res Inst Rambam CRIR, Div Oncol, Rambam Hlth Care Campus, Haifa, Israel; [Tabach, Yuval] Hebrew Univ Jerusalem, Fac Med, Inst Med Res Israel Canada IMRIC, Dept Dev Biol & Canc Res, Jerusalem, Israel; [Zohar, Yaniv] Technion Israel Inst Technol, Dept Pathol, Rambam Hlth Care Campus, Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Hebrew University of Jerusalem; Rambam Health Care Campus; Technion Israel Institute of Technology	Perets, R (corresponding author), Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Haifa, Israel.; Perets, R (corresponding author), Clin Res Inst Rambam CRIR, Div Oncol, Rambam Hlth Care Campus, Haifa, Israel.	Ru_Perets@RMC.gov.il	Gottlieb, Eyal/G-6450-2010	Gottlieb, Eyal/0000-0002-9770-0956; Perets, Ruth/0000-0001-7216-6577	Israel Science Foundation [1990/18]; Israel Cancer Research Fund's Len and Susan Mark Initiative for Ovarian and Uterine/MMMT Cancers; Israel Cancer Association's ICA USA Board of Directors; EU's Marie Curie Actions (FP7 People) program; Women's Health Fund at the Rambam Health Care Campus	Israel Science Foundation(Israel Science Foundation); Israel Cancer Research Fund's Len and Susan Mark Initiative for Ovarian and Uterine/MMMT Cancers; Israel Cancer Association's ICA USA Board of Directors; EU's Marie Curie Actions (FP7 People) program; Women's Health Fund at the Rambam Health Care Campus	RP is supported by grants from the Israel Science Foundation (1990/18), the Israel Cancer Research Fund's Len and Susan Mark Initiative for Ovarian and Uterine/MMMT Cancers, the Israel Cancer Association's ICA USA Board of Directors, the EU's Marie Curie Actions (FP7 People) program, and the Women's Health Fund at the Rambam Health Care Campus.	Adler EK, 2017, ONCOTARGET, V8, P108316, DOI 10.18632/oncotarget.22718; AMBROS RA, 1995, HUM PATHOL, V26, P1260, DOI 10.1016/0046-8177(95)90203-1; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Attias-Geva Z, 2012, EUR J CANCER, V48, P1570, DOI 10.1016/j.ejca.2011.09.014; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Ben-Ari Fuchs S, 2016, OMICS, V20, P139, DOI 10.1089/omi.2015.0168; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bleu M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11672-1; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Bouaoun L, 2016, HUM MUTAT, V37, P865, DOI 10.1002/humu.23035; Bowen NJ, 2007, GYNECOL ONCOL, V104, P331, DOI 10.1016/j.ygyno.2006.08.052; Brinton LA, 2013, GYNECOL ONCOL, V129, P277, DOI 10.1016/j.ygyno.2013.02.023; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cheng Y, 2014, MOL CANCER THER, V13, P675, DOI 10.1158/1535-7163.MCT-13-0416; de Cristofaro T, 2016, ONCOTARGET, V7, P41929, DOI 10.18632/oncotarget.9740; de Jonge MM, 2019, CLIN CANCER RES, V25, P7517, DOI 10.1158/1078-0432.CCR-19-0848; de Renty C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097434; di Magliano MP, 2000, P NATL ACAD SCI USA, V97, P13144; Di Palma T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-292; Dong PX, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-103; Elias KM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87988; Fadare O, 2012, AM J CANCER RES, V2, P335; Fader AN, 2010, CURR OPIN OBSTET GYN, V22, P21, DOI 10.1097/GCO.0b013e328334d8a3; Fu DJ, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.047035; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Ghannam-Shahbari D, 2018, ONCOGENE, V37, P2213, DOI 10.1038/s41388-017-0040-z; Goldman NA, 2006, MODERN PATHOL, V19, P1429, DOI 10.1038/modpathol.3800656; Gravina GL, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0085-1; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hardy LR, 2019, ONCOGENE, V38, P6003, DOI 10.1038/s41388-019-0842-2; Huang YF, 2014, J GASTROENTEROL, V49, P1441, DOI 10.1007/s00535-013-0900-4; Kotler E, 2018, MOL CELL, V71, P178, DOI 10.1016/j.molcel.2018.06.012; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Krzeslak A, 2012, PATHOL ONCOL RES, V18, P721, DOI 10.1007/s12253-012-9500-5; Kurman RJ, 2013, GYNECOL ONCOL, V129, P271, DOI 10.1016/j.ygyno.2013.03.029; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Laury AR, 2010, AM J SURG PATHOL, V34, P627, DOI 10.1097/PAS.0b013e3181da7687; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Lee Y, 2006, ADV ANAT PATHOL, V13, P1, DOI 10.1097/01.pap.0000201826.46978.e5; Lin X, 2012, PLANT METHODS, V8, DOI 10.1186/1746-4811-8-48; Lotan TL, 2009, AM J SURG PATHOL, V33, P1037, DOI 10.1097/PAS.0b013e3181962dcd; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Martinez JD, 1998, ONCOGENE, V16, P453, DOI 10.1038/sj.onc.1201565; Mayelzadeh F, 2007, ONCOGENE, V26, P2955, DOI 10.1038/sj.onc.1210110; Mittag J, 2007, ENDOCRINOLOGY, V148, P719, DOI 10.1210/en.2006-1054; Narlis M, 2007, J AM SOC NEPHROL, V18, P1121, DOI 10.1681/ASN.2006070739; Nonaka D, 2008, MODERN PATHOL, V21, P192, DOI 10.1038/modpathol.3801002; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Pennington KP, 2013, CANCER-AM CANCER SOC, V119, P332, DOI 10.1002/cncr.27720; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Rodriguez-Vilarrupla A, 2005, MOL CELL BIOL, V25, P7364, DOI 10.1128/MCB.25.16.7364-7374.2005; Santin AD, 2002, CLIN CANCER RES, V8, P1271; Sarfstein R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061537; Saule Claire, 2018, J Natl Cancer Inst, V110, DOI 10.1093/jnci/djx159; SHERMAN ME, 1995, HUM PATHOL, V26, P1268, DOI 10.1016/0046-8177(95)90204-X; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; SPIEGEL GW, 1995, AM J SURG PATHOL, V19, P417, DOI 10.1097/00000478-199504000-00003; Suarez AA, 2017, GYNECOL ONCOL, V144, P243, DOI 10.1016/j.ygyno.2016.12.010; Sun H, 2014, BRIT J CANCER, V111, P281, DOI 10.1038/bjc.2014.260; Tolcher MC, 2015, INT J GYNECOL PATHOL, V34, P57, DOI 10.1097/PGP.0000000000000109; Vergote IB, 2020, GYNECOL ONCOL, V156, P308, DOI 10.1016/j.ygyno.2019.11.012; Wettersten HI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113867; Winterhoff B, 2020, CURR OPIN OBSTET GYN, V32, P76, DOI 10.1097/GCO.0000000000000602; Zheng WX, 2005, GYNECOL ONCOL, V96, P579, DOI 10.1016/j.ygyno.2004.12.045; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	67	3	3	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5275	5285		10.1038/s41388-021-01925-z	http://dx.doi.org/10.1038/s41388-021-01925-z		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34244607				2022-12-28	WOS:000672114100001
J	Qiu, YF; Yang, Y; Yang, RY; Liu, CX; Hsu, JM; Jiang, Z; Sun, LL; Wei, YK; Li, CW; Yu, DH; Zhang, J; Hung, MC				Qiu, Yufan; Yang, Yi; Yang, Riyao; Liu, Chunxiao; Hsu, Jung-Mao; Jiang, Zhou; Sun, Linlin; Wei, Yongkun; Li, Chia-Wei; Yu, Dihua; Zhang, Jin; Hung, Mien-Chie			Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer	ONCOGENE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; EXTRACELLULAR VESICLES; EXPRESSION; BIOLOGY	Programmed cell death 1 (PD-1) is widely expressed in tumor-infiltrating lymphocytes (TILs) of triple-negative breast cancer (TNBC). As a dominant inhibitory immune checkpoint (ICP) receptor, cell surface PD-1 is well-known to transduce negative signaling of effector T cell activity during cell-cell contact. However, despite its well-documented inhibitory effects, higher PD-1 expression in TILs is significantly associated with longer survival in TNBC patients. This phenomenon raises an interesting question whether PD-1 harbors positive activity to enhance anti-tumor immunity. Here, we show that PD-1 is secreted in an exosomal form by activated T cells and can remotely interact with either cell surface or exosomal programmed death-ligand 1 (PD-L1), induce PD-L1 internalization via clathrin-mediated endocytosis, and thereby prevent subsequent cellular PD-L1: PD-1 interaction, restoring tumor surveillance through attenuating PD-L1-induced suppression of tumor-specific cytotoxic T cell activity. Our results, through revealing an anti-PD-L1 function of exosomal PD-1, provide a positive role to enhance cytotoxic T cell activity and a potential therapeutic strategy of modifying the exosome surface with membrane-bound inhibitory ICP receptors to attenuate the suppressive tumor immune microenvironment.	[Qiu, Yufan; Zhang, Jin] Tianjin Med Univ Canc Inst & Hosp, Treatment & Res Ctr, Dept Breast Canc Prevent 3, Tianjin, Peoples R China; [Qiu, Yufan; Zhang, Jin] Tianjin Med Univ Canc Inst & Hosp, Minist Educ, Key Lab Breast Canc Prevent & Therapy, Tianjin, Peoples R China; [Qiu, Yufan; Zhang, Jin] Tianjin Med Univ Canc Inst & Hosp, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China; [Qiu, Yufan; Zhang, Jin] Tianjin Med Univ Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Qiu, Yufan; Zhang, Jin] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Qiu, Yufan; Yang, Yi; Yang, Riyao; Liu, Chunxiao; Hsu, Jung-Mao; Jiang, Zhou; Sun, Linlin; Wei, Yongkun; Li, Chia-Wei; Yu, Dihua; Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Qiu, Yufan; Zhang, Jin] Tianjin Med Univ, Tianjin, Peoples R China; [Yang, Yi] Third Mil Med Univ, Southwest Hosp, Inst Pathol & Southwest Canc Ctr, Army Med Univ, Chongqing, Peoples R China; [Hsu, Jung-Mao; Hung, Mien-Chie] China Med Univ, Grad Inst Biomed Sci & Res Ctr Mol Med, Taichung 406, Taiwan; [Sun, Linlin] Tianjin Med Univ Gen Hosp, Lung Canc Inst, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Tianjin, Peoples R China; [Li, Chia-Wei] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Hung, Mien-Chie] Asia Univ, Dept Biotechnol, Taichung 413, Taiwan	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; University of Texas System; UTMD Anderson Cancer Center; Tianjin Medical University; Army Medical University; China Medical University Taiwan; Tianjin Medical University; Academia Sinica - Taiwan; Asia University Taiwan	Zhang, J (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Treatment & Res Ctr, Dept Breast Canc Prevent 3, Tianjin, Peoples R China.; Zhang, J (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Minist Educ, Key Lab Breast Canc Prevent & Therapy, Tianjin, Peoples R China.; Zhang, J (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.; Zhang, J (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.; Zhang, J (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin, Peoples R China.; Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.; Zhang, J (corresponding author), Tianjin Med Univ, Tianjin, Peoples R China.; Hung, MC (corresponding author), China Med Univ, Grad Inst Biomed Sci & Res Ctr Mol Med, Taichung 406, Taiwan.; Hung, MC (corresponding author), Asia Univ, Dept Biotechnol, Taichung 413, Taiwan.	zhangjin@tjmuch.com; mhung@cmu.edu.tw	Jiang, Zhou/ABF-2435-2021; Hung, Mien-Chie/ABD-5911-2021; Hsu, Jung-Mao/AAC-9527-2019; Li, Chia-Wei/AAC-8660-2019; Yang, Riyao/R-7593-2019	Jiang, Zhou/0000-0003-4247-2949; Hung, Mien-Chie/0000-0003-4317-4740; Li, Chia-Wei/0000-0002-2531-2866; Yang, Riyao/0000-0002-0278-4385; Qiu, Yufan/0000-0002-6791-9957	National Institutes of Health CCSG [CA016672]; Cancer Prevention and Research Institute of Texas [RP160710]; MD Anderson-China Medical University Sister Institution Fund; Ministry of Science and Technology in Taiwan [MOST 109-2327-B-039-003, MOST 109-2314-B-001-008]; Patel Memorial Breast Cancer Endowment Fund; National Natural Science Foundation of China [81672623]; Science and Technology Support Program of Tianjin, China [19YFZCSY0030]; China Scholarship Council [201906940042]	National Institutes of Health CCSG(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; MD Anderson-China Medical University Sister Institution Fund; Ministry of Science and Technology in Taiwan(Ministry of Science and Technology, Taiwan); Patel Memorial Breast Cancer Endowment Fund; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Support Program of Tianjin, China; China Scholarship Council(China Scholarship Council)	This work was funded in part by the following: grants from the National Institutes of Health CCSG CA016672; Cancer Prevention and Research Institute of Texas (RP160710); The MD Anderson-China Medical University Sister Institution Fund; Ministry of Science and Technology in Taiwan (MOST 109-2327-B-039-003 to MCH, MOST 109-2314-B-001-008 to CWL); Patel Memorial Breast Cancer Endowment Fund; The National Natural Science Foundation of China (No. 81672623); The Science and Technology Support Program of Tianjin, China (No. 19YFZCSY0030); The China Scholarship Council Award to YQ (No. 201906940042). We would like to thank the scientific editors in the Research Medical Library at MD Anderson Cancer Center for editorial assistance.	Bastos N, 2018, SEMIN CELL DEV BIOL, V78, P13, DOI 10.1016/j.semcdb.2017.08.009; Beit-Yannai E, 2018, J CELL MOL MED, V22, P2001, DOI 10.1111/jcmm.13479; Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235; Burugu S, 2017, ANN ONCOL, V28, P2977, DOI 10.1093/annonc/mdx557; Burugu S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1502128; Calvo V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072631; Chen L, 2019, MED SCI MONITOR, V25, P4877, DOI 10.12659/MSM.917058; Datar I, 2019, CLIN CANCER RES, V25, P4663, DOI 10.1158/1078-0432.CCR-18-4142; Diskin B, 2020, NAT IMMUNOL, V21, P442, DOI 10.1038/s41590-020-0620-x; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Fernandez-Poma SM, 2017, CANCER RES, V77, P3672, DOI 10.1158/0008-5472.CAN-17-0236; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Gros A, 2014, J CLIN INVEST, V124, P2246, DOI [10.1172/JC173639, 10.1172/JCI73639]; Gutierrez-Vazquez C, 2013, IMMUNOL REV, V251, P125, DOI 10.1111/imr.12013; Ha D, 2016, ACTA PHARM SIN B, V6, P287, DOI 10.1016/j.apsb.2016.02.001; Harano K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204513; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kalluri R, 2016, J CLIN INVEST, V126, P1208, DOI 10.1172/JCI81135; Latchman YE, 2004, P NATL ACAD SCI USA, V101, P10691, DOI 10.1073/pnas.0307252101; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Li CL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12574; Liu CX, 2021, J HEPATOL, V74, P907, DOI 10.1016/j.jhep.2020.09.030; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913; Lu J, 2018, IMMUNOL RES, V66, P313, DOI 10.1007/s12026-018-9000-0; Luan X, 2017, ACTA PHARMACOL SIN, V38, P754, DOI 10.1038/aps.2017.12; Maia J, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00018; Pardoll D, 2015, SEMIN ONCOL, V42, P523, DOI 10.1053/j.seminoncol.2015.05.003; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pegtel DM, 2019, ANNU REV BIOCHEM, V88, P487, DOI 10.1146/annurev-biochem-013118-111902; Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016; Pruneri G, 2016, ANN ONCOL, V27, P249, DOI 10.1093/annonc/mdv571; Ren XY, 2018, CANCER BIOL THER, V19, P373, DOI 10.1080/15384047.2018.1423919; Ruivo CF, 2017, CANCER RES, V77, P6480, DOI 10.1158/0008-5472.CAN-17-0994; Seo N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02865-1; Sharma P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-56542-4; Theodoraki MN, 2018, CLIN CANCER RES, V24, P896, DOI 10.1158/1078-0432.CCR-17-2664; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Tucci M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1387706; Vader P, 2016, ADV DRUG DELIVER REV, V106, P148, DOI 10.1016/j.addr.2016.02.006; Ventimiglia LN, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00084; Wang JL, 2014, MOL MED REP, V9, P125, DOI 10.3892/mmr.2013.1759; Wang XC, 2019, J MED GENET, V56, P29, DOI 10.1136/jmedgenet-2018-105439; Whiteside TL, 2016, J CLIN INVEST, V126, P1216, DOI 10.1172/JCI81136; Xie FT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1074-3; Yang JT, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6387924; Yang RY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21099-2; Yeong J, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0499-y	48	30	31	9	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					4992	5001		10.1038/s41388-021-01896-1	http://dx.doi.org/10.1038/s41388-021-01896-1		JUN 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34172932	hybrid, Green Published			2022-12-28	WOS:000667016100002
J	Shen, MQ; Zhang, RX; Jia, WZ; Zhu, ZP; Zhao, XP; Zhao, L; Huang, G; Liu, JJ				Shen, Mengqin; Zhang, Ruixue; Jia, Wenzhi; Zhu, Zongping; Zhao, Xiaoping; Zhao, Li; Huang, Gang; Liu, Jianjun			Nuclear scaffold protein p54(nrb)/NONO facilitates the hypoxia-enhanced progression of hepatocellular carcinoma	ONCOGENE			English	Article							LONG NONCODING RNA; LACTATE-DEHYDROGENASE; LUNG-CANCER; NONO; GROWTH	Hypoxia and related oxidative stress are closely related to the development and treatment of hepatocellular carcinoma (HCC). However, the mechanism mediated by hypoxia in HCC has not yet been elucidated. Here, we found multifunction scaffold protein p54(nrb)/NONO exerted pleiotropic effects to regulate hypoxia transcription signals, thereby enhancing the progression of liver cancer. Extensive analysis of clinical data demonstrated that NONO was significantly upregulated and represented as a poor prognostic indicator of HCC. The crucial role of NONO in driving angiogenesis and glycolysis, two well-known cancer phenotypes mediated by hypoxia, was examined in vitro an in vivo. Mechanistically, NONO interacted with and stabilized both HIF-1 and HIF-2 complexes thus activating the transcription of hypoxia-induced genes. Besides, NONO bound pre-mRNA and subsequent mRNA of these genes to facilitate them splicing and mRNA stability, respectively. Thus, NONO knockout seriously disrupted the expression of a cluster of HIF-1/2 targets and impeded hypoxia-enhanced progression in HCC. In conclusion, NONO functioned as a multipurpose scaffold that interacted with HIF-1/2 complex and their downstream transcripts to facilitate the expression of hypoxia-induced genes, allowing malignant proliferation, indicating that NONO might be a potential therapeutic target for HCC.	[Shen, Mengqin; Zhang, Ruixue; Jia, Wenzhi; Zhao, Xiaoping; Zhao, Li; Huang, Gang; Liu, Jianjun] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Inst Clin Nucl Med,Dept Nucl Med, Shanghai 200127, Peoples R China; [Zhu, Zongping] Qingdao Municipal Hosp Grp, Dept Nucl Med, Qingdao 266011, Peoples R China; [Huang, Gang] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China; [Liu, Jianjun] Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200127, Peoples R China	Shanghai Jiao Tong University; Qingdao Municipal Hospital; Shanghai University of Medicine & Health Sciences; Shanghai Jiao Tong University	Huang, G; Liu, JJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Inst Clin Nucl Med,Dept Nucl Med, Shanghai 200127, Peoples R China.; Huang, G (corresponding author), Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China.; Liu, JJ (corresponding author), Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200127, Peoples R China.	huanggang2245@163.com; RInuclear@126.com		Huang, Gang/0000-0002-9245-1276	National Natural Science Foundation of China [81771858, 81530053, 81601524]; Shanghai Key Laboratory of Molecular Imaging [18DZ2260400]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Key Laboratory of Molecular Imaging	This study was supported by grants from the National Natural Science Foundation of China (81771858, 81530053, 81601524) and Shanghai Key Laboratory of Molecular Imaging (18DZ2260400).	Albadari N, 2019, EXPERT OPIN DRUG DIS, V14, P667, DOI 10.1080/17460441.2019.1613370; Benegiamo G, 2018, CELL METAB, V27, P404, DOI 10.1016/j.cmet.2017.12.010; Choudhry H, 2015, ONCOGENE, V34, P4482, DOI 10.1038/onc.2014.378; Custodio N, 2016, CRIT REV BIOCHEM MOL, V51, P395, DOI 10.1080/10409238.2016.1230086; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; Feng PF, 2020, J CELL MOL MED, V24, P4368, DOI 10.1111/jcmm.15141; Fox AH, 2018, TRENDS BIOCHEM SCI, V43, P124, DOI 10.1016/j.tibs.2017.12.001; Hao XJ, 2013, HEPATOB PANCREAT DIS, V12, P617, DOI 10.1016/S1499-3872(13)60097-1; Hayashi Y, 2019, CANCER SCI, V110, P1510, DOI 10.1111/cas.13990; Hirose T, 2019, WIRES RNA, V10, DOI 10.1002/wrna.1545; Hu ZX, 2020, HEPATOLOGY, V72, P548, DOI 10.1002/hep.31062; Hua Q, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0773-y; Huang YH, 2016, CANCER RES, V76, P1549, DOI 10.1158/0008-5472.CAN-15-2073; Ippolito D, 2014, EUR J RADIOL, V83, P1665, DOI 10.1016/j.ejrad.2014.05.040; Jankowsky E, 2015, NAT REV MOL CELL BIO, V16, P533, DOI 10.1038/nrm4032; Jungermann K, 2000, HEPATOLOGY, V31, P255, DOI 10.1002/hep.510310201; Kessler Sonja M, 2019, Cell Physiol Biochem, V52, P787, DOI 10.33594/000000055; Kim SJ, 2020, THERANOSTICS, V10, P7974, DOI 10.7150/thno.45037; Knott GJ, 2016, NUCLEIC ACIDS RES, V44, P3989, DOI 10.1093/nar/gkw271; Lapenta F, 2018, CHEM SOC REV, V47, P3530, DOI 10.1039/c7cs00822h; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Mendez-Blanco C, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0159-1; Nobre AR, 2018, TRENDS CELL BIOL, V28, P941, DOI 10.1016/j.tcb.2018.06.008; Onodera T, 2019, CHEM PHARM BULL, V67, P186, DOI 10.1248/cpb.c18-00767; Pavao M, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-15; Pereira B, 2017, TRENDS CANCER, V3, P506, DOI 10.1016/j.trecan.2017.05.003; Qin H, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00927-w; Roos M, 2016, ACS CHEM BIOL, V11, P2773, DOI 10.1021/acschembio.6b00232; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720; Severi T, 2010, ACTA PHARMACOL SIN, V31, P1409, DOI 10.1038/aps.2010.142; Shen MQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0839-4; Shibuya K, 2015, ONCOTARGET, V6, P651, DOI 10.18632/oncotarget.2892; Tang WD, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2019.115235; Wang Y, 2009, NAT METHODS, V6, P825, DOI [10.1038/nmeth.1379, 10.1038/NMETH.1379]; Wu XQ, 2015, ACS CHEM BIOL, V10, P1476, DOI 10.1021/cb500851u; Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003; Xie RH, 2021, MOL THER, V29, P291, DOI 10.1016/j.ymthe.2020.08.018; Xiong XX, 2017, MOL PHARMACOL, V92, P246, DOI 10.1124/mol.116.107706; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Zhu Z, 2016, ONCOGENE, V35, P1399, DOI 10.1038/onc.2015.197	41	3	3	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4167	4183		10.1038/s41388-021-01848-9	http://dx.doi.org/10.1038/s41388-021-01848-9		JUN 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34079086	Green Published, hybrid			2022-12-28	WOS:000657217400003
J	Zhang, FF; Tang, XF; Fan, S; Liu, X; Sun, J; Ju, C; Liang, YP; Liu, RF; Zhou, RH; Yu, B; Zhang, CH; Zhang, ZP; Kang, TB; Huang, GF; Lv, XB				Zhang, Feifei; Tang, Xiaofeng; Fan, Song; Liu, Xia; Sun, Jun; Ju, Cheng; Liang, Yiping; Liu, Renfeng; Zhou, Ruihao; Yu, Bo; Zhang, Changhua; Zhang, Zhiping; Kang, Tiebang; Huang, Guofu; Lv, Xiao-Bin			Targeting the p300/NONO axis sensitizes melanoma cells to BRAF inhibitors	ONCOGENE			English	Article							STRAND BREAK REPAIR; ACQUIRED-RESISTANCE; DRIVES RESISTANCE; RAF KINASE; NONO; MECHANISM; P54(NRB); PROTEIN; GROWTH; SWITCH	BRAF inhibitors (BRAFi) that target BRAF V600E kinase, a driver mutation found in 50% of melanomas, show a significant antitumor response, but the common emergence of acquired resistance remains a challenge. Abnormal expression of RAF isoforms CRAF and ARAF reactivates pERK1/2, which plays crucial roles in the acquisition of resistance of melanoma cells. However, the mechanisms of dysregulation of RAF isoforms in resistant melanoma cells remain unknown. Here, we identified NONO interacted with and stabilized both CRAF and ARAF in melanoma cells, and that NONO was acetylated at 198K by p300 acetyltransferase, which stabilized NONO via antagonizing its ubiquitination/degradation mediated by RNF8. The upregulation of both p300 and NONO promoted the rebound of pERK1/2 and the subsequent resistance of melanoma cells to BRAFi, and the activation of ERK1/2 in turn induced p300 to form a positive feedback loop in resistant melanoma cells. There was a positive correlation between p300 and NONO in resistant melanoma cells and clinical samples, and p300 inhibitor C646 overcame the resistance of resistant melanoma cells to BRAF inhibitors in vitro and in vivo. Our findings reveal that targeting the positive feedback loop of p300-NONO-CRAF/ARAF-pERK1/2 may be excellent strategies to overcome the resistance of BRAF inhibitors for melanoma patients.	[Zhang, Feifei; Tang, Xiaofeng; Sun, Jun; Ju, Cheng; Liang, Yiping; Liu, Renfeng; Zhou, Ruihao; Yu, Bo; Zhang, Zhiping; Lv, Xiao-Bin] Nanchang Univ, Cent Lab, Jiangxi Key Lab Canc Metastasis & Precis Treatmen, Affiliated Hosp 3, Nanchang, Jiangxi, Peoples R China; [Fan, Song] Sun Yat Sen Univ, Dept Oral & Maxillofacial Surg, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China; [Liu, Xia] South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China; [Sun, Jun; Zhang, Changhua] Jiangxi Univ Tradit Chinese Med, Coll Pharm, Nanchang, Jiangxi, Peoples R China; [Ju, Cheng; Liu, Renfeng; Yu, Bo; Zhang, Zhiping] Nanchang Univ, Dept Orthoped, Affiliated Hosp 3, Nanchang, Jiangxi, Peoples R China; [Kang, Tiebang] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Huang, Guofu] Nanchang Univ, Affiliated Hosp 3, Dept Ophthalmol, Nanchang, Jiangxi, Peoples R China	Nanchang University; Sun Yat Sen University; South China University of Technology; Jiangxi University of Traditional Chinese Medicine; Nanchang University; State Key Lab Oncology South China; Sun Yat Sen University; Nanchang University	Lv, XB (corresponding author), Nanchang Univ, Cent Lab, Jiangxi Key Lab Canc Metastasis & Precis Treatmen, Affiliated Hosp 3, Nanchang, Jiangxi, Peoples R China.; Huang, GF (corresponding author), Nanchang Univ, Affiliated Hosp 3, Dept Ophthalmol, Nanchang, Jiangxi, Peoples R China.	hgf2222@sina.com; nclvxiaobin@sina.cn			National Natural Science Foundation of China [81672866, 81960501, 81560452, 81760552]; Natural Science Foundation of Jiangxi Province [20202BAB206041, 20161BAB205192, 20171ACB21073]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangxi Province(Natural Science Foundation of Jiangxi Province)	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81672866, 81960501 and 81560452 to XBL; No. 81760552 to XT); the Natural Science Foundation of Jiangxi Province (No. 20202BAB206041; Nos. 20161BAB205192 and 20171ACB21073 to XBL).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alfano L, 2016, ONCOGENE, V35, P567, DOI 10.1038/onc.2015.107; Alfano L, 2018, J CELL PHYSIOL, V233, P4338, DOI 10.1002/jcp.26269; Audrito V, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx198; Corre S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06951-2; Deshar R, 2019, NUCLEIC ACIDS RES, V47, P762, DOI 10.1093/nar/gky1166; Diaz-Martinez M, 2018, CANCER RES, V78, P1017, DOI 10.1158/0008-5472.CAN-17-1318; Feng PF, 2020, J CELL MOL MED, V24, P4368, DOI 10.1111/jcmm.15141; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Hu ZX, 2020, HEPATOLOGY, V72, P548, DOI 10.1002/hep.31062; Jaafar L, 2017, NUCLEIC ACIDS RES, V45, P1848, DOI 10.1093/nar/gkw1209; Janostiak R, 2019, ISCIENCE, V16, P453, DOI 10.1016/j.isci.2019.06.001; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Jun JH, 2010, J BIOL CHEM, V285, P36410, DOI 10.1074/jbc.M110.142307; Karoulia Z, 2017, NAT REV CANCER, V17, P676, DOI 10.1038/nrc.2017.79; Knott GJ, 2016, NUCLEIC ACIDS RES, V44, P3989, DOI 10.1093/nar/gkw271; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Li SY, 2014, NUCLEIC ACIDS RES, V42, P9771, DOI 10.1093/nar/gku650; Li SY, 2009, NUCLEIC ACIDS RES, V37, P6746, DOI 10.1093/nar/gkp741; Liu MH, 2016, ONCOTARGET, V7, P84951, DOI 10.18632/oncotarget.13069; Matallanas David, 2011, Genes Cancer, V2, P232, DOI 10.1177/1947601911407323; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Ohanna M, 2018, GENE DEV, V32, P448, DOI 10.1101/gad.305854.117; Parmenter TJ, 2014, CANCER DISCOV, V4, P423, DOI 10.1158/2159-8290.CD-13-0440; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Qin YY, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaw9960; Saei A, 2018, J EXP MED, V215, P1913, DOI 10.1084/jem.20171960; Schiffnery S, 2011, CARCINOGENESIS, V32, P1176, DOI 10.1093/carcin/bgr103; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Talebi A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04664-0; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Zhang KX, 2016, J CANCER RES THER, V12, pC131, DOI 10.4103/0973-1482.200613; Zhu Z, 2016, ONCOGENE, V35, P1399, DOI 10.1038/onc.2015.197	38	4	5	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4137	4150		10.1038/s41388-021-01834-1	http://dx.doi.org/10.1038/s41388-021-01834-1		MAY 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34017080				2022-12-28	WOS:000652439200001
J	Ribeiro, IP; Esteves, L; Santos, A; Barroso, L; Marques, F; Caramelo, F; Melo, JB; Carreira, IM				Ribeiro, Ilda Patricia; Esteves, Luisa; Santos, Ana; Barroso, Leonor; Marques, Francisco; Caramelo, Francisco; Melo, Joana Barbosa; Carreira, Isabel Marques			A seven-gene signature to predict the prognosis of oral squamous cell carcinoma	ONCOGENE			English	Article							NECK-CANCER; HEAD; METASTASES; MANAGEMENT; EXPRESSION	The prognosis of oral squamous cell carcinoma (OSCC) patients remains poor without implemented biomarkers in the clinical routine practice to help in the patient's management. With this study we aimed to identify specific prognostic biomarkers for OSCC using a whole genome technology as well as to verify the clinical utility of a head and neck cancer-specific multiplex ligation-dependent probe amplification (MLPA) panel. A genomic characterization of tumor samples from 62 OSCC patients was performed using array comparative genomic hybridization (aCGH) and a more straightforward and cost-effective molecular technology, MLPA. The identification of a genomic signature and prognosis biomarkers was carried out by applying several statistical methods. With aCGH we observed that the chromosomes most commonly altered were 3p, 3q, 5q, 6p, 7q, 8p, 8q, 11q, 15q, 17q, and 18q. The MLPA results showed that the chromosomes with a higher frequency of alterations were 3p, 3q, 8p, 8q, and 11q. We identified a genomic signature with seven genes OCLN (3p21.31), CLDN16 (3q29), SCRIB (3q29), IKBKB (3q22.3), PAK2 (8q22.3), PIK3CB (3q28), and YWHAZ (8q24.3) that together allow to differentiate the patients that developed metastases or relapses after primary tumor treatment, with an overall accuracy of 79%. Amplification of PIK3CB as a predictor of metastases or relapses development was validated using TCGA data. This amplified gene showed a reduction in more than 5 years in the median survival of the patients. The identified biomarkers might have a significant impact in the patients' management and could leverage the OSCC precision medicine.	[Ribeiro, Ilda Patricia; Esteves, Luisa; Santos, Ana; Melo, Joana Barbosa; Carreira, Isabel Marques] Univ Coimbra, Cytogenet & Genom Lab, Inst Cellular & Mol Biol, Fac Med, Coimbra, Portugal; [Ribeiro, Ilda Patricia; Marques, Francisco; Caramelo, Francisco; Melo, Joana Barbosa; Carreira, Isabel Marques] Univ Coimbra, Coimbra Inst Clin & Biomed Res iCBR, Coimbra, Portugal; [Ribeiro, Ilda Patricia; Marques, Francisco; Caramelo, Francisco; Melo, Joana Barbosa; Carreira, Isabel Marques] Fac Med, Ctr Invest Environm Genet & Oncobiol CIMAGO, Coimbra, Portugal; [Ribeiro, Ilda Patricia; Melo, Joana Barbosa; Carreira, Isabel Marques] Univ Coimbra, Ctr Innovat Biomed & Biotechnol CIBB, Coimbra, Portugal; [Ribeiro, Ilda Patricia; Marques, Francisco; Melo, Joana Barbosa; Carreira, Isabel Marques] Clin Acad Ctr Coimbra CACC, Coimbra, Portugal; [Barroso, Leonor] Coimbra Hosp & Univ Ctr CHUC, EPE, Dept Maxillofacial Surg, Coimbra, Portugal; [Marques, Francisco] Univ Coimbra, Dept Dent, Fac Med, Coimbra, Portugal; [Marques, Francisco] Coimbra Hosp & Univ Ctr CHUC, EPE, Stomatol Unit, Coimbra, Portugal; [Caramelo, Francisco] Univ Coimbra, Lab Biostat & Med Informat, ICBR, Fac Med, Coimbra, Portugal	Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra	Carreira, IM (corresponding author), Univ Coimbra, Cytogenet & Genom Lab, Inst Cellular & Mol Biol, Fac Med, Coimbra, Portugal.; Carreira, IM (corresponding author), Univ Coimbra, Coimbra Inst Clin & Biomed Res iCBR, Coimbra, Portugal.; Carreira, IM (corresponding author), Fac Med, Ctr Invest Environm Genet & Oncobiol CIMAGO, Coimbra, Portugal.; Carreira, IM (corresponding author), Univ Coimbra, Ctr Innovat Biomed & Biotechnol CIBB, Coimbra, Portugal.; Carreira, IM (corresponding author), Clin Acad Ctr Coimbra CACC, Coimbra, Portugal.	citogenetica@fmed.uc.pt	Melo, Joana B/AAY-8984-2020; Ribeiro, Ilda/K-6686-2014; Melo, Joana B/K-8347-2014; Carreira, Isabel M/C-7711-2018	Melo, Joana B/0000-0001-5049-2670; Ribeiro, Ilda/0000-0002-6096-8705; Melo, Joana B/0000-0001-5049-2670; Carreira, Isabel M/0000-0001-6842-1707	MRC-Holland	MRC-Holland	We thank MRC-Holland for the MLPA P428-B1 probe panel.	Al-Rawi N.H., 2014, J OROFACIAL SCI, V6, P99; Altman DG, 1991, PRACTICAL STAT MED R; Barrow J, 2011, NEURO-ONCOLOGY, V13, P212, DOI 10.1093/neuonc/noq158; Braakhuis BJM, 2005, ONCOLOGIST, V10, P493, DOI 10.1634/theoncologist.10-7-493; Chatterjee A, 2020, ORAL ONCOL, V104, DOI 10.1016/j.oraloncology.2020.104627; Gabusi A, 2020, VIRCHOWS ARCH, V476, P585, DOI 10.1007/s00428-019-02656-z; Gilyoma Japhet M, 2015, BMC Res Notes, V8, P772, DOI 10.1186/s13104-015-1773-9; Gupta A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0887-0; Jeong S, 2013, RADIAT ONCOL J, V31, P206, DOI 10.3857/roj.2013.31.4.206; Jung AC, 2013, CLIN CANCER RES, V19, P4174, DOI 10.1158/1078-0432.CCR-12-3690; Kuo SJ, 2010, ONCOL REP, V24, P759, DOI 10.3892/or_00000918; LEEMANS CR, 1994, CANCER-AM CANCER SOC, V73, P187, DOI 10.1002/1097-0142(19940101)73:1<187::AID-CNCR2820730132>3.0.CO;2-J; LEEMANS CR, 1993, CANCER, V71, P452, DOI 10.1002/1097-0142(19930115)71:2<452::AID-CNCR2820710228>3.0.CO;2-B; Li Y, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00256; Lin WH, 2015, CANCER INFORM, V14, P15, DOI 10.4137/CIN.S18964; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Nishimura Y, 2013, BRIT J CANCER, V108, P1324, DOI 10.1038/bjc.2013.65; Page A, 2017, GENES-BASEL, V8, DOI 10.3390/genes8120376; Pantvaidya G, 2020, ORAL ONCOL, V100, DOI 10.1016/j.oraloncology.2019.104476; Pierucci-Alves F, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.092262; RIBEIRO I, 2017, SCI REP-UK, V7; Ribeiro IP, 2016, MOL CYTOGENET, V9, DOI 10.1186/s13039-016-0293-1; Ribeiro IP, 2014, TUMOR BIOL, V35, P4687, DOI 10.1007/s13277-014-1614-9; Ribeiro IP, 2014, CELL ONCOL, V37, P29, DOI 10.1007/s13402-013-0161-5; Vincent-Chong VK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174865; Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0954-x; Zhong L, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4806-7	28	5	5	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3859	3869		10.1038/s41388-021-01806-5	http://dx.doi.org/10.1038/s41388-021-01806-5		MAY 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33972685				2022-12-28	WOS:000648930100002
J	Lindzen, M; Ghosh, S; Noronha, A; Drago, D; Nataraj, NB; Leitner, O; Carvalho, S; Zmora, E; Sapoznik, S; Shany, KB; Levanon, K; Aderka, D; Ramirez, BS; Dahlhoff, M; McNeish, I; Yarden, Y				Lindzen, Moshit; Ghosh, Soma; Noronha, Ashish; Drago, Diana; Nataraj, Nishanth Belugali; Leitner, Orith; Carvalho, Silvia; Zmora, Einav; Sapoznik, Stav; Shany, Keren Bahar; Levanon, Keren; Aderka, Dan; Ramirez, Belinda Sanchez; Dahlhoff, Maik; McNeish, Iain; Yarden, Yosef			Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53	ONCOGENE			English	Article							GRADE SEROUS CARCINOMA; GROWTH-FACTOR RECEPTOR; TUMOR INVASION; PROLIFERATION; CELLS; CXCL1; EGF; CHEMOTHERAPY; PHENOTYPE; LIGAND	Ovarian cancer (OvCA) remains one of the most devastating malignancies, but treatment options are still limited. We report that amphiregulin (AREG) can serve as an effective and safe pharmacological target in a syngeneic murine model. AREG is highly abundant in abdominal fluids of patients with advanced OvCa. In immunocompetent animals, depletion or overexpression of AREG respectively prolonged or shortened animal survival. A new antibody we generated in AREG-knockout mice recognized murine AREG and reproducibly prolonged animal survival in the syngeneic model. The underlying mechanism likely involves binding of wildtype p53 to AREG's promoter and autocrine activation of the epidermal growth factor receptor (EGFR), a step blocked by the antibody. Accordingly, depletion of p53 downregulated AREG secretion and conferred tolerance, whereas blocking an adaptive process involving CXCL1, which transactivates EGFR, might increase therapeutic efficacy. Consistent with these observations, analysis of OvCa patients revealed that high AREG correlates with poor prognosis of patients expressing wildtype TP53. In conclusion, clinical tests of the novel antibody are warranted; high AREG, normal TP53, and reduced CXCL1 activity might identify patients with OvCa who may derive therapeutic benefit.	[Lindzen, Moshit; Ghosh, Soma; Noronha, Ashish; Drago, Diana; Nataraj, Nishanth Belugali; Zmora, Einav; Yarden, Yosef] Weizmann Inst Sci, Dept Biol Regulat, Rehovot, Israel; [Leitner, Orith; Carvalho, Silvia] Weizmann Inst Sci, Biol Serv, Rehovot, Israel; [Sapoznik, Stav; Shany, Keren Bahar; Levanon, Keren; Aderka, Dan] Tel Aviv Univ, Chaim Sheba Med Ctr, Sheba Canc Res Ctr, Ramat Aviv, Israel; [Sapoznik, Stav; Shany, Keren Bahar; Levanon, Keren; Aderka, Dan] Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel; [Ramirez, Belinda Sanchez] Ctr Mol Immunol, Direct Immunol & Immunotherapy, Havana, Cuba; [Dahlhoff, Maik] Univ Vet Med Vienna, Inst Vivo & In Vitro Models, Vienna, Austria; [McNeish, Iain] Imperial Coll, London, England; [McNeish, Iain] Hammersmith Hosp, London, England	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; University of Veterinary Medicine Vienna; Imperial College London; Imperial College London	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Noronha, Ashish/GPG-0252-2022; Nataraj, Nishanth Belugali/AAB-9317-2021; Dahlhoff, Maik/AGH-1182-2022; Ghosh, Soma/HFZ-9279-2022; Noronha, Ashish/GPX-4834-2022	Noronha, Ashish/0000-0002-3415-6113; Nataraj, Nishanth Belugali/0000-0003-2970-6739; Ghosh, Soma/0000-0002-9133-8538; Noronha, Ashish/0000-0002-3415-6113; Carvalho, Silvia/0000-0003-2102-7723; McNeish, Iain/0000-0002-9387-7586; Drago-Garcia, Diana/0000-0001-6397-3123	Israel Cancer Research Fund (ICRF); Israel Science Foundation (ISF); European Research Council (ERC); Dr. Miriam and Sheldon G. Adelson Medical Research Foundation	Israel Cancer Research Fund (ICRF); Israel Science Foundation (ISF)(Israel Science Foundation); European Research Council (ERC)(European Research Council (ERC)European Commission); Dr. Miriam and Sheldon G. Adelson Medical Research Foundation	We thank all members of our laboratory for their kind help and insightful comments. This work was performed in the Marvin Tanner Laboratory for Research on Cancer. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair in Molecular Cell Biology. Our studies have been supported by the Israel Cancer Research Fund (ICRF), the Israel Science Foundation (ISF), the European Research Council (ERC; Oncombine Project), and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.	Berasain C, 2014, SEMIN CELL DEV BIOL, V28, P31, DOI 10.1016/j.semcdb.2014.01.005; Bolitho C, 2010, ENDOCR-RELAT CANCER, V17, P929, DOI 10.1677/ERC-10-0107; Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Carvalho S, 2016, ONCOGENE, V35, P438, DOI 10.1038/onc.2015.93; Castillo J, 2006, CANCER RES, V66, P6129, DOI 10.1158/0008-5472.CAN-06-0404; Cheng WL, 2011, ANN ONCOL, V22, P2267, DOI 10.1093/annonc/mdq739; Garrido G, 2004, HYBRIDOMA HYBRIDOM, V23, P168, DOI 10.1089/1536859041224280; Hosur V, 2018, FEBS OPEN BIO, V8, P702, DOI 10.1002/2211-5463.12407; Hsu D, 2010, LAB INVEST, V90, P1295, DOI 10.1038/labinvest.2010.100; Jamieson AM, 2013, SCIENCE, V340, P1230, DOI 10.1126/science.1233632; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jones S, 2012, J PATHOL, V226, P413, DOI 10.1002/path.3967; Kawanishi H, 2008, CLIN CANCER RES, V14, P2579, DOI 10.1158/1078-0432.CCR-07-1922; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Kochupurakkal BS, 2005, J BIOL CHEM, V280, P8503, DOI 10.1074/jbc.M413919200; Lee CH, 2015, ONCOTARGET, V6, P38866, DOI 10.18632/oncotarget.5640; Lieber S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1424672; Lindzen M, 2012, ONCOGENE, V31, P3505, DOI 10.1038/onc.2011.518; Lindzen M, 2010, P NATL ACAD SCI USA, V107, P12559, DOI 10.1073/pnas.1006218107; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Luppi F, 2007, LUNG CANCER, V56, P25, DOI 10.1016/j.lungcan.2006.11.014; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Pujade-Lauraine E, 2014, J CLIN ONCOL, V32, P1302, DOI 10.1200/JCO.2013.51.4489; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Sauer L, 2010, ONCOGENE, V29, P2628, DOI 10.1038/onc.2010.24; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Taira N, 2014, P NATL ACAD SCI USA, V111, P717, DOI 10.1073/pnas.1313675111; Togashi Y, 2017, CURR TOP MICROBIOL, V410, P3, DOI 10.1007/82_2017_58; Vang R, 2016, INT J GYNECOL PATHOL, V35, P48, DOI 10.1097/PGP.0000000000000207; Walton J, 2016, CANCER RES, V76, P6118, DOI 10.1158/0008-5472.CAN-16-1272; Walton JB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17119-1; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095; Zaiss DM, 2006, SCIENCE, V314, P1746, DOI 10.1126/science.1133715; Zaiss DMW, 2015, IMMUNITY, V42, P216, DOI 10.1016/j.immuni.2015.01.020	36	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3665	3679		10.1038/s41388-021-01784-8	http://dx.doi.org/10.1038/s41388-021-01784-8		APR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33941851	Green Published, hybrid			2022-12-28	WOS:000646512100001
J	Chueh, AC; Advani, G; Foroutan, M; Smith, J; Ng, N; Nandurkar, H; Lio, DS; Zhu, HJ; Chong, YP; Verkade, H; Fujita, DJ; Bjorge, J; Basheer, F; Lim, JP; Luk, I; Dhillon, A; Sakthianandeswaren, A; Mouradov, D; Sieber, O; Hollande, F; Mariadason, JM; Cheng, HC				Chueh, Anderly C.; Advani, Gahana; Foroutan, Momeneh; Smith, Jai; Ng, Nadia; Nandurkar, Harshal; Lio, Daisy S.; Zhu, Hong-Jian; Chong, Yuh-Ping; Verkade, Heather; Fujita, Donald J.; Bjorge, Jeffrey; Basheer, Faiza; Lim, Jet Phey; Luk, Ian; Dhillon, Amardeep; Sakthianandeswaren, Anuratha; Mouradov, Dmitri; Sieber, Oliver; Hollande, Frederic; Mariadason, John M.; Cheng, Heung-Chin			CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; SRC-FAMILY; C-SRC; HUMAN COLON; PHOSPHATASE-ACTIVITY; DNA METHYLATION; CELLS; EXPRESSION; ACTIVATION; CLONING	Hyperactivation of SRC-family protein kinases (SFKs) contributes to the initiation and progression of human colorectal cancer (CRC). Since oncogenic mutations of SFK genes are rare in human CRC, we investigated if SFK hyperactivation is linked to dysregulation of their upstream inhibitors, C-terminal SRC kinase (CSK) and its homolog CSK-homologous kinase (CHK/MATK). We demonstrate that expression of CHK/MATK but not CSK was significantly downregulated in CRC cell lines and primary tumours compared to normal colonic tissue. Investigation of the mechanism by which CHK/MATK expression is down-regulated in CRC cells uncovered hypermethylation of the CHK/MATK promoter in CRC cell lines and primary tumours. Promoter methylation of CHK/MATK was also observed in several other tumour types. Consistent with epigenetic silencing of CHK/MATK, genetic deletion or pharmacological inhibition of DNA methyltransferases increased CHK/MATK mRNA expression in CHK/MATK-methylated colon cancer cell lines. SFKs were hyperactivated in CHK/MATK-methylated CRC cells despite expressing enzymatically active CSK, suggesting loss of CHK/MATK contributes to SFK hyperactivation. Re-expression of CHK/MATK in CRC cell lines led to reduction in SFK activity via a non-catalytic mechanism, a reduction in anchorage-independent growth, cell proliferation and migration in vitro, and a reduction in tumour growth and metastasis in a zebrafish embryo xenotransplantation model in vivo, collectively identifying CHK/MATK as a novel putative tumour suppressor gene in CRC. Furthermore, our discovery that CHK/MATK hypermethylation occurs in the majority of tumours warrants its further investigation as a diagnostic marker of CRC.	[Chueh, Anderly C.; Luk, Ian; Mariadason, John M.] Austin Hosp, Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia; [Chueh, Anderly C.; Sakthianandeswaren, Anuratha; Mouradov, Dmitri; Sieber, Oliver] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia; [Chueh, Anderly C.; Sakthianandeswaren, Anuratha; Mouradov, Dmitri; Sieber, Oliver] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia; [Chueh, Anderly C.; Mariadason, John M.] Univ Melbourne, Austin Hosp, Dept Med, Heidelberg, Vic, Australia; [Chueh, Anderly C.; Sieber, Oliver] Monash Univ, Biomedicine Discovery Inst, Canc Program, Clayton, Vic, Australia; [Chueh, Anderly C.; Sieber, Oliver] Monash Univ, Biomedicine Discovery Inst, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Advani, Gahana; Ng, Nadia; Lio, Daisy S.; Verkade, Heather; Cheng, Heung-Chin] Univ Melbourne, Bio21 Inst, Dept Biochem & Pharmacol, Parkville, Vic, Australia; [Foroutan, Momeneh; Smith, Jai; Hollande, Frederic] Univ Melbourne, Dept Clin Pathol, Victorian Comprehens Canc Ctr, Parkville, Vic, Australia; [Foroutan, Momeneh; Smith, Jai; Hollande, Frederic] Univ Melbourne, Victorian Comprehens Canc Ctr, Ctr Canc Res, Parkville, Vic, Australia; [Nandurkar, Harshal] Monash Univ, Australian Ctr Blood Dis, Prahran, Vic, Australia; [Zhu, Hong-Jian; Sieber, Oliver] Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Parkville, Vic, Australia; [Chong, Yuh-Ping] RMIT Univ, Sch Hlth & Biomed Sci, Discipline Lab Med, Bundoora, Vic, Australia; [Fujita, Donald J.; Bjorge, Jeffrey] Univ Calgary, Cumming Sch Med, Dept Biochem & Mol Biol, Calgary, AB, Canada; [Basheer, Faiza; Lim, Jet Phey; Dhillon, Amardeep] Deakin Univ, Inst Mental & Phys Hlth & Clin Translat, Sch Med, Geelong, Vic, Australia; [Mariadason, John M.] La Trobe Univ, Sch Canc Med, Heidelberg, Vic, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; La Trobe University; Olivia Newton-John Cancer Research Institute; Walter & Eliza Hall Institute; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Monash University; Monash University; University of Melbourne; University of Melbourne; University of Melbourne; Monash University; Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Institute of Technology (RMIT); University of Calgary; Deakin University; La Trobe University	Chueh, AC (corresponding author), Austin Hosp, Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia.; Chueh, AC (corresponding author), Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia.; Chueh, AC (corresponding author), Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia.; Chueh, AC (corresponding author), Univ Melbourne, Austin Hosp, Dept Med, Heidelberg, Vic, Australia.; Chueh, AC (corresponding author), Monash Univ, Biomedicine Discovery Inst, Canc Program, Clayton, Vic, Australia.; Chueh, AC (corresponding author), Monash Univ, Biomedicine Discovery Inst, Dept Biochem & Mol Biol, Clayton, Vic, Australia.; Cheng, HC (corresponding author), Univ Melbourne, Bio21 Inst, Dept Biochem & Pharmacol, Parkville, Vic, Australia.	Anderly.Chueh@monash.edu; heung@unimelb.edu.au	Chüeh, Anderly C/AFC-2076-2022; Sieber, Oliver/ABA-9211-2021; Nandurkar, Harshal/AAO-7443-2020; BASHEER, FAIZA/GPF-8188-2022; Basheer, Faiza/AAW-5083-2021; Hollande, Frederic/GLS-4120-2022; Chueh, Anderly/AAF-9375-2022	Chüeh, Anderly C/0000-0003-1140-5516; Sieber, Oliver/0000-0001-9480-0786; BASHEER, FAIZA/0000-0003-4850-2205; Basheer, Faiza/0000-0003-4850-2205; Hollande, Frederic/0000-0002-7046-8392; Smith, Jai/0000-0003-4997-6189; Chong, Yuh Ping/0000-0002-9596-3242; Narwani, Gahana/0000-0003-3129-6249; Dhillon, Amardeep/0000-0002-6065-663X; Zhu, Hong-Jian/0000-0002-1478-995X; Mouradov, Dmitri/0000-0001-8149-816X; Foroutan, Momeneh/0000-0002-1440-0457	NHMRC [GNT1136119, 628727, 1050486]; Australian Brain Foundation [1141906]; NHMRC Senior Research fellowship [GNT1046092]; Tour de Cure Foundation, Australia; National Health and Medical Research Council of Australia [1164081]	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Brain Foundation; NHMRC Senior Research fellowship(National Health and Medical Research Council (NHMRC) of Australia); Tour de Cure Foundation, Australia; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	O. Sieber is a NHMRC Senior Research Fellow (GNT1136119); grant support to H.-J. Zhu: NHMRC project grant #628727, grant support to H.-C. Cheng: NHMRC project grant # 1050486 and Australian Brain Foundation, grant support to A. Dhillon: NHMRC project grants #1141906. J. Mariadason was supported by a NHMRC Senior Research fellowship (GNT1046092). F. Hollande received grants from the Tour de Cure Foundation, Australia (Senior Project grant) and the National Health and Medical Research Council of Australia (Grant #1164081).	Advani G, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0186-x; [Anonymous], 2014, JAMA, V312, P2566, DOI 10.1001/jama.2014.15746; AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; Boczek EE, 2019, J BIOL CHEM, V294, P13186, DOI 10.1074/jbc.RA119.008199; Cancer Genome Atlas N., 2012, NATURE, V487, P330, DOI [10.1038/nature11252, DOI 10.1038/NATURE11252]; Carethers JM, 2020, ANNU REV MED, V71, P59, DOI 10.1146/annurev-med-103018-123125; Chong YP, 2005, GROWTH FACTORS, V23, P233, DOI 10.1080/08977190500178877; Chong YP, 2004, J BIOL CHEM, V279, P20752, DOI 10.1074/jbc.M309865200; Chong YP, 2006, J BIOL CHEM, V281, P32988, DOI 10.1074/jbc.M602951200; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Constancio-Lund SS, 2009, MOL CARCINOGEN, V48, P156, DOI 10.1002/mc.20466; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; Cordero JB, 2014, EMBO J, V33, P1474, DOI 10.1002/embj.201387454; Druliner BR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21525-4; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Haber AL, 2017, NATURE, V551, P333, DOI 10.1038/nature24489; Hesson LB, 2016, MOL CANCER RES, V14, P1217, DOI 10.1158/1541-7786.MCR-16-0175; Hoekstra E, 2016, ONCOTARGET, V7, P21922, DOI 10.18632/oncotarget.7829; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kemble DJ, 2009, P NATL ACAD SCI USA, V106, P5070, DOI 10.1073/pnas.0806117106; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; Kong XQ, 2019, CANCER CELL, V35, P633, DOI 10.1016/j.ccell.2019.03.003; Lerner EC, 2005, J BIOL CHEM, V280, P40832, DOI 10.1074/jbc.M508782200; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Luebeck GE, 2019, CANCER RES, V79, P495, DOI 10.1158/0008-5472.CAN-18-1682; Luo YX, 2014, GASTROENTEROLOGY, V147, P418, DOI 10.1053/j.gastro.2014.04.039; MCVICAR DW, 1994, ONCOGENE, V9, P2037; Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; PARK JS, 1993, ONCOGENE, V8, P2627; Poh AR, 2017, CANCER CELL, V31, P563, DOI 10.1016/j.ccell.2017.03.006; PURCHIO AF, 1983, MOL CELL BIOL, V3, P1589, DOI 10.1128/MCB.3.9.1589; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Schneider C, 2019, NAT REV IMMUNOL, V19, P584, DOI 10.1038/s41577-019-0176-x; Scott A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177210; Shah NH, 2018, CRIT REV BIOCHEM MOL, V53, P535, DOI 10.1080/10409238.2018.1495173; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sirvent A, 2012, AM J CANCER RES, V2, P357; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Welman A, 2006, NEOPLASIA, V8, P905, DOI 10.1593/neo.06475; Westphalen CB, 2014, J CLIN INVEST, V124, P1283, DOI 10.1172/JCI73434; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yan KS, 2017, CELL STEM CELL, V21, P78, DOI 10.1016/j.stem.2017.06.014; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438; Zhu S, 2008, ONCOGENE, V27, P2027, DOI 10.1038/sj.onc.1210838; Zhu S, 2007, CANCER RES, V67, P10129, DOI 10.1158/0008-5472.CAN-06-4338	52	4	4	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3015	3029		10.1038/s41388-021-01755-z	http://dx.doi.org/10.1038/s41388-021-01755-z		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33767439				2022-12-28	WOS:000632824700001
J	Rawat, V; Malvi, P; Della Manna, D; Yang, ES; Bugide, S; Zhang, XC; Gupta, R; Wajapeyee, N				Rawat, Vipin; Malvi, Parmanand; Della Manna, Deborah; Yang, Eddy S.; Bugide, Suresh; Zhang, Xuchen; Gupta, Romi; Wajapeyee, Narendra			PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1	ONCOGENE			English	Article								Metabolic deregulation, a hallmark of cancer, fuels cancer cell growth and metastasis. Here, we show that phosphoserine phosphatase (PSPH), an enzyme of the serine metabolism pathway, is upregulated in patient-derived melanoma samples. PSPH knockdown using short hairpin RNAs (shRNAs) blocks melanoma tumor growth and metastasis in both cell culture and mice. To elucidate the mechanism underlying PSPH action, we evaluated PSPH shRNA-expressing melanoma cells using global metabolomics and targeted mRNA expression profiling. Metabolomics analysis showed an increase in 2-hydroxyglutarate (2-HG) levels in PSPH knockdown cells. 2-HG inhibits the TET family of DNA demethylases and the Jumonji family of histone demethylases (KDM and JMJD), which is known to impact gene expression. Consistent with these data, PSPH knockdown in melanoma cells showed reduced DNA 5-hydroxymethylcytosine (5hmC) and increased histone H3K4me3 modifications. 2-HG treatment also inhibited melanoma growth. The nCounter PanCancer Pathways Panel-based mRNA expression profiling revealed attenuation of a number of cancer-promoting pathways upon PSPH knockdown. In particular, PSPH was necessary for nuclear receptor NR4A1 expression. Ectopic NR4A1 expression partly rescued the growth of melanoma cells expressing PSPH shRNA. Collectively, these results link PSPH to the facilitation of melanoma growth and metastasis through suppression of 2-HG and thus activation of pro-oncogenic gene expression.	[Rawat, Vipin; Malvi, Parmanand; Bugide, Suresh; Gupta, Romi; Wajapeyee, Narendra] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; [Della Manna, Deborah; Yang, Eddy S.] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL USA; [Zhang, Xuchen] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Yale University	Wajapeyee, N (corresponding author), Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.	nwajapey@uab.edu	Bugide, Suresh/AAD-6053-2022; zhang, xu/GYE-3558-2022; rawat, vipin/AAJ-3623-2021	rawat, vipin/0000-0003-2070-2299; Gupta, Romi/0000-0001-5108-5962; Wajapeyee, Narendra/0000-0003-3306-349X; Zhang, Xuchen/0000-0002-1484-4672	NCATS NIH HHS [UL1 TR001863] Funding Source: Medline; NCI NIH HHS [R21 CA229927, R01 CA218008, R01 CA200919, R01 CA196566] Funding Source: Medline	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Bachelor MA, 2011, J DERMATOL SCI, V63, P164, DOI 10.1016/j.jdermsci.2011.06.001; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Cao LX, 2019, MOL CANCER THER, V18, P3, DOI 10.1158/1535-7163.MCT-18-0863; Chen JY, 2013, ONCOTARGET, V4, P2502, DOI 10.18632/oncotarget.1540; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; DiNardo CD, 2018, NEW ENGL J MED, V378, P2386, DOI 10.1056/NEJMoa1716984; Fan J, 2015, ACS CHEM BIOL, V10, P510, DOI 10.1021/cb500683c; Fischer GM, 2018, PIGM CELL MELANOMA R, V31, P11, DOI 10.1111/pcmr.12661; Gao S, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0648-4; Hausinger RP, 2004, CRIT REV BIOCHEM MOL, V39, P21, DOI 10.1080/10409230490440541; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; Jin HO, 2019, ANTICANCER RES, V39, P6723, DOI 10.21873/anticanres.13887; Kakadia S, 2018, ONCOTARGETS THER, V11, P7095, DOI 10.2147/OTT.S182721; Kampen KR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10508-2; Koo JS, 2015, AM J CLIN PATHOL, V143, P584, DOI 10.1309/AJCPXAYH10WENLTC; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Li SS, 2015, MOL CELL, V60, P408, DOI 10.1016/j.molcel.2015.09.024; Li XX, 2018, MOL CELL, V69, P480, DOI 10.1016/j.molcel.2018.01.001; Liao L, 2019, INT J BIOL SCI, V15, P183, DOI 10.7150/ijbs.29203; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Mattaini KR, 2016, J CELL BIOL, V214, P248, DOI 10.1083/jcb.201604085; McCabe A, 2005, JNCI-J NATL CANCER I, V97, P1808, DOI 10.1093/jnci/dji427; Mullarky E, 2011, PIGM CELL MELANOMA R, V24, P1112, DOI 10.1111/j.1755-148X.2011.00919.x; Nowicki TS, 2018, CANCER J, V24, P47, DOI 10.1097/PPO.0000000000000303; Pacold ME, 2016, NAT CHEM BIOL, V12, P452, DOI [10.1038/NCHEMBIO.2070, 10.1038/nchembio.2070]; Park SM, 2019, MOL CELLS, V42, P604, DOI 10.14348/molcells.2019.0160; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Ratnikov BI, 2017, ONCOGENE, V36, P147, DOI 10.1038/onc.2016.198; Sato K, 2017, ANTICANCER RES, V37, P2365, DOI 10.21873/anticanres.11574; Song ZW, 2018, GENE, V642, P43, DOI 10.1016/j.gene.2017.11.014; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Sullivan MR, 2019, CELL METAB, V29, P1410, DOI 10.1016/j.cmet.2019.02.015; Tan EH, 2010, ANN ONCOL, V21, P217, DOI 10.1093/annonc/mdp520; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; van Zijl F, 2011, MUTAT RES-REV MUTAT, V728, P23, DOI 10.1016/j.mrrev.2011.05.002; Wang CY, 2020, AM J CANCER RES, V10, P95; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81; Ye D, 2018, TRENDS CANCER, V4, P151, DOI 10.1016/j.trecan.2017.12.005; Zhan YY, 2012, NAT CHEM BIOL, V8, P897, DOI [10.1038/NCHEMBIO.1069, 10.1038/nchembio.1069]; Zhang BX, 2017, CELL REP, V19, P2289, DOI 10.1016/j.celrep.2017.05.067; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	49	5	5	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2448	2462		10.1038/s41388-021-01683-y	http://dx.doi.org/10.1038/s41388-021-01683-y		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33674745	Green Accepted			2022-12-28	WOS:000625607100002
J	Mai, J; Peng, XD; Tang, J; Du, T; Chen, YH; Wang, ZF; Zhang, HL; Huang, JH; Zhong, ZY; Yang, D; Li, ZL; Huang, Y; Feng, GK; Zhu, XF; Deng, R				Mai, Jia; Peng, Xiao-Dan; Tang, Jun; Du, Tian; Chen, Yu-Hong; Wang, Zi-Feng; Zhang, Hai-Liang; Huang, Jun-Hao; Zhong, Zhuo-Yan; Yang, Dong; Li, Zhi-Ling; Huang, Yun; Feng, Gong-Kan; Zhu, Xiao-Feng; Deng, Rong			AKT-mediated regulation of chromatin ubiquitylation and tumorigenesis through Mel18 phosphorylation	ONCOGENE			English	Article							POLYCOMB GROUP GENE; HISTONE H2A UBIQUITINATION; BREAST-CANCER; GROUP PROTEIN; SELF-RENEWAL; MEL-18; PROLIFERATION; EXPRESSION; REPRESSION; COMPLEX	Polycomb repressor complex 1 (PRC1) is linked to the regulation of gene expression and histone ubiquitylation conformation, which contributes to carcinogenesis. However, the upstream regulators of PRC1 biogenesis machinery remain obscure. Here, we report that the polycomb group-related mammalian gene Mel18 is a target of the protein kinase AKT. AKT phosphorylates Mel18 at T334 to disrupt the interaction between Mel18 and other PRC1 members, leading to attenuated PRC1-dependent ubiquitylation of histone H2A at Lys119. As such, PRC1 target genes, many of which are known oncogenes, are derepressed upon T334-Mel18 phosphorylation, which promotes malignant behaviours, including cell proliferation, tumour formation, migration and invasion, bone and brain metastatic lesion formation. Notably, a positive correlation between AKT activity and pT334-Mel18 is observed, and prognostic models based on p-AKT and pT334-Mel18 that predicted overall survival and distant metastasis-free survival in breast cancer patients are established. These findings have implications for understanding the role of AKT and its associated proteins in chromatin ubiquitylation, and also indicate the AKT-Mel18-H2AK119ub axis as a novel prognostic biomarker and therapeutic target for cancer patients.	[Mai, Jia; Peng, Xiao-Dan; Tang, Jun; Du, Tian; Chen, Yu-Hong; Wang, Zi-Feng; Zhang, Hai-Liang; Huang, Jun-Hao; Zhong, Zhuo-Yan; Yang, Dong; Li, Zhi-Ling; Huang, Yun; Feng, Gong-Kan; Zhu, Xiao-Feng; Deng, Rong] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Canc Ctr,State Key Lab Oncol South China, Guangzhou, Peoples R China; [Mai, Jia] Sichuan Univ, West China Univ Hosp 2, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ,Dept Lab Med, Chengdu, Sichuan, Peoples R China; [Tang, Jun; Du, Tian; Huang, Jun-Hao] Sun Yat Sen Univ, Dept Breast Oncol, Canc Ctr, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sichuan University; Sun Yat Sen University	Zhu, XF; Deng, R (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Canc Ctr,State Key Lab Oncol South China, Guangzhou, Peoples R China.	zhuxfeng@mail.sysu.edu.cn; dengrong@sysucc.org.cn			Natural Science Foundation of China [81772624, 81572605, 81772835, 81972481, 81630079, 81972855]; Science and Technology Project of Guangzhou [201803010007]; China Postdoctoral Science Foundation [2020M683107]; Natural Science Foundation of Guangdong Province [2019A1515011209]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Project of Guangzhou; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This study was supported by the Natural Science Foundation of China (81772624, 81572605, 81772835, 81972481, 81630079, and 81972855), the Science and Technology Project of Guangzhou (201803010007), China Postdoctoral Science Foundation (2020M683107) and the Natural Science Foundation of Guangdong Province (2019A1515011209).	Akasaka T, 1997, IMMUNITY, V7, P135, DOI 10.1016/S1074-7613(00)80516-6; Al-Zahrani KN, 2020, ONCOGENE, V39, P4592, DOI 10.1038/s41388-020-1315-3; Bhatnagar S, 2014, NATURE, V516, P116, DOI 10.1038/nature13955; Brown JS, 2017, PHARMACOL THERAPEUT, V172, P101, DOI 10.1016/j.pharmthera.2016.12.001; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chun TH, 2005, FEBS LETT, V579, P5275, DOI 10.1016/j.febslet.2005.08.050; Deng R, 2021, AUTOPHAGY, V17, P3011, DOI 10.1080/15548627.2020.1850609; Elderkin S, 2007, MOL CELL, V28, P107, DOI 10.1016/j.molcel.2007.08.009; Fujisaki S, 2003, BIOCHEM BIOPH RES CO, V300, P135, DOI 10.1016/S0006-291X(02)02791-2; Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002; Ghosh JC, 2019, ONCOGENE, V38, P6926, DOI 10.1038/s41388-019-0939-7; Guo BH, 2010, ANN ONCOL, V21, P2361, DOI 10.1093/annonc/mdq241; Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447; Kajiume T, 2004, EXP HEMATOL, V32, P571, DOI 10.1016/j.exphem.2004.03.001; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; Kimura M, 2001, IMMUNITY, V15, P275, DOI 10.1016/S1074-7613(01)00182-0; Klauke K, 2013, NAT CELL BIOL, V15, P353, DOI 10.1038/ncb2701; Kummar S, 2010, NAT REV DRUG DISCOV, V9, P843, DOI 10.1038/nrd3216; Lempiainen JK, 2020, ONCOGENE, V39, P2391, DOI 10.1038/s41388-020-1153-3; Li QQ, 2019, CELL REP, V28, P3406, DOI 10.1016/j.celrep.2019.08.066; Li X, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01272-2; Li ZL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17395-y; Liao SY, 2019, ONCOGENE, V38, P6723, DOI 10.1038/s41388-019-0928-x; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Mai J, 2019, THERANOSTICS, V9, P3541, DOI 10.7150/thno.32908; Marchi S, 2019, EMBO J, V38, DOI 10.15252/embj.201899435; Meng X, 2017, ONCOTARGET, V8, P72847, DOI 10.18632/oncotarget.20457; Morey L, 2015, CELL STEM CELL, V17, P300, DOI 10.1016/j.stem.2015.08.009; Nitulescu GM, 2018, INT J ONCOL, V53, P2319, DOI 10.3892/ijo.2018.4597; Nitulescu GM, 2016, INT J ONCOL, V48, P869, DOI 10.3892/ijo.2015.3306; Park JH, 2011, ONCOGENE, V30, P4578, DOI 10.1038/onc.2011.174; Perkail S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16589-8; Pietila M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10275-0; Scheuermann JC, 2010, NATURE, V465, P243, DOI 10.1038/nature08966; Su WJ, 2019, CANCER CELL, V36, P139, DOI 10.1016/j.ccell.2019.06.009; Tamburri S, 2020, MOL CELL, V77, P840, DOI 10.1016/j.molcel.2019.11.021; Uzawa K, 2013, CANCER MED-US, V2, P40, DOI 10.1002/cam4.56; Vidal M, 2017, EXP HEMATOL, V48, P12, DOI 10.1016/j.exphem.2016.12.006; Wan LX, 2018, MOL CELL, V69, P279, DOI 10.1016/j.molcel.2017.12.024; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang W, 2011, UROL ONCOL-SEMIN ORI, V29, P244, DOI 10.1016/j.urolonc.2009.02.004; Wang YN, 2016, MOL CELL, V63, P34, DOI 10.1016/j.molcel.2016.05.027; Won HY, 2012, FASEB J, V26, P5002, DOI 10.1096/fj.12-209247; Xing Y, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1154-8; Zhang XW, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-40; Zhang YL, 2018, NAT CELL BIOL, V20, P1181, DOI 10.1038/s41556-018-0178-0; Zhang Z, 2017, P NATL ACAD SCI USA, V114, pE7949, DOI 10.1073/pnas.1711158114; Zhao ZB, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1870-5	48	3	3	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2422	2436		10.1038/s41388-020-01602-7	http://dx.doi.org/10.1038/s41388-020-01602-7		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33664452				2022-12-28	WOS:000625833000003
J	Niu, GL; Hellmuth, I; Flisikowska, T; Pausch, H; Rieblinger, B; Carrapeiro, A; Schade, B; Bohm, B; Kappe, E; Fischer, K; Klinger, B; Steiger, K; Burgkart, R; Bourdon, JC; Saur, D; Kind, A; Schnieke, A; Flisikowski, K				Niu, Guanglin; Hellmuth, Isabel; Flisikowska, Tatiana; Pausch, Hubert; Rieblinger, Beate; Carrapeiro, Alexander; Schade, Benjamin; Boehm, Brigitte; Kappe, Eva; Fischer, Konrad; Klinger, Bernhard; Steiger, Katja; Burgkart, Reiner; Bourdon, Jean-Christophe; Saur, Dieter; Kind, Alexander; Schnieke, Angelika; Flisikowski, Krzysztof			Porcine model elucidates function of p53 isoform in carcinogenesis and reveals novel circTP53 RNA	ONCOGENE			English	Article							MUTANT P53; BREAST-CANCER; MESSENGER-RNA; DELTA-133P53; OSTEOSARCOMA; P63; P73; EXPRESSION; MUTATIONS; MOUSE	Recent years have seen an increasing number of genetically engineered pig models of human diseases including cancer. We previously generated pigs with a modified TP53 allele that carries a Cre-removable transcriptional stop signal in intron 1, and an oncogenic mutation TP53(R167H) (orthologous to human TP53(R175H)) in exon 5. Pigs with the unrecombined mutant allele (flTP53(R167H)) develop mainly osteosarcoma but also nephroblastomas and lymphomas. This observation suggested that TP53 gene dysfunction is itself the key initiator of bone tumorigenesis, but raises the question which aspects of the TP53 regulation lead to the development of such a narrow tumour spectrum. Molecular analysis of p53 revealed the presence of two internal TP53 promoters (Pint and P2) equivalent to those found in human. Consequently, both pig and human express TP53 isoforms. Data presented here strongly suggest that P2-driven expression of the mutant R167H-Delta 152p53 isoform (equivalent to the human R175H-Delta 160p53 isoform) and its circular counterpart circTP53 determine the tumour spectrum and play a critical role in the malignant transformation in flTP53(R167H) pigs. The detection of Delta 152p53 isoform mRNA in serum is indicative of tumorigenesis. Furthermore, we showed a tissue-specific p53-dependent deregulation of the p63 and p73 isoforms in these tumours. This study highlights important species-specific differences in the transcriptional regulation of TP53. Considering the similarities of TP53 regulation between pig and human, these observations provide useful pointers for further investigation into isoform function including the novel circTP53 in both the pig model and human patients.	[Niu, Guanglin; Hellmuth, Isabel; Flisikowska, Tatiana; Rieblinger, Beate; Carrapeiro, Alexander; Fischer, Konrad; Klinger, Bernhard; Kind, Alexander; Schnieke, Angelika; Flisikowski, Krzysztof] Tech Univ Munich, Chair Livestock Biotechnol, Munich, Germany; [Pausch, Hubert] Swiss Fed Inst Technol, Anim Genom, Zurich, Switzerland; [Schade, Benjamin; Boehm, Brigitte; Kappe, Eva] Bavarian Anim Hlth Serv, Dept Pathol, Poing, Germany; [Steiger, Katja] Tech Univ Munich, Inst Pathol, Sch Med, Munich, Germany; [Burgkart, Reiner] Tech Univ Munich, Klinikum Rechts Isar, Klin & Poliklin Orthopad & Sportorthopad, Munich, Germany; [Bourdon, Jean-Christophe] Univ Dundee, Sch Med, Jacqui Wood Canc Ctr, Dundee, Scotland; [Saur, Dieter] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med 2, Munich, Germany	Technical University of Munich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Technical University of Munich; Technical University of Munich; University of Dundee; Technical University of Munich	Flisikowski, K (corresponding author), Tech Univ Munich, Chair Livestock Biotechnol, Munich, Germany.	flisikowski@wzw.tum.de	JC, Bourdon/A-4439-2008; Pausch, Hubert/U-5934-2019; Saur, Dieter/O-8355-2015	JC, Bourdon/0000-0003-4623-9386; Pausch, Hubert/0000-0002-0501-6760; Saur, Dieter/0000-0001-5874-0210	German Research Foundation [SCHN 971/3-2, SFB 1321]; China Scholarship Council (CSC)	German Research Foundation(German Research Foundation (DFG)); China Scholarship Council (CSC)(China Scholarship Council)	This work was supported by the German Research Foundation grant nos. SCHN 971/3-2, SFB 1321 and China Scholarship Council (CSC). Open Access funding enabled and organized by Projekt DEAL.	Anbarasan T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246257; Avery-Kiejda KA, 2014, CARCINOGENESIS, V35, P586, DOI 10.1093/carcin/bgt411; Bernard H, 2013, ONCOGENE, V32, P2150, DOI 10.1038/onc.2012.242; Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776; Blackburn J, 2016, MOL CARCINOGEN, V55, P1940, DOI 10.1002/mc.22441; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bykov VJN, 2018, NAT REV CANCER, V18, P89, DOI 10.1038/nrc.2017.109; Campbell HG, 2012, CELL CYCLE, V11, P446, DOI 10.4161/cc.11.3.19054; Candeias MM, 2016, EMBO REP, V17, P1542, DOI 10.15252/embr.201541956; Chen NF, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1594-y; Chen S, 2008, CLIN EXP DERMATOL, V33, P634, DOI 10.1111/j.1365-2230.2008.02851.x; Chen Z, 2012, NATURE, V483, P613, DOI 10.1038/nature10937; Conforti F, 2012, AGING-US, V4, P202, DOI 10.18632/aging.100441; Denny SK, 2016, CELL, V166, P328, DOI 10.1016/j.cell.2016.05.052; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; Durfee RA, 2016, RHEUMATOL THER, V3, P221, DOI 10.1007/s40744-016-0046-y; Fane M, 2017, INT J CANCER, V140, P2634, DOI 10.1002/ijc.30603; Flisikowska T, 2016, THERIOGENOLOGY, V86, P433, DOI 10.1016/j.theriogenology.2016.04.058; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fragou A, 2017, MOL MED REP, V15, P1455, DOI 10.3892/mmr.2017.6162; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Gonfloni S, 2015, INT J DEV BIOL, V59, P87, DOI 10.1387/ijdb.150045sg; Guijarro MV, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00189; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hofstetter G, 2011, BRIT J CANCER, V105, P1593, DOI 10.1038/bjc.2011.433; Irwin MS, 2006, CANCER BIOL THER, V5, P804, DOI 10.4161/cbt.5.7.3023; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson JG, 2013, ONCOGENE, V32, P4325, DOI 10.1038/onc.2012.610; Joruiz SM, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026039; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kalla D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020488; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lee DS, 2014, STEM CELLS, V32, P2467, DOI 10.1002/stem.1733; Leuchs S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043323; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Lucena-Araujo AR, 2015, BLOOD, V126, P2302, DOI 10.1182/blood-2015-01-623330; Marcel V, 2010, FEBS LETT, V584, P4463, DOI 10.1016/j.febslet.2010.10.005; Mirabello L, 2009, INT J CANCER, V125, P229, DOI 10.1002/ijc.24320; Moll UM, 2003, CLIN CANCER RES, V9, P5437; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nutthasirikul N, 2013, INT J ONCOL, V42, P1181, DOI 10.3892/ijo.2013.1818; Ognjanovic S, 2012, CANCER-AM CANCER SOC, V118, P1387, DOI 10.1002/cncr.26390; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Peng YH, 2001, J BIOL CHEM, V276, P6874, DOI 10.1074/jbc.C000781200; Poole LA, 2017, CRIT REV BIOCHEM MOL, V52, P696, DOI 10.1080/10409238.2017.1380597; Robertson N, 2020, EXPERT OPIN DRUG DIS, V15, P893, DOI 10.1080/17460441.2020.1757644; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rogalla S, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201904992; Saalfrank A, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.19; Seki M, 2017, NAT GENET, V49, P1274, DOI 10.1038/ng.3900; Seva J, 2001, VET REC, V148, P147, DOI 10.1136/vr.148.5.147; Sieren JC, 2014, J CLIN INVEST, V124, P4052, DOI 10.1172/JCI75447; Slatter TL, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.149; Slatter TL, 2011, BLOOD, V117, P5166, DOI 10.1182/blood-2010-11-321851; Stindt MH, 2015, ONCOGENE, V34, P4300, DOI 10.1038/onc.2014.359; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhang J, 2019, P NATL ACAD SCI USA, V116, P24259, DOI 10.1073/pnas.1913919116; Zhang J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0719-3	59	13	13	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1896	1908		10.1038/s41388-021-01686-9	http://dx.doi.org/10.1038/s41388-021-01686-9		FEB 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33603167	Green Published, hybrid			2022-12-28	WOS:000619405600001
J	Chen, LF; Yuan, RF; Wen, CY; Liu, TD; Feng, Q; Deng, XQ; Du, YY; Peng, XG				Chen, Leifeng; Yuan, Rongfa; Wen, Chongyu; Liu, Tiande; Feng, Qian; Deng, Xueqiang; Du, Yunyan; Peng, Xiaogang			E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBP alpha	ONCOGENE			English	Article							PROTEIN; METASTASIS; SUPPRESSES; CELLS	Pancreatic cancer is one of the most fatal cancers in humans. While it thrives in a state of malnutrition, the mechanism by which pancreatic cancer cells adapt to metabolic stress through metabolic reprogramming remains unclear. Here, we showed that UBR5, an E3 ubiquitin ligase, was significantly upregulated in pancreatic cancer patient samples compared to the levels in adjacent normal tissues. Levels of UBR5 were closely related to a malignant phenotype and shorter survival among pancreatic cancer patients. Multivariate analyses also revealed that UBR5 overexpression was an independent predictor of poor outcomes among patients with pancreatic cancer. Functional assays revealed that UBR5 contributes to the growth of pancreatic cancer cells by inducing aerobic glycolysis. Furthermore, we demonstrated that UBR5 knockdown increased levels of fructose-1,6-bisphosphatase (FBP1), an important negative regulator in the process of aerobic glycolysis in many cancers. We found a significant negative correlation between levels of UBR5 and FBP1, further demonstrating that UBR5-induced aerobic glycolysis is dependent on FBP1 in pancreatic cancer cells. Mechanistically, UBR5 regulates FBP1 expression by modulating C/EBP alpha, directly binding to C/EBP alpha, and promoting its ubiquitination and degradation. Together, these results identify a mechanism used by pancreatic cancer cells to survive the nutrient-poor tumour microenvironment and also provide insight regarding the role of UBR5 in pancreatic cancer cell adaptation to metabolic stresses.	[Chen, Leifeng] Jiangxi Prov Clin Res Ctr Gen Surg Dis, Nanchang, Jiangxi, Peoples R China; [Chen, Leifeng; Yuan, Rongfa; Wen, Chongyu; Liu, Tiande; Feng, Qian; Deng, Xueqiang] Nanchang Univ, Affiliated Hosp 2, Dept Gen Surg, Nanchang, Jiangxi, Peoples R China; [Du, Yunyan] Nanchang Univ, Jiangxi Prov Peoples Hosp, Dept Med, Nanchang, Jiangxi, Peoples R China; [Peng, Xiaogang] Nanchang Univ, Affiliated Hosp 2, Jiangxi Prov Key Lab Mol Med, Nanchang, Jiangxi, Peoples R China	Nanchang University; Nanchang University; Nanchang University	Du, YY (corresponding author), Nanchang Univ, Jiangxi Prov Peoples Hosp, Dept Med, Nanchang, Jiangxi, Peoples R China.; Peng, XG (corresponding author), Nanchang Univ, Affiliated Hosp 2, Jiangxi Prov Key Lab Mol Med, Nanchang, Jiangxi, Peoples R China.	695728274@qq.com; pxg8205@163.com		Peng, Xiaogang/0000-0002-8173-5118	National Natural Science Foundation of China [81760523, 81560117, 32060166, 81960436, 81560396]; Project of the Jiangxi Provincial Department of Science and Technology [20171BAB215024, 20192BCB23023]; Project of the Jiangxi Provincial Department of Education [GJJ160251]; Project of the Jiangxi Provincial Health Commission [2017A264]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of the Jiangxi Provincial Department of Science and Technology; Project of the Jiangxi Provincial Department of Education; Project of the Jiangxi Provincial Health Commission	This study was supported by grants from the National Natural Science Foundation of China (nos. 81760523, 81560117, 32060166, 81960436 and 81560396), the Project of the Jiangxi Provincial Department of Science and Technology (nos. 20171BAB215024 and 20192BCB23023), the Project of the Jiangxi Provincial Department of Education (no. GJJ160251) and the Project of the Jiangxi Provincial Health Commission (no. 2017A264).	Bengoechea-Alonso MT, 2010, P NATL ACAD SCI USA, V107, P11817, DOI 10.1073/pnas.0913367107; Bolt MJ, 2015, ONCOGENE, V34, P154, DOI 10.1038/onc.2013.550; Breaux M, 2015, MOL CELL BIOL, V35, P3005, DOI 10.1128/MCB.00421-15; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; Cong JJ, 2018, CELL METAB, V28, P243, DOI 10.1016/j.cmet.2018.06.021; Flint TR, 2017, TRENDS MOL MED, V23, P451, DOI 10.1016/j.molmed.2017.03.001; Gonzalez D, 2017, J BIOL CHEM, V292, P18924, DOI 10.1074/jbc.M117.811109; Habrook CJ, 2017, CANCER CELL, V31, P5, DOI 10.1016/j.ccell.2016.12.006; Henderson MJ, 2002, J BIOL CHEM, V277, P26468, DOI 10.1074/jbc.M203527200; Hu MY, 2019, J CANCER, V10, P1870, DOI 10.7150/jca.28299; Ilic M, 2016, WORLD J GASTROENTERO, V22, P9694, DOI 10.3748/wjg.v22.i44.9694; Liao LQ, 2017, CANCER RES, V77, P2090, DOI 10.1158/0008-5472.CAN-16-2409; Lin SC, 2017, J PATHOL, V241, P638, DOI 10.1002/path.4868; Liu GM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1165-x; Liu TD, 2012, EXP CELL RES, V318, P1994, DOI 10.1016/j.yexcr.2012.04.017; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Maisonneuve P, 2019, PRESSE MED, V48, pE113, DOI 10.1016/j.lpm.2019.02.030; Matsuura K, 2017, ONCOGENE, V36, P1698, DOI 10.1038/onc.2016.336; Min HY, 2018, BIOMOL THER, V26, P45, DOI 10.4062/biomolther.2017.211; Pedersen TA, 2007, EMBO J, V26, P1081, DOI 10.1038/sj.emboj.7601563; Qin YY, 2014, ONCOL REP, V31, P2635, DOI 10.3892/or.2014.3145; Shearer RF, 2015, MOL CANCER RES, V13, P1523, DOI 10.1158/1541-7786.MCR-15-0383; Shi DB, 2015, CANCER LETT, V369, P376, DOI 10.1016/j.canlet.2015.08.029; Subbaiah VK, 2016, ONCOGENE, V35, P2062, DOI 10.1038/onc.2015.268; Tao YM, 2014, P NATL ACAD SCI USA, V111, pE4429, DOI 10.1073/pnas.1407139111; Wang B, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0888-y; Wang J, 2017, DIGEST DIS SCI, V62, P2781, DOI 10.1007/s10620-017-4732-6; Wattanavanitchakorn S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194252; Weng WH, 2014, ONCOL REP, V31, P1921, DOI 10.3892/or.2014.3005; Xie H, 2017, J BIOL CHEM, V292, P16825, DOI 10.1074/jbc.R117.799973; Yang J, 2017, CARCINOGENESIS, V38, P134, DOI 10.1093/carcin/bgw109; Yang M, 2016, BIOCHEM BIOPH RES CO, V478, P1624, DOI 10.1016/j.bbrc.2016.08.170; Yang Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08759-0; Zhang TY, 2014, P NATL ACAD SCI USA, V111, P12091, DOI 10.1073/pnas.1400230111	34	16	18	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					262	276		10.1038/s41388-020-01527-1	http://dx.doi.org/10.1038/s41388-020-01527-1		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33122826				2022-12-28	WOS:000582827800003
J	Rejeski, K; Duque-Afonso, J; Lubbert, M				Rejeski, Kai; Duque-Afonso, Jesus; Luebbert, Michael			AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; AML1-ETO FUSION PROTEIN; TARGET GENE; TUMOR-SUPPRESSOR; ASXL2 MUTATIONS; T(8/21) AML; GENOME-WIDE; MYELODYSPLASTIC SYNDROME; DIFFERENTIATION BLOCK; RETINOIC ACID	The chromosomal translocation t(8;21) and the resulting oncofusion gene AML1/ETO have long served as a prototypical genetic lesion to model and understand leukemogenesis. In this review, we describe the wide-ranging role of AML1/ETO in AML leukemogenesis, with a particular focus on the aberrant epigenetic regulation of gene transcription driven by this AML-defining mutation. We begin by analyzing how structural changes secondary to distinct genomic breakpoints and splice changes, as well as posttranscriptional modifications, influence AML1/ETO protein function. Next, we characterize how AML1/ETO recruits chromatin-modifying enzymes to target genes and how the oncofusion protein alters chromatin marks, transcription factor binding, and gene expression. We explore the specific impact of these global changes in the epigenetic network facilitated by the AML1/ETO oncofusion on cellular processes and leukemic growth. Furthermore, we define the genetic landscape of AML1/ETO-positive AML, presenting the current literature concerning the incidence of cooperating mutations in genes such as KIT, FLT3, and NRAS. Finally, we outline how alterations in transcriptional regulation patterns create potential vulnerabilities that may be exploited by epigenetically active agents and other therapeutics.	[Rejeski, Kai; Duque-Afonso, Jesus; Luebbert, Michael] Univ Freiburg, Med Ctr, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany; [Rejeski, Kai] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Hematol & Oncol, Munich, Germany; [Rejeski, Kai; Luebbert, Michael] German Canc Res Ctr, German Canc Consortium DKTK Freiburg Partner Site, Heidelberg, Germany; [Duque-Afonso, Jesus; Luebbert, Michael] Univ Freiburg, Fac Med, Freiburg, Germany	University of Freiburg; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg	Lubbert, M (corresponding author), Univ Freiburg, Med Ctr, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany.; Lubbert, M (corresponding author), German Canc Res Ctr, German Canc Consortium DKTK Freiburg Partner Site, Heidelberg, Germany.; Lubbert, M (corresponding author), Univ Freiburg, Fac Med, Freiburg, Germany.	michael.luebbert@uniklinik-freiburg.de	Rejeski, Kai/AIE-6115-2022	Rejeski, Kai/0000-0003-3905-0251; Duque-Afonso, Jesus/0000-0002-8287-5673	Forschungskommission UKF [DUQ1106/16]; Berta Ottenstein-Program for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg; DFG [DU 1287/5-1, FOR 2674, CRC 992, 192904750]; Jose Carreras Leukemia Foundation [R14/25]; DKTK	Forschungskommission UKF; Berta Ottenstein-Program for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg; DFG(German Research Foundation (DFG)); Jose Carreras Leukemia Foundation; DKTK	JD receives research support from the Forschungskommission UKF (DUQ1106/16), Berta Ottenstein-Program for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg, and from the DFG (DU 1287/5-1). ML received funding by the Jose Carreras Leukemia Foundation (Project ID R14/25), the DFG (FOR 2674, Project ID A05, A09, CRC 992 Medical Epigenetics, Project ID 192904750), and DKTK. We thank Carlos Duque-Afonso for graphic design. The cloning experiments of the novel AML1 (exon 6)/ETO MigR1-overexpression plasmid outlined in Fig. 1C, D includes original work by KR with the help of Pia Veratti. We extend our gratitude to all co-workers from the Lubbert laboratory who have worked on cloning the AML1 exon 6 variant, especially Sandra Nitsch and Margit Sauer. We also thank Dr. Cornelius Miething for his advice and expertise during the cloning experiments.	Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Arora R, 2016, CURR CANCER DRUG TAR, V16, P215, DOI 10.2174/1568009616666151113120146; Ben-Ami O, 2013, CELL REP, V4, P1131, DOI 10.1016/j.celrep.2013.08.020; Berg T, 2007, LEUKEMIA RES, V31, P497, DOI 10.1016/j.leukres.2006.08.008; Berg T, 2008, HAEMATOL-HEMATOL J, V93, P1728, DOI 10.3324/haematol.13044; Bolouri H, 2018, NAT MED, V24, P103, DOI 10.1038/nm.4439; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Buchi F, 2014, EPIGENETICS-US, V9, P387, DOI 10.4161/epi.27322; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen GF, 2019, FEBS J, V286, P901, DOI 10.1111/febs.14751; Chevalier N, 2010, LEUKEMIA, V24, P1779, DOI 10.1038/leu.2010.151; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Christen F, 2019, BLOOD, V133, P1140, DOI 10.1182/blood-2018-05-852822; Claus R, 2006, J LEUKOCYTE BIOL, V80, P1462, DOI 10.1189/jlb.0106005; Craddock CF, 2017, CLIN CANCER RES, V23, P6430, DOI 10.1158/1078-0432.CCR-17-1423; De Braekeleer E, 2011, FUTURE ONCOL, V7, P77, DOI [10.2217/fon.10.158, 10.2217/FON.10.158]; DeKelver RC, 2014, LEUKEMIA LYMPHOMA, V55, P884, DOI 10.3109/10428194.2013.815351; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DiNardo CD, 2018, NEW ENGL J MED, V378, P2386, DOI 10.1056/NEJMoa1716984; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Dou LP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12960-6; Duncavage EJ, 2021, NEW ENGL J MED, V384, P924, DOI 10.1056/NEJMoa2024534; Dunne J, 2012, LEUKEMIA, V26, P1131, DOI 10.1038/leu.2011.316; Duque-Afonso J, 2011, ONCOGENE, V30, P3062, DOI 10.1038/onc.2011.32; Duque-Afonso J, 2011, BRIT J HAEMATOL, V153, P612, DOI 10.1111/j.1365-2141.2011.08586.x; Essig A, 2014, LEUKEMIA RES, V38, P340, DOI 10.1016/j.leukres.2013.12.014; Faber ZJ, 2016, NAT GENET, V48, P1551, DOI 10.1038/ng.3709; Fang HT, 2012, P NATL ACAD SCI USA, V109, P2521, DOI 10.1073/pnas.1121341109; Fazi F, 2007, BLOOD, V109, P4432, DOI 10.1182/blood-2006-09-045781; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Fliegauf M, 2004, ONCOGENE, V23, P9070, DOI 10.1038/sj.onc.1208042; Fortier JM, 2010, LEUKEMIA, V24, P950, DOI 10.1038/leu.2010.61; Frank R, 1995, ONCOGENE, V11, P2667; Gao XN, 2015, LEUKEMIA, V29, P1730, DOI 10.1038/leu.2015.56; Gardini A, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000275; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Grinev VV, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20848-z; Haferlach T, 2019, BLOOD, V133, P1006, DOI 10.1182/blood-2019-01-896076; Hartmann L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11733; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Hollein A, 2019, HEMASPHERE, V3, DOI 10.1097/HS9.0000000000000178; Jahn N, 2017, LEUKEMIA, V31, P1012, DOI 10.1038/leu.2017.18; Jin W, 2013, ONCOGENE, V32, P1978, DOI 10.1038/onc.2012.204; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kohrs N, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005946; Komeno Y, 2014, BLOOD, V123, P3760, DOI 10.1182/blood-2013-08-521252; Koschmieder S, 2009, J CLIN ONCOL, V27, P619, DOI 10.1200/JCO.2008.17.9812; Kozu T, 2005, GENE CHROMOSOME CANC, V43, P45, DOI 10.1002/gcc.20165; LaFiura KM, 2008, ONCOGENE, V27, P4933, DOI 10.1038/onc.2008.134; Lausten-Thomsen U, 2011, BLOOD, V117, P186, DOI 10.1182/blood-2010-05-282764; Lavallee VP, 2016, BLOOD, V127, P2498, DOI 10.1182/blood-2016-03-703868; LENNY N, 1995, ONCOGENE, V11, P1761; Li YZ, 2016, BLOOD, V127, P233, DOI 10.1182/blood-2015-03-626671; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; Liddiard K, 2010, ONCOGENE, V29, P2005, DOI 10.1038/onc.2009.462; Lin S, 2017, BLOOD, V130, P1213, DOI 10.1182/blood-2016-11-750976; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu SJ, 2007, J PHARMACOL EXP THER, V321, P953, DOI 10.1124/jpet.106.118406; Liu SJ, 2005, CANCER RES, V65, P1277, DOI 10.1158/0008-5472.CAN-04-4532; Liu XS, 2016, ONCOGENE, V35, P3071, DOI 10.1038/onc.2015.371; Liu XS, 2014, GENE DEV, V28, P1917, DOI 10.1101/gad.245910.114; Liu YZ, 2006, CANCER CELL, V9, P249, DOI 10.1016/j.ccr.2006.03.012; Loke J, 2017, CELL REP, V19, P1654, DOI 10.1016/j.celrep.2017.05.005; Lorsbach RB, 2004, BLOOD, V103, P2522, DOI 10.1182/blood-2003-07-2439; Lubbert M, 2020, J CLIN ONCOL, V38, P257, DOI 10.1200/JCO.19.01053; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Maiques-Diaz A, 2012, LEUKEMIA, V26, P1329, DOI 10.1038/leu.2011.376; Mandoli A, 2016, CELL REP, V17, P2087, DOI 10.1016/j.celrep.2016.08.082; Mannari D, 2010, LEUKEMIA, V24, P891, DOI 10.1038/leu.2009.288; Marcucci G, 2020, BLOOD ADV, V4, P696, DOI 10.1182/bloodadvances.2019000492; Marneth AE, 2018, HAEMATOLOGICA, V103, pE395, DOI 10.3324/haematol.2017.180844; Martens JHA, 2012, BLOOD, V120, P4038, DOI 10.1182/blood-2012-05-429050; Martinez-Soria N, 2018, CANCER CELL, V34, P626, DOI 10.1016/j.ccell.2018.08.015; Meyer T, 2020, LEUKEMIA, V34, P404, DOI 10.1038/s41375-019-0578-6; Micol JB, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15429; Micol JB, 2014, BLOOD, V124, P1445, DOI 10.1182/blood-2014-04-571018; Ming Y, 2004, P NATL ACAD SCI USA, V101, P17186, DOI 10.1073/pnas.0406702101; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Nieborowska-Skorska M, 2019, BLOOD ADV, V3, P4050, DOI 10.1182/bloodadvances.2019000756; Oo ZM, 2018, LEUKEMIA LYMPHOMA, V59, P2188, DOI 10.1080/10428194.2017.1410882; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Paschka P, 2006, J CLIN ONCOL, V24, P3904, DOI 10.1200/JCO.2006.06.9500; Paschka P, 2018, LEUKEMIA, V32, P1621, DOI 10.1038/s41375-018-0129-6; Paschka P, 2013, BLOOD, V121, P170, DOI 10.1182/blood-2012-05-431486; Peterson LF, 2007, BLOOD, V109, P4392, DOI 10.1182/blood-2006-03-012575; Ponnusamy K, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.6; Ponnusamy K, 2014, HAEMATOLOGICA, V99, DOI 10.3324/haematol.2014.106088; Prebet T, 2014, J CLIN ONCOL, V32, P1242, DOI 10.1200/JCO.2013.50.3102; Ptasinska A, 2012, LEUKEMIA, V26, P1829, DOI 10.1038/leu.2012.49; Ptasinska A, 2019, CELL REP, V28, P3022, DOI 10.1016/j.celrep.2019.08.040; Ptasinska A, 2014, CELL REP, V8, P1974, DOI 10.1016/j.celrep.2014.08.024; Qi X, 2021, TOXICOL APPL PHARM, V417, DOI 10.1016/j.taap.2021.115459; Qiu JS, 2016, RNA, V22, P1535, DOI 10.1261/rna.056101.116; Monte ER, 2020, ONCOGENE, V39, P3195, DOI 10.1038/s41388-020-1209-4; ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109; Saeed S, 2012, BLOOD, V120, P3058, DOI 10.1182/blood-2011-10-386086; Shia WJ, 2012, BLOOD, V119, P4953, DOI 10.1182/blood-2011-04-347476; Shimada H, 2000, BLOOD, V96, P655; Shimizu K, 2000, BLOOD, V96, P288, DOI 10.1182/blood.V96.1.288.013k05_288_296; Shiroma Y, 2020, CANCER SCI, V111, P1058, DOI 10.1111/cas.14355; Solari L, 2013, LEUKEMIA, V27, P1397, DOI 10.1038/leu.2013.53; Sood R, 2017, BLOOD, V129, P2070, DOI 10.1182/blood-2016-10-687830; Stein EM, 2017, BLOOD, V130, P722, DOI 10.1182/blood-2017-04-779405; Stoner SA, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-0282-9; Sun XJ, 2013, NATURE, V500, P93, DOI 10.1038/nature12287; Tabe Y, 2007, CELL DEATH DIFFER, V14, P1443, DOI 10.1038/sj.cdd.4402139; Teppo S, 2016, GENOME RES, V26, P1468, DOI 10.1101/gr.193649.115; Thome CH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66223-2; Tiacci E, 2004, CANCER RES, V64, P7399, DOI 10.1158/0008-5472.CAN-04-1865; Tian WL, 2014, GENE, V542, P122, DOI 10.1016/j.gene.2014.03.046; Tian Y, 2018, J CELL BIOCHEM, V119, P3706, DOI 10.1002/jcb.26587; Tijchon E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226435; Tonks A, 2007, LEUKEMIA, V21, P2495, DOI 10.1038/sj.leu.2404961; Trombly DJ, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1445-0; Tyner JW, 2018, NATURE, V562, P526, DOI 10.1038/s41586-018-0623-z; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Vegi NM, 2016, CELL REP, V16, P498, DOI 10.1016/j.celrep.2016.05.094; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662; Wang ZD, 2021, LEUKEMIA LYMPHOMA, V62, P937, DOI 10.1080/10428194.2020.1849680; Wichmann C, 2015, LEUKEMIA, V29, P279, DOI 10.1038/leu.2014.179; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Xu Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12735-z; Yamato G, 2017, GENE CHROMOSOME CANC, V56, P382, DOI 10.1002/gcc.22443; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Yang GY, 2005, MOL CELL BIOL, V25, P5869, DOI 10.1128/MCB.25.14.5869-5879.2005; Yang YX, 2020, J MED CHEM, V63, P1337, DOI 10.1021/acs.jmedchem.9b01721; Yin JAL, 2012, BLOOD, V120, P2826, DOI 10.1182/blood-2012-06-435669; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhuang WY, 2013, ONCOL REP, V30, P185, DOI 10.3892/or.2013.2459	136	4	4	7	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5665	5676		10.1038/s41388-021-01952-w	http://dx.doi.org/10.1038/s41388-021-01952-w		JUL 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34331016	Green Published, hybrid			2022-12-28	WOS:000679620500005
J	Yin, XY; Landay, MF; Han, WP; Levitan, ES; Watkins, SC; Levenson, RM; Farkas, DL; Prochownik, EV				Yin, Xiao-ying; Landay, Melanie F.; Han, Weiping; Levitan, Edwin S.; Watkins, Simon C.; Levenson, Richard M.; Farkas, Daniel L.; Prochownik, Edward V.			Editorial Expression of Concern: Dynamic in vivo interactions among Myc network members	ONCOGENE			English	Editorial Material												edward_prochownik@poplar.chp.edu						Yin XY, 2001, ONCOGENE, V20, P4650, DOI 10.1038/sj.onc.1204606	1	0	0	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2021	40	44					6308	6308		10.1038/s41388-021-01953-9	http://dx.doi.org/10.1038/s41388-021-01953-9		JUL 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR3FG	34326468	Bronze			2022-12-28	WOS:000679262900001
J	Zhang, XQ; Dou, P; Akhtar, ML; Liu, F; Hu, XB; Yang, LJ; Yang, DP; Zhang, XH; Li, YQ; Qiao, SP; Li, K; Tang, R; Zhan, C; Ma, Y; Cheng, QX; Bai, Y; Han, F; Nie, H; Li, Y				Zhang, Xiaoqing; Dou, Peng; Akhtar, Muhammad Luqman; Liu, Fei; Hu, Xibo; Yang, Lijun; Yang, Depeng; Zhang, Xiaohan; Li, Yiqun; Qiao, Shupei; Li, Kai; Tang, Ran; Zhan, Chao; Ma, Yue; Cheng, Qixiang; Bai, Yan; Han, Fang; Nie, Huan; Li, Yu			NEU4 inhibits motility of HCC cells by cleaving sialic acids on CD44	ONCOGENE			English	Article							COLON-CANCER CELLS; MIGRATION; GLYCOSYLATION; EXPRESSION; ADHESION; BINDING; SURFACE; SIALYLATION; SUPPRESSION; RECOGNITION	Hepatocellular carcinoma (HCC) is an extremely metastatic tumor. Sialic acids (SAs) are associated with cancer development and metastasis. NEU4 is a sialidase that removes SAs from glycoconjugates, while the function of the NEU4 in HCC has not been clearly explored. In our research, we found the NEU4 expression was significantly down-regulated in HCC tissues, which was correlated with high grades and poor outcomes of HCC. The NEU4 expression could be regulated by histone acetylation. In the functional analysis of NEU4, the cell motility was inhibited when NEU4 was overexpressed, and restored when NEU4 expression was down-regulated. Similarly, NEU4 over-expressed HCC cells showed less metastasis in athymic nude mice. Further study revealed that NEU4 could inhibit cell migration by enzymatic decomposition of SAs. Our results verified a NEU4 active site (NEU4(E235)) and overexpressing inactivates NEU4(E235A) that weakens the inhibition ability to cell migration. Further, 70 kinds of specific interacting proteins of NEU4 including CD44 were identified through mass spectrum. Moreover, the alpha 2,3-linked SAs on CD44 were decreased and the hyaluronic acid (HA) binding ability was increased when NEU4 over-expressed or activated. Additionally, the mutation of CD44 with six N-glycosylation sites showed less sensibility to NEU4 on cell migration compared with wild-type CD44. In summary, our results revealed the mechanism of low expression of NEU4 in HCC and its inhibitory effect on cell migration by removal of SAs on CD44, which may provide new treatment strategies to control the motility and metastasis of HCC.	[Zhang, Xiaoqing; Dou, Peng; Akhtar, Muhammad Luqman; Liu, Fei; Hu, Xibo; Yang, Lijun; Yang, Depeng; Zhang, Xiaohan; Li, Yiqun; Qiao, Shupei; Li, Kai; Tang, Ran; Ma, Yue; Cheng, Qixiang; Bai, Yan; Han, Fang; Nie, Huan; Li, Yu] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150008, Heilongjiang, Peoples R China; [Zhan, Chao] Harbin Med Univ, Affiliated Hosp 3, Harbin 150006, Heilongjiang, Peoples R China	Harbin Institute of Technology; Harbin Medical University	Nie, H; Li, Y (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150008, Heilongjiang, Peoples R China.	nh1212@hit.edu.cn; liyugene@hit.edu.cn		Li, Kai/0000-0002-3062-3618; yang, depeng/0000-0001-8753-3106	National Natural Science Foundation of China [31771627]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (31771627).	Angata K, 2010, METHOD ENZYMOL, V479, P25, DOI 10.1016/S0076-6879(10)79002-9; Bassaganas S, 2014, PANCREAS, V43, P109, DOI 10.1097/MPA.0b013e31829d9090; BIRCH M, 1991, CANCER RES, V51, P6660; Borland G, 1998, IMMUNOLOGY, V93, P139; Chavas LMG, 2005, J BIOL CHEM, V280, P469, DOI 10.1074/jbc.M411506200; Comelli EM, 2003, GENE, V321, P155, DOI 10.1016/j.gene.2003.08.005; Finlay TM, 2010, GLYCOCONJUGATE J, V27, P329, DOI 10.1007/s10719-010-9281-6; Gong AH, 2020, J CELL SCI, V133, DOI 10.1242/jcs.244020; Grinchuk OV, 2018, MOL ONCOL, V12, P89, DOI 10.1002/1878-0261.12153; Guvench O, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00305; Harr JC, 2016, EMBO REP, V17, P139, DOI 10.15252/embr.201541809; Hou GJ, 2016, ONCOTARGET, V7, P64957, DOI 10.18632/oncotarget.11778; Katoh S, 1999, J IMMUNOL, V162, P5058; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Kongtawelert P, 2003, WORLD J GASTROENTERO, V9, P2178; Lagana A, 1995, CLIN CHIM ACTA, V243, P165, DOI 10.1016/0009-8981(95)06165-7; Lee M, 2010, INT J RADIAT ONCOL, V76, P1528, DOI 10.1016/j.ijrobp.2009.11.022; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; Li HY, 2018, CANCER LETT, V432, P121, DOI 10.1016/j.canlet.2018.06.009; Liu WZ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1027-6; Lv J, 2015, MED SCI MONIT BASIC, V21, P157, DOI 10.12659/MSMBR.893908; Lv Jun, 2015, Asian Pac J Cancer Prev, V16, P2693; Miyagi T, 2003, GLYCOCONJUGATE J, V20, P189, DOI 10.1023/B:GLYC.0000024250.48506.bf; Miyagi T, 2008, PROTEOMICS, V8, P3303, DOI 10.1002/pmic.200800248; Miyagi T, 2012, GLYCOBIOLOGY, V22, P880, DOI 10.1093/glycob/cws057; Monti E, 2004, GENOMICS, V83, P445, DOI 10.1016/j.ygeno.2003.08.019; Mozzi A, 2012, PROTEINS, V80, P1123, DOI 10.1002/prot.24013; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Nath S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0191-4; Ou LL, 2020, MOL MED REP, V21, P1449, DOI 10.3892/mmr.2020.10951; Painbeni T, 1997, EUR J CANCER, V33, P2216, DOI 10.1016/S0959-8049(97)00318-3; Quint K, 2011, VIRCHOWS ARCH, V459, P129, DOI 10.1007/s00428-011-1103-0; Rochman M, 2000, CELL ADHES COMMUN, V7, P331, DOI 10.3109/15419060009015004; Sano R, 2009, MOL CELL, V36, P500, DOI 10.1016/j.molcel.2009.10.021; Seyrantepe V, 2004, J BIOL CHEM, V279, P37021, DOI 10.1074/jbc.M404531200; Shiozaki K, 2015, FASEB J, V29, P2099, DOI 10.1096/fj.14-262543; Shiozaki K, 2011, J BIOL CHEM, V286, P21052, DOI 10.1074/jbc.M111.231191; Skelton TP, 1998, J CELL BIOL, V140, P431, DOI 10.1083/jcb.140.2.431; Sorice M, 2009, FASEB J, V23, P3298, DOI 10.1096/fj.08-128140; Sun HY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00401; Sun TY, 2017, AM J TRANSL RES, V9, P103; Takahashi K, 2012, J BIOL CHEM, V287, P14816, DOI 10.1074/jbc.M111.324186; Uemura T, 2009, ONCOGENE, V28, P1218, DOI 10.1038/onc.2008.471; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; Varki A, 2007, NATURE, V446, P1023, DOI 10.1038/nature05816; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427; Wu LS, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2020.11667; Yamaguchi K, 2005, BIOCHEM J, V390, P85, DOI 10.1042/BJ20050017; Yamaguchi K, 2006, BIOCHEM BIOPH RES CO, V346, P484, DOI 10.1016/j.bbrc.2006.05.136; Yamanami H, 2007, CANCER SCI, V98, P299, DOI 10.1111/j.1349-7006.2007.00403.x; Zong JB, 2013, ONCOL REP, V30, P3020, DOI 10.3892/or.2013.2742; Zong JB, 2009, ONCOL REP, V22, P953, DOI 10.3892/or_00000522	53	4	4	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5427	5440		10.1038/s41388-021-01955-7	http://dx.doi.org/10.1038/s41388-021-01955-7		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34282273				2022-12-28	WOS:000674560900002
J	Hagiwara, M; Fushimi, A; Yamashita, N; Bhattacharya, A; Rajabi, H; Long, MD; Yasumizu, Y; Oya, M; Liu, S; Kufe, D				Hagiwara, Masayuki; Fushimi, Atsushi; Yamashita, Nami; Bhattacharya, Atrayee; Rajabi, Hasan; Long, Mark D.; Yasumizu, Yota; Oya, Mototsugu; Liu, Song; Kufe, Donald			MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells	ONCOGENE			English	Article							TRANSCRIPTIONAL REPRESSION; PLURIPOTENCY; EXPRESSION; SUBUNIT; BAF180; STRESS; REPAIR; GENES; NANOG	The polybromo-associated PBAF (SWI/SNF) chromatin remodeling complex, which includes PBRM1, ARID2, and BRD7, regulates cell differentiation and genomic integrity. MUC1-C is an oncogenic protein that drives lineage plasticity in prostate cancer (PC) progression. The present work demonstrates that MUC1-C induces PBRM1, ARID2, and BRD7 expression by the previously unrecognized E2F1-mediated activation of their respective promoters. The functional significance of the MUC1-C -> PBAF pathway is supported by demonstrating involvement of MUC1-C in associating with nuclear PBAF and driving the NRF2 antioxidant gene transcriptome in PC cells. Mechanistically, MUC1-C forms a complex with NRF2 and PBRM1 on the NRF2 target SLC7A11 gene that encodes the xCT cystine-glutamate antiporter, increases chromatin accessibility and induces SLC7A11/xCT expression. We also show that MUC1-C and PBRM1 are necessary for induction of other NRF2 target genes, including G6PD and PGD that regulate the pentose phosphate pathway. Our results further demonstrate that MUC1-C integrates activation of PBRM1 with the regulation of antioxidant genes, ROS levels, pluripotency factor expression and the cancer stem cell (CSC) state. These findings reveal a role for MUC1-C in regulating PBAF, redox balance and lineage plasticity of PC CSC progression. Our findings also uncover involvement of MUC1-C in integrating the PBAF and BAF pathways in cancer.	[Hagiwara, Masayuki; Fushimi, Atsushi; Yamashita, Nami; Bhattacharya, Atrayee; Rajabi, Hasan; Kufe, Donald] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; [Long, Mark D.; Liu, Song] Roswell Park Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA; [Yasumizu, Yota; Oya, Mototsugu] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Keio University	Kufe, D (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu	Bhattacharya, Atrayee/AAJ-9314-2021	Bhattacharya, Atrayee/0000-0002-3322-6175; Long, Mark/0000-0003-1120-8176	National Cancer Institute of the National Institutes of Health [CA97098, CA166480, CA233084, CA232979]	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under grant numbers CA97098, CA166480 and CA233084 awarded to DK and CA232979 awarded to SL.	Ahmad R, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0608-9; Brownlee PM, 2014, CELL REP, V6, P973, DOI 10.1016/j.celrep.2014.02.012; Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; Guerrero-Martinez JA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20217-3; Hagiwara M, 2021, CANCER RES, V81, P1111, DOI 10.1158/0008-5472.CAN-20-2588; Harte MT, 2010, CANCER RES, V70, P2538, DOI 10.1158/0008-5472.CAN-09-2089; Hasegawa M, 2015, CLIN CANCER RES, V21, P2338, DOI 10.1158/1078-0432.CCR-14-3000; Hata T, 2019, CANCER RES, V79, P5711, DOI 10.1158/0008-5472.CAN-19-1034; Hata T, 2019, MOL CANCER THER, V18, P1744, DOI 10.1158/1535-7163.MCT-19-0156; Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001; Hiraki M, 2017, ONCOGENE, V36, P2791, DOI 10.1038/onc.2016.439; Hodges C, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026930; Hopson S, 2017, ACS CHEM BIOL, V12, P2482, DOI 10.1021/acschembio.7b00541; Huang Lei, 2010, Genes Cancer, V1, P239; Jeter CR, 2015, STEM CELLS, V33, P2381, DOI 10.1002/stem.2007; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kakarougkas A, 2014, MOL CELL, V55, P723, DOI 10.1016/j.molcel.2014.06.028; Kent LN, 2019, NAT REV CANCER, V19, P326, DOI 10.1038/s41568-019-0143-7; Kidder BL, 2009, STEM CELLS, V27, P317, DOI 10.1634/stemcells.2008-0710; King HW, 2017, ELIFE, V6, DOI 10.7554/eLife.22631; Kufe DW, 2020, CARCINOGENESIS, V41, P1173, DOI 10.1093/carcin/bgaa082; Li W, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137112; Lim JKM, 2019, P NATL ACAD SCI USA, V116, P9433, DOI 10.1073/pnas.1821323116; Liu XD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15959-6; Lu X, 2014, ONCOGENE, V33, P2655, DOI 10.1038/onc.2013.209; Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212; Miao D, 2018, SCIENCE, V359, P801, DOI 10.1126/science.aan5951; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Pan J, 2019, NAT GENET, V51, P618, DOI 10.1038/s41588-019-0363-5; Papamichos-Chronakis M, 2013, NAT REV GENET, V14, P62, DOI 10.1038/nrg3345; Porter EG, 2019, ISCIENCE, V15, P196, DOI 10.1016/j.isci.2019.04.027; Rajabi H, 2018, ONCOGENE, V37, P2079, DOI 10.1038/s41388-017-0096-9; Rajabi H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07850-0; Schick S, 2019, NAT GENET, V51, P1399, DOI 10.1038/s41588-019-0477-9; Somyajit K, 2017, SCIENCE, V358, P797, DOI 10.1126/science.aao3172; Tanabe A, 2020, CANCERS, V12, DOI 10.3390/cancers12102780; Vitale I, 2017, MOL CELL, V66, P306, DOI 10.1016/j.molcel.2017.04.006; Wu Q, 2017, EPIGENOMICS-UK, V9, P919, DOI 10.2217/epi-2017-0034; Yamamoto M, 2019, CANCER RES, V79, P2031, DOI 10.1158/0008-5472.CAN-18-3259; Yan ZJ, 2005, GENE DEV, V19, P1662, DOI 10.1101/gad.1323805; Yasumizu Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14219-6; Yin L, 2012, BLOOD, V119, P810, DOI 10.1182/blood-2011-07-369686; Zhang XL, 2014, STEM CELL REP, V3, P460, DOI 10.1016/j.stemcr.2014.07.004	44	11	11	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4930	4940		10.1038/s41388-021-01899-y	http://dx.doi.org/10.1038/s41388-021-01899-y		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34163028	hybrid, Green Published			2022-12-28	WOS:000664853000006
J	Zhang, JG; Guan, WC; Xu, XL; Wang, FC; Li, X; Xu, GX				Zhang, Jinguo; Guan, Wencai; Xu, Xiaolin; Wang, Fanchen; Li, Xin; Xu, Guoxiong			A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer	ONCOGENE			English	Article							CALCIUM-BINDING PROTEIN; MULTIDRUG-RESISTANCE; MESENCHYMAL TRANSITION; COLORECTAL-CANCER; UP-REGULATION; TGF-BETA; OVEREXPRESSION; MICRORNA; CELLS; EMT	The primary chemotherapy of ovarian cancer (OC) often acquires chemoresistance. Sorcin (SRI), a soluble resistance-related calcium-binding protein, has been reported to be an oncogenic protein in cancer. However, the molecular mechanisms of SRI regulation and the role and aberrant expression of SRI in chemoresistant OC remain unclear. Here, we identified SRI as a key driver of paclitaxel (PTX)-resistance and explored its regulatory mechanism. Using transcriptome profiles, qRT-PCR, proteomics, Western blot, immunohistochemistry, and bioinformatics analyses, we found that SRI was overexpressed in PTX-resistant OC cells and the overexpression of SRI was related to the poor prognosis of patients. SRI was a key molecule required for growth, migration, and PTX-resistance in vitro and in vivo and was involved in epithelial-mesenchymal transition (EMT) and stemness. Mechanistic studies showed that miR-142-5p directly bound to the 3MODIFIER LETTER PRIME-UTR of SRI to suppress its expression, whereas a transcription factor zinc-finger E-box binding homeobox 1 (ZEB1) inhibited the transcription of miR-142-5p by directly binding to the E-box fragment in the miR-142 promoter region. Furthermore, ZEB1 was negatively regulated by SRI which physically interacted with Smad4 to block its translocation from the cytosol to the nucleus. Taken together, our findings unveil a novel homeostatic loop of SRI that drives the PTX-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human OC. Targeting this SRI/Smad4/ZEB1/miR-142-5p loop may reverse the PTX-resistance.	[Zhang, Jinguo; Guan, Wencai; Xu, Xiaolin; Wang, Fanchen; Li, Xin; Xu, Guoxiong] Fudan Univ, Jinshan Hosp, Res Ctr Clin Med, Shanghai 201508, Peoples R China; [Zhang, Jinguo; Xu, Xiaolin; Wang, Fanchen; Li, Xin; Xu, Guoxiong] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Xu, Guoxiong] Fudan Univ, Jinshan Hosp, Ctr Tumor Diag & Therapy, Shanghai 201508, Peoples R China	Fudan University; Fudan University; Fudan University	Xu, GX (corresponding author), Fudan Univ, Jinshan Hosp, Res Ctr Clin Med, Shanghai 201508, Peoples R China.; Xu, GX (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Xu, GX (corresponding author), Fudan Univ, Jinshan Hosp, Ctr Tumor Diag & Therapy, Shanghai 201508, Peoples R China.	guoxiong.xu@fudan.edu.cn		Zhang, Jinguo/0000-0001-9952-9307; wencai, guan/0000-0001-8168-0711	National Natural Science Foundation of China [81872121]; Natural Science Foundation of Shanghai [17ZR1404100]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai)	We are thankful for all research participants and technical assistants involved in this research project. This work was supported by grants from the National Natural Science Foundation of China (grant no. 81872121) and the Natural Science Foundation of Shanghai (grant no. 17ZR1404100) to GX.	Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Baird RD, 2010, NAT REV CLIN ONCOL, V7, P575, DOI 10.1038/nrclinonc.2010.120; Battista T, 2020, CANCERS, V12, DOI 10.3390/cancers12040887; Bushweller JH, 2019, NAT REV CANCER, V19, P611, DOI 10.1038/s41568-019-0196-7; Caramel J, 2018, CANCER RES, V78, P30, DOI 10.1158/0008-5472.CAN-17-2476; Colotti G, 2014, MOLECULES, V19, P13976, DOI 10.3390/molecules190913976; Dabaghi M, 2016, GENET TEST MOL BIOMA, V20, P516, DOI 10.1089/gtmb.2016.0031; Deng LM, 2019, INT J ONCOL, V55, P451, DOI 10.3892/ijo.2019.4831; Fuxe J, 2010, CELL CYCLE, V9, P2363, DOI 10.4161/cc.9.12.12050; Gao YY, 2015, MOL MED REP, V11, P2118, DOI 10.3892/mmr.2014.2936; Genovese I, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.342; Gong ZH, 2014, ONCOL LETT, V8, P2393, DOI 10.3892/ol.2014.2543; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; He QC, 2011, ONCOL REP, V25, P237, DOI 10.3892/or_00001066; Hu H, 2020, ANTI-CANCER DRUG, V31, P483, DOI 10.1097/CAD.0000000000000894; Hu YH, 2014, BREAST CANCER RES TR, V143, P287, DOI 10.1007/s10549-013-2809-2; Ilari A, 2015, SCI REP-UK, V5, DOI 10.1038/srep16828; Islam F, 2018, EXP MOL PATHOL, V104, P98, DOI 10.1016/j.yexmp.2018.01.006; Jolly MK, 2019, PHARMACOL THERAPEUT, V194, P161, DOI 10.1016/j.pharmthera.2018.09.007; Katsuno Y, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aau8544; Kim JJ, 2013, J CELL BIOCHEM, V114, P1286, DOI 10.1002/jcb.24464; Koti M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-549; Lloyd KL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1101-8; Long L, 2019, EXP MOL PATHOL, V106, P116, DOI 10.1016/j.yexmp.2019.01.001; Madany Mecca, 2018, Discoveries (Craiova), V6, pe86, DOI 10.15190/d.2018.7; Maddalena F, 2011, CANCER RES, V71, P7659, DOI 10.1158/0008-5472.CAN-11-2172; Marmugi A, 2016, DIABETES, V65, P1009, DOI 10.2337/db15-1334; Mladinich Megan, 2016, Stem Cells Int, V2016, P5285892; Mohammad RM, 2015, SEMIN CANCER BIOL, V35, pS78, DOI 10.1016/j.semcancer.2015.03.001; Monk BJ, 2016, CURR PHARM DESIGN, V22, P4717, DOI 10.2174/1381612822666160505114326; NOMAN M, 2018, ONCOIMMUNOLOGY, V7; Orellana-Serradell O, 2019, ASIAN J ANDROL, V21, P460, DOI 10.4103/aja.aja_1_19; Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269; Parekh HK, 2002, BIOCHEM PHARMACOL, V63, P1149, DOI 10.1016/S0006-2952(02)00850-X; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Suarez J, 2013, AM J PHYSIOL-CELL PH, V304, pC248, DOI 10.1152/ajpcell.00039.2012; Sun YT, 2018, J CELL PHYSIOL, V233, P3066, DOI 10.1002/jcp.26087; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wang FC, 2020, AGING-US, V12, P11042, DOI 10.18632/aging.103317; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xie N, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0015-6; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yoshida T., 2016, PLOS ONE, V11, P0147344; Yu WX, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819892264; Zhang LY, 2016, CURR CANCER DRUG TAR, V16, P429, DOI 10.2174/1568009616666160404121105; Zhang XC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0176-3; Zhou DB, 2017, CELL SIGNAL, V35, P197, DOI 10.1016/j.cellsig.2017.04.009; Zhu W, 2020, EUR REV MED PHARMACO, V24, P4306, DOI 10.26355/eurrev_202004_21011	53	9	9	3	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4906	4918		10.1038/s41388-021-01891-6	http://dx.doi.org/10.1038/s41388-021-01891-6		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34163033	Green Published, hybrid			2022-12-28	WOS:000664853000002
J	Li, XY; Wu, ZM; He, J; Jin, YT; Chu, CY; Cao, Y; Gu, F; Wang, HY; Hou, CJ; Liu, XP; Zou, Q				Li, Xiaoyan; Wu, Zhengming; He, Jing; Jin, Yiting; Chu, Chengyu; Cao, Yun; Gu, Fei; Wang, Hongying; Hou, Chenjian; Liu, Xiuping; Zou, Qiang			OGT regulated O-GlcNAcylation promotes papillary thyroid cancer malignancy via activating YAP	ONCOGENE			English	Article							HIPPO PATHWAY; GLCNAC; TRANSFERASE; PHOSPHORYLATION; PROLIFERATION; MECHANISMS; NUCLEAR	The incidence of thyroid cancer is growing rapidly during the past decades worldwide. Although most thyroid tumors are curable, some patients diagnosed with distant metastases are associated with poor prognosis. The molecular mechanisms underlying these cases are still largely unknown. Here we found that the upregulated O-Linked N-Acetylglucosamine Transferase (OGT) expression and O-GlcNAcylation (O-GlcNAc) modification in papillary thyroid cancer (PTC) were essential in tumor growth and metastasis. Mass spectrometry analysis showed that YAP was the effector protein modified by OGT. In details, YAP Ser109 O-GlcNAcylation promoted the malignant phenotypes in PTC cells by inducing YAP Ser127 dephosphorylation and activation. Our work clearly showed the critical role of OGT and YAP played in PTC tumors and made it possible for us to seek the clinical potential of manipulating OGT/YAP activity in PTC targeted therapies. These findings also confirmed OGT worked in collaboration with classical Hippo pathway kinases as an upstream regulator of YAP in PTC tumors.	[Li, Xiaoyan; He, Jing; Jin, Yiting; Chu, Chengyu; Cao, Yun; Gu, Fei; Wang, Hongying; Zou, Qiang] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China; [Wu, Zhengming] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Wu, Zhengming] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Hou, Chenjian; Liu, Xiuping] Fudan Univ, Sch Basic Med Sci, Dept Pathol, Shanghai, Peoples R China; [Liu, Xiuping] Fudan Univ, Shanghai Peoples Hosp 5, Dept Pathol, Shanghai, Peoples R China	Fudan University; University of California System; University of California San Diego; University of California System; University of California San Diego; Fudan University; Fudan University	Zou, Q (corresponding author), Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China.; Liu, XP (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Pathol, Shanghai, Peoples R China.; Liu, XP (corresponding author), Fudan Univ, Shanghai Peoples Hosp 5, Dept Pathol, Shanghai, Peoples R China.	xpliu1228@fudan.edu.cn; zouqiang_hs@163.com		Li, Xiaoyan/0000-0002-1243-3845	National Nature Science Foundation of China and Science and Technology Commission of Shanghai Municipality [81602326];  [15411952503]	National Nature Science Foundation of China and Science and Technology Commission of Shanghai Municipality; 	This work was supported by grant no. 81602326 from the National Nature Science Foundation of China and Science and Technology Commission of Shanghai Municipality (No. 15411952503).	Akella NM, 2020, MOL CANCER RES, V18, P585, DOI 10.1158/1541-7786.MCR-19-0732; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Cao BJ, 2019, J CELL MOL MED, V23, P2384, DOI 10.1111/jcmm.14043; Carling T, 2014, ANNU REV MED, V65, P125, DOI 10.1146/annurev-med-061512-105739; Chen R, 2019, NAT CELL BIOL, V21, P1565, DOI 10.1038/s41556-019-0426-y; Cheng Y, 2016, ONCOL LETT, V12, P572, DOI 10.3892/ol.2016.4647; Coca-Pelaz A, 2020, ADV THER, V37, P3112, DOI 10.1007/s12325-020-01391-1; Di Domenico F, 2019, EXPERT REV NEUROTHER, V19, P1, DOI 10.1080/14737175.2019.1540932; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Duan FF, 2018, J HEPATOL, V68, P1191, DOI 10.1016/j.jhep.2018.02.003; Fardini Y, 2013, FRONT ENDOCRINOL, V4, DOI 10.3389/fendo.2013.00099; Ferrer CM, 2017, ONCOGENE, V36, P559, DOI 10.1038/onc.2016.228; Ferrer CM, 2016, J MOL BIOL, V428, P3282, DOI 10.1016/j.jmb.2016.05.028; Gloster TM, 2011, NAT CHEM BIOL, V7, P174, DOI 10.1038/NCHEMBIO.520; Gonzalez-Gonzalez Rogelio, 2011, ISRN Oncol, V2011, P915925, DOI 10.5402/2011/915925; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Itkonen HM, 2020, MOL CANCER RES, V18, P1512, DOI 10.1158/1541-7786.MCR-20-0339; Itkonen HM, 2019, THERANOSTICS, V9, P2183, DOI 10.7150/thno.30834; Jiang MZ, 2019, ONCOGENE, V38, P301, DOI 10.1038/s41388-018-0435-5; Jin L, 2020, CELL MOL BIOL LETT, V25, DOI 10.1186/s11658-020-00208-x; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kim SH, 2017, BIOCHEM BIOPH RES CO, V483, P793, DOI 10.1016/j.bbrc.2016.10.156; Lim H, 2017, JAMA-J AM MED ASSOC, V317, P1338, DOI 10.1001/jama.2017.2719; Lin Yi-Cheng, 2018, Oncotarget, V9, P31032, DOI 10.18632/oncotarget.25772; Liu ZM, 2019, APPL IMMUNOHISTO M M, V27, P59, DOI 10.1097/PAI.0000000000000544; Liu ZM, 2017, AM J TRANSL RES, V9, P3212; Lu H, 2020, GLYCOBIOLOGY; Ma ZY, 2013, AMINO ACIDS, V45, P719, DOI 10.1007/s00726-013-1543-8; Makwana V, 2019, BBA-GEN SUBJECTS, V1863, P1302, DOI 10.1016/j.bbagen.2019.04.002; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Moon S, 2017, EMBO REP, V18, P61, DOI 10.15252/embr.201642683; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nagashima S, 2017, CURR DRUG TARGETS, V18, P447, DOI 10.2174/1389450117666160112115641; Ortiz-Meoz RF, 2015, ACS CHEM BIOL, V10, P1392, DOI 10.1021/acschembio.5b00004; Peng CM, 2017, MOL CELL, V68, P591, DOI 10.1016/j.molcel.2017.10.010; Pepe F, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.35; Pobbati AV, 2015, STRUCTURE, V23, P2076, DOI 10.1016/j.str.2015.09.009; Saiselet Manuel, 2012, Front Endocrinol (Lausanne), V3, P133, DOI 10.3389/fendo.2012.00133; Seo HG, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02999-5; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Singh JP, 2015, CANCER LETT, V356, P244, DOI 10.1016/j.canlet.2014.04.014; Wang LS, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5033-y; Wu ZM, 2021, TRENDS BIOCHEM SCI, V46, P51, DOI 10.1016/j.tibs.2020.08.008; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Xu WQ, 2017, J HEPATOL, V67, P310, DOI 10.1016/j.jhep.2017.03.017; Zeidan Q, 2010, J CELL SCI, V123, P13, DOI 10.1242/jcs.053678; Zhang P, 2015, ONCOTARGETS THER, V8, P3305, DOI 10.2147/OTT.S82845; Zhang X, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15280; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zheng W, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1110-9; Zhu GZ, 2016, GLYCOBIOLOGY, V26, P820, DOI 10.1093/glycob/cww025	53	8	8	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4859	4871		10.1038/s41388-021-01901-7	http://dx.doi.org/10.1038/s41388-021-01901-7		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34155345				2022-12-28	WOS:000664006700001
J	Li, BR; Pei, GS; Yao, J; Ding, QQ; Jia, PL; Zhao, ZM				Li, Bingrui; Pei, Guangsheng; Yao, Jun; Ding, Qingqing; Jia, Peilin; Zhao, Zhongming			Cell-type deconvolution analysis identifies cancer-associated myofibroblast component as a poor prognostic factor in multiple cancer types	ONCOGENE			English	Article							STROMAL CELLS; TUMOR-CELLS; MITOMYCIN-C; FIBROBLASTS; FIBROSIS	Cancer-associated fibroblasts (CAFs) constitute a prominent component of the tumor microenvironment and play critical roles in cancer progression and drug resistance. Although recent studies indicate CAFs may consist of several CAF subtypes, the breadth of CAF heterogeneity and functional roles of CAF subtypes in cancer progression remain unclear. In this study, we implemented a cell-type deconvolutional approach to comprehensively characterize cell-type alternations across 18 cancer types from The Cancer Genome Atlas (TCGA). Pan-cancer survival analysis using deconvoluted CAF subtypes revealed myofibroblastic CAF (myCAF) composition as a poor prognostic factor in nine cancer types. Patients with higher myCAF compositions tend to have worse response to six antineoplastic drugs predicted by a lncRNA-based Elastic Net prediction model (LENP). In addition, integrative mutational analysis identified 14 and 413 genes associated with the differentiation degree of myCAF and inflammatory CAF (iCAF), respectively, with significant enrichment of genes involved in fibroblast and extracellular matrix (ECM)-related pathways. In summary, our findings systematically illustrated the complex roles of CAF subtypes in patient prognosis and drug response, and identified putative driver genes in CAF-subtype differentiation. These results provided novel therapeutic perspectives for targeting CAF subtypes in tumor microenvironment and arranging treatment scheme based on the CAF compositions in different cancer types.	[Li, Bingrui; Pei, Guangsheng; Jia, Peilin; Zhao, Zhongming] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Ctr Precis Hlth, Houston, TX 77030 USA; [Yao, Jun] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Ding, Qingqing] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Zhao, Zhongming] Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA; [Zhao, Zhongming] MD Anderson Canc Ctr, UT Hlth Grad Sch Biomed Sci, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; UTMD Anderson Cancer Center	Jia, PL; Zhao, ZM (corresponding author), Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Ctr Precis Hlth, Houston, TX 77030 USA.; Zhao, ZM (corresponding author), Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA.; Zhao, ZM (corresponding author), MD Anderson Canc Ctr, UT Hlth Grad Sch Biomed Sci, Houston, TX 77030 USA.	peilin.jia@gmail.com; zhongming.zhao@uth.tmc.edu		Li, Bingrui/0000-0002-4807-1452; Pei, Guangsheng/0000-0003-1804-7598	National Institutes of Health [R01LM012806]; Cancer Prevention and Research Institute of Texas grant (CPRIT) [RP180734, RP170668]; CPRIT [RP180734]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas grant (CPRIT); CPRIT	This work was partially supported by National Institutes of Health grant (R01LM012806) and the Cancer Prevention and Research Institute of Texas grant (CPRIT RP180734 and RP170668). Publication charges for this article have been funded by CPRIT RP180734.	Aboussekhra A, 2011, INT J DEV BIOL, V55, P841, DOI 10.1387/ijdb.113362aa; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Cho JG, 2018, EUR ARCH OTO-RHINO-L, V275, P2355, DOI 10.1007/s00405-018-5061-x; COBOS FA, 2020, NAT COMMUN, V11; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Elyada E, 2019, CANCER DISCOV, V9, P1102, DOI 10.1158/2159-8290.CD-19-0094; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fox NG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09989-y; Glastonbury CA, 2019, AM J HUM GENET, V104, P1013, DOI 10.1016/j.ajhg.2019.03.025; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Kadel D, 2019, CELL BIOL TOXICOL, V35, P407, DOI 10.1007/s10565-019-09461-z; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kobayashi H, 2019, NAT REV GASTRO HEPAT, V16, P282, DOI 10.1038/s41575-019-0115-0; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Mukaida N, 2016, WORLD J GASTROENTERO, V22, P5301, DOI 10.3748/wjg.v22.i23.5301; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Pei GS, 2021, GENOME RES, V31, P146, DOI 10.1101/gr.265769.120; Pei GS, 2019, BIOINFORMATICS, V35, P3842, DOI 10.1093/bioinformatics/btz138; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Ricard-Blum S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004978; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; SAPPINO AP, 1988, INT J CANCER, V41, P707, DOI 10.1002/ijc.2910410512; Shi YF, 2017, NAT REV DRUG DISCOV, V16, P35, DOI 10.1038/nrd.2016.193; Singh M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11049-4; Stunnenberg HG, 2016, CELL, V167, P1897, DOI 10.1016/j.cell.2016.12.002; Sturm G, 2019, BIOINFORMATICS, V35, pI436, DOI 10.1093/bioinformatics/btz363; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Sun Y, 2015, EUR J PHARMACOL, V765, P198, DOI 10.1016/j.ejphar.2015.08.002; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang X, 1999, BRIT J CANCER, V80, P1223, DOI 10.1038/sj.bjc.6690489; Wang YQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02951-4; Yoav Benjamini, 2001, Behavioural Brain Research, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Zheng J, 2019, QUANT BIOL, V7, P247, DOI 10.1007/s40484-019-0189-2	44	8	8	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4686	4694		10.1038/s41388-021-01870-x	http://dx.doi.org/10.1038/s41388-021-01870-x		JUN 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34140640				2022-12-28	WOS:000662838900002
J	Billing, O; Holmgren, Y; Nosek, D; Hedman, H; Hemmingsson, O				Billing, Ola; Holmgren, Ylva; Nosek, Daniel; Hedman, Hakan; Hemmingsson, Oskar			LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance	ONCOGENE			English	Article							NEGATIVE REGULATOR; BRAF(V600E) INHIBITION; RECEPTOR; GROWTH; CANCER; EXPRESSION; PROTEINS; GENES; LMO7; MUTATIONS	Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a pan-negative regulator of receptor tyrosine kinase (RTK) signaling and a tumor suppressor in several cancers, but its involvement in melanoma is largely unexplored. Here, we aim to determine the role of LRIG1 in melanoma tumorigenesis, RTK signaling, and BRAF inhibitor resistance. We find that LRIG1 is downregulated during early tumorigenesis and that LRIG1 affects activation of the epidermal growth factor receptor (EGFR) in melanoma cells. LRIG1-dependent regulation of EGFR signaling is evolutionary conserved to the roundworm C. elegans, where negative regulation of the EGFR-Ras-Raf pathway by sma-10/LRIG completely depends on presence of the receptor let-23/EGFR. In a cohort of metastatic melanoma patients, we observe an association between LRIG1 and survival in the triple wild-type subtype and in tumors with high EGFR expression. During in vitro development of BRAF inhibitor resistance, LRIG1 expression decreases; and mimics LRIG1 knockout cells for increased EGFR expression. Treating resistant cells with recombinant LRIG1 suppresses AKT activation and proliferation. Together, our results show that sma-10/LRIG is a conserved regulator of RTK signaling, add to our understanding of LRIG1 in melanoma and identifies recombinant LRIG1 as a potential therapeutic against BRAF inhibitor-resistant melanoma.	[Billing, Ola; Holmgren, Ylva; Hemmingsson, Oskar] Umea Univ, Dept Surg & Perioperat Sci Surg, Umea, Sweden; [Holmgren, Ylva; Hedman, Hakan] Umea Univ, Dept Radiat Sci Oncol, Umea, Sweden; [Nosek, Daniel] Umea Univ, Dept Med Biosci Pathol, Umea, Sweden; [Hemmingsson, Oskar] Umea Univ, Wallenberg Ctr Mol Med, Umea, Sweden	Umea University; Umea University; Umea University; Umea University	Billing, O (corresponding author), Umea Univ, Dept Surg & Perioperat Sci Surg, Umea, Sweden.	ola.billing@umu.se		Hemmingsson, Oskar/0000-0003-1732-168X; Billing, Ola/0000-0001-5824-6263	NIH Office of Research Infrastructure Programs [P40 OD010440]; Knut and Alice Wallenberg foundation; Wenner-Gren foundations; Swedish Society of Medicine [SLS-503511]; Cancer Research Foundation in Northern Sweden [LP 14-2059, LP 17-2151, LP 19-2207, LP 12-1936]; Region Vasterbotten [RV-371261, RV-644351, RV-762061]; Swedish Cancer Society [CAN 2018/546]; JC Kempe Memorial Foundation	NIH Office of Research Infrastructure Programs(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Knut and Alice Wallenberg foundation(Knut & Alice Wallenberg Foundation); Wenner-Gren foundations; Swedish Society of Medicine; Cancer Research Foundation in Northern Sweden; Region Vasterbotten; Swedish Cancer Society(Swedish Cancer Society); JC Kempe Memorial Foundation	We thank Carl Herdenberg, Lars Nilsson (Umea University) for discussions and Simon Tuck (Umea University) and Richard Padgett (Rutgers University, NJ, USA) for discussions and nematode strains. Some nematode strains were provided by the CGC, which is funded by NIH Office of Research Infrastructure Programs (P40 OD010440). We also thank Christina Lundin, Peter Hagglof, Annika Holmberg, Charlotte Nordstrom and Anette Berglund for technical assistance. This study was funded by the Knut and Alice Wallenberg foundation (OH), the Wenner-Gren foundations (OH), the Swedish Society of Medicine (OH, SLS-503511), Cancer Research Foundation in Northern Sweden (OH, LP 14-2059, LP 17-2151 and LP 19-2207; HH, LP 12-1936), Region Vasterbotten (OH, RV-371261, RV-644351, RV-762061), the Swedish Cancer Society (HH, CAN 2018/546) and JC Kempe Memorial Foundation (YH).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dedeic Z, 2011, J CELL SCI, V124, P1691, DOI 10.1242/jcs.080259; FERGUSON EL, 1985, GENETICS, V110, P17; Gleason RJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180681; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Goldoni S, 2007, ONCOGENE, V26, P368, DOI 10.1038/sj.onc.1209803; Gumienny TL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000963; Guo DS, 2004, GENOMICS, V84, P157, DOI 10.1016/j.ygeno.2004.01.013; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; HAN M, 1990, GENETICS, V126, P899; Holaska JM, 2006, HUM MOL GENET, V15, P3459, DOI 10.1093/hmg/ddl423; Johansson M, 2013, NEURO-ONCOLOGY, V15, P1200, DOI 10.1093/neuonc/not054; Karlsson T, 2008, J INVEST DERMATOL, V128, P1192, DOI 10.1038/sj.jid.5701175; Karlsson T, 2018, LUNG CANCER, V125, P174, DOI 10.1016/j.lungcan.2018.09.017; Kvarnbrink S, 2015, ACTA ONCOL, V54, P1113, DOI 10.3109/0284186X.2015.1021427; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Li W, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181165; Lindquist D, 2014, ACTA ONCOL, V53, P1135, DOI 10.3109/0284186X.2014.953258; Maixner A, 1998, DEV GENET, V23, P347, DOI 10.1002/(SICI)1520-6408(1998)23:4<347::AID-DVG9>3.0.CO;2-C; Mao F, 2017, J NEUROL SCI, V383, P56, DOI 10.1016/j.jns.2017.10.025; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Nilsson J, 2001, BIOCHEM BIOPH RES CO, V284, P1155, DOI 10.1006/bbrc.2001.5092; Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336; Oh YM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04980; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rouam S, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-150; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shah P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080915; Shattuck DL, 2007, MOL CELL BIOL, V27, P1934, DOI 10.1128/MCB.00757-06; Shin SY, 2009, J CELL SCI, V122, P425, DOI 10.1242/jcs.036319; Stefansson K, 2019, ONCOL REP, V42, P142, DOI 10.3892/or.2019.7138; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Suzuki Y, 2002, FEBS LETT, V521, P67, DOI 10.1016/S0014-5793(02)02824-7; Takeda H, 2015, NAT GENET, V47, P142, DOI 10.1038/ng.3175; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wang JX, 2016, J CELL COMMUN SIGNAL, V10, P191, DOI 10.1007/s12079-016-0349-3; Wang Y, 2013, BRIT J CANCER, V108, P1765, DOI 10.1038/bjc.2013.138; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xiang SJ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0844-x; Xiong J, 2019, CANCERS, V11, DOI 10.3390/cancers11030280; Xu YB, 2015, J MOL BIOL, V427, P1934, DOI 10.1016/j.jmb.2015.03.001; Yi W, 2011, EXP CELL RES, V317, P504, DOI 10.1016/j.yexcr.2010.11.005	50	4	4	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3707	3718		10.1038/s41388-021-01808-3	http://dx.doi.org/10.1038/s41388-021-01808-3		MAY 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33947959	hybrid, Green Published			2022-12-28	WOS:000647099200001
J	Kumagai, K; Takanashi, M; Ohno, S; Harada, Y; Fujita, K; Oikawa, K; Sudo, K; Ikeda, S; Nishi, H; Oikawa, K; Kuroda, M				Kumagai, Katsuyoshi; Takanashi, Masakatsu; Ohno, Shin-ichiro; Harada, Yuichirou; Fujita, Koji; Oikawa, Keiki; Sudo, Katsuko; Ikeda, Shun-ichi; Nishi, Hirotaka; Oikawa, Kosuke; Kuroda, Masahiko			WAPL induces cervical intraepithelial neoplasia modulated with estrogen signaling without HPV E6/E7	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS E6; SISTER-CHROMATID COHESION; RECEPTOR-ALPHA; PROGESTERONE-RECEPTOR; CANCER; CARCINOGENESIS; EXPRESSION; ONCOGENE; PROMOTES; SORORIN	Since cervical cancer still afflicts women around the world, it is necessary to understand the underlying mechanism of cervical cancer development. Infection with HPV is essential for the development of cervical intraepithelial neoplasia (CIN). In addition, estrogen receptor signaling is implicated in the development of cervical cancer. Previously, we have isolated human wings apart-like (WAPL), which is expected to cause chromosomal instability in the process of HPV-infected precancerous lesions to cervical cancer. However, the role of WAPL in the development of CIN is still unknown. In this study, in order to elucidate the role of WAPL in the early lesion, we established WAPL overexpressing mice (WAPL Tg mice) and HPV E6/E7 knock-in (KI) mice. WAPL Tg mice developed CIN lesion without HPV E6/E7. Interestingly, in WAPL Tg mice estrogen receptor 1 (ESR1) showed reduction as compared with the wild type, but cell growth factors MYC and Cyclin D1 controlled by ESR1 expressed at high levels. These results suggested that WAPL facilitates sensitivity of ESR1 mediated by some kind of molecule, and as a result, affects the expression of MYC and Cyclin D1 in cervical cancer cells. To detect such molecules, we performed microarray analysis of the uterine cervix in WAPL Tg mice, and focused MACROD1, a co-activator of ESR1. MACROD1 expression was increased in WAPL Tg mice compared with the wild type. In addition, knockdown of WAPL induced the downregulation of MACROD1, MYC, and Cyclin D1 but not ESR1 expression. Furthermore, ESR1 sensitivity assay showed lower activity in WAPL or MACROD1 downregulated cells than control cells. These data suggested that WAPL increases ESR1 sensitivity by activating MACROD1, and induces the expression of MYC and Cyclin D1. Therefore, we concluded that WAPL not only induces chromosomal instability in cervical cancer tumorigenesis, but also plays a key role in activating estrogen receptor signaling in early tumorigenesis.	[Kumagai, Katsuyoshi; Sudo, Katsuko] Tokyo Med Univ, Preclin Res Ctr, Tokyo, Japan; [Takanashi, Masakatsu; Ohno, Shin-ichiro; Harada, Yuichirou; Fujita, Koji; Oikawa, Keiki; Kuroda, Masahiko] Tokyo Med Univ, Dept Mol Pathol, Tokyo, Japan; [Ikeda, Shun-ichi] Kohseichuo Gen Hosp, Dept Obstet & Gynecol, Tokyo, Japan; [Nishi, Hirotaka] Tokyo Med Univ, Dept Obstet & Gynecol, Tokyo, Japan; [Oikawa, Kosuke] Wakayama Med Univ, Dept Pathol, Wakayama, Japan	Tokyo Medical University; Tokyo Medical University; Tokyo Medical University; Wakayama Medical University	Kuroda, M (corresponding author), Tokyo Med Univ, Dept Mol Pathol, Tokyo, Japan.	kuroda@tokyo-med.ac.jp	慎一郎, 大野/AAI-7736-2021	Kuroda, Masahiko/0000-0001-7052-4289; Takanashi, Masakatsu/0000-0002-7127-1153; Ohno, Shin-ichiro/0000-0003-1064-4750	Tokyo Medical University Foundation Cancer Research Fund;  [20K09654]	Tokyo Medical University Foundation Cancer Research Fund; 	We thank Dr. Shouichirou Mineo of Tokyo Medical University and Dr. Shinichi Miyagawa of Tokyo University of Science for their technical assistance and advice regarding the experiments. We appreciate Dr. Tohru Kiyono of the National Cancer Center Research Institute for his donating of pDONR201-16E6E7 vector. This work was partly supported by the Grants-in-Aid for Scientific Research of Education, Culture, Sports, Science and Technology, Japan (MEXT Grant), Grant number: (20K09654 to KK) and the Tokyo Medical University Foundation Cancer Research Fund.	Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chen M, 2019, CANCER SCI, V110, P2794, DOI 10.1111/cas.14140; Chen Q, 2016, ONCOTARGET, V7, P36115, DOI 10.18632/oncotarget.8741; Chen Q, 2014, ONCOTARGET, V5, P9092, DOI 10.18632/oncotarget.2377; Chung SH, 2010, TRENDS ENDOCRIN MET, V21, P504, DOI 10.1016/j.tem.2010.03.005; Chung SH, 2009, P NATL ACAD SCI USA, V106, P19467, DOI 10.1073/pnas.0911436106; Chung SH, 2008, CANCER RES, V68, P9928, DOI 10.1158/0008-5472.CAN-08-2051; den Boon JA, 2015, P NATL ACAD SCI USA, V112, pE3255, DOI 10.1073/pnas.1509322112; Duensing S, 2004, INT J CANCER, V109, P157, DOI 10.1002/ijc.11691; Duensing S, 2002, CANCER RES, V62, P7075; Gandhi R, 2006, CURR BIOL, V16, P2406, DOI 10.1016/j.cub.2006.10.061; Goldman JM, 2007, BIRTH DEFECTS RES B, V80, P84, DOI 10.1002/bdrb.20106; Gu TT, 2012, AM J PATHOL, V181, P652, DOI 10.1016/j.ajpath.2012.04.008; Han WD, 2007, ENDOCR-RELAT CANCER, V14, P741, DOI 10.1677/ERC-06-0082; Hara K, 2014, NAT STRUCT MOL BIOL, V21, P864, DOI 10.1038/nsmb.2880; Hong K, 2018, BMB REP, V51, P225, DOI 10.5483/BMBRep.2018.51.5.045; Hong MK, 2017, INT J GYNECOL CANCER, V27, P1247, DOI 10.1097/IGC.0000000000001004; Jin GX, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00147; Kobayashi D, 2011, INT J ONCOL, V38, P933, DOI 10.3892/ijo.2011.929; Kueng S, 2006, CELL, V127, P955, DOI 10.1016/j.cell.2006.09.040; Kurita T, 2010, DIFFERENTIATION, V80, P99, DOI 10.1016/j.diff.2010.06.007; Kuroda M, 2005, BRIT J CANCER, V92, P290, DOI 10.1038/sj.bjc.6602329; Kwasniewska A, 2011, ONCOL REP, V26, P153, DOI 10.3892/or.2011.1256; Li A, 2015, ONCOGENE, V34, P63, DOI 10.1038/onc.2013.529; Li SF, 2007, BIRTH DEFECTS RES B, V80, P246, DOI 10.1002/bdrb.20120; Li XJ, 2012, CHINESE MED J-PEKING, V125, P1695, DOI 10.3760/cma.j.issn.0366-6999.2012.10.004; Li YJ, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1225-6; Masuda S, 2013, NEW ENGL J MED, V369, P1171, DOI 10.1056/NEJMc1308785; Merkwitz C, 2016, LAB ANIM-UK, V50, P344, DOI 10.1177/0023677215617387; Miyagawaa S, 2015, P NATL ACAD SCI USA, V112, P12986, DOI 10.1073/pnas.1513550112; Nam Eun Ji, 2008, J Gynecol Oncol, V19, P162, DOI 10.3802/jgo.2008.19.3.162; Narisawa-Saito M, 2007, CANCER SCI, V98, P1505, DOI 10.1111/j.1349-7006.2007.00546.x; Nishiyama T, 2010, CELL, V143, P737, DOI 10.1016/j.cell.2010.10.031; Ohbayashi T, 2007, BIOCHEM BIOPH RES CO, V356, P699, DOI 10.1016/j.bbrc.2007.03.037; Oikawa K, 2004, CANCER RES, V64, P3545, DOI 10.1158/0008-5472.CAN-03-3822; Riley RR, 2003, CANCER RES, V63, P4862; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shai A, 2007, CANCER RES, V67, P1626, DOI 10.1158/0008-5472.CAN-06-3344; Snijders PJF, 2006, J PATHOL, V208, P152, DOI 10.1002/path.1866; Son J, 2018, J PATHOL, V245, P147, DOI 10.1002/path.5069; Son J, 2014, CARCINOGENESIS, V35, P489, DOI 10.1093/carcin/bgt350; Steenbergen RDM, 2014, NAT REV CANCER, V14, P395, DOI 10.1038/nrc3728; Tian LY, 2009, J ENDOCRINOL, V202, P167, DOI 10.1677/JOE-09-0054; Tsoumpou I, 2009, CANCER TREAT REV, V35, P210, DOI 10.1016/j.ctrv.2008.10.005; Yong KJ, 2016, ONCOTARGET, V7, P75425, DOI 10.18632/oncotarget.12251; Yuan X, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.69; Zang Li, 2018, Cell Physiol Biochem, V51, P2591, DOI 10.1159/000495931; Zhai YL, 2010, AM J PATHOL, V177, P884, DOI 10.2353/ajpath.2010.091166; Zhang NG, 2012, CELL CYCLE, V11, P2073, DOI 10.4161/cc.20241; Zhong PP, 2015, INT J CLIN EXP PATHO, V8, P2979; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	55	1	1	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3695	3706		10.1038/s41388-021-01787-5	http://dx.doi.org/10.1038/s41388-021-01787-5		MAY 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33947962	hybrid, Green Published			2022-12-28	WOS:000647084500004
J	Xu, LL; Liu, WZ; Li, TT; Hu, YY; Wang, Y; Huang, LJ; Wang, Y; Shao, SJ; Liu, XF; Zhan, QM				Xu, Lele; Liu, Wenzhong; Li, Tongtong; Hu, Yuying; Wang, Yu; Huang, Lijie; Wang, Yan; Shao, Shujuan; Liu, Xuefeng; Zhan, Qimin			Long non-coding RNA SMASR inhibits the EMT by negatively regulating TGF-beta/Smad signaling pathway in lung cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LNCRNA; METASTASIS; EXPRESSION; PROMOTES; REPRESSION; INTERACTS; TARGET; CELLS; MYC	TGF-beta/Smad signaling pathway plays an important role in EMT during cancer progression. Long non-coding RNAs (lncRNAs) are involved in various behaviors of cancer cells, including EMT. Here, we report a novel lncRNA adjacent to Smad3, named Smad3-associated long non-coding RNA (SMASR). SMASR is downregulated by TGF-beta via Smad2/3 in lung cancer cells. Knockdown of SMASR induces EMT and increases the migration and invasion of lung cancer cells. Moreover, knockdown of SMASR promotes the phosphorylation of Smad2/3. Mechanistically, SMASR interacts with Smad2/3 and inhibits the expression of TGFBR1, the TGF-beta type I receptor responsible for phosphorylation of Smad2/3, thus leading to inactivation of TGF-beta/Smad signaling pathway. Clinically, SMASR is downregulated in lung cancer tissues. Collectively, our findings prove a critical role of SMASR in EMT of lung cancer by forming a negative feedback loop with TGF-beta/Smad signaling pathway.	[Xu, Lele; Liu, Wenzhong; Li, Tongtong; Wang, Yu; Huang, Lijie; Liu, Xuefeng; Zhan, Qimin] Dalian Med Univ, Inst Canc Stern Cell, Dalian, Peoples R China; [Hu, Yuying; Wang, Yan; Zhan, Qimin] Peking Univ Canc Hosp & Inst, Lab Mol Oncol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China; [Shao, Shujuan] Dalian Med Univ, Liaoning Key Lab Prote, Dalian, Peoples R China	Dalian Medical University; Dalian Medical University	Liu, XF; Zhan, QM (corresponding author), Dalian Med Univ, Inst Canc Stern Cell, Dalian, Peoples R China.; Zhan, QM (corresponding author), Peking Univ Canc Hosp & Inst, Lab Mol Oncol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China.	ixuee@sina.com; zhanqimin@bjmu.edu.cn	Xu, Le/HDN-9623-2022		National Basic Research Program of China (973 Program) [2015CB553906]; National Natural Science Foundation of China [81988101, 81830086]; third round of public welfare development and reform pilot projects of Beijing Municipal Medical Research Institutes (Beijing Medical Research Institute) [2019-1]; Beijing Municipal Commission of Health and Family Planning Project [PXM2018_026279_000005]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); third round of public welfare development and reform pilot projects of Beijing Municipal Medical Research Institutes (Beijing Medical Research Institute); Beijing Municipal Commission of Health and Family Planning Project	This work was supported by the National Basic Research Program of China (973 Program) (2015CB553906), the National Natural Science Foundation of China (81988101 and 81830086), the third round of public welfare development and reform pilot projects of Beijing Municipal Medical Research Institutes (Beijing Medical Research Institute, 2019-1), and the Beijing Municipal Commission of Health and Family Planning Project (PXM2018_026279_000005). The results shown here are part based upon data generated by the TCGA Research Network:.	Acha-Sagredo A, 2020, BRIT J CANCER, V122, P1050, DOI 10.1038/s41416-020-0742-9; Arab K, 2014, MOL CELL, V55, P604, DOI 10.1016/j.molcel.2014.06.031; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Chen F, 2019, NAT CELL BIOL, V21, P498, DOI 10.1038/s41556-019-0299-0; Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003; Dimitrova N, 2014, MOL CELL, V54, P777, DOI 10.1016/j.molcel.2014.04.025; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Fan Y, 2014, CLIN CANCER RES, V20, P1531, DOI 10.1158/1078-0432.CCR-13-1455; Grelet S, 2017, NAT CELL BIOL, V19, P1105, DOI 10.1038/ncb3595; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hao Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112767; Hu WL, 2018, NAT CELL BIOL, V20, P492, DOI 10.1038/s41556-018-0066-7; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; MIAO H, 2019, JAMA NEUROL, V15; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Mondal T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8743; Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373; Postepska-Igielska A, 2015, MOL CELL, V60, P626, DOI 10.1016/j.molcel.2015.10.001; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Rodriguez-Mateo C, 2017, CELL DEATH DIFFER, V24, P785, DOI 10.1038/cdd.2017.9; Rossi M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09754-1; Sakai S, 2019, CANCER RES, V79, P2821, DOI 10.1158/0008-5472.CAN-18-3210; Sang LJ, 2018, MOL CELL, V72, P71, DOI 10.1016/j.molcel.2018.08.014; Sato M, 2003, J CLIN INVEST, V112, P1486, DOI 10.1172/JCI200319270; Schmitt AM, 2016, NAT GENET, V48, P1370, DOI 10.1038/ng.3673; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Singh M, 2018, PHARMACOL THERAPEUT, V182, P80, DOI 10.1016/j.pharmthera.2017.08.009; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trimarchi T, 2014, CELL, V158, P593, DOI 10.1016/j.cell.2014.05.049; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Wang L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt006; Wang LJ, 2015, CELL RES, V25, P335, DOI 10.1038/cr.2015.21; Wang P, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat2039; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Wang YQ, 2019, CANCER RES, V79, P3542, DOI 10.1158/0008-5472.CAN-18-2900; Wang ZH, 2018, CANCER CELL, V33, P706, DOI 10.1016/j.ccell.2018.03.006; Wu N, 2021, CELL DEATH DIFFER, V28, P219, DOI 10.1038/s41418-020-0596-y; Xia M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15818; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Yeung KT, 2017, MOL ONCOL, V11, P28, DOI 10.1002/1878-0261.12017; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-00321-0, 10.1038/s41467-017-01968-5]; Zheng C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2085-0	54	7	7	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3578	3592		10.1038/s41388-021-01760-2	http://dx.doi.org/10.1038/s41388-021-01760-2		APR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33931741				2022-12-28	WOS:000645887000002
J	Liu, LX; Zhang, XL; Ding, HY; Liu, X; Cao, DH; Liu, YQ; Liu, JW; Lin, C; Zhang, N; Wang, GN; Hou, JY; Huang, BQ; Zhang, Y; Lu, J				Liu, Lingxia; Zhang, Xiliu; Ding, Huayi; Liu, Xin; Cao, Donghui; Liu, Yingqi; Liu, Jiwei; Lin, Cong; Zhang, Na; Wang, Guannan; Hou, Jingyao; Huang, Baiqu; Zhang, Yu; Lu, Jun			Arginine and lysine methylation of MRPS23 promotes breast cancer metastasis through regulating OXPHOS	ONCOGENE			English	Article								Mitochondrial oxidative phosphorylation (OXPHOS) is a vital regulator of tumor metastasis. However, the mechanisms governing OXPHOS to facilitate tumor metastasis remain unclear. In this study, we discovered that arginine 21(R21) and lysine 108 (K108) of mitochondrial ribosomal protein S23 (MRPS23) was methylated by the protein arginine methyltransferase 7 (PRMT7) and SET-domain-containing protein 6 (SETD6), respectively. R21 methylation accelerated the poly-ubiquitin-dependent degradation of MRPS23 to a low level. The MRPS23 degradation inhibited OXPHOS with elevated mtROS level, which consequently increased breast cancer cell invasion and metastasis. In contrast, K108 methylation increased MRPS23 stability, and K108 methylation coordinated with R21 methylation to maintain a low level of MRPS23, which was in favor of supporting breast cancer cell survival through regulating OXPHOS. Consistently, R21 and K108 methylation was correlated with malignant breast carcinoma. Significantly, our findings unveil a unique mechanism of controlling OXPHOS by arginine and lysine methylation and point to the impact of the PRMT7-SETD6-MRPS23 axis during breast cancer metastasis.	[Liu, Lingxia; Zhang, Xiliu; Liu, Xin; Liu, Jiwei; Lin, Cong; Huang, Baiqu; Lu, Jun] Northeast Normal Univ, Minist Educ MOE, Key Lab Mol Epigenet, Changchun, Peoples R China; [Ding, Huayi; Liu, Yingqi; Zhang, Na; Hou, Jingyao; Zhang, Yu] Northeast Normal Univ, Inst Genet & Cytol, Changchun, Peoples R China; [Cao, Donghui] First Hosp Jilin Univ, Div Clin Res, Changchun, Peoples R China; [Wang, Guannan] Northeast Normal Univ, Natl Engn Lab Druggable Gene & Prot Screening, Changchun, Peoples R China	Northeast Normal University - China; Northeast Normal University - China; Jilin University; Northeast Normal University - China	Lu, J (corresponding author), Northeast Normal Univ, Minist Educ MOE, Key Lab Mol Epigenet, Changchun, Peoples R China.; Zhang, Y (corresponding author), Northeast Normal Univ, Inst Genet & Cytol, Changchun, Peoples R China.	zhangy288@nenu.edu.cn; luj809@nenu.edu.cn			National Natural Science Foundation of China [31770825, 31571317, 31570718, 31771335, 31870765]; Science and Technology Development Project of Jilin province [20180101232JC, 20180101234JC, 20200404106YY]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Development Project of Jilin province	This work was supported by the grants from the National Natural Science Foundation of China (grant numbers: 31770825, 31571317, 31570718, 31771335, and 31870765) and the Science and Technology Development Project of Jilin province (grant number: 20180101232JC, 20180101234JC, and 20200404106YY).	AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Baldwin RM, 2015, ONCOTARGET, V6, P3013, DOI 10.18632/oncotarget.3072; Bedford MT, 2007, J CELL SCI, V120, P4243, DOI 10.1242/jcs.019885; Biggar KK, 2015, NAT REV MOL CELL BIO, V16, P5, DOI 10.1038/nrm3915; Binda O, 2020, EPIGENETICS-US, V15, P26, DOI 10.1080/15592294.2019.1649529; Binda O, 2013, EPIGENETICS-US, V8, P177, DOI 10.4161/epi.23416; Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006; Boisvert Francois-Michel, 2005, Sci STKE, V2005, pre2, DOI 10.1126/stke.2712005re2; Chen GY, 2014, ACTA BIOCH BIOPH SIN, V46, P512, DOI 10.1093/abbs/gmu029; Dan L., 2011, NAT IMMUNOL, V12, P29, DOI DOI 10.1038/NI.1968; Del Rizzo PA, 2014, BBA-GENE REGUL MECH, V1839, P1404, DOI 10.1016/j.bbagrm.2014.06.008; Dewhirst MW, 2009, RADIAT RES, V172, P653, DOI 10.1667/RR1926.1; Feldman M, 2019, P NATL ACAD SCI USA, V116, P1235, DOI 10.1073/pnas.1804407116; Feng J, 2017, ONCOGENE, V36, P2775, DOI 10.1038/onc.2016.432; Ferreira TR, 2020, NUCLEIC ACIDS RES, V48, P5511, DOI 10.1093/nar/gkaa211; Fogal V, 2010, MOL CELL BIOL, V30, P1303, DOI 10.1128/MCB.01101-09; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gao Y, 2017, ONCOTARGET, V8, P71772, DOI 10.18632/oncotarget.17888; Gatza ML, 2014, NAT GENET, V46, P1051, DOI 10.1038/ng.3073; Geng PY, 2017, FASEB J, V31, P2287, DOI 10.1096/fj.201601196R; Gopisetty G, 2016, GENE, V589, P27, DOI 10.1016/j.gene.2016.05.008; Gupta SC, 2012, ANTIOXID REDOX SIGN, V16, P1295, DOI 10.1089/ars.2011.4414; Hamamoto R, 2015, NAT REV CANCER, V15, P110, DOI 10.1038/nrc3884; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hou P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.249; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Jain K, 2017, P NATL ACAD SCI USA, V114, P10101, DOI 10.1073/pnas.1706978114; Kenmochi N, 2001, GENOMICS, V77, P65, DOI 10.1006/geno.2001.6622; Kim HJ, 2017, SEMIN CANCER BIOL, V47, P67, DOI 10.1016/j.semcancer.2017.04.004; Klaestad E, 2020, BREAST CANCER RES TR, V180, P73, DOI 10.1007/s10549-020-05532-6; Kohda M, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005679; Le DD, 2012, CURR OPIN CHEM BIOL, V16, P507, DOI 10.1016/j.cbpa.2012.09.014; Liu FB, 2017, NAT CELL BIOL, V19, P1358, DOI 10.1038/ncb3630; O'Neill DJ., 2014, EPIGENETICS-US, V9, P9; Piao L, 2015, ONCOTARGET, V6, P16939, DOI 10.18632/oncotarget.4760; Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043; Pu M, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317709127; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Sullivan LB, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-17; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vershinin Z, 2016, J BIOL CHEM, V291, P6786, DOI 10.1074/jbc.M115.697292; Wang YP, 2016, MOL CELL, V64, P673, DOI 10.1016/j.molcel.2016.09.028; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wong TL, 2020, HEPATOLOGY, V71, P1279, DOI 10.1002/hep.30923; Wu WC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0961-7; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Yao RS, 2014, CANCER RES, V74, P5656, DOI 10.1158/0008-5472.CAN-14-0800; Zempel KEC, 2016, J PROTEOME RES, V15, P4436, DOI 10.1021/acs.jproteome.6b00521; Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045; Zhang ZL, 2003, GENOMICS, V81, P468, DOI 10.1016/S0888-7543(03)00004-1; Zhao L, 2015, CELL DEATH DIFFER, V22, P1630, DOI 10.1038/cdd.2015.6; Zhou C, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0196-z; Zielonka J, 2010, FREE RADICAL BIO MED, V48, P983, DOI 10.1016/j.freeradbiomed.2010.01.028; Zurita-Lopez CI, 2012, J BIOL CHEM, V287, P7859, DOI 10.1074/jbc.M111.336271	55	8	8	7	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3548	3563		10.1038/s41388-021-01785-7	http://dx.doi.org/10.1038/s41388-021-01785-7		APR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33927350				2022-12-28	WOS:000645517200001
J	Wu, SS; Liu, BD; Zhang, YH; Hong, RH; Liu, SH; Xiang, T; Tao, TY; Cai, JC; Wu, JH; Li, MF; Guan, HY				Wu, Shanshan; Liu, Bangdong; Zhang, Youhong; Hong, Ruohui; Liu, Shihua; Xiang, Tao; Tao, Tianyu; Cai, Junchao; Wu, Jueheng; Li, Mengfeng; Guan, Hongyu			Long non-coding RNA LEISA promotes progression of lung adenocarcinoma via enhancing interaction between STAT3 and IL-6 promoter	ONCOGENE			English	Article							CANCER; INFLAMMATION; TRANSCRIPTION; TARGETS; BIOLOGY; CELLS; PTEN; IL6	Long non-coding RNAs (lncRNAs) are emerging as a new class of regulators for a variety of biological processes and have been suggested to play pivotal roles in cancer development and progression. Our current study found that a lncRNA, designated enhancing IL-6/STAT3 signaling activation (LEISA, ENST00000603468), functioned as an oncogenic lncRNA in lung adenocarcinoma (LAD), a major form of non-small cell lung carcinoma, which is one of the most frequently diagnosed malignancies with high morbidity and mortality worldwide, and was involved in the regulation of STAT3 induced IL-6 transcription. Our data showed that LEISA was highly expressed in, and correlated with the clinical progression and prognosis of LAD. Ectopic expression of LEISA promoted the proliferation and suppressed apoptosis of LAD cells in vitro and in vivo. Mechanistically, we demonstrated that LEISA recruited STAT3 to bind the promoter of IL-6 and upregulated IL-6 expression. Taken together, our work identifies LEISA as a potential diagnostic biomarker and therapeutic target for LAD.	[Wu, Shanshan; Liu, Bangdong; Hong, Ruohui; Tao, Tianyu; Wu, Jueheng; Li, Mengfeng] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou, Guangdong, Peoples R China; [Wu, Shanshan] Guangdong Med Univ, Sch Basic Med Sci, Dept Biol, Zhanjiang, Guangdong, Peoples R China; [Zhang, Youhong; Li, Mengfeng] Southern Med Univ, Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China; [Liu, Shihua] Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Xiang, Tao; Guan, Hongyu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China; [Cai, Junchao] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Immunol, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Guangdong Medical University; Southern Medical University - China; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Wu, JH; Li, MF (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou, Guangdong, Peoples R China.; Li, MF (corresponding author), Southern Med Univ, Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China.; Guan, HY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China.	wujh@mail.sysu.edu.cn; limf@mail.sysu.edu.cn; ghongy@mail.sysu.edu.cn			National Key Research and Development Program of China [2017YFA0106300]; National Natural Science Foundation of China [81972170, 81820108025, 81621004, 81672296, 81922050, 81772473, 81802274]; Science and Technology Program of Guangzhou City [201803010039]; Guangdong MEPP Fund [GDOE [2019]A21]; Natural Science Foundation of Guangdong Province [2019A1515011174]; Fundamental Research Funds for the Central Universities [19ykpy162]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangzhou City; Guangdong MEPP Fund; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by the National Key Research and Development Program of China (2017YFA0106300) and the National Natural Science Foundation of China (81972170, 81820108025, 81621004, 81672296, 81922050, 81772473, 81802274); the Science and Technology Program of Guangzhou City (201803010039); the Guangdong MEPP Fund (NO. GDOE [2019]A21); the Natural Science Foundation of Guangdong Province (2019A1515011174); the Fundamental Research Funds for the Central Universities (19ykpy162).	Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brichory FM, 2001, P NATL ACAD SCI USA, V98, P9824, DOI 10.1073/pnas.171320598; Cai JC, 2018, NAT CELL BIOL, V20, P465, DOI 10.1038/s41556-018-0065-8; Cai JC, 2013, CANCER RES, V73, P5402, DOI 10.1158/0008-5472.CAN-13-0297; Calabrese LH, 2014, NAT REV RHEUMATOL, V10, P720, DOI 10.1038/nrrheum.2014.127; Chang RX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05852-8; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Deng SJ, 2019, CANCER RES, V79, P1398, DOI 10.1158/0008-5472.CAN-18-0419; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Engreitz JM, 2016, NATURE, V539, P452, DOI 10.1038/nature20149; Ettinger DS, 2015, J NATL COMPR CANC NE, V13, P515, DOI 10.6004/jnccn.2015.0071; Fang LS, 2019, ONCOGENE, V38, P896, DOI 10.1038/s41388-018-0484-9; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Guan HY, 2019, P NATL ACAD SCI USA, V116, P14019, DOI 10.1073/pnas.1900997116; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778; Hung T, 2010, RNA BIOL, V7, P582, DOI 10.4161/rna.7.5.13216; Iioka H, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1316; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577-018-0066-7; Kang SJ, 2019, IMMUNITY, V50, P1007, DOI 10.1016/j.immuni.2019.03.026; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704; Lai F, 2013, NATURE, V494, P497, DOI 10.1038/nature11884; Lederle W, 2011, INT J CANCER, V128, P2803, DOI 10.1002/ijc.25621; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Liu WJ, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107438; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Matsushita K, 2009, NATURE, V458, P1185, DOI 10.1038/nature07924; Peng WX, 2017, ONCOGENE, V36, P5661, DOI 10.1038/onc.2017.184; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Silva A, 2015, CANCERS, V7, P2169, DOI 10.3390/cancers7040884; Song LX, 2011, MOL CANCER THER, V10, P481, DOI 10.1158/1535-7163.MCT-10-0502; Tanaka T, 2014, CANCER IMMUNOL RES, V2, P288, DOI 10.1158/2326-6066.CIR-14-0022; Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Uehata T, 2013, CELL, V153, P1036, DOI 10.1016/j.cell.2013.04.034; Vinocha A, 2018, J CANCER RES THER, V14, pS758, DOI 10.4103/0973-1482.183217; Wang JX, 2019, MOL ONCOL, V13, P2344, DOI 10.1002/1878-0261.12538; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang X, 2016, J HEPATOL, V64, P1283, DOI 10.1016/j.jhep.2016.01.019; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Xing YH, 2017, CELL, V169, P664, DOI 10.1016/j.cell.2017.04.011; Ying Z, 2017, J CLIN INVEST, V127, P1725, DOI 10.1172/JCI90439; Yoon S, 2012, ONCOGENE, V31, P3467, DOI 10.1038/onc.2011.517; Yoon S, 2010, AUTOPHAGY, V6, P1125, DOI 10.4161/auto.6.8.13547; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	52	5	6	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3449	3459		10.1038/s41388-021-01769-7	http://dx.doi.org/10.1038/s41388-021-01769-7		APR 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33859372				2022-12-28	WOS:000640485900001
J	Chen, K; Hou, YF; Liao, R; Li, YZ; Yang, HJ; Gong, J				Chen, Kai; Hou, Yifu; Liao, Rui; Li, Youzan; Yang, Hongji; Gong, Jun			LncRNA SNHG6 promotes G1/S-phase transition in hepatocellular carcinoma by impairing miR-204-5p-mediated inhibition of E2F1	ONCOGENE			English	Article							LONG NONCODING RNA; CELL-PROLIFERATION; UP-REGULATION; CANCER; PROGRESSION; APOPTOSIS; GROWTH; CERNA; METHYLATION; METASTASIS	Emerging evidence suggests that long noncoding RNAs (lncRNAs) function as competitive endogenous RNA (ceRNA) targeting proteins and genes; however, the role of lncRNAs in hepatocellular carcinoma (HCC) is not well understood. We investigated the mechanism by which lncRNA SNHG6 promotes the development of HCC. RT-qPCR revealed upregulated lncRNA SNHG6 in the HCC setting. Elevated SNHG6 expression was indicative of poor prognosis in patients with HCC. SNHG6 overexpression resulted in increased cyclin D1, cyclin E1, and E2F1 expression both in vitro and in vivo. SNHG6 also promoted HCC cell proliferation by enhancing G1-S phase transition in vitro. Dual luciferase reporter assays, RIP, and RNA pull-down assays demonstrated SNHG6 competitively bound to miR-204-5p and inhibited its expression preventing miR-204-5p from targeting E2F1. Overexpression of miR-204-5p abolished the effect of SNHG6. Our data suggest that SNHG6 functions as a ceRNA that targets miR-204-5p resulting in an increased E2F1 expression and enhanced G1-S phase transition, thereby promoting the tumorigenesis of HCC.	[Chen, Kai; Hou, Yifu; Yang, Hongji] Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Organ Transplant Ctr, Chengdu, Peoples R China; [Chen, Kai; Hou, Yifu; Yang, Hongji; Gong, Jun] Chinese Acad Sci, Sichuan Translat Med Res Hosp, Chengdu, Peoples R China; [Chen, Kai; Hou, Yifu; Yang, Hongji] Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Ward Hepatobiliary Pancreat Surg 3, Chengdu, Peoples R China; [Liao, Rui; Li, Youzan] Southwest Med Univ, Sch Clin Med, Dept Hepatobiliary, Luzhou, Peoples R China; [Gong, Jun] Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Ward Hepatobiliary Pancreat Surg 2, Chengdu, Peoples R China	Sichuan Provincial People's Hospital; Chinese Academy of Sciences; Sichuan Provincial People's Hospital; Southwest Medical University; Sichuan Provincial People's Hospital	Yang, HJ (corresponding author), Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Organ Transplant Ctr, Chengdu, Peoples R China.; Yang, HJ; Gong, J (corresponding author), Chinese Acad Sci, Sichuan Translat Med Res Hosp, Chengdu, Peoples R China.; Yang, HJ (corresponding author), Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Ward Hepatobiliary Pancreat Surg 3, Chengdu, Peoples R China.; Gong, J (corresponding author), Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Ward Hepatobiliary Pancreat Surg 2, Chengdu, Peoples R China.	yanghongji99@163.com; 756772096@qq.com	Hou, Yifu/GYQ-7105-2022					Ali Syeda Z, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051723; Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629; Birgani MT, 2018, PATHOL ONCOL RES, V24, P329, DOI 10.1007/s12253-017-0241-3; Boon RA, 2016, J AM COLL CARDIOL, V67, P1214, DOI 10.1016/j.jacc.2015.12.051; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao C, 2017, ONCOGENE, V36, P1112, DOI 10.1038/onc.2016.278; Chang L, 2016, CANCER LETT, V383, P183, DOI 10.1016/j.canlet.2016.09.034; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chen L, 2013, J BIOL CHEM, V288, P14510, DOI 10.1074/jbc.M113.458737; Chen QC, 2018, J CELL PHYSIOL, V233, P1213, DOI 10.1002/jcp.25988; Chu Y, 2018, FEBS OPEN BIO, V8, P189, DOI 10.1002/2211-5463.12363; Duan SH, 2018, ONCOL RES, V26, P713, DOI 10.3727/096504017X15016337254641; Duan YJ, 2016, ONCOTARGET, V7, P45863, DOI 10.18632/oncotarget.10244; Duan YX, 2020, ONCOTARGETS THER, V13, P2701, DOI 10.2147/OTT.S237069; Farra R, 2015, BIOCHIMIE, V112, P85, DOI 10.1016/j.biochi.2015.02.015; Farra R, 2011, DIGEST LIVER DIS, V43, P1006, DOI 10.1016/j.dld.2011.07.007; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Ge YX, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005726; Greten TF, 2019, GASTROENTEROLOGY, V156, P510, DOI 10.1053/j.gastro.2018.09.051; Grieco FA, 2019, J MOL ENDOCRINOL, V63, P139, DOI 10.1530/JME-19-0066; Gu Y, 2018, ONCOL REP, V40, P1863, DOI 10.3892/or.2018.6621; He Y, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117656; HU F, 2018, CLIN INFECT DIS, V17; Huang JX, 2016, SCI REP-UK, V6, DOI 10.1038/srep20384; Huang Z, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01188-4; Ikeda K, 2006, J IMMUNOL METHODS, V317, P38, DOI 10.1016/j.jim.2006.09.010; Ingham M, 2017, J CLIN ONCOL, V35, P2949, DOI 10.1200/JCO.2016.69.0032; Jiang GB, 2017, BIOMED PHARMACOTHER, V90, P806, DOI 10.1016/j.biopha.2017.03.081; Jin Y, 2019, HEPATOL INT, V13, P180, DOI 10.1007/s12072-018-9920-8; Kent LN, 2019, NAT REV CANCER, V19, P326, DOI 10.1038/s41568-019-0143-7; Kumari A, 2015, CELL DEATH DIFFER, V22, P311, DOI 10.1038/cdd.2014.146; Li HM, 2020, ONCOTARGETS THER, V13, P757, DOI 10.2147/OTT.S224550; Li Y, 2018, LIFE SCI, V208, P295, DOI 10.1016/j.lfs.2018.07.032; Liu JY, 2019, PEERJ, V7, DOI 10.7717/peerj.7310; Long JY, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0817-y; Lu M, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110566; Ma L, 2017, ONCOL REP, V38, P2951, DOI 10.3892/or.2017.5971; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138; Parasramka MA, 2016, PHARMACOL THERAPEUT, V161, P67, DOI 10.1016/j.pharmthera.2016.03.004; Pecoraro A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51723-7; Putzer BM, 2013, TRENDS MOL MED, V19, P89, DOI 10.1016/j.molmed.2012.10.009; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Tsang FHC, 2015, LIVER INT, V35, P1597, DOI 10.1111/liv.12746; Wong CM, 2018, NAT REV GASTRO HEPAT, V15, P137, DOI 10.1038/nrgastro.2017.169; Wu G, 2019, CELL CYCLE, V18, P1849, DOI 10.1080/15384101.2019.1629772; Wu XJ, 2015, FEBS LETT, V589, P645, DOI 10.1016/j.febslet.2015.01.030; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Yuan SX, 2016, CANCER LETT, V379, P239, DOI 10.1016/j.canlet.2015.08.008; Zhang J, 2020, J CANCER, V11, P3199, DOI 10.7150/jca.33273; Zhang P, 2020, CANCER BIOMARK, V28, P381, DOI 10.3233/CBM-191064; Zhang Y, 2020, MOL NEUROBIOL, V57, P2377, DOI 10.1007/s12035-020-01887-5; Zhao HW, 2016, ONCOL RES, V23, P237, DOI 10.3727/096504016X14562725373671; Zhao LJ, 2019, AGING-US, V11, P7098, DOI 10.18632/aging.102240; Zheng SS, 2013, MOL CELL, V52, P37, DOI 10.1016/j.molcel.2013.08.039	57	9	9	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3217	3230		10.1038/s41388-021-01671-2	http://dx.doi.org/10.1038/s41388-021-01671-2		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33824472				2022-12-28	WOS:000637478800001
J	Wang, XS; Feng, M; Xiao, TF; Guo, BS; Liu, DY; Liu, CL; Pei, JP; Liu, QF; Xiao, Y; Rosin-Arbesfeld, R; Shi, Y; Zhou, Y; Yang, MX; Feng, YX; Jiang, YZ; Shao, ZM; Yu, K; Zhu, D				Wang, Xiaoshuang; Feng, Mei; Xiao, Tengfei; Guo, Baosen; Liu, Danyang; Liu, Chenglong; Pei, Jinpeng; Liu, Qiaofeng; Xiao, Yi; Rosin-Arbesfeld, Rina; Shi, Ying; Zhou, Yang; Yang, Mengxuan; Feng, Yu-Xiong; Jiang, Yizhou; Shao, Zhimin; Yu, Ker; Zhu, Di			BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer	ONCOGENE			English	Article								Treatment of patients with triple-negative breast cancer (TNBC) has been challenging due to a lack of well-defined molecular targets. The Wnt/beta-catenin pathway is known to be activated in many TNBC patients and BCL9 and BCL9L are important transcriptional co-activators of beta-catenin, but whether inhibition of BCL9/BCL9L can suppress TNBC growth and the underlying mechanism are not fully understood. Here we demonstrate that the expression of BCL9 and BCL9L is directly correlated with malignancy in TNBC patient tumors and that BCL9 and BCL9L promote tumor cell growth, cell migration and metastasis in TNBC models. Mechanistically, we found that BCL9/BCL9L promotes tumorigenicity through both the Wnt and TGF-beta pathways. Besides, BCL9/BCL9L expression inversely correlates with CD8(+) T cell infiltration in TNBC and BCL9/BCL9L inhibits the infiltration of CD8(+) T cells in the tumor microenvironment. hsBCL9(CT)-24, an inhibitor of BCL9/beta-catenin peptides, promotes intratumoral infiltration of cytotoxic T cells, reducing regulatory T cells (Treg) and increasing dendritic cells (DCs). Inhibition of BCL9/BCL9L and TGF-beta suppresses activity of Treg. TGF-beta signaling increases tumor infiltration of cytotoxic CD8(+) T cells. In accordance, genetic or pharmacological inhibition of BCL9/BCL9L synergizes with PD-1/L1 antibodies to inhibit tumor growth. In summary, these results suggest that targeting BCL9/BCL9L has a direct anti-tumor effect and also unleashes an anti-cancer immune response through inhibition of both Wnt and TGF-beta signaling, suggesting a viable therapeutic approach for TNBC treatment.	[Wang, Xiaoshuang; Feng, Mei; Liu, Chenglong; Pei, Jinpeng; Liu, Qiaofeng; Shi, Ying; Zhou, Yang; Yu, Ker; Zhu, Di] Fudan Univ, Sch Pharm, Dept Pharmacol, Shanghai, Peoples R China; [Xiao, Tengfei] XBH Biotech, Shanghai, Peoples R China; [Guo, Baosen] Shenzhen Digital Life Inst, Shenzhen, Guangdong, Peoples R China; [Liu, Danyang] Fudan Univ, Obstet & Gynecol Hosp, Shanghai, Peoples R China; [Xiao, Yi; Jiang, Yizhou; Shao, Zhimin] Fudan Univ, Dept Surg Breast Canc, Shanghai Canc Ctr, Shanghai, Peoples R China; [Rosin-Arbesfeld, Rina] Tel Aviv Univ, Dept Microbiol & Immunol, Sackler Fac Med, Tel Aviv, Israel; [Yang, Mengxuan; Feng, Yu-Xiong] Zhejiang Univ, Sch Med, Inst Translat Med, Affiliated Hosp 1, Hangzhou, Peoples R China; [Zhu, Di] Fudan Univ, Fudan Affiliated Zhongshan Hosp, Minhang Branch, Shanghai, Peoples R China; [Zhu, Di] Fudan Univ, Key Lab Smart Drug Delivery, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Tel Aviv University; Sackler Faculty of Medicine; Zhejiang University; Fudan University; Fudan University	Yu, K; Zhu, D (corresponding author), Fudan Univ, Sch Pharm, Dept Pharmacol, Shanghai, Peoples R China.; Zhu, D (corresponding author), Fudan Univ, Fudan Affiliated Zhongshan Hosp, Minhang Branch, Shanghai, Peoples R China.; Zhu, D (corresponding author), Fudan Univ, Key Lab Smart Drug Delivery, Shanghai, Peoples R China.	keryu@fudan.edu.cn; zhudi@fudan.edu.cn		Wang, Xiaoshaung/0000-0002-0725-9440; Liu, Chenglong/0000-0002-1657-6683	projects on the National Natural Science Foundation of China [81373442]; National Science and Technology Major Project of China [2018ZX09711002-008]; National Basic Research Program (973 Program) of China [2013CB932500]; Science and Technology Commission of Shanghai [18ZR1403900, 18JC1413800]; National Natural Science Foundation of China [81872895]; project on joint translational research in the School of Pharmacy and Minhang Hospital [RO-MY201712]	projects on the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project of China; National Basic Research Program (973 Program) of China(National Basic Research Program of China); Science and Technology Commission of Shanghai(Science & Technology Commission of Shanghai Municipality (STCSM)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); project on joint translational research in the School of Pharmacy and Minhang Hospital	The current study was supported by projects on the National Natural Science Foundation of China (81373442) (KY), National Science and Technology Major Project of China (2018ZX09711002-008) (KY), the National Basic Research Program (973 Program) of China (2013CB932500) (KY), the Science and Technology Commission of Shanghai (18ZR1403900, 18JC1413800) (DZ), the National Natural Science Foundation of China (81872895) (DZ), and the project on joint translational research in the School of Pharmacy and Minhang Hospital (RO-MY201712) (DZ).	Adachi S, 2004, CANCER RES, V64, P8496, DOI 10.1158/0008-5472.CAN-04-2254; Ahmadzadeh M, 2005, J IMMUNOL, V174, P5215, DOI 10.4049/jimmunol.174.9.5215; [Anonymous], 2019, CANCER DISCOV, V9; Augustin I, 2016, STEM CELL RES, V17, P607, DOI 10.1016/j.scr.2016.10.010; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Bilir B, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-280; Bishai WR, 2019, P AACR SPEC C TUM IM; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; de la Roche M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-199; Elsarraj HS, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0630-z; Feng M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau5240; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Fu CM, 2015, P NATL ACAD SCI USA, V112, P2823, DOI 10.1073/pnas.1414167112; Galluzzi L, 2019, TRENDS CELL BIOL, V29, P44, DOI 10.1016/j.tcb.2018.08.005; Gattinoni L, 2010, CLIN CANCER RES, V16, P4695, DOI 10.1158/1078-0432.CCR-10-0356; Gay DM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08586-3; Golovina TN, 2010, CANCER J, V16, P342, DOI 10.1097/PPO.0b013e3181eb336d; Guo X, 2008, GENE DEV, V22, P106, DOI 10.1101/gad.1590908; He Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-1002-1; Hong Y, 2015, CANCER RES, V75, P656, DOI 10.1158/0008-5472.CAN-14-2377; Jiang YZ, 2019, CANCER CELL, V35, P428, DOI 10.1016/j.ccell.2019.02.001; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; King TD, 2012, J CELL BIOCHEM, V113, P13, DOI 10.1002/jcb.23350; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Mani M, 2009, CANCER RES, V69, P7577, DOI 10.1158/0008-5472.CAN-09-0773; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Ovcaricek T, 2011, RADIOL ONCOL, V45, P46, DOI 10.2478/v10019-010-0054-4; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pohl SG, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.14; Rizvi NA, 2015, LANCET ONCOL, V16, P257, DOI 10.1016/S1470-2045(15)70054-9; Salgado R, 2015, JAMA ONCOL, V1, P448, DOI 10.1001/jamaoncol.2015.0830; Savas P, 2018, NAT MED, V24, P986, DOI 10.1038/s41591-018-0078-7; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Spranger S, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0089-6; Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Togashi Y, 2019, NAT REV CLIN ONCOL, V16, P356, DOI 10.1038/s41571-019-0175-7; van Loosdregt J, 2013, IMMUNITY, V39, P298, DOI 10.1016/j.immuni.2013.07.019; Wend P, 2013, EMBO MOL MED, V5, P264, DOI 10.1002/emmm.201201320; Xu YH, 2015, ONCOL REP, V34, P747, DOI 10.3892/or.2015.4056; Yang L, 2010, TRENDS IMMUNOL, V31, P220, DOI 10.1016/j.it.2010.04.002; Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601; Zatula N, 2014, ONCOTARGET, V5, P6770, DOI 10.18632/oncotarget.2252	50	7	7	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2982	2997		10.1038/s41388-021-01756-y	http://dx.doi.org/10.1038/s41388-021-01756-y		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33767438				2022-12-28	WOS:000632824700002
J	Wilson, K; Shiuan, E; Brantley-Sieders, DM				Wilson, Kalin; Shiuan, Eileen; Brantley-Sieders, Dana M.			Oncogenic functions and therapeutic targeting of EphA2 in cancer	ONCOGENE			English	Review								More than 25 years of research and preclinical validation have defined EphA2 receptor tyrosine kinase as a promising molecular target for clinical translation in cancer treatment. Molecular, genetic, biochemical, and pharmacological targeting strategies have been extensively tested in vitro and in vivo, and drugs like dasatinib, initially designed to target SRC family kinases, have been found to also target EphA2 activity. Other small molecules, therapeutic targeting antibodies, and peptide-drug conjugates are being tested, and more recently, approaches harnessing antitumor immunity against EphA2-expressing cancer cells have emerged as a promising strategy. This review will summarize preclinical studies supporting the oncogenic role of EphA2 in breast cancer, lung cancer, glioblastoma, and melanoma, while delineating the differing roles of canonical and noncanonical EphA2 signaling in each setting. This review also summarizes completed and ongoing clinical trials, highlighting the promise and challenges of targeting EphA2 in cancer.	[Wilson, Kalin; Shiuan, Eileen] Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA; [Brantley-Sieders, Dana M.] Vanderbilt Univ, Med Ctr, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA; [Brantley-Sieders, Dana M.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Brantley-Sieders, DM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA.; Brantley-Sieders, DM (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	dana.brantley@vumc.org		Brantley-Sieders, Dana/0000-0002-2751-6547	NCI NIH HHS [F30 CA216891, R01 CA177681] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Affinito A, 2020, MOL THER-NUCL ACIDS, V20, P176, DOI 10.1016/j.omtn.2020.02.005; Affinito A, 2019, MOL THER-NUCL ACIDS, V18, P99, DOI 10.1016/j.omtn.2019.08.015; Amato KR, 2016, CANCER RES, V76, P305, DOI 10.1158/0008-5472.CAN-15-0717; American Cancer Society,, 2020, COL CANC; Annunziata Christina M, 2013, Invest New Drugs, V31, P77, DOI 10.1007/s10637-012-9801-2; Arnato KR, 2014, J CLIN INVEST, V124, P2037, DOI 10.1172/JCI72522; Azimi A, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.406; Barquilla A, 2016, MOL BIOL CELL, V27, P2757, DOI 10.1091/mbc.E16-01-0048; Bennett G, 2020, MOL CANCER THER, V19, P1385, DOI 10.1158/1535-7163.MCT-19-1092; Bielamowicz K, 2018, NEURO-ONCOLOGY, V20, P506, DOI 10.1093/neuonc/nox182; Bin Fang W, 2005, ONCOGENE, V24, P7859, DOI 10.1038/sj.onc.1208937; Binda E, 2012, CANCER CELL, V22, P765, DOI 10.1016/j.ccr.2012.11.005; Brannan JM, 2009, CANCER PREV RES, V2, P1039, DOI 10.1158/1940-6207.CAPR-09-0212; Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154; Brantley-Sieders DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024426; Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1; Chan BA, 2015, TRANSL LUNG CANCER R, V4, P36, DOI 10.3978/j.issn.2218-6751.2014.05.01; Chee CE, 2013, ONCOLOGIST, V18, P1091, DOI 10.1634/theoncologist.2013-0255; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chen J, 2015, CYTOKINE GROWTH F R, V26, P1, DOI 10.1016/j.cytogfr.2014.05.001; Choi K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001226; Chow KKH, 2013, MOL THER, V21, P629, DOI 10.1038/mt.2012.210; Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; EASTY DJ, 1993, J INVEST DERMATOL, V101, P679, DOI 10.1111/1523-1747.ep12371675; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; EASTY DJ, 1995, CANCER RES, V55, P2528; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; Faoro L, 2010, J BIOL CHEM, V285, P18575, DOI 10.1074/jbc.M109.075085; Fattet L, 2020, DEV CELL, V54, P302, DOI 10.1016/j.devcel.2020.05.031; Ferluga S, 2016, ONCOTARGET, V7, P59860, DOI 10.18632/oncotarget.10978; Finn RS, 2011, CLIN CANCER RES, V17, P6905, DOI 10.1158/1078-0432.CCR-11-0288; Gambini L, 2018, ACS CHEM BIOL, V13, P2633, DOI 10.1021/acschembio.8b00556; Gokmen-Polar Y, 2011, BREAST CANCER RES TR, V127, P375, DOI 10.1007/s10549-010-1004-y; Gravina GL, 2019, CANCERS, V11, DOI 10.3390/cancers11030359; Guo CC, 2013, J THORAC ONCOL, V8, P301, DOI 10.1097/JTO.0b013e318282def7; Hamaoka Y, 2016, CELL SIGNAL, V28, P937, DOI 10.1016/j.cellsig.2016.04.009; Hasegawa J, 2016, CANCER BIOL THER, V17, P1158, DOI 10.1080/15384047.2016.1235663; Hatano M, 2005, NEOPLASIA, V7, P717, DOI 10.1593/neo.05277; Heinzlmeir S, 2016, ACS CHEM BIOL, V11, P3400, DOI 10.1021/acschembio.6b00709; Hess AR, 2001, CANCER RES, V61, P3250; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Himanen JP, 2009, EMBO REP, V10, P722, DOI 10.1038/embor.2009.91; Holmberg J, 2005, GENE DEV, V19, P462, DOI 10.1101/gad.326905; Ishikawa M, 2012, LUNG CANCER, V76, P431, DOI 10.1016/j.lungcan.2011.12.004; Jackson D, 2008, CANCER RES, V68, P9367, DOI 10.1158/0008-5472.CAN-08-1933; Kikawa KD, 2002, J BIOL CHEM, V277, P39274, DOI 10.1074/jbc.M207127200; Kim C, 2019, J THORAC ONCOL, V14, pS281, DOI 10.1016/j.jtho.2019.08.565; Kinch MS, 2003, CLIN CANCER RES, V9, P613; Kluger HM, 2011, CANCER-AM CANCER SOC, V117, P2202, DOI 10.1002/cncr.25766; Koch H, 2015, J PROTEOME RES, V14, P2617, DOI 10.1021/acs.jproteome.5b00161; Koshikawa N, 2015, CANCER RES, V75, P3327, DOI 10.1158/0008-5472.CAN-14-2798; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Larsen AB, 2007, MOL CANCER RES, V5, P283, DOI 10.1158/1541-7786.MCR-06-0321; Larsen AB, 2010, CELL SIGNAL, V22, P636, DOI 10.1016/j.cellsig.2009.11.018; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Liang LY, 2019, ONCOGENE, V38, P6567, DOI 10.1038/s41388-019-0931-2; Lim DA, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a018820; Lisabeth EM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009159; Liu FH, 2006, CANCER RES, V66, P10815, DOI 10.1158/0008-5472.CAN-06-1408; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Margaryan NV, 2009, CANCER BIOL THER, V8, P275, DOI 10.4161/cbt.8.3.7485; Miao BC, 2015, CANCER DISCOV, V5, P274, DOI 10.1158/2159-8290.CD-14-0295; Miao H, 2015, ONCOGENE, V34, P558, DOI 10.1038/onc.2013.590; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Mitri Z, 2016, CLIN CANCER RES, V22, P5706, DOI 10.1158/1078-0432.CCR-15-2845; Mo J, 2020, CELL ONCOL, V43, P655, DOI 10.1007/s13402-020-00511-x; Noblitt LW, 2004, CANCER GENE THER, V11, P757, DOI 10.1038/sj.cgt.7700761; North HA, 2013, CEREB CORTEX, V23, P1765, DOI 10.1093/cercor/bhs183; Okada H, 2008, J NEURO-ONCOL, V88, P245, DOI 10.1007/s11060-008-9566-9; Paraiso KHT, 2015, CANCER DISCOV, V5, P264, DOI 10.1158/2159-8290.CD-14-0293; Park JE, 2013, GENES-BASEL, V4, P334, DOI 10.3390/genes4030334; Parri M, 2009, CANCER RES, V69, P2072, DOI 10.1158/0008-5472.CAN-08-1845; Pollack IF, 2016, J NEURO-ONCOL, V130, P517, DOI 10.1007/s11060-016-2245-3; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Sakamoto A, 2018, ANTICANCER RES, V38, P3273, DOI 10.21873/anticanres.12592; Shen WS, 2014, GROWTH FACTORS, V32, P247, DOI 10.3109/08977194.2014.984806; Shitara K, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0679-9; Skoulidis F, 2019, NAT REV CANCER, V19, P495, DOI 10.1038/s41568-019-0179-8; Song W, 2017, ONCOGENE, V36, P5620, DOI 10.1038/onc.2017.170; Song WQ, 2020, MOL CANCER RES, V18, P1735, DOI 10.1158/1541-7786.MCR-20-0075; Song WQ, 2014, CANCER RES, V74, P2444, DOI 10.1158/0008-5472.CAN-13-2136; Sugiyama N, 2013, J CELL BIOL, V201, P467, DOI 10.1083/jcb.201205176; Tan YHC, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0159-6; Tarhini AA, 2016, MELANOMA MANAG, V3, P251, DOI 10.2217/mmt-2016-0016; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Udayakumar D, 2011, ONCOGENE, V30, P4921, DOI 10.1038/onc.2011.210; Vaught D, 2009, MOL BIOL CELL, V20, P2572, DOI 10.1091/mbc.E08-04-0378; Volz C, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107568; Wang LF, 2008, ONCOL REP, V19, P151; Weigelt B, 2010, MOL ONCOL, V4, P192, DOI 10.1016/j.molonc.2010.04.004; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; White BEP, 2014, CELL ADHES MIGR, V8, P327, DOI 10.4161/19336918.2014.970012; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Wykosky J, 2005, MOL CANCER RES, V3, P541, DOI 10.1158/1541-7786.MCR-05-0056; Yeddula N, 2015, P NATL ACAD SCI USA, V112, pE6476, DOI 10.1073/pnas.1520110112; Youngblood VM, 2016, CANCER RES, V76, P1825, DOI 10.1158/0008-5472.CAN-15-0847; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhang GQ, 2008, CANCER RES, V68, P1691, DOI 10.1158/0008-5472.CAN-07-2372; Zhou Y, 2017, BIOL PHARM BULL, V40, P1616, DOI 10.1248/bpb.b17-00446; Zhou Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8679; Zhuang GL, 2010, CANCER RES, V70, P299, DOI 10.1158/0008-5472.CAN-09-1845; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304	105	18	19	6	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2483	2495		10.1038/s41388-021-01714-8	http://dx.doi.org/10.1038/s41388-021-01714-8		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33686241	Green Accepted			2022-12-28	WOS:000626396000001
J	Riedel, M; Berthelsen, MF; Cai, HQ; Haldrup, J; Borre, M; Paludan, SR; Hager, H; Vendelbo, MH; Wagner, EF; Bakiri, L; Thomsen, MK				Riedel, Maria; Berthelsen, Martin F.; Cai, Huiqiang; Haldrup, Jakob; Borre, Michael; Paludan, Soren R.; Hager, Henrik; Vendelbo, Mikkel H.; Wagner, Erwin F.; Bakiri, Latifa; Thomsen, Martin K.			In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun	ONCOGENE			English	Article								Prostate cancer is a major global health concern with limited treatment options for advanced disease. Its heterogeneity challenges the identification of crucial driver genes implicated in disease progression. Activating protein-1 (AP-1) transcription factor is associated with cancer since the first identification of its subunits, the proto-oncogenes JUN and FOS. Whereas both JUN and FOS have been implicated in prostate cancer, this study provides the first functional evidence that FOS acts as a tumor suppressor during prostate cancer progression and invasion. Data mining revealed decreased FOS expression in prostate cancer and a further downregulation in metastatic disease, consistent with FOS expression in cell lines derived from different prostate cancer stages. FOS deficiency in prostate cancer cell lines increases cell proliferation and induces oncogenic pathway alterations. Importantly, in vivo CRISPR/Cas9-mediated Fos and Pten double mutation in murine prostate epithelium results in increased proliferation and invasiveness compared to the abrogation of Pten alone. Interestingly, enhanced Jun expression is observed in the murine prostatic intraepithelial neoplasia lacking Fos. CRISPR/Cas9-mediated knockout of Jun combined with Fos and Pten deficiency diminishes the increased proliferation rate in vivo but not the ability to form invasive disease. Overall, we demonstrate that loss of Fos promotes disease progression from clinical latent prostate cancer to advanced disease through accelerated proliferation and invasiveness, partly through Jun.	[Riedel, Maria; Berthelsen, Martin F.; Cai, Huiqiang; Haldrup, Jakob] Aarhus Univ, Dept Clin Med, Aarhus, Denmark; [Borre, Michael] Aarhus Univ Hosp, Dept Clin Med & Urol, Aarhus, Denmark; [Paludan, Soren R.; Thomsen, Martin K.] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Hager, Henrik] South Denmark Hosp, Vejle, Denmark; [Vendelbo, Mikkel H.] Aarhus Univ Hosp, Dept Nucl Med & PET Ctr, Aarhus, Denmark; [Wagner, Erwin F.] Med Univ Vienna MUV, Dept Dermatol, Lab Genes & Dis, Vienna, Austria; [Wagner, Erwin F.; Bakiri, Latifa] Med Univ Vienna MUV, Dept Lab Med, Lab Genes & Dis, Vienna, Austria; [Thomsen, Martin K.] Aarhus Univ, Aarhus Inst Adv Studies AIAS, Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University; Medical University of Vienna; Medical University of Vienna; Aarhus University	Thomsen, MK (corresponding author), Aarhus Univ, Dept Biomed, Aarhus, Denmark.; Thomsen, MK (corresponding author), Aarhus Univ, Aarhus Inst Adv Studies AIAS, Aarhus, Denmark.	mkt@biomed.au.dk	Thomsen, Martin/AAU-5014-2021	Thomsen, Martin/0000-0002-5055-7531; Vendelbo, Mikkel Holm/0000-0003-0431-2522; Paludan, Soren Riis/0000-0001-9180-4060; bakiri, latifa/0000-0002-6300-2420; Riedel, Maria/0000-0002-6545-0243; Wagner, Erwin F/0000-0001-7872-0196	Danish cancer society [R146-A9394, R204-A12490]; Ministry of health [4-1612-236/7]; AUFF NOVA [E-2o15-FLS-9-8]; Dagmar Marshalls Fond; Einar Willumsens Mindelegat; Harboefonden; Helge Peetz og Verner og hustru Vilma Peetz legat; Raimond og Dagmar Ringgaed-Bohns Fond; Aarhus University Research Foundation; Thora og Viggo Grove's Mindelegat; European Research Council [741888]; Medical University of Vienna	Danish cancer society(Danish Cancer Society); Ministry of health; AUFF NOVA; Dagmar Marshalls Fond; Einar Willumsens Mindelegat; Harboefonden; Helge Peetz og Verner og hustru Vilma Peetz legat; Raimond og Dagmar Ringgaed-Bohns Fond; Aarhus University Research Foundation; Thora og Viggo Grove's Mindelegat; European Research Council(European Research Council (ERC)European Commission); Medical University of Vienna	We thank Mette Simonsen for assistance with PET/MRI scanning. This work was funded by Danish cancer society (R146-A9394 and R204-A12490), Ministry of health (4-1612-236/7), AUFF NOVA (E-2o15-FLS-9-8), Dagmar Marshalls Fond, Einar Willumsens Mindelegat, Harboefonden, Helge Peetz og Verner og hustru Vilma Peetz legat, Raimond og Dagmar Ringgaed-Bohns Fond, The Aarhus University Research Foundation, and Thora og Viggo Grove's Mindelegat (all to MKT). EFW and LB are supported by the European Research Council (grant: ERC-AdG 2016 CSI-Fun-741888 to EFW) and the Medical University of Vienna.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chandran UR, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-45; Edwards J, 2004, J PATHOL, V204, P153, DOI 10.1002/path.1605; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Evans AJ, 2018, MODERN PATHOL, V31, pS110, DOI 10.1038/modpathol.2017.158; Feng ZW, 1998, ONCOGENE, V17, P2593, DOI 10.1038/sj.onc.1202195; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; Guo JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120332; Haeussler M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1012-2; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Hubner A, 2012, P NATL ACAD SCI USA, V109, P12046, DOI 10.1073/pnas.1209660109; Konishi N, 2008, CLIN CANCER RES, V14, P4408, DOI 10.1158/1078-0432.CCR-07-4120; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Millena AC, 2016, J BIOL CHEM, V291, P17964, DOI 10.1074/jbc.M116.714899; Min LH, 2012, NAT CELL BIOL, V14, P1203, DOI 10.1038/ncb2590; Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055; Parisotto M, 2013, MOL ONCOL, V7, P190, DOI 10.1016/j.molonc.2013.02.005; Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014; Riedel M, 2018, JOVE-J VIS EXP, DOI 10.3791/57525; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Thomsen MK, 2015, CELL DEATH DIFFER, V22, P574, DOI 10.1038/cdd.2014.213; Thomsen MK, 2010, CANCER RES, V70, P979, DOI 10.1158/0008-5472.CAN-09-2370; Wang GC, 2018, GENE DEV, V32, P1105, DOI 10.1101/gad.315739.118; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wenzel A, 2002, J NEUROCHEM, V80, P1089, DOI 10.1046/j.0022-3042.2002.00807.x; Xu RY, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109679; Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76	32	9	10	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2437	2447		10.1038/s41388-021-01724-6	http://dx.doi.org/10.1038/s41388-021-01724-6		MAR 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33674748	Green Accepted, Green Submitted			2022-12-28	WOS:000625607100006
J	Cui, KS; Yao, SR; Zhang, H; Zhou, MY; Liu, BX; Cao, YL; Fei, BJ; Huang, SL; Huang, ZH				Cui, Kaisa; Yao, Surui; Zhang, Han; Zhou, Mingyue; Liu, Bingxin; Cao, Yulin; Fei, Bojian; Huang, Shenglin; Huang, Zhaohui			Identification of an immune overdrive high-risk subpopulation with aberrant expression of FOXP3 and CTLA4 in colorectal cancer	ONCOGENE			English	Article								Colorectal cancer (CRC) is characterized by a heterogeneous tumor microenvironment (TME) that regulates cancer progression and therapeutic response. Overexpression of FOXP3 and CTLA4 is associated with immunosuppressive TME and poor prognosis in many cancer types. However, opposite results were reported in CRC. Thus, we performed comprehensive analyses to evaluate the exact prognostic value of FOXP3 and CTLA4 in CRC. Here, the expression levels of FOXP3 and CTLA4 were used to construct a subtyping system based on >1200 CRC patients from multiple independent public datasets. We revealed that, in CRC patients with relatively high expression of FOXP3, there exist two different subpopulations with opposite survival patterns according to CLTA4 expression. We further established a method for evaluating all cohorts and identified a novel FOXP3(High)CTLA4(High*) CRC risk subpopulation that accounts for 5-10% of CRC patients. Moreover, different methods of functional enrichment and immune evaluation were used to analyze the TME characteristics of different FOXP3/CTLA4 subtypes. The FOXP3(High)CTLA4(High*) CRC risk subpopulation was characterized by an immune overdrive TME phenotype, including high immune cell infiltration, low tumor purity, high immune checkpoint levels, and TGF-beta activation. Finally, the constructed FOXP3/CTLA4 subtyping system was further validated by quantitative RT-PCR, immunochemistry staining, and multicolor immunofluorescence in an independent CRC cohort we collected. This high-risk subpopulation was also observed in kidney cancers and low-grade glioma patients by a Pan-cancer analysis. Together, our study revealed that the established FOXP3/CTLA4 molecular subtyping system could be used to select treatment and management strategies for CRC and other cancers.	[Cui, Kaisa; Yao, Surui; Zhang, Han; Zhou, Mingyue; Liu, Bingxin; Cao, Yulin; Fei, Bojian; Huang, Zhaohui] Jiangnan Univ, Affiliated Hosp, Wuxi Canc Inst, Wuxi, Jiangsu, Peoples R China; [Cui, Kaisa; Zhang, Han; Zhou, Mingyue; Liu, Bingxin; Cao, Yulin; Huang, Zhaohui] Jiangnan Univ, Wuxi Sch Med, Lab Canc Epigenet, Wuxi, Jiangsu, Peoples R China; [Huang, Shenglin] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China; [Huang, Shenglin] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China	Jiangnan University; Jiangnan University; Fudan University; Fudan University	Huang, ZH (corresponding author), Jiangnan Univ, Affiliated Hosp, Wuxi Canc Inst, Wuxi, Jiangsu, Peoples R China.; Huang, ZH (corresponding author), Jiangnan Univ, Wuxi Sch Med, Lab Canc Epigenet, Wuxi, Jiangsu, Peoples R China.	zhaohuihuang@jiangnan.edu.cn	Huang, Zhaohui/S-9410-2019; Cui, Kaisa/AAM-6601-2020	Huang, Zhaohui/0000-0002-0117-9976; Cui, Kaisa/0000-0001-7255-2689; Fei, Bojian/0000-0002-3672-0216; Liu, Bingxin/0000-0002-6744-4912	National Natural Science Foundation of China [82002550, 81672328, 81972220]; Jiangsu Key Research and Development Plan [BE2019632]; Medical Key Professionals Program of Jiangsu Province [AF052141]; National First-class Discipline Program of Food Science and Technology [JUFSTR20180101]; Wuxi Medical Innovation Team [CXTP003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Key Research and Development Plan; Medical Key Professionals Program of Jiangsu Province; National First-class Discipline Program of Food Science and Technology; Wuxi Medical Innovation Team	We thank the TCGA, GEO, and CPTAC project. We thank the Affiliated Hospital of Jiangnan University for providing the CRC samples. This work was supported by grants from the National Natural Science Foundation of China (82002550, 81672328, and 81972220), Jiangsu Key Research and Development Plan (BE2019632), Medical Key Professionals Program of Jiangsu Province (AF052141), National First-class Discipline Program of Food Science and Technology (JUFSTR20180101), and Wuxi Medical Innovation Team (CXTP003).	Andrews LP, 2019, NAT IMMUNOL, V20, P1425, DOI 10.1038/s41590-019-0512-0; Bai XG, 2019, ONCOTARGETS THER, V12, P9527, DOI 10.2147/OTT.S224013; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Becht E, 2016, CLIN CANCER RES, V22, P4057, DOI 10.1158/1078-0432.CCR-15-2879; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Chew A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022047; Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003; Cui KS, 2020, ONCOGENE, V39, P786, DOI 10.1038/s41388-019-1026-9; Deng L, 2015, J THORAC ONCOL, V10, P1020, DOI 10.1097/JTO.0000000000000550; Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126; Eide PW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16747-x; Fakih M, 2019, J CLIN INVEST, V129, P4464, DOI 10.1172/JCI127046; Fiegle E, 2019, NEOPLASIA, V21, P932, DOI 10.1016/j.neo.2019.07.006; Freeman ZT, 2020, J CLIN INVEST, V130, P1405, DOI 10.1172/JCI128672; Ganapathi SK, 2014, BRIT J CANCER, V111, P1581, DOI 10.1038/bjc.2014.477; Gemignani, 2020, SEMIN CANCER BIOL; Giraldo NA, 2019, BRIT J CANCER, V120, P45, DOI 10.1038/s41416-018-0327-z; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Heinzerling L, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0152-y; Herrmann A, 2017, CANCER RES, V77, P5118, DOI 10.1158/0008-5472.CAN-16-0342; Iglesia MD, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw144; Lal A, 2013, BREAST CANCER RES TR, V139, P381, DOI 10.1007/s10549-013-2556-4; Lee HO, 2020, NAT GENET, V52, P594, DOI 10.1038/s41588-020-0636-z; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Lu LG, 2017, BREAST CANCER RES TR, V164, P689, DOI 10.1007/s10549-017-4281-x; Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Petitprez F, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00783-w; Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171; Punt S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0350-0; Raffin C, 2020, NAT REV IMMUNOL, V20, P158, DOI 10.1038/s41577-019-0232-6; Ramos-Casals M, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0160-6; Riera-Domingo C, 2020, PHYSIOL REV, V100, P1, DOI 10.1152/physrev.00018.2019; Rotte A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1259-z; Shi JY, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3633-6; Stack EC, 2014, METHODS, V70, P46, DOI 10.1016/j.ymeth.2014.08.016; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun XW, 2017, INT J IMMUNOPATH PH, V30, P201, DOI 10.1177/0394632017710415; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Toor SM, 2020, SEMIN CANCER BIOL, V65, P1, DOI 10.1016/j.semcancer.2019.06.021; Wei YF, 2018, LUNG CANCER, V125, P35, DOI 10.1016/j.lungcan.2018.09.002; Weller P, 2014, EUR J CANCER, V50, P1291, DOI 10.1016/j.ejca.2014.02.016; Wolf D, 2005, CLIN CANCER RES, V11, P8326, DOI 10.1158/1078-0432.CCR-05-1244; Wu CC, 2019, SCI CHINA LIFE SCI, V62, P640, DOI 10.1007/s11427-018-9461-5; Wu F, 2020, MOL ONCOL, V14, P2081, DOI 10.1002/1878-0261.12707; Xiang Z, 2019, IMMUNOPHARM IMMUNOT, V41, P386, DOI 10.1080/08923973.2018.1533968; Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z; Yang SC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0700-1; Yin Y, 2017, CLIN CANCER RES, V23, P7375, DOI 10.1158/1078-0432.CCR-17-1283; Yin Y, 2014, CLIN CANCER RES, V20, P6187, DOI 10.1158/1078-0432.CCR-14-1030; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu HM, 2015, CANCER IMMUNOL IMMUN, V64, P853, DOI 10.1007/s00262-015-1696-2; Zaravinos A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1372-z	58	6	6	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2130	2145		10.1038/s41388-021-01677-w	http://dx.doi.org/10.1038/s41388-021-01677-w		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33627780				2022-12-28	WOS:000621289100007
J	Campion, NJ; Ally, M; Jank, BJ; Ahmed, J; Alusi, G				Campion, Nicholas J.; Ally, Munira; Jank, Bernhard J.; Ahmed, Jahangir; Alusi, Ghassan			The molecular march of primary and recurrent nasopharyngeal carcinoma	ONCOGENE			English	Review							EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEINS; GROWTH-FACTOR RECEPTOR; REGULATORY T-CELLS; NUCLEAR ANTIGEN 1; ANTITUMOR-ACTIVITY; FUSION GENE; CYCLIN D1; PROGRESSION; RNA	Nasopharyngeal carcinoma (NPC) results from the aberrant and uncontrolled growth of the nasopharyngeal epithelium. It is highly associated with the Epstein-Barr virus, especially in regions where it is endemic. In the last decade, significant advances in genetic sequencing techniques have allowed the discovery of many new abnormal molecular processes that undoubtedly contribute to the establishment, growth and spread of this deadly disease. In this review, we consider NPC as EBV induced. We summarise the recent discoveries and how they add to our understanding of the pathophysiology of NPC in the context of genomics first in primary and then in recurrent disease. Overall, we find key early events lead to p16 inactivation and cyclin D1 expression, allowing latent viral infection. Host and viral factors work together to affect a variety of molecular pathways, the most fundamental being activation of NF-kappa B. Nonetheless, much still yearns to be discovered, especially in recurrent NPC.	[Campion, Nicholas J.; Ally, Munira; Ahmed, Jahangir; Alusi, Ghassan] Royal London Hosp, Barts Hlth NHS Trust, Dept Otorhinolaryngol & Head & Neck Surg, Whitechapel Rd, London E1 1BB, England; [Campion, Nicholas J.; Jank, Bernhard J.] Med Univ Vienna, Vienna Gen Hosp, Dept Otorhinolaryngol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria	Barts Health NHS Trust; Royal London Hospital; Medical University of Vienna	Campion, NJ (corresponding author), Royal London Hosp, Barts Hlth NHS Trust, Dept Otorhinolaryngol & Head & Neck Surg, Whitechapel Rd, London E1 1BB, England.; Campion, NJ (corresponding author), Med Univ Vienna, Vienna Gen Hosp, Dept Otorhinolaryngol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	nicholas.campion@meduniwien.ac.at		Campion, Nicholas James/0000-0003-3345-9486				Ahmed W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099163; Alajez NM, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.64; Almobarak AA, 2019, CUREUS, V11, DOI 10.7759/cureus.4210; Barth S, 2008, NUCLEIC ACIDS RES, V36, P666, DOI 10.1093/nar/gkm1080; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruce JP, 2015, J CLIN ONCOL, V33, P3346, DOI 10.1200/JCO.2015.60.7846; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; Chan ASC, 2002, INT J CANCER, V102, P300, DOI 10.1002/ijc.10689; Chen CL, 2001, HUM PATHOL, V32, P1240, DOI 10.1053/hupa.2001.28950; Chen C, 2013, CANCER CHEMOTH PHARM, V72, P315, DOI 10.1007/s00280-013-2196-8; Chen G, 2018, EUR REV MED PHARMACO, V22, P450, DOI 10.26355/eurrev_201801_14194; Chen L, 2017, ONCOTARGETS THER, V10, P2769, DOI 10.2147/OTT.S126907; Chen TC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10386-y; Chen YP, 2020, CELL RES, V30, P1024, DOI 10.1038/s41422-020-0374-x; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Cheng SY, 2019, BBA-MOL BASIS DIS, V1865, P1201, DOI 10.1016/j.bbadis.2019.01.015; Chin YM, 2015, INT J CANCER, V136, P678, DOI 10.1002/ijc.29035; Chow YP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42980; Chung AK, 2019, CANCER MED-US, V8, P5116, DOI 10.1002/cam4.2429; Dai W, 2016, CHIN CLIN ONCOL, V5, DOI 10.21037/cco.2016.03.06; Dai W, 2016, P NATL ACAD SCI USA, V113, P3317, DOI 10.1073/pnas.1523436113; Dai W, 2015, CANCER MED-US, V4, P1079, DOI 10.1002/cam4.451; Dawson CW, 2012, SEMIN CANCER BIOL, V22, P144, DOI 10.1016/j.semcancer.2012.01.004; Duan YM, 2015, CANCER LETT, V361, P67, DOI 10.1016/j.canlet.2015.02.037; Fogg M, 2013, VIROLOGY, V441, P107, DOI 10.1016/j.virol.2013.03.016; GAO W, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/404567; GOSSELIN J, 1991, EUR J IMMUNOL, V21, P203, DOI 10.1002/eji.1830210130; Hsu C, 2017, J CLIN ONCOL, V35, P4050, DOI 10.1200/JCO.2017.73.3675; Hua WF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.252; HUANG DP, 1994, CANCER RES, V54, P4003; Huang Zhen-xiao, 2010, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V45, P47; Huang ZX, 2014, INDIAN J OTOLARYNGOL, V66, pS120, DOI 10.1007/s12070-011-0359-7; Hui ABY, 2005, CANCER RES, V65, P8125, DOI 10.1158/0008-5472.CAN-05-0648; Hui EP, 2013, CANCER RES, V73, P1676, DOI 10.1158/0008-5472.CAN-12-2448; Iizasa H, 2010, J BIOL CHEM, V285, P33358, DOI 10.1074/jbc.M110.138362; Jiang N, 2014, ONCOL REP, V32, P1661, DOI 10.3892/or.2014.3376; Jin SZ, 2020, CELL RES, V30, P950, DOI 10.1038/s41422-020-00402-8; KHAN G, 1992, J CLIN PATHOL, V45, P616, DOI 10.1136/jcp.45.7.616; Kitagawa N, 2000, EMBO J, V19, P6742, DOI 10.1093/emboj/19.24.6742; Kung CP, 2011, J VIROL, V85, P4399, DOI 10.1128/JVI.01703-10; Lau KM, 2007, BRIT J CANCER, V96, P617, DOI 10.1038/sj.bjc.6603580; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Li J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001122; Li J, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/23723556.2014.976507; Li LQ, 2002, BLOOD, V99, P3725, DOI 10.1182/blood.V99.10.3725; Li YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14121; Li Z, 2015, ONCOTARGET, V6, P24291, DOI 10.18632/oncotarget.4552; Liao CL, 2020, CANCER SCI, V111, P857, DOI 10.1111/cas.14305; Lin DC, 2014, NAT GENET, V46, P866, DOI 10.1038/ng.3006; Longan L, 2000, J GEN VIROL, V81, P2245, DOI 10.1099/0022-1317-81-9-2245; Lung RWM, 2018, J PATHOL, V244, P394, DOI 10.1002/path.5018; Lyu XM, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007484; Ma BBY, 2015, INVEST NEW DRUG, V33, P985, DOI 10.1007/s10637-015-0264-0; Ma BBY, 2018, J CLIN ONCOL, V36, P1412, DOI 10.1200/JCO.2017.77.0388; Ma WS, 2017, ANTI-CANCER DRUG, V28, P230, DOI 10.1097/CAD.0000000000000448; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; Moody CA, 2003, J VIROL, V77, P8555, DOI 10.1128/JVI.77.15.8555-8561.2003; Nie GH, 2017, ONCOL LETT, V13, P4487, DOI 10.3892/ol.2017.6021; Nie Y, 2013, CANCER SCI, V104, P458, DOI 10.1111/cas.12092; Odumade OA, 2011, CLIN MICROBIOL REV, V24, P193, DOI 10.1128/CMR.00044-10; Ohtani N, 2003, J CELL BIOL, V162, P173, DOI 10.1083/jcb.200302085; Pan Y, 2017, ONCOGENE, V36, P1069, DOI 10.1038/onc.2016.271; Pan Y, 2013, ONCOGENE, V32, P2756, DOI 10.1038/onc.2012.294; Peng L, 2019, BRIT J RADIOL, V92, DOI 10.1259/bjr.20181031; Peng L, 2018, J CANCER, V9, P4510, DOI 10.7150/jca.27611; Randall RE, 2008, J GEN VIROL, V89, P1, DOI 10.1099/vir.0.83391-0; Ren SL, 2016, ONCOL REP, V36, P1861, DOI 10.3892/or.2016.4981; Roberge CJ, 1997, VIROLOGY, V238, P344, DOI 10.1006/viro.1997.8852; Rovedo M, 2007, J VIROL, V81, P84, DOI 10.1128/JVI.01302-06; Saridakis V, 2005, MOL CELL, V18, P25, DOI 10.1016/j.molcel.2005.02.029; Shah KM, 2009, ONCOGENE, V28, P3903, DOI 10.1038/onc.2009.249; Shen Y, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.20; Song YL, 2016, ONCOTARGET, V7, P36783, DOI 10.18632/oncotarget.9170; Sousa H, 2016, IMMUNOBIOLOGY, V221, P145, DOI 10.1016/j.imbio.2015.09.015; Stelow EB, 2017, HEAD NECK PATHOL, V11, P16, DOI 10.1007/s12105-017-0787-0; Tang M, 2010, GENES IMMUN, V11, P334, DOI 10.1038/gene.2009.109; Tempera I, 2016, J VIROL, V90, P345, DOI 10.1128/JVI.02318-15; Tsang CM, 2020, SEMIN CANCER BIOL, V61, P84, DOI 10.1016/j.semcancer.2019.09.006; Tsang CM, 2015, VIROL SIN, V30, P107, DOI 10.1007/s12250-015-3592-5; Tsang CM, 2012, P NATL ACAD SCI USA, V109, pE3473, DOI 10.1073/pnas.1202637109; Tsang NM, 2003, CANCER, V98, P2385, DOI 10.1002/cncr.11820; Tudor CS, 2012, BRIT J CANCER, V106, P1980, DOI 10.1038/bjc.2012.197; Vockerodt M, 2001, VIROLOGY, V280, P183, DOI 10.1006/viro.2000.0768; Wang C, 2017, ONCOL REP, V37, P2109, DOI 10.3892/or.2017.5489; Wang HY, 2019, CANCER MED-US, V8, P2705, DOI 10.1002/cam4.2146; Wang J, 2019, J ONCOL, V2019, DOI 10.1155/2019/1654724; Wang LW, 2017, J VIROL, V91, DOI 10.1128/JVI.01718-16; Wang LJ, 2014, CANCER LETT, V344, P188, DOI 10.1016/j.canlet.2013.10.023; Wang SM, 2014, MOL CANCER THER, V13, P3163, DOI 10.1158/1535-7163.MCT-14-0317; Wang YH, 2017, EUR J CANCER PREV, V26, P144, DOI 10.1097/CEJ.0000000000000221; Wood VHJ, 2007, ONCOGENE, V26, P4135, DOI 10.1038/sj.onc.1210496; Wu ZH, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020682; Xu T, 2015, ONCOL REP, V33, P1418, DOI 10.3892/or.2015.3739; Xu T, 2013, CURR ONCOL, V20, pE406, DOI 10.3747/co.20.1456; Xu YJ, 2019, CANCER LETT, V447, P33, DOI 10.1016/j.canlet.2019.01.022; Yang CF, 2016, ONCOGENE, V35, P3419, DOI 10.1038/onc.2015.402; Ye DM, 2020, J CANCER, V11, P1257, DOI 10.7150/jca.37415; You R, 2019, CANCER RES, V79, P5930, DOI 10.1158/0008-5472.CAN-18-3845; Yuan L, 2014, CANCER BIOL THER, V15, P1613, DOI 10.4161/15384047.2014.961874; Yuan YL, 2008, ANN OTO RHINOL LARYN, V117, P192, DOI 10.1177/000348940811700306; Zhan YT, 2020, J CANCER, V11, P4193, DOI 10.7150/jca.39354; Zhang J, 2019, ONCOGENE, V38, P4669, DOI 10.1038/s41388-019-0749-y; Zhang J, 2017, J VIROL, V91, DOI 10.1128/JVI.02168-16; Zhang L, 2017, MOL CANCER RES, V15, P1722, DOI 10.1158/1541-7786.MCR-17-0134; Zhang W., 2015, BIOMED RES INT, V2015, P618924, DOI DOI 10.1155/2015/618924; Zhao R, 2016, EBIOMEDICINE, V8, P30, DOI 10.1016/j.ebiom.2016.04.017; Zheng H, 2016, P NATL ACAD SCI USA, V113, P11283, DOI 10.1073/pnas.1607606113; Zheng X, 2018, J VIROL, V92, DOI 10.1128/JVI.01022-18; Zhong Q, 2018, CLIN CANCER RES, V24, P659, DOI 10.1158/1078-0432.CCR-17-0352; Zhou XH, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190415; Zhou YJ, 2017, ONCOTARGET, V8, P51210, DOI 10.18632/oncotarget.17214; Zhou YJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep43627	112	7	7	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1757	1774		10.1038/s41388-020-01631-2	http://dx.doi.org/10.1038/s41388-020-01631-2		JAN 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33479496				2022-12-28	WOS:000609352300001
J	Lin, WH; Chang, YW; Hong, MX; Hsu, TC; Lee, KC; Lin, C; Lee, JL				Lin, Wei-Hsin; Chang, Yi-Wen; Hong, Min-Xiang; Hsu, Te-Cheng; Lee, Ko-Chuan; Lin, Che; Lee, Jia-Lin			STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT-MET switch and cancer metastasis	ONCOGENE			English	Article							STEM-CELL PROPERTIES; BREAST-CANCER; TRANSITION; CARCINOMA	Epithelial-mesenchymal transition (EMT)/mesenchymal-epithelial transition (MET) processes are proposed to be a driving force of cancer metastasis. By studying metastasis in bone marrow-derived mesenchymal stem cell (BM-MSC)-driven lung cancer models, microarray time-series data analysis by systems biology approaches revealed BM-MSC-induced signaling triggers early dissemination of CD133(+)/CD83(+) cancer stem cells (CSCs) from primary sites shortly after STAT3 activation but promotes proliferation towards secondary sites. The switch from migration to proliferation was regulated by BM-MSC-secreted LIF and activated LIFR/p-ERK/pS727-STAT3 signaling to promote early disseminated cancer cells MET and premetastatic niche formation. Then, tumor-tropic BM-MSCs circulated to primary sites and triggered CD151(+)/CD38(+) cells acquiring EMT-associated CSC properties through IL6R/pY705-STAT3 signaling to promote tumor initiation and were also attracted by and migrated towards the premetastatic niche. In summary, STAT3 phosphorylation at tyrosine 705 and serine 727 differentially regulates the EMT-MET switch within the distinct molecular subtypes of CSCs to complete the metastatic process.	[Lin, Wei-Hsin; Chang, Yi-Wen; Lee, Ko-Chuan; Lee, Jia-Lin] Natl Tsing Hua Univ, Inst Mol & Cellular Biol, Hsinchu 30013, Taiwan; [Lin, Wei-Hsin] Natl Taiwan Univ Hosp, Dept Orthoped Surg, Taipei 100225, Taiwan; [Hong, Min-Xiang; Hsu, Te-Cheng] Natl Tsing Hua Univ, Inst Commun Engn, Hsinchu 30013, Taiwan; [Lin, Che] Natl Taiwan Univ, Dept Elect Engn, Taipei 10617, Taiwan; [Lin, Che] Natl Taiwan Univ, Grad Inst Commun Engn, Taipei 10617, Taiwan; [Lee, Jia-Lin] Natl Tsing Hua Univ, Dept Med Sci, Hsinchu 30013, Taiwan	National Tsing Hua University; National Taiwan University; National Taiwan University Hospital; National Tsing Hua University; National Taiwan University; National Taiwan University; National Tsing Hua University	Lee, JL (corresponding author), Natl Tsing Hua Univ, Inst Mol & Cellular Biol, Hsinchu 30013, Taiwan.; Lin, C (corresponding author), Natl Taiwan Univ, Dept Elect Engn, Taipei 10617, Taiwan.; Lin, C (corresponding author), Natl Taiwan Univ, Grad Inst Commun Engn, Taipei 10617, Taiwan.; Lee, JL (corresponding author), Natl Tsing Hua Univ, Dept Med Sci, Hsinchu 30013, Taiwan.	chelin@ntu.edu.tw; jllee@life.nthu.edu.tw	Hsu, Te-Cheng/ABG-6674-2021	Hsu, Te-Cheng/0000-0003-2686-925X; Lee, Jia-Lin/0000-0002-6984-1313; LIN, WEI-HSIN/0000-0001-6291-392X; Lin, Che/0000-0002-4986-311X	Taiwan Ministry of Science and Technology [NSC 104-2314-B-007-003]; National Taiwan University Hospital Hsin-Chu Branch; National Tsing Hua University Joint Research Program [106-J00XHV7, 107-Q2509E1]	Taiwan Ministry of Science and Technology; National Taiwan University Hospital Hsin-Chu Branch; National Tsing Hua University Joint Research Program	We acknowledge the Biomedical Science and Engineering Center, National Tsing Hua University, Hsinchu, Taiwan, for providing us with access and Wen-Ching Wang for providing technical advice regarding the use of the FACSAria III (BD Biosciences) flow cytometer. This work was supported by funds from the Taiwan Ministry of Science and Technology (grant NSC 104-2314-B-007-003) and the National Taiwan University Hospital Hsin-Chu Branch and National Tsing Hua University Joint Research Program (grants 106-J00XHV7 and 107-Q2509E1).	Bianco P, 2014, ANNU REV CELL DEV BI, V30, P677, DOI 10.1146/annurev-cellbio-100913-013132; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434; Chang YW, 2015, CANCER RES, V75, P3398, DOI 10.1158/0008-5472.CAN-14-3265; Chaturvedi P, 2013, J CLIN INVEST, V123, P189, DOI 10.1172/JCI64993; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Eyles J, 2010, J CLIN INVEST, V120, P2030, DOI 10.1172/JCI42002; Huang GY, 2014, STEM CELLS, V32, P1149, DOI 10.1002/stem.1609; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Klein CA, 2011, CURR OPIN GENET DEV, V21, P42, DOI 10.1016/j.gde.2010.10.011; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Liang CJ, 2019, CELL REP, V28, P1511, DOI 10.1016/j.celrep.2019.07.023; Liu SC, 2013, J CLIN INVEST, V123, P5269, DOI 10.1172/JCI63428; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Markopoulos GS, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101143; Nicola NA, 2015, CYTOKINE GROWTH F R, V26, P533, DOI 10.1016/j.cytogfr.2015.07.001; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pantel K, 2008, NAT REV CANCER, V8, P329, DOI 10.1038/nrc2375; Pavlidis N, 2015, J ADV RES, V6, P375, DOI 10.1016/j.jare.2014.11.007; Pierga JY, 2008, CLIN CANCER RES, V14, P7004, DOI 10.1158/1078-0432.CCR-08-0030; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Santamaria PG, 2017, MOL ONCOL, V11, P718, DOI 10.1002/1878-0261.12091; Schardt JA, 2005, CANCER CELL, V8, P227, DOI 10.1016/j.ccr.2005.08.003; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; van der Pluijm G, 2011, BONE, V48, P37, DOI 10.1016/j.bone.2010.07.023; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yang M, 1998, CANCER RES, V58, P4217	33	38	39	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					791	805		10.1038/s41388-020-01566-8	http://dx.doi.org/10.1038/s41388-020-01566-8		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33262462	hybrid, Green Published			2022-12-28	WOS:000595928700003
J	Singh, KB; Hahm, ER; Kim, SH; Wendell, SG; Singh, SV				Singh, Krishna B.; Hahm, Eun-Ryeong; Kim, Su-Hyeong; Wendell, Stacy G.; Singh, Shivendra V.			A novel metabolic function of Myc in regulation of fatty acid synthesis in prostate cancer	ONCOGENE			English	Article							C-MYC; CHROMOSOMAL-ANOMALIES; GENE; EXPRESSION; SYNTHASE; AMPLIFICATION; CARCINOMA; OVEREXPRESSION; ADENOCARCINOMA; ONCOGENE	A subset of human prostate cancer exhibits increased de novo synthesis of fatty acids, but the molecular driver(s) of this metabolic abnormality remains obscure. This study demonstrates a novel metabolic function of c-Myc (Myc) in regulation of fatty acid synthesis. The role of Myc in regulation of fatty acid synthesis was investigated by: (a) interrogation of the prostate cancer The Cancer Genome Atlas (TCGA) dataset, (b) chromatin immunoprecipitation, and (c) determination of the expression of fatty acid synthesis enzymes and targeted metabolomics using a mouse model and human specimens. The expression of MYC was positively associated with that of key fatty acid synthesis genes including ACLY, ACC1, and FASN in prostate cancer TCGA dataset. Chromatin immunoprecipitation revealed Myc occupancy at the promoters of ACLY, ACC1, and FASN. Prostate-specific overexpression of Myc in Hi-Myc transgenic mice resulted in overexpression of ACLY, ACC1, and FASN proteins in neoplastic lesions and increased circulating levels of total free fatty acids. Targeted metabolomics confirmed increased circulating levels of individual fatty acids in the plasma of Hi-Myc mice and human subjects when compared to corresponding controls. Immunohistochemistry also revealed a positive and statistically significant association in expression of Myc with that of ACC1 in human prostate adenocarcinoma specimens. We propose that Myc-regulated fatty acid synthesis is a valid target for therapy and/or prevention of prostate cancer.	[Singh, Krishna B.; Hahm, Eun-Ryeong; Kim, Su-Hyeong; Wendell, Stacy G.; Singh, Shivendra V.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA; [Singh, Shivendra V.] Univ Pittsburgh, Sch Med, UPMC Hillman Canc Ctr, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Singh, SV (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA.; Singh, SV (corresponding author), Univ Pittsburgh, Sch Med, UPMC Hillman Canc Ctr, Pittsburgh, PA 15213 USA.	singhs@upmc.edu	Singh, Krishna Beer/AAT-9496-2021	/0000-0002-4052-4373	National Cancer Institute [P30 CA047904]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the National Cancer Institute grant R01 CA225716 (to S.V.S.). This study used the Animal Facility and the Tissue and Research Pathology Facility partly supported by the National Cancer Institute grant P30 CA047904. The funders had no role in the design of the study, data collection, analysis or interpretation of the data, manuscript preparation or decision to submit the manuscript for publication.	BUTTYAN R, 1987, PROSTATE, V11, P327, DOI 10.1002/pros.2990110405; Chavarro JE, 2013, AM J EPIDEMIOL, V178, P1246, DOI 10.1093/aje/kwt136; Chen HW, 2012, PROSTATE CANCER P D, V15, P260, DOI 10.1038/pcan.2012.15; Edwards J, 2003, CLIN CANCER RES, V9, P5271; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; FOX SB, 1993, J UROLOGY, V150, P490, DOI 10.1016/S0022-5347(17)35533-7; Gao LN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063563; Gao YJ, 2014, CANCER LETT, V349, P15, DOI 10.1016/j.canlet.2014.03.015; Gouw AM, 2019, CELL METAB, V30, P556, DOI 10.1016/j.cmet.2019.07.012; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Jenkins RB, 1997, CANCER RES, V57, P524; Li XN, 2011, ANAL CHEM, V83, P3192, DOI 10.1021/ac103093w; Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879; Migita T, 2009, JNCI-J NATL CANCER I, V101, P519, DOI 10.1093/jnci/djp030; Miyoshi Y, 2000, PROSTATE, V43, P225, DOI 10.1002/(SICI)1097-0045(20000515)43:3<225::AID-PROS9>3.0.CO;2-7; NAG A, 1989, PROSTATE, V15, P115, DOI 10.1002/pros.2990150205; Priolo C, 2014, CANCER RES, V74, P7198, DOI 10.1158/0008-5472.CAN-14-1490; Rossi S, 2003, MOL CANCER RES, V1, P707; Rubin MA, 2011, J CLIN ONCOL, V29, P3659, DOI 10.1200/JCO.2011.35.1916; Schmidt LJ, 2013, CURR DRUG TARGETS, V14, P401; Scott KEN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029761; Shah US, 2006, HUM PATHOL, V37, P401, DOI 10.1016/j.humpath.2005.11.022; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singh KB, 2019, CARCINOGENESIS, V40, P1545, DOI 10.1093/carcin/bgz155; Singh KB, 2019, MOL CANCER THER, V18, P1800, DOI 10.1158/1535-7163.MCT-19-0046; Singh KB, 2018, CARCINOGENESIS, V39, P826, DOI 10.1093/carcin/bgy051; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Suburu J, 2012, PROSTAG OTH LIPID M, V98, P1, DOI 10.1016/j.prostaglandins.2012.03.003; Sun JS, 2007, PROSTATE, V67, P692, DOI 10.1002/pros.20543; Swinnen JV, 1996, ENDOCRINOLOGY, V137, P4468, DOI 10.1210/en.137.10.4468; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Vyas AR, 2016, J CELL BIOCHEM, V117, P2482, DOI 10.1002/jcb.25541; Wang SI, 1998, CLIN CANCER RES, V4, P811; WARBURG O, 1956, SCIENCE, V124, P269; Wu XY, 2014, AM J CLIN EXP UROL, V2, P111; Zeng W, 2015, INT J CLIN EXP PATHO, V8, P1878; Zhang Q, 2019, ONCOL LETT, V18, P4237, DOI 10.3892/ol.2019.10765	42	10	10	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					592	602		10.1038/s41388-020-01553-z	http://dx.doi.org/10.1038/s41388-020-01553-z		NOV 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33199826	Green Accepted			2022-12-28	WOS:000590042900002
J	Yuan, SK; Zhang, PT; Wen, LQ; Jia, SK; Wu, YF; Zhang, ZL; Guan, LZ; Yu, ZQ; Zhao, L				Yuan, Shukai; Zhang, Peitao; Wen, Liqi; Jia, Shikai; Wu, Yufan; Zhang, Zhenlei; Guan, Lizhao; Yu, Zhengquan; Zhao, Li			miR-22 promotes stem cell traits via activating Wnt/beta-catenin signaling in cutaneous squamous cell carcinoma	ONCOGENE			English	Article							COMPREHENSIVE CLINICOPATHOLOGICAL CLASSIFICATION; TUMOR-INITIATING CELLS; TGF-BETA; CANCER; SUPPRESSOR; TARGETS	Emerging evidence suggests that the cancer stem cells (CSCs) are key culprits of cancer metastasis and drug resistance. Understanding mechanisms regulating the critical oncogenic pathways and CSCs function could reveal new diagnostic and therapeutic strategies. We now report that miR-22, a miRNA critical for hair follicle stem/progenitor cell differentiation, promotes tumor initiation, progression, and metastasis by maintaining Wnt/beta-catenin signaling and CSCs function. Mechanistically, we find that miR-22 facilitates beta-catenin stabilization through directly repressing citrullinase PAD2. Moreover, miR-22 also relieves DKK1-mediated repression of Wnt/beta-catenin signaling by targeting a FosB-DDK1 transcriptional axis. miR-22 knockout mice showed attenuated Wnt/beta-catenin activity and Lgr5(+) CSCs penetrance, resulting in reduced occurrence, progression, and metastasis of chemically induced cutaneous squamous cell carcinoma (cSCC). Clinically, miR-22 is abundantly expressed in human cSCC. Its expression is even further elevated in the CSCs proportion, which negatively correlates with PAD2 and FosB expression. Inhibition of miR-22 markedly suppressed cSCC progression and increased chemotherapy sensitivity in vitro and in xenograft mice. Together, our results revealed a novel miR-22-WNT-CSCs regulatory mechanism in cSCC and highlight the important clinical application prospects of miR-22, a common target molecule for Wnt/beta-catenin signaling and CSCs, for patient stratification and therapeutic intervention.	[Yuan, Shukai; Wen, Liqi; Jia, Shikai; Wu, Yufan; Zhang, Zhenlei; Guan, Lizhao; Zhao, Li] Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Sch Basic Med Sci,Dept Biochem & Mol Biol, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China; [Zhang, Peitao] Tianjin Med Univ Gen Hosp, Dept Nucl Med, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Yu, Zhengquan] China Agr Univ, Coll Biol Sci, State Key Labs Agrobiotechnol, 2 Yuanmingyuan West Rd, Beijing 100094, Peoples R China	Tianjin Medical University; Tianjin Medical University; China Agricultural University	Zhao, L (corresponding author), Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Sch Basic Med Sci,Dept Biochem & Mol Biol, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.	shzhaoli@tmu.edu.cn			National Natural Science Foundation of China [81872235, 81702710]; Tianjin Municipal Science and Technology Commission [17JCQNJC11200]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Municipal Science and Technology Commission	This research work was supported by grants from the National Natural Science Foundation of China (81872235 to LZ, 81702710 to SY) and The Tianjin Municipal Science and Technology Commission (17JCQNJC11200 to SY).	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Cammareri P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12493; Cassarino DS, 2006, J CUTAN PATHOL, V33, P191, DOI 10.1111/j.0303-6987.2006.00516_1.x; Cassarino DS, 2006, J CUTAN PATHOL, V33, P261, DOI 10.1111/j.0303-6987.2006.00516.x; da Silva-Diz V, 2016, CANCER RES, V76, P1245, DOI 10.1158/0008-5472.CAN-15-1631; Garcia-Sancha N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092181; Ge YJ, 2016, NAT CELL BIOL, V18, P111, DOI 10.1038/ncb3275; Goldie SJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092201; Han MZ, 2020, BRAIN, V143, P512, DOI 10.1093/brain/awz406; Hussein NA, 2017, J CANCER RES CLIN, V143, P83, DOI 10.1007/s00432-016-2248-7; Jafarzadeh-Samani Z, 2017, CHIN CLIN ONCOL, V6, DOI 10.21037/cco.2017.03.01; Jian Z, 2017, J INVEST DERMATOL, V137, P31, DOI 10.1016/j.jid.2016.07.033; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Lapouge G, 2011, P NATL ACAD SCI USA, V108, P7431, DOI 10.1073/pnas.1012720108; Latil M, 2017, CELL STEM CELL, V20, P191, DOI 10.1016/j.stem.2016.10.018; Li S, 2018, ONCOGENE, V37, P884, DOI 10.1038/onc.2017.381; Lohcharoenkal W, 2016, J INVEST DERMATOL, V136, P2485, DOI 10.1016/j.jid.2016.06.630; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Mizrahi A, 2018, ONCOGENE, V37, P218, DOI 10.1038/onc.2017.315; Ordonez-Moran P, 2015, CANCER CELL, V28, P815, DOI 10.1016/j.ccell.2015.11.001; Oshimori N, 2015, CELL, V160, P963, DOI 10.1016/j.cell.2015.01.043; Patel GK, 2012, J INVEST DERMATOL, V132, P401, DOI 10.1038/jid.2011.317; Qu Y, 2018, NAT CHEM BIOL, V14, P94, DOI [10.1038/NCHEMBIO.2510, 10.1038/nchembio.2510]; Que SKT, 2018, J AM ACAD DERMATOL, V78, P237, DOI 10.1016/j.jaad.2017.08.059; Ra SH, 2011, MODERN PATHOL, V24, P963, DOI 10.1038/modpathol.2011.39; Riemondy K, 2015, ELIFE, V4, DOI 10.7554/eLife.07004; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Sanchez-Danes A, 2018, NATURE, V562, P434, DOI 10.1038/s41586-018-0603-3; Schober M, 2011, P NATL ACAD SCI USA, V108, P10544, DOI 10.1073/pnas.1107807108; Shao YX, 2019, CLIN LAB, V65, P491, DOI 10.7754/Clin.Lab.2018.180825; Sherwood V, 2016, J INVEST DERMATOL, V136, P1760, DOI 10.1016/j.jid.2016.05.108; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Song SJ, 2013, CELL STEM CELL, V13, P87, DOI 10.1016/j.stem.2013.06.003; Sun RF, 2019, FASEB J, V33, P5411, DOI 10.1096/fj.201801798RR; Tsuchiya N, 2011, CANCER RES, V71, P4628, DOI 10.1158/0008-5472.CAN-10-2475; Wang DP, 2019, ONCOL LETT, V17, P3355, DOI 10.3892/ol.2019.10011; Wang X, 2014, BIOCHEM BIOPH RES CO, V445, P175, DOI 10.1016/j.bbrc.2014.01.160; Yuan SK, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005253	39	9	9	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5799	5813		10.1038/s41388-021-01973-5	http://dx.doi.org/10.1038/s41388-021-01973-5		AUG 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34345013	Green Published, hybrid			2022-12-28	WOS:000681523500003
J	Du, SC; Yang, Z; Lu, XF; Yousuf, S; Zhao, M; Li, WX; Miao, J; Wang, XZ; Yu, H; Zhu, XY; Chen, H; Shi, LS; Xu, E; Xia, XF; Guan, WX				Du, Shangce; Yang, Zhi; Lu, Xiaofeng; Yousuf, Suhail; Zhao, Min; Li, Wenxi; Miao, Ji; Wang, Xingzhou; Yu, Heng; Zhu, Xinya; Chen, Hong; Shi, Linseng; Xu, En; Xia, Xuefeng; Guan, Wenxian			Anoikis resistant gastric cancer cells promote angiogenesis and peritoneal metastasis through C/EBP beta-mediated PDGFB autocrine and paracrine signaling	ONCOGENE			English	Article							TUMOR ANGIOGENESIS; MOLECULAR PATHWAYS; SURVIVAL; DETACHMENT; AUTOPHAGY; GROWTH; AXIS	Anoikis is a type of programmed cell death induced by loss of anchorage to the extracellular matrix (ECM). Anoikis resistance (AR) is crucial for the survival of metastatic cancer cells in blood, lymphatic circulation and distant organs. Compared to ordinary cancer cells, anoikis resistant cancer cells undergo various cellular and molecular alterations, probably characterizing the cells with unique features not limited to anoikis resistance. However, the molecular mechanisms connecting anoikis resistance to other metastatic properties are still poorly understood. Here, the biological interaction between anoikis resistance and angiogenesis as well as their involvement into peritoneal metastasis of gastric cancer (GC) were investigated in vitro and in vivo. The prognostic value of key components involved in this interaction was evaluated in the GC cohort. Compared to ordinary GC cells, GC(AR) cells exhibited stronger metastatic and pro-angiogenic traits corresponding to elevated PDGFB secretion. Mechanistically, transcription factor C/EBP beta facilitated PDGFB transcription by directly binding to and interacting with PDGFB promoter elements, subsequently increasing PDGFB secretion. Secreted PDGFB promoted the survival of detached GC cells through a C/EBP beta-dependent self-feedback loop. Moreover, secreted PDGFB promoted angiogenesis in metastases via activation of the MAPK/ERK signaling pathway in vascular endothelial cells. Both C/EBP beta activation level and PDGFB expression were significantly elevated in GC and correlated with metastatic progression and poor prognosis of patients with GC. Overall, interaction between GC(AR) cells and vascular endothelial cells promotes angiogenesis and peritoneal metastasis of GC based on C/EBP beta-mediated PDGFB autocrine and paracrine signaling. C/EBP beta-PDGFB-PDGFR beta-MAPK axis promises to be potential prognostic biomarkers and therapeutic targets for peritoneal metastasis of GC.	[Du, Shangce; Yang, Zhi; Lu, Xiaofeng; Zhao, Min; Yu, Heng; Zhu, Xinya; Chen, Hong; Shi, Linseng; Guan, Wenxian] Nanjing Med Univ, Dept Gastrointestinal Surg, Drum Tower Clin Med Coll, Nanjing, Peoples R China; [Du, Shangce; Yang, Zhi; Lu, Xiaofeng; Miao, Ji; Wang, Xingzhou; Xu, En; Xia, Xuefeng; Guan, Wenxian] Nanjing Univ, Dept Gastrointestinal Surg, Nanjing Drum Tower Hosp, Affiliated Hosp,Med Sch, Nanjing, Peoples R China; [Yousuf, Suhail] Heidelberg Univ Hosp, Dept Surg, Heidelberg, Germany; [Li, Wenxi] Heidelberg Univ, Fac Med, Heidelberg, Germany	Nanjing Medical University; Nanjing University; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Guan, WX (corresponding author), Nanjing Med Univ, Dept Gastrointestinal Surg, Drum Tower Clin Med Coll, Nanjing, Peoples R China.; Xu, E; Xia, XF; Guan, WX (corresponding author), Nanjing Univ, Dept Gastrointestinal Surg, Nanjing Drum Tower Hosp, Affiliated Hosp,Med Sch, Nanjing, Peoples R China.	657416504@qq.com; danielxuefeng@hotmail.com; 15850502391@163.com						Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6; Avivar-Valderas A, 2013, ONCOGENE, V32, P4932, DOI 10.1038/onc.2012.512; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chen N, 2013, AUTOPHAGY, V9, P1214, DOI 10.4161/auto.24870; Chen X, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.11.019; Cheng P, 2019, MOL THER-NUCL ACIDS, V18, P155, DOI 10.1016/j.omtn.2019.08.013; Chung AS, 2011, ANNU REV CELL DEV BI, V27, P563, DOI 10.1146/annurev-cellbio-092910-154002; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; Du SC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0953-7; Eddy RJ, 2017, TRENDS CELL BIOL, V27, P595, DOI 10.1016/j.tcb.2017.03.003; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Guo L, 2015, J BIOL CHEM, V290, P755, DOI 10.1074/jbc.R114.619957; Haemmerle M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00411-z; Hong SH, 2013, GASTRIC CANCER, V16, P290, DOI 10.1007/s10120-012-0182-1; Hosaka K, 2016, P NATL ACAD SCI USA, V113, pE5618, DOI 10.1073/pnas.1608384113; Hosaka K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3129; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jin K, 2017, J PATHOL, V241, P567, DOI 10.1002/path.4871; Jin LT, 2018, MOL CELL, V69, P87, DOI 10.1016/j.molcel.2017.11.025; Jitariu AA, 2018, CRIT REV ONCOL HEMAT, V131, P46, DOI 10.1016/j.critrevonc.2018.08.002; Kastana P, 2019, METHODS MOL BIOL, V1952, P219, DOI 10.1007/978-1-4939-9133-4_18; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Kirsch M, 2004, CANC TREAT, V117, P285; Kitadai Yasuhiko, 2011, Cancers (Basel), V3, P4245, DOI 10.3390/cancers3044245; Kuczynski EA, 2019, NAT REV CLIN ONCOL, V16, P469, DOI 10.1038/s41571-019-0181-9; La Porta S, 2018, J CLIN INVEST, V128, P834, DOI 10.1172/JCI94674; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liu TR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05982-z; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Ma WH, 2018, THERANOSTICS, V8, P5744, DOI 10.7150/thno.28898; Mazzone M, 2019, ANNU REV PHYSIOL, V81, P535, DOI 10.1146/annurev-physiol-020518-114721; McLean MIH, 2014, NAT REV GASTRO HEPAT, V11, P664, DOI 10.1038/nrgastro.2014.143; Nissen LJ, 2007, J CLIN INVEST, V117, P2766, DOI 10.1172/JCI32479; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pontes-Quero S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09875-7; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Shah MA, 2015, J CLIN ONCOL, V33, P1760, DOI 10.1200/JCO.2014.60.1799; Shen XF, 2018, J ALLERGY CLIN IMMUN, V141, P1929, DOI 10.1016/j.jaci.2018.01.005; Strilic B, 2017, CANCER CELL, V32, P282, DOI 10.1016/j.ccell.2017.07.001; Tamura A, 2017, BLOOD, V130, P1809, DOI 10.1182/blood-2017-03-772962; Thomassen I, 2014, INT J CANCER, V134, P622, DOI 10.1002/ijc.28373; Toubal A, 2013, J CLIN INVEST, V123, P362, DOI 10.1172/JCI64052; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang SY, 2013, GUT, V62, P496, DOI 10.1136/gutjnl-2011-301522; Wang SH, 2019, J PATHOL, V248, P204, DOI 10.1002/path.5246; Wang XH, 2019, CLIN CANCER RES, V25, P3128, DOI 10.1158/1078-0432.CCR-18-2804; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Xu Yong Zhong, 2013, Methods Mol Biol, V977, P79, DOI 10.1007/978-1-62703-284-1_7; Xue Y, 2012, NAT MED, V18, P100, DOI 10.1038/nm.2575; Yonemura Yutaka, 2003, Surg Oncol Clin N Am, V12, P635, DOI 10.1016/S1055-3207(03)00035-8; Zabielska-Koczywas K, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1114-4; Zhang Y, 2004, J BIOL CHEM, V279, P48342, DOI 10.1074/jbc.M407953200; Zhang YY, 2012, BIOCHEM BIOPH RES CO, V419, P550, DOI 10.1016/j.bbrc.2012.02.058	58	10	10	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5764	5779		10.1038/s41388-021-01988-y	http://dx.doi.org/10.1038/s41388-021-01988-y		AUG 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34341514				2022-12-28	WOS:000680382100002
J	Takagi, S; Sasaki, Y; Koike, S; Takemoto, A; Seto, Y; Haraguchi, M; Ukaji, T; Kawaguchi, T; Sugawara, M; Saito, M; Funauchi, Y; Ae, K; Matsumoto, S; Fujita, N; Katayama, R				Takagi, Satoshi; Sasaki, Yuki; Koike, Sumie; Takemoto, Ai; Seto, Yosuke; Haraguchi, Mizuki; Ukaji, Takao; Kawaguchi, Tokuichi; Sugawara, Minoru; Saito, Masanori; Funauchi, Yuki; Ae, Keisuke; Matsumoto, Seiichi; Fujita, Naoya; Katayama, Ryohei			Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis	ONCOGENE			English	Article							OSTEOGENIC-SARCOMA; CANCER; CHEMOTHERAPY; LPA(1); AGGRUS/PODOPLANIN; ANTAGONIST; MECHANISMS	Osteosarcoma is the most common primary malignant bone cancer, with high rates of pulmonary metastasis. Osteosarcoma patients with pulmonary metastasis have worse prognosis than those with localized disease, leading to dramatically reduced survival rates. Therefore, understanding the biological characteristics of metastatic osteosarcoma and the molecular mechanisms of invasion and metastasis of osteosarcoma cells will lead to the development of innovative therapeutic intervention for advanced osteosarcoma. Here, we identified that osteosarcoma cells commonly exhibit high platelet activation-inducing characteristics, and molecules released from activated platelets promote the invasiveness of osteosarcoma cells. Given that heat-denatured platelet releasate maintained the ability to promote osteosarcoma invasion, we focused on heat-tolerant molecules, such as lipid mediators in the platelet releasate. Osteosarcoma-induced platelet activation leads to abundant lysophosphatidic acid (LPA) release. Exposure to LPA or platelet releasate induced morphological changes and increased invasiveness of osteosarcoma cells. By analyzing publicly available transcriptome datasets and our in-house osteosarcoma patient-derived xenograft tumors, we found that LPA receptor 1 (LPAR1) is notably upregulated in osteosarcoma. LPAR1 gene KO in osteosarcoma cells abolished the platelet-mediated osteosarcoma invasion in vitro and the formation of early pulmonary metastatic foci in experimental pulmonary metastasis models. Of note, the pharmacological inhibition of LPAR1 by the orally available LPAR1 antagonist, ONO-7300243, prevented pulmonary metastasis of osteosarcoma in the mouse models. These results indicate that the LPA-LPAR1 axis is essential for the osteosarcoma invasion and metastasis, and targeting LPAR1 would be a promising therapeutic intervention for advanced osteosarcoma.	[Takagi, Satoshi; Sasaki, Yuki; Koike, Sumie; Takemoto, Ai; Seto, Yosuke; Haraguchi, Mizuki; Ukaji, Takao; Katayama, Ryohei] Japanese Fdn Canc Res, Canc Chemotherapy Ctr, Div Expt Chemotherapy, Tokyo, Japan; [Kawaguchi, Tokuichi; Sugawara, Minoru] Japanese Fdn Canc Res, Canc Precis Med Ctr, Project Dev Genom Based Canc Med, Tokyo, Japan; [Saito, Masanori; Funauchi, Yuki; Ae, Keisuke] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Orthoped Oncol, Tokyo, Japan; [Matsumoto, Seiichi] Japanese Fdn Canc Res, Canc Inst Hosp, Tarcoma Ctr, Tokyo, Japan; [Fujita, Naoya] Japanese Fdn Canc Res, Canc Chemotherapy Ctr, Tokyo, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Katayama, R (corresponding author), Japanese Fdn Canc Res, Canc Chemotherapy Ctr, Div Expt Chemotherapy, Tokyo, Japan.	ryohei.katayama@jfcr.or.jp	Saito, Masanori/GRR-1714-2022; Katayama, Ryohei/K-8537-2014	Katayama, Ryohei/0000-0001-7394-895X; Fujita, Naoya/0000-0002-9631-9264; Saito, Masanori/0000-0002-4139-4013	MEXT/JSPS KAKENHI [JP18H06187, JP19K22572, JP17H06327, JP19H03524, JP20K21554]; Acceleration Transformative Research for Medical Innovation (ACT-M) from Japan Agency for Medical Research and Development (AMED) [JP20im0210110]; Nippon Foundation; Tokyo Biochemical Research Foundation; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development (AMED) [JP21cm0106286, JP21cm0106205, JP21cm0106203]	MEXT/JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Acceleration Transformative Research for Medical Innovation (ACT-M) from Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Nippon Foundation(Nippon Foundation); Tokyo Biochemical Research Foundation; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED))	We thank Mr. Yuki Shimizu, Ms. Miho Takami, Ms. Tomoko Oh-Hara, and Ms. Harumi Shibata from JFCR for technical assistance. This study was supported in part by MEXT/JSPS KAKENHI grant number JP18H06187 (to S Takagi), JP19K22572 (to S Takagi), JP17H06327 (to N Fujita), JP19H03524 (to R Katayama), and JP20K21554 (to R Katayama). This study was also supported in part by the Project for Cancer Research and Therapeutic Evolution (P-CREATE) grant number JP21cm0106286 (to S Takagi), JP21cm0106205 (to N Fujita) and JP21cm0106203 (to R Katayama), the Acceleration Transformative Research for Medical Innovation (ACT-M) grant number JP20im0210110 (to N Fujita) from the Japan Agency for Medical Research and Development (AMED), the grant from Nippon Foundation (to N Fujita), and Grant-inAid from the Tokyo Biochemical Research Foundation (to S Takagi).	Aljubran AH, 2009, ANN ONCOL, V20, P1136, DOI 10.1093/annonc/mdn731; Allanore Y, 2018, ARTHRITIS RHEUMATOL, V70, P1634, DOI 10.1002/art.40547; Anderson RL, 2019, NAT REV CLIN ONCOL, V16, P185, DOI 10.1038/s41571-018-0134-8; Aoki J, 2004, SEMIN CELL DEV BIOL, V15, P477, DOI 10.1016/j.semcdb.2004.05.001; Bacci G, 2001, EUR J CANCER, V37, P2030, DOI 10.1016/S0959-8049(01)00229-5; Baeyens AAL, 2020, ANNU REV IMMUNOL, V38, P759, DOI 10.1146/annurev-immunol-081519-083952; Bambace NM, 2011, J THROMB HAEMOST, V9, P237, DOI 10.1111/j.1538-7836.2010.04131.x; Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123; Bousquet M, 2016, ANN ONCOL, V27, P738, DOI 10.1093/annonc/mdw009; Briccoli A, 2010, SURG ONCOL, V19, P193, DOI 10.1016/j.suronc.2009.05.002; Buergy D, 2012, INT J CANCER, V130, P2747, DOI 10.1002/ijc.27441; Casali PG, 2018, ANN ONCOL, V29, P79, DOI 10.1093/annonc/mdy310; Castelino FV, 2011, ARTHRITIS RHEUM-US, V63, P1405, DOI 10.1002/art.30262; Chatterjee M, 2020, J THROMB HAEMOST, V18, P543, DOI 10.1111/jth.14721; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; Durnali AG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152621; Franco AT, 2015, BLOOD, V126, P582, DOI 10.1182/blood-2014-08-531582; Fujita N, 2012, J BIOCHEM, V152, P407, DOI 10.1093/jb/mvs108; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Haemmerle M, 2018, CANCER CELL, V33, P965, DOI 10.1016/j.ccell.2018.03.002; Iwano S, 2018, SCIENCE, V359, P935, DOI 10.1126/science.aaq1067; Kager L, 2003, J CLIN ONCOL, V21, P2011, DOI 10.1200/JCO.2003.08.132; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Kempf-Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063; Knowlden S, 2014, J IMMUNOL, V192, P851, DOI 10.4049/jimmunol.1302831; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Leblanc R, 2018, BRIT J PHARMACOL, V175, P3100, DOI 10.1111/bph.14362; MEYERS PA, 1993, J CLIN ONCOL, V11, P449, DOI 10.1200/JCO.1993.11.3.449; Nagahashi M, 2018, CANCER SCI, V109, P3671, DOI 10.1111/cas.13802; Noguchi K, 2009, CURR OPIN PHARMACOL, V9, P15, DOI 10.1016/j.coph.2008.11.010; O'Donnell VB, 2014, CIRC RES, V114, P1185, DOI 10.1161/CIRCRESAHA.114.301597; Ohashi T, 2015, EXP DERMATOL, V24, P698, DOI 10.1111/exd.12752; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Overall CM, 2006, BRIT J CANCER, V94, P941, DOI 10.1038/sj.bjc.6603043; Palmer SM, 2018, CHEST, V154, P1061, DOI 10.1016/j.chest.2018.08.1058; Pradere JP, 2007, J AM SOC NEPHROL, V18, P3110, DOI 10.1681/ASN.2007020196; Riaz A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020215; Ribi S, 2015, ONCOTARGET, V6, P7727, DOI 10.18632/oncotarget.3115; Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276; ROSEN G, 1979, CANCER-AM CANCER SOC, V43, P2163, DOI 10.1002/1097-0142(197906)43:6<2163::AID-CNCR2820430602>3.0.CO;2-S; Salah S, 2014, MOL CLIN ONCOL, V2, P811, DOI 10.3892/mco.2014.325; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Stone RL, 2012, NEW ENGL J MED, V366, P610, DOI 10.1056/NEJMoa1110352; Tager AM, 2008, NAT MED, V14, P45, DOI 10.1038/nm1685; Takagi S, 2018, CLIN CANCER RES, V24, P2430, DOI 10.1158/1078-0432.CCR-17-2003; Takagi S, 2014, CANCER SCI, V105, P983, DOI 10.1111/cas.12464; Takagi S, 2014, INT J CANCER, V134, P2605, DOI 10.1002/ijc.28602; Takagi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073609; Takemoto A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42186; Xiang HJ, 2020, J CANCER, V11, P3519, DOI 10.7150/jca.41841; Zhang B, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018-020-1576-0	51	5	5	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5548	5558		10.1038/s41388-021-01956-6	http://dx.doi.org/10.1038/s41388-021-01956-6		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34302117	Green Published, hybrid			2022-12-28	WOS:000676064800003
J	Clements, ME; Holtslander, L; Edwards, C; Todd, V; Dooyema, SDR; Bullock, K; Bergdorf, K; Zahnow, CA; Connolly, RM; Johnson, RW				Clements, Miranda E.; Holtslander, Lauren; Edwards, Courtney; Todd, Vera; Dooyema, Samuel D. R.; Bullock, Kennady; Bergdorf, Kensey; Zahnow, Cynthia A.; Connolly, Roisin M.; Johnson, Rachelle W.			HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer	ONCOGENE			English	Article							BONE METASTASIS; RECEPTOR; CELLS; PHOSPHORYLATION; DIFFERENTIATION; ACETYLATION; SURVIVAL	Despite advances in breast cancer treatment, residual disease driven by dormant tumor cells continues to be a significant clinical problem. Leukemia inhibitory factor receptor (LIFR) promotes a dormancy phenotype in breast cancer cells and LIFR loss is correlated with poor patient survival. Herein, we demonstrate that histone deacetylase inhibitors (HDACi), which are in phase III clinical trials for breast cancer, epigenetically induced LIFR and activated a pro-dormancy program in breast cancer cells. HDACi slowed breast cancer cell proliferation and reduced primary tumor growth. Primary breast tumors from HDACi-treated patients had increased LIFR levels and reduced proliferation rates compared to pre-treatment levels. Recent Phase II clinical trial data studying entinostat and azacitidine in metastatic breast cancer revealed that induction of several pro-dormancy genes post-treatment was associated with prolonged patient survival. Together, these findings suggest HDACi as a potential therapeutic avenue to promote dormancy, prevent recurrence, and improve patient outcomes in breast cancer.	[Clements, Miranda E.; Edwards, Courtney; Todd, Vera; Johnson, Rachelle W.] Vanderbilt Univ, Program Canc Biol, Nashville, TN 37235 USA; [Clements, Miranda E.; Holtslander, Lauren; Edwards, Courtney; Todd, Vera; Bullock, Kennady; Johnson, Rachelle W.] Vanderbilt Univ, Vanderbilt Ctr Bone Biol, Dept Med, Div Clin Pharmacol,Med Ctr, Nashville, TN 37235 USA; [Holtslander, Lauren; Johnson, Rachelle W.] Vanderbilt Univ, Dept Med, Div Clin Pharmacol, Med Ctr, Nashville, TN 37235 USA; [Dooyema, Samuel D. R.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Bullock, Kennady; Bergdorf, Kensey] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA; [Zahnow, Cynthia A.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Oncol, Baltimore, MD USA; [Connolly, Roisin M.] Univ Coll Cork, Coll Med & Hlth, Canc Res UCC, Cork, Ireland; [Connolly, Roisin M.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Johns Hopkins University; Johns Hopkins Medicine; University College Cork; Johns Hopkins University; Johns Hopkins Medicine	Johnson, RW (corresponding author), Vanderbilt Univ, Program Canc Biol, Nashville, TN 37235 USA.; Johnson, RW (corresponding author), Vanderbilt Univ, Vanderbilt Ctr Bone Biol, Dept Med, Div Clin Pharmacol,Med Ctr, Nashville, TN 37235 USA.; Johnson, RW (corresponding author), Vanderbilt Univ, Dept Med, Div Clin Pharmacol, Med Ctr, Nashville, TN 37235 USA.	rachelle.johnson@vumc.org		Johnson, Rachelle/0000-0003-2755-9851	DoD Breakthrough Award [W81XWH-18-10029]; NIH [R00CA194198, P30CA068485]; Novartis; Puma Biotechnology; Merck; Genentech; Macrogenics	DoD Breakthrough Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis(Novartis); Puma Biotechnology; Merck(Merck & Company); Genentech(Roche HoldingGenentech); Macrogenics	MEC, LH, CE, and RWJ are supported by DoD Breakthrough Award W81XWH-18-10029 (RWJ), and VT and RWJ are supported by NIH award R00CA194198 (RWJ). This project was also supported by scholarship funds from NIH award P30CA068485 Vanderbilt-Ingram Cancer Center Support Grant. RMC has received research grants to institution from Novartis, Puma Biotechnology, Merck, Genentech, and Macrogenics.	Abaza MSI, 2014, INT J MOL MED, V34, P513, DOI 10.3892/ijmm.2014.1795; Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Almog N, 2013, TRANSCR-AUSTIN, V4, P177, DOI 10.4161/trns.25558; Almog N, 2009, CANCER RES, V69, P836, DOI 10.1158/0008-5472.CAN-08-2590; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Cackowski FC, 2017, J CELL BIOCHEM, V118, P891, DOI 10.1002/jcb.25768; Campbell JP, 2012, JOVE-J VIS EXP, DOI 10.3791/4260; Carlson P, 2019, NAT CELL BIOL, V21, P238, DOI 10.1038/s41556-018-0267-0; Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940; Clements ME, 2020, ONCOGENE, V39, P1318, DOI 10.1038/s41388-019-1064-3; Clements ME, 2019, CURR OSTEOPOROS REP, V17, P353, DOI 10.1007/s11914-019-00532-y; Cohen Adam L, 2017, JCO Precis Oncol, V1, DOI 10.1200/PO.16.00011; Connolly RM, 2017, CLIN CANCER RES, V23, P2691, DOI 10.1158/1078-0432.CCR-16-1729; Denoyer D, 2014, GROWTH FACTORS, V32, P63, DOI 10.3109/08977194.2014.894037; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; Eckschlager T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071414; El Touny LH, 2014, J CLIN INVEST, V124, P156, DOI 10.1172/JCI70259; Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360; Formisano L, 2017, CLIN CANCER RES, V23, P6138, DOI 10.1158/1078-0432.CCR-17-1232; Gawrzak S, 2018, NAT CELL BIOL, V20, P211, DOI 10.1038/s41556-017-0021-z; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gomis RR, 2017, MOL ONCOL, V11, P62, DOI 10.1016/j.molonc.2016.09.009; Harhous Z, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00150; Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785; Huang GY, 2014, STEM CELLS, V32, P1149, DOI 10.1002/stem.1609; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Iorns E, 2012, BREAST CANCER RES TR, V135, P79, DOI 10.1007/s10549-012-2068-7; Johnson RW, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00241; Johnson RW, 2016, NAT CELL BIOL, V18, P1078, DOI 10.1038/ncb3408; Kim RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035569; MORRIS VL, 1993, CLIN EXP METASTAS, V11, P103, DOI 10.1007/BF00880071; Oki T, 2014, SCI REP-UK, V4, DOI 10.1038/srep04012; Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953; Pernodet N, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3341; Sanger N, 2011, INT J CANCER, V129, P2522, DOI 10.1002/ijc.25895; Sosa MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7170; Suraweera A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00092; Wang XJ, 2017, CELL REP, V18, P933, DOI 10.1016/j.celrep.2016.12.081; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; YONEDA T, 1994, BREAST CANCER RES TR, V32, P73, DOI 10.1007/BF00666208; Yu-Lee LY, 2018, CANCER RES, V78, P2911, DOI 10.1158/0008-5472.CAN-17-1051; Yumoto K, 2016, SCI REP-UK, V6, DOI 10.1038/srep36520; Zeng HL, 2016, CANCER CELL, V30, P459, DOI 10.1016/j.ccell.2016.08.001; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	48	4	4	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5314	5326		10.1038/s41388-021-01931-1	http://dx.doi.org/10.1038/s41388-021-01931-1		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34247191	Green Accepted			2022-12-28	WOS:000671644900002
J	Wang, XL; Zhang, L; Song, YF; Jiang, Y; Zhang, D; Wang, R; Hu, TH; Han, S				Wang, Xiaoliang; Zhang, Li; Song, Yifu; Jiang, Yang; Zhang, Di; Wang, Run; Hu, Tianhao; Han, Sheng			MCM8 is regulated by EGFR signaling and promotes the growth of glioma stem cells through its interaction with DNA-replication-initiating factors	ONCOGENE			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; FUNCTIONAL-CHARACTERIZATION; COMPLEX; EXPRESSION; CANCER; ACTIVATION; PROGNOSIS; FAMILY; CDC6	Mini-chromosome maintenance (MCM) proteins are critical components of DNA-replication-licensing factors. MCM8 is an MCM protein that exhibits oncogenic functions in several human malignancies. However, the role of MCM8 in glioblastomas (GBMs) has remained unclear. In the present study, we investigated the biological functions and mechanisms of MCM8 in glioma stem cells (GSCs). The clinical relevance of MCM8 mRNA expression was explored via TCGA and REMBRANDT datasets. The effects of MCM8 on the self-renewal and tumorigenicity of GSCs were examined both in vitro and in vivo. The regulation of MCM8 expression and its interacting proteins were also evaluated. We found that the expression of MCM8 was elevated in high-grade gliomas and classical molecular subtypes and was inversely correlated with patient prognosis. GSCs had a significantly higher expression of MCM8 compared with that in normal glioma cells. Silencing of MCM8 induced G0/G1 arrest and apoptosis, as well as inhibited the proliferation and self-renewal of GSCs. Forced expression of MCM8 enhanced clonogenicity of GSCs both in vitro and in vivo. MCM8 expression was regulated by EGFR signaling, which was mediated by NF-kappa B (p65). MCM8 interacted with DNA-replication-initiating factors-including EZH2, CDC6, and CDCA2-and influenced these factors to associate with chromatin. In addition, MCM8 knockdown increased the sensitivity of GSCs to radiation and TMZ treatments. Our findings suggest that MCM8, regulated by the EGFR pathway, maintains the clonogenic and tumorigenic potential of GSCs through interaction with DNA-replication-initiating factors; hence, MCM8 may represent a novel therapeutic target in GBMs.	[Wang, Xiaoliang; Zhang, Li; Song, Yifu; Jiang, Yang; Wang, Run; Hu, Tianhao; Han, Sheng] China Med Univ, Hosp 1, Dept Neurosurg, Shenyang, Peoples R China; [Jiang, Yang] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Neurosurg, Sch Med, Shanghai, Peoples R China; [Zhang, Di] China Med Univ, Dept Pathol, Shenyang, Peoples R China	China Medical University; Shanghai Jiao Tong University; China Medical University	Han, S (corresponding author), China Med Univ, Hosp 1, Dept Neurosurg, Shenyang, Peoples R China.	hansheng2001_x@aliyun.com		Han, Sheng/0000-0001-6991-0529; song, yi fu/0000-0002-5096-5949	LiaoNing Revitalization Talents Program [XLYC1807253]; National Natural Science Foundation of China [81772653, 81402045]	LiaoNing Revitalization Talents Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Qingchang Li from the Department of Pathology at China Medical University for technological support and assistance with statistical analyses. This work was supported by the LiaoNing Revitalization Talents Program (No. XLYC1807253) and the National Natural Science Foundation of China (No. 81772653 and 81402045)	Azzarelli R, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.162693; Bowman RL, 2017, NEURO-ONCOLOGY, V19, P139, DOI 10.1093/neuonc/now247; Cai HQ, 2018, HUM PATHOL, V78, P182, DOI 10.1016/j.humpath.2018.04.024; Cai LL, 2015, INT J CLIN EXP PATHO, V8, P14180; De Ruysscher D, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0064-5; Erkan EP, 2014, ONCOGENE, V33, P4778, DOI 10.1038/onc.2013.423; Freeman A, 1999, CLIN CANCER RES, V5, P2121; Friedman HS, 2000, CLIN CANCER RES, V6, P2585; Gozuacik D, 2003, NUCLEIC ACIDS RES, V31, P570, DOI 10.1093/nar/gkg136; Greenall SA, 2019, NEURO-ONCOLOGY, V21, P1016, DOI 10.1093/neuonc/noz073; Guo SY, 2021, THERANOSTICS, V11, P4316, DOI 10.7150/thno.51745; Han S, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0552-y; Han S, 2015, J NEURO-ONCOL, V124, P45, DOI 10.1007/s11060-015-1818-x; He DM, 2017, ONCOGENE, V36, P3629, DOI 10.1038/onc.2017.123; Honeycutt KA, 2006, ONCOGENE, V25, P4027, DOI 10.1038/sj.onc.1209435; Hua C, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-526; Im JS, 2009, P NATL ACAD SCI USA, V106, P15628, DOI 10.1073/pnas.0908039106; Ishimi Y, 2018, GENES GENET SYST, V93, P125, DOI 10.1266/ggs.18-00026; Jiang Y, 2019, CANCER RES, V79, P2593, DOI 10.1158/0008-5472.CAN-18-3297; Jin X, 2017, NAT MED, V23, P1352, DOI 10.1038/nm.4415; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Lee KY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8744; Li XJ, 2018, MOL CELL, V72, P650, DOI 10.1016/j.molcel.2018.09.007; Liu YQ, 2017, J MOL CELL BIOL, V9, P178, DOI 10.1093/jmcb/mjx013; Liu ZK, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4056-8; Matson JP, 2017, ELIFE, V6, DOI 10.7554/eLife.30473; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mukherjee S, 2018, CELL REP, V23, P1651, DOI 10.1016/j.celrep.2018.04.016; Nishimura K, 2012, MOL CELL, V47, P511, DOI 10.1016/j.molcel.2012.05.047; Park J, 2013, MOL CELL BIOL, V33, P1632, DOI 10.1128/MCB.01503-12; Peng YP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164150; Song YF, 2019, THERANOSTICS, V9, P6019, DOI 10.7150/thno.35747; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; Volkening M, 2005, MOL CELL BIOL, V25, P1560, DOI 10.1128/MCB.25.4.1560-1568.2005; Wang QY, 2018, CLIN CANCER RES, V24, P950, DOI 10.1158/1078-0432.CCR-17-1475; Wang YF, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188415; Weller M, 2017, LANCET ONCOL, V18, pE315, DOI 10.1016/S1470-2045(17)30194-8; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Zhang X, 2014, MOL CANCER RES, V12, P1535, DOI 10.1158/1541-7786.MCR-13-0641	41	2	2	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4615	4624		10.1038/s41388-021-01888-1	http://dx.doi.org/10.1038/s41388-021-01888-1		JUN 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34131285				2022-12-28	WOS:000661812800002
J	Xi, SY; Cai, HP; Lu, JB; Zhang, Y; Yu, YJ; Chen, FR; Huang, QT; Wang, F; Chen, ZP				Xi, Shaoyan; Cai, Haiping; Lu, Jiabin; Zhang, Yu; Yu, Yanjiao; Chen, Furong; Huang, Qitao; Wang, Fang; Chen, Zhongping			The pseudogene PRELID1P6 promotes glioma progression via the hnHNPH1-Akt/mTOR axis	ONCOGENE			English	Article							NONCODING RNA; PROTEINS; CANCER; RECOGNITION; DYSFUNCTION; EXPRESSION; CARCINOMA; APOPTOSIS; UBIQUITIN; PATHWAYS	Research over the past decade has suggested important roles for pseudogenes in glioma. This study aimed to show that pseudogene PRELI domain-containing 1 pseudogene 6 (PRELID1P6) promotes glioma progression. Aberrant expression of genes was screened using The Cancer Genome Atlas database. We found that mRNA level of PRELID1P6 was highly upregulated in glioma and was associated with a shorter survival time. Functional studies showed that the knockdown of PRELID1P6 decreased cell proliferation, sphere formation, and clone formation ability and blocked the cell cycle transition at G0/G1, while overexpression of PRELID1P6 had the opposite effects. Mechanistically, knockdown of PRELID1P6 changed the cellular localization of heterogeneous nuclear ribonucleoprotein H1 (hnRNPH1) from nucleus to cytoplasm, which promoted ubiquitin-mediated degradation of hnRNPH1. RNA-sequence and gene set enrichment analysis suggested that knockdown of PRELID1P6 regulates the apoptosis signaling pathway. Western blotting showed that PRELID1P6 increased TRF2 expression by hnRNPH1-mediated alternative splicing effect and activated the Akt/mTOR pathway. Furthermore, Akt inhibitor MK2206 treatment reversed the oncogenic function of PRELID1P6. PRELID1P6 was also found to be negatively regulated by miR-1825. Our result showed that PRELID1P6 promotes glioma progression through the hnHNPH1-Akt/mTOR pathway. These findings shed new light on the important role of PRELID1P6 as a novel oncogene for glioma.	[Xi, Shaoyan; Lu, Jiabin; Zhang, Yu; Huang, Qitao] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Pathol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China; [Cai, Haiping; Yu, Yanjiao; Chen, Furong; Chen, Zhongping] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Neurosurg Neurooncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China; [Wang, Fang] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Mol Diagnost, Canc Ctr, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Chen, ZP (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Neurosurg Neurooncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.; Wang, F (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Mol Diagnost, Canc Ctr, Guangzhou, Peoples R China.	wangfang@sysucc.org.cn; chenzhp@sysucc.org.cn	wang, fang/GYD-4295-2022	chen, zhongping/0000-0002-6226-5771	National Natural Science Foundation of China (NSFC) [81902536]; Medical Scientific Research Foundation of Guangdong Province of China [20181030153136778]; Fundamental Research Funds for the Central Universities [20ykpy173, 17ykpy84]; National Basic Research Program of China (973) [2015CB755505]; NSFC [81872059]; National High Technology Research and Development Program of China (863) [2012AA02A508]; Guangzhou Science, Technology and Innovation Project [201508020125]; Science and Technology Planning Project [2016A020213004]; Natural Science Foundation of Guangdong Province [S2013040012894]; Guangdong Natural Science Foundation [2017A030310192]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Medical Scientific Research Foundation of Guangdong Province of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Basic Research Program of China (973)(National Basic Research Program of China); NSFC(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program of China (863)(National High Technology Research and Development Program of China); Guangzhou Science, Technology and Innovation Project; Science and Technology Planning Project; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province)	The study was approved by the Ethics Committee of Sun Yat-sen University Cancer Center with a no. of GZR2019-053. The authors thank Qi Zhao for the work of bioinformatics. This study was supported by grants from National Natural Science Foundation of China (NSFC; 81902536) and Medical Scientific Research Foundation of Guangdong Province of China (20181030153136778) and Fundamental Research Funds for the Central Universities (20ykpy173) to SX; National Basic Research Program of China (973; 2015CB755505), NSFC (81872059), the National High Technology Research and Development Program of China (863; 2012AA02A508), Guangzhou Science, Technology and Innovation Project (201508020125), Science and Technology Planning Project (2016A020213004) and Natural Science Foundation of Guangdong Province (S2013040012894) to ZC; and Guangdong Natural Science Foundation (2017A030310192) and the Fundamental Research Funds for the Central Universities (17ykpy84) for FW.	Aboudehen K, 2020, BBA-GENE REGUL MECH, V1863, DOI 10.1016/j.bbagrm.2019.194449; Barth RF, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0280-5; Bracken CP, 2016, NAT REV GENET, V17, P719, DOI 10.1038/nrg.2016.134; Chen CL, 2015, BIOMATERIALS, V44, P71, DOI 10.1016/j.biomaterials.2014.12.023; Chen X, 2012, TRENDS BIOCHEM SCI, V37, P457, DOI 10.1016/j.tibs.2012.08.005; Chen X, 2020, THERANOSTICS, V10, P1479, DOI 10.7150/thno.40659; da Silva MR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/150514; Deng JM, 2016, MOL NEUROBIOL, V53, P1132, DOI 10.1007/s12035-014-9080-3; Edwards LA, 2005, ONCOGENE, V24, P3596, DOI 10.1038/sj.onc.1208427; Gautrey H, 2015, RNA BIOL, V12, P1139, DOI 10.1080/15476286.2015.1076610; Geuens T, 2016, HUM GENET, V135, P851, DOI 10.1007/s00439-016-1683-5; Grammatikakis I, 2016, CELL CYCLE, V15, P3026, DOI 10.1080/15384101.2016.1222339; Grammatikakis I, 2016, CELL REP, V15, P926, DOI 10.1016/j.celrep.2016.03.080; Grice GL, 2016, CELL MOL LIFE SCI, V73, P3497, DOI 10.1007/s00018-016-2255-5; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Hu XL, 2018, CANCERS, V10, DOI 10.3390/cancers10080256; JACQ C, 1977, CELL, V12, P109, DOI 10.1016/0092-8674(77)90189-1; Karreth FA, 2015, CELL, V161, P319, DOI 10.1016/j.cell.2015.02.043; Kedzierska H, 2017, CANCER LETT, V396, P53, DOI 10.1016/j.canlet.2017.03.013; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li XM, 2016, ONCOTARGET, V7, P33440, DOI [10.18632/oncotarget.7961, 10.18632/oncotarget.6497]; Lian YF, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0333-9; Lu XJ, 2015, J MED GENET, V52, P17, DOI 10.1136/jmedgenet-2014-102785; Nagano T, 2008, SCIENCE, V322, P1717, DOI 10.1126/science.1163802; Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rynkeviciene R, 2019, CANCERS, V11, DOI 10.3390/cancers11010017; Sarkar S, 2013, BIOCHEM SOC T, V41, P1103, DOI 10.1042/BST20130134; Shan K, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.145; Shan YJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0759-7; Shen D, 2015, ONCOL REP, V34, P2715, DOI 10.3892/or.2015.4232; Sizoo EM, 2010, NEURO-ONCOLOGY, V12, P1162, DOI 10.1093/neuonc/nop045; Wang F, 2018, ORL J OTO-RHINO-LARY, V80, P227, DOI 10.1159/000489461; Wang L, 2013, CARCINOGENESIS, V34, P1773, DOI 10.1093/carcin/bgt139; Werner C, 2008, J AM COLL CARDIOL, V52, P470, DOI 10.1016/j.jacc.2008.04.034; Xing WL, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705339; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Xu WL, 2017, ONCOTARGET, V8, P51758, DOI 10.18632/oncotarget.17401; Yang N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.358; Zhang YQ, 2018, MOL MED REP, V18, P4239, DOI 10.3892/mmr.2018.9491	43	7	7	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4453	4467		10.1038/s41388-021-01854-x	http://dx.doi.org/10.1038/s41388-021-01854-x		JUN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34108621	hybrid, Green Published			2022-12-28	WOS:000659470200005
J	Sherman, J; Verstandig, G; Rowe, JW; Brumer, Y				Sherman, Jeff; Verstandig, Grant; Rowe, John W.; Brumer, Yisroel			Application of machine learning to large in vitro databases to identify drug-cancer cell interactions: azithromycin and KLK6 mutation status	ONCOGENE			English	Article							STEM-CELLS; MITOCHONDRIA	Recent advances in machine learning promise to yield novel insights by interrogation of large datasets ranging from gene expression and mutation data to CRISPR knockouts and drug screens. We combined existing and new algorithms with available experimental data to identify potentially clinically relevant relationships to provide a proof of principle for the promise of machine learning in oncological drug discovery. Specifically, we screened cell line data from the Cancer Dependency Map for the effects of azithromycin, which has been shown to kill cancer cells in vitro. Our findings demonstrate a strong relationship between Kallikrein Related Peptidase 6 (KLK6) mutation status and the ability of azithromycin to kill cancer cells in vitro. While the application of azithromycin showed no meaningful average effect in KLK6 wild-type cell lines, statistically significant enhancements of cell death are seen in multiple independent KLK6-mutated cancer cell lines. These findings suggest a potentially valuable clinical strategy in patients with KLK6-mutated malignancies.	[Sherman, Jeff; Verstandig, Grant; Brumer, Yisroel] Zephyr AI, Washington, DC 20010 USA; [Sherman, Jeff; Verstandig, Grant; Brumer, Yisroel] Red Cell Partners, Washington, DC 20549 USA; [Rowe, John W.] Columbia Univ, New York, NY USA	Columbia University	Sherman, J (corresponding author), Zephyr AI, Washington, DC 20010 USA.; Sherman, J (corresponding author), Red Cell Partners, Washington, DC 20549 USA.	sherman@redcellpartners.com		Rowe, John/0000-0002-3620-6612; Brumer, Yisroel/0000-0002-7046-0198; Sherman, Jeff/0000-0003-1377-0357				Ahmed N, 2016, BIOL CHEM, V397, P1265, DOI 10.1515/hsz-2016-0177; Bazaga A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67846-1; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Corsello SM, 2020, NAT CANCER, V1, P235, DOI 10.1038/s43018-019-0018-6; DepMap, 2020, BROAD DEPMAP 21Q1 PU, DOI 10.6084/m9.figshare.13681534.v1; Dezso Z, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-020-3442-9; Fiorillo M, 2019, AGING-US, V11, P2202, DOI 10.18632/aging.101905; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Haritos C, 2018, CLIN EXP MED, V18, P203, DOI 10.1007/s10238-018-0487-4; Jiang XP, 2019, ANTIBIOTICS-BASEL, V8, DOI 10.3390/antibiotics8030110; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Lamb R, 2015, ONCOTARGET, V6, P4569, DOI 10.18632/oncotarget.3174; Li FJ, 2017, ONCOL LETT, V14, P89, DOI 10.3892/ol.2017.6103; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Lundberg SM, 2017, ADV NEUR IN, V30; Lundberg SM, 2020, NAT MACH INTELL, V2, P56, DOI 10.1038/s42256-019-0138-9; Madhukar NS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12928-6; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Qiao XR, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0309-9; Raileanu LE, 2004, ANN MATH ARTIF INTEL, V41, P77, DOI 10.1023/B:AMAI.0000018580.96245.c6; Schrader CH, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0381-6; Shimada K, 2019, TOOL BROWSING CANC D, DOI 10.1101/2019.12.13.874776v1; Tamir A, 2014, J OVARIAN RES, V7, DOI 10.1186/s13048-014-0109-z; Travis J, 2015, SCIENCE, V350, P1456, DOI 10.1126/science.350.6267.1456; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Wang HM, 2019, DEV DYNAM, V248, P10, DOI 10.1002/dvdy.24678; Wang Shou-man, 2008, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V24, P1087	28	4	4	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3766	3770		10.1038/s41388-021-01807-4	http://dx.doi.org/10.1038/s41388-021-01807-4		MAY 2021	5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33953352				2022-12-28	WOS:000647503300001
J	Turgu, B; Zhang, F; El-Naggar, A; Negri, GL; Kogler, M; Tortola, L; Johnson, F; Ng, T; Li, A; Yapp, D; Lockwood, W; Martinez, D; Maris, JM; Daugaard, M; Penninger, JM; Hughes, CS; Sorensen, PH				Turgu, Busra; Zhang, Fan; El-Naggar, Amal; Negri, Gian Luca; Kogler, Melanie; Tortola, Luigi; Johnson, Fraser; Ng, Tony; Li, Amy; Yapp, Donald; Lockwood, William; Martinez, Daniel; Maris, John M.; Daugaard, Mads; Penninger, Josef M.; Hughes, Christopher S.; Sorensen, Poul H.			HACE1 blocks HIF1 alpha accumulation under hypoxia in a RAC1 dependent manner	ONCOGENE			English	Article								Uncovering the mechanisms that underpin how tumor cells adapt to microenvironmental stress is essential to better understand cancer progression. The HACE1 (HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase) gene is a tumor suppressor that inhibits the growth, invasive capacity, and metastasis of cancer cells. However, the direct regulatory pathways whereby HACE1 confers this tumor-suppressive effect remain to be fully elucidated. In this report, we establish a link between HACE1 and the major stress factor, hypoxia-inducible factor 1 alpha (HIF1 alpha). We find that HACE1 blocks the accumulation of HIF1 alpha during cellular hypoxia through decreased protein stability. This property is dependent on HACE1 E3 ligase activity and loss of Ras-related C3 botulinum toxin substrate 1 (RAC1), an established target of HACE1 mediated ubiquitinylation and degradation. In vivo, genetic deletion of Rac1 reversed the increased HIF1 alpha expression observed in Hace1(-/-) mice in murine KRas(G12D)-driven lung tumors. An inverse relationship was observed between HACE1 and HIF1 alpha levels in tumors compared to patient-matched normal kidney tissues, highlighting the potential pathophysiological significance of our findings. Together, our data uncover a previously unrecognized function for the HACE1 tumor suppressor in blocking HIF1 alpha accumulation under hypoxia in a RAC1-dependent manner.	[Turgu, Busra; El-Naggar, Amal; Johnson, Fraser; Li, Amy; Hughes, Christopher S.; Sorensen, Poul H.] British Columbia Canc Res Ctr, Dept Mol Oncol, Vancouver, BC, Canada; [Turgu, Busra] Univ British Columbia, Interdisciplinary Oncol Grad Program, Fac Med, Vancouver, BC, Canada; [Zhang, Fan; Daugaard, Mads] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada; [El-Naggar, Amal; Ng, Tony; Lockwood, William; Sorensen, Poul H.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [El-Naggar, Amal] Menoufia Univ, Dept Pathol, Fac Med, Shibin Al Kawm, Egypt; [Negri, Gian Luca] Canadas Michael Smith Genome Sci Ctr, BC Canc, Vancouver, BC, Canada; [Kogler, Melanie; Tortola, Luigi; Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, Vienna, Austria; [Tortola, Luigi] Swiss Fed Inst Technol, Inst Mol Hlth Sci, Dept Biol, Zurich, Switzerland; [Yapp, Donald] British Columbia Canc Res Ctr, Dept Expt Therapeut, Vancouver, BC, Canada; [Lockwood, William] British Columbia Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC, Canada; [Martinez, Daniel] Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA; [Maris, John M.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Maris, John M.] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA; [Penninger, Josef M.] Univ British Columbia, Life Sci Inst, Dept Med Genet, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia; Egyptian Knowledge Bank (EKB); Menofia University; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Swiss Federal Institutes of Technology Domain; ETH Zurich; British Columbia Cancer Agency; British Columbia Cancer Agency; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of British Columbia	Sorensen, PH (corresponding author), British Columbia Canc Res Ctr, Dept Mol Oncol, Vancouver, BC, Canada.; Sorensen, PH (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada.	psor@mail.ubc.ca	Penninger, Josef M/I-6860-2013; EL-Naggar, Amal/AAE-5565-2022; Daugaard, Mads/Y-6483-2018	Penninger, Josef M/0000-0002-8194-3777; EL-Naggar, Amal/0000-0002-3202-6171; Daugaard, Mads/0000-0001-8383-055X; Negri, Gian Luca/0000-0001-7722-8888; Tortola, Luigi/0000-0002-8480-2080; Turgu, Busra/0000-0002-0207-1115	Canada Institutes of Health Research (CIHR); Michael Smith Foundation for Health Research; CIHR Foundation [FDN-143280]; British Columbia Cancer Foundation; IMBA; Austrian Ministry of Sciences; Austrian Academy of Sciences; European Research Council (ERC) Advanced Grant; Era of Hope Innovator award; Canada 150 Grant; Swiss National Science Foundation [PBEZP3_145993]; Canadian Institutes of Health Research (CIHR) [377771]	Canada Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); CIHR Foundation(Canadian Institutes of Health Research (CIHR)); British Columbia Cancer Foundation; IMBA; Austrian Ministry of Sciences; Austrian Academy of Sciences; European Research Council (ERC) Advanced Grant(European Research Council (ERC)); Era of Hope Innovator award; Canada 150 Grant; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	The authors thank Joan Mathers, Michelle Pollard and Dr Karl Mechtler for helpful discussions; Dr Michael Ohh (University of Toronto) for providing the VHL-null RCC4 cell line; Dr. Thilo Hagen (National University of Singapore) for mutant HIF1 alpha plasmids; and Dr. Peggy Olive (British Columbia Cancer Research Center) for HRE-GFP plasmids. FZ was supported by fellowships from the Canada Institutes of Health Research (CIHR) and the Michael Smith Foundation for Health Research. This work is supported in part by a grant to PHS from CIHR Foundation [Grant#: FDN-143280], and by the British Columbia Cancer Foundation through generous donations from Team Finn and other riders in the Ride to Conquer Cancer. JMP is supported by grants from IMBA, the Austrian Ministry of Sciences, the Austrian Academy of Sciences, a European Research Council (ERC) Advanced Grant, an Era of Hope Innovator award, and a Canada 150 Grant. LT is supported by the Swiss National Science Foundation [Grant#: PBEZP3_145993]. MD is supported by the Canadian Institutes of Health Research (CIHR) [Grant#: 377771].	Acosta MI, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19471-2; Anglesio MS, 2004, HUM MOL GENET, V13, P2061, DOI 10.1093/hmg/ddh215; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Berra E, 2001, EMBO REP, V2, P615, DOI 10.1093/embo-reports/kve130; Bouzelfen A, 2017, LEUKEMIA RES, V60, P53, DOI 10.1016/j.leukres.2017.06.006; Cardama GA, 2017, INT J ONCOL, V51, P1025, DOI 10.3892/ijo.2017.4093; Castillo-Lluva S, 2013, ONCOGENE, V32, P1735, DOI 10.1038/onc.2012.189; Chen HY, 2013, EMBO MOL MED, V5, P723, DOI 10.1002/emmm.201202140; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; Daugaard M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3180; Day GJ, 1998, MOL CELL BIOL, V18, P7444, DOI 10.1128/MCB.18.12.7444; Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205; Diebold I, 2010, ANTIOXID REDOX SIGN, V13, P399, DOI 10.1089/ars.2009.3013; Du J, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0025213, 10.1371/journal.pone.0026204]; Duran RV, 2012, EMBO REP, V13, P121, DOI 10.1038/embor.2011.257; El-Naggar AM, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1276-4; El-Naggar AM, 2015, CANCER CELL, V27, P682, DOI 10.1016/j.ccell.2015.04.003; Fernandez CV, 2001, CANCER GENET CYTOGEN, V129, P165, DOI 10.1016/S0165-4608(01)00445-9; Goka ET, 2015, ONCOGENE, V34, P5395, DOI 10.1038/onc.2014.468; Gonzalez N, 2017, CELL SIGNAL, V30, P154, DOI 10.1016/j.cellsig.2016.12.002; Hibi K, 2008, ANTICANCER RES, V28, P1581; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; Huang YL, 2010, BLOOD, V115, P1226, DOI 10.1182/blood-2009-05-221275; Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032; Kaluz S, 2008, J CELL BIOCHEM, V104, P536, DOI 10.1002/jcb.21644; Karakashev SV, 2015, CANCER MANAG RES, V7, P253, DOI 10.2147/CMAR.S58285; Katoh H, 2006, J CELL SCI, V119, P56, DOI 10.1242/jcs.02720; Kenneth NS, 2008, BIOCHEM J, V414, P19, DOI 10.1042/BJ20081055; Kim I, 2019, ONCOGENE, V38, P3651, DOI 10.1038/s41388-019-0676-y; Kimbro KS, 2006, ENDOCR-RELAT CANCER, V13, P739, DOI 10.1677/erc.1.00728; Kogler M, 2020, CANCER RES, V80, P3009, DOI 10.1158/0008-5472.CAN-19-2270; Kohn KW, 2004, MOL BIOL CELL, V15, P3042, DOI 10.1091/mbc.e03-12-0897; Lawson CD, 2018, J CELL BIOL, V217, P447, DOI 10.1083/jcb.201612069; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Maldonado MD, 2018, CANCER RES, V78, P3101, DOI 10.1158/0008-5472.CAN-18-0619; Masson N, 2003, J CELL SCI, V116, P3041, DOI 10.1242/jcs.00655; Mettouchi Amel, 2012, Small GTPases, V3, P102, DOI 10.4161/sgtp.19221; Moroz E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005077; Ohh M, 2006, NEOPLASIA, V8, P623, DOI 10.1593/neo.06442; Onesto C, 2008, METHOD ENZYMOL, V439, P111, DOI 10.1016/S0076-6879(07)00409-0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Qutub AA, 2006, J CELL SCI, V119, P3467, DOI 10.1242/jcs.03087; Rohwer N, 2009, BRIT J CANCER, V100, P772, DOI 10.1038/sj.bjc.6604919; Rosenblatt AE, 2011, ENDOCR-RELAT CANCER, V18, P207, DOI 10.1677/ERC-10-0049; Rundqvist H, 2010, CURR TOP MICROBIOL, V345, P121, DOI 10.1007/82_2010_77; Sakata M, 2009, ANTICANCER RES, V29, P2231; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shuin T, 2006, JPN J CLIN ONCOL, V36, P337, DOI 10.1093/jjco/hyl052; Shutes A, 2007, J BIOL CHEM, V282, P35666, DOI 10.1074/jbc.M703571200; Slade I, 2010, J MED GENET, V47, P342, DOI 10.1136/jmg.2009.072983; Stewenius Y, 2008, GENE CHROMOSOME CANC, V47, P845, DOI 10.1002/gcc.20587; Sufan RI, 2006, NEOPLASIA, V8, P956, DOI 10.1593/neo.06520; Thelander EF, 2008, LEUKEMIA LYMPHOMA, V49, P477, DOI 10.1080/10428190701817282; Torrino S, 2011, DEV CELL, V21, P959, DOI 10.1016/j.devcel.2011.08.015; Turcotte S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427; Van Welden S, 2017, NAT REV GASTRO HEPAT, V14, P596, DOI 10.1038/nrgastro.2017.101; Wang YY, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0180-y; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009; Yu ZJ, 2019, ONCOL LETT, V17, P4361, DOI 10.3892/ol.2019.10139; Zhang L, 2007, NAT MED, V13, P1060, DOI 10.1038/nm1621; Zhong H, 2004, CANCER DETECT PREV, V28, P88, DOI 10.1016/j.cdp.2003.12.009	63	1	1	4	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					1988	2001		10.1038/s41388-021-01680-1	http://dx.doi.org/10.1038/s41388-021-01680-1		FEB 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33603169	hybrid, Green Published			2022-12-28	WOS:000619433100001
J	Netanely, D; Leibou, S; Parikh, R; Stern, N; Vaknine, H; Brenner, R; Amar, S; Factor, RH; Perluk, T; Frand, J; Nizri, E; Hershkovitz, D; Zemser-Werner, V; Levy, C; Shamir, R				Netanely, Dvir; Leibou, Stav; Parikh, Roma; Stern, Neta; Vaknine, Hananya; Brenner, Ronen; Amar, Sarah; Factor, Rivi Haiat; Perluk, Tomer; Frand, Jacob; Nizri, Eran; Hershkovitz, Dov; Zemser-Werner, Valentina; Levy, Carmit; Shamir, Ron			Classification of node-positive melanomas into prognostic subgroups using keratin, immune, and melanogenesis expression patterns	ONCOGENE			English	Article							GENE; CANCER; TOOL; CONTRIBUTES; DISCOVERY; DYNAMICS; EXPANDER; SUBTYPES; BIOLOGY	Cutaneous melanoma tumors are heterogeneous and show diverse responses to treatment. Identification of robust molecular biomarkers for classifying melanoma tumors into clinically distinct and homogenous subtypes is crucial for improving the diagnosis and treatment of the disease. In this study, we present a classification of melanoma tumors into four subtypes with different survival profiles based on three distinct gene expression signatures: keratin, immune, and melanogenesis. The melanogenesis expression pattern includes several genes that are characteristic of the melanosome organelle and correlates with worse survival, suggesting the involvement of melanosomes in melanoma aggression. We experimentally validated the secretion of melanosomes into surrounding tissues by melanoma tumors, which potentially affects the lethality of metastasis. We propose a simple molecular decision tree classifier for predicting a tumor's subtype based on representative genes from the three identified signatures. Key predictor genes were experimentally validated on melanoma samples taken from patients with varying survival outcomes. Our three-pattern approach for classifying melanoma tumors can contribute to advancing the understanding of melanoma variability and promote accurate diagnosis, prognostication, and treatment.	[Netanely, Dvir; Stern, Neta; Shamir, Ron] Tel Aviv Univ, Blavatnik Sch Comp Sci, Tel Aviv, Israel; [Leibou, Stav; Parikh, Roma; Nizri, Eran; Hershkovitz, Dov; Levy, Carmit] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Vaknine, Hananya; Brenner, Ronen; Amar, Sarah] Edith Wolfson Med Ctr, Dept Oncol, Holon, Israel; [Factor, Rivi Haiat; Perluk, Tomer; Frand, Jacob] Edith Wolfson Med Ctr, Dept Plast & Reconstruct Surg, Holon, Israel; [Nizri, Eran] Tel Aviv Sourasky Med Ctr, Dept Surg A, Tel Aviv, Israel; [Hershkovitz, Dov; Zemser-Werner, Valentina] Tel Aviv Sourasky Med Ctr, Inst Pathol, Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Shamir, R (corresponding author), Tel Aviv Univ, Blavatnik Sch Comp Sci, Tel Aviv, Israel.	rshamir@tau.ac.il	Shamir, Ron/E-6514-2011	Shamir, Ron/0000-0003-1889-9870; Netanely, Dvir/0000-0002-6861-2332	Israeli Science Foundation [1339/18]; GermanIsraeli Project DFG [RE 4193/1-1]; United States-Israel Binational Science Foundation, Jerusal em, Israel [2016694]; United States National Science Foundation; European Research Council under the European Union [726225]; Melanoma Research Alliance [402792]; Edmond J. Safra Center for Bioinformatics, Tel Aviv University	Israeli Science Foundation(Israel Science Foundation); GermanIsraeli Project DFG(German Research Foundation (DFG)); United States-Israel Binational Science Foundation, Jerusal em, Israel(US-Israel Binational Science Foundation); United States National Science Foundation(National Science Foundation (NSF)); European Research Council under the European Union(European Research Council (ERC)); Melanoma Research Alliance; Edmond J. Safra Center for Bioinformatics, Tel Aviv University	The results published here are based upon data generated by The Cancer Genome Atlas managed by the NCI and NHGRI. Information about TCGA can be found at http://ca ncergenome.nih.gov. The authors would like to thank Dr. Martin Lauss from Lund University for providing them with the assignment of TCGA melanoma samples to Lund subtypes. RS acknowledges the support of the Israeli Science Foundation (grant 1339/18), GermanIsraeli Project DFG RE 4193/1-1, and grant 2016694 from the United States-Israel Binational Science Foundation, Jerusal em, Israel, and the United States National Science Foundation. CL acknowledges grant support from the European Research Council under the European Union's Horizon 2020 research and innovation programme (grant agreement no. 726225) and Melanoma Research Alliance (402792). DN was supported in part by a fellowship from the Edmond J. Safra Center for Bioinformatics, Tel Aviv University.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Apalla Z., 2017, DERMATOL PRACT CONCE, V7, DOI [10.5826/dpc.0702a01, DOI 10.5826/DPC.0702A01]; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bell RE, 2016, GENOME RES, V26, P601, DOI 10.1101/gr.197194.115; Bellono NW, 2014, ELIFE, V3, DOI 10.7554/eLife.04543; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; Bland JM, 2004, BRIT MED J, V328, P1073, DOI 10.1136/bmj.328.7447.1073; Borgono CA, 2006, CLIN CANCER RES, V12, P1487, DOI 10.1158/1078-0432.CCR-05-2106; Chauvin JM, 2015, J CLIN INVEST, V125, P2046, DOI 10.1172/JCI80445; Chen KG, 2006, P NATL ACAD SCI USA, V103, P9903, DOI 10.1073/pnas.0600213103; Chen KG, 2009, PIGM CELL MELANOMA R, V22, P740, DOI 10.1111/j.1755-148X.2009.00630.x; Chen KG, 2009, JNCI-J NATL CANCER I, V101, P1259, DOI 10.1093/jnci/djp259; Chen KG, 2006, FROM MELANOCYTES TO MELANOMA: THE PROGRESSION TO MALIGNANCY, P591, DOI 10.1007/978-1-59259-994-3_33; Cirenajwis H, 2015, ONCOTARGET, V6, P12297, DOI 10.18632/oncotarget.3655; D'Mello SAN, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071144; Dror S, 2016, NAT CELL BIOL, V18, P1006, DOI 10.1038/ncb3399; Eckhart L, 2013, BBA-MOL CELL RES, V1833, P3471, DOI 10.1016/j.bbamcr.2013.06.010; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Horwitz RI, 1979, J CHRON DIS, V32, pII; Houghton AN, 2002, CANCER CELL, V2, P275, DOI 10.1016/S1535-6108(02)00161-7; Jonsson G, 2010, CLIN CANCER RES, V16, P3356, DOI 10.1158/1078-0432.CCR-09-2509; Kabbarah O, 2005, CANCER CELL, V8, P439, DOI 10.1016/j.ccr.2005.11.008; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lauss M, 2016, J INVEST DERMATOL, V136, P2502, DOI 10.1016/j.jid.2016.05.119; Lazova R, 2009, EXP DERMATOL, V18, P934, DOI 10.1111/j.1600-0625.2009.00933.x; Leonardi GC, 2018, INT J ONCOL, V52, P1071, DOI 10.3892/ijo.2018.4287; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Lin JY, 2007, NATURE, V445, P843, DOI 10.1038/nature05660; Liu XW, 2017, BIOMED PHARMACOTHER, V88, P595, DOI 10.1016/j.biopha.2017.01.112; Loh WY, 1997, STAT SINICA, V7, P815; Manieri NA, 2017, TRENDS IMMUNOL, V38, P20, DOI 10.1016/j.it.2016.10.002; Martins WK, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-76; MATTHEWS NH, 2017, EPIDEMIOLOGY MELANOM, P3; Netanely D, 2019, PROMO INTERACTIVE TO, DOI 10.1101/629584; Netanely D, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3142-5; Netanely D, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0724-2; Nsengimana J, 2015, ONCOTARGET, V6, P11683, DOI 10.18632/oncotarget.3549; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Ossio R, 2017, NAT REV CANCER, V17, P393, DOI 10.1038/nrc.2017.43; Podgorelec Vili, 2002, J Med Syst, V26, P445, DOI 10.1023/A:1016409317640; PRAAGMAN J, 1985, EUR J OPER RES, V19, P144, DOI 10.1016/0377-2217(85)90321-2; Rajkumar S, 2016, BRIT J CANCER, V115, P145, DOI 10.1038/bjc.2016.195; Rambow F, 2015, CELL REP, V13, P840, DOI 10.1016/j.celrep.2015.09.037; Raposo G, 2007, NAT REV MOL CELL BIO, V8, P786, DOI 10.1038/nrm2258; Scolyer RA, 2011, MOL ONCOL, V5, P124, DOI 10.1016/j.molonc.2011.03.002; Shain AH, 2016, NAT REV CANCER, V16, P345, DOI 10.1038/nrc.2016.37; Shamir, PROMO PROFILER MULTI; Shamir R, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-232; Sher YP, 2006, CANCER RES, V66, P11763, DOI 10.1158/0008-5472.CAN-06-3165; Swetter SM, 2019, J AM ACAD DERMATOL, V80, P208, DOI 10.1016/j.jaad.2018.08.055; Tomihari M, 2009, EXP DERMATOL, V18, P586, DOI 10.1111/j.1600-0625.2008.00830.x; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Ulitsky I, 2010, NAT PROTOC, V5, P303, DOI 10.1038/nprot.2009.230; Ward WH, 2017, CUTANEOUS MELANOMA: ETIOLOGY AND THERAPY, P79, DOI 10.15586/codon.cutaneousmelanoma.2017.ch6	55	4	4	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1792	1805		10.1038/s41388-021-01665-0	http://dx.doi.org/10.1038/s41388-021-01665-0		FEB 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564068	Green Published, hybrid			2022-12-28	WOS:000616489100010
J	Ye, ZD; Wang, DW; Lu, YY; He, YJ; Yu, JT; Wei, WJ; Chen, C; Wang, R; Zhang, L; Zhang, LR; Le, MTN; Cho, WC; Yang, MS; Zhang, HM; Yue, JB				Ye, Zuodong; Wang, Dawei; Lu, Yingying; He, Yunjiao; Yu, Jingting; Wei, Wenjie; Chen, Chang; Wang, Rui; Zhang, Liang; Zhang, Liangren; Le, Minh T. N.; Cho, William C.; Yang, Mengsu; Zhang, Hongmin; Yue, Jianbo			Vacuolin-1 inhibits endosomal trafficking and metastasis via CapZ beta	ONCOGENE			English	Article							ENDOCYTIC TRAFFICKING; VESICLE TRAFFICKING; CELL; INTEGRIN; GEFS; EXOCYTOSIS; EXPRESSION; REGULATORS; MORPHOLOGY; MIGRATION	Metastasis is the fundamental cause of cancer mortality, but there are still very few anti-metastatic drugs available. Endosomal trafficking has been implicated in tumor metastasis, and we have previously found that small chemical vacuolin-1 (V1) potently inhibits autophagosome-lysosome fusion and general endosomal-lysosomal degradation. Here, we assessed the anti-metastatic activity of V1 both in vitro and in vivo. V1 significantly inhibits colony formation, migration, and invasion of various cancer cells in vitro. It also compromises the assembly-disassembly dynamics of focal adhesions (FAs) by inhibiting the recycling and degradation of integrins. In various experimental or transgenic mouse models, V1 significantly suppresses the metastasis and/or tumor growth of breast cancer or melanoma. We further identified capping protein Z beta (CapZ beta) as a V1 binding protein and showed that it is required for the V1-mediated inhibition of migration and metastasis of cancer cells. Collectively, our results indicate that V1 targets CapZ beta to inhibit endosomal trafficking and metastasis.	[Ye, Zuodong; Wang, Dawei; Lu, Yingying; Yu, Jingting; Wang, Rui; Zhang, Liang; Yang, Mengsu; Yue, Jianbo] City Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China; [Ye, Zuodong; Wang, Dawei; Lu, Yingying; Wang, Rui; Zhang, Liang; Yang, Mengsu; Yue, Jianbo] City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China; [He, Yunjiao; Zhang, Hongmin] Southern Univ Sci & Technol, Dept Biol, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Shenzhen 518055, Peoples R China; [He, Yunjiao; Zhang, Hongmin] Southern Univ Sci & Technol, Shenzhen Key Lab Cell Microenvironm, Shenzhen 518055, Peoples R China; [Wei, Wenjie] South Univ Sci & Technol China, Res Core Facil, Shenzhen 518052, Peoples R China; [Chen, Chang; Zhang, Liangren] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China; [Le, Minh T. N.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore; [Cho, William C.] Queen Elizabeth Hosp, Dept Clin Oncol, 30 Gascoigne Rd, Hong Kong, Peoples R China; [Yue, Jianbo] City Univ Hong Kong, Chengdu Res Inst, Chengdu, Peoples R China	City University of Hong Kong; City University of Hong Kong; Southern University of Science & Technology; Southern University of Science & Technology; Southern University of Science & Technology; Peking University; National University of Singapore; City University of Hong Kong	Yue, JB (corresponding author), City Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China.; Yue, JB (corresponding author), City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China.; Yue, JB (corresponding author), City Univ Hong Kong, Chengdu Res Inst, Chengdu, Peoples R China.	jianbyue@cityu.edu.hk	Zhang, Liang/GWM-6088-2022; Zhang, Hongmin/S-9953-2017; Yue, Jianbo/K-8002-2015	Zhang, Hongmin/0000-0003-4356-3615; Yue, Jianbo/0000-0001-6384-5447; WANG, Rui/0000-0003-3830-4133; Lu, Yingying/0000-0002-5423-9522; Ye, zuodong/0000-0002-9575-6198; ZHANG, Liang/0000-0003-3100-8593	Hong Kong Research Grant Council (RGC) [11101717, 11103620]; NSFC [21778045, 32070702, 31670753, 31501116]; Guangdong Science and Technology Program [2017B030301018]; Shenzhen Science and Technology Innovation Committee [JCYJ201602291652 35739, JCYJ20170413141331470, JCYJ20160608140912962, SYS20140509142721429]; Sichuan Provincial Science and Technology Research Grant [2019YJ0633]; CASCroucher Funding Scheme	Hong Kong Research Grant Council (RGC)(Hong Kong Research Grants Council); NSFC(National Natural Science Foundation of China (NSFC)); Guangdong Science and Technology Program; Shenzhen Science and Technology Innovation Committee; Sichuan Provincial Science and Technology Research Grant; CASCroucher Funding Scheme	This work was supported by Hong Kong Research Grant Council (RGC) grants (11101717 and 11103620), NSFC (21778045, 32070702, 31670753, 31501116), CASCroucher Funding Scheme, Guangdong Science and Technology Program (2017B030301018), research grants from Shenzhen Science and Technology Innovation Committee (JCYJ201602291652 35739, JCYJ20170413141331470, JCYJ20160608140912962, ZD SYS20140509142721429), Sichuan Provincial Science and Technology Research Grant (2019YJ0633).	Alanko J, 2016, TRENDS CELL BIOL, V26, P391, DOI 10.1016/j.tcb.2016.02.001; Alday-Parejo B, 2019, CANCERS, V11, DOI 10.3390/cancers11070978; Alizadeh AM, 2014, TUMOR BIOL, V35, P8483, DOI 10.1007/s13277-014-2421-z; Anderson RL, 2019, NAT REV CLIN ONCOL, V16, P185, DOI 10.1038/s41571-018-0134-8; Barr F, 2010, CURR OPIN CELL BIOL, V22, P461, DOI 10.1016/j.ceb.2010.04.007; Bhuin T, 2014, EXP CELL RES, V328, P1, DOI 10.1016/j.yexcr.2014.07.027; Burridge K, 2017, FEBS J, V284, P3355, DOI 10.1111/febs.14195; Cerny J, 2004, EMBO REP, V5, P883, DOI 10.1038/sj.embor.7400243; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen C, 2017, MOLECULES, V22, DOI 10.3390/molecules22060891; Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279; Derivery E, 2009, DEV CELL, V17, P712, DOI 10.1016/j.devcel.2009.09.010; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; di Pietro F, 2017, CURR BIOL, V27, P2452, DOI 10.1016/j.cub.2017.06.055; Dubey, STATPEARLS, P2020; Edwards M, 2014, NAT REV MOL CELL BIO, V15, P677, DOI 10.1038/nrm3869; Elkin M, 2001, CURR PROTOC CELL BIO, V12; Fletcher SJ, 2010, TRENDS CELL BIOL, V20, P71, DOI 10.1016/j.tcb.2009.11.006; Fontebasso Yari, 2015, Critical Reviews in Oncogenesis, V20, P449, DOI 10.1615/CritRevOncog.v20.i5-6.150; Gandalovicova A, 2017, TRENDS CANCER, V3, P391, DOI 10.1016/j.trecan.2017.04.008; Goldenring JR, 2013, NAT REV CANCER, V13, P813, DOI 10.1038/nrc3601; Gomez-Cuadrado L, 2017, DIS MODEL MECH, V10, P1061, DOI 10.1242/dmm.030403; Guerra F, 2019, CANCERS, V11, DOI 10.3390/cancers11081096; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hamidi Hellyeh, 2018, Nat Rev Cancer, V18, P533, DOI 10.1038/s41568-018-0038-z; Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286; Huynh C, 2005, EMBO REP, V6, P843, DOI 10.1038/sj.embor.7400495; Ishida M, 2016, CELL STRUCT FUNCT, V41, P61, DOI 10.1247/csf.16008; Johannes L, 2020, CANCER METAST REV, V39, P375, DOI 10.1007/s10555-020-09880-z; Kinch LN, 2006, PROTEIN SCI, V15, P2669, DOI 10.1110/ps.062419006; Lamber EP, 2019, CURR OPIN CELL BIOL, V59, P34, DOI 10.1016/j.ceb.2019.03.004; Langemeyer L, 2018, TRENDS CELL BIOL, V28, P957, DOI 10.1016/j.tcb.2018.06.007; Levine Timothy P, 2013, Small GTPases, V4, P62, DOI 10.4161/sgtp.24262; Liu J, 2007, MOL BIOL CELL, V18, P1375, DOI 10.1091/mbc.E06-08-0725; Lu YY, 2014, AUTOPHAGY, V10, P1895, DOI 10.4161/auto.32200; MacDonald E, 2018, J CELL BIOL, V217, P2549, DOI 10.1083/jcb.201710051; Mellman I, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a016949; Mendoza P, 2014, CURR MOL MED, V14, P235, DOI 10.2174/1566524014666140128111347; Mendoza Pablo, 2014, Small GTPases, V5, pe28195, DOI 10.4161/sgtp.28195; Mukherjee K, 2016, HUM MOL GENET, V25, P1255, DOI 10.1093/hmg/ddw006; Muller Matthias P, 2018, Small GTPases, V9, P5, DOI 10.1080/21541248.2016.1276999; Naslavsky N, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216499; Novick Peter, 2016, Small GTPases, V7, P252; Palamidessi A, 2008, CELL, V134, P135, DOI 10.1016/j.cell.2008.05.034; Parachoniak CA, 2012, TRENDS CELL BIOL, V22, P231, DOI 10.1016/j.tcb.2012.02.002; Park, 2019, SEMIN CANCER BIOL; Paul NR, 2015, CURR BIOL, V25, pR1092, DOI 10.1016/j.cub.2015.09.049; Pfeffer SR, 2017, MOL BIOL CELL, V28, P712, DOI 10.1091/mbc.E16-10-0737; Poteryaev D, 2010, CELL, V141, P497, DOI 10.1016/j.cell.2010.03.011; Powelka AM, 2004, TRAFFIC, V5, P20, DOI 10.1111/j.1600-0854.2004.00150.x; Rajendran V, 2018, METHODS MOL BIOL, V1692, P89, DOI 10.1007/978-1-4939-7401-6_8; Rashid OM, 2013, J THORAC DIS, V5, P385, DOI 10.3978/j.issn.2072-1439.2013.06.17; Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Rosel D, 2019, TRENDS CANCER, V5, P755, DOI 10.1016/j.trecan.2019.10.011; Schmid SL, 2017, J CELL BIOL, V216, P2623, DOI 10.1083/jcb.201705017; Scott CC, 2014, SEMIN CELL DEV BIOL, V31, P2, DOI 10.1016/j.semcdb.2014.03.034; Shaik GM, 2009, CELL SIGNAL, V21, P1337, DOI 10.1016/j.cellsig.2009.04.001; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Teckchandani A, 2009, J CELL BIOL, V186, P98, DOI 10.1083/jcb.200812160; Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391; Yao F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138213; Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001	63	8	8	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1775	1791		10.1038/s41388-021-01662-3	http://dx.doi.org/10.1038/s41388-021-01662-3		FEB 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564074	Green Published, hybrid			2022-12-28	WOS:000616489100007
J	Sharma, S; Pei, XH; Xing, F; Wu, SY; Wu, KR; Tyagi, A; Zhao, D; Deshpande, R; Ruiz, MG; Singh, R; Lyu, F; Watabe, K				Sharma, Sambad; Pei, Xinhong; Xing, Fei; Wu, Shih-Ying; Wu, Kerui; Tyagi, Abhishek; Zhao, Dan; Deshpande, Ravindra; Ruiz, Marco Gabriel; Singh, Ravi; Lyu, Feng; Watabe, Kounosuke			Regucalcin promotes dormancy of prostate cancer	ONCOGENE			English	Article							SMOOTH-MUSCLE; RADICAL PROSTATECTOMY; MAMMARY-GLAND; HUMAN BREAST; PROTEIN; CELLS; GENE; EXPRESSION; PROLIFERATION; REVEALS	Prostate cancer is one of the leading causes of mortality in men. The major cause of death in prostate cancer patients can be attributed to metastatic spread of disease or tumor recurrence after initial treatment. Prostate tumors are known to remain undetected or dormant for a long period of time before they progress locoregionally or at distant sites as overt tumors. However, the molecular mechanism of dormancy is yet poorly understood. In this study, we performed a differential gene expression analysis and identified a gene, Regucalcin (RGN), which promotes dormancy of prostate cancer. We found that cancer patients expressing higher level of RGN showed significantly longer recurrence-free and overall- survival. Using a doxycycline-inducible RGN expression system, we showed that ectopic expression of RGN in prostate tumor cells induced dormancy in vivo, while following suppression of RGN triggered recurrence of tumor growth. On the other hand, silencing RGN in LNCap cells promoted its outgrowth in the tibia of mice. Importantly, RGN promoted multiple known hallmarks of tumor dormancy including activation of p38 MAPK, decrease in Erk signaling and inhibition of FOXM1 expression. Furthermore, we found that RGN significantly suppressed angiogenesis by increasing secretory miR-23c level in the exosomes. Intriguingly, FOXM1 was found to negatively regulate miR-23c expression in prostate cancer. In addition, we identified 11 RGN downstream target genes that independently predicted longer recurrence-free survival in patients. We found that expression of these genes was regulated by FOXM1 and/or p38 MAPK. These findings suggest a critical role of RGN in prostate cancer dormancy, and the utility of RGN signaling and exosomal miR-23c as biomarkers for predicting recurrence.	[Sharma, Sambad; Xing, Fei; Wu, Shih-Ying; Wu, Kerui; Tyagi, Abhishek; Zhao, Dan; Deshpande, Ravindra; Ruiz, Marco Gabriel; Lyu, Feng; Watabe, Kounosuke] Wake Forest Baptist Med Ctr, Dept Canc Biol, Winston Salem, NC 27157 USA; [Pei, Xinhong] Zhengzhou Univ, Affiliated Hosp 1, Dept Breast Surg, Zhengzhou 450052, Henan, Peoples R China	Wake Forest University; Wake Forest Baptist Medical Center; Zhengzhou University	Watabe, K (corresponding author), Wake Forest Baptist Med Ctr, Dept Canc Biol, Winston Salem, NC 27157 USA.	kwatabe@wakehealth.edu	Tyagi, Abhishek/AFZ-6213-2022; Tyagi, Abhishek/CAF-1274-2022; Zhao, Dan/Y-8065-2019; Deshpande, Ravindra/AAE-6392-2021; Singh, Ravi N/A-5740-2011	Tyagi, Abhishek/0000-0002-0155-2099; Tyagi, Abhishek/0000-0002-0155-2099; Zhao, Dan/0000-0002-5120-6725; Singh, Ravi N/0000-0003-0750-1804	NIH [RO1CA173499, RO1CA185650, RO1CA205067]; China Scholarship Council [2014084100701, 2018093]; National Institutes of Health [P30CA012197]; comprehensive cancer center of Wake Forest University	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council(China Scholarship Council); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); comprehensive cancer center of Wake Forest University	This work was supported by NIH grant RO1CA173499, RO1CA185650, and RO1CA205067 to KW. XP was supported by State Scholarship fund (2014084100701) by China Scholarship Council. FL was supported by State Scholarship fund 2018093 by China Scholarship Council. The tumor tissue and pathology shared resources, biostatistics/bioinformatics shared resources, flow cytometry, and cell engineering shared resources are supported by comprehensive cancer center of Wake Forest University and, National Institutes of Health Grant (P30CA012197). The funding agency had no role in study design, data collection, data analysis, interpretation, and writing of the report. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Amin KN, 2020, MICROVASC RES, V127, DOI 10.1016/j.mvr.2019.103924; Aslan C, 2019, J CELL PHYSIOL, V234, P16885, DOI 10.1002/jcp.28374; Ayala G, 2003, CLIN CANCER RES, V9, P4792; Aytes A, 2014, CANCER CELL, V25, P638, DOI 10.1016/j.ccr.2014.03.017; Boorjian SA, 2011, EUR UROL, V59, P893, DOI 10.1016/j.eururo.2011.02.026; Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698; Cackowski FC, 2019, PROSTATE, V79, P1715, DOI 10.1002/pros.23896; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chand V, 2019, MOL CANCER RES, V17, P1063, DOI 10.1158/1541-7786.MCR-18-0968; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen MH, 2011, CANCER CELL, V20, P173, DOI 10.1016/j.ccr.2011.07.013; Chery L, 2014, ONCOTARGET, V5, P9939, DOI 10.18632/oncotarget.2480; Corey E, 2002, PROSTATE, V52, P20, DOI 10.1002/pros.10091; Crumbaker M, 2017, CANCERS, V9, DOI 10.3390/cancers9040034; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Eckers JC, 2014, RADIAT RES, V182, P420, DOI 10.1667/RR13726.1; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Henderson JR, 1999, DEV DYNAM, V214, P229, DOI 10.1002/(SICI)1097-0177(199903)214:3<229::AID-AJA6>3.3.CO;2-J; Huang W, 2012, ONCOGENE, V31, P4527, DOI 10.1038/onc.2011.573; Huang YQ, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0820-4; Ishigami A, 2015, GERIATR GERONTOL INT, V15, P804, DOI 10.1111/ggi.12347; Jones CU, 2011, NEW ENGL J MED, V365, P107, DOI 10.1056/NEJMoa1012348; Kalluri R, 2016, J CLIN INVEST, V126, P1208, DOI 10.1172/JCI81135; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840; Kupelian P, 1996, UROLOGY, V48, P249, DOI 10.1016/S0090-4295(96)00167-7; Long X, 2009, J BIOL CHEM, V284, P33671, DOI 10.1074/jbc.M109.050419; Lyu TJ, 2013, EPIGENETICS-US, V8, P1330, DOI 10.4161/epi.26675; Maia C, 2009, J CELL BIOCHEM, V107, P667, DOI 10.1002/jcb.22158; Maia CJB, 2008, MOL CELL BIOCHEM, V311, P81, DOI 10.1007/s11010-007-9697-x; Marques R, 2015, EXP CELL RES, V330, P325, DOI 10.1016/j.yexcr.2014.08.007; Marques R, 2014, CELL MOL LIFE SCI, V71, P93, DOI 10.1007/s00018-013-1323-3; MIWA T, 1991, MOL CELL BIOL, V11, P3296, DOI 10.1128/MCB.11.6.3296; Morgan TM, 2009, CLIN CANCER RES, V15, P677, DOI 10.1158/1078-0432.CCR-08-1754; Nakagawa T, 2008, INT J MOL MED, V21, P605; Paulin D, 2004, EXP CELL RES, V301, P1, DOI 10.1016/j.yexcr.2004.08.004; Petit I, 2007, TRENDS IMMUNOL, V28, P299, DOI 10.1016/j.it.2007.05.007; Ribeiro Mara Fernandes, 2013, Curr Angiogenes, V2, P54; Shaked Y, 2014, CURR PHARM DESIGN, V20, P4920; Sharma S, 2019, EBIOMEDICINE, V44, P194, DOI 10.1016/j.ebiom.2019.05.038; Sharma S, 2016, J BIOL CHEM, V291, P19351, DOI 10.1074/jbc.M116.737379; Sharma S, 2014, FRONT BIOSCI-LANDMRK, V19, P339, DOI 10.2741/4211; Sosa MS, 2011, CLIN CANCER RES, V17, P5850, DOI 10.1158/1078-0432.CCR-10-2574; Tanjore H, 2006, AM J PATHOL, V168, P715, DOI 10.2353/ajpath.2006.051321; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Varisli L, 2013, GENET TEST MOL BIOMA, V17, P562, DOI 10.1089/gtmb.2012.0524; Vaz CV, 2016, CURR MOL MED, V16, P607, DOI 10.2174/156652401666616; Vaz CV, 2015, TRANSL RES, V166, P693, DOI 10.1016/j.trsl.2015.08.009; Vaz CV, 2015, BBA-MOL CELL RES, V1853, P2621, DOI 10.1016/j.bbamcr.2015.07.006; Wang J, 2017, ONCOL LETT, V13, P4979, DOI 10.3892/ol.2017.6050; Wu KR, 2017, BBA-REV CANCER, V1868, P538, DOI 10.1016/j.bbcan.2017.10.001; Xing F, 2018, CANCER RES, V78, P4316, DOI 10.1158/0008-5472.CAN-18-1102; Yamaguchi M, 2005, INT J MOL MED, V15, P371; YAMAGUCHI M, 1990, BIOCHEM MED METAB B, V43, P140, DOI 10.1016/0885-4505(90)90019-W; Yamaguchi M, 2018, INT J ONCOL, V53, P1313, DOI 10.3892/ijo.2018.4458; Yamaguchi M, 2017, MOL CELL BIOCHEM, V430, P37, DOI 10.1007/s11010-017-2952-x; Yamaguchi M, 2016, INT J ONCOL, V49, P812, DOI 10.3892/ijo.2016.3538; Yamaguchi M, 2016, INT J ONCOL, V48, P1955, DOI 10.3892/ijo.2016.3409; Yamaguchi M, 2015, J CANCER RES CLIN, V141, P1333, DOI 10.1007/s00432-014-1831-z; Yamaguchi M, 2013, APOPTOSIS, V18, P1145, DOI 10.1007/s10495-013-0859-x; Yang ZH, 2017, DIS MODEL MECH, V10, P39, DOI 10.1242/dmm.027417	62	3	3	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					1012	1026		10.1038/s41388-020-01565-9	http://dx.doi.org/10.1038/s41388-020-01565-9		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33323968	Green Accepted			2022-12-28	WOS:000599126500010
J	Attalla, S; Taifour, T; Bui, T; Muller, W				Attalla, Sherif; Taifour, Tarek; Bui, Tung; Muller, William			Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo	ONCOGENE			English	Review							EPITHELIAL-SPECIFIC DISRUPTION; MAMMARY-GLAND DEVELOPMENT; ENDOTHELIAL GROWTH-FACTOR; MIDDLE TUMOR-ANTIGEN; T-ANTIGEN; GENE-EXPRESSION; PROMOTES PROGRESSION; TYROSINE KINASE; RECEPTOR GENE; METASTASIS	Breast cancer is associated with the second highest cancer-associated deaths worldwide. Therefore, understanding the key events that determine breast cancer progression, modulation of the tumor-microenvironment and metastasis, which is the main cause of cancer-associated death, are of great importance. The mammary specific polyomavirus middle T antigen overexpression mouse model (MMTV-PyMT), first published in 1992, is the most commonly used genetically engineered mouse model (GEMM) for cancer research. Mammary lesions arising in MMTV-PyMT mice follow similar molecular and histological progression as human breast tumors, making it an invaluable tool for cancer researchers and instrumental in understanding tumor biology. In this review, we will highlight key studies that demonstrate the utility of PyMT derived GEMMs in understanding the molecular basis of breast cancer progression, metastasis and highlight its use as a pre-clinical tool for therapeutic discovery.	[Attalla, Sherif; Muller, William] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada; [Attalla, Sherif; Taifour, Tarek; Bui, Tung; Muller, William] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Taifour, Tarek; Muller, William] McGill Univ, Fac Med, Montreal, PQ H3A 1A3, Canada	McGill University; McGill University; McGill University	Muller, W (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada.; Muller, W (corresponding author), McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.; Muller, W (corresponding author), McGill Univ, Fac Med, Montreal, PQ H3A 1A3, Canada.	william.muller@mcgill.ca		Taifour, Tarek/0000-0002-1390-3597; Attalla, sattalla/0000-0003-4193-6393	McGill faculty of medicine Gosselin Graduate Studentship; McGill faculty of medicine; Canada Research Chair of Molecular Oncology; Terry Fox Research Institute Program Group Grant; National Institute of Health Research; Canadian Institute of Health Research the Canadian Cancer Society Impact Grant; Cancer Research Society	McGill faculty of medicine Gosselin Graduate Studentship; McGill faculty of medicine; Canada Research Chair of Molecular Oncology; Terry Fox Research Institute Program Group Grant; National Institute of Health Research(National Institute for Health Research (NIHR)); Canadian Institute of Health Research the Canadian Cancer Society Impact Grant(Canadian Institutes of Health Research (CIHR)); Cancer Research Society	SA is supported by the McGill faculty of medicine Gosselin Graduate Studentship. TT is supported by the MD/PhD stipend awarded by McGill faculty of medicine. WJM is supported by the Canada Research Chair of Molecular Oncology. This work was also supported by Terry Fox Research Institute Program Group Grant, National Institute of Health Research, Canadian Institute of Health Research the Canadian Cancer Society Impact Grant and Cancer Research Society.	Ahn R, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14638; Allen E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aak9679; Allred DC, 2001, ENDOCR-RELAT CANCER, V8, P47, DOI 10.1677/erc.0.0080047; Arun G, 2016, GENE DEV, V30, P34, DOI 10.1101/gad.270959.115; Asselin-Labat ML, 2011, MOL CELL BIOL, V31, P4609, DOI 10.1128/MCB.05766-11; Ben-David U, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12160; Boyd NF, 1998, CANCER EPIDEM BIOMAR, V7, P1133; Boyle ST, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0394-1; Brenner DR, 2020, CAN MED ASSOC J, V192, pE199, DOI 10.1503/cmaj.191292; Butt SA, 2015, MAGN RESON MED, V73, P51, DOI 10.1002/mrm.25095; Cai Y, 2017, TRANSCRIPTOMIC DYNAM, V18, P1; Cai Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24005-x; Cai Y, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3563-3; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; Cook RS, 2011, CANCER RES, V71, P3941, DOI 10.1158/0008-5472.CAN-10-3775; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dabrosin C, 2003, BREAST CANCER RES TR, V78, P1, DOI 10.1023/A:1022133219353; Dadi S, 2016, CELL, V164, P365, DOI 10.1016/j.cell.2016.01.002; Davie SA, 2007, TRANSGENIC RES, V16, P193, DOI 10.1007/s11248-006-9056-9; Decock J, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0545-8; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; Ekiz HA, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1480286; Esbona K, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0695-3; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Eyob H, 2013, CANCER DISCOV, V3, P751, DOI 10.1158/2159-8290.CD-12-0480; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510; Gill JK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1507; Gronbaek K, 2007, APMIS, V115, P1039, DOI 10.1111/j.1600-0463.2007.apm_636.xml.x; Gross ETE, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1268310; GROSS L, 1953, P SOC EXP BIOL MED, V83, P414; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Halaoui R, 2017, GENE DEV, V31, P1573, DOI 10.1101/gad.300566.117; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Hirukawa A, 2019, CELL REP, V29, P249, DOI 10.1016/j.celrep.2019.08.105; Hirukawa A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04864-8; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hodgson JG, 2005, CANCER RES, V65, P9695, DOI 10.1158/0008-5472.CAN-05-0755; Hunter KW, 2001, CANCER RES, V61, P8866; HUNTER T, 1984, EMBO J, V3, P73, DOI 10.1002/j.1460-2075.1984.tb01763.x; Jang I, 2019, CANCERS, V11, DOI 10.3390/cancers11050721; Jin MS, 2016, VIRCHOWS ARCH, V469, P183, DOI 10.1007/s00428-016-1953-6; Jones LM, 2016, CANCER RES, V76, P1416, DOI 10.1158/0008-5472.CAN-15-2770; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; Kesavan R, 2020, P NATL ACAD SCI USA, V117, P5923, DOI 10.1073/pnas.1921381117; Kim H, 2005, ONCOGENE, V24, P5629, DOI 10.1038/sj.onc.1208718; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; Li JR, 2011, J CLIN INVEST, V121, P4655, DOI 10.1172/JCI46134; Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; Lin EY, 2007, MOL ONCOL, V1, P288, DOI 10.1016/j.molonc.2007.10.003; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Lin YX, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0760-3; Lopez-Tarruella S, 2007, CLIN CANCER RES, V13, P6921, DOI 10.1158/1078-0432.CCR-07-1399; Lukes L, 2009, CANCER RES, V69, P310, DOI 10.1158/0008-5472.CAN-08-3520; Ma J, 2012, TUMOR BIOL, V33, P1983, DOI 10.1007/s13277-012-0458-4; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Maglione JE, 2001, CANCER RES, V61, P8298; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Marcotte R, 2012, P NATL ACAD SCI USA, V109, P2808, DOI 10.1073/pnas.1018861108; Martin LJ, 2010, CANCER EPIDEM BIOMAR, V19, P456, DOI 10.1158/1055-9965.EPI-09-0881; Mazzieri R, 2011, CANCER CELL, V19, P512, DOI 10.1016/j.ccr.2011.02.005; Montagna C, 2003, CANCER RES, V63, P2179; Movahedi K, 2012, CANCER RES, V72, P4165, DOI 10.1158/0008-5472.CAN-11-2994; Nakasone ES, 2012, CANCER CELL, V21, P488, DOI 10.1016/j.ccr.2012.02.017; Ni T, 2016, NAT CELL BIOL, V18, P1221, DOI 10.1038/ncb3425; Ohs I, 2017, CANCER RES, V77, P7059, DOI 10.1158/0008-5472.CAN-17-1032; Ojalvo LS, 2009, AM J PATHOL, V174, P1048, DOI 10.2353/ajpath.2009.080676; Ong SH, 2001, EMBO J, V20, P6327, DOI 10.1093/emboj/20.22.6327; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Ostuni R, 2015, TRENDS IMMUNOL, V36, P229, DOI 10.1016/j.it.2015.02.004; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Park YG, 2005, NAT GENET, V37, P1055, DOI 10.1038/ng1635; Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Putzer BM, 1997, P NATL ACAD SCI USA, V94, P10889, DOI 10.1073/pnas.94.20.10889; Qin JJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1206-z; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; Rao T, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3603; Rennhack J, 2017, J MAMMARY GLAND BIOL, V22, P71, DOI 10.1007/s10911-017-9374-y; Rennhack JP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11236-3; Ross C, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008743; Schwab LP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3087; Shiao SL, 2015, CANCER IMMUNOL RES, V3, P518, DOI 10.1158/2326-6066.CIR-14-0232; Simond AM, 2020, GENE DEV, V34, P1304, DOI 10.1101/gad.339424.120; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; Swiatnicki MR, 2020, J THORAC ONCOL, V15, pS20; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; Wagner KU, 2004, BREAST CANCER RES, V6, P31, DOI 10.1186/bcr723; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Weichand B, 2017, J EXP MED, V214, P2695, DOI 10.1084/jem.20160392; Welford AF, 2011, J CLIN INVEST, V121, P1969, DOI 10.1172/JCI44562; Welm AL, 2007, P NATL ACAD SCI USA, V104, P7570, DOI 10.1073/pnas.0702095104; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Winer A, 2018, MOL CANCER THER, V17, P1147, DOI 10.1158/1535-7163.MCT-17-0646; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Xiao B, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107571	113	28	30	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					475	491		10.1038/s41388-020-01560-0	http://dx.doi.org/10.1038/s41388-020-01560-0		NOV 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33235291	Green Published, hybrid			2022-12-28	WOS:000592588400001
J	Song, YF; Wang, MF; Tong, H; Tan, Y; Hu, X; Wang, K; Wan, XP				Song, Yunfeng; Wang, Mengfei; Tong, Huan; Tan, Yuan; Hu, Xiang; Wang, Kai; Wan, Xiaoping			Plasma exosomes from endometrial cancer patients contain LGALS3BP to promote endometrial cancer progression	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; SIGNALING PATHWAY; BINDING-PROTEIN; TUMOR-GROWTH; EXPRESSION; SUPERFAMILY; BIOMARKER; VESICLES; MEMBER; CELLS	Endometrial cancer (EC) is a common gynaecological cancer worldwide. Exosomes, secreted by living cells and detected in various body fluids, can exchange information between organs and compartments to affect cellular functions, such as proliferation, apoptosis, migration and angiogenesis. We hypothesise that plasma exosomal contents are altered during cancer progression and promote cancer growth and angiogenesis by delivering biomolecules to cancer and vascular endothelial cells. In this study, circulating exosomes derived from EC patients and age-matched healthy people were acquired by commercial kits. Cell counting kit-8, Transwell and Matrigel tube formation assays showed that circulating exosomes from EC patients promote EC cell growth and human umbilical vein endothelial cell (HUVEC) angiogenesis. Next, proteomic analysis and ELISA revealed that plasma exosomal lectin galactoside-binding soluble 3 binding protein (LGALS3BP) increased during EC progression. Moreover, to explore the function of exosomal LGALS3BP, we acquired exosomes containing high levels of LGALS3BP by overexpressing LGALS3BP in human embryonic kidney 293 cells, and we demonstrated that highly contained exosomal LGALS3BP contributed to EC cell proliferation and migration and HUVEC functions via the activation of the PI3K/AKT/VEGFA signalling pathway both in vitro and in vivo. Finally, high LGALS3BP expression was observed in human EC tissue, which indicated a poor prognosis. In addition, immunohistochemical analysis of human EC tissues revealed that LGALS3BP expression was correlated with VEGFA expression and blood vessel density. Hence, we proposed that plasma exosomes containing LGALS3BP contributed to EC growth and angiogenesis during EC progression, which also provided a novel perspective on EC diagnosis and prognosis.	[Song, Yunfeng; Wang, Mengfei; Tong, Huan; Tan, Yuan; Hu, Xiang; Wan, Xiaoping] Tongji Univ, Shanghai Matern & Infant Hosp 1, Dept Gynaecol, Sch Med, Shanghai, Peoples R China; [Wang, Kai] Tongji Univ, Shanghai Matern & Infant Hosp 1, Clin & Translat Res Ctr, Sch Med, Shanghai, Peoples R China	Tongji University; Tongji University	Wan, XP (corresponding author), Tongji Univ, Shanghai Matern & Infant Hosp 1, Dept Gynaecol, Sch Med, Shanghai, Peoples R China.; Wang, K (corresponding author), Tongji Univ, Shanghai Matern & Infant Hosp 1, Clin & Translat Res Ctr, Sch Med, Shanghai, Peoples R China.	kaiwangcn@yahoo.com; wanxiaoping@tongji.edu.cn		wan, xiaoping/0000-0001-6079-631X; wang, kai/0000-0003-2298-4816; Song, yunfeng/0000-0002-7373-3198	Shanghai Science and Technology Commission Innovation Plan [17411951600]; National Natural Science Foundation of China [81672574, 81972438]; Shanghai Key Clinical Specialty Programme [2017ZZ02015]	Shanghai Science and Technology Commission Innovation Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Key Clinical Specialty Programme	This work was supported by Shanghai Science and Technology Commission Innovation Plan (No. 17411951600), the National Natural Science Foundation of China (Nos. 81672574 and 81972438) and Shanghai Key Clinical Specialty Programme (No. 2017ZZ02015).	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Bhagirath D, 2018, CANCER RES, V78, P1833, DOI 10.1158/0008-5472.CAN-17-2069; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chatterjee S, 2013, J CLIN INVEST, V123, P1732, DOI 10.1172/JCI65385; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; IACOBELLI S, 1986, CANCER RES, V46, P3005; Jiang Y, 2019, BRAIN RES, V1722, DOI 10.1016/j.brainres.2019.146331; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; KOTHS K, 1993, J BIOL CHEM, V268, P14245; Ludwig AK, 2012, INT J BIOCHEM CELL B, V44, P11, DOI 10.1016/j.biocel.2011.10.005; Mariscal J, 2019, J PROTEOME RES, V18, P1043, DOI 10.1021/acs.jproteome.8b00750; Matei I, 2017, CELL, V170, P223, DOI 10.1016/j.cell.2017.06.047; Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581; Ozaki Y, 2004, ONCOL REP, V12, P1071; Pan C, 2018, MOL ONCOL, V12, P1935, DOI 10.1002/1878-0261.12371; Peng S, 2014, HEPATOLOGY, V60, P1264, DOI 10.1002/hep.27236; Piccolo E, 2013, J MOL MED, V91, P83, DOI 10.1007/s00109-012-0936-6; Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Pramanik KC, 2013, CARCINOGENESIS, V34, P2061, DOI 10.1093/carcin/bgt154; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Stampolidis P, 2015, ONCOGENE, V34, P39, DOI 10.1038/onc.2013.548; Teng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14448; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Wahlgren J, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks463; Wang JJ, 2018, CANCER BIOMARK, V21, P805, DOI 10.3233/CBM-170738; Wang M, 2018, CLIN TRANSL ONCOL, V20, P906, DOI 10.1007/s12094-017-1805-0; Weiderpass E, 2015, INT J EPIDEMIOL, V44, P3; Wen XL, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0170-6; Zhang XX, 2019, CELL SIGNAL, V63, DOI 10.1016/j.cellsig.2019.109359; Zhong H, 2000, CANCER RES, V60, P1541; Zhou H, 2006, KIDNEY INT, V69, P1471, DOI 10.1038/sj.ki.5000273	35	25	25	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					633	646		10.1038/s41388-020-01555-x	http://dx.doi.org/10.1038/s41388-020-01555-x		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33208911				2022-12-28	WOS:000590925500002
J	von Felden, J; Craig, AJ; Garcia-Lezana, T; Labgaa, I; Haber, PK; D'Avola, D; Asgharpour, A; Dieterich, D; Bonaccorso, A; Torres-Martin, M; Sia, D; Sung, MW; Tabrizian, P; Schwartz, M; Llovet, JM; Villanueva, A				von Felden, Johann; Craig, Amanda J.; Garcia-Lezana, Teresa; Labgaa, Ismail; Haber, Philipp K.; D'Avola, Delia; Asgharpour, Amon; Dieterich, Douglas; Bonaccorso, Antoinette; Torres-Martin, Miguel; Sia, Daniela; Sung, Max W.; Tabrizian, Parissa; Schwartz, Myron; Llovet, Josep M.; Villanueva, Augusto			Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma	ONCOGENE			English	Article							LIQUID BIOPSY; DOUBLE-BLIND; SORAFENIB; IDENTIFICATION; TARGETS	Little is known about the mutational landscape of advanced hepatocellular carcinoma (HCC), and predictive biomarkers of response to systemic therapies are lacking. We aimed to describe the mutational landscape of advanced HCC and to identify predictors of primary resistance to systemic therapies using circulating tumor DNA (ctDNA). We prospectively enrolled 121 patients between October 2015 and January 2019. We performed targeted ultra-deep sequencing of 25 genes and Digital Droplet PCR of TERT promoter, including sequential samples throughout treatment. Primary endpoint was progression-free survival (PFS) stratified by mutation profiles in ctDNA. Secondary endpoints were overall survival and objective response rate. The most frequent mutations in ctDNA of advanced HCC were TERT promoter (51%), TP53 (32%), CTNNB1 (17%), PTEN (8%), AXIN1, ARID2, KMT2D, and TSC2 (each 6%). TP53 and CTNNB1 mutations were mutually exclusive. Patients with mutations in the PI3K/MTOR pathway had significantly shorter PFS than those without these mutations after tyrosine kinase inhibitors (2.1 vs 3.7 months, p < 0.001), but not after immune checkpoint inhibition (CPI). WNT pathway mutations were not associated with PFS, overall survival, or objective response after CPI. Serial profiling of ctDNA in a subset correlated with treatment response. Mutation profiling of ctDNA in advanced HCC shows similar mutation frequencies for known HCC drivers compared to early stages and identifies predictive biomarkers of response to systemic therapies.	[von Felden, Johann] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany; [von Felden, Johann; Craig, Amanda J.; Garcia-Lezana, Teresa; Labgaa, Ismail; Haber, Philipp K.; D'Avola, Delia; Asgharpour, Amon; Dieterich, Douglas; Torres-Martin, Miguel; Sia, Daniela; Llovet, Josep M.; Villanueva, Augusto] Icahn Sch Med Mt Sinai, Liver Canc Program, Div Liver Dis, Tisch Canc Inst,Dept Med, New York, NY 10029 USA; [Labgaa, Ismail] Lausanne Univ Hosp CHUV, Dept Visceral Surg, Lausanne, Switzerland; [D'Avola, Delia] Clin Univ Navarra, Liver Unit, Pamplona, Spain; [D'Avola, Delia] Clin Univ Navarra, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Pamplona, Spain; [Bonaccorso, Antoinette; Tabrizian, Parissa; Schwartz, Myron] Icahn Sch Med Mt Sinai, Dept Surg, New York, NY 10029 USA; [Sung, Max W.; Villanueva, Augusto] Icahn Sch Med Mt Sinai, Dept Med, Div Hematol & Med Oncol, New York, NY 10029 USA; [Llovet, Josep M.] Univ Barcelona, Liver Canc Translat Res Lab, Hosp Clin, IDIBAPS, Catalonia, Spain; [Llovet, Josep M.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Catalonia, Spain	University of Hamburg; University Medical Center Hamburg-Eppendorf; Icahn School of Medicine at Mount Sinai; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Navarra; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; ICREA	Villanueva, A (corresponding author), Icahn Sch Med Mt Sinai, Liver Canc Program, Div Liver Dis, Tisch Canc Inst,Dept Med, New York, NY 10029 USA.; Villanueva, A (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Div Hematol & Med Oncol, New York, NY 10029 USA.	augusto.villanueva@mssm.edu	Llovet, Josep M/D-4340-2014; Llovet, Josep M/ABB-6264-2021	Llovet, Josep M/0000-0003-0547-2667; Llovet, Josep M/0000-0003-0547-2667; Torres Martin, Miguel/0000-0003-1589-8936; Craig, Amanda/0000-0001-8987-019X; Labgaa, Ismail/0000-0003-4286-2170; von Felden, Johann/0000-0003-2839-5174; Sia, Daniela/0000-0002-9000-611X	German Research Foundation [HA8754/1-1, FE1746/1-1]; National Cancer Institute Ruth L. Kirschstein NRSA Institutional Research Training Grant [CA078207]; Swiss National Science Foundation; Foundation Roberto Gianna Gonella; Foundation SICPA; Spanish Association for the Study of the Liver (Asociacion Espanola para el Estudio del Higado, AEEH); Nuovo Soldati Foundation; European Commission (EC)/Horizon 2020 Program (HEPCAR) [667273-2]; U.S. Department of Defense [CA150272P3]; Accelerator Award (CRUCK, AECC, AIRC) [C9380/A26813]; National Cancer Institute, Tisch Cancer Institute [P30-CA196521]; Samuel Waxman Cancer Research Foundation; Spanish National Health Institute [SAF2016-76390]; Generalitat de Catalunya/AGAUR [SGR-1358]	German Research Foundation(German Research Foundation (DFG)); National Cancer Institute Ruth L. Kirschstein NRSA Institutional Research Training Grant; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Foundation Roberto Gianna Gonella; Foundation SICPA; Spanish Association for the Study of the Liver (Asociacion Espanola para el Estudio del Higado, AEEH); Nuovo Soldati Foundation; European Commission (EC)/Horizon 2020 Program (HEPCAR)(European Commission); U.S. Department of Defense(United States Department of Defense); Accelerator Award (CRUCK, AECC, AIRC)(Fondazione AIRC per la ricerca sul cancro); National Cancer Institute, Tisch Cancer Institute; Samuel Waxman Cancer Research Foundation; Spanish National Health Institute(Spanish Government); Generalitat de Catalunya/AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)Generalitat de Catalunya)	JvF is supported by the German Research Foundation (FE1746/1-1). AJC is supported by the National Cancer Institute Ruth L. Kirschstein NRSA Institutional Research Training Grant (CA078207). IL is supported by a grant from the Swiss National Science Foundation, from Foundation Roberto & Gianna Gonella and Foundation SICPA. PKH is supported by the German Research Foundation (HA8754/1-1). DD is supported by the Grant for Studies Broadening from the Spanish Association for the Study of the Liver (Asociacion Espanola para el Estudio del Higado, AEEH) and the Cancer Research Grant from Nuovo Soldati Foundation. JML is supported by the European Commission (EC)/Horizon 2020 Program (HEPCAR, Ref. 667273-2), U.S. Department of Defense (CA150272P3), an Accelerator Award (CRUCK, AECC, AIRC) (HUNTER, Ref. C9380/A26813), National Cancer Institute, Tisch Cancer Institute (P30-CA196521), Samuel Waxman Cancer Research Foundation, Spanish National Health Institute (SAF2016-76390) and the Generalitat de Catalunya/AGAUR (SGR-1358). AV is supported by the U.S. Department of Defense (CA150272P3).	Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002; Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; [Anonymous], 2018, IARC DATA; [Anonymous], 2018, CDC LIVER CANC REPOR; Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9; Brunner SF, 2019, NATURE, V574, P538, DOI 10.1038/s41586-019-1670-9; Craig AJ, 2020, NAT REV GASTRO HEPAT, V17, P139, DOI 10.1038/s41575-019-0229-4; de Galarreta MR, 2019, CANCER DISCOV, V9, P1124, DOI 10.1158/2159-8290.CD-19-0074; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Finn RS, 2020, J CLIN ONCOL, V38, P193, DOI 10.1200/JCO.19.01307; Goodall J, 2017, CANCER DISCOV, V7, P1006, DOI 10.1158/2159-8290.CD-17-0261; Harding JJ, 2019, CLIN CANCER RES, V25, P2116, DOI 10.1158/1078-0432.CCR-18-2293; Howell J, 2019, EUR J CANCER, V116, P56, DOI 10.1016/j.ejca.2019.04.014; Huang A, 2017, J HEPATOL, V67, P293, DOI 10.1016/j.jhep.2017.03.005; Jiang PY, 2019, J HEPATOL, V71, P409, DOI 10.1016/j.jhep.2019.04.003; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Labgaa I, 2018, ONCOGENE, V37, P3740, DOI 10.1038/s41388-018-0206-3; Labgaa I, 2015, DISCOV MED, V19, P263; Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2019, J HEPATOL, V70, P1262, DOI 10.1016/j.jhep.2019.01.028; Luke JJ, 2019, CLIN CANCER RES, V25, P3074, DOI 10.1158/1078-0432.CCR-18-1942; Mansukhani S, 2018, CLIN CHEM, V64, P1626, DOI 10.1373/clinchem.2018.289629; Marrero JA, 2018, HEPATOLOGY, V68, P723, DOI 10.1002/hep.29913; Nault JC, 2020, HEPATOLOGY, V71, P164, DOI 10.1002/hep.30811; Nault JC, 2019, NAT REV GASTRO HEPAT, V16, P544, DOI 10.1038/s41575-019-0165-3; Ng CKY, 2018, ANN ONCOL, V29, P1286, DOI 10.1093/annonc/mdy083; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rothwell DG, 2019, NAT MED, V25, P738, DOI 10.1038/s41591-019-0380-z; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Sia D, 2017, GASTROENTEROLOGY, V153, P812, DOI 10.1053/j.gastro.2017.06.007; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; von Felden J, 2020, GUT, V69, P2025, DOI 10.1136/gutjnl-2019-320282; von Felden J, 2020, CURR OPIN GASTROEN, V36, P177, DOI 10.1097/MOG.0000000000000626; Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7; Xia HP, 2013, HEPATOLOGY, V58, P629, DOI 10.1002/hep.26369; YAU T, 2019, ANN ONCOL, V30, P29; Zhang H, 2018, ONCOL LETT, V15, P9377, DOI 10.3892/ol.2018.8536; Zhu AX, 2019, LANCET ONCOL, V20, P282, DOI 10.1016/S1470-2045(18)30937-9; Zhu AX, 2018, LANCET ONCOL, V19, P940, DOI 10.1016/S1470-2045(18)30351-6; Zhu M, 2019, CELL, V177, P608, DOI 10.1016/j.cell.2019.03.026	45	42	43	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					140	151		10.1038/s41388-020-01519-1	http://dx.doi.org/10.1038/s41388-020-01519-1		OCT 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33097857				2022-12-28	WOS:000582109700001
J	Tong, K; Kothari, OA; Haro, KS; Panda, A; Bandari, MM; Carrick, JN; Hur, JJ; Zhang, LJ; Chan, CS; Xing, JC; Gatza, ML; Ganesan, S; Verzi, MP				Tong, Kevin; Kothari, Om A.; Haro, Katherine S.; Panda, Anshuman; Bandari, Manisha M.; Carrick, Jillian N.; Hur, Joseph J.; Zhang, Lanjing; Chan, Chang S.; Xing, Jinchuan; Gatza, Michael L.; Ganesan, Shridar; Verzi, Michael P.			SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis	ONCOGENE			English	Article							ISLAND METHYLATOR PHENOTYPE; SPORADIC MICROSATELLITE INSTABILITY; BRAF MUTATION STATUS; COLORECTAL-CANCER; BETA-CATENIN; MOUSE MODELS; STEM-CELLS; REPEAT MARKERS; POOR SURVIVAL; COLON	BRAF-driven colorectal cancer is among the poorest prognosis subtypes of colon cancer. Previous studies suggest that BRAF-mutant serrated cancers frequently exhibit Microsatellite Instability (MSI) and elevated levels of WNT signaling. The loss of tumor-suppressor Smad4 in oncogenic BRAF-V600E mouse models promotes rapid serrated tumor development and progression, and SMAD4 mutations co-occur in human patient tumors with BRAF-V600E mutations. This study assesses the role of SMAD4 in early-stage serrated tumorigenesis. SMAD4 loss promotes microsatellite stable (MSS) serrated tumors in an oncogenic BRAF-V600E context, providing a model for MSS serrated cancers. Inactivation of Msh2 in these mice accelerated tumor formation, and whole-exome sequencing of both MSS and MSI serrated tumors derived from these mouse models revealed that all serrated tumors developed oncogenic WNT mutations, predominantly in the WNT-effector gene Ctnnb1 (beta-catenin). Mouse models mimicking the oncogenic beta-catenin mutation show that the combination of three oncogenic mutations (Ctnnb1, Braf, and Smad4) are critical to drive rapid serrated dysplasia formation. Re-analysis of human tumor data reveals BRAF-V600E mutations co-occur with oncogenic mutations in both WNT and SMAD4/TGF beta pathways. These findings identify SMAD4 as a critical factor in early-stage serrated cancers and helps broaden the knowledge of this rare but aggressive subset of colorectal cancer.	[Tong, Kevin; Kothari, Om A.; Haro, Katherine S.; Bandari, Manisha M.; Carrick, Jillian N.; Hur, Joseph J.; Xing, Jinchuan; Verzi, Michael P.] Rutgers State Univ, Human Genet Inst New Jersey HGINJ, Dept Genet, Piscataway, NJ 08854 USA; [Panda, Anshuman; Zhang, Lanjing; Gatza, Michael L.; Ganesan, Shridar; Verzi, Michael P.] Rutgers Canc Inst New Jersey CINJ, New Brunswick, NJ 08901 USA; [Zhang, Lanjing] Penn Med Princeton Med Ctr, Dept Pathol, Plainsboro, NJ USA; [Chan, Chang S.] Rutgers Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ USA; [Gatza, Michael L.] Univ Med & Dent New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Verzi, MP (corresponding author), Rutgers State Univ, Human Genet Inst New Jersey HGINJ, Dept Genet, Piscataway, NJ 08854 USA.; Verzi, MP (corresponding author), Rutgers Canc Inst New Jersey CINJ, New Brunswick, NJ 08901 USA.	verzi@biology.rutgers.edu	Zhang, Lanjing/AGY-7838-2022; Zhang, Lanjing/GZB-0260-2022; Panda, Anshuman/T-5101-2018	Zhang, Lanjing/0000-0001-5436-887X; Panda, Anshuman/0000-0001-7917-0317; Chan, Chang/0000-0001-9897-4759	NCI [5P30CA072720, 1R01CA243547, 1F32CA235829, 5K99CA245123, 5R01CA190558]; Rutgers Undergraduate Research Fellowships; Douglass Project STEM; ARESTY Summer Research Fellowships; NIDDK [1R01DK121915]; Rutgers Human Genetics Institute of New Jersey; Cancer Institute of New Jersey [5P30CA072720]; US Department of Defense; American Association for Cancer Research	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Rutgers Undergraduate Research Fellowships; Douglass Project STEM; ARESTY Summer Research Fellowships; NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Rutgers Human Genetics Institute of New Jersey; Cancer Institute of New Jersey; US Department of Defense(United States Department of Defense); American Association for Cancer Research	KT is funded by NCI (1F32CA235829, 5K99CA245123). OAK, KSH, MMB, and JNC were funded by Rutgers Undergraduate Research Fellowships, Douglass Project STEM, and ARESTY Summer Research Fellowships. MPV is funded by NCI (5R01CA190558), NIDDK (1R01DK121915), and supported by the Rutgers Human Genetics Institute of New Jersey and the Cancer Institute of New Jersey (5P30CA072720). SG is funded by NCI (5P30CA072720, 1R01CA243547) and the US Department of Defense. Authors also thank members of Verzi Lab, Rutgers Epigenetic Group, and Rutgers High Performance Computing for constructive input and expertise in Whole Exome Sequencing processing and analysis. Msh2KO mouse model was provided as a gift from Jiehui Deng and the Wong Lab. The authors would like to acknowledge the American Association for Cancer Research and its financial and material support in the development of the AACR Project GENIE registry, as well as members of the consortium for their commitment to data sharing. Interpretations are the responsibility of study authors.	AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Afgan E, 2016, NUCLEIC ACIDS RES, V44, pW3, DOI 10.1093/nar/gkw343; Alberici P, 2006, ONCOGENE, V25, P1841, DOI 10.1038/sj.onc.1209226; Alberici Paola, 2008, Pathogenetics, V1, P2, DOI 10.1186/1755-8417-1-2; Ando Y, 2020, CLIN J GASTROENTEROL, V13, P867, DOI 10.1007/s12328-020-01099-3; Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Andre T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699; Ang PW, 2009, CANCER LETT, V273, P221, DOI 10.1016/j.canlet.2008.08.001; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Bacher JW, 2005, MOL CARCINOGEN, V44, P285, DOI 10.1002/mc.20146; Barata P, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001065; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Basu Sayon, 2016, F1000Res, V5, DOI 10.12688/f1000research.7579.1; Biswas S, 2008, GENE CHROMOSOME CANC, V47, P95, DOI 10.1002/gcc.20511; Cancer Genome Atlas N., 2012, NATURE, V487, P330, DOI [10.1038/nature11252, DOI 10.1038/NATURE11252]; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chakravarty D, 2017, JCO PRECIS ONCOL, V1; Chang LS, 2018, APPL IMMUNOHISTO M M, V26, pE15, DOI 10.1097/PAI.0000000000000575; Chapnick DA, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-42; Chen XY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00301-9; Chouhan H, 2019, ASIA-PAC J CLIN ONCO, V15, P69, DOI 10.1111/ajco.13096; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Das S, 2020, CLIN COLORECTAL CANC, V19, P137, DOI 10.1016/j.clcc.2020.02.006; de Sousa EMF, 2011, CLIN CANCER RES, V17, P647, DOI 10.1158/1078-0432.CCR-10-1204; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Eto T, 2018, J PATHOL, V245, P445, DOI 10.1002/path.5098; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fernando WC, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/374926; Fodde R, 2002, EUR J CANCER, V38, P867, DOI 10.1016/S0959-8049(02)00040-0; Freeman TJ, 2012, GASTROENTEROLOGY, V142, P562, DOI 10.1053/j.gastro.2011.11.026; Fumagalli A, 2017, P NATL ACAD SCI USA, V114, pE2357, DOI 10.1073/pnas.1701219114; Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x; Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127; Gotovac JR, 2018, DISCOV MED, V26, P103; Guo TA, 2019, INT J CANCER, V145, P1625, DOI 10.1002/ijc.32489; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Hinoue T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008357; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; JENG MH, 1991, MOL ENDOCRINOL, V5, P1120, DOI 10.1210/mend-5-8-1120; Kabbarah O, 2003, MOL CARCINOGEN, V38, P155, DOI 10.1002/mc.10157; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Kane AM, 2020, NEOPLASIA, V22, P120, DOI 10.1016/j.neo.2019.12.002; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kucherlapati MH, 2010, GASTROENTEROLOGY, V138, P993, DOI 10.1053/j.gastro.2009.11.009; Lange S, 2020, NAT PROTOC, V15, P266, DOI 10.1038/s41596-019-0234-7; Lannagan TRM, 2019, GUT, V68, P684, DOI 10.1136/gutjnl-2017-315920; Leggett B, 2010, GASTROENTEROLOGY, V138, P2088, DOI 10.1053/j.gastro.2009.12.066; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu Q, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00799; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Mizuno T, 2018, EJSO-EUR J SURG ONC, V44, P684, DOI 10.1016/j.ejso.2018.02.247; O'Rourke KP, 2017, NAT BIOTECHNOL, V35, P577, DOI 10.1038/nbt.3837; Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473; Panarelli NC, 2015, AM J SURG PATHOL, V39, P313, DOI 10.1097/PAS.0000000000000380; Panda A, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00146; Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269; Perekatt AO, 2018, CANCER RES, V78, P4878, DOI 10.1158/0008-5472.CAN-18-0043; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Provost E, 2003, J BIOL CHEM, V278, P31781, DOI 10.1074/jbc.M304953200; Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014; Rex DK, 2012, AM J GASTROENTEROL, V107, P1315, DOI 10.1038/ajg.2012.161; Riemer P, 2015, ONCOGENE, V34, P3164, DOI 10.1038/onc.2014.247; Robinson JT, 2017, CANCER RES, V77, pE31, DOI 10.1158/0008-5472.CAN-17-0337; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Roper J, 2017, NAT BIOTECHNOL, V35, P569, DOI 10.1038/nbt.3836; Sakai E, 2018, CANCER RES, V78, P1334, DOI 10.1158/0008-5472.CAN-17-3303; Sakamoto N, 2017, ELIFE, V6, DOI 10.7554/eLife.20331; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schatoff EM, 2017, CURR COLORECT CANC R, V13, P101, DOI 10.1007/s11888-017-0354-9; Seppala TT, 2015, BRIT J CANCER, V112, P1966, DOI 10.1038/bjc.2015.160; Sinicrope FA, 2019, CLIN GASTROENTEROL H, V17, P391, DOI 10.1016/j.cgh.2018.06.038; Taieb J, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw272; Taketo MM, 2009, GASTROENTEROLOGY, V136, P780, DOI 10.1053/j.gastro.2008.12.049; Tanaka H, 2006, INT J CANCER, V118, P2765, DOI 10.1002/ijc.21701; Tao Y, 2019, CANCER CELL, V35, P315, DOI 10.1016/j.ccell.2019.01.005; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tian XX, 2009, BIOCHEM BIOPH RES CO, V380, P478, DOI 10.1016/j.bbrc.2009.01.124; Tong K, 2017, CELL REP, V21, P3833, DOI 10.1016/j.celrep.2017.11.104; Stormo Gary D, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1110s43, 10.1002/0471250953.bi1201s43]; Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Xia JX, 2006, J DERMATOL SCI, V41, P67, DOI 10.1016/j.jdermsci.2005.09.005; Xue X, 2013, JOVE-J VIS EXP, DOI 10.3791/50210; Yagyu R, 2004, INT J ONCOL, V25, P1343; Yamane L, 2014, WORLD J GASTROENTERO, V20, P2634, DOI 10.3748/wjg.v20.i10.2634; Yan P, 2016, CLIN CANCER RES, V22, P3037, DOI 10.1158/1078-0432.CCR-15-0939; Yang G, 2010, INT J BIOL SCI, V6, P1; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Yang YC, 2018, CANCER MANAG RES, V10, P3911, DOI 10.2147/CMAR.S169649; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhao PF, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0738-1	101	2	2	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					6034	6048		10.1038/s41388-021-01997-x	http://dx.doi.org/10.1038/s41388-021-01997-x		AUG 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34453124	Green Accepted			2022-12-28	WOS:000690353500001
J	Li, HR; Qi, ZH; Niu, YD; Yang, YF; Li, MJ; Pang, YY; Liu, MM; Cheng, X; Xu, MD; Wang, ZL				Li, Haoran; Qi, Zihao; Niu, Yongdong; Yang, Yufei; Li, Mengjiao; Pang, Yangyang; Liu, Mingming; Cheng, Xi; Xu, Midie; Wang, Ziliang			FBP1 regulates proliferation, metastasis, and chemoresistance by participating in C-MYC/STAT3 signaling axis in ovarian cancer	ONCOGENE			English	Article							FRUCTOSE-1,6-BISPHOSPHATASE; EXPRESSION; MYC; GLYCOLYSIS; METABOLISM; GROWTH; CELLS; BIOMARKERS; RESISTANCE; PATH	Fructose-1,6-bisphosphatase (FBP1) is a rate-limiting enzyme in gluconeogenesis and an important tumor suppressor in human malignancies. Here, we aimed to investigate the expression profile of FBP1 in ovarian cancer, the molecular mechanisms that regulate FBP1 expression and to examine how the FBP1 regulatory axis contributes to tumorigenesis and progression in ovarian cancer. We showed that FBP1 expression was significantly decreased in ovarian cancer tissues compared with normal ovarian tissues, and low-FBP1 expression predicted poor prognosis in patients with ovarian cancer. The enhanced expression of FBP1 in ovarian cancer cell lines suppressed proliferation and 2-D/3-D invasion, reduced aerobic glycolysis, and sensitized cancer cells to cisplatin-induced apoptosis. Moreover, DNA methylation and C-MYC binding at the promoter inhibited FBP1 expression. Furthermore, through physical interactions with signal transducer and activator of transcription 3 (STAT3), FBP1 suppressed nuclear translocation of STAT3 and exerted its non-metabolic enzymatic activity to induce the dysfunction of STAT3. Thus, our study suggests that FBP1 may be a valuable prognostic predictor for ovarian cancer. C-MYC-dependent downregulation of FBP1 acted as a tumor suppressor via modulating STAT3, and the C-MYC/FBP1/STAT3 axis could be a therapeutic target.	[Li, Haoran; Yang, Yufei; Li, Mengjiao; Cheng, Xi; Wang, Ziliang] Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai, Peoples R China; [Li, Haoran; Yang, Yufei; Li, Mengjiao; Cheng, Xi; Wang, Ziliang] Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, Shanghai, Peoples R China; [Li, Haoran; Yang, Yufei; Cheng, Xi; Xu, Midie; Wang, Ziliang] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Qi, Zihao] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Gen Surg, Sch Med, Shanghai, Peoples R China; [Niu, Yongdong] Shantou Univ Med Coll, Dept Pharmacol, Shantou, Peoples R China; [Yang, Yufei; Wang, Ziliang] Shanghai Univ Tradit Chinese Med, Shanghai Hosp Tradit Chinese Med, Clin Med Transformat Ctr, Shanghai, Peoples R China; [Yang, Yufei; Wang, Ziliang] Shanghai Univ Tradit Chinese Med, Shanghai Hosp Tradit Chinese Med, Off Acad Res, Shanghai, Peoples R China; [Pang, Yangyang] Fudan Univ, Shanghai Xuhui Cent Hosp, Zhongshan Xuhui Hosp, Shanghai, Peoples R China; [Liu, Mingming] Anhui Med Univ, Sch Pharm, Hefei, Peoples R China; [Xu, Midie] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China; [Xu, Midie] Fudan Univ, Biobank, Shanghai Canc Ctr, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Shanghai Jiao Tong University; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Fudan University; Anhui Medical University; Fudan University; Fudan University	Cheng, X; Wang, ZL (corresponding author), Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai, Peoples R China.; Cheng, X; Wang, ZL (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, Shanghai, Peoples R China.; Cheng, X; Xu, MD; Wang, ZL (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.; Wang, ZL (corresponding author), Shanghai Univ Tradit Chinese Med, Shanghai Hosp Tradit Chinese Med, Clin Med Transformat Ctr, Shanghai, Peoples R China.; Wang, ZL (corresponding author), Shanghai Univ Tradit Chinese Med, Shanghai Hosp Tradit Chinese Med, Off Acad Res, Shanghai, Peoples R China.; Xu, MD (corresponding author), Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China.; Xu, MD (corresponding author), Fudan Univ, Biobank, Shanghai Canc Ctr, Shanghai, Peoples R China.	cheng_xi1@hotmail.com; xumd27202003@sina.com; huf_zlwang@126.com	xu, midie/AFS-3427-2022; Wang, Zhiquan/HHS-6768-2022	xu, midie/0000-0003-1775-6608; Niu, Yongdong/0000-0002-5392-3736	National Natural Science Foundation of China [81502235, 81602078]; National Human Genetic Resources Sharing Service Platform [2005DKA21300]; Traditional Chinese Medicine Research Fund of Shanghai Municipal Commission of Health and Family Planning [WS-ZY1201]; Guangdong Provincial Science and technology Program [2014A020212285]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Human Genetic Resources Sharing Service Platform; Traditional Chinese Medicine Research Fund of Shanghai Municipal Commission of Health and Family Planning; Guangdong Provincial Science and technology Program	This work was supported by National Natural Science Foundation of China (81502235 and 81602078), by National Human Genetic Resources Sharing Service Platform (2005DKA21300), by Traditional Chinese Medicine Research Fund of Shanghai Municipal Commission of Health and Family Planning (WS-ZY1201), and by Guangdong Provincial Science and technology Program (2014A020212285).	Ai ZH, 2016, CANCER LETT, V373, P36, DOI 10.1016/j.canlet.2016.01.009; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bigl M, 2008, BIOCHEM BIOPH RES CO, V377, P720, DOI 10.1016/j.bbrc.2008.10.045; Bott AJ, 2015, CELL METAB, V22, P1068, DOI 10.1016/j.cmet.2015.09.025; Chen MQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025564; Chen SH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174136; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; de Castro DG, 2013, CLIN PHARMACOL THER, V93, P252, DOI 10.1038/clpt.2012.237; DeBerardinis RJ, 2008, GENET MED, V10, P267, DOI 10.1097/GIM.0b013e31818b0d9b; Delgado M Dolores, 2010, Genes Cancer, V1, P605, DOI 10.1177/1947601910377495; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Garrido P, 2015, J CELL PHYSIOL, V230, P191, DOI 10.1002/jcp.24698; Guo WH, 2011, J CANCER RES CLIN, V137, P65, DOI 10.1007/s00432-010-0860-5; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hijaz M, 2016, GYNECOL ONCOL, V142, P323, DOI 10.1016/j.ygyno.2016.06.005; Hsieh AL, 2015, SEMIN CELL DEV BIOL, V43, P11, DOI 10.1016/j.semcdb.2015.08.003; Hulleman E, 2009, BLOOD, V113, P2014, DOI 10.1182/blood-2008-05-157842; Jin X, 2017, CANCER RES, V77, P4328, DOI 10.1158/0008-5472.CAN-16-3143; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; Li B, 2014, NATURE, V513, P251, DOI 10.1038/nature13557; Li KC, 2016, BIOMED PHARMACOTHER, V84, P1144, DOI 10.1016/j.biopha.2016.10.050; Liu X, 2010, ONCOGENE, V29, P442, DOI 10.1038/onc.2009.332; Liu YF, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317708779; Loar P, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.10.883; Marin-Hernandez A, 2006, FEBS J, V273, P1975, DOI 10.1111/j.1742-4658.2006.05214.x; Qiu J, 2021, MOL CELL BIOCHEM, V476, P1, DOI 10.1007/s11010-020-03814-7; Sheng HY, 2015, CANCER INVEST, V33, P197, DOI 10.3109/07357907.2015.1020385; Shi L, 2017, NEOPLASMA, V64, P535, DOI 10.4149/neo_2017_407; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Soh MA, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-41; Wang B, 2020, THERANOSTICS, V10, P1033, DOI 10.7150/thno.38137; Wang B, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0888-y; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; Zhang J, 2016, MOL CELL BIOCHEM, V411, P331, DOI 10.1007/s11010-015-2595-8; Zhang YP, 2019, CELL CYCLE, V18, P2432, DOI 10.1080/15384101.2019.1648956; Zheng Y, 2018, AM J TRANSL RES, V10, P3086	38	7	7	4	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5938	5949		10.1038/s41388-021-01957-5	http://dx.doi.org/10.1038/s41388-021-01957-5		AUG 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34363022	hybrid, Green Published			2022-12-28	WOS:000682519100002
J	Zhu, HQ; Li, Q; Zhao, YL; Peng, H; Guo, LY; Zhu, J; Jiang, Z; Zeng, ZX; Xu, B; Chen, SS				Zhu, Hengqing; Li, Qing; Zhao, Yulan; Peng, Hong; Guo, Liangyun; Zhu, Jing; Jiang, Zi; Zeng, Zhaoxia; Xu, Bin; Chen, Sisi			Vaccinia-related kinase 2 drives pancreatic cancer progression by protecting Plk1 from Chfr-mediated degradation	ONCOGENE			English	Article							POLO-LIKE KINASES; VRK2; IDENTIFICATION; STABILIZATION; EPIDEMIOLOGY; ACCUMULATION; EXPRESSION; STABILITY; LIGASE; AURORA	As a key cell cycle regulator, polo-like kinase 1 (Plk1) has been recognized as a crucial factor involved in the progression of pancreatic cancer (PC). However, its regulatory mechanism is poorly understood. Here, we present evidence that Plk1 is a novel substrate of vaccinia-related kinase 2 (VRK2), a serine-threonine kinase that is highly expressed and predicts poor prognosis in PC. VRK2 phosphorylates Plk1 at threonine 210 and protects it from ubiquitin-dependent proteasomal degradation. We showed that mechanistically complement factor H-related protein (CFHR), as a major E3 ligase, promotes Plk1 degradation by ubiquitinating it at lysine 209. Phosphorylation of Plk1 at threonine 210 by VRK2 interferes with the interaction of Chfr with Plk1 and antagonizes Plk1 ubiquitination, thereby stabilizing the Plk1 protein. Taken together, our data reveal a mechanism of Plk1 overexpression in PC and provide evidence for targeting VRK2 as a potential therapeutic strategy.	[Zhu, Hengqing] Nanchang Univ, Dept Gen Surg, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China; [Zhu, Hengqing] Zhejiang Univ, Dept Thyroid Surg, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China; [Li, Qing] Nanchang Univ, Dept Pathol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China; [Zhao, Yulan] Zhejiang Univ, Dept Ultrasound Med, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China; [Peng, Hong] 908th Hosp Chinese Peoples Liberat Army Joint, Dept Colorectal Surg, Nanchang, Jiangxi, Peoples R China; [Guo, Liangyun] Nanchang Univ, Dept Ultrasound, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China; [Zhu, Jing; Jiang, Zi] Nanchang Univ, Dept Pharm, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China; [Zeng, Zhaoxia] Nanchang Univ, Dept Radiol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China; [Xu, Bin] Nanchang Univ, Dept Burns, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China; [Chen, Sisi] Nanchang Univ, Dept Neurol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China	Nanchang University; Zhejiang University; Nanchang University; Zhejiang University; Nanchang University; Nanchang University; Nanchang University; Nanchang University; Nanchang University	Xu, B (corresponding author), Nanchang Univ, Dept Burns, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.; Chen, SS (corresponding author), Nanchang Univ, Dept Neurol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China.	bxu1990@126.com; Cheinsee@163.com		Chen, Sisi/0000-0002-1908-5054	Scientific research and cultivation project of talents in the First Affiliated Hospital of Nanchang University [YFYPY202015]	Scientific research and cultivation project of talents in the First Affiliated Hospital of Nanchang University	This study was supported by the Scientific research and cultivation project of talents in the First Affiliated Hospital of Nanchang University (YFYPY202015).	Archambault V, 2009, NAT REV MOL CELL BIO, V10, P265, DOI 10.1038/nrm2653; Blanco S, 2006, FEBS J, V273, P2487, DOI 10.1111/j.1742-4658.2006.05256.x; Chen B, 2018, MOL MED REP, V18, P105, DOI 10.3892/mmr.2018.8941; de Carcer G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05429-5; Eckerdt F, 2005, J BIOL CHEM, V280, P36575, DOI 10.1074/jbc.M504548200; Fernandez IF, 2010, MOL CELL BIOL, V30, P4687, DOI 10.1128/MCB.01581-09; Golsteyn R M, 1996, Prog Cell Cycle Res, V2, P107; Grimont A, 2015, GUT, V64, P1790, DOI 10.1136/gutjnl-2014-307075; Ilic M, 2016, WORLD J GASTROENTERO, V22, P9694, DOI 10.3748/wjg.v22.i44.9694; Jeong YH, 2018, J NEUROCHEM, V147, P609, DOI 10.1111/jnc.14562; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kim JS, 2011, J BIOL CHEM, V286, P30615, DOI 10.1074/jbc.M111.231803; Kim S, 2015, MOL CELL BIOL, V35, P1754, DOI 10.1128/MCB.01325-14; Kim S, 2014, MOL CELL BIOL, V34, P643, DOI 10.1128/MCB.00756-13; Klerkx EPF, 2009, HISTOL HISTOPATHOL, V24, P749, DOI 10.14670/HH-24.749; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Li J, 2016, CELL CYCLE, V15, P711, DOI 10.1080/15384101.2016.1148838; Lin QJ, 2015, WORLD J GASTROENTERO, V21, P7988, DOI 10.3748/wjg.v21.i26.7988; Liu ZX, 2017, TRANSL ONCOL, V10, P22, DOI 10.1016/j.tranon.2016.10.003; Mahajan UM, 2016, GUT, V65, P1838, DOI 10.1136/gutjnl-2016-311393; Mai J, 2019, THERANOSTICS, V9, P3541, DOI 10.7150/thno.32908; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; McGuigan A, 2018, WORLD J GASTROENTERO, V24, P4846, DOI 10.3748/wjg.v24.i43.4846; Monsalve DM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.40; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; Nichols RJ, 2004, J BIOL CHEM, V279, P7934, DOI 10.1074/jbc.M310813200; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Sanz-Garcia M, 2008, MOL CELL PROTEOMICS, V7, P2199, DOI 10.1074/mcp.M700586-MCP200; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Shin CH, 2017, CELL DEATH DIFFER, V24, P1861, DOI 10.1038/cdd.2017.106; Shin SB, 2020, ONCOGENE, V39, P767, DOI 10.1038/s41388-019-1023-z; Song B, 2013, MOL CANCER THER, V12, P58, DOI 10.1158/1535-7163.MCT-12-0632; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Tesli M, 2016, BRIT J PSYCHIAT, V209, P114, DOI 10.1192/bjp.bp.115.161950; Vazquez-Cedeira M, 2012, J BIOL CHEM, V287, P42739, DOI 10.1074/jbc.M112.404285; Wen DH, 2017, CELL REP, V21, P2147, DOI 10.1016/j.celrep.2017.10.085; Xiao DB, 2016, MOL CELL, V64, P493, DOI 10.1016/j.molcel.2016.09.016; Xin XF, 2019, ACS APPL MATER INTER, V11, P14647, DOI 10.1021/acsami.9b02756; Yabar CS, 2016, GASTROENTEROL CLIN N, V45, P429, DOI 10.1016/j.gtc.2016.04.003	39	4	4	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4663	4674		10.1038/s41388-021-01893-4	http://dx.doi.org/10.1038/s41388-021-01893-4		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34140642				2022-12-28	WOS:000662838900003
J	Sherman, J; Verstandig, G; Brumer, Y				Sherman, Jeff; Verstandig, Grant; Brumer, Yisroel			Application of machine learning to large in-vitro databases to identify cancer cell characteristics: telomerase reverse transcriptase (TERT) expression	ONCOGENE			English	Article								Advances in biotechnology and machine learning have created an enhanced environment for unearthing and exploiting previously unrecognized relationships between genomic and epigenetic data with potential therapeutic implications. We applied advanced algorithms to data from the Cancer Dependency Map to uncover increasingly complex relationships. Specifically, we investigate characteristics of tumor cell lines with varying levels of telomerase reverse transcriptase (TERT) expression in liver cancer. The findings indicate that the effect of CRISPR knockout of Histone Deacetylase 1 (HDAC1) and numerous individual respiratory complex I genes is strongly related to the level of TERT expression, with knockout being particularly efficacious at killing or inhibiting growth of tumor cells with low levels of TERT expression for HDAC1 and high levels for Complex I genes. These findings suggest key biomarkers for therapeutic efficacy and yield novel potential pathways for drug development and provide further proof of principle for the potential of artificial intelligence in oncology.	[Sherman, Jeff; Verstandig, Grant; Brumer, Yisroel] Zephyr AI, Washington, DC 20006 USA; [Sherman, Jeff; Verstandig, Grant; Brumer, Yisroel] Red Cell Partners, Washington, DC 20011 USA		Sherman, J (corresponding author), Zephyr AI, Washington, DC 20006 USA.; Sherman, J (corresponding author), Red Cell Partners, Washington, DC 20011 USA.	sherman@redcellpartners.com		Sherman, Jeff/0000-0003-1377-0357; Brumer, Yisroel/0000-0002-7046-0198				Amisaki M, 2019, CANCER SCI, V110, P550, DOI 10.1111/cas.13884; Bazaga A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67846-1; DepMap Broad, 2020, DEPMAP 21Q1 PUBL FIG, DOI [10.6084/m9.figshare.13681534.v1, DOI 10.6084/M9.FIGSHARE.13681534.V1]; Dezso Z, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-020-3442-9; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Indran IR, 2011, CANCER RES, V71, P266, DOI 10.1158/0008-5472.CAN-10-1588; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Koh CM, 2015, J CLIN INVEST, V125, P2109, DOI 10.1172/JCI79134; Liu TT, 2016, GENES-BASEL, V7, DOI 10.3390/genes7070038; Madhukar NS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12928-6; Rosen J, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101543; Saretzki G, 2014, CURR PHARM DESIGN, V20, P6386, DOI 10.2174/1381612820666140630095606; Seynnaeve B, 2017, SCI REP-UK, V7, DOI 10.1038/srep45704; Sherman J, 2021, ONCOGENE, V40, P3766, DOI 10.1038/s41388-021-01807-4; Shimada K, 2019, TOOL BROWSING CANC D, DOI 10.1101/2019.12.13.874776v1; Travis J, 2015, SCIENCE, V350, P1456, DOI 10.1126/science.350.6267.1456; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Urra FA, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00118; Yuan XT, 2019, ONCOGENE, V38, P6172, DOI 10.1038/s41388-019-0872-9; Yuan XT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133338	20	2	2	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					5038	5041		10.1038/s41388-021-01894-3	http://dx.doi.org/10.1038/s41388-021-01894-3		JUN 2021	4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34135463				2022-12-28	WOS:000662140500001
J	Shapira, S; Finkelshtein, E; Kazanov, D; Naftali, E; Stepansky, I; Loyter, A; Elbirt, D; Hay-Levy, M; Brazowski, E; Bedny, F; Dekel, R; Hershkovitz, D; Blachar, A; Wolf, I; Arber, N				Shapira, Shiran; Finkelshtein, Eynat; Kazanov, Dina; Naftali, Esmira; Stepansky, Irena; Loyter, Abraham; Elbirt, Daniel; Hay-Levy, Mori; Brazowski, Eli; Bedny, Faina; Dekel, Roy; Hershkovitz, Dov; Blachar, Arye; Wolf, Ido; Arber, Nadir			Integrase-derived peptides together with CD24-targeted lentiviral particles inhibit the growth of CD24 expressing cancer cells	ONCOGENE			English	Article							HIV-1 INTEGRASE; REV; GENE; CARCINOGENESIS; REPLICATION; MARKER	The integration of viral DNA into the host genome is mediated by viral integrase, resulting in the accumulation of double-strand breaks. Integrase-derived peptides (INS and INR) increase the number of integration events, leading to escalated genomic instability that induces apoptosis. CD24 is a surface protein expressed mostly in cancer cells and is very rarely found in normal cells. Here, we propose a novel targeted cancer therapeutic platform based on the lentiviral integrase, stimulated by integrase-derived peptides, that are specifically delivered to cancerous cells via CD24 antigen-antibody targeting. INS and INR were synthesized and humanized and anti-CD24 antibodies were fused to the lentivirus envelope. The activity, permeability, stability, solubility, and toxicity of these components were analyzed. Cell death was measured by fluorescent microscopy and enzymatic assays and potency were tested in vitro and in vivo. Lentivirus particles, containing non-functional DNA led to massive cell death (40-70%). Raltegravir, an antiretroviral drug, inhibited the induction of apoptosis. In vivo, single and repeated administrations of INS/INR were well tolerated without any adverse effects. Tumor development in nude mice was significantly inhibited (by 50%) as compared to the vehicle arm. In summary, a novel and generic therapeutic platform for selective cancer cell eradication with excellent efficacy and safety are presented.	[Shapira, Shiran; Kazanov, Dina; Hay-Levy, Mori; Dekel, Roy; Arber, Nadir] Sourasky Med Ctr, Hlth Promot Ctr, Tel Aviv, Israel; [Shapira, Shiran; Kazanov, Dina; Hay-Levy, Mori; Dekel, Roy; Arber, Nadir] Sourasky Med Ctr, Integrated Canc Prevent Ctr, Tel Aviv, Israel; [Shapira, Shiran; Arber, Nadir] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Finkelshtein, Eynat; Naftali, Esmira] Zion Med BV, De Bilt, Netherlands; [Stepansky, Irena; Wolf, Ido] Tel Aviv Med Ctr & Sch Med, Oncol Div, Tel Aviv, Israel; [Loyter, Abraham] Hebrew Univ Jerusalem, Alexander Inst Life Sci, Dept Biol Chem, Jerusalem, Israel; [Elbirt, Daniel] Hadassah Hebrew Univ, Clin Immunol Allergy & AIDS Ctr Kaplan Med Ctr, Med Sch Jerusalem, Rehovot, Israel; [Brazowski, Eli; Bedny, Faina; Hershkovitz, Dov] Tel Aviv Sourasky Med Ctr, Pathol Inst, Tel Aviv, Israel; [Blachar, Arye] Tel Aviv Sourasky Med Ctr, Dept Radiol, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Arber, N (corresponding author), Sourasky Med Ctr, Hlth Promot Ctr, Tel Aviv, Israel.; Arber, N (corresponding author), Sourasky Med Ctr, Integrated Canc Prevent Ctr, Tel Aviv, Israel.; Arber, N (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	nadir@tlvmc.gov.il						Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Cooper A, 2013, NATURE, V498, P376, DOI 10.1038/nature12274; Craigie R, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006890; Fogel M, 1999, CANCER LETT, V143, P87, DOI 10.1016/S0304-3835(99)00195-0; Gelderblom HC, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-60; Grewe B, 2010, J GEN VIROL, V91, P1893, DOI 10.1099/vir.0.022509-0; Gromova I, 1999, ELECTROPHORESIS, V20, P241, DOI 10.1002/(SICI)1522-2683(19990201)20:2<241::AID-ELPS241>3.3.CO;2-1; HUANG LR, 1995, CANCER RES, V55, P4717; Kammerer R, 2004, J PATHOL, V204, P258, DOI 10.1002/path.1657; Lesbats P, 2016, CHEM REV, V116, P12730, DOI 10.1021/acs.chemrev.6b00125; Levin A, 2010, NUCLEUS-PHILA, V1, P190, DOI 10.4161/nucl.1.2.11300; Levin A, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-31; Levin A, 2010, BIOPOLYMERS, V93, P740, DOI 10.1002/bip.21469; Levin A, 2009, PROTEIN ENG DES SEL, V22, P753, DOI 10.1093/protein/gzp060; Levin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004155; Redston M, 2001, MODERN PATHOL, V14, P236, DOI 10.1038/modpathol.3880292; Rosenbluh J, 2007, J BIOL CHEM, V282, P15743, DOI 10.1074/jbc.M609864200; Rutsaert S, 2019, J ANTIMICROB CHEMOTH, V74, P3030, DOI 10.1093/jac/dkz269; Rutsaert S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35403-6; Rutsaert S, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0399-0; Sagiv E, 2006, BIOMED PHARMACOTHER, V60, P280, DOI 10.1016/j.biopha.2006.06.006; Sagiv E, 2008, CANCER RES, V68, P2803, DOI 10.1158/0008-5472.CAN-07-6463; Sagiv E, 2006, GASTROENTEROLOGY, V131, P630, DOI 10.1053/j.gastro.2006.04.028; Senner V, 1999, J NEUROPATH EXP NEUR, V58, P795, DOI 10.1097/00005072-199908000-00002; Shapira S, 2011, GASTROENTEROLOGY, V140, P935, DOI 10.1053/j.gastro.2010.12.004; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yoder KE, 2000, J VIROL, V74, P11191, DOI 10.1128/JVI.74.23.11191-11200.2000	27	0	0	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3815	3825		10.1038/s41388-021-01779-5	http://dx.doi.org/10.1038/s41388-021-01779-5		MAY 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33958722	Green Published, hybrid			2022-12-28	WOS:000648041500002
J	Fang, R; Wang, XT; Xia, QY; Zhao, M; Zhang, H; Wang, X; Ye, SB; Cheng, K; Liang, Y; Cheng, Y; Gu, YY; Rao, Q				Fang, Ru; Wang, Xiaotong; Xia, Qiuyuan; Zhao, Ming; Zhang, Hao; Wang, Xuan; Ye, Shengbing; Cheng, Kai; Liang, Yan; Cheng, Yang; Gu, Yayun; Rao, Qiu			Nuclear translocation of ASPL-TFE3 fusion protein creates favorable metabolism by mediating autophagy in translocation renal cell carcinoma	ONCOGENE			English	Article								The ASPL-TFE3 fusion gene, resulting from t(X;17)(p11.2;q25.3), is one of the most commonly identified fusion genes in Xp11 translocation renal cell carcinoma (tRCC). However, its roles and underlying mechanism in RCC development are not yet clear. Here, we identified ASPL-TFE3 fusion as the most common tRCC subtype in a Chinese population (29/126, 23.03%). This fusion protein translocated into the nucleus and promoted RCC cell proliferation both in vitro and in vivo. Mechanistically, the fusion protein transcriptionally activated the lysosome-autophagy pathway by binding to the promoters of lysosome-related genes. Autophagy, activated by ASPL-TFE3, enabled RCC cells to escape energy stress by promoting the utilization of proteins and lipids. Moreover, we found that the ASPL-TFE3 fusion escaped regulation by the classic mTOR-TFE3 signal and instead activated phospho-mTOR and its downstream targets. Finally, targeting both autophagy and the mTOR axis resulted in a greater antiproliferative effect than single pathway inhibition. In summary, these results confirmed the ASPL-TFE3 fusion as a master regulator of metabolic adaptation mediated by autophagy in tRCC. The simultaneous manipulation of autophagy and the mTOR axis may represent a novel treatment strategy for ASPL-TFE3 fusion RCC.	[Fang, Ru; Wang, Xiaotong; Xia, Qiuyuan; Wang, Xuan; Ye, Shengbing; Cheng, Kai; Liang, Yan; Rao, Qiu] Nanjing Univ, Jinling Hosp, Dept Pathol, Sch Med, Nanjing, Jiangsu, Peoples R China; [Zhao, Ming] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Peoples Hosp, Dept Pathol, Hangzhou, Zhejiang, Peoples R China; [Zhang, Hao] Nanjing Med Univ, Nanjing Hosp 1, Dept Nephrol, Nanjing, Jiangsu, Peoples R China; [Cheng, Yang] Nanjing Med Univ, Hlth Management Ctr, Geriatr Hosp, Nanjing, Jiangsu, Peoples R China; [Gu, Yayun] Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China	Nanjing University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Rao, Q (corresponding author), Nanjing Univ, Jinling Hosp, Dept Pathol, Sch Med, Nanjing, Jiangsu, Peoples R China.; Cheng, Y (corresponding author), Nanjing Med Univ, Hlth Management Ctr, Geriatr Hosp, Nanjing, Jiangsu, Peoples R China.; Gu, YY (corresponding author), Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.	yangchengjsnj@163.com; yayungu@njmu.edu.cn; raoqiu1103@126.com			National Natural Science Foundation of China [81872095, 81903385, 81902836, 81802557]; National Natural Science Foundation of Jiangsu Province [BK20180291]; Natural Science Foundation of Zhejiang Province [LY21H160052]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	This work was supported by the National Natural Science Foundation of China (81872095 to QR, 81903385 to YC, 81902836 to YG, and 81802557 to QX), the National Natural Science Foundation of Jiangsu Province (BK20180291 to QX), and Natural Science Foundation of Zhejiang Province (LY21H160052 to MZ).	Aquila S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071725; Argani P, 2002, AM J SURG PATHOL, V26, P1553, DOI 10.1097/00000478-200212000-00003; Argani P, 2001, AM J PATHOL, V159, P179, DOI 10.1016/S0002-9440(10)61684-7; Argani P, 2001, AM J PATHOL, V158, P2089, DOI 10.1016/S0002-9440(10)64680-9; Calio A, 2017, MODERN PATHOL, V30, P407, DOI 10.1038/modpathol.2016.200; Cheng J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15671-5; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Damayanti NP, 2018, CLIN CANCER RES, V24, P5977, DOI 10.1158/1078-0432.CCR-18-0269; Di Malta C, 2017, SCIENCE, V356, P1188, DOI 10.1126/science.aag2553; Ellis CL, 2014, MODERN PATHOL, V27, P875, DOI 10.1038/modpathol.2013.208; Fang R, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.152867; Gao MQ, 2010, ONCOGENE, V29, P2672, DOI 10.1038/onc.2010.35; Goranov AI, 2009, GENE DEV, V23, P1408, DOI 10.1101/gad.1777309; Ho H, 2011, PIGM CELL MELANOMA R, V24, P595, DOI 10.1111/j.1755-148X.2011.00889.x; Ishiguro N, 2016, NEOPLASIA, V18, P626, DOI 10.1016/j.neo.2016.08.001; Jaksch M, 2008, CANCER RES, V68, P7882, DOI 10.1158/0008-5472.CAN-08-0723; Kepp O, 2020, AUTOPHAGY, V16, P1166, DOI 10.1080/15548627.2020.1758417; Komai Y, 2009, CLIN CANCER RES, V15, P1170, DOI 10.1158/1078-0432.CCR-08-1183; Lim CY, 2016, J CELL BIOL, V214, P653, DOI 10.1083/jcb.201607005; Lopez-Hernandez T, 2020, NAT CELL BIOL, V22, P815, DOI 10.1038/s41556-020-0535-7; Lu SY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173771; Martina JA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004754; Martina JA, 2013, J CELL BIOL, V200, P475, DOI 10.1083/jcb.201209135; Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184; Napolitano G, 2020, NATURE, V585, P597, DOI 10.1038/s41586-020-2444-0; Ozturk DG, 2019, AUTOPHAGY, V15, P375, DOI 10.1080/15548627.2018.1531197; Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587; Rao Q, 2015, AM J SURG PATHOL, V39, P1181, DOI 10.1097/PAS.0000000000000502; Rao Q, 2012, AM J SURG PATHOL, V36, P1327, DOI 10.1097/PAS.0b013e31825aafb5; Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Wang XT, 2018, MODERN PATHOL, V31, P1346, DOI 10.1038/s41379-018-0051-5; Wang XT, 2016, HISTOPATHOLOGY, V69, P450, DOI 10.1111/his.12949; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; Weterman MAJ, 2001, ONCOGENE, V20, P1414, DOI 10.1038/sj.onc.1204213; Xia QY, 2020, AM J SURG PATHOL, V44, P477, DOI 10.1097/PAS.0000000000001408; Xia QY, 2018, HISTOPATHOLOGY, V72, P786, DOI 10.1111/his.13439; Xia QY, 2017, MODERN PATHOL, V30, P416, DOI 10.1038/modpathol.2016.204; Yin QY, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201911036; Yin XQ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1101-7	40	4	5	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3303	3317		10.1038/s41388-021-01776-8	http://dx.doi.org/10.1038/s41388-021-01776-8		APR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33846569				2022-12-28	WOS:000639635100003
J	Hutchinson, SA; Websdale, A; Cioccoloni, G; Roberg-Larsen, H; Lianto, P; Kim, B; Rose, A; Soteriou, C; Pramanik, A; Wastall, LM; Williams, BJ; Henn, MA; Chen, JJ; Ma, LQ; Moore, JB; Nelson, E; Hughes, TA; Thorne, JL				Hutchinson, Samantha A.; Websdale, Alex; Cioccoloni, Giorgia; Roberg-Larsen, Hanne; Lianto, Priscilia; Kim, Baek; Rose, Ailsa; Soteriou, Chrysa; Pramanik, Arindam; Wastall, Laura M.; Williams, Bethany J.; Henn, Madeline A.; Chen, Joy J.; Ma, Liqian; Moore, J. Bernadette; Nelson, Erik; Hughes, Thomas A.; Thorne, James L.			Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer	ONCOGENE			English	Article								Triple negative breast cancer (TNBC) is challenging to treat successfully because targeted therapies do not exist. Instead, systemic therapy is typically restricted to cytotoxic chemotherapy, which fails more often in patients with elevated circulating cholesterol. Liver x receptors are ligand-dependent transcription factors that are homeostatic regulators of cholesterol, and are linked to regulation of broad-affinity xenobiotic transporter activity in non-tumor tissues. We show that LXR ligands confer chemotherapy resistance in TNBC cell lines and xenografts, and that LXRalpha is necessary and sufficient to mediate this resistance. Furthermore, in TNBC patients who had cancer recurrences, LXRalpha and ligands were independent markers of poor prognosis and correlated with P-glycoprotein expression. However, in patients who survived their disease, LXRalpha signaling and P-glycoprotein were decoupled. These data reveal a novel chemotherapy resistance mechanism in this poor prognosis subtype of breast cancer. We conclude that systemic chemotherapy failure in some TNBC patients is caused by co-opting the LXRalpha:P-glycoprotein axis, a pathway highly targetable by therapies that are already used for prevention and treatment of other diseases.	[Hutchinson, Samantha A.; Websdale, Alex; Cioccoloni, Giorgia; Lianto, Priscilia; Soteriou, Chrysa; Moore, J. Bernadette; Thorne, James L.] Univ Leeds, Sch Food Sci & Nutr, Leeds, W Yorkshire, England; [Hutchinson, Samantha A.] Inst Canc Res, London, England; [Roberg-Larsen, Hanne] Univ Oslo, Dept Chem, Oslo, Norway; [Kim, Baek; Wastall, Laura M.; Williams, Bethany J.] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England; [Rose, Ailsa; Pramanik, Arindam; Hughes, Thomas A.] Univ Leeds, Sch Med, Leeds, W Yorkshire, England; [Henn, Madeline A.; Chen, Joy J.; Ma, Liqian; Nelson, Erik] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL USA; [Nelson, Erik] Univ Illinois, Canc Ctr Illinois, Urbana, IL USA; [Nelson, Erik] Univ Illinois, Div Nutr Sci, Urbana, IL USA; [Nelson, Erik] Univ Illinois, Canc Ctr, Chicago, IL USA; [Nelson, Erik] Univ Illinois, Carl R Woese Inst Genom Biol, Anticanc Discovery Pets People Theme, Urbana, IL USA; [Hughes, Thomas A.; Thorne, James L.] Univ Leeds, Fac Med & Hlth, Leeds Breast Canc Res Grp, Leeds, W Yorkshire, England	University of Leeds; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Oslo; University of Leeds; University of Leeds; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Urbana-Champaign; University of Leeds	Thorne, JL (corresponding author), Univ Leeds, Sch Food Sci & Nutr, Leeds, W Yorkshire, England.; Hughes, TA (corresponding author), Univ Leeds, Sch Med, Leeds, W Yorkshire, England.; Hughes, TA; Thorne, JL (corresponding author), Univ Leeds, Fac Med & Hlth, Leeds Breast Canc Res Grp, Leeds, W Yorkshire, England.	t.hughes@leeds.ac.uk; j.l.thorne@leeds.ac.uk	Pramanik, Arindam/AAD-1192-2019; Hughes, Thomas A/O-8031-2015; Nelson, Erik/B-5158-2013	Pramanik, Arindam/0000-0002-5827-6267; Hughes, Thomas A/0000-0003-1169-3386; Hutchinson, Samantha/0000-0003-4780-2441; Soteriou, Chrysa/0000-0002-2808-1215; Kim, Baek/0000-0001-9759-7533; Nelson, Erik/0000-0002-8887-1905; Moore, J Bernadette/0000-0003-4750-1550; Chen, Joy/0000-0002-3703-4787; Ma, Liqian/0000-0002-0264-9263	Breast Cancer Action [3T57/9R17-02]; Breast Cancer UK [PO-180309]; University of Leeds School of Food Science and Nutrition; British Endocrine Society; National Cancer Institute of the National Institutes of Health [R01CA234025]; School of Food Science and Nutrition; Leeds Doctoral Scholarships	Breast Cancer Action; Breast Cancer UK; University of Leeds School of Food Science and Nutrition; British Endocrine Society; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); School of Food Science and Nutrition; Leeds Doctoral Scholarships	GC was supported by a grant funding from Breast Cancer Action (3T57/9R17-02). The human metabolite data collection and analysis, immunohistochemistry, and antibody validation performed by AW was supported by a grant from Breast Cancer UK (PO-180309) and by the University of Leeds School of Food Science and Nutrition. The British Endocrine Society provided an equipment award (NOV2016) allowing the development of the high throughput chemotherapy efflux assay. SAH, CS, and PL were supported with Leeds Doctoral Scholarships and School of Food Science and Nutrition consumables support. ERN was supported by the National Cancer Institute of the National Institutes of Health (R01CA234025).	Baek AE, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00910-z; Bagegni NA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222358; Bauriaud-Mallet M, 2019, J STEROID BIOCHEM, V192, DOI 10.1016/j.jsbmb.2019.105390; Brennan SF, 2017, CRIT REV FOOD SCI, V57, P1999, DOI 10.1080/10408398.2012.724481; Chlebowski RT, 2006, JNCI-J NATL CANCER I, V98, P1767, DOI 10.1093/jnci/djj494; CLARE K, 1995, ATHEROSCLEROSIS, V118, P67, DOI 10.1016/0021-9150(95)05594-M; Dalenc F, 2017, J STEROID BIOCHEM, V169, P210, DOI 10.1016/j.jsbmb.2016.06.010; Das S, 2013, J BIOL CHEM, V288, P11824, DOI 10.1074/jbc.M112.432302; De Cicco P, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071514; Dias IHK, 2018, REDOX BIOL, V16, P139, DOI 10.1016/j.redox.2018.02.014; dos Santos CR, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-132; Eccles SA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3493; ElAli A, 2012, BRAIN PATHOL, V22, P175, DOI 10.1111/j.1750-3639.2011.00517.x; Garrigues A, 2002, P NATL ACAD SCI USA, V99, P10347, DOI 10.1073/pnas.162366399; Guillemot-Legris O, 2016, SCI REP-UK, V6, DOI 10.1038/srep19694; Hutchinson SA, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112618; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jiang L, 2019, J ONCOL, V2019, DOI 10.1155/2019/7479518; Kim B, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1625-y; Kim BJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0057460, 10.1371/journal.pone.0068422]; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Liu BL, 2017, BREAST CANCER RES TR, V164, P1, DOI 10.1007/s10549-017-4246-0; Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908; Nguyen VTM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10044; Poirot M, 2018, BIOCHEM PHARMACOL, V153, P75, DOI 10.1016/j.bcp.2018.01.046; Saint-Pol J, 2013, BRAIN RES, V1517, P1, DOI 10.1016/j.brainres.2013.04.008; Shahoei SH, 2019, ENDOCRINOLOGY, V160, P1573, DOI 10.1210/en.2019-00025; Sozen E, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8520746; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; Tavazoie MF, 2018, CELL, V172, P825, DOI 10.1016/j.cell.2017.12.026; Thorne JL, 2020, P NUTR SOC, V79, P367, DOI 10.1017/S0029665120000099; Thorne JL, 2018, BBA-GENE REGUL MECH, V1861, P996, DOI 10.1016/j.bbagrm.2018.08.005; Toledo E, 2015, JAMA INTERN MED, V175, P1752, DOI 10.1001/jamainternmed.2015.4838; Wouters E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01811; Wu Q, 2013, CELL REP, V5, P637, DOI 10.1016/j.celrep.2013.10.006; Xia LY, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-01907-7; Yang MY, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8030167	37	13	13	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2872	2883		10.1038/s41388-021-01720-w	http://dx.doi.org/10.1038/s41388-021-01720-w		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742124	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000630675000004
J	Wang, YH; Chan, YT; Hung, TH; Hung, JT; Kuo, MW; Wang, SH; Huang, YL; Lin, YJ; Chen, SC; Yu, JC; Wu, JC; Yu, J; Yu, AL				Wang, Ya-Hui; Chan, Yu-Tzu; Hung, Tsai-Hsien; Hung, Jung-Tung; Kuo, Ming-Wei; Wang, Sheng-Hung; Huang, Yenlin; Lin, Yu-Ju; Chen, Shin-Cheh; Yu, Jyh-Cherng; Wu, Jen-Chine; Yu, John; Yu, Alice L.			Transmembrane and coiled-coil domain family 3 (TMCC3) regulates breast cancer stem cell and AKT activation	ONCOGENE			English	Article								Cancer stem cells (CSC) play a pivotal role in cancer metastasis and resistance to therapy. Previously, we compared the phosphoproteomes of breast cancer stem cells (BCSCs) enriched subpopulation and non-BCSCs sorted from breast cancer patient-derived xenograft (PDX), and identified a function unknown protein, transmembrane and coiled-coil domain family 3 (TMCC3) to be a potential enrichment marker for BCSCs. We demonstrated greater expression of TMCC3 in BCSCs than non-BCSCs and higher expression of TMCC3 in metastatic lymph nodes and lungs than in primary tumor of breast cancer PDXs. TMCC3 silencing suppressed mammosphere formation, ALDH activity and cell migration in vitro, along with reduced tumorigenicity and metastasis in vivo. Mechanistically, we found that AKT activation was reduced by TMCC3 silencing, but enhanced by TMCC3 overexpression. We further demonstrated that TMCC3 interacted directly with AKT through its 1-153 a.a. domain by cell-free biochemical assay in vitro and co-immunoprecipitation and interaction domain mapping assays in vivo. Based on domain truncation studies, we showed that the AKT-interacting domain of TMCC3 was essential for TMCC3-induced AKT activation, self-renewal, and metastasis. Clinically, TMCC3 mRNA expression in 202 breast cancer specimens as determined by qRT-PCR assay showed that higher TMCC3 expression correlated with poorer clinical outcome of breast cancer, including early-stage breast cancer. Multivariable analysis identified TMCC3 expression as an independent risk factor for survival. These findings suggest that TMCC3 is crucial for maintenance of BCSCs features through AKT regulation, and TMCC3 expression has independent prognostic significance in breast cancer. Thus, TMCC3 may serve as a new target for therapy directed against CSCs.	[Wang, Ya-Hui; Chan, Yu-Tzu; Hung, Tsai-Hsien; Hung, Jung-Tung; Kuo, Ming-Wei; Wang, Sheng-Hung; Lin, Yu-Ju; Wu, Jen-Chine; Yu, John; Yu, Alice L.] Chang Gung Mem Hosp Linkou, Inst Stem Cell & Translat Canc Res, Taoyuan, Taiwan; [Huang, Yenlin] Chang Gung Mem Hosp Linkou, Dept Anat Pathol, Taoyuan, Taiwan; [Huang, Yenlin; Yu, John; Yu, Alice L.] Chang Gung Univ, Taoyuan, Taiwan; [Chen, Shin-Cheh] Chang Gung Mem Hosp Linkou, Gen Surg Dept, Taoyuan, Taiwan; [Yu, Jyh-Cherng] Triserv Gen Hosp, Natl Def Med Ctr, Dept Surg, Div Gen Surg, Taipei, Taiwan; [Yu, Alice L.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; National Defense Medical Center; Tri-Service General Hospital; University of California System; University of California San Diego	Yu, J; Yu, AL (corresponding author), Chang Gung Mem Hosp Linkou, Inst Stem Cell & Translat Canc Res, Taoyuan, Taiwan.; Yu, J; Yu, AL (corresponding author), Chang Gung Univ, Taoyuan, Taiwan.; Yu, AL (corresponding author), Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA.	johnyu@gate.sinica.edu.tw; alyu@ucsd.edu		yu, alice/0000-0003-2444-0505; Yu, John/0000-0002-3237-4272; Hung, Jung-Tung/0000-0001-7161-1915	Ministry of Science and Technology in Taiwan [MOST106-3114-B-182A-001, MOST106-2811-B-182A-017, MOST107-2321-B-182A-005, MOST107-2811-B182A-504, MOST108-2321-B-182A-004, MOST 108-2811-B-182A-505, MOST109-2321-B-182A-005, MOST109-2811-B-182A-501]; Taiwan Biosignature for Breast Cancer [BP004]; Chang Gung Medical Foundation [OMRPG3C0011-16, CMRPG3F0973, CMRPG3G1531-1533]; Chang Gung Postdoctoral Fellowship	Ministry of Science and Technology in Taiwan(Ministry of Science and Technology, Taiwan); Taiwan Biosignature for Breast Cancer; Chang Gung Medical Foundation; Chang Gung Postdoctoral Fellowship	This study was supported by grants to ALY from the Ministry of Science and Technology in Taiwan (MOST106-3114-B-182A-001, MOST106-2811-B-182A-017, MOST107-2321-B-182A-005, MOST107-2811-B182A-504, MOST108-2321-B-182A-004, MOST 108-2811-B-182A-505, MOST109-2321-B-182A-005, MOST109-2811-B-182A-501), Taiwan Biosignature for Breast Cancer (BP004), and Chang Gung Medical Foundation (OMRPG3C0011-16). Grant from Chang Gung Medical Foundation (CMRPG3F0973 to JY; CMRPG3G1531-1533 to JTH) and Chang Gung Postdoctoral Fellowship Award to YHW.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ayob AZ, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0426-4; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bose S, 2006, MODERN PATHOL, V19, P238, DOI 10.1038/modpathol.3800525; Bozorgi A, 2015, J BREAST CANCER, V18, P303, DOI 10.4048/jbc.2015.18.4.303; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Chan YT, 2020, INT J CANCER, V146, P1674, DOI 10.1002/ijc.32588; Chang WW, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3423; Chappell WH, 2011, ONCOTARGET, V2, P135, DOI 10.18632/oncotarget.240; Clark DW, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.11.82; Cochrane CR, 2015, CANCERS, V7, P1554, DOI 10.3390/cancers7030851; Croker AK, 2009, J CELL MOL MED, V13, P2236, DOI 10.1111/j.1582-4934.2008.00455.x; Desai A, 2019, STEM CELL TRANSL MED, V8, P75, DOI 10.1002/sctm.18-0123; DESOUSA E, 2016, CANCERS, V8, P60, DOI DOI 10.3390/cancers8070060; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Hopkins PCR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055810; Hopkins PCR, 2011, J ALZHEIMERS DIS, V26, P239, DOI 10.3233/JAD-2011-102115; Hoyer MJ, 2018, CELL, V175, P254, DOI 10.1016/j.cell.2018.08.030; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Jain MV, 2015, CELL CYCLE, V14, P2109, DOI 10.1080/15384101.2015.1041692; Johnston HE, 2018, MOL CELL PROTEOMICS, V17, P776, DOI 10.1074/mcp.RA117.000539; Kahn M, 2018, PROG MOL BIOL TRANSL, V153, P209, DOI 10.1016/bs.pmbts.2017.11.007; Kaltschmidt C, 2019, CANCERS, V11, DOI 10.3390/cancers11050655; Kim LC, 2017, ONCOGENE, V36, P2191, DOI 10.1038/onc.2016.363; Kroon P, 2013, CANCER RES, V73, P5288, DOI 10.1158/0008-5472.CAN-13-0874; Kume H, 2014, MOL CELL PROTEOMICS, V13, P1471, DOI 10.1074/mcp.M113.037093; Kuo MW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004980; Latifi A, 2011, J CELL BIOCHEM, V112, P2850, DOI 10.1002/jcb.23199; Li JL, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-49; Liao Y, 2010, AM J TRANSL RES, V2, P19; Lombardo Y, 2015, JOVE-J VIS EXP, DOI 10.3791/52671; Mahajan K, 2012, J CELL PHYSIOL, V227, P3178, DOI 10.1002/jcp.24065; Matsui WH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004765; Petersen OW, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003160; Prossomariti A, 2020, CELL MOL GASTROENTER, V10, P491, DOI 10.1016/j.jcmgh.2020.04.007; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Saadin K, 2013, EXPERT REV MOL DIAGN, V13, P49, DOI [10.1586/erm.12.117, 10.1586/ERM.12.117]; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shorning BY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124507; Sohn WJ, 2016, BMB REP, V49, P629, DOI 10.5483/BMBRep.2016.49.11.151; Swiatkowski P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01826-w; Vieira AF, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00248; Wang T, 2016, CANCER BIOL THER, V17, P698, DOI 10.1080/15384047.2016.1190488; Wang W, 2019, J CLIN INVEST, V129, P1015, DOI 10.1172/JCI97712; Wang YK, 2010, CARCINOGENESIS, V31, P1376, DOI 10.1093/carcin/bgq120; Wisesa S, 2019, BIOCHEM J, V476, P3241, DOI 10.1042/BCJ20190359; Yap TA, 2015, CURR OPIN PHARMACOL, V23, P98, DOI 10.1016/j.coph.2015.05.016; Yeo HL, 2019, INT J CANCER, V144, P1996, DOI 10.1002/ijc.31891; Yin H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024080; Yudushkin I, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9020067; Zhang C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085206	53	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2858	2871		10.1038/s41388-021-01729-1	http://dx.doi.org/10.1038/s41388-021-01729-1		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742122	hybrid, Green Published			2022-12-28	WOS:000630675000002
J	Ali, MM; Di Marco, M; Mahale, S; Jachimowicz, D; Kosalai, ST; Reischl, S; Statello, L; Mishra, K; Darnfors, C; Kanduri, M; Kanduri, C				Ali, Mohamad Moustafa; Di Marco, Mirco; Mahale, Sagar; Jachimowicz, Daniel; Kosalai, Subazini Thankaswamy; Reischl, Silke; Statello, Luisa; Mishra, Kankadeb; Darnfors, Catarina; Kanduri, Meena; Kanduri, Chandrasekhar			LY6K-AS lncRNA is a lung adenocarcinoma prognostic biomarker and regulator of mitotic progression	ONCOGENE			English	Article							LONG NONCODING RNAS; 14-3-3 PROTEINS; GENE-EXPRESSION; HISTONE CODE; ORGANIZATION; PROTEOLYSIS; MECHANISMS; RESISTANCE; LANDSCAPE; IMPACT	Recent advances in genomics unraveled several actionable mutational drivers in lung cancer, leading to promising therapies such as tyrosine kinase inhibitors and immune checkpoint inhibitors. However, the tumors' acquired resistance to the newly-developed as well as existing therapies restricts life quality improvements. Therefore, we investigated the noncoding portion of the human transcriptome in search of alternative actionable targets. We identified an antisense transcript, LY6K-AS, with elevated expression in lung adenocarcinoma (LUAD) patients, and its higher expression in LUAD patients predicts poor survival outcomes. LY6K-AS abrogation interfered with the mitotic progression of lung cancer cells resulting in unfaithful chromosomal segregation. LY6K-AS interacts with and stabilizes 14-3-3 proteins to regulate the transcription of kinetochore and mitotic checkpoint proteins. We also show that LY6K-AS regulates the levels of histone H3 lysine 4 trimethylation (H3K4me3) at the promoters of kinetochore members. Cisplatin treatment and LY6K-AS silencing affect many common pathways enriched in cell cycle-related functions. LY6K-AS silencing affects the growth of xenografts derived from wildtype and cisplatin-resistant lung cancer cells. Collectively, these data indicate that LY6K-AS silencing is a promising therapeutic option for LUAD that inhibits oncogenic mitotic progression.	[Ali, Mohamad Moustafa; Di Marco, Mirco; Mahale, Sagar; Jachimowicz, Daniel; Kosalai, Subazini Thankaswamy; Reischl, Silke; Statello, Luisa; Mishra, Kankadeb; Kanduri, Chandrasekhar] Univ Gothenburg, Inst Biomed, Dept Med Biochem & Cell Biol, Gothenburg, Sweden; [Darnfors, Catarina] Sahlgrens Univ Hosp, Dept Clin Pathol & Genet, Gothenburg, Sweden; [Kanduri, Meena] Sahlgrens Univ Hosp, Dept Clin Chem & Transfus Med, Gothenburg, Sweden	University of Gothenburg; Sahlgrenska University Hospital; Sahlgrenska University Hospital	Kanduri, C (corresponding author), Univ Gothenburg, Inst Biomed, Dept Med Biochem & Cell Biol, Gothenburg, Sweden.	kanduri.chandrasekhar@gu.se	Statello, Luisa/AAU-5115-2021; Ali, Mohamad Moustafa/ABF-5464-2020	Statello, Luisa/0000-0001-8261-4214; Ali, Mohamad Moustafa/0000-0002-4902-0550; Di Marco, Amerigo Mirco/0000-0001-8890-233X; Reischl, Silke/0000-0003-4822-4137; Kanduri, Chandrasekhar/0000-0001-6271-9078	Knut and Alice Wallenberg Foundation [KAW2014.0057]; Swedish Foundation for Strategic Research [RB13-0204]; Swedish Cancer Research foundation [Cancerfonden] [CAN2018/591]; Swedish Research Council [2017-02834]; Barncancerfonden [PR2018-0090]; Ingabritt Och Arne Lundbergs forskningsstiftelse; LUA/ ALF	Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Cancer Research foundation [Cancerfonden](Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Barncancerfonden; Ingabritt Och Arne Lundbergs forskningsstiftelse; LUA/ ALF	This work was supported by the grants from Knut and Alice Wallenberg Foundation [KAW2014.0057]; Swedish Foundation for Strategic Research [RB13-0204]; Swedish Cancer Research foundation [Cancerfonden: Kontrakt no. CAN2018/591]; Swedish Research Council [2017-02834]; Barncancerfonden [PR2018-0090]; Ingabritt Och Arne Lundbergs forskningsstiftelse and LUA/ ALF (to CK). The Proteomics Core Facility at Gothenburg University, performed the analysis for protein identification. We acknowledge the Centre for Cellular Imaging at the University of Gothenburg for assisting in microscopy.	Akhade VS, 2017, ADV EXP MED BIOL, V1008, P47, DOI 10.1007/978-981-10-5203-3_2; Ali M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04082-2; Balbin OA, 2015, GENOME RES, V25, P1068, DOI 10.1101/gr.180596.114; Bose A, 2019, J BIOSCIENCES, V44, DOI 10.1007/s12038-019-9867-5; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen DY, 2015, INT J ONCOL, V46, P818, DOI 10.3892/ijo.2014.2740; de Groot PM, 2018, TRANSL LUNG CANCER R, V7, P220, DOI 10.21037/tlcr.2018.05.06; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dominguez-Brauer C, 2015, MOL CELL, V60, P524, DOI 10.1016/j.molcel.2015.11.006; Galluzzi L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.428; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gardino AK, 2011, SEMIN CELL DEV BIOL, V22, P688, DOI 10.1016/j.semcdb.2011.09.008; Gavet O, 2010, DEV CELL, V18, P533, DOI 10.1016/j.devcel.2010.02.013; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Holland AJ, 2012, EMBO REP, V13, P501, DOI 10.1038/embor.2012.55; Hosing AS, 2008, CELL CYCLE, V7, P3171, DOI 10.4161/cc.7.20.6812; Isaka T, 2003, J HISTOCHEM CYTOCHEM, V51, P1343, DOI 10.1177/002215540305101011; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Kasahara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2879; Kasahara K, 2010, EMBO J, V29, P2802, DOI 10.1038/emboj.2010.157; Kornienko AE, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0873-8; Lara-Gonzalez P, 2019, DEV CELL, V51, P313, DOI 10.1016/j.devcel.2019.09.005; Lassmann T, 2011, BIOINFORMATICS, V27, P130, DOI 10.1093/bioinformatics/btq614; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Lischetti T, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.970484; MacDonald N, 2005, MOL CELL, V20, P199, DOI 10.1016/j.molcel.2005.08.032; Mahale S, 2016, SCI REP-UK, V6, DOI 10.1038/s41598-016-0030-3; Marchese FP, 2016, MOL CELL, V63, P397, DOI 10.1016/j.molcel.2016.06.031; Montes M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7967; NISHIMURA K, 2019, NAT COMMUN, V10; Nowicki TS, 2018, CANCER J, V24, P47, DOI 10.1097/PPO.0000000000000303; Ohhata T, 2011, GENE DEV, V25, P1702, DOI 10.1101/gad.16997911; Ooi AT, 2014, CANCER PREV RES, V7, P487, DOI 10.1158/1940-6207.CAPR-13-0372; Pandey GK, 2014, CANCER CELL, V26, P722, DOI 10.1016/j.ccell.2014.09.014; Pandey RR, 2008, MOL CELL, V32, P232, DOI 10.1016/j.molcel.2008.08.022; Qi WQ, 2005, INT J CANCER, V113, P359, DOI 10.1002/ijc.20492; Raungrut P, 2014, ASIAN PAC J CANCER P, V15, P3513, DOI 10.7314/APJCP.2014.15.8.3513; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roeten MSF, 2018, CANCER CHEMOTH PHARM, V81, P227, DOI 10.1007/s00280-017-3489-0; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Siemeister G, 2019, CLIN CANCER RES, V25, P1404, DOI 10.1158/1078-0432.CCR-18-0628; Subhash S, 2018, NUCLEIC ACIDS RES, V46, P9384, DOI 10.1093/nar/gky635; Subhash S, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1250-z; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Uetake Y, 2010, CURR BIOL, V20, P1666, DOI 10.1016/j.cub.2010.08.018; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Vedadi M, 2017, PROTEIN SCI, V26, P662, DOI 10.1002/pro.3129; White NM, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0429-8; Winter S, 2008, EMBO J, V27, P88, DOI 10.1038/sj.emboj.7601954; Wu H, 2017, TRENDS GENET, V33, P540, DOI 10.1016/j.tig.2017.05.004; Wu SG, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0777-1; Zippo A, 2009, CELL, V138, P1122, DOI 10.1016/j.cell.2009.07.031	57	5	5	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2463	2478		10.1038/s41388-021-01696-7	http://dx.doi.org/10.1038/s41388-021-01696-7		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33674747				2022-12-28	WOS:000625607100003
J	Feng, MX; Wang, YS; Bi, L; Zhang, PJ; Wang, HZ; Zhao, ZX; Mao, JH; Wei, GW				Feng, Maoxiao; Wang, Yunshan; Bi, Lei; Zhang, Pengju; Wang, Huaizhi; Zhao, Zhongxi; Mao, Jian-Hua; Wei, Guangwei			CRL4A(DTL) degrades DNA-PKcs to modulate NHEJ repair and induce genomic instability and subsequent malignant transformation	ONCOGENE			English	Article								Genomic instability induced by DNA damage and improper DNA damage repair is one of the main causes of malignant transformation and tumorigenesis. DNA double strand breaks (DSBs) are the most detrimental form of DNA damage, and nonhomologous end-joining (NHEJ) mechanisms play dominant and priority roles in initiating DSB repair. A well-studied oncogene, the ubiquitin ligase Cullin 4A (CUL4A), is reported to be recruited to DSB sites in genomic DNA, but whether it regulates NHEJ mechanisms of DSB repair is unclear. Here, we discovered that the CUL4A-DTL ligase complex targeted the DNA-PKcs protein in the NHEJ repair pathway for nuclear degradation. Overexpression of either CUL4A or DTL reduced NHEJ repair efficiency and subsequently increased the accumulation of DSBs. Moreover, we demonstrated that overexpression of either CUL4A or DTL in normal cells led to genomic instability and malignant proliferation. Consistent with the in vitro findings, in human precancerous lesions, CUL4A expression gradually increased with increasing malignant tendency and was negatively correlated with DNA-PKcs and positively correlated with gamma-H2AX expression. Collectively, this study provided strong evidence that the CUL4A-DTL axis increases genomic instability and enhances the subsequent malignant transformation of normal cells by inhibiting NHEJ repair. These results also suggested that CUL4A may be a prognostic marker of precancerous lesions and a potential therapeutic target in cancer.	[Feng, Maoxiao; Wei, Guangwei] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ,Dept Cell Biol, Jinan, Shandong, Peoples R China; [Wang, Yunshan] Cheeloo Coll Med, Hosp 2, Dept Clin Lab, Jinan, Shandong, Peoples R China; [Wang, Yunshan; Bi, Lei; Zhang, Pengju; Mao, Jian-Hua] Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA 94720 USA; [Bi, Lei] Nanjing Univ Chinese Med, Sch Preclin Med, Nanjing, Jiangsu, Peoples R China; [Zhang, Pengju] Shandong Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Expt Teratol,Minist Educ, Jinan, Shandong, Peoples R China; [Wang, Huaizhi] Univ Chinese Acad Sci, Chongqing Gen Hosp, Inst Hepatopancreatobiliary Surg, Chongqing, Peoples R China; [Zhao, Zhongxi] Shandong Univ, Sch Pharmaceut Sci, Jinan, Shandong, Peoples R China	Shandong University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Nanjing University of Chinese Medicine; Shandong University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Shandong University	Wei, GW (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ,Dept Cell Biol, Jinan, Shandong, Peoples R China.; Mao, JH (corresponding author), Lawrence Berkeley Natl Lab, Biol Syst & Engn Div, Berkeley, CA 94720 USA.	jhmao@lbl.gov; gwwei@email.sdu.edu.cn	Mao, Jian-Hua/EIZ-8595-2022	Mao, Jian-Hua/0000-0001-9320-6021; wang, yunshan/0000-0003-4873-054X	National Key R&D Program of China [2017YFC1308600]; National Natural Science Foundation of China [81872148, 81874040]; Natural Science Foundation of Shandong Province [ZR2019MH002]; Key Research and Development Projects in of Shandong Province [2019GSF108218]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Key Research and Development Projects in of Shandong Province	This work was supported by the National Key R&D Program of China (No.2017YFC1308600), National Natural Science Foundation of China (81872148, 81874040), Natural Science Foundation of Shandong Province (ZR2019MH002), and Key Research and Development Projects in of Shandong Province (2019GSF108218).	Abbas T, 2008, GENE DEV, V22, P2496, DOI 10.1101/gad.1676108; Abbas T, 2013, MOL CELL, V49, P1147, DOI 10.1016/j.molcel.2013.02.003; Abbas T, 2011, CELL CYCLE, V10, P241, DOI 10.4161/cc.10.2.14530; Abbas T, 2010, MOL CELL, V40, P9, DOI 10.1016/j.molcel.2010.09.014; Allen C, 2003, MOL CANCER RES, V1, P913; Arnoult N, 2017, NATURE, V549, P548, DOI 10.1038/nature24023; Baranes-Bachar K, 2018, MOL CELL, V69, P866, DOI 10.1016/j.molcel.2018.02.002; Batenburg NL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02114-x; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Beskow C, 2009, BRIT J CANCER, V101, P816, DOI 10.1038/sj.bjc.6605201; Bolzan AD, 2018, MUTAT RES-REV MUTAT, V775, P51, DOI 10.1016/j.mrrev.2018.02.003; Bondar T, 2006, MOL CELL BIOL, V26, P2531, DOI 10.1128/MCB.26.7.2531-2539.2006; Chang HHY, 2017, NAT REV MOL CELL BIO, V18, P495, DOI 10.1038/nrm.2017.48; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Davis AJ, 2014, NUCLEIC ACIDS RES, V42, P11487, DOI 10.1093/nar/gku824; Espejel S, 2004, J CELL BIOL, V167, P627, DOI 10.1083/jcb.200407178; Goodwin JF, 2015, CANCER CELL, V28, P97, DOI 10.1016/j.ccell.2015.06.004; Gupta A, 2002, INT J RADIAT ONCOL, V52, P822, DOI 10.1016/S0360-3016(01)02739-0; Hall JR, 2014, CELL CYCLE, V13, P3602, DOI 10.4161/15384101.2014.962957; Han CH, 2015, CELL CYCLE, V14, P1103, DOI 10.4161/15384101.2014.973740; Han JH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01759-y; Han JH, 2013, CELL, V155, P817, DOI 10.1016/j.cell.2013.10.014; Hannah J, 2009, DNA REPAIR, V8, P536, DOI 10.1016/j.dnarep.2009.01.011; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Higa LA, 2006, CELL CYCLE, V5, P1675, DOI 10.4161/cc.5.15.3149; Ihara M, 2019, J RADIAT RES, V60, P171, DOI 10.1093/jrr/rry097; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; Kais Z, 2016, CELL REP, V15, P2488, DOI 10.1016/j.celrep.2016.05.031; Kim HB, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-46; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; Lee J, 2007, MOL CELL, V26, P775, DOI 10.1016/j.molcel.2007.06.001; Lee J, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00021; Leung-Pineda V, 2009, CANCER RES, V69, P2630, DOI 10.1158/0008-5472.CAN-08-3382; Li BH, 2006, BLOOD, V107, P4291, DOI 10.1182/blood-2005-08-3349; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Liu JF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4830; Liu LR, 2009, MOL CELL, V34, P451, DOI 10.1016/j.molcel.2009.04.020; Liu XS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9325; Lu HM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02146-3; Meir M, 2015, NUCLEIC ACIDS RES, V43, P4517, DOI 10.1093/nar/gkv270; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Mohiuddin IS, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00635; Moon JJ, 2019, EXP BIOL MED, V244, P227, DOI 10.1177/1535370219826031; Nishitani H, 2008, J BIOL CHEM, V283, P29045, DOI 10.1074/jbc.M806045200; Oda H, 2010, MOL CELL, V40, P364, DOI 10.1016/j.molcel.2010.10.011; Pastwa E, 2003, ACTA BIOCHIM POL, V50, P891; Pyun BJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.43; Rao F, 2014, MOL CELL, V54, P119, DOI 10.1016/j.molcel.2014.02.020; Reichermeier KM, 2020, MOL CELL, V77, P1092, DOI 10.1016/j.molcel.2019.12.013; Ren SC, 2012, J MOL MED, V90, P1121, DOI 10.1007/s00109-012-0885-0; Scherer PC, 2016, P NATL ACAD SCI USA, V113, P3503, DOI 10.1073/pnas.1525580113; Serrano MA, 2013, ONCOGENE, V32, P2452, DOI 10.1038/onc.2012.257; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Sibanda BL, 2017, SCIENCE, V355, P520, DOI 10.1126/science.aak9654; Simsek D, 2010, NAT STRUCT MOL BIOL, V17, P410, DOI 10.1038/nsmb.1773; Srinivasan G, 2019, P NATL ACAD SCI USA, V116, P17438, DOI 10.1073/pnas.1903150116; Surucu B, 2008, J BIOL CHEM, V283, P30025, DOI 10.1074/jbc.M803053200; Wang YS, 2014, CANCER RES, V74, P520, DOI 10.1158/0008-5472.CAN-13-2182; Waning DL, 2008, BLOOD, V112, P320, DOI 10.1182/blood-2007-11-126300; Yang YF, 2016, MOL CELL, V62, P507, DOI 10.1016/j.molcel.2016.04.014; Zeng M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11364; Zhang Q, 2016, MOL CELL, V61, P419, DOI 10.1016/j.molcel.2015.12.010; Zhou Y, 2017, MOL CELL, V65, P91, DOI 10.1016/j.molcel.2016.11.004	64	4	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2096	2111		10.1038/s41388-021-01690-z	http://dx.doi.org/10.1038/s41388-021-01690-z		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33627782	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000621289100001
J	Xing, YF; Chen, L; Gu, HF; Yang, CL; Zhao, J; Chen, ZH; Xiong, M; Kazobinka, G; Liu, YQ; Hou, T				Xing, Yifei; Chen, Liang; Gu, Haifeng; Yang, Chenlu; Zhao, Jun; Chen, Zhaohui; Xiong, Ming; Kazobinka, Gallina; Liu, Yaqiong; Hou, Teng			Downregulation of NUDT21 contributes to cervical cancer progression through alternative polyadenylation	ONCOGENE			English	Article								Nudix Hydrolase 21 (NUDT21), an alternative polyadenylation (APA)-regulatory protein, exhibits tumor-suppressive effects. However, its role in cervical cancer (CxCa) remains unknown. In the present study, we found that NUDT21 expression was reduced in CxCa tissues and cells, and NUDT21 levels were highly associated with the clinical prognosis of patients with CxCa. Knockdown of NUDT21 promoted CxCa cell proliferation, migration, and invasion in vitro, as well as tumorigenesis and lung metastasis in vivo. Overexpression of NUDT21 produces the opposite effects. Moreover, we performed polyadenylation site sequencing (PAS-Seq) and identified 457 transcripts with lengthened 3 ' untranslated regions (3 ' UTRs) upon NUDT21 overexpression. In particular, NUDT21 modulated the expression of several genes involved in fatty acid metabolism and the Wnt and NF-kappa B signaling pathways in CxCa development. Taken together, our study demonstrated that the APA regulatory effect of NUDT21 is an important mechanism for CxCa suppression.	[Xing, Yifei; Chen, Liang; Zhao, Jun; Chen, Zhaohui; Xiong, Ming; Kazobinka, Gallina; Hou, Teng] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Urol, Wuhan 430022, Peoples R China; [Gu, Haifeng; Hou, Teng] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Yang, Chenlu] Women & Children Hosp Guangdong Prov, Dept Gynecol & Obstet, Guangzhou 510080, Guangdong, Peoples R China; [Kazobinka, Gallina] La Nouvelle Polyclin Cent Bujumbura, Urol Unit, Bujumbura 378, Burundi; [Liu, Yaqiong] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Dept Gynecol & Obstet, Guangzhou 510000, Guangdong, Peoples R China	Huazhong University of Science & Technology; State Key Lab Oncology South China; Sun Yat Sen University; Guangzhou Medical University	Hou, T (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Urol, Wuhan 430022, Peoples R China.; Hou, T (corresponding author), Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China.; Liu, YQ (corresponding author), Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Dept Gynecol & Obstet, Guangzhou 510000, Guangdong, Peoples R China.	lyqgynecol@126.com; h1aiyan@hust.edu.cn		Hou, Teng/0000-0002-2267-0078	National Natural Science Foundation of China [81772714, 81402303]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The study was supported by the National Natural Science Foundation of China (Grant no. 81772714; 81402303).	Abadi MHJN, 2019, CANCER LETT, V459, P112, DOI 10.1016/j.canlet.2019.114430; Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Brumbaugh J, 2018, CELL, V172, P106, DOI 10.1016/j.cell.2017.11.023; Chu Y, 2019, ONCOGENE, V38, P4154, DOI 10.1038/s41388-019-0714-9; Creemers EE, 2016, CIRC RES, V118, P433, DOI 10.1161/CIRCRESAHA.115.307082; Elit LM, 2014, EXPERT REV ANTICANC, V14, P319, DOI 10.1586/14737140.2014.866041; Erson-Bensan AE, 2016, J MOL ENDOCRINOL, V57, pF29, DOI 10.1530/JME-16-0070; Friedlander M, 2002, ONCOLOGIST, V7, P342; Gruber AJ, 2019, NAT REV GENET, V20, P599, DOI 10.1038/s41576-019-0145-z; Husseinzadeh N, 2014, GYNECOL ONCOL, V135, P359, DOI 10.1016/j.ygyno.2014.08.013; Jin JB, 2018, MOL CELL ENDOCRINOL, V461, P155, DOI 10.1016/j.mce.2017.09.005; Katoh M, 2007, INT J MOL MED, V19, P699; Lareau LF, 2004, CURR OPIN STRUC BIOL, V14, P273, DOI 10.1016/j.sbi.2004.05.002; Li SS, 2019, LAB INVEST, V99, P1321, DOI 10.1038/s41374-019-0252-7; Li XJ, 2020, ONCOGENE, V39, P891, DOI 10.1038/s41388-019-1030-0; Lou JC, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00420; Ma LY, 2014, P NATL ACAD SCI USA, V111, P9, DOI 10.1073/pnas.1321025111; Martinez FJ, 2016, NEURON, V92, P780, DOI 10.1016/j.neuron.2016.09.050; Martinez-Reyes I, 2018, GENE DEV, V32, P463, DOI 10.1101/gad.315168.118; Masamha CP, 2018, CARCINOGENESIS, V39, P2, DOI 10.1093/carcin/bgx096; Masamha CP, 2014, NATURE, V510, P412, DOI 10.1038/nature13261; Morale MG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21416-8; Naga CHP, 2018, CURR OPIN ONCOL, V30, P323, DOI 10.1097/CCO.0000000000000471; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012; Pu Y, 2014, HUM IMMUNOL, V75, P740, DOI 10.1016/j.humimm.2014.05.004; Shang CL, 2018, CANCER RES, V78, P877, DOI 10.1158/0008-5472.CAN-17-2356; Singh AK, 2019, FASEB J, V33, P2526, DOI 10.1096/fj.201801513R; Song ZW, 2016, MED SCI MONITOR, V22, P4475, DOI 10.12659/MSM.898569; Sun M, 2017, CANCER LETT, V410, P158, DOI 10.1016/j.canlet.2017.09.026; Wang W, 2019, INT J CANCER, V144, P1345, DOI 10.1002/ijc.31757; Weng TT, 2019, J CLIN INVEST, V129, P1984, DOI 10.1172/JCI122106; Wu XH, 2011, P NATL ACAD SCI USA, V108, P12533, DOI 10.1073/pnas.1019732108; Yang Q, 2010, P NATL ACAD SCI USA, V107, P10062, DOI 10.1073/pnas.1000848107; Zhang L, 2018, CANCER MANAG RES, V10, P4311, DOI 10.2147/CMAR.S173496	34	7	8	3	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2051	2064		10.1038/s41388-021-01693-w	http://dx.doi.org/10.1038/s41388-021-01693-w		FEB 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33619322				2022-12-28	WOS:000620414400001
J	Guo, ZY; Dai, YC; Hu, WT; Zhang, YS; Cao, ZF; Pei, WW; Liu, NG; Nie, J; Wu, AQ; Mao, WD; Chang, L; Li, BY; Pei, HL; Hei, TK; Zhou, GM				Guo, Ziyang; Dai, Yingchu; Hu, Wentao; Zhang, Yongsheng; Cao, Zhifei; Pei, Weiwei; Liu, Ningang; Nie, Jing; Wu, Anqing; Mao, Weidong; Chang, Lei; Li, Bingyan; Pei, Hailong; Hei, Tom K.; Zhou, Guangming			The long noncoding RNA CRYBG3 induces aneuploidy by interfering with spindle assembly checkpoint via direct binding with Bub3	ONCOGENE			English	Article								Aneuploidy is a hallmark of genomic instability that leads to tumor initiation, progression, and metastasis. CDC20, Bub1, and Bub3 form the mitosis checkpoint complex (MCC) that binds the anaphase-promoting complex or cyclosome (APC/C), a crucial factor of the spindle assembly checkpoint (SAC), to ensure the bi-directional attachment and proper segregation of all sister chromosomes. However, just how MCC is regulated to ensure normal mitosis during cellular division remains unclear. In the present study, we demonstrated that LNC CRYBG3, an ionizing radiation-inducible long noncoding RNA, directly binds with Bub3 and interrupts its interaction with CDC20 to result in aneuploidy. The 261-317 (S3) residual of the LNC CRYBG3 sequence is critical for its interaction with Bub3 protein. Overexpression of LNC CRYBG3 leads to aneuploidy and promotes tumorigenesis and metastasis of lung cancer cells, implying that LNC CRYBG3 is a novel oncogene. These findings provide a novel mechanistic basis for the pathogenesis of NSCLC after exposure to ionizing radiation as well as a potential target for the diagnosis, treatment, and prognosis of an often fatal disease.	[Guo, Ziyang; Dai, Yingchu; Hu, Wentao; Pei, Weiwei; Liu, Ningang; Nie, Jing; Wu, Anqing; Chang, Lei; Li, Bingyan; Pei, Hailong; Zhou, Guangming] Soochow Univ, State Key Lab Radiat Med & Protect, Collaborat Innovat Ctr Radiol Med Jiangsu Higher, Sch Radiat Med & Protect,Inst Space Life Sci,Med, Suzhou 215123, Peoples R China; [Guo, Ziyang; Hei, Tom K.] Columbia Univ, Ctr Radiol Res, Coll Phys & Surg, Med Ctr, New York, NY 10027 USA; [Zhang, Yongsheng; Cao, Zhifei; Mao, Weidong] Soochow Univ, Med Coll, Affiliated Hosp 2, Dept Pathol, Suzhou 215123, Peoples R China	Soochow University - China; Columbia University; Soochow University - China	Pei, HL; Zhou, GM (corresponding author), Soochow Univ, State Key Lab Radiat Med & Protect, Collaborat Innovat Ctr Radiol Med Jiangsu Higher, Sch Radiat Med & Protect,Inst Space Life Sci,Med, Suzhou 215123, Peoples R China.; Hei, TK (corresponding author), Columbia Univ, Ctr Radiol Res, Coll Phys & Surg, Med Ctr, New York, NY 10027 USA.	hlpei@suda.edu.cn; tkh1@cumc.columbia.edu; gmzhou@suda.edu.cn	li, bing/GWQ-9617-2022; Liu, Ning-Ang/GLN-4757-2022		China National Natural Science Foundation [82073480, 81773463, 81872622]; National Key R&D Program of China [2018YFC0115704]; US National Institutes of Health [R01-ES 011804-10]	China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the China National Natural Science Foundation awards (Nos. 82073480, 81773463, 81872622), National Key R&D Program of China (No. 2018YFC0115704), and the US National Institutes of Health grant R01-ES 011804-10.	Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen HY, 2018, J CANCER, V9, P2580, DOI 10.7150/jca.24896; Collin P, 2013, NAT CELL BIOL, V15, P1378, DOI 10.1038/ncb2855; Duan Z, 2007, MOL CELL BIOL, V27, P6889, DOI 10.1128/MCB.00762-07; Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Grabsch H, 2003, J PATHOL, V200, P16, DOI 10.1002/path.1324; Guo ZY, 2019, CHEM BIOL DRUG DES, V93, P874, DOI 10.1111/cbdd.13477; Gurley Kay E, 2015, Cold Spring Harb Protoc, V2015, DOI 10.1101/pdb.prot077446; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Herzog F, 2009, SCIENCE, V323, P1477, DOI 10.1126/science.1163300; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hu WT, 2014, RNA BIOL, V11, P1189, DOI 10.4161/rna.34345; Hu WTY, 2014, J RADIAT RES, V55, P10, DOI 10.1093/jrr/rrt078; Kato T, 2012, J SURG ONCOL, V106, P423, DOI 10.1002/jso.23109; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Lischetti T, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.970484; Logarinho E, 2008, MOL BIOL CELL, V19, P1798, DOI 10.1091/mbc.E07-07-0633; Ma MZ, 2016, CANCER RES, V76, P5361, DOI 10.1158/0008-5472.CAN-15-3047; MANCHESTER KL, 1995, TRENDS CELL BIOL, V5, P384, DOI 10.1016/S0962-8924(00)89080-7; McWhorter JE, 1929, ANN SURG, V90, P1, DOI 10.1097/00000658-192907000-00001; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nagano T, 2011, CELL, V145, P178, DOI 10.1016/j.cell.2011.03.014; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Overlack K, 2017, CURR BIOL, V27, P2915, DOI 10.1016/j.cub.2017.08.033; Park YH, 2015, TOXICOL APPL PHARM, V287, P240, DOI 10.1016/j.taap.2015.06.008; Pei HL, 2018, CANCER RES, V78, P4563, DOI 10.1158/0008-5472.CAN-18-0988; Pei HL, 2018, CELL CYCLE, V17, P1115, DOI 10.1080/15384101.2018.1480217; Pei HL, 2017, CELL CYCLE, V16, P113, DOI 10.1080/15384101.2016.1259039; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Rasnick D, 1999, BIOCHEM J, V340, P621, DOI 10.1042/0264-6021:3400621; Ricke RM, 2008, TRENDS GENET, V24, P457, DOI 10.1016/j.tig.2008.07.002; Rodrigues CFD, 2009, MUTAT RES-FUND MOL M, V670, P42, DOI 10.1016/j.mrfmmm.2009.07.004; Senger DR, 2002, AM J PATHOL, V160, P195, DOI 10.1016/S0002-9440(10)64363-5; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Sun M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.256; Sun M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-68; Tsai MC, 2011, CANCER RES, V71, P3, DOI 10.1158/0008-5472.CAN-10-2483; Wang Y, 2013, CANCER RES, V73, P4801, DOI 10.1158/0008-5472.CAN-12-3273; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; White NM, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-3498; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zhang EB, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1523-0; Zhiwei W, 2013, CURR PHARM DESIGN, V19; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	51	10	10	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1821	1835		10.1038/s41388-020-01601-8	http://dx.doi.org/10.1038/s41388-020-01601-8		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564066	hybrid, Green Published			2022-12-28	WOS:000616489100004
J	Kang, W; Zhang, JL; Huang, TT; Zhou, YH; Wong, CC; Chan, RCK; Dong, YJ; Wu, F; Zhang, B; Wu, WKK; Chan, MWY; Cheng, ASL; Yu, J; Wong, N; Lo, KW; To, KF				Kang, Wei; Zhang, Jinglin; Huang, Tingting; Zhou, Yuhang; Wong, Chi Chun; Chan, Ronald C. K.; Dong, Yujuan; Wu, Feng; Zhang, Bin; Wu, William K. K.; Chan, Michael W. Y.; Cheng, Alfred S. L.; Yu, Jun; Wong, Nathalie; Lo, Kwok Wai; To, Ka Fai			NOTCH3, a crucial target of miR-491-5p/miR-875-5p, promotes gastric carcinogenesis by upregulating PHLDB2 expression and activating Akt pathway	ONCOGENE			English	Article							GAMMA SECRETASE INHIBITOR; SIGNALING PATHWAY; MICRORNA EXPRESSION; PHASE-II; CANCER; RO4929097; GROWTH; TUMORIGENESIS; ONCOGENE; INVASION	Aberrant Notch activation has been implicated in multiple malignancies and the identification of NOTCH receptors and related pathways is critical for targeted therapy. In this study, we aim to delineate the most prominent dysregulated NOTCH receptor and comprehensively reveal its deregulation in gastric cancer (GC). In the four Notch members, NOTCH3 was found uniformly upregulated and associated with poor clinical outcomes in multiple GC datasets. siRNA-mediated NOTCH3 knockdown demonstrated antitumor effects by suppressing cell proliferation, inhibiting monolayer formation, and impairing cell invasion abilities. Its depletion also induced early and late apoptosis. NOTCH3 was confirmed to be a direct target of two tumor suppressor microRNAs (miRNAs), namely miR-491-5p and miR-875-5p. The activation of NOTCH3 is partly due to the silence of these two miRNAs. Through RNA-seq profiling and functional validation, PHLDB2 was identified as a potent functional downstream modulator for NOTCH3 in gastric carcinogenesis. PHLDB2 expression demonstrated a positive correlation with NOTCH3, but was negatively correlated with miR-491-5p. Akt-mTOR was revealed as the downstream signaling of PHLDB2. The NOTCH3-PHLDB2-Akt co-activation was found in 33.7% GC patients and the activation of this axis predicted poor clinical outcome. GC cells treated with siNOTCH3, siPHLDB2, miR-491-5p, miR-875-5p, were more sensitive to Cisplatin and 5-FU. Taken together, the NOTCH3-PHLDB2-Akt cascade plays oncogenic role in gastric carcinogenesis and serves as a therapeutic target. Our study provided insights into Notch-mediated underlying molecular mechanisms and implied translational potential.	[Kang, Wei; Zhang, Jinglin; Huang, Tingting; Zhou, Yuhang; Chan, Ronald C. K.; Wu, Feng; Wong, Nathalie; Lo, Kwok Wai; To, Ka Fai] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Translat Oncol, Hong Kong, Peoples R China; [Kang, Wei; Zhang, Jinglin; Huang, Tingting; Zhou, Yuhang; Wong, Chi Chun; Dong, Yujuan; Yu, Jun; To, Ka Fai] Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China; [Kang, Wei; Zhang, Jinglin; Huang, Tingting; Zhou, Yuhang; Wong, Nathalie; Lo, Kwok Wai; To, Ka Fai] Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Zhang, Bin] Nanjing Univ, Med Sch, Dept Gastroenterol, Affiliated Drum Tower Hosp, Nanjing, Peoples R China; [Wu, William K. K.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Peoples R China; [Chan, Michael W. Y.] Natl Chung Cheng Univ, Dept Life Sci, Chiayi, Taiwan; [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Nanjing University; Chinese University of Hong Kong; National Chung Cheng University; Chinese University of Hong Kong; Chinese University of Hong Kong	Kang, W (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Translat Oncol, Hong Kong, Peoples R China.; Kang, W (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China.; Kang, W (corresponding author), Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.	weikang@cuhk.edu.hk	wu, william/HII-5817-2022; Wu, William K.K./A-3277-2009; huang, ting/GRR-3141-2022; KANG, Wei/C-5451-2016; Dong, Yujuan/AAS-3467-2021	Wu, William K.K./0000-0002-5662-5240; KANG, Wei/0000-0002-4651-677X; Wong, Chi Chun/0000-0003-1362-3541	Research Grants Council of the Hong Kong Special Administrative Region, China [CUHK 14100019, 14118518]; CUHK Direct Grant for Research from The Chinese University of Hong Kong [2019.001]	Research Grants Council of the Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council); CUHK Direct Grant for Research from The Chinese University of Hong Kong	The manuscript is under support of Research Grants Council of the Hong Kong Special Administrative Region, China [Project No.: CUHK 14100019 and 14118518 (for GRF projects)], and CUHK Direct Grant for Research (2019.001) from The Chinese University of Hong Kong.	Andersson ER, 2014, NAT REV DRUG DISCOV, V13, P359, DOI 10.1038/nrd4252; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bauer L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044566; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Capaccione KM, 2013, CARCINOGENESIS, V34, P1420, DOI 10.1093/carcin/bgt127; Chen G, 2017, BIOCHEM BIOPH RES CO, V487, P90, DOI 10.1016/j.bbrc.2017.04.023; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Jesus-Acosta A, 2014, INVEST NEW DRUG, V32, P739, DOI 10.1007/s10637-014-0083-8; Denoyelle C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.389; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fernandez-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Gong FC, 2016, AM J TRANSL RES, V8, P485; Guo LY, 2012, WORLD J GASTROENTERO, V18, P7262, DOI 10.3748/wjg.v18.i48.7262; He PY, 2017, ONCOL REP, V38, P3554, DOI 10.3892/or.2017.6037; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Hsu KW, 2012, CARCINOGENESIS, V33, P1459, DOI 10.1093/carcin/bgs165; Huang TT, 2015, ONCOTARGET, V6, P18012, DOI 10.18632/oncotarget.4000; Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006; Ji DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085116; Kang H, 2012, HISTOPATHOLOGY, V61, P576, DOI 10.1111/j.1365-2559.2012.04274.x; Kang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033919; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Kim SJ, 2016, ONCOGENE, V35, P251, DOI 10.1038/onc.2015.80; Kimura K, 2007, CANCER SCI, V98, P155, DOI 10.1111/j.1349-7006.2006.00369.x; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359; Liu LZ, 2007, CANCER RES, V67, P6325, DOI 10.1158/0008-5472.CAN-06-4261; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Luistro L, 2009, CANCER RES, V69, P7672, DOI 10.1158/0008-5472.CAN-09-1843; Mathe EA, 2009, CLIN CANCER RES, V15, P6192, DOI 10.1158/1078-0432.CCR-09-1467; Molaei Fatemeh, 2018, Iranian Biomedical Journal, V22, P217, DOI 10.22034/ibj.22.4.217; Nair JS, 2013, ANTICANCER RES, V33, P1307; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Ozawa T, 2014, ANN SURG ONCOL, V21, P2650, DOI 10.1245/s10434-014-3659-9; Pasto A, 2014, CANCER RES, V74, P2106, DOI 10.1158/0008-5472.CAN-13-2022; Piazzi G, 2012, CELL CYCLE, V11, P4323, DOI 10.4161/cc.22388; Pine SR, 2008, DIS MARKERS, V24, P257, DOI 10.1155/2008/396281; Polkowski W, 1999, ANN SURG ONCOL, V6, P290, DOI 10.1007/s10434-999-0290-2; Qian CJ, 2015, MOL CELL BIOCHEM, V401, P165, DOI 10.1007/s11010-014-2304-z; Qian ZL, 2014, GENE CHROMOSOME CANC, V53, P883, DOI 10.1002/gcc.22196; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Serafin V, 2011, J PATHOL, V224, P448, DOI 10.1002/path.2895; Strosberg JR, 2012, EUR J CANCER, V48, P997, DOI 10.1016/j.ejca.2012.02.056; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Takebe N, 2014, PHARMACOL THERAPEUT, V141, P140, DOI 10.1016/j.pharmthera.2013.09.005; Tolcher AW, 2012, J CLIN ONCOL, V30, P2348, DOI 10.1200/JCO.2011.36.8282; Vilimas T, 2007, NAT MED, V13, P70, DOI 10.1038/nm1524; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Wu WKK, 2010, CANCER LETT, V295, P144, DOI 10.1016/j.canlet.2010.04.025; Yeh TS, 2009, CANCER RES, V69, P5039, DOI 10.1158/0008-5472.CAN-08-4021; Yuan X, 2015, CANCER LETT, V369, P20, DOI 10.1016/j.canlet.2015.07.048; Zhang H, 2014, BRIT J CANCER, V110, P2283, DOI 10.1038/bjc.2014.135; Zhang TN, 2016, ONCOTARGET, V7, P42225, DOI 10.18632/oncotarget.9944; Zhao Q, 2015, ONCOL REP, V34, P979, DOI 10.3892/or.2015.4013; Zhou QOL, 2010, J BIOL CHEM, V285, P27581, DOI 10.1074/jbc.M110.146886	59	14	15	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1578	1594		10.1038/s41388-020-01579-3	http://dx.doi.org/10.1038/s41388-020-01579-3		JAN 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33452458	hybrid, Green Published			2022-12-28	WOS:000607998600006
J	Yu, ZY; Jiang, XY; Qin, L; Deng, HX; Wang, JL; Ren, W; Li, HB; Zhao, L; Liu, HX; Yan, H; Shi, WG; Wang, Q; Luo, CJ; Long, B; Zhou, HN; Sun, H; Jiao, ZY				Yu, Zeyuan; Jiang, Xiangyan; Qin, Long; Deng, Haixiao; Wang, Jianli; Ren, Wen; Li, Hongbin; Zhao, Lei; Liu, Huanxiang; Yan, Hong; Shi, Wengui; Wang, Qi; Luo, Changjiang; Long, Bo; Zhou, Huinian; Sun, Hui; Jiao, Zuoyi			A novel UBE2T inhibitor suppresses Wnt/beta-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination	ONCOGENE			English	Article							CONJUGATING ENZYME UBE2T; E2; WNT; METHYLATION; PROMOTER; PATHWAY; FANCD2; BINDS; DNA	Dysregulation of the Wnt/beta-catenin signaling pathway is critically involved in gastric cancer (GC) progression. However, current Wnt pathway inhibitors being studied in preclinical or clinical settings for other cancers such as colorectal and pancreatic cancers are either too cytotoxic or insufficiently efficacious for GC. Thus, we screened new potent targets from beta-catenin destruction complex associated with GC progression from clinical samples, and found that scaffolding protein RACK1 deficiency plays a significant role in GC progression, but not APC, AXIN, and GSK3 beta. Then, we identified its upstream regulator UBE2T which promotes GC progression via hyperactivating the Wnt/beta-catenin signaling pathway through the ubiquitination and degradation of RACK1 at the lysine K172, K225, and K257 residues independent of an E3 ligase. Indeed, UBE2T protein level is negatively associated with prognosis in GC patients, suggesting that UBE2T is a promising target for GC therapy. Furthermore, we identified a novel UBE2T inhibitor, M435-1279, and suggested that M435-1279 acts inhibit the Wnt/beta-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1, resulting in suppression of GC progression with lower cytotoxicity in the meantime. Overall, we found that increased UBE2T levels promote GC progression via the ubiquitination of RACK1 and identified a novel potent inhibitor providing a balance between growth inhibition and cytotoxicity as well, which offer a new opportunity for the specific GC patients with aberrant Wnt/beta-catenin signaling.	[Yu, Zeyuan; Jiang, Xiangyan; Deng, Haixiao; Luo, Changjiang; Long, Bo; Zhou, Huinian; Jiao, Zuoyi] Lanzhou Univ, Hosp 2, Dept Gen Surg, Lanzhou 730000, Gansu, Peoples R China; [Qin, Long; Wang, Jianli; Ren, Wen; Li, Hongbin; Zhao, Lei; Shi, Wengui; Sun, Hui; Jiao, Zuoyi] Lanzhou Univ, Hosp 2, Cuiying Expt Ctr, Lanzhou 730000, Gansu, Peoples R China; [Liu, Huanxiang] Lanzhou Univ, Sch Pharm, Lanzhou 730000, Gansu, Peoples R China; [Yan, Hong] Lanzhou Univ, Hosp 2, Dept Pathol, Lanzhou 730000, Gansu, Peoples R China; [Wang, Qi] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Canc Ctr, Boston, MA 02215 USA	Lanzhou University; Lanzhou University; Lanzhou University; Lanzhou University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Jiao, ZY (corresponding author), Lanzhou Univ, Hosp 2, Dept Gen Surg, Lanzhou 730000, Gansu, Peoples R China.; Sun, H; Jiao, ZY (corresponding author), Lanzhou Univ, Hosp 2, Cuiying Expt Ctr, Lanzhou 730000, Gansu, Peoples R China.	yaohy04@126.com; jiaozy@lzu.edu.cn	ZHOU, Huinian/AAD-9279-2022	Jiang, Xiangyan/0000-0002-2685-2899; Liu, Huanxiang/0000-0002-9284-3667; Jiao, Zuoyi/0000-0003-1942-0905	National Natural Science Foundation of China [31670847]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (31670847).	Abdi E, 2019, CANCER MED-US, V8, P6114, DOI 10.1002/cam4.2497; Ajani JA, 2016, J NATL COMPR CANC NE, V14, P1286, DOI 10.6004/jnccn.2016.0137; Al-Batran SE, 2019, LANCET, V393, P1948, DOI 10.1016/S0140-6736(18)32557-1; Alagpulinsa DA, 2019, BLOOD ADV, V3, P3968, DOI 10.1182/bloodadvances.2019000181; Alpi A, 2007, MOL CELL BIOL, V27, P8421, DOI 10.1128/MCB.00504-07; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Bang YJ, 2010, LANCET, V376, P1302; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cats A, 2018, LANCET ONCOL, V19, P616, DOI 10.1016/S1470-2045(18)30132-3; Chiurillo MA, 2015, WORLD J EXP MED, V5, P84, DOI [10.5493/wjem.v5.i2.84, DOI 10.5493/wjem.v5.i2.84, DOI 10.5493/WJEM.V5.I2.84]; Clement G, 2004, CANCER RES, V64, P6867, DOI 10.1158/0008-5472.CAN-03-2503; Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012; Day JP, 2018, FUTUR SCI OA, V4, DOI 10.4155/fsoa-2018-0022; Deng YZ, 2012, GASTROENTEROLOGY, V142, P812, DOI 10.1053/j.gastro.2011.12.046; Dzobo K, 2019, OMICS, V23, P517, DOI 10.1089/omi.2019.0147; Fischer AS, 2019, BIOMEDICINES, V7, DOI 10.3390/biomedicines7020044; Flanagan DJ, 2019, CANCER RES, V79, P5901, DOI 10.1158/0008-5472.CAN-19-1362; Fomenkov A, 2004, CELL CYCLE, V3, P1285, DOI 10.4161/cc.3.10.1155; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gomez-Martin C, 2012, J CLIN PATHOL, V65, P751, DOI 10.1136/jclinpath-2012-200774; Jung YS, 2020, EXP MOL MED, V52, P183, DOI 10.1038/s12276-020-0380-6; Lee DG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5423; Liu LL, 2019, CANCER MANAG RES, V11, P8359, DOI 10.2147/CMAR.S202631; Liu NN, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2351-9; Longerich S, 2009, J BIOL CHEM, V284, P23182, DOI 10.1074/jbc.C109.038075; Luo CJ, 2017, ONCOTARGET, V8, P32639, DOI 10.18632/oncotarget.15947; Machida YJ, 2006, MOL CELL, V23, P589, DOI 10.1016/j.molcel.2006.06.024; Mao J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.515; Mazzoni SM, 2014, CANCER LETT, V355, P1, DOI 10.1016/j.canlet.2014.09.018; Morreale FE, 2017, J MED CHEM, V60, P8183, DOI 10.1021/acs.jmedchem.7b01071; Morreale FE, 2017, J MED CHEM, V60, P4093, DOI 10.1021/acs.jmedchem.7b00147; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Palle J, 2020, DRUGS, V80, P401, DOI 10.1007/s40265-020-01272-5; Pan KF, 2008, WORLD J GASTROENTERO, V14, P1570, DOI 10.3748/wjg.14.1570; Perez-Pena J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17836-7; Rickman KA, 2015, CELL REP, V12, P35, DOI 10.1016/j.celrep.2015.06.014; Sadowski M, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-19; Tan CQ, 2014, PHARMACOECONOMICS, V32, P235, DOI 10.1007/s40273-013-0065-2; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Ueki T, 2009, CANCER RES, V69, P8752, DOI 10.1158/0008-5472.CAN-09-1809; van Kappel EC, 2017, BRIT J PHARMACOL, V174, P4575, DOI 10.1111/bph.13922; Vila IK, 2017, CANCER CELL, V31, P208, DOI 10.1016/j.ccell.2017.01.003; Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610; Yang HJ, 2018, GASTRIC CANCER, V21, P237, DOI 10.1007/s10120-017-0741-6; Yin J, 2020, J ENVIRON SCI, V89, P65, DOI 10.1016/j.jes.2019.09.025	47	22	24	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					1027	1042		10.1038/s41388-020-01572-w	http://dx.doi.org/10.1038/s41388-020-01572-w		DEC 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33323973	Green Published, hybrid			2022-12-28	WOS:000599126500004
J	Wang, FX; Lau, JKC; Yu, J				Wang, Feixue; Lau, Jennie Ka Ching; Yu, Jun			The role of natural killer cell in gastrointestinal cancer: killer or helper	ONCOGENE			English	Review							NK CELLS; COLORECTAL-CANCER; HEPATOCELLULAR-CARCINOMA; TUMOR-CELLS; IN-VIVO; PHASE-I; CYTOTOXIC ACTIVITY; ANTITUMOR-ACTIVITY; ADOPTIVE TRANSFER; PERIPHERAL-BLOOD	Gastrointestinal cancer is one of the leading health problems worldwide, with a high morbidity and mortality. To date, harnessing both the innate and adaptive immune system against cancer provides a selective and effective therapeutic strategy for patients. As a first line defense against cancer, natural killer (NK) cells can swiftly target and lyse tumor cells without prior activation. In addition to its pivotal role in innate immunity, NK cells also play unique roles in the adaptive immune system as it enhance anti-tumor adaptive immune responses through secretion of cytokines and retaining an immunological memory. All these characteristics make NK cell a promising anti-cancer agent for patients. In spite of scarce infiltration and impaired function of NK cells in tumors, and the fact that tumors easily develop resistant mechanisms to evade the attacks from endogenous NK cells, multiple strategies have been developed to boost anti-tumor effect of NK cells and abolish tumor resistance. Some examples include adoptive transfer of NK cells after ex vivo activation and expansion; restoration of NK cell function using immune checkpoint inhibitors, and monoclonal antibody or cytokine treatment. Preclinical data have shown encouraging results, suggesting that NK cells hold great potential in cancer therapy. In this review, we discuss NK cells' cytotoxicity and modulation function in GI cancer and the current application in clinical therapy.	[Wang, Feixue; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst,Dept Med & Therapeut,State, Hong Kong, Peoples R China; [Lau, Jennie Ka Ching] Chinese Univ Hong Kong, SHHO Coll, Fac Med, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst,Dept Med & Therapeut,State, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Jun, Yu/D-8569-2015	Jun, Yu/0000-0001-5008-2153	RGC-CRF Hong Kong [C4041-17GF, C7026-18G]; RGC Theme-based Research Scheme Hong Kong [T12-703/19-R]	RGC-CRF Hong Kong; RGC Theme-based Research Scheme Hong Kong	The project was supported by RGC-CRF Hong Kong (C4041-17GF; C7026-18G); RGC Theme-based Research Scheme Hong Kong (T12-703/19-R).	Acoba JD, 2017, PHASE IB II STUDY AL, V35, pTPS510; ALBINI A, 2017, ANN ONCOL S, V28, pvi11, DOI DOI 10.1093/annonc/mdx422.028; Ames E, 2015, J IMMUNOL, V195, P4010, DOI 10.4049/jimmunol.1500447; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Ardolino M, 2014, J CLIN INVEST, V124, P4781, DOI 10.1172/JCI74337; Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110; Bald T, 2020, NAT IMMUNOL, V21, P835, DOI 10.1038/s41590-020-0728-z; BARLOZZARI T, 1983, J IMMUNOL, V131, P1024; Barry KC, 2018, NAT MED, V24, P1178, DOI 10.1038/s41591-018-0085-8; Berchem G, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1062968; Bjordahl R, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-3576; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Brackett CM, 2016, P NATL ACAD SCI USA, V113, pE874, DOI 10.1073/pnas.1521359113; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruno A, 2018, FASEB J, V32, P5365, DOI 10.1096/fj.201701103R; Calmeiro J, 2018, HIGHLIGHTING ROLE DC, P25; Chen SS, 2016, ONCOL LETT, V12, P1868, DOI 10.3892/ol.2016.4835; David JM, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-3821; de Andrade LF, 2018, SCIENCE, V359, P1537, DOI 10.1126/science.aao0505; Deauvieau F, 2015, INT J CANCER, V136, P1085, DOI 10.1002/ijc.29087; Dogra P, 2020, CELL, V180, P749, DOI 10.1016/j.cell.2020.01.022; Dotan E, 2017, J CLIN ONCOL, V35, P3338, DOI 10.1200/JCO.2017.73.9011; Duan XH, 2011, MED ONCOL, V28, P466, DOI 10.1007/s12032-010-9480-9; Dubois S, 2017, CANCER IMMUNOL RES, V5, P929, DOI 10.1158/2326-6066.CIR-17-0279; Dupaul-Chicoine J, 2015, IMMUNITY, V43, P751, DOI 10.1016/j.immuni.2015.08.013; Easom NJW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01009; Ferlazzo G, 2004, J IMMUNOL, V172, P1333, DOI 10.4049/jimmunol.172.3.1333; Freud AG, 2017, IMMUNITY, V47, P820, DOI 10.1016/j.immuni.2017.10.008; Geller MA, 2011, CYTOTHERAPY, V13, P98, DOI 10.3109/14653249.2010.515582; Gharagozloo M, 2015, BRATISL MED J, V116, P296, DOI 10.4149/BLL_2015_056; Halama N, 2011, CLIN CANCER RES, V17, P678, DOI 10.1158/1078-0432.CCR-10-2173; Han B, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6248590; Harmon C, 2019, CANCER IMMUNOL RES, V7, P335, DOI 10.1158/2326-6066.CIR-18-0481; He H, 2016, SCI REP-UK, V6, DOI 10.1038/srep27711; Hermanson DL, 2016, STEM CELLS, V34, P93, DOI 10.1002/stem.2230; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Hsu J, 2018, J CLIN INVEST, V128, P4654, DOI 10.1172/JCI99317; Imai K, 2000, LANCET, V356, P1795, DOI 10.1016/S0140-6736(00)03231-1; Ishikawa T, 2018, INT J CANCER, V142, P2599, DOI 10.1002/ijc.31285; Jinushi M, 2005, J HEPATOL, V43, P1013, DOI 10.1016/j.jhep.2005.05.026; Jobin G, 2017, GASTROENTEROLOGY, V153, P980, DOI 10.1053/j.gastro.2017.06.009; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; Kim HR, 2004, CANCER IMMUNOL IMMUN, V53, P461, DOI 10.1007/s00262-003-0461-0; Kono K, 2002, CANCER RES, V62, P5813; Krause SW, 2004, CLIN CANCER RES, V10, P3699, DOI 10.1158/1078-0432.CCR-03-0683; Langhans B, 2015, J HEPATOL, V62, P398, DOI 10.1016/j.jhep.2014.08.038; Lanier LL, 2001, NAT IMMUNOL, V2, P23, DOI 10.1038/83130; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; Li HJ, 2018, GUT, V67, P2035, DOI 10.1136/gutjnl-2017-314098; Li LY, 2018, CYTOTHERAPY, V20, P134, DOI 10.1016/j.jcyt.2017.09.009; Li TJ, 2012, CANCER LETT, V318, P154, DOI 10.1016/j.canlet.2011.12.020; Li Y, 2018, CELL STEM CELL, V23, P181, DOI 10.1016/j.stem.2018.06.002; Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607; Liu Y, 2017, ONCOGENE, V36, P6143, DOI 10.1038/onc.2017.209; Lopez-Soto A, 2017, CANCER CELL, V32, P135, DOI 10.1016/j.ccell.2017.06.009; Lu CG, 2020, MOL IMMUNOL, V122, P200, DOI 10.1016/j.molimm.2020.04.016; Malmberg KJ, 2017, SEMIN IMMUNOL, V31, P20, DOI 10.1016/j.smim.2017.08.002; Mantovani S, 2019, HEPATOLOGY, V69, P1165, DOI 10.1002/hep.30235; Margolin K, 2018, CLIN CANCER RES, V24, P5552, DOI 10.1158/1078-0432.CCR-18-0945; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Mimura K, 2014, INT J CANCER, V135, P1390, DOI 10.1002/ijc.28780; Mocikat R, 2003, IMMUNITY, V19, P561, DOI 10.1016/S1074-7613(03)00264-4; Morvan MG, 2016, NAT REV CANCER, V16, P7, DOI 10.1038/nrc.2015.5; Oppenheim DE, 2014, BRIT J CANCER, V110, P1221, DOI 10.1038/bjc.2014.35; Pernot S, 2020, GASTRIC CANCER, V23, P73, DOI 10.1007/s10120-019-00983-3; Pinho MJ, 2011, CELL COMMUN ADHES, V18, P45, DOI 10.3109/15419061.2011.610911; ROBERTSON MJ, 1990, BLOOD, V76, P2421; Rothe A, 2014, INT J CANCER, V134, P2829, DOI 10.1002/ijc.28609; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Sakamoto N, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0632-8; Schirrmann T, 2002, CANCER GENE THER, V9, P390, DOI 10.1038/sj.cgt.7700453; Schmohl JU, 2016, TARGET ONCOL, V11, P353, DOI 10.1007/s11523-015-0391-8; Schmohl JU, 2017, CANCER RES TREAT, V49, P1140, DOI 10.4143/crt.2016.491; Screpanti V, 2005, MOL IMMUNOL, V42, P495, DOI 10.1016/j.molimm.2004.07.033; Rocca YS, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00413; Spiegel A, 2016, CANCER DISCOV, V6, P630, DOI 10.1158/2159-8290.CD-15-1157; Sun HY, 2019, HEPATOLOGY, V70, P168, DOI 10.1002/hep.30347; Sun JC, 2011, NAT REV IMMUNOL, V11, P645, DOI 10.1038/nri3044; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Tam YK, 2003, CYTOTHERAPY, V5, P259, DOI 10.1080/14653240310001523; Trotta AM, 2016, CANCER IMMUNOL RES, V4, P366, DOI 10.1158/2326-6066.CIR-15-0184; Vallera DA, 2016, CLIN CANCER RES, V22, P3440, DOI 10.1158/1078-0432.CCR-15-2710; Vallera DA, 2013, CANCER BIOTHER RADIO, V28, P274, DOI 10.1089/cbr.2012.1329; van Hall T, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0761-3; Viry E, 2014, AUTOPHAGY, V10, P173, DOI 10.4161/auto.26924; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Wallin RPA, 2003, EUR J IMMUNOL, V33, P2727, DOI 10.1002/eji.200324070; Wang L, 2017, CELL PHYSIOL BIOCHEM, V44, P1038, DOI 10.1159/000485404; Wang W, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00368; Woll PS, 2009, BLOOD, V113, P6094, DOI 10.1182/blood-2008-06-165225; Xiao L, 2019, MOL THER, V27, P1114, DOI 10.1016/j.ymthe.2019.03.011; Xu C, 2019, HUM GENE THER, V30, P459, DOI 10.1089/hum.2018.011; Yang Y, 2016, CANCER IMMUNOL RES, V4, P215, DOI 10.1158/2326-6066.CIR-15-0118; Zhang Q, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/4263520; Zhang Q, 2018, NAT IMMUNOL, V19, P723, DOI 10.1038/s41590-018-0132-0; Zhao JJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep05177; Zhou XM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02821; Zhu Ling-Yan, 2009, Ai Zheng, V28, P1198	99	31	31	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					717	730		10.1038/s41388-020-01561-z	http://dx.doi.org/10.1038/s41388-020-01561-z		DEC 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33262461	hybrid, Green Published			2022-12-28	WOS:000595928700001
J	Li, MD; Ma, DH; Chang, ZJ				Li, Mengdi; Ma, Danhui; Chang, Zhijie			Current understanding of CREPT and p15RS, carboxy-terminal domain (CTD)-interacting proteins, in human cancers	ONCOGENE			English	Review							RNA-POLYMERASE-II; PROMOTES TUMOR-GROWTH; CELL-CYCLE; TRANSCRIPTION TERMINATION; POOR-PROGNOSIS; PROLIFERATION; EXPRESSION; INTERACTS; GENE; IDENTIFICATION	CREPT and p15RS, also named RPRD1B and RPRD1A, are RPRD (regulation of nuclear pre-mRNA-domain-containing) proteins containing C-terminal domain (CTD)-interacting domain (CID), which mediates the binding to the CTD of Rpb1, the largest subunit of RNA polymerase II (RNAPII). CREPT and p15RS are highly conserved, with a common yeast orthologue Rtt103. Intriguingly, human CREPT and p15RS possess opposite functions in the regulation of cell proliferation and tumorigenesis. While p15RS inhibits cell proliferation, CREPT promotes cell cycle and tumor growth. Aberrant expression of both CREPT and p15RS was found in numerous types of cancers. At the molecular level, both CREPT and p15RS were reported to regulate gene transcription by interacting with RNAPII. However, CREPT also exerts a key function in the processes linked to DNA damage repairs. In this review, we summarized the recent studies regarding the biological roles of CREPT and p15RS, as well as the molecular mechanisms underlying their activities. Fully revealing the mechanisms of CREPT and p15RS functions will not only provide new insights into understanding gene transcription and maintenance of DNA stability in tumors, but also promote new approach development for tumor diagnosis and therapy.	[Li, Mengdi; Ma, Danhui; Chang, Zhijie] Tsinghua Univ, Sch Med, State Key Lab Membrane Biol, Beijing 100084, Peoples R China	Tsinghua University	Chang, ZJ (corresponding author), Tsinghua Univ, Sch Med, State Key Lab Membrane Biol, Beijing 100084, Peoples R China.	zhijiec@tsinghua.edu.cn		Chang, Zhijie/0000-0003-1567-3227; Ma, Danhui/0000-0002-0552-4300	Chinese National Major Scientific Research Program [2016YFA0500301]; National Natural Science Foundation of China [81830092, 81230044]	Chinese National Major Scientific Research Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the Chinese National Major Scientific Research Program (2016YFA0500301), and grants from the National Natural Science Foundation of China (81830092, 81230044).	Aguilera A, 2012, MOL CELL, V46, P115, DOI 10.1016/j.molcel.2012.04.009; Ali I, 2019, MOL CELL, V74, P1164, DOI 10.1016/j.molcel.2019.04.008; Barilla D, 2001, P NATL ACAD SCI USA, V98, P445, DOI 10.1073/pnas.021545298; Belotserkovskii BP, 2013, NUCLEIC ACIDS RES, V41, P1817, DOI 10.1093/nar/gks1333; Buratowski S, 2005, CURR OPIN CELL BIOL, V17, P257, DOI 10.1016/j.ceb.2005.04.003; Chapman RD, 2008, TRENDS GENET, V24, P289, DOI 10.1016/j.tig.2008.03.010; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Collin P, 2019, MOL CELL, V73, P655, DOI 10.1016/j.molcel.2018.12.002; Ding LD, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1211-8; Doerks T, 2002, GENOME RES, V12, P47, DOI 10.1101/gr.203201; Dolan ME, 2017, CLIN CANCER RES, V23, P5757, DOI 10.1158/1078-0432.CCR-16-3224; Egloff S, 2012, MOL CELL, V45, P111, DOI 10.1016/j.molcel.2011.11.006; Fan XZ, 2018, J BIOL CHEM, V293, P7618, DOI 10.1074/jbc.RA118.001969; Guhua JXY, 2003, J CHIN PATHOL, V19, P1300; Harlen KM, 2017, NAT REV MOL CELL BIO, V18, P263, DOI 10.1038/nrm.2017.10; Hsin JP, 2012, GENE DEV, V26, P2119, DOI 10.1101/gad.200303.112; Ingham RJ, 2005, MOL CELL BIOL, V25, P7092, DOI 10.1128/MCB.25.16.7092-7106.2005; Jasnovidova O, 2017, P NATL ACAD SCI USA, V114, P11133, DOI 10.1073/pnas.1712450114; Jasnovidova O, 2017, EMBO REP, V18, P906, DOI 10.15252/embr.201643723; Jiang J, 2019, CHEM-BIOL INTERACT, V302, P74, DOI 10.1016/j.cbi.2019.02.004; Jin K, 2018, J CELL BIOCHEM, V119, P1083, DOI 10.1002/jcb.26277; Jung HM, 2009, J CELL BIOCHEM, V106, P703, DOI 10.1002/jcb.22063; Kamieniarz-Gdula K, 2019, MOL CELL, V74, P158, DOI 10.1016/j.molcel.2019.01.027; Kim M, 2004, NATURE, V432, P517, DOI 10.1038/nature03041; Komor MA, 2020, INT J CANCER, V146, P1979, DOI 10.1002/ijc.32627; Kuang YS, 2018, WORLD J GASTROENTERO, V24, P475, DOI 10.3748/wjg.v24.i4.475; Li J, 2018, MOL CARCINOGEN, V57, P1408, DOI 10.1002/mc.22866; Li WM, 2018, CANCER SCI, V109, P1012, DOI 10.1111/cas.13524; Liang Z, 2017, BIOCHEM BIOPH RES CO, V493, P263, DOI 10.1016/j.bbrc.2017.09.033; Liu CX, 2015, J BIOL CHEM, V290, P9701, DOI 10.1074/jbc.M114.620872; Liu J, 2002, BIOCHEM BIOPH RES CO, V299, P880, DOI 10.1016/S0006-291X(02)02684-0; Liu T, 2016, AM J TRANSL RES, V8, P2097; Long L, 2018, J NUTR, V148, P834, DOI 10.1093/jn/nxy047; Lu DD, 2012, CANCER CELL, V21, P92, DOI 10.1016/j.ccr.2011.12.016; Lunde BM, 2010, NAT STRUCT MOL BIOL, V17, P1195, DOI 10.1038/nsmb.1893; Ma DH, 2020, THERANOSTICS, V10, P3708, DOI 10.7150/thno.41677; Ma JT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174309; Marechal A, 2014, MOL CELL, V53, P235, DOI 10.1016/j.molcel.2013.11.002; Mei KR, 2014, SCI CHINA LIFE SCI, V57, P97, DOI 10.1007/s11427-013-4589-7; Meinhart A, 2004, NATURE, V430, P223, DOI 10.1038/nature02679; Morales JC, 2014, NUCLEIC ACIDS RES, V42, P4996, DOI 10.1093/nar/gku160; Motea EA, 2018, CLIN CANCER RES, V24, P6459, DOI 10.1158/1078-0432.CCR-17-1118; Ni ZY, 2014, NAT STRUCT MOL BIOL, V21, P686, DOI 10.1038/nsmb.2853; Ni ZY, 2011, TRANSCR-AUSTIN, V2, P237, DOI 10.4161/trns.2.5.17803; Noble CG, 2005, NAT STRUCT MOL BIOL, V12, P144, DOI 10.1038/nsmb887; Park JS, 2004, CANCER LETT, V214, P19, DOI 10.1016/j.canlet.2004.04.012; Patidar PL, 2016, NUCLEIC ACIDS RES, V44, P1718, DOI 10.1093/nar/gkv1492; Patturajan M, 1998, MOL CELL BIOL, V18, P2406, DOI 10.1128/MCB.18.4.2406; Ren LL, 2019, THERANOSTICS, V9, P449, DOI 10.7150/thno.29055; Schroder S, 2013, MOL CELL, V52, P314, DOI 10.1016/j.molcel.2013.10.009; She YG, 2014, INT J CLIN EXP PATHO, V7, P6596; Srividya I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031288; STERNER DE, 1995, MOL CELL BIOL, V15, P5716; Stirling PC, 2012, GENE DEV, V26, P163, DOI 10.1101/gad.179721.111; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Sugiyama T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042962; Sun M, 2018, BIOCHEM BIOPH RES CO, V496, P1183, DOI 10.1016/j.bbrc.2018.01.167; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Tucker JF, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005873; Vasiljeva L, 2006, MOL CELL, V21, P239, DOI 10.1016/j.molcel.2005.11.028; Wang Y, 2014, ONCOL REP, V31, P1389, DOI 10.3892/or.2014.2990; Wei MH, 2019, BIOCHIMIE, V162, P116, DOI 10.1016/j.biochi.2019.04.014; Weintraub AS, 2017, CELL, V171, P1573, DOI 10.1016/j.cell.2017.11.008; Wen N, 2020, J INT MED RES, V48, DOI 10.1177/0300060519895089; Wu YY, 2010, J BIOL CHEM, V285, P34621, DOI 10.1074/jbc.M110.148791; Yu SX, 2019, INT J CLIN EXP PATHO, V12, P3301; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zhang XC, 2012, CELL CYCLE, V11, P1988, DOI 10.4161/cc.20400; Zhang XY, 2005, PROG BIOCHEM BIOPHYS, V32, P771; Zhang YQ, 2018, ONCOGENE, V37, P3485, DOI 10.1038/s41388-018-0161-z; Zhang YQ, 2014, J BIOL CHEM, V289, P22589, DOI 10.1074/jbc.M114.560979; Zhang ZH, 2019, BIOCHEM BIOPH RES CO, V509, P746, DOI 10.1016/j.bbrc.2018.12.176; Zheng GX, 2016, BIOCHEM BIOPH RES CO, V480, P436, DOI 10.1016/j.bbrc.2016.10.067	73	4	4	5	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					705	716		10.1038/s41388-020-01544-0	http://dx.doi.org/10.1038/s41388-020-01544-0		NOV 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33239754				2022-12-28	WOS:000592629300001
J	Alula, KM; Delgado-Deida, Y; Jackson, DN; Venuprasad, K; Theiss, AL				Alula, Kibrom M.; Delgado-Deida, Yaritza; Jackson, Dakota N.; Venuprasad, K.; Theiss, Arianne L.			Nuclear partitioning of Prohibitin 1 inhibits Wnt/beta-catenin-dependent intestinal tumorigenesis	ONCOGENE			English	Article							BETA-CATENIN; PATHWAY; ACTIVATION; CELLS; AXIN; APC; EXPRESSION; CARCINOMA; PROTEINS; SURVIVAL	The Wnt/beta-catenin signaling pathway is aberrantly activated in the majority of colorectal cancer cases due to somatic mutations in the adenomatous polyposis coli (APC) gene. Prohibitin 1 (PHB1) serves pleiotropic cellular functions with dynamic subcellular trafficking, facilitating signaling crosstalk between organelles. Nuclear-localized PHB1 is an important regulator of gene transcription. Using mice with inducible intestinal epithelial cell (IEC)-specific deletion of Phb1 (Phb1(i Delta IEC)) and mice with IEC-specific overexpression of Phb1 (Phb1Tg), we demonstrate that IEC-specific PHB1 combats intestinal tumorigenesis in the Apc(Min/+) mouse model by inhibiting Wnt/beta-catenin signaling. Forced nuclear accumulation of PHB1 in human RKO or SW48 CRC cell lines increased AXIN1 expression and decreased cell viability. PHB1 deficiency in CRC cells decreased AXIN1 expression and increased beta-catenin activation that was abolished by XAV939, a pharmacological AXIN stabilizer. These results define a role of PHB1 in inhibiting the Wnt/beta-catenin pathway to influence the development of intestinal tumorigenesis. Induction of nuclear PHB1 trafficking provides a novel therapeutic option to influence AXIN1 expression and the beta-catenin destruction complex in Wnt-driven intestinal tumorigenesis.	[Alula, Kibrom M.; Delgado-Deida, Yaritza; Theiss, Arianne L.] Univ Colorado, Dept Med, Div Gastroenterol & Hepatol, Aurora, CO 80045 USA; [Jackson, Dakota N.] Baylor Univ, Med Ctr, Baylor Scott & White Res Inst, Dept Internal Med,Div Gastroenterol, Dallas, TX USA; [Venuprasad, K.] Univ Texas Southwestern Med Ctr Dallas, Coll Med, Dallas, TX 75390 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Baylor Health Care System; Baylor University; Baylor University Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas	Theiss, AL (corresponding author), Univ Colorado, Dept Med, Div Gastroenterol & Hepatol, Aurora, CO 80045 USA.	arianne.theiss@cuanschutz.edu		poojary, venuprasd/0000-0001-8986-9092	National Institutes of Health [R01-DK117001]; Litwin IBD Pioneers Crohn's Colitis Foundation [301869]; GI & Liver Innate Immune Program (GALIIP)-University of Colorado Anschutz	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Litwin IBD Pioneers Crohn's Colitis Foundation; GI & Liver Innate Immune Program (GALIIP)-University of Colorado Anschutz	We thank Jie Han (Baylor Scott & White Research Institute) for technical assistance. This work was supported by National Institutes of Health grants R01-DK117001 (ALT), Litwin IBD Pioneers Crohn's Colitis Foundation 301869 (ALT), and GI & Liver Innate Immune Program (GALIIP)-University of Colorado Anschutz (ALT).	Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Basmadjian C, 2013, FUTURE MED CHEM, V5, P2185, DOI 10.4155/fmc.13.177; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bourges I, 2004, BIOCHEM J, V383, P491, DOI 10.1042/BJ20040256; Chen DB, 2010, INT J ONCOL, V37, P355, DOI 10.3892/ijo_00000684; Chia IV, 2005, MOL CELL BIOL, V25, P4371, DOI 10.1128/MCB.25.11.4371-4376.2005; Chiu CF, 2013, ONCOGENE, V32, P777, DOI 10.1038/onc.2012.86; Chowdhury D, 2017, CURR DRUG TARGETS, V18, P1836, DOI 10.2174/1389450117666160824161225; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Delgado-Deida Y, 2020, GASTROENTEROL REP, V8, P215, DOI 10.1093/gastro/goaa025; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Hammoudi A, 2013, BIOCHEM BIOPH RES CO, V440, P364, DOI 10.1016/j.bbrc.2013.08.076; Hsieh SY, 2006, PROTEOMICS, V6, P5322, DOI 10.1002/pmic.200500541; Jackson DN, 2020, CANCER RES, V80, P3519, DOI 10.1158/0008-5472.CAN-20-0216; Jackson DN, 2020, GUT, V69, P1928, DOI 10.1136/gutjnl-2019-319523; Jackson DN, 2020, GUT MICROBES, V11, P285, DOI 10.1080/19490976.2019.1592421; Kathiria AS, 2012, CANCER RES, V72, P5778, DOI 10.1158/0008-5472.CAN-12-0603; Kim DM, 2017, ONCOL REP, V37, P3201, DOI 10.3892/or.2017.5599; Ko KS, 2010, HEPATOLOGY, V52, P2096, DOI 10.1002/hep.23919; Krishnamurthy N, 2018, CANCER TREAT REV, V62, P50, DOI 10.1016/j.ctrv.2017.11.002; Lau T, 2013, CANCER RES, V73, P3132, DOI 10.1158/0008-5472.CAN-12-4562; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Ma LL, 2017, ONCOTARGET, V8, P76340, DOI 10.18632/oncotarget.19394; Mavila N, 2018, HEPATOL COMMUN, V2, P1583, DOI 10.1002/hep4.1257; Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peng YT, 2015, APOPTOSIS, V20, P1135, DOI 10.1007/s10495-015-1143-z; Rastogi S, 2006, J BIOL CHEM, V281, P2951, DOI 10.1074/jbc.M508669200; Schatoff EM, 2017, CURR COLORECT CANC R, V13, P101, DOI 10.1007/s11888-017-0354-9; Theiss AL, 2007, FASEB J, V21, P197, DOI 10.1096/fj.06-6801com; Theiss AL, 2011, BBA-MOL CELL RES, V1813, P1137, DOI 10.1016/j.bbamcr.2011.01.033; Theiss AL, 2009, GASTROENTEROLOGY, V137, P199, DOI 10.1053/j.gastro.2009.03.033; Thuaud F, 2013, CHEM BIOL, V20, P316, DOI 10.1016/j.chembiol.2013.02.006; Tortelote GG, 2017, CELL SIGNAL, V40, P30, DOI 10.1016/j.cellsig.2017.08.008; Tsutsumi T, 2009, HEPATOLOGY, V50, P378, DOI 10.1002/hep.22998; Wang D, 2020, CELL MOL LIFE SCI, V77, P3525, DOI 10.1007/s00018-020-03475-1; Wang ZH, 2016, GENETICS, V203, P269, DOI 10.1534/genetics.115.183244; Yu LL, 2017, CANCER RES, V77, P1564, DOI 10.1158/0008-5472.CAN-16-2074; Zhou TB, 2013, J RECEPT SIG TRANSD, V33, P28, DOI 10.3109/10799893.2012.752006	41	4	4	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					369	383		10.1038/s41388-020-01538-y	http://dx.doi.org/10.1038/s41388-020-01538-y		NOV 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33144683	Green Accepted			2022-12-28	WOS:000585016500002
J	Abd-Elrahman, I; Nassar, T; Khairi, N; Perlman, R; Benita, S; Ben Yehuda, D				Abd-Elrahman, Ihab; Nassar, Taher; Khairi, Noha; Perlman, Riki; Benita, Simon; Ben Yehuda, Dina			Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma	ONCOGENE			English	Article							GAUSSIA LUCIFERASE; PROTEIN LIVIN; CD40 ANTIGEN; CANCER; APOPTOSIS; DELIVERY; RESISTANCE; INHIBITOR; THERAPY; SYSTEM	We previously showed that Livin, an inhibitor of apoptosis protein, is specifically cleaved to produce a truncated protein, tLivin, and demonstrated its paradoxical proapoptotic activity. We further demonstrated that mini-tLivin (MTV), a 70 amino acids derivative of tLivin, is a proapoptotic protein as potent as tLivin. Based on these findings, in this study we aimed to develop a venue to target MTV for the treatment of diffuse large B-cell lymphoma (DLBCL). MTV was conjugated to poly (lactide-co-glycolic acid) surface-activated nanoparticles (NPs). In order to target MTV-NPs we also conjugated CD40 ligand (CD40L) to the surface of the NPs and evaluated the efficacy of the bifunctional CD40L-MTV-NPs. In vitro, CD40L-MTV-NPs elicited significant apoptosis of DLBCL cells. In a disseminated mouse model of DLBCL, 37.5% of MTV-NPs treated mice survived at the end of the experiment. Targeting MTV-NPs using CD40L greatly improved survival and 71.4% of these mice survived. CD40L-MTV-NPs also greatly reduced CNS involvement of DLBCL. Only 20% of these mice presented infiltration of lymphoma to the brain in comparison to 77% of the MTV-NPs treated mice. In a subcutaneous mouse model, CD40L-MTV-NPs significantly reduced tumor volume in correlation with significant increased caspase-3 activity. Thus, targeted MTV-NPs suggest a novel approach to overcome apoptosis resistance in cancer.	[Abd-Elrahman, Ihab; Khairi, Noha; Perlman, Riki; Ben Yehuda, Dina] Hadassah Med Org, Dept Hematol, Jerusalem, Israel; [Nassar, Taher; Benita, Simon] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Inst Drug Res, Jerusalem, Israel; [Ben Yehuda, Dina] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Ben Yehuda, D (corresponding author), Hadassah Med Org, Dept Hematol, Jerusalem, Israel.; Ben Yehuda, D (corresponding author), Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel.	Dbyehuda@hadassah.org.il		abd-elrahman, ihab/0000-0003-2012-2024	Kamin Incentive Program, Israel Innovation Authority; Dorot foundation; Eleanor Fox; Aleen and David M. Epstein Fund for Hematology/oncology research	Kamin Incentive Program, Israel Innovation Authority; Dorot foundation; Eleanor Fox; Aleen and David M. Epstein Fund for Hematology/oncology research	We thank Galina Skarzinski for immunohistochemistry. This work was supported by Kamin Incentive Program, Israel Innovation Authority (DBY and SB), Dorot foundation (DBY), Eleanor Fox (DBY), and Aleen and David M. Epstein Fund for Hematology/oncology research (DBY).	Abd-Elrahman I, 2009, CANCER RES, V69, P5475, DOI 10.1158/0008-5472.CAN-09-0424; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Bartok E, 2013, NAT METHODS, V10, P147, DOI [10.1038/NMETH.2327, 10.1038/nmeth.2327]; Bicho A, 2010, INT J PHARMACEUT, V399, P80, DOI 10.1016/j.ijpharm.2010.08.005; Bierman P, 2005, HEMATOL ONCOL CLIN N, V19, P597, DOI 10.1016/j.hoc.2005.05.003; Bovenberg MSS, 2012, ANAL CHEM, V84, P1189, DOI 10.1021/ac202833r; Bugajska U, 2002, J NATL CANCER I, V94, P1381; Calimeri T., 2019, ANN LYMPHOMA, V3, P7, DOI DOI 10.21037/AOL.2019.06.01; Carreno BM, 2009, CLIN CANCER RES, V15, P3277, DOI 10.1158/1078-0432.CCR-08-2502; Carvalho C, 2009, CURR MED CHEM, V16, P3267, DOI 10.2174/092986709788803312; Chavez JC, 2019, THER ADV HEMATOL, V10, DOI 10.1177/2040620719841581; Chen WC, 2010, BLOOD, V115, P4778, DOI 10.1182/blood-2009-12-257386; Choi J, 2007, BLOOD, V109, P471, DOI 10.1182/blood-2006-07-032557; Chung E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008316; Dong XW, 2009, CANCER RES, V69, P3918, DOI 10.1158/0008-5472.CAN-08-2747; Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009; FESSI H, 1989, INT J PHARM, V55, pR1, DOI 10.1016/0378-5173(89)90281-0; Foo J, 2014, J THEOR BIOL, V355, P10, DOI 10.1016/j.jtbi.2014.02.025; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; Georgopoulos NT, 2007, INT J CANCER, V121, P1373, DOI 10.1002/ijc.22846; Ghose A, 2015, CL LYMPH MYELOM LEUK, V15, P451, DOI 10.1016/j.clml.2015.02.026; Girotti MR, 2013, CANCER DISCOV, V3, P487, DOI 10.1158/2159-8290.CD-13-0131; Goldstein D, 2007, BIOMED PHARMACOTHER, V61, P97, DOI 10.1016/j.biopha.2006.08.005; Harush-Frenkel O, 2010, TOXICOL APPL PHARM, V246, P83, DOI 10.1016/j.taap.2010.04.011; Hostager BS, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00376; Huang LF, 2020, BIOMATER SCI-UK, V8, P2376, DOI 10.1039/d0bm00129e; Inoue Y, 2011, MOL IMAGING, V10, P377, DOI 10.2310/7290.2010.00057; Jia J, 2015, MOL MED REP, V11, P1623, DOI 10.3892/mmr.2014.2953; Jin Y, 2010, MOL PHARMACEUT, V7, P196, DOI 10.1021/mp900205r; Karra N, 2013, SMALL, V9, P4221, DOI 10.1002/smll.201301417; Kojima C, 2013, NANOMED-NANOTECHNOL, V9, P767, DOI 10.1016/j.nano.2013.01.004; Lazar I, 2012, ONCOLOGY-BASEL, V82, P197, DOI 10.1159/000334234; Liang XJ, 2010, METHODS MOL BIOL, V596, P467, DOI 10.1007/978-1-60761-416-6_21; Lu Y, 2004, ADV DRUG DELIVER REV, V56, P1621, DOI 10.1016/j.addr.2004.05.002; Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3; Milane L, 2011, MOL PHARMACEUT, V8, P185, DOI 10.1021/mp1002653; Muhamad N, 2018, INT J NANOMED, V13, P3921, DOI 10.2147/IJN.S165210; Nachmias B, 2004, SEMIN CANCER BIOL, V14, P231, DOI 10.1016/j.semcancer.2004.04.002; Nachmias B, 2003, CANCER RES, V63, P6340; Nachmias B, 2007, APOPTOSIS; Nagamitsu A, 2009, JPN J CLIN ONCOL, V39, P756, DOI 10.1093/jjco/hyp074; Niers JM, 2011, MOL THER, V19, P1090, DOI 10.1038/mt.2011.17; Phongpradist R, 2010, CURR PHARM DESIGN, V16, P2321, DOI 10.2174/138161210791920450; Rubenstein JL, 2003, BLOOD, V101, P466, DOI 10.1182/blood-2002-06-1636; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Schultze J, 1999, LANCET, V354, P1225, DOI 10.1016/S0140-6736(99)90130-7; SCHULTZE JL, 1995, P NATL ACAD SCI USA, V92, P8200, DOI 10.1073/pnas.92.18.8200; Shi JQ, 2012, MOL CANCER THER, V11, P2045, DOI 10.1158/1535-7163.MCT-11-1036; Shiloach T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101075; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; Stiff PJ, 2013, NEW ENGL J MED, V369, P1681, DOI 10.1056/NEJMoa1301077; Szocinski JL, 2002, BLOOD, V100, P217, DOI 10.1182/blood.V100.1.217; T Georgopoulos N, 2006, CELL DEATH DIFFER, V13, P1789, DOI 10.1038/sj.cdd.4401859; UCKUN FM, 1990, BLOOD, V76, P2449; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Wang SN, 2010, BIOSENS BIOELECTRON, V26, P778, DOI 10.1016/j.bios.2010.06.025; Wennhold K, 2017, ONCOTARGET, V8, P27740, DOI 10.18632/oncotarget.7720; Wilhelm S, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.14; Young LS, 1998, IMMUNOL TODAY, V19, P502, DOI 10.1016/S0167-5699(98)01340-1	61	0	0	5	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					334	344		10.1038/s41388-020-01529-z	http://dx.doi.org/10.1038/s41388-020-01529-z		OCT 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33128043				2022-12-28	WOS:000585769600001
J	Dong, CP; Cesarano, A; Bombaci, G; Reiter, JL; Yu, CY; Wang, Y; Jiang, ZY; Abu Zaid, M; Huang, K; Lu, XB; Walker, BA; Perna, F; Liu, YL				Dong, Chuanpeng; Cesarano, Annamaria; Bombaci, Giuseppe; Reiter, Jill L.; Yu, Christina Y.; Wang, Yue; Jiang, Zhaoyang; Abu Zaid, Mohammad; Huang, Kun; Lu, Xiongbin; Walker, Brian A.; Perna, Fabiana; Liu, Yunlong			Intron retention-induced neoantigen load correlates with unfavorable prognosis in multiple myeloma	ONCOGENE			English	Article							INTERNATIONAL STAGING SYSTEM; CHECKPOINT BLOCKADE; CELL; EXPRESSION; PATHWAY; FAMILY	Neoantigen peptides arising from genetic alterations may serve as targets for personalized cancer vaccines and as positive predictors of response to immune checkpoint therapy. Mutations in genes regulating RNA splicing are common in hematological malignancies leading to dysregulated splicing and intron retention (IR). In this study, we investigated IR as a potential source of tumor neoantigens in multiple myeloma (MM) patients and the relationship of IR-induced neoantigens (IR-neoAg) with clinical outcomes. MM-specific IR events were identified in RNA-sequencing data from the Multiple Myeloma Research Foundation CoMMpass study after removing IR events that also occurred in normal plasma cells. We quantified the IR-neoAg load by assessing IR-induced novel peptides that were predicted to bind to major histocompatibility complex (MHC) molecules. We found that high IR-neoAg load was associated with poor overall survival in both newly diagnosed and relapsed MM patients. Further analyses revealed that poor outcome in MM patients with high IR-neoAg load was associated with high expression levels of T-cell co-inhibitory molecules and elevated interferon signaling activity. We also found that MM cells exhibiting high IR levels had lower MHC-II protein abundance and treatment of MM cells with a spliceosome inhibitor resulted in increased MHC-I protein abundance. Our findings suggest that IR-neoAg may represent a novel biomarker of MM patient clinical outcome and further that targeting RNA splicing may serve as a potential therapeutic strategy to prevent MM immune escape and promote response to checkpoint blockade.	[Dong, Chuanpeng; Reiter, Jill L.; Wang, Yue; Jiang, Zhaoyang; Huang, Kun; Lu, Xiongbin; Walker, Brian A.; Liu, Yunlong] Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA; [Dong, Chuanpeng; Huang, Kun; Liu, Yunlong] Indiana Univ Purdue Univ, Sch Informat & Comp, Dept BioHlth Informat, Indianapolis, IN 46202 USA; [Cesarano, Annamaria; Bombaci, Giuseppe; Yu, Christina Y.; Abu Zaid, Mohammad; Walker, Brian A.; Perna, Fabiana] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Reiter, Jill L.; Wang, Yue; Lu, Xiongbin; Liu, Yunlong] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Jiang, Zhaoyang] Zionsville Community High Sch, Boone, IN 46077 USA; [Abu Zaid, Mohammad; Huang, Kun; Lu, Xiongbin; Walker, Brian A.; Perna, Fabiana; Liu, Yunlong] Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA; [Huang, Kun] Indiana Univ Sch Med, Dept Biostat & Hlth Data Sci, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Liu, YL (corresponding author), Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA.; Liu, YL (corresponding author), Indiana Univ Purdue Univ, Sch Informat & Comp, Dept BioHlth Informat, Indianapolis, IN 46202 USA.; Perna, F (corresponding author), Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA.; Liu, YL (corresponding author), Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.; Perna, F; Liu, YL (corresponding author), Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA.	fabperna@iu.edu; yunliu@iu.edu	Abu Zaid, Mohammad/AFO-3625-2022; Reiter, Jill L/J-3335-2013; Reiter, Jill/AGZ-7331-2022	Reiter, Jill L/0000-0001-5460-2355; Reiter, Jill/0000-0001-5460-2355; Wang, Yue/0000-0003-4671-8547; Dong, Chuanpeng/0000-0001-5068-0495; Huang, Kun/0000-0002-8530-370X	Indiana University Grand Challenge Precision Health Initiative; NIH, National Cancer Institute (NCI) [P30 CA082709]; NIH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [U54 DK106846]; NIH instrumentation grant [1S10D012270]; Leukemia Research Foundation grant	Indiana University Grand Challenge Precision Health Initiative; NIH, National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)National Research Council of Science & Technology (NST), Republic of Korea); NIH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH instrumentation grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia Research Foundation grant	The work was supported by the Indiana University Grand Challenge Precision Health Initiative. This study used the Multiple Myeloma Research Foundation (MMRF) CoMMpass Dataset. The authors acknowledge the efforts of the MMRF research consortium to provide the fundamental resource for our study. MM cell lines were provided by Dr. David Roodman, Indiana University School of Medicine. The authors thank the members of the Indiana University Melvin and Bren Simon Cancer Center (IUSCCC) Flow Cytometry Resource Facility (FCRF) for their outstanding technical support. The IUSCCC FCRF is funded in part by NIH, National Cancer Institute (NCI) grant P30 CA082709 and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant U54 DK106846. The FCRF is supported in part by NIH instrumentation grant 1S10D012270. F.P. is supported by a Leukemia Research Foundation grant and G.B. is a Kroemer Family Fellow in Myeloma Research.	Agirre X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08679-z; Ahmad IA, 1996, AM STAT, V50, P324, DOI 10.2307/2684929; Anczukow O, 2012, NAT STRUCT MOL BIOL, V19, P220, DOI 10.1038/nsmb.2207; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Apcher S, 2011, P NATL ACAD SCI USA, V108, P11572, DOI 10.1073/pnas.1104104108; Bailey P, 2016, SCI REP-UK, V6, DOI 10.1038/srep35848; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Braunschweig U, 2014, GENOME RES, V24, P1774, DOI 10.1101/gr.177790.114; Brogna S, 2009, NAT STRUCT MOL BIOL, V16, P107, DOI 10.1038/nsmb.1550; Buchner M, 2014, CURR OPIN HEMATOL, V21, P341, DOI 10.1097/MOH.0000000000000048; Chabot B, 2016, J CELL BIOL, V212, P13, DOI 10.1083/jcb.201510032; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Chretien ML, 2015, BLOOD, V126, P2713, DOI 10.1182/blood-2015-06-650242; Cowan AJ, 2018, JAMA ONCOL, V4, P1221, DOI 10.1001/jamaoncol.2018.2128; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dufva O, 2020, CANCER CELL, V38, P380, DOI 10.1016/j.ccell.2020.06.002; Frankiw L, 2019, NAT REV IMMUNOL, V19, P675, DOI 10.1038/s41577-019-0195-7; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242; Gu SS, 2021, CANCER DISCOV, V11, P1524, DOI 10.1158/2159-8290.CD-20-0812; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hoyos LE, 2018, CANCER CELL, V34, P181, DOI 10.1016/j.ccell.2018.07.008; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Jacob AG, 2017, HUM GENET, V136, P1043, DOI 10.1007/s00439-017-1791-x; Jensen MA, 2014, NAT STRUCT MOL BIOL, V21, P189, DOI 10.1038/nsmb.2756; Jimenez-Vacas JM, 2020, EBIOMEDICINE, V51, DOI 10.1016/j.ebiom.2019.11.008; Kadash-Edmondson KE, 2019, IRIS BIG DATA INFORM; Kawano Y, 2018, J CLIN INVEST, V128, P2487, DOI 10.1172/JCI88169; Lesokhin AM, 2019, CANCER IMMUNOL RES, V7, P1224, DOI 10.1158/2326-6066.CIR-19-0148; Liu J, 2012, ONKOLOGIE, V35, P335, DOI 10.1159/000338941; Lopes R, 2021, CANCERS, V13, DOI 10.3390/cancers13040625; Lu SX, 2021, CELL, V184, P4032, DOI 10.1016/j.cell.2021.05.038; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Merryman RW, 2017, BLOOD ADV, V1, P2643, DOI 10.1182/bloodadvances.2017012534; Miller A, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.94; Mohamed A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227455; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Orenbuch R, 2020, BIOINFORMATICS, V36, P33, DOI 10.1093/bioinformatics/btz474; Palumbo A, 2015, J CLIN ONCOL, V33, P2863, DOI 10.1200/JCO.2015.61.2267; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Perumal D, 2020, CLIN CANCER RES, V26, P450, DOI 10.1158/1078-0432.CCR-19-2309; Rahman MA, 2020, CELL, V180, P208, DOI 10.1016/j.cell.2019.12.011; Ren YX, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1744947; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; SCHEMPER M, 1992, STATISTICIAN, V41, P455, DOI 10.2307/2349009; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sedgwick P, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e509; Shen LH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50738-4; Shien K, 2016, LUNG CANCER, V99, P79, DOI 10.1016/j.lungcan.2016.06.016; Smart AC, 2018, NAT BIOTECHNOL, V36, P1056, DOI 10.1038/nbt.4239; Tan DJ, 2020, NPJ GENOM MED, V5, DOI 10.1038/s41525-020-00159-4; Teoh PJ, 2018, BLOOD, V132, P1304, DOI 10.1182/blood-2018-02-832576; Walker BA, 2019, LEUKEMIA, V33, P159, DOI 10.1038/s41375-018-0196-8; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Wong JJL, 2013, CELL, V154, P583, DOI 10.1016/j.cell.2013.06.052; Xie RH, 2019, CANCER LETT, V449, P31, DOI 10.1016/j.canlet.2019.01.041; Yang RY, 2018, BIORXIV; Yap K, 2012, GENE DEV, V26, P1209, DOI 10.1101/gad.188037.112; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zelle-Rieser C, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0345-3; Zhang D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16649-z; Zhang J, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0369-7; Zhao RH, 2013, P NATL ACAD SCI USA, V110, P9879, DOI 10.1073/pnas.1303524110	64	7	7	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6130	6138		10.1038/s41388-021-02005-y	http://dx.doi.org/10.1038/s41388-021-02005-y		SEP 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34504297	hybrid, Green Published			2022-12-28	WOS:000694570400001
J	Brahma, MK; Gilglioni, EH; Zhou, L; Trepo, E; Chen, PY; Gurzov, EN				Brahma, Manoja K.; Gilglioni, Eduardo H.; Zhou, Lang; Trepo, Eric; Chen, Pengyu; Gurzov, Esteban N.			Oxidative stress in obesity-associated hepatocellular carcinoma: sources, signaling and therapeutic challenges	ONCOGENE			English	Review							NONALCOHOLIC FATTY LIVER; PROTEIN-TYROSINE PHOSPHATASES; NITRIC-OXIDE SYNTHASE; BCL-2 FAMILY PROTEINS; NF-KAPPA-B; CO-DELIVERY; MITOCHONDRIAL-FUNCTION; REVERSIBLE OXIDATION; INSULIN SENSITIVITY; NLRP3 INFLAMMASOME	Obesity affects more than 650 million individuals worldwide and is a well-established risk factor for the development of hepatocellular carcinoma (HCC). Oxidative stress can be considered as a bona fide tumor promoter, contributing to the initiation and progression of liver cancer. Indeed, one of the key events involved in HCC progression is excessive levels of reactive oxygen species (ROS) resulting from the fatty acid influx and chronic inflammation. This review provides insights into the different intracellular sources of obesity-induced ROS and molecular mechanisms responsible for hepatic tumorigenesis. In addition, we highlight recent findings pointing to the role of the dysregulated activity of BCL-2 proteins and protein tyrosine phosphatases (PTPs) in the generation of hepatic oxidative stress and ROS-mediated dysfunctional signaling, respectively. Finally, we discuss the potential and challenges of novel nanotechnology strategies to prevent ROS formation in obesity-associated HCC.	[Brahma, Manoja K.; Gilglioni, Eduardo H.; Gurzov, Esteban N.] Univ Libre Bruxelles, Signal Transduct & Metab Lab, Lab Gastroenterol Expt & Endotools, Brussels, Belgium; [Zhou, Lang; Chen, Pengyu] Auburn Univ, Mat Res & Educ Ctr, Auburn, AL 36849 USA; [Trepo, Eric] Univ Libre Bruxelles, Dept Gastroenterol Hepatopancreatol & Digest Onco, CUB Hop Erasme, Brussels, Belgium; [Trepo, Eric] Univ Libre Bruxelles, Lab Expt Gastroenterol, Brussels, Belgium	Universite Libre de Bruxelles; Auburn University System; Auburn University; Universite Libre de Bruxelles; Universite Libre de Bruxelles	Gurzov, EN (corresponding author), Univ Libre Bruxelles, Signal Transduct & Metab Lab, Lab Gastroenterol Expt & Endotools, Brussels, Belgium.	esteban.gurzov@ulb.be	Trépo, Eric/ABD-9339-2021	BRAHMA, MANOJA/0000-0003-3191-0720; Gilglioni, Eduardo Hideo/0000-0001-5137-4051	Fonds National de la Recherche Scientifique (FNRS)-MIS grant [33650793]; FNRS-WELBIO grant [35112672]; FNRS-CDR grant [35275350]; European Research Council (ERC) Consolidator grant METAPTPs [GA817940]; JDRF Career Development Award [CDA-2019-758-A-N]; National Science Foundation grant [CBET-1943302]; National Institutes of Health grant [R35GM133795]	Fonds National de la Recherche Scientifique (FNRS)-MIS grant(Fonds de la Recherche Scientifique - FNRS); FNRS-WELBIO grant(Fonds de la Recherche Scientifique - FNRSWELBIO); FNRS-CDR grant; European Research Council (ERC) Consolidator grant METAPTPs(European Research Council (ERC)); JDRF Career Development Award(Juvenile Diabetes Research Foundation); National Science Foundation grant(National Science Foundation (NSF)); National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Pu Chun Ke for critical reading of the manuscript. This work was supported by Fonds National de la Recherche Scientifique (FNRS)-MIS grant (33650793), FNRS-WELBIO grant (35112672), FNRS-CDR grant (35275350), European Research Council (ERC) Consolidator grant METAPTPs (GA817940), a JDRF Career Development Award (CDA-2019-758-A-N), National Science Foundation grant (CBET-1943302) and National Institutes of Health grant (R35GM133795). E.T. and E.N.G. are Research Associates of the FNRS, Belgium.	Al-Serri A, 2012, J HEPATOL, V56, P448, DOI 10.1016/j.jhep.2011.05.029; Anstee QM, 2019, NAT REV GASTRO HEPAT, V16, P411, DOI 10.1038/s41575-019-0145-7; Baffy G, 2018, ADV EXP MED BIOL, V1061, P63, DOI 10.1007/978-981-10-8684-7_6; Bartneck Matthias, 2014, Hepatobiliary Surg Nutr, V3, P364, DOI 10.3978/j.issn.2304-3881.2014.11.02; Bedoui S, 2020, NAT REV MOL CELL BIO, V21, P678, DOI 10.1038/s41580-020-0270-8; Bellanti F, 2017, FREE RADICAL BIO MED, V111, P173, DOI 10.1016/j.freeradbiomed.2017.01.023; Bessone F, 2019, CELL MOL LIFE SCI, V76, P99, DOI 10.1007/s00018-018-2947-0; Bettaieb A, 2015, GASTROENTEROLOGY, V149, P468, DOI 10.1053/j.gastro.2015.04.009; Bhattacharya S, 2008, BIOORG MED CHEM LETT, V18, P5856, DOI 10.1016/j.bmcl.2008.06.029; Bian XL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14420; Boivin B, 2008, P NATL ACAD SCI USA, V105, P9959, DOI 10.1073/pnas.0804336105; Bourebaba L, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051294; Broadfield LA, 2021, CANCER RES, V81, P1988, DOI 10.1158/0008-5472.CAN-20-1954; Brown KE, 2001, AM J PATHOL, V159, P2081, DOI 10.1016/S0002-9440(10)63059-3; Cao N, 2011, BIOMATERIALS, V32, P2222, DOI 10.1016/j.biomaterials.2010.11.061; Cao SS, 2014, ANTIOXID REDOX SIGN, V21, P396, DOI 10.1089/ars.2014.5851; Cheng HW, 2018, MAT SCI ENG C-MATER, V83, P210, DOI 10.1016/j.msec.2017.08.075; Cho CY, 2006, CELL METAB, V3, P367, DOI 10.1016/j.cmet.2006.03.006; D'Hollander A, 2017, BIOMATERIALS, V123, P15, DOI 10.1016/j.biomaterials.2017.01.007; Dai Q, 2014, ANGEW CHEM INT EDIT, V53, P5093, DOI 10.1002/anie.201309464; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Derdak Z, 2013, J HEPATOL, V58, P785, DOI 10.1016/j.jhep.2012.11.042; Dubois MJ, 2006, NAT MED, V12, P549, DOI 10.1038/nm1397; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Emdin CA, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008629; Fares R, 2015, LIVER INT, V35, P1574, DOI 10.1111/liv.12707; Forrester SJ, 2018, CIRC RES, V122, P877, DOI 10.1161/CIRCRESAHA.117.311401; Fransen M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061126; Fukushima A, 2010, DIABETES, V59, P1906, DOI 10.2337/db09-1365; Giordano A, 2005, CELL DEATH DIFFER, V12, P603, DOI 10.1038/sj.cdd.4401636; Glick D, 2012, MOL CELL BIOL, V32, P2570, DOI 10.1128/MCB.00167-12; Goh GBB, 2016, DIGEST DIS SCI, V61, P1226, DOI 10.1007/s10620-016-4095-4; Grohmann M, 2018, CELL, V175, P1289, DOI 10.1016/j.cell.2018.09.053; Gross A, 2017, CELL DEATH DIFFER, V24, P1348, DOI 10.1038/cdd.2017.22; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Guri Y, 2017, CANCER CELL, V32, P807, DOI 10.1016/j.ccell.2017.11.011; Gurzov EN, 2015, TRENDS ENDOCRIN MET, V26, P30, DOI 10.1016/j.tem.2014.10.004; Gurzov EN, 2014, CELL METAB, V20, P85, DOI 10.1016/j.cmet.2014.05.011; Haque A, 2011, CELL, V147, P185, DOI 10.1016/j.cell.2011.08.036; Hsu MF, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101658; Huang YD, 2018, CANCERS, V10, DOI 10.3390/cancers10030082; Huang YQ, 2019, THERANOSTICS, V9, P4391, DOI 10.7150/thno.32462; Husseini UK, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4752-4; Kale J, 2018, CELL DEATH DIFFER, V25, P65, DOI 10.1038/cdd.2017.186; Kanda T, 2018, WORLD J GASTROENTERO, V24, P2661, DOI 10.3748/wjg.v24.i25.2661; Ke PC, 2017, ACS NANO, V11, P11773, DOI 10.1021/acsnano.7b08008; Kelkar SS, 2011, BIOCONJUGATE CHEM, V22, P1879, DOI 10.1021/bc200151q; Khan AA, 2016, BIOMED PHARMACOTHER, V81, P394, DOI 10.1016/j.biopha.2016.04.033; Kim J, 2021, J CONTROL RELEASE, V330, P920, DOI 10.1016/j.jconrel.2020.10.065; Kim M, 2017, CURR PHARM DESIGN, V23, P4226, DOI [10.2174/1381612823666170710145019, 10.2174/1381612823666170616082125]; Kim TH, 2016, ENDOCR-RELAT CANCER, V23, P813, DOI 10.1530/ERC-16-0219; Koliaki C, 2015, CELL METAB, V21, P739, DOI 10.1016/j.cmet.2015.04.004; Krishnan N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02252-2; Kumar M, 2014, CANCER RES, V74, P3271, DOI 10.1158/0008-5472.CAN-13-2015; Kumar P, 2022, ARCH PHYSIOL BIOCHEM, V128, P836, DOI 10.1080/13813455.2020.1733024; Lally JSV, 2019, CELL METAB, V29, P174, DOI 10.1016/j.cmet.2018.08.020; Lee S, 2017, ONCOTARGET, V8, P63370, DOI 10.18632/oncotarget.18812; Li DC, 2004, CANCER SCI, V95, P644, DOI 10.1111/j.1349-7006.2004.tb03323.x; Li XY, 2020, NUCLEIC ACIDS RES, V48, P8255, DOI 10.1093/nar/gkaa615; Liang S, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00017; Lismont C, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00035; Litwak SA, 2017, DIABETES, V66, P2973, DOI 10.2337/db17-0348; Liu DP, 2011, ANTIOXID REDOX SIGN, V15, P1669, DOI 10.1089/ars.2010.3644; Liu MX, 2018, ONCOGENE, V37, P1637, DOI 10.1038/s41388-017-0070-6; Liu MC, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00677-4; Llovet JM, 2021, NAT REV GASTRO HEPAT, V18, P293, DOI 10.1038/s41575-020-00395-0; Loh K, 2009, CELL METAB, V10, P260, DOI 10.1016/j.cmet.2009.08.009; Lou YW, 2008, FEBS J, V275, P69, DOI 10.1111/j.1742-4658.2007.06173.x; Loughran PA, 2005, P NATL ACAD SCI USA, V102, P13837, DOI 10.1073/pnas.0503926102; Luedde T, 2011, NAT REV GASTRO HEPAT, V8, P108, DOI 10.1038/nrgastro.2010.213; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Marquardt JU, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01421; Masarone M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9547613; Matsuo K, 2010, J BIOL CHEM, V285, P39750, DOI 10.1074/jbc.M110.153734; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Merino D, 2018, CANCER CELL, V34, P879, DOI 10.1016/j.ccell.2018.11.004; Mobasher MA, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.150; Nahon P, 2009, HEPATOLOGY, V50, P1484, DOI 10.1002/hep.23187; Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001; Nakajima W., 2016, INTEGR CANC SCI THER, V3, P437, DOI [10.15761/icst.1000184, DOI 10.15761/ICST.1000184]; Ning Q, 2019, ACS APPL MATER INTER, V11, P10578, DOI 10.1021/acsami.9b00634; Nisha R, 2021, MOL PHARMACEUT, V18, P1102, DOI 10.1021/acs.molpharmaceut.0c01024; Nishida N, 2016, J GASTROEN HEPATOL, V31, P1646, DOI 10.1111/jgh.13318; Nishino T, 2008, FEBS J, V275, P3278, DOI 10.1111/j.1742-4658.2008.06489.x; Ostman A, 2011, J BIOCHEM, V150, P345, DOI 10.1093/jb/mvr104; Ramalho RM, 2006, EUR J GASTROEN HEPAT, V18, P21, DOI 10.1097/00042737-200601000-00005; Raza Sana, 2019, Hepatoma Res, V5, P42, DOI 10.20517/2394-5079.2019.014; Schneider J, 2018, CHEM RES TOXICOL, V31, P447, DOI 10.1021/acs.chemrestox.7b00329; Scotcher J, 2011, J AM SOC MASS SPECTR, V22, P888, DOI 10.1007/s13361-011-0088-x; Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3; Sparacino-Watkins CE, 2014, J BIOL CHEM, V289, P10345, DOI 10.1074/jbc.M114.555177; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; Stolz DB, 2002, HEPATOLOGY, V36, P81, DOI 10.1053/jhep.2002.33716; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Sunny NE, 2017, TRENDS ENDOCRIN MET, V28, P250, DOI 10.1016/j.tem.2016.11.006; Susnow N, 2009, SEMIN CANCER BIOL, V19, P42, DOI 10.1016/j.semcancer.2008.12.002; Tanaka T, 1997, HEPATOLOGY, V26, P283, DOI 10.1002/hep.510260205; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Tao JY, 2021, HEPATOLOGY, V74, P741, DOI 10.1002/hep.31730; Tian GX, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00004; Tiganis T, 2011, TRENDS PHARMACOL SCI, V32, P82, DOI 10.1016/j.tips.2010.11.006; Tomita K, 2012, J HEPATOL, V57, P837, DOI 10.1016/j.jhep.2012.05.013; Tummala KS, 2014, CANCER CELL, V26, P826, DOI 10.1016/j.ccell.2014.10.002; Wali JA, 2018, CELL DEATH DIFFER, V25, P217, DOI 10.1038/cdd.2017.168; Wang B, 2010, J HEPATOL, V53, P508, DOI 10.1016/j.jhep.2010.03.026; Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126; Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022; Wen YK, 2021, CELL MOL IMMUNOL, V18, P45, DOI 10.1038/s41423-020-00558-8; Wilson GK, 2014, J HEPATOL, V61, P1397, DOI 10.1016/j.jhep.2014.08.025; Wree A, 2014, HEPATOLOGY, V59, P898, DOI 10.1002/hep.26592; Xu E, 2012, DIABETES, V61, P1949, DOI 10.2337/db11-1502; Ye Z, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201706600; Yoboue ED, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0033-4; Younossi Z, 2018, NAT REV GASTRO HEPAT, V15, P11, DOI 10.1038/nrgastro.2017.109; Yu M, 2018, ARTIF CELL NANOMED B, V46, P323, DOI 10.1080/21691401.2017.1307215; Zhang H, 2015, INT J NANOMED, V10, P1909, DOI 10.2147/IJN.S77125; Zhou Y., 2019, J NANOMATERIALS, V2019, P1	119	13	13	4	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5155	5167		10.1038/s41388-021-01950-y	http://dx.doi.org/10.1038/s41388-021-01950-y		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34290399	Green Accepted			2022-12-28	WOS:000677857200002
J	Kobelt, D; Perez-Hernandez, D; Fleuter, C; Dahlmann, M; Zincke, F; Smith, J; Migotti, R; Popp, O; Burock, S; Walther, W; Dittmar, G; Mertins, P; Stein, U				Kobelt, Dennis; Perez-Hernandez, Daniel; Fleuter, Claudia; Dahlmann, Mathias; Zincke, Fabian; Smith, Janice; Migotti, Rebekka; Popp, Oliver; Burock, Susen; Walther, Wolfgang; Dittmar, Gunnar; Mertins, Philipp; Stein, Ulrike			The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasis	ONCOGENE			English	Article							ERK1/2 MAP KINASES; AZD6244 ARRY-142886; CELL-SURVIVAL; IN-VIVO; PROGRESSION; MELANOMA; OVEREXPRESSION; SPECIFICITY; ACTIVATION; RESISTANCE	Cancer metastasis causes >90% of cancer deaths and remains a major treatment challenge. Here we deciphered the impact of tyrosine phosphorylation of MACC1, a causative driver for cancer metastasis, for cancer cell signaling and novel interventions to restrict cancer metastasis. We identified MACC1 as new MEK1 substrate. MEK1 directly phosphorylates MACC1, leading to accelerated and increased ERK1 activation. Mutating in silico predicted hierarchical MACC1 tyrosine phosphorylation sites abrogates MACC1-induced migration, invasion, and MET expression, a transcriptional MACC1 target. Targeting MEK1 by RNAi or clinically applicable MEK1 inhibitors AZD6244 and GSK1120212 reduces MACC1 tyrosine phosphorylation and restricts MACC1-induced metastasis formation in mice. Although MEK1 levels, contrary to MACC1, are not of prognostic relevance for CRC patients, MEK1 expression was found indispensable for MACC1-induced metastasis. This study identifies MACC1 as new MEK1 substrate for tyrosine phosphorylation decisively impacting cell motility, tumor growth, and metastasis. Thus, MAP kinase signaling is not linear leading to ERK activation, but branches at the level of MEK1. This fundamental finding opens new therapeutic options for targeting the MEK1/MACC1 axis as novel vulnerability in patients at high risk for metastasis. This might be extended from CRC to further solid tumor entities.	[Kobelt, Dennis; Fleuter, Claudia; Dahlmann, Mathias; Zincke, Fabian; Smith, Janice; Walther, Wolfgang; Stein, Ulrike] Charite Univ Med Berlin, Expt & Clin Res Ctr, Translat Oncol Solid Tumors, Berlin, Germany; [Kobelt, Dennis; Fleuter, Claudia; Dahlmann, Mathias; Zincke, Fabian; Smith, Janice; Walther, Wolfgang; Stein, Ulrike] Helmholtz Assoc, Max Delbruck Ctr Mol Med, Berlin, Germany; [Kobelt, Dennis; Dahlmann, Mathias; Zincke, Fabian; Stein, Ulrike] German Canc Consortium DKTK, Heidelberg, Germany; [Perez-Hernandez, Daniel; Migotti, Rebekka; Popp, Oliver; Dittmar, Gunnar; Mertins, Philipp] Helmholtz Assoc, Mass Spectrometry Core Unit, Max Delbruck Ctr Mol Med, Berlin, Germany; [Popp, Oliver; Mertins, Philipp] Berlin Inst Hlth BIH, Berlin, Germany; [Burock, Susen] Charite Univ Med Berlin, Charite Comprehens Canc Ctr, Berlin, Germany; [Perez-Hernandez, Daniel; Dittmar, Gunnar] Luxembourg Inst Hlth, Proteome & Genome Res Lab, Strassen, Luxembourg	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Luxembourg Institute of Health	Stein, U (corresponding author), Charite Univ Med Berlin, Expt & Clin Res Ctr, Translat Oncol Solid Tumors, Berlin, Germany.; Stein, U (corresponding author), Helmholtz Assoc, Max Delbruck Ctr Mol Med, Berlin, Germany.; Stein, U (corresponding author), German Canc Consortium DKTK, Heidelberg, Germany.	ustein@mdc-berlin.de	; Dittmar, Gunnar/B-6383-2016	Dahlmann, Mathias/0000-0002-0036-5283; Dittmar, Gunnar/0000-0003-3647-8623; Stein, Ulrike/0000-0001-7006-282X; Burock, Susen/0000-0002-0964-4174; Perez Hernandez, Daniel/0000-0003-0266-9050	German Cancer Consortium (DKTK); Preclinical Comprehensive Cancer Center (PCCC); Projekt DEAL	German Cancer Consortium (DKTK); Preclinical Comprehensive Cancer Center (PCCC); Projekt DEAL	This work was supported by grants from the German Cancer Consortium (DKTK; to US) and from the Preclinical Comprehensive Cancer Center (PCCC; to US). Open Access funding enabled and organized by Projekt DEAL.	Akinleye A, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-27; Ashktorab H, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0971-0; Becker M, 2002, BRIT J CANCER, V87, P1328, DOI 10.1038/sj.bjc.6600573; Budczies J, 2020, SEMIN CANCER BIOL, V60, P365, DOI 10.1016/j.semcancer.2019.08.010; Burock S, 2015, WORLD J GASTROENTERO, V21, P333, DOI 10.3748/wjg.v21.i1.333; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231; Duan GY, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004049; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Flanigan SA, 2013, CLIN CANCER RES, V19, P6219, DOI 10.1158/1078-0432.CCR-13-0145; Germann UA, 2017, MOL CANCER THER, V16, P2351, DOI 10.1158/1535-7163.MCT-17-0456; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; Grimaldi AM, 2017, AM J CLIN DERMATOL, V18, P745, DOI 10.1007/s40257-017-0292-y; Haass NK, 2008, CLIN CANCER RES, V14, P230, DOI 10.1158/1078-0432.CCR-07-1440; Hagemann C, 2013, NEURO-ONCOLOGY, V15, P1696, DOI 10.1093/neuonc/not136; Huang LL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00977-0; Huang PH, 2010, MOL BIOSYST, V6, P1227, DOI 10.1039/c001196g; Hunter T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020644; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Ilm K, 2016, ONCOTARGET, V7, P53443, DOI 10.18632/oncotarget.10803; Ilm K, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0316-2; Juneja M, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2000784; Juneja M, 2013, MOL ONCOL, V7, P929, DOI 10.1016/j.molonc.2013.05.003; Kaneko T, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-32; Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Koelzer VH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1150-z; Kyriakakis E, 2017, CELL SIGNAL, V35, P163, DOI 10.1016/j.cellsig.2017.04.004; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Lavoie H, 2020, NAT REV MOL CELL BIO, V21, P607, DOI 10.1038/s41580-020-0255-7; Lederer A, 2015, HEPATOLOGY, V62, P841, DOI 10.1002/hep.27885; Lemos C, 2016, CLIN CANCER RES, V22, P2812, DOI 10.1158/1078-0432.CCR-15-1425; Link T, 2019, MOL ONCOL, V13, P1268, DOI 10.1002/1878-0261.12484; Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4; Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438; Martin-Liberal J, 2014, EXPERT OPIN DRUG SAF, V13, P483, DOI 10.1517/14740338.2014.892578; Mudduluru G, 2017, MECH MOL CARCINOGENE, V1, P11; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nitsche U, 2012, ANN SURG, V256, P763, DOI 10.1097/SLA.0b013e318272de87; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; Pichorner A, 2012, CLIN EXP METASTAS, V29, P573, DOI 10.1007/s10585-012-9472-6; Radhakrishnan H, 2018, CANCER METAST REV, V37, P805, DOI 10.1007/s10555-018-9771-8; Raghu VK, 2018, BIOCHEM BIOPH RES CO, V495, P659, DOI 10.1016/j.bbrc.2017.11.065; Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261; Rohr UP, 2017, ANN ONCOL, V28, P1869, DOI 10.1093/annonc/mdx207; Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005; Roskoski R, 2012, BIOCHEM BIOPH RES CO, V417, P5, DOI 10.1016/j.bbrc.2011.11.145; Rozevsky Y, 2020, ACS NANO, V14, P13964, DOI 10.1021/acsnano.0c06375; Schmid F, 2016, ONCOGENE, V35, P5942, DOI 10.1038/onc.2015.451; Schmid F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-49; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stein Ulrike, 2007, V176, P61; Stein U, 2013, EXPERT OPIN THER TAR, V17, P1039, DOI 10.1517/14728222.2013.815727; Stein U, 2010, J MOL MED, V88, P11, DOI 10.1007/s00109-009-0537-1; Stein U, 2009, CELL CYCLE, V8, P2467, DOI 10.4161/cc.8.15.9018; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Sun DW, 2015, INT J CLIN EXP MED, V8, P4769; Tang ZJ, 2015, CELL, V160, P729, DOI 10.1016/j.cell.2015.01.028; Wang G, 2015, TUMOR BIOL, V36, P1055, DOI 10.1007/s13277-014-2736-9; Wright CJM, 2013, DRUGS, V73, P1245, DOI 10.1007/s40265-013-0096-1; Wu ZZ, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/252043; Xue Z, 2018, CELL RES, V28, P719, DOI 10.1038/s41422-018-0044-4; Yamaguchi T, 2011, INT J ONCOL, V39, P23, DOI 10.3892/ijo.2011.1015; Yang BC, 2017, CANCER LETT, V388, P167, DOI 10.1016/j.canlet.2016.11.037; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Zeiser R, 2014, RECENT RESULTS CANC, V201, P241, DOI 10.1007/978-3-642-54490-3_15; Zhao Y, 2016, ONCOTARGET, V7, P62966, DOI 10.18632/oncotarget.11287	75	6	6	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5286	5301		10.1038/s41388-021-01917-z	http://dx.doi.org/10.1038/s41388-021-01917-z		JUL 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34247190	hybrid, Green Published			2022-12-28	WOS:000671644900001
J	Carotti, S; Zingariello, M; Francesconi, M; D'Andrea, L; Latasa, MU; Colyn, L; Fernandez-Barrena, MG; Flammia, RS; Falchi, M; Righi, D; Pedini, G; Pantano, F; Bagni, C; Perrone, G; Rana, RA; Avila, MA; Morini, S; Zalfa, F				Carotti, Simone; Zingariello, Maria; Francesconi, Maria; D'Andrea, Laura; Latasa, M. Ujue; Colyn, Leticia; Fernandez-Barrena, Maite G.; Flammia, Rocco Simone; Falchi, Mario; Righi, Daniela; Pedini, Giorgia; Pantano, Francesco; Bagni, Claudia; Perrone, Giuseppe; Rana, Rosa Alba; Avila, Matias A.; Morini, Sergio; Zalfa, Francesca			Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge	ONCOGENE			English	Article							MESSENGER-RNA TRANSPORT; HEPATOCELLULAR-CARCINOMA; MYOSIN VA; FMRP; TRANSLATION; METASTASIS; EXPRESSION; ACTIN; IDENTIFICATION; ESTABLISHMENT	Intrahepatic cholangiocarcinoma (iCCA) is a rare malignancy of the intrahepatic biliary tract with a very poor prognosis. Although some clinicopathological parameters can be prognostic factors for iCCA, the molecular prognostic markers and potential mechanisms of iCCA have not been well investigated. Here, we report that the Fragile X mental retardation protein (FMRP), a RNA binding protein functionally absent in patients with the Fragile X syndrome (FXS) and also involved in several types of cancers, is overexpressed in human iCCA and its expression is significantly increased in iCCA metastatic tissues. The silencing of FMRP in metastatic iCCA cell lines affects cell migration and invasion, suggesting a role of FMRP in iCCA progression. Moreover, we show evidence that FMRP is localized at the invasive front of human iCCA neoplastic nests and in pseudopodia and invadopodia protrusions of migrating and invading iCCA cancer cells. Here FMRP binds several mRNAs encoding key proteins involved in the formation and/or function of these protrusions. In particular, we find that FMRP binds to and regulates the expression of Cortactin, a critical regulator of invadopodia formation. Altogether, our findings suggest that FMRP could promote cell invasiveness modulating membrane plasticity and invadopodia formation at the leading edges of invading iCCA cells.	[Carotti, Simone; Zingariello, Maria; Francesconi, Maria; D'Andrea, Laura; Flammia, Rocco Simone; Morini, Sergio; Zalfa, Francesca] Campus Biomed Univ, Dept Med, Res Unit Microscop & Ultrastruct Anat, Rome, Italy; [Carotti, Simone; Righi, Daniela; Perrone, Giuseppe; Zalfa, Francesca] Campus Biomed Univ Hosp, Dept Pathol, Predict Mol Diagnost Unit, Rome, Italy; [Latasa, M. Ujue; Colyn, Leticia; Fernandez-Barrena, Maite G.; Avila, Matias A.] Univ Navarra, Hepatol Program, Ctr Appl Med Res CIMA, Pamplona, Spain; [Latasa, M. Ujue; Colyn, Leticia; Fernandez-Barrena, Maite G.; Avila, Matias A.] IdiSNA, Pamplona, Spain; [Fernandez-Barrena, Maite G.] Ctr Investigac Biomed Red Enfermedades Hepat & Di, Madrid, Spain; [Falchi, Mario] Ist Super Sanita, Natl AIDS Ctr, Rome, Italy; [Pedini, Giorgia; Bagni, Claudia] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy; [Pantano, Francesco] Campus Biomed Univ, Med Oncol Dept, Rome, Italy; [Bagni, Claudia] Univ Lausanne, Dept Fundamental Neurosci, Lausanne, Switzerland; [Perrone, Giuseppe] Campus Biomed Univ, Res Unit Pathol, Rome, Italy; [Rana, Rosa Alba] Univ G DAnnunzio, Med & Aging Sci Dept, Chieti, Italy	University Campus Bio-Medico - Rome Italy; University Campus Bio-Medico - Rome Italy; University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; University Campus Bio-Medico - Rome Italy; University of Lausanne; University Campus Bio-Medico - Rome Italy; G d'Annunzio University of Chieti-Pescara	Morini, S; Zalfa, F (corresponding author), Campus Biomed Univ, Dept Med, Res Unit Microscop & Ultrastruct Anat, Rome, Italy.; Zalfa, F (corresponding author), Campus Biomed Univ Hosp, Dept Pathol, Predict Mol Diagnost Unit, Rome, Italy.	s.morini@unicampus.it; f.zalfa@unicampus.it	Perrone, Giuseppe/GLR-7098-2022; Avila, Matias A/Y-6342-2019; Flammia, Rocco Simone/ABC-2869-2021; Morini, Sergio/AAB-8540-2022; Pantano, Francesco/D-8459-2012	Avila, Matias A/0000-0001-6570-3557; Flammia, Rocco Simone/0000-0002-3129-0544; Morini, Sergio/0000-0001-6137-2404; Pantano, Francesco/0000-0002-2894-9686; Bagni, Claudia/0000-0002-4419-210X; Colyn, Leticia/0000-0002-7403-9149; Falchi, Mario/0000-0002-8290-5406; D'Andrea, Laura/0000-0002-2042-9782	FIRB 2010 funds [RBAP10447J_005]; Pathology Dept. and Predictive Molecular Diagnostic Division funds; Hepacare Project from Fundacion La Caixa; AECC Grant for Rare and Childhood cancers from Instituto de Salud Carlos III [FIS PI16/01126]; Gobierno de Navarra Salud [58/17]; FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal de Investigacion [PID2019-104878RB-100/AEI/10.13039/501100011033]; Fundacion Eugenio Rodriguez Pascual; Italian Fragile X Association; PRIN2017 89LFKB; Etat de Vaud	FIRB 2010 funds; Pathology Dept. and Predictive Molecular Diagnostic Division funds; Hepacare Project from Fundacion La Caixa; AECC Grant for Rare and Childhood cancers from Instituto de Salud Carlos III; Gobierno de Navarra Salud; FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal de Investigacion; Fundacion Eugenio Rodriguez Pascual; Italian Fragile X Association; PRIN2017 89LFKB; Etat de Vaud	This research was supported by FIRB 2010 funds (RBAP10447J_005) to RAR, by Pathology Dept. and Predictive Molecular Diagnostic Division funds to GP, by private funds to SM and by Hepacare Project from Fundacion La Caixa, AECC Grant for Rare and Childhood cancers 2017 call, grant FIS PI16/01126 from Instituto de Salud Carlos III, grant 58/17 from Gobierno de Navarra Salud, grant PID2019-104878RB-100/AEI/10.13039/501100011033 from FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal de Investigacion, and Fundacion Eugenio Rodriguez Pascual to MAA and MGF-B. MGF-B is a Ramon y Cajal Fellow (RYC2018-00244475-1) and LC is a predoctoral fellow of the Gobierno de Navarra. GP was supported by the Italian Fragile X Association and PRIN2017 89LFKB and Etat de Vaud to CB. We thank Franca Abbruzzese for technical help with time lapse confocal acquisitions and Prof. R. Suzanne Zukin for the plasmid expressing human FMRP.	Arjonen A, 2011, CELL ADHES MIGR, V5, P421, DOI 10.4161/cam.5.5.17723; Ascano M, 2012, NATURE, V492, P382, DOI 10.1038/nature11737; Bagni C, 2019, NEURON, V101, P1070, DOI 10.1016/j.neuron.2019.02.041; Bagni C, 2013, AM J MED GENET A, V161, P2809, DOI 10.1002/ajmg.a.36241; Bagni C, 2012, J CLIN INVEST, V122, P4314, DOI 10.1172/JCI63141; Banales JM, 2016, NAT REV GASTRO HEPAT, V13, P261, DOI 10.1038/nrgastro.2016.51; Barcena-Varela M, 2019, HEPATOLOGY, V69, P587, DOI 10.1002/hep.30168; Beaty BT, 2014, EUR J CELL BIOL, V93, P438, DOI 10.1016/j.ejcb.2014.07.003; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Bhakar AL, 2012, ANNU REV NEUROSCI, V35, P417, DOI 10.1146/annurev-neuro-060909-153138; Bhogal B, 2011, NAT NEUROSCI, V14, P1517, DOI 10.1038/nn.2950; Bravo-Cordero JJ, 2012, CURR OPIN CELL BIOL, V24, P277, DOI 10.1016/j.ceb.2011.12.004; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Clements O, 2020, J HEPATOL, V72, P95, DOI 10.1016/j.jhep.2019.09.007; D'Hulst C, 2006, BRAIN RES, V1121, P238, DOI 10.1016/j.brainres.2006.08.115; Darnell JC, 2011, CELL, V146, P247, DOI 10.1016/j.cell.2011.06.013; Davidovic L, 2007, HUM MOL GENET, V16, P3047, DOI 10.1093/hmg/ddm263; De Rubeis S, 2010, MOL CELL NEUROSCI, V43, P43, DOI 10.1016/j.mcn.2009.09.013; Di Grazia A., 2020, CELL MOL GASTROENTER, V20, P30172; Dianat N, 2014, HEPATOLOGY, V60, P700, DOI 10.1002/hep.27165; Dictenberg JB, 2008, DEV CELL, V14, P926, DOI 10.1016/j.devcel.2008.04.003; Didiot MC, 2008, NUCLEIC ACIDS RES, V36, P4902, DOI 10.1093/nar/gkn472; Eddy RJ, 2017, TRENDS CELL BIOL, V27, P595, DOI 10.1016/j.tcb.2017.03.003; Elizalde M, 2014, J CLIN INVEST, V124, P2909, DOI 10.1172/JCI74382; Ferrari F, 2007, MOL CELL NEUROSCI, V34, P343, DOI 10.1016/j.mcn.2006.11.015; Filippini A, 2017, RNA BIOL, V14, P1580, DOI 10.1080/15476286.2017.1338232; Gkogkas CG, 2014, CELL REP, V9, P1742, DOI 10.1016/j.celrep.2014.10.064; Gross C, 2012, NEUROPSYCHOPHARMACOL, V37, P178, DOI 10.1038/npp.2011.137; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Insall RH, 2009, DEV CELL, V17, P310, DOI 10.1016/j.devcel.2009.08.012; Janusz A, 2013, J NEUROSCI, V33, P18234, DOI 10.1523/JNEUROSCI.2207-13.2013; Kalkunte R, 2007, ARCH DIS CHILD, V92, P795, DOI 10.1136/adc.2006.103382; Kao DI, 2010, P NATL ACAD SCI USA, V107, P15601, DOI 10.1073/pnas.1010564107; Kurokawa Y, 2003, J HEPATOL, V39, P1004, DOI 10.1016/S0168-8278(03)00473-2; KUSAKA Y, 1988, RES EXP MED, V188, P367, DOI 10.1007/BF01851205; Li L, 2018, CANCER CELL, V33, P736, DOI 10.1016/j.ccell.2018.02.011; Li Y, 2003, J CANCER RES CLIN, V129, P43, DOI 10.1007/s00432-002-0396-4; Liao GN, 2015, WIRES RNA, V6, P1, DOI 10.1002/wrna.1265; Lindsay AJ, 2014, BIOL CELL, V106, P57, DOI 10.1111/boc.201200076; Liu YF, 2007, ONCOL REP, V18, P943; Luca R, 2013, EMBO MOL MED, V5, P1523, DOI 10.1002/emmm.201302847; MacGrath SM, 2012, J CELL SCI, V125, P1621, DOI 10.1242/jcs.093781; Maurin T, 2018, NUCLEIC ACIDS RES, V46, P6344, DOI 10.1093/nar/gky267; Mavros MN, 2014, JAMA SURG, V149, P565, DOI 10.1001/jamasurg.2013.5137; Mili S, 2008, NATURE, V453, P115, DOI 10.1038/nature06888; Miyashiro KY, 2003, NEURON, V37, P417, DOI 10.1016/S0896-6273(03)00034-5; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Napoli I, 2008, CELL, V134, P1042, DOI 10.1016/j.cell.2008.07.031; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Pollard TD, 2009, SCIENCE, V326, P1208, DOI 10.1126/science.1175862; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Rizvi S, 2018, NAT REV CLIN ONCOL, V15, P95, DOI 10.1038/nrclinonc.2017.157; Rizvi S, 2017, J HEPATOL, V67, P632, DOI 10.1016/j.jhep.2017.03.026; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; Schultz-Pedersen S, 2001, AM J MED GENET, V103, P226, DOI 10.1002/ajmg.1533; Sidhu H, 2014, J NEUROSCI, V34, P9867, DOI 10.1523/JNEUROSCI.1162-14.2014; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Sirica AE, 2019, HEPATOLOGY, V69, P1803, DOI 10.1002/hep.30289; Srivastava A, 2015, FEBS OPEN BIO, V5, P705, DOI 10.1016/j.fob.2015.07.005; Stumpf CR, 2011, CURR OPIN GENET DEV, V21, P474, DOI 10.1016/j.gde.2011.03.007; Taniuchi K, 2014, ONCOTARGET, V5, P6832, DOI 10.18632/oncotarget.2257; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Vira VA., 2009, EXTRACELL MATRIX PRO, V522, P211, DOI [10.1007/978-1-59745-413-1_15, DOI 10.1007/978-1-59745-413-1_15]; Wang YZ, 2013, J CLIN ONCOL, V31, P1188, DOI 10.1200/JCO.2012.41.5984; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Xing Z, 2016, ONCOTARGET, V7, P75394, DOI 10.18632/oncotarget.12215; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zach S, 2015, J STEM CELL RES TRAN, V2, P1013; Zalfa F, 2003, CELL, V112, P317, DOI 10.1016/S0092-8674(03)00079-5; Zalfa F, 2007, NAT NEUROSCI, V10, P578, DOI 10.1038/nn1893; Zalfa F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.521; Zhang MQ, 2007, P NATL ACAD SCI USA, V104, P10057, DOI 10.1073/pnas.0700169104	74	3	3	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					4033	4049		10.1038/s41388-021-01824-3	http://dx.doi.org/10.1038/s41388-021-01824-3		MAY 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	34017076	hybrid, Green Published			2022-12-28	WOS:000652439200002
J	Hu, YM; Liu, FF; Jia, XC; Wang, PL; Gu, TX; Liu, H; Liu, TT; Wei, HF; Chen, HY; Zhao, JZ; Yang, R; Chen, YY; Dong, ZG; Liu, KD				Hu, Yamei; Liu, Fangfang; Jia, Xuechao; Wang, Penglei; Gu, Tingxuan; Liu, Hui; Liu, Tingting; Wei, Huifang; Chen, Hanyong; Zhao, Jiuzhou; Yang, Ran; Chen, Yingying; Dong, Zigang; Liu, Kangdong			Periplogenin suppresses the growth of esophageal squamous cell carcinoma in vitro and in vivo by targeting STAT3	ONCOGENE			English	Article							TYROSINE PHOSPHORYLATION; CANCER; ACTIVATION; INHIBITOR; APOPTOSIS; PATHWAY; JAK1	The mortality rate of esophageal squamous cell carcinoma (ESCC) is higher than that of other cancers worldwide owing to a lack of therapeutic targets and related drugs. This study aimed to find new drugs by targeting an efficacious therapeutic target in ESCC patients. Signal transducer and activator of transcription 3 (STAT3) is hyperactive in ESCC. Herein, we identified a novel STAT3 inhibitor, periplogenin, which strongly inhibited phosphorylation of STAT3 at Tyr705. Docking models and pull-down assays revealed that periplogenin bound directly and specifically to STAT3, leading to significant suppression of subsequent dimerization, nuclear import, and transcription activities. In addition, STAT3 knockdown cell lines were insensitive to periplogenin, whereas in contrast, STAT3-overexpressing cells were more sensitive to periplogenin, indicating that STAT3 was a target of periplogenin. Intraperitoneally administered periplogenin exhibited efficacious therapeutic effects in ESCC patient-derived xenograft models and dramatically impaired the phosphorylation of STAT3 and expression levels of STAT3-mediated downstream genes. Thus, our study demonstrated that periplogenin acted as a new STAT3 inhibitor, suppressing the growth of ESCC in vitro and in vivo, providing a basis for its potential application in ESCC treatment and prevention.	[Hu, Yamei; Liu, Fangfang; Jia, Xuechao; Wang, Penglei; Gu, Tingxuan; Liu, Hui; Liu, Tingting; Wei, Huifang; Chen, Yingying; Dong, Zigang; Liu, Kangdong] Zhengzhou Univ, Acad Med Sci, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China; [Hu, Yamei; Liu, Fangfang; Jia, Xuechao; Wang, Penglei; Gu, Tingxuan; Liu, Hui; Liu, Tingting; Wei, Huifang; Yang, Ran; Dong, Zigang; Liu, Kangdong] China US Henan Hormel Canc Inst, Zhengzhou 450008, Henan, Peoples R China; [Liu, Kangdong] Zhengzhou Univ, Prov Cooperat Innovat Ctr Canc Chemoprevent, Zhengzhou, Henan, Peoples R China; [Liu, Kangdong] Canc Chemoprevent Int Collaborat Lab, Zhengzhou, Henan, Peoples R China; [Dong, Zigang; Liu, Kangdong] State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Henan, Peoples R China; [Chen, Hanyong] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; [Zhao, Jiuzhou] Zhengzhou Univ, Affiliated Canc Hosp, Dept Mol Pathol, Zhengzhou 450008, Henan, Peoples R China	Zhengzhou University; Zhengzhou University; University of Minnesota System; Zhengzhou University	Dong, ZG; Liu, KD (corresponding author), Zhengzhou Univ, Acad Med Sci, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China.; Dong, ZG; Liu, KD (corresponding author), China US Henan Hormel Canc Inst, Zhengzhou 450008, Henan, Peoples R China.; Liu, KD (corresponding author), Zhengzhou Univ, Prov Cooperat Innovat Ctr Canc Chemoprevent, Zhengzhou, Henan, Peoples R China.; Liu, KD (corresponding author), Canc Chemoprevent Int Collaborat Lab, Zhengzhou, Henan, Peoples R China.; Dong, ZG; Liu, KD (corresponding author), State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Henan, Peoples R China.	zgdong@hci-cn.org; kdliu@zzu.edu.cn			National Science Foundation of China [81872335]; Henan Key Science and Technology Program [161100510300]; National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program", China [2018ZX09711002]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Henan Key Science and Technology Program; National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program", China	This work was supported by a grant from the National Science Foundation of China (No. 81872335); Henan Key Science and Technology Program 161100510300; National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program", China (No. 2018ZX09711002). We thank Kyle Vaughn Laster, PhD, from China-US (Henan) Hormel Cancer Institute for polishing parts of this manuscript.	Bai LC, 2019, CANCER CELL, V36, P498, DOI 10.1016/j.ccell.2019.10.002; Banerjee K, 2016, INT J CANCER, V138, P2570, DOI 10.1002/ijc.29923; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buenz EJ, 2018, ANNU REV PHARMACOL, V58, P509, DOI 10.1146/annurev-pharmtox-010617-052703; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chung SY, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0084-z; Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David B, 2015, PHYTOCHEM REV, V14, P299, DOI 10.1007/s11101-014-9367-z; Gadina M, 2018, J LEUKOCYTE BIOL, V104, P499, DOI 10.1002/JLB.5RI0218-084R; Han N, 2010, PLANTA MED, V76, P561, DOI 10.1055/s-0029-1240600; Hindley C, 2013, BIOCHEM J, V451, P135, DOI 10.1042/BJ20121627; Hong D, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5272; Horiguchi A, 2010, BRIT J CANCER, V102, P1592, DOI 10.1038/sj.bjc.6605691; Hussain SF, 2007, CANCER RES, V67, P9630, DOI 10.1158/0008-5472.CAN-07-1243; Huynh J, 2019, NAT REV CANCER, V19, P82, DOI 10.1038/s41568-018-0090-8; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Jonker DJ, 2018, LANCET GASTROENTEROL, V3, P263, DOI 10.1016/S2468-1253(18)30009-8; Kato K, 2014, ESOPHAGUS-TOKYO, V11, P183, DOI 10.1007/s10388-014-0427-7; Khazaei S, 2018, INT J CANCER MANAG, V11, DOI 10.5812/ijcm.10059; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li YZ, 2015, P NATL ACAD SCI USA, V112, P1839, DOI 10.1073/pnas.1424171112; Li Z, 2019, INT J ANAL CHEM, V2019, DOI 10.1155/2019/1639619; Liu H, 2020, THERANOSTICS, V10, P6201, DOI 10.7150/thno.46137; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Lohberger B, 2018, PHYTOMEDICINE, V51, P162, DOI 10.1016/j.phymed.2018.10.008; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8; Nobili S, 2009, PHARMACOL RES, V59, P365, DOI 10.1016/j.phrs.2009.01.017; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; Okines A, 2010, NAT REV CLIN ONCOL, V7, P231, DOI 10.1038/nrclinonc.2010.20; Pan R, 2017, INT J CANCER, V141, P1315, DOI 10.1002/ijc.30825; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Phillips TJ, 2018, BLOOD, V132, P293, DOI 10.1182/blood-2017-10-812701; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Redell MS, 2011, BLOOD, V117, P5701, DOI 10.1182/blood-2010-04-280123; Silva KAS, 2015, J BIOL CHEM, V290, P11177, DOI 10.1074/jbc.M115.641514; Shen ZY, 2002, INT J MOL MED, V10, P641; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Smyth EC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.48; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Spera D, 2007, PLANTA MED, V73, P384, DOI 10.1055/s-2007-967133; Tai WT, 2014, HEPATOLOGY, V59, P190, DOI 10.1002/hep.26640; Van Rompaey L, 2013, J IMMUNOL, V191, P3568, DOI 10.4049/jimmunol.1201348; van Rossum PSN, 2018, NAT REV GASTRO HEPAT, V15, P235, DOI 10.1038/nrgastro.2017.162; Xiong AL, 2014, CANCERS, V6, P926, DOI 10.3390/cancers6020926; Yang JB, 2008, CELL RES, V18, P443, DOI 10.1038/cr.2008.41; Yang YJ, 2021, ANTI-CANCER AGENT ME, V21, P61, DOI 10.2174/1871520620666200708104559; Ye HX, 2020, J BIOMED NANOTECHNOL, V16, P1406, DOI 10.1166/jbn.2020.2978; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yuan Q, 2019, AGING-US, V11, P9530, DOI 10.18632/aging.102402; Zhang HY, 2016, INT J PHARMACEUT, V502, P98, DOI 10.1016/j.ijpharm.2016.02.024; Zhang T, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.305; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	59	1	2	2	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					3942	3958		10.1038/s41388-021-01817-2	http://dx.doi.org/10.1038/s41388-021-01817-2		MAY 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	33986510				2022-12-28	WOS:000650146400001
J	Wanior, M; Kramer, A; Knapp, S; Joerger, AC				Wanior, Marek; Kraemer, Andreas; Knapp, Stefan; Joerger, Andreas C.			Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy	ONCOGENE			English	Review							BAF COMPLEX; ARID1A EXPRESSION; DNA-BINDING; HISTONE H3; INACTIVATING MUTATIONS; SYNTHETIC LETHALITY; TUMOR PROGRESSION; BROMODOMAIN; INHIBITORS; TARGET	Multi-subunit ATPase-dependent chromatin remodelling complexes SWI/SNF (switch/sucrose non-fermentable) are fundamental epigenetic regulators of gene transcription. Functional genomic studies revealed a remarkable mutation prevalence of SWI/SNF-encoding genes in 20-25% of all human cancers, frequently driving oncogenic programmes. Some SWI/SNF-mutant cancers are hypersensitive to perturbations in other SWI/SNF subunits, regulatory proteins and distinct biological pathways, often resulting in sustained anticancer effects and synthetic lethal interactions. Exploiting these vulnerabilities is a promising therapeutic strategy. Here, we review the importance of SWI/SNF chromatin remodellers in gene regulation as well as mechanisms leading to assembly defects and their role in cancer development. We will focus in particular on emerging strategies for the targeted therapy of SWI/SNF-deficient cancers using chemical probes, including proteolysis targeting chimeras, to induce synthetic lethality.	[Wanior, Marek; Kraemer, Andreas; Knapp, Stefan; Joerger, Andreas C.] Goethe Univ Frankfurt, Inst Pharmaceut Chem, Frankfurt, Germany; [Wanior, Marek; Kraemer, Andreas; Knapp, Stefan; Joerger, Andreas C.] Buchmann Inst Mol Life Sci BMLS, Struct Genom Consortium SGC, Frankfurt, Germany; [Kraemer, Andreas; Knapp, Stefan] Frankfurt Canc Inst FCI, Frankfurt, Germany; [Knapp, Stefan; Joerger, Andreas C.] German Translat Canc Network DKTK, Site Frankfurt Mainz, Frankfurt, Germany	Goethe University Frankfurt	Knapp, S; Joerger, AC (corresponding author), Goethe Univ Frankfurt, Inst Pharmaceut Chem, Frankfurt, Germany.; Knapp, S; Joerger, AC (corresponding author), Buchmann Inst Mol Life Sci BMLS, Struct Genom Consortium SGC, Frankfurt, Germany.; Knapp, S; Joerger, AC (corresponding author), German Translat Canc Network DKTK, Site Frankfurt Mainz, Frankfurt, Germany.	knapp@pharmchem.uni-frankfurt.de; joerger@pharmchem.uni-frankfurt.de	Knapp, Stefan/AAG-2347-2019	Knapp, Stefan/0000-0001-5995-6494; Kramer, Andreas/0000-0003-3294-2660; Joerger, Andreas/0000-0002-1232-0138	SGC; AbbVie [1097737]; Bayer AG; Boehringer Ingelheim; Canada Foundation for Innovation; Eshelman Institute for Innovation; Genentech; Genome Canada through Ontario Genomics Institute [OGI-196]; EU/EFPIA/OICR/McGill/KTH/Diamond, Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant] [875510]; Janssen; Merck KGaA (aka EMD in Canada); Merck KGaA (aka EMD in US); Merck Co (aka MSD); Pfizer; Sao Paulo Research Foundation-FAPESP; Takeda; Wellcome [106169/ZZ14/Z]; Research Training Group Translational Research Innovation-Pharma (TRIP) - Else Kroner-Fresenius Foundation (EKFS); German cancer network DKTK; FCI; German Research Foundation (DFG) [JO 1473/1-3]	SGC; AbbVie(AbbVie); Bayer AG(Bayer AG); Boehringer Ingelheim(Boehringer Ingelheim); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Eshelman Institute for Innovation; Genentech(Roche HoldingGenentech); Genome Canada through Ontario Genomics Institute(Genome Canada); EU/EFPIA/OICR/McGill/KTH/Diamond, Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant]; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck KGaA (aka EMD in Canada); Merck KGaA (aka EMD in US); Merck Co (aka MSD); Pfizer(Pfizer); Sao Paulo Research Foundation-FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Takeda(Takeda Pharmaceutical Company Ltd); Wellcome; Research Training Group Translational Research Innovation-Pharma (TRIP) - Else Kroner-Fresenius Foundation (EKFS); German cancer network DKTK; FCI(Fonds der Chemischen Industrie); German Research Foundation (DFG)(German Research Foundation (DFG))	We thank Susanne Muller-Knapp and John Spencer for helpful discussions and for their critical reading of the paper. We are grateful for support by the SGC, a registered charity (no: 1097737) that receives funds from; AbbVie, Bayer AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genentech, Genome Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH/Diamond, Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (aka EMD in Canada and US), Merck & Co (aka MSD outside Canada and US), Pfizer, Sao Paulo Research Foundation-FAPESP, Takeda and Wellcome [106169/ZZ14/Z]. MW is also grateful for support by the Research Training Group Translational Research Innovation-Pharma (TRIP), supported by the Else Kroner-Fresenius Foundation (EKFS). SK, ACJ and AK are thankful for support by the German cancer network DKTK and the FCI. ACJ is supported by German Research Foundation (DFG) grant JO 1473/1-3.	Adhikari B, 2020, NAT CHEM BIOL, V16, P1179, DOI 10.1038/s41589-020-00652-y; Agraz-Doblas A, 2020, PREPRINT, DOI [10.1101/2020.01.10.898726., DOI 10.1101/2020.01.10.898726]; Albrecht BK, 2016, U.S. Patent, Patent No. [WO2016138114 A1, 2016138114]; Alexander JM, 2015, DEVELOPMENT, V142, P1418, DOI 10.1242/dev.109496; Alimova I, 2019, INT J CANCER, V144, P1983, DOI 10.1002/ijc.31873; Allen MD, 2020, PROTEIN SCI, V29, P1047, DOI 10.1002/pro.3820; Allen MD, 2015, STRUCTURE, V23, P1344, DOI 10.1016/j.str.2015.04.021; Alpsoy A, 2018, J BIOL CHEM, V293, P3892, DOI 10.1074/jbc.RA117.001065; Arbely E, 2011, P NATL ACAD SCI USA, V108, P8251, DOI 10.1073/pnas.1105028108; Arrowsmith CH, 2015, NAT CHEM BIOL, V11, P536, DOI 10.1038/nchembio.1867; Bai J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059772; Banito A, 2018, CANCER CELL, V34, P346, DOI 10.1016/j.ccell.2018.07.006; Bennetzen MV, 2010, MOL CELL PROTEOMICS, V9, P1314, DOI 10.1074/mcp.M900616-MCP200; Bitler BG, 2017, NAT CELL BIOL, V19, P962, DOI 10.1038/ncb3582; Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799; Bosse T, 2013, MODERN PATHOL, V26, P1525, DOI 10.1038/modpathol.2013.96; Bracken AP, 2019, GENE DEV, V33, P936, DOI 10.1101/gad.326066.119; Brien GL., 2018, ELIFE, V7, P3892; Carugo A, 2019, CANCER CELL, V35, P204, DOI 10.1016/j.ccell.2019.01.006; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan-Penebre E, 2017, MOL CANCER THER, V16, P850, DOI 10.1158/1535-7163.MCT-16-0678; Chandler RL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7118; Chandrasekaran R, 2007, BIOCHEM BIOPH RES CO, V355, P661, DOI 10.1016/j.bbrc.2007.01.193; Charlop-Powers Z, 2010, CELL RES, V20, P529, DOI 10.1038/cr.2010.43; Cheng JX, 2008, MODERN PATHOL, V21, P647, DOI 10.1038/modpathol.2008.44; Cho H, 2013, HUM PATHOL, V44, P1365, DOI 10.1016/j.humpath.2012.11.007; Chory EJ, 2020, ACS CHEM BIOL, V15, P1685, DOI 10.1021/acschembio.0c00312; Clapier CR, 2017, NAT REV MOL CELL BIO, V18, P407, DOI 10.1038/nrm.2017.26; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Clark PGK, 2015, ANGEW CHEM INT EDIT, V54, P6217, DOI 10.1002/anie.201501394; Cochran AG, 2019, NAT REV DRUG DISCOV, V18, P609, DOI 10.1038/s41573-019-0030-7; Crawford TD, 2017, BIOORG MED CHEM LETT, V27, P3534, DOI 10.1016/j.bmcl.2017.05.063; Crew AP, 2019, U.S. Patent, Patent No. [WO20190300521, 20190300521]; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Deribe YL, 2018, NAT MED, V24, P1627, DOI 10.1038/s41591-018-0173-9; Deribe YL, 2018, NAT MED, V24, P1047, DOI 10.1038/s41591-018-0019-5; Drost J, 2010, NAT CELL BIOL, V12, P380, DOI 10.1038/ncb2038; Ehrenhofer-Wolfer K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48152-x; Farnaby W, 2019, NAT CHEM BIOL, V15, P672, DOI 10.1038/s41589-019-0294-6; Fedorov O, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500723; Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Frye SV, 2010, NAT CHEM BIOL, V6, P159, DOI 10.1038/nchembio.296; Fukumoto T, 2018, CELL REP, V22, P3393, DOI 10.1016/j.celrep.2018.03.019; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gerstenberger BS, 2016, J MED CHEM, V59, P4800, DOI 10.1021/acs.jmedchem.6b00012; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Guo CM, 2013, CLIN CHIM ACTA, V417, P39, DOI 10.1016/j.cca.2012.12.012; Hay DA, 2015, MEDCHEMCOMM, V6, P1381, DOI 10.1039/c5md00152h; He S, 2020, SCIENCE, V367, P875, DOI 10.1126/science.aaz9761; Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480; Hodges C, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026930; Hoffman GR, 2014, P NATL ACAD SCI USA, V111, P3128, DOI 10.1073/pnas.1316793111; Hohmann AF, 2016, NAT CHEM BIOL, V12, P672, DOI 10.1038/nchembio.2115; Hong AL., 2019, ELIFE, V8, P818; Howard TP, 2019, CANCER RES, V79, P2404, DOI 10.1158/0008-5472.CAN-18-3066; Hoyer J, 2012, AM J HUM GENET, V90, P565, DOI 10.1016/j.ajhg.2012.02.007; Huang KJ, 2020, CELL CYCLE, V19, P758, DOI 10.1080/15384101.2020.1729450; Januario T, 2017, P NATL ACAD SCI USA, V114, P12249, DOI 10.1073/pnas.1703966114; Joerger AC, 2016, ANNU REV BIOCHEM, V85, P375, DOI 10.1146/annurev-biochem-060815-014710; Jones SE, 2017, CANCER RES, V77, P7014, DOI 10.1158/0008-5472.CAN-17-2056; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kaelin WG, 2009, GENOME MED, V1, DOI 10.1186/gm99; Karim RM, 2020, J MED CHEM, V63, P3227, DOI 10.1021/acs.jmedchem.9b01980; Kelso TWR, 2017, ELIFE, V6, DOI [10.7554/eLife.30506.001, 10.7554/eLife.30506]; Kim KH, 2015, NAT MED, V21, P1491, DOI 10.1038/nm.3968; Knipstein JA, 2012, NEURO-ONCOLOGY, V14, P175, DOI 10.1093/neuonc/nor208; Kohashi K, 2017, CANCER SCI, V108, P547, DOI 10.1111/cas.13173; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Karmer KF, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071537; Langer LF, 2019, ELIFE, V8, DOI 10.7554/eLife.45672; Lee D, 2017, ONCOTARGETS THER, V10, P4153, DOI 10.2147/OTT.S139664; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Liao LL, 2019, MOL ONCOL, V13, P811, DOI 10.1002/1878-0261.12434; Lu T, 2018, ACTA PHARMACOL SIN, V39, P1544, DOI 10.1038/aps.2017.188; Manceau G, 2013, INT J CANCER, V132, P2217, DOI 10.1002/ijc.27900; Marian CA, 2018, CELL CHEM BIOL, V25, P1443, DOI 10.1016/j.chembiol.2018.08.004; Martin LJ, 2016, J MED CHEM, V59, P4462, DOI 10.1021/acs.jmedchem.5b01865; Mashtalir N, 2020, CELL, V183, P802, DOI 10.1016/j.cell.2020.09.051; Mashtalir N, 2018, CELL, V175, P1272, DOI 10.1016/j.cell.2018.09.032; Mathur R, 2017, NAT GENET, V49, P296, DOI 10.1038/ng.3744; McBride MJ, 2018, CANCER CELL, V33, P1128, DOI 10.1016/j.ccell.2018.05.002; Michel BC, 2018, NAT CELL BIOL, V20, P1410, DOI 10.1038/s41556-018-0221-1; Miller RE, 2016, MOL CANCER THER, V15, P1472, DOI 10.1158/1535-7163.MCT-15-0554; Molina JR, 2018, NAT MED, V24, P1036, DOI 10.1038/s41591-018-0052-4; Muller S, 2018, ELIFE, V7, DOI 10.7554/eLife.34311; Muscat A, 2016, CLIN CANCER RES, V22, P3560, DOI 10.1158/1078-0432.CCR-15-2260; Myrianthopoulos V, 2016, J MED CHEM, V59, P8787, DOI 10.1021/acs.jmedchem.6b00355; Nakayama RT, 2017, NAT GENET, V49, P1613, DOI 10.1038/ng.3958; Nalawansha DA, 2020, CELL CHEM BIOL, V27, P998, DOI 10.1016/j.chembiol.2020.07.020; Nargund AM, 2017, CELL REP, V18, P2893, DOI 10.1016/j.celrep.2017.02.074; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Nijman SMB, 2011, FEBS LETT, V585, P1, DOI 10.1016/j.febslet.2010.11.024; Oba A, 2017, J HEPATOL, V66, P942, DOI 10.1016/j.jhep.2016.12.026; Ochoa D, 2020, NAT BIOTECHNOL, V38, P365, DOI 10.1038/s41587-019-0344-3; Ogiwara H, 2019, CANCER CELL, V35, P177, DOI 10.1016/j.ccell.2018.12.009; Oike T, 2013, CANCER RES, V73, P5508, DOI 10.1158/0008-5472.CAN-12-4593; Papillon JPN, 2018, J MED CHEM, V61, P10155, DOI 10.1021/acs.jmedchem.8b01318; Park Y, 2019, CLIN CANCER RES, V25, P5584, DOI 10.1158/1078-0432.CCR-18-4222; Pavlidou EN., 2020, WORLD ACAD SCI J, V2, P49, DOI [10.3892/wasj.2020.37, DOI 10.3892/WASJ.2020.37]; Peng G, 2009, NAT CELL BIOL, V11, P865, DOI 10.1038/ncb1895; Pettersson Mariell, 2019, Drug Discov Today Technol, V31, P15, DOI 10.1016/j.ddtec.2019.01.002; Porter EG, 2017, J BIOL CHEM, V292, P2601, DOI 10.1074/jbc.M116.746875; Pyo JS, 2018, HUM PATHOL, V73, P66, DOI 10.1016/j.humpath.2017.12.013; Reisman DN, 2003, CANCER RES, V63, P560; Remillard D, 2017, ANGEW CHEM INT EDIT, V56, P5738, DOI 10.1002/anie.201611281; Samartzis EP, 2014, ONCOTARGET, V5, P5295, DOI 10.18632/oncotarget.2092; Santen GWE, 2012, NAT GENET, V44, P379, DOI 10.1038/ng.2217; Schick S, 2019, NAT GENET, V51, P1399, DOI 10.1038/s41588-019-0477-9; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Shorstova T, 2019, CANCER RES, V79, P2761, DOI 10.1158/0008-5472.CAN-18-1545; Sima XX, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222305; Slade D, 2020, GENE DEV, V34, P360, DOI 10.1101/gad.334516.119; Slaughter MJ, 2018, J BIOL CHEM, V293, P13592, DOI 10.1074/jbc.RA118.003381; Smith MJ, 2014, CANCER GENET-NY, V207, P373, DOI 10.1016/j.cancergen.2014.04.001; Stanton BZ, 2017, NAT GENET, V49, P282, DOI 10.1038/ng.3735; Sun HB, 2007, BIOCHEM BIOPH RES CO, V358, P435, DOI 10.1016/j.bbrc.2007.04.139; Sutherell CL, 2016, J MED CHEM, V59, P5095, DOI 10.1021/acs.jmedchem.5b01997; Tagal V, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14098; Theodoulou NH, 2016, J MED CHEM, V59, P1425, DOI 10.1021/acs.jmedchem.5b00256; van der Vaart A, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay3823; Vangamudi B, 2015, CANCER RES, V75, P3865, DOI 10.1158/0008-5472.CAN-14-3798; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vidler LR, 2012, J MED CHEM, V55, P7346, DOI 10.1021/jm300346w; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; WANG XF, 2017, NAT GENET, V49, P289, DOI [DOI 10.1038/NG.3746, 10.1038/ng.3746]; Wang XY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08657-5; Wanior M, 2020, J MED CHEM, V63, P14680, DOI 10.1021/acs.jmedchem.0c01242; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Wilson BG, 2014, MOL CELL BIOL, V34, P1136, DOI 10.1128/MCB.01372-13; Wilson BG, 2010, CANCER CELL, V18, P316, DOI 10.1016/j.ccr.2010.09.006; Wu CJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05694-4; Wu Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08234-2; Xia X, 2016, NAT STRUCT MOL BIOL, V23, P722, DOI 10.1038/nsmb.3259; Xue YK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09774-x; Zhang L, 2018, TECHNOL CANCER RES T, V17, DOI 10.1177/1533034618754475; Zoppi V, 2019, J MED CHEM, V62, P699, DOI 10.1021/acs.jmedchem.8b01413	141	20	20	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3637	3654		10.1038/s41388-021-01781-x	http://dx.doi.org/10.1038/s41388-021-01781-x		MAY 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33941852	Green Published, hybrid			2022-12-28	WOS:000646512200002
J	Zhang, Q; Tang, Q; Liu, WY; Hu, CP; Liu, XY; Liu, YL; Zhou, M; Lai, WJ; Sheng, FF; Yang, HB; Huang, JB; Li, GB				Zhang, Qian; Tang, Qin; Liu, Wuyi; Hu, Changpeng; Liu, Xiaoyu; Liu, Yali; Zhou, Min; Lai, Wenjing; Sheng, Fangfang; Yang, Haibo; Huang, Jingbin; Li, Guobing			Novel role of CAP1 in regulation RNA polymerase II-mediated transcription elongation depends on its actin-depolymerization activity in nucleoplasm	ONCOGENE			English	Article								Lung cancer is one of the most intractable diseases with high incidence and mortality worldwide. Adenylate cyclase-associated protein 1 (CAP1), a well-known actin depolymerization factor, is recently reported to be an oncogene accelerating cancer cell proliferation. However, the physiological significance of CAP1 in lung cancer is incompletely understood and the novel functions of CAP1 in transcriptional regulation remain unknown. Here we found that CAP1 was highly expressed in lung cancer tissues and cells, which was also negatively associated with prognosis in lung cancer patients. Moreover, CAP1 promoted A549 cells proliferation by promoting protein synthesis to accelerate cell cycle progression. Mechanistically, we revealed that CAP1 facilitated cyclin-dependent kinase 9 (CDK9)-mediated RNA polymerases (Pol) II-Ser2 phosphorylation and subsequent transcription elongation, and CAP1 performed its function in this progress depending on its actin-depolymerization activity in nucleoplasm. Furthermore, our in vivo findings confirmed that CAP1-promoted A549 xenograft tumor growth was associated with CDK9-mediated Pol II-Ser2 phosphorylation. Our study elucidates a novel role of CAP1 in modulating transcription by promoting polymerase II phosphorylation and suggests that CAP1 is a newly identified biomarker for lung cancer treatment and prognosis prediction.	[Zhang, Qian; Tang, Qin; Liu, Wuyi; Hu, Changpeng; Liu, Xiaoyu; Liu, Yali; Zhou, Min; Lai, Wenjing; Sheng, Fangfang; Yang, Haibo; Huang, Jingbin; Li, Guobing] Army Med Univ, Affiliated Hosp 2, Dept Pharm, Chongqing, Peoples R China	Army Medical University	Huang, JB; Li, GB (corresponding author), Army Med Univ, Affiliated Hosp 2, Dept Pharm, Chongqing, Peoples R China.	hjb20091364@126.com; guobingl@126.com		Hu, Changpeng/0000-0002-3033-4023	National Natural Science Foundation of China [81874357]; Youth Talent Project of Army Medical University [2019R050]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Talent Project of Army Medical University	This work was supported by National Natural Science Foundation of China (Grant No. 81874357) and the Youth Talent Project of Army Medical University (Grant No. 2019R050).	Almuzzaini B, 2016, FASEB J, V30, P2860, DOI 10.1096/fj.201600280R; Arimbasseri AG, 2016, TRENDS BIOCHEM SCI, V41, P546, DOI 10.1016/j.tibs.2016.03.003; Bertling E, 2004, MOL BIOL CELL, V15, P2324, DOI 10.1091/mbc.E04-01-0048; Blank HM, 2017, CELL CYCLE, V16, P905, DOI 10.1080/15384101.2017.1312851; Bock FJ, 2015, MOL CELL, V58, P959, DOI 10.1016/j.molcel.2015.01.037; BOGOMOLETZ WV, 1990, EUR J CANCER, V26, P1042, DOI 10.1016/0277-5379(90)90047-W; Brar GA, 2015, NAT REV MOL CELL BIO, V16, P651, DOI 10.1038/nrm4069; Buratowski S, 2009, MOL CELL, V36, P541, DOI 10.1016/j.molcel.2009.10.019; Chen F, 2015, GENE DEV, V29, P39, DOI 10.1101/gad.246173.114; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; Fan HT, 2017, NUCLEIC ACIDS RES, V45, P11043, DOI 10.1093/nar/gkx719; Fomproix N, 2004, EXP CELL RES, V294, P140, DOI 10.1016/j.yexcr.2003.10.028; FREEMAN NL, 1995, J BIOL CHEM, V270, P5680, DOI 10.1074/jbc.270.10.5680; Gieni RS, 2009, BIOCHEM CELL BIOL, V87, P283, DOI 10.1139/O08-133; Gilchrist DA, 2008, GENE DEV, V22, P1921, DOI 10.1101/gad.1643208; Hasan R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112653; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Hoeffer CA, 2011, P NATL ACAD SCI USA, V108, P3383, DOI 10.1073/pnas.1013063108; Hofmann WA, 2004, NAT CELL BIOL, V6, P1094, DOI 10.1038/ncb1182; Hu P, 2004, GENE DEV, V18, P3010, DOI 10.1101/gad.1250804; Kolegova ES, 2019, B EXP BIOL MED+, V167, P393, DOI 10.1007/s10517-019-04534-9; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Larsen JE, 2011, CLIN CHEST MED, V32, P703, DOI 10.1016/j.ccm.2011.08.003; Lee MJ, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a005918; Liang H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14771; Liu YH, 2014, PATHOL RES PRACT, V210, P169, DOI 10.1016/j.prp.2013.11.011; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Lu HS, 2018, NATURE, V558, P318, DOI 10.1038/s41586-018-0174-3; Moriyama K, 2002, J CELL SCI, V115, P1591; Obrdlik A, 2011, NUCLEUS-PHILA, V2, P72, DOI 10.4161/nucl.2.1.14508; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Olausson KH, 2014, J BIOL CHEM, V289, P34601, DOI 10.1074/jbc.M114.569244; Pawlus MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072358; Percipalle P, 2006, J CELL BIOL, V172, P967, DOI 10.1083/jcb.200512083; Percipalle P, 2013, NUCLEUS-AUSTIN, V4, P43, DOI 10.4161/nucl.22798; Perez-Ortin JE, 2013, J MOL BIOL, V425, P3750, DOI 10.1016/j.jmb.2013.02.029; Philimonenko VV, 2004, NAT CELL BIOL, V6, P1165, DOI 10.1038/ncb1190; Proudfoot NJ, 2016, SCIENCE, V352, DOI 10.1126/science.aad9926; Qi TY, 2011, J BIOL CHEM, V286, P15171, DOI 10.1074/jbc.M110.184374; Riss TL, 2011, METHODS MOL BIOL, V740, P103, DOI 10.1007/978-1-61779-108-6_12; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Serebryannyy LA, 2016, J CELL SCI, V129, P3412, DOI 10.1242/jcs.195867; Serin G, 1996, BIOCHIMIE, V78, P530, DOI 10.1016/0300-9084(96)84759-6; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith ER, 2008, P NATL ACAD SCI USA, V105, P8575, DOI 10.1073/pnas.0804379105; Srivastava R, 2015, BIOTECHNOL ADV, V33, P856, DOI 10.1016/j.biotechadv.2015.07.008; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Tan M, 2013, ONCOL REP, V30, P1639, DOI 10.3892/or.2013.2607; Van Der Kelen K, 2009, CRIT REV BIOCHEM MOL, V44, P143, DOI 10.1080/10409230902882090; Vieu E, 2006, NAT CELL BIOL, V8, P650, DOI 10.1038/ncb0706-650; Wang J, 2016, J BIOL CHEM, V291, P25239, DOI 10.1074/jbc.M116.735886; White-Gilbertson S, 2009, MOL ONCOL, V3, P402, DOI 10.1016/j.molonc.2009.05.003; Wu LP, 2003, EUKARYOT CELL, V2, P256, DOI 10.1128/EC.2.2.256-264.2003; Xie SS, 2018, J CANCER, V9, P2825, DOI 10.7150/jca.25993; Yamaguchi K, 2005, J BIOL CHEM, V280, P32569, DOI 10.1074/jbc.M503201200; Ye J, 2008, GENE DEV, V22, P322, DOI 10.1101/gad.455908; Yee NS, 2012, BIOL OPEN, V1, P295, DOI 10.1242/bio.2012539; Yoo YD, 2007, J BIOL CHEM, V282, P7616, DOI 10.1074/jbc.M607596200; Zhang HT, 2013, J BIOL CHEM, V288, P20966, DOI 10.1074/jbc.M113.484535; Zhang YF, 2017, BBA-GENE REGUL MECH, V1860, P246, DOI 10.1016/j.bbagrm.2016.10.010; Zhou Q, 2012, ANNU REV BIOCHEM, V81, P119, DOI 10.1146/annurev-biochem-052610-095910	61	1	1	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3492	3509		10.1038/s41388-021-01789-3	http://dx.doi.org/10.1038/s41388-021-01789-3		APR 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33911205				2022-12-28	WOS:000645202500001
J	Fischietti, M; Eckerdt, F; Blyth, GT; Arslan, AD; Mati, WM; Oku, CV; Perez, RE; Lee-Chang, C; Kosciuczuk, EM; Saleiro, D; Beauchamp, EM; Lesniak, MS; Verzella, D; Sun, LY; Fish, EN; Yang, GY; Qiang, WA; Platanias, LC				Fischietti, Mariafausta; Eckerdt, Frank; Blyth, Gavin T.; Arslan, Ahmet D.; Mati, William M.; Oku, Chidera, V; Perez, Ricardo E.; Lee-Chang, Catalina; Kosciuczuk, Ewa M.; Saleiro, Diana; Beauchamp, Elspeth M.; Lesniak, Maciej S.; Verzella, Daniela; Sun, Leyu; Fish, Eleanor N.; Yang, Guang-Yu; Qiang, Wenan; Platanias, Leonidas C.			Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article								We provide evidence that a member of the human Schlafen (SLFN) family of proteins, SLFN5, is overexpressed in human pancreatic ductal adenocarcinoma (PDAC). Targeted deletion of SLFN5 results in decreased PDAC cell proliferation and suppresses PDAC tumorigenesis in in vivo PDAC models. Importantly, high expression levels of SLFN5 correlate with worse outcomes in PDAC patients, implicating SLFN5 in the pathophysiology of PDAC that leads to poor outcomes. Our studies establish novel regulatory effects of SLFN5 on cell cycle progression through binding/blocking of the transcriptional repressor E2F7, promoting transcription of key genes that stimulate S phase progression. Together, our studies suggest an essential role for SLFN5 in PDAC and support the potential for developing new therapeutic approaches for the treatment of pancreatic cancer through SLFN5 targeting.	[Fischietti, Mariafausta; Eckerdt, Frank; Blyth, Gavin T.; Arslan, Ahmet D.; Mati, William M.; Oku, Chidera, V; Perez, Ricardo E.; Lee-Chang, Catalina; Kosciuczuk, Ewa M.; Saleiro, Diana; Beauchamp, Elspeth M.; Lesniak, Maciej S.; Platanias, Leonidas C.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Fischietti, Mariafausta; Blyth, Gavin T.; Arslan, Ahmet D.; Mati, William M.; Oku, Chidera, V; Perez, Ricardo E.; Kosciuczuk, Ewa M.; Saleiro, Diana; Beauchamp, Elspeth M.; Platanias, Leonidas C.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Eckerdt, Frank; Lee-Chang, Catalina; Lesniak, Maciej S.] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Chicago, IL 60611 USA; [Kosciuczuk, Ewa M.; Beauchamp, Elspeth M.; Platanias, Leonidas C.] Jesse Brown Vet Affairs Med Ctr, Dept Med, Chicago, IL 60612 USA; [Verzella, Daniela] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy; [Sun, Leyu; Yang, Guang-Yu] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Fish, Eleanor N.] Univ Hlth Network, Toronto Gen Hosp Res Inst, Toronto, ON, Canada; [Fish, Eleanor N.] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Qiang, Wenan] Northwestern Univ, Dept Obstet & Gynecol, Feinberg Sch Med, Evanston, IL USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; University of L'Aquila; Northwestern University; Feinberg School of Medicine; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Northwestern University; Feinberg School of Medicine	Platanias, LC (corresponding author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.; Platanias, LC (corresponding author), Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA.; Platanias, LC (corresponding author), Jesse Brown Vet Affairs Med Ctr, Dept Med, Chicago, IL 60612 USA.	l-platanias@northwestern.edu	Lee-Chang, Catalina/AAA-1808-2021; Kosciuczuk, Ewa Maria/AAD-2815-2022	Lee-Chang, Catalina/0000-0002-7675-2124; Fischietti, Mariafausta/0000-0002-5691-689X; Qiang, Wenan/0000-0001-5068-7128	National Institutes of Health [R01-NS113352, R01CA77816, R01-CA121192]; Department of Veterans Affairs [I01-CX000916]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs)	National Institutes of Health [R01-NS113352, R01CA77816, R01-CA121192]; Department of Veterans Affairs [I01-CX000916]	Arslan AD, 2017, ONCOGENE, V36, P6006, DOI 10.1038/onc.2017.205; Back SA, 1999, J NEUROSCI METH, V91, P47, DOI 10.1016/S0165-0270(99)00062-X; Badea L, 2008, HEPATO-GASTROENTEROL, V55, P2016; Beauchamp EM, 2019, BLOOD, V133, P1171, DOI 10.1182/blood-2018-08-870089; Brown M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0226917; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Chen DT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133562; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chung SJ, 2019, CLIN CANCER RES, V25, P2290, DOI 10.1158/1078-0432.CCR-18-1620; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Di Carlo C, 2018, WORLD J STEM CELLS, V10, P172, DOI 10.4252/wjsc.v10.i11.172; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Fischietti M, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00053-18; Fletcher SJ, 2015, J CLIN INVEST, V125, P3600, DOI 10.1172/JCI80347; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Grimont A, 2015, GUT, V64, P1790, DOI 10.1136/gutjnl-2014-307075; Guo LJ, 2019, EUR J PHARMACOL, V862, DOI 10.1016/j.ejphar.2019.172630; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Joukov V, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aar4195; Katsoulidis E, 2010, J BIOL CHEM, V285, P40333, DOI 10.1074/jbc.M110.151076; Katsoulidis E, 2009, J BIOL CHEM, V284, P25051, DOI 10.1074/jbc.M109.030445; Kent LN, 2016, J CLIN INVEST, V126, P2955, DOI 10.1172/JCI85506; Lee CJ, 2008, J CLIN ONCOL, V26, P2806, DOI 10.1200/JCO.2008.16.6702; Li J, 2008, DEV CELL, V14, P62, DOI 10.1016/j.devcel.2007.10.017; Li MQ, 2012, NATURE, V491, P125, DOI 10.1038/nature11433; Liu FR, 2018, CELL BIOL INT, V42, P2, DOI 10.1002/cbin.10778; Mavrommatis E, 2013, J BIOL CHEM, V288, P33006, DOI 10.1074/jbc.M113.460741; Mavrommatis E, 2013, J INTERF CYTOK RES, V33, P206, DOI 10.1089/jir.2012.0133; Mitxelena J, 2016, NUCLEIC ACIDS RES, V44, P5557, DOI 10.1093/nar/gkw146; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Napoles OC, 2017, J GASTROENTEROL, V52, P39, DOI 10.1007/s00535-016-1202-4; Petropoulos M, 2019, TRENDS BIOCHEM SCI, V44, P752, DOI 10.1016/j.tibs.2019.03.011; Razzak Mina, 2012, Nat Rev Urol, V9, P605, DOI 10.1038/nrurol.2012.188; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Sassano A, 2015, MOL CELL BIOL, V35, P2684, DOI 10.1128/MCB.00019-15; Seong RK, 2017, IMMUNOBIOLOGY, V222, P979, DOI 10.1016/j.imbio.2017.07.002; Soper A, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01823; Stewart ZA, 2003, TRENDS PHARMACOL SCI, V24, P139, DOI 10.1016/S0165-6147(03)00026-9; Thurlings I, 2017, ONCOGENE, V36, P829, DOI 10.1038/onc.2016.251; Wan GQ, 2019, CELL SIGNAL, V59, P1, DOI 10.1016/j.cellsig.2019.03.004; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; Westendorp B, 2012, NUCLEIC ACIDS RES, V40, P3511, DOI 10.1093/nar/gkr1203; Xia ZQ, 2012, J IMMUNOL, V188, P3315, DOI 10.4049/jimmunol.1102775	44	3	3	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3273	3286		10.1038/s41388-021-01761-1	http://dx.doi.org/10.1038/s41388-021-01761-1		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33846574	Green Accepted			2022-12-28	WOS:000639635100001
J	Jing, CY; Fu, YP; Zhou, C; Zhang, MX; Yi, Y; Huang, JL; Gan, W; Zhang, J; Zheng, SS; Zhang, BH; Qiu, SJ				Jing, Chu-Yu; Fu, Yi-Peng; Zhou, Cheng; Zhang, Mei-Xia; Yi, Yong; Huang, Jin-Long; Gan, Wei; Zhang, Juan; Zheng, Su-Su; Zhang, Bo-Heng; Qiu, Shuang-Jian			Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2/osteopontin/Wnt signaling axis	ONCOGENE			English	Article								Intrahepatic cholangiocarcinoma (ICC) is a highly fatal malignancy characterized by a vast amount of intra-tumoral fibroblasts. These fibroblasts are potentially implicated in maintaining the high aggressiveness of ICC, whereas its pro-cancer mechanisms remain scarcely reported. Here, by establishing co-culture models of ICC cells and hepatic stellate cells (HSCs), we identified that HSCs triggered the expression of nuclear receptor family 4 subgroup A member 2 (NR4A2), a transcription factor previously reported as a molecular switch between inflammation and cancer, in ICC cells. Functionally, NR4A2 promotes tumor proliferation, metastatic potentiality and represents an independent prognostic indicator for overall survival in ICC patients. Mechanistically, NR4A2 upregulates osteopontin (OPN) expression through transcriptional activation and thereby augments the activity of Wnt/beta-catenin signaling. Intriguingly, in the context of co-culture, vascular endothelial growth factor (VEGF), a previously proved NR4A2 stimulus, not only enhances NR4A2 expression, but also can be blunted by the interference of the NR4A2-OPN axis. Altogether, this study suggests the NR4A2/OPN/Wnt signaling axis to be a pivotal executor of HSC-instigated cancer-promoting roles in ICC, and the NR4A2/OPN/VEGF positive feedback loop may help to reinforce the effect.	[Jing, Chu-Yu; Zhou, Cheng; Yi, Yong; Huang, Jin-Long; Gan, Wei; Zhang, Juan; Zheng, Su-Su; Zhang, Bo-Heng; Qiu, Shuang-Jian] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Key Lab Carcinogenesis & Canc Invas,Chinese Minis, 180 Fenglin Rd, Shanghai 200032, Peoples R China; [Jing, Chu-Yu; Zhou, Cheng; Yi, Yong; Huang, Jin-Long; Gan, Wei; Zhang, Juan; Zheng, Su-Su; Zhang, Bo-Heng; Qiu, Shuang-Jian] Fudan Univ, Shanghai Med Sch, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, 180 Fenglin Rd, Shanghai 200032, Peoples R China; [Fu, Yi-Peng] Fudan Univ, Dept Breast Surg, Obstet & Gynecol Hosp, 419 Fangxie Rd, Shanghai 200090, Peoples R China; [Zhou, Cheng; Yi, Yong; Huang, Jin-Long; Gan, Wei; Qiu, Shuang-Jian] Fudan Univ, Zhongshan Hosp, Dept Liver Surg & Transplantat, 180 Fenglin Rd, Shanghai 200032, Peoples R China; [Zhang, Mei-Xia] Nanchang Univ, Dept Gastroenterol, Affiliated Hosp 1, 17 Yongwaizheng St, Nanchang 330006, Jiangxi, Peoples R China; [Zhang, Bo-Heng] Fudan Univ, Ctr Evidence Based Med, Shanghai Med Sch, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Nanchang University; Fudan University	Zhang, BH; Qiu, SJ (corresponding author), Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Key Lab Carcinogenesis & Canc Invas,Chinese Minis, 180 Fenglin Rd, Shanghai 200032, Peoples R China.; Zhang, BH; Qiu, SJ (corresponding author), Fudan Univ, Shanghai Med Sch, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, 180 Fenglin Rd, Shanghai 200032, Peoples R China.; Fu, YP (corresponding author), Fudan Univ, Dept Breast Surg, Obstet & Gynecol Hosp, 419 Fangxie Rd, Shanghai 200090, Peoples R China.; Qiu, SJ (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Liver Surg & Transplantat, 180 Fenglin Rd, Shanghai 200032, Peoples R China.; Zhang, BH (corresponding author), Fudan Univ, Ctr Evidence Based Med, Shanghai Med Sch, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.	fyp0076@163.com; zhang.boheng@zs-hospital.sh.cn; qiu.shuangjian@zs-hospital.sh.cn		Jing, Chuyu/0000-0001-8057-4677; Fu, Yi-Peng/0000-0002-4229-6714	National Natural Science Foundation of China [81772510, 81902419, 81902993, 82072677, 82072672]; National Key Research and Development Program of China [2017YFC0908101, 2017YFC0908102]; Research Programs of Science and Technology Commission Foundation of Shanghai [18XD1401100]; Medical and Health Key Programs of Science and Technology Plan of Xiamen [3502Z20191105]; Research and Development Program of Zhongshan Hospital, Fudan University [2020ZSFZ13, 2019ZSFZ13, 2018ZSFZ055, ZSLC62, 2019-275, 2020-312, 2021-353]; 2020 Youth Talent Program of Obstetrics & Gynecology Hospital of Fudan University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Research Programs of Science and Technology Commission Foundation of Shanghai; Medical and Health Key Programs of Science and Technology Plan of Xiamen; Research and Development Program of Zhongshan Hospital, Fudan University; 2020 Youth Talent Program of Obstetrics & Gynecology Hospital of Fudan University	This project is supported by the National Natural Science Foundation of China (NO.81772510; NO.81902419; NO.81902993; NO. 82072677, NO. 82072672); National Key Research and Development Program of China (NO.2017YFC0908101 and NO.2017YFC0908102); Research Programs of Science and Technology Commission Foundation of Shanghai (NO.18XD1401100); Medical and Health Key Programs of Science and Technology Plan of Xiamen (NO.3502Z20191105); 2020 Youth Talent Program of Obstetrics & Gynecology Hospital of Fudan University obtained by Dr. YiPeng Fu and Research and Development Program of Zhongshan Hospital, Fudan University (NO. 2020ZSFZ13, NO. 2019ZSFZ13, NO. 2018ZSFZ055, NO. ZSLC62, NO. ZHZS17, NO. 2019-275, NO. 2020-312, NO. 2021-353).	Ahmed M, 2016, CANCER CELL, V30, P432, DOI 10.1016/j.ccell.2016.08.002; Akeson A, 2010, MICROVASC RES, V80, P65, DOI 10.1016/j.mvr.2010.02.001; [Anonymous], CANCER DISCOV, V7; Bertuccio P, 2019, J HEPATOL, V71, P104, DOI 10.1016/j.jhep.2019.03.013; Bridgewater J, 2014, J HEPATOL, V60, P1268, DOI 10.1016/j.jhep.2014.01.021; Cadamuro M, 2013, HEPATOLOGY, V58, P1042, DOI 10.1002/hep.26384; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Cheng JT, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.7; Coulouarn C, 2014, J HEPATOL, V60, P1306, DOI 10.1016/j.jhep.2014.02.003; Crean D, 2015, J IMMUNOL, V195, P1436, DOI 10.4049/jimmunol.1402039; Cuiffo BG, 2014, CELL STEM CELL, V15, P762, DOI 10.1016/j.stem.2014.10.001; Dai J, 2009, ONCOGENE, V28, P3412, DOI 10.1038/onc.2009.189; Fingas CD, 2011, HEPATOLOGY, V54, P2076, DOI 10.1002/hep.24588; Gentilini A, 2012, J HEPATOL, V57, P813, DOI 10.1016/j.jhep.2012.06.012; Goradel NH, 2019, J CELL PHYSIOL, V234, P5683, DOI 10.1002/jcp.27411; Han YF, 2012, WORLD J GASTROENTERO, V18, P6865, DOI 10.3748/wjg.v18.i47.6865; Han YF, 2013, EUR J CANCER, V49, P3420, DOI 10.1016/j.ejca.2013.06.001; Han YF, 2013, CANCER-AM CANCER SOC, V119, P3436, DOI 10.1002/cncr.28228; Ji JL, 2015, HEPATOLOGY, V62, P481, DOI 10.1002/hep.27822; Jing CY, 2018, ONCOLOGIST, V23, P1482, DOI 10.1634/theoncologist.2017-0439; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Karki K, 2020, J NEURO-ONCOL, V146, P25, DOI 10.1007/s11060-019-03349-y; Kothari AN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5040039; Lammi J, 2004, MOL ENDOCRINOL, V18, P1546, DOI 10.1210/me.2003-0247; Li L, 2017, HEPATOLOGY, V65, P501, DOI 10.1002/hep.28735; Li P, 2015, CELL RES, V25, P588, DOI 10.1038/cr.2015.51; McEvoy C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00007; Mohan HM, 2012, CLIN CANCER RES, V18, P3223, DOI 10.1158/1078-0432.CCR-11-2953; Okabe H, 2009, ANN SURG ONCOL, V16, P2555, DOI 10.1245/s10434-009-0568-4; Paule B, 2007, ONCOLOGY-BASEL, V72, P105, DOI 10.1159/000111117; Primrose JN, 2019, LANCET ONCOL, V20, P663, DOI 10.1016/S1470-2045(18)30915-X; Raja R, 2014, ONCOGENE, V33, P2053, DOI 10.1038/onc.2013.171; Ramchandani D, 2015, BBA-REV CANCER, V1855, P202, DOI 10.1016/j.bbcan.2015.02.003; Saha SK, 2016, ONCOLOGIST, V21, P594, DOI 10.1634/theoncologist.2015-0446; Sanmamed MF, 2018, CELL, V175, P313, DOI 10.1016/j.cell.2018.09.035; Sekiya T, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1272; Shigeishi H, 2011, CANCER LETT, V307, P227, DOI 10.1016/j.canlet.2011.04.008; Sirica AE, 2019, HEPATOLOGY, V69, P1803, DOI 10.1002/hep.30289; Smyth MJ, 2016, NAT REV CLIN ONCOL, V13, P143, DOI 10.1038/nrclinonc.2015.209; Sulpice L, 2013, HEPATOLOGY, V58, P1992, DOI 10.1002/hep.26577; Urtasun R, 2012, HEPATOLOGY, V55, P594, DOI 10.1002/hep.24701; Weber CE, 2015, ONCOGENE, V34, P4821, DOI 10.1038/onc.2014.410; Wu LM, 2018, BRIT J HAEMATOL, V183, P445, DOI 10.1111/bjh.15548; Zagani R, 2009, GASTROENTEROLOGY, V137, P1358, DOI 10.1053/j.gastro.2009.06.039; Zhao DZ, 2011, INT J CANCER, V128, P2602, DOI 10.1002/ijc.25600; Zheng Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0226-x; Zhu Y, 2019, GUT, V68, P1653, DOI 10.1136/gutjnl-2019-318419	48	7	7	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2910	2922		10.1038/s41388-021-01705-9	http://dx.doi.org/10.1038/s41388-021-01705-9		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742120				2022-12-28	WOS:000630675000006
J	Fukasawa, K; Kadota, T; Horie, T; Tokumura, K; Terada, R; Kitaguchi, Y; Park, G; Ochiai, S; Iwahashi, S; Okayama, Y; Hiraiwa, M; Yamada, T; Iezaki, T; Kaneda, K; Yamamoto, M; Kitao, T; Shirahase, H; Hazawa, M; Wong, RW; Todo, T; Hirao, A; Hinoi, E				Fukasawa, Kazuya; Kadota, Takuya; Horie, Tetsuhiro; Tokumura, Kazuya; Terada, Ryuichi; Kitaguchi, Yuka; Park, Gyujin; Ochiai, Shinsuke; Iwahashi, Sayuki; Okayama, Yasuka; Hiraiwa, Manami; Yamada, Takanori; Iezaki, Takashi; Kaneda, Katsuyuki; Yamamoto, Megumi; Kitao, Tatsuya; Shirahase, Hiroaki; Hazawa, Masaharu; Wong, Richard W.; Todo, Tomoki; Hirao, Atsushi; Hinoi, Eiichi			CDK8 maintains stemness and tumorigenicity of glioma stem cells by regulating the c-MYC pathway	ONCOGENE			English	Article								Glioblastoma (GBM) is the most malignant form of glioma. Glioma stem cells (GSCs) contribute to the initiation, progression, and recurrence of GBM as a result of their self-renewal potential and tumorigenicity. Cyclin-dependent kinase 8 (CDK8) belongs to the transcription-related CDK family. Although CDK8 has been shown to be implicated in the malignancy of several types of cancer, its functional role and mechanism in gliomagenesis remain largely unknown. Here, we demonstrate how CDK8 plays an essential role in maintaining stemness and tumorigenicity in GSCs. The genetic inhibition of CDK8 by shRNA or CRISPR interference resulted in an abrogation of the self-renewal potential and tumorigenicity of patient-derived GSCs, which could be significantly rescued by the ectopic expression of c-MYC, a stem cell transcription factor. Moreover, we demonstrated that the pharmacological inhibition of CDK8 significantly attenuated the self-renewal potential and tumorigenicity of GSCs. CDK8 expression was significantly higher in human GBM tissues than in normal brain tissues, and its expression was positively correlated with stem cell markers including c-MYC and SOX2 in human GBM specimens. Additionally, CDK8 expression is associated with poor survival in GBM patients. Collectively, these findings highlight the importance of the CDK8-c-MYC axis in maintaining stemness and tumorigenicity in GSCs; these findings also identify the CDK8-c-MYC axis as a potential target for GSC-directed therapy.	[Fukasawa, Kazuya; Kadota, Takuya; Horie, Tetsuhiro; Tokumura, Kazuya; Terada, Ryuichi; Kitaguchi, Yuka; Park, Gyujin; Ochiai, Shinsuke; Iwahashi, Sayuki; Okayama, Yasuka; Hiraiwa, Manami; Yamada, Takanori; Iezaki, Takashi; Hinoi, Eiichi] Gifu Pharmaceut Univ, Dept Bioact Mol, Lab Pharmacol, Gifu, Japan; [Kadota, Takuya; Yamamoto, Megumi; Kitao, Tatsuya; Shirahase, Hiroaki] Kyoto Pharmaceut Ind Co Ltd, Drug Discovery Res Dept, Kyoto, Japan; [Kitaguchi, Yuka; Kaneda, Katsuyuki] Kanazawa Univ, Grad Sch, Div Pharmaceut Sci, Lab Mol Pharmacol, Kanazawa, Ishikawa, Japan; [Hazawa, Masaharu; Wong, Richard W.] Kanazawa Univ, Inst Frontier Sci Initiat, Cell Bion Res Unit, Kanazawa, Ishikawa, Japan; [Wong, Richard W.; Hirao, Atsushi] Kanazawa Univ, WPI Nano Life Sci Inst WPI Nano LSI, Kanazawa, Ishikawa, Japan; [Todo, Tomoki] Univ Tokyo, Inst Med Sci, Div Innovat Canc Therapy, Tokyo, Japan; [Hirao, Atsushi] Kanazawa Univ, Canc Res Inst, Div Mol Genet, Canc & Stem Cell Res Program, Kanazawa, Ishikawa, Japan; [Hinoi, Eiichi] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Gifu, Japan	Gifu Pharmaceutical University; Kyoto Pharmaceutical Industries Co., Ltd.; Kanazawa University; Kanazawa University; Kanazawa University; University of Tokyo; Kanazawa University; Gifu University	Hinoi, E (corresponding author), Gifu Pharmaceut Univ, Dept Bioact Mol, Lab Pharmacol, Gifu, Japan.	hinoi-e@gifu-pu.ac.jp	Wong, Richard W./E-9155-2011	Wong, Richard/0000-0002-2131-6595; Fukasawa, Kazuya/0000-0002-1845-0275; Horie, Tetsuhiro/0000-0002-2095-9425	Japan Society for the Promotion of Science [20H03407]; Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University	We wish to thank Dr. H. Hojo (University of Tokyo) for technical training in RNA-seq data analysis. RNA-seq data and survival analysis were performed using the super-computing resource provided by Human Genome Center, the Institute of Medical Science, the University of Tokyo. This work was supported in part by the Japan Society for the Promotion of Science (20H03407 to EH), and the Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University.	Adler AS, 2012, CANCER RES, V72, P2129, DOI 10.1158/0008-5472.CAN-11-3886; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; [Anonymous], 2018, N Engl J Med, V379, P2582, DOI 10.1056/NEJMx180043; Bancerek J, 2013, IMMUNITY, V38, P250, DOI 10.1016/j.immuni.2012.10.017; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bragelmann J, 2017, CLIN CANCER RES, V23, P1829, DOI 10.1158/1078-0432.CCR-16-0094; Broude EV, 2015, CURR CANCER DRUG TAR, V15, P739, DOI 10.2174/156800961508151001105814; Chen MQ, 2017, P NATL ACAD SCI USA, V114, P10208, DOI 10.1073/pnas.1710467114; Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021; Conaway RC, 2011, CURR OPIN GENET DEV, V21, P225, DOI 10.1016/j.gde.2011.01.013; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Galbraith MD, 2013, CELL, V153, P1327, DOI 10.1016/j.cell.2013.04.048; Gu WT, 2013, CELL CYCLE, V12, P987, DOI 10.4161/cc.24003; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kitao T, 2019, YAKUGAKU ZASSHI, V139, P19, DOI 10.1248/yakushi.18-00154-2; Knuesel MT, 2009, MOL CELL BIOL, V29, P650, DOI 10.1128/MCB.00993-08; Kumar SK, 2015, BLOOD, V125, P443, DOI 10.1182/blood-2014-05-573741; Laderian B, 2017, SEMIN ONCOL, V44, P395, DOI 10.1053/j.seminoncol.2018.03.006; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Martinez-Fabregas J, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108545; McCleland ML, 2015, J PATHOL, V237, P508, DOI 10.1002/path.4596; Meyer M, 2015, P NATL ACAD SCI USA, V112, P851, DOI 10.1073/pnas.1320611111; Ostrom QT, 2019, J NEURO-ONCOL, V142, P27, DOI 10.1007/s11060-018-03073-z; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pelish HE, 2015, NATURE, V526, P273, DOI 10.1038/nature14904; Putz EM, 2013, CELL REP, V4, P437, DOI 10.1016/j.celrep.2013.07.012; Quevedo M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10502-8; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Rinkenbaugh AL, 2016, ONCOTARGET, V7, P69173, DOI 10.18632/oncotarget.12507; Sachdeva R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51270-1; Serrao A, 2018, ONCOGENE, V37, P4792, DOI 10.1038/s41388-018-0316-y; Shi Y, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aah6816; Sledge GW, 2017, J CLIN ONCOL, V35, P2875, DOI 10.1200/JCO.2017.73.7585; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Taatjes DJ, 2010, TRENDS BIOCHEM SCI, V35, P315, DOI 10.1016/j.tibs.2010.02.004; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Venere M, 2011, GLIA, V59, P1148, DOI 10.1002/glia.21185; Waghmare I, 2014, STEM CELL TRANSL MED, V3, P1262, DOI 10.5966/sctm.2014-0086; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Wasylishen Amanda R, 2010, Genes Cancer, V1, P532, DOI 10.1177/1947601910378024; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Westerling T, 2007, MOL CELL BIOL, V27, P6177, DOI 10.1128/MCB.01302-06; Witalisz-Siepracka A, 2018, CANCER IMMUNOL RES, V6, P458, DOI 10.1158/2326-6066.CIR-17-0183; Xu DZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7641; Xu W, 2015, CANCER LETT, V356, P613, DOI 10.1016/j.canlet.2014.10.008; Zhang JF, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0694-9; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zheng H, 2008, COLD SH Q B, V73, P427, DOI 10.1101/sqb.2008.73.047; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090	56	17	17	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2803	2815		10.1038/s41388-021-01745-1	http://dx.doi.org/10.1038/s41388-021-01745-1		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33727660				2022-12-28	WOS:000629505700001
J	Formaggio, N; Rubin, MA; Theurillat, JP				Formaggio, Nicolo; Rubin, Mark A.; Theurillat, Jean-Philippe			Loss and revival of androgen receptor signaling in advanced prostate cancer	ONCOGENE			English	Review							N-MYC; NEUROENDOCRINE DIFFERENTIATION; LINEAGE PLASTICITY; TUMOR-SUPPRESSOR; RESISTANCE; MECHANISMS; EXPRESSION; CELLS; EZH2; ADENOCARCINOMA	Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens have emerged and have been successfully implemented in clinical practice. That said, the stronger inhibition of the AR signaling axis has led in recent years to an increase of prostate cancers that de-differentiate into AR-negative disease. Unfortunately, this process is intimately linked with a poor prognosis. Here, we review the molecular mechanisms that enable cancer cells to switch from an AR-positive to an AR-negative disease and efforts to prevent/revert this process and thereby maintain/restore AR-dependence.	[Formaggio, Nicolo; Theurillat, Jean-Philippe] Univ Svizzera Italiana, Inst Oncol Res, Lugano, Switzerland; [Rubin, Mark A.] Univ Bern, Dept BioMed Res, Bern, Switzerland; [Rubin, Mark A.] Univ Bern, Bern Ctr Precis Med, Bern, Switzerland; [Rubin, Mark A.] Inselspital Bern, Bern, Switzerland	Universita della Svizzera Italiana; University of Bern; University of Bern	Theurillat, JP (corresponding author), Univ Svizzera Italiana, Inst Oncol Res, Lugano, Switzerland.; Rubin, MA (corresponding author), Univ Bern, Dept BioMed Res, Bern, Switzerland.; Rubin, MA (corresponding author), Univ Bern, Bern Ctr Precis Med, Bern, Switzerland.; Rubin, MA (corresponding author), Inselspital Bern, Bern, Switzerland.	mark.rubin@dbmr.unibe.ch; jean-philippe.theurillat@ior.usi.ch		Rubin, Mark/0000-0002-8321-9950	Universita della Svizzera italiana	Universita della Svizzera italiana	Open Access funding provided by Universita della Svizzera italiana.	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Akamatsu S, 2015, CELL REP, V12, P922, DOI 10.1016/j.celrep.2015.07.012; Akashi T, 2006, ONCOL REP, V16, P831; Alumkal JJ, 2020, P NATL ACAD SCI USA, V117, P12315, DOI 10.1073/pnas.1922207117; Aparicio AM, 2013, CLIN CANCER RES, V19, P3621, DOI 10.1158/1078-0432.CCR-12-3791; Beltran H, 2019, CLIN CANCER RES, V25, P6916, DOI 10.1158/1078-0432.CCR-19-1423; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2014, CLIN CANCER RES, V20, P2846, DOI 10.1158/1078-0432.CCR-13-3309; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Berger A, 2019, J CLIN INVEST, V129, P3924, DOI 10.1172/JCI127961; Berman-Booty LD, 2015, ENDOCR-RELAT CANCER, V22, pR33, DOI 10.1530/ERC-14-0393; Bernasocchi T, 2020, BIORXIV, DOI [10.1101/2020.07.08.193581, DOI 10.1101/2020.07.08.193581]; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Chandrasekar T, 2015, TRANSL ANDROL UROL, V4, P365, DOI 10.3978/j.issn.2223-4683.2015.05.02; Chen WY, 2019, CANCER LETT, V440, P35, DOI 10.1016/j.canlet.2018.10.004; Chlenski A, 2001, PROSTATE, V47, P66; Conteduca V, 2019, EUR J CANCER, V121, P7, DOI 10.1016/j.ejca.2019.08.011; Cyrta J, 2020, BIORXIV, DOI [10.1101/2020.03.06.949131, DOI 10.1101/2020.03.06.949131]; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Dehm SM, 2011, ENDOCR-RELAT CANCER, V18, pR183, DOI 10.1530/ERC-11-0141; Deng J, 1999, MOL BRAIN RES, V71, P23, DOI 10.1016/S0169-328X(99)00147-3; Di Donato M, 2019, CANCERS, V11, DOI 10.3390/cancers11060784; Edwards J, 2003, CLIN CANCER RES, V9, P5271; Epstein JI, 2014, AM J SURG PATHOL, V38, P756, DOI 10.1097/PAS.0000000000000208; Flanagan JJ, 2019, MOL CELL ENDOCRINOL, V493, DOI 10.1016/j.mce.2019.110452; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Flechon A, 2011, ANN ONCOL, V22, P2476, DOI 10.1093/annonc/mdr004; Foster BA, 1997, CANCER RES, V57, P3325; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Gao S, 2016, CELL REP, V17, P966, DOI 10.1016/j.celrep.2016.09.064; Gravina GL, 2010, PROSTATE, V70, P1166, DOI 10.1002/pros.21151; Groner AC, 2016, CANCER CELL, V29, P846, DOI 10.1016/j.ccell.2016.04.012; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Ho LN, 2009, P NATL ACAD SCI USA, V106, P5187, DOI 10.1073/pnas.0812888106; Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Jeter CR, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.41; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Karanikolas BDW, 2010, PROSTATE, V70, P675, DOI 10.1002/pros.21112; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kleb B, 2016, EPIGENETICS-US, V11, P184, DOI 10.1080/15592294.2016.1146851; Kregel S, 2020, NEOPLASIA, V22, P111, DOI 10.1016/j.neo.2019.12.003; Kregel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053701; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Kuwahara A, 2010, DEVELOPMENT, V137, P1035, DOI 10.1242/dev.046417; Kwon OJ, 2020, ONCOGENE, V39, P7142, DOI 10.1038/s41388-020-01487-6; Labrecque MP, 2019, J CLIN INVEST, V129, P4492, DOI 10.1172/JCI128212; Lam HM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00167; Lapuk AV, 2012, J PATHOL, V227, P286, DOI 10.1002/path.4047; Lee JK, 2016, CANCER CELL, V29, P536, DOI 10.1016/j.ccell.2016.03.001; Lin D, 2015, ONCOTARGET, V6, P1806, DOI 10.18632/oncotarget.2809; Linn Douglas E, 2010, Genes Cancer, V1, P908, DOI 10.1177/1947601910388271; Loriot Y, 2009, ANN ONCOL, V20, P703, DOI 10.1093/annonc/mdn694; Lotan TL, 2011, MODERN PATHOL, V24, P820, DOI 10.1038/modpathol.2011.7; Malik V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11054-7; Metzger AL, 2019, PROSTATE, V79, P1457, DOI 10.1002/pros.23864; Mishra R, 2018, J CLIN INVEST, V128, P4472, DOI 10.1172/JCI99397; Mohammad OS, 2017, CANCERS, V9, DOI 10.3390/cancers9120166; Molloy Niamh H, 2011, Cancers (Basel), V3, P510, DOI 10.3390/cancers3010510; Monsef N, 2009, PROSTATE, V69, P909, DOI 10.1002/pros.20934; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Nagakawa O, 2004, ONCOL REP, V12, P837; Nakayama T, 2000, LAB INVEST, V80, P1789, DOI 10.1038/labinvest.3780190; Neklesa T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.259; Niederst MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7377; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Paranjape AN, 2016, ONCOGENE, V35, P5963, DOI 10.1038/onc.2015.498; Park JW, 2018, SCIENCE, V362, P91, DOI 10.1126/science.aat5749; Park JW, 2017, MODERN PATHOL, V30, P1262, DOI 10.1038/modpathol.2017.44; Puca L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04495-z; Rafiee MR, 2016, MOL CELL, V64, P624, DOI 10.1016/j.molcel.2016.09.019; Randolph TL, 1997, MODERN PATHOL, V10, P612; Rapp UR, 2008, CELL CYCLE, V7, P45, DOI 10.4161/cc.7.1.5203; Rotinen M, 2018, NAT MED, V24, P1887, DOI 10.1038/s41591-018-0241-1; Saraon Punit, 2014, EJIFCC, V25, P42; Sarkar S, 2017, MOL CANCER RES, V15, P1063, DOI 10.1158/1541-7786.MCR-17-0062; Scaccianoce E, 2003, ONCOL RES, V14, P101, DOI 10.3727/000000003108748658; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Sharp A, 2019, J CLIN INVEST, V129, P192, DOI 10.1172/JCI122819; Sigala S, 2002, EUR J ENDOCRINOL, V147, P407, DOI 10.1530/eje.0.1470407; Small E. J., 2014, ANN ONCOLOGY, V25, piv255; Sotomayor P, 2009, PROSTATE, V69, P401, DOI 10.1002/pros.20895; Stoyanova T, 2013, P NATL ACAD SCI USA, V110, P20111, DOI 10.1073/pnas.1320565110; Tang AQ, 2017, ONCOTARGET, V8, P23937, DOI 10.18632/oncotarget.14893; Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teply BA, 2018, LANCET ONCOL, V19, P76, DOI 10.1016/S1470-2045(17)30906-3; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Uysal-Onganer P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-55; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Xiong XZ, 2018, CELL REP, V25, P3006, DOI 10.1016/j.celrep.2018.11.065; Yang XZ, 2005, CANCER RES, V65, P5263, DOI 10.1158/0008-5472.CAN-05-0162; Yoo AS, 2009, NATURE, V460, P642, DOI 10.1038/nature08139; Yu XP, 2009, PROSTATE, V69, P249, DOI 10.1002/pros.20877; Zhang LH, 2020, NEURO-ONCOLOGY, V22, P1797, DOI 10.1093/neuonc/noaa138; Zhang XQ, 2003, ONCOGENE, V22, P6704, DOI 10.1038/sj.onc.1206764; Zhang ZD, 2020, CANCER CELL, V37, P584, DOI 10.1016/j.ccell.2020.03.001; Zou M, 2017, CANCER DISCOV, V7, P736, DOI 10.1158/2159-8290.CD-16-1174	105	21	21	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1205	1216		10.1038/s41388-020-01598-0	http://dx.doi.org/10.1038/s41388-020-01598-0		JAN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420371	hybrid, Green Published			2022-12-28	WOS:000607346000016
J	Zhang, YL; Kong, Y; Ma, Y; Ni, SL; Wikerholmen, T; Xi, KY; Zhao, FH; Zhao, ZM; Wang, JP; Huang, B; Chen, AJ; Yao, Z; Han, MZ; Feng, ZC; Hu, YT; Thorsen, F; Wang, J; Li, XG				Zhang, Yulin; Kong, Yang; Ma, Yuan; Ni, Shilei; Wikerholmen, Tobias; Xi, Kaiyan; Zhao, Feihu; Zhao, Zhimin; Wang, Junpeng; Huang, Bin; Chen, Anjing; Yao, Zhong; Han, Mingzhi; Feng, Zichao; Hu, Yaotian; Thorsen, Frits; Wang, Jian; Li, Xingang			Loss of COPZ1 induces NCOA4 mediated autophagy and ferroptosis in glioblastoma cell lines	ONCOGENE			English	Article							IRON; CANCER; METABOLISM; DEATH; TEMOZOLOMIDE; DEGRADATION; COATOMER; FERRITIN; BIOLOGY; SCREEN	Dysregulated iron metabolism is a hallmark of many cancers, including glioblastoma (GBM). However, its role in tumor progression remains unclear. Herein, we identified coatomer protein complex subunit zeta 1 (COPZ1) as a therapeutic target candidate which significantly dysregulated iron metabolism in GBM cells. Overexpression of COPZ1 was associated with increasing tumor grade and poor prognosis in glioma patients based on analysis of expression data from the publicly available database The Cancer Genome Atlas (P < 0.001). Protein levels of COPZ1 were significantly increased in GBM compared to non-neoplastic brain tissue samples in immunohistochemistry and western blot analysis. SiRNA knockdown of COPZ1 suppressed proliferation of U87MG, U251 and P3#GBM in vitro. Stable expression of a COPZ1 shRNA construct in U87MG inhibited tumor growth in vivo by similar to 60% relative to controls at day 21 after implantation (P < 0.001). Kaplan-Meier analysis of the survival data demonstrated that the overall survival of tumor bearing animals increased from 20.8 days (control) to 27.8 days (knockdown, P < 0.05). COPZ1 knockdown also led to the increase in nuclear receptor coactivator 4 (NCOA4), resulting in the degradation of ferritin, and a subsequent increase in the intracellular levels of ferrous iron and ultimately ferroptosis. These data demonstrate that COPZ1 is a critical mediator in iron metabolism. The COPZ1/NCOA4/FTH1 axis is therefore a novel therapeutic target for the treatment of human GBM.	[Zhang, Yulin; Kong, Yang; Ma, Yuan; Ni, Shilei; Xi, Kaiyan; Zhao, Feihu; Zhao, Zhimin; Wang, Junpeng; Huang, Bin; Chen, Anjing; Yao, Zhong; Feng, Zichao; Hu, Yaotian; Thorsen, Frits; Wang, Jian; Li, Xingang] Shandong Univ, Dept Neurosurg, Qilu Hosp, Cheeloo Coll Med, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Zhang, Yulin; Kong, Yang; Ma, Yuan; Ni, Shilei; Xi, Kaiyan; Zhao, Feihu; Zhao, Zhimin; Wang, Junpeng; Huang, Bin; Chen, Anjing; Yao, Zhong; Feng, Zichao; Hu, Yaotian; Thorsen, Frits; Wang, Jian; Li, Xingang] Shandong Univ, Dept Neurosurg, Inst Brain & Brain Inspired Sci, Cheeloo Coll Med, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Zhang, Yulin; Kong, Yang; Ma, Yuan; Ni, Shilei; Xi, Kaiyan; Zhao, Feihu; Zhao, Zhimin; Wang, Junpeng; Huang, Bin; Chen, Anjing; Yao, Zhong; Feng, Zichao; Hu, Yaotian; Wang, Jian; Li, Xingang] Shandong Key Lab Brain Funct Remodeling, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Zhang, Yulin; Kong, Yang; Wikerholmen, Tobias; Han, Mingzhi; Thorsen, Frits; Wang, Jian] Univ Bergen, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway; [Thorsen, Frits] Univ Bergen, Dept Biomed, Mol Imaging Ctr, Jonas Lies Vei 91, N-5009 Bergen, Norway	Shandong University; Shandong University; University of Bergen; University of Bergen	Thorsen, F; Wang, J; Li, XG (corresponding author), Shandong Univ, Dept Neurosurg, Qilu Hosp, Cheeloo Coll Med, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Thorsen, F; Wang, J; Li, XG (corresponding author), Shandong Univ, Dept Neurosurg, Inst Brain & Brain Inspired Sci, Cheeloo Coll Med, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Wang, J; Li, XG (corresponding author), Shandong Key Lab Brain Funct Remodeling, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Thorsen, F; Wang, J (corresponding author), Univ Bergen, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway.; Thorsen, F (corresponding author), Univ Bergen, Dept Biomed, Mol Imaging Ctr, Jonas Lies Vei 91, N-5009 Bergen, Norway.	Frits.Thorsen@uib.no; Jian.Wang@uib.no; lixg@sdu.edu.cn	Huang, Bin/AAT-4514-2021; Chen, Anjing/GYE-2355-2022	Wikerholmen, Tobias/0000-0002-2925-6144; Zhang, Yulin/0000-0002-0031-1808	National Natural Science Foundation of China [81972351, 81874082, 82073219, 81702474]; Department of Science & Technology of Shandong Province [2017CXGC1502, 2018GSF118094, 2018CXGC1503]; Special Foundation for Taishan Scholars [tshw201502056, ts20110814, tsqn201909173]; China Postdoctoral Science Foundation [2018M642666]; Jinan Science and Technology Bureau of Shandong Province [2019GXRC006, 201821049]; Shandong Research Institute of Industrial Technology	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Science & Technology of Shandong Province; Special Foundation for Taishan Scholars; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Jinan Science and Technology Bureau of Shandong Province; Shandong Research Institute of Industrial Technology	This work was supported by the National Natural Science Foundation of China (81972351, 81874082, 82073219, and 81702474), the Department of Science & Technology of Shandong Province (2017CXGC1502, 2018GSF118094 and 2018CXGC1503), the Special Foundation for Taishan Scholars (tshw201502056, ts20110814 and tsqn201909173), the China Postdoctoral Science Foundation (2018M642666), the Jinan Science and Technology Bureau of Shandong Province (2019GXRC006 and 201821049) and the Shandong Research Institute of Industrial Technology.	Anania MC, 2017, CANCER LETT, V410, P201, DOI 10.1016/j.canlet.2017.09.024; Angeli JPF, 2019, NAT REV CANCER, V19, P405, DOI 10.1038/s41568-019-0149-1; Beck R, 2009, FEBS LETT, V583, P2701, DOI 10.1016/j.febslet.2009.07.032; Chen JJ, 2018, TRENDS CELL BIOL, V28, P77, DOI 10.1016/j.tcb.2017.11.007; Collinet C, 2010, NATURE, V464, P243, DOI 10.1038/nature08779; Cooper MS, 2019, BRAIN, V142, DOI 10.1093/brain/awz183; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218; Dowdle WE, 2014, NAT CELL BIOL, V16, P1069, DOI 10.1038/ncb3053; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Gao MH, 2019, MOL CELL, V73, P354, DOI 10.1016/j.molcel.2018.10.042; Gao MH, 2016, CELL RES, V26, P1021, DOI 10.1038/cr.2016.95; Han MZ, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201910924; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hassannia B, 2019, CANCER CELL, V35, P830, DOI 10.1016/j.ccell.2019.04.002; Hou W, 2016, AUTOPHAGY, V12, P1425, DOI 10.1080/15548627.2016.1187366; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Legendre C, 2015, TRENDS ENDOCRIN MET, V26, P322, DOI 10.1016/j.tem.2015.03.008; Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143; Madsen E, 2007, ANNU REV NEUROSCI, V30, P317, DOI 10.1146/annurev.neuro.30.051606.094232; Mancias JD, 2015, ELIFE, V4, DOI 10.7554/eLife.10308; Mancias JD, 2014, NATURE, V509, P105, DOI 10.1038/nature13148; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mleczko-Sanecka K, 2017, HAEMATOLOGICA, V102, P1173, DOI 10.3324/haematol.2016.162917; Mleczko-Sanecka K, 2014, BLOOD, V123, P1574, DOI 10.1182/blood-2013-07-515957; Murphy MP, 2018, NAT CELL BIOL, V20, P1104, DOI 10.1038/s41556-018-0209-x; Pignatello JJ, 2006, CRIT REV ENV SCI TEC, V36, P1, DOI 10.1080/10643380500326564; Razi M, 2009, J CELL BIOL, V185, P305, DOI 10.1083/jcb.200810098; Ryu MS, 2017, J CLIN INVEST, V127, P1786, DOI 10.1172/JCI90519; Salvador GA, 2010, BIOFACTORS, V36, P103, DOI 10.1002/biof.80; Schoenfeld JD, 2017, CANCER CELL, V31, P487, DOI 10.1016/j.ccell.2017.02.018; Shin D, 2020, REDOX BIOL, V30, DOI 10.1016/j.redox.2019.101418; Shtutman M, 2011, P NATL ACAD SCI USA, V108, P12449, DOI 10.1073/pnas.1103842108; Simon T, 2020, ONCOGENE, V39, P4477, DOI 10.1038/s41388-020-1308-2; Sosa V, 2013, AGEING RES REV, V12, P376, DOI 10.1016/j.arr.2012.10.004; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sukseree S, 2020, AUTOPHAGY, V16, P1851, DOI 10.1080/15548627.2019.1709764; Sun X, 2015, ONCOGENE, V34, P5617, DOI 10.1038/onc.2015.32; Teng J, 2018, NEURO-ONCOLOGY, V20, P642, DOI 10.1093/neuonc/nox198; Theil EC, 2004, ANNU REV NUTR, V24, P327, DOI 10.1146/annurev.nutr.24.012003.132212; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; van Swelm RPL, 2020, NAT REV NEPHROL, V16, P77, DOI 10.1038/s41581-019-0197-5; Wang YF, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010095; Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158; Zhang YL, 2020, ACS APPL MATER INTER, V12, P43408, DOI 10.1021/acsami.0c12042; Zhang ZL, 2018, AUTOPHAGY, V14, P2083, DOI 10.1080/15548627.2018.1503146	47	42	43	6	32	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1425	1439		10.1038/s41388-020-01622-3	http://dx.doi.org/10.1038/s41388-020-01622-3		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33420375	hybrid, Green Published			2022-12-28	WOS:000607346000013
J	Bergin, CJ; Zouggar, A; Haebe, JR; Masibag, AN; Desrochers, FM; Reilley, SY; Agrawal, G; Benoit, YD				Bergin, Christopher J.; Zouggar, Aicha; Haebe, Joshua R.; Masibag, Angelique N.; Desrochers, Francois M.; Reilley, Simon Y.; Agrawal, Gautam; Benoit, Yannick D.			G9a controls pluripotent-like identity and tumor-initiating function in human colorectal cancer	ONCOGENE			English	Article							STEM-CELLS; HISTONE H3; IDENTIFICATION; METHYLATION; METASTASIS; FEATURES	Colorectal tumors are hierarchically organized and governed by populations of self-renewing cancer stem cells, representing one of the deadliest types of cancers worldwide. Emergence of cancer stemness phenotype depends on epigenetic reprogramming, associated with profound transcriptional changes. As described for pluripotent reprogramming, epigenetic modifiers play a key role in cancer stem cells by establishing embryonic stem-like transcriptional programs, thus impacting the balance between self-renewal and differentiation. We identified overexpression of histone methyltransferase G9a as a risk factor for colorectal cancer, associated with shorter relapse-free survival. Moreover, using human transformed pluripotent cells as a surrogate model for cancer stem cells, we observed that G9a activity is essential for the maintenance of embryonic-like transcriptional signature promoting self-renewal, tumorigenicity, and undifferentiated state. Such a role was also applicable to colorectal cancer, where inhibitors of G9a histone methyltransferase function induced intestinal differentiation while restricting tumor-initiating activity in patient-derived colorectal tumor samples. Finally, by integrating transcriptome profiling with G9a/H3K9me2 loci co-occupancy, we identified the canonical Wnt pathway, epithelial-to-mesenchyme transition, and extracellular matrix organization as potential targets of such a chromatin regulation mechanism in colorectal cancer stem cells. Overall, our findings provide novel insights on the role of G9a as a driver of cancer stem cell phenotype, promoting self-renewal, tumorigenicity, and undifferentiated state.	[Bergin, Christopher J.; Zouggar, Aicha; Haebe, Joshua R.; Masibag, Angelique N.; Desrochers, Francois M.; Reilley, Simon Y.; Agrawal, Gautam; Benoit, Yannick D.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Benoit, YD (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada.	ybenoit@uottawa.ca		Bergin, Chris/0000-0003-3610-6184; Benoit, Yannick/0000-0002-6677-4020	Cancer Research Society [22778, 24039]; Ontario Ministry of Research, Innovation and Science [ER17-13-012]; CIHR [PJT-173541]; National Science and Engineering Research Council [RGPIN-2018-06521, DGECR-2018-00029]	Cancer Research Society; Ontario Ministry of Research, Innovation and Science; CIHR(Canadian Institutes of Health Research (CIHR)); National Science and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work was supported by grants from the Cancer Research Society (#22778 and #24039), the Ontario Ministry of Research, Innovation and Science (ER17-13-012), the CIHR (PJT-173541), and the National Science and Engineering Research Council (RGPIN-2018-06521 and DGECR-2018-00029).	Ardeljan D, 2017, CLIN CHEM, V63, P816, DOI 10.1373/clinchem.2016.257444; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Benoit YD, 2017, CELL CHEM BIOL, V24, P833, DOI 10.1016/j.chembiol.2017.05.026; Benoit YD, 2014, CLIN CANCER RES, V20, P5372, DOI 10.1158/1078-0432.CCR-13-2491; Bergin CJ, 2020, GENES-BASEL, V11, DOI 10.3390/genes11060616; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Castro-Diaz N, 2014, GENE DEV, V28, P1397, DOI 10.1101/gad.241661.114; Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Feldman N, 2006, NAT CELL BIOL, V8, P188, DOI 10.1038/ncb1353; Gifford CA, 2013, CELL, V153, P1149, DOI 10.1016/j.cell.2013.04.037; Grade M, 2007, CANCER RES, V67, P41, DOI 10.1158/0008-5472.CAN-06-1514; Jung G, 2020, NAT REV GASTRO HEPAT, V17, P111, DOI 10.1038/s41575-019-0230-y; Kato S, 2020, CANCER DISCOV, V10, P980, DOI 10.1158/2159-8290.CD-19-0532; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Lehnertz B, 2014, GENE DEV, V28, P317, DOI 10.1101/gad.236794.113; Lenstra DC, 2018, BIOORG MED CHEM LETT, V28, P1234, DOI 10.1016/j.bmcl.2018.02.043; Lima-Fernandes E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09309-4; Liu SL, 2015, ONCOTARGET, V6, P6887, DOI 10.18632/oncotarget.3159; Lu XY, 2014, NAT STRUCT MOL BIOL, V21, P423, DOI 10.1038/nsmb.2799; Luo CW, 2017, RADIOTHER ONCOL, V124, P395, DOI 10.1016/j.radonc.2017.03.002; Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034; Mozzetta C, 2014, MOL CELL, V53, P277, DOI 10.1016/j.molcel.2013.12.005; Nakazawa T, 2012, HUM PATHOL, V43, P834, DOI 10.1016/j.humpath.2011.07.009; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Pangeni RP, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00879-5; Perez CA, 2007, ONCOGENE, V26, P7363, DOI 10.1038/sj.onc.1210561; Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056; Sachlos E, 2012, CELL, V149, P1284, DOI 10.1016/j.cell.2012.03.049; Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wainwright EN, 2017, TRENDS CANCER, V3, P372, DOI 10.1016/j.trecan.2017.04.004; Wang HJ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0147-5; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Werbowetski-Ogilvie TE, 2012, STEM CELLS, V30, P392, DOI 10.1002/stem.1017; Werbowetski-Ogilvie TE, 2009, NAT BIOTECHNOL, V27, P91, DOI 10.1038/nbt.1516; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107; Zhang T, 2016, CELL REP, V15, P77, DOI 10.1016/j.celrep.2016.03.007	43	13	13	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1191	1202		10.1038/s41388-020-01591-7	http://dx.doi.org/10.1038/s41388-020-01591-7		DEC 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323965	Green Published, hybrid			2022-12-28	WOS:000599126500012
J	Zhang, Y; Yan, Q; Gong, LQ; Xu, H; Liu, BL; Fang, XN; Yu, DD; Li, L; Wei, T; Wang, Y; Wong, CN; Lyu, Z; Tang, Y; Sham, PC; Guan, XY				Zhang, Yu; Yan, Qian; Gong, Lanqi; Xu, Hang; Liu, Beilei; Fang, Xiaona; Yu, Dandan; Li, Lei; Wei, Ting; Wang, Ying; Wong, Ching Ngar; Lyu, Zhaojie; Tang, Ying; Sham, Pak Chung; Guan, Xin-Yuan			C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism	ONCOGENE			English	Article							VIRUS X PROTEIN; HEPATOCELLULAR-CARCINOMA; AEROBIC GLYCOLYSIS; TUMOR-SUPPRESSOR; LIVER-CANCER; METASTASIS; ACTIVATION; INTEGRATION; EXPRESSION; PATHWAY	Chronic hepatitis B virus (HBV) infection is strongly associated with the initiation and development of hepatocellular carcinoma (HCC). However, the genetic alterations and pathogenesis mechanisms remain significantly unexplored, especially for HBV-induced metabolic reprogramming. Analysis of integration breakpoints in HBV-positive HCC samples revealed the preferential clustering pattern within the 3 '-end of X gene in the HBV genome, leading to the production of C-terminal truncated X protein (Ct-HBx). In this study, we not only characterized the oncogenic role of two Ct-HBx (HBx-120 and HBx-134) via in vitro and in vivo functional assays but also deciphered their underlying molecular mechanisms. Gene expression profiling by transcriptome sequencing identified potential targets of Ct-HBx and novel malignant hallmarks such as glycolysis, cell cycle, and m-TORC1 signaling in Ct-HBx-expressing cells. TXNIP, a well-established regulator of glucose metabolism, was shown to be downregulated by Ct-HBx and play a pivotal role in Ct-HBx-mediated HCC progression. Suppression of TXNIP is frequently observed in HCC patients with Ct-HBx expression and significantly (P = 0.015) correlated to a poorer prognosis. Re-introduction of TXNIP attenuated the metabolic reprogramming induced by the Ct-HBx and inhibited the tumor growth in the mice model. Further study suggested that Ct-HBx could downregulate TXNIP via a transcriptional repressor nuclear factor of activated T cells 2 (NFACT2). Collectively, our findings indicate that TXNIP plays a critical role in Ct-HBx-mediated hepatocarcinogenesis, serving as a novel therapeutic strategy in HCC treatment.	[Zhang, Yu; Gong, Lanqi; Liu, Beilei; Fang, Xiaona; Yu, Dandan; Li, Lei; Wang, Ying; Wong, Ching Ngar; Lyu, Zhaojie; Tang, Ying; Guan, Xin-Yuan] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China; [Zhang, Yu; Gong, Lanqi; Liu, Beilei; Fang, Xiaona; Yu, Dandan; Li, Lei; Wang, Ying; Wong, Ching Ngar; Lyu, Zhaojie; Tang, Ying; Guan, Xin-Yuan] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China; [Yan, Qian] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Res Ctr Med Sci, Guangzhou 510030, Peoples R China; [Yan, Qian; Guan, Xin-Yuan] Univ Hong Kong, Shenzhen Hosp, Dept Clin Oncol, Shenzhen 518053, Peoples R China; [Xu, Hang; Sham, Pak Chung] Univ Hong Kong, Li Ka Shing Fac Med, Dept Psychiat, Hong Kong, Peoples R China; [Yu, Dandan] Southern Univ Sci & Technol, Dept Biol, Shenzhen 518055, Peoples R China; [Wei, Ting] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou 510282, Peoples R China; [Guan, Xin-Yuan] Sun Yat Sen Univ, State Key Lab Oncol Southern China, Canc Ctr, Guangzhou 510060, Peoples R China	University of Hong Kong; University of Hong Kong; Guangdong Academy of Medical Sciences & Guangdong General Hospital; University of Hong Kong; University of Hong Kong; Southern University of Science & Technology; Southern Medical University - China; State Key Lab Oncology South China; Sun Yat Sen University	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, Shenzhen Hosp, Dept Clin Oncol, Shenzhen 518053, Peoples R China.; Guan, XY (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol Southern China, Canc Ctr, Guangzhou 510060, Peoples R China.	xyguan@hku.hk			Hong Kong Research Grant Council (RGC) [C7065-18GF, C7026-18GF, T12-704/16-R]; Research Grant Council (RGC) [17143716]; National Key R&D Program of China [2017YFC1309000]; National Natural Science Foundation of China [81903049, 81772554]; Shenzhen Peacock Team Project [KQTD201533117210153, KQTD2018041118502879]	Hong Kong Research Grant Council (RGC)(Hong Kong Research Grants Council); Research Grant Council (RGC)(Hong Kong Research Grants Council); National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Peacock Team Project	This project was supported by grants from the Hong Kong Research Grant Council (RGC) grants including Collaborative Research Funds (C7065-18GF and C7026-18GF), Theme-based Research Scheme (T12-704/16-R), Research Grant Council (RGC) grants including GRF (17143716), the National Key R&D Program of China (2017YFC1309000), National Natural Science Foundation of China (81903049, 81772554), and The Shenzhen Peacock Team Project (KQTD201533117210153, KQTD2018041118502879). Professor Xin-Yuan Guan is Sophie YM Chan Professor in Cancer Research.	Arzumanyan A, 2011, CANCER RES, V71, P3701, DOI 10.1158/0008-5472.CAN-10-3951; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Chambers JW, 2010, J VIROL, V84, P1867, DOI 10.1128/JVI.02123-09; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Delgado T, 2010, P NATL ACAD SCI USA, V107, P10696, DOI 10.1073/pnas.1004882107; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Hardie DG, 2015, CLIN CANCER RES, V21, P3836, DOI 10.1158/1078-0432.CCR-14-3300; He L, 2018, MOL CELL, V70, P949, DOI 10.1016/j.molcel.2018.04.024; He ZL, 2017, ONCOL LETT, V14, P1323, DOI 10.3892/ol.2017.6296; Huang JF, 2013, HEPATOLOGY, V57, P1882, DOI 10.1002/hep.26195; Hui STY, 2008, P NATL ACAD SCI USA, V105, P3921, DOI 10.1073/pnas.0800293105; Ishikawa T, 2010, WORLD J GASTROENTERO, V16, P2463, DOI 10.3748/wjg.v16.i20.2463; Jeon JH, 2005, CANCER RES, V65, P4485, DOI 10.1158/0008-5472.CAN-04-2271; Ji SR, 2016, CLIN CANCER RES, V22, P3950, DOI 10.1158/1078-0432.CCR-15-2380; Jin HO, 2011, ONCOGENE, V30, P3792, DOI 10.1038/onc.2011.102; Kaadige MR, 2009, P NATL ACAD SCI USA, V106, P14878, DOI 10.1073/pnas.0901221106; Keng VW, 2011, HEPATOLOGY, V53, P781, DOI 10.1002/hep.24091; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Li XJ, 2014, J HEPATOL, V60, P975, DOI 10.1016/j.jhep.2013.12.014; Liu XW, 2016, MOL MED REP, V14, P2311, DOI 10.3892/mmr.2016.5472; Liu Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14813-y; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; Lo AKF, 2015, J PATHOL, V237, P238, DOI 10.1002/path.4575; Ma NF, 2008, CLIN CANCER RES, V14, P5061, DOI 10.1158/1078-0432.CCR-07-5082; Ma T, 2015, ANGIOGENESIS, V18, P477, DOI 10.1007/s10456-015-9475-4; Malone CF, 2017, CANCER DISCOV, V7, P1450, DOI 10.1158/2159-8290.CD-17-0177; Noch E, 2012, MOL CANCER THER, V11, P14, DOI 10.1158/1535-7163.MCT-11-0517; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Pusapati RV, 2016, CANCER CELL, V29, P548, DOI 10.1016/j.ccell.2016.02.018; Quetier I, 2015, J GEN VIROL, V96, P614, DOI 10.1099/vir.0.070680-0; Schoder H, 2007, J NUCL MED, V48, p4S; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Sheth SS, 2006, ONCOGENE, V25, P3528, DOI 10.1038/sj.onc.1209394; Sung WK, 2012, NAT GENET, V44, P765, DOI 10.1038/ng.2295; Suzuki J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05854-6; Sze KMF, 2013, HEPATOLOGY, V57, P131, DOI 10.1002/hep.25979; Thai M, 2014, CELL METAB, V19, P694, DOI 10.1016/j.cmet.2014.03.009; Wang Y, 2002, J PATHOL, V197, P610, DOI 10.1002/path.1150; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wu N, 2013, MOL CELL, V49, P1167, DOI 10.1016/j.molcel.2013.01.035; Xiao L, 2014, ONCOGENE, V33, P4568, DOI 10.1038/onc.2014.32; Yang WJ, 2009, HEPATOLOGY, V49, P1515, DOI 10.1002/hep.22833; Ye JB, 2014, CANCER DISCOV, V4, P1406, DOI 10.1158/2159-8290.CD-14-0250; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Zhang R, 2016, AM J CANCER RES, V6, P312; Zhou Q, 2011, FUTURE ONCOL, V7, P1149, DOI [10.2217/FON.11.95, 10.2217/fon.11.95]	50	24	25	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1147	1161		10.1038/s41388-020-01593-5	http://dx.doi.org/10.1038/s41388-020-01593-5		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323975	hybrid, Green Published			2022-12-28	WOS:000599126500007
J	Han, AN; Purwin, TJ; Bechtel, N; Liao, C; Chua, V; Seifert, E; Sato, T; Schug, ZT; Speicher, DW; Harbour, JW; Aplin, AE				Han, Anna; Purwin, Timothy J.; Bechtel, Nelisa; Liao, Connie; Chua, Vivian; Seifert, Erin; Sato, Takami; Schug, Zachary T.; Speicher, David W.; William Harbour, J.; Aplin, Andrew E.			BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors	ONCOGENE			English	Article							TARGETING CANCER METABOLISM; FATTY-ACID OXIDATION; CELL-METABOLISM; GENE; EXPRESSION; PROTEIN; ASSOCIATION; GLYCOLYSIS; REGULATOR; SUBTYPES	Cancer cell metabolism is a targetable vulnerability; however, a precise understanding of metabolic heterogeneity is required. Inactivating mutations in BRCA1-associated protein 1 (BAP1) are associated with metastasis in uveal melanoma (UM), the deadliest adult eye cancer. BAP1 functions in UM remain unclear. UM patient sample analysis divided BAP1 mutant UM tumors into two subgroups based on oxidative phosphorylation (OXPHOS) gene expression suggesting metabolic heterogeneity. Consistent with patient data, transcriptomic analysis of BAP1 mutant UM cell lines also showed OXPHOShigh or OXPHOSlow subgroups. Integrated RNA sequencing, metabolomics, and molecular analyses showed that OXPHOS(high)BAP1 mutant UM cells utilize glycolytic and nucleotide biosynthesis pathways, whereas OXPHOS(low)BAP1 mutant UM cells employ fatty acid oxidation. Furthermore, the two subgroups responded to different classes of metabolic suppressors. Our findings indicate that targeting cancer metabolism is a promising therapeutic option for BAP1 mutant UM; however, tailored approaches may be required due to metabolic heterogeneities.	[Han, Anna; Purwin, Timothy J.; Bechtel, Nelisa; Liao, Connie; Chua, Vivian; Aplin, Andrew E.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA; [Seifert, Erin] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; [Sato, Takami] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA; [Sato, Takami; Aplin, Andrew E.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Schug, Zachary T.; Speicher, David W.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA; [Speicher, David W.] Wistar Inst Anat & Biol, Prote & Metab Facil, 3601 Spruce St, Philadelphia, PA 19104 USA; [William Harbour, J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33101 USA; [William Harbour, J.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33101 USA; [William Harbour, J.] Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33101 USA	Jefferson University; Jefferson University; Jefferson University; Jefferson University; The Wistar Institute; The Wistar Institute; Bascom Palmer Eye Institute; University of Miami; University of Miami; University of Miami	Aplin, AE (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA.; Aplin, AE (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.	Andrew.Aplin@Jefferson.edu		Purwin, Timothy/0000-0002-7053-8039; Schug, Zachary/0000-0003-4197-8227; Han, Anna/0000-0001-8180-6214	Melanoma Research Alliance team science award [559058]; National Institutes of Health (NIH)/National Cancer Institute (NCI) [R01 CA196278, R01 CA253977, P50CA174523]; National Cancer Center; American Association for Cancer Research (AACR)/Ocular Melanoma Foundation; NCI [P01 CA114046];  [P30CA010815];  [S10OD023586]	Melanoma Research Alliance team science award; National Institutes of Health (NIH)/National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Center; American Association for Cancer Research (AACR)/Ocular Melanoma Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; 	We thank Dr. Sergio Roman-Roman (Uveal Melanoma Translational Group, Department of Translational Research, Institute Curie, PSL Research University, Paris, France) for cell lines. We thank Dr. Michele Carbone (University of Hawaii Cancer Center, Honolulu, HI, USA) for BAP1 cDNA. This work was supported by a Melanoma Research Alliance team science award (#559058) to AEA and JWH. Further support was from National Institutes of Health (NIH)/National Cancer Institute (NCI), R01 CA196278 and R01 CA253977 to AEA, P50CA174523 to DWS and fellowships from the National Cancer Center and American Association for Cancer Research (AACR)/Ocular Melanoma Foundation (OMF) awarded to AH and VC. This work was also supported by grant from NCI P01 CA114046. The Wistar Proteomics and Metabolomics Facility was supported by P30CA010815 and S10OD023586.	Amirouchene-Angelozzi N, 2014, MOL ONCOL, V8, P1508, DOI 10.1016/j.molonc.2014.06.004; Baughman JM, 2016, CELL REP, V16, P583, DOI 10.1016/j.celrep.2016.05.096; Bononi A, 2017, CELL DEATH DIFFER, V24, P1694, DOI 10.1038/cdd.2017.95; Camarda R, 2016, NAT MED, V22, P427, DOI 10.1038/nm.4055; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Cheng HY, 2017, MOL CANCER THER, V16, P516, DOI 10.1158/1535-7163.MCT-16-0552; Chua V, 2018, CURR OPIN ONCOL, V30, P134, DOI 10.1097/CCO.0000000000000425; Daemen A, 2015, P NATL ACAD SCI USA, V112, pE4410, DOI 10.1073/pnas.1501605112; Dai FY, 2017, P NATL ACAD SCI USA, V114, P3192, DOI 10.1073/pnas.1619588114; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Desler Claus, 2012, J Aging Res, V2012, P192503, DOI 10.1155/2012/192503; Dey A, 2012, SCIENCE, V337, P1541, DOI 10.1126/science.1221711; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Gaude E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13041; Goodwin J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15503; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Hebert L, 2017, ONCOTARGET, V8, P72513, DOI 10.18632/oncotarget.19872; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Izawa T, 2015, CELL REP, V11, P1625, DOI 10.1016/j.celrep.2015.05.019; JAGER MJ, 2020, NAT REV DIS PRIMERS, V6, P1, DOI DOI 10.1038/s41572-019-0135-7; Johansson PA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16276-8; Jones NP, 2012, DRUG DISCOV TODAY, V17, P232, DOI 10.1016/j.drudis.2011.12.017; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kalirai H, 2014, BRIT J CANCER, V111, P1373, DOI 10.1038/bjc.2014.417; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Karlsson J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15606-0; Klebe S, 2015, BIOMARK RES, V3, DOI 10.1186/s40364-015-0040-5; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liem Minh Phan, 2014, Cancer Biology Medicine, V11, P1, DOI 10.7497/j.issn.2095-3941.2014.01.001; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luke JJ, 2015, PIGM CELL MELANOMA R, V28, P135, DOI 10.1111/pcmr.12304; Luo WJ, 2013, BIOINFORMATICS, V29, P1830, DOI 10.1093/bioinformatics/btt285; Ma JF, 2013, EXPERT REV PROTEOMIC, V10, P365, DOI 10.1586/14789450.2013.820536; Matatall KA, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-371; Misaghi S, 2009, MOL CELL BIOL, V29, P2181, DOI 10.1128/MCB.01517-08; Molina JR, 2018, NAT MED, V24, P1036, DOI 10.1038/s41591-018-0052-4; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Pacella I, 2018, P NATL ACAD SCI USA, V115, pE6546, DOI 10.1073/pnas.1720113115; Peng XX, 2018, CELL REP, V23, P255, DOI 10.1016/j.celrep.2018.03.077; Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043; Postow MA, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.9074; Rai K, 2016, CLIN GENET, V89, P285, DOI 10.1111/cge.12630; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Scheuermann JC, 2010, NATURE, V465, P243, DOI 10.1038/nature08966; Seedor RS, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.9592; SHIELDS JA, 1991, SURV OPHTHALMOL, V36, P161, DOI 10.1016/0039-6257(91)90001-V; Singh Arun D, 2005, Ophthalmol Clin North Am, V18, P75, DOI 10.1016/j.ohc.2004.07.002; Singh AD, 2011, OPHTHALMOLOGY, V118, P1881, DOI 10.1016/j.ophtha.2011.01.040; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; van Essen TH, 2014, BRIT J OPHTHALMOL, V98, P1738, DOI 10.1136/bjophthalmol-2014-305047; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Vivas-Garcia Y, 2020, MOL CELL, V77, P120, DOI 10.1016/j.molcel.2019.10.014; Wang A, 2016, J CLIN PATHOL, V69, P750, DOI 10.1136/jclinpath-2016-203866; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD608, DOI 10.1093/nar/gkx1089; Yu H, 2010, MOL CELL BIOL, V30, P5071, DOI 10.1128/MCB.00396-10; Yu LL, 2017, CANCER RES, V77, P1564, DOI 10.1158/0008-5472.CAN-16-2074	62	19	19	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					618	632		10.1038/s41388-020-01554-y	http://dx.doi.org/10.1038/s41388-020-01554-y		NOV 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33208912	Green Accepted			2022-12-28	WOS:000590925500001
J	de Pedro, I; Galan-Vidal, J; Freije, A; de Diego, E; Gandarillas, A				de Pedro, Isabel; Galan-Vidal, Jesus; Freije, Ana; de Diego, Ernesto; Gandarillas, Alberto			p21CIP1 controls the squamous differentiation response to replication stress	ONCOGENE			English	Article							CELL-CYCLE EXIT; HUMAN KERATINOCYTES; DNA-REPLICATION; P21 EXPRESSION; MITOTIC EXIT; C-MYC; P53; P21(WAF1/CIP1); CANCER; SKIN	The control of cell fate is critical to homeostasis and cancer. Cell cycle cdk inhibitor p21CIP1 has a central and paradoxical role in the regulatory crossroads leading to senescence, apoptosis, or differentiation. p21 is an essential target of tumor suppressor p53, but it also is regulated independently. In squamous self-renewal epithelia continuously exposed to mutagenesis, p21 controls cell fate by mechanisms still intriguing. We previously identified a novel epidermoid DNA damage-differentiation response. We here show that p21 intervenes in the mitosis block that is required for the squamous differentiation response to cell cycle deregulation and replication stress. The inactivation of endogenous p21 in human primary keratinocytes alleviated the differentiation response to oncogenic loss of p53 or overexpression of the DNA replication major regulator Cyclin E. The bypass of p21-induced mitotic block involving upregulation of Cyclin B allowed DNA damaged cells to escape differentiation and continue to proliferate. In addition, loss of p21 drove keratinocytes from differentiation to apoptosis upon moderate UV irradiation. The results show that p21 is required to drive keratinocytes towards differentiation in response to genomic stress and shed light into its dual and paradoxical role in carcinogenesis.	[de Pedro, Isabel; Galan-Vidal, Jesus; Freije, Ana; de Diego, Ernesto; Gandarillas, Alberto] Inst Res Marques de Valdecilla IDIVAL, Cell Cycle Stem Cell Fate & Canc Lab France Suppl, Santander 39011, Spain; [de Diego, Ernesto] Hosp Univ Marques de Valdecilla, Paediat Surg, Santander 39008, Spain; [Gandarillas, Alberto] INSERM, Languedoc Roussillon, F-34394 Montpellier, France	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Institut National de la Sante et de la Recherche Medicale (Inserm)	Gandarillas, A (corresponding author), Inst Res Marques de Valdecilla IDIVAL, Cell Cycle Stem Cell Fate & Canc Lab France Suppl, Santander 39011, Spain.; Gandarillas, A (corresponding author), INSERM, Languedoc Roussillon, F-34394 Montpellier, France.	agandarillas@idival.org	Vidal, Jesús Galán/AAN-3015-2021	Galan Vidal, Jesus/0000-0001-9105-2401	Instituto de Salud Carlos III/FEDER (AG; Spain) [PI14/00900, PI17/01307]; ISCIII-FEDER [PI1400900]; IFC (Industrial Farmaceutica Cantabria); Asociacion Espanola Contra el Cancer (AECC; Spain) [PRDCA19003GALA]	Instituto de Salud Carlos III/FEDER (AG; Spain); ISCIII-FEDER(Spanish Government); IFC (Industrial Farmaceutica Cantabria); Asociacion Espanola Contra el Cancer (AECC; Spain)	This work was funded by Instituto de Salud Carlos III/FEDER (AG; Spain), grants PI14/00900 and PI17/01307. IdP was in part supported by lab resources, by ISCIII-FEDER PI1400900 and by a scholarship from IFC (Industrial Farmaceutica Cantabria, currently Cantabria Labs; Spain). JG is recipient of a predoctoral scholarship from Asociacion Espanola Contra el Cancer (AECC; Spain), PRDCA19003GALA. We thank Jeannette G. Cook for the doxycycline-inducible Cyclin E construct.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Alonso-Lecue P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.259; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; Aylon Y, 2011, MOL ONCOL, V5, P315, DOI 10.1016/j.molonc.2011.07.007; Borowiec AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077507; Brash DE, 2006, BRIT J DERMATOL, V154, P8, DOI 10.1111/j.1365-2133.2006.07230.x; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; de Pedro I, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1130-8; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; El-Deiry WS, 2016, CANCER RES, V76, P5189, DOI 10.1158/0008-5472.CAN-16-2055; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Freije A, 2012, ONCOGENE, V31, P5180, DOI 10.1038/onc.2012.22; Freije A, 2020, METHODS MOL BIOL, V2109, P113, DOI 10.1007/7651_2019_238; Freije A, 2014, CELL REP, V9, P1349, DOI 10.1016/j.celrep.2014.10.012; Galanos P, 2016, NAT CELL BIOL, V18, P777, DOI 10.1038/ncb3378; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 2012, CELL CYCLE, V11, P4507, DOI 10.4161/cc.22529; Georgakilas AG, 2017, TRENDS MOL MED, V23, P310, DOI 10.1016/j.molmed.2017.02.001; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harvat BL, 1998, J CELL SCI, V111, P1185; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kim JS, 2007, MOL CELL BIOL, V27, P662, DOI 10.1128/MCB.00537-06; Kolly C, 2005, J INVEST DERMATOL, V124, P1014, DOI 10.1111/j.0022-202X.2005.23655.x; Kreis NN, 2015, ONCOGENE, V34, P1758, DOI 10.1038/onc.2014.133; Kumar MG, 1999, ARCH DERMATOL RES, V291, P37, DOI 10.1007/s004030050381; le Pelletier F, 2001, J INVEST DERMATOL, V117, P1324; Liu M, 1999, J INVEST DERMATOL, V113, P283, DOI 10.1046/j.1523-1747.1999.00657.x; Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424; Matson JP, 2017, ELIFE, V6, DOI 10.7554/eLife.30473; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Molinuevo R, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202001063; Mullers E, 2014, CELL CYCLE, V13, P2733, DOI 10.4161/15384101.2015.945831; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; PONTEN J, 1995, INT J CANCER, V60, P1, DOI 10.1002/ijc.2910600102; Potapova TA, 2006, NATURE, V440, P954, DOI 10.1038/nature04652; Ren ZP, 1997, AM J PATHOL, V150, P1791; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; Ritchie A, 2009, CELL DEATH DIFFER, V16, P838, DOI 10.1038/cdd.2009.13; Sanz-Gomez N, 2020, METHODS MOL BIOL, V2109, P83, DOI 10.1007/7651_2019_237; Sanz-Gomez N, 2020, CELL DEATH DIFFER, V27, P2451, DOI 10.1038/s41418-020-0515-2; Sanz-Gomez N, 2018, HEAD NECK-J SCI SPEC, V40, P2487, DOI 10.1002/hed.25376; SHEA CR, 1992, AM J PATHOL, V141, P25; Teixeira LK, 2017, ADV EXP MED BIOL, V1042, P527, DOI 10.1007/978-981-10-6955-0_22; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Weinberg WC, 2002, CRIT REV ORAL BIOL M, V13, P453, DOI 10.1177/154411130201300603; Yook JI, 1998, ORAL ONCOL, V34, P198, DOI 10.1016/S1368-8375(97)00091-2; Zanet J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015701; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	51	2	2	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					152	162		10.1038/s41388-020-01520-8	http://dx.doi.org/10.1038/s41388-020-01520-8		OCT 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33097856				2022-12-28	WOS:000582109700002
J	Qiu, PX; Hou, WL; Wang, HT; Lei, KKW; Wang, SW; Chen, WP; Pardeshi, LA; Prothro, K; Shukla, Y; Su, SSM; Schrump, DS; Chen, Q; Deng, CX; Xu, XL; Wang, RH				Qiu, Pengxiang; Hou, Weilong; Wang, Haitao; Lei, Kimmy Ka Wing; Wang, Shaowei; Chen, Weiping; Pardeshi, Lakhansing Arun; Prothro, Katherine; Shukla, Yashvita; Su, Samson Sek Man; Schrump, David S.; Chen, Qiang; Deng, Chu-Xia; Xu, Xiaoling; Wang, Ruihong			Sirt1 deficiency upregulates glutathione metabolism to prevent hepatocellular carcinoma initiation in mice	ONCOGENE			English	Article							OXIDATIVE DNA-DAMAGE; CELL-SURVIVAL; HEPATOCYTE DEATH; NRF2; LIVER; TRANSCRIPTION; MODULATION; GROWTH; PROLIFERATION; DEACETYLATION	Sirtuin-1 (SIRT1) is involved in various metabolic pathways, including fatty acid synthesis and gluconeogenesis in the liver. However, its role in initiation and progression of liver cancer remains unclear. Studying Sirt1 liver-specific knockout (LKO) mice in combination with diethylnitrosamine (DEN) treatment, we demonstrated that loss of Sirt1 rendered mice resistant to DEN-induced hepatocellular carcinoma (HCC) development. RNA-seq revealed that livers from LKO mice exhibited an enrichment in glutathione metabolism eight months after DEN challenge. Sirt1 deficiency elevated the expression of glutathione-s-transferase family genes by increasing the level of Nrf2, a key regulator of glutathione metabolism. Hence, LKO livers displayed a reductive environment with an increased ratio of GSH to GSSG and an elevated GSH level. Furthermore, using CRISPR knockout techniques, we confirmed that the impairment of HCC formation in LKO mice is mainly dependent on NRF2 signaling. Meanwhile, HCC induced by DEN could be blocked by the administration of N-acetyl cysteine (NAC) when administered one month after DEN challenge. However, NAC treatment starting five months after DEN injection was not able to prevent tumor development. In conclusion, our findings indicate that a reductive environment orchestrated by glutathione metabolism at an early stage can prevent the initiation of HCC.	[Qiu, Pengxiang; Hou, Weilong; Wang, Haitao; Lei, Kimmy Ka Wing; Wang, Shaowei; Pardeshi, Lakhansing Arun; Su, Samson Sek Man; Chen, Qiang; Deng, Chu-Xia; Xu, Xiaoling; Wang, Ruihong] Univ Macau, Fac Hlth Sci, Canc Ctr, Macau, Peoples R China; [Qiu, Pengxiang; Su, Samson Sek Man; Chen, Qiang; Deng, Chu-Xia; Xu, Xiaoling] Univ Macau, Fac Hlth Sci, Ctr Precis Med Res & Training, Macau, Peoples R China; [Chen, Weiping] Natl Inst Diabet & Digest & Kidney Dis, Bethesda, MD USA; [Prothro, Katherine; Shukla, Yashvita; Schrump, David S.; Wang, Ruihong] NCI, Thorac Surg Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	University of Macau; University of Macau; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Deng, CX; Xu, XL; Wang, RH (corresponding author), Univ Macau, Fac Hlth Sci, Canc Ctr, Macau, Peoples R China.; Deng, CX; Xu, XL (corresponding author), Univ Macau, Fac Hlth Sci, Ctr Precis Med Res & Training, Macau, Peoples R China.; Wang, RH (corresponding author), NCI, Thorac Surg Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	cxdeng@um.edu.mo; xiaolingx@um.edu.mo; ruihongw@nih.gov	Chen, Wei/GZK-7348-2022	Wang, Haitao/0000-0001-6910-974X; Qiu, Pengxiang/0000-0003-1766-3727; Pardeshi, Lakhansing/0000-0003-0702-5465	University of Macau [SRG2015-00008-FHS, MYRG2016-00054-FHS, MYRG2017-00096-FHS, MYRG2019-0064-FHS, CPG202000004-FHS]	University of Macau	This project was supported by grants SRG2015-00008-FHS, MYRG2016-00054-FHS and MYRG2017-00096-FHS to RHW; MYRG2019-0064-FHS to XLX; and CPG202000004-FHS to CXD from the University of Macau.	Agarwal A, 2004, AM J PATHOL, V164, P1683, DOI 10.1016/S0002-9440(10)63727-3; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Alves-Fernandes DK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133153; Amini A, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0092-7; Anstee QM, 2019, NAT REV GASTRO HEPAT, V16, P411, DOI 10.1038/s41575-019-0145-7; Atkuri KR, 2009, P NATL ACAD SCI USA, V106, P3941, DOI 10.1073/pnas.0813409106; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cabello CM, 2007, CURR OPIN INVEST DR, V8, P1022; Circu ML, 2012, BBA-MOL CELL RES, V1823, P1767, DOI 10.1016/j.bbamcr.2012.06.019; Cuadrado A, 2003, J BIOL CHEM, V278, P241, DOI 10.1074/jbc.M201010200; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Deng J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1016-8; Frohlich DA, 2008, ONCOGENE, V27, P4353, DOI 10.1038/onc.2008.79; Higgs MR, 2014, J GEN VIROL, V95, P991, DOI 10.1099/vir.0.059485-0; Huang ZZ, 2001, FASEB J, V15, P19, DOI 10.1096/fj.00-0445fje; Imai S, 2014, TRENDS CELL BIOL, V24, P464, DOI 10.1016/j.tcb.2014.04.002; Jayakumar S, 2015, MUTAT RES-FUND MOL M, V779, P33, DOI 10.1016/j.mrfmmm.2015.06.007; Jeong Jaemin, 2007, Exp Mol Med, V39, P8; Jungst C, 2004, HEPATOLOGY, V39, P1663, DOI 10.1002/hep.20241; Kang JS, 2007, CANCER RES, V67, P11141, DOI 10.1158/0008-5472.CAN-07-1369; Kawai Y, 2011, J BIOL CHEM, V286, P7629, DOI 10.1074/jbc.M110.208173; Kim SB, 2012, P NATL ACAD SCI USA, V109, pE2949, DOI 10.1073/pnas.1207718109; Kolaja KL, 1997, TOXICOL APPL PHARM, V143, P380, DOI 10.1006/taap.1996.8089; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Malhi H, 2010, PHYSIOL REV, V90, P1165, DOI 10.1152/physrev.00061.2009; Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212; Mao B, 2014, ONCOGENE, V33, P1468, DOI 10.1038/onc.2013.88; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Palacios JA, 2010, J CELL BIOL, V191, P1299, DOI 10.1083/jcb.201005160; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Portmann S, 2013, MOL CANCER THER, V12, P499, DOI 10.1158/1535-7163.MCT-12-0700; Satoh H, 2016, CANCER RES, V76, P3088, DOI 10.1158/0008-5472.CAN-15-1584; Satoh H, 2013, CANCER RES, V73, P4158, DOI 10.1158/0008-5472.CAN-12-4499; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; Tanaka H, 2008, BRIT J CANCER, V98, P580, DOI 10.1038/sj.bjc.6604204; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Wai Ling Khoo TS., 2019, TYROSINE KINASE INHI; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wang RH, 2011, J CLIN INVEST, V121, P4477, DOI 10.1172/JCI46243; Wang RH, 2010, INT J BIOL SCI, V6, P682; Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151; YANG CS, 1990, DRUG METAB REV, V22, P147, DOI 10.3109/03602539009041082; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	50	0	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					6023	6033		10.1038/s41388-021-01993-1	http://dx.doi.org/10.1038/s41388-021-01993-1		AUG 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34433910				2022-12-28	WOS:000688395700001
J	Fatima, I; Barman, S; Uppada, J; Chauhan, S; Rauth, S; Rachagani, S; Ponnusamy, MP; Smith, L; Talmon, G; Singh, AB; Batra, SK; Dhawan, P				Fatima, Iram; Barman, Susmita; Uppada, JayaPrakash; Chauhan, Shailender; Rauth, Sanchita; Rachagani, Satyanarayana; Ponnusamy, Moorthy Palanimuthu; Smith, Lynette; Talmon, Geoffrey; Singh, Amar B.; Batra, Surinder K.; Dhawan, Punita			MASTL regulates EGFR signaling to impact pancreatic cancer progression	ONCOGENE			English	Article							NUCLEAR-ENVELOPE BREAKDOWN; GREATWALL KINASE; CELL; GALECTIN-3; RECEPTOR; PROTEIN; EXPRESSION; PHOSPHORYLATION; GEMCITABINE; ACTIVATION	Pancreatic cancer (PC) remains a major cause of cancer-related deaths primarily due to its inherent potential of therapy resistance. Checkpoint inhibitors have emerged as promising anti-cancer agents when used in combination with conventional anti-cancer therapies. Recent studies have highlighted a critical role of the Greatwall kinase (microtubule-associated serine/threonine-protein kinase-like (MASTL)) in promoting oncogenic malignancy and resistance to anti-cancer therapies; however, its role in PC remains unknown. Based on a comprehensive investigation involving PC patient samples, murine models of PC progression (Kras;PdxCre-KC and Kras;p53;PdxCre-KPC), and loss and gain of function studies, we report a previously undescribed critical role of MASTL in promoting cancer malignancy and therapy resistance. Mechanistically, MASTL promotes PC by modulating the epidermal growth factor receptor protein stability and, thereupon, kinase signaling. We further demonstrate that combinatorial therapy targeting MASTL promotes the efficacy of the cell-killing effects of Gemcitabine using both genetic and pharmacological inhibitions. Taken together, this study identifies a key role of MASTL in promoting PC progression and its utility as a novel target in promoting sensitivity to the anti-PC therapies.	[Fatima, Iram; Barman, Susmita; Rauth, Sanchita; Rachagani, Satyanarayana; Ponnusamy, Moorthy Palanimuthu; Singh, Amar B.; Batra, Surinder K.; Dhawan, Punita] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Uppada, JayaPrakash] Univ Alabama, Alabama Life Res Inst, Coll Community Hlth Sci, Tuscaloosa, AL USA; [Chauhan, Shailender] Univ Arizona, Cellular & Mol Med, Canc Ctr UAHS, Tucson, AZ USA; [Smith, Lynette] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE USA; [Talmon, Geoffrey] Univ Nebraska Med Ctr, Dept Pathl, Omaha, NE USA; [Singh, Amar B.; Dhawan, Punita] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE 69101 USA; [Batra, Surinder K.; Dhawan, Punita] Univ Nebraska Med Ctr, Buffett Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Alabama System; University of Alabama Tuscaloosa; University of Arizona; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Medical Center	Dhawan, P (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Dhawan, P (corresponding author), VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE 69101 USA.; Dhawan, P (corresponding author), Univ Nebraska Med Ctr, Buffett Canc Ctr, Omaha, NE 68198 USA.	punita.dhawan@unmc.edu	Barman, Susmita/AAY-8311-2021; Chauhan, Shailender Singh/AAM-5269-2020	Chauhan, Shailender Singh/0000-0002-1975-2734; Barman, Susmita/0000-0002-0491-8498	VA merit [BX002086, DK124095, BX002761]; NIH/NCI [CA250383, CA216746]; Nebraska Research Initiative (NRI); NCI [P30 CA36727, NIH-1P50 CA 127297-01A2]	VA merit(US Department of Veterans Affairs); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Nebraska Research Initiative (NRI); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by BX002086 (VA merit), CA250383 (NIH/NCI), CA216746 (NIH/NCI), and Nebraska Research Initiative (NRI) to PD and DK124095 and BX002761 (VA merit) to ABS. We also acknowledge NCI Cancer Center Support Grant P30 CA36727, NIH-1P50 CA 127297-01A2 for tissue arrays obtained.	Alvarez-Fernandez M, 2018, CELL DEATH DIFFER, V25, P828, DOI 10.1038/s41418-017-0024-0; Alvarez-Fernandez M, 2014, BIOESSAYS, V36, P757, DOI 10.1002/bies.201400040; Alvarez-Fernandez M, 2013, P NATL ACAD SCI USA, V110, P17374, DOI 10.1073/pnas.1310745110; Ammarah U, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23246-0; Anania MC, 2015, ONCOTARGET, V6, P34629, DOI 10.18632/oncotarget.5282; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Barman S, 2018, J NUTR BIOCHEM, V54, P113, DOI 10.1016/j.jnutbio.2017.11.008; Cabrera M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136878; Castilho PV, 2009, MOL BIOL CELL, V20, P4777, DOI 10.1091/mbc.E09-07-0643; Chang WA, 2017, ONCOL LETT, V14, P5077, DOI 10.3892/ol.2017.6882; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Cruz JJ, 2007, ANN ONCOL, V18, P421, DOI 10.1093/annonc/mdl175; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; El Ayachi I, 2019, CANCER RES, V79, P982, DOI 10.1158/0008-5472.CAN-18-1069; Fatima I, 2020, CANCER MED-US, V9, P6322, DOI 10.1002/cam4.3141; Fatima I, 2019, CANCERS, V11, DOI 10.3390/cancers11122039; Fatima Iram, 2018, PLoS One, V13, pe0197796, DOI 10.1371/journal.pone.0197796; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Gharbi-Ayachi A, 2010, SCIENCE, V330, P1673, DOI 10.1126/science.1197048; Gowrikumar S, 2019, ONCOGENE, V38, P6566, DOI 10.1038/s41388-019-0864-9; Heinemann V, 2002, SEMIN ONCOL, V29, P9, DOI 10.1053/sonc.2002.37372; Huch M, 2013, EMBO J, V32, P2708, DOI 10.1038/emboj.2013.204; Kleespies A, 2006, DRUG RESIST UPDATE, V9, P1, DOI 10.1016/j.drup.2006.02.002; Kucinska M, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0371-1; Kuo HY, 2016, GLYCOBIOLOGY, V26, P155, DOI 10.1093/glycob/cwv088; Lambert A, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919875568; Li J, 2019, COMPUT STRUCT BIOTEC, V17, P498, DOI 10.1016/j.csbj.2019.03.016; Li PP, 2016, CELL, V167, P973, DOI 10.1016/j.cell.2016.10.025; Liu W, 2012, J INVEST DERMATOL, V132, P2828, DOI 10.1038/jid.2012.211; Lorca T, 2013, ONCOGENE, V32, P537, DOI 10.1038/onc.2012.79; Markowska AI, 2011, J BIOL CHEM, V286, P29913, DOI 10.1074/jbc.M111.226423; Martinez-Bosch N, 2014, CANCER RES, V74, P3512, DOI 10.1158/0008-5472.CAN-13-3013; Marzec K, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00162; Mizrahi JD, 2020, LANCET, V395, P2008, DOI 10.1016/S0140-6736(20)30974-0; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Nedaeinia R, 2014, CURR DRUG TARGETS, V15, P1293, DOI 10.2174/1389450115666141125123003; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Oberstein PE, 2013, THER ADV GASTROENTER, V6, P321, DOI 10.1177/1756283X13478680; Ocasio CA, 2016, ONCOTARGET, V7, P71182, DOI 10.18632/oncotarget.11511; Oliveira-Cunha Melissa, 2011, Cancers (Basel), V3, P1513, DOI 10.3390/cancers3021513; Orozco CA, 2018, P NATL ACAD SCI USA, V115, pE3769, DOI 10.1073/pnas.1722434115; Oyanadel C, 2018, MOL BIOL CELL, V29, P557, DOI 10.1091/mbc.E16-05-0301; Piyush T, 2017, CELL DEATH DIFFER, V24, P1937, DOI 10.1038/cdd.2017.119; Pryczynicz A, 2008, ANTICANCER RES, V28, P1399; R Core Team, 2015, R LANGUAGE ENV STAT; Ren DP, 2017, J BIOL CHEM, V292, P10026, DOI 10.1074/jbc.M117.778233; Reshi I, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00366-18; Rogers S, 2018, ONCOGENE, V37, P4518, DOI 10.1038/s41388-018-0295-z; Roth Marc T, 2020, F1000Res, V9, DOI 10.12688/f1000research.21981.1; Ruess DA, 2017, DRUG AGING, V34, P331, DOI 10.1007/s40266-017-0453-y; Sun XJ, 2017, ONCOL LETT, V14, P7283, DOI 10.3892/ol.2017.7155; Torres MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080580; Uppada SB, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0848-3; Vera J, 2015, ELIFE, V4, DOI 10.7554/eLife.10115; Voets E, 2012, MOL CELL BIOL, V32, P1334, DOI 10.1128/MCB.00213-12; Voets E, 2010, CELL CYCLE, V9, P3591, DOI 10.4161/cc.9.17.12832; Wang L, 2014, ONCOTARGET, V5, P11479, DOI 10.18632/oncotarget.2565; Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052; Yao YL, 2019, CARBOHYD POLYM, V204, P111, DOI 10.1016/j.carbpol.2018.10.008; Yoon YN, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4600-6; Zaffaroni N, 2001, EUR J CANCER, V37, P1953, DOI 10.1016/S0959-8049(01)00227-1	61	4	4	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5691	5704		10.1038/s41388-021-01951-x	http://dx.doi.org/10.1038/s41388-021-01951-x		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34331012	Green Accepted			2022-12-28	WOS:000679620500004
J	Liu, CF; Armstrong, CM; Ning, S; Yang, JC; Lou, W; Lombard, AP; Zhao, JG; Wu, CY; Yu, AM; Evans, CP; Tepper, CG; Li, PK; Gao, AC				Liu, Chengfei; Armstrong, Cameron M.; Ning, Shu; Yang, Joy C.; Lou, Wei; Lombard, Alan P.; Zhao, Jinge; Wu, Chun-Yi; Yu, Aiming; Evans, Christopher P.; Tepper, Clifford G.; Li, Pui-kai; Gao, Allen C.			ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling	ONCOGENE			English	Article							SPLICE VARIANTS; FULL-LENGTH; INCREASED SURVIVAL; ENZALUTAMIDE; DEGRADATION; RESISTANCE; EXPRESSION; THERAPY; PROTEOSTASIS; ABIRATERONE	Targeting androgen signaling with the second-generation anti-androgen drugs, such as enzalutamide (Enza), abiraterone (Abi), apalutamide (Apal), and darolutamide (Daro), is the mainstay for the treatment of castration-resistant prostate cancer (CRPC). While these treatments are effective initially, resistance occurs frequently. Continued expression of androgen receptor (AR) and its variants such as AR-V7 despite AR-targeted therapy contributes to treatment resistance and cancer progression in advanced CRPC patients. This highlights the need for new strategies blocking continued AR signaling. Here, we identify a novel AR/AR-V7 degrader (ARVib) and found that ARVib effectively degrades AR/AR-V7 protein and attenuates AR/AR-V7 downstream target gene expression in prostate cancer cells. Mechanistically, ARVib degrades AR/AR-V7 protein through the ubiquitin-proteasome pathway mediated by HSP70/STUB1 machinery modulation. ARVib suppresses HSP70 expression and promotes STUB1 nuclear translocation, where STUB1 binds to AR/AR-V7 and promotes its ubiquitination and degradation. ARVib significantly inhibits resistant prostate tumor growth and improves enzalutamide treatment in vitro and in vivo. These data suggest that ARVib has potential for development as an AR/AR-V7 degrader to treat resistant CRPC.	[Liu, Chengfei; Armstrong, Cameron M.; Ning, Shu; Yang, Joy C.; Lou, Wei; Lombard, Alan P.; Zhao, Jinge; Evans, Christopher P.; Gao, Allen C.] Univ Calif Davis, Dept Urol Surg, Davis, CA 95616 USA; [Liu, Chengfei; Wu, Chun-Yi; Yu, Aiming; Evans, Christopher P.; Tepper, Clifford G.; Gao, Allen C.] Univ Calif Davis, UC Davis Comprehens Canc Ctr, Davis, CA 95616 USA; [Wu, Chun-Yi; Yu, Aiming; Tepper, Clifford G.] Univ Calif Davis, Dept Biochem & Mol Med, Davis, CA 95616 USA; [Li, Pui-kai] Ohio State Univ, Div Med Chem & Pharmacognosy, Coll Pharm, Columbus, OH 43210 USA; [Gao, Allen C.] VA Northern Calif Hlth Care Syst, Sacramento, CA 94553 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University System of Ohio; Ohio State University	Gao, AC (corresponding author), Univ Calif Davis, Dept Urol Surg, Davis, CA 95616 USA.; Gao, AC (corresponding author), Univ Calif Davis, UC Davis Comprehens Canc Ctr, Davis, CA 95616 USA.; Gao, AC (corresponding author), VA Northern Calif Hlth Care Syst, Sacramento, CA 94553 USA.	acgao@ucdavis.edu	Ning, Shu/GYE-0167-2022	Ning, Shu/0000-0002-6514-0376; Li, Pui Kai/0000-0002-4831-7213; Yu, Aiming/0000-0003-1441-4012; Wu, Chun-Yi/0000-0003-2642-0380	U.S. Department of Veterans Affairs, Office of Research & Development BLD [I01BX0002653]; BLR&D Research Career Scientist Award [IK6BX005222]; NCI [P30CA093373];  [CA179970];  [CA 225836];  [DOD PC150229];  [DOD PC180180]	U.S. Department of Veterans Affairs, Office of Research & Development BLD(US Department of Veterans Affairs); BLR&D Research Career Scientist Award; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; ; ; 	This work was supported in part by grants CA179970 (ACG), CA 225836 (ACG), DOD PC150229 (ACG), DOD PC180180 (ACG), and the U.S. Department of Veterans Affairs, Office of Research & Development BL&D grant number I01BX0002653 (ACG), BLR&D Research Career Scientist Award IK6BX005222 (ACG). ACG is also a Senior Research Career Scientist at VA Northern California Health Care System, Mather, California. The Genomics Shared Resource is supported by Cancer Center Support Grant P30CA093373 awarded by the NCI.	Abe Miyako, 2004, Clin Prostate Cancer, V3, P49, DOI 10.3816/CGC.2004.n.013; Andersen RJ, 2010, CANCER CELL, V17, P535, DOI 10.1016/j.ccr.2010.04.027; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Azad AA, 2015, NAT REV UROL, V12, P26, DOI 10.1038/nrurol.2014.320; Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448; Cardile V, 2003, ANTICANCER RES, V23, P4921; Chan SC, 2012, J BIOL CHEM, V287, P19736, DOI 10.1074/jbc.M112.352930; Chen W, 2017, CELL SIGNAL, V41, P89, DOI 10.1016/j.cellsig.2017.04.001; Dalal K, 2018, EUR J MED CHEM, V157, P1164, DOI 10.1016/j.ejmech.2018.08.059; Dalal K, 2014, J BIOL CHEM, V289, P26417, DOI 10.1074/jbc.M114.553818; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Fizazi K, 2019, NEW ENGL J MED, V380, P1235, DOI 10.1056/NEJMoa1815671; Gadd MS, 2017, NAT CHEM BIOL, V13, P514, DOI [10.1038/nchembio.2329, 10.1038/NCHEMBIO.2329]; Ge ZQ, 2018, CELL REP, V23, P213, DOI 10.1016/j.celrep.2018.03.047; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Ippolito JE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159675; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Khan S, 2019, NAT MED, V25, P1938, DOI 10.1038/s41591-019-0668-z; Kregel S, 2020, NEOPLASIA, V22, P111, DOI 10.1016/j.neo.2019.12.003; Kwegyir-Afful AK, 2015, ONCOTARGET, V6, P27440, DOI 10.18632/oncotarget.4578; Lallous N, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-015-0864-1; Liu CF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07178-x; Liu CF, 2016, ONCOTARGET, V7, P32210, DOI 10.18632/oncotarget.8493; Liu CF, 2015, CANCER RES, V75, P1413, DOI 10.1158/0008-5472.CAN-14-3080; Liu CF, 2014, CLIN CANCER RES, V20, P3198, DOI 10.1158/1078-0432.CCR-13-3296; Liu YF, 2011, CELL RES, V21, P867, DOI 10.1038/cr.2011.75; Lu CX, 2013, TRANSL ANDROL UROL, V2, P178, DOI 10.3978/j.issn.2223-4683.2013.09.08; Markowski MC, 2017, JCO PRECIS ONCOL, V1; Martinez-Jimenez F, 2020, NAT CANCER, V1, P122, DOI 10.1038/s43018-019-0001-2; McGrath MJ, 2013, CANCER RES, V73, P5066, DOI 10.1158/0008-5472.CAN-12-4520; Moses MA, 2018, CANCER RES, V78, P4022, DOI 10.1158/0008-5472.CAN-17-3728; Nguyen HM, 2017, PROSTATE, V77, P654, DOI 10.1002/pros.23313; Paramore A, 2003, NAT REV DRUG DISCOV, V2, P611, DOI 10.1038/nrd1159; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Raina K, 2016, P NATL ACAD SCI USA, V113, P7124, DOI 10.1073/pnas.1521738113; Ren AX, 2008, CANCER RES, V68, P2266, DOI 10.1158/0008-5472.CAN-07-6248; Rerole AL, 2011, METHODS MOL BIOL, V787, P205, DOI 10.1007/978-1-61779-295-3_16; Rodriguez-Gonzalez A, 2008, ONCOGENE, V27, P7201, DOI 10.1038/onc.2008.320; Salami J, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0105-8; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shi XB, 2002, CANCER RES, V62, P1496; Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546; Stanton BZ, 2018, SCIENCE, V359, DOI 10.1126/science.aao5902; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Wang H, 2016, MOL CLIN ONCOL, V5, P326, DOI 10.3892/mco.2016.963; Wang RH, 2017, EUR UROL, V72, P835, DOI 10.1016/j.eururo.2017.04.005; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546; Zhao Y, 2014, J INTERCULT ETHNOPHA, V3, P68, DOI 10.5455/jice.20140123040224	53	9	9	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5379	5392		10.1038/s41388-021-01914-2	http://dx.doi.org/10.1038/s41388-021-01914-2		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34272475	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000673332300001
J	Lyu, L; Lin, TC; McCarty, N				Lyu, Lin; Lin, Tsung-Chin; McCarty, Nami			TRIM44 mediated p62 deubiquitination enhances DNA damage repair by increasing nuclear FLNA and 53BP1 expression	ONCOGENE			English	Article							COMET ASSAY; PATHWAYS; PROLIFERATION; AUTOPHAGY; MIGRATION; UBIQUITIN; PROTEINS; INVASION; TARGETS; CELLS	Cancer cells show increases in protein degradation pathways, including autophagy, during progression to meet the increased protein degradation demand and support cell survival. On the other hand, reduced autophagy activity during aging is associated with a reduced DNA damage response and increased genomic instability. Therefore, it is a puzzling how DNA repair can be increased in cancer cells that are resistant to chemotherapies or during progression when autophagy activity is intact or increased. We discovered that tripartite motif containing 44 (TRIM44) is a pivotal element regulating the DNA damage response in cancer cells with intact autophagy. TRIM44 deubiquitinates p62, an autophagy substrate, which leads to its oligomerization. This prevents p62 localization to the nucleus upon irradiation. Increased cytoplasmic retention of p62 by TRIM44 prevents the degradation of FLNA and 53BP1, which increases DNA damage repair. Together, our data support TRIM44 a potential therapeutic target for therapy-resistant tumor cells with intact autophagy.	[Lyu, Lin; Lin, Tsung-Chin; McCarty, Nami] Univ Texas Hlth Sci Ctr Houston, Ctr Stem Cell & Regenerat Dis, Brown Fdn Inst Mol Med Prevent Human Dis IMM, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	McCarty, N (corresponding author), Univ Texas Hlth Sci Ctr Houston, Ctr Stem Cell & Regenerat Dis, Brown Fdn Inst Mol Med Prevent Human Dis IMM, Houston, TX 77030 USA.	nami.mccarty@uth.tmc.edu		Lyu, Lin/0000-0001-9771-0110	NIH [R01CA181319]; CPRIT grant [RP20093]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT grant	This work is supported by NIH grant (R01CA181319) and CPRIT grant (RP20093) given to NM.	Ahmed KM, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00672-17; Anderson KC., 2011, ONCOLOGY-BASEL, V25, pS3; Blanpain C, 2011, CELL STEM CELL, V8, P16, DOI 10.1016/j.stem.2010.12.012; Boehrer S, 2009, ONCOGENE, V28, P2205, DOI 10.1038/onc.2009.69; Cambiaghi V, 2012, ADV EXP MED BIOL, V770, P77; Chen Z, 2019, LEUKEMIA, V33, P469, DOI 10.1038/s41375-018-0222-x; Chen Z, 2014, BLOOD, V123, P2204, DOI 10.1182/blood-2013-07-517136; Dietlein F, 2014, TRENDS GENET, V30, P326, DOI 10.1016/j.tig.2014.06.003; Gogineni VR, 2011, CANCER LETT, V313, P64, DOI 10.1016/j.canlet.2011.08.022; Gourzones-Dmitriev C, 2013, CELL CYCLE, V12, P2760, DOI 10.4161/cc.25951; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Herrero AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121581; Hewitt G, 2016, AUTOPHAGY, V12, P1917, DOI 10.1080/15548627.2016.1210368; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Jarvinen AK, 2008, GENE CHROMOSOME CANC, V47, P500, DOI 10.1002/gcc.20551; Kashimoto K, 2012, CANCER SCI, V103, P2021, DOI 10.1111/j.1349-7006.2012.02407.x; Kawabata H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091931; Kawaguchi T, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317700409; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; Klaude M, 1996, MUTAT RES-DNA REPAIR, V363, P89, DOI 10.1016/0921-8777(95)00063-1; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Lindahl T, 2004, NATURE, V427, P598, DOI 10.1038/427598a; Luo QQ, 2015, INT J CLIN ONCOL, V20, P508, DOI 10.1007/s10147-014-0752-9; Michels TC, 2017, AM FAM PHYSICIAN, V95, P373; Mirman Z, 2020, GENE DEV, V34, P7, DOI 10.1101/gad.333237.119; Munshi NC, 2013, CLIN CANCER RES, V19, P3337, DOI 10.1158/1078-0432.CCR-12-1881; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Nubel U, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000855; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Ong CAJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju050; Pan JA, 2016, MOL CELL, V62, P149, DOI 10.1016/j.molcel.2016.03.015; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Pankiv S, 2010, J BIOL CHEM, V285, P5941, DOI 10.1074/jbc.M109.039925; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Rodgers K, 2016, J CELL PHYSIOL, V231, P15, DOI 10.1002/jcp.25053; Shammas MA, 2009, BLOOD, V113, P2290, DOI 10.1182/blood-2007-05-089193; Tan YY, 2017, ONCOL RES, V25, P1253, DOI 10.3727/096504017X14854310794561; Terry LJ, 2007, SCIENCE, V318, P1412, DOI 10.1126/science.1142204; Torgovnick A, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00157; Velkova A, 2010, CELL CYCLE, V9, P1421, DOI 10.4161/cc.9.7.11256; Walters DK, 2011, LEUKEMIA, V25, P1344, DOI 10.1038/leu.2011.94; Wang YN, 2016, MOL CELL, V63, P34, DOI 10.1016/j.molcel.2016.05.027; Yamada Y, 2017, CANCER SCI, V108, P32, DOI 10.1111/cas.13105	45	4	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5116	5130		10.1038/s41388-021-01890-7	http://dx.doi.org/10.1038/s41388-021-01890-7		JUL 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34211088	Green Accepted			2022-12-28	WOS:000668832500001
J	Zhang, Z; Min, L; Li, HC; Chen, L; Zhao, Y; Liu, S; Guo, QD; Zhu, ST; Li, P; Zhang, ST				Zhang, Zheng; Min, Li; Li, Hengcun; Chen, Lei; Zhao, Yu; Liu, Si; Guo, Qingdong; Zhu, Shengtao; Li, Peng; Zhang, Shutian			Asporin represses gastric cancer apoptosis via activating LEF1-mediated gene transcription independent of beta-catenin	ONCOGENE			English	Article							TUMOR MICROENVIRONMENT; BORRMANN TYPE; WNT; SUSCEPTIBILITY; COACTIVATOR; PROTEINS; PROTECTS; INVASION; PATHWAY; TARGET	Asporin (ASPN) presents in the tumor microenvironment and exhibits a cancer-promoting effect as a stroma protein. Even though ASPN has already been observed inside cancer cells, the functions of intracellular ASPN and its underlying mechanisms remain unknown. Here we reported that ASPN was upregulated in different stages of gastric cancer (GC), and associated with a poor prognosis. Moreover, we found that ASPN markedly inhibited GC cell apoptosis and promoted cell growth in vitro and in vivo. Further mechanism investigations revealed that ASPN directly binding to lymphoid enhancer-binding factor 1 (LEF1) and promoted LEF1-mediated gene transcription independent of beta-catenin, the classic co-factor in the Wnt/LEF1 pathway. We also demonstrated that ASPN selectively facilitated LEF1 binding to and activating the promoters of PTGS2, IL6, and WISP1 to promote their transcription. The suppression of cell apoptosis by ASPN overexpression could be attenuated by LEF1 knockdown or 100 mu M aspirin (PTGS2 inhibitor), and siASPN mediated apoptosis could be rescued by LEF1 ectopic expression or adding recombinant IL6. Therefore, we concluded that ASPN repressed GC cell apoptosis via activating LEF1-mediated gene transcription independent of beta-catenin, which could serve as a potential prognostic biomarker in GC patients.	[Zhang, Zheng; Min, Li; Li, Hengcun; Chen, Lei; Zhao, Yu; Liu, Si; Guo, Qingdong; Zhu, Shengtao; Li, Peng; Zhang, Shutian] Capital Med Univ, Beijing Key Lab Precancerous Lesion Digest Dis, Natl Clin Res Ctr Digest Dis, Dept Gastroenterol,Beijing Friendship Hosp,Beijin, Beijing, Peoples R China	Capital Medical University	Li, P; Zhang, ST (corresponding author), Capital Med Univ, Beijing Key Lab Precancerous Lesion Digest Dis, Natl Clin Res Ctr Digest Dis, Dept Gastroenterol,Beijing Friendship Hosp,Beijin, Beijing, Peoples R China.	lipeng@ccmu.edu.cn; zhangshutian@ccmu.edu.cn	; Min, Li/T-8107-2018	Li, Peng/0000-0003-2927-2758; Min, Li/0000-0001-9595-5536; Zhang, Zheng/0000-0002-0822-7985	National Natural Science Foundation of China [81570507, 81702314]; National Key Research and Development Program of China [2017YFC0113600]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China	This study was supported by National Natural Science Foundation of China (81570507, 81702314) and National Key Research and Development Program of China (2017YFC0113600).	Acebron SP, 2016, TRENDS CELL BIOL, V26, P956, DOI 10.1016/j.tcb.2016.07.009; An JY, 2008, J GASTROINTEST SURG, V12, P1364, DOI 10.1007/s11605-008-0516-9; Badgwell B, 2016, LANCET ONCOL, V17, P1628, DOI 10.1016/S1470-2045(16)30521-6; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Castellana B, 2012, J CANCER, V3, P175, DOI 10.7150/jca.4120; Chiurillo MA, 2015, WORLD J EXP MED, V5, P84, DOI [10.5493/wjem.v5.i2.84, DOI 10.5493/wjem.v5.i2.84, DOI 10.5493/WJEM.V5.I2.84]; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; Cottini F, 2014, NAT MED, V20, P599, DOI 10.1038/nm.3562; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Cui JA, 2011, NUCLEIC ACIDS RES, V39, P1197, DOI 10.1093/nar/gkq960; D'Errico M, 2009, EUR J CANCER, V45, P461, DOI 10.1016/j.ejca.2008.10.032; Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017; Hrckulak D, 2016, CANCERS, V8, DOI 10.3390/cancers8070070; Hughes RM, 2019, CANCER RES, V79, P3636, DOI 10.1158/0008-5472.CAN-18-2931; Hurley PJ, 2016, CLIN CANCER RES, V22, P448, DOI 10.1158/1078-0432.CCR-15-0256; Ikegawa S, 2008, CURR MED CHEM, V15, P724, DOI 10.2174/092986708783885237; Ikeguchi M, 2004, IN VIVO, V18, P577; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kessler M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9989; Kim HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016694; Kizawa H, 2005, NAT GENET, V37, P138, DOI 10.1038/ng1496; Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200; Lee HH, 2018, ANN SURG ONCOL, V25, P778, DOI 10.1245/s10434-018-7051-z; Li C, 2009, ONCOLOGY-BASEL, V77, P197, DOI 10.1159/000236018; Li HC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1376-9; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Lordick F, 2014, CANCER TREAT REV, V40, P692, DOI 10.1016/j.ctrv.2014.03.002; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; Luehders K, 2015, DEVELOPMENT, V142, P3351, DOI 10.1242/dev.124438; Luo JW, 2019, TRANSL ONCOL, V12, P475, DOI 10.1016/j.tranon.2018.11.010; Maris P, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001871; Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Packham S, 2015, ONCOGENE, V34, P2227, DOI 10.1038/onc.2014.165; Park JH, 2018, MOL CELLS, V41, P290, DOI 10.14348/molcells.2018.2167; Perez-Garijo A, 2015, DEVELOPMENT, V142, P3253, DOI 10.1242/dev.127878; Pinto M, 2003, J PATHOL, V200, P32, DOI 10.1002/path.1327; Rodriguez-Lopez J, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1920; Santiago L, 2017, AM J CANCER RES, V7, P1389; Satoyoshi R, 2015, ONCOGENE, V34, P650, DOI 10.1038/onc.2013.584; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Simkova D, 2016, BIOMED PAP, V160, P467, DOI 10.5507/bp.2016.037; Song YJ, 2017, BRIT J CANCER, V116, P973, DOI 10.1038/bjc.2017.54; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; STEWART D, 2014, JNCI-J NATL CANCER I, V106; Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902; Uhlen M, 2016, NAT METHODS, V13, P823, DOI [10.1038/nmeth.3995, 10.1038/NMETH.3995]; Uka R, 2020, ONCOGENE, V39, P4132, DOI 10.1038/s41388-020-1267-7; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Wang L, 2018, ANN ONCOL, V29, P352, DOI 10.1093/annonc/mdx689; Wang LL, 2017, CANCER LETT, V398, P24, DOI 10.1016/j.canlet.2017.04.001; Warsito D, 2012, EMBO REP, V13, P244, DOI 10.1038/embor.2011.251; Wenzel J, 2020, ONCOGENE, V39, P3893, DOI 10.1038/s41388-020-1259-7; Wu H, 2016, ONCOTARGET, V7, P73402, DOI 10.18632/oncotarget.12336	55	2	2	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4552	4566		10.1038/s41388-021-01858-7	http://dx.doi.org/10.1038/s41388-021-01858-7		JUN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34127813				2022-12-28	WOS:000661408100001
J	Wu, J; Li, L; Zhang, HB; Zhao, YQ; Zhang, HH; Wu, SY; Xu, B				Wu, Jie; Li, Lan; Zhang, Huibo; Zhao, Yaqi; Zhang, Haohan; Wu, Siyi; Xu, Bin			A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma	ONCOGENE			English	Article							PROGNOSTIC VALUE; MUTATIONS; IMMUNOTHERAPY; MACROPHAGE; LANDSCAPE; CELLS	Tumor microenvironment (TME) has been reported to exhibit a crucial effect in lung cancer. Therefore, this study was aimed to investigate the genes associated with TME and develop a risk score to predict the overall survival (OS) of patients with lung adenocarcinoma (LUAD) based on these genes. The immune and stromal scores were generated by the ESTIMATE algorithm for LUAD patients in The Cancer Genome Atlas (TCGA) database. Differentially expressed gene and weighted gene co-expression network analyses were used to derive immune- and stromal-related genes. The Least Absolute Shrinkage and Selection Operator (LASSO)-Cox regression was applied for further selection and the selected genes were inputted into stepwise regression to develop TME-related risk score (TMErisk) which was further validated in Gene Expression Omnibus (GEO) datasets. TMErisk-related biological phenotypes were analyzed in function enrichment, tumor immune signature, and tumor mutation signature. The patient's response to immunotherapy was inferred by the tumor immune dysfunction and exclusion (TIDE) score and immunophenoscore (IPS). According to our results, TMErisk was developed based on SERPINE1, CX3CR1, CD200R1, GBP1, IRF1, STAP1, LOX, and OR7E47P. Furthermore, high TMErisk was identified as a poor factor for OS in TCGA and GEO datasets, as well as in subgroup analysis with different gender, smoking status, age, race, anatomic site, therapies, and tumor-node-metastasis (TNM) stages. Higher TMErisk is also associated negatively with the abundance of B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and other stromal or immune cells. Several genes of the human leukocyte antigen (HLA) family and immune checkpoints were less expressed in the high-TMErisk group. Mutations of 19 genes occurred more frequently in the high-TMErisk group. These mutations may be associated with TME change and indicate patients' response to immunotherapy. According to our analyses, a lower TMErisk score may indicate better response and OS outcome of immunotherapy.	[Wu, Jie; Li, Lan; Zhang, Huibo; Zhao, Yaqi; Zhang, Haohan; Wu, Siyi; Xu, Bin] Wuhan Univ, Renmin Hosp, Canc Ctr, Wuhan, Peoples R China	Wuhan University	Xu, B (corresponding author), Wuhan Univ, Renmin Hosp, Canc Ctr, Wuhan, Peoples R China.	xubin_oneology@whu.edu.cn	Wu, Jie/ABG-2502-2021	Wu, Jie/0000-0003-0935-342X; Zhang, Huibo/0000-0001-7312-6841	Wuhan University Medical Faculty Innovation Seed Fund Cultivation Project [TFZZ2018025]; Chen xiao-ping foundation for the development of science and technology of Hubei province [CXPJJH12000001-2020313]; National Natural Science Foundation of China [81670123, 81670144]	Wuhan University Medical Faculty Innovation Seed Fund Cultivation Project; Chen xiao-ping foundation for the development of science and technology of Hubei province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from Wuhan University Medical Faculty Innovation Seed Fund Cultivation Project (grant no. TFZZ2018025), Chen xiao-ping foundation for the development of science and technology of Hubei province (grant no. CXPJJH12000001-2020313), and the National Natural Science Foundation of China (grant nos. 81670123 and 81670144).	Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Aran D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9971; Assoun S, 2019, LUNG CANCER, V132, P65, DOI 10.1016/j.lungcan.2019.04.005; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Bender E, 2014, NATURE, V513, pS2, DOI 10.1038/513S2a; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Camidge DR, 2019, NAT REV CLIN ONCOL, V16, P341, DOI 10.1038/s41571-019-0173-9; Carter BW, 2016, J THORAC IMAG, V31, P201, DOI 10.1097/RTI.0000000000000213; Choi H, 2018, THERANOSTICS, V8, P1956, DOI 10.7150/thno.23767; Conroy MJ, 2020, ADV EXP MED BIOL, V1231, P1, DOI 10.1007/978-3-030-36667-4_1; De Simone M, 2016, IMMUNITY, V45, P1135, DOI 10.1016/j.immuni.2016.10.021; Denton AE, 2018, ADV EXP MED BIOL, V1060, P99, DOI 10.1007/978-3-319-78127-3_6; Duffy MJ, 2004, CURR PHARM DESIGN, V10, P39, DOI 10.2174/1381612043453559; Erin N, 2015, ONCOGENE, V34, P3860, DOI 10.1038/onc.2014.317; Frankel T, 2017, ADV EXP MED BIOL, V1036, P51, DOI 10.1007/978-3-319-67577-0_4; Garg N, 2010, J THROMB HAEMOST, V8, P1847, DOI 10.1111/j.1538-7836.2010.03907.x; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Giraldo NA, 2017, CLIN CANCER RES, V23, P4416, DOI 10.1158/1078-0432.CCR-16-2848; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2018, CANCER CELL, V33, P853, DOI 10.1016/j.ccell.2018.04.001; Jamal-Hanjani M, 2015, CLIN CANCER RES, V21, P1258, DOI 10.1158/1078-0432.CCR-14-1429; Jia D, 2018, AGING-US, V10, P592, DOI 10.18632/aging.101415; Johnston RJ, 2019, NATURE, V574, P565, DOI 10.1038/s41586-019-1674-5; Kinoshita T, 2016, ANN ONCOL, V27, P2117, DOI 10.1093/annonc/mdw319; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Marinelli D, 2020, ANN ONCOL, V31, P1746, DOI 10.1016/j.annonc.2020.08.2105; Martinez-Terroba E, 2018, J PATHOL, V245, P421, DOI 10.1002/path.5096; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Ohri CM, 2009, EUR RESPIR J, V33, P118, DOI 10.1183/09031936.00065708; Rakaee M, 2019, NEOPLASIA, V21, P282, DOI 10.1016/j.neo.2019.01.005; Schmall A, 2015, AM J RESP CRIT CARE, V191, P437, DOI 10.1164/rccm.201406-1137OC; Sun H, 2020, EBIOMEDICINE, V60, DOI 10.1016/j.ebiom.2020.102990; Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3; Travis WD, 2013, J CLIN ONCOL, V31, P992, DOI 10.1200/JCO.2012.46.9270; Wang H, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01212; Wang SX, 2019, ELIFE, V8, DOI 10.7554/eLife.49020; Wojas-Krawczyk K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081915; Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043; Xu WH, 2019, AGING-US, V11, P6999, DOI 10.18632/aging.102233; Yan HM, 2019, CANCER IMMUNOL IMMUN, V68, P1971, DOI 10.1007/s00262-019-02408-7; Yang S, 2020, J CELL PHYSIOL, V235, P1025, DOI 10.1002/jcp.29018; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zeng DQ, 2019, CANCER IMMUNOL RES, V7, P737, DOI 10.1158/2326-6066.CIR-18-0436; Zhang YT, 2020, CANCER BIOL MED, V17, P32, DOI 10.20892/j.issn.2095-3941.2019.0372; Zhao LQ, 2020, AGING-US, V12, P14556, DOI 10.18632/aging.103502	49	58	58	13	65	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4413	4424		10.1038/s41388-021-01853-y	http://dx.doi.org/10.1038/s41388-021-01853-y		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34108619				2022-12-28	WOS:000659470200004
J	Barnoud, T; Indeglia, A; Murphy, ME				Barnoud, Thibaut; Indeglia, Alexandra; Murphy, Maureen E.			Shifting the paradigms for tumor suppression: lessons from the p53 field	ONCOGENE			English	Review							CELL-CYCLE ARREST; EARLY EMBRYONIC LETHALITY; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; SPLICING REGULATOR; DNA-DAMAGE; WILD-TYPE; CANCER; MUTATIONS; APOPTOSIS	The TP53 gene continues to hold distinction as the most frequently mutated gene in cancer. Since its discovery in 1979, hundreds of research groups have devoted their efforts toward understanding why this gene is so frequently selected against by tumors, with the hopes of harnessing this information toward the improved therapy of cancer. The result is that this protein has been meticulously analyzed in tumor and normal cells, resulting in over 100,000 publications, with an average of 5000 papers published on p53 every year for the past decade. The journey toward understanding p53 function has been anything but straightforward; in fact, the field is notable for the numerous times that established paradigms not only have been shifted, but in fact have been shattered or reversed. In this review, we will discuss the manuscripts, or series of manuscripts, that have most radically changed our thinking about how this tumor suppressor functions, and we will delve into the emerging challenges for the future in this important area of research. It is hoped that this review will serve as a useful historical reference for those interested in p53, and a useful lesson on the need to be flexible in the face of established paradigms.	[Barnoud, Thibaut; Indeglia, Alexandra; Murphy, Maureen E.] Wistar Inst Anat & Biol, Program Mol & Cellular Oncogenesis, 3601 Spruce St, Philadelphia, PA 19104 USA; [Indeglia, Alexandra] Univ Penn, Dept Biochem & Mol Biophys, Perelman Sch Med, Philadelphia, PA USA	The Wistar Institute; University of Pennsylvania; Pennsylvania Medicine	Murphy, ME (corresponding author), Wistar Inst Anat & Biol, Program Mol & Cellular Oncogenesis, 3601 Spruce St, Philadelphia, PA 19104 USA.	mmurphy@wistar.org		Barnoud, Thibaut/0000-0001-5588-6281; Murphy, Maureen/0000-0001-7644-7296	National Institutes of Health [R01 CA201430, CA102184, K99 CA241367]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health (R01 CA201430 and CA102184 to MEM, and K99 CA241367 to TB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors would like to apologize for all the investigators whose references could not be included in this article due to space constraints. The authors would also like to thank Keerthana Gnanapradeepan, Jessica C. Leung, and Joshua L. D. Parris in the Murphy lab for assistance and thoughtful discussions. Figures were created with BioRender.com under a paid subscription to AI.	Aubrey BJ, 2018, CELL DEATH DIFFER, V25, P104, DOI 10.1038/cdd.2017.169; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; Barnoud T, 2020, CANCER RES, V80, P5270, DOI 10.1158/0008-5472.CAN-20-0397; Barnoud Thibaut, 2019, Oncotarget, V10, P1217, DOI 10.18632/oncotarget.26660; Berger SL, 2010, CELL, V142, P17, DOI 10.1016/j.cell.2010.06.026; Bieging-Rolett KT, 2020, MOL CELL, V80, P452, DOI 10.1016/j.molcel.2020.10.022; Biton J, 2018, CLIN CANCER RES, V24, P5710, DOI 10.1158/1078-0432.CCR-18-0163; Blagih J, 2020, J CELL SCI, V133, DOI 10.1242/jcs.237453; Blagih J, 2020, CELL REP, V30, P481, DOI 10.1016/j.celrep.2019.12.028; Boeckler FM, 2008, P NATL ACAD SCI USA, V105, P10360, DOI 10.1073/pnas.0805326105; Boettcher S, 2019, SCIENCE, V365, P599, DOI 10.1126/science.aax3649; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Campbell PJ, 2020, NATURE, V578, P82, DOI 10.1038/s41586-020-1969-6; Chen JD, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026104; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2004, CELL CYCLE, V3, P429; Chu B, 2019, NAT CELL BIOL, V21, P579, DOI 10.1038/s41556-019-0305-6; Cortez MA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv303; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dong ZY, 2017, CLIN CANCER RES, V23, P3012, DOI 10.1158/1078-0432.CCR-16-2554; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011; Gnanapradeepan K, 2020, ELIFE, V9, DOI 10.7554/eLife.55994; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsiue EHC, 2021, SCIENCE, V371, P1009, DOI 10.1126/science.abc8697; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Jennis M, 2016, GENE DEV, V30, P918, DOI 10.1101/gad.275891.115; Jiang DD, 2011, P NATL ACAD SCI USA, V108, P17123, DOI 10.1073/pnas.1111245108; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Joerger AC, 2006, P NATL ACAD SCI USA, V103, P15056, DOI 10.1073/pnas.0607286103; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; Kadosh E, 2020, NATURE, V586, P133, DOI 10.1038/s41586-020-2541-0; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kang R, 2019, FREE RADICAL BIO MED, V133, P162, DOI 10.1016/j.freeradbiomed.2018.05.074; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Leu JIJ, 2019, P NATL ACAD SCI USA, V116, P8390, DOI 10.1073/pnas.1821277116; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; LUNA RMD, 1995, NATURE, V378, P203; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mantovani F, 2019, CELL DEATH DIFFER, V26, P199, DOI 10.1038/s41418-018-0246-9; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mello SS, 2017, CANCER CELL, V32, P460, DOI 10.1016/j.ccell.2017.09.007; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Murphy ME, 2004, CELL CYCLE, V3, P836; Muys BR, 2021, GENE DEV, V35, P102, DOI 10.1101/gad.342634.120; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; Fernandez-Fernandez MR, 2011, PROTEIN ENG DES SEL, V24, P41, DOI 10.1093/protein/gzq074; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schulz-Heddergott R, 2018, CANCER CELL, V34, P298, DOI 10.1016/j.ccell.2018.07.004; Schulz-Heddergott R, 2018, CANCERS, V10, DOI 10.3390/cancers10060188; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Singh KS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14151-9; Smith KR, 2012, P ROY SOC B-BIOL SCI, V279, P1389, DOI 10.1098/rspb.2011.1697; Speidel D, 2010, TRENDS CELL BIOL, V20, P14, DOI 10.1016/j.tcb.2009.10.002; Sullivan KD, 2018, CELL DEATH DIFFER, V25, P133, DOI 10.1038/cdd.2017.174; Tarangelo A, 2018, CELL REP, V22, P569, DOI 10.1016/j.celrep.2017.12.077; Valente LJ, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201908212; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Vicens A, 2018, GENES-BASEL, V9, DOI 10.3390/genes9120582; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Vousden KH, 2009, BIOCHEM SOC T, V37, P511, DOI 10.1042/BST0370511; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang PY, 2013, NEW ENGL J MED, V368, P1027, DOI 10.1056/NEJMoa1214091; Wang SJ, 2016, CELL REP, V17, P366, DOI 10.1016/j.celrep.2016.09.022; White E, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026120; Williams AB, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026070; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Xie YC, 2017, CELL REP, V20, P1692, DOI 10.1016/j.celrep.2017.07.055; Yang X, 2003, CELL DEATH DIFFER, V10, P400, DOI 10.1038/cj.cdd.4401182; Yu X, 2018, CLIN CANCER RES, V24, P4505, DOI 10.1158/1078-0432.CCR-18-0822	95	7	7	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4281	4290		10.1038/s41388-021-01852-z	http://dx.doi.org/10.1038/s41388-021-01852-z		JUN 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34103683	Green Accepted			2022-12-28	WOS:000659032900006
J	Chen, Z; Shao, YL; Wang, LL; Lin, J; Zhang, JB; Ding, Y; Gao, BB; Liu, DH; Gao, XN				Chen, Ze; Shao, Yang-Liu; Wang, Li-Li; Lin, Ji; Zhang, Ji-Bin; Ding, Yi; Gao, Bin-bin; Liu, Dai-Hong; Gao, Xiao-Ning			YTHDF2 is a potential target of AML1/ETO-HIF1 alpha loop-mediated cell proliferation in t(8;21) AML	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; GENE-EXPRESSION PROFILES; CANCER; DIFFERENTIATION; LEUKEMOGENESIS; AML1-ETO; PROMOTE	The t(8;21) fusion product, AML1/ETO, and hypoxia-inducible factor 1 alpha (HIF1 alpha) form a feed-forward transcription loop that cooperatively transactivates the DNA methyltransferase 3a gene promoter that leads to DNA hypermethylation and drives leukemia cell growth. Suppression of the RNA N-6-methyladenosine (m(6)A)-reader enzyme YTH N-6-methyladenosine RNA binding protein 2 (YTHDF2) specifically compromises cancer stem cells in acute myeloid leukemia (AML) but promotes hematopoietic stem cell expansion without derailing normal hematopoiesis. However, the relevance of expression between AML1/ETO-HIF1 alpha loop and YTHDF2, and its functional relationship with t(8;21) AML have not been documented. Here, we show that YTHDF2 is highly expressed in t(8;21) AML patients and associated with a higher risk of relapse and inferior relapse-free survival. Knockdown of YTHDF2 in leukemia cells causes an impaired cell proliferation rate in vitro and in mice. Mechanistically, HIF1 alpha is able to bind to the hypoxia-response elements of the 5 '-untranslated region of the YTHDF2 gene and promotes the transactivity of the YTHDF2 promoter. Knockdown and overexpression of either AML1/ETO or HIF1 alpha resulted in decreased and increased YTHDF2 protein and mRNA expression in t(8;21) AML cells. In particular, knockdown of YTHDF2 resulted in increased global mRNA m(6)A levels in t(8;21) AML cells, accompanied by increased TNF receptor superfamily member 1b (TNFRSF1b) mRNA and protein expression levels. Last, we demonstrated that the m(6)A methylation and expression levels of the TNFRSF1b gene were both negatively correlated with HIF1 alpha expression levels. In conclusion, YTHDF2 is a downstream target of the AML1/ETO-HIF1 alpha loop and promotes cell proliferation probably by modulating the global m(6)A methylation in t(8;21) AML.	[Chen, Ze; Shao, Yang-Liu; Wang, Li-Li; Ding, Yi; Gao, Bin-bin; Liu, Dai-Hong; Gao, Xiao-Ning] Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing, Peoples R China; [Lin, Ji] Chinese Peoples Liberat Army Gen Hosp, Grad Sch, Dept Basic Med, Beijing, Peoples R China; [Zhang, Ji-Bin] Chinese Peoples Liberat Army Gen Hosp, Dept Cardiol, Beijing, Peoples R China	Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital	Liu, DH; Gao, XN (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing, Peoples R China.	daihongrm@163.com; gaoxn@263.net	wang, lili/HDL-7210-2022	Yu, Li/0000-0001-6872-2665; Gao, Xiaoning/0000-0003-2035-7472	National Natural Science Foundation of China [82070149, 81870109, 81670135]; Natural Science Foundation of Beijing Municipality [7202191]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Beijing Municipality(Beijing Natural Science Foundation)	This work was partially supported by grants from the National Natural Science Foundation of China (82070149, 81870109, and 81670135 to X-NG), the Natural Science Foundation of Beijing Municipality (7202191 to X-NG).	Al-Harbi S, 2020, BLOOD ADV, V4, P229, DOI 10.1182/bloodadvances.2019000168; Appelbaum FR, 2006, BRIT J HAEMATOL, V135, P165, DOI 10.1111/j.1365-2141.2006.06276.x; Barbieri I, 2017, NATURE, V552, P126, DOI 10.1038/nature24678; Cheng JM, 2017, CELL CYCLE, V16, P1404, DOI 10.1080/15384101.2017.1327488; de Jonge HJM, 2010, BLOOD, V116, P1747, DOI 10.1182/blood-2010-03-270991; Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626; Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020; Gao XN, 2015, LEUKEMIA, V29, P1730, DOI 10.1038/leu.2015.56; Hou J, 2019, CANCER RES, V79; Hou JJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1082-3; Kuhnl A, 2011, BLOOD, V118, P6362, DOI 10.1182/blood-2011-04-350850; Li JF, 2018, ONCOTARGET, V9, P3752, DOI 10.18632/oncotarget.23365; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Li ZR, 2018, CELL RES, V28, P904, DOI 10.1038/s41422-018-0072-0; Marcucci G, 2005, J CLIN ONCOL, V23, P5705, DOI 10.1200/JCO.2005.15.610; Paris J, 2019, CELL STEM CELL, V25, P137, DOI 10.1016/j.stem.2019.03.021; Prebet T, 2009, J CLIN ONCOL, V27, P4747, DOI 10.1200/JCO.2008.21.0674; Schlenk RF, 2004, J CLIN ONCOL, V22, P3741, DOI 10.1200/JCO.2004.03.012; Scrucca L, 2007, BONE MARROW TRANSPL, V40, P381, DOI 10.1038/sj.bmt.1705727; Sheng H, 2020, CARCINOGENESIS, V41, P541, DOI 10.1093/carcin/bgz152; Shia WJ, 2012, BLOOD, V119, P4953, DOI 10.1182/blood-2011-04-347476; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang H, 2018, CELL RES, V28, P1035, DOI 10.1038/s41422-018-0082-y; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Weng HY, 2018, CELL STEM CELL, V22, P191, DOI 10.1016/j.stem.2017.11.016; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006	31	14	14	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3786	3798		10.1038/s41388-021-01818-1	http://dx.doi.org/10.1038/s41388-021-01818-1		MAY 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33958724				2022-12-28	WOS:000648041500006
J	Chen, T; Wang, XL; Li, C; Zhang, HW; Liu, Y; Han, DW; Li, YM; Li, Z; Luo, D; Zhang, N; Zheng, MZ; Chen, B; Wang, LJ; Zhao, WJ; Yang, QF				Chen, Tong; Wang, Xiaolong; Li, Chen; Zhang, Hanwen; Liu, Ying; Han, Dianwen; Li, Yaming; Li, Zheng; Luo, Dan; Zhang, Ning; Zheng, Meizhu; Chen, Bing; Wang, Lijuan; Zhao, Wenjing; Yang, Qifeng			CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation	ONCOGENE			English	Article							NUCLEAR FACTOR-I; CIRCULAR RNA; PROLIFERATION; BINDING; INTERACTS; ROLES	Emerging evidence has demonstrated that circular RNAs (circRNAs) play critical roles in the development and progression of human cancer. However, the biological functions and underlying mechanisms of circRNAs in triple-negative breast cancer (TNBC) remain to be investigated. In our present study, we found that the novel circRNA circHIF1A was significantly overexpressed in breast cancer tissues and that it was associated with metastasis, poor prognosis, and the TNBC subtype. Gain- and loss-of-function experiments were conducted to investigate the biological roles of circHIF1A in TNBC. Overexpression of circHIF1A significantly promoted TNBC growth and metastasis in vitro and in vivo, while knockdown of circHIF1A exerted the opposite effects. Mechanistically, circHIF1A modulated the expression and translocation of NFIB through posttranscriptional and posttranslational modifications, resulting in the activation of the AKT/STAT3 signaling pathway and inhibition of P21. The RNA binding protein FUS could regulate the biogenesis of circHIF1A by interacting with the flanking intron, and FUS was transcriptionally regulated by NFIB, thus forming the circHIF1A/NFIB/FUS positive feedback loop. Moreover, circHIF1A could be packaged into exosomes and was upregulated in the plasma of breast cancer patients. Our findings indicated that circHIF1A played a critical role in the growth and metastasis of TNBC via a positive feedback loop and that circHIF1A could be a promising biomarker for breast cancer diagnosis and a potential therapeutic target for TNBC treatment.	[Chen, Tong; Wang, Xiaolong; Li, Chen; Zhang, Hanwen; Liu, Ying; Han, Dianwen; Li, Yaming; Li, Zheng; Luo, Dan; Zhang, Ning; Yang, Qifeng] Shandong Univ, Qilu Hosp, Dept Breast Surg, Gen Surg, Jinan, Shandong, Peoples R China; [Zheng, Meizhu] Shandong First Med Univ, Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Breast Surg, Jinan, Shandong, Peoples R China; [Chen, Bing; Wang, Lijuan; Zhao, Wenjing; Yang, Qifeng] Shandong Univ, Pathol Tissue Bank, Qilu Hosp, Jinan, Shandong, Peoples R China; [Yang, Qifeng] Shandong Univ, Res Inst Breast Canc, Jinan, Shandong, Peoples R China	Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Shandong University; Shandong University	Yang, QF (corresponding author), Shandong Univ, Qilu Hosp, Dept Breast Surg, Gen Surg, Jinan, Shandong, Peoples R China.; Yang, QF (corresponding author), Shandong Univ, Pathol Tissue Bank, Qilu Hosp, Jinan, Shandong, Peoples R China.; Yang, QF (corresponding author), Shandong Univ, Res Inst Breast Canc, Jinan, Shandong, Peoples R China.	qifengy_sdu@163.com	Zhang, Hanwen/CAG-1998-2022; Zhang, Ning/GOJ-8058-2022; yang, qiang/GYJ-0971-2022; Zhang, Ning/GNP-1966-2022	Zhang, Ning/0000-0002-6430-4236; Yang, Qifeng/0000-0003-0576-8513; Li, Chen/0000-0001-6994-1253	National Key Research and Development Program [2020YFA0712400, 2018YFC0114705]; Special Foundation for Taishan Scholars [ts20190971]; National Natural Science Foundation of China [81672613, 81874119, 82072912, 82004122]; Shandong Provincial Natural Science Foundation, China [ZR2019LZL003, ZR201911010260, ZR201911050391]; Special Support Plan for National High Level Talents (Ten Thousand Talents Program) [W01020103]; Foundation from Clinical Research Center of Shandong University [2020SDUCRCA015]; Qilu Hospital Clinical New Technology Developing Foundation [2018-7, 2019-3]	National Key Research and Development Program; Special Foundation for Taishan Scholars; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Provincial Natural Science Foundation, China(Natural Science Foundation of Shandong Province); Special Support Plan for National High Level Talents (Ten Thousand Talents Program); Foundation from Clinical Research Center of Shandong University; Qilu Hospital Clinical New Technology Developing Foundation	This work was supported by National Key Research and Development Program (No. 2020YFA0712400; No. 2018YFC0114705), Special Foundation for Taishan Scholars (No. ts20190971), National Natural Science Foundation of China (No. 81672613; No. 81874119; No. 82072912; No. 82004122), Shandong Provincial Natural Science Foundation, China (No. ZR2019LZL003, No. ZR201911010260, No. ZR201911050391), Special Support Plan for National High Level Talents (Ten Thousand Talents Program W01020103), Foundation from Clinical Research Center of Shandong University (No.2020SDUCRCA015), Qilu Hospital Clinical New Technology Developing Foundation (No. 2018-7; No. 2019-3).	Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Chan SH, 2014, ONCOGENE, V33, P4496, DOI 10.1038/onc.2014.10; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; de Rinaldis E, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-643; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dong YP, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0370-2; Du WW, 2017, EUR HEART J, V38, P1402, DOI 10.1093/eurheartj/ehw001; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Errichelli L, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14741; Fanale D, 2018, ADV EXP MED BIOL, V1087, P109, DOI 10.1007/978-981-13-1426-1_9; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hentze MW, 2013, EMBO J, V32, P923, DOI 10.1038/emboj.2013.53; Hong HQ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2183-z; Hu YP, 2019, AGING-US, V11, P8068, DOI 10.18632/aging.102122; Ji DG, 2019, BIOCHEM BIOPH RES CO, V512, P176, DOI 10.1016/j.bbrc.2019.03.049; Jin B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01173-x; Kobayashi H, 2016, BBA-GENE REGUL MECH, V1859, P71, DOI 10.1016/j.bbagrm.2015.08.007; Lagier-Tourenne C, 2010, HUM MOL GENET, V19, pR46, DOI 10.1093/hmg/ddq137; Li J, 2019, J CELL BIOCHEM, V120, P7725, DOI 10.1002/jcb.28046; Li JQ, 2015, AM J CANCER RES, V5, P472; Li ZH, 2018, CANCER LETT, V432, P237, DOI 10.1016/j.canlet.2018.04.035; Liang HF, 2017, AM J CANCER RES, V7, P1566; Liu RZ, 2019, J PATHOL, V247, P186, DOI 10.1002/path.5182; Liu ZY, 2019, CANCER SCI, V110, P86, DOI 10.1111/cas.13833; Liu ZH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1287-1; Moon HG, 2011, MOL ONCOL, V5, P538, DOI 10.1016/j.molonc.2011.08.002; Pan B, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.01096; Sang YT, 2019, MOL THER, V27, P1638, DOI 10.1016/j.ymthe.2019.05.011; Sato S, 2005, GASTROENTEROLOGY, V129, P1225, DOI 10.1053/j.gastro.2005.07.025; Shao SQ, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109582; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Wang AH, 2019, EUR REV MED PHARMACO, V23, P8310, DOI 10.26355/eurrev_201910_19142; WANG S, 2019, MOL CANCER, V18; Wu CQ, 2018, ONCOL REP, V40, P1565, DOI 10.3892/or.2018.6574; Xie MY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01208-3; Xue DW, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1072-5; Yang R, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0933-7; Yang Z, 2020, GASTRIC CANCER, V23, P449, DOI 10.1007/s10120-019-01019-6; Yang ZG, 2017, MOL THER, V25, P2062, DOI 10.1016/j.ymthe.2017.05.022; Yasuda K, 2017, J CELL BIOL, V216, P1015, DOI 10.1083/jcb.201608022; Yu T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0776-8; Zhang XO, 2016, GENOME RES, V26, P1277, DOI 10.1101/gr.202895.115; Zhang XN, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0959-5; Zhang ZR, 2018, EBIOMEDICINE, V34, P267, DOI 10.1016/j.ebiom.2018.07.036; Zheng XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01183-9	49	27	28	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2756	2771		10.1038/s41388-021-01739-z	http://dx.doi.org/10.1038/s41388-021-01739-z		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33714984				2022-12-28	WOS:000628485300004
J	Pan, YW; Han, H; Labbe, KE; Zhang, H; Wong, KK				Pan, Yuanwang; Han, Han; Labbe, Kristen E.; Zhang, Hua; Wong, Kwok-Kin			Recent advances in preclinical models for lung squamous cell carcinoma	ONCOGENE			English	Review								Lung squamous cell carcinoma (LUSC) represents a major subtype of non-small cell lung cancer with limited treatment options. Previous studies have elucidated the complex genetic landscape of LUSC and revealed multiple altered genes and pathways. However, in stark contrast to lung adenocarcinoma, few targetable driver mutations have been established so far and targeted therapies for LUSC remain unsuccessful. Immunotherapy has revolutionized LUSC treatment and is currently approved as the new standard of care. To gain a better understanding of the LUSC biology, improved modeling systems are urgently needed. Preclinical models, particularly those mimicking human disease with an intact tumor immune microenvironment, are an invaluable tool to study cancer development and evaluate new therapeutic targets. Here, we discuss recent advances in LUSC preclinical models, with a focus on genetically engineered mouse models (GEMMs) and organoids, in the context of evolving precision medicine and immunotherapy.	[Pan, Yuanwang; Han, Han; Labbe, Kristen E.; Zhang, Hua; Wong, Kwok-Kin] NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, Div Hematol & Med Oncol, New York, NY 10003 USA	New York University; NYU Langone Medical Center	Zhang, H; Wong, KK (corresponding author), NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, Div Hematol & Med Oncol, New York, NY 10003 USA.	Hua.Zhang@nyulangone.org; Kwok-Kin.Wong@nyulangone.org	Zhang, Hua/AAV-2344-2020	Zhang, Hua/0000-0001-7704-4712; Labbe, Kristen/0000-0001-6731-5849; wong, kwok kin/0000-0001-6323-235X	AstraZeneca; Janssen; Pfizer/Array Biopharma; Novartis; Merck; Zentalis; Takeda; BMS; Mirati; Alkermes; Merus; Amgen; Ansun Biopharma; Enliven Therapeutics; Tvardi Therapeutics; Delfi Diagnostics; Dracen Pharmaceuticals	AstraZeneca(AstraZeneca); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Pfizer/Array Biopharma; Novartis(Novartis); Merck(Merck & Company); Zentalis; Takeda(Takeda Pharmaceutical Company Ltd); BMS(Bristol-Myers Squibb); Mirati; Alkermes; Merus; Amgen(Amgen); Ansun Biopharma; Enliven Therapeutics; Tvardi Therapeutics; Delfi Diagnostics; Dracen Pharmaceuticals	KKW is a founder and equity holder of G1 Therapeutics and has consulting and sponsored research with: AstraZeneca, Janssen, Pfizer/Array Biopharma, Novartis, Merck, Zentalis; as well as sponsored research (only) with: Takeda, BMS, Mirati, Alkermes, Merus, Amgen, Ansun Biopharma, Enliven Therapeutics, Tvardi Therapeutics, Delfi Diagnostics, and Dracen Pharmaceuticals. No potential conflicts of interest were disclosed by the other authors.	Aggarwal C, 2019, J THORAC ONCOL, V14, P1847, DOI 10.1016/j.jtho.2019.05.041; [Anonymous], 2021, CANCER DISCOV, V11, pOF3; Aref AR, 2018, LAB CHIP, V18, P3129, DOI 10.1039/c8lc00322j; Azpilikueta A, 2016, J THORAC ONCOL, V11, P524, DOI 10.1016/j.jtho.2016.01.013; Barkauskas CE, 2017, DEVELOPMENT, V144, P986, DOI 10.1242/dev.140103; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Bendell JC, 2018, CLIN CANCER RES, V24, P3253, DOI 10.1158/1078-0432.CCR-17-3421; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Camolotto SA, 2018, ELIFE, V7, DOI 10.7554/eLife.38579; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Chow E, 2006, CLIN GENET, V70, P409, DOI 10.1111/j.1399-0004.2006.00704.x; Chow RD, 2017, NAT NEUROSCI, V20, P1329, DOI 10.1038/nn.4620; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Dijkstra KK, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107588; Dotto GP, 2016, CANCER CELL, V29, P622, DOI 10.1016/j.ccell.2016.04.004; Drost J, 2018, NAT REV CANCER, V18, P407, DOI 10.1038/s41568-018-0007-6; Ekman S, 2012, J THORAC ONCOL, V7, P947, DOI 10.1097/JTO.0b013e31825581bd; Fang R, 2014, J THORAC ONCOL, V9, P254, DOI 10.1097/JTO.0000000000000056; Ferone G, 2016, CANCER CELL, V30, P519, DOI 10.1016/j.ccell.2016.09.001; Fujii M, 2016, CELL STEM CELL, V18, P827, DOI 10.1016/j.stem.2016.04.003; Fukuoka M, 2011, J CLIN ONCOL, V29, P2866, DOI 10.1200/JCO.2010.33.4235; Fumagalli A, 2017, P NATL ACAD SCI USA, V114, pE2357, DOI 10.1073/pnas.1701219114; Gao YJ, 2011, PROTEIN CELL, V2, P99, DOI 10.1007/s13238-011-1021-6; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gazdar AF, 2016, J THORAC ONCOL, V11, P287, DOI 10.1016/j.jtho.2015.10.009; Gengenbacher N, 2017, NAT REV CANCER, V17, P751, DOI 10.1038/nrc.2017.92; Hai J, 2020, CLIN CANCER RES, V26, P3431, DOI 10.1158/1078-0432.CCR-19-1627; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Han XK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4261; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Henneman L, 2015, P NATL ACAD SCI USA, V112, P8409, DOI 10.1073/pnas.1500223112; Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346; Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183; Herbst RS, 2015, CLIN CANCER RES, V21, P1514, DOI 10.1158/1078-0432.CCR-13-3473; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Huijbers IJ, 2015, NAT PROTOC, V10, P1755, DOI 10.1038/nprot.2015.114; Huijbers IJ, 2014, EMBO MOL MED, V6, P212, DOI 10.1002/emmm.201303297; Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960; Inoue A, 2013, ANN ONCOL, V24, P54, DOI 10.1093/annonc/mds214; Jenkins RW, 2018, CANCER DISCOV, V8, P196, DOI 10.1158/2159-8290.CD-17-0833; Jeong Y, 2017, CANCER DISCOV, V7, P86, DOI 10.1158/2159-8290.CD-16-0127; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kellar A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/621324; Kim M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11867-6; Kim Y, 2014, J CLIN ONCOL, V32, P121, DOI 10.1200/JCO.2013.50.8556; Kwon MC, 2013, MOL ONCOL, V7, P165, DOI 10.1016/j.molonc.2013.02.010; Langer CJ, 2019, J THORAC ONCOL, V14, P1839, DOI 10.1016/j.jtho.2019.05.029; Lazarus KA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05790-5; Lee SH, 2018, CELL, V173, P515, DOI 10.1016/j.cell.2018.03.017; Li CG, 2015, SCI REP-UK, V5, DOI 10.1038/srep14237; Li FM, 2015, CANCER CELL, V27, P698, DOI 10.1016/j.ccell.2015.04.001; Liu J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09843-1; Liu Y, 2020, CELL REP, V30, P771, DOI 10.1016/j.celrep.2019.12.071; Lu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011022; Maresch R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10770; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; Middleton G, 2020, NATURE, V583, P807, DOI 10.1038/s41586-020-2481-8; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Mollaoglu G, 2018, IMMUNITY, V49, P764, DOI 10.1016/j.immuni.2018.09.020; Momcilovic M, 2018, CANCER CELL, V33, P905, DOI 10.1016/j.ccell.2018.04.002; Morgan KM, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00002; Mukhopadhyay A, 2014, CELL REP, V8, P40, DOI 10.1016/j.celrep.2014.05.036; Neal JT, 2018, CELL, V175, P1972, DOI 10.1016/j.cell.2018.11.021; Neal JT, 2016, ANNU REV PATHOL-MECH, V11, P199, DOI 10.1146/annurev-pathol-012615-044249; NETTESHEIM P, 1971, JNCI-J NATL CANCER I, V47, P697; Ng SR, 2020, P NATL ACAD SCI USA, V117, P513, DOI 10.1073/pnas.1821893117; Nogova L, 2017, J CLIN ONCOL, V35, P157, DOI 10.1200/JCO.2016.67.2048; Ohe Y, 2008, CLIN CANCER RES, V14, P4206, DOI 10.1158/1078-0432.CCR-07-5143; Paik Paul K, 2019, Am Soc Clin Oncol Educ Book, V39, pe198, DOI 10.1200/EDBK_237829; Paik PK, 2015, CANCER DISCOV, V5, P610, DOI 10.1158/2159-8290.CD-14-1129; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Paz-Ares L, 2021, LANCET ONCOL, V22, P198, DOI 10.1016/S1470-2045(20)30641-0; Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014; Premsrirut PK, 2011, CELL, V145, P145, DOI 10.1016/j.cell.2011.03.012; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Redman MW, 2020, LANCET ONCOL, V21, P1589, DOI 10.1016/S1470-2045(20)30475-7; REHM S, 1991, AM J PATHOL, V139, P413; Ren CL, 2019, NEW ENGL J MED, V380, P1981, DOI 10.1056/NEJMc1903253; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106; Rogers ZN, 2018, NAT GENET, V50, P483, DOI 10.1038/s41588-018-0083-2; Rogers ZN, 2017, NAT METHODS, V14, P737, DOI 10.1038/nmeth.4297; Romero R, 2017, NAT MED, V23, P1362, DOI 10.1038/nm.4407; Roper J, 2017, NAT BIOTECHNOL, V35, P569, DOI 10.1038/nbt.3836; Ruiz EJ, 2019, J EXP MED, V216, P450, DOI 10.1084/jem.20180742; Saborowski M, 2014, GENE DEV, V28, P85, DOI 10.1101/gad.232082.113; Sachs N, 2019, EMBO J, V38, DOI 10.15252/embj.2018100300; Sachs N, 2018, CELL, V172, P373, DOI 10.1016/j.cell.2017.11.010; Sanchez-Danes A, 2018, NAT REV CANCER, V18, P549, DOI 10.1038/s41568-018-0024-5; Sanchez-Rivera FJ, 2014, NATURE, V516, P428, DOI 10.1038/nature13906; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schuette W, 2005, J CLIN ONCOL, V23, P8389, DOI 10.1200/JCO.2005.02.3739; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Shi RS, 2020, CLIN CANCER RES, V26, P1162, DOI 10.1158/1078-0432.CCR-19-1376; Singh AP, 2018, EXPERT OPIN DRUG DIS, V13, P347, DOI 10.1080/17460441.2018.1437137; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Tabernero J, 2015, J CLIN ONCOL, V33, P3401, DOI 10.1200/JCO.2014.60.7341; Tata PR, 2018, DEV CELL, V44, P679, DOI 10.1016/j.devcel.2018.02.024; Tiriac H, 2018, CANCER DISCOV, V8, P1112, DOI 10.1158/2159-8290.CD-18-0349; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Vansteenkiste JF, 2015, J THORAC ONCOL, V10, P1319, DOI 10.1097/JTO.0000000000000607; Wang GC, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aao5508; Wang Y, 2004, CANCER RES, V64, P1647, DOI 10.1158/0008-5472.CAN-03-3273; Winters IP, 2018, NAT REV GENET, V19, P741, DOI 10.1038/s41576-018-0053-7; Xiao ZX, 2013, CANCER CELL, V23, P527, DOI 10.1016/j.ccr.2013.03.009; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Xue W, 2014, NATURE, V514, P380, DOI 10.1038/nature13589; Yang JCH, 2015, LANCET ONCOL, V16, P141, DOI 10.1016/S1470-2045(14)71173-8; Yin H, 2019, NAT REV CLIN ONCOL, V16, P281, DOI 10.1038/s41571-019-0166-8; Yuki K, 2020, TRENDS IMMUNOL, V41, P652, DOI 10.1016/j.it.2020.06.010; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-00321-0, 10.1038/s41467-017-01968-5]; Zhou C, 2015, ANN ONCOL, V26, P1877, DOI 10.1093/annonc/mdv276	116	10	10	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2817	2829		10.1038/s41388-021-01723-7	http://dx.doi.org/10.1038/s41388-021-01723-7		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33707749				2022-12-28	WOS:000627660400003
J	Reinsborough, CW; Ipas, H; Abell, NS; Gouws, EB; Williams, JP; Mercado, M; Van den Berg, C; Xhemalce, B				Reinsborough, Calder W.; Ipas, Helene; Abell, Nathan S.; Gouws, Ellen B.; Williams, J. Paige; Mercado, Marvin; Van den Berg, Carla; Xhemalce, Blerta			BCDIN3D RNA methyltransferase stimulates Aldolase C expression and glycolysis through let-7 microRNA in breast cancer cells	ONCOGENE			English	Article							MAMMALIAN PROTEIN; PRE-MICRORNA; URIDYLATION; IDENTIFICATION; ZCCHC11; BIOGENESIS; RECRUITS; FAMILY; TUMORS; LOCI	Type II diabetes (T2D) and specific cancers share many risk factors, however, the molecular mechanisms underlying these connections are often not well-understood. BCDIN3D is an RNA modifying enzyme that methylates specific precursor microRNAs and tRNA(His). In addition to breast cancer, BCDIN3D may also be linked to metabolism, as its gene locus is associated with obesity and T2D. In order to uncover metabolic pathways regulated by BCDIN3D in cancer, we performed an unbiased analysis of the metabolome, transcriptome, and proteome of breast cancer cells depleted for BCDIN3D. Intersection of these analyses showed that BCDIN3D-depleted cells have increased levels of Fructose 1,6 Bisphosphate (F1,6-BP), the last six-carbon glycolytic intermediate accompanied by reduced glycolytic capacity. We further show that elevated F1,6-BP is due to downregulation of Aldolase C (ALDOC), an enzyme that cleaves F1,6-BP mainly in the brain, but whose high expression/amplification is associated with poor prognosis in breast cancer. BCDIN3D regulates ALDOC through a non-canonical mechanism involving the crucial let-7 microRNA family and its target site on the 3 ' UTR of ALDOC. Overall, our results reveal an important connection between BCDIN3D, let-7 and glycolysis that may be relevant to breast cancer, obesity, and T2D.	[Reinsborough, Calder W.; Ipas, Helene; Abell, Nathan S.; Gouws, Ellen B.; Williams, J. Paige; Mercado, Marvin; Xhemalce, Blerta] Univ Texas Austin, LiveStrong Canc Inst, Dept Mol Biosci, Dell Med Sch, 2500 Speedway, Austin, TX 78712 USA; [Abell, Nathan S.] Stanford Univ, Sch Med, Dept Genet, 300 Pasteur Dr, Stanford, CA 94305 USA; [Van den Berg, Carla] Univ Texas Austin, Dell Med Sch, Coll Pharm, Div Pharmacol & Toxicol, Austin, TX 78723 USA; [Van den Berg, Carla] Univ Texas Austin, Dell Med Sch, Dept Oncol, Austin, TX 78723 USA	University of Texas System; University of Texas Austin; Stanford University; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Xhemalce, B (corresponding author), Univ Texas Austin, LiveStrong Canc Inst, Dept Mol Biosci, Dell Med Sch, 2500 Speedway, Austin, TX 78712 USA.	b.xhemalce@austin.utexas.edu		Xhemalce, Blerta/0000-0002-0517-9607	NIH [R01-GM127802]; DOD-CDMRP-BCRP [W81XWH-16-1-0352]; Welch Foundation [F1859]; STORM Therapeutics; CPRIT [RR160093]; CPRIT Core Facility Support Grants [RP120348, RP170002]; DHHS/NCI Cancer Center Support Grant (CCSG) [P30 CA16672]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD-CDMRP-BCRP(United States Department of Defense); Welch Foundation(The Welch Foundation); STORM Therapeutics; CPRIT; CPRIT Core Facility Support Grants; DHHS/NCI Cancer Center Support Grant (CCSG)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	BX was supported by NIH (R01-GM127802, DOD-CDMRP-BCRP (W81XWH-16-1-0352), Welch Foundation (F1859), STORM Therapeutics, and start-up funds. CVDB was partly supported by CPRIT (RR160093). This study made use of the MD Anderson Science Park facilities supported by CPRIT Core Facility Support Grants RP120348 and RP170002 and P30 CA16672 DHHS/NCI Cancer Center Support Grant (CCSG).	Auyeung VC, 2013, CELL, V152, P844, DOI 10.1016/j.cell.2013.01.031; Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006; Berndt SI, 2013, NAT GENET, V45, P501, DOI 10.1038/ng.2606; Blazer LL, 2017, SLAS DISCOV, V22, P32, DOI 10.1177/1087057116666276; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Faehnle CR, 2014, NATURE, V514, P252, DOI 10.1038/nature13553; Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666; Hagan JP, 2009, NAT STRUCT MOL BIOL, V16, P1021, DOI 10.1038/nsmb.1676; Heo I, 2012, CELL, V151, P521, DOI 10.1016/j.cell.2012.09.022; Heo I, 2009, CELL, V138, P696, DOI 10.1016/j.cell.2009.08.002; Huangyang PW, 2020, CELL METAB, V31, P174, DOI 10.1016/j.cmet.2019.10.012; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jenkins DE, 2005, BREAST CANCER RES, V7, pR444, DOI 10.1186/bcr1026; Jones MR, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003105; Jones MR, 2009, NAT CELL BIOL, V11, P1157, DOI 10.1038/ncb1931; Kim B, 2015, EMBO J, V34, P1801, DOI 10.15252/embj.201590931; Kim K, 2018, RNA, V24, P892, DOI 10.1261/rna.065862.118; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li MQ, 2019, CELL METAB, V30, P508, DOI 10.1016/j.cmet.2019.05.018; Lin SC, 2020, NAT REV MOL CELL BIO, V21, P714, DOI 10.1038/s41580-020-00305-x; Lin SB, 2015, RNA BIOL, V12, P792, DOI 10.1080/15476286.2015.1058478; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Martinez A, 2017, NUCLEIC ACIDS RES, V45, P5423, DOI 10.1093/nar/gkx051; McCall MN, 2017, GENOME RES, V27, P1769, DOI 10.1101/gr.222067.117; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Reinsborough CW, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008273; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schapira M, 2016, ACS CHEM BIOL, V11, P575, DOI 10.1021/acschembio.5b00781; Schwartz MW, 2013, NATURE, V503, P59, DOI 10.1038/nature12709; Shelton SB, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006139; Shi DS, 2015, INT J MOL SCI, V16, P13004, DOI 10.3390/ijms160613004; Thorleifsson G, 2009, NAT GENET, V41, P18, DOI 10.1038/ng.274; Thornton JE, 2014, NUCLEIC ACIDS RES, V42, P11777, DOI 10.1093/nar/gku805; Walley AJ, 2009, NAT REV GENET, V10, P431, DOI 10.1038/nrg2594; Xhemalce B, 2012, CELL, V151, P278, DOI 10.1016/j.cell.2012.08.041; Yao L, 2016, ONCOTARGET, V7, P53895, DOI 10.18632/oncotarget.9656; Zhang CS, 2017, NATURE, V548, P112, DOI 10.1038/nature23275; Zhu L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217603; Zhu WC, 2000, GENE, V245, P329, DOI 10.1016/S0378-1119(00)00048-2	42	9	9	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2395	2406		10.1038/s41388-021-01702-y	http://dx.doi.org/10.1038/s41388-021-01702-y		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33664453	Green Accepted			2022-12-28	WOS:000625833000004
J	Xiao, YN; Jin, L; Deng, CL; Guan, Y; Kalogera, E; Ray, U; Thirusangu, P; Staub, J; Bhattacharya, SS; Xu, HT; Fang, XL; Shridhar, V				Xiao, Yinan; Jin, Ling; Deng, Chaolin; Guan, Ye; Kalogera, Eleftheria; Ray, Upasana; Thirusangu, Prabhu; Staub, Julie; Bhattacharya, Sayantani Sarkar; Xu, Haotian; Fang, Xiaoling; Shridhar, Viji			Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer	ONCOGENE			English	Article							PHASE-II; THERAPEUTIC TARGET; OVARIAN-CANCER; TUMOR-GROWTH; AUTOPHAGY; GLYCOLYSIS; COMBINATION; METASTASIS; EXPRESSION; INDUCTION	The advanced or recurrent endometrial cancer (EC) has a poor prognosis because of chemoresistance. 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a glycolytic enzyme, is overexpressed in a variety of human cancers and plays important roles in promoting tumor cell growth. Here, we showed that high expression of PFKFB3 in EC cell lines is associated with chemoresistance. Pharmacological inhibition of PFKFB3 with PFK158 and or genetic downregulation of PFKFB3 dramatically suppressed cell proliferation and enhanced the sensitivity of EC cells to carboplatin (CBPt) and cisplatin (Cis). Moreover, PFKFB3 inhibition resulted in reduced glucose uptake, ATP production, and lactate release. Notably, we found that PFK158 with CBPt or Cis exerted strong synergistic antitumor activity in chemoresistant EC cell lines, HEC-1B and ARK-2 cells. We also found that the combination of PFK158 and CBPt/Cis induced apoptosis- and autophagy-mediated cell death through inhibition of the Akt/mTOR signaling pathway. Mechanistically, we found that PFK158 downregulated the CBPt/Cis-induced upregulation of RAD51 expression and enhanced CBPt/Cis-induced DNA damage as demonstrated by an increase in gamma-H2AX levels in HEC-1B and ARK-2 cells, potentially revealing a means to enhance PFK158-induced chemosensitivity. More importantly, PFK158 treatment, either as monotherapy or in combination with CBPt, led to a marked reduction in tumor growth in two chemoresistant EC mouse xenograft models. These data suggest that PFKFB3 inhibition alone or in combination with standard chemotherapy may be used as a novel therapeutic strategy for improved therapeutic efficacy and outcomes of advanced and recurrent EC patients.	[Xiao, Yinan; Jin, Ling; Ray, Upasana; Thirusangu, Prabhu; Staub, Julie; Bhattacharya, Sayantani Sarkar; Shridhar, Viji] Mayo Clin, Dept Expt Pathol, Rochester, MN 55905 USA; [Xiao, Yinan; Fang, Xiaoling] Cent South Univ, Xiangya Hosp 2, Dept Obstet & Gynecol, Changsha, Hunan, Peoples R China; [Deng, Chaolin] Mayo Clin, Dept Gastroenterol & Hepatol, Rochester, MN USA; [Guan, Ye] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; [Kalogera, Eleftheria] Mayo Clin, Div Gynecol Oncol, Rochester, MN USA; [Xu, Haotian] Wayne State Univ, Dept Comp Sci, Detroit, MI 48202 USA	Mayo Clinic; Central South University; Mayo Clinic; University of Michigan System; University of Michigan; Mayo Clinic; Wayne State University	Shridhar, V (corresponding author), Mayo Clin, Dept Expt Pathol, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Sarkar Bhattacharya, Sayantani/AAG-6222-2020	Sarkar Bhattacharya, Sayantani/0000-0001-8971-7566; Xiao, Yinan/0000-0003-3873-9444; Ray, Upasana/0000-0002-9804-6888	National Institutes of Health [P50CA136393]; Department of Experimental Pathology and Laboratory Medicine; Mayo Clinic; China Scholarship Council (CSC)	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Experimental Pathology and Laboratory Medicine; Mayo Clinic; China Scholarship Council (CSC)(China Scholarship Council)	We would like to thank Dr. Gottfried E. Konecny (UCLA Medical Center, Santa Monica), who provided the EC cell lines used in this study; Dr. Daniel Billadeau (Mayo Clinic, Rochester, MN) for providing the RFP-GFP-LC3B plasmid; Dr. Scott Kaufmann (Mayo Clinic, Rochester, MN) for providing the DR-GFP and I-SceI plasmids; the contributions of the Pathology Research Core laboratory, the Microscopy Core laboratory, and the Flow Cytometry Facility, Mayo Clinic, Rochester, MN. This work is supported in part by the National Institutes of Health P50CA136393 and the Department of Experimental Pathology and Laboratory Medicine and the Mayo Clinic (VS). The support provided by China Scholarship Council (CSC) during a visit of YX to Mayo Clinic is acknowledged.	Arend RC, 2018, GYNECOL ONCOL, V150, P569, DOI 10.1016/j.ygyno.2018.05.015; Atsumi T, 2002, CANCER RES, V62, P5881; Bhattacharya SS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1916-3; Bobarykina AY, 2006, ACTA BIOCHIM POL, V53, P789, DOI 10.18388/abp.2006_3308; Cantelmo AR, 2016, CANCER CELL, V30, P968, DOI 10.1016/j.ccell.2016.10.006; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Clem BF, 2013, MOL CANCER THER, V12, P1461, DOI 10.1158/1535-7163.MCT-13-0097; Cortez MA, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.47; De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037; Emons G, 2016, GYNECOL ONCOL, V140, P450, DOI 10.1016/j.ygyno.2015.12.025; Farkas T, 2009, AUTOPHAGY, V5, P1018, DOI 10.4161/auto.5.7.9443; Galluzzi L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.428; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Guan Y, 2018, ELIFE, V7, DOI 10.7554/eLife.33549; Gustafsson NMS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06287-x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ngo H, 2015, MOL BIOL REP, V42, P825, DOI 10.1007/s11033-014-3764-7; Hong KJ, 2015, AM J CANCER RES, V5, P2422; Huang Z, 2016, INT J CANCER, V139, P23, DOI 10.1002/ijc.29990; Ji MM, 2015, AUTOPHAGY, V11, P2160, DOI 10.1080/15548627.2015.1082024; Jia WZ, 2018, ONCOGENE, V37, P1685, DOI 10.1038/s41388-017-0072-4; Jones NL, 2017, INT J CANCER, V140, P1396, DOI 10.1002/ijc.30537; Jung DB, 2015, ONCOTARGET, V6, P4992, DOI 10.18632/oncotarget.3214; Kessler R, 2008, J NEURO-ONCOL, V86, P257, DOI 10.1007/s11060-007-9471-7; Khurana A, 2015, ONCOTARGET, V6, P36354, DOI 10.18632/oncotarget.5632; Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939; Li HM, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0481-1; Liu Y, 2020, ONCOGENE, V39, P6190, DOI 10.1038/s41388-020-01422-9; Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735; Minchenko OH, 2005, BIOCHIMIE, V87, P1005, DOI 10.1016/j.biochi.2005.04.007; Mondal S, 2019, INT J CANCER, V144, P178, DOI 10.1002/ijc.31868; Morice P, 2016, LANCET, V387, P1094, DOI 10.1016/S0140-6736(15)00130-0; Moxley KM, 2010, ONCOLOGIST, V15, P1026, DOI 10.1634/theoncologist.2010-0087; Myers AP, 2020, INT J CANCER, V147, P413, DOI 10.1002/ijc.32783; Nagathihalli NS, 2011, BBA-REV CANCER, V1816, P209, DOI 10.1016/j.bbcan.2011.07.004; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Ray-Coquard I, 2013, BRIT J CANCER, V108, P1771, DOI 10.1038/bjc.2013.183; Roncolato F, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012160.pub2; ROY D, 2017, SCI REP UK, V7; Rozengurt E, 2014, MOL CANCER THER, V13, P2477, DOI 10.1158/1535-7163.MCT-14-0330; Schoors S, 2014, CELL METAB, V19, P37, DOI 10.1016/j.cmet.2013.11.008; Shafer A, 2010, INT J CANCER, V126, P1144, DOI 10.1002/ijc.24837; Shi LL, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.44; Shi WK, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0435-y; Shteingauz A, 2015, CANCER RES, V75, P3946, DOI 10.1158/0008-5472.CAN-15-0037; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Slomovitz BM, 2012, CLIN CANCER RES, V18, P5856, DOI 10.1158/1078-0432.CCR-12-0662; Tsoref D, 2014, GYNECOL ONCOL, V135, P184, DOI 10.1016/j.ygyno.2014.06.033; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward A, 2015, CANCER TREAT REV, V41, P35, DOI 10.1016/j.ctrv.2014.10.006; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Yan SY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215415; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60	53	16	16	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1409	1424		10.1038/s41388-020-01621-4	http://dx.doi.org/10.1038/s41388-020-01621-4		JAN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33420377	hybrid, Green Published			2022-12-28	WOS:000607346000014
J	Han, CH; Zhang, AL; Liu, ZD; Moore, C; Fu, YX				Han, Chuanhui; Zhang, Anli; Liu, Zhida; Moore, Casey; Fu, Yang-Xin			Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy	ONCOGENE			English	Review							DEPENDENT ANTITUMOR IMMUNITY; ARYL-HYDROCARBON RECEPTOR; PD-L1 EXPRESSION; STING ACTIVATION; T-CELLS; INHIBITION; INDUCTION; BLOCKADE; CDK4/6; MERTK	Recently, immune checkpoint blockade (ICB), especially anti-programmed death 1 (anti-PD-1) and anti-programmed death-ligand 1 (anti-PD-L1) therapy, has become an increasingly appealing therapeutic strategy for cancer patients. However, only a small portion of patients responds to anti-PD treatment. Therefore, treatment strategies are urgently needed to reverse the ICB-resistant tumor microenvironment (TME). It has become clear that the TME has diminished innate sensing that is critical to activate adaptive immunity. In addition, tumor cells upregulate various immunosuppressive factors to diminish the immune response and resist immunotherapy. In this review, we briefly update the current small molecular drugs that could synergize with immunotherapy, especially anti-PD therapy. We will discuss the modes of action by those drugs including inducing innate sensing and limiting immunosuppressive factors in the TME.	[Han, Chuanhui; Zhang, Anli; Liu, Zhida; Moore, Casey; Fu, Yang-Xin] UT Southwestern Med Ctr, Dept Pathol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Fu, YX (corresponding author), UT Southwestern Med Ctr, Dept Pathol, Dallas, TX 75390 USA.	Yang-Xin.Fu@utsouthwestern.edu		fu, yang-xin/0000-0001-8441-6617; ZHANG, ANLI/0000-0001-7847-6541	Cancer Prevention and Research Institute of Texas (CPRIT) [RR150072]	Cancer Prevention and Research Institute of Texas (CPRIT)	We thank members of Prof. Yang-Xin Fu lab for fruitful discussions. This work was supported by Cancer Prevention and Research Institute of Texas (CPRIT) grant RR150072 given to Y-XF.	Ahn J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4723; Al-Obeidi FA, 2000, ONCOGENE, V19, P5690, DOI 10.1038/sj.onc.1203926; [Anonymous], 2020, J CLIN ONCOL, DOI DOI 10.1200/JCO.2020.38.15_suppl.1051; Antonioli L, 2013, TRENDS MOL MED, V19, P355, DOI 10.1016/j.molmed.2013.03.005; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Beaver JA, 2015, CLIN CANCER RES, V21, P4760, DOI 10.1158/1078-0432.CCR-15-1185; Bosurgi L, 2017, SCIENCE, V356, P1072, DOI 10.1126/science.aai8132; Botti G, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1150-7; Bryn T, 2008, INT IMMUNOL, V20, P235, DOI 10.1093/intimm/dxm134; Cheng BB, 2018, EUR J MED CHEM, V157, P582, DOI 10.1016/j.ejmech.2018.08.028; Cook RS, 2013, J CLIN INVEST, V123, P3231, DOI 10.1172/JCI67655; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Crittenden MR, 2016, ONCOTARGET, V7, P78653, DOI 10.18632/oncotarget.11823; Deng JH, 2018, CANCER DISCOV, V8, P216, DOI 10.1158/2159-8290.CD-17-0915; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Di Virgilio F, 2018, NAT REV CANCER, V18, P601, DOI 10.1038/s41568-018-0037-0; Ding LY, 2018, CELL REP, V25, P2972, DOI 10.1016/j.celrep.2018.11.054; Du WT, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.124184; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gandhi R, 2010, NAT IMMUNOL, V11, P846, DOI 10.1038/ni.1915; Giampazolias E, 2017, NAT CELL BIOL, V19, P1116, DOI 10.1038/ncb3596; Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465; Guo ZQ, 2017, ONCOTARGET, V8, P89761, DOI 10.18632/oncotarget.21125; Gutierrez-Vazquez C, 2018, IMMUNITY, V48, P19, DOI 10.1016/j.immuni.2017.12.012; Hamilton E, 2016, CANCER TREAT REV, V45, P129, DOI 10.1016/j.ctrv.2016.03.002; Han CH, 2020, NAT IMMUNOL, V21, P546, DOI 10.1038/s41590-020-0641-5; Heidegger S, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau8943; Hoglen NC, 2004, J PHARMACOL EXP THER, V309, P634, DOI 10.1124/jpet.103.062034; Holmgaard RB, 2013, J EXP MED, V210, P1389, DOI 10.1084/jem.20130066; Holtzhausen A, 2019, CANCER IMMUNOL RES, V7, P1672, DOI 10.1158/2326-6066.CIR-19-0008; Huang Q, 2011, NAT MED, V17, P860, DOI 10.1038/nm.2385; Karavitis J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046342; Kasikara C, 2019, CANCER RES, V79, P2669, DOI 10.1158/0008-5472.CAN-18-2614; Kim H, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz5683; Kitai Y, 2017, J IMMUNOL, V198, P1649, DOI 10.4049/jimmunol.1601694; Kitanaka N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208955; Labadie BW, 2019, CLIN CANCER RES, V25, P1462, DOI 10.1158/1078-0432.CCR-18-2882; Lang XT, 2019, CANCER DISCOV, V9, P1673, DOI 10.1158/2159-8290.CD-19-0338; Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303; Li XG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11238-1; Li YK, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1074374; Liu YY, 2018, CANCER CELL, V33, P480, DOI 10.1016/j.ccell.2018.02.005; Liu ZD, 2020, CELL MOL IMMUNOL, V17, P13, DOI 10.1038/s41423-019-0341-y; Liu ZD, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav6473; Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Looby E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-190; Lu HL, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00083; Mahanonda R, 2007, J IMMUNOL, V178, P1151, DOI 10.4049/jimmunol.178.2.1151; Maj T, 2017, NAT IMMUNOL, V18, P1332, DOI 10.1038/ni.3868; Mangsbo SM, 2010, J IMMUNOTHER, V33, P225, DOI 10.1097/CJI.0b013e3181c01fcb; Mao YM, 2014, CLIN CANCER RES, V20, P4096, DOI 10.1158/1078-0432.CCR-14-0635; McKenzie JA, 2018, JNCI-J NATL CANCER I, V110, P777, DOI 10.1093/jnci/djx257; Mender I, 2020, CANCER CELL, V38, P400, DOI 10.1016/j.ccell.2020.05.020; Mender I, 2015, CANCER DISCOV, V5, P82, DOI 10.1158/2159-8290.CD-14-0609; Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670; MINAKUCHI R, 1990, J IMMUNOL, V145, P2616; Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013; Myers KV, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1022-2; Nishii Naoto, 2018, Oncotarget, V9, P13301, DOI 10.18632/oncotarget.24327; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; Pantelidou C, 2019, CANCER DISCOV, V9, P722, DOI 10.1158/2159-8290.CD-18-1218; Prima V, 2017, P NATL ACAD SCI USA, V114, P1117, DOI 10.1073/pnas.1612920114; Qin X., 2010, CELL MOL BIOL, V56; Ramanjulu JM, 2018, NATURE, V564, P439, DOI 10.1038/s41586-018-0705-y; Rodriguez PC, 2002, J BIOL CHEM, V277, P21123, DOI 10.1074/jbc.M110675200; Rothlin CV, 2014, INFLAMM BOWEL DIS, V20, P1472, DOI 10.1097/MIB.0000000000000050; Sato-Kaneko F, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93397; Schaer DA, 2018, CELL REP, V22, P2978, DOI 10.1016/j.celrep.2018.02.053; Sen T, 2019, CANCER DISCOV, V9, P646, DOI 10.1158/2159-8290.CD-18-1020; Shae D, 2019, NAT NANOTECHNOL, V14, P269, DOI 10.1038/s41565-018-0342-5; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shimizu K, 2018, ANTICANCER RES, V38, P4637, DOI 10.21873/anticanres.12768; Shimizu K, 2017, CANCER MANAG RES, V9, P741, DOI 10.2147/CMAR.S146897; Sivick KE, 2018, CELL REP, V25, P3074, DOI 10.1016/j.celrep.2018.11.047; Spranger S, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-3; Steggerda SM, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0308-4; Tang HL, 2019, J PHARMACOL EXP THER, V368, P401, DOI 10.1124/jpet.118.254359; Tran L, 2017, CANCER IMMUNOL RES, V5, P1141, DOI 10.1158/2326-6066.CIR-17-0235; Tudor DV, 2020, CANCER BIOL MED, V17, P20, DOI 10.20892/j.issn.2095-3941.2019.0339; van der Zanden SY, 2020, TRENDS IMMUNOL, V41, P493, DOI 10.1016/j.it.2020.04.004; Wang ZN, 2019, J CLIN INVEST, V129, P4850, DOI 10.1172/JCI127471; Wei HF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084927; Wiemer AJ, 2011, J IMMUNOL, V187, P3663, DOI 10.4049/jimmunol.1100103; Wu JJ, 2020, IMMUNITY, V53, P115, DOI 10.1016/j.immuni.2020.06.009; Yang XB, 2020, ONCOLOGIST, V25, P470, DOI 10.1634/theoncologist.2019-0563; Yokoyama Y, 2019, CANCER RES, V79, P1996, DOI 10.1158/0008-5472.CAN-18-2022; Zhang JF, 2018, NATURE, V553, P91, DOI 10.1038/nature25015; Zhou Y, 2020, IMMUNITY, V52, P357, DOI 10.1016/j.immuni.2020.01.014; Zhu HF, 2018, NAT PRODUCT BIOPROSP, V8, P297, DOI 10.1007/s13659-018-0177-7; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	91	4	4	1	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					885	898		10.1038/s41388-020-01575-7	http://dx.doi.org/10.1038/s41388-020-01575-7		DEC 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33288883				2022-12-28	WOS:000599011200002
J	Yao, LF; Xuan, Y; Zhang, HY; Yang, B; Ma, XL; Wang, TZ; Meng, TY; Sun, WS; Wei, HB; Ma, XQ; Moses, R; Xiao, JR; Zhang, P; Ge, C; Li, JJ; Li, L; Li, XT; Li, JB; Zhang, BH				Yao, Liangfang; Xuan, Yang; Zhang, Haiyang; Yang, Bo; Ma, Xinglong; Wang, Tianzhen; Meng, Tianyuan; Sun, Wenshe; Wei, Haibin; Ma, Xueqing; Moses, Robb; Xiao, Jianru; Zhang, Pei; Ge, Chao; Li, Jinjun; Li, Lei; Li, Xiaotao; Li, Jinbao; Zhang, Bianhong			Reciprocal REG gamma-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma	ONCOGENE			English	Article							PROTEASOME ACTIVATOR; PI3K/AKT/MTOR PATHWAY; MTOR PATHWAY; CELL-GROWTH; CANCER; INHIBITION; PHOSPHATASES; INVOLVEMENT; RESISTANCE; HYPOXIA	Despite significant progression in the study of hepatocellular carcinoma (HCC), the role of the proteasome in regulating cross talk between mTOR signaling and glycolysis in liver cancer progression is not fully understood. Here, we demonstrate that deficiency of REG gamma, a proteasome activator, in mice significantly attenuates DEN-induced liver tumor formation. Ablation of REG gamma increases the stability of PP2Ac (protein phosphatase 2 catalytic subunit) in vitro and in vivo, which dephosphorylates PRAS40 (AKT1 substrate 1) and stabilizes the interaction between PRAS40 and Raptor to inactive mTORC1-mediated hyper-glycolytic metabolism. In the DEN-induced animal model and clinical hepato-carcinoma samples, high levels of REG gamma in HCC tumor regions contribute to reduced expression of PP2Ac, leading to accumulation of phosphorylated PRAS40 and mTORC1-mediated activation of HIF1 alpha. Interestingly, mTORC1 enhances REG gamma activity in HCC, forming a positive feedback regulatory loop. In conclusion, our study identifies REG gamma-PP2Ac-PRAS40 axis as a new layer in regulating mTORC1 activity and downstream glycolytic alterations during HCC development, highlighting the REG gamma-proteasome as a potential target for personalized HCC therapy.	[Yao, Liangfang; Xuan, Yang; Zhang, Haiyang; Yang, Bo; Ma, Xinglong; Wang, Tianzhen; Meng, Tianyuan; Sun, Wenshe; Wei, Haibin; Ma, Xueqing; Li, Lei; Li, Xiaotao; Zhang, Bianhong] East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Sch Life Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China; [Yao, Liangfang; Li, Jinbao] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Anesthesiol, Shanghai 201620, Peoples R China; [Moses, Robb; Li, Xiaotao] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA; [Xiao, Jianru] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, 415 Fengyang Rd, Shanghai 200003, Peoples R China; [Zhang, Pei] Second Chengdu Municipal Hosp, Dept Pathol, Chengdu 610017, Peoples R China; [Ge, Chao; Li, Jinjun] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Med, Shanghai 200032, Peoples R China	East China Normal University; Shanghai Jiao Tong University; Baylor College of Medicine; Naval Medical University; Shanghai Jiao Tong University	Li, XT; Zhang, BH (corresponding author), East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Sch Life Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.; Li, JB (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Anesthesiol, Shanghai 201620, Peoples R China.; Li, XT (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA.	xiaotaol@bcm.edu; lijingbaoshanghai@163.com; bhzhang@bio.ecnu.edu.cn	Xiao, Jian/GYU-4351-2022	wenshe, sun/0000-0003-3290-0671	National Natural Science Foundation of China [31730017, 31670882, 81672883]; Science and Technology Commission of Shanghai Municipality [19JC1411900, 16ZR1410000, 16QA1401500]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by the National Natural Science Foundation of China (31730017, 31670882, 81672883), the Science and Technology Commission of Shanghai Municipality (19JC1411900, 16ZR1410000, 16QA1401500). We thank Dr. Wei Liu from Zhejiang University for providing TSC2<SUP>-/-</SUP> cell line. We also thank the ECNU Multifunctional Platform for Innovation (011) for keeping and raising mice.	Agani F, 2013, CURR CANCER DRUG TAR, V13, P245, DOI 10.2174/1568009611313030003; Alfarouk Khalid O, 2011, Cancers (Basel), V3, P408, DOI 10.3390/cancers3010408; Alqahtani A, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55090526; Bhat M, 2013, HEPATOLOGY, V58, P810, DOI 10.1002/hep.26323; Chen XY, 2007, MOL CELL, V26, P843, DOI 10.1016/j.molcel.2007.05.022; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; Chong ZZ, 2016, DRUG DISCOV TODAY, V21, P1222, DOI 10.1016/j.drudis.2016.04.005; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dhanasekaran R, 2016, J HEPATOL, V64, P736, DOI 10.1016/j.jhep.2015.09.008; Ding M, 2016, NAT CELL BIOL, V18, P319, DOI 10.1038/ncb3311; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; Gao X, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17667-7; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gill KS, 2016, BBA-REV CANCER, V1866, P87, DOI 10.1016/j.bbcan.2016.06.005; Guo JF, 2017, CANCER LETT, V386, P161, DOI 10.1016/j.canlet.2016.08.018; Han XQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100380; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; He J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-75; Hindupur SK, 2018, NATURE, V555, P678, DOI 10.1038/nature26140; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Karim S, 2012, WORLD J GASTROENTERO, V18, P6771, DOI 10.3748/wjg.v18.i46.6771; Khemlina G, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0712-x; Kunter I, 2014, ONCOL REP, V31, P573, DOI 10.3892/or.2013.2932; Laursen Lucas, 2014, Nature, V516, pS2, DOI 10.1038/516S2a; Li S, 2015, CELL DEATH DIFFER, V22, P1000, DOI 10.1038/cdd.2014.188; Li XT, 2007, MOL CELL, V26, P831, DOI 10.1016/j.molcel.2007.05.028; Li XT, 2006, CELL, V124, P381, DOI 10.1016/j.cell.2005.11.037; Lin D, 2015, WORLD J GASTROENTERO, V21, P12171, DOI 10.3748/wjg.v21.i42.12171; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Matter MS, 2014, J HEPATOL, V60, P855, DOI 10.1016/j.jhep.2013.11.031; Mendez-Blanco C, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0159-1; Mi WT, 2015, ONCOTARGET, V6, P13962, DOI 10.18632/oncotarget.3920; Miyamoto H, 2007, J VIROL, V81, P1727, DOI 10.1128/JVI.01683-06; Moncsek A, 2015, APOPTOSIS, V20, P1211, DOI 10.1007/s10495-015-1149-6; Moriishi K, 2007, P NATL ACAD SCI USA, V104, P1661, DOI 10.1073/pnas.0607312104; Munoz-Sanchez J, 2019, J APPL TOXICOL, V39, P556, DOI 10.1002/jat.3749; Obre E, 2015, INT J BIOCHEM CELL B, V59, P167, DOI 10.1016/j.biocel.2014.12.008; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sun WJ, 2009, CELL SIGNAL, V21, P95, DOI 10.1016/j.cellsig.2008.09.012; Wang QW, 2018, CLIN CANCER RES, V24, P2015, DOI 10.1158/1078-0432.CCR-17-2986; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Xiong S, 2014, BRIT J CANCER, V110, P353, DOI 10.1038/bjc.2013.728; Yao LF, 2019, J AUTOIMMUN, V103, DOI 10.1016/j.jaut.2019.05.010; Yu J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3248-y; Zannini L, 2008, CELL CYCLE, V7, P504, DOI 10.4161/cc.7.4.5355; Zhu AX, 2014, JAMA-J AM MED ASSOC, V312, P57, DOI 10.1001/jama.2014.7189	48	6	6	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					677	692		10.1038/s41388-020-01558-8	http://dx.doi.org/10.1038/s41388-020-01558-8		NOV 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33230243				2022-12-28	WOS:000591975500001
J	Zarei, M; Giannikou, K; Du, H; Liu, HJ; Duarte, M; Johnson, S; Nassar, AH; Widlund, HR; Henske, EP; Long, HW; Kwiatkowski, DJ				Zarei, Mahsa; Giannikou, Krinio; Du, Heng; Liu, Heng-Jia; Duarte, Melissa; Johnson, Sneha; Nassar, Amin H.; Widlund, Hans R.; Henske, Elizabeth P.; Long, Henry W.; Kwiatkowski, David J.			MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61	ONCOGENE			English	Article							TUBEROUS SCLEROSIS COMPLEX; CELL-GROWTH; MICROPHTHALMIA; GENE; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION; TUMORIGENESIS; ACTIVATION; EXPRESSION	Tuberous sclerosis complex (TSC) is an autosomal dominant tumor suppressor syndrome, characterized by tumor development in multiple organs, including renal angiomyolipoma. Biallelic loss of TSC1 or TSC2 is a known genetic driver of angiomyolipoma development, however, whether an altered transcriptional repertoire contributes to TSC-associated tumorigenesis is unknown. RNA-seq analyses showed that MITF A isoform (MITF-A) was consistently highly expressed in angiomyolipoma, immunohistochemistry showed microphthalmia-associated transcription factor nuclear localization, and Chromatin immuno-Precipitation Sequencing analysis showed that the MITF-A transcriptional start site was highly enriched with H3K27ac marks. Using the angiomyolipoma cell line 621-101, MITF knockout (MITF.KO) and MITF-A overexpressing (MITF.OE) cell lines were generated. MITF.KO cells showed markedly reduced growth and invasion in vitro, and were unable to form xenografted tumors. In contrast, MITF.OE cells grew faster in vitro and as xenografted tumors compared to control cells. RNA-Seq analysis showed that both ID2 and Cysteine-rich angiogenic inducer 61 (CYR61) expression levels were increased in the MITF.OE cells and reduced in the MITF.KO cells, and luciferase assays showed this was due to transcriptional effects. Importantly, CYR61 overexpression rescued MITF.KO cell growth in vitro and tumor growth in vivo. These findings suggest that MITF-A is a transcriptional oncogenic driver of angiomyolipoma tumor development, acting through regulation of CYR61.	[Zarei, Mahsa; Giannikou, Krinio; Du, Heng; Nassar, Amin H.; Kwiatkowski, David J.] Brigham & Womens Hosp, Dept Med, Canc Genet Lab, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Zarei, Mahsa; Giannikou, Krinio; Du, Heng; Liu, Heng-Jia; Duarte, Melissa; Nassar, Amin H.; Widlund, Hans R.; Henske, Elizabeth P.; Long, Henry W.; Kwiatkowski, David J.] Harvard Med Sch, Boston, MA 02115 USA; [Zarei, Mahsa; Johnson, Sneha] Texas A&M Univ, Dept Vet Physiol & Pharmacol, Coll Vet Med & Biomed Sci, College Stn, TX 77843 USA; [Giannikou, Krinio; Duarte, Melissa; Long, Henry W.] Dana Farber Canc Inst, Dept Med Oncol, Ctr Funct Canc Epigenet, Boston, MA 02115 USA; [Liu, Heng-Jia; Henske, Elizabeth P.] Brigham & Womens Hosp, Dept Med, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Widlund, Hans R.] Brigham & Womens Hosp, Dept Dermatol, 75 Francis St, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Texas A&M University System; Texas A&M University College Station; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Kwiatkowski, DJ (corresponding author), Brigham & Womens Hosp, Dept Med, Canc Genet Lab, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.; Kwiatkowski, DJ (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	dk@rics.bwh.harvard.edu	Giannikou, Krinio/AAC-9214-2022	Nassar, Amin/0000-0002-8084-9105; Zarei, Mahsa/0000-0002-0554-6163; Du, Heng/0000-0001-9067-0910	Engles Fund for TSC and LAM; University of Pennsylvania Orphan Disease Center; LAM Foundation; NIH NCI [1P01CA120964];  [DOD-18-1-0592];  [DOD-17-1-0205]	Engles Fund for TSC and LAM; University of Pennsylvania Orphan Disease Center; LAM Foundation; NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; 	This work was supported by the Engles Fund for TSC and LAM; the University of Pennsylvania Orphan Disease Center in partnership with the LAM Foundation; DOD-18-1-0592 (MZ), DOD-17-1-0205 (KG), and the NIH NCI 1P01CA120964 (DJK).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Badri KR, 2013, AM J RESP CRIT CARE, V187, P663, DOI 10.1164/ajrccm.187.6.663; Ben-Sahra I, 2016, SCIENCE, V351, P728, DOI 10.1126/science.aad0489; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; BONETTI F, 1993, AM J SURG PATHOL, V17, P1092, DOI 10.1097/00000478-199311000-00002; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Dhar A., 2010, Experimental Oncology, V32, P2; Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gery S, 2005, CLIN CANCER RES, V11, P7243, DOI 10.1158/1078-0432.CCR-05-0231; Giannikou K, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006242; Harbst K, 2012, CLIN CANCER RES, V18, P4026, DOI 10.1158/1078-0432.CCR-12-0343; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Henske EP, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.35; Hoek KS, 2008, PIGM CELL MELANOMA R, V21, P665, DOI 10.1111/j.1755-148X.2008.00505.x; Hsiao JJ, 2014, ARCH BIOCHEM BIOPHYS, V563, P28, DOI 10.1016/j.abb.2014.07.019; Huang YT, 2016, ONCOTARGET, V7, P1663, DOI 10.18632/oncotarget.6411; Johansson CH, 2013, MELANOMA RES, V23, P360, DOI 10.1097/CMR.0b013e328362f9cd; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Lau LF, 2011, CELL MOL LIFE SCI, V68, P3149, DOI 10.1007/s00018-011-0778-3; Li CG, 2014, J EXP MED, V211, P15, DOI 10.1084/jem.20131080; Lin MT, 2005, CLIN CANCER RES, V11, P5809, DOI 10.1158/1078-0432.CCR-04-2639; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Martin KR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15816; Mayer S, 2017, ONCOL LETT, V14, P2334, DOI 10.3892/ol.2017.6406; McCormack FX, 2011, NEW ENGL J MED, V364, P1595, DOI 10.1056/NEJMoa1100391; NELLIST M, 1993, CELL, V75, P1305; Tong XJ, 2004, ONCOGENE, V23, P4847, DOI 10.1038/sj.onc.1207628; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wellbrock C, 2015, PIGM CELL MELANOMA R, V28, P390, DOI 10.1111/pcmr.12370; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6; Yu J, 2004, AM J PHYSIOL-LUNG C, V286, pL694, DOI 10.1152/ajplung.00204.2003; Zarei M, 2019, J EXP MED, V216, P2635, DOI 10.1084/jem.20190251; Zarei M, 2017, CANCER RES, V77, P4460, DOI 10.1158/0008-5472.CAN-17-0015; Zavala-Pompa A, 2001, AM J SURG PATHOL, V25, P65, DOI 10.1097/00000478-200101000-00007; Zhang HY, 2011, P NATL ACAD SCI USA, V108, P2270, DOI 10.1073/pnas.1019603108; Zhang YN, 2014, NATURE, V513, P440, DOI 10.1038/nature13492	46	6	6	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					112	126		10.1038/s41388-020-01504-8	http://dx.doi.org/10.1038/s41388-020-01504-8		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33082558	Green Accepted			2022-12-28	WOS:000582339900001
J	Miller, AK; Tavera, G; Dominguez, RL; Camargo, MC; Waterboer, T; Wilson, KT; Williams, SM; Morgan, DR				Miller, Anna K.; Tavera, Gloria; Dominguez, Ricardo L.; Camargo, M. Constanza; Waterboer, Tim; Wilson, Keith T.; Williams, Scott M.; Morgan, Douglas R.			Ornithine decarboxylase (ODC1) gene variant (rs2302615) is associated with gastric cancer independently of Helicobacter pylori CagA serostatus	ONCOGENE			English	Article							CHRONIC ATROPHIC GASTRITIS; INCREASED RISK; MACROPHAGE ACTIVATION; INFECTION; SUSCEPTIBILITY; POLYMORPHISMS; INFLAMMATION; METAANALYSIS; ADENOCARCINOMA; PREVALENCE	The primary cause of gastric cancer is chronic infection with Helicobacter pylori (H. pylori), particularly the high-risk genotype cagA, and risk modification by human genetic variants. We studied 94 variants in 54 genes for association with gastric cancer, including rs2302615 in ornithine decarboxylase (ODC1), which may affect response to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO). Our population-based, case-control study included 1366 individuals (664 gastric cancer cases and 702 controls) from Western Honduras, a high incidence region of Latin America. CagA seropositivity was strongly associated with cancer (OR = 3.6; 95% CI: 2.6, 5.1). The ODC1 variant rs2302615 was associated with gastric cancer (OR = 1.36; p = 0.018) in a model adjusted for age, sex, and CagA serostatus. Two additional single nucleotide polymorphisms (SNPs) in CASP1 (rs530537) and TLR4 (rs1927914) genes were also associated with gastric cancer in univariate models as well as models adjusted for age, sex, and CagA serostatus. The ODC1 SNP association with gastric cancer was stronger in individuals who carried the TT genotype at the associating TLR4 polymorphism, rs1927914 (OR = 1.77; p = 1.85 x 10(-3)). In conclusion, the ODC1 variant, rs2302615, is associated with gastric cancer and supports chemoprevention trials with DFMO, particularly in individuals homozygous for the T allele at rs1927914.	[Miller, Anna K.; Williams, Scott M.] Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA; [Tavera, Gloria; Williams, Scott M.] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Dominguez, Ricardo L.] Minist Hlth, Hosp Occidente, Santa Rosa De Copan, Copan, Honduras; [Camargo, M. Constanza] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA; [Waterboer, Tim] German Canc Res Ctr, Infect & Canc Epidemiol, Heidelberg, Germany; [Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Div Gastroenterol Hepatol & Nutr, Nashville, TN USA; [Wilson, Keith T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA; [Morgan, Douglas R.] Univ Alabama Birmingham UAB, UAB Div Gastroenterol & Hepatol, Birmingham, AL 35294 USA	Case Western Reserve University; Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Helmholtz Association; German Cancer Research Center (DKFZ); Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University of Alabama System; University of Alabama Birmingham	Williams, SM (corresponding author), Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA.; Williams, SM (corresponding author), Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA.; Morgan, DR (corresponding author), Univ Alabama Birmingham UAB, UAB Div Gastroenterol & Hepatol, Birmingham, AL 35294 USA.	smw154@case.edu; drmorgan@uabmc.edu	Camargo, M. Constanza/R-9891-2016; Williams, Scott/Q-4812-2019	Camargo, M. Constanza/0000-0002-1065-2198; Williams, Scott/0000-0002-4835-9544; Miller, Anna/0000-0003-0504-6510; Wilson, Keith/0000-0003-4421-1830	U.S. National Cancer Institute [P01CA028842, R01CA190612, K07 CA125588, PAR-15-155, P30CA068485, P01CA116087]; Veterans Affairs Merit Review grant [I01CX002171]; Department of Defense [W81XWH-18-1-0301]; NIH [T32HL007567]; National Library of Medicine [1R01LM010098]	U.S. National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs Merit Review grant(US Department of Veterans Affairs); Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Library of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	This study was funded in part by the U.S. National Cancer Institute (P01CA028842 (DRM, KTW, SMW), R01CA190612 (DRM, KTW), K07 CA125588 (DRM), PAR-15-155 (DRM), P30CA068485 (DRM, KTW), P01CA116087 (KTW)), Veterans Affairs Merit Review grant I01CX002171 (KTW), Department of Defense grant W81XWH-18-1-0301 (KTW), NIH T32HL007567 (AKM), and National Library of Medicine 1R01LM010098 (SMW). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the paper. SBR, RLD, RM, and DRM had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. DRM had final responsibility for the decision to submit for publication.	Abnet CC, 2010, NAT GENET, V42, P764, DOI 10.1038/ng.649; Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3; Asim M, 2010, J BIOL CHEM, V285, P20343, DOI 10.1074/jbc.M110.116988; Auton A., 2015, NATURE, V7571, P68, DOI 10.1038/nature15393; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BLASER MJ, 1995, CANCER RES, V55, P2111; Bonder MJ, 2016, NAT GENET, V48, P1407, DOI 10.1038/ng.3663; Bonequi P, 2013, CANCER CAUSE CONTROL, V24, P217, DOI 10.1007/s10552-012-0110-z; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burucoa C, 2017, HELICOBACTER, V22, DOI 10.1111/hel.12403; Butt J, 2020, CANCER CAUSE CONTROL, V31, P601, DOI 10.1007/s10552-020-01295-z; Cai H, 2016, INT J EPIDEMIOL, V45, P774, DOI 10.1093/ije/dyw078; Camargo MC, 2012, CANCER EPIDEM BIOMAR, V21, P20, DOI 10.1158/1055-9965.EPI-11-0834; Castano-Rodriguez N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098899; Chaturvedi R, 2015, ONCOGENE, V34, P3429, DOI 10.1038/onc.2014.273; Cheng Y, 2005, J BIOL CHEM, V280, P22492, DOI 10.1074/jbc.C500122200; Cho LY, 2015, GASTRIC CANCER, V18, P495, DOI 10.1007/s10120-014-0396-5; Correa P, 1996, CANCER EPIDEM BIOMAR, V5, P477; de Martel C, 2006, DIGEST DIS SCI, V51, P2292, DOI 10.1007/s10620-006-9210-5; de Martel C, 2020, LANCET GLOB HEALTH, V8, pE180, DOI 10.1016/S2214-109X(19)30488-7; Dominguez RL, 2013, CANCER CAUSE CONTROL, V24, P233, DOI 10.1007/s10552-012-0109-5; El-Omar EM, 2003, GASTROENTEROLOGY, V124, P1193, DOI 10.1016/S0016-5085(03)00157-4; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Epplein M, 2012, CANCER EPIDEM BIOMAR, V21, P2185, DOI 10.1158/1055-9965.EPI-12-0792-T; Fox JG, 2007, J CLIN INVEST, V117, P60, DOI 10.1172/JCI30111; Gao L, 2009, CANCER RES, V69, P2973, DOI 10.1158/0008-5472.CAN-08-3477; Gong YF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149629; Gonzalez-Hormazabal P, 2020, MOL BIOL REP, V47, P9239, DOI 10.1007/s11033-020-05943-0; Greene CS, 2015, NAT GENET, V47, P569, DOI 10.1038/ng.3259; Haley KP, 2016, GASTROENT RES PRACT, V2016, DOI 10.1155/2016/3019362; Hardbower DM, 2017, ONCOGENE, V36, P3807, DOI 10.1038/onc.2017.23; Hardbower DM, 2017, P NATL ACAD SCI USA, V114, pE751, DOI 10.1073/pnas.1614958114; Hardbower DM, 2014, J LEUKOCYTE BIOL, V96, P201, DOI 10.1189/jlb.4BT0214-099R; Hardbower DM, 2013, GUT MICROBES, V4, P475, DOI 10.4161/gmic.25583; Hitzler I, 2012, J IMMUNOL, V188, P3594, DOI 10.4049/jimmunol.1103212; Jakszyn P, 2006, CARCINOGENESIS, V27, P1497, DOI 10.1093/carcin/bgl019; Jensen Klaus Hojgaard, 2018, Oncotarget, V9, P9043, DOI 10.18632/oncotarget.24138; Jin JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106580; Kavermann H, 2003, J EXP MED, V197, P813, DOI 10.1084/jem.20021531; Kim JJ, 2002, GASTROENTEROLOGY, V123, P542, DOI 10.1053/gast.2002.34751; Koch KN, 2015, GUT MICROBES, V6, P382, DOI 10.1080/19490976.2015.1105427; Koch KN, 2015, J CLIN INVEST, V125, P3297, DOI 10.1172/JCI79337; Kodaman N, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00290; Kodaman N, 2014, P NATL ACAD SCI USA, V111, P1455, DOI 10.1073/pnas.1318093111; Kolde R, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0515-8; Kupfer SS, 2017, GASTROENTEROLOGY, V152, P926, DOI 10.1053/j.gastro.2017.02.026; Kurilshikov A, 2017, TRENDS IMMUNOL, V38, P633, DOI 10.1016/j.it.2017.06.003; La Torre G, 2009, TUMORI, V95, P13; Li W, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18452-1; Li X, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftu024; Martinez ME, 2003, P NATL ACAD SCI USA, V100, P7859, DOI 10.1073/pnas.1332465100; Michel A, 2009, HELICOBACTER, V14, P525, DOI 10.1111/j.1523-5378.2009.00723.x; Miller KD, 2018, CA-CANCER J CLIN, V68, P425, DOI 10.3322/caac.21494; Mondaca S, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.03.27; Morgan DR, 2006, CLIN GASTROENTEROL H, V4, P1103, DOI 10.1016/j.cgh.2006.05.025; Pabla BS, 2020, CLIN GASTROENTEROL H, V18, P347, DOI 10.1016/j.cgh.2019.05.032; Park JY, 2018, TOXINS, V10, DOI 10.3390/toxins10040163; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Peek RM, 1995, LAB INVEST, V73, P760; Pegg AE, 2006, J BIOL CHEM, V281, P14529, DOI 10.1074/jbc.R500031200; Pegg AE, 2009, IUBMB LIFE, V61, P880, DOI 10.1002/iub.230; Pormohammad A, 2018, MICROB PATHOGENESIS, V118, P214, DOI 10.1016/j.micpath.2018.03.004; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; REPLOGLE ML, 1995, AM J EPIDEMIOL, V142, P856, DOI 10.1093/oxfordjournals.aje.a117725; Rolig AS, 2013, INFECT IMMUN, V81, P1382, DOI 10.1128/IAI.00044-13; Rowland M, 2006, GASTROENTEROLOGY, V130, P65, DOI 10.1053/j.gastro.2005.11.004; Sakamoto H, 2008, NAT GENET, V40, P730, DOI 10.1038/ng.152; Shi YY, 2011, NAT GENET, V43, P1215, DOI 10.1038/ng.978; Sierra JC, 2020, ONCOGENE, V39, P4465, DOI 10.1038/s41388-020-1304-6; Sierra JC, 2019, P NATL ACAD SCI USA, V116, P5077, DOI 10.1073/pnas.1814497116; Singh K, 2018, CANCER RES, V78, P4303, DOI 10.1158/0008-5472.CAN-18-0116; Smith Sinead M, 2014, World J Gastrointest Pathophysiol, V5, P133, DOI 10.4291/wjgp.v5.i3.133; Snaith Ailsa, 2008, Expert Rev Gastroenterol Hepatol, V2, P577, DOI 10.1586/17474124.2.4.577; Song HR, 2013, MOL CARCINOGEN, V52, P155, DOI 10.1002/mc.22063; Su B, 2003, INFECT IMMUN, V71, P3496, DOI 10.1128/IAI.71.6.3496-3502.2003; Takenaka R, 2004, MICROBIOL-SGM, V150, P3913, DOI 10.1099/mic.0.27527-0; Tavera G, 2018, CURR GENET MED REP, V6, P199, DOI 10.1007/s40142-018-0153-x; Terlizzi M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00670; Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109; Tian J, 2019, CANCER BIOL MED, V16, P361, DOI 10.20892/j.issn.2095-3941.2018.0290; Torres J, 2013, CANCER CAUSE CONTROL, V24, P249, DOI 10.1007/s10552-012-0114-8; Varga MG, 2021, GUT MICROBES, V13, P1, DOI 10.1080/19490976.2020.1862613; Venerito M, 2018, HELICOBACTER, V23, DOI 10.1111/hel.12518; Wang TR, 2014, INT J CLIN EXP PATHO, V7, P6950; Weck MN, 2009, EPIDEMIOLOGY, V20, P569, DOI 10.1097/EDE.0b013e3181a3d5f4; Wilson KT, 2007, GASTROENTEROLOGY, V133, P288, DOI 10.1053/j.gastro.2007.05.008; Yang JC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/248585; Zambon CF, 2005, CYTOKINE, V29, P141, DOI 10.1016/j.cyto.2004.10.013; Zell JA, 2010, J NATL CANCER I, V102, P1513, DOI 10.1093/jnci/djq325; Zell JA, 2009, CLIN CANCER RES, V15, P6208, DOI 10.1158/1078-0432.CCR-09-0592; Zhu YL, 2017, EXP THER MED, V14, P3304, DOI 10.3892/etm.2017.4904	91	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5963	5969		10.1038/s41388-021-01981-5	http://dx.doi.org/10.1038/s41388-021-01981-5		AUG 2021	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34376808	Green Accepted, Green Submitted			2022-12-28	WOS:000683685200001
J	Kanda, M; Shimizu, D; Nakamura, S; Sawaki, K; Umeda, S; Miwa, T; Tanaka, H; Inokawa, Y; Hattori, N; Hayashi, M; Tanaka, C; Nakayama, G; Iguchi, Y; Katsuno, M; Kodera, Y				Kanda, Mitsuro; Shimizu, Dai; Nakamura, Shunsuke; Sawaki, Koichi; Umeda, Shinichi; Miwa, Takashi; Tanaka, Haruyoshi; Inokawa, Yoshikuni; Hattori, Norifumi; Hayashi, Masamichi; Tanaka, Chie; Nakayama, Goro; Iguchi, Yohei; Katsuno, Masahisa; Kodera, Yasuhiro			Blockade of CHRNB2 signaling with a therapeutic monoclonal antibody attenuates the aggressiveness of gastric cancer cells	ONCOGENE			English	Article							PERITONEAL METASTASIS; PROLIFERATION; RECEPTORS; SMOKING; GENES	Here, we evaluated the therapeutic potential of antibodies (Abs) targeting cholinergic receptor nicotinic beta 2 subunit (CHRNB2) in gastric cancer. To investigate the effects of these Abs on malignant phenotypes in vitro and in mouse xenograft models, we generated gene knockouts through genome editing, performed RNA interference-mediated knockdown of gene expression, and ectopically expressed CHRNB2 in gastric cancer cells. The effects of anti-CHRNB2 Abs on the proliferation of cancer cells were evaluated both in vitro and in vivo. We determined the effects of Chrnb2 deficiency on mice and the clinical significance of CHRNB2 expression in gastric cancer clinical specimens. Knockdown of CHRNB2 attenuated gastric cancer cell proliferation, whereas forced overexpression of CHRNB2 increased cell proliferation. Knockout of CHRNB2 significantly influenced cell survival and functions associated with metastasis. The effects of polyclonal Abs targeting the C- and N-termini of CHRNB2 guided the development of anti-CHRNB2 monoclonal Abs that inhibited the growth of gastric cancer cells in vitro and in vivo. Pathway analysis revealed that CHRNB2 interfered with signaling through the PI3K-AKT and JAK-STAT pathways. Chrnb2-deficient mice exhibited normal reproduction, organ functions, and motor functions. CHRNB2 regulates multiple oncological phenotypes associated with metastasis, and blockade of CHRNB2 expression using specific Abs shows promise for controlling metastasis in gastric cancer.	[Kanda, Mitsuro; Shimizu, Dai; Nakamura, Shunsuke; Sawaki, Koichi; Umeda, Shinichi; Miwa, Takashi; Tanaka, Haruyoshi; Inokawa, Yoshikuni; Hattori, Norifumi; Hayashi, Masamichi; Tanaka, Chie; Nakayama, Goro; Kodera, Yasuhiro] Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Nagoya, Aichi, Japan; [Iguchi, Yohei; Katsuno, Masahisa] Nagoya Univ, Grad Sch Med, Dept Neurol, Nagoya, Aichi, Japan	Nagoya University; Nagoya University	Kanda, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Nagoya, Aichi, Japan.	m-kanda@med.nagoya-u.ac.jp	Kanda, Mitsuro/M-4891-2014; Hayashi, Masamichi/P-9743-2015	Kanda, Mitsuro/0000-0001-5464-3819; Hayashi, Masamichi/0000-0001-6875-2303; Tanaka, Haruyoshi/0000-0003-0079-8422	Japan Agency for Medical Research and Development [20H03750, 17lm0203005j0001]; Center for Advanced Medicine and Clinical Research at Nagoya University; Japan Research Foundation for Clinical Pharmacology; Foundation for Promotion of Cancer Research; Kobayashi Foundation for Cancer Research; Mochida Memorial Foundation for Medical and Pharmaceutical Research	Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Center for Advanced Medicine and Clinical Research at Nagoya University; Japan Research Foundation for Clinical Pharmacology; Foundation for Promotion of Cancer Research; Kobayashi Foundation for Cancer Research(Kobayashi Foundation for Cancer Research); Mochida Memorial Foundation for Medical and Pharmaceutical Research	We thank Edanz Group (https://en-author-services.edanz.com/ac) and the SPRINGER NATURE English Language Editing service (https://authorservices.springernature.com/language-editing/) for editing a draft of this manuscript. This work was supported by a Grant-in-Aid for Scientific Research (B, 20H03750), the Japan Agency for Medical Research and Development (17lm0203005j0001, 2017); the Center for Advanced Medicine and Clinical Research at Nagoya University (2018); a grant (2018) from the Japan Research Foundation for Clinical Pharmacology, Foundation for Promotion of Cancer Research, Kobayashi Foundation for Cancer Research; and the Mochida Memorial Foundation for Medical and Pharmaceutical Research.	Ambrosi P, 2013, RECENT PAT ANTI-CANC, V8, P38; Bang YJ, 2010, LANCET, V376, P1302; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Calcagno DQ, 2013, WORLD J GASTROENTERO, V19, P1182, DOI 10.3748/wjg.v19.i8.1182; Chen JW, 2019, SURG ONCOL, V31, P46, DOI 10.1016/j.suronc.2019.09.003; Chen ZH, 2015, INT J CLIN EXP MED, V8, P9063; Cheng WL, 2020, J CANCER, V11, P1125, DOI 10.7150/jca.36359; Dasgupta P, 2009, INT J CANCER, V124, P36, DOI 10.1002/ijc.23894; Ehringer MA, 2007, AM J MED GENET B, V144B, P596, DOI 10.1002/ajmg.b.30464; Gao JF, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0072-1; Ibrahim SM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35254-1; Janjigian YY, 2013, J SURG ONCOL, V107, P237, DOI 10.1002/jso.23263; Kanda M, 2020, MOL THER-NUCL ACIDS, V22, P791, DOI 10.1016/j.omtn.2020.10.001; Kanda M, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01251-0; Kanda M, 2020, GASTRIC CANCER, V23, P203, DOI 10.1007/s10120-019-00995-z; Kanda M, 2018, ONCOGENE, V37, P5355, DOI 10.1038/s41388-018-0335-8; Kanda M, 2018, ANN SURG, V267, P495, DOI 10.1097/SLA.0000000000002096; Kanda M, 2016, INT J CANCER, V138, P721, DOI 10.1002/ijc.29803; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Miwa T, 2021, BRIT J CANCER, V124, P1449, DOI 10.1038/s41416-021-01271-7; Muro K, 2016, LANCET ONCOL, V17, P717, DOI 10.1016/S1470-2045(16)00175-3; Pedersen JE, 2019, BMC EVOL BIOL, V19, DOI 10.1186/s12862-018-1341-8; Perkins KA, 2009, CANCER EPIDEM BIOMAR, V18, P2608, DOI 10.1158/1055-9965.EPI-09-0166; Razzak Mina, 2014, Nat Rev Clin Oncol, V11, P499, DOI 10.1038/nrclinonc.2014.138; Schaal C, 2014, MOL CANCER RES, V12, P14, DOI 10.1158/1541-7786.MCR-13-0541; Shen Lin, 2013, Lancet Oncol, V14, pe535, DOI 10.1016/S1470-2045(13)70436-4; Shitara K, 2018, LANCET, V392, P123, DOI 10.1016/S0140-6736(18)31257-1; Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Thrift AP, 2020, CLIN GASTROENTEROL H, V18, P534, DOI 10.1016/j.cgh.2019.07.045; Umeda S, 2020, INT J CANCER, V146, P2865, DOI 10.1002/ijc.32705; Vandamme N, 2020, CANCER RES, V80, P2983, DOI 10.1158/0008-5472.CAN-19-2373; Velazquez EJ, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01198-8; Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170; Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025; Zahavi D, 2020, ANTIBODIES, V9, DOI 10.3390/antib9030034; Zhang ZW, 2019, J CANCER, V10, P3860, DOI 10.7150/jca.31291; Zhao Rongqing, 2020, Antib Ther, V3, P63, DOI 10.1093/abt/tbaa004	39	4	4	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5495	5504		10.1038/s41388-021-01945-9	http://dx.doi.org/10.1038/s41388-021-01945-9		JUL 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34331011				2022-12-28	WOS:000679620500001
J	Wang, J; Yan, HB; Zhang, Q; Liu, WY; Jiang, YH; Peng, G; Wu, FZ; Liu, X; Yang, PY; Liu, F				Wang, Jie; Yan, Hai-Bo; Zhang, Qian; Liu, Wei-Yan; Jiang, Ying-Hua; Peng, Gang; Wu, Fei-Zhen; Liu, Xin; Yang, Peng-Yuan; Liu, Feng			Enhancement of E-cadherin expression and processing and driving of cancer cell metastasis by ARID1A deficiency	ONCOGENE			English	Article							REMODELING GENE ARID1A; TUMOR-SUPPRESSOR; MUTATIONS; LANDSCAPE; INVASION; MIGRATION; CLEAVAGE; FRAGMENT; DOMAIN	The ARID1A gene, which encodes a subunit of the SWI/SNF chromatin remodeling complex, has been found to be frequently mutated in many human cancer types. However, the function and mechanism of ARID1A in cancer metastasis are still unclear. Here, we show that knockdown of ARID1A increases the ability of breast cancer cells to proliferate, migrate, invade, and metastasize in vivo. The ARID1A-related SWI/SNF complex binds to the second exon of CDH1 and negatively modulates the expression of E-cadherin/CDH1 by recruiting the transcriptional repressor ZEB2 to the CDH1 promoter and excluding the presence of RNA polymerase II. The silencing of CDH1 attenuated the migration, invasion, and metastasis of breast cancer cells in which ARID1A was silenced. ARID1A depletion increased the intracellular enzymatic processing of E-cadherin and the production of C-terminal fragment 2 (CTF2) of E-cadherin, which stabilized beta-catenin by competing for binding to the phosphorylation and degradation complex of beta-catenin. The matrix metalloproteinase inhibitor GM6001 inhibited the production of CTF2. In zebrafish and nude mice, ARID1A silencing or CTF2 overexpression activated beta-catenin signaling and promoted migration/invasion and metastasis of cancer cells in vivo. The inhibitors GM6001, BB94, and ICG-001 suppressed the migration and invasion of cancer cells with ARID1A-deficiency. Our findings provide novel insights into the mechanism of ARID1A metastasis and offer a scientific basis for targeted therapy of ARID1A-deficient cancer cells.	[Wang, Jie; Yan, Hai-Bo; Zhang, Qian; Liu, Wei-Yan; Jiang, Ying-Hua; Yang, Peng-Yuan; Liu, Feng] Fudan Univ, Minhang Hosp, Shanghai, Peoples R China; [Wang, Jie; Yan, Hai-Bo; Zhang, Qian; Liu, Wei-Yan; Jiang, Ying-Hua; Yang, Peng-Yuan; Liu, Feng] Fudan Univ, Int Colab Med Epigenet & Metab, Minist Sci & Technol, Inst Biomed Sci,Shanghai Key Lab Med Epigenet, Shanghai, Peoples R China; [Peng, Gang] Fudan Univ, Inst Brain Sci, Shanghai, Peoples R China; [Wu, Fei-Zhen; Yang, Peng-Yuan; Liu, Feng] Fudan Univ, Sch Basic Med Sci, Dept Syst Biol Med, Shanghai, Peoples R China; [Liu, Xin] Shanghai Univ Tradit Chinese Med, Shanghai Municipal Hosp Tradit Chinese Med, Dept Cent Lab Med, Shanghai, Peoples R China; [Yang, Peng-Yuan] Fudan Univ, Dept Chem, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Shanghai University of Traditional Chinese Medicine; Fudan University	Yang, PY; Liu, F (corresponding author), Fudan Univ, Minhang Hosp, Shanghai, Peoples R China.; Yang, PY; Liu, F (corresponding author), Fudan Univ, Int Colab Med Epigenet & Metab, Minist Sci & Technol, Inst Biomed Sci,Shanghai Key Lab Med Epigenet, Shanghai, Peoples R China.; Yang, PY; Liu, F (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Syst Biol Med, Shanghai, Peoples R China.; Yang, PY (corresponding author), Fudan Univ, Dept Chem, Shanghai, Peoples R China.	pyyang@fudan.edu.cn; liuf@fudan.edu.cn	Wu, Feizhen/AGR-5215-2022	Wang, Jie/0000-0002-4134-1624; peng, gang/0000-0001-6625-5426; LIU, Feng/0000-0003-1933-9437	National Natural Science Foundation of China (NSFC) [81572833, 22074020]; Chinese National Key Program on Basic Research Grant [2011CB910702, 2013CB911202]; Natural Science Foundation of Shanghai [14ZR1402100]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Chinese National Key Program on Basic Research Grant; Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai)	We acknowledge Yi-Yuan Ren, Jia-Hui Li, and Xiao-Qiang Chai for their helps in experiments. The work was supported by the National Natural Science Foundation of China (NSFC) (81572833, 22074020), Chinese National Key Program on Basic Research Grant (2011CB910702, 2013CB911202), and the Natural Science Foundation of Shanghai (14ZR1402100).	Berns K, 2016, CLIN CANCER RES, V22, P5238, DOI 10.1158/1078-0432.CCR-15-2996; Bitler BG, 2017, NAT CELL BIOL, V19, P962, DOI 10.1038/ncb3582; Chandler RL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7118; Cho HD, 2015, J BREAST CANCER, V18, P339, DOI 10.4048/jbc.2015.18.4.339; Fearon ER, 2003, CANCER CELL, V3, P307, DOI 10.1016/S1535-6108(03)00087-4; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Guan B, 2011, CANCER RES, V71, P6718, DOI 10.1158/0008-5472.CAN-11-1562; Guo X, 2018, ONCOGENE, V37, P5939, DOI 10.1038/s41388-018-0371-4; Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480; Hu CB, 2018, J HEPATOL, V68, P465, DOI 10.1016/j.jhep.2017.10.028; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; Kim H, 2012, BBA-MOL BASIS DIS, V1822, P509, DOI 10.1016/j.bbadis.2011.12.015; Li C, 2017, NEOPLASMA, V64, P367, DOI 10.4149/neo_2017_307; Liang H, 2012, GENOME RES, V22, P2120, DOI 10.1101/gr.137596.112; Liang X, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1007-x; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marchio C, 2017, J PATHOL, V241, P405, DOI 10.1002/path.4837; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; Ng CKY, 2017, CLIN CANCER RES, V23, P3859, DOI 10.1158/1078-0432.CCR-16-2857; Noe V, 2001, J CELL SCI, V114, P111; Pinheiro H, 2012, HUM MOL GENET, V21, P4253, DOI 10.1093/hmg/dds248; Ryniers F, 2002, BIOL CHEM, V383, P159, DOI 10.1515/BC.2002.016; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Sanchez-Tillo E, 2011, AM J CANCER RES, V1, P897; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Simcha I, 2001, MOL BIOL CELL, V12, P1177, DOI 10.1091/mbc.12.4.1177; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Sun XX, 2016, CELL STEM CELL, V18, P456, DOI 10.1016/j.stem.2016.03.001; Svensson S, 2015, CLIN CANCER RES, V21, P3794, DOI 10.1158/1078-0432.CCR-15-0204; Tsurusaki Y, 2014, CLIN GENET, V85, P548, DOI 10.1111/cge.12225; Uncel M, 2019, EUR J BREAST HEALTH, V15, P125, DOI 10.5152/ejbh.2019.4677; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Cespedes MV, 2010, AM J PATHOL, V177, P2067, DOI 10.2353/ajpath.2010.100079; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wu JN, 2013, CANCER DISCOV, V3, P35, DOI 10.1158/2159-8290.CD-12-0361; Xu GT, 2020, NAT GENET, V52, P198, DOI 10.1038/s41588-019-0554-0; Yan HB, 2014, CARCINOGENESIS, V35, P867, DOI 10.1093/carcin/bgt398; Zhang Q, 2016, ONCOTARGET, V7, P46127, DOI 10.18632/oncotarget.10060; Zhu M, 2019, CELL, V177, P608, DOI 10.1016/j.cell.2019.03.026	46	5	5	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5468	5481		10.1038/s41388-021-01930-2	http://dx.doi.org/10.1038/s41388-021-01930-2		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34290402				2022-12-28	WOS:000677857200003
J	Kaluz, S; Zhang, Q; Kuranaga, Y; Yang, H; Osuka, S; Bhattacharya, D; Devi, NS; Mun, J; Wang, W; Zhang, RW; Goodman, MM; Grossniklaus, HE; Van Meir, EG				Kaluz, Stefan; Zhang, Qing; Kuranaga, Yuki; Yang, Hua; Osuka, Satoru; Bhattacharya, Debanjan; Devi, Narra S.; Mun, Jiyoung; Wang, Wei; Zhang, Ruiwen; Goodman, Mark M.; Grossniklaus, Hans E.; Van Meir, Erwin G.			Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth	ONCOGENE			English	Article							VEGF-A; CANCER; BREAST; MODEL; PEDF	Uveal melanoma (UM) is the most prevalent primary intraocular malignancy in adults, and patients that develop metastases (similar to 50%) survive <1 year, highlighting the urgent need for new therapies. TCGA has recently revealed that a hypoxia gene signature is associated with poor UM patient prognosis. Here we show that expression of hypoxia-regulated collagen prolyl-4-hydroxylase genes P4HA1 and P4HA2 is significantly upregulated in UM patients with metastatic disease and correlates with poor prognosis, suggesting these enzymes might be key tumor drivers. We targeted hypoxia-induced expression of P4HA1/2 in UM with KCN1, a hypoxia inducible factor-1 (HIF-1) pathway inhibitor and found potent inhibition of primary and metastatic disease and extension of animal survival, without overt side effects. At the molecular level, KCN1 antagonized hypoxia-induced expression of P4HA1 and P4HA2, which regulate collagen maturation and deposition in the extracellular matrix. The treatment decreased prolyl hydroxylation, induced proteolytic cleavage and rendered a disordered structure to collagen VI, the main collagen produced by UM, and reduced UM cell invasion. Together, these data demonstrate that extracellular collagen matrix formation can be targeted in UM by inhibiting hypoxia-induced P4HA1 and P4HA2 expression, warranting further development of this strategy in patients with uveal melanoma.	[Kaluz, Stefan; Osuka, Satoru; Bhattacharya, Debanjan; Devi, Narra S.; Van Meir, Erwin G.] Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA; [Kaluz, Stefan; Goodman, Mark M.; Grossniklaus, Hans E.; Van Meir, Erwin G.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; [Zhang, Qing; Yang, Hua; Grossniklaus, Hans E.] Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA; [Zhang, Qing] Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha, Hunan, Peoples R China; [Kuranaga, Yuki; Osuka, Satoru; Van Meir, Erwin G.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA; [Osuka, Satoru; Van Meir, Erwin G.] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA; [Mun, Jiyoung; Goodman, Mark M.] Emory Univ, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA; [Wang, Wei; Zhang, Ruiwen] Univ Houston, Dept Pharmacol & Pharmaceut Sci, Houston, TX USA; [Wang, Wei; Zhang, Ruiwen] Univ Houston, Coll Pharm, Drug Discovery Inst, Houston, TX 77030 USA; [Grossniklaus, Hans E.] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; [Van Meir, Erwin G.] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Central South University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Emory University; University of Houston System; University of Houston; University of Houston System; University of Houston; Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA.; Grossniklaus, HE; Van Meir, EG (corresponding author), Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.; Grossniklaus, HE (corresponding author), Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA.; Van Meir, EG (corresponding author), Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA.; Van Meir, EG (corresponding author), Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA.; Grossniklaus, HE (corresponding author), Emory Univ, Dept Pathol, Atlanta, GA 30322 USA.; Van Meir, EG (corresponding author), Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.	ophtheg@emory.edu; evanmeir@uab.edu			NIH [R01 CA116804, R01 CA176001, R01 CA180805, R24 EY017045, P30 EY06360, P30 CA138292, P30 CA13148]; National Natural Science Foundation of China [NNS81201808]; Fight For Sight Postdoctoral Award; Emory Melanoma Prevention and Research Discovery Fund; Winship Cancer Institute pilot grant; Central South University Lieying pilot grant; V Foundation; Max Cure Foundation; Samuel Waxman Cancer Research Foundation; Alan B. Slifka Foundation; Research to Prevent Blindness, Inc.	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fight For Sight Postdoctoral Award; Emory Melanoma Prevention and Research Discovery Fund; Winship Cancer Institute pilot grant; Central South University Lieying pilot grant; V Foundation; Max Cure Foundation; Samuel Waxman Cancer Research Foundation; Alan B. Slifka Foundation; Research to Prevent Blindness, Inc.(Research to Prevent Blindness (RPB))	This work was supported in part by grants from the NIH (R01 CA116804, R01 CA176001, R01 CA180805, R24 EY017045, P30 EY06360, P30 CA138292 and P30 CA13148), the National Natural Science Foundation of China (NNS81201808), the Fight For Sight Postdoctoral Award, the Emory Melanoma Prevention and Research Discovery Fund, a Winship Cancer Institute pilot grant, a Central South University Lieying pilot grant, the V Foundation, the Max Cure Foundation, the Samuel Waxman Cancer Research Foundation, the Alan B. Slifka Foundation, and an unrestricted grant from Research to Prevent Blindness, Inc.	Asnaghi L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105372; Canty EG, 2005, J CELL SCI, V118, P1341, DOI 10.1242/jcs.01731; Chattopadhyay C, 2016, CANCER-AM CANCER SOC, V122, P2299, DOI 10.1002/cncr.29727; Chen PW, 2013, TRENDS MOL MED, V19, P410, DOI 10.1016/j.molmed.2013.04.001; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Dai X, 2017, ONCOTARGET, V8, P99245, DOI 10.18632/oncotarget.22104; Diener-West M, 2001, ARCH OPHTHALMOL-CHIC, V119, P969; Dogrusoz M, 2018, ACTA OPHTHALMOL, V96, P331, DOI 10.1111/aos.13580; Dong L, 2019, CLIN CANCER RES, V25, P2206, DOI 10.1158/1078-0432.CCR-18-1368; el Filali M, 2010, INVEST OPHTH VIS SCI, V51, P2329, DOI 10.1167/iovs.09-4739; Ferguson Jalisa H, 2017, J Enzyme Inhib Med Chem, V32, P992, DOI 10.1080/14756366.2017.1347784; Filleur S, 2009, J CELL BIOCHEM, V106, P769, DOI 10.1002/jcb.22072; Gangemi R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029989; Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959-8049(01)00171-X; Gilkes DM, 2013, CANCER RES, V73, P3285, DOI 10.1158/0008-5472.CAN-12-3963; Gilkes DM, 2013, J BIOL CHEM, V288, P10819, DOI 10.1074/jbc.M112.442939; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Grimmer C, 2006, AM J PATHOL, V169, P491, DOI 10.2353/ajpath.2006.050738; Harbour JW, 2014, OPHTHALMOLOGY, V121, P1281, DOI 10.1016/j.ophtha.2013.12.014; Hofbauer KH, 2003, EUR J BIOCHEM, V270, P4515, DOI 10.1046/j.1432-1033.2003.03846.x; Hu K, 2016, ONCOTARGET, V7, P7816, DOI 10.18632/oncotarget.6868; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Klein CA, 2008, SCIENCE, V321, P1785, DOI 10.1126/science.1164853; Lattier JM, 2013, CLIN EXP METASTAS, V30, P969, DOI 10.1007/s10585-013-9596-3; Laurent C, 2011, CANCER RES, V71, P666, DOI 10.1158/0008-5472.CAN-10-0605; Mooring SR, 2011, J MED CHEM, V54, P8471, DOI 10.1021/jm201018g; Mouriaux F, 2014, INVEST OPHTH VIS SCI, V55, P1277, DOI 10.1167/iovs.13-13345; Mun JY, 2012, BIOORGAN MED CHEM, V20, P4590, DOI 10.1016/j.bmc.2012.04.064; Onken MD, 2006, J MOL DIAGN, V8, P567, DOI 10.2353/jmoldx.2006.060077; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Shi Q, 2012, ACS MED CHEM LETT, V3, P620, DOI 10.1021/ml300042k; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Stegen S, 2019, NATURE, V565, P511, DOI 10.1038/s41586-019-0874-3; Sullivan RJ, 2015, CLIN CANCER RES, V21, P2424, DOI 10.1158/1078-0432.CCR-14-1650; Tan C, 2011, BIOORG MED CHEM LETT, V21, P5528, DOI 10.1016/j.bmcl.2011.06.099; Van Meir EG, 1997, INT J CANCER, V71, P310; Walker C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103028; Wang W, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0044883, 10.1371/journal.pone.0052488]; Xiong GF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-1; Yin SM, 2012, CLIN CANCER RES, V18, P6623, DOI 10.1158/1078-0432.CCR-12-0861; Zhang Q, 2011, INVEST OPHTH VIS SCI, V52, P2662, DOI 10.1167/iovs.10-6794	44	4	5	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5182	5191		10.1038/s41388-021-01919-x	http://dx.doi.org/10.1038/s41388-021-01919-x		JUL 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34218269	Green Accepted			2022-12-28	WOS:000669300400002
J	Boone, MA; Taslim, C; Crow, JC; Selich-Anderson, J; Byrum, AK; Showpnil, IA; Sunkel, BD; Wang, M; Stanton, BZ; Theisen, ER; Lessnick, SL				Boone, Megann A.; Taslim, Cenny; Crow, Jesse C.; Selich-Anderson, Julia; Byrum, Andrea K.; Showpnil, Iftekhar A.; Sunkel, Benjamin D.; Wang, Meng; Stanton, Benjamin Z.; Theisen, Emily R.; Lessnick, Stephen L.			The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma	ONCOGENE			English	Article							FUSION PROTEIN; DOMAIN; TRANSLOCATION; EWS; TRANSFORMATION; PARTNERSHIPS; EXPRESSION; GENERATION; LANDSCAPE; CHROMATIN	Ewing sarcoma is an aggressive bone cancer of children and young adults defined by the presence of a chromosomal translocation: t(11;22)(q24;q12). The encoded protein, EWS/FLI, fuses the amino-terminal domain of EWS to the carboxyl-terminus of FLI. The EWS portion is an intrinsically disordered transcriptional regulatory domain, while the FLI portion contains an ETS DNA-binding domain and two flanking regions of unknown function. Early studies using non-Ewing sarcoma models provided conflicting information on the roles of each domain of FLI in EWS/FLI oncogenic function. We therefore sought to define the specific contributions of each FLI domain to EWS/FLI activity in a well-validated Ewing sarcoma model and, in doing so, to better understand Ewing sarcoma development mediated by the fusion protein. We analyzed a series of engineered EWS/FLI mutants with alterations in the FLI portion using a variety of assays. Fluorescence anisotropy, CUT&RUN, and ATAC-sequencing experiments revealed that the isolated ETS domain is sufficient to maintain the normal DNA-binding and chromatin accessibility function of EWS/FLI. In contrast, RNA-sequencing and soft agar colony formation assays revealed that the ETS domain alone was insufficient for transcriptional regulatory and oncogenic transformation functions of the fusion protein. We found that an additional alpha-helix immediately downstream of the ETS domain is required for full transcriptional regulation and EWS/FLI-mediated oncogenesis. These data demonstrate a previously unknown role for FLI in transcriptional regulation that is distinct from its DNA-binding activity. This activity is critical for the cancer-causing function of EWS/FLI and may lead to novel therapeutic approaches.	[Boone, Megann A.; Stanton, Benjamin Z.; Theisen, Emily R.; Lessnick, Stephen L.] Ohio State Univ, Biomed Sci Grad Program, Columbus, OH 43210 USA; [Boone, Megann A.; Taslim, Cenny; Crow, Jesse C.; Selich-Anderson, Julia; Byrum, Andrea K.; Showpnil, Iftekhar A.; Sunkel, Benjamin D.; Wang, Meng; Stanton, Benjamin Z.; Theisen, Emily R.; Lessnick, Stephen L.] Nationwide Childrens Hosp, Abigail Wexner Res Inst, Ctr Childhood Canc & Blood Dis, Columbus, OH 43210 USA; [Showpnil, Iftekhar A.; Stanton, Benjamin Z.; Theisen, Emily R.; Lessnick, Stephen L.] Ohio State Univ, Mol Cellular & Dev Biol Grad Program, Columbus, OH 43210 USA; [Stanton, Benjamin Z.; Theisen, Emily R.; Lessnick, Stephen L.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Lessnick, SL (corresponding author), Ohio State Univ, Biomed Sci Grad Program, Columbus, OH 43210 USA.; Lessnick, SL (corresponding author), Nationwide Childrens Hosp, Abigail Wexner Res Inst, Ctr Childhood Canc & Blood Dis, Columbus, OH 43210 USA.; Lessnick, SL (corresponding author), Ohio State Univ, Mol Cellular & Dev Biol Grad Program, Columbus, OH 43210 USA.; Lessnick, SL (corresponding author), Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA.	stephen.lessnick@nationwidechildrens.org		Sunkel, Benjamin/0000-0003-1376-9567; Theisen, Emily/0000-0003-2923-1198; Boone, Megann/0000-0002-7806-8027; Stanton, Benjamin/0000-0002-2613-2955	National Institute of Health [T32 GM068412, U54 CA231641]	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Research reported in this publication was supported by the National Institute of Health award T32 GM068412 to MAB, and U54 CA231641 to SLL. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. SLL declares a competing interest as a member of the advisory board for Salarius Pharmaceuticals. SLL is also a listed inventor on United States Patent No. US 7,939,253 B2, "Methods and compositions for the diagnosis and treatment of Ewing's sarcoma," and United States Patent No. US 8,557,532, "Diagnosis and treatment of drug-resistant Ewing's sarcoma." This does not alter our adherence to Oncogene policies on sharing data and materials.	Arvand A, 2001, CANCER RES, V61, P5311; AURIAS A, 1983, CR ACAD SCI III-VIE, V296, P1105; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Boulay G, 2017, CELL, V171, P163, DOI 10.1016/j.cell.2017.07.036; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Braunreiter CL, 2006, CELL CYCLE, V5, P2753, DOI 10.4161/cc.5.23.3505; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Erkizan HV, 2010, CLIN CANCER RES, V16, P4077, DOI 10.1158/1078-0432.CCR-09-2261; Gangwal K, 2008, CELL CYCLE, V7, P3127, DOI 10.4161/cc.7.20.6892; Gangwal Kunal, 2010, Genes Cancer, V1, P177; Gu ZG, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4625-x; Hodges HC, 2018, NAT STRUCT MOL BIOL, V25, P61, DOI 10.1038/s41594-017-0007-3; Hou CX, 2015, BIOCHEMISTRY-US, V54, P7365, DOI 10.1021/acs.biochem.5b01121; Johnson KM, 2017, P NATL ACAD SCI USA, V114, P9870, DOI 10.1073/pnas.1701872114; Kim S, 2006, MOL CELL BIOL, V26, P2467, DOI 10.1128/MCB.26.7.2467-2478.2006; Kovar Heinrich, 2011, Sarcoma, V2011, P1, DOI 10.1155/2011/837474; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; Longhi A, 2012, CANCER-AM CANCER SOC, V118, P5050, DOI 10.1002/cncr.27493; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maag Jesper L V, 2018, F1000Res, V7, P1576, DOI 10.12688/f1000research.16409.2; MAO XH, 1994, J BIOL CHEM, V269, P18216; Martinez-Ramirez A, 2003, CANCER GENET CYTOGEN, V141, P138, DOI 10.1016/S0165-4608(02)00670-2; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Mendiola M, 2006, INT J CANCER, V118, P1381, DOI 10.1002/ijc.21578; Pishas KI, 2018, MOL CANCER THER, V17, P1902, DOI 10.1158/1535-7163.MCT-18-0373; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Regan MC, 2013, P NATL ACAD SCI USA, V110, P13374, DOI 10.1073/pnas.1301726110; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Sankar S, 2013, ONCOGENE, V32, P5089, DOI 10.1038/onc.2012.525; Sankar S, 2014, CLIN CANCER RES, V20, P4584, DOI 10.1158/1078-0432.CCR-14-0072; Sankar S, 2011, CANCER GENET-NY, V204, P351, DOI 10.1016/j.cancergen.2011.07.008; Sizemore GM, 2017, NAT REV CANCER, V17, P337, DOI 10.1038/nrc.2017.20; Skene PJ, 2017, ELIFE, V6, DOI 10.7554/eLife.21856; Spahn L, 2003, ONCOGENE, V22, P6819, DOI 10.1038/sj.onc.1206810; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Theisen Emily R, 2019, Genes Cancer, V10, P21, DOI 10.18632/genesandcancer.188; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhu LJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-237; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	48	7	7	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4759	4769		10.1038/s41388-021-01876-5	http://dx.doi.org/10.1038/s41388-021-01876-5		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34145397	hybrid, Green Submitted, Green Published			2022-12-28	WOS:000663295300003
J	Jiang, Y; Wang, ZL; Ying, CT; Hu, JF; Zeng, T; Gao, L				Jiang, Yang; Wang, Zhenlin; Ying, Chenting; Hu, Jiangfeng; Zeng, Tao; Gao, Liang			FMR1/circCHAF1A/miR-211-5p/HOXC8 feedback loop regulates proliferation and tumorigenesis via MDM2-dependent p53 signaling in GSCs	ONCOGENE			English	Article							CIRCULAR RNAS; STEM-CELL; CANCER; PHOSPHORYLATION; ANGIOGENESIS; EXPRESSION; APOPTOSIS; CHAF1A; GROWTH	Glioma is the most common and fatal primary malignant brain tumor. Glioma stem cells (GSCs) may be an important factor in glioma cell proliferation, invasion, chemoradiotherapy tolerance, and recurrence. Therefore, discovering novel GSCs related circular RNAs (circRNAs) may finds out a prospective target for the treatment of glioma. A novel circRNA-CHAF1A (circCHAF1A) was first found in our study. CircCHAF1A was overexpressed in glioma and related to the low survival rate. Functionally, it was found that no matter in vitro or in vivo, circCHAF1A can facilitate the proliferation and tumorigenesis of TP53wt GSCs. Mechanistically, circCHAF1A upregulated transcription factor HOXC8 expression in GSCs through miR-211-5p sponging. Then, HOXC8 can transcriptionally upregulate MDM2 expression and inhibited the antitumor effect of p53. Furtherly, the RNA binding protein FMR1 can bind to and promoted the expression of circCHAF1A via maintaining its stability, while HOXC8 also transcribed the FMR1 expression to form a feedback loop, which may be involved in the malignant transformation of glioma. The novel feedback loop among FMR1, circCHAF1A, miR-211-5p, and HOXC8 in GSCs can facilitate the proliferation and tumorigenesis of glioma and GSCs. It also provided a helpful biomarker for diagnosis and prognostic evaluation of glioma and may be applied to molecular targeted therapy.	[Jiang, Yang; Zeng, Tao; Gao, Liang] Tongji Univ, Shanghai Peoples Hosp 10, Dept Neurosurg, Sch Med, Shanghai, Peoples R China; [Wang, Zhenlin; Ying, Chenting] Shanghai Jiao Tong Univ, Dept Surg, Shanghai Gen Hosp, Sch Med, Shanghai, Peoples R China; [Hu, Jiangfeng] Shanghai Jiao Tong Univ, Dept Gastroenterol, Shanghai Gen Hosp, Sch Med, Shanghai, Peoples R China	Tongji University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Gao, L (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Dept Neurosurg, Sch Med, Shanghai, Peoples R China.	lianggaoh@126.com			National Natural Science Foundation of China [81900544]; Key disciplines-B neurosurgery of Shanghai Tenth People's Hospital [DS04! 02! 18014]; Shanghai Sailing Program [19YF1439000, 21YF1449900]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key disciplines-B neurosurgery of Shanghai Tenth People's Hospital; Shanghai Sailing Program	We thank Zhitao Jing at the Department of Neurosurgery, The First Affiliated Hospital of China Medical University for molecular experimental technical support. This work was supported by the National Natural Science Foundation of China (81900544), Key disciplines-B neurosurgery of Shanghai Tenth People's Hospital (DS04! 02! 18014), and the Shanghai Sailing Program (No. 19YF1439000, No. 21YF1449900).	Arnold A, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-00940-7; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; Ebert MS, 2010, RNA, V16, P2043, DOI 10.1261/rna.2414110; Gong C, 2019, MOL CARCINOGEN, V58, P1863, DOI 10.1002/mc.23079; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; He JH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1120-1; He QR, 2018, MOL THER-NUCL ACIDS, V10, P331, DOI 10.1016/j.omtn.2017.12.014; He ZW, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1065-7; Hsu PJ, 2019, J BIOL CHEM, V294, P19889, DOI 10.1074/jbc.AC119.010078; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huang TZ, 2017, CANCER CELL, V32, P840, DOI 10.1016/j.ccell.2017.11.005; Jiang Y, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01691-y; Jiang Y, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102651; Jiang Y, 2019, EBIOMEDICINE, V48, P36, DOI 10.1016/j.ebiom.2019.09.037; Jiang Y, 2018, EBIOMEDICINE, V37, P78, DOI 10.1016/j.ebiom.2018.10.053; Jiang Y, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0210-1; Kosti A, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02115-y; Lapointe S, 2018, LANCET, V392, P432, DOI 10.1016/S0140-6736(18)30990-5; Li X, 2018, MOL CELL, V71, P428, DOI 10.1016/j.molcel.2018.06.034; Liang Tingyu, 2018, Chin Neurosurg J, V4, P24, DOI 10.1186/s41016-018-0132-9; Lin J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2474-4; Liu HL, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0016-4; Liu TZ, 2017, EXP THER MED, V14, P4681, DOI 10.3892/etm.2017.5201; Liu XB, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01625-8; Luo Z, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01203-8; Lyu DB, 2017, RNA BIOL, V14, P1000, DOI 10.1080/15476286.2016.1227904; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Paz I, 2014, NUCLEIC ACIDS RES, V42, pW361, DOI 10.1093/nar/gku406; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Sadik A, 2020, CELL, V182, P1252, DOI 10.1016/j.cell.2020.07.038; SANGER HL, 1976, P NATL ACAD SCI USA, V73, P3852, DOI 10.1073/pnas.73.11.3852; Shao LQ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1845-1; Shen LY, 2019, CANCER SCI, V110, P1735, DOI 10.1111/cas.13993; Sun JK, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1121-0; Suva ML, 2020, CANCER CELL, V37, P630, DOI 10.1016/j.ccell.2020.04.001; Wang ZL, 2021, ONCOGENE, V40, P1458, DOI 10.1038/s41388-020-01635-y; Wu PQ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1771-2; Xia DD, 2017, BIOCHEM BIOPH RES CO, V486, P191, DOI 10.1016/j.bbrc.2017.03.026; Xing Z, 2016, ONCOTARGET, V7, P75394, DOI 10.18632/oncotarget.12215; Yang XS, 2018, ONCOGENE, V37, P6399, DOI 10.1038/s41388-018-0416-8; Yang YB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx166; Yu J, 2018, J HEPATOL, V68, P1214, DOI 10.1016/j.jhep.2018.01.012; Zalfa F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.521; Zang JK, 2020, J NEUROSCI RES, V98, P87, DOI 10.1002/jnr.24356; Zeng Y, 2017, THERANOSTICS, V7, P3842, DOI 10.7150/thno.19764; Zhang J, 2019, INT J BIOCHEM CELL B, V114, DOI 10.1016/j.biocel.2019.06.005; Zhang J, 2017, J NEURO-ONCOL, V133, P553, DOI 10.1007/s11060-017-2464-2; Zhang LG, 2019, CANCER CELL, V36, P302, DOI 10.1016/j.ccell.2019.07.009; Zheng LX, 2018, EBIOMEDICINE, V38, P69, DOI 10.1016/j.ebiom.2018.11.009; Zhu ZL, 2019, THERANOSTICS, V9, P8294, DOI 10.7150/thno.36256	50	13	14	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4094	4110		10.1038/s41388-021-01833-2	http://dx.doi.org/10.1038/s41388-021-01833-2		MAY 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34017077				2022-12-28	WOS:000652439200005
J	Tan, JH; Zheng, X; Li, MC; Ye, F; Song, CY; Xu, C; Zhang, XX; Li, WQ; Wang, Y; Zeng, SQ; Li, HY; Chen, G; Huang, XY; Ma, D; Liu, D; Gao, QL				Tan, Jiahong; Zheng, Xu; Li, Mengchen; Ye, Fei; Song, Chunyan; Xu, Cheng; Zhang, Xiaoxue; Li, Wenqian; Wang, Ya; Zeng, Shaoqing; Li, Huayi; Chen, Gang; Huang, Xiaoyuan; Ma, Ding; Liu, Dan; Gao, Qinglei			C/EBP beta promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer	ONCOGENE			English	Article							DNA MISMATCH REPAIR; PARP INHIBITORS; CELL-LINES; EXPRESSION; CISPLATIN; IDENTIFICATION; DEFICIENCY; TOXICITY; BREAST; DAMAGE	PARP inhibitors (PARPi) are efficacious in treating high-grade serous ovarian cancer (HG-SOC) with homologous recombination (HR) deficiency. However, they exhibit suboptimal efficiency in HR-proficient cancers. Here, we found that the expression of CCAAT/enhancer-binding protein beta (C/EBP beta), a transcription factor, was inversely correlated with PARPi sensitivity in vitro and in vivo, both in HR-proficient condition. High C/EBP beta expression enhanced PARPi tolerance; PARPi treatment in turn induced C/EBP beta expression. C/EBP beta directly targeted and upregulated multiple HR genes (BRCA1, BRIP1, BRIT1, and RAD51), thereby inducing restoration of HR capacity and mediating acquired PARPi resistance. C/EBP beta is a key regulator of the HR pathway and an indicator of PARPi responsiveness. Targeting C/EBP beta could induce HR deficiency and rescue PARPi sensitivity accordingly. Our findings indicate that HR-proficient patients may benefit from PARPi via targeting C/EBP beta, and C/EBP beta expression levels enable predicting and tracking PARPi responsiveness during treatment.	[Tan, Jiahong; Zheng, Xu; Li, Mengchen; Song, Chunyan; Xu, Cheng; Zhang, Xiaoxue; Li, Wenqian; Wang, Ya; Zeng, Shaoqing; Li, Huayi; Chen, Gang; Huang, Xiaoyuan; Ma, Ding; Liu, Dan; Gao, Qinglei] Huazhong Univ Sci & Technol, Tongji Med Coll, Canc Biol Res Ctr, Key Lab,Minist Educ,Tongji Hosp, Wuhan, Peoples R China; [Tan, Jiahong; Zheng, Xu; Song, Chunyan; Xu, Cheng; Zhang, Xiaoxue; Li, Wenqian; Wang, Ya; Zeng, Shaoqing; Li, Huayi; Chen, Gang; Huang, Xiaoyuan; Ma, Ding; Liu, Dan; Gao, Qinglei] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, Wuhan, Peoples R China; [Ye, Fei] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Neurosurg, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Liu, D; Gao, QL (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Canc Biol Res Ctr, Key Lab,Minist Educ,Tongji Hosp, Wuhan, Peoples R China.; Liu, D; Gao, QL (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, Wuhan, Peoples R China.	tj_liudan@tjh.tjmu.edu.cn; qingleigao@hotmail.com		Jiahong, Tan/0000-0002-5748-4697	National Sci-Tech Support Projects [2018ZX10301402-002]; National Key Basic Research Program of China [2015CB553903]; National Natural Science Foundation of China [82072889, 81974405, 81772787]; Chinese Society of Clinical Oncology [Y-2019AZZD-0359]; Leading Talents of Science and Technology Innovation in National Ten Thousand Talents Plan [[2019]252]; Tongji Hospital (HUST) Foundation for Excellent Young Scientist [2020YBKY024]	National Sci-Tech Support Projects; National Key Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Society of Clinical Oncology; Leading Talents of Science and Technology Innovation in National Ten Thousand Talents Plan; Tongji Hospital (HUST) Foundation for Excellent Young Scientist	This work was supported by National Sci-Tech Support Projects (2018ZX10301402-002), National Key Basic Research Program of China (2015CB553903), National Natural Science Foundation of China (82072889, 81974405, and 81772787), Chinese Society of Clinical Oncology (Y-2019AZZD-0359), Leading Talents of Science and Technology Innovation in National Ten Thousand Talents Plan ([2019]252), and Tongji Hospital (HUST) Foundation for Excellent Young Scientist (2020YBKY024). We sincerely thank all participants in the study.	Aebi S, 1996, CANCER RES, V56, P3087; Bian L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1100-5; Bian X, 2018, ONCOGENE, V37, P341, DOI 10.1038/onc.2017.326; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Cortez AJ, 2018, CANCER CHEMOTH PHARM, V81, P17, DOI 10.1007/s00280-017-3501-8; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; Dhawan MS, 2017, CLIN CANCER RES, V23, P6400, DOI 10.1158/1078-0432.CCR-17-0703; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Dong QZ, 2019, CANCER RES, V79, P819, DOI 10.1158/0008-5472.CAN-18-1273; Fang Y, 2019, CANCER CELL, V35, P851, DOI 10.1016/j.ccell.2019.05.001; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; HE X, 2015, MOL CANCER, V14; Ji T, 2013, CANCER LETT, V341, P231, DOI 10.1016/j.canlet.2013.08.022; Kim H, 2017, CLIN CANCER RES, V23, P3097, DOI 10.1158/1078-0432.CCR-16-2273; Konecny GE, 2019, EBIOMEDICINE, V43, P9, DOI 10.1016/j.ebiom.2019.04.009; Korch C, 2012, GYNECOL ONCOL, V127, P241, DOI 10.1016/j.ygyno.2012.06.017; Kurbacher CM, 2011, METHODS MOL BIOL, V731, P161, DOI 10.1007/978-1-61779-080-5_15; Lee IC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030290; Lheureux S, 2019, CA-CANCER J CLIN, V69, P280, DOI 10.3322/caac.21559; Lheureux S, 2019, LANCET, V393, P1240, DOI 10.1016/S0140-6736(18)32552-2; LI A, 2019, J HEMATOL ONCOL, V12; Liu DH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02627-5; Liu Q, 2018, ONCOGENE, V37, P2793, DOI 10.1038/s41388-018-0130-6; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Marques M, 2019, ONCOGENE, V38, P2177, DOI 10.1038/s41388-018-0568-6; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; Miller AL, 2019, EBIOMEDICINE, V44, P419, DOI 10.1016/j.ebiom.2019.05.035; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Papp E, 2018, CELL REP, V25, P2617, DOI 10.1016/j.celrep.2018.10.096; Peasland A, 2011, BRIT J CANCER, V105, P372, DOI 10.1038/bjc.2011.243; Penning TD, 2010, CURR OPIN DRUG DISC, V13, P577; Pignochino Y, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0652-5; Robinson LS, 2015, EBIOMEDICINE, V2, P1827, DOI 10.1016/j.ebiom.2015.10.022; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Sato Y, 2007, DIABETOLOGIA, V50, P481, DOI 10.1007/s00125-006-0480-4; Schurch NJ, 2016, RNA, V22, P839, DOI 10.1261/rna.053959.115; Shen YQ, 2015, J PHARMACOL EXP THER, V353, P446, DOI 10.1124/jpet.114.222448; Stewart RA, 2018, CANCER RES, V78, P6717, DOI 10.1158/0008-5472.CAN-18-2652; Sun CY, 2018, CANCER CELL, V33, P401, DOI 10.1016/j.ccell.2018.01.019; Sun CG, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-0844-0; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Taverna P, 2000, CANCER CHEMOTH PHARM, V46, P507, DOI 10.1007/s002800000186; Wang J, 2017, ONCOGENE, V36, P5939, DOI 10.1038/onc.2017.197; Wang ZH, 2019, CELL REP, V28, P655, DOI 10.1016/j.celrep.2019.06.054; Yamaguchi H, 2018, ONCOGENE, V37, P208, DOI 10.1038/onc.2017.311; Yasukawa M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030272; Yi JY, 2019, EBIOMEDICINE, V43, P225, DOI 10.1016/j.ebiom.2019.03.027; YU S, 2018, CLIN INFECT DIS, V9; Yuan Y, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-16; Zahnow CA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001033; Zheng RB, 2019, NUCLEIC ACIDS RES, V47, pD729, DOI 10.1093/nar/gky1094; Zhu H, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01167-9	55	4	4	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3845	3858		10.1038/s41388-021-01788-4	http://dx.doi.org/10.1038/s41388-021-01788-4		MAY 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33966038	Green Published, hybrid			2022-12-28	WOS:000648369800001
J	Lv, Y; Wang, Y; Song, Y; Wang, SS; Cheng, KW; Zhang, ZQ; Yao, J; Zhou, LN; Ling, ZY; Cao, C				Lv, Yan; Wang, Yin; Song, Yu; Wang, Shu-Sheng; Cheng, Kai-wen; Zhang, Zhi-qing; Yao, Jin; Zhou, Li-na; Ling, Zhuo-yan; Cao, Cong			LncRNA PINK1-AS promotes G alpha i1-driven gastric cancer tumorigenesis by sponging microRNA-200a	ONCOGENE			English	Article							GROWTH-INHIBITION; NONCODING RNAS; METASTASIS; PROLIFERATION; CARCINOGENESIS; REQUIREMENT; STATISTICS; APOPTOSIS	Gastric cancer (GC) is one of the leading causes of human mortality around the world. We have previously shown that G alpha i1 (the inhibitory subunit 1 of the heterotrimeric guanine nucleotide-binding protein) recruitment to ligand-activated receptor tyrosine kinases (RTKs) is essential for signaling. Testing its role in GC cancer-promoting functions, we found that G alpha i1 is upregulated in human GC, correlating with poor overall survival. In established and primary human GC cells, G alpha i1 shRNA (small hairpin RNA) or knockout produced significant anti-GC cell activity, proliferation and migration was inhibited, and apoptosis was activated. Conversely, ectopic G alpha i1 overexpression promoted proliferation and migration of GC cells in vitro. By examining the tumor-suppressive miRNA microRNA-200a (miR-200a), we found that miR-200a directly silenced G alpha i1 to induce anti-GC cell activity. The expression of miR-200a was downregulated in human GC, correlating with upregulation of a novel miR-200a-targeting long non-coding RNA (LncRNA), PINK1 (PTEN Induced Kinase 1)-AS. RNA immunoprecipitation, RNA-pull down, and RNA fluorescence in situ hybridization assays confirmed that PINK1-AS directly binds to miR-200a. Silencing PINK1-AS in GC cells led to miR-200a accumulation, G alpha i1 downregulation, and inhibition of GC cell progression in vitro, whereas PINK1-AS upregulation produced the converse results. Significantly, anti-GC cell activity induced by PINK1-AS shRNA was ameliorated by the expression of miR-200a antisense or the 3MODIFIER LETTER PRIME-UTR (untranslated region)-depleted G alpha i1. In vivo, the growth of subcutaneous MGC-803 xenografts in nude mice was inhibited by PINK1-AS shRNA, but accelerated by PINK1-AS overexpression. Patient-derived GC xenograft growth in nude mice was largely inhibited after intratumoral injection of PINK1-AS shRNA lentivirus. In conclusion, PINK1-AS promotes G alpha i1-driven GC progression by sponging miR-200a.	[Lv, Yan; Cao, Cong] Soochow Univ, Affiliated Zhangjiagang Hosp, Ctr Translat Med, Suzhou, Peoples R China; [Wang, Yin; Cheng, Kai-wen; Zhang, Zhi-qing; Cao, Cong] Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou, Peoples R China; [Wang, Yin; Cheng, Kai-wen; Zhang, Zhi-qing; Cao, Cong] Soochow Univ, Inst Neurosci, Suzhou, Peoples R China; [Song, Yu] Soochow Univ, Affiliated Zhangjiagang Hosp, Dept Oncol, Suzhou, Peoples R China; [Wang, Shu-Sheng] Soochow Univ, Affiliated Zhangjiagang Hosp, Dept Gen Surg, Suzhou, Peoples R China; [Yao, Jin] Nanjing Med Univ, Affiliated Eye Hosp, Nanjing, Peoples R China; [Zhou, Li-na] Jiangsu Univ, Affiliated Kunshan Hosp, Dept Radiotherapy & Oncol, Kunshan, Peoples R China; [Ling, Zhuo-yan] Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou, Peoples R China; [Cao, Cong] Nanjing Med Univ, Suzhou Municipal Hosp, Affiliated Suzhou Hosp, North Dist, Suzhou, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China; Nanjing Medical University; Jiangsu University; Soochow University - China; Nanjing Medical University	Cao, C (corresponding author), Soochow Univ, Affiliated Zhangjiagang Hosp, Ctr Translat Med, Suzhou, Peoples R China.; Cao, C (corresponding author), Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou, Peoples R China.; Cao, C (corresponding author), Soochow Univ, Inst Neurosci, Suzhou, Peoples R China.; Yao, J (corresponding author), Nanjing Med Univ, Affiliated Eye Hosp, Nanjing, Peoples R China.; Zhou, LN (corresponding author), Jiangsu Univ, Affiliated Kunshan Hosp, Dept Radiotherapy & Oncol, Kunshan, Peoples R China.; Ling, ZY (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou, Peoples R China.; Cao, C (corresponding author), Nanjing Med Univ, Suzhou Municipal Hosp, Affiliated Suzhou Hosp, North Dist, Suzhou, Peoples R China.	dryaojin@yahoo.com; zhoulinaks@163.com; lingzhuoyan@126.com; caocong@suda.edu.cn	Zhou, Li/GSE-4531-2022		National Natural Science Foundation of China [81922025, 81802386, 81970823, 81974388, 81302195, 31371139, 81571282, 81771457, 81670878]; Natural Science Foundation of Jiangsu Province [BK20170060]; Priority Academic Program Development of Jiangsu Higher Education Institutions; Suzhou People's Livelihood Science and Technology project [sysd2018205]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Priority Academic Program Development of Jiangsu Higher Education Institutions; Suzhou People's Livelihood Science and Technology project	This work was generously supported by grants from the National Natural Science Foundation of China (81922025, 81802386, 81970823, 81974388, 81302195, 31371139, 81571282, 81771457, and 81670878), and the Natural Science Foundation of Jiangsu Province (BK20170060), a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions, Suzhou People's Livelihood Science and Technology project (sysd2018205). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the paper.	Bai JY, 2021, THERANOSTICS, V11, P4894, DOI 10.7150/thno.56383; Bang YJ, 2010, LANCET, V376, P1302; Cao C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000118; Chen WZ, 2018, BIOCHEM BIOPH RES CO, V499, P913, DOI 10.1016/j.bbrc.2018.04.019; Chen Z, 2013, CANCER-AM CANCER SOC, V119, P1985, DOI 10.1002/cncr.28002; Dan J, 2018, BIOMED PHARMACOTHER, V99, P931, DOI 10.1016/j.biopha.2018.01.164; Feng L, 2020, AGING-US, V12, P707, DOI 10.18632/aging.102651; Gu Y, 2015, FUTURE ONCOL, V11, P2427, DOI 10.2217/fon.15.175; Guo TS, 2018, CELL BIOL INT, V42, P506, DOI 10.1002/cbin.10924; Hao NB, 2017, ONCOTARGET, V8, P81572, DOI 10.18632/oncotarget.19197; He WM, 2019, ONCOGENE, V38, P4637, DOI 10.1038/s41388-019-0747-0; HEDNER C, 2016, ONCOGENE, V11; HUO X, 2017, WORLD J GASTROENTERO, V16; JI D, 2014, ASIAN PAC J CANCER P, V9; Li DD, 2020, MOL THER-NUCL ACIDS, V19, P109, DOI 10.1016/j.omtn.2019.11.003; Li H, 2014, ONCOTARGET, V5, P2318, DOI 10.18632/oncotarget.1913; Li PH, 2014, ASIAN PAC J CANCER P, V15, P10381, DOI 10.7314/APJCP.2014.15.23.10381; Li Y, 2017, CANCER LETT, V395, P31, DOI 10.1016/j.canlet.2017.02.035; Liu HT, 2018, CANCER RES, V78, P5877, DOI 10.1158/0008-5472.CAN-18-1011; Liu YY, 2018, ONCOGENE, V37, P2890, DOI 10.1038/s41388-018-0184-5; Ma LN, 2019, NUCLEIC ACIDS RES, V47, pD128, DOI 10.1093/nar/gky960; Marshall J, 2018, P NATL ACAD SCI USA, V115, pE3549, DOI 10.1073/pnas.1722493115; Mirzaei S, 2019, EUR J PHARMACOL, V857, DOI 10.1016/j.ejphar.2019.172426; Niu ZS, 2017, WORLD J GASTROENTERO, V23, P5860, DOI 10.3748/wjg.v23.i32.5860; Park CK, 2016, ONCOTARGET, V7, P72099, DOI 10.18632/oncotarget.12291; Peng WZ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0197-7; Qi P, 2015, INT J CANCER, V137, P1269, DOI 10.1002/ijc.29516; Satoh T, 2015, GASTRIC CANCER, V18, P824, DOI 10.1007/s10120-014-0420-9; Satoh T, 2014, J CLIN ONCOL, V32, P2039, DOI 10.1200/JCO.2013.53.6136; Shah MA, 2014, NAT REV CLIN ONCOL, V11, P438, DOI [10.1038/nrclinonc.2013.231-c2, 10.1038/nrclinonc.2013.231]; Shrestha S, 2014, CANCER MED-US, V3, P878, DOI 10.1002/cam4.246; Siegel Rebecca L, 2019, CA Cancer J Clin, V69, P7, DOI 10.3322/caac.21551; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Statello L, 2021, NAT REV MOL CELL BIO, V22, P96, DOI 10.1038/s41580-020-00315-9; Sun J, 2018, THERANOSTICS, V8, P4695, DOI 10.7150/thno.26203; Sun M, 2016, CANCER RES, V76, P6299, DOI 10.1158/0008-5472.CAN-16-0356; Sun M, 2016, HISTOL HISTOPATHOL, V31, P33, DOI 10.14670/HH-11-655; Sun TT, 2016, CANCER DISCOV, V6, P784, DOI 10.1158/2159-8290.CD-15-0921; Tan HD, 2020, THERANOSTICS, V10, P8880, DOI 10.7150/thno.47548; Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170; Wang WY, 2015, INT J CARDIOL, V181, P180, DOI 10.1016/j.ijcard.2014.10.148; Wei GH, 2017, EUR REV MED PHARMACO, V21, P3850; Wong H, 2013, THER ADV GASTROENTER, V6, P15, DOI 10.1177/1756283X12453636; Xie SS, 2020, CANCER LETT, V493, P55, DOI 10.1016/j.canlet.2020.06.022; Yang L, 2015, EXP CELL RES, V332, P47, DOI 10.1016/j.yexcr.2014.12.017; Yang X, 2015, CANCER LETT, V360, P119, DOI 10.1016/j.canlet.2015.02.035; YUAN L, 2020, HISTOL HISTOPATHOL, V19; ZHANG G, 2018, CANCER RES, V17; Zhang XH, 2019, AGING-US, V11, P11358, DOI 10.18632/aging.102533; Zhang YM, 2015, J INVEST DERMATOL, V135, P181, DOI 10.1038/jid.2014.326; Zhao J, 2018, ONCOGENE, V37, P4094, DOI 10.1038/s41388-018-0250-z	51	13	13	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3826	3844		10.1038/s41388-021-01812-7	http://dx.doi.org/10.1038/s41388-021-01812-7		MAY 2021	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33958720				2022-12-28	WOS:000648041500004
J	Bencomo-Alvarez, AE; Rubio, AJ; Olivas, IM; Gonzalez, MA; Ellwood, R; Fiol, CR; Eide, CA; Lara, JJ; Barreto-Vargas, C; Jave-Suarez, LF; Nteliopoulos, G; Reid, AG; Milojkovic, D; Druker, BJ; Apperley, J; Khorashad, JS; Eiring, AM				Bencomo-Alvarez, Alfonso E.; Rubio, Andres J.; Olivas, Idaly M.; Gonzalez, Mayra A.; Ellwood, Rebecca; Fiol, Carme Ripoll; Eide, Christopher A.; Lara, Joshua J.; Barreto-Vargas, Christian; Jave-Suarez, Luis F.; Nteliopoulos, Georgios; Reid, Alistair G.; Milojkovic, Dragana; Druker, Brian J.; Apperley, Jane; Khorashad, Jamshid S.; Eiring, Anna M.			Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; STEM-CELLS; CML STEM; IMATINIB; THERAPY; INHIBITION; GENE; RESISTANT; STAT3; TRANSCRIPTION	Tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 have revolutionized therapy for chronic myeloid leukemia (CML), paving the way for clinical development in other diseases. Despite success, targeting leukemic stem cells and overcoming drug resistance remain challenges for curative cancer therapy. To identify drivers of kinase-independent TKI resistance in CML, we performed genome-wide expression analyses on TKI-resistant versus sensitive CML cell lines, revealing a nuclear factor-kappa B (NF-kappa B) expression signature. Nucleocytoplasmic fractionation and luciferase reporter assays confirmed increased NF-kappa B activity in the nucleus of TKI-resistant versus sensitive CML cell lines and CD34(+) patient samples. Two genes that were upregulated in TKI-resistant CML cells were proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), both members of the 19S regulatory complex in the 26S proteasome. PSMD1 and PSMD3 were also identified as survival-critical genes in a published small hairpin RNA library screen of TKI resistance. We observed markedly higher levels of PSMD1 and PSMD3 mRNA in CML patients who had progressed to the blast phase compared with the chronic phase of the disease. Knockdown of PSMD1 or PSMD3 protein correlated with reduced survival and increased apoptosis in CML cells, but not in normal cord blood CD34(+) progenitors. Luciferase reporter assays and immunoblot analyses demonstrated that PSMD1 and PSMD3 promote NF-kappa B protein expression in CML, and that signal transducer and activator of transcription 3 (STAT3) further activates NF-kappa B in scenarios of TKI resistance. Our data identify NF-kappa B as a transcriptional driver in TKI resistance, and implicate PSMD1 and PSMD3 as plausible therapeutic targets worthy of future investigation in CML and possibly other malignancies.	[Bencomo-Alvarez, Alfonso E.; Rubio, Andres J.; Gonzalez, Mayra A.; Lara, Joshua J.; Eiring, Anna M.] Texas Tech Univ, Hlth Sci Ctr El Paso, Ctr Emphasis Canc, Dept Mol & Translat Med,Paul L Foster Sch Med, El Paso, TX 79905 USA; [Olivas, Idaly M.; Eiring, Anna M.] Texas Tech Univ, Grad Sch Biomed Sci, Hlth Sci Ctr El Paso, El Paso, TX USA; [Ellwood, Rebecca; Fiol, Carme Ripoll; Nteliopoulos, Georgios; Milojkovic, Dragana; Apperley, Jane; Khorashad, Jamshid S.] Imperial Coll London, Ctr Haematol, Dept Med, London, England; [Eide, Christopher A.; Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol Med Oncol, Portland, OR 97201 USA; [Barreto-Vargas, Christian] Univ Guadalajara, Guadalajara, Jalisco, Mexico; [Jave-Suarez, Luis F.] Ctr Invest Biomed Occidente, Inst Mexicano Seguro Social, Guadalajara, Jalisco, Mexico; [Nteliopoulos, Georgios] Imperial Coll London, Dept Surg & Canc, London, England; [Reid, Alistair G.] Royal Liverpool Univ Hosp, Mol Pathol Unit, Liverpool Clin Labs, Liverpool, Merseyside, England	Texas Tech University System; Texas Tech University; Texas Tech University System; Texas Tech University; Imperial College London; Oregon Health & Science University; Universidad de Guadalajara; Instituto Mexicano del Seguro Social; Imperial College London; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Eiring, AM (corresponding author), Texas Tech Univ, Hlth Sci Ctr El Paso, Ctr Emphasis Canc, Dept Mol & Translat Med,Paul L Foster Sch Med, El Paso, TX 79905 USA.	anna.eiring@ttuhsc.edu	Jave-Suarez, Luis Felipe/T-7036-2018; Eiring, Anna M./ABA-8673-2020	Jave-Suarez, Luis Felipe/0000-0001-6209-5031; Eiring, Anna M./0000-0001-6533-9150; Bencomo-Alvarez, Alfonso Enrique/0000-0002-1771-8532; Apperley, Jane/0000-0002-1710-1794; Ellwood, Rebecca/0000-0002-0412-7530	Imperial BRC Genomics Facility, Imperial College London; National Institute for Health Research (NIHR); National Cancer Institute of the National Institutes of Health [K22CA216008-04, R01CA065823-21]; Consejo Nacional de Ciencia y Tecnologia (CONACyT)	Imperial BRC Genomics Facility, Imperial College London; National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Consejo Nacional de Ciencia y Tecnologia (CONACyT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	The authors would like to thank the Imperial BRC Genomics Facility, Imperial College London for providing resources and support that have contributed to the results reported within this paper. The Imperial BRC Genomics Facility is supported by the National Institute for Health Research (NIHR) to the Imperial Biomedical Research Centre. Research reported in this publication was supported in part by the National Cancer Institute of the National Institutes of Health under award numbers K22CA216008-04 (AME) and R01CA065823-21 (BJD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. CBV is grateful for scholarship obtained through support from Consejo Nacional de Ciencia y Tecnologia (CONACyT). We also wish to thank Michael Deininger, MD, PhD, from the University of Utah Huntsman Cancer Institute, for providing the cell lines used in this study. We thank Jessica M. Hernando, MT, ASCP (CM) and her team at the University Medical Center of El Paso (El Paso, TX, USA) for graciously donating the discarded cord blood used in this study. The authors are thankful to Shrikanth Gadad, PhD and Rajkumar Lakshmanaswamy, PhD for critical review of the paper.	Aichberger KJ, 2011, AM J HEMATOL, V86, P533, DOI 10.1002/ajh.22037; Baba T, 2013, J EXP MED, V210, P2661, DOI 10.1084/jem.20130112; Bencomo-Alvarez AE, 2019, BRIT J HAEMATOL, V186, P524, DOI 10.1111/bjh.16074; Bocchia M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00194; Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874; Breccia M, 2010, EXPERT OPIN THER TAR, V14, P1157, DOI 10.1517/14728222.2010.522570; Caocci G, 2019, HEMATOL ONCOL, V37, P296, DOI 10.1002/hon.2606; Carra G, 2016, ONCOTARGET, V7, P66287, DOI 10.18632/oncotarget.11507; Chen JQ, 2013, CURR OPIN IMMUNOL, V25, P4, DOI 10.1016/j.coi.2012.12.005; Chen YM, 2013, LEUKEMIA LYMPHOMA, V54, P1411, DOI 10.3109/10428194.2012.745525; Chiu CF, 2016, P NATL ACAD SCI USA, V113, pE2526, DOI 10.1073/pnas.1522612113; Chomel JC, 2011, BLOOD, V118, P3657, DOI 10.1182/blood-2011-02-335497; Chorzalska A, 2018, MOL ONCOL, V12, P630, DOI 10.1002/1878-0261.12186; Chu S, 2011, BLOOD, V118, P5565, DOI 10.1182/blood-2010-12-327437; Cilloni D, 2006, LEUKEMIA, V20, P61, DOI 10.1038/sj.leu.2403998; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721; Dai YJ, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.143; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Eiring A M, 2014, Leuk Suppl, V3, pS5, DOI 10.1038/leusup.2014.3; Eiring AM, 2015, LEUKEMIA, V29, P2328, DOI 10.1038/leu.2015.196; Eiring AM, 2015, LEUKEMIA, V29, P586, DOI 10.1038/leu.2014.245; Fararjeh AS, 2019, CANCERS, V11, DOI 10.3390/cancers11040527; Fisher DAC, 2017, LEUKEMIA, V31, P1962, DOI 10.1038/leu.2016.377; Fukuoka M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201796; Gallipoli P, 2013, BLOOD, V122, P3335, DOI 10.1182/blood-2013-02-485607; Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245; Giustacchini A, 2017, NAT MED, V23, P692, DOI 10.1038/nm.4336; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Hamilton A, 2012, BLOOD, V119, P1501, DOI 10.1182/blood-2010-12-326843; Han SH, 2017, LEUKEMIA, V31, P1659, DOI 10.1038/leu.2017.107; Han SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-97; Heaney NB, 2010, BLOOD, V115, P2241, DOI 10.1182/blood-2008-06-164582; Im E, 2016, BMB REP, V49, P459, DOI 10.5483/BMBRep.2016.49.9.094; Jain P, 2019, BLOOD ADV, V3, P851, DOI 10.1182/bloodadvances.2018025874; Janssen L, 2019, LEUKEMIA, V33, P2116, DOI 10.1038/s41375-019-0443-7; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kagoya Y, 2014, J CLIN INVEST, V124, P528, DOI 10.1172/JCI68101; Khorashad JS, 2015, BLOOD, V125, P1772, DOI 10.1182/blood-2014-08-588855; Lam LT, 2008, BLOOD, V111, P3701, DOI 10.1182/blood-2007-09-111948; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Lounnas N, 2009, INT J CANCER, V125, P308, DOI 10.1002/ijc.24294; Lu ZZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-112; Mahon FX, 2010, LANCET ONCOL, V11, P1029, DOI 10.1016/S1470-2045(10)70233-3; McWeeney SK, 2010, BLOOD, V115, P315, DOI 10.1182/blood-2009-03-210732; Mendez-Ferrer S, 2020, NAT REV CANCER, V20, P285, DOI 10.1038/s41568-020-0245-2; Minson AG, 2019, BLOOD ADV, V3, P1084, DOI 10.1182/bloodadvances.2018028035; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; NOWELL PC, 1960, SCIENCE, V132, P1497; O'Hare T, 2012, NAT REV CANCER, V12, P513, DOI 10.1038/nrc3317; Oh B, 2013, ANTI-CANCER DRUG, V24, P20, DOI 10.1097/CAD.0b013e32835a0fbd; Okumura T, 2018, J BIOCHEM, V163, P19, DOI 10.1093/jb/mvx053; Orlova A, 2019, CANCERS, V11, DOI 10.3390/cancers11121930; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Reynaud D, 2011, CANCER CELL, V20, P661, DOI 10.1016/j.ccr.2011.10.012; Rousselot P, 2014, J CLIN ONCOL, V32, P424, DOI 10.1200/JCO.2012.48.5797; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Santos FPS, 2011, CL LYMPH MYELOM LEUK, V11, P355, DOI 10.1016/j.clml.2011.06.004; Shen N, 2019, ONCOTARGETS THER, V12, P2355, DOI 10.2147/OTT.S197535; Srinivasula SM, 2008, MOL CELL, V30, P123, DOI 10.1016/j.molcel.2008.03.008; Styczynski J, 2012, WSPOLCZESNA ONKOL, V16, P210, DOI 10.5114/wo.2012.29286; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Traer E, 2012, LEUKEMIA, V26, P1140, DOI 10.1038/leu.2011.325; Tsvetkov P, 2017, P NATL ACAD SCI USA, V114, P382, DOI 10.1073/pnas.1619067114; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Wei W, 2013, APOPTOSIS, V18, P1060, DOI 10.1007/s10495-013-0854-2; Welner RS, 2015, CANCER CELL, V27, P671, DOI 10.1016/j.ccell.2015.04.004; Yamada T, 2014, LEUKEMIA RES, V38, P210, DOI 10.1016/j.leukres.2013.10.006; Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707; Yu ZY, 2002, BIOCHEM J, V367, P97, DOI 10.1042/BJ20020588; Zhang B, 2016, BLOOD, V128, P2671, DOI 10.1182/blood-2015-11-679928; Zhang B, 2012, CANCER CELL, V21, P577, DOI 10.1016/j.ccr.2012.02.018; Zhang TQ, 2019, CELL BIOL INT, V43, P98, DOI 10.1002/cbin.11026; Zhang XD, 2016, CANCER CELL, V29, P639, DOI 10.1016/j.ccell.2016.03.026	76	8	8	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2697	2710		10.1038/s41388-021-01732-6	http://dx.doi.org/10.1038/s41388-021-01732-6		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33712704	hybrid, Green Published			2022-12-28	WOS:000628201500001
J	Liu, YB; Li, XZ; Zhang, H; Zhang, MM; Wei, YL				Liu, Yanbin; Li, Xingzhi; Zhang, Hui; Zhang, Mingming; Wei, Yanli			HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer	ONCOGENE			English	Article							MESSENGER-RNA; 3'-UNTRANSLATED REGION; EXPRESSION; PROTEIN; IDENTIFICATION; CYCLOOXYGENASE-2; INHIBITOR; LIGANDS; TARGET; BINDS	Despite the well-established role of CMTM6 in the stabilization of cell surface PD-L1 in cancer cells, the mechanisms underlying CMTM6 expression and regulation are still largely unknown. Here we unexpectedly find a strikingly positive correlation between CMTM6 and Hu-Antigen R (HuR) expression in most types of cancer. Mechanistically, we elucidate HuR stabilizes CMTM6 mRNA via direct association with AU-rich elements (AREs) in its 3'UTR and predominantly upregulates CMTM6, which is readily abolished by HuR-specific inhibitor, MS-444. Phenotypically, we notice abundant cell surface PD-L1 in HuR-high cancer cells, which significantly inhibits immune activation of co-cultured T cells as indicated by IL-2 production. Treatment with MS-444 completely relieves immune suppression imposed by HuR-overexpression and further stimulates immune responses. Ectopic HuR accelerates allograft tumor progression in vivo, which is greatly compromised by simultaneous administration with MS-444. Our study uncovers a novel mechanism in control of CMTM6 and therefore PD-L1 expression, and suggests the potential of combining HuR inhibitor with PD-1/PD-L1 antibodies for cancer immunotherapy.	[Liu, Yanbin; Zhang, Hui] Jining Med Univ, Inst Immunol & Mol Med, Jining, Peoples R China; [Liu, Yanbin] BioBox Sci Inc, Guangzhou, Peoples R China; [Li, Xingzhi] Longgang Dist Peoples Hosp Shenzhen, Dept Urol Surg, Shenzhen, Peoples R China; [Zhang, Mingming; Wei, Yanli] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Peoples R China	Jining Medical University; Sun Yat Sen University	Liu, YB (corresponding author), Jining Med Univ, Inst Immunol & Mol Med, Jining, Peoples R China.; Liu, YB (corresponding author), BioBox Sci Inc, Guangzhou, Peoples R China.	yanbliu@hotmail.com			National Natural Science Foundation of China [81672796]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of China, No. 81672796 to YBL.	Allegri L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43894-0; Blanco FF, 2016, ONCOTARGET, V7, P74043, DOI 10.18632/oncotarget.12189; Brennan SE, 2009, CANCER RES, V69, P5168, DOI 10.1158/0008-5472.CAN-08-4238; Burr ML, 2017, NATURE, V549, P101, DOI 10.1038/nature23643; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8; Chen L, 2020, CANCER IMMUNOL RES, V8, P179, DOI 10.1158/2326-6066.CIR-19-0394; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Coelho MA, 2017, IMMUNITY, V47, P1083, DOI 10.1016/j.immuni.2017.11.016; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fialcowitz-White EJ, 2007, J BIOL CHEM, V282, P20948, DOI 10.1074/jbc.M701751200; Filippova N, 2011, MOL CANCER RES, V9, P648, DOI 10.1158/1541-7786.MCR-10-0325; Gao F, 2019, BIOCHEM BIOPHYS REP, V20, DOI 10.1016/j.bbrep.2019.100690; GRAUS F, 1987, ACTA NEUROL SCAND, V75, P249, DOI 10.1111/j.1600-0404.1987.tb07928.x; Graus F, 1986, Neurologia, V1, P11; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Guan XD, 2018, EBIOMEDICINE, V35, P233, DOI 10.1016/j.ebiom.2018.08.012; Kang MJ, 2008, GASTROENTEROLOGY, V135, P2030, DOI 10.1053/j.gastro.2008.08.009; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Lai KKY, 2017, GASTROENTEROLOGY, V152, P1477, DOI 10.1053/j.gastro.2017.01.021; Lal S, 2017, MOL CANCER RES, V15, P696, DOI 10.1158/1541-7786.MCR-16-0361; Lang M, 2017, CANCER RES, V77, P2424, DOI 10.1158/0008-5472.CAN-15-1726; Liu JZ, 2007, BLOOD, V110, P296, DOI 10.1182/blood-2006-10-051482; Loflin P, 2001, FEBS LETT, V509, P267, DOI 10.1016/S0014-5793(01)03176-3; Meisner NC, 2007, NAT CHEM BIOL, V3, P508, DOI 10.1038/nchembio.2007.14; Mezzadra R, 2017, NATURE, V549, P106, DOI 10.1038/nature23669; Mrena J, 2005, CLIN CANCER RES, V11, P7362, DOI 10.1158/1078-0432.CCR-05-0764; Muralidharan R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07787-4; Nabors LB, 2001, CANCER RES, V61, P2154; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Peng WD, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00427-17; Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Spolski R, 2018, NAT REV IMMUNOL, V18, P648, DOI 10.1038/s41577-018-0046-y; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Twa DDW, 2014, BLOOD, V123, P2062, DOI 10.1182/blood-2013-10-535443; Wang JP, 2019, CANCER BIOL THER, V20, P979, DOI 10.1080/15384047.2019.1591673; Wang XJ, 2019, NATURE, V571, P127, DOI 10.1038/s41586-019-1340-y; Wang ZH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138780; Wu XQ, 2015, ACS CHEM BIOL, V10, P1476, DOI 10.1021/cb500851u; Young LE, 2009, GASTROENTEROLOGY, V136, P1669, DOI 10.1053/j.gastro.2009.01.010	44	11	11	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2230	2242		10.1038/s41388-021-01689-6	http://dx.doi.org/10.1038/s41388-021-01689-6		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33649535	hybrid, Green Published			2022-12-28	WOS:000623739900006
J	Ahmed, SF; Buetow, L; Gabrielsen, M; Lilla, S; Sibbet, GJ; Sumpton, D; Zanivan, S; Hedley, A; Clark, W; Huang, DT				Ahmed, Syed Feroj; Buetow, Lori; Gabrielsen, Mads; Lilla, Sergio; Sibbet, Gary J.; Sumpton, David; Zanivan, Sara; Hedley, Ann; Clark, William; Huang, Danny T.			E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis	ONCOGENE			English	Article							GAIN-OF-FUNCTION; C-CBL; DOWN-REGULATION; TYROSINE PHOSPHORYLATION; NEGATIVE REGULATION; MYELOID-LEUKEMIA; STRUCTURAL BASIS; ADAPTER PROTEIN; EGF RECEPTOR; CIN85	Casitas B-lineage lymphoma (CBL) is a ubiquitin ligase (E3) that becomes activated upon Tyr371-phosphorylation and targets receptor protein tyrosine kinases for ubiquitin-mediated degradation. Deregulation of CBL and its E3 activity is observed in myeloproliferative neoplasms and other cancers, including breast, colon, and prostate cancer. Here, we explore the oncogenic mechanism of E3-inactive CBL mutants identified in myeloproliferative neoplasms. We show that these mutants bind strongly to CIN85 under normal growth conditions and alter the CBL interactome. Lack of E3 activity deregulates CIN85 endosomal trafficking, leading to an altered transcriptome that amplifies signaling events to promote oncogenesis. Disruption of CBL mutant interactions with EGFR or CIN85 reduces oncogenic transformation. Given the importance of the CBL-CIN85 interaction in breast cancers, we examined the expression levels of CIN85, CBL, and the status of Tyr371-phosphorylated CBL (pCBL) in human breast cancer tissue microarrays. Interestingly, pCBL shows an inverse correlation with both CIN85 and CBL, suggesting that high expression of inactivated CBL could coordinate with CIN85 for breast cancer progression. Inhibition of the CBL-CIN85 interaction with a proline-rich peptide of CBL that binds CIN85 reduced the proliferation of MDA-MB-231 cells. Together, these results provide a rationale for exploring the potential of targeting the EGFR-CBL-CIN85 axis in CBL-inactivated mutant cancers.	[Ahmed, Syed Feroj; Buetow, Lori; Gabrielsen, Mads; Lilla, Sergio; Sibbet, Gary J.; Sumpton, David; Zanivan, Sara; Hedley, Ann; Clark, William; Huang, Danny T.] Canc Res UK Beatson Inst, Glasgow, Lanark, Scotland; [Zanivan, Sara; Huang, Danny T.] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland	Beatson Institute; University of Glasgow	Huang, DT (corresponding author), Canc Res UK Beatson Inst, Glasgow, Lanark, Scotland.; Huang, DT (corresponding author), Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland.	d.huang@beatson.gla.ac.uk	Zanivan, Sara/GOV-5505-2022; Huang, Danny/AAM-3631-2021	Huang, Danny/0000-0002-6192-259X; Ahmed, Syed Feroj/0000-0003-1033-2538; Gabrielsen, Mads/0000-0002-9848-2276; Sumpton, David/0000-0002-9004-4079	Beatson Institute's Cancer Research UK core funding [A17196]; Cancer Research UK [A23278/A29256, C596/A12935]; European Research Council (ERC) under the European Union [647849]	Beatson Institute's Cancer Research UK core funding; Cancer Research UK(Cancer Research UK); European Research Council (ERC) under the European Union(European Research Council (ERC))	This work was supported by the Beatson Institute's Cancer Research UK core funding (A17196), Cancer Research UK (A23278/A29256) to DTH and (C596/A12935) to SZ, and European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement no. 647849) to DTH. We thank Catherine Winchester for her assistance in critically reviewing this manuscript and Core Services and Advanced Technologies at the Cancer Research UK Beatson Institute (C596/A17196), with particular thanks to Proteomics, Histology, and Molecular Technologies services.	Ahmad G, 2014, INT J BIOCHEM CELL B, V57, P123, DOI 10.1016/j.biocel.2014.10.019; Ahmed SF, 2015, MOL THER, V23, P255, DOI 10.1038/mt.2014.202; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Bandi SR, 2009, BLOOD, V114, P4197, DOI 10.1182/blood-2008-12-190934; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Buetow L, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0298-6; Caligiuri MA, 2007, BLOOD, V110, P1022, DOI 10.1182/blood-2006-12-061176; Cascio S, 2015, CANCERS, V7, P342, DOI 10.3390/cancers7010342; Cascio S, 2013, ONCOTARGET, V4, P1700, DOI 10.18632/oncotarget.1265; Clara JA, 2016, CANCER BIOL MED, V13, P360, DOI 10.20892/j.issn.2095-3941.2016.0043; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dou H, 2013, NAT STRUCT MOL BIOL, V20, P982, DOI 10.1038/nsmb.2621; Dou H, 2012, NAT STRUCT MOL BIOL, V19, P184, DOI 10.1038/nsmb.2231; Dufour C, 2008, BONE, V42, P1032, DOI 10.1016/j.bone.2008.02.009; Fernandes MS, 2010, J BIOL CHEM, V285, P32596, DOI 10.1074/jbc.M110.106161; Grand FH, 2009, BLOOD, V113, P6182, DOI 10.1182/blood-2008-12-194548; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Jozic D, 2005, NAT STRUCT MOL BIOL, V12, P972, DOI 10.1038/nsmb1000; Kales SC, 2010, CANCER RES, V70, P4789, DOI 10.1158/0008-5472.CAN-10-0610; Kang JM, 2012, ONCOGENE, V31, P5123, DOI 10.1038/onc.2012.18; Kassenbrock CK, 2004, J BIOL CHEM, V279, P28017, DOI 10.1074/jbc.M404114200; Knight JF, 2008, BRIT J CANCER, V99, P1849, DOI 10.1038/sj.bjc.6604774; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Miura-Shimura Y, 2003, J BIOL CHEM, V278, P38495, DOI 10.1074/jbc.M305656200; Nadeau S, 2012, BIOCH ANAL BIOCH, P7921, DOI DOI 10.4172/2161-1009.S6-001; Nadeau SA, 2017, J BIOL CHEM, V292, P3666, DOI 10.1074/jbc.M116.772723; Nakata Y, 2017, BLOOD, V129, P2148, DOI 10.1182/blood-2016-06-724658; Nam JM, 2007, EMBO J, V26, P647, DOI 10.1038/sj.emboj.7601534; Ng C, 2008, EMBO J, V27, P804, DOI 10.1038/emboj.2008.18; Niemeyer CM, 2010, NAT GENET, V42, P794, DOI 10.1038/ng.641; Nihal M, 2016, ONCOTARGET, V7, P53869, DOI 10.18632/oncotarget.10861; Paul Manash K, 2004, Int J Med Sci, V1, P101; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; Rathinam C, 2010, CANCER CELL, V18, P341, DOI 10.1016/j.ccr.2010.09.008; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Ronning SB, 2011, EXP CELL RES, V317, P1804, DOI 10.1016/j.yexcr.2011.05.016; Samoylenko A, 2012, CARCINOGENESIS, V33, P1976, DOI 10.1093/carcin/bgs228; Sanada M, 2009, NATURE, V460, P904, DOI 10.1038/nature08240; Sargin B, 2007, BLOOD, V110, P1004, DOI 10.1182/blood-2007-01-066076; Schroeder B, 2012, MOL BIOL CELL, V23, P3602, DOI 10.1091/mbc.E11-08-0666; Schroeder B, 2010, EMBO J, V29, P3039, DOI 10.1038/emboj.2010.190; Smit GDV, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000217; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	54	2	2	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2149	2164		10.1038/s41388-021-01684-x	http://dx.doi.org/10.1038/s41388-021-01684-x		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33627783	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000621289100005
J	Chen, H; Bian, AW; Yang, LF; Yin, X; Wang, J; Ti, CW; Miao, Y; Peng, SH; Xu, SF; Liu, MY; Qiu, WW; Yi, ZF				Chen, Huang; Bian, Aiwu; Yang, Lian-fang; Yin, Xuan; Wang, Jie; Ti, Chaowen; Miao, Ying; Peng, Shihong; Xu, Shifen; Liu, Mingyao; Qiu, Wen-Wei; Yi, Zhengfang			Targeting STAT3 by a small molecule suppresses pancreatic cancer progression	ONCOGENE			English	Article							TRANSCRIPTION FACTOR STAT3; SIGNAL TRANSDUCER; MITOCHONDRIAL STAT3; HUMAN BREAST; INHIBITOR; ACTIVATION; GROWTH; TOFACITINIB; SUPPORTS; PATHWAY	Pancreatic cancer is lethal in over 90% of cases since it is resistant to current therapeutic strategies. The key role of STAT3 in promoting pancreatic cancer progression has been proven, but effective interventions that suppress STAT3 activities are limited. The development of novel anticancer agents that directly target STAT3 may have potential clinical benefits for pancreatic cancer treatment. Here, we report a new small-molecule inhibitor (N4) with potent antitumor bioactivity, which inhibits multiple oncogenic processes in pancreatic cancer. N4 blocked STAT3 and phospho-tyrosine (pTyr) peptide interactions in fluorescence polarization (FP) assay, specifically abolished phosphor-STAT3 (Tyr705), and suppressed expression of STAT3 downstream genes. The mechanism involved the direct binding of N4 to the STAT3 SH2 domain, thereby, the STAT3 dimerization, STAT3-EGFR, and STAT3-NF-kappa B cross-talk were efficiently inhibited. In animal models of pancreatic cancer, N4 was well tolerated, suppressed tumor growth and metastasis, and significantly prolonged survival of tumor-bearing mice. Our results offer a preclinical proof of concept for N4 as a candidate therapeutic compound for pancreatic cancer.	[Chen, Huang; Bian, Aiwu; Ti, Chaowen; Miao, Ying; Peng, Shihong; Liu, Mingyao; Yi, Zhengfang] East China Normal Univ, Shanghai 200241, Peoples R China; [Chen, Huang; Bian, Aiwu; Ti, Chaowen; Miao, Ying; Peng, Shihong; Liu, Mingyao; Yi, Zhengfang] East China Normal Univ, Shanghai Fengxian Dist Cent Hosp Joint Ctr Transl, Shanghai Key Lab Regulatory Biol Inst Biomed Sci, Shanghai 200241, Peoples R China; [Chen, Huang; Bian, Aiwu; Ti, Chaowen; Miao, Ying; Peng, Shihong; Liu, Mingyao; Yi, Zhengfang] East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China; [Yang, Lian-fang; Wang, Jie; Qiu, Wen-Wei; Yi, Zhengfang] East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai 200241, Peoples R China; [Yin, Xuan; Xu, Shifen] Shanghai Univ Tradit Chinese Med, Shanghai Municipal Hosp Tradit Chinese Med, Shanghai, Peoples R China	East China Normal University; East China Normal University; East China Normal University; East China Normal University; Shanghai University of Traditional Chinese Medicine	Liu, MY; Yi, ZF (corresponding author), East China Normal Univ, Shanghai 200241, Peoples R China.; Liu, MY; Yi, ZF (corresponding author), East China Normal Univ, Shanghai Fengxian Dist Cent Hosp Joint Ctr Transl, Shanghai Key Lab Regulatory Biol Inst Biomed Sci, Shanghai 200241, Peoples R China.; Liu, MY; Yi, ZF (corresponding author), East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.; Qiu, WW; Yi, ZF (corresponding author), East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai 200241, Peoples R China.	myliu@bio.ecnu.edu.cn; wwqiu@chem.ecnu.edu.cn; zfyi@bio.ecnu.edu.cn		chen, huang/0000-0003-2507-5044	National Natural Science Foundation of China [82073310, 81773204, 81830083, 81802970]; Science and Technology Commission of Shanghai Municipality [20JC1417900, 11DZ2260300]; National Key R&D Program of China [2018YFA0507001]; Innovation program of Shanghai Municipal Education Commission [2017-01-07-00-05-E00011]; Shanghai Science and Technology Council [18ZR1411200]; Shenzhen Municipal Government of China [KQTD20170810160226082]; ECNU Construction Fund of Innovation and Entrepreneurship Laboratory [44400-20201-532300/021]; ECNU Public Platform for Innovation [011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); National Key R&D Program of China; Innovation program of Shanghai Municipal Education Commission(Innovation Program of Shanghai Municipal Education Commission); Shanghai Science and Technology Council; Shenzhen Municipal Government of China; ECNU Construction Fund of Innovation and Entrepreneurship Laboratory; ECNU Public Platform for Innovation	This study was supported by National Natural Science Foundation of China (82073310, 81773204, 81830083, and 81802970), The Science and Technology Commission of Shanghai Municipality (20JC1417900, 11DZ2260300), National Key R&D Program of China (2018YFA0507001), Innovation program of Shanghai Municipal Education Commission (2017-01-07-00-05-E00011), Shanghai Science and Technology Council (18ZR1411200), Shenzhen Municipal Government of China (KQTD20170810160226082), ECNU Construction Fund of Innovation and Entrepreneurship Laboratory (44400-20201-532300/021), and ECNU Public Platform for Innovation (011).	Ahmad R, 2008, CANCER RES, V68, P2920, DOI 10.1158/0008-5472.CAN-07-3036; Bharadwaj U, 2016, ONCOTARGET, V7, P26307, DOI 10.18632/oncotarget.8368; Brambilla L, 2015, MOL ONCOL, V9, P1194, DOI 10.1016/j.molonc.2015.02.012; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908; Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002; Furtek SL, 2016, ACS CHEM BIOL, V11, P308, DOI 10.1021/acschembio.5b00945; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Genini D, 2017, P NATL ACAD SCI USA, V114, pE4924, DOI 10.1073/pnas.1615730114; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; He YD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13122; Houg DS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0842-9; Huang C, 2012, CYTOKINE GROWTH F R, V23, P25, DOI 10.1016/j.cytogfr.2012.01.003; Huynh J, 2019, NAT REV CANCER, V19, P82, DOI 10.1038/s41568-018-0090-8; Jerabek-Willemsen M, 2011, ASSAY DRUG DEV TECHN, V9, P342, DOI 10.1089/adt.2011.0380; Jung KH, 2017, CLIN CANCER RES, V23, P5537, DOI 10.1158/1078-0432.CCR-16-2253; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Lai PS, 2015, EXPERT OPIN THER PAT, V25, P1397, DOI 10.1517/13543776.2015.1086749; Lee JW, 2019, NATURE, V567, P249, DOI 10.1038/s41586-019-1004-y; Lee JY, 2005, BIOCHEM BIOPH RES CO, V334, P764, DOI 10.1016/j.bbrc.2005.06.162; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Miklossy G, 2013, NAT REV DRUG DISCOV, V12, P611, DOI 10.1038/nrd4088; Nagathihalli NS, 2016, ONCOTARGET, V7, P65982, DOI 10.18632/oncotarget.11786; Scholz A, 2003, GASTROENTEROLOGY, V125, P891, DOI 10.1016/S0016-5085(03)01064-3; Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201; Shao H, 2003, CANCER RES, V63, P3923; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tolcher A, 2018, ONCOLOGIST, V23, P658, DOI 10.1634/theoncologist.2017-0325; Toyonaga T, 2003, CANCER LETT, V201, P107, DOI 10.1016/S0304-3835(03)00482-8; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; van Vollenhoven RF, 2012, NEW ENGL J MED, V367, P508, DOI 10.1056/NEJMoa1112072; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; Wienken CJ, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1093; Wilkinson B, 2014, NEW ENGL J MED, V371, P1164, DOI 10.1056/NEJMc1408607; Wong ALA, 2017, EXPERT OPIN INV DRUG, V26, P883, DOI 10.1080/13543784.2017.1351941; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhang B, 2019, CELL, V176, P636, DOI 10.1016/j.cell.2019.01.003; Zhang T, 2017, ONCOGENE, V36, P6627, DOI 10.1038/onc.2017.270; Zhang XL, 2013, CANCER RES, V73, P1922, DOI 10.1158/0008-5472.CAN-12-3175; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109; Zhao W, 2010, J BIOL CHEM, V285, P35855, DOI 10.1074/jbc.M110.154088	42	16	16	5	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1440	1457		10.1038/s41388-020-01626-z	http://dx.doi.org/10.1038/s41388-020-01626-z		JAN 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33420372	Green Published, hybrid			2022-12-28	WOS:000607346000003
J	Li, CS; Yao, H; Wang, HB; Fang, JY; Xu, J				Li, Chushu; Yao, Han; Wang, Huanbin; Fang, Jing-Yuan; Xu, Jie			Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity	ONCOGENE			English	Article							SELECTIVE AUTOPHAGY; SIGNALING PATHWAYS; MEDIATED CLEAVAGE; CANCER; EXPRESSION; CALPAIN; REVEALS; COMPLEX; CA2+; MEK	Cancer cell expression of PD-L1 leads to T cells exhaustion by transducing co-inhibitory signal, and further understanding the regulation of PD-L1 in cancer cells may provide additional therapeutic strategies. Here by drug repurposing screen, we identified amlodipine as a potent inhibitor of PD-L1 expression in cancer cells. Further survey of calcium-associated pathways revealed calpain-dependent stabilization of the PD-L1 protein. Intracellular calcium delivered an operational signal to calpain-dependent Beclin-1 cleavage, blocking autophagic degradation of PD-L1 accumulated on recycling endosome (RE). Blocking calcium flux by amlodipine depleted PD-L1 expression and increased CD8+ T-cell infiltration in tumor tissues but not in myocardium, causing dose-dependent tumor suppression in vivo. Rescuing PD-L1 expression eliminated the effects of amlodipine, suggesting the PD-L1-dependent effect of amlodipine. These results reveal a calcium-dependent mechanism controlling PD-L1 degradation, and highlight calcium flux blockade as a potential strategy for combinatorial immunotherapy.	[Li, Chushu; Yao, Han; Wang, Huanbin; Fang, Jing-Yuan] Shanghai Jiao Tong Univ, Renji Hosp,Sch Med,Minist Hlth, Div Gastroenterol & Hepatol,Key Lab Gastroenterol, State Key Lab Oncogenes & Related Genes,Shanghai, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China; [Xu, Jie] Fudan Univ, Zhongshan Xuhui Hosp, Inst Biomed Sci, Shanghai, Peoples R China; [Xu, Jie] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Gastroenterol & Hepatol, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China	Shanghai Jiao Tong University; Fudan University; Shanghai Jiao Tong University	Xu, J (corresponding author), Fudan Univ, Zhongshan Xuhui Hosp, Inst Biomed Sci, Shanghai, Peoples R China.; Xu, J (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Gastroenterol & Hepatol, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.	jie_xu@fudan.edu.cn	li, chu/GPS-7224-2022; Xu, Jie/K-3712-2019	Xu, Jie/0000-0001-9163-3898; Li, Chushu/0000-0001-6658-2208	National Natural Science Foundation of China [82030104, 81874050, 81572326]; Basic Research Projects of Shanghai Science and Technology Innovation Action Plan [20JC1410700]; National Key R & D Program of China [2016YFC0906002]; Fudan University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Basic Research Projects of Shanghai Science and Technology Innovation Action Plan; National Key R & D Program of China; Fudan University	This work was supported by National Natural Science Foundation of China (No: 82030104, 81874050, 81572326), Basic Research Projects of Shanghai Science and Technology Innovation Action Plan (20JC1410700); National Key R & D Program of China (2016YFC0906002, 2016YFC0906002), Tang Scholar (JX), and Startup Research Funding of Fudan University.	Anding AL, 2017, DEV CELL, V41, P10, DOI 10.1016/j.devcel.2017.02.016; Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Barcelo C, 2020, CANCERS, V12, DOI 10.3390/cancers12020391; Beese CJ, 2020, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00373; Blander JM, 2018, ANNU REV IMMUNOL, V36, P717, DOI 10.1146/annurev-immunol-041015-055523; Bong AHL, 2018, BBA-MOL CELL RES, V1865, P1786, DOI 10.1016/j.bbamcr.2018.05.015; Bootman MD, 2018, CELL CALCIUM, V70, P32, DOI 10.1016/j.ceca.2017.08.005; Bulsara K.G., 2020, STATPEARLS; Burr ML, 2017, NATURE, V549, P101, DOI 10.1038/nature23643; Cao DL, 2019, CANCER RES, V79, P2604, DOI 10.1158/0008-5472.CAN-18-3842; Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78; Cha JH, 2018, MOL CELL, V71, P606, DOI 10.1016/j.molcel.2018.07.030; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Geng Y, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125326; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Guo YJ, 2012, J CELL SCI, V125, P1706, DOI 10.1242/jcs.093203; Hamasaki M, 2013, NATURE, V495, P389, DOI 10.1038/nature11910; Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991; Hong SD, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1094598; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Kang SH, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1515057; Kaplon H, 2019, MABS-AUSTIN, V11, P219, DOI 10.1080/19420862.2018.1556465; Kayamori H, 2018, INT HEART J, V59, P607, DOI 10.1536/ihj.17-265; Kim I, 2011, ANTIOXID REDOX SIGN, V14, P1919, DOI 10.1089/ars.2010.3768; Knaevelsrud H, 2013, AUTOPHAGY, V9, P1639, DOI 10.4161/auto.26124; KOIDE Y, 1988, P NATL ACAD SCI USA, V85, P3120, DOI 10.1073/pnas.85.9.3120; Kon E, 2019, DRUG RESIST UPDATE, V45, P13, DOI 10.1016/j.drup.2019.07.004; Li CW, 2018, CANCER CELL, V33, P187, DOI 10.1016/j.ccell.2018.01.009; Li CW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12632; Li J, 2019, EXP CELL RES, V374, P304, DOI 10.1016/j.yexcr.2018.12.001; Liu L, 2015, CLIN CANCER RES, V21, P1639, DOI 10.1158/1078-0432.CCR-14-2339; Loi S, 2016, CLIN CANCER RES, V22, P1499, DOI 10.1158/1078-0432.CCR-15-1125; Longatti A, 2012, J CELL BIOL, V197, P659, DOI 10.1083/jcb.201111079; Ma L, 2019, INTERDISCIP SCI, V11, P266, DOI 10.1007/s12539-019-00331-0; Maher CM, 2018, MOL CANCER RES, V16, P243, DOI 10.1158/1541-7786.MCR-17-0166; Marie N, 2005, BIOCHEM J, V389, P223, DOI 10.1042/BJ20042116; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mohan N, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1624128; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Ota K, 2015, CLIN CANCER RES, V21, P4014, DOI 10.1158/1078-0432.CCR-15-0016; Pan MR, 2020, CANCERS, V12, DOI 10.3390/cancers12010094; Pavel M, 2017, FEBS J, V284, P672, DOI 10.1111/febs.13931; Pimentel-Muinos FX, 2014, AUTOPHAGY, V10, P397, DOI 10.4161/auto.27244; Puri C, 2018, DEV CELL, V45, P114, DOI 10.1016/j.devcel.2018.03.008; Puri C, 2013, CELL, V154, P1285, DOI 10.1016/j.cell.2013.08.044; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Russo R, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.29; Shaughnessy M, 2019, INT J ONCOL, V55, P1090, DOI 10.3892/ijo.2019.4873; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Sun F, 2016, TUMOR BIOL, V37, P15467, DOI 10.1007/s13277-016-5353-y; Syn NL, 2017, LANCET ONCOL, V18, pE731, DOI 10.1016/S1470-2045(17)30607-1; Wang HB, 2019, NAT CHEM BIOL, V15, P42, DOI 10.1038/s41589-018-0161-x; Wang L, 2008, NAT IMMUNOL, V9, P186, DOI 10.1038/ni1548; Wang XJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1148-5; Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79; Xia HG, 2010, AUTOPHAGY, V6, P61, DOI 10.4161/auto.6.1.10326; Yamashita S, 2017, AUTOPHAGY, V13, P980, DOI 10.1080/15548627.2017.1291113; Yao H, 2019, NAT BIOMED ENG, V3, P306, DOI 10.1038/s41551-019-0375-6; Yen WL, 2010, J CELL BIOL, V188, P101, DOI 10.1083/jcb.200904075; Yla-Anttila P, 2009, AUTOPHAGY, V5, P1180; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang Z, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00213-8; Zhao Q, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.66; Zhou CH, 2012, AUTOPHAGY, V8, P1215, DOI 10.4161/auto.20284	66	10	11	6	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1128	1146		10.1038/s41388-020-01592-6	http://dx.doi.org/10.1038/s41388-020-01592-6		DEC 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323966	Green Submitted			2022-12-28	WOS:000599126500011
J	Xu, H; Liu, L; Li, WL; Zou, DW; Yu, J; Wang, LF; Wong, CC				Xu, Hui; Liu, Lei; Li, Weilin; Zou, Duowu; Yu, Jun; Wang, Lifu; Wong, Chi Chun			Transcription factors in colorectal cancer: molecular mechanism and therapeutic implications	ONCOGENE			English	Review							NF-KAPPA-B; KRUPPEL-LIKE FACTOR-4; CELL-CYCLE ARREST; TUMOR-SUPPRESSIVE PROPERTIES; ENDOTHELIAL GROWTH-FACTOR; APOPTOSIS IN-VITRO; ACTIVATED T-CELLS; FORKHEAD BOX M1; COLON-CANCER; NUCLEAR-FACTOR	Colorectal cancer (CRC) is a major cause of cancer mortality worldwide, however, the molecular mechanisms underlying the pathogenesis of CRC remain largely unclear. Recent studies have revealed crucial roles of transcription factors in CRC development. Transcription factors essential for the regulation of gene expression by interacting with transcription corepressor/enhancer complexes and they orchestrate downstream signal transduction. Deregulation of transcription factors is a frequent occurrence in CRC, and the accompanying drastic changes in gene expression profiles play fundamental roles in multistep process of tumorigenesis, from cellular transformation, disease progression to metastatic disease. Herein, we summarized current and emerging key transcription factors that participate in CRC tumorigenesis, and highlighted their oncogenic or tumor suppressive functions. Moreover, we presented critical transcription factors of CRC, emphasized the major molecular mechanisms underlying their effect on signal cascades associated with tumorigenesis, and summarized of their potential as molecular biomarkers for CRC prognosis therapeutic response, as well as drug targets for CRC treatment. A better understanding of transcription factors involved in the development of CRC will provide new insights into the pathological mechanisms and reveal novel prognostic biomarkers and therapeutic strategies for CRC.	[Xu, Hui; Liu, Lei; Zou, Duowu; Wang, Lifu] Shanghai Jiao Tong Univ, Sch Med, Dept Gastroenterol, Ruijin Hosp, Shanghai, Peoples R China; [Xu, Hui; Yu, Jun; Wong, Chi Chun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Xu, Hui; Yu, Jun; Wong, Chi Chun] Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Li, Weilin] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Genet, Boston, MA 02115 USA	Shanghai Jiao Tong University; Chinese University of Hong Kong; Chinese University of Hong Kong; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Liu, L; Wang, LF (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Gastroenterol, Ruijin Hosp, Shanghai, Peoples R China.; Wong, CC (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Wong, CC (corresponding author), Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.	ll11860@rjh.com.cn; lifuwang@sjtu.edu.cn; chichun.wong@cuhk.edu.hk	; Jun, Yu/D-8569-2015	Wong, Chi Chun/0000-0003-1362-3541; Jun, Yu/0000-0001-5008-2153	Natural Science Foundation of China [81802331, 81772501]; Research Grants Council-General Research Fund (RGC-GRF), Hong Kong [14101917, 14108718, 14163817, 14110819]; Heath and Medical Research Fund (HMRF) [06170686]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Grants Council-General Research Fund (RGC-GRF), Hong Kong; Heath and Medical Research Fund (HMRF)	This project was supported by the Natural Science Foundation of China (81802331, 81772501), Research Grants Council-General Research Fund (RGC-GRF; 14101917, 14108718, 14163817 and 14110819), Hong Kong; Heath and Medical Research Fund (HMRF) (06170686).	Abdelrahim M, 2005, MOL PHARMACOL, V68, P317, DOI 10.1124/mol.105.011825; Ahmed M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0406-1; Arques O, 2016, CLIN CANCER RES, V22, P644, DOI 10.1158/1078-0432.CCR-14-3081; Ashida Reiko, 2005, Inflammopharmacology, V13, P113, DOI 10.1163/156856005774423935; Bajpai R, 2017, CRIT REV ONCOL HEMAT, V113, P1, DOI 10.1016/j.critrevonc.2017.02.024; Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148; Bella L, 2014, SEMIN CANCER BIOL, V29, P32, DOI 10.1016/j.semcancer.2014.07.008; Ben-David E, 2014, CANCER RES, V74, P5532, DOI 10.1158/0008-5472.CAN-14-0932; Binion DG, 2008, GUT, V57, P1509, DOI 10.1136/gut.2008.152496; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Buettner R, 2002, CLIN CANCER RES, V8, P945; Bullock MD, 2013, BRIT J CANCER, V109, P387, DOI 10.1038/bjc.2013.355; Cervantes-Madrid DL, 2017, ONCOL LETT, V13, P1411, DOI 10.3892/ol.2017.5571; Chang WC, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-94; Chen FF, 2016, ONCOL REP, V35, P1227, DOI 10.3892/or.2015.4515; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen YJ, 2009, CHEM-BIOL INTERACT, V181, P440, DOI 10.1016/j.cbi.2009.07.004; Chhabra A, 2007, ONCOL REP, V18, P953; Chintharlapalli S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-371; Conkright MD, 2005, TRENDS CELL BIOL, V15, P457, DOI 10.1016/j.tcb.2005.07.007; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Corvinus FM, 2005, NEOPLASIA, V7, P545, DOI 10.1593/neo.04571; Cruz-Correa M, 2018, GASTROENTEROLOGY, V155, P668, DOI 10.1053/j.gastro.2018.05.031; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; Daniel C, 2014, INT J CANCER, V134, P1767, DOI 10.1002/ijc.28329; Dehner M, 2008, J BIOL CHEM, V283, P19201, DOI 10.1074/jbc.M710366200; Demir S, 2020, HAEMATOLOGICA, V105, P170, DOI 10.3324/haematol.2018.199364; Du W, 2012, J CELL PHYSIOL, V227, P2421, DOI 10.1002/jcp.22977; Dunleavy K, 2009, BLOOD, V113, P6069, DOI 10.1182/blood-2009-01-199679; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; de Mattos SF, 2008, MOL CANCER THER, V7, P3237, DOI 10.1158/1535-7163.MCT-08-0398; Fitzgerald KA, 2014, EXPERT OPIN THER TAR, V18, P633, DOI 10.1517/14728222.2014.896904; Furqan M, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-90; Gambhir S, 2015, WORLD J GASTROENTERO, V21, P3174, DOI 10.3748/wjg.v21.i11.3174; Gerlach K, 2012, CANCER RES, V72, P4340, DOI 10.1158/0008-5472.CAN-11-4155; Germani A, 2014, CANCER LETT, V344, P110, DOI 10.1016/j.canlet.2013.10.035; Ghaleb AM, 2016, MOL CANCER RES, V14, P385, DOI 10.1158/1541-7786.MCR-15-0410; Goel A, 2004, INT J CANCER, V112, P754, DOI 10.1002/ijc.20472; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Groner B, 2017, MOL CELL ENDOCRINOL, V451, P1, DOI 10.1016/j.mce.2017.05.033; Halasi M, 2013, MOL CANCER THER, V12, P245, DOI 10.1158/1535-7163.MCT-12-0712; Haydon AMM, 2006, GUT, V55, P62, DOI 10.1136/gut.2005.068189; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hong X, 2012, MOL MED REP, V5, P1215, DOI 10.3892/mmr.2012.801; Hosoi Y, 2004, INT J ONCOL, V25, P461; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hubbard JM, 2017, DRUGS, V77, P1091, DOI 10.1007/s40265-017-0759-4; Hui KY, 2014, CANCER LETT, V354, P189, DOI 10.1016/j.canlet.2014.08.009; Iacopetta B, 2006, ANN ONCOL, V17, P842, DOI 10.1093/annonc/mdl035; Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175; Imamura Y, 2005, ANTICANCER RES, V25, P2627; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Itoh N, 2002, CANCER, V94, P3127, DOI 10.1002/cncr.10591; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jiang WH, 2015, SURG ONCOL, V24, P220, DOI 10.1016/j.suronc.2015.05.004; Jin H, 2015, ONCOL REP, V33, P3171, DOI 10.3892/or.2015.3938; Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8-6-508; Kappelmann M, 2014, EUR J CELL BIOL, V93, P76, DOI 10.1016/j.ejcb.2013.10.003; Khaleghpour K, 2004, CARCINOGENESIS, V25, P241, DOI 10.1093/carcin/bgg195; Kodach LL, 2010, CARCINOGENESIS, V31, P1567, DOI 10.1093/carcin/bgq147; Konstantinopoulos PA, 2011, JAMA-J AM MED ASSOC, V305, P2349, DOI 10.1001/jama.2011.727; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kunnumakkara AB, 2007, CANCER RES, V67, P3853, DOI 10.1158/0008-5472.CAN-06-4257; Lagadec P, 2008, BRIT J CANCER, V98, P335, DOI 10.1038/sj.bjc.6604082; Lai PS, 2015, EXPERT OPIN THER PAT, V25, P1397, DOI 10.1517/13543776.2015.1086749; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Lee CWL, 2010, CANCER RES, V70, P4243, DOI 10.1158/0008-5472.CAN-09-3805; Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li DW, 2013, CLIN CANCER RES, V19, P62, DOI 10.1158/1078-0432.CCR-12-1588; Li XL, 2015, WORLD J GASTROENTERO, V21, P84, DOI 10.3748/wjg.v21.i1.84; Liang HS, 2011, CANCER LETT, V313, P91, DOI 10.1016/j.canlet.2011.08.028; Lin L, 2011, CANCER RES, V71, P7226, DOI 10.1158/0008-5472.CAN-10-4660; Liu SH, 2014, GASTROENTEROLOGY, V147, P847, DOI 10.1053/j.gastro.2014.06.006; Liu Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0856-3; Lu SY, 2010, INT J CANCER, V126, P416, DOI 10.1002/ijc.24761; Lund IK, 2011, CURR DRUG TARGETS, V12, P1744; Luo H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.3; Madrigal P, 2018, TRENDS CELL BIOL, V28, P509, DOI 10.1016/j.tcb.2018.04.009; Mariani F, 2014, WORLD J GASTROENTERO, V20, P9716, DOI 10.3748/wjg.v20.i29.9716; Marzi L, 2016, BRIT J CANCER, V115, P1223, DOI 10.1038/bjc.2016.313; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mishra L, 2005, ONCOGENE, V24, P5775, DOI 10.1038/sj.onc.1208924; Nagarsheth N, 2016, CANCER RES, V76, P275, DOI 10.1158/0008-5472.CAN-15-1938; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Ogino S, 2007, VIRCHOWS ARCH, V450, P529, DOI 10.1007/s00428-007-0398-3; Okugawa Y, 2015, GASTROENTEROLOGY, V149, P1204, DOI 10.1053/j.gastro.2015.07.011; Page BDG, 2011, EXPERT OPIN THER PAT, V21, P65, DOI 10.1517/13543776.2011.539205; Pandey MK, 2012, INT J CANCER, V130, P213, DOI 10.1002/ijc.25997; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Patel M, 2018, TRANSL RES, V197, P43, DOI 10.1016/j.trsl.2018.02.002; Patel NV, 2010, CANCER EPIDEM BIOMAR, V19, P2631, DOI 10.1158/1055-9965.EPI-10-0677; Poynter JN, 2009, CANCER EPIDEM BIOMAR, V18, P2745, DOI 10.1158/1055-9965.EPI-09-0517; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Qazi AK, 2015, CANCER LETT, V359, P47, DOI 10.1016/j.canlet.2014.12.034; Qi WT, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-219; Qi WT, 2011, AM J PHYSIOL-GASTR L, V300, pG264, DOI 10.1152/ajpgi.00416.2010; Rajitha B, 2016, CANCER LETT, V373, P227, DOI 10.1016/j.canlet.2016.01.052; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Robbs BK, 2008, MOL CELL BIOL, V28, P7168, DOI 10.1128/MCB.00256-08; Roger L, 2010, J CELL SCI, V123, P1295, DOI 10.1242/jcs.061002; Russo A, 2005, J CLIN ONCOL, V23, P7518, DOI 10.1200/JCO.2005.00.471; Sakai E, 2016, CANCER SCI, V107, P820, DOI 10.1111/cas.12930; Sakamoto KM, 2009, CLIN CANCER RES, V15, P2583, DOI 10.1158/1078-0432.CCR-08-1137; Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383; Sampurno S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.119; Sandoval Salemiz, 2009, Adv Hematol, V2009, P634292, DOI 10.1155/2009/634292; Sarkar M, 2015, ONCOGENE, V34, P5843, DOI 10.1038/onc.2015.42; Schaffer M, 2015, CURR OPIN CLIN NUTR, V18, P605, DOI 10.1097/MCO.0000000000000227; Schulz-Heddergott R, 2018, CANCER CELL, V34, P298, DOI 10.1016/j.ccell.2018.07.004; Seo HS, 2008, CANCER RES, V68, P6065, DOI 10.1158/0008-5472.CAN-07-5376; Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shen H, 2011, CURR PHARM DESIGN, V17, P560, DOI 10.2174/138161211795222603; Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104; Shi Q, 2001, CANCER RES, V61, P4143; Shoeb M, 2013, FREE RADICAL BIO MED, V63, P280, DOI 10.1016/j.freeradbiomed.2013.05.039; Song IS, 2015, GASTROENTEROLOGY, V149, P1006, DOI 10.1053/j.gastro.2015.06.007; Song KH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.462; Soong R, 2009, BRIT J CANCER, V100, P676, DOI 10.1038/sj.bjc.6604899; Spano JP, 2006, EUR J CANCER, V42, P2668, DOI 10.1016/j.ejca.2006.07.006; Stein Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246197; Steven A, 2015, MOL CANCER RES, V13, P1248, DOI 10.1158/1541-7786.MCR-14-0590; Subramaniam MM, 2009, AM J GASTROENTEROL, V104, P426, DOI 10.1038/ajg.2008.141; Subramaniam MM, 2009, BBA-REV CANCER, V1796, P315, DOI 10.1016/j.bbcan.2009.07.004; Sunami Y, 2011, J CLIN INVEST, V121, P2551, DOI 10.1172/JCI58454; Sung JJY, 2008, GUT, V57, P1166, DOI 10.1136/gut.2007.146316; Takayama T, 2006, J GASTROENTEROL, V41, P185, DOI 10.1007/s00535-006-1801-6; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tortola S, 1999, J CLIN ONCOL, V17, P1375, DOI 10.1200/JCO.1999.17.5.1375; Tripathi MK, 2014, CANCER RES, V74, P6947, DOI 10.1158/0008-5472.CAN-14-1592; Uddin S, 2011, AM J PATHOL, V178, P537, DOI 10.1016/j.ajpath.2010.10.020; Vaiopoulos AG, 2013, J MOL MED, V91, P1029, DOI 10.1007/s00109-013-1045-x; van Grevenynghe J, 2012, CYTOKINE GROWTH F R, V23, P215, DOI 10.1016/j.cytogfr.2012.05.008; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Waby JS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-275; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wang D, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00897-z; Wang F, 2013, J PATHOL, V229, P12, DOI 10.1002/path.4078; Wang XW, 2017, ONCOL LETT, V13, P2867, DOI 10.3892/ol.2017.5851; Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539; Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425; Wierstra I, 2013, ADV CANCER RES, V119, P191, DOI 10.1016/B978-0-12-407190-2.00016-2; Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112; Xie FC, 2015, J MED CHEM, V58, P5075, DOI 10.1021/acs.jmedchem.5b00468; Xiong H, 2008, NEOPLASIA, V10, P287, DOI 10.1593/neo.07971; Xiong H, 2009, LAB INVEST, V89, P717, DOI 10.1038/labinvest.2009.11; Xu J, 2008, J CANCER RES CLIN, V134, P891, DOI 10.1007/s00432-008-0353-y; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang KK, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0158-1; Yang VW, 2019, MOL CANCER RES, V17, P165, DOI 10.1158/1541-7786.MCR-18-0399; Yeh JE, 2013, CURR OPIN ONCOL, V25, P652, DOI 10.1097/01.cco.0000432528.88101.1a; Yoshida Y, 2007, GASTROENTEROLOGY, V132, P1420, DOI 10.1053/j.gastro.2007.01.036; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yu LL, 2004, WORLD J GASTROENTERO, V10, P3255, DOI 10.3748/wjg.v10.i22.3255; Yue M, 2018, CELL CYCLE, V17, P240, DOI 10.1080/15384101.2017.1407892; Zhang J, 2017, RECENT PAT ANTI-CANC, V12, P247, DOI [10.2174/1574892812666170508124932, 10.2174/1574892812666170424144352]; Zhang W, 2006, MOL CELL BIOL, V26, P2055, DOI 10.1128/MCB.26.6.2055-2064.2006; Zhang WH, 2005, AM J CLIN PATHOL, V124, P11, DOI 10.1309/T1H2Y2CHWY7PD2BN; Zhang X, 2017, ONCOGENE, V36, P807, DOI 10.1038/onc.2016.249; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067; Zhao YY, 2013, ONCOL REP, V30, P1782, DOI 10.3892/or.2013.2627; Zhou XJ, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0677-x	170	19	19	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1555	1569		10.1038/s41388-020-01587-3	http://dx.doi.org/10.1038/s41388-020-01587-3		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33323976				2022-12-28	WOS:000599126500009
J	Fan, KJ; Spassova, I; Gravemeyer, J; Ritter, C; Horny, K; Lange, A; Gambichler, T; Odum, N; Schrama, D; Schadendorf, D; Ugurel, S; Becker, JC				Fan, Kaiji; Spassova, Ivelina; Gravemeyer, Jan; Ritter, Cathrin; Horny, Kai; Lange, Anja; Gambichler, Thilo; Odum, Niels; Schrama, David; Schadendorf, Dirk; Ugurel, Selma; Becker, Juergen C.			Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53	ONCOGENE			English	Article							DOWN-REGULATION; EXPRESSION; MICRORNAS; MELANOMA; GENE; ANGIOGENESIS; RELEVANCE; YAP1; CSL	Merkel cell carcinoma (MCC) is a highly invasive and metastatic skin cancer. While high expression of miR-375 is a characteristic of MCC, it seems not to contribute to the malignant phenotype of MCC cells. miR-375 enrichment in MCC-derived extracellular vesicles suggests its intercellular signaling function. Here, we demonstrate that horizontally transferred miR-375 causes fibroblast polarization toward cancer-associated fibroblasts (CAFs). The polarization is evidenced by phenotypic changes and induction of alpha-SMA, CXCL2, and IL-1 beta. Fibroblast polarization is inhibited by specific antagomirs and mimicked by experimental miR-375 expression. Mechanistically, miR-375 downregulates RBPJ and p53, two key players regulating fibroblast polarization. In clinical MCC samples, in situ hybridization located miR-375 in CAFs, which correlated with high alpha-SMA protein and low RBPJ and TP53 expression; single-cell RNAseq revealed a disparate fibroblast polarization negatively correlating with p53 pathway-related gene expression. Thus, the functional role of miR-375 in MCC is to generate a pro-tumorigenic microenvironment by inducing fibroblast polarization.	[Fan, Kaiji; Spassova, Ivelina; Gravemeyer, Jan; Ritter, Cathrin; Horny, Kai; Becker, Juergen C.] Univ Hosp Essen, Dept Translat Skin Canc Res, Essen, Germany; [Fan, Kaiji; Spassova, Ivelina; Gravemeyer, Jan; Ritter, Cathrin; Horny, Kai; Schadendorf, Dirk; Becker, Juergen C.] German Canc Consortium DKTK, Essen, Germany; [Fan, Kaiji; Spassova, Ivelina; Gravemeyer, Jan; Ritter, Cathrin; Horny, Kai; Becker, Juergen C.] German Canc Res Ctr, Heidelberg, Germany; [Fan, Kaiji] Med Univ Graz, Dept Dermatol, Graz, Austria; [Lange, Anja] Univ Duisburg Essen, Fac Biol, Res Grp Bioinformat, Essen, Germany; [Gambichler, Thilo] Ruhr Univ Bochum, Dept Dermatol, Skin Canc Ctr, Bochum, Germany; [Odum, Niels] Univ Copenhagen, Dept Immunol & Microbiol, LEO Fdn, Skin Immunol Res Ctr, Copenhagen, Denmark; [Schrama, David] Univ Hosp Wurzburg, Dept Dermatol, Wurzburg, Germany; [Schadendorf, Dirk; Ugurel, Selma; Becker, Juergen C.] Univ Hosp Essen, Dept Dermatol, Essen, Germany	University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Medical University of Graz; University of Duisburg Essen; Ruhr University Bochum; University of Copenhagen; University of Wurzburg; University of Duisburg Essen	Becker, JC (corresponding author), Univ Hosp Essen, Dept Translat Skin Canc Res, Essen, Germany.; Becker, JC (corresponding author), German Canc Consortium DKTK, Essen, Germany.; Becker, JC (corresponding author), German Canc Res Ctr, Heidelberg, Germany.; Becker, JC (corresponding author), Univ Hosp Essen, Dept Dermatol, Essen, Germany.	j.becker@dkfz.de		Schadendorf, Dirk/0000-0003-3524-7858; Fan, Kaiji/0000-0003-4310-4515; Schrama, David/0000-0002-6931-8194	Deutsches Krebsforschungszentrum (DKFZ) [DKTK ED03]; Projekt DEAL	Deutsches Krebsforschungszentrum (DKFZ)(Helmholtz Association); Projekt DEAL	This work was funded by DKTK ED03 from Deutsches Krebsforschungszentrum (DKFZ) including funding for KF. Open Access funding enabled and organized by Projekt DEAL.	Abraham KJ, 2016, AM J PATHOL, V186, P1025, DOI 10.1016/j.ajpath.2015.11.020; Arandkar S, 2018, P NATL ACAD SCI USA, V115, P6410, DOI 10.1073/pnas.1719076115; Becker JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.77; Bhome R, 2018, CANCER LETT, V420, P228, DOI 10.1016/j.canlet.2018.02.002; Bussard KM, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0740-2; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Chen XM, 2019, NAT REV DRUG DISCOV, V18, P99, DOI 10.1038/s41573-018-0004-1; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Cui H, 2015, ONCOGENE, V34, P3640, DOI 10.1038/onc.2014.300; Dror S, 2016, NAT CELL BIOL, V18, P1006, DOI 10.1038/ncb3399; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Fan KJ, 2020, CANCERS, V12, DOI 10.3390/cancers12030529; Fan KJ, 2020, J INVEST DERMATOL, V140, P56, DOI 10.1016/j.jid.2019.06.135; Fan K, 2018, CLIN CANCER RES, V24, P5873, DOI 10.1158/1078-0432.CCR-18-1184; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Frank AC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08989-2; Goruppi S, 2017, CELL REP, V20, P2468, DOI 10.1016/j.celrep.2017.08.048; Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008-5472.CAN-10-4455; Hudson J, 2013, EXP MOL PATHOL, V95, P62, DOI 10.1016/j.yexmp.2013.05.001; Ishii G, 2016, ADV DRUG DELIVER REV, V99, P186, DOI 10.1016/j.addr.2015.07.007; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Khare D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03053; Kogure T, 2011, HEPATOLOGY, V54, p1278A; Konstantinell A, 2016, PROTEOMICS, V16, P2587, DOI 10.1002/pmic.201600223; Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0; Kourembanas S, 2015, ANNU REV PHYSIOL, V77, P13, DOI 10.1146/annurev-physiol-021014-071641; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Liang XL, 2016, J CELL SCI, V129, P2182, DOI 10.1242/jcs.170373; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lindahl LM, 2016, ONCOTARGET, V7, P45730, DOI 10.18632/oncotarget.10160; Liu JT, 2019, HEPATOLOGY, V70, P241, DOI 10.1002/hep.30607; Liu Y, 2016, CANCER LETT, V370, P125, DOI 10.1016/j.canlet.2015.10.011; Liu YX, 2013, DNA REPAIR, V12, P741, DOI 10.1016/j.dnarep.2013.06.002; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Nishikawa E, 2011, CANCER RES, V71, P6165, DOI 10.1158/0008-5472.CAN-11-1020; Pang WJ, 2015, CANCER SCI, V106, P1362, DOI 10.1111/cas.12747; Paulson KG, 2014, AM J CLIN PATHOL, V142, P452, DOI 10.1309/AJCPIKDZM39CRPNC; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; Poy MN, 2009, P NATL ACAD SCI USA, V106, P5813, DOI 10.1073/pnas.0810550106; Prager-Khoutorsky M, 2011, NAT CELL BIOL, V13, P1457, DOI 10.1038/ncb2370; Procopio MG, 2015, NAT CELL BIOL, V17, P1193, DOI 10.1038/ncb3228; Renwick N, 2013, J CLIN INVEST, V123, P2694, DOI 10.1172/JCI68760; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; Seto AG, 2018, BRIT J HAEMATOL, V183, P428, DOI 10.1111/bjh.15547; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Szczyrba J, 2011, MOL CANCER RES, V9, P791, DOI 10.1158/1541-7786.MCR-10-0573; Thayanithy V, 2014, TRANSL RES, V164, P359, DOI 10.1016/j.trsl.2014.05.011; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van der Pol E, 2012, PHARMACOL REV, V64, P676, DOI 10.1124/pr.112.005983; Walsh NM, 2016, HUM PATHOL, V52, P190, DOI 10.1016/j.humpath.2016.02.002; Wardhani LO, 2019, HUM PATHOL, V84, P52, DOI 10.1016/j.humpath.2018.09.003; Wheat R, 2014, CANCERS, V6, P1047, DOI 10.3390/cancers6021047; Xie H, 2014, J INVEST DERMATOL, V134, P507, DOI 10.1038/jid.2013.355; Xu R, 2018, NAT REV CLIN ONCOL, V15, P617, DOI 10.1038/s41571-018-0036-9; Yan JW, 2014, INT J CANCER, V135, P1011, DOI 10.1002/ijc.28563; Yan W, 2018, NAT CELL BIOL, V20, P597, DOI 10.1038/s41556-018-0083-6; Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007	60	16	16	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					980	996		10.1038/s41388-020-01576-6	http://dx.doi.org/10.1038/s41388-020-01576-6		DEC 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33311552	hybrid, Green Published			2022-12-28	WOS:000598100200001
J	Abdullah, A; Akhand, SS; Paez, JSP; Brown, W; Pan, L; Libring, S; Badamy, M; Dykuizen, E; Solorio, L; Tao, WA; Wendt, MK				Abdullah, Ammara; Akhand, Saeed Salehin; Paez, Juan Sebastian Paez; Brown, Wells; Pan, Li; Libring, Sarah; Badamy, Michael; Dykuizen, Emily; Solorio, Luis; Tao, W. Andy; Wendt, Michael K.			Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; CELL MIGRATION; ACTIVATION; EXPRESSION; FAMILY; COMBINATION; BEVACIZUMAB; INHIBITION; ERLOTINIB; OUTGROWTH	Human epidermal growth factor receptor 2 (HER2)-amplified breast cancers are treated using targeted antibodies and kinase inhibitors, but resistance to these therapies leads to systemic tumor recurrence of metastatic disease. Herein, we conducted gene expression analyses of HER2 kinase inhibitor-resistant cell lines as compared to their drug-sensitive counterparts. These data demonstrate the induction of epithelial-mesenchymal transition (EMT), which included enhanced expression of fibroblast growth factor receptor 1 (FGFR1) and axonal guidance molecules known as neuropilins (NRPs). Immunoprecipitation of FGFR1 coupled with mass spectroscopy indicated that FGFR1 forms a physical complex with NRPs, which is enhanced upon induction of EMT. Confocal imaging revealed that FGFR1 and NRP1 predominantly interact throughout the cytoplasm. Along these lines, short hairpin RNA-mediated depletion of NRP1, but not the use of NRP1-blocking antibodies, inhibited FGFR signaling and reduced tumor cell growth in vitro and in vivo. Our results further indicate that NRP1 upregulation during EMT is mediated via binding of the chromatin reader protein, bromodomain containing 4 (BRD4) in the NRP1 proximal promoter region. Pharmacological inhibition of BRD4 decreased NRP1 expression and ablated FGF-mediated tumor cell growth. Overall, our studies indicate that NRPs facilitate aberrant growth factor signaling during EMT-associated drug resistance and metastasis. Pharmacological combination of epigenetic modulators with FGFR-targeted kinase inhibitors may provide improved outcomes for breast cancer patients with drug-resistant metastatic disease.	[Abdullah, Ammara; Akhand, Saeed Salehin; Paez, Juan Sebastian Paez; Brown, Wells; Pan, Li; Badamy, Michael; Dykuizen, Emily; Tao, W. Andy; Wendt, Michael K.] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; [Libring, Sarah; Solorio, Luis] Purdue Univ, Dept Biomed Engn, W Lafayette, IN 47907 USA; [Dykuizen, Emily; Solorio, Luis; Tao, W. Andy; Wendt, Michael K.] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Wendt, MK (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA.; Wendt, MK (corresponding author), Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA.	mwendt@purdue.edu		dykhuizen, emily/0000-0003-3072-1469; Libring, Sarah/0000-0001-8336-5862	American Cancer Society Research Scholar Grant [RSG-CSM-130259]; National Cancer Institute [R01CA207751]; METavivor Translational Research Award; Purdue Center for Cancer Research via its NIH NCI [P30CA023168]; NIH-funded Indiana Clinical and Translational Sciences Institute	American Cancer Society Research Scholar Grant(American Cancer Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); METavivor Translational Research Award; Purdue Center for Cancer Research via its NIH NCI; NIH-funded Indiana Clinical and Translational Sciences Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by an American Cancer Society Research Scholar Grant (RSG-CSM-130259), the National Cancer Institute (R01CA207751), and a METavivor Translational Research Award, to M. K.W. We also acknowledge the support of the Purdue Center for Cancer Research via its NIH NCI grant (P30CA023168). We thank Genentech for supplying the antiNRP1 antibody YW107.4. We also acknowledge the personnel for the use of the facilities within the Bindley Bioscience Center, a core facility of the NIH-funded Indiana Clinical and Translational Sciences Institute.	Ali R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1034-7; Azuma K, 2014, ONCOTARGET, V5, P5908, DOI 10.18632/oncotarget.1866; Azuma K, 2011, BIOCHEM BIOPH RES CO, V407, P219, DOI 10.1016/j.bbrc.2011.03.002; Benedetti R, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810116; Brown WS, 2016, ONCOTARGET, V7, P83424, DOI 10.18632/oncotarget.13117; Brown WS, 2016, MOL CANCER THER, V15, P2096, DOI 10.1158/1535-7163.MCT-16-0136; Bumbaca D, 2012, BRIT J PHARMACOL, V166, P368, DOI 10.1111/j.1476-5381.2011.01777.x; Cagnoni G, 2014, ONCOGENE, V33, P4795, DOI 10.1038/onc.2013.474; Chen CX, 2016, MOL MED REP, V13, P188, DOI 10.3892/mmr.2015.4556; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Chua V, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809081; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Dey JH, 2010, CANCER RES, V70, P4151, DOI 10.1158/0008-5472.CAN-09-4479; Dickler MN, 2008, CLIN CANCER RES, V14, P7878, DOI 10.1158/1078-0432.CCR-08-0141; Dickler MN, 2009, BREAST CANCER RES TR, V115, P115, DOI 10.1007/s10549-008-0055-9; Elsheikh SE, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1665; Er EE, 2018, NAT CELL BIOL, V20, P966, DOI 10.1038/s41556-018-0138-8; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Grandclement Camille, 2011, Cancers (Basel), V3, P1899, DOI 10.3390/cancers3021899; Hanker AB, 2017, CLIN CANCER RES, V23, P4323, DOI 10.1158/1078-0432.CCR-16-2287; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Herzog B, 2011, MOL BIOL CELL, V22, P2766, DOI 10.1091/mbc.E09-12-1061; Issitt T, 2019, ISCIENCE, V11, P205, DOI 10.1016/j.isci.2018.12.005; Jarvis A, 2010, J MED CHEM, V53, P2215, DOI 10.1021/jm901755g; Kachel P, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1135-y; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Lee TW, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0443-3; Liang WC, 2007, J MOL BIOL, V366, P815, DOI 10.1016/j.jmb.2006.11.021; Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444; Patnaik A, 2014, CANCER CHEMOTH PHARM, V73, P951, DOI 10.1007/s00280-014-2426-8; Qian X, 2014, ONCOGENE, V33, P3411, DOI 10.1038/onc.2013.310; Rastelli F, 2010, TUMORI J, V96, P875, DOI 10.1177/548.6505; Rexer Brent N., 2012, Critical Reviews in Oncogenesis, V17, P1; Rizzolio S, 2018, J CLIN INVEST, V128, P3976, DOI 10.1172/JCI99257; Rizzolio S, 2012, CANCER RES, V72, P5801, DOI 10.1158/0008-5472.CAN-12-0995; Sharpe R, 2011, CLIN CANCER RES, V17, P5275, DOI 10.1158/1078-0432.CCR-10-2727; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Shinde A, 2018, MOL CANCER RES, V16, P1579, DOI 10.1158/1541-7786.MCR-18-0151; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Smith IE, 2007, J CLIN ONCOL, V25, P3816, DOI 10.1200/JCO.2006.09.6578; Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037; Sutton LM, 2010, AM J CLIN PATHOL, V134, P782, DOI 10.1309/AJCPRMD3ARUO5WPN; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; Valdembri D, 2009, PLOS BIOL, V7, P115, DOI 10.1371/journal.pbio.1000025; Vivekanandhan S, 2019, SEMIN CANCER BIOL, V54, P72, DOI 10.1016/j.semcancer.2018.01.014; Weekes CD, 2014, INVEST NEW DRUG, V32, P653, DOI 10.1007/s10637-014-0071-z; Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377; Wendt MK, 2015, NEOPLASIA, V17, P124, DOI 10.1016/j.neo.2014.11.009; Wendt MK, 2011, MOL BIOL CELL, V22, P2423, DOI 10.1091/mbc.E11-04-0306; WENDT MK, 2014, BREAST CANCER RES, V16; West DC, 2005, J BIOL CHEM, V280, P13457, DOI 10.1074/jbc.M410924200; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Yates LR, 2017, CANCER CELL, V32, P169, DOI 10.1016/j.ccell.2017.07.005; Zhang L, 2013, CANCER RES, V73, P3316, DOI 10.1158/0008-5472.CAN-12-3015; Zhao MF, 2015, SCI REP-UK, V5, DOI 10.1038/srep12713	56	9	9	4	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					322	333		10.1038/s41388-020-01530-6	http://dx.doi.org/10.1038/s41388-020-01530-6		OCT 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33128042	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000585769600002
J	Chronopoulos, A; Kalluri, R				Chronopoulos, Antonios; Kalluri, Raghu			Emerging role of bacterial extracellular vesicles in cancer	ONCOGENE			English	Review							OUTER-MEMBRANE VESICLES; DENDRITIC CELLS; GUT MICROBIOME; HOST-CELLS; NOD1; IMMUNITY; MEDIATE; RELEASE; ANTIGEN; INNATE	Shedding of microbial extracellular vesicles constitutes a universal mechanism for inter-kingdom and intra-kingdom communication that is conserved among prokaryotic and eukaryotic microbes. In this review we delineate fundamental aspects of bacterial extracellular vesicles (BEVs) including their biogenesis, cargo composition, and interactions with host cells. We critically examine the evidence that BEVs from the host gut microbiome can enter the circulatory system to disseminate to distant organs and tissues. The potential involvement of BEVs in carcinogenesis is evaluated and future research ideas explored. We further discuss the potential of BEVs in microbiome-based liquid biopsies for cancer diagnostics and bioengineering strategies for cancer therapy.	[Chronopoulos, Antonios; Kalluri, Raghu] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Metastasis Res Ctr, Houston, TX 77030 USA; [Kalluri, Raghu] Rice Univ, Dept Bioengn, Houston, TX 77005 USA; [Kalluri, Raghu] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Rice University; Baylor College of Medicine	Kalluri, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Metastasis Res Ctr, Houston, TX 77030 USA.; Kalluri, R (corresponding author), Rice Univ, Dept Bioengn, Houston, TX 77005 USA.; Kalluri, R (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	rkalluri@mdanderson.org	Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Arroyo V, 2016, SEMIN LIVER DIS, V36, P109, DOI 10.1055/s-0036-1583202; Athman JJ, 2015, J IMMUNOL, V195, P1044, DOI 10.4049/jimmunol.1402894; Aykut B, 2019, NATURE, V574, P264, DOI 10.1038/s41586-019-1608-2; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Bitto NJ, 2018, IMMUNOL CELL BIOL, V96, P1120, DOI 10.1111/imcb.12190; Bitto NJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07288-4; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brown L, 2015, NAT REV MICROBIOL, V13, P620, DOI 10.1038/nrmicro3480; Canas MA, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00498; Castillo DJ, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00148; Cecil JD, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01017; Cecil JD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151967; Chatterjee D, 2013, J BIOL CHEM, V288, P4299, DOI 10.1074/jbc.M112.408302; Chen CC, 2016, CELL MOL BIOENG, V9, P509, DOI 10.1007/s12195-016-0458-3; Chu HT, 2016, SCIENCE, V352, P1116, DOI 10.1126/science.aad9948; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Deatherage BL, 2012, INFECT IMMUN, V80, P1948, DOI 10.1128/IAI.06014-11; Ellis TN, 2010, MICROBIOL MOL BIOL R, V74, P81, DOI 10.1128/MMBR.00031-09; Emery DC, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00195; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Gilbert JA, 2018, NAT MED, V24, P392, DOI 10.1038/nm.4517; Giri PK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002461; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gopalakrishnan V, 2018, CANCER CELL, V33, P570, DOI 10.1016/j.ccell.2018.03.015; Gu L, 2019, SHOCK, V51, P256, DOI 10.1097/SHK.0000000000001129; Hughes DT, 2008, NAT REV MICROBIOL, V6, P111, DOI 10.1038/nrmicro1836; Human Microbiome Project Consortium, 2012, Nature, V486, P207, DOI 10.1038/nature11234; Jones EJ, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00057; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kang CS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076520; Kaparakis M, 2010, CELL MICROBIOL, V12, P372, DOI 10.1111/j.1462-5822.2009.01404.x; Kaparakis-Liaskos M, 2015, NAT REV IMMUNOL, V15, P375, DOI 10.1038/nri3837; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kim OY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00729-8; Lauder AP, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0172-3; Lee EY, 2007, PROTEOMICS, V7, P3143, DOI [10.1002/pmic.200700196, 10.1002/pmic.200790083]; Lee HSW, 2007, INFECT IMMUN, V75, P4449, DOI 10.1128/IAI.00222-07; Lelouard H, 2012, GASTROENTEROLOGY, V142, P592, DOI 10.1053/j.gastro.2011.11.039; Macia L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010107; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; McDole JR, 2012, NATURE, V483, P345, DOI 10.1038/nature10863; McQuade JL, 2019, LANCET ONCOL, V20, pE77, DOI 10.1016/S1470-2045(18)30952-5; Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101; Morad G, 2019, ACS NANO, V13, P13853, DOI 10.1021/acsnano.9b04397; Motwani M, 2019, NAT REV GENET, V20, P657, DOI 10.1038/s41576-019-0151-1; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; O'Neill HC, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.16pe8; Orench-Rivera N, 2016, CELL MICROBIOL, V18, P1525, DOI 10.1111/cmi.12676; Park JY, 2017, EXP NEUROBIOL, V26, P369, DOI 10.5607/en.2017.26.6.369; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peterson J, 2009, GENOME RES, V19, P2317, DOI 10.1101/gr.096651.109; Petousis-Harris H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00683; Petousis-Harris H, 2017, LANCET, V390, P1603, DOI 10.1016/S0140-6736(17)31449-6; Pleguezuelos-Manzano C, 2020, NATURE, V580, P269, DOI 10.1038/s41586-020-2080-8; Poore GD, 2020, NATURE, V579, P567, DOI 10.1038/s41586-020-2095-1; Prados-Rosales R, 2011, J CLIN INVEST, V121, P1471, DOI 10.1172/JCI44261; Pushalkar S, 2018, CANCER DISCOV, V8, P403, DOI 10.1158/2159-8290.CD-17-1134; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Riley DR, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003107; Riquelme E, 2019, CELL, V178, P795, DOI 10.1016/j.cell.2019.07.008; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Salter SJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0087-z; Schwechheimer C, 2015, NAT REV MICROBIOL, V13, P605, DOI 10.1038/nrmicro3525; Sender R, 2016, CELL, V164, P337, DOI 10.1016/j.cell.2016.01.013; Shah B, 2012, SHOCK, V37, P621, DOI 10.1097/SHK.0b013e318250de5d; Shen Y, 2012, CELL HOST MICROBE, V12, P509, DOI 10.1016/j.chom.2012.08.004; Stentz R, 2018, BIOCHEM SOC T, V46, P1021, DOI 10.1042/BST20180114; Takiishi T, 2017, TISSUE BARRIERS, V5, DOI 10.1080/21688370.2017.1373208; Thay B, 2014, INFECT IMMUN, V82, P4034, DOI 10.1128/IAI.01980-14; Tierney BT, 2019, CELL HOST MICROBE, V26, P283, DOI 10.1016/j.chom.2019.07.008; Toyofuku M, 2019, NAT REV MICROBIOL, V17, P13, DOI 10.1038/s41579-018-0112-2; Tsatsaronis JA, 2018, TRENDS MICROBIOL, V26, P401, DOI 10.1016/j.tim.2018.02.009; Tulkens J, 2020, NAT PROTOC, V15, P40, DOI 10.1038/s41596-019-0236-5; Tulkens J, 2020, GUT, V69, P191, DOI 10.1136/gutjnl-2018-317726; Turnbaugh PJ, 2010, P NATL ACAD SCI USA, V107, P7503, DOI 10.1073/pnas.1002355107; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Ursell LK, 2012, NUTR REV, V70, pS38, DOI 10.1111/j.1753-4887.2012.00493.x; Vesikari T, 2013, LANCET, V381, P825, DOI 10.1016/S0140-6736(12)61961-8; Vidakovics MLAP, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000724; Wilson MR, 2019, SCIENCE, V363, P709, DOI 10.1126/science.aar7785; Yang Jinho, 2018, Transl Clin Pharmacol, V26, P103, DOI 10.12793/tcp.2018.26.3.103; Young VB, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j831; Yu YJ, 2018, ACTA PHARMACOL SIN, V39, P514, DOI 10.1038/aps.2017.82; Zhao KL, 2013, INFECT IMMUN, V81, P4509, DOI 10.1128/IAI.01008-13; Zitvogel L, 2018, SCIENCE, V359, P1366, DOI 10.1126/science.aar6918	87	43	44	6	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2020	39	46					6951	6960		10.1038/s41388-020-01509-3	http://dx.doi.org/10.1038/s41388-020-01509-3		OCT 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OQ9FF	33060855	Bronze, Green Published			2022-12-28	WOS:000577946300002
J	Cabot, D; Brun, S; Paco, N; Ginesta, MM; Gendrau-Sanclemente, N; Abuasaker, B; Ruiz-Farina, T; Barcelo, C; Cuatrecasas, M; Bosch, M; Rentero, C; Pons, G; Estanyol, JM; Capella, G; Jaumot, M; Agell, N				Cabot, Debora; Brun, Sonia; Paco, Noelia; Ginesta, Mireia M.; Gendrau-Sanclemente, Nuria; Abuasaker, Baraa; Ruiz-Farina, Triana; Barcelo, Carles; Cuatrecasas, Miriam; Bosch, Marta; Rentero, Carles; Pons, Gabriel; Estanyol, Josep M.; Capella, Gabriel; Jaumot, Montserrat; Agell, Neus			KRAS phosphorylation regulates cell polarization and tumorigenic properties in colorectal cancer	ONCOGENE			English	Article							K-RAS; ONCOGENIC KRAS; ALPHA-CATENIN; CALMODULIN; EXPRESSION; PROTEINS; IDENTIFICATION; ASSOCIATION; PROMOTES; MODELS	Oncogenic mutations of KRAS are found in the most aggressive human tumors, including colorectal cancer. It has been suggested that oncogenic KRAS phosphorylation at Ser181 modulates its activity and favors cell transformation. Using nonphosphorylatable (S181A), phosphomimetic (S181D), and phospho-/dephosphorylatable (S181) oncogenic KRAS mutants, we analyzed the role of this phosphorylation to the maintenance of tumorigenic properties of colorectal cancer cells. Our data show that the presence of phospho-/dephosphorylatable oncogenic KRAS is required for preserving the epithelial organization of colorectal cancer cells in 3D cultures, and for supporting subcutaneous tumor growth in mice. Interestingly, gene expression differed according to the phosphorylation status of KRAS. In DLD-1 cells, CTNNA1 was only expressed in phospho-/dephosphorylatable oncogenic KRAS-expressing cells, correlating with cell polarization. Moreover, lack of oncogenic KRAS phosphorylation leads to changes in expression of genes related to cell invasion, such as SERPINE1, PRSS1,2,3, and NEO1, and expression of phosphomimetic oncogenic KRAS resulted in diminished expression of genes involved in enterocyte differentiation, such as HNF4G. Finally, the analysis, in a public data set of human colorectal cancer, of the gene expression signatures associated with phosphomimetic and nonphosphorylatable oncogenic KRAS suggests that this post-translational modification regulates tumor progression in patients.	[Cabot, Debora; Brun, Sonia; Paco, Noelia; Gendrau-Sanclemente, Nuria; Abuasaker, Baraa; Ruiz-Farina, Triana; Barcelo, Carles; Bosch, Marta; Rentero, Carles; Estanyol, Josep M.; Jaumot, Montserrat; Agell, Neus] Univ Barcelona, Fac Med & Ciencies Salut, Dept Biomed, Barcelona, Spain; [Cabot, Debora; Brun, Sonia; Paco, Noelia; Abuasaker, Baraa; Barcelo, Carles; Cuatrecasas, Miriam; Bosch, Marta; Rentero, Carles; Jaumot, Montserrat; Agell, Neus] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain; [Ginesta, Mireia M.; Capella, Gabriel] Catalan Inst Oncol, Hosp Llobregat, Hereditary Canc Program, ICO IDIBELL,Translat Res Lab, Barcelona, Spain; [Ginesta, Mireia M.; Capella, Gabriel] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Cuatrecasas, Miriam] Univ Barcelona, Dept Fonaments Clin, Fac Med & Ciencies Salut, Barcelona, Spain; [Cuatrecasas, Miriam] Hosp Clin Barcelona, Pathol Dept, Barcelona, Spain; [Cuatrecasas, Miriam] Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain; [Cuatrecasas, Miriam] Hosp Clin Barcelona, Tumor Bank Biobank, Barcelona, Spain; [Pons, Gabriel] Univ Barcelona, Fac Med & Ciencies Salut, Dept Ciencies Fisiol, Barcelona, Spain; [Pons, Gabriel] Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain; [Estanyol, Josep M.] Univ Barcelona, Prote Unit, CCiT UB, Barcelona, Spain; [Gendrau-Sanclemente, Nuria] Hosp Duran & Reynals, Catalan Inst Oncol, Inst Invest Biomed Bellvitge IDIBELL, Program Canc Therapeut Resistance ProCURE, Barcelona, Spain; [Barcelo, Carles] Inst Invest Sanitaria Illes Balears IdISBa, Palma De Mallorca, Spain	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Institut Investigacio Sanitaria Illes Balears (IdISBa)	Jaumot, M; Agell, N (corresponding author), Univ Barcelona, Fac Med & Ciencies Salut, Dept Biomed, Barcelona, Spain.; Jaumot, M; Agell, N (corresponding author), Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain.	mjaumot@ub.edu; neusagell@ub.edu	Rentero Alfonso, Carles/L-4430-2017; BARCELO, PhD, CARLES/K-4299-2014	Rentero Alfonso, Carles/0000-0003-4684-0278; Gendrau, Nuria/0000-0002-7761-3695; Bosch, Marta/0000-0003-3934-6781; Estanyol Ullate, Josep M/0000-0001-8621-0057; BARCELO, PhD, CARLES/0000-0003-2551-2136; Brun, Sonia/0000-0002-2056-3180; Agell, Neus/0000-0002-1205-6074; Jaumot, Montserrat/0000-0003-2864-357X; Morell Ginesta, Mireia/0000-0002-1708-0110	Ministerio de Economia y Competitividad; FEDER funds-a way to build Europe [SAF2016-76239-R, PID2019-105483RB-I00, SAF2015-68016-R]; CIBERONC; Government of Catalonia [2017SGR1282, SLT002/16/0037]; Instituto de Salud Carlos III [PI17/01304]; FPU fellowship from Ministerio de Educacion, Cultura y Deporte; Generalitat de Catalunya; University of Barcelona; Serra Hunter Program (Generalitat de Catalunya)	Ministerio de Economia y Competitividad(Spanish Government); FEDER funds-a way to build Europe; CIBERONC; Government of Catalonia(Generalitat de Catalunya); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); FPU fellowship from Ministerio de Educacion, Cultura y Deporte; Generalitat de Catalunya(Generalitat de Catalunya); University of Barcelona; Serra Hunter Program (Generalitat de Catalunya)(Generalitat de Catalunya)	We thank the personnel of the Advanced Microscopy Unit of CCiT-UB (Campus Clinic) for help in setting up image acquisition and analysis. This work was supported by grants from the Ministerio de Economia y Competitividad and co funded by FEDER funds-a way to build Europe- (SAF2016-76239-R and PID2019-105483RB-I00 to NA, SAF2015-68016-R to GC), CIBERONC and the Government of Catalonia (grants 2017SGR1282 and PERIS SLT002/16/0037), and from Instituto de Salud Carlos III (grant PI17/01304 to MC); a FPU fellowship from Ministerio de Educacion, Cultura y Deporte for DC, a FI fellowship from Generalitat de Catalunya for NP, and a Predoc-UB from University of Barcelona to BA; CR is supported by the Serra Hunter Program (Generalitat de Catalunya).	Alvarez-Moya B, 2010, ONCOGENE, V29, P5911, DOI 10.1038/onc.2010.298; Barcelo C, 2014, GASTROENTEROLOGY, V147, P882, DOI 10.1053/j.gastro.2014.06.041; Barcelo C, 2014, CANCER RES, V74, P1190, DOI 10.1158/0008-5472.CAN-13-1750; Barcelo C, 2013, J CELL SCI, V126, P4553, DOI 10.1242/jcs.123737; Berg KCG, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0691-y; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brookes MJ, 2006, GUT, V55, P1449, DOI 10.1136/gut.2006.094060; Chandra A, 2012, NAT CELL BIOL, V14, P148, DOI 10.1038/ncb2394; Chaturvedi V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40886-y; Compton CC, 2003, MODERN PATHOL, V16, P376, DOI 10.1097/01.MP.0000062859.46942.93; Cortazar AR, 2018, CANCER RES, V78, P6320, DOI 10.1158/0008-5472.CAN-18-1669; Elia AEH, 2015, MOL CELL, V60, P280, DOI 10.1016/j.molcel.2015.09.011; Garrido E, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006552; Gogarten SM, 2012, BIOINFORMATICS, V28, P3329, DOI 10.1093/bioinformatics/bts610; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hou ZL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0922-x; Hu DG, 2016, DRUG METAB REV, V48, P47, DOI 10.3109/03602532.2015.1131292; Humphries BA, 2019, MOL CANCER RES, V17, P1142, DOI 10.1158/1541-7786.MCR-18-0836; Inder KL, 2009, J BIOL CHEM, V284, P28410, DOI 10.1074/jbc.M109.001537; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee SK, 2018, EMBO REP, V19, DOI 10.15252/embr.201846060; Li SJ, 2018, BIOMED PHARMACOTHER, V105, P83, DOI 10.1016/j.biopha.2018.05.119; Lindeboom RGH, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20188227; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez-Alcala C, 2008, J BIOL CHEM, V283, P10621, DOI 10.1074/jbc.M706238200; Maher DM, 2011, MOL CANCER RES, V9, P531, DOI 10.1158/1541-7786.MCR-10-0443; Maiden SL, 2011, J CELL BIOL, V195, P543, DOI 10.1083/jcb.201103106; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Roman-Fernandez A, 2016, TRAFFIC, V17, P1244, DOI 10.1111/tra.12417; Santiago L, 2017, AM J CANCER RES, V7, P1389; Sasaki AT, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001518; Shalom-Feuerstein R, 2008, CANCER RES, V68, P6608, DOI 10.1158/0008-5472.CAN-08-1117; Shibata H, 2007, P NATL ACAD SCI USA, V104, P18199, DOI 10.1073/pnas.0705730104; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Short SP, 2017, J CLIN INVEST, V127, P4462, DOI 10.1172/JCI77217; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Vartanian S, 2013, J BIOL CHEM, V288, P2403, DOI 10.1074/jbc.M112.394130; Villalonga P, 2002, J BIOL CHEM, V277, P37929, DOI 10.1074/jbc.M202245200; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001; Wang Jingyu, 2018, Oncotarget, V9, P18018, DOI 10.18632/oncotarget.22933; Wang MT, 2015, CELL, V163, P1237, DOI 10.1016/j.cell.2015.10.041; Yamamoto H, 2003, J PATHOL, V199, P176, DOI 10.1002/path.1277; Yang MH, 2012, P NATL ACAD SCI USA, V109, P10843, DOI 10.1073/pnas.1201487109; Yin N, 2019, CANCER CELL, V36, P156, DOI 10.1016/j.ccell.2019.07.002	50	0	0	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5730	5740		10.1038/s41388-021-01967-3	http://dx.doi.org/10.1038/s41388-021-01967-3		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34333552	Green Accepted			2022-12-28	WOS:000679771600002
J	Pal, A; Barrett, TF; Paolini, R; Parikh, A; Puram, SV				Pal, Ananya; Barrett, Thomas F.; Paolini, Rachel; Parikh, Anuraag; Puram, Sidharth V.			Partial EMT in head and neck cancer biology: a spectrum instead of a switch	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; CIRCULATING TUMOR-CELLS; E-CADHERIN; EXTRACAPSULAR SPREAD; MALIGNANT BEHAVIOR; CARCINOMA; EXPRESSION; PLASTICITY; PATHWAY; TRANSCRIPTION	Our understanding of epithelial-to-mesenchymal transition (EMT) has slowly evolved from a simple two state, binary model to a multi-step, dynamic continuum of epithelial-to-mesenchymal plasticity, with metastable intermediate transition states that may drive cancer metastasis. Head and neck cancer is no exception, and in this review, we use head and neck as a case study for how partial-EMT (p-EMT) cell states may play an important role in cancer progression. In particular, we summarize recent in vitro and in vivo studies that uncover these intermediate transition states, which exhibit both epithelial and mesenchymal properties and appear to have distinct advantages in migration, survival in the bloodstream, and seeding and propagation within secondary metastatic sites. We then summarize the common and distinct regulators of p-EMT as well as methodologies for identifying this unique cellular subpopulation, with a specific emphasis on the role of cutting-edge technologies, such as single cell approaches. Finally, we propose strategies to target p-EMT cells, highlighting potential opportunities for therapeutic intervention to specifically target the process of metastasis. Thus, although significant challenges remain, including numerous gaps in current knowledge, a deeper understanding of EMT plasticity and a genuine identification of EMT as spectrum rather than a switch will be critical for improving patient diagnosis and treatment across oncology.	[Pal, Ananya; Barrett, Thomas F.; Paolini, Rachel; Puram, Sidharth V.] Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA; [Parikh, Anuraag] Columbia Univ, Vagelos Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg, New York, NY USA; [Puram, Sidharth V.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Columbia University; Washington University (WUSTL)	Puram, SV (corresponding author), Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA.; Puram, SV (corresponding author), Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.	sidpuram@wustl.edu		Puram, Sidharth/0000-0003-3543-889X	NIH/NCI [K08CA237732]; Cancer Research Foundation [P20-0563]; Doris Duke Foundation; American Cancer Society; V Foundation [V2019-005]; Washington University Dean's Scholars Program; National Institute of Deafness and Other Communication Disorders [T32DC000022]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research Foundation; Doris Duke Foundation(Doris Duke Charitable Foundation (DDCF)); American Cancer Society(American Cancer Society); V Foundation; Washington University Dean's Scholars Program; National Institute of Deafness and Other Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was graciously supported by an NIH/NCI K08CA237732 as well as the Cancer Research Foundation: P20-0563, Doris Duke Foundation, American Cancer Society, V Foundation: V2019-005, and the Washington University Dean's Scholars Program (SVP). This work was also supported by the National Institute of Deafness and Other Communication Disorders (T32DC000022) (TFB).	Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Aiello NM, 2018, DEV CELL, V45, P681, DOI 10.1016/j.devcel.2018.05.027; Amintas S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072653; Armstrong AJ, 2011, MOL CANCER RES, V9, P997, DOI 10.1158/1541-7786.MCR-10-0490; Bhatia S, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00071; Bhatia S, 2017, BIOCHEM J, V474, P3269, DOI 10.1042/BCJ20160782; Biddle A, 2016, EBIOMEDICINE, V4, P138, DOI 10.1016/j.ebiom.2016.01.007; Birchmeier C, 1996, ACTA ANAT, V156, P217; Bocci F, 2019, INTEGR BIOL-UK, V11, P251, DOI 10.1093/intbio/zyz021; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Burger GA, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00162; Cai JH, 2019, CANCER RES TREAT, V51, P252, DOI 10.4143/crt.2017.613; Campbell K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10269-y; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Chen S, 2018, ONCOL LETT, V15, P7144, DOI 10.3892/ol.2018.8219; Cho SJ, 2018, ARCH PATHOL LAB MED, V142, P952, DOI 10.5858/arpa.2018-0082-RA; Chui MH, 2013, INT J CANCER, V132, P1487, DOI 10.1002/ijc.27745; Ciftci R, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.e11526; De Cecco L, 2015, ONCOTARGET, V6, P9627, DOI 10.18632/oncotarget.3301; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Deng SJ, 2018, ONCOGENE, V37, P5811, DOI 10.1038/s41388-018-0382-1; Devarajan E, 2012, INT J CANCER, V131, P1023, DOI 10.1002/ijc.26493; Dhasarathy A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026514; Dohadwala M, 2010, OTOLARYNG HEAD NECK, V142, P753, DOI 10.1016/j.otohns.2010.01.034; Espinoza I, 2013, PHARMACOL THERAPEUT, V139, P95, DOI 10.1016/j.pharmthera.2013.02.003; Evans AJ, 2007, MOL CELL BIOL, V27, P157, DOI 10.1128/MCB.00892-06; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fustaino V, 2017, ONCOTARGET, V8, P103340, DOI 10.18632/oncotarget.21132; George JT, 2017, CANCER RES, V77, P6415, DOI 10.1158/0008-5472.CAN-16-3521; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Godin L, 2020, CANCERS, V12, DOI 10.3390/cancers12040906; Gonzalez VD, 2018, CELL REP, V22, P1875, DOI 10.1016/j.celrep.2018.01.053; GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333; Grosse-Wilde A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126522; Harb J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0763-9; He P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32737-z; Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200; Hou JM, 2012, J CLIN ONCOL, V30, P525, DOI 10.1200/JCO.2010.33.3716; Hou JM, 2011, AM J PATHOL, V178, P989, DOI 10.1016/j.ajpath.2010.12.003; Huang RYJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.442; Hugo HJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-235; Ivanovic V, 2006, CLIN CHIM ACTA, V371, P191, DOI 10.1016/j.cca.2006.02.027; Ji AL, 2020, CELL, V182, P497, DOI 10.1016/j.cell.2020.05.039; Jolly MK, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101542; Jolly MK, 2018, BBA-REV CANCER, V1870, P151, DOI 10.1016/j.bbcan.2018.07.001; Jolly MK, 2017, MOL ONCOL, V11, P739, DOI 10.1002/1878-0261.12084; Jolly MK, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0023-9; Jolly MK, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0962; Joosse SA, 2015, EMBO MOL MED, V7, P1, DOI 10.15252/emmm.201303698; Jung AR, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60707-x; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Karacosta LG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13441-6; Karaosmanoglu O, 2018, CELL ONCOL, V41, P439, DOI 10.1007/s13402-018-0384-6; Kim JM, 2013, EUR ARCH OTO-RHINO-L, V270, P1137, DOI 10.1007/s00405-012-2161-x; Kinker GS, 2020, NAT GENET, V52, P1208, DOI 10.1038/s41588-020-00726-6; Kisoda S, 2020, ORAL DIS, V26, P1149, DOI 10.1111/odi.13351; Kohler I, 2015, J GASTROEN HEPATOL, V30, P78, DOI 10.1111/jgh.12752; Kojc N, 2009, VIRCHOWS ARCH, V454, P549, DOI 10.1007/s00428-009-0771-5; Kroger C, 2019, P NATL ACAD SCI USA, V116, P7353, DOI 10.1073/pnas.1812876116; Kurimoto R, 2016, INT J ONCOL, V48, P1825, DOI 10.3892/ijo.2016.3419; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Latil M, 2017, CELL STEM CELL, V20, P191, DOI 10.1016/j.stem.2016.10.018; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lecharpentier A, 2011, BRIT J CANCER, V105, P1338, DOI 10.1038/bjc.2011.405; Lee WY, 2014, ANN SURG ONCOL, V21, P1904, DOI 10.1245/s10434-014-3567-z; Li J, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5917-5; Liang FL, 2013, PATHOL RES PRACT, V209, P269, DOI 10.1016/j.prp.2013.01.009; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McMahon S, 2006, J BIOL CHEM, V281, P24171, DOI 10.1074/jbc.M604507200; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Miao JW, 2014, INT J ONCOL, V45, P165, DOI 10.3892/ijo.2014.2422; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Nguyen PT, 2011, HISTOL HISTOPATHOL, V26, P147, DOI 10.14670/HH-26.147; Nijkamp MM, 2011, RADIOTHER ONCOL, V99, P344, DOI 10.1016/j.radonc.2011.05.066; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Panchy N, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01479; Papadaki MA, 2019, MOL CANCER THER, V18, P437, DOI 10.1158/1535-7163.MCT-18-0584; Parikh AS, 2019, ORAL ONCOL, V99, DOI 10.1016/j.oraloncology.2019.104458; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Polioudaki H, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1386-7; Puram SV, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2018.1448244; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Qi ZT, 2021, CANCERS, V13, DOI 10.3390/cancers13061230; Qi ZT, 2019, ORAL ONCOL, V99, DOI 10.1016/j.oraloncology.2019.104441; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Ruscetti M, 2015, CANCER RES, V75, P2749, DOI 10.1158/0008-5472.CAN-14-3476; Saitoh M, 2018, J BIOCHEM, V164, P257, DOI 10.1093/jb/mvy047; Sanchez-Tillo E, 2012, CELL MOL LIFE SCI, V69, P3429, DOI 10.1007/s00018-012-1122-2; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617; Sha YT, 2020, NUCLEIC ACIDS RES, V48, P9505, DOI 10.1093/nar/gkaa725; Simpson A, 2017, TARGET ONCOL, V12, P571, DOI 10.1007/s11523-017-0514-5; Sirin AH, 2019, TECH COLOPROCTOL, V23, P333, DOI 10.1007/s10151-019-01959-2; Stepan KO, 2020, ORAL ONCOL, V110, DOI 10.1016/j.oraloncology.2020.104893; Storci G, 2010, J CELL PHYSIOL, V225, P682, DOI 10.1002/jcp.22264; Strauss R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016186; Suarez-Causado A, 2015, BBA-MOL CELL RES, V1853, P2453, DOI 10.1016/j.bbamcr.2015.05.017; Subbalakshmi AR, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.553342; Tada H, 2020, ANTICANCER RES, V40, P3559, DOI 10.21873/anticanres.14345; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tomson AM, 1996, CLIN EXP METASTAS, V14, P501, DOI 10.1007/BF00115110; Tretbar Sandy, 2019, Oncotarget, V10, P1507, DOI 10.18632/oncotarget.26682; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; TUCKER G C, 1988, Development (Cambridge), V103, P81; van Dijk D, 2018, CELL, V174, P716, DOI 10.1016/j.cell.2018.05.061; Viebahn C, 1995, ACTA ANAT, V154, P79; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wan YH, 2020, HEAD NECK-J SCI SPEC, V42, P1067, DOI 10.1002/hed.26104; Wang RY, 2016, ONCOL RES, V24, P225, DOI 10.3727/096504016X14648701447931; Williams ED, 2019, NAT REV CANCER, V19, P716, DOI 10.1038/s41568-019-0213-x; Wu SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123976; Xiong HG, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1254-4; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu WT, 2015, CELL ADHES MIGR, V9, P317, DOI 10.1080/19336918.2015.1016686; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zaravinos A., 2015, J ONCOL, V2015, DOI DOI 10.1155/2015/865816; Zhang H, 2003, BLOOD, V101, P2253, DOI 10.1182/blood-2002-02-0629; Zhang JY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005304; Zhang L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-108; Zidar N, 2011, HUM PATHOL, V42, P482, DOI 10.1016/j.humpath.2010.07.020	128	17	17	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5049	5065		10.1038/s41388-021-01868-5	http://dx.doi.org/10.1038/s41388-021-01868-5		JUL 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34239045	Green Accepted			2022-12-28	WOS:000670851600003
J	Bi, O; Anene, CA; Nsengimana, J; Shelton, M; Roberts, W; Newton-Bishop, J; Boyne, JR				Bi, O.; Anene, C. A.; Nsengimana, J.; Shelton, M.; Roberts, W.; Newton-Bishop, J.; Boyne, J. R.			SFPQ promotes an oncogenic transcriptomic state in melanoma	ONCOGENE			English	Article							SPLICING-FACTOR; CANCER CELLS; RNA; BINDING; PROLIFERATION; PROGRESSION; LNCRNA; EXPRESSION; DYSREGULATION; TUMORIGENESIS	The multifunctional protein, splicing factor, proline- and glutamine-rich (SFPQ) has been implicated in numerous cancers often due to interaction with coding and non-coding RNAs, however, its role in melanoma remains unclear. We report that knockdown of SFPQ expression in melanoma cells decelerates several cancer-associated cell phenotypes, including cell growth, migration, epithelial to mesenchymal transition, apoptosis, and glycolysis. RIP-seq analysis revealed that the SFPQ-RNA interactome is reprogrammed in melanoma cells and specifically enriched with key melanoma-associated coding and long non-coding transcripts, including SOX10, AMIGO2 and LINC00511 and in most cases SFPQ is required for the efficient expression of these genes. Functional analysis of two SFPQ-enriched lncRNA, LINC00511 and LINC01234, demonstrated that these genes independently contribute to the melanoma phenotype and a more detailed analysis of LINC00511 indicated that this occurs in part via modulation of the miR-625-5p/PKM2 axis. Importantly, analysis of a large clinical cohort revealed that elevated expression of SFPQ in primary melanoma tumours may have utility as a prognostic biomarker. Together, these data suggest that SFPQ is an important driver of melanoma, likely due to SFPQ-RNA interactions promoting the expression of numerous oncogenic transcripts.	[Bi, O.; Shelton, M.; Boyne, J. R.] Univ Huddersfield, Sch Appl Sci, Huddersfield, W Yorkshire, England; [Anene, C. A.] Queen Mary Univ London, Barts Canc Inst, Ctr Canc Genom & Computat Biol, London, England; [Nsengimana, J.] Newcastle Univ, Fac Med Sci, Populat Hlth Sci Inst, Newcastle, England; [Roberts, W.] Leeds Beckett Univ, Sch Clin & Appl Sci, Leeds, W Yorkshire, England; [Newton-Bishop, J.] Univ Leeds, Sch Med, Leeds, W Yorkshire, England	University of Huddersfield; University of London; Queen Mary University London; Newcastle University - UK; Leeds Beckett University; University of Leeds	Boyne, JR (corresponding author), Univ Huddersfield, Sch Appl Sci, Huddersfield, W Yorkshire, England.	j.r.boyne@hud.ac.uk	Nsengimana, Jeremie/AGK-5625-2022; Boyne, James/AAU-6616-2021; Anene, Chinedu Anthony/AAI-7643-2021	Boyne, James/0000-0003-1219-6453; Anene, Chinedu Anthony/0000-0002-3591-3358; Newton-Bishop, Julia/0000-0001-9147-6802	British Skin Foundation award [030/s/18]; MRC award [MR/M019012/1]	British Skin Foundation award; MRC award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors would like to thank Dr. M.J. Thornton and Dr. S. Sikkink for assistance with primary melanocyte cell culture and Prof. M. Dickman for providing the pSFPQ-FLAG construct. This work was funded by a personal scholarship to OB by Mr. Shaukat Ali, British Skin Foundation award to JRB (030/s/18) and MRC award MR/M019012/1 to JNB.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Akhbari P, 2018, J INVEST DERMATOL, V138, P2343, DOI 10.1016/j.jid.2018.03.1527; Anene C, 2018, BBA-MOL BASIS DIS, V1864, P2633, DOI 10.1016/j.bbadis.2018.04.013; Baquero-Perez B, 2019, ELIFE, V8, DOI 10.7554/eLife.47261; Bottini S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01126-x; Chai YQ, 2016, CANCER MED-US, V5, P1588, DOI 10.1002/cam4.710; Chen XE., 2020, BIOSCIENCE REP, V40, P40; Chen YH, 2020, MOL THER-NUCL ACIDS, V19, P168, DOI 10.1016/j.omtn.2019.10.035; Chen ZS, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1070-0; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; de Silva HC, 2019, CELL MOL LIFE SCI, V76, P2015, DOI 10.1007/s00018-019-03033-4; Deng HH, 2019, AGING-US, V11, P5975, DOI 10.18632/aging.102156; Djulbegovic MB, 2020, INT J BIOL MACROMOL, V150, P1281, DOI 10.1016/j.ijbiomac.2019.10.139; Duan M, 2020, CANCER MANAG RES, V12, P2141, DOI 10.2147/CMAR.S229013; Fontanals-Cirera B, 2017, MOL CELL, V68, P731, DOI 10.1016/j.molcel.2017.11.004; Gao ZZ, 2019, RNA BIOL, V16, P940, DOI 10.1080/15476286.2019.1602436; Garbe C, 2009, CLIN DERMATOL, V27, P3, DOI 10.1016/j.clindermatol.2008.09.001; Ghosh Papia, 2009, Expert Rev Dermatol, V4, P131, DOI 10.1586/edm.09.2; Graf SA, 2014, J INVEST DERMATOL, V134, P2212, DOI 10.1038/jid.2014.128; Gu Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209338; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hochberg-Laufer H, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008459; Hopkins TG, 2016, NUCLEIC ACIDS RES, V44, P1227, DOI 10.1093/nar/gkv1515; Hu L, 2018, ONCOL LETT, V16, P294, DOI 10.3892/ol.2018.8637; Hu YP, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1097-9; Hu ZX, 2020, HEPATOLOGY, V72, P548, DOI 10.1002/hep.31062; Hua JT, 2018, CELL, V174, P564, DOI 10.1016/j.cell.2018.06.014; Hui L, 2019, PEERJ, V7, DOI 10.7717/peerj.7456; Imamura K, 2014, MOL CELL, V53, P393, DOI 10.1016/j.molcel.2014.01.009; Jaafar L, 2017, NUCLEIC ACIDS RES, V45, P1848, DOI 10.1093/nar/gkw1209; Ji Q, 2014, BRIT J CANCER, V111, P736, DOI 10.1038/bjc.2014.383; Kaneko S, 2007, GENE DEV, V21, P1779, DOI 10.1101/gad.1565207; Ke YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035678; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li Y, 2018, ONCOTARGETS THER, V11, P1403, DOI 10.2147/OTT.S149511; Lin MG, 2018, EUR REV MED PHARMACO, V22, P3370, DOI 10.26355/eurrev_201806_15158; Lu J, 2018, J ALZHEIMERS DIS, V61, P1311, DOI 10.3233/JAD-170659; Luisier R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04373-8; Mitobe Y, 2020, CANCER RES, V80, P2230, DOI 10.1158/0008-5472.CAN-19-3095; Gallardo CM, 2019, NUCLEIC ACIDS RES, V47, P5381, DOI 10.1093/nar/gkz235; Muralidhar S, 2019, CANCER RES, V79, P5986, DOI 10.1158/0008-5472.CAN-18-3927; Nsengimana J, 2018, J CLIN INVEST, V128, P2048, DOI 10.1172/JCI95351; Pellarin I, 2020, ONCOGENE, V39, P4390, DOI 10.1038/s41388-020-1292-6; Perron G, 2018, CELL REP, V23, P1639, DOI 10.1016/j.celrep.2018.04.031; Qiu T, 2015, KAOHSIUNG J MED SCI, V31, P553, DOI 10.1016/j.kjms.2015.10.002; Rajesh C, 2011, NUCLEIC ACIDS RES, V39, P132, DOI 10.1093/nar/gkq738; Ren WQ, 2019, J CELL BIOCHEM, V120, P5417, DOI 10.1002/jcb.27820; Roeder C, 2005, ARCH DERMATOL RES, V296, P314, DOI 10.1007/s00403-004-0527-7; Ru Y, 2018, ONCOTARGETS THER, V11, P5695, DOI 10.2147/OTT.S163774; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Shao R, 2012, INT J CANCER, V130, P544, DOI 10.1002/ijc.26015; Snijders AP, 2015, RNA, V21, P347, DOI 10.1261/rna.045138.114; Sun CC, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.94; Takayama K, 2017, P NATL ACAD SCI USA, V114, P10461, DOI 10.1073/pnas.1706076114; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Volders PJ, 2015, NUCLEIC ACIDS RES, V43, P4363, DOI 10.1093/nar/gkv295; Wang B, 2019, BIOCHEM BIOPH RES CO, V509, P143, DOI 10.1016/j.bbrc.2018.12.091; Wang D, 2016, BIOCHEM BIOPH RES CO, V473, P959, DOI 10.1016/j.bbrc.2016.03.161; Wang ZH, 2018, CANCER CELL, V33, P706, DOI 10.1016/j.ccell.2018.03.006; Wesley UV, 1999, J EXP MED, V190, P311, DOI 10.1084/jem.190.3.311; Williamson AJK, 2004, J BIOL CHEM, V279, P47912, DOI 10.1074/jbc.M409035200; Wu CF, 2013, J GENET GENOMICS, V40, P179, DOI 10.1016/j.jgg.2013.03.001; Xue JH, 2020, THORAC CANCER, V11, P2570, DOI 10.1111/1759-7714.13576; Zeng CW, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0884-z; Zhang GY, 2018, BIOMARKERS, V23, P435, DOI 10.1080/1354750X.2018.1443509; Zhang J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1835-3; Zhao XH, 2018, J CELL MOL MED, V22, P655, DOI 10.1111/jcmm.13351; Zhu FY, 2019, EUR REV MED PHARMACO, V23, P8377, DOI 10.26355/eurrev_201910_19149; Zhu YH, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01223-w	70	5	5	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5192	5203		10.1038/s41388-021-01912-4	http://dx.doi.org/10.1038/s41388-021-01912-4		JUL 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34218270	hybrid, Green Accepted, Green Published			2022-12-28	WOS:000669300400003
J	Wei, Y; Huang, CX; Xiao, X; Chen, DP; Shan, H; He, HH; Kuang, DM				Wei, Yuan; Huang, Chun-Xiang; Xiao, Xiao; Chen, Dong-Ping; Shan, Hong; He, Huanhuan; Kuang, Dong-Ming			B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments	ONCOGENE			English	Review							TERTIARY LYMPHOID STRUCTURES; HEPATOCELLULAR-CARCINOMA; IL-10 PRODUCTION; BAFF-RECEPTOR; PLASMA-CELLS; T-CELLS; IMMUNITY; IMMUNOTHERAPY; COMPLEMENT; SUBSET	B cells constitute a major component of tumor-infiltrating leukocytes. However, the influence of these cells on malignancy is currently under debate, reflecting the heterogeneity of B cell subsets in tumors. With recent advances, it becomes apparent that this debate includes not only the evaluation of B cells themselves, but also the underlying immune microenvironment network, which scripts the highly heterogeneous B cell populations in tumors and directs the roles of those sub-populations in disease progression and clinical treatment. In this review, we summarize recent findings on the heterogeneous subset composition of B cells in both human and mouse tumor models and their different impacts on disease progression. We further describe the multidimensional interplays between B cells and other immune cells in the tumor microenvironment, which account for the regulation of B cell differentiation and function in situ. We also assess the potential influences of distinct sub-tumor locations on B cell function in primary tumors during development and those under immunotherapy treatment. Illuminating the heterogeneous nature of B cell subset composition, generation, localization, and related immune network in tumor is of immense significance for comprehensively understanding B cell response in tumor and designing more efficacious cancer immunotherapies.	[Wei, Yuan; Shan, Hong; He, Huanhuan; Kuang, Dong-Ming] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China; [Wei, Yuan; Huang, Chun-Xiang; Chen, Dong-Ping; Kuang, Dong-Ming] Sun Yat Sen Univ, Sch Life Sci, MOE Key Lab Gene Funct & Regulat, State Key Lab Biocontrol, Guangzhou, Peoples R China; [Xiao, Xiao] QIMR Berghofer Med Res Inst, Canc Program, Herston, Qld, Australia	Sun Yat Sen University; Sun Yat Sen University; QIMR Berghofer Medical Research Institute	Shan, H; He, HH; Kuang, DM (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China.; Kuang, DM (corresponding author), Sun Yat Sen Univ, Sch Life Sci, MOE Key Lab Gene Funct & Regulat, State Key Lab Biocontrol, Guangzhou, Peoples R China.	shanhong@mail.sysu.edu.cn; hehh23@mail.sysu.edu.cn; kdming@mail.sysu.edu.cn		Xiao, Christos/0000-0003-0402-4221; He, Huanhuan/0000-0002-5903-0840; Wei, Yuan/0000-0001-5694-8835; shan, hong/0000-0001-6640-1390; Kuang, Dong-Ming/0000-0003-3570-9717	National Natural Science Foundation of China [82025016, 31830025, 81901585]; Natural Science Foundation of Guangdong Province, China [2018B030308010, 2019A1515011770, 2020A1515010895]; China Postdoctoral Science Foundation [2020T130738, 2019M653191, 2019M653169, BX20180398]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We sincerely apologize to those colleagues whose important work is not included in this paper. The presentation of a complete and extensive review is extremely challenging owing to the plethora of literature related to the topic described in this review. We apologize in advance for any inadvertent omission. This work was supported by project grants from the National Natural Science Foundation of China (82025016, 31830025, and 81901585); the Natural Science Foundation of Guangdong Province, China (2018B030308010, 2019A1515011770, and 2020A1515010895); and the China Postdoctoral Science Foundation (2020T130738, 2019M653191, 2019M653169, and BX20180398).	Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Andreu P, 2010, CANCER CELL, V17, P121, DOI 10.1016/j.ccr.2009.12.019; Avelos AM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00092; Bagheri Y, 2019, EUR CYTOKINE NETW, V30, P107, DOI 10.1684/ecn.2019.0434; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Bournazos S, 2020, NAT REV IMMUNOL, V20, P633, DOI 10.1038/s41577-020-00410-0; Bruno TC, 2017, CANCER IMMUNOL RES, V5, P898, DOI 10.1158/2326-6066.CIR-17-0075; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen MM, 2016, CANCER DISCOV, V6, P1182, DOI 10.1158/2159-8290.CD-16-0329; Cornillet M, 2019, GASTROENTEROLOGY, V157, P1067, DOI 10.1053/j.gastro.2019.06.023; Cyster JG, 2019, CELL, V177, P524, DOI 10.1016/j.cell.2019.03.016; Drago JZ, 2021, NAT REV CLIN ONCOL, V18, P327, DOI 10.1038/s41571-021-00470-8; Elsner RA, 2020, IMMUNITY, V53, P1136, DOI 10.1016/j.immuni.2020.11.006; Fillatreau S, 2021, NAT REV RHEUMATOL, V17, P98, DOI 10.1038/s41584-020-00544-4; Fridman WH, 2020, GASTROENTEROLOGY, V158, P303, DOI 10.1053/j.gastro.2019.09.045; Ganti SN, 2015, SCI REP-UK, V5, DOI 10.1038/srep12255; Garaud S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129641; Garaud S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02660; Germain C, 2014, AM J RESP CRIT CARE, V189, P832, DOI 10.1164/rccm.201309-1611OC; Glass DR, 2020, IMMUNITY, V53, P217, DOI 10.1016/j.immuni.2020.06.013; Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025; Gunderson AJ, 2016, CANCER DISCOV, V6, P270, DOI 10.1158/2159-8290.CD-15-0827; Han TS, 2019, GASTROENTEROLOGY, V156, P1140, DOI 10.1053/j.gastro.2018.11.059; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Hernandez-Ruiz M, 2017, J INTERF CYTOK RES, V37, P62, DOI 10.1089/jir.2016.0076; Hollern DP, 2019, CELL, V179, P1191, DOI 10.1016/j.cell.2019.10.028; Hong S, 2018, IMMUNITY, V49, P695, DOI 10.1016/j.immuni.2018.08.012; Hu XH, 2019, NAT GENET, V51, P560, DOI 10.1038/s41588-018-0339-x; Hua C, 2016, J AUTOIMMUN, V73, P64, DOI 10.1016/j.jaut.2016.06.002; Hua ZL, 2020, IMMUNOL REV, V296, P24, DOI 10.1111/imr.12859; Huang Q, 2019, CELL MOL IMMUNOL, V16, P87, DOI 10.1038/s41423-018-0014-2; Iglesia MD, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw144; Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249; Jaya FNM, 2019, J TRANSL AUTOIMMUN, V2, DOI 10.1016/j.jtauto.2019.100011; Ji L, 2020, CANCER RES, V80, P2004, DOI 10.1158/0008-5472.CAN-19-3074; Karagiannis P, 2013, CANCER RES, V73, DOI [10.1172/JCI65579, 10.1158/1538-7445.TUMIMM2012-B65]; Kuang DM, 2008, J IMMUNOL, V181, P3089, DOI 10.4049/jimmunol.181.5.3089; Kuang DM, 2007, BLOOD, V110, P587, DOI 10.1182/blood-2007-01-068031; Kuang DM, 2014, J CLIN INVEST, V124, P4657, DOI 10.1172/JCI74381; Kuang DM, 2011, J HEPATOL, V54, P948, DOI 10.1016/j.jhep.2010.08.041; Kuang DM, 2010, HEPATOLOGY, V51, P154, DOI 10.1002/hep.23291; Kurtenkov O, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9579828; Lang XT, 2019, CANCER DISCOV, V9, P1673, DOI 10.1158/2159-8290.CD-19-0338; Lechner A, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1535293; Lighaam LC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01913; Liu JL, 2021, CELL MOL GASTROENTER, V12, P251, DOI 10.1016/j.jcmgh.2021.02.008; Liu RX, 2015, HEPATOLOGY, V62, P1779, DOI 10.1002/hep.28020; Liu Y, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8509805; Lu YW, 2020, CELL, V180, P1081, DOI 10.1016/j.cell.2020.02.015; Ma KY, 2020, CELL MOL IMMUNOL, V17, P421, DOI 10.1038/s41423-019-0308-z; Mauri C, 2021, IMMUNOL REV, V299, P5, DOI 10.1111/imr.12964; Medler TR, 2018, CANCER CELL, V34, P561, DOI 10.1016/j.ccell.2018.09.003; Michaud HA, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.955684; Molina-Sanchez P, 2020, GASTROENTEROLOGY, V159, DOI 10.1053/j.gastro.2020.08.015; Morcrette G, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1583547; Moriyama M, 2017, CURR TOP MICROBIOL, V401, P75, DOI 10.1007/82_2016_40; Muntasell A, 2017, CURR OPIN IMMUNOL, V45, P73, DOI 10.1016/j.coi.2017.01.003; Nielsen JS, 2012, CLIN CANCER RES, V18, P3281, DOI 10.1158/1078-0432.CCR-12-0234; Obeng, NATURE; Obieglo K, 2019, EUR J IMMUNOL, V49, P1226, DOI 10.1002/eji.201847858; Oh JE, 2019, NATURE, V571, P122, DOI 10.1038/s41586-019-1285-1; Okada Y, 2018, J AUTOIMMUN, V88, P103, DOI 10.1016/j.jaut.2017.10.011; Ouyang FZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13453; Ozga AJ, 2021, IMMUNITY, V54, P859, DOI 10.1016/j.immuni.2021.01.012; Paijens ST, 2021, CELL MOL IMMUNOL, V18, P842, DOI 10.1038/s41423-020-00565-9; Patidar A, 2018, CYTOKINE, V104, P114, DOI 10.1016/j.cyto.2017.10.004; Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Qian L, 2017, MOL MED REP, V16, P5693, DOI 10.3892/mmr.2017.7269; Ren ZH, 2016, CANCER DISCOV, V6, P477, DOI 10.1158/2159-8290.CD-16-0307; Rosser EC, 2014, NAT MED, V20, P1334, DOI 10.1038/nm.3680; Roumenina LT, 2019, NAT REV CANCER, V19, P698, DOI 10.1038/s41568-019-0210-0; Saulep-Easton D, 2016, LEUKEMIA, V30, P163, DOI 10.1038/leu.2015.174; Schioppa T, 2011, P NATL ACAD SCI USA, V108, P10662, DOI 10.1073/pnas.1100994108; Shalapour S, 2015, NATURE, V521, P94, DOI 10.1038/nature14395; Shang J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.582657; Sharonov GV, 2020, NAT REV IMMUNOL, V20, P294, DOI 10.1038/s41577-019-0257-x; Shen T, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00501-x; Smulski CR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02285; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Su SC, 2018, CELL, V175, P442, DOI 10.1016/j.cell.2018.09.007; Takahashi R, 2021, GUT, V70, P330, DOI 10.1136/gutjnl-2019-319912; Tezuka H, 2011, IMMUNITY, V34, P247, DOI 10.1016/j.immuni.2011.02.002; van de Veen W, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz3559; Verma R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00979; Wang RX, 2014, NAT MED, V20, P633, DOI 10.1038/nm.3554; Wang SS, 2019, CELL MOL IMMUNOL, V16, P6, DOI 10.1038/s41423-018-0027-x; Wei Y, 2019, J CLIN INVEST, V129, P3347, DOI 10.1172/JCI127726; Wei Y, 2019, GASTROENTEROLOGY, V156, P1890, DOI 10.1053/j.gastro.2019.01.250; Wu Y, 2013, HEPATOLOGY, V57, P1107, DOI 10.1002/hep.26192; Xiao X, 2016, CANCER DISCOV, V6, P546, DOI 10.1158/2159-8290.CD-15-1408; Xu W, 2014, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00504; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017; Yang CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064159; Yang ZN, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abb0737; Yazdi MT, 2015, CANCER IMMUNOL IMMUN, V64, P1109, DOI 10.1007/s00262-015-1716-2; Zeng QH, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb6296; Zhang CY, 2016, IMMUNITY, V44, P913, DOI 10.1016/j.immuni.2016.04.003; Zhang Z, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1571388	100	7	7	4	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4737	4745		10.1038/s41388-021-01918-y	http://dx.doi.org/10.1038/s41388-021-01918-y		JUN 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34188249				2022-12-28	WOS:000668080200001
J	Kimura, H; Sada, R; Takada, N; Harada, A; Doki, Y; Eguchi, H; Yamamoto, H; Kikuchi, A				Kimura, Hirokazu; Sada, Ryota; Takada, Naoki; Harada, Akikazu; Doki, Yuichiro; Eguchi, Hidetoshi; Yamamoto, Hideki; Kikuchi, Akira			The Dickkopf1 and FOXM1 positive feedback loop promotes tumor growth in pancreatic and esophageal cancers	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; WNT; DKK1; LUNG; TARGET; GENE; CONTRIBUTES; SPECIFICITY; EXPRESSION; REGULATOR	Dickkopf1 (DKK1) is overexpressed in various cancers and promotes cancer cell proliferation by binding to cytoskeleton-associated protein 4 (CKAP4). However, the mechanisms underlying DKK1 expression are poorly understood. RNA sequence analysis revealed that expression of the transcription factor forkhead box M1 (FOXM1) and its target genes concordantly fluctuated with expression of DKK1 in pancreatic ductal adenocarcinoma (PDAC) cells. DKK1 knockdown decreased FOXM1 expression and vice versa in PDAC and esophageal squamous cell carcinoma (ESCC) cells. Inhibition of either the DKK1-CKAP4-AKT pathway or the ERK pathway suppressed FOXM1 expression, and simultaneous inhibition of both pathways showed synergistic effects. A FOXM1 binding site was identified in the 5MODIFIER LETTER PRIME-untranslated region of the DKK1 gene, and its depletion decreased DKK1 expression and cancer cell proliferation. Clinicopathological and database analysis revealed that PDAC and ESCC patients who simultaneously express DKK1 and FOXM1 have a poorer prognosis. Multivariate analysis demonstrated that expression of both DKK1 and FOXM1 is the independent prognostic factor in ESCC patients. Although it has been reported that FOXM1 enhances Wnt signaling, FOXM1 induced DKK1 expression independently of Wnt signaling in PDAC and ESCC cells. These results suggest that DKK1 and FOXM1 create a positive feedback loop to promote cancer cell proliferation.	[Kimura, Hirokazu; Sada, Ryota; Takada, Naoki; Harada, Akikazu; Yamamoto, Hideki; Kikuchi, Akira] Osaka Univ, Grad Sch Med, Dept Mol Biol & Biochem, Suita, Osaka, Japan; [Doki, Yuichiro; Eguchi, Hidetoshi] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka, Japan	Osaka University; Osaka University	Kikuchi, A (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Biol & Biochem, Suita, Osaka, Japan.	akikuchi@molbiobc.med.osaka-u.ac.jp		Sada, Ryota/0000-0003-3403-0542; Kikuchi, Akira/0000-0003-3378-9522	Ministry of Education, Culture, Sports, Science and Technology of Japan [16H06374, 16H06944, 18K15064, 20K16330, 20K07311]; Japan Agency for Medical Research and development, AMED [18cm0106132h0001, 20cm0106152h0002]; Yasuda Memorial Foundation; Ichiro Kanehara Foundation of the Promotion of Medical Science Medical Care; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Agency for Medical Research and development, AMED(Japan Agency for Medical Research and Development (AMED)); Yasuda Memorial Foundation; Ichiro Kanehara Foundation of the Promotion of Medical Science Medical Care; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University	This work was supported by Grants-in-Aid for Scientific Research (2016-2021) (No. 16H06374) to AK, for Young Scientists (Start-up) (2016-2017) (No. 16H06944) to HK, for Early-Career Scientists (2018-2019) (No. 18K15064) to HK, for Early-Career Scientists (2020-2021) (No. 20K16330) to RS, for Scientific Research (C) (2020-2022) (No. 20K07311) to HY from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and also supported by the Project for Cancer Research And Therapeutic Evolution (P-CREATE) (2018) (18cm0106132h0001) and (2019-2021) (20cm0106152h0002) to AK from the Japan Agency for Medical Research and development, AMED, and by grants to AK from the Yasuda Memorial Foundation, the Ichiro Kanehara Foundation of the Promotion of Medical Science & Medical Care, and by Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University to AK.	Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Aoyagi K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018196; Arensman MD, 2014, ONCOGENE, V33, P899, DOI 10.1038/onc.2013.23; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; Eisinger-Mathason TSK, 2015, P NATL ACAD SCI USA, V112, pE3402, DOI 10.1073/pnas.1420005112; Gartel AL, 2017, CANCER RES, V77, P3135, DOI 10.1158/0008-5472.CAN-16-3566; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Golson ML, 2016, DEVELOPMENT, V143, P4558, DOI 10.1242/dev.112672; Haeberle L, 2019, TRANSL GASTROENT HEP, V4, DOI 10.21037/tgh.2019.06.02; Han SX, 2015, ONCOTARGET, V6, P19907, DOI 10.18632/oncotarget.4529; Haniu M, 2011, PROTEIN SCI, V20, P1802, DOI 10.1002/pro.705; Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647; Hussain M, 2009, CANCER RES, V69, P3570, DOI 10.1158/0008-5472.CAN-08-2807; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Kagey MH, 2017, BRIT J PHARMACOL, V174, P4637, DOI 10.1111/bph.13894; Kajiwara C, 2018, CANCER RES, V78, P6107, DOI 10.1158/0008-5472.CAN-18-1749; Kikuchi A, 2017, BRIT J PHARMACOL, V174, P4651, DOI 10.1111/bph.13863; Kimura H, 2019, CLIN CANCER RES, V25, P1936, DOI 10.1158/1078-0432.CCR-18-2124; Kimura H, 2016, J CLIN INVEST, V126, P2689, DOI 10.1172/JCI84658; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mikheev AM, 2008, BREAST CANCER RES TR, V112, P263, DOI 10.1007/s10549-007-9867-2; Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311; Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Park HJ, 2009, EMBO J, V28, P2908, DOI 10.1038/emboj.2009.239; Peters CJ, 2010, GASTROENTEROLOGY, V139, P1995, DOI 10.1053/j.gastro.2010.05.080; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Renz BW, 2018, CANCER CELL, V33, P75, DOI 10.1016/j.ccell.2017.11.007; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Sada R, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aat9519; Sakane H, 2010, J CELL SCI, V123, P360, DOI 10.1242/jcs.058008; Shinno N, 2018, ONCOGENE, V37, P3471, DOI 10.1038/s41388-018-0179-2; Suzuki R, 2007, BRIT J HAEMATOL, V138, P624, DOI 10.1111/j.1365-2141.2007.06702.x; Wang IC, 2014, ONCOGENE, V33, P5391, DOI 10.1038/onc.2013.475; Yamabuki T, 2007, CANCER RES, V67, P2517, DOI 10.1158/0008-5472.CAN-06-3369; Yamamoto H, 2008, DEV CELL, V15, P37, DOI 10.1016/j.devcel.2008.04.015; Yoshida Y, 2007, GASTROENTEROLOGY, V132, P1420, DOI 10.1053/j.gastro.2007.01.036; Zhang H, 2016, TUMOR BIOL, V37, P11321, DOI 10.1007/s13277-016-4995-0; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zhang YQ, 2013, CANCER RES, V73, P4909, DOI 10.1158/0008-5472.CAN-12-4384	45	7	7	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4486	4502		10.1038/s41388-021-01860-z	http://dx.doi.org/10.1038/s41388-021-01860-z		JUN 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34117362	Green Published, hybrid			2022-12-28	WOS:000660409400002
J	Liu, WB; Huang, YS; Wang, DD; Han, F; Chen, HQ; Chen, JP; Jiang, X; Cao, J; Liu, JY				Liu, Wenbin; Huang, Yongsheng; Wang, Dandan; Han, Fei; Chen, Hongqiang; Chen, Jianping; Jiang, Xiao; Cao, Jia; Liu, Jinyi			MPDZ as a novel epigenetic silenced tumor suppressor inhibits growth and progression of lung cancer through the Hippo-YAP pathway	ONCOGENE			English	Article							DNA METHYLATION; BREAST-CANCER; YAP/TAZ; MUPP1; PROTEIN; HYPERMETHYLATION; INACTIVATION; ANGIOMOTIN; DIAGNOSIS; PROGNOSIS	MPDZ also named MUPP1 is involved in signal transduction mediated by the formation of protein complexes. However, the expression regulation, clinical significance, potential function, and mechanism of this gene in lung cancer remain unclear. Methylation status of MPDZ was measured by methylation-specific PCR and bisulfite genomic sequencing. Kaplan-Meier and Cox regression analyses were performed to identify the prognostic value of MPDZ. The tumor suppressing effects of MPDZ were determined in vitro and in vivo. The target molecules and signaling pathway that mediated the function of MPDZ were also identified. MPDZ methylation was identified in 61.2% of primary lung cancer tissues and most lung cancer cell lines but not in normal lung tissues. MPDZ expression was significantly downregulated in lung cancer tissues and negatively associated with DNA hypermethylation, and attenuated MPDZ expression predicted a poor outcome. Furthermore, MPDZ overexpression prominently dampened cell growth, migration, and invasion of tumor cells. Conversely, MPDZ knockdown promoted cell proliferation, migration, and invasion in vitro and in vivo. Moreover, MPDZ deficiency promotes tumor metastasis and reduces the survival of MPDZ knockout mice. Importantly, MPDZ promotes tumor suppressor ability that depends on the Hippo pathway-mediated repression of YAP. MPDZ activates the phosphorylation of YAP (Ser127) and inhibits YAP expression through stabilizing MST1 and interaction with LATS1. We first identified and validated that MPDZ methylation and expression could be a good diagnostic marker and independent prognostic factor for lung cancer. MPDZ functions as a tumor suppressor by inhibiting cell proliferation, migration, and invasion through regulating the Hippo-YAP signaling pathway.	[Liu, Wenbin; Huang, Yongsheng; Wang, Dandan; Han, Fei; Chen, Hongqiang; Chen, Jianping; Jiang, Xiao; Cao, Jia; Liu, Jinyi] Third Mil Med Univ, Army Med Univ, Coll Prevent Med, Inst Toxicol, Chongqing, Peoples R China	Army Medical University	Liu, WB; Cao, J; Liu, JY (corresponding author), Third Mil Med Univ, Army Med Univ, Coll Prevent Med, Inst Toxicol, Chongqing, Peoples R China.	liuwenbin@tmmu.edu.cn; caojia1962@126.com; jinyiliutmmu@163.com	liu, wen/HGE-3071-2022; Han, Fei/AAG-9260-2020	Han, Fei/0000-0002-0265-5487; liu, jin-yi/0000-0003-1803-7752; Huang, Yongsheng/0000-0002-8449-7522	National Natural Science Foundation of China [81573179]; Natural Science Foundation Project of Chongqing CSTC of China [cstc2018jcyjAX0233]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation Project of Chongqing CSTC of China	This work was supported by grants from the National Natural Science Foundation of China (No. 81573179) and the Natural Science Foundation Project of Chongqing CSTC of China (No. cstc2018jcyjAX0233). The authors sincerely thank Yajing Li for technical help.	Belinsky SA, 2015, ANNU REV PHYSIOL, V77, P453, DOI 10.1146/annurev-physiol-021014-072018; Berger AH, 2016, CANCER CELL, V30, P214, DOI 10.1016/j.ccell.2016.06.022; Coyne CB, 2004, J BIOL CHEM, V279, P48079, DOI 10.1074/jbc.M409061200; De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045; Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142; Feldner A, 2017, EMBO MOL MED, V9, P890, DOI 10.15252/emmm.201606430; Guillaume JL, 2008, J BIOL CHEM, V283, P16762, DOI 10.1074/jbc.M802069200; Han F, 2015, ONCOGENE, V34, P4391, DOI 10.1038/onc.2014.370; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hsu YL, 2015, ONCOGENE, V34, P4056, DOI 10.1038/onc.2014.333; Hubers AJ, 2015, BRIT J CANCER, V112, P1105, DOI 10.1038/bjc.2014.636; Ishiuchi T, 2009, J CELL BIOL, V185, P959, DOI 10.1083/jcb.200811030; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Krapivinsky G, 2004, NEURON, V43, P563, DOI 10.1016/j.neuron.2004.08.003; Lanaspa MA, 2008, P NATL ACAD SCI USA, V105, P15797, DOI 10.1073/pnas.0805761105; Lanaspa MA, 2007, P NATL ACAD SCI USA, V104, P13672, DOI 10.1073/pnas.0702752104; Lee YS, 2013, CANCER CELL, V24, P603, DOI 10.1016/j.ccr.2013.10.003; Li E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a019133; Liu JL, 2018, J PATHOL, V244, P71, DOI 10.1002/path.4995; Liu W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.65; Liu WB, 2015, ONCOTARGET, V6, P21225, DOI 10.18632/oncotarget.4237; Liu WB, 2015, MOL CARCINOGEN, V54, P312, DOI 10.1002/mc.22101; Liu WB, 2014, INT J CANCER, V134, P1311, DOI 10.1002/ijc.28472; Liu Y, 2003, CARCINOGENESIS, V24, P1897, DOI 10.1093/carcin/bgg169; Martin TA, 2004, EUR J CANCER, V40, P2717, DOI 10.1016/j.ejca.2004.08.008; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Mohammad HP, 2015, CANCER CELL, V28, P57, DOI 10.1016/j.ccell.2015.06.002; Nawaz I, 2014, EPIGENETICS-US, V9, P1138, DOI 10.4161/epi.29499; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Sheu JJC, 2009, CANCER EPIDEM BIOMAR, V18, P2709, DOI 10.1158/1055-9965.EPI-09-0349; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Tetzlaff F, 2018, ELIFE, V7, DOI 10.7554/eLife.32860; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Walko G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14744; Wang J, 2016, J BIOL CHEM, V291, P17988, DOI 10.1074/jbc.M115.711275; Wen XL, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0170-6; Wrangle J, 2014, CLIN CANCER RES, V20, P1856, DOI 10.1158/1078-0432.CCR-13-2109; Yang JN, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809540; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yuan S, 2016, ONCOGENE, V35, P6120, DOI 10.1038/onc.2016.149; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhang YL, 2018, CANCER RES, V78, P2305, DOI 10.1158/0008-5472.CAN-17-2867; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhu HB, 2013, HEPATOLOGY, V58, P2012, DOI 10.1002/hep.26587	49	5	5	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4468	4485		10.1038/s41388-021-01857-8	http://dx.doi.org/10.1038/s41388-021-01857-8		JUN 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34108620				2022-12-28	WOS:000659470200001
J	Chen, J; Na, RS; Xiao, C; Wang, X; Wang, YP; Yan, DW; Song, GH; Liu, XI; Chen, JY; Lu, HJ; Chen, CY; Tang, HM; Zhuang, GH; Fan, GJ; Peng, ZH				Chen, Jian; Na, Risi; Xiao, Chao; Wang, Xiao; Wang, Yupeng; Yan, Dongwang; Song, Guohe; Liu, Xueni; Chen, Jiayi; Lu, Huijun; Chen, Chunyan; Tang, Huamei; Zhuang, Guohong; Fan, Guangjian; Peng, Zhihai			The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy	ONCOGENE			English	Article							GLYCINE; METABOLISM; METASTASIS; SERINE; CELLS; PKM2; RISK; GENE	5-Fluorouracil (5-FU)-based chemotherapy is the first-line treatment for colorectal cancer (CRC) but is hampered by chemoresistance. Despite its impact on patient survival, the mechanism underlying chemoresistance against 5-FU remains poorly understood. Here, we identified serine hydroxymethyltransferase-2 (SHMT2) as a critical regulator of 5-FU chemoresistance in CRC. SHMT2 inhibits autophagy by binding cytosolic p53 instead of metabolism. SHMT2 prevents cytosolic p53 degradation by inhibiting the binding of p53 and HDM2. Under 5-FU treatment, SHMT2 depletion promotes autophagy and inhibits apoptosis. Autophagy inhibitors decrease low SHMT2-induced 5-FU resistance in vitro and in vivo. Finally, the lethality of 5-FU treatment to CRC cells was enhanced by treatment with the autophagy inhibitor chloroquine in patient-derived and CRC cell xenograft models. Taken together, our findings indicate that autophagy induced by low SHMT2 levels mediates 5-FU resistance in CRC. These results reveal the SHMT2-p53 interaction as a novel therapeutic target and provide a potential opportunity to reduce chemoresistance.	[Chen, Jian] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Thorac Surg, Shanghai, Peoples R China; [Na, Risi; Tang, Huamei; Peng, Zhihai] Xiamen Univ, Sch Med, Xiang An Hosp, Dept Gen Surg, Xiamen, Peoples R China; [Xiao, Chao] Fu Dan Univ, Sch Med, Hua Shan Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Wang, Xiao] Sun Yat Sen Univ, Dept Gastrointestinal Surg, Affiliated Hosp 5, Zhuhai, Peoples R China; [Wang, Yupeng; Song, Guohe] Fu Dan Univ, Sch Med, Zhong Shan Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Yan, Dongwang; Liu, Xueni; Chen, Jiayi; Fan, Guangjian] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Translat Med Ctr, Shanghai, Peoples R China; [Lu, Huijun] Guigang City Peoples Hosp, Dept Pathol, Guigang, Guangxi, Peoples R China; [Chen, Chunyan] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Pathol, Shanghai, Peoples R China; [Tang, Huamei; Zhuang, Guohong; Peng, Zhihai] Xiamen Univ, Organ Transplantat Inst, Sch Med, Fujian Prov Key Lab Organ & Tissue Regenerat, Xiamen, Peoples R China	Tongji University; Xiamen University; Fudan University; Sun Yat Sen University; Fudan University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Xiamen University	Tang, HM; Peng, ZH (corresponding author), Xiamen Univ, Sch Med, Xiang An Hosp, Dept Gen Surg, Xiamen, Peoples R China.; Fan, GJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Translat Med Ctr, Shanghai, Peoples R China.; Tang, HM; Zhuang, GH; Peng, ZH (corresponding author), Xiamen Univ, Organ Transplantat Inst, Sch Med, Fujian Prov Key Lab Organ & Tissue Regenerat, Xiamen, Peoples R China.	tanghuamei2014@163.com; zhgh@xmu.edu.cn; ytfan@126.com; pengzhihai1958@163.com	Chen, Jiayi/GZM-5106-2022		National Natural Science Foundation of China [81530044, 81802343, 81871931, 81602069, 81220108021, 81702337, 81602616]; Medical Guidance Project of Shanghai Science and Technology Commission [17411968200, 19QA1407100]; Natural Science Foundation of Shanghai Municipality [16ZR1427700, 16CR2008A]; National Science and Technology Major Project of China [2017ZX10203206]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Guidance Project of Shanghai Science and Technology Commission; Natural Science Foundation of Shanghai Municipality(Natural Science Foundation of Shanghai); National Science and Technology Major Project of China	We acknowledge the National Natural Science Foundation of China (81530044, 81802343, 81871931, 81602069, 81220108021, 81702337, 81602616), the Medical Guidance Project of Shanghai Science and Technology Commission (17411968200, 19QA1407100), and the Natural Science Foundation of Shanghai Municipality (16ZR1427700). Shanghai 3-year action plan to promote the clinical skills and clinical innovation capacity of municipal hospitals (No. 16CR2008A). National Science and Technology Major Project of China Grant 2017ZX10203206.	Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Anderson DJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008305; Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Bao XR, 2016, ELIFE, V5, DOI 10.7554/eLife.10575; Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002; Chen DT, 2012, J GASTROINTEST SURG, V16, P905, DOI 10.1007/s11605-011-1815-0; Chen SN, 2016, TUMOR BIOL, V37, P2321, DOI 10.1007/s13277-015-3800-9; Chowdhury RM, 2018, J STOMATOL ORAL MAXI, V119, P37, DOI 10.1016/j.jormas.2017.11.001; DALLE PP, 2016, NAT COMMUN, V7, DOI [10.1038/ncomms13254, DOI 10.1038/NC0MMS13254]; Fan GJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20208-x; Golden EB, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14504; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002; Harris I, 2012, CELL RES, V22, P447, DOI 10.1038/cr.2011.203; HASHIZUME O, 2015, SCI REP-UK, V5; Hong Y, 2010, CLIN EXP METASTAS, V27, P83, DOI 10.1007/s10585-010-9305-4; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Kelemen Linda E., 2012, Frontiers in Genetics, V3, P33, DOI 10.3389/fgene.2012.00033; Kim D, 2015, NATURE, V520, P363, DOI 10.1038/nature14363; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Lee GY, 2014, CANCER RES, V74, P3114, DOI 10.1158/0008-5472.CAN-13-2683; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Long M, 2017, TRENDS ENDOCRIN MET, V28, P818, DOI 10.1016/j.tem.2017.09.001; Lorente J, 2018, BIOL REV, V93, P152, DOI 10.1111/brv.12337; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Morscher RJ, 2018, NATURE, V554, P128, DOI 10.1038/nature25460; Nature, 2021, NATURE; Ning SL, 2018, GASTROENT RES PRACT, V2018, DOI 10.1155/2018/4369253; Nyfeler B, 2016, AUTOPHAGY, V12, P1206, DOI 10.1080/15548627.2016.1170265; Piffoux M, 2021, BRIT J CANCER, V124, P333, DOI 10.1038/s41416-020-01039-5; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; Ron-Harel N, 2016, CELL METAB, V24, P104, DOI 10.1016/j.cmet.2016.06.007; Ryan BM, 2014, INT J CANCER, V134, P1399, DOI 10.1002/ijc.28457; Saha S, 2018, BIOMED PHARMACOTHER, V104, P485, DOI 10.1016/j.biopha.2018.05.007; Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338; Sanz-Pamplona R, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-46; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Son SM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16886-2; Song GH, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0427-7; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Thandi RS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17310-5; Walden M, 2019, NATURE, V570, P194, DOI 10.1038/s41586-019-1232-1; WEI Z, 2018, NAT COMMUN, V9; Woo CC, 2016, ONCOTARGET, V7, P53005, DOI 10.18632/oncotarget.10415; Xiao C, 2018, CANCER SCI, V109, P1075, DOI 10.1111/cas.13516; Xu MY, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007071; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yang X, 2018, CANCER RES, V78, P372, DOI 10.1158/0008-5472.CAN-17-1912; Zhao EH, 2016, CELL REP, V14, P506, DOI 10.1016/j.celrep.2015.12.053; Zheng H, 2013, CELL REP, V5, P180, DOI 10.1016/j.celrep.2013.08.025	55	11	11	6	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					3974	3988		10.1038/s41388-021-01815-4	http://dx.doi.org/10.1038/s41388-021-01815-4		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	33990700	hybrid, Green Published			2022-12-28	WOS:000650652500001
J	Mao, LF; Yuan, WJ; Cai, KM; Lai, C; Huang, CH; Xu, Y; Zhong, SW; Yang, C; Wang, R; Zeng, PW; Huang, HY; Chen, ZK; Chen, ZH				Mao, Linfeng; Yuan, Weijie; Cai, Kaimei; Lai, Chen; Huang, Changhao; Xu, Yi; Zhong, Shangwei; Yang, Chen; Wang, Ran; Zeng, Pengwei; Huang, Heyuan; Chen, Zhikang; Chen, Zihua			EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis	ONCOGENE			English	Article							ANNEXIN A2; POOR-PROGNOSIS; PHOSPHORYLATION; INVASION; NUCLEAR; PROLIFERATION; MIGRATION; COMPLEX; GROWTH; SIGNAL	Erythropoietin-producing hepatocellular receptor A2 (EphA2) is a key member of the receptor tyrosine kinase (RTK) family, while YES Proto-Oncogene 1 (YES1) is a non-receptor tyrosine kinase (nRTK) and annexin A2 (ANXA2) belongs to the calcium-dependent phospholipid-binding protein family annexins. Here, we show that EphA2, YES1, and ANXA2 form a signal axis, in which YES1 activated by EphA2 phosphorylates ANXA2 at Tyr24 site, leading to ANXA2 activation and increased ANXA2 nuclear distribution in gastric cancer (GC) cells. Overexpression (OE) of YES1 increases, while knockdown (KD) of YES1 or ANXA2 decreases GC cell invasion and migration in vitro and tumor growth in mouse models. Reexpression of wildtype (WT) rather than mutant ANXA2 (Tyr24F) in ANXA2 knockdown (ANXA2-KD) GC cells restores YES1-induced cell invasion and migration, while neither WT nor mutant ANXA2 (Tyr24F) can restore cell invasion and migration in YES1-KD GC cells. In addition, the activation of EphA2-YES1-ANXA2 pathway is correlated with poor prognosis. Thus, our results establish EphA2-YES1-ANXA2 axis as a novel pathway that drives GC invasion and metastasis, targeting this pathway would be an efficient way for the treatment of GC.	[Mao, Linfeng; Yuan, Weijie; Lai, Chen; Huang, Changhao; Yang, Chen; Wang, Ran; Zeng, Pengwei; Huang, Heyuan; Chen, Zhikang; Chen, Zihua] Cent South Univ CSU, Xiangya Hosp, Dept Gen Surg, Changsha, Hunan, Peoples R China; [Mao, Linfeng; Yuan, Weijie; Huang, Changhao; Yang, Chen; Zeng, Pengwei; Huang, Heyuan; Chen, Zihua] CSU, Xiangya Hosp, Dept Gastrointestinal Surg, Changsha, Hunan, Peoples R China; [Mao, Linfeng; Cai, Kaimei; Lai, Chen; Huang, Changhao; Xu, Yi; Zhong, Shangwei; Yang, Chen; Wang, Ran; Zeng, Pengwei; Huang, Heyuan; Chen, Zhikang; Chen, Zihua] CSU, Xiangya Hosp, Hunan Prov Key Lab Precis Diag & Treatment Gastro, Changsha, Hunan, Peoples R China; [Yuan, Weijie; Lai, Chen; Wang, Ran; Chen, Zhikang] CSU, Xiangya Hosp, Dept Colorectal & Anus Surg, Changsha, Hunan, Peoples R China; [Chen, Zhikang; Chen, Zihua] CSU, Xiangya Hosp, Int Joint Res Ctr Minimally Invas Endoscop Techno, Changsha, Hunan, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University	Chen, ZH (corresponding author), Cent South Univ CSU, Xiangya Hosp, Dept Gen Surg, Changsha, Hunan, Peoples R China.; Chen, ZH (corresponding author), CSU, Xiangya Hosp, Dept Gastrointestinal Surg, Changsha, Hunan, Peoples R China.; Chen, ZH (corresponding author), CSU, Xiangya Hosp, Hunan Prov Key Lab Precis Diag & Treatment Gastro, Changsha, Hunan, Peoples R China.; Chen, ZH (corresponding author), CSU, Xiangya Hosp, Int Joint Res Ctr Minimally Invas Endoscop Techno, Changsha, Hunan, Peoples R China.	zihuachenxy@126.com		Yang, Chen/0000-0002-2502-4960; Mao, Lin-feng/0000-0001-8113-1253; Zhong, Shangwei/0000-0002-8587-6452	Natural Science Foundation of China [81974386]; Research and Development program in Key Areas of Hunan Province [2019SK2143]; Natural Science Foundation of Hunan Province [2018JJ6065]; Innovation Research Project of CSU [2019zzts335]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research and Development program in Key Areas of Hunan Province; Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); Innovation Research Project of CSU	This study was supported by Natural Science Foundation of China (81974386), Research and Development program in Key Areas of Hunan Province (2019SK2143), Natural Science Foundation of Hunan Province (2018JJ6065) and Innovation Research Project of CSU (2019zzts335). We thank Advanced Research Center and Cancer Research Institute of CSU for providing some GC cell lines.	Ajani JA, 2016, J NATL COMPR CANC NE, V14, P1286, DOI 10.6004/jnccn.2016.0137; Alam Muhammad S, 2018, Curr Protoc Immunol, V123, pe58, DOI 10.1002/cpim.58; Anselmino N, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030467; Aukrust I, 2017, FEBS OPEN BIO, V7, P160, DOI 10.1002/2211-5463.12173; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chasserot-Golaz S, 2005, MOL BIOL CELL, V16, P1108, DOI 10.1091/mbc.E04-07-0627; Christensen MV, 2018, INT J ONCOL, V52, P5, DOI 10.3892/ijo.2017.4197; Das S, 2010, BIOCHEMISTRY-US, V49, P2216, DOI 10.1021/bi9013038; de Graauw M, 2008, MOL CELL BIOL, V28, P1029, DOI 10.1128/MCB.01247-07; De Robertis M, 2017, CLIN CANCER RES, V23, P159, DOI 10.1158/1078-0432.CCR-16-0709; Eberhard DA, 2001, J CELL SCI, V114, P3155; Emoto K, 2001, ANTICANCER RES, V21, P1339; Eusebi LH, 2020, J GASTROEN HEPATOL, V35, P1495, DOI 10.1111/jgh.15037; Fahling M, 2019, AM J PHYSIOL-RENAL, V316, pF101, DOI 10.1152/ajprenal.00361.2018; Fan YL, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1147-7; Fei F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00182; Garmendia I, 2019, AM J RESP CRIT CARE, V200, P888, DOI 10.1164/rccm.201807-1292OC; Grindheim AK, 2017, BBA-GEN SUBJECTS, V1861, P2515, DOI 10.1016/j.bbagen.2017.08.024; Grindheim AK, 2016, J CELL SCI, V129, P314, DOI 10.1242/jcs.173195; Hamamoto Y, 2020, GASTRIC CANCER, V23, P363, DOI 10.1007/s10120-020-01067-3; Hamanaka N, 2019, CANCER RES, V79, P5734, DOI 10.1158/0008-5472.CAN-18-3376; Hou FT, 2012, MED ONCOL, V29, P2691, DOI 10.1007/s12032-011-0127-2; Huang CH, 2020, INT J CANCER, V146, P1937, DOI 10.1002/ijc.32609; Huang J, 2014, ONCOGENE, V33, P2737, DOI 10.1038/onc.2013.238; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; Ieguchi K, 2019, CANCER SCI, V110, P841, DOI 10.1111/cas.13942; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; Jost M, 1996, BBA-MOL CELL RES, V1313, P283, DOI 10.1016/0167-4889(96)00101-2; Kazami T, 2015, ONCOGENE, V34, P4177, DOI 10.1038/onc.2014.345; Kpetemey M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0428-8; Li JY, 2019, CANCER LETT, V444, P162, DOI 10.1016/j.canlet.2018.12.011; Li RX, 2014, MOL CELL BIOCHEM, V396, P295, DOI 10.1007/s11010-014-2164-6; Li WL, 2018, ONCOGENE, V37, P4903, DOI 10.1038/s41388-018-0341-x; Ma S, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0851-y; Markosyan N, 2019, J CLIN INVEST, V129, P3594, DOI 10.1172/JCI127755; Oliveira L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029963; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Peng Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1164-y; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Sirvent A, 2015, PROTEOMICS, V15, P232, DOI 10.1002/pmic.201400162; Song W, 2017, ONCOGENE, V36, P5620, DOI 10.1038/onc.2017.170; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854; Wang T, 2019, CANCER BIOL MED, V16, P671, DOI 10.20892/j.issn.2095-3941.2019.0228; Wang Yu-qing, 2012, Cancer Biology Medicine, V9, P248, DOI 10.7497/j.issn.2095-3941.2012.04.005; Xie R, 2019, J ONCOL, V2019, DOI 10.1155/2019/4035460; Yoshida N, 2021, GUT, V70, P67, DOI 10.1136/gutjnl-2019-319631; Zhou Y, 2017, BIOL PHARM BULL, V40, P1616, DOI 10.1248/bpb.b17-00446; Zhou Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8679	50	10	10	4	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3610	3623		10.1038/s41388-021-01786-6	http://dx.doi.org/10.1038/s41388-021-01786-6		MAY 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33941853	Green Published, hybrid			2022-12-28	WOS:000646512200001
J	Wang, YY; Chen, YK; Lo, S; Chi, TC; Chen, YH; Hu, SCS; Chen, YW; Jiang, SS; Tsai, FY; Liu, WT; Li, RN; Hsieh, YC; Huang, CJ; Yuan, SSF				Wang, Yen-Yun; Chen, Yuk-Kwan; Lo, Steven; Chi, Tsung-Chen; Chen, Yi-Hua; Hu, Stephen Chu-Sung; Chen, Ya-Wen; Jiang, Shih Sheng; Tsai, Fang-Yu; Liu, Wangta; Li, Ruei-Nian; Hsieh, Ya-Ching; Huang, Chih-Jen; Yuan, Shyng-Shiou F.			MRE11 promotes oral cancer progression through RUNX2/CXCR4/AKT/FOXA2 signaling in a nuclease-independent manner	ONCOGENE			English	Article								MRE11, the nuclease component of RAD50/MRE11/NBS1 DNA repair complex which is essential for repair of DNA double-strand-breaks in normal cells, has recently garnered attention as a critical factor in solid tumor development. Herein we report the crucial role of MRE11 in oral cancer progression in a nuclease-independent manner and delineate its key downstream effectors including CXCR4. MRE11 expression in oral cancer samples was positively associated with tumor size, cancer stage and lymph node metastasis, and was predictive of poorer patient survival and radiotherapy resistance. MRE11 promoted cell proliferation/migration/invasion in a nuclease-independent manner but enhanced radioresistance via a nuclease-dependent pathway. The nuclease independent promotion of EMT and metastasis was mediated by RUNX2, CXCR4, AKT, and FOXA2, while CXCR4 neutralizing antibody mitigated these effects in vitro and in vivo. Collectively, MRE11 may serve as a crucial prognostic factor and therapeutic target in oral cancer, displaying dual nuclease dependent and independent roles that permit separate targeting of tumor vulnerabilities in oral cancer treatment.	[Wang, Yen-Yun; Chen, Yuk-Kwan] Kaohsiung Med Univ, Sch Dent, Coll Dent Med, Kaohsiung, Taiwan; [Wang, Yen-Yun; Chi, Tsung-Chen; Chen, Yi-Hua; Yuan, Shyng-Shiou F.] Kaohsiung Med Univ Hosp, Translat Res Ctr, Kaohsiung, Taiwan; [Wang, Yen-Yun; Yuan, Shyng-Shiou F.] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan; [Wang, Yen-Yun; Chen, Yuk-Kwan; Liu, Wangta; Yuan, Shyng-Shiou F.] Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung, Taiwan; [Chen, Yuk-Kwan] Kaohsiung Med Univ Hosp, Div Oral Pathol & Maxillofacial Radiol, Kaohsiung, Taiwan; [Chen, Yuk-Kwan] Kaohsiung Med Univ, Coll Dent Med, Oral & Maxillofacial Imaging Ctr, Kaohsiung, Taiwan; [Lo, Steven] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland; [Hu, Stephen Chu-Sung] Kaohsiung Med Univ, Dept Dermatol, Coll Med, Kaohsiung, Taiwan; [Hu, Stephen Chu-Sung] Kaohsiung Med Univ Hosp, Dept Dermatol, Kaohsiung, Taiwan; [Chen, Ya-Wen; Jiang, Shih Sheng; Tsai, Fang-Yu] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan; [Liu, Wangta] Kaohsiung Med Univ, Dept Biotechnol, Coll Life Sci, Kaohsiung, Taiwan; [Li, Ruei-Nian] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung, Taiwan; [Hsieh, Ya-Ching] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Huang, Chih-Jen] Kaohsiung Med Univ Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan; [Huang, Chih-Jen] Kaohsiung Med Univ, Dept Radiat Oncol, Coll Med, Fac Med, Kaohsiung, Taiwan; [Yuan, Shyng-Shiou F.] Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan; [Yuan, Shyng-Shiou F.] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan; [Yuan, Shyng-Shiou F.] Natl ChiaoTung Univ, Dept Biol Sci & Technol, Coll Biol Sci & Technol, Hsinchu, Taiwan; [Yuan, Shyng-Shiou F.] Natl Chiao Tung Univ, Ctr Intelligent Drug Syst & Smart Biodevices IDS2, Hsinchu, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; University of Glasgow; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Health Research Institutes - Taiwan; Kaohsiung Medical University; Kaohsiung Medical University; University of Glasgow; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Yuan, SSF (corresponding author), Kaohsiung Med Univ Hosp, Translat Res Ctr, Kaohsiung, Taiwan.; Yuan, SSF (corresponding author), Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan.; Yuan, SSF (corresponding author), Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung, Taiwan.; Yuan, SSF (corresponding author), Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan.; Yuan, SSF (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan.; Yuan, SSF (corresponding author), Natl ChiaoTung Univ, Dept Biol Sci & Technol, Coll Biol Sci & Technol, Hsinchu, Taiwan.; Yuan, SSF (corresponding author), Natl Chiao Tung Univ, Ctr Intelligent Drug Syst & Smart Biodevices IDS2, Hsinchu, Taiwan.	yuanssf@ms33.hinet.net		Chen, Yuk-Kwan/0000-0001-6800-273X; Chen, Yi-Hua/0000-0002-4390-1090	Ministry of Health and Welfare of Taiwan [MOHW109-TDU-B-212-134016]; "Center For Intelligent Drug Systems and Smart Bio-devices (IDS2B)" from The Featured Areas Research Center Program within Ministry of Education in Taiwan; Kaohsiung Medical University Hospital [KMUH105-5R32, KMUH106-6R41, KMUH106-6R83, KMUH107-7R36]; Kaohsiung Medical University [KMU-DK108005]; Kaohsiung Medical University Research Center Grant (Center for Cancer Research) [KMU-TC108A04-0, KMU-TC108A04-1]; Ministry of Science and Technology, Taiwan [107-2314-B-037-097]; Taiwan Bioinformatics Institute Core Facility (National Core Facility Program for Biotechnology) [MOST 109-2319-B-400-001]	Ministry of Health and Welfare of Taiwan; "Center For Intelligent Drug Systems and Smart Bio-devices (IDS2B)" from The Featured Areas Research Center Program within Ministry of Education in Taiwan; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Research Center Grant (Center for Cancer Research); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Taiwan Bioinformatics Institute Core Facility (National Core Facility Program for Biotechnology)	This work was financially supported by grants from the Ministry of Health and Welfare (MOHW109-TDU-B-212-134016, Health and welfare surcharge of tobacco products) of Taiwan and from "Center For Intelligent Drug Systems and Smart Bio-devices (IDS2B)" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education in Taiwan. This work was also supported by grants from the Kaohsiung Medical University Hospital (KMUH105-5R32, KMUH106-6R41, KMUH106-6R83, KMUH107-7R36), Kaohsiung Medical University (Research Center Grant KMU-DK108005), Kaohsiung Medical University Research Center Grant (Center for Cancer Research KMU-TC108A04-0, KMU-TC108A04-1), the Ministry of Science and Technology, Taiwan (grant number 107-2314-B-037-097), and Taiwan Bioinformatics Institute Core Facility (National Core Facility Program for Biotechnology, MOST 109-2319-B-400-001).	Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003; Herrero AB, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00098; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Chatterjee S, 2014, ADV CANCER RES, V124, P31, DOI 10.1016/B978-0-12-411638-2.00002-1; Chen C, 2013, P NATL ACAD SCI USA, V110, P20605, DOI 10.1073/pnas.1306328110; Chen TC, 2012, ORAL ONCOL, V48, P623, DOI 10.1016/j.oraloncology.2012.01.015; Cohen-Solal KA, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0404-3; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Ghani WMN, 2013, ASIAN PAC J CANCER P, V14, P1957, DOI 10.7314/APJCP.2013.14.3.1957; Guo ZJ, 2016, ONCOTARGET, V7, P20999, DOI 10.18632/oncotarget.8236; Gupta GP, 2013, MOL CELL, V52, P353, DOI 10.1016/j.molcel.2013.09.001; Gupta N, 2016, NEPAL J EPIDEMIOL, V6, P613, DOI 10.3126/nje.v6i4.17255; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Hill L, 2013, INT J CANCER, V132, P745, DOI 10.1002/ijc.27708; Huang CS, 2014, J AM SOC NEPHROL, V25, P1486, DOI 10.1681/ASN.2013070773; Huang YL, 2015, HUM MOL GENET, V24, P3506, DOI 10.1093/hmg/ddv102; Li ZG, 2017, CANCER RES, V77, P3169, DOI 10.1158/0008-5472.CAN-16-2787; Ma YX, 2019, AGING-US, V11, P3969, DOI 10.18632/aging.102032; Minchom A, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918786658; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nag S, 2014, CURR MED CHEM, V21, P553, DOI 10.2174/09298673113206660325; Pernas S, 2018, LANCET ONCOL, V19, P812, DOI 10.1016/S1470-2045(18)30147-5; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; Piscitello D, 2018, ONCOGENE, V37, P427, DOI 10.1038/onc.2017.340; Radisavljevic Z, 2013, J CELL PHYSIOL, V228, P522, DOI 10.1002/jcp.24167; Rishi L, 2014, BLOOD, V123, P2389, DOI 10.1182/blood-2013-07-511683; Rozengurt E, 2014, MOL CANCER THER, V13, P2477, DOI 10.1158/1535-7163.MCT-14-0330; Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979; Spehalski E, 2017, CANCER RES, V77, P5327, DOI 10.1158/0008-5472.CAN-17-1355; Symington LS, 2016, CRIT REV BIOCHEM MOL, V51, P195, DOI 10.3109/10409238.2016.1172552; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Taylor EM, 2016, FUTURE ONCOL, V12, P221, DOI 10.2217/fon.15.292; Uchida D, 2003, EXP CELL RES, V290, P289, DOI 10.1016/S0014-4827(03)00344-6; Vag T, 2018, EJNMMI RES, V8, DOI 10.1186/s13550-018-0442-0; Vanharanta S, 2013, CANCER DISCOV, V3, P1103, DOI 10.1158/2159-8290.CD-13-0481; Yuan SSF, 2012, JNCI-J NATL CANCER I, V104, P1485, DOI 10.1093/jnci/djs355; Zaidi SK, 2007, P NATL ACAD SCI USA, V104, P19861, DOI 10.1073/pnas.0709650104; Zhang Z, 2015, CANCER LETT, V361, P240, DOI 10.1016/j.canlet.2015.03.008; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	40	5	5	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3510	3532		10.1038/s41388-021-01698-5	http://dx.doi.org/10.1038/s41388-021-01698-5		APR 2021	23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33927349	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000645517200002
J	Lin, YL; Zhou, XH; Yang, KF; Chen, YT; Wang, LZ; Luo, WX; Li, YJ; Liao, JR; Zhou, YT; Lei, YM; Zhang, YT; Wu, DH; Cai, LM				Lin, Yanling; Zhou, Xiaohan; Yang, Kaifan; Chen, Yuting; Wang, Lingzhi; Luo, Wenxiao; Li, Yujiang; Liao, Jinrong; Zhou, Yingtong; Lei, Yiming; Zhang, Yanting; Wu, Dehua; Cai, Longmei			Protein tyrosine phosphatase receptor type D gene promotes radiosensitivity via STAT3 dephosphorylation in nasopharyngeal carcinoma	ONCOGENE			English	Article								Radiotherapy is essential to the treatment of nasopharyngeal carcinoma (NPC) and acquired or innate resistance to this therapeutic modality is a major clinical problem. However, the underlying molecular mechanisms in the radiation resistance in NPC are not fully understood. Here, we reanalyzed the microarray data from public databases and identified the protein tyrosine phosphatase receptor type D (PTPRD) as a candidate gene. We found that PTPRD was downregulated in clinical NPC tissues and NPC cell lines with its promoter hypermethylated. Functional assays revealed that PTPRD overexpression sensitized NPC to radiation in vitro and in vivo. Importantly, miR-454-3p directly targets PTPRD to inhibit its expression and biological effect. Interestingly, mechanistic analyses indicate that PTPRD directly dephosphorylates STAT3 to enhance Autophagy-Related 5 (ATG5) transcription, resulting in triggering radiation-induced autophagy. The immunohistochemical staining of 107 NPC revealed that low PTPRD and high p-STAT3 levels predicted poor clinical outcome. Overall, we showed that PTPRD promotes radiosensitivity by triggering radiation-induced autophagy via the dephosphorylation of STAT3, thus providing a potentially useful predictive biomarker for NPC radiosensitivity and drug target for NPC radiosensitization.	[Lin, Yanling; Zhou, Xiaohan; Chen, Yuting; Luo, Wenxiao; Zhou, Yingtong; Wu, Dehua; Cai, Longmei] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China; [Yang, Kaifan] Southern Med Univ, Nanfang Hosp, Dept Orthopaed, Div Spine Surg, Guangzhou, Peoples R China; [Wang, Lingzhi; Lei, Yiming; Zhang, Yanting] Southern Med Univ, Nanfang Hosp, Clin Med Coll 1, Guangzhou, Peoples R China; [Li, Yujiang] Southern Med Univ, Huiqiao Med Ctr, Dept Thorac & Cardiovasc Surg, Guangzhou, Peoples R China; [Li, Yujiang] Southern Med Univ, Dongguan Peoples Hosp, Affiliated Dongguan Peoples Hosp, Dept Thorac & Cardiovasc Surg, Dongguan, Peoples R China; [Liao, Jinrong] Southern Med Univ, Zhujiang Hosp, Clin Med Coll 2, Guangzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	Wu, DH; Cai, LM (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China.	wudehua.gd@gmail.com; cailongmeibestlove@163.com		Chen, Yuting/0000-0002-0262-9721; Wu, De-Hua/0000-0003-0560-0016; Yang, Kaifan/0000-0003-4166-0198	National Natural Science Foundation of China [81773111, 81702696]; Natural Science Foundation of Guangdong Province [2017A030310040]; Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University [2017J004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University	We are grateful to Prof. Musheng Zeng (Sun Yat-sen University Cancer Center, China) and Prof. George S.W. Tsao (University of Hong Kong, China) for their support. This work was supported by the National Natural Science Foundation of China (grant Nos. 81773111 and 81702696), the Natural Science Foundation of Guangdong Province (grant No. 2017A030310040), and the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University (grant No. 2017J004).	Blanchard P, 2015, LANCET ONCOL, V16, P645, DOI 10.1016/S1470-2045(15)70126-9; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai LM, 2015, ONCOGENE, V34, P2156, DOI 10.1038/onc.2014.341; Cai LM, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00939; Cai LM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8353; Chai EZP, 2016, PHARMACOL THERAPEUT, V162, P86, DOI 10.1016/j.pharmthera.2015.10.004; Chan ATC, 2012, ANN ONCOL, V23, P83, DOI 10.1093/annonc/mds266; Chang LH, 2019, AM J CANCER RES, V9, P1922; Chen QP, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00232; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Cui DR, 2020, CELL REP, V30, P497, DOI 10.1016/j.celrep.2019.12.032; Digomann D, 2019, AUTOPHAGY, V15, P1850, DOI 10.1080/15548627.2019.1639302; Funato K, 2011, EXP THER MED, V2, P457, DOI 10.3892/etm.2011.231; Hale AN, 2013, AUTOPHAGY, V9, P951, DOI 10.4161/auto.24273; Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270; Jiang W, 2015, MOL CANCER THER, V14, P2864, DOI 10.1158/1535-7163.MCT-15-0260; Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058; Kim M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092708; Kim W, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091105; Kohno T, 2010, GENE CHROMOSOME CANC, V49, P342, DOI 10.1002/gcc.20746; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Li H, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0618-0; Li L, 2020, CURR MOL PHARMACOL, V13, P31, DOI 10.2174/1874467212666190809154518; Li Y, 2019, BIOSCIENCE REP, V39, DOI [10.1038/s41388-021-01768-8, DOI 10.1038/S41388-021-01768-8]; Li YQ, 2018, CLIN CANCER RES, V24, P6495, DOI 10.1158/1078-0432.CCR-18-0532; Liu DD, 2018, J AGR FOOD CHEM, V66, P11757, DOI 10.1021/acs.jafc.8b04704; Liu YL, 2020, J CELL MOL MED, V24, P9135, DOI 10.1111/jcmm.15550; Luftig M, 2013, J CLIN INVEST, V123, P4999, DOI 10.1172/JCI73416; Meng J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2327-1; Nunez FJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaq1427; Peng H, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-0997-7; Peyser ND, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135750; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Ren XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14053; Thilakasiri PS, 2021, SEMIN CANCER BIOL, V68, P31, DOI 10.1016/j.semcancer.2019.09.022; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Vehlow A, 2019, AUTOPHAGY, V15, P1487, DOI 10.1080/15548627.2019.1618540; Wang XH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01120; Wu AH, 2019, INT J CLIN EXP PATHO, V12, P4222; Yang SM, 2019, BIOCHEM CELL BIOL, V97, P364, DOI 10.1139/bcb-2017-0343; Yu HY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0660-4; Yu XT, 2017, ONCOTARGET, V8, P98798, DOI 10.18632/oncotarget.22000; Zhang J, 2019, NEOPLASIA, V21, P311, DOI 10.1016/j.neo.2019.01.006; Zhang J, 2019, CANCER RES, V79, P747, DOI 10.1158/0008-5472.CAN-18-1754; Zhu QW, 2021, AUTOPHAGY, V17, P1667, DOI 10.1080/15548627.2020.1781368	45	9	9	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3101	3117		10.1038/s41388-021-01768-8	http://dx.doi.org/10.1038/s41388-021-01768-8		APR 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33824475	hybrid, Green Published			2022-12-28	WOS:000637478800005
J	Nehme, Z; Pasquereau, S; Ahmad, SH; Coaquette, A; Molimard, C; Monnien, F; Algros, MP; Adotevi, O; Assaf, MD; Feugeas, JP; Herbein, G				Nehme, Zeina; Pasquereau, Sebastien; Haidar Ahmad, Sandy; Coaquette, Alain; Molimard, Chloe; Monnien, Franck; Algros, Marie-Paule; Adotevi, Olivier; Diab Assaf, Mona; Feugeas, Jean-Paul; Herbein, Georges			Polyploid giant cancer cells, stemness and epithelial-mesenchymal plasticity elicited by human cytomegalovirus	ONCOGENE			English	Article								A growing body of evidence is recognizing human cytomegalovirus (HCMV) as a potential oncogenic virus. We hereby provide the first experimental in vitro evidence for HCMV as a reprogramming vector, through the induction of dedifferentiation of mature human mammary epithelial cells (HMECs), generation of a polyploid giant cancer cell (PGCC) phenotype characterized by sustained growth of blastomere-like cells, in concordance with the acquisition of embryonic stem cells characteristics and epithelial-mesenchymal plasticity. HCMV presence parallels the succession of the observed cellular and molecular events potentially ensuing the transformation process. Correlation between PGCCs detection and HCMV presence in breast cancer tissue further validates our hypothesis in vivo. Our study indicates that some clinical HCMV strains conserve the potential to transform HMECs and fit with a "blastomere-like" model of oncogenesis, which may be relevant in the pathophysiology of breast cancer and other adenocarcinoma, especially of poor prognosis.	[Nehme, Zeina; Pasquereau, Sebastien; Haidar Ahmad, Sandy; Herbein, Georges] Univ Bourgogne France Comte, Dept Pathogens & Inflammat, EPILAB, EA4266, Besancon, France; [Nehme, Zeina; Haidar Ahmad, Sandy; Diab Assaf, Mona] Lebanese Univ, Beirut, Lebanon; [Coaquette, Alain; Herbein, Georges] CHRU Besancon, Dept Virol, Besancon, France; [Molimard, Chloe; Monnien, Franck; Algros, Marie-Paule] CHRU Besancon, Dept Pathol, Besancon, France; [Adotevi, Olivier; Feugeas, Jean-Paul] Univ Bourgogne Franche Comte, Interact Greffon Hote Tumeur Ingn Cellulaire & Ge, INSERM, EFS BFC,UMR1098,RIGHT, Besancon, France	Universite de Franche-Comte; Lebanese University; Universite de Franche-Comte; CHU Besancon; Universite de Franche-Comte; CHU Besancon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte	Herbein, G (corresponding author), Univ Bourgogne France Comte, Dept Pathogens & Inflammat, EPILAB, EA4266, Besancon, France.; Herbein, G (corresponding author), CHRU Besancon, Dept Virol, Besancon, France.	georges.herbein@univ-fcomte.fr	Adotevi, Olivier/AAX-8290-2021	Pasquereau, Sebastien/0000-0002-9291-797X; Nehme, Zeina/0000-0002-4750-6389; adotevi, olivier/0000-0002-7742-136X; Haidar Ahmad, sandy/0000-0001-5375-0874	University of Franche-Comte; Region Franche-Comte; municipality of Habbouch	University of Franche-Comte; Region Franche-Comte(Region Bourgogne-Franche-Comte); municipality of Habbouch	This work was supported by grants from the University of Franche-Comte, and the Region Franche-Comte. Z.N. is a recipient of a doctoral scholarship from the municipality of Habbouch. The funders had no role in the data collection, analysis, patient recruitment, or decision to publish. We thank DImaCell Imaging Ressource Center, University of Bourgogne Franche-Comte, Faculty of Health Sciences, 25000 Besancon, France for technical support.	Al Moussawi F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30109-1; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aloia A, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0652-6; Belzile JP, 2014, J VIROL, V88, P4021, DOI 10.1128/JVI.03492-13; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chuang PK, 2019, P NATL ACAD SCI USA, V116, P3518, DOI 10.1073/pnas.1816946116; Coaquette A, 2004, CLIN INFECT DIS, V39, P155, DOI 10.1086/421496; Cobbs CS, 2002, CANCER RES, V62, P3347; Cojohari O, 2016, J VIROL, V90, P6443, DOI 10.1128/JVI.00214-16; Collins-McMillen D, 2019, P NATL ACAD SCI USA, V116, P17492, DOI 10.1073/pnas.1900783116; Coronel R, 2015, J VIROL, V89, P5615, DOI 10.1128/JVI.00305-15; Dai XF, 2015, AM J CANCER RES, V5, P2929; Dimri G, 2005, BREAST CANCER RES, V7, P171, DOI 10.1186/bcr1275; Fei F, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0277-8; Fornara O, 2016, CELL DEATH DIFFER, V23, P261, DOI 10.1038/cdd.2015.91; FURUKAWA T, 1984, VIROLOGY, V137, P191, DOI 10.1016/0042-6822(84)90023-0; Ganem D, 2010, J CLIN INVEST, V120, P939, DOI 10.1172/JCI40567; GEDER L, 1976, SCIENCE, V192, P1134, DOI 10.1126/science.179143; HEIEREN MH, 1988, TRANSPLANTATION, V46, P426, DOI 10.1097/00007890-198809000-00018; Hein SM, 2016, ONCOGENE, V35, P1461, DOI 10.1038/onc.2015.206; Herbein G, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.567116; Hoffding MK, 2015, STEM CELL RES, V14, P39, DOI 10.1016/j.scr.2014.11.003; Huang YH, 2014, HISTOPATHOLOGY, V64, P494, DOI 10.1111/his.12257; Huesing A, 2012, J MED GENET, V49, P601, DOI 10.1136/jmedgenet-2011-100716; Jha HC, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5010018; Khan KA, 2009, J IMMUNOL, V182, P7784, DOI 10.4049/jimmunol.0803800; Knudsen ES, 2015, CELL CYCLE, V14, P109, DOI 10.4161/15384101.2014.967118; Kumar A, 2018, EBIOMEDICINE, V30, P167, DOI 10.1016/j.ebiom.2018.03.015; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lee EYHP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003236; Lepiller Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059591; Ling GQ, 2012, ONCOL LETT, V4, P1264, DOI 10.3892/ol.2012.916; Liu JS, 2020, SEMIN CANCER BIOL, V60, P380, DOI 10.1016/j.semcancer.2019.09.005; Liu JS, 2018, SEMIN CANCER BIOL, V53, P1, DOI 10.1016/j.semcancer.2018.07.004; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Lopez-Sanchez LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099143; Lu X, 2014, ONCOGENE, V33, P2655, DOI 10.1038/onc.2013.209; Luo JF, 2017, AM J TRANSL RES, V9, P5671; Luo MH, 2010, J VIROL, V84, P3528, DOI 10.1128/JVI.02161-09; Manners O, 2018, CURR OPIN VIROL, V32, P60, DOI 10.1016/j.coviro.2018.08.014; McFarlane S, 2011, VIROLOGY, V414, P83, DOI 10.1016/j.virol.2011.03.005; Michaelis M, 2009, NEOPLASIA, V11, P1, DOI 10.1593/neo.81178; Morales-Sanchez A, 2014, VIRUSES-BASEL, V6, P4047, DOI 10.3390/v6104047; Munz C, 2019, NAT REV MICROBIOL, V17, P691, DOI 10.1038/s41579-019-0249-7; Newbold RF, 2002, MUTAGENESIS, V17, P539, DOI 10.1093/mutage/17.6.539; Niu N, 2017, ONCOGENE, V36, P4887, DOI 10.1038/onc.2017.72; Niu N, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.75; Oberstein A, 2017, P NATL ACAD SCI USA, V114, pE8244, DOI 10.1073/pnas.1710799114; Odeberg J, 2006, J VIROL, V80, P8929, DOI 10.1128/JVI.00676-06; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534; Prichard MN, 2008, J VIROL, V82, P5054, DOI 10.1128/JVI.02174-07; Rodilla V, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6040103; Romaniuk A, 2019, MOL BIOL REP, V46, P1401, DOI 10.1007/s11033-018-4496-x; Sinzger C, 2008, CURR TOP MICROBIOL, V325, P63; Soroceanu L, 2015, CANCER RES, V75, P3065, DOI 10.1158/0008-5472.CAN-14-3307; Straat K, 2009, JNCI-J NATL CANCER I, V101, P488, DOI 10.1093/jnci/djp031; Taher C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056795; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tanabe K, 2013, P NATL ACAD SCI USA, V110, P12172, DOI 10.1073/pnas.1310291110; Tata PR, 2013, NATURE, V503, P218, DOI 10.1038/nature12777; Tsai HL, 1996, J BIOL CHEM, V271, P3534; Wang D, 2014, ONCOTARGET, V5, P10803, DOI 10.18632/oncotarget.2506; Wang MH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0013-8; Weljie AM, 2011, INT J BIOCHEM CELL B, V43, P981, DOI 10.1016/j.biocel.2010.08.009; White E, 2006, CELL DEATH DIFFER, V13, P1371, DOI 10.1038/sj.cdd.4401941; Xiong SM, 2019, TRENDS CELL BIOL, V29, P623, DOI 10.1016/j.tcb.2019.05.001; Yamashita N, 2018, CLIN BREAST CANCER, V18, pE1003, DOI 10.1016/j.clbc.2018.02.002; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yu KR, 2012, STEM CELLS, V30, P876, DOI 10.1002/stem.1052; Yu W, 2017, STEM CELL RES, V19, P139, DOI 10.1016/j.scr.2017.01.011; Yu YJ, 2011, TRENDS MICROBIOL, V19, P360, DOI 10.1016/j.tim.2011.04.002; Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zheng L, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1825	76	15	16	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3030	3046		10.1038/s41388-021-01715-7	http://dx.doi.org/10.1038/s41388-021-01715-7		MAR 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33767437				2022-12-28	WOS:000632820300001
J	Esquer, H; Zhou, Q; Nemkov, T; Abraham, AD; Rinaldetti, S; Chen, YC; Zhang, XH; Orman, MV; D'Alessandro, A; Ferrer, M; Messersmith, WA; LaBarbera, DV				Esquer, Hector; Zhou, Qiong; Nemkov, Travis; Abraham, Adedoyin D.; Rinaldetti, Sebastien; Chen, Yu-Chi; Zhang, Xiaohu; Orman, Michael, V; D'Alessandro, Angelo; Ferrer, Marc; Messersmith, Wells A.; LaBarbera, Daniel, V			Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer	ONCOGENE			English	Article								Epithelial-mesenchymal transition (EMT) is a driving force in promoting malignant cancer, including initiation, growth, and metastasis. EMT is a dynamic process that can undergo a mesenchymal-epithelial transition (MET) and partial transitions between both phenotypes, termed epithelial-mesenchymal plasticity (EMP). In cancer, the acquisition of EMP results in a spectrum of phenotypes, promoting tumor cell heterogeneity and resistance to standard of care therapy. Here we describe a real-time fluorescent dual-reporter for vimentin and E-cadherin, biomarkers of the mesenchymal and epithelial cell phenotypes, respectively. Stable dual-reporter cell lines generated from colorectal (SW620), lung (A549), and breast (MDA-MB-231) cancer demonstrate a spectrum of EMT cell phenotypes. We used the dual-reporter to isolate the quasi epithelial, epithelial/mesenchymal, and mesenchymal phenotypes. Although EMT is a dynamic process, these isolated quasi-EMTphenotypes remain stable to spontaneous EMP in the absence of stimuli and during prolonged cell culture. However, the quasi-EMT phenotypes can readily be induced to undergo EMT or MET with growth factors or small molecules. Moreover, isolated EMT phenotypes display different tumorigenic properties and are morphologically and metabolically distinct. 3D high-content screening of similar to 23,000 compounds using dual-reporter mesenchymal SW620 tumor organoids identified small molecule probes that modulate EMT, and a subset of probes that effectively induced MET. The tools, probes, and models described herein provide a coherent mechanistic understanding of mesenchymal cell plasticity. Future applications utilizing this technology and probes are expected to advance our understanding of EMT and studies aimed at therapeutic strategies targeting EMT.	[Esquer, Hector; Zhou, Qiong; Abraham, Adedoyin D.; Rinaldetti, Sebastien; Orman, Michael, V; LaBarbera, Daniel, V] Univ Colorado, Dept Pharmaceut Sci, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus CU AMC, Aurora, CO 80045 USA; [Nemkov, Travis; D'Alessandro, Angelo] Univ Colorado, Dept Biochem & Mol Genet, Anschutz Med Campus, Aurora, CO USA; [Chen, Yu-Chi; Zhang, Xiaohu; Ferrer, Marc] NIH, Early Translat Branch, Natl Ctr Adv Translat Sci NCATS, Rockville, MD USA; [D'Alessandro, Angelo; Messersmith, Wells A.; LaBarbera, Daniel, V] Univ Colorado Canc Ctr UCCC, Aurora, CO 80045 USA; [D'Alessandro, Angelo; Messersmith, Wells A.; LaBarbera, Daniel, V] Univ Colorado, Anschutz Med Campus, Aurora, CO 80045 USA; [Messersmith, Wells A.] Univ Colorado, Div Med Oncol, Sch Med, Anschutz Med Campus, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; National Institutes of Health (NIH) - USA; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	LaBarbera, DV (corresponding author), Univ Colorado, Dept Pharmaceut Sci, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus CU AMC, Aurora, CO 80045 USA.; LaBarbera, DV (corresponding author), Univ Colorado Canc Ctr UCCC, Aurora, CO 80045 USA.; LaBarbera, DV (corresponding author), Univ Colorado, Anschutz Med Campus, Aurora, CO 80045 USA.	daniel.labarbera@cuanschutz.edu	D'Alessandro, Angelo/AAA-4695-2019	D'Alessandro, Angelo/0000-0002-2258-6490; Rinaldetti, Sebastien/0000-0003-1053-3831; Esquer, Hector/0000-0002-1911-1523	Department of Defense Peer Reviewed Cancer Research Program [W81XWH-18-1-0142]; NIH NCI [1R01CA251361-01]; The ALSAM Foundation Therapeutic Innovation Grant; NIH Training Grant [5T32HL7171-42]; Cancer Foundation of Luxembourg; UCCC NIH NCI designated cancer center [P30CA046934]	Department of Defense Peer Reviewed Cancer Research Program(United States Department of Defense); NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); The ALSAM Foundation Therapeutic Innovation Grant; NIH Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Foundation of Luxembourg; UCCC NIH NCI designated cancer center	This research was supported in part by grants awarded to DVL from the Department of Defense Peer Reviewed Cancer Research Program (W81XWH-18-1-0142), the NIH NCI (1R01CA251361-01), and The ALSAM Foundation Therapeutic Innovation Grant. TN was supported by a NIH Training Grant (5T32HL7171-42). SR was supported by the Cancer Foundation of Luxembourg. We thank the Eli Lilly and Company Open Innovation Drug Discovery Program, particularly Evan Castetter and Maria Jose Lorite, for providing the BIC library. We also thank CU AMC shared resource laboratories, including the Drug Discovery and Development Shared Resource (HTS/HCS Discovery Arm), MS Metabolomics, Flow Cytometry, and NMR. These shared resources are supported in part by the UCCC NIH NCI designated cancer center (P30CA046934). We are grateful to Claudia Esquer for graphic design input of Fig. 6.	Abraham AD, 2019, J MED CHEM, V62, P10182, DOI 10.1021/acs.jmedchem.9b01065; Ackland ML, 2003, LAB INVEST, V83, P435, DOI 10.1097/01.LAB.0000059927.97515.FD; Bai FW, 2012, J BIOL CHEM, V287, P30653, DOI 10.1074/jbc.M112.385583; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Beharry Z, 2011, P NATL ACAD SCI USA, V108, P528, DOI 10.1073/pnas.1013214108; Bierie B, 2017, P NATL ACAD SCI USA, V114, pE2337, DOI 10.1073/pnas.1618298114; Bighetti-Trevisan RL, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9618065; Buchser W., 2004, ASSAY GUIDANCE MANUA; Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7; Choi BJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15139-5; Clasquin Michelle F, 2012, Curr Protoc Bioinformatics, VChapter 14, DOI 10.1002/0471250953.bi1411s37; Cojoc M, 2015, CANCER RES, V75, P1482, DOI 10.1158/0008-5472.CAN-14-1924; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Esquer H, 2020, SLAS DISCOV, V25, P734, DOI 10.1177/2472555220926921; Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Hale JS, 2014, STEM CELLS, V32, P1746, DOI 10.1002/stem.1716; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jacobsen A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24982-z; Jia DY, 2019, P NATL ACAD SCI USA, V116, P3909, DOI 10.1073/pnas.1816391116; Kashiwagi S, 2010, BRIT J CANCER, V103, P249, DOI 10.1038/sj.bjc.6605735; Kroger C, 2019, P NATL ACAD SCI USA, V116, P7353, DOI 10.1073/pnas.1812876116; Lee Sang-Kyu, 2018, Advances in Biological Regulation, V68, P46, DOI 10.1016/j.jbior.2018.01.001; Leggett SE, 2016, INTEGR BIOL-UK, V8, P1133, DOI 10.1039/c6ib00139d; Li HX, 2019, NAT MED, V25, P850, DOI 10.1038/s41591-019-0404-8; Li Q, 2011, J BIOMOL SCREEN, V16, P141, DOI 10.1177/1087057110392995; Longo N, 2016, BBA-MOL CELL RES, V1863, P2422, DOI 10.1016/j.bbamcr.2016.01.023; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcucci F, 2016, NAT REV DRUG DISCOV, V15, P311, DOI 10.1038/nrd.2015.13; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P1271, DOI 10.4161/cc.10.8.15330; McDonald PC, 2015, PRINCIPLES OF STEM CELL BIOLOGY AND CANCER: FUTURE APPLICATIONS AND THERAPEUTICS, P103; Moore SF, 2013, J BIOL CHEM, V288, P3918, DOI 10.1074/jbc.M112.429936; Nemkov T, 2019, METHODS MOL BIOL, V1978, P13, DOI 10.1007/978-1-4939-9236-2_2; Nemkov T, 2017, RAPID COMMUN MASS SP, V31, P663, DOI 10.1002/rcm.7834; Raimundo N, 2011, TRENDS MOL MED, V17, P641, DOI 10.1016/j.molmed.2011.06.001; Richardson F, 2012, ANTICANCER RES, V32, P537; Rodriguez-Pinilla SM, 2007, J CLIN PATHOL, V60, P1006, DOI 10.1136/jcp.2006.042143; San-Millan I, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01536; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sciacovelli M, 2017, FEBS J, V284, P3132, DOI 10.1111/febs.14090; Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Toiyama Y, 2013, CARCINOGENESIS, V34, P2548, DOI 10.1093/carcin/bgt282; Vlachostergios PJ, 2015, CANCER BIOMARK, V15, P725, DOI 10.3233/CBM-150514; Voon DC, 2017, MOL ONCOL, V11, P878, DOI 10.1002/1878-0261.12082; Walenta S, 2003, J CANCER RES CLIN, V129, P321, DOI 10.1007/s00432-003-0450-x; Wang CH, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1265-2; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9; Ye HB, 2016, CELL STEM CELL, V19, P23, DOI 10.1016/j.stem.2016.06.001; Ye ZH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163162; Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107; Ying M, 2016, ONCOGENE, V35, P4358, DOI [10.1038/onc.2015.503, 10.1038/onc.2016.29]; Yun JA, 2014, ONCOLOGY-BASEL, V86, P318, DOI 10.1159/000360794; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang FX, 2018, PROG NEUROBIOL, V171, P72, DOI 10.1016/j.pneurobio.2018.09.006; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zhang XJ, 2013, INT J BIOL SCI, V9, P1108, DOI 10.7150/ijbs.7232	59	7	7	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2884	2897		10.1038/s41388-021-01728-2	http://dx.doi.org/10.1038/s41388-021-01728-2		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742123	Green Accepted			2022-12-28	WOS:000630675000001
J	Li, HJ; Han, XG; Yang, SB; Wang, YJ; Dong, Y; Tang, TT				Li, Hanjun; Han, Xiuguo; Yang, Shengbing; Wang, Yongjie; Dong, Yang; Tang, Tingting			FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53	ONCOGENE			English	Article								Osteosarcoma has a poor prognosis, and the poor understanding of the genetic drivers of osteosarcoma hinders further improvement in therapeutic approaches. Transcription factor forkhead box P1 (FOXP1) is a crucial modulator in skeletal development and aging. Here, we determined the role and regulatory mechanisms of FOXP1 in osteosarcoma. Higher FOXP1 expression correlated with malignancy in both osteosarcoma cell lines and clinical biopsies. FOXP1 overexpression and knockdown in osteosarcoma cell lines revealed that FOXP1 promoted proliferation, tumor sphere formation, migration and invasion, and inhibited anoikis. Mechanistically, FOXP1 acted as a repressor of P21 and RB (retinoblastoma protein) transcription, and directly interacted with the tumor suppressor p53 to inhibit its activity. Extracellular signal-regulated kinase/c-Jun N-terminal kinase (ERK/JNK) signaling and c-JUN/c-FOS transcription factors were found to be upstream activators of FOXP1. Moreover, FOXP1 silencing via lentivirus or adeno-associated virus (AAV)-mediated delivery of shRNA suppressed osteosarcoma development and progression in cell-derived and patient-derived xenograft animal models. Taken together, we demonstrate that FOXP1, which is transactivated by ERK/JNK-c-JUN/c-FOS, drives osteosarcoma development by regulating the p53-P21/RB signaling cascade, suggesting that FOXP1 is a potential target for osteosarcoma therapy.	[Li, Hanjun; Yang, Shengbing; Tang, Tingting] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants, Dept Orthoped Surg,Sch Med, Shanghai, Peoples R China; [Han, Xiuguo] Shanghai Jiao Tong Univ, Xin Hua Hosp, Dept Orthoped Surg, Sch Med, Shanghai, Peoples R China; [Wang, Yongjie; Dong, Yang] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthopaed, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Tang, TT (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants, Dept Orthoped Surg,Sch Med, Shanghai, Peoples R China.; Dong, Y (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthopaed, Shanghai, Peoples R China.	dongyang6405@163.com; ttt@sjtu.edu.cn	Tang, Tingting/B-1361-2013	Tang, Tingting/0000-0002-1670-7452; Wang, Yongjie/0000-0001-7035-5382; Li, Hanjun/0000-0002-7017-8782	National Natural Science Foundation of China [81802679]; Shanghai Science and Technology Development Fund [18DZ2291200]; China Postdoctoral Science Foundation [2018M632136, 2019T120348]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Development Fund; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This project was supported by the National Natural Science Foundation of China (81802679), the Shanghai Science and Technology Development Fund (18DZ2291200), and China Postdoctoral Science Foundation (2018M632136 and 2019T120348) to HL.	Armesilla-Diaz A, 2009, EXP CELL RES, V315, P3598, DOI 10.1016/j.yexcr.2009.08.004; Bates GJ, 2008, BREAST CANCER RES TR, V111, P453, DOI 10.1007/s10549-007-9812-4; Behjati S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15936; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Brown PJ, 2016, LEUKEMIA, V30, P605, DOI 10.1038/leu.2015.299; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Chen HJ, 2018, BIOCHEM BIOPH RES CO, V503, P1434, DOI 10.1016/j.bbrc.2018.07.060; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Chokas AL, 2010, J BIOL CHEM, V285, P13304, DOI 10.1074/jbc.M109.088468; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Coventon J, 2017, J BONE ONCOL, V8, P4, DOI 10.1016/j.jbo.2017.07.001; Dasen JS, 2008, CELL, V134, P304, DOI 10.1016/j.cell.2008.06.019; Dekker JD, 2016, P NATL ACAD SCI USA, V113, pE577, DOI 10.1073/pnas.1524677113; Deng Q, 2019, ELIFE, V8, DOI 10.7554/eLife.50208; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Du L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0745-0; Feng XM, 2011, NAT IMMUNOL, V12, P544, DOI 10.1038/ni.2034; Fittall MW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04530-z; Flori M, 2016, BLOOD, V127, P1438, DOI [10.1182/blood-2015-08662635, 10.1182/blood-2015-08-662635]; Fox SB, 2004, CLIN CANCER RES, V10, P3521, DOI 10.1158/1078-0432.CCR-03-0461; Gabut M, 2011, CELL, V147, P132, DOI 10.1016/j.cell.2011.08.023; Gascoyne DM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128513; Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16; Han XG, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201902246; Han YJ, 2019, J CLIN INVEST, V129, P1895, DOI 10.1172/JCI124590; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939; Hieronymus H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01198-9; Hu H, 2006, NAT IMMUNOL, V7, P819, DOI 10.1038/ni1358; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Kim JH, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1110-3; Koon HB, 2007, EXPERT OPIN THER TAR, V11, P955, DOI 10.1517/14728222.11.7.955; Leishman E, 2013, DEVELOPMENT, V140, P3809, DOI 10.1242/dev.097477; Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130; Li HJ, 2017, J CLIN INVEST, V127, P1241, DOI 10.1172/JCI89511; Li SR, 2012, DEVELOPMENT, V139, P2500, DOI 10.1242/dev.079699; Lin YH, 2017, TRENDS MOL MED, V23, P737, DOI 10.1016/j.molmed.2017.06.004; Liu P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12988-8; MALKIN D, 1994, ANNU REV GENET, V28, P443; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MILLER CW, 1990, CANCER RES, V50, P7950; Mirabello L, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv101; Mohseny AB, 2011, LAB INVEST, V91, P1195, DOI 10.1038/labinvest.2011.72; Mottok A, 2018, BLOOD, V131, P226, DOI 10.1182/blood-2017-08-799080; Naudin C, 2017, BLOOD, V129, P2493, DOI 10.1182/blood-2016-10-747436; Papachristou DJ, 2003, BONE, V32, P364, DOI 10.1016/S8756-3282(03)00026-7; Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111; Quist T, 2015, ONCOGENE, V34, P4278, DOI 10.1038/onc.2014.354; Sagaert X, 2006, J CLIN ONCOL, V24, P2490, DOI 10.1200/JCO.2006.05.6150; Sheng H, 2019, CANCER BIOL THER, V20, P537, DOI 10.1080/15384047.2018.1537999; Shu WG, 2007, DEVELOPMENT, V134, P1991, DOI 10.1242/dev.02846; Spaeth JM, 2015, DIABETOLOGIA, V58, P1836, DOI 10.1007/s00125-015-3635-3; Streubel B, 2005, LEUKEMIA, V19, P652, DOI 10.1038/sj.leu.2403644; Takayama K, 2008, BIOCHEM BIOPH RES CO, V374, P388, DOI 10.1016/j.bbrc.2008.07.056; Tao JN, 2014, CANCER CELL, V26, P390, DOI 10.1016/j.ccr.2014.07.023; ter Huurne M, 2020, STEM CELL REP, V14, P175, DOI 10.1016/j.stemcr.2020.01.001; Usui N, 2017, GENE DEV, V31, P2039, DOI 10.1101/gad.305037.117; van Keimpema M, 2017, HAEMATOLOGICA, V102, P573, DOI 10.3324/haematol.2016.156455; van Keimpema M, 2014, BLOOD, V124, P3431, DOI 10.1182/blood-2014-01-553412; WADAYAMA B, 1994, CANCER RES, V54, P3042; Walker MP, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005654; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Wang X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091501; WANG ZQ, 1995, CANCER RES, V55, P6244; Xu SQ, 2018, P NATL ACAD SCI USA, V115, P8799, DOI 10.1073/pnas.1721820115; Xu WT, 2009, CANCER LETT, V281, P32, DOI 10.1016/j.canlet.2009.02.022; Yang JL, 2011, CANCER-AM CANCER SOC, V117, P4925, DOI 10.1002/cncr.26116; Yin ZX, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12308; Zhang YZ, 2010, GENE DEV, V24, P1746, DOI 10.1101/gad.1929210; Zhao HX, 2015, DEV BIOL, V398, P242, DOI 10.1016/j.ydbio.2014.12.007	71	10	10	10	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2785	2802		10.1038/s41388-021-01742-4	http://dx.doi.org/10.1038/s41388-021-01742-4		MAR 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33716296				2022-12-28	WOS:000628816100002
J	Pan, ZH; Liu, CQ; Zhi, YF; Xie, ZY; Wu, L; Jiang, MH; Zhang, YJ; Zhou, R; Zhao, L				Pan, Zhihua; Liu, Chaoqun; Zhi, Yunfei; Xie, Zhiyue; Wu, Ling; Jiang, Muhong; Zhang, Yujie; Zhou, Rui; Zhao, Liang			LIMK1 nuclear translocation promotes hepatocellular carcinoma progression by increasing p-ERK nuclear shuttling and by activating c-Myc signalling upon EGF stimulation	ONCOGENE			English	Article							FACTOR RECEPTOR INHIBITION; KINASE 1; ACTIN DYNAMICS; GROWTH; CETUXIMAB; COFILIN; PHOSPHORYLATION; SENSITIVITY; THREONINE; SERINE	LIM kinase 1 (LIMK1) is a serine/threonine and tyrosine kinase that is predominantly located in the cytoplasm. In our study, nuclear translocation of LIMK1 in clinical hepatocellular carcinoma (HCC) samples was demonstrated for the first time, especially in samples from those with intravascular tumour thrombus. LIMK1 was overexpressed in HCC tissues, and nuclear LIMK1 expression was associated with poor prognosis in HCC patients. Although the effects of cytoplasmic LIMK1 on cofilin phosphorylation and actin filament dynamics have been well studied, the function of nuclear LIMK1 is still unclear. Gain- and loss-of-function experiments were performed both in vitro and in vivo and demonstrated a correlation between nuclear LIMK1 and the enhanced aggressive phenotype of HCC. EGF could drive the nuclear translocation of LIMK1 by activating the interaction of p-ERK and LIMK1 and facilitating their roles in nuclear shuttling. Moreover, nuclear LIMK1 could directly bind to the promoter region of c-Myc and stimulate c-Myc transcription. Although the EGFR monoclonal antibody cetuximab has a poor therapeutic effect on advanced HCC patients, in vivo animal study showed that cetuximab achieved a significant inhibitory effect on the progression of nuclear LIMK1-overexpressing HCC cells. In addition, recent data have demonstrated the potential of cetuximab in combination therapy for HCC patients with LIMK1 nuclear translocation.	[Pan, Zhihua; Liu, Chaoqun; Zhi, Yunfei; Xie, Zhiyue; Wu, Ling; Jiang, Muhong; Zhang, Yujie; Zhou, Rui; Zhao, Liang] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Peoples R China; [Pan, Zhihua; Liu, Chaoqun; Zhi, Yunfei; Xie, Zhiyue; Wu, Ling; Jiang, Muhong; Zhang, Yujie; Zhou, Rui; Zhao, Liang] Southern Med Univ, Dept Pathol, Guangdong Prov Key Lab Mol Tumor Pathol, Sch Basic Med Sci, Guangzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China	Zhou, R; Zhao, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Peoples R China.; Zhou, R; Zhao, L (corresponding author), Southern Med Univ, Dept Pathol, Guangdong Prov Key Lab Mol Tumor Pathol, Sch Basic Med Sci, Guangzhou, Peoples R China.	yaruisunny@sina.com; liangsmu@foxmail.com	Zhi, Yunfei/GQI-2937-2022	Zhi, Yunfei/0000-0002-0084-6810	National Natural Science Foundation of China [81773082, 81872423, 81972813, 81702903]; Guangdong Natural Science Foundation [2017A030310038, 2018B030311036, 2019A1515010974]; Fork Ying Tung Education Foundation [161035]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Fork Ying Tung Education Foundation	This work was supported by the National Natural Science Foundation of China (Nos. 81773082, 81872423, 81972813, 81702903), Guangdong Natural Science Foundation (2017A030310038, 2018B030311036, 2019A1515010974) and Fork Ying Tung Education Foundation (161035).	Abu Dayyeh BK, 2011, GASTROENTEROLOGY, V141, P141, DOI 10.1053/j.gastro.2011.03.045; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Asnacios A, 2008, CANCER-AM CANCER SOC, V112, P2733, DOI 10.1002/cncr.23489; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; Bonomi PD, 2018, ANN ONCOL, V29, P1701, DOI 10.1093/annonc/mdy196; Buonaguro L, 2013, J HEPATOL, V59, P897, DOI 10.1016/j.jhep.2013.05.031; Caruso S., 2020, HEPATOLOGY, V35, P331; Chen W, 2012, LIVER INT, V32, P70, DOI 10.1111/j.1478-3231.2011.02631.x; Craig AJ, 2020, NAT REV GASTRO HEPAT, V17, P139, DOI 10.1038/s41575-019-0229-4; Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200; Ding XF, 2019, GASTROENTEROLOGY, V157, P1630, DOI 10.1053/j.gastro.2019.09.005; Fuchs BC, 2008, CANCER RES, V68, P2391, DOI 10.1158/0008-5472.CAN-07-2460; Fuchs BC, 2014, HEPATOLOGY, V59, P1577, DOI 10.1002/hep.26898; Gao QZ, 2020, ONCOGENE, V39, P3926, DOI 10.1038/s41388-020-1266-8; Ge LS, 2004, J HEPATOL, V41, P823, DOI 10.1016/j.jhep.2004.07.021; Gebbia V, 2007, ANN ONCOL, V18, P5, DOI 10.1093/annonc/mdm215; Goldberg Richard M, 2005, Nat Rev Drug Discov, VSuppl, pS10; Hamill S, 2016, MOL CELL, V62, P397, DOI 10.1016/j.molcel.2016.04.001; Hirsch FR, 2013, J THORAC ONCOL, V8, P373, DOI 10.1097/JTO.0b013e31827ed0ff; Huang JB, 2020, J CELL MOL MED, V24, P4698, DOI 10.1111/jcmm.15138; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kim E, 2018, HEPATOLOGY, V67, P2287, DOI 10.1002/hep.29738; Kremer D, 2009, P NATL ACAD SCI USA, V106, P9087, DOI 10.1073/pnas.0900204106; LAGOUTTE E, 2016, INT J BIOCHEM CELL B, V6; Lee SH, 2010, NAT MED, V16, P665, DOI 10.1038/nm.2143; Li WY, 2019, LIVER INT, V39, P147, DOI 10.1111/liv.13957; Liao Q, 2017, BRIT J CANCER, V117, P563, DOI 10.1038/bjc.2017.193; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Llovet JM, 2018, NAT REV CLIN ONCOL, V15, P599, DOI 10.1038/s41571-018-0073-4; Maiello E, 2007, Ann Oncol, V18 Suppl 6, pvi8, DOI 10.1093/annonc/mdm216; Maik-Rachline G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051194; McConnell BV, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-75; Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111; NUNOUE K, 1995, ONCOGENE, V11, P701; Ohashi K, 2000, BIOCHEM BIOPH RES CO, V276, P1178, DOI 10.1006/bbrc.2000.3599; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Perugorria MJ, 2019, NAT REV GASTRO HEPAT, V16, P121, DOI 10.1038/s41575-018-0075-9; Po'uha ST, 2010, ONCOGENE, V29, P597, DOI 10.1038/onc.2009.367; PROSCHEL C, 1995, ONCOGENE, V11, P1271; Schofield AV, 2013, BIOCHEM BIOPH RES CO, V436, P571, DOI 10.1016/j.bbrc.2013.05.076; Schofield AV., 2014, ADV BIOSCI BIOTECHNO, V05, P353, DOI [10.4236/abb.2014.54043, DOI 10.4236/ABB.2014.54043]; Sheng H, 2020, EUR REV MED PHARMACO, V24, P2625, DOI 10.26355/eurrev_202003_20531; Simhadri PK, 2017, ANN NEUROL, V82, P429, DOI 10.1002/ana.25028; Spitz F, 2012, NAT REV GENET, V13, P613, DOI 10.1038/nrg3207; Stanyon CA, 1999, INT J BIOCHEM CELL B, V31, P389, DOI 10.1016/S1357-2725(98)00116-2; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793; Yang N, 1998, EXP CELL RES, V241, P242, DOI 10.1006/excr.1998.4053; Yao Z, 2001, ONCOGENE, V20, P7588, DOI 10.1038/sj.onc.1204963; Zhao CC, 2020, CANCER LETT, V493, P120, DOI 10.1016/j.canlet.2020.08.006; Zhu AX, 2007, CANCER-AM CANCER SOC, V110, P581, DOI 10.1002/cncr.22829	52	6	6	2	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2581	2595		10.1038/s41388-021-01736-2	http://dx.doi.org/10.1038/s41388-021-01736-2		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33686242				2022-12-28	WOS:000626396000006
J	Monsivais, D; Vasquez, YM; Chen, FJ; Zhang, YQ; Chandrashekar, DS; Faver, JC; Masand, RP; Scheurer, ME; Varambally, S; Matzuk, MM; Creighton, CJ				Monsivais, Diana; Vasquez, Yasmin M.; Chen, Fengju; Zhang, Yiqun; Chandrashekar, Darshan S.; Faver, John C.; Masand, Ramya P.; Scheurer, Michael E.; Varambally, Sooryanarayana; Matzuk, Martin M.; Creighton, Chad J.			Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers	ONCOGENE			English	Article								Proteomic signatures associated with clinical measures of more aggressive cancers could yield molecular clues as to disease drivers. Here, utilizing the Clinical Proteomic Tumor Analysis Consortium (CPTAC) mass-spectrometry-based proteomics datasets, we defined differentially expressed proteins and mRNAs associated with higher grade or higher stage, for each of seven cancer types (breast, colon, lung adenocarcinoma, clear cell renal, ovarian, uterine, and pediatric glioma), representing 794 patients. Widespread differential patterns of total proteins and phosphoproteins involved some common patterns shared between different cancer types. More proteins were associated with higher grade than higher stage. Most proteomic signatures predicted patient survival in independent transcriptomic datasets. The proteomic grade signatures, in particular, involved DNA copy number alterations. Pathways of interest were enriched within the grade-associated proteins across multiple cancer types, including pathways of altered metabolism, Warburg-like effects, and translation factors. Proteomic grade correlations identified protein kinases having functional impact in vitro in uterine endometrial cancer cells, including MAP3K2, MASTL, and TTK. The protein-level grade and stage associations for all proteins profiled-along with corresponding information on phosphorylation, pathways, mRNA expression, and copy alterations-represent a resource for identifying new potential targets. Proteomic analyses are often concordant with corresponding transcriptomic analyses, but with notable exceptions.	[Monsivais, Diana; Vasquez, Yasmin M.; Faver, John C.; Matzuk, Martin M.] Baylor Coll Med, Ctr Drug Discovery, Houston, TX 77030 USA; [Monsivais, Diana; Vasquez, Yasmin M.; Faver, John C.; Masand, Ramya P.; Matzuk, Martin M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Chen, Fengju; Zhang, Yiqun; Scheurer, Michael E.; Creighton, Chad J.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Div Biostat, Houston, TX 77030 USA; [Chandrashekar, Darshan S.; Varambally, Sooryanarayana] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL 35294 USA; [Chandrashekar, Darshan S.; Varambally, Sooryanarayana] Univ Alabama Birmingham, Dept Pathol, Mol & Cellular Pathol, Birmingham, AL 35294 USA; [Scheurer, Michael E.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Scheurer, Michael E.] Texas Childrens Hosp, Texas Childrens Canc Ctr, Houston, TX 77030 USA; [Varambally, Sooryanarayana] Univ Alabama Birmingham, Informat Inst, Birmingham, AL USA; [Creighton, Chad J.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Creighton, Chad J.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA; [Creighton, Chad J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Baylor College of Medicine; Baylor College of Medicine; Texas Children's Cancer Center; University of Alabama System; University of Alabama Birmingham; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Monsivais, D (corresponding author), Baylor Coll Med, Ctr Drug Discovery, Houston, TX 77030 USA.; Monsivais, D (corresponding author), Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.; Creighton, CJ (corresponding author), Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Div Biostat, Houston, TX 77030 USA.; Creighton, CJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.; Creighton, CJ (corresponding author), Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.; Creighton, CJ (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.	diana.monsivais@bcm.edu; creighto@bcm.edu	Zhang, YiQun/HCI-2427-2022	Scheurer, Michael/0000-0002-8379-6088; Faver, John/0000-0002-0181-9283; Monsivais, Diana/0000-0001-5660-6392	National Institutes of Health (NIH) [P30CA125123, P20CA221729, R00HD096057]; Cancer Prevention Research Institute of Texas [RP160805]; Burroughs Wellcome Fund	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas; Burroughs Wellcome Fund(Burroughs Wellcome Fund)	This research was conducted using data made available by The Clinical Proteomic Tumor Analysis Consortium (CPTAC), The Children's Brain Tumor Tissue Consortium (CBTTC), and The Cancer Genome Atlas (TCGA) Consortium. This work was supported by National Institutes of Health (NIH) grants P30CA125123 (CJC), P20CA221729 (MMM), R00HD096057 (DM), and a Core Facility Support Award from the Cancer Prevention Research Institute of Texas (RP160805 (MMM)). Diana Monsivais holds a PDEP Award from the Burroughs Wellcome Fund. We thank Jonathan Kurie for critical reading of the manuscript.	Ahmad S, 2018, BIOCHEM BIOPH RES CO, V496, P205, DOI 10.1016/j.bbrc.2018.01.027; Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bonome T, 2005, CANCER RES, V65, P10602, DOI 10.1158/0008-5472.CAN-05-2240; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen F, 2017, ONCOGENE, V36, P1384, DOI 10.1038/onc.2016.303; Chen FJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13528-0; Chen FJ, 2018, CLIN CANCER RES, V24, P2182, DOI 10.1158/1078-0432.CCR-17-3378; Chen GA, 2003, P NATL ACAD SCI USA, V100, P13537, DOI 10.1073/pnas.2233850100; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; Clark DJ, 2019, CELL, V179, P964, DOI 10.1016/j.cell.2019.10.007; Creighton C, 2003, FEBS LETT, V540, P167, DOI 10.1016/S0014-5793(03)00259-X; Creighton CJ, 2008, RNA, V14, P2290, DOI 10.1261/rna.1188208; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Creighton CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034546; Crijns APG, 2009, PLOS MED, V6, P181, DOI 10.1371/journal.pmed.1000024; Denkert C, 2009, J PATHOL, V218, P273, DOI 10.1002/path.2547; Dou YC, 2020, CELL, V180, P729, DOI 10.1016/j.cell.2020.01.026; Dressman HK, 2007, J CLIN ONCOL, V25, P517, DOI 10.1200/JCO.2006.06.3743; Edwards NJ, 2015, J PROTEOME RES, V14, P2707, DOI 10.1021/pr501254j; Ellis MJ, 2013, CANCER DISCOV, V3, P1108, DOI 10.1158/2159-8290.CD-13-0219; Fatima I, 2020, CANCER MED-US, V9, P6322, DOI 10.1002/cam4.3141; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gillette MA, 2020, CELL, V182, P200, DOI 10.1016/j.cell.2020.06.013; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Libouban MAA, 2017, ONCOTARGET, V8, P38309, DOI 10.18632/oncotarget.16213; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Louis DN, 2014, BRAIN PATHOL, V24, P429, DOI 10.1111/bpa.12171; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Slenter DN, 2018, NUCLEIC ACIDS RES, V46, pD661, DOI 10.1093/nar/gkx1064; Sridhar R, 2000, PHARM RES-DORDR, V17, P1345, DOI 10.1023/A:1007507224529; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Vasaikar S, 2019, CELL, V177, P1035, DOI 10.1016/j.cell.2019.03.030; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Yoshihara K, 2012, CLIN CANCER RES, V18, P1374, DOI 10.1158/1078-0432.CCR-11-2725; Yu J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3248-y; Yuan Y, 2014, NAT BIOTECHNOL, V32, P644, DOI 10.1038/nbt.2940; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438; Zhang H, 2016, CELL, V166, P755, DOI 10.1016/j.cell.2016.05.069; Zhao HJ, 2006, PLOS MED, V3, P115, DOI 10.1371/journal.pmed.0030013	46	9	9	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2081	2095		10.1038/s41388-021-01681-0	http://dx.doi.org/10.1038/s41388-021-01681-0		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33627787	Green Accepted			2022-12-28	WOS:000621289100003
J	Chen, DJ; Parker, TM; Bhat-Nakshatri, P; Chu, XN; Liu, YL; Wang, Y; Nakshatri, H				Chen, Duojiao; Parker, Taylor M.; Bhat-Nakshatri, Poornima; Chu, Xiaona; Liu, Yunlong; Wang, Yue; Nakshatri, Harikrishna			Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression	ONCOGENE			English	Article							PIONEER TRANSCRIPTION FACTORS; BREAST-CANCER; ER-ALPHA; TAMOXIFEN RESISTANCE; DNA-BINDING; FOXA1; ENHANCERS; REVEALS; RECRUITMENT; REPRESSION	Chromatin accessibility is central to basal and inducible gene expression. Through ATAC-seq experiments in estrogen receptor-positive (ER+) breast cancer cell line MCF-7 and integration with multi-omics data, we found estradiol (E2) induced chromatin accessibility changes in a small number of breast cancer-relevant E2-regulated genes. As expected, open chromatin regions associated with E2-inducible gene expression showed enrichment of estrogen response element (ERE) and those associated with E2-repressible gene expression were enriched for ERE, PBX1, and PBX3. While a significant number of open chromatin regions showed pioneer factor FOXA1 occupancy in the absence of E2, E2-treatment further enhanced FOXA1 occupancy suggesting that ER-E2 enhances chromatin occupancy of FOXA1 to a subset of E2-regulated genes. Surprisingly, promoters of 80% and enhancers of 60% of E2-inducible genes displayed closed chromatin configuration both in the absence and presence of E2. Integration of ATAC-seq data with ER alpha ChIP-seq data revealed that similar to 40% ER alpha binding sites in the genome are found in chromatin regions that are not accessible as per ATAC-seq. Such ER alpha binding regions were enriched for binding sites of multiple nuclear receptors including ER, ESRRB, ERR gamma, COUP-TFII (NR2F2), RAR alpha, EAR2 as well as traditional pioneer factors FOXA1 and GATA3. Similar data were also obtained when ER alpha ChIP-seq data were integrated with MNase-seq and DNase-seq data sets. In summation, our results reveal complex mechanisms of ER-E2 interaction with nucleosomes. Notably, "closed chromatin" configuration as defined by ATAC-seq or by other techniques is not necessarily associated with lack of gene expression and technical limitations may preclude ATAC-seq to demonstrate accessibility of chromatin regions that are bound by ER alpha.	[Chen, Duojiao; Chu, Xiaona; Liu, Yunlong; Wang, Yue] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Parker, Taylor M.; Bhat-Nakshatri, Poornima; Nakshatri, Harikrishna] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA; [Nakshatri, Harikrishna] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Nakshatri, Harikrishna] Roudebush VA Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Wang, Y (corresponding author), Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.; Nakshatri, H (corresponding author), Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.; Nakshatri, H (corresponding author), Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.; Nakshatri, H (corresponding author), Roudebush VA Med Ctr, Indianapolis, IN 46202 USA.	yuewang@iu.edu; hnakshat@iupui.edu	Chen, Duojiao/GRY-2410-2022	Wang, Yue/0000-0003-4671-8547; Nakshatri, Harikrishna/0000-0001-8876-0052	Susan G Komen for the Cure [SAC110025]	Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation)	Susan G Komen for the Cure (SAC110025 to HN) supported this work. We also thank the members of the Medical Genomics core for sequencing and help with data analyses.	Abba MC, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-37; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Andersson R, 2020, NAT REV GENET, V21, P71, DOI 10.1038/s41576-019-0173-8; Bhat-Nakshatri P, 2008, MOL CELL BIOL, V28, P7487, DOI 10.1128/MCB.00799-08; Brambati A, 2020, MUTAT RES-REV MUTAT, V784, DOI 10.1016/j.mrrev.2020.108300; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Castellano-Pozo M, 2013, MOL CELL, V52, P583, DOI 10.1016/j.molcel.2013.10.006; Cheung E, 2010, ANNU REV PHYSIOL, V72, P191, DOI 10.1146/annurev-physiol-021909-135840; Chung CY, 2019, CELL REP, V29, P495, DOI 10.1016/j.celrep.2019.08.089; Cocce KJ, 2019, CELL REP, V29, P889, DOI 10.1016/j.celrep.2019.09.032; Costantino L, 2015, CURR OPIN CELL BIOL, V34, P39, DOI 10.1016/j.ceb.2015.04.008; D'Souza AD, 2018, BBA-GENE REGUL MECH, V1861, P158, DOI 10.1016/j.bbagrm.2017.12.008; De Bosscher K, 2020, NAT REV ENDOCRINOL, V16, P363, DOI 10.1038/s41574-020-0349-5; Drouin J, 2014, MOL ENDOCRINOL, V28, P989, DOI 10.1210/me.2014-1084; Dumelie JG, 2017, ELIFE, V6, DOI 10.7554/eLife.28306; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Pham D, 2019, CELL REP, V29, P1203, DOI 10.1016/j.celrep.2019.09.064; Esnault C, 2017, MOL CELL, V65, P1081, DOI 10.1016/j.molcel.2017.02.005; Fleming JD, 2013, GENOME RES, V23, P1195, DOI 10.1101/gr.148080.112; Gao TS, 2020, NUCLEIC ACIDS RES, V48, pD58, DOI 10.1093/nar/gkz980; Glont SE, 2019, CELL REP, V26, P2558, DOI 10.1016/j.celrep.2019.02.036; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Guertin MJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004613; Hah N, 2011, CELL, V145, P622, DOI 10.1016/j.cell.2011.03.042; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Iwafuchi-Doi M, 2016, MOL CELL, V62, P79, DOI 10.1016/j.molcel.2016.03.001; Jiang GJ, 2019, THERANOSTICS, V9, P6501, DOI 10.7150/thno.34874; Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263; Liu Z, 2018, J CELL BIOL, V217, P1181, DOI 10.1083/jcb.201710038; Liu ZJ, 2014, CELL, V159, P358, DOI 10.1016/j.cell.2014.08.027; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Magnani L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002368; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Meers MP, 2019, MOL CELL, V75, P562, DOI 10.1016/j.molcel.2019.05.025; Mueller B, 2017, GENE DEV, V31, P451, DOI 10.1101/gad.293118.116; Murakami S, 2019, MOL CANCER RES, V17, P2356, DOI 10.1158/1541-7786.MCR-19-0393; Nardini M, 2013, CELL, V152, P132, DOI 10.1016/j.cell.2012.11.047; Nardone V, 2017, BBA-GENE REGUL MECH, V1860, P571, DOI 10.1016/j.bbagrm.2016.09.006; Oldfield AJ, 2014, MOL CELL, V55, P708, DOI 10.1016/j.molcel.2014.07.005; Paakinaho V, 2019, CELL REP, V28, P3523, DOI 10.1016/j.celrep.2019.08.039; Sato S, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.190116; Stork CT, 2016, ELIFE, V5, DOI 10.7554/eLife.17548; Swinstead EE, 2018, ENDOCR-RELAT CANCER, V25, pR385, DOI 10.1530/ERC-18-0033; Swinstead EE, 2016, CELL, V165, P593, DOI 10.1016/j.cell.2016.02.067; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; Wu YM, 2018, CANCER RES, V78, P671, DOI 10.1158/0008-5472.CAN-17-1327; Yang F, 2017, MOL CELL, V66, P321, DOI 10.1016/j.molcel.2017.03.019; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111; Zhu C, 2019, MOL CELL, V75, P791, DOI 10.1016/j.molcel.2019.06.010; Zhuang T, 2015, ONCOTARGET, V6, P43853, DOI 10.18632/oncotarget.6081	55	3	3	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1332	1346		10.1038/s41388-020-01607-2	http://dx.doi.org/10.1038/s41388-020-01607-2		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420376				2022-12-28	WOS:000607346000007
J	Fu, JJ; Liao, L; Balaji, KS; Wei, CL; Kim, J; Peng, JZ				Fu, Junjiang; Liao, Li; Balaji, Kyathegowdanadoddi Srinivasa; Wei, Chunli; Kim, Jaehoon; Peng, Jiangzhou			Epigenetic modification and a role for the E3 ligase RNF40 in cancer development and metastasis	ONCOGENE			English	Review							HISTONE H2B MONOUBIQUITINATION; UBIQUITIN-PROTEIN LIGASE; DNA-DAMAGE; TUMOR-SUPPRESSOR; RING DOMAIN; RNF20; UBIQUITYLATION; TRANSCRIPTION; ELONGATION; ATM	RNF40 (OMIM: 607700) is a really interesting new gene (RING) finger E3 ubiquitin ligase containing multiple coiled-coil domains and a C-terminal RING finger motif, which engage in protein-DNA and protein-protein interactions. RNF40 encodes a polypeptide of 1001 amino acids with a predicted molecular mass of 113,678 Da. RNF40 and its paralog RNF20 form a stable heterodimer complex that can monoubiquitylate histone H2B at lysine 120 as well as other nonhistone proteins. Cancer is a major public health problem and the second leading cause of death. Through its protein ubiquitylation activity, RNF40 acts as a tumor suppressor or oncogene to play major epigenetic roles in cancer development, progression, and metastasis, highlighting the essential function of RNF40 and the importance of studying it. In this review, we summarize current knowledge about RNF40 gene structure and the role of RNF40 in histone H2B monoubiquitylation, DNA damage repair, apoptosis, cancer development, and metastasis. We also underscore challenges in applying this information to cancer prognosis and prevention and highlight the urgent need for additional investigations of RNF40 as a potential target for cancer therapeutics.	[Fu, Junjiang; Liao, Li; Wei, Chunli] Southwest Med Univ, Res Ctr Preclin Med, Key Lab Epigenet & Oncol, Luzhou 646000, Sichuan, Peoples R China; [Balaji, Kyathegowdanadoddi Srinivasa] Univ Mysore, Teresian Coll, Teresian Res Ctr, Post Graduat Dept Studies & Res Biotechnol, Mysore 570011, Karnataka, India; [Kim, Jaehoon] Korea Adv Inst Sci & Technol, Dept Biol Sci, Daejeon 34141, South Korea; [Peng, Jiangzhou] Southern Med Univ, Affiliated Hosp 3, Dept Thorac Surg, Guangzhou 510500, Guangdong, Peoples R China	Southwest Medical University; University of Mysore; Korea Advanced Institute of Science & Technology (KAIST); Southern Medical University - China	Fu, JJ (corresponding author), Southwest Med Univ, Res Ctr Preclin Med, Key Lab Epigenet & Oncol, Luzhou 646000, Sichuan, Peoples R China.; Kim, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Daejeon 34141, South Korea.; Peng, JZ (corresponding author), Southern Med Univ, Affiliated Hosp 3, Dept Thorac Surg, Guangzhou 510500, Guangdong, Peoples R China.	fujunjiang@hotmail.com; kimjaehoon@kaist.edu; jiangzhou83@163.com	Kim, Jaehoon/G-2711-2011; K, Balaji/HGB-2214-2022	Kim, Jaehoon/0000-0003-4035-0438; /0000-0002-7236-8993; peng, jiangzhou/0000-0002-8058-8988; Fu, Junjiang/0000-0002-0708-2200	National Natural Science Foundation of China [82073263, 81672887, 81172049, 30371493]; Joint Research Foundation of Luzhou City and Southwest Medical University [2018LZXNYDYL01]; Foundation of Department of Science and Technology of Guangdong Province [2011B061300016]; National Research Foundation of Korea [2018R1A5A1024261, 2019R1A2C2090830]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Joint Research Foundation of Luzhou City and Southwest Medical University; Foundation of Department of Science and Technology of Guangdong Province; National Research Foundation of Korea(National Research Foundation of Korea)	This study is financially supported by grants from the National Natural Science Foundation of China (82073263, 81672887, 81172049, and 30371493) and the Joint Research Foundation of Luzhou City and Southwest Medical University (2018LZXNYDYL01) to JF, from Foundation of Department of Science and Technology of Guangdong Province (2011B061300016) to JP, and from the National Research Foundation of Korea (2018R1A5A1024261 and 2019R1A2C2090830) to JK.	Ahmad A, 2019, ADV EXP MED BIOL, V1152, P217, DOI 10.1007/978-3-030-20301-6_10; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Bedi U, 2015, ONCOGENE, V34, P465, DOI 10.1038/onc.2013.558; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brown P, 2013, HEMATOL-AM SOC HEMAT, P596, DOI 10.1182/asheducation-2013.1.596; Burke MJ, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00042; Castro PG, 2018, LEUKEMIA, V32, P323, DOI 10.1038/leu.2017.216; Chatterton Z, 2014, EPIGENETICS-US, V9, P459, DOI 10.4161/epi.27585; Chen JQ, 2009, BBA-REV CANCER, V1796, P162, DOI 10.1016/j.bbcan.2009.06.003; Chen S, 2012, CELL RES, V22, P1402, DOI 10.1038/cr.2012.114; Chen ZJ, 2019, ELIFE, V8, DOI 10.7554/eLife.48281; Chernikova SB, 2012, CANCER RES, V72, P2111, DOI 10.1158/0008-5472.CAN-11-2209; Chin LS, 2002, J BIOL CHEM, V277, P35071, DOI 10.1074/jbc.M203300200; Clouaire T, 2018, MOL CELL, V72, P250, DOI 10.1016/j.molcel.2018.08.020; Cole AJ, 2015, ENDOCR-RELAT CANCER, V22, pT19, DOI 10.1530/ERC-14-0185; Dantuma NP, 2016, EMBO J, V35, P6, DOI 10.15252/embj.201592595; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Dickson KA, 2016, HUM MOL GENET, V25, P5460, DOI 10.1093/hmg/ddw362; Diebold ML, 2010, J BIOL CHEM, V285, P38389, DOI 10.1074/jbc.M110.146696; Duan Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12648; Fan P, 2019, CANCER DRUG RESIST, V2, P198, DOI 10.20517/cdr.2019.13; Feng RM, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0368-6; Foglizzo M, 2016, J MOL BIOL, V428, P4073, DOI 10.1016/j.jmb.2016.07.025; Fu JW, 2020, MOL BIOL REP, V47, P4383, DOI 10.1007/s11033-020-05478-4; Fu SY, 2017, ONCOTARGET, V8, P43866, DOI 10.18632/oncotarget.16704; Fuchs G, 2014, BBA-GENE REGUL MECH, V1839, P694, DOI 10.1016/j.bbagrm.2014.01.002; Fujita K, 2019, WORLD J MENS HEALTH, V37, P288, DOI 10.5534/wjmh.180040; Gallego LD, 2020, NATURE, V579, P592, DOI 10.1038/s41586-020-2097-z; Ghouri Yezaz Ahmed, 2017, J Carcinog, V16, P1, DOI 10.4103/jcar.JCar_9_16; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hahn MA, 2012, HUM MOL GENET, V21, P559, DOI 10.1093/hmg/ddr490; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; In S, 2019, NUCLEIC ACIDS RES, V47, P2840, DOI 10.1093/nar/gkz006; Jaaskelainen T, 2012, MOL CELL ENDOCRINOL, V350, P87, DOI 10.1016/j.mce.2011.11.025; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Karpiuk O, 2012, MOL CELL, V46, P705, DOI 10.1016/j.molcel.2012.05.022; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Kosinsky RL, 2019, J CROHNS COLITIS, V13, P362, DOI 10.1093/ecco-jcc/jjy165; Lee NS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10463; Li CL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03455-x; Li XS, 2010, MOL CELL BIOL, V30, P1673, DOI 10.1128/MCB.00540-09; Liu L, 2018, ONCOGENE, V37, P148, DOI 10.1038/onc.2017.313; Liu ZQ, 2020, DIGEST LIVER DIS, V52, P240, DOI 10.1016/j.dld.2019.11.001; Liu ZX, 2009, MOL BIOL CELL, V20, P757, DOI 10.1091/mbc.E08-09-0983; Ma Xiaomei, 2006, Yale J Biol Med, V79, P85; Marsh DJ, 2019, GENES-BASEL, V10, DOI 10.3390/genes10010067; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Melling N, 2016, PATHOL ONCOL RES, V22, P95, DOI 10.1007/s12253-015-9977-9; Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016; Mladenov E, 2016, SEMIN CANCER BIOL, V37-38, P51, DOI 10.1016/j.semcancer.2016.03.003; Moyal L, 2011, MOL CELL, V41, P529, DOI 10.1016/j.molcel.2011.02.015; Nakamura K, 2011, MOL CELL, V41, P515, DOI 10.1016/j.molcel.2011.02.002; Nyame YA, 2020, EUR UROL, V77, P53, DOI 10.1016/j.eururo.2019.09.018; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Palomera-Sanchez Z, 2011, DNA REPAIR, V10, P119, DOI 10.1016/j.dnarep.2010.10.010; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Pirngruber J, 2009, EMBO REP, V10, P894, DOI 10.1038/embor.2009.108; Prenzel T, 2011, CANCER RES, V71, P5739, DOI 10.1158/0008-5472.CAN-11-1896; Ramachandran S, 2016, CELL REP, V15, P1554, DOI 10.1016/j.celrep.2016.04.041; Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072; Rawla P, 2019, WORLD J ONCOL, V10, P63, DOI 10.14740/wjon1191; Rawla P, 2018, WSPOLCZESNA ONKOL, V22, P141, DOI 10.5114/wo.2018.78941; Ren ZH, 2020, CANCER COMMUN, V40, P81, DOI 10.1002/cac2.12009; Robson A, 2019, P NATL ACAD SCI USA, V116, P14049, DOI 10.1073/pnas.1808341116; Roos WP, 2016, NAT REV CANCER, V16, P20, DOI 10.1038/nrc.2015.2; Sadeghi L, 2014, NAT STRUCT MOL BIOL, V21, P236, DOI 10.1038/nsmb.2776; Schneider D, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0698-x; Shah VJ, 2018, J CELL SCI, V131, DOI 10.1242/jcs.213868; Shema E, 2008, GENE DEV, V22, P2664, DOI 10.1101/gad.1703008; Shema E, 2011, MOL CELL, V42, P477, DOI 10.1016/j.molcel.2011.03.011; Shiloh Y, 2011, FEBS LETT, V585, P2795, DOI 10.1016/j.febslet.2011.07.034; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; So CC, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00488-18; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Tarcic O, 2017, CELL DEATH DIFFER, V24, P694, DOI 10.1038/cdd.2016.126; Tarcic O, 2016, CELL REP, V14, P1462, DOI 10.1016/j.celrep.2016.01.020; Thaler S, 2015, INT J CANCER, V137, P686, DOI 10.1002/ijc.29404; Torre LA, 2017, CANCER EPIDEM BIOMAR, V26, P444, DOI 10.1158/1055-9965.EPI-16-0858; Trujillo KM, 2012, MOL CELL, V48, P734, DOI 10.1016/j.molcel.2012.09.019; Urasaki Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036775; Wei CL, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20193443; Wei CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep29822; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Wu C, 2020, J MOL CELL BIOL, V12, P113, DOI 10.1093/jmcb/mjz045; Xie WH, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2482-4; Xie WH, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1159-5; Zhang F, 2014, J AM CHEM SOC, V136, P12884, DOI 10.1021/ja507863d; Zhang F, 2011, MOL CELL, V41, P384, DOI 10.1016/j.molcel.2011.01.024; Zheng XY, 2018, INT J CLIN EXP PATHO, V11, P2901; Zhu B, 2005, MOL CELL, V20, P601, DOI 10.1016/j.molcel.2005.09.025	92	14	14	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					465	474		10.1038/s41388-020-01556-w	http://dx.doi.org/10.1038/s41388-020-01556-w		NOV 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33199825	Green Published, hybrid			2022-12-28	WOS:000590042900001
J	Wilhelm, A; Marschalek, R				Wilhelm, Alexander; Marschalek, Rolf			The role of reciprocal fusions in MLL-r acute leukemia: studying the chromosomal translocation t(4;11)	ONCOGENE			English	Article							COMPLEX; MUTATIONS; PROTEIN; INFANT; ELONGATION; ACTIVATION; TARGET; MODEL	Leukemia patients bearing the t(4;11)(q21;q23) translocations can be divided into two subgroups: those expressing both reciprocal fusion genes, and those that have only the MLL-AF4 fusion gene. Moreover, a recent study has demonstrated that patients expressing both fusion genes have a better outcome than patients that are expressing the MLL-AF4 fusion protein alone. All this may point to a clonal process where the reciprocal fusion gene AF4-MLL could be lost during disease progression, as this loss may select for a more aggressive type of leukemia. Therefore, we were interested in unraveling the decisive role of the AF4-MLL fusion protein at an early timepoint of disease development. We designed an experimental model system where the MLL-AF4 fusion protein was constitutively expressed, while an inducible AF4-MLL fusion gene was induced for only 48 h. Subsequently, we investigated genome-wide changes by RNA- and ATAC-Seq experiments at distinct timepoints. These analyses revealed that the expression of AF4-MLL for only 48 h was sufficient to significantly change the genomic landscape (transcription and chromatin) even on a longer time scale. Thus, we have to conclude that the AF4-MLL fusion protein works through a hit-and-run mechanism, probably necessary to set up pre-leukemic conditions, but being dispensable for later disease progression.	[Wilhelm, Alexander; Marschalek, Rolf] Goethe Univ Frankfurt, Inst Pharmaceut Biol DCAL, Frankfurt, Germany	Goethe University Frankfurt	Marschalek, R (corresponding author), Goethe Univ Frankfurt, Inst Pharmaceut Biol DCAL, Frankfurt, Germany.	Rolf.Marschalek@em.uni-frankfurt.de		Wilhelm, Alexander/0000-0003-0904-3376; Marschalek, Rolf/0000-0003-4870-3445	DFG [Ma 1876/12-1, Ma 1876/13-1]; Wilhelm Sander Foundation [2018.070.1, 2018.070.2]; Projekt DEAL	DFG(German Research Foundation (DFG)); Wilhelm Sander Foundation; Projekt DEAL	This work is funded by DFG grants Ma 1876/12-1 and Ma 1876/13-1, and grant 2018.070.1 and 2018.070.2 from the Wilhelm Sander Foundation. Open Access funding enabled and organized by Projekt DEAL.	Agraz-Doblas A, 2019, HAEMATOLOGICA, V104, P1176, DOI 10.3324/haematol.2018.206375; Andersson AK, 2015, NAT GENET, V47, P330, DOI 10.1038/ng.3230; Bardini M, 2010, LEUKEMIA, V24, P169, DOI 10.1038/leu.2009.203; Benedikt A, 2011, LEUKEMIA, V25, P135, DOI 10.1038/leu.2010.249; Bitoun E, 2007, HUM MOL GENET, V16, P92, DOI 10.1093/hmg/ddl444; Bursen A, 2010, BLOOD, V115, P3570, DOI 10.1182/blood-2009-06-229542; Cho S, 2010, CELL CYCLE, V9, P1697, DOI 10.4161/cc.9.9.11346; Chu SH, 2018, BLOOD ADV, V2, P2478, DOI 10.1182/bloodadvances.2018021592; Corces MR, 2017, NAT METHODS, V14, P959, DOI [10.1038/NMETH.4396, 10.1038/nmeth.4396]; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Kowarz E, 2007, LEUKEMIA, V21, P1232, DOI 10.1038/sj.leu.2404686; Kowarz E, 2015, BIOTECHNOL J, V10, P647, DOI 10.1002/biot.201400821; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Lin S, 2016, CANCER CELL, V30, P737, DOI 10.1016/j.ccell.2016.10.008; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo ZJ, 2012, NAT REV MOL CELL BIO, V13, P543, DOI 10.1038/nrm3417; Mansur MB, 2017, BBA-REV CANCER, V1868, P521, DOI 10.1016/j.bbcan.2017.10.005; Marschalek R, 2020, BBA-GENE REGUL MECH, V1863, DOI 10.1016/j.bbagrm.2020.194547; Meyer C, 2018, LEUKEMIA, V32, P273, DOI 10.1038/leu.2017.213; Milne TA, 2005, P NATL ACAD SCI USA, V102, P14765, DOI 10.1073/pnas.0503630102; Prelle C, 2013, LEUKEMIA, V27, P1425, DOI 10.1038/leu.2012.365; Rossler T, 2013, PHARMAZIE, V68, P601, DOI 10.1691/ph.2013.6514; Secker KA, 2020, CANCERS, V12, DOI 10.3390/cancers12061487; Sharaf-Eldein M, 2018, CLIN LAB, V64, P1429, DOI 10.7754/Clin.Lab.2018.180308; Tyagi A, 2019, INT J HEMATOL, V110, P205, DOI 10.1007/s12185-019-02666-2; Wang AY, 2021, CANCER GENOM PROTEOM, V18, P43, DOI 10.21873/cgp.20240; Wilkinson AC, 2013, CELL REP, V3, P116, DOI 10.1016/j.celrep.2012.12.016; Wu Sharon, 2019, Metabol Open, V2, P100009, DOI 10.1016/j.metop.2019.100009; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004	29	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6093	6102		10.1038/s41388-021-02001-2	http://dx.doi.org/10.1038/s41388-021-02001-2		SEP 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34489550	Green Published, hybrid			2022-12-28	WOS:000692963000001
J	Cen, B; Wei, J; Wang, DZ; Xiong, Y; Shay, JW; DuBois, RN				Cen, Bo; Wei, Jie; Wang, Dingzhi; Xiong, Ying; Shay, Jerry W.; DuBois, Raymond N.			Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer	ONCOGENE			English	Article							EXPRESSION; IMMUNOTHERAPY; MUTATIONS; MECHANISM; LIGAND-1; BLOCKADE; RECEPTOR; ESCAPE	PD-L1 expression is elevated in various human cancers, including colorectal cancer. High levels of PD-L1 expressed on tumor epithelial cells are one of the potential mechanisms by which tumor cells become resistant to immune attack. However, PD-L1 regulation in tumor cells is not fully understood. Here we demonstrate that mutations in the adenomatous polyposis coli (APC) gene lead to colonic epithelial cell resistance to CD8(+) T cell cytotoxicity by induction of PD-L1 expression. Mechanistically, this occurs as a result of the beta-catenin/TCF4 complex binding to the PD-L1 promoter, leading to increased transcription. Our findings not only reveal a novel mechanism by which APC mutations induce tumor immune evasion via an immune checkpoint pathway but also pave the way for developing beta-catenin or TCF4 inhibitors as possible new options for immune checkpoint inhibition.	[Cen, Bo; Wei, Jie; Wang, Dingzhi; Xiong, Ying; DuBois, Raymond N.] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Shay, Jerry W.] Univ Texas Southwestern Med Ctr Dallas, Div Digest & Liver Dis, Dept Cell Biol, Dallas, TX 75390 USA	Medical University of South Carolina; University of Texas System; University of Texas Southwestern Medical Center Dallas	DuBois, RN (corresponding author), Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	duboisrn@musc.edu		DuBois, Raymond/0000-0002-6385-7154; Shay, Jerry W./0000-0001-5052-0627	Flow Cytometry & Cell Sorting Unit, Hollings Cancer Center, Medical University of South Carolina [P30 CA138313]	Flow Cytometry & Cell Sorting Unit, Hollings Cancer Center, Medical University of South Carolina	This work was supported in part by Flow Cytometry & Cell Sorting Unit, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313).	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Cha JH, 2019, MOL CELL, V76, P359, DOI 10.1016/j.molcel.2019.09.030; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Du LY, 2020, J EXP MED, V217, DOI 10.1084/jem.20191115; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; McIntyre RE, 2015, BIOESSAYS, V37, P909, DOI 10.1002/bies.201500032; Ohigashi Y, 2005, CLIN CANCER RES, V11, P2947, DOI 10.1158/1078-0432.CCR-04-1469; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Peng J, 2015, CANCER RES, V75, P5034, DOI 10.1158/0008-5472.CAN-14-3098; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Roig AI, 2010, GASTROENTEROLOGY, V138, P1012, DOI 10.1053/j.gastro.2009.11.052; Salvatore L, 2019, CANCERS, V11, DOI 10.3390/cancers11111765; Song MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065821; Strome SE, 2003, CANCER RES, V63, P6501; TARMIN L, 1995, CANCER RES, V55, P2035; Thompson RH, 2005, UROLOGY, V66, P10, DOI 10.1016/j.urology.2005.06.010; Zhu JJ, 2014, HUM IMMUNOL, V75, P348, DOI 10.1016/j.humimm.2014.01.006	23	8	8	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					5984	5992		10.1038/s41388-021-01972-6	http://dx.doi.org/10.1038/s41388-021-01972-6		AUG 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34385594	Green Accepted			2022-12-28	WOS:000684526700002
J	Cronin, R; Brooke, GN; Prischi, F				Cronin, Ryan; Brooke, Greg N.; Prischi, Filippo			The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance	ONCOGENE			English	Review							EPIDERMAL-GROWTH-FACTOR; BOX-BINDING PROTEIN-1; ANDROGEN RECEPTOR; RSK FAMILY; POSTTRANSLATIONAL MODIFICATION; INTEGRIN ACTIVATION; BREAST-CANCER; TARGETING RSK; YB-1 YBX1; RAS-ERK	Prostate cancer (PCa) is the second most commonly occurring cancer in men, with over a million new cases every year worldwide. Tumor growth and disease progression is mainly dependent on the Androgen Receptor (AR), a ligand dependent transcription factor. Standard PCa therapeutic treatments include androgen-deprivation therapy and AR signaling inhibitors. Despite being successful in controlling the disease in the majority of men, the high frequency of disease progression to aggressive and therapy resistant stages (termed castrate resistant prostate cancer) has led to the search for new therapeutic targets. The p90 ribosomal S6 kinase (RSK1-4) family is a group of highly conserved Ser/Thr kinases that holds promise as a novel target. RSKs are effector kinases that lay downstream of the Ras/Raf/MEK/ERK signaling pathway, and aberrant activation or expression of RSKs has been reported in several malignancies, including PCa. Despite their structural similarities, RSK isoforms have been shown to perform nonredundant functions and target a wide range of substrates involved in regulation of transcription and translation. In this article we review the roles of the RSKs in proliferation and motility, cell cycle control and therapy resistance in PCa, highlighting the possible interplay between RSKs and AR in mediating disease progression. In addition, we summarize the current advances in RSK inhibitor development and discuss their potential clinical benefits.	[Cronin, Ryan; Brooke, Greg N.; Prischi, Filippo] Univ Essex, Sch Life Sci, Colchester, Essex, England	University of Essex	Brooke, GN; Prischi, F (corresponding author), Univ Essex, Sch Life Sci, Colchester, Essex, England.	gbrooke@essex.ac.uk; fprischi@essex.ac.uk	Prischi, Filippo/I-4844-2019	Prischi, Filippo/0000-0003-2107-938X; Brooke, Greg/0000-0003-4501-4134	Leverhulme Trust [RPG-2018-230]; Wellcome Trust [205767/Z/16/Z]; Rosetree Trust [M702]; Peter Nicholls scholarship	Leverhulme Trust(Leverhulme Trust); Wellcome Trust(Wellcome TrustEuropean Commission); Rosetree Trust(Rosetrees Trust); Peter Nicholls scholarship	FP acknowledges support from The Leverhulme Trust grant (RPG-2018-230) and The Wellcome Trust grant (205767/Z/16/Z). GB had funding from the Rosetree Trust (M702). RC was supported by a Peter Nicholls scholarship. All figures were created with Biorender.com.	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Aronchik I, 2014, MOL CANCER RES, V12, P803, DOI 10.1158/1541-7786.MCR-13-0595; Bennett NC, 2010, INT J BIOCHEM CELL B, V42, P813, DOI 10.1016/j.biocel.2009.11.013; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Boutros R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067822; Brooke GN, 2009, CURR GENOMICS, V10, P18, DOI 10.2174/138920209787581307; Campi R, 2019, EUR UROL FOCUS, V5, P1029, DOI 10.1016/j.euf.2018.04.001; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Casalvieri KA, 2017, TRENDS CANCER, V3, P302, DOI 10.1016/j.trecan.2017.03.004; Chan HM, 2001, J CELL SCI, V114, P2363; Chao OSP, 2006, ONCOGENE, V25, P4458, DOI 10.1038/sj.onc.1209421; Chen C, 2013, P NATL ACAD SCI USA, V110, P20605, DOI 10.1073/pnas.1306328110; Chen L, 2016, MOL CANCER THER, V15, P2107, DOI 10.1158/1535-7163.MCT-16-0241; Cheng Y, 2017, MOLECULES, V22, DOI 10.3390/molecules22101551; Clark DE, 2005, CANCER RES, V65, P3108; Clarkl DE, 2001, EMBO J, V20, P3484, DOI 10.1093/emboj/20.13.3484; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Cuesta R, 2016, ONCOTARGET, V7, P27567, DOI 10.18632/oncotarget.8375; Cuzick J, 2014, LANCET ONCOL, V15, pE484, DOI 10.1016/S1470-2045(14)70211-6; Dart DA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071694; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Dolfini D, 2013, ONCOGENE, V32, P4189, DOI 10.1038/onc.2012.521; Dolfini D, 2013, CELL DEATH DIFFER, V20, P676, DOI 10.1038/cdd.2013.13; Dong J, 2019, MOL CANCER THER, V18, P39, DOI 10.1158/1535-7163.MCT-18-0432; Dummler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200; Edgar AJ, 2014, BIOSCIENCE REP, V34, P28, DOI 10.1042/BSR20130094; Eisenmann KM, 2003, CANCER RES, V63, P8330; Eisinger-Mathason TSK, 2010, STEROIDS, V75, P191, DOI 10.1016/j.steroids.2009.12.010; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gandhi J, 2018, PROSTATE CANCER P D, V21, P22, DOI 10.1038/s41391-017-0023-8; Gawecka JE, 2012, J BIOL CHEM, V287, P43424, DOI 10.1074/jbc.M112.423046; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Gioeli D, 2012, MOL CELL ENDOCRINOL, V352, P70, DOI 10.1016/j.mce.2011.07.004; Gogl G, 2018, FEBS J, V285, P46, DOI 10.1111/febs.14311; Hatzivassiliou G, 2012, MOL CANCER THER, V11, P1143, DOI 10.1158/1535-7163.MCT-11-1010; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; Helsen C, 2014, MOL CELL ENDOCRINOL, V382, P97, DOI 10.1016/j.mce.2013.09.009; Huo H, 2019, ONCOL REP, V42, P2777, DOI 10.3892/or.2019.7328; Jackson SP, 2001, BIOCHEM SOC T, V29, P655, DOI 10.1042/BST0290655; Jakobsen NA, 2016, J CLIN UROL, V9, P3, DOI 10.1177/2051415816656121; Jin LT, 2013, MOL CELL BIOL, V33, P2574, DOI 10.1128/MCB.01677-12; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; Joo SS, 2009, J PINEAL RES, V47, P8, DOI 10.1111/j.1600-079X.2009.00682.x; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Katzenwadel A, 2015, CANCER LETT, V367, P12, DOI 10.1016/j.canlet.2015.06.021; Kim J, 2004, J CELL BIOCHEM, V93, P233, DOI 10.1002/jcb.20228; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Koryakina Y, 2014, ENDOCR-RELAT CANCER, V21, pT131, DOI 10.1530/ERC-13-0472; Lamont KR, 2010, ADV CANCER RES, V107, P137, DOI 10.1016/S0065-230X(10)07005-3; Lara R, 2013, CANCER RES, V73, P5301, DOI 10.1158/0008-5472.CAN-12-4448; Lavin MF, 2007, ONCOGENE, V26, P7749, DOI 10.1038/sj.onc.1210880; Law JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012661; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Li QY, 2019, ONCOTARGETS THER, V12, P5907, DOI 10.2147/OTT.S208988; Liao MM, 2001, METH MOL B, V176, P67; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Ludwik KA, 2018, CANCER RES, V78, P2014, DOI 10.1158/0008-5472.CAN-17-2063; Ludwik KA, 2016, EXPERT OPIN THER PAT, V26, P1061, DOI 10.1080/13543776.2016.1212839; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marinkovich MP, 2007, NAT REV CANCER, V7, P370, DOI 10.1038/nrc2089; Matsumoto T, 2013, ANNU REV PHYSIOL, V75, P201, DOI 10.1146/annurev-physiol-030212-183656; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Mei Y, 2020, J BIOCHEM, V167, P603, DOI 10.1093/jb/mvaa009; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Miller CJ, 2018, TRENDS BIOCHEM SCI, V43, P380, DOI 10.1016/j.tibs.2018.02.009; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nguyen TL, 2008, ANTI-CANCER AGENT ME, V8, P710, DOI 10.2174/187152008785914770; Packer JR, 2016, BBA-MOL CELL RES, V1863, P1238, DOI 10.1016/j.bbamcr.2016.02.016; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Perez-Cornago A, 2017, BRIT J CANCER, V117, P1562, DOI 10.1038/bjc.2017.312; Pine Angela C, 2016, F1000Res, V5, DOI 10.12688/f1000research.8019.1; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Prabhu L, 2015, GENES DIS, V2, P240, DOI 10.1016/j.gendis.2015.05.001; Rana K, 2014, ASIAN J ANDROL, V16, P169, DOI 10.4103/1008-682X.122590; Roffe M, 2015, CELL SIGNAL, V27, P1630, DOI 10.1016/j.cellsig.2015.04.004; Romeo Y, 2013, ONCOGENE, V32, P2917, DOI 10.1038/onc.2012.312; Romeo Y, 2012, BIOCHEM J, V441, P553, DOI 10.1042/BJ20110289; Romeo Y, 2011, EXPERT OPIN THER TAR, V15, P5, DOI 10.1517/14728222.2010.531014; Rubin MA, 2011, J CLIN ONCOL, V29, P3659, DOI 10.1200/JCO.2011.35.1916; Santer FR, 2015, SEMIN CANCER BIOL, V35, P133, DOI 10.1016/j.semcancer.2015.08.005; Shi GX, 2018, P NATL ACAD SCI USA, V115, pE190, DOI 10.1073/pnas.1708584115; Shiota M, 2014, PROSTATE, V74, P959, DOI 10.1002/pros.22813; Shiota M, 2011, ENDOCR-RELAT CANCER, V18, P505, DOI 10.1530/ERC-11-0017; Smith JA, 2005, CANCER RES, V65, P1027; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Subbiah V, 2020, TRENDS CANCER, V6, P797, DOI 10.1016/j.trecan.2020.05.009; Sulzmaier FJ, 2016, ONCOTARGET, V7, P79855, DOI 10.18632/oncotarget.13084; Sulzmaier FJ, 2013, CANCER RES, V73, P6099, DOI 10.1158/0008-5472.CAN-13-1087; Tan M H Eileen, 2015, Acta Pharmacol Sin, V36, P3, DOI 10.1038/aps.2014.18; van Royen ME, 2012, J CELL SCI, V125, P1970, DOI 10.1242/jcs.096792; Vial D, 2012, J BIOL CHEM, V287, P40371, DOI 10.1074/jbc.M112.389577; Wen SM, 2020, ASIAN J UROL, V7, P203, DOI 10.1016/j.ajur.2019.11.001; Wu CF, 2014, ONCOGENE, V33, P2385, DOI 10.1038/onc.2013.182; Yu G, 2015, MOL CANCER RES, V13, P348, DOI 10.1158/1541-7786.MCR-14-0384-T; Yu XZ, 2020, MOL CELL, V79, P812, DOI 10.1016/j.molcel.2020.06.031; Zarif JC, 2016, CELL SIGNAL, V28, P348, DOI 10.1016/j.cellsig.2016.01.013; Zaru R, 2007, NAT IMMUNOL, V8, P1227, DOI 10.1038/ni1517; Zoubeidi A, 2010, CANCER RES, V70, P2307, DOI 10.1158/0008-5472.CAN-09-3252	98	5	5	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3775	3785		10.1038/s41388-021-01810-9	http://dx.doi.org/10.1038/s41388-021-01810-9		MAY 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33972681	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000648930100004
J	Woodley, CM; Romer, AS; Wang, J; Guarnaccia, AD; Elion, DL; Maxwell, JN; Guerrazzi, K; McCann, TS; Popay, TM; Matlock, BK; Flaherty, DK; Lorey, SL; Liu, Q; Tansey, WP; Weissmiller, AM				Woodley, Chase M.; Romer, Alexander S.; Wang, Jing; Guarnaccia, Alissa D.; Elion, David L.; Maxwell, Jack N.; Guerrazzi, Kiana; McCann, Tyler S.; Popay, Tessa M.; Matlock, Brittany K.; Flaherty, David K.; Lorey, Shelly L.; Liu, Qi; Tansey, William P.; Weissmiller, April M.			Multiple interactions of the oncoprotein transcription factor MYC with the SWI/SNF chromatin remodeler	ONCOGENE			English	Article							SANT DOMAIN; COMPLEX; TARGET	The SNF5 subunit of the SWI/SNF chromatin remodeling complex has been shown to act as a tumor suppressor through multiple mechanisms, including impairing the ability of the oncoprotein transcription factor MYC to bind chromatin. Beyond SNF5, however, it is unknown to what extent MYC can access additional SWI/SNF subunits or how these interactions affect the ability of MYC to drive transcription, particularly in SNF5-null cancers. Here, we report that MYC interacts with multiple SWI/SNF components independent of SNF5. We show that MYC binds the pan-SWI/SNF subunit BAF155 through the BAF155 SWIRM domain, an interaction that is inhibited by the presence of SNF5. In SNF5-null cells, MYC binds with remaining SWI/SNF components to essential genes, although for a purpose that is distinct from chromatin remodeling. Analysis of MYC-SWI/SNF target genes in SNF5-null cells reveals that they are associated with core biological functions of MYC linked to protein synthesis. These data reveal that MYC can bind SWI/SNF in an SNF5-independent manner and that SNF5 modulates access of MYC to core SWI/SNF complexes. This work provides a framework in which to interrogate the influence of SWI/SNF on MYC function in cancers in which SWI/SNF or MYC are altered.	[Woodley, Chase M.; Guarnaccia, Alissa D.; Elion, David L.; Guerrazzi, Kiana; McCann, Tyler S.; Popay, Tessa M.; Lorey, Shelly L.; Tansey, William P.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA; [Romer, Alexander S.; Maxwell, Jack N.; Weissmiller, April M.] Middle Tennessee State Univ, Dept Biol, Murfreesboro, TN 37130 USA; [Wang, Jing; Liu, Qi] Vanderbilt Univ, Med Ctr, Ctr Quantitat Sci, Nashville, TN USA; [Wang, Jing; Liu, Qi] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Matlock, Brittany K.; Flaherty, David K.] Vanderbilt Univ, Med Ctr, Med Ctr Flow Cytometry Shared Resource, Nashville, TN USA; [Tansey, William P.] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA	Vanderbilt University; Middle Tennessee State University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Weissmiller, AM (corresponding author), Middle Tennessee State Univ, Dept Biol, Murfreesboro, TN 37130 USA.	april.weissmiller@mtsu.edu		Guarnaccia, Alissa/0000-0003-4195-2158; Popay, Tessa/0000-0002-4694-8804; Wang, Jing/0000-0003-2775-9001; Weissmiller, April/0000-0003-4505-0530; Woodley, Chase/0000-0001-7121-7504	NIH [CA68485, DK20593, DK58404, DK59637, EY08126]; Rally Foundation for Childhood Cancer Research Young Investigator Award [T32CA119925]; NIH/NCI [F31CA225065, T32CA009582, CA247833]; Alex's Lemonade Stand Foundation; St. Baldrick's Foundation; Robert J. Kleberg and Helen C. Kleberg Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rally Foundation for Childhood Cancer Research Young Investigator Award; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Alex's Lemonade Stand Foundation; St. Baldrick's Foundation; Robert J. Kleberg and Helen C. Kleberg Foundation	Special thanks to Dr. Scott Hiebert for his invaluable contributions. We would also like to thank the Vanderbilt University Medical Center Flow Cytometry Shared Resource, the Vanderbilt University Chemical Synthesis Core, the Vanderbilt Cell Imaging Shared Resource (CISR), and the Vanderbilt University Medical Center Technologies for Advanced Genomics (VANTAGE) Core for their critical assistance in this project. The Nikon Center of Excellence located in CISR is supported by NIH grants CA68485, DK20593, DK58404, DK59637, and EY08126. This work was supported by The Rally Foundation for Childhood Cancer Research Young Investigator Award and T32CA119925 to A.M.W, by the NIH/NCI, F31CA225065 and T32CA009582 to A.D.G, and grants from Alex's Lemonade Stand Foundation, St. Baldrick's Foundation, the Robert J. Kleberg and Helen C. Kleberg Foundation, and grant CA247833 from the NIH/NCI to W.P.T.	Alpsoy A, 2018, J BIOL CHEM, V293, P3892, DOI 10.1074/jbc.RA117.001065; Alver BH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14648; Boyer LA, 2004, NAT REV MOL CELL BIO, V5, P158, DOI 10.1038/nrm1314; Boyer LA, 2002, MOL CELL, V10, P935, DOI 10.1016/S1097-2765(02)00634-2; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101; Gadd S, 2010, LAB INVEST, V90, P724, DOI 10.1038/labinvest.2010.66; Gatchalian J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07528-9; Genovese G, 2017, NATURE, V542, P362, DOI 10.1038/nature21064; Hohmann AF, 2014, TRENDS GENET, V30, P356, DOI 10.1016/j.tig.2014.05.001; JI H, 2011, PLOS ONE, V6; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Mashtalir N, 2018, CELL, V175, P1272, DOI 10.1016/j.cell.2018.09.032; McBride MJ, 2018, CANCER CELL, V33, P1128, DOI 10.1016/j.ccell.2018.05.002; Michel BC, 2018, NAT CELL BIOL, V20, P1410, DOI 10.1038/s41556-018-0221-1; Mittal P, 2020, NAT REV CLIN ONCOL, V17, P435, DOI 10.1038/s41571-020-0357-3; Nabet B, 2018, NAT CHEM BIOL, V14, P431, DOI 10.1038/s41589-018-0021-8; Nakayama RT, 2017, NAT GENET, V49, P1613, DOI 10.1038/ng.3958; Orlando KA, 2020, ELIFE, V9, DOI 10.7554/eLife.59073; Pan J, 2019, NAT GENET, V51, P618, DOI 10.1038/s41588-019-0363-5; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reddy D, 2018, NAT CELL BIOL, V20, P1332, DOI 10.1038/s41556-018-0246-5; Shain AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055119; Sohn DH, 2007, J BIOL CHEM, V282, P10614, DOI 10.1074/jbc.M610563200; Stark R, 2011, R PACKAGE VERSION, V100, P4; Stojanova A, 2016, CELL CYCLE, V15, P1693, DOI 10.1080/15384101.2016.1146836; Tansey, 2015, OPEN ACCESS J SCI TE, V3, DOI [10.11131/2015/101124, DOI 10.11131/2015/101124]; Tansey W.P., 2014, NEW J SCI, V2014, P1; Thomas LR, 2016, ONCOGENE, V35, P3613, DOI 10.1038/onc.2015.416; Thomas LR, 2015, MOL CELL, V58, P440, DOI 10.1016/j.molcel.2015.02.028; Vierbuchen T, 2017, MOL CELL, V68, P1067, DOI 10.1016/j.molcel.2017.11.026; WANG J, 2018, BMC GENOMICS, V19; Wang L, 2014, CANCER CELL, V25, P21, DOI 10.1016/j.ccr.2013.12.007; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WANG XF, 2017, NAT GENET, V49, P289, DOI [DOI 10.1038/NG.3746, 10.1038/ng.3746]; Wang X, 2011, J CLIN INVEST, V121, P3834, DOI 10.1172/JCI37210; Wang XY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08657-5; Weissmiller AM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10022-5; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445	47	4	4	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3593	3609		10.1038/s41388-021-01804-7	http://dx.doi.org/10.1038/s41388-021-01804-7		APR 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33931740	Green Accepted			2022-12-28	WOS:000645887000004
J	Jung, HR; Oh, Y; Na, D; Min, S; Kang, J; Jang, D; Shin, S; Kim, J; Lee, SE; Jeong, EM; An, JY; Sung, CO; Lee, WS; Lee, C; Cho, SY				Jung, Hae Rim; Oh, Yumi; Na, Deukchae; Min, Seoyeon; Kang, Jinjoo; Jang, Dongjun; Shin, Seungjae; Kim, Jiwon; Lee, Sang Eun; Jeong, Eui Man; An, Joon Yong; Sung, Chang Ohk; Lee, Won-Suk; Lee, Charles; Cho, Sung-Yup			CRISPR screens identify a novel combination treatment targeting BCL-X-L and WNT signaling for KRAS/BRAF-mutated colorectal cancers	ONCOGENE			English	Article								Metastatic or recurrent colorectal cancer (CRC) patients require systemic chemotherapy, but the therapeutic options of targeted agents remain limited. CRC patients with KRAS or BRAF gene mutations exhibit a worse prognosis and are resistant to anti-EGFR treatment. Previous studies have shown that the expression of anti-apoptotic protein BCL-X-L is increased in CRC patients with KRAS/BRAF mutations, suggesting BCL-X-L as a therapeutic target for this subgroup. Here, we performed genome-wide CRISPR/Cas9 screens of cell lines with KRAS mutations to investigate the factors required for sensitivity to BCL-X-L inhibitor ABT-263 using single-guide RNAs (sgRNAs) that induce loss-of-function mutations. In the presence of ABT-263, sgRNAs targeting negative regulators of WNT signaling (resulting in WNT activation) were enriched, whereas sgRNAs targeting positive regulators of WNT signaling (resulting in WNT inhibition) were depleted in ABT-263-resistant cells. The activation of WNT signaling was highly associated with an increased expression ratio of anti- to pro-apoptotic BCL-2 family genes in CRC samples. Genetic and pharmacologic inhibition of WNT signaling using beta-catenin short hairpin RNA or TNIK inhibitor NCB-0846, respectively, augmented ABT-263-induced cell death in KRAS/BRAF-mutated cells. Inhibition of WNT signaling resulted in transcriptional repression of the anti-apoptotic BCL-2 family member, MCL1, via the functional inhibition of the beta-catenin-containing complex at the MCL1 promoter. In addition, the combination of ABT-263 and NCB-0846 exhibited synergistic effects in in vivo patient-derived xenograft (PDX) models with KRAS mutations. Our data provide a novel targeted combination treatment strategy for the CRC patient subgroup with KRAS or BRAF mutations.	[Jung, Hae Rim; Oh, Yumi] Seoul Natl Univ, Dept Biochem & Mol Biol, Coll Med, Seoul, South Korea; [Jung, Hae Rim; Oh, Yumi; Cho, Sung-Yup] Seoul Natl Univ, Med Res Ctr, Genom Med Inst, Coll Med, Seoul, South Korea; [Na, Deukchae] Ewha Womans Univ, Ewha Inst Convergence Med, Mokdong Hosp, Seoul, South Korea; [Min, Seoyeon; Kang, Jinjoo; Lee, Charles] Ewha Womans Univ, Dept Life Sci, Seoul, South Korea; [Jang, Dongjun; Shin, Seungjae; Kim, Jiwon; Lee, Sang Eun; Cho, Sung-Yup] Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul, South Korea; [Jeong, Eui Man] Jeju Natl Univ, Coll Pharm, Dept Pharm, Jeju City, Jeju Special Se, South Korea; [Jeong, Eui Man] Jeju Natl Univ, Interdisciplinary Grad Program Adv Convergence Te, Jeju City, Jeju Special Se, South Korea; [Jeong, Eui Man] Jeju Natl Univ, Biohlth Mat Core Facil Ctr, Jeju City, Jeju Special Se, South Korea; [Jeong, Eui Man] Jeju Natl Univ, Pract Translat Res Ctr, Jeju City, Jeju Special Se, South Korea; [An, Joon Yong] Korea Univ, Coll Hlth Sci, Sch Biosyst & Biomed Sci, Seoul, South Korea; [Sung, Chang Ohk] Univ Ulsan, Asan Med Ctr, Dept Pathol, Coll Med, Seoul, South Korea; [Lee, Won-Suk] Gachon Univ, Gil Med Ctr, Dept Surg, Incheon, South Korea; [Lee, Charles] Jackson Lab Genom Med, Farmington, CT USA; [Cho, Sung-Yup] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Ewha Womans University; Ewha Womans University; Seoul National University (SNU); Jeju National University; Jeju National University; Jeju National University; Jeju National University; Korea University; University of Ulsan; Asan Medical Center; Gachon University; Jackson Laboratory; Seoul National University (SNU)	Cho, SY (corresponding author), Seoul Natl Univ, Med Res Ctr, Genom Med Inst, Coll Med, Seoul, South Korea.; Cho, SY (corresponding author), Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul, South Korea.; Cho, SY (corresponding author), Seoul Natl Univ, Canc Res Inst, Seoul, South Korea.	csybio@snu.ac.kr		Sung, Chang Ohk/0000-0002-8567-456X; An, Joon-Yong/0000-0001-8839-6297	National Research Foundation of Korea (NRF) - Korea government (MSIP) [2017R1C1B2002183]; Bio & Medical Technology Development Program of the NRF - Ministry of Science ICT [2018M3A9F3056902, 2019M3E5D4066900]; Creative-Pioneering Researchers Program through Seoul National University [800-20200510]; Collaborative Research Program of SNU Boramae Medical Center [800-20200005]; Basic Medical Science from Seoul National University College of Medicine [800-20200005]	National Research Foundation of Korea (NRF) - Korea government (MSIP); Bio & Medical Technology Development Program of the NRF - Ministry of Science ICT; Creative-Pioneering Researchers Program through Seoul National University; Collaborative Research Program of SNU Boramae Medical Center; Basic Medical Science from Seoul National University College of Medicine	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (grant No. 2017R1C1B2002183); the Bio & Medical Technology Development Program of the NRF funded by the Ministry of Science & ICT (grant No. 2018M3A9F3056902 and 2019M3E5D4066900); Creative-Pioneering Researchers Program through Seoul National University (grant No. 800-20200510); and the Collaborative Research Program of SNU Boramae Medical Center and Basic Medical Science from Seoul National University College of Medicine (grant No. 800-20200005).	Bendell J, 2018, ANN ONCOL, V29, P123, DOI 10.1093/annonc/mdy208.003; Billard C, 2013, MOL CANCER THER, V12, P1691, DOI 10.1158/1535-7163.MCT-13-0058; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Booy EP, 2011, ONCOGENE, V30, P2367, DOI 10.1038/onc.2010.616; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cho SY, 2017, MOL CANCER THER, V16, P2178, DOI 10.1158/1535-7163.MCT-16-0735; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Croce CM, 2016, CANCER RES, V76, P5914, DOI 10.1158/0008-5472.CAN-16-1248; DeStefanis RA, 2019, CURR COLORECT CANC R, V15, P61, DOI 10.1007/s11888-019-00430-6; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Eguchi M, 2005, MED CHEM, V1, P467, DOI 10.2174/1573406054864098; Faber AC, 2014, CANCER DISCOV, V4, P42, DOI 10.1158/2159-8290.CD-13-0315; Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gui JH, 2011, HUM CELL, V24, P121, DOI 10.1007/s13577-011-0023-2; Halilovic E, 2010, CANCER RES, V70, P6804, DOI 10.1158/0008-5472.CAN-10-0409; Herbst A, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-74; Ho SY, 2015, BIOORG MED CHEM LETT, V25, P5472, DOI 10.1016/j.bmcl.2015.10.032; Hoeflich KP, 2012, CANCER RES, V72, P210, DOI 10.1158/0008-5472.CAN-11-1515; Holt SV, 2012, CANCER RES, V72, P1804, DOI 10.1158/0008-5472.CAN-11-1780; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016; Jung YS, 2020, EXP MOL MED, V52, P183, DOI 10.1038/s12276-020-0380-6; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Krishnamurthy N, 2018, CANCER TREAT REV, V62, P50, DOI 10.1016/j.ctrv.2017.11.002; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Martini G, 2017, WORLD J GASTROENTERO, V23, P4675, DOI 10.3748/wjg.v23.i26.4675; Masuda M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12586; McBride A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00192; Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Phipps AI, 2015, GASTROENTEROLOGY, V148, P77, DOI 10.1053/j.gastro.2014.09.038; Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171; Schuijers J, 2015, CELL STEM CELL, V16, P158, DOI 10.1016/j.stem.2014.12.006; Senichkin VV, 2019, TRENDS CELL BIOL, V29, P549, DOI 10.1016/j.tcb.2019.03.004; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shitashige M, 2010, CANCER RES, V70, P5024, DOI 10.1158/0008-5472.CAN-10-0306; Shkoda A, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001376; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Wang BB, 2019, NAT PROTOC, V14, P756, DOI 10.1038/s41596-018-0113-7; Wang L, 2020, ACS MED CHEM LETT, V11, P1829, DOI 10.1021/acsmedchemlett.9b00568; Yeung P., 2014, CANCER RES, V74, pS1907; Yoshida N, 2015, ANTICANCER RES, V35, P4403; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304	49	5	5	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3287	3302		10.1038/s41388-021-01777-7	http://dx.doi.org/10.1038/s41388-021-01777-7		APR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33846570				2022-12-28	WOS:000639635100005
J	Cheng, C; Pei, XF; Li, SW; Yang, J; Li, CX; Tang, JJ; Hu, KS; Huang, GF; Min, WP; Sang, Y				Cheng, Chun; Pei, Xiaofeng; Li, Si-Wei; Yang, Jun; Li, Chenxi; Tang, Jianjun; Hu, Kaishun; Huang, Guofu; Min, Wei-Ping; Sang, Yi			CRISPR/Cas9 library screening uncovered methylated PKP2 as a critical driver of lung cancer radioresistance by stabilizing beta-catenin	ONCOGENE			English	Article								Radiation resistance is a major cause of lung cancer treatment failure. Armadillo (ARM) superfamily proteins participate in various fundamental cellular processes; however, whether ARM proteins regulate radiation resistance is not fully understood. Here, we used an unbiased CRISPR/Cas9 library screen and identified plakophilin 2 (PKP2), a member of the ARM superfamily of proteins, as a critical driver of radiation resistance in lung cancer. The PKP2 level was significantly higher after radiotherapy than before radiotherapy, and high PKP2 expression after radiotherapy predicted poor overall survival (OS) and postprogression survival (PPS). Mechanistically, mass spectrometry analysis identified that PKP2 was methylated at the arginine site and interacted with protein arginine methyltransferase 1 (PRMT1). Methylation of PKP2 by PRMT1 stabilized beta-catenin by recruiting USP7, further inducing LIG4, a key DNA ligase in nonhomologous end-joining (NHEJ) repair. Concomitantly, PKP2-induced radioresistance depended on facilitating LIG4-mediated NHEJ repair in lung cancer. More strikingly, after exposure to irradiation, treatment with the PRMT1 inhibitor C-7280948 abolished PKP2-induced radioresistance, and C-7280948 is a potential radiosensitizer in lung cancer. In summary, our results demonstrate that targeting the PRMT1/PKP2/beta-catenin/LIG4 pathway is an effective approach to overcome radiation resistance in lung cancer.	[Cheng, Chun; Yang, Jun; Li, Chenxi; Huang, Guofu; Sang, Yi] Nanchang Univ, Affiliated Hosp 3, Dept Ctr Lab, Jiangxi Key Lab Canc Metastasis & Precis Treatmen, Nanchang, Jiangxi, Peoples R China; [Pei, Xiaofeng] Sun Yat Sen Univ, Canc Ctr, Affiliated Hosp 5, Dept Thorac Oncol, Zhuhai, Guangdong, Peoples R China; [Li, Si-Wei] Huazhong Univ Sci & Technol, Dept Oncol, Tongji Huangzhou Hosp, Wuhan, Hubei, Peoples R China; [Tang, Jianjun] Nanchang Univ, Dept Resp, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China; [Hu, Kaishun] Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Med Res Ctr, Sun Yat Sen Mem Hosp, Guangzhou, Guangdong, Peoples R China; [Min, Wei-Ping] Univ Western Ontario, Dept Surg Pathol & Oncol, London, ON, Canada	Nanchang University; Sun Yat Sen University; Huazhong University of Science & Technology; Nanchang University; Sun Yat Sen University; Western University (University of Western Ontario)	Sang, Y (corresponding author), Nanchang Univ, Affiliated Hosp 3, Dept Ctr Lab, Jiangxi Key Lab Canc Metastasis & Precis Treatmen, Nanchang, Jiangxi, Peoples R China.	ndsfy001889@ncu.edu.cn		Hu, Kaishun/0000-0003-2157-6239; Sang, Yi/0000-0001-6534-0741	special fund for Jiangxi Key Laboratory [20171BCD40026]; Jiangxi Provincial Natural Science Foundation of China [20192BAB215039]; Natural Science Foundation of China [81772821]	special fund for Jiangxi Key Laboratory; Jiangxi Provincial Natural Science Foundation of China; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from the special fund for Jiangxi Key Laboratory (20171BCD40026 to YS), the Jiangxi Provincial Natural Science Foundation of China (20192BAB215039 to YS) and the Natural Science Foundation of China (81772821 to KH).	Adams MM, 2005, CELL CYCLE, V4, P1854, DOI 10.4161/cc.4.12.2282; Arimoto K, 2014, MOL CELL BIOL, V34, P3843, DOI 10.1128/MCB.00758-14; Biau J, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01009; Blanc RS, 2017, MOL CELL, V65, P8, DOI 10.1016/j.molcel.2016.11.003; Boisvert FM, 2005, CELL CYCLE, V4, P1834, DOI 10.4161/cc.4.12.2250; Chang JY, 2013, CANCER-AM CANCER SOC, V119, P3402, DOI 10.1002/cncr.28217; Chen DJ, 2007, CLIN CANCER RES, V13, P6555, DOI 10.1158/1078-0432.CCR-07-1610; Chen XY, 2002, J BIOL CHEM, V277, P10512, DOI 10.1074/jbc.M108765200; Coates JC, 2003, TRENDS CELL BIOL, V13, P463, DOI 10.1016/S0962-8924(03)00167-3; Coon D, 2008, CLIN LUNG CANCER, V9, P217, DOI 10.3816/CLC.2008.n.032; Demirag GG, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-1; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Dubash AD, 2016, J CELL BIOL, V212, P425, DOI 10.1083/jcb.201507018; Fischer-Keso R, 2014, MOL CELL BIOL, V34, P4244, DOI 10.1128/MCB.00766-14; Gul IS, 2017, CELL MOL LIFE SCI, V74, P525, DOI 10.1007/s00018-016-2319-6; Hao XL, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152438; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Hsu JHR, 2017, CANCER RES, V77, P4613, DOI 10.1158/0008-5472.CAN-17-0216; Jeong YK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030871; Jun S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10994; Kanamoto T, 2002, EMBO J, V21, P1219, DOI 10.1093/emboj/21.5.1219; Kim BH, 2020, CLIN CANCER RES, V26, P265, DOI 10.1158/1078-0432.CCR-19-0610; Kim MR, 2015, MOL CANCER RES, V13, P319, DOI 10.1158/1541-7786.MCR-14-0098-T; Laird JH, 2018, CLIN CANCER RES, V24, P5143, DOI 10.1158/1078-0432.CCR-18-0401; Lee SY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0577-4; Li D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05286-2; Martin-Padron J, 2020, ONCOGENE, V39, P5479, DOI 10.1038/s41388-019-1129-3; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; Montenegro MF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.85; Montenegro MF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70289-3; Nanavaty P, 2014, CANCER CONTROL, V21, P9, DOI 10.1177/107327481402100102; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Niell N, 2018, INT J CANCER, V142, P792, DOI 10.1002/ijc.31104; Novellasdemunt L, 2017, CELL REP, V21, P612, DOI 10.1016/j.celrep.2017.09.072; Rubin SM, 2019, NATURE, V569, P343, DOI 10.1038/d41586-019-01319-y; SEOL JH, 2018, MUTAT RES-FUND MOL M, V809, P81, DOI DOI 10.1016/J.MRFMMM.2017.07.002; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Su DX, 2018, J CLIN INVEST, V128, P4280, DOI 10.1172/JCI120518; Suchankova J, 2014, EUR J HISTOCHEM, V58, P1, DOI 10.4081/ejh.2014.2389; Takahashi H, 2012, UROLOGY, V79, DOI 10.1016/j.urology.2011.08.049; Tewari R, 2010, TRENDS CELL BIOL, V20, P470, DOI 10.1016/j.tcb.2010.05.003; Vadnais C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03817-5; Vartak SV, 2018, FEBS J, V285, P3959, DOI 10.1111/febs.14661; Wang Y, 2016, FEBS LETT, V590, P4586, DOI 10.1002/1873-3468.12485; Williams GJ, 2014, DNA REPAIR, V17, P110, DOI 10.1016/j.dnarep.2014.02.009; Wu CYJ, 2020, NEURO-ONCOLOGY, V22, P253, DOI 10.1093/neuonc/noz189; Wu CT, 2015, J MOL MED, V93, P73, DOI 10.1007/s00109-014-1206-6; Yang JH, 2014, NUCLEIC ACIDS RES, V42, P9908, DOI 10.1093/nar/gku705; Zhan TZ, 2019, SEMIN CANCER BIOL, V55, P106, DOI 10.1016/j.semcancer.2018.04.001; Zhang BL, 2019, ACTA BIOCH BIOPH SIN, V51, P375, DOI 10.1093/abbs/gmz015; Zhang DP, 2017, NEUROPATHOLOGY, V37, P207, DOI 10.1111/neup.12363; Zhou WQ, 2019, ONCOTARGETS THER, V12, P8275, DOI 10.2147/OTT.S220536	52	7	7	3	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2842	2857		10.1038/s41388-021-01692-x	http://dx.doi.org/10.1038/s41388-021-01692-x		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742119				2022-12-28	WOS:000630675000003
J	Jalalirad, M; Haddad, TC; Salisbury, JL; Radisky, D; Zhang, MZ; Schroeder, M; Tuma, A; Leof, E; Carter, JM; Degnim, AC; Boughey, JC; Sarkaria, J; Yu, J; Wang, LW; Liu, MC; Zammataro, L; Malatino, L; Galanis, E; Ingle, JN; Goetz, MP; D'Assoro, AB				Jalalirad, Mohammad; Haddad, Tufia C.; Salisbury, Jeffrey L.; Radisky, Derek; Zhang, Minzhi; Schroeder, Mark; Tuma, Ann; Leof, Eduard; Carter, Jodi M.; Degnim, Amy C.; Boughey, Judy C.; Sarkaria, Jann; Yu, Jia; Wang, Liewei; Liu, Minetta C.; Zammataro, Luca; Malatino, Lorenzo; Galanis, Evanthia; Ingle, James N.; Goetz, Matthew P.; D'Assoro, Antonino B.			Aurora-A kinase oncogenic signaling mediates TGF-beta-induced triple-negative breast cancer plasticity and chemoresistance	ONCOGENE			English	Article								Triple-negative breast cancer (TNBCs) account for 15-20% of all breast cancers and represent the most aggressive subtype of this malignancy. Early tumor relapse and progression are linked to the enrichment of a sub-fraction of cancer cells, termed breast tumor-initiating cells (BTICs), that undergo epithelial to mesenchymal transition (EMT) and typically exhibit a basal-like CD44(high)/CD24(low) and/or ALDH1(high) phenotype with critical cancer stem-like features such as high self-renewal capacity and intrinsic (de novo) resistance to standard of care chemotherapy. One of the major mechanisms responsible for the intrinsic drug resistance of BTICs is their high ALDH1 activity leading to inhibition of chemotherapy-induced apoptosis. In this study, we demonstrated that aurora-A kinase (AURKA) is required to mediate TGF-beta-induced expression of the SNAI1 gene, enrichment of ALDH1(high) BTICs, self-renewal capacity, and chemoresistance in TNBC experimental models. Significantly, the combination of docetaxel (DTX) with dual TGF-beta and AURKA pharmacologic targeting impaired tumor relapse and the emergence of distant metastasis. We also showed in unique chemoresistant TNBC cells isolated from patient-derived TNBC brain metastasis that dual TGF-beta and AURKA pharmacologic targeting reversed cancer plasticity and enhanced the sensitivity of TNBC cells to DTX-based-chemotherapy. Taken together, these findings reveal for the first time the critical role of AURKA oncogenic signaling in mediating TGF-beta-induced TNBC plasticity, chemoresistance, and tumor progression.	[Jalalirad, Mohammad; Haddad, Tufia C.; Zhang, Minzhi; Yu, Jia; Wang, Liewei; Liu, Minetta C.; Galanis, Evanthia; Ingle, James N.; Goetz, Matthew P.; D'Assoro, Antonino B.] Mayo Clin, Dept Oncol, Coll Med, Rochester, MN 55905 USA; [Salisbury, Jeffrey L.; Radisky, Derek; Leof, Eduard] Mayo Clin, Dept Biochem & Mol Biol, Coll Med, Rochester, MN USA; [Schroeder, Mark; Tuma, Ann; Sarkaria, Jann] Mayo Clin, Dept Radiat Oncol, Coll Med, Rochester, MN USA; [Carter, Jodi M.; Liu, Minetta C.] Mayo Clin, Dept Lab Med & Pathol, Coll Med, Rochester, MN USA; [Degnim, Amy C.; Boughey, Judy C.] Mayo Clin, Dept Surg, Coll Med, Rochester, MN USA; [Zammataro, Luca] Yale Univ, Dept Oncol, New Heaven, CT USA; [Malatino, Lorenzo] Univ Catania, Dept Clin & Expt Med, Catania, Italy; [Galanis, Evanthia] Mayo Clin, Dept Mol Med, Coll Med, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Yale University; University of Catania; Mayo Clinic	D'Assoro, AB (corresponding author), Mayo Clin, Dept Oncol, Coll Med, Rochester, MN 55905 USA.	dassoro.antonio@mayo.edu	Malatino, Lorenzo/I-7319-2018	Malatino, Lorenzo/0000-0003-2944-2729; Carter, Jodi/0000-0002-5973-0732	Intramural RECDA; Nan Sawyer Award; Randy Shaver Cancer Research and Community Fund; Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE) NIH [CA116201]; Mayo Clinic Breast Cancer SPORE NIH [CA116201]; Prospect Creek Foundation; Mayo Clinic Comprehensive Cancer Center;  [NCI-CA214893];  [NCI-CA72836]	Intramural RECDA; Nan Sawyer Award; Randy Shaver Cancer Research and Community Fund; Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE) NIH; Mayo Clinic Breast Cancer SPORE NIH; Prospect Creek Foundation; Mayo Clinic Comprehensive Cancer Center; ; 	This study was supported by Intramural RECDA, The Nan Sawyer Award, the Randy Shaver Cancer Research and Community Fund, the Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE) NIH CA116201 Developmental Research Program, and NCI-CA214893 to ABD, NCI-CA72836 to JLS, the Mayo Clinic Breast Cancer SPORE NIH CA116201 to JI and MG, the Prospect Creek Foundation to EG, and the Mayo Clinic Comprehensive Cancer Center.	Ahmad A, 2019, ADV EXP MED BIOL, V1152, P1, DOI 10.1007/978-3-030-20301-6_1; Alamgeer M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3648; Ascolani G, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004199; Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Bierie B, 2008, CANCER RES, V68, P1809, DOI 10.1158/0008-5472.CAN-07-5597; Boss DS, 2009, ONCOLOGIST, V14, P780, DOI 10.1634/theoncologist.2009-0019; Cammareri P, 2010, CANCER RES, V70, P4655, DOI 10.1158/0008-5472.CAN-09-3953; Chiorean R, 2013, BREAST, V22, P1026, DOI 10.1016/j.breast.2013.08.007; Connolly EC, 2011, CANCER RES, V71, P2339, DOI 10.1158/0008-5472.CAN-10-2941; D'Assoro AB, 2014, ONCOGENE, V33, P599, DOI 10.1038/onc.2012.628; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; D'Assoro AB, 2016, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00295; Daly AC, 2008, MOL CELL BIOL, V28, P6889, DOI 10.1128/MCB.01192-08; de Carcer G, 2014, NAT CELL BIOL, V16, P504, DOI 10.1038/ncb2978; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; Goepfert TM, 2007, INT J CANCER, V120, P985, DOI 10.1002/ijc.22420; Haddad TC, 2018, BREAST CANCER RES TR, V168, P639, DOI 10.1007/s10549-017-4616-7; Huddle BC, 2018, J MED CHEM, V61, P8754, DOI 10.1021/acs.jmedchem.8b00930; Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377; Jiang HL, 2015, ONCOTARGET, V6, P16352, DOI 10.18632/oncotarget.3877; Karicheva O, 2016, ONCOTARGET, V7, P64109, DOI 10.18632/oncotarget.11627; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Lee YY, 2012, CANCER RES, V72, DOI [10.1158/1538-7445.AM2012-4651, 10.1158/0008-5472.CAN-12-2397]; Leontovich AA, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1020-0; Leontovich AA, 2013, ONCOL REP, V29, P1785, DOI 10.3892/or.2013.2313; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lyons TG, 2019, ADV EXP MED BIOL, V1152, P377, DOI 10.1007/978-3-030-20301-6_20; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Moreira MP, 2018, EXP CELL RES, V363, P283, DOI 10.1016/j.yexcr.2018.01.018; Motomura H, 2020, ANTICANCER RES, V40, P35, DOI 10.21873/anticanres.13924; Ohmine S, 2018, ONCOL REP, V39, P1725, DOI 10.3892/or.2018.6239; Opyrchal M, 2017, ONCOTARGET, V8, P91803, DOI 10.18632/oncotarget.20610; Opyrchal M, 2014, INT J ONCOL, V45, P1193, DOI 10.3892/ijo.2014.2523; Pandy JGP, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6253-5; Perera M., 2010, Cancer Genomics & Proteomics, V7, P217; Shionome Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055457; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Siggelkow W, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-562; Smith AL, 2012, CLIN CANCER RES, V18, P4514, DOI 10.1158/1078-0432.CCR-11-3224; Sridharan S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01311; Staff S, 2010, ONCOL REP, V23, P307, DOI 10.3892/or_00000637; Szasz AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056707; Tan AR, 2009, BREAST CANCER RES TR, V115, P453, DOI 10.1007/s10549-008-0184-1; Taylor MA, 2011, GENE EXPRESSION, V15, P117, DOI 10.3727/105221611X13176664479322; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wahdan-Alaswad R, 2016, CELL CYCLE, V15, P1046, DOI 10.1080/15384101.2016.1152432; Yagata H, 2011, BREAST CANCER-TOKYO, V18, P165, DOI 10.1007/s12282-011-0254-9; Yang G, 2013, INT J CANCER, V133, P275, DOI 10.1002/ijc.28032; Zhang L, 2013, MOL CELL, V51, P559, DOI 10.1016/j.molcel.2013.07.014; Zheng FM, 2014, MOL CANCER THER, V13, P1991, DOI 10.1158/1535-7163.MCT-13-1029	52	15	15	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2509	2523		10.1038/s41388-021-01711-x	http://dx.doi.org/10.1038/s41388-021-01711-x		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33674749	Green Published, hybrid			2022-12-28	WOS:000625607100005
J	Galbraith, LCA; Mui, E; Nixon, C; Hedley, A; Strachan, D; MacKay, G; Sumpton, D; Sansom, OJ; Leung, HY; Ahmad, I				Galbraith, Laura C. A.; Mui, Ernest; Nixon, Colin; Hedley, Ann; Strachan, David; MacKay, Gillian; Sumpton, David; Sansom, Owen J.; Leung, Hing Y.; Ahmad, Imran			PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer	ONCOGENE			English	Article								Peroxisome Proliferator-Activated Receptor Gamma (PPARG) is one of the three members of the PPAR family of transcription factors. Besides its roles in adipocyte differentiation and lipid metabolism, we recently demonstrated an association between PPARG and metastasis in prostate cancer. In this study a functional effect of PPARG on AKT serine/threonine kinase 3 (AKT3), which ultimately results in a more aggressive disease phenotype was identified. AKT3 has previously been shown to regulate PPARG co-activator 1 alpha (PGC1 alpha) localisation and function through its action on chromosome maintenance region 1 (CRM1). AKT3 promotes PGC1 alpha localisation to the nucleus through its inhibitory effects on CRM1, a known nuclear export protein. Collectively our results demonstrate how PPARG over-expression drives an increase in AKT3 levels, which in turn has the downstream effect of increasing PGC1 alpha localisation within the nucleus, driving mitochondrial biogenesis. Furthermore, this increase in mitochondrial mass provides higher energetic output in the form of elevated ATP levels which may fuel the progression of the tumour cell through epithelial to mesenchymal transition (EMT) and ultimately metastasis.	[Galbraith, Laura C. A.; Mui, Ernest; Nixon, Colin; Hedley, Ann; Strachan, David; MacKay, Gillian; Sumpton, David; Sansom, Owen J.; Leung, Hing Y.; Ahmad, Imran] Canc Res UK Beatson Inst, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland; [Galbraith, Laura C. A.; Sansom, Owen J.; Leung, Hing Y.; Ahmad, Imran] Univ Glasgow, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland	Beatson Institute; University of Glasgow	Ahmad, I (corresponding author), Canc Res UK Beatson Inst, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.; Ahmad, I (corresponding author), Univ Glasgow, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland.	imran.ahmad@glasgow.ac.uk	Ahmad, Imran/GRJ-0536-2022	Galbraith, Laura/0000-0002-1396-4226; Sumpton, David/0000-0002-9004-4079; Sansom, Owen J./0000-0001-9540-3010; Ahmad, Imran/0000-0002-4404-1926; Leung, Hing Y./0000-0002-3933-3975	Cancer Research UK Clinician Scientist Fellowship award [C49745/A19661]; CRUK core award [A17196]	Cancer Research UK Clinician Scientist Fellowship award; CRUK core award	This work was supported by Cancer Research UK Clinician Scientist Fellowship award to (C49745/A19661; IA) and CRUK core award to CRUK Beatson Institute A17196 (OJS, CN, AH, DS, DS, & GM).	Ahmad I, 2016, P NATL ACAD SCI USA, V113, P8290, DOI 10.1073/pnas.1601571113; BHALLA K, 2011, BBA-MOL CELL BIOL L, V71, P6888; Brunmeir R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061738; Burns KA, 2007, BBA-MOL CELL BIOL L, V1771, P952, DOI 10.1016/j.bbalip.2007.04.018; CHURCH D, 2011, GENOME BIOL, V9; Corum DG, 2014, FASEB J, V28, P395, DOI 10.1096/fj.13-235382; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Ding LA, 2017, J BIOL CHEM, V292, P9283, DOI 10.1074/jbc.M116.773739; Ding L, 2012, CELL METAB, V15, P861, DOI 10.1016/j.cmet.2012.04.020; Fan WW, 2015, CURR OPIN CELL BIOL, V33, P49, DOI 10.1016/j.ceb.2014.11.002; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fernandez-Marcos PJ, 2011, AM J CLIN NUTR, V93, p884S, DOI 10.3945/ajcn.110.001917; FISHER S, 2011, FASEB J, V12; Floyd ZE, 2012, BBA-MOL BASIS DIS, V1822, P1090, DOI 10.1016/j.bbadis.2012.03.014; FORNEROD M, 1997, BBA-REV CANCER, V16, P807; Galbraith L, 2018, PHARMACOL RES, V131, P177, DOI 10.1016/j.phrs.2018.02.022; Geiger TR, 2009, BBA-REV CANCER, V1796, P293, DOI 10.1016/j.bbcan.2009.07.006; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Huggins C, 1941, CANCER RES, V1, P293; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Kaminski L, 2019, CANCER RES, V79, P3268, DOI 10.1158/0008-5472.CAN-18-2043; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim M, 2016, ACTA BIOCH BIOPH SIN, V48, P447, DOI 10.1093/abbs/gmw014; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; LOVE M, 2014, NAT METHODS, V15; Madhunapantula SV, 2009, PIGM CELL MELANOMA R, V22, P400, DOI 10.1111/j.1755-148X.2009.00585.x; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; March HN, 2011, NAT GENET, V43, P1202, DOI 10.1038/ng.990; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Phung TL, 2015, CANCER RES, V75, P40, DOI 10.1158/0008-5472.CAN-13-2961; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; PUIGSERVER P, 1998, AM J CLIN NUTR, V92, P829; Siegel R., 2015, CA-CANCER J CLIN, V65, P29, DOI [10.3322/caac.21254, DOI 10.3322/CAAC.21254, DOI 10.3322/caac.21208]; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Torrano V, 2016, NAT CELL BIOL, V18, P645, DOI 10.1038/ncb3357; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wright GL, 2008, FASEB J, V22, P3264, DOI 10.1096/fj.08-106468; WU Z, 1999, NAT GENET, V98, P115; Wu ZG, 2013, J CELL SCI, V126, P3417, DOI 10.1242/jcs.126854; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	41	22	22	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2355	2366		10.1038/s41388-021-01707-7	http://dx.doi.org/10.1038/s41388-021-01707-7		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33654198	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000624398900005
J	Butti, R; Nimma, R; Kundu, G; Bulbule, A; Kumar, TVS; Gunasekaran, VP; Tomar, D; Kumar, D; Mane, A; Gill, SS; Patil, T; Weber, GF; Kundu, GC				Butti, Ramesh; Nimma, Ramakrishna; Kundu, Gautam; Bulbule, Anuradha; Kumar, Totakura V. S.; Gunasekaran, Vinoth Prasanna; Tomar, Deepti; Kumar, Dhiraj; Mane, Anupama; Gill, Satyajit S.; Patil, Tushar; Weber, Georg F.; Kundu, Gopal C.			Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression	ONCOGENE			English	Article								Tumor-stroma interactions are important determinants for the disease course in cancer. While stromal influence has been known to often play a tumor-promoting role, incomplete mechanistic insight into this phenomenon has prevented its therapeutic targeting. Stromal fibroblasts can be activated by tumor cells to differentiate into cancer-associated fibroblasts (CAFs), that exhibit the traits of myofibroblasts, and in turn, they increase cancer aggressiveness. Here, we report the crosstalk between the cancer cells and stromal fibroblasts that leads to tumor progression. The process is initiated by secretion of a chemokine like protein, osteopontin (OPN) from the cancer cells that differentiates the fibroblasts to myofibroblasts. Tumor-derived OPN achieves this transition by engaging CD44 and alpha v beta 3 integrins on the fibroblast surface, which mediates signaling via Akt and ERK to induce Twist1-dependent gene expression. The OPN-driven CAFs then secrete CXCL12, which in turn triggers epithelial to mesenchymal transition (EMT) in the tumor cells. OPN, produced by the cancer cells, and CXCL12, secreted by activated fibroblasts, are necessary and sufficient to perpetuate the crosstalk. Knocking out OPN in carcinogen-induced mammary tumors or knocking down OPN in cancer cells and fibroblast co-implanted xenografts abrogates myofibroblast differentiation, Twist1, and CXCL12 expression. OPN expression is correlated with CAF-specific gene signature as shown by breast tumor tissue microarray consisting of 100 patient specimens. Bioinformatics analyses have confirmed that the expression of OPN is significantly correlated with the expression of myofibroblast-specific markers as demonstrated in human breast carcinoma dataset of 2509 patients. Our findings describe OPN and CXCL12 act as compelling targets to curb the tumor-promoting features of the stromal components and further suggested that OPN-regulated CXCL12 network might act as potential therapeutic target for the management of CAF-mediated breast cancer progression.	[Butti, Ramesh; Nimma, Ramakrishna; Bulbule, Anuradha; Kumar, Totakura V. S.; Gunasekaran, Vinoth Prasanna; Tomar, Deepti; Kundu, Gopal C.] Natl Ctr Cell Sci, Pune, Maharashtra, India; [Kundu, Gautam] NIA, Baltimore, MD 21224 USA; [Mane, Anupama; Gill, Satyajit S.] Jehangir Hosp, Pune, Maharashtra, India; [Patil, Tushar] Yashwantrao Chavan Mem Hosp, Pune, Maharashtra, India; [Weber, Georg F.] Univ Cincinnati, Cincinnati, OH USA; [Kundu, Gopal C.] KIIT Deemed Univ, Inst Eminence, Sch Biotechnol, Bhubaneswar, Odisha, India; [Kundu, Gopal C.] KIIT Deemed Univ, Inst Eminence, Kalinga Inst Med Sci KIMS, Bhubaneswar, Odisha, India; [Kumar, Dhiraj] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Ohio; University of Cincinnati; Kalinga Institute of Industrial Technology (KIIT); Kalinga Institute of Industrial Technology (KIIT); University of Texas System; UTMD Anderson Cancer Center	Kundu, GC (corresponding author), Natl Ctr Cell Sci, Pune, Maharashtra, India.; Kundu, GC (corresponding author), KIIT Deemed Univ, Inst Eminence, Sch Biotechnol, Bhubaneswar, Odisha, India.; Kundu, GC (corresponding author), KIIT Deemed Univ, Inst Eminence, Kalinga Inst Med Sci KIMS, Bhubaneswar, Odisha, India.	gopalc.kundu@kiit.ac.in	Kumar, Dhiraj/AAJ-6305-2020; Butti, Ramesh/ABF-7762-2021	Kumar, Dhiraj/0000-0002-6085-5911; Gunasekaran, Vinoth prasanna/0000-0001-5610-0770	National Centre for Cell Science, Pune, India; Council of Scientific and Industrial Research (CSIR), Govt. of India; Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Govt. of India; Intramural Research Program of the NIH, National Institute of Ageing	National Centre for Cell Science, Pune, India; Council of Scientific and Industrial Research (CSIR), Govt. of India(Council of Scientific & Industrial Research (CSIR) - India); Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Govt. of India; Intramural Research Program of the NIH, National Institute of Ageing	This work was primarily supported by National Centre for Cell Science, Pune, India (to GCK). RB, RN, and DT were supported by Council of Scientific and Industrial Research (CSIR), Govt. of India. VPG is supported by Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Govt. of India. This research was supported in part by the Intramural Research Program of the NIH, National Institute of Ageing.	Avgustinova A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10305; Bandopadhyay M, 2014, EXPERT OPIN THER TAR, V18, P883, DOI 10.1517/14728222.2014.925447; Belev B, 2012, PERIOD BIOL, V114, P511; Bossung V, 2010, CURR OPIN OBSTET GYN, V22, P79, DOI 10.1097/GCO.0b013e328334e462; Bremnes RM, 2011, J THORAC ONCOL, V6, P209, DOI 10.1097/JTO.0b013e3181f8a1bd; Butti R, 2015, MULTITARGETED APPROA, P113; Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756; Cao HM, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090985; Castello LM, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/4049098; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Chakraborty G, 2008, J CELL MOL MED, V12, P2305, DOI 10.1111/j.1582-4934.2008.00263.x; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Das S, 2013, J BIOL CHEM, V288, P11824, DOI 10.1074/jbc.M112.432302; Dine J, 2017, ASIA-PAC J ONCOL NUR, V4, P127, DOI 10.4103/apjon.apjon_4_17; Dong CY, 2014, STEM CELLS, V32, P3173, DOI 10.1002/stem.1803; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Graessmann M, 2007, ONCOGENE, V26, P2840, DOI 10.1038/sj.onc.1210096; Hellerstedt BA, 2002, CA-CANCER J CLIN, V52, P154, DOI 10.3322/canjclin.52.3.154; Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181; Johnson GA, 2003, BIOL REPROD, V69, P1458, DOI 10.1095/biolreprod.103.020651; Kale S, 2014, ONCOGENE, V33, P2295, DOI 10.1038/onc.2013.184; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Klement JD, 2018, J CLIN INVEST, V128, P5549, DOI 10.1172/JCI123360; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Kothari AN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5040039; Kumar D, 2016, J INVEST DERMATOL, V136, P2462, DOI 10.1016/j.jid.2016.07.024; Kumar S, 2012, CURR MOL MED, V12, P952, DOI 10.2174/156652412802480826; Kumar V, 2010, CANCER RES, V70, P10381, DOI 10.1158/0008-5472.CAN-10-1470; Kuo PC, 2015, J AM COLL SURGEONS, V221, P642; Lee KW, 2015, CANCER RES, V75, P73, DOI 10.1158/0008-5472.CAN-14-0350; Lenga Y, 2008, CIRC RES, V102, P319, DOI 10.1161/CIRCRESAHA.107.160408; Madar S, 2013, TRENDS MOL MED, V19, P447, DOI 10.1016/j.molmed.2013.05.004; Martin MA, 2005, STEM CELLS DEV, V14, P493, DOI 10.1089/scd.2005.14.493; McCarthy JB, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00048; Mi ZY, 2011, CARCINOGENESIS, V32, P477, DOI 10.1093/carcin/bgr009; Mikheeva SA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-194; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Ng L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126219; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pang H, 2011, CANCER BIOTHER RADIO, V26, P165, DOI 10.1089/cbr.2010.0838; Parrinello S, 2005, J CELL SCI, V118, P485, DOI 10.1242/jcs.01635; Pietras A, 2014, CELL STEM CELL, V14, P357, DOI 10.1016/j.stem.2014.01.005; Pio GM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177640; Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295; Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005; Rasanen K, 2010, EXP CELL RES, V316, P2713, DOI 10.1016/j.yexcr.2010.04.032; Ray P, 2015, ONCOGENE, V34, P2043, DOI 10.1038/onc.2014.157; Sangaletti S, 2014, CANCER RES, V74, P4706, DOI 10.1158/0008-5472.CAN-13-3334; Sharon Y, 2015, CANCER RES, V75, P963, DOI 10.1158/0008-5472.CAN-14-1990; Sung CO, 2011, AM J PATHOL, V179, P1827, DOI 10.1016/j.ajpath.2011.06.032; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tuck AB, 2007, J CELL BIOCHEM, V102, P859, DOI 10.1002/jcb.21520; Xu K, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0674-8; Xu YY, 2015, MOL CLIN ONCOL, V3, P357, DOI 10.3892/mco.2014.480; Zhang RH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023831	58	12	12	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2002	2017		10.1038/s41388-021-01663-2	http://dx.doi.org/10.1038/s41388-021-01663-2		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33603163				2022-12-28	WOS:000619433100004
J	Yoon, H; Tang, CM; Banerjee, S; Yebra, M; Noh, S; Burgoyne, AM; Torre, JD; De Siena, M; Liu, MY; Klug, LR; Choi, YY; Hosseini, M; Delgado, AL; Wang, ZY; French, RP; Lowy, A; DeMatteo, RP; Heinrich, MC; Molinolo, AA; Gutkind, JS; Harismendy, O; Sicklick, JK				Yoon, Hyunho; Tang, Chih-Min; Banerjee, Sudeep; Yebra, Mayra; Noh, Sangkyu; Burgoyne, Adam M.; Torre, Jorge De la; Siena, Martina De; Liu, Mengyuan; Klug, Lillian R.; Choi, Yoon Young; Hosseini, Mojgan; Delgado, Antonio L.; Wang, Zhiyong; French, Randall P.; Lowy, Andrew; DeMatteo, Ronald P.; Heinrich, Michael C.; Molinolo, Alfredo A.; Gutkind, J. Silvio; Harismendy, Olivier; Sicklick, Jason K.			Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis	ONCOGENE			English	Article							IMATINIB MESYLATE; C-KIT; RECEPTOR; COMBINATION; ACTIVATION; MUTATIONS; MULTICENTER; INHIBITOR; KINASE; LIGAND	Targeted therapies for gastrointestinal stromal tumor (GIST) are modestly effective, but GIST cannot be cured with single agent tyrosine kinase inhibitors. In this study, we sought to identify new therapeutic targets in GIST by investigating the tumor microenvironment. Here, we identified a paracrine signaling network by which cancer-associated fibroblasts (CAFs) drive GIST growth and metastasis. Specifically, CAFs isolated from human tumors were found to produce high levels of platelet-derived growth factor C (PDGFC), which activated PDGFC-PDGFRA signal transduction in GIST cells that regulated the expression of SLUG, an epithelial-mesenchymal transition (EMT) transcription factor and downstream target of PDGFRA signaling. Together, this paracrine induce signal transduction cascade promoted tumor growth and metastasis in vivo. Moreover, in metastatic GIST patients, SLUG expression positively correlated with tumor size and mitotic index. Given that CAF paracrine signaling modulated GIST biology, we directly targeted CAFs with a dual PI3K/mTOR inhibitor, which synergized with imatinib to increase tumor cell killing and in vivo disease response. Taken together, we identified a previously unappreciated cellular target for GIST therapy in order to improve disease control and cure rates.	[Yoon, Hyunho; Tang, Chih-Min; Banerjee, Sudeep; Yebra, Mayra; Noh, Sangkyu; Burgoyne, Adam M.; Torre, Jorge De la; Siena, Martina De; Delgado, Antonio L.; French, Randall P.; Lowy, Andrew; Sicklick, Jason K.] Univ Calif San Diego, Dept Surg, Div Surg Oncol, Moores Canc Ctr, San Diego, CA 92103 USA; [Banerjee, Sudeep] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA; [Siena, Martina De] Fdn Policlin A Gemelli Catholic Univ Rome, Gastroenterol & Digest Endoscopy, Rome, Italy; [Liu, Mengyuan; DeMatteo, Ronald P.] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; [Klug, Lillian R.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA; [Klug, Lillian R.; Heinrich, Michael C.] Oregon Hlth & Sci Univ, Portland VA Hlth Care Syst, Knight Canc Inst, Portland, OR 97201 USA; [Choi, Yoon Young; Harismendy, Olivier] Univ Calif San Diego, Moores Canc Ctr, Div Biomed Informat, San Diego, CA 92103 USA; [Choi, Yoon Young] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea; [Hosseini, Mojgan; Molinolo, Alfredo A.] Univ Calif San Diego, Dept Pathol, Moores Canc Ctr, San Diego, CA 92103 USA; [Wang, Zhiyong; Gutkind, J. Silvio] Univ Calif San Diego, Dept Pharmacol, Moores Canc Ctr, San Diego, CA 92103 USA	University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of Pennsylvania; Oregon Health & Science University; Oregon Health & Science University; University of California System; University of California San Diego; Yonsei University; Yonsei University Health System; University of California System; University of California San Diego; University of California System; University of California San Diego	Sicklick, JK (corresponding author), Univ Calif San Diego, Dept Surg, Div Surg Oncol, Moores Canc Ctr, San Diego, CA 92103 USA.	jsicklick@health.ucsd.edu	Gutkind, J. Silvio/J-1201-2016; Harismendy, Olivier/AAM-2072-2021; De Siena, Martina/AAB-8566-2022	Gutkind, J. Silvio/0000-0002-5150-4482; Harismendy, Olivier/0000-0002-8098-9888; De Siena, Martina/0000-0003-4913-7254; Heinrich, Michael/0000-0003-3790-0478	National Institutes of Health (NIH) [P30CA023100]; NIH [R01 CA226803, RO1 CA155620]; Food and Drug Administration [R01 FD006334]; Jonathan David Foundation; GIST Research Fund; GIST Cancer Research Fund; SDH Research Fund; VA Merit Review Grant [2l01BX000338-05]; Kristen Ann Carr Fund	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food and Drug Administration(United States Department of Health & Human Services); Jonathan David Foundation; GIST Research Fund; GIST Cancer Research Fund; SDH Research Fund; VA Merit Review Grant(US Department of Veterans Affairs); Kristen Ann Carr Fund	We thank T. Reya for her critical review of the manuscript. This work was supported in part by National Institutes of Health (NIH) grant nos. P30CA023100 (JKS, AM), as well as NIH grant (R01 CA226803) (RO1 CA155620) (AML), Food and Drug Administration (R01 FD006334, JKS), Jonathan David Foundation (JKS, MCH), GIST Research Fund (JKS), GIST Cancer Research Fund (MCH), SDH Research Fund (JKS), VA Merit Review Grant 2l01BX000338-05 (MCH), and Kristen Ann Carr Fund (JKS).	Anderberg C, 2009, CANCER RES, V69, P369, DOI 10.1158/0008-5472.CAN-08-2724; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; [Anonymous], 2020, CANCER DISCOV, V10, P1438, DOI 10.1158/2159-8290.cd-rw2020-124; Blanke CD, 2008, J CLIN ONCOL, V26, P626, DOI 10.1200/JCO.2007.13.4452; Boikos SA, 2016, JAMA ONCOL, V2, P922, DOI 10.1001/jamaoncol.2016.0256; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Cao RH, 2002, FASEB J, V16, P1575, DOI 10.1096/fj.02-0319com; Corless CL, 2008, ANNU REV PATHOL-MECH, V3, P557, DOI 10.1146/annurev.pathmechdis.3.121806.151538; Corless CL, 2011, NAT REV CANCER, V11, P865, DOI 10.1038/nrc3143; Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1; Dhillon S, 2020, DRUGS, V80, P1133, DOI 10.1007/s40265-020-01348-2; Dhillon S, 2020, DRUGS, V80, P433, DOI 10.1007/s40265-020-01275-2; Dolgin E, 2020, CANCER DISCOV, V10, P334, DOI 10.1158/2159-8290.CD-NB2020-002; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Edris B, 2013, P NATL ACAD SCI USA, V110, P3501, DOI 10.1073/pnas.1222893110; Ekpe-Adewuyi E, 2016, ONCOTARGET, V7, P83684, DOI 10.18632/oncotarget.13299; Floris G, 2013, CLIN CANCER RES, V19, P620, DOI 10.1158/1078-0432.CCR-12-2853; Goehrig D, 2019, GUT, V68, P693, DOI 10.1136/gutjnl-2018-317570; Grunewald S, 2021, CANCER DISCOV, V11, P108, DOI 10.1158/2159-8290.CD-20-0487; Hayashi Y, 2015, GASTROENTEROLOGY, V149, P420, DOI 10.1053/j.gastro.2015.04.006; Heinrich MC, 2020, LANCET ONCOL, V21, P935, DOI 10.1016/S1470-2045(20)30269-2; Hessmann E, 2018, GUT, V67, P497, DOI 10.1136/gutjnl-2016-311954; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Janku Filip, 2020, J Clin Oncol, V38, P3294, DOI 10.1200/JCO.20.00522; Joensuu H, 2015, J CLIN ONCOL, V33, P634, DOI 10.1200/JCO.2014.57.4970; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; McDermott U, 2009, CANCER RES, V69, P3937, DOI 10.1158/0008-5472.CAN-08-4327; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Pulkka OP, 2017, BRIT J CANCER, V116, P1195, DOI 10.1038/bjc.2017.82; Ray Katrina, 2020, Nat Rev Gastroenterol Hepatol, V17, P452, DOI 10.1038/s41575-020-0336-2; Ruffini F, 2017, ONCOTARGET, V8, P66833, DOI 10.18632/oncotarget.18706; Schoffski P, 2010, ANN ONCOL, V21, P1990, DOI 10.1093/annonc/mdq076; Shi E, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1075-6; Sicklick JK, 2013, J GASTROINTEST SURG, V17, P1997, DOI 10.1007/s11605-013-2243-0; Taguchi T, 2002, LAB INVEST, V82, P663, DOI 10.1038/labinvest.3780461; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Van Looy T, 2014, CLIN CANCER RES, V20, P6071, DOI 10.1158/1078-0432.CCR-14-1823; Vitiello GA, 2019, J CLIN INVEST, V129, P1863, DOI 10.1172/JCI124108; Wang LX, 2017, MED SCI MONITOR, V23, P3808, DOI 10.12659/MSM.906038; Wiley SZ, 2018, FASEB J, V32, P1170, DOI 10.1096/fj.201700834R; Zook P, 2017, CLIN CANCER RES, V23, P171, DOI 10.1158/1078-0432.CCR-16-0529	45	13	13	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					1957	1973		10.1038/s41388-021-01685-w	http://dx.doi.org/10.1038/s41388-021-01685-w		FEB 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33603171	hybrid, Green Published			2022-12-28	WOS:000619405600003
J	Liu, XW; Wang, F; Xu, CW; Chen, XR; Hou, X; Li, Q; Li, PS; Xie, Z; Liu, YD; Chang, LP; Guan, YF; Zhang, XC; Yang, L; Wang, H; Yi, X; Zhang, JJ; Xia, XF; Moran, C; Chen, LK				Liu, Xuewen; Wang, Fang; Xu, Chunwei; Chen, Xinru; Hou, Xue; Li, Qian; Li, Pansong; Xie, Zhi; Liu, Yongdong; Chang, Lianpeng; Guan, Yanfang; Zhang, Xuchao; Yang, Ling; Wang, Hui; Yi, Xin; Zhang, Jianjun; Xia, Xuefeng; Moran, Cesar; Chen, Likun			Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma	ONCOGENE			English	Article							MOLECULAR CHARACTERIZATION; POOR-PROGNOSIS; KRAS MUTATION; LUNG; EGFR; IDENTIFICATION; AMPLIFICATION	Pulmonary sarcomatoid carcinoma (PSC) contains carcinomatous component (CaC) and sarcomatous component (SaC). Herein, we explored the genomic origin and intratumor heterogeneity (ITH) of PSC. We collected 31 resected PSC tumors and obtained CaC and SaC by laser capture microdissection for next-generation sequencing. The majority of PSCs (97%) had component-shared alterations. Driver mutations in EGFR, KRAS, MET, PIK3CA, and EML4-ALK fusion were mostly component-shared. Twenty-seven (87%) PSCs had component-private alterations. Compared with pure lung adenocarcinoma (LUAD), adenocarcinoma component of PSC showed lower EGFR incidence. Compared with other typical sarcomas, numerous genes of SaC exhibited significant differences. CaC and SaC had equivalent and proportional tumor mutation burden (TMB), as well as PD-L1 level. Compared with LUAD, SaC had significant higher TMB and more patients with high PD-L1 expression (tumor proportion score >= 50%). PSC with lower proportion of component-shared alterations (trunk-ratio) had a prolonged disease-free survival (DFS), regardless of the influence of clinical factors. We conclude that most PSCs originate from a monoclone accompanied by genomic ITH which is a potential independent prognostic factor, and more proportion of PSCs may be beneficial from immune checkpoint inhibitors.	[Liu, Xuewen] Cent South Univ, Xiangya Hosp 3, Dept Oncol, Changsha 410013, Hunan, Peoples R China; [Wang, Fang] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Mol Diagnost,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Xu, Chunwei] Nanjing Univ Sch Med, Jinling Hosp, Dept Resp Med, Nanjing 210002, Jiangsu, Peoples R China; [Chen, Xinru; Hou, Xue; Chen, Likun] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Med Oncol,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Li, Qian; Li, Pansong; Chang, Lianpeng; Guan, Yanfang; Yang, Ling; Yi, Xin; Xia, Xuefeng] Geneplus Beijing, Beijing 102206, Peoples R China; [Xie, Zhi; Zhang, Xuchao] Guangdong Gen Hosp GGH, Guangdong Prov Key Lab Translat Med Lung Canc, Guangdong Lung Canc Inst, Guangzhou 510080, Guangdong, Peoples R China; [Xie, Zhi; Zhang, Xuchao] Guangdong Acad Med Sci, Guangzhou 510080, Guangdong, Peoples R China; [Liu, Yongdong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510080, Guangdong, Peoples R China; [Wang, Hui] Cent South Univ, Hunan Canc Hosp, Dept Radiat Oncol, Changsha 410013, Hunan, Peoples R China; [Wang, Hui] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha 410013, Hunan, Peoples R China; [Wang, Hui] Hunan Prov Key Lab Translat Radiat Oncol, Changsha 410013, Hunan, Peoples R China; [Zhang, Jianjun] Univ Texas MD Anderson Canc Ctr, Dept Genom Med & Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Moran, Cesar] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Central South University; State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Sun Yat Sen University; Central South University; Central South University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chen, LK (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Med Oncol,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.; Moran, C (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.	cesarmoran@mdanderson.org; chenlk@sysucc.org.cn	zhang, xu/GYE-3558-2022; zhang, xu/GRX-9733-2022; zhang, xian/GYA-0290-2022; Zhang, xiaoyu/GXA-3206-2022	Li, Qian/0000-0001-9413-1877	National Natural Science Foundation of China [81572270]; Nature Science Foundation of Hunan Province [2017JJ3188]; Foundation of Hunan Health Committee Research Plan [A2017005]; Foundation of Wisdom Gathering and Talent Cultivating Program from the Third Xiangya Hospital	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Nature Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); Foundation of Hunan Health Committee Research Plan; Foundation of Wisdom Gathering and Talent Cultivating Program from the Third Xiangya Hospital	This study was supported by the National Natural Science Foundation of China (81572270), Nature Science Foundation of Hunan Province (2017JJ3188), Foundation of Hunan Health Committee Research Plan (A2017005) and Foundation of Wisdom Gathering and Talent Cultivating Program from the Third Xiangya Hospital.	Babacan NA, 2020, CLIN LUNG CANCER, V21, pE456, DOI 10.1016/j.cllc.2020.02.022; Bevilacqua C, 2018, MOL ASPECTS MED, V59, P5, DOI 10.1016/j.mam.2017.09.003; Blaukovitsch M, 2006, VIRCHOWS ARCH, V449, P455, DOI 10.1007/s00428-006-0256-8; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Chang YL, 2011, ANN SURG ONCOL, V18, P2952, DOI 10.1245/s10434-011-1621-7; Chen FM, 2019, ONCOTARGETS THER, V12, P3321, DOI 10.2147/OTT.S196751; Chen K, 2009, NAT METHODS, V6, P677, DOI [10.1038/NMETH.1363, 10.1038/nmeth.1363]; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cimpeanu E, 2020, WORLD J CLIN CASES, V8, P97, DOI 10.12998/wjcc.v8.i1.97; D'Angelo SP, 2011, J CLIN ONCOL, V29, P2066, DOI 10.1200/JCO.2010.32.6181; Fallet V, 2015, ANN ONCOL, V26, P1748, DOI 10.1093/annonc/mdv232; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Goto T, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3059-1; Italiano A, 2009, INT J CANCER, V125, P2479, DOI 10.1002/ijc.24610; Kaira K, 2010, J THORAC ONCOL, V5, P460, DOI 10.1097/JTO.0b013e3181ce3e3c; Kim S, 2015, EUR J CANCER, V51, P2698, DOI 10.1016/j.ejca.2015.08.013; LAUSEN B, 1992, BIOMETRICS, V48, P73, DOI 10.2307/2532740; Leone A, 2011, INT J CANCER, V128, P732, DOI 10.1002/ijc.25335; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li J, 2012, BIOINFORMATICS, V28, P1307, DOI 10.1093/bioinformatics/bts146; Li Y, 2018, LUNG CANCER, V122, P113, DOI 10.1016/j.lungcan.2018.06.001; Liang XH, 2019, INT J CLIN ONCOL, V24, P1061, DOI 10.1007/s10147-019-01454-6; Lin G, 2020, ANN ONCOL, V31, P517, DOI 10.1016/j.annonc.2020.01.014; Lin YB, 2016, AM J CLIN ONCOL-CANC, V39, P215, DOI 10.1097/COC.0000000000000101; Liu XW, 2016, J CLIN ONCOL, V34, P794, DOI 10.1200/JCO.2015.62.0674; Lococo F, 2016, J THORAC ONCOL, V11, P1282, DOI 10.1016/j.jtho.2016.04.020; Manzotti G, 2019, CLIN CANCER RES, V25, P2348, DOI 10.1158/1078-0432.CCR-18-2364; Martin LW, 2007, ANN THORAC SURG, V84, P973, DOI 10.1016/j.athoracsur.2007.03.099; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; McGranahan N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1408; Mehrad M, 2018, HISTOPATHOLOGY, V73, P207, DOI 10.1111/his.13505; Nakagomi Takahiro, 2018, Oncotarget, V9, P10635, DOI 10.18632/oncotarget.24365; Nong JY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05327-w; Pelosi G, 2012, LUNG CANCER, V77, P507, DOI 10.1016/j.lungcan.2012.05.093; Pelosi G, 2010, INT J SURG PATHOL, V18, P103, DOI 10.1177/1066896908330049; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/nmeth.2883, 10.1038/NMETH.2883]; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Schrock AB, 2017, J THORAC ONCOL, V12, P932, DOI 10.1016/j.jtho.2017.03.005; Sim JK, 2018, KOREAN J INTERN MED, V33, P737, DOI 10.3904/kjim.2017.245; Terra SBSP, 2016, MODERN PATHOL, V29, P824, DOI 10.1038/modpathol.2016.89; Tong JH, 2016, CLIN CANCER RES, V22, P3048, DOI 10.1158/1078-0432.CCR-15-2061; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Vieira T, 2013, J THORAC ONCOL, V8, P1574, DOI 10.1097/01.JTO.0000437008.00554.90; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Weissferdt A, 2017, HUM PATHOL, V63, P14, DOI 10.1016/j.humpath.2016.12.010; Yendamuri S, 2012, SURGERY, V152, P397, DOI 10.1016/j.surg.2012.05.007; Yu YF, 2019, J CANCER RES THER, V15, P909, DOI 10.4103/jcrt.JCRT_591_18	47	11	11	2	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					821	832		10.1038/s41388-020-01573-9	http://dx.doi.org/10.1038/s41388-020-01573-9		DEC 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33273725				2022-12-28	WOS:000599064900001
J	Pham, TQ; Robinson, K; Xu, L; Pavlova, MN; Skapek, SX; Chen, EY				Pham, Thao Q.; Robinson, Kristin; Xu, Lin; Pavlova, Maria N.; Skapek, Stephen X.; Chen, Eleanor Y.			HDAC6 promotes growth, migration/invasion, and self-renewal of rhabdomyosarcoma	ONCOGENE			English	Article							CANCER STEM-CELLS; DIFFERENTIATION; DEACETYLATION; METASTASIS; DYNAMICS; REVEALS; PATHWAY; COMPLEX; STATE; RAC1	Rhabdomyosarcoma (RMS) is a devastating pediatric sarcoma. The survival outcomes remain poor for patients with relapsed or metastatic disease. Effective targeted therapy is lacking due to our limited knowledge of the underlying cellular and molecular mechanisms leading to disease progression. In this study, we used functional assays in vitro and in vivo (zebrafish and xenograft mouse models) to demonstrate the crucial role of HDAC6, a cytoplasmic histone deacetylase, in driving RMS tumor growth, self-renewal, and migration/invasion. Treatment with HDAC6-selective inhibitors recapitulates the HDAC6 loss-of-function phenotypes. HDAC6 regulates cytoskeletal dynamics to promote tumor cell migration and invasion. RAC1, a Rho family GTPase, is an essential mediator of HDAC6 function, and is necessary and sufficient for RMS cell migration and invasion. High expression of RAC1 correlates with poor clinical prognosis in RMS patients. Targeting the HDAC6-RAC1 axis represents a promising therapeutic option for improving survival outcomes of RMS patients.	[Pham, Thao Q.; Robinson, Kristin; Pavlova, Maria N.; Chen, Eleanor Y.] Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USA; [Xu, Lin; Skapek, Stephen X.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Xu, Lin] Univ Texas Southwestern Med Ctr Dallas, Quantitat Biomed Res Ctr, Dept Populat & Data Sci, Dallas, TX 75390 USA	University of Washington; University of Washington Seattle; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Chen, EY (corresponding author), Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USA.	eleanor2@uw.edu		Chen, Eleanor/0000-0003-4372-7560	NIH [R01 CA196882]; Children's Cancer Fund; Rally Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Cancer Fund; Rally Foundation	The authors want to thank Terra Vleeshouwer-Neumann and Amy Chen for technical assistance with some experiments. EYC is supported by NIH R01 CA196882. Lin Xu is supported by Children's Cancer Fund and Rally Foundation.	BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Chen DM, 2017, CELL STEM CELL, V20, P621, DOI 10.1016/j.stem.2017.02.003; Chen EY, 2014, P NATL ACAD SCI USA, V111, P5349, DOI 10.1073/pnas.1317731111; Chen EY, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003727; Dogterom M, 2019, NAT REV MOL CELL BIO, V20, P38, DOI 10.1038/s41580-018-0067-1; Du FY, 2019, WORLD J STEM CELLS, V11, P398, DOI 10.4252/wjsc.v11.i7.398; Gao YS, 2007, MOL CELL BIOL, V27, P8637, DOI 10.1128/MCB.00393-07; Goto N, 2019, P NATL ACAD SCI USA, V116, P12996, DOI 10.1073/pnas.1900251116; Guo FK, 2006, J BIOL CHEM, V281, P18652, DOI 10.1074/jbc.M603508200; Hayes MN, 2018, CELL STEM CELL, V22, P414, DOI 10.1016/j.stem.2018.02.002; Hosoyama T, 2011, CLIN CANCER RES, V17, P2757, DOI 10.1158/1078-0432.CCR-10-3445; Hu S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag0339; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Ignatius MS, 2018, ELIFE, V7, DOI 10.7554/eLife.37202; Ignatius MS, 2012, CANCER CELL, V21, P680, DOI 10.1016/j.ccr.2012.03.043; Jankowski K, 2003, CANCER RES, V63, P7926; Kamai T, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-164; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kozyreva VK, 2014, MOL CANCER RES, V12, P681, DOI 10.1158/1541-7786.MCR-13-0654; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Lof-Ohlin ZM, 2017, NAT CELL BIOL, V19, P1313, DOI 10.1038/ncb3628; Marampon F, 2017, CANCER LETT, V397, P1, DOI 10.1016/j.canlet.2017.03.028; Miekus K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.199; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Phelps MP, 2016, P NATL ACAD SCI USA, V113, P15090, DOI 10.1073/pnas.1610270114; Saygin C, 2019, CELL STEM CELL, V24, P25, DOI 10.1016/j.stem.2018.11.017; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Tran ADA, 2007, J CELL SCI, V120, P1469, DOI 10.1242/jcs.03431; Vleeshouwer-Neumann T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144320; Walter D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019506; Wu JY, 2018, J BIOL CHEM, V293, P1976, DOI 10.1074/jbc.M117.795955; Wu LF, 2011, FEBS LETT, V585, P1322, DOI 10.1016/j.febslet.2011.03.067; Xu L, 2018, CELL REP, V24, P238, DOI 10.1016/j.celrep.2018.06.006; Yang MH, 2013, MOL CANCER RES, V11, P1072, DOI 10.1158/1541-7786.MCR-13-0040-T; Yang W, 2018, CANCER LETT, V415, P164, DOI 10.1016/j.canlet.2017.12.005; Yin ZS, 2018, ONCOL LETT, V16, P7082, DOI 10.3892/ol.2018.9504; Zhang XH, 2007, MOL CELL, V27, P197, DOI 10.1016/j.molcel.2007.05.033; Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613	40	10	10	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					578	591		10.1038/s41388-020-01550-2	http://dx.doi.org/10.1038/s41388-020-01550-2		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33199827	Green Accepted			2022-12-28	WOS:000590042900003
J	Wang, XG; Song, YQ; Chen, W; Ding, N; Liu, WP; Xie, Y; Wang, YN; Zhu, J; Zeng, CQ				Wang, Xiaogan; Song, Yuqin; Chen, Wei; Ding, Ning; Liu, Weiping; Xie, Yan; Wang, Yinan; Zhu, Jun; Zeng, Changqing			Germline variants of DNA repair genes in early onset mantle cell lymphoma	ONCOGENE			English	Article							NON-HODGKINS-LYMPHOMA; MICROSATELLITE INSTABILITY; MOLECULAR PATHOGENESIS; CANCER; EXPRESSION; ASSOCIATION; DEFICIENCY; SIGNATURES; ALIGNMENT; PATIENT	Although somatic mutations of DNA repair genes are frequent in mantle cell lymphoma (MCL), our understanding of their germline defects is limited. In a Chinese family with maternal Lynch syndrome and paternal B cell non-Hodgkin lymphoma, one sibling developed both Lynch syndrome and MCL. Lynch syndrome is caused by heterozygous mutations in mismatch repair (MMR) genes. To understand the genetic predispositions in the family, we performed exome sequencing and analyses of affected individuals and their tumor samples. A novel germline indel, MLH1 Gly101fsX1, was identified as the cause of Lynch syndrome, and unstable microsatellite loci and mutational signatures as evidence of defective MMR were revealed in the MCL sample. Furthermore, we included additional 15 MCL patients with early onset, and found by exome sequencing that 11 patients carried heterozygous germline variants of 20 DNA repair genes, including MSH2 in MMR. In the MCL with MSH2 Arg359fsX16, unstable microsatellite loci and defective MMR signatures were also found. In addition, five patients also had heterozygous germline variants of genes involved in B cell functions. Thus, our study found germline variants of genes in single-strand break repair, double-strand break repair, and Fanconi anemia pathway in early onset MCL; and for the first time we identified germline defects of MMR in two MCLs.	[Wang, Xiaogan; Song, Yuqin; Ding, Ning; Liu, Weiping; Xie, Yan; Zhu, Jun] Peking Univ Canc Hosp & Inst, Minist Educ, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China; [Wang, Xiaogan; Chen, Wei; Zeng, Changqing] Chinese Acad Sci, Beijing Inst Genom, CAS Key Lab Genom & Precis Med, Beijing, Peoples R China; [Chen, Wei; Zeng, Changqing] China Natl Ctr Bioinformat, Beijing, Peoples R China; [Wang, Yinan] Hebei Tangshan Peoples Hosp, Tangshan, Hebei, Peoples R China; [Zeng, Changqing] Univ Chinese Acad Sci, Beijing, Peoples R China	Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Zhu, J (corresponding author), Peking Univ Canc Hosp & Inst, Minist Educ, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China.; Zeng, CQ (corresponding author), Chinese Acad Sci, Beijing Inst Genom, CAS Key Lab Genom & Precis Med, Beijing, Peoples R China.; Zeng, CQ (corresponding author), China Natl Ctr Bioinformat, Beijing, Peoples R China.; Zeng, CQ (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.	zhu-jun2017@outlook.com; czeng@big.ac.cn			Key Research Program of the Chinese Academy of Sciences [KJZD-EWL06-2]; National Natural Science Foundation of China [81972807, 81670187, 81470368]; National High Technology Research and Development Program (863 Program) of China [2012AA022502]; Beijing Natural Science Foundation [7202025]; China Postdoctoral Science Foundation [2013M541009]	Key Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program (863 Program) of China(National High Technology Research and Development Program of China); Beijing Natural Science Foundation(Beijing Natural Science Foundation); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by grants from the Key Research Program of the Chinese Academy of Sciences (KJZD-EWL06-2) (CZ), the National Natural Science Foundation of China (81972807, 81670187 and 81470368) (YS and JZ), the National High Technology Research and Development Program (863 Program) of China (2012AA022502) (CZ), the Beijing Natural Science Foundation (7202025) (YS), and the China Postdoctoral Science Foundation (2013M541009) (XW). We thank Sheng Li for the help in the interview of relatives of the family and collection of their samples. We are grateful to Yunfei Shi for pathological review. Further thanks are due to Wen Zheng, Ningjing Lin, Meifeng Tu, Xiaopei Wang, Lingyan Ping, Zhitao Ying, Lijuan Deng, Chen Zhang, Tingting Du, Meng Wu, Xin Len, and Feier Feng for their help in collection of clinical information. We are grateful to Caixia Guo for advice and help in revision.	Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76; Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Blokzijl F, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0539-0; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheah CY, 2016, J CLIN ONCOL, V34, P1256, DOI 10.1200/JCO.2015.63.5904; Cheah CY, 2015, J CLIN PATHOL, V68, P755, DOI 10.1136/jclinpath-2015-203039; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cuceu C, 2018, CANCERS, V10, DOI 10.3390/cancers10070233; de Miranda NFCC, 2013, J EXP MED, V210, P1729, DOI 10.1084/jem.20122842; Degroote A, 2013, LEUKEMIA LYMPHOMA, V54, P812, DOI 10.3109/10428194.2012.723211; Dreyling M, 2017, ANN ONCOL, V28, P62, DOI [10.1093/annonc/mdx223, 10.1093/annonc/mdx289]; Du ZL, 2019, GENOM PROTEOM BIOINF, V17, P229, DOI 10.1016/j.gpb.2019.07.002; Elenitoba-Johnson KSJ, 2018, ANNU REV PATHOL-MECH, V13, P193, DOI 10.1146/annurev-pathol-020117-043803; Ferrari Vittorio, 1999, Recenti Progressi in Medicina, V90, P81; Hirano K, 2002, DIS COLON RECTUM, V45, P273, DOI 10.1007/s10350-004-6161-9; Huet S, 2018, NAT REV CANCER, V18, P224, DOI 10.1038/nrc.2017.127; Jares P, 2007, NAT REV CANCER, V7, P750, DOI 10.1038/nrc2230; Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587-019-0201-4; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Kotoula V, 2002, LEUKEMIA LYMPHOMA, V43, P393, DOI 10.1080/10428190290006215; Kratz CP, 2008, LEUKEMIA, V22, P1078, DOI 10.1038/sj.leu.2405008; Krueger S, 2008, EUR J HUM GENET, V16, P62, DOI 10.1038/sj.ejhg.5201923; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Lindsley AW, 2016, J ALLERGY CLIN IMMUN, V137, P179, DOI 10.1016/j.jaci.2015.06.002; Lynch HT, 2015, NAT REV CANCER, V15, P181, DOI 10.1038/nrc3878; Moffitt AB, 2017, J CLIN ONCOL, V35, P955, DOI 10.1200/JCO.2016.71.7603; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Ortega-Molina A, 2015, NAT MED, V21, P1199, DOI 10.1038/nm.3943; Perez-Galan P, 2011, BLOOD, V117, P26, DOI 10.1182/blood-2010-04-189977; Pineda M, 2008, GENE CHROMOSOME CANC, V47, P326, DOI 10.1002/gcc.20536; Puente XS, 2018, BLOOD, V131, P2283, DOI 10.1182/blood-2017-10-764373; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Renkonen E, 2003, J CLIN ONCOL, V21, P3629, DOI 10.1200/JCO.2003.03.181; Ripperger T, 2016, EUR J MED GENET, V59, P133, DOI 10.1016/j.ejmg.2015.12.014; Ripperger T, 2010, HAEMATOL-HEMATOL J, V95, P841, DOI 10.3324/haematol.2009.015503; Rosty C, 2000, MODERN PATHOL, V13, P586, DOI 10.1038/modpathol.3880100; Salipante SJ, 2014, CLIN CHEM, V60, P1192, DOI 10.1373/clinchem.2014.223677; Sanz-Vaque L, 2001, HAEMATOLOGICA, V86, P181; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Smedby Karin E., 2014, Journal of the National Cancer Institute Monographs, P76, DOI 10.1093/jncimonographs/lgu007; Sud A, 2019, BLOOD, V132, P960, DOI 10.1182/blood.2019001362; Supek F, 2015, NATURE, V521, P81, DOI 10.1038/nature14173; Taylor J, 2017, BLOOD, V130, P410, DOI 10.1182/blood-2017-02-734541; Teruya-Feldstein J, 2002, LEUKEMIA LYMPHOMA, V43, P1619, DOI 10.1080/1042819021000002956; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Tian T, 2020, LAB INVEST, V100, P1397, DOI 10.1002/cam4.2870; Vogt N, 2017, LEUKEMIA LYMPHOMA, V58, P1530, DOI 10.1080/10428194.2016.1248965; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Zhang JY, 2015, NAT MED, V21, P1190, DOI 10.1038/nm.3940	51	5	5	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					551	563		10.1038/s41388-020-01542-2	http://dx.doi.org/10.1038/s41388-020-01542-2		NOV 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33191405				2022-12-28	WOS:000589571100001
J	Liu, ZY; Wang, AQ; Pu, YY; Li, ZW; Xue, RD; Zhang, C; Xiang, X; Jian-Yu, E; Bu, ZD; Bai, F; Ji, JF				Liu, Ziyang; Wang, Anqiang; Pu, Yingying; Li, Zhongwu; Xue, Ruidong; Zhang, Chong; Xiang, Xiao; Jian-Yu, E.; Bu, Zhaode; Bai, Fan; Ji, Jiafu			Genomic and transcriptomic profiling of hepatoid adenocarcinoma of the stomach	ONCOGENE			English	Article							STEM-CELLS; TUMOR; CANCER; METASTASIS; METHIONINE; MUTATIONS; CARCINOMA; DIFFERENTIATION; HETEROGENEITY; TRANSITION	Hepatoid adenocarcinoma of the stomach (HAS), a rare subtype of gastric cancer (GC), has a low incidence but a high mortality rate. Little is known about the molecular features of HAS. Here we applied whole-exome sequencing (WES) on 58 tumours and the matched normal controls from 54 HAS patients, transcriptome sequencing on 30 HAS tumours, and single-cell RNA sequencing (scRNA-seq) on one HAS tumour. Our results reveal that the adenocarcinomatous component and hepatocellular-like component of the same HAS tumour originate monoclonally, and HAS is likely to initiate from pluripotent precursor cells. HAS has high stemness and high methionine cycle activity compared to classical GC. Two genes in the methionine cycle, MAT2A, and AHCY are potential targets for HAS treatments. We provide the first integrative genomic profiles of HAS, which may facilitate its diagnosis, prognosis, and treatment.	[Liu, Ziyang; Pu, Yingying; Xue, Ruidong; Zhang, Chong; Bai, Fan] Peking Univ, Biomed Pioneering Innovat Ctr BIOPIC, Sch Life Sci, Beijing, Peoples R China; [Wang, Anqiang; Bu, Zhaode; Ji, Jiafu] Peking Univ, Dept Gastrointestinal Surg, Canc Hosp & Inst, Minist Educ,Lab Carcinogenesis & Translat Res, Beijing, Peoples R China; [Pu, Yingying] Wuhan Univ, Frontier Sci Ctr Immunol & Metab, Sch Med, Med Res Inst, Wuhan, Peoples R China; [Pu, Yingying] Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan, Peoples R China; [Pu, Yingying] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ KLOBM, Key Lab Oral Biomed, Wuhan, Peoples R China; [Li, Zhongwu] Peking Univ, Dept Pathol, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China; [Xue, Ruidong] Peking Univ First Hosp, Translat Canc Res Ctr, Beijing, Peoples R China; [Xiang, Xiao] Peking Univ Peoples Hosp, Beijing Key Surg Basic Res Lab Liver Cirrhosis &, Dept Hepatobilliary Surg, Beijing, Peoples R China; [Jian-Yu, E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Ji, Jiafu] Peking Univ, Dept Biobank, Minist Educ, Key Lab Carcinogenesis & Translat Res,Canc Hosp &, Beijing, Peoples R China	Peking University; Peking University; Wuhan University; Wuhan University; Wuhan University; Peking University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Peking University	Bai, F (corresponding author), Peking Univ, Biomed Pioneering Innovat Ctr BIOPIC, Sch Life Sci, Beijing, Peoples R China.; Bu, ZD; Ji, JF (corresponding author), Peking Univ, Dept Gastrointestinal Surg, Canc Hosp & Inst, Minist Educ,Lab Carcinogenesis & Translat Res, Beijing, Peoples R China.; Ji, JF (corresponding author), Peking Univ, Dept Biobank, Minist Educ, Key Lab Carcinogenesis & Translat Res,Canc Hosp &, Beijing, Peoples R China.	buzhaode@cjcrcn.org; jijiafu@hsc.pku.edu.cn		Bu, Zhaode/0000-0001-8728-9676; Liu, Ziyang/0000-0002-3067-9523; E, Jian-Yu/0000-0002-6175-6974; Xue, Ruidong/0000-0002-5743-805X; Zhang, Chong/0000-0001-5072-5219	National Science and Technology Major Project [2018ZX10302205, 2019YFC1315702]; Guangdong Province Key Research and Development Program [2019B020226002]; Peking University Clinical Scientist Program [BMU2019LCKXJ011]; National Science Foundation for Young Scientists of China [81802735]; Beijing Youth Talent Plan [QML20191101]; 'San Ming' Project of Shenzhen city, China [SZSM201612051]; Beijing Municipal Science and Technology Commission NOVA Program [2010B033]	National Science and Technology Major Project; Guangdong Province Key Research and Development Program; Peking University Clinical Scientist Program; National Science Foundation for Young Scientists of China; Beijing Youth Talent Plan; 'San Ming' Project of Shenzhen city, China; Beijing Municipal Science and Technology Commission NOVA Program	This work was financially supported by the National Science and Technology Major Project (2018ZX10302205, 2019YFC1315702), the Guangdong Province Key Research and Development Program (2019B020226002) to F. Bai; Peking University Clinical Scientist Program (BMU2019LCKXJ011); National Science Foundation for Young Scientists of China (No. 81802735); Beijing Youth Talent Plan (No. QML20191101); 'San Ming' Project of Shenzhen city, China (No. SZSM201612051) and Beijing Municipal Science and Technology Commission NOVA Program (2010B033).	Akazawa Y, 2018, HUM PATHOL, V78, P79, DOI 10.1016/j.humpath.2018.04.022; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021; Bort R, 2006, DEV BIOL, V290, P44, DOI 10.1016/j.ydbio.2005.11.006; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu, 2017, Cell, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Christenser S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12594-8; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Comoglio PM, 2018, NAT REV CANCER, V18, P341, DOI 10.1038/s41568-018-0002-y; DeLaForest A, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00044; Ding X, 2019, BRAIN RES, V1717, P117, DOI 10.1016/j.brainres.2019.03.035; Favero F, 2015, ANN ONCOL, V26, P64, DOI 10.1093/annonc/mdu479; Fu DJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13847-2; Gao Q, 2019, CELL, V179, P561, DOI 10.1016/j.cell.2019.08.052; Gao X, 2019, NATURE, V572, P397, DOI 10.1038/s41586-019-1437-3; Gaude E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13041; Gibbons DL, 2018, DEV DYNAM, V247, P555, DOI 10.1002/dvdy.24485; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Harvey A, 2019, STEM CELL REP, V13, P573, DOI 10.1016/j.stemcr.2019.09.003; ISHIKURA H, 1986, CANCER, V58, P119, DOI 10.1002/1097-0142(19860701)58:1<119::AID-CNCR2820580121>3.0.CO;2-U; Jiang H, 2020, P NATL ACAD SCI USA, V117, P4770, DOI 10.1073/pnas.1914937117; Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Khemlina G, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0712-x; Kim E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09780-z; Kim JE, 2009, MODERN PATHOL, V22, P1312, DOI 10.1038/modpathol.2009.98; Kim KM, 2014, ASIA-PAC J CLIN ONCO, V10, P297, DOI 10.1111/ajco.12263; Kim S, 2018, NAT METHODS, V15, P591, DOI 10.1038/s41592-018-0051-x; Komninou D, 2006, NUTR CANCER, V54, P202, DOI 10.1207/s15327914nc5402_6; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Lan SW, 2019, LUNG CANCER, V132, P154, DOI 10.1016/j.lungcan.2019.04.025; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lin L, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1362-2; Liu PY, 2012, CARCINOGENESIS, V33, P1270, DOI 10.1093/carcin/bgs148; Liu XW, 2010, AM J SURG PATHOL, V34, P1465, DOI 10.1097/PAS.0b013e3181f0a873; Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Nakanishi Y, 2013, NAT GENET, V45, P98, DOI 10.1038/ng.2481; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Qing T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04221-7; Reid MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07868-6; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/nmeth.2883, 10.1038/NMETH.2883]; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Scholnick SB, 2003, GENE CHROMOSOME CANC, V38, P281, DOI 10.1002/gcc.10279; Shafiei S, 2019, EXP MOL PATHOL, V108, P164, DOI 10.1016/j.yexmp.2019.04.015; Shiraki N, 2014, CELL METAB, V19, P780, DOI 10.1016/j.cmet.2014.03.017; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Su JS, 2013, WORLD J GASTROENTERO, V19, P321, DOI 10.3748/wjg.v19.i3.321; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wang Q, 2017, CELL STEM CELL, V20, P70, DOI 10.1016/j.stem.2016.10.002; Wang YK, 2019, GASTRIC CANCER, V22, P1183, DOI 10.1007/s10120-019-00965-5; Wang ZX, 2019, NAT MED, V25, P825, DOI 10.1038/s41591-019-0423-5; Xu W, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.27; Xue RD, 2019, CANCER CELL, V35, P932, DOI 10.1016/j.ccell.2019.04.007; Yonemura Y, 2002, EXP ONCOL, V24, P89; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang P, 2019, CELL REP, V27, P1934, DOI 10.1016/j.celrep.2019.04.052; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035	70	4	4	9	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5705	5717		10.1038/s41388-021-01976-2	http://dx.doi.org/10.1038/s41388-021-01976-2		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34326469				2022-12-28	WOS:000679262800001
J	Fan, XY; Wang, YT; Jiang, TH; Liu, T; Jin, YL; Du, KL; Niu, YL; Zhang, CX; Liu, ZY; Lei, YL; Bu, YQ				Fan, Xiaoyan; Wang, Yitao; Jiang, Tinghui; Liu, Tao; Jin, Yuelei; Du, Kailong; Niu, Yulong; Zhang, Chunxue; Liu, Zhongyu; Lei, Yunlong; Bu, Youquan			B-Myb accelerates colorectal cancer progression through reciprocal feed-forward transactivation of E2F2	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; CELL; PROLIFERATION; CONTRIBUTES; OVEREXPRESSION; ACTIVATION; CYCLIN-D1; FAMILY	B-Myb is an important transcription factor that plays a critical role in gene expression regulation and tumorigenesis. However, its functional implication in colorectal cancer remains elusive. In this study, we found that B-Myb was significantly upregulated at both mRNA and protein levels in colorectal cancer samples compared to non-tumor counterparts. B-Myb overexpression accelerated cell proliferation, cell cycle progression and cell motility in colorectal cancer cells, and promoted tumor growth in orthotopic nude mouse models in vivo. In contrast, B-Myb depletion inhibited these malignant phenotypes. Mechanistic investigations revealed that E2F2 was a novel transcriptional target of B-Myb and is essential to B-Myb-induced malignant phenotypes. Notably, B-Myb and E2F2 exhibited positive expression correlation, and interacted with each other in colorectal cancer cells. In addition to their autoregulatory mechanisms, B-Myb and E2F2 can also directly transactivate each other, thus constituting consolidated reciprocal feed-forward transactivation loops. Moreover, both B-Myb and E2F2 are required for the activation of ERK and AKT signaling pathways in colorectal cancer cells. Taken together, our data clarified a critical role for B-Myb in colorectal cancer and unraveled an exquisite mutual collaboration and reciprocal cross regulation between B-Myb and E2F2 that contribute to the malignant progression of human colorectal cancer.	[Fan, Xiaoyan; Wang, Yitao; Jiang, Tinghui; Liu, Tao; Jin, Yuelei; Du, Kailong; Zhang, Chunxue; Lei, Yunlong; Bu, Youquan] Chongqing Med Univ, Dept Biochem & Mol Biol, Coll Basic Med Sci, Chongqing 400016, Peoples R China; [Wang, Yitao; Jin, Yuelei; Niu, Yulong; Liu, Zhongyu; Lei, Yunlong; Bu, Youquan] Chongqing Med Univ, Canc Res Ctr, Mol Med, Chongqing 400016, Peoples R China; [Fan, Xiaoyan] Taizhou Univ, Taizhou Univ Hosp, Dermopath Res Inst, Taizhou, Peoples R China	Chongqing Medical University; Chongqing Medical University; Taizhou University	Lei, YL; Bu, YQ (corresponding author), Chongqing Med Univ, Dept Biochem & Mol Biol, Coll Basic Med Sci, Chongqing 400016, Peoples R China.; Lei, YL; Bu, YQ (corresponding author), Chongqing Med Univ, Canc Res Ctr, Mol Med, Chongqing 400016, Peoples R China.	leiyunlong@126.com; buyqcn@cqmu.edu.cn	Niu, Yulong/GQI-0688-2022	Niu, Yulong/0000-0002-1361-6272; yi tao, wang/0000-0002-1516-4548; Lei, Yunlong/0000-0002-7918-0221	National Natural Science Foundation of China [81672301, 81872014]; Basic Sciences and Advanced Technology Key Project of CQ CSTC [cstc2017jcyjBX0069]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Basic Sciences and Advanced Technology Key Project of CQ CSTC	This work was supported in part by grants-in-aid from the National Natural Science Foundation of China (No. 81672301 to YB and no. 81872014 to YL), the Basic Sciences and Advanced Technology Key Project of CQ CSTC (No. cstc2017jcyjBX0069). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Prof. David P. Molloy for checking the language of our manuscript.	Bayley R, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188407; Blais A, 2005, GENE DEV, V19, P1499, DOI 10.1101/gad.1325605; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Calvisi DF, 2011, HEPATOLOGY, V53, P1226, DOI 10.1002/hep.24174; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Cooper CS, 2006, LUNG CANCER, V54, P155, DOI 10.1016/j.lungcan.2006.07.005; Fan XY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051479; Feng XF, 2017, ONCOTARGET, V8, P63605, DOI 10.18632/oncotarget.18868; Frau M, 2011, J HEPATOL, V55, P111, DOI 10.1016/j.jhep.2010.10.031; Huang CL, 2007, CLIN CANCER RES, V13, P6938, DOI 10.1158/1078-0432.CCR-07-1539; Ji Y, 2013, INT J BIOCHEM CELL B, V45, P645, DOI 10.1016/j.biocel.2012.12.002; Jiang M, 2016, MOL CELL BIOL, V36, P2945, DOI 10.1128/MCB.00370-16; Jin YL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18060860; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; Kent LN, 2019, NAT REV CANCER, V19, P326, DOI 10.1038/s41568-019-0143-7; Kheirelseid EAH, 2013, J GASTROINTEST ONCOL, V4, P144, DOI 10.3978/j.issn.2078-6891.2013.010; Mega S, 2005, DIS ESOPHAGUS, V18, P109, DOI 10.1111/j.1442-2050.2005.00463.x; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Mowla SN, 2014, AGING CELL, V13, P773, DOI 10.1111/acel.12242; Musa J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.244; Nientiedt M, 2021, J CANCER RES CLIN, V147, P129, DOI 10.1007/s00432-020-03392-7; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; O'Connell MJ, 2010, J CLIN ONCOL, V28, P3937, DOI 10.1200/JCO.2010.28.9538; Papetti M, 2011, AM J PHYSIOL-GASTR L, V301, pG508, DOI 10.1152/ajpgi.00066.2011; Reimer D, 2006, ANN NY ACAD SCI, V1091, P270, DOI 10.1196/annals.1378.073; Ren F, 2015, AM J CANCER RES, V5, P1542; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sandberg ML, 2005, DEV CELL, V8, P153, DOI 10.1016/j.devcel.2004.12.015; Scheijen B, 2004, J BIOL CHEM, V279, P10476, DOI 10.1074/jbc.M313682200; Sharma N, 2006, J BIOL CHEM, V281, P36124, DOI 10.1074/jbc.M604152200; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Thorner AR, 2009, ONCOGENE, V28, P742, DOI 10.1038/onc.2008.430; Timmers C, 2007, MOL CELL BIOL, V27, P65, DOI 10.1128/MCB.02147-06; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; Wang YT, 2015, BBA-GENE REGUL MECH, V1849, P1133, DOI 10.1016/j.bbagrm.2015.07.002; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Xanthoulis A, 2014, APPL IMMUNOHISTO M M, V22, P471, DOI 10.1097/PAI.0b013e3182598198; Xanthoulis A, 2013, WORLD J GASTROENTERO, V19, P3189, DOI 10.3748/wjg.v19.i21.3189; Zhou J, 2019, THERANOSTICS, V9, P5577, DOI 10.7150/thno.34663	39	5	5	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5613	5625		10.1038/s41388-021-01961-9	http://dx.doi.org/10.1038/s41388-021-01961-9		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34316028	hybrid, Green Published			2022-12-28	WOS:000677949900001
J	Seto-Tetsuo, F; Arioka, M; Miura, K; Inoue, T; Igawa, K; Tomooka, K; Takahashi-Yanaga, F; Sasaguri, T				Seto-Tetsuo, Fumi; Arioka, Masaki; Miura, Koichi; Inoue, Takeru; Igawa, Kazunobu; Tomooka, Katsuhiko; Takahashi-Yanaga, Fumi; Sasaguri, Toshiyuki			DIF-1 inhibits growth and metastasis of triple-negative breast cancer through AMPK-mediated inhibition of the mTORC1-S6K signaling pathway	ONCOGENE			English	Article							DIFFERENTIATION-INDUCING FACTOR; FACTOR-I; MESENCHYMAL TRANSITION; CYCLIN D1; PHOSPHORYLATION SITES; MTOR; EXPRESSION; MUTATIONS; SNAIL; P53	We have previously reported that the differentiation-inducing factor-1 (DIF-1), a compound identified in Dictyostelium discoideum, suppresses the growth of MCF-7 breast cancer cells by inactivating p70 ribosomal protein S6 kinase (p70(S6K)). Therefore, we first examined whether the same mechanism operates in other breast cancer cells, especially triple-negative breast cancer (TNBC), the most aggressive and refractory phenotype of breast cancer. We also investigated the mechanism by which DIF-1 suppresses p70(S6K) by focusing on the AMPK-mTORC1 system. We found that DIF-1 induces phosphorylation of AMPK and Raptor and dephosphorylation of p70(S6K) in multiple TNBC cell lines. Next, we examined whether AMPK-mediated inhibition of p70(S6K) leads to the suppression of proliferation and migration/infiltration of TNBC cells. DIF-1 significantly reduced the expression levels of cyclin D1 by suppressing the translation of STAT3 and strongly suppressed the expression levels of Snail, which led to the suppression of growth and motility, respectively. Finally, we investigated whether DIF-1 exerts anticancer effects on TNBC in vivo. Intragastric administration of DIF-1 suppressed tumor growth and spontaneous lung metastasis of 4T1-Luc cells injected into the mammary fat pad of BALB/c mice. DIF-1 is expected to lead to the development of anticancer drugs, including anti-TNBC, by a novel mechanism.	[Seto-Tetsuo, Fumi; Arioka, Masaki; Miura, Koichi; Inoue, Takeru; Sasaguri, Toshiyuki] Kyushu Univ, Fac Med Sci, Dept Clin Pharmacol, Fukuoka, Japan; [Igawa, Kazunobu; Tomooka, Katsuhiko] Kyushu Univ, Inst Mat Chem & Engn, Kasuga, Japan; [Takahashi-Yanaga, Fumi] Univ Occupat & Environm Hlth, Sch Med, Dept Pharmacol, Kitakyushu, Fukuoka, Japan	Kyushu University; Kyushu University; University of Occupational & Environmental Health - Japan	Arioka, M; Sasaguri, T (corresponding author), Kyushu Univ, Fac Med Sci, Dept Clin Pharmacol, Fukuoka, Japan.	arioka.masaki.118@m.kyushu-u.ac.jp; sasaguri.toshiyuki.922@m.kyushu-u.ac.jp		Tetsuo, Fumi/0000-0002-6443-9827	JSPS KAKENHI [JP17K15581, JP20K07292, JP20K22709]; Fukuoka Foundation for Sound Health Cancer Research Fund; Kaibara Morikazu Medical Science Promotion Foundation; Society for Women's Health Science Research	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Fukuoka Foundation for Sound Health Cancer Research Fund; Kaibara Morikazu Medical Science Promotion Foundation(Kaibara Morikazu Medical Science Promotion Foundation); Society for Women's Health Science Research	We appreciate the technical support provided by the Research Support Center at the Graduate School of Medical Sciences of Kyushu University. This study was supported by JSPS KAKENHI Grant Numbers JP17K15581, JP20K07292, JP20K22709, by Fukuoka Foundation for Sound Health Cancer Research Fund to MA, by Kaibara Morikazu Medical Science Promotion Foundation to MA, and by Society for Women's Health Science Research to FTY.	Agarwal S, 2016, MOL CANCER RES, V14, P66, DOI 10.1158/1541-7786.MCR-15-0159; Agarwal S, 2015, J BIOL CHEM, V290, P27473, DOI 10.1074/jbc.M115.665133; Arioka M, 2017, BIOCHEM PHARMACOL, V138, P31, DOI 10.1016/j.bcp.2017.05.004; Ban HS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162568; Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burgstaller S, 2009, AMINO ACIDS, V36, P297, DOI 10.1007/s00726-008-0066-1; Campbell K, 2016, DEVELOPMENT, V143, P4291, DOI 10.1242/dev.139071; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chen L, 2014, BREAST CANCER RES TR, V147, P609, DOI 10.1007/s10549-014-3112-6; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; DeSantis CE, 2016, CA-CANCER J CLIN, V66, P31, DOI 10.3322/caac.21320; Casas SD, 2019, CUREUS, V11, DOI 10.7759/cureus.4963; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Faria J, 2019, J MAMMARY GLAND BIOL, V24, P111, DOI 10.1007/s10911-019-09429-z; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Figueiredo VC, 2017, CELL MOL LIFE SCI, V74, P2537, DOI 10.1007/s00018-017-2481-5; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Handa N, 2011, ACTA CRYSTALLOGR D, V67, P480, DOI 10.1107/S0907444911010201; He JC, 2019, BREAST CANCER RES TR, V178, P263, DOI 10.1007/s10549-019-05380-z; Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078-0432.CCR-03-0325; Howlader NR, 2020, BREAST CANCER RES TR, V182, P739, DOI 10.1007/s10549-020-05738-8; Hua H, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0754-1; Hui L, 2006, ONCOGENE, V25, P7305, DOI 10.1038/sj.onc.1209735; Iriki T, 2017, LUNG CANCER, V106, P22, DOI 10.1016/j.lungcan.2017.01.003; Jhaveri K, 2016, CLIN BREAST CANCER, V16, P113, DOI 10.1016/j.clbc.2015.11.006; Jingushi K, 2013, J PHARMACOL SCI, V121, P103, DOI 10.1254/jphs.12204FP; Jingushi K, 2012, BIOCHEM PHARMACOL, V83, P47, DOI 10.1016/j.bcp.2011.10.001; Jiralerspong S, 2009, J CLIN ONCOL, V27, P3297, DOI 10.1200/JCO.2009.19.6410; Kubokura N, 2015, J PHARMACOL SCI, V127, P446, DOI 10.1016/j.jphs.2015.03.005; Lee JS, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1202-4; Liu QS, 2013, CANCER RES, V73, P2574, DOI 10.1158/0008-5472.CAN-12-1702; Ma JH, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-0527-z; Matsuda T, 2010, J PHARMACOL SCI, V112, P320, DOI 10.1254/jphs.09348FP; Mori J, 2005, EXP CELL RES, V310, P426, DOI 10.1016/j.yexcr.2005.07.024; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; Nakamura K, 2017, J EPIDEMIOL, V27, pS58, DOI 10.1016/j.je.2016.12.009; Parajuli P, 2001, CANCER RES, V61, P8227; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Peart O, 2017, RADIOL TECHNOL, V88, p519M; Pon YL, 2008, CANCER RES, V68, P6524, DOI 10.1158/0008-5472.CAN-07-6302; Rosner M, 2010, AMINO ACIDS, V38, P223, DOI 10.1007/s00726-008-0230-7; Sabbatinelli J, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01523; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schaffer BE, 2015, CELL METAB, V22, P907, DOI 10.1016/j.cmet.2015.09.009; Shimizu K, 2004, CANCER RES, V64, P2568, DOI 10.1158/0008-5472.CAN-03-3551; Son H, 2010, TOX RESEARCH, V26, P245, DOI 10.5487/TR.2010.26.4.245; Stevens KN, 2013, CANCER RES, V73, P2025, DOI 10.1158/0008-5472.CAN-12-1699; Sugden C, 2015, MOL BIOL CELL, V26, P805, DOI 10.1091/mbc.E14-08-1319; Takahashi-Yanaga F, 2006, J BIOL CHEM, V281, P38489, DOI 10.1074/jbc.M605205200; Takahashi-Yanaga F, 2014, BIOCHEM PHARMACOL, V89, P340, DOI 10.1016/j.bcp.2014.03.006; Tao K, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-228; Tetsuo F, 2019, CANCER SCI, V110, P3761, DOI 10.1111/cas.14204; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Yao H, 2017, ONCOTARGET, V8, P1913, DOI 10.18632/oncotarget.12284; Yin L, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-01296-5; Yunokawa M, 2012, CANCER SCI, V103, P1665, DOI 10.1111/j.1349-7006.2012.02359.x; Zhang A, 2013, ONCOL LETT, V6, P339, DOI 10.3892/ol.2013.1385	63	4	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5579	5589		10.1038/s41388-021-01958-4	http://dx.doi.org/10.1038/s41388-021-01958-4		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34304250				2022-12-28	WOS:000677232000001
J	Palma, FR; Ratti, BA; Paviani, V; Coelho, DR; Miguel, R; Danes, JM; Zaichik, SV; de Abreu, AL; Silva, SO; Chen, YL; Silverstein, RL; Karan, U; Jones, DP; Bonini, MG				Palma, Flavio R.; Ratti, Bianca A.; Paviani, Veronica; Coelho, Diego R.; Miguel, Rodrigo; Danes, Jeanne M.; Zaichik, Sofia, V; de Abreu, Andre L.; Silva, Sueli O.; Chen, Yiliang; Silverstein, Roy L.; Karan, Uppal; Jones, Dean P.; Bonini, Marcelo G.			AMPK-deficiency forces metformin-challenged cancer cells to switch from carbohydrate metabolism to ketogenesis to support energy metabolism	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; PATHWAY	Epidemiologic studies in diabetic patients as well as research in model organisms have indicated the potential of metformin as a drug candidate for the treatment of various types of cancer, including breast cancer. To date most of the anti-cancer properties of metformin have, in large part, been attributed either to the inhibition of mitochondrial NADH oxidase complex (Complex I in the electron transport chain) or the activation of AMP-activated kinase (AMPK). However, it is becoming increasingly clear that AMPK activation may be critical to alleviate metabolic and energetic stresses associated with tumor progression suggesting that it may, in fact, attenuate the toxicity of metformin instead of promoting it. Here, we demonstrate that AMPK opposes the detrimental effects of mitochondrial complex I inhibition by enhancing glycolysis at the expense of, and in a manner dependent on, pyruvate availability. We also found that metformin forces cells to rewire their metabolic grid in a manner that depends on AMPK, with AMPK-competent cells upregulating glycolysis and AMPK-deficient cell resorting to ketogenesis. In fact, while the killing effects of metformin were largely rescued by pyruvate in AMPKcompetent cells, AMPK-deficient cells required instead acetoacetate, a product of fatty acid catabolism indicating a switch from sugar to fatty acid metabolism as a central resource for ATP production in these cells. In summary, our results indicate that AMPK activation is not responsible for metformin anticancer activity and may instead alleviate energetic stress by activating glycolysis.	[Palma, Flavio R.; Paviani, Veronica; Coelho, Diego R.; Miguel, Rodrigo; Danes, Jeanne M.; Bonini, Marcelo G.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; [Palma, Flavio R.; Paviani, Veronica; Coelho, Diego R.; Danes, Jeanne M.; Chen, Yiliang; Silverstein, Roy L.; Bonini, Marcelo G.] Med Coll Wisconsin, Dept Med & Biophys, Milwaukee, WI 53226 USA; [Ratti, Bianca A.; de Abreu, Andre L.; Silva, Sueli O.] Univ Estadual Maringa, Ave Colombo 5790, BR-87020900 Maringa, PR, Brazil; [Karan, Uppal; Jones, Dean P.] Emory Univ, Sch Med, Dept Med, 615 Michael St NE, Atlanta, GA 30322 USA; [Zaichik, Sofia, V; de Abreu, Andre L.] Univ Illinois, Dept Med, 909 S Wolcott Ave,COMRB 1131, Chicago, IL 60612 USA; [Chen, Yiliang; Silverstein, Roy L.] Versiti, Blood Res Inst, Milwaukee, WI 53226 USA	Northwestern University; Feinberg School of Medicine; Medical College of Wisconsin; Universidade Estadual de Maringa; Emory University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Versiti Blood Center of Wisconsin	Bonini, MG (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA.; Bonini, MG (corresponding author), Med Coll Wisconsin, Dept Med & Biophys, Milwaukee, WI 53226 USA.	marcelo.bonini@northwestern.edu	Silva, Sueli/P-2164-2017	Silva, Sueli/0000-0001-9303-0804; Palma, Flavio/0000-0003-4350-2708; Chen, Yiliang/0000-0001-9786-8305; Paviani Sampaio, Veronica/0000-0003-0718-2436	U.S. National Institutes of Health, NIAID [R01AI131267]; NIEHS [R01028149]; NCI [R01CA216882]; DOD/ARO [72983]; American Heart Association Scientist Development Grant [17SDG33661117]	U.S. National Institutes of Health, NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD/ARO(United States Department of Defense); American Heart Association Scientist Development Grant(American Heart Association)	The authors acknowledge the technical assistance of Mr. Matheus Pedrosa for his assistance with figure designs, Dr. Juliana C. P. Calado and Metabolomics core from the Robert Lurie Comprehensive Cancer Center for metabolomics analysis. The authors are grateful for funding from the U.S. National Institutes of Health, NIAID R01AI131267 (to MGB); NIEHS R01028149 (to MGB); NCI R01CA216882 (to MGB) and DOD/ARO grant number 72983 (to MGB); and American Heart Association Scientist Development Grant #17SDG33661117 (to YC).	Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080; Bo S, 2012, J ENDOCRINOL INVEST, V35, P231, DOI 10.1007/BF03345423; Cazzaniga M, 2009, CANCER EPIDEM BIOMAR, V18, P701, DOI 10.1158/1055-9965.EPI-08-0871; Cheong JH, 2011, MOL CANCER THER, V10, P2350, DOI 10.1158/1535-7163.MCT-11-0497; DJAVADIOHANIANCE L, 1975, J BIOL CHEM, V250, P9397; Eichner LJ, 2019, CELL METAB, V29, P285, DOI 10.1016/j.cmet.2018.10.005; Feng Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.59; Ferreira GD, 2014, EUR J OBSTET GYN R B, V175, P157, DOI 10.1016/j.ejogrb.2014.01.009; Ferretti AC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39556-w; Flory J, 2019, JAMA-J AM MED ASSOC, V321, P1926, DOI 10.1001/jama.2019.3805; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; GUTMAN M, 1970, P NATL ACAD SCI USA, V65, P763, DOI 10.1073/pnas.65.3.763; Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013; Hart PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7053; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175; Menendez JA, 2012, CELL CYCLE, V11, P2782, DOI 10.4161/cc.20948; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Spinelli JB, 2017, SCIENCE, V358, P941, DOI 10.1126/science.aam9305; Tennakoon JB, 2014, ONCOGENE, V33, P5251, DOI 10.1038/onc.2013.463; Xu J, 2012, CRIT REV FOOD SCI, V52, P373, DOI 10.1080/10408398.2010.500245; Zhao HX, 2019, NAT CELL BIOL, V21, P476, DOI 10.1038/s41556-019-0296-3; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	25	7	7	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5455	5467		10.1038/s41388-021-01943-x	http://dx.doi.org/10.1038/s41388-021-01943-x		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34290400	Green Accepted			2022-12-28	WOS:000677857200004
J	Fu, JJ; Su, XR; Li, ZH; Deng, L; Liu, XW; Feng, XC; Peng, J				Fu, Jianjiang; Su, Xiaorui; Li, Zhihua; Deng, Ling; Liu, Xiawei; Feng, Xuancheng; Peng, Juan			HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence	ONCOGENE			English	Review							HEPATOCYTE GROWTH-FACTOR; CELL LUNG-CANCER; EXON 14 MUTATIONS; TYROSINE KINASE INHIBITOR; SCATTER FACTOR HGF/SF; C-MET; BREAST-CANCER; PROGNOSTIC VALUE; FACTOR RECEPTOR; THERAPEUTIC TARGET	This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor (HGF) /mesenchymal-epithelial transition factor (c-MET)) signaling pathway in cancers. First, we generalize the compelling influence of HGF/c-MET pathway on multiple cellular processes. Then, we present the genomic characterization of HGF/c-MET pathway in carcinogenesis. Furthermore, we extensively illustrate the malignant biological behaviors of HGF/c-MET pathway in cancers, in which hyperactive HGF/c-MET signaling is considered as a hallmark. In addition, we investigate the current clinical trials of HGF/c-MET-targeted therapy in cancers. We find that although HGF/c-MET-targeted therapy has led to breakthroughs in certain cancers, monotherapy of targeting HGF/c-MET has failed to demonstrate significant clinical efficacy in most cancers. With the advantage of the combinations of HGF/c-MET-targeted therapy, the exploration of more options of combinational targeted therapy in cancers may be the major challenge in the future.	[Fu, Jianjiang; Su, Xiaorui; Liu, Xiawei; Feng, Xuancheng; Peng, Juan] Guangzhou Med Univ, Affiliated Hosp 3, Dept Pathol, Guangzhou, Peoples R China; [Fu, Jianjiang; Su, Xiaorui; Li, Zhihua; Liu, Xiawei; Feng, Xuancheng; Peng, Juan] Guangzhou Med Univ, Clin Sch 3, Guangzhou, Peoples R China; [Fu, Jianjiang; Su, Xiaorui; Li, Zhihua; Liu, Xiawei; Feng, Xuancheng; Peng, Juan] Key Lab Reprod & Genet Guangdong Higher Educ Inst, Guangzhou, Peoples R China; [Li, Zhihua] Guangzhou Med Univ, Affiliated Hosp 3, Dept Fetal Med & Prenatal Diag, Guangzhou, Peoples R China; [Deng, Ling] Sun Yat Sen Univ Canc Ctr, Dept Mol Diagnost, Guangzhou, Peoples R China	Guangzhou Medical University; Guangzhou Medical University; Guangzhou Medical University; Sun Yat Sen University	Feng, XC; Peng, J (corresponding author), Guangzhou Med Univ, Affiliated Hosp 3, Dept Pathol, Guangzhou, Peoples R China.; Feng, XC; Peng, J (corresponding author), Guangzhou Med Univ, Clin Sch 3, Guangzhou, Peoples R China.; Feng, XC; Peng, J (corresponding author), Key Lab Reprod & Genet Guangdong Higher Educ Inst, Guangzhou, Peoples R China.	2816924339@qq.com; pengjuan1979@yahoo.com	Peng, Juan/GXF-2029-2022	Peng, Juan/0000-0001-6308-3040; Liu, Xiawei/0000-0001-9508-1832; Feng, Xuancheng/0000-0002-8722-6306	National Natural Science Foundation of China [81602631]; Guangdong Natural Science Foundation of China [2016A030310280]; Students' Laboratory Open Project of Guangzhou Medical University [C195015021]; Elite Talents Training Plan of the Third Affiliated Hospital of Guangzhou Medical University; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation: "Climbing Program" Special Funds [pdjh2020b0490]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation of China(National Natural Science Foundation of Guangdong Province); Students' Laboratory Open Project of Guangzhou Medical University; Elite Talents Training Plan of the Third Affiliated Hospital of Guangzhou Medical University; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation: "Climbing Program" Special Funds	This work has been supported by the National Natural Science Foundation of China (No. 81602631), the Guangdong Natural Science Foundation of China (No. 2016A030310280), the Students' Laboratory Open Project of Guangzhou Medical University (No. C195015021), 2017 Elite Talents Training Plan of the Third Affiliated Hospital of Guangzhou Medical University (J.P.), and Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation: "Climbing Program" Special Funds (No. pdjh2020b0490).	Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002; Aebersold DM, 2003, ONCOGENE, V22, P8519, DOI 10.1038/sj.onc.1206968; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Antonia SJ, 2016, LANCET ONCOL, V17, P883, DOI 10.1016/S1470-2045(16)30098-5; Aparicio T, 2021, TARGET ONCOL, V16, P381, DOI 10.1007/s11523-021-00811-8; Asaoka Y, 2010, BIOCHEM BIOPH RES CO, V394, P1042, DOI 10.1016/j.bbrc.2010.03.120; Awad MM, 2016, J CLIN ONCOL, V34, P721, DOI 10.1200/JCO.2015.63.4600; Baltschukat S, 2019, CLIN CANCER RES, V25, P3164, DOI 10.1158/1078-0432.CCR-18-2814; Bao ZS, 2014, GENOME RES, V24, P1765, DOI 10.1101/gr.165126.113; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bender S, 2016, NAT MED, V22, P1314, DOI 10.1038/nm.4204; Bertran-Alamillo J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09734-5; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Burbridge MF, 2013, MOL CANCER THER, V12, P1749, DOI 10.1158/1535-7163.MCT-13-0075; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Catenacci DVT, 2017, CANCER-AM CANCER SOC, V123, P1061, DOI 10.1002/cncr.30437; Chang LL, 2019, ACTA PHARM SIN B, V9, P484, DOI 10.1016/j.apsb.2019.03.001; Charytonowicz E, 2009, CANCER LETT, V279, P126, DOI 10.1016/j.canlet.2008.09.039; Che L, 2020, GUT, V69, P177, DOI 10.1136/gutjnl-2018-317581; Cheng FL, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1269-x; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Choi J, 2018, APPL IMMUNOHISTO M M, V26, P445, DOI 10.1097/PAI.0000000000000448; Choueiri TK, 2015, NEW ENGL J MED, V373, P1814, DOI 10.1056/NEJMoa1510016; Choueiri TK, 2020, J CLIN ONCOL, V38; Choueiri TK, 2017, J CLIN ONCOL, V35, P591, DOI 10.1200/JCO.2016.70.7398; Choueiri TK, 2016, LANCET ONCOL, V17, P917, DOI 10.1016/S1470-2045(16)30107-3; Ciccarese C, 2016, CANCER TREAT REV, V49, P37, DOI 10.1016/j.ctrv.2016.07.003; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Conrotto P, 2004, ONCOGENE, V23, P5131, DOI 10.1038/sj.onc.1207650; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Corso S, 2013, CANCER DISCOV, V3, P978, DOI 10.1158/2159-8290.CD-13-0040; Cui JJ, 2011, J MED CHEM, V54, P6342, DOI 10.1021/jm2007613; Dai L, 2015, BLOOD, V126, P2821, DOI 10.1182/blood-2015-07-658823; Dang H, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1166-4; Daniel SK, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0226-9; Davis IJ, 2010, CANCER RES, V70, P639, DOI 10.1158/0008-5472.CAN-09-1121; De Bacco F, 2011, J NATL CANCER I, V103, P645, DOI 10.1093/jnci/djr093; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Doi T, 2020, INVEST NEW DRUG, V38, P1175, DOI 10.1007/s10637-019-00859-4; Drilon A, 2020, NAT MED, V26, P47, DOI 10.1038/s41591-019-0716-8; Drilon AE, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.108; Du F, 2020, ONCOGENE, V39, P3522, DOI 10.1038/s41388-020-1233-4; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Engstrom LD, 2017, CLIN CANCER RES, V23, P6661, DOI 10.1158/1078-0432.CCR-17-1192; Fan GF, 2016, GENE DEV, V30, P1542, DOI 10.1101/gad.284166.116; Flores-Tellez TNJ, 2017, WORLD J GASTROENTERO, V23, P6750, DOI 10.3748/wjg.v23.i37.6750; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GHERARDI E, 1993, SYM SOC EXP BIOL, V47, P163; Gibney GT, 2013, ANN ONCOL, V24, P343, DOI 10.1093/annonc/mds463; Gille J, 1998, J INVEST DERMATOL, V111, P1160, DOI 10.1046/j.1523-1747.1998.00418.x; Gow CH, 2017, LUNG CANCER, V103, P82, DOI 10.1016/j.lungcan.2016.12.001; Goyal L, 2013, CLIN CANCER RES, V19, P2310, DOI 10.1158/1078-0432.CCR-12-2791; Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005; Gupta A, 2008, CLIN CANCER RES, V14, P7385, DOI 10.1158/1078-0432.CCR-07-5110; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harding JJ, 2019, CLIN CANCER RES, V25, P2116, DOI 10.1158/1078-0432.CCR-18-2293; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; Hofmann F, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012796.pub2; Huang KH, 2018, ONCOL REP, V40, P294, DOI 10.3892/or.2018.6447; Huang WC, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4529-9; Huang X, 2019, AUTOPHAGY, V15, P1258, DOI 10.1080/15548627.2019.1580105; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Vuong HG, 2018, LUNG CANCER, V123, P76, DOI 10.1016/j.lungcan.2018.07.006; Jagadeeswaran R, 2006, CANCER RES, V66, P352, DOI 10.1158/0008-5472.CAN-04-4567; Jahangiri A, 2017, P NATL ACAD SCI USA, V114, pE8685, DOI 10.1073/pnas.1701821114; Jankowski K, 2003, CANCER RES, V63, P7926; Jeon HM, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.67; Joo KM, 2012, CANCER RES, V72, P3828, DOI 10.1158/0008-5472.CAN-11-3760; JUCKER M, 1994, LEUKEMIA RES, V18, P7, DOI 10.1016/0145-2126(94)90003-5; Kadoyama K, 2009, NEUROSCI RES, V65, P194, DOI 10.1016/j.neures.2009.06.016; Kelley RK, 2017, ANN ONCOL, V28, P528, DOI 10.1093/annonc/mdw651; Kim H, 2016, J CANCER RES CLIN, V142, P707, DOI 10.1007/s00432-015-2072-5; Kim JH, 2018, J CANCER, V9, P1836, DOI 10.7150/jca.24980; Kim JH, 2017, ONCOTARGET, V8, P90351, DOI 10.18632/oncotarget.20087; Kim JH, 2017, ONCOTARGET, V8, P73098, DOI 10.18632/oncotarget.20392; Kim JH, 2017, ONCOTARGET, V8, P75478, DOI 10.18632/oncotarget.20796; Kondo S, 2013, INT J CLIN ONCOL, V18, P207, DOI 10.1007/s10147-011-0361-9; Kong LR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15318-5; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Krishnaswamy S, 2009, CLIN CANCER RES, V15, P5714, DOI 10.1158/1078-0432.CCR-09-0070; Kubo Y, 2019, J DERMATOL SCI, V93, P33, DOI 10.1016/j.jdermsci.2018.10.001; Kurzrock R, 2011, J CLIN ONCOL, V29, P2660, DOI 10.1200/JCO.2010.32.4145; LAGUDA B, 1991, ANN HUM GENET, V55, P213, DOI 10.1111/j.1469-1809.1991.tb00415.x; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Lee SJ, 2018, CLIN COLORECTAL CANC, V17, P165, DOI 10.1016/j.clcc.2018.02.013; Lee SJ, 2013, ANTICANCER RES, V33, P5179; Li A, 2017, CLIN CANCER RES, V23, P4929, DOI 10.1158/1078-0432.CCR-16-3273; Li H, 2019, GASTROENTEROLOGY, V156, P1849, DOI 10.1053/j.gastro.2019.01.252; Li YQ, 2011, P NATL ACAD SCI USA, V108, P9951, DOI 10.1073/pnas.1016912108; Liang QL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0122-5; Liu XW, 2016, J CLIN ONCOL, V34, P794, DOI 10.1200/JCO.2015.62.0674; Liu Y, 2015, WORLD J GASTROENTERO, V21, P3706, DOI 10.3748/wjg.v21.i12.3706; Lux A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133305; Ma PC, 2008, GENE CHROMOSOME CANC, V47, P1025, DOI 10.1002/gcc.20604; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Ma PC, 2003, CANCER RES, V63, P6272; Marona P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030272; Maulik G, 2002, CLIN CANCER RES, V8, P620; Michikoshi H, 2013, CANCER LETT, V335, P472, DOI 10.1016/j.canlet.2013.03.008; Miura Y, 2003, BIOCHEM BIOPH RES CO, V305, P160, DOI 10.1016/S0006-291X(03)00725-3; Morell RJ, 2020, J NEUROSCI, V40, P2976, DOI 10.1523/JNEUROSCI.2278-19.2020; Moro-Sibilot D, 2019, ANN ONCOL, V30, P1985, DOI 10.1093/annonc/mdz407; Mujtaba G, 2015, J MED GENET, V52, P548, DOI 10.1136/jmedgenet-2015-103023; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Nakamura Y, 2008, CANCER SCI, V99, P14, DOI 10.1111/j.1349-7006.2007.00640.x; Nakayama M, 2013, CYTOKINE, V62, P446, DOI 10.1016/j.cyto.2013.04.006; Nassar D, 2016, ANNU REV PATHOL-MECH, V11, P47, DOI 10.1146/annurev-pathol-012615-044438; Nault JC, 2020, HEPATOLOGY, V71, P164, DOI 10.1002/hep.30811; Navis AC, 2015, ACTA NEUROPATHOL, V130, P131, DOI 10.1007/s00401-015-1420-5; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Ou SHI, 2011, J THORAC ONCOL, V6, P942, DOI 10.1097/JTO.0b013e31821528d3; Oyama T, 1998, PATHOL INT, V48, P763, DOI 10.1111/j.1440-1827.1998.tb03835.x; Paik PK, 2020, NEW ENGL J MED, V383, P931, DOI 10.1056/NEJMoa2004407; Park DJ, 2014, ANN SURG ONCOL, V21, P1130, DOI 10.1245/s10434-013-3429-0; Park K, 2021, LUNG CANCER, V155, P127, DOI 10.1016/j.lungcan.2021.03.012; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Peng H, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-1038; Peng JF, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/6594016; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Penuel E, 2013, MOL CANCER THER, V12, P1122, DOI 10.1158/1535-7163.MCT-13-0015; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Previdi S, 2010, EUR J CANCER, V46, P1679, DOI 10.1016/j.ejca.2010.02.036; Puccini A, 2019, DRUG SAFETY, V42, P211, DOI 10.1007/s40264-018-0780-x; Puri N, 2007, CLIN CANCER RES, V13, P2246, DOI 10.1158/1078-0432.CCR-06-0776; Pyo JS, 2016, PATHOL RES PRACT, V212, P710, DOI 10.1016/j.prp.2016.05.006; Rath P, 2013, TRANSL ONCOL, V6, P104, DOI 10.1593/tlo.13127; Ready N, 2019, J THORAC ONCOL, V14, P237, DOI 10.1016/j.jtho.2018.10.003; Recondo G, 2020, CLIN CANCER RES, V26, P2615, DOI 10.1158/1078-0432.CCR-19-3608; Ren JL, 2017, PANMINERVA MED, V59, P97, DOI 10.23736/S0031-0808.16.03228-6; Rodon J, 2017, EUR J CANCER, V81, P142, DOI 10.1016/j.ejca.2017.05.007; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; Roohullah A, 2018, INVEST NEW DRUG, V36, P886, DOI 10.1007/s10637-018-0588-7; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Saltarella I, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-018-0691-4; Saygin C, 2019, CELL STEM CELL, V24, P25, DOI 10.1016/j.stem.2018.11.017; Scarpino S, 2004, J PATHOL, V202, P352, DOI 10.1002/path.1522; Schiefer AI, 2015, HISTOPATHOLOGY, V67, P799, DOI 10.1111/his.12709; Schlumberger M, 2017, ANN ONCOL, V28, P2813, DOI 10.1093/annonc/mdx479; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schoffski P, 2017, ANN ONCOL, V28, P3000, DOI 10.1093/annonc/mdx527; Schultz JM, 2009, AM J HUM GENET, V85, P25, DOI 10.1016/j.ajhg.2009.06.003; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shen MQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0839-4; Shojaei F, 2010, CANCER RES, V70, P10090, DOI 10.1158/0008-5472.CAN-10-0489; Skoulidis F, 2019, NAT REV CANCER, V19, P495, DOI 10.1038/s41568-019-0179-8; Skrzypek K, 2015, ONCOTARGET, V6, P31378, DOI 10.18632/oncotarget.5145; Smith DC, 2013, J CLIN ONCOL, V31, P412, DOI 10.1200/JCO.2012.45.0494; Smith M, 2016, J CLIN ONCOL, V34, P3005, DOI 10.1200/JCO.2015.65.5597; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Solomon BJ, 2018, J CLIN ONCOL, V36, P2251, DOI 10.1200/JCO.2017.77.4794; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Suzuki M, 2005, J BIOL CHEM, V280, P6409, DOI 10.1074/jbc.M406714200; Szturz P, 2017, ORAL ONCOL, V74, P68, DOI 10.1016/j.oraloncology.2017.09.009; Taulli R, 2006, CANCER RES, V66, P4742, DOI 10.1158/0008-5472.CAN-05-4292; Tavian D, 2000, INT J CANCER, V87, P644, DOI 10.1002/1097-0215(20000901)87:5<644::AID-IJC4>3.3.CO;2-N; THALER FJ, 1985, CANCER RES, V45, P2545; Tong CYK, 2004, J NEUROSURG, V100, P187, DOI 10.3171/ped.2004.100.2.0187; Tsuji T, 2017, ONCOTARGET, V8, P71805, DOI 10.18632/oncotarget.17895; Umeki K, 1999, ONCOLOGY-BASEL, V56, P314, DOI 10.1159/000011985; van den Bent M, 2020, J NEURO-ONCOL, V146, P79, DOI 10.1007/s11060-019-03337-2; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Vsiansky V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28672-8; Wakelee HA, 2017, CANCER CHEMOTH PHARM, V79, P923, DOI 10.1007/s00280-017-3283-z; Wang F, 2016, BREAST, V28, P45, DOI 10.1016/j.breast.2016.04.016; Wang HY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00055; Wang Y, 2021, ONCOLOGIST, V26, P178, DOI 10.1002/onco.13545; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Westover D, 2018, ANN ONCOL, V29, pI10, DOI 10.1093/annonc/mdx703; Wolf J, 2020, NEW ENGL J MED, V383, P944, DOI 10.1056/NEJMoa2002787; Wu F, 2006, DIGEST LIVER DIS, V38, P490, DOI 10.1016/j.dld.2006.03.007; Wu YL, 2020, LANCET RESP MED, V8, P1132, DOI 10.1016/S2213-2600(20)30154-5; Wu YL, 2018, J CLIN ONCOL, V36, P3101, DOI 10.1200/JCO.2018.77.7326; Wu YL, 2018, J THORAC ONCOL, V13, P1539, DOI 10.1016/j.jtho.2018.06.012; Xie Q, 2012, P NATL ACAD SCI USA, V109, P570, DOI 10.1073/pnas.1119059109; Xing F, 2018, CANCER RES, V78, P4316, DOI 10.1158/0008-5472.CAN-18-1102; Yan B, 2018, EXP CELL RES, V371, P63, DOI 10.1016/j.yexcr.2018.07.041; Yan SC, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0296-y; Yao JF, 2019, J BIOCHEM MOL TOXIC, V33, DOI 10.1002/jbt.22316; Zagouri F, 2013, BRIT J CANCER, V108, P1100, DOI 10.1038/bjc.2013.31; Zambelli A, 2021, ADV EXP MED BIOL, V1270, P31, DOI 10.1007/978-3-030-47189-7_2; ZARNEGAR R, 1989, CANCER RES, V49, P3314; Zhang Y, 2014, MOL MED REP, V10, P1013, DOI 10.3892/mmr.2014.2293; Zhang YR, 2020, CANCER RES, V80, P30, DOI 10.1158/0008-5472.CAN-19-1389; Zhang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0750-2; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343	194	25	26	6	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4625	4651		10.1038/s41388-021-01863-w	http://dx.doi.org/10.1038/s41388-021-01863-w		JUN 2021	27	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34145400				2022-12-28	WOS:000663295300002
J	Yang, X; Chen, Y; Zhou, Y; Wu, C; Li, Q; Wu, J; Hu, WW; Zhao, WQ; Wei, W; Wu, CP; Jiang, JT; Ji, M				Yang, Xin; Chen, Yan; Zhou, You; Wu, Chen; Li, Qing; Wu, Jun; Hu, Wen Wei; Zhao, Wei Qing; Wei, Wei; Wu, Chang Ping; Jiang, Jing Ting; Ji, Mei			GPC5 suppresses lung cancer progression and metastasis via intracellular CTDSP1/AhR/ARNT signaling axis and extracellular exosome secretion	ONCOGENE			English	Article							ANTITUMOR IMMUNITY; TUMOR-GROWTH; GLYPICAN-5; GENE; MICRORNAS; NICHE; MECHANISMS; TRANSITION; EXPRESSION; SMOKERS	Lung cancer is the leading cause of cancer-related death worldwide. Glypican-5 (GPC5) is a member of heparan sulfate proteoglycans, and its biological importance in initiation and progression of lung cancer remains controversial. In the present study, we revealed that GPC5 transcriptionally enhanced the expression of CTDSP1 (miR-26b host gene) via AhR-ARNT pathway, and such up-regulation of CTDSP1 intracellularly contributed to the inhibited proliferation of lung cancer cells. Moreover, exosomes derived from GPC5-overexpressing human lung cancer cells (GPC5-OE-derived exosomes) had an extracellular repressive effect on human lymphatic endothelial cells (hLECs), leading to decreased tube formation and migration. Comparison between GPC5-WT- and GPC5-OE-derived exosomes showed that miR-26b (embedded within introns of CTDSP1 gene) was significantly up-regulated in GPC5-OE-derived exosomes and critical to the influence on hLECs. On the mechanism, we demonstrated that miR-26b transferred into hLECs directly targeted to PTK2 3'-UTR and led to PTK2 down-regulation, resulting in defects in tube formation and migration of hLECs. By uncovering the regulation network among GPC5, miR-26b, miR-26b host gene (CTDSP1), and target gene (PTK2), our findings demonstrated that GPC5 functioned as a tumor suppressor in human lung cancer.	[Yang, Xin; Chen, Yan; Wu, Chen; Wu, Jun; Hu, Wen Wei; Zhao, Wei Qing; Wei, Wei; Wu, Chang Ping; Ji, Mei] Soochow Univ, Dept Oncol, Affiliated Hosp 3, Changzhou, Peoples R China; [Yang, Xin; Zhou, You; Jiang, Jing Ting] Jiangsu Engn Res Ctr Tumor Immunotherapy, Changzhou, Peoples R China; [Yang, Xin; Zhou, You; Jiang, Jing Ting] Soochow Univ, Inst Cell Therapy, Changzhou, Peoples R China; [Zhou, You; Jiang, Jing Ting] Soochow Univ, Affiliated Hosp 3, Dept Tumor Biol Treatment, Changzhou, Peoples R China; [Li, Qing] Soochow Univ, Affiliated Hosp 3, Dept Pathol, Changzhou, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China	Yang, X; Ji, M (corresponding author), Soochow Univ, Dept Oncol, Affiliated Hosp 3, Changzhou, Peoples R China.; Yang, X; Jiang, JT (corresponding author), Jiangsu Engn Res Ctr Tumor Immunotherapy, Changzhou, Peoples R China.; Yang, X; Jiang, JT (corresponding author), Soochow Univ, Inst Cell Therapy, Changzhou, Peoples R China.; Jiang, JT (corresponding author), Soochow Univ, Affiliated Hosp 3, Dept Tumor Biol Treatment, Changzhou, Peoples R China.	yangxindoctor@163.com; jiangjingting@suda.edu.cn; zlkjimei@163.com	Zhou, You/GMW-4434-2022		Natural Science Foundation of China [82072561]; Natural Science Youth Foundation of China [81501971, 31701111, 31700792]; China Postdoctoral Science Foundation [2018M630603]; Natural Science Youth Foundation of Jiangsu Province [BK20150252, BK20170295]; Human Resource Summit Grant of Jiangsu Province [WSW-142]; Youth Medical Professionals Foundation of Jiangsu Province [QNRC2016279]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Youth Foundation of China; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Youth Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Human Resource Summit Grant of Jiangsu Province; Youth Medical Professionals Foundation of Jiangsu Province	This work was supported by grants from the Natural Science Foundation of China (82072561), the Natural Science Youth Foundation of China (81501971, 31701111, 31700792), Project funded by China Postdoctoral Science Foundation (2018M630603), the Natural Science Youth Foundation of Jiangsu Province (BK20150252, BK20170295), the Human Resource Summit Grant of Jiangsu Province (WSW-142), and the Youth Medical Professionals Foundation of Jiangsu Province (QNRC2016279).	Alitalo K, 2011, NAT MED, V17, P1371, DOI 10.1038/nm.2545; Ameres SL, 2007, CELL, V130, P101, DOI 10.1016/j.cell.2007.04.037; Bang C, 2014, J CLIN INVEST, V124, P2136, DOI 10.1172/JCI70577; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Broekman ML, 2018, NAT REV NEUROL, V14, P482, DOI 10.1038/s41582-018-0025-8; Butler JM, 2010, NAT REV CANCER, V10, P138, DOI 10.1038/nrc2791; Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693; Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8; Chen Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11420; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Devarakonda S, 2015, LANCET ONCOL, V16, pE342, DOI 10.1016/S1470-2045(15)00077-7; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Hulsmans M, 2013, CARDIOVASC RES, V100, P7, DOI 10.1093/cvr/cvt161; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Kruspig B, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao2565; LeBleu VS, 2019, IMMUNITY, V50, P547, DOI 10.1016/j.immuni.2019.02.019; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li FC, 2011, J CELL BIOL, V192, P691, DOI 10.1083/jcb.201008087; Li YF, 2011, J THORAC ONCOL, V6, P2, DOI 10.1097/JTO.0b013e3181fd6b04; Li YF, 2010, LANCET ONCOL, V11, P321, DOI 10.1016/S1470-2045(10)70042-5; Li Y, 2013, ONCOL LETT, V6, P1565, DOI 10.3892/ol.2013.1622; Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204; Mallory AC, 2004, EMBO J, V23, P3356, DOI 10.1038/sj.emboj.7600340; Nishimura R, 2013, CANCER SCI, V104, P856, DOI 10.1111/cas.12173; Noone A, 2017, SEER CANC STAT REV C; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Ovrevik J, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0048-8; Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016; Swanson HI, 2002, CHEM-BIOL INTERACT, V141, P63, DOI 10.1016/S0009-2797(02)00066-2; Tian YA, 2009, BIOCHEM PHARMACOL, V77, P670, DOI 10.1016/j.bcp.2008.10.023; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Veugelers M, 1997, GENOMICS, V40, P24, DOI 10.1006/geno.1996.4518; Wang SW, 2016, ONCOTARGET, V7, P79722, DOI 10.18632/oncotarget.12945; Wang Z, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1056-9; Williamson D, 2007, CANCER RES, V67, P57, DOI 10.1158/0008-5472.CAN-06-1650; Xu R, 2018, NAT REV CLIN ONCOL, V15, P617, DOI 10.1038/s41571-018-0036-9; Yang X, 2013, CANCER LETT, V341, P265, DOI 10.1016/j.canlet.2013.08.020; Yuan S, 2016, ONCOGENE, V35, P6120, DOI 10.1038/onc.2016.149; Zhang CW, 2016, TUMOR BIOL, V37, P6413, DOI 10.1007/s13277-015-4499-3; Zhang CW, 2011, MOL GENET METAB, V103, P104, DOI 10.1016/j.ymgme.2011.02.005; Zhang J, 2015, GENOM PROTEOM BIOINF, V13, P17, DOI 10.1016/j.gpb.2015.02.001; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010; Zhu Y, 2012, NUCLEIC ACIDS RES, V40, P4615, DOI 10.1093/nar/gkr1278	48	5	5	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4307	4323		10.1038/s41388-021-01837-y	http://dx.doi.org/10.1038/s41388-021-01837-y		JUN 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34079082				2022-12-28	WOS:000657217400004
J	Voronina, N; Aichmuller, C; Kolb, T; Korshunov, A; Ryzhova, M; Barnholtz-Sloan, J; Cioffi, G; Sill, M; von Deimling, A; Pfister, SM; Gronych, J; Jones, DTW; Frisen, J; Zapatka, M; Ernst, A				Voronina, Natalia; Aichmueller, Christian; Kolb, Thorsten; Korshunov, Andrey; Ryzhova, Marina; Barnholtz-Sloan, Jill; Cioffi, Gino; Sill, Martin; von Deimling, Andreas; Pfister, Stefan M.; Gronych, Jan; Jones, David T. W.; Frisen, Jonas; Zapatka, Marc; Ernst, Aurelie			The age of adult pilocytic astrocytoma cells	ONCOGENE			English	Article								Adult pilocytic astrocytomas (PAs) have been regarded as indistinguishable from pediatric PAs in terms of genome-wide expression and methylation patterns. It has been unclear whether adult PAs arise early in life and remain asymptomatic until adulthood, or whether they develop during adulthood. We sought to determine the age and origin of adult human PAs using two types of "marks" in the genomic DNA. First, we analyzed the DNA methylation patterns of adult and pediatric PAs to distinguish between PAs of different anatomic locations (n = 257 PA and control brain tissues). Second, we measured the concentration of nuclear bomb test-derived C-14 in genomic DNA (n = 14 cases), which indicates the time point of the formation of human cell populations. Our data suggest that adult and pediatric PAs developing in the infratentorial brain are closely related and potentially develop from precursor cells early in life, whereas supratentorial PAs might show age and location-specific differences.	[Voronina, Natalia; Kolb, Thorsten; Ernst, Aurelie] DKFZ, Grp Genome Instabil Tumors, Heidelberg, Germany; [Aichmueller, Christian; Zapatka, Marc] DKFZ Heidelberg Ctr Personalized Oncol HIPO, DKFZ, Div Mol Genet, Heidelberg, Germany; [Aichmueller, Christian; Zapatka, Marc] German Canc Consortium DKTK, Heidelberg, Germany; [Korshunov, Andrey; von Deimling, Andreas] DKFZ, Heidelberg Univ Hosp, Dept Neuropathol, Heidelberg, Germany; [Korshunov, Andrey; von Deimling, Andreas] DKFZ, CCU Neuropathol, Heidelberg, Germany; [Ryzhova, Marina] NN Burdenko Inst Neurosurg, Moscow, Russia; [Barnholtz-Sloan, Jill; Cioffi, Gino] Case Western Reserve Univ, Sch Med, Dept Populat & Quantitat Hlth Sci, Cleveland, OH USA; [Barnholtz-Sloan, Jill; Cioffi, Gino] Cent Brain Tumor Registry US, Hinsdale, IL USA; [Sill, Martin; Pfister, Stefan M.] Hopp Childrens Canc Ctr Heidelberg KiTZ, Heidelberg, Germany; [Sill, Martin; Pfister, Stefan M.] DKFZ, Div Pediat Neurooncol, Heidelberg, Germany; [Sill, Martin; Pfister, Stefan M.] DKFZ, German Canc Consortium DKTK, Heidelberg, Germany; [Sill, Martin; Pfister, Stefan M.] Heidelberg Univ Hosp, Dept Pediat Oncol Hematol & Immunol, Heidelberg, Germany; [Gronych, Jan] DKFZ, Div Pediat Neurooncol, Hopp Childrens Canc Ctr Heidelberg KiTZ, Heidelberg, Germany; [Gronych, Jan] DKFZ, German Canc Consortium DKTK, Heidelberg, Germany; [Jones, David T. W.] Hopp Childrens Canc Ctr Heidelberg KiTZ, Pediat Glioma Res Grp, Heidelberg, Germany; [Frisen, Jonas] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Gronych, Jan] Roche Diagnost Deutschland GmbH, Mannheim, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Russian Academy of Medical Sciences; N.N.Burdenko National Medical Research Center of Neurosurgery; Case Western Reserve University; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Karolinska Institutet	Ernst, A (corresponding author), DKFZ, Grp Genome Instabil Tumors, Heidelberg, Germany.	a.ernst@dkfz.de	Barnholtz-Sloan, Jill/A-4817-2011; von Deimling, Andreas/F-7774-2013; Zapatka, Marc/G-9896-2013; Pfister, Stefan M/F-6860-2013	Barnholtz-Sloan, Jill/0000-0001-6190-9304; von Deimling, Andreas/0000-0002-5863-540X; Zapatka, Marc/0000-0001-8287-5967; Pfister, Stefan M/0000-0002-5447-5322	Else Kroner-Fresenius Foundation; Fritz Thyssen Foundation; Wilhelm Sander Foundation; Centers for Disease Control and Prevention (CDC) [75D30119C06056]; American Brain Tumor Association; Sontag Foundation; Musella Foundation; National Brain Tumor Society; Children's Brain Tumor Foundation; Uncle Kory Foundation; Zelda Dorin Tetenbaum Memorial Fund; Cancer Prevention and Research Institute of Texas (CPRIT) [RP160097T]; Novocure	Else Kroner-Fresenius Foundation; Fritz Thyssen Foundation; Wilhelm Sander Foundation; Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); American Brain Tumor Association; Sontag Foundation; Musella Foundation; National Brain Tumor Society; Children's Brain Tumor Foundation; Uncle Kory Foundation; Zelda Dorin Tetenbaum Memorial Fund; Cancer Prevention and Research Institute of Texas (CPRIT); Novocure(Novocure Limited)	We thank the Else Kroner-Fresenius Foundation, the Fritz Thyssen Foundation and the Wilhelm Sander Foundation for funding. We thank Peter Lichter for the discussions. We thank Helena Lonnqvist for support with the DNA extraction, Frauke Devens and Michaela Hergt for support with the immunohistology and Andrea Wittmann for help with tumor tissue collection. We thank the team of the Department of Physics of the Uppsala University for the AMS measurements, and Karl Hakansson and Lars Beckel in particular. We thank Nada Jabado and Almos Klekner for kindly searching for potentially suitable samples, even though the tissues did not meet the criteria for retrospective birth-dating, we are very grateful to both of them for trying to help. Funding for CBTRUS was provided by the Centers for Disease Control and Prevention (CDC) under contract no. 75D30119C06056, the American Brain Tumor Association, The Sontag Foundation, Novocure, the Musella Foundation, National Brain Tumor Society, the Children's Brain Tumor Foundation, the Uncle Kory Foundation, the Zelda Dorin Tetenbaum Memorial Fund, as well as private and in-kind donations. QTO is supported by a Research Training Grant from the Cancer Prevention and Research Institute of Texas (CPRIT; RP160097T). Contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC.	Aichmuller CF, 2020, NEURO-ONCOLOGY, V22, P1327, DOI 10.1093/neuonc/noaa035; Antonelli Manila, 2018, Oncotarget, V9, P13807, DOI 10.18632/oncotarget.24480; Bergmann O, 2009, SCIENCE, V324, P98, DOI 10.1126/science.1164680; Brokinkel B, 2015, NEUROPATH APPL NEURO, V41, P258, DOI 10.1111/nan.12145; Buhl JL, 2019, CLIN CANCER RES, V25, P1851, DOI 10.1158/1078-0432.CCR-18-1965; Capper D, 2018, NATURE, V555, P469, DOI 10.1038/nature26000; Ernst A, 2014, CELL, V156, P1072, DOI 10.1016/j.cell.2014.01.044; Fernandez AF, 2012, GENOME RES, V22, P407, DOI 10.1101/gr.119867.110; Gerstung M, 2020, NATURE, V578, P122, DOI 10.1038/s41586-019-1907-7; Hovestadt V, 2014, NATURE, V510, P537, DOI 10.1038/nature13268; Huttner HB, 2018, EBIOMEDICINE, V27, P176, DOI 10.1016/j.ebiom.2017.12.020; Janzarik WG, 2007, NEUROPEDIATRICS, V38, P61, DOI 10.1055/s-2007-984451; Korber V, 2019, CANCER CELL, V35, P692, DOI 10.1016/j.ccell.2019.02.007; Kratz CP, 2017, CLIN CANCER RES, V23, pE38, DOI 10.1158/1078-0432.CCR-17-0408; Lambert SR, 2013, ACTA NEUROPATHOL, V126, P291, DOI 10.1007/s00401-013-1124-7; Magrini S, 2013, J NEURO-ONCOL, V115, P103, DOI 10.1007/s11060-013-1200-9; Miller JA, 2014, NATURE, V508, P199, DOI 10.1038/nature13185; Mitoma H, 2020, CEREBELLUM, V19, P131, DOI 10.1007/s12311-019-01091-9; Moran S, 2016, LANCET ONCOL, V17, P1386, DOI 10.1016/S1470-2045(16)30297-2; Northcott PA, 2011, ACTA NEUROPATHOL, V122, P231, DOI 10.1007/s00401-011-0846-7; Sexton-Oates A, 2018, MOL ONCOL, V12, P1219, DOI 10.1002/1878-0261.12062; Sharma MK, 2007, CANCER RES, V67, P890, DOI 10.1158/0008-5472.CAN-06-0973; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Spalding KL, 2005, CELL, V122, P133, DOI 10.1016/j.cell.2005.04.028; Theeler BJ, 2014, NEURO-ONCOLOGY, V16, P841, DOI 10.1093/neuonc/not246; Vladoiu MC, 2019, NATURE, V572, P67, DOI 10.1038/s41586-019-1158-7; Yeung MSY, 2019, NATURE, V566, P538, DOI 10.1038/s41586-018-0842-3; Zheng SJC, 2018, NAT METHODS, V15, P1059, DOI 10.1038/s41592-018-0213-x	29	4	4	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2830	2841		10.1038/s41388-021-01738-0	http://dx.doi.org/10.1038/s41388-021-01738-0		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33731860	hybrid, Green Published			2022-12-28	WOS:000629880400001
J	Gollavilli, PN; Parma, B; Siddiqui, A; Yang, H; Ramesh, V; Napoli, F; Schwab, A; Natesan, R; Mielenz, D; Asangani, IA; Brabletz, T; Pilarsky, C; Ceppi, P				Gollavilli, Paradesi Naidu; Parma, Beatrice; Siddiqui, Aarif; Yang, Hai; Ramesh, Vignesh; Napoli, Francesca; Schwab, Annemarie; Natesan, Ramakrishnan; Mielenz, Dirk; Asangani, Irfan Ahmed; Brabletz, Thomas; Pilarsky, Christian; Ceppi, Paolo			The role of miR-200b/c in balancing EMT and proliferation revealed by an activity reporter	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; CELL-PROLIFERATION; TARGETING EMT; FEEDBACK LOOP; CANCER; MICRORNAS; METASTASIS; ZEB1; PLASTICITY	Since their discovery, microRNAs (miRNAs) have been widely studied in almost every aspect of biology and medicine, leading to the identification of important gene regulation circuits and cellular mechanisms. However, investigations are generally focused on the analysis of their downstream targets and biological functions in overexpression and knockdown approaches, while miRNAs endogenous levels and activity remain poorly understood. Here, we used the cellular plasticity-regulating process of epithelial-to-mesenchymal transition (EMT) as a model to show the efficacy of a fluorescent sensor to separate cells with distinct EMT signatures, based on miR-200b/c activity. The system was further combined with a CRISPR-Cas9 screening platform to unbiasedly identify miR-200b/c upstream regulating genes. The sensor allows to infer miRNAs fundamental biological properties, as profiling of sorted cells indicated miR-200b/c as a molecular switch between EMT differentiation and proliferation, and suggested a role for metabolic enzymes in miR-200/EMT regulation. Analysis of miRNAs endogenous levels and activity for in vitro and in vivo applications could lead to a better understanding of their biological role in physiology and disease.	[Gollavilli, Paradesi Naidu; Parma, Beatrice; Siddiqui, Aarif; Ramesh, Vignesh; Napoli, Francesca; Schwab, Annemarie; Ceppi, Paolo] Friedrich Alexander Univ Erlangen Nuremberg FAU, Interdisciplinary Ctr Clin Res IZKF, Erlangen, Germany; [Siddiqui, Aarif; Ceppi, Paolo] Univ Southern Denmark, Dept Biochem & Mol Biol, Odense, Denmark; [Yang, Hai; Pilarsky, Christian] Friedrich Alexander Univ Erlangen Nuremberg FAU, Dept Surg, Odense, Denmark; [Yang, Hai; Pilarsky, Christian] Univ Hosp Erlangen, Erlangen, Germany; [Natesan, Ramakrishnan; Asangani, Irfan Ahmed] Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA USA; [Mielenz, Dirk] Friedrich Alexander Univ Erlangen Nuremberg, Dept Mol Immunol, Erlangen, Germany; [Brabletz, Thomas] Friedrich Alexander Univ Erlangen Nuremberg, Dept Expt Med 1, Erlangen, Germany; [Napoli, Francesca] Univ Turin, Dept Oncol, San Luigi Hosp, Turin, Italy	University of Erlangen Nuremberg; University of Southern Denmark; University of Erlangen Nuremberg; University of Pennsylvania; Pennsylvania Medicine; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Turin	Ceppi, P (corresponding author), Friedrich Alexander Univ Erlangen Nuremberg FAU, Interdisciplinary Ctr Clin Res IZKF, Erlangen, Germany.; Ceppi, P (corresponding author), Univ Southern Denmark, Dept Biochem & Mol Biol, Odense, Denmark.	pceppi@bmb.sdu.dk	Ceppi, Paolo/GPS-8668-2022; Natesan, Ramakrishnan/AAM-6473-2021	Natesan, Ramakrishnan/0000-0002-7888-9255; Schwab, Annemarie/0000-0002-6351-5920; Gollavilli, Paradesi Naidu/0000-0003-0956-1296; Ceppi, Paolo/0000-0002-3632-8476; Siddiqui, Mohammad Aarif/0000-0003-4308-3398	Interdisciplinary Center for Clinical Research of the University of Erlangen-Nuremberg; German Research Foundation [DFG-CE-281/5-1]; IASLC Young Investigator Award; EU [861196]; Projekt DEAL	Interdisciplinary Center for Clinical Research of the University of Erlangen-Nuremberg; German Research Foundation(German Research Foundation (DFG)); IASLC Young Investigator Award; EU(European Commission); Projekt DEAL	This work was supported by the Interdisciplinary Center for Clinical Research of the University of Erlangen-Nuremberg (PC) and the German Research Foundation grant DFG-CE-281/5-1 (PC). PC was also supported by IASLC Young Investigator Award. CP and HY were supported by the EU (MSCA grant no.: 861196). Open Access funding enabled and organized by Projekt DEAL.	Amendola M, 2005, NAT BIOTECHNOL, V23, P108, DOI 10.1038/nbt1049; Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Behan FM, 2019, NATURE, V568, P511, DOI 10.1038/s41586-019-1103-9; Bosson AD, 2014, MOL CELL, V56, P347, DOI 10.1016/j.molcel.2014.09.018; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Brustikova K, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00045; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Carter JV, 2019, ONCOL LETT, V18, P3994, DOI 10.3892/ol.2019.10753; Ceppi P, 2014, ONCOGENE, V33, P269, DOI 10.1038/onc.2013.55; Ceppi P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6238; Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052; Davis FM, 2014, TRENDS PHARMACOL SCI, V35, P479, DOI 10.1016/j.tips.2014.06.006; Diaz-Lopez A, 2014, CANCER MANAG RES, V6, P205, DOI 10.2147/CMAR.S38156; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Ebert MS, 2010, CURR BIOL, V20, pR858, DOI 10.1016/j.cub.2010.08.052; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200; Feng XL, 2014, CANCER LETT, V344, P166, DOI 10.1016/j.canlet.2013.11.004; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Hugo HJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3580; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kroger C, 2019, P NATL ACAD SCI USA, V116, P7353, DOI 10.1073/pnas.1812876116; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; Lima RT, 2011, EUR J CANCER, V47, P163, DOI 10.1016/j.ejca.2010.11.005; Mandal M, 2016, INTEGR BIOL-UK, V8, P167, DOI 10.1039/c5ib00219b; Moustakas A, 2012, SEMIN CANCER BIOL, V22, P446, DOI 10.1016/j.semcancer.2012.04.002; Mukherji S, 2011, NAT GENET, V43, P854, DOI 10.1038/ng.905; Mullokandov G, 2012, NAT METHODS, V9, P840, DOI [10.1038/NMETH.2078, 10.1038/nmeth.2078]; Nagaraj AB, 2019, STEM CELL REP, V12, P122, DOI 10.1016/j.stemcr.2018.12.002; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Olivieri F, 2013, AGEING RES REV, V12, P1056, DOI 10.1016/j.arr.2013.05.001; Pan Y, 2015, RNA BIOL, V12, P276, DOI 10.1080/15476286.2015.1017208; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Ramesh V, 2020, TRENDS CANCER, V6, P942, DOI 10.1016/j.trecan.2020.06.005; Rubio CA, 2007, J GASTROEN HEPATOL, V22, P1877, DOI 10.1111/j.1440-1746.2007.04839.x; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Savagner P, 2010, ANN ONCOL, V21, P89, DOI 10.1093/annonc/mdq292; Schwab A, 2018, CANCER RES, V78, P1604, DOI 10.1158/0008-5472.CAN-17-2834; Shi Guiling, 2018, Oncotarget, V9, P6771, DOI 10.18632/oncotarget.23645; Siddiqui A, 2017, J PATHOL, V242, P221, DOI 10.1002/path.4897; Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thomson DW, 2011, NUCLEIC ACIDS RES, V39, P6845, DOI 10.1093/nar/gkr330; Tian WH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029551; Nguyen-Vu T, 2016, ONCOTARGET, V7, P42159, DOI 10.18632/oncotarget.9895; Trumbach D, 2015, CELL TISSUE RES, V359, P161, DOI 10.1007/s00441-014-1911-z; Wang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056664; Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9; Zhang XH, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.37	60	7	8	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2309	2322		10.1038/s41388-021-01708-6	http://dx.doi.org/10.1038/s41388-021-01708-6		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33654197	Green Published, hybrid			2022-12-28	WOS:000624398900002
J	Kim, HJ; Kim, JY; Jung, CW; Lee, YS; An, JY; Kim, EH; Kim, KH; Lee, SP; Park, JY; Park, MJ				Kim, Hee-Jin; Kim, Jeong-Yub; Jung, Chan-Woong; Lee, Young-Sun; An, Joon-Yong; Kim, Eun Ho; Kim, Ki-Hong; Lee, Sang Pyung; Park, Jae-Yong; Park, Myung-Jin			ANO1 regulates the maintenance of stemness in glioblastoma stem cells by stabilizing EGFRvIII	ONCOGENE			English	Article							CHLORIDE CHANNEL TMEM16A; GROWTH-FACTOR RECEPTOR; TUMOR-GROWTH; CANCER; EXPRESSION; PROTEIN; CONTRIBUTES; GLIOMA; IDENTIFICATION; CONCOMITANT	Glioblastoma multiforme (GBM) or glioblastoma is the most deadly malignant brain tumor in adults. GBM is difficult to treat mainly due to the presence of glioblastoma stem cells (GSCs). Epidermal growth factor receptor variant III (EGFRvIII) has been linked to stemness and malignancy of GSCs; however, the regulatory mechanism of EGFRvIII is largely unknown. Here, we demonstrated that Anoctamin-1 (ANO1), a Ca2+-activated Cl- channel, interacts with EGFRvIII, increases its protein stability, and supports the maintenance of stemness and tumor progression in GSCs. Specifically, shRNA-mediated knockdown and pharmacological inhibition of ANO1 suppressed the self-renewal, invasion activities, and expression of EGFRvIII and related stem cell factors, including NOTCH1, nestin, and SOX2 in GSCs. Conversely, ANO1 overexpression enhanced the above phenomena. Mechanistically, ANO1 protected EGFRvIII from proteasomal degradation by directly binding to it. ANO1 knockdown significantly increased survival in mice and strongly suppressed local invasion of GSCs in an in vivo intracranial mouse model. Collectively, these results suggest that ANO1 plays a crucial role in the maintenance of stemness and invasiveness of GSCs by regulating the expression of EGFRvIII and related signaling molecules, and can be considered a promising therapeutic target for GBM treatment.	[Kim, Hee-Jin; Kim, Jeong-Yub; Jung, Chan-Woong; Park, Myung-Jin] Korea Inst Radiol & Med Sci, Radiat Therapeut Dev Team, Div Radiat Canc Sci, Seoul, South Korea; [Kim, Hee-Jin; Lee, Young-Sun; An, Joon-Yong; Park, Jae-Yong] Korea Univ, Sch Biosyst & Biomed Sci, Coll Hlth Sci, Seoul, South Korea; [Jung, Chan-Woong] Korea Univ, Dept Life Sci, Seoul, South Korea; [Kim, Eun Ho] Daegu Catholic Univ, Sch Med, Dept Biochem, Daegu, South Korea; [Kim, Ki-Hong] Daegu Catholic Univ, Dept Neurosurg, Sch Med, Daegu, South Korea; [Lee, Sang Pyung] Halla Gen Hosp, Dept Neurosurg, Jeju, South Korea	Korea Institute of Radiological & Medical Sciences; Korea University; Korea University; Catholic University of Daegu; Catholic University of Daegu	Park, MJ (corresponding author), Korea Inst Radiol & Med Sci, Radiat Therapeut Dev Team, Div Radiat Canc Sci, Seoul, South Korea.; Park, JY (corresponding author), Korea Univ, Sch Biosyst & Biomed Sci, Coll Hlth Sci, Seoul, South Korea.	jaeyong68@korea.ac.kr; mjpark@kirams.re.kr	Kim, Heejin/HII-8568-2022	An, Joon-Yong/0000-0001-8839-6297	National Research Foundation of Korea [NRF-2017M3A9C4092979]; Korea Institute of Radiological and Medical Sciences (KIRAMS) - Ministry of Science and ICT (MSIT), the Republic of Korea [50531-2019]	National Research Foundation of Korea(National Research Foundation of Korea); Korea Institute of Radiological and Medical Sciences (KIRAMS) - Ministry of Science and ICT (MSIT), the Republic of Korea	This work was supported by the Bio-Synergy Research Project (NRF-2017M3A9C4092979 to JYP) of the National Research Foundation of Korea, and by a grant from the Korea Institute of Radiological and Medical Sciences (KIRAMS), funded by the Ministry of Science and ICT (MSIT), the Republic of Korea (No. 50531-2019 to MJP).	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bill A, 2015, ONCOTARGET, V6, P9173, DOI 10.18632/oncotarget.3277; Bill A, 2014, J BIOL CHEM, V289, P11029, DOI 10.1074/jbc.M114.549188; Bleeker FE, 2012, J NEURO-ONCOL, V108, P11, DOI 10.1007/s11060-011-0793-0; Britschgi A, 2013, P NATL ACAD SCI USA, V110, pE1026, DOI 10.1073/pnas.1217072110; Caputo A, 2008, SCIENCE, V322, P590, DOI 10.1126/science.1163518; Carles A, 2006, ONCOGENE, V25, P1821, DOI 10.1038/sj.onc.1209203; Carneiro A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-98; Cheng L, 2011, BIOCHEM BIOPH RES CO, V406, P643, DOI 10.1016/j.bbrc.2011.02.123; Cho H, 2012, NAT NEUROSCI, V15, P1015, DOI 10.1038/nn.3111; Crottes D, 2019, CELL CALCIUM, V82, DOI 10.1016/j.ceca.2019.06.004; Crottes D, 2019, P NATL ACAD SCI USA, V116, P13026, DOI 10.1073/pnas.1900703116; De la Fuente R, 2008, MOL PHARMACOL, V73, P758, DOI 10.1124/mol.107.043208; de la Iglesia N, 2009, CURR MOL MED, V9, P580; Del Vecchio CA, 2013, ONCOGENE, V32, P2670, DOI 10.1038/onc.2012.280; Duvvuri U, 2012, CANCER RES, V72, P3270, DOI 10.1158/0008-5472.CAN-12-0475-T; Emlet DR, 2014, CANCER RES, V74, P1238, DOI 10.1158/0008-5472.CAN-13-1407; Eskilsson E, 2016, NEURO-ONCOLOGY, V18, P1644, DOI 10.1093/neuonc/now113; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gallego O, 2015, CURR ONCOL, V22, pE273, DOI 10.3747/co.22.2436; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688; Huang F, 2012, P NATL ACAD SCI USA, V109, P16354, DOI 10.1073/pnas.1214596109; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Ji QS, 2019, J CELL PHYSIOL, V234, P7856, DOI 10.1002/jcp.27865; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Katoh M, 2003, INT J ONCOL, V22, P1375; Lee YS, 2016, BIOCHEM BIOPH RES CO, V475, P216, DOI 10.1016/j.bbrc.2016.05.077; Lee YS, 2016, SCI REP-UK, V6, DOI 10.1038/srep26413; Liu F, 2015, ONCOTARGET, V6, P11585, DOI 10.18632/oncotarget.3412; Liu J, 2014, MOL MED REP, V9, P1068, DOI 10.3892/mmr.2014.1888; Liu W, 2012, CANCER LETT, V326, P41, DOI 10.1016/j.canlet.2012.07.015; Ma MM, 2017, HYPERTENSION, V69, P892, DOI 10.1161/HYPERTENSIONAHA.116.08874; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Oh U, 2016, PFLUG ARCH EUR J PHY, V468, P443, DOI 10.1007/s00424-016-1790-0; Pedemonte N, 2014, PHYSIOL REV, V94, P419, DOI 10.1152/physrev.00039.2011; Sauter DRP, 2015, PFLUG ARCH EUR J PHY, V467, P1495, DOI 10.1007/s00424-014-1598-8; Schroeder BC, 2008, CELL, V134, P1019, DOI 10.1016/j.cell.2008.09.003; Shiwarski DJ, 2014, CLIN CANCER RES, V20, P4673, DOI 10.1158/1078-0432.CCR-14-0363; Simon S, 2013, CANCER RES, V73, P3661, DOI 10.1158/0008-5472.CAN-12-3839; Singh SK, 2003, CANCER RES, V63, P5821; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sui YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115443; Wang H, 2019, CANCER LETT, V455, P48, DOI 10.1016/j.canlet.2019.04.027; Wang H, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0720-x; Yang YD, 2008, NATURE, V455, P1210, DOI 10.1038/nature07313; Yin J, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002152	50	3	3	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1490	1502		10.1038/s41388-020-01612-5	http://dx.doi.org/10.1038/s41388-020-01612-5		JAN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452454				2022-12-28	WOS:000607998600007
J	Liu, PI; Chang, AC; Lai, JL; Lin, TH; Tsai, CH; Chen, PC; Jiang, YJ; Lin, LW; Huang, WC; Yang, SF; Tang, CH				Liu, Po-, I; Chang, An-Chen; Lai, Jiun-Lin; Lin, Tien-Huang; Tsai, Chun-Hao; Chen, Po-Chun; Jiang, Ya-Jing; Lin, Liang-Wei; Huang, Wei-Chien; Yang, Shun-Fa; Tang, Chih-Hsin			Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases	ONCOGENE			English	Article							PROSTATE-CANCER; PLUS MELATONIN; CELLS; ANGIOGENESIS; CHEMOTHERAPY; METAANALYSIS; METABOLISM; MODULATION; MECHANISMS; STRATEGIES	Cancer-related bone erosion occurs frequently in bone metastasis and is associated with severe complications such as chronic bone pain, fractures, and lower survival rates. In recognition of the fact that the darkness hormone melatonin is capable of regulating bone homeostasis, we explored its therapeutic potential in bone metastasis. We found that melatonin directly reduces osteoclast differentiation, bone resorption activity and promotes apoptosis of mature osteoclasts. We also observed that melatonin inhibits RANKL production in lung and prostate cancer cells by downregulating the p38 MAPK pathway, which in turn prevents cancer-associated osteoclast differentiation. In lung and prostate bone metastasis models, twice-weekly melatonin treatment markedly reduced tumor volumes and numbers of osteolytic lesions. Melatonin also substantially lowered the numbers of TRAP-positive osteoclasts in tibia bone marrow and RANKL expression in tumor tissue. These findings show promise for melatonin in the treatment of bone metastases.	[Liu, Po-, I; Lai, Jiun-Lin; Jiang, Ya-Jing; Huang, Wei-Chien; Tang, Chih-Hsin] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan; [Liu, Po-, I] Asia Univ Hosp, Dept Gen Thorac Surg, Taichung, Taiwan; [Chang, An-Chen; Chen, Po-Chun] Shin Kong Wu Ho Su Mem Hosp, Translat Med Ctr, Taipei, Taiwan; [Lin, Tien-Huang] Buddhist Tzu Chi Gen Hosp, Dept Urol, Taichung Branch, Taichung, Taiwan; [Lin, Tien-Huang] Tzu Chi Univ, Sch Postbaccalaureate Chinese Med, Hualien, Taiwan; [Tsai, Chun-Hao] China Med Univ Hosp, Dept Orthoped Surg, Taichung, Taiwan; [Tsai, Chun-Hao; Lin, Liang-Wei; Tang, Chih-Hsin] China Med Univ, Sch Med, Taichung, Taiwan; [Chen, Po-Chun] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan; [Chen, Po-Chun; Tang, Chih-Hsin] Asia Univ, Coll Hlth Sci, Dept Biotechnol, Taichung, Taiwan; [Yang, Shun-Fa] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Yang, Shun-Fa] Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan; [Tang, Chih-Hsin] China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan	China Medical University Taiwan; Shin Kong Wu Ho Su Memorial Hospital; Buddhist Tzu Chi General Hospital; Taichung Tzu Chi Hospital; Tzu Chi University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; China Medical University Taiwan	Tang, CH (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.; Tang, CH (corresponding author), China Med Univ, Sch Med, Taichung, Taiwan.; Tang, CH (corresponding author), Asia Univ, Coll Hlth Sci, Dept Biotechnol, Taichung, Taiwan.; Yang, SF (corresponding author), Chung Shan Med Univ, Inst Med, Taichung, Taiwan.; Yang, SF (corresponding author), Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan.; Tang, CH (corresponding author), China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan.	ysf@csmu.edu.tw; chtang@mail.cmu.edu.tw	Yang, Shun-Fa/AAN-1519-2020; Chang, An-Chen/ABB-6915-2021; Huang, Wei-Chien/D-1740-2012	Yang, Shun-Fa/0000-0002-0365-7927; Chang, An-Chen/0000-0002-9544-9980; Huang, Wei-Chien/0000-0001-6467-8716	Taiwan's Ministry of Science and Technology [MOST 108-2320-B-039-026-, MOST 109-2320-B-341-002-]; China Medical University Hospital [DMR-110-102]; Shin Kong Wu Ho-Su Memorial Hospital [2020SKHBND001]; China Medical University under the Higher Education Sprout Project, Ministry of Education, Taiwan [CMRCCHM-3-1]; Asia University Hospital [10951002]; Chung Shan Medical University Hospital, Taiwan [CSH-2020-E-001-Y3]	Taiwan's Ministry of Science and Technology; China Medical University Hospital; Shin Kong Wu Ho-Su Memorial Hospital; China Medical University under the Higher Education Sprout Project, Ministry of Education, Taiwan; Asia University Hospital; Chung Shan Medical University Hospital, Taiwan	This study was supported by grants from Taiwan's Ministry of Science and Technology (MOST 108-2320-B-039-026-, MOST 109-2320-B-341-002-), China Medical University Hospital (DMR-110-102), Shin Kong Wu Ho-Su Memorial Hospital (2020SKHBND001), China Medical University under the Higher Education Sprout Project, Ministry of Education, Taiwan (CMRCCHM-3-1), Asia University Hospital (10951002) and Chung Shan Medical University Hospital, Taiwan (CSH-2020-E-001-Y3).	Anderson G, 2015, MULT SCLER RELAT DIS, V4, P112, DOI 10.1016/j.msard.2014.12.001; [Anonymous], 2018, Nat Rev Dis Primers, V4, P18002, DOI 10.1038/nrdp.2018.2; Arendt J, 2006, CHRONOBIOL INT, V23, P21, DOI 10.1080/07420520500464361; Ayoub MA, 2004, MOL PHARMACOL, V66, P312, DOI 10.1124/mol.104.000398; Bang J, 2012, RHEUMATOL INT, V32, P379, DOI 10.1007/s00296-010-1641-9; Benjamin Biju, 2016, Osteoporos Sarcopenia, V2, P77, DOI 10.1016/j.afos.2016.03.003; Bi HD, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00234; Boafo A, 2019, NAT SCI SLEEP, V11, P1, DOI 10.2147/NSS.S181365; Brown JE, 2005, JNCI-J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002; Chang AC, 2018, CANCER LETT, V426, P47, DOI 10.1016/j.canlet.2018.03.050; Chao CC, 2019, CLIN SCI, V133, P709, DOI 10.1042/CS20180945; Chen PC, 2013, CARCINOGENESIS, V34, P1669, DOI 10.1093/carcin/bgt103; Chen Q, 2002, INT IMMUNOPHARMACOL, V2, P1443, DOI 10.1016/S1567-5769(02)00088-7; Chin Hong, 2015, Fed Pract, V32, P24; Chuang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078022; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Cordoba-Moreno MO, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61652-5; Cutando A, 2014, ONCOL LETT, V7, P923, DOI 10.3892/ol.2014.1813; Dauchy RT, 2014, CANCER RES, V74, P4099, DOI 10.1158/0008-5472.CAN-13-3156; do Amaral FG, 2018, ARCH ENDOCRIN METAB, V62, P472, DOI 10.20945/2359-3997000000066; Farach-Carson MC, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00163; Fowler TW, 2015, J CELL SCI, V128, P683, DOI 10.1242/jcs.157834; Golan K, 2019, EXP HEMATOL, V78, P1, DOI 10.1016/j.exphem.2019.08.008; Golan K, 2018, CELL STEM CELL, V23, P572, DOI 10.1016/j.stem.2018.08.002; Guise TA, 2003, CLIN ORTHOP RELAT R, pS32, DOI 10.1097/01.blo.0000093055.96273.69; Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078-0432.CCR-06-1007; Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008-5472.CAN-05-1317; Han Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06304-x; Huang CC, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12560; Jahanban-Esfahlan R, 2018, BRIT J PHARMACOL, V175, P3230, DOI 10.1111/bph.13898; Jung B, 2006, CANCER RES, V66, P9789, DOI 10.1158/0008-5472.CAN-06-1776; Kim HJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061142; Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12; Kim TK, 2013, FASEB J, V27, P2742, DOI 10.1096/fj.12-224691; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219; Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911-005-5399-8; Leaw B, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00199; Lee HP, 2020, FOOD AGR IMMUNOL, V31, P193, DOI 10.1080/09540105.2020.1713055; Lee HP, 2019, FOOD AGR IMMUNOL, V30, P1033, DOI 10.1080/09540105.2019.1660623; Lee HP, 2019, J FUNCT FOODS, V52, P537, DOI 10.1016/j.jff.2018.11.040; Leja-Szpak A, 2018, PHARMACOL REP, V70, P1079, DOI 10.1016/j.pharep.2018.05.007; Li Y, 2017, ONCOTARGET, V8, P39896, DOI 10.18632/oncotarget.16379; LISSONI P, 1995, BRIT J CANCER, V71, P854, DOI 10.1038/bjc.1995.164; LISSONI P, 1994, TUMORI, V80, P464, DOI 10.1177/030089169408000611; Liu JB, 2016, ANNU REV PHARMACOL, V56, P361, DOI 10.1146/annurev-pharmtox-010814-124742; Liu JF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091491; Lopez-Canul M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102452; Lv JW, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12557; Lyu HC, 2019, J CLIN ENDOCR METAB, V104, P1753, DOI 10.1210/jc.2018-02236; Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321; Maria S, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12465; Markus RP, 2018, BRIT J PHARMACOL, V175, P3239, DOI 10.1111/bph.14083; Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027; Menendez-Menendez J, 2018, INT J ENDOCRINOL, V2018, DOI 10.1155/2018/3271948; Meng XT, 2018, MOL MED REP, V17, P7202, DOI 10.3892/mmr.2018.8729; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; Otto S, 2018, CANCER TREAT REV, V69, P177, DOI 10.1016/j.ctrv.2018.06.007; Pandi-Perumal SR, 2013, NEUROTOX RES, V23, P267, DOI 10.1007/s12640-012-9337-4; Roth JA, 1999, J BIOL CHEM, V274, P22041, DOI 10.1074/jbc.274.31.22041; Rouach V, 2018, J BONE ONCOL, V12, P91, DOI 10.1016/j.jbo.2018.07.011; Schmid-Alliana A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010148; Seely D, 2012, INTEGR CANCER THER, V11, P293, DOI 10.1177/1534735411425484; Shupp AB, 2018, CANCERS, V10, DOI 10.3390/cancers10060182; Singh VA, 2014, SINGAP MED J, V55, P539, DOI 10.11622/smedj.2014138; Slominski AT, 2018, J INVEST DERMATOL, V138, P490, DOI 10.1016/j.jid.2017.10.025; Slominski AT, 2017, CELL MOL LIFE SCI, V74, P3913, DOI 10.1007/s00018-017-2617-7; Slominski AT, 2017, EXP DERMATOL, V26, P563, DOI 10.1111/exd.13208; Slominski RM, 2012, MOL CELL ENDOCRINOL, V351, P152, DOI 10.1016/j.mce.2012.01.004; Palmer ACS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231379; Steger Guenther G, 2011, Ther Adv Med Oncol, V3, P233, DOI 10.1177/1758834011412656; Svensson E, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016022; Tordjman S, 2017, CURR NEUROPHARMACOL, V15, P434, DOI 10.2174/1570159X14666161228122115; van Dam PA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092183; Wang B, 2019, J CELL PHYSIOL, V234, P1008, DOI 10.1002/jcp.27090; Wang MF, 2019, BIOCHEM PHARMACOL, V166, P23, DOI 10.1016/j.bcp.2019.05.005; Wang Y, 2018, ONCOTARGETS THER, V11, P7895, DOI 10.2147/OTT.S174100; Watanabe M, 2008, J OBSTET GYNAECOL RE, V34, P567, DOI 10.1111/j.1447-0756.2008.00818.x; Watkins LR, 2020, GENES-BASEL, V11, DOI 10.3390/genes11060694; Wu MH, 2012, J CELL PHYSIOL, V227, P3016, DOI 10.1002/jcp.23043; Wutzl A, 2006, WIEN KLIN WOCHENSCHR, V118, P473, DOI 10.1007/s00508-006-0644-8; Yang YC, 2019, ENVIRON TOXICOL, V34, P203, DOI 10.1002/tox.22674	82	13	13	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1503	1515		10.1038/s41388-020-01613-4	http://dx.doi.org/10.1038/s41388-020-01613-4		JAN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452455				2022-12-28	WOS:000607998600005
J	Yousefi, H; Vatanmakanian, M; Mahdiannasser, M; Mashouri, L; Alahari, NV; Monjezi, MR; Ilbeigi, S; Alahari, SK				Yousefi, Hassan; Vatanmakanian, Mousa; Mahdiannasser, Mojdeh; Mashouri, Ladan; Alahari, Nikhilesh V.; Monjezi, Mohammad Rafiee; Ilbeigi, Shahrzad; Alahari, Suresh K.			Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance	ONCOGENE			English	Review							BINDING PROTEIN NISCHARIN; ALPHA-V INTEGRINS; CELL-ADHESION; CLINICAL-SIGNIFICANCE; MONOCLONAL-ANTIBODY; TUMOR ANGIOGENESIS; LINKED KINASE; UP-REGULATION; PROMOTES RESISTANCE; THERAPEUTIC TARGETS	Integrins are cell adhesion receptors, which are typically transmembrane glycoproteins that connect to the extracellular matrix (ECM). The function of integrins regulated by biochemical events within the cells. Understanding the mechanisms of cell growth by integrins is important in elucidating their effects on tumor progression. One of the major events in integrin signaling is integrin binding to extracellular ligands. Another event is distant signaling that gathers chemical signals from outside of the cell and transmit the signals upon cell adhesion to the inside of the cell. In normal breast tissue, integrins function as checkpoints to monitor effects on cell proliferation, while in cancer tissue these functions altered. The combination of tumor microenvironment and its associated components determines the cell fate. Hypoxia can increase the expression of several integrins. The exosomal integrins promote the growth of metastatic cells. Expression of certain integrins is associated with increased metastasis and decreased prognosis in cancers. In addition, integrin-binding proteins promote invasion and metastasis in breast cancer. Targeting specific integrins and integrin-binding proteins may provide new therapeutic approaches for breast cancer therapies. This review will examine the current knowledge of integrins' role in breast cancer.	[Yousefi, Hassan; Vatanmakanian, Mousa; Alahari, Suresh K.] LSUHSC, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Mahdiannasser, Mojdeh] Univ Tehran Med Sci, Sch Med, Dept Med Genet, Tehran, Iran; [Mashouri, Ladan] Univ Arkansas Med Sci, Little Rock, AR 72205 USA; [Alahari, Nikhilesh V.] Louisiana State Univ, Baton Rouge, LA 70803 USA; [Monjezi, Mohammad Rafiee] Shiraz Univ Med Sci, Dept Immunol, T Cell Memory Lab, Shiraz, Iran; [Ilbeigi, Shahrzad] Shiraz Univ Med Sci, Dept Med Genet, Shiraz, Iran	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Tehran University of Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Louisiana State University System; Louisiana State University; Shiraz University of Medical Science; Shiraz University of Medical Science	Alahari, SK (corresponding author), LSUHSC, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.	salaha@lsuhsc.edu	Monjezi, Mohammad Rafiee/AAU-4322-2021	ilbeigi, Shahrzad/0000-0001-5143-7614; rafiee monjezi, mohammad/0000-0002-6765-9868				Abou Faycal C, 2018, BRIT J CANCER, V118, P1596, DOI 10.1038/s41416-018-0128-4; Adorno-Cruz V, 2019, BIORXIV, DOI 10.1101/583062; Ahmed KM, 2013, CANCER RES, V73, P3737, DOI 10.1158/0008-5472.CAN-12-3537; Alahari SK, 2004, EMBO J, V23, P2777, DOI 10.1038/sj.emboj.7600291; Alahari SK, 2000, J CELL BIOL, V151, P1141, DOI 10.1083/jcb.151.6.1141; Alanko J, 2015, NAT CELL BIOL, V17, P1412, DOI 10.1038/ncb3250; Alday-Parejo B, 2019, CANCERS, V11, DOI 10.3390/cancers11070978; Alghisi GC, 2006, ENDOTHELIUM-J ENDOTH, V13, P113, DOI 10.1080/10623320600698037; Allan AL, 2006, AM J PATHOL, V169, P233, DOI 10.2353/ajpath.2006.051152; Aluwihare P, 2009, J CELL SCI, V122, P227, DOI 10.1242/jcs.035246; Annis MG, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0936-8; Aoudjit Fawzi, 2012, Chemother Res Pract, V2012, P283181, DOI 10.1155/2012/283181; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Ata R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010189; Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Badaoui M, 2017, ONCOTARGET, V9, P24653, DOI DOI 10.18632/ONCOTARGET.19065; Bahrami A, 2018, J CELL BIOCHEM, V119, P213, DOI 10.1002/jcb.26136; Baltes F, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2020.118663; Baranwal S, 2011, J NATL CANCER I, V103, P1513, DOI 10.1093/jnci/djr350; Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6; Barnawi R, 2019, INT J CANCER, V145, P830, DOI 10.1002/ijc.32183; BARROWMCGEE R, 2016, NAT COMMUN, V7; Bendeck MP, 2000, ARTERIOSCL THROM VAS, V20, P1467, DOI 10.1161/01.ATV.20.6.1467; Berardi DE, 2017, CANCER RES TREAT, V49, P869, DOI 10.4143/crt.2016.378; Bianchi-Smiraglia A, 2013, ONCOGENE, V32, P3049, DOI 10.1038/onc.2012.320; Bierie B, 2017, P NATL ACAD SCI USA, V114, pE2337, DOI 10.1073/pnas.1618298114; Bill A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041179; Blandin AF, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00279; Boudreau N, 2003, BREAST CANCER RES, V5, P140, DOI 10.1186/bcr589; Brezillon S, 2013, FEBS J, V280, P2369, DOI 10.1111/febs.12210; Brooks DLP, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0510-x; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Campbell PS, 2019, J CELL PHYSIOL, V234, P108, DOI 10.1002/jcp.27013; Cao ZY, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0248-8; Casalou Cristina, 2016, Small GTPases, V7, P270; Cen JY, 2019, CANCERS, V11, DOI 10.3390/cancers11121946; Chen J, 2015, MOL MED REP, V12, P77, DOI 10.3892/mmr.2015.3373; Chen Q, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003257; Cheng Y, 2019, EUR J PHARM SCI, V128, P8, DOI 10.1016/j.ejps.2018.11.023; Chia WJ, 2009, BBA-REV CANCER, V1795, P110, DOI 10.1016/j.bbcan.2008.10.001; Chikina AS, 2019, BIOL CELL, V111, P245, DOI 10.1111/boc.201800078; Chiu YC, 2009, CARCINOGENESIS, V30, P1651, DOI 10.1093/carcin/bgp156; Choi J, 2015, LUNG CANCER, V90, P22, DOI 10.1016/j.lungcan.2015.06.023; Chung AH, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0740-2; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Clark AG, 2015, CURR OPIN CELL BIOL, V36, P13, DOI 10.1016/j.ceb.2015.06.004; Cooper J, 2019, CANCER CELL, V35, P347, DOI 10.1016/j.ccell.2019.01.007; Cordone I, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0827-4; Costa RLB, 2018, BREAST CANCER RES TR, V169, P397, DOI 10.1007/s10549-018-4697-y; Cui HX, 2011, ONCOL REP, V25, P1365, DOI 10.3892/or.2011.1192; da Silva RG, 2010, AM J PATHOL, V177, P1534, DOI 10.2353/ajpath.2010.100043; Danhier F, 2012, MOL PHARMACEUT, V9, P2961, DOI 10.1021/mp3002733; Davis PJ, 2016, NAT REV ENDOCRINOL, V12, P111, DOI 10.1038/nrendo.2015.205; De Franceschi N, 2015, J CELL SCI, V128, P839, DOI 10.1242/jcs.161653; Uzair ID, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00139; Desgrosellier JS, 2014, DEV CELL, V30, P295, DOI 10.1016/j.devcel.2014.06.005; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dewangan J, 2018, LIFE SCI, V193, P9, DOI 10.1016/j.lfs.2017.11.045; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; Ding YM, 2008, MOL CELL BIOL, V28, P3742, DOI 10.1128/MCB.01832-07; Dome B, 2005, INT J CANCER, V116, P27, DOI 10.1002/ijc.20991; Donate F, 2008, CLIN CANCER RES, V14, P2137, DOI 10.1158/1078-0432.CCR-07-4530; Dong SL, 2020, INT J CANCER, V146, P2576, DOI 10.1002/ijc.32690; Doolittle E, 2015, ACS NANO, V9, P8012, DOI 10.1021/acsnano.5b01552; dos Santos PB, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-104; Eastlack SC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198945; Elaimy AL, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aau1165; EREMO AG, 2020, SCI REP UK, V10; Fang RP, 2020, ONCOGENE, V39, P2290, DOI 10.1038/s41388-019-1146-2; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; FeldingHabermann B, 1996, J BIOL CHEM, V271, P5892, DOI 10.1074/jbc.271.10.5892; Foubert P, 2011, METHODS MOL BIOL, V757, P471, DOI 10.1007/978-1-61779-166-6_27; Fournier HN, 2002, J BIOL CHEM, V277, P20895, DOI 10.1074/jbc.M200200200; Freeman TC, 2013, BIOCHEMISTRY-US, V52, P7082, DOI 10.1021/bi400678y; Gajbhiye KR, 2019, J DRUG TARGET, V27, P111, DOI 10.1080/1061186X.2018.1473409; Gamble JR, 2009, AM J PATHOL, V175, P2217, DOI 10.2353/ajpath.2009.090076; Geiger C, 2000, EMBO J, V19, P2525, DOI 10.1093/emboj/19.11.2525; Germain M, 2010, J PATHOL, V220, P370, DOI 10.1002/path.2654; Ghatak S, 2016, AM J PATHOL, V186, P3011, DOI 10.1016/j.ajpath.2016.06.021; Gil-Bazo I, 2003, Rev Med Univ Navarra, V47, P22; Glenisson Mathilde, 2012, Genes Cancer, V3, P63, DOI 10.1177/1947601912449832; Gligorijevic B, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001995; Glukhova MA, 2013, CURR OPIN CELL BIOL, V25, P633, DOI 10.1016/j.ceb.2013.06.010; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Goel HL, 2012, CELL ADHES MIGR, V6, P554, DOI 10.4161/cam.22419; Goodman SL, 2012, TRENDS PHARMACOL SCI, V33, P405, DOI 10.1016/j.tips.2012.04.002; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hamidi H, 2019, NAT REV CANCER, V19, P179, DOI 10.1038/s41568-019-0112-1; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanker AB, 2017, CANCER RES, V77, P3280, DOI 10.1158/0008-5472.CAN-16-2808; Hassan H, 2013, FEBS J, V280, P2216, DOI 10.1111/febs.12111; Hayashi H, 2008, J BIOL CHEM, V283, P23791, DOI 10.1074/jbc.M800190200; Hedrick E, 2017, MOL CARCINOGEN, V56, P2066, DOI 10.1002/mc.22662; Hersey P, 2010, CANCER-AM CANCER SOC, V116, P1526, DOI 10.1002/cncr.24821; Hirota S, 2015, DEVELOPMENT, V142, P4363, DOI 10.1242/dev.113746; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Hong IK, 2012, J BIOL CHEM, V287, P32027, DOI 10.1074/jbc.M111.314443; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hou S, 2016, SCI REP-UK, V6, DOI 10.1038/srep18430; Hsu EC, 2016, CARCINOGENESIS, V37, P430, DOI 10.1093/carcin/bgw020; Hsu EC, 2015, NEOPLASIA, V17, P497, DOI 10.1016/j.neo.2015.06.001; Huang R, 2018, DRUG DELIV, V25, P757, DOI 10.1080/10717544.2018.1446474; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Humphries JD, 2006, J CELL SCI, V119, P3901, DOI 10.1242/jcs.03098; Hussain M, 2016, CLIN CANCER RES, V22, P3192, DOI 10.1158/1078-0432.CCR-15-2512; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ibrahim SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085737; Indira Chandran Vineesh, 2015, Oncoscience, V2, P207; Flamini MI, 2017, HORM CANCER-US, V8, P16, DOI 10.1007/s12672-016-0280-3; Ivanova IA, 2013, ONCOGENE, V32, P5582, DOI 10.1038/onc.2013.277; Ivaska J, 2011, ANNU REV CELL DEV BI, V27, P291, DOI 10.1146/annurev-cellbio-092910-154017; Jain P, 2013, J BIOL CHEM, V288, P15495, DOI 10.1074/jbc.M112.418103; Jakubzig B, 2018, CANCERS, V10, DOI 10.3390/cancers10120495; Jiang L, 2017, BRIT J CANCER, V117, P695, DOI 10.1038/bjc.2017.214; Jin H, 2006, CANCER RES, V66, P2146, DOI 10.1158/0008-5472.CAN-05-2704; Jin LJ, 2013, CANCER RES, V73, P2884, DOI 10.1158/0008-5472.CAN-12-2162; Ju JLA, 2017, MOL CANCER RES, V15, P723, DOI 10.1158/1541-7786.MCR-16-0338; Juliano R, 2004, INTEGRIN REGULATION; Kale S, 2015, ONCOGENE, V34, P5408, DOI 10.1038/onc.2015.315; Kapp TG, 2013, EXPERT OPIN THER PAT, V23, P1273, DOI 10.1517/13543776.2013.818133; Katoh D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.27; Katz E, 2007, INT J BIOCHEM CELL B, V39, P715, DOI 10.1016/j.biocel.2006.11.004; Keely S, 2009, FASEB J, V23, P1338, DOI 10.1096/fj.08-125344; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Koike T, 2004, P NATL ACAD SCI USA, V101, P8132, DOI 10.1073/pnas.0402088101; Kong TQ, 2004, P NATL ACAD SCI USA, V101, P10440, DOI 10.1073/pnas.0401339101; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Kovacheva M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194918; Kracun D, 2014, ANTIOXID REDOX SIGN, V20, P1964, DOI 10.1089/ars.2013.5286; Kwon A, 2020, J CELL PHYSIOL, V235, P4494, DOI 10.1002/jcp.29326; Kwon MJ, 2012, BRIT J CANCER, V106, P923, DOI 10.1038/bjc.2012.11; Lee JW, 2014, BMB REP, V47, P483, DOI 10.5483/BMBRep.2014.47.9.146; Lee SA, 2011, FRONT BIOSCI-LANDMRK, V16, P1752, DOI 10.2741/3818; Li DS, 2004, MOL CELL BIOL, V24, P3838, DOI 10.1128/MCB.24.9.3838-3848.2004; Li LQ, 2017, ONCOTARGET, V8, P106876, DOI 10.18632/oncotarget.22449; Li WT, 2015, ONCOL REP, V34, P1345, DOI 10.3892/or.2015.4103; Li YF, 2019, BIOMATERIALS, V188, P160, DOI 10.1016/j.biomaterials.2018.10.019; Li ZQ, 2018, ENDOCRINOLOGY, V159, P285, DOI 10.1210/en.2017-00693; Lin HY, 2016, STEROIDS, V114, P59, DOI 10.1016/j.steroids.2016.05.006; Lin HY, 2009, AM J PHYSIOL-CELL PH, V296, pC980, DOI 10.1152/ajpcell.00305.2008; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4; Liu Z, 2013, CURR MOL MED, V13, P1487, DOI 10.2174/1566524013666131111115347; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2011.439, 10.1038/onc.2012.147]; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Loges Sonja, 2010, Genes Cancer, V1, P12, DOI 10.1177/1947601909356574; Lu S, 2008, CLIN CANCER RES, V14, P1050, DOI 10.1158/1078-0432.CCR-07-4116; Castiglioni JL, 2016, J APPL LOGIC, V15, P1, DOI [10.4103/1477-3163.176223, 10.1016/j.jal.2015.11.001]; Luo J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0694-6; Malek-Hosseini Z, 2017, BREAST CANCER-TOKYO, V24, P742, DOI 10.1007/s12282-017-0773-0; Maltsev OV, 2016, ANGEW CHEM INT EDIT, V55, P1535, DOI 10.1002/anie.201508709; Mardilovich K, 2009, CANCER RES, V69, P8894, DOI 10.1158/0008-5472.CAN-09-1152; Marelli UK, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00222; Maric G, 2015, ONCOGENE, V34, P5494, DOI 10.1038/onc.2015.8; Marsico G, 2018, TRENDS CANCER, V4, P537, DOI 10.1016/j.trecan.2018.05.009; Martin TA, 2014, ONCOL REP, V31, P262, DOI 10.3892/or.2013.2813; Maziveyi M, 2019, CANCER RES, V79, P2152, DOI 10.1158/0008-5472.CAN-18-0842; Maziveyi M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0764-6; Metwaly HA, 2018, ARCH BIOCHEM BIOPHYS, V652, P50, DOI 10.1016/j.abb.2018.06.007; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Momeny M., 2017, SCI REP, V7; Mon NN, 2017, ONCOL LETT, V13, P955, DOI 10.3892/ol.2016.5521; Moral MEG, 2017, CURR TOP MED CHEM, V17, P3425, DOI 10.2174/1568026618666180118154514; Moreno-Layseca P, 2019, NAT CELL BIOL, V21, P122, DOI 10.1038/s41556-018-0223-z; Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3; Moschos SJ, 2010, J IMMUNOTHER, V33, P316, DOI 10.1097/CJI.0b013e3181c1f216; Mould AP, 2004, CURR OPIN CELL BIOL, V16, P544, DOI 10.1016/j.ceb.2004.07.003; Moule AP, 2014, BIOCHEM J, V464, P301, DOI 10.1042/BJ20141047; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Naik MU, 2011, INT J BIOCHEM CELL B, V43, P120, DOI 10.1016/j.biocel.2010.10.003; Naik MU, 2011, INT J CANCER, V128, P587, DOI 10.1002/ijc.25388; Nam JM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3454; Nam K, 2017, ONCOTARGET, V8, P35804, DOI 10.18632/oncotarget.16208; Nistico P, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0459-x; Novitskaya V, 2014, ONCOGENE, V33, P2779, DOI 10.1038/onc.2013.231; O'Day SJ, 2012, INVEST NEW DRUG, V30, P1074, DOI 10.1007/s10637-011-9639-z; Oh S, 2017, BMB REP, V50, P132, DOI 10.5483/BMBRep.2017.50.3.189; Ohtoshi A, 2000, BIOCHEM BIOPH RES CO, V267, P947, DOI 10.1006/bbrc.1999.2007; Pang MF, 2016, CANCER RES, V76, P5277, DOI 10.1158/0008-5472.CAN-16-0579; Park HJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56276-3; Patsialou A., 2013, INTRAVITAL, V2; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Peeney D, 2020, CARCINOGENESIS, V41, P313, DOI 10.1093/carcin/bgz172; Peng WJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53984-8; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Pio GM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177640; Porter HA, 2013, CANCER LETT, V338, P239, DOI 10.1016/j.canlet.2013.03.030; Pramanik D, 2008, J MED CHEM, V51, P7298, DOI 10.1021/jm800915y; Raab-Westphal S, 2017, CANCERS, V9, DOI 10.3390/cancers9090110; Radisky ES, 2015, FRONT BIOSCI-LANDMRK, V20, P1144, DOI 10.2741/4364; Ramovs V, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1146-8; Ranjan A, 2016, CANCER RES, V76, P877, DOI 10.1158/0008-5472.CAN-15-1233; Ratcliffe CDH, 2019, J CELL BIOL, V218, P285, DOI 10.1083/jcb.201804106; Rathinam R, 2010, CANCER METAST REV, V29, P223, DOI 10.1007/s10555-010-9211-x; Ria T, 2002, HAEMATOLOGICA, V87, P836; Ricart AD, 2008, CLIN CANCER RES, V14, P7924, DOI 10.1158/1078-0432.CCR-08-0378; Rolli M, 2003, P NATL ACAD SCI USA, V100, P9482, DOI 10.1073/pnas.1633689100; Rose A, 2011, ROLE GPNMB BREAST TU; Ruegg C, 2010, RECENT RESULTS CANC, V180, P83, DOI 10.1007/978-3-540-78281-0_6; Ruegg C, 2004, BBA-REV CANCER, V1654, P51, DOI 10.1016/j.bbcan.2003.09.003; Ryu MH, 2010, BIOCHEM BIOPH RES CO, V393, P11, DOI 10.1016/j.bbrc.2010.01.060; Sainio Annele, 2014, Mol Cell Ther, V2, P14, DOI 10.1186/2052-8426-2-14; Sato H, 2015, CLIN EXP METASTAS, V32, P405, DOI 10.1007/s10585-015-9705-6; Sayyad MR, 2019, BREAST CANCER RES TR, V178, P35, DOI 10.1007/s10549-019-05347-0; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Senese R, 2014, J ENDOCRINOL, V221, pR1, DOI 10.1530/JOE-13-0573; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Sese M, 2017, ONCOTARGET, V8, P114856, DOI 10.18632/oncotarget.23145; Shahidi M, 2018, MED MOL MORPHOL, V51, P21, DOI 10.1007/s00795-017-0168-5; Shao N, 2015, CANCER LETT, V364, P165, DOI 10.1016/j.canlet.2015.05.009; Sharma C, 2012, CELL MOL LIFE SCI, V69, P2233, DOI 10.1007/s00018-012-0924-6; Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871; Shen M, 2019, CANCER CELL, V35, P64, DOI 10.1016/j.ccell.2018.11.016; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; Siddharth S, 2018, INT J BIOCHEM CELL B, V102, P151, DOI 10.1016/j.biocel.2018.07.011; Sin S, 2011, J NATL CANCER I, V103, P1323, DOI 10.1093/jnci/djr290; Singh C, 2018, BIOCHEM BIOPH RES CO, V499, P374, DOI 10.1016/j.bbrc.2018.03.169; Smuczek B, 2017, EXP CELL RES, V358, P323, DOI 10.1016/j.yexcr.2017.07.005; Sorensen BH, 2015, CELL PHYSIOL BIOCHEM, V36, P111, DOI 10.1159/000374057; Stewart RL, 2015, LAB INVEST, V95, P976, DOI 10.1038/labinvest.2015.82; Stipp CS, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399409001355; Sun ZQ, 2019, NAT CELL BIOL, V21, P25, DOI 10.1038/s41556-018-0234-9; Tai YL, 2015, SCI REP-UK, V5, DOI 10.1038/srep16408; Tang CH, 2009, PROSTATE, V69, P1781, DOI 10.1002/pros.21029; Thomas GJ, 2001, J INVEST DERMATOL, V116, P898, DOI 10.1046/j.1523-1747.2001.01352.x; Tolomelli A, 2017, CANCERS, V9, DOI 10.3390/cancers9070078; Touihri-Barakati I, 2017, EUR J PHARMACOL, V797, P153, DOI 10.1016/j.ejphar.2017.01.006; Travis MA, 2003, TRENDS PHARMACOL SCI, V24, P192, DOI 10.1016/S0165-6147(03)00069-5; Trepat X, 2012, COMPR PHYSIOL, V2, P2369, DOI 10.1002/cphy.c110012; van der Flier A, 2010, DEVELOPMENT, V137, P2439, DOI 10.1242/dev.049551; Vicente-Manzanares M, 2018, CURR OPIN CELL BIOL, V55, P17, DOI 10.1016/j.ceb.2018.05.010; Villanueva J, 2008, CURR ONCOL REP, V10, P439, DOI 10.1007/s11912-008-0067-y; Vlahakis NE, 2007, J BIOL CHEM, V282, P15187, DOI 10.1074/jbc.M609323200; Wang PB, 2011, J CELL BIOL, V195, P499, DOI 10.1083/jcb.201104128; Wang XW, 2017, CELL PHYSIOL BIOCHEM, V43, P1413, DOI 10.1159/000481873; Wang ZS, 2019, INT J CANCER, V145, P2767, DOI 10.1002/ijc.32359; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wei R, 2017, J CANCER, V8, P2173, DOI 10.7150/jca.20480; Wirth M, 2014, EUR UROL, V65, P897, DOI 10.1016/j.eururo.2013.05.051; Yang L, 2015, ONCOTARGET, V6, P25755, DOI 10.18632/oncotarget.4697; Yang XWH, 2008, CANCER RES, V68, P3204, DOI 10.1158/0008-5472.CAN-07-2949; Yao HR, 2016, BREAST CANCER RES TR, V157, P489, DOI 10.1007/s10549-016-3844-6; Yin HL, 2016, INT J MOL SCI, V17; Yom CK, 2011, BREAST CANCER RES TR, V128, P647, DOI 10.1007/s10549-010-1150-2; You WK, 2014, ANGIOGENESIS, V17, P61, DOI 10.1007/s10456-013-9378-1; Yuan J, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0579-y; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang WZ, 2011, BRAZ J MED BIOL RES, V44, P642, DOI [10.1590/S0100-879X2011007500072, 10.1590/S0100-879X2011000700005]; Zhang Y, 2018, CELL PHYSIOL BIOCHEM, V46, P1737, DOI 10.1159/000489249; Zhu W, 2017, ONCOGENE, V36, P2619, DOI 10.1038/onc.2016.428; Zhu WY, 2017, CANCER RES, V77, P4823, DOI 10.1158/0008-5472.CAN-17-0025	253	26	27	5	31	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1043	1063		10.1038/s41388-020-01588-2	http://dx.doi.org/10.1038/s41388-020-01588-2		JAN 2021	21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33420366				2022-12-28	WOS:000607346000015
J	Zheng, XC; Lu, ST; He, ZX; Huang, HH; Yao, ZC; Miao, YT; Cai, CQ; Zou, F				Zheng, Xianchong; Lu, Sitong; He, Zhanxin; Huang, Hehai; Yao, Zhuocheng; Miao, Yutian; Cai, Chunqing; Zou, Fei			MCU-dependent negative sorting of miR-4488 to extracellular vesicles enhances angiogenesis and promotes breast cancer metastatic colonization	ONCOGENE			English	Article							MICROENVIRONMENTAL REGULATION; NICHE FORMATION; EXOSOMES; UNIPORTER; FRACTALKINE; COMPONENT; PROTEIN	Based on Stephen Paget's well-established theory, both cell-autonomous and non-cell-autonomous mechanisms are crucial for metastasis. Although the mitochondrial calcium uniporter (MCU) has been suggested to be involved in breast cancer (BC) progression via cell-autonomous mechanisms, whether it assists the metastasis of BC cells through non-cell-autonomous mechanisms remains unclear. This study aimed to demonstrate that the MCU regulates BC metastatic colonization via non-cell-autonomous mechanisms. The results suggested that extracellular vesicles (EVs) derived from MCU-downregulated MDA-MB-231 cells suppressed angiogenesis in the metastatic niche in a nude mouse model, thereby hindering the colonization of BC cells. Mechanistically, we revealed that the MCU negatively correlated with miR-4488 in EVs derived from BC cells. Significantly, miR-4488 was determined to suppress angiogenesis of vascular endothelial cells by directly targeting angiogenic CX3CL1. Furthermore, we identified miR-4488 as being significantly downregulated in serum EVs from patients with triple-negative BC. Hence, this study suggests that MCU-dependent negative sorting of miR-4488 to EVs enhances angiogenesis in the metastatic niche and, thus, favors the metastatic colonization of BC cells.	[Zheng, Xianchong; Lu, Sitong; He, Zhanxin; Huang, Hehai; Yao, Zhuocheng; Miao, Yutian; Cai, Chunqing; Zou, Fei] Southern Med Univ, Sch Publ Hlth, Dept Occupat Hlth & Occupat Med, Guangzhou 510515, Peoples R China; [Zheng, Xianchong] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China	Southern Medical University - China; State Key Lab Oncology South China; Sun Yat Sen University	Cai, CQ; Zou, F (corresponding author), Southern Med Univ, Sch Publ Hlth, Dept Occupat Hlth & Occupat Med, Guangzhou 510515, Peoples R China.	h_zcn@126.com; zfei@smu.edu.cn			National Natural Science Foundation of China [81671860, 81741131]; Natural Science Foundation of Guangdong Province [2015A030310100]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	We thank Prof. Tiebang Kang and Prof. Hailin Tang from Sun Yat-Sen University Cancer Center for providing us BC clinical samples. We thank Dr. Sihua Qin from Clinical Laboratory, Nanfang Hospital of Southern Medical University for helping us on NTA. This work was supported by the National Natural Science Foundation of China under Grant 81671860 and 81741131; the Natural Science Foundation of Guangdong Province under Grant 2015A030310100.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Bielenberg DR, 2015, CANCER J, V21, P267, DOI 10.1097/PPO.0000000000000138; Cha DJ, 2015, ELIFE, V4, DOI 10.7554/eLife.07197; Cheng L, 2014, KIDNEY INT, V86, P433, DOI 10.1038/ki.2013.502; Corrigan L, 2014, J CELL BIOL, V206, P671, DOI 10.1083/jcb.201401072; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Curry MC, 2013, BIOCHEM BIOPH RES CO, V434, P695, DOI 10.1016/j.bbrc.2013.04.015; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Fan GC, 2014, BLOOD, V124, P3669, DOI 10.1182/blood-2014-10-607846; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Garcia-Silva S, 2016, NAT CELL BIOL, V18, P911, DOI 10.1038/ncb3404; Hall DD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096866; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Janas T, 2015, FEBS LETT, V589, P1391, DOI 10.1016/j.febslet.2015.04.036; Kavanagh EL, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.82; Kornilov R, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2017.1422674; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Matamala N, 2015, CLIN CHEM, V61, P1098, DOI 10.1373/clinchem.2015.238691; Ozawa PMM, 2018, BREAST CANCER RES TR, V172, P713, DOI 10.1007/s10549-018-4925-5; O'Brien K, 2013, EUR J CANCER, V49, P1845, DOI 10.1016/j.ejca.2013.01.017; Tosar JP, 2015, NUCLEIC ACIDS RES, V43, P5601, DOI 10.1093/nar/gkv432; Ribatti D, 2006, CLIN EXP MED, V6, P145, DOI 10.1007/s10238-006-0117-4; Ribatti D, 2016, TRANSL ONCOL, V9, P453, DOI 10.1016/j.tranon.2016.07.002; Santangelo L, 2016, CELL REP, V17, P799, DOI 10.1016/j.celrep.2016.09.031; Szukiewicz D, 2013, MEDIAT INFLAMM, V2013, DOI [DOI 10.1155/2013/437576, 10.1155/2013/437576]; Takemoto-Kimura S, 2017, J NEUROCHEM, V141, P808, DOI 10.1111/jnc.14020; Tang SH, 2015, BIOCHEM BIOPH RES CO, V458, P186, DOI 10.1016/j.bbrc.2015.01.092; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Tosatto A, 2016, EMBO MOL MED, V8, P569, DOI 10.15252/emmm.201606255; Villarroya-Beltri C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3980; Volin MV, 2010, PATHOBIOLOGY, V77, P7, DOI 10.1159/000272949; Whiteside TL, 2016, J CLIN INVEST, V126, P1216, DOI 10.1172/JCI81136; Xu R, 2018, NAT REV CLIN ONCOL, V15, P617, DOI 10.1038/s41571-018-0036-9; You JJ, 2007, INVEST OPHTH VIS SCI, V48, P5290, DOI 10.1167/iovs.07-0187; Zhang Y, 2014, TRENDS CELL BIOL, V24, P153, DOI 10.1016/j.tcb.2013.09.007; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007	46	15	16	3	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2020	39	46					6975	6989		10.1038/s41388-020-01514-6	http://dx.doi.org/10.1038/s41388-020-01514-6		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OQ9FF	33067576				2022-12-28	WOS:000578435000001
J	Zhang, F; Li, P; Liu, S; Yang, MQ; Zeng, SS; Deng, JJ; Chen, DY; Yi, YM; Liu, H				Zhang, Fan; Li, Pan; Liu, Shuang; Yang, Mingqiang; Zeng, Shanshan; Deng, Junjian; Chen, Danyang; Yi, Yanmei; Liu, Hao			beta-Catenin-CCL2 feedback loop mediates crosstalk between cancer cells and macrophages that regulates breast cancer stem cells	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; BETA-CATENIN; CHEMOATTRACTANT PROTEIN-1; CCL2; ACTIVATION; EXPRESSION; COMPLEX; TRANSACTIVATION; POLARIZATION; FIBROBLASTS	Breast cancer is the most frequently diagnosed cancer among women worldwide. Though advances in diagnosis and treatment have prolonged overall survival (OS) for patients with breast cancer, metastasis remains the major obstacles to improved survival for breast cancer patients. The existence of breast cancer stem cells (BCSCs) is a major reason underlying cancer metastasis and recurrence. Therefore, understanding the molecular pathways sustaining BCSC properties and targeting BCSCs will ultimately improve breast cancer treatments. In this study, we found that activation of beta-Catenin directly regulated CCL2 expression at the transcriptional level, and in turn promoted macrophages infiltration and M2 polarization. Moreover, macrophages co-cultured with breast cancer cells showed a significant increase in CCL2 expression and promoted beta-Catenin-induced BCSCs properties, whereas depletion of CCL2 by adding neutralizing antibodies suppressed BSCSs properties. In addition, we found that beta-Catenin-mediated CCL2 secretion recruited macrophages into tumor microenvironment and promoted breast cancer growth and metastasis in vivo. Clinically, we observed a significant positive correlation between beta-Catenin, CCL2 and CD163 expression, and increased expression of beta-Catenin, CCL2 and CD163 predicted poor prognosis in breast cancer. Furthermore, pharmacological inhibition of CCR2 and beta-Catenin synergistically suppressed BCSC properties and breast cancer growth. Collectively, our findings suggested that beta-Catenin-mediated CCL2 secretion forms a paracrine feedback loop between breast cancer cells and macrophages, which in turn promotes BCSC properties and supports breast cancer growth and metastasis. Targeting beta-Catenin/CCL2 signaling might be an effective strategy for breast cancer therapy.	[Zhang, Fan] Wuhan Univ, Renmin Hosp, Dept Pharm, Wuhan, Hubei, Peoples R China; [Li, Pan; Liu, Shuang; Yang, Mingqiang; Zeng, Shanshan; Chen, Danyang; Liu, Hao] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Guangzhou, Guangdong, Peoples R China; [Deng, Junjian] Wuhan Univ, Renmin Hosp, Dept Canc Ctr, Wuhan, Hubei, Peoples R China; [Yi, Yanmei] Guangdong Med Univ, Sch Basic Med, Zhanjiang, Guangdong, Peoples R China	Wuhan University; Guangzhou Medical University; Wuhan University; Guangdong Medical University	Chen, DY; Liu, H (corresponding author), Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Guangzhou, Guangdong, Peoples R China.; Yi, YM (corresponding author), Guangdong Med Univ, Sch Basic Med, Zhanjiang, Guangdong, Peoples R China.	cdy026@126.com; yiymei@gdmu.edu.cn; haoliu2020@163.com		Liu, Hao/0000-0001-6338-4003; Chen, Danyang/0000-0002-7894-9457	National Natural Science Foundation of China [81702819, 81772825, 81972194]; Guangdong Natural Science Funds [2017A030313500, 2019A1515010113]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Funds	This work was supported by the National Natural Science Foundation of China (81702819, 81772825, 81972194), grants from Guangdong Natural Science Funds (2017A030313500, 2019A1515010113).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Amini-Nik S, 2014, J CLIN INVEST, V124, P2599, DOI 10.1172/JCI62059; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; [Anonymous], 2019, CA-CANCER J CLIN, DOI [DOI 10.3322/CAAC.21551, DOI 10.3322/caac.21551]; Bai XP, 2018, CANCER TREAT REV, V69, P152, DOI 10.1016/j.ctrv.2018.07.004; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Brown JM, 2017, CLIN CANCER RES, V23, P3241, DOI 10.1158/1078-0432.CCR-16-3122; Chen CH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06152-x; Chen JQ, 2011, CANCER CELL, V19, P541, DOI 10.1016/j.ccr.2011.02.006; Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818; Daly C, 2003, MICROCIRCULATION, V10, P247, DOI 10.1038/sj.mn.7800190; Dehnel N, 2017, CURR OPIN PHARMACOL, V35, P12, DOI 10.1016/j.coph.2017.04.007; Ellsworth RE, 2017, SEMIN CELL DEV BIOL, V64, P65, DOI 10.1016/j.semcdb.2016.08.025; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gilles C, 2003, CANCER RES, V63, P2658; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Hamburg-Shields E, 2015, J PATHOL, V235, P686, DOI 10.1002/path.4481; Hsu DSS, 2014, CANCER CELL, V26, P534, DOI 10.1016/j.ccell.2014.09.002; Jamiyan T, 2020, VIRCHOWS ARCH, V477, P767, DOI 10.1007/s00428-020-02855-z; Jang GB, 2015, CANCER RES, V75, P1691, DOI 10.1158/0008-5472.CAN-14-2041; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; KOELWYN GJ, 2017, NAT REV CANCER, V17, P620, DOI DOI 10.1038/NRC.2017.78; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu M, 2018, CELL PHYSIOL BIOCHEM, V51, P1679, DOI 10.1159/000495673; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Mestdagt M, 2006, INT J CANCER, V118, P35, DOI 10.1002/ijc.21291; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Obeid E, 2013, INT J ONCOL, V43, P5, DOI 10.3892/ijo.2013.1938; Ou BC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1906-5; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Raggi C, 2016, ONCOGENE, V35, P671, DOI 10.1038/onc.2015.132; Roca H, 2009, J BIOL CHEM, V284, P34342, DOI 10.1074/jbc.M109.042671; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sarode P, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6105; Schade B, 2013, CANCER RES, V73, P4474, DOI 10.1158/0008-5472.CAN-12-3925; Soria G, 2008, CANCER LETT, V267, P271, DOI 10.1016/j.canlet.2008.03.018; Su SC, 2014, CANCER CELL, V25, P605, DOI 10.1016/j.ccr.2014.03.021; Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943; Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567; Ueno T, 2000, CLIN CANCER RES, V6, P3282; van Zoelen MAD, 2011, MOL IMMUNOL, V48, P1468, DOI 10.1016/j.molimm.2011.04.001; Waks AG, 2019, JAMA-J AM MED ASSOC, V321, P288, DOI 10.1001/jama.2018.19323; Watson AL, 2013, CANCER DISCOV, V3, P674, DOI 10.1158/2159-8290.CD-13-0081; Webster S, 2020, SUPPORT CARE CANCER, V28, P1041, DOI 10.1007/s00520-019-05218-w; Williams CB, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2015.25; Yang J, 2013, STEM CELLS, V31, P248, DOI 10.1002/stem.1281; Yang Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0818-0; Yao M, 2016, MODERN PATHOL, V29, P810, DOI 10.1038/modpathol.2016.78; Ye YC, 2019, CANCER RES, V79, P4160, DOI 10.1158/0008-5472.CAN-18-1691; Yoshimura T, 2018, CELL MOL IMMUNOL, V15, P335, DOI 10.1038/cmi.2017.135; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang F, 2015, PROTEOMICS, V15, P773, DOI 10.1002/pmic.201300494; Zhao SJ, 2018, ONCOGENE, V37, P1049, DOI 10.1038/onc.2017.403	61	9	10	3	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5854	5865		10.1038/s41388-021-01986-0	http://dx.doi.org/10.1038/s41388-021-01986-0		AUG 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34345015				2022-12-28	WOS:000681523500005
J	Yan, Y; Narayan, A; Cho, S; Cheng, ZQ; Liu, JO; Zhu, H; Wang, GN; Wharram, B; Lisok, A; Brummet, M; Saeki, H; Huang, T; Gabrielson, K; Gabrielson, E; Cope, L; Kanaan, YM; Afsari, A; Naab, T; Yfantis, HG; Ambs, S; Pomper, MG; Sukumar, S; Merino, VF				Yan, Yu; Narayan, Athira; Cho, Soonweng; Cheng, Zhiqiang; Liu, Jun O.; Zhu, Heng; Wang, Guannan; Wharram, Bryan; Lisok, Ala; Brummet, Mary; Saeki, Harumi; Huang, Tao; Gabrielson, Kathleen; Gabrielson, Edward; Cope, Leslie; Kanaan, Yasmine M.; Afsari, Ali; Naab, Tammey; Yfantis, Harris G.; Ambs, Stefan; Pomper, Martin G.; Sukumar, Saraswati; Merino, Vanessa F.			CRY beta B2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer	ONCOGENE			English	Article							AFRICAN-AMERICAN; TRANSLATION; CELLS; DRUG; OVEREXPRESSION; STABILIZATION; PHENOTYPE; REGIONS; MODEL	Expression of beta-crystallin B2 (CRY beta B2) is elevated in African American (AA) breast tumors. The underlying mechanisms of CRY beta B2-induced malignancy and the association of CRY beta B2 protein expression with survival have not yet been described. Here, we report that the expression of CRY beta B2 in breast cancer cells increases stemness, growth, and metastasis. Transcriptomics data revealed that CRY beta B2 upregulates genes that are functionally associated with unfolded protein response, oxidative phosphorylation, and DNA repair, while down-regulating genes related to apoptosis. CRY beta B2 in tumors promotes de-differentiation, an increase in mesenchymal markers and cancer-associated fibroblasts, and enlargement of nucleoli. Proteome microarrays identified a direct interaction between CRY beta B2 and the nucleolar protein, nucleolin. CRY beta B2 induces nucleolin, leading to the activation of AKT and EGFR signaling. CRISPR studies revealed a dependency on nucleolin for the pro-tumorigenic effects of CRY beta B2. Triple-negative breast cancer (TNBC) xenografts with upregulated CRY beta B2 are distinctively sensitive to the nucleolin aptamer, AS-1411. Lastly, in AA patients, higher levels of nucleolar CRY beta B2 in primary TNBC correlates with decreased survival. In summary, CRY beta B2 is upregulated in breast tumors of AA patients and induces oncogenic alterations consistent with an aggressive cancer phenotype. CRY beta B2 increases sensitivity to nucleolin inhibitors and may promote breast cancer disparity.	[Yan, Yu; Narayan, Athira; Wharram, Bryan; Lisok, Ala; Brummet, Mary; Pomper, Martin G.; Merino, Vanessa F.] Johns Hopkins Univ, Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD 21218 USA; [Yan, Yu; Huang, Tao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Breast & Thyroid Surg, Wuhan, Peoples R China; [Yan, Yu; Cho, Soonweng; Liu, Jun O.; Wang, Guannan; Gabrielson, Kathleen; Cope, Leslie; Pomper, Martin G.; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Cheng, Zhiqiang; Liu, Jun O.; Zhu, Heng; Pomper, Martin G.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Saeki, Harumi; Gabrielson, Kathleen] Johns Hopkins Univ, Dept Mol & Comparat Pathobiol, Sch Med, Baltimore, MD USA; [Saeki, Harumi; Gabrielson, Kathleen; Gabrielson, Edward] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Kanaan, Yasmine M.] Howard Univ, Coll Med, Dept Microbiol, Washington, DC USA; [Afsari, Ali; Naab, Tammey] Howard Univ, Coll Med, Dept Pathol, Washington, DC USA; [Yfantis, Harris G.] Baltimore Vet Affairs Med Ctr, Pathol & Lab Med, Baltimore, MD USA; [Ambs, Stefan] NCI, Mol Epidemiol Sect, Lab Human Carcinogenesis, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Huazhong University of Science & Technology; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard University; Howard University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Merino, VF (corresponding author), Johns Hopkins Univ, Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD 21218 USA.; Sukumar, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.	saras@jhmi.edu; vmerino1@jhmi.edu	Cheng, Zhiqiang/F-5016-2016	Cheng, Zhiqiang/0000-0002-4371-0104; Yan, Yu/0000-0003-2309-9464	DOD BCRP Center of Excellence Grant [W81XWH-04-1-0595]; DOD BCRP [W81XWH-15-1-0017]; Division of Nuclear Medicine and Molecular Imaging	DOD BCRP Center of Excellence Grant; DOD BCRP(United States Department of Defense); Division of Nuclear Medicine and Molecular Imaging	This work was funded by the DOD BCRP Center of Excellence Grant W81XWH-04-1-0595 to S.S, DOD BCRP, W81XWH-15-1-0017 to V.M and the Division of Nuclear Medicine and Molecular Imaging.	Abdelmohsen K, 2011, NUCLEIC ACIDS RES, V39, P8513, DOI 10.1093/nar/gkr488; Alvandi F, 2014, ONCOLOGIST, V19, P94, DOI 10.1634/theoncologist.2013-0077; Anders F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175451; Atchley DP, 2008, J CLIN ONCOL, V26, P4282, DOI 10.1200/JCO.2008.16.6231; Barrow MA, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1191-3; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; BUGLER B, 1982, EUR J BIOCHEM, V128, P475; Carotenuto P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091090; Chen CY, 2000, GENE DEV, V14, P1236; Chen Z, 2016, SAUDI MED J, V37, P1312, DOI 10.15537/smj.2016.12.15972; Cho B, 2021, JAMA ONCOL, V7, P1016, DOI 10.1001/jamaoncol.2021.1254; Churpek JE, 2015, BREAST CANCER RES TR, V149, P31, DOI 10.1007/s10549-014-3195-0; Dawson PJ, 1996, AM J PATHOL, V148, P313; Derenzini M, 1998, AM J PATHOL, V152, P1291; DERENZINI M, 1989, ACTA CYTOL, V33, P491; DeSantis CE, 2016, CA-CANCER J CLIN, V66, P31, DOI 10.3322/caac.21320; Di Segni A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002310; Dietze EC, 2015, NAT REV CANCER, V15, P248, DOI 10.1038/nrc3896; Field LA, 2012, CANCER-AM CANCER SOC, V118, P1334, DOI 10.1002/cncr.26405; Fonseca NA, 2015, BIOMATERIALS, V69, P76, DOI 10.1016/j.biomaterials.2015.08.007; Foss CA, 2019, MOL IMAGING BIOL, V21, P473, DOI 10.1007/s11307-018-1228-5; Gao Q, 2014, BIOCHEM BIOPH RES CO, V453, P37, DOI 10.1016/j.bbrc.2014.09.049; Gieniec KA, 2019, BRIT J CANCER, V121, P293, DOI 10.1038/s41416-019-0509-3; Graw J, 2009, EXP EYE RES, V88, P173, DOI 10.1016/j.exer.2008.10.011; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jovov B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030168; Konishi H, 2011, P NATL ACAD SCI USA, V108, P17773, DOI 10.1073/pnas.1110969108; Li L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18222-z; Liedtke T, 2007, MOL CELL PROTEOMICS, V6, P895, DOI 10.1074/mcp.M600245-MCP200; Lv YR, 2014, MOL CELL BIOL, V34, P4513, DOI 10.1128/MCB.00524-14; Mahotka C, 2018, LEUKEMIA, V32, P1865, DOI 10.1038/s41375-018-0090-4; Martin DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004531; Menashe I, 2009, J NATL CANCER I, V101, P993, DOI 10.1093/jnci/djp176; Merino VF, 2016, CANCER RES, V76, P2013, DOI 10.1158/0008-5472.CAN-15-1619; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Otake Y, 2007, BLOOD, V109, P3069, DOI 10.1182/blood-2006-08-043257; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Paulucci DJ, 2017, ONCOTARGET, V8, P5196, DOI 10.18632/oncotarget.14122; Pomper MG, 2009, CELL RES, V19, P370, DOI 10.1038/cr.2008.329; Rosenberg JE, 2014, INVEST NEW DRUG, V32, P178, DOI 10.1007/s10637-013-0045-6; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Shin SH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06606-2; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Sturtz LA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-62; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tu Zhigang, 2012, Small GTPases, V3, P163, DOI 10.4161/sgtp.19884; Wallace TA, 2008, CANCER RES, V68, P927, DOI 10.1158/0008-5472.CAN-07-2608; Xie QP, 2016, ONCOTARGET, V7, P16636, DOI 10.18632/oncotarget.7674; Yakhni M, 2019, AM J CANCER RES, V9, P1043; Yang A, 2011, J BIOL CHEM, V286, P43370, DOI 10.1074/jbc.M111.225185; Yang YG, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0547-5; Zeng Sulin, 2018, Cancer Transl Med, V4, P70, DOI 10.4103/ctm.ctm_22_18	52	4	4	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5752	5763		10.1038/s41388-021-01975-3	http://dx.doi.org/10.1038/s41388-021-01975-3		AUG 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34341513				2022-12-28	WOS:000680382100001
J	Xu, F; Jiang, LY; Zhao, QW; Zhang, ZBA; Liu, YX; Yang, SS; Yu, MD; Chen, HP; Zhang, JY; Zhang, JT				Xu, Fang; Jiang, Liya; Zhao, Qianwei; Zhang, Zhibiao; Liu, Yixian; Yang, Shuangshuang; Yu, Mengdan; Chen, Huiping; Zhang, Jianying; Zhang, Jintao			Whole-transcriptome and proteome analyses identify key differentially expressed mRNAs, miRNAs, lncRNAs and circRNAs associated with HCC	ONCOGENE			English	Article							LONG NONCODING RNAS; LIVER-CANCER CELL; HEPATOCELLULAR-CARCINOMA; BIG DATA; ROLES; RISK	Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer and one of the leading causes of cancer-related death worldwide. To gain more insights into the transcriptomic landscape and molecular mechanism of HCC, we performed TMT-labelled tandem mass spectrometry (n = 4) and whole-transcriptome sequencing (n = 3) based on HCC tumour (T) and adjacent normal (N) tissues from seven HCC patients. To comprehensively evaluate the gene-regulatory circuits in HCC, differential expression and enrichment analyses were performed on the differentially expressed proteins (DEPs), genes (DEGs), miRNAs (555), lncRNAs (29) and circRNAs (895). A total of 977 proteins and 243 genes were found to be differentially expressed in HCC tumours compared with adjacent normal tissues. HCC data from The Cancer Genome Atlas were used to validate the results. Combined with the results above, 56 DEP-DEGs with common changes in relative quantity were identified. Functional pathway analysis showed that the DEP-DEGs were mainly enriched in the spliceosome and various metabolic processes. Bioinformatics analysis showed that hsa-miR-1266-5p, hsa-miR-128-1-5p, hsa-miR-139-5p, hsa-miR-34b-3p and hsa-miR-570-3p were involved in the regulation of the hub genes mentioned above. The crucial coexpression (lncRNA-mRNA, circRNA-mRNA) and competing endogenous RNA interaction axes showed the possible functions of the lncRNAs and circRNAs. We explored potential cancer biomarkers by combining proteomic and transcriptomic studies. Our study provides a valuable resource for understanding regulatory mechanisms at the RNA level and may ultimately further assist in the development of diagnostic and/or therapeutic targets for HCC.	[Xu, Fang; Jiang, Liya; Zhao, Qianwei; Liu, Yixian; Yang, Shuangshuang; Chen, Huiping; Zhang, Jianying; Zhang, Jintao] Zhengzhou Univ, Henan Inst Med & Pharmaceut Sci, Zhengzhou, Peoples R China; [Xu, Fang; Jiang, Liya; Zhao, Qianwei; Liu, Yixian; Yang, Shuangshuang; Chen, Huiping; Zhang, Jianying; Zhang, Jintao] Zhengzhou Univ, BGI Coll, Zhengzhou, Peoples R China; [Jiang, Liya; Zhang, Zhibiao] Zhengzhou Univ, Sch Life Sci, Zhengzhou, Peoples R China; [Yu, Mengdan] Zhengzhou Univ, Sch Basic Med Sci, Zhengzhou, Peoples R China; [Zhang, Jianying; Zhang, Jintao] Zhengzhou Univ, Henan Key Lab Tumor Epidemiol, Zhengzhou, Peoples R China; [Zhang, Jianying; Zhang, Jintao] Zhengzhou Univ, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Peoples R China	Zhengzhou University; Zhengzhou University; Zhengzhou University; Zhengzhou University; Zhengzhou University; Zhengzhou University	Zhang, JY; Zhang, JT (corresponding author), Zhengzhou Univ, Henan Inst Med & Pharmaceut Sci, Zhengzhou, Peoples R China.; Zhang, JY; Zhang, JT (corresponding author), Zhengzhou Univ, BGI Coll, Zhengzhou, Peoples R China.; Zhang, JY; Zhang, JT (corresponding author), Zhengzhou Univ, Henan Key Lab Tumor Epidemiol, Zhengzhou, Peoples R China.; Zhang, JY; Zhang, JT (corresponding author), Zhengzhou Univ, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Peoples R China.	jianyingzhang@hotmail.com; zhangjt_66@126.com		Xu, Fang/0000-0002-5722-0798	Natural Science Foundation of Henan Province [182300410361]; Major Project of Science and Technology in Henan Province [161100311400]; National Science and Technology Major Project of China [2018ZX10302205]; Project of Basic Research Fund of Henan Institute of Medical and Pharmacological Sciences [2020BP0107, 2020BP0111]; Zhengzhou Major Project for Collaborative Innovation [18XTZX12007]; Key Scientific and Technological Project of Henan Province [212102310124]	Natural Science Foundation of Henan Province; Major Project of Science and Technology in Henan Province; National Science and Technology Major Project of China; Project of Basic Research Fund of Henan Institute of Medical and Pharmacological Sciences; Zhengzhou Major Project for Collaborative Innovation; Key Scientific and Technological Project of Henan Province	We gratefully acknowledge Henan Key Laboratory of Pharmacology for Liver Diseases for providing experimental platform support. We thank Dr. Jianxiang Shi for assistance in bioinformatic analysis. This work was supported by grants from Natural Science Foundation of Henan Province (No. 182300410361); the Major Project of Science and Technology in Henan Province (No. 161100311400); the National Science and Technology Major Project of China (No. 2018ZX10302205); Project of Basic Research Fund of Henan Institute of Medical and Pharmacological Sciences (No. 2020BP0107; No. 2020BP0111); Zhengzhou Major Project for Collaborative Innovation (18XTZX12007) and The Key Scientific and Technological Project of Henan Province (No. 212102310124).	Alqahtani A, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55090526; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen B, 2016, CLIN PHARMACOL THER, V99, P285, DOI 10.1002/cpt.318; Chen SZ, 2019, CANCER LETT, V460, P1, DOI 10.1016/j.canlet.2019.114428; Chen TC, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008346; Chen XJ, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010066; Dhanasekaran R, 2019, GASTROENTEROLOGY, V156, P492, DOI 10.1053/j.gastro.2018.11.001; DiStefano JK, 2019, CANCERS, V11, DOI 10.3390/cancers11040486; Dragomir MP, 2020, GUT, V69, P748, DOI 10.1136/gutjnl-2019-318279; Du ZH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72510-9; El Khodiry A, 2018, WORLD J GASTROENTERO, V24, P549, DOI 10.3748/wjg.v24.i5.549; Fu J, 2018, CANCER LETT, V412, P283, DOI 10.1016/j.canlet.2017.10.008; Fujiwara N, 2018, J HEPATOL, V68, P526, DOI 10.1016/j.jhep.2017.09.016; He J, 2019, CANCER LETT, V450, P98, DOI 10.1016/j.canlet.2019.02.033; Henley SJ, 2020, CANCER-AM CANCER SOC, V126, P2225, DOI 10.1002/cncr.32802; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang Z, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01188-4; Jiang Y, 2019, NATURE, V567, P257, DOI 10.1038/s41586-019-0987-8; Kim YA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082883; Kohl M, 2011, METHODS MOL BIOL, V696, P291, DOI 10.1007/978-1-60761-987-1_18; Kong S, 2020, CANCER LETT, V483, P59, DOI 10.1016/j.canlet.2020.04.006; Lanzafame M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030682; Li L, 2016, CANCER LETT, V379, P191, DOI 10.1016/j.canlet.2015.07.018; Lim LJ, 2019, CANCER RES, V79, P5131, DOI 10.1158/0008-5472.CAN-19-0255; Lin YH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123742; Liu YX, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2020.12378; Llovet JM, 2018, NAT REV CLIN ONCOL, V15, P599, DOI 10.1038/s41571-018-0073-4; Mahipal A, 2019, MOL TRANSL MED, P225, DOI 10.1007/978-3-030-21540-8_11; Mahpour A, 2021, JHEP REP, V3, DOI 10.1016/j.jhepr.2020.100177; Nekvindova J, 2020, BIOCHEM PHARMACOL, V177, DOI 10.1016/j.bcp.2020.113912; Niu ZS, 2020, WORLD J GASTROENTERO, V26, DOI 10.3748/wjg.v26.i29.4240; Sasaki R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061406; Shi J, 2019, J CANCER, V10, P4892, DOI 10.7150/jca.32768; Sia D, 2017, GASTROENTEROLOGY, V152, P745, DOI 10.1053/j.gastro.2016.11.048; Tseng CS, 2005, AM J GASTROENTEROL, V100, P1758, DOI 10.1111/j.1572-0241.2005.41857.x; Umeda S, 2019, EXPERT REV MOL DIAGN, V19, P725, DOI 10.1080/14737159.2019.1638254; Wei L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1086-z; Wooden B, 2017, GASTROENTEROLOGY, V152, P53, DOI 10.1053/j.gastro.2016.09.065; Xu G, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01581-5; Yan TM, 2015, PHARM RES-DORDR, V32, P1141, DOI 10.1007/s11095-014-1525-x; Ye X, 2019, HEPATOLOGY, V69, P2489, DOI 10.1002/hep.30519; Yin YT, 2019, J CANCER, V10, P5015, DOI 10.7150/jca.30828; Yousry A, 2019, SEMIN LIVER DIS, V39, P463, DOI 10.1055/s-0039-1688442; Zhang H, 2020, INT J ONCOL, V56, P18, DOI 10.3892/ijo.2019.4909; Zhao QW, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.572663; Zhao YB, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108487	47	6	5	6	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4820	4831		10.1038/s41388-021-01908-0	http://dx.doi.org/10.1038/s41388-021-01908-0		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34155346				2022-12-28	WOS:000664006700003
J	Lin, YH; Wu, MH; Liu, YC; Lyu, PC; Yeh, CT; Lin, KH				Lin, Yang-Hsiang; Wu, Meng-Han; Liu, Yi-Chung; Lyu, Ping-Chiang; Yeh, Chau-Ting; Lin, Kwang-Huei			LINC01348 suppresses hepatocellular carcinoma metastasis through inhibition of SF3B3-mediated EZH2 pre-mRNA splicing	ONCOGENE			English	Article							HEPATITIS-B-VIRUS; LONG NONCODING RNA; X PROTEIN; C-JUN; EMERGING ROLES; HBX PROTEIN; CANCER; REVEALS; GENE; TRANSCRIPTION	Long non-coding RNAs (lncRNA) play crucial roles in hepatocellular carcinoma (HCC) progression. However, the specific functions of lncRNAs in alternative splicing (AS) and the metastatic cascade in liver cancer remain largely unclear. In this study, we identified a novel lncRNA, LINC01348, which was significantly downregulated in HCC and correlated with survival functions in HCC patients. Ectopic expression of LINC01348 induced marked inhibition of cell growth, and metastasis in vitro and in vivo. Conversely, these phenotypes were reversed upon knockdown of LINC01348. Mechanistically, LINC01348 complexed with splicing factor 3b subunit 3 (SF3B3) acted as a modulator of EZH2 pre-mRNA AS, and induced alterations in JNK/c-Jun activity and expression of Snail. Notably, C-terminal truncated HBx (Ct-HBx) negatively regulated LINC01348 through c-Jun signaling. Our data collectively highlight those novel regulatory associations involving LINC01348/SF3B3/EZH2/JNK/c-Jun/Snail are an important determinant of metastasis in HCC cells and support the potential utility of targeting LINC01348 as a therapeutic strategy for HCC.	[Lin, Yang-Hsiang; Yeh, Chau-Ting; Lin, Kwang-Huei] Chang Gung Mem Hosp, Liver Res Ctr, Taoyuan, Taiwan; [Lin, Yang-Hsiang; Wu, Meng-Han; Lin, Kwang-Huei] Chang Gung Univ, Dept Biochem, Coll Med, Taoyuan, Taiwan; [Liu, Yi-Chung] Inst Populat Sci, Natl Hlth Res Inst, Zhunan, Taiwan; [Lyu, Ping-Chiang] Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Dept Life Sci, Hsinchu, Taiwan; [Lin, Kwang-Huei] Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan, Taiwan; Chang Gung Univ, Grad Inst Biomed Sci, Coll Med, Taoyuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; National Health Research Institutes - Taiwan; National Tsing Hua University; Chang Gung University of Science & Technology; Chang Gung University	Yeh, CT; Lin, KH (corresponding author), Chang Gung Mem Hosp, Liver Res Ctr, Taoyuan, Taiwan.; Lin, KH (corresponding author), Chang Gung Univ, Dept Biochem, Coll Med, Taoyuan, Taiwan.	chautingy@gmail.com; khlin@mail.cgu.edu.tw		Liu, Yi-Chung/0000-0003-1437-0363; Lin, Kwang-Huei/0000-0002-5649-2222	Chang Gung Memorial Hospital, Taoyuan, Taiwan [CMRPD1H0631-0633, CMRPD1K0291, NMRPD1G0941-0943, NMRPD1G0951-0953, CMRPG3H0721-0723, NZRPG3G0171-0173, NMRPG3H0561, NRRPG3J0141]; Ministry of Science and Technology of the Republic of China [MOST 106-2320-B-182-031-MY3, 106-2320-B-182-032-MY3, 109-2320-B-182-011, MOST 106-2321-B-182A-004-MY3, MOST 107-2320-B-182A-028-, MOST 108-2320-B182A-004-]	Chang Gung Memorial Hospital, Taoyuan, Taiwan(Chang Gung Memorial Hospital); Ministry of Science and Technology of the Republic of China(Ministry of Science and Technology, Taiwan)	This work was supported by grants from Chang Gung Memorial Hospital, Taoyuan, Taiwan (CMRPD1H0631-0633, CMRPD1K0291, NMRPD1G0941-0943, and NMRPD1G0951-0953 to K-HL; CMRPG3H0721-0723, NZRPG3G0171-0173, NMRPG3H0561, NRRPG3J0141 to Y-HL) and from the Ministry of Science and Technology of the Republic of China (MOST 106-2320-B-182-031-MY3; 106-2320-B-182-032-MY3; and 109-2320-B-182-011 to K-HL; MOST 106-2321-B-182A-004-MY3, MOST 107-2320-B-182A-028-, MOST 108-2320-B182A-004-to Y-HL).	Chen K, 2017, CLIN CANCER RES, V23, P3428, DOI 10.1158/1078-0432.CCR-16-2020; Chen RY, 2020, CELL DEATH DIFFER, V27, P1259, DOI 10.1038/s41418-019-0413-7; Chen XC, 2018, BMB REP, V51, P280, DOI 10.5483/BMBRep.2018.51.6.025; Cougot D, 2007, J BIOL CHEM, V282, P4277, DOI 10.1074/jbc.M606774200; Di CX, 2019, CELL DEATH DIFFER, V26, P1181, DOI 10.1038/s41418-018-0231-3; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; El Marabti E, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00080; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Finci LI, 2018, GENE DEV, V32, P309, DOI 10.1101/gad.311043.117; Gao SB, 2014, MOL CANCER RES, V12, P1388, DOI 10.1158/1541-7786.MCR-14-0034; Ghafouri-Fard S, 2019, BIOMED PHARMACOTHER, V111, P51, DOI 10.1016/j.biopha.2018.12.070; Giannelli G, 2016, J HEPATOL, V65, P798, DOI 10.1016/j.jhep.2016.05.007; Grzenda A, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-3; He RZ, 2019, GENES DIS, V6, P6, DOI 10.1016/j.gendis.2019.01.003; Hodo Y, 2013, CLIN CANCER RES, V19, P1827, DOI 10.1158/1078-0432.CCR-12-1641; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Iyer S, 2011, MOL CARCINOGEN, V50, P972, DOI 10.1002/mc.20767; Jiang MC, 2019, AM J CANCER RES, V9, P1354; Kong JL, 2016, CANCER LETT, V380, P476, DOI 10.1016/j.canlet.2016.07.015; Lee S, 2016, ONCOGENE, V35, P1857, DOI 10.1038/onc.2015.251; Li SL, 2019, HEPATOLOGY, V69, P359, DOI 10.1002/hep.30158; Lim JK, 2020, AM J GASTROENTEROL, V115, P1429, DOI 10.14309/ajg.0000000000000651; Long YC, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao2110; Luo ZL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9457; Lurje I, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061465; Mai HM, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1213-0; Mu WP, 2018, EPIGENET CHROMATIN, V11, DOI 10.1186/s13072-018-0242-9; Park JW, 2019, J HEPATOL, V70, P684, DOI 10.1016/j.jhep.2018.11.029; Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016; Qian Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep33039; Quetier I, 2015, J GEN VIROL, V96, P614, DOI 10.1099/vir.0.070680-0; Romero-Barrios N, 2018, NUCLEIC ACIDS RES, V46, P2169, DOI 10.1093/nar/gky095; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shi J, 2005, BRIT J CANCER, V92, P607, DOI 10.1038/sj.bjc.6602333; Singal AG, 2020, J HEPATOL, V72, P250, DOI 10.1016/j.jhep.2019.08.025; Srisuttee R, 2012, ONCOL REP, V28, P276, DOI 10.3892/or.2012.1798; Sze KMF, 2013, HEPATOLOGY, V57, P131, DOI 10.1002/hep.25979; Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011; Tunissiolli Nathalia Martines, 2017, Asian Pac J Cancer Prev, V18, P863; Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55; Uchino K, 2011, CANCER-AM CANCER SOC, V117, P4475, DOI 10.1002/cncr.25960; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wang J, 2016, TARGET ONCOL, V11, P723, DOI 10.1007/s11523-016-0446-5; Wang Yunwu, 2018, Oncotarget, V9, P11783, DOI 10.18632/oncotarget.24364; Yeh CT, 2012, J HEPATOL, V57, P484, DOI 10.1016/j.jhep.2012.06.003; Yip WK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022888; Zong XY, 2020, CANCER RES, V80, P4371, DOI 10.1158/0008-5472.CAN-20-0458	52	11	11	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4675	4685		10.1038/s41388-021-01905-3	http://dx.doi.org/10.1038/s41388-021-01905-3		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34140643				2022-12-28	WOS:000662838900001
J	Kunou, S; Shimada, K; Takai, M; Sakamoto, A; Aoki, T; Hikita, T; Kagaya, Y; Iwamoto, E; Sanada, M; Shimada, S; Hayakawa, F; Oneyama, C; Kiyoi, H				Kunou, Shunsuke; Shimada, Kazuyuki; Takai, Mika; Sakamoto, Akihiko; Aoki, Tomohiro; Hikita, Tomoya; Kagaya, Yusuke; Iwamoto, Eisuke; Sanada, Masashi; Shimada, Satoko; Hayakawa, Fumihiko; Oneyama, Chitose; Kiyoi, Hitoshi			Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma	ONCOGENE			English	Article							PROMOTE TUMOR-GROWTH; B-CELL LYMPHOMA; HODGKIN-LYMPHOMA; PHASE-II; APOPTOSIS; RITUXIMAB; DEXAMETHASONE; MICROVESICLES; GEMCITABINE; SURVIVAL	The tumor microenvironment is deeply involved in the process of tumor growth and development. In this study, we focused on cancer-associated fibroblasts (CAFs) and their derived exosomes on the lymphoma microenvironment to uncover their clinical significance. CAFs were established from primary lymphoma samples, and exosomes secreted from CAFs were obtained by standard procedures. We then investigated the roles of CAFs and their derived exosomes in the survival and drug resistance of lymphoma cells. CAFs supported the survival of lymphoma cells through increased glycolysis, and the extent differed among CAFs. Exosomes were identified as a major component of the extracellular vesicles from CAFs, and they also supported the survival of lymphoma cells. The suppression of RAB27B, which is involved in the secretion of exosomes, using a specific siRNA resulted in reduced exosome secretion and decreased survival of lymphoma cells. Moreover, anti-pyrimidine drug resistance was induced in the presence of exosomes through the suppression of the pyrimidine transporter, equilibrative nucleoside transporter 2 (ENT2), and the suppression of ENT2 was significant in in vivo experiments and clinical samples. RNA sequencing analysis of miRNAs in exosomes identified miR-4717-5p as one of the most abundant miRNAs in the exosome, which suppressed the expression of ENT2 and induced anti-pyrimidine drug resistance in vitro. Our results suggest that exosomes including miR-4717-5p secreted from CAFs play a pivotal role in the lymphoma microenvironment, indicating that they are a promising therapeutic target.	[Kunou, Shunsuke; Shimada, Kazuyuki; Takai, Mika; Sakamoto, Akihiko; Aoki, Tomohiro; Kagaya, Yusuke; Hayakawa, Fumihiko; Kiyoi, Hitoshi] Nagoya Univ, Dept Hematol & Oncol, Grad Sch Med, Nagoya, Aichi, Japan; [Takai, Mika] Otsuka Pharmaceut Co Ltd, Fujii Mem Res Inst, Otsu, Shiga, Japan; [Hikita, Tomoya; Oneyama, Chitose] Aichi Canc Ctr, Div Canc Cell Regulat, Res Inst, Nagoya, Aichi, Japan; [Hikita, Tomoya; Oneyama, Chitose] Nagoya Univ, Dept Target & Drug Discovery, Grad Sch Med, Nagoya, Aichi, Japan; [Iwamoto, Eisuke; Sanada, Masashi] Natl Hosp Org Nagoya Med Ctr, Dept Adv Diag, Clin Res Ctr, Nagoya, Aichi, Japan; [Shimada, Satoko] Nagoya Univ Hosp, Dept Pathol & Clin Labs, Nagoya, Aichi, Japan	Nagoya University; Otsuka Pharmaceutical; Aichi Cancer Center; Nagoya University; Nagoya Medical Center; Nagoya University	Shimada, K (corresponding author), Nagoya Univ, Dept Hematol & Oncol, Grad Sch Med, Nagoya, Aichi, Japan.	kshimada@med.nagoya-u.ac.jp	Shimada, Kazuyuki/I-7120-2014; Sakamoto, Akihiko/GXH-2664-2022	Shimada, Kazuyuki/0000-0002-1075-9219; Sakamoto, Akihiko/0000-0003-0788-3646	Program to Disseminate Tenure Tracking System, MEXT, Japan; JSPS [17K09922, 20K08751]; Practical Research for Innovative Cancer Control, MHLW/AMED, Japan; Hori Sciences and Arts Foundation; Takeda Science Foundation; JST PRESTO [JP1005457]	Program to Disseminate Tenure Tracking System, MEXT, Japan; JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Practical Research for Innovative Cancer Control, MHLW/AMED, Japan; Hori Sciences and Arts Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); JST PRESTO(Japan Science & Technology Agency (JST))	This work was supported by the Program to Disseminate Tenure Tracking System, MEXT, Japan, by a JSPS Grant-in-Aid for Scientific Research (C) 17K09922 and 20K08751; by the Practical Research for Innovative Cancer Control, MHLW/AMED, Japan; by The Hori Sciences and Arts Foundation; by The Takeda Science Foundation grant to K.S.; and by JST PRESTO JP1005457 to C.O. We thank Mr. Kuniyoshi Kitou, Ms. Kazuko Matsuba, Ms. Yuko Katayama, and Mr. Yoshiaki Inagaki (Nagoya University) for IHC work; and Ms. Yoko Matsuyama, Ms. Chika Wakamatsu, Ms. Manami Kira, Ms. Yukie Konishi, Ms. Yuko Kojima, Ms. Konomi Ooyama, and Ms. Saori Kanamori (Nagoya University) for assistance with laboratory work.	An J, 2013, J CANCER RES CLIN, V139, P379, DOI 10.1007/s00432-012-1328-6; Aoki T, 2017, ONCOTARGET, V8, P13085, DOI 10.18632/oncotarget.14393; Arimany-Nardi C, 2015, PHARMACOGENOMICS J, V15, P363, DOI 10.1038/tpj.2014.77; Armand P, 2016, J CLIN ONCOL, V34, P3733, DOI 10.1200/JCO.2016.67.3467; Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Coiffier B, 2010, BLOOD, V116, P2040, DOI 10.1182/blood-2010-03-276246; Crump M, 2004, CANCER-AM CANCER SOC, V101, P1835, DOI 10.1002/cncr.20587; Crump M, 2017, BLOOD, V130, P1800, DOI 10.1182/blood-2017-03-769620; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; Gopal AK, 2010, LEUKEMIA LYMPHOMA, V51, P1523, DOI 10.3109/10428194.2010.491137; Hagos Y, 2015, AM J PHYSIOL-RENAL, V308, pF330, DOI 10.1152/ajprenal.00467.2014; Horwitz S, 2019, LANCET, V393, P229, DOI 10.1016/S0140-6736(18)32984-2; Ishida T, 2012, J CLIN ONCOL, V30, P837, DOI 10.1200/JCO.2011.37.3472; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Richards KE, 2017, ONCOGENE, V36, P1770, DOI 10.1038/onc.2016.353; Sakamoto A, 2019, CANCER SCI, V110, P269, DOI 10.1111/cas.13873; Shimada K, 2016, LEUKEMIA, V30, P1568, DOI 10.1038/leu.2016.67; Shimada K, 2012, EXP HEMATOL, V40, P724, DOI 10.1016/j.exphem.2012.05.007; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Smith A, 2015, BRIT J CANCER, V112, P1575, DOI 10.1038/bjc.2015.94; Sugimoto K, 2015, SCI REP-UK, V5, DOI 10.1038/srep13054; Svensson KJ, 2011, P NATL ACAD SCI USA, V108, P13147, DOI 10.1073/pnas.1104261108; Takagi Y, 2016, CANCER SCI, V107, P1270, DOI 10.1111/cas.13001; Taskinen M, 2007, CLIN CANCER RES, V13, P5784, DOI 10.1158/1078-0432.CCR-07-0778; Taylor DD, 2003, CLIN CANCER RES, V9, P5113	32	9	9	1	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					3989	4003		10.1038/s41388-021-01829-y	http://dx.doi.org/10.1038/s41388-021-01829-y		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	33994542	hybrid, Green Published			2022-12-28	WOS:000651026600001
J	Rangel, DF; Dubeau, L; Park, R; Chan, PC; Ha, DP; Pulido, MA; Mullen, DJ; Vorobyova, I; Zhou, BY; Borok, Z; Offringa, IA; Lee, AS				Rangel, Daisy Flores; Dubeau, Louis; Park, Ryan; Chan, Priscilla; Ha, Dat P.; Pulido, Mario A.; Mullen, Daniel J.; Vorobyova, Ivetta; Zhou, Beiyun; Borok, Zea; Offringa, Ite A.; Lee, Amy S.			Endoplasmic reticulum chaperone GRP78/BiP is critical for mutant Kras-driven lung tumorigenesis	ONCOGENE			English	Article							CANCER-CELLS; PROTEINS; KNOCKOUT; SURVIVAL	Lung cancer is the leading cause of cancer mortality worldwide and KRAS is the most commonly mutated gene in lung adenocarcinoma (LUAD). The 78-kDa glucose-regulated protein GRP78/BiP is a key endoplasmic reticulum chaperone protein and a major pro-survival effector of the unfolded protein response (UPR). Analysis of the Cancer Genome Atlas database and immunostain of patient tissues revealed that compared to normal lung, GRP78 expression is generally elevated in human lung cancers, including tumors bearing the KRAS(G12D) mutation. To test the requirement of GRP78 in human lung oncogenesis, we generated mouse models containing floxed Grp78 and Kras Lox-Stop-Lox G12D (Kras(LSL-G12D)) alleles. Simultaneous activation of the Kras(G12D) allele and knockout of the Grp78 alleles were achieved in the whole lung or selectively in lung alveolar epithelial type 2 cells known to be precursors for adenomas that progress to LUAD. Here we report that GRP78 haploinsufficiency is sufficient to suppress Kras(G12D)-mediated lung tumor progression and prolong survival. Furthermore, GRP78 knockdown in human lung cancer cell line A427 (Kras(G12D/+)) leads to activation of UPR and apoptotic markers and loss of cell viability. Our studies provide evidence that targeting GRP78 represents a novel therapeutic approach to suppress mutant KRAS-mediated lung tumorigenesis.	[Rangel, Daisy Flores; Chan, Priscilla; Ha, Dat P.; Borok, Zea; Offringa, Ite A.; Lee, Amy S.] Univ Southern Calif, Keck Sch Med, Dept Biochem & Mol Med, Los Angeles, CA 90007 USA; [Rangel, Daisy Flores; Dubeau, Louis; Chan, Priscilla; Ha, Dat P.; Pulido, Mario A.; Mullen, Daniel J.; Offringa, Ite A.; Lee, Amy S.] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA; [Dubeau, Louis] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90007 USA; [Park, Ryan; Vorobyova, Ivetta] Univ Southern Calif, Keck Sch Med, Dept Radiol, Los Angeles, CA 90007 USA; [Pulido, Mario A.; Mullen, Daniel J.; Offringa, Ite A.] Univ Southern Calif, Keck Sch Med, Dept Surg, Los Angeles, CA 90007 USA; [Zhou, Beiyun; Borok, Zea] Univ Southern Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90007 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Lee, AS (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Biochem & Mol Med, Los Angeles, CA 90007 USA.; Lee, AS (corresponding author), Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA.	amylee@usc.edu	Ha, Dat/AFS-3983-2022	Ha, Dat/0000-0002-2592-1223; Borok, Zea/0000-0001-8673-8177; Chan, Priscilla/0000-0003-1338-363X	NIH [R01 CA027607, R35 HL135747]; Judy and Larry Freeman Chair; NIH Diversity Supplements; Hastings Foundation; Ralph Edgington Chair;  [P30 CA014089];  [1S10OD012371];  [1S10OD18500]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Judy and Larry Freeman Chair; NIH Diversity Supplements(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hastings Foundation; Ralph Edgington Chair; ; ; 	We thank Hal Chapman for the SPC-Cre mice, Peter Conti and Jennifer Choi for assistance with PET/CT, and Jorge Nieva and Robert Hsu for tumor samples. The work was supported by NIH grants R01 CA027607 and the Judy and Larry Freeman Chair (ASL), NIH Diversity Supplements (DFR), the Hastings Foundation (BZ, ZB), and NIH grant R35 HL135747 and Ralph Edgington Chair (ZB). We thank the USC Norris Comprehensive Cancer Translational Pathology Core and the USC Molecular Imaging Center (supported by P30 CA014089, 1S10OD012371 and 1S10OD18500) for technical assistance.	Bakewell Suzanne J, 2018, Oncotarget, V9, P29698, DOI 10.18632/oncotarget.25679; Burris HA, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000154; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Cerezo M, 2016, CANCER CELL, V29, P805, DOI 10.1016/j.ccell.2016.04.013; Chae YC, 2012, CANCER CELL, V22, P331, DOI 10.1016/j.ccr.2012.07.015; Chapman HA, 2011, J CLIN INVEST, V121, P2855, DOI 10.1172/JCI57673; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; De Raedt T, 2011, CANCER CELL, V20, P400, DOI 10.1016/j.ccr.2011.08.014; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Desai TJ, 2014, NATURE, V507, P190, DOI 10.1038/nature12930; Du TD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10824-7; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Gifford JB, 2016, MOL CANCER THER, V15, P1043, DOI 10.1158/1535-7163.MCT-15-0774; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Imai H, 2017, THORAC CANCER, V8, P379, DOI 10.1111/1759-7714.12463; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Kwon D, 2018, LUNG CANCER, V122, P131, DOI 10.1016/j.lungcan.2018.06.005; Lee AS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40919; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Lizardo MM, 2016, NEOPLASIA, V18, P699, DOI 10.1016/j.neo.2016.09.001; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Ma X, 2015, DIS MARKERS, V2015, P1, DOI 10.1155/2015/814670; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pobre KFR, 2019, J BIOL CHEM, V294, P2098, DOI 10.1074/jbc.REV118.002804; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374; Shen JL, 2017, P NATL ACAD SCI USA, V114, pE4020, DOI 10.1073/pnas.1616060114; Uramoto H, 2007, ANTICANCER RES, V27, P2297; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wey S, 2012, BLOOD, V119, P817, DOI 10.1182/blood-2011-06-357384; Ye RS, 2010, DIABETES, V59, P6, DOI 10.2337/db09-0755; Zhang XY, 2019, DRUG DES DEV THER, V13, P1357, DOI 10.2147/DDDT.S198400; Zhang Y, 2010, J BIOL CHEM, V285, P15065, DOI 10.1074/jbc.M109.087445	37	2	2	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3624	3632		10.1038/s41388-021-01791-9	http://dx.doi.org/10.1038/s41388-021-01791-9		APR 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33931739	Green Accepted			2022-12-28	WOS:000645887000001
J	Lee, HC; Ou, CH; Huang, YC; Hou, PC; Creighton, CJ; Lin, YS; Hu, CY; Lin, SC				Lee, Hsiu-Chi; Ou, Chien-Hui; Huang, Yun-Chen; Hou, Pei-Chi; Creighton, Chad J.; Lin, Yi-Syuan; Hu, Che-Yuan; Lin, Shih-Chieh			YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer	ONCOGENE			English	Article							HIPPO PATHWAY; INCREASED SURVIVAL; SIZE-CONTROL; MITOXANTRONE; ABIRATERONE; PREDNISONE; DOCETAXEL; GROWTH	Metastatic castration-resistant prostate cancer (mCRPC) is a malignant and lethal disease caused by relapse after androgen-deprivation (ADT) therapy. Since enzalutamide is innovated and approved by US FDA as a new treatment option for mCRPC patients, drug resistance for enzalutamide is a critical issue during clinical usage. Although several underlying mechanisms causing enzalutamide resistance were previously identified, most of them revealed that drug resistant cells are still highly addicted to androgen and AR functions. Due to the numerous physical functions of AR in men, innovated AR-independent therapy might alleviate enzalutamide resistance and prevent production of adverse side effects. Here, we have identified that yes-associated protein 1 (YAP1) is overexpressed in enzalutamide-resistant (EnzaR) cells. Furthermore, enzalutamide-induced YAP1 expression is mediated through the function of chicken ovalbumin upstream promoter transcription factor 2 (COUP-TFII) at the transcriptional and the post-transcriptional levels. Functional analyses reveal that YAP1 positively regulates numerous genes related to cancer stemness and lipid metabolism and interacts with COUP-TFII to form a transcriptional complex. More importantly, YAP1 inhibitor attenuates the growth and cancer stemness of EnzaR cells in vitro and in vivo. Finally, YAP1, COUP-TFII, and miR-21 are detected in the extracellular vesicles (EVs) isolated from EnzaR cells and sera of patients. In addition, treatment with EnzaR-EVs induces the abilities of cancer stemness, lipid metabolism and enzalutamide resistance in its parental cells. Taken together, these results suggest that YAP1 might be a crucial factor involved in the development of enzalutamide resistance and can be an alternative therapeutic target in prostate cancer.	[Lee, Hsiu-Chi; Hou, Pei-Chi; Lin, Shih-Chieh] Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan, Taiwan; [Ou, Chien-Hui; Hu, Che-Yuan] Natl Cheng Kung Univ & Hosp, Coll Med, Dept Urol, Tainan, Taiwan; [Huang, Yun-Chen; Lin, Shih-Chieh] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, Tainan, Taiwan; [Creighton, Chad J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Div Biostat, Dept Med, Houston, TX 77030 USA; [Lin, Yi-Syuan; Lin, Shih-Chieh] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan; [Hu, Che-Yuan] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; Baylor College of Medicine; National Cheng Kung University; National Cheng Kung University	Lee, HC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan, Taiwan.	Jaylin@mail.ncku.edu.tw	Hu, Che-Yuan/AGP-5540-2022	Hu, Che-Yuan/0000-0001-5151-4552; Hou, Pei-Chi/0000-0002-3709-5934	Ministry of Science and Technology [MOST 108-2628-B-006-003, MOST 109-2636-B-006-006]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	We thank Yen-Yu Lai and Yi-Chen Tang for technical assistance and Chu-An Wang for proofreading the manuscript. This study was supported by research grants from Ministry of Science and Technology (MOST 108-2628-B-006-003 and MOST 109-2636-B-006-006).	Abel S, 2019, J AM OSTEOPATH ASSOC, V119, P763, DOI 10.7556/jaoa.2019.126; Abudurexiti M, 2020, PROSTATE, V80, P950, DOI 10.1002/pros.24027; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Bainbridge A, 2020, NUCLEIC ACIDS RES, V48, P5366, DOI 10.1093/nar/gkaa271; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Borgmann H, 2018, EUR UROL, V73, P4, DOI 10.1016/j.eururo.2017.08.012; Brave M, 2020, CLIN CANCER RES, V26, P4717, DOI 10.1158/1078-0432.CCR-19-3835; Cerasuolo M, 2020, CANCER RES, V80, P1564, DOI 10.1158/0008-5472.CAN-18-3637; Coutinho I, 2016, ENDOCR-RELAT CANCER, V23, pT179, DOI 10.1530/ERC-16-0422; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Del Re M, 2017, EUR UROL, V71, P680, DOI 10.1016/j.eururo.2016.08.012; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Henry N, 2009, NAT CLIN PRACT UROL, V6, P164, DOI 10.1038/ncpuro1317; Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536; Jiang N, 2015, ONCOGENE, V34, P2764, DOI 10.1038/onc.2014.206; Jiang N, 2017, ONCOTARGET, V8, P115054, DOI 10.18632/oncotarget.23014; Klein EA, 2009, UROL ONCOL-SEMIN ORI, V27, P67, DOI 10.1016/j.urolonc.2008.04.001; Kong YF, 2018, J BIOL CHEM, V293, P14328, DOI 10.1074/jbc.RA118.004442; Korpal M, 2013, CANCER DISCOV, V3, P1030, DOI 10.1158/2159-8290.CD-13-0142; Kuser-Abali G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9126; Li HC, 2020, THERANOSTICS, V10, P7053, DOI 10.7150/thno.41388; Lin SC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11418; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Lukka H, 2006, Curr Oncol, V13, P81; Miyazawa Y, 2019, PROSTATE, V79, P1462, DOI 10.1002/pros.23865; Nguyen LT, 2015, CANCER CELL, V27, P797, DOI 10.1016/j.ccell.2015.05.005; Ning YM, 2015, ONCOLOGIST, V20, P960, DOI 10.1634/theoncologist.2015-0166; Peak TC, 2020, MOL CARCINOGEN, V59, P62, DOI 10.1002/mc.23129; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Stoykova GE, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112626; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Tumaneng K, 2012, CURR BIOL, V22, pR368, DOI 10.1016/j.cub.2012.03.003; Wang LM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz8031; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Zadra G, 2019, P NATL ACAD SCI USA, V116, P631, DOI 10.1073/pnas.1808834116; Zhang L, 2015, MOL CELL BIOL, V35, P1350, DOI 10.1128/MCB.00102-15; Zhang ZD, 2020, CANCER CELL, V37, P584, DOI 10.1016/j.ccell.2020.03.001; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	42	14	14	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2407	2421		10.1038/s41388-021-01718-4	http://dx.doi.org/10.1038/s41388-021-01718-4		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33664454	Green Published, hybrid			2022-12-28	WOS:000625833000001
J	Wu, RF; Li, KK; Yuan, MH; Luo, KQ				Wu, Renfei; Li, Koukou; Yuan, Mingheng; Luo, Kathy Qian			Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells	ONCOGENE			English	Article							INDUCED APOPTOSIS; EXPRESSION; TRK; SURVIVAL; PATHWAY	Cellular heterogeneity and the lack of metastatic biomarkers limit the diagnosis of and development of therapies for metastatic triple-negative breast cancer (TNBC). Thus, development of new clinically relevant markers is urgently needed. By using RNA-seq analysis, we found that nerve growth factor receptor (NGFR) was highly expressed in metastatic lung clones of MDA-MB-231 cells. This high level of NGFR expression was necessary for TNBC cells to grow into tumor spheres under nonadhesive conditions, resist anoikis, promote primary tumor growth and increase metastasis in mice. NGFR was also expressed at a high level in a greater number of TNBC patients (45%) than non-TNBC patients (23%), enriched in higher grade tumors, and negatively correlated with the overall survival of TNBC patients. Mechanistic analysis indicated that NGFR exerted its prometastatic effects by binding with neurotrophic receptor tyrosine kinase 3 (TrkC) mainly through a ligand-independent manner, which activated the MEK-ERK1-ZEB1 and PI3K-AKT signaling pathways, increased the level of fibronectin, and decreased the expression of PUMA. Notably, we observed that NGFR expression in TrkC-positive metastatic clones reduced cellular sensitivity to anti-Trk therapy. Moreover, WNT family member 5a (WNT5A) and TrkC activated NGFR transcription in a ZEB1-dependent manner. Taken together, this study identified NGFR as a novel driver for transforming TNBC into higher grade metastatic tumors. Our findings provide the basis for the future development of NGFR as a diagnostic and prognostic marker for determining the metastatic potential of TNBC and as a therapeutic target for treating TNBC patients.	[Wu, Renfei; Li, Koukou; Yuan, Mingheng; Luo, Kathy Qian] Univ Macau, Fac Hlth Sci, Taipa, Macao, Peoples R China	University of Macau	Luo, KQ (corresponding author), Univ Macau, Fac Hlth Sci, Taipa, Macao, Peoples R China.	kluo@um.edu.mo		Luo, Kathy Qian/0000-0001-7454-9547; Wu, Renfei/0000-0002-8847-7254	Science and Technology Development Fund (FDCT), Macao SAR, China [083/2016/A2, 068/2017/A2]	Science and Technology Development Fund (FDCT), Macao SAR, China	This project was funded by The Science and Technology Development Fund (FDCT), Macao SAR, China (File no. 083/2016/A2 and 068/2017/A2).	Anand P, 2015, BIOTECHNOL BIOENG, V112, P1673, DOI 10.1002/bit.25572; Ardini E, 2016, MOL CANCER THER, V15, P628, DOI 10.1158/1535-7163.MCT-15-0758; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Brewster AM, 2014, LANCET ONCOL, V15, pE625, DOI 10.1016/S1470-2045(14)70364-X; Celia-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chang JL, 2019, J CELL BIOL, V218, P2456, DOI 10.1083/jcb.201903066; Chiu LY, 2017, ONCOGENE, V36, P242, DOI 10.1038/onc.2016.195; Cocco E, 2018, NAT REV CLIN ONCOL, V15, P731, DOI 10.1038/s41571-018-0113-0; Contreras-Zarate MJ, 2019, ONCOGENE, V38, P4685, DOI 10.1038/s41388-019-0756-z; Deng XF, 2017, INT J CLIN EXP PATHO, V10, P11685; Elsum IA, 2013, J CELL SCI, V126, P3990, DOI 10.1242/jcs.129387; Faulkner S, 2018, AM J PATHOL, V188, P229, DOI 10.1016/j.ajpath.2017.09.008; Fu A, 2016, ONCOTARGET, V7, P50239, DOI 10.18632/oncotarget.10360; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Hondermarck H, 2012, CYTOKINE GROWTH F R, V23, P357, DOI 10.1016/j.cytogfr.2012.06.004; Howlader N., 2021, SEER CANC STAT REV, P1975; Jin W, 2010, CARCINOGENESIS, V31, P1939, DOI 10.1093/carcin/bgq180; Katsura A, 2017, MOL ONCOL, V11, P1241, DOI 10.1002/1878-0261.12098; Koren S, 2015, MOL CELL, V60, P537, DOI 10.1016/j.molcel.2015.10.031; Lagadec C, 2009, ONCOGENE, V28, P1960, DOI 10.1038/onc.2009.61; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lee S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182666; Luo KQ, 2001, BIOCHEM BIOPH RES CO, V283, P1054, DOI 10.1006/bbrc.2001.4896; Ma SJ, 2017, CANCER LETT, V388, P239, DOI 10.1016/j.canlet.2016.12.001; Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Restivo G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01573-6; Saadipour K, 2017, J BIOL CHEM, V292, P16594, DOI 10.1074/jbc.M117.788729; Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Verbeke S, 2010, CELL SIGNAL, V22, P1864, DOI 10.1016/j.cellsig.2010.07.014; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Wang JP, 2017, J CANCER, V8, P674, DOI 10.7150/jca.16901	38	8	8	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2165	2181		10.1038/s41388-021-01691-y	http://dx.doi.org/10.1038/s41388-021-01691-y		FEB 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33627781				2022-12-28	WOS:000621289100002
J	Chen, L; Zhang, YA; Shu, X; Chen, Q; Wei, TT; Wang, HM; Wang, XR; Wu, QR; Zhang, XM; Liu, XY; Zheng, SY; Huang, L; Xiao, JY; Jiang, C; Yang, B; Wang, ZP; Guo, X				Chen, Lu; Zhang, Yanan; Shu, Xin; Chen, Qiong; Wei, Tiantian; Wang, Heman; Wang, Xiaorong; Wu, Qirou; Zhang, Xiaomei; Liu, Xiaoyan; Zheng, Suya; Huang, Lan; Xiao, Junyu; Jiang, Chao; Yang, Bing; Wang, Zhiping; Guo, Xing			Proteasome regulation by reversible tyrosine phosphorylation at the membrane	ONCOGENE			English	Article								Reversible phosphorylation has emerged as an important mechanism for regulating 26S proteasome function in health and disease. Over 100 phospho-tyrosine sites of the human proteasome have been detected, and yet their function and regulation remain poorly understood. Here we show that the 19S subunit Rpt2 is phosphorylated at Tyr439, a strictly conserved residue within the C-terminal HbYX motif of Rpt2 that is essential for 26S proteasome assembly. Unexpectedly, we found that Y439 phosphorylation depends on Rpt2 membrane localization mediated by its N-myristoylation. Multiple receptors tyrosine kinases can trigger Rpt2-Y439 phosphorylation by activating Src, a N-myristoylated tyrosine kinase. Src directly phosphorylates Rpt2-Y439 in vitro and negatively regulates 26S proteasome activity at cellular membranes, which can be reversed by the membrane-associated isoform of protein tyrosine phosphatase nonreceptor type 2 (PTPN2). In H1975 lung cancer cells with activated Src, blocking Rpt2-Y439 phosphorylation by the Y439F mutation conferred partial resistance to the Src inhibitor saracatinib both in vitro and in a mouse xenograft tumor model, and caused significant changes of cellular responses to saracatinib at the proteome level. Our study has defined a novel mechanism involved in the spatial regulation of proteasome function and provided new insights into tyrosine kinase inhibitor-based anticancer therapies.	[Chen, Lu; Zhang, Yanan; Shu, Xin; Chen, Qiong; Wang, Heman; Wu, Qirou; Zhang, Xiaomei; Liu, Xiaoyan; Zheng, Suya; Jiang, Chao; Yang, Bing; Guo, Xing] Zhejiang Univ, Inst Life Sci, Zhejiang Prov Key Lab Canc Mol Cell Biol, Hangzhou, Peoples R China; [Wei, Tiantian; Xiao, Junyu] Peking Univ, Acad Adv Interdisciplinary Studies, Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China; [Wang, Xiaorong; Huang, Lan] Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92717 USA; [Wang, Xiaorong; Huang, Lan] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92717 USA; [Wang, Zhiping] Zhejiang Univ, Sch Med, Ctr Neurosci, Hangzhou, Peoples R China; [Wang, Zhiping] Zhejiang Univ, Sch Med, Dept Neurol, NHC & CAMS Key Lab Med Neurobiol,Affiliated Hosp, Hangzhou, Peoples R China	Zhejiang University; Peking University; University of California System; University of California Irvine; University of California System; University of California Irvine; Zhejiang University; Zhejiang University	Guo, X (corresponding author), Zhejiang Univ, Inst Life Sci, Zhejiang Prov Key Lab Canc Mol Cell Biol, Hangzhou, Peoples R China.; Wang, ZP (corresponding author), Zhejiang Univ, Sch Med, Ctr Neurosci, Hangzhou, Peoples R China.; Wang, ZP (corresponding author), Zhejiang Univ, Sch Med, Dept Neurol, NHC & CAMS Key Lab Med Neurobiol,Affiliated Hosp, Hangzhou, Peoples R China.	z4wang@zju.edu.cn; xguo@zju.edu.cn	Liu, XiaoYan/GQA-7216-2022	Xiao, Junyu/0000-0003-1822-1701	Natural Science Foundation of China [31671391, 31870762, 91953103, 31671039]; Zhejiang Natural Science Foundation [LR18C050001]; Fundamental Research Funds for the Central Universities [2016QN81011]; Zhejiang University; National Key Research and Development Plan of the Ministry of Science and Technology of China [2016YF0501000]; NIH [R01GM074830]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Natural Science Foundation(Natural Science Foundation of Zhejiang Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Zhejiang University; National Key Research and Development Plan of the Ministry of Science and Technology of China; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Drs. Xin-Hua Feng, Hai Song, Bin Zhao (Life Sciences Institute, Zhejiang University, LSI-ZJU), Zhong-Yin Zhang (Purdue University), Shigeo Murata (The University of Tokyo), and Susan Lindquist (Massachusetts Institute of Technology) for crucial constructs, cell lines, and reagents. We are grateful for the critical and encouraging comments from Drs. Kun-Liang Guan, Anne-Claude Gingras, Benjamin Neel, Tony Hunter, and Tony Tiganis. We appreciate the technical assistance from Xiaorui Jiang, Fei Zhang, and the Core Facilities of LSI-ZJU. XG was supported by Natural Science Foundation of China (31671391, 31870762), Zhejiang Natural Science Foundation (LR18C050001), Fundamental Research Funds for the Central Universities (2016QN81011), and the startup funding from Zhejiang University. BY was funded by Natural Science Foundation of China (91953103). ZW was supported by Natural Science Foundation of China (31671039) and National Key Research and Development Plan of the Ministry of Science and Technology of China (2016YF0501000). LH was funded by NIH (R01GM074830).	Albert S, 2017, P NATL ACAD SCI USA, V114, P13726, DOI 10.1073/pnas.1716305114; Alevizopoulos K, 2014, CURR DRUG TARGETS, V15, P988, DOI 10.2174/1389450115666140908125025; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Bard JAM, 2018, ANNU REV BIOCHEM, V87, P697, DOI 10.1146/annurev-biochem-062917-011931; Barr AJ, 2010, FUTURE MED CHEM, V2, P1563, DOI [10.4155/fmc.10.241, 10.4155/FMC.10.241]; Bose S, 2001, BIOCHEM J, V353, P291, DOI 10.1042/0264-6021:3530291; Budenholzer L, 2017, J MOL BIOL, V429, P3500, DOI 10.1016/j.jmb.2017.05.027; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Collins GA, 2017, CELL, V169, P792, DOI 10.1016/j.cell.2017.04.023; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Eisele MR, 2018, CELL REP, V24, P1301, DOI 10.1016/j.celrep.2018.07.004; Feng Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00850-0; Finley D, 2020, CSH PERSPECT BIOL, V12, DOI 10.1101/cshperspect.a033985; Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607; Formisano L, 2015, ONCOTARGET, V6, P26090, DOI 10.18632/oncotarget.4636; Frankson R, 2017, CANCER RES, V77, P5701, DOI 10.1158/0008-5472.CAN-17-1510; Guerrero C, 2008, P NATL ACAD SCI USA, V105, P13333, DOI 10.1073/pnas.0801870105; Guo X, 2017, PROTEIN CELL, V8, P255, DOI 10.1007/s13238-017-0382-x; Guo X, 2016, NAT CELL BIOL, V18, P202, DOI 10.1038/ncb3289; Hein MY, 2015, CELL, V163, P712, DOI 10.1016/j.cell.2015.09.053; Hemmis CW, 2019, J BIOL CHEM, V294, P9659, DOI 10.1074/jbc.AC119.008881; Heun Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184404; Huang XL, 2016, NAT STRUCT MOL BIOL, V23, P778, DOI 10.1038/nsmb.3273; Hunter T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020644; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; Kikuchi J, 2010, PROTEOMICS, V10, P2769, DOI 10.1002/pmic.200900283; Kim YC, 2011, J BIOL CHEM, V286, P26652, DOI 10.1074/jbc.M111.246793; Kimura A, 2016, J PROTEOMICS, V130, P33, DOI 10.1016/j.jprot.2015.08.021; Kimura A, 2012, BIOCHEMISTRY-US, V51, P8856, DOI 10.1021/bi3007862; Kimura Y, 2003, ARCH BIOCHEM BIOPHYS, V409, P341, DOI 10.1016/S0003-9861(02)00639-2; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kolch W, 2010, NAT REV CANCER, V10, P618, DOI 10.1038/nrc2900; Kumar B, 2010, J BIOL CHEM, V285, P39523, DOI 10.1074/jbc.M110.153627; Kumar P, 2017, J PROTEOME RES, V16, P2789, DOI 10.1021/acs.jproteome.7b00065; Li DP, 2015, CELL REP, V10, P484, DOI 10.1016/j.celrep.2014.12.044; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Liu XY, 2020, P NATL ACAD SCI USA, V117, P328, DOI 10.1073/pnas.1912531117; Liu X, 2006, MOL CELL, V22, P317, DOI 10.1016/j.molcel.2006.04.007; Lokireddy S, 2015, P NATL ACAD SCI USA, V112, pE7176, DOI 10.1073/pnas.1522332112; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Moritz A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000998; Muppirala M, 2013, BBA-MOL CELL RES, V1833, P1125, DOI 10.1016/j.bbamcr.2013.01.004; Murata S, 2018, NAT IMMUNOL, V19, P923, DOI 10.1038/s41590-018-0186-z; Murata S, 2009, NAT REV MOL CELL BIO, V10, P104, DOI 10.1038/nrm2630; Park S, 2013, NATURE, V497, P512, DOI 10.1038/nature12123; Park S, 2009, NATURE, V459, P866, DOI 10.1038/nature08065; Ramachandran KV, 2017, NAT STRUCT MOL BIOL, V24, P419, DOI 10.1038/nsmb.3389; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; Satoh K, 2001, BIOCHEMISTRY-US, V40, P314, DOI 10.1021/bi001815n; Schmidt M, 2014, BBA-MOL CELL RES, V1843, P13, DOI 10.1016/j.bbamcr.2013.08.012; Scott JD, 2009, SCIENCE, V326, P1220, DOI 10.1126/science.1175668; Sharma K, 2014, CELL REP, V8, P1583, DOI 10.1016/j.celrep.2014.07.036; Shibahara T, 2002, EUR J BIOCHEM, V269, P1474, DOI 10.1046/j.1432-1033.2002.02792.x; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Smith DM, 2007, MOL CELL, V27, P731, DOI 10.1016/j.molcel.2007.06.033; St-Denis N, 2016, CELL REP, V17, P2488, DOI 10.1016/j.celrep.2016.10.078; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TANAKA K, 1990, BIOCHEMISTRY-US, V29, P3777, DOI 10.1021/bi00467a026; Tang M, 2017, THERANOSTICS, V7, P1346, DOI 10.7150/thno.18804; Thinon E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5919; Tibes R, 2005, ANNU REV PHARMACOL, V45, P357, DOI 10.1146/annurev.pharmtox.45.120403.100124; van Vliet C, 2005, NAT IMMUNOL, V6, P253, DOI 10.1038/ni1169; VerPlank JJS, 2017, BIOCHEM J, V474, P3355, DOI 10.1042/BCJ20160809; Wang JH, 2015, MOL CELL, V58, P710, DOI 10.1016/j.molcel.2015.05.002; Wang XR, 2007, BIOCHEMISTRY-US, V46, P3553, DOI 10.1021/bi061994u; Wei J, 2019, NATURE, V576, P471, DOI 10.1038/s41586-019-1821-z; Wiede F, 2020, EMBO J, V39, DOI 10.15252/embj.2019103637; Ye Diana Zi, 2012, Cell Logist, V2, P105; Ye Z, 2015, SCI REP-UK, V5, DOI 10.1038/srep16599; Zhang S, 2009, J AM CHEM SOC, V131, P13072, DOI 10.1021/ja903733z; Zhang ZY, 2017, ACCOUNTS CHEM RES, V50, P122, DOI 10.1021/acs.accounts.6b00537; Zong C, 2006, CIRC RES, V99, P372, DOI 10.1161/01.RES.0000237389.40000.02	74	3	3	1	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					1942	1956		10.1038/s41388-021-01674-z	http://dx.doi.org/10.1038/s41388-021-01674-z		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33603165	Green Submitted, Green Accepted			2022-12-28	WOS:000619433100003
J	Li, XL; Su, X; Liu, R; Pan, YS; Fang, JK; Cao, LJ; Feng, C; Shang, QW; Chen, YJ; Shao, CS; Shi, YF				Li, Xiaolei; Su, Xiao; Liu, Rui; Pan, Yongsha; Fang, Jiankai; Cao, Lijuan; Feng, Chao; Shang, Qianwen; Chen, Yongjing; Shao, Changshun; Shi, Yufang			HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression	ONCOGENE			English	Article								Despite the widespread use of the blockade of immune checkpoints, for a significant number of cancer patients, these therapies have proven ineffective, presumably due to the immunosuppressive nature of the tumor microenvironment (TME). Critical drivers of immune escape in the TME include tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), which not only mediate immune suppression, but also facilitate metastatic dissemination and impart resistance to immunotherapies. Thus, strategies that convert them into tumor fighters may offer great therapeutic potential. In this study, we evaluated whether pharmacologic modulation of macrophage phenotype by HDAC inhibitors (HDACi) could produce an anti-tumor effect. We demonstrated that low-dose HDACi trichostatin-A (TSA) markedly reshaped the tumor immune microenvironment by modulating the suppressive activity of infiltrating macrophages and inhibiting the recruitment of MDSCs in various tumors. These actions, in turn, augmented anti-tumor immune responses and further enhanced anti-tumor effects of immunotherapies. HDAC inhibition, however, also upregulated PD-L1, thereby limiting the beneficial therapeutic effects. Indeed, combining low-dose TSA with anti-PD-L1 in this model significantly enhanced the durability of tumor reduction and prolonged survival of tumor-bearing mice, compared with the effect of either treatment alone. These data introduce HDAC inhibition as a potential means to harness the anti-tumor potential of macrophages in cancer therapy.	[Li, Xiaolei; Su, Xiao; Liu, Rui; Pan, Yongsha; Fang, Jiankai; Cao, Lijuan; Feng, Chao; Shang, Qianwen; Chen, Yongjing; Shao, Changshun; Shi, Yufang] Soochow Univ, Affiliated Hosp 1, State Key Lab Radiat Med & Protect, Inst Translat Med,Med Coll, Suzhou 215123, Jiangsu, Peoples R China	Soochow University - China	Shao, CS; Shi, YF (corresponding author), Soochow Univ, Affiliated Hosp 1, State Key Lab Radiat Med & Protect, Inst Translat Med,Med Coll, Suzhou 215123, Jiangsu, Peoples R China.	shaoc@suda.edu.cn; yfshi@suda.edu.cn	Shi, Yufang/AAE-4431-2020; li, Xiaolei/V-1383-2019; Shao, Changshun/AAD-8977-2022	Shi, Yufang/0000-0001-8964-319X; li, Xiaolei/0000-0002-2697-6496; Shao, Changshun/0000-0003-2618-9342	National Natural Science Foundation of China [81930085, 81672797, 81530043]; National Key R&D Program of China [2018YFA0107500]; State Key Laboratory of Radiation Medicine and Protection, Soochow University [GZN1201804, GZN1201903]; Natural Science Foundation of the Jiangsu Higher Education Institutions of China [20KJB180005]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; State Key Laboratory of Radiation Medicine and Protection, Soochow University; Natural Science Foundation of the Jiangsu Higher Education Institutions of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (81930085, 81672797, and 81530043), National Key R&D Program of China (2018YFA0107500), State Key Laboratory of Radiation Medicine and Protection, Soochow University (GZN1201804 and GZN1201903), and The Natural Science Foundation of the Jiangsu Higher Education Institutions of China (20KJB180005).	Amit I, 2016, NAT IMMUNOL, V17, P18, DOI 10.1038/ni.3325; Armeanu S, 2005, CANCER RES, V65, P6321, DOI 10.1158/0008-5472.CAN-04-4252; Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42; Butowski N, 2016, NEURO-ONCOLOGY, V18, P557, DOI 10.1093/neuonc/nov245; Cao K, 2015, ONCOGENE, V34, P5960, DOI 10.1038/onc.2015.46; Christiansen AJ, 2011, P NATL ACAD SCI USA, V108, P4141, DOI 10.1073/pnas.1011037108; Cittera E, 2007, J IMMUNOL, V178, P6616, DOI 10.4049/jimmunol.178.10.6616; Coussens LM, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003285; Cui SN, 2019, INT IMMUNOPHARMACOL, V77, DOI 10.1016/j.intimp.2019.105973; Demaria O, 2019, NATURE, V574, P45, DOI 10.1038/s41586-019-1593-5; Flores-Toro JA, 2020, P NATL ACAD SCI USA, V117, P1129, DOI 10.1073/pnas.1910856117; Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510; Ghoneim HE, 2017, CELL, V170, DOI 10.1016/j.cell.2017.06.007; Gul N, 2015, CANCER RES, V75, P5008, DOI 10.1158/0008-5472.CAN-15-1330; Guerriero JL, 2017, NATURE, V543, P428, DOI 10.1038/nature21409; Gul N, 2014, J CLIN INVEST, V124, P812, DOI 10.1172/JCI66776; Halili MA, 2010, J LEUKOCYTE BIOL, V87, P1103, DOI 10.1189/jlb.0509363; Henning AN, 2018, NAT REV IMMUNOL, V18, P340, DOI 10.1038/nri.2017.146; Ino Y, 2013, BRIT J CANCER, V108, P914, DOI 10.1038/bjc.2013.32; Kim YD, 2020, J CANCER, V11, P4059, DOI 10.7150/jca.44622; Klug F, 2013, CANCER CELL, V24, P589, DOI 10.1016/j.ccr.2013.09.014; Laengle J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000195; Li XL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1102-3; Li XL, 2019, CELL MOL IMMUNOL, V16, P28, DOI 10.1038/s41423-018-0086-z; Li XL, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0578-4; Lin H, 2018, J CLIN INVEST, V128, P805, DOI 10.1172/JCI96113; Lu ZH, 2020, NATURE, V579, P284, DOI 10.1038/s41586-020-2054-x; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Morel D, 2020, NAT REV CLIN ONCOL, V17, P91, DOI 10.1038/s41571-019-0267-4; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nguyen A, 2018, CELL REP, V24, P642, DOI 10.1016/j.celrep.2018.06.040; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Nywening TM, 2018, GUT, V67, P1112, DOI 10.1136/gutjnl-2017-313738; Orillion A, 2017, CLIN CANCER RES, V23, P5187, DOI 10.1158/1078-0432.CCR-17-0741; Philip M, 2017, NATURE, V545, P452, DOI 10.1038/nature22367; Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528; Pucci F, 2009, BLOOD, V114, P901, DOI 10.1182/blood-2009-01-200931; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Rodriguez PC, 2003, J IMMUNOL, V171, P1232, DOI 10.4049/jimmunol.171.3.1232; Romano E, 2015, P NATL ACAD SCI USA, V112, P6140, DOI 10.1073/pnas.1417320112; Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Skov S, 2005, CANCER RES, V65, P11136, DOI 10.1158/0008-5472.CAN-05-0599; Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52; Tang HD, 2018, J CLIN INVEST, V128, P580, DOI 10.1172/JCI96061; Topper MJ, 2020, NAT REV CLIN ONCOL, V17, P75, DOI 10.1038/s41571-019-0266-5; Ugel S, 2015, J CLIN INVEST, V125, P3365, DOI 10.1172/JCI80006; Van Dyken SJ, 2013, ANNU REV IMMUNOL, V31, P317, DOI 10.1146/annurev-immunol-032712-095906; VANROOIJEN N, 1988, VIRCHOWS ARCH B, V54, P241; Xie ZQ, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1734268; Xiong HZ, 2019, CANCER RES, V79, P1493, DOI 10.1158/0008-5472.CAN-18-3208; Yau HL, 2019, TRENDS CELL BIOL, V29, P31, DOI 10.1016/j.tcb.2018.07.006	55	32	32	4	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1836	1850		10.1038/s41388-020-01636-x	http://dx.doi.org/10.1038/s41388-020-01636-x		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564072	Green Published, hybrid			2022-12-28	WOS:000616489100003
J	Xiong, YY; Ju, LG; Yuan, LS; Chen, L; Wang, G; Xu, HM; Peng, TC; Luo, YW; Xiao, Y; Wang, XH				Xiong, Yaoyi; Ju, Lingao; Yuan, Lushun; Chen, Liang; Wang, Gang; Xu, Huimin; Peng, Tianchen; Luo, Yongwen; Xiao, Yu; Wang, Xinghuan			KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer	ONCOGENE			English	Article							PI3K/AKT PATHWAY; THERAPY; TARGET	KNSTRN is a component of the mitotic spindle, which was rarely investigated in tumorigenesis. AKT plays an essential role in tumorigenesis by modulating the phosphorylation of various substrates. The activation of AKT is regulated by PTEN and PIP3. Here, we prove KNSTRN is positively correlated with malignancy of bladder cancer and KNSTRN activates AKT phosphorylation at Thr308 and Ser473. More importantly, our study reveals that both KNSTRN and PTEN interact with PH domain of AKT at cell membrane. The amount of KNSTRN interacted with AKT is negatively related to PTEN. Furthermore, PIP3 pull-down assay proves that KNSTRN promoted AKT movement to PIP3. These data suggest KNSTRN may activate AKT phosphorylation by promoting AKT movement to PIP3 and alleviating PTEN suppression. Based on the activation of AKT phosphorylation, our study demonstrates that KNSTRN promotes bladder cancer metastasis and gemcitabine resistance in vitro and in vivo. Meanwhile, the effect of KNSTRN on tumorigenesis and gemcitabine resistance could be restored by AKT specific inhibitor MK2206 or AKT overexpression. In conclusion, we identify an oncogene KNSTRN that promotes tumorigenesis and gemcitabine resistance by activating AKT phosphorylation and may serve as a therapeutic target in bladder cancer.	[Xiong, Yaoyi; Chen, Liang; Xu, Huimin; Peng, Tianchen; Luo, Yongwen; Xiao, Yu; Wang, Xinghuan] Wuhan Univ, Zhongnan Hosp, Dept Urol, Wuhan, Peoples R China; [Ju, Lingao; Wang, Gang; Xiao, Yu] Wuhan Univ, Zhongnan Hosp, Dept Biol Repositories, Wuhan, Peoples R China; [Ju, Lingao; Wang, Gang; Xiao, Yu] Human Genet Resource Preservat Ctr Hubei Prov, Wuhan, Peoples R China; [Ju, Lingao; Wang, Gang; Xiao, Yu; Wang, Xinghuan] Chinese Acad Med Sci, Res Ctr Wuhan Infect Dis & Canc, Wuhan, Peoples R China; [Yuan, Lushun] Leiden Univ Med Ctr, Dept Internal Med, Div Nephrol, Leiden, Netherlands; [Chen, Liang] Natl Inst Environm Hlth Sci, Signal Transduct Lab, Durham, NC USA; [Xiao, Yu] Wuhan Univ, Zhongnan Hosp, Lab Precis Med, Wuhan, Peoples R China; [Wang, Xinghuan] Wuhan Univ, Med Res Inst, Wuhan, Peoples R China	Wuhan University; Wuhan University; Chinese Academy of Medical Sciences - Peking Union Medical College; Leiden University; Leiden University Medical Center (LUMC); Wuhan University; Wuhan University	Xiao, Y; Wang, XH (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Urol, Wuhan, Peoples R China.; Xiao, Y (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Biol Repositories, Wuhan, Peoples R China.; Xiao, Y (corresponding author), Human Genet Resource Preservat Ctr Hubei Prov, Wuhan, Peoples R China.; Xiao, Y; Wang, XH (corresponding author), Chinese Acad Med Sci, Res Ctr Wuhan Infect Dis & Canc, Wuhan, Peoples R China.; Xiao, Y (corresponding author), Wuhan Univ, Zhongnan Hosp, Lab Precis Med, Wuhan, Peoples R China.; Wang, XH (corresponding author), Wuhan Univ, Med Res Inst, Wuhan, Peoples R China.	yu.xiao@whu.edu.cn; wangxinghuan@whu.edu.cn	Xiao, Yu/AGA-4786-2022; Ju, Lingao/ADP-8482-2022	Xiao, Yu/0000-0003-1377-9685; Ju, Lingao/0000-0003-0813-3628	Improvement Project for Theranostic ability on Difficulty miscellaneous disease (Tumor) from National Health Commission of China [ZLYNXM202006]; National Natural Science Foundation of China [81772730, 31900902, 81902603]	Improvement Project for Theranostic ability on Difficulty miscellaneous disease (Tumor) from National Health Commission of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The authors wish to acknowledge thank Dr Xiaoling Li from NIEHS for critical editing during the preparation of this paper. The excellent technical assistance of Ms Yayun Fang and Ms Danni Shan is gratefully acknowledged. We would like to acknowledge the the TCGA databases for free use. This work was supported by the Improvement Project for Theranostic ability on Difficulty miscellaneous disease (Tumor) from National Health Commission of China (ZLYNXM202006) and National Natural Science Foundation of China to XW (81772730), LJ (31900902) and GW (81902603).	Albers P, 2011, ANN ONCOL, V22, P288, DOI 10.1093/annonc/mdq398; Bergman AM, 2002, DRUG RESIST UPDATE, V5, P19, DOI 10.1016/S1368-7646(02)00002-X; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao DL, 2019, CANCER RES, V79, P2604, DOI 10.1158/0008-5472.CAN-18-3842; Choo Z, 2016, ONCOTARGET, V7, P34229, DOI 10.18632/oncotarget.8748; Chu N, 2018, CELL, V174, P897, DOI 10.1016/j.cell.2018.07.003; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Daizumoto K, 2018, CANCER RES, V78, P2233, DOI 10.1158/0008-5472.CAN-17-2528; Delaloge S, 2017, LANCET ONCOL, V18, P1293, DOI 10.1016/S1470-2045(17)30514-4; Dunsch AK, 2011, J CELL BIOL, V192, P959, DOI 10.1083/jcb.201008023; Friese A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11407; Gao X, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2530-0; Houede N, 2015, PHARMACOL THERAPEUT, V145, P1, DOI 10.1016/j.pharmthera.2014.06.004; Kaidanovich-Beilin O, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00040; Kern DM, 2017, ELIFE, V6, DOI 10.7554/eLife.26866; Kern DM, 2016, J CELL BIOL, V213, P315, DOI 10.1083/jcb.201510117; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee CS, 2014, NAT GENET, V46, P1060, DOI 10.1038/ng.3091; Li WJ, 2019, CELL DEATH DIFFER, V26, P1379, DOI 10.1038/s41418-018-0211-7; Liu BL, 2019, ONCOL REP, V41, P2168, DOI 10.3892/or.2019.7019; LoRusso PM, 2016, J CLIN ONCOL, V34, P3803, DOI 10.1200/JCO.2014.59.0018; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343; Mini E, 2006, ANN ONCOL, V17, pV7, DOI 10.1093/annonc/mdj941; Miyamoto DT, 2018, LANCET ONCOL, V19, pE683, DOI 10.1016/S1470-2045(18)30693-4; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Qin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep38791; Shelley MD, 2012, BJU INT, V109, P496, DOI 10.1111/j.1464-410X.2011.10880.x; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Toker A, 2015, CANCER CELL, V28, P143, DOI 10.1016/j.ccell.2015.07.010; van der Vos KE, 2011, ANTIOXID REDOX SIGN, V14, P579, DOI 10.1089/ars.2010.3419; van Rhijn BWG, 2009, EUR UROL, V56, P430, DOI 10.1016/j.eururo.2009.06.028; Wang GH, 2019, NAT CELL BIOL, V21, P214, DOI 10.1038/s41556-018-0266-1; Webb AE, 2014, TRENDS BIOCHEM SCI, V39, P159, DOI 10.1016/j.tibs.2014.02.003; Wong K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08081-1; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang PZ, 2017, NAT MED, V23, P1055, DOI 10.1038/nm.4379	41	13	13	4	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1595	1608		10.1038/s41388-020-01634-z	http://dx.doi.org/10.1038/s41388-020-01634-z		JAN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33452459				2022-12-28	WOS:000607998600008
J	Luo, JH; Liu, S; Tao, JY; Ren, BG; Luo, K; Chen, ZH; Nalesnik, M; Cieply, K; Ma, TZ; Cheng, SY; Chen, Q; Michalopoulos, GK; Nelson, JB; Bhargava, R; Zhang, J; Ma, DQ; Jarrard, D; Pennathur, A; Luketich, JD; DeFranco, DB; Monga, SP; Tseng, G; Yu, YP				Luo, Jian-Hua; Liu, Silvia; Tao, Junyan; Ren, Bao-Guo; Luo, Katherine; Chen, Zhang-Hui; Nalesnik, Michael; Cieply, Kathleen; Ma, Tianzhou; Cheng, Shi-Yuan; Chen, Qi; Michalopoulos, George K.; Nelson, Joel B.; Bhargava, Rohit; Zhang, Jun; Ma, Deqin; Jarrard, David; Pennathur, Arjun; Luketich, James D.; DeFranco, Donald B.; Monga, Satdarshan Paul; Tseng, George; Yu, Yan-Ping			Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; NF-KAPPA-B; TUMOR-SUPPRESSOR; ONCOGENIC ACTIVITY; PROSTATE-CANCER; PTEN; GENE; MAINTENANCE; NUCLEOLAR; NOPP140	Inactivation of Pten gene through deletions and mutations leading to excessive pro-growth signaling pathway activations frequently occurs in cancers. Here, we report a Pten derived pro-cancer growth gene fusion Pten-NOLC1 originated from a chr10 genome rearrangement and identified through a transcriptome sequencing analysis of human cancers. Pten-NOLC1 fusion is present in primary human cancer samples and cancer cell lines from different organs. The product of Pten-NOLC1 is a nuclear protein that interacts and activates promoters of EGFR, c-MET, and their signaling molecules. Pten-NOLC1 promotes cancer proliferation, growth, invasion, and metastasis, and reduces the survival of animals xenografted with Pten-NOLC1-expressing cancer cells. Genomic disruption of Pten-NOLC1 induces cancer cell death, while genomic integration of this fusion gene into the liver coupled with somatic Pten deletion produces spontaneous liver cancers in mice. Our studies indicate that Pten-NOLC1 gene fusion is a driver for human cancers.	[Luo, Jian-Hua; Liu, Silvia; Tao, Junyan; Ren, Bao-Guo; Chen, Zhang-Hui; Nalesnik, Michael; Cieply, Kathleen; Michalopoulos, George K.; Bhargava, Rohit; Monga, Satdarshan Paul; Yu, Yan-Ping] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; [Luo, Katherine; Tseng, George] Columbia Univ, Dept Biol, 1212 Amsterdam Ave, New York, NY 10027 USA; [Ma, Tianzhou] Univ Pittsburgh, Sch Med, Dept Biostat, Pittsburgh, PA 15261 USA; [Cheng, Shi-Yuan] Northwestern Univ, Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Chen, Qi] Univ Kansas, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA; [Nelson, Joel B.] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA 15261 USA; [Zhang, Jun] Univ Iowa, Dept Med, Iowa City, IA 52242 USA; [Ma, Deqin] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; [Jarrard, David] Univ Wisconsin, Dept Urol, Madison, WI 53792 USA; [Pennathur, Arjun; Luketich, James D.] Univ Pittsburgh, Sch Med, Dept Thorac Surg, Pittsburgh, PA 15261 USA; [DeFranco, Donald B.] Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; [Ma, Tianzhou] Univ Maryland, Sch Publ Hlth, Dept Epidemiol & Biostat, College Pk, MD 20742 USA; [Zhang, Jun] Univ Kansas, Med Ctr, Dept Med, Kansas City, KS 66160 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University; University of Kansas; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Iowa; University of Iowa; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Maryland; University of Maryland College Park; University of Kansas; University of Kansas Medical Center	Luo, JH; Yu, YP (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA.	luoj@msx.upmc.edu; ypyu@pitt.edu	Luo, jian/HGE-7331-2022; Ma, Tianzhou/AAC-8221-2021; Yu, Yan/GYV-4514-2022	Ma, Tianzhou/0000-0003-3605-0811; Luo, Jianhua/0000-0002-3189-4225; Cheng, Shiyuan/0000-0003-1737-0588; Zhang, Jun/0000-0001-7886-6187	NCI NIH HHS [P30 CA086862, R56 CA229262, R01 CA250227, R01 CA098249, R01 CA251155] Funding Source: Medline; NIDDK NIH HHS [P30 DK120531] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker SJ, 2007, CELL, V128, P25, DOI 10.1016/j.cell.2006.12.023; BENSON ES, 1961, POSTGRAD MED, V30, pA22; Chen HK, 1999, MOL CELL BIOL, V19, P8536; Chen ZH, 2017, GASTROENTEROLOGY, V153, P1120, DOI 10.1053/j.gastro.2016.12.036; Chen ZH, 2017, NAT BIOTECHNOL, V35, P543, DOI 10.1038/nbt.3843; Chen ZH, 2015, J BIOL CHEM, V290, P1404, DOI 10.1074/jbc.M114.622761; Gao XS, 2011, BMB REP, V44, P70, DOI 10.5483/BMBRep.2011.44.1.70; Han YC, 2013, J PATHOL, V230, P184, DOI 10.1002/path.4169; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He DM, 2017, ONCOGENE, V36, P3629, DOI 10.1038/onc.2017.123; Hwang YC, 2009, AM J PATHOL, V175, P342, DOI 10.2353/ajpath.2009.080931; Isaac C, 1998, J CELL BIOL, V142, P319, DOI 10.1083/jcb.142.2.319; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Lee YM, 1996, MOL CELL BIOL, V16, P4257; Li AG, 2006, MOL CELL, V23, P575, DOI 10.1016/j.molcel.2006.06.028; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Luo JH, 2015, AM J PATHOL, V185, P1834, DOI 10.1016/j.ajpath.2015.03.008; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; PAI CY, 1995, J CELL SCI, V108, P1911; Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021; Renvoise B, 2009, HUM MOL GENET, V18, P1181, DOI 10.1093/hmg/ddp009; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Tsai YT, 2008, J BIOMED SCI, V15, P471, DOI 10.1007/s11373-007-9226-7; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Yan-Ping Y., 2019, ONCOTARGET; Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241; Yu GY, 2006, AM J PATHOL, V168, P597, DOI 10.2353/ajpath.2006.050620; Yu YP, 2014, AM J PATHOL, V184, P2840, DOI 10.1016/j.ajpath.2014.06.025; Yu YP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092820; Yu Yan-Ping, 2019, Oncotarget, V10, P3352; Yu YP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38550-6; Zuo ZH, 2017, MOL CARCINOGEN, V56, P315, DOI 10.1002/mc.22494	40	4	4	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1064	1076		10.1038/s41388-020-01582-8	http://dx.doi.org/10.1038/s41388-020-01582-8		DEC 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323972	Green Accepted			2022-12-28	WOS:000599126500006
J	Sari, IN; Yang, YG; Wijaya, YT; Jun, N; Lee, S; Kim, KS; Bajaj, J; Oehler, VG; Kim, SH; Choi, SY; Park, SH; Kim, DW; Reya, T; Han, J; Kwon, HY				Sari, Ita Novita; Yang, Ying-Gui; Wijaya, Yoseph Toni; Jun, Nayoung; Lee, Sanghyun; Kim, Kwang Seock; Bajaj, Jeevisha; Oehler, Vivian G.; Kim, Soo-Hyun; Choi, Soo-Young; Park, Sa-Hee; Kim, Dong-Wook; Reya, Tannishtha; Han, Jaeseok; Kwon, Hyog Young			AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth	ONCOGENE			English	Article							POLYAMINE BIOSYNTHESIS INHIBITOR; PHASE-II TRIAL; GENE-EXPRESSION; ESCHERICHIA-COLI; CANCER; METABOLISM; SPERMINE; SAM486A; STRESS; TARGETS	Polyamines are critical elements in mammals, but it remains unknown whether adenosyl methionine decarboxylase (AMD1), a rate-limiting enzyme in polyamine synthesis, is required for myeloid leukemia. Here, we found that leukemic stem cells (LSCs) were highly differentiated, and leukemia progression was severely impaired in the absence of AMD1 in vivo. AMD1 was highly upregulated as chronic myeloid leukemia (CML) progressed from the chronic phase to the blast crisis phase, and was associated with the poor prognosis of CML patients. In addition, the pharmacological inhibition of AMD1 by AO476 treatment resulted in a robust reduction of the progression of leukemic cells both in vitro and in vivo. Mechanistically, AMD1 depletion induced loss of mitochondrial membrane potential and accumulation of reactive oxygen species (ROS), resulting in the differentiation of LSCs via oxidative stress and aberrant activation of unfolded protein response (UPR) pathway, which was partially rescued by the addition of polyamine. These results indicate that AMD1 is an essential element in the progression of myeloid leukemia and could be an attractive target for the treatment of the disease.	[Sari, Ita Novita; Yang, Ying-Gui; Wijaya, Yoseph Toni; Jun, Nayoung; Lee, Sanghyun; Kim, Kwang Seock; Han, Jaeseok; Kwon, Hyog Young] Soonchunhyang Univ, Soonchunhyang Inst Medibio Sci, Cheonan, South Korea; [Yang, Ying-Gui] Southern Med Univ, Shenzhen Hosp, Clin Innovat & Res Ctr CIRC, Shenzhen Key Lab Viral Oncol, Shenzhen, Peoples R China; [Bajaj, Jeevisha; Reya, Tannishtha] Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA; [Bajaj, Jeevisha; Reya, Tannishtha] Sanford Consortium Regenerat Med, La Jolla, CA USA; [Oehler, Vivian G.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA; [Kim, Soo-Hyun; Choi, Soo-Young; Park, Sa-Hee; Kim, Dong-Wook] Catholic Univ Korea, Catholic Leukemia Res Inst, Seoul, South Korea; [Kim, Dong-Wook] Catholic Univ Korea, Seoul St Marys Hosp, Dept Hematol, Seoul, South Korea; [Reya, Tannishtha] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Soonchunhyang University; Southern Medical University - China; University of California System; University of California San Diego; Fred Hutchinson Cancer Center; Catholic University of Korea; Catholic University of Korea; Seoul St. Mary's Hospital; Duke University	Kwon, HY (corresponding author), Soonchunhyang Univ, Soonchunhyang Inst Medibio Sci, Cheonan, South Korea.	hykwon@sch.ac.kr		KIM, Kwang Seock/0000-0002-3329-1225; Sari, Ita Novita/0000-0001-9475-7992; Wijaya, Yoseph Toni/0000-0003-3002-8592	National Research Foundation of Korea [NRF-2020R1A2C1003791, NRF-2019R1A5A8083404]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHID) - Ministry of Health & Welfare, Republic of Korea [HI15C1647]; Global Research Development Center [NRF-2016K1A4A3914725]	National Research Foundation of Korea(National Research Foundation of Korea); Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHID) - Ministry of Health & Welfare, Republic of Korea; Global Research Development Center	This work was supported by the National Research Foundation of Korea (NRF-2020R1A2C1003791 and NRF-2019R1A5A8083404), the grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHID), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI15C1647) and Global Research Development Center (NRF-2016K1A4A3914725).	Abreu RD, 2009, J BIOL CHEM, V284, P12125, DOI 10.1074/jbc.M809605200; Agostinelli E, 2007, AMINO ACIDS, V33, P175, DOI 10.1007/s00726-007-0510-7; Basuroy UK, 2006, J BIOCHEM, V139, P27, DOI 10.1093/jb/mvj022; Battelli C, 2006, MOL CELL NEUROSCI, V31, P85, DOI 10.1016/j.mcn.2005.09.003; Ferreira AMC, 2016, J CHROMATOGR A, V1444, P32, DOI 10.1016/j.chroma.2016.03.054; Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243; Das KC, 2004, MOL CELL BIOCHEM, V262, P127, DOI 10.1023/B:MCBI.0000038227.91813.79; delaVega AL, 1996, J BACTERIOL, V178, P3715, DOI 10.1128/jb.178.13.3715-3721.1996; Fujisawa S, 2005, ANTICANCER RES, V25, P965; Gamble LD, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00162; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; Gugliucci A, 2004, CLIN CHIM ACTA, V344, P23, DOI 10.1016/j.cccn.2004.02.022; Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001; Ito T, 2010, NATURE, V466, P765, DOI 10.1038/nature09171; Ji AR, 2010, EXP MOL MED, V42, P175, DOI 10.3858/emm.2010.42.3.018; Jung IL, 2003, BIOCHEM BIOPH RES CO, V301, P915, DOI 10.1016/S0006-291X(03)00064-0; Kabbarah O, 2003, AM J PATHOL, V162, P755, DOI 10.1016/S0002-9440(10)63872-2; Kim JS, 2006, ENVIRON TOXICOL PHAR, V22, P160, DOI 10.1016/j.etap.2006.02.003; Kwon HY, 2015, CELL STEM CELL, V17, P152, DOI 10.1016/j.stem.2015.06.006; Larque E, 2007, NUTRITION, V23, P87, DOI 10.1016/j.nut.2006.09.006; Liao CZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep10754; Luo M, 2018, CELL METAB, V28, P69, DOI 10.1016/j.cmet.2018.06.006; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; McStay GP, 2002, BIOCHEM J, V367, P541, DOI 10.1042/BJ20011672; Millward MJ, 2005, INVEST NEW DRUG, V23, P253, DOI 10.1007/s10637-005-6734-z; MUSCARI C, 1995, MOL CELL BIOCHEM, V144, P125, DOI 10.1007/BF00944391; Paridaens R, 2000, BRIT J CANCER, V83, P594, DOI 10.1054/bjoc.2000.1305; Park SM, 2014, J EXP MED, V211, P71, DOI 10.1084/jem.20130736; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; Pegg AE, 2009, IUBMB LIFE, V61, P880, DOI 10.1002/iub.230; Pless M, 2004, CLIN CANCER RES, V10, P1299, DOI 10.1158/1078-0432.CCR-0977-03; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Rider JE, 2007, AMINO ACIDS, V33, P231, DOI 10.1007/s00726-007-0513-4; RUSSELL DH, 1971, NATURE-NEW BIOL, V233, P144, DOI 10.1038/newbio233144a0; Sagor GHM, 2013, TRANSGENIC RES, V22, P595, DOI 10.1007/s11248-012-9666-3; Sava IG, 2006, FREE RADICAL BIO MED, V41, P1272, DOI 10.1016/j.freeradbiomed.2006.07.008; Scuoppo C, 2012, NATURE, V487, P244, DOI 10.1038/nature11126; Segawa T, 2002, ONCOGENE, V21, P8749, DOI 10.1038/sj.onc.1205992; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; SIMON MS, 1990, INVEST NEW DRUG, V8, pS79; Siu LL, 2002, CLIN CANCER RES, V8, P2157; Soda K, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-95; SOHAL RS, 1986, ADV FREE RADICAL BIO, V2, P117, DOI 10.1016/S8755-9668(86)80026-6; Stewart TM, 2018, J BIOL CHEM, V293, P18736, DOI 10.1074/jbc.TM118.003337; TIBURCIO AF, 1994, BIOCHEM SOC T, V22, pS455, DOI 10.1042/bst022455s; Tkachenko AG, 2003, BIOCHEMISTRY-MOSCOW+, V68, P850, DOI 10.1023/A:1025790729797; Urdiales JL, 2001, EUR J GASTROEN HEPAT, V13, P1015, DOI 10.1097/00042737-200109000-00003; van Zuylen L, 2004, CLIN CANCER RES, V10, P1949, DOI 10.1158/1078-0432.CCR-02-0995; Vu LP, 2017, NAT GENET, V49, P866, DOI 10.1038/ng.3854; Walker JA, 2017, JAIDS-J ACQ IMM DEF, V74, P583, DOI 10.1097/QAI.0000000000001297; Xu LJ, 2020, CARCINOGENESIS, V41, P214, DOI 10.1093/carcin/bgz098; Zimdahl B, 2014, NAT GENET, V46, P245, DOI 10.1038/ng.2889	52	6	6	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					603	617		10.1038/s41388-020-01547-x	http://dx.doi.org/10.1038/s41388-020-01547-x		NOV 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33203990				2022-12-28	WOS:000590200200001
J	Han, SS; Wen, KK; Vyas, YM				Han, Seong-Su; Wen, Kuo-Kuang; Vyas, Yatin M.			Deficiency of Wiskott-Aldrich syndrome protein has opposing effect on the pro-oncogenic pathway activation in nonmalignant versus malignant lymphocytes	ONCOGENE			English	Article							KAPPA-B; CANCER; WASP; CELLS; TRANSFORMATION; HALLMARKS; LYMPHOMA; INVASION; GENES; CDC42	Immunodeficiency is associated with cancer risk. Accordingly, hematolymphoid cancers develop in Wiskott-Aldrich syndrome (WAS), an X-linked primary immunodeficiency disorder (PID) resulting from the deficiency of WAS-protein (WASp) expressed predominantly in the hematolymphoid cell lineages. Despite the correlation between WASp deficiency and hematolymphoid cancers, the molecular mechanism underlying the oncogenic role of WASp is incompletely understood. Employing the WASp-sufficient and WASp-deficient cell-pair model of human T and B lymphocytes, we show that WASp deficiency differentially influences hyperactivation versus inhibition of both CDC42:ERK1/2 and NF-kappa B:AP-1 pro-oncogenic signaling pathways in nonmalignant versus malignant T and B lymphocytes. Furthermore, WASp deficiency induces a cell-type specific up/down-modulation of the DNA-binding activities of NF-kappa B, AP-1, and multiple other transcription factors with known roles in oncogenesis. We propose that WASp functions as a putative "tumor-suppressor" protein in normal T and B cells, and "oncoprotein" in a subset of established T and B cell malignancies that are not associated with the NPM-ALK fusion.	[Han, Seong-Su; Wen, Kuo-Kuang; Vyas, Yatin M.] Carver Coll Med, Div Pediat Hematol Oncol, Iowa City, IA 52242 USA; [Han, Seong-Su; Wen, Kuo-Kuang; Vyas, Yatin M.] Stead Family Univ Iowa, Childrens Hosp, Iowa City, IA 52242 USA		Vyas, YM (corresponding author), Carver Coll Med, Div Pediat Hematol Oncol, Iowa City, IA 52242 USA.; Vyas, YM (corresponding author), Stead Family Univ Iowa, Childrens Hosp, Iowa City, IA 52242 USA.	yatin-vyas@uiowa.edu		Han, Seong-Su/0000-0001-9824-6751; Vyas, Yatin/0000-0002-4595-0267	NIH [R21AI138051, R01AI146380]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by the NIH grant R21AI138051 and R01AI146380 (to YMV).	Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148; Bosticardo M, 2009, BLOOD, V113, P6288, DOI 10.1182/blood-2008-12-115253; Castellano G, 2010, CELL CYCLE, V9, P557, DOI 10.4161/cc.9.3.10554; Chaturvedi MM, 2011, ONCOGENE, V30, P1615, DOI 10.1038/onc.2010.566; Cheminant M, 2019, J ALLERGY CLIN IMMUN, V143, P2311, DOI 10.1016/j.jaci.2019.01.046; Davuluri G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110627; Escoll M, 2017, ONCOGENE, V36, P3515, DOI 10.1038/onc.2016.518; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; FARBER E, 1995, CANCER RES, V55, P3759; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hidalgo-Sastre A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.127275; Hou JX, 2017, AM J TRANSL RES, V9, P403; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kawanishi S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081808; Keszei M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1468954; Kurisu S, 2005, ONCOGENE, V24, P1309, DOI 10.1038/sj.onc.1208177; Lee EYHP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003236; Li H, 2019, CANCER RES, V79, P2167, DOI 10.1158/0008-5472.CAN-18-1253; Liu CH, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001704; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Maldonado MD, 2018, CANCER RES, V78, P3101, DOI 10.1158/0008-5472.CAN-18-0619; Meacham CE, 2009, NAT GENET, V41, P1133, DOI 10.1038/ng.451; Menotti M, 2019, NAT MED, V25, P130, DOI 10.1038/s41591-018-0262-9; Morris HT, 2018, J PATHOL, V245, P337, DOI 10.1002/path.5086; Murga-Zamalloa CA, 2017, ONCOGENE, V36, P2085, DOI 10.1038/onc.2016.366; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Ramkumar C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3598; Rey-Suarez I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14335-8; Sadhukhan S, 2014, J IMMUNOL, V193, P150, DOI 10.4049/jimmunol.1302923; Sarkar K, 2018, J ALLERGY CLIN IMMUN, V142, P219, DOI 10.1016/j.jaci.2017.11.023; Sarkar K, 2015, BLOOD, V126, P1670, DOI 10.1182/blood-2015-05-646182; Sarkar K, 2014, BLOOD, V124, P3409, DOI 10.1182/blood-2014-07-587642; Schrank BR, 2018, NATURE, V559, P61, DOI 10.1038/s41586-018-0237-5; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; Stengel K, 2011, CELL SIGNAL, V23, P1415, DOI 10.1016/j.cellsig.2011.04.001; Stieglitz E, 2015, NAT GENET, V47, P1326, DOI 10.1038/ng.3400; Taylor MD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000813; Tong L, 2014, BIOSCIENCE REP, V34, P283, DOI 10.1042/BSR20140021; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang Li-Hui, 2018, Cell Physiol Biochem, V51, P2647, DOI 10.1159/000495956; Wang Wenmeng, 2017, Critical Reviews in Oncogenesis, V22, P1, DOI 10.1615/CritRevOncog.2017021314; Wen KK, 2020, J ALLERGY CLIN IMMUN, V145, P324, DOI 10.1016/j.jaci.2019.09.026	44	3	3	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					345	354		10.1038/s41388-020-01533-3	http://dx.doi.org/10.1038/s41388-020-01533-3		NOV 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33139832	Green Accepted			2022-12-28	WOS:000584356100001
J	Yoshida, A; Choi, J; Jin, HR; Li, Y; Bajpai, S; Qie, S; Diehl, JA				Yoshida, Akihiro; Choi, Jaewoo; Jin, Hong Ri; Li, Yan; Bajpai, Sagar; Qie, Shuo; Diehl, J. Alan			Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3	ONCOGENE			English	Article							D1; PHOSPHORYLATION; OVEREXPRESSION; EXPRESSION; TARGETS; PHASE; UBIQUITINATION; ACCUMULATION; PROTEOLYSIS; PROGRESSION	Overexpression of D-type cyclins in human cancer frequently occurs as a result of protein stabilization, emphasizing the importance of identification of the machinery that regulates their ubiqutin-dependent degradation. Cyclin D3 is overexpressed in similar to 50% of Burkitt's lymphoma correlating with a mutation of Thr-283. However, the E3 ligase that regulates phosphorylated cyclin D3 and whether a stabilized, phosphorylation deficient mutant of cyclin D3, has oncogenic activity are undefined. We describe the identification of SCF-Fbxl8 as the E3 ligase for Thr-283 phosphorylated cyclin D3. SCF-Fbxl8 poly-ubiquitylates p-Thr-283 cyclin D3 targeting it to the proteasome. Functional investigation demonstrates that Fbxl8 antagonizes cell cycle progression, hematopoietic cell proliferation, and oncogene-induced transformation through degradation of cyclin D3, which is abolished by expression of cyclin D3T283A, a non-phosphorylatable mutant. Clinically, the expression of cyclin D3 is inversely correlated with the expression of Fbxl8 in lymphomas from human patients implicating Fbxl8 functions as a tumor suppressor. Highlights Fbxl8 suppresses cell division, cell proliferation, and tumorigenesis through phosphorylation-dependent degradation of cyclin D3. Fbxl8 suppresses oncogene-induced transformation of hematopoietic cells and lymphoma cell proliferation through cyclin D3 degradation.	[Yoshida, Akihiro; Bajpai, Sagar; Qie, Shuo; Diehl, J. Alan] Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Biochem, Cleveland, OH 44106 USA; [Yoshida, Akihiro; Jin, Hong Ri; Li, Yan; Bajpai, Sagar] Med Univ South Carolina, Hollings Canc Ctr, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Yoshida, Akihiro; Qie, Shuo; Diehl, J. Alan] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Choi, Jaewoo] Univ Penn, Abramson Canc Ctr, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA	Case Western Reserve University; Medical University of South Carolina; Case Western Reserve University; University of Pennsylvania; Pennsylvania Medicine	Diehl, JA (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Biochem, Cleveland, OH 44106 USA.; Diehl, JA (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.	jad283@case.edu	Qie, Shuo/O-4382-2015	Qie, Shuo/0000-0002-3481-3582; , J. Alan/0000-0001-9854-5049	National Institutes of Health [R01CA093237, P01CA098101]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr. Louis M. Staudt for providing Gumbus cell line. This work was supported by grants from National Institutes of Health: R01CA093237, P01CA098101 (JAD).	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bu YW, 2018, NAT CELL BIOL, V20, P104, DOI 10.1038/s41556-017-0006-y; Casanovas O, 2004, ONCOGENE, V23, P7537, DOI 10.1038/sj.onc.1208040; Chen BB, 2012, ONCOGENE, V31, P2566, DOI 10.1038/onc.2011.432; Chen BB, 2012, BLOOD, V119, P3132, DOI 10.1182/blood-2011-06-358911; de Leeuw R, 2018, CLIN CANCER RES, V24, P4201, DOI 10.1158/1078-0432.CCR-18-0410; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dong H, 2020, CANCER MED-US, V9, P1790, DOI 10.1002/cam4.2829; Gladden AB, 2006, ONCOGENE, V25, P998, DOI 10.1038/sj.onc.1209147; Kim JK, 2009, J CELL PHYSIOL, V220, P292, DOI 10.1002/jcp.21791; Li Y, 2015, CANCER DISCOV, V5, P288, DOI 10.1158/2159-8290.CD-14-0625; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Nagasawa S, 2001, J SURG ONCOL, V78, P208, DOI 10.1002/jso.1152; Ott MM, 1997, BLOOD, V90, P3154, DOI 10.1182/blood.V90.8.3154; Qie S, 2016, J MOL MED, V94, P1313, DOI 10.1007/s00109-016-1475-3; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Sawai CM, 2012, CANCER CELL, V22, P452, DOI 10.1016/j.ccr.2012.09.016; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Vaites LP, 2011, MOL CELL BIOL, V31, P4513, DOI 10.1128/MCB.05733-11; Yoshida A, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax6352; Yoshida A, 2016, CANCER RES, V76, P2990, DOI 10.1158/0008-5472.CAN-15-2931	31	6	6	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					292	306		10.1038/s41388-020-01532-4	http://dx.doi.org/10.1038/s41388-020-01532-4		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33122824	hybrid, Green Published			2022-12-28	WOS:000582827800001
J	Kundu, A; Kowarz, E; Marschalek, R				Kundu, Arpita; Kowarz, Eric; Marschalek, Rolf			The role of reciprocal fusions in MLL-r acute leukemia: studying the chromosomal translocation t(6;11)	ONCOGENE			English	Article							METHYLTRANSFERASE ACTIVITY; ADHERENS JUNCTIONS; CELL-ADHESION; PHD FINGERS; CPG DNA; DOMAIN; BINDING; PROTEIN; MENIN; AF6	Leukemia patients bearing t(6;11)(q27;q23) translocations can be divided in two subgroups: those with breakpoints in the major breakpoint cluster region of MLL (introns 9-10; associated mainly with AML M1/4/5), and others with breakpoints in the minor breakpoint cluster region (introns 21-23), associated with T-ALL. We cloned all four of the resulting fusion genes (MLL-AF6, AF6-MLL, exMLL-AF6, AF6-shMLL) and subsequently transfected them to generate stable cell culture models. Their molecular function was tested by inducing gene expression for 48 h in a Doxycycline-dependent fashion. Here, we present our results upon differential gene expression (DGE) that were obtained by the "Massive Analyses of cDNA Ends" (MACE-Seq) technology, an established 3 '-end based RNA-Seq method. Our results indicate that the PHD/BD domain, present in the AF6-MLL and the exMLL-AF6 fusion protein, is responsible for chromatin activation in a genome-wide fashion. This led to strong deregulation of transcriptional processes involving protein-coding genes, pseudogenes, non-annotated genes, and RNA genes, e.g., LincRNAs and microRNAs, respectively. While cooperation between the MLL-AF6 and AF6-MLL fusion proteins appears to be required for the above-mentioned effects, exMLL-AF6 is able to cause similar effects on its own. The exMLL-AF6/AF6-shMLL co-expressing cell line displayed the induction of a myeloid-specific and a T-cell specific gene signature, which may explain the T-ALL disease phenotype observed in patients with such breakpoints. This again demonstrated that MLL fusion proteins are instructive and allow to study their pathomolecular mechanisms.	[Kundu, Arpita; Kowarz, Eric; Marschalek, Rolf] Goethe Univ Frankfurt, Bioctr, Inst Pharmaceut Biol DCAL, Max von Laue Str 9, D-60438 Frankfurt, Germany	Goethe University Frankfurt	Marschalek, R (corresponding author), Goethe Univ Frankfurt, Bioctr, Inst Pharmaceut Biol DCAL, Max von Laue Str 9, D-60438 Frankfurt, Germany.	Rolf.Marschalek@em.uni-frankfurt.de		Marschalek, Rolf/0000-0003-4870-3445	DFG [Ma 1876/12-1, Ma 1876/13-1]; Wilhelm Sander foundation [2018.070.1, 2018.070.2]; Projekt DEAL	DFG(German Research Foundation (DFG)); Wilhelm Sander foundation; Projekt DEAL	This work is funded by DFG grants Ma 1876/12-1 and Ma 1876/13-1, and grants 2018.070.1 and 2018.070.2 from the Wilhelm Sander foundation. Open Access funding enabled and organized by Projekt DEAL.	Ali M, 2014, BBA-MOL CELL RES, V1843, P366, DOI 10.1016/j.bbamcr.2013.11.016; Allen MD, 2006, EMBO J, V25, P4503, DOI 10.1038/sj.emboj.7601340; Andriano N, 2019, BRIT J HAEMATOL, V185, P563, DOI 10.1111/bjh.15534; Ayton PM, 2004, MOL CELL BIOL, V24, P10470, DOI 10.1128/MCB.24.23.10470-10478.2004; Bach C, 2009, ONCOGENE, V28, P815, DOI 10.1038/onc.2008.443; Balgobind BV, 2009, BLOOD, V114, P2489, DOI 10.1182/blood-2009-04-215152; Begay-Muller V, 2002, FEBS LETT, V521, P36, DOI 10.1016/S0014-5793(02)02814-4; Birke M, 2002, NUCLEIC ACIDS RES, V30, P958, DOI 10.1093/nar/30.4.958; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Cao F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014102; Chang PY, 2010, J MOL BIOL, V400, P137, DOI 10.1016/j.jmb.2010.05.005; Corces MR, 2017, NAT METHODS, V14, P959, DOI [10.1038/NMETH.4396, 10.1038/nmeth.4396]; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Hom RA, 2010, J MOL BIOL, V400, P145, DOI 10.1016/j.jmb.2010.04.067; Kowarz E, 2015, BIOTECHNOL J, V10, P647, DOI 10.1002/biot.201400821; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Liedtke M, 2010, BLOOD, V116, P63, DOI 10.1182/blood-2009-09-243386; Liu H, 2007, GENE DEV, V21, P2385, DOI 10.1101/gad.1574507; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Manara E, 2014, BLOOD, V124, P263, DOI 10.1182/blood-2013-09-525741; Marschalek R, 2020, BBA-GENE REGUL MECH, V1863, DOI 10.1016/j.bbagrm.2020.194547; Marschalek R, 2019, HAEMATOLOGICA, V104, P1098, DOI 10.3324/haematol.2018.213397; Meyer C, 2018, LEUKEMIA, V32, P273, DOI 10.1038/leu.2017.213; Milne TA, 2005, P NATL ACAD SCI USA, V102, P14765, DOI 10.1073/pnas.0503630102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Milne TA, 2010, MOL CELL, V38, P853, DOI 10.1016/j.molcel.2010.05.011; Nakanishi H, 2004, BIOL CHEM, V385, P885, DOI 10.1515/BC.2004.116; Okumura N, 2018, CORNEA, V37, P633, DOI 10.1097/ICO.0000000000001526; Pannekoek WJ, 2009, BBA-BIOMEMBRANES, V1788, P790, DOI 10.1016/j.bbamem.2008.12.010; Park S, 2010, BIOCHEMISTRY-US, V49, P6576, DOI 10.1021/bi1009387; Risner LE, 2013, J BIOL CHEM, V288, P29901, DOI 10.1074/jbc.M113.474858; Rivard N, 2009, FRONT BIOSCI-LANDMRK, V14, P510, DOI 10.2741/3259; Rossler T, 2013, PHARMAZIE, V68, P601, DOI 10.1691/ph.2013.6514; Sharaf-Eldein M, 2018, CLIN LAB, V64, P1429, DOI 10.7754/Clin.Lab.2018.180308; Smith MJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01326-5; Southall SM, 2009, MOL CELL, V33, P181, DOI 10.1016/j.molcel.2008.12.029; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Wachter K, 2014, CANCER LETT, V352, P196, DOI 10.1016/j.canlet.2014.06.016; Wang AY, 2021, CANCER GENOM PROTEOM, V18, P43, DOI 10.21873/cgp.20240; Wang JY, 2012, BLOOD, V119, P1151, DOI 10.1182/blood-2011-06-362079; Wang ZX, 2010, CELL, V141, P1183, DOI 10.1016/j.cell.2010.05.016; Xia ZB, 2003, P NATL ACAD SCI USA, V100, P8342, DOI 10.1073/pnas.1436338100; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; Yokoyama A, 2008, CANCER CELL, V14, P36, DOI 10.1016/j.ccr.2008.05.003	48	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5902	5912		10.1038/s41388-021-01983-3	http://dx.doi.org/10.1038/s41388-021-01983-3		AUG 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34354240	hybrid, Green Published			2022-12-28	WOS:000681543500001
J	Lu, LQ; Zhang, J; Fan, W; Li, Y; Wang, JH; Li, TWH; Torres, LB; Mato, JM; Liu, T; Seki, E; Matsuda, M; Tomasi, ML; Bhowmick, NA; Yang, HP; Lu, SC				Lu, Liqing; Zhang, Jing; Fan, Wei; Li, Yuan; Wang, Jiaohong; Li, Tony W. H.; Torres, Lucia Barbier; Mato, Jose M.; Liu, Ting; Seki, Ekihiro; Matsuda, Michitaka; Tomasi, Maria Lauda; Bhowmick, Neil A.; Yang, Heping; Lu, Shelly C.			Deregulated 14-3-3 zeta and methionine adenosyltransferase alpha 1 interplay promotes liver cancer tumorigenesis in mice and humans	ONCOGENE			English	Article							EXPRESSION; CHOLANGIOCARCINOMA; TRANSCRIPTION; METHYLATION; PROTEINS; BINDING; GROWTH	Methionine adenosyltransferase 1A (MAT1A) is a tumor suppressor downregulated in hepatocellular carcinoma and cholangiocarcinoma, two of the fastest rising cancers worldwide. We compared MAT alpha 1 (protein encoded by MAT1A) interactome in normal versus cancerous livers by mass spectrometry to reveal interactions with 14-3-3 zeta. The MAT alpha 1/14-3-3 zeta complex was critical for the expression of 14-3-3 zeta. Similarly, the knockdown and small molecule inhibitor for 14-3-3 zeta (BV02), and ChIP analysis demonstrated the role of 14-3-3 zeta in suppressing MAT1A expression. Interaction between MAT alpha 1 and 14-3-3 zeta occurs directly and is enhanced by AKT2 phosphorylation of MAT alpha 1. Blocking their interaction enabled nuclear MAT alpha 1 translocation and inhibited tumorigenesis. In contrast, overexpressing 14-3-3 zeta lowered nuclear MAT alpha 1 levels and promoted tumor progression. However, tumor-promoting effects of 14-3-3 zeta were eliminated when liver cancer cells expressed mutant MAT alpha 1 unable to interact with 14-3-3 zeta. Taken together, the reciprocal negative regulation that MAT alpha 1 and 14-3-3 zeta exert is a key mechanism in liver tumorigenesis.	[Lu, Liqing; Zhang, Jing; Fan, Wei; Li, Yuan; Wang, Jiaohong; Li, Tony W. H.; Torres, Lucia Barbier; Seki, Ekihiro; Matsuda, Michitaka; Tomasi, Maria Lauda; Yang, Heping; Lu, Shelly C.] Cedars Sinai Med Ctr, Karsh Div Gastroenterol & Hepatol, Los Angeles, CA 90048 USA; [Lu, Liqing; Liu, Ting] Cent South Univ, Xiangya Hosp, Key Lab Canc Prote, Chinese Minist Hlth, Changsha, Hunan, Peoples R China; [Zhang, Jing] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China; [Li, Yuan; Liu, Ting] Cent South Univ, Xiangya Hosp, Dept Gastroenterol, Changsha, Hunan, Peoples R China; [Mato, Jose M.] Ctr Invest Biomed Red Enfermedades Hepat & Digest, CIC BioGUNE, Technol, Pk Bizkaia, Derio, Bizkaia, Spain; [Bhowmick, Neil A.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Bhowmick, Neil A.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Canc Biol Program, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Central South University; Huazhong University of Science & Technology; Central South University; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; CIC bioGUNE; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Yang, HP; Lu, SC (corresponding author), Cedars Sinai Med Ctr, Karsh Div Gastroenterol & Hepatol, Los Angeles, CA 90048 USA.	Heping.yang@cshs.org; shelly.lu@cshs.org	Torres, Lucia/GZM-2707-2022; Seki, Ekihiro/K-2481-2016; Mato, Jose/A-5187-2011	Seki, Ekihiro/0000-0002-9472-6085; Mato, Jose/0000-0003-1264-3153	NIH [DK123763, P01CA233452]; Natural Science Foundation General Program of Hunan Province [2018JJ2664]; Plan Nacional of I+D [SAF2017-88041-R]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Science Foundation General Program of Hunan Province; Plan Nacional of I+D	This work was supported by NIH grants DK123763 (HP Yang, JM Mato and SC Lu), P01CA233452 (HP Yang, E Seki, ML Tomasi, N Bhowmick, and SC Lu), Natural Science Foundation General Program of Hunan Province NO.2018JJ2664 (T Liu), and Plan Nacional of I+D SAF2017-88041-R (JM Mato). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bergamaschi A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2913; Ewald F, 2013, INT J CANCER, V133, P2065, DOI 10.1002/ijc.28214; Fan W, 2017, HEPATOLOGY, V65, P1249, DOI 10.1002/hep.28964; Frau M, 2013, J HEPATOL, V59, P830, DOI 10.1016/j.jhep.2013.04.031; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Johnson C, 2010, BIOCHEM J, V427, P69, DOI 10.1042/BJ20091834; Li Y, 2020, HEPATOLOGY, V72, P1682, DOI 10.1002/hep.31196; Liu HY, 2011, AM J PATHOL, V178, P652, DOI 10.1016/j.ajpath.2010.10.023; Liu T, 2018, GASTROENTEROLOGY, V155, P557, DOI 10.1053/j.gastro.2018.04.032; Lu SC, 2012, PHYSIOL REV, V92, P1515, DOI 10.1152/physrev.00047.2011; Mroweh M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041794; Murray B, 2019, WORLD J GASTROENTERO, V25, P4300, DOI 10.3748/wjg.v25.i31.4300; Murray B, 2019, HEPATOLOGY, V70, P2018, DOI 10.1002/hep.30762; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Peng H, 2013, HEPATOLOGY, V57, P2299, DOI 10.1002/hep.26258; Perez C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161672; Reytor E, 2009, FASEB J, V23, P3347, DOI 10.1096/fj.09-130187; Ridder DA, 2021, CANCERS, V13, DOI 10.3390/cancers13040744; Root A, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0905-y; Su R, 2016, ONCOTARGET, V7, P77430, DOI 10.18632/oncotarget.12679; Tang YF, 2015, INT J CLIN EXP PATHO, V8, P15845; Tomasi ML, 2012, J CELL PHYSIOL, V227, P1583, DOI 10.1002/jcp.22875; Torres L, 2000, FASEB J, V14, P95, DOI 10.1096/fasebj.14.1.95; Vazquez-Chantada M, 2010, GASTROENTEROLOGY, V138, P1943, DOI 10.1053/j.gastro.2010.01.032; Wang C, 2016, LIVER INT, V36, P1176, DOI 10.1111/liv.13055; Xia QL, 2019, J CELL PHYSIOL, V234, P4851, DOI 10.1002/jcp.27283; Xu XD, 2004, ONCOL REP, V11, P25; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang HP, 2016, HEPATOLOGY, V64, P439, DOI 10.1002/hep.28541; Yang HP, 2013, J CLIN INVEST, V123, P285, DOI 10.1172/JCI63861; Yang HP, 2011, GASTROENTEROLOGY, V141, P378, DOI 10.1053/j.gastro.2011.03.044; Yu M, 2013, BBA-GENE REGUL MECH, V1829, P970, DOI 10.1016/j.bbagrm.2013.04.004	32	3	4	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5866	5879		10.1038/s41388-021-01980-6	http://dx.doi.org/10.1038/s41388-021-01980-6		AUG 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34349244	Green Accepted, Green Published			2022-12-28	WOS:000681143600001
J	Wang, BK; Zhang, W; Zhang, G; Kwong, L; Lu, HZ; Tan, JF; Sadek, N; Xiao, M; Zhang, J; Labrie, M; Randell, S; Beroard, A; Sugarman, E; Rebecca, VW; Wei, Z; Lu, YL; Mills, GB; Field, J; Villanueva, J; Xu, XW; Herlyn, M; Guo, W				Wang, Beike; Zhang, Wei; Zhang, Gao; Kwong, Lawrence; Lu, Hezhe; Tan, Jiufeng; Sadek, Norah; Xiao, Min; Zhang, Jie; Labrie, Marilyne; Randell, Sergio; Beroard, Aurelie; Sugarman, Eric; Rebecca, Vito W.; Wei, Zhi; Lu, Yiling; Mills, Gordon B.; Field, Jeffrey; Villanueva, Jessie; Xu, Xiaowei; Herlyn, Meenhard; Guo, Wei			Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma	ONCOGENE			English	Article							GENE COPY NUMBER; MAMMALIAN TARGET; PHASE-II; ADAPTIVE RESISTANCE; PROTEIN EXPRESSION; CONFER RESISTANCE; RAPAMYCIN MTOR; MAPK PATHWAY; CANCER; AKT	Targeting MAPK pathway using a combination of BRAF and MEK inhibitors is an efficient strategy to treat melanoma harboring BRAF-mutation. The development of acquired resistance is inevitable due to the signaling pathway rewiring. Combining western blotting, immunohistochemistry, and reverse phase protein array (RPPA), we aim to understanding the role of the mTORC1 signaling pathway, a center node of intracellular signaling network, in mediating drug resistance of BRAF-mutant melanoma to the combination of BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) therapy. The mTORC1 signaling pathway is initially suppressed by BRAFi and MEKi combination in melanoma but rebounds overtime after tumors acquire resistance to the combination therapy (CR) as assayed in cultured cells and PDX models. In vitro experiments showed that a subset of CR melanoma cells was sensitive to mTORC1 inhibition. The mTOR inhibitors, rapamycin and NVP-BEZ235, induced cell cycle arrest and apoptosis in CR cell lines. As a proof-of-principle, we demonstrated that rapamycin and NVP-BEZ235 treatment reduced tumor growth in CR xenograft models. Mechanistically, AKT or ERK contributes to the activation of mTORC1 in CR cells, depending on PTEN status of these cells. Our study reveals that mTOR activation is essential for drug resistance of melanoma to MAPK inhibitors, and provides insight into the rewiring of the signaling networks in CR melanoma.	[Wang, Beike; Zhang, Wei; Guo, Wei] Univ Penn, Sch Arts & Sci, Dept Biol, Philadelphia, PA 19104 USA; [Zhang, Gao; Tan, Jiufeng; Sadek, Norah; Xiao, Min; Randell, Sergio; Beroard, Aurelie; Sugarman, Eric; Rebecca, Vito W.; Villanueva, Jessie; Herlyn, Meenhard] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program & Melanoma Res, 3601 Spruce St, Philadelphia, PA 19104 USA; [Kwong, Lawrence] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Lu, Hezhe] Mt Sinai Hosp, Ctr Syst Biol, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Zhang, Jie; Wei, Zhi] New Jersey Inst Technol, Dept Comp Sci, Newark, NJ 07102 USA; [Labrie, Marilyne; Mills, Gordon B.] Oregon Hlth & Sci Univ, Sch Med, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Labrie, Marilyne; Mills, Gordon B.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA; [Lu, Yiling] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Div Canc Med, Houston, TX 77030 USA; [Field, Jeffrey] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA; [Xu, Xiaowei] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Zhang, Gao] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Dept Neurosurg, Durham, NC USA; [Zhang, Gao] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	University of Pennsylvania; The Wistar Institute; University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; New Jersey Institute of Technology; Oregon Health & Science University; Oregon Health & Science University; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Duke University; Duke University	Guo, W (corresponding author), Univ Penn, Sch Arts & Sci, Dept Biol, Philadelphia, PA 19104 USA.; Herlyn, M (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program & Melanoma Res, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.org; guowei@sas.upenn.edu		Labrie, Marilyne/0000-0003-3957-5533	NIH [R35GM141832, P01 CA114046, P50 CA174523, U54 CA224070]; DoD PRCRP [WX1XWH-16-1-0119 [CA150619]]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD PRCRP	This work was supported by NIH R35GM141832, P01 CA114046, P50 CA174523, U54 CA224070, DoD PRCRP WX1XWH-16-1-0119 [CA150619], and a kind gift from the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation to MH and GBM.	Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887; Ali M, 2017, BMB REP, V50, P601, DOI 10.5483/BMBRep.2017.50.12.206; Amaral T, 2017, EUR J CANCER, V73, P93, DOI 10.1016/j.ejca.2016.12.012; Atefi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028973; Ben-Sahra I, 2017, CURR OPIN CELL BIOL, V45, P72, DOI 10.1016/j.ceb.2017.02.012; Boussemart L, 2014, NATURE, V513, P105, DOI 10.1038/nature13572; Carlo MI, 2016, ONCOLOGIST, V21, P787, DOI 10.1634/theoncologist.2016-0145; Corcoran RB, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005753; Corcoran RB, 2011, ONCOTARGET, V2, P336; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deng W, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2011.00950.x; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; El Zaoui I, 2019, INVEST OPHTH VIS SCI, V60, P2764, DOI 10.1167/iovs.18-26508; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Fazio N, 2016, ANTICANCER RES, V36, P713; Gopal YNV, 2014, CANCER RES, V74, P7037, DOI 10.1158/0008-5472.CAN-14-1392; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Greger JG, 2012, MOL CANCER THER, V11, P909, DOI 10.1158/1535-7163.MCT-11-0989; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Hu-Lieskovan S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4691; Iadevaia V, 2012, BIOCHEM SOC T, V40, P168, DOI 10.1042/BST20110682; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; John T, 2009, ONCOGENE, V28, pS14, DOI 10.1038/onc.2009.197; Kappelmann-Fenzl M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1821-9; Kim LC, 2017, ONCOGENE, V36, P2191, DOI 10.1038/onc.2016.363; Krepler C, 2017, CELL REP, V21, P1953, DOI 10.1016/j.celrep.2017.10.021; Krepler C, 2016, CLIN CANCER RES, V22, P1592, DOI 10.1158/1078-0432.CCR-15-1762; Kumar SM, 2005, AM J PATHOL, V166, P823, DOI 10.1016/S0002-9440(10)62303-6; Kwitkowski VE, 2010, ONCOLOGIST, V15, P428, DOI 10.1634/theoncologist.2009-0178; Kwong LN, 2015, J CLIN INVEST, V125, P1459, DOI 10.1172/JCI78954; Laplante M, 2009, CURR BIOL, V19, pR1046, DOI 10.1016/j.cub.2009.09.058; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Libutti S, 2015, NEUROENDOCRINOLOGY, V102, P131; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Long GV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6694; LoRusso PM, 2016, J CLIN ONCOL, V34, P3803, DOI 10.1200/JCO.2014.59.0018; Lu HZ, 2017, NATURE, V550, P133, DOI 10.1038/nature24040; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Menzies AM, 2014, LANCET ONCOL, V15, pE371, DOI 10.1016/S1470-2045(14)70072-5; Meric-Bernstam F, 2009, J CLIN ONCOL, V27, P2278, DOI 10.1200/JCO.2008.20.0766; Moriceau G, 2015, CANCER CELL, V27, P240, DOI 10.1016/j.ccell.2014.11.018; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Penna I, 2016, ONCOTARGET, V7, P3947, DOI 10.18632/oncotarget.6600; Pongas G, 2016, ONCOLOGIST, V21, P1033, DOI 10.1634/theoncologist.2016-0243; Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886; Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Rojo F, 2007, CLIN CANCER RES, V13, P81, DOI 10.1158/1078-0432.CCR-06-1560; Romano G, 2018, CANCER DISCOV, V8, P556, DOI 10.1158/2159-8290.CD-17-0745; Salazar R, 2015, J CLIN ONCOL, V33, P4102; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]; Schieke SM, 2006, J BIOL CHEM, V281, P27643, DOI 10.1074/jbc.M603536200; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Shi HB, 2014, CANCER DISCOV, V4, P69, DOI 10.1158/2159-8290.CD-13-0279; Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008-5472.CAN-11-0140; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Silva JM, 2014, MOL CANCER RES, V12, P447, DOI 10.1158/1541-7786.MCR-13-0224-T; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Subbiah V, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.18.00189; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Sweetlove M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00135; Teh JLF, 2018, CANCER DISCOV, V8, P568, DOI 10.1158/2159-8290.CD-17-0699; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Wang J, 2015, PIGM CELL MELANOMA R, V28, P572, DOI 10.1111/pcmr.12390; Welsh SJ, 2016, EUR J CANCER, V62, P76, DOI 10.1016/j.ejca.2016.04.005; Xie XQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055096; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Zuo Q, 2018, ONCOGENE, V37, P3275, DOI 10.1038/s41388-018-0205-4	87	13	13	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5590	5599		10.1038/s41388-021-01911-5	http://dx.doi.org/10.1038/s41388-021-01911-5		JUL 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34304249	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000677232000002
J	Mei, L; Qv, MY; Bao, HY; He, QQ; Xu, YN; Zhang, Q; Shi, W; Ren, QL; Yan, ZY; Xu, CY; Tang, C; Hussain, M; Zeng, LH; Wu, XM				Mei, Liu; Qv, Meiyu; Bao, Hangyang; He, Qiangqiang; Xu, Yana; Zhang, Qin; Shi, Wei; Ren, Qianlei; Yan, Ziyi; Xu, Chengyun; Tang, Chao; Hussain, Musaddique; Zeng, Ling-Hui; Wu, Ximei			SUMOylation activates large tumour suppressor 1 to maintain the tissue homeostasis during Hippo signalling	ONCOGENE			English	Article							CELL-PROLIFERATION; SUMO E3-LIGASES; KINASE-ACTIVITY; HUMAN HOMOLOG; SIZE-CONTROL; ORGAN SIZE; PATHWAY; YAP; DROSOPHILA; PHOSPHORYLATION	Large tumour suppressor (LATS) 1/2, the core kinases of Hippo signalling, are critical for maintaining tissue homeostasis. Here, we investigate the role of SUMOylation in the regulation of LATS activation. High cell density induces the expression of components of the SUMOylation machinery and enhances the SUMOylation and activation of Lats1 but not Lats2, whereas genetic deletion of the SUMOylation E2 ligase, Ubc9, abolishes this Lats1 activation. Moreover, SUMOylation occurs at the K830 (mouse K829) residue to activate LATS1 and depends on the PIAS1/2 E3 ligase. Whereas the K830 deSUMOylation mutation of LATS1 found in the human metastatic prostate cancers eliminates the kinase activity by attenuating the formation of the phospho-MOB1/phospho-LATS1 complex. As a result, the LATS1(K830R) transgene phenocopies Yap transgene to cause the oversized livers in mice, whereas Lats1(K829R) knock-in phenocopies the deletion of Lats1 in causing the reproductive and endocrine defects and ovary tumours in mice. Thus, SUMOylation-mediated LATS1 activation is an integral component of Hippo signalling in the regulation of tissues homeostasis.	[Mei, Liu; Qv, Meiyu; He, Qiangqiang; Xu, Yana; Zhang, Qin; Shi, Wei; Yan, Ziyi; Xu, Chengyun; Tang, Chao; Hussain, Musaddique; Wu, Ximei] Zhejiang Univ, Dept Pharmacol, Sch Med, Hangzhou, Peoples R China; [Mei, Liu] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27515 USA; [Qv, Meiyu; Xu, Yana; Tang, Chao; Hussain, Musaddique; Wu, Ximei] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed, Sch Med, Hangzhou, Peoples R China; [Bao, Hangyang] Zhejiang Chinese Med Univ, Dept Physiol, Coll Basic Med Sci, Hangzhou, Peoples R China; [Shi, Wei] Univ N Carolina, Dept Biol & Genet, Chapel Hill, NC 27515 USA; [Ren, Qianlei; Zeng, Ling-Hui] Zhejiang Univ City Coll, Dept Pharmacol, Hangzhou, Peoples R China	Zhejiang University; University of North Carolina; University of North Carolina Chapel Hill; Zhejiang University; Zhejiang Chinese Medical University; University of North Carolina; University of North Carolina Chapel Hill; Zhejiang University City College	Wu, XM (corresponding author), Zhejiang Univ, Dept Pharmacol, Sch Med, Hangzhou, Peoples R China.; Wu, XM (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed, Sch Med, Hangzhou, Peoples R China.; Zeng, LH (corresponding author), Zhejiang Univ City Coll, Dept Pharmacol, Hangzhou, Peoples R China.	zenglh@zucc.edu.cn; xiwu@zju.edu.cn		Hussain, Musaddique/0000-0001-8766-6339; Wu, Ximei/0000-0002-3316-893X	973 Programme [2018YFC1004404]; National Natural Science Foundation of China [31871395, 31801207, 81741043, 31571493]	973 Programme(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by 973 Programme (No. 2018YFC1004404) and National Natural Science Foundation of China (Nos. 31871395, 31801207, 81741043, 31571493). We thank Dr. Bin Zhao from Zhejiang University Life Science Institute for constructs and Dr. Congyi Wang from Tongji Hospital of Huazhong University of Science and Technology for Ubc9<SUP>flox/flox</SUP> founder mice.	Aukrust I, 2013, J BIOL CHEM, V288, P5951, DOI 10.1074/jbc.M112.393769; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Eifler K, 2015, TRENDS BIOCHEM SCI, V40, P779, DOI 10.1016/j.tibs.2015.09.006; Eswar Narayanan, 2008, V426, P145, DOI 10.1007/978-1-60327-058-8_8; Flotho A, 2013, ANNU REV BIOCHEM, V82, P357, DOI 10.1146/annurev-biochem-061909-093311; Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; He XY, 2018, DIABETOLOGIA, V61, P881, DOI 10.1007/s00125-017-4523-9; Kim MJ, 2016, EMBO REP, V17, P64, DOI 10.15252/embr.201540809; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Li R, 2013, CANCER RES, V73, P5742, DOI 10.1158/0008-5472.CAN-13-0538; Li W, 2014, CANCER CELL, V26, P48, DOI 10.1016/j.ccr.2014.05.001; Liao X, 2013, INT J MOL MED, V32, P1110, DOI 10.3892/ijmm.2013.1480; Liu NH, 2016, CANCER LETT, V378, P38, DOI 10.1016/j.canlet.2016.05.010; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Mei L, 2017, CANCER LETT, V386, P1, DOI 10.1016/j.canlet.2016.11.009; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Moroishi T, 2015, GENE DEV, V29, P1271, DOI 10.1101/gad.262816.115; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nacerddine K, 2005, DEV CELL, V9, P769, DOI 10.1016/j.devcel.2005.10.007; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Pefani DE, 2014, NAT CELL BIOL, V16, P962, DOI 10.1038/ncb3035; Rabellino A, 2017, CANCER RES, V77, P1542, DOI 10.1158/0008-5472.CAN-16-2958; Ritho J, 2015, CELL REP, V12, P734, DOI 10.1016/j.celrep.2015.07.002; Rubio T, 2013, MOL BIOL CELL, V24, P1801, DOI 10.1091/mbc.E12-11-0806; Schimmel J, 2014, MOL CELL, V53, P1053, DOI 10.1016/j.molcel.2014.02.001; Seeler JS, 2017, NAT REV CANCER, V17, P184, DOI 10.1038/nrc.2016.143; Severgnini M, 2012, CYTOTECHNOLOGY, V64, P187, DOI 10.1007/s10616-011-9407-0; Si Y, 2017, CANCER RES, V77, P4868, DOI 10.1158/0008-5472.CAN-17-0391; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tang FY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13591-7; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Wang XD, 2015, NAT IMMUNOL, V16, P1195, DOI 10.1038/ni.3259; Eswar Narayanan, 2007, Curr Protoc Protein Sci, VChapter 2, DOI [10.1002/cpbi.3, 10.1002/cpps.20, 10.1002/0471250953.bi0506s15, 10.1002/0471140864.ps0209s50]; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Yagil Z, 2010, TRENDS IMMUNOL, V31, P199, DOI 10.1016/j.it.2010.01.005; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; Yang Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8961; Yi J, 2016, HEPATOLOGY, V64, P1757, DOI 10.1002/hep.28768; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zhang H, 2016, NAT GENET, V48, P537, DOI 10.1038/ng.3536; Zhang Q, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118655	45	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5357	5366		10.1038/s41388-021-01937-9	http://dx.doi.org/10.1038/s41388-021-01937-9		JUL 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34267330				2022-12-28	WOS:000673880800001
J	Sun, HY; Zhou, R; Zheng, YN; Wen, ZW; Zhang, DL; Zeng, DQ; Wu, JH; Huang, ZH; Rong, XX; Huang, N; Sun, L; Bin, JP; Liao, YL; Shi, M; Liao, WJ				Sun, Huiying; Zhou, Rui; Zheng, Yannan; Wen, Zhaowei; Zhang, Dingling; Zeng, Dongqiang; Wu, Jianhua; Huang, Zhenhua; Rong, Xiaoxiang; Huang, Na; Sun, Li; Bin, Jianping; Liao, Yulin; Shi, Min; Liao, Wangjun			CRIP1 cooperates with BRCA2 to drive the nuclear enrichment of RAD51 and to facilitate homologous repair upon DNA damage induced by chemotherapy	ONCOGENE			English	Article							ADVANCED GASTRIC-CANCER; GASTROESOPHAGEAL JUNCTION CANCER; DOUBLE-BLIND; COLORECTAL-CANCER; 1ST-LINE THERAPY; INTESTINAL-TYPE; CAPECITABINE; OVEREXPRESSION; EXPRESSION; PROTEIN-1	Homologous recombination (HR) repair is an important determinant of chemosensitivity. However, the mechanisms underlying HR regulation remain largely unknown. Cysteine-rich intestinal protein 1 (CRIP1) is a member of the LIM/double-zinc finger protein family and is overexpressed and associated with prognosis in several tumor types. However, to date, the functional role of CRIP1 in cancer biology is poorly understood. Here we found that CRIP1 downregulation causes HR repair deficiency with concomitant increase in cell sensitivity to cisplatin, epirubicin, and the poly ADP-ribose polymerase (PARP) inhibitor olaparib in gastric cancer cells. Mechanistically, upon DNA damage, CRIP1 is deubiquitinated and upregulated by activated AKT signaling. CRIP1, in turn, promotes nuclear enrichment of RAD51, which is a prerequisite step for HR commencement, by stabilizing BRCA2 to counteract FBXO5-targeted RAD51 degradation and by binding to the core domain of RAD51 (RAD51(184-257)) in coordination with BRCA2, to facilitate nuclear export signal masking interactions between BRCA2 and RAD51. Moreover, through mass spectrometry screening, we found that KPNA4 is at least one of the carriers controlling the nucleo-cytoplasmic distribution of the CRIP1-BRCA2-RAD51 complex in response to chemotherapy. Consistent with these findings, RAD51 inhibitors block the CRIP1-mediated HR process, thereby restoring chemotherapy sensitivity of gastric cancer cells with high CRIP1 expression. Analysis of patient specimens revealed an abnormally high level of CRIP1 expression in GC tissues compared to that in the adjacent normal mucosa and a significant negative association between CRIP1 expression and survival time in patient cohorts with different types of solid tumors undergoing genotoxic treatments. In conclusion, our study suggests an essential function of CRIP1 in promoting HR repair and facilitating gastric cancer cell adaptation to genotoxic therapy.	[Sun, Huiying; Zhou, Rui; Zheng, Yannan; Wen, Zhaowei; Zhang, Dingling; Zeng, Dongqiang; Wu, Jianhua; Huang, Zhenhua; Rong, Xiaoxiang; Huang, Na; Sun, Li; Shi, Min; Liao, Wangjun] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Bin, Jianping; Liao, Yulin] Southern Med Univ, Nanfang Hosp, Dept Cardiol, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China	Zhou, R; Liao, WJ (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China.	dr.zhourui@qq.com; nfyyliaowj@163.com	Zeng, Dongqiang/C-3828-2019	Zeng, Dongqiang/0000-0001-9724-8325	National Natural Science Foundation of China [81772580]; Natural Science Foundation of Guangdong Province of China [2020A1515110686]; President Foundation of Nanfang Hospital, Southern Medical University [2020C020]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province of China(National Natural Science Foundation of Guangdong Province); President Foundation of Nanfang Hospital, Southern Medical University	We thank Lei Li for technical support with liquid chromatography-tandem mass spectrometry. We also thank the members of WL's Laboratory for advice and discussion. This work was supported by the National Natural Science Foundation of China (number 82073303 to WL), National Natural Science Foundation of China (number 81772580 to WL), Natural Science Foundation of Guangdong Province of China (2020A1515110686 to RZ), and President Foundation of Nanfang Hospital, Southern Medical University (2020C020 to RZ).	Balluff B, 2011, AM J PATHOL, V179, P2720, DOI 10.1016/j.ajpath.2011.08.032; Bang YJ, 2017, LANCET ONCOL, V18, P1637, DOI 10.1016/S1470-2045(17)30682-4; Baumhoer D, 2011, ONCOTARGET, V2, P970; Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342; Catenacci DVT, 2017, LANCET ONCOL, V18, P1467, DOI 10.1016/S1470-2045(17)30566-1; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; Ghezraoui H, 2014, MOL CELL, V55, P829, DOI 10.1016/j.molcel.2014.08.002; Han Z, 2008, DIGEST DIS SCI, V53, P1801, DOI 10.1007/s10620-007-9824-2; He GY, 2019, AM J TRANSL RES, V11, P3578; Hecht JR, 2016, J CLIN ONCOL, V34, P443, DOI 10.1200/JCO.2015.62.6598; Huang R, 2015, MOL CELL, V57, P456, DOI 10.1016/j.molcel.2014.12.013; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jeyasekharan AD, 2013, NAT STRUCT MOL BIOL, V20, P1191, DOI 10.1038/nsmb.2666; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; Klein HL, 2008, DNA REPAIR, V7, P686, DOI 10.1016/j.dnarep.2007.12.008; Latonen L, 2010, PHOTODERMATOL PHOTO, V26, P70, DOI 10.1111/j.1600-0781.2010.00488.x; Li HG, 2017, CELL PHYSIOL BIOCHEM, V43, P2037, DOI 10.1159/000484184; Liu W, 2012, J CLIN GASTROENTEROL, V46, pE31, DOI 10.1097/MCG.0b013e31823457ea; Lordick F, 2013, LANCET ONCOL, V14, P490, DOI 10.1016/S1470-2045(13)70102-5; Ludyga N, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-28; Luo KT, 2016, GENE DEV, V30, P2581, DOI 10.1101/gad.289439.116; Ma HR, 2018, INT J CANCER, V142, P2578, DOI 10.1002/ijc.31274; Marzio A, 2019, MOL CELL, V73, P224, DOI 10.1016/j.molcel.2018.11.003; Motegi A, 2019, SEMIN CANCER BIOL, V58, P29, DOI 10.1016/j.semcancer.2019.02.005; Ohtsu A, 2013, J CLIN ONCOL, V31, P3935, DOI 10.1200/JCO.2012.48.3552; Pannunzio NR, 2018, J BIOL CHEM, V293, P10512, DOI 10.1074/jbc.TM117.000374; Ramanathan RK, 2015, CANCER-AM CANCER SOC, V121, P2193, DOI 10.1002/cncr.29363; Schild D, 2010, NUCLEIC ACIDS RES, V38, P1061, DOI 10.1093/nar/gkp1063; Shah MA, 2017, JAMA ONCOL, V3, P620, DOI 10.1001/jamaoncol.2016.5580; Smith MA, 2014, TRENDS CELL BIOL, V24, P575, DOI [10.1016/J.tcb.2014.04.009, 10.1016/j.tcb.2014.04.009]; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Waddell T, 2013, LANCET ONCOL, V14, P481, DOI 10.1016/S1470-2045(13)70096-2; Wang L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147613; Wiegmans AP, 2015, MOL CANCER THER, V14, P2321, DOI 10.1158/1535-7163.MCT-15-0374; Wright WD, 2018, J BIOL CHEM, V293, P10524, DOI 10.1074/jbc.TM118.000372; Xu L, 2017, CANCER LETT, V393, P76, DOI 10.1016/j.canlet.2017.02.014; Xu NH, 2012, J ONCOL, V2012, DOI 10.1155/2012/951724; Yan SY, 2011, WORLD J GASTROENTERO, V17, P1501, DOI 10.3748/wjg.v17.i11.1501; Zhang LZ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1117-z; Zhang W, 2017, J PROTEOMICS, V152, P172, DOI 10.1016/j.jprot.2016.11.002; Zhao WX, 2017, NATURE, V550, P360, DOI 10.1038/nature24060	42	8	8	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5342	5355		10.1038/s41388-021-01932-0	http://dx.doi.org/10.1038/s41388-021-01932-0		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34262130	Green Published, hybrid			2022-12-28	WOS:000673426400001
J	Wang, JY; Xiu, J; Baca, Y; Battaglin, F; Arai, H; Kawanishi, N; Soni, S; Zhang, W; Millstein, J; Salhia, B; Goldberg, RM; Philip, PA; Seeber, A; Hwang, JJ; Shields, AF; Marshall, JL; Astsaturov, I; Lockhart, AC; Gatalica, Z; Korn, WM; Lenz, HJ				Wang, Jingyuan; Xiu, Joanne; Baca, Yasmine; Battaglin, Francesca; Arai, Hiroyuki; Kawanishi, Natsuko; Soni, Shivani; Zhang, Wu; Millstein, Joshua; Salhia, Bodour; Goldberg, Richard M.; Philip, Philip A.; Seeber, Andreas; Hwang, Jimmy J.; Shields, Anthony F.; Marshall, John L.; Astsaturov, Igor; Craig Lockhart, A.; Gatalica, Zoran; Michael Korn, W.; Lenz, Heinz-Josef			Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer	ONCOGENE			English	Article							ADENOCARCINOMA; LANDSCAPE; BURDEN	Frequent mutations of genes in the histone-lysine N-methyltransferase 2 (KMT2) family members were identified in gastric cancers (GCs). Understanding how gene mutations of KMT2 family affect cancer progression and tumor immune microenvironment may provide new treatment strategies. A total of 1245 GCs were analyzed using next-generation sequencing, whole transcriptome sequencing, immunohistochemistry (Caris Life Sciences, Phoenix, AZ). The overall mutation rate of genes in the KMT2 family was 10.6%. Compared to KMT2-wild-type GCs, genes involved in epigenetic modification, receptor tyrosine kinases/MAPK/PI3K, and DNA damage repair (DDR) pathways had higher mutation rates in KMT2-mutant GCs (p < 0.05). Significantly higher rates of high tumor mutational burden, microsatellite instability-high/mismatch-repair deficiency (dMMR), and PD-L1 positivity were observed in KMT2-mutant GCs (p < 0.01), compared to KMT2-wild-type GCs. The association between PD-L1 positivity and KMT2 mutations remained significant in the proficient-MMR and microsatellite stable subgroup. Based on transcriptome data from the TCGA, cell cycle, metabolism, and interferon-alpha/beta response pathways were significantly upregulated in KMT2-mutant GCs than in KMT2-wild-type GCs. Patients with KMT2 mutation treated with immune checkpoint inhibitors had longer median overall survival compared to KMT2-wild-type patients with metastatic solid tumors (35 vs. 16 months, HR = 0.73, 95% CI: 0.62-0.87, p = 0.0003). In conclusion, this is the largest study to investigate the distinct molecular features between KMT2-mutant and KMT2-wild-type GCs to date. Our data indicate that GC patients with KMT2 mutations may benefit from ICIs and drugs targeting DDR, MAPK/PI3K, metabolism, and cell cycle pathways.	[Wang, Jingyuan] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China; [Wang, Jingyuan; Battaglin, Francesca; Arai, Hiroyuki; Kawanishi, Natsuko; Soni, Shivani; Zhang, Wu; Lenz, Heinz-Josef] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90007 USA; [Xiu, Joanne; Baca, Yasmine; Gatalica, Zoran; Michael Korn, W.] Caris Life Sci, Phoenix, AZ USA; [Millstein, Joshua] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA 90007 USA; [Salhia, Bodour] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Translat Genom, Los Angeles, CA 90007 USA; [Goldberg, Richard M.] West Virginia Univ, Canc Inst, Morgantown, WV 26506 USA; [Philip, Philip A.; Shields, Anthony F.] Wayne State Univ, Dept Oncol, Karmanos Canc Inst, Detroit, MI USA; [Seeber, Andreas] Innsbruck Med Univ, Dept Hematol & Oncol, Innsbruck, Austria; [Hwang, Jimmy J.] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA; [Marshall, John L.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC 20007 USA; [Astsaturov, Igor] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Craig Lockhart, A.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA	Peking University; University of Southern California; University of Southern California; University of Southern California; West Virginia University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Medical University of Innsbruck; Carolinas HealthCare System; Georgetown University; Fox Chase Cancer Center; University of Miami	Lenz, HJ (corresponding author), Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90007 USA.	Lenz@usc.edu	Battaglin, Francesca/C-2746-2017	Battaglin, Francesca/0000-0002-9869-0163; Arai, Hiroyuki/0000-0002-1886-7070	National Cancer Institute [P30CA 014089]; Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Victoria and Philip Wilson Research Fund; San Pedro Peninsula Cancer Guild; V Foundation for Cancer Research; Eddie Money Research Fund	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Victoria and Philip Wilson Research Fund; San Pedro Peninsula Cancer Guild; V Foundation for Cancer Research; Eddie Money Research Fund	This work was supported by the National Cancer Institute [P30CA 014089 to H-JL], Gloria Borges WunderGlo Foundation, Dhont Family Foundation, Victoria and Philip Wilson Research Fund, San Pedro Peninsula Cancer Guild, the V Foundation for Cancer Research, Eddie Money Research Fund.	Alam H, 2020, CANCER CELL, V37, P599, DOI 10.1016/j.ccell.2020.03.005; Bang YJ, 2010, LANCET, V376, P1302; Bang YJ, 2017, LANCET ONCOL, V18, P1637, DOI 10.1016/S1470-2045(17)30682-4; BECHT E, 2016, GENOME BIOL, V17; Chen H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01113; Chen KX, 2015, P NATL ACAD SCI USA, V112, P1107, DOI 10.1073/pnas.1422640112; Cho SJ, 2018, CLIN CANCER RES, V24, P6556, DOI 10.1158/1078-0432.CCR-17-1679; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Fagan RJ, 2019, CANCER LETT, V458, P56, DOI 10.1016/j.canlet.2019.05.024; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Ge S, 2017, AM J CANCER RES, V7, P1540; Italiano A, 2018, LANCET ONCOL, V19, P649, DOI 10.1016/S1470-2045(18)30145-1; Je EM, 2013, NEOPLASMA, V60, P188, DOI 10.4149/neo_2013_025; Jia QZ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127901; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kantidakis T, 2016, GENE DEV, V30, P408, DOI 10.1101/gad.275453.115; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Lake J, 2018, PEDIATR BLOOD CANCER, V65; Li XC, 2018, JAMA ONCOL, V4, P1691, DOI 10.1001/jamaoncol.2018.2805; Lv SD, 2019, EPIGENETICS-US, DOI 10.1080/15592294.2019.1634985; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Mardis ER, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0684-0; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Mitani S, 2020, CANCERS, V12, DOI 10.3390/cancers12020400; Okamura R, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000438; Park Y, 2019, CLIN CANCER RES, V25, P5584, DOI 10.1158/1078-0432.CCR-18-4222; Rampias T, 2019, EMBO REP, V20, DOI 10.15252/embr.201846821; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Salem ME, 2018, ONCOLOGIST, V23, P1319, DOI 10.1634/theoncologist.2018-0143; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Tokunaga R, 2019, CLIN CANCER RES, V25, P3096, DOI 10.1158/1078-0432.CCR-18-3388; Wang F, 2019, ANN ONCOL, V30, P1479, DOI 10.1093/annonc/mdz197; Wang GC, 2020, CANCER DISCOV, V10, P1912, DOI 10.1158/2159-8290.CD-19-1448; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang L, 2018, NAT MED, V24, P758, DOI 10.1038/s41591-018-0034-6; Yang L, 2018, ONCOL REP, V40, P479, DOI 10.3892/or.2018.6445; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246	38	7	7	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4894	4905		10.1038/s41388-021-01840-3	http://dx.doi.org/10.1038/s41388-021-01840-3		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34163031				2022-12-28	WOS:000664853000004
J	Truong, TH; Benner, EA; Hagen, KM; Temiz, NA; Kerkvliet, CP; Wang, Y; Cortes-Sanchez, E; Yang, CH; Pengo, T; Guillen, KP; Welm, BE; Telang, S; Lange, CA; Ostrander, JH; Trousdell, MC; Camila				Truong, Thu H.; Benner, Elizabeth A.; Hagen, Kyla M.; Temiz, Nuri A.; Kerkvliet, Carlos Perez; Wang, Ying; Cortes-Sanchez, Emilio; Yang, Chieh-Hsiang; Pengo, Thomas; Guillen, Katrin P.; Welm, Bryan E.; Telang, Sucheta; Lange, Carol A.; Ostrander, Julie H.; Trousdell, Marygrace C.; Camila			PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer	ONCOGENE			English	Article							STEM-CELL MARKERS; COACTIVATOR; RECEPTOR; PELP1; AIB1; INHIBITOR; PATHWAY; PFK-158; GROWTH; SRC-3	Recurrence of metastatic breast cancer stemming from acquired endocrine and chemotherapy resistance remains a health burden for women with luminal (ER+) breast cancer. Disseminated ER+ tumor cells can remain viable but quiescent for years to decades. Contributing factors to metastatic spread include the maintenance and expansion of breast cancer stem cells (CSCs). Breast CSCs frequently exist as a minority population in therapy resistant tumors. In this study, we show that cytoplasmic complexes composed of steroid receptor (SR) co-activators, PELP1 and SRC-3, modulate breast CSC expansion through upregulation of the HIF-activated metabolic target genes PFKFB3 and PFKFB4. Seahorse metabolic assays demonstrated that cytoplasmic PELP1 influences cellular metabolism by increasing both glycolysis and mitochondrial respiration. PELP1 interacts with PFKFB3 and PFKFB4 proteins, and inhibition of PFKFB3 and PFKFB4 kinase activity blocks PELP1-induced tumorspheres and protein-protein interactions with SRC-3. PFKFB4 knockdown inhibited in vivo emergence of circulating tumor cell (CTC) populations in mammary intraductal (MIND) models. Application of PFKFB inhibitors in combination with ER targeted therapies blocked tumorsphere formation in multiple models of advanced breast cancer including tamoxifen (TamR) and paclitaxel (TaxR) resistant models, murine tumor cells, and ER+ patient-derived organoids (PDxO). Together, our data suggest that PELP1, SRC-3, and PFKFBs cooperate to drive ER+ tumor cell populations that include CSCs and CTCs. Identifying non-ER pharmacological targets offers a useful approach to blocking metastatic escape from standard of care ER/estrogen (E2)-targeted strategies to overcome endocrine and chemotherapy resistance.	[Truong, Thu H.; Benner, Elizabeth A.; Hagen, Kyla M.; Temiz, Nuri A.; Kerkvliet, Carlos Perez; Wang, Ying; Lange, Carol A.; Ostrander, Julie H.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA; [Temiz, Nuri A.] Univ Minnesota, Inst Hlth Informat, Minneapolis, MN USA; [Cortes-Sanchez, Emilio; Yang, Chieh-Hsiang; Guillen, Katrin P.; Welm, Bryan E.] Univ Utah, Dept Oncol Sci, Salt Lake City, UT USA; [Cortes-Sanchez, Emilio; Yang, Chieh-Hsiang; Guillen, Katrin P.; Welm, Bryan E.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Trousdell, Marygrace C.; Camila] Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA; [Pengo, Thomas] Univ Minnesota, Informat Inst, Minneapolis, MN USA; [Welm, Bryan E.] Univ Utah, Dept Surg, Salt Lake City, UT USA; [Telang, Sucheta] Univ Louisville, Dept Med, James Graham Brown Canc Ctr, Div Med Oncol & Hematol, Louisville, KY 40292 USA; [Lange, Carol A.; Ostrander, Julie H.] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA; [Lange, Carol A.] Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Cold Spring Harbor Laboratory; University of Minnesota System; University of Minnesota Twin Cities; Utah System of Higher Education; University of Utah; University of Louisville; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Lange, CA; Ostrander, JH (corresponding author), Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.; Lange, CA; Ostrander, JH (corresponding author), Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA.; Lange, CA (corresponding author), Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA.	lange047@umn.edu; hans1354@umn.edu	; Pengo, Thomas/D-5867-2013	Truong, Thu/0000-0003-2394-551X; Wang, Ying/0000-0001-9052-0023; Perez, Ph.D., Carlos/0000-0003-2530-840X; Pengo, Thomas/0000-0002-9632-918X; Trousdell, Marygrace/0000-0002-4824-7040	NIH [R01 CA236948, R01 CA229697, F32 CA210340, T32 HL007741, U54 CA224076, R01 CA248158-01, R01 AG069727-01]; ACS Institutional Research Grant [124166-IRG-58-001-52-IRG5]; University of Minnesota Masonic Cancer Center; Tickle Family Land Grant Endowed Chair in Breast Cancer Research; National Center for Advancing Translational Sciences of the NIH [UL1TR000114]; Department of Defense [W81XWH-14-1-0417]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS Institutional Research Grant; University of Minnesota Masonic Cancer Center; Tickle Family Land Grant Endowed Chair in Breast Cancer Research; National Center for Advancing Translational Sciences of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Department of Defense(United States Department of Defense)	This work was supported by NIH grants R01 CA236948 (JHO, CAL), R01 CA229697 (CAL), F32 CA210340 (THT), T32 HL007741 (THT), U54 CA224076 (BEW), R01 CA248158-01 (CODS), and R01 AG069727-01 (CODS). ACS Institutional Research Grant #124166-IRG-58-001-52-IRG5 (JHO), University of Minnesota Masonic Cancer Center (CAL, JHO), the Tickle Family Land Grant Endowed Chair in Breast Cancer Research (CAL), National Center for Advancing Translational Sciences of the NIH Award UL1TR000114 (JHO), and Department of Defense W81XWH-14-1-0417 (BEW). We thank Bruce Lindgren for biostatistics support, and the Masonic Cancer Center Biostatistics and Bioinformatics, Analytical Biochemistry, University Imaging Core (UIC), and Flow Cytometry cores. We also thank Zohar Sachs and Michael Franklin for critical reading of this manuscript.	Anderson TMR, 2018, MOL CANCER RES, V16, P1761, DOI 10.1158/1541-7786.MCR-18-0410; Anderson TMR, 2016, CANCER RES, V76, P1653, DOI 10.1158/0008-5472.CAN-15-2510; Banerjee Arindam, 2018, Oncotarget, V9, P23274, DOI 10.18632/oncotarget.25299; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Bosco DB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128511; Burandt E, 2013, BREAST CANCER RES TR, V137, P745, DOI 10.1007/s10549-013-2406-4; Chesney J, 2014, ONCOTARGET, V5, P6670, DOI 10.18632/oncotarget.2213; Chu Z., 2021, BREAST CANC PATIENT, DOI [10.1101/2021.02.28.433268, DOI 10.1101/2021]; Dasgupta S, 2018, NATURE, V556, P249, DOI 10.1038/s41586-018-0018-1; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Dwyer AR, 2021, BRIT J CANCER, V124, P217, DOI 10.1038/s41416-020-01094-y; Gao RF, 2018, THERANOSTICS, V8, P6248, DOI 10.7150/thno.28721; Giordano A, 2012, MOL CANCER THER, V11, P2526, DOI 10.1158/1535-7163.MCT-12-0460; Girard BJ, 2017, J BIOL CHEM, V292, P339, DOI 10.1074/jbc.M116.739847; Girard BJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121206; Girard BJ, 2014, MOL CELL ENDOCRINOL, V382, P642, DOI 10.1016/j.mce.2013.07.031; Habashy HO, 2010, BREAST CANCER RES TR, V120, P603, DOI 10.1007/s10549-009-0419-9; Imamura Y, 2015, ONCOL REP, V33, P1837, DOI 10.3892/or.2015.3767; Kilgour E, 2020, CANCER CELL, V37, P485, DOI 10.1016/j.ccell.2020.03.012; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Kumar R, 2009, CLIN CANCER RES, V15, P4123, DOI 10.1158/1078-0432.CCR-08-2347; Liu Y, 2014, BRIT J CANCER, V110, P2063, DOI 10.1038/bjc.2014.105; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mondal S, 2019, INT J CANCER, V144, P178, DOI 10.1002/ijc.31868; Moore N, 2011, J ONCOL, V2011, DOI 10.1155/2011/396076; Nair BC, 2010, CANCER RES, V70, P7166, DOI 10.1158/0008-5472.CAN-10-0628; O'Neill S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39789-9; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Raj GV, 2017, ELIFE, V6, DOI 10.7554/eLife.26857; Ravindranathan P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2912; Redman R, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-CT206; Rohira AD, 2017, CANCER RES, V77, P4293, DOI 10.1158/0008-5472.CAN-16-2982; Sflomos G, 2016, CANCER CELL, V29, P407, DOI 10.1016/j.ccell.2016.02.002; Shi LL, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.44; Song XZ, 2016, P NATL ACAD SCI USA, V113, P4970, DOI 10.1073/pnas.1604274113; Tasdemir N, 2018, CANCER RES, V78, P6209, DOI 10.1158/0008-5472.CAN-18-1416; Telang S, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.PANCA16-B90; Torres-Arzayus MI, 2006, CANCER RES, V66, P11381, DOI 10.1158/0008-5472.CAN-06-2316; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Truong TH, 2018, MOL CANCER RES, V16, P707, DOI 10.1158/1541-7786.MCR-17-0598; Vadlamudi RK, 2005, CANCER RES, V65, P7724, DOI 10.1158/0008-5472.CAN-05-0614; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Vlashi E, 2014, BREAST CANCER RES TR, V146, P525, DOI 10.1007/s10549-014-3051-2; Wang XQ, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-77; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yang YZ, 2018, HORM CANCER-US, V9, P371, DOI 10.1007/s12672-018-0343-8; Yao L, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0882-2	50	6	6	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4384	4397		10.1038/s41388-021-01871-w	http://dx.doi.org/10.1038/s41388-021-01871-w		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34103681	Green Accepted			2022-12-28	WOS:000659032900004
J	Wang, SP; Cao, K; Liao, YT; Zhang, W; Zheng, JH; Li, XC; Huang, MT; Zhong, YH; Hu, X; Chen, D; Wang, YJ				Wang, Shouping; Cao, Kun; Liao, Yuting; Zhang, Wei; Zheng, Jihua; Li, Xiaocui; Huang, Mengting; Zhong, Yonghao; Hu, Xiao; Chen, De; Wang, Yanjie			CDCA2 protects against oxidative stress by promoting BRCA1-NRF2 signaling in hepatocellular carcinoma	ONCOGENE			English	Article							CELL-PROLIFERATION; GENE FAMILY; E3 LIGASE; CANCER; TRANSCRIPTION; NRF2; PATHWAY; EXPRESSION; MUTATIONS; APOPTOSIS	Hepatocellular carcinoma (HCC) patients mostly suffer from poor survival outcomes. It is necessary to identify effective therapeutic targets to improve prognosis for HCC patients. Here, we report a new factor, CDCA2, in promoting HCC development. CDCA2 amplification is an independent risk factor for the recurrence and survival of HCC patients, which is positively correlated with elevated level of alpha-fetoprotein (AFP), high histological grade, large tumor size, advanced TNM stage, and poor prognosis for HCC patients. In HCC cells, CDCA2 promotes cell growth and inhibits apoptosis. Mechanistically, CDCA2's transcription is activated through the binding of E2F2/E2F8 with its promoter. CDCA2 depletion contributes to the suppression of cell proliferation and induction of apoptosis due to reactive oxygen species (ROS)-mediated stress, which can be reversed by antioxidants N-acetyl cysteine (NAC) and glutathione (GSH). Interestingly, we found that CDCA2 triggers the BRCA1-NRF2 cascade, which elevates antioxidant response and attenuates ROS levels. In response to oxidative stress, CDCA2 promotes BRCA1's chromatin relocalization to NRF2, activating NRF2-driven downstream signaling (HO-1, TXNRD1, and NQO1), which then protects HCC cells against oxidative damage. In conclusion, our results reveal that CDCA2 is a prognostic biomarker for HCC patients, and present the E2F2/E2F8-CDCA2-BRCA1-NRF2-ROS signaling axis that have implications for HCC therapeutics.	[Wang, Shouping; Zhang, Wei; Li, Xiaocui; Huang, Mengting; Wang, Yanjie] Guangzhou Med Univ, Dept Anesthesiol, Affiliated Hosp 3, Guangzhou, Peoples R China; [Cao, Kun] Guangdong Med Univ, Inst Aging Res, Guangdong Prov Key Lab Med Mol Diagnost, Dongguan, Peoples R China; [Liao, Yuting; Zheng, Jihua] Gen Hosp Southern Theater Command, Dept Radiotherapy, Guangzhou, Peoples R China; [Zhong, Yonghao] Shenzhen Futian Dist, Dept Surg, Peoples Hosp 2, Shenzhen, Peoples R China; [Hu, Xiao] Second Peoples Hosp Guangdong Prov, Dept Surg, Guangzhou, Peoples R China; [Chen, De; Wang, Yanjie] Guangzhou Med Univ, Biomed Res Ctr, Affiliated Hosp 3, Guangzhou, Peoples R China	Guangzhou Medical University; Guangdong Medical University; Southern Theater Command General Hospital; Guangzhou Medical University	Wang, YJ (corresponding author), Guangzhou Med Univ, Dept Anesthesiol, Affiliated Hosp 3, Guangzhou, Peoples R China.; Chen, D; Wang, YJ (corresponding author), Guangzhou Med Univ, Biomed Res Ctr, Affiliated Hosp 3, Guangzhou, Peoples R China.	drchende@gzhmu.edu.cn; YanjieW@outlook.com			National Natural Science Foundation of China [82002104]; Science and technology project of Guangzhou [201707010379]; Natural Science Youth Project of the Third Affiliated Hospital of Guangzhou Medical University [2019Q07, 2019B06]; Guangdong Basic and Applied Basic Research Foundation [2019A1515110659]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and technology project of Guangzhou; Natural Science Youth Project of the Third Affiliated Hospital of Guangzhou Medical University; Guangdong Basic and Applied Basic Research Foundation	This work was supported by the National Natural Science Foundation of China (No. 81672393), Science and technology project of Guangzhou (No. 201707010379), Natural Science Youth Project of the Third Affiliated Hospital of Guangzhou Medical University (No. 2019Q07, 2019B06), the National Natural Science Foundation of China (82002104, to KC), Guangdong Basic and Applied Basic Research Foundation (2019A1515110659, to KC).	Bae I, 2004, CANCER RES, V64, P7893, DOI 10.1158/0008-5472.CAN-04-1119; Baiz D, 2014, WORLD J GASTROENTERO, V20, P795, DOI 10.3748/wjg.v20.i3.795; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao L, 2007, CARCINOGENESIS, V28, P1401, DOI 10.1093/carcin/bgm060; Chen CX, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.01.99; Chen D, 2020, THERANOSTICS, V10, P8558, DOI 10.7150/thno.44873; Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029; Chen XP, 2010, FREE RADICAL RES, V44, P587, DOI 10.3109/10715761003709802; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; El-Daher MT, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0061-y; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Gorbunova V, 2016, CELL, V165, P1312, DOI 10.1016/j.cell.2016.05.061; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Gorrini C, 2013, J EXP MED, V210, P1529, DOI 10.1084/jem.20121337; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hill SJ, 2014, GENE DEV, V28, P1957, DOI 10.1101/gad.241620.114; Huang GQ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0770-y; Huang JZ, 2017, MOL CELL, V68, P171, DOI 10.1016/j.molcel.2017.09.015; Huang JZ, 2016, J PATHOL, V239, P186, DOI 10.1002/path.4716; Jeong Y, 2017, CANCER DISCOV, V7, P86, DOI 10.1158/2159-8290.CD-16-0127; Kim H, 2005, ONCOGENE, V24, P1252, DOI 10.1038/sj.onc.1208282; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Metallo CM, 2013, MOL CELL, V49, P388, DOI 10.1016/j.molcel.2013.01.018; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Thang PM, 2016, INT J ONCOL, V49, P1385, DOI 10.3892/ijo.2016.3649; Rezazadeh S, 2019, NUCLEIC ACIDS RES, V47, P7914, DOI 10.1093/nar/gkz528; Saha T, 2009, FEBS LETT, V583, P1535, DOI 10.1016/j.febslet.2009.04.005; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Shen ZQ, 2018, ONCOTARGETS THER, V11, P891, DOI 10.2147/OTT.S154754; Shi R, 2017, ONCOTARGET, V8, P19768, DOI 10.18632/oncotarget.15519; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Sugawara S, 2018, J HUM GENET, V63, P657, DOI 10.1038/s10038-018-0437-8; Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Teng YQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06586-3; Uchida F, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-321; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vagnarelli P, 2014, ADV EXP MED BIOL, V773, P401, DOI 10.1007/978-1-4899-8032-8_18; Wang H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6095; Wiel C, 2019, CELL, V178, P330, DOI 10.1016/j.cell.2019.06.005; Wu BW, 2020, J CANCER, V11, P5727, DOI 10.7150/jca.46554; Xanthoulis A, 2013, WORLD J GASTROENTERO, V19, P3189, DOI 10.3748/wjg.v19.i21.3189; Xu IMJ, 2016, P NATL ACAD SCI USA, V113, pE725, DOI 10.1073/pnas.1508779113; Xu YJ, 2018, MOL MED REP, V17, P1507, DOI 10.3892/mmr.2017.8095; Zhan L, 2014, CELL SIGNAL, V26, P1075, DOI 10.1016/j.cellsig.2014.01.008; Zhang YX, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00725; Zou YZ, 2020, AGING-US, V12, P25304, DOI 10.18632/aging.104131	49	5	5	7	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4368	4383		10.1038/s41388-021-01855-w	http://dx.doi.org/10.1038/s41388-021-01855-w		JUN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34103686				2022-12-28	WOS:000659032900007
J	Wang, Y; Yu, HT; Xie, XZ; Deng, T; Ye, LY; Wu, LJ; Ding, XW; Yang, Z; Zhu, QD; Li, JJ; Zheng, YH; Yu, ZP; Chen, G				Wang, Yi; Yu, Haitao; Xie, Xiaozai; Deng, Tuo; Ye, Longyun; Wu, Lijun; Ding, Xiwei; Yang, Zhen; Zhu, Qiandong; Li, Junjian; Zheng, Yihu; Yu, Zhengping; Chen, Gang			Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway	ONCOGENE			English	Article							GROWTH-FACTOR; INTRAHEPATIC CHOLANGIOCARCINOMA; GALLBLADDER CARCINOMA; PROGNOSTIC-FACTORS; PHASE-II; VEGF; GEMCITABINE; EXPRESSION; RECEPTOR; ENDOTHELIUM	Cholangiocarcinoma (CCA) is aggressive and has poor clinical outcomes because of typically delayed diagnosis and a lack of effective non-surgical therapeutic options. Recent studies have shown that plasmalemma vesicle-associated protein (PLVAP) is related to angiogenesis in various tumors, and in vivo PLVAP targeting therapy has been proven effective against hepatocellular carcinoma and pancreatic cancer. The goal of this study was to determine the potential therapeutic utility of targeting PLVAP and thus angiogenesis in CCA and explore the underlying molecular mechanisms. We found that the PLVAP expression levels were significantly higher in CCA tissues when compared with matched adjacent non-tumor tissues obtained from a total of 90 CCA patients; higher expression levels of PLVAP were associated with shorter overall survival of patients. In addition, overexpression of PLVAP was associated with higher micro-vessel density in CCA tissues. In a PLVAP overexpressing CCA patient-derived xenograft model, a novel humanized anti-PLVAP antibody in combination with Gemcitabine plus Cisplatin was significantly inhibited tumor growth. Molecular analysis of CCA cells co-cultured with human umbilical vascular endothelial cells or human hepatic sinusoidal endothelial cells showed that Dickkopf-related protein 1 (DKK1) secreted by CCA cells activated the PI3K/Akt pathway after binding to its receptor, cytoskeleton-associated protein 4 (CKAP4), resulting in the upregulation of PLVAP. Thus, CCA cells increased the angiogenic potency of endothelial cells in a paracrine fashion. Consistently, patients bearing CKAP4 and PLVAP overexpressing tumors had a poor prognosis. In conclusion, the DKK1/CKAP4/PI3K/PLVAP pathway increases angiogenesis in CCA and is therefore a potential anti-angiogenic target.	[Wang, Yi] Wenzhou Med Univ, Sch Publ Hlth & Management, Div Prevent Med, Wenzhou, Peoples R China; [Yu, Haitao; Xie, Xiaozai; Deng, Tuo; Ye, Longyun; Wu, Lijun; Zhu, Qiandong; Li, Junjian; Zheng, Yihu; Yu, Zhengping; Chen, Gang] Wenzhou Med Univ, Key Lab Diag & Treatment Severe Hepatopancreat Di, Affiliated Hosp 1, Wenzhou, Peoples R China; [Yu, Haitao; Xie, Xiaozai; Deng, Tuo; Ye, Longyun; Wu, Lijun; Zhu, Qiandong; Li, Junjian; Zheng, Yihu; Yu, Zhengping; Chen, Gang] Wenzhou Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Wenzhou, Peoples R China; [Ding, Xiwei] Nanjing Univ, Dept Gastroenterol, Affiliated Hosp, Med Sch,Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China; [Yang, Zhen] Shandong Univ, Dept Infect Dis, Shandong Prov Hosp, Jinan, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; Nanjing University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University	Wang, Y (corresponding author), Wenzhou Med Univ, Sch Publ Hlth & Management, Div Prevent Med, Wenzhou, Peoples R China.; Chen, G (corresponding author), Wenzhou Med Univ, Key Lab Diag & Treatment Severe Hepatopancreat Di, Affiliated Hosp 1, Wenzhou, Peoples R China.; Chen, G (corresponding author), Wenzhou Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Wenzhou, Peoples R China.	wang.yi@wmu.edu.cn; chen.gang@wmu.edu.cn	Chen, Gang/ABG-9894-2021	Wang, Yi/0000-0002-0558-7491	National Natural Science Foundation of China [81201953, 81772628, 82072685, 81703310]; Project of National Health Council [WKJ-ZJ-1706]; Project of Zhejiang Province [WKJ-ZJ-1706]; Natural Science Foundation of Zhejiang Province [LY17H160047]; Public Projects of Zhejiang Province [2016C37127, 2018C37114]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of National Health Council; Project of Zhejiang Province; Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); Public Projects of Zhejiang Province	We thank Jungang Zhao, Yifan Tong, Ziyan Chen, and Mingxun Wang for discussing the paper. We also appreciate Sina Zhang for her help with statistical analysis and bioinformatics analysis. We are deeply thankful to Prof Lewis R.Roberts (Mayo Clinic, USA) for valuable advice and discussions on the paper. This work was supported by the National Natural Science Foundation of China (Grant No. 81201953, 81772628, 82072685 to GC and 81703310 to YW); the Joint Projects of National Health Council and Zhejiang Province (No.WKJ-ZJ-1706 to GC); the Natural Science Foundation of Zhejiang Province (No.LY17H160047 to GC); the Public Projects of Zhejiang Province (No.2016C37127 to ZPY and 2018C37114 to YW).	Aparicio S, 2015, NAT REV CANCER, V15, P311, DOI 10.1038/nrc3944; Banales JM, 2016, NAT REV GASTRO HEPAT, V13, P261, DOI 10.1038/nrgastro.2016.51; Bengala C, 2010, BRIT J CANCER, V102, P68, DOI 10.1038/sj.bjc.6605458; Brechon M, 2018, INVEST NEW DRUG, V36, P156, DOI 10.1007/s10637-017-0492-6; Cassidy JW, 2015, CANCER RES, V75, P2963, DOI 10.1158/0008-5472.CAN-15-0727; Cavalloni G, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2136-1; Deharvengt SJ, 2012, J CELL MOL MED, V16, P2690, DOI 10.1111/j.1582-4934.2012.01587.x; El-Khoueiry AB, 2014, BRIT J CANCER, V110, P882, DOI 10.1038/bjc.2013.801; El-Khoueiry AB, 2012, INVEST NEW DRUG, V30, P1646, DOI 10.1007/s10637-011-9719-0; Hall C, 2017, CANCER LETT, V386, P179, DOI 10.1016/j.canlet.2016.11.025; Ioannidou S, 2006, P NATL ACAD SCI USA, V103, P16770, DOI 10.1073/pnas.0603501103; Kennedy L, 2018, HEPATOLOGY, V68, P1042, DOI 10.1002/hep.29898; Kim JH, 2008, CANCER-AM CANCER SOC, V113, P1614, DOI 10.1002/cncr.23787; Kimura H, 2019, CLIN CANCER RES, V25, P1936, DOI 10.1158/1078-0432.CCR-18-2124; Kimura H, 2016, J CLIN INVEST, V126, P2689, DOI 10.1172/JCI84658; Klein D, 2008, HEPATOLOGY, V47, P1018, DOI 10.1002/hep.22084; Marti P, 2015, HEPATOLOGY, V62, P1497, DOI 10.1002/hep.27992; Matsuyama M, 2015, INVEST NEW DRUG, V33, P490, DOI 10.1007/s10637-014-0197-z; Mittal K, 2014, SEMIN ONCOL, V41, P235, DOI 10.1053/j.seminoncol.2014.02.007; Mobius C, 2007, EJSO-EUR J SURG ONC, V33, P1025, DOI 10.1016/j.ejso.2007.02.020; Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054; Paes KT, 2011, INVEST OPHTH VIS SCI, V52, P6452, DOI 10.1167/iovs.10-7146; Peng H, 2016, ONCOTARGET, V7, P17220, DOI 10.18632/oncotarget.7948; Phoenix TN, 2016, CANCER CELL, V29, P508, DOI 10.1016/j.ccell.2016.03.002; Rantakari P, 2016, NATURE, V538, P392, DOI 10.1038/nature19814; Rantakari P, 2015, NAT IMMUNOL, V16, P386, DOI 10.1038/ni.3101; Rizvi S, 2013, GASTROENTEROLOGY, V145, P1215, DOI 10.1053/j.gastro.2013.10.013; Shaib Y, 2004, SEMIN LIVER DIS, V24, P115, DOI 10.1055/s-2004-828889; Shi RY, 2013, CANCER-AM CANCER SOC, V119, P993, DOI 10.1002/cncr.27788; Shi XD, 2016, ONCOTARGET, V7, P70378, DOI 10.18632/oncotarget.11859; Shinno N, 2018, ONCOGENE, V37, P3471, DOI 10.1038/s41388-018-0179-2; Shirabe K, 2004, AM J SURG, V187, P538, DOI 10.1016/j.amjsurg.2003.12.044; Shirota T, 2015, MOL CANCER THER, V14, P1985, DOI 10.1158/1535-7163.MCT-15-0069; Shroff RT, 2017, BRIT J CANCER, V116, P1402, DOI 10.1038/bjc.2017.119; Stan RV, 2012, DEV CELL, V23, P1203, DOI 10.1016/j.devcel.2012.11.003; Strickland LA, 2005, J PATHOL, V206, P466, DOI 10.1002/path.1805; Tichauer KM, 2014, MOL IMAGING BIOL, V16, P372, DOI 10.1007/s11307-013-0692-1; Valle Juan, 2010, N Engl J Med, V362, P1273, DOI 10.1056/NEJMoa0908721; Wang YY, 2009, CLIN CANCER RES, V15, P5784, DOI 10.1158/1078-0432.CCR-09-0814; Wang Y, 2016, CANCER LETT, V380, P163, DOI 10.1016/j.canlet.2016.05.017; Xu YF, 2019, ONCOGENE, V38, P868, DOI 10.1038/s41388-018-0485-8; Yoshikawa D, 2008, BRIT J CANCER, V98, P418, DOI 10.1038/sj.bjc.6604129; Zhang JQ, 2013, AM J PATHOL, V182, P1629, DOI 10.1016/j.ajpath.2013.01.045	44	7	7	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4324	4337		10.1038/s41388-021-01844-z	http://dx.doi.org/10.1038/s41388-021-01844-z		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34079085				2022-12-28	WOS:000657217400001
J	Tian, BQ; Liu, JD; Zhang, NS; Song, YM; Xu, YY; Xie, MY; Wang, BW; Hua, H; Shen, Y; Li, YK; Yang, M				Tian, Baoqing; Liu, Jiandong; Zhang, Nasha; Song, Yemei; Xu, Yeyang; Xie, Mengyu; Wang, Bowen; Hua, Hui; Shen, Yue; Li, Yankang; Yang, Ming			Oncogenic SNORD12B activates the AKT-mTOR-4EBP1 signaling in esophageal squamous cell carcinoma via nucleus partitioning of PP-1 alpha	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; SMALL NUCLEOLAR RNAS; SUSCEPTIBILITY LOCI; NONCODING RNAS; CANCER; RISK; EXPRESSION; PROTEIN; SNORNA; PROLIFERATION	Esophageal cancer is a complex malignancy and the sixth leading cause of cancer death worldwide. In Eastern Asia including China, about 90% of all incident cases have esophageal squamous cell carcinoma (ESCC). Mounting evidence elucidates that aberrant expression of various non-coding RNAs (ncRNAs) contributes to ESCC progression, but it remains unclear how small nucleolar RNAs (snoRNAs) are involved in ESCC development. We systemically screened clinically relevant snoRNAs in ESCC via integrative analyses of The Cancer Genome Atlas (TCGA) data and validation in ESCC tissues. We found that snoRNA SNORD12B was one of the most evidently upregulated snoRNAs in ESCC specimens and its high expression was significantly associated with poor prognosis of patients. SNORD12B profoundly promoted proliferation, migration, invasion, and metastasis of ESCC cells in vitro and in vivo, indicating its oncogene nature. In particular, SNORD12B could interact with PP-1 alpha, one of the three catalytic subunits of serine/threonine protein phosphatase 1, which is a major phosphatase that directly dephosphorylates AKT to suppress its activation. Interestingly, high levels of SNORD12B in ESCC cells could break interactions between 14-3-3 zeta and PP-1 alpha, abolish the retention of PP-1 alpha in the cytosol by 14-3-3 zeta and relocate PP-1 alpha from the cytosol to the nucleus. This led to sequestered PP-1 alpha in the nucleus, enhanced phosphorylation of AKT in the cytosol, activated AKT-mTOR-4EBP1 signaling, and, thus, ESCC progression. These insights would improve our understanding of how snoRNAs contribute to tumorigenesis and highlight the potential of snoRNAs as future therapeutic targets against cancers.	[Tian, Baoqing; Liu, Jiandong; Zhang, Nasha; Song, Yemei; Hua, Hui; Yang, Ming] Shandong First Med Univ, Shandong Canc Hosp & Inst, Canc Res Ctr, Shandong Prov Key Lab Radiat Oncol, Jinan, Shandong, Peoples R China; [Tian, Baoqing; Liu, Jiandong; Zhang, Nasha; Song, Yemei; Hua, Hui; Yang, Ming] Shandong Acad Med Sci, Jinan, Shandong, Peoples R China; [Xu, Yeyang; Xie, Mengyu; Wang, Bowen; Shen, Yue; Li, Yankang] Shandong Univ, Cheeloo Coll Med, Jinan, Shandong, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Shandong University	Yang, M (corresponding author), Shandong First Med Univ, Shandong Canc Hosp & Inst, Canc Res Ctr, Shandong Prov Key Lab Radiat Oncol, Jinan, Shandong, Peoples R China.; Yang, M (corresponding author), Shandong Acad Med Sci, Jinan, Shandong, Peoples R China.	aaryoung@yeah.net	Yang, Ming/G-4705-2012	Yang, Ming/0000-0002-7722-7487	National Natural Science Foundation of China [31671300, 31871306]; Taishan Scholars Program of Shandong Province [tsqn20161060]; Program of Science and Technology for the youth innovation team in universities of Shandong Province [2020KJL001]; Medical and Health Science and Technology Development Plan of Shandong Province [2019WS202]; Youth Foundation Programs of Shandong Academy of Medical Sciences [2018-28]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province; Program of Science and Technology for the youth innovation team in universities of Shandong Province; Medical and Health Science and Technology Development Plan of Shandong Province; Youth Foundation Programs of Shandong Academy of Medical Sciences	This work was supported by the National Natural Science Foundation of China (31671300, 31871306); Taishan Scholars Program of Shandong Province (tsqn20161060); Program of Science and Technology for the youth innovation team in universities of Shandong Province (2020KJL001); Medical and Health Science and Technology Development Plan of Shandong Province (2019WS202); Youth Foundation Programs of Shandong Academy of Medical Sciences (2018-28). The authors would like to thank the many individuals who participated in the study.	Abnet CC, 2018, GASTROENTEROLOGY, V154, P360, DOI 10.1053/j.gastro.2017.08.023; Abnet CC, 2012, HUM MOL GENET, V21, P2132, DOI 10.1093/hmg/dds029; Abnet CC, 2010, NAT GENET, V42, P764, DOI 10.1038/ng.649; Baillat D, 2005, CELL, V123, P265, DOI 10.1016/j.cell.2005.08.019; Brameier M, 2011, NUCLEIC ACIDS RES, V39, P675, DOI 10.1093/nar/gkq776; Bratkovic T, 2014, BBA-GENE REGUL MECH, V1839, P438, DOI 10.1016/j.bbagrm.2014.04.009; Cao PB, 2018, GASTROENTEROLOGY, V155, P542, DOI 10.1053/j.gastro.2018.04.020; Chang J, 2018, NAT GENET, V50, P338, DOI 10.1038/s41588-018-0045-8; Chen YS, 2020, THERANOSTICS, V10, P4983, DOI 10.7150/thno.43046; Cui R, 2009, GASTROENTEROLOGY, V137, P1768, DOI 10.1053/j.gastro.2009.07.070; Dupuis-Sandoval F, 2015, WIRES RNA, V6, P381, DOI 10.1002/wrna.1284; Ender C, 2008, MOL CELL, V32, P519, DOI 10.1016/j.molcel.2008.10.017; Falaleeva M, 2016, P NATL ACAD SCI USA, V113, pE1625, DOI 10.1073/pnas.1519292113; Fan RH, 2018, ONCOL LETT, V15, P6497, DOI 10.3892/ol.2018.8087; Fong LY, 2020, P NATL ACAD SCI USA, V117, P6075, DOI 10.1073/pnas.1920333117; Gong J, 2017, CELL REP, V21, P1968, DOI 10.1016/j.celrep.2017.10.070; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Huang CL, 2017, NUCLEIC ACIDS RES, V45, P8647, DOI 10.1093/nar/gkx651; Islami F, 2004, BRIT J CANCER, V90, P1402, DOI 10.1038/sj.bjc.6601737; Jerome M, 2014, ARCH BIOCHEM BIOPHYS, V558, P28, DOI 10.1016/j.abb.2014.06.012; Kishore S, 2006, SCIENCE, V311, P230, DOI 10.1126/science.1118265; Li JG, 2014, GUT, V63, P1700, DOI 10.1136/gutjnl-2013-305806; Li YK, 2020, CARCINOGENESIS, V41, P1195, DOI 10.1093/carcin/bgaa069; Liu J., 2020, NAT COMMUN, V11; Luo AP, 2019, ONCOGENE, V38, P4990, DOI 10.1038/s41388-019-0771-0; Matera AG, 2007, NAT REV MOL CELL BIO, V8, P209, DOI 10.1038/nrm2124; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]; Schubert T, 2012, MOL CELL, V48, P434, DOI 10.1016/j.molcel.2012.08.021; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Siprashvili Z, 2016, NAT GENET, V48, P53, DOI 10.1038/ng.3452; SUDO K, 2019, JAMA NETW OPEN, V2; Tan DSW, 2017, NAT MED, V23, P1167, DOI 10.1038/nm.4401; Tanaka F, 2010, GUT, V59, P1457, DOI 10.1136/gut.2009.205724; Tran GD, 2005, INT J CANCER, V113, P456, DOI 10.1002/ijc.20616; Wang LD, 2010, NAT GENET, V42, P759, DOI 10.1038/ng.648; Wang XY, 2015, J BIOL CHEM, V290, P3925, DOI 10.1074/jbc.M114.596866; Wu C, 2014, NAT GENET, V46, P1001, DOI 10.1038/ng.3064; Wu C, 2012, NAT GENET, V44, P1090, DOI 10.1038/ng.2411; Wu C, 2011, NAT GENET, V43, P679, DOI 10.1038/ng.849; Wu M, 2009, INT J CANCER, V124, P1907, DOI 10.1002/ijc.24142; Xiao L, 2010, CELL DEATH DIFFER, V17, P1448, DOI 10.1038/cdd.2010.16; Xu L, 2016, CLIN CANCER RES, V22, P773, DOI 10.1158/1078-0432.CCR-15-0737; You BH, 2019, P NATL ACAD SCI USA, V116, P24620, DOI 10.1073/pnas.1912126116; Yuan JP, 2020, ONCOGENE, V39, P6664, DOI 10.1038/s41388-020-01460-3; Zhang HF, 2019, CLIN CANCER RES, V25, P1989, DOI 10.1158/1078-0432.CCR-18-0773; Zhang NS, 2020, THERANOSTICS, V10, P9378, DOI 10.7150/thno.48247; Zhang NS, 2020, BIOCHEM PHARMACOL, V172, DOI 10.1016/j.bcp.2019.113772; Zhang XD, 2018, NUCLEIC ACIDS RES, V46, P1793, DOI 10.1093/nar/gkx1259; Zhou FB, 2017, NAT CELL BIOL, V19, P844, DOI 10.1038/ncb3563	50	11	12	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3734	3747		10.1038/s41388-021-01809-2	http://dx.doi.org/10.1038/s41388-021-01809-2		MAY 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33941854				2022-12-28	WOS:000646512300001
J	Kakumani, PK; Guitart, T; Houle, F; Harvey, LM; Goyer, B; Germain, L; Gebauer, F; Simard, MJ				Kakumani, Pavan Kumar; Guitart, Tanit; Houle, Francois; Harvey, Louis-Mathieu; Goyer, Benjamin; Germain, Lucie; Gebauer, Fatima; Simard, Martin J.			CSDE1 attenuates microRNA-mediated silencing of PMEPA1 in melanoma	ONCOGENE			English	Article							RNA-BINDING PROTEINS; MESSENGER-RNA; TRANSLATIONAL REPRESSION; DROSOPHILA UNR; HUR; UPSTREAM; PHOSPHORYLATION; PROGRESSION; DOMAINS; TARGETS	MicroRNAs and RNA-binding proteins (RBPs) primarily target the 3 ' UTR of mRNAs to control their translation and stability. However, their co-regulatory effects on specific mRNAs in physiology and disease are yet to be fully explored. CSDE1 is an RBP that promotes metastasis in melanoma and mechanisms underlying its oncogenic activities need to be completely defined. Here we report that CSDE1 interacts with specific miRNA-induced silencing complexes (miRISC) in melanoma. We find an association of CSDE1 with AGO2, the essential component of miRISC, which is facilitated by target mRNAs and depends on the first cold shock domain of CSDE1. Both CSDE1 and AGO2 bind to 3 ' UTR of PMEPA1. CSDE1 counters AGO2 binding, leading to an increase of PMEPA1 expression. We also identify a miRNA, miR-129-5p, that represses PMEPA1 expression in melanoma. Collectively, our results show that PMEPA1 promotes tumorigenic traits and that CSDE1 along with miR-129-5p/AGO2 miRISC act antagonistically to fine-tune PMEPA1 expression toward the progression of melanoma.	[Kakumani, Pavan Kumar; Houle, Francois; Harvey, Louis-Mathieu; Simard, Martin J.] Univ Laval, Res Ctr, Oncol Div, CHU Quebec, Quebec City, PQ, Canada; [Kakumani, Pavan Kumar; Houle, Francois; Harvey, Louis-Mathieu; Simard, Martin J.] Univ Laval, Canc Res Ctr, Quebec City, PQ, Canada; [Guitart, Tanit; Gebauer, Fatima] Barcelona Inst Sci & Technol, Gene Regulat Stem Cells & Canc Programme, Ctr Genom Regulat CRG, Barcelona, Spain; [Goyer, Benjamin; Germain, Lucie] Univ Laval, Ctr Rech, Axe Med Regeneratrice, CHU Quebec Univ Laval, Quebec City, PQ, Canada; [Goyer, Benjamin; Germain, Lucie] Univ Laval, LOEX, Ctr Rech Organogenese Expt, Quebec City, PQ, Canada; [Goyer, Benjamin; Germain, Lucie] Univ Laval, Fac Med, Dept Chirurg, Quebec City, PQ, Canada; [Gebauer, Fatima] Univ Pompeu Fabra UPF, Barcelona, Spain	Laval University; Laval University; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Laval University; Laval University; Laval University; Pompeu Fabra University	Kakumani, PK; Simard, MJ (corresponding author), Univ Laval, Res Ctr, Oncol Div, CHU Quebec, Quebec City, PQ, Canada.; Kakumani, PK; Simard, MJ (corresponding author), Univ Laval, Canc Res Ctr, Quebec City, PQ, Canada.	pavan-kumar.kakumani@crchudequebec.ulaval.ca; Martin.Simard@crchudequebec.ulaval.ca	Kakumani, Pavan Kumar/AFH-9007-2022; Guitart, Tanit/G-9772-2015; Gebauer, Fatima/E-7725-2015	Kakumani, Pavan Kumar/0000-0002-8755-860X; Guitart, Tanit/0000-0003-2992-9895; Harvey, Louis-Mathieu/0000-0002-4745-7820; Gebauer, Fatima/0000-0001-7563-0013; Germain, Lucie/0000-0001-8883-6491; Simard, Martin/0000-0002-3189-9309	Canadian Institutes of Health Research (CIHR); Fonds de Recherche du Quebec-Sante (FRQ-S); CIHR [FDN-143213]; Spanish Ministry of Science and Innovation (MICINN) [PGC2018-099697-B-I00]; "la Caixa" Foundation [100010434, LCF/PR/HR17/52150016]; Catalan Government [2017SGR534]; Center of Excellence Severo Ochoa	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Fonds de Recherche du Quebec-Sante (FRQ-S); CIHR(Canadian Institutes of Health Research (CIHR)); Spanish Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); "la Caixa" Foundation(La Caixa Foundation); Catalan Government; Center of Excellence Severo Ochoa	The Canadian Institutes of Health Research (CIHR) supported this work. PKK and LMH are recipients of scholarship from Fonds de Recherche du Quebec-Sante (FRQ-S). MJS is a Research Chair from FRQ-S. LG was supported by the CIHR (FDN-143213). FG was supported by grants from the Spanish Ministry of Science and Innovation (MICINN, PGC2018-099697-B-I00), "la Caixa" Foundation (ID:100010434) under the agreement LCF/PR/HR17/52150016, the Catalan Government (2017SGR534) and the Center of Excellence Severo Ochoa.	Abaza I, 2006, GENE DEV, V20, P380, DOI 10.1101/gad.371906; Abaza I, 2008, RNA, V14, P482, DOI 10.1261/rna.802908; Abdelaziz M, 2019, J BIOCHEM, V165, P411, DOI 10.1093/jb/mvz022; Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Ahuja D, 2016, RNA BIOL, V13, P1152, DOI 10.1080/15476286.2016.1229734; Aksenenko M, 2019, BMC DERMATOL, V19, DOI 10.1186/s12895-018-0081-1; Amalia R, 2019, CELL SIGNAL, V59, P24, DOI 10.1016/j.cellsig.2019.03.016; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Bohn JA, 2018, NUCLEIC ACIDS RES, V46, P362, DOI 10.1093/nar/gkx1120; Bottini S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01126-x; Chang TC, 2004, GENE DEV, V18, P2010, DOI 10.1101/gad.1219104; Connerty P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010031; Cornelis S, 2005, NUCLEIC ACIDS RES, V33, P3095, DOI 10.1093/nar/gki611; Dinur M, 2006, MOL ENDOCRINOL, V20, P1652, DOI 10.1210/me.2005-0333; Dormoy-Raclet Virginie, 2005, RNA Biol, V2, pe27; Duncan K, 2006, GENE DEV, V20, P368, DOI 10.1101/gad.371406; Elatmani H, 2011, STEM CELLS, V29, P1504, DOI 10.1002/stem.712; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Fattore L, 2019, CELL DEATH DIFFER, V26, P1267, DOI 10.1038/s41418-018-0205-5; Feng SJ, 2016, MOL MED REP, V13, P4030, DOI 10.3892/mmr.2016.5033; Fishbein L, 2017, CANCER CELL, V31, P181, DOI 10.1016/j.ccell.2017.01.001; Fournier PGJ, 2015, CANCER CELL, V27, P809, DOI 10.1016/j.ccell.2015.04.009; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Friend K, 2012, NAT STRUCT MOL BIOL, V19, P176, DOI 10.1038/nsmb.2214; Gebert LFR, 2019, NAT REV MOL CELL BIO, V20, P21, DOI 10.1038/s41580-018-0045-7; Golden RJ, 2017, NATURE, V542, P197, DOI 10.1038/nature21025; Goyer B, 2019, J TISSUE ENG REGEN M, V13, P2300, DOI 10.1002/term.2959; Hollmann NM, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107930; Huberdeau MQ, 2019, FEBS J, V286, P642, DOI 10.1111/febs.14666; Huberdeau MQ, 2017, EMBO J, V36, P2088, DOI 10.15252/embj.201696386; Iadevaia V, 2015, BIOMOLECULES, V5, P2207, DOI 10.3390/biom5042207; Jannot G, 2011, METHODS MOL BIOL, V725, P233, DOI 10.1007/978-1-61779-046-1_16; Ji JX, 2020, ONCOGENE, V39, P1125, DOI 10.1038/s41388-019-1050-9; Jiang Peng, 2012, Microrna, V1, P70; Jonas S, 2015, NAT REV GENET, V16, P421, DOI 10.1038/nrg3965; Kakumani PK, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.201900632; Kamenska A, 2016, NUCLEIC ACIDS RES, V44, P6318, DOI 10.1093/nar/gkw565; Karginov FV, 2013, GENE DEV, V27, P1624, DOI 10.1101/gad.215939.113; Kaye JA, 2009, NEURON, V61, P57, DOI 10.1016/j.neuron.2008.11.012; Kedde M, 2007, CELL, V131, P1273, DOI 10.1016/j.cell.2007.11.034; Kedde M, 2010, NAT CELL BIOL, V12, P1014, DOI 10.1038/ncb2105; Keene JD, 2007, NAT REV GENET, V8, P533, DOI 10.1038/nrg2111; Kelly TJ, 2019, RNA, V25, P1291, DOI 10.1261/rna.071621.119; Kim HH, 2009, GENE DEV, V23, P1743, DOI 10.1101/gad.1812509; Kishore S, 2010, BRIEF FUNCT GENOMICS, V9, P391, DOI 10.1093/bfgp/elq028; Kundu P, 2012, NUCLEIC ACIDS RES, V40, P5088, DOI 10.1093/nar/gks148; Lee HJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01744-5; Li G, 2019, ONCOL LETT, V17, P5777, DOI 10.3892/ol.2019.10241; Li YH, 2018, J MOL BIOL, V430, P285, DOI 10.1016/j.jmb.2017.12.006; Li ZZ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1923-4; Liu Q, 2018, BIOMED PHARMACOTHER, V105, P420, DOI 10.1016/j.biopha.2018.05.105; Ma LJ, 2019, J CELL BIOCHEM, V120, P7527, DOI 10.1002/jcb.28027; Martinez-Useros J, 2019, J CLIN MED, V8, DOI 10.3390/jcm8040560; Mihailovich M, 2010, BIOESSAYS, V32, P109, DOI 10.1002/bies.200900122; Militti C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5762; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Nam JW, 2014, MOL CELL, V53, P1031, DOI 10.1016/j.molcel.2014.02.013; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Pereira B, 2017, TRENDS CANCER, V3, P506, DOI 10.1016/j.trecan.2017.05.003; Qian H, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.28; Qiu ZS, 2019, ACTA BIOCH BIOPH SIN, V51, P997, DOI 10.1093/abbs/gmz096; Schadendorf D, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.3; Schepens B, 2007, EMBO J, V26, P158, DOI 10.1038/sj.emboj.7601468; Sternburg EL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33596-4; Nguyen TTV, 2014, CANCER SCI, V105, P334, DOI 10.1111/cas.12355; van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107; Wan P, 2020, J CELL PHYSIOL, V235, P5689, DOI 10.1002/jcp.29501; Wang SC, 2019, PATHOL RES PRACT, V215, P676, DOI 10.1016/j.prp.2018.12.024; Wurth L, 2016, CANCER CELL, V30, P694, DOI 10.1016/j.ccell.2016.10.004; Xu Y, 2012, BRIT J CANCER, V106, P553, DOI 10.1038/bjc.2011.568; Xue YC, 2013, CELL, V152, P82, DOI 10.1016/j.cell.2012.11.045; Young LE, 2012, MOL CANCER RES, V10, P167, DOI 10.1158/1541-7786.MCR-11-0337	72	5	5	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3231	3244		10.1038/s41388-021-01767-9	http://dx.doi.org/10.1038/s41388-021-01767-9		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33833398				2022-12-28	WOS:000638023600002
J	Bernardino-Sgherri, J; Siberchicot, C; Auvre, F; Busso, D; Brocas, C; El Masri, G; Lioutsko, A; Ferri, F; Radicella, JP; Romeo, PH; Bravard, A				Bernardino-Sgherri, Jacqueline; Siberchicot, Capucine; Auvre, Frederic; Busso, Didier; Brocas, Clementine; El Masri, Ghazi; Lioutsko, Anna; Ferri, Federica; Radicella, J. Pablo; Romeo, Paul-Henri; Bravard, Anne			Tumor resistance to radiotherapy is triggered by an ATM/TAK1-dependent-increased expression of the cellular prion protein	ONCOGENE			English	Article							BREAST-CANCER CELLS; GENE-EXPRESSION; STEM-CELLS; TAK1; TRANSCRIPTION; INHIBITION; ACTIVATION; SURVIVAL; ATM	In solid cancers, high expression of the cellular prion protein (PrPC) is associated with stemness, invasiveness, and resistance to chemotherapy, but the role of PrPC in tumor response to radiotherapy is unknown. Here, we show that, in neuroblastoma, breast, and colorectal cancer cell lines, PrPC expression is increased after ionizing radiation (IR) and that PrPC deficiency increases radiation sensitivity and decreases radiation-induced radioresistance in tumor cells. In neuroblastoma cells, IR activates ATM that triggers TAK1-dependent phosphorylation of JNK and subsequent activation of the AP-1 transcription factor that ultimately increases PRNP promoter transcriptional activity through an AP-1 binding site in the PRNP promoter. Importantly, we show that this ATM-TAK1-PrPC pathway mediated radioresistance is activated in all tumor cell lines studied and that pharmacological inhibition of TAK1 activity recapitulates the effects of PrPC deficiency. Altogether, these results unveil how tumor cells activate PRNP to acquire resistance to radiotherapy and might have implications for therapeutic targeting of solid tumors radioresistance.	[Bernardino-Sgherri, Jacqueline; Ferri, Federica; Romeo, Paul-Henri; Bravard, Anne] Univ Paris Saclay, Univ Paris, Genet Stabil Stem Cells & Radiat, LRTS,UMRE008,Inserm,U1274,CEA, Fontenay Aux Roses, France; [Bernardino-Sgherri, Jacqueline; Siberchicot, Capucine; Auvre, Frederic; El Masri, Ghazi; Lioutsko, Anna; Radicella, J. Pablo; Bravard, Anne] Univ Paris Saclay, Univ Paris, Genet Stabil Stem Cells & Radiat, LRIG,UMRE008,CEA, Fontenay Aux Roses, France; [Busso, Didier; Brocas, Clementine] Univ Paris Saclay, Univ Paris, Genet Stabil Stem Cells & Radiat, CIGEX,UMRE008,Inserm,U1274,CEA, Fontenay Aux Roses, France; [Auvre, Frederic] CEA, LGRK, DRF, IBFJ,iRCM,SCSR, Evry, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Bernardino-Sgherri, J; Bravard, A (corresponding author), Univ Paris Saclay, Univ Paris, Genet Stabil Stem Cells & Radiat, LRTS,UMRE008,Inserm,U1274,CEA, Fontenay Aux Roses, France.; Bernardino-Sgherri, J; Bravard, A (corresponding author), Univ Paris Saclay, Univ Paris, Genet Stabil Stem Cells & Radiat, LRIG,UMRE008,CEA, Fontenay Aux Roses, France.	Jacqueline.bernardino@cea.fr; anne.bravard@cea.fr	Radicella, J. Pablo/AAU-3178-2020	Radicella, J. Pablo/0000-0002-8807-7226; BRAVARD, Anne/0000-0002-0314-9092; Bernardino-Sgherri, Jacqueline/0000-0003-3980-4041	DIM-Stem-Pole; INSERM; Foundation ARC; CEA; French National Electricity Company (EDF); Transverse Division No 4 [4]; Radiobiology Program (PRIONRAD) of the French Alternative Energies and Atomic Energy Commission (CEA)	DIM-Stem-Pole; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Foundation ARC; CEA(French Atomic Energy Commission); French National Electricity Company (EDF); Transverse Division No 4; Radiobiology Program (PRIONRAD) of the French Alternative Energies and Atomic Energy Commission (CEA)	The authors thank Guillaume Pitton for lentiviruses productions; Nathalie Dechamps for flow cytometric cell sorting, at the IRCM Flow Cytometry Shared Resource (established by equipment grants from DIM-Stem-Pole, INSERM, Foundation ARC, and CEA); Marilene Lopes (Lab of Neurobiology and Stem Cells, Sao-Paulo, Brazil) for kindly providing the plasmid used for generating SH-SY5Y CRISPR KO cells; Sophie Mouillet-Richard, Francois Leteurtre and Jerome Lebeau for providing colorectal, and breast cancer cell lines.This work was supported by the French National Electricity Company (EDF), the Transverse Division No 4 (Segment no 4 Radiobiology headed by Christophe Carles) and the Radiobiology Program (PRIONRAD) of the French Alternative Energies and Atomic Energy Commission (CEA).	Atkinson CJ, 2019, MOL ONCOL, V13, P725, DOI 10.1002/1878-0261.12411; Bellingham SA, 2009, J BIOL CHEM, V284, P1291, DOI 10.1074/jbc.M804755200; Berger ND, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0283; Bravard A, 2015, NUCLEIC ACIDS RES, V43, P904, DOI 10.1093/nar/gku1342; Buch K, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-1; Cheng YY, 2014, MOL CARCINOGEN, V53, P686, DOI 10.1002/mc.22021; Dery MA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3398; Du L, 2013, CANCER RES, V73, P2682, DOI 10.1158/0008-5472.CAN-12-3759; Fan YH, 2013, APOPTOSIS, V18, P1224, DOI 10.1007/s10495-013-0864-0; Gil M, 2016, BIOCHEM BIOPH RES CO, V470, P213, DOI 10.1016/j.bbrc.2016.01.038; Giorgia M, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20222; Guan S, 2017, ONCOTARGET, V8, P33666, DOI 10.18632/oncotarget.16895; Han MW, 2014, ANTICANCER RES, V34, P1449; Huang YWA, 2017, CELL, V168, P427, DOI 10.1016/j.cell.2016.12.044; Iglesia RP, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0518-1; Kefayat A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55605-w; Le Corre D, 2019, EBIOMEDICINE, V46, P94, DOI 10.1016/j.ebiom.2019.07.036; Lee JH, 2018, BIOMOL THER, V26, P313, DOI 10.4062/biomolther.2017.033; Liu XJ, 2017, CELL RES, V27, P764, DOI 10.1038/cr.2017.41; Mahal SP, 2001, GENE, V268, P105, DOI 10.1016/S0378-1119(01)00424-3; Martin-Lanneree S, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00055; Melisi D, 2011, JNCI-J NATL CANCER I, V103, P1190, DOI 10.1093/jnci/djr243; Meslin F, 2007, CANCER RES, V67, P10910, DOI 10.1158/0008-5472.CAN-07-0512; Piro G, 2015, BRIT J CANCER, V113, P878, DOI 10.1038/bjc.2015.283; Qin KF, 2009, J BIOL CHEM, V284, P4582, DOI 10.1074/jbc.M808410200; Ryskalin L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205107; Salvesen O, 2019, NEUROCHEM INT, V130, DOI 10.1016/j.neuint.2018.11.010; Santoro R, 2017, DRUG RESIST UPDATE, V33-35, P36, DOI 10.1016/j.drup.2017.10.004; Schulz A, 2019, CANCERS, V11, DOI 10.3390/cancers11060862; Siberchicot C, 2020, HAEMATOLOGICA, V105, P1216, DOI 10.3324/haematol.2018.205716; Span PN, 2019, CANCERS, V11, DOI 10.3390/cancers11101555; Wang ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep32737; Watt NT, 2007, FREE RADICAL BIO MED, V43, P959, DOI 10.1016/j.freeradbiomed.2007.06.004; Weizman N, 2003, J BIOL CHEM, V278, P6741, DOI 10.1074/jbc.M211168200; Wiegmans AP, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124092; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10; Zhou SN, 2020, CRIT REV ONCOL HEMAT, V150, DOI 10.1016/j.critrevonc.2020.102961; Zhuang DX, 2012, INT J CANCER, V130, P309, DOI 10.1002/ijc.25985	39	9	9	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3460	3469		10.1038/s41388-021-01746-0	http://dx.doi.org/10.1038/s41388-021-01746-0		MAR 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33767435				2022-12-28	WOS:000632820300006
J	Zhang, G; Yang, Y; Hu, H; Liu, KY; Li, BY; Zhu, Y; Wang, ZY; Wu, QF; Mei, YD				Zhang, Guang; Yang, Yang; Hu, Hao; Liu, Kaiyue; Li, Bingyan; Zhu, Yu; Wang, Zhongyu; Wu, Qingfa; Mei, Yide			Energy stress-induced linc01564 activates the serine synthesis pathway and facilitates hepatocellular carcinogenesis	ONCOGENE			English	Article								Cancer cells undergo metabolic adaption to sustain their survival and growth under metabolic stress conditions, yet the underlying mechanism remains largely unclear. It is also not known if lncRNAs contribute to this metabolic adaption of cancer cells. Here we show that linc01564 is induced in response to glucose deprivation by the transcription factor ATF4. Linc01564 functions to facilitate hepatocellular carcinoma cell survival under glucose deprivation by activating the serine synthesis pathway. Mechanistically, linc01564 acts as a competing endogenous RNA for miR-107/103a-3p and attenuates the inhibitory effect of miR-107/103a-3p on PHGDH, the rate-limiting enzyme of the serine synthesis pathway, thereafter leading to increased PHGDH expression. Furthermore, linc01564 is able to promote hepatocellular carcinogenesis via PHGDH. Together, these findings suggest that linc01564 is an important player in the regulation of metabolic adaption of cancer cells and also implicate linc01564 as a potential therapeutic target for cancer.	[Zhang, Guang; Yang, Yang; Hu, Hao; Liu, Kaiyue; Li, Bingyan; Zhu, Yu; Wang, Zhongyu; Wu, Qingfa; Mei, Yide] Univ Sci & Technol China, Sch Basic Med Sci, Div Life Sci & Med,CAS Key Lab Innate Immun & Chr, Affiliated Hosp 1,USTC,Hefei Natl Lab Phys Sci Mi, Hefei, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS	Mei, YD (corresponding author), Univ Sci & Technol China, Sch Basic Med Sci, Div Life Sci & Med,CAS Key Lab Innate Immun & Chr, Affiliated Hosp 1,USTC,Hefei Natl Lab Phys Sci Mi, Hefei, Anhui, Peoples R China.	meiyide@ustc.edu.cn			Ministry of Science and Technology of China [2019YFA0802600]; National Natural Science Foundation of China [91957108, 31671487, 31871440]; Collaborative Innovation Programs of Hefei Science Center, CAS [2019HSC-CIP010]; Fundamental Research Funds For Central Universities [WK9110000007, YD2070002007]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Collaborative Innovation Programs of Hefei Science Center, CAS; Fundamental Research Funds For Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by grants from the Ministry of Science and Technology of China (2019YFA0802600), National Natural Science Foundation of China (91957108, 31671487, and 31871440), Collaborative Innovation Programs of Hefei Science Center, CAS (2019HSC-CIP010), and the Fundamental Research Funds For Central Universities (WK9110000007 and YD2070002007).	Adams CM, 2007, J BIOL CHEM, V282, P16744, DOI 10.1074/jbc.M610510200; Ala U, 2013, P NATL ACAD SCI USA, V110, P7154, DOI 10.1073/pnas.1222509110; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Chen HY, 2012, CANCER RES, V72, P3631, DOI 10.1158/0008-5472.CAN-12-0667; Chen PS, 2011, J CLIN INVEST, V121, P3442, DOI 10.1172/JCI45390; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Deng SJ, 2019, CANCER RES, V79, P1398, DOI 10.1158/0008-5472.CAN-18-0419; DeNicola GM, 2015, NAT GENET, V47, P1475, DOI 10.1038/ng.3421; Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Finnerty JR, 2010, J MOL BIOL, V402, P491, DOI 10.1016/j.jmb.2010.07.051; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang YA, 2018, BIOINFORMATICS, V34, P812, DOI 10.1093/bioinformatics/btx672; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Kartha RV, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00008; Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li XX, 2018, MOL CELL, V69, P480, DOI 10.1016/j.molcel.2018.01.001; Lin CR, 2018, TRENDS CELL BIOL, V28, P287, DOI 10.1016/j.tcb.2017.11.008; Liu J, 2020, J CLIN INVEST, V130, P3253, DOI 10.1172/JCI132876; Liu XW, 2016, NAT CELL BIOL, V18, P431, DOI 10.1038/ncb3328; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Ma ML, 2019, HEPATOLOGY, V70, P215, DOI 10.1002/hep.30602; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176; Mattaini KR, 2016, J CELL BIOL, V214, P248, DOI 10.1083/jcb.201604085; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Mullarky E, 2016, P NATL ACAD SCI USA, V113, P1778, DOI 10.1073/pnas.1521548113; Mullarky E, 2011, PIGM CELL MELANOMA R, V24, P1112, DOI 10.1111/j.1755-148X.2011.00919.x; Nilsson LM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002573; Pacold ME, 2016, NAT CHEM BIOL, V12, P452, DOI [10.1038/NCHEMBIO.2070, 10.1038/nchembio.2070]; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Polytarchou C, 2012, P NATL ACAD SCI USA, V109, P14470, DOI 10.1073/pnas.1212811109; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Reid MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07868-6; Samanta D, 2016, CANCER RES, V76, P4430, DOI 10.1158/0008-5472.CAN-16-0530; Silva-Fisher JM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15547-8; SNELL K, 1986, TRENDS BIOCHEM SCI, V11, P241, DOI 10.1016/0968-0004(86)90184-2; Su XY, 2017, ANAL CHEM, V89, P5941, DOI 10.1021/acs.analchem.7b00396; Sullivan MR, 2019, CELL METAB, V29, P1410, DOI 10.1016/j.cmet.2019.02.015; Sun LC, 2015, CELL RES, V25, P429, DOI 10.1038/cr.2015.33; Sun M, 2015, ENDOCR REV, V36, P25, DOI 10.1210/er.2014-1034; Tang JY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11447-8; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Townsend DM, 2003, BIOMED PHARMACOTHER, V57, P145, DOI 10.1016/S0753-3322(03)00043-X; Trajkovski M, 2011, NATURE, V474, P649, DOI 10.1038/nature10112; Turco C, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00427; VAUPEL P, 1989, CANCER RES, V49, P6449; Wang CF, 2019, P NATL ACAD SCI USA, V116, P14620, DOI 10.1073/pnas.1903432116; Wang Y, 2016, BIOCHEM BIOPH RES CO, V480, P455, DOI 10.1016/j.bbrc.2016.10.070; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wei L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12606-7; Wortel IMN, 2017, TRENDS ENDOCRIN MET, V28, P794, DOI 10.1016/j.tem.2017.07.003; Xiao ZD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00902-z; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81; Yao RW, 2019, NAT CELL BIOL, V21, P542, DOI 10.1038/s41556-019-0311-8; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Zhang BX, 2017, CELL REP, V19, P2289, DOI 10.1016/j.celrep.2017.05.067; Zhu JH, 2016, TRANSL ONCOL, V9, P592, DOI 10.1016/j.tranon.2016.08.003	73	8	8	5	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2936	2951		10.1038/s41388-021-01749-x	http://dx.doi.org/10.1038/s41388-021-01749-x		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742121				2022-12-28	WOS:000630655600002
J	Wei, T; Ji, XW; Gao, Y; Zhu, XM; Xiao, GR				Wei, Tian; Ji, Xiaowen; Gao, Yan; Zhu, Xiaomei; Xiao, Guiran			ZnT7 RNAi favors Raf(GOF)scrib(-/-)-induced tumor growth and invasion in Drosophila through JNK signaling pathway	ONCOGENE			English	Article; Early Access								The disruption of zinc homeostasis has been identified in patients suffering from various cancers, but a causative relationship has not yet been established. Drosophila melanogaster has become a powerful model to study cancer biology. Here using a Drosophila model of malignant tumor Raf(GOF)scrib(-/-), we observed that the tumor growth, invasion and migration were enhanced by silencing dZnT7, a zinc transporter localized on the Golgi apparatus. Further study indicated that the zinc deficiency in Golgi of dZnT7 RNAi resulted in ER stress which could activate the c-Jun-N-terminal Kinase (JNK) signaling and this process is mediated by Atg9. Lastly, we demonstrated that the exacerbation of dZnT7 RNAi on tumor was promoted by JNK signaling-dependent cell autonomous and non-autonomous autophagy. These findings suggest that zinc homeostasis in secretory compartments may provide a new therapeutic target for tumor treatment.	[Wei, Tian; Ji, Xiaowen; Gao, Yan; Xiao, Guiran] Hefei Univ Technol, Sch Food & Biol Engn, Hefei 230009, Anhui, Peoples R China; [Zhu, Xiaomei] Anhui Med Univ, Sch Basic Med Sci, Hefei 230032, Anhui, Peoples R China	Hefei University of Technology; Anhui Medical University	Xiao, GR (corresponding author), Hefei Univ Technol, Sch Food & Biol Engn, Hefei 230009, Anhui, Peoples R China.	xiaoguiran@hfut.edu.cn		Wei, Tian/0000-0001-7270-0979; Xiao, Guiran/0000-0002-1238-1838	National Natural Science Foundation of China [31671284]; Fundamental Research Funds for the Central Universities [JZ2020HGPA0115]; Youth Science and Technology Talents Support Program (2020) by Anhui Association for Science and Technology [RCTJ202001]; National Postdoctoral Program for Innovative Talents [BX201600045]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Youth Science and Technology Talents Support Program (2020) by Anhui Association for Science and Technology; National Postdoctoral Program for Innovative Talents	This project was funded by the National Natural Science Foundation of China (31671284), the Fundamental Research Funds for the Central Universities (JZ2020HGPA0115), Youth Science and Technology Talents Support Program (2020) by Anhui Association for Science and Technology (RCTJ202001), and the National Postdoctoral Program for Innovative Talents (BX201600045). The authors appreciate the gifts of fly stocks from Dr. Bing Zhou and Dr. Jose C. PASTOR-PAREJA. The authors are also grateful to the Bloomington Drosophila Stock Center, the Vienna Drosophila RNAi Center and Tsinghua Fly Center for fly stocks.	Antoniou X, 2011, J ALZHEIMERS DIS, V24, P633, DOI 10.3233/JAD-2011-091567; Bafaro E, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.29; Bali A, 2017, INT J DEV BIOL, V61, P551, DOI 10.1387/ijdb.170077bs; Beira JV, 2016, CHROMOSOMA, V125, P573, DOI 10.1007/s00412-016-0595-4; Bin BH, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/9365747; Biteau B, 2011, EXP GERONTOL, V46, P349, DOI 10.1016/j.exger.2010.11.003; Bubici C, 2014, BRIT J PHARMACOL, V171, P24, DOI 10.1111/bph.12432; Calap-Quintana P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071456; Cousins RJ, 2006, J BIOL CHEM, V281, P24085, DOI 10.1074/jbc.R600011200; Dechen KS, 2015, INT J BIOCHEM CELL B, V60, P23, DOI 10.1016/j.biocel.2014.12.017; Dhanasekaran Danny N, 2017, Genes Cancer, V8, P682, DOI 10.18632/genesandcancer.155; Doggett K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-57; Eom SJ, 2001, MOL PHARMACOL, V59, P981, DOI 10.1124/mol.59.5.981; Franklin RB, 2007, ARCH BIOCHEM BIOPHYS, V463, P211, DOI 10.1016/j.abb.2007.02.033; Groth C, 2013, DEVELOPMENT, V140, P3018, DOI 10.1242/dev.088336; Hershfinkel M, 2007, MOL MED, V13, P331, DOI 10.2119/2006-00038.Hershfinkel; Hrabeta J, 2016, J MOL MED, V94, P1199, DOI 10.1007/s00109-016-1454-8; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Kambe T, 2015, PHYSIOL REV, V95, P749, DOI 10.1152/physrev.00035.2014; Katheder NS, 2017, NATURE, V541, P417, DOI 10.1038/nature20815; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Kolenko V, 2013, NAT REV UROL, V10, P219, DOI 10.1038/nrurol.2013.43; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kushnir T, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006860; Lang ML, 2012, PLOS GENET, V8, P623, DOI 10.1371/journal.pgen.1002683; Lee H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021533; Li DD, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020667; Liang D, 2013, CELL SIGNAL, V25, P1126, DOI 10.1016/j.cellsig.2013.02.003; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Liu SN, 2016, SCI REP-UK, V6, DOI 10.1038/srep38003; Ma XJ, 2017, CELL REP, V19, P2657, DOI 10.1016/j.celrep.2017.05.092; Ma XJ, 2012, CELL RES, V22, P425, DOI 10.1038/cr.2011.135; MacDonald RS, 2000, J NUTR, V130, p1500S, DOI 10.1093/jn/130.5.1500S; Manic G, 2014, MOL CELL ONCOL, V1, DOI 10.4161/mco.29911; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Mishra-Gorur K, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039727; Missirlis F, 2007, GENETICS, V177, P89, DOI 10.1534/genetics.107.075150; Newsome TP, 2000, DEVELOPMENT, V127, P851; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pan Z, 2017, FRONT BIOSCI-LANDMRK, V22, P623, DOI 10.2741/4507; Pastor-Pareja JC, 2013, ANNU REV GENET, V47, P51, DOI 10.1146/annurev-genet-110711-155414; Poillet-Perez L, 2019, GENE DEV, V33, P610, DOI 10.1101/gad.325514.119; Prasad AS, 2013, ADV NUTR, V4, P176, DOI 10.3945/an.112.003210; Qin QH, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-101; Richards CD, 2016, ARCH BIOCHEM BIOPHYS, V611, P142, DOI 10.1016/j.abb.2016.07.015; Richardson HE, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4258387; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Schroeder MC, 2013, ONCOGENE, V32, P4471, DOI 10.1038/onc.2012.476; Sheng ZT, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008863; Sonoshita M, 2017, CURR TOP DEV BIOL, V121, P287, DOI 10.1016/bs.ctdb.2016.07.008; Sousa CM, 2016, NATURE, V536, P479, DOI 10.1038/nature19084; Sun YH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1350-6; Takatani-Nakase T, 2018, BIOL PHARM BULL, V41, P1517, DOI 10.1248/bpb.b18-00086; Tang HW, 2013, DEV CELL, V27, P489, DOI 10.1016/j.devcel.2013.10.017; Tepaamorndech S, 2011, CANCER LETT, V308, P33, DOI 10.1016/j.canlet.2011.04.011; Troost T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049007; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Villegas SN, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039032; Wang XX, 2009, FASEB J, V23, P2650, DOI 10.1096/fj.08-126649; Weber U, 2000, DEVELOPMENT, V127, P3619; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Willsey HR, 2016, ELIFE, V5, DOI 10.7554/eLife.11491; Wu H, 2009, MECH DEVELOP, V126, P624, DOI 10.1016/j.mod.2009.06.1082; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; Xiao GR, 2019, CELL REP, V26, P748, DOI 10.1016/j.celrep.2018.12.053; Xiao GR, 2018, FRONT GENET, V8, DOI 10.3389/fgene.2017.00234; Xiao GR, 2016, ARCH BIOCHEM BIOPHYS, V611, P134, DOI 10.1016/j.abb.2016.04.016; Xiao GR, 2014, ELIFE, V3, DOI 10.7554/eLife.03191; Xu R, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012912; Xue J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109180; Yan M, 2008, J NUTR, V138, P667, DOI 10.1093/jn/138.4.667; Yu HJ, 2009, BIOCHEM J, V417, P133, DOI 10.1042/BJ20081421; Zang YR, 2015, ELIFE, V4, DOI 10.7554/eLife.07187; Zeke A, 2016, MICROBIOL MOL BIOL R, V80, P793, DOI 10.1128/MMBR.00043-14; Zhang L, 2007, BRAIN RES BULL, V74, P278, DOI 10.1016/j.brainresbull.2007.06.022; Zhang XL, 2018, KIDNEY BLOOD PRESS R, V43, P500, DOI 10.1159/000488697	77	4	4	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-021-01703-x	http://dx.doi.org/10.1038/s41388-021-01703-x		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QP3MA	33649534				2022-12-28	WOS:000623739900001
J	Morgan, EL; Patterson, MR; Barba-Moreno, D; Scarth, JA; Wilson, A; Macdonald, A				Morgan, Ethan L.; Patterson, Molly R.; Barba-Moreno, Diego; Scarth, James A.; Wilson, Adam; Macdonald, Andrew			The deubiquitinase (DUB) USP13 promotes Mcl-1 stabilisation in cervical cancer	ONCOGENE			English	Article								Protein ubiquitination is a critical regulator of cellular homeostasis. Aberrations in the addition or removal of ubiquitin can result in the development of cancer and key components of the ubiquitination machinery serve as oncogenes or tumour suppressors. An emerging target in the development of cancer therapeutics are the deubiquitinase (DUB) enzymes that remove ubiquitin from protein substrates. Whether this class of enzyme plays a role in cervical cancer has not been fully explored. By interrogating the cervical cancer data from the TCGA consortium, we noted that the DUB USP13 is amplified in similar to 15% of cervical cancer cases. We confirmed that USP13 expression was increased in cervical cancer cell lines, cytology samples from patients with cervical disease and in cervical cancer tissue. Depletion of USP13 inhibited cervical cancer cell proliferation. Mechanistically, USP13 bound to, deubiquitinated and stabilised Mcl-1, a pivotal member of the anti-apoptotic BCL-2 family. Furthermore, reduced Mcl-1 expression partially contributed to the observed proliferative defect in USP13 depleted cells. Importantly, the expression of USP13 and Mcl-1 proteins correlated in cervical cancer tissue. Finally, we demonstrated that depletion of USP13 expression or inhibition of USP13 enzymatic activity increased the sensitivity of cervical cancer cells to the BH3 mimetic inhibitor ABT-263. Together, our data demonstrates that USP13 is a potential oncogene in cervical cancer that functions to stabilise the pro-survival protein Mcl-1, offering a potential therapeutic target for these cancers.	[Morgan, Ethan L.; Patterson, Molly R.; Barba-Moreno, Diego; Scarth, James A.; Wilson, Adam; Macdonald, Andrew] Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Leeds, W Yorkshire, England; [Morgan, Ethan L.; Patterson, Molly R.; Barba-Moreno, Diego; Scarth, James A.; Wilson, Adam; Macdonald, Andrew] Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds, W Yorkshire, England; [Morgan, Ethan L.] Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA	University of Leeds; University of Leeds; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Morgan, EL; Macdonald, A (corresponding author), Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Leeds, W Yorkshire, England.; Morgan, EL; Macdonald, A (corresponding author), Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds, W Yorkshire, England.; Morgan, EL (corresponding author), Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA.	ethan.morgan@nih.gov; a.macdonald@leeds.ac.uk		Scarth, James/0000-0002-0076-6853; Patterson, Molly/0000-0001-6246-7181; Macdonald, Andrew/0000-0002-5978-4693; Morgan, Ethan/0000-0002-6487-5450	Wellcome Institutional Strategic Support Fund (ISSF) [204825/Z/16/Z]; Medical Research Council (MRC) [MR/K012665, MR/S001697/1]; Biotechnology and Biological Sciences Research Council [BB/M011151/1]; Faculty of Biological Sciences, University of Leeds scholarship; MRC [MR/S001697/1, MR/K012665/1] Funding Source: UKRI	Wellcome Institutional Strategic Support Fund (ISSF); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Faculty of Biological Sciences, University of Leeds scholarship(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Wellcome Institutional Strategic Support Fund (ISSF) funding to ELM (204825/Z/16/Z) and Medical Research Council (MRC) funding to AM (MR/K012665 and MR/S001697/1). MRP is funded by Biotechnology and Biological Sciences Research Council studentship (BB/M011151/1). JAS is funded by a Faculty of Biological Sciences, University of Leeds scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akutsu M, 2016, J CELL SCI, V129, P875, DOI 10.1242/jcs.183954; Alwan HAJ, 2007, J BIOL CHEM, V282, P1658, DOI 10.1074/jbc.M604711200; An J, 2008, CANCER CELL, V14, P394, DOI 10.1016/j.ccr.2008.10.007; Ashkenazi A, 2017, NAT REV DRUG DISCOV, V16, P273, DOI 10.1038/nrd.2016.253; Bansal N, 2008, ANTICANCER RES, V28, P1763; Barghout SH, 2019, LEUKEMIA, V33, P37, DOI 10.1038/s41375-018-0167-0; Boyer SN, 1996, CANCER RES, V56, P4620; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Chen C, 2014, IMMUNOLOGY, V142, P307, DOI 10.1111/imm.12255; Chen S, 2012, CANCER RES, V72, P4225, DOI 10.1158/0008-5472.CAN-12-1118; Chung YW, 2002, BIOCHEM BIOPH RES CO, V293, P1248; Clague MJ, 2010, CELL, V143, P682, DOI 10.1016/j.cell.2010.11.012; Crawford RAF, 1998, BRIT J CANCER, V78, P210, DOI 10.1038/bjc.1998.466; Crosbie EJ, 2013, LANCET, V382, P889, DOI 10.1016/S0140-6736(13)60022-7; Das D, 2019, MBIO, V10, DOI 10.1128/mBio.00263-19; De Blasio A, 2018, J CELL PHYSIOL, V233, P8482, DOI 10.1002/jcp.26786; del Rio R, 2008, GENES IMMUN, V9, P115, DOI 10.1038/sj.gene.6364455; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Fang XG, 2017, J EXP MED, V214, P245, DOI 10.1084/jem.20151673; Fields Alan P., 2015, Advances in Biological Regulation, V60, P47, DOI 10.1016/j.jbior.2015.10.009; Ge ZQ, 2018, CELL REP, V23, P213, DOI 10.1016/j.celrep.2018.03.047; Griffiths DA, 2013, J VIROL, V87, P13853, DOI 10.1128/JVI.02159-13; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13525; He CB, 2015, EMBO MOL MED, V7, P1426, DOI 10.15252/emmm.201404976; Hodge CD, 2015, ACS CHEM BIOL, V10, P1718, DOI 10.1021/acschembio.5b00222; Huang XD, 2016, CELL RES, V26, P484, DOI 10.1038/cr.2016.31; Huh K, 2007, J VIROL, V81, P9737, DOI 10.1128/JVI.00881-07; Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216; Karim R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003384; Kiprianova I, 2015, NEOPLASIA, V17, P564, DOI 10.1016/j.neo.2015.07.003; Kiran S, 2018, MOL CELL, V72, P823, DOI 10.1016/j.molcel.2018.09.019; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Lee WS, 2015, INT J ONCOL, V46, P2154, DOI 10.3892/ijo.2015.2890; Lehoux M, 2014, J VIROL, V88, P8545, DOI 10.1128/JVI.00379-14; Leverson JD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4642; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lian Benedict Shi Xiang, 2018, BMC Res Notes, V11, P197, DOI 10.1186/s13104-018-3302-0; Liu J, 2015, BBA-REV CANCER, V1855, P50, DOI 10.1016/j.bbcan.2014.11.005; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Mazumder S, 2012, CANCER RES, V72, P3069, DOI 10.1158/0008-5472.CAN-11-4106; McHugh Angela, 2018, Oncotarget, V9, P20265, DOI 10.18632/oncotarget.24750; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Morgan EL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008624; Morgan EL, 2019, CANCERS, V11, DOI 10.3390/cancers11121934; Morgan EL, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007835; Morgan EL, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006975; Muller M, 2015, FUTURE VIROL, V10, P27, DOI 10.2217/fvl.14.99; Mukherjee N, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2646-2; Bello JOM, 2015, VIRUSES-BASEL, V7, P4734, DOI 10.3390/v7082842; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Park MK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08481-x; Pentland L, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005752; PIM D, 1992, ONCOGENE, V7, P27; Rahman SFA, 2020, BIOCHEM BIOPHYS REP, V22, DOI 10.1016/j.bbrep.2020.100756; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Senichkin VV, 2020, CELL DEATH DIFFER, V27, P405, DOI 10.1038/s41418-019-0486-3; Spangle JM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003237; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; Sun XX, 2015, P NATL ACAD SCI USA, V112, P3734, DOI 10.1073/pnas.1411713112; Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Turnbull AP, 2017, NATURE, V550, P481, DOI 10.1038/nature24451; Vale C, 2008, J CLIN ONCOL, V26, P5802, DOI 10.1200/JCO.2008.16.4368; Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801; Wang B, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-98; Wang Y, 2017, ONCOGENE, V36, P1644, DOI 10.1038/onc.2016.330; Wasson CW, 2017, ONCOTARGET, V8, P103581, DOI 10.18632/oncotarget.21658; Wei AH, 2020, BLOOD REV, V44, DOI 10.1016/j.blre.2020.100672; Wetherill LF, 2018, ANTIVIR RES, V158, P113, DOI 10.1016/j.antiviral.2018.08.005; Wu LQ, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0936-5; Wu XW, 2020, CELL DEATH DIFFER, V27, P55, DOI 10.1038/s41418-019-0339-0; Xu GW, 2010, BLOOD, V115, P2251, DOI 10.1182/blood-2009-07-231191; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zhang BY, 2005, ONCOGENE, V24, P2585, DOI 10.1038/sj.onc.1208453; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874; Zhang SZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02693-9; Zhang T, 2012, MED ONCOL, V29, P1985, DOI 10.1007/s12032-011-0005-y; Zhao XS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1421; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	81	11	11	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2112	2129		10.1038/s41388-021-01679-8	http://dx.doi.org/10.1038/s41388-021-01679-8		FEB 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33627786	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000621289100008
J	Fletcher, R; Tong, JS; Risnik, D; Leibowitz, BJ; Wang, YJ; Concha-Benavente, F; DeLiberty, JM; Stolz, DB; Pai, RK; Ferris, RL; Schoen, RE; Yu, J; Zhang, L				Fletcher, Rochelle; Tong, Jingshan; Risnik, Denise; Leibowitz, Brian J.; Wang, Yi-Jun; Concha-Benavente, Fernando; DeLiberty, Jonathan M.; Stolz, Donna B.; Pai, Reet K.; Ferris, Robert L.; Schoen, Robert E.; Yu, Jian; Zhang, Lin			Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN-RESPONSE; APC-DEFICIENT CELLS; INDUCED APOPTOSIS; CANCER CHEMOPREVENTION; SULINDAC; MECHANISMS; PATHWAYS; NSAIDS; COLON	Use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with reduced risk of colorectal cancer (CRC). However, the mechanism by which NSAIDs suppress colorectal tumorigenesis remains unclear. We previously showed that NSAIDs selectively kill emerging tumor cells via death receptor (DR) signaling and a synthetic lethal interaction mediated by the proapoptotic Bcl-2 family protein BID. In this study, we found NSAIDs induce endoplasmic reticulum (ER) stress to activate DR signaling and BID in tumor suppression. Importantly, our results unveiled an ER stress- and BID-dependent immunogenic effect of NSAIDs, which may be critical for tumor suppression. NSAID treatment induced hallmarks of immunogenic cell death (ICD) in CRC cells and colonic epithelial cells upon loss of APC tumor suppressor, and elevated tumor-infiltrating lymphocytes (TILs) in the polyps of APC(Min/+) mice. ER stress inhibition or BID deletion abrogated the antitumor and immunogenic effects of NSAIDs. Furthermore, increased ER stress and TILs were detected in human advanced adenomas from NSAID-treated patients. Together, our results suggest that NSAIDs induce ER stress- and BID-mediated ICD to restore immunosurveillance and suppress colorectal tumor formation.	[Fletcher, Rochelle; Tong, Jingshan; Risnik, Denise; Leibowitz, Brian J.; Wang, Yi-Jun; Concha-Benavente, Fernando; Stolz, Donna B.; Pai, Reet K.; Ferris, Robert L.; Schoen, Robert E.; Yu, Jian; Zhang, Lin] UPMC Hillman Canc Ctr, Pittsburgh, PA 15232 USA; [Fletcher, Rochelle; Tong, Jingshan; Risnik, Denise; Wang, Yi-Jun; DeLiberty, Jonathan M.; Zhang, Lin] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Leibowitz, Brian J.; Pai, Reet K.; Yu, Jian] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Concha-Benavente, Fernando; Ferris, Robert L.] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA; [Concha-Benavente, Fernando; Ferris, Robert L.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA; [Stolz, Donna B.] Univ Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA USA; [Schoen, Robert E.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; [Schoen, Robert E.] Univ Pittsburgh, Sch Med, Dept Epidemiol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhang, L (corresponding author), UPMC Hillman Canc Ctr, Pittsburgh, PA 15232 USA.; Zhang, L (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA.	zhanglx@upmc.edu	Wang, Yixuan/GZK-6559-2022; Wang, Yijun/GXW-1763-2022; Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009; wang, yixuan/GXW-2866-2022; Wang, Yin/HCI-9352-2022; Wang, Yu/GZL-9655-2022; wang, yi/GVT-8516-2022	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Risnik, Denise/0000-0001-8843-7968; DeLiberty, Jonathan/0000-0001-6001-6678; Tong, Jingshan/0000-0003-1640-5769	U.S. National Institute of Health [R01CA172136, R01CA203028, R01CA217141, R01CA236271, R01CA247231, U19AI068021, R01CA215481, U01CA152753, P30CA047904]	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Dr. Michael T. Lotze and our lab members for discussion and critical reading and Ms. Dorothy Coe for technical assistance. This work is supported by U.S. National Institute of Health grants (R01CA172136, R01CA203028, R01CA217141, R01CA236271, and R01CA247231 to LZ; U19AI068021 and R01CA215481 to JY; U01CA152753 to RES). This project used the UPMC Hillman Cancer Center shared facilities that were supported in part by award P30CA047904.	Bank A, 2008, CANCER RES, V68, P276, DOI 10.1158/0008-5472.CAN-07-5242; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Berg AK, 2013, J CLIN PHARMACOL, V53, P403, DOI 10.1002/jcph.26; Bezu L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00187; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Cao Y, 2016, GASTROENTEROLOGY, V151, P879, DOI 10.1053/j.gastro.2016.07.030; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chen DS, 2018, P NATL ACAD SCI USA, V115, P3930, DOI 10.1073/pnas.1717190115; Drew DA, 2016, NAT REV CANCER, V16, P173, DOI 10.1038/nrc.2016.4; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Fletcher R, 2018, BBA-REV CANCER, V1869, P138, DOI 10.1016/j.bbcan.2017.12.002; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Gurpinar E, 2014, CLIN CANCER RES, V20, P1104, DOI 10.1158/1078-0432.CCR-13-1573; He Q, 2003, ONCOGENE, V22, P2674, DOI 10.1038/sj.onc.1206363; Huang Y, 2001, CANCER RES, V61, P6918; Keller JJ, 2003, CANCER BIOL THER, V2, pS140; Kepp O, 2015, SEMIN CANCER BIOL, V33, P86, DOI 10.1016/j.semcancer.2015.02.004; Kim JY, 2016, ANTICANCER RES, V36, P2705; Knickelbein K, 2018, ONCOGENE, V37, P4599, DOI 10.1038/s41388-018-0289-x; Kohli M, 2004, P NATL ACAD SCI USA, V101, P16897, DOI 10.1073/pnas.0403405101; Kratochvilova K, 2016, EUR J CELL BIOL, V95, P115, DOI 10.1016/j.ejcb.2016.02.002; LEE SC, 1995, BIOCHEM PHARMACOL, V49, P1567, DOI 10.1016/0006-2952(95)00093-F; Leibowitz B, 2014, P NATL ACAD SCI USA, V111, P16520, DOI 10.1073/pnas.1415178111; Lonnroth Christina, 2008, Cancer Immun, V8, P5; Lopez-Abaitero A, 2009, J IMMUNOTHER, V32, P465, DOI 10.1097/CJI.0b013e3181a1c24e; Lu M, 2014, SCIENCE, V345, P98, DOI 10.1126/science.1254312; Ma L, 2019, SCIENCE, V365, P162, DOI 10.1126/science.aav8692; Marzbani E, 2013, CANCER PREV RES, V6, P764, DOI 10.1158/1940-6207.CAPR-13-0036; Oslowski CM, 2011, METHOD ENZYMOL, V490, P71, DOI 10.1016/B978-0-12-385114-7.00004-0; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Pereira Felipe V, 2018, Oncotarget, V9, P25808, DOI 10.18632/oncotarget.25380; Pozzi C, 2016, NAT MED, V22, P624, DOI 10.1038/nm.4078; Qiu W, 2010, P NATL ACAD SCI USA, V107, P20027, DOI 10.1073/pnas.1010430107; Qiu W, 2009, CANCER RES, V69, P4999, DOI 10.1158/0008-5472.CAN-09-0262; Rufo N, 2017, TRENDS CANCER, V3, P643, DOI 10.1016/j.trecan.2017.07.002; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schuler PJ, 2014, CLIN CANCER RES, V20, P2433, DOI 10.1158/1078-0432.CCR-13-2617; Seed MP, 1997, CANCER RES, V57, P1625; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; STRONG HA, 1987, XENOBIOTICA, V17, P685, DOI 10.3109/00498258709043976; STRONG HA, 1985, CLIN PHARMACOL THER, V38, P387, DOI 10.1038/clpt.1985.192; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Tan X, 2019, CANCER RES, V79, P1191, DOI 10.1158/0008-5472.CAN-18-3223; Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356; Tong J, 2017, ONCOGENE, V36, P787, DOI 10.1038/onc.2016.247; Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Wang YJ, 2018, GENES DIS, V5, P194, DOI 10.1016/j.gendis.2018.05.003; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang L, 2010, NATURE, V464, P1058, DOI 10.1038/nature08871; Zhang XB, 2013, CANCER PREV RES, V6, P1337, DOI 10.1158/1940-6207.CAPR-13-0220	55	9	9	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2035	2050		10.1038/s41388-021-01687-8	http://dx.doi.org/10.1038/s41388-021-01687-8		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33603166	Green Accepted			2022-12-28	WOS:000619405600002
J	Wang, L; Liang, D; Xiong, X; Lin, YS; Zhu, JL; Yao, ZM; Wang, SH; Guo, Y; Chen, YP; Geary, K; Pan, YL; Zhou, FY; Gao, SG; Zhang, DZ; Yeung, SCJ; Zhang, H				Wang, Lu; Liang, Du; Xiong, Xiao; Lin, Yusheng; Zhu, Jianlin; Yao, Zhimeng; Wang, Shuhong; Guo, Yi; Chen, Yuping; Geary, Kyla; Pan, Yunlong; Zhou, Fuyou; Gao, Shegan; Zhang, Dianzheng; Yeung, Sai-Ching Jim; Zhang, Hao			Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling	ONCOGENE			English	Article								Smoking is one of the most impactful lifestyle-related risk factors in many cancer types including esophageal squamous cell carcinoma (ESCC). As the major component of tobacco and e-cigarettes, nicotine is not only responsible for addiction to smoking but also a carcinogen. Here we report that nicotine enhances ESCC cancer malignancy and tumor-initiating capacity by interacting with cholinergic receptor nicotinic alpha 7 subunit (CHRNA7) and subsequently activating the JAK2/STAT3 signaling pathway. We found that aberrant CHRNA7 expression can serve as an independent prognostic factor for ESCC patients. In multiple ESCC mouse models, dextromethorphan and metformin synergistically repressed nicotine-enhanced cancer-initiating cells (CIC) properties and inhibited ESCC progression. Mechanistically, dextromethorphan non-competitively inhibited nicotine binding to CHRNA7 while metformin downregulated CHRNA7 expression by antagonizing nicotine-induced promoter DNA hypomethylation of CHRNA7. Since dextromethorphan and metformin are two safe FDA-approved drugs with minimal undesirable side-effects, the combination of these drugs has a high potential as either a preventive and/or a therapeutic strategy against nicotine-promoted ESCC and perhaps other nicotine-sensitive cancer types as well.	[Wang, Lu; Liang, Du; Xiong, Xiao; Lin, Yusheng; Zhu, Jianlin; Yao, Zhimeng; Wang, Shuhong; Pan, Yunlong; Zhang, Hao] Jinan Univ, Dept Gen Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Wang, Lu; Liang, Du; Xiong, Xiao; Lin, Yusheng; Zhu, Jianlin; Yao, Zhimeng; Wang, Shuhong; Pan, Yunlong; Zhang, Hao] Jinan Univ, Inst Precis Canc Med & Pathol, Sch Med, Guangzhou, Guangdong, Peoples R China; [Liang, Du] Univ Groningen, Dept Biomed Sci Cells & Syst, Sect Mol Cell Biol & Radiat Oncol, Univ Med Ctr Groningen, Groningen, Netherlands; [Lin, Yusheng] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands; [Guo, Yi] Shantou Univ, Endoscopy Ctr, Coll Med, Affiliated Canc Hosp, Shantou, Guangdong, Peoples R China; [Chen, Yuping] Shantou Univ, Dept Thorac Surg, Affiliated Canc Hosp, Coll Med, Shantou, Guangdong, Peoples R China; [Geary, Kyla; Zhang, Dianzheng] Philadelphia Coll Osteopath Med, Dept Biomed Sci, 4170 City Ave, Philadelphia, PA 19131 USA; [Zhou, Fuyou] Henan Univ Sci & Technol, Affiliated Hosp 4, Anyang 455001, Henan, Peoples R China; [Zhou, Fuyou] Anyang Tumor Hosp, Dept Thorac Surg, Anyang 455001, Henan, Peoples R China; [Gao, Shegan] Henan Univ Sci & Technol, Coll Clin Med, Henan Key Lab Canc Epigenet, Affiliated Hosp 1, Luoyang 471003, Peoples R China; [Yeung, Sai-Ching Jim] Univ Texas MD Anderson Canc Ctr, Dept Emergency Med, Houston, TX 77030 USA; [Yeung, Sai-Ching Jim] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA	Jinan University; Jinan University; University of Groningen; University of Groningen; Shantou University; Shantou University; Henan University of Science & Technology; Henan University of Science & Technology; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Zhang, H (corresponding author), Jinan Univ, Dept Gen Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.; Zhang, H (corresponding author), Jinan Univ, Inst Precis Canc Med & Pathol, Sch Med, Guangzhou, Guangdong, Peoples R China.	haolabcancercenter@163.com	Yeung, Sai-Ching/AAI-6178-2021	Yeung, Sai-Ching/0000-0001-5170-0822; Du, Liang/0000-0002-1191-2465; Wang, Lu/0000-0003-2617-655X; Lin, Yusheng/0000-0002-3693-3377	National Natural Science Foundation of China [82072683, 81773087, 81071736, 81572876, 30973508, 82002491]; Natural Science Foundation of Guangdong Province of China [9151018004000000, 2020A1515110049]; Special Project on the Integration of Industry, Education and Research of Guangdong Province [2011A090100024]; China Postdoctoral Science Foundation [2020M673078]; Flagship specialty construction project-General surgery [711003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province of China(National Natural Science Foundation of Guangdong Province); Special Project on the Integration of Industry, Education and Research of Guangdong Province; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Flagship specialty construction project-General surgery	The work was supported by a grant in part by the National Natural Science Foundation of China (82072683, 81773087, 81071736, 81572876, and 30973508 to HZ; 82002491 to LW); the Natural Science Foundation of Guangdong Province of China (9151018004000000 to HZ; 2020A1515110049 to LW); the Science and Technology Planning Project of Guangdong Province of China (2019A030317024 to HZ); Special Project on the Integration of Industry, Education and Research of Guangdong Province (2011A090100024 to HZ); China Postdoctoral Science Foundation (2020M673078 to LW); Flagship specialty construction project-General surgery (Funding no.: 711003).	Al-Wadei MH, 2016, EUR J CANCER, V52, P188, DOI 10.1016/j.ejca.2015.10.003; Bridgeman SC, 2018, DIABETES OBES METAB, V20, P1553, DOI 10.1111/dom.13262; Chen XT, 2013, J CLIN INVEST, V123, P2576, DOI 10.1172/JCI68143; Cummings JL, 2015, JAMA-J AM MED ASSOC, V314, P1242, DOI 10.1001/jama.2015.10214; Cuyas E, 2018, ONCOGENE, V37, P963, DOI 10.1038/onc.2017.367; Damaj MI, 2005, J PHARMACOL EXP THER, V312, P780, DOI 10.1124/jpet.104.075093; Dennis Phillip A, 2005, Cancer Epidemiol Biomarkers Prev, V14, P764, DOI 10.1158/1055-9965.EPI-04-0652; Dong HM, 2017, J PATHOL, V241, P448, DOI 10.1002/path.4839; Egleton RD, 2008, TRENDS PHARMACOL SCI, V29, P151, DOI 10.1016/j.tips.2007.12.006; El-Toukhy S, 2018, TOB CONTROL, V27, pS62, DOI 10.1136/tobaccocontrol-2018-054315; Feng Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.59; Fillon M, 2019, CA-CANCER J CLIN, V69, P83, DOI 10.3322/caac.21468; Guha P, 2014, BREAST CANCER RES TR, V145, P5, DOI 10.1007/s10549-014-2912-z; Hallden S, 2016, J INTERN MED, V279, P388, DOI 10.1111/joim.12454; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Improgo MRD, 2010, PROG NEUROBIOL, V92, P212, DOI 10.1016/j.pneurobio.2010.05.003; Karam-Hage M, 2014, CA-CANCER J CLIN, V64, P273, DOI 10.3322/caac.21231; Kreslake JM, 2008, AM J PUBLIC HEALTH, V98, P1685, DOI 10.2105/AJPH.2007.125542; Lee HW, 2018, P NATL ACAD SCI USA, V115, pE1560, DOI 10.1073/pnas.1718185115; Li H, 2015, LUNG CANCER, V88, P1, DOI 10.1016/j.lungcan.2015.01.017; Lin YS, 2019, CLIN CANCER RES, V25, P3035, DOI 10.1158/1078-0432.CCR-18-3169; Martin E, 2015, CONTEMP CLIN TRIALS, V41, P146, DOI 10.1016/j.cct.2015.01.012; Mineur YS, 2010, TRENDS PHARMACOL SCI, V31, P580, DOI 10.1016/j.tips.2010.09.004; Moerke MJ, 2020, PHARMACOL REV, V72, P527, DOI 10.1124/pr.119.018028; Momi N, 2013, ONCOGENE, V32, P1384, DOI 10.1038/onc.2012.163; Nelson KA, 1997, NEUROLOGY, V48, P1212, DOI 10.1212/WNL.48.5.1212; Nimmakayala RK, 2018, GASTROENTEROLOGY, V155, P892, DOI 10.1053/j.gastro.2018.05.041; Paleari L, 2009, AM J RESP CRIT CARE, V179, P1141, DOI 10.1164/rccm.200806-908OC; Parada E, 2010, FREE RADICAL BIO MED, V49, P1815, DOI 10.1016/j.freeradbiomed.2010.09.017; Sang CN, 2002, ANESTHESIOLOGY, V96, P1053, DOI 10.1097/00000542-200205000-00005; Schaal C, 2014, MOL CANCER RES, V12, P14, DOI 10.1158/1541-7786.MCR-13-0541; Wang L, 2019, CANCER LETT, V450, P22, DOI 10.1016/j.canlet.2019.02.014; Wang SH, 2020, CLIN CANCER RES, V26, P4921, DOI 10.1158/1078-0432.CCR-20-0113; Wright MJ, 2006, PHARMACOL BIOCHEM BE, V85, P507, DOI 10.1016/j.pbb.2006.09.020; Xiong X, 2020, P NATL ACAD SCI USA, V117, P6726, DOI 10.1073/pnas.1913433117; Yan L, 2015, ONCOGENE, V34, P3076, DOI 10.1038/onc.2014.236; Zhang Q, 2020, BRIT J CANCER, V122, P904, DOI 10.1038/s41416-020-0730-0; Zhong T, 2017, ONCOGENE, V36, P2345, DOI 10.1038/onc.2016.391	38	10	10	5	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					1974	1987		10.1038/s41388-021-01682-z	http://dx.doi.org/10.1038/s41388-021-01682-z		FEB 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33603170	Green Published, hybrid			2022-12-28	WOS:000619433100002
J	Eagen, KP; French, CA				Eagen, Kyle P.; French, Christopher A.			Supercharging BRD4 with NUT in carcinoma	ONCOGENE			English	Review							BROMODOMAIN PROTEIN BRD4; CELL-CYCLE PROGRESSION; MIDLINE CARCINOMA; C-MYC; TRANSCRIPTION FACTORS; GENE-EXPRESSION; SELECTIVE-INHIBITION; REVEALS PRINCIPLES; SUPER-ENHANCERS; P-TEFB	NUT carcinoma (NC) is an extremely aggressive squamous cancer with no effective therapy. NC is driven, most commonly, by the BRD4-NUT fusion oncoprotein. BRD4-NUT combines the chromatin-binding bromo- and extraterminal domain-containing (BET) protein, BRD4, with an unstructured, poorly understood protein, NUT, which recruits and activates the histone acetyltransferase p300. Recruitment of p300 to chromatin by BRD4 is believed to lead to the formation of hyperacetylated nuclear foci, as seen by immunofluorescence. BRD4-NUT nuclear foci correspond with massive contiguous regions of chromatin co-enriched with BRD4-NUT, p300, and acetylated histones, termed "megadomains" (MD). Megadomains stretch for as long as 2 MB. Proteomics has defined a BRD4-NUT chromatin complex in which members that associate with BRD4 also exist as rare NUT-fusion partners. This suggests that the common pathogenic denominator is the presence of both BRD4 and NUT, and that the function of BRD4-NUT may mimic that of wild-type BRD4. If so, then MDs may function as massive super-enhancers, activating transcription in a BET-dependent manner. Common targets of MDs across multiple NCs and tissues are three stem cell-related transcription factors frequently implicated in cancer: MYC, SOX2, and TP63. Recently, MDs were found to form a novel nuclear sub-compartment, called subcompartment M (subM), where MD-MD interactions occur both intra- and inter-chromosomally. Included in subM are MYC, SOX2, and TP63. Here we explore the possibility that if MDs are simply large super-enhancers, subM may exist in other cell systems, with broad implications for how 3D organization of the genome may function in gene regulation and maintenance of cell identity. Finally, we discuss how our knowledge of BRD4-NUT function has been leveraged for the therapeutic development of first-in-class BET inhibitors and other targeted strategies.	[Eagen, Kyle P.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Biochem & Mol Genet,Simpson Querrey Inst Epi, Chicago, IL 60611 USA; [French, Christopher A.] Brigham & Womens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Eagen, KP (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Biochem & Mol Genet,Simpson Querrey Inst Epi, Chicago, IL 60611 USA.; French, CA (corresponding author), Brigham & Womens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA.	eagen@northwestern.edu; Cfrench@bwh.harvard.edu		French, Christopher/0000-0002-7434-4987; Eagen, Kyle/0000-0002-2610-8664				Abbas HA, 2018, CANCER RES, V78, P451, DOI 10.1158/0008-5472.CAN-17-1803; Alekseyenko Artyom A, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2130s109; Alekseyenko AA, 2017, P NATL ACAD SCI USA, V114, pE4184, DOI 10.1073/pnas.1702086114; Alekseyenko AA, 2015, GENE DEV, V29, P1507, DOI 10.1101/gad.267583.115; Alexandrova EM, 2013, CELL DEATH DIFFER, V20, P1698, DOI 10.1038/cdd.2013.122; aniakas A, 2020, JAMA ONCOL; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Beesley AH, 2014, BRIT J CANCER, V110, P1189, DOI 10.1038/bjc.2014.54; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Bragelmann J, 2017, CELL REP, V20, P2833, DOI 10.1016/j.celrep.2017.08.082; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Chau NG, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkz094; Chen YL, 2018, CELL DEATH DIFFER, V25, P2118, DOI 10.1038/s41418-018-0132-5; Chiang CT, 2009, J CELL PHYSIOL, V219, P117, DOI 10.1002/jcp.21656; Coude MM, 2015, ONCOTARGET, V6, P17698, DOI 10.18632/oncotarget.4131; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; de Marval PLM, 2004, MOL CELL BIOL, V24, P7538, DOI 10.1128/MCB.24.17.7538-7547.2004; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dey A, 2000, MOL CELL BIOL, V20, P6537, DOI 10.1128/MCB.20.17.6537-6549.2000; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Di Micco R, 2014, CELL REP, V9, P234, DOI 10.1016/j.celrep.2014.08.055; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Faivre EJ, 2020, NATURE, V578, P306, DOI 10.1038/s41586-020-1930-8; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; French CA, 2003, CANCER RES, V63, P304; French CA, 2017, WHO CLASSIFICATION H; French CA, 2018, PATHOL INT, V68, P583, DOI 10.1111/pin.12727; French CA, 2014, CANCER DISCOV, V4, P928, DOI 10.1158/2159-8290.CD-14-0014; Giacobbe A, 2016, ONCOGENE, V35, P1602, DOI 10.1038/onc.2015.230; Gillespie MA, 2020, MOL CELL, V78, P960, DOI 10.1016/j.molcel.2020.03.031; Grayson AR, 2014, ONCOGENE, V33, P1736, DOI 10.1038/onc.2013.126; Guo LD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17350-x; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Hamdan FH, 2018, P NATL ACAD SCI USA, V115, pE12343, DOI 10.1073/pnas.1812915116; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Henssen A, 2013, ONCOTARGET, V4, DOI 10.18632/oncotarget.1534; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Herranz D, 2014, NAT MED, V20, P1130, DOI 10.1038/nm.3665; Hinze L, 2019, CANCER CELL, V35, P664, DOI 10.1016/j.ccell.2019.03.004; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Konermann S, 2018, CELL, V173, P665, DOI 10.1016/j.cell.2018.02.033; Lanza M, 2006, CELL CYCLE, V5, P1996, DOI 10.4161/cc.5.17.3188; Lasko LM, 2017, NATURE, V550, P128, DOI 10.1038/nature24028; Latina A, 2016, ONCOGENE, V35, P1493, DOI 10.1038/onc.2015.222; Lee JK, 2017, ANN ONCOL, V28, P890, DOI 10.1093/annonc/mdw686; Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292; Li N, 2016, MOL CELL, V63, P470, DOI 10.1016/j.molcel.2016.06.035; Liao SD, 2018, GENE DEV, V32, P1188, DOI 10.1101/gad.315648.118; Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Maher OM, 2015, PEDIATR BLOOD CANCER, V62, P715, DOI 10.1002/pbc.25350; Malovannaya A, 2011, CELL, V145, P787, DOI 10.1016/j.cell.2011.05.006; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Matzuk MM, 2012, CELL, V150, P673, DOI 10.1016/j.cell.2012.06.045; McCleland ML, 2016, J CLIN INVEST, V126, P639, DOI 10.1172/JCI83265; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Morrison-Smiths CD, 2020, MOL CANCER THER, V19, P1406, DOI 10.1158/1535-7163.MCT-20-0087; Mukhopadhyay A, 2014, CELL REP, V8, P40, DOI 10.1016/j.celrep.2014.05.036; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Ortega E, 2018, NATURE, V562, P538, DOI 10.1038/s41586-018-0621-1; Palmer AC, 2017, CELL, V171, P1678, DOI 10.1016/j.cell.2017.11.009; Piha-Paul SA, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkz093; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Qiu HF, 2015, ONCOTARGET, V6, P6915, DOI 10.18632/oncotarget.3126; Rahman S, 2011, MOL CELL BIOL, V31, P2641, DOI 10.1128/MCB.01341-10; Rao SSP, 2017, CELL, V171, P305, DOI 10.1016/j.cell.2017.09.026; Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021; Reynoird N, 2010, EMBO J, V29, P2943, DOI 10.1038/emboj.2010.176; Riquelme E, 2014, J THORAC ONCOL, V9, P998, DOI 10.1097/JTO.0000000000000202; Rizk M, 2019, DRUG TODAY, V55, P315, DOI 10.1358/dot.2019.55.5.2958475; Roe JS, 2015, MOL CELL, V58, P1028, DOI 10.1016/j.molcel.2015.04.011; Romero FA, 2017, J MED CHEM, V60, P9162, DOI 10.1021/acs.jmedchem.7b00796; Rosencrance CD, 2020, MOL CELL, V78, P112, DOI 10.1016/j.molcel.2020.03.018; Saint-Andre V, 2016, GENOME RES, V26, P385, DOI 10.1101/gr.197590.115; Schwartz BE, 2011, CANCER RES, V71, P2686, DOI 10.1158/0008-5472.CAN-10-3513; Sheppard GS, 2020, J MED CHEM, V63, P5585, DOI 10.1021/acs.jmedchem.0c00628; Shiota H, 2018, CELL REP, V24, P3477, DOI 10.1016/j.celrep.2018.08.069; Shiota H, 2018, MOL CANCER RES, V16, P1826, DOI 10.1158/1541-7786.MCR-18-0474; Spruijt CG, 2016, CELL REP, V17, P783, DOI 10.1016/j.celrep.2016.09.037; Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Stirnweiss A, 2017, ONCOTARGET, V8, P112313, DOI 10.18632/oncotarget.22862; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; Tilson MP, 2014, HEAD NECK PATHOL, V8, P141, DOI 10.1007/s12105-013-0496-2; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Vito D, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2019.100785; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang HF, 2014, P NATL ACAD SCI USA, V111, P705, DOI 10.1073/pnas.1315023111; Wang RR, 2015, J BIOL CHEM, V290, P2744, DOI 10.1074/jbc.M114.600759; Wang RR, 2014, CANCER RES, V74, P3332, DOI 10.1158/0008-5472.CAN-13-2658; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Watanabe H, 2014, J CLIN INVEST, V124, P1636, DOI 10.1172/JCI71545; Westcott JM, 2020, CANCER RES, V80, P3933, DOI 10.1158/0008-5472.CAN-20-0014; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Wu T, 2018, CELL REP, V25, P1756, DOI 10.1016/j.celrep.2018.10.003; Wyce A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072967; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Yan YQ, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910659; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang ZY, 2008, MOL CELL BIOL, V28, P967, DOI 10.1128/MCB.01020-07; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; Zhang X, 2020, ONCOGENE, V39, P4770, DOI 10.1038/s41388-020-1301-9	114	16	16	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1396	1408		10.1038/s41388-020-01625-0	http://dx.doi.org/10.1038/s41388-020-01625-0		JAN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452461	Green Accepted			2022-12-28	WOS:000607998600003
J	Plowman, PN; Plowman, CE				Plowman, P. N.; Plowman, C. E.			Onco-ontogeny recapitulates phylogeny - a consideration	ONCOGENE			English	Article							CONSENSUS MOLECULAR SUBTYPES; BRAIN-STEM GLIOMAS; COLORECTAL-CANCER; PATTERNS; MODIFIER; FUMARATE; CELLS	Cancers necessarily rely on the (embryologic) fundamental growth patterning genes to serve their uncontrolled growth. Studying a cancer's behavior, depending on which side of an embryological divide it derives, together with its transcriptome and its relationship to immigrant cells with stem cell potential, intercellular signaling and transducer cascades to transcription factors-all help our understanding of the cancer phenotype. To these can be added the acquired methylome and possibly a "knock-on" metabolome. These aspects are reviewed in the context of Haeckel's law.	[Plowman, P. N.] St Bartholomews Hosp, Dept Clin Oncol, London, England; [Plowman, C. E.] UCL, London, England	University of London; Queen Mary University London; University of London; University College London	Plowman, PN (corresponding author), St Bartholomews Hosp, Dept Clin Oncol, London, England.	nick.plowman1@nhs.net						Aiello NM, 2016, DIS MODEL MECH, V9, P105, DOI 10.1242/dmm.023184; Al-Olabi L, 2018, J CLIN INVEST, V128, P1496, DOI 10.1172/JCI98589; Ashrafian H, 2010, CANCER RES, V70, P9153, DOI 10.1158/0008-5472.CAN-10-1949; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Cohen AL, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0345-4; Daoud EV, 2018, J NEUROPATH EXP NEUR, V77, P302, DOI 10.1093/jnen/nly006; Fessler E, 2016, ONCOGENE, V35, P6026, DOI 10.1038/onc.2016.134; Fontana E, 2019, ANN ONCOL, V30, P520, DOI 10.1093/annonc/mdz052; Fromme Julia Elisabeth, 2018, Oncotarget, V9, P32204, DOI 10.18632/oncotarget.25941; Gomez DR, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.19.00201; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Irving C, 2000, DEVELOPMENT, V127, P177; Jiao XM, 2019, CANCER RES, V79, P4801, DOI 10.1158/0008-5472.CAN-19-1167; Kinsler VA, 2020, HARPERS TXB PEDIAT D, P1283; Li HJ, 2012, DEV BIOL, V371, P156, DOI 10.1016/j.ydbio.2012.08.023; Liu J, 2019, J PATHOL, V247, P481, DOI 10.1002/path.5207; Maffeis V, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01255; Makabe T, 2019, CARCINOGENESIS, V40, P611, DOI 10.1093/carcin/bgz046; May CL, 2010, MOL CELL ENDOCRINOL, V323, P70, DOI 10.1016/j.mce.2009.12.009; Mi ZY, 2011, CARCINOGENESIS, V32, P477, DOI 10.1093/carcin/bgr009; Mo J, 2020, CANCER RES TREAT, V52, P74, DOI 10.4143/crt.2019.062; Nishikawa G, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1508-2; Oberheim-Bush NA, 2020, P AM SOC CLIN ONCOL; Padmanaban V, 2019, NATURE, V573, P439, DOI 10.1038/s41586-019-1526-3; Palma DA, 2019, LANCET, V393, P2051, DOI 10.1016/S0140-6736(18)32487-5; Perrone-Capano C, 2000, INT J DEV BIOL, V44, P679; Pinheiro M, 2015, BRIT J CANCER, V113, P686, DOI 10.1038/bjc.2015.281; Plava J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0960-z; Plowman PN, 2004, BRIT J NEUROSURG, V18, P500, DOI 10.1080/02688690400012400; Schreck KC, 2019, J NEURO-ONCOL, V143, P87, DOI 10.1007/s11060-019-03134-x; Sciacovelli M, 2016, NATURE, V540, DOI 10.1038/nature20144; Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353; Shen MM, 2007, DEVELOPMENT, V134, P1023, DOI 10.1242/dev.000166; Sulkowski PL, 2018, NAT GENET, V50, P1086, DOI 10.1038/s41588-018-0170-4; Summerbell ER, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6197; Tapial S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47014-w; Theeler BJ, 2015, J NEUROL SCI, V353, P92, DOI 10.1016/j.jns.2015.04.014; Turajlic S, 2018, CELL, V173, P581, DOI 10.1016/j.cell.2018.03.057; Wallace AS, 2011, WORLD J GASTROENTERO, V17, P4937, DOI 10.3748/wjg.v17.i45.4937; Whitehall VLJ, 2014, EPIGENETICS-US, V9, P1454, DOI 10.4161/15592294.2014.971624; Xu YF, 2007, HUM MOL GENET, V16, pR14, DOI 10.1093/hmg/ddl486	42	0	0	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1542	1550		10.1038/s41388-020-01624-1	http://dx.doi.org/10.1038/s41388-020-01624-1		JAN 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452457				2022-12-28	WOS:000607998600004
J	Ma, JF; Weng, L; Bastian, BC; Chen, X				Ma, Jiafang; Weng, Li; Bastian, Boris C.; Chen, Xu			Functional characterization of uveal melanoma oncogenes	ONCOGENE			English	Article							ACTIVATING MUTATIONS; SOMATIC MUTATIONS; GNA11 MUTATIONS; ALPHA-SUBUNIT; SF3B1; PHOSPHORYLATION; EXPRESSION; PLATFORM; RASGRP3; PATHWAY	Uveal melanoma (UM) is a currently untreatable form of melanoma with a 50% mortality rate. Characterization of the essential signaling pathways driving this cancer is critical to develop target therapies. Activating mutations in the G alpha q signaling pathway at the level of GNAQ, GNA11, or rarely CYSLTR2 or PLC beta 4 are considered alterations driving proliferation in UM and several other neoplastic disorders. Here, we systematically examined the oncogenic signaling output of various mutations recurrently identified in human tumors. We demonstrate that CYSLTR2 -> GNAQ/11 -> PLC beta act in a linear signaling cascade that, via protein kinase C (PKC), activates in parallel the MAP-kinase and FAK/Yes-associated protein pathways. Using genetic ablation and pharmacological inhibition, we show that the PKC/RasGRP3/MAPK signaling branch is the essential component that drives the proliferation of UM. Only inhibition of the MAPK branch but not the FAK branch synergizes with inhibition of the proximal cascade, providing a blueprint for combination therapy. All oncogenic signaling could be extinguished by the novel GNAQ/11 inhibitor YM-254890, in all UM cells with driver mutation in the G alpha q subunit or the upstream receptor. Our findings highlight the GNAQ/11 -> PLC beta -> PKC -> MAPK pathway as the central signaling axis to be suppressed pharmacologically to treat for neoplastic disorders with G alpha q pathway mutations.	[Ma, Jiafang; Weng, Li; Bastian, Boris C.; Chen, Xu] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Ma, Jiafang; Weng, Li; Bastian, Boris C.; Chen, Xu] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Ma, Jiafang; Weng, Li; Bastian, Boris C.; Chen, Xu] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Bastian, BC; Chen, X (corresponding author), Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.; Bastian, BC; Chen, X (corresponding author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.; Bastian, BC; Chen, X (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.	Boris.Bastian@ucsf.edu; Xu.Chen@ucsf.edu		chen, xu/0000-0003-2524-4979	National Cancer Institute [CA220481, CA142873]; Gerson and Barbara Baker Distinguished Professorship	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gerson and Barbara Baker Distinguished Professorship	This work was supported by R35 grant CA220481 and R01 grant CA142873 from the National Cancer Institute and the Gerson and Barbara Baker Distinguished Professorship (all to BCB). We thank Han Yue for providing help for IP1 assay. We thank the Preclinical Therapeutics, Laboratory for Cell Analysis of University of California, San Francisco for technical support and analyses.	Amirouchene-Angelozzi N, 2014, MOL ONCOL, V8, P1508, DOI 10.1016/j.molonc.2014.06.004; Annala S, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aau5948; ARNESEN K, 1985, INT OPHTHALMOL, V7, P143, DOI 10.1007/BF00128360; Ayturk UM, 2016, AM J HUM GENET, V98, P789, DOI 10.1016/j.ajhg.2016.03.009; Bean GR, 2017, MODERN PATHOL, V30, P722, DOI 10.1038/modpathol.2016.234; Cao J, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw660; Carvajal RD, 2018, J CLIN ONCOL, V36, P1232, DOI 10.1200/JCO.2017.74.1090; Carvajal RD, 2014, JAMA-J AM MED ASSOC, V311, P2397, DOI 10.1001/jama.2014.6096; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen X, 2014, ONCOGENE, V33, P4724, DOI 10.1038/onc.2013.418; Chen X, 2017, CANCER CELL, V31, P685, DOI 10.1016/j.ccell.2017.04.002; Couto JA, 2017, ANGIOGENESIS, V20, P303, DOI 10.1007/s10456-016-9538-1; Couto JA, 2016, PLAST RECONSTR SURG, V137, p77E, DOI 10.1097/PRS.0000000000001868; Di Veroli GY, 2016, BIOINFORMATICS, V32, P2866, DOI 10.1093/bioinformatics/btw230; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Feng XD, 2019, CANCER CELL, V35, P457, DOI 10.1016/j.ccell.2019.01.009; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Furney SJ, 2013, CANCER DISCOV, V3, P1122, DOI 10.1158/2159-8290.CD-13-0330; Goldsmith ZG, 2007, ONCOGENE, V26, P3122, DOI 10.1038/sj.onc.1210407; Griewank KG, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2012.00971.x; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harbour JW, 2013, NAT GENET, V45, P133, DOI 10.1038/ng.2523; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Heasley LE, 1996, MOL CELL BIOL, V16, P648; JHON DY, 1993, J BIOL CHEM, V268, P6654; Johansson P, 2016, ONCOTARGET, V7, P4624, DOI 10.18632/oncotarget.6614; Joseph NM, 2018, AM J SURG PATHOL, V42, P1201, DOI 10.1097/PAS.0000000000001110; Kamato D., 2015, FRONTIERS CARDIOVASC, V2, P1, DOI [10.3389/FCVM.2015.00014/BIBTEX, DOI 10.3389/FCVM.2015.00014/BIBTEX]; Kapiteijn E, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-CT068; Kim YJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63391-z; Kostenis E, 2020, J BIOL CHEM, V295, P5206, DOI 10.1074/jbc.REV119.007061; Kuschak M, 2020, BRIT J PHARMACOL, V177, P1898, DOI 10.1111/bph.14960; Lapadula D, 2019, MOL CANCER RES, V17, P963, DOI 10.1158/1541-7786.MCR-18-0574; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE CW, 1994, J BIOL CHEM, V269, P25335; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Li BC, 2019, J CLIN INVEST, V129, P1167, DOI 10.1172/JCI122440; Lim YH, 2016, AM J HUM GENET, V99, P443, DOI 10.1016/j.ajhg.2016.06.010; Malfacini D, 2019, J BIOL CHEM, V294, P5747, DOI 10.1074/jbc.RA118.007250; Martin M, 2013, NAT GENET, V45, P933, DOI 10.1038/ng.2674; Martins L, 2017, J MOL GRAPH MODEL, V76, P429, DOI 10.1016/j.jmgm.2017.07.011; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; Maziarz M, 2018, J BIOL CHEM, V293, P19586, DOI 10.1074/jbc.RA118.005291; Moore AR, 2018, CELL REP, V22, P2455, DOI 10.1016/j.celrep.2018.01.081; Moore AR, 2016, NAT GENET, V48, P675, DOI 10.1038/ng.3549; Murali R, 2012, ACTA NEUROPATHOL, V123, P457, DOI 10.1007/s00401-012-0948-x; Nakashima M, 2014, J HUM GENET, V59, P691, DOI 10.1038/jhg.2014.95; Onken MD, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aao6852; Piperno-Neumann S, 2020, MOL CANCER THER, V19, P1031, DOI 10.1158/1535-7163.MCT-19-0098; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Schank TE, 2019, CANCERS, V11, DOI 10.3390/cancers11081048; Schneider B, 2019, PATHOL ONCOL RES, V25, P1319, DOI 10.1007/s12253-017-0371-7; Schrage R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10156; Shain AH, 2019, NAT GENET, V51, P1123, DOI 10.1038/s41588-019-0440-9; Sheng XA, 2016, EUR J CANCER, V65, P156, DOI 10.1016/j.ejca.2016.06.019; Shirley MD, 2013, NEW ENGL J MED, V368, P1971, DOI 10.1056/NEJMoa1213507; Singh Arun D, 2005, Ophthalmol Clin North Am, V18, P75, DOI 10.1016/j.ohc.2004.07.002; Sugihara T, 2018, MOL CANCER RES, V16, P1556, DOI 10.1158/1541-7786.MCR-18-0158; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Tanjoni I, 2010, CANCER BIOL THER, V9, P764, DOI 10.4161/cbt.9.10.11434; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; Thomas AC, 2016, J INVEST DERMATOL, V136, P770, DOI 10.1016/j.jid.2015.11.027; Tietze D, 2019, J CHEM INF MODEL, V59, P4361, DOI 10.1021/acs.jcim.9b00433; Trinquet E, 2006, ANAL BIOCHEM, V358, P126, DOI 10.1016/j.ab.2006.08.002; van Dinten LC, 2005, INVEST OPHTH VIS SCI, V46, P24, DOI 10.1167/iovs.04-0961; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	73	17	17	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					806	820		10.1038/s41388-020-01569-5	http://dx.doi.org/10.1038/s41388-020-01569-5		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33262460	Green Submitted, Green Accepted			2022-12-28	WOS:000595928700005
J	Yu, JQ; Wang, NZ; Gong, ZQ; Liu, LP; Yang, SL; Chen, GG; Lai, PBS				Yu, Jianqing; Wang, Nuozhou; Gong, Zhongqin; Liu, Liping; Yang, Shengli; Chen, George Gong; Lai, Paul Bo San			Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma	ONCOGENE			English	Article							PROTON PUMP INHIBITORS; TRANSCRIPTION; EXPRESSION; SURVIVAL; PROTEIN	Sorafenib resistance has become the main obstacle in the effective treatment of advanced hepatocellular carcinoma (HCC) patients. Activation of nuclear factor kappa B (NF-kappa B) is a newly identified mechanism that contributes to desensitized sorafenib. Cytochrome P450 1A2 (CYP1A2) functions as a tumor suppressor in HCC and its expression is negatively associated with NF-kappa B in the liver. This study aimed to study whether CYP1A2 could overcome sorafenib resistance. To investigate whether CYP1A2 and NF-kappa B p65 played roles in sorafenib desensitization, we established sorafenib-resistant (SR) HCC cells. SR cells decreased the expression of CYP1A2 along with the upregulation of NF-kappa B p65. CYP1A2 overexpression attenuated SR cell proliferation, increased sorafenib sensitivity, and inhibited the NF-kappa B pathway, whereas CYP1A2 silence showed opposite effects. Sorafenib, in combination with omeprazole, a CYP1A2 inducer, significantly hindered the growth and invasion of SR cells in vitro as well as decreased the tumor growth in vivo. The combination treatment markedly increased CYP1A2 expression and inhibited the sorafenib-induced NF-kappa B signaling. In addition, the overexpression of NF-kappa B p65 stimulated the SR cell growth and desensitized sorafenib in SR cells, where CYP1A2 overexpression reversed the phenomenon. Lastly, the majority of HCC tissue samples displayed decreased CYP1A2 but increased NF-kappa B p65 protein expression. Collectively, CYP1A2 can sensitize SR cells to sorafenib via inhibiting NF-kappa B p65 axis. Omeprazole in combination with sorafenib exerts a synergistic effect in alleviating acquired sorafenib resistance.	[Yu, Jianqing; Wang, Nuozhou; Gong, Zhongqin; Chen, George Gong; Lai, Paul Bo San] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Fac Med, Hong Kong, Peoples R China; [Liu, Liping] Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Hepatobiliary & Pancreas Surg, Shenzhen 524000, Guangdong, Peoples R China; [Yang, Shengli] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Canc Ctr, Wuhan 430022, Peoples R China; [Chen, George Gong] Chinese Univ Hong Kong, Prince Walves Hosp, Fac Med, Dept Otorhinolaryngol Head & Neck Surg, Hong Kong, Peoples R China; [Chen, George Gong] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Guangdong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Jinan University; Huazhong University of Science & Technology; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen	Chen, GG; Lai, PBS (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Fac Med, Hong Kong, Peoples R China.; Chen, GG (corresponding author), Chinese Univ Hong Kong, Prince Walves Hosp, Fac Med, Dept Otorhinolaryngol Head & Neck Surg, Hong Kong, Peoples R China.; Chen, GG (corresponding author), Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Guangdong, Peoples R China.	gchen@cuhk.edu.hk; paullai@cuhk.edu.hk	Lai, Paul BS/K-8556-2015	Lai, Paul BS/0000-0002-9469-6728; Chen, George/0000-0001-7276-3830; Gong, Zhongqin/0000-0002-7030-0581	Research Grants Council of the Hong Kong SAR [CUHK14117015]	Research Grants Council of the Hong Kong SAR(Hong Kong Research Grants Council)	We thank technical supports from Dr. Jianwei Ren, Mr. Rocky Lok-kee Ho and Ms. Suk-ying Chun. This study was supported by a grant from the Research Grants Council of the Hong Kong SAR, CUHK14117015.	Abdel-Wahab AF, 2019, PHARMACOL RES, V150, DOI 10.1016/j.phrs.2019.104511; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen CH, 2019, J CLIN PHARMACOL, V59, P350, DOI 10.1002/jcph.1329; Chen H, 2014, WORLD J GASTROENTERO, V20, P8681, DOI 10.3748/wjg.v20.i26.8681; Chen JCH, 2016, ONCOTARGET, V7, P85450, DOI 10.18632/oncotarget.13398; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; de Argila CM, 2005, DRUGS, V65, P97; Dudgeon C, 2012, ONCOGENE, V31, P4848, DOI 10.1038/onc.2011.644; FRUCHT H, 1991, DIGEST DIS SCI, V36, P394, DOI 10.1007/BF01298865; Galmiche A, 2014, CANCER LETT, V346, P159, DOI 10.1016/j.canlet.2013.12.028; Haibe-Kains B, 2013, NATURE, V504, P389, DOI 10.1038/nature12831; Hellum BH, 2007, BASIC CLIN PHARMACOL, V100, P23, DOI 10.1111/j.1742-7843.2007.00011.x; Jing HR, 2012, J SURG RES, V176, P63, DOI 10.1016/j.jss.2011.09.001; Kuo HP, 2013, CANCER CELL, V24, P423, DOI 10.1016/j.ccr.2013.08.019; Li F, 2010, BBA-REV CANCER, V1805, P167, DOI 10.1016/j.bbcan.2010.01.002; Li J, 2018, CANCER BIOL THER, V19, P1057, DOI 10.1080/15384047.2018.1480280; Liang L, 2020, ONCOL LETT, V19, P519, DOI 10.3892/ol.2019.11090; Lin WY, 2010, GASTROENTEROLOGY, V138, P2509, DOI 10.1053/j.gastro.2010.03.008; Liu ZZ, 2019, SAUDI J GASTROENTERO, V25, P167, DOI 10.4103/sjg.SJG_290_18; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Lo J, 2015, HEPATOLOGY, V62, P534, DOI 10.1002/hep.27859; Luciani F, 2004, JNCI-J NATL CANCER I, V96, P1702, DOI 10.1093/jnci/djh305; MACNAB GM, 1976, BRIT J CANCER, V34, P509, DOI 10.1038/bjc.1976.205; Neelgundmath M, 2015, BIOORG MED CHEM LETT, V25, P893, DOI 10.1016/j.bmcl.2014.12.065; Papagerakis S, 2014, CANCER PREV RES, V7, P1258, DOI 10.1158/1940-6207.CAPR-14-0002; Qiu YX, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-1005-y; Ray EM, 2017, J HEPATOCELL CARCINO, V4, P131, DOI 10.2147/JHC.S124366; REN JW, 2016, PLOS ONE, V11, DOI DOI 10.1371/JOURNAL.PONE.0153863; Sainz B, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-103; Shen ZT, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6312-y; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Tatebe S, 2015, CIRC J, V79, P1215, DOI 10.1253/circj.CJ-15-0367; Taylor S, 2015, DRUG RESIST UPDATE, V23, P69, DOI 10.1016/j.drup.2015.08.004; Wang NZ, 2020, CANCER LETT, V472, P70, DOI 10.1016/j.canlet.2019.12.026; Wang YT, 2020, EXP CELL RES, V386, DOI 10.1016/j.yexcr.2019.111739; Waris G, 2003, J BIOL CHEM, V278, P40778, DOI 10.1074/jbc.M303248200; Weil R, 1999, MOL CELL BIOL, V19, P6345; Wu JM, 2009, CANCER LETT, V278, P145, DOI 10.1016/j.canlet.2008.12.031; Xie C, 2020, HEPATOLOGY, V71, P1660, DOI 10.1002/hep.30931; Xu YM, 2016, CANCER LETT, V371, P171, DOI 10.1016/j.canlet.2015.11.034; Yamada T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1297-7; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012; Zhu YJ, 2017, ACTA PHARMACOL SIN, V38, P614, DOI 10.1038/aps.2017.5	46	10	10	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					492	507		10.1038/s41388-020-01545-z	http://dx.doi.org/10.1038/s41388-020-01545-z		NOV 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33184472				2022-12-28	WOS:000588868700001
J	Eustace, NJ; Anderson, JC; Warram, JM; Widden, HN; Pedersen, RT; Alrefai, H; Patel, Z; Hicks, PH; Placzek, WJ; Gillespie, GY; Hjelmeland, AB; Willey, CD				Eustace, Nicholas J.; Anderson, Joshua C.; Warram, Jason M.; Widden, Hayley N.; Pedersen, Rune T.; Alrefai, Hasan; Patel, Zeel; Hicks, Patricia H.; Placzek, William J.; Gillespie, G. Yancey; Hjelmeland, Anita B.; Willey, Christopher D.			A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma	ONCOGENE			English	Article							PI3K PATHWAY; RADIATION SENSITIVITY; MOLECULAR-MECHANISMS; CANCER; RESISTANCE; PHOSPHORYLATION; APOPTOSIS; PEPTIDE; CALCIUM; GROWTH	Glioblastoma (GBM) is an aggressive malignancy with limited effectiveness of standard of care therapies including surgery, radiation, and temozolomide chemotherapy necessitating novel therapeutics. Unfortunately, GBMs also harbor several signaling alterations that protect them from traditional therapies that rely on apoptotic programmed cell death. Because almost all GBM tumors have dysregulated phosphoinositide signaling as part of that process, we hypothesized that peptide mimetics derived from the phospholipid binding domain of Myristoylated alanine-rich C-kinase substrate (MARCKS) could serve as a novel GBM therapeutic. Using molecularly classified patient-derived xenograft (PDX) lines, cultured in stem-cell conditions, we demonstrate that cell permeable MARCKS effector domain (ED) peptides potently target all GBM molecular classes while sparing normal human astrocytes. Cell death mechanistic testing revealed that these peptides produce rapid cytotoxicity in GBM that overcomes caspase inhibition. Moreover, we identify a GBM-selective cytolytic death mechanism involving plasma membrane targeting and intracellular calcium accumulation. Despite limited relative partitioning to the brain, tail-vein peptide injection revealed tumor targeting in intracranially implanted GBM PDX. These results indicate that MARCKS ED peptide therapeutics may overcome traditional GBM resistance mechanisms, supporting further development of similar agents.	[Eustace, Nicholas J.; Anderson, Joshua C.; Alrefai, Hasan; Patel, Zeel; Hicks, Patricia H.; Willey, Christopher D.] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL 35294 USA; [Warram, Jason M.] Univ Alabama Birmingham, Dept Otolaryngol, Birmingham, AL USA; [Widden, Hayley N.; Placzek, William J.] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL USA; [Pedersen, Rune T.] ChemoMetec, DK-3450 Allerod, Denmark; [Gillespie, G. Yancey] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA; [Hjelmeland, Anita B.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Willey, CD (corresponding author), Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL 35294 USA.	cwilley@uabmc.edu		Eustace, Nicholas/0000-0002-2483-7863; Placzek, William/0000-0003-4096-8617; Alrefai, Hasan/0000-0002-7240-8748; Gillespie, George/0000-0001-6436-9542; Anderson, Joshua/0000-0002-6977-9054; Pedersen, Rune Troelsgaard/0000-0002-0655-1351	National Institutes of Health (UAB MSTP training Grant) [T32GM008361]; National Institutes of Health (UAB Training Program in Brain Tumor Biology) [T32NS048039]; American Cancer Society [RSG-14-071-01-TBG]; UAB Physician Scientist Training Program Medical Student Summer Research Training Program; UAB Department of Radiation Oncology	National Institutes of Health (UAB MSTP training Grant)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (UAB Training Program in Brain Tumor Biology)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); UAB Physician Scientist Training Program Medical Student Summer Research Training Program; UAB Department of Radiation Oncology	This work was supported by funding from the National Institutes of Health (the UAB MSTP training Grant: T32GM008361 and the UAB Training Program in Brain Tumor Biology: T32NS048039), the American Cancer Society RSG-14-071-01-TBG, the UAB Physician Scientist Training Program Medical Student Summer Research Training Program, and an intramural research grant from the UAB Department of Radiation Oncology.	Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Babiychuk EB, 2011, CELL DEATH DIFFER, V18, P80, DOI 10.1038/cdd.2010.81; Birge RB, 2016, CELL DEATH DIFFER, V23, P962, DOI 10.1038/cdd.2016.11; Boohaker RJ, 2012, CURR MED CHEM, V19, P3794; Brudvig JJ, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00407; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31; Chang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.407; Chen CH, 2017, ONCOGENE, V36, P3588, DOI 10.1038/onc.2016.510; Chen CH, 2014, AM J RESP CRIT CARE, V190, P1127, DOI 10.1164/rccm.201408-1505OC; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Collatz MB, 1997, CELL CALCIUM, V21, P453, DOI 10.1016/S0143-4160(97)90056-7; Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025; de Boer E, 2016, MOL IMAGING BIOL, V18, P232, DOI 10.1007/s11307-015-0892-y; Denley A, 2009, MOL CANCER RES, V7, P1132, DOI 10.1158/1541-7786.MCR-09-0068; Dinca A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020263; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fong LWR, 2017, CANCER METAST REV, V36, P737, DOI 10.1007/s10555-017-9709-6; Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4; Gimple RC, 2019, CANCER DISCOV, V9, P1248, DOI 10.1158/2159-8290.CD-19-0061; Groothuis DR, 2000, NEURO-ONCOLOGY, V2, P45, DOI 10.1093/neuonc/2.1.45; Haar CP, 2012, NEUROCHEM RES, V37, P1192, DOI 10.1007/s11064-011-0701-1; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Iqbal S, 2020, ACS CHEM NEUROSCI, V11, P1944, DOI 10.1021/acschemneuro.0c00139; Jarboe JS, 2012, CLIN CANCER RES, V18, P3030, DOI 10.1158/1078-0432.CCR-11-3091; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Kastelowitz N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04494-y; Keoni Chanel Li, 2015, J Cell Death, V8, P1, DOI 10.4137/JCD.S23844; Kepp O, 2009, APOPTOSIS, V14, P364, DOI 10.1007/s10495-008-0303-9; Krakstad C, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-135; Langhans J, 2017, ONCOGENESIS, V6, DOI 10.1038/s41389-017-0004-8; Li XM, 2016, ONCOTARGET, V7, P33440, DOI [10.18632/oncotarget.7961, 10.18632/oncotarget.6497]; Micallef J, 2009, CANCER RES, V69, P7548, DOI 10.1158/0008-5472.CAN-08-4783; Morton LA, 2013, ACS CHEM BIOL, V8, P218, DOI 10.1021/cb300429e; Nichol D, 2015, NEURO-ONCOLOGY, V17, P1183, DOI 10.1093/neuonc/nov124; Panzarini E, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.51; Rohrbach TD, 2017, ONCOL LETT, V13, P1216, DOI 10.3892/ol.2016.5550; Rohrbach TD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140870; Sarkaria JN, 2006, CLIN CANCER RES, V12, P2264, DOI 10.1158/1078-0432.CCR-05-2510; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tanabe A, 2006, BIOCHEM BIOPH RES CO, V345, P156, DOI 10.1016/j.bbrc.2006.04.082; Tchoghandjian A, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.214; Toulany M, 2015, SEMIN CANCER BIOL, V35, P180, DOI 10.1016/j.semcancer.2015.07.003; Vadlakondalf L, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00085; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wen PY, 2012, NEURO-ONCOLOGY, V14, P819, DOI 10.1093/neuonc/nos117; Wijaya J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122544; Willey CD, 2015, SEMIN RADIAT ONCOL, V25, P273, DOI 10.1016/j.semradonc.2015.05.008; Wlodkowic D, 2011, METHOD CELL BIOL, V103, P55, DOI 10.1016/B978-0-12-385493-3.00004-8; Zhivotovsky B, 2011, CELL CALCIUM, V50, P211, DOI 10.1016/j.ceca.2011.03.003	53	5	5	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2020	39	46					6961	6974		10.1038/s41388-020-01511-9	http://dx.doi.org/10.1038/s41388-020-01511-9		OCT 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OQ9FF	33077834	Green Accepted			2022-12-28	WOS:000579741400002
J	Zhang, SY; Guo, XM; Liu, XF; Zhong, ZX; Yang, SL; Wang, HH				Zhang, Shaoyang; Guo, Xueming; Liu, Xiufeng; Zhong, Zhixiong; Yang, Shulan; Wang, Haihe			Adaptor SH3BGRL promotes breast cancer metastasis through PFN1 degradation by translational STUB1 upregulation	ONCOGENE			English	Article							KAPPA-B; CELL MOTILITY; PROFILIN; PROTEIN; PROLIFERATION; SUPPRESSION; INHIBITION; BIOMARKER	Metastatic recurrence is still a major challenge in breast cancer treatment, but the underlying mechanisms remain unclear. Here, we report that a small adaptor protein, SH3BGRL, is upregulated in the majority of breast cancer patients, especially elevated in those with metastatic relapse, indicating it as a marker for the poor prognosis of breast cancer. Physiologically, SH3BGRL can multifunctionally promote breast cancer cell tumorigenicity, migration, invasiveness, and efficient lung colonization in nude mice. Mechanistically, SH3BGRL downregulates the acting-binding protein profilin 1 (PFN1) by accelerating the translation of the PFN1 E3 ligase, STUB1 via SH3BGRL interaction with ribosomal proteins, or/and enhancing the interaction of PFN1 with STUB1 to accelerate PFN1 degradation. Loss of PFN1 consequently contributes to downstream multiple activations of AKT, NF-B-k, and WNT signaling pathways. In contrast, the forced expression of compensatory PFN1 in SH3BGRL-high cells efficiently neutralizes SH3BGRL-induced metastasis and tumorigenesis with PTEN upregulation and PI3K-AKT signaling inactivation. Clinical analysis validates that SH3BGRL expression is negatively correlated with PFN1 and PTEN levels, but positively to the activations of AKT, NF-B-k, and WNT signaling pathways in breast patient tissues. Our results thus suggest that SH3BGRL is a valuable prognostic factor and a potential therapeutic target for preventing breast cancer progression and metastasis.	[Zhang, Shaoyang; Liu, Xiufeng; Yang, Shulan] Sun Yat Sen Univ, Affiliated Hosp 1, Translat Med Ctr, Guangzhou, Peoples R China; [Zhang, Shaoyang; Wang, Haihe] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Peoples R China; [Guo, Xueming; Zhong, Zhixiong] Meizhou City Peoples Hosp, Ctr Hlth Examinat, Guangzhou, Guangdong, Peoples R China; [Guo, Xueming; Zhong, Zhixiong] Guangdong Prov Key Lab Precis Med & Clin Translat, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Yang, SL (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Translat Med Ctr, Guangzhou, Peoples R China.; Wang, HH (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Peoples R China.	yangshl3@mail.sysu.edu.cn; wanghaih@mail.sysu.edu.cn		Yang, Shu-Lan/0000-0002-6864-2195; Zhong, Zhixiong/0000-0002-3200-3105; , Haihe/0000-0002-9302-2334; Guo, Xuemin/0000-0003-2929-7461	National Science Foundation of China [81672704]; Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translation Research of Hakka Population [2018B030322003KF02]; Natural Science Foundation of Guangdong Province [2021A1515010999]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translation Research of Hakka Population; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This work was supported by National Science Foundation of China (No. 81672704), the Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translation Research of Hakka Population (2018B030322003KF02), and Natural Science Foundation of Guangdong Province (No. 2021A1515010999) to WH.	Abba MC, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-37; Bae YH, 2010, P NATL ACAD SCI USA, V107, P21547, DOI 10.1073/pnas.1002309107; Bae YH, 2009, J CELL PHYSIOL, V219, P354, DOI 10.1002/jcp.21677; Birbach A, 2008, BIOESSAYS, V30, P994, DOI 10.1002/bies.20822; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; Choi YN, 2014, BIOCHEM BIOPH RES CO, V446, P1060, DOI 10.1016/j.bbrc.2014.03.061; Das T, 2009, J CELL PHYSIOL, V218, P436, DOI 10.1002/jcp.21618; Ding Z, 2014, ONCOGENE, V33, P2065, DOI 10.1038/onc.2013.166; Egeo A, 1998, BIOCHEM BIOPH RES CO, V247, P302, DOI 10.1006/bbrc.1998.8763; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gronborg M, 2006, MOL CELL PROTEOMICS, V5, P157, DOI 10.1074/mcp.M500178-MCP200; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hohenester E, 2013, CELL ADHES MIGR, V7, P56, DOI 10.4161/cam.21831; Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675; Jockusch BM, 2007, REV PHYSIOL BIOCH P, V159, P131, DOI 10.1007/112_2007_704; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Li H, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01577-z; Loibl S, 2021, LANCET, V397, P1750, DOI 10.1016/S0140-6736(20)32381-3; Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036; Majid SM, 2006, ONCOGENE, V25, P756, DOI 10.1038/sj.onc.1209107; Mouneimne G, 2012, CANCER CELL, V22, P615, DOI 10.1016/j.ccr.2012.09.027; Lino MAM, 2014, J PROTEOMICS, V111, P198, DOI 10.1016/j.jprot.2014.04.019; Nagaraj N, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.81; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tong F, 2016, DEV GENES EVOL, V226, P287, DOI 10.1007/s00427-016-0552-5; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Waks Adrienne G, 2019, JAMA, V321, P288, DOI 10.1001/jama.2018.19323; Wang H, 2016, ONCOGENE, V35, P3303, DOI 10.1038/onc.2015.391; Werner CJ, 2008, PROTEOME SCI, V6, DOI 10.1186/1477-5956-6-8; Witke W, 2004, TRENDS CELL BIOL, V14, P461, DOI 10.1016/j.tcb.2004.07.003; Wu N, 2006, PROTEOMICS, V6, P6095, DOI 10.1002/pmic.200500321; Xu LM, 2018, LEUKEMIA LYMPHOMA, V59, P918, DOI 10.1080/10428194.2017.1344843; Yarmola EG, 2006, TRENDS BIOCHEM SCI, V31, P197, DOI 10.1016/j.tibs.2006.02.006; Yin L, 2005, PROTEINS, V61, P213, DOI 10.1002/prot.20523; Zoidakis J, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.009449; Zou L, 2010, J CELL PHYSIOL, V223, P623, DOI 10.1002/jcp.22058	41	2	2	4	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5677	5690		10.1038/s41388-021-01970-8	http://dx.doi.org/10.1038/s41388-021-01970-8		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34331014				2022-12-28	WOS:000679620500003
J	Huang, SB; Deng, WG; Wang, P; Yan, Y; Xie, CB; Cao, XL; Chen, M; Zhang, CL; Shi, DB; Dong, YX; Cheng, P; Xu, HL; Zhu, WK; Hu, ZC; Tang, B; Zhu, JY				Huang, Shaobin; Deng, Wuguo; Wang, Peng; Yan, Yue; Xie, Chuanbo; Cao, Xiaoling; Chen, Miao; Zhang, Changlin; Shi, Dingbo; Dong, Yunxian; Cheng, Pu; Xu, Hailin; Zhu, Wenkai; Hu, Zhicheng; Tang, Bing; Zhu, Jiayuan			Fermitin family member 2 promotes melanoma progression by enhancing the binding of p-alpha-Pix to Rac1 to activate the MAPK pathway	ONCOGENE			English	Article							STAGE-III MELANOMA; METASTATIC MELANOMA; KINDLIN-2 PROMOTES; CANCER CELLS; BRAF; INHIBITION; VEMURAFENIB; RESISTANCE; SURVIVAL; MORTALITY	We identified fermitin family member 2 (FERMT2, also known as kindlin-2) as a potential target in A375 cell line by siRNA library screening. Drugs that target mutant BRAF kinase lack durable efficacy in the treatment of melanoma because of acquired resistance, thus the identification of novel therapeutic targets is needed. Immunohistochemistry was used to identify kindlin-2 expression in melanoma samples. The interaction between kindlin-2 and Rac1 or p-Rac/Cdc42 guanine nucleotide exchange factor 6 (alpha-Pix) was investigated. Finally, the tumor suppressive role of kindlin-2 was validated in vitro and in vivo. Analysis of clinical samples and Oncomine data showed that higher levels of kindlin-2 predicted a more advanced T stage and M stage and facilitated metastasis and recurrence. Kindlin-2 knockdown significantly inhibited melanoma growth and migration, whereas kindlin-2 overexpression had the inverse effects. Further study showed that kindlin-2 could specifically bind to p-alpha-Pix(S13) and Rac1 to induce a switch from the inactive Rac1-GDP conformation to the active Rac1-GTP conformation and then stimulate the downstream MAPK pathway. Moreover, we revealed that a Rac1 inhibitor suppressed melanoma growth and metastasis and the combination of the Rac1 inhibitor and vemurafenib resulted in a better therapeutic outcome than monotherapy in melanoma with high kindlin-2 expression and BRAF mutation. Our results demonstrated that kindlin-2 promoted melanoma progression, which was attributed to specific binding to p-alpha-Pix(S13) and Rac1 to stimulate the downstream MAPK pathway. Thus, kindlin-2 could be a potential therapeutic target for treating melanoma.	[Huang, Shaobin; Wang, Peng; Cao, Xiaoling; Dong, Yunxian; Cheng, Pu; Xu, Hailin; Hu, Zhicheng; Tang, Bing; Zhu, Jiayuan] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China; [Huang, Shaobin; Deng, Wuguo; Yan, Yue; Xie, Chuanbo; Chen, Miao; Zhang, Changlin; Shi, Dingbo] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China; [Huang, Shaobin] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China; [Zhu, Wenkai] Portland State Univ, Dept Chem, Portland, OR 97207 USA	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Portland State University	Hu, ZC; Tang, B; Zhu, JY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China.	huzhch5@mail.sysu.edu.cn; tangbing@mail.sysu.edu.cn; zhujiay@mail.sysu.edu.cn			National Natural Science Foundation of China [81702761, 81772925, 81871565]; Natural Science Foundation of Guangdong Province [2016A03031100, 2015A030313018]; Science and Technology Planning Project of Guangdong Province [2016B090916001]; Sun Yat-sen University Clinical Research 5010 Program [2013001, 2018003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Planning Project of Guangdong Province; Sun Yat-sen University Clinical Research 5010 Program	This work was supported in part by the National Natural Science Foundation of China (81702761, 81772925, 81871565), the Natural Science Foundation of Guangdong Province (2016A03031100, 2015A030313018), the Science and Technology Planning Project of Guangdong Province (2016B090916001), the Sun Yat-sen University Clinical Research 5010 Program (2013001, 2018003).	Amin MB, 2017, AJCC CANC STAGING MA, V8th; Balch C, 1992, RADIOTHERAPY MELANOM; Barbaric J, 2016, EUR J CANCER, V55, P47, DOI 10.1016/j.ejca.2015.11.019; Bottcher RT, 2017, J CELL BIOL, V216, P3785, DOI 10.1083/jcb.201701176; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Casado-Medrano V, 2018, BIOCHEM SOC T, V46, P1003, DOI 10.1042/BST20170519; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ducreux M, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919856494; Dudnik E, 2019, CLIN LUNG CANCER, V20, P278, DOI 10.1016/j.cllc.2019.03.007; Eggermont AMM, 2016, NEW ENGL J MED, V375, P1845, DOI 10.1056/NEJMoa1611299; Eggermont AMM, 2008, LANCET, V372, P117, DOI 10.1016/S0140-6736(08)61033-8; Falini B, 2019, HEMATOL ONCOL, V37, P30, DOI 10.1002/hon.2594; Fecher LA, 2008, CURR OPIN ONCOL, V20, P183, DOI 10.1097/CCO.0b013e3282f5271c; Feng JH, 2016, MOL CANCER THER, V15, P1163, DOI 10.1158/1535-7163.MCT-15-0973; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Guo L, 2018, J CELL BIOL, V217, P1431, DOI 10.1083/jcb.201612177; Guy GP, 2015, MMWR-MORBID MORTAL W, V64, P591; Haga Raquel B, 2016, Small GTPases, V7, P207; Halaban R, 2015, CLIN THER, V37, P682, DOI 10.1016/j.clinthera.2014.10.027; Hong M, 2019, CANCER MANAG RES, V11, P369, DOI 10.2147/CMAR.S186236; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; HUHN J, 2019, INT MICROBIOL; Joly MM, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0868-8; Kim G, 2014, CLIN CANCER RES, V20, P4994, DOI 10.1158/1078-0432.CCR-14-0776; KNIPPLER CM, 2019, ENDOCR RELAT CANC; Lin J, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0603-4; Long GV, 2017, ANN ONCOL, V28, P1631, DOI 10.1093/annonc/mdx176; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327; Ma J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066275; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Margiotta A, 2017, BBA-MOL CELL RES, V1864, P367, DOI 10.1016/j.bbamcr.2016.11.020; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Ou YW, 2016, ONCOTARGET, V7, P74872, DOI 10.18632/oncotarget.12439; Pedini F, 2019, MOL ONCOL, V13, P1836, DOI 10.1002/1878-0261.12506; Peng JX, 2019, ONCOL REP, V41, P224, DOI 10.3892/or.2018.6838; Pluskota E, 2017, J PHYSIOL-LONDON, V595, P6443, DOI 10.1113/JP274380; Qi LH, 2016, SCI CHINA LIFE SCI, V59, P1123, DOI 10.1007/s11427-016-0025-0; Qin Y, 2013, PIGM CELL MELANOMA R, V26, P97, DOI 10.1111/pcmr.12031; Robert C, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw435.37; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Sandru A, 2014, J Med Life, V7, P572; Shen ZL, 2013, J SURG ONCOL, V108, P106, DOI 10.1002/jso.23353; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Sossey-Alaoui K, 2017, CANCER RES, V77, P5129, DOI 10.1158/0008-5472.CAN-16-2337; Spagnolo F, 2015, ONCOTARGETS THER, V8, P157, DOI 10.2147/OTT.S39096; Sullivan RJ, 2019, NAT MED, V25, P929, DOI 10.1038/s41591-019-0474-7; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Wang P, 2018, INT J BIOCHEM CELL B, V105, P41, DOI 10.1016/j.biocel.2018.09.022; Wang P, 2017, SCI CHINA LIFE SCI, V60, P1214, DOI 10.1007/s11427-016-9044-5; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Wei CY, 2019, AGING-US, V11, P6273, DOI 10.18632/aging.102187; Wiebe CB, 2003, J PERIODONTOL, V74, P25, DOI 10.1902/jop.2003.74.1.25; Wu CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8531; Yang JR, 2016, GENE, V576, P571, DOI 10.1016/j.gene.2015.11.005; Yasuda-Yamahara M, 2018, MATRIX BIOL, V68-69, P263, DOI 10.1016/j.matbio.2018.01.003; Yoshida N, 2017, CANCER LETT, V390, P103, DOI 10.1016/j.canlet.2017.01.008; Zhou K, 2018, LAB INVEST, V98, P989, DOI 10.1038/s41374-018-0071-2	58	4	4	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5626	5638		10.1038/s41388-021-01954-8	http://dx.doi.org/10.1038/s41388-021-01954-8		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34321603	Green Published, hybrid			2022-12-28	WOS:000678443300002
J	Liu, Y; Nelson, MV; Bailey, C; Zhang, P; Zheng, P; Dome, JS; Liu, Y; Wang, Y				Liu, Yan; Nelson, Marie, V; Bailey, Christopher; Zhang, Peng; Zheng, Pan; Dome, Jeffrey S.; Liu, Yang; Wang, Yin			Targeting the HIF-1 alpha-IGFBP2 axis therapeutically reduces IGF1-AKT signaling and blocks the growth and metastasis of relapsed anaplastic Wilms tumor	ONCOGENE			English	Article							BINDING-PROTEIN 2; INDUCIBLE FACTOR 1-ALPHA; IGF-I RECEPTOR; GENE-EXPRESSION; BREAST-CANCER; STEM-CELLS; HYPOXIA; PTEN; SURVIVAL; IGFBP-2	For patients with anaplastic Wilms tumor (WiT), metastasis and recurrence are common, and prognosis is generally poor. Novel therapies are needed to improve outcomes for patients with this high-risk WiT. A potential contributor to WiT development is constitutive activation of AKT by insulin-like growth factor 1 (IGF1) and its receptor (IGF1R) signaling pathway, but the complete underlying mechanism remains unclear. Here, we demonstrate that the hypoxia-inducible factor 1 alpha (HIF-1 alpha)-IGF binding protein 2 (IGFBP2) axis and the tumor-specific IGF1A are key players for constitutive activation of IGF1-AKT signaling leading to the tumor malignancy. HIF-1 alpha and IGFBP2 are highly expressed in a majority of WiT patient samples. Deficiency of either HIF-1 alpha or IGFBP2 or IGF1 in the tumor cells significantly impairs tumor growth and nearly abrogates metastasis in xenografted mice. Pharmacologic targeting of HIF-1 alpha by echinomycin delivered via nanoliposomes can efficiently restrain growth and metastasis of patient-derived relapsed anaplastic WiT xenografts. Liposomal echinomycin is more potent and effective in inhibiting WiT growth than vincristine in an anaplastic WiT mouse model, and eliminates metastasis by suppressing HIF-1 alpha targets and the HIF-1 alpha-IGFBP2 axis, which governs IGF1-AKT signaling.	[Liu, Yan; Bailey, Christopher; Zhang, Peng; Zheng, Pan; Liu, Yang; Wang, Yin] Univ Maryland, Sch Med, Inst Human Virol, Div Canc & Immunol Res, Baltimore, MD 21201 USA; [Nelson, Marie, V; Dome, Jeffrey S.] Childrens Natl Hosp, Ctr Canc & Immunol Res, Washington, DC USA; [Zheng, Pan; Liu, Yang] OncoC4 Inc, Rockville, MD 20850 USA	University System of Maryland; University of Maryland Baltimore; Children's National Health System	Liu, Y; Liu, Y; Wang, Y (corresponding author), Univ Maryland, Sch Med, Inst Human Virol, Div Canc & Immunol Res, Baltimore, MD 21201 USA.; Liu, Y (corresponding author), OncoC4 Inc, Rockville, MD 20850 USA.	yanliu@ihv.umaryland.edu; ywang@ihv.umaryland.edu		Wang, Yin/0000-0002-4749-3768	National Institutes of Health National Cancer Institute [CA171972, CA183030, CA219150, CA227671]	National Institutes of Health National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the grants from the National Institutes of Health National Cancer Institute CA171972, CA183030 (Y.L.), and CA219150, CA227671 (Y.W.).	Alami J, 2003, INT J CANCER, V107, P365, DOI 10.1002/ijc.11429; Ambrosini-Spaltro A, 2011, APPL IMMUNOHISTO M M, V19, P318, DOI 10.1097/PAI.0b013e3128052936; Bailey CM, 2020, NANOMED-NANOTECHNOL, V29, DOI 10.1016/j.nano.2020.102278; Barton ER, 2010, J APPL PHYSIOL, V108, P1069, DOI 10.1152/japplphysiol.01308.2009; Bielen A, 2012, P NATL ACAD SCI USA, V109, pE1267, DOI 10.1073/pnas.1105034109; Brahmkhatri VP, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/538019; Chekhonin VP, 2013, CURR CANCER DRUG TAR, V13, P423, DOI 10.2174/15680096113139990074; Chen XL, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-72; De Bels D, 2011, NEW ENGL J MED, V365, P1845, DOI 10.1056/NEJMc1110602; Dean SJR, 2014, AM J CLIN PATHOL, V141, P323, DOI 10.1309/AJCPR11DEAYPTUSL; Dome JS, 2015, J CLIN ONCOL, V33, P2999, DOI 10.1200/JCO.2015.62.1888; Dome JS, 2002, J PEDIAT HEMATOL ONC, V24, P192, DOI 10.1097/00043426-200203000-00007; Dungwa JV, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-390; Durzynska J, 2013, ENDOCRINOLOGY, V154, P1215, DOI 10.1210/en.2012-1992; Emerling BM, 2008, P NATL ACAD SCI USA, V105, P2622, DOI 10.1073/pnas.0706790105; Feldser D, 1999, CANCER RES, V59, P3915; Foulstone EJ, 2013, ENDOCRINOLOGY, V154, P1780, DOI 10.1210/en.2012-1970; Geller JI, 2016, UROL ONCOL-SEMIN ORI, V34, P50, DOI 10.1016/j.urolonc.2015.10.012; GERMAINLEE EL, 1992, BIOCHEM J, V281, P413, DOI 10.1042/bj2810413; HASELBACHER GK, 1987, P NATL ACAD SCI USA, V84, P1104, DOI 10.1073/pnas.84.4.1104; Hu QH, 2011, J CLIN INVEST, V121, P174, DOI 10.1172/JCI43772; Hua H, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00904-3; Huang YF, 2008, BRIT J CANCER, V99, P1096, DOI 10.1038/sj.bjc.6604661; Karth J, 2000, J PEDIATR SURG, V35, P1749, DOI 10.1053/jpsu.2000.19241; Kim YW, 2013, INT J ONCOL, V43, P539, DOI 10.3892/ijo.2013.1961; King ER, 2011, GYNECOL ONCOL, V123, P13, DOI 10.1016/j.ygyno.2011.06.016; Liou JM, 2010, J CLIN ENDOCR METAB, V95, P1717, DOI 10.1210/jc.2009-2668; Lu J, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0197-x; Mavinkurve-Groothuis AMC, 2015, PEDIATR BLOOD CANCER, V62, P598, DOI 10.1002/pbc.25357; Mireuta M, 2010, GROWTH FACTORS, V28, P243, DOI 10.3109/08977191003745472; Miyamoto S, 2007, CANCER SCI, V98, P685, DOI 10.1111/j.1349-7006.2007.00448.x; Newman B, 2012, CANCER RES, V72, P4551, DOI 10.1158/0008-5472.CAN-11-3600; Perks CM, 2007, ONCOGENE, V26, P5966, DOI 10.1038/sj.onc.1210397; Qiang L, 2012, CELL DEATH DIFFER, V19, P284, DOI 10.1038/cdd.2011.95; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; Rigiracciolo DC, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9041010; ROGHANI M, 1991, J CLIN ENDOCR METAB, V73, P658, DOI 10.1210/jcem-73-3-658; Sasso G, 2010, J PEDIAT HEMATOL ONC, V32, pE264, DOI 10.1097/MPH.0b013e3181e7931a; SCHILSKY RL, 1991, INVEST NEW DRUG, V9, P269; Sciarra A, 2010, EUR UROL, V58, P315, DOI 10.1016/j.eururo.2010.05.019; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; Shen XC, 2012, MOL CELL BIOL, V32, P4116, DOI 10.1128/MCB.01011-12; Shiratsuchi I, 2011, ANTICANCER RES, V31, P2541; Simpson A, 2017, TARGET ONCOL, V12, P571, DOI 10.1007/s11523-017-0514-5; VINCENT TS, 1994, PEDIATR PATHOL, V14, P723, DOI 10.3109/15513819409023344; Wamaitha SE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14629-x; Wang HM, 2006, MODERN PATHOL, V19, P1149, DOI 10.1038/modpathol.3800637; Wang Y, 2020, ONCOGENE, V39, P3015, DOI 10.1038/s41388-020-1201-z; Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006; Wegert J, 2017, J PATHOL CLIN RES, V3, P234, DOI 10.1002/cjp2.77; Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009; Yau SW, 2015, J CELL COMMUN SIGNAL, V9, P125, DOI 10.1007/s12079-015-0261-2; ZUMKELLER W, 1993, EUR J CANCER, V29A, P1973, DOI 10.1016/0959-8049(93)90455-O; Zundel W, 2000, GENE DEV, V14, P391	55	5	5	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4809	4819		10.1038/s41388-021-01907-1	http://dx.doi.org/10.1038/s41388-021-01907-1		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34155347	Green Accepted			2022-12-28	WOS:000664006700002
J	McAndrews, KM; Vazquez-Arreguin, K; Kwak, C; Sugimoto, H; Zheng, XF; Li, BR; Kirtley, ML; LeBleu, VS; Kalluri, R				McAndrews, Kathleen M.; Vazquez-Arreguin, Karina; Kwak, Changsoo; Sugimoto, Hikaru; Zheng, Xiaofeng; Li, Bingrui; Kirtley, Michelle L.; LeBleu, Valerie S.; Kalluri, Raghu			alpha SMA(+) fibroblasts suppress Lgr5(+) cancer stem cells and restrain colorectal cancer progression	ONCOGENE			English	Article							CARCINOMA-ASSOCIATED FIBROBLASTS; GROWTH-FACTOR-BETA; MOLECULAR SUBTYPES; GENE-EXPRESSION; TUMOR; METASTASIS; IDENTIFICATION; PHENOTYPE; STROMA; MODEL	The development and progression of solid tumors is dependent on cancer cell autonomous drivers and the tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs) in the TME possess both tumor-promoting and tumor-restraining functions. In the current study, we interrogated the role of alpha SMA(+) CAFs in a genetic mouse model of metastatic colorectal cancer (CRC). Selective depletion of alpha SMA(+) CAFs resulted in increased tumor invasiveness, lymph node metastasis, and reduced overall survival. Depletion of alpha SMA(+) CAFs reduced BMP4 and increased TGF beta 1 secretion from stromal cells, and was associated with increased Lgr5(+) cancer stem-like cells (CSCs) and the generation of an immunosuppressive TME with increased frequency of Foxp3(+) regulatory T cells and suppression of CD8(+) T cells. This study demonstrates that alpha SMA(+) CAFs in CRC exert tumor-restraining functions via BMP4/TGF beta 1 paracrine signaling that serves to suppress Lgr5(+) CSCs and promote anti-tumor immunity, ultimately limiting CRC progression.	[McAndrews, Kathleen M.; Vazquez-Arreguin, Karina; Kwak, Changsoo; Sugimoto, Hikaru; Zheng, Xiaofeng; Li, Bingrui; Kirtley, Michelle L.; LeBleu, Valerie S.; Kalluri, Raghu] Univ Texas MD Anderson Canc Ctr, Metastasis Res Ctr, Dept Canc Biol, Houston, TX 77030 USA; [LeBleu, Valerie S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Kalluri, Raghu] Rice Univ, Dept Bioengn, Houston, TX 77005 USA; [Kalluri, Raghu] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Northwestern University; Feinberg School of Medicine; Rice University; Baylor College of Medicine	Kalluri, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Metastasis Res Ctr, Dept Canc Biol, Houston, TX 77030 USA.; Kalluri, R (corresponding author), Rice Univ, Dept Bioengn, Houston, TX 77005 USA.; Kalluri, R (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	rkalluri@mdanderson.org	Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X; McAndrews, Kathleen/0000-0002-4092-4991	MD Anderson Cancer Center; Ruth L. Kirschstein National Research Service Award [5T32CA186892, CA016672]	MD Anderson Cancer Center; Ruth L. Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by research funds provided by the MD Anderson Cancer Center. KV-A is supported by Ruth L. Kirschstein National Research Service Award 5T32CA186892. We thank Dr. Ronald DePinho for providing the iKAP mouse model and for insightful comments on the manuscript. We thank Dr. Adam Boutin for his generous help with the project, Dr. Krishnan Mahadevan for advice on proliferative index determination, and Patience Kelly for assistance with slide scanning and staining. The Advanced Technology Genomics Core is supported by the core grant CA016672(ATCG).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Becker LM, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107701; Blockhuys S, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.10.106006; Boutin AT, 2017, GENE DEV, V31, P370, DOI 10.1101/gad.293449.116; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Centers for Disease Control and Prevention, 2019, COL CANC STAT; Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023; Damaghi M, 2020, EVOL APPL, V13, P2689, DOI 10.1111/eva.13075; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fiori ME, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0994-2; Fu S, 2004, AM J TRANSPLANT, V4, P1614, DOI 10.1111/j.1600-6143.2004.00566.x; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; HAGGITT RC, 1985, GASTROENTEROLOGY, V89, P326; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Kobayashi H, 2021, GASTROENTEROLOGY, V160, P1224, DOI 10.1053/j.gastro.2020.11.011; LeBleu VS, 2020, FASEB J, V34, P3519, DOI 10.1096/fj.201903188R; LeBleu VS, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.029447; LeBleu VS, 2013, NAT MED, V19, P1047, DOI 10.1038/nm.3218; LeBleu VS, 2013, NAT MED, V19, P227, DOI 10.1038/nm.2989; Liu L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159947; Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ma HJ, 2014, CANCER LETT, V344, P74, DOI 10.1016/j.canlet.2013.10.017; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; Moo-Young TA, 2009, J IMMUNOTHER, V32, P12, DOI 10.1097/CJI.0b013e318189f13c; Nakanishi Y, 2013, NAT GENET, V45, P98, DOI 10.1038/ng.2481; Nurmik M, 2020, INT J CANCER, V146, P895, DOI 10.1002/ijc.32193; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Otranto M, 2012, CELL ADHES MIGR, V6, P203, DOI 10.4161/cam.20377; Powell DW, 2011, ANNU REV PHYSIOL, V73, P213, DOI 10.1146/annurev.physiol.70.113006.100646; Qi Z, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13824; Roulis M, 2020, NATURE, V580, P524, DOI 10.1038/s41586-020-2166-3; Sadanandam A, 2014, CELL CYCLE, V13, P353, DOI 10.4161/cc.27769; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Stzepourginski I, 2017, P NATL ACAD SCI USA, V114, pE506, DOI 10.1073/pnas.1620059114; Vellinga TT, 2016, ONCOGENE, V35, P5263, DOI 10.1038/onc.2016.60; Veschi V, 2020, ONCOGENE, V39, P987, DOI 10.1038/s41388-019-1047-4; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; Wan YY, 2007, IMMUNOL REV, V220, P199, DOI 10.1111/j.1600-065X.2007.00565.x; Woolston A, 2019, CANCER CELL, V36, P35, DOI 10.1016/j.ccell.2019.05.013; Wu XB, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108708; Zhang YC, 2020, ANNU REV PHYSIOL, V82, P251, DOI 10.1146/annurev-physiol-021119-034500; Zhang ZY, 2018, INT J ONCOL, V53, P1869, DOI 10.3892/ijo.2018.4536	53	9	9	3	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4440	4452		10.1038/s41388-021-01866-7	http://dx.doi.org/10.1038/s41388-021-01866-7		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34108617	Green Accepted			2022-12-28	WOS:000659470200006
J	Snigdha, K; Singh, A; Kango-Singh, M				Snigdha, Kirti; Singh, Amit; Kango-Singh, Madhuri			Yorkie-Cactus (I kappa B alpha)-JNK axis promotes tumor growth and progression in Drosophila	ONCOGENE			English	Article							CELL POLARITY; ONCOGENIC RAS; MATRIX METALLOPROTEINASES; TISSUE OVERGROWTH; IMMUNE-RESPONSE; NECROSIS-FACTOR; HIPPO PATHWAY; JNK; RECEPTOR; CANCER	Presence of inflammatory factors in the tumor microenvironment is well-documented yet their specific role in tumorigenesis is elusive. The core inflammatory pathways like the Toll-Like Receptor (TLR) and the Tumor Necrosis Factor (TNF) pathway are conserved in Drosophila. We induced GFP-marked epithelial tumors by expressing activated oncogenic forms of Ras(V12) or Yorkie (Yki(3SA), mammalian YAP) in scribble deficient cells (scrib(RNAi), mammalian SCRIB) to study the role of inflammatory factors in tumorigenesis. Similar to Ras(V12)scrib(RNAi), we found that Yki(3SA)scrib(RNAi) form invasive neoplastic lethal tumors that induce a systemic inflammatory response. We identified Cactus (Cact, mammalian I kappa B alpha), the negative regulator of TLR, as a key player in tumor growth. Cact accumulates in the cytoplasm in Drosophila tumor models, similar to squamous cell carcinoma in mice models and human patients where cytoplasmic I kappa B alpha favors oncogenic transformation. Further, cact is transcriptionally upregulated in tumors, and downregulation of Cact affects tumor growth. We investigated if TLR or TNF pathway affect tumor growth through activation of Jun N-terminal Kinase (JNK) pathway and its target Matrix Metalloprotease1 (MMP1). Genetically manipulating levels of TLR components or TNF receptors showed that Cact acts upstream of JNK signaling and regulates JNK via a non-canonical mechanism during tumorigenesis. Further, Hippo coactivator Yki transcriptionally regulates cact expression, and downregulation of Yki or Cact is sufficient to cause downregulation of JNK-mediated signaling that promotes tumorigenesis. Here, we report a link between Hippo, I kappa B alpha and JNK signaling that may induce inflammation and innate immune response in tumorigenesis.	[Snigdha, Kirti; Singh, Amit; Kango-Singh, Madhuri] Univ Dayton, Dept Biol, Dayton, OH 45469 USA; [Singh, Amit; Kango-Singh, Madhuri] Univ Dayton, Ctr Tissue Regenerat & Engn Dayton TREND, Dayton, OH 45469 USA; [Singh, Amit; Kango-Singh, Madhuri] Univ Dayton, Premed Programs, Dayton, OH 45469 USA; [Singh, Amit; Kango-Singh, Madhuri] Univ Dayton, Integrat Sci & Engn Ctr ISE, Dayton, OH 45469 USA	University of Dayton; University of Dayton; University of Dayton; University of Dayton	Kango-Singh, M (corresponding author), Univ Dayton, Dept Biol, Dayton, OH 45469 USA.; Kango-Singh, M (corresponding author), Univ Dayton, Ctr Tissue Regenerat & Engn Dayton TREND, Dayton, OH 45469 USA.; Kango-Singh, M (corresponding author), Univ Dayton, Premed Programs, Dayton, OH 45469 USA.; Kango-Singh, M (corresponding author), Univ Dayton, Integrat Sci & Engn Ctr ISE, Dayton, OH 45469 USA.	mkangosingh1@udayton.edu		Kango-Singh, Madhuri/0000-0003-2447-6997; Singh, Amit/0000-0002-2962-2255; SNIGDHA, KIRTI/0000-0002-8618-1628	Graduate Program of University of Dayton; Schuellein Endowed Chair in Biology from University of Dayton; NIH [1R15 GM124654-1, R01CA183991]; University of Dayton	Graduate Program of University of Dayton; Schuellein Endowed Chair in Biology from University of Dayton; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Dayton	We would like to thank the anonymous reviewers for their helpful comments that have helped make this manuscript better. We thank Dr. A. Bergmann, Dr. Stephen Cohen, the Bloomington Drosophila Stock Center, and the Drosophila Studies Hybridoma Bank for flies and antibodies. KS acknowledges the Teaching Assistantship and Graduate Student Summer Fellowship from the Graduate Program of University of Dayton. AS is supported by funding from Start-up research funds, the Schuellein Endowed Chair in Biology from the University of Dayton, and NIH 1R15 GM124654-1. MKS is supported by start-up research funds from the University of Dayton, and a subaward from NIH grant R01CA183991 (PI Nakano).	Andersen DS, 2015, NATURE, V522, P482, DOI 10.1038/nature14298; Arefin B, 2017, G3-GENES GENOM GENET, V7, P2139, DOI 10.1534/g3.117.039487; Atkins M, 2016, CURR BIOL, V26, P2101, DOI 10.1016/j.cub.2016.06.035; Beaucher M, 2007, DEV BIOL, V303, P625, DOI 10.1016/j.ydbio.2006.12.001; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Bergmann A, 1996, MECH DEVELOP, V60, P109, DOI 10.1016/S0925-4773(96)00607-7; BIREMBAUT P, 1985, J PATHOL, V145, P283, DOI 10.1002/path.1711450402; Bretscher AJ, 2015, BIOL OPEN, V4, P355, DOI 10.1242/bio.201410595; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Bunker BD, 2015, ELIFE, V4, DOI 10.7554/eLife.03189; Byun PK, 2019, CURR BIOL, V29, P2790, DOI 10.1016/j.cub.2019.07.012; Mulero MC, 2013, CANCER CELL, V24, P151, DOI 10.1016/j.ccr.2013.06.003; Cellurale C, 2011, MOL CELL BIOL, V31, P1565, DOI 10.1128/MCB.01122-10; Chen CL, 2012, P NATL ACAD SCI USA, V109, P484, DOI 10.1073/pnas.1113882109; Cordero JB, 2010, DEV CELL, V18, P999, DOI 10.1016/j.devcel.2010.05.014; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Doggett K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-57; Dominguez M, 2014, SEMIN CELL DEV BIOL, V28, P78, DOI 10.1016/j.semcdb.2014.04.012; Enomoto M, 2015, DEV BIOL, V403, P162, DOI 10.1016/j.ydbio.2015.05.001; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; Germani F, 2018, GENETICS, V208, P473, DOI 10.1534/genetics.117.300256; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hauling T, 2014, BIOL OPEN, V3, P250, DOI 10.1242/bio.20146494; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hong X, 2014, EMBO J, V33, P2447, DOI 10.15252/embj.201489385; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Ito K, 1997, DEVELOPMENT, V124, P761; Kanda H, 2002, J BIOL CHEM, V277, P28372, DOI 10.1074/jbc.C200324200; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Kango-Singh M, 2003, DEV BIOL, V256, P48, DOI 10.1016/S0012-1606(02)00123-9; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kauppila S, 2003, ONCOGENE, V22, P4860, DOI 10.1038/sj.onc.1206715; Kulshammer E, 2015, DIS MODEL MECH, V8, P1279, DOI 10.1242/dmm.020719; La Marca JE, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00042; Liu B, 2016, CELL, V164, P406, DOI 10.1016/j.cell.2015.12.029; Ma X, 2016, ONCOGENE, V35, P846, DOI 10.1038/onc.2015.137; Ma XJ, 2015, P NATL ACAD SCI USA, V112, P1065, DOI 10.1073/pnas.1415020112; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mao YP, 2017, ONCOTARGET, V8, P110877, DOI 10.18632/oncotarget.22865; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Martinelli C, 2005, J ENDOTOXIN RES, V11, P243, DOI 10.1179/09680510SX37411; Mishra-Gorur K, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039727; Morimoto Kenta, 2017, J Vis Exp, DOI 10.3791/55901; Muzzopappa M, 2017, P NATL ACAD SCI USA, V114, pE7291, DOI 10.1073/pnas.1701791114; Villegas SN, 2018, CELL REP, V22, P2541, DOI 10.1016/j.celrep.2018.02.049; Oh H, 2009, DEV BIOL, V335, P188, DOI 10.1016/j.ydbio.2009.08.026; Ohsawa S, 2011, DEV CELL, V20, P315, DOI 10.1016/j.devcel.2011.02.007; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Parisi F, 2014, CELL REP, V6, P855, DOI 10.1016/j.celrep.2014.01.039; Parvy JP, 2019, ELIFE, V8, DOI 10.7554/eLife.45061; Patel PH, 2015, NAT CELL BIOL, V17, P1182, DOI 10.1038/ncb3214; Ramet M, 2002, DEV BIOL, V241, P145, DOI 10.1006/dbio.2001.0502; ROTH S, 1991, DEVELOPMENT, V112, P371; Rudrapatna VA, 2014, ONCOGENE, V33, P2801, DOI 10.1038/onc.2013.232; Shaukat Z, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/369286; Snigdha K, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00085; Sun GP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004324; Sun GP, 2011, DEV BIOL, V350, P139, DOI 10.1016/j.ydbio.2010.11.036; Tournier Cathy, 2013, Genes Cancer, V4, P397, DOI 10.1177/1947601913486349; Tremmel DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067789; Tzou P, 2000, IMMUNITY, V13, P737, DOI 10.1016/S1074-7613(00)00072-8; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Valanne S, 2011, J IMMUNOL, V186, P649, DOI 10.4049/jimmunol.1002302; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Verghese S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047173; Vidal M, 2007, CANCER RES, V67, P10278, DOI 10.1158/0008-5472.CAN-07-1376; Waghmare I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158081; Wang X, 2008, ACTA PHARMACOL SIN, V29, P1275, DOI 10.1111/j.1745-7254.2008.00889.x; Willsey HR, 2016, ELIFE, V5, DOI 10.7554/eLife.11491; Yang CC, 2015, P NATL ACAD SCI USA, V112, P1785, DOI 10.1073/pnas.1420850112; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049	80	1	1	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4124	4136		10.1038/s41388-021-01831-4	http://dx.doi.org/10.1038/s41388-021-01831-4		MAY 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34017079				2022-12-28	WOS:000652439200003
J	Yang, WT; Chen, M; Xu, R; Zheng, PS				Yang, Wen-Ting; Chen, Mei; Xu, Rui; Zheng, Peng-Sheng			PRDM4 inhibits cell proliferation and tumorigenesis by inactivating the PI3K/AKT signaling pathway through targeting of PTEN in cervical carcinoma	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; TROPHOBLAST INVASION; STEM-CELLS; CANCER; GENE; METHYLATION; EXPRESSION; MUTATION; FAMILY	PR domain zinc finger protein 4 (PRDM4) is a transcription factor that plays key roles in stem cell self-renewal and tumorigenesis. However, its biological role and exact mechanism in cervical cancer remain unknown. Here, both immunohistochemistry (IHC) and Western blot assays demonstrated that the expression of PRDM4 in cervical cancer tissues was much lower than that in the normal cervix. A xenograft assay showed that PRDM4 overexpression in the cervical cancer cell lines SiHa and HeLa dramatically inhibited cell proliferation and tumorigenic potential in vivo. Conversely, the silencing of PRDM4 promoted cervical cancer cell proliferation and tumorigenic potential. Mechanistically, PRDM4 induced cell cycle arrest at the transition from G0/G1 phase to S phase by upregulating p27 and p21 expression and downregulating Cyclin D1 and CDK4 expression. Furthermore, the PI3K/AKT signaling pathway was inactivated in PRDM4-overexpressing cells, which decreased the levels of p-AKT and upregulated the expression of PTEN, an inhibitor of the PI3K/AKT signaling pathway, at both the transcriptional and translational levels. Dual-luciferase reporter assays and qChIP assays confirmed that PRDM4 transactivated the expression of PTEN by binding to two specific regions in the PTEN promoter. Furthermore, PTEN silencing or a PTEN inhibitor rescued the cell defects induced by PRDM4 overexpression. Therefore, our data suggest that PRDM4 inhibits cell proliferation and tumorigenesis by downregulating the activity of the PI3K/AKT signaling pathway by directly transactivating PTEN expression in cervical cancer.	[Yang, Wen-Ting; Chen, Mei; Zheng, Peng-Sheng] Xi An Jiao Tong Univ, Dept Reprod Med, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China; [Yang, Wen-Ting; Zheng, Peng-Sheng] Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Xian, Shaanxi, Peoples R China; [Xu, Rui] Xi An Jiao Tong Univ, Shaanxi Canc Hosp, Coll Med, Dept Internal Med 1, Xian, Peoples R China	Xi'an Jiaotong University; Ministry of Education, China; Xi'an Jiaotong University	Zheng, PS (corresponding author), Xi An Jiao Tong Univ, Dept Reprod Med, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China.; Zheng, PS (corresponding author), Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Xian, Shaanxi, Peoples R China.	zpsheng@mail.xjtu.edu.cn			National Natural Science Foundation of China [81472728, 81672910, 81602307]; Xi'an Municipal Science and Technology Bureau [2019115213YX007SF040(6)]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Xi'an Municipal Science and Technology Bureau	This work was supported by a grant from the National Natural Science Foundation of China (Nos 81472728, 81672910, and 81602307) and the Xi'an Municipal Science and Technology Bureau (No. 2019115213YX007SF040(6)).	Bikoff EK, 2008, NAT GENET, V40, P934, DOI 10.1038/ng0808-934; Bogani D, 2013, MOL CELL BIOL, V33, P3936, DOI 10.1128/MCB.00498-13; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Carnero A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00252; Casamassimi A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072648; Chittka A, 2012, J BIOL CHEM, V287, P42995, DOI 10.1074/jbc.M112.392746; Cui N, 2016, ONCOTARGET, V7, P26152, DOI 10.18632/oncotarget.8434; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8; Di Zazzo Erika, 2013, Biology (Basel), V2, P107, DOI 10.3390/biology2010107; Fog CK, 2012, BIOESSAYS, V34, P50, DOI 10.1002/bies.201100107; Hadziselimovic F, 2018, GENES-BASEL, V9, DOI 10.3390/genes9080391; Harima Y, 2001, INT J ONCOL, V18, P493; Hohenauer T, 2012, DEVELOPMENT, V139, P2267, DOI 10.1242/dev.070110; Kedde M, 2010, NAT CELL BIOL, V12, P1014, DOI 10.1038/ncb2105; LI L, 2018, CELL DEATH DIS, V9; Liu H, 2018, EMBO REP, V19, DOI 10.15252/embr.201745180; Liu XL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0081-9; Ma X, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171612; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Naseem A, 2019, J CELL BIOCHEM, V120, P15851, DOI 10.1002/jcb.28856; Orel N, 2007, J Stem Cells Regen Med, V2, P216; Rizvi MMA, 2011, J CANCER RES CLIN, V137, P1255, DOI 10.1007/s00432-011-0994-0; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song NJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0904-3; Su TH, 2000, GYNECOL ONCOL, V76, P193, DOI 10.1006/gyno.1999.5659; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wang HY, 2015, ONCOTARGET, V6, P20711, DOI 10.18632/oncotarget.4133; Wen SY, 2015, ONCOGENE, V34, P717, DOI 10.1038/onc.2014.9; Yang WT, 2012, CANCER-AM CANCER SOC, V118, P3691, DOI 10.1002/cncr.26698; Yang XH, 1999, GENOMICS, V61, P319, DOI 10.1006/geno.1999.5967; Zeng YT, 2019, ONCOGENE, V38, P6940, DOI 10.1038/s41388-019-0906-3; Zhang J, 2018, BIOMED PHARMACOTHER, V100, P168, DOI 10.1016/j.biopha.2018.02.016; Zhang Y, 2020, MOL THER, V28, P631, DOI 10.1016/j.ymthe.2019.11.025; Zhang Y, 2017, MOL THER, V25, P2394, DOI 10.1016/j.ymthe.2017.06.028; Zhu Zhaohui, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P354	35	3	3	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3318	3330		10.1038/s41388-021-01765-x	http://dx.doi.org/10.1038/s41388-021-01765-x		APR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33846573	Green Published, hybrid			2022-12-28	WOS:000639635100004
J	Hao, TS; Zhang, CX; Wang, ZQ; Buck, A; Vonderfecht, SL; Ermel, R; Kim, Y; Chen, WY				Hao, Taisen; Zhang, Chunxiao; Wang, Zhiqiang; Buck, Alison; Vonderfecht, Steven L.; Ermel, Richard; Kim, Young; Chen, WenYong			An aging mouse model of human chronic myeloid leukemia	ONCOGENE			English	Article								Chronic myeloid leukemia (CML) is an age-dependent blood malignancy. Like many other age-dependent human diseases, laboratory animal research of CML uses young mice that do not factor in the influence of aging. To understand how aging may impact animal modeling of human age-dependent diseases, we established the first aging mouse model of human CML in BALB/c mice in the advanced age defined by 75% survival. This model was developed by noncytotoxic depletion of bone marrow lineage-positive cells followed by BCR-ABL retroviral transduction and transplantation. CML developed in aging mice shared many similarities to that in young mice, but had increased incidence of anemia that is often seen in human CML. Importantly, we showed that aging of both donor hematopoietic stem cells and recipient bone marrow niche impacted BCR-ABL mediated leukemogenesis and leukemia spectrum. Optimal CML induction relied on age-matching for donors and recipients, and cross-transplantation between young and old mice produced a mixture of different leukemia. Therefore, our model provides initial evidence of the feasibility and merit of CML modeling in aging mice and offers a new tool for future studies of CML stem cell drug resistance and therapeutic intervention in which aging would be taken into consideration as an influencing factor.	[Hao, Taisen; Zhang, Chunxiao; Wang, Zhiqiang; Chen, WenYong] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA; [Buck, Alison] City Hope Natl Med Ctr, Eugene & Ruth Roberts Summer Student Acad, Duarte, CA USA; [Vonderfecht, Steven L.] Vet Pathol, Reno, NV USA; [Ermel, Richard] City Hope Natl Med Ctr, Beckman Res Inst, Ctr Comparat Med, Duarte, CA USA; [Kim, Young] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope	Chen, WY (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA.	wechen@coh.org		Zhang, Chunxiao/0000-0001-5543-4509; Chen, WenYong/0000-0001-6913-5729	NIH National Cancer Institute and National Institute of Aging [UH2/3 CA213385]; NIH Office of the Director [3UH3CA213385-05S1]; City of Hope Center for Cancer and Aging; Norton Basic Research Fund; National Cancer Institute [P30CA33572]	NIH National Cancer Institute and National Institute of Aging; NIH Office of the Director(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); City of Hope Center for Cancer and Aging; Norton Basic Research Fund; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the grants UH2/3 CA213385 (co-sponsored by NIH National Cancer Institute and National Institute of Aging) and 3UH3CA213385-05S1 (sponsored by NIH Office of the Director), as well as institutional grants from the City of Hope Center for Cancer and Aging, and Norton Basic Research Fund to WYC. Research reported in this publication included work performed in the Animal Resources Center and Flow Cytometry Core supported by the National Cancer Institute under the award P30CA33572. The content is solely the responsibility of the authors and do not necessarily represent the official views of the NIH.	Alexander TB, 2018, NATURE, V562, P373, DOI 10.1038/s41586-018-0436-0; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Brubaker AL, 2013, J IMMUNOL, V190, P1746, DOI 10.4049/jimmunol.1201213; Butcher SK, 2001, J LEUKOCYTE BIOL, V70, P881; Chomel JC, 2011, BLOOD, V118, P3657, DOI 10.1182/blood-2011-02-335497; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; de Haan G, 2018, BLOOD, V131, P479, DOI 10.1182/blood-2017-06-746412; Deininger MWN, 2003, PHARMACOL REV, V55, P401, DOI 10.1124/pr.55.3.4; Dell Ralph B, 2002, ILAR J, V43, P207; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Duarte D, 2018, BLOOD, V131, P1507, DOI 10.1182/blood-2017-12-784132; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Florian MC, 2012, CELL STEM CELL, V10, P520, DOI 10.1016/j.stem.2012.04.007; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hamamyh T, 2020, PHARMACOLOGY, V105, P630, DOI 10.1159/000507295; Hao T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48445-1; Hehlmann R, 2007, LANCET, V370, P342, DOI 10.1016/S0140-6736(07)61165-9; Helbling PM, 2019, CELL REP, V29, P3313, DOI 10.1016/j.celrep.2019.11.004; Ho YH, 2020, HAEMATOLOGICA, V105, P38, DOI 10.3324/haematol.2018.211334; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; Hsieh MY, 2014, BLOOD, V123, P2401, DOI 10.1182/blood-2014-01-547943; Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Ko PS, 2017, CURR MED RES OPIN, V33, P1737, DOI 10.1080/03007995.2017.1356708; Koptyra M, 2006, BLOOD, V108, P319, DOI 10.1182/blood-2005-07-2815; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Liu ZY, 2020, HEMATOLOGY, V25, P181, DOI 10.1080/16078454.2020.1765563; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; Moura MS, 2019, HEMATOL TRANSF CELL, V41, P329, DOI 10.1016/j.htct.2019.03.006; Nowell PC, 2007, J CLIN INVEST, V117, P2033, DOI 10.1172/JCI31771; Oyekunle AA, 2016, CLIN MED INSIGHTS-BL, V9, P9, DOI 10.4137/CMBD.S31562; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Perrotti D, 2010, J CLIN INVEST, V120, P2254, DOI 10.1172/JCI41246; Pophali PA, 2016, CANCER J, V22, P40, DOI 10.1097/PPO.0000000000000165; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; ROWLEY JD, 1980, CLIN HAEMATOL, V9, P55; Smith, 2007, MOUSE BIOMEDICAL RES, P623, DOI [10.1016/B978-012369454-6/50053-4, DOI 10.1016/B978-012369454-6/50053-4)]; Van Etten RA, 2002, ONCOGENE, V21, P8643, DOI 10.1038/sj.onc.1206091; Walz C, 2012, BLOOD, V119, P3550, DOI 10.1182/blood-2011-12-397554; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Wang XF, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0574-7; Wang ZQ, 2015, STEM CELLS, V33, P3437, DOI 10.1002/stem.2218; Wendel HG, 2006, P NATL ACAD SCI USA, V103, P7444, DOI 10.1073/pnas.0602402103; Wolach O, 2015, BLOOD, V125, P2477, DOI 10.1182/blood-2014-10-551465; Wolff NC, 2005, BLOOD, V105, P3995, DOI 10.1182/blood-2004-09-3534; Wolff NC, 2001, BLOOD, V98, P2808, DOI 10.1182/blood.V98.9.2808; Ye D, 2006, BLOOD, V107, P4917, DOI 10.1182/blood-2005-10-4110; Yuan HF, 2012, BLOOD, V119, P1904, DOI 10.1182/blood-2011-06-361691; Yuan R, 2009, AGING CELL, V8, P277, DOI 10.1111/j.1474-9726.2009.00478.x; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	56	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3152	3163		10.1038/s41388-021-01770-0	http://dx.doi.org/10.1038/s41388-021-01770-0		APR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33824471	Green Accepted			2022-12-28	WOS:000637478800002
J	Yeo, AT; Jun, HJ; Appleman, VA; Zhang, PY; Varma, H; Sarkaria, JN; Charest, A				Yeo, Alan T.; Jun, Hyun Jung; Appleman, Vicky A.; Zhang, Piyan; Varma, Hemant; Sarkaria, Jann N.; Charest, Al			EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma	ONCOGENE			English	Article								Focal amplification of epidermal growth factor receptor (EGFR) and its ligand-independent, constitutively active EGFRvIII mutant form are prominent oncogenic drivers in glioblastoma (GBM). The EGFRvIII gene rearrangement is considered to be an initiating event in the etiology of GBM, however, the mechanistic details of how EGFRvIII drives cellular transformation and tumor maintenance remain unclear. Here, we report that EGFRvIII demonstrates a reliance on PDGFRA co-stimulatory signaling during the tumorigenic process in a genetically engineered autochthonous GBM model. This dependency exposes liabilities that were leveraged using kinase inhibitors treatments in EGFRvIII-expressing GBM patient-derived xenografts (PDXs), where simultaneous pharmacological inhibition of EGFRvIII and PDGFRA kinase activities is necessary for anti-tumor efficacy. Our work establishes that EGFRvIII-positive tumors have unexplored vulnerabilities to targeted agents concomitant to the EGFR kinase inhibitor repertoire.	[Yeo, Alan T.; Jun, Hyun Jung; Appleman, Vicky A.; Zhang, Piyan; Charest, Al] Harvard Med Sch, Beth Israel Deaconess Med, Dept Med, Boston, MA 02115 USA; [Yeo, Alan T.] Tufts Univ, Sch Med, Sackler Sch Grad Studies, Boston, MA 02111 USA; [Varma, Hemant] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA; [Sarkaria, Jann N.] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA; [Charest, Al] Beth Israel Deaconess Med Ctr, Canc Res Inst, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Tufts University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Mayo Clinic; Harvard University; Beth Israel Deaconess Medical Center	Charest, A (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med, Dept Med, Boston, MA 02115 USA.; Charest, A (corresponding author), Beth Israel Deaconess Med Ctr, Canc Res Inst, Boston, MA 02215 USA.	acharest@bidmc.harvard.edu			NIH [R01 CA229784, R21 CA245337]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by NIH grants R01 CA229784 and R21 CA245337 to AC and by internal funding to the Mayo Clinic GBM PDX National Resource to JNS.	Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bedard PL, 2015, CLIN CANCER RES, V21, P730, DOI 10.1158/1078-0432.CCR-14-1814; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brown AP, 2007, CANCER CHEMOTH PHARM, V59, P671, DOI 10.1007/s00280-006-0323-5; Chakravarty D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08940-9; Chen PH, 2013, BBA-PROTEINS PROTEOM, V1834, P2176, DOI 10.1016/j.bbapap.2012.10.015; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Darmanis S, 2017, CELL REP, V21, P1399, DOI 10.1016/j.celrep.2017.10.030; Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990; deCarvalho AC, 2018, NAT GENET, V50, P708, DOI 10.1038/s41588-018-0105-0; Ebbesen SH, 2016, P NATL ACAD SCI USA, V113, P3030, DOI 10.1073/pnas.1523693113; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Felsberg J, 2017, CLIN CANCER RES, V23, P6846, DOI 10.1158/1078-0432.CCR-17-0890; Fernandes H, 2001, J BIOL CHEM, V276, P5375, DOI 10.1074/jbc.M005599200; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Francis JM, 2014, CANCER DISCOV, V4, P956, DOI 10.1158/2159-8290.CD-13-0879; Gajadhar AS, 2012, MOL CANCER RES, V10, P428, DOI 10.1158/1541-7786.MCR-11-0531; Gan HK, 2013, FEBS J, V280, P5350, DOI 10.1111/febs.12393; Garnett J, 2013, NEOPLASIA, V15, P73, DOI 10.1593/neo.121536; Greenall SA, 2015, ONCOGENE, V34, P5277, DOI 10.1038/onc.2014.448; Grilley-Olson JE, 2016, INVEST NEW DRUG, V34, P740, DOI 10.1007/s10637-016-0377-0; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Hwang Y, 2011, MOL CANCER RES, V9, P1199, DOI 10.1158/1541-7786.MCR-11-0229; Jun HJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05036-4; Kancha RK, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-39; Kastenhuber ER, 2014, ACTA NEUROPATHOL, V127, P747, DOI 10.1007/s00401-013-1217-3; Lemmon MA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020768; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Luwor RB, 2004, ONCOGENE, V23, P6095, DOI 10.1038/sj.onc.1207870; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; McNeill RS, 2017, NEURO-ONCOLOGY, V19, P1469, DOI 10.1093/neuonc/nox044; Meyer M, 2015, P NATL ACAD SCI USA, V112, P851, DOI 10.1073/pnas.1320611111; Montano N, 2011, NEOPLASIA, V13, P1113, DOI 10.1593/neo.111338; Nathanson DA, 2014, SCIENCE, V343, P72, DOI 10.1126/science.1241328; Nishikawa Ryo, 2004, Brain Tumor Pathol, V21, P53, DOI 10.1007/BF02484510; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Paul MD, 2019, CHEM REV, V119, P5881, DOI 10.1021/acs.chemrev.8b00467; Reardon DA, 2014, NEURO-ONCOLOGY, V16, pviii7, DOI 10.1093/neuonc/nou232; Roskoski R, 2019, PHARMACOL RES, V139, P395, DOI 10.1016/j.phrs.2018.11.014; Roskoski R, 2018, PHARMACOL RES, V129, P65, DOI 10.1016/j.phrs.2018.01.021; Rutkowska A, 2019, J ONCOL, V2019, DOI 10.1155/2019/1092587; Sarkaria JN, 2007, MOL CANCER THER, V6, P1167, DOI 10.1158/1535-7163.MCT-06-0691; Sarkaria JN, 2006, CLIN CANCER RES, V12, P2264, DOI 10.1158/1078-0432.CCR-05-2510; Schram AM, 2018, BRIT J CANCER, V119, P1471, DOI 10.1038/s41416-018-0322-4; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103; Shinojima N, 2003, CANCER RES, V63, P6962; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Stec W., 2018, ONCOTARGET, V9, P8560, DOI [DOI 10.18632/ONCOTARGET.24058, 10.18632/oncotarget.24058]; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Szerlip NJ, 2012, P NATL ACAD SCI USA, V109, P3041, DOI 10.1073/pnas.1114033109; Tolcher AW, 2015, CANCER CHEMOTH PHARM, V75, P183, DOI 10.1007/s00280-014-2615-5; Turner KM, 2017, NATURE, V543, P122, DOI 10.1038/nature21356; van den Bent MJ, 2015, NEURO-ONCOLOGY, V17, P935, DOI 10.1093/neuonc/nov013; Vaubel RA, 2020, CLIN CANCER RES, V26, P1094, DOI 10.1158/1078-0432.CCR-19-0909; Verhaak RGW, 2019, NAT REV CANCER, V19, P283, DOI 10.1038/s41568-019-0128-6; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wainberg ZA, 2017, TARGET ONCOL, V12, P775, DOI 10.1007/s11523-017-0530-5; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Weller M, 2009, J CLIN ONCOL, V27, P5743, DOI 10.1200/JCO.2009.23.0805; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Xing YM, 2015, DEV BIOL, V408, P56, DOI 10.1016/j.ydbio.2015.10.002; Ymer Susie I, 2011, Cancers (Basel), V3, P2032, DOI 10.3390/cancers3022032; Zhou S, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800029; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106	67	3	3	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2682	2696		10.1038/s41388-021-01721-9	http://dx.doi.org/10.1038/s41388-021-01721-9		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33707748	Green Accepted			2022-12-28	WOS:000627660400002
J	Purayil, HT; Zhang, YS; Black, JB; Gharaibeh, R; Daaka, Y				Purayil, Hamsa Thayele; Zhang, Yushan; Black, Joseph B.; Gharaibeh, Raad; Daaka, Yehia			Nuclear beta Arrestin1 regulates androgen receptor function in castration resistant prostate cancer	ONCOGENE			English	Article							BETA-ARRESTIN 1; EMERGING MECHANISMS; ADRENERGIC-RECEPTOR; LINEAGE PLASTICITY; EXPORT SIGNAL; IDENTIFICATION; PROGRESSION; EXPRESSION; PROTEIN; KINASE	Progression of prostate cancer (PC) to terminal castration-resistant PC (CRPC) involves a diverse set of intermediates, and androgen receptor (AR) is the key mediator of PC initiation and progression to CRPC. Hence, identification of factors involved in the regulation of AR expression and function is a necessary first-step to improve disease outcome. In this study, we identified ubiquitous beta Arrestin 1 (beta Arr1) as a regulator of AR function in CRPC. Unbiased gene expression analysis of public datasets revealed increased levels of ARRB1 (the gene encoding beta Arr1) in CRPC when compared to normal tissue. Further, beta Arr1 expression correlated with enhanced AR transcriptional function in these datasets. The beta Arr1 partitions to both nucleus and cytosol and mechanistic studies showed that nuclear, and not cytosolic, beta Arr1 formed a complex with AR and AR-coregulator beta Catenin and that the heterotrimeric protein complex was recruited to androgen-response elements of AR-regulated genes. Functionally, we demonstrate that depletion of beta Arr1 attenuates PC cell and tumor growth and metastasis, and rescued expression of nuclear, but not cytosolic, beta Arr1 restores the PC colony growth and invasion of Matrigel in vitro and tumor growth and metastasis in mice. The targeting of beta Arr1-regulated AR transcriptional function may be used in the development of new drugs to treat lethal CRPC.	[Purayil, Hamsa Thayele; Zhang, Yushan; Black, Joseph B.; Daaka, Yehia] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32611 USA; [Gharaibeh, Raad] Univ Florida, Coll Med, Dept Med, Gainesville, FL USA; [Zhang, Yushan] Univ Oklahoma, Hlth Sci Ctr, Stephen Canc Ctr, Norman, OK 73019 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma - Norman	Daaka, Y (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32611 USA.	ydaaka@ufl.edu		THAYELE PURAYIL, HAMSA/0000-0002-7211-3659	Florida Academic Cancer Center Alliance	Florida Academic Cancer Center Alliance	This work was supported, in part, by the Florida Academic Cancer Center Alliance (to YD) and the UFHCC (to RG).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Bao BY, 2008, PROSTATE, V68, P839, DOI 10.1002/pros.20749; Beltran H, 2019, CLIN CANCER RES, V25, P43, DOI 10.1158/1078-0432.CCR-18-1912; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; Buchanan FG, 2006, P NATL ACAD SCI USA, V103, P1492, DOI 10.1073/pnas.0510562103; Cianfrocca R, 2014, LIFE SCI, V118, P179, DOI 10.1016/j.lfs.2014.01.078; Claessens F, 2014, NAT REV UROL, V11, P712, DOI 10.1038/nrurol.2014.243; Dasgupta P, 2011, JNCI-J NATL CANCER I, V103, P317, DOI 10.1093/jnci/djq541; Dehm SM, 2011, ENDOCR-RELAT CANCER, V18, pR183, DOI 10.1530/ERC-11-0141; El-Khoury V, 2018, BRIT J CANCER, V119, P580, DOI 10.1038/s41416-018-0200-0; Fereshteha M, 2012, P NATL ACAD SCI USA, V109, P12532, DOI 10.1073/pnas.1209815109; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Lakshmikanthan V, 2009, P NATL ACAD SCI USA, V106, P9379, DOI 10.1073/pnas.0900258106; Lee E, 2013, P NATL ACAD SCI USA, V110, P15710, DOI 10.1073/pnas.1218168110; Lefkowitz RJ, 2004, TRENDS PHARMACOL SCI, V25, P413, DOI 10.1016/j.tips.2004.06.006; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma L, 2007, J CELL SCI, V120, P213, DOI 10.1242/jcs.03338; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Nyquist MD, 2013, P NATL ACAD SCI USA, V110, P17492, DOI 10.1073/pnas.1308587110; Purayil HT, 2015, ONCOGENE, V34, P3144, DOI 10.1038/onc.2014.252; Rosano L, 2013, ONCOGENE, V32, P5066, DOI 10.1038/onc.2012.527; Rosano L, 2009, P NATL ACAD SCI USA, V106, P2806, DOI 10.1073/pnas.0807158106; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shenoy SK, 2012, ONCOGENE, V31, P282, DOI 10.1038/onc.2011.238; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Taplin ME, 2007, NAT CLIN PRACT ONCOL, V4, P236, DOI 10.1038/ncponc0765; Terada N, 2010, CANCER RES, V70, P1606, DOI 10.1158/0008-5472.CAN-09-2984; Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078-0432.CCR-05-0525; Tocci P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11045-8; Wang LG, 2012, ASIAN PAC J CANCER P, V13, P5671, DOI 10.7314/APJCP.2012.13.11.5671; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Xiao K, 2007, P NATL ACAD SCI USA, V104, P12011, DOI 10.1073/pnas.0704849104; Zecchini V, 2014, EMBO J, V33, P1365, DOI 10.15252/embj.201386874; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-00321-0, 10.1038/s41467-017-01968-5]; Zhang YX, 2017, J BIOL CHEM, V292, P8933, DOI 10.1074/jbc.M116.770420; Zhang YS, 2017, CANCER LETT, V391, P50, DOI 10.1016/j.canlet.2017.01.007	42	3	3	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2610	2620		10.1038/s41388-021-01730-8	http://dx.doi.org/10.1038/s41388-021-01730-8		MAR 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33692468				2022-12-28	WOS:000627285600001
J	Milewski, D; Shukla, S; Gryder, BE; Pradhan, A; Donovan, J; Sudha, P; Vallabh, S; Pyros, A; Xu, Y; Barski, A; Szabo, S; Turpin, B; Pressey, JG; Millay, DP; Khan, J; Kalinichenko, VV; Kalin, TV				Milewski, David; Shukla, Samriddhi; Gryder, Berkley E.; Pradhan, Arun; Donovan, Johnny; Sudha, Parvathi; Vallabh, Sushmitha; Pyros, Athena; Xu, Yan; Barski, Artem; Szabo, Sara; Turpin, Brian; Pressey, Joseph G.; Millay, Douglas P.; Khan, Javed; Kalinichenko, Vladimir V.; Kalin, Tanya, V			FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma	ONCOGENE			English	Article							TRANSCRIPTION FACTOR FOXF1; TRANS-RETINOIC ACID; ALVEOLAR RHABDOMYOSARCOMA; RESPONSE FACTOR; PHASE-2 TRIAL; GROWTH-FACTOR; FUSION GENE; EXPRESSION; IDENTIFICATION; DIFFERENTIATION	The PAX3-FOXO1 fusion protein is the key oncogenic driver in fusion positive rhabdomyosarcoma (FP-RMS), an aggressive soft tissue malignancy with a particularly poor prognosis. Identifying key downstream targets of PAX3-FOXO1 will provide new therapeutic opportunities for treatment of FP-RMS. Herein, we demonstrate that Forkhead Box F1 (FOXF1) transcription factor is uniquely expressed in FP-RMS and is required for FP-RMS tumorigenesis. The PAX3-FOXO1 directly binds to FOXF1 enhancers and induces FOXF1 gene expression. CRISPR/Cas9 mediated inactivation of either FOXF1 coding sequence or FOXF1 enhancers suppresses FP-RMS tumorigenesis even in the presence of PAX3-FOXO1 oncogene. Knockdown or genetic knockout of FOXF1 induces myogenic differentiation in PAX3-FOXO1-positive FP-RMS. Over-expression of FOXF1 decreases myogenic differentiation in primary human myoblasts. In FP-RMS tumor cells, FOXF1 protein binds chromatin near enhancers associated with FP-RMS gene signature. FOXF1 cooperates with PAX3-FOXO1 and E-box transcription factors MYOD1 and MYOG to regulate FP-RMS-specific gene expression. Altogether, FOXF1 functions downstream of PAX3-FOXO1 to promote FP-RMS tumorigenesis.	[Milewski, David; Shukla, Samriddhi; Pradhan, Arun; Donovan, Johnny; Sudha, Parvathi; Pyros, Athena; Xu, Yan; Kalinichenko, Vladimir V.; Kalin, Tanya, V] Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Perinatal Inst, Cincinnati, OH 45229 USA; [Milewski, David; Gryder, Berkley E.; Khan, Javed] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA; [Vallabh, Sushmitha; Barski, Artem] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH USA; [Xu, Yan; Barski, Artem; Szabo, Sara; Turpin, Brian; Pressey, Joseph G.; Millay, Douglas P.; Kalinichenko, Vladimir V.; Kalin, Tanya, V] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45221 USA; [Barski, Artem] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH USA; [Szabo, Sara] Cincinnati Childrens Hosp Med Ctr, Dept Pathol, Cincinnati, OH USA; [Turpin, Brian; Pressey, Joseph G.] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH USA; [Millay, Douglas P.] Cincinnati Childrens Hosp Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH USA; [Kalinichenko, Vladimir V.] Cincinnati Childrens Hosp Med Ctr, Ctr Lung Regenerat Med, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Kalin, TV (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Perinatal Inst, Cincinnati, OH 45229 USA.; Kalin, TV (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45221 USA.	tatiana.kalin@cchmc.org	Milewski, David/GPF-5870-2022; Shukla, Samriddhi/AAF-1876-2021	Milewski, David/0000-0002-9778-8548; Shukla, Samriddhi/0000-0002-3771-4184; Pressey, Joseph/0000-0003-1816-3281; Barski, Artem/0000-0002-1861-5316; Szabo, Sara/0000-0002-6212-7264	NIH [R01 CA142724, R01 HL132849, R01 HL141174]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Tien Le for technical assistance. This work was supported by the NIH grants R01 CA142724 (TVK), R01 HL132849 (TVK), R01 HL141174 (VVK).	Alaggio R, 2016, AM J SURG PATHOL, V40, P224, DOI 10.1097/PAS.0000000000000538; Black M, 2020, MOL BIOL CELL, V31, P1411, DOI 10.1091/mbc.E19-07-0413; Black M, 2018, CELL REP, V23, P442, DOI 10.1016/j.celrep.2018.03.067; Bolte C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11175-3; Bolte C, 2015, J BIOL CHEM, V290, P7563, DOI 10.1074/jbc.M114.609487; Brewster AM, 2007, J CLIN ONCOL, V25, P1974, DOI 10.1200/JCO.2006.05.9873; Cai YQ, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad1899; Cai YQ, 2013, J BIOL CHEM, V288, P22527, DOI 10.1074/jbc.M113.455089; Cairns J, 2018, EMBO REP, V19, DOI 10.15252/embr.201744767; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Chen L, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005075; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Cheng XH, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004656; DAMORE ESG, 1994, MODERN PATHOL, V7, P69; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; Dias P, 2000, AM J PATHOL, V156, P399, DOI 10.1016/S0002-9440(10)64743-8; Ebauer M, 2007, ONCOGENE, V26, P7267, DOI 10.1038/sj.onc.1210525; Feng YF, 2013, EXP CELL RES, V319, P1124, DOI 10.1016/j.yexcr.2013.02.009; Goda C, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008692; Gryder BE, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101103; Gryder BE, 2020, NAT PROTOC, V15, P1209, DOI 10.1038/s41596-019-0285-9; Gryder BE, 2019, NAT GENET, V51, P1714, DOI 10.1038/s41588-019-0534-4; Gryder BE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11046-7; Gryder BE, 2017, CANCER DISCOV, V7, P884, DOI 10.1158/2159-8290.CD-16-1297; Hakozaki M, 2013, HUM CELL, V26, P149, DOI 10.1007/s13577-013-0067-6; Hinson ARP, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00183; Hoggatt AM, 2013, J BIOL CHEM, V288, P28477, DOI 10.1074/jbc.M113.478974; Iland HJ, 2012, BLOOD, V120, P1570, DOI 10.1182/blood-2012-02-410746; Jothi M, 2012, CELL CYCLE, V11, P895, DOI 10.4161/cc.11.5.19346; Kalin TV, 2008, AM J RESP CELL MOL, V39, P390, DOI 10.1165/rcmb.2008-0044OC; Kalinichenko VV, 2002, J BIOL CHEM, V277, P12369, DOI 10.1074/jbc.M112162200; Kartashov AV, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0720-3; Kikuchi K, 2008, BIOCHEM BIOPH RES CO, V365, P568, DOI 10.1016/j.bbrc.2007.11.017; Lae M, 2007, J PATHOL, V212, P143, DOI 10.1002/path.2170; Liu QC, 2012, J MOL CELL BIOL, V4, P386, DOI 10.1093/jmcb/mjs045; Lo PK, 2010, CANCER RES, V70, P6047, DOI 10.1158/0008-5472.CAN-10-1576; Machanick P, 2011, BIOINFORMATICS, V27, P1696, DOI 10.1093/bioinformatics/btr189; Mahlapuu M, 2001, DEVELOPMENT, V128, P155; Mehner C, 2014, MOL CANCER RES, V12, P1430, DOI 10.1158/1541-7786.MCR-13-0557-T; Mercado GE, 2008, GENE CHROMOSOME CANC, V47, P510, DOI 10.1002/gcc.20554; Milewski D, 2017, ONCOGENE, V36, P850, DOI 10.1038/onc.2016.254; Milewski D, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007097; Nilsson G, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2196-2; Ognjanovic S, 2009, CANCER-AM CANCER SOC, V115, P4218, DOI 10.1002/cncr.24465; Otabe O, 2017, ONCOL REP, V37, P98, DOI 10.3892/or.2016.5213; Pappo AS, 2014, CANCER-AM CANCER SOC, V120, P2448, DOI 10.1002/cncr.28728; Pradhan A, 2019, AM J RESP CRIT CARE, V200, P1045, DOI 10.1164/rccm.201810-1897OC; Rekhi B, 2018, ANN DIAGN PATHOL, V36, P50, DOI 10.1016/j.anndiagpath.2018.07.002; Ren XM, 2019, AM J RESP CRIT CARE, V200, P1164, DOI 10.1164/rccm.201812-2312OC; Ren XM, 2014, CIRC RES, V115, P709, DOI 10.1161/CIRCRESAHA.115.304382; Ren XM, 2010, MOL CELL BIOL, V30, P5381, DOI 10.1128/MCB.00876-10; Robinson JT, 2018, CELL SYST, V6, P256, DOI 10.1016/j.cels.2018.01.001; Rudzinski ER, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26645; Schoffski P, 2013, EUR J CANCER, V49, P3219, DOI 10.1016/j.ejca.2013.06.010; Schoffski P, 2018, EUR J CANCER, V94, P156, DOI 10.1016/j.ejca.2018.02.011; Shao Z, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-3-r16; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Skrzypek K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0693-8; Smith LM, 2002, MED PEDIATR ONCOL, V38, P398, DOI 10.1002/mpo.10060; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Stewart E, 2018, CANCER CELL, V34, P411, DOI 10.1016/j.ccell.2018.07.012; STRATTON MR, 1989, CANCER RES, V49, P6324; Sun LF, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aai8583; Sun WY, 2015, MODERN PATHOL, V28, P1214, DOI 10.1038/modpathol.2015.82; Szafranski P, 2014, AM J MED GENET A, V164, P2013, DOI 10.1002/ajmg.a.36606; Taulli R, 2006, CANCER RES, V66, P4742, DOI 10.1158/0008-5472.CAN-05-4292; Taylor AC, 2000, MED PEDIATR ONCOL, V35, P96, DOI 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z; Taylor JG, 2009, J CLIN INVEST, V119, P3395, DOI 10.1172/JCI39703; Tenente IM, 2017, ELIFE, V6, DOI 10.7554/eLife.19214; Thakore PI, 2015, NAT METHODS, V12, P1143, DOI 10.1038/nmeth.3630; Ustiyan V, 2018, DEV BIOL, V443, P50, DOI 10.1016/j.ydbio.2018.08.011; Ustiyan V, 2012, DEV BIOL, V370, P198, DOI 10.1016/j.ydbio.2012.07.028; Vallabh S, 2018, METHODS MOL BIOL, V1783, P343, DOI 10.1007/978-1-4939-7834-2_17; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Wang SY, 2018, NEOPLASIA, V20, P996, DOI 10.1016/j.neo.2018.08.004; Williamson D, 2005, J CLIN ONCOL, V23, P880, DOI 10.1200/JCO.2005.11.078; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Zhang Y, 2013, J HEPATOL, V59, P1255, DOI 10.1016/j.jhep.2013.07.009; Zhao ZH, 2015, INT J CLIN EXP PATHO, V8, P13814	80	5	6	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2182	2199		10.1038/s41388-021-01694-9	http://dx.doi.org/10.1038/s41388-021-01694-9		FEB 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33627785	Green Accepted			2022-12-28	WOS:000621289100004
J	Xiang, X; Langlois, S; St-Pierre, ME; Blinder, A; Charron, P; Graber, TE; Fowler, SL; Baird, SD; Bennett, SAL; Alain, T; Cowan, KN				Xiang, Xiao; Langlois, Stephanie; St-Pierre, Marie-Eve; Blinder, Anna; Charron, Philippe; Graber, Tyson E.; Fowler, Stephanie L.; Baird, Stephen D.; Bennett, Steffany A. L.; Alain, Tommy; Cowan, Kyle N.			Identification of pannexin 1-regulated genes, interactome, and pathways in rhabdomyosarcoma and its tumor inhibitory interaction with AHNAK	ONCOGENE			English	Article								Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children, is an aggressive cancer with a poor prognosis. Despite current management, the 5-year survival rate for patients with metastatic RMS is similar to 30%; underscoring the need to develop better treatment strategies. We have recently reported that pannexin 1 (PANX1) levels are downregulated in RMS and that restoring its expression inhibits RMS progression. Here, we have surveyed and characterized the molecular changes induced by PANX1 re-expression in RMS. We cataloged transcriptomic changes in this context by RNA sequencing. At the protein level, we unveiled PANX1 interactors using BioID, complemented by co-immunoprecipitation coupled to high-performance liquid chromatography/electrospray ionization tandem mass spectrometry performed in PANX1-enriched fractions. Using these data, we generated searchable public databases for the PANX1 interactome and changes to the RMS transcriptome occurring when PANX1 expression is restored. STRING network analyses revealed a PANX1 interactome involving plasma membrane and cytoskeleton-associated proteins including the previously undescribed interactor AHNAK. Indeed, AHNAK knockdown abrogated the PANX1-mediated reduction in RMS cell viability and migration. Using these unbiased approaches, we bring insight to the mechanisms by which PANX1 inhibits RMS progression, identifying the cell migration protein AHNAK as a key modifier of PANX1-mediated changes in RMS malignant properties.	[Xiang, Xiao; Langlois, Stephanie; St-Pierre, Marie-Eve; Blinder, Anna; Charron, Philippe; Graber, Tyson E.; Baird, Stephen D.; Alain, Tommy; Cowan, Kyle N.] Childrens Hosp Eastern Ontario, Res Inst, Mol Biomed Program, Ottawa, ON, Canada; [Xiang, Xiao; Blinder, Anna; Cowan, Kyle N.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Langlois, Stephanie; Cowan, Kyle N.] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Surg, Ottawa, ON, Canada; [Fowler, Stephanie L.; Bennett, Steffany A. L.; Alain, Tommy] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Fowler, Stephanie L.; Bennett, Steffany A. L.] Univ Ottawa, Neural Regenerat Lab, Ottawa, ON, Canada; [Fowler, Stephanie L.; Bennett, Steffany A. L.] Univ Ottawa, Ottawa Inst Syst Biol, Ottawa, ON, Canada; [Fowler, Stephanie L.] UCL, UK Dementia Res Inst, London, England	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Ottawa; University of London; University College London	Cowan, KN (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Mol Biomed Program, Ottawa, ON, Canada.; Cowan, KN (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada.; Cowan, KN (corresponding author), Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Surg, Ottawa, ON, Canada.	kcowan@cheo.on.ca		Xiang, Xiao/0000-0002-3969-1668; Fowler, Stephanie/0000-0001-6693-9959	Cancer Research Society (CRS) [19080, 21453]; Ontario Graduate Scholarship (OGS); Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII-GSST)	Cancer Research Society (CRS); Ontario Graduate Scholarship (OGS)(Ontario Graduate Scholarship); Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII-GSST)	This study was supported by the Cancer Research Society (CRS, Operating Grants 19080 and 21453, KNC), Ontario Graduate Scholarship (OGS, XX), and Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII-GSST, XX).	Bargiotas P, 2011, P NATL ACAD SCI USA, V108, P20772, DOI 10.1073/pnas.1018262108; Benaud C, 2004, J CELL BIOL, V164, P133, DOI 10.1083/jcb.200307098; Bennett, 2016, METHOD MOL BIOL, P9; Bhalla-Gehi R, 2010, J BIOL CHEM, V285, P9147, DOI 10.1074/jbc.M109.082008; Boassa D, 2007, J BIOL CHEM, V282, P31733, DOI 10.1074/jbc.M702422200; Boyce AKJ, 2018, BBA-BIOMEMBRANES, V1860, P72, DOI 10.1016/j.bbamem.2017.03.004; Chekeni FB, 2010, NATURE, V467, P863, DOI 10.1038/nature09413; Chen B, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0522-4; Chen C., 2019, FRONT ONCOL, V9, P1; Chiu YH, 2018, J GEN PHYSIOL, V150, P19, DOI 10.1085/jgp.201711888; Cowan KN, 2012, CELL COMMUN ADHES, V19, P45, DOI 10.3109/15419061.2012.712575; Cui H, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005084; Dobson Christine C., 2016, Critical Reviews in Oncogenesis, V21, P221, DOI 10.1615/CritRevOncog.2016016996; Dossi E, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar3796; Fowler SL, 2013, J PROTEOME RES, V12, P2597, DOI 10.1021/pr301166p; Frank SB, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0341-x; Freeman TJ, 2019, CANCERS, V11, DOI 10.3390/cancers11010102; Gentil BJ, 2003, J HISTOCHEM CYTOCHEM, V51, P339, DOI 10.1177/002215540305100309; Gentil EJ, 2005, J CELL PHYSIOL, V203, P362, DOI 10.1002/jcp.20232; Good ME, 2018, CIRC RES, V122, P606, DOI 10.1161/CIRCRESAHA.117.312380; HASHIMOTO T, 1993, J CELL SCI, V105, P275; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang YC, 2007, FASEB J, V21, P732, DOI 10.1096/fj.06-6628com; Keller C, 2013, FEBS J, V280, P4323, DOI 10.1111/febs.12421; Komuro A, 2004, P NATL ACAD SCI USA, V101, P4053, DOI 10.1073/pnas.0308619101; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Lai CPK, 2007, CANCER RES, V67, P1545, DOI 10.1158/0008-5472.CAN-06-1396; Langlois Stephanie, 2017, Adv Exp Med Biol, V925, P57, DOI 10.1007/5584_2016_53; Langlois S, 2014, J BIOL CHEM, V289, P30717, DOI 10.1074/jbc.M114.572131; Lee IH, 2014, ONCOGENE, V33, P4675, DOI 10.1038/onc.2014.69; Lee IH, 2008, J BIOL CHEM, V283, P6312, DOI 10.1074/jbc.M706878200; Liu HF, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109090; Locovei S, 2006, FEBS LETT, V580, P239, DOI 10.1016/j.febslet.2005.12.004; Ma HL, 2012, MOL IMAGING, V11, P487, DOI 10.2310/7290.2012.00012; Ma WH, 2009, J PHARMACOL EXP THER, V328, P409, DOI 10.1124/jpet.108.146365; Malempati S, 2012, PEDIATR BLOOD CANCER, V59, P5, DOI 10.1002/pbc.24118; Mauro A, 2002, J CELL SCI, V115, P3587, DOI 10.1242/jcs.00037; Minde DP, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0758-y; Nie ZZ, 2000, J INVEST DERMATOL, V114, P1044, DOI 10.1046/j.1523-1747.2000.00949.x; Parham DM, 2013, ADV ANAT PATHOL, V20, P387, DOI 10.1097/PAP.0b013e3182a92d0d; Peng R, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1113-3; Penuela S, 2007, J CELL SCI, V120, P3772, DOI 10.1242/jcs.009514; Penuela S, 2012, J BIOL CHEM, V287, P29184, DOI 10.1074/jbc.M112.377176; Pham TL, 2018, J CELL PHYSIOL, V233, P7057, DOI 10.1002/jcp.26629; Proulx AA, 1997, CELL GROWTH DIFFER, V8, P533; Puri PL, 2000, GENE DEV, V14, P574; Richter K, 2014, FASEB J, V28, P45, DOI 10.1096/fj.13-229252; Roux KJ, 2012, J CELL BIOL, V196, P801, DOI 10.1083/jcb.201112098; Salim C, 2009, GLIA, V57, P535, DOI 10.1002/glia.20782; Seminario-Vidal L, 2011, J BIOL CHEM, V286, P26277, DOI 10.1074/jbc.M111.260562; Shankar J, 2010, CANCER RES, V70, P3780, DOI 10.1158/0008-5472.CAN-09-4439; Sheppard HM, 2016, MELANOMA RES, V26, P108, DOI 10.1097/CMR.0000000000000228; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; Silva TA, 2016, ONCOTARGET, V7, P49998, DOI 10.18632/oncotarget.10307; Sudo H, 2014, INT J ONCOL, V44, P530, DOI 10.3892/ijo.2013.2183; Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016; Wicki-Stordeur LE, 2014, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00287; Wicki-Stordeur LE, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-62; Wicki-Stordeur LE, 2013, CELL COMMUN ADHES, V20, P73, DOI 10.3109/15419061.2013.791681; Xiang X, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0100-4; Xu XX, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00124; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang YL, 2017, CANCER BIOL MED, V14, P90, DOI 10.20892/j.issn.2095-3941.2016.0086; Zhang ZW, 2019, J CANCER, V10, P3860, DOI 10.7150/jca.31291	66	7	7	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1868	1883		10.1038/s41388-020-01623-2	http://dx.doi.org/10.1038/s41388-020-01623-2		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564071	Green Published, hybrid			2022-12-28	WOS:000616489100005
J	Levine, AJ				Levine, Arnold J.			Spontaneous and inherited TP53 genetic alterations	ONCOGENE			English	Review							P53 TUMOR-SUPPRESSOR; STEM-CELLS; CLONAL HEMATOPOIESIS; CANCER; MUTATIONS; TISSUE; DOMAIN; POLYMORPHISM; METHYLATION; SELECTION	The p53 protein is a transcription factor that prevents tumors from developing. In spontaneous and inherited cancers there are many different missense mutations in the DNA binding domain of the TP53 gene that contributes to tumor formation. These mutations produce a wide distribution in the transcriptional capabilities of the mutant p53 proteins with over four logs differences in the efficiencies of forming cancers in many diverse tissue types. These inherited and spontaneous TP53 mutations produce proteins that interact with both genetic and epigenetic cellular modifiers of p53 function and their inherited polymorphisms to produce a large number of diverse phenotypes in individual patients. This manuscript reviews these variables and discusses how the combinations of TP53 genetic alterations interact with genetic polymorphisms, epigenetic alterations, and environmental factors to begin predicting and modifying patient outcomes and provide a better understanding for new therapeutic opportunities.	[Levine, Arnold J.] Inst Adv Study, Olden Lane, Princeton, NJ 08540 USA	Institute for Advanced Study - USA	Levine, AJ (corresponding author), Inst Adv Study, Olden Lane, Princeton, NJ 08540 USA.	alevine@ias.edu			NIH, NCI PO1	NIH, NCI PO1	The author thanks S Christen for help in the preparation of this review and Drs. K.C. de Andrade, M. Murphy and G. Zambetti for their critical reading and suggestions for the improvement of this review. The ideas, some of the experiments and results discussed in this review were supported by a grant from the NIH, NCI PO1- to A. J. Levine.	Amadou A, 2018, CURR OPIN ONCOL, V30, P23, DOI 10.1097/CCO.0000000000000423; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Barker N, 2013, DEVELOPMENT, V140, P2484, DOI 10.1242/dev.083113; Barnoud T, 2019, J MOL CELL BIOL, V11, P578, DOI 10.1093/jmcb/mjz052; Barnoud T, 2018, CANCER RES, V78, P5694, DOI 10.1158/0008-5472.CAN-18-1327; Baugh EH, 2018, CELL DEATH DIFFER, V25, P154, DOI 10.1038/cdd.2017.180; Belyi VA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001198; Blanpain C, 2006, ANNU REV CELL DEV BI, V22, P339, DOI 10.1146/annurev.cellbio.22.010305.104357; Blokzijl F, 2016, NATURE, V538, P260, DOI 10.1038/nature19768; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bowman RL, 2018, CELL STEM CELL, V22, P157, DOI 10.1016/j.stem.2018.01.011; de Andrade KC, 2019, HUM MUTAT, V40, P97, DOI 10.1002/humu.23673; de Andrade KC, 2017, HUM MUTAT, V38, P1723, DOI 10.1002/humu.23320; Dubrovsky G, 2018, CURR OPIN PEDIATR, V30, P424, DOI 10.1097/MOP.0000000000000630; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Garber, LI FRAUMENI SYNDROME; Gnanapradeepan K, 2020, ELIFE, V9, DOI 10.7554/eLife.55994; Haigis KM, 2019, SCIENCE, V363, P1150, DOI 10.1126/science.aaw3472; Hainaut P, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026179; Harmeyer KM, 2017, TRENDS CANCER, V3, P713, DOI 10.1016/j.trecan.2017.08.004; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; Horvath S, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1030-0; Hu DL, 2018, ISCIENCE, V9, P84, DOI 10.1016/j.isci.2018.10.012; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jaiswal S, 2019, SCIENCE, V366, P586, DOI 10.1126/science.aan4673; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jennis M, 2016, GENE DEV, V30, P918, DOI 10.1101/gad.275891.115; Jeong SI, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0867-4; Kakiuchi N, 2021, NAT REV CANCER, V21, P239, DOI 10.1038/s41568-021-00335-3; Lee MG, 2014, P NATL ACAD SCI USA, V111, P15532, DOI 10.1073/pnas.1411746111; Leu JIJ, 2020, P NATL ACAD SCI USA, V117, P26804, DOI 10.1073/pnas.2009943117; Levine AJ, 2020, NAT REV CANCER, V20, P471, DOI 10.1038/s41568-020-0262-1; Levine AJ, 2019, CANCER CELL, V35, P10, DOI 10.1016/j.ccell.2018.11.009; Levine AJ, 2019, ANNU REV CANC BIOL, V3, P21, DOI 10.1146/annurev-cancerbio-030518-055455; Levine AJ, 2017, GENE DEV, V31, P1195, DOI 10.1101/gad.298984.117; Levine AJ, 2015, COLD SH Q B, V80, P139, DOI 10.1101/sqb.2015.80.027631; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; Mello SS, 2018, CURR OPIN CELL BIOL, V51, P65, DOI 10.1016/j.ceb.2017.11.005; Mizukami H, 2019, J BIOCHEM, V165, P335, DOI 10.1093/jb/mvy106; Murphy ME, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0007-9; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olivier Magali, 2004, IARC Sci Publ, P247; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Pinto EM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba3231; Post SM, 2010, CANCER CELL, V18, P220, DOI 10.1016/j.ccr.2010.07.010; Salk JJ, 2019, CELL REP, V28, P132, DOI 10.1016/j.celrep.2019.05.109; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Silver AJ, 2019, ADV CANCER RES, V141, P85, DOI 10.1016/bs.acr.2018.12.003; Singh KS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14151-9; Stacey SN, 2011, NAT GENET, V43, P1098, DOI 10.1038/ng.926; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takeda H, 2015, NAT GENET, V47, P142, DOI 10.1038/ng.3175; Takeo M, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a023267; Tukiainen T, 2017, NATURE, V550, P244, DOI 10.1038/nature24265; Victoria-Acosta G, 2015, SCI REP-UK, V5, DOI 10.1038/srep14838; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Weissman IL, 2015, P NATL ACAD SCI USA, V112, P8922, DOI 10.1073/pnas.1505464112; Welch JS, 2016, NEW ENGL J MED, V375, P2023, DOI 10.1056/NEJMoa1605949; Williams MJ, 2020, ELIFE, V9, DOI 10.7554/eLife.48714; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yi L, 2014, ONCOTARGET, V5, P8924, DOI 10.18632/oncotarget.2441; Yi L, 2012, CANCER RES, V72, P5635, DOI 10.1158/0008-5472.CAN-12-1451; Yokoyama A, 2019, NATURE, V565, P312, DOI 10.1038/s41586-018-0811-x; Zhu JJ, 2016, P NATL ACAD SCI USA, V113, P9822, DOI 10.1073/pnas.1610387113	72	7	7	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					5975	5983		10.1038/s41388-021-01991-3	http://dx.doi.org/10.1038/s41388-021-01991-3		AUG 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34389799	hybrid, Green Published			2022-12-28	WOS:000684753600001
J	Zhao, L; Jiang, LY; Zhang, M; Zhang, Q; Guan, QT; Li, YL; He, M; Zhang, JD; Wei, MJ				Zhao, Lin; Jiang, Longyang; Zhang, Ming; Zhang, Qiang; Guan, Qiutong; Li, Yalun; He, Miao; Zhang, Jingdong; Wei, Minjie			NF-kappa B-activated SPRY4-IT1 promotes cancer cell metastasis by downregulating TCEB1 mRNA via Staufen1-mediated mRNA decay	ONCOGENE			English	Article							UP-REGULATION; ADENOCARCINOMA; STAUFEN1	Previous study demonstrated that most long non-coding RNAs (lncRNAs) function as competing endogenous RNAs or molecular sponges to negatively modulate miRNA and regulate tumor development. However, the molecular mechanisms of lncRNAs in cancer are not fully understood. Our study describes the role of the lncRNA SPRY4 intronic transcript 1 (SPRY4-IT1) in cancer metastasis by mechanisms related to Staufen1 (STAU1)-mediated mRNA decay (SMD). Briefly, we found that, high SPRY4-IT1 expression was associated with aggressiveness and poor outcome in human colorectal, breast and ovarian cancer tissues. In addition, functional assays revealed that SPRY4-IT1 significantly promoted colorectal, breast and ovarian cancer metastasis in vitro and in vivo. Mechanistically, microarray analyses identified several differentially-expressed genes upon SPRY4-IT1 overexpression in HCT 116 colorectal cancer cells. Among them, the 3 '-UTR of transcription elongation factor B subunit 1 (TCEB1) mRNA can base-pair with the Alu element in the 3 '-UTR of SPRY4-IT1. Moreover, SPRY4-IT1 was found to bind STAU1, promote STAU1 recruitment to the 3 '-UTR of TCEB1 mRNA, and affect TCEB1 mRNA stability and expression, resulting in hypoxia-inducible factor 1 alpha (HIF-1 alpha) upregulation, and thereby affecting cancer cell metastasis. In addition, STAU1 depletion abrogated TCEB1 SMD and alleviated the pro-metastatic effect of SPRY4-IT1 overexpression. Significantly, we revealed that SPRY4-IT1 is also transactivated by NF-kappa B/p65, which activates SPRY4-IT1 to inhibit TCEB1 expression, and subsequently upregulate HIF-1 alpha. In conclusion, our results highlight a novel mechanism of cytoplasmic lncRNA SPRY4-IT1 in which SPRY4-IT1 affecting TCEB1 mRNA stability via STAU1-mediated degradation during cancer metastasis.	[Zhao, Lin; Jiang, Longyang; Zhang, Ming; Zhang, Qiang; Guan, Qiutong; He, Miao; Wei, Minjie] China Med Univ, Sch Pharm, Dept Pharmacol, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China; [Zhao, Lin; Jiang, Longyang; Zhang, Ming; Zhang, Qiang; Guan, Qiutong; He, Miao; Wei, Minjie] China Med Univ, Liaoning Key Lab Mol Targeted Antitumor Drug Dev, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China; [Li, Yalun] China Med Univ, Hosp 1, Dept Anorectal Surg, Shenyang, Peoples R China; [Zhang, Jingdong] China Med Univ, Med Oncol Dept Gastrointestinal Canc, Liaoning Canc Hosp & Inst, Canc Hosp, Shenyang, Peoples R China	China Medical University; China Medical University; China Medical University; China Medical University	Wei, MJ (corresponding author), China Med Univ, Sch Pharm, Dept Pharmacol, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China.; Wei, MJ (corresponding author), China Med Univ, Liaoning Key Lab Mol Targeted Antitumor Drug Dev, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China.; Zhang, JD (corresponding author), China Med Univ, Med Oncol Dept Gastrointestinal Canc, Liaoning Canc Hosp & Inst, Canc Hosp, Shenyang, Peoples R China.	jdzhang@cancerhosp-ln-cmu.com; weiminjiecmu@163.com	Zhang, Jing/GWZ-7332-2022; Zhang, Jing/HII-4294-2022		Shengjing Hospital of China Medical University; National Natural Science Foundation of China [82073884, 82073281, 81673475, U1608281, 81573462, 31828005]; Key R&D Guidance Plan Projects in Liaoning Province [2019JH8/10300011]; Liaoning Province Doctoral Scientific Research Foundation [20180540036]; Liaoning Revitalization Talents Program [XLYC1807201]; Shenyang ST Projects [Z18-4-020]	Shengjing Hospital of China Medical University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key R&D Guidance Plan Projects in Liaoning Province; Liaoning Province Doctoral Scientific Research Foundation; Liaoning Revitalization Talents Program; Shenyang ST Projects	This study was supported by the First Hospital and the Shengjing Hospital of China Medical University. The authors thank all the doctors and nurses for their great help in collecting tissue samples. This work was supported by grants from National Natural Science Foundation of China (No. 82073884, 82073281, 81673475, U1608281, 81573462, 31828005), Key R&D Guidance Plan Projects in Liaoning Province (2019JH8/10300011), Liaoning Province Doctoral Scientific Research Foundation (No 20180540036), Liaoning Revitalization Talents Program (No. XLYC1807201), Shenyang S&T Projects (Z18-4-020).	Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Bulatov E, 2015, J BIOL CHEM, V290, P4178, DOI 10.1074/jbc.M114.616664; Cao SG, 2019, MOL THER-NUCL ACIDS, V17, P455, DOI 10.1016/j.omtn.2019.04.030; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Cho H, 2012, MOL CELL, V46, P495, DOI 10.1016/j.molcel.2012.03.009; Cong ZZ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1361-3; Damas ND, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13875; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Gong CG, 2009, GENE DEV, V23, P54, DOI 10.1101/gad.1717309; Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887; Han QR, 2019, ONCOGENE, V38, P3019, DOI 10.1038/s41388-018-0614-4; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Khaitan D, 2011, CANCER RES, V71, P3852, DOI 10.1158/0008-5472.CAN-10-4460; Kim MY, 2014, NUCLEIC ACIDS RES, V42, P6999, DOI 10.1093/nar/gku388; Kim YK, 2005, CELL, V120, P195, DOI 10.1016/j.cell.2004.11.050; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Lee B, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602505; Li WY, 2014, CANCER CELL, V25, P557, DOI 10.1016/j.ccr.2014.04.014; Liang HH, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0870-5; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Liu JY, 2018, BRIT J CANCER, V118, P1617, DOI 10.1038/s41416-018-0116-8; Ma WJ, 2020, J CELL PHYSIOL, V235, P7849, DOI 10.1002/jcp.29438; Moon BS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02720-9; Okumura F, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00010; Park E, 2013, WIRES RNA, V4, P423, DOI 10.1002/wrna.1168; Patel M, 2018, TRANSL RES, V197, P43, DOI 10.1016/j.trsl.2018.02.002; Ren Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0758-4; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sun M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.256; Tan XC, 2018, J CLIN INVEST, V128, P3198, DOI 10.1172/JCI122740; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang YQ, 2017, CELL DEATH DIFFER, V24, P2089, DOI 10.1038/cdd.2017.129; Wu TY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0354-y; Xie M, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0595-9; Xu TP, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.205; Xu Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0747-x; Yamaki Y, 2016, MOL CELL BIOCHEM, V414, P1, DOI 10.1007/s11010-015-2643-4; Yang CQ, 2020, MOL THER-NUCL ACIDS, V20, P866, DOI 10.1016/j.omtn.2020.05.004; Yang Q, 2013, MOL CANCER RES, V11, P1497, DOI 10.1158/1541-7786.MCR-13-0214; Yang XZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0874-1; Yao Y, 2018, GENE, V659, P52, DOI 10.1016/j.gene.2018.03.048; Ye TB, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1074-6; Yu GF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16781-9	45	8	8	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4919	4929		10.1038/s41388-021-01900-8	http://dx.doi.org/10.1038/s41388-021-01900-8		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34163032	hybrid, Green Published			2022-12-28	WOS:000664853000001
J	Atashrazm, F; Ellis, S				Atashrazm, Farzaneh; Ellis, Sarah			The polarity protein PARD3 and cancer	ONCOGENE			English	Review							ASYMMETRIC CELL-DIVISION; EPITHELIAL TIGHT JUNCTION; C-ELEGANS; DEFECTIVE EXPRESSION; BINDING-PARTNERS; MAMMALIAN PAR3; MUTATION-RATE; COMPLEX; ADHESION; GENE	Tissue disorganisation is one of the main hallmarks of cancer. Polarity proteins are responsible for the arrangement of cells within epithelial tissues through the asymmetric organisation of cellular components. Partition defective 3 (PARD3) is a master regulator of the Par polarity complex primarily due to its ability to form large complexes via its self-homologous binding domain. In addition to its role in polarity, PARD3 is a scaffolding protein that binds to intracellular signalling molecules, many of which are frequently deregulated in cancer. The role of PARD3 has been implicated in multiple solid cancers as either a tumour suppressor or promoter. This dual functionality is both physiologically and cell context dependent. In this review, we will discuss PARD3's role in tumourigenesis in both laboratory and clinical settings. We will also review several of the mechanisms underpinning PARD3's function including its association with intracellular signalling pathways and its role in the regulation of asymmetric cell division.	[Atashrazm, Farzaneh] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3000, Australia; [Atashrazm, Farzaneh] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Ellis, Sarah] La Trobe Univ, Olivia Newton John Canc Res Inst, Victoria, Vic, Australia; [Ellis, Sarah] La Trobe Univ, Sch Canc Med, Victoria, Vic, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; La Trobe University; Olivia Newton-John Cancer Research Institute; La Trobe University	Atashrazm, F (corresponding author), Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3000, Australia.; Atashrazm, F (corresponding author), Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia.; Ellis, S (corresponding author), La Trobe Univ, Olivia Newton John Canc Res Inst, Victoria, Vic, Australia.; Ellis, S (corresponding author), La Trobe Univ, Sch Canc Med, Victoria, Vic, Australia.	f.atashrazm@gmail.com; sarah.ellis@onjcri.org.au		Ellis, Sarah/0000-0002-5772-6051; Atashrazm, Farzaneh/0000-0003-3471-8160				Ahmed SM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14867; Alberti S, 2019, CELL, V176, P419, DOI 10.1016/j.cell.2018.12.035; Ali NJA, 2016, J INVEST DERMATOL, V136, P2406, DOI 10.1016/j.jid.2016.07.011; Archibald A, 2015, ONCOGENE, V34, P3199, DOI 10.1038/onc.2014.242; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Benton R, 2003, CELL, V115, P691, DOI 10.1016/S0092-8674(03)00938-3; Bonastre E, 2015, CANCER RES, V75, P1287, DOI 10.1158/0008-5472.CAN-14-2444; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; Brown S, 2017, NATURE, V548, P334, DOI 10.1038/nature23304; Bultje RS, 2009, NEURON, V63, P189, DOI 10.1016/j.neuron.2009.07.004; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Catterall R, 2020, INT J CANCER, V146, P1578, DOI 10.1002/ijc.32691; Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632; Chen S, 2013, DEV CELL, V24, P26, DOI 10.1016/j.devcel.2012.11.014; Chen XY, 2006, J CELL BIOL, V172, P671, DOI 10.1083/jcb.200510061; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Cowan CR, 2004, ANNU REV CELL DEV BI, V20, P427, DOI 10.1146/annurev.cellbio.19.111301.113823; Das S, 2015, P NATL ACAD SCI USA, V112, pE267, DOI 10.1073/pnas.1409667112; De P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050382; Diamantopoulou Z, 2017, CANCER CELL, V31, P621, DOI 10.1016/j.ccell.2017.03.007; Djiane A, 2005, CELL, V121, P621, DOI 10.1016/j.cell.2005.03.014; Dong ZQ, 2012, NEURON, V74, P65, DOI 10.1016/j.neuron.2012.01.031; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Dziengelewski C, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201805122; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Ebnet K, 2003, J CELL SCI, V116, P3879, DOI 10.1242/jcs.00704; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Facciuto F, 2014, MOL ONCOL, V8, P533, DOI 10.1016/j.molonc.2014.01.002; Fang CM, 2001, CELL RES, V11, P223, DOI 10.1038/sj.cr.7290090; Fang LH, 2007, CELL RES, V17, P100, DOI 10.1038/sj.cr.7310145; Feldman JL, 2012, CURR BIOL, V22, P575, DOI 10.1016/j.cub.2012.02.044; Feng W, 2008, J BIOL CHEM, V283, P23440, DOI 10.1074/jbc.M802482200; Funahashi Y, 2013, J NEUROSCI, V33, P13270, DOI 10.1523/JNEUROSCI.4210-12.2013; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Gao L, 2002, GENE, V294, P99, DOI 10.1016/S0378-1119(02)00681-9; Gomes MD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11325-3; Gont A, 2014, ONCOTARGET, V5, P11541, DOI 10.18632/oncotarget.2580; Grill SW, 2001, NATURE, V409, P630, DOI 10.1038/35054572; Guo XJ, 2016, CLIN EXP MED, V16, P357, DOI 10.1007/s10238-015-0365-2; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Halaoui R, 2017, GENE DEV, V31, P1573, DOI 10.1101/gad.300566.117; Hao Y, 2010, CURR BIOL, V20, P1809, DOI 10.1016/j.cub.2010.09.032; Hapak SM, 2018, CELL MOL LIFE SCI, V75, P2735, DOI 10.1007/s00018-018-2828-6; Harris TJC, 2005, J CELL BIOL, V170, P813, DOI 10.1083/jcb.200505127; Hawkins ED, 2008, ONCOGENE, V27, P7003, DOI 10.1038/onc.2008.350; HEDDLE JA, 1975, NATURE, V258, P359, DOI 10.1038/258359a0; HOLLIDAY R, 1993, MUTAT RES, V285, P61, DOI 10.1016/0027-5107(93)90052-H; Holly RW, 2020, CURR BIOL, V30, P893, DOI 10.1016/j.cub.2019.12.055; Hong E, 2010, DEV BIOL, V341, P335, DOI 10.1016/j.ydbio.2010.01.034; Horikoshi Y, 2011, CELL STRUCT FUNCT, V36, P97, DOI 10.1247/csf.11005; Horikoshi Y, 2009, J CELL SCI, V122, P1595, DOI 10.1242/jcs.043174; Huebner RJ, 2014, DEVELOPMENT, V141, P1085, DOI 10.1242/dev.103333; Huo YL, 2014, NAT CELL BIOL, V16, P526, DOI 10.1038/ncb2969; Hurd TW, 2003, CURR BIOL, V13, P2082, DOI 10.1016/j.cub.2003.11.020; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Inaba M, 2015, ELIFE, V4, DOI 10.7554/eLife.04960; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh N, 2010, CYTOSKELETON, V67, P297, DOI 10.1002/cm.20444; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jha HC, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005801; Kelsom C, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-38; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kim MK, 2018, BMB REP, V51, P126, DOI 10.5483/BMBRep.2018.51.3.015; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; Knoblich JA, 2010, NAT REV MOL CELL BIO, V11, P849, DOI 10.1038/nrm3010; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kohjima M, 2002, BIOCHEM BIOPH RES CO, V299, P641, DOI 10.1016/S0006-291X(02)02698-0; Kono K, 2019, ELIFE, V8, DOI 10.7554/eLife.45559; Krahn MP, 2010, CURR BIOL, V20, P636, DOI 10.1016/j.cub.2010.01.065; Lang CF, 2017, DEVELOPMENT, V144, P3405, DOI 10.1242/dev.139063; Lechler T, 2005, NATURE, V437, P275, DOI 10.1038/nature03922; Li JJ, 2019, CANCER MED-US, V8, P2288, DOI 10.1002/cam4.2063; Li TY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317698393; Li TY, 2017, BIOCHEM BIOPH RES CO, V482, P1037, DOI 10.1016/j.bbrc.2016.11.154; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Ling J, 2020, J CELL SCI, V133, DOI 10.1242/jcs.249102; Liu ZH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17462-4; Loeffler D, 2019, NATURE, V573, P426, DOI 10.1038/s41586-019-1531-6; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Lv XB, 2015, EMBO REP, V16, P975, DOI 10.15252/embr.201439951; Mangeol P, 2020, SUPER RESOLUTION IMA, DOI 10.1101/2020.08.12.248674; Martin E, 2021, FEBS J, V288, P7073, DOI 10.1111/febs.15710; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Matsuzawa K, 2016, MOL BIOL CELL, V27, P1511, DOI 10.1091/mbc.E15-09-0670; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; McCaffrey LM, 2009, GENE DEV, V23, P1450, DOI 10.1101/gad.1795909; Mescher M, 2017, J EXP MED, V214, P339, DOI 10.1084/jem.20160596; Mizuno K, 2003, J BIOL CHEM, V278, P31240, DOI 10.1074/jbc.M303593200; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Montcouquiol M, 2006, J NEUROSCI, V26, P5265, DOI 10.1523/JNEUROSCI.4680-05.2006; Morais-de-Sa E, 2010, CELL, V141, P509, DOI 10.1016/j.cell.2010.02.040; Morrow A, 2019, ELIFE, V8, DOI 10.7554/eLife.48482; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; NAKAMURA H, 2016, BMC CANCER, V16; Nam SC, 2003, DEVELOPMENT, V130, P4363, DOI 10.1242/dev.00648; Neumuller RA, 2009, GENE DEV, V23, P2675, DOI 10.1101/gad.1850809; Nishant KT, 2009, BIOESSAYS, V31, P912, DOI 10.1002/bies.200900017; Nishimura T, 2005, NAT CELL BIOL, V7, P270, DOI 10.1038/ncb1227; Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118; Oliaro J, 2010, J IMMUNOL, V185, P367, DOI 10.4049/jimmunol.0903627; Piraino SW, 2019, ENCY CANC, P551, DOI DOI 10.1016/B978-0-12-801238-3.65045-6; Poulson ND, 2010, J CELL BIOL, V191, P915, DOI 10.1083/jcb.201008001; Ravid S, 2014, CELL ADHES MIGR, V8, P378, DOI 10.4161/cam.29387; ROCHE J, 2018, CANCERS, V10; Romero G, 2011, ADV PHARMACOL, V62, P279, DOI 10.1016/B978-0-12-385952-5.00003-8; Rothenberg SM, 2010, CANCER RES, V70, P2158, DOI 10.1158/0008-5472.CAN-09-3458; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Simoes SD, 2010, DEV CELL, V19, P377, DOI 10.1016/j.devcel.2010.08.011; Slater M, 2005, HISTOPATHOLOGY, V47, P170, DOI 10.1111/j.1365-2559.2005.02155.x; Supek F, 2015, NATURE, V521, P81, DOI 10.1038/nature14173; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Tan B, 2020, CURR BIOL, V30, P2791, DOI 10.1016/j.cub.2020.05.032; Terawaki S, 2010, EMBO J, V29, P236, DOI 10.1038/emboj.2009.323; Tong S, 2016, ONCOTARGET, V7, P64260, DOI 10.18632/oncotarget.11728; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanlandewijck Michael, 2018, Oncotarget, V9, P5716, DOI 10.18632/oncotarget.23788; Vorhagen S, 2018, ONCOGENE, V37, P5136, DOI 10.1038/s41388-018-0313-1; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Wang L, 2017, MED SCI MONITOR, V23, P2382, DOI 10.12659/MSM.903380; Wang YG, 2006, EMBO J, V25, P5058, DOI 10.1038/sj.emboj.7601384; Wang ZZ, 2009, EMBO J, V28, P2360, DOI 10.1038/emboj.2009.190; Watts JL, 1996, DEVELOPMENT, V122, P3133; Wen WY, 2018, J MOL BIOL, V430, P3504, DOI 10.1016/j.jmb.2017.09.013; WIESCHAUS E, 1986, ROUX ARCH DEV BIOL, V195, P63, DOI 10.1007/BF00444042; Williams E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189081; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Wu H, 2007, MOL CELL, V28, P886, DOI 10.1016/j.molcel.2007.10.028; Xue B, 2013, NAT CELL BIOL, V15, P189, DOI 10.1038/ncb2663; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Ying Z, 2018, NAT CELL BIOL, V20, P1256, DOI 10.1038/s41556-018-0218-9; Zen K, 2009, ONCOGENE, V28, P2910, DOI 10.1038/onc.2009.148; Zhang HY, 2006, NAT CELL BIOL, V8, P227, DOI 10.1038/ncb1368; Zhang P, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.21; Zhang XP, 2019, ONCOGENE, V38, P699, DOI 10.1038/s41388-018-0447-1; Zhang Y, 2013, STRUCTURE, V21, P997, DOI 10.1016/j.str.2013.04.004; Zheng JH, 2017, EUR J GYNAECOL ONCOL, V38, P199, DOI 10.12892/ejgo3440.2017; Zhou PJ, 2019, ONCOGENE, V38, P2192, DOI 10.1038/s41388-018-0580-x; Zhou PJ, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0609-y; Zhou QY, 2017, CELL SIGNAL, V38, P49, DOI 10.1016/j.cellsig.2017.06.016; Zhou Y, 2008, ACTA BIOCH BIOPH SIN, V40, P729, DOI 10.1111/j.1745-7270.2008.00452.x; Zitzelsberger H, 2004, GENE CHROMOSOME CANC, V40, P55, DOI 10.1002/gcc.20024	145	8	8	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4245	4262		10.1038/s41388-021-01813-6	http://dx.doi.org/10.1038/s41388-021-01813-6		JUN 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34099863				2022-12-28	WOS:000658593300001
J	Saraon, P; Pathmanathan, S; Snider, J; Lyakisheva, A; Wong, V; Stagljar, I				Saraon, Punit; Pathmanathan, Shivanthy; Snider, Jamie; Lyakisheva, Anna; Wong, Victoria; Stagljar, Igor			Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches	ONCOGENE			English	Review							TARGETED PROTEIN-DEGRADATION; ANTITUMOR-ACTIVITY; EGFR MUTANTS; ACTIVATION; GROWTH; MET; RESISTANCE; INHIBITION; DRIVEN; CELLS	Receptor tyrosine kinases (RTKs) are transmembrane receptors of great clinical interest due to their role in disease, notably cancer. Since their discovery, several mechanisms of RTK dysregulation have been identified, resulting in multiple cancer types displaying 'oncogenic addiction' to RTKs. As a result, RTKs have represented a major class for targeted therapeutics over the past two decades, with numerous small molecule-based tyrosine kinase inhibitor (TKI) therapeutics having been developed and clinically approved for several cancers. However, many of the current RTK inhibitor treatments eventually result in the rapid development of acquired resistance and subsequent tumor relapse. Recent technological advances and tools are being generated for the identification of novel RTK small molecule therapeutics. These newer technologies will be important for the identification of diverse types of RTK inhibitors, targeting both the receptors themselves as well as key cellular factors that play important roles in the RTK signaling cascade.	[Saraon, Punit] Ontario Inst Canc Res, Drug Discovery Program, Toronto, ON, Canada; [Pathmanathan, Shivanthy; Snider, Jamie; Lyakisheva, Anna; Wong, Victoria; Stagljar, Igor] Univ Toronto, Donnelly Ctr, Toronto, ON, Canada; [Pathmanathan, Shivanthy; Stagljar, Igor] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [Stagljar, Igor] Univ Toronto, Dept Biochem, Toronto, ON, Canada; [Stagljar, Igor] Mediterranean Inst Life Sci, Split, Croatia; [Stagljar, Igor] Univ Split, Sch Med, Split, Croatia	Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates; University of Toronto; University of Toronto; University of Toronto; University of Split	Stagljar, I (corresponding author), Univ Toronto, Donnelly Ctr, Toronto, ON, Canada.; Stagljar, I (corresponding author), Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.; Stagljar, I (corresponding author), Univ Toronto, Dept Biochem, Toronto, ON, Canada.; Stagljar, I (corresponding author), Mediterranean Inst Life Sci, Split, Croatia.; Stagljar, I (corresponding author), Univ Split, Sch Med, Split, Croatia.	igor.stagljar@utoronto.ca						Alshareef A, 2016, SCI REP-UK, V6, DOI 10.1038/srep33710; Baro M, 2019, CLIN CANCER RES, V25, P784, DOI 10.1158/1078-0432.CCR-18-0792; Bender S, 2016, NAT MED, V22, P1314, DOI 10.1038/nm.4204; Bhargava R, 2005, MODERN PATHOL, V18, P1027, DOI 10.1038/modpathol.3800438; Bhullar KS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0804-2; Bondeson DP, 2018, CELL CHEM BIOL, V25, P78, DOI 10.1016/j.chembiol.2017.09.010; Bondeson DP, 2015, NAT CHEM BIOL, V11, P611, DOI [10.1038/NCHEMBIO.1858, 10.1038/nchembio.1858]; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Burslem GM, 2020, CELL, V181, P102, DOI 10.1016/j.cell.2019.11.031; Burslem GM, 2019, CANCER RES, V79, P4744, DOI 10.1158/0008-5472.CAN-19-1236; Burslem GM, 2018, J AM CHEM SOC, V140, P16428, DOI 10.1021/jacs.8b10320; Burslem GM, 2018, CELL CHEM BIOL, V25, P67, DOI 10.1016/j.chembiol.2017.09.009; Castelli MS, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.535; Charest A, 2003, P NATL ACAD SCI USA, V100, P916, DOI 10.1073/pnas.242741799; Chen CHB, 2003, P NATL ACAD SCI USA, V100, P9226, DOI 10.1073/pnas.1332660100; Chen YNP, 2016, NATURE, V535, P148, DOI 10.1038/nature18621; Cheng HY, 2015, CANCER RES, V75, P2737, DOI 10.1158/0008-5472.CAN-15-0370; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Chung BM, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-84; Citri A, 2004, EMBO REP, V5, P1165, DOI 10.1038/sj.embor.7400300; Cocco E, 2018, NAT REV CLIN ONCOL, V15, P731, DOI 10.1038/s41571-018-0113-0; Comoglio PM, 2018, NAT REV CANCER, V18, P341, DOI 10.1038/s41568-018-0002-y; Contessa JN, 2008, CANCER RES, V68, P3803, DOI 10.1158/0008-5472.CAN-07-6389; Contessa JN, 2010, CLIN CANCER RES, V16, P3205, DOI 10.1158/1078-0432.CCR-09-3331; Cromm PM, 2018, J AM CHEM SOC, V140, P17019, DOI 10.1021/jacs.8b08008; Dance M, 2008, CELL SIGNAL, V20, P453, DOI 10.1016/j.cellsig.2007.10.002; Dart ML, 2018, ACS MED CHEM LETT, V9, P546, DOI 10.1021/acsmedchemlett.8b00081; Daver N, 2019, LEUKEMIA, V33, P299, DOI 10.1038/s41375-018-0357-9; De Meyts P, 2015, BIOESSAYS, V37, P389, DOI 10.1002/bies.201400190; Drilon A, 2020, NAT MED, V26, P47, DOI 10.1038/s41591-019-0716-8; Du ZF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0782-4; Ducray SP, 2019, CANCERS, V11, DOI 10.3390/cancers11081074; Esposito CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024071; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Flavahan WA, 2016, NATURE, V529, P110, DOI 10.1038/nature16490; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Gan HK, 2013, FEBS J, V280, P5350, DOI 10.1111/febs.12393; Goh LK, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a017459; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Gujral TS, 2006, CANCER RES, V66, P10741, DOI 10.1158/0008-5472.CAN-06-3329; Harbinski F, 2012, CANCER DISCOV, V2, P948, DOI 10.1158/2159-8290.CD-12-0237; Heldin J, 2019, EXP CELL RES, V380, P69, DOI 10.1016/j.yexcr.2019.04.004; Henderson MJ, 2020, SLAS DISCOV, V25, P137, DOI 10.1177/2472555219877183; IM J, 2020, NAT COMMUN, V11; Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138; Jia Y, 2016, NATURE, V534, P129, DOI 10.1038/nature17960; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Katoh M, 2019, NAT REV CLIN ONCOL, V16, P105, DOI 10.1038/s41571-018-0115-y; Kentsis A, 2012, NAT MED, V18, P1118, DOI 10.1038/nm.2819; Kilpatrick LE, 2017, BIOCHEM PHARMACOL, V136, P62, DOI 10.1016/j.bcp.2017.04.006; Klaver E, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039602; Kobayashi H, 2019, NAT PROTOC, V14, P1084, DOI 10.1038/s41596-019-0129-7; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lopez-Sambrooks C, 2016, NAT CHEM BIOL, V12, P1023, DOI 10.1038/nchembio.2194; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Macdonald JL, 2008, P NATL ACAD SCI USA, V105, P112, DOI 10.1073/pnas.0707080105; Macdonald-Obermann JL, 2014, J BIOL CHEM, V289, P26178, DOI 10.1074/jbc.M114.586826; Machleidt T, 2015, ACS CHEM BIOL, V10, P1797, DOI 10.1021/acschembio.5b00143; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Mak HHL, 2007, ONCOGENE, V26, P7213, DOI 10.1038/sj.onc.1210522; Mellman I, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a016949; Menard L, 2018, CANCER RES, V78, P3267, DOI 10.1158/0008-5472.CAN-17-2195; Molhoek KR, 2011, MELANOMA RES, V21, P274, DOI 10.1097/CMR.0b013e328343a1d6; Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606; Mulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680; Niederst MJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004652; Oh DY, 2020, NAT REV CLIN ONCOL, V17, P33, DOI 10.1038/s41571-019-0268-3; Ohashi Y, 2018, ONCOTARGET, V9, P1641, DOI 10.18632/oncotarget.22895; Ohashi Y, 2016, CANCER RES, V76, P3895, DOI 10.1158/0008-5472.CAN-15-2220; ORCI L, 1991, CELL, V64, P1183; OSTRANDER GK, 1988, CANCER RES, V48, P1091; Paiva SL, 2019, CURR OPIN CHEM BIOL, V50, P111, DOI 10.1016/j.cbpa.2019.02.022; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Perrin J, 2020, NAT BIOTECHNOL, V38, P303, DOI 10.1038/s41587-019-0388-4; Petschnigg J, 2017, J MOL BIOL, V429, P280, DOI 10.1016/j.jmb.2016.12.006; Petschnigg J, 2014, NAT METHODS, V11, P585, DOI [10.1038/NMETH.2895, 10.1038/nmeth.2895]; Pietras K, 2008, PLOS MED, V5, P123, DOI 10.1371/journal.pmed.0050019; Robertson MJ, 2014, NAT PROTOC, V9, P1592, DOI 10.1038/nprot.2014.106; Rosendale M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12434-9; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; Salami J, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0105-8; Sambrooks CL, 2018, CANCER RES, V78, P5094, DOI 10.1158/0008-5472.CAN-18-0505; Saraon P, 2020, NAT CHEM BIOL, V16, P577, DOI 10.1038/s41589-020-0484-2; Savitski MM, 2018, CELL, V173, P260, DOI 10.1016/j.cell.2018.02.030; Savitski MM, 2014, SCIENCE, V346, P55, DOI 10.1126/science.1255784; Schapira M, 2019, NAT REV DRUG DISCOV, V18, P949, DOI 10.1038/s41573-019-0047-y; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sholl LM, 2009, CANCER RES, V69, P8341, DOI 10.1158/0008-5472.CAN-09-2477; Shtiegman K, 2007, ONCOGENE, V26, P6968, DOI 10.1038/sj.onc.1210503; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Stoddart LA, 2018, TRENDS PHARMACOL SCI, V39, P136, DOI 10.1016/j.tips.2017.10.006; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Tamirat MZ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222814; Tape CJ, 2016, CELL, V165, P1818, DOI [10.1016/j.cell.2016.03.029, 10.1016/j.cell.2016.05.079]; Tejada ML, 2006, CLIN CANCER RES, V12, P2676, DOI 10.1158/1078-0432.CCR-05-1770; Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854; To C, 2019, CANCER DISCOV, V9, P926, DOI 10.1158/2159-8290.CD-18-0903; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Villasenor R, 2016, CURR OPIN CELL BIOL, V39, P53, DOI 10.1016/j.ceb.2016.02.002; Villasenor R, 2015, ELIFE, V4, DOI 10.7554/eLife.06156; von Kleist L, 2011, CELL, V146, P471, DOI 10.1016/j.cell.2011.06.025; Wang L, 2020, J MED CHEM, V63, P1281, DOI 10.1021/acs.jmedchem.9b01659; Wang YN, 2010, BIOCHEM BIOPH RES CO, V399, P498, DOI 10.1016/j.bbrc.2010.07.096; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Yao Z, 2017, MOL CELL, V65, P347, DOI 10.1016/j.molcel.2016.12.004; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zhao P, 2018, BIOCHEM BIOPH RES CO, V502, P332, DOI 10.1016/j.bbrc.2018.05.154; Zhao Q, 2017, J AM CHEM SOC, V139, P680, DOI 10.1021/jacs.6b08536; Zsebik B, 2006, IMMUNOL LETT, V104, P146, DOI 10.1016/j.imlet.2005.11.018	113	27	27	4	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4079	4093		10.1038/s41388-021-01841-2	http://dx.doi.org/10.1038/s41388-021-01841-2		JUN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34079087				2022-12-28	WOS:000657217400008
J	Watson, MJ; Berger, PL; Banerjee, K; Frank, SB; Tang, L; Ganguly, SS; Hostetter, G; Winn, M; Miranti, CK				Watson, M. J.; Berger, P. L.; Banerjee, K.; Frank, S. B.; Tang, L.; Ganguly, S. S.; Hostetter, G.; Winn, M.; Miranti, C. K.			Aberrant CREB1 activation in prostate cancer disrupts normal prostate luminal cell differentiation	ONCOGENE			English	Article								The molecular mechanisms of luminal cell differentiation are not understood well enough to determine how differentiation goes awry during oncogenesis. Using RNA-Seq analysis, we discovered that CREB1 plays a central role in maintaining new luminal cell survival and that oncogenesis dramatically changes the CREB1-induced transcriptome. CREB1 is active in luminal cells, but not basal cells. We identified ING4 and its E3 ligase, JFK, as CREB1 transcriptional targets in luminal cells. During luminal cell differentiation, transient induction of ING4 expression is followed by a peak in CREB1 activity, while JFK increases concomitantly with CREB1 activation. Transient expression of ING4 is required for luminal cell induction; however, failure to properly down-regulate ING4 leads to luminal cell death. Consequently, blocking CREB1 increased ING4 expression, suppressed JFK, and led to luminal cell death. Thus, CREB1 is responsible for the suppression of ING4 required for luminal cell survival and maintenance. Oncogenic transformation by suppressing PTEN resulted in constitutive activation of CREB1. However, the tumor cells could no longer fully differentiate into luminal cells, failed to express ING4, and displayed a unique CREB1 transcriptome. Blocking CREB1 in tumorigenic cells suppressed tumor growth in vivo, rescued ING4 expression, and restored luminal cell formation, but ultimately induced luminal cell death. IHC of primary prostate tumors demonstrated a strong correlation between loss of ING4 and loss of PTEN. This is the first study to define a molecular mechanism whereby oncogenic loss of PTEN, leading to aberrant CREB1 activation, suppresses ING4 expression causing disruption of luminal cell differentiation.	[Watson, M. J.; Berger, P. L.; Hostetter, G.; Winn, M.; Miranti, C. K.] Van Andel Res Inst, Ctr Canc & Cell Biol, Grand Rapids, MI 49503 USA; [Banerjee, K.; Frank, S. B.; Tang, L.; Ganguly, S. S.; Miranti, C. K.] Univ Arizona, Dept Cellular & Mol Med, Canc Ctr, Tucson, AZ 85724 USA	Van Andel Institute; University of Arizona	Miranti, CK (corresponding author), Van Andel Res Inst, Ctr Canc & Cell Biol, Grand Rapids, MI 49503 USA.; Miranti, CK (corresponding author), Univ Arizona, Dept Cellular & Mol Med, Canc Ctr, Tucson, AZ 85724 USA.	cmiranti@email.arizona.edu		Watson, McLane/0000-0001-5778-7690; Frank, Sander/0000-0001-7591-944X	DOD; VAI	DOD(United States Department of Defense); VAI	MJW, PLB, KB, SBF, TL, SSG CKM -2 grants from DOD; GH, MW -VAI.	Abate-Shen C, 2008, DIFFERENTIATION, V76, P717, DOI 10.1111/j.1432-0436.2008.00292.x; Berger PL, 2017, PROSTATE, V77, P49, DOI 10.1002/pros.23249; Berger PL, 2014, CANCER RES, V74, P3357, DOI 10.1158/0008-5472.CAN-13-3076; Bhat NR, 2007, NEUROCHEM RES, V32, P293, DOI 10.1007/s11064-006-9274-9; Brandi F, 2018, ONCOL LETT, V16, P6238, DOI 10.3892/ol.2018.9417; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; Capaldo CT, 2015, SEMIN CELL DEV BIOL, V42, P22, DOI 10.1016/j.semcdb.2015.04.003; Chang H, 2015, ANN DIAGN PATHOL, V19, P330, DOI 10.1016/j.anndiagpath.2015.06.010; Cheng JC, 2008, BLOOD, V111, P1182, DOI 10.1182/blood-blood-2007-04-083600; Chhabra A, 2007, ONCOL REP, V18, P953; Cizmecioglu O, 2008, CELL CYCLE, V7, P3548, DOI 10.4161/cc.7.22.7071; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Edick MJ, 2007, MOL BIOL CELL, V18, P2481, DOI 10.1091/mbc.E06-04-0261; Fang ZJ, 2016, ONCOTARGET, V7, P78055, DOI 10.18632/oncotarget.12938; Frank SB, 2017, J CELL SCI, V130, P1952, DOI 10.1242/jcs.197152; Frank SB, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0341-x; Garcia GE, 2006, NEOPLASIA, V8, P523, DOI 10.1593/neo.05745; Garcia-Hernandez V, 2017, ANN NY ACAD SCI, V1397, P66, DOI 10.1111/nyas.13360; Gmyrek GA, 2001, AM J PATHOL, V159, P579, DOI 10.1016/S0002-9440(10)61729-4; Gu TT, 2011, CANCER RES, V71, P2821, DOI 10.1158/0008-5472.CAN-10-3399; Henry GH, 2018, CELL REP, V25, P3530, DOI 10.1016/j.celrep.2018.11.086; Hung T, 2009, MOL CELL, V33, P248, DOI 10.1016/j.molcel.2008.12.016; Jeong SG, 2017, BIOCHEM BIOPH RES CO, V482, P182, DOI 10.1016/j.bbrc.2016.11.031; Kim JH, 2018, BONE, V107, P188, DOI 10.1016/j.bone.2017.12.005; Kirschner N, 2013, J INVEST DERMATOL, V133, P1161, DOI 10.1038/jid.2012.507; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Kwon OJ, 2016, STEM CELLS, V34, P191, DOI 10.1002/stem.2217; Lalonde ME, 2013, GENE DEV, V27, P2009, DOI 10.1101/gad.223396.113; Lamb LE, 2010, J CELL SCI, V123, P266, DOI 10.1242/jcs.054502; Landeira BS, 2018, CEREB CORTEX, V28, P538, DOI 10.1093/cercor/bhw387; Liu WN, 2013, CANCER-AM CANCER SOC, V119, P2405, DOI 10.1002/cncr.27954; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Magnusdottir E, 2007, P NATL ACAD SCI USA, V104, P14988, DOI 10.1073/pnas.0707323104; Martins G, 2008, ANNU REV IMMUNOL, V26, P133, DOI 10.1146/annurev.immunol.26.021607.090241; Melnikova VO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012452; Mochizuki M, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005920; Palacios A, 2010, J MOL BIOL, V396, P1117, DOI 10.1016/j.jmb.2009.12.049; Rahman F, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600506; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Ruan K, 2015, SCI REP-UK, V5, DOI 10.1038/srep12720; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; Steven A, 2016, ONCOTARGET, V7, P35454, DOI 10.18632/oncotarget.7721; Sunkel B, 2016, NUCLEIC ACIDS RES, V44, P4105, DOI 10.1093/nar/gkv1528; Thangapazham R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-16; Thway K, 2012, AM J SURG PATHOL, V36, pE1, DOI 10.1097/PAS.0b013e31825485c5; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang JN, 2012, CANCER RES, V72, P3786, DOI 10.1158/0008-5472.CAN-12-0523; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Xiao GQ, 2020, AM J CLIN PATHOL, V153, P407, DOI 10.1093/ajcp/aqz183; Yan JL, 2007, P NATL ACAD SCI USA, V104, P1841, DOI 10.1073/pnas.0605562104; Yan RR, 2015, GENE DEV, V29, P672, DOI 10.1101/gad.254292.114; Zhang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06177-2; Zhu Q, 2017, ACTA BIOCH BIOPH SIN, V49, P609, DOI 10.1093/abbs/gmx053	54	4	4	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3260	3272		10.1038/s41388-021-01772-y	http://dx.doi.org/10.1038/s41388-021-01772-y		APR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33846571				2022-12-28	WOS:000639635100002
J	Lao, MY; Zhang, XZ; Ma, T; Xu, J; Yang, HS; Duan, Y; Ying, HG; Zhang, XY; Guo, CX; Qiu, JY; Bai, XL; Liang, TB				Lao, Mengyi; Zhang, Xiaozhen; Ma, Tao; Xu, Jian; Yang, Hanshen; Duan, Yi; Ying, Honggang; Zhang, Xiaoyu; Guo, Chengxiang; Qiu, Junyu; Bai, Xueli; Liang, Tingbo			Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells	ONCOGENE			English	Article								Therapeutic strategies to treat pancreatic ductal adenocarcinoma (PDAC) remain unsatisfying and limited. Therefore, it is imperative to fully determine the mechanisms underlying PDAC progression. In the present study, we report a novel role of regulator of calcineurin 1, isoform 4 (RCAN1.4) in regulating PDAC progression. We demonstrated that RCAN1.4 expression was decreased significantly in PDAC tissues compared with that in para-cancerous tissues, and correlated with poor prognosis of patients with pancreatic cancer. In vitro, stable high expression of RCAN1.4 could suppress the metastasis and proliferation and angiogenesis of pancreatic tumor cells. In addition, interferon alpha inducible protein 27 (IFI27) was identified as having a functional role in RCAN1.4-mediated PDAC migration and invasion, while VEGFA play a vital role in RCAN1.4-mediated PDAC angiogenesis. Analysis of mice with subcutaneously/orthotopic implanted xenograft tumors and liver metastasis model confirmed that RCAN1.4 could modulate the growth, metastasis, and angiogenesis of tumors via IFI27/VEGFA in vivo. In conclusion, our results suggested that RCAN1.4 suppresses the growth, metastasis, and angiogenesis of PDAC, functioning partly via IFI27 and VEGFA. Importantly, our results provided possible diagnostic criteria and therapeutic targets for PDAC.	[Lao, Mengyi; Zhang, Xiaozhen; Ma, Tao; Xu, Jian; Yang, Hanshen; Duan, Yi; Ying, Honggang; Zhang, Xiaoyu; Guo, Chengxiang; Qiu, Junyu; Bai, Xueli; Liang, Tingbo] Zhejiang Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China; [Lao, Mengyi; Zhang, Xiaozhen; Ma, Tao; Xu, Jian; Yang, Hanshen; Duan, Yi; Ying, Honggang; Zhang, Xiaoyu; Guo, Chengxiang; Qiu, Junyu; Bai, Xueli; Liang, Tingbo] Zhejiang Prov Key Lab Pancreat Dis, Hangzhou, Peoples R China; [Lao, Mengyi; Zhang, Xiaozhen; Ma, Tao; Xu, Jian; Yang, Hanshen; Duan, Yi; Ying, Honggang; Zhang, Xiaoyu; Guo, Chengxiang; Qiu, Junyu; Bai, Xueli; Liang, Tingbo] Zhejiang Prov Innovat Ctr Study Pancreat Dis, Hangzhou, Peoples R China	Zhejiang University	Bai, XL; Liang, TB (corresponding author), Zhejiang Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China.; Bai, XL; Liang, TB (corresponding author), Zhejiang Prov Key Lab Pancreat Dis, Hangzhou, Peoples R China.; Bai, XL; Liang, TB (corresponding author), Zhejiang Prov Innovat Ctr Study Pancreat Dis, Hangzhou, Peoples R China.	shirleybai@zju.edu.cn; liangtingbo@zju.edu.cn	Zhang, xiaoyu/GXA-3206-2022; Yang, Hanshen/HII-7604-2022	Yang, Hanshen/0000-0001-5220-1996; Zhang, Xiaozhen/0000-0003-3567-8789	National Natural Science Foundation of China [U20A20378, 81871925, 81672337, 82071867, 82071748]; National Key Research and Development Program [2019YFC1316000]; Key Research and Development Program of Zhejiang Province [2019C03019, 2020C03117]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program; Key Research and Development Program of Zhejiang Province	We thank Mr. Minghua Sun for his technical support during sample processing. This study was supported by the National Natural Science Foundation of China (U20A20378, to T-BL; 81871925, 81672337, and 82071867 to X-LB; 82071748 to TM), the National Key Research and Development Program (2019YFC1316000 to T-BL), and the Key Research and Development Program of Zhejiang Province (2019C03019 to T-BL; 2020C03117 to X-LB).	Baek KH, 2009, NATURE, V459, P1126, DOI 10.1038/nature08062; Cheriyath V, 2011, J INTERF CYTOK RES, V31, P173, DOI 10.1089/jir.2010.0105; Chiaravalli M, 2017, CANCER TREAT REV, V60, P32, DOI 10.1016/j.ctrv.2017.08.007; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Hampton T, 2005, JAMA-J AM MED ASSOC, V293, P284, DOI 10.1001/jama.293.3.284; Hasle H, 2000, LANCET, V355, P165, DOI 10.1016/S0140-6736(99)05264-2; Hasle H, 2001, LANCET ONCOL, V2, P429, DOI 10.1016/S1470-2045(00)00435-6; Jang C, 2011, KOREAN J PHYSIOL PHA, V15, P299, DOI 10.4196/kjpp.2011.15.5.299; Jin HJ, 2017, GASTROENTEROLOGY, V153, P799, DOI 10.1053/j.gastro.2017.05.045; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Lee JC, 2013, BIOCHEM BIOPH RES CO, V440, P50, DOI 10.1016/j.bbrc.2013.09.033; Liu NL, 2014, ONCOTARGET, V5, P4959, DOI 10.18632/oncotarget.2067; Martinez-Martineza S, 2009, P NATL ACAD SCI USA, V106, P6117, DOI 10.1073/pnas.0812544106; Mihalich A, 2012, GYNECOL ENDOCRINOL, V28, P216, DOI 10.3109/09513590.2011.588746; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Rosebeck S, 2008, APOPTOSIS, V13, P562, DOI 10.1007/s10495-008-0190-0; Ryeom S, 2008, CANCER CELL, V13, P420, DOI 10.1016/j.ccr.2008.02.018; Satge D, 2001, B ACAD NAT MED PARIS, V185, P1239, DOI 10.1016/S0001-4079(19)34447-4; Song ZS, 2018, EXP CELL RES, V372, P118, DOI 10.1016/j.yexcr.2018.09.017; Suomela S, 2004, J INVEST DERMATOL, V122, P717, DOI 10.1111/j.0022-202X.2004.22322.x; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wang CJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90651; Wang H, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1371-0; Wang-Gillam A, 2016, LANCET, V387, P545, DOI 10.1016/S0140-6736(15)00986-1; Yang QH, 2002, LANCET, V359, P1019, DOI 10.1016/S0140-6736(02)08092-3	25	4	4	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3136	3151		10.1038/s41388-021-01763-z	http://dx.doi.org/10.1038/s41388-021-01763-z		APR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33824473	hybrid, Green Published			2022-12-28	WOS:000637478800004
J	Mantilla-Rojas, C; Yu, M; Rinella, ES; Lynch, RM; Perry, A; Jaimes-Alvarado, J; Anderson, KR; Barba, E; Bourgeois, EJ; Konganti, K; Threadgill, DW				Mantilla-Rojas, Carolina; Yu, Ming; Rinella, Erica S.; Lynch, Rachel M.; Perry, Amie; Jaimes-Alvarado, Jorge; Anderson, Kathryn R.; Barba, Estefania; Bourgeois, Evann J.; Konganti, Kranti; Threadgill, David W.			A molecular subtype of colorectal cancers initiates independently of epidermal growth factor receptor and has an accelerated growth rate mediated by IL10-dependent anergy	ONCOGENE			English	Article							CELL LUNG-CANCER; MOUSE MODELS; COLON; MUTATIONS; CETUXIMAB; MICE; CARCINOMAS; INHIBITOR; GEFITINIB; ADENOMAS	Although epidermal growth factor receptor (EGFR)-targeted therapies are approved for colorectal cancer (CRC) treatment, only 15% of CRC patients respond to EGFR inhibition. Here, we show that colorectal cancers (CRC) can initiate and grow faster through an EGFR-independent mechanism, irrespective of the presence of EGFR, in two different mouse models using tissue-specific ablation of Egfr. The growth benefit in the absence of EGFR is also independent of Kras status. An EGFR-independent gene expression signature, also observed in human CRCs, revealed that anergy-inducing genes are overexpressed in EGFR-independent polyps, suggesting increased infiltration of anergic lymphocytes promotes an accelerated growth rate that is partially caused by escape from cell-mediated immune responses. Many genes in the EGFR-independent gene expression signature are downstream targets of interleukin 10 receptor alpha (IL10RA). We further show that IL10 is detectable in serum from mice with EGFR-independent colon polyps. Using organoids in vitro and Src ablation in vivo, we show that IL10 contributes to growth of EGFR-independent CRCs, potentially mediated by the well-documented role of SRC in IL10 signaling. Based on these data, we show that the combination of an EGFR inhibitor with an anti-IL10 neutralizing antibody results in decreased cell proliferation in organoids and in decreased polyp size in pre-clinical models harboring EGFR-independent CRCs, providing a new therapeutic intervention for CRCs resistant to EGFR inhibitor therapies.	[Mantilla-Rojas, Carolina; Threadgill, David W.] Texas A&M Univ, Interdisciplinary Program Genet, College Stn, TX 77843 USA; [Mantilla-Rojas, Carolina; Lynch, Rachel M.; Perry, Amie; Jaimes-Alvarado, Jorge; Anderson, Kathryn R.; Barba, Estefania; Bourgeois, Evann J.; Threadgill, David W.] Texas A&M Univ, Dept Mol & Cellular Med, College Stn, TX 77843 USA; [Yu, Ming; Rinella, Erica S.; Lynch, Rachel M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27515 USA; [Yu, Ming] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA; [Rinella, Erica S.] GeneDx, Gaithersburg, MD USA; [Perry, Amie] Thompson Bishop Sparks State Diagnost Lab, Auburn, AL USA; [Konganti, Kranti; Threadgill, David W.] Texas A&M Univ, Texas A&M Inst Genome Sci & Soc, College Stn, TX 77843 USA; [Threadgill, David W.] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; [Threadgill, David W.] Texas A&M Univ, Dept Nutr, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; University of North Carolina; University of North Carolina Chapel Hill; Fred Hutchinson Cancer Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Threadgill, DW (corresponding author), Texas A&M Univ, Interdisciplinary Program Genet, College Stn, TX 77843 USA.; Threadgill, DW (corresponding author), Texas A&M Univ, Dept Mol & Cellular Med, College Stn, TX 77843 USA.; Threadgill, DW (corresponding author), Texas A&M Univ, Texas A&M Inst Genome Sci & Soc, College Stn, TX 77843 USA.; Threadgill, DW (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.; Threadgill, DW (corresponding author), Texas A&M Univ, Dept Nutr, College Stn, TX 77843 USA.	dwt@tamu.edu		Lynch, Rachel/0000-0001-8164-0744; Mantilla Rojas, Carolina/0000-0002-3320-2122	NIH [R01 CA092479]; NIEHS [P30 ES029067]; Tom and Jean McMullin Chair of Genetics;  [F31 AT002835];  [F32 CA168301];  [T32 OD011083]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Tom and Jean McMullin Chair of Genetics; ; ; 	This work was supported by fellowships F31 AT002835 (ESR), F32 CA168301 (RML), T32 OD011083 (AP), and by NIH grants R01 CA092479 (DWT), NIEHS P30 ES029067, and the Tom and Jean McMullin Chair of Genetics (DWT). We thank members of the Threadgill lab for constructive criticism on manuscript drafts; Dr. Andrew Hillhouse and the Texas A&M Institute for Genome Sciences and Society's (TIGSS) Molecular Genomics Core for RNAseq data generation; and Kristen Hanneman for mouse husbandry. The results published here are in whole or part based upon data generated by The Cancer Genome Atlas managed by the NCI and NHGRI. Information about TCGA can be found at http://ca ncergenome.nih.gov..	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Becker C, 2005, GUT, V54, P950, DOI 10.1136/gut.2004.061283; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Chen L, 2019, ONCOL REP, V42, P595, DOI 10.3892/or.2019.7206; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Edin S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047045; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Golas JM, 2005, CANCER RES, V65, P5358, DOI 10.1158/0008-5472.CAN-04-2484; Herbeuval JP, 2004, J IMMUNOL, V172, P4630, DOI 10.4049/jimmunol.172.7.4630; Hsu TI, 2016, ONCOTARGET, V7, P20840, DOI 10.18632/oncotarget.7894; Hung KE, 2010, P NATL ACAD SCI USA, V107, P1565, DOI 10.1073/pnas.0908682107; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jackstadt R, 2016, J PATHOL, V238, P141, DOI 10.1002/path.4645; Jackute J, 2018, BMC IMMUNOL, V19, DOI 10.1186/s12865-018-0241-4; Kamizato M, 2009, J GASTROENTEROL, V44, P1172, DOI 10.1007/s00535-009-0119-6; Karapetis CS, 2014, CLIN CANCER RES, V20, P744, DOI 10.1158/1078-0432.CCR-13-0606; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kuraguchi M, 2006, PLOS GENET, V2, P1362, DOI 10.1371/journal.pgen.0020146; Lee TC, 2009, GENESIS, V47, P85, DOI 10.1002/dvg.20464; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mager LF, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00096; Martinelli E, 2009, CLIN EXP IMMUNOL, V158, P1, DOI 10.1111/j.1365-2249.2009.03992.x; Martins M, 2018, ADV EXP MED BIOL, V1110, P113, DOI 10.1007/978-3-030-02771-1_8; MASUI H, 1984, CANCER RES, V44, P1002; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Moran AE, 2004, J BIOL CHEM, V279, P43261, DOI 10.1074/jbc.M404276200; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Mounir M, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006701; Olson TJP, 2014, CANCER PREV RES, V7, P105, DOI 10.1158/1940-6207.CAPR-13-0163; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, JNCI-J NATL CANCER I, V96, P1117, DOI 10.1093/jnci/djh244; Parseghian CM, 2019, CLIN CANCER RES, V25, P6899, DOI 10.1158/1078-0432.CCR-19-0823; Pizarro TT, 2000, AM J PHYSIOL-GASTR L, V278, pG665, DOI 10.1152/ajpgi.2000.278.5.G665; Putoczki TL, 2013, CANCER CELL, V24, P257, DOI 10.1016/j.ccr.2013.06.017; Ren JZ, 2019, J CANCER RES CLIN, V145, P1111, DOI 10.1007/s00432-019-02883-6; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Saqib Uzma, 2018, Oncotarget, V9, P17937, DOI 10.18632/oncotarget.24788; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Schumacher D, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008076; Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Troiani T, 2013, CLIN CANCER RES, V19, P6751, DOI 10.1158/1078-0432.CCR-13-0423; Warmuth M, 2003, CURR PHARM DESIGN, V9, P2043, DOI 10.2174/1381612033454126; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Yang YH, 2014, J CANCER RES CLIN, V140, P1927, DOI 10.1007/s00432-014-1741-0; Zhao S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139598	51	2	2	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3047	3059		10.1038/s41388-021-01752-2	http://dx.doi.org/10.1038/s41388-021-01752-2		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33767440	Green Accepted			2022-12-28	WOS:000632820300005
J	Wei, T; Ji, XW; Gao, Y; Zhu, XM; Xiao, GR				Wei, Tian; Ji, Xiaowen; Gao, Yan; Zhu, Xiaomei; Xiao, Guiran			ZnT7 RNAi favors Raf(GOF)scrib(-/-) -induced tumor growth and invasion in Drosophila through JNK signaling pathway	ONCOGENE			English	Article							ZINC TRANSPORTERS; CELL-DEATH; CANCER; AUTOPHAGY; TRAFFICKING; DEFICIENCY; HOMEOSTASIS; METABOLISM; ACTIVATION; INTERACTS	The disruption of zinc homeostasis has been identified in patients suffering from various cancers, but a causative relationship has not yet been established. Drosophila melanogaster has become a powerful model to study cancer biology. Here using a Drosophila model of malignant tumor Raf(GOF) scrib(-/-), we observed that the tumor growth, invasion and migration were enhanced by silencing dZnT7, a zinc transporter localized on the Golgi apparatus. Further study indicated that the zinc deficiency in Golgi of dZnT7 RNAi resulted in ER stress which could activate the c-Jun-N-terminal Kinase (JNK) signaling and this process is mediated by Atg9. Lastly, we demonstrated that the exacerbation of dZnT7 RNAi on tumor was promoted by JNK signaling-dependent cell autonomous and non-autonomous autophagy. These findings suggest that zinc homeostasis in secretory compartments may provide a new therapeutic target for tumor treatment.	[Wei, Tian; Ji, Xiaowen; Gao, Yan; Xiao, Guiran] Hefei Univ Technol, Sch Food & Biol Engn, Hefei 230009, Anhui, Peoples R China; [Zhu, Xiaomei] Anhui Med Univ, Sch Basic Med Sci, Hefei 230032, Anhui, Peoples R China	Hefei University of Technology; Anhui Medical University	Xiao, GR (corresponding author), Hefei Univ Technol, Sch Food & Biol Engn, Hefei 230009, Anhui, Peoples R China.	xiaoguiran@hfut.edu.cn		Wei, Tian/0000-0001-7270-0979; Xiao, Guiran/0000-0002-1238-1838	National Natural Science Foundation of China [31671284]; Fundamental Research Funds for the Central Universities [JZ2020HGPA0115]; Youth Science and Technology Talents Support Program (2020) by Anhui Association for Science and Technology [RCTJ202001]; National Postdoctoral Program for Innovative Talents [BX201600045]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Youth Science and Technology Talents Support Program (2020) by Anhui Association for Science and Technology; National Postdoctoral Program for Innovative Talents	This project was funded by the National Natural Science Foundation of China (31671284), the Fundamental Research Funds for the Central Universities (JZ2020HGPA0115), Youth Science and Technology Talents Support Program (2020) by Anhui Association for Science and Technology (RCTJ202001), and the National Postdoctoral Program for Innovative Talents (BX201600045). The authors appreciate the gifts of fly stocks from Dr. Bing Zhou and Dr. Jose C. PASTOR-PAREJA. The authors are also grateful to the Bloomington Drosophila Stock Center, the Vienna Drosophila RNAi Center and Tsinghua Fly Center for fly stocks.	Antoniou X, 2011, J ALZHEIMERS DIS, V24, P633, DOI 10.3233/JAD-2011-091567; Bafaro E, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.29; Bali A, 2017, INT J DEV BIOL, V61, P551, DOI 10.1387/ijdb.170077bs; Beira JV, 2016, CHROMOSOMA, V125, P573, DOI 10.1007/s00412-016-0595-4; Bin BH, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/9365747; Biteau B, 2011, EXP GERONTOL, V46, P349, DOI 10.1016/j.exger.2010.11.003; Bubici C, 2014, BRIT J PHARMACOL, V171, P24, DOI 10.1111/bph.12432; Calap-Quintana P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071456; Cousins RJ, 2006, J BIOL CHEM, V281, P24085, DOI 10.1074/jbc.R600011200; Dechen KS, 2015, INT J BIOCHEM CELL B, V60, P23, DOI 10.1016/j.biocel.2014.12.017; Dhanasekaran Danny N, 2017, Genes Cancer, V8, P682, DOI 10.18632/genesandcancer.155; Doggett K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-57; Eom SJ, 2001, MOL PHARMACOL, V59, P981, DOI 10.1124/mol.59.5.981; Franklin RB, 2007, ARCH BIOCHEM BIOPHYS, V463, P211, DOI 10.1016/j.abb.2007.02.033; Groth C, 2013, DEVELOPMENT, V140, P3018, DOI 10.1242/dev.088336; Hershfinkel M, 2007, MOL MED, V13, P331, DOI 10.2119/2006-00038.Hershfinkel; Hrabeta J, 2016, J MOL MED, V94, P1199, DOI 10.1007/s00109-016-1454-8; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Kambe T, 2015, PHYSIOL REV, V95, P749, DOI 10.1152/physrev.00035.2014; Katheder NS, 2017, NATURE, V541, P417, DOI 10.1038/nature20815; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Kolenko V, 2013, NAT REV UROL, V10, P219, DOI 10.1038/nrurol.2013.43; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kushnir T, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006860; Lang ML, 2012, PLOS GENET, V8, P623, DOI 10.1371/journal.pgen.1002683; Lee H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021533; Li DD, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020667; Liang D, 2013, CELL SIGNAL, V25, P1126, DOI 10.1016/j.cellsig.2013.02.003; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Liu SN, 2016, SCI REP-UK, V6, DOI 10.1038/srep38003; Ma XJ, 2017, CELL REP, V19, P2657, DOI 10.1016/j.celrep.2017.05.092; Ma XJ, 2012, CELL RES, V22, P425, DOI 10.1038/cr.2011.135; MacDonald RS, 2000, J NUTR, V130, p1500S, DOI 10.1093/jn/130.5.1500S; Manic G, 2014, MOL CELL ONCOL, V1, DOI 10.4161/mco.29911; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Mishra-Gorur K, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039727; Missirlis F, 2007, GENETICS, V177, P89, DOI 10.1534/genetics.107.075150; Newsome TP, 2000, DEVELOPMENT, V127, P851; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pan Z, 2017, FRONT BIOSCI-LANDMRK, V22, P623, DOI 10.2741/4507; Pastor-Pareja JC, 2013, ANNU REV GENET, V47, P51, DOI 10.1146/annurev-genet-110711-155414; Poillet-Perez L, 2019, GENE DEV, V33, P610, DOI 10.1101/gad.325514.119; Prasad AS, 2013, ADV NUTR, V4, P176, DOI 10.3945/an.112.003210; Qin QH, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-101; Richards CD, 2016, ARCH BIOCHEM BIOPHYS, V611, P142, DOI 10.1016/j.abb.2016.07.015; Richardson HE, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4258387; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Schroeder MC, 2013, ONCOGENE, V32, P4471, DOI 10.1038/onc.2012.476; Sheng ZT, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008863; Sonoshita M, 2017, CURR TOP DEV BIOL, V121, P287, DOI 10.1016/bs.ctdb.2016.07.008; Sousa CM, 2016, NATURE, V536, P479, DOI 10.1038/nature19084; Sun YH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1350-6; Takatani-Nakase T, 2018, BIOL PHARM BULL, V41, P1517, DOI 10.1248/bpb.b18-00086; Tang HW, 2013, DEV CELL, V27, P489, DOI 10.1016/j.devcel.2013.10.017; Tepaamorndech S, 2011, CANCER LETT, V308, P33, DOI 10.1016/j.canlet.2011.04.011; Troost T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049007; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Villegas SN, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039032; Wang XX, 2009, FASEB J, V23, P2650, DOI 10.1096/fj.08-126649; Weber U, 2000, DEVELOPMENT, V127, P3619; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Willsey HR, 2016, ELIFE, V5, DOI 10.7554/eLife.11491; Wu H, 2009, MECH DEVELOP, V126, P624, DOI 10.1016/j.mod.2009.06.1082; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; Xiao GR, 2019, CELL REP, V26, P748, DOI 10.1016/j.celrep.2018.12.053; Xiao GR, 2018, FRONT GENET, V8, DOI 10.3389/fgene.2017.00234; Xiao GR, 2016, ARCH BIOCHEM BIOPHYS, V611, P134, DOI 10.1016/j.abb.2016.04.016; Xiao GR, 2014, ELIFE, V3, DOI 10.7554/eLife.03191; Xu R, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012912; Xue J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109180; Yan M, 2008, J NUTR, V138, P667, DOI 10.1093/jn/138.4.667; Yu HJ, 2009, BIOCHEM J, V417, P133, DOI 10.1042/BJ20081421; Zang YR, 2015, ELIFE, V4, DOI 10.7554/eLife.07187; Zeke A, 2016, MICROBIOL MOL BIOL R, V80, P793, DOI 10.1128/MMBR.00043-14; Zhang L, 2007, BRAIN RES BULL, V74, P278, DOI 10.1016/j.brainresbull.2007.06.022; Zhang XL, 2018, KIDNEY BLOOD PRESS R, V43, P500, DOI 10.1159/000488697	77	4	4	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2217	2229		10.1038/s41388-021-01703-x	http://dx.doi.org/10.1038/s41388-021-01703-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33649534				2022-12-28	WOS:000746143800005
J	Patel, PS; Algouneh, A; Hakem, R				Patel, Parasvi S.; Algouneh, Arash; Hakem, Razq			Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand	ONCOGENE			English	Review								The principle of synthetic lethality, which refers to the loss of viability resulting from the disruption of two genes, which, individually, do not cause lethality, has become an attractive target approach due to the development and clinical success of Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). In this review, we present the most recent findings on the use of PARPi in the clinic, which are currently approved for second-line therapy for advanced ovarian and breast cancer associated with mutations of BRCA1 or BRCA2 (BRCA1/2) genes. PARPi efficacy, however, appears to be limited by acquired and inherent resistance, highlighting the need for alternative and synergistic targets to eliminate these tumors. Here, we explore other identified synthetic lethal interactors of BRCA1/2, including DNA polymerase theta (POLQ), Fanconi anemia complementation group D2 (FANDC2), radiation sensitive 52 (RAD52), Flap structure-specific endonuclease 1 (FEN1), and apurinic/apyrimidinic endodeoxyribonuclease 2 (APE2), as well as other protein and nonprotein targets, for BRCA1/2-mutated cancers and their implications for future therapies. A wealth of information now exists for phenotypic and functional characterization of these novel synthetic lethal interactors of BRCA1/2, and leveraging these findings can pave the way for the development of new targeted therapies for patients suffering from these cancers.	[Patel, Parasvi S.; Algouneh, Arash; Hakem, Razq] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Patel, Parasvi S.; Hakem, Razq] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Algouneh, Arash; Hakem, Razq] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto	Hakem, R (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.; Hakem, R (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.; Hakem, R (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	rhakem@uhnres.utoronto.ca		Hakem, Razqallah/0000-0001-5948-7931; Algouneh, Arash/0000-0002-2080-4941	Canadian Institutes of Health Research [FDN 143214]; Canadian Cancer Society [705367, 706439]; STARS21; Terry Fox Foundation; Princess Margaret Cancer Foundation; Department of Medical Biophysics, University of Toronto; Ontario Graduate Scholarship, Government of Ontario; Canada Graduate Scholarships for Master's program; Ontario Graduate Scholarship; Department of Laboratory Medicine and Pathobiology, University of Toronto; Lee K. and Margaret Lau Chair in Breast Cancer Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society(Canadian Cancer Society (CCS)); STARS21; Terry Fox Foundation; Princess Margaret Cancer Foundation(University of Toronto); Department of Medical Biophysics, University of Toronto; Ontario Graduate Scholarship, Government of Ontario; Canada Graduate Scholarships for Master's program; Ontario Graduate Scholarship(Ontario Graduate Scholarship); Department of Laboratory Medicine and Pathobiology, University of Toronto(University of Toronto); Lee K. and Margaret Lau Chair in Breast Cancer Research	We thank M.A. Pujana for critical reading of the paper. We would also like to thank all the members of the Hakem laboratory for helpful discussions. We apologize to investigators we were unable to reference due to length limitations. RH holds the Lee K. and Margaret Lau Chair in Breast Cancer Research, which is a joint project with the University of Toronto and The Princess Margaret hospital. RH is supported by the Canadian Institutes of Health Research (FDN 143214), and the Canadian Cancer Society (705367 and 706439). PSP is supported by STARS21, Terry Fox Foundation, Princess Margaret Cancer Foundation, Department of Medical Biophysics, University of Toronto, and the Ontario Graduate Scholarship, Government of Ontario. AA is supported by Canada Graduate Scholarships for Master's program, Ontario Graduate Scholarship, and the Department of Laboratory Medicine and Pathobiology, University of Toronto.	Abdel-Fatah TMA, 2014, MOL ONCOL, V8, P1326, DOI 10.1016/j.molonc.2014.04.009; Alvarez-Quilon A, 2020, MOL CELL, V78, P1152, DOI 10.1016/j.molcel.2020.05.021; Bane AL, 2007, AM J SURG PATHOL, V31, P121, DOI 10.1097/01.pas.0000213351.49767.0f; Bhargava R, 2016, TRENDS GENET, V32, P566, DOI 10.1016/j.tig.2016.06.007; Blessing C, 2020, MOL CELL, V80, P862, DOI 10.1016/j.molcel.2020.10.009; Boboila C, 2010, P NATL ACAD SCI USA, V107, P3034, DOI 10.1073/pnas.0915067107; Bryan TM, 2019, MOLECULES, V24, DOI 10.3390/molecules24193439; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Burkovics P, 2006, NUCLEIC ACIDS RES, V34, P2508, DOI 10.1093/nar/gkl259; Burkovics P, 2009, NUCLEIC ACIDS RES, V37, P4247, DOI 10.1093/nar/gkp357; Carbajosa S, 2019, CLIN CANCER RES, V25, P4049, DOI 10.1158/1078-0432.CCR-18-3516; Ceccaldi R, 2015, NATURE, V518, P258, DOI 10.1038/nature14184; Chen CC, 2018, ANNU REV CANC BIOL, V2, P313, DOI 10.1146/annurev-cancerbio-030617-050502; Chen HX, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00909; Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066; Chopra N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16142-7; Cramer-Morales K, 2013, BLOOD, V122, P1293, DOI 10.1182/blood-2013-05-501072; Davies H, 2017, NAT MED, V23, P517, DOI 10.1038/nm.4292; Dungrawala H, 2015, MOL CELL, V59, P998, DOI 10.1016/j.molcel.2015.07.030; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng WJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12234-1; Feng ZH, 2011, P NATL ACAD SCI USA, V108, P686, DOI 10.1073/pnas.1010959107; Fernandez-Vidal A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5285; Gibb B, 2014, NAT STRUCT MOL BIOL, V21, P893, DOI 10.1038/nsmb.2886; Goff JP, 2009, RADIAT RES, V172, P165, DOI 10.1667/RR1598.1; Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387; Gossage L, 2007, MOL DIAGN THER, V11, P361, DOI 10.1007/BF03256260; Grasby JA, 2012, TRENDS BIOCHEM SCI, V37, P74, DOI 10.1016/j.tibs.2011.10.003; Guikema JEJ, 2007, J EXP MED, V204, P3017, DOI 10.1084/jem.20071289; Guo E, 2020, P NATL ACAD SCI USA, V117, P19415, DOI 10.1073/pnas.2009237117; Hanamshet K, 2016, GENES-BASEL, V7, DOI 10.3390/genes7090063; He LF, 2017, MOL ONCOL, V11, P640, DOI 10.1002/1878-0261.12058; He LF, 2016, EBIOMEDICINE, V14, P32, DOI 10.1016/j.ebiom.2016.11.012; Hengel SR, 2016, ELIFE, V5, DOI 10.7554/eLife.14740; Hewitt G, 2021, MOL CELL, V81, P767, DOI 10.1016/j.molcel.2020.12.006; Horton JK, 2014, MOL CANCER RES, V12, P1128, DOI 10.1158/1541-7786.MCR-13-0502; Hromas R, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0912-8; Huang F, 2016, NUCLEIC ACIDS RES, V44, P4189, DOI 10.1093/nar/gkw087; Jensen KA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60656-5; Jensen RB, 2010, NATURE, V467, P678, DOI 10.1038/nature09399; Joo W, 2011, SCIENCE, V333, P312, DOI 10.1126/science.1205805; Juhasz S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb8626; Kais Z, 2008, CANCER BIOL THER, V7, P1540, DOI 10.4161/cbt.7.10.7053; Kais Z, 2016, CELL REP, V15, P2488, DOI 10.1016/j.celrep.2016.05.031; Kent T, 2016, ELIFE, V5, DOI 10.7554/eLife.13740; Kent T, 2015, NAT STRUCT MOL BIOL, V22, P230, DOI 10.1038/nsmb.2961; Knipscheer P, 2009, SCIENCE, V326, P1698, DOI 10.1126/science.1182372; Krais JJ, 2020, CANCER RES, V80, P2848, DOI 10.1158/0008-5472.CAN-19-3033; Krokan HE, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012583; Kumar S, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0129-9; Larsen E, 2003, MOL CELL BIOL, V23, P5346, DOI 10.1128/MCB.23.15.5346-5353.2003; Li H, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01227-0; Lieberman R, 2016, MOL CARCINOGEN, V55, P953, DOI 10.1002/mc.22334; Lim KS, 2018, MOL CELL, V72, P925, DOI 10.1016/j.molcel.2018.10.045; Lok BH, 2013, ONCOGENE, V32, P3552, DOI 10.1038/onc.2012.391; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Lossaint G, 2013, MOL CELL, V51, P678, DOI 10.1016/j.molcel.2013.07.023; Ma CJ, 2017, J BIOL CHEM, V292, P11702, DOI 10.1074/jbc.M117.794545; Malacaria E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09196-9; Mateo J, 2019, ANN ONCOL, V30, P1437, DOI 10.1093/annonc/mdz192; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Mateos-Gomez PA, 2017, NAT STRUCT MOL BIOL, V24, P1116, DOI 10.1038/nsmb.3494; Mateos-Gomez PA, 2015, NATURE, V518, P254, DOI 10.1038/nature14157; Mengwasser KE, 2019, MOL CELL, V73, P885, DOI 10.1016/j.molcel.2018.12.008; Mersch J, 2015, CANCER-AM CANCER SOC, V121, P269, DOI 10.1002/cncr.29041; Morales JC, 2014, CRIT REV EUKAR GENE, V24, P15, DOI 10.1615/CritRevEukaryotGeneExpr.2013006875; Motycka TA, 2004, J BIOL CHEM, V279, P13634, DOI 10.1074/jbc.M313779200; Mouw KW, 2017, CANCER DISCOV, V7, P675, DOI 10.1158/2159-8290.CD-17-0226; Murai J, 2014, MOL CANCER THER, V13, P433, DOI 10.1158/1535-7163.MCT-13-0803; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Nakanishi K, 2011, NAT STRUCT MOL BIOL, V18, P500, DOI 10.1038/nsmb.2029; Nalepa G, 2018, NAT REV CANCER, V18, P168, DOI 10.1038/nrc.2017.116; Neff RT, 2017, THER ADV MED ONCOL, V9, P519, DOI 10.1177/1758834017714993; Nepal M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081804; Nieminuszczy J, 2019, MOL CELL, V75, P605, DOI 10.1016/j.molcel.2019.05.026; Nikolova T, 2009, ANTICANCER RES, V29, P2453; Noordermeer SM, 2019, TRENDS CELL BIOL, V29, P820, DOI 10.1016/j.tcb.2019.07.008; Patel PS, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI140105; Pines A, 2012, J CELL BIOL, V199, P235, DOI 10.1083/jcb.201112132; Pommier Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9246; Przetocka S, 2018, MOL CELL, V72, P568, DOI 10.1016/j.molcel.2018.09.014; Raab M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1395; Renaud E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053693; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Saharia A, 2010, J BIOL CHEM, V285, P27057, DOI 10.1074/jbc.M110.112276; Schlacher K, 2012, CANCER CELL, V22, P106, DOI 10.1016/j.ccr.2012.05.015; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Schwab RA, 2015, MOL CELL, V60, P351, DOI 10.1016/j.molcel.2015.09.012; Sharp MF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64868-7; Shi TY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050461; Shima N, 2004, MOL CELL BIOL, V24, P10381, DOI 10.1128/MCB.24.23.10381-10389.2004; Singh P, 2008, MOL CANCER RES, V6, P1710, DOI 10.1158/1541-7786.MCR-08-0269; Srinivasan G, 2019, P NATL ACAD SCI USA, V116, P17438, DOI 10.1073/pnas.1903150116; Sullivan-Reed K, 2018, CELL REP, V23, P3127, DOI 10.1016/j.celrep.2018.05.034; Sun CF, 2020, CELL MOL LIFE SCI, V77, P3583, DOI 10.1007/s00018-020-03493-z; Thompson LH, 2012, MUTAT RES-REV MUTAT, V751, P158, DOI 10.1016/j.mrrev.2012.06.002; van Pel DM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003254; Verma P, 2021, NAT CELL BIOL, V23, P160, DOI 10.1038/s41556-020-00624-3; Vikas P, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00570; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wei LZ, 2015, P NATL ACAD SCI USA, V112, pE3495, DOI 10.1073/pnas.1507105112; Wei LZ, 2011, CANCER SCI, V102, P1840, DOI 10.1111/j.1349-7006.2011.02037.x; Willis J, 2013, P NATL ACAD SCI USA, V110, P10592, DOI 10.1073/pnas.1301445110; Wood RD, 2016, DNA REPAIR, V44, P22, DOI 10.1016/j.dnarep.2016.05.003; Xu H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14432; Yang Q, 2019, BIOCHEM BIOPH RES CO, V514, P713, DOI 10.1016/j.bbrc.2019.04.201; Yi M, 2019, EXP HEMATOL ONCOL, V8, DOI 10.1186/s40164-019-0154-9; Yousefzadeh MJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004654; Zarrizi R, 2020, J CLIN INVEST, V130, P4069, DOI 10.1172/JCI127521; Zhang BY, 2020, ACTA PHARM SIN B, V10, P615, DOI 10.1016/j.apsb.2019.08.008; Zhang L, 2014, GENET MOL RES, V13, P228, DOI 10.4238/2014.January.14.2; Zhang YY, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/2514090; Zimmer J, 2016, MOL CELL, V61, P449, DOI 10.1016/j.molcel.2015.12.004; Zong DL, 2019, MOL CELL, V73, P1267, DOI 10.1016/j.molcel.2018.12.010	114	26	26	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3001	3014		10.1038/s41388-021-01744-2	http://dx.doi.org/10.1038/s41388-021-01744-2		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33716297				2022-12-28	WOS:000628816100001
J	Lin, CC; Yang, WH; Lin, YT; Tang, XH; Chen, PH; Ding, CKC; Qu, DC; Alvarez, JV; Chi, JT				Lin, Chao-Chieh; Yang, Wen-Hsuan; Lin, Yi-Tzu; Tang, Xiaohu; Chen, Po-Han; Ding, Chien-Kuang Cornelia; Qu, Dan Chen; Alvarez, James V.; Chi, Jen-Tsan			DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway	ONCOGENE			English	Article								Recurrent breast cancer presents significant challenges with aggressive phenotypes and treatment resistance. Therefore, novel therapeutics are urgently needed. Here, we report that murine recurrent breast tumor cells, when compared with primary tumor cells, are highly sensitive to ferroptosis. Discoidin Domain Receptor Tyrosine Kinase 2 (DDR2), the receptor for collagen I, is highly expressed in ferroptosis-sensitive recurrent tumor cells and human mesenchymal breast cancer cells. EMT regulators, TWIST and SNAIL, significantly induce DDR2 expression and sensitize ferroptosis in a DDR2-dependent manner. Erastin treatment induces DDR2 upregulation and phosphorylation, independent of collagen I. Furthermore, DDR2 knockdown in recurrent tumor cells reduces clonogenic proliferation. Importantly, both the ferroptosis protection and reduced clonogenic growth may be compatible with the compromised YAP/TAZ upon DDR2 inhibition. Collectively, these findings identify the important role of EMT-driven DDR2 upregulation in recurrent tumors in maintaining growth advantage but activating YAP/TAZ-mediated ferroptosis susceptibility, providing potential strategies to eradicate recurrent breast cancer cells with mesenchymal features.	[Lin, Chao-Chieh; Yang, Wen-Hsuan; Lin, Yi-Tzu; Chen, Po-Han; Ding, Chien-Kuang Cornelia; Qu, Dan Chen; Chi, Jen-Tsan] Duke Univ, Dept Mol Genet & Microbiol, Sch Med, Durham, NC 27710 USA; [Lin, Chao-Chieh; Yang, Wen-Hsuan; Lin, Yi-Tzu; Chen, Po-Han; Ding, Chien-Kuang Cornelia; Qu, Dan Chen; Chi, Jen-Tsan] Duke Univ, Ctr Genom & Computat Biol, Sch Med, Durham, NC 27710 USA; [Tang, Xiaohu] Michigan Technol Univ, Dept Biol Sci, Houghton, MI 49931 USA; [Alvarez, James V.] Duke Univ, Dept Pharmacol & Canc Biol, Sch Med, Durham, NC 27710 USA	Duke University; Duke University; Michigan Technological University; Duke University	Chi, JT (corresponding author), Duke Univ, Dept Mol Genet & Microbiol, Sch Med, Durham, NC 27710 USA.; Chi, JT (corresponding author), Duke Univ, Ctr Genom & Computat Biol, Sch Med, Durham, NC 27710 USA.	jentsan.chi@duke.edu	Yang, Wen-Hsuan/GVU-4518-2022; Lin, Chao-Chieh/AAC-9102-2022; Yang, Wen-Hsuan/GVU-6615-2022; Tang, Xiaohu/AAX-4577-2021; Yang, Wen-Hsuan/AAY-9158-2021; CHEN, PO-HAN/ABB-6690-2021	Lin, Chao-Chieh/0000-0001-5890-9004; Yang, Wen-Hsuan/0000-0001-5780-6839; Yang, Wen-Hsuan/0000-0001-5780-6839; CHEN, PO-HAN/0000-0002-9471-4471; Chi, Jen-Tsan/0000-0003-3433-903X; Tang, Mark/0000-0001-6367-4991	DOD [W81XWH-17-1-0143, W81XWH-15-1-0486, W81XWH-19-1-0842, W81XWH-20-1-0907]; NIH [R01GM124062, R01NS111588-01A1, 1R21-AI149205]	DOD(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are grateful for technical support from the members of the Chi lab. We also appreciate the generosity of Dr. Everardo Macias for allowing access to the Incucyte S3. We acknowledge the financial support in part by DOD grants (W81XWH-17-1-0143, W81XWH-15-1-0486, W81XWH-19-1-0842, W81XWH-20-1-0907), and NIH grants (R01GM124062, 1R01NS111588-01A1, 1R21-AI149205).	Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; Bayer SVH, 2019, ELIFE, V8, DOI 10.7554/eLife.45508; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Boxer RB, 2004, CANCER CELL, V6, P577, DOI 10.1016/j.ccr.2004.10.013; Burdo J, 2006, J HISTOCHEM CYTOCHEM, V54, P549, DOI 10.1369/jhc.5A6840.2006; Chen PH, 2020, CELL DEATH DIFFER, V27, P1008, DOI 10.1038/s41418-019-0393-7; Chen PH, 2017, MOL CELL ONCOL, V4, DOI 10.1080/23723556.2017.1361501; Chen PH, 2017, EMBO J, V36, P2233, DOI 10.15252/embj.201696113; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; Corsa CAS, 2016, CELL REP, V15, P2510, DOI 10.1016/j.celrep.2016.05.033; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Ding CKC, 2020, NAT METAB, V2, P270, DOI 10.1038/s42255-020-0181-1; Dixon SJ, 2014, ELIFE, V3, DOI 10.7554/eLife.02523; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/NCHEMBIO.2239, 10.1038/nchembio.2239]; Du K, 2019, INHIBITING XCT SLC7A, DOI [10.1101/2019.12.23.886259, DOI 10.1101/2019.12.23.886259]; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Fan Y, 2016, AM J TRANSL RES, V8, P2845; Fox DB, 2020, NAT METAB, V2, P318, DOI 10.1038/s42255-020-0191-z; Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011; Gonzalez ME, 2017, CELL REP, V18, P1215, DOI 10.1016/j.celrep.2016.12.079; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Grither WR, 2018, P NATL ACAD SCI USA, V115, pE7786, DOI 10.1073/pnas.1805020115; Grither WR, 2018, ONCOGENE, V37, P1714, DOI 10.1038/s41388-017-0043-9; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Hammerman PS, 2011, CANCER DISCOV, V1, P78, DOI 10.1158/2159-8274.CD-11-0005; Hayano M, 2016, CELL DEATH DIFFER, V23, P270, DOI 10.1038/cdd.2015.93; Huang CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076421; Hwang PY, 2019, CANCER RES, V79, P1899, DOI 10.1158/0008-5472.CAN-18-2828; Ikeda K, 2002, J BIOL CHEM, V277, P19206, DOI 10.1074/jbc.M201078200; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07126-7; Kimbung S, 2015, SEMIN CANCER BIOL, V35, P85, DOI 10.1016/j.semcancer.2015.08.009; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koo JH, 2020, GENE DEV, V34, P72, DOI 10.1101/gad.331546.119; Lamar JM, 2019, J BIOL CHEM, V294, P2302, DOI 10.1074/jbc.RA118.004364; Li P, 2016, GENE DEV, V30, P798, DOI 10.1101/gad.274951.115; Lin Chao-Chieh, 2020, Oncotarget, V11, P3562, DOI 10.18632/oncotarget.27749; Lin CC, 2020, CELL DEATH DIFFER, V27, P2234, DOI 10.1038/s41418-020-0499-y; Lin CC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03422-6; Linkermann A, 2014, P NATL ACAD SCI USA, V111, P16836, DOI 10.1073/pnas.1415518111; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Mabe NW, 2018, J CLIN INVEST, V128, P4413, DOI 10.1172/JCI99481; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Sasaki S, 2017, ANTICANCER RES, V37, P2587, DOI 10.21873/anticanres.11603; Si Y, 2017, CANCER RES, V77, P4868, DOI 10.1158/0008-5472.CAN-17-0391; Skouta R, 2014, J AM CHEM SOC, V136, P4551, DOI 10.1021/ja411006a; Slocum E, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1142-z; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Tang X, 2017, ONCOGENE, V36, P4235, DOI 10.1038/onc.2016.394; Tang XH, 2016, CANCER RES, V76, P1892, DOI 10.1158/0008-5472.CAN-15-2328; Tang XH, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005158; Terai H, 2015, ACS CHEM BIOL, V10, P2687, DOI 10.1021/acschembio.5b00655; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Toy KA, 2015, BREAST CANCER RES TR, V150, P9, DOI 10.1007/s10549-015-3285-7; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Tsai MC, 2016, ONCOTARGET, V7, P78918, DOI 10.18632/oncotarget.12912; Tu MM, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav2437; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Walsh LA, 2011, MATRIX BIOL, V30, P243, DOI 10.1016/j.matbio.2011.03.007; Wu J, 2019, NATURE, V572, P402, DOI 10.1038/s41586-019-1426-6; Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158; Yang K, 2005, J BIOL CHEM, V280, P39058, DOI 10.1074/jbc.M506921200; Yang WH, 2020, MOL CELL ONCOL, V7, DOI 10.1080/23723556.2019.1699375; Yang WH, 2020, MOL CANCER RES, V18, P79, DOI 10.1158/1541-7786.MCR-19-0691; Yang WH, 2019, CELL REP, V28, P2501, DOI 10.1016/j.celrep.2019.07.107; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang K, 2013, NAT CELL BIOL, V15, P677, DOI 10.1038/ncb2743	72	24	25	4	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2018	2034		10.1038/s41388-021-01676-x	http://dx.doi.org/10.1038/s41388-021-01676-x		FEB 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33603168	Green Accepted			2022-12-28	WOS:000619433100005
J	Goss, KL; Koppenhafer, SL; Waters, T; Terry, WW; Wen, KK; Wu, M; Ostergaard, J; Gordon, PM; Gordon, DJ				Goss, Kelli L.; Koppenhafer, Stacia L.; Waters, Torin; Terry, William W.; Wen, Kuo-Kuang; Wu, Meng; Ostergaard, Jason; Gordon, Peter M.; Gordon, David J.			The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors	ONCOGENE			English	Article							TARGETED PROTEIN-DEGRADATION; RIBONUCLEOTIDE REDUCTASE R2; REPLICATION STRESS; KINASE INHIBITOR; PHASE-I; CANCER; WEE1; HOMOHARRINGTONINE; GEMCITABINE; ACTIVATION	Ribonucleotide reductase (RNR), which is a heterodimeric tetramer composed of RRM1 and RRM2 subunits, is the rate-limiting enzyme in the synthesis of deoxyribonucleoside triphosphates (dNTPs) and essential for both DNA replication and the repair of DNA damage. The activity of RNR is coordinated with the cell cycle and regulated by fluctuations in the level of the RRM2 subunit. Multiple cancer types, including Ewing sarcoma tumors, are sensitive to inhibitors of RNR or a reduction in the levels of either the RRM1 or RRM2 subunits of RNR. Here, we show that the expression of the RRM2 protein is dependent on active protein synthesis and that 4E-BP1, a repressor of cap-dependent protein translation, specifically regulates the level of the RRM2 protein. Furthermore, inhibition of mTORC1/2, but not mTORC1, activates 4E-BP1, inhibits protein synthesis, and reduces the level of the RRM2 protein in multiple sarcoma cell lines. This effect of mTORC1/2 inhibitors on protein synthesis and RRM2 levels was rescued in cell lines with the CRISPR/Cas9-mediated knockout of 4E-BP1. In addition, the inducible expression of a mutant 4E-BP1 protein that cannot be phosphorylated by mTOR blocked protein synthesis and inhibited the growth of Ewing sarcoma cells in vitro and in vivo in a xenograft. Overall, these results provide insight into the multifaceted regulation of RRM2 protein levels and identify a regulatory link between protein translation and DNA replication.	[Goss, Kelli L.; Koppenhafer, Stacia L.; Waters, Torin; Terry, William W.; Gordon, David J.] Univ Iowa, Dept Pediat, Div Pediat Hematol Oncol, Iowa City, IA 52242 USA; [Wen, Kuo-Kuang; Wu, Meng] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; [Ostergaard, Jason; Gordon, Peter M.] Univ Minnesota, Dept Pediat, Div Pediat Hematol Oncol, Minneapolis, MN 55455 USA	University of Iowa; University of Iowa; University of Minnesota System; University of Minnesota Twin Cities	Gordon, DJ (corresponding author), Univ Iowa, Dept Pediat, Div Pediat Hematol Oncol, Iowa City, IA 52242 USA.	david-j-gordon@uiowa.edu		Gordon, David/0000-0003-1830-4371; Wu, Meng/0000-0003-2222-0736	University of Iowa Dance Marathon Award; Holden Comprehensive Cancer Center Sarcoma Multidisciplinary Oncology Group Seed Grant; University of Iowa Oberley Seed Grant; St. Baldrick's Research Foundation; Aiming for a Cure Foundation; Matt Morrell and Natalie Sanchez Pediatric Cancer Research Foundation; NIH [R37-CA217910]; University of Iowa [NIH/NCI P30CA086862]; RPPA Core Facility at MD Anderson Cancer Center (NCI) [CA16672]	University of Iowa Dance Marathon Award; Holden Comprehensive Cancer Center Sarcoma Multidisciplinary Oncology Group Seed Grant; University of Iowa Oberley Seed Grant; St. Baldrick's Research Foundation; Aiming for a Cure Foundation; Matt Morrell and Natalie Sanchez Pediatric Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Iowa; RPPA Core Facility at MD Anderson Cancer Center (NCI)	DJG is supported by a University of Iowa Dance Marathon Award, a Holden Comprehensive Cancer Center Sarcoma Multidisciplinary Oncology Group Seed Grant, a University of Iowa Oberley Seed Grant, St. Baldrick's Research Foundation, Aiming for a Cure Foundation, The Matt Morrell and Natalie Sanchez Pediatric Cancer Research Foundation, and NIH Grant R37-CA217910. We would also like to acknowledge the use of the University of Iowa Flow Cytometry and High Throughput Screening Core Facilities (NIH/NCI P30CA086862), as well as the RPPA Core Facility at MD Anderson Cancer Center (NCI #CA16672).	Aye Y, 2015, ONCOGENE, V34, P2011, DOI 10.1038/onc.2014.155; Ayuso MI, 2010, J BIOL CHEM, V285, P34355, DOI 10.1074/jbc.M110.135103; Burslem GM, 2018, CELL CHEM BIOL, V25, P67, DOI 10.1016/j.chembiol.2017.09.009; Cerqueira NMFSA, 2005, CURR MED CHEM, V12, P1283, DOI 10.2174/0929867054020981; Cerqueira NMFSA, 2007, RECENT PAT ANTI-CANC, V2, P11; Chabes AL, 2004, J BIOL CHEM, V279, P10796, DOI 10.1074/jbc.M312482200; Chang LS, 2020, MOL CANCER THER, V19, P731, DOI 10.1158/1535-7163.MCT-19-0809; Chen R, 2011, BLOOD, V117, P156, DOI 10.1182/blood-2010-01-262808; Choi SH, 2019, GENE DEV, V33, P418, DOI 10.1101/gad.322339.118; Clark NA, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3689-3; De Gassart A, 2016, EMBO REP, V17, P1471, DOI 10.15252/embr.201642194; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Do K, 2015, J CLIN ONCOL, V33, P3409, DOI 10.1200/JCO.2014.60.4009; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Goss KL, 2017, ONCOTARGET, V8, P87016, DOI 10.18632/oncotarget.18776; Goss KL, 2016, ONCOTARGET, V7, P63003, DOI 10.18632/oncotarget.11416; Gurel G, 2009, J MOL BIOL, V389, P146, DOI 10.1016/j.jmb.2009.04.005; Guo XE, 2014, CURR DRUG TARGETS, V15, P2, DOI 10.2174/1389450114666140106095151; Hafner M, 2016, NAT METHODS, V13, P521, DOI [10.1038/NMETH.3853, 10.1038/nmeth.3853]; Hai J, 2017, CLIN CANCER RES, V23, P6993, DOI 10.1158/1078-0432.CCR-17-1098; He ZF, 2017, ONCOTARGET, V8, P41422, DOI 10.18632/oncotarget.17440; Hill SJ, 2018, CANCER DISCOV, V8, P1404, DOI 10.1158/2159-8290.CD-18-0474; Hinnebusch AG, 2016, SCIENCE, V352, P1413, DOI 10.1126/science.aad9868; Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162; Iyer DR, 2017, GENES-BASEL, V8, DOI 10.3390/genes8020074; Jones SE, 2017, CANCER RES, V77, P7014, DOI 10.1158/0008-5472.CAN-17-2056; Ki DH, 2019, ONCOGENE, V38, P6585, DOI 10.1038/s41388-019-0965-5; Kim JR, 2018, INT J MOL SCI, V19, pE674, DOI [10.3390/ijms19030674, DOI 10.1186/s12881-018-0722-6]; Knott MML, 2019, CANCER METAST REV, V38, P625, DOI 10.1007/s10555-019-09839-9; Koppenhafer SL, 2020, MOL CANCER RES, V18, P91, DOI 10.1158/1541-7786.MCR-19-0585; Koppenhafer SL, 2018, MOL CANCER THER, V17, P2676, DOI 10.1158/1535-7163.MCT-18-0260; Kotova I, 2003, EUR J BIOCHEM, V270, P1791, DOI 10.1046/j.1432-1033.2003.03541.x; Lai AC, 2017, NAT REV DRUG DISCOV, V16, P101, DOI 10.1038/nrd.2016.211; Lam SSY, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf3735; Laroche-Clary A, 2018, ANN ONCOL, V29, P1023, DOI 10.1093/annonc/mdy039; Larsson KM, 2004, NAT STRUCT MOL BIOL, V11, P1142, DOI 10.1038/nsmb838; Lecona E, 2014, EXP CELL RES, V329, P26, DOI 10.1016/j.yexcr.2014.09.019; Lee EYHP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003236; Lee JA, 2016, PEDIATR BLOOD CANCER, V63, P1552, DOI 10.1002/pbc.26058; Leijen S, 2016, J CLIN ONCOL, V34, P4371, DOI 10.1200/JCO.2016.67.5991; Li X., 2020, HAEMATOLOGICA, DOI [10.3324/haematol.2019.233445, DOI 10.3324/HAEMAT0L.2019.233445]; Li XY, 2019, HAEMATOLOGICA, V104, P2225, DOI 10.3324/haematol.2018.201343; Liu Y, 2017, CANCER RES, V77, P5068, DOI 10.1158/0008-5472.CAN-17-0567; Lowery CD, 2019, CLIN CANCER RES, V25, P2278, DOI 10.1158/1078-0432.CCR-18-2728; Lowery CD, 2017, CLIN CANCER RES, V23, P4354, DOI 10.1158/1078-0432.CCR-16-2876; Moorthy NSHN, 2013, MINI-REV MED CHEM, V13, P1862, DOI 10.2174/13895575113136660090; Muller D, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.121951; Murai J, 2019, PHARMACOL THERAPEUT, V201, P94, DOI 10.1016/j.pharmthera.2019.05.009; Musa J, 2016, ONCOGENE, V35, P4675, DOI 10.1038/onc.2015.515; Neklesa TK, 2017, PHARMACOL THERAPEUT, V174, P138, DOI 10.1016/j.pharmthera.2017.02.027; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; Okimoto RA, 2019, J CLIN INVEST, V129, P3401, DOI 10.1172/JCI126366; Paiva SL, 2019, CURR OPIN CHEM BIOL, V50, P111, DOI 10.1016/j.cbpa.2019.02.022; Pettersson Mariell, 2019, Drug Discov Today Technol, V31, P15, DOI 10.1016/j.ddtec.2019.01.002; Pfister SX, 2015, CANCER CELL, V28, P557, DOI 10.1016/j.ccell.2015.09.015; Qin XY, 2016, CELL CYCLE, V15, P781, DOI 10.1080/15384101.2016.1151581; Rundle S, 2017, CANCERS, V9, DOI 10.3390/cancers9050041; Saini P, 2015, ONCOTARGET, V6, P13072, DOI 10.18632/oncotarget.3865; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Slotkin EK, 2015, MOL CANCER THER, V14, P395, DOI 10.1158/1535-7163.MCT-14-0711; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Stewart E, 2018, CANCER CELL, V34, P411, DOI 10.1016/j.ccell.2018.07.012; Stewart E, 2017, NATURE, V549, P96, DOI 10.1038/nature23647; Tang RP, 2006, MOL CANCER THER, V5, P723, DOI 10.1158/1535-7163.MCT-05-0164; Tang SW, 2015, CLIN CANCER RES, V21, P4184, DOI 10.1158/1078-0432.CCR-14-2112; Truman AW, 2015, J PROTEOMICS, V112, P285, DOI 10.1016/j.jprot.2014.09.028; van der Donk WA, 1998, BIOCHEMISTRY-US, V37, P6419, DOI 10.1021/bi9729357; Wallez Y, 2018, MOL CANCER THER, V17, P1670, DOI 10.1158/1535-7163.MCT-18-0010; Wang H, 2006, SEMIN ONCOL, V33, P513, DOI 10.1053/j.seminoncol.2006.04.013; Wang XH, 2014, MOL CELL ENDOCRINOL, V382, P8, DOI 10.1016/j.mce.2013.09.003; Wang ZY, 2019, CANCER RES, V79, P1438, DOI 10.1158/0008-5472.CAN-18-1220; Zhang YW, 2009, J BIOL CHEM, V284, P18085, DOI 10.1074/jbc.M109.003020; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao JY, 2017, ONCOTARGET, V8, P6319, DOI 10.18632/oncotarget.14062; Zhou BS, 2013, CANCER RES, V73, P6484, DOI 10.1158/0008-5472.CAN-13-1094; Zoppoli G, 2012, P NATL ACAD SCI USA, V109, P15030, DOI 10.1073/pnas.1205943109	77	2	2	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					564	577		10.1038/s41388-020-01552-0	http://dx.doi.org/10.1038/s41388-020-01552-0		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33191406	Green Accepted			2022-12-28	WOS:000589571100002
J	Ahuja, A; Journo, G; Eitan, R; Rubin, E; Shamay, M				Ahuja, Anuj; Journo, Guy; Eitan, Ron; Rubin, Eitan; Shamay, Meir			High levels of LINE-1 transposable elements expressed in Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma	ONCOGENE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; ENDOGENOUS RETROVIRUS HERV-K18; ENCODED REVERSE-TRANSCRIPTASE; GENE-EXPRESSION; CELL-PROLIFERATION; DNA; RETROTRANSPOSITION; DIFFERENTIATION; HYPOMETHYLATION; IDENTIFICATION	Kaposi's sarcoma-associated herpesvirus (KSHV, HHV-8) is a gamma herpesvirus associated with several human malignancies. Transposable elements (TEs) are ubiquitous in eukaryotic genomes, occupying about 45% of the human genome. TEs have been linked with a variety of disorders and malignancies, though the precise nature of their contribution to many of them has yet to be elucidated. Global transcriptome analysis for differentially expressed TEs in KSHV-associated primary effusion lymphoma (PEL) cells (BCBL1 and BC3) revealed large number of differentially expressed TEs. These differentially expressed TEs include LTR transposons, long interspersed nuclear elements (LINEs), and short interspersed nuclear elements (SINEs). Further analysis of LINE-1 (L1) elements revealed expression upregulation, hypo-methylation, and transition into open chromatin in PEL. In agreement with high L1 expression, PEL cells express ORF1 protein and possess high reverse transcriptase (RT)-activity. Interestingly, inhibition of this RT-activity suppressed PEL cell growth. Collectively, we identified high expression of TEs, and specifically of L1 as a critical component in the proliferation of PEL cells. This observation is relevant for the treatment of KSHV-associated malignancies since they often develop in AIDS patients that are treated with RT inhibitors with potent inhibition for both HIV and L1 RT activity.	[Ahuja, Anuj; Journo, Guy; Eitan, Ron; Shamay, Meir] Bar Ilan Univ, Azrieli Fac Med, Daniella Lee Casper Lab Viral Oncol, Safed, Israel; [Rubin, Eitan] Ben Gurion Univ Negev, Shraga Segal Dept Microbiol & Immunol, Fac Hlth Sci, IL-84105 Beer Sheva, Israel	Bar Ilan University; Ben Gurion University	Shamay, M (corresponding author), Bar Ilan Univ, Azrieli Fac Med, Daniella Lee Casper Lab Viral Oncol, Safed, Israel.	meir.shamay@biu.ac.il	Ahuja, Anuj/ABA-2550-2021; Rubin, Eitan/E-5256-2011	Ahuja, Anuj/0000-0002-0558-1356; Rubin, Eitan/0000-0002-7807-4005	Israel Science Foundation [1134/16]; Israel Cancer Association - Walter Bela foundation [20150095, 20161143]; Research Career Development Award from the Israel Cancer Research Fund [01282]; Elias, Genevieve, and Georgianna Atol Charitable Trust	Israel Science Foundation(Israel Science Foundation); Israel Cancer Association - Walter Bela foundation; Research Career Development Award from the Israel Cancer Research Fund; Elias, Genevieve, and Georgianna Atol Charitable Trust	We would like to thank S. Diane hayward, Richard F. Ambinder, Jeffrey Vieira, Shou-Jiang (SJ) Gao, Milana Frenkel-Morgenstern, and Ronit Sarid for cell lines. This work was supported by grants from the Israel Science Foundation (https://www.isf.org.il) (1134/16), the Israel Cancer Association (20150095, 20161143) funded by the Walter Bela foundation, and a Research Career Development Award from the Israel Cancer Research Fund (https://www.icrfonline.org/) (01282) to MS. We are grateful for the support of the Elias, Genevieve, and Georgianna Atol Charitable Trust to the Daniella Lee Casper Laboratory in Viral Oncology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.	Alisch RS, 2006, GENE DEV, V20, P210, DOI 10.1101/gad.1380406; Alves G, 1996, GENE, V176, P39, DOI 10.1016/0378-1119(96)00205-3; Ardeljan D, 2019, MOBILE DNA-UK, V11, DOI 10.1186/s13100-019-0191-2; Aschacher T, 2016, ONCOGENE, V35, P94, DOI 10.1038/onc.2015.65; Babushok DV, 2007, HUM MUTAT, V28, P527, DOI 10.1002/humu.20486; Beck CR, 2011, ANNU REV GENOM HUM G, V12, P187, DOI 10.1146/annurev-genom-082509-141802; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Burger D, 2006, BRIT J CLIN PHARMACO, V61, P148, DOI 10.1111/j.1365-2125.2005.02536.x; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Crauwels H, 2013, AIDS REV, V15, P87; Criscione SW, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2800-5; Dai LX, 2011, BMC BIOCHEM, V12, DOI 10.1186/1471-2091-12-18; Dai L, 2018, ONCOGENE, V37, P4534, DOI 10.1038/s41388-018-0282-4; de Koning APJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002384; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Erichsen L, 2018, SAUDI J BIOL SCI, V25, P1220, DOI 10.1016/j.sjbs.2018.02.005; Goering W, 2011, CARCINOGENESIS, V32, P1484, DOI 10.1093/carcin/bgr181; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hata K, 1997, GENE, V189, P227, DOI 10.1016/S0378-1119(96)00856-6; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Henke-Gendo C, 2004, CURR OPIN INFECT DIS, V17, P53, DOI 10.1097/00001432-200402000-00011; Johnson WE, 2015, ANNU REV VIROL, V2, P135, DOI 10.1146/annurev-virology-100114-054945; Jones RB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001547; Jonsson ME, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11150-8; Journo G, 2018, J VIROL, V92, DOI 10.1128/JVI.00008-18; Karijolich J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005260; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Klein U, 2003, BLOOD, V101, P4115, DOI 10.1182/blood-2002-10-3090; Kopylova E, 2012, BIOINFORMATICS, V28, P3211, DOI 10.1093/bioinformatics/bts611; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Landriscina M, 2005, J CLIN ENDOCR METAB, V90, P5663, DOI 10.1210/jc.2005-0367; Lee E, 2012, SCIENCE, V337, P967, DOI 10.1126/science.1222077; Lee J, 2007, GENE, V390, P18, DOI 10.1016/j.gene.2006.08.029; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Menendez L, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-12; Nakayama R, 2019, ONCOGENE, V38, P4340, DOI 10.1038/s41388-019-0726-5; Oakes CC, 2016, NAT GENET, V48, P253, DOI 10.1038/ng.3488; Oricchio E, 2007, ONCOGENE, V26, P4226, DOI 10.1038/sj.onc.1210214; Patnala R, 2014, BREAST CANCER RES TR, V143, P239, DOI 10.1007/s10549-013-2812-7; Pizzato M, 2009, J VIROL METHODS, V156, P1, DOI 10.1016/j.jviromet.2008.10.012; Poole LJ, 2002, J VIROL, V76, P3395, DOI 10.1128/JVI.76.7.3395-3420.2002; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sciamanna E, 2005, ONCOGENE, V24, P3923, DOI 10.1038/sj.onc.1208562; Sciamanna I, 2013, ONCOTARGET, V4, P2271, DOI 10.18632/oncotarget.1403; Shamay M, 2010, J BIOL CHEM, V285, P36377, DOI 10.1074/jbc.M110.155721; Sharma M, 2013, J ANTIMICROB CHEMOTH, V68, P250, DOI 10.1093/jac/dks404; Shukla R, 2013, CELL, V153, P101, DOI 10.1016/j.cell.2013.02.032; Sutkowski N, 2001, IMMUNITY, V15, P579, DOI 10.1016/S1074-7613(01)00210-2; Sutkowski N, 2004, J VIROL, V78, P7852, DOI 10.1128/JVI.78.14.7852-7860.2004; Tangkijvanich P, 2007, CLIN CHIM ACTA, V379, P127, DOI 10.1016/j.cca.2006.12.029; Tinari A, 2008, INT J IMMUNOPATH PH, V21, P999, DOI 10.1177/039463200802100425; Tolani B, 2014, ONCOGENE, V33, P2928, DOI 10.1038/onc.2013.242; Vermeire J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050859; Vieira J, 2004, VIROLOGY, V325, P225, DOI 10.1016/j.virol.2004.03.049; Viollet C, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006143; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Wang HW, 2004, NAT GENET, V36, P687, DOI 10.1038/ng1384; Xie Y, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1076; Zheng YN, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0733-y	61	0	1	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					536	550		10.1038/s41388-020-01549-9	http://dx.doi.org/10.1038/s41388-020-01549-9		NOV 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33188297				2022-12-28	WOS:000589573800001
J	He, D; Wang, D; Lu, P; Yang, N; Xue, ZG; Zhu, XM; Zhang, P; Fan, GP				He, Di; Wang, Di; Lu, Ping; Yang, Nan; Xue, Zhigang; Zhu, Xianmin; Zhang, Peng; Fan, Guoping			Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations	ONCOGENE			English	Article							NF-KAPPA-B; ETS TRANSCRIPTION FACTOR; NONCODING RNA; NECROSIS-FACTOR; CANCER; EXPRESSION; METASTASIS; PROGRESSION; INDUCTION; ACTIVATOR	Lung adenocarcinoma (LUAD) harboring EGFR mutations prevails in Asian population. However, the inter-patient and intra-tumor heterogeneity has not been addressed at single-cell resolution. Here we performed single-cell RNA sequencing (scRNA-seq) of total 125,674 cells from seven stage-I/II LUAD samples harboring EGFR mutations and five tumor-adjacent lung tissues. We identified diverse cell types within the tumor microenvironment (TME) in which myeloid cells and T cells were the most abundant stromal cell types in tumors and adjacent lung tissues. Within tumors, accompanied by an increase in CD1C(+) dendritic cells, the tumor-associated macrophages (TAMs) showed pro-tumoral functions without signature gene expression of defined M1 or M2 polarization. Tumor-infiltrating T cells mainly displayed exhausted and regulatory T-cell features. The adenocarcinoma cells can be categorized into different subtypes based on their gene expression signatures in distinct pathways such as hypoxia, glycolysis, cell metabolism, translation initiation, cell cycle, and antigen presentation. By performing pseudotime trajectory, we found that ELF3 was among the most upregulated genes in more advanced tumor cells. In response to secretion of inflammatory cytokines (e.g., IL1B) from immune infiltrates, ELF3 in tumor cells was upregulated to trigger the activation of PI3K/Akt/NF-kappa B pathway and elevated expression of proliferation and anti-apoptosis genes such as BCL2L1 and CCND1. Taken together, our study revealed substantial heterogeneity within early-stage LUAD harboring EGFR mutations, implicating complex interactions among tumor cells, stromal cells and immune infiltrates in the TME.	[He, Di; Zhu, Xianmin; Fan, Guoping] ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China; [He, Di; Wang, Di; Zhu, Xianmin; Zhang, Peng] Tongji Univ, Shanghai Pulm Hosp, Sch Life Sci & Technol, Dept Thorac Surg, Shanghai 200433, Peoples R China; [Lu, Ping; Xue, Zhigang] Tongji Univ, Tongji Hosp, Translat Ctr Stem Cell Res, Dept Regenerat Med,Sch Med, Shanghai 200065, Peoples R China; [Yang, Nan] Zhangjiang High Tech Pk Ltd, PharmaLegacy Labs Shanghai Co, Bldg 7,388 Jialilue Rd, Shanghai 201203, Peoples R China; [Fan, Guoping] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA	ShanghaiTech University; Tongji University; Tongji University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Zhu, XM; Fan, GP (corresponding author), ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China.; Zhu, XM; Zhang, P (corresponding author), Tongji Univ, Shanghai Pulm Hosp, Sch Life Sci & Technol, Dept Thorac Surg, Shanghai 200433, Peoples R China.; Fan, GP (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.	xianminzhu@hotmail.com; zhangpeng1121@aliyun.com; gfan@mednet.ucla.edu	Zhu, Xianmin/M-6437-2017	Zhu, Xianmin/0000-0003-1405-9700; Fan, Guoping/0000-0001-5235-6410; Lu, Ping/0000-0002-0127-3911	National Program on Key Basic Research Project (973 Program) [2015CB964702, 2015CB964601]; National Natural Science Foundation of China [81570521, 81470244, 81622001, 81430026, 91642108, 31871288]; Experimental Animal Research Fund, Science and Technology Commission of Shanghai Municipality [18140903900, 15140903900]; Fundamental Research Funds for the Central Universities	National Program on Key Basic Research Project (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Experimental Animal Research Fund, Science and Technology Commission of Shanghai Municipality; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	We thank Wei Jiang at Genergy Bio-technology (Shanghai) Co., Ltd and Minghui Li at Sinotech Genomics (Shenzhen) Co., Ltd for their contribution in library construction, sequencing and data analysis. The work was supported by National Program on Key Basic Research Project (973 Program 2015CB964702, 2015CB964601); National Natural Science Foundation of China (81570521, 81470244, 81622001, 81430026, 91642108, 31871288); Experimental Animal Research Fund, Science and Technology Commission of Shanghai Municipality (18140903900, 15140903900); Fundamental Research Funds for the Central Universities (Xianmin Zhu and Peng Zhang).	Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; AlHossiny M, 2016, CANCER RES, V76, P3376, DOI 10.1158/0008-5472.CAN-15-2654; Altorki NK, 2019, NAT REV CANCER, V19, P9, DOI 10.1038/s41568-018-0081-9; Apostolopoulos V, 2015, CELL MOL LIFE SCI, V72, P4475, DOI 10.1007/s00018-015-2014-z; Apte RN, 2006, EUR J CANCER, V42, P751, DOI 10.1016/j.ejca.2006.01.010; Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060; Bishop JA, 2010, HUM PATHOL, V41, P20, DOI 10.1016/j.humpath.2009.06.014; Bouillez A, 2017, ONCOGENE, V36, P4037, DOI 10.1038/onc.2017.47; Campbell MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079114; Campbell MJ, 2011, BREAST CANCER RES TR, V128, P703, DOI 10.1007/s10549-010-1154-y; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chen HM, 2019, ONCOL REP, V41, P570, DOI 10.3892/or.2018.6807; Chiossone L, 2018, NAT REV IMMUNOL, V18, P671, DOI 10.1038/s41577-018-0061-z; Chittezhath M, 2014, IMMUNITY, V41, P815, DOI 10.1016/j.immuni.2014.09.014; Cortot AB, 2014, EUR RESPIR REV, V23, P356, DOI 10.1183/09059180.00004614; Dong PX, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00471; Enfield KSS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13295-y; Engblom C, 2016, NAT REV CANCER, V16, P447, DOI 10.1038/nrc.2016.54; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Goossens P, 2019, CELL METAB, V29, P1376, DOI 10.1016/j.cmet.2019.02.016; Grall F, 2003, ARTHRITIS RHEUM, V48, P1249, DOI 10.1002/art.10942; Guha A, 2012, P NATL ACAD SCI USA, V109, P12592, DOI 10.1073/pnas.1204710109; Guo XY, 2018, NAT MED, V24, P978, DOI 10.1038/s41591-018-0045-3; Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Hu P, 2017, MOL CELL, V68, P1006, DOI 10.1016/j.molcel.2017.11.017; Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Klein AM, 2015, CELL, V161, P1187, DOI 10.1016/j.cell.2015.04.044; Lambrechts D, 2018, NAT MED, V24, P1277, DOI 10.1038/s41591-018-0096-5; Lanitis E, 2017, ANN ONCOL, V28, P18, DOI 10.1093/annonc/mdx238; Laoui D, 2014, CANCER RES, V74, P24, DOI 10.1158/0008-5472.CAN-13-1196; Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014; Li HJ, 2019, CELL, V176, P775, DOI 10.1016/j.cell.2018.11.043; Longoni N, 2013, CANCER RES, V73, P4533, DOI 10.1158/0008-5472.CAN-12-4537; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Milette S, 2019, J PATHOL, V247, P589, DOI 10.1002/path.5241; Min JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135817; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mukhtar RA, 2012, ANN SURG ONCOL, V19, P3979, DOI 10.1245/s10434-012-2415-2; Murdoch C, 2005, INT J CANCER, V117, P701, DOI 10.1002/ijc.21422; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Oliver JR, 2012, LAB INVEST, V92, P320, DOI 10.1038/labinvest.2011.186; Oliver JR, 2011, LAB INVEST, V91, P1514, DOI 10.1038/labinvest.2011.100; Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055; Ozes ON, 1999, NATURE, V401, P82; Peng JY, 2019, CELL RES, V29, P725, DOI 10.1038/s41422-019-0195-y; Peterson VM, 2017, NAT BIOTECHNOL, V35, P936, DOI 10.1038/nbt.3973; Pocha K, 2020, CLIN CANCER RES, V26, P2231, DOI 10.1158/1078-0432.CCR-19-2184; Psallidas I, 2013, ONCOGENE, V32, P528, DOI 10.1038/onc.2012.57; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Reynolds SD, 2002, AM J RESP CRIT CARE, V166, P1498, DOI 10.1164/rccm.200204-285OC; Seow WJ, 2017, HUM MOL GENET, V26, P454, DOI 10.1093/hmg/ddw414; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun Y, 2019, CANCERS, V216, P1; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Torre LA, 2016, ADV EXP MED BIOL, V893, P1, DOI 10.1007/978-3-319-24223-1_1; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Wang H, 2018, INT J BIOCHEM CELL B, V94, P98, DOI 10.1016/j.biocel.2017.12.002; Wang JL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.206; Wang YQ, 2017, GENOM PROTEOM BIOINF, V15, P14, DOI 10.1016/j.gpb.2017.01.001; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Wu J, 2008, CELL RES, V18, P649, DOI 10.1038/cr.2008.57; Xiao G, 2012, P NATL ACAD SCI USA, V109, P15419, DOI 10.1073/pnas.1206370109; Xu X, 2012, P NATL ACAD SCI USA, V109, P4910, DOI 10.1073/pnas.1112499109; Zacharias WJ, 2018, NATURE, V555, P251, DOI 10.1038/nature25786; Zhang L, 2019, ARTIF CELL NANOMED B, V47, P2516, DOI 10.1080/21691401.2019.1626409; Zhang YM, 2014, INFLAMMATION, V37, P1240, DOI 10.1007/s10753-014-9851-z; Zhang Z, 2019, NUCLEIC ACIDS RES, V47, pD8, DOI 10.1093/nar/gky993; Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049; Zheng LB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0399-y; Zheng PM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0465-5	77	52	53	4	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					355	368		10.1038/s41388-020-01528-0	http://dx.doi.org/10.1038/s41388-020-01528-0		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33144684	Green Published, hybrid			2022-12-28	WOS:000585016500001
J	Zhu, M; Peng, RQ; Liang, X; Lan, ZD; Tang, M; Hou, PP; Song, JH; Mak, CSL; Park, J; Zheng, SE; Huang, AL; Ma, XD; Chen, RD; Chang, Q; Logothetis, CJ; Jain, AK; Lin, SH; Katayama, H; Hanash, S; Wang, GC				Zhu, Ming; Peng, Ruiqing; Liang, Xin; Lan, Zhengdao; Tang, Ming; Hou, Pingping; Song, Jian H.; Mak, Celia Sze Ling; Park, Jiwon; Zheng, Shui-er; Huang, Ailing; Ma, Xingdi; Chen, Ruidong; Chang, Qing; Logothetis, Christopher J.; Jain, Abhinav K.; Lin, Sue-Hwa; Katayama, Hiroyuki; Hanash, Samir; Wang, Guocan			P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis	ONCOGENE			English	Article							HIPPO PATHWAY; TUMOR-SUPPRESSOR; SWI/SNF COMPLEX; YAP; GROWTH; COLLAGEN; KRAS; TRANSCRIPTION; APOPTOSIS; P73	Yes-associated protein 1 (YAP1), a key player in the Hippo pathway, has been shown to play a critical role in tumor progression. However, the role of YAP1 in prostate cancer cell invasion, migration, and metastasis is not well defined. Through functional, transcriptomic, epigenomic, and proteomic analyses, we showed that prolyl hydroxylation of YAP1 plays a critical role in the suppression of cell migration, invasion, and metastasis in prostate cancer. Knockdown (KD) or knockout (KO) of YAP1 led to an increase in cell migration, invasion, and metastasis in prostate cancer cells. Microarray analysis showed that the EMT pathway was activated in Yap1-KD cells. ChIP-seq analysis showed that YAP1 target genes are enriched in pathways regulating cell migration. Mass spectrometry analysis identified P4H prolyl hydroxylase in the YAP1 complex and YAP1 was hydroxylated at multiple proline residues. Proline-to-alanine mutations of YAP1 isoform 3 identified proline 174 as a critical residue, and its hydroxylation suppressed cell migration, invasion, and metastasis. KO of P4ha2 led to an increase in cell migration and invasion, which was reversed upon Yap1 KD. Our study identified a novel regulatory mechanism of YAP1 by which P4HA2-dependent prolyl hydroxylation of YAP1 determines its transcriptional activities and its function in prostate cancer metastasis.	[Zhu, Ming; Peng, Ruiqing; Liang, Xin; Song, Jian H.; Mak, Celia Sze Ling; Park, Jiwon; Zheng, Shui-er; Huang, Ailing; Chen, Ruidong; Logothetis, Christopher J.; Lin, Sue-Hwa; Wang, Guocan] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Zhu, Ming; Peng, Ruiqing; Liang, Xin; Song, Jian H.; Mak, Celia Sze Ling; Park, Jiwon; Zheng, Shui-er; Huang, Ailing; Chen, Ruidong; Logothetis, Christopher J.; Lin, Sue-Hwa; Wang, Guocan] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Houston, TX 77030 USA; [Peng, Ruiqing] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China; [Lan, Zhengdao; Hou, Pingping; Ma, Xingdi; Wang, Guocan] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Tang, Ming; Chang, Qing] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Jain, Abhinav K.] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis & Epigen Profi, Houston, TX 77030 USA; [Lin, Sue-Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Katayama, Hiroyuki; Hanash, Samir] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; State Key Lab Oncology South China; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wang, GC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.; Wang, GC (corresponding author), Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Houston, TX 77030 USA.; Wang, GC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.	gwang6@mdanderson.org			MDACC (Moon Shot, IRG); UT STARs Award; NIH [R00 CA194289, P50 CA140388, R01CA174798, 5P50CA140388, P30CA016672]; Cancer Prevention Research Institute of Texas [RP150179, RP190252]	MDACC (Moon Shot, IRG); UT STARs Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas	We thank Ronald DePinho and Haoqiang Ying for helpful discussions, Sarah E. Townsend for editing, and Dr Timothy C. Thompson for providing RM-1 cells. GW is supported by the funding from MDACC (Moon Shot, IRG, and PCRP), UT STARs Award, NIH R00 CA194289, and P50 CA140388. SHL is supported by grants from the NIH R01CA174798 (S.-H. Lin, L.-y. Yu-Lee), NIH 5P50CA140388 (C. Logothetis, S.-H. Lin), and Cancer Prevention Research Institute of Texas grants RP150179 & RP190252 (S.-H. Lin and L.-Y. Yu-Lee). This study is supported by NIH P30CA016672 for the use of Research Animal Support Facility, Flow Cytometry and Cellular Imaging Core Facility, and Functional Genomics Core.	Aro E, 2015, J BIOL CHEM, V290, P16964, DOI 10.1074/jbc.M115.662635; Becker JS, 2016, TRENDS GENET, V32, P29, DOI 10.1016/j.tig.2015.11.001; Calses PC, 2019, TRENDS CANCER, V5, P297, DOI 10.1016/j.trecan.2019.04.001; Chakravarthi BVSK, 2014, ONCOTARGET, V5, P6654, DOI 10.18632/oncotarget.2208; Chen YA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00060; Cheng SY, 2020, PROSTATE CANCER P D, V23, P661, DOI 10.1038/s41391-020-0229-z; Cheung P, 2020, CELL STEM CELL, V27, P590, DOI 10.1016/j.stem.2020.07.003; Cottini F, 2014, NAT MED, V20, P599, DOI 10.1038/nm.3562; Discher DE, 2017, ANNU REV BIOPHYS, V46, P295, DOI 10.1146/annurev-biophys-062215-011206; Ehsanian R, 2010, ONCOGENE, V29, P6160, DOI 10.1038/onc.2010.339; Gilkes DM, 2013, CANCER RES, V73, P3285, DOI 10.1158/0008-5472.CAN-12-3963; Gorres KL, 2010, CRIT REV BIOCHEM MOL, V45, P106, DOI 10.3109/10409231003627991; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hiemer SE, 2014, J BIOL CHEM, V289, P13461, DOI 10.1074/jbc.M113.529115; Holster T, 2007, J BIOL CHEM, V282, P2512, DOI 10.1074/jbc.M606608200; Hoxha S, 2020, CANCER RES, V80, P2512, DOI 10.1158/0008-5472.CAN-19-2415; Isfort I, 2019, CLIN CANCER RES, V25, P3718, DOI 10.1158/1078-0432.CCR-17-3553; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kim M, 2015, CELL REP, V11, P270, DOI 10.1016/j.celrep.2015.03.015; Kim TW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9769; Kuser-Abali G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9126; Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063; Li SJ, 2019, NUCLEIC ACIDS RES, V47, pW206, DOI 10.1093/nar/gkz332; Ma SH, 2019, ANNU REV BIOCHEM, V88, P577, DOI 10.1146/annurev-biochem-013118-111829; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541; Nguyen LT, 2015, CANCER CELL, V27, P797, DOI 10.1016/j.ccell.2015.05.005; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Ou CL, 2017, ONCOTARGET, V8, P75727, DOI 10.18632/oncotarget.20155; Pekowska A, 2011, EMBO J, V30, P4198, DOI 10.1038/emboj.2011.295; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Su WJ, 2019, CANCER CELL, V36, P139, DOI 10.1016/j.ccell.2019.06.009; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; van Huizen NA, 2019, J PROTEOME RES, V18, P2045, DOI 10.1021/acs.jproteome.8b00930; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Xiong GF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-1; Yan FJ, 2020, BBA-GEN SUBJECTS, V1864, DOI 10.1016/j.bbagen.2019.07.006; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Yu SJ, 2013, CLIN CANCER RES, V19, P1389, DOI 10.1158/1078-0432.CCR-12-1959; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang B, 2007, ONCOGENE, V26, P7153, DOI 10.1038/sj.onc.1210509; Zhang L, 2015, MOL CELL BIOL, V35, P1350, DOI 10.1128/MCB.00102-15; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997; Zurlo G, 2016, BBA-REV CANCER, V1866, P208, DOI 10.1016/j.bbcan.2016.09.004	47	3	5	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					6049	6056		10.1038/s41388-021-02000-3	http://dx.doi.org/10.1038/s41388-021-02000-3		SEP 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34471235	Green Accepted, Green Submitted			2022-12-28	WOS:000691942100001
J	Zeng, Z; Zhao, Y; Chen, QY; Zhu, S; Niu, Y; Ye, Z; Hu, P; Chen, D; Xu, P; Chen, JH; Hu, CJ; Hu, YH; Xu, FY; Tang, J; Wang, F; Han, SB; Huang, MQ; Wang, CY; Zhao, G				Zeng, Zhu; Zhao, Yong; Chen, QingYong; Zhu, Shuai; Niu, Yi; Ye, Zeng; Hu, Ping; Chen, Ding; Xu, Peng; Chen, Jinghuang; Hu, Chaojie; Hu, Yuhang; Xu, Fengyu; Tang, Jiang; Wang, Fan; Han, Shengbo; Huang, Mengqi; Wang, Chunyou; Zhao, Gang			Hypoxic exosomal HIF-1 alpha-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis	ONCOGENE			English	Article							DRUG-RESISTANCE; INDUCIBLE FACTOR-1-ALPHA; MEDIATED TRANSFER; CHEMOTHERAPY; HIF-1-ALPHA; INHIBITION; RNA	Research has indicated that hypoxia profoundly contributes to chemoresistance of pancreatic cancer (PC), while the precise mechanism has not been fully elucidated. In this study, we report a hypoxic exosomal circular RNA (circRNA)-mediated mechanism of conferred chemoresistance in PC cells. Gemcitabine (GEM) resistance was enhanced in normoxic PC cells incubated with exosomes derived from hypoxic PC cells. CircRNA microarray displayed that circZNF91 was remarkably increased in hypoxic exosomes of PC cells compared with normoxic exosomes. Overexpression of circZNF91 obviously stimulated chemoresistance in PC cells, while knockdown of circZNF91 retarded the hypoxic exosome-transmitted chemoresistance. Mechanistically, the hypoxic-induced exosomal circZNF91 transmitted into normoxic PC cells could competitively bind to miR-23b-3p, which deprives the inhibition of miR-23b-3p on expression of deacetylase Sirtuin1 (SIRT1). Consequently, the upregulated SIRT1 enhanced deacetylation-dependent stability of HIF-1 alpha protein, leading to glycolysis and GEM chemoresistance of recipient PC cells. In addition, we revealed that the increased circZNF91 in hypoxic exosome was attributed to the transcriptional regulation by HIF-1 alpha. Coincidently, transmission of hypoxic exosomes into subcutaneous xenografts in nude mice obviously facilitated the chemoresistance of transplanted PC tumor, which could be reversed by depletion of circZNF91 or upregulation of miR-23b-3p. Furthermore, clinical data showed that circZNF91 was significantly upregulated in PC tissues and correlated with overexpression of glycolytic enzymes and short overall survival time. Collectively, exosomal circZNF91 can function as a cargo mediating the signal transmission between hypoxic and normoxic tumor cells to promote GEM chemoresistance of PC and may potentially serve as a therapeutic target.	[Zeng, Zhu; Zhao, Yong; Chen, QingYong; Zhu, Shuai; Ye, Zeng; Hu, Ping; Chen, Ding; Xu, Peng; Chen, Jinghuang; Hu, Chaojie; Hu, Yuhang; Xu, Fengyu; Tang, Jiang; Wang, Fan; Han, Shengbo; Huang, Mengqi; Zhao, Gang] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Emergency Surg, Wuhan, Peoples R China; [Niu, Yi] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Gastrointestinal Surg, Wuhan, Peoples R China; [Wang, Chunyou] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pancreat Surg, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Zhao, G (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Emergency Surg, Wuhan, Peoples R China.	gangzhao@hust.edu.cn			National Science Foundation Committee of China [81372666, 81672406, 81802450, 81802377]; Clinical Research Physician Program of Tongji Medical College, Huazhong University of Science and Technology	National Science Foundation Committee of China; Clinical Research Physician Program of Tongji Medical College, Huazhong University of Science and Technology	The National Science Foundation Committee of China (Grant Number: 81372666, 81672406 to GZ; 81802450 to SZ; 81802377 to YN); and Clinical Research Physician Program of Tongji Medical College, Huazhong University of Science and Technology to GZ supported this study.	Abraham J, 2015, LEUKEMIA LYMPHOMA, V56, P26, DOI 10.3109/10428194.2014.907890; An Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.123; Bednar F, 2020, CANCER DISCOV, V10, P762, DOI 10.1158/2159-8290.CD-20-0359; Boeckel JN, 2015, CIRC RES, V117, P884, DOI 10.1161/CIRCRESAHA.115.306319; Borji M, 2019, BIOCHEM GENET, V57, P507, DOI 10.1007/s10528-019-09905-5; Cho HS, 2019, GENES-BASEL, V10, DOI 10.3390/genes10121008; Christenson ES, 2020, LANCET ONCOL, V21, pE135, DOI 10.1016/S1470-2045(19)30795-8; da Costa WL, 2020, JAMA ONCOL, V6, P1163, DOI 10.1001/jamaoncol.2020.0562; Ding CY, 2020, CANCER LETT, V479, P1, DOI 10.1016/j.canlet.2020.03.002; Doktorova H, 2015, BIOMED PAP, V159, P166, DOI 10.5507/bp.2015.025; Dong CJ, 2019, ONCOTARGETS THER, V12, P1947, DOI 10.2147/OTT.S186922; Halbrook CJ, 2019, CELL METAB, V29, P1390, DOI 10.1016/j.cmet.2019.02.001; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hosein AN, 2020, NAT REV GASTRO HEPAT, V17, P487, DOI 10.1038/s41575-020-0300-1; Icard P, 2018, DRUG RESIST UPDATE, V38, P1, DOI 10.1016/j.drup.2018.03.001; Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9; Joo HY, 2015, BIOCHEM BIOPH RES CO, V462, P294, DOI 10.1016/j.bbrc.2015.04.119; Karasic TB, 2019, JAMA ONCOL, V5, P993, DOI 10.1001/jamaoncol.2019.0684; Klotz R, 2020, LANCET ONCOL, V21, pE295, DOI 10.1016/S1470-2045(20)30179-0; Kristensen LS, 2018, RNA BIOL, V15, P280, DOI 10.1080/15476286.2017.1409931; Lane JS, 2020, CANCERS, V12, DOI 10.3390/cancers12061530; Lin SC, 2011, J CLIN INVEST, V121, P1905, DOI 10.1172/JCI44362; Oon CE, 2015, EUR J PHARMACOL, V757, P59, DOI 10.1016/j.ejphar.2015.03.064; Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000; Paulson AS, 2013, GASTROENTEROLOGY, V144, P1316, DOI 10.1053/j.gastro.2013.01.078; Robey IF, 2005, NEOPLASIA, V7, P324, DOI 10.1593/neo.04430; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shukla SK, 2017, CANCER CELL, V32, P71, DOI 10.1016/j.ccell.2017.06.004; Siegel RL., 2020, CA-CANCER J CLIN, V70; Takahashi K, 2014, FEBS OPEN BIO, V4, P458, DOI 10.1016/j.fob.2014.04.007; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Wang JP, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.11891; Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048; Wang XY, 2020, MOL ONCOL, V14, P539, DOI 10.1002/1878-0261.12629; Warfel NA, 2014, CURR MED CHEM, V21, P3021, DOI 10.2174/0929867321666140414101056; Xu RH, 2005, CANCER RES, V65, P613; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Yokoi K, 2004, CLIN CANCER RES, V10, P2299, DOI 10.1158/1078-0432.CCR-03-0488; Yoon JH, 2012, METHODS, V58, P81, DOI 10.1016/j.ymeth.2012.07.004; Zeng Z, 2019, THERANOSTICS, V9, P5298, DOI 10.7150/thno.34559; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105; Zhang JG, 2014, CANCER SCI, V105, P445, DOI 10.1111/cas.12364; Zhou WK, 2019, J CELL BIOCHEM, V120, P19635, DOI 10.1002/jcb.29270	44	34	34	4	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5505	5517		10.1038/s41388-021-01960-w	http://dx.doi.org/10.1038/s41388-021-01960-w		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34294845				2022-12-28	WOS:000678017100002
J	Lequeux, A; Noman, MZ; Xiao, MLN; Van Moer, K; Hasmim, M; Benoit, A; Bosseler, M; Viry, E; Arakelian, T; Berchem, G; Chouaib, S; Janji, B				Lequeux, Audrey; Noman, Muhammad Zaeem; Xiao, Malina; Van Moer, Kris; Hasmim, Meriem; Benoit, Alice; Bosseler, Manon; Viry, Elodie; Arakelian, Tsolere; Berchem, Guy; Chouaib, Salem; Janji, Bassam			Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy	ONCOGENE			English	Article							HYPOXIA; SUSCEPTIBILITY; OPPORTUNITIES; AUTOPHAGY; THERAPY; BIOLOGY; GROWTH; LYSIS	Hypoxia is a key factor responsible for the failure of therapeutic response in most solid tumors and promotes the acquisition of tumor resistance to various antitumor immune effectors. Reshaping the hypoxic immune suppressive tumor microenvironment to improve cancer immunotherapy is still a relevant challenge. We investigated the impact of inhibiting HIF-1 alpha transcriptional activity on cytotoxic immune cell infiltration into B16-F10 melanoma. We showed that tumors expressing a deleted form of HIF-1 alpha displayed increased levels of NK and CD8(+) effector T cells in the tumor microenvironment, which was associated with high levels of CCL2 and CCL5 chemokines. We showed that combining acriflavine, reported as a pharmacological agent preventing HIF-1 alpha/HIF-1 beta dimerization, dramatically improved the benefit of cancer immunotherapy based on TRP-2 peptide vaccination and anti-PD-1 blocking antibody. In melanoma patients, we revealed that tumors exhibiting high CCL5 are less hypoxic, and displayed high NK, CD3(+), CD4(+) and CD8(+) T cell markers than those having low CCL5. In addition, melanoma patients with high CCL5 in their tumors survive better than those having low CCL5. This study provides the pre-clinical proof of concept for a novel triple combination strategy including blocking HIF-1 alpha transcription activity along vaccination and PD-1 blocking immunotherapy.	[Lequeux, Audrey; Noman, Muhammad Zaeem; Xiao, Malina; Van Moer, Kris; Hasmim, Meriem; Benoit, Alice; Bosseler, Manon; Viry, Elodie; Arakelian, Tsolere; Berchem, Guy; Janji, Bassam] Luxembourg Inst Hlth LIH, Dept Oncol, Tumor Immunotherapy & Microenvironm TIME Grp, Luxembourg, Luxembourg; [Berchem, Guy] Ctr Hosp Luxembourg, Dept Hematooncol, Luxembourg, Luxembourg; [Chouaib, Salem] Gustave Roussy, Integrat Tumor Immunol & Genet Oncol, INSERM, UMR 1186, Villejuif, France; [Chouaib, Salem] Gulf Med Univ, Thumbay Res Inst Precis Med, Ajman, U Arab Emirates	Luxembourg Institute of Health; Luxembourg Hospital Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Janji, B (corresponding author), Luxembourg Inst Hlth LIH, Dept Oncol, Tumor Immunotherapy & Microenvironm TIME Grp, Luxembourg, Luxembourg.	bassam.janji@lih.lu	Berchem, Guy/C-9364-2014	Berchem, Guy/0000-0003-0157-2257; Arakelian, Tsolere/0000-0002-0079-9268	Luxembourg Institute of Health; FNRS Televie [7.4535.16, 7.6505.18, 7.4606.18]; Luxembourg National Research Fund [C18/BM/12670304/COMBATIC, PRIDE15/10675146/CANBIO]; Fondation Cancer, Luxembourg [FC/2018/06]; Kriibskrank Kanner Foundation, Luxembourg (2019); Janssen Cilag Pharma; Roche Pharma, Action LIONS Vaincre le Cancer Luxembourg; Sheik Hamdan Bin Rashid Al Maktoum Foundation, United Arab Emirates	Luxembourg Institute of Health; FNRS Televie(Fonds de la Recherche Scientifique - FNRS); Luxembourg National Research Fund(Luxembourg National Research Fund); Fondation Cancer, Luxembourg; Kriibskrank Kanner Foundation, Luxembourg (2019); Janssen Cilag Pharma; Roche Pharma, Action LIONS Vaincre le Cancer Luxembourg; Sheik Hamdan Bin Rashid Al Maktoum Foundation, United Arab Emirates	We thank Dr Anne Largeot from Tumor Stroma interactions group (Luxembourg Institute of Health) for her technical assistance. This work was supported by Luxembourg Institute of Health and grants from FNRS Televie (grants 7.4535.16, 7.6505.18 and no7.4606.18); Luxembourg National Research Fund (C18/BM/12670304/COMBATIC and PRIDE15/10675146/CANBIO); Fondation Cancer, Luxembourg (FC/2018/06); Kriibskrank Kanner Foundation, Luxembourg (2019); Janssen Cilag Pharma; Roche Pharma, Action LIONS Vaincre le Cancer Luxembourg and Sheik Hamdan Bin Rashid Al Maktoum Foundation, United Arab Emirates.	Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110; Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992; Berchem G, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1062968; BOTTAZZI B, 1992, J IMMUNOL, V148, P1280; Brown CE, 2007, J IMMUNOL, V179, P3332, DOI 10.4049/jimmunol.179.5.3332; Burke JD, 2019, SEMIN IMMUNOL, V43, DOI 10.1016/j.smim.2019.05.002; Chouaib S, 2017, ONCOGENE, V36, P439, DOI 10.1038/onc.2016.225; Colliez F, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00010; Deng J, 2019, CANCER IMMUNOL RES, V7, P1079, DOI 10.1158/2326-6066.CIR-18-0507; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Jayaprakash P, 2018, J CLIN INVEST, V128, P5137, DOI 10.1172/JCI96268; Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106; Lequeux A, 2019, CANCER LETT, V458, P13, DOI 10.1016/j.canlet.2019.05.021; McKeown SR, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130676; Messai Y, 2016, EUR UROL, V70, P623, DOI 10.1016/j.eururo.2015.11.029; Noman MZ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax7881; Noman MZ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091083; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Noman MZ, 2012, CANCER RES, V72, P4629, DOI 10.1158/0008-5472.CAN-12-1383; Noman MZ, 2011, CANCER RES, V71, P5976, DOI 10.1158/0008-5472.CAN-11-1094; Scharping NE, 2017, CANCER IMMUNOL RES, V5, P9, DOI 10.1158/2326-6066.CIR-16-0103; Scholz CC, 2013, CURR OPIN PHARMACOL, V13, P646, DOI 10.1016/j.coph.2013.04.009; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Shannon AM, 2003, CANCER TREAT REV, V29, P297, DOI 10.1016/S0305-7372(03)00003-3; Span PN, 2015, SEMIN NUCL MED, V45, P101, DOI 10.1053/j.semnuclmed.2014.10.002; Stathopoulos GT, 2008, JNCI-J NATL CANCER I, V100, P1464, DOI 10.1093/jnci/djn325; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105; Zhang HM, 2015, P NATL ACAD SCI USA, V112, pE6215, DOI 10.1073/pnas.1520032112	30	31	32	3	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4725	4735		10.1038/s41388-021-01846-x	http://dx.doi.org/10.1038/s41388-021-01846-x		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34155342	Green Published, hybrid			2022-12-28	WOS:000664006400003
J	Liu, X; Li, LY; Si, FS; Huang, L; Zhao, YJ; Zhang, CC; Hoft, DF; Peng, GY				Liu, Xia; Li, Lingyun; Si, Fusheng; Huang, Lan; Zhao, Yangjing; Zhang, Chenchen; Hoft, Daniel F.; Peng, Guangyong			NK and NKT cells have distinct properties and functions in cancer	ONCOGENE			English	Article							KILLER T-CELLS; BREAST-CANCER; TUMOR MICROENVIRONMENT; ANTITUMOR-ACTIVITY; SELF-TOLERANCE; ACTIVATION; EXPRESSION; EXHAUSTION; IMMUNITY; DYSFUNCTION	Natural killer (NK) and natural killer T (NKT) cells are two important cell subsets of the innate immune system. NK and NKT cells share many phenotypes and functions for anti-tumor immunity; however, the dynamic changes in phenotypes and functional interactions within the tumor microenvironment during tumor development and progression are unknown. Here we report that NK and NKT cells have distinct properties, metabolic profiles, and functions during tumor development. Using the mouse E0771 breast cancer and B16 melanoma models, we found that both NK and NKT cells are dynamically involved in the immune responses to cancer but have distinct distributions and phenotypic profiles in tumor sites and other peripheral organs during the course of tumor development and progression. In the early stages of tumor development, both NK and NKT cells exhibit effector properties. In the later cancer stages, NK and NKT cells have impaired cytotoxic capacities and dysfunctional states. NK cells become senescent cells, while NKT cells, other than invariant NKT (iNKT) cells, are exhausted in the advanced cancers. In contrast, iNKT cells develop increases in activation and effector function within the breast tumor microenvironment. In addition, senescent NK cells have heightened glucose and lipid metabolism, but exhausted NKT cells display unbalanced metabolism in tumor microenvironments of both breast cancer and melanoma tumor models. These studies provide a better understanding of the dynamic and distinct functional roles of NK and NKT cells in anti-tumor immunity, which may facilitate the development of novel immunotherapies targeting NK and NKT cells for cancer treatment.	[Liu, Xia; Li, Lingyun; Si, Fusheng; Huang, Lan; Zhao, Yangjing; Zhang, Chenchen; Hoft, Daniel F.; Peng, Guangyong] St Louis Univ, Sch Med, Div Infect Dis Allergy & Immunol, St Louis, MO 63104 USA; [Liu, Xia; Li, Lingyun; Si, Fusheng; Huang, Lan; Zhao, Yangjing; Zhang, Chenchen; Hoft, Daniel F.; Peng, Guangyong] St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO 63104 USA; [Hoft, Daniel F.; Peng, Guangyong] St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University; Saint Louis University	Peng, GY (corresponding author), St Louis Univ, Sch Med, Div Infect Dis Allergy & Immunol, St Louis, MO 63104 USA.; Peng, GY (corresponding author), St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO 63104 USA.; Peng, GY (corresponding author), St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA.	guangyong.peng@health.slu.edu	Zhang, Chenchen/GPW-7947-2022	Zhang, Chenchen/0000-0003-4519-3435	American Cancer Society [RSG10-160-01-LIB]; Melanoma Research Alliance; NIH [CA184379, CA242188, CA237149, AG067441]	American Cancer Society(American Cancer Society); Melanoma Research Alliance; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was partially supported by grants from the American Cancer Society (RSG10-160-01-LIB, to GP), Melanoma Research Alliance (to GP), and the NIH (CA184379, CA242188, CA237149, and AG067441 to GP).	Ardolino M, 2014, J CLIN INVEST, V124, P4781, DOI 10.1172/JCI74337; Baitsch L, 2012, TRENDS IMMUNOL, V33, P364, DOI 10.1016/j.it.2012.02.006; Baitsch L, 2011, J CLIN INVEST, V121, P2350, DOI 10.1172/JCI46102; Bates JP, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4441-3; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Chiossone L, 2009, BLOOD, V113, P5488, DOI 10.1182/blood-2008-10-187179; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710; Fu BQ, 2011, IMMUNOLOGY, V133, P350, DOI 10.1111/j.1365-2567.2011.03446.x; Gajewski TF, 2011, CURR OPIN IMMUNOL, V23, P286, DOI 10.1016/j.coi.2010.11.013; Gardiner CM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00367; Gill S, 2012, BLOOD, V119, P5758, DOI 10.1182/blood-2012-03-415364; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Hasmim M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00482; Hsu J, 2018, J CLIN INVEST, V128, P4654, DOI 10.1172/JCI99317; Hu ZSI, 2018, CURR BREAST CANCER R, V10, P35, DOI 10.1007/s12609-018-0274-y; Huang Y, 2015, ONCOTARGET, V6, P17462, DOI 10.18632/oncotarget.3958; Izhak L, 2013, CANCER RES, V73, P1514, DOI 10.1158/0008-5472.CAN-12-2567; Keppel MP, 2015, J IMMUNOL, V194, P1954, DOI 10.4049/jimmunol.1402099; Kim YH, 2017, J IMMUNOL, V199, P3478, DOI 10.4049/jimmunol.1700567; Kobayashi T, 2019, MOL IMMUNOL, V115, P3, DOI [10.1016/J.molimm.2017.11.021, 10.1016/j.molimm.2017.11.021]; Krneta T, 2016, CELL MOL IMMUNOL, V13, P628, DOI 10.1038/cmi.2015.42; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; Liu X, 2020, J CLIN INVEST, V130, P1073, DOI 10.1172/JCI133679; Liu X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02689-5; Liu Y, 2017, ONCOGENE, V36, P6143, DOI 10.1038/onc.2017.209; Lyons TG, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0701-2; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; Mah AY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95128; Mah AY, 2016, CRIT REV IMMUNOL, V36, P131, DOI 10.1615/CritRevImmunol.2016017387; Mamessier E, 2011, J CLIN INVEST, V121, P3609, DOI 10.1172/JCI45816; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; McEwen-Smith RM, 2015, CANCER IMMUNOL RES, V3, P425, DOI 10.1158/2326-6066.CIR-15-0062; Moretta L, 2014, INT ARCH ALLERGY IMM, V164, P253, DOI 10.1159/000365632; Motohashi S, 2009, J IMMUNOL, V182, P2492, DOI 10.4049/jimmunol.0800126; Muller-Durovic B, 2016, J IMMUNOL, V197, P2891, DOI 10.4049/jimmunol.1600590; O'Konek JJ, 2013, CLIN CANCER RES, V19, P4404, DOI 10.1158/1078-0432.CCR-12-2169; Parekh VV, 2005, J CLIN INVEST, V115, P2572, DOI 10.1172/JCI24762; Pietra G, 2012, CANCER RES, V72, P1407, DOI 10.1158/0008-5472.CAN-11-2544; Polk A, 2018, CANCER TREAT REV, V63, P122, DOI 10.1016/j.ctrv.2017.12.008; Sag D, 2014, J CLIN INVEST, V124, P3725, DOI 10.1172/JCI72308; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schule Jana M, 2004, J Transl Med, V2, P45, DOI 10.1186/1479-5876-2-45; Shifrin N, 2014, SEMIN IMMUNOL, V26, P138, DOI 10.1016/j.smim.2014.02.007; Shin JH, 2013, P NATL ACAD SCI USA, V110, P12391, DOI 10.1073/pnas.1302856110; Smyth MJ, 2000, J EXP MED, V191, P661, DOI 10.1084/jem.191.4.661; Stojanovic A, 2014, J IMMUNOL, V192, P4184, DOI 10.4049/jimmunol.1302091; Terabe M, 2008, ADV CANCER RES, V101, P277, DOI 10.1016/S0065-230X(08)00408-9; Thommen DS, 2018, CANCER CELL, V33, P547, DOI 10.1016/j.ccell.2018.03.012; Ververs FA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01192; Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174; Webb JR, 2010, GYNECOL ONCOL, V118, P228, DOI 10.1016/j.ygyno.2010.05.016; Webb TJ, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw055; Xia LY, 2019, CELL METAB, V29, P103, DOI 10.1016/j.cmet.2018.09.020; Yamasaki K, 2011, CLIN IMMUNOL, V138, P255, DOI 10.1016/j.clim.2010.11.014; Ye J, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.994398; Ye J, 2014, EMBO MOL MED, V6, P1294, DOI 10.15252/emmm.201403918; Ye J, 2013, J IMMUNOL, V190, P2403, DOI 10.4049/jimmunol.1202369; Ye J, 2012, BLOOD, V120, P2021, DOI 10.1182/blood-2012-03-416040; Yu JH, 2013, TRENDS IMMUNOL, V34, P573, DOI 10.1016/j.it.2013.07.005; Zhao YJ, 2020, CELL MOL IMMUNOL, V17, P27, DOI 10.1038/s41423-019-0344-8	63	8	8	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4521	4537		10.1038/s41388-021-01880-9	http://dx.doi.org/10.1038/s41388-021-01880-9		JUN 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34120141				2022-12-28	WOS:000660811300002
J	Chen, Q; Shen, P; Ge, WL; Yang, TY; Wang, WJ; Meng, LD; Huang, XM; Zhang, YH; Cao, SJ; Miao, Y; Jiang, KR; Zhang, JJ				Chen, Qun; Shen, Peng; Ge, Wan-Li; Yang, Tao-Yue; Wang, Wu-Jun; Meng, Ling-Dong; Huang, Xu-Min; Zhang, Yi-Han; Cao, Shou-Ji; Miao, Yi; Jiang, Kui-Rong; Zhang, Jing-Jing			Roundabout homolog 1 inhibits proliferation via the YY1-ROBO1-CCNA2-CDK2 axis in human pancreatic cancer	ONCOGENE			English	Article							CYCLIN A2; DUCTAL ADENOCARCINOMA; CELL-PROLIFERATION; CDK2	Pancreatic cancer (PC) is highly malignant and has a high mortality with a 5-year survival rate of less than 8%. As a member of the roundabout immunoglobulin superfamily of proteins, ROBO1 plays an important role in embryogenesis and organogenesis and also inhibits metastasis in PC. Our study was designed to explore whether ROBO1 has effects on the proliferation of PC and its specific mechanism. The expression of ROBO1 was higher in cancer tissues than in matched adjacent tissues by immunohistochemistry (IHC) and qRT-PCR. Low ROBO1 expression is associated with PC progression and poor prognosis. Overexpression of ROBO1 can inhibit the proliferation of PC cells in vitro, and the S phase fraction can also be induced. Further subcutaneous tumor formation in nude mice showed that ROBO1 overexpression can significantly inhibit tumor growth. YY1 was found to directly bind to the promoter region of ROBO1 to promote transcription by a luciferase reporter gene assay, a chromatin immunoprecipitation (ChIP) and an electrophoretic mobility shift assay (EMSA). Mechanistic studies showed that YY1 can inhibit the development of PC by directly regulating ROBO1 via the CCNA2/CDK2 axis. Taken together, our results suggest that ROBO1 may be involved in the development and progression of PC by regulating cell proliferation and shows that ROBO1 may be a novel and promising therapeutic target for PC.	[Chen, Qun; Shen, Peng; Ge, Wan-Li; Yang, Tao-Yue; Meng, Ling-Dong; Huang, Xu-Min; Zhang, Yi-Han; Cao, Shou-Ji; Miao, Yi; Jiang, Kui-Rong; Zhang, Jing-Jing] Nanjing Med Univ, Affiliated Hosp 1, Pancreas Ctr, Nanjing, Peoples R China; [Chen, Qun; Shen, Peng; Ge, Wan-Li; Yang, Tao-Yue; Meng, Ling-Dong; Huang, Xu-Min; Zhang, Yi-Han; Cao, Shou-Ji; Miao, Yi; Jiang, Kui-Rong; Zhang, Jing-Jing] Nanjing Med Univ, Pancreas Inst, Nanjing, Peoples R China; [Wang, Wu-Jun] Nanjing Univ Chinese Med, Nanjing, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing University of Chinese Medicine	Jiang, KR; Zhang, JJ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Pancreas Ctr, Nanjing, Peoples R China.; Jiang, KR; Zhang, JJ (corresponding author), Nanjing Med Univ, Pancreas Inst, Nanjing, Peoples R China.	jiangkuirong@njmu.edu.cn; zhangjingjing@njmu.edu.cn		chen, qun/0000-0002-9034-9825	National Natural Science Foundation of China [81871980, 81572337, 81672449]; National Science Foundation for Distinguished Young Scholars of China [81902455]; Jiangsu Key Medical Discipline [ZDXKA2016005]; Innovation Capability Development Project of Jiangsu Province [BM2015004]; Priority Academic Program AQ3 Development of Jiangsu Higher Education Institutions (PAPD) [JX10231801]; Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Outstanding Talent [JCRCA2016009]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Foundation for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); Jiangsu Key Medical Discipline; Innovation Capability Development Project of Jiangsu Province; Priority Academic Program AQ3 Development of Jiangsu Higher Education Institutions (PAPD); Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Outstanding Talent	This study was supported by the National Natural Science Foundation of China (Nos. 81871980, 81572337, 81672449); the National Science Foundation for Distinguished Young Scholars of China (No. 81902455); the Jiangsu Key Medical Discipline (General Surgery; ZDXKA2016005); the Innovation Capability Development Project of Jiangsu Province (No. BM2015004); the Priority Academic Program AQ3 Development of Jiangsu Higher Education Institutions (PAPD, JX10231801) and the Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Outstanding Talent (to Yi Miao, JCRCA2016009).	Chantrill LA, 2015, CLIN CANCER RES, V21, P2029, DOI 10.1158/1078-0432.CCR-15-0426; Dachineni R, 2016, MOL CANCER RES, V14, P241, DOI 10.1158/1541-7786.MCR-15-0360; Gao D, 2018, FEBS J, V285, P4229, DOI 10.1111/febs.14665; Gohrig A, 2014, CANCER RES, V74, P1529, DOI 10.1158/0008-5472.CAN-13-1012; Gopinathan L, 2014, CANCER RES, V74, P3870, DOI 10.1158/0008-5472.CAN-13-3440; Honda A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039249; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Kong RR, 2015, J CLIN INVEST, V125, P4407, DOI 10.1172/JCI81673; Leyva-Diaz E, 2014, CURR BIOL, V24, P494, DOI 10.1016/j.cub.2014.01.042; Liu DF, 2018, INT J CANCER, V142, P1392, DOI 10.1002/ijc.31173; Liu JH, 2018, ANGIOGENESIS, V21, P237, DOI 10.1007/s10456-017-9592-3; Mitchell KA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13732-y; Moore NL, 2014, J STEROID BIOCHEM, V144, P471, DOI 10.1016/j.jsbmb.2014.09.009; Parray A, 2014, INT J CANCER, V135, P2493, DOI 10.1002/ijc.28919; Patten DK, 2018, NAT MED, V24, P1469, DOI 10.1038/s41591-018-0091-x; Peng XF, 2018, CELL BIOL INT, V42, P589, DOI 10.1002/cbin.10935; Pinho AV, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07497-z; Pommier A, 2018, SCIENCE, V360, P1202, DOI 10.1126/science.aao4908; Qin F, 2015, SCI REP-UK, V5, DOI 10.1038/srep09977; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Wang B, 2014, INT J RADIAT ONCOL, V90, P53, DOI 10.1016/j.ijrobp.2014.04.055; XIA Y, 2019, CELL PROLIFERAT, V52; Zhang JJ, 2017, CANCER LETT, V408, P144, DOI 10.1016/j.canlet.2017.08.032; Zhang JJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-130; Zhang QH, 2017, J CELL BIOL, V216, P3133, DOI 10.1083/jcb.201607111	25	10	10	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2772	2784		10.1038/s41388-021-01741-5	http://dx.doi.org/10.1038/s41388-021-01741-5		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33714986				2022-12-28	WOS:000628485300002
J	Periyasamy, M; Singh, AK; Gemma, C; Farzan, R; Allsopp, RC; Shaw, JA; Charmsaz, S; Young, LS; Cunnea, P; Coombes, RC; Gyorffy, B; Buluwela, L; Ali, S				Periyasamy, Manikandan; Singh, Anup K.; Gemma, Carolina; Farzan, Raed; Allsopp, Rebecca C.; Shaw, Jacqueline A.; Charmsaz, Sara; Young, Leonie S.; Cunnea, Paula; Coombes, R. Charles; Gyorffy, Balazs; Buluwela, Lakjaya; Ali, Simak			Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-kappa B	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; SIGNALING PATHWAY; DEAMINASE APOBEC3B; CATALYTIC SUBUNIT; MUTAGENESIS; EVOLUTION; FAMILY; DEFICIENCY; PROTEINS; REVEALS	The mutagenic APOBEC3B (A3B) cytosine deaminase is frequently over-expressed in cancer and promotes tumour heterogeneity and therapy resistance. Hence, understanding the mechanisms that underlie A3B over-expression is important, especially for developing therapeutic approaches to reducing A3B levels, and consequently limiting cancer mutagenesis. We previously demonstrated that A3B is repressed by p53 and p53 mutation increases A3B expression. Here, we investigate A3B expression upon treatment with chemotherapeutic drugs that activate p53, including 5-fluorouracil, etoposide and cisplatin. Contrary to expectation, these drugs induced A3B expression and concomitant cellular cytosine deaminase activity. A3B induction was p53-independent, as chemotherapy drugs stimulated A3B expression in p53 mutant cells. These drugs commonly activate ATM, ATR and DNA-PKcs. Using specific inhibitors and gene knockdowns, we show that activation of DNA-PKcs and ATM by chemotherapeutic drugs promotes NF-kappa B activity, with consequent recruitment of NF-kappa B to the A3B gene promoter to drive A3B expression. Further, we find that A3B knockdown re-sensitises resistant cells to cisplatin, and A3B knockout enhances sensitivity to chemotherapy drugs. Our data highlight a role for A3B in resistance to chemotherapy and indicate that stimulation of A3B expression by activation of DNA repair and NF-kappa B pathways could promote cancer mutations and expedite chemoresistance.	[Periyasamy, Manikandan; Singh, Anup K.; Gemma, Carolina; Farzan, Raed; Cunnea, Paula; Coombes, R. Charles; Buluwela, Lakjaya; Ali, Simak] Imperial Coll London, Dept Surg & Canc, London W12 0NN, England; [Allsopp, Rebecca C.; Shaw, Jacqueline A.] Univ Leicester, Dept Canc Studies & Canc Res UK, Leicester Ctr, Leicester, Leics, England; [Charmsaz, Sara; Young, Leonie S.] Royal Coll Surgeons Ireland, Dept Surg, Endocrine Oncol Res Grp, Dublin, Ireland; [Gyorffy, Balazs] Semmelweis Univ, Dept Bioinformat, Budapest, Hungary; [Gyorffy, Balazs] Semmelweis Univ, Dept Pediat 2, Budapest, Hungary; [Gyorffy, Balazs] Inst Enzymol, MTA TTK Lendulet Canc Biomarker Res Grp, Budapest, Hungary; [Farzan, Raed] King Saud Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Riyadh, Saudi Arabia	Imperial College London; University of Leicester; Royal College of Surgeons - Ireland; Semmelweis University; Semmelweis University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; King Saud University	Ali, S (corresponding author), Imperial Coll London, Dept Surg & Canc, London W12 0NN, England.	simak.ali@imperial.ac.uk	Gyorffy, Balazs/AAA-9135-2021; Farzan, Raed/AAD-2486-2020; Ali, Simak/M-6912-2018	Gyorffy, Balazs/0000-0002-5772-3766; Farzan, Raed/0000-0003-1189-6319; Gemma, Carolina/0000-0002-4890-9972; Periyasamy, Manikandan/0000-0001-7626-2531; Cunnea, Paula/0000-0002-3699-4911; Shaw, Jacqui/0000-0003-4227-503X; Ali, Simak/0000-0002-1320-0816; Coombes, Raoul Charles/0000-0002-4811-1100	Cancer Research UK [C37/A18784]; LMS/NIHR Imperial Biomedical Research Centre Flow Cytometry Facility; Imperial Experimental Cancer Medicine Centre; Imperial NIHR Biomedical Research Centre; Cancer Research UK Imperial Centre	Cancer Research UK(Cancer Research UK); LMS/NIHR Imperial Biomedical Research Centre Flow Cytometry Facility; Imperial Experimental Cancer Medicine Centre; Imperial NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Cancer Research UK Imperial Centre	We thank Dr B Vogelstein for p53-null HCT116 cells. We are grateful to Dr S Langdon for the PEA1 and PEA2 lines. Our thanks also go to Drs. S Hong and L Magnani for their kind gift of PEOO3 cells. This study was supported by Cancer Research UK grant C37/A18784. We thank the LMS/NIHR Imperial Biomedical Research Centre Flow Cytometry Facility for support. Additional support was provided by the Imperial Experimental Cancer Medicine Centre, Imperial NIHR Biomedical Research Centre, and the Cancer Research UK Imperial Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.	Andrysik Z, 2017, GENOME RES, V27, P1645, DOI 10.1101/gr.220533.117; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beshiri ML, 2012, P NATL ACAD SCI USA, V109, P18499, DOI 10.1073/pnas.1216724109; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; Ding QR, 2013, CELL STEM CELL, V12, P393, DOI 10.1016/j.stem.2013.03.006; Faltas BM, 2016, NAT GENET, V48, P1490, DOI 10.1038/ng.3692; Fang Y, 2015, MOL CELL BIOCHEM, V399, P269, DOI 10.1007/s11010-014-2253-6; Gadducci A, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0484-6; Gavande NS, 2016, PHARMACOL THERAPEUT, V160, P65, DOI 10.1016/j.pharmthera.2016.02.003; Green AM, 2019, DNA REPAIR, V83, DOI 10.1016/j.dnarep.2019.102700; Hadian K, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001712; Hong SP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11721-9; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; KUBO K, 1992, BIOCHEMISTRY-US, V31, P3703, DOI 10.1021/bi00129a020; LANGDON SP, 1988, CANCER RES, V48, P6166; Law EK, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1601737; Leonard B, 2016, CLIN CANCER RES, V22, P4746, DOI 10.1158/1078-0432.CCR-15-2910; Leonard B, 2015, CANCER RES, V75, P4538, DOI 10.1158/0008-5472.CAN-15-2171-T; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Maruyama W, 2016, BIOCHEM BIOPH RES CO, V478, P1466, DOI 10.1016/j.bbrc.2016.08.148; McDaniel YZ, 2020, NUCLEIC ACIDS RES, V48, P1353, DOI 10.1093/nar/gkz1164; McGranahan N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1408; Menendez D, 2017, MOL CANCER RES, V15, P735, DOI 10.1158/1541-7786.MCR-17-0019; Nik-Zainal S, 2014, NAT GENET, V46, P487, DOI 10.1038/ng.2955; Nowarski R, 2012, BLOOD, V120, P366, DOI 10.1182/blood-2012-01-402123; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Peng YL, 2005, CANCER RES, V65, P1670, DOI 10.1158/0008-5472.CAN-04-3451; Periyasamy M, 2017, NUCLEIC ACIDS RES, V45, P11056, DOI 10.1093/nar/gkx721; Periyasamy M, 2015, CELL REP, V13, P108, DOI 10.1016/j.celrep.2015.08.066; Podolin PL, 2005, J PHARMACOL EXP THER, V312, P373, DOI 10.1124/jpet.104.074484; Pommier Y, 2014, DNA REPAIR, V19, P114, DOI 10.1016/j.dnarep.2014.03.020; Poulos RC, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007779; Rajagopalan S, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000467; Refsland EW, 2010, NUCLEIC ACIDS RES, V38, P4274, DOI 10.1093/nar/gkq174; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; Roper N, 2019, CELL REP, V26, P2651, DOI 10.1016/j.celrep.2019.02.028; Sabatel H, 2011, BIOCHEM PHARMACOL, V82, P1371, DOI 10.1016/j.bcp.2011.07.105; Salter JD, 2016, TRENDS BIOCHEM SCI, V41, P578, DOI 10.1016/j.tibs.2016.05.001; Schmitt C, 2018, ONCOL REP, V40, P2742, DOI 10.3892/or.2018.6698; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Serebrenik AA, 2020, CLIN CANCER RES, V26, P3397, DOI 10.1158/1078-0432.CCR-19-2786; Stenglein MD, 2010, NAT STRUCT MOL BIOL, V17, P222, DOI 10.1038/nsmb.1744; Strickson S, 2013, BIOCHEM J, V451, P427, DOI 10.1042/BJ20121651; Stronach EA, 2011, NEOPLASIA, V13, P1069, DOI 10.1593/neo.111032; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; Taylor BJM, 2013, ELIFE, V2, DOI 10.7554/eLife.00534; Treiber T, 2017, MOL CELL, V66, P270, DOI 10.1016/j.molcel.2017.03.014; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Venkatesan S, 2018, ANN ONCOL, V29, P563, DOI 10.1093/annonc/mdy003; Wilson DM, 2010, TRENDS BIOCHEM SCI, V35, P247, DOI 10.1016/j.tibs.2010.01.003; Wyatt MD, 2009, CELL MOL LIFE SCI, V66, P788, DOI 10.1007/s00018-008-8557-5; Zaky A, 2008, NUCLEIC ACIDS RES, V36, P1555, DOI 10.1093/nar/gkm1173	58	8	8	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1077	1090		10.1038/s41388-020-01583-7	http://dx.doi.org/10.1038/s41388-020-01583-7		DEC 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323971	Green Submitted, Green Accepted			2022-12-28	WOS:000599126500005
J	Hu, ZH; Wang, XH; Li, D; Cao, LD; Cui, HX; Xu, GQ				Hu, Zhanhong; Wang, Xiaohui; Li, Dan; Cao, Lindong; Cui, Hongxia; Xu, Guoqiang			UFBP1, a key component in ufmylation, enhances drug sensitivity by promoting proteasomal degradation of oxidative stress-response transcription factor Nrf2	ONCOGENE			English	Article							CANCER CELLS; INHIBITION; EXPRESSION; RESISTANCE; UFM1	The key component in the UFM1 conjugation system, UFM1-binding and PCI domain-containing protein 1 (UFBP1), regulates many biological processes. Recently it has been shown that low UFBP1 protein level is associated with the worse outcome of gastric cancer patients. However, how it responses to the sensitivity of gastric cancer to chemotherapy drugs and the underlying molecular mechanism remain elusive. Here, we discovered that high UFBP1 expression increases the progression-free survival of advanced gastric cancer patients treated with platinum-based chemotherapy. Cell-line based studies unveiled that UFBP1 expression enhances while UFBP1 knockdown attenuates the sensitivity of gastric cancer cells to cisplatin. High-throughput SILAC-based quantitative proteomic analysis revealed that the protein level of aldo-keto reductase 1Cs (AKR1Cs) is significantly downregulated by UFBP1. Flow cytometry analysis showed that UFBP1 expression increases while UFBP1 knockdown reduces reactive oxygen species upon cisplatin treatment. We further disclosed that UFBP1 attenuates the gene expression of AKR1Cs and the transcription activity of the master oxidative stress-response transcription factor Nrf2 (nuclear factor erythroid-2-related factor 2). Detailed mechanistic studies manifested that UFBP1 promotes the formation of K48-linked polyubiquitin chains on Nrf2 and thus augments its proteasome-mediated degradation. Experiments using genetic depletion and pharmacological activation in vitro and in vivo demonstrated that UFBP1 enhances the sensitivity of gastric cancer cells to cisplatin through the Nrf2/AKR1C axis. Overall, this work discovered a novel prognostic biomarker for gastric cancer patients treated with platinum-based chemotherapy and elucidated the underlying molecular mechanism, which may benefit to future personalized chemotherapy.	[Hu, Zhanhong; Wang, Xiaohui; Li, Dan; Cao, Lindong; Xu, Guoqiang] Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou 215123, Jiangsu, Peoples R China; [Hu, Zhanhong; Wang, Xiaohui; Li, Dan; Cao, Lindong; Xu, Guoqiang] Soochow Univ, Coll Pharmaceut Sci, Jiangsu Key Lab Prevent & Translat Med Geriatr Di, Suzhou 215123, Jiangsu, Peoples R China; [Hu, Zhanhong] Soochow Univ, Dept Pharm, Affiliated Hosp 2, Suzhou 215004, Jiangsu, Peoples R China; [Cui, Hongxia] Soochow Univ, Dept Pathol, Affiliated Hosp 2, Suzhou 215004, Jiangsu, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China	Xu, GQ (corresponding author), Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou 215123, Jiangsu, Peoples R China.; Xu, GQ (corresponding author), Soochow Univ, Coll Pharmaceut Sci, Jiangsu Key Lab Prevent & Translat Med Geriatr Di, Suzhou 215123, Jiangsu, Peoples R China.	gux2002@suda.edu.cn	Xiaohui, Wang/AFS-7746-2022	Xu, Guoqiang/0000-0002-4753-4769	National Key R&D Program of China [2019YFA0802400]; National Natural Science Foundation of China [31700722, 31971353]; Suzhou Bureau of Science and Technology (Basic Research in Medical and Health Sciences) [SYS201718]; Talent Program in Six Major Disciplines in Jiangsu Province [SWYY-080]; Open Project of Jiangsu Key Laboratory of Neuropsychiatric Diseases [KIS1722]; Open Project Program of the State Key Laboratory of Proteomics [SKLP-O201905]; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX17_2040]; Natural Science Foundation of Jiangsu Higher Education Institutes of China [17KJA180010]; National Center for International Research [2017B01012]; Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Suzhou Bureau of Science and Technology (Basic Research in Medical and Health Sciences); Talent Program in Six Major Disciplines in Jiangsu Province; Open Project of Jiangsu Key Laboratory of Neuropsychiatric Diseases; Open Project Program of the State Key Laboratory of Proteomics; Postgraduate Research & Practice Innovation Program of Jiangsu Province; Natural Science Foundation of Jiangsu Higher Education Institutes of China; National Center for International Research; Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions	We are grateful to Drs. Xinliang Mao (Soochow University) and Siwang Yu (Peking University) for kindly providing plasmids and to Dr. Guanghui Wang (Soochow University) for fruitful discussion. MS analyses were performed at the Mass Spectrometry core facility of the Medical School of Soochow University. This work was supported by the National Key R&D Program of China (2019YFA0802400), the National Natural Science Foundation of China (31700722 & 31971353), Suzhou Bureau of Science and Technology (Basic Research in Medical and Health Sciences, SYS201718), Talent Program in Six Major Disciplines in Jiangsu Province (SWYY-080), Open Project of Jiangsu Key Laboratory of Neuropsychiatric Diseases (KIS1722), Open Project Program of the State Key Laboratory of Proteomics (SKLP-O201905), Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX17_2040), Natural Science Foundation of Jiangsu Higher Education Institutes of China (17KJA180010), National Center for International Research (2017B01012), a project funded by the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions.	Bortolozzi R, 2018, BRIT J CANCER, V118, P985, DOI 10.1038/s41416-018-0014-0; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai YF, 2019, CELL DISCOV, V5, DOI 10.1038/s41421-018-0070-x; Cai YF, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005643; Chen CC, 2013, BIOCHEM PHARMACOL, V86, P872, DOI 10.1016/j.bcp.2013.07.025; Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; Duan QQ, 2019, J PROTEOME RES, V18, P2903, DOI 10.1021/acs.jproteome.9b00208; Egunsola AT, 2017, J CLIN INVEST, V127, P1475, DOI 10.1172/JCI90193; Gambardella V, 2019, CLIN CANCER RES, V25, P1639, DOI 10.1158/1078-0432.CCR-18-2421; Guo DK, 2019, ACTA PHARMACOL SIN, V40, P26, DOI 10.1038/s41401-018-0064-0; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Hou XO, 2015, ACTA PHARMACOL SIN, V36, P1300, DOI 10.1038/aps.2015.54; Hu SQ, 2015, CNS NEUROSCI THER, V21, P953, DOI 10.1111/cns.12472; Ivanova T, 2013, GUT, V62, P22, DOI 10.1136/gutjnl-2011-301113; Jung KA, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/423965; Lee JY, 2017, J GENET, V96, P1041, DOI 10.1007/s12041-017-0854-z; Liang JR, 2020, CELL, V180, P1160, DOI 10.1016/j.cell.2020.02.017; Lin JX, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1416-4; Lin JX, 2018, WORLD J GASTROENTERO, V24, P3898, DOI 10.3748/wjg.v24.i34.3898; Liu J, 2020, NAT CELL BIOL, V22, P1056, DOI 10.1038/s41556-020-0559-z; Neziri Dashurie, 2016, J Nephropathol, V5, P65, DOI 10.15171/jnp.2016.13; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Qin B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09175-0; Roh JL, 2017, REDOX BIOL, V11, P254, DOI 10.1016/j.redox.2016.12.010; Rukova B, 2014, BIOTECHNOL BIOTEC EQ, V28, P518, DOI 10.1080/13102818.2014.933501; Tanaka Y, 2011, HUM MOL GENET, V20, P3507, DOI 10.1093/hmg/ddr249; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Walczak CP, 2019, P NATL ACAD SCI USA, V116, P1299, DOI 10.1073/pnas.1816202116; Wang LH, 2020, CELL RES, V30, DOI 10.1038/s41422-019-0236-6; Wang SY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.450; Wang XJ, 2006, CANCER RES, V66, P10983, DOI 10.1158/0008-5472.CAN-06-2298; Wang ZF, 2019, NUCLEIC ACIDS RES, V47, P4124, DOI 10.1093/nar/gkz110; Washington K, 2010, ANN SURG ONCOL, V17, P3077, DOI 10.1245/s10434-010-1362-z; Wu TD, 2014, GENE DEV, V28, P708, DOI 10.1101/gad.238246.114; Xi P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064231; Xu GQ, 2013, J BIOL CHEM, V288, P29573, DOI 10.1074/jbc.M113.472092; Yakirevich E, 2016, CLIN CANCER RES, V22, P3831, DOI 10.1158/1078-0432.CCR-15-3000; Yoo HM, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00036; Yoo HM, 2014, MOL CELL, V56, P261, DOI 10.1016/j.molcel.2014.08.007; Zhao Y, 2016, CHEM BIODIVERS, V13, P1186, DOI 10.1002/cbdv.201600012; Zhu Y, 2018, J PROTEOME RES, V17, P1509, DOI 10.1021/acs.jproteome.7b00843	43	8	8	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					647	662		10.1038/s41388-020-01551-1	http://dx.doi.org/10.1038/s41388-020-01551-1		NOV 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33219317				2022-12-28	WOS:000591146100002
J	Kung, CP; Cottrell, KA; Ryu, S; Bramel, ER; Kladney, RD; Bao, EA; Freeman, EC; Sabloak, T; Maggi, L; Weber, JD				Kung, Che-Pei; Cottrell, Kyle A.; Ryu, Sua; Bramel, Emily R.; Kladney, Raleigh D.; Bao, Emily A.; Freeman, Eric C.; Sabloak, Thwisha; Maggi Jr., Leonard; Weber, Jason D.			Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer	ONCOGENE			English	Article							GENOMIC LANDSCAPE; RNA; INTERFERON; STRESS; SUPPRESSES; EXPRESSION; DIVERSITY; APOPTOSIS	Triple-negative breast cancer (TNBC) is the deadliest form of breast cancer. Unlike other types of breast cancer that can be effectively treated by targeted therapies, no such targeted therapy exists for all TNBC patients. The ADAR1 enzyme carries out A-to-I editing of RNA to prevent sensing of endogenous double-stranded RNAs. ADAR1 is highly expressed in breast cancer including TNBC. Here, we demonstrate that expression of ADAR1, specifically its p150 isoform, is required for the survival of TNBC cell lines. In TNBC cells, knockdown of ADAR1 attenuates proliferation and tumorigenesis. Moreover, ADAR1 knockdown leads to robust translational repression. ADAR1-dependent TNBC cell lines also exhibit elevated IFN stimulated gene expression. IFNAR1 reduction significantly rescued the proliferative defects of ADAR1 loss. These findings establish ADAR1 as a novel therapeutic target for TNBC tumors.	[Kung, Che-Pei; Cottrell, Kyle A.; Ryu, Sua; Bramel, Emily R.; Kladney, Raleigh D.; Bao, Emily A.; Freeman, Eric C.; Sabloak, Thwisha; Maggi Jr., Leonard; Weber, Jason D.] Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA; [Weber, Jason D.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, Siteman Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	Weber, JD (corresponding author), Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA.; Weber, JD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Siteman Canc Ctr, St Louis, MO 63110 USA.	jweber@wustl.edu	Kung, Che-Pei/I-6276-2019	Kung, Che-Pei/0000-0002-1150-4998; Bramel, Emily/0000-0003-2593-2579; Ryu, Sua/0000-0002-5098-4963; Maggi, Leonard/0000-0003-0138-0984; Weber, Jason/0000-0002-1069-6983	National Institute of Health [R01CA190986, F32GM131514, TL1TR002344]; Department of Defense [W81XWH-18-1-0025]; Longer Life Foundation: A RGA/Washington University partnership	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Longer Life Foundation: A RGA/Washington University partnership	This work was supported by R01CA190986 (JDW), F32GM131514 (KAC), and TL1TR002344 (C-PK) from the National Institute of Health, and W81XWH-18-1-0025 from the Department of Defense (JDW). This work was supported by the Longer Life Foundation: A RGA/Washington University partnership. We thank Kazuko Nishikura (The Wistar Institute) for providing ADAR1 expressing constructs. The results shown here are in whole or part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.	Ademuyiwa F, 2017, BREAST CANCER RES TR, V161, P491, DOI 10.1007/s10549-016-4062-y; Anantharaman A, 2017, FEBS LETT, V591, P2890, DOI 10.1002/1873-3468.12795; Anders Carey K, 2016, Am Soc Clin Oncol Educ Book, V35, P34, DOI 10.14694/EDBK_159135; Apicelli AJ, 2008, MOL CELL BIOL, V28, P1068, DOI 10.1128/MCB.00484-07; Binothman N, 2017, EBIOMEDICINE, V21, P65, DOI 10.1016/j.ebiom.2017.06.023; Brenot A, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0042-x; Chen LL, 2013, NAT MED, V19, P209, DOI 10.1038/nm.3043; Chung HC, 2018, CELL, V172, P811, DOI 10.1016/j.cell.2017.12.038; Crews LA, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0370-3; Dar AC, 2005, CELL, V122, P887, DOI 10.1016/j.cell.2005.06.044; Dave B, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw292; Doherty MR, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1136-x; Doherty MR, 2017, P NATL ACAD SCI USA, V114, P13792, DOI 10.1073/pnas.1713728114; Forys JT, 2014, CELL REP, V7, P514, DOI 10.1016/j.celrep.2014.03.026; Fumagalli D, 2015, CELL REP, V13, P277, DOI 10.1016/j.celrep.2015.09.032; Gannon HS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07824-4; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; George CX, 2016, J BIOL CHEM, V291, P6158, DOI 10.1074/jbc.M115.709014; Gumireddy K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10715; Han L, 2015, CANCER CELL, V28, DOI 10.1016/j.ccell.2015.08.013; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Holcik M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00264; Ishizuka JJ, 2019, NATURE, V565, P43, DOI 10.1038/s41586-018-0768-9; Kung CP, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00762; Lan Q, 2019, ONCOGENE, V38, P2814, DOI 10.1038/s41388-018-0624-2; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Li Y, 2017, ELIFE, V6, DOI [10.7554/eLife.29914, 10.7554/eLife.25687]; Li ZQ, 2012, J VIROL, V86, P3787, DOI 10.1128/JVI.06307-11; Liddicoat BJ, 2015, SCIENCE, V349, P1115, DOI 10.1126/science.aac7049; Liu HY, 2019, NAT MED, V25, P95, DOI 10.1038/s41591-018-0302-5; Liu HY, 2017, DEV CELL, V41, P392, DOI 10.1016/j.devcel.2017.04.024; Lo PK, 2018, ELIFE, V7, DOI 10.7554/eLife.31334; Mannion NM, 2014, CELL REP, V9, P1482, DOI 10.1016/j.celrep.2014.10.041; Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062; McFarland JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06916-5; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Nakano M, 2017, J BIOL CHEM, V292, P4873, DOI 10.1074/jbc.M117.775684; Paz-Yaacov N, 2015, CELL REP, V13, P267, DOI 10.1016/j.celrep.2015.08.080; Peng XX, 2018, CANCER CELL, V33, P817, DOI 10.1016/j.ccell.2018.03.026; Perou CM, 2011, ONCOLOGIST, V16, P61, DOI 10.1634/theoncologist.2011-S1-61; Pestal K, 2015, IMMUNITY, V43, P933, DOI 10.1016/j.immuni.2015.11.001; Pujantell M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13580-0; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sagredo EA, 2018, BIOL RES, V51, DOI 10.1186/s40659-018-0185-4; Sakurai M, 2017, NAT STRUCT MOL BIOL, V24, P534, DOI 10.1038/nsmb.3403; Shigeyasu K, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99976; Sidrauski C, 2015, ELIFE, V4, DOI 10.7554/eLife.07314; SILVERMAN RH, 1983, J VIROL, V46, P1051, DOI 10.1128/JVI.46.3.1051-1055.1983; Snell LM, 2017, TRENDS IMMUNOL, V38, P542, DOI 10.1016/j.it.2017.05.005; Song In Hye, 2017, Tumour Biol, V39, p1010428317734816, DOI 10.1177/1010428317734816; Waks AG, 2019, JAMA-J AM MED ASSOC, V321, P288, DOI 10.1001/jama.2018.19323; Wang QD, 2004, J BIOL CHEM, V279, P4952, DOI 10.1074/jbc.M310162200	52	16	17	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					189	202		10.1038/s41388-020-01515-5	http://dx.doi.org/10.1038/s41388-020-01515-5		OCT 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33110236	Green Accepted			2022-12-28	WOS:000582768100002
J	Li, HW; Zhao, LX; Lau, YS; Zhang, C; Han, RZ				Li, Haiwen; Zhao, Lixia; Lau, Yeh Siang; Zhang, Chen; Han, Renzhi			Genome-wide CRISPR screen identifies LGALS2 as an oxidative stress-responsive gene with an inhibitory function on colon tumor growth	ONCOGENE			English	Article							MOUSE MODEL; CANCER; COLITIS; INACTIVATION; INFLAMMATION; GALECTINS; TISSUE; ROLES; STAT3; ROS	Colorectal cancer is the third leading cause of cancer-related deaths in the United States and the third most common cancer in men and women. Around 20% colon cancer cases are closely linked with colitis. Both environmental and genetic factors are thought to contribute to colon inflammation and tumor development. However, the genetic factors regulating colitis and colon tumorigenesis remain elusive. Since reactive oxygen species (ROS) is vitally involved in tissue inflammation and tumorigenesis, here we employed a genome-wide CRISPR knockout screening approach to systemically identify the genetic factors involved in the regulation of oxidative stress. Next generation sequencing (NGS) showed that over 600 gRNAs including the ones targeting LGALS2 were highly enriched in cells survived after sublethal H2O2 challenge. LGALS2 encodes the glycan-binding protein Galectin 2 (Gal2), which is predominantly expressed in the gastrointestinal tract and downregulated in human colon tumors. To examine the role of Gal2 in colitis, we employed the dextran sodium sulfate (DSS)-induced acute colitis model in mice with (WT) or without Lgals2 (Gal2-KO) and showed that Gal2 deficiency ameliorated DSS-induced colitis. We further demonstrated that Gal2-KO mice developed significantly larger tumors than WT mice using Azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced colorectal cancer model. We found that STAT3 phosphorylation was significantly increased in Gal2-deficient tumors as compared to those in WT mice. Gal2 overexpression decreased the proliferation of human colon tumor epithelial cells and blunted H2O2-induced STAT3 phosphorylation. Overall, our results demonstrate that Gal2 plays a suppressive role in colon tumor growth and highlights the therapeutic potential of Gal2 in colon cancer.	[Li, Haiwen; Zhao, Lixia; Lau, Yeh Siang; Zhang, Chen; Han, Renzhi] Ohio State Univ, Wexner Med Ctr, Biophys Grad Program, Davis Heart & Lung Res Inst,Biomed Sci Grad Progr, Columbus, OH 43210 USA; [Lau, Yeh Siang] Sunway Univ, Sch Healthcare & Med Sci, Bandar Sunway 47500, Selangor, Malaysia	University System of Ohio; Ohio State University; Sunway University	Han, RZ (corresponding author), Ohio State Univ, Wexner Med Ctr, Biophys Grad Program, Davis Heart & Lung Res Inst,Biomed Sci Grad Progr, Columbus, OH 43210 USA.	renzhi.han@osumc.edu		Han, Renzhi/0000-0002-8202-9186	US National Institutes of Health [R01 HL116546]; Parent Project Muscular Dystrophy award	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Parent Project Muscular Dystrophy award	RH is supported by US National Institutes of Health Grant (R01 HL116546) and a Parent Project Muscular Dystrophy award. We thank Dr Chao Liu for assistance in bioinformatic analysis.	Akoumianakis I, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav5055; Aran D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01027-z; Barrow H, 2011, CLIN CANCER RES, V17, P7035, DOI 10.1158/1078-0432.CCR-11-1462; Bi P, 2017, SCIENCE, V356, P323, DOI 10.1126/science.aam9361; Blaser H, 2016, TRENDS CELL BIOL, V26, P249, DOI 10.1016/j.tcb.2015.12.002; Califice S, 2004, ONCOGENE, V23, P7527, DOI 10.1038/sj.onc.1207997; Chen SD, 2015, CELL, V160, P1246, DOI 10.1016/j.cell.2015.02.038; COOPER HS, 1993, LAB INVEST, V69, P238; Diniz TC, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/171756; Dubreuil MM, 2020, CELL REP, V30, P1417, DOI 10.1016/j.celrep.2020.01.013; Fang BL, 2014, CANCERS, V6, P494, DOI 10.3390/cancers6010494; Francescone R, 2015, INFLAMM BOWEL DIS, V21, P409, DOI 10.1097/MIB.0000000000000236; Graham DB, 2020, NATURE, V578, P527, DOI 10.1038/s41586-020-2025-2; Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6; Guo JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007982; Han J, 2018, CELL REP, V23, P596, DOI 10.1016/j.celrep.2018.03.045; Hokama A, 2008, WORLD J GASTROENTERO, V14, P5133, DOI 10.3748/wjg.14.5133; Houessinon A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0526-2; Johannes L, 2018, J CELL SCI, V131, DOI 10.1242/jcs.208884; Jung JH, 2012, J GASTROENTEROL, V47, P37, DOI 10.1007/s00535-011-0463-1; Kalthoff S, 2010, J BIOL CHEM, V285, P5993, DOI 10.1074/jbc.M109.075770; Kennedy RJ, 2000, BRIT J SURG, V87, P1346, DOI 10.1046/j.1365-2168.2000.01615.x; Kim SW, 2013, CELL ONCOL, V36, P169, DOI 10.1007/s13402-013-0124-x; Kobayashi T, 2010, LEUKEMIA, V24, P843, DOI 10.1038/leu.2010.25; Langbein S, 2007, HISTOPATHOLOGY, V51, P681, DOI 10.1111/j.1365-2559.2007.02852.x; Li HW, 2019, FASEB J, V33, P2928, DOI 10.1096/fj.201801173R; Li Y, 2019, P NATL ACAD SCI USA, V116, P9527, DOI 10.1073/pnas.1900867116; Morgens DW, 2016, NAT BIOTECHNOL, V34, P634, DOI 10.1038/nbt.3567; Nagy N, 2002, GUT, V50, P392, DOI 10.1136/gut.50.3.392; Orr SL, 2013, GLYCOBIOLOGY, V23, P363, DOI 10.1093/glycob/cws150; Orsolic N, 2014, EUR J NUTR, V53, P1217, DOI 10.1007/s00394-013-0622-7; Paclik D, 2008, J MOL MED, V86, P1395, DOI 10.1007/s00109-007-0290-2; Park RJ, 2017, NAT GENET, V49, P193, DOI 10.1038/ng.3741; Perse M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/718617; Prasad S, 2017, CANCER LETT, V387, P95, DOI 10.1016/j.canlet.2016.03.042; Sakakura M, 2018, FEBS J, V285, P1129, DOI 10.1111/febs.14397; Satelli A, 2011, INT J CANCER, V129, P799, DOI 10.1002/ijc.25750; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shen YJ, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.1137.1137; Srivastava J, 2016, MOL CARCINOGEN, V55, P1889, DOI 10.1002/mc.22438; Suzuki R, 2006, CARCINOGENESIS, V27, P162, DOI 10.1093/carcin/bgi205; Takaishi S, 2007, CANCER SCI, V98, P284, DOI 10.1111/j.1349-7006.2007.00392.x; Tamura M, 2016, J BIOCHEM, V160, P233, DOI 10.1093/jb/mvw029; Tamura M, 2015, BIOCHEM BIOPH RES CO, V457, P712, DOI 10.1016/j.bbrc.2015.01.055; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Tong Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034959; Xu J, 2018, J PATHOL CLIN RES, V4, P135, DOI 10.1002/cjp2.92; Xu J, 2015, SKELET MUSCLE, V5, DOI 10.1186/s13395-015-0069-z; Yang XXO, 2008, J EXP MED, V205, P1063, DOI 10.1084/jem.20071978; Yildirim C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124347; Zhang JX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4350965	52	14	14	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					177	188		10.1038/s41388-020-01523-5	http://dx.doi.org/10.1038/s41388-020-01523-5		OCT 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33110234	hybrid, Green Published			2022-12-28	WOS:000582768100005
J	Ukai, S; Honma, R; Sakamoto, N; Yamamoto, Y; Pham, QT; Harada, K; Takashima, T; Taniyama, D; Asai, R; Fukada, K; Naka, K; Tanabe, K; Ohdan, H; Yasui, W				Ukai, Shoichi; Honma, Ririno; Sakamoto, Naoya; Yamamoto, Yusuke; Pham, Quoc Thang; Harada, Kenji; Takashima, Tsuyoshi; Taniyama, Daiki; Asai, Ryuichi; Fukada, Kaho; Naka, Kazuhito; Tanabe, Kazuaki; Ohdan, Hideki; Yasui, Wataru			Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell	ONCOGENE			English	Article							DRUG-RESISTANCE; EXPRESSION; LEUCOVORIN; INTERACTS; TISSUE	5-FU is one of the key drugs in the treatment of gastric cancer (GC). Much evidence has shown that cancer stem cells (CSCs) play a key role in the acquisition of drug resistance. The organoid is a novel 3D cell culture system technology that sustains stem-cell-driven formation of near-physiological, self-renewing tissues using specific niche factors in a dish. In this study, we established GC organoids (GCOs) and gradually treated them with higher concentrations of 5-FU. We successfully harvested four 5-FU-resistant GCOs, which were supported by significant changes in the expression of molecules related to 5-FU metabolism. We then performed microarray analysis using three normal gastric organoids and three pairs of 5-FU-resistant and parental GCOs. Through the comparison of expression profiles and further validation, we chose KHDRBS3 as a target gene. We found KHDRBS3 to be an independent prognostic factor in GC patients, especially in GC patients treated with 5-FU chemotherapy. We also determined that KHDRBS3 might play an important role in the acquisition of stem cell-like features, such as multi-drug resistance and organoid formation, by regulating CD44 variant expression. We found KHDRBS3, which is thought to play an important role in the acquisition of characteristics of CSCs in GC, to be a promising candidate marker for predicting therapeutic effect and prognosis in GC patients.	[Ukai, Shoichi; Honma, Ririno; Sakamoto, Naoya; Pham, Quoc Thang; Harada, Kenji; Takashima, Tsuyoshi; Taniyama, Daiki; Asai, Ryuichi; Fukada, Kaho; Yasui, Wataru] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Mol Pathol, Hiroshima, Japan; [Yamamoto, Yusuke] Natl Canc Ctr, Div Mol & Cellular Med, Tokyo, Japan; [Naka, Kazuhito] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Stem Cell Biol, Hiroshima, Japan; [Tanabe, Kazuaki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Hlth Care Adults, Hiroshima, Japan; [Ohdan, Hideki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Gastroenterol & Transplant Surg, Hiroshima, Japan	Hiroshima University; National Cancer Center - Japan; Hiroshima University; Hiroshima University; Hiroshima University	Yasui, W (corresponding author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Mol Pathol, Hiroshima, Japan.	wyasui@hiroshima-u.ac.jp	tanabe, kazuaki/S-6282-2019; Ohdan, Hideki/G-4719-2019; Pham, Quoc Thang/AAP-5919-2021	Ohdan, Hideki/0000-0002-9066-1288; Pham, Quoc Thang/0000-0001-8787-367X; Ukai, Shoichi/0000-0001-8491-1183; Harada, Kenji/0000-0002-8995-2846; TSUYOSHI, TAKASHIMA/0000-0003-1362-3883	Japan Society for the Promotion of Science [JP15H04713, JP16K08691, JP16H06999, 26670175, JP16K15247]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	The present study was supported by Grants in Aid for Scientific Research (JP15H04713, JP16K08691, JP16H06999) and for Challenging Exploratory Research (26670175, JP16K15247) from the Japan Society for the Promotion of Science.	Al-Batran SE, 2016, LANCET ONCOL, V17, P1697, DOI 10.1016/S1470-2045(16)30531-9; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Gao YY, 2019, INT J CLIN EXP PATHO, V12, P1095; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Honma R, 2017, GASTRIC CANCER, V20, P960, DOI 10.1007/s10120-017-0714-9; Ishikawa A, 2020, ONCOL REP, V43, P581, DOI 10.3892/or.2019.7422; Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125; Lei KF, 2011, ONCOL REP, V26, P1115, DOI 10.3892/or.2011.1369; Matsumoto Y, 2018, CANCER MED-US, V7, P454, DOI 10.1002/cam4.1296; Mazzoldi EL, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020368; Nakamura A, 2014, GASTRIC CANCER, V17, P188, DOI 10.1007/s10120-013-0249-7; Okuyama K, 2019, PATHOL ONCOL RES, V25, P603, DOI 10.1007/s12253-018-0529-y; Pacifico MD, 2006, INT J CANCER, V118, P1460, DOI 10.1002/ijc.21504; Sakamoto N, 2014, CANCER SCI, V105, P236, DOI 10.1111/cas.12330; Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Seidlitz T, 2019, GUT, V68, P207, DOI 10.1136/gutjnl-2017-314549; Shen XM, 2015, CELL BIOCHEM BIOPHYS, V71, P1653, DOI 10.1007/s12013-014-0387-5; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Steele NG, 2019, CELL MOL GASTROENTER, V7, P161, DOI 10.1016/j.jcmgh.2018.09.008; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Wang WG, 2004, CANCER RES, V64, P8167, DOI 10.1158/0008-5472.CAN-04-0970; Yang HHN, 2018, CELL STEM CELL, V23, P882, DOI 10.1016/j.stem.2018.09.016	25	14	16	5	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2020	39	50					7265	7278		10.1038/s41388-020-01492-9	http://dx.doi.org/10.1038/s41388-020-01492-9		OCT 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PD4HE	33046798	Green Submitted			2022-12-28	WOS:000578784100002
J	Tan, P; Wang, ML; Zhong, AL; Wang, YY; Du, JJ; Wang, J; Qi, L; Bi, ZY; Zhang, P; Lin, TH; Zhang, JP; Yang, L; Chen, JY; Han, P; Gong, QY; Liu, Y; Chen, C; Wei, Q				Tan, Ping; Wang, Manli; Zhong, Ailing; Wang, Yiyun; Du, Jiajia; Wang, Jian; Qi, Lu; Bi, Zhanying; Zhang, Peng; Lin, Tianhai; Zhang, Jiapeng; Yang, Lu; Chen, Jingyao; Han, Ping; Gong, Qiyong; Liu, Yu; Chen, Chong; Wei, Qiang			SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis	ONCOGENE			English	Article							SIRTUIN 1; HYPOXIA; MECHANISMS; PROMOTER; CELLS	There are unmet clinical needs for novel therapeutic targets and drugs for bladder cancer. Majority of previous work relied on limited bladder cancer cell lines, which could not well represent the tumor heterogeneity and pathology of this disease. Recently, it has been shown that cancer organoids can recapitulate pathological and molecular properties of bladder cancer. Here, we report, by our knowledge, the first bladder cancer organoid-based small molecule screening for epigenetic drugs. We found that SRT1720, a Sirtuin 1 (SIRT1) activator, significantly inhibits the growth of both mouse and human bladder cancer organoids. And it also restrains the development of mouse in situ bladder cancer and human PDX bladder cancer. Mutation of Sirt1 promotes the growth of cancer organoids and decreases their sensitivity to SRT1720, which validate Sirt1 as the target of SRT1720 in bladder cancer. Mechanistically, SRT1720 treatment represses the hypoxia pathway through deacetylating HIF1 alpha by activating Sirt1. Genetic or pharmaceutic inhibitions of HIF mimic the anti-tumor effect of SRT1720. Furthermore, the SIRT1-repressed gene signature is associated with the hypoxia target gene signature and poor prognosis in human bladder cancers. Thus, our study demonstrates the power of cancer organoid-based drug discovery and, in principle, identifies SRT1720 as a new treatment for bladder cancer.	[Tan, Ping; Wang, Manli; Zhong, Ailing; Wang, Yiyun; Du, Jiajia; Wang, Jian; Qi, Lu; Bi, Zhanying; Zhang, Peng; Lin, Tianhai; Zhang, Jiapeng; Yang, Lu; Chen, Jingyao; Han, Ping; Gong, Qiyong; Liu, Yu; Chen, Chong; Wei, Qiang] Sichuan Univ, West China Hosp, Dept Urol, Inst Urol,Dept Thorac Oncol,State Key Lab Biother, Chengdu, Peoples R China; [Tan, Ping; Wang, Manli; Zhong, Ailing; Wang, Yiyun; Du, Jiajia; Wang, Jian; Qi, Lu; Bi, Zhanying; Zhang, Peng; Lin, Tianhai; Zhang, Jiapeng; Yang, Lu; Chen, Jingyao; Han, Ping; Gong, Qiyong; Liu, Yu; Chen, Chong; Wei, Qiang] Sichuan Univ, Canc Ctr, Huaxi MR Res Ctr HMRRC, Dept Radiol,West China Hosp, Chengdu, Peoples R China	Sichuan University; Sichuan University	Chen, C; Wei, Q (corresponding author), Sichuan Univ, West China Hosp, Dept Urol, Inst Urol,Dept Thorac Oncol,State Key Lab Biother, Chengdu, Peoples R China.; Chen, C; Wei, Q (corresponding author), Sichuan Univ, Canc Ctr, Huaxi MR Res Ctr HMRRC, Dept Radiol,West China Hosp, Chengdu, Peoples R China.	chongchen@scu.edu.cn; weiqiang@scu.edu.cn	Chen, Chong/AAR-4186-2021; Gong, Qiyong/W-3052-2019	Chen, Chong/0000-0002-6787-0495; Gong, Qiyong/0000-0002-5912-4871; Zhong, Ailing/0000-0002-8044-1222; TAN, PING/0000-0002-7445-3577	National Key R&D Program of China [2017YFA0505600]; National Natural Science Foundation of China [82002692]; 1.3.5. Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYGD18011, ZY2016104]; Post-Doctor Research Project of Sichuan University [2021SCU12016]; Post-Doctor Research Project, West China Hospital, Sichuan University [19HXBH057]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 1.3.5. Project for Disciplines of Excellence, West China Hospital, Sichuan University; Post-Doctor Research Project of Sichuan University; Post-Doctor Research Project, West China Hospital, Sichuan University	This work was supported by the National Key R&D Program of China (Grant No. 2017YFA0505600), National Natural Science Foundation of China (Grant No. 82002692), 1.3.5. Project for Disciplines of Excellence, West China Hospital, Sichuan University (Grant No. ZYGD18011 and ZY2016104), Post-Doctor Research Project of Sichuan University (Grant No. 2021SCU12016), and Post-Doctor Research Project, West China Hospital, Sichuan University (Grant No. 19HXBH057).	Berdik C, 2017, NATURE, V551, pS34, DOI 10.1038/551S34a; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764; Carafa V, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00038; Chen J, 2019, HUM CELL, V32, P193, DOI 10.1007/s13577-019-00237-5; Chen JY, 2021, CANCER GENE THER, V28, P112, DOI 10.1038/s41417-020-0190-y; Chen R, 2011, J BIOL CHEM, V286, P13869, DOI 10.1074/jbc.M110.175414; Chini CCS, 2016, CLIN CANCER RES, V22, P2496, DOI 10.1158/1078-0432.CCR-15-1760; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Dioum EM, 2009, SCIENCE, V324, P1289, DOI 10.1126/science.1169956; Drost J, 2017, DEVELOPMENT, V144, P968, DOI 10.1242/dev.140566; Dudziec E, 2011, CLIN CANCER RES, V17, P1287, DOI 10.1158/1078-0432.CCR-10-2017; Faleiro I, 2017, ONCOTARGET, V8, P12484, DOI 10.18632/oncotarget.14226; Farghali H, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8765954; Geng H, 2012, J BIOL CHEM, V287, P35496, DOI 10.1074/jbc.M112.400697; Gillet JP, 2011, P NATL ACAD SCI USA, V108, P18708, DOI 10.1073/pnas.1111840108; Groselj B, 2013, RADIOTHER ONCOL, V108, P429, DOI 10.1016/j.radonc.2013.06.021; Hu QX, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3781904; Huch M, 2013, REGEN MED, V8, P385, DOI 10.2217/rme.13.39; Joo HY, 2015, BIOCHEM BIOPH RES CO, V462, P294, DOI 10.1016/j.bbrc.2015.04.119; Julien C, 2009, J NEUROPATH EXP NEUR, V68, P48, DOI 10.1097/NEN.0b013e3181922348; Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817; Laemmle A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033433; Lahusen TJ, 2015, MOL CANCER THER, V14, P183, DOI 10.1158/1535-7163.MCT-14-0584; Lee James T, 2013, Genes Cancer, V4, P112, DOI 10.1177/1947601913484496; Lee SH, 2018, CELL, V173, P515, DOI 10.1016/j.cell.2018.03.017; Li HT, 2016, INT NEUROUROL J, V20, P84, DOI 10.5213/inj.1632752.376; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Loriot Y, 2019, NEW ENGL J MED, V381, P338, DOI 10.1056/NEJMoa1817323; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Mitchell SJ, 2014, CELL REP, V6, P836, DOI 10.1016/j.celrep.2014.01.031; Mullenders J, 2019, P NATL ACAD SCI USA, V116, P4567, DOI 10.1073/pnas.1803595116; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Shin DH, 2014, CANCER RES, V74, P298, DOI 10.1158/0008-5472.CAN-13-2620; Sussmuth SD, 2015, BRIT J CLIN PHARMACO, V79, P465, DOI 10.1111/bcp.12512; Sun J, 2018, CELL STEM CELL, V23, P355, DOI 10.1016/j.stem.2018.07.018; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; van der Meer AJ, 2015, CRIT CARE MED, V43, pE199, DOI 10.1097/CCM.0000000000000949; Vlachostergios PJ, 2018, NAT REV CLIN ONCOL, V15, P495, DOI 10.1038/s41571-018-0026-y; Wang Y, 2016, IMMUNITY, V44, P1337, DOI 10.1016/j.immuni.2016.05.009; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Willyard C, 2015, NATURE, V523, P520, DOI 10.1038/523520a; Wolff EM, 2005, NAT CLIN PRACT UROL, V2, P502, DOI 10.1038/ncpuro0318; Wu BH, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0040-2; Yang Z, 2017, CLIN CANCER RES, V23, P6673, DOI 10.1158/1078-0432.CCR-17-0882; Yates DR, 2007, CLIN CANCER RES, V13, P2046, DOI 10.1158/1078-0432.CCR-06-2476; Zeng L, 2009, GERIATR GERONTOL INT, V9, P7, DOI 10.1111/j.1447-0594.2008.00504.x; Zhao H, 2019, INT J ONCOL, V54, P893, DOI 10.3892/ijo.2019.4683	51	7	7	9	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6081	6092		10.1038/s41388-021-01999-9	http://dx.doi.org/10.1038/s41388-021-01999-9		SEP 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34471236				2022-12-28	WOS:000691942100002
J	Yu, P; Zhu, X; Zhu, JL; Han, YB; Zhang, H; Zhou, X; Yang, L; Xia, YZ; Zhang, C; Kong, LY				Yu, Pei; Zhu, Xiong; Zhu, Jia-Le; Han, Yu-Bao; Zhang, Hao; Zhou, Xiang; Yang, Lei; Xia, Yuan-Zheng; Zhang, Chao; Kong, Ling-Yi			The Chk2-PKM2 axis promotes metabolic control of vasculogenic mimicry formation in p53-mutated triple-negative breast cancer	ONCOGENE			English	Article							MUTANT P53; VASCULAR MIMICRY; CHK2; KINASE; EXPRESSION; CELLS; SENESCENCE; PROGRESSION; METASTASIS; ACTIVATION	Vasculogenic mimicry (VM) formation, which participates in the process of neovascularization, is highly activated in p53-mutated triple-negative breast cancer (TNBC). Here, we show that Chk2 is negatively correlated with VM formation in p53-mutated TNBC. Its activation by DNA-damaging agents such as cisplatin, etoposide, and DPT reduces VM formation. Mechanistically, the Chk2-PKM2 axis plays an important role in the inhibition of VM formation at the level of metabolic regulation. Chk2 promotes the Chk2-PKM2 interaction through the Chk2 SCD (SQ/TQ cluster domain) and the PKM2 C domain. Furthermore, Chk2 promotes the nuclear export of PKM2 by phosphorylating PKM2 at Ser100. P-PKM2 S100 reduces VM formation by decreasing glucose flux, and the PKM2 S100A mutation abolishes the inhibition of glucose flux and VM formation induced by Chk2 activation. Overall, this study proposes a novel strategy of VM suppression through Chk2 induction, which prevents PKM2-mediated glucose flux in p53-mutated TNBC.	[Yu, Pei; Zhu, Jia-Le; Han, Yu-Bao; Zhang, Hao; Yang, Lei; Xia, Yuan-Zheng; Zhang, Chao; Kong, Ling-Yi] China Pharmaceut Univ, Sch Tradit Chinese Pharm, Jiangsu Key Lab Bioact Nat Prod Res, Nanjing, Peoples R China; [Yu, Pei; Zhu, Jia-Le; Han, Yu-Bao; Zhang, Hao; Yang, Lei; Xia, Yuan-Zheng; Zhang, Chao; Kong, Ling-Yi] China Pharmaceut Univ, Sch Tradit Chinese Pharm, State Key Lab Nat Med, Nanjing, Peoples R China; [Zhu, Xiong] China Pharmaceut Univ, Med & Chem Inst, Nanjing, Peoples R China; [Zhou, Xiang] China Pharmaceut Univ, Dept Sci China, Nanjing, Peoples R China	China Pharmaceutical University; China Pharmaceutical University; China Pharmaceutical University; China Pharmaceutical University	Zhang, C; Kong, LY (corresponding author), China Pharmaceut Univ, Sch Tradit Chinese Pharm, Jiangsu Key Lab Bioact Nat Prod Res, Nanjing, Peoples R China.; Zhang, C; Kong, LY (corresponding author), China Pharmaceut Univ, Sch Tradit Chinese Pharm, State Key Lab Nat Med, Nanjing, Peoples R China.	zhangchao@cpu.edu.cn; cpu_lykong@126.com		Zhang, Chao/0000-0002-8163-9716; , Pei Yu/0000-0001-6729-4443	National Natural Science Foundation of China [81872986, 81872889]; "Double First-Class" University project [CPU2018GF03]; Ministry of Education of China, and the State Administration of Foreign Export Affairs of China [B18056]; Drug Innovation Major Project [2018ZX09711-001-007, 2018ZX09735002-003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); "Double First-Class" University project; Ministry of Education of China, and the State Administration of Foreign Export Affairs of China; Drug Innovation Major Project	This work was supported by the National Natural Science Foundation of China (81872986, 81872889), the "Double First-Class" University project (CPU2018GF03), the 111 Project from the Ministry of Education of China, and the State Administration of Foreign Export Affairs of China (B18056), the Drug Innovation Major Project (2018ZX09711-001-007, 2018ZX09735002-003).	Aliouat-Denis CM, 2005, MOL CANCER RES, V3, P627, DOI 10.1158/1541-7786.MCR-05-0121; Alkema NG, 2014, GYNECOL ONCOL, V133, P591, DOI 10.1016/j.ygyno.2014.03.557; Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251; Ashwell S, 2008, CLIN CANCER RES, V14, P4032, DOI 10.1158/1078-0432.CCR-07-5138; Bartkova J, 2004, ONCOGENE, V23, P8545, DOI 10.1038/sj.onc.1207878; Carlessi L, 2007, MOL CANCER THER, V6, P935, DOI 10.1158/1535-7163.MCT-06-0567; Chen CR, 2005, CANCER RES, V65, P6017, DOI 10.1158/0008-5472.CAN-05-0677; Chen YP, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax5819; Cheng TY, 2018, ONCOGENE, V37, P1730, DOI 10.1038/s41388-017-0086-y; Dai BJ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1404; Dando I, 2016, IUBMB LIFE, V68, P722, DOI 10.1002/iub.1534; Delgado-Bellido D, 2019, CELL DEATH DIFFER, V26, P348, DOI 10.1038/s41418-018-0125-4; Delgado-Bellido D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0631-x; Fernandez-Cortes M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00803; Gomez-Escudero J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50866-x; Gong C, 2015, J BIOL CHEM, V290, P14811, DOI 10.1074/jbc.M115.652628; Guo QQ, 2020, EMBO J, V39, DOI 10.15252/embj.2019103111; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hess AR, 2003, CANCER RES, V63, P4757; Hsu PC, 2019, ONCOGENE, V38, P1166, DOI 10.1038/s41388-018-0506-7; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; Kilpivaara O, 2005, INT J CANCER, V113, P575, DOI 10.1002/ijc.20638; Kwon Jiyun, 2019, Exp Mol Med, V51, P1, DOI 10.1038/s12276-019-0232-4; Langer EM, 2018, ONCOGENE, V37, P1005, DOI 10.1038/onc.2017.356; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Li TB, 2017, NAT METHODS, V14, P61, DOI 10.1038/nmeth.4083; Liang J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12431; Liu K, 2017, P NATL ACAD SCI USA, V114, pE3766, DOI 10.1073/pnas.1619832114; Liu S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1411-x; Liu TJ, 2013, ONCOGENE, V32, P544, DOI 10.1038/onc.2012.85; Lulli M, 2021, CANCER RES, V81, P2861, DOI 10.1158/0008-5472.CAN-20-3134; Ma CX, 2012, J CLIN INVEST, V122, P1541, DOI 10.1172/JCI58765; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Meng J, 2019, ONCOGENE, V38, P228, DOI 10.1038/s41388-018-0428-4; Mukhopadhyay UK, 2019, JNCI-J NATL CANCER I, V111, P1202, DOI 10.1093/jnci/djz051; Muller PAJ, 2013, ONCOGENE, V32, P1252, DOI 10.1038/onc.2012.148; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Nayak D, 2017, CELL DEATH DIFFER, V24, P1275, DOI 10.1038/cdd.2017.70; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Perona R, 2008, CLIN TRANSL ONCOL, V10, P538, DOI 10.1007/s12094-008-0248-5; Pommier Y, 2006, CLIN CANCER RES, V12, P2657, DOI 10.1158/1078-0432.CCR-06-0743; Quiros-Gonzalez I, 2018, BRIT J CANCER, V118, P1098, DOI 10.1038/s41416-018-0033-x; Schneider JG, 2006, CELL METAB, V4, P377, DOI 10.1016/j.cmet.2006.10.002; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Sun T, 2010, HEPATOLOGY, V51, P545, DOI 10.1002/hep.23311; Sun Y, 1999, MOL CARCINOGEN, V24, P25, DOI 10.1002/(SICI)1098-2744(199901)24:1<25::AID-MC4>3.3.CO;2-J; Tang QS, 2020, TRENDS CANCER, V6, P62, DOI 10.1016/j.trecan.2019.11.004; Tat SK, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2782; Vogiatzi F, 2016, P NATL ACAD SCI USA, V113, pE8433, DOI 10.1073/pnas.1612711114; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wang Y, 2018, J CELL MOL MED, V22, P3475, DOI 10.1111/jcmm.13625; Wei Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14041; Williamson SC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13322; Xiao Z, 2006, MOL CANCER THER, V5, P1935, DOI 10.1158/1535-7163.MCT-06-0077; Yan W, 2018, NAT CELL BIOL, V20, P597, DOI 10.1038/s41556-018-0083-6; Yang JN, 2016, CANCER LETT, V383, P18, DOI 10.1016/j.canlet.2016.09.012; Yang P, 2014, CELL SIGNAL, V26, P1853, DOI 10.1016/j.cellsig.2014.03.020; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yang ZH, 2015, EXP MOL PATHOL, V98, P352, DOI 10.1016/j.yexmp.2015.03.030; Yu WW, 2019, ONCOGENE, V38, P1225, DOI 10.1038/s41388-018-0463-1; Zhang Q, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1282-6; Zhang SW, 2007, CANCER LETT, V254, P157, DOI 10.1016/j.canlet.2006.12.036; Zhao N, 2012, MED ONCOL, V29, P3599, DOI 10.1007/s12032-012-0245-5; Zhao WJ, 2018, CELL PHYSIOL BIOCHEM, V45, P1590, DOI 10.1159/000487724	67	4	4	4	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5262	5274		10.1038/s41388-021-01933-z	http://dx.doi.org/10.1038/s41388-021-01933-z		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34244606				2022-12-28	WOS:000672114100002
J	Kaida, A; Yamamoto, S; Parrales, A; Young, ED; Ranjan, A; Alalem, MA; Morita, K; Oikawa, Y; Harada, H; Ikeda, T; Thomas, SM; Diaz, FJ; Iwakuma, T				Kaida, Atsushi; Yamamoto, Satomi; Parrales, Alejandro; Young, Eric D.; Ranjan, Atul; Alalem, Mohamed A.; Morita, Kei-ichi; Oikawa, Yu; Harada, Hiroyuki; Ikeda, Tohru; Thomas, Sufi M.; Diaz, Francisco J.; Iwakuma, Tomoo			DNAJA1 promotes cancer metastasis through interaction with mutant p53	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; TP53 MUTATIONS; HEAD; IDENTIFICATION; ARCHITECTURE; PROGRESSION; CHAPERONES; DISEASE	Accumulation of mutant p53 (mutp53) is crucial for its oncogenic gain of function activity. DNAJA1, a member of J-domain containing proteins or heat shock protein 40, is shown to prevent unfolded mutp53 from proteasomal degradation. However, the biological function of DNAJA1 remains largely unknown. Here we show that DNAJA1 promotes tumor metastasis by accumulating unfolded mutp53. Levels of DNAJA1 in head and neck squamous cell carcinoma (HNSCC) tissues were higher than those in normal tissues. Knockdown of DNAJA1 in HNSCC cell lines carrying unfolded mutp53 significantly decreased the levels of mutp53, filopodia/lamellipodia formation, migratory potential, and active forms of CDC42/RAC1, which were not observed in HNSCC cells with DNA contact mutp53, wild-type p53, or p53 null. Such mutp53-dependent functions of DNAJA1 were supported by the observation that DNAJA1 selectively bound to unfolded mutp53. Moreover, DNAJA1 knockdown in HNSCC cells carrying unfolded mutp53 inhibited primary tumor growth and metastases to the lymph nodes and lungs. Our study suggests that DNAJA1 promotes HNSCC metastasis mainly in a manner dependent on mutp53 status, suggesting DNAJA1 as a potential therapeutic target for HNSCC harboring unfolded mutp53.	[Kaida, Atsushi; Yamamoto, Satomi; Parrales, Alejandro; Young, Eric D.; Ranjan, Atul; Iwakuma, Tomoo] Univ Kansas, Med Ctr, Dept Canc Biol, Lawrence, KS 66045 USA; [Kaida, Atsushi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral Radiat Oncol, Tokyo, Japan; [Parrales, Alejandro; Ranjan, Atul; Alalem, Mohamed A.; Iwakuma, Tomoo] Childrens Mercy Res Inst, Dept Pediat, Kansas City, MO 64108 USA; [Morita, Kei-ichi] Grad Sch Med & Dent Sci, Dept Maxillofacial Surg, Tokyo, Japan; [Morita, Kei-ichi] Bioresource Res Ctr, Tokyo, Japan; [Oikawa, Yu; Harada, Hiroyuki] Grad Sch Med & Dent Sci, Dept Oral & Maxillofacial Surg, Tokyo, Japan; [Ikeda, Tohru] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral Pathol, Tokyo, Japan; [Thomas, Sufi M.] Dept Otolaryngol Head & Neck Surg, Kansas City, KS USA; [Diaz, Francisco J.] Univ Kansas, Med Ctr, Dept Biostat & Data Sci, Kansas City, KS USA	University of Kansas; University of Kansas Medical Center; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Kansas; University of Kansas Medical Center	Iwakuma, T (corresponding author), Univ Kansas, Med Ctr, Dept Canc Biol, Lawrence, KS 66045 USA.; Iwakuma, T (corresponding author), Childrens Mercy Res Inst, Dept Pediat, Kansas City, MO 64108 USA.	tiwakuma@cmh.edu	Thomas, Sufi Mary/AFR-1642-2022	Thomas, Sufi Mary/0000-0001-5370-0842; Young, Eric/0000-0002-0014-1482	NIH [R01 CA174735, R01 CA214916, P30 CA168524]; Braden's Hope For Childhood Cancer; Masonic Cancer Alliance	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Braden's Hope For Childhood Cancer; Masonic Cancer Alliance	We thank Elizabeth Thoenen for technical assistance, helpful discussion, and editing of the manuscript, as well as Dr. Kei Sakamoto for tumor specimen collection. This study is supported by NIH R01 CA174735 (TI), R01 CA214916 (TI), Braden's Hope For Childhood Cancer (TI), Masonic Cancer Alliance (TI), and NIH P30 CA168524 (RAJ).	Ahn BY, 2010, ONCOGENE, V29, P1155, DOI 10.1038/onc.2009.413; Chen CY, 2013, CANCER RES, V73, P4009, DOI 10.1158/0008-5472.CAN-12-4066; Chen CY, 2009, J PATHOL, V219, P347, DOI 10.1002/path.2604; Chen JS, 2001, BLOOD, V97, P2115, DOI 10.1182/blood.V97.7.2115; Chen KY, 2021, CANCERS, V13, DOI 10.3390/cancers13010138; Cyr Douglas M, 2015, Subcell Biochem, V78, P91, DOI 10.1007/978-3-319-11731-7_4; Ergulen E, 2016, BIOCHEM J, V473, P3889, DOI 10.1042/BCJ20160440; Escoll M, 2017, ONCOGENE, V36, P3515, DOI 10.1038/onc.2016.518; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317; He HL, 2015, EXP MOL PATHOL, V98, P338, DOI 10.1016/j.yexmp.2015.03.029; Iyer SV, 2016, ONCOTARGET, V7, P5401, DOI 10.18632/oncotarget.6634; Kampinga HH, 2010, NAT REV MOL CELL BIO, V11, P579, DOI 10.1038/nrm2941; Large AT, 2009, BIOCHEM SOC T, V37, P46, DOI 10.1042/BST0370046; Liu TT, 2012, ONCOL LETT, V4, P1274, DOI 10.3892/ol.2012.903; Mantovani F, 2019, CELL DEATH DIFFER, V26, P199, DOI 10.1038/s41418-018-0246-9; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Nishizawa S, 2012, CANCER RES, V72, P2844, DOI 10.1158/0008-5472.CAN-11-3062; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Parrales A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194224; Parrales A, 2018, CELL DEATH DIFFER, V25, P460, DOI 10.1038/s41418-017-0026-y; Parrales A, 2016, NAT CELL BIOL, V18, P1233, DOI 10.1038/ncb3427; Parrales A, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00288; Peltonen JK, 2010, HEAD NECK ONCOL, V2, DOI 10.1186/1758-3284-2-36; Poeta ML, 2007, NEW ENGL J MED, V357, P2552, DOI 10.1056/NEJMoa073770; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Sakabe M, 2017, P NATL ACAD SCI USA, V114, P10918, DOI 10.1073/pnas.1704030114; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Tracz-Gaszewska Z, 2017, ONCOTARGET, V8, P82123, DOI 10.18632/oncotarget.18899; Uno Y, 2019, ANN SURG ONCOL, V26, P836, DOI 10.1245/s10434-018-07149-y; VOJTESEK B, 1995, ONCOGENE, V10, P389; Walerych D, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00289; Xu DD, 2019, MOL CARCINOGEN, V58, P2052, DOI 10.1002/mc.23097; Yang SS, 2020, ONCOGENE, V39, P249, DOI 10.1038/s41388-019-0978-0; Yang T, 2014, BIOCHEM BIOPH RES CO, V455, P298, DOI 10.1016/j.bbrc.2014.11.011; Yue XT, 2017, GENE DEV, V31, P1641, DOI 10.1101/gad.301564.117; Zhou G, 2016, J CELL BIOCHEM, V117, P2682, DOI 10.1002/jcb.25592	40	6	6	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					5013	5025		10.1038/s41388-021-01921-3	http://dx.doi.org/10.1038/s41388-021-01921-3		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34183772	Green Accepted			2022-12-28	WOS:000667587200003
J	Wu, Y; Guo, QH; Ju, XZ; Hu, ZX; Xia, LF; Deng, Y; Zhao, P; Zhang, M; Shao, Y; Huang, SL; He, XH; Wen, H; Wu, XH				Wu, Yong; Guo, Qinhao; Ju, Xingzhu; Hu, Zhixiang; Xia, Lingfang; Deng, Yu; Zhao, Ping; Zhang, Meng; Shao, Yang; Huang, Shenglin; He, Xianghuo; Wen, Hao; Wu, Xiaohua			HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway	ONCOGENE			English	Article							NONCODING RNAS; PROTEINS; METASTASIS; BINDING; AXIS	Numerous studies suggest an important role for copy number alterations (CNAs) in cancer progression. However, CNAs of long intergenic noncoding RNAs (lincRNAs) in ovarian cancer (OC) and their potential functions have not been fully investigated. Here, based on analysis of The Cancer Genome Atlas (TCGA) database, we identified in this study an oncogenic lincRNA termed LINC00662 that exhibited a significant correlation between its CNA and its increased expression. LINC00662 overexpression is highly associated with malignant features in OC patients and is a prognostic indicator. LINC00662 significantly promotes OC cell proliferation and metastasis in vitro and in vivo. Mechanistically, LINC00662 is stabilized by heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1). Moreover, LINC00662 exerts oncogenic effects by interacting with glucose-regulated protein 78 (GRP78) and preventing its ubiquitination in OC cells, leading to activation of the oncogenic p38 MAPK signaling pathway. Taken together, our results define an oncogenic role for LINC00662 in OC progression mediated via GRP78/p38 signaling, with potential implications regarding therapeutic targets for OC.	[Wu, Yong; Guo, Qinhao; Ju, Xingzhu; Xia, Lingfang; Wen, Hao; Wu, Xiaohua] Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Wu, Yong; Guo, Qinhao; Ju, Xingzhu; Xia, Lingfang; Zhang, Meng; Wen, Hao; Wu, Xiaohua] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Hu, Zhixiang; Huang, Shenglin; He, Xianghuo] Fudan Univ, Shanghai Canc Ctr, Inst Biomed Sci, Key Lab Med Epigenet & Metab, Shanghai 200032, Peoples R China; [Hu, Zhixiang; Shao, Yang; Huang, Shenglin; He, Xianghuo; Wu, Xiaohua] Fudan Univ, Canc Inst, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Deng, Yu] Zhejiang Univ, Affiliated Hosp 1, Dept Pathol, Sch Med, Hangzhou 310000, Peoples R China; [Zhao, Ping] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Pathol, Sch Med, Shanghai 200001, Peoples R China; [Zhang, Meng; Shao, Yang] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Zhejiang University; Shanghai Jiao Tong University; Fudan University	Wen, H; Wu, XH (corresponding author), Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Wen, H; Wu, XH (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Wu, XH (corresponding author), Fudan Univ, Canc Inst, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.	wenhao_fdc@163.com; wu.xh@fudan.edu.cn	He, Xianghuo/I-1497-2014; Shao, Yang/AAH-1251-2020	He, Xianghuo/0000-0001-8872-668X; Shao, Yang/0000-0002-3239-4265	National Natural Science Foundation of China [81972431, 81902641, 82002747, 82002500]; Shanghai Sailing Program [20YF1408000]; Shanghai Anticancer Association EYAS PROJECT [SACA-CY19A07]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Sailing Program; Shanghai Anticancer Association EYAS PROJECT	This work was supported by grants from the National Natural Science Foundation of China (no. 81972431, 81902641, 82002747, 82002500), the Shanghai Sailing Program (no. 20YF1408000), and the Shanghai Anticancer Association EYAS PROJECT (no. SACA-CY19A07).	Andor N, 2017, CANCER RES, V77, P2179, DOI 10.1158/0008-5472.CAN-16-1553; Bailly C, 2019, BIOCHEM PHARMACOL, V163, P269, DOI 10.1016/j.bcp.2019.02.038; Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bertone-Johnson ER, 2005, LANCET, V365, P101, DOI 10.1016/S0140-6736(05)17716-2; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Cao W, 2017, ORAL ONCOL, V65, P94, DOI 10.1016/j.oraloncology.2016.12.017; Cao XL, 2020, GENES GENOM, V42, P1361, DOI 10.1007/s13258-020-01001-y; Cerezo M, 2016, CANCER CELL, V29, P805, DOI 10.1016/j.ccell.2016.04.013; Chang YW, 2016, ONCOGENE, V35, P1517, DOI 10.1038/onc.2015.214; Cheng B, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-019-1510-7; Chu LZ, 2019, AGING-US, V11, P1456, DOI 10.18632/aging.101845; Cohen M, 2011, CANCER LETT, V309, P104, DOI 10.1016/j.canlet.2011.05.022; Decorsiere A, 2011, GENE DEV, V25, P220, DOI 10.1101/gad.607011; Diederichs S, 2016, EMBO MOL MED, V8, P442, DOI 10.15252/emmm.201506055; Du TD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10824-7; Garneau D, 2005, J BIOL CHEM, V280, P22641, DOI 10.1074/jbc.M501070200; Gong WJ, 2018, J BIOCHEM, V164, P461, DOI 10.1093/jb/mvy078; Grammatikakis I, 2016, CELL REP, V15, P926, DOI 10.1016/j.celrep.2016.03.080; Grohar PJ, 2016, CELL REP, V14, P598, DOI 10.1016/j.celrep.2015.12.063; Guo T, 2020, CELL DEATH DIFFER, V27, P2191, DOI 10.1038/s41418-020-0494-3; Guo T, 2019, AGING-US, V11, P4890, DOI 10.18632/aging.102082; Indovina P, 2017, J CELL PHYSIOL, V232, P129, DOI 10.1002/jcp.25397; Jonas K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082969; Karst AM, 2014, CANCER RES, V74, P1141, DOI 10.1158/0008-5472.CAN-13-2247; Kneissig M, 2019, CURR OPIN GENET DEV, V54, P25, DOI 10.1016/j.gde.2019.02.005; Lauer S, 2019, CURR GENET, V65, P1287, DOI 10.1007/s00294-019-00980-0; Lheureux S, 2019, CA-CANCER J CLIN, V69, P280, DOI 10.3322/caac.21559; Li ZN, 2020, ORAL ONCOL, V103, DOI 10.1016/j.oraloncology.2020.104591; Liu Z, 2018, BIOCHEM BIOPH RES CO, V505, P843, DOI 10.1016/j.bbrc.2018.09.191; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Ransohoff JD, 2018, NAT REV MOL CELL BIO, V19, P143, DOI 10.1038/nrm.2017.104; Ried T, 2019, MOL ASPECTS MED, V69, P48, DOI 10.1016/j.mam.2019.07.007; Shaker OG, 2019, IUBMB LIFE, V71, P1322, DOI 10.1002/iub.2039; Shishkin SS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030745; Sun LL, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00137; Tan SS, 2011, J PATHOL, V223, P81, DOI 10.1002/path.2795; Thornton M, 2013, INT J CANCER, V133, P1408, DOI 10.1002/ijc.28137; Tian XH, 2020, MOL ONCOL, V14, P462, DOI 10.1002/1878-0261.12606; Topp MD, 2014, MOL ONCOL, V8, P656, DOI 10.1016/j.molonc.2014.01.008; Turunen JJ, 2013, RNA, V19, P380, DOI 10.1261/rna.036715.112; Wang HM, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01385; Watanabe T, 2009, MOL CANCER RES, V7, P1582, DOI 10.1158/1541-7786.MCR-09-0064; Xu D, 2019, CANCERS, V11, DOI 10.3390/cancers11101502; Zhao S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1401-z; Zong L, 2019, ONCOGENE, V38, P5281, DOI 10.1038/s41388-019-0792-8	47	3	3	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4770	4782		10.1038/s41388-021-01884-5	http://dx.doi.org/10.1038/s41388-021-01884-5		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34148056	Green Published, hybrid			2022-12-28	WOS:000663492900001
J	Garcia-Navas, R; Liceras-Boillos, P; Gomez, C; Baltanas, FC; Calzada, N; Nuevo-Tapioles, C; Cuezva, JM; Santos, E				Garcia-Navas, Rosula; Liceras-Boillos, Pilar; Gomez, Carmela; Baltanas, Fernando C.; Calzada, Nuria; Nuevo-Tapioles, Cristina; Cuezva, Jose M.; Santos, Eugenio			Critical requirement of SOS1 RAS-GEF function for mitochondrial dynamics, metabolism, and redox homeostasis	ONCOGENE			English	Article							OXIDATIVE STRESS; CELL-PROLIFERATION; ACTIVATION; FISSION; SUPEROXIDE; INDUCTION; PATHWAYS; CANCER; FUSION; MASS	SOS1 ablation causes specific defective phenotypes in MEFs including increased levels of intracellular ROS. We showed that the mitochondria-targeted antioxidant MitoTEMPO restores normal endogenous ROS levels, suggesting predominant involvement of mitochondria in generation of this defective SOS1-dependent phenotype. The absence of SOS1 caused specific alterations of mitochondrial shape, mass, and dynamics accompanied by higher percentage of dysfunctional mitochondria and lower rates of electron transport in comparison to WT or SOS2-KO counterparts. SOS1-deficient MEFs also exhibited specific alterations of respiratory complexes and their assembly into mitochondrial supercomplexes and consistently reduced rates of respiration, glycolysis, and ATP production, together with distinctive patterns of substrate preference for oxidative energy metabolism and dependence on glucose for survival. RASless cells showed defective respiratory/metabolic phenotypes reminiscent of those of SOS1-deficient MEFs, suggesting that the mitochondrial defects of these cells are mechanistically linked to the absence of SOS1-GEF activity on cellular RAS targets. Our observations provide a direct mechanistic link between SOS1 and control of cellular oxidative stress and suggest that SOS1-mediated RAS activation is required for correct mitochondrial dynamics and function.	[Garcia-Navas, Rosula; Liceras-Boillos, Pilar; Gomez, Carmela; Baltanas, Fernando C.; Calzada, Nuria; Santos, Eugenio] Univ Salamanca, Ctr Invest Canc, Inst Biol Mol & Celular Canc, CSIC, Salamanca, Spain; [Garcia-Navas, Rosula; Liceras-Boillos, Pilar; Gomez, Carmela; Baltanas, Fernando C.; Calzada, Nuria; Santos, Eugenio] Ctr Invest Biomed Red Canc Canc CIBERONC, Madrid, Spain; [Nuevo-Tapioles, Cristina; Cuezva, Jose M.] Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa3, CSIC, Madrid, Spain; [Nuevo-Tapioles, Cristina; Cuezva, Jose M.] Ctr Invest Biomed Red Canc Enfermedades Raras CIB, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	Santos, E (corresponding author), Univ Salamanca, Ctr Invest Canc, Inst Biol Mol & Celular Canc, CSIC, Salamanca, Spain.; Santos, E (corresponding author), Ctr Invest Biomed Red Canc Canc CIBERONC, Madrid, Spain.	esantos@usal.es	Baltanas, Fernando C./D-4756-2018; Nuevo-Tapioles, Cristina/AAT-5772-2021; Nuevo-Tapioles, Cristina/F-5970-2016; Baltanas, Fernando C./AAU-7451-2021	Baltanas, Fernando C./0000-0001-8110-0991; Nuevo-Tapioles, Cristina/0000-0001-5809-2030; Baltanas, Fernando C./0000-0001-8110-0991; Cuezva Marcos, Jose Manuel/0000-0003-1118-248X; Santos, Eugenio/0000-0003-3565-0321	ISCIII-MCUI [FIS PI19/00934, CIBERONC-CB16/12/00352]; Junta de Castilla y Leon [SA264P18-UIC 076]; Ramon Areces Foundation [CIVP19A5942]; FEDER funds	ISCIII-MCUI; Junta de Castilla y Leon(Junta de Castilla y Leon); Ramon Areces Foundation; FEDER funds(European Commission)	This work was supported by grants from ISCIII-MCUI (FIS PI19/00934 and CIBERONC-CB16/12/00352), Junta de Castilla y Leon (SA264P18-UIC 076), and Ramon Areces Foundation (CIVP19A5942). The research was co-financed by FEDER funds.	Amendola CR, 2019, NATURE, V576, P482, DOI 10.1038/s41586-019-1832-9; Amer YO, 2018, BBA-BIOENERGETICS, V1859, P868, DOI 10.1016/j.bbabio.2018.04.005; Enriquez JA, 2016, ANNU REV PHYSIOL, V78, P533, DOI 10.1146/annurev-physiol-021115-105031; Apostolova N, 2010, BRIT J PHARMACOL, V160, P2069, DOI 10.1111/j.1476-5381.2010.00866.x; Azrak SS, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-731; Babu D, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00031; Baker N, 2019, MITOCHONDRION, V49, P259, DOI 10.1016/j.mito.2019.06.003; Baltanas FC, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188445; Baltanas FC, 2013, MOL CELL BIOL, V33, P4562, DOI 10.1128/MCB.01026-13; Bandaru P, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a031534; Barrientos A, 2002, GENE, V286, P53, DOI 10.1016/S0378-1119(01)00803-4; Bartolini D, 2015, FREE RADICAL BIO MED, V88, P466, DOI 10.1016/j.freeradbiomed.2015.06.039; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Buday L, 2008, BBA-REV CANCER, V1786, P178, DOI 10.1016/j.bbcan.2008.05.001; Byun JK, 2019, EMBO REP, V20, DOI 10.15252/embr.201847451; Caruana NJ, 2020, BIOCHEM SOC T, V48, P621, DOI 10.1042/BST20190930; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Cuezva JM, 2002, CANCER RES, V62, P6674; Demine S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080795; Ding S, 2020, BIOGENESIS NDUFS3 LE, DOI 10.22.350587; Dong J, 2008, ANTIOXID REDOX SIGN, V10, P2023, DOI 10.1089/ars.2007.2019; Drose S, 2012, ADV EXP MED BIOL, V748, P145, DOI 10.1007/978-1-4614-3573-0_6; Drosten M, 2014, P NATL ACAD SCI USA, V111, P15155, DOI 10.1073/pnas.1417549111; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Dudkina NV, 2010, BBA-BIOENERGETICS, V1797, P664, DOI 10.1016/j.bbabio.2009.12.013; Esteban LM, 2000, MOL CELL BIOL, V20, P6410, DOI 10.1128/MCB.20.17.6410-6413.2000; Gerboth S, 2018, LEUKEMIA, V32, P820, DOI 10.1038/leu.2017.267; Guo RY, 2018, BIOMED J, V41, P9, DOI 10.1016/j.bj.2017.12.001; Hong YA, 2018, ANTIOXID REDOX SIGN, V28, P1543, DOI 10.1089/ars.2017.7207; Iershov A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09598-9; Jha Pooja, 2016, Curr Protoc Mouse Biol, V6, P1, DOI 10.1002/9780470942390.mo150182; Kim H, 1999, J AM CHEM SOC, V121, P4902, DOI 10.1021/ja990190h; Koeberle SC, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101388; Kortum RL, 2011, P NATL ACAD SCI USA, V108, P12407, DOI 10.1073/pnas.1104295108; Kunkel GH, 2016, HEART FAIL REV, V21, P499, DOI 10.1007/s10741-016-9561-8; Lee HC, 2002, J BIOMED SCI, V9, P517, DOI 10.1007/BF02254978; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Lee YK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15061; Liang HL, 2010, FREE RADICAL BIO MED, V49, P1550, DOI 10.1016/j.freeradbiomed.2010.08.018; Liceras-Boillos P, 2016, ONCOGENE, V35, P6389, DOI 10.1038/onc.2016.169; Liceras-Boillos P, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00049-18; Liesa M, 2013, CELL METAB, V17, P491, DOI 10.1016/j.cmet.2013.03.002; Markevich NI, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.557721; Martinez-Reyes I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13668-3; Maus M, 2017, CELL METAB, V25, P698, DOI 10.1016/j.cmet.2016.12.021; Mishra P, 2014, CELL METAB, V19, P630, DOI 10.1016/j.cmet.2014.03.011; Monteiro LD, 2020, METHODSX, V7, DOI 10.1016/j.mex.2020.100938; Nagdas S, 2019, CELL REP, V28, P1845, DOI 10.1016/j.celrep.2019.07.031; Nazarewicz RR, 2013, ANTIOXID REDOX SIGN, V19, P344, DOI 10.1089/ars.2013.5185; Ong SB, 2015, EUR J PHARMACOL, V763, P104, DOI 10.1016/j.ejphar.2015.04.056; Peng JY, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002212; Pernas L, 2016, ANNU REV PHYSIOL, V78, P505, DOI 10.1146/annurev-physiol-021115-105011; Pierre S, 2011, BIOCHEM PHARMACOL, V82, P1049, DOI 10.1016/j.bcp.2011.07.072; Qian XL, 2000, EMBO J, V19, P642, DOI 10.1093/emboj/19.4.642; Raghunath A, 2018, REDOX BIOL, V17, P297, DOI 10.1016/j.redox.2018.05.002; Ren Y, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2019.101154; Sanchez-Caballero L, 2016, BBA-BIOENERGETICS, V1857, P980, DOI 10.1016/j.bbabio.2016.03.031; Scarpulla RC, 2012, TRENDS ENDOCRIN MET, V23, P459, DOI 10.1016/j.tem.2012.06.006; Schrepfer E, 2016, MOL CELL, V61, P683, DOI 10.1016/j.molcel.2016.02.022; Semenza GL, 2017, EMBO J, V36, P252, DOI 10.15252/embj.201695204; Seo BJ, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101599; Serasinghe MN, 2017, HANDB EXP PHARMACOL, V240, P159, DOI 10.1007/164_2016_38; Seyfried TN, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101761; Son MJ, 2015, CELL DEATH DIFFER, V22, P1957, DOI 10.1038/cdd.2015.43; Suire S, 2019, J LEUKOCYTE BIOL, V106, P815, DOI 10.1002/JLB.2HI0918-359RR; Tan ZQ, 2016, MOL CANCER THER, V15, P774, DOI 10.1158/1535-7163.MCT-15-0621; Tao S, 2014, CANCER RES, V74, P7430, DOI 10.1158/0008-5472.CAN-14-1439; Toma-Fukai S, 2019, MOLECULES, V24, DOI 10.3390/molecules24183308; Valvona CJ, 2016, BRAIN PATHOL, V26, P3, DOI 10.1111/bpa.12299; Villena JA, 2015, FEBS J, V282, P647, DOI 10.1111/febs.13175; Vogel RO, 2007, J BIOL CHEM, V282, P7582, DOI 10.1074/jbc.M609410200; Wang DW, 2020, J CANCER, V11, P5042, DOI 10.7150/jca.45553; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; Wong GS, 2018, NAT MED, V24, P968, DOI 10.1038/s41591-018-0022-x; You XN, 2018, BLOOD, V132, P2575, DOI 10.1182/blood-2018-09-874107; Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222; Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001; Zanotti F, 2009, BIOCHEM BIOPH RES CO, V384, P43, DOI 10.1016/j.bbrc.2009.04.046; Zarich N, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-018-0111-1; Zhang Z, 2020, BRIT J CANCER, V122, P209, DOI 10.1038/s41416-019-0658-4	80	6	6	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4538	4551		10.1038/s41388-021-01886-3	http://dx.doi.org/10.1038/s41388-021-01886-3		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34120142	hybrid, Green Published			2022-12-28	WOS:000660811300001
J	Shariati, M; Evans, KW; Zheng, XF; Bristow, CA; Ng, PKS; Rizvi, YQ; Tapia, C; Yang, F; Carugo, A; Heffernan, TP; Peoples, MD; Tripathy, D; Meric-Bernstam, F				Shariati, Maryam; Evans, Kurt W.; Zheng, Xiaofeng; Bristow, Christopher A.; Ng, Patrick Kwok-Shing; Rizvi, Yasmeen Q.; Tapia, Coya; Yang, Fei; Carugo, Alessandro; Heffernan, Timothy P.; Peoples, Michael D.; Tripathy, Debu; Meric-Bernstam, Funda			Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations	ONCOGENE			English	Article							DOMAIN RECEPTOR 1; THERAPY; AKT; PHOSPHORYLATION; PALBOCICLIB; FULVESTRANT; COMBINATION; DISCOVERY; COMPLEX; POTENT	Molecular alterations in the PI3K/AKT pathway occur frequently in hormone receptor-positive breast tumors. Patients with ER-positive, HER2-negative metastatic breast cancer are often treated with CDK4/6 inhibitors such as palbociclib in combination with endocrine therapy. Although this is an effective regimen, most patients ultimately progress. The purpose of this study was identifying synthetic lethality partners that can enhance palbociclib's antitumor efficacy in the presence of PIK3CA/AKT1 mutations. We utilized a barcoded shRNA library to determine critical targets for survival in isogenic MCF7 cells with PIK3CA/AKT1 mutations. We demonstrated that the efficacy of palbociclib is reduced in the presence of PIK3CA/AKT1 mutations. We also identified that the downregulation of discoidin domain receptor 1 (DDR1) is synthetically lethal with palbociclib. DDR1 knockdown and DDR1 pharmacological inhibitor decreased cell growth and inhibited cell cycle progression in all cell lines, while enhanced the sensitivity of PIK3CA/AKT1 mutant cells to palbociclib. Combined treatment of palbociclib and 7rh further induced cell cycle arrest in PIK3CA/AKT1 mutant cell lines. In vivo, 7rh significantly enhanced palbociclib's antitumor efficacy. Our data indicates that DDR1 inhibition can augment cell cycle suppressive effect of palbociclib and could be effective strategy for targeted therapy of ER-positive, HER2-negative breast cancers with PI3K pathway activation.	[Shariati, Maryam; Evans, Kurt W.; Rizvi, Yasmeen Q.; Tapia, Coya; Yang, Fei; Meric-Bernstam, Funda] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA; [Zheng, Xiaofeng] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Bristow, Christopher A.; Carugo, Alessandro; Heffernan, Timothy P.; Peoples, Michael D.] Univ Texas MD Anderson Canc Ctr, Ctr Coclin Trials, Houston, TX 77030 USA; [Bristow, Christopher A.; Carugo, Alessandro; Heffernan, Timothy P.; Peoples, Michael D.] Univ Texas MD Anderson Canc Ctr, Inst Appl Canc Sci, Houston, TX 77030 USA; [Ng, Patrick Kwok-Shing; Meric-Bernstam, Funda] Univ Texas MD Anderson Canc Ctr, Sheikh Khalifa Bin Zayed Inst Personalized Canc T, Houston, TX 77030 USA; [Tapia, Coya; Yang, Fei] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Tripathy, Debu] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Meric-Bernstam, Funda] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Meric-Bernstam, F (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA.; Meric-Bernstam, F (corresponding author), Univ Texas MD Anderson Canc Ctr, Sheikh Khalifa Bin Zayed Inst Personalized Canc T, Houston, TX 77030 USA.; Meric-Bernstam, F (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA.	fmeric@mdanderson.org		Carugo, Alessandro/0000-0001-5182-3320	Nellie B. Connally Breast Cancer Research Endowment; Center for Clinical and Translational Sciences (CTSA-Informatics) [1UL1TR003167-01]; MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer; Cancer Prevention Institute of Texas [RP150535]; Cancer Center Support Grant (CCSG) by National Cancer Institute (NCI) [CA-16672]	Nellie B. Connally Breast Cancer Research Endowment; Center for Clinical and Translational Sciences (CTSA-Informatics); MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer; Cancer Prevention Institute of Texas; Cancer Center Support Grant (CCSG) by National Cancer Institute (NCI)	This work was funded in part by the Nellie B. Connally Breast Cancer Research Endowment, The Center for Clinical and Translational Sciences (CTSA-Informatics) #1UL1TR003167-01, the MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer, and the Cancer Prevention Institute of Texas Grant RP150535: Precision Oncology Decision Support Core. The MD Anderson Reverse Phase Protein Array Core Facility and Histology, Pathology, and Imaging Core were funded by the Cancer Center Support Grant (CCSG) funded by National Cancer Institute (NCI) #CA-16672.	Ambrogio C, 2016, NAT MED, V22, P270, DOI 10.1038/nm.4041; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Andre F., 2018, ANN ONCOL, V29, DOI 10.1093/annonc/mdy424.010; [Anonymous], 2018, N Engl J Med, V379, P2582, DOI 10.1056/NEJMx180043; [Anonymous], 2016, PALBOCICLIB PACKAGE; Assent D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116006; Beaver JA, 2013, CLIN CANCER RES, V19, P5413, DOI 10.1158/1078-0432.CCR-13-0884; Belfiore A, 2018, CELL ADHES MIGR, V12, P305, DOI 10.1080/19336918.2018.1445953; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cortes J, 2017, CANCER TREAT REV, V61, P53, DOI 10.1016/j.ctrv.2017.09.011; Cristofanilli M, 2018, EUR J CANCER, V104, P21, DOI 10.1016/j.ejca.2018.08.011; Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0; Das S, 2006, CANCER RES, V66, P8123, DOI 10.1158/0008-5472.CAN-06-1215; Day PJ, 2009, P NATL ACAD SCI USA, V106, P4166, DOI 10.1073/pnas.0809645106; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Dogruluk T, 2015, CANCER RES, V75, P5341, DOI 10.1158/0008-5472.CAN-15-1654; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Franco J, 2014, ONCOTARGET, V5, P6512, DOI 10.18632/oncotarget.2270; Gadiya M, 2018, CELL ADHES MIGR, V12, P315, DOI 10.1080/19336918.2018.1520556; Gao MS, 2013, J MED CHEM, V56, P3281, DOI 10.1021/jm301824k; Gordus A, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2008.72; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Hu J, 2007, BIOINFORMATICS, V23, P1986, DOI 10.1093/bioinformatics/btm283; Hyman DM, 2017, J CLIN ONCOL, V35, P2251, DOI 10.1200/JCO.2017.73.0143; Jansen VM, 2017, CANCER RES, V77, P2488, DOI 10.1158/0008-5472.CAN-16-2653; Ju ZL, 2015, BIOINFORMATICS, V31, P912, DOI 10.1093/bioinformatics/btu736; Juric D, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-P3-14-01; Koh M, 2015, INT J CANCER, V136, pE508, DOI 10.1002/ijc.29154; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Mata R, 2016, ONCOTARGET, V7, P7683, DOI 10.18632/oncotarget.6524; Meric-Bernstam F, 2018, JCO PRECIS ONCOL, V2, P1, DOI 10.1200/PO.17.00245; Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039; O'Leary B, 2018, CANCER DISCOV, V8, P1390, DOI 10.1158/2159-8290.CD-18-0264; Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Saby C, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00462; Shariati M, 2019, EXPERT OPIN INV DRUG, V28, P977, DOI 10.1080/13543784.2019.1676726; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Vehlow A, 2019, CELL REP, V26, P3672, DOI 10.1016/j.celrep.2019.02.096; VILLALBA M, 2019, SCI REP-UK, V9; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Wander SA, 2020, CANCER DISCOV, V10, P1174, DOI 10.1158/2159-8290.CD-19-1390	44	4	4	7	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4425	4439		10.1038/s41388-021-01819-0	http://dx.doi.org/10.1038/s41388-021-01819-0		JUN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34108622	Green Submitted			2022-12-28	WOS:000659470200002
J	Prokakis, E; Dyas, A; Grun, R; Fritzsche, S; Bedi, U; Kazerouni, ZB; Kosinsky, RL; Johnsen, SA; Wegwitz, F				Prokakis, Evangelos; Dyas, Anna; Gruen, Regina; Fritzsche, Sonja; Bedi, Upasana; Kazerouni, Zahra B.; Kosinsky, Robyn L.; Johnsen, Steven A.; Wegwitz, Florian			USP22 promotes HER2-driven mammary carcinoma aggressiveness by suppressing the unfolded protein response	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; CANCER CELLS; RESISTANCE; SAGA; ACTIVATION; APOPTOSIS; UBIQUITINATION; TRANSCRIPTION; DEGRADATION; SENSITIVITY	The Ubiquitin-Specific Protease 22 (USP22) is a deubiquitinating subunit of the mammalian SAGA transcriptional co-activating complex. USP22 was identified as a member of the so-called "death-from-cancer" signature predicting therapy failure in cancer patients. However, the importance and functional role of USP22 in different types and subtypes of cancer remain largely unknown. In the present study, we leveraged human cell lines and genetic mouse models to investigate the role of USP22 in HER2-driven breast cancer (HER2(+)-BC) and demonstrate for the first time that USP22 is required for the tumorigenic properties in murine and human HER2(+)-BC models. To get insight into the underlying mechanisms, we performed transcriptome-wide gene expression analyses and identified the Unfolded Protein Response (UPR) as a pathway deregulated upon USP22 loss. The UPR is normally induced upon extrinsic or intrinsic stresses that can promote cell survival and recovery if shortly activated or programmed cell death if activated for an extended period. Strikingly, we found that USP22 actively suppresses UPR induction in HER2(+)-BC cells by stabilizing the major endoplasmic reticulum (ER) chaperone HSPA5. Consistently, loss of USP22 renders tumor cells more sensitive to apoptosis and significantly increases the efficiency of therapies targeting the ER folding capacity. Together, our data suggest that therapeutic strategies targeting USP22 activity may sensitize tumor cells to UPR induction and could provide a novel, effective approach to treat HER2(+)-BC.	[Prokakis, Evangelos; Dyas, Anna; Gruen, Regina; Fritzsche, Sonja; Kazerouni, Zahra B.; Kosinsky, Robyn L.; Johnsen, Steven A.; Wegwitz, Florian] Univ Med Ctr Gottingen, Dept Gen Visceral & Pediat Surg, Gottingen, Germany; [Dyas, Anna] Univ Cambridge, Hutchison MRC Res Ctr, MRC Canc Unit, Box 197,Cambridge Biomed Campus, Cambridge CB2 0XZ, England; [Fritzsche, Sonja; Wegwitz, Florian] Univ Med Ctr Gottingen, Dept Gynecol & Obstet, Gottingen, Germany; [Bedi, Upasana] Jawaharlal Nehru Univ, Chromatin Remodeling Lab, Sch Life Sci, New Delhi 110067, India; [Kosinsky, Robyn L.; Johnsen, Steven A.] Mayo Clin, Gene Regulatory Mech & Mol Epigenet Lab, Div Gastroenterol & Hepatol, 200 First St SW, Rochester, MN 55905 USA	University of Cambridge; University of Gottingen; Jawaharlal Nehru University, New Delhi; Mayo Clinic	Johnsen, SA; Wegwitz, F (corresponding author), Univ Med Ctr Gottingen, Dept Gen Visceral & Pediat Surg, Gottingen, Germany.; Wegwitz, F (corresponding author), Univ Med Ctr Gottingen, Dept Gynecol & Obstet, Gottingen, Germany.; Johnsen, SA (corresponding author), Mayo Clin, Gene Regulatory Mech & Mol Epigenet Lab, Div Gastroenterol & Hepatol, 200 First St SW, Rochester, MN 55905 USA.	johnsen.steven@mayo.edu; fwegwit@gwdg.de	Johnsen, Steven/AAX-2322-2020	Johnsen, Steven/0000-0003-1198-5805; Prokakis, Dr. rer. nat. Evangelos/0000-0001-9297-1821; Fritzsche, Sonja/0000-0003-3335-3534; Wegwitz, Florian/0000-0003-0750-6998	Deutsche Krebshilfe [111600]	Deutsche Krebshilfe(Deutsche Krebshilfe)	We would like to thank S. Bolte, N. Molitor and the staff of the European Neuroscience Institute Gottingen for assistance in the animal handling administration, F. Alves (Translational Molecular Imaging, Max Planck Institute for Experimental Medicine, Gottingen) for access to the IncuCyte (R) Live Cell Analysis System (Sartorius AG). Also, we would especially like to thank Xin Wang and Ana Patricia Kutschat for providing precious feedback to this work. Moreover, we would like to thank the TCGA Research Network for the free access of patient-derived mRNA-seq and survival data (https://www.cancer.gov/tcga).In addition, we would like to thank Dr. Wiebke Mobius (Max Planck Institute of Experimental Medicine Electron Microscopy Core Unit Dept. of Neurogenetics, Gottingen) for her technical support. This work was supported by funding from the Deutsche Krebshilfe to S.A.J. (111600).	Appenzeller-Herzog C, 2012, TRENDS CELL BIOL, V22, P274, DOI 10.1016/j.tcb.2012.02.006; Atanassov BS, 2016, MOL CELL, V62, P558, DOI 10.1016/j.molcel.2016.03.030; Bailly C, 2019, BIOCHEM PHARMACOL, V163, P269, DOI 10.1016/j.bcp.2019.02.038; Baumann J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2611-8; Brooks AC, 2014, J MOL CELL CARDIOL, V76, P138, DOI 10.1016/j.yjmcc.2014.08.011; Cai Z, 2020, J EXP MED, V217, DOI 10.1084/jem.20191174; Casas C, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00177; Cerezo M, 2016, CANCER CELL, V29, P805, DOI 10.1016/j.ccell.2016.04.013; Cha JH, 2018, MOL CELL, V71, P606, DOI 10.1016/j.molcel.2018.07.030; Chen X, 2011, J CELL BIOL, V192, P825, DOI 10.1083/jcb.201008090; Darini C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10138-8; Dittrich A, 2014, J MAMMARY GLAND BIOL, V19, P253, DOI 10.1007/s10911-014-9329-5; Dobin Alexander, 2015, Curr Protoc Bioinformatics, V51, DOI 10.1002/0471250953.bi1114s51; Gao YY, 2014, FEBS LETT, V588, P878, DOI 10.1016/j.febslet.2014.02.016; Gennaro VJ, 2018, P NATL ACAD SCI USA, V115, pE9298, DOI 10.1073/pnas.1807704115; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]; Harbeck N, 2018, CURR OPIN OBSTET GYN, V30, P55, DOI 10.1097/GCO.0000000000000431; Hayner JN, 2018, BBA-GENE REGUL MECH, V1861, P72, DOI 10.1016/j.bbagrm.2018.01.002; Helmlinger D, 2017, TRENDS BIOCHEM SCI, V42, P850, DOI 10.1016/j.tibs.2017.09.001; Huang X, 2019, CANCER IMMUNOL RES, V7, P1580, DOI 10.1158/2326-6066.CIR-18-0910; Ibrahim IM, 2019, LIFE SCI, V226, P156, DOI 10.1016/j.lfs.2019.04.022; Ishizawa J, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aac4380; Iurlaro R, 2016, FEBS J, V283, P2640, DOI 10.1111/febs.13598; Jeusset LMP, 2017, CANCERS, V9, DOI 10.3390/cancers9120167; Kim D, 2017, J CELL PHYSIOL, V232, P3664, DOI 10.1002/jcp.25841; Komurov K, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.25; Kopp MC, 2019, NAT STRUCT MOL BIOL, V26, P1053, DOI 10.1038/s41594-019-0324-9; Kosinsky RL, 2015, ONCOTARGET, V6, P37906, DOI 10.18632/oncotarget.5412; Kosinsky RL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2141-9; Kosinsky RL, 2020, CELL DEATH DIFFER, V27, P1328, DOI 10.1038/s41418-019-0420-8; Koutelou E, 2010, CURR OPIN CELL BIOL, V22, P374, DOI 10.1016/j.ceb.2010.03.005; Kumler I, 2014, CANCER TREAT REV, V40, P259, DOI 10.1016/j.ctrv.2013.09.002; Lang G, 2011, MOL CELL BIOL, V31, P3734, DOI 10.1128/MCB.05231-11; Lim C, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1137-y; Lin ZH, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.28; Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024; Ling SB, 2017, MOL ONCOL, V11, P682, DOI 10.1002/1878-0261.12067; Liu XL, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03435-y; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Martin-Perez R, 2014, CANCER RES, V74, P1766, DOI 10.1158/0008-5472.CAN-13-1747; McCann JJ, 2020, CANCER RES, V80, P430, DOI 10.1158/0008-5472.CAN-19-1033; McConkey DJ, 2017, BIOCHEM BIOPH RES CO, V482, P450, DOI 10.1016/j.bbrc.2016.11.047; Melo-Cardenas J, 2018, BLOOD, V132, P423, DOI 10.1182/blood-2017-10-811760; Millet A, 2016, J MED CHEM, V59, P8276, DOI 10.1021/acs.jmedchem.6b00547; Mishra VK, 2017, NUCLEIC ACIDS RES, V45, P6334, DOI 10.1093/nar/gkx212; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; Prenzel T, 2011, CANCER RES, V71, P5739, DOI 10.1158/0008-5472.CAN-11-1896; Ruggiero C, 2018, MOL CELL ENDOCRINOL, V474, P57, DOI 10.1016/j.mce.2018.02.010; Schoenhacker-Alte B, 2017, CANCER LETT, V404, P79, DOI 10.1016/j.canlet.2017.07.009; Shubin AV, 2016, ONCOTARGET, V7, P55863, DOI 10.18632/oncotarget.10150; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284; Wang L, 2014, EPIGENOMICS-UK, V6, P329, DOI [10.2217/EPI.14.22, 10.2217/epi.14.22]; Wang SL, 2020, CELL DEATH DIFFER, V27, P3131, DOI 10.1038/s41418-020-0568-2; Wang Y, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00612-y; Wienken M, 2016, MOL CELL, V61, P68, DOI 10.1016/j.molcel.2015.12.008; Xiao HB, 2015, BIOCHEM BIOPH RES CO, V460, P703, DOI 10.1016/j.bbrc.2015.03.093; Xu XW, 2017, CLIN CANCER RES, V23, P5123, DOI 10.1158/1078-0432.CCR-16-2191; Yang GH, 2000, TOXICOL APPL PHARM, V162, P207, DOI 10.1006/taap.1999.8842; Yao XL, 2020, AM J CANCER RES, V10, P838; Zhang HJ, 2018, CANCER LETT, V433, P186, DOI 10.1016/j.canlet.2018.07.002; Zhang J, 2017, ONCOTARGET, V8, P24728, DOI 10.18632/oncotarget.15798; Zhang LH, 2010, J CELL BIOCHEM, V110, P1299, DOI 10.1002/jcb.22679; Zhang T., 2020, EMBO MOL MED, V12, P1; Zhang XY, 2008, MOL CELL, V29, P102, DOI 10.1016/j.molcel.2007.12.015; Zhang YX, 2011, J CANCER RES CLIN, V137, P1245, DOI 10.1007/s00432-011-0998-9; Zhou AD, 2016, NAT CELL BIOL, V18, P954, DOI 10.1038/ncb3396	69	12	12	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					4004	4018		10.1038/s41388-021-01814-5	http://dx.doi.org/10.1038/s41388-021-01814-5		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	34007022	hybrid, Green Published			2022-12-28	WOS:000651700100001
J	Chen, SS; Du, YY; Xu, B; Li, Q; Yang, L; Jiang, Z; Zeng, ZX; Chen, LF				Chen, Sisi; Du, Yunyan; Xu, Bin; Li, Qing; Yang, Le; Jiang, Zi; Zeng, Zhaoxia; Chen, Leifeng			Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance	ONCOGENE			English	Article							CANCER; VRK2; PHOSPHORYLATION; RESISTANCE; MECHANISMS; EXPRESSION; CROSSTALK; STABILITY; CELLS	Hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options. Sorafenib is the only Food and Drug Administration (FDA)-approved first-line targeted drug for the treatment of advanced HCC. However, its effect on patient survival is limited. Recently, studies have demonstrated that the imbalance between apoptosis and autophagy plays a critical role in chemoresistance, and it is hypothesised that restoring the balance between these processes is a potential treatment strategy for improving chemoresistance in cancer. However, there is currently no evidence supporting this hypothesis. We aimed to investigate if vaccinia-related kinase 2 (VRK2), a serine/threonine protein kinase, confers sorafenib resistance in HCC cells. Here, we found that VRK2 was enriched in sorafenib-resistant HCC cells and patient-derived xenografts. Both in vivo and in vitro evidences showed that VRK2 blunts the efficacy of sorafenib against hepatocellular carcinoma by disturbing the balance between apoptosis and autophagy. Mechanistically, VRK2 promotes the phosphorylation of Bcl-2 by activating JNK1/MAPK8, thereby enhancing the dissociation of Bcl-2 from Beclin-1 and promoting the formation of the Beclin-1-Atg14-Vps34 complex, which facilitates autophagy. Furthermore, VRK2-induced phosphorylation of Bcl-2 promotes the interaction of Bcl-2 with BAX, thereby inhibiting apoptosis. In conclusion, targeting VRK2 for modulation of the balance between autophagy and apoptosis may be a novel strategy for overcoming sorafenib resistance in HCC.	[Chen, Sisi; Chen, Leifeng] Nanchang Univ, Affiliated Hosp 2, Dept Gen Surg, Nanchang, Jiangxi, Peoples R China; [Du, Yunyan] Nanchang Univ, Jiangxi Prov Peoples Hosp, Dept Med, Nanchang, Jiangxi, Peoples R China; [Xu, Bin] Nanchang Univ, Dept Burns, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China; [Li, Qing] Nanchang Univ, Affiliated Hosp 2, Dept Pathol, Nanchang, Jiangxi, Peoples R China; [Yang, Le; Jiang, Zi] Nanchang Univ, Affiliated Hosp 2, Dept Pharm, Nanchang, Jiangxi, Peoples R China; [Zeng, Zhaoxia] Nanchang Univ, Affiliated Hosp 2, Dept Radiol, Nanchang, Jiangxi, Peoples R China	Nanchang University; Nanchang University; Nanchang University; Nanchang University; Nanchang University; Nanchang University	Chen, LF (corresponding author), Nanchang Univ, Affiliated Hosp 2, Dept Gen Surg, Nanchang, Jiangxi, Peoples R China.	18770099029@126.com		Chen, Sisi/0000-0002-1908-5054; chen, Leifeng/0000-0001-8305-1900	National Natural Science Foundation of China [81760523]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (81760523).	Almarzooq S, 2020, MOL BIOL REP, V47, P5127, DOI 10.1007/s11033-020-05584-3; Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Birendra KC, 2017, MOL BIOL CELL, V28, P2241, DOI 10.1091/mbc.E17-03-0138; Blanco S, 2006, FEBS J, V273, P2487, DOI 10.1111/j.1742-4658.2006.05256.x; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cabral LKD, 2020, CANCERS, V12, DOI 10.3390/cancers12061576; Choo SP, 2016, CANCER-AM CANCER SOC, V122, P3430, DOI 10.1002/cncr.30237; Fernandez IF, 2010, MOL CELL BIOL, V30, P4687, DOI 10.1128/MCB.01581-09; Gao LX, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0478-9; Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x; Goyal L, 2019, CLIN CANCER RES, V25, P80, DOI 10.1158/1078-0432.CCR-18-0847; Ho CJ, 2019, CANCERS, V11, DOI 10.3390/cancers11111775; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Keating GM, 2017, TARGET ONCOL, V12, P243, DOI 10.1007/s11523-017-0484-7; Kfir-Erenfeld S, 2010, LEUKEMIA LYMPHOMA, V51, P1968, DOI 10.3109/10428194.2010.506570; Kim R, 2002, CANCER CHEMOTH PHARM, V50, P343, DOI 10.1007/s00280-002-0522-7; Kim S, 2015, MOL CELL BIOL, V35, P1754, DOI 10.1128/MCB.01325-14; Kulik L, 2019, GASTROENTEROLOGY, V156, P477, DOI 10.1053/j.gastro.2018.08.065; Lazarou M, 2015, NATURE, V524, P309, DOI 10.1038/nature14893; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Li Ming, 2018, Mol Neuropsychiatry, V4, P119, DOI 10.1159/000493941; Li Y, 2015, BASIC CLIN PHARMACOL, V116, P216, DOI 10.1111/bcpt.12365; Liu J, 2019, ACS CHEM NEUROSCI, V10, P792, DOI 10.1021/acschemneuro.8b00356; Liu J, 2018, AUTOPHAGY, V14, P845, DOI 10.1080/15548627.2017.1390636; Lu S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0681-z; Maejima Y, 2013, NAT MED, V19, P1478, DOI 10.1038/nm.3322; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Meyer T, 2017, LANCET GASTROENTEROL, V2, P565, DOI 10.1016/S2468-1253(17)30156-5; Mokdad AA, 2017, CHIN CLIN ONCOL, V6, DOI 10.21037/cco.2017.04.04; Monsalve DM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.40; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; Ou JJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08902-x; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Perez-Hernandez M, 2019, CANCERS, V11, DOI 10.3390/cancers11101599; Rubinstein AD, 2012, J CELL SCI, V125, P5259, DOI 10.1242/jcs.115865; Sisinni L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040857; Tong M, 2018, J HEPATOL, V69, P826, DOI 10.1016/j.jhep.2018.05.034; Vasilevskaya IA, 2016, MOL CANCER RES, V14, P753, DOI 10.1158/1541-7786.MCR-16-0035; Vazquez-Cedeira M, 2012, J BIOL CHEM, V287, P42739, DOI 10.1074/jbc.M112.404285; Vega FM, 2003, FEBS LETT, V544, P176, DOI 10.1016/S0014-5793(03)00501-5; Wang KW, 2015, CELL CYCLE, V14, P1631, DOI 10.1080/15384101.2015.1038685; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Yang XW, 2015, INT J CLIN PHARM-NET, V37, P1047, DOI 10.1007/s11096-015-0151-y; Zhao XL, 2013, CANCER INVEST, V31, P555, DOI 10.3109/07357907.2013.834925; Zhu YJ, 2017, ACTA PHARMACOL SIN, V38, P614, DOI 10.1038/aps.2017.5	48	2	2	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3378	3393		10.1038/s41388-021-01780-y	http://dx.doi.org/10.1038/s41388-021-01780-y		APR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33875785	hybrid			2022-12-28	WOS:000641218600003
J	Cingoz, A; Ozyerli-Goknar, E; Morova, T; Seker-Polat, F; Selvan, ME; Gumus, ZH; Bhere, D; Shah, KL; Solaroglu, I; Bagci-Onder, T				Cingoz, Ahmet; Ozyerli-Goknar, Ezgi; Morova, Tunc; Seker-Polat, Fidan; Esai Selvan, Myvizhi; Gumus, Zeynep Hulya; Bhere, Deepak; Shah, Khalid; Solaroglu, Ihsan; Bagci-Onder, Tugba			Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization	ONCOGENE			English	Article								Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumor cell-specific apoptosis, making it a prime therapeutic candidate. However, many tumor cells are either innately TRAIL-resistant, or they acquire resistance with adaptive mechanisms that remain poorly understood. In this study, we generated acquired TRAIL resistance models using multiple glioblastoma (GBM) cell lines to assess the molecular alterations in the TRAIL-resistant state. We selected TRAIL-resistant cells through chronic and long-term TRAIL exposure and noted that they showed persistent resistance both in vitro and in vivo. Among known TRAIL-sensitizers, proteosome inhibitor Bortezomib, but not HDAC inhibitor MS-275, was effective in overcoming resistance in all cell models. This was partly achieved through upregulating death receptors and pro-apoptotic proteins, and downregulating major anti-apoptotic members, Bcl-2 and Bcl-xL. We showed that CRISPR/Cas9 mediated silencing of DR5 could block Bortezomib-mediated re-sensitization, demonstrating its critical role. While overexpression of Bcl-2 or Bcl-xL was sufficient to confer resistance to TRAIL-sensitive cells, it failed to override Bortezomib-mediated re-sensitization. With RNA sequencing in multiple paired TRAIL-sensitive and TRAIL-resistant cells, we identified major alterations in inflammatory signaling, particularly in the NF-kappa B pathway. Inhibiting NF-kappa B substantially sensitized the most resistant cells to TRAIL, however, the sensitization effect was not as great as what was observed with Bortezomib. Together, our findings provide new models of acquired TRAIL resistance, which will provide essential tools to gain further insight into the heterogeneous therapy responses within GBM tumors. Additionally, these findings emphasize the critical importance of combining proteasome inhibitors and pro-apoptotic ligands to overcome acquired resistance.	[Cingoz, Ahmet; Ozyerli-Goknar, Ezgi; Seker-Polat, Fidan; Bagci-Onder, Tugba] Koc Univ, Res Ctr Translat Med, Brain Canc Res & Therapy Lab, TR-34450 Istanbul, Turkey; [Cingoz, Ahmet; Ozyerli-Goknar, Ezgi; Morova, Tunc; Seker-Polat, Fidan; Gumus, Zeynep Hulya; Solaroglu, Ihsan; Bagci-Onder, Tugba] Koc Univ, Sch Med, TR-34450 Istanbul, Turkey; [Esai Selvan, Myvizhi; Gumus, Zeynep Hulya] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Esai Selvan, Myvizhi; Gumus, Zeynep Hulya] Icahn Sch Med Mt Sinai, Icahn Inst Data Sci & Genom Technol, New York, NY 10029 USA; [Bhere, Deepak; Shah, Khalid] Harvard Med Sch, Brigham & Womens Hosp, Ctr Stem Cell Therapeut & Imaging, Boston, MA 02115 USA; [Solaroglu, Ihsan] Koc Univ, Sch Med, Dept Neurosurg, TR-34010 Istanbul, Turkey	Koc University; Koc University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Koc University	Bagci-Onder, T (corresponding author), Koc Univ, Res Ctr Translat Med, Brain Canc Res & Therapy Lab, TR-34450 Istanbul, Turkey.; Bagci-Onder, T (corresponding author), Koc Univ, Sch Med, TR-34450 Istanbul, Turkey.	tuonder@ku.edu.tr	Cingoz, Ahmet/AAG-4228-2019; Selvan, Myvizhi Esai/AAC-9982-2020; Onder, Tugba Bagci/AAN-1392-2021	Cingoz, Ahmet/0000-0002-1111-7752; Selvan, Myvizhi Esai/0000-0003-4640-5727; Bagci Onder, Tugba/0000-0003-3646-2613; Ozyerli Goknar, Ezgi/0000-0003-0202-8165; Gumus, Zeynep/0000-0002-7364-2202; Bhere, Deepak/0000-0003-4142-5518	Scientific and Technological Research Council of Turkey (TUBITAK) [3501]; Marie Curie FP7 Career Reintegration Grant (EC) [618673]; BAGEP; NIH/NCI [U24 CA210993]; Icahn Institute; NIH [R01CA201148]; Presidency of Turkey, Presidency of Strategy and Budget	Scientific and Technological Research Council of Turkey (TUBITAK)(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); Marie Curie FP7 Career Reintegration Grant (EC); BAGEP; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Icahn Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Presidency of Turkey, Presidency of Strategy and Budget	Financial support was obtained from The Scientific and Technological Research Council of Turkey (TUBITAK) (3501), Marie Curie FP7 Career Reintegration Grant (EC Grant # 618673), and BAGEP. ZHG and ME acknowledge NIH/NCI U24 CA210993 and start-up funds from the Icahn Institute. KS acknowledges the NIH R01CA201148. The authors gratefully acknowledge the use of services and facilities of the Koc University Research Center for Translational Medicine (KUTTAM), funded by the Presidency of Turkey, Presidency of Strategy and Budget.	Albeck JG, 2008, MOL CELL, V30, P11, DOI 10.1016/j.molcel.2008.02.012; Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; Bagci-Onder T, 2013, ONCOGENE, V32, P2818, DOI 10.1038/onc.2012.304; Bagci-Onder T, 2011, CANCER RES, V71, P154, DOI 10.1158/0008-5472.CAN-10-1601; Berens Michael E., 1999, Neoplasia (New York), V1, P208, DOI 10.1038/sj.neo.7900034; Bhere D, 2015, ADV CANCER RES, V127, P159, DOI 10.1016/bs.acr.2015.04.012; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Bychkov ML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109756; Chen GG, 2005, J CELL PHYSIOL, V203, P127, DOI 10.1002/jcp.20230; Chen KF, 2009, J BIOL CHEM, V284, P11121, DOI 10.1074/jbc.M806268200; Chen WJ, 2010, MOL PHARMACOL, V77, P416, DOI 10.1124/mol.109.061226; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; Cristofanon S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.163; de Wilt LHAM, 2013, CRIT REV ONCOL HEMAT, V85, P363, DOI 10.1016/j.critrevonc.2012.08.001; Delbridge ARD, 2015, CELL DEATH DIFFER, V22, P1071, DOI 10.1038/cdd.2015.50; Diessenbacher P, 2008, J INVEST DERMATOL, V128, P1134, DOI 10.1038/sj.jid.5701141; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Flusberg DA, 2013, MOL BIOL CELL, V24, P2186, DOI 10.1091/mbc.E12-10-0737; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Fulda S, 2015, SEMIN CANCER BIOL, V31, P84, DOI 10.1016/j.semcancer.2014.05.002; Fulda S, 2011, ONCOTARGET, V2, P418; Ganten TM, 2005, HEPATOLOGY, V42, P588, DOI 10.1002/hep.20807; Han B, 2015, ONCOTARGET, V6, P17532, DOI 10.18632/oncotarget.3947; Hetschko H, 2008, J NEURO-ONCOL, V86, P265, DOI 10.1007/s11060-007-9472-6; Hoey T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001056; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Huang SB, 2008, CANCER RES, V68, P2944, DOI 10.1158/0008-5472.CAN-07-2508; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Kandasamy K, 2008, MOL CANCER THER, V7, P1091, DOI 10.1158/1535-7163.MCT-07-2368; Kaya-Aksoy E, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0144-z; Khaw SL, 2009, LEUKEMIA LYMPHOMA, V50, P1069, DOI 10.1080/10428190903015644; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Koschny R, 2007, HEPATOLOGY, V45, P649, DOI 10.1002/hep.21555; Koschny R, 2014, J NEUROPATH EXP NEUR, V73, P1034, DOI 10.1097/NEN.0000000000000129; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Kurt IC, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.288; Lane D, 2006, MOL CANCER THER, V5, P509, DOI 10.1158/1535-7163.MCT-05-0362; Lee TJ, 2006, BIOCHEM BIOPH RES CO, V351, P1024, DOI 10.1016/j.bbrc.2006.10.163; Li Z, 2011, J BIOL CHEM, V286, P21164, DOI 10.1074/jbc.M110.207571; Lickliter JD, 2007, BRIT J CANCER, V96, P600, DOI 10.1038/sj.bjc.6603599; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Messaoudi K, 2015, DRUG DISCOV TODAY, V20, P899, DOI 10.1016/j.drudis.2015.02.011; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Naumann I, 2011, CLIN CANCER RES, V17, P3204, DOI 10.1158/1078-0432.CCR-10-2451; Nikrad M, 2005, MOL CANCER THER, V4, P443; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sasportas LS, 2009, P NATL ACAD SCI USA, V106, P4822, DOI 10.1073/pnas.0806647106; Seker F, 2019, CANCERS, V11, DOI 10.3390/cancers11111651; Senbabaoglu F, 2016, CANCER BIOL THER, V17, P546, DOI 10.1080/15384047.2016.1167292; Serrano-Saenz S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1293-3; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Singh TR, 2005, ONCOGENE, V24, P4609, DOI 10.1038/sj.onc.1208585; Song JJ, 2007, J BIOL CHEM, V282, P319, DOI 10.1074/jbc.M608065200; Song JH, 2008, J BIOL CHEM, V283, P25003, DOI 10.1074/jbc.M802511200; Spencer SL, 2009, NATURE, V459, P428, DOI 10.1038/nature08012; Stavrovskaya AA, 2016, BIOCHEMISTRY-MOSCOW+, V81, P91, DOI 10.1134/S0006297916020036; Stuckey DW, 2013, TRENDS MOL MED, V19, P685, DOI 10.1016/j.molmed.2013.08.007; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Unterkircher T, 2011, CLIN CANCER RES, V17, P4019, DOI 10.1158/1078-0432.CCR-11-0075; von Karstedt S, 2017, NAT REV CANCER, V17, P352, DOI 10.1038/nrc.2017.28; Warren CFA, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1407-6; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wilting RH, 2012, DRUG RESIST UPDATE, V15, P21, DOI 10.1016/j.drup.2012.01.008; Wood TE, 2010, MOL CANCER THER, V9, P246, DOI 10.1158/1535-7163.MCT-09-0495	70	3	3	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3201	3216		10.1038/s41388-021-01697-6	http://dx.doi.org/10.1038/s41388-021-01697-6		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33767436				2022-12-28	WOS:000632820300004
J	Ezrova, Z; Nahacka, Z; Stursa, J; Werner, L; Vlcak, E; Viziova, PK; Berridge, MV; Sedlacek, R; Zobalova, R; Rohlena, J; Boukalova, S; Neuzil, J				Ezrova, Zuzana; Nahacka, Zuzana; Stursa, Jan; Werner, Lukas; Vlcak, Erik; Kralova Viziova, Petra; Berridge, Michael V.; Sedlacek, Radislav; Zobalova, Renata; Rohlena, Jakub; Boukalova, Stepana; Neuzil, Jiri			SMAD4 loss limits the vulnerability of pancreatic cancer cells to complex I inhibition via promotion of mitophagy	ONCOGENE			English	Article								Pancreatic cancer is one of the deadliest forms of cancer, which is attributed to lack of effective treatment options and drug resistance. Mitochondrial inhibitors have emerged as a promising class of anticancer drugs, and several inhibitors of the electron transport chain (ETC) are being clinically evaluated. We hypothesized that resistance to ETC inhibitors from the biguanide class could be induced by inactivation of SMAD4, an important tumor suppressor involved in transforming growth factor beta (TGF beta) signaling, and associated with altered mitochondrial activity. Here we show that, paradoxically, both TGF beta-treatment and the loss of SMAD4, a downstream member of TGF beta signaling cascade, induce resistance to biguanides, decrease mitochondrial respiration, and fragment the mitochondrial network. Mechanistically, the resistance of SMAD4-deficient cells is mediated by increased mitophagic flux driven by MAPK/ERK signaling, whereas TGF beta-induced resistance is autophagy-independent and linked to epithelial-to-mesenchymal transition (EMT). Interestingly, mitochondria-targeted tamoxifen, a complex I inhibitor under clinical trial, overcomes resistance mediated by SMAD4-deficiency or TGF beta signaling. Our data point to differential mechanisms underlying the resistance to treatment in PDAC arising from TGF beta signaling and SMAD4 loss, respectively. The findings will help the development of mitochondria-targeted therapy for pancreatic cancer patients with SMAD4 as a plausible predictive marker.	[Ezrova, Zuzana; Nahacka, Zuzana; Stursa, Jan; Werner, Lukas; Zobalova, Renata; Rohlena, Jakub; Boukalova, Stepana; Neuzil, Jiri] Czech Acad Sci, Inst Biotechnol, Prague, Czech Republic; [Ezrova, Zuzana] Charles Univ Prague, Fac Sci, Prague, Czech Republic; [Vlcak, Erik] Czech Acad Sci, Inst Mol Genet, Prague, Czech Republic; [Kralova Viziova, Petra; Sedlacek, Radislav] Czech Acad Sci, Inst Mol Genet, Czech Ctr Phenogen, Prague, Czech Republic; [Berridge, Michael V.] Malaghan Inst Med Res, Wellington, New Zealand; [Neuzil, Jiri] Griffith Univ, Sch Med Sci, Southport, Qld, Australia	Czech Academy of Sciences; Institute of Biotechnology of the Czech Academy of Sciences; Charles University Prague; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Malaghan Institute; Victoria University Wellington; Griffith University	Boukalova, S; Neuzil, J (corresponding author), Czech Acad Sci, Inst Biotechnol, Prague, Czech Republic.; Neuzil, J (corresponding author), Griffith Univ, Sch Med Sci, Southport, Qld, Australia.	stepana.boukalova@ibt.cas.cz; j.neuzil@griffith.edu.au	WERNER, LUKÁŠ/AAL-7888-2021; Stursa, Jan/J-4255-2014; Rohlena, Jakub/H-6699-2014; Králová Viziová, Petra/AGJ-5763-2022; Boukalova, Stepana/H-2610-2014; Ezrova, Zuzana/W-3595-2017	Rohlena, Jakub/0000-0001-5427-6502; Boukalova, Stepana/0000-0002-6478-4604; Vlcak, Erik/0000-0003-4911-2380; Zobalova, Renata/0000-0002-9097-4700; Ezrova, Zuzana/0000-0002-4174-6066; Nahacka, Zuzana/0000-0003-0477-2764	Czech Health Research Council [NV16-31604A]; Czech Science Foundation [19-20553S, 20-18513S, 20-11724Y, 18-02550S]; Grant Agency of Charles University [GAUK1100217]; project International mobility grant of researchers of the Institute of Biotechnology CAS, v. v. i. from the ESF [CZ.02.2.69/0.0/0.0/16_027/0008353]; BIOCEV from the ERDF [CZ.1.05/1.1.00/02.0109]; Ministry of Education, Youth and Sports of the Czech Republic at the CZ-OPENSCREEN: National infrastructure for chemical biology [LO1220]; Czech-BioImaging large RI projects - (MEYS CR) [LM2015062, CZ.02.1.01/0.0/0.0/16_013/0001775]; program "Projects of Large Research, Development, and Innovations Infrastructures" [CESNET LM2015042]; Czech Academy of Sciences [RVO 68378050]; project of support program for large infrastructures for research, experimental development and innovation Czech Centre for Phenogenomics by MEYS CR [LM2018126]; MEYS; ESIF [CZ.02.1.01/0.0/0.0/16_013/0001789, CZ.02.1.01/0.0/0.0/18_046/0015861, CZ.1.05/2.1.00/19.0395];  [RVO: 86652036]	Czech Health Research Council; Czech Science Foundation(Grant Agency of the Czech Republic); Grant Agency of Charles University; project International mobility grant of researchers of the Institute of Biotechnology CAS, v. v. i. from the ESF; BIOCEV from the ERDF; Ministry of Education, Youth and Sports of the Czech Republic at the CZ-OPENSCREEN: National infrastructure for chemical biology; Czech-BioImaging large RI projects - (MEYS CR); program "Projects of Large Research, Development, and Innovations Infrastructures"; Czech Academy of Sciences(Czech Academy of Sciences); project of support program for large infrastructures for research, experimental development and innovation Czech Centre for Phenogenomics by MEYS CR; MEYS; ESIF; 	This work was supported by Czech Health Research Council grants (NV16-31604A) to JN, Czech Science Foundation grants (19-20553S, 20-18513S, 20-11724Y and 18-02550S), and Grant Agency of Charles University (GAUK1100217) to ZE. SB was supported by a project International mobility grant of researchers of the Institute of Biotechnology CAS, v. v. i. (CZ.02.2.69/0.0/0.0/16_027/0008353) from the ESF. Further support was provided by BIOCEV CZ.1.05/1.1.00/02.0109 from the ERDF, RVO: 86652036 and the Ministry of Education, Youth and Sports of the Czech Republic (LO1220) at the CZ-OPENSCREEN: National infrastructure for chemical biology. We acknowledge the Imaging Methods Core Facility at BIOCEV and Microscopy Centre -Electron Microscopy Core Facility, IMG AS CR, institutions supported by the Czech-BioImaging large RI projects (LM2015062 and CZ.02.1.01/0.0/0.0/16_013/0001775, funded by MEYS CR) for their support with obtaining scientific data presented in this paper. Access to computing and storage facilities owned by parties and projects contributing to the National Grid Infrastructure MetaCentrum provided under the program "Projects of Large Research, Development, and Innovations Infrastructures" (CESNET LM2015042), is greatly appreciated. Research data were collected in cooperation with the employees of the Czech Centre for Phenogenomics supported by the Czech Academy of Sciences RVO 68378050 and by the project of support program for large infrastructures for research, experimental development and innovation LM2018126 Czech Centre for Phenogenomics provided by MEYS CR. Further support was provided by MEYS and ESIF (CZ.02.1.01/0.0/0.0/16_013/0001789, CZ.02.1.01/0.0/0.0/18_046/0015861, and CZ.1.05/2.1.00/19.0395).	Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Bajzikova M, 2019, CELL METAB, V29, P399, DOI 10.1016/j.cmet.2018.10.014; Basso D, 2017, ONCOTARGET, V8, P84928, DOI 10.18632/oncotarget.20863; Blackford A, 2009, CLIN CANCER RES, V15, P4674, DOI 10.1158/1078-0432.CCR-09-0227; Boukalova S, 2016, MOL CANCER THER, V15, P2875, DOI 10.1158/1535-7163.MCT-15-1021; Bridges HR, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0287-9; Chae YK, 2016, ONCOTARGET, V7, P40767, DOI 10.18632/oncotarget.8194; Chen YW, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-181; Chen YH, 2020, J CELL PHYSIOL, V235, P1903, DOI 10.1002/jcp.29108; Cheng G, 2016, CANCER RES, V76, P3904, DOI 10.1158/0008-5472.CAN-15-2534; Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008; Costanza B, 2019, INT J CANCER, V145, P1570, DOI 10.1002/ijc.32247; Cottet-Rousselle C, 2011, CYTOM PART A, V79A, P405, DOI 10.1002/cyto.a.21061; Dagda RK, 2008, AUTOPHAGY, V4, P770, DOI 10.4161/auto.6458; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; Fullerton PT, 2015, MOL ENDOCRINOL, V29, P1440, DOI 10.1210/me.2015-1102; Georgakopoulos ND, 2017, NAT CHEM BIOL, V13, P136, DOI [10.1038/NCHEMBIO.2287, 10.1038/nchembio.2287]; Hernandez G, 2013, AUTOPHAGY, V9, P1852, DOI 10.4161/auto.26501; Hubackova S, 2019, CELL DEATH DIFFER, V26, P276, DOI 10.1038/s41418-018-0118-3; Katayama H, 2011, CHEM BIOL, V18, P1042, DOI 10.1016/j.chembiol.2011.05.013; Katsuno Y, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aau8544; Laker RC, 2014, J BIOL CHEM, V289, P12005, DOI 10.1074/jbc.M113.530527; Leone A, 2014, CANCER TREAT RES, V159, P355, DOI 10.1007/978-3-642-38007-5_21; Liang C, 2020, GUT, V69, P888, DOI 10.1136/gutjnl-2018-317163; Liang C, 2020, AUTOPHAGY, V16, P486, DOI 10.1080/15548627.2019.1628540; Mao L, 2017, ONCOL LETT, V14, P647, DOI 10.3892/ol.2017.6209; Molina JR, 2018, NAT MED, V24, P1036, DOI 10.1038/s41591-018-0052-4; Naguib A, 2018, CELL REP, V23, P58, DOI 10.1016/j.celrep.2018.03.032; Ozawa H, 2017, CLIN CANCER RES, V23, P5162, DOI 10.1158/1078-0432.CCR-16-1686; Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269; Pecinova A, 2019, BIOFACTORS, V45, P703, DOI 10.1002/biof.1548; Rawla P, 2019, WORLD J ONCOL, V10, P10, DOI 10.14740/wjon1166; Rodriguez-Garcia A, 2017, FEBS J, V284, P3437, DOI 10.1111/febs.14201; Rohlenova K, 2017, ANTIOXID REDOX SIGN, V26, P84, DOI 10.1089/ars.2016.6677; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shi S, 2015, CANCER LETT, V360, P227, DOI 10.1016/j.canlet.2015.02.014; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Sica V, 2020, INT J CANCER, V146, P10, DOI 10.1002/ijc.32616; Springer W, 2011, AUTOPHAGY, V7, P266, DOI 10.4161/auto.7.3.14348; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Tan AS, 2015, CELL METAB, V21, P81, DOI 10.1016/j.cmet.2014.12.003; Tauber J, 2013, INT J BIOCHEM CELL B, V45, P593, DOI 10.1016/j.biocel.2012.11.019; Um JH, 2018, JOVE-J VIS EXP, DOI 10.3791/58099; Urra FA, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00118; Valente AJ, 2017, ACTA HISTOCHEM, V119, P315, DOI 10.1016/j.acthis.2017.03.001; Wang F, 2018, CLIN CANCER RES, V24, P3176, DOI 10.1158/1078-0432.CCR-17-3435; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Wasserman I, 2019, CLIN CANCER RES, V25, P1948, DOI 10.1158/1078-0432.CCR-18-1726; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xia X, 2015, TUMOR BIOL, V36, P111, DOI 10.1007/s13277-014-2883-z; Yalcin A, 2017, BIOCHEM BIOPH RES CO, V484, P687, DOI 10.1016/j.bbrc.2017.01.178; Zhang C, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0628-8; Zhang YE, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022129; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	54	5	5	2	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2539	2552		10.1038/s41388-021-01726-4	http://dx.doi.org/10.1038/s41388-021-01726-4		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33686239				2022-12-28	WOS:000626396000002
J	Li, Y; Liu, M; Yang, ST; Fuller, AM; Eisinger-Mathason, TSK; Yang, SY				Li, Yang; Liu, Min; Yang, Shuting; Fuller, Ashley M.; Karin Eisinger-Mathason, T. S.; Yang, Shuying			RGS12 is a novel tumor suppressor in osteosarcoma that inhibits YAP-TEAD1-Ezrin signaling	ONCOGENE			English	Article								Osteosarcoma (OS) is the most common primary malignancy of the bone that predominantly affects children and adolescents. Hippo pathway is a crucial regulator of organ size and tumorigenesis. However, how Hippo pathway regulates the occurrence of osteosarcoma is largely unknown. Here, we reported the regulator of G protein signaling protein 12 (RGS12) is a novel Hippo pathway regulator and tumor suppressor of osteosarcoma. Depletion of Rgs12 promotes osteosarcoma progression and lung metastasis in an orthotopic xenograft mouse model. Our data showed that the knockdown of RGS12 upregulates Ezrin expression through promoting the GNA12/13-RhoA-YAP pathway. Moreover, RGS12 negatively regulates the transcriptional activity of YAP/TEAD1 complex through its PDZ domain function to inhibit the expression and function of the osteosarcoma marker Ezrin. PDZ domain peptides of RGS12 can inhibit the development of intratibial tumor and lung metastases. Collectively, this study identifies that the RGS12 is a novel tumor suppressor in osteosarcoma through inhibiting YAP-TEAD1-Ezrin signaling pathway and provides a proof of principle that targeting RGS12 may be a therapeutic strategy for osteosarcoma.	[Li, Yang; Liu, Min; Yang, Shuting; Yang, Shuying] Univ Penn, Sch Dent Med, Dept Basic & Translat Sci, Philadelphia, PA 19104 USA; [Fuller, Ashley M.; Karin Eisinger-Mathason, T. S.] Univ Penn, Abramson Family Canc Res Inst, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA; [Yang, Shuying] Univ Penn, Sch Dent Med, Sch Engn & Appl Sci, Ctr Innovat & Precis Dent, Philadelphia, PA 19104 USA; [Yang, Shuying] Univ Penn, Sch Med, Penn Ctr Musculoskeletal Disorders, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Yang, SY (corresponding author), Univ Penn, Sch Dent Med, Dept Basic & Translat Sci, Philadelphia, PA 19104 USA.; Yang, SY (corresponding author), Univ Penn, Sch Dent Med, Sch Engn & Appl Sci, Ctr Innovat & Precis Dent, Philadelphia, PA 19104 USA.; Yang, SY (corresponding author), Univ Penn, Sch Med, Penn Ctr Musculoskeletal Disorders, Philadelphia, PA 19104 USA.	shuyingy@upenn.edu		Li, Yang/0000-0002-7375-3025; Yang, Shuying/0000-0002-7126-6901	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [AR061052]; National Institute on Aging (NIA) [AG048388]	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, AR061052), the National Institute on Aging (NIA, AG048388) awarded to SY.	Abramow-Newerly M, 2006, CELL SIGNAL, V18, P579, DOI 10.1016/j.cellsig.2005.08.010; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Bouvier C, 2016, ONCOTARGET, V7, P64702, DOI 10.18632/oncotarget.11876; Bradley SJ, 2016, P NATL ACAD SCI USA, V113, P4524, DOI 10.1073/pnas.1521706113; Brusgard JL, 2015, ONCOTARGET, V6, P28132, DOI 10.18632/oncotarget.4654; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; Chai JW, 2017, BIOCHEM BIOPH RES CO, V488, P297, DOI 10.1016/j.bbrc.2017.05.032; Chatterjee TK, 2002, MOL CELL BIOL, V22, P4334, DOI 10.1128/MCB.22.12.4334-4345.2002; Cho H., 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P107, DOI 10.2174/1568008043339938; Fromigue O, 2011, J BONE MINER RES, V26, P1533, DOI 10.1002/jbmr.343; Fukuda H, 2016, BIOCHEM BIOPH RES CO, V471, P63, DOI 10.1016/j.bbrc.2016.01.179; Gross JD, 2018, J PSYCHOPHARMACOL, V32, P191, DOI 10.1177/0269881117742100; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Holden JK, 2018, CANCERS, V10, DOI 10.3390/cancers10030081; Hurst JH, 2009, BIOCHEM PHARMACOL, V78, P1289, DOI 10.1016/j.bcp.2009.06.028; Igarashi K, 2020, CANCER LETT, V469, P332, DOI 10.1016/j.canlet.2019.10.028; Ji Q, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-266; Jules J, 2015, PROG MOL BIOL TRANSL, V133, P47, DOI 10.1016/bs.pmbts.2015.02.002; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Keinan D, 2014, FRONT BIOSCI-LANDMRK, V19, P634, DOI 10.2741/4232; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lee HJ, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-8; Li Y, 2017, FEBS J, V284, P948, DOI 10.1111/febs.14026; Li ZQ, 2019, J BONE MINER RES, V34, P752, DOI 10.1002/jbmr.3645; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Meyers PA, 2005, J CLIN ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031; Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854; Mohri Z, 2017, J THORAC DIS, V9, pE507, DOI 10.21037/jtd.2017.03.179; Ng AYH, 2019, ELIFE, V8, DOI 10.7554/eLife.42951; Ren L, 2014, ADV EXP MED BIOL, V804, P181, DOI 10.1007/978-3-319-04843-7_10; Rozengurt E, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-017-0005-2; Sabile AA, 2012, J BONE MINER RES, V27, P58, DOI 10.1002/jbmr.535; Stewart A, 2015, PROG MOL BIOL TRANSL, V133, P1, DOI 10.1016/bs.pmbts.2015.03.002; Tang QL, 2018, ONCOGENE, V37, P3617, DOI 10.1038/s41388-018-0231-2; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Wang DY, 2016, CHIN J CANCER, V35, P1, DOI 10.1186/s40880-016-0109-z; Wang GY, 2005, J BONE MINER RES, V20, P1022, DOI 10.1359/JBMR.050113; Wang YQ, 2017, CANCER RES, V77, P4247, DOI 10.1158/0008-5472.CAN-17-0669; Xu MZ, 2011, ONCOGENE, V30, P1229, DOI 10.1038/onc.2010.504; Yang SY, 2013, GENESIS, V51, P201, DOI 10.1002/dvg.22373; Yang SY, 2007, J BONE MINER RES, V22, P45, DOI 10.1359/JBMR.061007; Yang Z, 2014, ONCOL REP, V32, P1265, DOI 10.3892/or.2014.3305; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yuan X, 2015, CELL DEATH DIFFER, V22, P2046, DOI 10.1038/cdd.2015.45; Yuan X, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11024; Zhang L, 2009, FLY, V3, P68, DOI 10.4161/fly.3.1.7788; Zhang WQ, 2017, J CELL MOL MED, V21, P2663, DOI 10.1111/jcmm.13182; Zhang WJ, 2014, CELL RES, V24, P331, DOI 10.1038/cr.2014.10; Zhang YC, 2014, CELL SIGNAL, V26, P2504, DOI 10.1016/j.cellsig.2014.07.031; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001	56	10	11	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2553	2566		10.1038/s41388-020-01599-z	http://dx.doi.org/10.1038/s41388-020-01599-z		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33686240	Green Accepted			2022-12-28	WOS:000626396000003
J	Cheung, BB; Kleynhans, A; Mittra, R; Kim, PY; Holien, JK; Nagy, Z; Ciampa, OC; Seneviratne, JA; Mayoh, C; Raipuria, M; Gadde, S; Massudi, H; Wong, IPL; Tan, O; Gong, A; Suryano, A; Diakiw, SM; Liu, B; Arndt, GM; Liu, T; Kumar, N; Sangfelt, O; Zhu, SZ; Norris, MD; Haber, M; Carter, DR; Parker, MW; Marshall, GM				Cheung, Belamy B.; Kleynhans, Ane; Mittra, Rituparna; Kim, Patrick Y.; Holien, Jessica K.; Nagy, Zsuzsanna; Ciampa, Olivia C.; Seneviratne, Janith A.; Mayoh, Chelsea; Raipuria, Mukesh; Gadde, Satyanarayana; Massudi, Hassina; Wong, Iris Poh Ling; Tan, Owen; Gong, Andrew; Suryano, Aldwin; Diakiw, Sonya M.; Liu, Bing; Arndt, Greg M.; Liu, Tao; Kumar, Naresh; Sangfelt, Olle; Zhu, Shizhen; Norris, Murray D.; Haber, Michelle; Carter, Daniel R.; Parker, Michael W.; Marshall, Glenn M.			A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma	ONCOGENE			English	Article								Histone deacetylase (HDAC) inhibitors are effective in MYCN-driven cancers, because of a unique need for HDAC recruitment by the MYCN oncogenic signal. However, HDAC inhibitors are much more effective in combination with other anti-cancer agents. To identify novel compounds which act synergistically with HDAC inhibitor, such as suberanoyl hydroxamic acid (SAHA), we performed a cell-based, high-throughput drug screen of 10,560 small molecule compounds from a drug-like diversity library and identified a small molecule compound (SE486-11) which synergistically enhanced the cytotoxic effects of SAHA. Effects of drug combinations on cell viability, proliferation, apoptosis and colony forming were assessed in a panel of neuroblastoma cell lines. Treatment with SAHA and SE486-11 increased MYCN ubiquitination and degradation, and markedly inhibited tumorigenesis in neuroblastoma xenografts, and, MYCN transgenic zebrafish and mice. The combination reduced ubiquitin-specific protease 5 (USP5) levels and increased unanchored polyubiquitin chains. Overexpression of USP5 rescued neuroblastoma cells from the cytopathic effects of the combination and reduced unanchored polyubiquitin, suggesting USP5 is a therapeutic target of the combination. SAHA and SE486-11 directly bound to USP5 and the drug combination exhibited a 100-fold higher binding to USP5 than individual drugs alone in microscale thermophoresis assays. MYCN bound to the USP5 promoter and induced USP5 gene expression suggesting that USP5 and MYCN expression created a forward positive feedback loop in neuroblastoma cells. Thus, USP5 acts as an oncogenic cofactor with MYCN in neuroblastoma and the novel combination of HDAC inhibitor with SE486-11 represents a novel therapeutic approach for the treatment of MYCN-driven neuroblastoma.	[Cheung, Belamy B.; Kleynhans, Ane; Mittra, Rituparna; Kim, Patrick Y.; Nagy, Zsuzsanna; Ciampa, Olivia C.; Seneviratne, Janith A.; Mayoh, Chelsea; Raipuria, Mukesh; Gadde, Satyanarayana; Massudi, Hassina; Wong, Iris Poh Ling; Tan, Owen; Gong, Andrew; Suryano, Aldwin; Diakiw, Sonya M.; Liu, Bing; Arndt, Greg M.; Liu, Tao; Norris, Murray D.; Haber, Michelle; Carter, Daniel R.; Marshall, Glenn M.] UNSW Sydney, Childrens Canc Inst, Lowy Canc Res Ctr, Sydney, NSW, Australia; [Cheung, Belamy B.; Nagy, Zsuzsanna; Mayoh, Chelsea; Raipuria, Mukesh; Massudi, Hassina] UNSW Sydney, Sch Womens & Childrens Hlth, Sydney, NSW, Australia; [Holien, Jessica K.] St Vincents Inst Med Res, ACRF Rat Drug Discovery Ctr, Fitzroy, Vic, Australia; [Holien, Jessica K.; Parker, Michael W.] RMIT Univ, Sch Sci, Coll Sci Engn & Hlth, Melbourne, Vic, Australia; [Gadde, Satyanarayana; Kumar, Naresh] UNSW Sydney, Sch Chem, Sydney, NSW, Australia; [Sangfelt, Olle] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Zhu, Shizhen] Mayo Clin, Dept Biochem & Mol Biol, Canc Ctr, Rochester, MN USA; [Zhu, Shizhen] Mayo Clin, Dept Biochem & Mol Biol, Ctr Individualized Med, Rochester, MN USA; [Norris, Murray D.] Univ New South Wales, Ctr Childhood Canc Res Sydney, Sydney, NSW, Australia; [Carter, Daniel R.] Univ Technol Sydney, Sch Biomed Engn, Sydney, NSW, Australia; [Parker, Michael W.] Univ Melbourne, Bio21 Mol Sci & Biotechnol Inst, Parkville, Vic, Australia; [Marshall, Glenn M.] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia	Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; St. Vincent's Institute of Medical Research; Royal Melbourne Institute of Technology (RMIT); University of New South Wales Sydney; Karolinska Institutet; Mayo Clinic; Mayo Clinic; University of New South Wales Sydney; University of Technology Sydney; University of Melbourne	Cheung, BB; Marshall, GM (corresponding author), UNSW Sydney, Childrens Canc Inst, Lowy Canc Res Ctr, Sydney, NSW, Australia.; Cheung, BB (corresponding author), UNSW Sydney, Sch Womens & Childrens Hlth, Sydney, NSW, Australia.; Marshall, GM (corresponding author), Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia.	bcheung@ccia.unsw.edu.au; g.marshall@unsw.edu.au	Parker, Michael W/F-9069-2013; Mayoh, Chelsea/AAE-7349-2021; Holien, Jess/V-7005-2019	Parker, Michael W/0000-0002-3101-1138; Mayoh, Chelsea/0000-0002-6398-3046; Holien, Jess/0000-0002-8735-2871; Cheung, Belamy/0000-0001-8784-860X; Tan, Owen/0000-0002-0303-7138; Carter, Daniel/0000-0002-8464-238X; Haber, Michelle/0000-0003-2036-8817; Gadde, Satyanarayana/0000-0003-2910-6899; Seneviratne, Janith Ananda/0000-0003-0413-5829; Liu, Tao/0000-0001-6244-7316; Ciampa, Olivia/0000-0002-4073-6798	National Health and Medical Research Council (NHMRC) Australia [APP1016699]; Cancer Institute NSW [10/TPG/1-13]; Cancer Council NSW [PG-11-06]; Australia Postgraduate Research Award, UNSW Sydney, Australia; Steven Walter Children's Cancer Foundation; NHMRC [APP1125171]; Neuroblastoma Australia [APP571073]; Cure Cancer Australia Foundation; Leukemia Foundation; Swedish Childhood Cancer Foundation; Swedish Cancer Society; Swedish Research Council; NHMRC Independent Research Institutes Infrastructure Support Scheme; Victorian State Government; ACRF Drug Discovery Centre; Children's Cancer Institute; Lowy Cancer Research Centre; UNSW Sydney; NSW, Australia [2052]	National Health and Medical Research Council (NHMRC) Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW; Cancer Council NSW(Cancer Council New South Wales); Australia Postgraduate Research Award, UNSW Sydney, Australia; Steven Walter Children's Cancer Foundation; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Neuroblastoma Australia; Cure Cancer Australia Foundation; Leukemia Foundation; Swedish Childhood Cancer Foundation(European Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); NHMRC Independent Research Institutes Infrastructure Support Scheme(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government; ACRF Drug Discovery Centre; Children's Cancer Institute; Lowy Cancer Research Centre; UNSW Sydney; NSW, Australia	This work was supported by Program Grants (GMM, MDN, MH) from the National Health and Medical Research Council (NHMRC) Australia (APP1016699), Cancer Institute NSW (10/TPG/1-13), Cancer Council NSW (PG-11-06), and an Australia Postgraduate Research Award, UNSW Sydney, Australia (AK, SG). This work was also supported by the Steven Walter Children's Cancer Foundation, NHMRC (Project grant APP1125171 and Neuroblastoma Australia (GMM, BBC); (Project grant APP571073; Senior Principal Research Fellowship to MWP), Cure Cancer Australia Foundation, Leukemia Foundation and 5-point Foundation (Postdoctoral Fellowships to JKH). The Swedish Childhood Cancer Foundation, the Swedish Cancer Society, Swedish Research Council (OS, ASR). Infrastructure support from the NHMRC Independent Research Institutes Infrastructure Support Scheme and the Victorian State Government Operational Infrastructure Support Program to St Vincent's Institute are gratefully acknowledged, as is the support from the ACRF Drug Discovery Centre, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, NSW 2052, Australia. We would also like to thank Dr Shuai Li and Dr Cassie Flachs who helped on the zebrafish experiment of the project. The HA-tagged MYCN vector was kindly provided by Professor Wei Gu (Columbia University, New York).	Avvakumov GV, 2012, BIOCHEMISTRY-US, V51, P1188, DOI 10.1021/bi200854q; Carabet LA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010120; Carter DR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1803; Chen JB, 2013, J MED CHEM, V56, P3645, DOI 10.1021/jm400179b; Chen YH, 2016, EMBO J, V35, P668, DOI 10.15252/embj.201592810; Cheung BB, 2015, MOL ONCOL, V9, P1484, DOI 10.1016/j.molonc.2015.04.005; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang M, 2016, DIS MODEL MECH, V9, P811, DOI 10.1242/dmm.024166; Davis Mindy I, 2015, Drug Target Rev, V2, P60; Dayal S, 2009, J BIOL CHEM, V284, P5030, DOI 10.1074/jbc.M805871200; Duvic M, 2007, BIOL-TARGETS THER, V1, P377; Fan YH, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.400; Fouladi M, 2010, J CLIN ONCOL, V28, P3623, DOI 10.1200/JCO.2009.25.9119; Gryder BE, 2012, FUTURE MED CHEM, V4, P505, DOI [10.4155/FMC.12.3, 10.4155/fmc.12.3]; Guo YF., 2020, SCI TRANSL MED, V12, P1; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Horiuchi D, 2012, J EXP MED, V209, P679, DOI 10.1084/jem.20111512; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; Koach J, 2019, CANCER RES, V79, P5652, DOI 10.1158/0008-5472.CAN-19-1112; Kocak H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.84; Lindsey DF, 1998, J BIOL CHEM, V273, P29178, DOI 10.1074/jbc.273.44.29178; Ling D, 2012, EUR J CANCER, V48, P3278, DOI 10.1016/j.ejca.2012.02.067; Liu Y, 2017, ONCOTARGET, V8, P50655, DOI 10.18632/oncotarget.16901; Marshall GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002135; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Mueller S, 2011, CANCER LETT, V306, P223, DOI 10.1016/j.canlet.2011.03.010; Ortega-Atienza S, 2016, AM J PATHOL, V186, P2857, DOI 10.1016/j.ajpath.2016.06.022; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Reyes-Turcu FE, 2006, CELL, V124, P1197, DOI 10.1016/j.cell.2006.02.038; Rouge L, 2016, STRUCTURE, V24, P1335, DOI 10.1016/j.str.2016.05.020; Ruiz-Perez MV, 2017, GENES-BASEL, V8, DOI 10.3390/genes8040113; Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713; Tavana O, 2016, NAT MED, V22, P1180, DOI 10.1038/nm.4180; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Whitfield JR, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00010; Williams RD, 2010, CLIN CANCER RES, V16, P2036, DOI 10.1158/1078-0432.CCR-09-2890; Zhang XL, 2017, CELL REP, V18, P2932, DOI 10.1016/j.celrep.2017.02.065; Zhang YJ, 2015, EPIGENOMICS-UK, V7, P5, DOI [10.2217/EPI.14.62, 10.2217/epi.14.62]	42	5	5	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2367	2381		10.1038/s41388-021-01712-w	http://dx.doi.org/10.1038/s41388-021-01712-w		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33658627	hybrid, Green Published			2022-12-28	WOS:000625039900003
J	Pan, JK; Lin, CH; Kuo, YL; Ger, LP; Cheng, HC; Yao, YC; Hsiao, MC; Lu, PJ				Pan, Jhih-Kai; Lin, Cheng-Han; Kuo, Yao-Lung; Ger, Luo-Ping; Cheng, Hui-Chuan; Yao, Yun-Chin; Hsiao, Michael; Lu, Pei-Jung			MiR-211 determines brain metastasis specificity through SOX11/NGN2 axis in triple-negative breast cancer	ONCOGENE			English	Article								Brian metastasis, which is diagnosed in 30% of triple-negative breast cancer (TNBC) patients with metastasis, causes poor survival outcomes. Growing evidence has characterized miRNAs involving in breast cancer brain metastasis; however, currently, there is a lack of prognostic plasma-based indicator for brain metastasis. In this study, high level of miR-211 can act as brain metastatic prognostic marker in vivo. High miR-211 drives early and specific brain colonization through enhancing trans-blood-brain barrier (BBB) migration, BBB adherence, and stemness properties of tumor cells and causes poor survival in vivo. SOX11 and NGN2 are the downstream targets of miR-211 and negatively regulate miR-211-mediated TNBC brain metastasis in vitro and in vivo. Most importantly, high miR-211 is correlated with poor survival and brain metastasis in TNBC patients. Our findings suggest that miR-211 may be used as an indicator for TNBC brain metastasis.	[Pan, Jhih-Kai; Lin, Cheng-Han; Cheng, Hui-Chuan; Lu, Pei-Jung] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan; [Kuo, Yao-Lung] Natl Cheng Kung Univ Hosp, Dept Gen Surg, Tainan, Taiwan; [Ger, Luo-Ping] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung, Taiwan; [Yao, Yun-Chin] Natl Cheng Kung Univ Hosp, Clin Med Res Ctr, Tainan, Taiwan; [Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Hsiao, Michael] Kaohsiung Med Univ, Dept Biochem, Coll Med, Kaohsiung, Taiwan; [Lu, Pei-Jung] Natl Cheng Kung Univ Hosp, Dept Clin Med Res, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; Kaohsiung Veterans General Hospital; National Cheng Kung University; National Cheng Kung University Hospital; Academia Sinica - Taiwan; Kaohsiung Medical University; National Cheng Kung University; National Cheng Kung University Hospital	Lu, PJ (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan.; Lu, PJ (corresponding author), Natl Cheng Kung Univ Hosp, Dept Clin Med Res, Tainan, Taiwan.	pjlu2190@mail.ncku.edu.tw	Hsiao, Michael/U-6238-2019	Hsiao, Michael/0000-0001-8529-9213; Lin, Cheng-Han/0000-0001-5444-3999; Lu, Pei-Jung/0000-0002-8143-5668	Ministry of Science and Technology, Taiwan [MOST 105-2320-B-006-054, 106-2320-B-006-066-MY3, MOST 107-2320-B-006-064-MY3]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by the Ministry of Science and Technology, Taiwan [MOST 105-2320-B-006-054, 106-2320-B-006-066-MY3 and MOST 107-2320-B-006-064-MY3] to P-JL.	Achrol AS, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-018-0055-y; Avraham HK, 2014, J PATHOL, V232, P369, DOI 10.1002/path.4304; Banks WA, 2016, NAT REV DRUG DISCOV, V15, P275, DOI 10.1038/nrd.2015.21; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Chang CC, 2018, ONCOL LETT, V15, P8107, DOI 10.3892/ol.2018.8295; Chen LL, 2017, BRIT J CANCER, V117, P78, DOI 10.1038/bjc.2017.150; Chen WJ, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0047-0; Chen YF, 2016, CANCER RES, V76, P4872, DOI 10.1158/0008-5472.CAN-15-1664; Croset M, 2018, CANCER RES, V78, P5259, DOI 10.1158/0008-5472.CAN-17-3058; Debeb BG, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw026; Gril B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05030-w; Hide T, 2009, CANCER RES, V69, P7953, DOI 10.1158/0008-5472.CAN-09-2006; Hsu TI, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.12; Jilaveanu LB, 2015, CLIN CANCER RES, V21, P2138, DOI 10.1158/1078-0432.CCR-14-0861; Li B, 2013, ONCOGENE, V32, P2952, DOI 10.1038/onc.2012.313; Li HY, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0918-2; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu DT, 2014, ASIAN PAC J CANCER P, V15, P5483, DOI 10.7314/APJCP.2014.15.13.5483; Lyle LT, 2016, CLIN CANCER RES, V22, P5287, DOI 10.1158/1078-0432.CCR-15-1836; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Okuda H, 2013, CANCER RES, V73, P1434, DOI 10.1158/0008-5472.CAN-12-2037; Pardridge WM, 2016, EXPERT OPIN DRUG DEL, V13, P963, DOI 10.1517/17425247.2016.1171315; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Sevenich L, 2014, NAT CELL BIOL, V16, P876, DOI 10.1038/ncb3011; Shepherd JH, 2016, ONCOTARGET, V7, P13106, DOI 10.18632/oncotarget.7437; Sirkisoon Sherona R, 2016, Front Biosci (Elite Ed), V8, P245; Tiwary S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26636-6; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Wu KR, 2015, J BIOL CHEM, V290, P9842, DOI 10.1074/jbc.M114.602185; Xiao YS, 2020, J CELL PHYSIOL, V235, P7295, DOI 10.1002/jcp.29629; Xing F, 2016, CANCER RES, V76, P4970, DOI 10.1158/0008-5472.CAN-15-3541; Yang Z, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919853449; Zhang LX, 2011, CANCER RES, V71, P645, DOI 10.1158/0008-5472.CAN-10-1910; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhou WC, 2017, CELL STEM CELL, V21, P591, DOI 10.1016/j.stem.2017.10.002	36	9	9	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1737	1751		10.1038/s41388-021-01654-3	http://dx.doi.org/10.1038/s41388-021-01654-3		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33536579	Green Published, hybrid			2022-12-28	WOS:000614320700001
J	Jung, H; Lee, KS; Choi, JK				Jung, Hyunchul; Lee, Kang Seon; Choi, Jung Kyoon			Comprehensive characterisation of intronic mis-splicing mutations in human cancers	ONCOGENE			English	Article							MESSENGER-RNA DECAY; ANTISENSE OLIGONUCLEOTIDES; SPLICING FACTORS; GENOME; IDENTIFICATION; NONSENSE; ANNOTATION; SUPPRESSOR; MECHANISM; VARIANTS	Previous studies studying mis-splicing mutations were based on exome data and thus our current knowledge is largely limited to exons and the canonical splice sites. To comprehensively characterise intronic mis-splicing mutations, we analysed 1134 pan-cancer whole genomes and transcriptomes together with 3022 normal control samples. The ratio-based splicing analysis resulted in 678 somatic intronic mutations, with 46% residing in deep introns. Among the 309 deep intronic single nucleotide variants, 245 altered core splicing codes, with 38% activating cryptic splice sites, 12% activating cryptic polypyrimidine tracts, and 36% and 12% disrupting authentic polypyrimidine tracts and branchpoints, respectively. All the intronic cryptic splice sites were created at pre-existing GT/AG dinucleotides or by GC-to-GT conversion. Notably, 85 deep intronic mutations indicated gain of splicing enhancers or loss of splicing silencers. We found that 64 tumour suppressors were affected by intronic mutations and blood cancers showed higher proportion of deep intronic mutations. In particular, a telomere maintenance gene, POT1, was recurrently mis-spliced by deep intronic mutations in blood cancers. We validated a pseudoexon activation involving a splicing silencer in POT1 by CRISPR/Cas9. Our results shed light on previously unappreciated mechanisms by which noncoding mutations acting on splicing codes in deep introns contribute to tumourigenesis.	[Jung, Hyunchul; Lee, Kang Seon; Choi, Jung Kyoon] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon 34141, South Korea; [Jung, Hyunchul] Wellcome Sanger Inst, Canc Ageing & Somat Mutat Programme, Cambridge, England; [Choi, Jung Kyoon] Penta Medix Co Ltd, Seongnam Si 13449, Gyeongi Do, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Wellcome Trust Sanger Institute	Jung, H; Choi, JK (corresponding author), Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon 34141, South Korea.; Jung, H (corresponding author), Wellcome Sanger Inst, Canc Ageing & Somat Mutat Programme, Cambridge, England.; Choi, JK (corresponding author), Penta Medix Co Ltd, Seongnam Si 13449, Gyeongi Do, South Korea.	hj6@sanger.ac.uk; jungkyoon@kaist.ac.kr			Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Korean government (MSIT) [2017M3A9A7050612]; National Research Foundation of Korea - Korean Government [NRF-2020R1A6A3A03039805]	Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Korean government (MSIT)(National Research Foundation of KoreaMinistry of Science & ICT (MSIT), Republic of Korea); National Research Foundation of Korea - Korean Government(National Research Foundation of KoreaKorean Government)	This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2017M3A9A7050612). HJ was supported by a grant from the National Research Foundation of Korea funded by the Korean Government (NRF-2020R1A6A3A03039805).	Alexander RP, 2010, NAT REV GENET, V11, P559, DOI 10.1038/nrg2814; Alsamman K, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171672; Bolli N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3997; Brogna S, 2009, NAT STRUCT MOL BIOL, V16, P107, DOI 10.1038/nsmb.1550; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cornish AJ, 2019, BLOOD ADV, V3, P21, DOI 10.1182/bloodadvances.2018026419; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Cummings BB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5209; Davoli T, 2013, CELL, V155, P948, DOI 10.1016/j.cell.2013.10.011; de Miranda NFCC, 2014, BLOOD, V124, P2544, DOI 10.1182/blood-2013-12-546309; De Paoli L, 2013, LEUKEMIA LYMPHOMA, V54, P1087, DOI 10.3109/10428194.2012.723706; Diederichs S, 2016, EMBO MOL MED, V8, P442, DOI 10.15252/emmm.201506055; Dong XS, 2020, ONCOGENE, V39, P2231, DOI 10.1038/s41388-019-1138-2; Dvinge H, 2016, NAT REV CANCER, V16, P413, DOI 10.1038/nrc.2016.51; El Marabti E, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00080; Erkelenz S, 2013, RNA, V19, P96, DOI 10.1261/rna.037044.112; Fairbrother WG, 2004, NUCLEIC ACIDS RES, V32, pW187, DOI 10.1093/nar/gkh393; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Fu XD, 2014, NAT REV GENET, V15, P689, DOI 10.1038/nrg3778; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Havens MA, 2016, NUCLEIC ACIDS RES, V44, P6549, DOI 10.1093/nar/gkw533; Jaganathan K, 2019, CELL, V176, P535, DOI 10.1016/j.cell.2018.12.015; Jayasinghe RG, 2018, CELL REP, V23, P270, DOI 10.1016/j.celrep.2018.03.052; Jung- H, 2015, NAT GENET, V47, P1242, DOI 10.1038/ng.3414; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Ke SD, 2011, GENOME RES, V21, P1360, DOI 10.1101/gr.119628.110; Khurana E, 2016, NAT REV GENET, V17, P93, DOI 10.1038/nrg.2015.17; Kornblihtt AR, 2013, NAT REV MOL CELL BIO, V14, P153, DOI 10.1038/nrm3525; Kremer LS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15824; Lewandowska MA, 2013, INT J CLIN EXP PATHO, V6, P2675; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Lindeboom RGH, 2016, NAT GENET, V48, P1112, DOI 10.1038/ng.3664; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Lopez-Bigas N, 2005, FEBS LETT, V579, P1900, DOI 10.1016/j.febslet.2005.02.047; Lorenz R, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748-7188-6-26; Mercer TR, 2015, GENOME RES, V25, P290, DOI 10.1101/gr.182899.114; Morin RD, 2016, CLIN CANCER RES, V22, P2290, DOI 10.1158/1078-0432.CCR-15-2123; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; Parker JDK, 2016, CSH MOL CASE STUD, V2, DOI 10.1101/mcs.a000679; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Pinzaru AM, 2016, CELL REP, V15, P2170, DOI 10.1016/j.celrep.2016.05.008; Ramsay AJ, 2013, NAT GENET, V45, P526, DOI 10.1038/ng.2584; Rinaldi C, 2018, NAT REV NEUROL, V14, P9, DOI 10.1038/nrneurol.2017.148; Scotti MM, 2016, NAT REV GENET, V17, P19, DOI 10.1038/nrg.2015.3; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Shiraishi Y, 2018, GENOME RES, V28, P1111, DOI 10.1101/gr.231951.117; Sibley CR, 2016, NAT REV GENET, V17, P407, DOI 10.1038/nrg.2016.46; Sickmier EA, 2006, MOL CELL, V23, P49, DOI 10.1016/j.molcel.2006.05.025; Signal B, 2018, BIOINFORMATICS, V34, P920, DOI 10.1093/bioinformatics/btx688; Soemedi R, 2017, NAT GENET, V49, P848, DOI 10.1038/ng.3837; Sterne-Weiler T, 2011, GENOME RES, V21, P1563, DOI 10.1101/gr.118638.110; Supek F, 2014, CELL, V156, P1324, DOI 10.1016/j.cell.2014.01.051; Taggart AJ, 2017, GENOME RES, V27, P639, DOI 10.1101/gr.202820.115; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Vaz-Drago R, 2017, HUM GENET, V136, P1093, DOI 10.1007/s00439-017-1809-4; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Vorechovsky I, 2006, NUCLEIC ACIDS RES, V34, P4630, DOI 10.1093/nar/gkl535; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041; Wang Y, 2012, NAT STRUCT MOL BIOL, V19, P1044, DOI 10.1038/nsmb.2377; Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010; Yeo G, 2004, J COMPUT BIOL, V11, P377, DOI 10.1089/1066527041410418	64	6	6	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1347	1361		10.1038/s41388-020-01614-3	http://dx.doi.org/10.1038/s41388-020-01614-3		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420369	hybrid, Green Published			2022-12-28	WOS:000607346000005
J	Teinturier, R; Luo, YK; Decaussin-Petrucci, M; Vlaeminck-Guillem, V; Vacherot, F; Firlej, V; Bonnavion, R; Abou Ziki, R; Gherardi, S; Goddard, I; Gadot, N; Bertolino, P; Le Romancer, M; Zhang, CX				Teinturier, Romain; Luo, Yakun; Decaussin-Petrucci, Myriam; Vlaeminck-Guillem, Virginie; Vacherot, Francis; Firlej, Virginie; Bonnavion, Remy; Abou Ziki, Razan; Gherardi, Samuele; Goddard, Isabelle; Gadot, Nicolas; Bertolino, Philippe; Le Romancer, Muriel; Zhang, Chang Xian			Men1 disruption in Nkx3.1-deficient mice results in AR(low)/CD44(+) microinvasive carcinoma development with the dysregulated AR pathway	ONCOGENE			English	Article							PROSTATE-CANCER; CELLS; GENE; MECHANISMS; COMPLEX	Dysregulated androgen receptor (AR) plays a crucial role in prostate cancer (PCa) development, though further factors involved in its regulation remain to be identified. Recently, paradoxical results were reported on the implication of the MEN1 gene in PCa. To dissect its role in prostate luminal cells, we generated a mouse model with inducible Men1 disruption in Nkx3.1-deficient mice in which mouse prostatic intraepithelial neoplasia (mPIN) occur. Prostate glands from mutant and control mice were analyzed pathologically and molecularly; cellular and molecular analyses were carried out in PCa cell lines after MEN1 knockdown (KD) by siRNA. Double-mutant mice developed accelerated mPIN and later displayed microinvasive adenocarcinoma. Markedly, early-stage lesions exhibited a decreased expression of AR and its target genes, accompanied by reduced CK18 and E-cadherin expression, suggesting a shift from a luminal to a dedifferentiated epithelial phenotype. Intriguingly, over 60% of menin-deficient cells expressed CD44 at a later stage. Furthermore, MEN1 KD led to the increase in CD44 expression in PC3 cells re-expressing AR. Menin bound to the proximal AR promoter and regulated AR transcription via the H3K4me3 histone mark. Interestingly, the cell proliferation of AR-dependent cells (LNCaP, 22Rv1, and VCaP), but not of AR-independent cells (DU145, PC3), responded strongly to MEN1 silencing. Finally, menin expression was found reduced in some human PCa. These findings highlight the regulation of the AR promoter by menin and the crosstalk between menin and the AR pathway. Our data could be useful for better understanding the increasingly reported AR-negative/NE-negative subtype of PCa and the mechanisms underlying its development.	[Teinturier, Romain; Luo, Yakun; Decaussin-Petrucci, Myriam; Vlaeminck-Guillem, Virginie; Bonnavion, Remy; Abou Ziki, Razan; Gherardi, Samuele; Bertolino, Philippe; Le Romancer, Muriel; Zhang, Chang Xian] Univ Claude Bernard Lyon 1, Univ Lyon, Ctr Rech Cancerol Lyon, Ctr Leon Berard,INSERM 1052,CNRS 5286, F-69008 Lyon, France; [Decaussin-Petrucci, Myriam; Vlaeminck-Guillem, Virginie] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Ctr Biol & Anatomopathol Sud, F-69495 Lyon, France; [Vacherot, Francis; Firlej, Virginie] Univ Paris Est Creteil, TRePCa, F-94010 Creteil, France; [Firlej, Virginie] Hop Univ Henri Mondor, Plateforme Ressources Biol, F-94000 Creteil, France; [Goddard, Isabelle] Univ Claude Bernard Lyon 1, Univ Lyon, Lab Modeles Tumoraux,INSERM 1052,CNRS 5286, Ctr Rech Cancerol Lyon CRCL,Fdn Synergie Lyon Can, F-69373 Lyon, France; [Gadot, Nicolas] Univ Claude Bernard Lyon 1, Univ Lyon, INSERM 1052,CNRS 5286,Ctr Leon Berard, Plateforme Anatomopathol Rech,Ctr Rech Cancerol L, F-69373 Lyon, France; [Teinturier, Romain] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Bonnavion, Remy] Max Planck Inst Heart & Lung Res, Bad Nauheim, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; CHU Lyon; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; Karolinska Institutet; Max Planck Society	Zhang, CX (corresponding author), Univ Claude Bernard Lyon 1, Univ Lyon, Ctr Rech Cancerol Lyon, Ctr Leon Berard,INSERM 1052,CNRS 5286, F-69008 Lyon, France.	chang.zhang@lyon.unicancer.fr	Firlej, Virginie/AFQ-6362-2022; Bertolino, philippe/D-4072-2018; DECAUSSIN PETRUCCI, MYRIAM/GWZ-7373-2022	Firlej, Virginie/0000-0003-4132-0695; Bertolino, philippe/0000-0001-8064-8269; Bonnavion, Remy/0000-0002-7389-4282; LUO, YAKUN/0000-0002-9644-5025	Epigenetics Cancer Program [ASC14092CSA]; Fondation de l'Association pour la Recherche contre le Cancer [SFI20101201530]; Ligue Inter-regionale contre le Cancer [R19040CC]; Association Le Cancer du Sein Parlons-en; Region Auvergne, Rhone-Alpes [SICORRA22425]; French Ministry of Higher Education and Research; Societe Francaise d'Endocrinologie; Fondation ARC, France; China Scholarship Council; Association "G04MEDIA S.A.R.L," Lebanon	Epigenetics Cancer Program; Fondation de l'Association pour la Recherche contre le Cancer; Ligue Inter-regionale contre le Cancer; Association Le Cancer du Sein Parlons-en; Region Auvergne, Rhone-Alpes(Region Auvergne-Rhone-Alpes); French Ministry of Higher Education and Research; Societe Francaise d'Endocrinologie; Fondation ARC, France; China Scholarship Council(China Scholarship Council); Association "G04MEDIA S.A.R.L," Lebanon	This study was supported by Epigenetics & Cancer Program (ASC14092CSA), the Fondation de l'Association pour la Recherche contre le Cancer (SFI20101201530), the Ligue Inter-regionale contre le Cancer (R19040CC), the Association Le Cancer du Sein Parlons-en, and the Region Auvergne, Rhone-Alpes, (SICORRA22425). RT and RB were the recipients of a PhD fellowship from French Ministry of Higher Education and Research, and of a 4th year doctoral fellowship from Societe Francaise d'Endocrinologie and the Fondation ARC, France, respectively. YL was the recipient of a PhD fellowship from China Scholarship Council. RAZ was the recipient of a PhD fellowship from Association "G04MEDIA S.A.R.L," Lebanon.	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Altintas DM, 2011, MOL CELL ENDOCRINOL, V332, P149, DOI 10.1016/j.mce.2010.10.007; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Bertolino P, 2003, CANCER RES, V63, P4836; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Dreijerink KMA, 2017, CELL REP, V18, P2359, DOI 10.1016/j.celrep.2017.02.025; Dreijerink KMA, 2014, NEW ENGL J MED, V371, P583, DOI 10.1056/NEJMc1406028; Floc'h N, 2012, CANCER RES, V72, P4483, DOI 10.1158/0008-5472.CAN-12-0283; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Li QH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06067-7; Liu X, 2015, ONCOTARGET, V6, P23959, DOI 10.18632/oncotarget.4260; Malik R, 2015, NAT MED, V21, P344, DOI 10.1038/nm.3830; Paris PL, 2009, PROSTATE CANCER P D, V12, P184, DOI 10.1038/pcan.2008.45; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rybak AP, 2015, ONCOTARGET, V6, P1900, DOI 10.18632/oncotarget.2953; Seigne C, 2013, J PATHOL, V229, P546, DOI 10.1002/path.4146; Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Srinivasan D, 2019, J CELL BIOCHEM, V120, P2413, DOI 10.1002/jcb.27573; Thiel AT, 2012, BIOESSAYS, V34, P771, DOI 10.1002/bies.201200007; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004	25	3	3	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1118	1127		10.1038/s41388-020-01589-1	http://dx.doi.org/10.1038/s41388-020-01589-1		DEC 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323967				2022-12-28	WOS:000599126500008
J	Na, YJ; Hall, A; Choi, KM; Hu, L; Rose, J; Coover, RA; Miller, A; Hennigan, RF; Dombi, E; Kim, MO; Subramanian, S; Ratner, N; Wu, JQ				Na, Youjin; Hall, Ashley; Choi, Kwangmin; Hu, Liang; Rose, Jonathan; Coover, Robert A.; Miller, Adam; Hennigan, Robert F.; Dombi, Eva; Kim, Mi-Ok; Subramanian, Subbaya; Ratner, Nancy; Wu, Jianqiang			MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK	ONCOGENE			English	Article							IN-VIVO; SCHWANN-CELLS; MOUSE MODEL; MIR-155; CANCER; DIFFERENTIATION; INHIBITION; ACTIVATION; TYPE-1; ROLES	MicroRNAs (miRs) are small non-coding RNAs that can have large impacts on oncogenic pathways. Possible functions of dysregulated miRs have not been studied in neurofibromatosis type 1 (NF1) plexiform neurofibromas (PNFs). In PNFs, Schwann cells (SCs) have biallelic NF1 mutations necessary for tumorigenesis. We analyzed a miR microarray comparing with normal and PNF SCs and identified differences in miR expression, and we validated in mouse PNFs versus normal mouse SCs by qRT-PCR. Among these, miR-155 was a top overexpressed miR, and its expression was regulated by RAS/MAPK signaling. Overexpression of miR-155 increased mature Nf1(-/-) mouse SC proliferation. In SC precursors, which model tumor-initiating cells, pharmacological and genetic inhibition of miR-155 decreased PNF-derived sphere numbers in vitro, and we identified Maf as a miR-155 target. In vivo, global deletion of miR-155 significantly decreased tumor number and volume, increasing mouse survival. Fluorescent nanoparticles entered PNFs, suggesting that an anti-miR might have therapeutic potential. However, treatment of established PNFs using anti-miR-155 peptide nucleic acid-loaded nanoparticles marginally decreased tumor numbers and did not reduce tumor growth. These results suggest that miR-155 plays a functional role in PNF growth and/or SC proliferation, and that targeting neurofibroma miRs is feasible, and might provide novel therapeutic opportunities.	[Na, Youjin; Hall, Ashley; Choi, Kwangmin; Hu, Liang; Rose, Jonathan; Coover, Robert A.; Miller, Adam; Hennigan, Robert F.; Ratner, Nancy; Wu, Jianqiang] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Div Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Dombi, Eva] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA; [Kim, Mi-Ok] UCSF, Dept Epidemiol & Biostat, Box 0128,1450 3rd St,Suite 285, San Francisco, CA 94143 USA; [Subramanian, Subbaya] Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA; [Ratner, Nancy; Wu, Jianqiang] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA; [Coover, Robert A.] High Point Univ, Fred Wilson Sch Pharm, Pharmaceut Sci, One Univ Pkwy, High Point, NC 27268 USA	Cincinnati Children's Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; University System of Ohio; University of Cincinnati	Wu, JQ (corresponding author), Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Div Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.; Wu, JQ (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA.	Jianqiang.wu@cchmc.org		Coover, Robert/0000-0001-8153-6912; RATNER, NANCY/0000-0001-5030-9354; Rose, Jonathan/0000-0002-6262-2433	NIH [R01 NS097233, NIH R0 NS28840, R37 NS096356]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Drs. Mark Saltzman and Christopher J. Cheng (Yale School of Engineering and Applied Science) for providing fluorescence-conjugated nanoparticles to fulfill part of the in vivo experiments. This work was supported by NIH R01 NS097233 to J.W. NIH R0 NS28840 and R37 NS096356 to N.R.	Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109; Banerjee A, 2010, EUR J IMMUNOL, V40, P225, DOI 10.1002/eji.200939381; Baulcombe D, 2002, SCIENCE, V297, P2002, DOI 10.1126/science.1077906; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Boyd KP, 2009, J AM ACAD DERMATOL, V61, P1, DOI 10.1016/j.jaad.2008.12.051; Brundage ME, 2014, ONCOGENE, V33, P5626, DOI 10.1038/onc.2013.506; Chai GL, 2010, CANCER SCI, V101, P1997, DOI 10.1111/j.1349-7006.2010.01616.x; Chen ZG, 2019, CANCER DISCOV, V9, P114, DOI 10.1158/2159-8290.CD-18-0151; Chene CJ, 2011, BIOMATERIALS, V32, P6194, DOI 10.1016/j.biomaterials.2011.04.053; Dombi E, 2016, NEW ENGL J MED, V375, P2550, DOI 10.1056/NEJMoa1605943; Fabani MM, 2010, NUCLEIC ACIDS RES, V38, P4466, DOI 10.1093/nar/gkq160; Ganguly S, 2008, OLIGONUCLEOTIDES, V18, P277, DOI 10.1089/oli.2008.0140; Gong M, 2012, NEURO-ONCOLOGY, V14, P1007, DOI 10.1093/neuonc/nos124; Gordon JEA, 2013, BRIT J HAEMATOL, V162, P162, DOI 10.1111/bjh.12364; Gross AM, 2020, NEW ENGL J MED, V382, P1430, DOI 10.1056/NEJMoa1912735; Hall A, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau8389; Higgs Gadareth, 2013, J Clin Bioinforma, V3, P17, DOI 10.1186/2043-9113-3-17; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Jousma E, 2015, PEDIATR BLOOD CANCER, V62, P1709, DOI 10.1002/pbc.25546; Kim M, 2018, GENE DEV, V32, P645, DOI 10.1101/gad.310490.117; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; Kraniak JM, 2010, MOL CELL BIOCHEM, V344, P267, DOI 10.1007/s11010-010-0551-1; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Le LQ, 2007, ONCOGENE, V26, P4609, DOI 10.1038/sj.onc.1210261; Liu M, 2020, J CLIN INVEST, V130, P2081, DOI 10.1172/JCI131335; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; Martin Elizabeth C, 2014, Genes Cancer, V5, P353; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Prada CE, 2013, ACTA NEUROPATHOL, V125, P159, DOI 10.1007/s00401-012-1056-7; Presneau N, 2013, BRIT J CANCER, V108, P964, DOI 10.1038/bjc.2012.518; Radomska KJ, 2019, CANCER DISCOV, V9, P130, DOI 10.1158/2159-8290.CD-18-0156; Ratner N, 2015, NAT REV CANCER, V15, P290, DOI 10.1038/nrc3911; Rice FL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216527; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Sherman LS, 2001, METHOD ENZYMOL, V333, P348; Solomon J, 2004, COMPUT MED IMAG GRAP, V28, P257, DOI 10.1016/j.compmedimag.2004.03.002; Su W, 2014, J IMMUNOL, V192, P358, DOI 10.4049/jimmunol.1301397; Subramanian S, 2010, J PATHOL, V220, P58, DOI 10.1002/path.2633; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Trotta R, 2013, BLOOD, V121, P3126, DOI 10.1182/blood-2012-12-467597; Varan A, 2016, CLIN GENET, V89, P341, DOI 10.1111/cge.12625; Vasilatou D, 2010, EUR J HAEMATOL, V84, P1, DOI 10.1111/j.1600-0609.2009.01348.x; Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Wu JQ, 2016, CELL REP, V14, P1979, DOI 10.1016/j.celrep.2016.01.074; Wu JQ, 2012, PEDIATR BLOOD CANCER, V58, P173, DOI 10.1002/pbc.23015; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Yin QY, 2008, J BIOL CHEM, V283, P2654, DOI 10.1074/jbc.M708218200; Zhang C, 2015, DIABETES-METAB RES, V31, P773, DOI 10.1002/dmrr.2676; Zhang Y, 2012, BLOOD, V120, P1678, DOI 10.1182/blood-2012-02-410647; Zheng H, 2008, CANCER CELL, V13, P117, DOI 10.1016/j.ccr.2008.01.002; Zhou Y, 2019, CLIN NEUROL NEUROSUR, V176, P103, DOI 10.1016/j.clineuro.2018.12.005; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	60	4	4	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					951	963		10.1038/s41388-020-01581-9	http://dx.doi.org/10.1038/s41388-020-01581-9		DEC 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33293695	Green Accepted			2022-12-28	WOS:000599053400002
J	Zhang, JN; Jiang, XY; Yin, J; Dou, SY; Xie, XL; Liu, T; Wang, YJ; Wang, SL; Zhou, X; Zhang, DX; Jiang, HQ				Zhang, Jiuna; Jiang, Xiaoyu; Yin, Jie; Dou, Shiying; Xie, Xiaoli; Liu, Ting; Wang, Yijun; Wang, Shuling; Zhou, Xue; Zhang, Dongxuan; Jiang, Huiqing			RNF141 interacts with KRAS to promote colorectal cancer progression	ONCOGENE			English	Article							K-RAS; HUMAN COLON; PROTEINS; MUTATIONS; GENE; LOCALIZATION; ASSOCIATION; EXPRESSION; LIGASES; GROWTH	RING finger proteins (RNFs) play a critical role in cancer initiation and progression. RNF141 is a member of RNFs family; however, its clinical significance, roles, and mechanism in colorectal cancer (CRC) remain poorly understood. Here, we examined the expression of RNF141 in 64 pairs of CRC and adjacent normal tissues by real-time PCR, Western blot, and immunohistochemical analysis. We found that there was more expression of RNF141 in CRC tissue compared with its adjacent normal tissue and high RNF141 expression associated with T stage. In vivo and in vitro functional experiments were conducted and revealed the oncogenic role of RNF141 in CRC. RNF141 knockdown suppressed proliferation, arrested the cell cycle in the G1 phase, inhibited migration, invasion and HUVEC tube formation but promoted apoptosis, whereas RNF141 overexpression exerted the opposite effects in CRC cells. The subcutaneous xenograft models showed that RNF141 knockdown reduced tumor growth, but its overexpression promoted tumor growth. Mechanistically, liquid chromatography-tandem mass spectrometry indicated RNF141 interacted with KRAS, which was confirmed by Co-immunoprecipitation, Immunofluorescence assay. Further analysis with bimolecular fluorescence complementation (BiFC) and Glutathione-S-transferase (GST) pull-down assays showed that RNF141 could directly bind to KRAS. Importantly, the upregulation of RNF141 increased GTP-bound KRAS, but its knockdown resulted in a reduction accordingly. Next, we demonstrated that RNF141 induced KRAS activation via increasing its enrichment on the plasma membrane not altering total KRAS expression, which was facilitated by the interaction with LYPLA1. Moreover, KRAS silencing partially abolished the effect of RNF141 on cell proliferation and apoptosis. In addition, our findings presented that RNF141 functioned as an oncogene by upregulating KRAS activity in a manner of promoting KRAS enrichment on the plasma membrane in CRC.	[Zhang, Jiuna; Jiang, Xiaoyu; Yin, Jie; Dou, Shiying; Xie, Xiaoli; Liu, Ting; Wang, Yijun; Wang, Shuling; Zhou, Xue; Zhang, Dongxuan; Jiang, Huiqing] Hebei Med Univ, Hosp 2, Hebei Inst Gastroenterol, Dept Gastroenterol,Hebei Key Lab Gastroenterol, Shijiazhuang, Hebei, Peoples R China; [Zhang, Jiuna] Hebei Engn Univ, Affiliated Hosp, Dept Gastroenterol, Handan, Peoples R China	Hebei Medical University	Jiang, HQ (corresponding author), Hebei Med Univ, Hosp 2, Hebei Inst Gastroenterol, Dept Gastroenterol,Hebei Key Lab Gastroenterol, Shijiazhuang, Hebei, Peoples R China.	jianghuiqing1959@sina.com	Wang, Yu/GZL-9655-2022; wang, yixuan/GXW-2866-2022; Wang, Yijun/GXW-1763-2022; Wang, Yixuan/GZK-6559-2022; Wang, Yin/HCI-9352-2022; wang, yi/GVT-8516-2022		National Natural Science Foundation of China [81702324, 81770601, 81602529]; Natural Science Foundation of Hebei Province, China [H2018206176, H2017206141]; Medical Science Research Project of Hebei Province, China [20190510]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hebei Province, China(Natural Science Foundation of Hebei Province); Medical Science Research Project of Hebei Province, China	This work was supported by the National Natural Science Foundation of China (81702324, 81770601, and 81602529), Natural Science Foundation of Hebei Province, China (H2018206176 and H2017206141); Medical Science Research Project of Hebei Province, China (20190510).	Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Baietti MF, 2016, EMBO MOL MED, V8, P288, DOI 10.15252/emmm.201505972; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Castagnola P, 2005, BBA-REV CANCER, V1756, P115, DOI 10.1016/j.bbcan.2005.06.003; Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0; Dekker FJ, 2010, NAT CHEM BIOL, V6, P449, DOI 10.1038/nchembio.362; Deng WQ, 2009, GENET MOL BIOL, V32, P594, DOI 10.1590/S1415-47572009005000062; Dohlman HG, 2019, J BIOL CHEM, V294, P18613, DOI 10.1074/jbc.REV119.011068; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Friday BB, 2005, BBA-REV CANCER, V1756, P127, DOI 10.1016/j.bbcan.2005.08.001; Geng R, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.400; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Hobbs GA, 2016, J CELL SCI, V129, P1287, DOI 10.1242/jcs.182873; Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960; Inamura K, 2018, CANCERS, V10, DOI 10.3390/cancers10010026; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; Jaworska AM, 2020, STEM CELLS, V38, P165, DOI 10.1002/stem.3109; Jiang XM, 2015, MOL CELL, V58, P522, DOI 10.1016/j.molcel.2015.03.015; Jura N, 2006, MOL CELL, V21, P679, DOI 10.1016/j.molcel.2006.02.011; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Koveitypour Z, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0361-4; Lee DW, 2017, CANCER-AM CANCER SOC, V123, P3513, DOI 10.1002/cncr.30760; Levinson AM, 2017, J AM CHEM SOC, V139, P7632, DOI 10.1021/jacs.7b02988; Lieu CH, 2019, CLIN CANCER RES, V25, P5852, DOI 10.1158/1078-0432.CCR-19-0899; Liu L, 2018, ONCOGENE, V37, P148, DOI 10.1038/onc.2017.313; Martinelli E, 2020, ANN ONCOL, V31, P30, DOI 10.1016/j.annonc.2019.10.007; McCormick F, 2015, CLIN CANCER RES, V21, P1797, DOI 10.1158/1078-0432.CCR-14-2662; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111; Papke B, 2017, SCIENCE, V355, P1158, DOI 10.1126/science.aam7622; Prior IA, 2001, J CELL SCI, V114, P1603; Sasaki AT, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001518; Schmick M, 2015, TRENDS CELL BIOL, V25, P190, DOI 10.1016/j.tcb.2015.02.004; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Senft D, 2018, NAT REV CANCER, V18, P69, DOI 10.1038/nrc.2017.105; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Smakman N, 2005, BBA-REV CANCER, V1756, P103, DOI 10.1016/j.bbcan.2005.07.001; Song HX, 2008, BMB REP, V41, P664, DOI 10.5483/BMBRep.2008.41.9.664; Tan ZL, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax5576; Tsai FD, 2015, P NATL ACAD SCI USA, V112, P779, DOI 10.1073/pnas.1412811112; Veggiani G, 2019, PHARMACOL THERAPEUT, V199, P139, DOI 10.1016/j.pharmthera.2019.03.003; Venuto S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050510; Wang XW, 2014, GUT LIVER, V8, P487, DOI 10.5009/gnl13133; Wang YX, 2013, J MED CHEM, V56, P5219, DOI 10.1021/jm3017706; Zhu J, 2016, ONCOGENE, V35, P1955, DOI 10.1038/onc.2015.260	51	3	3	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5829	5842		10.1038/s41388-021-01877-4	http://dx.doi.org/10.1038/s41388-021-01877-4		AUG 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34345014	hybrid, Green Published			2022-12-28	WOS:000681523500006
J	Hamalian, S; Guth, R; Runa, F; Sanchez, F; Vickers, E; Agajanian, M; Molnar, J; Nguyen, T; Gamez, J; Humphries, JD; Nayak, A; Humphries, MJ; Tchou, J; Zervantonakis, IK; Kelber, JA				Hamalian, Sarkis; Guth, Robert; Runa, Farhana; Sanchez, Francesca; Vickers, Eric; Agajanian, Megan; Molnar, Justin; Nguyen, Tuan; Gamez, Joshua; Humphries, Jonathan D.; Nayak, Anupma; Humphries, Martin J.; Tchou, Julia; Zervantonakis, Ioannis K.; Kelber, Jonathan A.			A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers	ONCOGENE			English	Article							THERAPY; HETEROGENEITY; GROWTH	Intercellular mechanisms by which the stromal microenvironment contributes to solid tumor progression and targeted therapy resistance remain poorly understood, presenting significant clinical hurdles. PEAK1 (Pseudopodium-Enriched Atypical Kinase One) is an actin cytoskeleton- and focal adhesion-associated pseudokinase that promotes cell state plasticity and cancer metastasis by mediating growth factor-integrin signaling crosstalk. Here, we determined that stromal PEAK1 expression predicts poor outcomes in HER2-positive breast cancers high in SNAI2 expression and enriched for MSC content. Specifically, we identified that the fibroblastic stroma in HER2-positive breast cancer patient tissue stains positive for both nuclear SNAI2 and cytoplasmic PEAK1. Furthermore, mesenchymal stem cells (MSCs) and cancer-associated fibroblasts (CAFs) express high PEAK1 protein levels and potentiate tumorigenesis, lapatinib resistance and metastasis of HER2-positive breast cancer cells in a PEAK1-dependent manner. Analysis of PEAK1-dependent secreted factors from MSCs revealed INHBA/activin-A as a necessary factor in the conditioned media of PEAK1-expressing MSCs that promotes lapatinib resistance. Single-cell CycIF analysis of MSC-breast cancer cell co-cultures identified enrichment of p-Akt(high)/p-gH2AX(low), MCL1(high)/p-gH2AX(low) and GRP78(high)/VIMhigh breast cancer cell subpopulations by the presence of PEAK1-expressing MSCs and lapatinib treatment. Bioinformatic analyses on a PEAK1-centric stroma-tumor cell gene set and follow-up immunostaining of co-cultures predict targeting antiapoptotic and stress pathways as a means to improve targeted therapy responses and patient outcomes in HER2-positive breast cancer and other stroma-rich malignancies. These data provide the first evidence that PEAK1 promotes tumorigenic phenotypes through a previously unrecognized SNAI2-PEAK1-INHBA stromal cell axis.	[Hamalian, Sarkis; Guth, Robert; Runa, Farhana; Sanchez, Francesca; Vickers, Eric; Agajanian, Megan; Molnar, Justin; Nguyen, Tuan; Gamez, Joshua; Kelber, Jonathan A.] Calif State Univ Northridge, Dept Biol, Northridge, CA 91330 USA; [Humphries, Jonathan D.; Humphries, Martin J.] Univ Manchester, Fac Biol Med & Hlth, Wellcome Ctr Cell Matrix Res, Manchester, Lancs, England; [Nayak, Anupma] Hosp Univ Penn, Dept Pathol & Lab Med, 3400 Spruce St, Philadelphia, PA 19104 USA; [Nayak, Anupma] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Tchou, Julia] Univ Penn, Perelman Sch Med, Abramson Canc Ctr,Rena Rowan Breast Ctr, Div Endocrine & Oncol Surg,Dept Surg, Philadelphia, PA 19104 USA; [Zervantonakis, Ioannis K.] Univ Pittsburgh, Dept Bioengn, Ctr Bioengn, Pittsburgh, PA 15213 USA; [Humphries, Jonathan D.] Manchester Metropolitan Univ, Dept Life Sci, Manchester, Lancs, England	California State University System; California State University Northridge; University of Manchester; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Manchester Metropolitan University	Kelber, JA (corresponding author), Calif State Univ Northridge, Dept Biol, Northridge, CA 91330 USA.	jonathan.kelber@csun.edu	Humphries, Jonathan D./AAE-7760-2022; Zervantonakis, Ioannis/ADS-2519-2022	Humphries, Jonathan D./0000-0002-8953-7079; Zervantonakis, Ioannis/0000-0003-2386-9553; Agajanian, Megan/0000-0002-1296-5665	California State University Northridge College of Science and Mathematics; Wellcome Centre for Cell-Matrix Research at the University of Manchester; Ludwig Center at Harvard Medical School; Sidney Stern Memorial Trust; Sutter family; Aylozyan Family Foundation; NIH NCI [R00CA222554]; DOD [W81XWH-14-1-0222]; Cancer Research UK [C13329/A21671]; NCI Cancer Center Support Grant [2P30CA016520]; Linda and Paul Richardson Breast Cancer Research Funds; NSF [DUE1842386]; NIH NIGMS [SC1GM121182]; ASCB MAC Visiting Professorship; US-UK Fulbright-CRUK Scholar Award	California State University Northridge College of Science and Mathematics; Wellcome Centre for Cell-Matrix Research at the University of Manchester; Ludwig Center at Harvard Medical School; Sidney Stern Memorial Trust; Sutter family; Aylozyan Family Foundation; NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); Cancer Research UK(Cancer Research UK); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Linda and Paul Richardson Breast Cancer Research Funds; NSF(National Science Foundation (NSF)); NIH NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); ASCB MAC Visiting Professorship; US-UK Fulbright-CRUK Scholar Award	We thank Dr. Joan Brugge for sponsorship of Dr. Jonathan Kelber's ASCB-MAC Visiting Professorship and helpful discussions during the experiment design and manuscript writing/revising phases. We thank Dr. Lesley Ellies for providing Py230 cells. We thank members of the Developmental Oncogene Laboratory at California State University Northridge for valuable feedback during manuscript preparation. This work was supported by California State University Northridge College of Science and Mathematics; Wellcome Centre for Cell-Matrix Research at the University of Manchester; Ludwig Center at Harvard Medical School; Sidney Stern Memorial Trust; Sutter family; Aylozyan Family Foundation; NIH NCI grant R00CA222554 (to I.K.Z.); DOD grant W81XWH-14-1-0222 (to I.K.Z.); Cancer Research UK programme grant C13329/A21671 (to M.J.H.); NCI Cancer Center Support Grant 2P30CA016520 (to J.T.); Linda and Paul Richardson Breast Cancer Research Funds (to J.T.); NSF Grant DUE1842386 (to C.S./A.A. for support of T.N.); NIH NIGMS grant SC1GM121182 (to J.A.K.); ASCB MAC Visiting Professorship (to J.A.K.); and US-UK Fulbright-CRUK Scholar Award (to J.A.K.).	Agajanian M, 2015, BIOCHEM BIOPH RES CO, V465, P606, DOI 10.1016/j.bbrc.2015.08.071; Agajanian M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135748; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Bartoschek M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07582-3; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Bashari MH, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0686-4; Chastney MR, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202003038; Ding CB, 2019, CANCER LETT, V442, P383, DOI 10.1016/j.canlet.2018.11.014; Ding CB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0817-1; Do MT, 2017, ONCOGENE, V36, P5757, DOI 10.1038/onc.2017.183; El-Haibi CP, 2012, P NATL ACAD SCI USA, V109, P17460, DOI 10.1073/pnas.1206653109; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fluegen G, 2017, NAT CELL BIOL, V19, P120, DOI 10.1038/ncb3465; Gori S, 2012, ANN ONCOL, V23, P1436, DOI 10.1093/annonc/mdr474; Gupta PB, 2019, CELL STEM CELL, V24, P65, DOI 10.1016/j.stem.2018.11.011; Guth R, 2019, BIOCHEM BIOPH RES CO, V519, P838, DOI 10.1016/j.bbrc.2019.09.075; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Horton ER, 2015, NAT CELL BIOL, V17, P1577, DOI 10.1038/ncb3257; Huang LL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0320-8; Kabraji S, 2018, CLIN CANCER RES, V24, P1795, DOI 10.1158/1078-0432.CCR-17-3351; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kelber JA, 2012, CANCER RES, V72, P2554, DOI 10.1158/0008-5472.CAN-11-3552; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Landis MD, 2005, ONCOGENE, V24, P5173, DOI 10.1038/sj.onc.1208712; Lin JR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9390; Marusyk A, 2020, CANCER CELL, V37, P471, DOI 10.1016/j.ccell.2020.03.007; Marusyk A, 2016, CANCER RES, V76, P6495, DOI 10.1158/0008-5472.CAN-16-1457; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Pawlikowska P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73632-w; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Qu YD, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0992-4; Runa F, 2017, Curr Mol Biol Rep, V3, P218, DOI 10.1007/s40610-017-0073-7; Seachrist DD, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0857-y; Smith JC, 2008, PHILOS T R SOC B, V363, P1387, DOI 10.1098/rstb.2007.2256; Stoletov K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04743-2; Tchou J, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-39; Wang HW, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0024-3; Wang YC, 2010, P NATL ACAD SCI USA, V107, P10920, DOI 10.1073/pnas.0914776107; Yang ZY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0732-6; Yeh HW, 2019, CANCER RES, V79, P3797, DOI 10.1158/0008-5472.CAN-18-2019; Yuan S, 2019, CANCER DISCOV, V9, P837, DOI 10.1158/2159-8290.CD-19-0015; Zervantonakis IK, 2020, P NATL ACAD SCI USA, V117, P16500, DOI 10.1073/pnas.2000648117; Zheng Y, 2013, NATURE, V499, P166, DOI 10.1038/nature12308; Zijlstra A, 2002, CANCER RES, V62, P7083; Zijlstra A, 2008, CANCER CELL, V13, P221, DOI 10.1016/j.ccr.2008.01.031; Zoeller JJ, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0020-z	46	6	6	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5224	5235		10.1038/s41388-021-01906-2	http://dx.doi.org/10.1038/s41388-021-01906-2		JUL 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34239043	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000670851600002
J	Liebs, S; Eder, T; Klauschen, F; Schutte, M; Yaspo, ML; Keilholz, U; Tinhofer, I; Kidess-Sigal, E; Braunholz, D				Liebs, Sandra; Eder, Theresa; Klauschen, Frederick; Schuette, Moritz; Yaspo, Marie-Laure; Keilholz, Ulrich; Tinhofer, Ingeborg; Kidess-Sigal, Evelyn; Braunholz, Diana			Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; ACQUIRED-RESISTANCE; DNA; HETEROGENEITY; BLOOD; HEAD; METASTASIS; EVOLUTION; BIOMARKER; SURVIVAL	Genetic investigation of tumor heterogeneity and clonal evolution in solid cancers could be assisted by the analysis of liquid biopsies. However, tumors of various entities might release different quantities of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) into the bloodstream, potentially limiting the diagnostic potential of liquid biopsy in distinct tumor histologies. Patients with advanced colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), and melanoma (MEL) were enrolled in the study, representing tumors with different metastatic patterns. Mutation profiles of cfDNA, CTCs, and tumor tissue were assessed by panel sequencing, targeting 327 cancer-related genes. In total, 30 tissue, 18 cfDNA, and 7 CTC samples from 18 patients were sequenced. Best concordance between the mutation profile of tissue and cfDNA was achieved in CRC and MEL, possibly due to the remarkable heterogeneity of HNSCC (63%, 55% and 11%, respectively). Concordance especially depended on the amount of cfDNA used for library preparation. While 21 of 27 (78%) tissue mutations were retrieved in high-input cfDNA samples (30-100 ng, N = 8), only 4 of 65 (6%) could be detected in low-input samples (<30 ng, N = 10). CTCs were detected in 13 of 18 patients (72%). However, downstream analysis was limited by poor DNA quality, allowing targeted sequencing of only seven CTC samples isolated from four patients. Only one CTC sample reflected the mutation profile of the respective tumor. Private mutations, which were detected in CTCs but not in tissue, suggested the presence of rare subclones. Our pilot study demonstrated superiority of cfDNA- compared to CTC-based mutation profiling. It was further shown that CTCs may serve as additional means to detect rare subclones possibly involved in treatment resistance. Both findings require validation in a larger patient cohort.	[Liebs, Sandra; Eder, Theresa; Klauschen, Frederick; Braunholz, Diana] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany; [Liebs, Sandra; Keilholz, Ulrich] Charite Univ Med Berlin, Charite Comprehens Canc Ctr, Berlin, Germany; [Liebs, Sandra; Eder, Theresa; Klauschen, Frederick; Schuette, Moritz; Keilholz, Ulrich; Tinhofer, Ingeborg; Kidess-Sigal, Evelyn; Braunholz, Diana] Free Univ Berlin, Berlin, Germany; [Liebs, Sandra; Eder, Theresa; Klauschen, Frederick; Schuette, Moritz; Keilholz, Ulrich; Tinhofer, Ingeborg; Kidess-Sigal, Evelyn; Braunholz, Diana] Humboldt Univ, Berlin, Germany; [Liebs, Sandra; Eder, Theresa; Klauschen, Frederick; Schuette, Moritz; Keilholz, Ulrich; Tinhofer, Ingeborg; Kidess-Sigal, Evelyn; Braunholz, Diana] Berlin Inst Hlth, Berlin, Germany; [Eder, Theresa; Tinhofer, Ingeborg; Kidess-Sigal, Evelyn; Braunholz, Diana] Charite Univ Med Berlin, Dept Radiooncol & Radiotherapy, Berlin, Germany; [Klauschen, Frederick] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany; [Schuette, Moritz] Alacris Theranost GmbH, Berlin, Germany; [Yaspo, Marie-Laure] Max Planck Inst Mol Genet, Dept Vertebrate Genom, Otto Warburg Lab Gene Regulat & Syst Biol Canc, Berlin, Germany; [Kidess-Sigal, Evelyn] Charite Univ Med Berlin, Dept Med, Div Hepatol & Gastroenterol, Berlin, Germany; [Kidess-Sigal, Evelyn] Berlin Inst Hlth BIH, Berlin, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health	Liebs, S (corresponding author), German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany.; Liebs, S (corresponding author), Charite Univ Med Berlin, Charite Comprehens Canc Ctr, Berlin, Germany.; Liebs, S (corresponding author), Free Univ Berlin, Berlin, Germany.; Liebs, S (corresponding author), Humboldt Univ, Berlin, Germany.; Liebs, S (corresponding author), Berlin Inst Hlth, Berlin, Germany.	sandra.liebs@charite.de	Klauschen, Frederick/C-5637-2015	Klauschen, Frederick/0000-0002-9131-2389; Kidess-Sigal, Evelyn/0000-0002-8590-9699; Liebs, Sandra/0000-0002-7099-0340	Berliner Krebsgesellschaft [BRFF201520]; German Cancer Consortium (DKTK) - National German Health Centers by the Federal German Ministry of Education and Research; Projekt DEAL	Berliner Krebsgesellschaft; German Cancer Consortium (DKTK) - National German Health Centers by the Federal German Ministry of Education and Research; Projekt DEAL	Our analysis was financed by the Berliner Krebsgesellschaft (BRFF201520) and partly supported by the German Cancer Consortium (DKTK), which is funded as one of the National German Health Centers by the Federal German Ministry of Education and Research. Open Access funding enabled and organized by Projekt DEAL.	Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Bhak, COMPREHENSIVE MUTATI, V2019; Castro-Giner F, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00728-3; Cayrefourcq L, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070755; Cohen SJ, 2008, J CLIN ONCOL, V26, P3213, DOI 10.1200/JCO.2007.15.8923; COSMIC, 2004, CAT SOM MUT CANC; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; De Luca F, 2016, ONCOTARGET, V7, P26107, DOI 10.18632/oncotarget.8431; Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011; Eder T, 2019, EUR J CANCER, V116, P67, DOI 10.1016/j.ejca.2019.04.015; Fernandez-Garcia D, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1235-8; Fisher R, 2013, BRIT J CANCER, V108, P479, DOI 10.1038/bjc.2012.581; Freidin MB, 2015, CLIN CHEM, V61, P1299, DOI 10.1373/clinchem.2015.242453; Galot R, 2020, ORAL ONCOL, V104, DOI 10.1016/j.oraloncology.2020.104631; Genna A, 2020, CANCERS, V12, DOI 10.3390/cancers12061632; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gorges K, 2019, CANCERS, V11, DOI 10.3390/cancers11111685; Gray ES, 2015, ONCOTARGET, V6, P42008, DOI 10.18632/oncotarget.5788; Grisanti S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103918; Haber DA, 2014, CANCER DISCOV, V4, P650, DOI 10.1158/2159-8290.CD-13-1014; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hristozova T, 2011, ANN ONCOL, V22, P1878, DOI 10.1093/annonc/mdr130; Hu BG, 2020, CANCER MED-US, V9, P2686, DOI 10.1002/cam4.2871; Institute for Research in Biomedicine, 2018, CANC GEN INT; Khan KH, 2018, CANCER DISCOV, V8, P1270, DOI 10.1158/2159-8290.CD-17-0891; Khoja L, 2013, J INVEST DERMATOL, V133, P1582, DOI 10.1038/jid.2012.468; Kidess E, 2015, ONCOTARGET, V6, P2549, DOI 10.18632/oncotarget.3041; Kidess E, 2013, GENOME MED, V5, DOI 10.1186/gm474; Kuhlmann JD, 2014, CLIN CHEM, V60, P1282, DOI 10.1373/clinchem.2014.224808; Lack J, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1138-3; Lebofsky R, 2015, MOL ONCOL, V9, P783, DOI 10.1016/j.molonc.2014.12.003; Leemans CR, 2018, NAT REV CANCER, V18, P269, DOI 10.1038/nrc.2018.11; Liebs S, 2019, CANCER MED-US, V8, P3761, DOI 10.1002/cam4.2219; Lin SY, 2018, JCO PRECIS ONCOL, V2, P1, DOI 10.1200/PO.17.00225; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Majidpoor J, 2021, MED ONCOL, V38, DOI 10.1007/s12032-020-01447-w; Manier S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04001-5; Martelotto LG, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3658; Mazurek AM, 2016, ORAL ONCOL, V54, P36, DOI 10.1016/j.oraloncology.2015.12.002; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Oellerich M, 2019, THER DRUG MONIT, V41, P115, DOI 10.1097/FTD.0000000000000566; Onidani K, 2019, CANCER SCI, V110, P2590, DOI 10.1111/cas.14092; Pailler E, 2015, ANN ONCOL, V26, P1408, DOI 10.1093/annonc/mdv165; Pestrin M, 2015, MOL ONCOL, V9, P749, DOI 10.1016/j.molonc.2014.12.001; Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4; Salvianti F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049843; Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870; Tamborero D, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0531-8; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Tayoun T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101145; Wang YX, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8507; Yap SA, 2020, BIOTECHNIQUES, V69, P99, DOI 10.2144/btn-2020-0028; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522	54	9	9	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5204	5212		10.1038/s41388-021-01928-w	http://dx.doi.org/10.1038/s41388-021-01928-w		JUL 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34230613	Green Published, hybrid			2022-12-28	WOS:000670148000001
J	Ruan, DY; Li, T; Wang, YN; Meng, Q; Li, Y; Yu, K; Wang, M; Lin, JF; Luo, LZ; Wang, DS; Lin, JZ; Bai, L; Liu, ZX; Zhao, Q; Wu, XY; Ju, HQ; Xu, RH				Ruan, Dan-Yun; Li, Ting; Wang, Ying-Nan; Meng, Qi; Li, Yang; Yu, Kai; Wang, Min; Lin, Jin-Fei; Luo, Li-Zhi; Wang, De-Shen; Lin, Jun-Zhong; Bai, Long; Liu, Ze-Xian; Zhao, Qi; Wu, Xiang-Yuan; Ju, Huai-Qiang; Xu, Rui-Hua			FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis	ONCOGENE			English	Article							CELL-PROLIFERATION; SELF-RENEWAL; RNA; DEMETHYLASE; MTA1; DEGRADATION; EXPRESSION; STABILITY; PROTEIN	Fat mass and obesity-associated protein (FTO), an N6-methyladenosine (m(6)A) demethylase, participates in tumor progression and metastasis in many malignancies, but its role in colorectal cancer (CRC) is still unclear. Here, we found that FTO protein levels, but not RNA levels, were downregulated in CRC tissues. Reduced FTO protein expression was correlated with a high recurrence rate and poor prognosis in resectable CRC patients. Moreover, we demonstrated that hypoxia restrained FTO protein expression, mainly due to an increase in ubiquitin-mediated protein degradation. The serine/threonine kinase receptor associated protein (STRAP) might served as the E3 ligase and K216 was the major ubiquitination site responsible for hypoxia-induced FTO degradation. FTO inhibited CRC metastasis both in vitro and in vivo. Mechanistically, FTO exerted a tumor suppressive role by inhibiting metastasis-associated protein 1 (MTA1) expression in an m(6)A-dependent manner. Methylated MTA1 transcripts were recognized by an m(6)A "reader", insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2), which then stabilized its mRNA. Together, our findings highlight the critical role of FTO in CRC metastasis and reveal a novel epigenetic mechanism by which the hypoxic tumor microenvironment promotes CRC metastasis.	[Ruan, Dan-Yun; Li, Ting; Wang, Ying-Nan; Meng, Qi; Yu, Kai; Wang, Min; Lin, Jin-Fei; Luo, Li-Zhi; Wang, De-Shen; Bai, Long; Liu, Ze-Xian; Zhao, Qi; Ju, Huai-Qiang; Xu, Rui-Hua] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Ruan, Dan-Yun; Li, Yang; Wu, Xiang-Yuan] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Guangdong Key Lab Liver Dis, Guangzhou, Peoples R China; [Wang, Ying-Nan] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China; [Lin, Jun-Zhong] Sun Yat Sen Univ, Canc Ctr, Dept Colorectal Surg, Guangzhou, Peoples R China; [Ju, Huai-Qiang; Xu, Rui-Hua] Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College	Ju, HQ; Xu, RH (corresponding author), Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China.; Ju, HQ; Xu, RH (corresponding author), Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou, Peoples R China.	juhq@sysucc.org.cn; xurh@sysucc.org.cn	xu, rui/GRX-5734-2022; Xu, Rui-Hua/AAW-4766-2021	Xu, Rui-Hua/0000-0001-9771-8534; Yu, Kai/0000-0003-3343-2902	National Natural Science Foundation of China [81930065, 81871951, 82022052, 81903163]; Science and Technology Program of Guangdong [2019B020227002]; Science and Technology Program of Guangzhou [201904020046]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2019-I2M-5-036]; Open Funds of State Key Laboratory of Oncology in South China [KY013712]; Medical Scientific Research Foundation of Guangdong Province [A2021115]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangdong; Science and Technology Program of Guangzhou; CAMS Innovation Fund for Medical Sciences (CIFMS); Open Funds of State Key Laboratory of Oncology in South China; Medical Scientific Research Foundation of Guangdong Province	This research was supported by the National Natural Science Foundation of China (81930065, 81871951, 82022052, 81903163), Science and Technology Program of Guangdong (2019B020227002), Science and Technology Program of Guangzhou (201904020046), CAMS Innovation Fund for Medical Sciences (CIFMS) (2019-I2M-5-036), Open Funds of State Key Laboratory of Oncology in South China (KY013712) and Medical Scientific Research Foundation of Guangdong Province (A2021115).	Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen GF, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00265-z; Chen X, 2013, BIOINFORMATICS, V29, P1614, DOI 10.1093/bioinformatics/btt196; Chen ZH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1178-z; Christensen J, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-274; Cong L, 2011, J BIOL CHEM, V286, P43793, DOI 10.1074/jbc.M111.267237; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0; Deng XL, 2018, CELL RES, V28, P507, DOI 10.1038/s41422-018-0034-6; Fedeles BI, 2015, J BIOL CHEM, V290, P20734, DOI 10.1074/jbc.R115.656462; He LE, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1109-9; Huang H, 2020, CANCER RES, V80, P3200, DOI 10.1158/0008-5472.CAN-19-4044; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Huang Y, 2019, CANCER CELL, V35, P677, DOI 10.1016/j.ccell.2019.03.006; Huff S, 2021, ACS CHEM BIOL, V16, P324, DOI 10.1021/acschembio.0c00841; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Ju HQ, 2019, JNCI-J NATL CANCER I, V111, P584, DOI 10.1093/jnci/djy160; Li DQ, 2009, P NATL ACAD SCI USA, V106, P17493, DOI 10.1073/pnas.0908027106; Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1038-7; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Liu XM, 2020, HEPATOLOGY, V72, P2029, DOI 10.1002/hep.31222; Niu Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1004-4; Ohshiro K, 2010, EMBO REP, V11, P691, DOI 10.1038/embor.2010.99; Peng W, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1408-4; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Rong ZX, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00369; Roundtree IA, 2017, ELIFE, V6, DOI 10.7554/eLife.31311; Toh Y, 2014, CANCER METAST REV, V33, P891, DOI 10.1007/s10555-014-9516-2; Vasaikar S, 2019, CELL, V177, P1035, DOI 10.1016/j.cell.2019.03.030; Wang RA, 2014, CANCER METAST REV, V33, P1001, DOI 10.1007/s10555-014-9525-1; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang YJ, 2021, RNA BIOL, V18, P131, DOI 10.1080/15476286.2020.1804697; Wang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1105-0; Weber CE, 2012, SURG ONCOL, V21, P172, DOI 10.1016/j.suronc.2011.09.001; Wu XY, 2013, NUCLEIC ACIDS RES, V41, P2644, DOI 10.1093/nar/gks1453; Xu KW, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320916024; Xu RH, 2018, LANCET ONCOL, V19, P660, DOI 10.1016/S1470-2045(18)30140-2; Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0; Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422-018-0040-8; Ye S, 2016, FEBS LETT, V590, P1641, DOI 10.1002/1873-3468.12205; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhu TY, 2018, J MOL BIOL, V430, P363, DOI 10.1016/j.jmb.2017.12.003; Zhu W, 2020, J CELL MOL MED, V24, P3521, DOI 10.1111/jcmm.15042; Zhu W, 2012, GUT, V61, P562, DOI 10.1136/gutjnl-2011-300207; Zhuang CS, 2019, J CELL MOL MED, V23, P2163, DOI 10.1111/jcmm.14128; Zou DL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1045-1	48	30	31	5	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5168	5181		10.1038/s41388-021-01916-0	http://dx.doi.org/10.1038/s41388-021-01916-0		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34218271	hybrid, Green Published			2022-12-28	WOS:000669300400001
J	Casillas, AL; Chauhan, SS; Toth, RK; Sainz, AG; Clements, AN; Jensen, CC; Langlais, PR; Miranti, CK; Cress, AE; Warfel, NA				Casillas, Andrea L.; Chauhan, Shailender S.; Toth, Rachel K.; Sainz, Alva G.; Clements, Amber N.; Jensen, Corbin C.; Langlais, Paul R.; Miranti, Cindy K.; Cress, Anne E.; Warfel, Noel A.			Direct phosphorylation and stabilization of HIF-1 alpha by PIM1 kinase drives angiogenesis in solid tumors	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; PROSTATE-CANCER CELLS; TRANSCRIPTION FACTOR; MEDIATES RESISTANCE; GROWTH; THERAPY; VHL; ACTIVATION; EXPRESSION; HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA	Angiogenesis is essential for the sustained growth of solid tumors. Hypoxia-inducible factor 1 (HIF-1) is a master regulator of angiogenesis and constitutive activation of HIF-1 is frequently observed in human cancers. Therefore, understanding the mechanisms governing the activation of HIF-1 is critical for successful therapeutic targeting of tumor angiogenesis. Herein, we establish a new regulatory mechanism responsible for the constitutive activation of HIF-1 alpha in cancer, irrespective of oxygen tension. PIM1 kinase directly phosphorylates HIF-1 alpha at threonine 455, a previously uncharacterized site within its oxygen-dependent degradation domain. This phosphorylation event disrupts the ability of prolyl hydroxylases to bind and hydroxylate HIF-1 alpha, interrupting its canonical degradation pathway and promoting constitutive transcription of HIF-1 target genes. Moreover, phosphorylation of the analogous site in HIF-2 alpha (S435) stabilizes the protein through the same mechanism, indicating post-translational modification within the oxygen-dependent degradation domain as a mechanism of regulating the HIF-alpha subunits. In vitro and in vivo models demonstrate that expression of PIM1 is sufficient to stabilize HIF-1 alpha and HIF-2 alpha in normoxia and stimulate angiogenesis in a HIF-1-dependent manner. CRISPR mutants of HIF-1 alpha (Thr455D) promoted increased tumor growth, proliferation, and angiogenesis. Moreover, HIF-1 alpha-T455D xenograft tumors were refractory to the anti-angiogenic and cytotoxic effects of PIM inhibitors. These data identify a new signaling axis responsible for hypoxia-independent activation of HIF-1 and expand our understanding of the tumorigenic role of PIM1 in solid tumors.	[Casillas, Andrea L.; Clements, Amber N.; Jensen, Corbin C.] Univ Arizona, Canc Biol Grad Interdisciplinary Program, Tucson, AZ USA; [Chauhan, Shailender S.; Toth, Rachel K.; Miranti, Cindy K.; Cress, Anne E.; Warfel, Noel A.] Univ Arizona, Ctr Canc, Tucson, AZ 85724 USA; [Sainz, Alva G.] Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA; [Langlais, Paul R.] Univ Arizona, Dept Med, Tucson, AZ USA; [Miranti, Cindy K.; Cress, Anne E.; Warfel, Noel A.] Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ 85724 USA	University of Arizona; University of Arizona; Salk Institute; University of Arizona; University of Arizona	Warfel, NA (corresponding author), Univ Arizona, Ctr Canc, Tucson, AZ 85724 USA.; Warfel, NA (corresponding author), Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ 85724 USA.	warfelna@arizona.edu	Chauhan, Shailender Singh/AAM-5269-2020	Chauhan, Shailender Singh/0000-0002-1975-2734; Clements, Amber/0000-0002-6883-7558; Toth, Rachel/0000-0001-8897-5045; Warfel, Noel/0000-0001-6410-9011; Cress, Anne/0000-0001-6194-0061; Casillas, Andrea L/0000-0002-2059-3048	National Cancer Institute [T32CA009213]; American Cancer Society [RSG-16-159-01-CDD]; Department of Defense PCRP [W81XWH-19-1-0455]; National Institute of Health [P30CA023074]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Department of Defense PCRP(United States Department of Defense); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We would like to thank the following shared resources at the University of Arizona Cancer Center for their help and support: EMSR, TACMASR, Gene Editing, and Biostatistics. We would also like to thank Dr. Dan Buster for performing in vitro kinase assays and Brenda Baggett and Dr. Marty Pagel for assisting with in vivo imaging. Studies were supported by funding from the National Cancer Institute (T32CA009213) on behalf of ALC, American Cancer Society (RSG-16-159-01-CDD) to NAW, and Department of Defense PCRP (W81XWH-19-1-0455) to NAW. A Cancer Center Support grant from the National Institute of Health (P30CA023074) also supported this research.	Baba Y, 2010, AM J PATHOL, V176, P2292, DOI 10.2353/ajpath.2010.090972; Baldewijns MM, 2010, J PATHOL, V221, P125, DOI 10.1002/path.2689; Bielenberg DR, 2015, CANCER J, V21, P267, DOI 10.1097/PPO.0000000000000138; Braso-Maristany F, 2017, NAT MED, V23, P526, DOI 10.1038/nm0417-526c; Brault L, 2010, HAEMATOL-HEMATOL J, V95, P1004, DOI 10.3324/haematol.2009.017079; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bullen JW, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf0583; Bullock AN, 2005, J BIOL CHEM, V280, P41675, DOI 10.1074/jbc.M510711200; Bushweller JH, 2019, NAT REV CANCER, V19, P611, DOI 10.1038/s41568-019-0196-7; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Cardenas-Rodriguez J, 2013, MAGN RESON IMAGING, V31, P497, DOI 10.1016/j.mri.2012.10.008; Casillas AL, 2018, CLIN CANCER RES, V24, P169, DOI 10.1158/1078-0432.CCR-17-1318; Cen B, 2014, MOL CELL BIOL, V34, P2517, DOI 10.1128/MCB.00147-14; Chauhan SS, 2020, ONCOGENE, V39, P2597, DOI 10.1038/s41388-020-1168-9; Chauhan Shailender S, 2018, Oncoscience, V5, P254, DOI 10.18632/oncoscience.458; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Fallah J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0752-z; Filtz TM, 2014, TRENDS PHARMACOL SCI, V35, P76, DOI 10.1016/j.tips.2013.11.005; Flugel D, 2007, MOL CELL BIOL, V27, P3253, DOI 10.1128/MCB.00015-07; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gao XA, 2019, BREAST CANCER-TOKYO, V26, P663, DOI 10.1007/s12282-019-00966-3; Hammerman PS, 2005, BLOOD, V105, P4477, DOI 10.1182/blood-2004-09-3706; Hartwich J, 2013, J PEDIATR SURG, V48, P39, DOI 10.1016/j.jpedsurg.2012.10.016; Huang CY, 2013, J NUTR BIOCHEM, V24, P1596, DOI 10.1016/j.jnutbio.2013.01.010; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kettenbach AN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001497; Kurmasheva RT, 2006, BRIT J CANCER, V95, P955, DOI 10.1038/sj.bjc.6603353; Lee S, 2007, GYNECOL ONCOL, V106, P311, DOI 10.1016/j.ygyno.2007.03.041; Liu ZJ, 2015, J ZHEJIANG UNIV-SC B, V16, P32, DOI 10.1631/jzus.B1400221; Malone T, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2019.107454; Markou A, 2020, CANCERS, V12, DOI 10.3390/cancers12051188; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Moody SE, 2015, ONCOGENE, V34, P2061, DOI 10.1038/onc.2014.153; Mylonis I, 2006, J BIOL CHEM, V281, P33095, DOI 10.1074/jbc.M605058200; Nawijn MC, 2011, NAT REV CANCER, V11, P23, DOI 10.1038/nrc2986; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Qu YC, 2016, MED SCI MONITOR, V22, P4254, DOI 10.12659/MSM.898223; Rapisarda A, 2002, CANCER RES, V62, P4316; Rebello Richard J., 2018, Advances in Biological Regulation, V67, P163, DOI 10.1016/j.jbior.2017.10.010; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Santio NM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130340; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; TANNOCK IF, 1968, BRIT J CANCER, V22, P258, DOI 10.1038/bjc.1968.34; Tong D, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.74; Wang C, 2013, J SURG RES, V185, P595, DOI 10.1016/j.jss.2013.06.004; Warfel NA, 2016, MOL CANCER THER, V15, P1637, DOI 10.1158/1535-7163.MCT-15-1018; Warfel NA, 2015, PHARMACOL THERAPEUT, V151, P41, DOI 10.1016/j.pharmthera.2015.03.001; Warfel NA, 2013, CELL CYCLE, V12, P3689, DOI 10.4161/cc.26930; Xie Y, 2006, ONCOGENE, V25, P70, DOI 10.1038/sj.onc.1209058; Xu DZ, 2010, J BIOL CHEM, V285, P38944, DOI 10.1074/jbc.M110.160325; Zhang M, 2018, CANCER SCI, V109, P1468, DOI 10.1111/cas.13562; Zhao W, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0998-y; Zhong H, 2000, CANCER RES, V60, P1541	57	3	3	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5142	5152		10.1038/s41388-021-01915-1	http://dx.doi.org/10.1038/s41388-021-01915-1		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34211090	Green Submitted, Green Accepted			2022-12-28	WOS:000668832400001
J	Naso, FD; Boi, D; Ascanelli, C; Pamfil, G; Lindon, C; Paiardini, A; Guarguaglini, G				Naso, Francesco Davide; Boi, Dalila; Ascanelli, Camilla; Pamfil, Georgiana; Lindon, Catherine; Paiardini, Alessandro; Guarguaglini, Giulia			Nuclear localisation of Aurora-A: its regulation and significance for Aurora-A functions in cancer	ONCOGENE			English	Review							SMALL-MOLECULE INHIBITORS; RNA-POLYMERASE-II; N-MYC; BREAST-CANCER; C-MYC; KINASE INHIBITOR; ONCOGENE; IDENTIFICATION; DEGRADATION; EXPRESSION	The Aurora-A kinase regulates cell division, by controlling centrosome biology and spindle assembly. Cancer cells often display elevated levels of the kinase, due to amplification of the gene locus, increased transcription or post-translational modifications. Several inhibitors of Aurora-A activity have been developed as anti-cancer agents and are under evaluation in clinical trials. Although the well-known mitotic roles of Aurora-A point at chromosomal instability, a hallmark of cancer, as a major link between Aurora-A overexpression and disease, recent evidence highlights the existence of non-mitotic functions of potential relevance. Here we focus on a nuclear-localised fraction of Aurora-A with oncogenic roles. Interestingly, this pool would identify not only non-mitotic, but also kinase-independent functions of the kinase. We review existing data in the literature and databases, examining potential links between Aurora-A stabilisation and localisation, and discuss them in the perspective of a more effective targeting of Aurora-A in cancer therapy.	[Naso, Francesco Davide; Pamfil, Georgiana; Guarguaglini, Giulia] Sapienza Univ Rome, Inst Mol Biol & Pathol, Natl Res Council Italy, Rome, Italy; [Boi, Dalila; Paiardini, Alessandro] Sapienza Univ Rome, Dept Biochem Sci, Rome, Italy; [Ascanelli, Camilla; Lindon, Catherine] Univ Cambridge, Dept Pharmacol, Cambridge, England	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Sapienza University Rome; University of Cambridge	Guarguaglini, G (corresponding author), Sapienza Univ Rome, Inst Mol Biol & Pathol, Natl Res Council Italy, Rome, Italy.; Paiardini, A (corresponding author), Sapienza Univ Rome, Dept Biochem Sci, Rome, Italy.; Lindon, C (corresponding author), Univ Cambridge, Dept Pharmacol, Cambridge, England.	acl34@cam.ac.uk; alessandro.paiardini@uniroma1.it; giulia.guarguaglini@uniroma1.it		Paiardini, Alessandro/0000-0001-9078-7545; Lindon, Catherine/0000-0003-3554-2574; Ascanelli, Camilla/0000-0002-6266-2822	Royal Society International Exchanges grant [IES\R3\170195]; BBSRC [BB/R004137/1]; AstraZeneca Ph.D. studentship; Associazione Italiana Ricerca sul Cancro (AIRC MFAG) [20447]	Royal Society International Exchanges grant; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); AstraZeneca Ph.D. studentship(AstraZeneca); Associazione Italiana Ricerca sul Cancro (AIRC MFAG)(Fondazione AIRC per la ricerca sul cancro)	We thank people from the Guarguaglini, Paiardini and Lindon labs for insightful discussions. This work was made possible by a Royal Society International Exchanges grant (IES\R3\170195) to CL and GG. Work in CL's lab is funded by BBSRC (BB/R004137/1) and CA is a recipient of an AstraZeneca Ph.D. studentship. AP is funded by Associazione Italiana Ricerca sul Cancro (AIRC MFAG id. 20447).	Adhikari B, 2020, NAT CHEM BIOL, V16, P1179, DOI 10.1038/s41589-020-00652-y; Albihn A, 2010, ADV CANCER RES, V107, P163, DOI 10.1016/S0065-230X(10)07006-5; Almeida EG, 2020, NUCLEIC ACIDS RES, V48, P7844, DOI 10.1093/nar/gkaa570; Amin M, 2016, INVEST NEW DRUG, V34, P84, DOI 10.1007/s10637-015-0306-7; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Anastassiadis T, 2011, NAT BIOTECHNOL, V29, P1039, DOI 10.1038/nbt.2017; Puig-Butille JA, 2017, J INVEST DERMATOL, V137, P1297, DOI 10.1016/j.jid.2017.01.021; Aradottir M, 2015, J PATHOL CLIN RES, V1, P33, DOI 10.1002/cjp2.6; Asteriti IA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00283; Asteriti IA, 2017, ONCOTARGET, V8, P32117, DOI 10.18632/oncotarget.16738; Asteriti IA, 2014, ONCOTARGET, V5, P6229, DOI 10.18632/oncotarget.2190; Asteriti IA, 2010, BBA-REV CANCER, V1806, P230, DOI 10.1016/j.bbcan.2010.08.001; Bamborough P, 2008, J MED CHEM, V51, P7898, DOI 10.1021/jm8011036; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; Bavetsias V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00278; Bertolin G, 2020, CELL MOL LIFE SCI, V77, P1031, DOI 10.1007/s00018-019-03310-2; Bertolin G, 2018, ELIFE, V7, DOI 10.7554/eLife.38111; Bibby RA, 2009, J BIOL CHEM, V284, P33177, DOI 10.1074/jbc.M109.032722; Bondeson DP, 2018, CELL CHEM BIOL, V25, P78, DOI 10.1016/j.chembiol.2017.09.010; Brockmann M, 2013, CANCER CELL, V24, P75, DOI 10.1016/j.ccr.2013.05.005; Buchel G, 2017, CELL REP, V21, P3483, DOI 10.1016/j.celrep.2017.11.090; Burgess SG, 2018, EMBO J, V37, DOI 10.15252/embj.201797902; Burgess SG, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160089; Byrum AK, 2019, J CELL BIOL, V218, P422, DOI 10.1083/jcb.201803003; D'Assoro AB, 2014, ONCOGENE, V33, P599, DOI 10.1038/onc.2012.628; Dai Q, 2004, CANCER EPIDEM BIOMAR, V13, P2065; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dauch D, 2016, NAT MED, V22, P744, DOI 10.1038/nm.4107; de Groot CO, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00285; den Hollander J, 2010, BLOOD, V116, P1498, DOI 10.1182/blood-2009-11-251074; Ding X, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00045; Donovan KA, 2020, CELL, V183, P1714, DOI 10.1016/j.cell.2020.10.038; dos Santos EO, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0494-6; Du J, 2019, MOL CANCER THER, V18, P2207, DOI 10.1158/1535-7163.MCT-18-0529; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Garcia-Escudero R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-193; Garrido G, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00088; Gomes SM, 2020, CELL ONCOL, V43, P445, DOI 10.1007/s13402-020-00498-5; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grant R, 2018, OPEN BIOL, V8, DOI [10.1098/rsob.170272, DOI 10.1098/RSOB.170272]; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Gustafson WC, 2014, CANCER CELL, V26, P414, DOI 10.1016/j.ccr.2014.07.015; Hasanov E, 2017, ONCOGENE, V36, P3450, DOI 10.1038/onc.2016.495; Hegde AM., 2015, INVESTIGATING INTERA, P625; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hsueh KW, 2011, FEBS LETT, V585, P2671, DOI 10.1016/j.febslet.2011.07.031; Inamdar KV, 2008, MODERN PATHOL, V21, P1428, DOI 10.1038/modpathol.2008.173; Janecek M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28528; Joukov V, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aar4195; Kitajima S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000944; Kongsema M, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.57; Konstantinidou M, 2019, EXPERT OPIN DRUG DIS, V14, P1255, DOI 10.1080/17460441.2019.1659242; Kwon YW, 2012, MOL CANCER RES, V10, P834, DOI 10.1158/1541-7786.MCR-12-0025; Lake EW, 2018, P NATL ACAD SCI USA, V115, pE11894, DOI 10.1073/pnas.1811158115; Lassus H, 2011, GYNECOL ONCOL, V120, P11, DOI 10.1016/j.ygyno.2010.09.003; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Levens David, 2010, Genes Cancer, V1, P547; Liao GB, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0266-6; Lin XR, 2020, AM J CANCER RES, V10, P2705; Liu X, 2016, ONCOTARGET, V7, P33152, DOI 10.18632/oncotarget.8888; Magnaghi-Jaulin L, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9010028; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Meyer HJ, 2014, CELL, V157, P910, DOI 10.1016/j.cell.2014.03.037; Mikhaylova O, 2008, MOL CELL BIOL, V28, P2701, DOI 10.1128/MCB.01231-07; Morrish F, 2008, CELL CYCLE, V7, P1054, DOI 10.4161/cc.7.8.5739; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Piskacek S, 2007, GENOMICS, V89, P756, DOI 10.1016/j.ygeno.2007.02.003; Rannou Y, 2008, CELL CYCLE, V7, P3012, DOI 10.4161/cc.7.19.6718; Richards MW, 2016, P NATL ACAD SCI USA, V113, P13726, DOI 10.1073/pnas.1610626113; Roeschert I, 2021, NAT CANCER, V2, P312, DOI 10.1038/s43018-020-00171-8; Santoro A, 2019, CELL REP, V26, P624, DOI 10.1016/j.celrep.2018.12.071; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Schwab M, 2004, CANCER LETT, V204, P179, DOI 10.1016/S0304-3835(03)00454-3; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Sillars-Hardebol AH, 2010, TUMOR BIOL, V31, P89, DOI 10.1007/s13277-009-0012-1; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Sun HZ, 2014, BBA-MOL CELL RES, V1843, P934, DOI 10.1016/j.bbamcr.2014.01.019; Takahashi Y, 2015, ANN ONCOL, V26, P935, DOI 10.1093/annonc/mdv034; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Tatsuka M, 2009, MOL CARCINOGEN, V48, P810, DOI 10.1002/mc.20525; Tayyar Y, 2017, CRIT REV ONCOL HEMAT, V119, P59, DOI 10.1016/j.critrevonc.2017.09.006; Thul PJ, 2017, SCIENCE, V356, DOI 10.1126/science.aal3321; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Wang R, 2020, BIORXIV, V2; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Willems E, 2018, CELL DIV, V13, DOI 10.1186/s13008-018-0040-6; Yan M, 2016, MED RES REV, V36, P1036, DOI 10.1002/med.21399; Yan VC, 2020, TRENDS CANCER, V6, P924, DOI 10.1016/j.trecan.2020.05.010; Yang G, 2013, INT J CANCER, V133, P275, DOI 10.1002/ijc.28032; Yang N, 2017, ONCOGENE, V36, P3428, DOI 10.1038/onc.2016.490; Yang N, 2019, J CELL MOL MED, V23, P6442, DOI 10.1111/jcmm.14538; Yau R, 2016, NAT CELL BIOL, V18, P579, DOI 10.1038/ncb3358; Yoshida GJ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0835-y; Zheng FM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10180; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	99	6	6	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					3917	3928		10.1038/s41388-021-01766-w	http://dx.doi.org/10.1038/s41388-021-01766-w		MAY 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	33981003	hybrid, Green Published			2022-12-28	WOS:000650165600001
J	Kamada, S; Namekawa, T; Ikeda, K; Suzuki, T; Kagawa, M; Takeshita, H; Yano, A; Okamoto, K; Ichikawa, T; Horie-Inoue, K; Kawakami, S; Inoue, S				Kamada, Shuhei; Namekawa, Takeshi; Ikeda, Kazuhiro; Suzuki, Takashi; Kagawa, Makoto; Takeshita, Hideki; Yano, Akihiro; Okamoto, Koji; Ichikawa, Tomohiko; Horie-Inoue, Kuniko; Kawakami, Satoru; Inoue, Satoshi			Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma	ONCOGENE			English	Article							HORMONE-RELATED PROTEIN; HUMORAL HYPERCALCEMIA; SUNITINIB RESISTANCE; GENE-EXPRESSION; RETINOIC ACID; IN-VITRO; ANTIBODY; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION	Tyrosine kinase inhibitors (TKIs) are used as targeted drugs for advanced renal cell carcinoma (RCC), although most cases eventually progress by acquiring resistance. Cancer stemness plays critical roles in tumor aggressiveness and therapeutic resistance, and dipeptidyl peptidase IV (DPP4) has been recently identified as a cancer stemness-related protein. A question arises whether DPP4 contributes to TKI efficacy in RCC. We established patient-derived RCC spheroids and showed that DPP4 expression is associated with stemness-related gene expression. TKI sunitinib resistance was rescued by DPP4 inhibition using sitagliptin or specific siRNAs in RCC cells and tumors. DPP4 expression can be inducible by retinoic acid and repressed by ALDH1A inhibition. Among type 2 diabetes patients with clinical RCC tumors, higher TKI efficacy is observed in those bearing DPP4(high) tumors treated with DPP4 inhibitors. This study provides new insights into TKI resistance and drug repositioning of DPP4 inhibitor as a promising strategy for advanced RCC.	[Kamada, Shuhei; Namekawa, Takeshi; Ikeda, Kazuhiro; Horie-Inoue, Kuniko; Inoue, Satoshi] Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan; [Kamada, Shuhei; Namekawa, Takeshi; Ichikawa, Tomohiko] Chiba Univ, Grad Sch Med, Dept Urol, Chiba, Japan; [Suzuki, Takashi] Tohoku Univ, Grad Sch Med, Dept Pathol & Histotechnol, Sendai, Miyagi, Japan; [Kagawa, Makoto; Takeshita, Hideki; Yano, Akihiro; Kawakami, Satoru] Saitama Med Univ, Dept Urol, Saitama Med Ctr, Saitama, Japan; [Okamoto, Koji] Natl Canc Ctr, Res Inst, Div Canc Differentiat, Tokyo, Japan; [Inoue, Satoshi] Tokyo Metropolitan Inst Gerontol, Dept Syst Aging Sci & Med, Tokyo, Japan	Saitama Medical University; Chiba University; Tohoku University; Saitama Medical University; National Cancer Center - Japan; Tokyo Metropolitan Institute of Gerontology	Inoue, S (corresponding author), Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan.; Inoue, S (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Syst Aging Sci & Med, Tokyo, Japan.	sinoue@tmig.or.jp	TAKESHITA, Hideki/AFN-5038-2022	TAKESHITA, Hideki/0000-0002-1512-6904; Ichikawa, Tomohiko/0000-0002-8637-4163; Kagawa, Makoto/0000-0002-4294-438X; Suzuki, Takashi/0000-0003-0195-815X; Kamada, Shuhei/0000-0002-9024-0176	Support Project of Strategic Research Center in Private Universities from the MEXT; Practical Research for Innovative Cancer Control [JP18ck0106194]; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from Japan Agency for Medical Research and Development (AMED) [JP18cm0106144]; Japan Society for the Promotion of Science [15K15353, 20K21667, 17H04205]; Vehicle Racing Commemorative Foundation	Support Project of Strategic Research Center in Private Universities from the MEXT; Practical Research for Innovative Cancer Control; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Vehicle Racing Commemorative Foundation	We thank S. Kitayama, W. Sato, S. Shiba, Y. Okada, and S. Aoki for their technical support and valuable comments. This study was supported by the Support Project of Strategic Research Center in Private Universities from the MEXT (to SI), the Practical Research for Innovative Cancer Control (JP18ck0106194 to KI) and the Project for Cancer Research and Therapeutic Evolution (P-CREATE, JP18cm0106144 to SI) from Japan Agency for Medical Research and Development (AMED), and grants from the Japan Society for the Promotion of Science (15K15353 and 20K21667 to SI, and 17H04205 to K-HI) and the Vehicle Racing Commemorative Foundation (to K-HI).	Adelaiye-Ogala R, 2017, CANCER RES, V77, P6651, DOI 10.1158/0008-5472.CAN-17-0899; Angevin E, 2017, BRIT J CANCER, V116, P1126, DOI 10.1038/bjc.2017.62; Bauvois B, 2000, ONCOGENE, V19, P265, DOI 10.1038/sj.onc.1203292; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; BULENS F, 1995, J BIOL CHEM, V270, P7167, DOI 10.1074/jbc.270.13.7167; Christopherson KW, 2002, J IMMUNOL, V169, P7000, DOI 10.4049/jimmunol.169.12.7000; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Corro C, 2018, J PATHOL CLIN RES, V4, P3, DOI 10.1002/cjp2.91; da Silva RB, 2015, NAT IMMUNOL, V16, P850, DOI 10.1038/ni.3201; Decalf J, 2016, EMBO MOL MED, V8, P679, DOI 10.15252/emmm.201506145; Diaz-Montero CM, 2016, BRIT J CANCER, V115, P920, DOI 10.1038/bjc.2016.263; Dong, 2017, NAT COMMUN, V8; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Enz N, 2019, PHARMACOL THERAPEUT, V198, P135, DOI 10.1016/j.pharmthera.2019.02.015; FAHN HJ, 1991, J UROLOGY, V145, P248, DOI 10.1016/S0022-5347(17)38305-2; Fendler A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14700-7; Ghani FI, 2011, BIOCHEM BIOPH RES CO, V404, P735, DOI 10.1016/j.bbrc.2010.12.054; Ghatalia P, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0458-0; Guo FJ, 2014, CELL SIGNAL, V26, P1998, DOI 10.1016/j.cellsig.2014.05.008; Hatipoglu G, 2015, CANCER SCI, V106, P160, DOI 10.1111/cas.12580; Holst JJ, 2009, MOL CELL ENDOCRINOL, V297, P127, DOI 10.1016/j.mce.2008.08.012; Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Inamoto T, 2006, CLIN CANCER RES, V12, P3470, DOI 10.1158/1078-0432.CCR-06-0361; Ishibashi K, 2017, ONCOTARGET, V8, P55230, DOI 10.18632/oncotarget.19420; Ishiguro T, 2016, CANCER RES, V76, P150, DOI 10.1158/0008-5472.CAN-15-0361; Joeckel E, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-42; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Larrinaga G, 2012, AM J PHYSIOL-RENAL, V303, pF1584, DOI 10.1152/ajprenal.00477.2012; Long Z, 2017, FREE RADICAL BIO MED, V113, P71, DOI 10.1016/j.freeradbiomed.2017.09.016; Luo L, 2019, ONCOL LETT, V18, P1442, DOI 10.3892/ol.2019.10442; Makhov P, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0388-1; Mehta RJ, 2012, BREAST CANCER RES TR, V131, P881, DOI 10.1007/s10549-011-1482-6; Miyake M, 2012, ONCOL LETT, V3, P1195, DOI 10.3892/ol.2012.662; Namekawa T, 2020, INT J CANCER, V146, P1099, DOI 10.1002/ijc.32505; Oguro T, 2013, EUR J CANCER, V49, P1715, DOI 10.1016/j.ejca.2012.11.038; Onuma E, 2005, CLIN CANCER RES, V11, P4198, DOI 10.1158/1078-0432.CCR-04-2531; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Papworth K, 2005, TUMOR BIOL, V26, P201, DOI 10.1159/000086953; Pinheiro MM, 2017, EUR J PHARM SCI, V100, P17, DOI 10.1016/j.ejps.2016.12.040; Pujadas G, 2017, ENDOCRINE, V56, P509, DOI 10.1007/s12020-016-1052-0; Qin CJ, 2018, CANCER LETT, V420, P26, DOI 10.1016/j.canlet.2018.01.064; Rohrborn D, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00386; Sakai I, 2013, BJU INT, V112, pE211, DOI 10.1111/j.1464-410X.2012.11655.x; Shiba S, 2019, ENDOCRINOLOGY, V160, P1895, DOI 10.1210/en.2019-00362; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Stany MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021121; Sun CK, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt181; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Varna M, 2015, CLIN CANCER RES, V21, P916, DOI 10.1158/1078-0432.CCR-14-0666; Varona A, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-193; Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315; Wronkowitz N, 2014, BBA-MOL BASIS DIS, V1842, P1613, DOI 10.1016/j.bbadis.2014.06.004; Xin H, 2009, CANCER RES, V69, P2506, DOI 10.1158/0008-5472.CAN-08-4323; Xu J, 2018, LAB INVEST, V98, P1333, DOI 10.1038/s41374-018-0080-1	55	8	8	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3899	3913		10.1038/s41388-021-01822-5	http://dx.doi.org/10.1038/s41388-021-01822-5		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33972682				2022-12-28	WOS:000648930100005
J	Wang, F; Liao, Y; Zhang, M; Zhu, Y; Wang, WJ; Cai, HS; Liang, JF; Song, F; Hou, C; Huang, SJ; Zhang, YD; Wang, C; Hou, JS				Wang, Fang; Liao, Yan; Zhang, Ming; Zhu, Yue; Wang, Wenjin; Cai, Hongshi; Liang, Jianfeng; Song, Fan; Hou, Chen; Huang, Shuojin; Zhang, Yadong; Wang, Cheng; Hou, Jinsong			N6-methyladenosine demethyltransferase FTO-mediated autophagy in malignant development of oral squamous cell carcinoma	ONCOGENE			English	Article							METHYLTRANSFERASE METTL3 PROMOTES; DECREASED EXPRESSION; CANCER; RNA; TRANSLATION; METHYLATION; TUMORIGENESIS; PROGRESSION; MTOR; PROLIFERATION	N6-methyladenosine (m(6)A) is the most abundant internal mRNA modification in eukaryotes and plays an important role in tumorigenesis. However, the underlying mechanism remains largely unclear. Here, we established a cell model of rapamycin-induced autophagy to screen m(6)A-modifying enzymes. We found that m(6)A demethylase fat mass and obesity-associated protein (FTO) plays a key role in regulating autophagy and tumorigenesis by targeting the gene encoding eukaryotic translation initiation factor gamma 1 (eIF4G1) in oral squamous cell carcinoma (OSCC). Knocked down of FTO expression in OSCC cell lines, resulting in downregulation of eIF4G1 along with enhanced autophagic flux and inhibition of tumorigenesis. Rapamycin inhibited FTO activity, and directly targeted eIF4G1 transcripts and mediated their expression in an m(6)A-dependent manner. Dual-luciferase reporter and mutagenesis assays confirmed that YTH N6-methyladenosine RNA-binding protein 2 (YTHDF2) targets eIF4G1. Conclusively, after FTO silencing, YTHDF2 captured eIF4G1 transcripts containing m(6)A, resulting in mRNA degradation and decreased expression of eIF4G1 protein, thereby promoting autophagy and reducing tumor occurrence. Therefore, rapamycin may regulate m(6)A levels, determining the autophagic flux of OSCC, thereby affecting the biological characteristics of cancer cells. This insight expands our understanding of the crosstalk between autophagy and RNA methylation in tumorigenesis, which is essential for therapeutic strategy development for OSCC.	[Wang, Fang; Liao, Yan; Zhang, Ming; Zhu, Yue; Wang, Wenjin; Cai, Hongshi; Liang, Jianfeng; Song, Fan; Hou, Chen; Huang, Shuojin; Zhang, Yadong; Wang, Cheng; Hou, Jinsong] Sun Yat Sen Univ, Hosp Stomatol, Dept Oral & Maxillofacial Surg, Guanghua Sch Stomatol, Guangzhou, Peoples R China; [Wang, Fang; Liao, Yan; Zhang, Ming; Zhu, Yue; Wang, Wenjin; Cai, Hongshi; Liang, Jianfeng; Song, Fan; Hou, Chen; Huang, Shuojin; Zhang, Yadong; Wang, Cheng; Hou, Jinsong] Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Wang, C; Hou, JS (corresponding author), Sun Yat Sen Univ, Hosp Stomatol, Dept Oral & Maxillofacial Surg, Guanghua Sch Stomatol, Guangzhou, Peoples R China.; Wang, C; Hou, JS (corresponding author), Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China.	wangch75@mail.sysu.edu.cn; houjs@mail.sysu.edu.cn	wang, fang/GYD-4295-2022		National Natural Science Foundation of China [81874128, 82072994]; Sun Yat-sen University Clinical Research 5010 Program [2015018]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sun Yat-sen University Clinical Research 5010 Program	This work was supported by the National Natural Science Foundation of China (Grant Nos. 81874128 and 82072994); Sun Yat-sen University Clinical Research 5010 Program (Grant No. 2015018).	Braunstein S, 2007, MOL CELL, V28, P501, DOI 10.1016/j.molcel.2007.10.019; Caccamo A, 2010, J BIOL CHEM, V285, P13107, DOI 10.1074/jbc.M110.100420; Cai HS, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01446; Cai XL, 2018, CANCER LETT, V415, P11, DOI 10.1016/j.canlet.2017.11.018; Cao YY, 2016, ONCOTARGET, V7, P24242, DOI 10.18632/oncotarget.8168; Chen GH, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8480762; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; Chen YB, 2012, J SURG ONCOL, V105, P542, DOI 10.1002/jso.22151; Cheung MK, 2013, INT J OBESITY, V37, P744, DOI 10.1038/ijo.2012.77; Comtesse N, 2007, INT J CANCER, V120, P2538, DOI 10.1002/ijc.22585; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Day TA, 2019, CLIN CANCER RES, V25, P1156, DOI 10.1158/1078-0432.CCR-18-2024; Dell'Anno I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144856; Diao PF, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1742-x; Fang WY, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-32; Fang YJ, 2020, ONCOTARGETS THER, V13, P10431, DOI 10.2147/OTT.S266389; Fatscher T, 2014, RNA, V20, P1579, DOI 10.1261/rna.044933.114; Gassen NC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13659-4; Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049; Gulati P, 2013, P NATL ACAD SCI USA, V110, P2557, DOI 10.1073/pnas.1222796110; Hale CM, 2016, AUTOPHAGY, V12, P713, DOI 10.1080/15548627.2016.1147669; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ho AS, 2017, J CLIN ONCOL, V35, P3601, DOI 10.1200/JCO.2016.71.1176; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jacob JA, 2017, CLIN CHIM ACTA, V468, P85, DOI 10.1016/j.cca.2017.01.028; Jaiswal PK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0947-2; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Jin SH, 2018, CELL RES, V28, P955, DOI 10.1038/s41422-018-0069-8; Kademani D, 2008, J ORAL MAXIL SURG, V66, P2151, DOI 10.1016/j.joms.2008.06.030; Kao YY, 2019, CANCER LETT, V456, P40, DOI 10.1016/j.canlet.2019.04.028; Ke SD, 2015, GENE DEV, V29, P2037, DOI 10.1101/gad.269415.115; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Li JF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01267-6; Li Y, 2019, DIGEST DIS SCI, V64, P1503, DOI 10.1007/s10620-018-5452-2; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Lin XY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09865-9; Liu L, 2017, ONCOGENE, V36, P5874, DOI 10.1038/onc.2017.193; Liu L, 2020, MOL THER, V28, P2177, DOI 10.1016/j.ymthe.2020.06.024; Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333; Mupparapu Mel, 2018, Dent Clin North Am, V62, P47, DOI 10.1016/j.cden.2017.08.003; Parihar M, 2021, CLIN COLORECTAL CANC, V20, pE61, DOI 10.1016/j.clcc.2020.08.006; Park EH, 2011, EMBO J, V30, P302, DOI 10.1038/emboj.2010.312; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Ramirez-Valle F, 2008, J CELL BIOL, V181, P293, DOI 10.1083/jcb.200710215; Rao SVK, 2013, ASIAN PAC J CANCER P, V14, P5567, DOI 10.7314/APJCP.2013.14.10.5567; Schaefer L, 2017, FEBS J, V284, P10, DOI 10.1111/febs.13963; Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827; Stolz A, 2014, NAT CELL BIOL, V16, P495, DOI 10.1038/ncb2979; Towers CG, 2016, EBIOMEDICINE, V14, P15, DOI 10.1016/j.ebiom.2016.10.034; Tu LX, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-78; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wang XX, 2020, AUTOPHAGY, V16, P1221, DOI 10.1080/15548627.2019.1659617; Weng JQ, 2014, ORAL ONCOL, V50, P983, DOI 10.1016/j.oraloncology.2014.06.020; Won KY, 2010, HUM PATHOL, V41, P107, DOI 10.1016/j.humpath.2009.07.006; Xia Q, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.572904; Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0; Yonekawa T, 2013, ESSAYS BIOCHEM, V55, P105, DOI [10.1042/BSE0550105, 10.1042/bse0550105]; Zanoni DK, 2019, ORAL ONCOL, V90, P115, DOI 10.1016/j.oraloncology.2019.02.001; Zhao W, 2020, MOL THER-NUCL ACIDS, V19, P405, DOI 10.1016/j.omtn.2019.11.022; Zhao Z, 2016, AM J CANCER RES, V6, P2162; Zhou J, 2015, NATURE, V526, P591, DOI 10.1038/nature15377; Zhu X, 2020, ONCOTARGETS THER, V13, P10515, DOI 10.2147/OTT.S266095	66	22	23	3	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3885	3898		10.1038/s41388-021-01820-7	http://dx.doi.org/10.1038/s41388-021-01820-7		MAY 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33972683				2022-12-28	WOS:000648930100003
J	Lei, G; Zhang, YL; Hong, T; Zhang, XD; Liu, XG; Mao, C; Yan, YL; Koppula, P; Cheng, WJ; Sood, AK; Liu, JS; Gan, BY				Lei, Guang; Zhang, Yilei; Hong, Ting; Zhang, Xudong; Liu, Xiaoguang; Mao, Chao; Yan, Yuelong; Koppula, Pranavi; Cheng, Weijie; Sood, Anil K.; Liu, Jinsong; Gan, Boyi			Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity	ONCOGENE			English	Article								Ferroptosis, a form of regulated cell death triggered by lipid peroxidation, was recently identified as an important mechanism in radiotherapy (RT)-mediated tumor suppression and radioresistance, although the exact genetic contexts in which to target ferroptosis in RT remains to be defined. p53 is the most commonly mutated gene in human cancers and a major effector to RT. Here, we identify ferroptosis as a critical mechanism to mediate p53 function in tumor radiosensitivity. Mechanistically, RT-mediated p53 activation antagonizes RT-induced SLC7A11 expression and represses glutathione synthesis, thereby promoting RT-induced lipid peroxidation and ferroptosis. p53 deficiency promotes radioresistance in cancer cells or tumors at least partly through SLC7A11-mediated ferroptosis inhibition. Ferroptosis inducers (FINs) that inhibit SLC7A11 exert significant radiosensitizing effects in tumor organoids and patient-derived xenografts with p53 mutation or deficiency. Finally, we show that RT-induced ferroptosis correlates with p53 activation and better clinical outcomes to RT in cancer patients. Together, our study uncovers a previously unappreciated role of ferroptosis in p53-mediated radiosensitization and suggest using FINs in combination with RT to treat p53-mutant cancers.	[Lei, Guang; Zhang, Yilei; Liu, Xiaoguang; Mao, Chao; Yan, Yuelong; Koppula, Pranavi; Cheng, Weijie; Gan, Boyi] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Hong, Ting; Zhang, Xudong; Liu, Jinsong] Univ Texas MD Anderson Canc Ctr, Dept Anat Pathol, Houston, TX 77030 USA; [Koppula, Pranavi; Gan, Boyi] Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA; [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Gan, BY (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.; Gan, BY (corresponding author), Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA.	bgan@mdanderson.org	Gan, Boyi/HDM-4206-2022; Koppula, Pranavi/P-7226-2019; Zhang, Yilei/I-8997-2014; Sood, Anoop Kumar/A-7344-2013	Koppula, Pranavi/0000-0002-7567-1891; Zhang, Yilei/0000-0003-1407-0301; Sood, Anoop Kumar/0000-0001-5702-4108; LIU, XIAOGUANG/0000-0001-6977-5128; Yan, Yuelong/0000-0001-8495-6445; Lei, Guang/0000-0002-3282-0666; Gan, Boyi/0000-0001-8884-6040; Sood, Anil/0000-0003-4242-1762; ZHANG, XUDONG/0000-0003-1896-4898; , chao/0000-0002-8685-8539	Institutional Research Fund from The University of Texas MD Anderson Cancer Center; RO Strategic Initiatives (ROSI) Boot Walk Seed Award from The University of Texas MD Anderson Cancer Center; Department of Defense Kidney Cancer Research Program [KC180131]; National Institutes of Health [R01CA181196, R01CA244144, R01CA247992]; American Cancer Society [P50 CA217685]; MD Anderson Moon Shot Program in Ovarian Cancer; CPRIT Research Training Grant [RP170067]; University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences; National Institutes of Health Cancer Center Support Grant [P30CA016672]	Institutional Research Fund from The University of Texas MD Anderson Cancer Center; RO Strategic Initiatives (ROSI) Boot Walk Seed Award from The University of Texas MD Anderson Cancer Center; Department of Defense Kidney Cancer Research Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); MD Anderson Moon Shot Program in Ovarian Cancer; CPRIT Research Training Grant; University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences; National Institutes of Health Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research was supported by Institutional Research Fund and RO Strategic Initiatives (ROSI) Boot Walk Seed Award from The University of Texas MD Anderson Cancer Center, KC180131 from Department of Defense Kidney Cancer Research Program, and R01CA181196, R01CA244144, and R01CA247992 from the National Institutes of Health (to BG); P50 CA217685, American Cancer Society, and MD Anderson Moon Shot Program in Ovarian Cancer (to AKS). BG was an Andrew Sabin Family Fellow. PK is supported by CPRIT Research Training Grant (RP170067) and Dr. John J. Kopchick Research Award from The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. This research has also been supported by the National Institutes of Health Cancer Center Support Grant P30CA016672 to The University of Texas MD Anderson Cancer Center.	Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012; Baidoo KE, 2013, CLIN CANCER RES, V19, P530, DOI 10.1158/1078-0432.CCR-12-0298; Bykov VJN, 2018, NAT REV CANCER, V18, P89, DOI 10.1038/nrc.2017.109; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chu B, 2019, NAT CELL BIOL, V21, P579, DOI 10.1038/s41556-019-0305-6; Conrad M, 2012, AMINO ACIDS, V42, P231, DOI 10.1007/s00726-011-0867-5; Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Drost J, 2018, NAT REV CANCER, V18, P407, DOI 10.1038/s41568-018-0007-6; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Feng H, 2020, CELL REP, V30, P3411, DOI 10.1016/j.celrep.2020.02.049; Gan BY, 2019, CANCER RES, V79, P1749, DOI 10.1158/0008-5472.CAN-19-0487; Gao MH, 2019, MOL CELL, V73, P354, DOI 10.1016/j.molcel.2018.10.042; Gout PW, 2001, LEUKEMIA, V15, P1633, DOI 10.1038/sj.leu.2402238; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Jaffray DA, 2012, NAT REV CLIN ONCOL, V9, P688, DOI 10.1038/nrclinonc.2012.194; Jennis M, 2016, GENE DEV, V30, P918, DOI 10.1101/gad.275891.115; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Kopper O, 2019, NAT MED, V25, P838, DOI 10.1038/s41591-019-0422-6; Koppula P, 2021, PROTEIN CELL, V12, P599, DOI 10.1007/s13238-020-00789-5; Koppula P, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0288-x; Lang XT, 2019, CANCER DISCOV, V9, P1673, DOI 10.1158/2159-8290.CD-19-0338; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Lei G, 2020, CELL RES, V30, P146, DOI 10.1038/s41422-019-0263-3; Leu JIJ, 2019, P NATL ACAD SCI USA, V116, P8390, DOI 10.1073/pnas.1821277116; Li M, 2019, NEW ENGL J MED, V380, P569, DOI 10.1056/NEJMra1806175; Lin AF, 2014, CANCER RES, V74, P1682, DOI 10.1158/0008-5472.CAN-13-1729; Liu T, 2019, CANCER RES, V79, P1913, DOI 10.1158/0008-5472.CAN-18-3037; Liu XG, 2021, GENES DIS, V8, P731, DOI 10.1016/j.gendis.2020.11.010; Liu XG, 2020, NAT CELL BIOL, V22, DOI 10.1038/s41556-020-0496-x; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Ou Y, 2016, P NATL ACAD SCI USA, V113, pE6806, DOI 10.1073/pnas.1607152113; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Seibt TM, 2019, FREE RADICAL BIO MED, V133, P144, DOI 10.1016/j.freeradbiomed.2018.09.014; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Tarangelo A, 2018, CELL REP, V22, P569, DOI 10.1016/j.celrep.2017.12.077; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang LY, 2020, CELL DEATH DIFFER, V27, P662, DOI 10.1038/s41418-019-0380-z; Xiao ZD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00902-z; Xie L, 2011, J CANCER RES CLIN, V137, P1739, DOI 10.1007/s00432-011-1050-9; Xie YC, 2017, CELL REP, V20, P1692, DOI 10.1016/j.celrep.2017.07.055; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Ye LF, 2020, ACS CHEM BIOL, V15, P469, DOI 10.1021/acschembio.9b00939; Zhang Y, 2019, CELL CHEM BIOL, V26, P623, DOI 10.1016/j.chembiol.2019.01.008; Zhang YL, 2020, CANCER RES, V80, P2243, DOI 10.1158/0008-5472.CAN-19-3580; Zhang YL, 2019, MOL CELL ONCOL, V6, DOI 10.1080/23723556.2018.1536845; Zhang YL, 2018, NAT CELL BIOL, V20, P1181, DOI 10.1038/s41556-018-0178-0; Zheng H, 2014, ONCOGENE, V33, P734, DOI 10.1038/onc.2013.6	50	46	47	8	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3533	3547		10.1038/s41388-021-01790-w	http://dx.doi.org/10.1038/s41388-021-01790-w		APR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33927351	Green Accepted			2022-12-28	WOS:000645517200003
J	Xiao, Q; Gan, YQ; Li, YM; Fan, LL; Liu, JQ; Lu, PY; Liu, JX; Chen, AA; Shu, G; Yin, G				Xiao, Qing; Gan, Yaqi; Li, Yimin; Fan, Lili; Liu, Jiaqi; Lu, Pengyan; Liu, Jiaxin; Chen, Aoao; Shu, Guang; Yin, Gang			MEF2A transcriptionally upregulates the expression of ZEB2 and CTNNB1 in colorectal cancer to promote tumor progression	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; GROWTH-FACTOR; METASTASIS; DEGRADATION; DOWNSTREAM; ACTIVATION; TRANSITION; REPRESSOR; P38	Colorectal cancer (CRC) is one of the leading cancers worldwide, accounting for high morbidity and mortality. The mechanisms governing tumor growth and metastasis in CRC require detailed investigation. The results of the present study indicated that the transcription factor (TF) myocyte enhancer factor 2A (MEF2A) plays a dual role in promoting proliferation and metastasis of CRC by inducing the epithelial-mesenchymal transition (EMT) and activation of WNT/beta-catenin signaling. Aberrant expression of MEF2A in CRC clinical specimens was significantly associated with poor prognosis and metastasis. Functionally, MEF2A directly binds to the promoter region to initiate the transcription of ZEB2 and CTNNB1. Simultaneous activation of the expression of EMT-related TFs and Wnt/beta-catenin signaling by MEF2A overexpression induced the EMT and increased the frequency of tumor formation and metastasis. The present study identified a new critical oncogene involved in the growth and metastasis of CRC, providing a potential novel therapeutic target for CRC intervention.	[Xiao, Qing; Gan, Yaqi; Li, Yimin; Fan, Lili; Liu, Jiaqi; Lu, Pengyan; Liu, Jiaxin; Yin, Gang] Cent South Univ, Sch Basic Med Sci, Xiangya Hosp, Dept Pathol, Changsha, Peoples R China; [Chen, Aoao] Cent South Univ, Sch Basic Med Sci, Dept Immunol, Changsha, Peoples R China; [Shu, Guang] Cent South Univ, Sch Basic Med Sci, Dept Histol & Embryol, Changsha, Peoples R China; [Yin, Gang] Cent South Univ, Sch Basic Med Sci, China Africa Res Ctr Infect Dis, Changsha, Peoples R China	Central South University; Central South University; Central South University; Central South University	Yin, G (corresponding author), Cent South Univ, Sch Basic Med Sci, Xiangya Hosp, Dept Pathol, Changsha, Peoples R China.; Yin, G (corresponding author), Cent South Univ, Sch Basic Med Sci, China Africa Res Ctr Infect Dis, Changsha, Peoples R China.	gangyin@csu.edu.cn		Liu, Jiaxin/0000-0002-8903-114X; Gan, Yaqi/0000-0001-8097-4603; Yin, Gang/0000-0003-3753-0753	National Key RAMP;D Program of China, Stem Cell and Translational Research [2016YFA0102000]; National Natural Science Foundation of China [81572900]; Student Innovation Project of Central South University [1053320183731]	National Key RAMP;D Program of China, Stem Cell and Translational Research; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Student Innovation Project of Central South University	This work was supported by the National Key R&D Program of China, Stem Cell and Translational Research (no. 2016YFA0102000); National Natural Science Foundation of China (no. 81572900); and Student Innovation Project of Central South University (no. 1053320183731).	[Anonymous], 2016, MOL CELL BIOL, V36, P330; Bai XL, 2015, ONCOGENE, V34, P4089, DOI 10.1038/onc.2014.337; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Brown FC, 2018, CANCER DISCOV, V8, P478, DOI 10.1158/2159-8290.CD-17-1271; Chen DL, 2017, THERANOSTICS, V7, P4836, DOI 10.7150/thno.20942; Chen HH, 2015, CIRC RES, V117, P671, DOI 10.1161/CIRCRESAHA.114.305777; Chen SX, 2012, CELL, V151, P41, DOI 10.1016/j.cell.2012.08.028; Clark RI, 2013, CELL, V155, P435, DOI 10.1016/j.cell.2013.09.007; Deczkowska A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00769-0; Di Giorgio E, 2018, BBA-REV CANCER, V1870, P261, DOI 10.1016/j.bbcan.2018.05.007; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Gjyshi A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26670-4; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; He Y, 2017, ONCOGENE, V36, P3490, DOI 10.1038/onc.2016.492; Herglotz J, 2016, BLOOD, V127, P572, DOI 10.1182/blood-2015-04-643270; Hua F, 2019, GASTROENTEROLOGY, V156, P708, DOI 10.1053/j.gastro.2018.10.031; Ishikawa F, 2010, ONCOGENE, V29, P909, DOI 10.1038/onc.2009.387; Kim JM, 2017, INTEGR CANCER THER, V16, P360, DOI 10.1177/1534735416670987; Li L, 2018, PHYSIOL GENOMICS, V50, P10, DOI 10.1152/physiolgenomics.00076.2017; Liu JJ, 2015, CELL PHYSIOL BIOCHEM, V36, P155, DOI 10.1159/000374060; Ma LN, 2014, CANCER RES, V74, P1452, DOI 10.1158/0008-5472.CAN-13-2171; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Mehta PB, 2001, ONCOGENE, V20, P5359, DOI 10.1038/sj.onc.1204688; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; Ryan RJH, 2015, CANCER DISCOV, V5, P1058, DOI 10.1158/2159-8290.CD-15-0370; Shalizi A, 2006, SCIENCE, V311, P1012, DOI 10.1126/science.1122513; She H, 2012, J NEUROCHEM, V122, P1203, DOI 10.1111/j.1471-4159.2012.07860.x; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Snyder CM, 2013, DEVELOPMENT, V140, P31, DOI 10.1242/dev.081851; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Sreekumar R, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.3115; Su L, 2016, CANCER RES, V76, P5054, DOI 10.1158/0008-5472.CAN-16-0246; Tang XL, 2005, J NEUROSCI, V25, P4823, DOI 10.1523/JNEUROSCI.1331-05.2005; Tung B, 2017, P NATL ACAD SCI USA, V114, pE707, DOI 10.1073/pnas.1610383114; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wang FF, 2017, CANCER LETT, V388, P85, DOI 10.1016/j.canlet.2016.11.031; Xiang JY, 2020, GASTROENTEROLOGY, V158, P664, DOI 10.1053/j.gastro.2019.10.025; Xiang JY, 2017, CANCER LETT, V400, P117, DOI 10.1016/j.canlet.2017.04.037; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhang L, 2014, AUTOPHAGY, V10, P1015, DOI 10.4161/auto.28477; Zhang M, 2015, HYPERTENSION, V65, P335, DOI 10.1161/HYPERTENSIONAHA.114.04467	43	6	6	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3364	3377		10.1038/s41388-021-01774-w	http://dx.doi.org/10.1038/s41388-021-01774-w		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33863999	Green Published, hybrid			2022-12-28	WOS:000640748600001
J	Kim, ES; Nam, SM; Song, HK; Lee, S; Kim, K; Lim, HK; Lee, H; Kang, KT; Kwon, YJ; Chun, YJ; Park, SY; Jung, J; Moon, A				Kim, Eun-Sook; Nam, Su-Min; Song, Hye Kyung; Lee, Seungeun; Kim, Kyoungmee; Lim, Hyun Kyung; Lee, Hyunsook; Kang, Kyu-Tae; Kwon, Yeo-Jung; Chun, Young-Jin; Park, So Yeon; Jung, Joohee; Moon, Aree			CCL8 mediates crosstalk between endothelial colony forming cells and triple-negative breast cancer cells through IL-8, aggravating invasion and tumorigenicity	ONCOGENE			English	Article							NF-KAPPA-B; PROGENITOR CELLS; IN-VIVO; GENE-EXPRESSION; TUBE FORMATION; ANGIOGENESIS; METASTASIS; GROWTH; CD34; PROLIFERATION	Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a poor prognosis for which no effective therapeutic measures are currently available. The present study aimed to investigate whether interactions with endothelial colony-forming cells (ECFCs) promote aggressive progression of TNBC cells. Herein, using an indirect co-culture system, we showed that co-culture increased the invasive and migratory phenotypes of both MDA-MB-231 TNBC cells and ECFCs. Through a cytokine antibody array and RT-PCR analysis, we revealed that co-culture markedly induced secretion of the chemokine C-C motif ligand (CCL)8 from ECFCs and that of interleukin (IL)-8 from MDA-MB-231 cells. CCL8 was crucial for ECFC-induced IL-8 secretion and invasion of MDA-MB-231 cells as well as for MDA-MB-231-enhanced MMP-2 secretion and angiogenesis of ECFCs. We suggest c-Jun as a transcription factor for CCL8-induced IL-8 expression in MDA-MB-231 cells. IL-8 was important for co-culture-induced CCL8 and MMP-2 upregulation and invasion of ECFCs. Notably, our findings reveal a positive feedback loop between CCL8 and IL-8, which contributes to the aggressive phenotypes of both ECFC and TNBC cells. Using an MDA-MB-231 cell-based xenograft model, we show that tumor growth and metastasis are increased by co-injected ECFCs in vivo. Increased expression of IL-8 was observed in tissues with bone metastases in mice injected with conditioned media from co-cultured cells. High IL-8 levels are correlated with poor recurrence-free survival in TNBC patients. Together, these results suggest that CCL8 and IL-8 mediate the crosstalk between ECFCs and TNBC, leading to aggravation of tumorigenicity in TNBC.	[Kim, Eun-Sook; Nam, Su-Min; Lee, Seungeun; Kim, Kyoungmee; Lim, Hyun Kyung; Lee, Hyunsook; Kang, Kyu-Tae; Jung, Joohee; Moon, Aree] Duksung Womens Univ, Coll Pharm, Duksung Innovat Drug Ctr, Seoul, South Korea; [Song, Hye Kyung] Duksung Womens Univ, Coll Chem, Seoul, South Korea; [Kwon, Yeo-Jung; Chun, Young-Jin] Chung Ang Univ, Coll Pharm, Seoul, South Korea; [Park, So Yeon] Seoul Natl Univ, Bundang Hosp, Dept Pathol, Coll Med, Seongnam, South Korea	Duksung Women's University; Duksung Women's University; Chung Ang University; Seoul National University (SNU)	Jung, J; Moon, A (corresponding author), Duksung Womens Univ, Coll Pharm, Duksung Innovat Drug Ctr, Seoul, South Korea.	joohee@duksung.ac.kr; armoon@duksung.ac.kr		Park, So Yeon/0000-0002-0299-7268	National Research Foundation of Korea [2016R1A6A1A03007648, 2019R1A2C1009773]	National Research Foundation of Korea(National Research Foundation of Korea)	The present study was supported by the National Research Foundation of Korea (no. 2016R1A6A1A03007648 and no. 2019R1A2C1009773).	Afshar Moghaddam Noushin, 2015, Iran J Pathol, V10, P89; An GL, 2019, ONCOL REP, V42, P2499, DOI 10.3892/or.2019.7344; Andre F, 2012, ANN ONCOL, V23, P46, DOI 10.1093/annonc/mds195; Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102; Bianconi D, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920928635; Cassetta L, 2019, CANCER CELL, V35, P588, DOI 10.1016/j.ccell.2019.02.009; CONNOLLY KM, 1993, J HISTOCHEM CYTOCHEM, V41, P1, DOI 10.1177/41.1.7678022; DELIA D, 1993, BLOOD, V81, P1001; Engels K, 1997, J PATHOL, V181, P207; Fadini GP, 2012, CIRC RES, V110, P624, DOI 10.1161/CIRCRESAHA.111.243386; Farmaki E, 2016, ONCOGENE, V35, P6309, DOI 10.1038/onc.2016.161; Finkenzeller G, 2009, CELL PROLIFERAT, V42, P498, DOI 10.1111/j.1365-2184.2009.00610.x; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fong YC, 2008, J BONE MINER RES, V23, P961, DOI 10.1359/JBMR.080206; Freund A, 2003, ONCOGENE, V22, P256, DOI 10.1038/sj.onc.1206113; Gomez-Cuadrado L, 2017, DIS MODEL MECH, V10, P1061, DOI 10.1242/dmm.030403; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Halama N, 2016, CANCER CELL, V29, P587, DOI 10.1016/j.ccell.2016.03.005; Halvorsen EC, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1150398; Hoffmann OI, 2015, J BIOTECHNOL, V205, P14, DOI 10.1016/j.jbiotec.2015.02.029; Huang SY, 2002, AM J PATHOL, V161, P125, DOI 10.1016/S0002-9440(10)64164-8; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Khanjani S, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/504952; Khodarev NN, 2003, J CELL SCI, V116, P1013, DOI 10.1242/jcs.00281; Kivisto KT, 1995, BRIT J CLIN PHARMACO, V40, P523, DOI 10.1111/j.1365-2125.1995.tb05796.x; Kwon YH, 2012, BIOMOL THER, V20, P158, DOI 10.4062/biomolther.2012.20.2.158; Lambert E, 2004, CRIT REV ONCOL HEMAT, V49, P187, DOI 10.1016/j.critrevonc.2003.09.008; Le Bourhis X, 2010, BREAST CANCER RES TR, V120, P17, DOI 10.1007/s10549-009-0686-5; Lee HM, 2016, BIOMOL THER, V24, P62, DOI 10.4062/biomolther.2015.172; Lee H, 2018, KOREAN J PHYSIOL PHA, V22, P705, DOI 10.4196/kjpp.2018.22.6.705; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Liu L, 2012, CARDIOVASC RES, V94, P3, DOI 10.1093/cvr/cvs108; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; McKenney JK, 2001, AM J SURG PATHOL, V25, P1167, DOI 10.1097/00000478-200109000-00007; Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306; Melero-Martin JM, 2008, CIRC RES, V103, P194, DOI 10.1161/CIRCRESAHA.108.178590; Melero-Martin JM, 2007, BLOOD, V109, P4761, DOI 10.1182/blood-2006-12-062471; Mencarelli A, 2013, TRANSL ONCOL, V6, P784, DOI 10.1593/tlo.13499; MIETTINEN M, 1994, MODERN PATHOL, V7, P82; Miller LJ, 1998, ANTICANCER RES, V18, P77; Neophytou C, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00031; Paschalaki KE, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00295; Riedlinger T, 2019, FASEB J, V33, P4188, DOI 10.1096/fj.201801638R; Rody A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3035; Sato T, 2017, J CANCER, V8, P704, DOI 10.7150/jca.18027; Sicoli D, 2014, CANCER RES, V74, P7103, DOI 10.1158/0008-5472.CAN-14-0612; Singh JK, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3436; Smadja DM, 2010, ARTERIOSCL THROM VAS, V30, P2544, DOI 10.1161/ATVBAHA.110.213751; Snoussi K, 2006, HUM IMMUNOL, V67, P13, DOI 10.1016/j.humimm.2006.03.018; Snoussi K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-283; Song H, 2006, CANCER RES, V66, P10487, DOI 10.1158/0008-5472.CAN-06-1461; Sunaga N, 2014, BRIT J CANCER, V110, P2047, DOI 10.1038/bjc.2014.110; Tsutsui Shinichi, 2003, Breast Cancer, V10, P312, DOI 10.1007/BF02967651; Uzzan B, 2004, CANCER RES, V64, P2941, DOI 10.1158/0008-5472.CAN-03-1957; Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y; Velasco-Velazquez M, 2012, CANCER RES, V72, P3839, DOI 10.1158/0008-5472.CAN-11-3917; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; Yin WJ, 2009, BREAST CANCER RES TR, V115, P325, DOI 10.1007/s10549-008-0096-0; Yuan A, 2002, J CLIN ONCOL, V20, P900, DOI 10.1200/JCO.20.4.900; Zhang WW, 2018, FASEB J, V32, P276, DOI 10.1096/fj.201700237RR; Zhang X, 2020, LAB INVEST, V100, P619, DOI 10.1038/s41374-019-0345-3; Zhao K, 2018, CARCINOGENESIS, V39, P588, DOI 10.1093/carcin/bgy007; Zheng HC, 2006, ANTICANCER RES, V26, P3579; Zhou J, 2018, CELL BIOL INT, V42, P365, DOI 10.1002/cbin.10909	67	5	5	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3245	3259		10.1038/s41388-021-01758-w	http://dx.doi.org/10.1038/s41388-021-01758-w		APR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33833397				2022-12-28	WOS:000638023600001
J	Ma, SQ; Zhang, L; Ren, Y; Dai, W; Chen, TQ; Luo, LP; Zeng, J; Mi, K; Lang, JY; Cao, BR				Ma, Shiqi; Zhang, Lu; Ren, Yuan; Dai, Wei; Chen, Tingqing; Luo, Liping; Zeng, Juan; Mi, Kun; Lang, Jinyi; Cao, Bangrong			Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer	ONCOGENE			English	Article								Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective against non-small cell lung cancer (NSCLC) with EGFR-activating mutations. The mechanisms underlying EGFR-TKI resistance are not fully understood. This study aimed to analyze the effects of seven EGFR ligands on EGFR-TKI sensitivity in NSCLC cells and patients. Cells with EGFR E746-A750del mutation were treated with recombinant EGFR ligands, and analyzed for cell viability, proliferation, and apoptosis. shRNA knockdown of endogenous Epiregulin (EREG) or overexpression of exogenous EREG and immunofluorescence experiments were carried out. Public gene expression datasets were used for tumor microenvironment and clinical assessment. Among the EGFR ligands, EREG significantly diminished cellular sensitivity to TKIs and was associated with decreased response to erlotinib in NSCLC patients. EREG induced AKT phosphorylation and attenuated TKI-induced cellular apoptosis in an ErbB2-dependent manner. EREG induced the formation of the EGFR/ErbB2 heterodimer regardless of gefitinib treatment. However, overexpression or knockdown of EREG in cancer cells had little impact on TKI sensitivity. Single-cell RNA sequencing data revealed that EREG was predominantly expressed in macrophages in the tumor microenvironment. In addition, EREG-enriched macrophage conditional medium induced EGFR-TKI resistance. These findings shed new light on the mechanism underlying EGFR-TKI resistance, and suggest macrophage-produced intratumoral EREG as a novel regulator and biomarker for EGFR-TKI therapy in NSCLC.	[Ma, Shiqi; Zhang, Lu; Ren, Yuan; Chen, Tingqing; Luo, Liping; Zeng, Juan; Mi, Kun; Lang, Jinyi; Cao, Bangrong] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Radiat Oncol Key Lab Sichuan Prov, Chengdu, Peoples R China; [Dai, Wei] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Dept Thorac Surg, Chengdu, Peoples R China; [Cao, Bangrong] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Dept Biobank, Chengdu, Peoples R China	University of Electronic Science & Technology of China; University of Electronic Science & Technology of China; University of Electronic Science & Technology of China	Lang, JY; Cao, BR (corresponding author), Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Radiat Oncol Key Lab Sichuan Prov, Chengdu, Peoples R China.; Cao, BR (corresponding author), Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Dept Biobank, Chengdu, Peoples R China.	langjy610@163.com; caobangrong@uestc.edu.cn		Luo, Liping/0000-0002-2673-9749; lang, jinyi/0000-0002-5406-8671	National Natural Science Foundation of China [81602731]; Science and Technology Department of Sichuan Province [2019YJ0573, 2020YJ0453]; Innovation Program of Sichuan Medical Association Science for Youth [Q18009]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Department of Sichuan Province; Innovation Program of Sichuan Medical Association Science for Youth	This work was supported by the National Natural Science Foundation of China (Grant No. 81602731), the Science and Technology Department of Sichuan Province (Grant Nos. 2019YJ0573 and 2020YJ0453), and the Innovation Program of Sichuan Medical Association Science for Youth (Grant No. Q18009).	Bauer AK, 2017, MOL CARCINOGEN, V56, P94, DOI 10.1002/mc.22475; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Chen JC, 2016, PHYSIOL REV, V96, P1025, DOI 10.1152/physrev.00030.2015; De Luca A, 2008, J CELL PHYSIOL, V214, P559, DOI 10.1002/jcp.21260; Du ZF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0782-4; Freed DM, 2017, CELL, V171, P683, DOI 10.1016/j.cell.2017.09.017; Hsu CC, 2020, J THORAC ONCOL, V15, P50, DOI 10.1016/j.jtho.2019.09.006; Ishikawa N, 2005, CANCER RES, V65, P9176, DOI 10.1158/0008-5472.CAN-05-1556; Kakiuchi S, 2004, HUM MOL GENET, V13, P3029, DOI 10.1093/hmg/ddh331; Kim ES, 2011, CANCER DISCOV, V1, P44, DOI 10.1158/2159-8274.CD-10-0010; Kim TM, 2015, J THORAC ONCOL, V10, P1736, DOI 10.1097/JTO.0000000000000688; Lim B, 2020, CANCER CELL, V37, P456, DOI 10.1016/j.ccell.2020.03.008; Massip-Copiz M, 2018, J CELL BIOCHEM, V119, P2911, DOI 10.1002/jcb.26483; Mok T, 2016, LUNG CANCER, V98, P1, DOI 10.1016/j.lungcan.2016.04.023; Nagano T, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110212; Ono T, 2020, INVEST NEW DRUG, V38, P885, DOI 10.1007/s10637-020-00919-0; Poole JA, 2020, AM J PHYSIOL-LUNG C, V318, pL180, DOI 10.1152/ajplung.00039.2019; Recondo G, 2018, NAT REV CLIN ONCOL, V15, P694, DOI 10.1038/s41571-018-0081-4; Riese DJ, 2014, SEMIN CELL DEV BIOL, V28, P49, DOI 10.1016/j.semcdb.2014.03.005; Roepstorff K, 2009, TRAFFIC, V10, P1115, DOI 10.1111/j.1600-0854.2009.00943.x; Santoni-Rugiu E, 2019, CANCERS, V11, DOI 10.3390/cancers11070923; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Sunaga N, 2015, LUNG CANCER-TARGETS, V6, P91, DOI 10.2147/LCTT.S60427; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Vlaicu P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-197; Vollebergh MA, 2010, J THORAC ONCOL, V5, P1939, DOI 10.1097/JTO.0b013e3181f77a39; Wang YJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1277-x; Westover D, 2018, ANN ONCOL, V29, pI10, DOI 10.1093/annonc/mdx703; Zhang J, 2008, CANCER PREV RES, V1, P201, DOI 10.1158/1940-6207.CAPR-08-0014; Zilionis R, 2019, IMMUNITY, V50, P1317, DOI 10.1016/j.immuni.2019.03.009	30	12	12	2	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2596	2609		10.1038/s41388-021-01734-4	http://dx.doi.org/10.1038/s41388-021-01734-4		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33750895				2022-12-28	WOS:000626816500002
J	Avila-Lopez, PA; Guerrero, G; Nunez-Martinez, HN; Peralta-Alvarez, CA; Hernandez-Montes, G; Alvarez-Hilario, LG; Herrera-Goepfert, R; Albores-Saavedra, J; Villegas-Sepulveda, N; Cedillo-Barron, L; Montes-Gomez, AE; Vargas, M; Schnoor, M; Recillas-Targa, F; Hernandez-Rivas, R				Avila-Lopez, P. A.; Guerrero, G.; Nunez-Martinez, H. N.; Peralta-Alvarez, C. A.; Hernandez-Montes, G.; Alvarez-Hilario, L. G.; Herrera-Goepfert, R.; Albores-Saavedra, J.; Villegas-Sepulveda, N.; Cedillo-Barron, L.; Montes-Gomez, A. E.; Vargas, M.; Schnoor, M.; Recillas-Targa, F.; Hernandez-Rivas, R.			H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article								Pancreatic ductal adenocarcinoma (PDAC) is one of the most intractable and devastating malignant tumors. Epigenetic modifications such as DNA methylation and histone modification regulate tumor initiation and progression. However, the contribution of histone variants in PDAC is unknown. Here, we demonstrated that the histone variant H2A.Z is highly expressed in PDAC cell lines and PDAC patients and that its overexpression correlates with poor prognosis. Moreover, all three H2A.Z isoforms (H2A.Z.1, H2A.Z.2.1, and H2A.Z.2.2) are highly expressed in PDAC cell lines and PDAC patients. Knockdown of these H2A.Z isoforms in PDAC cell lines induces a senescent phenotype, cell cycle arrest in phase G2/M, increased expression of cyclin-dependent kinase inhibitor CDKN2A/p16, SA-beta-galactosidase activity and interleukin 8 production. Transcriptome analysis of H2A.Z-depleted PDAC cells showed altered gene expression in fatty acid biosynthesis pathways and those that regulate cell cycle and DNA damage repair. Importantly, depletion of H2A.Z isoforms reduces the tumor size in a mouse xenograft model in vivo and sensitizes PDAC cells to gemcitabine. Overexpression of H2A.Z.1 and H2A.Z.2.1 more than H2A.Z.2.2 partially restores the oncogenic phenotype. Therefore, our data suggest that overexpression of H2A.Z isoforms enables cells to overcome the oncoprotective barrier associated with senescence, favoring PDAC tumor grow and chemoresistance. These results make H2A.Z a potential candidate as a diagnostic biomarker and therapeutic target for PDAC.	[Avila-Lopez, P. A.; Alvarez-Hilario, L. G.; Villegas-Sepulveda, N.; Cedillo-Barron, L.; Montes-Gomez, A. E.; Vargas, M.; Schnoor, M.; Hernandez-Rivas, R.] Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Biomed Mol, Mexico City, DF, Mexico; [Guerrero, G.; Nunez-Martinez, H. N.; Peralta-Alvarez, C. A.; Recillas-Targa, F.] Univ Nacl Autonoma Mexico, Dept Genet Mol, Inst Fisiol Celular, Ciudad Univ, Mexico City, DF, Mexico; [Hernandez-Montes, G.] Univ Nacl Autonoma Mexico, Coordinac Invest Cient, Red Apoyo Invest, Ciudad Univ, Mexico City, DF, Mexico; [Herrera-Goepfert, R.] Inst Nacl Cancerol, Dept Patol, Mexico City, DF, Mexico; [Albores-Saavedra, J.] Med Clin & Fdn, Dept Patol, Mexico City, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Instituto Nacional de Cancerologia (INCAN)	Hernandez-Rivas, R (corresponding author), Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Biomed Mol, Mexico City, DF, Mexico.	rohernan@cinvestav.mx		Herrera-Goepfert, Roberto/0000-0001-7901-2378; Villegas-Sepulveda, Nicolas/0000-0001-9489-2545; Hernandez, Rosaura/0000-0002-5275-0730; Peralta-Alvarez, Carlos Alberto/0000-0001-6103-5133; Avila Lopez, Pedro Antonio/0000-0002-0104-0771; VARGAS, MIGUEL/0000-0002-3031-9798; Nunez, Hober Nelson/0000-0003-1726-2499	Fondo Sectorial de Investigacion en Salud y Seguridad Social [SS/IMSS/ISSSTE-CONACyt (272364)]; Consejo Nacional de Ciencia y Tecnologia fellowship [396917]	Fondo Sectorial de Investigacion en Salud y Seguridad Social; Consejo Nacional de Ciencia y Tecnologia fellowship	This work was supported by the Fondo Sectorial de Investigacion en Salud y Seguridad Social SS/IMSS/ISSSTE-CONACyt (272364) to RHR; PAA-L was supported by the Consejo Nacional de Ciencia y Tecnologia fellowship 396917.	Akada M, 2005, CLIN CANCER RES, V11, P3094, DOI 10.1158/1078-0432.CCR-04-1785; BALL DJ, 1983, FEBS LETT, V154, P166, DOI 10.1016/0014-5793(83)80896-5; Bauden M, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0139-4; Bonisch C, 2012, NUCLEIC ACIDS RES, V40, P5951, DOI 10.1093/nar/gks267; Buschbeck M, 2017, NAT REV MOL CELL BIO, V18, P299, DOI 10.1038/nrm.2016.166; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Dryhurst D, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-86; Faast R, 2001, CURR BIOL, V11, P1183, DOI 10.1016/S0960-9822(01)00329-3; Gevry N, 2007, GENE DEV, V21, P1869, DOI 10.1101/gad.1545707; Gire V, 2015, CELL CYCLE, V14, P297, DOI 10.1080/15384101.2014.1000134; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Hu GQ, 2013, CELL STEM CELL, V12, P180, DOI 10.1016/j.stem.2012.11.003; Iguchi Eriko, 2016, Yale Journal of Biology and Medicine, V89, P575; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kikuchi I, 2010, CELL BIOL INT, V34, P645, DOI 10.1042/CBI20090398; Kim K, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-34; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lamaa A, 2020, ELIFE, V9, DOI 10.7554/eLife.53375; Lomberk G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04383-6; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Maeda M, 2009, LIFE SCI, V84, P119, DOI 10.1016/j.lfs.2008.11.009; Mattera L, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000983; Maze I, 2014, NAT REV GENET, V15, P259, DOI 10.1038/nrg3673; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Muniz L, 2017, CELL REP, V21, P2433, DOI 10.1016/j.celrep.2017.11.006; Neureiter D, 2014, WORLD J GASTROENTERO, V20, P7830, DOI 10.3748/wjg.v20.i24.7830; Oldfield LE, 2017, TRENDS CANCER, V3, P336, DOI 10.1016/j.trecan.2017.04.005; Prieur A, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1473; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Ridgway P, 2004, J BIOL CHEM, V279, P43815, DOI 10.1074/jbc.M408409200; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Skene PJ, 2013, DEVELOPMENT, V140, P2513, DOI 10.1242/dev.091439; Surface LE, 2016, CELL REP, V14, P1142, DOI 10.1016/j.celrep.2015.12.100; Svotelis A, 2010, CELL CYCLE, V9, P364, DOI 10.4161/cc.9.2.10465; Talbert PB, 2017, NAT REV MOL CELL BIO, V18, P115, DOI 10.1038/nrm.2016.148; Valdes-Mora F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01393-8; Vardabasso C, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1073417; Vardabasso C, 2015, MOL CELL, V59, P75, DOI 10.1016/j.molcel.2015.05.009; Vardabasso C, 2014, CELL MOL LIFE SCI, V71, P379, DOI 10.1007/s00018-013-1343-z; Yang B, 2018, INT J ONCOL, V52, P1235, DOI 10.3892/ijo.2018.4292; Yang HD, 2016, ONCOTARGET, V7, P11412, DOI 10.18632/oncotarget.7194	42	9	9	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2065	2080		10.1038/s41388-021-01664-1	http://dx.doi.org/10.1038/s41388-021-01664-1		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33627784	Green Published, hybrid			2022-12-28	WOS:000621289100006
J	Buckup, M; Rice, MA; Hsu, EC; Garcia-Marques, F; Liu, SQ; Aslan, M; Bermudez, A; Huang, JT; Pitteri, SJ; Stoyanova, T				Buckup, Mark; Rice, Meghan A.; Hsu, En-Chi; Garcia-Marques, Fernando; Liu, Shiqin; Aslan, Merve; Bermudez, Abel; Huang, Jiaoti; Pitteri, Sharon J.; Stoyanova, Tanya			Plectin is a regulator of prostate cancer growth and metastasis	ONCOGENE			English	Article							ABIRATERONE ACETATE; SURVIVAL ANALYSIS; DOUBLE-BLIND; CLUSTERIN; ENZALUTAMIDE; MEN; NEUROENDOCRINE; EXPRESSION; INHIBITOR; INTEGRITY	Prostate cancer is responsible for over 30,000 US deaths annually, attributed largely to incurable metastatic disease. Here, we demonstrate that high levels of plectin are associated with localized and metastatic human prostate cancer when compared to benign prostate tissues. Knock-down of plectin inhibits prostate cancer cell growth and colony formation in vitro, and growth of prostate cancer xenografts in vivo. Plectin knock-down further impairs aggressive and invasive cellular behavior assessed by migration, invasion, and wound healing in vitro. Consistently, plectin knock-down cells have impaired metastatic colonization to distant sites including liver, lung, kidney, bone, and genitourinary system. Plectin knock-down inhibited number of metastases per organ, as well as decreased overall metastatic burden. To gain insights into the role of plectin in prostate cancer growth and metastasis, we performed proteomic analysis of prostate cancer plectin knock-down xenograft tissues. Gene set enrichment analysis shows an increase in levels of proteins involved with extracellular matrix and laminin interactions, and a decrease in levels of proteins regulating amino acid metabolism, cytoskeletal proteins, and cellular response to stress. Collectively these findings demonstrate that plectin is an important regulator of prostate cancer cell growth and metastasis.	[Buckup, Mark; Rice, Meghan A.; Hsu, En-Chi; Garcia-Marques, Fernando; Liu, Shiqin; Aslan, Merve; Bermudez, Abel; Pitteri, Sharon J.; Stoyanova, Tanya] Stanford Univ, Dept Radiol, Canary Ctr Stanford Canc Early Detect, Palo Alto, CA 94304 USA; [Huang, Jiaoti] Duke Univ, Dept Pathol, Durham, NC 27706 USA	Stanford University; Duke University	Stoyanova, T (corresponding author), Stanford Univ, Dept Radiol, Canary Ctr Stanford Canc Early Detect, Palo Alto, CA 94304 USA.	stanya@stanford.edu	Hsu, En-Chi/AAH-4589-2021	Hsu, En-Chi/0000-0002-5671-6169; Rice, Meghan/0000-0003-4578-0461; Garcia-Marques, Fernando/0000-0002-2105-2905; Buckup, Mark/0000-0001-6938-3474	Canary Foundation; National Institutes of Health/National Cancer Institute (NCI) [R37CA240822, R01CA244281, R03CA230819]; CDMRP [W81XWH1810141]	Canary Foundation; National Institutes of Health/National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CDMRP(United States Department of Defense)	TS is supported by the Canary Foundation, the National Institutes of Health/National Cancer Institute (NCI) R37CA240822, R01CA244281 and R03CA230819. MAR is supported by the CDMRP through Award No. W81XWH1810141.	Andra K, 1997, GENE DEV, V11, P3143, DOI 10.1101/gad.11.23.3143; Bausch D, 2011, CLIN CANCER RES, V17, P302, DOI 10.1158/1078-0432.CCR-10-0999; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Bekelman JE, 2018, J ONCOL PRACT, V14, P618, DOI 10.1200/JOP.18.00434; Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698; Burch TC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065005; Burgstaller G, 2010, MOL BIOL CELL, V21, P3362, DOI 10.1091/mbc.E10-02-0094; Damber JE, 2008, LANCET, V371, P1710, DOI 10.1016/S0140-6736(08)60729-1; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; de Wit R, 2019, NEW ENGL J MED, V381, P2506, DOI 10.1056/NEJMoa1911206; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; Drake CG, 2014, ONCOLOGY-NY, V28, P974; Evans CP, 2016, EUR UROL, V70, P675, DOI 10.1016/j.eururo.2016.03.017; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Gatto L, 2012, BIOINFORMATICS, V28, P288, DOI 10.1093/bioinformatics/btr645; Graff JN, 2015, EXPERT OPIN PHARMACO, V16, P749, DOI 10.1517/14656566.2015.1016911; Hsu EC, 2020, P NATL ACAD SCI USA, V117, P2032, DOI 10.1073/pnas.1905384117; Huang JT, 2005, AM J PATHOL, V166, P1807, DOI 10.1016/S0002-9440(10)62490-X; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Katada K, 2012, J PROTEOMICS, V75, P1803, DOI 10.1016/j.jprot.2011.12.018; Kim N, 2012, ALCOHOL CLIN EXP RES, V36, P72, DOI 10.1111/j.1530-0277.2011.01588.x; Knott SRV, 2018, NATURE, V554, P378, DOI 10.1038/nature25465; Koster J, 2004, MOL BIOL CELL, V15, P1211, DOI 10.1091/mbc.E03-09-0697; Kyriakopoulos CE, 2018, J CLIN ONCOL, V36, P1080, DOI 10.1200/JCO.2017.75.3657; Litjens SHM, 2006, TRENDS CELL BIOL, V16, P376, DOI 10.1016/j.tcb.2006.05.004; Mi HY, 2019, NAT PROTOC, V14, P703, DOI 10.1038/s41596-019-0128-8; Navarro P, 2014, J PROTEOME RES, V13, P1234, DOI 10.1021/pr4006958; Osmanagic-Myers S, 2004, J BIOL CHEM, V279, P18701, DOI 10.1074/jbc.M312382200; Osmanagic-Myers S, 2006, J CELL BIOL, V174, P557, DOI 10.1083/jcb.200605172; Osmanagic-Myers S, 2015, J CELL SCI, V128, P4138, DOI 10.1242/jcs.172056; Peng M, 2019, CANCER MANAG RES, V11, P2405, DOI 10.2147/CMAR.S196273; Porporato PE, 2016, CELL MOL LIFE SCI, V73, P1349, DOI 10.1007/s00018-015-2100-2; Raymond AC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51004-3; Rice MA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00801; Rice MA, 2019, MOL CANCER THER, V18, P1230, DOI 10.1158/1535-7163.MCT-18-0804; Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470-2045(14)71205-7; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Ryan CJ, 2010, J CLIN ONCOL, V28, P1481, DOI 10.1200/JCO.2009.24.1281; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scaltriti M, 2004, CANCER RES, V64, P6174, DOI 10.1158/0008-5472.CAN-04-0920; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Sevik J, 2004, EUR J BIOCHEM, V271, P1873, DOI [10.1111/j.1432-1033.2004.04095.x, DOI 10.1111/J.1432-1033.2004.04095.X]; Shapiro B, 2015, ONCOTARGET, V6, P34389, DOI 10.18632/oncotarget.5360; Shin SJ, 2013, P NATL ACAD SCI USA, V110, P19414, DOI 10.1073/pnas.1309720110; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252; Song JG, 2015, STRUCTURE, V23, P558, DOI 10.1016/j.str.2015.01.011; Stoyanova T, 2016, P NATL ACAD SCI USA, V113, pE6457, DOI 10.1073/pnas.1614529113; Strmiska V, 2019, BBA-REV CANCER, V1871, P248, DOI 10.1016/j.bbcan.2019.01.001; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/nmeth.3901, 10.1038/NMETH.3901]; Wang C, 2015, ONCOTARGET, V6, P2903, DOI 10.18632/oncotarget.3093; Wang J, 2010, CANCER RES, V70, P10182, DOI 10.1158/0008-5472.CAN-10-2414; Wiche G, 1998, J CELL SCI, V111, P2477; Wiche Gerhard, 2011, Bioarchitecture, V1, P14; Winter L, 2013, ACTA NEUROPATHOL, V125, P77, DOI 10.1007/s00401-012-1026-0; Yoneyama MS, 2014, EUR J CELL BIOL, V93, P157, DOI 10.1016/j.ejcb.2014.03.002; Zhou WM, 2014, ONCOL LETT, V8, P1175, DOI 10.3892/ol.2014.2287; Zhu Y, 2018, EBIOMEDICINE, V30, P148, DOI 10.1016/j.ebiom.2018.03.032	59	11	11	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					663	676		10.1038/s41388-020-01557-9	http://dx.doi.org/10.1038/s41388-020-01557-9		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33219316	Green Accepted			2022-12-28	WOS:000591146100001
J	Schmidt, AK; Pudelko, K; Boekenkamp, JE; Berger, K; Kschischo, M; Bastians, H				Schmidt, Ann-Kathrin; Pudelko, Karoline; Boekenkamp, Jan-Eric; Berger, Katharina; Kschischo, Maik; Bastians, Holger			The p53/p73-p21(CIP1) tumor suppressor axis guards against chromosomal instability by restraining CDK1 in human cancer cells	ONCOGENE			English	Article							DNA-REPLICATION; CYCLE; P53; P21; ARREST; KINASE; PROLIFERATION; INACTIVATION; EXPRESSION; P21(WAF1)	Whole chromosome instability (W-CIN) is a hallmark of human cancer and contributes to the evolvement of aneuploidy. W-CIN can be induced by abnormally increased microtubule plus end assembly rates during mitosis leading to the generation of lagging chromosomes during anaphase as a major form of mitotic errors in human cancer cells. Here, we show that loss of the tumor suppressor genes TP53 and TP73 can trigger increased mitotic microtubule assembly rates, lagging chromosomes, and W-CIN. CDKN1A, encoding for the CDK inhibitor p21(CIP1), represents a critical target gene of p53/p73. Loss of p21(CIP1) unleashes CDK1 activity which causes W-CIN in otherwise chromosomally stable cancer cells. Consequently, induction of CDK1 is sufficient to induce abnormal microtubule assembly rates and W-CIN. Vice versa, partial inhibition of CDK1 activity in chromosomally unstable cancer cells corrects abnormal microtubule behavior and suppresses W-CIN. Thus, our study shows that the p53/p73 - p21(CIP1) tumor suppressor axis, whose loss is associated with W-CIN in human cancer, safeguards against chromosome missegregation and aneuploidy by preventing abnormally increased CDK1 activity.	[Schmidt, Ann-Kathrin; Pudelko, Karoline; Berger, Katharina; Bastians, Holger] Georg August Univ Gottingen, Gottingen Ctr Mol Biosci GZMB, D-37077 Gottingen, Germany; [Schmidt, Ann-Kathrin; Pudelko, Karoline; Berger, Katharina; Bastians, Holger] Univ Med Ctr Gottingen UMG, Inst Mol Oncol, Sect Cellular Oncol, D-37077 Gottingen, Germany; [Boekenkamp, Jan-Eric; Kschischo, Maik] Univ Appl Sci Koblenz, Dept Math & Technol, D-53424 Remagen, Germany	University of Gottingen	Bastians, H (corresponding author), Georg August Univ Gottingen, Gottingen Ctr Mol Biosci GZMB, D-37077 Gottingen, Germany.; Bastians, H (corresponding author), Univ Med Ctr Gottingen UMG, Inst Mol Oncol, Sect Cellular Oncol, D-37077 Gottingen, Germany.	holger.bastians@uni-goettingen.de		Boekenkamp, Jan-Eric/0000-0002-1662-0349; Bastians, Holger/0000-0001-7915-3648; Schmidt, Ann-Kathrin/0000-0001-8100-5177	Wilhelm Sander-Stiftung; Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft [FOR2800]; Projekt DEAL	Wilhelm Sander-Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Projekt DEAL	We thank Magdalena Hennecke for technical assistance. We are grateful to Thorsten Stiewe, Linda Wordeman, Matthias Schmidt, Makato Iimori, and Lienhard Schmitz for providing plasmids and cell lines. This work was supported by grants from the Wilhelm Sander-Stiftung, from the Deutsche Krebshilfe, and from the Deutsche Forschungsgemeinschaft to HB and by the FOR2800 funded by the Deutsche Forschungsgemeinschaft (MK and HB). Open Access funding enabled and organized by Projekt DEAL.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Bakhoum SF, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a029611; Bakhoum SF, 2009, CURR BIOL, V19, P1937, DOI 10.1016/j.cub.2009.09.055; Bakhoum SF, 2009, NAT CELL BIOL, V11, P27, DOI 10.1038/ncb1809; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bohly N, 2019, CELL CYCLE, V18, P2770, DOI 10.1080/15384101.2019.1658477; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Crncec A, 2019, FEBS LETT, V593, P2868, DOI 10.1002/1873-3468.13635; Di CX, 2013, CELL CYCLE, V12, P1861, DOI 10.4161/cc.24967; Dong SM, 2002, INT J CANCER, V98, P370, DOI 10.1002/ijc.10204; Engelmann D, 2015, ONCOGENE, V34, P4287, DOI 10.1038/onc.2014.365; Ertych N, 2016, P NATL ACAD SCI USA, V113, P1817, DOI 10.1073/pnas.1525129113; Ertych N, 2014, NAT CELL BIOL, V16, P779, DOI 10.1038/ncb2994; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Garcia-Gutierrez L, 2019, GENES-BASEL, V10, DOI 10.3390/genes10030244; Gregan J, 2011, TRENDS CELL BIOL, V21, P374, DOI 10.1016/j.tcb.2011.01.003; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; Kreis NN, 2014, ONCOGENE, V33, P5716, DOI 10.1038/onc.2013.518; Kreis NN, 2019, CANCERS, V11, DOI 10.3390/cancers11091220; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li JX, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-01817-8; Luddecke S, 2016, ONCOGENE, V35, P2398, DOI 10.1038/onc.2015.290; Maas AM, 2013, CANCER LETT, V332, P229, DOI 10.1016/j.canlet.2011.07.030; Maia ARR, 2012, J CELL BIOL, V199, P285, DOI 10.1083/jcb.201203091; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nam HJ, 2014, NAT CELL BIOL, V16, P535, DOI 10.1038/ncb2952; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Ogino S, 2006, J PATHOL, V210, P147, DOI 10.1002/path.2030; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sansregret L, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a028373; Santaguida S, 2017, DEV CELL, V41, P638, DOI 10.1016/j.devcel.2017.05.022; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Schmidt M, 2017, MOLECULES, V22, DOI 10.3390/molecules22122045; Sheltzer JM, 2011, TRENDS GENET, V27, P446, DOI 10.1016/j.tig.2011.07.003; Silkworth WT, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-19; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Stepanova T, 2003, J NEUROSCI, V23, P2655; Stolz A, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.960768; Stolz A, 2015, EMBO REP, V16, P490, DOI 10.15252/embr.201439410; Stolz A, 2010, BIOCHEM SOC T, V38, P1704, DOI 10.1042/BST0381704; Stolz A, 2010, NAT CELL BIOL, V12, P492, DOI 10.1038/ncb2051; Sur S, 2016, MOL CELL BIOCHEM, V416, P33, DOI 10.1007/s11010-016-2693-2; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Turajlic S, 2019, NAT REV GENET, V20, P404, DOI 10.1038/s41576-019-0114-6; Umbreit NT, 2020, SCIENCE, V368, P282, DOI 10.1126/science.aba0712; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; WALDMAN T, 1995, CANCER RES, V55, P5187; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; Zhang CZ, 2015, NATURE, V522, P179, DOI 10.1038/nature14493	60	9	9	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					436	451		10.1038/s41388-020-01524-4	http://dx.doi.org/10.1038/s41388-020-01524-4		NOV 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33168930	Green Published, hybrid			2022-12-28	WOS:000587997700001
J	Xu, LG; Huan, L; Guo, TA; Wu, YJ; Liu, YF; Wang, QF; Huang, SL; Xu, Y; Liang, LH; He, XH				Xu, Linguo; Huan, Lin; Guo, Tianan; Wu, Yangjun; Liu, Yanfang; Wang, Qifeng; Huang, Shenglin; Xu, Ye; Liang, Linhui; He, Xianghuo			LncRNA SNHG11 facilitates tumor metastasis by interacting with and stabilizing HIF-1 alpha	ONCOGENE			English	Article							LONG NONCODING RNA; ALPHA; CANCER; LOCALIZATION; DEGRADATION; HIF-1	Epigenetic alteration is one of the hallmarks of colorectal cancer (CRC). Many driver genes are regulated by DNA methylation in CRC. However, the role of DNA methylation regulating lncRNAs remain elusive. Here, we identify that SNHG11 (small nucleolar RNA host gene 11) is upregulated by promotor hypomethylation in CRC and is associated with poor prognosis in CRC patients. SNHG11 can promote CRC cell migration and metastasis under hypoxia. Interestingly, the DNA-binding motif of SNHG11 is similar to that of HIF-1 alpha. In addition, SNHG11-associated genes are enriched with members of the HIF-1 signaling pathway in CRC. Mechanistically, SNHG11 binds to the pVHLrecognition sites on HIF-1 alpha, thus blocking the interaction of pVHL with HIF-1 alpha and preventing its ubiquitination and degradation. Moreover, SNHG11 upregulates the expression of HIF-1 alpha target genes, i.e., AK4, ENO1, HK2, and Twist1. Notably, SNHG11 can bind to the HRE sites in the promoter of these genes and increase their transcription. In summary, these results identify a SNHG11/ HIF-1 alpha axis that plays a pivotal role in tumor invasion and metastasis.	[Xu, Linguo; Huan, Lin; Wu, Yangjun; Liu, Yanfang; Huang, Shenglin; Liang, Linhui; He, Xianghuo] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Shanghai 200032, Peoples R China; [Xu, Linguo; Huan, Lin; Wu, Yangjun; Liu, Yanfang; Huang, Shenglin; Liang, Linhui; He, Xianghuo] Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Shanghai 200032, Peoples R China; [Xu, Linguo; Huan, Lin; Guo, Tianan; Wu, Yangjun; Liu, Yanfang; Wang, Qifeng; Huang, Shenglin; Xu, Ye; Liang, Linhui; He, Xianghuo] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Guo, Tianan; Xu, Ye] Fudan Univ, Dept Colorectal Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Wang, Qifeng] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Liang, Linhui; He, Xianghuo] Fudan Univ, Shanghai Canc Ctr, Key Lab Breast Canc Shanghai, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University; Fudan University	Liang, LH; He, XH (corresponding author), Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Shanghai 200032, Peoples R China.; Liang, LH; He, XH (corresponding author), Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Shanghai 200032, Peoples R China.; Xu, Y; Liang, LH; He, XH (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.	xuye021@163.com; lianglinhui@fudan.edu.cn; xhhe@fudan.edu.cn	liang, linhui/AAW-4176-2021; xu, ye/GQO-8972-2022; liu, yan/HGV-1365-2022; liu, yan/HCI-5542-2022; He, Xianghuo/I-1497-2014; Huan, Lin/W-1334-2018; Huang, Shenglin/N-9472-2018	He, Xianghuo/0000-0001-8872-668X; Huan, Lin/0000-0002-5791-4482; xu, ye/0000-0003-0455-4556; Huang, Shenglin/0000-0003-1279-0794	National Natural Science Foundation of China [81672366, 81930123, 81790252]; China Postdoctoral Science Foundation [2020M671006]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by grants from National Natural Science Foundation of China (81672366, 81930123, 81790252) and China Postdoctoral Science Foundation (2020M671006).	Athauda A, 2019, CANCER TREAT REV, V73, P31, DOI 10.1016/j.ctrv.2018.12.004; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003; Chu Ci, 2012, J Vis Exp, DOI 10.3791/3912; Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Gao S, 2014, FASEB J, V28, P1880, DOI 10.1096/fj.12-220152; Groulx I, 2002, MOL CELL BIOL, V22, P5319, DOI 10.1128/MCB.22.15.5319-5336.2002; Gudenas BL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34708-w; Han P, 2015, RNA BIOL, V12, P1094, DOI 10.1080/15476286.2015.1063770; Han P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0583-1; Hou Y, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00936; Huan L, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1122-z; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jan YH, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0698-5; Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425; Kondo Y, 2017, CANCER SCI, V108, P1927, DOI 10.1111/cas.13342; Krishnamachary B, 2003, CANCER RES, V63, P1138; Lee ST, 2010, STROKE, V41, P1646, DOI 10.1161/STROKEAHA.110.579649; Li ZJ, 2020, J CELL BIOCHEM, V121, P2406, DOI 10.1002/jcb.29463; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Mas-Ponte D, 2017, RNA, V23, P1080, DOI 10.1261/rna.060814.117; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Moinova HR, 2002, P NATL ACAD SCI USA, V99, P4562, DOI 10.1073/pnas.062459899; Neve B, 2018, CANCERS, V10, DOI 10.3390/cancers10110440; Pefanis E, 2015, CELL, V161, P774, DOI 10.1016/j.cell.2015.04.034; Saldana-Meyer R, 2019, MOL CELL, V76, P412, DOI 10.1016/j.molcel.2019.08.015; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shi LL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1332-8; Shih JW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15874; Sigova AA, 2015, SCIENCE, V350, P978, DOI 10.1126/science.aad3346; Sun YT, 2019, CANCERS, V11, DOI 10.3390/cancers11020216; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yan SY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0853-9; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Zhan PP, 2017, MOL CARCINOGEN, V56, P1427, DOI 10.1002/mc.22603; Zhao W, 2019, J CELL PHYSIOL, V234, P14519, DOI 10.1002/jcp.28143	39	29	31	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2020	39	46					7005	7018		10.1038/s41388-020-01512-8	http://dx.doi.org/10.1038/s41388-020-01512-8		OCT 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OQ9FF	33060856	hybrid, Green Published			2022-12-28	WOS:000577946300003
J	Guo, W; Zhang, CY; Feng, PP; Li, MY; Wang, X; Xia, Y; Chen, DW; Li, JX				Guo, Wei; Zhang, Cuiyu; Feng, Panpan; Li, Mingying; Wang, Xia; Xia, Yuan; Chen, Dawei; Li, Jingxin			M6A methylation of DEGS2, a key ceramide-synthesizing enzyme, is involved in colorectal cancer progression through ceramide synthesis	ONCOGENE			English	Article							STEM-LIKE CELLS; DIHYDROCERAMIDE DESATURASE; EXPRESSION; N-6-METHYLADENOSINE; SUPPRESSOR; TUMORS	N6-methyladenosine (m6A) is the most prevalent RNA epigenetic regulator in cancer. However, the understanding of m6A modification on lipid metabolism regulation in colorectal cancer (CRC) is very limited. Here, we observed that human CRCs exhibited increased m6A mRNA methylation mediated by dysregulation of m6A erasers and readers. By performing methylated RNA-immunoprecipitation sequencing (MeRIP-seq) and transcriptomic sequencing (RNA-seq), we identified DEGS2 as a downstream target of m6A dysregulation. Overexpression or knockdown of DEGS2 confirmed the role of DEGS2 in proliferation, invasion and metastasis of CRC both in vitro and in vivo. Mechanistic studies identified the specific m6A modification site within DEGS2 mRNA, and mutation of this target site was found to drastically enhance the proliferative and invasive ability of CRC cells in vitro and promote tumorigenicity in vivo. Lipidome analysis showed that lipid metabolism was dysregulated in CRC. Moreover, ceramide synthesis was suppressed due to DEGS2 upregulation mediated by m6A modification in CRC tissues. Our findings highlight that the function of DEGS2 m6A methylation in CRC and extend the understanding of the importance of RNA epigenetics in cancer biology.	[Guo, Wei] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Colorectal Surg, Jinan, Shandong, Peoples R China; [Zhang, Cuiyu; Wang, Xia; Li, Jingxin] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Physiol, Jinan, Shandong, Peoples R China; [Feng, Panpan; Li, Mingying; Xia, Yuan] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Hematol, Jinan, Shandong, Peoples R China; [Chen, Dawei] Univ Liege, CHU, Interdisciplinary Cluster Appl Genoprote GIGA Ste, Fac Med,Lab Med Chem, Liege, Belgium	Shandong University; Shandong University; Shandong University; University of Liege	Li, JX (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Physiol, Jinan, Shandong, Peoples R China.	ljingxin@sdu.edu.cn	Li, Jing/GYU-5036-2022	Chen, Dawei/0000-0002-2541-4512; wang, xia/0000-0002-4294-8022; Guo, Wei/0000-0001-8405-832X	National Natural Science Foundation of China [82000779, 31971061]; Taishan Pandeng Scholar Program of Shandong Province [tspd20210321]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Pandeng Scholar Program of Shandong Province	This work was supported in part by the National Natural Science Foundation of China (82000779, 31971061); and Taishan Pandeng Scholar Program of Shandong Province (tspd20210321).	Antony J, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf8175; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai XL, 2018, CANCER LETT, V415, P11, DOI 10.1016/j.canlet.2017.11.018; Casasampere M, 2016, CHEM PHYS LIPIDS, V197, P33, DOI 10.1016/j.chemphyslip.2015.07.025; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Chen HR, 2021, GASTROENTEROLOGY, V160, P1284, DOI 10.1053/j.gastro.2020.11.013; Dang W, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00417; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760; Engel M, 2018, GENES BRAIN BEHAV, V17, DOI 10.1111/gbb.12428; Fabrias G, 2012, PROG LIPID RES, V51, P82, DOI 10.1016/j.plipres.2011.12.002; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gao X, 2010, ONCOGENE, V29, P4555, DOI 10.1038/onc.2010.213; Garborg K, 2013, ANN ONCOL, V24, P1963, DOI 10.1093/annonc/mdt157; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hua WF, 2018, GYNECOL ONCOL, V151, P356, DOI 10.1016/j.ygyno.2018.09.015; Lan Q, 2019, CANCER RES, V79, P1285, DOI 10.1158/0008-5472.CAN-18-2965; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1038-7; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Liu J, 2018, NAT CELL BIOL, V20, P1074, DOI 10.1038/s41556-018-0174-4; Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885; Mathiyalagan P, 2019, CIRCULATION, V139, P518, DOI 10.1161/CIRCULATIONAHA.118.033794; Meyer KD, 2017, ANNU REV CELL DEV BI, V33, P319, DOI 10.1146/annurev-cellbio-100616-060758; Meyer KD, 2014, NAT REV MOL CELL BIO, V15, P313, DOI 10.1038/nrm3785; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Sargent D, 2009, J CLIN ONCOL, V27, P872, DOI 10.1200/JCO.2008.19.5362; Selzner M, 2001, CANCER RES, V61, P1233; Shen CQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01190-w; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Tong JY, 2018, FRONT MED-PRC, V12, P481, DOI 10.1007/s11684-018-0654-8; Tuncel G, 2019, MED ONCOL, V36, DOI 10.1007/s12032-019-1260-6; Visvanathan A, 2018, ONCOGENE, V37, P522, DOI 10.1038/onc.2017.351; Xu JH, 2020, ONCOL REP, V44, P973, DOI 10.3892/or.2020.7665; Yang X, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1146-4; Yang Y, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0740-0; Yang Y, 2019, J CLIN ENDOCR METAB, V104, P665, DOI 10.1210/jc.2018-00619; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhao BXS, 2017, NAT REV MOL CELL BIO, V18, P31, DOI 10.1038/nrm.2016.132	42	6	6	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5913	5924		10.1038/s41388-021-01987-z	http://dx.doi.org/10.1038/s41388-021-01987-z		AUG 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34363020	Green Published, hybrid			2022-12-28	WOS:000682519100001
J	Whately, KM; Voronkova, MA; Maskey, A; Gandhi, J; Loskutov, J; Choi, H; Yanardag, S; Chen, DQ; Wen, SJ; Margaryan, NV; Smolkin, MB; Purazo, ML; Hu, GQ; Pugacheva, EN				Whately, Kristina M.; Voronkova, Maria A.; Maskey, Abha; Gandhi, Jasleen; Loskutov, Juergen; Choi, Hyeran; Yanardag, Sila; Chen, Dongquan; Wen, Sijin; Margaryan, Naira, V; Smolkin, Matthew B.; Purazo, Marc L.; Hu, Gangqing; Pugacheva, Elena N.			Nuclear Aurora-A kinase-induced hypoxia signaling drives early dissemination and metastasis in breast cancer: implications for detection of metastatic tumors	ONCOGENE			English	Article							INDUCIBLE FACTOR-1-ALPHA; MESENCHYMAL TRANSITION; DOWN-REGULATION; EXPRESSION; SURVIVAL; ACTIVATION; PROGNOSIS; CARCINOMA; THERAPY	Metastatic breast cancer causes most breast cancer-associated deaths, especially in triple negative breast cancers (TNBC). The metastatic drivers of TNBCs are still poorly understood, and effective treatment non-existent. Here we reveal that the presence of Aurora-A Kinase (AURKA) in the nucleus and metastatic dissemination are molecularly connected through HIF1 (Hypoxia-Inducible Factor-1) signaling. Nuclear AURKA activates transcription of "hypoxia-induced genes" under normoxic conditions (pseudohypoxia) and without upregulation of oxygen-sensitive HIF1A subunit. We uncover that AURKA preferentially binds to HIF1B and co-localizes with the HIF complex on DNA. The mass-spectrometry analysis of the AURKA complex further confirmed the presence of CBP and p300 along with other TFIIB/RNApol II components. Importantly, the expression of multiple HIF-dependent genes induced by nuclear AURKA (N-AURKA), including migration/invasion, survival/death, and stemness, promote early cancer dissemination. These results indicate that nuclear, but not cytoplasmic, AURKA is a novel driver of early metastasis. Analysis of clinical tumor specimens revealed a correlation between N-AURKA presence and decreased patient survival. Our results establish a mechanistic link between two critical pathways in cancer metastasis, identifying nuclear AURKA as a crucial upstream regulator of the HIF1 transcription complex and a target for anti-metastatic therapy.	[Whately, Kristina M.; Voronkova, Maria A.; Maskey, Abha; Loskutov, Juergen; Choi, Hyeran; Yanardag, Sila; Margaryan, Naira, V; Purazo, Marc L.; Pugacheva, Elena N.] West Virginia Univ, Dept Biochem, Morgantown, WV 26506 USA; [Whately, Kristina M.; Voronkova, Maria A.; Maskey, Abha; Loskutov, Juergen; Yanardag, Sila; Wen, Sijin; Purazo, Marc L.; Hu, Gangqing; Pugacheva, Elena N.] West Virginia Univ, WVU Canc Inst, Sch Med, Morgantown, WV 26506 USA; [Gandhi, Jasleen; Hu, Gangqing] West Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; [Chen, Dongquan] UAB Comprehens Canc Ctr, Dept Med, Div Prevent Med, Birmingham, AL USA; [Wen, Sijin] West Virginia Univ, Sch Publ Hlth, Dept Biostat, Morgantown, WV 26506 USA; [Smolkin, Matthew B.] West Virginia Univ, Dept Pathol, Morgantown, WV 26506 USA	West Virginia University; West Virginia University; West Virginia University; University of Alabama System; University of Alabama Birmingham; West Virginia University; West Virginia University	Pugacheva, EN (corresponding author), West Virginia Univ, Dept Biochem, Morgantown, WV 26506 USA.; Pugacheva, EN (corresponding author), West Virginia Univ, WVU Canc Inst, Sch Med, Morgantown, WV 26506 USA.	epugacheva@hsc.wvu.edu		Yanardag, Sila/0000-0002-0658-3978; Whately, Kristina/0000-0002-5908-8145; Maskey, Abha/0000-0003-3688-5376; Gandhi, Jasleen/0000-0001-5724-4194; Voronkova, Maria/0000-0001-9778-5032	WVUCI; NIH [P20 RR016440, P30 RR032138/GM103488, P30GM103488, P30RR032138, RCP1101809, P20RR016440, U54GM104942, S10RR026378, GM104942, GM103434, OD016165, GM121322, P20GM103434, U54 GM-104942]; NIH-NCI [CA148671]; National Cancer Institute of the National Institutes of Health [CA148671]	WVUCI; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank WVU HSC Office of Graduate Research and Education for outstanding administrative support, WVU Tissue Bank, Genetic Tumor Modeling Core, and Animal Models & Imaging Facilities, supported by the WVUCI and NIH grants P20 RR016440, P30 RR032138/GM103488, and S10RR026378. Flow Cytometry Facility was supported by NIH grants P30GM103488, P30RR032138, and RCP1101809. Bioinformatics Core by NIH grants P20GM103434 and U54 GM-104942. This work was supported by a grant from NIH-NCI CA148671 to ENP. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number CA148671 (to ENP). Small animal imaging and cell image analysis were performed in the West Virginia University Animal Models & Imaging Facility, supported by NIH grants P20RR016440, P30GM103488, U54GM104942, P20GM103434, and S10RR026378. The flow cytometry analysis was done in WVU Flow Cytometry & Single Cell Core Facility, supported by NIH grants GM121322, GM104942, GM103434, and OD016165. The genetic tumor modeling (GTM) core facility provided animal models supported by NIH grant GM121322. The WVU Bioinformatics Core Facility supported by NIH grants P20GM103434 and U54 GM-104942 assisted with RNA-Seq data analysis and interpretation.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Andrzejewski S, 2017, CELL METAB, V26, P778, DOI 10.1016/j.cmet.2017.09.006; Azab AK, 2012, BLOOD, V119, P5782, DOI 10.1182/blood-2011-09-380410; Baba Y, 2009, NEOPLASIA, V11, P418, DOI 10.1593/neo.09154; Bierie B, 2017, P NATL ACAD SCI USA, V114, pE2337, DOI 10.1073/pnas.1618298114; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Briassouli P, 2007, CANCER RES, V67, P1689, DOI 10.1158/0008-5472.CAN-06-2272; Brooks DLP, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0510-x; Chen A, 2018, ONCOGENE, V37, P4214, DOI 10.1038/s41388-018-0259-3; D'Assoro AB, 2014, ONCOGENE, V33, P599, DOI 10.1038/onc.2012.628; De Bock K, 2011, NAT REV CLIN ONCOL, V8, P393, DOI 10.1038/nrclinonc.2011.83; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Friedl P, 2011, CURR OPIN CELL BIOL, V23, P55, DOI 10.1016/j.ceb.2010.10.015; Generali D, 2006, CLIN CANCER RES, V12, P4562, DOI 10.1158/1078-0432.CCR-05-2690; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Gruber G, 2004, BREAST CANCER RES, V6, pR191, DOI 10.1186/bcr775; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hayashi Y, 2019, CANCER SCI, V110, P1510, DOI 10.1111/cas.13990; Ice RJ, 2013, CANCER RES, V73, P3168, DOI 10.1158/0008-5472.CAN-12-4008; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jones BC, 2017, MOL CANCER RES, V15, P670, DOI 10.1158/1541-7786.MCR-16-0411; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kozyreva VK, 2016, MOL CANCER THER, V15, P1809, DOI 10.1158/1535-7163.MCT-15-0688; Mao JH, 2007, CANCER CELL, V11, P161, DOI 10.1016/j.ccr.2006.11.025; Melchionna R, 2010, CARDIOVASC RES, V86, P293, DOI 10.1093/cvr/cvp393; Nadler Y, 2008, CLIN CANCER RES, V14, P4455, DOI 10.1158/1078-0432.CCR-07-5268; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Orlando IMC, 2020, HAEMATOLOGICA, V105, P2774, DOI 10.3324/haematol.2019.236406; Pankova K, 2010, CELL MOL LIFE SCI, V67, P63, DOI 10.1007/s00018-009-0132-1; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; SEMENZA GL, 2016, BBA-MOL CELL RES, V1863, P382, DOI DOI 10.1016/J.BBAMCR.2015.05.036; Tanaka E, 2005, CLIN CANCER RES, V11, P1827, DOI 10.1158/1078-0432.CCR-04-1627; Tatsuka M, 2009, MOL CARCINOGEN, V48, P810, DOI 10.1002/mc.20525; Wang LH, 2010, CANCER RES, V70, P9118, DOI 10.1158/0008-5472.CAN-10-1246; Wang W, 2014, CLIN CHIM ACTA, V428, P32, DOI 10.1016/j.cca.2013.10.018; Xu HT, 2006, PATHOL INT, V56, P375, DOI 10.1111/j.1440-1827.2006.01974.x; Xu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056919; Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154; Yang N, 2017, ONCOGENE, V36, P3428, DOI 10.1038/onc.2016.490; Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365; Zheng FM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10180	44	3	3	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5651	5664		10.1038/s41388-021-01969-1	http://dx.doi.org/10.1038/s41388-021-01969-1		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34326467	Green Accepted			2022-12-28	WOS:000679262900002
J	Majhi, PD; Griner, NB; Mayfield, JA; Compton, S; Kane, JJ; Baptiste, TA; Dunphy, KA; Roberts, AL; Schneider, SS; Savage, EM; Patel, D; Blackburn, AC; Maurus, KJ; Wiesmuller, L; Jerry, DJ				Majhi, Prabin Dhangada; Griner, Nicholas B.; Mayfield, Jacob A.; Compton, Shannon; Kane, Jeffrey J.; Baptiste, Trevor A.; Dunphy, Karen A.; Roberts, Amy L.; Schneider, Sallie S.; Savage, Evan M.; Patel, Divyen; Blackburn, Anneke C.; Maurus, Kim Joana; Wiesmueller, Lisa; Jerry, D. Joseph			Genetic modifiers regulating DNA replication and double-strand break repair are associated with differences in mammary tumors in mouse models of Li-Fraumeni syndrome	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY GENES; CANCER; RADIATION; MICE; P53; APOPTOSIS; TUMORIGENESIS; MUTATION; ALLELES	Breast cancer is the most common tumor among women with inherited variants in the TP53 tumor suppressor, but onset varies widely suggesting interactions with genetic or environmental factors. Rodent models haploinsufficent for Trp53 also develop a wide variety of malignancies associated with Li-Fraumeni syndrome, but BALB/c mice are uniquely susceptible to mammary tumors and is genetically linked to the Suprmam1 locus on chromosome 7. To define mechanisms that interact with deficiencies in p53 to alter susceptibility to mammary tumors, we fine mapped the Suprmam1 locus in females from an N2 backcross of BALB/cMed and C57BL/6J mice. A major modifier was localized within a 10 cM interval on chromosome 7. The effect of the locus on DNA damage responses was examined in the parental strains and mice that are congenic for C57BL/6J alleles on the BALB/cMed background (SM1-Trp53(+/-)). The mammary epithelium of C57BL/6J-Trp53(+/-) females exhibited little radiation-induced apoptosis compared to BALB/cMed-Trp53(+/-) and SM1-Trp53(+/-) females indicating that the Suprmam1(B6/B6) alleles could not rescue repair of radiation-induced DNA double-strand breaks mostly relying on non-homologous end joining. In contrast, the Suprmam1(B6/B6) alleles in SM1-Trp53(+/-) mice were sufficient to confer the C57BL/6J-Trp53(+/-) phenotypes in homology-directed repair and replication fork progression. The Suprmam1(B6/B6) alleles in SM1-Trp53(+/-) mice appear to act in trans to regulate a panel of DNA repair and replication genes which lie outside the locus.	[Majhi, Prabin Dhangada; Griner, Nicholas B.; Compton, Shannon; Baptiste, Trevor A.; Dunphy, Karen A.; Roberts, Amy L.; Jerry, D. Joseph] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; [Majhi, Prabin Dhangada] Ravenshaw Univ, Dept Bot, Cuttack, Odisha, India; [Mayfield, Jacob A.] Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, 75 Francis St, Boston, MA 02115 USA; [Kane, Jeffrey J.] Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA; [Schneider, Sallie S.] Univ Massachusetts, Med Sch Baystate, Dept Surg, Springfield, MA USA; [Schneider, Sallie S.; Jerry, D. Joseph] Pioneer Valley Life Sci Inst, Springfield, MA 01199 USA; [Savage, Evan M.; Patel, Divyen] Genome Explorat, Memphis, TN USA; [Blackburn, Anneke C.] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT, Australia; [Maurus, Kim Joana; Wiesmueller, Lisa] Ulm Univ, Dept Obstet & Gynecol, Ulm, Germany	University of Massachusetts System; University of Massachusetts Amherst; Ravenshaw University; Harvard University; Brigham & Women's Hospital; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; Australian National University; John Curtin School of Medical Research; Ulm University	Jerry, DJ (corresponding author), Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA.; Jerry, DJ (corresponding author), Pioneer Valley Life Sci Inst, Springfield, MA 01199 USA.; Wiesmuller, L (corresponding author), Ulm Univ, Dept Obstet & Gynecol, Ulm, Germany.	lisa.wiesmueller@uni-ulm.de; jjerry@vasci.umass.edu		Roberts, Amy/0000-0003-0178-1737; Mayfield, Jacob/0000-0002-5762-6755; Compton, Shannon/0000-0001-9372-1891	National Institute of Environmental Health Sciences of the National Institutes of Health [R01CA105452, U01ES026140]; Department of Defense [W81XWH-15-1-0217]; Rays of Hope Center for Breast Cancer Research; University Grants Commission (India); German Research Foundation (DFG, Research Training Group 2554); DFG	National Institute of Environmental Health Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Department of Defense(United States Department of Defense); Rays of Hope Center for Breast Cancer Research; University Grants Commission (India)(University Grants Commission, India); German Research Foundation (DFG, Research Training Group 2554)(German Research Foundation (DFG)); DFG(German Research Foundation (DFG))	Research reported in this publication was supported, in part, by the National Institute of Environmental Health Sciences of the National Institutes of Health under award number R01CA105452 (DJJ), U01ES026140 (DJJ, SSS), the Department of Defense under contract #W81XWH-15-1-0217 (DJJ) and the Rays of Hope Center for Breast Cancer Research (DJJ), University Grants Commission (India) for Raman Fellowship for post-doctoral research (PDM) as well as by the German Research Foundation (DFG, Research Training Group 2554 to LW) and by the DFG-funded Graduate School of Molecular Medicine, Ulm University (PhD fellowship to KJM).	Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Amadou A, 2018, CURR OPIN ONCOL, V30, P23, DOI 10.1097/CCO.0000000000000423; Backlund MG, 2001, CANCER RES, V61, P6577; Becker KA, 2005, ONCOGENE, V24, P6345, DOI 10.1038/sj.onc.1208787; Blackburn AC, 2003, CANCER RES, V63, P2364; Blackburn AC, 2007, AM J PATHOL, V170, P2030, DOI 10.2353/ajpath.2007.060512; Bohringer M, 2013, ONCOGENE, V32, P5458, DOI 10.1038/onc.2013.38; Bouaoun L, 2016, HUM MUTAT, V37, P865, DOI 10.1002/humu.23035; Bowman-Colin C, 2013, P NATL ACAD SCI USA, V110, P8632, DOI 10.1073/pnas.1305362110; Broman KW, 2003, BIOINFORMATICS, V19, P889, DOI 10.1093/bioinformatics/btg112; Chang HHY, 2017, NAT REV MOL CELL BIO, V18, P495, DOI 10.1038/nrm.2017.48; Chen JJ, 1999, CANCER RES, V59, p1752S; Deniz M, 2017, ONCOTARGET, V8, P98660, DOI 10.18632/oncotarget.21720; Didion JP, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-34; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Donehower LA, 2019, CELL REP, V28, P3010, DOI 10.1016/j.celrep.2019.08.061; Dudgeon C, 2014, GENE DEV, V28, P2613, DOI 10.1101/gad.252148.114; Fletcher O, 2011, JNCI-J NATL CANCER I, V103, P425, DOI 10.1093/jnci/djq563; Fortuno C, 2018, HUM MUTAT, V39, P1764, DOI 10.1002/humu.23656; Hansen SA, 2016, DIS MODEL MECH, V9, P1139, DOI 10.1242/dmm.025767; Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jalan M, 2019, CANCERS, V11, DOI 10.3390/cancers11071038; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Karanam K, 2012, MOL CELL, V47, P320, DOI 10.1016/j.molcel.2012.05.052; Keimling M, 2012, FASEB J, V26, P2094, DOI 10.1096/fj.11-200790; Koch JG, 2007, MAMM GENOME, V18, P300, DOI 10.1007/s00335-007-9028-2; Kolishovski G, 2019, MAMM GENOME, V30, P353, DOI 10.1007/s00335-019-09821-4; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li YR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14261-4; Majhi PD, 2020, ENVIRON HEALTH PERSP, V128, DOI 10.1289/EHP5221; Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563; Milne RL, 2016, ENDOCR-RELAT CANCER, V23, pT69, DOI 10.1530/ERC-16-0277; Mori N, 1995, GENOMICS, V30, P553, DOI 10.1006/geno.1995.1276; MORI N, 1995, GENOMICS, V25, P609, DOI 10.1016/0888-7543(95)80001-3; Okayasu R, 2000, CANCER RES, V60, P4342; Ramos EM, 2014, EUR J HUM GENET, V22, P144, DOI 10.1038/ejhg.2013.96; Ratnadiwakara M, 2019, J STEROID BIOCHEM, V188, P48, DOI 10.1016/j.jsbmb.2018.12.004; Sasaki H, 2001, AM J PATHOL, V159, P359, DOI 10.1016/S0002-9440(10)61702-6; Schoenfelder S, 2019, NAT REV GENET, V20, P437, DOI 10.1038/s41576-019-0128-0; Scully R, 2019, NAT REV MOL CELL BIO, V20, P698, DOI 10.1038/s41580-019-0152-0; Snijders AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045394; Tchatchou S, 2010, HUM MUTAT, V31, P60, DOI 10.1002/humu.21134; Ullrich RL, 1996, RADIAT RES, V146, P353, DOI 10.2307/3579468; Wang JR, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S3-S13; Weil MM, 1997, GENOMICS, V45, P626, DOI 10.1006/geno.1997.4999; Weil MM, 2001, GENOMICS, V72, P73, DOI 10.1006/geno.2000.6465; Wendt C, 2019, ACTA ONCOL, V58, P135, DOI 10.1080/0284186X.2018.1529428; Xu J., 2005, CURR PROTOC MOL BIOL; Yan HX, 2012, CARCINOGENESIS, V33, P2001, DOI 10.1093/carcin/bgs238; Yu YJ, 2001, CANCER RES, V61, P1820; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001	54	1	1	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					5026	5037		10.1038/s41388-021-01892-5	http://dx.doi.org/10.1038/s41388-021-01892-5		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34183771	Green Accepted			2022-12-28	WOS:000667587200001
J	Zhang, JY; Liu, Y; Tan, JY; Zhang, YM; Wong, CW; Lin, ZQ; Liu, XC; Sander, M; Yan, XZ; Liang, LB; Song, DL; Dan, J; Zhou, YW; Cai, J; Lin, Y; Liang, JK; Hu, J; Yan, GM; Zhu, WB				Zhang, Jiayu; Liu, Ying; Tan, Jingyi; Zhang, Yanming; Wong, Chun-Wa; Lin, Ziqing; Liu, Xincheng; Sander, Max; Yan, Xiaozhi; Liang, Lebin; Song, Deli; Dan, Jia; Zhou, Yuwei; Cai, Jing; Lin, Yuan; Liang, Jiankai; Hu, Jun; Yan, Guangmei; Zhu, Wenbo			Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC	ONCOGENE			English	Article							CANCER STATISTICS; VIRUS; IDENTIFICATION; PATHWAYS	Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype among breast tumors and remains a challenge even for the most current therapeutic regimes. Here, we demonstrate that oncolytic alphavirus M1 effectively kills both TNBC and non-TNBC. ER-stress and apoptosis pathways are responsible for the cell death in non-TNBC as reported in other cancer types, yet the cell death in TNBC does not depend on these pathways. Transcriptomic analysis reveals that the M1 virus activates necroptosis in TNBC, which can be pharmacologically blocked by necroptosis inhibitors. By screening a library of clinically available compounds commonly used for breast cancer treatment, we find that Doxorubicin enhances the oncolytic effect of the M1 virus by up to 100-fold specifically in TNBC in vitro, and significantly stalls the tumor growth of TNBC in vivo, through promoting intratumoral virus replication and further triggering apoptosis in addition to necroptosis. These findings reveal a novel antitumor mechanism and a new combination regimen of the M1 oncolytic virus in TNBC, and highlight a need to bridge molecular diagnosis with virotherapy.	[Zhang, Jiayu; Tan, Jingyi; Zhang, Yanming; Wong, Chun-Wa; Liu, Xincheng; Liang, Lebin; Song, Deli; Dan, Jia; Zhou, Yuwei; Cai, Jing; Lin, Yuan; Liang, Jiankai; Hu, Jun; Yan, Guangmei; Zhu, Wenbo] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Dept Pharmacol, Guangzhou 510080, Peoples R China; [Liu, Ying] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, 600 Tianhe Rd, Guangzhou 510630, Peoples R China; [Lin, Ziqing; Sander, Max; Yan, Xiaozhi] Guangzhou Virotech Pharmaceut Co Ltd, 3 Lanyue Rd,Sci Pk, Guangzhou 510663, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Zhu, WB (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Dept Pharmacol, Guangzhou 510080, Peoples R China.	zhuwenbo@mail.sysu.edu.cn		Wong, Chun-wa/0000-0003-3476-9283; Lin, Yuan/0000-0002-7152-0965; zhang, Jiayu/0000-0003-1132-1101	National Natural Science Foundation of China [81872886]; Fundamental Research Funds for the Central Universities [19ykpy36, 19ykpy166]; Guangdong Basic and Applied Basic Research Foundation [2020A1515011446]; Pioneering talents project of Guangzhou Development Zone, Guangdong Province [CY2018-012]; Leading Team for Entrepreneurship in Guangzhou, Guangdong Province [201809020004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Guangdong Basic and Applied Basic Research Foundation; Pioneering talents project of Guangzhou Development Zone, Guangdong Province; Leading Team for Entrepreneurship in Guangzhou, Guangdong Province	We thank all authors who contributed to this work. This work was supported by the National Natural Science Foundation of China (No. 81872886), Fundamental Research Funds for the Central Universities (19ykpy36 and 19ykpy166), Guangdong Basic and Applied Basic Research Foundation (2020A1515011446), Pioneering talents project of Guangzhou Development Zone, Guangdong Province (CY2018-012), and Leading Team for Entrepreneurship in Guangzhou, Guangdong Province (201809020004).	Adair RA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003578; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Brown CM, 1998, TROP ANIM HEALTH PRO, V30, P241, DOI 10.1023/A:1005079229232; Budhwani M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00322; Cai J, 2021, HUM GENE THER, V32, P138, DOI 10.1089/hum.2020.271; de Graaf JF, 2018, CYTOKINE GROWTH F R, V41, P28, DOI 10.1016/j.cytogfr.2018.03.006; Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549-008-0086-2; DeSantis CE, 2017, CA-CANCER J CLIN, V67, P439, DOI 10.3322/caac.21412; Forrest RA, 2012, BIOCHEM PHARMACOL, V83, P1602, DOI 10.1016/j.bcp.2012.02.026; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; Gong YT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1029-8; Goradel NH, 2021, CURR PROB CANCER, V45, DOI 10.1016/j.currproblcancer.2020.100639; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hu J, 2009, CELL CYCLE, V8, P3328, DOI 10.4161/cc.8.20.9832; Jensen EC, 2013, ANAT REC, V296, P378, DOI 10.1002/ar.22641; Kok F, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20198955; Lawler SE, 2017, JAMA ONCOL, V3, P841, DOI 10.1001/jamaoncol.2016.2064; Lazear HM, 2019, IMMUNITY, V50, P907, DOI 10.1016/j.immuni.2019.03.025; Lin Y, 2014, P NATL ACAD SCI USA, V111, pE4504, DOI 10.1073/pnas.1408759111; Liu SZ, 2017, P NATL ACAD SCI USA, V114, pE7450, DOI 10.1073/pnas.1707531114; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Miest TS, 2014, NAT REV MICROBIOL, V12, P23, DOI 10.1038/nrmicro3140; Moskovskich A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46952-9; Muhuri M, 2021, HUM GENE THER, V32, P136, DOI 10.1089/hum.2021.29150.mmu; Pang BX, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2921; Poh A, 2016, CANCER DISCOV, V6, P6, DOI 10.1158/2159-8290.CD-NB2015-158; Pu ZQ, 2020, J CELL MOL MED, V24, P14171, DOI 10.1111/jcmm.16028; Rehman H, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0158-5; Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596-018-0103-9; Russell SJ, 2012, NAT BIOTECHNOL, V30, P658, DOI 10.1038/nbt.2287; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Silke J, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003845; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Tan YQ, 2018, HUM GENE THER, V29, P950, DOI 10.1089/hum.2017.055; Tanzer MC, 2016, CELL DEATH DIFFER, V23, P1185, DOI 10.1038/cdd.2015.169; Thorn CF, 2011, PHARMACOGENET GENOM, V21, P440, DOI 10.1097/FPC.0b013e32833ffb56; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Turnbull S, 2015, VIRUSES-BASEL, V7, P6291, DOI 10.3390/v7122938; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Wahba HA, 2015, CANCER BIOL MED, V12, P106, DOI 10.7497/j.issn.2095-3941.2015.0030; Wen JS, 2007, VIRUS GENES, V35, P597, DOI 10.1007/s11262-007-0110-3; Wen SH, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0625-9; Willson J, 2020, NAT REV MOL CELL BIO, V21, P63, DOI 10.1038/s41580-019-0201-8; WU J, 2020, CANCERS, V12; XIAO X, 2018, NAT COMMUN, V9; Yang F, 2014, BBA-REV CANCER, V1845, P84, DOI 10.1016/j.bbcan.2013.12.002; Yang F, 2013, CURR BIOL, V23, P782, DOI 10.1016/j.cub.2013.03.043; Zhang HP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam7996; Zhang HP, 2016, HUM GENE THER, V27, P700, DOI 10.1089/hum.2016.038; Zhang J, 2016, CELL MOL LIFE SCI, V73, P2153, DOI 10.1007/s00018-016-2190-5; Zhu WB, 2021, HUM GENE THER, V32, P158, DOI 10.1089/hum.2020.273	52	5	5	1	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4783	4795		10.1038/s41388-021-01869-4	http://dx.doi.org/10.1038/s41388-021-01869-4		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34155344				2022-12-28	WOS:000664006400001
J	Launonen, KM; Paakinaho, V; Sigismondo, G; Malinen, M; Sironen, R; Hartikainen, JM; Laakso, H; Visakorpi, T; Krijgsveld, J; Niskanen, EA; Palvimo, JJ				Launonen, Kaisa-Mari; Paakinaho, Ville; Sigismondo, Gianluca; Malinen, Marjo; Sironen, Reijo; Hartikainen, Jaana M.; Laakso, Hanna; Visakorpi, Tapio; Krijgsveld, Jeroen; Niskanen, Einari A.; Palvimo, Jorma J.			Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SIM2; RESPONSE ELEMENT; LUNG-CANCER; GENE; COREGULATOR; METASTASIS; THERAPY; INHIBITION; EXPRESSION; PHENOTYPE	Treatment of prostate cancer confronts resistance to androgen receptor (AR)-targeted therapies. AR-associated coregulators and chromatin proteins hold a great potential for novel therapy targets. Here, we employed a powerful chromatin-directed proteomics approach termed ChIP-SICAP to uncover the composition of chromatin protein network, the chromatome, around endogenous AR in castration resistant prostate cancer (CRPC) cells. In addition to several expected AR coregulators, the chromatome contained many nuclear proteins not previously associated with the AR. In the context of androgen signaling in CRPC cells, we further investigated the role of a known AR-associated protein, a chromatin remodeler SMARCA4 and that of SIM2, a transcription factor without a previous association with AR. To understand their role in chromatin accessibility and AR target gene expression, we integrated data from ChIP-seq, RNA-seq, ATAC-seq and functional experiments. Despite the wide co-occurrence of SMARCA4 and AR on chromatin, depletion of SMARCA4 influenced chromatin accessibility and expression of a restricted set of AR target genes, especially those involved in cell morphogenetic changes in epithelial-mesenchymal transition. The depletion also inhibited the CRPC cell growth, validating SMARCA4's functional role in CRPC cells. Although silencing of SIM2 reduced chromatin accessibility similarly, it affected the expression of a much larger group of androgen-regulated genes, including those involved in cellular responses to external stimuli and steroid hormone stimulus. The silencing also reduced proliferation of CRPC cells and tumor size in chick embryo chorioallantoic membrane assay, further emphasizing the importance of SIM2 in CRPC cells and pointing to the functional relevance of this potential prostate cancer biomarker in CRPC cells. Overall, the chromatome of AR identified in this work is an important resource for the field focusing on this important drug target.	[Launonen, Kaisa-Mari; Paakinaho, Ville; Laakso, Hanna; Niskanen, Einari A.; Palvimo, Jorma J.] Univ Eastern Finland, Fac Hlth Sci, Inst Biomed, Kuopio, Finland; [Sigismondo, Gianluca; Krijgsveld, Jeroen] German Canc Res Ctr, Heidelberg, Germany; [Malinen, Marjo] Univ Eastern Finland, Dept Environm & Biol Sci, Joensuu, Finland; [Sironen, Reijo; Hartikainen, Jaana M.] Univ Eastern Finland, Inst Clin Med Clin Pathol & Forens Med, Kuopio, Finland; [Sironen, Reijo] Kuopio Univ Hosp, Dept Clin Pathol, Kuopio, Finland; [Visakorpi, Tapio] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland; [Visakorpi, Tapio] Tampere Univ Hosp, Tays Canc Ctr, Tampere, Finland; [Visakorpi, Tapio] Fimlab Labs, Tampere, Finland; [Krijgsveld, Jeroen] Heidelberg Univ, Fac Med, Heidelberg, Germany	University of Eastern Finland; Helmholtz Association; German Cancer Research Center (DKFZ); University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Tampere University; Tampere University; Tampere University Hospital; Ruprecht Karls University Heidelberg	Palvimo, JJ (corresponding author), Univ Eastern Finland, Fac Hlth Sci, Inst Biomed, Kuopio, Finland.	jorma.palvimo@uef.fi	Niskanen, Einari/F-2883-2017; Hartikainen, Jaana/E-6256-2015	Niskanen, Einari/0000-0001-9471-7026; Paakinaho, Ville/0000-0003-4204-1436; Hartikainen, Jaana/0000-0001-8267-1905; Launonen, Kaisa-Mari/0000-0003-2770-0464; Palvimo, Jorma/0000-0003-2373-0578	Excellence Cluster CellNetworks [EXC81]; UEF DPMM; Academy of Finland; Sigrid Juselius Foundation; Cancer Foundation Finland; Paavo Koistinen Foundation; University of Eastern Finland (UEF); Kuopio University Hospital	Excellence Cluster CellNetworks; UEF DPMM; Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Cancer Foundation Finland; Paavo Koistinen Foundation; University of Eastern Finland (UEF); Kuopio University Hospital	G.S. and J.K. acknowledge the Excellence Cluster CellNetworks (EXC81). This paper was supported by UEF DPMM, Academy of Finland, Sigrid Juselius Foundation, Cancer Foundation Finland, and Paavo Koistinen Foundation. Open access funding provided by University of Eastern Finland (UEF) including Kuopio University Hospital.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Agoulnik IU, 2009, STEROIDS, V74, P669, DOI 10.1016/j.steroids.2009.02.007; Ailiken G, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0205-4; Aleman MJ, 2005, P NATL ACAD SCI USA, V102, P12765, DOI 10.1073/pnas.0505484102; Annala M, 2015, ONCOTARGET, V6, P6235, DOI 10.18632/oncotarget.3359; Arredouani MS, 2009, CLIN CANCER RES, V15, P5794, DOI 10.1158/1078-0432.CCR-09-0911; Centenera MM, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a030478; Cyrta J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19328-1; DAHMANE N, 1995, P NATL ACAD SCI USA, V92, P9191, DOI 10.1073/pnas.92.20.9191; DeYoung MP, 2003, CANCER LETT, V200, P25, DOI 10.1016/S0304-3835(03)00409-9; DeYoung MP, 2003, P NATL ACAD SCI USA, V100, P4760, DOI 10.1073/pnas.0831000100; Ding YF, 2019, J CLIN INVEST, V129, P759, DOI 10.1172/JCI123557; Fine SW, 2018, MODERN PATHOL, V31, pS122, DOI 10.1038/modpathol.2017.164; Giles KA, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148-021-01023-7; Halvorsen OJ, 2007, CLIN CANCER RES, V13, P892, DOI 10.1158/1078-0432.CCR-06-1207; Hankey W, 2020, CANCER RES, V80, P2427, DOI 10.1158/0008-5472.CAN-19-3447; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Heemers HV, 2009, MOL ENDOCRINOL, V23, P572, DOI 10.1210/me.2008-0363; Hu J, 2020, ARCH PATHOL LAB MED, V144, P320, DOI 10.5858/arpa.2019-0434-RA; Huang Y, 2010, CANCER BIOL THER, V9, P204, DOI 10.4161/cbt.9.3.10960; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; Kron KJ, 2017, NAT GENET, V49, P1336, DOI 10.1038/ng.3930; Kwak HI, 2007, CARCINOGENESIS, V28, P259, DOI 10.1093/carcin/bgl122; Labrecque MP, 2019, J CLIN INVEST, V129, P4492, DOI 10.1172/JCI128212; Lambert JP, 2014, J PROTEOMICS, V100, P55, DOI 10.1016/j.jprot.2013.12.022; Lambert JP, 2012, PROTEOMICS, V12, P1609, DOI 10.1002/pmic.201100547; Lazar JE, 2020, CELL REP, V31, DOI [10.1015/j.celrep.2020.107788, 10.1016/j.celrep.2020.107788]; Lempiainen JK, 2017, MOL CELL PROTEOMICS, V16, P1462, DOI 10.1074/mcp.M117.067488; Lu B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028837; Lv DJ, 2019, THERANOSTICS, V9, P5166, DOI 10.7150/thno.33972; Matsubara D, 2013, CANCER SCI, V104, P266, DOI 10.1111/cas.12065; Metz RP, 2006, J BIOL CHEM, V281, P10839, DOI 10.1074/jbc.M508858200; Morris SA, 2014, NAT STRUCT MOL BIOL, V21, P73, DOI 10.1038/nsmb.2718; Muthuswami R, 2019, J CELL PHYSL; O'Rourke DJ, 2012, CLIN CHIM ACTA, V413, P561, DOI 10.1016/j.cca.2011.11.027; Paakinaho V, 2019, CELL REP, V28, P3523, DOI 10.1016/j.celrep.2019.08.039; Paakinaho V, 2014, NUCLEIC ACIDS RES, V42, P1575, DOI 10.1093/nar/gkt1033; Paltoglou S, 2017, CANCER RES, V77, P3417, DOI 10.1158/0008-5472.CAN-16-1616; Pearson SJ, 2019, ONCOGENE, V38, P2611, DOI 10.1038/s41388-018-0622-4; Pomerantz MM, 2015, NAT GENET, V47, P1346, DOI 10.1038/ng.3419; Qin Q, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-1934-6; Rachidi M, 2005, INT J DEV NEUROSCI, V23, P475, DOI 10.1016/j.ijdevneu.2005.05.004; Rafiee MR, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20199370; Rafiee MR, 2016, MOL CELL, V64, P624, DOI 10.1016/j.molcel.2016.09.019; Rajaram P, 2020, MOLECULES, V25, DOI 10.3390/molecules25102448; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Roesley SNA, 2018, CELL CYCLE, V17, P1559, DOI 10.1080/15384101.2018.1493414; Roy N, 2015, GENE DEV, V29, P658, DOI 10.1101/gad.256628.114; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Sandoval GJ, 2018, MOL CELL, V71, P554, DOI 10.1016/j.molcel.2018.06.040; Schick S, 2019, NAT GENET, V51, P1399, DOI 10.1038/s41588-019-0477-9; Sharma A, 2017, MOL ONCOL, V11, P655, DOI 10.1002/1878-0261.12059; Sharma NL, 2014, NUCLEIC ACIDS RES, V42, P6256, DOI 10.1093/nar/gku281; Stelloo S, 2018, ONCOGENE, V37, P313, DOI 10.1038/onc.2017.330; Swinstead EE, 2016, BIOESSAYS, V38, P1150, DOI 10.1002/bies.201600137; Toropainen S, 2015, NUCLEIC ACIDS RES, V43, P848, DOI 10.1093/nar/gku1375; Wang GC, 2018, GENE DEV, V32, P1105, DOI 10.1101/gad.315739.118; Wong YNS, 2014, NAT REV CLIN ONCOL, V11, P365, DOI 10.1038/nrclinonc.2014.72; Woods SL, 2002, J BIOL CHEM, V277, P10236, DOI 10.1074/jbc.M110752200; Woods S, 2008, NUCLEIC ACIDS RES, V36, P3716, DOI 10.1093/nar/gkn247; Wu DL, 2017, CURR OPIN STRUC BIOL, V43, P1, DOI 10.1016/j.sbi.2016.09.011; Xu LY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221051; Yang YY, 2019, BBA-GENE REGUL MECH, V1862, P834, DOI 10.1016/j.bbagrm.2019.05.005; Yu ZY, 2014, CLIN CANCER RES, V20, P1590, DOI 10.1158/1078-0432.CCR-13-1863; Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6; Zhou Z, 2015, ONCOTARGETS THER, V8, P3603, DOI 10.2147/OTT.S95500	67	9	9	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4567	4579		10.1038/s41388-021-01887-2	http://dx.doi.org/10.1038/s41388-021-01887-2		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34127815	hybrid, Green Published			2022-12-28	WOS:000661408100003
J	Guo, M; Goudarzi, KM; Abedi, S; Pieber, M; Sjoberg, E; Behnan, J; Zhang, XM; Harris, RA; Bartek, J; Lindstrom, MS; Nister, M; Hagerstrand, D				Guo, Min; Goudarzi, Kaveh M.; Abedi, Shiva; Pieber, Melanie; Sjoberg, Elin; Behnan, Jinan; Zhang, Xing-Mei; Harris, Robert A.; Bartek, Jiri; Lindstrom, Mikael S.; Nister, Monica; Hagerstrand, Daniel			SFRP2 induces a mesenchymal subtype transition by suppression of SOX2 in glioblastoma	ONCOGENE			English	Article							STEM-LIKE CELLS; GROWTH-FACTOR; INTRATUMORAL HETEROGENEITY; KINASE INHIBITOR; CONNECTIVITY MAP; TUMOR; EXPRESSION; EGFR; PROLIFERATION; AMPLIFICATION	Intratumoral heterogeneity is a characteristic of glioblastomas that contain an intermixture of cell populations displaying different glioblastoma subtype gene expression signatures. Proportions of these populations change during tumor evolution, but the occurrence and regulation of glioblastoma subtype transition is not well described. To identify regulators of glioblastoma subtypes we utilized a combination of in vitro experiments and in silico analyses, using experimentally generated as well as publicly available data. Through this combined approach SOX2 was identified to confer a proneural glioblastoma subtype gene expression signature. SFRP2 was subsequently identified as a SOX2-antagonist, able to induce a mesenchymal glioblastoma subtype signature. A subset of patient glioblastoma samples with high SFRP2 and low SOX2 expression was particularly enriched with mesenchymal subtype samples. Phenotypically, SFRP2 decreased tumor sphere formation, stemness as assessed by limiting dilution assay, and overall cell proliferation but increased cell motility, whereas SOX2 induced the opposite effects. Furthermore, an SFRP2/non-canonical-WNT/KLF4/PDGFR/phospho-AKT/SOX2 signaling axis was found to be involved in the mesenchymal transition. Analysis of human tumor tissue spatial gene expression patterns showed distinct expression of SFRP2- and SOX2-correlated genes in vascular and cellular areas, respectively. Finally, conditioned media from SFRP2 overexpressing cells increased CD206 on macrophages. Together, these findings present SFRP2 as a SOX2-antagonist with the capacity to induce a mesenchymal subtype transition in glioma cells located in vascular tumor areas, highlighting its role in glioblastoma tumor evolution and intratumoral heterogeneity.	[Guo, Min; Abedi, Shiva; Nister, Monica; Hagerstrand, Daniel] Karolinska Inst, Dept Oncol Pathol, BioClinicum, Solna, Sweden; [Guo, Min] Capital Med Univ, Beijing Tiantan Hosp, Dept Radiol, Beijing, Peoples R China; [Goudarzi, Kaveh M.] Karolinska Inst, Dept Oncol Pathol, Sci Life Lab, Solna, Sweden; [Pieber, Melanie; Zhang, Xing-Mei; Harris, Robert A.] Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Solna, Sweden; [Sjoberg, Elin] Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, Uppsala, Sweden; [Behnan, Jinan] Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, Solna, Sweden; [Behnan, Jinan] Albert Einstein Coll Med, Dept Neurosurg, Bronx, NY 10467 USA; [Bartek, Jiri; Lindstrom, Mikael S.] Karolinska Inst, Dept Med Biochem & Biophys, Solna, Sweden; [Bartek, Jiri] Danish Canc Soc Res Ctr, Copenhagen, Denmark; [Hagerstrand, Daniel] Karolinska Inst, Dept Mol Med & Surg, BioClinicum, Solna, Sweden	Karolinska Institutet; Capital Medical University; Karolinska Institutet; Karolinska Institutet; Uppsala University; Karolinska Institutet; Yeshiva University; Albert Einstein College of Medicine; Karolinska Institutet; Danish Cancer Society; Karolinska Institutet	Guo, M (corresponding author), Karolinska Inst, Dept Oncol Pathol, BioClinicum, Solna, Sweden.; Guo, M (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Radiol, Beijing, Peoples R China.	min.guo@ki.se	Sjöberg, Elin/AFQ-2245-2022; Hägerstrand, Daniel/AAH-3009-2019; Lindström, Mikael S/AAA-1451-2019; Hägerstrand, Daniel C/D-1584-2014	Hägerstrand, Daniel/0000-0001-7270-0776; Lindström, Mikael S/0000-0003-1148-8497; Hägerstrand, Daniel C/0000-0001-7270-0776; Behnan, Jinan/0000-0001-5780-0971; Harris, Robert/0000-0003-4990-509X	Chinese Scholarship Council; Karolinska Institutet KID funding; European Commission, Research Executive Agency Marie S.Curie Individual Fellowships, H2020MSCA-IF-2018 [844948]; Swedish Cancer Society [150733, CAN 2014/836, 160334, CAN 2017/737, 180538, 2019 190316Pj]; Swedish Research Council [VR-MH 2014-46602-117891-30, K201467X-15399-10-4, VR-MH 2018-02452]; King Gustaf V's Jubilee Foundation [164102]; The Cancer Society in Stockholm [2015151213, 2018-181223]; Swedish Childhood Cancer Foundation [PR2014-0021, PR 2017-0062]; Stockholm County Council (SLL); Magnus Bergvall's stiftelse	Chinese Scholarship Council(China Scholarship Council); Karolinska Institutet KID funding(Karolinska Institutet); European Commission, Research Executive Agency Marie S.Curie Individual Fellowships, H2020MSCA-IF-2018; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); King Gustaf V's Jubilee Foundation; The Cancer Society in Stockholm; Swedish Childhood Cancer Foundation(European Commission); Stockholm County Council (SLL)(Stockholm County Council); Magnus Bergvall's stiftelse	MG: The Chinese Scholarship Council. KMG: Karolinska Institutet KID funding. JB: European Commission, Research Executive Agency Marie S.Curie Individual Fellowships, H2020MSCA-IF-2018 (Project: 844948). JB: The Swedish Cancer Society (JB, contract 150733); The Swedish Research Council (VR-MH 2014-46602-117891-30). MSL: Karolinska Institutet Funds; King Gustaf V's Jubilee Foundation (contract 164102). MN: Karolinska Institutet Funds; LA-private donations; The Swedish Cancer Society (CAN 2014/836, contract 160334, CAN 2017/737, contract 180538, and 2019 190316Pj); The Cancer Society in Stockholm (2015151213 and 2018-181223); The Swedish Research Council (K201467X-15399-10-4, VR-MH 2018-02452); The Swedish Childhood Cancer Foundation (PR2014-0021 and PR 2017-0062); Stockholm County Council (SLL). DH: Karolinska Institutet Funds; Magnus Bergvall's stiftelse; LA-private donations.	An ZJ, 2019, CELL REP, V29, P1986, DOI 10.1016/j.celrep.2019.10.026; Baer K, 2007, EXP NEUROL, V204, P828, DOI 10.1016/j.expneurol.2006.12.008; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Brinkmann EM, 2016, J BIOL CHEM, V291, P13730, DOI 10.1074/jbc.M116.733766; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cooper LAD, 2012, AM J PATHOL, V180, P2108, DOI 10.1016/j.ajpath.2012.01.040; Garros-Regulez L, 2016, EXPERT OPIN THER TAR, V20, P393, DOI 10.1517/14728222.2016.1151002; Goudarzi KM, 2018, CANCER RES, V78, P5901, DOI 10.1158/0008-5472.CAN-18-0320; Guo Min, 2020, Neurooncol Adv, V2, pvdaa061, DOI 10.1093/noajnl/vdaa061; Hagerstrand D, 2006, ONCOGENE, V25, P4913, DOI 10.1038/sj.onc.1209497; Hagerstrand D, 2011, NEURO-ONCOLOGY, V13, P1178, DOI 10.1093/neuonc/nor113; Han MZ, 2020, BRAIN, V143, P512, DOI 10.1093/brain/awz406; HERMANSON M, 1992, CANCER RES, V52, P3213; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; Jeong CH, 2010, STEM CELLS, V28, P2141, DOI 10.1002/stem.540; Kaffes I, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1655360; Kong WH, 2012, EVOL DEV, V14, P168, DOI 10.1111/j.1525-142X.2012.00533.x; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu LJ, 2017, NAT CELL BIOL, V19, P177, DOI 10.1038/ncb3474; Marques S, 2016, SCIENCE, V352, P1326, DOI 10.1126/science.aaf6463; Meyer M, 2015, P NATL ACAD SCI USA, V112, P851, DOI 10.1073/pnas.1320611111; Minata M, 2019, CELL REP, V26, P1893, DOI 10.1016/j.celrep.2019.01.076; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Puchalski RB, 2018, SCIENCE, V360, P660, DOI 10.1126/science.aaf2666; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Savary K, 2013, ONCOGENE, V32, P5409, DOI 10.1038/onc.2013.67; Segerman A, 2016, CELL REP, V17, P2994, DOI 10.1016/j.celrep.2016.11.056; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Szerlip NJ, 2012, P NATL ACAD SCI USA, V109, P3041, DOI 10.1073/pnas.1114033109; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tang JM, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0074-2; Taylor TE, 2012, CURR CANCER DRUG TAR, V12, P197; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wald JH, 2017, ONCOGENE, V36, P5158, DOI 10.1038/onc.2017.126; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Wang Z, 2019, ONCOGENE, V38, P5250, DOI 10.1038/s41388-019-0790-x; Wurth R, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00144; Xie Y, 2015, EBIOMEDICINE, V2, P1351, DOI 10.1016/j.ebiom.2015.08.026; Zhao Z, 2021, GENOM PROTEOM BIOINF, V19, P1, DOI 10.1016/j.gpb.2020.10.005; Zheng B, 2009, J BIOL CHEM, V284, P22773, DOI 10.1074/jbc.M109.026989	52	5	5	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5066	5080		10.1038/s41388-021-01825-2	http://dx.doi.org/10.1038/s41388-021-01825-2		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34021259	hybrid, Green Published			2022-12-28	WOS:000652945900002
J	Leon, LM; Gautier, M; Allan, R; Ilie, M; Nottet, N; Pons, N; Paquet, A; Lebrigand, K; Truchi, M; Fassy, J; Magnone, V; Kinnebrew, G; Radovich, M; Cheok, MHC; Barbry, P; Vassaux, G; Marquette, CH; Ponzio, G; Ivan, M; Pottier, N; Hofman, P; Mari, B; Rezzonico, R				Leon, Laura Moreno; Gautier, Marine; Allan, Richard; Ilie, Marius; Nottet, Nicolas; Pons, Nicolas; Paquet, Agnes; Lebrigand, Kevin; Truchi, Marin; Fassy, Julien; Magnone, Virginie; Kinnebrew, Garrett; Radovich, Milan; Cheok, Meyling Hua-Chen; Barbry, Pascal; Vassaux, Georges; Marquette, Charles-Hugo; Ponzio, Gilles; Ivan, Mircea; Pottier, Nicolas; Hofman, Paul; Mari, Bernard; Rezzonico, Roger			The nuclear hypoxia-regulated NLUCAT1 long noncoding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress (vol 38, pg 7146, 2019)	ONCOGENE			English	Correction												mari@unice.fr; rezzonico@ipmc.cnrs.fr	Vassaux, Georges/N-9724-2016; REZZONICO, Roger/N-9626-2016; Moreno Leon, Laura/AGP-7137-2022; Cheok, Meyling/AFS-4025-2022; Mari, Bernard P/GVS-3100-2022; Cheok, Meyling h/C-3822-2014; Mari, Bernard/Q-5832-2019; Barbry, Pascal/O-5021-2016	Vassaux, Georges/0000-0002-1149-7716; REZZONICO, Roger/0000-0002-8460-1641; Moreno Leon, Laura/0000-0002-5560-1765; Cheok, Meyling/0000-0002-7820-8026; Mari, Bernard P/0000-0002-0422-9182; Cheok, Meyling h/0000-0002-7820-8026; Mari, Bernard/0000-0002-0422-9182; Barbry, Pascal/0000-0001-9632-6483				Leon LM, 2019, ONCOGENE, V38, P7146, DOI 10.1038/s41388-019-0935-y	1	3	3	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2621	2621		10.1038/s41388-021-01670-3	http://dx.doi.org/10.1038/s41388-021-01670-3		MAR 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33686243	Bronze			2022-12-28	WOS:000626396000004
J	Ma, HH; Zhang, FQ; Zhou, L; Cao, TY; Sun, DC; Wen, SX; Zhu, JP; Xiong, ZQY; Tsau, MT; Cheng, ML; Hung, LM; Zhou, YM; Li, QX				Ma, Huanhuan; Zhang, Fengqiong; Zhou, Lin; Cao, Tingyan; Sun, Dachao; Wen, Shixiong; Zhu, Jinpei; Xiong, Zhaoqianyu; Tsau, Ming-Tong; Cheng, Mei-Ling; Hung, Li-Man; Zhou, Yanming; Li, Qinxi			c-Src facilitates tumorigenesis by phosphorylating and activating G6PD	ONCOGENE			English	Article								Glucose-6-phosphate dehydrogenase (G6PD) is the first and rate-limiting enzyme in pentose phosphate pathway (PPP), excessive activation of which has been considered to be involved in tumorigenesis. Here, we show that tyrosine kinase c-Src interacts with and phosphorylates G6PD at Tyr 112. This phosphorylation enhances catalytic activity of G6PD by dramatically decreasing its K-m value and increasing its K-cat value for substrate glucose-6-phosphate. Activated G6PD therefore augments the PPP flux for NADPH and ribose-5-phosphate production which is required for detoxification of intracellular reactive oxygen species (ROS) and biosynthesis of cancer cells, and eventually contributes to tumorigenesis. Consistently, c-Src activation is closely correlated with tyrosine phosphorylation and activity of G6PD in clinical colorectal cancer samples. We thus uncover another aspect of c-Src in promoting cell proliferation and tumorigenesis, deepening our understanding of c-Src as a proto-oncogene.	[Ma, Huanhuan; Zhang, Fengqiong; Zhou, Lin; Cao, Tingyan; Sun, Dachao; Wen, Shixiong; Zhu, Jinpei; Xiong, Zhaoqianyu; Li, Qinxi] Xiamen Univ, State Key Lab Cellular Stress Biol, Innovat Ctr Cell Signaling Network, Sch Life Sci, Xiamen, Fujian, Peoples R China; [Tsau, Ming-Tong; Cheng, Mei-Ling] Chang Gung Univ, Hlth Aging Res Ctr, Metabol Core Lab, Taoyuan, Taiwan; [Cheng, Mei-Ling] Chang Gung Mem Hosp, Clin Metabol Core Lab, Taoyuan, Taiwan; [Cheng, Mei-Ling; Hung, Li-Man] Chang Gung Univ, Dept & Grad Inst Biomed Sci, Coll Med, Taoyuan, Taiwan; [Hung, Li-Man] Chang Gung Univ, Ctr Hlth & Aging Res, Taoyuan, Taiwan; [Hung, Li-Man] Chang Gung Mem Hosp, Kidney Res Ctr, Taoyuan, Taiwan; [Zhou, Yanming] Xiamen Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreatovasc Surg, Xiamen, Fujian, Peoples R China	Xiamen University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Xiamen University	Li, QX (corresponding author), Xiamen Univ, State Key Lab Cellular Stress Biol, Innovat Ctr Cell Signaling Network, Sch Life Sci, Xiamen, Fujian, Peoples R China.	liqinxi@xmu.edu.cn	Ma, Huan-Huan/G-8768-2017	Ma, Huan-Huan/0000-0001-8029-6814	National Natural Science Foundation of China, China [U1705287, 91857102]; Open Research Fund of State Key Laboratory of Cellular Stress Biology, Xiamen University [SKLCSB2020KF002, SKLCSB2019KF005]	National Natural Science Foundation of China, China(National Natural Science Foundation of China (NSFC)); Open Research Fund of State Key Laboratory of Cellular Stress Biology, Xiamen University	This work was supported by the National Natural Science Foundation of China, China (U1705287 and 91857102) and the Open Research Fund of State Key Laboratory of Cellular Stress Biology, Xiamen University (SKLCSB2020KF002 and SKLCSB2019KF005).	Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Cho ES, 2018, BIOMOL THER, V26, P29, DOI 10.4062/biomolther.2017.179; COCCO P, 1987, J EPIDEMIOL COMMUN H, V41, P89, DOI 10.1136/jech.41.2.89; Fang ZS, 2016, BBA-MOL CELL RES, V1863, P2245, DOI 10.1016/j.bbamcr.2016.05.016; FORTELEONI G, 1988, TUMORI, V74, P665, DOI 10.1177/030089168807400608; Fury MG, 2011, ANTICANCER RES, V31, P249; Gucalp A, 2011, CLIN BREAST CANCER, V11, P306, DOI 10.1016/j.clbc.2011.03.021; Gupte RS, 2009, FREE RADICAL BIO MED, V47, P219, DOI 10.1016/j.freeradbiomed.2009.01.028; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Jiang P, 2014, PROTEIN CELL, V5, P592, DOI 10.1007/s13238-014-0082-8; Ju HQ, 2017, ONCOGENE, V36, P6282, DOI 10.1038/onc.2017.227; Li TY, 2016, MOL CELL, V62, P359, DOI 10.1016/j.molcel.2016.04.009; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lin RT, 2015, NAT CELL BIOL, V17, P1484, DOI 10.1038/ncb3255; Liu XG, 2020, NAT CELL BIOL, V22, DOI 10.1038/s41556-020-0496-x; Ma HH, 2020, CELL REP, V30, P4235, DOI 10.1016/j.celrep.2020.03.005; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Musumeci F, 2012, FUTURE MED CHEM, V4, P799, DOI [10.4155/fmc.12.29, 10.4155/FMC.12.29]; Pan JS, 2009, WORLD J GASTROENTERO, V15, P1702, DOI 10.3748/wjg.15.1702; Pan S, 2009, ARTERIOSCL THROM VAS, V29, P895, DOI 10.1161/ATVBAHA.109.184812; Rajeshkumar NV, 2009, CLIN CANCER RES, V15, P4138, DOI 10.1158/1078-0432.CCR-08-3021; Rao XJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9468; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Stincone A, 2015, BIOL REV, V90, P927, DOI 10.1111/brv.12140; Tang HY, 2015, ANTIOXID REDOX SIGN, V22, P744, DOI 10.1089/ars.2014.6142; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tsouko E, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.18; Wang YP, 2014, EMBO J, V33, P1304, DOI 10.1002/embj.201387224; Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Zhang CH, 2014, ANTI-CANCER AGENT ME, V14, P280, DOI 10.2174/18715206113136660337; Zhang J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13732	35	7	8	0	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2567	2580		10.1038/s41388-021-01673-0	http://dx.doi.org/10.1038/s41388-021-01673-0		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33686238				2022-12-28	WOS:000626396000005
J	Zheng, R; Du, ML; Ge, YQ; Gao, F; Xin, JY; Lv, Q; Qin, C; Zhu, Y; Gu, CY; Wang, MY; Zhu, QY; Guo, Z; Ben, S; Chu, HY; Ye, DW; Zhang, ZD; Wang, ML				Zheng, Rui; Du, Mulong; Ge, Yuqiu; Gao, Fang; Xin, Junyi; Lv, Qiang; Qin, Chao; Zhu, Yao; Gu, Chengyuan; Wang, Mengyun; Zhu, Qiuyuan; Guo, Zheng; Ben, Shuai; Chu, Haiyan; Ye, Dingwei; Zhang, Zhengdong; Wang, Meilin			Identification of low-frequency variants of UGT1A3 associated with bladder cancer risk by next-generation sequencing	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; ANDROGEN RECEPTOR; GERMLINE MUTATIONS; CODING VARIANTS; RARE VARIANTS; MESSENGER-RNA; LUNG-CANCER; SUSCEPTIBILITY; POLYMORPHISMS; BREAST	Although genome-wide association studies (GWASs) have successfully revealed many common risk variants for bladder cancer, the heritability is still largely unexplained. We hypothesized that low-frequency variants involved in bladder cancer risk could reveal the unexplained heritability. Next-generation sequencing of 113 patients and 118 controls was conducted on 81 genes/regions of known bladder cancer GWAS loci. A two-stage validation comprising 3,350 cases and 4,005 controls was performed to evaluate the effects of low-frequency variants on bladder cancer risk. Biological experiments and techniques, including electrophoretic mobility shift assays, CRISPR/Cas9, RNA-Seq, and bioinformatics approaches, were performed to assess the potential functions of low-frequency variants. The low-frequency variant rs28898617 was located in the first exon of UGT1A3 and was significantly associated with increased bladder cancer risk (odds ratio = 1.50, P = 3.10 x 10(-6)). Intriguingly, rs28898617 was only observed in the Asian population, but monomorphism was observed in the European population. The risk-associated G allele of rs28898617 increased UGT1A3 expression, facilitated UGT1A3 transcriptional activity, and enhanced the binding activity. In addition, UGT1A3 deletion significantly inhibited the proliferation, invasion, and migration of bladder cancer cells and xenograft tumor growth. Mechanistically, UGT1A3 induced LAMC2 expression by binding CBP and promoting histone acetylation, which remarkably promoted the progression of bladder cancer. This is the first targeted sequencing study to reveal that the novel low-frequency variant rs28898617 and its associated gene UGT1A3 are involved in bladder cancer development, providing new insights into the genetic architecture of bladder cancer.	[Zheng, Rui; Du, Mulong; Ge, Yuqiu; Xin, Junyi; Zhu, Qiuyuan; Guo, Zheng; Ben, Shuai; Chu, Haiyan; Zhang, Zhengdong; Wang, Meilin] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Dept Environm Genom, Nanjing, Peoples R China; [Zheng, Rui; Ge, Yuqiu; Gao, Fang; Xin, Junyi; Zhu, Qiuyuan; Guo, Zheng; Ben, Shuai; Chu, Haiyan; Zhang, Zhengdong; Wang, Meilin] Nanjing Med Univ, Dept Genet Toxicol, Key Lab Modern Toxicol, Minist Educ,Ctr Global Hlth,Sch Publ Hlth, Nanjing, Peoples R China; [Du, Mulong] Nanjing Med Univ, Sch Publ Hlth, Ctr Global Hlth, Dept Biostat, Nanjing, Peoples R China; [Gao, Fang] Southeast Univ, Key Lab Environm Med Engn, Minist Educ China, Sch Publ Hlth, Nanjing, Peoples R China; [Lv, Qiang; Qin, Chao] Nanjing Med Univ, Affiliated Hosp 1, Dept Urol, Nanjing, Peoples R China; [Zhu, Yao; Gu, Chengyuan; Wang, Mengyun; Ye, Dingwei] Fudan Univ, Shanghai Canc Ctr, Dept Urol, Shanghai, Peoples R China; [Wang, Meilin] Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Municipal Hosp, Gusu Sch, Nanjing, Peoples R China; [Wang, Meilin] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Nanjing, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Ministry of Education, China; Southeast University - China; Nanjing Medical University; Fudan University; Nanjing Medical University; Nanjing Medical University	Zhang, ZD; Wang, ML (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Dept Environm Genom, Nanjing, Peoples R China.; Zhang, ZD; Wang, ML (corresponding author), Nanjing Med Univ, Dept Genet Toxicol, Key Lab Modern Toxicol, Minist Educ,Ctr Global Hlth,Sch Publ Hlth, Nanjing, Peoples R China.; Wang, ML (corresponding author), Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Municipal Hosp, Gusu Sch, Nanjing, Peoples R China.; Wang, ML (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Nanjing, Peoples R China.	drzdzhang@njmu.edu.cn; mwang@njmu.edu.cn	zhang, zheng/HCH-9684-2022	Xin, Junyi/0000-0001-6677-3936; Ye, Ding-wei/0000-0002-6761-5195	National Natural Science Foundation of China [81673264]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and PreventiveMedicine)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and PreventiveMedicine)	This study was supported in part by the National Natural Science Foundation of China (81673264) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and PreventiveMedicine). We are grateful to all the people who helped us accomplish this project. We thank Genesky Biotechnologies Inc. (Shanghai, China) for providing technical assistance.	1000 Genomes Project Consortium, 2012, Nature, V491, P56, DOI 10.1038/nature11632; Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Bao LM, 2016, CELL BIOL TOXICOL, V32, P419, DOI 10.1007/s10565-016-9343-z; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen YK, 2006, DRUG METAB DISPOS, V34, P1462, DOI 10.1124/dmd.106.009761; Dobruch J, 2016, EUR UROL, V69, P300, DOI 10.1016/j.eururo.2015.08.037; Eichler EE, 2010, NAT REV GENET, V11, P446, DOI 10.1038/nrg2809; Ewing CM, 2012, NEW ENGL J MED, V366, P141, DOI 10.1056/NEJMoa1110000; Freedman ND, 2011, JAMA-J AM MED ASSOC, V306, P737, DOI 10.1001/jama.2011.1142; Fuchsberger C, 2016, NATURE, V536, P41, DOI 10.1038/nature18642; Ghasemzadeh A, 2016, CLIN CANCER RES, V22, P793, DOI 10.1158/1078-0432.CCR-15-1135; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Gu JM, 2018, INT J MOL MED, V42, P1603, DOI 10.3892/ijmm.2018.3730; Gudmundsson J, 2012, NAT GENET, V44, P1326, DOI 10.1038/ng.2437; Hanioka N, 2012, BASIC CLIN PHARMACOL, V110, P253, DOI 10.1111/j.1742-7843.2011.00790.x; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hong SN, 2016, GUT, V65, P788, DOI 10.1136/gutjnl-2014-308617; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Inoue S, 2018, MOL CELL ENDOCRINOL, V465, P73, DOI 10.1016/j.mce.2017.06.021; Ionita-Laza I, 2013, AM J HUM GENET, V92, P841, DOI 10.1016/j.ajhg.2013.04.015; Iwai M, 2004, J HUM GENET, V49, P123, DOI 10.1007/s10038-003-0119-y; Izumi K, 2013, MOL CARCINOGEN, V52, P94, DOI 10.1002/mc.21833; Jin GF, 2015, AM J HUM GENET, V96, P832, DOI 10.1016/j.ajhg.2015.03.009; Jing YF, 2014, CANCER LETT, V348, P135, DOI 10.1016/j.canlet.2014.03.018; Kandimalla R, 2013, NAT REV UROL, V10, P327, DOI 10.1038/nrurol.2013.89; Khan A, 2018, NUCLEIC ACIDS RES, V46, pD260, DOI 10.1093/nar/gkx1126; Koutros S, 2016, INT J EPIDEMIOL, V45, P792, DOI 10.1093/ije/dyv195; Leslie EJ, 2015, AM J HUM GENET, V96, P397, DOI 10.1016/j.ajhg.2015.01.004; Li BS, 2008, AM J HUM GENET, V83, P311, DOI 10.1016/j.ajhg.2008.06.024; Liang Y, 2018, CELL DEATH DIFFER, V25, P1980, DOI 10.1038/s41418-018-0084-9; Lin DY, 2011, AM J HUM GENET, V89, P354, DOI [10.1016/j.ajhg.2011.07.015., 10.1016/j.ajhg.2011.07.015]; Lombard AP, 2015, ENDOCR-RELAT CANCER, V22, pR265, DOI 10.1530/ERC-15-0209; Loveday C, 2011, NAT GENET, V43, P879, DOI 10.1038/ng.893; Ma Zhicheng, 2013, Mol Carcinog, V52, P916, DOI 10.1002/mc.21932; Mancuso N, 2016, NAT GENET, V48, P30, DOI 10.1038/ng.3446; Mucci LA, 2016, JAMA-J AM MED ASSOC, V315, P68, DOI 10.1001/jama.2015.17703; Nakamura A, 2008, DRUG METAB DISPOS, V36, P1461, DOI 10.1124/dmd.108.021428; Ockenga J, 2003, GASTROENTEROLOGY, V124, P1802, DOI 10.1016/S0016-5085(03)00294-4; Rothman N, 2010, NAT GENET, V42, P978, DOI 10.1038/ng.687; Ruark E, 2013, NATURE, V493, P406, DOI 10.1038/nature11725; Sathe A, 2018, METHODS MOL BIOL, V1655, P335, DOI 10.1007/978-1-4939-7234-0_23; Shyr D, 2013, BIOL PROCED ONLINE, V15, DOI 10.1186/1480-9222-15-4; Siegel RL, 2018, CA-CANCER J CLIN, V68, P30; Smith SC, 2009, AM J PATHOL, V174, P371, DOI 10.2353/ajpath.2009.080538; Strassburg CP, 1999, BIOCHEM J, V338, P489, DOI 10.1042/0264-6021:3380489; Stratton MR, 2008, NAT GENET, V40, P17, DOI 10.1038/ng.2007.53; Suer E, 2016, WORLD J UROL, V34, P847, DOI 10.1007/s00345-015-1710-5; Sun F, 2015, CARCINOGENESIS, V36, P757, DOI 10.1093/carcin/bgv040; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Turati F, 2013, ANN ONCOL, V24, P2651, DOI 10.1093/annonc/mdt280; Vogel A, 2001, GASTROENTEROLOGY, V121, P1136, DOI 10.1053/gast.2001.28655; Wang L, 2018, XENOBIOTICA, V48, P357, DOI 10.1080/00498254.2017.1323139; Wang ML, 2016, CANCER RES, V76, P3277, DOI 10.1158/0008-5472.CAN-15-2564; Wang ML, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11478; Wang P, 2014, GENE CHROMOSOME CANC, V53, P98, DOI 10.1002/gcc.22121; Wang SY, 2013, GUT, V62, P496, DOI 10.1136/gutjnl-2011-301522; Wu JL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00134; Yilmaz Latif, 2015, Asian Pac J Cancer Prev, V16, P1651; Yu XN, 2017, MOL VIS, V23, P296; Zhang YF, 2014, CANCER EPIDEM BIOMAR, V23, P622, DOI 10.1158/1055-9965.EPI-13-1043; Zhu M, 2017, GASTROENTEROLOGY, V152, P2011, DOI 10.1053/j.gastro.2017.02.017	62	3	3	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2382	2394		10.1038/s41388-021-01672-1	http://dx.doi.org/10.1038/s41388-021-01672-1		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33658628	Green Published			2022-12-28	WOS:000625009600001
J	Bie, QL; Song, H; Chen, XK; Yang, X; Shi, S; Zhang, LH; Zhao, R; Wei, L; Zhang, BG; Xiong, HB; Zhang, B				Bie, Qingli; Song, Hui; Chen, Xinke; Yang, Xiao; Shi, Shuo; Zhang, Lihua; Zhao, Rou; Wei, Li; Zhang, Baogui; Xiong, Huabao; Zhang, Bin			IL-17B/IL-17RB signaling cascade contributes to self-renewal and tumorigenesis of cancer stem cells by regulating Beclin-1 ubiquitination	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; DRUG-RESISTANCE; AUTOPHAGY; PATHWAY; IL-17B; METASTASIS; INTERLEUKIN-17B; TRANSPLANTATION; MIGRATION	Cancer stem cells (CSCs) are characterized by robust self-renewal and tumorigenesis and are responsible for metastasis, drug resistance, and angiogenesis. However, the molecular mechanisms for the regulation of CSC homeostasis are incompletely understood. This study demonstrated that the interleukin-17 (IL-17)B/IL-17RB signaling cascade promotes the self-renewal and tumorigenesis of CSCs by inducing Beclin-1 ubiquitination. We found that IL-17RB expression was significantly upregulated in spheroid cells and Lgr5-positive cells from the same tumor tissues of patients with gastric cancer (GC), which was closely correlated with the degree of cancer cell differentiation. Recombinant IL-17B (rIL-17B) promoted the sphereformation ability of CSCs in vitro and enhanced tumor growth and metastasis in vivo. Interestingly, IL-17B induced autophagosome formation and cleavage-mediated transformation of LC3 in CSCs and 293T cells. Furthermore, inhibition of autophagy activation by ATG7 knockdown reversed rIL-17B-induced self-renewal of GC cells. In addition, we showed that IL-17B also promoted K63-mediated ubiquitination of Beclin-1 by mediating the binding of tumor necrosis factor receptorassociated factor 6 to Beclin-1. Silencing IL-17RB expression abrogated the effects of IL-17B on Beclin-1 ubiquitination and autophagy activation in GC cells. Finally, we showed that IL-17B level in the serum of GC patients was positively correlated with IL-17RB expression in GC tissues, and IL-17B could induce IL-17RB expression in GC cells. Overall, the results elucidate the novel functions of IL-17B for CSCs and suggest that the intervention of the IL-17B/IL-17RB signaling pathway may provide new therapeutic targets for the treatment of cancer.	[Bie, Qingli; Song, Hui; Chen, Xinke; Yang, Xiao; Shi, Shuo; Zhang, Lihua; Zhao, Rou; Wei, Li; Zhang, Bin] Jining Med Univ, Dept Lab Med, Affiliated Hosp Jining Med Univ, Jining, Shandong, Peoples R China; [Bie, Qingli; Zhang, Bin] Jining Med Univ, Inst Forens Med & Lab Med, Jining, Shandong, Peoples R China; [Zhang, Baogui] Jining Med Univ, Dept Gen Surg, Affiliated Hosp, Jining, Shandong, Peoples R China; [Xiong, Huabao] Jining Med Univ, Inst Immunol & Mol Med, Jining, Shandong, Peoples R China	Jining Medical University; Jining Medical University; Jining Medical University; Jining Medical University	Zhang, B (corresponding author), Jining Med Univ, Dept Lab Med, Affiliated Hosp Jining Med Univ, Jining, Shandong, Peoples R China.; Zhang, B (corresponding author), Jining Med Univ, Inst Forens Med & Lab Med, Jining, Shandong, Peoples R China.; Xiong, HB (corresponding author), Jining Med Univ, Inst Immunol & Mol Med, Jining, Shandong, Peoples R China.	xionghb1@yahoo.com; zhb861109@163.com	Zhang, Bin/HCP-1386-2022; B, Zhang/R-4316-2019	B, Zhang/0000-0002-2879-379X	National Natural Science Foundation of China [81702439, 81802446, 81602160]; Tai Shan Young Scholar Foundation of Shandong Province [tsqn201909192]; Shandong Provincial Natural Science Foundation [ZR2019BH050, ZR2020YQ59]; Ph.D. Research Foundation of the Affiliated Hospital of Jining Medical University [2018-BS-001, 2018-BS-013]; Project of Health and Family Planning Commision of Shandong province [2017WS513]; Jining Medical University Teacher Research Support Fund [JYFC2018FKJ035]; Project of Health and Family Planning Commission of Shandong Province [2017WS513]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tai Shan Young Scholar Foundation of Shandong Province; Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province); Ph.D. Research Foundation of the Affiliated Hospital of Jining Medical University; Project of Health and Family Planning Commision of Shandong province; Jining Medical University Teacher Research Support Fund; Project of Health and Family Planning Commission of Shandong Province	This study was supported by grants from the National Natural Science Foundation of China (Nos. 81702439, 81802446, 81602160), Tai Shan Young Scholar Foundation of Shandong Province (No. tsqn201909192), Shandong Provincial Natural Science Foundation (No. ZR2019BH050, ZR2020YQ59), Ph.D. Research Foundation of the Affiliated Hospital of Jining Medical University (No. 2018-BS-001, 2018-BS-013), the Project of Health and Family Planning Commision of Shandong province (No. 2017WS513), Jining Medical University Teacher Research Support Fund (No. JYFC2018FKJ035) and the Project of Health and Family Planning Commission of Shandong Province (No. 2017WS513).	Ahmad Rizwan, 2016, Biochem Pharmacol (Los Angel), V5, DOI 10.4172/2167-0501.1000202; Bie QL, 2017, MOL IMMUNOL, V90, P50, DOI 10.1016/j.molimm.2017.07.004; Bie QL, 2017, ONCOTARGET, V8, P18914, DOI 10.18632/oncotarget.14835; Bie QL, 2016, SCI REP-UK, V6, DOI 10.1038/srep25447; Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016; Chu BX, 2020, J CELL MOL MED, V24, P14366, DOI 10.1111/jcmm.16055; Corro C, 2018, J PATHOL CLIN RES, V4, P3, DOI 10.1002/cjp2.91; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Guo HZ, 2019, FASEB J, V33, P9565, DOI 10.1096/fj.201900099R; Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019; Huang CK, 2014, ONCOGENE, V33, P2968, DOI 10.1038/onc.2013.268; Huang F, 2018, WORLD J GASTROENTERO, V24, P4643, DOI 10.3748/wjg.v24.i41.4643; Huang SC, 2017, EMBO MOL MED, V9, P1660, DOI 10.15252/emmm.201606914; Ichinohe N, 2017, STEM CELLS, V35, P920, DOI 10.1002/stem.2548; Jiang YX, 2017, ONCOGENE, V36, P1256, DOI 10.1038/onc.2016.291; Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Laprevotte E, 2017, ONCOTARGET, V8, P113360, DOI 10.18632/oncotarget.23008; Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773; Li LQ, 2018, EUR REV MED PHARMACO, V22, P3402, DOI 10.26355/eurrev_201806_15162; Li L, 2019, CANCER LETT, V452, P191, DOI 10.1016/j.canlet.2019.03.027; Li XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15909; Luo YL, 2016, CANCER LETT, V375, P390, DOI 10.1016/j.canlet.2016.03.012; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Maycotte P, 2015, MOL CANCER RES, V13, P651, DOI 10.1158/1541-7786.MCR-14-0487; Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333; Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Palmieri M, 2017, CELL CYCLE, V16, P1237, DOI 10.1080/15384101.2017.1337968; Qiang L, 2017, AUTOPHAGY, V13, P2086, DOI 10.1080/15548627.2017.1380757; Ramirez-Carrozzi V, 2019, J IMMUNOL, V202, P1935, DOI 10.4049/jimmunol.1800696; Ren L, 2017, MOL IMMUNOL, V90, P126, DOI 10.1016/j.molimm.2017.06.034; Saad MA, 2019, LIFE SCI, V218, P284, DOI 10.1016/j.lfs.2019.01.002; Sharif T, 2017, AUTOPHAGY, V13, P264, DOI 10.1080/15548627.2016.1260808; Shi CS, 2010, AUTOPHAGY, V6, P986, DOI 10.4161/auto.6.7.13288; Shi CS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000751; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smith AG, 2019, J PATHOL, V247, P708, DOI 10.1002/path.5222; Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Teng YS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1312-z; Vlashi E, 2015, SEMIN CANCER BIOL, V31, P28, DOI 10.1016/j.semcancer.2014.07.001; Whelan KA, 2017, ONCOGENE, V36, P4843, DOI 10.1038/onc.2017.102; Wu HH, 2015, J EXP MED, V212, P333, DOI 10.1084/jem.20141702; Xia P, 2015, AM J CANCER RES, V5, P1602; Xiang T, 2015, ONCOGENE, V34, P165, DOI 10.1038/onc.2013.537; Yamaguchi Y, 2007, J IMMUNOL, V179, P7128, DOI 10.4049/jimmunol.179.10.7128; Yang DP, 2019, IMMUNITY, V50, P692, DOI 10.1016/j.immuni.2019.02.001; Yang SW, 2016, ONCOTARGET, V7, P39279, DOI 10.18632/oncotarget.9827; Yang YF, 2018, CANCER LETT, V422, P44, DOI 10.1016/j.canlet.2018.02.037; You ZB, 2005, BIOCHEM BIOPH RES CO, V326, P624, DOI 10.1016/j.bbrc.2004.11.087; Zhang B, 2018, STEM CELLS, V36, P990, DOI 10.1002/stem.2821	53	7	7	5	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2200	2216		10.1038/s41388-021-01699-4	http://dx.doi.org/10.1038/s41388-021-01699-4		MAR 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33649532	hybrid, Green Published			2022-12-28	WOS:000623739900005
J	Varone, E; Decio, A; Chernorudskiy, A; Minoli, L; Brunelli, L; Ioli, F; Piotti, A; Pastorelli, R; Fratelli, M; Gobbi, M; Giavazzi, R; Zito, E				Varone, Ersilia; Decio, Alessandra; Chernorudskiy, Alexander; Minoli, Lucia; Brunelli, Laura; Ioli, Federica; Piotti, Arianna; Pastorelli, Roberta; Fratelli, Maddalena; Gobbi, Marco; Giavazzi, Raffaella; Zito, Ester			The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions	ONCOGENE			English	Article								Solid tumors are often characterized by a hypoxic microenvironment which contributes, through the hypoxia-inducible factor HIF-1, to the invasion-metastasis cascade. Endoplasmic reticulum (ER) stress also leads tumor cells to thrive and spread by inducing a transcriptional and translational program, the Unfolded Protein Response (UPR), aimed at restoring ER homeostasis. We studied ERO1 alpha (henceforth ERO1), a protein disulfide oxidase with the tumor-relevant characteristic of being positively regulated by both ER stress and hypoxia. Analysis of the redox secretome indicated that pro-angiogenic HIF-1 targets, were blunted in ERO1-devoid breast cancer cells under hypoxic conditions. ERO1 deficiency reduced tumor cell migration and lung metastases by impinging on tumor angiogenesis, negatively regulating the upstream ATF4/CHOP branch of the UPR and selectively impeding oxidative folding of angiogenic factors, among which VEGF-A. Thus, ERO1 deficiency acted synergistically with the otherwise feeble curative effects of anti-angiogenic therapy in aggressive breast cancer murine models and it might be exploited to treat cancers with pathological HIF-1-dependent angiogenesis. Furthermore, ERO1 levels are higher in the more aggressive basal breast tumors and correlate inversely with the disease- and metastasis-free interval of breast cancer patients. Thus, taking advantage of our in vitro data on ERO1-regulated gene products we identified a gene set associated with ERO1 expression in basal tumors and related to UPR, hypoxia, and angiogenesis, whose levels might be investigated in patients as a hallmark of tumor aggressiveness and orient those with lower levels toward an effective anti-angiogenic therapy.	[Varone, Ersilia; Decio, Alessandra; Chernorudskiy, Alexander; Brunelli, Laura; Ioli, Federica; Piotti, Arianna; Pastorelli, Roberta; Fratelli, Maddalena; Gobbi, Marco; Giavazzi, Raffaella; Zito, Ester] Ist Ric Farmacol Mario Negri IRCCS, Milan, Italy; [Minoli, Lucia] Univ Milan, Dept Vet Med, Mouse & Anim Pathol Lab, Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan	Zito, E (corresponding author), Ist Ric Farmacol Mario Negri IRCCS, Milan, Italy.	ester.zito@marionegri.it	Gobbi, Marco/J-2638-2016; Brunelli, Laura/J-8664-2018; Chernorudskiy, Alexander/ABE-4390-2021; Varone, Ersilia/ABE-4711-2021; Decio, Alessandra/J-5250-2018; Minoli, Lucia/AAB-8777-2022	Gobbi, Marco/0000-0003-1014-6225; Brunelli, Laura/0000-0002-5465-9586; Chernorudskiy, Alexander/0000-0002-8175-5688; Varone, Ersilia/0000-0002-1537-3358; Decio, Alessandra/0000-0002-1845-7063; Minoli, Lucia/0000-0001-8938-4319; Piotti, Arianna/0000-0003-3614-8202	AIRC [MFAG 20018, IG 23520]; Cariplo Grant [2017-0896]	AIRC(Fondazione AIRC per la ricerca sul cancro); Cariplo Grant(Fondazione Cariplo)	We are indebted to David Ron, in whose lab some of the reagents were developed, to Enrico Garattini for providing breast tumor cell lines and Nica Borgese for the critical reading of the paper. This study was supported by AIRC MFAG 20018 grant to EZ, Cariplo Grant 2017-0896 to AD and AIRC IG 23520 to RG.	Abcouwer SF, 2002, INVEST OPHTH VIS SCI, V43, P2791; Blais JD, 2010, J BIOL CHEM, V285, P20993, DOI 10.1074/jbc.M110.126599; Canovi M, 2014, SENSORS-BASEL, V14, P10864, DOI 10.3390/s140610864; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chin KT, 2011, FASEB J, V25, P2583, DOI 10.1096/fj.11-184622; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; Cruz-Munoz W, 2008, CANCER RES, V68, P4500, DOI 10.1158/0008-5472.CAN-08-0041; Cubillos-Ruiz JR, 2017, CELL, V168, P692, DOI 10.1016/j.cell.2016.12.004; Dey S, 2015, J CLIN INVEST, V125, P2592, DOI 10.1172/JCI78031; Dore-Savard L, 2016, SCI REP-UK, V6, DOI 10.1038/srep39460; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Ghosh R, 2010, PLOS ONE, V5, pA104, DOI 10.1371/journal.pone.0009575; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Iyer S, 2011, FEBS J, V278, P4304, DOI 10.1111/j.1742-4658.2011.08350.x; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mandal K, 2011, ANGEW CHEM INT EDIT, V50, P8029, DOI 10.1002/anie.201103237; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; May D, 2005, ONCOGENE, V24, P1011, DOI 10.1038/sj.onc.1208325; Nakatsu MN, 2003, LAB INVEST, V83, P1873, DOI 10.1097/01.LAB.0000107160.81875.33; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Pozzer D, 2019, REDOX BIOL, V20, P354, DOI 10.1016/j.redox.2018.10.017; Rutkevich LA, 2012, MOL BIOL CELL, V23, P2017, DOI 10.1091/mbc.E12-02-0102; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Sitohy B, 2012, CANCER RES, V72, P1909, DOI 10.1158/0008-5472.CAN-11-3406; Tanaka T, 2016, BRIT J CANCER, V114, P1227, DOI 10.1038/bjc.2016.105; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; VARTANIAN RK, 1994, AM J PATHOL, V144, P1188; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang YG, 2012, CANCER RES, V72, P5396, DOI 10.1158/0008-5472.CAN-12-0474; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Yang SK, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1134-4; Zhang YN, 2019, EBIOMEDICINE, V41, P408, DOI 10.1016/j.ebiom.2019.02.041; Zito E, 2015, FREE RADICAL BIO MED, V83, P299, DOI 10.1016/j.freeradbiomed.2015.01.011; Zito E, 2013, ANTIOXID REDOX SIGN, V18, P1666, DOI 10.1089/ars.2012.4966; Zito E, 2012, MOL CELL, V48, P39, DOI 10.1016/j.molcel.2012.08.010; Zito E, 2010, MOL CELL, V40, P787, DOI 10.1016/j.molcel.2010.11.010; Zito E, 2010, J CELL BIOL, V188, P821, DOI 10.1083/jcb.200911086	45	16	16	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1721	1736		10.1038/s41388-021-01659-y	http://dx.doi.org/10.1038/s41388-021-01659-y		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33531624	hybrid, Green Published			2022-12-28	WOS:000613991700001
J	Westendorp, F; Karpus, ON; Koelink, PJ; Vermeulen, JLM; Meisner, S; Koster, J; Buller, NVJA; Wildenberg, ME; Muncan, V; van den Brink, GR				Westendorp, Florien; Karpus, Olga N.; Koelink, Pim J.; Vermeulen, Jacqueline L. M.; Meisner, Sander; Koster, Jan; Buller, Nike V. J. A.; Wildenberg, Manon E.; Muncan, Vanesa; van den Brink, Gijs R.			Epithelium-derived Indian Hedgehog restricts stromal expression of ErbB family members that drive colonic tumor cell proliferation	ONCOGENE			English	Article							INTESTINAL EPITHELIUM; HOMEOSTASIS; GROWTH; ACTIVATION; RECEPTORS; POLYPOSIS; ADENOMA; GENE	Indian Hedgehog (Ihh) is a morphogen expressed by epithelial cells in the small intestine and colon that signals in a paracrine manner to gp38+ stromal cells. The loss of Ihh signaling results in increased epithelial proliferation, lengthening and multiplication of intestinal crypts and the activation of a stromal cell immune response. How Ihh controls epithelial proliferation through the stroma and how it affects colorectal cancer development remains poorly defined. To study the influence of Ihh signaling on the earliest stage of colorectal carcinogenesis, we used a well characterized mouse model in which both alleles of the Adenoma Polyposis Coli (Apc) gene could be inducibly deleted, leading to instant transformation of the colonic epithelium to an adenomatous phenotype. Concurrent deletion of Ihh from the adenomatous colonic epithelium of Apc inducible double mutant mice resulted in a remarkable increase in the hyperproliferative epithelial phenotype and increased accumulation of Lgr5+ stem cells. Transcriptional profiling of sorted colonic gp38+ fibroblasts showed upregulation of three ErbB pathway ligands (EREG, BTC, and NRG1) in Apc(-/-)Ihh(-/-) double mutant mice. We found that recombinant EREG, BTC, and NRG1 but not Lgr5 ligand R-Spondin promoted growth and proliferation of Apc double mutant colonic organoids. Thus, the loss of Ihh enhances Apc-driven colonic adenomagenesis via upregulation of ErbB pathway family members in colonic stromal cells. Our findings highlight the critical role of epithelium-derived Indian Hedgehog as a stromal tumor suppressor in the intestine.	[Westendorp, Florien; Karpus, Olga N.; Koelink, Pim J.; Vermeulen, Jacqueline L. M.; Meisner, Sander; Buller, Nike V. J. A.; Wildenberg, Manon E.; Muncan, Vanesa; van den Brink, Gijs R.] Univ Amsterdam, Tytgat Inst Liver & Intestinal Res, Amsterdam Gastroenterol & Metab, Amsterdam UMC, Amsterdam, Netherlands; [Westendorp, Florien; Karpus, Olga N.; Koelink, Pim J.; Vermeulen, Jacqueline L. M.; Meisner, Sander; Buller, Nike V. J. A.; Wildenberg, Manon E.; Muncan, Vanesa; van den Brink, Gijs R.] Univ Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam Gastroenterol & Metab, Amsterdam UMC, Amsterdam, Netherlands; [Koster, Jan] Univ Amsterdam, Dept Oncogen, Amsterdam UMC, Amsterdam, Netherlands; [van den Brink, Gijs R.] F Hoffmann La Roche & Cie AG, Roche Innovat Ctr Basel, Basel, Switzerland	University of Amsterdam; University of Amsterdam; University of Amsterdam; Roche Holding	Westendorp, F (corresponding author), Univ Amsterdam, Tytgat Inst Liver & Intestinal Res, Amsterdam Gastroenterol & Metab, Amsterdam UMC, Amsterdam, Netherlands.; Westendorp, F (corresponding author), Univ Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam Gastroenterol & Metab, Amsterdam UMC, Amsterdam, Netherlands.	b.f.westendorp@amsterdamumc.nl		Koster, Jan/0000-0002-0890-7585; Wildenberg, Manon Elisabeth/0000-0003-0671-818X	Netherlands Organization for Scientific Research (NWO) [016140605]	Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	We thank our colleagues Berend Hooibrink and Toni van Capel from the Department of Experimental Immunology at the Amsterdam UMC, location AMC, for support with cell sorting, and the AMC Animal Research Facility (ARIA) for help with mouse experiments. We thank S.M. van Neerven and prof. dr. L. Vermeulen for providing Lgr5-EGFR-IRES-cre<SUP>ERT2</SUP>-Apc<SUP>fl/fl</SUP> colon organoids. This work was financially supported by a VICI grant (016140605) from the Netherlands Organization for Scientific Research (NWO) to GRB.	Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Berlin J, 2013, CLIN CANCER RES, V19, P258, DOI 10.1158/1078-0432.CCR-12-1800; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Buller NVJA, 2015, GASTROENTEROLOGY, V148, P170, DOI 10.1053/j.gastro.2014.10.006; Buller NVJA, 2012, PHYSIOLOGY, V27, P148, DOI 10.1152/physiol.00003.2012; Cai XY, 2015, ONCOTARGETS THER, V8, DOI 10.2147/OTT.S71034; Dunker N, 2002, GASTROENTEROLOGY, V122, P1364, DOI 10.1053/gast.2002.32991; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Frampton JE, 2018, DRUGS, V78, P1145, DOI 10.1007/s40265-018-0948-9; Gerling M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12321; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Hanna A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0509-3; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; International Agency for Research on Cancer, GLOBAL CANC OBSERVAT; Jackstadt R, 2016, J PATHOL, V238, P141, DOI 10.1002/path.4645; Karpus ON, 2019, CELL REP, V26, P3698, DOI 10.1016/j.celrep.2019.02.101; Kolterud A, 2009, GASTROENTEROLOGY, V137, P618, DOI 10.1053/j.gastro.2009.05.002; Mazumdar T, 2011, CANCER RES, V71, P1092, DOI 10.1158/0008-5472.CAN-10-2315; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; NAKAMURA Y, 1992, TOHOKU J EXP MED, V168, P141, DOI 10.1620/tjem.168.141; Preston SL, 2003, CANCER RES, V63, P3819; Razzaque MS, 2005, J PATHOL, V207, P453, DOI 10.1002/path.1870; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Shi T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013054; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tebbutt N, 2013, NAT REV CANCER, V13, P663, DOI 10.1038/nrc3559; van den Brink GR, 2007, PHYSIOL REV, V87, P1343, DOI 10.1152/physrev.00054.2006; van den Brink GR, 2007, CANCER CELL, V11, P109, DOI 10.1016/j.ccr.2007.01.003; van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304; van Dop WA, 2010, GASTROENTEROLOGY, V139, P1665, DOI 10.1053/j.gastro.2010.07.045; van Dop WA, 2009, GASTROENTEROLOGY, V136, P2195, DOI 10.1053/j.gastro.2009.02.068; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Warren CM, 2006, CELL SIGNAL, V18, P923, DOI 10.1016/j.cellsig.2005.12.007; Westendorp BF, 2018, CELL MOL GASTROENTER, V5, P67, DOI 10.1016/j.jcmgh.2017.08.004; Xie H, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050394; Xie PX, 2018, J AM ACAD DERMATOL, V79, P1089, DOI 10.1016/j.jaad.2018.07.004; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; You SH, 2010, UPSALA J MED SCI, V115, P169, DOI 10.3109/03009731003668316; Zacharias WJ, 2011, DEV BIOL, V355, P152, DOI 10.1016/j.ydbio.2011.04.025	47	2	2	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1628	1643		10.1038/s41388-020-01633-0	http://dx.doi.org/10.1038/s41388-020-01633-0		JAN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33479497				2022-12-28	WOS:000609352300003
J	Lin, SH; Zhang, XC; Huang, GH; Cheng, L; Lv, J; Zheng, DW; Lin, SM; Wang, SN; Wu, QT; Long, YG; Li, BH; Wei, W; Liu, PT; Pei, DQ; Li, YQ; Wen, ZS; Cui, SZ; Li, P; Sun, XF; Wu, YL; Yao, Y				Lin, Shouheng; Zhang, Xuchao; Huang, Guohua; Cheng, Lin; Lv, Jiang; Zheng, Diwei; Lin, Simiao; Wang, Suna; Wu, Qiting; Long, Youguo; Li, Baiheng; Wei, Wei; Liu, Pentao; Pei, Duanqing; Li, Yangqiu; Wen, Zhesheng; Cui, Shuzhong; Li, Peng; Sun, Xiaofang; Wu, Yilong; Yao, Yao			Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells	ONCOGENE			English	Article							CORRELATE; EOTAXIN-1; MICROENVIRONMENT; EXPRESSION; PATHWAYS; MARKER; STAGE	Myeloid-derived suppressor cells (MDSCs) suppress antitumor immune activities and facilitate cancer progression. Although the concept of immunosuppressive MDSCs is well established, the mechanism that MDSCs regulate non-small cell lung cancer (NSCLC) progression through the paracrine signals is still lacking. Here, we reported that the infiltration of MDSCs within NSCLC tissues was associated with the progression of cancer status, and was positively correlated with the Patient-derived xenograft model establishment, and poor patient prognosis. Intratumoral MDSCs directly promoted NSCLC metastasis and highly expressed chemokines that promote NSCLC cells invasion, including CCL11. CCL11 was capable of activating the AKT and ERK signaling pathways to promote NSCLC metastasis through the epithelial-mesenchymal transition (EMT) process. Moreover, high expression of CCL11 was associated with a poor prognosis in lung cancer as well as other types of cancer. Our findings underscore that MDSCs produce CCL11 to promote NSCLC metastasis via activation of ERK and AKT signaling and induction of EMT, suggesting that the MDSCs-CCL11-ERK/AKT-EMT axis contains potential targets for NSCLC metastasis treatment.	[Lin, Shouheng; Sun, Xiaofang] Guangzhou Med Univ, Affiliated Hosp 3, Key Lab Major Obstetr Dis Guangdong Prov, Key Lab Reprod & Genet Guangdong Higher Educ Inst, Guangzhou, Guangdong, Peoples R China; [Lin, Shouheng; Cheng, Lin; Lv, Jiang; Zheng, Diwei; Lin, Simiao; Wang, Suna; Wu, Qiting; Long, Youguo; Pei, Duanqing; Li, Peng; Yao, Yao] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, State Key Lab Resp Dis, Guangdong Prov Key Lab Stem Cell & Regenerat Med, Guangzhou, Peoples R China; [Lin, Shouheng; Cheng, Lin; Pei, Duanqing; Li, Peng; Sun, Xiaofang] Bioland Lab, Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou, Peoples R China; [Zhang, Xuchao; Wu, Yilong] Guangdong Acad Med Sci, Guangdong Prov Key Lab Translat Med Lung Canc, Guangdong Lung Canc Inst, Med Res Ctr, Guangzhou, Peoples R China; [Huang, Guohua] Southern Med Univ, Nanfang Hosp, Dept Resp Med, Guangzhou, Peoples R China; [Li, Baiheng] Hunan Zhaotai Biopharmaceut Co Ltd, Changsha, Peoples R China; [Wei, Wei] Guangdong Cord Blood Bank, Guangzhou, Guangdong, Peoples R China; [Liu, Pentao] Univ Hong Kong, Li Ka Shing Fac Med, Stem Cell & Regenerat Med Ctr, Sch Biomed Sci, Hong Kong, Peoples R China; [Li, Yangqiu] Jinan Univ, Med Coll, Inst Hematol, Guangzhou, Peoples R China; [Wen, Zhesheng] Sun Yat Sen Univ, Dept Thorac Oncol, Canc Ctr, Guangzhou, Peoples R China; [Cui, Shuzhong] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China	Guangzhou Medical University; Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; State Key Laboratory of Respiratory Disease; Guangzhou Regenerative Medicine & Health Guangdong Laboratory (Bioisland Laboratory); Guangdong Academy of Medical Sciences & Guangdong General Hospital; Southern Medical University - China; University of Hong Kong; Jinan University; Sun Yat Sen University; Guangzhou Medical University	Sun, XF (corresponding author), Guangzhou Med Univ, Affiliated Hosp 3, Key Lab Major Obstetr Dis Guangdong Prov, Key Lab Reprod & Genet Guangdong Higher Educ Inst, Guangzhou, Guangdong, Peoples R China.; Yao, Y (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, State Key Lab Resp Dis, Guangdong Prov Key Lab Stem Cell & Regenerat Med, Guangzhou, Peoples R China.; Sun, XF (corresponding author), Bioland Lab, Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou, Peoples R China.; Wu, YL (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Key Lab Translat Med Lung Canc, Guangdong Lung Canc Inst, Med Res Ctr, Guangzhou, Peoples R China.	xiaofangsun@gzhmu.edu.cn; syylwu@live.cn; yao_yao@gibh.ac.cn	zhang, xian/GYA-0290-2022; Wu, Yi-Long/AAB-9137-2022; Li, Peng/AER-7520-2022; zhang, xu/GRX-9733-2022; yao, yao/HHZ-7438-2022; Wu, Yi-Long/GRJ-9238-2022; Zhang, xiaoyu/GXA-3206-2022; zhang, xu/GYE-3558-2022	Wu, Yi-Long/0000-0002-3611-0258; lin, shouheng/0000-0002-6248-5926	Strategic Priority Research Program of the Chinese Academy of Sciences [XDB19030205]; National Key Research and Development Plan [2017YFE0131600, 2019YFA0111500]; National Natural Science Foundation of China [81961128003, 81972672, 31872800, 81773301, 82003054]; China Postdoctoral Science Foundation [2018M640771]; Guangdong Provincial Significant New Drugs Development [2019B020202003]; Guangdong Basic and Applied Basic Research Foundation [2019A1515110084, 2019A1515010062, 2020A1515011516]; Guangdong Special Support Program [2017TX04R102]; Science and Technology Planning Project of Guangdong Province [2017B030314056]; Natural Science Foundation of Guangdong Province [2020A0505100062]; Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [2017B030314120]; Guangzhou City Science and Technology Key Topics Project [201904020025]; Guangzhou Science and Technology Plan Project [201907010042, 201904010473]; Foundation of Guangzhou Science and Information Technology of Guangzhou Key Project [201803040009]; Guangzhou Regenerative Medicine and Health Guangdong Laboratory Frontier Research Program [2018GZR110105003]; Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZR0201002]; Research Program of the Hefei Institute of Stem Cell and Regenerative Medicine [2019YF001]; Science and Technology Program of Guangzhou [202002020083]	Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Key Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Guangdong Provincial Significant New Drugs Development; Guangdong Basic and Applied Basic Research Foundation; Guangdong Special Support Program; Science and Technology Planning Project of Guangdong Province; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer; Guangzhou City Science and Technology Key Topics Project; Guangzhou Science and Technology Plan Project; Foundation of Guangzhou Science and Information Technology of Guangzhou Key Project; Guangzhou Regenerative Medicine and Health Guangdong Laboratory Frontier Research Program; Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory; Research Program of the Hefei Institute of Stem Cell and Regenerative Medicine; Science and Technology Program of Guangzhou	We thank the cancer patients who donated their tissues. This work was supported by Strategic Priority Research Program of the Chinese Academy of Sciences (XDB19030205); and National Key Research and Development Plan (2017YFE0131600, 2019YFA0111500); and National Natural Science Foundation of China (81961128003; 81972672; 31872800; 81773301; 82003054); and China Postdoctoral Science Foundation (2018M640771); and Guangdong Provincial Significant New Drugs Development (2019B020202003); and Guangdong Basic and Applied Basic Research Foundation (2019A1515110084, 2019A1515010062, 2020A1515011516); and Guangdong Special Support Program (2017TX04R102); and Science and Technology Planning Project of Guangdong Province (2017B030314056); and Natural Science Foundation of Guangdong Province (2020A0505100062); and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (2017B030314120); and Guangzhou City Science and Technology Key Topics Project (201904020025); and Guangzhou Science and Technology Plan Project (201907010042, 201904010473) and Foundation of Guangzhou Science and Information Technology of Guangzhou Key Project (201803040009); and Guangzhou Regenerative Medicine and Health Guangdong Laboratory Frontier Research Program (2018GZR110105003); and Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2018GZR0201002); and Research Program of the Hefei Institute of Stem Cell and Regenerative Medicine (2019YF001); and Science and Technology Program of Guangzhou (202002020083).	Agarwal M, 2013, PROSTATE, V73, P573, DOI 10.1002/pros.22597; Alzahrani AS, 2019, SEMIN CANCER BIOL, V59, P125, DOI 10.1016/j.semcancer.2019.07.009; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Blank S, 2017, ONCOTARGET, V8, P47518, DOI 10.18632/oncotarget.17671; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Huang A, 2013, CANCER IMMUNOL IMMUN, V62, P1439, DOI 10.1007/s00262-013-1450-6; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; John T, 2011, CLIN CANCER RES, V17, P134, DOI 10.1158/1078-0432.CCR-10-2224; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Lai YX, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0470-7; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Levina V, 2009, CLIN CANCER RES, V15, P2647, DOI 10.1158/1078-0432.CCR-08-2024; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Lin SH, 2018, MABS-AUSTIN, V10, P1301, DOI 10.1080/19420862.2018.1518948; Lin SH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01713; Lindau D, 2012, IMMUNOLOGY, V137, P589, DOI 10.1111/imm.12036; Liu H, 2019, NEOPLASMA, V66, P487, DOI 10.4149/neo_2018_181029N805; Mao YM, 2013, CANCER RES, V73, P3877, DOI 10.1158/0008-5472.CAN-12-4115; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Meyer C, 2014, CANCER IMMUNOL IMMUN, V63, P247, DOI 10.1007/s00262-013-1508-5; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Miyagaki T, 2011, CANCER RES, V71, P2056, DOI 10.1158/0008-5472.CAN-10-3764; Miyagaki T, 2010, J INVEST DERMATOL, V130, P2304, DOI 10.1038/jid.2010.128; NAGY A, 2018, SCI REP UK, V8; Oh K, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3473; Ouzounova M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14979; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Rodriguez PC, 2004, CANCER RES, V64, P5839, DOI 10.1158/0008-5472.CAN-04-0465; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sun HL, 2012, WORLD J GASTROENTERO, V18, P3303, DOI 10.3748/wjg.v18.i25.3303; Tian M, 2016, ONCOTARGET, V7, P32617, DOI 10.18632/oncotarget.8958; Tian W, 2016, ONCOL REP, V35, P2171, DOI 10.3892/or.2016.4561; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Wang DZ, 2017, CANCER RES, V77, P3655, DOI 10.1158/0008-5472.CAN-16-3199; Wang L, 2013, J IMMUNOL, V190, P794, DOI 10.4049/jimmunol.1202088; Watanabe-Takano H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127888; Xu WF, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1118-y; Xu WT, 2015, CELL ADHES MIGR, V9, P317, DOI 10.1080/19336918.2015.1016686; Yang ZZ, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-0843-1; Ye W, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0156-y; Zajkowska M, 2020, CANCERS, V12, DOI 10.3390/cancers12061383; Zhang GB, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.977164; Zhao F, 2012, IMMUNOLOGY, V136, P176, DOI 10.1111/j.1365-2567.2012.03566.x; Zhu F, 2014, ONCOL REP, V31, P2049, DOI 10.3892/or.2014.3060; Zohny SF, 2010, MED ONCOL, V27, P1246, DOI 10.1007/s12032-009-9366-x	49	12	13	3	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1476	1489		10.1038/s41388-020-01605-4	http://dx.doi.org/10.1038/s41388-020-01605-4		JAN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452453				2022-12-28	WOS:000607998600011
J	Zhang, Z; Zhang, J; Diao, LX; Han, L				Zhang, Zhao; Zhang, Jian; Diao, Lixia; Han, Leng			Small non-coding RNAs in human cancer: function, clinical utility, and characterization	ONCOGENE			English	Review							POLYMERASE-III TRANSCRIPTION; SMALL NUCLEOLAR RNAS; MICRORNA SIGNATURES; BREAST-CANCER; EXPRESSION; ATLAS; PIRNA; IDENTIFICATION; METASTASIS; CARCINOMA	Small non-coding RNAs (sncRNAs) play critical roles in multiple regulatory processes, including transcription, post-transcription, and translation. Emerging evidence reveals the critical roles of sncRNAs in cancer development and their potential role as biomarkers and/or therapeutic targets. In this paper, we review recent research on four sncRNA species with functional significance in cancer: small nucleolar RNAs, transfer RNA, small nuclear RNAs, and piwi-interacting RNAs. We introduce their functional roles in tumorigenesis and discuss the potential utility of sncRNAs as prognostic and diagnostic biomarkers and therapeutic targets. We further summarize approaches to characterize sncRNAs in a high-throughput manner, including the specific library construction and computational framework. Our review provides a perspective of the functions, clinical utility, and characterization of sncRNAs in cancer.	[Zhang, Zhao; Zhang, Jian; Han, Leng] Univ Texas Hlth Sci Ctr Houston, Dept Biochem & Mol Biol, McGovern Med Sch, Houston, TX 77030 USA; [Diao, Lixia] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center	Zhang, Z; Han, L (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Biochem & Mol Biol, McGovern Med Sch, Houston, TX 77030 USA.; Diao, LX (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.	zzzczeus@163.com; ldiao@mdanderson.org; leng.han@uth.tmc.edu	Han, Leng/HCH-3491-2022; ZHANG, Jian/E-7203-2010	Han, Leng/0000-0002-7380-2640; zhang, zhao/0000-0002-3757-8469; ZHANG, Jian/0000-0001-8870-515X	Cancer Prevention Research Institute of Texas (CPRIT) [RR150085, RP190570]; UTHealth Innovation for the Cancer Prevention Research Training Program Postdoctoral Fellowship (Cancer Prevention and Research Institute of Texas) [RP160015]	Cancer Prevention Research Institute of Texas (CPRIT); UTHealth Innovation for the Cancer Prevention Research Training Program Postdoctoral Fellowship (Cancer Prevention and Research Institute of Texas)	We regret that the space limitations have prevented us from including all the relevant literature. This work was supported by the Cancer Prevention Research Institute of Texas (CPRIT; RR150085 and RP190570) to the CPRIT Scholar in Cancer Research (LH). This work was also supported by UTHealth Innovation for the Cancer Prevention Research Training Program Postdoctoral Fellowship (Cancer Prevention and Research Institute of Texas grant # RP160015). We thank LeeAnn Chastain for editorial assistance.	Andersen PR, 2017, NATURE, V549, P54, DOI 10.1038/nature23482; Bachellerie JP, 2002, BIOCHIMIE, V84, P775, DOI 10.1016/S0300-9084(02)01402-5; Balaratnam S, 2018, NUCLEIC ACIDS RES, V46, P10635, DOI 10.1093/nar/gky728; Beggs JD, 2005, BIOCHEM SOC T, V33, P433, DOI 10.1042/BST0330433; Campbell PJ, 2020, NATURE, V578, P82, DOI 10.1038/s41586-020-1969-6; Cao PB, 2018, GASTROENTEROLOGY, V155, P542, DOI 10.1053/j.gastro.2018.04.020; Chalbatani GM, 2019, PRACT LAB MED, V13, DOI 10.1016/j.plabm.2018.e00113; Chan PP, 2016, NUCLEIC ACIDS RES, V44, pD184, DOI 10.1093/nar/gkv1309; Chen WJ, 2015, CURR BIOL, V25, pR181, DOI 10.1016/j.cub.2014.11.059; Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905; Cheng J, 2011, CLIN CHIM ACTA, V412, P1621, DOI 10.1016/j.cca.2011.05.015; Cheng Z, 2017, ONCOTARGET, V8, P112867, DOI 10.18632/oncotarget.22842; Chu A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv808; Chu HY, 2015, CANCER LETT, V356, P561, DOI 10.1016/j.canlet.2014.10.004; Clarke CJ, 2016, CURR BIOL, V26, P755, DOI 10.1016/j.cub.2016.01.045; Cui L, 2017, GASTROENTEROLOGY, V153, P292, DOI 10.1053/j.gastro.2017.03.050; Dever TE, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a013706; Dong XH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01627; Dudda JC, 2013, IMMUNITY, V38, P742, DOI 10.1016/j.immuni.2012.12.006; Dupuis-Sandoval F, 2015, WIRES RNA, V6, P381, DOI 10.1002/wrna.1284; Dvinge H, 2019, GENOME RES, V29, P1591, DOI 10.1101/gr.246678.118; Erber L, 2020, RNA BIOL, V17, P23, DOI 10.1080/15476286.2019.1664250; Fang XL, 2017, J MOL CELL BIOL, V9, P243, DOI 10.1093/jmcb/mjw048; Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240; Gao L, 2015, INT J CANCER, V136, pE623, DOI 10.1002/ijc.29169; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Gong J, 2017, CELL REP, V21, P1968, DOI 10.1016/j.celrep.2017.10.070; Goodarzi H, 2016, CELL, V165, P1416, DOI 10.1016/j.cell.2016.05.046; Grady WM, 2010, GUT, V59, P706, DOI 10.1136/gut.2009.200022; Grewal SS, 2015, BBA-GENE REGUL MECH, V1849, P898, DOI 10.1016/j.bbagrm.2014.12.005; Hernandez-Alias X, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20199275; Hoffmann A, 2018, BIOINFORMATICS, V34, P1116, DOI 10.1093/bioinformatics/btx756; INOUE D, 2019, BLOOD S, V134, DOI DOI 10.1182/blood-2019-124616; Isakova A, 2020, P NATL ACAD SCI USA, V117, P25634, DOI 10.1073/pnas.2002277117; Jorjani H, 2016, NUCLEIC ACIDS RES, V44, P5068, DOI 10.1093/nar/gkw386; Kassavetis GA, 2001, EMBO J, V20, P2823, DOI 10.1093/emboj/20.11.2823; Kiss T, 2010, MOL CELL, V37, P597, DOI 10.1016/j.molcel.2010.01.032; Korsunsky I, 2017, J INVEST MED, V65, P1068, DOI 10.1136/jim-2017-000457; Kosmyna B., 2020, BIORXIV, DOI [10.1101/2020.01.24.917260, DOI 10.1101/2020.01.24.917260]; Lee YJ, 2016, BIOMATERIALS, V101, P143, DOI 10.1016/j.biomaterials.2016.05.052; Li YP, 2015, MOL MED, V21, P381, DOI 10.2119/molmed.2014.00203; Liang JN, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00587; Liu YM, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01228-z; Liu YM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1052-9; Mannoor K, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-104; Martinez VD, 2015, SCI REP-UK, V5, DOI 10.1038/srep10423; Moyano M, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0133-5; Murillo OD, 2019, CELL, V177, P463, DOI 10.1016/j.cell.2019.02.018; Oh JM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13993-7; Olson P, 2009, GENE DEV, V23, P2152, DOI 10.1101/gad.1820109; Pan T, 2018, CELL RES, V28, P395, DOI 10.1038/s41422-018-0013-y; Paranjape T, 2009, GUT, V58, P1546, DOI 10.1136/gut.2009.179531; Pavon-Eternod M, 2009, NUCLEIC ACIDS RES, V37, P7268, DOI 10.1093/nar/gkp787; Pedroza-Torres A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01404; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Romano G, 2017, CARCINOGENESIS, V38, P485, DOI 10.1093/carcin/bgx026; Santos M, 2019, TRENDS MOL MED, V25, P853, DOI 10.1016/j.molmed.2019.05.011; Schorn AJ, 2017, CELL, V170, P61, DOI 10.1016/j.cell.2017.06.013; Shigematsu M, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx005; Shuai SM, 2019, NATURE, V574, P712, DOI 10.1038/s41586-019-1651-z; Siprashvili Z, 2016, NAT GENET, V48, P53, DOI 10.1038/ng.3452; Su H, 2014, ONCOGENE, V33, P1348, DOI 10.1038/onc.2013.89; Suzuki HI, 2015, ONCOGENE, V34, P3085, DOI 10.1038/onc.2014.254; Suzuki H, 2019, NATURE, V574, P707, DOI 10.1038/s41586-019-1650-0; Taft RJ, 2009, RNA, V15, P1233, DOI 10.1261/rna.1528909; Tan LP, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0940-3; Vickers KC, 2015, TRENDS BIOCHEM SCI, V40, P4, DOI 10.1016/j.tibs.2014.10.009; Vinson V., 2015, SCIENCE, V349, p1178.3, DOI [10.1126/science.349.6253.1178-c, DOI 10.1126/science.349.6253.1178-c, DOI 10.1126/SCIENCE.349.6253.1178-C]; Wang XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep28260; Warashina M, 2001, RNA, V13, P277, DOI [10.1016/B978-008043408-7/50037-X, DOI 10.1016/B978-008043408-7/50037-X]; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wong CM, 2018, NAT REV GASTRO HEPAT, V15, P137, DOI 10.1038/nrgastro.2017.169; Xiang Y, 2018, TRENDS CANCER, V4, P823, DOI 10.1016/j.trecan.2018.09.009; Xing Y, 2006, NUCLEIC ACIDS RES, V34, P3150, DOI 10.1093/nar/gkl396; Yang QY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11312-8; Yang Y, 2018, ONCOL LETT, V15, P368, DOI 10.3892/ol.2017.7338; Zhang Z, 2020, RNA BIOL, V17, P1674, DOI 10.1080/15476286.2019.1657744; Zhang Z, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0239-8; Zheng D, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0170-5; Zheng GQ, 2015, NAT METHODS, V12, P835, DOI [10.1038/NMETH.3478, 10.1038/nmeth.3478]; Zheng TS, 2010, INT J CANCER, V126, P2, DOI 10.1002/ijc.24782; Zhou FB, 2017, NAT CELL BIOL, V19, P844, DOI 10.1038/ncb3563	84	11	11	6	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1570	1577		10.1038/s41388-020-01630-3	http://dx.doi.org/10.1038/s41388-020-01630-3		JAN 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33452456				2022-12-28	WOS:000607998600002
J	Al-Akhrass, H; Conway, JRW; Poulsen, ASA; Paatero, I; Kaivola, J; Padzik, A; Andersen, OM; Ivaska, J				Al-Akhrass, Hussein; Conway, James R. W.; Poulsen, Annemarie Svane Aavild; Paatero, Ilkka; Kaivola, Jasmin; Padzik, Artur; Andersen, Olav M.; Ivaska, Johanna			A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance	ONCOGENE			English	Article							AMYLOID PRECURSOR PROTEIN; BREAST-CANCER; NERVOUS-SYSTEM; INHIBITION; TRASTUZUMAB; CONTRIBUTES; TRAFFICKING; FULVESTRANT; EXPRESSION; METASTASES	Current evidence indicates that resistance to the tyrosine kinase-type cell surface receptor (HER2)-targeted therapies is frequently associated with HER3 and active signaling via HER2-HER3 dimers, particularly in the context of breast cancer. Thus, understanding the response to HER2-HER3 signaling and the regulation of the dimer is essential to decipher therapy relapse mechanisms. Here, we investigate a bidirectional relationship between HER2-HER3 signaling and a type-1 transmembrane sorting receptor, sortilin-related receptor (SorLA; SORL1). We demonstrate that heregulin-mediated signaling supports SorLA transcription downstream of the mitogen-activated protein kinase pathway. In addition, we demonstrate that SorLA interacts directly with HER3, forming a trimeric complex with HER2 and HER3 to attenuate lysosomal degradation of the dimer in a Ras-related protein Rab4-dependent manner. In line with a role for SorLA in supporting the stability of the HER2 and HER3 receptors, loss of SorLA compromised heregulin-induced cell proliferation and sensitized metastatic anti-HER2 therapy-resistant breast cancer cells to neratinib in cancer spheroids in vitro and in vivo in a zebrafish brain xenograft model.	[Al-Akhrass, Hussein; Conway, James R. W.; Paatero, Ilkka; Kaivola, Jasmin; Padzik, Artur; Ivaska, Johanna] Univ Turku, Turku Biosci Ctr, FI-20520 Turku, Finland; [Al-Akhrass, Hussein; Conway, James R. W.; Paatero, Ilkka; Kaivola, Jasmin; Padzik, Artur; Ivaska, Johanna] Abo Akad Univ, FI-20520 Turku, Finland; [Poulsen, Annemarie Svane Aavild; Andersen, Olav M.] Aarhus Univ, Dept Biomed, Danish Res Inst Translat Neurosci DANDRITE Nord E, Aarhus, Denmark	University of Turku; Abo Akademi University; Aarhus University	Al-Akhrass, H; Ivaska, J (corresponding author), Univ Turku, Turku Biosci Ctr, FI-20520 Turku, Finland.; Al-Akhrass, H; Ivaska, J (corresponding author), Abo Akad Univ, FI-20520 Turku, Finland.	hussein.al-akhrass@utu.fi; joivaska@utu.fi		Kaivola, Jasmin/0000-0002-1437-1828; Ivaska, Johanna/0000-0002-6295-6556; Al-Akhrass, Hussein/0000-0002-9630-3000	Academy of Finland [312517]; Academy of Finland CoE for Translational Cancer Biology; European Research Council CoG grant [615258]; Sigrid Juselius Foundation; Finnish Cancer Organization; Finnish Cultural Foundation Central Fund [190150]; European Union's Horizon 2020 research and innovation program under Marie Sklodowska-Curie grant [841973]; Independent Research Fund Denmark [DFF-4004-00371]; TuDMM Doctoral Program, University of Turku	Academy of Finland(Academy of Finland); Academy of Finland CoE for Translational Cancer Biology; European Research Council CoG grant; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Cancer Organization; Finnish Cultural Foundation Central Fund; European Union's Horizon 2020 research and innovation program under Marie Sklodowska-Curie grant; Independent Research Fund Denmark; TuDMM Doctoral Program, University of Turku	We thank J. Siivonen and P. Laasola for technical assistance. H. Hamidi is acknowledged for illustrations and editing of the manuscript. The Ivaska laboratory is acknowledged for lively discussions and critical feedback on the manuscript. Guillaume Jacquemet, Jukka Westermarck, Majid Momeny, and Patrick Brest are acknowledged for critical reading of the manuscript. The Cell Imaging and Cytometry and Genome Editing core facilities (Turku Bioscience Centre, University of Turku and Abo Akademi University and Biocenter, Finland); the EuroBioimaging node in Turku and the Zebrafish core facility (Turku Bioscience Centre, University of Turku and Abo Akademi University) are acknowledged for services, instrumentation, and expertise. This study was supported by the Academy of Finland (J. Ivaska grant 312517), the Academy of Finland CoE for Translational Cancer Biology (J. Ivaska), the European Research Council CoG grant 615258 (J. Ivaska), the Sigrid Juselius Foundation (J. Ivaska) and the Finnish Cancer Organization (J. Ivaska). H. AlAkhrass has been supported by the Finnish Cultural Foundation Central Fund 190150. J.R.W. Conway has been supported by the European Union's Horizon 2020 research and innovation program under Marie Sklodowska-Curie grant agreement 841973. O.M. Andersen has been supported by The Independent Research Fund Denmark grant DFF-4004-00371. J. Kaivola has been supported by TuDMM Doctoral Program, University of Turku.	Al-Akhrass H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01172-5; Amin DN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000389; Andersen OM, 2005, P NATL ACAD SCI USA, V102, P13461, DOI 10.1073/pnas.0503689102; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Baselga J, 2017, LANCET ONCOL, V18, P904, DOI 10.1016/S1470-2045(17)30376-5; Bertelsen V, 2014, MEMBRANES, V4, P424, DOI 10.3390/membranes4030424; Boulbes DR, 2015, BREAST CANCER RES TR, V151, P501, DOI 10.1007/s10549-015-3414-3; Caldieri G, 2018, PROG MOL SUBCELL BIO, V57, P235, DOI 10.1007/978-3-319-96704-2_9; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Croucher DR, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf0793; Ding Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06651-x; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Fazio M, 2020, NAT REV CANCER, V20, P263, DOI 10.1038/s41568-020-0252-3; Fjorback AW, 2012, J NEUROSCI, V32, P1467, DOI 10.1523/JNEUROSCI.2272-11.2012; Freal A, 2019, NEURON, V104, P305, DOI 10.1016/j.neuron.2019.07.029; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Gijsen M, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000563; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grant BD, 2009, NAT REV MOL CELL BIO, V10, P597, DOI 10.1038/nrm2755; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Hutcheson IR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2848; Jacobsen L, 2002, FEBS LETT, V511, P155, DOI 10.1016/S0014-5793(01)03299-9; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kang JC, 2014, MABS-AUSTIN, V6, P340, DOI 10.4161/mabs.27658; Kodack DP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4682; Kodack DP, 2015, CANCER CELL, V27, P163, DOI 10.1016/j.ccell.2015.01.001; Kodack DP, 2012, P NATL ACAD SCI USA, V109, pE3119, DOI 10.1073/pnas.1216078109; Liu JY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07258-y; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Mehmedbasic A, 2015, J BIOL CHEM, V290, P3359, DOI 10.1074/jbc.M114.619940; Mei L, 2014, NEURON, V83, P27, DOI 10.1016/j.neuron.2014.06.007; Mishra R, 2020, P A I C C AUT ROBOT, P124, DOI 10.1109/ICCAR49639.2020.9108074; Navaroli DM, 2012, P NATL ACAD SCI USA, V109, pE471, DOI 10.1073/pnas.1115495109; Nusinow DP, 2020, CELL, V180, P387, DOI 10.1016/j.cell.2019.12.023; Olson EM, 2013, ANN ONCOL, V24, P1526, DOI 10.1093/annonc/mdt036; Paatero I, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BioProtoc.3027; Parachoniak CA, 2011, DEV CELL, V20, P751, DOI 10.1016/j.devcel.2011.05.007; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Peuhu E, 2017, DEVELOPMENT, V144, P4103, DOI 10.1242/dev.154229; Pietila M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10275-0; Research C for DE and, 2020, FDA APPR NER MET HER; Rhost S, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1060-5; Roselli S, 2015, ONCOTARGET, V6, P10473, DOI 10.18632/oncotarget.3401; Sato T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127360; Schmidt V, 2016, J CLIN INVEST, V126, P2706, DOI 10.1172/JCI84708; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Small SA, 2015, NAT REV NEUROSCI, V16, P126, DOI 10.1038/nrn3896; Tomas A, 2014, TRENDS CELL BIOL, V24, P26, DOI 10.1016/j.tcb.2013.11.002; Tubbesing K, 2020, MOL CANCER RES, P19; Vaught DB, 2012, CANCER RES, V72, P2672, DOI 10.1158/0008-5472.CAN-11-3594; Wang CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8597; White RM, 2008, CELL STEM CELL, V2, P183, DOI 10.1016/j.stem.2007.11.002; Willnow TE, 2010, REV NEUROSCIENCE, V21, P315; Willnow TE, 2008, NAT REV NEUROSCI, V9, P899, DOI 10.1038/nrn2516; Xia WL, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3480; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309; Zhang SY, 2013, CANCER RES, V73, P5764, DOI 10.1158/0008-5472.CAN-12-1803; Zhang YQ, 2016, CANCER LETT, V382, P176, DOI 10.1016/j.canlet.2016.08.026	65	10	10	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1300	1317		10.1038/s41388-020-01604-5	http://dx.doi.org/10.1038/s41388-020-01604-5		JAN 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420373	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000607346000002
J	Bala, P; Singh, AK; Kavadipula, P; Kotapalli, V; Sabarinathan, R; Bashyam, MD				Bala, Pratyusha; Singh, Anurag Kumar; Kavadipula, Padmavathi; Kotapalli, Viswakalyan; Sabarinathan, Radhakrishnan; Bashyam, Murali Dharan			Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer	ONCOGENE			English	Article							CHROMATIN-REMODELING COMPLEX; INACTIVATING MUTATIONS; GENOME; GENE; REQUIRES; SUBUNIT; BAF200; CELLS; APC	Early-onset sporadic rectal cancer (EOSRC) is a unique and predominant colorectal cancer (CRC) subtype in India. In order to understand the tumorigenic process in EOSRC, we performed whole-exome sequencing of 47 microsatellite stable EOSRC samples. Signature 1 was the predominant mutational signature in EOSRC, as previously shown in other CRC exome studies. More importantly, we identified TP53, KRAS, APC, PIK3R1, SMAD4 and ZNF880 as significantly mutated (q < 0.1) and ARID1A and ARID2 as near-significantly mutated (restricted hypothesis testing; q < 0.1) candidate drivers. Unlike the other candidates, the tumorigenic potential of ARID2, encoding a component of the SWI/SNF chromatin remodeling complex, is largely unexplored in CRC. shRNA-mediated ARID2 knockdown performed in different CRC cell lines resulted in significant alterations in transcript levels of cancer-related target genes. More importantly, ARID2 knockdown promoted several tumorigenic features including cell viability, proliferation, ability to override contact inhibition of growth, and migration besides significantly increasing tumor formation ability in nude mice. The observed gain in tumorigenic features was rescued upon ectopic expression of wild type but not mutant ARID2. Analyses of the TCGA pan-cancer dataset revealed several modes of ARID2 inactivation and of the CRC dataset revealed poorer survival in patients with ARID2 alterations. We therefore propose ARID2 as a novel tumor suppressor in CRC.	[Bala, Pratyusha; Kavadipula, Padmavathi; Kotapalli, Viswakalyan; Bashyam, Murali Dharan] Ctr DNA Fingerprinting & Diagnost, Lab Mol Oncol, Hyderabad 500039, India; [Bala, Pratyusha] Manipal Acad Higher Educ, Grad Studies, Manipal 576104, India; [Singh, Anurag Kumar; Sabarinathan, Radhakrishnan] Tata Inst Fundamental Res, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); Manipal Academy of Higher Education (MAHE); Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)	Bashyam, MD (corresponding author), Ctr DNA Fingerprinting & Diagnost, Lab Mol Oncol, Hyderabad 500039, India.	bashyam@cdfd.org.in		Bashyam, M D/0000-0002-1967-5249	Department of Science and Technology, Government of India [SB/SO/HS-007/2013]; University Grants Commission, Government of India; NCBS-TIFR; Ramanujan fellowship (SERB) [SB/S2/RJN-071/2018]; Department of Atomic Energy, Government of India [12-RD-TFR-5.04-0800]	Department of Science and Technology, Government of India(Department of Science & Technology (India)); University Grants Commission, Government of India(University Grants Commission, India); NCBS-TIFR; Ramanujan fellowship (SERB); Department of Atomic Energy, Government of India(Department of Atomic Energy (DAE))	We thank the patients for kindly agreeing to be a part of the study. We are grateful to Dr Swarnalata Gowrishankar, Apollo Hospitals, Hyderabad and Dr Satish Rao, Krishna Institute of Medical Sciences, Hyderabad for evaluation of ARID2 IHC stains on CRC TMA. We also thank Dr Asmita Gupta, Department of Science and Technology National Postdoctoral Fellow, Laboratory of Molecular Oncology, CDFD, Hyderabad, for help in generating Fig. S4a. The work was supported by a grant (SB/SO/HS-007/2013) from the Department of Science and Technology, Government of India to MDB. PB, a registered PhD student of Manipal Academy of Higher Education, is grateful to the University Grants Commission, Government of India for junior and senior research fellowships. We acknowledge CDFD's Sophisticated Equipment Facility for fluorescence microscopy and Sanger sequencing and the Experimental Animal Facility, for nude mice experiments. RS acknowledges funding support from NCBS-TIFR, and Ramanujan fellowship (SERB, SB/S2/RJN-071/2018). RS and AKS acknowledge support of the Department of Atomic Energy, Government of India, under project no. 12-R&D-TFR-5.04-0800.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; [Anonymous], 2013, CLIN TRANSL GASTROEN, V4, pe39, DOI DOI 10.1038/ncomms3873; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Bracken AP, 2019, GENE DEV, V33, P936, DOI 10.1101/gad.326066.119; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cajuso T, 2014, INT J CANCER, V135, P611, DOI 10.1002/ijc.28705; Carlson RV, 2004, BRIT J CLIN PHARMACO, V57, P695, DOI 10.1111/j.1365-2125.2004.02103.x; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; de Castro RO, 2017, J BIOL CHEM, V292, P8459, DOI 10.1074/jbc.M117.778183; de la Chapelle A, 2010, J CLIN ONCOL, V28, P3380, DOI 10.1200/JCO.2009.27.0652; Duan YJ, 2016, ONCOTARGET, V7, P45863, DOI 10.18632/oncotarget.10244; Ellrott K, 2018, CELL SYST, V6, P271, DOI 10.1016/j.cels.2018.03.002; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gaedcke J, 2010, RADIOTHER ONCOL, V94, P76, DOI 10.1016/j.radonc.2009.10.001; Garcia M, 2018, BIORXIV, DOI [10.1101/316976, DOI 10.1101/316976]; Gori K., 2018, SIGFIT FLEXIBLE BAYE, DOI [10.1101/372896, DOI 10.1101/372896]; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hofseth LJ, 2020, NAT REV GASTRO HEPAT, V17, P352, DOI 10.1038/s41575-019-0253-4; Jones RP, 2017, BRIT J CANCER, V116, P923, DOI 10.1038/bjc.2017.37; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Karczewski K.J., 2019, GENOMICS, DOI [10.1101/531210, DOI 10.1101/531210]; Khursheed M, 2013, BRIT J CANCER, V108, P2056, DOI 10.1038/bjc.2013.200; Kim MP, 2018, CELL DEATH DIFFER, V25, P161, DOI 10.1038/cdd.2017.185; Kumar R, 2018, GENE CHROMOSOME CANC, V57, P304, DOI 10.1002/gcc.22531; Kumar R, 2018, J MOL MED, V96, P135, DOI 10.1007/s00109-017-1607-4; Kurosaki T, 2019, NAT REV MOL CELL BIO, V20, P406, DOI 10.1038/s41580-019-0126-2; Laskar RS, 2015, MOL CARCINOGEN, V54, P1786, DOI 10.1002/mc.22250; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee CC, 2012, J BIOL CHEM, V287, P2798, DOI 10.1074/jbc.M111.258947; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Manceau G, 2013, INT J CANCER, V132, P2217, DOI 10.1002/ijc.27900; Martincorena I, 2018, CELL, V173, P1823, DOI 10.1016/j.cell.2018.06.001; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Meisenberg C, 2019, MOL CELL, V73, P212, DOI 10.1016/j.molcel.2018.11.001; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Mularoni L, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0994-0; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Neumann J, 2009, PATHOL RES PRACT, V205, P858, DOI 10.1016/j.prp.2009.07.010; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Raman R, 2014, MOL CARCINOGEN, V53, pE181, DOI 10.1002/mc.21976; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Schell MJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11743; Shorstova T, 2019, CANCER RES, V79, P2761, DOI 10.1158/0008-5472.CAN-18-1545; Sondka Z, 2018, NAT REV CANCER, V18, P696, DOI 10.1038/s41568-018-0060-1; Tamborero D, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0531-8; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Wall JD, 2019, NATURE, V576, P106, DOI 10.1038/s41586-019-1793-z; Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645; Wang JY, 2007, HEPATO-GASTROENTEROL, V54, P2259; Xu FH, 2012, J BIOL CHEM, V287, P5033, DOI 10.1074/jbc.M111.279968; Yan ZJ, 2005, GENE DEV, V19, P1662, DOI 10.1101/gad.1323805	54	8	8	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					863	874		10.1038/s41388-020-01537-z	http://dx.doi.org/10.1038/s41388-020-01537-z		DEC 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33262464	Green Submitted			2022-12-28	WOS:000595928700004
J	Li, Y; Li, L; Qin, J; Wu, JY; Dai, XM; Xu, JM				Li, Yang; Li, Lei; Qin, Jun; Wu, Junyi; Dai, Xueming; Xu, Junming			OSR1 phosphorylates the Smad2/3 linker region and induces TGF-beta 1 autocrine to promote EMT and metastasis in breast cancer	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; STEM-CELLS; EXPRESSION; ACTIVATION; RESISTANCE; TURNOVER; GENE; WNK1	Oxidative stress-responsive kinase 1 (OSR1) plays a critical role in multiple carcinogenic signal pathways, and its overexpression has been found in various types of cancer; however, the pathophysiological role of OSR1 in breast cancer has not been evaluated. This study aims to elaborate on the role of OSR1 in breast cancer metastasis and the specific regulatory mechanism. Our results showed that OSR1 mRNA and protein were upregulated in both human breast cancer samples and cell lines. Moreover, phosphorylated OSR1 (p-OSR1) was an independent poor prognostic indicator in patients with breast cancer. OSR1 upregulation induced epithelial-to-mesenchymal transition (EMT) in normal and malignant mammary epithelial cells with the increasing metastatic capacity. In contrast, deleting OSR1 in aggressive breast cancer cells inhibited these phenotypes. OSR1 is the critical activator for transcription factors of EMT. Mechanistically, we found that OSR1 can directly interact and phosphorylate the linker region of Smad2 at Thr220 and Smad3 at Thr179. Phosphorylated Smad2/3 translocated into the nucleus to enhance transforming growth factor-beta 1 (TGF-beta 1) autocrine signalling and increase the transcription of EMT regulators. Importantly, interruption of the OSR1-Smad2/3-TGF-beta 1 signalling axis elicited a robust anti-EMT and anti-metastatic effect in vitro and in vivo. Taken together, we conclude that OSR1-mediated Smad2/3-TGF-beta 1 signalling promotes EMT and metastasis representing a promising therapeutic target in breast cancer treatment.	[Li, Yang; Li, Lei; Qin, Jun; Wu, Junyi; Dai, Xueming; Xu, Junming] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Gen Surg, 100 Haining Rd, Shanghai 200080, Peoples R China	Shanghai Jiao Tong University	Xu, JM (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Gen Surg, 100 Haining Rd, Shanghai 200080, Peoples R China.	junmingxusur@hotmail.com		Li, Yang/0000-0002-5882-2301	National Natural Science Foundation of China [81670595, 81970568]; Shanghai Natural Science Funds [16ZR1428200]; Excellent Youth Medical Talents Program of Shanghai General Hospital [06N1702011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Natural Science Funds; Excellent Youth Medical Talents Program of Shanghai General Hospital	This work was supported by the National Natural Science Foundation of China (81670595, 81970568), Shanghai Natural Science Funds (16ZR1428200), and the Excellent Youth Medical Talents Program of Shanghai General Hospital (06N1702011).	Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; AlAmri MA, 2017, CHEMMEDCHEM, V12, P639, DOI 10.1002/cmdc.201700077; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Aragon E, 2011, GENE DEV, V25, P1275, DOI 10.1101/gad.2060811; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Burington B, 2008, CLIN CANCER RES, V14, P4821, DOI 10.1158/1078-0432.CCR-07-4568; Chen W, 2004, J BIOL CHEM, V279, P11129, DOI 10.1074/jbc.M313562200; Chen ZH, 2011, RESP PHYSIOL NEUROBI, V176, P110, DOI 10.1016/j.resp.2011.02.001; Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008; Conti A, 2018, PROTEOM CLIN APPL, V12, DOI 10.1002/prca.201800041; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Ernest NJ, 2005, AM J PHYSIOL-CELL PH, V288, pC1451, DOI 10.1152/ajpcell.00503.2004; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Galliher Amy J, 2006, Future Oncol, V2, P743, DOI 10.2217/14796694.2.6.743; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Hung JY, 2017, ONCOTARGET, V8, P63691, DOI 10.18632/oncotarget.19475; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Ju HR, 2003, CANCER LETT, V196, P197, DOI 10.1016/S0304-3835(03)00237-4; Kankanamalage SG, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0287-1; Krueger EM, 2011, ANN NEUROSCI, V18, P70, DOI 10.5214/ans.0972.7531.1118212; Lampropoulos P, 2012, CANCER LETT, V314, P1, DOI 10.1016/j.canlet.2011.09.041; Li Y, 2020, BREAST CANCER RES TR, V182, P35, DOI 10.1007/s10549-020-05671-w; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Niimi H, 2007, J CELL BIOL, V176, P695, DOI 10.1083/jcb.200612129; Nishida H, 2012, HYPERTENSION, V60, P981, DOI 10.1161/HYPERTENSIONAHA.112.201509; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Ruan HY, 2017, AM J CANCER RES, V7, P543; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi XN, 2018, ONCOL REP, V40, P1592, DOI 10.3892/or.2018.6533; Shyamasundar S, 2016, INT J ONCOL, V49, P2629, DOI 10.3892/ijo.2016.3761; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Solomon A, 2004, GENETICS, V167, P161, DOI 10.1534/genetics.167.1.161; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Tamari M, 1999, J HUM GENET, V44, P116, DOI 10.1007/s100380050121; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tu SW, 2011, P NATL ACAD SCI USA, V108, P1385, DOI 10.1073/pnas.1018567108; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Wang GN, 2009, J BIOL CHEM, V284, P9663, DOI 10.1074/jbc.M809281200; Wtighton KH, 2008, CELL SIGNAL, V20, P1579, DOI 10.1016/j.cellsig.2008.02.003; Yeh HW, 2018, NAT CELL BIOL, V20, P479, DOI 10.1038/s41556-018-0062-y; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zeng GC, 2000, INT J CANCER, V88, P53, DOI 10.1002/1097-0215(20001001)88:1<53::AID-IJC8>3.0.CO;2-7; Zhou YY, 2017, ONCOTARGET, V8, P66328, DOI 10.18632/oncotarget.20240; Zhu W, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-31	53	9	10	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					68	84		10.1038/s41388-020-01499-2	http://dx.doi.org/10.1038/s41388-020-01499-2		OCT 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33051597				2022-12-28	WOS:000577556100004
J	Qiao, S; Lu, WH; Glorieux, C; Li, JJ; Zeng, PT; Meng, N; Zhang, HQ; Wen, SJ; Huang, P				Qiao, Shuang; Lu, Wenhua; Glorieux, Christophe; Li, Jiangjiang; Zeng, Peiting; Meng, Ning; Zhang, Huiqin; Wen, Shijun; Huang, Peng			Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer	ONCOGENE			English	Article							ISOCITRATE DEHYDROGENASE; CELLS; MITOCHONDRIA; MUTATIONS; PROMOTES; STRESS; APOPTOSIS; INVASION; GENES; ROS	Although the role of isocitrate dehydrogenase (IDH) mutation in promoting cancer development has been well-characterized, the impact of wild-type IDH on cancer cells remains unclear. Here we show that the wild-type isocitrate dehydrogenase 2 (IDH2) is highly expressed in colorectal cancer (CRC) cells, and plays an unexpected role in protecting the cancer cells from oxidative damage. Genetic abrogation of IDH2 in CRC cells leads to reactive oxygen species (ROS)-mediated DNA damage and an accumulation of 8-oxoguanine with DNA strand breaks, which activates DNA damage response (DDR) with elevated gamma H2AX and phosphorylation of ataxia telangiectasia-mutated (ATM) protein, leading to a partial cell cycle arrest and eventually cell senescence. Mechanistically, the suppression of IDH2 results in a reduction of the tricarboxylic acid (TCA) cycle activity due to a decrease in the conversion of isocitrate to alpha-ketoglutarate (alpha-KG) with a concurrent decrease in NADPH production, leading to ROS accumulation and oxidative DNA damage. Importantly, abrogation of IDH2 inhibits CRC cell growth in vitro and in vivo, and renders CRC cells more vulnerable to DNA-damaging drugs. Screening of an FDA-approved drug library has identified oxaliplatin as a compound highly effective against CRC cells when IDH2 was suppressed. Our study has uncovered an important role of the wild-type IDH2 in protecting DNA from oxidative damage, and provides a novel biochemical basis for developing metabolic intervention strategy for cancer treatment.	[Qiao, Shuang; Lu, Wenhua; Glorieux, Christophe; Li, Jiangjiang; Zeng, Peiting; Meng, Ning; Zhang, Huiqin; Wen, Shijun; Huang, Peng] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol Southern China, Canc Ctr, Guangzhou, Peoples R China; [Wen, Shijun; Huang, Peng] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou, Peoples R China; [Huang, Peng] Sun Yat Sen Univ, Metab Innovat Canc, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Wen, SJ; Huang, P (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol Southern China, Canc Ctr, Guangzhou, Peoples R China.; Wen, SJ; Huang, P (corresponding author), Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou, Peoples R China.; Huang, P (corresponding author), Sun Yat Sen Univ, Metab Innovat Canc, Guangzhou, Peoples R China.	wenshj@sysucc.org.cn; huangpeng@sysucc.org.cn	Zhang, Hui/HHN-8494-2022; Wen, Shijun/Q-2571-2015	QIAO, Shuang/0000-0002-9095-4128; Wen, Shijun/0000-0002-9347-8243	National Key R&D Program of China [2020YFA0803300, 2018YFC0910203]; National Natural Science Foundation of China [81872440, 81672952]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We would like to thank Yanyu Zhang, Mingquan Zhang and Bing-ling Luo for technical assistance, Haijing Deng and Dr. Hui Zhang for helpful discussions. Some of the cartoons in this article were created using the drawing tools provided by BioRender (https://biorender.com).This work was support in part by grants from the National Key R&D Program of China (2020YFA0803300, 2018YFC0910203), and from the National Natural Science Foundation of China (81872440, 81672952).	Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Bergaggio E, 2019, CANCERS, V11, DOI 10.3390/cancers11040563; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Cha H, 2017, REDOX BIOL, V13, P32, DOI 10.1016/j.redox.2017.05.009; DALZIEL K, 1980, FEBS LETT, V117, pK45, DOI 10.1016/0014-5793(80)80569-2; Dang L, 2017, ANNU REV BIOCHEM, V86, P305, DOI 10.1146/annurev-biochem-061516-044732; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jezek P, 2020, ANTIOXID REDOX SIGN, V33, P903, DOI 10.1089/ars.2019.7902; King A, 2006, ONCOGENE, V25, P4675, DOI 10.1038/sj.onc.1209594; Klaunig JE, 2018, CURR PHARM DESIGN, V24, P4771, DOI 10.2174/1381612825666190215121712; Kong MJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0537-6; Li JJ, 2018, THERANOSTICS, V8, P4050, DOI 10.7150/thno.21524; Liu WR, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-32; Luo J, 2005, NEUROCHEM INT, V47, P449, DOI 10.1016/j.neuint.2005.07.002; Lv Q, 2012, EXP THER MED, V4, P801, DOI 10.3892/etm.2012.676; Matt S, 2016, CELL MOL LIFE SCI, V73, P2829, DOI 10.1007/s00018-016-2130-4; McBrayer SK, 2018, CELL, V175, P101, DOI 10.1016/j.cell.2018.08.038; Molenaar RJ, 2018, ONCOGENE, V37, P1949, DOI 10.1038/s41388-017-0077-z; Molenaar RJ, 2018, CLIN CANCER RES, V24, P1705, DOI 10.1158/1078-0432.CCR-17-2796; Molenaar RJ, 2015, CANCER RES, V75, P4790, DOI 10.1158/0008-5472.CAN-14-3603; Montalban-Bravo G, 2018, FUTURE ONCOL, V14, P979, DOI 10.2217/fon-2017-0523; Neuzil J, 2006, FEBS LETT, V580, P5125, DOI 10.1016/j.febslet.2006.05.072; Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Salehi F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32308-2; Short NJ, 2020, CANCER DISCOV, V10, P506, DOI 10.1158/2159-8290.CD-19-1011; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Sulkowski PL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2463; Tian GY, 2015, CELL PHYSIOL BIOCHEM, V37, P2405, DOI 10.1159/000438593; Torrens-Mas M, 2017, J CELL BIOCHEM, V118, P397, DOI 10.1002/jcb.25653; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Waitkus MS, 2018, CANCER CELL, V34, P186, DOI 10.1016/j.ccell.2018.04.011; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Wu DD, 2016, TUMOR BIOL, V37, P5225, DOI 10.1007/s13277-015-4358-2; Wu LL, 2004, CLIN CHIM ACTA, V339, P1, DOI 10.1016/j.cccn.2003.09.010; Yan H, 2009, CANCER RES, V69, P9157, DOI 10.1158/0008-5472.CAN-09-2650; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang H, 2012, CLIN CANCER RES, V18, P5562, DOI 10.1158/1078-0432.CCR-12-1773; Yang YH, 2016, J CELL PHYSIOL, V231, P2570, DOI 10.1002/jcp.25349; Yen KE, 2010, ONCOGENE, V29, P6409, DOI 10.1038/onc.2010.444; Zhou LS, 2016, EMBO REP, V17, P811, DOI 10.15252/embr.201541643	47	5	5	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5880	5892		10.1038/s41388-021-01968-2	http://dx.doi.org/10.1038/s41388-021-01968-2		AUG 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34349242				2022-12-28	WOS:000681143600002
J	Jiang, CH; McKay, RM; Le, LQ				Jiang, Chunhui; McKay, Renee M.; Le, Lu Q.			Tumorigenesis in neurofibromatosis type 1: role of the microenvironment	ONCOGENE			English	Review							NERVE SHEATH TUMORS; PHASE-II TRIAL; SCHWANN-CELLS; NF1 LOSS; TGF-BETA; GROWTH; PLEXIFORM; EXPRESSION; DIFFERENTIATION; PROLIFERATION	Neurofibromatosis Type 1 (NF1) is one of the most common inherited neurological disorders and predisposes patients to develop benign and malignant tumors. Neurofibromas are NF1-associated benign tumors but can cause substantial discomfort and disfigurement. Numerous studies have shown that neurofibromas arise from the Schwann cell lineage but both preclinical mouse models and clinical trials have demonstrated that the neurofibroma tumor microenvironment contributes significantly to tumorigenesis. This offers the opportunity for targeting new therapeutic vulnerabilities to treat neurofibromas. However, a translational gap exists between deciphering the contribution of the neurofibroma tumor microenvironment and clinically applying this knowledge to treat neurofibromas. Here, we discuss the key cellular and molecular components in the neurofibroma tumor microenvironment that can potentially be targeted therapeutically to advance neurofibroma treatment.	[Jiang, Chunhui; McKay, Renee M.; Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, UTSW Comprehens Neurofibromatosis Clin, Dallas, TX USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, Dallas, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, UTSW Comprehens Neurofibromatosis Clin, Dallas, TX USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, Dallas, TX USA.	Lu.Le@UTSouthwestern.edu		Le, Lu/0000-0003-2817-5382; McKay, Renee/0000-0001-5976-1996	Burroughs Wellcome Fund; National Cancer Institute of the NIH [R01 CA166593]; Developmental and Hyperactive RAS Tumor SPORE [U54 CA196519]; US Department of Defense [W81XWH-21-1-0651]; Neurofibromatosis Therapeutic Acceleration Program; NF1 Research Consortium Fund; Giorgio Foundation	Burroughs Wellcome Fund(Burroughs Wellcome Fund); National Cancer Institute of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Developmental and Hyperactive RAS Tumor SPORE; US Department of Defense(United States Department of Defense); Neurofibromatosis Therapeutic Acceleration Program; NF1 Research Consortium Fund; Giorgio Foundation	LQL is the Thomas L. Shield, M.D. Endowed Professor in Dermatology. He held a Career Award for Medical Scientists from the Burroughs Wellcome Fund, and is supported by funding from the National Cancer Institute of the NIH (R01 CA166593) and the Developmental and Hyperactive RAS Tumor SPORE (U54 CA196519); the US Department of Defense (W81XWH-21-1-0651); the Neurofibromatosis Therapeutic Acceleration Program; the NF1 Research Consortium Fund; and the Giorgio Foundation.	Atit RP, 1999, J INVEST DERMATOL, V112, P835, DOI 10.1046/j.1523-1747.1999.00609.x; Babovic-Vuksanovic D, 2006, NEUROLOGY, V67, P1860, DOI 10.1212/01.wnl.0000243231.12248.67; Bergoug M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112365; Bonner JC, 2004, CYTOKINE GROWTH F R, V15, P255, DOI 10.1016/j.cytogfr.2004.03.006; Brosseau JP, 2021, ACTA NEUROPATHOL COM, V9, DOI 10.1186/s40478-020-01103-4; Brosseau JP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07452-y; Brosseau JP, 2018, NEUROLOGY, V91, pS14, DOI 10.1212/WNL.0000000000005788; Chen ZG, 2019, CANCER DISCOV, V9, P114, DOI 10.1158/2159-8290.CD-18-0151; Chen ZG, 2014, CANCER CELL, V26, P695, DOI 10.1016/j.ccell.2014.09.009; Choi K, 2017, SCI REP-UK, V7, DOI 10.1038/srep43315; Dallas SL, 2005, J BIOL CHEM, V280, P18871, DOI 10.1074/jbc.M410762200; Dolivo DM, 2017, CYTOKINE GROWTH F R, V38, P49, DOI 10.1016/j.cytogfr.2017.09.003; Dombi E, 2007, NEUROLOGY, V68, P643, DOI 10.1212/01.wnl.0000250332.89420.e6; Driskell RR, 2013, NATURE, V504, P277, DOI 10.1038/nature12783; Dundr P, 2009, PATHOL INT, V59, P86, DOI 10.1111/j.1440-1827.2008.02333.x; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Fletcher Jonathan S, 2020, Neurooncol Adv, V2, pi23, DOI 10.1093/noajnl/vdz045; Fricker FR, 2011, FUTUR NEUROL, V6, P809, DOI 10.2217/FNL.11.45; Fricker FR, 2011, J NEUROSCI, V31, P3225, DOI 10.1523/JNEUROSCI.2568-10.2011; Gorlewicz A, 2009, NEUROBIOL DIS, V34, P245, DOI 10.1016/j.nbd.2009.01.011; Gross AM, 2020, NEW ENGL J MED, V382, P1430, DOI 10.1056/NEJMoa1912735; Hagel C, 2012, NEUROPATHOLOGY, V32, P406, DOI 10.1111/j.1440-1789.2011.01276.x; Harboe M, 2018, GLIA, V66, P934, DOI 10.1002/glia.23293; Harigai R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24484-y; Henderson NC, 2020, NATURE, V587, P555, DOI 10.1038/s41586-020-2938-9; Hirbe AC, 2014, LANCET NEUROL, V13, P834, DOI 10.1016/S1474-4422(14)70063-8; JAAKKOLA S, 1989, J CLIN INVEST, V84, P253, DOI 10.1172/JCI114148; Jessen KR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020487; Joseph NM, 2008, CANCER CELL, V13, P129, DOI 10.1016/j.ccr.2008.01.003; KADONO T, 1994, BIOCHEM BIOPH RES CO, V198, P827, DOI 10.1006/bbrc.1994.1118; Kim Y, 2008, J BIOL CHEM, V283, P22513, DOI 10.1074/jbc.M708319200; Le LQ, 2007, ONCOGENE, V26, P4609, DOI 10.1038/sj.onc.1210261; Le LQ, 2011, CANCER RES, V71, P4686, DOI 10.1158/0008-5472.CAN-10-4577; Liao CP, 2018, J CLIN INVEST, V128, P2848, DOI 10.1172/JCI99424; Liao CP, 2016, ONCOTARGET, V7, P61500, DOI 10.18632/oncotarget.11133; Linneberg C, 2015, ASN NEURO, V7, DOI 10.1177/1759091415602859; Mascharak S, 2021, SCIENCE, V372, P362, DOI 10.1126/science.aba2374; Mashour GA, 2001, ONCOGENE, V20, P97, DOI 10.1038/sj.onc.1204026; Misa K, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13383; Mo J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139807; Moleirinho S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060028; Park J, 2012, J CLIN INVEST, V122, P4243, DOI 10.1172/JCI63930; Parrinello S, 2010, CELL, V143, P145, DOI 10.1016/j.cell.2010.08.039; Parrinello S, 2008, GENE DEV, V22, P3335, DOI 10.1101/gad.490608; PELTONEN J, 1986, ANN NY ACAD SCI, V486, P260, DOI 10.1111/j.1749-6632.1986.tb48079.x; Piersma B, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00059; Prada CE, 2013, ACTA NEUROPATHOL, V125, P159, DOI 10.1007/s00401-012-1056-7; Radomska KJ, 2019, CANCER DISCOV, V9, P130, DOI 10.1158/2159-8290.CD-18-0156; Ribeiro S, 2013, CELL REP, V5, P126, DOI 10.1016/j.celrep.2013.08.033; Riccardi VM, 2015, AM J MED GENET A, V167, P1570, DOI 10.1002/ajmg.a.37045; RICCARDI VM, 1987, ARCH DERMATOL, V123, P1011, DOI 10.1001/archderm.123.8.1011; Rice FL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216527; Robertson KA, 2012, LANCET ONCOL, V13, P1218, DOI 10.1016/S1470-2045(12)70414-X; Ronellenfitsch MW, 2020, J CLIN INVEST, V130, P2488, DOI 10.1172/JCI130787; Saito H, 2007, ONCOGENE, V26, P4714, DOI 10.1038/sj.onc.1210250; Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; Sun K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4485; Toole BP, 2009, CLIN CANCER RES, V15, P7462, DOI 10.1158/1078-0432.CCR-09-0479; Wang-Gillam A, 2019, J CLIN ONCOL, V37, P1041, DOI 10.1200/JCO.19.00056; Wehner D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00143-0; Widemann BC, 2014, PEDIATR BLOOD CANCER, V61, P1598, DOI 10.1002/pbc.25041; Wishart AL, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc3175; Woodhoo A, 2009, NAT NEUROSCI, V12, P839, DOI 10.1038/nn.2323; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Yang FC, 2008, CELL, V135, P437, DOI 10.1016/j.cell.2008.08.041; Yang FC, 2006, HUM MOL GENET, V15, P2421, DOI 10.1093/hmg/ddl165; Zheng H, 2008, CANCER CELL, V13, P117, DOI 10.1016/j.ccr.2008.01.002; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	70	4	4	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5781	5787		10.1038/s41388-021-01979-z	http://dx.doi.org/10.1038/s41388-021-01979-z		AUG 2021	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34345017	Green Accepted			2022-12-28	WOS:000681523500002
J	Tang, J; Peng, WY; Feng, YX; Le, X; Wang, K; Xiang, Q; Li, LL; Wang, Y; Xu, C; Mu, JH; Xu, K; Ji, P; Tao, Q; Huang, AL; Deng, CX; Lin, Y; Xiang, TX				Tang, Jun; Peng, Weiyan; Feng, Yixiao; Le, Xin; Wang, Kang; Xiang, Qin; Li, Lili; Wang, Yan; Xu, Can; Mu, Junhao; Xu, Ke; Ji, Ping; Tao, Qian; Huang, Ailong; Deng, Chu-Xia; Lin, Yong; Xiang, Tingxiu			Cancer cells escape p53's tumor suppression through ablation of ZDHHC1-mediated p53 palmitoylation	ONCOGENE			English	Article							S-ACYLATION; PROTEIN; DNA; METHYLATION; ACETYLATION	The inactivation of tumor-suppressor genes contributes heavily to oncogenesis. The mutation of TP53 has been well-studied and recognized as a major factor in the development of tumors. Yet other means of p53 inactivation has not been well-elucidated. We previously identified a hypermethylated gene ZDHHC1 that suppresses tumor growth when the expression was restored, but the specific mechanism was yet to be found. The protein product of ZDHHC1 is an S-palmitoyltransferase and we have identified p53 as a substrate for ZDHHC1-mediated palmitoylation, specifically at the C135, C176, and C275 residues. The novel form of post-translational modification of p53 is required for the nuclear translocation of the tumor suppressor. p53 recruited DNMT3A to ZDHHC1 promoter and is responsible for the hypermethylation of ZDHHC1. The epigenetic feedback loop formed by ZDHHC1 and p53 sheds light on the inactivation of p53 without the presence of genetic mutations.	[Tang, Jun; Peng, Weiyan; Feng, Yixiao; Le, Xin; Wang, Kang; Xiang, Qin; Wang, Yan; Xu, Can; Mu, Junhao; Xu, Ke; Tao, Qian; Xiang, Tingxiu] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Mol Oncol & Epigenet, Chongqing, Peoples R China; [Li, Lili; Tao, Qian] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Canc Epigenet Lab,Shatin, Dept Clin Oncol,State Key Lab Translat Oncol, Hong Kong, Peoples R China; [Li, Lili; Tao, Qian] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Ji, Ping] Chongqing Med Univ, Affiliated Stomatol Hosp, Chongqing, Peoples R China; [Huang, Ailong] Chongqing Med Univ, Dept Infect Dis, MOE Key Lab Mol Biol Infect Dis, Chongqing, Peoples R China; [Deng, Chu-Xia] Univ Macau, Fac Hlth Sci, Macau, Peoples R China; [Lin, Yong] Lovelace Resp Res Inst, Albuquerque, NM USA	Chongqing Medical University; Chinese University of Hong Kong; Chinese University of Hong Kong; Chongqing Medical University; Chongqing Medical University; University of Macau; Lovelace Respiratory Research Institute	Xiang, TX (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Mol Oncol & Epigenet, Chongqing, Peoples R China.	xiangtx@cqmu.edu.cn	Li, Lili/Q-5750-2018	Li, Lili/0000-0002-0292-5889	National Natural Science Foundation of China [81872380, 81572769]; Natural Science Foundation of Chongqing [cstc2018jscx-mszdX0039]; Research Grants Council, University Grants Committee (HK) [14115920]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Chongqing(Natural Science Foundation of Chongqing); Research Grants Council, University Grants Committee (HK)	This study was supported by the National Natural Science Foundation of China (#81872380, #81572769), Natural Science Foundation of Chongqing (cstc2018jscx-mszdX0039), and Research Grants Council, University Grants Committee (HK) (#14115920).	Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Blanc Mathieu, 2015, F1000Res, V4, P261, DOI 10.12688/f1000research.6464.1; Brigidi GS, 2013, JOVE-J VIS EXP, DOI 10.3791/50031; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brownlee C, 2019, CELL, V176, P805, DOI 10.1016/j.cell.2018.12.001; Cao N, 2016, BMC MOL BIOL, V17, DOI 10.1186/s12867-016-0065-9; Chamberlain LH, 2015, PHYSIOL REV, V95, P341, DOI 10.1152/physrev.00032.2014; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Daniotti JL, 2017, TRAFFIC, V18, P699, DOI 10.1111/tra.12510; De I, 2018, EUR J CELL BIOL, V97, P319, DOI 10.1016/j.ejcb.2018.03.005; Drisdel RC, 2004, BIOTECHNIQUES, V36, P276, DOI 10.2144/04362RR02; Fraser NJ, 2020, BIOCHEM SOC T, V48, P281, DOI 10.1042/BST20190707; Gao HG, 1997, CARCINOGENESIS, V18, P473, DOI 10.1093/carcin/18.3.473; Gluck S, 2012, BREAST CANCER RES TR, V132, P781, DOI 10.1007/s10549-011-1412-7; Gnanapradeepan K, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00124; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jung HY, 2007, J BIOL CHEM, V282, P35293, DOI 10.1074/jbc.M705181200; Ko PJ, 2018, EMBO REP, V19, DOI 10.15252/embr.201846666; Le X, 2020, THERANOSTICS, V10, P9495, DOI 10.7150/thno.45631; Leong WF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004135; Levine AJ, 2020, NAT REV CANCER, V20, P471, DOI 10.1038/s41568-020-0262-1; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Resh MD, 2017, BIOCHEM SOC T, V45, P409, DOI 10.1042/BST20160233; Runkle KB, 2016, MOL CELL, V62, P385, DOI 10.1016/j.molcel.2016.04.003; Tabaczar S, 2017, EXP BIOL MED, V242, P1150, DOI 10.1177/1535370217707732; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Xiang TX, 2019, THERANOSTICS, V9, P8182, DOI 10.7150/thno.34983; Yao H, 2019, NAT BIOMED ENG, V3, P306, DOI 10.1038/s41551-019-0375-6; Yeste-Velasco M, 2014, J PATHOL, V232, P566, DOI 10.1002/path.4327; Zhang Y, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0459-2	35	5	5	6	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5416	5426		10.1038/s41388-021-01949-5	http://dx.doi.org/10.1038/s41388-021-01949-5		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34282274	Green Published, hybrid			2022-12-28	WOS:000674560900001
J	Chen, CH; Wang, BW; Hsiao, YC; Wu, CY; Cheng, FJ; Hsia, TC; Chen, CY; Wang, YH; Weihua, Z; Chou, RH; Tang, CH; Chen, YJ; Wei, YL; Hsu, JL; Tu, CY; Hung, MC; Huang, WC				Chen, Chia-Hung; Wang, Bo-Wei; Hsiao, Yu-Chun; Wu, Chun-Yi; Cheng, Fang-Ju; Hsia, Te-Chun; Chen, Chih-Yi; Wang, Yihua; Weihua, Zhang; Chou, Ruey-Hwang; Tang, Chih-Hsin; Chen, Yun-Ju; Wei, Ya-Ling; Hsu, Jennifer L.; Tu, Chih-Yen; Hung, Mien-Chie; Huang, Wei-Chien			PKC delta-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; BREAST-CANCER CELLS; LUNG-CANCER; GLUCOSE-TRANSPORTER; EARLY PREDICTION; EXPRESSION; PROTEIN; PHOSPHORYLATION; OVEREXPRESSION	The tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have been widely used for non-small cell lung cancer (NSCLC) patients, but the development of acquired resistance remains a therapeutic hurdle. The reduction of glucose uptake has been implicated in the anti-tumor activity of EGFR TKIs. In this study, the upregulation of the active sodium/glucose co-transporter 1 (SGLT1) was found to confer the development of acquired EGFR TKI resistance and was correlated with the poorer clinical outcome of the NSCLC patients who received EGFR TKI treatment. Blockade of SGLT1 overcame this resistance in vitro and in vivo by reducing glucose uptake in NSCLC cells. Mechanistically, SGLT1 protein was stabilized through the interaction with PKC delta-phosphorylated (Thr678) EGFR in the TKI-resistant cells. Our findings revealed that PKC delta/EGFR axis-dependent SGLT1 upregulation was a critical mechanism underlying the acquired resistance to EGFR TKIs. We suggest co-targeting PKC delta/SGLT1 as a potential strategy to improve the therapeutic efficacy of EGFR TKIs in NSCLC patients.	[Chen, Chia-Hung; Hsia, Te-Chun; Tu, Chih-Yen] China Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Taichung, Taiwan; [Chen, Chia-Hung; Tang, Chih-Hsin; Tu, Chih-Yen] China Med Univ, Sch Med, Taichung, Taiwan; [Chen, Chia-Hung; Hsia, Te-Chun] China Med Univ, Dept Resp Therapy, Taichung, Taiwan; [Wang, Bo-Wei; Hsiao, Yu-Chun; Chou, Ruey-Hwang; Wei, Ya-Ling; Hsu, Jennifer L.; Hung, Mien-Chie; Huang, Wei-Chien] China Med Univ, Ctr Mol Med, Res Ctr Canc Biol, Taichung, Taiwan; [Wang, Bo-Wei; Hsiao, Yu-Chun; Chou, Ruey-Hwang; Wei, Ya-Ling; Hsu, Jennifer L.; Hung, Mien-Chie; Huang, Wei-Chien] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan; [Wang, Bo-Wei; Hsiao, Yu-Chun; Hung, Mien-Chie; Huang, Wei-Chien] China Med Univ, Drug Dev Ctr, Taichung, Taiwan; [Hsiao, Yu-Chun; Cheng, Fang-Ju; Chou, Ruey-Hwang; Hung, Mien-Chie; Huang, Wei-Chien] China Med Univ, PhD Program Canc Biol & Drug Discovery, Taichung, Taiwan; [Hsiao, Yu-Chun; Cheng, Fang-Ju; Chou, Ruey-Hwang; Hung, Mien-Chie; Huang, Wei-Chien] Acad Sinica, Taichung, Taiwan; [Wu, Chun-Yi] Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei, Taiwan; [Cheng, Fang-Ju; Tang, Chih-Hsin] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan; [Cheng, Fang-Ju; Hsu, Jennifer L.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Hsia, Te-Chun] China Med Univ Hosp, Hyperbar Oxygen Therapy Ctr, Dept Internal Med, Taichung, Taiwan; [Chen, Chih-Yi] Chung Shan Med Univ, Inst Med, Dept Surg, Div Thorac Surg, Taichung, Taiwan; [Wang, Yihua] Univ Southampton, Fac Environm & Life Sci, Biol Sci, Southampton, Hants, England; [Wang, Yihua] Univ Southampton, Inst Life Sci, Southampton, Hants, England; [Weihua, Zhang] Univ Houston, Dept Biol & Biochem, Houston, TX USA; [Chen, Yun-Ju] E Da Hosp, Dept Med Res, Kaohsiung, Taiwan; [Chen, Yun-Ju] I Shou Univ, Sch Med Int Students, Kaohsiung, Taiwan; [Chen, Yun-Ju] E Da Hosp, Dept Pharm, Kaohsiung, Taiwan; [Huang, Wei-Chien] Asia Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; China Medical University Taiwan; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; Chung Shan Medical University; University of Southampton; University of Southampton; University of Houston System; University of Houston; E-Da Hospital; I Shou University; E-Da Hospital; Asia University Taiwan	Tu, CY (corresponding author), China Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Taichung, Taiwan.; Tu, CY (corresponding author), China Med Univ, Sch Med, Taichung, Taiwan.; Hung, MC; Huang, WC (corresponding author), China Med Univ, Ctr Mol Med, Res Ctr Canc Biol, Taichung, Taiwan.; Hung, MC; Huang, WC (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.; Hung, MC; Huang, WC (corresponding author), China Med Univ, Drug Dev Ctr, Taichung, Taiwan.; Hung, MC; Huang, WC (corresponding author), China Med Univ, PhD Program Canc Biol & Drug Discovery, Taichung, Taiwan.; Hung, MC; Huang, WC (corresponding author), Acad Sinica, Taichung, Taiwan.; Huang, WC (corresponding author), Asia Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan.	chesttu@gmail.com; mhung@cmu.edu.tw; whuang@mail.cmu.edu.tw	Wang, Bo/AAU-1329-2021; Hung, Mien-Chie/ABD-5911-2021; Chou, Ruey-Hwang/K-8541-2013	Wang, Bo/0000-0001-8947-8526; Hung, Mien-Chie/0000-0003-4317-4740; Chou, Ruey-Hwang/0000-0002-2297-2180; Wang, Yihua/0000-0001-5561-0648; Cheng, Fang-Ju/0000-0001-6104-7185	Ministry of Science Technology, Taiwan [MOST 108-2314-B-039-032]; China Medical University [CMU106-ASIA-18]; China Medical University Hospital [DMR-108-012, DMR-109-212, DMR-109-213]; "Drug Development Center, China Medical University" from The Featured Areas Research Center Program by the Ministry of Education (MOE) in Taiwan; Medical Research Council [MR/S025480/1]	Ministry of Science Technology, Taiwan; China Medical University(China Medical University); China Medical University Hospital; "Drug Development Center, China Medical University" from The Featured Areas Research Center Program by the Ministry of Education (MOE) in Taiwan; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Experiments and data analysis were performed in part through the use of the Medical Research Core Facilities in the Office of Research & Development at China Medical University, Taichung, Taiwan. This research was funded in part by the following: Ministry of Science Technology, Taiwan (grant number: MOST 108-2314-B-039-032), China Medical University (grant number: CMU106-ASIA-18), and China Medical University Hospital (DMR-108-012, DMR-109-212, DMR-109-213). This work was also financially supported by the "Drug Development Center, China Medical University" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. Y. Wang was supported by Medical Research Council (MR/S025480/1). We would like to thank Iona J. MacDonald from China Medical University, Taichung, Taiwan, for her English language revision of this manuscript.	Ancey PB, 2018, FEBS J, V285, P2926, DOI 10.1111/febs.14577; Apicella M, 2018, CELL METAB, V28, P848, DOI 10.1016/j.cmet.2018.08.006; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Barrio JR, 2020, J NUCL MED, V61, P931, DOI 10.2967/jnumed.119.237446; Blodgett AB, 2011, DIABETES TECHNOL THE, V13, P743, DOI 10.1089/dia.2011.0041; Carey KD, 2006, CANCER RES, V66, P8163, DOI 10.1158/0008-5472.CAN-06-0453; Chen CH, 2017, MOL ONCOL, V11, P1273, DOI 10.1002/1878-0261.12102; Chen WS, 2015, ONCOTARGET, V6, P25962, DOI 10.18632/oncotarget.4504; Chen Y, 2017, ONCOTARGET, V8, P63813, DOI 10.18632/oncotarget.19130; Chen YJ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/682380; Cheng FJ, 2021, ONCOGENE, V40, P1162, DOI 10.1038/s41388-020-01597-1; Chou YT, 2010, CANCER RES, V70, P8822, DOI 10.1158/0008-5472.CAN-10-0638; Dicembrini I, 2019, DIABETES OBES METAB, V21, P1871, DOI 10.1111/dom.13745; Dietrich M, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.06.018; Feinmesser RL, 1999, J BIOL CHEM, V274, P16168, DOI 10.1074/jbc.274.23.16168; Gorzalczany Y, 2011, CANCER LETT, V310, P207, DOI 10.1016/j.canlet.2011.07.002; Guo GF, 2011, MED ONCOL, V28, pS197, DOI 10.1007/s12032-010-9696-8; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hachemi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087629; Hsia TC, 2013, MOL PHARMACOL, V83, P857, DOI 10.1124/mol.112.082743; Hsiao YC, 2015, ONCOTARGET, V6, P37965, DOI 10.18632/oncotarget.5700; Hudson CD, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.125; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Husain H, 2017, MOL CANCER THER, V16, P265, DOI 10.1158/1535-7163.MCT-16-0105; Hussein YR, 2011, TRANSL ONCOL, V4, P321, DOI 10.1593/tlo.11256; Janku F, 2013, ONCOTARGET, V4, P463, DOI 10.18632/oncotarget.886; Jia Y, 2016, NATURE, V534, P129, DOI 10.1038/nature17960; Jin N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10427-2; Kaida H, 2016, EUR J RADIOL, V85, P1804, DOI 10.1016/j.ejrad.2016.08.007; Kanwal A, 2012, ANAL BIOCHEM, V429, P70, DOI 10.1016/j.ab.2012.07.003; Ke EE, 2016, TRENDS PHARMACOL SCI, V37, P887, DOI 10.1016/j.tips.2016.09.003; Khuong HT, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-012-0322-3; Kim JH, 2018, CANCER RES, V78, P4482, DOI 10.1158/0008-5472.CAN-18-0117; Kim J, 2019, NAT CELL BIOL, V21, P63, DOI 10.1038/s41556-018-0205-1; Kluba M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139971; Kunimasa K, 2017, CANCER SCI, V108, P1368, DOI 10.1111/cas.13266; Lapuerta P, 2015, DIABETES VASC DIS RE, V12, P101, DOI 10.1177/1479164114563304; Lee PC, 2018, CANCER CELL, V34, P954, DOI 10.1016/j.ccell.2018.11.007; Li L, 2019, CANCER LETT, V452, P191, DOI 10.1016/j.canlet.2019.03.027; Lim SO, 2016, CANCER RES, V76, P1284, DOI 10.1158/0008-5472.CAN-15-2478; Lin HW, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/719578; Liu ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080721; Liu TC, 2017, AM J CANCER RES, V7, P187; Llado A, 2004, MOL BIOL CELL, V15, P4877, DOI 10.1091/mbc.E04-02-0127; Lypova N, 2019, J BIOL CHEM, V294, P10530, DOI 10.1074/jbc.RA119.007784; Ma RS, 2019, CANCER BIOL THER, V20, P1206, DOI 10.1080/15384047.2019.1599665; Makinoshima H, 2014, J BIOL CHEM, V289, P20813, DOI 10.1074/jbc.M114.575464; Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314; McCracken AN, 2013, TRENDS ENDOCRIN MET, V24, P200, DOI 10.1016/j.tem.2013.01.002; Miller S, 2010, AUTOPHAGY, V6, P805, DOI 10.1126/science.1184429; Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674; Momcilovic M, 2017, CELL REP, V18, P601, DOI 10.1016/j.celrep.2016.12.061; Moruno Felix, 2012, Cells, V1, P372, DOI 10.3390/cells1030372; Murtuza A, 2019, CANCER RES, V79, P689, DOI 10.1158/0008-5472.CAN-18-1281; Musso G, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1328; Nagarajan A, 2016, TRENDS CANCER, V2, P365, DOI 10.1016/j.trecan.2016.06.002; Recondo G, 2018, NAT REV CLIN ONCOL, V15, P694, DOI 10.1038/s41571-018-0081-4; Ren JG, 2013, PROSTATE, V73, P1453, DOI 10.1002/pros.22692; Rieg T, 2018, DIABETOLOGIA, V61, P2079, DOI 10.1007/s00125-018-4654-7; Sasaki H, 2012, MOL MED REP, V5, P599, DOI 10.3892/mmr.2011.736; Scafoglio C, 2015, P NATL ACAD SCI USA, V112, pE4111, DOI 10.1073/pnas.1511698112; Skoulidis F, 2019, NAT REV CANCER, V19, P495, DOI 10.1038/s41568-019-0179-8; Su H, 2006, CLIN CANCER RES, V12, P5659, DOI 10.1158/1078-0432.CCR-06-0368; Sunaga N, 2008, LUNG CANCER, V59, P203, DOI 10.1016/j.lungcan.2007.08.012; Suzuki Shuhei, 2018, Oncotarget, V9, P32667, DOI 10.18632/oncotarget.25994; Tu CY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/168949; Wang CW, 2015, INT J BIOCHEM CELL B, V64, P239, DOI 10.1016/j.biocel.2015.04.006; Wang L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0242-x; Wang ZL, 2016, INT J ONCOL, V48, P2558, DOI 10.3892/ijo.2016.3468; Weihua Z, 2008, CANCER CELL, V13, P385, DOI 10.1016/j.ccr.2008.03.015; Wu SG, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0777-1; Xu QL, 2017, ONCOTARGET, V8, P9557, DOI 10.18632/oncotarget.13771; Yamazaki Y, 2018, EUR J PHARMACOL, V822, P25, DOI 10.1016/j.ejphar.2018.01.003; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Zambrowicz B, 2012, CLIN PHARMACOL THER, V92, P158, DOI 10.1038/clpt.2012.58; Zander T, 2011, J CLIN ONCOL, V29, P1701, DOI 10.1200/JCO.2010.32.4939; Zhang H, 2017, ONCOL REP, V37, P1765, DOI 10.3892/or.2017.5367	78	4	4	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4796	4808		10.1038/s41388-021-01889-0	http://dx.doi.org/10.1038/s41388-021-01889-0		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34155348	Green Accepted, hybrid, Green Published			2022-12-28	WOS:000664006700005
J	Zhang, Y; Wang, Y; Zhou, D; Wang, K; Wang, X; Wang, X; Jiang, Y; Zhao, M; Yu, RT; Zhou, XP				Zhang, Yu; Wang, Yan; Zhou, Ding; Wang, Kai; Wang, Xu; Wang, Xiang; Jiang, Yang; Zhao, Min; Yu, Rutong; Zhou, Xiuping			Radiation-induced YAP activation confers glioma radioresistance via promoting FGF2 transcription and DNA damage repair	ONCOGENE			English	Article							FIBROBLAST-GROWTH-FACTOR; GLIOBLASTOMA RADIORESISTANCE; HIPPO PATHWAY; CELLS; INVASION; PROTEIN; EXPRESSION; MIGRATION; AKT	Although radiotherapy is a well-known effective non-surgical treatment for malignant gliomas, the therapeutic efficacy is severely limited due to the radioresistance of tumor cells. Previously, we demonstrated that Yes-associated protein (YAP) promotes glioma malignant progression. However, whether YAP plays a role in radioresistance and its potential value in cancer treatment are still unclear. In this study, we found that high YAP expression is associated with poor prognosis in malignant glioma patients undergoing radiotherapy. Research in immortalized cell lines and primary cells from GBM patients revealed that YAP exhibited a radioresistant effect on gliomas via promoting DNA damage repair. Mechanistically, after radiation, YAP was translocated into the nucleus, where it promoted the expression and secretion of FGF2, leading to MAPK-ERK pathway activation. FGF2 is a novel target gene of YAP. Inhibition of YAP-FGF2-MAPK signaling sensitizes gliomas to radiotherapy and prolongs the survival of intracranial cell-derived and patient-derived xenograft models. These results suggest that YAP-FGF2-MAPK is a key mechanism of radioresistance and is an actionable target for improving radiotherapy efficacy.	[Zhang, Yu; Wang, Yan; Zhou, Ding; Wang, Kai; Wang, Xu; Wang, Xiang; Jiang, Yang; Zhao, Min; Yu, Rutong; Zhou, Xiuping] Xuzhou Med Univ, Inst Nervous Syst Dis, Xuzhou, Jiangsu, Peoples R China; [Zhang, Yu; Wang, Yan; Zhou, Ding; Wang, Kai; Wang, Xu; Wang, Xiang; Jiang, Yang; Zhao, Min; Yu, Rutong; Zhou, Xiuping] Xuzhou Med Univ, Affiliated Hosp, Dept Neurosurg, Xuzhou, Jiangsu, Peoples R China; [Zhang, Yu; Wang, Yan; Zhou, Ding; Wang, Kai; Wang, Xu; Wang, Xiang; Jiang, Yang; Zhao, Min; Yu, Rutong; Zhou, Xiuping] Xuzhou Med Univ, Grad Sch, Xuzhou, Jiangsu, Peoples R China	Xuzhou Medical University; Xuzhou Medical University; Xuzhou Medical University	Yu, RT; Zhou, XP (corresponding author), Xuzhou Med Univ, Inst Nervous Syst Dis, Xuzhou, Jiangsu, Peoples R China.; Yu, RT; Zhou, XP (corresponding author), Xuzhou Med Univ, Affiliated Hosp, Dept Neurosurg, Xuzhou, Jiangsu, Peoples R China.; Yu, RT; Zhou, XP (corresponding author), Xuzhou Med Univ, Grad Sch, Xuzhou, Jiangsu, Peoples R China.	yu.rutong@163.com; xpzhou@xzhmu.edu.cn			National Natural Science Foundation of China [81872053, 81902526, 82072770]; Natural Science Foundation of Jiangsu province [BK20201458]; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX19_2225]; Social Development Project of XuZhou [KC20125]; Youth Science and Technology Innovation Team Cultivation Program of Xuzhou Medical University [TD2020002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu province(Natural Science Foundation of Jiangsu Province); Postgraduate Research & Practice Innovation Program of Jiangsu Province; Social Development Project of XuZhou; Youth Science and Technology Innovation Team Cultivation Program of Xuzhou Medical University	We thank the supports from Professor Longzhen Zhang and Professor Lingyu Zeng at the Affiliated Hospital of Xuzhou Medical University. This work was supported by the National Natural Science Foundation of China (numbers 81872053, 81902526, and 82072770); Natural Science Foundation of Jiangsu province (number BK20201458); the Postgraduate Research & Practice Innovation Program of Jiangsu Province (number KYCX19_2225), Social Development Project of XuZhou (number KC20125), and Youth Science and Technology Innovation Team Cultivation Program of Xuzhou Medical University (number TD2020002).	Ader I, 2002, ONCOGENE, V21, P6471, DOI 10.1038/sj.onc.1205838; Ader I, 2014, EUR J CANCER, V50, P2351, DOI 10.1016/j.ejca.2014.05.012; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Ciamporcero E, 2016, ONCOGENE, V35, P1541, DOI 10.1038/onc.2015.219; CohenJonathan E, 1997, CANCER RES, V57, P1364; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Fernandez A, 2012, ONCOGENE, V31, P1923, DOI 10.1038/onc.2011.379; Georgiou V, 2019, REV NEUROSCIENCE, V30, P543, DOI 10.1515/revneuro-2018-0051; Golding SE, 2009, CANCER BIOL THER, V8, P730, DOI 10.4161/cbt.8.8.7927; Gouaze-Andersson V, 2016, CANCER RES, V76, P3036, DOI 10.1158/0008-5472.CAN-15-2058; Gulston M, 2002, NUCLEIC ACIDS RES, V30, P3464, DOI 10.1093/nar/gkf467; Han D, 2020, STEM CELLS DEV, V29, P1240, DOI 10.1089/scd.2019.0281; Han XT, 2017, ONCOTARGET, V8, P100931, DOI 10.18632/oncotarget.21753; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hu HM, 2018, CELL, V175, P1665, DOI 10.1016/j.cell.2018.09.038; Hua G, 2016, ONCOGENE, V35, P2247, DOI 10.1038/onc.2015.288; Ibrahimi OA, 2004, BIOCHEMISTRY-US, V43, P4724, DOI 10.1021/bi0352320; Jiang T, 2021, CANCER LETT, V499, P60, DOI 10.1016/j.canlet.2020.10.050; Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288; Kim MH, 2017, CELL MOL LIFE SCI, V74, P1457, DOI 10.1007/s00018-016-2412-x; Liu XJ, 2015, J NEURO-ONCOL, V125, P113, DOI 10.1007/s11060-015-1901-3; Liu YP, 2016, CELL MOL NEUROBIOL, V36, P737, DOI 10.1007/s10571-015-0254-y; Ma JH, 2019, CANCER CELL, V35, P504, DOI [10.1016/j.ccell.2019.01.020, 10.1016/j.ccell.2019.04.011]; Marampon F, 2014, INT J ONCOL, V44, P2121, DOI 10.3892/ijo.2014.2358; Miao FA, 2019, J NEURO-ONCOL, V143, P221, DOI 10.1007/s11060-019-03163-6; Morgenroth A, 2014, ONCOTARGET, V5, P5483, DOI 10.18632/oncotarget.2123; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Sudol M, 2012, SEMIN CELL DEV BIOL, V23, P827, DOI 10.1016/j.semcdb.2012.05.002; Toyoda K, 2013, CELL MOL NEUROBIOL, V33, P489, DOI 10.1007/s10571-013-9913-z; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wang X, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12636; Wang Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0606-1; Yan JF, 2019, J CELL PHYSIOL, V234, P13014, DOI 10.1002/jcp.27971; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zhang L, 2019, ONCOGENE, V38, P2788, DOI 10.1038/s41388-018-0626-0; Zhang Y, 2018, J MOL NEUROSCI, V64, P262, DOI 10.1007/s12031-017-1018-6; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhou XP, 2017, NEURO-ONCOLOGY, V19, P1628, DOI 10.1093/neuonc/nox104; Zhou Z, 2011, HEPATO-GASTROENTEROL, V58, P2156, DOI 10.5754/hge11234	39	17	17	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4580	4591		10.1038/s41388-021-01878-3	http://dx.doi.org/10.1038/s41388-021-01878-3		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34127812	hybrid, Green Published			2022-12-28	WOS:000661408100004
J	Ramsden, DA; Nussenzweig, A				Ramsden, Dale A.; Nussenzweig, Andre			Mechanisms driving chromosomal translocations: lost in time and space	ONCOGENE			English	Review							DOUBLE-STRAND BREAKS; POLY(ADP-RIBOSE) POLYMERASE-1; SPATIAL PROXIMITY; LIGASE-III; DNA; REPAIR; RECOMBINATION; MOBILITY; REPLICATION; GENOME	Translocations arise when an end of one chromosome break is mistakenly joined to an end from a different chromosome break. Since translocations can lead to developmental disease and cancer, it is important to understand the mechanisms leading to these chromosome rearrangements. We review how characteristics of the sources and the cellular responses to chromosome breaks contribute to the accumulation of multiple chromosome breaks at the same moment in time. We also discuss the important role for chromosome break location; how translocation potential is impacted by the location of chromosome breaks both within chromatin and within the nucleus, as well as the effect of altered mobility of chromosome breaks. A common theme in work addressing both temporal and spatial contributions to translocation is that there is no shortage of examples of factors that promote translocation in one context, but have no impact or the opposite impact in another. Accordingly, a clear message for future work on translocation mechanism is that unlike normal DNA metabolic pathways, it isn't easily modeled as a simple, linear pathway that is uniformly followed regardless of differing cellular contexts.	[Ramsden, Dale A.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27515 USA; [Ramsden, Dale A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Ramsden, Dale A.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27515 USA; [Nussenzweig, Andre] NIH, Lab Genome Integr, Bldg 10, Bethesda, MD 20892 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA	Ramsden, DA (corresponding author), Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27515 USA.; Ramsden, DA (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA.; Ramsden, DA (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27515 USA.	dale_ramsden@med.unc.edu			NCI [CA222092, CA097096]; DOD [W81XWH-18-1-004]; Intramural Research Program of the NIH	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	D.A.R's laboratory was supported by NCI grants CA222092 and CA097096 and DOD grant W81XWH-18-1-004. The A.N. laboratory is supported by the Intramural Research Program of the NIH.	Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Aymard F, 2017, NAT STRUCT MOL BIOL, V24, P353, DOI 10.1038/nsmb.3387; Boboila C, 2010, P NATL ACAD SCI USA, V107, P3034, DOI 10.1073/pnas.0915067107; Boboila C, 2010, J EXP MED, V207, P417, DOI 10.1084/jem.20092449; Bredemeyer AL, 2008, J IMMUNOL, V181, P2620, DOI 10.4049/jimmunol.181.4.2620; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Brunet E, 2018, ADV EXP MED BIOL, V1044, P15, DOI 10.1007/978-981-13-0593-1_2; Bunting SF, 2013, NAT REV CANCER, V13, P443, DOI 10.1038/nrc3537; Caldecott KW, 2014, DNA REPAIR, V19, P108, DOI 10.1016/j.dnarep.2014.03.021; Callen E, 2007, CELL, V130, P63, DOI 10.1016/j.cell.2007.06.016; Canela A, 2019, MOL CELL, V75, P252, DOI 10.1016/j.molcel.2019.04.030; Canela A, 2017, CELL, V170, P507, DOI 10.1016/j.cell.2017.06.034; Caridi CP, 2018, NATURE, V559, P54, DOI 10.1038/s41586-018-0242-8; Carvajal-Garcia J, 2020, P NATL ACAD SCI USA, V117, P8476, DOI 10.1073/pnas.1921791117; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Cho NW, 2014, CELL, V159, P108, DOI 10.1016/j.cell.2014.08.030; Day TA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15110; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Difilippantonio S, 2008, NATURE, V456, P529, DOI 10.1038/nature07476; Dimitrova N, 2008, NATURE, V456, P524, DOI 10.1038/nature07433; Dion V, 2012, NAT CELL BIOL, V14, P502, DOI 10.1038/ncb2465; Fisher AEO, 2007, MOL CELL BIOL, V27, P5597, DOI 10.1128/MCB.02248-06; Gao SJ, 2016, DNA REPAIR, V42, P1, DOI 10.1016/j.dnarep.2016.03.013; Ghezraoui H, 2014, MOL CELL, V55, P829, DOI 10.1016/j.molcel.2014.08.002; Gomez-Herreros F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00307-y; Gothe HJ, 2019, MOL CELL, V75, P267, DOI 10.1016/j.molcel.2019.05.015; Gunn A, 2011, J BIOL CHEM, V286, P42470, DOI 10.1074/jbc.M111.309252; Hanzlikova H, 2017, NUCLEIC ACIDS RES, V45, P2546, DOI 10.1093/nar/gkw1246; Kramara J, 2018, TRENDS GENET, V34, P518, DOI 10.1016/j.tig.2018.04.002; Krawczyk PM, 2012, J CELL SCI, V125, P2127, DOI 10.1242/jcs.089847; Kruhlak MJ, 2006, J CELL BIOL, V172, P823, DOI 10.1083/jcb.200510015; Layer JV, 2018, P NATL ACAD SCI USA, V115, P10076, DOI 10.1073/pnas.1801591115; Lee K, 2008, NATURE, V454, P543, DOI 10.1038/nature07054; Li YL, 2020, NATURE, V578, P112, DOI 10.1038/s41586-019-1913-9; Lin SG, SUPPRESSES ALTERNATI, V2021; Lobachev K, 2004, CURR BIOL, V14, P2107, DOI 10.1016/j.cub.2004.11.051; Lobrich M, 1998, RADIAT RES, V150, P619, DOI 10.2307/3579884; Lottersberger F, 2015, CELL, V163, P880, DOI 10.1016/j.cell.2015.09.057; Lu GQ, 2016, P NATL ACAD SCI USA, V113, P1256, DOI 10.1073/pnas.1521597113; Mateos-Gomez PA, 2015, NATURE, V518, P254, DOI 10.1038/nature14157; Mine-Hattab J, 2012, NAT CELL BIOL, V14, P510, DOI 10.1038/ncb2472; Morton LM, 2021, SCIENCE, V372, P705, DOI 10.1126/science.abg2538; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Pannunzio NR, 2018, TRENDS BIOCHEM SCI, V43, P490, DOI 10.1016/j.tibs.2018.04.004; Pannunzio NR, 2014, DNA REPAIR, V17, P74, DOI 10.1016/j.dnarep.2014.02.006; Pommier Y, 2016, NAT REV MOL CELL BIO, V17, P703, DOI 10.1038/nrm.2016.111; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Richardson CD, 2016, NAT BIOTECHNOL, V34, P339, DOI 10.1038/nbt.3481; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; Roukos V, 2013, SCIENCE, V341, P660, DOI 10.1126/science.1237150; Rulten SL, 2011, MOL CELL, V41, P33, DOI 10.1016/j.molcel.2010.12.006; Sakofsky CJ, 2017, CRIT REV BIOCHEM MOL, V52, P395, DOI 10.1080/10409238.2017.1314444; Schrank BR, 2018, NATURE, V559, P61, DOI 10.1038/s41586-018-0237-5; Scully R, 2019, NAT REV MOL CELL BIO, V20, P698, DOI 10.1038/s41580-019-0152-0; Shima N, 2004, MOL CELL BIOL, V24, P10381, DOI 10.1128/MCB.24.23.10381-10389.2004; Simsek D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002080; Soutoglou E, 2007, NAT CELL BIOL, V9, P675, DOI 10.1038/ncb1591; Sternberg SH, 2014, NATURE, V507, P62, DOI 10.1038/nature13011; Stracker TH, 2011, NAT REV MOL CELL BIO, V12, P90, DOI 10.1038/nrm3047; Sudmant PH, 2015, NATURE, V526, P75, DOI 10.1038/nature15394; Sunder S, 2019, P NATL ACAD SCI USA, V116, P9481, DOI 10.1073/pnas.1818595116; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; Uuskula-Reimand L, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1043-8; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; Waters CA, 2014, DNA REPAIR, V17, P39, DOI 10.1016/j.dnarep.2014.02.008; Weinstock David M, 2007, Nat Cell Biol, V9, P978; Whalen JM, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107635; Wray J, 2013, BLOOD, V121, P4359, DOI 10.1182/blood-2012-10-460527; Wyatt DW, 2016, MOL CELL, V63, P662, DOI 10.1016/j.molcel.2016.06.020; Yousefzadeh MJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004654; Yu W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19060-w; Zhang F, 2009, NAT GENET, V41, P849, DOI 10.1038/ng.399; Zhang Y, 2012, CELL, V148, P908, DOI 10.1016/j.cell.2012.02.002; Zhang Y, 2011, NAT STRUCT MOL BIOL, V18, P80, DOI 10.1038/nsmb.1940	79	9	9	3	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4263	4270		10.1038/s41388-021-01856-9	http://dx.doi.org/10.1038/s41388-021-01856-9		JUN 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34103687	Green Accepted			2022-12-28	WOS:000659032900001
J	Fernandes, M; Jamme, P; Cortot, AB; Kherrouche, Z; Tulasne, D				Fernandes, Marie; Jamme, Philippe; Cortot, Alexis B.; Kherrouche, Zoulika; Tulasne, David			When the MET receptor kicks in to resist targeted therapies	ONCOGENE			English	Review							GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; C-MET; DRIVEN RESISTANCE; TRASTUZUMAB RESISTANCE; GEFITINIB RESISTANCE; ACTIVATING MUTATIONS; MOLECULAR-MECHANISMS	Although targeted therapies have increased the life expectancy of patients with druggable molecular alterations directly involved in tumor development, the efficacy of these therapies is limited by acquired resistances leading to treatment failure. Most targeted therapies, including ones exploiting therapeutic antibodies and kinase inhibitors, are directed against receptor tyrosine kinases (RTKs) or major signaling hubs. Resistances to these therapies arise when inhibition of these targets is bypassed through activation of alternative signaling pathways. In recent years, activation of the receptor tyrosine kinase MET has been shown to promote resistance to various targeted therapies. This casts MET as important actor in resistance. In this review, we describe how the MET receptor triggers resistance to targeted therapies against RTKs such as EGFR, VEGFR, and HER2 and against signaling hubs such as BRAF. We also describe how MET can be its own resistance factor, as illustrated by on-target resistance of lung tumors harboring activating mutations causing MET exon 14 skipping. Interestingly, investigation of all these situations reveals functional physiological relationships between MET and the target of the therapy to which the cancer becomes resistant, suggesting that resistance stems from preexisting mechanisms. Identification of MET as a resistance factor opens the way to co-treatment strategies that are being tested in current clinical trials.	[Fernandes, Marie; Jamme, Philippe; Cortot, Alexis B.; Kherrouche, Zoulika; Tulasne, David] Univ Lille, CHU Lille, Inst Pasteur Lille, CNRS,UMR9020,Inserm,U1277,CANTHER,Canc Heterogene, Lille, France; [Cortot, Alexis B.] Univ Lille, CHU, Thorac Oncol Dept, Lille, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille	Tulasne, D (corresponding author), Univ Lille, CHU Lille, Inst Pasteur Lille, CNRS,UMR9020,Inserm,U1277,CANTHER,Canc Heterogene, Lille, France.	david.tulasne@ibl.cnrs.fr	KHERROUCHE, Zoulika/HHN-0213-2022; Tulasne, David/AAR-5287-2020	Tulasne, David/0000-0002-6764-7242	CNRS; Institut Pasteur de Lille; INSERM; Canceropole Nord-Ouest; Ligue Contre le Cancer, Comites Nord et Aisne; Agence nationale de la recherche; Institut National du Cancer	CNRS(Centre National de la Recherche Scientifique (CNRS)); Institut Pasteur de Lille; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Canceropole Nord-Ouest; Ligue Contre le Cancer, Comites Nord et Aisne; Agence nationale de la recherche(French National Research Agency (ANR)); Institut National du Cancer(Institut National du Cancer (INCA) France)	This work was supported by the CNRS, the Institut Pasteur de Lille, and INSERM, and by grants from the "Canceropole Nord-Ouest", the "Ligue Contre le Cancer, Comites Nord et Aisne", the "Agence nationale de la recherche" and the "Institut National du Cancer".	Agarwal S, 2009, BRIT J CANCER, V100, P941, DOI 10.1038/sj.bjc.6604937; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Awad MM, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.9069; Bahcall M, 2016, CANCER DISCOV, V6, P1334, DOI 10.1158/2159-8290.CD-16-0686; Baldacci S, 2018, LUNG CANCER, V125, P57, DOI 10.1016/j.lungcan.2018.09.008; Baldacci S, 2017, ONCOTARGET, V8, P105103, DOI 10.18632/oncotarget.21707; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Bertotti A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000643; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; Bruix J, 2012, J HEPATOL, V57, P821, DOI 10.1016/j.jhep.2012.06.014; Byeon HK, 2016, MOL CARCINOGEN, V55, P1678, DOI 10.1002/mc.22418; Calvi C, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003228; Camidge DR, 2019, J CLIN ONCOL, V37, P855, DOI 10.1200/JCO.19.00033; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Cascone T, 2017, CLIN CANCER RES, V23, P5489, DOI 10.1158/1078-0432.CCR-16-3216; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chia SK, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0836-3; Chmielowiec J, 2007, J CELL BIOL, V177, P151, DOI 10.1083/jcb.200701086; Choueiri TK, 2016, LANCET ONCOL, V17, P917, DOI 10.1016/S1470-2045(16)30107-3; Ciamporcero E, 2015, MOL CANCER THER, V14, P101, DOI 10.1158/1535-7163.MCT-14-0094; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cortot AB, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw262; Cortot AB, 2014, EUR RESPIR REV, V23, P356, DOI 10.1183/09059180.00004614; Daudigeos-Dubus E, 2017, INT J ONCOL, V50, P203, DOI 10.3892/ijo.2016.3792; Descarpentries C, 2018, J THORAC ONCOL, V13, P1873, DOI 10.1016/j.jtho.2018.08.2023; Donev IS, 2011, CLIN CANCER RES, V17, P2260, DOI 10.1158/1078-0432.CCR-10-1993; Dong HJ, 2016, LUNG CANCER, V102, P118, DOI 10.1016/j.lungcan.2016.11.006; Drilon A, 2020, NAT MED, V26, P47, DOI 10.1038/s41591-019-0716-8; Duplaquet L, 2020, ELIFE, V9, DOI 10.7554/eLife.50041; Duplaquet L, 2018, ONCOGENE, V37, P3200, DOI 10.1038/s41388-018-0185-4; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Engstrom LD, 2017, CLIN CANCER RES, V23, P6661, DOI 10.1158/1078-0432.CCR-17-1192; Escudier B, 2018, J CLIN ONCOL, V36, P765, DOI 10.1200/JCO.2017.74.7352; Fischer OM, 2004, J BIOL CHEM, V279, P28970, DOI 10.1074/jbc.M402508200; Flaifel A, 2019, CLIN CANCER RES, V25, P6080, DOI 10.1158/1078-0432.CCR-19-1135; Fujino T, 2019, J THORAC ONCOL, V14, P1753, DOI 10.1016/j.jtho.2019.06.023; Giovannetti E, 2018, CANCER DRUG RESIST, V1, P82, DOI 10.20517/cdr.2018.05; Griffioen AW, 2012, CLIN CANCER RES, V18, P3961, DOI 10.1158/1078-0432.CCR-12-0002; Guo R, 2019, J CLIN ONCOL, V37; Hashigasako A, 2004, J BIOL CHEM, V279, P26445, DOI 10.1074/jbc.M314254200; HASSAN M, 2019, SCI REP-UK, V9; Haura EB, 2019, J CLIN ONCOL, V37; Heist RS, 2016, J THORAC ONCOL, V11, P1242, DOI 10.1016/j.jtho.2016.06.013; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Ishikawa D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062104; Jamme P, 2020, J THORAC ONCOL, V15, P741, DOI 10.1016/j.jtho.2020.01.027; Janne PA, 2016, J THORAC ONCOL, V11, P737, DOI 10.1016/j.jtho.2016.01.022; Jeffers M, 1999, ONCOGENE, V18, P5120, DOI 10.1038/sj.onc.1202902; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jin W, 2019, J THORAC ONCOL, V14, pE137, DOI 10.1016/j.jtho.2019.04.021; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Kasahara K, 2010, CLIN CANCER RES, V16, P4616, DOI 10.1158/1078-0432.CCR-10-0383; Khoury H, 2005, MOL BIOL CELL, V16, P550, DOI 10.1091/mbc.E04-07-0567; Knauf JA, 2018, J CLIN INVEST, V128, P4086, DOI 10.1172/JCI120966; Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lai GG, 2019, J CLIN ONCOL, V37, P876, DOI 10.1200/JCO.18.00177; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Le XN, 2018, CLIN CANCER RES, V24, P6195, DOI 10.1158/1078-0432.CCR-18-1542; Lefebvre J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.377; Leighl NB, 2017, ONCOTARGET, V8, P69651, DOI 10.18632/oncotarget.18753; Leone JP, 2020, BREAST CANCER RES TR, V179, P113, DOI 10.1007/s10549-019-05445-z; Li A, 2017, CLIN CANCER RES, V23, P4929, DOI 10.1158/1078-0432.CCR-16-3273; Loibl S, 2016, ANN ONCOL, V27, P1519, DOI 10.1093/annonc/mdw197; LONGATI P, 1994, ONCOGENE, V9, P49; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maritano D, 2000, ONCOGENE, V19, P1354, DOI 10.1038/sj.onc.1203431; Michaelso MD, 2019, ONCOLOGIST, V24, P1151, DOI 10.1634/theoncologist.2018-0749; Minuti G, 2012, BRIT J CANCER, V107, P793, DOI 10.1038/bjc.2012.335; Moores SL, 2016, CANCER RES, V76, P3942, DOI 10.1158/0008-5472.CAN-15-2833; Mueller KL, 2008, CANCER RES, V68, P3314, DOI 10.1158/0008-5472.CAN-08-0132; Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379; Nakajima M, 1999, CANCER, V85, P1894; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Obaid NM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030585; Ou SHI, 2017, J THORAC ONCOL, V12, P145, DOI 10.1016/j.jtho.2016.09.131; Oxnard GR, 2018, JAMA ONCOL, V4, P1527, DOI 10.1001/jamaoncol.2018.2969; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Paik PK, 2020, NEW ENGL J MED, V383, P931, DOI 10.1056/NEJMoa2004407; Patnaik A, 2018, CANCER CHEMOTH PHARM, V82, P407, DOI 10.1007/s00280-018-3623-7; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Pietrantonio F, 2016, CANCER DISCOV, V6, P963, DOI 10.1158/2159-8290.CD-16-0297; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Ramalingam SS, 2018, ANN ONCOL, V29; Recondo G, 2020, CLIN CANCER RES, V26, P2615, DOI 10.1158/1078-0432.CCR-19-3608; Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Rotow JK, 2020, CLIN CANCER RES, V26, P439, DOI 10.1158/1078-0432.CCR-19-1667; Sanchez-Vega F, 2019, CANCER DISCOV, V9, P199, DOI 10.1158/2159-8290.CD-18-0598; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Scagliotti G, 2015, J CLIN ONCOL, V33, P2667, DOI 10.1200/JCO.2014.60.7317; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schoenfeld AJ, 2020, CLIN CANCER RES, V26, P2654, DOI [10.1158/10780432.CCR-19-3563, 10.1158/1078-0432.CCR-19-3563]; Sehnal D, 2018, WORKSH MOL GRAPH VIS, P29, DOI [/10.5555/3293503.3293509, DOI 10.5555/3293503.3293509]; Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240; Sequist LV, 2020, LANCET ONCOL, V21, P373, DOI 10.1016/S1470-2045(19)30785-5; Sequist LV, 2011, J CLIN ONCOL, V29, P3307, DOI 10.1200/JCO.2010.34.0570; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Shitara K, 2020, JPN J CLIN ONCOL, V50, P859, DOI 10.1093/jjco/hyaa042; Spigel DR, 2017, J CLIN ONCOL, V35, P412, DOI 10.1200/JCO.2016.69.2160; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Suzawa K, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.19.00011; Suzawa K, 2019, CLIN CANCER RES, V25, P1248, DOI 10.1158/1078-0432.CCR-18-1640; Takahashi N, 2016, ONCOTARGET, V7, P4925, DOI 10.18632/oncotarget.6753; Takeuchi S, 2012, AM J PATHOL, V181, P1034, DOI 10.1016/j.ajpath.2012.05.023; Tan EH, 2018, CLIN PHARM DRUG DEV, V7, P532, DOI 10.1002/cpdd.427; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Van Cutsem E, 2014, CLIN CANCER RES, V20, P4240, DOI 10.1158/1078-0432.CCR-13-2752; Vernieri C, 2019, CRIT REV ONCOL HEMAT, V139, P53, DOI 10.1016/j.critrevonc.2019.05.001; Virzi AR, 2018, P NATL ACAD SCI USA, V115, P10058, DOI 10.1073/pnas.1721147115; Wagner JP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003994; Wakelee H, 2017, CLIN LUNG CANCER, V18, P50, DOI 10.1016/j.cllc.2016.09.013; Werbin JL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12257-y; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Wolf J, 2020, NEW ENGL J MED, V383, P944, DOI 10.1056/NEJMoa2002787; Wu YL, 2020, LANCET RESP MED, V8, P1132, DOI 10.1016/S2213-2600(20)30154-5; Wu YL, 2018, J CLIN ONCOL, V36, P3101, DOI 10.1200/JCO.2018.77.7326; Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779; Yamada T, 2012, J THORAC ONCOL, V7, P272, DOI 10.1097/JTO.0b013e3182398e69; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Yano S, 2011, J THORAC ONCOL, V6, P2011, DOI 10.1097/JTO.0b013e31823ab0dd; Yoshioka T, 2019, CANCER SCI, V110, P2549, DOI 10.1111/cas.14089; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0750-2; Zhang Y, 2017, LUNG CANCER, V113, P69, DOI 10.1016/j.lungcan.2017.09.006; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343	141	6	6	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4061	4078		10.1038/s41388-021-01835-0	http://dx.doi.org/10.1038/s41388-021-01835-0		MAY 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34031544				2022-12-28	WOS:000653694600001
J	Duarte, HO; Rodrigues, JG; Gomes, C; Hensbergen, PJ; Ederveen, ALH; de Ru, AH; Mereiter, S; Polonia, A; Fernandes, E; Ferreira, JA; van Veelen, PA; Santos, LL; Wuhrer, M; Gomes, J; Reis, CA				Duarte, Henrique O.; Rodrigues, Joana G.; Gomes, Catarina; Hensbergen, Paul J.; Ederveen, Agnes L. Hipgrave; de Ru, Arnoud H.; Mereiter, Stefan; Polonia, Antonio; Fernandes, Elisabete; Ferreira, Jose A.; van Veelen, Peter A.; Santos, Lucio L.; Wuhrer, Manfred; Gomes, Joana; Reis, Celso A.			ST6Gal1 targets the ectodomain of ErbB2 in a site-specific manner and regulates gastric cancer cell sensitivity to trastuzumab	ONCOGENE			English	Article							GLYCOSYLATION; RECEPTOR; SIALYLATION; EXPRESSION; EGFR	The clinical performance of the therapeutic monoclonal antibody trastuzumab in the treatment of ErbB2-positive unresectable gastric cancer (GC) is severely hampered by the emergence of molecular resistance. Trastuzumab's target epitope is localized within the extracellular domain of the oncogenic cell surface receptor tyrosine kinase (RTK) ErbB2, which is known to undergo extensive N-linked glycosylation. However, the site-specific glycan repertoire of ErbB2, as well as the detailed molecular mechanisms through which specific aberrant glycan signatures functionally impact the malignant features of ErbB2-addicted GC cells, including the acquisition of trastuzumab resistance, remain elusive. Here, we demonstrate that ErbB2 is modified with both alpha 2,6- and alpha 2,3-sialylated glycan structures in GC clinical specimens. In-depth mass spectrometry-based glycomic and glycoproteomic analysis of ErbB2's ectodomain disclosed a site-specific glycosylation profile in GC cells, in which the ST6Gal1 sialyltransferase specifically targets ErbB2 N-glycosylation sites occurring within the receptor's trastuzumab-binding domain. Abrogation of ST6Gal1 expression reshaped the cellular and ErbB2-specific glycomes, expanded the cellular half-life of the ErbB2 receptor, and sensitized ErbB2-dependent GC cells to trastuzumab-induced cytotoxicity through the stabilization of ErbB dimers at the cell membrane, and the decreased activation of both ErbB2 and EGFR RTKs. Overall, our data demonstrates that ST6Gal1-mediated aberrant alpha 2,6-sialylation actively tunes the resistance of ErbB2-driven GC cells to trastuzumab.	[Duarte, Henrique O.; Rodrigues, Joana G.; Gomes, Catarina; Mereiter, Stefan; Polonia, Antonio; Gomes, Joana; Reis, Celso A.] Univ Porto, i3S Inst Invest & Inovacao Saude, Porto, Portugal; [Duarte, Henrique O.; Rodrigues, Joana G.; Gomes, Catarina; Mereiter, Stefan; Polonia, Antonio; Gomes, Joana; Reis, Celso A.] Univ Porto, IPATIMUP Inst Mol Pathol & Immunol, Porto, Portugal; [Duarte, Henrique O.; Rodrigues, Joana G.; Reis, Celso A.] Univ Porto, ICBAS Inst Biomed Sci Abel Salazar, Porto, Portugal; [Hensbergen, Paul J.; Ederveen, Agnes L. Hipgrave; de Ru, Arnoud H.; van Veelen, Peter A.; Wuhrer, Manfred] Leiden Univ, Ctr Prote & Metabol, Med Ctr, Leiden, Netherlands; [Polonia, Antonio] Univ Porto, Dept Pathol, IPATIMUP, IPATIMUP Diagnost, Porto, Portugal; [Fernandes, Elisabete; Ferreira, Jose A.; Santos, Lucio L.] Portuguese Inst Oncol, IPO Porto Res Ctr, Expt Pathol & Therapeut Grp, Porto, Portugal; [Santos, Lucio L.] Portuguese Inst Oncol, Dept Surg Oncol, Porto, Portugal; [Reis, Celso A.] Univ Porto, Fac Med, Porto, Portugal; [Mereiter, Stefan] Austrian Acad Sci, Inst Mol Biotechnol, IMBA, Vienna, Austria	Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto; Universidade do Porto; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Universidade do Porto; Universidade de Coimbra; Universidade de Coimbra; Universidade do Porto; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Gomes, J; Reis, CA (corresponding author), Univ Porto, i3S Inst Invest & Inovacao Saude, Porto, Portugal.; Gomes, J; Reis, CA (corresponding author), Univ Porto, IPATIMUP Inst Mol Pathol & Immunol, Porto, Portugal.; Reis, CA (corresponding author), Univ Porto, ICBAS Inst Biomed Sci Abel Salazar, Porto, Portugal.; Reis, CA (corresponding author), Univ Porto, Fac Med, Porto, Portugal.	joanag@ipatimup.pt; celsor@ipatimup.pt	REIS, Celso A/B-9969-2008; Gomes, Catarina/CAJ-5505-2022; Wuhrer, Manfred/ABE-9168-2020; Ferreira, José Alexandre/ABM-1695-2022; Oliveira Duarte, Henrique/AAZ-7387-2021; Gomes, Joana/K-9031-2013	REIS, Celso A/0000-0002-0286-6639; Wuhrer, Manfred/0000-0002-0814-4995; Ferreira, José Alexandre/0000-0002-0097-6148; Hipgrave Ederveen, Agnes/0000-0003-1689-0442; Rodrigues, Joana/0000-0001-5890-6620; Hensbergen, Paul/0000-0002-3193-5445; Gomes, Joana/0000-0002-8832-2703; Gomes, Catarina/0000-0002-0352-6783; van Veelen, Peter/0000-0002-7898-9408; Mereiter, Stefan/0000-0002-4832-3090; Fernandes, Elisabete/0000-0002-9907-7432; Duarte, Henrique/0000-0001-8641-8368	FEDER funds through the Operational Program for Competitiveness Factors COMPETE 2020 [POCI-01-0145-FEDER-016585, POCI-01-0145-FEDER-007274]; Foundation for Science and Technology (FCT) [PTDC/BBB-EBI/0567/2014, UID/BIM/04293/2013, PTDC/MED-QUI/29780/2017]; Norte Portugal Regional Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) [NORTE-01-0145-FEDER-000051]; FCT; Programa Operacional Potencial Humano (POPH); BiotechHealth Program (Doctoral Program on Cellular and Molecular Biotechnology Applied to Health Sciences) - FCT [PD/0016/2012]; FCT [PD/BD/128407/2017, SFRH/BD/136736/2018, CEECIND/03186/2017]; Investment Grant NWO Medium - ZonMw [91116004]	FEDER funds through the Operational Program for Competitiveness Factors COMPETE 2020; Foundation for Science and Technology (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); Norte Portugal Regional Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); Programa Operacional Potencial Humano (POPH); BiotechHealth Program (Doctoral Program on Cellular and Molecular Biotechnology Applied to Health Sciences) - FCT; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); Investment Grant NWO Medium - ZonMw	This work was funded by FEDER funds through the Operational Program for Competitiveness Factors COMPETE 2020 (POCI-01-0145-FEDER-016585; POCI-01-0145-FEDER-007274) and national funds through the Foundation for Science and Technology (FCT), under the projects: PTDC/BBB-EBI/0567/2014 to CAR and UID/BIM/04293/2013; PTDC/MED-QUI/29780/2017 to CG; and the project NORTE-01-0145-FEDER-000051, supported by Norte Portugal Regional Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). HOD was supported by FCT through the FCT Ph.D. Programs and by Programa Operacional Potencial Humano (POPH), specifically by the BiotechHealth Program (Doctoral Program on Cellular and Molecular Biotechnology Applied to Health Sciences), with the reference PD/0016/2012 funded by FCT. HOD (PD/BD/128407/2017), JGR (SFRH/BD/136736/2018), and JAF (CEECIND/03186/2017) are financially supported by FCT. This work was supported in part by an Investment Grant NWO Medium with project number 91116004 to PAvV, which is (partially) financed by ZonMw.	Alexander KL, 2020, J BIOL CHEM, V295, P14153, DOI 10.1074/jbc.RA120.014887; Bang YJ, 2010, LANCET, V376, P1302; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bern Marshall, 2012, Curr Protoc Bioinformatics, VChapter 13, DOI 10.1002/0471250953.bi1320s40; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936; Britain CM, 2018, J OVARIAN RES, V11, DOI 10.1186/s13048-018-0385-0; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; COLCHER D, 1981, P NATL ACAD SCI-BIOL, V78, P3199, DOI 10.1073/pnas.78.5.3199; Contessa JN, 2008, CANCER RES, V68, P3803, DOI 10.1158/0008-5472.CAN-07-6389; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; D'Errico M, 2009, EUR J CANCER, V45, P461, DOI 10.1016/j.ejca.2008.10.032; Duarte HO, 2018, HELICOBACTER, V23, DOI 10.1111/hel.12523; Duarte HO, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112262; Duarte HO, 2020, MASSIVE, DOI [10.25345/C5B38P, DOI 10.25345/C5B38P]; Freitas D, 2019, EBIOMEDICINE, V40, P349, DOI 10.1016/j.ebiom.2019.01.017; Gomes C, 2019, THERANOSTICS, V9, P7431, DOI 10.7150/thno.33858; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Kaszuba K, 2015, P NATL ACAD SCI USA, V112, P4334, DOI 10.1073/pnas.1503262112; Klinger M, 2004, CANCER RES, V64, P1087, DOI 10.1158/0008-5472.CAN-03-2435; Lageveen-Kammeijer GSM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09910-7; Liu B, 2019, J COMB OPTIM, V38, P1, DOI 10.1007/s10878-018-0361-z; Liu NH, 2018, ONCOL REP, V40, P2997, DOI 10.3892/or.2018.6680; Liu QQ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1208-x; Liu YC, 2011, P NATL ACAD SCI USA, V108, P11332, DOI 10.1073/pnas.1107385108; Lonowski LA, 2017, NAT PROTOC, V12, P581, DOI 10.1038/nprot.2016.165; Maadi H, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4143-x; Marcos NT, 2004, CANCER RES, V64, P7050, DOI 10.1158/0008-5472.CAN-04-1921; Mereiter S, 2019, CANCER CELL, V36, P6, DOI 10.1016/j.ccell.2019.06.006; Mereiter S, 2019, FEBS LETT, V593, P1675, DOI 10.1002/1873-3468.13432; Narimatsu Y, 2018, GLYCOBIOLOGY, V28, P295, DOI 10.1093/glycob/cwx101; Peiris D, 2017, SCI REP-UK, V7, DOI 10.1038/srep43006; Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Smyth EC, 2016, ANN ONCOL, V27, pv38, DOI 10.1093/annonc/mdw350; Swindall AF, 2013, CANCER RES, V73, P2368, DOI 10.1158/0008-5472.CAN-12-3424; Swindall AF, 2011, J BIOL CHEM, V286, P22982, DOI 10.1074/jbc.M110.211375; Terashima M, 2012, CLIN CANCER RES, V18, P5992, DOI 10.1158/1078-0432.CCR-12-1318; Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839; Wang YC, 2015, SCI REP-UK, V5, DOI 10.1038/srep13317	42	14	14	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3719	3733		10.1038/s41388-021-01801-w	http://dx.doi.org/10.1038/s41388-021-01801-w		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33947960	Green Published, hybrid			2022-12-28	WOS:000647084500005
J	Azizi, N; Toma, J; Martin, M; Khalid, MF; Mousavi, F; Win, PW; Borrello, MT; Steele, N; Shi, JQ; di Magliano, MP; Pin, CL				Azizi, Nawab; Toma, Jelena; Martin, Mickenzie; Khalid, Muhammad Faran; Mousavi, Fatemeh; Win, Phyo Wei; Borrello, Maria Teresa; Steele, Nina; Shi, Jiaqi; di Magliano, Marina Pasca; Pin, Christopher L.			Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer	ONCOGENE			English	Article								The unfolded protein response (UPR) is activated in pancreatic pathologies and suggested as a target for therapeutic intervention. In this study, we examined activating transcription factor 3 (ATF3), a mediator of the UPR that promotes acinar-to-ductal metaplasia (ADM) in response to pancreatic injury. Since ADM is an initial step in the progression to pancreatic ductal adenocarcinoma (PDAC), we hypothesized that ATF3 is required for initiation and progression of PDAC. We generated mice carrying a germline mutation of Atf3 (Atf3(-/-)) combined with acinar-specific induction of oncogenic KRAS (Ptf1a(creERT/+)Kras(G12D/+)). Atf3(-/-) mice with (termed APK) and without KRAS(G12D) were exposed to cerulein-induced pancreatitis. In response to recurrent pancreatitis, Atf3(-/-) mice showed decreased ADM and enhanced regeneration based on morphological and biochemical analysis. Similarly, an absence of ATF3 reduced spontaneous pancreatic intraepithelial neoplasia (PanIN) formation and PDAC in Ptf1a(creERT/+)Kras(G12D/+) mice. In response to injury, KRAS(G12D) bypassed the requirement for ATF3 with a dramatic loss in acinar tissue and PanIN formation observed regardless of ATF3 status. Compared to Ptf1a(creERT/+)Kras(G12D/+) mice, APK mice exhibited a significant decrease in pancreatic and total body weight, did not progress through to PDAC, and showed altered pancreatic fibrosis and immune cell infiltration. These findings suggest a complex, multifaceted role for ATF3 in pancreatic cancer pathology.	[Azizi, Nawab; Toma, Jelena; Martin, Mickenzie; Khalid, Muhammad Faran; Mousavi, Fatemeh; Win, Phyo Wei; Pin, Christopher L.] Childrens Hlth Res Inst, London, ON, Canada; [Azizi, Nawab; Toma, Jelena; Martin, Mickenzie; Mousavi, Fatemeh; Pin, Christopher L.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Toma, Jelena; Pin, Christopher L.] Univ Western Ontario, Dept Oncol, London, ON, Canada; [Martin, Mickenzie] Univ Western Ontario, Dept Biol, London, ON, Canada; [Khalid, Muhammad Faran; Win, Phyo Wei; Pin, Christopher L.] Univ Western Ontario, Dept Paediat, London, ON, Canada; [Borrello, Maria Teresa] Aix Marseille Univ, Ctr Canc Res Marseille, INSERM, CNRS,UMR 7258,U1068, Marseille, France; [Borrello, Maria Teresa] Inst Paoli Calmettes, Marseille, France; [Steele, Nina; Shi, Jiaqi] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [di Magliano, Marina Pasca] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Pin, CL (corresponding author), Childrens Hlth Res Inst, London, ON, Canada.; Pin, CL (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada.; Pin, CL (corresponding author), Univ Western Ontario, Dept Oncol, London, ON, Canada.; Pin, CL (corresponding author), Univ Western Ontario, Dept Paediat, London, ON, Canada.	cpin@uwo.ca		Shi, Jiaqi/0000-0003-4893-1587; Azizi, Nawab/0000-0003-1474-6543	Canadian Institutes of Health Research (MOP) [PJT166029]; Cancer Research Society of Canada; Rob Lutterman Foundation for Pancreatic Cancer Research; University of Western Ontario; Ontario Graduate Scholarships; Cancer Research and Technology Training (CaRTT) program; NSERC summer studentship; National Cancer Institute of the National Institutes of Health [K08CA234222]; London Regional Cancer Centre Catalyst Grant	Canadian Institutes of Health Research (MOP)(Canadian Institutes of Health Research (CIHR)); Cancer Research Society of Canada; Rob Lutterman Foundation for Pancreatic Cancer Research; University of Western Ontario; Ontario Graduate Scholarships(Ontario Graduate Scholarship); Cancer Research and Technology Training (CaRTT) program; NSERC summer studentship(Natural Sciences and Engineering Research Council of Canada (NSERC)); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); London Regional Cancer Centre Catalyst Grant	The authors wish to acknowledge the ongoing support of several national research funding agencies for this work including the Canadian Institutes of Health Research (MOP#PJT166029), the Cancer Research Society of Canada, and the Rob Lutterman Foundation for Pancreatic Cancer Research. This work would not be possible without specific support from a London Regional Cancer Centre Catalyst Grant, co-supported by Keith Sammit and an internal bridge grant from the University of Western Ontario. NA and JT were funded by studentships from the Ontario Graduate Scholarships and Cancer Research and Technology Training (CaRTT) program. MFK was supported by an NSERC summer studentship. JS was supported by National Cancer Institute of the National Institutes of Health under award number K08CA234222.	B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563; Bandyopadhyay S, 2006, CANCER RES, V66, P11983, DOI 10.1158/0008-5472.CAN-06-0943; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Boespflug ND, 2014, BLOOD, V123, P2084, DOI 10.1182/blood-2013-06-510909; Carriere C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027725; Chang YS, 2017, P NATL ACAD SCI USA, V114, pE7159, DOI 10.1073/pnas.1700455114; Chien WW, 2014, ONCOTARGET, V5, P4881, DOI 10.18632/oncotarget.2051; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Dawn B, 2004, CARDIOVASC RES, V64, P61, DOI 10.1016/j.cardiores.2004.05.011; Delous M, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002754; Fazio EN, 2017, MOL BIOL CELL, V28, P2347, DOI 10.1091/mbc.E17-04-0254; Garcia-Carbonero N, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092468; Gardian K, 2012, J CANCER, V3, P285, DOI 10.7150/jca.4537; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Hackl C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-668; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Helm O, 2014, INT J CANCER, V135, P843, DOI 10.1002/ijc.28736; Hess DA, 2011, GASTROENTEROLOGY, V141, P1463, DOI 10.1053/j.gastro.2011.06.045; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Iida K, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-38; Iwawaki T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013052; Je YJ, 2014, BIOCHEM BIOPH RES CO, V444, P81, DOI 10.1016/j.bbrc.2014.01.010; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Johnson CL, 2004, MECH DEVELOP, V121, P261, DOI 10.1016/j.mod.2004.01.003; Kadowaki H, 2013, GENES-BASEL, V4, P306, DOI 10.3390/genes4030306; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kim DE, 2017, J EXP MED, V214, P2349, DOI 10.1084/jem.20170724; Kim KJ, 2015, BIOMOL THER, V23, P134, DOI 10.4062/biomolther.2014.107; Kopp JL, 2011, DEVELOPMENT, V138, P653, DOI 10.1242/dev.056499; Kowalik AS, 2007, AM J PHYSIOL-GASTR L, V292, pG1123, DOI 10.1152/ajpgi.00512.2006; Kubisch CH, 2007, AM J PHYSIOL-GASTR L, V292, pG1804, DOI 10.1152/ajpgi.00078.2007; Kurahara H, 2011, J SURG RES, V167, pE211, DOI 10.1016/j.jss.2009.05.026; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Mallano T, 2016, ANN RHEUM DIS, V75, P586, DOI 10.1136/annrheumdis-2014-206214; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; Pin CL, 2000, ANAT REC, V259, P157, DOI 10.1002/(SICI)1097-0185(20000601)259:2<157::AID-AR6>3.0.CO;2-0; Pin CL, 2001, J CELL BIOL, V155, P519, DOI 10.1083/jcb.200105060; Pinho AV, 2011, GUT, V60, P958, DOI 10.1136/gut.2010.225920; Prevot PP, 2012, GUT, V61, P1723, DOI 10.1136/gutjnl-2011-300266; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Roy N, 2016, GENE DEV, V30, P2669, DOI 10.1101/gad.291021.116; Shi G, 2013, ONCOGENE, V32, P1950, DOI 10.1038/onc.2012.210; Song HM, 2016, BIOMOL THER, V24, P140, DOI 10.4062/biomolther.2015.109; Song XX, 2012, THORAC CANCER, V3, P217, DOI 10.1111/j.1759-7714.2011.00110.x; Steele NG, 2021, CLIN CANCER RES, V27, P2023, DOI 10.1158/1078-0432.CCR-20-3715; Thakur PC, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1562-z; Tsuda M, 2018, J CLIN INVEST, V128, P3475, DOI 10.1172/JCI94287; Wang A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-268; Wu XW, 2010, NATURE, V465, P368, DOI 10.1038/nature08996; Yadav D, 2013, GASTROENTEROLOGY, V144, P1252, DOI 10.1053/j.gastro.2013.01.068; Yan F, 2017, ONCOTARGET, V8, P47020, DOI 10.18632/oncotarget.16638; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Young CC, 2019, CELL MOL GASTROENTER, V7, P93, DOI 10.1016/j.jcmgh.2018.09.004	55	6	6	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3118	3135		10.1038/s41388-021-01771-z	http://dx.doi.org/10.1038/s41388-021-01771-z		APR 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33864001	Green Submitted, Green Accepted			2022-12-28	WOS:000640748600003
J	Tsuji, T; Maeda, Y; Kita, K; Murakami, K; Saya, H; Takemura, H; Inaki, N; Oshima, M; Oshima, H				Tsuji, Toshikatsu; Maeda, Yusuke; Kita, Kenji; Murakami, Kazuhiro; Saya, Hideyuki; Takemura, Hirofumi; Inaki, Noriyuki; Oshima, Masanobu; Oshima, Hiroko			FOXO3 is a latent tumor suppressor for FOXO3-positive and cytoplasmic-type gastric cancer cells	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; PROSTAGLANDIN E-2; ACTIVATION; RESISTANCE; AKT; METASTASIS; SURVIVAL; PATHWAY; WNT	FOXO3 is a member of the FOXO transcription factors thought to play a tumor-suppressor role in gastrointestinal cancer, while tumor-promoting function of FOXO3 has also been reported. These results suggest a context-dependent function of FOXO3 in tumor development. However, the relationship between the FOXO3 expression pattern and its role in tumorigenesis has not been elucidated. We examined the FOXO3 expression in 65 human primary gastric cancer and patient-derived xenograft tissues by immunohistochemistry and identified three subtypes according to subcellular localization: FOXO3-nuclear accumulated (FOXO3-Nuc), FOXO3-nuclear/cytoplasmic or cytoplasmic distributed (FOXO3-Cyt), and FOXO3-negative. In the FOXO3-Cyt gastric cancer cells, the expression of the constitutive active mutant FOXO3 (Act-ER FOXO3) induced the nuclear accumulation of FOXO3 and significantly suppressed colony formation and proliferation. The inhibition of the PI3K-AKT pathway by inhibitor treatment also suppressed the proliferation of FOXO3-Cyt gastric cancer cells, which was associated with the nuclear accumulation of endogenous FOXO3. Furthermore, the expression of Act-ER FOXO3 by an endogenous promoter significantly suppressed gastric tumorigenesis in Gan mice, a model of gastric cancer. Finally, treatment of FOXO3-Cyt human gastric cancer-derived organoids with an AKT inhibitor significantly suppressed the survival and proliferation. These results indicate that FOXO3 is a latent tumor suppressor for FOXO3-Cyt-type gastric cancer cells and that activation of the PI3K-AKT pathway protects this type of gastric cancer cell from FOXO3-mediated growth suppression via constitutive nuclear export. Thus, the inhibition of the PI3K-AKT pathway and nuclear translocation of endogenous FOXO3 may have therapeutic applications in the treatment of FOXO3-positive and cytoplasmic-type gastric cancer.	[Tsuji, Toshikatsu; Maeda, Yusuke; Oshima, Masanobu; Oshima, Hiroko] Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa, Japan; [Tsuji, Toshikatsu; Takemura, Hirofumi] Kanazawa Univ, Dept Thorac Cardiovasc & Gen Surg, Kanazawa, Ishikawa, Japan; [Tsuji, Toshikatsu] Ishikawa Prefectural Cent Hosp, Dept Surg Gastroenterol, Kanazawa, Ishikawa, Japan; [Maeda, Yusuke; Saya, Hideyuki] Keio Univ, Sch Med, Div Gene Regulat, Inst Adv Med Res IAMR, Tokyo, Japan; [Kita, Kenji] Kanazawa Univ, Canc Res Inst, Cent Res Resource Branch, Kanazawa, Ishikawa, Japan; [Murakami, Kazuhiro] Kanazawa Univ, Canc Res Inst, Div Stem Cell Biol, Kanazawa, Ishikawa, Japan; [Inaki, Noriyuki] Kanazawa Univ, Dept Surg Gastroenterol, Kanazawa, Ishikawa, Japan; [Oshima, Masanobu; Oshima, Hiroko] Kanazawa Univ, WPI Nanolife Sci Inst NanoLSI, Kanazawa, Ishikawa, Japan	Kanazawa University; Kanazawa University; Ishikawa Prefectural Central Hospital; Keio University; Kanazawa University; Kanazawa University; Kanazawa University; Kanazawa University	Oshima, H (corresponding author), Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa, Japan.; Oshima, H (corresponding author), Kanazawa Univ, WPI Nanolife Sci Inst NanoLSI, Kanazawa, Ishikawa, Japan.	hoshima@staff.kanazawa-u.ac.jp	Inaki, Noriyuki/B-4361-2018; Oshima, Masanobu/F-9958-2014; Kita, Kenji/D-8437-2015	Inaki, Noriyuki/0000-0002-4241-5015; Oshima, Masanobu/0000-0002-3304-0004; Murakami, Kazuhiro/0000-0003-1759-9542; Saya, Hideyuki/0000-0001-6610-1902; Kita, Kenji/0000-0002-4622-6633	Ministry of Education, Culture, Sports, Science and Technology of Japan [18H04030, 19H03498]; AMED from the Japan Agency for Medical Research and Development, Japan [20ck0106541h0001]; Takeda Science Foundation	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); AMED from the Japan Agency for Medical Research and Development, Japan; Takeda Science Foundation(Takeda Science Foundation (TSF))	We thank, Manami Watanabe, Ayako Tsuda, and Yoshie Jomen for their technical assistance. This work was supported by Grants-in-Aid for Scientific Research (A) (18H04030) and (B) (19H03498) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; AMED (20ck0106541h0001) from the Japan Agency for Medical Research and Development, Japan; Takeda Science Foundation.	Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bullock MD, 2013, BRIT J CANCER, V109, P387, DOI 10.1038/bjc.2013.355; de Brachene AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y; Echizen K, 2019, ONCOGENE, V38, P4250, DOI 10.1038/s41388-019-0702-0; Echizen K, 2016, CANCER SCI, V107, P391, DOI 10.1111/cas.12901; Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Hofmann C, 2007, GASTROENTEROLOGY, V132, P587, DOI 10.1053/j.gastro.2006.11.017; Hornsveld M, 2018, SEMIN CANCER BIOL, V50, P90, DOI 10.1016/j.semcancer.2017.11.017; Hornsveld M, 2016, CELL DEATH DIFFER, V23, P1483, DOI 10.1038/cdd.2016.33; Hornsveld M, 2018, CANCER RES, V78, P2356, DOI 10.1158/0008-5472.CAN-17-2511; Jiramongkol Y, 2020, CANCER METAST REV, V39, P681, DOI 10.1007/s10555-020-09883-w; Li L, 2019, J CLIN INVEST, V129, P2374, DOI 10.1172/JCI122256; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; LIU Y, 2018, MOL CANCER, V17; Miyoshi H, 2012, SCIENCE, V338, P108, DOI 10.1126/science.1223821; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014; Oshima H, 2011, CANCER SCI, V102, P713, DOI 10.1111/j.1349-7006.2011.01847.x; Oshima H, 2011, GASTROENTEROLOGY, V140, P596, DOI 10.1053/j.gastro.2010.11.007; Oshima H, 2009, CANCER SCI, V100, P1779, DOI 10.1111/j.1349-7006.2009.01258.x; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Penrose HM, 2019, CELL MOL GASTROENTER, V7, P391, DOI 10.1016/j.jcmgh.2018.10.003; Putker M, 2015, ANTIOXID REDOX SIGN, V22, P15, DOI 10.1089/ars.2014.6056; Storz P, 2009, MOL CELL BIOL, V29, P4906, DOI 10.1128/MCB.00077-09; Tan P, 2015, GASTROENTEROLOGY, V149, P1153, DOI 10.1053/j.gastro.2015.05.059; Tan SH, 2020, NATURE, V578, P437, DOI 10.1038/s41586-020-1973-x; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3; Yang XJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0061801, 10.1371/journal.pone.0062181]; Yeo H, 2013, EMBO J, V32, P2589, DOI 10.1038/emboj.2013.186; Yu S, 2015, INT J CLIN EXP PATHO, V8, P2963	41	7	7	4	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3072	3086		10.1038/s41388-021-01757-x	http://dx.doi.org/10.1038/s41388-021-01757-x		APR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33795838	hybrid, Green Published			2022-12-28	WOS:000635873300002
J	Chen, YY; Cheng, WY; Shi, HY; Huang, SS; Chen, HR; Liu, DB; Xu, WQ; Yu, J; Wang, JG				Chen, Yiyun; Cheng, Wing Yin; Shi, Hongyu; Huang, Shengshuo; Chen, Huarong; Liu, Dabin; Xu, Weiqi; Yu, Jun; Wang, Jiguang			Classifying gastric cancer using FLORA reveals clinically relevant molecular subtypes and highlights LINC01614 as a biomarker for patient prognosis	ONCOGENE			English	Article								Molecular-based classifications of gastric cancer (GC) were recently proposed, but few of them robustly predict clinical outcomes. While mutation and expression signature of protein-coding genes were used in previous molecular subtyping methods, the noncoding genome in GC remains largely unexplored. Here, we developed the fast long-noncoding RNA analysis (FLORA) method to study RNA sequencing data of GC cases, and prioritized tumor-specific long-noncoding RNAs (lncRNAs) by integrating clinical and multi-omic data. We uncovered 1235 tumor-specific lncRNAs, based on which three subtypes were identified. The lncRNA-based subtype 3 (L3) represented a subgroup of intestinal GC with worse survival, characterized by prevalent TP53 mutations, chromatin instability, hypomethylation, and over-expression of oncogenic lncRNAs. In contrast, the lncRNA-based subtype 1 (L1) has the best survival outcome, while LINC01614 expression further segregated a subgroup of L1 cases with worse survival and increased chance of developing distal metastasis. We demonstrated that LINC01614 over-expression is an independent prognostic factor in L1 and network-based functional prediction implicated its relevance to cell migration. Over-expression and CRISPR-Cas9-guided knockout experiments further validated the functions of LINC01614 in promoting GC cell growth and migration. Altogether, we proposed a lncRNA-based molecular subtype of GC that robustly predicts patient survival and validated LINC01614 as an oncogenic lncRNA that promotes GC proliferation and migration.	[Chen, Yiyun; Shi, Hongyu; Huang, Shengshuo; Wang, Jiguang] Hong Kong Univ Sci & Technol, Ctr Syst Biol & Human Hlth, Div Life Sci, Hong Kong, Peoples R China; [Chen, Yiyun; Shi, Hongyu; Huang, Shengshuo; Wang, Jiguang] Hong Kong Univ Sci & Technol, Ctr Syst Biol & Human Hlth, Dept Chem & Biol Engn, State Key Lab Mol Neurosci, Hong Kong, Peoples R China; [Cheng, Wing Yin; Chen, Huarong; Liu, Dabin; Xu, Weiqi; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst, Inst Digest Dis, Hong Kong, Peoples R China; [Cheng, Wing Yin; Chen, Huarong; Liu, Dabin; Xu, Weiqi; Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,CUHK Shenzhen Res Inst, Hong Kong, Peoples R China; [Xu, Weiqi] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Dept Oncol,Dept Hepat Surg, Shanghai, Peoples R China; [Wang, Jiguang] Hong Kong Ctr Neurodegenerat Dis, Hong Kong Sci Pk, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Chinese University of Hong Kong; Chinese University of Hong Kong; Fudan University	Wang, JG (corresponding author), Hong Kong Univ Sci & Technol, Ctr Syst Biol & Human Hlth, Div Life Sci, Hong Kong, Peoples R China.; Wang, JG (corresponding author), Hong Kong Univ Sci & Technol, Ctr Syst Biol & Human Hlth, Dept Chem & Biol Engn, State Key Lab Mol Neurosci, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Dept Med & Therapeut, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci,CUHK Shenzhen Res Inst, Hong Kong, Peoples R China.; Wang, JG (corresponding author), Hong Kong Ctr Neurodegenerat Dis, Hong Kong Sci Pk, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk; jgwang@ust.hk	Chen, Huarong/ABZ-5810-2022; Liu, Dabin/GNH-2648-2022; chen, huarong/ABH-8561-2020; Jun, Yu/D-8569-2015	chen, huarong/0000-0003-2192-1864; Liu, Dabin/0000-0002-3811-8317; Chen, Yiyun/0000-0003-3886-2100; Jun, Yu/0000-0001-5008-2153	NSFC Excellent Young Scientists Fund (Hong Kong and Macau) [31922088]; HK CRF [C4039-19GF, C7065-18GF]; Hong Kong Epigenomics Project [LKCCFL18SC01-E]; HK ITC grant [ITCPD/17-9]; Department of Science and Technology of Guangdong Province [2020A0505090007]; HK RGC-CRF Fund [C6021-19EF]	NSFC Excellent Young Scientists Fund (Hong Kong and Macau); HK CRF; Hong Kong Epigenomics Project; HK ITC grant; Department of Science and Technology of Guangdong Province; HK RGC-CRF Fund	The authors were supported by NSFC Excellent Young Scientists Fund (Hong Kong and Macau) (No. 31922088), HK CRF grants (Nos. C4039-19GF and C7065-18GF), the Hong Kong Epigenomics Project (LKCCFL18SC01-E), HK ITC grant (ITCPD/17-9), and grants from the Department of Science and Technology of Guangdong Province (No. 2020A0505090007). This research made use of the computing resources of the X-GPU cluster supported by the HK RGC-CRF Fund: C6021-19EF.	Arnes L, 2019, GUT, V68, P499, DOI 10.1136/gutjnl-2017-314353; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; Gan L, 2019, INT J ONCOL, V54, P2157, DOI 10.3892/ijo.2019.4773; Hajjari M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0670-0; Hashad D, 2016, J CLIN LAB ANAL, V30, P1100, DOI 10.1002/jcla.21987; He CY, 2020, CLIN TRANSL MED, V10, P353, DOI 10.1002/ctm2.32; Hu WL, 2018, NAT CELL BIOL, V20, P492, DOI 10.1038/s41556-018-0066-7; Huang GW, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4058-6; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Khan MR, 2019, DATABASE-OXFORD, DOI 10.1093/database/bay136; Lei ZD, 2013, GASTROENTEROLOGY, V145, P554, DOI 10.1053/j.gastro.2013.05.010; Li XC, 2016, CANCER RES, V76, P1724, DOI 10.1158/0008-5472.CAN-15-2443; Liu AN, 2018, J CELL MOL MED, V22, P4034, DOI 10.1111/jcmm.13483; Liu G, 2016, ONCOL RES, V23, P99, DOI 10.3727/096504015X14496932933575; Liu Y, 2018, CANCER CELL, V33, P721, DOI 10.1016/j.ccell.2018.03.010; Ma HW, 2017, ONCOTARGET, V8, P52211, DOI 10.18632/oncotarget.11075; O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189; Oh SC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04179-8; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Pefanis E, 2014, NATURE, V514, P389, DOI 10.1038/nature13580; Petrelli F, 2017, J GASTROINTEST ONCOL, V8, P148, DOI 10.21037/jgo.2017.01.10; Qiu M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.203; Raveh E, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0458-2; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Serra O, 2019, CANCER TREAT REV, V77, P29, DOI 10.1016/j.ctrv.2019.05.005; Sohn BH, 2017, CLIN CANCER RES, V23, P4441, DOI 10.1158/1078-0432.CCR-16-2211; Sun ZF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14595-3; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Xavier-Magalhaes Ana, 2018, Oncotarget, V9, P15740, DOI 10.18632/oncotarget.24597; Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x; Yoon SJ, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06814-4; Zerbino DR, 2018, NUCLEIC ACIDS RES, V46, pD754, DOI 10.1093/nar/gkx1098; Zhang EB, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1523-0; Zhou JC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10221; Zhou XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11516	39	18	18	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2898	2909		10.1038/s41388-021-01743-3	http://dx.doi.org/10.1038/s41388-021-01743-3		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742127	hybrid, Green Published			2022-12-28	WOS:000630675000005
J	Cui, CH; Liu, Y; Gerloff, D; Rohde, C; Pauli, C; Kohn, M; Misiak, D; Oellerich, T; Schwartz, S; Schmidt, LH; Wiewrodt, R; Marra, A; Hillejan, L; Bartel, F; Wickenhauser, C; Huttelmaier, S; Gollner, S; Zhou, FB; Edemir, B; Muller-Tidow, C				Cui, Chunhong; Liu, Yi; Gerloff, Dennis; Rohde, Christian; Pauli, Cornelius; Koehn, Marcel; Misiak, Danny; Oellerich, Thomas; Schwartz, Schraga; Schmidt, Lars-Henning; Wiewrodt, Rainer; Marra, Alessandro; Hillejan, Ludger; Bartel, Frank; Wickenhauser, Claudia; Huettelmaier, Stefan; Goellner, Stefanie; Zhou, Fengbiao; Edemir, Bayram; Mueller-Tidow, Carsten			NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration	ONCOGENE			English	Article							NONCODING RNA; DYSKERATOSIS-CONGENITA; SELF-RENEWAL; SNORNA U50; MUTATIONS; PSEUDOURIDYLATION; RECOGNITION; MICRORNAS; PROMOTES; MODOMICS	Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide underlining the urgent need for new biomarkers and therapeutic targets for this disease. Long noncoding RNAs are critical players in NSCLC but the role of small RNA species is not well understood. In the present study, we investigated the role of H/ACA box small nucleolar RNAs (snoRNAs) and snoRNA-bound ribonucleoproteins (snoRNPs) in the tumorigenesis of NSCLC. H/ACA box snoRNPs including the NOP10 core protein were highly expressed in NSCLC. High levels of either NOP10 mRNA or protein were associated with poor prognosis in NSCLC patients. Loss of NOP10 and subsequent reduction of H/ACA box snoRNAs and rRNA pseudouridylation inhibited lung cancer cell growth, colony formation, migration, and invasion. A focused CRISPR/Cas9 snoRNA knockout screen revealed that genomic deletion of SNORA65, SNORA7A, and SNORA7B reduced proliferation of lung cancer cells. In line, high levels of SNORA65, SNORA7A, and SNORA7B were observed in primary lung cancer specimens with associated changes in rRNA pseudouridylation. Knockdown of either SNORA65 or SNORA7A/B inhibited growth and colony formation of NSCLC cell lines. Our data indicate that specific H/ACA box snoRNAs and snoRNA-associated proteins such as NOP10 have an oncogenic role in NSCLC providing new potential biomarkers and therapeutic targets for the disease.	[Cui, Chunhong; Liu, Yi; Rohde, Christian; Goellner, Stefanie; Zhou, Fengbiao; Mueller-Tidow, Carsten] Heidelberg Univ, Dept Med Hematol Oncol & Rheumatol 5, D-69120 Heidelberg, Germany; [Gerloff, Dennis; Pauli, Cornelius; Edemir, Bayram] Martin Luther Univ Halle Wittenberg, Dept Hematol & Oncol, D-06120 Halle, Saale, Germany; [Koehn, Marcel; Misiak, Danny; Huettelmaier, Stefan; Goellner, Stefanie] Martin Luther Univ Halle Wittenberg, Inst Mol Med, D-06120 Halle, Saale, Germany; [Oellerich, Thomas] Goethe Univ, Dept Med 2, Hematol Oncol, D-60590 Frankfurt, Germany; [Oellerich, Thomas] German Canc Res Ctr, German Canc Consortium, D-69120 Heidelberg, Germany; [Oellerich, Thomas] Frankfurt Canc Inst, Dept Mol Diagnost Translat Prote, D-60596 Frankfurt, Germany; [Schwartz, Schraga] Weizmann Inst Sci, Rehovot, Israel; [Schmidt, Lars-Henning; Wiewrodt, Rainer] Univ Munster, Dept Med A, D-48149 Munster, Germany; [Marra, Alessandro] Rems Murr Kliniken, Dept Surg, Thorac Surg, D-71364 Winnenden, Germany; [Hillejan, Ludger] Niels Stensen Kliniken, Dept Thorac Surg, D-49179 Ostercappeln, Germany; [Bartel, Frank; Wickenhauser, Claudia] Martin Luther Univ Halle Wittenberg, Inst Pathol, D-06097 Halle, Saale, Germany; [Mueller-Tidow, Carsten] Natl Ctr Tumor Dis NCT, D-69120 Heidelberg, Germany; [Cui, Chunhong] Shanghai Univ Med & Hlth Sci, Shanghai 201318, Peoples R China; [Gerloff, Dennis] Martin Luther Univ Halle Wittenberg, Dept Dermatol & Venereol, D-06120 Halle, Saale, Germany; [Schmidt, Lars-Henning] Klinikum Ingolstadt, Klin Pneumol Beatmungsmed & Thorakale Onkol, D-85049 Ingolstadt, Germany	Ruprecht Karls University Heidelberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Weizmann Institute of Science; University of Munster; Martin Luther University Halle Wittenberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Shanghai University of Medicine & Health Sciences; Martin Luther University Halle Wittenberg	Muller-Tidow, C (corresponding author), Heidelberg Univ, Dept Med Hematol Oncol & Rheumatol 5, D-69120 Heidelberg, Germany.; Muller-Tidow, C (corresponding author), Natl Ctr Tumor Dis NCT, D-69120 Heidelberg, Germany.	Carsten.Mueller-Tidow@med.uni-heidelberg.de	Misiak, Danny/AAV-9317-2020; Hüttelmaier, Stefan/AAQ-1203-2021; Zhou, Fengbiao/AAL-3221-2021	Misiak, Danny/0000-0001-5931-8425; Zhou, Fengbiao/0000-0002-9221-1096; Cui, Chunhong/0000-0002-7705-204X	German Research Foundation (DFG) [ZH831/1-1, MU1328/15-1, MU1328/18-1]; German Cancer Aid (DKH) [70112974, 70113908]; German Jose-Carreras Leukemia Foundation (DJCLS) [22R/2017]	German Research Foundation (DFG)(German Research Foundation (DFG)); German Cancer Aid (DKH)(Deutsche Krebshilfe); German Jose-Carreras Leukemia Foundation (DJCLS)	We thank Katrin Nerger for excellent technical assistance and Dr. sc. agr. Volker Eckstein and Stefanie Hofmann for cell sorting. We are grateful to Annette Becker, M.A., for help with project organization. Research reported in this publication was (in part) supported by funds from the German Research Foundation (DFG; ZH831/1-1 to F. Z., MU1328/15-1 and MU1328/18-1 to C.M-T.), the German Cancer Aid (DKH; Projects 70112974 and 70113908 to C.M-T.) and the German Jose-Carreras Leukemia Foundation (DJCLS; 22R/2017 to C.M-T).	Alter BP, 2009, BLOOD, V113, P6549, DOI 10.1182/blood-2008-12-192880; Aubrey BJ, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026062; Bakin AV, 1998, METH MOL B, V77, P297; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bellodi C, 2013, CELL REP, V3, P1493, DOI 10.1016/j.celrep.2013.04.030; Bellodi C, 2010, CANCER RES, V70, P6026, DOI 10.1158/0008-5472.CAN-09-4730; Boccaletto P, 2018, NUCLEIC ACIDS RES, V46, pD303, DOI 10.1093/nar/gkx1030; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Chang LS, 2002, BIOCHEM BIOPH RES CO, V299, P196, DOI 10.1016/S0006-291X(02)02623-2; Chen JB, 2018, J CANCER, V9, P4774, DOI 10.7150/jca.25811; Chen LY, 2015, SCI REP-UK, V5, DOI 10.1038/srep08588; Dong XY, 2008, HUM MOL GENET, V17, P1031, DOI 10.1093/hmg/ddm375; Dong XY, 2009, J GENET GENOMICS, V36, P447, DOI 10.1016/S1673-8527(08)60134-4; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Fernandez-Marcelo T, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0195-9; Gainor JF, 2013, CLIN CANCER RES, V19, P4273, DOI 10.1158/1078-0432.CCR-13-0318; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Jordan EJ, 2017, CANCER DISCOV, V7, P596, DOI 10.1158/2159-8290.CD-16-1337; Kiss AM, 2002, NUCLEIC ACIDS RES, V30, P4643, DOI 10.1093/nar/gkf592; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; de Sousa VML, 2018, PATHOBIOLOGY, V85, P96, DOI 10.1159/000487440; Lekka E, 2018, FEBS LETT, V592, P2884, DOI 10.1002/1873-3468.13182; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lu QC, 2018, FASEB J, V32, P3957, DOI 10.1096/fj.201701237RR; Machnicka Magdalena A, 2013, Nucleic Acids Res, V41, pD262, DOI 10.1093/nar/gks1007; Mannoor K, 2012, BBA-REV CANCER, V1826, P121, DOI 10.1016/j.bbcan.2012.03.005; Massenet S, 2017, RNA BIOL, V14, P680, DOI 10.1080/15476286.2016.1243646; McMahon M, 2015, WIRES RNA, V6, P173, DOI 10.1002/wrna.1266; Mei YP, 2012, ONCOGENE, V31, P2794, DOI 10.1038/onc.2011.449; Meier UT, 2005, CHROMOSOMA, V114, P1, DOI 10.1007/s00412-005-0333-9; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Okugawa Y, 2017, GUT, V66, P107, DOI 10.1136/gutjnl-2015-309359; Pao W, 2004, SEMIN CANCER BIOL, V14, P33, DOI 10.1016/j.semcancer.2003.11.005; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Penzo M, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8020038; Polacek N, 2005, CRIT REV BIOCHEM MOL, V40, P285, DOI 10.1080/10409230500326334; Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC; Schmidt LH, 2011, J THORAC ONCOL, V6, P1984, DOI 10.1097/JTO.0b013e3182307eac; Schwartz S, 2014, CELL, V159, P148, DOI 10.1016/j.cell.2014.08.028; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638; Torre LA, 2016, ADV EXP MED BIOL, V893, P1, DOI 10.1007/978-3-319-24223-1_1; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; Walne AJ, 2007, HUM MOL GENET, V16, P1619, DOI 10.1093/hmg/ddm111; Yoshihama Maki, 2013, BMC Res Notes, V6, P426, DOI 10.1186/1756-0500-6-426; Zaringhalam M, 2016, METHODS, V107, P63, DOI 10.1016/j.ymeth.2016.03.001; Zhang Y, 2017, STEM CELLS, V35, P222, DOI 10.1002/stem.2490; Zhou FB, 2017, NAT CELL BIOL, V19, P844, DOI 10.1038/ncb3563	53	17	17	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					909	921		10.1038/s41388-020-01570-y	http://dx.doi.org/10.1038/s41388-020-01570-y		DEC 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33288886	Green Published, hybrid			2022-12-28	WOS:000599015000001
J	Han, J; Qu, HB; Han, ML; Ding, YC; Xie, MW; Hu, JG; Chen, YW; Dong, HY				Han, Jing; Qu, Hongbo; Han, Mingli; Ding, Yichao; Xie, Mingwei; Hu, Jianguo; Chen, Yuanwen; Dong, Huaying			MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer	ONCOGENE			English	Article							RNA; METASTASIS; BIOMARKERS; PROLIFERATION; EMTANSINE; LAPATINIB; HER2	Trastuzumab resistance has been becoming a major obstacle for treatment of HER-2-positive breast cancer patients. Increasing evidence suggests that mesenchymal stem cells (MSCs) play critical roles during the formation of drug resistance, however, the underlying mechanism is not well known. In this study, mass spectrometry, RNA pulldown and RNA immunoprecipitation assays were performed to verify the direct interactions among AGAP2-AS1 and other associated targets, such as human antigen R (HuR), miR-15a-5p, and carnitine palmitoyl transferase 1 (CPT1). In vitro and in vivo experimental assays were done to clarify the functional role of AGAP2-AS1 in trastuzumab resistance, stemness, and fatty acid oxidation (FAO). The results showed that MSC co-culture induced trastuzumab resistance. AGAP2-AS1 was upregulated in MSC-cultured cells, and knockdown of AGAP2-AS1 reversed the MSC-mediated trastuzumab resistance. Furthermore, MSC culture-induced AGAP2-AS1 regulates stemness and trastuzumab resistance via activating FAO. Mechanistically, AGAP2-AS1 is associated with HuR, and the AGAP2-AS1-HuR complex could directly bind to the CPT1, increasing its expression via improving RNA stability. In addition, AGAP2-AS1 could serve as ceRNA via sponging miR-15a-5p and releasing CPT1 mRNA. Clinically, increased expression of serum AGAP2-AS1 predicts poor response to trastuzumab treatment in breast cancer patients. In conclusion, MSC culture-induced AGAP2-AS1 caused stemness and trastuzumab resistance via promoting CPT1 expression and inducing FAO. Our results provide new insight of the role of MSCs in trastuzumab resistance and AGAP2-AS1 could be promising predictive biomarker and therapeutic target for HER-2+ breast cancer patients.	[Han, Jing; Ding, Yichao; Xie, Mingwei; Dong, Huaying] Hainan Med Univ, Hainan Affiliated Hosp, Hainan Gen Hosp, Dept Gen Surg, Haikou 570311, Hainan, Peoples R China; [Qu, Hongbo] First Peoples Hosp Chenzhou City, Dept Breast & Thyroid Surg, Chenzhou City 423000, Hunan, Peoples R China; [Han, Mingli] Zhengzhou Univ, Affiliated Hosp 1, Dept Breast Surg, Zhengzhou 450052, Peoples R China; [Hu, Jianguo] Chongqing Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Chongqing 400010, Peoples R China; [Chen, Yuanwen] Univ Chinese Acad Sci, Chongqing Renji Hosp, Dept Gen Surg, Chongqing 400062, Peoples R China	Hainan Medical University; Zhengzhou University; Chongqing Medical University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Dong, HY (corresponding author), Hainan Med Univ, Hainan Affiliated Hosp, Hainan Gen Hosp, Dept Gen Surg, Haikou 570311, Hainan, Peoples R China.	dr_dhy@163.com		Dong, Huaying/0000-0002-4905-6940	National Natural Science Foundation of China [81960475, 82072932]; "Nanhai series" talent cultivation program of Hainan Province	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); "Nanhai series" talent cultivation program of Hainan Province	This study is supported by National Natural Science Foundation of China (81960475, 82072932) and The "Nanhai series" talent cultivation program of Hainan Province.	Amadori D, 2011, EUR J CANCER, V47, P2091, DOI 10.1016/j.ejca.2011.05.005; Arshi A, 2018, MOL THER-NUCL ACIDS, V12, P751, DOI 10.1016/j.omtn.2018.07.014; Bai Y, 2019, J CELL PHYSIOL, V234, P18837, DOI 10.1002/jcp.28522; Bakheet T, 2018, BBA-GENE REGUL MECH, V1861, P167, DOI 10.1016/j.bbagrm.2017.12.006; Bighin C, 2013, FUTURE ONCOL, V9, P955, DOI [10.2217/fon.13.74, 10.2217/FON.13.74]; Boero S, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0680-0; Borst P, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120066; Chen RS, 2020, J CELL BIOCHEM, V121, P4043, DOI 10.1002/jcb.29573; Choi HJ, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101589; Cuiffo BG, 2014, CELL STEM CELL, V15, P762, DOI 10.1016/j.stem.2014.10.001; Di C, 2015, EXP THER MED, V9, P289, DOI 10.3892/etm.2014.2141; Dong HY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0875-3; Freudenberg JA, 2009, EXP MOL PATHOL, V87, P1, DOI 10.1016/j.yexmp.2009.05.001; Gallardo A, 2012, BRIT J CANCER, V106, P1367, DOI 10.1038/bjc.2012.85; Ghoveud E, 2020, NEUROMOL MED, V22, P111, DOI 10.1007/s12017-019-08570-6; Han ML, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1145-5; He WM, 2019, ONCOGENE, V38, P4637, DOI 10.1038/s41388-019-0747-0; HUANG P, 2018, SCI REP UK, V8; Hui BQ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1384-9; Kang M, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0845-9; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li N, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0828-0; Li ZX, 2019, EXP THER MED, V18, P435, DOI 10.3892/etm.2019.7629; Liu ZK, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1188-x; Liu ZX, 2019, ONCOGENE, V38, P88, DOI 10.1038/s41388-018-0407-9; Lorenz R, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748-7188-6-26; Luo N, 2020, J CELL BIOCHEM, V121, P4176, DOI 10.1002/jcb.29572; Montemurro F, 2014, MOL ONCOL, V8, P20, DOI 10.1016/j.molonc.2013.08.013; Pereira B, 2017, TRENDS CANCER, V3, P506, DOI 10.1016/j.trecan.2017.05.003; PEREZ EA, 2019, BMC CANCER, V19; Pike LS, 2011, BBA-BIOENERGETICS, V1807, P726, DOI 10.1016/j.bbabio.2010.10.022; Ponde N, 2018, BREAST CANCER RES TR, V168, P631, DOI 10.1007/s10549-017-4628-3; Qian C, 2019, J CELL PHYSIOL, V234, P11620, DOI 10.1002/jcp.27819; Rahman M, 2015, METABOLITES, V5, P571, DOI 10.3390/metabo5040571; Seebach C, 2010, INJURY, V41, P731, DOI 10.1016/j.injury.2010.02.017; Seymour L, 2017, LANCET ONCOL, V18, pE143, DOI 10.1016/S1470-2045(17)30074-8; Shetty P, 2017, ANN CLIN BIOCHEM, V54, P463, DOI 10.1177/0004563216665867; Shi SJ, 2015, ONCOTARGET, V6, P11652, DOI 10.18632/oncotarget.3457; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Song XY, 2020, J CELL MOL MED, V24, P772, DOI 10.1111/jcmm.14786; Storti CB, 2020, EXP MOL PATHOL, V112, DOI 10.1016/j.yexmp.2019.104354; Tian T, 2018, MOL THER-NUCL ACIDS, V12, P359, DOI 10.1016/j.omtn.2018.05.018; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124; Wu L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2426-z; Yang XJ, 2020, EXP THER MED, V19, P3097, DOI 10.3892/etm.2020.8558; Zhang JW, 2017, NUCLEIC ACIDS RES, V45, P2849, DOI 10.1093/nar/gkw991; Zhang W, 2018, INT J ONCOL, V53, P527, DOI 10.3892/ijo.2018.4412; Zhu HY, 2018, BIOCHEM BIOPH RES CO, V496, P1308, DOI 10.1016/j.bbrc.2018.02.006	48	34	34	5	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					833	847		10.1038/s41388-020-01574-8	http://dx.doi.org/10.1038/s41388-020-01574-8		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33273726				2022-12-28	WOS:000599064900002
J	Alsafadi, S; Dayot, S; Tarin, M; Houy, A; Bellanger, D; Cornella, M; Wassef, M; Waterfall, JJ; Lehnert, E; Roman-Roman, S; Stern, MH; Popova, T				Alsafadi, Samar; Dayot, Stephane; Tarin, Malcy; Houy, Alexandre; Bellanger, Dorine; Cornella, Michele; Wassef, Michel; Waterfall, Joshua J.; Lehnert, Erik; Roman-Roman, Sergio; Stern, Marc-Henri; Popova, Tatiana			Genetic alterations ofSUGP1mimic mutant-SF3B1splice pattern in lung adenocarcinoma and other cancers	ONCOGENE			English	Article							SPLICING FACTOR SF3B1; MUTATIONS	Genes involved in 3 '-splice site recognition during mRNA splicing constitute an emerging class of oncogenes.SF3B1is the most frequently mutated splicing factor in cancer, and SF3B1 mutants corrupt branchpoint recognition leading to usage of cryptic 3 '-splice sites and subsequent aberrant junctions. For a comprehensive determination of alterations leading to this splicing pattern, we performed a pan-TCGA screening for SF3B1-specific aberrant acceptor usage. While the most of aberrant 3 '-splice patterns were explained bySF3B1mutations, we also detected nineSF3B1wild-type tumors (including five lung adenocarcinomas). Genomic profile analysis of these tumors identified somatic mutations combined with loss-of-heterozygosity in the splicing factorSUGP1in five of these cases. Modeling ofSUGP1loss and mutations in cell lines showed that both alterations induced mutant-SF3B1-like aberrant splicing. Our study provides definitive evidence that genetic alterations ofSUGP1genocopySF3B1mutations in lung adenocarcinoma and other cancers.	[Alsafadi, Samar; Tarin, Malcy; Waterfall, Joshua J.; Roman-Roman, Sergio] PSL Res Univ, Inst Curie, Translat Res Dept, Paris, France; [Alsafadi, Samar; Dayot, Stephane; Houy, Alexandre; Bellanger, Dorine; Cornella, Michele; Waterfall, Joshua J.; Stern, Marc-Henri; Popova, Tatiana] PSL Res Univ, Equipe Labellisee Ligue Natl Canc, DNA Repair & Uveal Melanoma DRUM, Inst Curie,INSERM U830, Paris, France; [Wassef, Michel] Sorbonne Univ, PSL Res Univ, Inst Curie, Paris, France; [Wassef, Michel] CNRS, UMR3215, INSERM, U934, Paris, France; [Lehnert, Erik] Seven Bridges Genom, Konigesberg, MA USA	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm)	Stern, MH (corresponding author), PSL Res Univ, Equipe Labellisee Ligue Natl Canc, DNA Repair & Uveal Melanoma DRUM, Inst Curie,INSERM U830, Paris, France.	marc-henri.stern@curie.fr	Alsafadi, Samar/C-4659-2017; Stern, Marc-Henri/A-2728-2011; Bellanger, Dorine/AAC-2235-2022	Alsafadi, Samar/0000-0002-0060-1346; Stern, Marc-Henri/0000-0002-8100-2272; Waterfall, Joshua/0000-0002-3762-5050; Wassef, Michel/0000-0003-3748-5112; Tarin, Malcy/0000-0002-3865-9631	SIRIC Curie [INCa-DGOSInserm_12554]; European Union's Horizon 2020 project "UM Cure 2020" [667787]; Ligue Nationale Contre le Cancer (Labellisation); Canceropole Emergence from Canceropole Ile-de-France [EMERG-1 2017 ImmunSplice]; Federal funds from the National Cancer Institute, National Institutes of Health [HHSN261201400008C, HHSN261201500003I, 17x146]	SIRIC Curie; European Union's Horizon 2020 project "UM Cure 2020"; Ligue Nationale Contre le Cancer (Labellisation); Canceropole Emergence from Canceropole Ile-de-France; Federal funds from the National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The translational group of UM at Institut Curie is supported by SIRIC Curie (Grant INCa-DGOSInserm_12554) and the European Union's Horizon 2020 project "UM Cure 2020" (grant no. 667787). This work benefits also from financial support of the Ligue Nationale Contre le Cancer (Labellisation) and a grant from Canceropole Emergence from Canceropole Ile-de-France (EMERG-1 2017 ImmunSplice). The Seven Bridges Cancer Genomics Cloud has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, contract no. HHSN261201400008C and ID/IQ agreement no. 17x146 under contract no. HHSN261201500003I.	Agafonov DE, 2011, MOL CELL BIOL, V31, P2667, DOI 10.1128/MCB.05266-11; Agudelo D, 2017, NAT METHODS, V14, P615, DOI [10.1038/NMETH.4265, 10.1038/nmeth.4265]; Alsafadi S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10615; Bryant DW, 2010, BIOINFORMATICS, V26, P1500, DOI 10.1093/bioinformatics/btq206; Cretu C, 2016, MOL CELL, V64, P307, DOI 10.1016/j.molcel.2016.08.036; Darman RB, 2015, CELL REP, V13, P1033, DOI 10.1016/j.celrep.2015.09.053; DeBoever C, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004105; Dehghannasiri R, 2019, P NATL ACAD SCI USA, V116, P15524, DOI 10.1073/pnas.1900391116; Dvinge H, 2016, NAT REV CANCER, V16, P413, DOI 10.1038/nrc.2016.51; Furney SJ, 2013, CANCER DISCOV, V3, P1122, DOI 10.1158/2159-8290.CD-13-0330; Harbour JW, 2013, NAT GENET, V45, P133, DOI 10.1038/ng.2523; Ilagan JO, 2015, GENOME RES, V25, P14, DOI 10.1101/gr.181016.114; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Inoue D, 2019, NATURE, V574, P432, DOI 10.1038/s41586-019-1646-9; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Kong Y, 2014, MELANOMA RES, V24, P332, DOI 10.1097/CMR.0000000000000071; Lau JW, 2017, CANCER RES, V77, pE3, DOI 10.1158/0008-5472.CAN-17-0387; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Liu ZQ, 2020, CANCER DISCOV, V10, P806, DOI 10.1158/2159-8290.CD-19-1330; Liu ZQ, 2020, P NATL ACAD SCI USA, V117, P10305, DOI 10.1073/pnas.1922622117; Maguire SL, 2015, J PATHOL, V235, P571, DOI 10.1002/path.4483; Martin M, 2013, NAT GENET, V45, P933, DOI 10.1038/ng.2674; Obeng EA, 2019, CANCER DISCOV, V9, P1493, DOI 10.1158/2159-8290.CD-19-0399; Papaemmanuil E, 2011, NEW ENGL J MED, V365, P1384, DOI 10.1056/NEJMoa1103283; Plaschka C, 2018, NATURE, V559, P420, DOI 10.1038/s41586-018-0323-8; Popova T, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r128; Quesada V, 2012, NAT GENET, V44, P47, DOI 10.1038/ng.1032; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Sampson ND, 2003, GENE, V305, P91, DOI 10.1016/S0378-1119(02)01230-1; Seiler M, 2018, CELL REP, V23, P282, DOI 10.1016/j.celrep.2018.01.088; Suzuki H, 2019, NATURE, V574, P707, DOI 10.1038/s41586-019-1650-0; van der Feltz C, 2019, CRIT REV BIOCHEM MOL, V54, P443, DOI 10.1080/10409238.2019.1691497; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016; Will CL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003707; Xu XD, 2005, CELL, V120, P59, DOI 10.1016/j.cell.2004.11.036; Zhang J, 2019, MOL CELL, V76, P82, DOI 10.1016/j.molcel.2019.07.017	36	3	3	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					85	96		10.1038/s41388-020-01507-5	http://dx.doi.org/10.1038/s41388-020-01507-5		OCT 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33057152	Green Published, hybrid			2022-12-28	WOS:000577230500001
J	Horiguchi, H; Kadomatsu, T; Miyata, K; Terada, K; Sato, M; Torigoe, D; Morinaga, J; Moroishi, T; Oike, Y				Horiguchi, Haruki; Kadomatsu, Tsuyoshi; Miyata, Keishi; Terada, Kazutoyo; Sato, Michio; Torigoe, Daisuke; Morinaga, Jun; Moroishi, Toshiro; Oike, Yuichi			Stroma-derived ANGPTL2 establishes an anti-tumor microenvironment during intestinal tumorigenesis	ONCOGENE			English	Article							ANGIOPOIETIN-LIKE PROTEIN-2; CANCER; MACROPHAGES; CELLS; EXPRESSION; ANTIBODY; ROLES; MECHANISMS; INFECTION; SUBSETS	Previous studies show that tumor cell-derived angiopoietin-like protein 2 (ANGPTL2) functions as a tumor promoter in some cancer contexts. However, we recently reported that host ANGPTL2 also shows tumor suppressive activity by enhancing dendritic cell-mediated CD8(+)T cell anti-tumor immune responses in mouse kidney cancer and murine syngeneic models. However, mechanisms underlying ANGPTL2-mediated tumor suppression are complex and not well known. Here, we investigated ANGPTL2 tumor suppressive function in chemically-induced intestinal tumorigenesis. ANGPTL2 deficiency enhanced intestinal tumor growth in an experimental mouse colitis-associated colon cancer (CAC) model.Angptl2-deficient mice also showed a decrease not only in CD8(+)T cell responses but in CD4(+)T cell responses during intestinal tumorigenesis. Furthermore, we show that stroma-derived ANGPTL2 can activate the myeloid immune response. Notably, ANGPTL2 drove generation of immunostimulatory macrophages via the NF-kappa B pathway, accelerating CD4(+)T helper 1 (Th1) cell activation. These findings overall provide novel insight into the complex mechanisms underlying ANGPTL2 anti-tumor function in cancer pathology.	[Horiguchi, Haruki; Kadomatsu, Tsuyoshi; Miyata, Keishi; Terada, Kazutoyo; Sato, Michio; Morinaga, Jun; Oike, Yuichi] Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Kumamoto 8608556, Japan; [Horiguchi, Haruki; Oike, Yuichi] Kumamoto Univ, Grad Sch Med Sci, Dept Aging & Geriatr Med, Kumamoto 8608556, Japan; [Kadomatsu, Tsuyoshi; Miyata, Keishi; Terada, Kazutoyo; Moroishi, Toshiro; Oike, Yuichi] Kumamoto Univ, Grad Sch Med Sci, Ctr Metab Regulat Hlth Aging CMHA, Kumamoto 8608556, Japan; [Sato, Michio; Torigoe, Daisuke] Kumamoto Univ, Inst Resource Dev & Anal IRDA, Kumamoto 8600811, Japan; [Moroishi, Toshiro] Kumamoto Univ, Dept Cell Signaling & Metab Med, Fac Life Sci, Kumamoto 8608556, Japan; [Moroishi, Toshiro] Japan Sci & Technol Agcy JST, Precursory Res Embryon Sci & Technol PRESTO, Kawaguchi 3320012, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University; Japan Science & Technology Agency (JST)	Kadomatsu, T; Oike, Y (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Kumamoto 8608556, Japan.; Oike, Y (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Aging & Geriatr Med, Kumamoto 8608556, Japan.; Kadomatsu, T; Oike, Y (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Ctr Metab Regulat Hlth Aging CMHA, Kumamoto 8608556, Japan.	tkado@gpo.kumamoto-u.ac.jp; oike@gpo.kumamoto-u.ac.jp	Miyata, Keishi/HGF-1876-2022	Miyata, Keishi/0000-0003-0336-1859; Moroishi, Toshiro/0000-0001-6419-3882; SATO, MICHIO/0000-0001-9339-1642	Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [18K07236, 18K15246]; Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST) [13417915]; CREST program of the Japan Agency for Medical Research and Development (AMED) [JP18gm0610007]; Takeda Science Foundation	Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)); CREST program of the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Takeda Science Foundation(Takeda Science Foundation (TSF))	We thank Kiyoka Tabu, Noriko Shirai, and Sayomi Iwaki for technical assistance. This work was supported by the Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (grant 18K07236 to TK, grant 18K15246 to HH), the Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST) (grant 13417915 to YO), the CREST program of the Japan Agency for Medical Research and Development (AMED) (grant JP18gm0610007 to YO), and the Takeda Science Foundation (HH, TK).	Advani R, 2018, NEW ENGL J MED, V379, P1711, DOI 10.1056/NEJMoa1807315; Aoi J, 2011, CANCER RES, V71, P7502, DOI 10.1158/0008-5472.CAN-11-1758; Bain CC, 2013, MUCOSAL IMMUNOL, V6, P498, DOI 10.1038/mi.2012.89; Bain CC, 2014, IMMUNOL REV, V260, P102, DOI 10.1111/imr.12192; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Borst J, 2018, NAT REV IMMUNOL, V18, P635, DOI 10.1038/s41577-018-0044-0; Chung KY, 2010, J CLIN ONCOL, V28, P3485, DOI 10.1200/JCO.2010.28.3994; De Calisto J, 2012, EUR J IMMUNOL, V42, P3136, DOI 10.1002/eji.201243061; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Endo M, 2012, CANCER RES, V72, P1784, DOI 10.1158/0008-5472.CAN-11-3878; Galdiero MR, 2016, INT J CANCER, V139, P446, DOI 10.1002/ijc.30076; Gnjatic S, 2003, P NATL ACAD SCI USA, V100, P8862, DOI 10.1073/pnas.1133324100; Hato T, 2008, TRENDS CARDIOVAS MED, V18, P6, DOI 10.1016/j.tcm.2007.10.003; Ho WL, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0334-6; Horiguchi H, 2019, GENE DEV, V33, P1641, DOI 10.1101/gad.329417.119; Horiguchi H, 2017, EMBO J, V36, P409, DOI 10.15252/embj.201695690; Horiguchi H, 2014, CANCER SCI, V105, P1550, DOI 10.1111/cas.12554; Kadomatsu T, 2014, TRENDS ENDOCRIN MET, V25, P245, DOI 10.1016/j.tem.2014.03.012; Kather JN, 2019, BRIT J CANCER, V120, P871, DOI 10.1038/s41416-019-0441-6; Kennedy R, 2008, IMMUNOL REV, V222, P129, DOI 10.1111/j.1600-065X.2008.00616.x; Khalil H, 2013, JOVE-J VIS EXP, V12, P1; Kikuchi R, 2008, CANCER RES, V68, P5067, DOI 10.1158/0008-5472.CAN-08-0062; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Kubota Y, 2005, GENE EXPR PATTERNS, V5, P679, DOI 10.1016/j.modgep.2005.02.006; Kuchiike D, 2013, ANTICANCER RES, V33, P2881; Kuraishy A, 2011, IMMUNITY, V35, P467, DOI 10.1016/j.immuni.2011.09.006; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Masuda T, 2015, SCI REP-UK, V5, DOI 10.1038/srep09170; Moynihan KD, 2017, CANCER RES, V77, P5215, DOI 10.1158/0008-5472.CAN-17-1340; Na YR, 2019, NAT REV GASTRO HEPAT, V16, P531, DOI 10.1038/s41575-019-0172-4; Netsirisawan P, 2015, CANCER GENOM PROTEOM, V12, P201; Odagiri H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004612; Oike Y, 2003, P NATL ACAD SCI USA, V100, P9494, DOI 10.1073/pnas.1531901100; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Osumi H, 2020, CANCER SCI, V111, P1241, DOI 10.1111/cas.14337; RUGTVEIT J, 1994, GUT, V35, P669, DOI 10.1136/gut.35.5.669; Rugtveit J, 1997, GASTROENTEROLOGY, V112, P1493, DOI 10.1016/S0016-5085(97)70030-1; Saleh M, 2011, NAT REV IMMUNOL, V11, P9, DOI 10.1038/nri2891; Sheng JP, 2015, IMMUNITY, V43, P382, DOI 10.1016/j.immuni.2015.07.016; Soncin I, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02834-8; Tabata M, 2009, CELL METAB, V10, P178, DOI 10.1016/j.cmet.2009.08.003; Tamoutounour S, 2012, EUR J IMMUNOL, V42, P3150, DOI 10.1002/eji.201242847; Tay RE, 2021, CANCER GENE THER, V28, P5, DOI 10.1038/s41417-020-0183-x; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Weigmann B, 2007, NAT PROTOC, V2, P2307, DOI 10.1038/nprot.2007.315; Wirtz S, 2017, NAT PROTOC, V12, P1295, DOI 10.1038/nprot.2017.044; Yanagita T, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89140; Yugami M, 2016, J BIOL CHEM, V291, P18843, DOI 10.1074/jbc.M116.720870; Zhang L, 2020, CELL, V181, P442, DOI 10.1016/j.cell.2020.03.048	52	6	8	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					55	67		10.1038/s41388-020-01505-7	http://dx.doi.org/10.1038/s41388-020-01505-7		OCT 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33051596				2022-12-28	WOS:000577556100002
J	Soshnikova, NV; Tatarskiy, EV; Tatarskiy, VV; Klimenko, NS; Shtil, AA; Nikiforov, MA; Georgieva, SG				Soshnikova, N. V.; Tatarskiy, E. V.; Tatarskiy, V. V.; Klimenko, N. S.; Shtil, A. A.; Nikiforov, M. A.; Georgieva, S. G.			PHF10 subunit of PBAF complex mediates transcriptional activation by MYC	ONCOGENE			English	Article							CHROMATIN REMODELING COMPLEXES; COACTIVATOR SAYP; SWI/SNF COMPLEX; C-MYC; PHD FINGER; MUTATIONS; INI1; IDENTIFICATION; HSNF5/INI1; PROTEINS	The PBAF complex, a member of SWI/SNF family of chromatin remodelers, plays an essential role in transcriptional regulation. We revealed a disease progression associated elevation of PHF10 subunit of PBAF in clinical melanoma samples. In melanoma cell lines, PHF10 interacts with MYC and facilitates the recruitment of PBAF complex to target gene promoters, therefore, augmenting MYC transcriptional activation of genes involved in the cell cycle progression. Depletion of either PHF10 or MYC induced G1 accumulation and a senescence-like phenotype. Our data identify PHF10 as a pro-oncogenic mechanism and an essential novel link between chromatin remodeling and MYC-dependent gene transcription.	[Soshnikova, N. V.; Tatarskiy, E. V.; Georgieva, S. G.] Russian Acad Sci, Inst Gene Biol, Dept Eukaryot Transcript Factors, Moscow, Russia; [Soshnikova, N. V.] Russian Acad Sci, Engelhardt Inst Mol Biol, Ctr Precis Genome Editing & Genet Technol Biomed, Moscow, Russia; [Tatarskiy, V. V.; Shtil, A. A.] Russian Acad Sci, Inst Gene Biol, Lab Mol Oncobiol, Moscow, Russia; [Klimenko, N. S.] Russian Acad Sci, Inst Gene Biol, Ctr Precis Genome Editing & Genet Technol Biomed, Moscow, Russia; [Nikiforov, M. A.] Wake Forest Univ, Dept Canc Biol, Winston Salem, NC 27101 USA; [Georgieva, S. G.] Russian Acad Sci, Engelhardt Inst Mol Biol, Dept Transcript Factors, Moscow, Russia	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Wake Forest University; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Soshnikova, NV; Georgieva, SG (corresponding author), Russian Acad Sci, Inst Gene Biol, Dept Eukaryot Transcript Factors, Moscow, Russia.; Soshnikova, NV (corresponding author), Russian Acad Sci, Engelhardt Inst Mol Biol, Ctr Precis Genome Editing & Genet Technol Biomed, Moscow, Russia.; Georgieva, SG (corresponding author), Russian Acad Sci, Engelhardt Inst Mol Biol, Dept Transcript Factors, Moscow, Russia.	nsoshnikova@genebiology.ru; sofia.georgieva2021@gmail.com	Klimenko, Natalia/V-9017-2018	Klimenko, Natalia/0000-0001-9640-0102	Ministry of Science and Higher Education of the Russian Federation [075-15-2019-1661]	Ministry of Science and Higher Education of the Russian Federation	We thank the Center for Precision Genome Editing and Genetic Technologies for Biomedicine (Institute of Gene Biology) supported by Ministry of Science and Higher Education of the Russian Federation (075-15-2019-1661) for providing the equipment.	Anbunathan H, 2019, CLIN CANCER RES, V25, P5156, DOI 10.1158/1078-0432.CCR-18-3052; Bagnasco L, 2007, FASEB J, V21, P1256, DOI 10.1096/fj.06-7082com; Banga SS, 2009, CYTOGENET GENOME RES, V126, P227, DOI 10.1159/000251960; Biegel JA, 1999, CANCER RES, V59, P74; Brechalov AV, 2016, MOL BIOL+, V50, P278, DOI 10.1134/S0026893316010039; Brechalov AV, 2014, CELL CYCLE, V13, P1970, DOI 10.4161/cc.28922; Buscarlet M, 2014, BLOOD, V123, P1720, DOI 10.1182/blood-2013-02-483495; Centore RC, 2020, TRENDS GENET, V36, P936, DOI 10.1016/j.tig.2020.07.011; Chalkley GE, 2008, MOL CELL BIOL, V28, P2920, DOI 10.1128/MCB.02217-07; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Egorov AA, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2706-8; Garcia-Gutierrez L, 2019, GENES-BASEL, V10, DOI 10.3390/genes10030244; Georgieva SG., 2020, TRANSFORMATION, V12, P115; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Ishizaka A, 2012, J BIOL CHEM, V287, P11924, DOI 10.1074/jbc.M111.322792; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Krasteva V, 2017, EXP HEMATOL, V48, P58, DOI 10.1016/j.exphem.2016.11.008; Lessard J, 2007, NEURON, V55, P201, DOI 10.1016/j.neuron.2007.06.019; Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401; Lu BJ, 2019, J CANCER, V10, P223, DOI 10.7150/jca.26978; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; Mashtalir N, 2018, CELL, V175, P1272, DOI 10.1016/j.cell.2018.09.032; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; Middeljans E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033834; Mittal P, 2020, NAT REV CLIN ONCOL, V17, P435, DOI 10.1038/s41571-020-0357-3; Panov VV, 2012, NUCLEIC ACIDS RES, V40, P2445, DOI 10.1093/nar/gkr1165; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Poole CJ, 2017, GENES-BASEL, V8, DOI 10.3390/genes8050142; Ramirez F, 2014, NUCLEIC ACIDS RES, V42, pW187, DOI 10.1093/nar/gku365; Ribeiro-Silva C, 2019, DNA REPAIR, V77, P87, DOI 10.1016/j.dnarep.2019.03.007; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Saladi SV, 2010, STEM CELL REV REP, V6, P62, DOI 10.1007/s12015-010-9120-y; Sammak S, 2018, FEBS J, V285, P4165, DOI 10.1111/febs.14660; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Shidlovskii YV, 2005, EMBO J, V24, P97, DOI 10.1038/sj.emboj.7600508; Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Stojanova A, 2016, CELL CYCLE, V15, P1693, DOI 10.1080/15384101.2016.1146836; Trotter Kevin W, 2008, Nucl Recept Signal, V6, pe004, DOI 10.1621/nrs.06004; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Viryasova GM, 2019, BBA-MOL CELL RES, V1866, DOI 10.1016/j.bbamcr.2019.118525; Vorobyeva NE, 2012, NUCLEIC ACIDS RES, V40, P7319, DOI 10.1093/nar/gks472; Vorobyeva NE, 2009, P NATL ACAD SCI USA, V106, P11049, DOI 10.1073/pnas.0901801106; Zeng L, 2010, NATURE, V466, P258, DOI 10.1038/nature09139; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258	54	5	5	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6071	6080		10.1038/s41388-021-01994-0	http://dx.doi.org/10.1038/s41388-021-01994-0		AUG 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34465901	Green Accepted			2022-12-28	WOS:000691653200001
J	Sun, L; Patai, AV; Hogenson, TL; Fernandez-Zapico, ME; Qin, B; Sinicrope, FA				Sun, Lei; Patai, Arpad V.; Hogenson, Tara L.; Fernandez-Zapico, Martin E.; Qin, Bo; Sinicrope, Frank A.			Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; BCL2 FAMILY; RNA EXOSOME; ACTIVATION; PHOSPHORYLATION; APOPTOSIS; BIM; KINASE; CELLS; BAX	Colorectal cancer (CRC) cells have low or absent tumor cell PD-L1 expression that we previously demonstrated can confer chemotherapy resistance. Here, we demonstrate that PD-L1 depletion enhances JNK activity resulting in increased Bim(Thr116) phosphorylation and its sequestration by MCL-1 and BCL-2. Activated JNK signaling in PD-L1-depeted cells was due to reduced mRNA stability of the CYLD deubiquitinase. PD-L1 was found to compete with the ribonuclease EXOSC10 for binding to CYLD mRNA. Thus, loss of PD-L1 promoted binding and degradation of CYLD mRNA by EXOSC10 which enhanced JNK activity. An irreversible JNK inhibitor (JNK-IN-8) reduced Bim(Thr116) phosphorylation and unsequestered Bim from MCL-1 and BCL-2 to promote apoptosis. In cells lacking PD-L1, treatment with JNK-IN-8, an MCL-1 antagonist (AZD5991), or their combination promoted apoptosis and reduced long-term clonogenic survival by anticancer drugs. Similar effects of the JNK inhibitor on cell viability were observed in CRC organoids with suppression of PD-L1. These data indicate that JNK inhibition may represent a promising strategy to overcome drug resistance in CRC cells with low or absent PD-L1 expression.	[Sun, Lei; Patai, Arpad V.; Qin, Bo; Sinicrope, Frank A.] Mayo Clin, Gastrointestinal Res Unit, Rochester, MN 55905 USA; [Sun, Lei] Guangzhou Med Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Guangzhou, Peoples R China; [Hogenson, Tara L.; Fernandez-Zapico, Martin E.] Mayo Clin, Div Oncol Res, Dept Oncol, Schulze Ctr Novel Therapeut, Rochester, MN USA; [Sinicrope, Frank A.] Mayo Clin, Dept Med, Rochester, MN 55905 USA; [Sinicrope, Frank A.] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA; [Sinicrope, Frank A.] Mayo Comprehens Canc Ctr, Rochester, MN 55905 USA	Mayo Clinic; Guangzhou Medical University; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Qin, B; Sinicrope, FA (corresponding author), Mayo Clin, Gastrointestinal Res Unit, Rochester, MN 55905 USA.; Sinicrope, FA (corresponding author), Mayo Clin, Dept Med, Rochester, MN 55905 USA.; Sinicrope, FA (corresponding author), Mayo Clin, Dept Oncol, Rochester, MN 55905 USA.; Sinicrope, FA (corresponding author), Mayo Comprehens Canc Ctr, Rochester, MN 55905 USA.	Qin.Bo@mayo.edu; Sinicrope.Frank@mayo.edu		Sinicrope, Frank/0000-0002-2907-1000	NCI [R01 CA210509-01A1]; Mayo Clinic Center for Biomedical Discovery Pilot Grant Program; Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Rosztoczy Foundation Hungarian Scholarship Program	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Mayo Clinic Center for Biomedical Discovery Pilot Grant Program; Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Rosztoczy Foundation Hungarian Scholarship Program	This study was supported, by NCI R01 CA210509-01A1 and Mayo Clinic Center for Biomedical Discovery Pilot Grant Program (both to FAS). LS is supported by the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. AP is supported by the Rosztoczy Foundation Hungarian Scholarship Program.	Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Biswas SC, 2007, J BIOL CHEM, V282, P29368, DOI 10.1074/jbc.M702634200; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Delmas A, 2015, ONCOTARGET, V6, P15250, DOI 10.18632/oncotarget.3888; Dong HD, 1999, NAT MED, V5, P1365; Ebelt ND, 2017, ONCOTARGET, V8, P104894, DOI 10.18632/oncotarget.20581; Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723; Feng DF, 2019, ONCOGENE, V38, P6752, DOI 10.1038/s41388-019-0919-y; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Haeusgen W, 2011, EUR J CELL BIOL, V90, P536, DOI 10.1016/j.ejcb.2010.11.008; Hamanishi J, 2016, INT J CLIN ONCOL, V21, P462, DOI 10.1007/s10147-016-0959-z; Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568-019-0116-x; Hayakawa J, 2004, MOL CELL, V16, P521, DOI 10.1016/j.molcel.2004.10.024; Hubner A, 2008, MOL CELL, V30, P415, DOI 10.1016/j.molcel.2008.03.025; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kulangara K, 2019, ARCH PATHOL LAB MED, V143, P330, DOI 10.5858/arpa.2018-0043-OA; Laine Aaron, 2005, Sci STKE, V2005, pre5, DOI 10.1126/stke.2812005re5; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Lipner MB, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.129905; Noguchi T, 2005, J BIOL CHEM, V280, P37033, DOI 10.1074/jbc.M506771200; Pefanis E, 2015, CELL, V161, P774, DOI 10.1016/j.cell.2015.04.034; Qin B, 2015, CELL REP, V10, P1324, DOI 10.1016/j.celrep.2015.01.066; Qiu XY, 2018, BBA-MOL BASIS DIS, V1864, P1754, DOI 10.1016/j.bbadis.2018.03.002; Ramkissoon A, 2019, CLIN CANCER RES, V25, P4117, DOI 10.1158/1078-0432.CCR-18-3224; Ramsdale R, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1111; Sheng J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20090; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Soderquist RS, 2016, MOL CANCER THER, V15, P2011, DOI 10.1158/1535-7163.MCT-16-0031; Sun SC, 2010, CELL DEATH DIFFER, V17, P25, DOI 10.1038/cdd.2009.43; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Tron AE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07551-w; Tu XY, 2019, MOL CELL, V74, P1215, DOI 10.1016/j.molcel.2019.04.005; Vasilevskaya I, 2003, DRUG RESIST UPDATE, V6, P147, DOI 10.1016/S1368-7646(03)00043-8; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Wyss J, 2019, CLIN COLORECTAL CANC, V18, pE20, DOI 10.1016/j.clcc.2018.09.007; Xue L, 2007, DEV CELL, V13, P446, DOI 10.1016/j.devcel.2007.07.012; Yu J, 2018, J CLIN INVEST, V128, P2376, DOI 10.1172/JCI97924; Zhang T, 2012, CHEM BIOL, V19, P140, DOI 10.1016/j.chembiol.2011.11.010; Zinder JC, 2017, GENE DEV, V31, P88, DOI 10.1101/gad.294769.116	48	0	0	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5105	5115		10.1038/s41388-021-01910-6	http://dx.doi.org/10.1038/s41388-021-01910-6		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34193942				2022-12-28	WOS:000668403200002
J	Melocchi, V; Dama, E; Mazzarelli, F; Cuttano, R; Colangelo, T; Di Candia, L; Lugli, E; Veronesi, G; Pelosi, G; Ferretti, GM; Taurchini, M; Graziano, P; Bianchi, F				Melocchi, Valentina; Dama, Elisa; Mazzarelli, Francesco; Cuttano, Roberto; Colangelo, Tommaso; Di Candia, Leonarda; Lugli, Enrico; Veronesi, Giulia; Pelosi, Giuseppe; Ferretti, Gian Maria; Taurchini, Marco; Graziano, Paolo; Bianchi, Fabrizio			Aggressive early-stage lung adenocarcinoma is characterized by epithelial cell plasticity with acquirement of stem-like traits and immune evasion phenotype	ONCOGENE			English	Article							INTRATUMORAL HETEROGENEITY; HEMATOPOIETIC STEM; GENE-EXPRESSION; IN-VITRO; CLASSIFICATION; METASTASIS; IDENTIFICATION; PROLIFERATION; PROGRESSION; ASSOCIATION	Lung adenocarcinoma (LUAD) is the main non-small-cell lung cancer diagnosed in similar to 40-50% of all lung cancer cases. Despite the improvements in early detection and personalized medicine, even a sizable fraction of patients with early-stage LUAD would experience disease relapses and adverse prognosis. Previous reports indicated the existence of LUAD molecular subtypes characterized by specific gene expression and mutational profiles, and correlating with prognosis. However, the biological and molecular features of such subtypes have not been further explored. Consequently, the mechanisms driving the emergence of aggressive LUAD remained unclear. Here, we adopted a multi-tiered approach ranging from molecular to functional characterization of LUAD and used it on multiple cohorts of patients (for a total of 1227 patients) and LUAD cell lines. We investigated the tumor transcriptome and the mutational and immune gene expression profiles, and we used LUAD cell lines for cancer cell phenotypic screening. We found that loss of lung cell lineage and gain of stem cell-like characteristics, along with mutator and immune evasion phenotypes, explain the aggressive behavior of a specific subset of lung adenocarcinoma that we called C1-LUAD, including early-stage disease. This subset can be identified using a 10-gene prognostic signature. Poor prognosis patients appear to have this specific molecular lung adenocarcinoma subtype which is characterized by peculiar molecular and biological features. Our data support the hypothesis that transformed lung stem/progenitor cells and/or reprogrammed epithelial cells with CSC characteristics are hallmarks of this aggressive disease. Such discoveries suggest alternative, more aggressive, therapeutic strategies for early-stage C1-LUAD.	[Melocchi, Valentina; Dama, Elisa; Mazzarelli, Francesco; Cuttano, Roberto; Colangelo, Tommaso; Bianchi, Fabrizio] Fdn IRCCS Casa Sollievo Sofferenza, Canc Biomarkers Unit, San Giovanni Rotondo, Italy; [Di Candia, Leonarda; Graziano, Paolo] Fdn IRCCS Casa Sollievo Sofferenza, Pathol Unit, San Giovanni Rotondo, Italy; [Lugli, Enrico] Humanitas Clin & Res Ctr IRCCS, Lab Translat Immunol, Milan, Italy; [Veronesi, Giulia] IRCCS San Raffaele Sci Inst, Div Thorac Surg, Milan, Italy; [Pelosi, Giuseppe] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy; [Pelosi, Giuseppe] IRCCS MultiMed, Interhosp Pathol Div, Milan, Italy; [Ferretti, Gian Maria; Taurchini, Marco] Fdn IRCCS Casa Sollievo Sofferenza, Thorac Surg Unit, San Giovanni Rotondo, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; IRCCS Multimedica	Bianchi, F (corresponding author), Fdn IRCCS Casa Sollievo Sofferenza, Canc Biomarkers Unit, San Giovanni Rotondo, Italy.	f.bianchi@operapadrepio.it	Lugli, Enrico/AAB-7933-2019; Cuttano, Roberto/B-5884-2017; Mazzarelli, Francesco/AAC-4749-2020; Graziano, Paolo/AAC-9802-2022; Bianchi, Fabrizio/W-7037-2019; MELOCCHI, VALENTINA/B-5747-2017; DAMA, ELISA/C-2709-2017; COLANGELO, TOMMASO/B-6119-2017; Pelosi, Giuseppe/F-5073-2012	Lugli, Enrico/0000-0002-1964-7678; Cuttano, Roberto/0000-0003-4150-2114; Mazzarelli, Francesco/0000-0002-9912-6820; Graziano, Paolo/0000-0001-7066-7896; Bianchi, Fabrizio/0000-0001-7412-8638; MELOCCHI, VALENTINA/0000-0001-9656-3681; DAMA, ELISA/0000-0001-6918-6577; COLANGELO, TOMMASO/0000-0002-6927-403X; Pelosi, Giuseppe/0000-0003-4725-4692	Associazione Italiana Ricerca sul Cancro [MFAG-17568, IG-22827, IG-20676, 19548]; Italian Ministry of Health [GR-2016-02363975]; Umberto Veronesi Foundation; Pezcoller Foundation	Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy); Umberto Veronesi Foundation(Fondazione Umberto Veronesi); Pezcoller Foundation	We are grateful to Teresa Nittoli for technical assistance and Chiara Di Giorgio for critically editing the manuscript. This study was performed in accordance We are grateful to Teresa Nittoli for technical assistance and Chiara Di Giorgio for critically editing the manuscript. This study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Fondazione IRCCS Casa Sollievo della Sofferenza (ref. number: BIO-POLMONE - V1.0_08 Giu 16). All authors gave their consent to publication. The gene expression data used in this study are publicly available as indicated in the "Methods" and Supplementary Information sections. This work was supported by the Associazione Italiana Ricerca sul Cancro [MFAG-17568 and IG-22827 to FB; IG-20676 to EL], the Italian Ministry of Health [GR-2016-02363975 and CLEARLY to FB]. RC was supported by a fellowship from the Umberto Veronesi Foundation and the Pezcoller Foundation. TC was supported by a fellowship from the Associazione Italiana Ricerca sul Cancro (#19548) and the Umberto Veronesi Foundation.with the Declaration of Helsinki and was approved by the Ethics Committee of the Fondazione IRCCS Casa Sollievo della Sofferenza (ref. number: BIO-POLMONE - V1.0_08 Giu 16). All authors gave their consent to publication. The gene expression data used in this study are publicly available as indicated in the "Methods" and Supplementary Information sections. This work was supported by the Associazione Italiana Ricerca sul Cancro [MFAG-17568 and IG-22827 to FB; IG-20676 to EL], the Italian Ministry of Health [GR-2016-02363975 and CLEARLY to FB]. RC was supported by a fellowship from the Umberto Veronesi Foundation and the Pezcoller Foundation. TC was supported by a fellowship from the Associazione Italiana Ricerca sul Cancro (#19548) and the Umberto Veronesi Foundation.	Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Alvisi G, 2020, J CLIN INVEST, V130, P3137, DOI 10.1172/JCI130426; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bianchi F, 2007, J CLIN INVEST, V117, P3436, DOI 10.1172/JCI32007; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bremnes RM, 2016, J THORAC ONCOL, V11, P789, DOI 10.1016/j.jtho.2016.01.015; Bryant CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011712; Burkholder B, 2014, BBA-REV CANCER, V1845, P182, DOI 10.1016/j.bbcan.2014.01.004; Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]; Care A, 1999, ONCOGENE, V18, P1993, DOI 10.1038/sj.onc.1202498; Chen F, 2017, ONCOGENE, V36, P1384, DOI 10.1038/onc.2016.303; Cheung WKC, 2015, ONCOGENE, V34, P5771, DOI 10.1038/onc.2015.85; Dama E, 2017, CLIN CANCER RES, V23, P62, DOI 10.1158/1078-0432.CCR-15-3005; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; de Koning HJ, 2020, NEW ENGL J MED, V382, P503, DOI 10.1056/NEJMoa1911793; Devarakonda S, 2015, LANCET ONCOL, V16, pE342, DOI 10.1016/S1470-2045(15)00077-7; Dolatshad H, 2015, LEUKEMIA, V29, P1092, DOI [10.1038/leu.2014.331, 10.1038/leu.2015.178]; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Fares J, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0134-x; Ferone G, 2016, CANCER CELL, V30, P519, DOI 10.1016/j.ccell.2016.09.001; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Grindel BJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25435-3; Han B, 2018, AM J CANCER RES, V8, P810; Jaillon S, 2020, NAT REV CANCER, V20, P485, DOI 10.1038/s41568-020-0281-y; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Kumar PA, 2011, CELL, V147, P525, DOI 10.1016/j.cell.2011.10.001; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Marjanovic ND, 2020, CANCER CELL, V38, P229, DOI 10.1016/j.ccell.2020.06.012; McCauley KB, 2018, STEM CELL REP, V10, P1579, DOI 10.1016/j.stemcr.2018.03.013; Miranda A, 2019, P NATL ACAD SCI USA, V116, P9020, DOI 10.1073/pnas.1818210116; Moises J, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0542-z; Monterisi S, 2018, ONCOGENE, V37, P3575, DOI 10.1038/s41388-018-0229-9; Nazarov PV, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3819-y; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Orkin SH, 2011, CELL, V145, P835, DOI 10.1016/j.cell.2011.05.019; Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4; Pribluda A, 2015, CLIN CANCER RES, V21, P2916, DOI 10.1158/1078-0432.CCR-14-1213; Reynolds SD, 2002, AM J RESP CRIT CARE, V166, P1498, DOI 10.1164/rccm.200204-285OC; Richards CH, 2011, FUTURE ONCOL, V7, P1223, DOI [10.2217/fon.11.99, 10.2217/FON.11.99]; Schabath MB, 2016, ONCOGENE, V35, P3209, DOI 10.1038/onc.2015.375; Schoenfeld A, 2020, CLIN CANCER RES, V26, P5701, DOI 10.1158/1078-0432.CCR-20-1825; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sonzogni A, 2017, J PATHOL CLIN RES, V3, P139, DOI 10.1002/cjp2.67; Staempfli MR, 2009, NAT REV IMMUNOL, V9, P377, DOI 10.1038/nri2530; Swanton C, 2015, CANCER DISCOV, V5, P704, DOI 10.1158/2159-8290.CD-15-0344; Takeuchi T, 2006, J CLIN ONCOL, V24, P1679, DOI 10.1200/JCO.2005.03.8224; Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334; Tata PR, 2018, DEV CELL, V44, P679, DOI 10.1016/j.devcel.2018.02.024; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; Tian CX, 2020, CANCER RES, V80, P1461, DOI 10.1158/0008-5472.CAN-19-2578; Tokheim C, 2019, CELL SYST, V9, P9, DOI 10.1016/j.cels.2019.05.005; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Wolf J, 2020, NEW ENGL J MED, V383, P944, DOI 10.1056/NEJMoa2002787; Xu NZ, 2019, J HISTOCHEM CYTOCHEM, V67, P453, DOI 10.1369/0022155419829050; Yan XP, 2013, ONCOL REP, V30, P2733, DOI 10.3892/or.2013.2784; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Yu H, 2016, J THORAC ONCOL, V11, P964, DOI 10.1016/j.jtho.2016.04.014; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930; Zuo W, 2015, NATURE, V517, P616, DOI 10.1038/nature13903	62	3	3	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					4980	4991		10.1038/s41388-021-01909-z	http://dx.doi.org/10.1038/s41388-021-01909-z		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34172935				2022-12-28	WOS:000667016100001
J	Kim, SY; Shen, Q; Son, K; Kim, HS; Yang, HD; Na, MJ; Shin, E; Yu, S; Kang, K; You, JS; Yu, KR; Jeong, SM; Lee, EK; Ahn, YM; Park, WS; Nam, SW				Kim, Sang Yean; Shen, Qingyu; Son, Keunhong; Kim, Hyung Seok; Yang, Hee Doo; Na, Min Jeong; Shin, Eunbi; Yu, Suji; Kang, Keunsoo; You, Jueng Soo; Yu, Kyung-Rok; Jeong, Seung Min; Lee, Eun Kyung; Ahn, Young Min; Park, Won Sang; Nam, Suk Woo			SMARCA4 oncogenic potential via IRAK1 enhancer to activate Gankyrin and AKR1B10 in liver cancer	ONCOGENE			English	Article							COMPLEXES; ARID1A	SWItch/Sucrose Non-Fermentable (SWI/SNF) is a multiprotein complex essential for the regulation of eukaryotic gene expression. SWI/SNF complex genes are genetically altered in over 20% of human malignancies, but the aberrant regulation of the SWI/SNF subunit genes and subsequent dysfunction caused by abnormal expression of subunit gene in cancer, remain poorly understood. Among the SWI/SNF subunit genes, SMARCA4, SMARCC1, and SMARCA2 were identified to be overexpressed in human hepatocellular carcinoma (HCC). Modulation of SMARCA4, SMARCC1, and SMARCA2 inhibited in vitro tumorigenesis of HCC cells. However, SMARCA4-targeting elicited remarkable inhibition in an in vivo Ras-transgenic mouse HCC model (Ras-Tg), and high expression levels of SMARCA4 significantly associated with poor prognosis in HCC patients. Furthermore, most HCC patients (72-86%) showed SMARCA4 overexpression compared to healthy controls. To identify SMARCA4-specific active enhancers, mapping, and analysis of chromatin state in liver cancer cells were performed. Integrative analysis of SMARCA4-regulated genes and active chromatin enhancers suggested 37 genes that are strongly activated by SMARCA4 in HCC. Through chromatin immunoprecipitation-qPCR and luciferase assays, we demonstrated that SMARCA4 activates Interleukin-1 receptor-associated kinase 1 (IRAK1) expression through IRAK1 active enhancer in HCC. We then showed that transcriptional activation of IRAK1 induces oncoprotein Gankyrin and aldo-keto reductase family 1 member B10 (AKR1B10) in HCC. The regulatory mechanism of the SMARCA4-IRAK1-Gankyrin, AKR1B10 axis was further demonstrated in HCC cells and in vivo Ras-Tg mice. Our results suggest that aberrant overexpression of SMARCA4 causes SWI/SNF to promote IRAK1 enhancer to activate oncoprotein Gankyrin and AKR1B10, thereby contributing to hepatocarcinogenesis.	[Kim, Sang Yean; Shen, Qingyu; Na, Min Jeong; Shin, Eunbi; Yu, Suji; Park, Won Sang; Nam, Suk Woo] Catholic Univ Korea, Dept Pathol, Coll Med, 222 Banpo Daero, Seoul 06591, South Korea; [Kim, Sang Yean; Na, Min Jeong; Shin, Eunbi; Yu, Suji; Park, Won Sang; Nam, Suk Woo] Catholic Univ Korea, Funct RNom Res Ctr, 222 Banpo Daero, Seoul 06591, South Korea; [Kim, Sang Yean; Na, Min Jeong; Shin, Eunbi; Yu, Suji; Nam, Suk Woo] Catholic Univ Korea, Grad Sch Med, Dept Biomed Hlth Sci, 222 Banpo Daero, Seoul 06591, South Korea; [Son, Keunhong; Kang, Keunsoo] Dankook Univ, Dept Microbiol, Cheonan 31116, South Korea; [Kim, Hyung Seok; Yang, Hee Doo; Nam, Suk Woo] NEORNAT Inc, Rm 305 Med Sch Bldg,222 Banpo Daero, Seoul, South Korea; [You, Jueng Soo] Konkuk Univ, Res Inst Med Sci, Sch Med, Dept Biochem, Seoul 05029, South Korea; [Yu, Kyung-Rok] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 08826, South Korea; [Jeong, Seung Min; Lee, Eun Kyung] Catholic Univ Korea, Dept Biochem, Coll Med, 222 Banpo Daero, Seoul 06591, South Korea; [Ahn, Young Min] Kyung Hee Univ, Dept Kidney Syst, Coll Oriental Med, Seoul 02447, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Dankook University; Konkuk University; Konkuk University Medical Center; Seoul National University (SNU); Catholic University of Korea; Kyung Hee University	Nam, SW (corresponding author), Catholic Univ Korea, Dept Pathol, Coll Med, 222 Banpo Daero, Seoul 06591, South Korea.; Nam, SW (corresponding author), Catholic Univ Korea, Funct RNom Res Ctr, 222 Banpo Daero, Seoul 06591, South Korea.; Nam, SW (corresponding author), Catholic Univ Korea, Grad Sch Med, Dept Biomed Hlth Sci, 222 Banpo Daero, Seoul 06591, South Korea.; Nam, SW (corresponding author), NEORNAT Inc, Rm 305 Med Sch Bldg,222 Banpo Daero, Seoul, South Korea.	swnam@catholic.ac.kr	SHEN, QINGYU/U-8848-2018	Kim, Hyung Seok/0000-0003-2784-0109	National Research Foundation (NRF) of Korea [2017R1A2B3002989, 2021M3E5E7021893]	National Research Foundation (NRF) of Korea(National Research Foundation of Korea)	We acknowledge support from the National Research Foundation (NRF) of Korea (2017R1A2B3002989 and 2021M3E5E7021893).	Alver BH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14648; Buscarlet M, 2014, BLOOD, V123, P1720, DOI 10.1182/blood-2013-02-483495; Cao DL, 1998, J BIOL CHEM, V273, P11429, DOI 10.1074/jbc.273.19.11429; Cheng BY, 2018, CANCER RES, V78, P2332, DOI 10.1158/0008-5472.CAN-17-2445; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Hu B, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12791; Jubierre L, 2016, ONCOGENE, V35, P5179, DOI 10.1038/onc.2016.50; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Mashtalir N, 2018, CELL, V175, P1272, DOI 10.1016/j.cell.2018.09.032; Mathur R, 2017, NAT GENET, V49, P296, DOI 10.1038/ng.3744; Michel BC, 2018, NAT CELL BIOL, V20, P1410, DOI 10.1038/s41556-018-0221-1; O'Neil NJ, 2017, NAT REV GENET, V18, P613, DOI 10.1038/nrg.2017.47; Saladi SV, 2017, CANCER CELL, V31, P35, DOI 10.1016/j.ccell.2016.12.001; Shlyueva D, 2014, NAT REV GENET, V15, P272, DOI 10.1038/nrg3682; Su B, 2015, HEPATOLOGY, V61, P585, DOI 10.1002/hep.27551; Sun XX, 2017, CANCER CELL, V32, P574, DOI 10.1016/j.ccell.2017.10.007; Wang AG, 2005, J HEPATOL, V43, P836, DOI 10.1016/j.jhep.2005.04.012; Wang P, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2289-3; Yang HD, 2019, HEPATOLOGY, V70, P1262, DOI 10.1002/hep.30657	19	6	5	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4652	4662		10.1038/s41388-021-01875-6	http://dx.doi.org/10.1038/s41388-021-01875-6		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34140644				2022-12-28	WOS:000662838900004
J	Goydel, RS; Rader, C				Goydel, Rebecca S.; Rader, Christoph			Antibody-based cancer therapy	ONCOGENE			English	Review							IMMUNOGENIC CELL-DEATH; IMMUNOTHERAPY; STRATEGIES; MOLECULES; ANTIGEN; SITE	Over the past 25 years, antibody therapeutics have emerged as clinically and commercially successful pharmaceuticals, rapidly approaching 100 Food and Drug Administration approvals with combined annual global sales exceeding $100 billion. Nearly half of the marketed antibody therapeutics are used in oncology. These antibody-based cancer therapies can be broken down into three categories based on their different mechanisms of action, i.e., (i) natural properties, (ii) engagement of cytotoxic T cells, and (iii) delivery of cytotoxic payloads. Both natural and engineered properties of the antibody molecule are founded on its highly stable and modular architecture. In this review we provide an overview and outlook of the rapidly evolving landscape of antibody-based cancer therapy.	[Goydel, Rebecca S.; Rader, Christoph] Scripps Res Inst, Dept Immunol & Microbiol, Jupiter, FL 92037 USA	Scripps Research Institute	Rader, C (corresponding author), Scripps Res Inst, Dept Immunol & Microbiol, Jupiter, FL 92037 USA.	crader@scripps.edu		Rader, Christoph/0000-0001-9955-3454	Klorfine Foundation; Frenchman's Creek Women for Cancer Research; National Institutes of Health [R01 CA174844, R01 CA181258, R01 CA204484, R21 CA229961]	Klorfine Foundation; Frenchman's Creek Women for Cancer Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We acknowledge support by predoctoral stipends from the Klorfine Foundation and the Frenchman's Creek Women for Cancer Research (to R.S.G.) and National Institutes of Health Grants R01 CA174844, R01 CA181258, R01 CA204484, and R21 CA229961 (to C.R.). We thank Dr. HaJeung Park from the X-Ray Crystallography Core of The Scripps Research Institute (Jupiter, FL) for contributing Fig. 1C.	Alfaleh MA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01986; Beck A, 2017, NAT REV DRUG DISCOV, V16, P315, DOI 10.1038/nrd.2016.268; Beerli RR, 2010, MABS-AUSTIN, V2, P365, DOI 10.4161/mabs.12187; Brerski RJ, 2016, CURR OPIN IMMUNOL, V40, P62, DOI 10.1016/j.coi.2016.03.002; Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y; Brinkmann U, 2017, MABS-AUSTIN, V9, P182, DOI 10.1080/19420862.2016.1268307; Clynes RA, 2019, ANNU REV MED, V70, P437, DOI 10.1146/annurev-med-062617-035821; Cotton AD, 2021, J AM CHEM SOC, V143, P593, DOI 10.1021/jacs.0c10008; Daher M, 2021, CANCER DISCOV, V11, P45, DOI 10.1158/2159-8290.CD-20-0556; Denkberg G, 2002, P NATL ACAD SCI USA, V99, P9421, DOI 10.1073/pnas.132285699; Desnoyers LR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006682; Dougan M, 2020, J CLIN INVEST, V130, P51, DOI 10.1172/JCI131194; Ellerman D, 2019, METHODS, V154, P102, DOI 10.1016/j.ymeth.2018.10.026; Feng MY, 2019, NAT REV CANCER, V19, P568, DOI 10.1038/s41568-019-0183-z; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Goydel RS, 2020, J BIOL CHEM, V295, P5995, DOI 10.1074/jbc.RA120.012791; Green DJ, 2017, CANCER RES, V77, P2191, DOI 10.1158/0008-5472.CAN-16-2523; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; Hodgins JJ, 2019, J CLIN INVEST, V129, P3499, DOI 10.1172/JCI129338; Hong MH, 2020, CANCER CELL, V38, P473, DOI 10.1016/j.ccell.2020.07.005; Hsiue EHC, 2021, SCIENCE, V371, P1009, DOI 10.1126/science.abc8697; Johnston RJ, 2019, NATURE, V574, P565, DOI 10.1038/s41586-019-1674-5; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kamata-Sakurai M, 2021, CANCER DISCOV, V11, P158, DOI 10.1158/2159-8290.CD-20-0328; Kaplon H, 2021, MABS-AUSTIN, V13, DOI 10.1080/19420862.2020.1860476; Kobayashi H, 2019, ACCOUNTS CHEM RES, V52, P2332, DOI 10.1021/acs.accounts.9b00273; Kraeber-Bodere F, 2003, CLIN CANCER RES, V9, p3973S; Kreitman RJ, 2011, CLIN CANCER RES, V17, P6398, DOI 10.1158/1078-0432.CCR-11-0487; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Labrijn AF, 2019, NAT REV DRUG DISCOV, V18, P585, DOI 10.1038/s41573-019-0028-1; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Lemery S, 2017, NEW ENGL J MED, V377, P1409, DOI 10.1056/NEJMp1709968; Liu RN, 2020, ANTIBODIES, V9, DOI 10.3390/antib9040064; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Mayes PA, 2018, NAT REV DRUG DISCOV, V17, P509, DOI 10.1038/nrd.2018.75; Mazor R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01261; Mitsunaga M, 2011, NAT MED, V17, P1685, DOI 10.1038/nm.2554; Muller P, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4925; Neri D, 2016, CURR OPIN IMMUNOL, V40, P96, DOI 10.1016/j.coi.2016.03.006; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Rader C, 2020, CURR OPIN BIOTECH, V65, P9, DOI 10.1016/j.copbio.2019.11.020; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Rosenberg SA, 2014, J IMMUNOL, V192, P5451, DOI 10.4049/jimmunol.1490019; Sadelain M, 2017, NATURE, V545, P423, DOI 10.1038/nature22395; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Scott DE, 2016, NAT REV DRUG DISCOV, V15, P533, DOI 10.1038/nrd.2016.29; Srivastava S, 2021, CANCER CELL, V39, P193, DOI 10.1016/j.ccell.2020.11.005; Stadtmauer EA, 2020, SCIENCE, V367, P1001, DOI 10.1126/science.aba7365; Walsh SJ, 2021, CHEM SOC REV, V50, P1305, DOI 10.1039/d0cs00310g; Wang LX, 2019, ANNU REV BIOCHEM, V88, P433, DOI 10.1146/annurev-biochem-062917-012911; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Wu XF, 2019, METHODS, V154, P3, DOI 10.1016/j.ymeth.2018.08.010; Zheng SM, 2016, MABS-AUSTIN, V8, P551, DOI 10.1080/19420862.2015.1136762	53	17	17	1	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3655	3664		10.1038/s41388-021-01811-8	http://dx.doi.org/10.1038/s41388-021-01811-8		MAY 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33947958	Green Accepted			2022-12-28	WOS:000647099200002
J	Wei, YY; Lu, W; Yu, YH; Zhai, YM; Guo, HZ; Yang, SX; Zhao, C; Zhang, YJ; Liu, JL; Liu, YH; Fei, J; Shi, J				Wei, Yanyu; Lu, Wei; Yu, Yehua; Zhai, Yuanmei; Guo, Hezhou; Yang, Shaoxin; Zhao, Chong; Zhang, Yanjie; Liu, Jiali; Liu, Yuhui; Fei, Jian; Shi, Jun			miR-29c&b2 encourage extramedullary infiltration resulting in the poor prognosis of acute myeloid leukemia	ONCOGENE			English	Article							MICRORNA-29 FAMILY; EXPRESSION; GROWTH; AML; PROMOTES; CANCER; IDENTIFICATION; ABNORMALITIES; DIAGNOSIS; INVASION	Extramedullary infiltration (EMI), as a concomitant symptom of acute myeloid leukemia (AML), is associated with low complete remission and poor prognosis in AML. However, the mechanism of EMI remains indistinct. Clinical trials showed that increased miR-29s were associated with a poor overall survival in AML [14]. Nevertheless, they were proved to work as tumor suppressor genes by encouraging apoptosis and inhibiting proliferation in vitro. These contradictory results led us to the hypothesis that miR-29s may play a notable role in the prognosis of AML rather than leukemogenesis. Thus, we explored the specimens of AML patients and addressed this issue into miR-29c&b2 knockout mice. As a result, a poor overall survival and invasive blast cells were observed in high miR-29c&b2-expression patients, and the wildtype mice presented a shorter survival with heavier leukemia infiltration in extramedullary organs. Subsequently, we found that the miR-29c&b2 inside leukemia cells promoted EMI, but not the one in the microenvironment. The analysis of signal pathway revealed that miR-29c&b2 could target HMG-box transcription factor 1 (Hbp1) directly, then reduced Hbp1 bound to the promoter of non-muscle myosin IIB (Myh10) as a transcript inhibitor. Thus, increased Myh10 encouraged the migration of leukemia cells. Accordingly, AML patients with EMI were confirmed to have high miR- 29c&b2 and MYH10 with low HBP1. Therefore, we identify that miR-29c&b2 contribute to the poor prognosis of AML patients by promoting EMI, and related genes analyses are prospectively feasible in assessment of AML outcome.	[Wei, Yanyu; Lu, Wei; Yu, Yehua; Guo, Hezhou; Yang, Shaoxin; Zhao, Chong; Zhang, Yanjie; Liu, Jiali; Shi, Jun] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Hematol, Shanghai, Peoples R China; [Zhai, Yuanmei] Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Dept Hematol, Shanghai, Peoples R China; [Liu, Yuhui; Fei, Jian] Tongji Univ, Sch Life Sci & Technol, Shanghai, Peoples R China; [Fei, Jian] SMOC, Shanghai Engn Res Ctr Model Organisms, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Tongji University	Shi, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Hematol, Shanghai, Peoples R China.; Fei, J (corresponding author), Tongji Univ, Sch Life Sci & Technol, Shanghai, Peoples R China.; Fei, J (corresponding author), SMOC, Shanghai Engn Res Ctr Model Organisms, Shanghai, Peoples R China.	jfei@tongji.edu.cn; junshi@sjtu.edu.cn		Liu, Yuhui/0000-0002-5952-8948	National Natural Science Foundation of China [81870132, 81261120568]; Science and Technology Commission of Shanghai Municipality [18DZ2290700,18DZ2293500]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	This study was supported by the National Natural Science Foundation of China (No. 81870132, 81261120568) and the Science and Technology Commission of Shanghai Municipality (18DZ2290700,18DZ2293500).	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bollaert E, 2019, CELL MOL LIFE SCI, V76, P1529, DOI 10.1007/s00018-019-03012-9; Butrym A, 2016, ONCOTARGET, V7, P30250, DOI 10.18632/oncotarget.7172; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Chang H, 2004, LEUKEMIA RES, V28, P1007, DOI 10.1016/j.leukres.2004.01.006; Chen W, 1996, J VIROL, V70, P7773, DOI 10.1128/JVI.70.11.7773-7782.1996; Chen X, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160576; Cochrane DR, 2012, MOL CELL ENDOCRINOL, V355, P15, DOI 10.1016/j.mce.2011.12.020; DAWSON PJ, 1963, CANCER RES, V23, P349; DEHARVEN E, 1960, J BIOPHYS BIOCHEM CY, V7, P747, DOI 10.1083/jcb.7.4.747; Dohner H, 2017, BLOOD, V129, P424, DOI 10.1182/blood-2016-08-733196; Estey EH, 2018, AM J HEMATOL, V93, P1267, DOI 10.1002/ajh.25214; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Garzon R, 2009, BLOOD, V114, P5331, DOI 10.1182/blood-2009-03-211938; Gong JN, 2014, CELL DEATH DIFFER, V21, P100, DOI 10.1038/cdd.2013.133; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Gutzman JH, 2015, DEV BIOL, V397, P103, DOI 10.1016/j.ydbio.2014.10.017; Han YC, 2010, J EXP MED, V207, P475, DOI 10.1084/jem.20090831; Hu GH, 2020, CL LYMPH MYELOM LEUK, V20, pE813, DOI 10.1016/j.clml.2020.06.009; Hugo HJ, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0880-z; Junge A, 2018, HEMATOL ONCOL, V36, P576, DOI 10.1002/hon.2516; Kiani FA, 2014, P NATL ACAD SCI USA, V111, pE2947, DOI 10.1073/pnas.1401862111; Kobayashi R, 2007, PEDIATR BLOOD CANCER, V48, P393, DOI 10.1002/pbc.20824; Kwon JJ, 2019, MOL THER-ONCOLYTICS, V12, P173, DOI 10.1016/j.omto.2018.12.011; Lackie, 1986, CRAWLING MOVEMENT CE, P145; Le Goff C, 2011, HUM MOL GENET, V20, pR163, DOI 10.1093/hmg/ddr361; Li Y, 2017, CANCER LETT, V397, P111, DOI 10.1016/j.canlet.2017.03.032; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Padmanaban V, 2019, NATURE, V573, P439, DOI 10.1038/s41586-019-1526-3; Patel SS, 2018, BLOOD, V131, P2816, DOI 10.1182/blood-2018-01-828467; Paulson KE, 2007, CANCER RES, V67, P6136, DOI 10.1158/0008-5472.CAN-07-0567; Qu XQ, 2018, ONCOL LETT, V16, P853, DOI 10.3892/ol.2018.8735; Ridge LA, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007068; Robaina MC, 2015, EXP MOL PATHOL, V98, P200, DOI 10.1016/j.yexmp.2015.03.006; Robert-Paganin J, 2020, CHEM REV, V120, P5, DOI 10.1021/acs.chemrev.9b00264; Rostas JW, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-200; Su CY, 2018, CANCER MED-US, V7, P2485, DOI 10.1002/cam4.1294; Sun R, 2018, CANCER RES, V78, P5274, DOI 10.1158/0008-5472.CAN-17-3647; Sun XJ, 2015, CELL PHYSIOL BIOCHEM, V37, P707, DOI 10.1159/000430389; Sun XH, 2015, MOL CELL BIOCHEM, V403, P139, DOI 10.1007/s11010-015-2344-z; THIELE J, 1985, PATHOL RES PRACT, V179, P328, DOI 10.1016/S0344-0338(85)80142-4; VIADANA E, 1978, ONCOLOGY, V35, P87, DOI 10.1159/000225262; Wang Y, 2018, MED SCI MONITOR, V24, P9110, DOI 10.12659/MSM.911523; Wu H, 2016, GUT, V65, P1850, DOI 10.1136/gutjnl-2014-308430; Xu J, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0337-3; XU W, 2017, NAT COMMUN, V8; Yan ZY, 2014, FEBS LETT, V588, P3038, DOI 10.1016/j.febslet.2014.06.017; Yang ZR, 2013, BIOCHEM BIOPH RES CO, V434, P143, DOI 10.1016/j.bbrc.2013.03.054; Zhao JJ, 2010, BLOOD, V115, P2630, DOI 10.1182/blood-2009-09-243147; Zhou T, 2019, INT CONF COMP INFO, P1, DOI 10.1080/08880018.2019.1683107; Zhu CL, 2013, CLIN BIOCHEM, V46, P49, DOI 10.1016/j.clinbiochem.2012.09.002; Zhu JQ, 2015, CANCER RES, V75, P1580, DOI 10.1158/0008-5472.CAN-14-1027; Zhu LH, 2015, GENET MOL RES, V14, P6028, DOI 10.4238/2015.June.1.20; 刘景华, 2014, [中国实用内科杂志, Chinese Journal of Practical Internal Medicine], V34, P1112	54	0	0	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3434	3448		10.1038/s41388-021-01775-9	http://dx.doi.org/10.1038/s41388-021-01775-9		APR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33888868				2022-12-28	WOS:000642379300001
J	Ali, R; Alblihy, A; Miligy, IM; Alabdullah, ML; Alsaleem, M; Toss, MS; Algethami, M; Abdel-Fatah, T; Moseley, P; Chan, S; Mongan, NP; Narayan, S; Rakha, EA; Madhusudan, S				Ali, Reem; Alblihy, Adel; Miligy, Islam M.; Alabdullah, Muslim L.; Alsaleem, Mansour; Toss, Michael S.; Algethami, Mashael; Abdel-Fatah, Tarek; Moseley, Paul; Chan, Stephen; Mongan, Nigel P.; Narayan, Satya; Rakha, Emad A.; Madhusudan, Srinivasan			Molecular disruption of DNA polymerase beta for platinum sensitisation and synthetic lethality in epithelial ovarian cancers	ONCOGENE			English	Article							BASE EXCISION-REPAIR; POLY(ADP-RIBOSE) PAR POLYMER; GLYCOHYDROLASE PARG; CELLS; MECHANISMS; NAD(+); REPLICATION; DEFICIENT; PATHWAYS; DAMAGE	Targeting PARP1 [Poly(ADP-Ribose) Polymerase 1] for synthetic lethality is a new strategy for BRCA germ-line mutated or platinum sensitive ovarian cancers. However, not all patients respond due to intrinsic or acquired resistance to PARP1 inhibitor. Development of alternative synthetic lethality approaches is a high priority. DNA polymerase beta (Pol beta), a critical player in base excision repair (BER), interacts with PARP1 during DNA repair. Here we show that pol beta deficiency is a predictor of platinum sensitivity in human ovarian tumours. Pol beta depletion not only increased platinum sensitivity but also reduced invasion, migration and impaired EMT (epithelial to mesenchymal transition) of ovarian cancer cells. Pol beta small molecular inhibitors (Pamoic acid and NSC666719) were selectively toxic to BRCA2 deficient cells and associated with double-strand breaks (DSB) accumulation, cell cycle arrest and increased apoptosis. Interestingly, PARG [Poly(ADP-Ribose) Glycohydrolase] inhibitor (PDD00017273) [but not PARP1 inhibitor (Olaparib)] was synthetically lethal in pol beta deficient cells. Selective toxicity to PDD00017273 was associated with poly (ADP-ribose) accumulation, reduced nicotinamide adenine dinucleotide (NAD(+)) level, DSB accumulation, cell cycle arrest and increased apoptosis. In human tumours, pol beta-PARG co-expression adversely impacted survival in patients. Our data provide evidence that pol beta targeting is a novel strategy and warrants further pharmaceutical development in epithelial ovarian cancers.	[Ali, Reem; Alblihy, Adel; Alabdullah, Muslim L.; Algethami, Mashael; Madhusudan, Srinivasan] Univ Nottingham, Sch Med, Div Canc & Stem Cells, Translat Oncol, Nottingham, England; [Alblihy, Adel] King Fahad Secur Coll KFSC, Med Ctr, Riyadh, Saudi Arabia; [Miligy, Islam M.; Alabdullah, Muslim L.; Alsaleem, Mansour; Toss, Michael S.; Rakha, Emad A.] Univ Nottingham, Acad Pathol, Div Canc & Stem Cells, Sch Med, Nottingham, England; [Miligy, Islam M.] Menoufia Univ, Dept Pathol, Fac Med, Menoufia, Egypt; [Abdel-Fatah, Tarek; Moseley, Paul; Chan, Stephen; Madhusudan, Srinivasan] Nottingham Univ Hosp, Dept Oncol, Nottingham, England; [Mongan, Nigel P.] Univ Nottingham, Ctr Canc Sci, Fac Med & Hlth Sci, Sutton Bonington Campus, Loughborough, Leics, England; [Mongan, Nigel P.] Weill Cornell Med, Dept Pharmacol, New York, NY USA; [Narayan, Satya] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL USA	University of Nottingham; University of Nottingham; Egyptian Knowledge Bank (EKB); Menofia University; Nottingham University Hospital NHS Trust; University of Nottingham; University of Nottingham; Cornell University; State University System of Florida; University of Florida	Madhusudan, S (corresponding author), Univ Nottingham, Sch Med, Div Canc & Stem Cells, Translat Oncol, Nottingham, England.; Madhusudan, S (corresponding author), Nottingham Univ Hosp, Dept Oncol, Nottingham, England.	srinivasan.madhusudan@nottingham.ac.uk		Madhusudan, Srinivasan/0000-0002-5354-5480; Mongan, Nigel/0000-0001-5438-1126	Naaz-Coker Ovarian Cancer Fellowship, University of Nottingham, UK	Naaz-Coker Ovarian Cancer Fellowship, University of Nottingham, UK	Research in Madhusudan lab is supported by Naaz-Coker Ovarian Cancer Fellowship, University of Nottingham, UK.	Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Beaufort CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103988; Blaschuk OW, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0039; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Croteau DL, 2017, CELL CYCLE, V16, P491, DOI 10.1080/15384101.2017.1285631; D'Andrea AD, 2018, DNA REPAIR, V71, P172, DOI 10.1016/j.dnarep.2018.08.021; DELFINI C, 1985, P NATL ACAD SCI USA, V82, P2220, DOI 10.1073/pnas.82.8.2220; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; Dianov GL, 2013, NUCLEIC ACIDS RES, V41, P3483, DOI 10.1093/nar/gkt076; Dong ZM, 2006, DIS ESOPHAGUS, V19, P172, DOI 10.1111/j.1442-2050.2006.00560.x; Farina AR, 2014, CANCERS, V6, P240, DOI 10.3390/cancers6010240; Fathers C, 2012, CELL CYCLE, V11, P990, DOI 10.4161/cc.11.5.19482; Fisher AEO, 2007, MOL CELL BIOL, V27, P5597, DOI 10.1128/MCB.02248-06; Fouquerel E, 2014, DNA REPAIR, V23, P27, DOI 10.1016/j.dnarep.2014.09.004; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gogola E, 2018, CANCER CELL, V33, P1078, DOI 10.1016/j.ccell.2018.05.008; Gravells P, 2017, DNA REPAIR, V52, P81, DOI 10.1016/j.dnarep.2017.02.010; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Hazan C, 2008, BMC STRUCT BIOL, V8, DOI 10.1186/1472-6807-8-22; Iwatsuki M, 2009, J SURG ONCOL, V100, P261, DOI 10.1002/jso.21275; Jaiswal AS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123808; Jaiswal AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016691; Jaiswal AS, 2009, MOL CANCER RES, V7, P1973, DOI 10.1158/1541-7786.MCR-09-0309; Khanra K, 2012, CANCER BIOMARK, V11, P155, DOI 10.3233/CBM-2012-00275; Koh DW, 2005, CELL CYCLE, V4, P397, DOI 10.4161/cc.4.3.1559; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; Lombard DB, 2009, AGING-US, V1, P12, DOI 10.18632/aging.100014; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Loret N, 2019, CANCERS, V11, DOI 10.3390/cancers11060838; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Min W, 2009, FRONT BIOSCI-LANDMRK, V14, P1619, DOI 10.2741/3329; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Moore K, 2018, NEW ENGL J MED, V379, P2495, DOI 10.1056/NEJMoa1810858; Moustakas A, 2016, J CLIN MED, V5, DOI 10.3390/jcm5070063; Oughtred R, 2019, NUCLEIC ACIDS RES, V47, pD529, DOI 10.1093/nar/gky1079; Parlanti E, 2007, NUCLEIC ACIDS RES, V35, P1569, DOI 10.1093/nar/gkl1159; Pascal JM, 2015, DNA REPAIR, V32, P10, DOI 10.1016/j.dnarep.2015.04.008; Pillay N, 2019, CANCER CELL, V35, P519, DOI 10.1016/j.ccell.2019.02.004; Pu H, 2014, CARCINOGENESIS, V35, P2592, DOI 10.1093/carcin/bgu183; Raudenska M., 2019, SCI REP-UK, V9, DOI [10.1038/s41598-018-38199-7, DOI 10.1038/S41598-018-38199-7]; Raudenska M, 2019, METALLOMICS, V11, P1182, DOI 10.1039/c9mt00049f; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Sobol RW, 2001, PROG NUCLEIC ACID RE, V68, P57; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Starcevic D, 2004, CELL CYCLE, V3, P998; Sweasy JB, 2003, PROG NUCLEIC ACID RE, V73, P137, DOI 10.1016/S0079-6603(03)01005-5; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/S1470-2045(16)30559-9, 10.1016/s1470-2045(16)30559-9]; Weyemi U, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10711; Wong SHM, 2018, CRIT REV ONCOL HEMAT, V121, P11, DOI 10.1016/j.critrevonc.2017.11.010; Yang J, 2010, ONCOGENE, V29, P463, DOI 10.1038/onc.2009.327; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103	55	6	6	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2496	2508		10.1038/s41388-021-01710-y	http://dx.doi.org/10.1038/s41388-021-01710-y		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33674744	hybrid, Green Published			2022-12-28	WOS:000625607100004
J	Ma, RR; Zhang, H; Chen, HF; Zhang, GH; Tian, YR; Gao, P				Ma, Ran-Ran; Zhang, Hui; Chen, Hong-Fang; Zhang, Guo-Hao; Tian, Ya-Ru; Gao, Peng			MiR-19a/miR-96-mediated low expression of KIF26A suppresses metastasis by regulating FAK pathway in gastric cancer	ONCOGENE			English	Article								Gastric cancer (GC) is one of the most common malignant neoplasms. Invasion and metastasis are the main causes of GC-related deaths. Recently, kinesins were discovered to be involved in tumor development. The aim of this study was to elucidate the roles of kinesin superfamily protein 26A (KIF26A) in GC and its underlying molecular mechanism in regulating tumor invasion and metastasis. Using real-time quantitative polymerase chain reaction (qPCR) and immunohistochemistry (IHC), we showed that KIF26A expression was lower in GC tissues without lymph node metastasis (LNM) than in nontumorous gastric mucosa, and even lower in GC tissues with LNM than in GC tissues without LNM. Functional experiments showed that KIF26A inhibited migration and invasion of GC cells. We further identified focal-adhesion kinase (FAK), phosphatidylinositol 3-kinase regulatory subunit alpha (PI3KR1), VAV3, Rac1 and p21-activated kinase 2, and beta-PAK (PAK3) as downstream effectors of KIF26A in the focal-adhesion pathway, and we found that KIF26A could regulate FAK mRNA expression through inhibiting c-MYC by MAPK pathway. c-MYC could bind to the promoter of FAK and activate FAK transcription. Moreover, we found that KIF26A-mediated inactivation of the focal-adhesion pathway could reduce the occurrence of the epithelial-to-mesenchymal transition (EMT) by increasing expression of E-cadherin and reducing that of Snail. Luciferase assays and Western blotting revealed that miR-19a and miR-96 negatively regulate KIF26A. Finally, we found that decreased expression of KIF26A has been positively correlated with histological differentiation, Lauren classification, LNM, distal metastasis, and clinical stage, as well as poor survival in patients with GC. These data indicate that KIF26A could inhibit GC migration and invasion by regulating the focal-adhesion pathway and repressing the occurrence of EMT.	[Ma, Ran-Ran; Zhang, Hui; Chen, Hong-Fang; Zhang, Guo-Hao; Tian, Ya-Ru; Gao, Peng] Shandong Univ, Sch Basic Med Sci, Minist Educ, Key Lab Expt Teratol, Jinan, Peoples R China; [Ma, Ran-Ran; Zhang, Hui; Chen, Hong-Fang; Zhang, Guo-Hao; Tian, Ya-Ru; Gao, Peng] Shandong Univ, Sch Basic Med Sci, Dept Pathol, Jinan, Peoples R China; [Ma, Ran-Ran; Zhang, Hui; Gao, Peng] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan, Peoples R China; [Chen, Hong-Fang] Yidu Cent Hosp Weifang, Dept Pathol, Weifang, Peoples R China	Shandong University; Shandong University; Shandong University	Gao, P (corresponding author), Shandong Univ, Sch Basic Med Sci, Minist Educ, Key Lab Expt Teratol, Jinan, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Pathol, Jinan, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Qilu Hosp, Dept Pathol, Jinan, Peoples R China.	gaopeng@sdu.edu.cn			National Natural Science Foundation of China [81872362, 82072665]; Taishan Scholars Program of Shandong Province [ts201511096]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province	This study was supported by the National Natural Science Foundation of China (Grant No. 81872362 and 82072665) and the Taishan Scholars Program of Shandong Province (Grant No. ts201511096).	Akhshi TK, 2014, CYTOSKELETON, V71, P1, DOI 10.1002/cm.21150; Avizienyte E, 2005, CURR OPIN CELL BIOL, V17, P542, DOI 10.1016/j.ceb.2005.08.007; Bachmann A, 2015, BIOCHEM SOC T, V43, P79, DOI 10.1042/BST20140280; Baquero P, 2016, MOL CARCINOGEN, V55, P1639, DOI 10.1002/mc.22415; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Castillo A, 2007, CANCER RES, V67, P10138, DOI 10.1158/0008-5472.CAN-07-0326; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chandrasekaran G, 2015, BRIT J CANCER, V113, P693, DOI 10.1038/bjc.2015.264; Chen X, 2016, J PATHOL, V239, P459, DOI 10.1002/path.4743; Corson TW, 2006, INT J CANCER, V119, P1088, DOI 10.1002/ijc.21954; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Gao P, 2013, ONCOGENE, V32, P491, DOI 10.1038/onc.2012.61; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hippo Y, 2002, CANCER RES, V62, P233; Ho JN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108248; Hung PF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061664; Korb T, 2004, EXP CELL RES, V299, P236, DOI 10.1016/j.yexcr.2004.06.001; Lawrence CJ, 2004, J CELL BIOL, V167, P19, DOI 10.1083/jcb.200408113; Li PF, 2014, WORLD J GASTROENTERO, V20, P5411, DOI 10.3748/wjg.v20.i18.5411; Lin YW, 2014, CURR PHARM DESIGN, V20, P1698, DOI 10.2174/13816128113199990512; Liu XR, 2013, CANCER SCI, V104, P651, DOI 10.1111/cas.12138; Magnelli L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082893; Miki H, 2005, TRENDS CELL BIOL, V15, P467, DOI 10.1016/j.tcb.2005.07.006; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Muroyama A, 2017, DEVELOPMENT, V144, P3012, DOI 10.1242/dev.153171; Niwa S, 2015, ANAT SCI INT, V90, P1, DOI 10.1007/s12565-014-0259-5; Petit V, 2000, BIOL CELL, V92, P477, DOI 10.1016/S0248-4900(00)01101-1; Pharoah PDP, 2001, GASTROENTEROLOGY, V121, P1348, DOI 10.1053/gast.2001.29611; Qin S, 2013, ASIAN PAC J CANCER P, V14, P835, DOI 10.7314/APJCP.2013.14.2.835; Qu YP, 2013, CLIN CHIM ACTA, V424, P53, DOI 10.1016/j.cca.2013.05.002; Rath O, 2012, NAT REV CANCER, V12, P527, DOI 10.1038/nrc3310; Serrels A, 2011, CELL ADHES MIGR, V5, P360, DOI 10.4161/cam.5.4.17290; Stangel D, 2015, J SURG RES, V197, P91, DOI 10.1016/j.jss.2015.03.070; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Volkov V A, 2013, Ross Fiziol Zh Im I M Sechenova, V99, P153; Wang L, 2018, CELL REP, V24, P2894, DOI 10.1016/j.celrep.2018.05.075; Wang Q, 2013, CANCER EPIDEMIOL, V37, P79, DOI 10.1016/j.canep.2012.08.011; Wang TH, 2016, MOL CARCINOGEN, V55, P366, DOI 10.1002/mc.22286; Wu Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.110; Yang L, 2006, WORLD J GASTROENTERO, V12, P17, DOI 10.3748/wjg.v12.i1.17; Yang T, 2013, CANCER SCI, V104, P552, DOI 10.1111/cas.12128; Yu Y, 2010, CANCER-AM CANCER SOC, V116, P5150, DOI 10.1002/cncr.25461; Zhang H, 2017, ONCOGENE, V36, P5609, DOI 10.1038/onc.2017.163; Zhang JF, 2014, ONCOL REP, V31, P1357, DOI 10.3892/or.2013.2934; Zhou RY, 2009, CELL, V139, P802, DOI 10.1016/j.cell.2009.10.023; Zhu HB, 2013, BIOCHEM BIOPH RES CO, V438, P97, DOI 10.1016/j.bbrc.2013.07.032; Zou JX, 2014, MOL CANCER RES, V12, P539, DOI 10.1158/1541-7786.MCR-13-0459	48	7	8	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2524	2538		10.1038/s41388-020-01610-7	http://dx.doi.org/10.1038/s41388-020-01610-7		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33674746				2022-12-28	WOS:000625607100001
J	Yamaguchi, J; Kokuryo, T; Yokoyama, Y; Ebata, T; Ochiai, Y; Nagino, M				Yamaguchi, Junpei; Kokuryo, Toshio; Yokoyama, Yukihiro; Ebata, Tomoki; Ochiai, Yosuke; Nagino, Masato			Premalignant pancreatic cells seed stealth metastasis in distant organs in mice	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; DISSEMINATED TUMOR-CELLS; EARLY DISSEMINATION; CANCER; MECHANISMS; EXPRESSION; INVASION; DORMANCY	Recent findings suggest that the dissemination of tumor cells occurs at the early stage of breast and pancreatic carcinogenesis, which is known as early dissemination. The evidence of early dissemination has been demonstrated predominantly in the bloodstream and bone marrow; however, limited evidence has revealed the existence and behavior of disseminated cells in distant organs. Here, we show that premalignant pancreatic cells seed distant stealth metastasis that eventually develops into manifest metastasis. By analyzing lineage-labeled pancreatic cancer mouse models (KPCT/TFF1KO; Pdx1-Cre/LSL-KRAS(G1)(2D)/LSL-p53(R172H)/LSL-tdTomato/TFF1KO), we found that premalignant pancreatic cells, rather than mature malignant cells, were prone to enter the bloodstream and reside in the bone marrow, liver, and lung. While these metastatic cells exhibited the characteristics of the cells of host organs and did not behave as malignant cells, they underwent malignant transformation and formed distinct tumors. Surprisingly, the manifestation of distant metastasis occurred even before tumor development in the primary site. Our data revealed that disseminated premalignant cells reside stealthily in distant organs and evolve in parallel with the progression of the primary tumor. These observations suggest that we must rebuild a therapeutic strategy for metastatic pancreatic cancer.	[Yamaguchi, Junpei; Kokuryo, Toshio; Yokoyama, Yukihiro; Ebata, Tomoki; Ochiai, Yosuke; Nagino, Masato] Nagoya Univ, Dept Surg, Div Surg Oncol, Grad Sch Med,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668560, Japan	Nagoya University	Yamaguchi, J (corresponding author), Nagoya Univ, Dept Surg, Div Surg Oncol, Grad Sch Med,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668560, Japan.	jumpei@med.nagoya-u.ac.jp	Nagino, Masato/I-7342-2014	Yamaguchi, Junpei/0000-0002-5892-5271	Japan Society for the Promotion of Science (JSPS) [17K10695, 20H03751]	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by the Japan Society for the Promotion of Science (JSPS) and Grants-in-Aid for Scientific Research (KAKENHI) (grant number 17K10695 and 20H03751).	Ao Z, 2015, CANCER RES, V75, P4681, DOI 10.1158/0008-5472.CAN-15-1633; Banys M, 2012, BREAST CANCER RES TR, V131, P801, DOI 10.1007/s10549-011-1478-2; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Clawson GA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184451; Fizazi K, 2015, ANN ONCOL, V26, pV133, DOI 10.1093/annonc/mdv305; Gast CE, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat7828; Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029; Greco FA, 2009, SEMIN ONCOL, V36, P6, DOI 10.1053/j.seminoncol.2008.10.007; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Kang YB, 2013, CANCER CELL, V23, P573, DOI 10.1016/j.ccr.2013.04.017; Klein CA, 2002, LANCET, V360, P683, DOI 10.1016/S0140-6736(02)09838-0; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Kurashige M, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0137-0; Liu QF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61487-0; Min S, 2013, CANCER GENE THER, V20, P379, DOI 10.1038/cgt.2013.36; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Ochiai Y, 2020, HEPATOLOGY, V72, P503, DOI 10.1002/hep.31039; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; Rhim AD, 2014, GASTROENTEROLOGY, V146, P647, DOI 10.1053/j.gastro.2013.12.007; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Sanger N, 2011, INT J CANCER, V129, P2522, DOI 10.1002/ijc.25895; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Soutto M, 2015, GUT, V64, P1028, DOI 10.1136/gutjnl-2014-307191; Sunagawa M, 2017, PANCREATOLOGY, V17, P782, DOI 10.1016/j.pan.2017.07.188; Sutton TL, 2019, CELL MOL GASTROENTER, V8, P595, DOI 10.1016/j.jcmgh.2019.07.002; Wang LD, 2015, GENE DEV, V29, P171, DOI 10.1101/gad.253591.114; Yamaguchi J, 2018, J CLIN INVEST, V128, P3619, DOI 10.1172/JCI97755; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010	32	3	3	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2273	2284		10.1038/s41388-021-01706-8	http://dx.doi.org/10.1038/s41388-021-01706-8		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33649537				2022-12-28	WOS:000623739900003
J	Bai, J; Yokomizo-Nakano, T; Kubota, S; Sun, YQ; Kanai, A; Iimori, M; Harada, H; Iwama, A; Sashida, G				Bai, Jie; Yokomizo-Nakano, Takako; Kubota, Sho; Sun, Yuqi; Kanai, Akinori; Iimori, Mihoko; Harada, Hironori; Iwama, Atsushi; Sashida, Goro			Overexpression of Hmga2 activates Igf2bp2 and remodels transcriptional program of Tet2-deficient stem cells in myeloid transformation	ONCOGENE			English	Article							SELF-RENEWAL; MYELOFIBROSIS; GENE; EZH2; MOUSE; PATHOGENESIS; MUTATIONS; PROTEINS; PROMOTES; BINDING	High Mobility Group AT-hook 2 (HMGA2) is a chromatin modifier and its overexpression has been found in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Level of Hmga2 expression is fine-tuned by Lin28b-Let-7 axis and Polycomb Repressive Complex 2, in which deletion of Ezh2 leads to activation of Hmga2 expression in hematopoietic stem cells. To elucidate the mechanisms by which the overexpression of HMGA2 helps transformation of stem cells harboring a driver mutation of TET2, we generated an Hmga2-expressing Tet2-deficient mouse model showing the progressive phenotypes of MDS and AML. The overexpression of Hmga2 remodeled the transcriptional program of Tet2-deficient stem and progenitor cells, leading to the impaired differentiation of myeloid cells. Furthermore, Hmga2 was bound to a proximal region of Igf2bp2 oncogene, and activated its transcription, leading to enhancing self-renewal of Tet2-deficient stem cells that was suppressed by inhibition of the DNA binding of Hmga2. These combinatory effects on the transcriptional program and cellular function were not redundant to those in Tet2-deficient cells. The present results elucidate that Hmga2 targets key oncogenic pathways during the transformation and highlight the Hmga2-Igf2bp2 axis as a potential target for therapeutic intervention.	[Bai, Jie; Yokomizo-Nakano, Takako; Kubota, Sho; Sun, Yuqi; Iimori, Mihoko; Sashida, Goro] Kumamoto Univ, Int Res Ctr Med Sci IRCMS, Lab Transcript Regulat Leukemogenesis, Kumamoto, Japan; [Kanai, Akinori] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Oncol, Hiroshima, Japan; [Harada, Hironori] Tokyo Univ Pharm & Life Sci, Lab Oncol, Tokyo, Japan; [Iwama, Atsushi] Univ Tokyo, Ctr Stem Cell Biol & Regenerat Med, Inst Med Sci, Div Stem Cell & Mol Med, Tokyo, Japan	Kumamoto University; Hiroshima University; Tokyo University of Pharmacy & Life Sciences; University of Tokyo	Sashida, G (corresponding author), Kumamoto Univ, Int Res Ctr Med Sci IRCMS, Lab Transcript Regulat Leukemogenesis, Kumamoto, Japan.	sashidag@kumamoto-u.ac.jp	Sashida, Goro/N-5259-2014	Sashida, Goro/0000-0003-2318-5987; Kubota, Sho/0000-0001-6119-1259	Daiichi Sankyo Foundation of Life Science; Uehara Memorial Foundation; Princess Takamatsu Cancer Research Fund; Japanese Society of Hematology; International Joint Usage/Research Center, the Institute of Medical Science, the University of Tokyo; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [16KT0113, 18H02842, 19K22640, 19K08842]	Daiichi Sankyo Foundation of Life Science; Uehara Memorial Foundation(Uehara Memorial Foundation); Princess Takamatsu Cancer Research Fund; Japanese Society of Hematology; International Joint Usage/Research Center, the Institute of Medical Science, the University of Tokyo; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The authors thank the members of the Sashida Laboratory for their discussions during the preparation of this manuscript and Mr. Shinji Kudoh and Dr. Takaaki Ito for their technical help. This work was supported in part by a grant from the Daiichi Sankyo Foundation of Life Science (to GS), the Uehara Memorial Foundation (to GS), the Princess Takamatsu Cancer Research Fund (to GS), the Japanese Society of Hematology (to GS), International Joint Usage/Research Center, the Institute of Medical Science, the University of Tokyo (to GS), and Grants-in-Aid for Scientific Research (16KT0113, 18H02842, 19K22640 and 19K08842) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.	Abdel-Wahab O, 2013, J EXP MED, V210, P2641, DOI 10.1084/jem.20131141; Cabezas-Wallscheid N, 2014, CELL STEM CELL, V15, P507, DOI 10.1016/j.stem.2014.07.005; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; Cleynen I, 2007, MOL CANCER RES, V5, P363, DOI 10.1158/1541-7786.MCR-06-0331; Copley MR, 2013, NAT CELL BIOL, V15, P916, DOI 10.1038/ncb2783; Dai N, 2017, ELIFE, V6, DOI [10.7554/eLife.27155.001, 10.7554/eLife.27155]; Degrauwe N, 2016, CELL REP, V15, P1634, DOI 10.1016/j.celrep.2016.04.086; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Dutta A, 2017, BLOOD, V130, P920, DOI 10.1182/blood-2016-12-757344; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Guglielmelli P, 2007, STEM CELLS, V25, P165, DOI 10.1634/stemcells.2006-0351; Hasegawa N, 2017, LEUKEMIA, V31, P861, DOI 10.1038/leu.2016.268; He X, 2018, CELL PHYSIOL BIOCHEM, V51, P1945, DOI 10.1159/000495719; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Kishi Y, 2012, NAT NEUROSCI, V15, P1127, DOI 10.1038/nn.3165; Marquis M, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0103-6; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; Muto T, 2013, J EXP MED, V210, P2627, DOI 10.1084/jem.20131144; Nimer SD, 2008, BLOOD, V111, P4841, DOI 10.1182/blood-2007-08-078139; Nishino J, 2008, CELL, V135, P227, DOI 10.1016/j.cell.2008.09.017; Oguro H, 2012, J EXP MED, V209, P445, DOI 10.1084/jem.20111709; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Oshima M, 2016, EXP HEMATOL, V44, P282, DOI 10.1016/j.exphem.2015.12.009; Pellagatti A, 2010, LEUKEMIA, V24, P756, DOI 10.1038/leu.2010.31; Pellagatti A, 2018, BLOOD, V132, P1225, DOI 10.1182/blood-2018-04-843771; Platzbecker U, 2017, LANCET ONCOL, V18, P1338, DOI 10.1016/S1470-2045(17)30615-0; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Rowe RG, 2016, J EXP MED, V213, P1497, DOI 10.1084/jem.20151912; Sashida G, 2016, J EXP MED, V213, P1459, DOI 10.1084/jem.20151121; Shastri A, 2017, BLOOD, V129, P1586, DOI 10.1182/blood-2016-10-696062; Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343; Shimizu T, 2016, J EXP MED, V213, P1479, DOI 10.1084/jem.20151136; Sperling AS, 2017, NAT REV CANCER, V17, P5, DOI 10.1038/nrc.2016.112; Sternberg A, 2005, BLOOD, V106, P2982, DOI 10.1182/blood-2005-04-1543; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Watanabe-Okochi N, 2008, BLOOD, V111, P4297, DOI 10.1182/blood-2007-01-068346; Yokomizo-Nakano T, 2020, CANCER RES, V80, P2523, DOI 10.1158/0008-5472.CAN-19-3167; Zhang XT, 2016, NAT GENET, V48, P1014, DOI 10.1038/ng.3610; Zhou T, 2015, BLOOD, V126, P1057, DOI 10.1182/blood-2015-01-624239	39	4	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1531	1541		10.1038/s41388-020-01629-w	http://dx.doi.org/10.1038/s41388-020-01629-w		JAN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452460				2022-12-28	WOS:000607998600010
J	Swoboda, A; Soukup, R; Eckel, O; Kinslechner, K; Wingelhofer, B; Schorghofer, D; Sternberg, C; Pham, HTT; Vallianou, M; Horvath, J; Stoiber, D; Kenner, L; Larue, L; Poli, V; Beermann, F; Yokota, T; Kubicek, S; Krausgruber, T; Rendeiro, AF; Bock, C; Zenz, R; Kovacic, B; Aberger, F; Hengstschlager, M; Petzelbauer, P; Mikula, M; Moriggl, R				Swoboda, Alexander; Soukup, Robert; Eckel, Oliver; Kinslechner, Katharina; Wingelhofer, Bettina; Schoerghofer, David; Sternberg, Christina; Pham, Ha T. T.; Vallianou, Maria; Horvath, Jaqueline; Stoiber, Dagmar; Kenner, Lukas; Larue, Lionel; Poli, Valeria; Beermann, Friedrich; Yokota, Takashi; Kubicek, Stefan; Krausgruber, Thomas; Rendeiro, Andre F.; Bock, Christoph; Zenz, Rainer; Kovacic, Boris; Aberger, Fritz; Hengstschlaeger, Markus; Petzelbauer, Peter; Mikula, Mario; Moriggl, Richard			STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway	ONCOGENE			English	Article							MICROPHTHALMIA TRANSCRIPTION FACTOR; STEM-CELLS; EXPRESSION; GENE; RESISTANCE; CANCER; SUPPRESSION; MELANOCYTES; PROGRESSION; ACTIVATION	Metastatic melanoma is hallmarked by its ability of phenotype switching to more slowly proliferating, but highly invasive cells. Here, we tested the impact of signal transducer and activator of transcription 3 (STAT3) on melanoma progression in association with melanocyte inducing transcription factor (MITF) expression levels. We established a mouse melanoma model for deleting Stat3 in melanocytes with specific expression of human hyperactive NRAS(Q61K) in an Ink4a-deficient background, two frequent driver mutations in human melanoma. Mice devoid of Stat3 showed early disease onset with higher proliferation in primary tumors, but displayed significantly diminished lung, brain, and liver metastases. Whole-genome expression profiling of tumor-derived cells also showed a reduced invasion phenotype, which was further corroborated by 3D melanoma model analysis. Notably, loss or knockdown of STAT3 in mouse or human cells resulted in the upregulation of MITF and induction of cell proliferation. Mechanistically we show that STAT3-induced CAAT Box Enhancer Binding Protein (CEBP) expression was sufficient to suppress MITF transcription. Epigenetic analysis by ATAC-seq confirmed that CEBPa/b binding to the MITF enhancer region silenced the MITF locus. Finally, by classification of patient-derived melanoma samples, we show that STAT3 and MITF act antagonistically and hence contribute differentially to melanoma progression. We conclude that STAT3 is a driver of the metastatic process in melanoma and able to antagonize MITF via direct induction of CEBP family member transcription.	[Swoboda, Alexander; Wingelhofer, Bettina; Pham, Ha T. T.; Horvath, Jaqueline; Stoiber, Dagmar; Kenner, Lukas; Moriggl, Richard] Ludwig Boltzmann Inst Canc Res, Vienna, Austria; [Swoboda, Alexander; Eckel, Oliver; Wingelhofer, Bettina; Pham, Ha T. T.; Moriggl, Richard] Univ Vet Med, Inst Anim Breeding & Genet, Vienna, Austria; [Soukup, Robert; Eckel, Oliver; Kinslechner, Katharina; Schoerghofer, David; Vallianou, Maria; Kovacic, Boris; Hengstschlaeger, Markus; Mikula, Mario] Med Univ Vienna, Inst Med Genet, Ctr Pathobiochem & Genet, Vienna, Austria; [Sternberg, Christina; Aberger, Fritz] Univ Salzburg, Canc Cluster Salzburg, Dept Biosci, Salzburg, Austria; [Horvath, Jaqueline; Stoiber, Dagmar] Med Univ Vienna, Ctr Physiol & Pharmacol, Inst Pharmacol, Vienna, Austria; [Kenner, Lukas] Med Univ Vienna, Inst Clin Pathol, Vienna, Austria; [Kenner, Lukas] Univ Vet Med, Unit Pathol Lab Anim, Vienna, Austria; [Kenner, Lukas] Med Univ Vienna, CBMed Core Lab2, Vienna, Austria; [Larue, Lionel] Inst Curie Normal & Pathol Dev Melanocytes, CNRS, INSERM, UMR3347,U1021 Equipe Labellisee, Orsay, France; [Poli, Valeria] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Turin, Italy; [Beermann, Friedrich] Swiss Fed Inst Technol Lausanne, ISREC, Lausanne, Switzerland; [Yokota, Takashi] Kanazawa Univ, Grad Sch Med Sci, Dept Stem Cell Biol, Kanazawa, Ishikawa, Japan; [Kubicek, Stefan; Krausgruber, Thomas; Rendeiro, Andre F.; Bock, Christoph] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Bock, Christoph] Med Univ Vienna, Dept Lab Med, Vienna, Austria; [Bock, Christoph] Max Planck Inst Informat, Saarland Informat Campus, Saarbrucken, Germany; [Zenz, Rainer] Med Univ Vienna, Inst Canc Res, Vienna, Austria; [Petzelbauer, Peter] Med Univ Vienna, Dept Dermatol, Skin & Endothelium Res Div SERD, Vienna, Austria	Ludwig Boltzmann Institute; University of Veterinary Medicine Vienna; Medical University of Vienna; Salzburg University; Medical University of Vienna; Medical University of Vienna; University of Veterinary Medicine Vienna; Medical University of Vienna; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; University of Turin; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Kanazawa University; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Medical University of Vienna; Max Planck Society; Medical University of Vienna; Medical University of Vienna	Moriggl, R (corresponding author), Ludwig Boltzmann Inst Canc Res, Vienna, Austria.; Moriggl, R (corresponding author), Univ Vet Med, Inst Anim Breeding & Genet, Vienna, Austria.; Mikula, M (corresponding author), Med Univ Vienna, Inst Med Genet, Ctr Pathobiochem & Genet, Vienna, Austria.	mario.mikula@meduniwien.ac.at; richard.moriggl@vetmeduni.ac.at	Bock, Christoph/AAE-7618-2019; Kubicek, Stefan/C-2089-2017; Yokota, Takashi/J-8483-2015; petzelbauer, peter/GLU-3941-2022; Rendeiro, André F./AAC-4747-2019; Krausgruber, Thomas/H-8490-2018	Bock, Christoph/0000-0001-6091-3088; Kubicek, Stefan/0000-0003-0855-8343; Rendeiro, André F./0000-0001-9362-5373; Krausgruber, Thomas/0000-0002-1374-0329; Petzelbauer, Peter/0000-0001-7080-5259; Moriggl, Richard/0000-0003-0918-9463; Kenner, Lukas/0000-0003-2184-1338; Aberger, Fritz/0000-0003-2009-6305	Austrian Science Fund (FWF) [AIRC IG16930, SFB-F061, SFB-F047, P 25336-B13]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank Safia Zahma, Birgit Schutz, Eva Bauer, Michaela Schlederer, and Karin Neumuller for excellent technical assistance. We also thank the Biomedical Sequencing Facility at CeMM for assistance with next-generation sequencing. VP was supported by the grant AIRC IG16930, AS, OE, RZ, and RM were supported by a private melanoma research donation from Liechtenstein, RM was further supported by two network grants SFB-F061 and SFB-F047, and RS, KK, MV, and MM were supported by P 25336-B13, all from the Austrian Science Fund (FWF).	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Anastas JN, 2014, J CLIN INVEST, V124, P2877, DOI 10.1172/JCI70156; Bu X, 2016, TRENDS MOL MED, V22, P448, DOI 10.1016/j.molmed.2016.04.008; Cao HH, 2016, SCI REP-UK, V6, DOI 10.1038/srep21731; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Delmas V, 2003, GENESIS, V36, P73, DOI 10.1002/gene.10197; Fofaria NM, 2014, ONCOTARGET, V5, P7051, DOI 10.18632/oncotarget.2251; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Goding CR, 2019, GENE DEV, V33, P983, DOI 10.1101/gad.324657.119; Gong AH, 2015, CANCER RES, V75, P2337, DOI 10.1158/0008-5472.CAN-14-2800; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Grabner B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7285; He WZ, 2018, CANCER RES, V78, P3293, DOI 10.1158/0008-5472.CAN-17-3131; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Huser L, 2018, INT J CANCER, V143, P3131, DOI 10.1002/ijc.31609; Igelmann S, 2019, CANCERS, V11, DOI 10.3390/cancers11101428; Jeffs AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008461; Ji ZY, 2015, J INVEST DERMATOL, V135, P1863, DOI 10.1038/jid.2015.105; Kemper K, 2014, CANCER RES, V74, P5937, DOI 10.1158/0008-5472.CAN-14-1174; Kinslechner K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051063; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Kulesza DW, 2019, CELL BIOL INT, V43, P613, DOI 10.1002/cbin.11134; Lacreusette A, 2007, ONCOGENE, V26, P881, DOI 10.1038/sj.onc.1209844; Ladstein RG, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-140; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lee JW, 2019, NATURE, V567, P249, DOI 10.1038/s41586-019-1004-y; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; Li FZ, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00031; Luciani F, 2011, DEVELOPMENT, V138, P3943, DOI 10.1242/dev.067447; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mirea MA, 2020, CANCERS, V12, DOI 10.3390/cancers12092508; Musteanu M, 2010, GASTROENTEROLOGY, V138, P1003, DOI 10.1053/j.gastro.2009.11.049; Niu GL, 1999, CANCER RES, V59, P5059; Ohanna M, 2013, ONCOTARGET, V4, P2212, DOI 10.18632/oncotarget.1143; Pencik J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8736; Qi XP, 2013, IMMUNITY, V39, P97, DOI 10.1016/j.immuni.2013.06.012; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shenoy AK, 2016, J CLIN INVEST, V126, P4174, DOI 10.1172/JCI86623; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Steder M, 2013, CANCER CELL, V24, P512, DOI 10.1016/j.ccr.2013.08.023; Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang Y, 2008, P NATL ACAD SCI USA, V105, P2445, DOI 10.1073/pnas.0705395105; Tang Y, 2012, STEM CELLS, V30, P2645, DOI 10.1002/stem.1225; Tu TJ, 2011, ONCOLOGY-BASEL, V80, P181, DOI 10.1159/000328518; Verastegui C, 2000, J BIOL CHEM, V275, P30757, DOI 10.1074/jbc.C000445200; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Weidenfeld K, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00381; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; Yokoyama S, 2008, PIGM CELL MELANOMA R, V21, P457, DOI 10.1111/j.1755-148X.2008.00480.x	58	15	16	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1091	1105		10.1038/s41388-020-01584-6	http://dx.doi.org/10.1038/s41388-020-01584-6		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323974	Green Accepted			2022-12-28	WOS:000599126500003
J	Song, Y; Zeng, SS; Zheng, GP; Chen, DY; Li, P; Yang, MQ; Luo, K; Yin, J; Gu, YX; Zhang, ZJ; Jia, XT; Qiu, N; He, ZM; Li, HS; Liu, H				Song, Ying; Zeng, Shanshan; Zheng, Guopei; Chen, Danyang; Li, Pan; Yang, Mingqiang; Luo, Kai; Yin, Jiang; Gu, Yixue; Zhang, Zhijie; Jia, Xiaoting; Qiu, Ni; He, Zhimin; Li, Hongsheng; Liu, Hao			FOXO3a-driven miRNA signatures suppresses VEGF-A/NRP1 signaling and breast cancer metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ENDOTHELIAL GROWTH-FACTOR; TUMOR PROGRESSION; FOXO3A; VEGF; MICROENVIRONMENT; NEUROPILIN-1; ACTIVATION; EXPRESSION; KNOCKDOWN	Metastasis remains the major obstacle to improved survival for breast cancer patients. Downregulation of FOXO3a transcription factor in breast cancer is causally associated with the development of metastasis through poorly understood mechanisms. Here, we report that FOXO3a is functionally related to the inhibition of VEGF-A/NRP1 signaling and to the consequent suppression of breast cancer metastasis. We show that FOXO3a directly induces miR-29b-2 and miR-338 expression. Ectopic expression of miR-29b-2/miR-338 significantly suppresses EMT, migration/invasion, and in vivo metastasis of breast cancer. Moreover, we demonstrate that miR-29b-2 directly targets VEGF-A while miR-338 directly targets NRP1, and show that regulation of miR-29b-2 and miR-338 mediates the ability of FOXO3a to suppress VEGF-A/NRP1 signaling and breast cancer metastasis. Clinically, our results show that the FOXO3a-miR-29b-2/miR-338-VEGF-A/NRP1 axis is dysregulated and plays a critical role in disease progression in breast cancer. Collectively, our findings propose that FOXO3a functions as a metastasis suppressor, and define a novel signaling axis of FOXO3a-miRNA-VEGF-A/NRP1 in breast cancer, which might be potential therapeutic targets for breast cancer.	[Song, Ying; Zeng, Shanshan; Zheng, Guopei; Chen, Danyang; Li, Pan; Yang, Mingqiang; Luo, Kai; Yin, Jiang; Gu, Yixue; Zhang, Zhijie; Jia, Xiaoting; Qiu, Ni; He, Zhimin; Li, Hongsheng; Liu, Hao] Canc Hosp, Guangzhou 510095, Peoples R China; [Song, Ying; Zeng, Shanshan; Zheng, Guopei; Chen, Danyang; Li, Pan; Yang, Mingqiang; Luo, Kai; Yin, Jiang; Gu, Yixue; Zhang, Zhijie; Jia, Xiaoting; Qiu, Ni; He, Zhimin; Li, Hongsheng; Liu, Hao] Inst Guangzhou Med Univ, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Guangzhou 510095, Peoples R China		He, ZM; Li, HS; Liu, H (corresponding author), Canc Hosp, Guangzhou 510095, Peoples R China.; He, ZM; Li, HS; Liu, H (corresponding author), Inst Guangzhou Med Univ, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Guangzhou 510095, Peoples R China.	hezhimin2005@yahoo.com; lihongsheng@gzhmu.edu.cn; haoliu2020@163.com		Liu, Hao/0000-0001-6338-4003; SONG, YING/0000-0002-5781-0317	National Natural Science Foundation of China [81772825, 81402497, 81672616, 81272450]; Guangdong Natural Science Funds for Distinguished Young Scholars [2016A030306003]; Guangdong Special Support Program [2017TQ04R809]; Guangdong Natural Science Funds [2017A030313500, 2017A030313867]; Science and Technology Program of Guangzhou [201707010381, 201707010354]; Clinical Key Specialty Project of Guangzhou Medical University [2020-05]; Guangzhou key medical discipline construction project fund	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Funds for Distinguished Young Scholars; Guangdong Special Support Program; Guangdong Natural Science Funds; Science and Technology Program of Guangzhou; Clinical Key Specialty Project of Guangzhou Medical University; Guangzhou key medical discipline construction project fund	This work was supported by the National Natural Science Foundation of China (81772825, 81402497, 81672616, and 81272450), supported by grants from Guangdong Natural Science Funds for Distinguished Young Scholars (No.2016A030306003), Supported by Guangdong Special Support Program (2017TQ04R809), grants from Guangdong Natural Science Funds (2017A030313500 and 2017A030313867), the Science and Technology Program of Guangzhou (201707010381 and 201707010354), Clinical Key Specialty Project of Guangzhou Medical University (No. 2020-05), and Guangzhou key medical discipline construction project fund.	Allen JE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004828; Bando H, 2005, BRIT J CANCER, V92, P553, DOI 10.1038/sj.bjc.6602374; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cheng CW, 2015, ONCOTARGET, V6, P44222, DOI 10.18632/oncotarget.5826; Chou CC, 2014, CANCER RES, V74, P4783, DOI 10.1158/0008-5472.CAN-14-0135; Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Ghosh S, 2008, HUM PATHOL, V39, P1835, DOI 10.1016/j.humpath.2008.06.004; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]; Herzog B, 2011, MOL BIOL CELL, V22, P2766, DOI 10.1091/mbc.E09-12-1061; Hornsveld M, 2018, CANCER RES, V78, P2356, DOI 10.1158/0008-5472.CAN-17-2511; Jin Y, 2015, INT J ONCOL, V47, P1594, DOI 10.3892/ijo.2015.3114; Jubb AM, 2012, J PATHOL, V226, P50, DOI 10.1002/path.2989; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Karaman S, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.151019; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Li J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1046-x; Liu H, 2020, CELL DEATH DIFFER, V27, P966, DOI 10.1038/s41418-019-0389-3; Liu H, 2015, CELL SIGNAL, V27, P510, DOI 10.1016/j.cellsig.2015.01.001; Liu YQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0751-3; Lu Jing, 2009, Cancer Res, V69, P4951, DOI 10.1158/0008-5472.CAN-09-0099; Luo M, 2019, CANCER LETT, V455, P26, DOI 10.1016/j.canlet.2019.04.019; Luo MN, 2016, CANCER LETT, V373, P1, DOI 10.1016/j.canlet.2016.01.010; Ma ZQ, 2018, SEMIN CANCER BIOL, V50, P21, DOI 10.1016/j.semcancer.2018.02.004; Ni D, 2014, CLIN CANCER RES, V20, P1779, DOI 10.1158/1078-0432.CCR-13-1687; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ru P, 2012, MOL CANCER THER, V11, P1166, DOI 10.1158/1535-7163.MCT-12-0100; Saharinen P, 2011, TRENDS MOL MED, V17, P347, DOI 10.1016/j.molmed.2011.01.015; Shiota M, 2010, CLIN CANCER RES, V16, P5654, DOI 10.1158/1078-0432.CCR-10-0376; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Spill F, 2016, CURR OPIN BIOTECH, V40, P41, DOI 10.1016/j.copbio.2016.02.007; Stafford LJ, 2008, INT J BIOCHEM CELL B, V40, P874, DOI 10.1016/j.biocel.2007.12.016; Storz P, 2009, MOL CELL BIOL, V29, P4906, DOI 10.1128/MCB.00077-09; Su JC, 2016, SCI REP-UK, V6, DOI 10.1038/srep28888; Sun F, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0611-0; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Wang K, 2010, J BIOL CHEM, V285, P16958, DOI 10.1074/jbc.M109.093005; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2009, CLIN CANCER RES, V15, P752, DOI 10.1158/1078-0432.CCR-08-0124; Yeung KT, 2017, MOL ONCOL, V11, P28, DOI 10.1002/1878-0261.12017; Zou YY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1872	45	17	18	4	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					777	790		10.1038/s41388-020-01562-y	http://dx.doi.org/10.1038/s41388-020-01562-y		DEC 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33262463	Green Published, hybrid			2022-12-28	WOS:000595928700008
J	Tan, IL; Arifa, RDN; Rallapalli, H; Kana, V; Lao, ZM; Sanghrajka, RM; Bayin, NS; Tanne, A; Wojcinski, A; Korshunov, A; Bhardwaj, N; Merad, M; Turnbull, DH; Lafaille, JJ; Joyner, AL				Tan, I-Li; Arifa, Raquel Duque Nascimento; Rallapalli, Harikrishna; Kana, Veronika; Lao, Zhimin; Sanghrajka, Reeti Mayur; Sumru Bayin, N.; Tanne, Antoine; Wojcinski, Alexandre; Korshunov, Andrey; Bhardwaj, Nina; Merad, Miriam; Turnbull, Daniel H.; Lafaille, Juan J.; Joyner, Alexandra L.			CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model	ONCOGENE			English	Article							MICROGLIA; EXPRESSION; LANDSCAPE; SYSTEM; GROWTH; BETA	The immune microenvironment of tumors can play a critical role in promoting or inhibiting tumor progression depending on the context. We present evidence that tumor-associated macrophages/microglia (TAMs) can promote tumor progression in the sonic hedgehog subgroup of medulloblastoma (SHH-MB). By combining longitudinal manganese-enhanced magnetic resonance imaging (MEMRI) and immune profiling of a sporadic mouse model of SHH-MB, we found the density of TAMs is higher in the similar to 50% of tumors that progress to lethal disease. Furthermore, reducing regulatory T cells or eliminating B and T cells in Rag1 mutants does not alter SHH-MB tumor progression. As TAMs are a dominant immune component in tumors and are normally dependent on colony-stimulating factor 1 receptor (CSF1R), we treated mice with a CSF1R inhibitor, PLX5622. Significantly, PLX5622 reduces a subset of TAMs, prolongs mouse survival, and reduces the volume of most tumors within 4 weeks of treatment. Moreover, concomitant with a reduction in TAMs the percentage of infiltrating cytotoxic T cells is increased, indicating a change in the tumor environment. Our studies in an immunocompetent preclinical mouse model demonstrate TAMs can have a functional role in promoting SHH-MB progression. Thus, CSF1R inhibition could have therapeutic potential for a subset of SHH-MB patients.	[Tan, I-Li; Lao, Zhimin; Sanghrajka, Reeti Mayur; Sumru Bayin, N.; Wojcinski, Alexandre; Joyner, Alexandra L.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Tan, I-Li; Sanghrajka, Reeti Mayur; Joyner, Alexandra L.] Cornell Univ, Weill Grad Sch Med Sci, Biochem Cell & Mol Biol Program, New York, NY 10021 USA; [Arifa, Raquel Duque Nascimento; Rallapalli, Harikrishna; Turnbull, Daniel H.; Lafaille, Juan J.] NYU, Sch Med, Skirball Inst Biomol Med, New York, NY USA; [Kana, Veronika; Tanne, Antoine; Bhardwaj, Nina; Merad, Miriam] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Tanne, Antoine] Agenus Inc, Lexington, MA USA; [Korshunov, Andrey] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, Heidelberg, Germany; [Korshunov, Andrey] Univ Hosp, Dept Neuropathol, Heidelberg, Germany	Memorial Sloan Kettering Cancer Center; Cornell University; New York University; Icahn School of Medicine at Mount Sinai; Agenus Inc; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Joyner, AL (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.; Joyner, AL (corresponding author), Cornell Univ, Weill Grad Sch Med Sci, Biochem Cell & Mol Biol Program, New York, NY 10021 USA.	joynera@mskcc.org		Kana, Veronika/0000-0002-9362-3156; Turnbull, Daniel/0000-0003-0889-5155; Bhardwaj, Nina/0000-0003-1865-4187	MSKCC Brain Tumor Center fellowship; National Cancer Institute Cancer Center Support Grant [P30 CA008748-48];  [R01CA192176]	MSKCC Brain Tumor Center fellowship; National Cancer Institute Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); 	We thank the Joyner lab members for helpful discussions and comments on the manuscript. We are grateful to Andrey Rymar and Parmveer Singh at Plexxikon for providing the PLX5622 used in these studies. We appreciate the technical assistance from Daniel Stephen, and Yu-Jung Chen. We also thank the Center for comparative medicine and pathology and the Integrated Genomics Operation (IGO) core facilities of MSKCC for outstanding technical support. This work was supported by the following grants: R01CA192176 (ALJ), MSKCC Brain Tumor Center fellowship (AW), and a National Cancer Institute Cancer Center Support Grant [P30 CA008748-48].	Archer TC, 2018, CANCER CELL, V34, P396, DOI 10.1016/j.ccell.2018.08.004; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Bockmayr M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1462430; Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055; Cavalli FMG, 2017, CANCER CELL, V31, P737, DOI 10.1016/j.ccell.2017.05.005; CELADA A, 1989, EUR J IMMUNOL, V19, P1103, DOI 10.1002/eji.1830190621; Corcoran RB, 2008, CANCER RES, V68, P8788, DOI 10.1158/0008-5472.CAN-08-2135; Gate D, 2014, P NATL ACAD SCI USA, V111, pE3458, DOI 10.1073/pnas.1412489111; Greter M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00249; Gyori D, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120631; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Huang YB, 2018, NAT NEUROSCI, V21, P530, DOI 10.1038/s41593-018-0090-8; Kana V, 2019, J EXP MED, V216, P2265, DOI 10.1084/jem.20182037; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Lee C, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4457-8; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Machold R, 2005, NEURON, V48, P17, DOI 10.1016/j.neuron.2005.08.028; Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Margol AS, 2015, CLIN CANCER RES, V21, P1457, DOI 10.1158/1078-0432.CCR-14-1144; Martin Allison M, 2018, Oncotarget, V9, P19177, DOI 10.18632/oncotarget.24951; Maximov V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10458-9; McNeill KA, 2016, NEUROL CLIN, V34, P981, DOI 10.1016/j.ncl.2016.06.014; Mi HY, 2019, NUCLEIC ACIDS RES, V47, pD419, DOI 10.1093/nar/gky1038; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Murata D, 2018, J NEUROSURG, V128, P710, DOI 10.3171/2016.11.JNS16991; Northcott PA, 2017, NATURE, V547, P311, DOI 10.1038/nature22973; Northcott PA, 2012, NAT REV CANCER, V12, P818, DOI 10.1038/nrc3410; Peranzoni E, 2018, P NATL ACAD SCI USA, V115, pE4041, DOI 10.1073/pnas.1720948115; Pham CD, 2016, CLIN CANCER RES, V22, P582, DOI 10.1158/1078-0432.CCR-15-0713; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Quail DF, 2016, SCIENCE, V352, DOI 10.1126/science.aad3018; Rallapalli H, 2020, MAGN RESON MED, V83, P214, DOI 10.1002/mrm.27904; Ramaswamy V, 2017, J CLIN ONCOL, V35, P2355, DOI 10.1200/JCO.2017.72.7842; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Schmidt A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00051; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan IL, 2018, P NATL ACAD SCI USA, V115, P3392, DOI 10.1073/pnas.1717815115; Tanori M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-53; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Togashi Y, 2019, NAT REV CLIN ONCOL, V16, P356, DOI 10.1038/s41571-019-0175-7; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Vermeulen JF, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1398877; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; Yang M, 2018, CANCER RES, V78, P5492, DOI 10.1158/0008-5472.CAN-18-1367; Yao MJ, 2020, CELL, V180, P502, DOI 10.1016/j.cell.2019.12.024; Zhu Y, 2014, CANCER RES, V74, P5057, DOI 10.1158/0008-5472.CAN-13-3723	52	18	18	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					396	407		10.1038/s41388-020-01536-0	http://dx.doi.org/10.1038/s41388-020-01536-0		NOV 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33159168	Green Accepted			2022-12-28	WOS:000587081500001
J	Chen, PX; Li, S; Zhang, K; Zhao, RC; Cui, JF; Zhou, W; Liu, YC; Zhang, L; Cheng, YF				Chen, Pengxiang; Li, Song; Zhang, Ke; Zhao, Renchang; Cui, Jianfeng; Zhou, Wei; Liu, Yuchen; Zhang, Lin; Cheng, Yufeng			N-6-methyladenosine demethylase ALKBH5 suppresses malignancy of esophageal cancer by regulating microRNA biogenesis and RAI1 expression	ONCOGENE			English	Article							UP-REGULATION; NUCLEAR-RNA; METASTASIS; PROLIFERATION; TRANSITION; CARCINOMA; CELLS; YAP	N-6-Methyladenosine (m(6)A) is the most prevalent epigenetic RNA modification and is vital in regulating malignancies. The roles of m(6)A modifiers on noncoding RNAs have not been fully investigated in esophageal cancer. By screening all m(6)A modifiers, ALKBH5 was the most potent member related to patient outcomes and suppressing esophageal cancer malignancy in cell and animal models. It demethylated pri-miR-194-2 and inhibited miR-194-2 biogenesis through an m(6)A/DGCR8-dependent manner. RAI1, previously considered as a circadian clock transcriptional regulator, was the main target of miR-194-2. It enhanced transcription of Hippo pathway upstream genes by binding to their 3 ' UTR and suppressed YAP/TAZ nuclear translocation. The ALKBH5/miR-194-2/RAI1 axis was also validated in clinical samples. In addition, the increased malignancy by low ALKBH5 was abolished by the YAP inhibitor verteporfin. Our findings uncover a critical role of ALKBH5 in miRNAs biogenesis and provide novel insight for developing treatment strategies in esophageal cancer.	[Chen, Pengxiang; Zhou, Wei; Liu, Yuchen; Zhang, Lin; Cheng, Yufeng] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Radiat Oncol, Jinan, Peoples R China; [Chen, Pengxiang; Li, Song] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Lab Basic Med Sci, Jinan, Peoples R China; [Li, Song] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Dept Med Oncol, Jinan, Peoples R China; [Zhang, Ke] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Dept Gen Med, Jinan, Peoples R China; [Zhao, Renchang] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Thorac Surg Dept, Jinan, Peoples R China; [Cui, Jianfeng] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Dept Urol, Jinan, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University; Shandong University; Shandong University	Zhang, L; Cheng, YF (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Radiat Oncol, Jinan, Peoples R China.	linzhangsdu@163.com; yufengchengsdu@163.com	liu, yuchen/GYQ-6286-2022	Li, Song/0000-0002-5023-9111	National Natural Science Foundation of China [81773228, 81972850, 81601999]; Postdoctoral Science Foundation of China [2018M640637]; Special Fund for Taishan Scholar Project [ts20190973]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation); Special Fund for Taishan Scholar Project	Alexandra Marshall from Marshall Medical Communications provided editorial assistance during manuscript preparation. This study was supported by the National Natural Science Foundation of China (81773228 and 81972850 to Y.C.; 81601999 to L.Z.); Postdoctoral Science Foundation of China (2018M640637 to L.Z.), and Special Fund for Taishan Scholar Project (ts20190973 to Y.C.).	Alarcon CR, 2015, NATURE, V519, P482, DOI 10.1038/nature14281; Barfield R, 2019, SLEEP, V42, DOI 10.1093/sleep/zsz101; Batista PJ, 2014, CELL STEM CELL, V15, P707, DOI 10.1016/j.stem.2014.09.019; Boone PM, 2011, AM J MED GENET A, V155A, P2024, DOI 10.1002/ajmg.a.34098; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen H, 2018, AM J RESP CELL MOL, V58, P391, DOI 10.1165/rcmb.2017-0237OC; Chen XY, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1033-z; Chen YH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01239-w; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Cui M, 2018, EXP THER MED, V15, P1048, DOI 10.3892/etm.2017.5492; Das R, 2017, CANCER RES, V77, P1021, DOI 10.1158/0008-5472.CAN-16-2529; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724; Fustin JM, 2013, CELL, V155, P793, DOI 10.1016/j.cell.2013.10.026; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Han B, 2020, NANOTOXICOLOGY, V14, P1, DOI 10.1080/17435390.2019.1661041; Han J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1036-9; Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043; Hou HY, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.153087; Jaffrey SR, 2017, GENOME MED, V9, DOI 10.1186/s13073-016-0395-8; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375; Lan Q, 2019, CANCER RES, V79, P1285, DOI 10.1158/0008-5472.CAN-18-2965; Li P, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0402-6; Liu JY, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-349; Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432; Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885; Meyer KD, 2015, CELL, V163, P999, DOI 10.1016/j.cell.2015.10.012; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Peng W, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1408-4; Qu Y, 2019, EXP THER MED, V18, P2993, DOI 10.3892/etm.2019.7896; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Shen C, 2020, CELL STEM CELL, V27, P64, DOI 10.1016/j.stem.2020.04.009; Song SM, 2014, CANCER RES, V74, P4170, DOI 10.1158/0008-5472.CAN-13-3569; Su XD, 2014, J THORAC DIS, V6, P949, DOI 10.3978/j.issn.2072-1439.2014.07.14; Tang B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1128-6; Thongon N, 2016, ONCOTARGET, V7, P26551, DOI 10.18632/oncotarget.8437; Wang C, 2016, BRIT J CANCER, V115, P1548, DOI 10.1038/bjc.2016.367; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wei HL, 2017, CANCER SCI, V108, P478, DOI 10.1111/cas.13138; Wu X, 2014, ONCOGENE, V33, P1506, DOI 10.1038/onc.2013.108; Xia TL, 2020, CANCER MANAG RES, V12, P5729, DOI 10.2147/CMAR.S245019; Yi YC, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01233-2; Zhang JL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09712-x; Zhang J, 2014, ONCOL REP, V31, P1157, DOI 10.3892/or.2013.2960; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049	49	10	10	4	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5600	5612		10.1038/s41388-021-01966-4	http://dx.doi.org/10.1038/s41388-021-01966-4		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34312488				2022-12-28	WOS:000678988300002
J	Song, S; Fan, G; Li, Q; Su, Q; Zhang, XY; Xue, XF; Wang, ZM; Qian, CA; Jin, Z; Li, BZ; Zhuang, WZ				Song, Sha; Fan, Gao; Li, Qi; Su, Qi; Zhang, Xinyun; Xue, Xiaofeng; Wang, Zhiming; Qian, Chen'ao; Jin, Zhou; Li, Bingzong; Zhuang, Wenzhuo			IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma	ONCOGENE			English	Article							M(6)A READER YTHDF2; ONCOMETABOLITE 2-HYDROXYGLUTARATE; REVEALS; HETEROGENEITY; TRANSCRIPTOME; INHIBITOR; MUTATIONS; PATTERNS; LEUKEMIA; CELLS	Epigenetic alterations have been previously shown to contribute to multiple myeloma (MM) pathogenesis via DNA methylations and histone modifications. RNA methylation, a novel epigenetic modification, is required for cancer cell survival, and targeting this pathway has been proposed as a new therapeutic strategy. The extent to the N6-methyladenosine (m6A)-regulatory pathway functions in MM remains unknown. Here, we show that an imbalance of RNA methylation may underlies the tumorigenesis of MM. Mechanistically, isocitrate dehydrogenase 2 (IDH2) is highly expressed in CD138(+) cells from MM and its levels appear a progressive increase in the progression of plasma cell dyscrasias. Downregulation of IDH2 increases global m6A RNA levels and reduces myeloma cell growth in vitro, decreases the burden of disease and prolongs overall survival in vivo. IDH2 regulates RNA methylation by activating the RNA demethylase FTO, which is an alpha-KG-dependent dioxygenase. Furthermore, IDH2-mediated FTO activation decreases the m6A level on WNT7B transcripts, then increases WNT7B expression and thus activated Wnt signaling pathway. Moreover, survival analysis indicates that the elevated expression of IDH2 predicts a poor prognosis. Higher expression of FTO is related to higher International Staging System (ISS) stage and higher Revised-ISS (R-ISS) stage of MM. Collectively, our studies reveal that IDH2 regulates global m6A RNA modification in MM via targeting RNA demethylases FTO. The imbalance of m6A methylation activates the Wnt signaling pathway by enhancing the WNT7B expression, and thus promoting tumorigenesis and progression of MM. IDH2 might be used as a therapeutic target and a possible prognostic factor for MM.	[Song, Sha; Fan, Gao; Su, Qi; Wang, Zhiming; Jin, Zhou; Zhuang, Wenzhuo] Soochow Univ, Sch Biol & Basic Med Sci, Dept Cell Biol, Suzhou, Peoples R China; [Song, Sha] Westlake Univ, Sch Life Sci, Hangzhou, Peoples R China; [Li, Qi; Zhang, Xinyun; Xue, Xiaofeng; Li, Bingzong] Soochow Univ, Affiliated Hosp 2, Dept Hematol, Suzhou, Peoples R China; [Qian, Chen'ao] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA	Soochow University - China; Westlake University; Soochow University - China; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhuang, WZ (corresponding author), Soochow Univ, Sch Biol & Basic Med Sci, Dept Cell Biol, Suzhou, Peoples R China.; Li, BZ (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Hematol, Suzhou, Peoples R China.	lbzwz0907@hotmail.com; zhuangwenzhuo@suda.edu.cn	li, bz/GVR-7133-2022; li, bing/GWQ-9617-2022		Natural Science Foundation of Jiangsu Province China [BK20201408]; Clinical Key Diagnosis and Treatment Technologies in Suzhou City [LCZX201805]; Jiangsu Social Development Project-New Clinical Diagnosis and Treatment Technology [BE2019664]; Scientific and Technological Projects of People's Livelihood in Suzhou City [SS201856]; Fifth Phase of "333 High-level Talents Training Project" in Jiangsu Province [BRA2018138]; National Clinical Research Center for Hematologic Diseases	Natural Science Foundation of Jiangsu Province China(Natural Science Foundation of Jiangsu Province); Clinical Key Diagnosis and Treatment Technologies in Suzhou City; Jiangsu Social Development Project-New Clinical Diagnosis and Treatment Technology; Scientific and Technological Projects of People's Livelihood in Suzhou City; Fifth Phase of "333 High-level Talents Training Project" in Jiangsu Province; National Clinical Research Center for Hematologic Diseases	The research leading to these results has received funding from Natural Science Foundation of Jiangsu Province China (BK20201408), Clinical Key Diagnosis and Treatment Technologies in Suzhou City (LCZX201805), Jiangsu Social Development Project-New Clinical Diagnosis and Treatment Technology (BE2019664), Scientific and Technological Projects of People's Livelihood in Suzhou City (SS201856), The Fifth Phase of "333 High-level Talents Training Project" in Jiangsu Province (BRA2018138) and National Clinical Research Center for Hematologic Diseases.	Agnelli L, 2009, GENE CHROMOSOME CANC, V48, P603, DOI 10.1002/gcc.20668; Alzrigat M, 2018, SEMIN CANCER BIOL, V51, P101, DOI 10.1016/j.semcancer.2017.09.007; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Anderson NM, 2018, PROTEIN CELL, V9, P216, DOI 10.1007/s13238-017-0451-1; Bartosovic M, 2017, NUCLEIC ACIDS RES, V45, P11356, DOI 10.1093/nar/gkx778; Bianchi G, 2015, BLOOD, V125, P3049, DOI 10.1182/blood-2014-11-568881; Chng WJ, 2007, CANCER RES, V67, P2982, DOI 10.1158/0008-5472.CAN-06-4046; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Danziger SA, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003323; Dimopoulos K, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.29; Gutierrez NC, 2007, LEUKEMIA, V21, P541, DOI 10.1038/sj.leu.2404520; Hausinger RP, 2004, CRIT REV BIOCHEM MOL, V39, P21, DOI 10.1080/10409230490440541; Herr CQ, 2018, TRENDS BIOCHEM SCI, V43, P517, DOI 10.1016/j.tibs.2018.04.002; Ivanova I, 2017, MOL CELL, V67, P1059, DOI 10.1016/j.molcel.2017.08.003; Kats LM, 2014, CELL STEM CELL, V14, P329, DOI 10.1016/j.stem.2013.12.016; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Levin A, 2018, TRANSL RES, V201, P49, DOI 10.1016/j.trsl.2018.05.003; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Li ZR, 2018, CELL RES, V28, P904, DOI 10.1038/s41422-018-0072-0; Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015; Lopez-Corral L, 2014, HAEMATOLOGICA, V99, P1365, DOI 10.3324/haematol.2013.087809; Mattioli M, 2005, ONCOGENE, V24, P2461, DOI 10.1038/sj.onc.1208447; Mulligan G, 2007, BLOOD, V109, P3177, DOI 10.1182/blood-2006-09-044974; Palumbo A, 2015, J CLIN ONCOL, V33, P2863, DOI 10.1200/JCO.2015.61.2267; Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004; Paris J, 2019, CELL STEM CELL, V25, P137, DOI 10.1016/j.stem.2019.03.021; Repana D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-018-1612-0; Shi HL, 2019, MOL CELL, V74, P640, DOI 10.1016/j.molcel.2019.04.025; Spaan I, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0615-3; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Szalat R, 2015, CURR OPIN GENET DEV, V30, P56, DOI 10.1016/j.gde.2015.03.008; van Andel H, 2019, LEUKEMIA, V33, P1063, DOI 10.1038/s41375-019-0404-1; van de Donk NWCJ, 2016, IMMUNOL REV, V270, P95, DOI 10.1111/imr.12389; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Vu LP, 2019, CANCER DISCOV, V9, P25, DOI 10.1158/2159-8290.CD-18-0959; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Xie C, 2011, NUCLEIC ACIDS RES, V39, pW316, DOI 10.1093/nar/gkr483; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang H, 2012, CLIN CANCER RES, V18, P5562, DOI 10.1158/1078-0432.CCR-12-1773; Zhao X, 2014, CELL RES, V24, P1403, DOI 10.1038/cr.2014.151; Zhou J, 2018, MOL CELL, V69, P636, DOI 10.1016/j.molcel.2018.01.019	42	5	5	3	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5393	5402		10.1038/s41388-021-01939-7	http://dx.doi.org/10.1038/s41388-021-01939-7		JUL 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34274946				2022-12-28	WOS:000673748200001
J	Karunanithi, S; Liu, RF; Hou, YC; Gonzalez, G; Oldford, N; Roe, AJ; Idipilly, N; Gupta, K; Amara, CS; Putluri, S; Lee, GK; Valentin-Goyco, J; Stetson, L; Moreton, SA; Putluri, V; Kavuri, SM; Saunthararajah, Y; de Lima, M; Tochtrop, GP; Putluri, N; Wald, DN				Karunanithi, Sheelarani; Liu, Ruifu; Hou, Yongchun; Gonzalez, Giancarlo; Oldford, Natasha; Roe, Anne Jessica; Idipilly, Nethrie; Gupta, Kalpana; Amara, Chandra Sekhar; Putluri, Satwikreddy; Lee, Grace Kyueun; Valentin-Goyco, Juan; Stetson, Lindsay; Moreton, Stephen A.; Putluri, Vasanta; Kavuri, Shyam M.; Saunthararajah, Yogen; de Lima, Marcos; Tochtrop, Gregory P.; Putluri, Nagireddy; Wald, David N.			Thioredoxin reductase is a major regulator of metabolism in leukemia cells	ONCOGENE			English	Article							OXIDATIVE STRESS; INHIBITION; APOPTOSIS; SYSTEM	Despite the fact that AML is the most common acute leukemia in adults, patient outcomes are poor necessitating the development of novel therapies. We identified that inhibition of Thioredoxin Reductase (TrxR) is a promising strategy for AML and report a highly potent and specific inhibitor of TrxR, S-250. Both pharmacologic and genetic inhibition of TrxR impairs the growth of human AML in mouse models. We found that TrxR inhibition leads to a rapid and marked impairment of metabolism in leukemic cells subsequently leading to cell death. TrxR was found to be a major and direct regulator of metabolism in AML cells through impacts on both glycolysis and the TCA cycle. Studies revealed that TrxR directly regulates GAPDH leading to a disruption of glycolysis and an increase in flux through the pentose phosphate pathway (PPP). The combined inhibition of TrxR and the PPP led to enhanced leukemia growth inhibition. Overall, TrxR abrogation, particularly with S-250, was identified as a promising strategy to disrupt AML metabolism.	[Karunanithi, Sheelarani; Liu, Ruifu; Gonzalez, Giancarlo; Oldford, Natasha; Roe, Anne Jessica; Idipilly, Nethrie; Gupta, Kalpana; Lee, Grace Kyueun; Valentin-Goyco, Juan; Stetson, Lindsay; Wald, David N.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Karunanithi, Sheelarani; Hou, Yongchun; Roe, Anne Jessica; Idipilly, Nethrie; Moreton, Stephen A.; Wald, David N.] CuronBiotech Inc, Cleveland, OH 44106 USA; [Amara, Chandra Sekhar; Putluri, Satwikreddy; Putluri, Nagireddy] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Putluri, Vasanta; Putluri, Nagireddy] Baylor Coll Med, Alkek Ctr Mol Discovery, Dan L Duncan Canc Ctr, Adv Technol Core, Houston, TX 77030 USA; [Kavuri, Shyam M.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Kavuri, Shyam M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Saunthararajah, Yogen] Cleveland Clin Fdn, Dept Translat Hematol & Oncol Res, 9500 Euclid Ave, Cleveland, OH 44195 USA; [de Lima, Marcos] Univ Hosp Cleveland, Dept Med, Med Ctr, 2074 Abington Rd, Cleveland, OH 44106 USA; [Tochtrop, Gregory P.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; [Wald, David N.] Louis Stokes Cleveland VA Med Ctr, Dept Pathol, Cleveland, OH 44106 USA	Case Western Reserve University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Wald, DN (corresponding author), Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.; Wald, DN (corresponding author), CuronBiotech Inc, Cleveland, OH 44106 USA.; Wald, DN (corresponding author), Louis Stokes Cleveland VA Med Ctr, Dept Pathol, Cleveland, OH 44106 USA.	dnw@case.edu			Case Comprehensive Cancer Center [P30CA043703]; NIH [U24DK097153, R43CA22870]; VA medical center grant [I01BX004995]; American Cancer Society (ACS) [127430-RSG-15-105-01-CNE]; NIH/NCI [R01CA216426, R01CA220297];  [W81XWH-18-10035];  [W81XWH-18-1-0084]	Case Comprehensive Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA medical center grant; American Cancer Society (ACS)(American Cancer Society); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; 	analysis of the mass spectrometry data. This research was supported by the Hematopoietic Biorepository and Cellular Therapy, Athymic Animal and Preclinical Therapeutics, Proteomics and Cytometry and Imaging Microscopy Shared Resources of the Case Comprehensive Cancer Center (P30CA043703). The research was also supported by the NIH grant R43CA22870 (D.N.W. and Y.H.) and VA medical center grant I01BX004995. Targeted metabolomics performed at the University of Michigan metabolomics core was supported by the NIH grant U24DK097153. This research was supported by American Cancer Society (ACS) Award 127430-RSG-15-105-01-CNE (N.P.), NIH/NCI R01CA220297 (N.P), and NIH/NCI R01CA216426 (N.P.). W81XWH-18-10035 and W81XWH-18-1-0084 to S.M.K.	American Cancer Society, 2018, CANC FACTS FIG, DOI [10.1182/blood-2015-12-687814, DOI 10.1182/BLOOD-2015-12-687814]; Arner ESJ, 2009, BBA-GEN SUBJECTS, V1790, P495, DOI 10.1016/j.bbagen.2009.01.014; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arnold JM., 2019, ONCOGENE, P3138; BEUTLER JA, 1985, BRAIN RES, V330, P135, DOI 10.1016/0006-8993(85)90014-9; Cassidy PB, 2015, PIGM CELL MELANOMA R, V28, P685, DOI 10.1111/pcmr.12398; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chapuis N, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00405; Chaturvedi A, 2013, BLOOD, V122, P2877, DOI 10.1182/blood-2013-03-491571; Daloso DM, 2015, P NATL ACAD SCI USA, V112, pE1392, DOI 10.1073/pnas.1424840112; De Kouchkovsky I, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.50; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Dong NZ, 1999, ACTA PHARMACOL SIN, V20, P267; Fritz-Wolf K, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1382; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gupta K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021203; Hou W, 2016, EUR J MED CHEM, V122, P149, DOI 10.1016/j.ejmech.2016.06.021; Kaplan A, 2015, ACS MED CHEM LETT, V6, P966, DOI 10.1021/acsmedchemlett.5b00014; Leonoudakis D, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/8302636; Levis M, 2013, BLOOD, V122, P2770, DOI 10.1182/blood-2013-09-522441; Li L, 2015, REDOX BIOL, V4, P127, DOI 10.1016/j.redox.2014.12.001; Lincoln DT, 2003, ANTICANCER RES, V23, P2425; Liu XD, 2011, CHEM RES TOXICOL, V24, P726, DOI 10.1021/tx2000152; Lomenick Brett, 2011, Curr Protoc Chem Biol, V3, P163; Lomenick B, 2009, P NATL ACAD SCI USA, V106, P21984, DOI 10.1073/pnas.0910040106; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Peng XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep28080; Pfleger J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.202; Pollyea DA, 2018, NAT MED, V24, P1859, DOI 10.1038/s41591-018-0233-1; Radenkovic F, 2017, BIOCHEM PHARMACOL, V146, P42, DOI 10.1016/j.bcp.2017.09.009; Rana S, 2010, FASEB J, V24, P2126, DOI 10.1096/fj.09-148999; Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008-5472.CAN-12-1370; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Schmidtmann E, 2014, MOL PLANT, V7, P156, DOI 10.1093/mp/sst144; Shipman M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041278; Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015; Sriskanthadevan S, 2015, BLOOD, V125, P2120, DOI 10.1182/blood-2014-08-594408; Stafford WC, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaf7444; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Urig S, 2006, SEMIN CANCER BIOL, V16, P452, DOI 10.1016/j.semcancer.2006.09.004; Vantaku V, 2019, CLIN CANCER RES, V25, P3689, DOI 10.1158/1078-0432.CCR-18-1515; Yu R, 1997, J BIOL CHEM, V272, P28962, DOI 10.1074/jbc.272.46.28962; Zhang BX, 2017, EXPERT OPIN THER PAT, V27, P547, DOI 10.1080/13543776.2017.1272576; Zhang JM, 2019, MED RES REV, V39, P5, DOI 10.1002/med.21507; Zhang JM, 2017, TRENDS PHARMACOL SCI, V38, P794, DOI 10.1016/j.tips.2017.06.001; Zhang JM, 2017, BBA-MOL BASIS DIS, V1863, P129, DOI 10.1016/j.bbadis.2016.10.019	46	6	6	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5236	5246		10.1038/s41388-021-01924-0	http://dx.doi.org/10.1038/s41388-021-01924-0		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34239044	Green Accepted			2022-12-28	WOS:000670851600001
J	Xiang, Z; Zhou, ZJ; Song, SZ; Li, J; Ji, J; Yan, RL; Wang, JX; Cai, W; Hu, WJ; Zang, L; Zhu, ZG; Zhang, Z; Li, M; Yu, YY				Xiang, Zhen; Zhou, Zhijun; Song, Shuzheng; Li, Jun; Ji, Jun; Yan, Ranlin; Wang, Jiexuan; Cai, Wei; Hu, Wenjun; Zang, Lu; Zhu, Zhenggang; Zhang, Zhen; Li, Min; Yu, Yingyan			Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways	ONCOGENE			English	Article							GLUCOCORTICOIDS; EXPRESSION; COVID-19; CELLS	T cell exhaustion plays critical roles in tumor immune evasion. Novel strategies to suppress immune evasion are in urgent need. We aimed to identify potential compounds to target T cell exhaustion and increase response to immune checkpoint inhibitors (ICIs). Differentially expressed genes (DEGs) were identified between tumors with different immune evasion potential by comparing the transcriptome data. DEGs were then analyzed in the Connectivity Map (CMap) platform to identify potential compounds to increase response to ICIs. Gene set enrichment analysis, LDH release assay, Chromatin immunoprecipitation (ChIP), and Co-IP were performed to explore the potential mechanisms in vitro. Patients derived organoids and humanized xenograft mouse model were utilized to validate the finding ex vivo and in vivo. We identified 25 potential compounds that may play critical roles in regulating tumor immune evasion. We further pinpointed a specific compound, dexamethasone, which shows potent anti-tumor effect in multiple cancer cell lines when cocultured with T cells. Dexamethasone can suppress T cell exhaustion by decreasing the activity of two immune checkpoints simultaneously, including PD-L1 and IDO1. Functional study shows dexamethasone can increase the sensitivity of ICIs in coculture system, 3D organoid model and humanized mouse model. Mechanism study shows dexamethasone mediated transcriptional suppression of PD-L1 and IDO1 depends on the nuclear translocation of GR/STAT3 complex. These findings demonstrate dexamethasone can suppress immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways.	[Xiang, Zhen; Song, Shuzheng; Li, Jun; Ji, Jun; Yan, Ranlin; Wang, Jiexuan; Cai, Wei; Hu, Wenjun; Zang, Lu; Zhu, Zhenggang; Yu, Yingyan] Shanghai Jiao Tong Univ, Dept Gen Surg, Sch Med, Ruijin Hosp,Shanghai Inst Digest Surg, Shanghai, Peoples R China; [Xiang, Zhen; Song, Shuzheng; Li, Jun; Ji, Jun; Yan, Ranlin; Wang, Jiexuan; Cai, Wei; Hu, Wenjun; Zang, Lu; Zhu, Zhenggang; Yu, Yingyan] Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Sch Med, Shanghai, Peoples R China; [Zhou, Zhijun; Li, Min] Univ Oklahoma, Dept Med, Hlth Sci Ctr, Oklahoma City, OK 73104 USA; [Zhou, Zhijun; Li, Min] Univ Oklahoma, Dept Surg, Hlth Sci Ctr, Oklahoma City, OK 73104 USA; [Zhang, Zhen] Fudan Univ, Shanghai Med Coll, Dept Radiat Oncol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China; [Zhang, Zhen] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Fudan University; Fudan University	Yu, YY (corresponding author), Shanghai Jiao Tong Univ, Dept Gen Surg, Sch Med, Ruijin Hosp,Shanghai Inst Digest Surg, Shanghai, Peoples R China.; Yu, YY (corresponding author), Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Sch Med, Shanghai, Peoples R China.; Li, M (corresponding author), Univ Oklahoma, Dept Med, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.; Li, M (corresponding author), Univ Oklahoma, Dept Surg, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.; Zhang, Z (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Radiat Oncol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China.; Zhang, Z (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China.	zhen_zhang@fudan.edu.cn; Min-Li@ouhsc.edu; yingyan3y@sjtu.edu.cn	Zhou, Zhijun/AAU-9428-2021	Zhou, Zhijun/0000-0003-2226-2223	Chinese National Key Program [MOST-2017YFC0908300, 2016YFC1303200]; National Natural Science Foundation of China [82072602, 81772505]; Shanghai Science and Technology Committee [20DZ2201900, 18411953100]; cross-institute innovation foundation of Shanghai Jiao Tong University [YG2017ZD01]; Innovation Foundation of Translational Medicine of Shanghai Jiao Tong University School of Medicine [TM202001, 15ZH4001, TM201617, TM 201702]; Technology Transfer Project of Science & Technology Dept. Shanghai Jiao Tong University School of Medicine; Innovation Foundation for Doctor's Degree [BXJ201914]	Chinese National Key Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee(Shanghai Science & Technology Committee); cross-institute innovation foundation of Shanghai Jiao Tong University; Innovation Foundation of Translational Medicine of Shanghai Jiao Tong University School of Medicine; Technology Transfer Project of Science & Technology Dept. Shanghai Jiao Tong University School of Medicine; Innovation Foundation for Doctor's Degree	We acknowledge the open database of CCLE, TCGA and CMap. This project is partially supported by the Chinese National Key Program (MOST-2017YFC0908300 and 2016YFC1303200), the National Natural Science Foundation of China (82072602 and 81772505), Shanghai Science and Technology Committee (20DZ2201900 and 18411953100), the cross-institute innovation foundation of Shanghai Jiao Tong University (YG2017ZD01), the Innovation Foundation of Translational Medicine of Shanghai Jiao Tong University School of Medicine (TM202001, 15ZH4001, TM201617 and TM 201702), Technology Transfer Project of Science & Technology Dept. Shanghai Jiao Tong University School of Medicine, and Innovation Foundation for Doctor's Degree (BXJ201914) grants to Y. Yu.	AlBahrani S, 2021, J EPIDEMIOL GLOB HEA, V11, P233, DOI 10.2991/jegh.k.210112.001; [Anonymous], 2017, Cancer Discov, V7, pOF2, DOI 10.1158/2159-8290.CD-NB2017-100; Arbour KC, 2018, J CLIN ONCOL, V36, P2872, DOI 10.1200/JCO.2018.79.0006; Arumuggam N, 2015, PHYTOTHER RES, V29, P805, DOI 10.1002/ptr.5327; Badros A, 2017, BLOOD, V130, P1189, DOI 10.1182/blood-2017-03-775122; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Calagua C, 2017, CLIN CANCER RES, V23, P6812, DOI 10.1158/1078-0432.CCR-17-0807; Charles P, 2021, ANN RHEUM DIS, DOI 10.1136/annrheumdis-2021-219986; CONN DL, 1988, J RHEUMATOL, V15, P1181; De Santis M, 2021, ANN RHEUM DIS, DOI 10.1136/annrheumdis-2021-220044; Delavan B, 2018, DRUG DISCOV TODAY, V23, P382, DOI 10.1016/j.drudis.2017.10.009; Egberts JH, 2008, CANCER BIOL THER, V7, P1044, DOI 10.4161/cbt.7.7.6099; Fu HY, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2854186; Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834; Gruver-Yates Amanda L, 2013, Cells, V2, P202, DOI 10.3390/cells2020202; Harpaz I, 2013, EUR J IMMUNOL, V43, P758, DOI 10.1002/eji.201242613; Hsieh TC, 2022, ANN HEMATOL, V101, P431, DOI 10.1007/s00277-021-04457-4; Komiya T, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00423; Langlais D, 2012, MOL CELL, V47, P38, DOI 10.1016/j.molcel.2012.04.021; Langut Y, 2017, P NATL ACAD SCI USA, V114, P13655, DOI 10.1073/pnas.1714587115; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lau J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14572; Li GR, 2020, DIABETES RES CLIN PR, V168, DOI 10.1016/j.diabres.2020.108441; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Manzotti G, 2015, CELL CYCLE, V14, P2578, DOI 10.1080/15384101.2015.1033591; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; Muller AJ, 2019, SEMIN IMMUNOPATHOL, V41, P41, DOI 10.1007/s00281-018-0702-0; Nanki K, 2018, CELL, V174, P856, DOI 10.1016/j.cell.2018.07.027; Neal JT, 2018, CELL, V175, P1972, DOI 10.1016/j.cell.2018.11.021; Opitz CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019823; Ott M, 2015, GLIA, V63, P78, DOI 10.1002/glia.22734; Pitt JM, 2016, IMMUNITY, V44, P1255, DOI 10.1016/j.immuni.2016.06.001; Pontali E, 2021, J ALLERGY CLIN IMMUN, V147, P1217, DOI 10.1016/j.jaci.2021.01.024; Ramiro S, ANN RHEUM DIS, P2021; Ramiro S, 2020, ANN RHEUM DIS, V79, P1143, DOI 10.1136/annrheumdis-2020-218479; Robinson PC, 2021, LANCET RHEUMATOL, V3, pE168, DOI 10.1016/S2665-9913(21)00005-9; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Sun YP, 2009, J IMMUNOL, V182, P5899, DOI 10.4049/jimmunol.0804388; Venkitaraman R, 2015, EUR UROL, V67, P673, DOI 10.1016/j.eururo.2014.10.004; Wang J, 2019, CELL, V176, P334, DOI 10.1016/j.cell.2018.11.010; Xiang Z, 2017, ONCOGENE, V36, P5122, DOI 10.1038/onc.2017.108; Xiang Z, 2019, FRONT MED-PRC, V13, P24, DOI 10.1007/s11684-019-0679-7; Xiang Z, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00861; Yang RX, 2021, INT J BIOL SCI, V17, P1530, DOI 10.7150/ijbs.58695	49	14	14	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					5002	5012		10.1038/s41388-021-01897-0	http://dx.doi.org/10.1038/s41388-021-01897-0		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34175886	hybrid, Green Published			2022-12-28	WOS:000666835600001
J	Li, JJ; Chen, XL; Zhu, LQ; Lao, ZH; Zhou, TH; Zang, LJ; Ge, WY; Jiang, MY; Xu, JX; Cao, Y; Du, SQ; Yu, Y; Fan, GJ; Wang, HX				Li, Junjian; Chen, Xiaoliang; Zhu, Liqun; Lao, Zhenghong; Zhou, Tianhao; Zang, Lijuan; Ge, Weiyu; Jiang, Mengyi; Xu, Jingxuan; Cao, Yuan; Du, Shaoqian; Yu, Yue; Fan, Guangjian; Wang, Hongxia			SOX9 is a critical regulator of TSPAN8-mediated metastasis in pancreatic cancer	ONCOGENE			English	Article							STEM-CELLS; TUMOR; TETRASPANINS; EXPRESSION; INVASION; TSPAN8; CO-029; EGFR; TRANSCRIPTION; INDUCTION	Pancreatic ductal adenocarcinoma (PDAC) is the deadliest cancer mainly owing to its proclivity to early metastasis and the lack of effective targeted therapeutic drugs. Hence, understanding the molecular mechanisms underlying early invasion and metastasis by PDAC is imperative for improving patient outcomes. The present study identified that upregulation of TSPAN8 expression in PDAC facilitates metastasis in vivo and in vitro. We found SOX9 as a key transcriptional regulator of TSPAN8 expression in response to EGF stimulation. SOX9 modulation was sufficient to positively regulate endogenous expression of TSPAN8, with concomitant in vitro phenotypic changes such as loss of cell-matrix adherence and increased invasion. Moreover, increased SOX9 and TSPAN8 levels were shown to correlate in human pancreatic cancer specimens and downregulated in vitro by EGFR tyrosine kinase inhibitors. High expression of SOX9 and TSPAN8 has been associated with tumor stage, poor prognosis and poor patient survival in PDAC. In conclusion, this study highlights the importance of the EGF-SOX9-TSPAN8 signaling cascade in the control of PDAC invasion and implies that TSPAN8 may be a promising novel therapeutic target for the treatment of PDAC.	[Li, Junjian] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai, Peoples R China; [Li, Junjian; Zhou, Tianhao; Ge, Weiyu; Xu, Jingxuan; Cao, Yuan; Du, Shaoqian; Wang, Hongxia] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Oncol, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai, Peoples R China; [Chen, Xiaoliang] Shenzhen Guangming Dist Ctr Dis Control & Prevent, Ctr Chron Dis Control & Prevent, Shenzhen, Peoples R China; [Zhu, Liqun] Liyang Peoples Hosp, Dept Oncol, Liyang, Peoples R China; [Lao, Zhenghong] Deqing Peoples Hosp, Dept Oncol, Huzhou, Peoples R China; [Zang, Lijuan] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Pathol Ctr, Sch Med, Shanghai, Peoples R China; [Jiang, Mengyi] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Med Oncol, East Campus, Shanghai, Peoples R China; [Yu, Yue] Shanghai Expt Sch, Shanghai, Peoples R China; [Fan, Guangjian] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Translat Med Ctr, Sch Med, Shanghai, Peoples R China	Shanghai University of Medicine & Health Sciences; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Wang, HX (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Oncol, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai, Peoples R China.; Fan, GJ (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Translat Med Ctr, Sch Med, Shanghai, Peoples R China.	gjfan@shsmu.edu.cn; whx365@126.com	Li, Junjian/GSN-5570-2022	Li, Junjian/0000-0001-7970-4163; Xu, Jingxuan/0000-0002-9678-7906	National Natural Science Funds [82073269, 81772802]; Shanghai Science and Technology Innovation Action Plan [20XD1402800]; Clinical Research Plan of SHDC [SHDC2020CR2065B]; Construction Project of Shanghai Key Laboratory of Molecular Imaging [18DZ2260400]; Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program of Medical Technology of SUMHS); Huzhou Natural Science Funds [2017YZ11]	National Natural Science Funds(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Innovation Action Plan; Clinical Research Plan of SHDC; Construction Project of Shanghai Key Laboratory of Molecular Imaging; Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program of Medical Technology of SUMHS); Huzhou Natural Science Funds	This work was supported by the National Natural Science Funds (grant number 82073269 and 81772802), Shanghai Science and Technology Innovation Action Plan (grant number 20XD1402800) and Clinical Research Plan of SHDC (grant number SHDC2020CR2065B) to H.X.W., the Construction Project of Shanghai Key Laboratory of Molecular Imaging (grant number 18DZ2260400) and Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program of Medical Technology of SUMHS, 2018-2020) to J.J.L. and the Huzhou Natural Science Funds (grant number 2017YZ11) to Z.H.L.	Agaesse G, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.11; Anami K, 2016, GASTRIC CANCER, V19, P370, DOI 10.1007/s10120-015-0478-z; Chakravarty G, 2011, EXP BIOL MED, V236, P145, DOI 10.1258/ebm.2010.010086; Charrin S, 2014, J CELL SCI, V127, P3641, DOI 10.1242/jcs.154906; Chen NM, 2015, GASTROENTEROLOGY, V148, P1024, DOI 10.1053/j.gastro.2015.01.033; Chen T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01024-2; Cheung M, 2003, DEVELOPMENT, V130, P5681, DOI 10.1242/dev.00808; Dellle Cave D, 2020, ONCOGENE, V39, P4271, DOI 10.1038/s41388-020-1289-1; El Kharbili M, 2019, ONCOGENE, V38, P3781, DOI 10.1038/s41388-019-0691-z; Fang TT, 2016, ONCOTARGET, V7, P40630, DOI 10.18632/oncotarget.9769; Gesierich S, 2005, CLIN CANCER RES, V11, P2840, DOI 10.1158/1078-0432.CCR-04-1935; Giampieri R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215990; Greco C, 2010, CANCER RES, V70, P7674, DOI 10.1158/0008-5472.CAN-09-4482; Grimont A, 2015, GUT, V64, P1790, DOI 10.1136/gutjnl-2014-307075; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Hessmann E, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5272498; Higashihara T, 2017, PANCREAS, V46, P1296, DOI 10.1097/MPA.0000000000000945; Hu B, 2017, ONCOL LETT, V14, P7583, DOI 10.3892/ol.2017.7160; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kaushik G, 2021, ONCOGENE, V40, P848, DOI 10.1038/s41388-020-01564-w; Kawaguchi Y, 2013, J CLIN INVEST, V123, P1881, DOI 10.1172/JCI66022; Kim TK, 2015, BIOCHEM BIOPH RES CO, V468, P774, DOI 10.1016/j.bbrc.2015.11.031; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Kyuno D, 2019, TRANSL ONCOL, V12, P191, DOI 10.1016/j.tranon.2018.08.021; Larsimont JC, 2015, CELL STEM CELL, V17, P60, DOI 10.1016/j.stem.2015.05.008; Ling SZ, 2011, CANCER RES, V71, P3812, DOI 10.1158/0008-5472.CAN-10-3072; Liu HW, 2015, CELL BIOCHEM BIOPHYS, V73, P205, DOI 10.1007/s12013-015-0647-z; Luanpitpong S, 2016, ONCOGENE, V35, P2824, DOI 10.1038/onc.2015.351; Mu W, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020319; Mu W, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01359; Nedaeinia R, 2014, CURR DRUG TARGETS, V15, P1293, DOI 10.2174/1389450115666141125123003; Park CS, 2016, ONCOGENE, V35, P4540, DOI 10.1038/onc.2015.520; Park SJ, 2015, INT J CLIN EXP PATHO, V8, P8298; Pishvaian MJ, 2020, LANCET ONCOL, V21, P508, DOI 10.1016/S1470-2045(20)30074-7; Pritchett J, 2011, TRENDS MOL MED, V17, P166, DOI 10.1016/j.molmed.2010.12.001; Rana S, 2011, INT J BIOCHEM CELL B, V43, P106, DOI 10.1016/j.biocel.2010.10.002; Shi JG, 2018, INT J ONCOL, V52, P179, DOI 10.3892/ijo.2017.4201; Shi ZC, 2015, NUCLEIC ACIDS RES, V43, P6257, DOI 10.1093/nar/gkv568; Shih HP, 2012, DEVELOPMENT, V139, P2488, DOI 10.1242/dev.078634; Si JL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-92; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sun L, 2013, STEM CELLS, V31, P1454, DOI 10.1002/stem.1394; Swartling FJ, 2012, CANCER CELL, V21, P601, DOI 10.1016/j.ccr.2012.04.012; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; Tang L, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0232-1; Blasco MT, 2019, CANCER CELL, V35, P573, DOI 10.1016/j.ccell.2019.03.002; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Voglstaetter M, 2019, J PATHOL, V248, P421, DOI 10.1002/path.5281; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wang HB, 2013, INT J CANCER, V133, P416, DOI 10.1002/ijc.28044; Wang LD, 2019, GENE DEV, V33, P641, DOI 10.1101/gad.323303.118; Yan SY, 2018, GENE, V679, P138, DOI 10.1016/j.gene.2018.08.038; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yue GGL, 2015, AM J CANCER RES, V5, P3570; Yue SJ, 2015, ONCOTARGET, V6, P2366, DOI 10.18632/oncotarget.2958; Zhou H, 2018, ONCOGENE, V37, P912, DOI 10.1038/onc.2017.393; Zhu RX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10739-3	58	7	8	7	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4884	4893		10.1038/s41388-021-01864-9	http://dx.doi.org/10.1038/s41388-021-01864-9		JUN 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34163029	hybrid, Green Published			2022-12-28	WOS:000664853000005
J	Bi, XY; Lou, PB; Song, YL; Sheng, XL; Liu, RQ; Deng, M; Yang, X; Li, GL; Yuan, SK; Zhang, HL; Jiao, BW; Zhang, B; Xue, LX; Liu, ZH; Plikus, MV; Ren, FZ; Gao, S; Zhao, L; Yu, ZQ				Bi, Xueyun; Lou, Pengbo; Song, Yongli; Sheng, Xiaole; Liu, Ruiqi; Deng, Min; Yang, Xu; Li, Guilin; Yuan, Shukai; Zhang, Honglei; Jiao, Baowei; Zhang, Bing; Xue, Lixiang; Liu, Zhihua; Plikus, Maksim, V; Ren, Fazheng; Gao, Shan; Zhao, Li; Yu, Zhengquan			Msi1 promotes breast cancer metastasis by regulating invadopodia-mediated extracellular matrix degradation via the Timp3-Mmp9 pathway	ONCOGENE			English	Article							BINDING PROTEIN MUSASHI1; TISSUE INHIBITORS; RNA; METALLOPROTEINASES; INVASION; CORTACTIN; MIGRATION; CELLS; TRAFFICKING; ASSOCIATION	Metastasis is the main cause of death in breast cancer patients. The initial step of metastasis is invadopodia-mediated extracellular matrix (ECM) degradation, which enables local breast tumor cells to invade surrounding tissues. However, the molecular mechanism underlying invadopodia-mediated metastasis remains largely unknown. Here we found that the RNA-binding protein Musashi1 (Msi1) exhibited elevated expression in invasive breast tumors and promoted lung metastasis of mammary cancer cells. Suppression of Msi1 reduced invadopodia formation in mammary cancer cells. Furthermore, Msi1 deficiency decreased the expression and activity of Mmp9, an important enzyme in ECM degradation. Mechanistically, Msi1 directly suppressed Timp3, an endogenous inhibitor of Mmp9. In clinical breast cancer specimens, TIMP3 and MSI1 levels were significantly inversely correlated both in normal breast tissue and breast cancer tissues and associated with overall survival in breast cancer patients. Taken together, our findings demonstrate that the MSI1-TIMP3-MMP9 cascade is critical for invadopodia-mediated onset of metastasis in breast cancer, providing novel insights into a promising therapeutic strategy for breast cancer metastasis.	[Bi, Xueyun; Lou, Pengbo; Sheng, Xiaole; Liu, Ruiqi; Deng, Min; Yang, Xu; Li, Guilin; Yu, Zhengquan] China Agr Univ, Coll Biol Sci, Dept Nutr & Hlth, Key Lab Precis Nutr & Food Qual,Minist Educ, Beijing, Peoples R China; [Song, Yongli] Inner Mongolia Univ, State Key Lab Reprod Regulat & Breeding Grassland, Coll Life Sci, Hohhot, Peoples R China; [Song, Yongli] Inner Mongolia Univ, Res Ctr Anim Genet Resources Mongolia Plateau, Coll Life Sci, Hohhot, Peoples R China; [Yuan, Shukai; Zhao, Li] Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc,Sch Basic Med Sci,Key Lab, Tianjins Clin Res Ctr Canc,Dept Biochem & Mol Bio, Tianjin, Peoples R China; [Zhang, Honglei] Yunnan Univ Chinese Med, Ctr Sci Res, Kunming, Yunnan, Peoples R China; [Jiao, Baowei] Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Kunming, Yunnan, Peoples R China; [Zhang, Bing] China Agr Univ, Coll Vet Med, Beijing, Peoples R China; [Xue, Lixiang] Peking Univ Third Hosp, Med Res Ctr, Dept Radiat Oncol, Beijing, Peoples R China; [Liu, Zhihua] Chinese Acad Med Sci, Natl Canc Ctr, State Key Lab Mol Oncol, Canc Hosp, Beijing, Peoples R China; [Plikus, Maksim, V] Univ Calif Irvine, Dept Dev & Cell Biol, Ctr Complex Biol Syst, Sue & Bill Gross Stem Cell Res Ctr, Irvine, CA 92717 USA; [Ren, Fazheng] China Agr Univ, Coll Food Sci & Nutr Engn, Dept Nutr & Hlth, Key Lab Precis Nutr & Food Qual,Minist Educ, Beijing, Peoples R China; [Gao, Shan] Chinese Acad Sci, Suzhou Inst Biomed Engn & Technol, CAS Key Lab Biomed Diagnost, Suzhou, Jiangsu, Peoples R China	China Agricultural University; Inner Mongolia University; Inner Mongolia University; Tianjin Medical University; Yunnan University of Chinese Medicine; Chinese Academy of Sciences; Kunming Institute of Zoology; China Agricultural University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; University of California System; University of California Irvine; China Agricultural University; Chinese Academy of Sciences; Suzhou Institute of Biomedical Engineering & Technology, CAS	Yu, ZQ (corresponding author), China Agr Univ, Coll Biol Sci, Dept Nutr & Hlth, Key Lab Precis Nutr & Food Qual,Minist Educ, Beijing, Peoples R China.; Zhao, L (corresponding author), Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc,Sch Basic Med Sci,Key Lab, Tianjins Clin Res Ctr Canc,Dept Biochem & Mol Bio, Tianjin, Peoples R China.	shzhaoli@tmu.edu.cn; zyu@cau.edu.cn	邓, 敏/GRS-4423-2022	邓, 敏/0000-0002-0338-8253; Plikus, Maksim/0000-0002-8845-2559; Bi, Xueyun/0000-0002-0367-0590; Lou, Pengbo/0000-0002-7525-0173; Yuan, Shukai/0000-0003-0354-5113; JIAO, BAOWEI/0000-0001-8559-9160	National Natural Science Foundation of China [81772984, 81572614]; Beijing Nature Foundation Grant [5162018]; Major Project for Cultivation Technology [2016ZX08008001, 2014ZX08008001]; Basic Research Program [2019TC227, 2019TC088]; SKLAB Open Grant [2020SKLAB6-18]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Nature Foundation Grant; Major Project for Cultivation Technology; Basic Research Program; SKLAB Open Grant	This work is supported by the National Natural Science Foundation of China (Nos. 81772984, 81572614), Beijing Nature Foundation Grant (5162018), the Major Project for Cultivation Technology (2016ZX08008001, 2014ZX08008001), Basic Research Program (2019TC227, 2019TC088), and SKLAB Open Grant (2020SKLAB6-18). The authors thank the members of the laboratory animal center in China Agricultural University for their assistance in animal care.	Abreu RD, 2009, J BIOL CHEM, V284, P12125, DOI 10.1074/jbc.M809605200; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Ala-Aho R, 2005, BIOCHIMIE, V87, P273, DOI 10.1016/j.biochi.2004.12.009; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; Artym Vira V., 2009, V522, P211, DOI 10.1007/978-1-59745-413-1_15; Ascano M, 2013, CURR OPIN GENET DEV, V23, P20, DOI 10.1016/j.gde.2013.01.003; Olivares-Urbano MA, 2020, J CELL MOL MED, V24, P139, DOI 10.1111/jcmm.14671; Ayala I, 2008, J CELL SCI, V121, P369, DOI 10.1242/jcs.008037; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003; Carman CV, 2007, IMMUNITY, V26, P784, DOI 10.1016/j.immuni.2007.04.015; Castagnino A, 2018, ONCOGENE, V37, P6425, DOI 10.1038/s41388-018-0422-x; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chen HY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09504-7; Cheung KJ, 2016, SCIENCE, V352, P167, DOI 10.1126/science.aaf6546; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Courtneidge SA, 2005, COLD SH Q B, V70, P167, DOI 10.1101/sqb.2005.70.014; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Fehm T, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2349; Fox RG, 2016, NATURE, V534, P407, DOI 10.1038/nature17988; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Gong PJ, 2017, HUM PATHOL, V65, P53, DOI 10.1016/j.humpath.2016.12.026; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Henras AK, 2008, CELL MOL LIFE SCI, V65, P2334, DOI 10.1007/s00018-008-8027-0; Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001; Jacob A, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00004; Kang MH, 2017, ONCOGENE, V36, P1745, DOI 10.1038/onc.2016.327; Katz Y, 2014, ELIFE, V3, DOI 10.7554/eLife.03915; Khokha R, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004333; Li M, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01587-x; Li N, 2015, CELL REP, V13, P2440, DOI 10.1016/j.celrep.2015.11.022; Li W, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0495-y; Lin JC, 2018, RADIOTHER ONCOL, V129, P352, DOI 10.1016/j.radonc.2018.09.014; Mehner C, 2014, ONCOTARGET, V5, P2736, DOI 10.18632/oncotarget.1932; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Nahas GR, 2016, FASEB J, V30, P149, DOI 10.1096/fj.15-278770; Okano H, 2002, J CELL SCI, V115, P1355; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Owyong M, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201800226; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Paz H, 2014, ONCOGENE, V33, P4193, DOI 10.1038/onc.2013.393; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Raimondi C, 2011, BREAST CANCER RES TR, V130, P449, DOI 10.1007/s10549-011-1373-x; Sanchez-Diaz PC, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-280; Schoumacher M, 2010, J CELL BIOL, V189, P541, DOI 10.1083/jcb.200909113; Shi JY, 2018, J INVEST DERMATOL, V138, P2253, DOI 10.1016/j.jid.2018.03.1521; Sun Y, 2015, ONCOL REP, V33, P338, DOI 10.3892/or.2014.3585; Tinhofer I, 2014, INT J RADIAT BIOL, V90, P622, DOI 10.3109/09553002.2014.886798; Vo DT, 2011, RNA BIOL, V8, P817, DOI 10.4161/rna.8.5.16041; Wang S, 2009, P NATL ACAD SCI USA, V106, P151, DOI 10.1073/pnas.0808703105; Wang XY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-221; Wang ZQ, 2017, DEV CELL, V43, P186, DOI 10.1016/j.devcel.2017.09.012; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Zhang Z, 2018, ARCH GYNECOL OBSTET, V297, P433, DOI 10.1007/s00404-017-4598-z	57	6	7	4	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4832	4845		10.1038/s41388-021-01873-8	http://dx.doi.org/10.1038/s41388-021-01873-8		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34155343				2022-12-28	WOS:000664006400002
J	Wang, HY; Wang, X; Zhang, HY; Deng, T; Liu, R; Liu, Y; Li, HL; Bai, M; Ning, T; Wang, JY; Ge, SH; Ba, Y				Wang, Huiya; Wang, Xia; Zhang, Haiyang; Deng, Ting; Liu, Rui; Liu, Ying; Li, Hongli; Bai, Ming; Ning, Tao; Wang, Junyi; Ge, Shaohua; Ba, Yi			The HSF1/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MUL1/ULK1 pathway in colorectal cancer	ONCOGENE			English	Article							ADJUVANT CHEMOTHERAPY; OPEN-LABEL; CELLS; CHEMORESISTANCE; MIR-135B-5P; MICRORNAS; TUMORIGENESIS; FLUOROURACIL; LEUCOVORIN; MECHANISM	Oxaliplatin (oxa) is widely used in the treatment of colorectal cancer (CRC), but the development of oxaliplatin resistance is a major obstacle to the therapeutic efficacy in patients. MicroRNAs (miRNAs), endogenous noncoding RNAs measuring between 22 and 24 nucleotides, have been shown to be involved in the development of CRC drug resistance. However, the mechanism by which differentially expressed miRNAs induce chemotherapy resistance in CRC has not been fully elucidated to date. Here, we showed the differentially expressed miRNAs in oxaliplatin-sensitive and oxaliplatin-resistant CRC cells through miRNA microarray technology and found that miR-135b-5p was significantly increased in oxaliplatin-resistant cells. And miR-135b-5p was increased in the serum of colorectal cancer patients. More importantly, the miR-135b-5p level in the serum of oxaliplatin-resistant patients was further increased compared to that of oxaliplatin-sensitive patients. Recent studies have shown that protective autophagy is an important mechanism that promotes drug resistance in tumors. The potential role of miR-135b-5p in inducing protective autophagy and promoting oxaliplatin resistance was evaluated in two stable oxaliplatin-resistant CRC cell lines and their parental cells. We further identified MUL1 as a direct downstream target of miR-135b-5p and showed that MUL1 could degrade the key molecule of autophagy, ULK1, through ubiquitination. Mouse xenograft models were adopted to evaluate the correlation between miR-135b-5p and oxaliplatin-induced autophagy in vivo. Furthermore, we also investigated the regulatory factors for the upregulation of miR-135b-5p in CRC cells under oxaliplatin chemotoxicity. These results indicated that miR-135b-5p upregulation in colorectal cancer could induce protective autophagy through the MUL1/ULK1 signaling pathway and promote oxaliplatin resistance. Targeting miR-135b-5p may provide a new treatment strategy for reversing oxaliplatin resistance in CRC.	[Wang, Huiya; Wang, Xia; Zhang, Haiyang; Deng, Ting; Liu, Rui; Liu, Ying; Li, Hongli; Bai, Ming; Ning, Tao; Wang, Junyi; Ge, Shaohua; Ba, Yi] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China	Tianjin Medical University	Ba, Y (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.	bayi@tjmuch.com	wang, junyi/GYA-3213-2022		National Natural Science Foundation of China [82072664, 81772629, 81802363, 81702431, 81772843, 81974374]; Demonstrative Research Platform of Clinical Evaluation Technology for New Anticancer Drugs [2018ZX09201015]; Tianjin Science Foundation [18JCQNJC81900, 18JCYBJC92000, 18JCYBJC25400, 18JCYBJC92900, 20JCYBJC00100]; Science & Technology Development Fund of the Tianjin Education Commission for Higher Education [2018KJ046, 2017KJ227]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Demonstrative Research Platform of Clinical Evaluation Technology for New Anticancer Drugs; Tianjin Science Foundation(Natural Science Foundation of Tianjin); Science & Technology Development Fund of the Tianjin Education Commission for Higher Education	This work was supported by grants from the National Natural Science Foundation of China (Nos. 82072664, 81772629, 81802363, 81702431, 81772843, 81974374) and the Demonstrative Research Platform of Clinical Evaluation Technology for New Anticancer Drugs (No. 2018ZX09201015). This work was also supported by the Tianjin Science Foundation (Nos. 18JCQNJC81900, 18JCYBJC92000, 18JCYBJC25400, 18JCYBJC92900, 20JCYBJC00100) and the Science & Technology Development Fund of the Tianjin Education Commission for Higher Education (2018KJ046, 2017KJ227). The funders had no role in the study design, the data collection and analysis, the interpretation of the data, the writing of the report, and the decision to submit this article for publication.	Andre T, 2018, J CLIN ONCOL, V36, P1469, DOI 10.1200/JCO.2017.76.0355; Bai M, 2019, MOL THER, V27, P1772, DOI 10.1016/j.ymthe.2019.06.018; Bertoli G, 2015, THERANOSTICS, V5, P1122, DOI 10.7150/thno.11543; Chen H, 2019, ONCOTARGETS THER, V12, P3869, DOI 10.2147/OTT.S207938; Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Hong YS, 2014, LANCET ONCOL, V15, P1245, DOI 10.1016/S1470-2045(14)70377-8; Iqbal MA, 2019, MOL ASPECTS MED, V70, P3, DOI 10.1016/j.mam.2018.07.003; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Li J, 2015, AUTOPHAGY, V11, P1216, DOI 10.1080/15548627.2015.1017180; Li W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001487; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu B, 2017, MOL CARCINOGEN, V56, P2669, DOI 10.1002/mc.22710; Liu T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0981-7; Lorente J, 2018, BIOL REV, V93, P152, DOI 10.1111/brv.12337; Lv ZD, 2019, J CELL PHYSIOL, V234, P10819, DOI 10.1002/jcp.27906; Magalhaes L, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4980-7; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Mishra S, 2016, CRIT REV ONCOL HEMAT, V98, P12, DOI 10.1016/j.critrevonc.2015.10.003; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Neuspiel M, 2008, CURR BIOL, V18, P102, DOI 10.1016/j.cub.2007.12.038; Pan XF, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1660-8; Poultsides GA, 2009, J CLIN ONCOL, V27, P3379, DOI 10.1200/JCO.2008.20.9817; Puri R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11636-5; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Seo HA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010029; Shao LL, 2019, FASEB J, V33, P264, DOI 10.1096/fj.201701456RR; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; Su WM, 2016, BIOMED PHARMACOTHER, V84, P123, DOI 10.1016/j.biopha.2016.09.027; Sun W, 2020, THERANOSTICS, V10, P1981, DOI 10.7150/thno.37621; Umezu T, 2014, BLOOD, V124, P3748, DOI 10.1182/blood-2014-05-576116; Vihervaara A, 2014, J CELL SCI, V127, P261, DOI 10.1242/jcs.132605; Wang N, 2016, ONCOL LETT, V11, P543, DOI 10.3892/ol.2015.3970; Wang Q, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00308; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Zachari M, 2017, ESSAYS BIOCHEM, V61, P585, DOI 10.1042/EBC20170021; Zhang BC, 2008, CELL RES, V18, P900, DOI 10.1038/cr.2008.75; Zhang Y, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1024-3; Zhang ZL, 2017, BIOMED PHARMACOTHER, V96, P1341, DOI 10.1016/j.biopha.2017.11.074; Zhou CF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01237-y	45	9	9	4	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4695	4708		10.1038/s41388-021-01898-z	http://dx.doi.org/10.1038/s41388-021-01898-z		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34140641				2022-12-28	WOS:000662838900005
J	McNamara, KM; Gobert, AP; Wilson, KT				McNamara, Kara M.; Gobert, Alain P.; Wilson, Keith T.			The role of polyamines in gastric cancer	ONCOGENE			English	Review							INITIATION-FACTOR 5A; ORNITHINE-DECARBOXYLASE ACTIVITY; HELICOBACTER-PYLORI; HYPUSINE MODIFICATION; MACROPHAGE APOPTOSIS; ALPHA-DIFLUOROMETHYLORNITHINE; DEOXYHYPUSINE HYDROXYLASE; SPERMINE OXIDASE; IMMUNE-RESPONSE; CELL VIABILITY	Advancements in our understanding of polyamine molecular and cellular functions have led to increased interest in targeting polyamine metabolism for anticancer therapeutic benefits. The polyamines putrescine, spermidine, and spermine are polycationic alkylamines commonly found in all living cells and are essential for cellular growth and survival. This review summarizes the existing research on polyamine metabolism and function, specifically the role of polyamines in gastric immune cell and epithelial cell function. Polyamines have been implicated in a multitude of cancers, but in this review, we focus on the role of polyamine dysregulation in the context of Helicobacter pylori-induced gastritis and subsequent progression to gastric cancer. Due to the emerging implication of polyamines in cancer development, there is an increasing number of promising clinical trials using agents to target the polyamine metabolic pathway for potential chemoprevention and anticancer therapy.	[McNamara, Kara M.; Gobert, Alain P.; Wilson, Keith T.] Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37212 USA; [McNamara, Kara M.; Wilson, Keith T.] Program Canc Biol, Nashville, TN 37232 USA; [Gobert, Alain P.; Wilson, Keith T.] Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA; [Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Wilson, Keith T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Wilson, KT (corresponding author), Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37212 USA.; Wilson, KT (corresponding author), Program Canc Biol, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA.	keith.wilson@vumc.org		Wilson, Keith/0000-0003-4421-1830	NIH [R01CA190612, P01CA116087, P01CA028842, R21AI142042, T32CA009592]; Veterans Affairs Merit Review grants [I01BX001453, I01CX002171]; Department of Defense [W81XWH-18-1-0301]; Crohn's & Colitis Foundation Senior Research Award [703003]; Vanderbilt Center for Mucosal Inflammation and Cancer; Vanderbilt Digestive Disease Research Center (NIH) [P30DK058404]; Thomas F. Frist Sr. Endowment	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs Merit Review grants(US Department of Veterans Affairs); Department of Defense(United States Department of Defense); Crohn's & Colitis Foundation Senior Research Award; Vanderbilt Center for Mucosal Inflammation and Cancer; Vanderbilt Digestive Disease Research Center (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Thomas F. Frist Sr. Endowment	This work was funded by NIH grants R01CA190612 (K.T.W.), P01CA116087 (K.T.W.), P01CA028842 (K.T.W.), and R21AI142042 (K.T.W.); Veterans Affairs Merit Review grants I01BX001453 and I01CX002171 (K.T.W.); Department of Defense grant W81XWH-18-1-0301 (K.T.W.); Crohn's & Colitis Foundation Senior Research Award 703003 (K.T.W.); the Thomas F. Frist Sr. Endowment (K.T.W.); and the Vanderbilt Center for Mucosal Inflammation and Cancer (K.T.W.). K.T.W. also receives support from the Vanderbilt Digestive Disease Research Center (NIH grant P30DK058404). K.M.M. was supported by NIH grant T32CA009592.	ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; Aksu M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11952; Anderson CF, 2002, J LEUKOCYTE BIOL, V72, P101; Asim M, 2010, J BIOL CHEM, V285, P20343, DOI 10.1074/jbc.M110.116988; Barry DP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017510; Blaser MJ, 1997, J CLIN INVEST, V100, P759, DOI 10.1172/JCI119588; Bussiere FI, 2005, J BIOL CHEM, V280, P2409, DOI 10.1074/jbc.C400498200; Cano VSP, 2008, FEBS J, V275, P44, DOI 10.1111/j.1742-4658.2007.06172.x; Chaturvedi R, 2015, ONCOGENE, V34, P3429, DOI 10.1038/onc.2014.273; Chaturvedi R, 2004, J BIOL CHEM, V279, P40161, DOI 10.1074/jbc.M401370200; Chaturvedi R, 2014, AMINO ACIDS, V46, P531, DOI 10.1007/s00726-013-1531-z; Chaturvedi R, 2010, GASTROENTEROLOGY, V139, P1686, DOI 10.1053/j.gastro.2010.06.060; Chen KY, 1997, BIOL SIGNAL, V6, P105; Cheng Y, 2005, J BIOL CHEM, V280, P22492, DOI 10.1074/jbc.C500122200; Coni S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03174-6; Constanza Camargo M., 2007, Acta Gastroenterologica Latinoamericana, V37, P238; CORREA P, 1994, CANCER RES, V54, pS1941; CORREA P, 1992, CANCER RES, V52, P6735; Correa P, 2010, AM J GASTROENTEROL, V105, P493, DOI 10.1038/ajg.2009.728; Devens BH, 2000, PROSTATE CANCER P D, V3, P275, DOI 10.1038/sj.pcan.4500420; Ehrnstrom RA, 2006, SCAND J GASTROENTERO, V41, P12, DOI 10.1080/00365520510024106; Elitsur Y, 1999, LIFE SCI, V65, P1373, DOI 10.1016/S0024-3205(99)00376-8; Etemadi A, 2020, LANCET GASTROENTEROL, V5, P42, DOI 10.1016/S2468-1253(19)30328-0; Gamble LD, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau1099; Ge S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03121-2; Gobert AP, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108510; Gobert AP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01242; Gobert AP, 2017, CURR TOP MICROBIOL, V400, P27, DOI 10.1007/978-3-319-50520-6_2; Gobert AP, 2002, J IMMUNOL, V168, P4692, DOI 10.4049/jimmunol.168.9.4692; Gutierrez E, 2013, MOL CELL, V51, P35, DOI 10.1016/j.molcel.2013.04.021; Hardbower DM, 2017, P NATL ACAD SCI USA, V114, pE751, DOI 10.1073/pnas.1614958114; Hardbower DM, 2016, J CLIN INVEST, V126, P3296, DOI 10.1172/JCI83585; Hardbower DM, 2014, J LEUKOCYTE BIOL, V96, P201, DOI 10.1189/jlb.4BT0214-099R; Hirasawa R, 1999, AM J GASTROENTEROL, V94, P2398; Hooi JKY, 2017, GASTROENTEROLOGY, V153, P420, DOI 10.1053/j.gastro.2017.04.022; HORN Y, 1987, EUR J CANCER CLIN ON, V23, P1103, DOI 10.1016/0277-5379(87)90141-6; Iishi H, 1997, INT J CANCER, V73, P113; Jenkins ZA, 2001, GENOMICS, V71, P101, DOI 10.1006/geno.2000.6418; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338; Konturek PC, 2003, DIGEST DIS SCI, V48, P36, DOI 10.1023/A:1021774029089; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kountouras J, 2005, HEPATO-GASTROENTEROL, V52, P1305; Kramer DL, 2008, J BIOL CHEM, V283, P4241, DOI 10.1074/jbc.M706806200; Lewis ND, 2011, J IMMUNOL, V186, P3632, DOI 10.4049/jimmunol.1003431; Li DD, 2018, CLIN TRANSL MED, V7, DOI 10.1186/s40169-018-0184-7; Linsalata M, 1998, ITAL J GASTROENTEROL, V30, P484; LoGiudice Nicole, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6010012; LUNDELL L, 1986, SCAND J GASTROENTERO, V21, P829, DOI 10.3109/00365528609011126; Ma JL, 2012, J NATL CANCER I, V104, P488, DOI 10.1093/jnci/djs003; Maier B, 2010, J CLIN INVEST, V120, P2156, DOI 10.1172/JCI38924; MAMONT PS, 1978, BIOCHEM BIOPH RES CO, V81, P58, DOI 10.1016/0006-291X(78)91630-3; Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13; MATSUI I, 1981, J BIOL CHEM, V256, P2454; Mera R, 2005, GUT, V54, P1536, DOI 10.1136/gut.2005.072009; Mera RM, 2018, GUT, V67, P1239, DOI 10.1136/gutjnl-2016-311685; Meyskens FL, 2008, CANCER PREV RES, V1, P32, DOI 10.1158/1940-6207.CAPR-08-0042; Miao XP, 2007, WORLD J GASTROENTERO, V13, P2867, DOI 10.3748/wjg.v13.i20.2867; Michael AJ, 2016, J BIOL CHEM, V291, P14896, DOI 10.1074/jbc.R116.734780; Millward MJ, 2005, INVEST NEW DRUG, V23, P253, DOI 10.1007/s10637-005-6734-z; Milovic V, 2003, BIOCHEM SOC T, V31, P381, DOI 10.1042/BST0310381; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Munder M, 2009, BRIT J PHARMACOL, V158, P638, DOI 10.1111/j.1476-5381.2009.00291.x; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; Murray-Stewart T, 2016, ONCOGENE, V35, P5480, DOI 10.1038/onc.2016.91; Nakanishi S, 2016, AMINO ACIDS, V48, P2353, DOI 10.1007/s00726-016-2275-3; NASS MMK, 1984, CANCER RES, V44, P2677; Nishimura K, 2012, AMINO ACIDS, V42, P703, DOI 10.1007/s00726-011-0986-z; Okugawa Y, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1740-z; Oliveira C, 2015, LANCET ONCOL, V16, pE60, DOI 10.1016/S1470-2045(14)71016-2; Pallmann N, 2015, J BIOL CHEM, V290, P18343, DOI 10.1074/jbc.M115.664490; Park JH, 2006, P NATL ACAD SCI USA, V103, P51, DOI 10.1073/pnas.0509348102; Park MH, 1997, BIOL SIGNAL, V6, P115; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; Park MH, 2018, J BIOL CHEM, V293, P18710, DOI 10.1074/jbc.TM118.003341; PATCHETT SE, 1995, GUT, V37, P13, DOI 10.1136/gut.37.1.13; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; Pegg AE, 2006, J BIOL CHEM, V281, P14529, DOI 10.1074/jbc.R500031200; Pegg AE, 2009, IUBMB LIFE, V61, P880, DOI 10.1002/iub.230; Pelechano V, 2017, NUCLEIC ACIDS RES, V45, P7326, DOI 10.1093/nar/gkx479; Piazuelo MB, 2021, GASTROENTEROLOGY, V160, P1106, DOI 10.1053/j.gastro.2020.11.017; Pless M, 2004, CLIN CANCER RES, V10, P1299, DOI 10.1158/1078-0432.CCR-0977-03; PRAKASH NJ, 1978, CANCER RES, V38, P3059; Qiu SQ, 2017, CANCER SCI, V108, P163, DOI 10.1111/cas.13122; Rawla P, 2019, GASTROENTEROL REV, V14, P26, DOI 10.5114/pg.2018.80001; Romero-Gallo J, 2008, LAB INVEST, V88, P328, DOI 10.1038/labinvest.3700719; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; SAYDJARI R, 1991, CANCER INVEST, V9, P415, DOI 10.3109/07357909109084639; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; Schuller AP, 2017, MOL CELL, V66, P194, DOI 10.1016/j.molcel.2017.03.003; Sholler GLS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32659-w; Sierra JC, 2020, ONCOGENE, V39, P4465, DOI 10.1038/s41388-020-1304-6; Sierra JC, 2019, P NATL ACAD SCI USA, V116, P5077, DOI 10.1073/pnas.1814497116; Sievert H, 2014, DIS MODEL MECH, V7, P963, DOI 10.1242/dmm.014449; Takashima T, 2002, ALIMENT PHARM THERAP, V16, P167, DOI 10.1046/j.1365-2036.16.s2.20.x; TATSUTA M, 1995, CARCINOGENESIS, V16, P2107, DOI 10.1093/carcin/16.9.2107; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Vakal S, 2020, MOLECULES, V25, DOI 10.3390/molecules25061293; van Zuylen L, 2004, CLIN CANCER RES, V10, P1949, DOI 10.1158/1078-0432.CCR-02-0995; Vujcic S, 2003, BIOCHEM J, V370, P19, DOI 10.1042/BJ20021779; WANG JY, 1990, AM J PHYSIOL, V259, pG584; Wang X, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.114637; Wang YL, 2003, BIOCHEM BIOPH RES CO, V304, P605, DOI 10.1016/S0006-291X(03)00636-3; Wei G, 2007, MOL CARCINOGEN, V46, P611, DOI 10.1002/mc.20350; Wilson KT, 2007, GASTROENTEROLOGY, V133, P288, DOI 10.1053/j.gastro.2007.05.008; Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10; Xu AG, 2004, BIOCHEM J, V384, P585, DOI 10.1042/BJ20041232; Xu AG, 2001, J BIOL CHEM, V276, P2555, DOI 10.1074/jbc.M008982200; Xu CX, 2011, MOL BIOL REP, V38, P949, DOI 10.1007/s11033-010-0188-x; Xu F, 2020, CANCER MANAG RES, V12, P1789, DOI 10.2147/CMAR.S225229; Xu HX, 2004, CANCER RES, V64, P8521, DOI 10.1158/0008-5472.CAN-04-3511; Xu X, 2012, EXP BIOL MED, V237, P435, DOI 10.1258/ebm.2011.011199; You WC, 2006, JNCI-J NATL CANCER I, V98, P974, DOI 10.1093/jnci/djj264	113	7	7	3	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4399	4412		10.1038/s41388-021-01862-x	http://dx.doi.org/10.1038/s41388-021-01862-x		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34108618	Green Accepted			2022-12-28	WOS:000659470200003
J	You, J; Li, JY; Ke, CL; Xiao, YR; Lu, CH; Huang, FK; Mi, YJ; Xia, RM; Li, QY				You, Jun; Li, Jiayi; Ke, Chunlin; Xiao, Yanru; Lu, Chuanhui; Huang, Fakun; Mi, Yanjun; Xia, Rongmu; Li, Qiyuan			Oncogenic long intervening noncoding RNA Linc00284 promotes c-Met expression by sponging miR-27a in colorectal cancer	ONCOGENE			English	Article							THERAPEUTIC TARGET; HGF/C-MET; REGULATORY NETWORK; SIGNALING PATHWAY; MICRORNA; CONSTRUCTION; BIOMARKERS; MIRNA	Emerging evidences suggest that long noncoding RNA (lncRNA) plays a vital role in tumorigenesis and cancer progression. Here, the aim of this study is to investigate the biological function of long intervening noncoding RNA Linc00284 in colorectal cancer (CRC). The expression levels of Linc00284, miR-27a and c-Met were evaluated by qPCR and/or Western blotting. Immunohistochemistry was used to detect the expression of Ki67 and Phh3 in tumor tissues. The interaction between Linc00284, miR-27a and c-Met was validated by luciferase reporter assay and RNA immunoprecipitation (RIP) assay. Cell function experiments, including CCK-8, wound-healing and transwell invasion assays, were conducted. The in vivo studies were performed with the subcutaneous tumor xenograft mouse models. Our findings reveal that Linc00284 is upregulated in CRC tissues and colorectal cancer cell lines HCT116 and SW480 in comparison with corresponding para-carcinoma tissues and human fetal colonic mucosa cells FHC. High expression of Linc00284 in tumor tissues is associated with tumor metastasis and predicts a poor clinical outcome in CRC patients. Serum Linc00284 is increased, while miR-27a is decreased in CRC patients compared to healthy controls. ROC curve analysis indicates that serum Linc00284 and miR-27a produce the area under the curve (AUC) value of at 0.8151 and 0.7316 in patients with colorectal cancer compared to healthy individuals, respectively. Additionally, results in vitro and in vivo experiments suggest that Linc00284 silencing significantly suppresses CRC cell proliferation and/or invasion. Mechanistically, Linc00284 promotes c-Met expression by acting as miR-27a sponge, leading to the activation of downstream signaling pathways, thereby causing malignant phenotypes of CRC cells. Taken together, Linc00284 exhibits oncogenic function and the disturbance of Linc00284/miR-27a/c-Met regulatory axis contributes to CRC progression, providing new insight into the pathogenesis of colorectal cancer. Importantly, the expression levels of serum Linc00284 and miR-27a may serve as clinical biomarkers for CRC diagnosis.	[You, Jun] Xiamen Univ, Canc Ctr, Affiliated Hosp 1, Dept Gastrointestinal Oncol Surg, Xiamen, Fujian, Peoples R China; [You, Jun] Fujian Med Univ, Sch Clin Med, Fuzhou, Fujian, Peoples R China; [Li, Jiayi] Fujian Med Univ, Sch Clin Med, Dept Med Oncol,Xiamen Univ, Xiamen Key Lab Antitumor Drug Transformat Res,Aff, Xiamen, Fujian, Peoples R China; [Ke, Chunlin] Fujian Med Univ, Dept Radiotherapy, Affiliated Hosp 1, Fuzhou, Fujian, Peoples R China; [Xiao, Yanru] Fujian Med Univ, Dept Med Oncol, Affiliated Hosp 1, Xiamen, Fujian, Peoples R China; [Lu, Chuanhui] Fujian Med Univ, Teaching Hosp, Xiamen Canc Ctr, Dept Colorectal Canc Surg,Xiamen Univ,Affiliated, Xiamen, Fujian, Peoples R China; [Huang, Fakun] Fujian Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp 1, Fuzhou, Fujian, Peoples R China; [Mi, Yanjun] Fujian Med Univ, Xiamen Key Lab Thorac Tumor Diag & Treatment, Inst Lung Canc, Dept Med Oncol,Sch Clin Med,Xiamen Univ,Affiliate, Xiamen, Fujian, Peoples R China; [Xia, Rongmu] Xiamen Univ, Sch Med, Xiamen, Fujian, Peoples R China; [Li, Qiyuan] Xiamen Univ, Natl Inst Data Sci Hlth & Med, Sch Med, Xiamen, Fujian, Peoples R China	Xiamen University; Fujian Medical University; Fujian Medical University; Xiamen University; Fujian Medical University; Fujian Medical University; Fujian Medical University; Xiamen University; Fujian Medical University; Fujian Medical University; Xiamen University; Xiamen University; Xiamen University	Ke, CL (corresponding author), Fujian Med Univ, Dept Radiotherapy, Affiliated Hosp 1, Fuzhou, Fujian, Peoples R China.; Mi, YJ (corresponding author), Fujian Med Univ, Xiamen Key Lab Thorac Tumor Diag & Treatment, Inst Lung Canc, Dept Med Oncol,Sch Clin Med,Xiamen Univ,Affiliate, Xiamen, Fujian, Peoples R China.; Xia, RM (corresponding author), Xiamen Univ, Sch Med, Xiamen, Fujian, Peoples R China.; Li, QY (corresponding author), Xiamen Univ, Natl Inst Data Sci Hlth & Med, Sch Med, Xiamen, Fujian, Peoples R China.	ke_chunlin@yeah.net; Miyj77@xmu.edu.cn; xiarongmu@126.com; liqiyuanxm@126.com	rongmu, xia/CAG-5933-2022	rongmu, xia/0000-0002-8678-1367; Li, Qiyuan/0000-0002-8934-8948	National Natural Science Foundation of China [81871877]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (No. 81871877).	Acunzo Mario, 2015, Adv Biol Regul, V57, P1, DOI 10.1016/j.jbior.2014.09.013; Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Chae DK, 2017, MOL CARCINOGEN, V56, P1992, DOI 10.1002/mc.22655; Chen SY, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0959-5; Chi Victor, 2007, J Vis Exp, P308, DOI 10.3791/308; Czyz M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123844; Drobatz Kenneth J, 2009, J Vet Cardiol, V11 Suppl 1, pS33, DOI 10.1016/j.jvc.2009.03.004; Gupta SC, 2017, INT J CANCER, V140, P1955, DOI 10.1002/ijc.30546; Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Jae N, 2019, VASC PHARMACOL, V114, P13, DOI 10.1016/j.vph.2018.03.003; Li XW, 2019, J CANCER, V10, P2836, DOI 10.7150/jca.31361; Liang JT, 2017, ONCOTARGET, V8, P82991, DOI 10.18632/oncotarget.19635; Liu JW, 2019, DIGEST DIS SCI, V64, P1868, DOI 10.1007/s10620-019-05506-9; Lu SR, 2018, EXP THER MED, V16, P4879, DOI 10.3892/etm.2018.6775; Matsumoto K, 2017, CANCER SCI, V108, P296, DOI 10.1111/cas.13156; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Mo Hong-Nan, 2017, Chronic Dis Transl Med, V3, P148, DOI 10.1016/j.cdtm.2017.06.002; Parizadeh SM, 2019, IUBMB LIFE, V71, P802, DOI 10.1002/iub.2063; Pothula SP, 2017, ONCOTARGET, V8, P76722, DOI 10.18632/oncotarget.20822; Puccini A, 2019, DRUG SAFETY, V42, P211, DOI 10.1007/s40264-018-0780-x; Ruan ZY, 2019, FASEB J, V33, P12047, DOI 10.1096/fj.201900101RR; Shen P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18092003; Shin VY, 2014, WORLD J GASTROENTERO, V20, P10432, DOI 10.3748/wjg.v20.i30.10432; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song MY, 2015, GASTROENTEROLOGY, V148, P1244, DOI 10.1053/j.gastro.2014.12.035; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Vidovic D, 2020, CELL DEATH DIFFER, V27, P363, DOI 10.1038/s41418-019-0362-1; Vishnoi A, 2017, METHODS MOL BIOL, V1509, P1, DOI 10.1007/978-1-4939-6524-3_1; Wan WB, 2019, EUR REV MED PHARMACO, V23, P6453, DOI 10.26355/eurrev_201908_18528; Wang SS, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/9696285; Wang Z, 2014, DIAGN PATHOL, V9; Xing C, 2018, CLIN LAB, V64, P1661, DOI 10.7754/Clin.Lab.2018.180419; Xu J, 2019, MOL MED REP, V20, P5021, DOI 10.3892/mmr.2019.10736; You WK, 2008, BMB REP, V41, P833, DOI 10.5483/BMBRep.2008.41.12.833; Zhang HL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113295; Zhang JC, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00893; Zhao YJ, 2018, ONCOL REP, V39, P1197, DOI 10.3892/or.2018.6207; Zhen Q, 2015, CYTOGENET GENOME RES, V146, P1, DOI 10.1159/000434741; Zhou L, 2016, ONCOTARGET, V7, P51943, DOI 10.18632/oncotarget.10460	42	9	9	2	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4151	4166		10.1038/s41388-021-01839-w	http://dx.doi.org/10.1038/s41388-021-01839-w		MAY 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34050266	Green Published, hybrid			2022-12-28	WOS:000655826000001
J	Blondel-Tepaz, E; Leverve, M; Sokrat, B; Paradis, JS; Kosic, M; Saha, K; Auffray, C; Lima-Fernandes, E; Zamborlini, A; Poupon, A; Gaboury, L; Findlay, J; Baillie, GS; Enslen, H; Bouvier, M; Angers, S; Marullo, S; Scott, MGH				Blondel-Tepaz, Elodie; Leverve, Marie; Sokrat, Badr; Paradis, Justine S.; Kosic, Milena; Saha, Kusumika; Auffray, Cedric; Lima-Fernandes, Evelyne; Zamborlini, Alessia; Poupon, Anne; Gaboury, Louis; Findlay, Jane; Baillie, George S.; Enslen, Herve; Bouvier, Michel; Angers, Stephane; Marullo, Stefano; Scott, Mark G. H.			The RanBP2/RanGAP1-SUMO complex gates beta-arrestin2 nuclear entry to regulate the Mdm2-p53 signaling axis	ONCOGENE			English	Article							BETA-ARRESTINS; SUMO MODIFICATION; EXPORT SIGNAL; BINDING-SITES; PROTEIN; SUMOYLATION; RECEPTOR; LOCALIZATION; RAN; PHOSPHORYLATION	Mdm2 antagonizes the tumor suppressor p53. Targeting the Mdm2-p53 interaction represents an attractive approach for the treatment of cancers with functional p53. Investigating mechanisms underlying Mdm2-p53 regulation is therefore important. The scaffold protein beta-arrestin2 (beta-arr2) regulates tumor suppressor p53 by counteracting Mdm2.beta-arr2 nucleocytoplasmic shuttling displaces Mdm2 from the nucleus to the cytoplasm resulting in enhanced p53 signaling. beta-arr2 is constitutively exported from the nucleus, via a nuclear export signal, but mechanisms regulating its nuclear entry are not completely elucidated. beta-arr2 can be SUMOylated, but no information is available on how SUMO may regulate beta-arr2 nucleocytoplasmic shuttling. While we found beta-arr2 SUMOylation to be dispensable for nuclear import, we identified a non-covalent interaction between SUMO and beta-arr2, via a SUMO interaction motif (SIM), that is required for beta-arr2 cytonuclear trafficking. This SIM promotes association of beta-arr2 with the multimolecular RanBP2/RanGAP1-SUMO nucleocytoplasmic transport hub that resides on the cytoplasmic filaments of the nuclear pore complex. Depletion of RanBP2/RanGAP1-SUMO levels result in defective beta-arr2 nuclear entry. Mutation of the SIM inhibits beta-arr2 nuclear import, its ability to delocalize Mdm2 from the nucleus to the cytoplasm and enhanced p53 signaling in lung and breast tumor cell lines. Thus, a beta-arr2 SIM nuclear entry checkpoint, coupled with active beta-arr2 nuclear export, regulates its cytonuclear trafficking function to control the Mdm2-p53 signaling axis.	[Blondel-Tepaz, Elodie; Leverve, Marie; Saha, Kusumika; Auffray, Cedric; Lima-Fernandes, Evelyne; Enslen, Herve; Marullo, Stefano; Scott, Mark G. H.] Inst Cochin, U1016, INSERM, Paris, France; [Blondel-Tepaz, Elodie; Leverve, Marie; Saha, Kusumika; Auffray, Cedric; Lima-Fernandes, Evelyne; Enslen, Herve; Marullo, Stefano; Scott, Mark G. H.] CNRS, UMR8104, Paris, France; [Blondel-Tepaz, Elodie; Leverve, Marie; Saha, Kusumika; Auffray, Cedric; Lima-Fernandes, Evelyne; Enslen, Herve; Marullo, Stefano; Scott, Mark G. H.] Univ Paris, Paris, France; [Sokrat, Badr] Univ Montreal, Inst Res Immunol & Canc IRIC, Montreal, PQ, Canada; [Sokrat, Badr; Paradis, Justine S.; Gaboury, Louis; Bouvier, Michel] Univ Montreal, Dept Biochem & Mol Med, Montreal, PQ, Canada; [Paradis, Justine S.; Bouvier, Michel] Univ Montreal, Mol Biol Program, Montreal, PQ, Canada; [Kosic, Milena; Angers, Stephane] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Kosic, Milena; Angers, Stephane] Univ Toronto, Dept Biochem, Toronto, ON, Canada; [Zamborlini, Alessia] Univ Paris Saclay, Inst Integrat Biol Cell I2BC, CNRS, CEA, Gif Sur Yvette, France; [Poupon, Anne] Univ Tours, IFCE, CNRS, INRA,PRC, Nouzilly, France; [Gaboury, Louis] Univ Montreal, Dept Pathol & Cell Biol, IRIC, Montreal, PQ, Canada; [Findlay, Jane; Baillie, George S.] Univ Glasgow, Coll Vet Med & Life Sci, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universite de Montreal; Universite de Montreal; Universite de Montreal; University of Toronto; University of Toronto; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); INRAE; Universite de Tours; Universite de Montreal; University of Glasgow	Scott, MGH (corresponding author), Inst Cochin, U1016, INSERM, Paris, France.; Scott, MGH (corresponding author), CNRS, UMR8104, Paris, France.; Scott, MGH (corresponding author), Univ Paris, Paris, France.	mark.scott@inserm.fr	Angers, Stephane/E-1432-2014; Enslen, Hervé/AAH-4492-2021; Marullo, Stefano/C-6142-2008; Zamborlini, Alessia/ABE-2256-2021; Bouvier, Michel/H-2758-2014	Angers, Stephane/0000-0001-7241-9044; Enslen, Hervé/0000-0001-9741-5293; Marullo, Stefano/0000-0001-9604-9973; Zamborlini, Alessia/0000-0002-8902-1996; Sokrat, Badr/0000-0002-5770-1858; Bouvier, Michel/0000-0003-1128-0100; Scott, Mark G.H./0000-0002-1557-1856	"Investments for the Future" program [ANR-11-LABX-0071, ANR-11-IDEX-0005-01]; Fondation ARC pour la Recherche sur le Cancer ("Projet ARC"); Ligue contre le Cancer; Royal Society; France Canada Research Fund; CNRS; INSERM; CIHR Foundation [FDN148431]; MESR; Fondation ARC pour la Recherche sur le Cancer doctoral fellowships	"Investments for the Future" program; Fondation ARC pour la Recherche sur le Cancer ("Projet ARC")(Fondation ARC pour la Recherche sur le Cancer); Ligue contre le Cancer(Ligue nationale contre le cancer); Royal Society(Royal Society of London); France Canada Research Fund; CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CIHR Foundation(Canadian Institutes of Health Research (CIHR)); MESR(Ministry of Research, France); Fondation ARC pour la Recherche sur le Cancer doctoral fellowships	We thank Dr. A. Benmerah for helpful discussion, Dr. J. Liotard for excellent technical assistance, and the Institut Cochin Imaging (IMAG'IC) and Sequencing platforms (GENOM'IC). The Institut Cochin lab is part of the Who am I? laboratory of excellence (grant ANR-11-LABX-0071), funded by the "Investments for the Future" program operated by The French National Research Agency (grant ANR-11-IDEX-0005-01). This work was funded by grants from the Fondation ARC pour la Recherche sur le Cancer ("Projet ARC" to MGHS), Ligue contre le Cancer (to MGHS), Royal Society ("International Joint Project Scheme" to MGHS and GSB), France Canada Research Fund (to MGHS and SA), CNRS, and INSERM. The work in the laboratory of M.B. was supported by a CIHR Foundation (FDN148431) grant. M.B. holds the Canada Research Chair in Signal transduction and Molecular Pharmacology. EBT was funded by MESR and Fondation ARC pour la Recherche sur le Cancer doctoral fellowships.	Alexander RA, 2020, CELL MOL LIFE SCI, V77, P5259, DOI 10.1007/s00018-020-03471-5; Beauclair G, 2015, BIOINFORMATICS, V31, P3483, DOI 10.1093/bioinformatics/btv403; Blondel-Tepaz E, 2019, METHODS MOL BIOL, V1957, P251, DOI 10.1007/978-1-4939-9158-7_16; Bolger GB, 2006, BIOCHEM J, V398, P23, DOI 10.1042/BJ20060423; Boularan C, 2007, P NATL ACAD SCI USA, V104, P18061, DOI 10.1073/pnas.0705550104; Brandariz-Nunez A, 2013, VIROLOGY, V435, P463, DOI 10.1016/j.virol.2012.09.042; Enslen Herve, 2014, Handb Exp Pharmacol, V219, P405, DOI 10.1007/978-3-642-41199-1_21; Flotho A, 2013, ANNU REV BIOCHEM, V82, P357, DOI 10.1146/annurev-biochem-061909-093311; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gonzalez-Santamaria J, 2011, J VIROL, V85, P12890, DOI 10.1128/JVI.05628-11; Guo DH, 2004, NAT GENET, V36, P837, DOI 10.1038/ng1391; Hashizume C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.370; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hutten S, 2008, MOL BIOL CELL, V19, P2300, DOI 10.1091/mbc.E07-12-1279; Hutten S, 2009, J CELL SCI, V122, P1100, DOI 10.1242/jcs.040154; Jakobs A, 2007, NAT METHODS, V4, P245, DOI 10.1038/NMETH1006; Javadi A, 2017, ELIFE, V6, DOI 10.7554/eLife.24578; Kerscher O, 2007, EMBO REP, V8, P550, DOI 10.1038/sj.embor.7400980; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Laporte SA, 2019, METHODS MOL BIOL, V1957, P9, DOI 10.1007/978-1-4939-9158-7_2; Li RW, 2012, J VIROL, V86, P5412, DOI 10.1128/JVI.00314-12; Li X, 2010, BIOCHEM J, V428, P55, DOI 10.1042/BJ20091672; Lima-Fernandes E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5431; Lima-Fernandes E, 2011, EMBO J, V30, P2557, DOI 10.1038/emboj.2011.178; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat7650; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Monteith JA, 2016, MOL ONCOL, V10, P1207, DOI 10.1016/j.molonc.2016.05.007; Namkung Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12178; Paradis JS, 2015, P NATL ACAD SCI USA, V112, pE5160, DOI 10.1073/pnas.1508836112; Peterson YK, 2017, PHARMACOL REV, V69, P256, DOI 10.1124/pr.116.013367; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sakin V, 2015, J BIOL CHEM, V290, P23589, DOI 10.1074/jbc.M115.660118; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Singh R, 2014, J BIOL CHEM, V289, P19383, DOI 10.1074/jbc.M114.575159; Walde S, 2012, TRAFFIC, V13, P218, DOI 10.1111/j.1600-0854.2011.01302.x; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Wang PY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092482; Werner A, 2012, MOL CELL, V46, P287, DOI 10.1016/j.molcel.2012.02.017; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Wyatt D, 2011, J BIOL CHEM, V286, P3884, DOI 10.1074/jbc.M110.152116; Xiao N, 2015, J BIOL CHEM, V290, P1927, DOI 10.1074/jbc.M114.608703; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; Zhang XH, 2020, BIOCHEM PHARMACOL, V178, DOI 10.1016/j.bcp.2020.114049	48	4	4	2	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2243	2257		10.1038/s41388-021-01704-w	http://dx.doi.org/10.1038/s41388-021-01704-w		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33649538	Bronze, Green Submitted, Green Accepted			2022-12-28	WOS:000623739900002
J	Yang, Y; Ma, YD; Gao, HB; Peng, TS; Shi, HJ; Tang, YX; Li, H; Chen, L; Hu, KS; Han, AJ				Yang, Yang; Ma, Yuedong; Gao, Huabin; Peng, Tingsheng; Shi, Huijuan; Tang, Yunxiang; Li, Hui; Chen, Lin; Hu, Kaishun; Han, Anjia			A novel HDGF-ALCAM axis promotes the metastasis of Ewing sarcoma via regulating the GTPases signaling pathway	ONCOGENE			English	Article							CELL-ADHESION MOLECULE; GROWTH-FACTOR; ACTIN POLYMERIZATION; CDC42 GTPASES; RHO; RAC; MIGRATION; CANCER; DOMAIN; ACTIVATION	Ewing sarcoma (ES) is a type of highly aggressive pediatric tumor in bones and soft tissues and its metastatic spread remains the most powerful predictor of poor outcome. We previously identified that the transcription factor hepatoma-derived growth factor (HDGF) promotes ES tumorigenesis. However, the mechanisms underlying ES metastasis remain unclear. Here, we show that HDGF drives ES metastasis in vitro and in vivo, and HDGF reduces metastasis-free survival (MFS) in two independent large cohorts of human ES patients. Integrative analyses of HDGF ChIP-seq and gene expression profiling in ES cells reveal that HDGF regulates multiple metastasis-associated genes, among which activated leukocyte cell adhesion molecule (ALCAM) emerges as a major HDGF target and a novel metastasis-suppressor in ES. HDGF down-regulates ALCAM, induces expression and activation of the downstream effectors Rho-GTPase Rac1 and Cdc42, and promotes actin cytoskeleton remodeling and cell-matrix adhesion. In addition, repression of ALCAM and activation of Rac1 and Cdc42 are required for the pro-metastatic functions of HDGF in vitro. Moreover, analyses in murine models with ES tumor orthotopic implantation and experimental metastasis, as well as in human ES samples, demonstrate the associations among HDGF, ALCAM, and GTPases expression levels. Furthermore, high HDGF/low ALCAM expression define a subgroup of patients harboring the worst MFS. These findings suggest that the HDGF/ALCAM/GTPases axis represents a promising therapeutic target for limiting ES metastasis.	[Yang, Yang; Gao, Huabin; Peng, Tingsheng; Shi, Huijuan; Tang, Yunxiang; Li, Hui; Chen, Lin; Han, Anjia] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510080, Peoples R China; [Ma, Yuedong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Cardiol, Guangzhou 510080, Peoples R China; [Hu, Kaishun] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Med Res Ctr, Guangzhou 510120, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Han, AJ (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510080, Peoples R China.; Hu, KS (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Med Res Ctr, Guangzhou 510120, Peoples R China.	huksh3@mail.sysu.edu.cn; hananjia@mail.sysu.edu.cn		Chen, Lin/0000-0002-7552-8673; Hu, Kaishun/0000-0003-2157-6239	National Nature Science Foundation in China [81772862, 81402413, 81402000]; Fundamental Research Funds for the Sun Yat-sen Universities [16ykpy42]	National Nature Science Foundation in China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Sun Yat-sen Universities	This work was supported by grants from the National Nature Science Foundation in China (81772862 and 81402413 to YY, and 81402000 to HL) and from the Fundamental Research Funds for the Sun Yat-sen Universities (16ykpy42 to YY).	Anderson S, 2016, P NATL ACAD SCI USA, V113, pE5481, DOI 10.1073/pnas.1610994113; Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; Bar-Shavit R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081320; Cotterill SJ, 2000, J CLIN ONCOL, V18, P3108, DOI 10.1200/JCO.2000.18.17.3108; Everett AD, 2001, J BIOL CHEM, V276, P37564, DOI 10.1074/jbc.M105109200; Franzetti GA, 2017, ONCOGENE, V36, P3505, DOI 10.1038/onc.2016.498; Granowetter L, 2009, J CLIN ONCOL, V27, P2536, DOI 10.1200/JCO.2008.19.1478; Jansen S, 2018, PHARMACOL THERAPEUT, V183, P1, DOI 10.1016/j.pharmthera.2017.09.002; Kazanietz MG, 2017, CANCER RES, V77, P5445, DOI 10.1158/0008-5472.CAN-17-1456; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kijima N, 2012, NEURO-ONCOLOGY, V14, P1254, DOI 10.1093/neuonc/nor202; Kishima Y, 2002, J BIOL CHEM, V277, P10315, DOI 10.1074/jbc.M111122200; Kung ML, 2012, BIOCHEM BIOPH RES CO, V425, P169, DOI 10.1016/j.bbrc.2012.07.060; Lunter PC, 2005, CANCER RES, V65, P8801, DOI 10.1158/0008-5472.CAN-05-0378; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Maldonado MD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00201; Maldonado MD, 2018, CANCER RES, V78, P3101, DOI 10.1158/0008-5472.CAN-18-0619; Mao JS, 2008, CANCER SCI, V99, P2120, DOI 10.1111/j.1349-7006.2008.00928.x; Masedunskas A, 2006, FEBS LETT, V580, P2637, DOI 10.1016/j.febslet.2006.04.013; Mendoza-Naranjo A, 2013, EMBO MOL MED, V5, P1087, DOI 10.1002/emmm.201202343; Moreau V, 1998, FEBS LETT, V427, P353, DOI 10.1016/S0014-5793(98)00443-8; NAKAMURA H, 1994, J BIOL CHEM, V269, P25143; Nameki N, 2005, PROTEIN SCI, V14, P756, DOI 10.1110/ps.04975305; Nelissen JMDT, 2000, MOL BIOL CELL, V11, P2057, DOI 10.1091/mbc.11.6.2057; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Penna E, 2013, CANCER RES, V73, P4098, DOI 10.1158/0008-5472.CAN-12-3686; Riggi N, 2007, CANCER LETT, V254, P1, DOI 10.1016/j.canlet.2006.12.009; Satterfield L, 2017, INT J CANCER, V141, P2062, DOI 10.1002/ijc.30909; Savola S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-17; Sechler M, 2017, ONCOGENE, V36, P4150, DOI 10.1038/onc.2017.44; Swart GWM, 2002, EUR J CELL BIOL, V81, P313, DOI 10.1078/0171-9335-00256; van Kempen LCLT, 2004, J INVEST DERMATOL, V122, P1293, DOI 10.1111/j.0022-202X.2004.22531.x; van Kilsdonk JWJ, 2008, CANCER RES, V68, P3671, DOI 10.1158/0008-5472.CAN-07-5767; Wang CH, 2011, BIOCHEM J, V433, P127, DOI 10.1042/BJ20100589; Wei YP, 2020, HEPATOLOGY, V71, P130, DOI 10.1002/hep.30795; Woldu SL, 2018, NAT REV UROL, V15, P83, DOI 10.1038/nrurol.2017.184; Yang J, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-101; Yang J, 2009, J MOL BIOL, V386, P938, DOI 10.1016/j.jmb.2008.12.080; Yang Y, 2014, J CLIN PATHOL, V67, DOI 10.1136/jclinpath-2013-201705; Yang Y, 2013, J PATHOL, V231, P323, DOI 10.1002/path.4241; Yao HH, 2011, J NEUROSCI, V31, P5942, DOI 10.1523/JNEUROSCI.5618-10.2011; Zhang Z, 2014, ONCOGENE, V33, P3374, DOI 10.1038/onc.2013.337	44	13	12	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					731	745		10.1038/s41388-020-01485-8	http://dx.doi.org/10.1038/s41388-020-01485-8		NOV 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33239755				2022-12-28	WOS:000592629300002
J	Zhang, QY; Zhou, W; Yu, S; Ju, YJ; To, SKY; Wong, AST; Jiao, YF; Poon, TCW; Tam, KY; Lee, LTO				Zhang, Qingyu; Zhou, Wei; Yu, Shan; Ju, Yaojun; To, Sally Kit Yan; Wong, Alice Sze Tsai; Jiao, Yufei; Poon, Terence Chuen Wai; Tam, Kin Yip; Lee, Leo Tsz On			Metabolic reprogramming of ovarian cancer involves ACSL1-mediated metastasis stimulation through upregulated protein myristoylation	ONCOGENE			English	Article							FATTY-ACID OXIDATION; TYROSINE KINASE; BREAST-CANCER; C-SRC; ACTIVATION; INHIBITION; STRESS; CELLS; ACSL1; LINKS	As a result of the hostile microenvironment, metabolic alterations are required to enable the malignant growth of cancer cells. To understand metabolic reprogramming during metastasis, we conducted shotgun proteomic analysis of highly metastatic (HM) and non-metastatic (NM) ovarian cancer cells. The results suggest that the genes involved in fatty-acid (FA) metabolism are upregulated, with consequent increases of phospholipids with relatively short FA chains (myristic acid, MA) in HM cells. Among the upregulated proteins, ACSL1 expression could convert the lipid profile of NM cells to that similar of HM cells and make them highly aggressive. Importantly, we demonstrated that ACSL1 activates the AMP-activated protein kinase and Src pathways via protein myristoylation and finally enhances FA beta oxidation. Patient samples and tissue microarray data also suggested that omentum metastatic tumours have higher ACSL1 expression than primary tumours and a strong association with poor clinical outcome. Overall, our data reveal that ACSL1 enhances cancer metastasis by regulating FA metabolism and myristoylation.	[Zhang, Qingyu; Yu, Shan; Lee, Leo Tsz On] Univ Macau, Fac Hlth Sci, Canc Ctr, Taipa, Macau, Peoples R China; [Zhang, Qingyu] Guangdong Med Univ, Affiliated Hosp, Dept Obstet & Gynaecol, Zhanjiang 524001, Guangdong, Peoples R China; [Zhou, Wei] China Pharmaceut Univ, Sch Tradit Chinese Pharm, State Key Lab Nat Med, Nanjing 210009, Peoples R China; [Ju, Yaojun; Poon, Terence Chuen Wai; Tam, Kin Yip] Univ Macau, Fac Hlth Sci, Prote Metabol & Drug Dev Core, Taipa, Macau, Peoples R China; [To, Sally Kit Yan; Wong, Alice Sze Tsai] Univ Hong Kong, Sch Biol Sci, Pokfulam Rd, Hong Kong, Peoples R China; [Jiao, Yufei] Harbin Med Univ, Affiliated Hosp 2, Dept Pathol, Harbin 150001, Peoples R China; [Lee, Leo Tsz On] Univ Macau, Fac Hlth Sci, Ctr Reprod Dev & Aging, Taipa, Macau, Peoples R China	University of Macau; Guangdong Medical University; China Pharmaceutical University; University of Macau; University of Hong Kong; Harbin Medical University; University of Macau	Lee, LTO (corresponding author), Univ Macau, Fac Hlth Sci, Canc Ctr, Taipa, Macau, Peoples R China.; Lee, LTO (corresponding author), Univ Macau, Fac Hlth Sci, Ctr Reprod Dev & Aging, Taipa, Macau, Peoples R China.	LTOLee@um.edu.mo	Lee, Leo T.O./AAB-1581-2021; Wong, Alice/AFJ-4595-2022; Tam, Kin/A-7812-2011	Wong, Alice/0000-0002-0676-6475; Tam, Kin/0000-0001-5507-8524	Science and Technology Development Fund, Macau SAR [0016/2020/A1]; University of Macau [MYRG2019-00075-FHS]; Hong Kong Research Grant Council [GRF17105919]	Science and Technology Development Fund, Macau SAR; University of Macau; Hong Kong Research Grant Council(Hong Kong Research Grants Council)	This work and LTOL were funded by The Science and Technology Development Fund, Macau SAR (File no. 0016/2020/A1) and University of Macau (File. no. MYRG2019-00075-FHS). ASTW was supported by Hong Kong Research Grant Council grant GRF17105919. We acknowledge the Animal Research Core Facility from University of Macau for their support in the animal experiments.	Aebersold R, 2016, NATURE, V537, P347, DOI 10.1038/nature19949; Anbalagan M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033017; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Cui M, 2014, BIOCHEM BIOPH RES CO, V444, P270, DOI 10.1016/j.bbrc.2014.01.051; Das U, 2012, CURR CANCER DRUG TAR, V12, P667, DOI 10.2174/156800912801784857; Deng L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1201-x; Dian C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14847-3; Dirat B, 2010, ENDOCR DEV, V19, P45, DOI 10.1159/000316896; Fullerton MD, 2013, NAT MED, V19, P1649, DOI 10.1038/nm.3372; Jeon Sang-Min, 2012, Cell Logist, V2, P197; Kim S, 2017, CANCER RES, V77, P6950, DOI 10.1158/0008-5472.CAN-17-0981; Kim S, 2017, J BIOL CHEM, V292, P18422, DOI [10.1074/jbc.M117.798827, 10.1074/jbc.m117.798827]; Liang JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8926; Lobo S, 2009, J BIOL CHEM, V284, P18347, DOI 10.1074/jbc.M109.017244; Lopez-Mejia IC, 2017, MOL CELL, V68, P336, DOI 10.1016/j.molcel.2017.09.034; Mizrachy-Schwartz S, 2011, J BIOL CHEM, V286, P15268, DOI 10.1074/jbc.M110.211813; Oakhill JS, 2010, P NATL ACAD SCI USA, V107, P19237, DOI 10.1073/pnas.1009705107; Park JH, 2016, CELL REP, V14, P2154, DOI 10.1016/j.celrep.2016.02.004; Patwardhan P, 2010, MOL CELL BIOL, V30, P4094, DOI 10.1128/MCB.00246-10; Pengetnze Y, 2003, BIOCHEM BIOPH RES CO, V309, P377, DOI 10.1016/j.bbrc.2003.08.012; Pike LS, 2011, BBA-BIOENERGETICS, V1807, P726, DOI 10.1016/j.bbabio.2010.10.022; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Resh MD, 2013, CURR BIOL, V23, pR431, DOI 10.1016/j.cub.2013.04.024; Sanchez-Martinez R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11612-3; Sulejmani Essilvo, 2018, Oncoscience, V5, P3, DOI 10.18632/oncoscience.391; Tang Y, 2018, ONCOL LETT, V16, P1390, DOI 10.3892/ol.2018.8843; Thinon E, 2016, ACS CHEM BIOL, V11, P2165, DOI 10.1021/acschembio.6b00371; Thinon E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5919; To SKY, 2017, ONCOGENE, V36, P5927, DOI 10.1038/onc.2017.185; Tryfonopoulos D, 2011, ANN ONCOL, V22, P2234, DOI 10.1093/annonc/mdq757; Tucker SL, 2014, CLIN CANCER RES, V20, P3280, DOI 10.1158/1078-0432.CCR-14-0445; Udenwobele DI, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00751; Viollet B, 2006, J PHYSIOL-LONDON, V574, P41, DOI 10.1113/jphysiol.2006.108506; Wang Y, 2017, BIOCHEM BIOPH RES CO, V484, P565, DOI 10.1016/j.bbrc.2017.01.126; Wiener JR, 2003, GYNECOL ONCOL, V88, P73, DOI 10.1006/gyno.2002.6851; Yen MC, 2017, ONCOL REP, V37, P3253, DOI 10.3892/or.2017.5610; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200	38	12	13	4	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					97	111		10.1038/s41388-020-01516-4	http://dx.doi.org/10.1038/s41388-020-01516-4		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33082557				2022-12-28	WOS:000582339900002
